<SEC-DOCUMENT>0001193125-26-071776.txt : 20260225
<SEC-HEADER>0001193125-26-071776.hdr.sgml : 20260225
<ACCEPTANCE-DATETIME>20260225163117
ACCESSION NUMBER:		0001193125-26-071776
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		126
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260225
DATE AS OF CHANGE:		20260225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innoviva, Inc.
		CENTRAL INDEX KEY:			0001080014
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				943265960
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30319
		FILM NUMBER:		26679272

	BUSINESS ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
		BUSINESS PHONE:		6502389600

	MAIL ADDRESS:	
		STREET 1:		1350 OLD BAYSHORE HIGHWAY
		STREET 2:		SUITE 400
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	THERAVANCE INC
		DATE OF NAME CHANGE:	20020207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED MEDICINE INC
		DATE OF NAME CHANGE:	20000302
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>inva-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-02-25T16:04:39.3423+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:inva="http://www.inva.com/20251231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_b7b36e0b-b301-4469-9fab-d0f484005491" name="dei:EntityCentralIndexKey" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb">0001080014</ix:nonNumeric><ix:nonNumeric id="F_53b1dad4-f054-41cd-9ce2-8adc44e8f7d9" name="dei:AmendmentFlag" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb">false</ix:nonNumeric><ix:nonNumeric id="F_39bb3937-57a8-423d-bdaa-2f559b4b98e4" name="dei:DocumentFiscalPeriodFocus" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb">FY</ix:nonNumeric><ix:nonFraction id="F_535b341f-6db5-401b-a3a5-8bf671fbdba5" name="us-gaap:CommitmentsAndContingencies" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ccc3aab4-a06b-4ff8-8274-4eb2a635f659" name="us-gaap:CommitmentsAndContingencies" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_6a206859-f8ee-400b-9d66-43ec2846665f" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric id="F_17be60db-4ed3-4806-a6df-7a78528c373a" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric id="F_e88a4c0d-7875-4370-83b2-18dc892d7674" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_4bc47aec-cd74-43b5-88dc-6e2c9250c57b" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_a8d055de-5223-43f2-950c-df6e42a40b2d" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_392076d3-b2a9-4556-8800-6b9f6d3a290c">P36M</ix:nonNumeric><ix:nonNumeric id="F_0cf4230b-14d7-4c03-83f4-80f2b6b31b1a" name="us-gaap:LeaseExpirationDate1" contextRef="C_aea5d4fa-0e83-4b75-87db-300c5e0bf84e" format="ixt:date-monthname-day-year-en">December 31, 2027</ix:nonNumeric><ix:nonNumeric id="F_f563af2d-08d9-49fd-bae4-6b8f93526198" name="us-gaap:LeaseExpirationDate1" contextRef="C_147f547c-e68b-4615-a58e-a8401c3a3cb7" format="ixt:date-monthname-day-year-en">March 31, 2029</ix:nonNumeric><ix:nonNumeric id="F_7683dbb5-aa29-4655-8dae-71a88a149d59" name="us-gaap:LeaseExpirationDate1" contextRef="C_752dd2b0-0df3-4258-a0cf-06ce4b3c92b9" format="ixt:date-monthname-day-year-en">March 31, 2029</ix:nonNumeric><ix:nonNumeric id="F_f5f169b5-7b43-492f-b75e-5037a78edaec" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e">http://fasb.org/us-gaap/2025#LiabilitiesAndStockholdersEquity</ix:nonNumeric><ix:nonNumeric id="F_886ab7f6-fedd-4b48-b757-553a486cfc22" name="us-gaap:AssetAcquisitionDateOfAcquisitionAgreement" contextRef="C_b3eec335-a345-4b7c-9e97-3ceddf99d1e9" format="ixt:date-year-month-day">2025-09-30</ix:nonNumeric><ix:nonNumeric id="F_d97c91ae-1703-4480-a2ca-20778c18458e" name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="C_a676b1bd-fe43-4060-abbc-19a8821970e5" format="ixt:date-month-day-year">01-01-2030</ix:nonNumeric><ix:nonNumeric id="F_e2ca3e4b-1265-4708-9028-4bacbb4bf6a7" name="us-gaap:TaxCreditCarryforwardExpirationDate" contextRef="C_9ddc8c4a-6ab2-40b5-8423-f2cd290e57a1" format="ixt:date-month-day-year">01-01-2033</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="inva-20251231.xsd"/></ix:references><ix:resources><xbrli:context id="C_807e8809-f1a2-4c0a-ac41-7942e7f10fcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCAndC2PreferredStockAndCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80b69809-f556-4828-a636-e7d70a0f4529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80f755ab-2884-4b9f-8f1a-e93170c6f575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81f83795-0714-4c71-99b4-f4a03319bbcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_82023995-c0c9-4e2f-af7b-9dff1c4313ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_820fc30b-7e3c-4f31-9d93-e486eb026d85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8227b866-0a9c-4af9-b3ec-85e210a8c096"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8290bc3e-4b79-45b4-8dd5-a2d83da40c0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_82eb691b-750a-475a-837f-1b1397fcb267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">inva:LyndraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83fb2c06-5584-44c0-9816-0548d07c70bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_845eaa74-fc53-4af0-b138-f622d45b3c0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8480b31f-e5a9-455f-8428-4e043a8d826b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8636f737-54f5-4f04-95a2-1c6e8e58eb52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8683d1cb-18f6-4da0-8993-dbb80feae90a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86b41774-5017-4fc1-8e1b-cf811b6c4737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CostReimbursementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8714bccf-5bf2-42d4-bc52-49b4f39a126d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:InterimSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_874e94af-935a-439b-ab00-df1390a5e34b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87678ce3-d91f-42c7-8014-482b4e96c0b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8807e583-90bb-4bf2-b789-04fcccd5635c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88e66bcc-24ad-406e-bb93-f1e47d153eb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89417c7c-4dcb-4c3c-be0a-04a18955e9b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-06</xbrli:startDate><xbrli:endDate>2023-10-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89c9f170-6554-4259-8589-a870931960d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:FirstAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-31</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89cd5c2d-43bc-4a05-9084-5d42b8515c2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89ffeb43-b4e5-4cd3-b24e-9d0133812b42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a0737aa-6de6-4c43-ae8f-624230637866"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a27a178-7498-4039-b7ec-3acbc3e22557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8b6e7ffc-19c9-414a-8790-449480c681de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:ManufacturingStageTransferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8baf7a29-4878-46db-844e-4be322782050"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c3d0ea3-a6a0-43b3-ad32-fa7162ce8c28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c7fde10-e15b-46cf-8152-abd34dd01bd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8c8a8e9b-18d0-4f56-bd91-01b41b53e196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d1ae2b7-8b25-4684-9b73-d88cea1e9a93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d782d9a-b93f-45ae-a7ce-ee978ddef5a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:SarissaCapitalManagementLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d85403b-c00a-43af-9139-4133780be452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e78c83c-a602-4c9e-a0ca-fd8929e943fd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e7f501b-989e-4f9f-9cee-6b92a787012e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaTRCHoldingsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonAndPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f658d7a-8b07-41db-8980-8e9b1025a6a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f7758c5-cb43-4beb-b145-ea2ab98c407a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8fdc954b-b47d-4c5f-a782-7e29908c95eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8ff7ff5d-59d7-482d-b9ff-48452108446f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9064ceea-cc8b-4413-9774-0740e1e4c1bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91adb269-1218-4185-8ed5-66c8ab8bbcdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91cb662c-7d72-4446-a053-6b76cc6d61c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_920caa91-234c-4ad4-9f03-0cc64046f9bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9290e126-1791-4a2c-9976-a9357f71a1c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93087703-617b-4b4a-81e7-31843c5aa650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:AmendedZaiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_933e0662-5284-40a5-af01-95acd4469d1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9384f77e-6605-4a4c-8810-bf720c3d9a70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_948f1041-1e2d-4225-b512-dbe9786f6151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95f17691-1422-4df6-a2c2-e728a595c89b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:InternalExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_963ef00c-7831-40dd-b4ea-a644dc525f00"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:SoftwareAndComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_967bf8ab-5e86-4683-ac2b-d23837fdf808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_97c7c246-dcd0-459f-ba1c-f296e715a8bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9813ff06-8065-4d1b-980c-30aab6fdf680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98398386-f407-4e2e-a939-d8ab60856a68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_983b3e15-da6b-4fb2-b179-654eb3026eeb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98625368-01db-4a5e-b3d8-d97b38cb185c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99fff56a-0af3-445d-bdc0-14b8847ce8ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a9972fa-1809-4264-b6eb-ab4488000164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ab9bd6f-8303-47cb-a451-087e49e1d4f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ba2a047-11ad-4eed-8953-9ae11217e2fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9bab53bf-5b1c-458d-ab5d-5fa3f3cca83c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c1f6269-1e70-48f2-b51f-c346e1e9651e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c250d42-4b6f-46b7-8b87-dfca0a66338c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c59249e-0a1f-4f59-9c53-c8fe277b09ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ce22bb4-5077-4fc2-a00b-d5ce7b0d778d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-13</xbrli:startDate><xbrli:endDate>2024-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ce67c09-bbaa-4af5-9443-47f86c908063"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ce90413-1653-4365-815b-e666974c1fc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d19a8d1-6525-465e-9818-4f4be4f7b334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ZEVTERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d514a06-f501-41ad-b742-a81bd23946be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9d82a4f6-9c62-4ef3-a79a-b60ecce3c1dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9db59475-42c5-4b23-ad54-3fcbd23354de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9ddc8c4a-6ab2-40b5-8423-f2cd290e57a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9de3ffb5-8381-4662-89f6-a8481e573820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PrivatelyHeldHealthcareCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dfa9bcd-fbe2-4b00-b6d2-00a31a357835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e3bc0e6-f47d-404f-8fee-30b5fd642601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:CordenPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e87c016-5304-4333-83a4-195cc836505e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">inva:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9eb30f32-b122-4799-abad-e4b9a0d5cea5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:AmendedZaiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a08b10dd-5488-446a-93cd-e5dd9322693a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a0a9ffa5-48e7-43db-b94b-727a9650a8a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ZEVTERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a13ce0ca-7bd6-470f-b4bc-7bce7c7cce0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a16a824d-5e09-43a8-8e7c-eb26e31d2066"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2de673d-5a6d-4d89-a1af-5b182aea45da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a53dc6ea-0c8a-49d1-a28b-56b625f3832d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:DurlobactamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a549f046-b516-43a9-94af-3971494cee27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesDWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a5a5f201-5589-4683-9f98-e0775b868585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a60c1143-acae-40be-9475-53a07ff86264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a632ca34-f6ea-445b-b4f9-b800f457ca17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a676b1bd-fe43-4060-abbc-19a8821970e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6940b34-904b-444f-9ffb-b6b2e2a80b84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6f00937-2ee4-4566-bd68-45c44b998d3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a73231bb-c2af-46c2-9a92-d48cf8356bc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:DurlobactamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7a1c802-2b70-41a1-b1ab-0f6ea7991b5c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a81a0298-20b0-4919-aeae-4999deb69182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-10</xbrli:startDate><xbrli:endDate>2023-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a94d4668-3b04-4736-b7cd-35be25a3ced1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa99c31d-93ff-49a4-ada3-316eb33c9414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aac97a17-df6e-4461-927e-d6634b600e0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab3f6fa0-6707-4052-910b-d4481b963aad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab4cbb1c-525e-4e91-8915-9c00d3a0db21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaTRCHoldingsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abebdb2e-7b66-4a80-a391-a715e9a19b73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac9f1546-4eb3-464f-9fd9-e5fcbd5159b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_accf2b2f-48d9-429a-b115-90bfc9822af1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad016aed-b782-4802-bf40-a81d9aac47a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad7b15a7-04fe-4b2d-aaa8-50707a9474c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GeorgeWashingtonUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_add7605c-d6b6-415c-ad09-46eb5bbbfb4b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_add7b0b6-f915-44d8-9105-5a165235bb5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae3b7e65-0767-4226-b024-9f30a53a662d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae44ab8e-7504-455a-a5c7-18b720494066"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aea5d4fa-0e83-4b75-87db-300c5e0bf84e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:BurlingameCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af13deae-2d89-4cf9-98df-3d7c55d81d4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_af252bef-3fef-4ac4-af1c-26d65e57e80a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af50c412-1762-4092-9219-e0cb77f51b0e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1AndD2PreferredStockAndCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af76bb07-dc3c-4511-8750-d747dbdf4012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b0306b74-2ec2-4940-b3af-88916e13af8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0999027-f0c9-4ef8-ad7d-78766bc3abbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b0a0b85c-bd15-4eea-be59-38094513a363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b17848ff-54df-4b86-b3cd-386a1ff12968"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1909c77-5037-4101-951b-72d1da39afc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1c1c252-d197-4e74-b2b2-f01842ca2233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:DurlobactamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1c51e57-65da-49fa-ae45-c34168f6b7ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b25d8758-99b0-4893-a9e8-7d66f0af9020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2a12880-40dd-4a30-8ea9-b9ba0ea9cc66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2be7da7-0eaa-4d69-b26f-885c2d1e7254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b335f87a-f5ca-4232-8677-8903d59dd87c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3b3003f-d16b-4948-beec-32f75f482d34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanTwentyTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3eec335-a345-4b7c-9e97-3ceddf99d1e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">inva:LyndraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b3f2abfb-4337-4fab-9c5b-7e5c28bbffed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4012fc1-478c-4326-af9a-abfcc793f2a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4075dc6-049f-43ce-ad83-c920b6727849"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4464bad-246b-476e-bbdb-5189b9e3455c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanTwentyTwentyThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b44bc8f0-aa9e-48fd-9fb8-b5701d1d6bf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SyndeoTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4c7d24e-1946-466d-b882-1f82aca2913e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4d781bc-915c-4c41-9106-511763a665d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b531a65e-a381-43b5-9fc1-7c2a415d40f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:InternalExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b59f5a94-681e-4e5c-b302-d0358109e1fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b657fd3f-8dca-44dc-a4ed-6c972e7986a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-23</xbrli:startDate><xbrli:endDate>2026-01-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6b5484e-26f7-475f-aad3-d4fff0a4c327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:AmendedZaiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6f9a97f-7c68-4a85-8e85-ea9cf6cc6220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b772694b-7101-44aa-8dc2-322e6c88ba68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7886827-2301-4eae-ac39-e1b0cfe79560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b804b54f-6e17-4b9b-bc14-506d13cd2e58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b931adf2-501a-4565-a5c0-0fce4fa655a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b977836a-3754-4918-ab34-119c8e6e97e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b996eed8-dfe9-4e4c-91e3-6efd62f73797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9c78e4a-7998-49df-8911-c4a60d08df86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9d838c8-9363-4704-8fc8-ac7fe6933ce0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_baeb567b-ccbe-4999-a205-466cd47101ba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:BasileaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb0d3213-3fd7-4233-90d1-9955a45217a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb1be382-95cb-4b4d-9141-588145edc4e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb34b526-ff51-4bd5-9372-e24b00a45ea7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bb80b0bd-8c31-447f-bb15-56034f4a4f2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc424098-7c86-48ee-a261-2e346af6f356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc6304c8-3e91-4a96-bdf1-8803fdcad919"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcb70ba8-9c6a-40aa-acaa-7cbf42dfc814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd8929dd-2601-4ff3-b3c5-49946bfb7b0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:LexingtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdd9c91e-8090-4b5c-afa1-5fde995c9182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be14d1aa-9ffc-4de3-b4ae-142c0c538bae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be450a6d-2206-415e-accd-57ca23a7c915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bec30008-f686-4815-ac74-3fb4d99703f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bf1e7354-aeed-4914-83a6-37a509ddd35f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf257858-aaa7-4585-83a4-5200623ef35c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c010fb75-cf30-4376-bfd0-a2b399f45c3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0f46e83-20e1-4f0a-ac38-a2cdd4a209c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c10fa9b1-45fb-45df-9763-f7e84d16c427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c2aa978f-4b90-4e27-bcd0-10e52fef449d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-06-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c301f3b4-0e6f-4ec9-97f7-2af4d7bc4e41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c43a1118-656f-4694-8c43-8a7ccd87ef7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c44315cf-58b6-4df1-a7fb-545a3c2a85c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c554b608-b6a5-40f5-8cdd-07a2aa79f2ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5950ca0-b841-4a30-a532-7b67bb117316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c66f1b13-03bc-4b24-a6a3-cd400090f9ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6c8e559-7887-449a-bda4-21ea384a9d5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6f23cff-6ae1-42a0-aeb9-137bb05864f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c76fc58c-a666-4494-993c-5441e34ded35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:BasileaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c7ab2f82-2276-40f6-9084-327d9a8463bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginAbNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c7bb82e1-094a-43f1-9fb5-4b8ca5b929fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8120c77-f833-4318-8b71-285654ebe1a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c92d98ef-aaeb-428e-9c70-9239d3850fc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c9724995-83e8-4e3f-ac0a-df8eb2d7e801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c99c2a28-4992-4873-a475-9fde89e0026a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9dd44c1-e335-4444-826a-cca2d606205b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9ea7908-47f3-4091-b474-5d9827ca0b02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca4eb91e-0456-4f17-b035-ed0e47cc770a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca9df07c-03f1-4863-b309-11e88116df42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb2b5dab-8579-446e-acf0-02b095195b73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cb9d2f79-476b-4ddd-9d0f-a6df0b98ff4c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:AstrazenecaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ZoliflodacinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbc75e73-16d5-41ff-9fc0-e3415e4303d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:Outstanding2028NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbc79b2e-83c4-4eb8-a3b9-5535187253c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccbbfa18-4020-412e-b2de-ffea359a8cdd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PrivatelyHeldHealthcareCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd026123-bf98-4ceb-963d-51e954864642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd1ae492-3baa-4fd2-89f9-afa8f30347b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd448608-93c9-4efb-8910-d496892f68f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd6017c9-4e6d-48a6-b778-fdb58ebeeb24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd9cf8cd-caf0-4230-972b-b59ef42f7629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdc0f154-9e15-4dde-bfd0-dcb748170232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cdd50e55-f430-4309-b1e7-fe3c5bc72c13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cde889ec-684b-433c-ada2-fcc698632fea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce943a5c-4a0c-4116-8b1d-c757694d1ea7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cfb09673-608d-4b9a-af24-b826da8f9edc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfe17d12-81a1-4510-9340-bf18810ec8cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cffa7db5-8a40-42ec-a6b5-dae4eff5e8a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d029c0a8-0421-4544-b742-f93ceeea6d0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d16801eb-dbe6-41b0-b0a9-f2ce69282a79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-03</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d1a545a6-5a9b-4ad3-bbfb-5c5207b1a1f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2c0826f-e79a-4fce-bf90-c8a92ab2dc99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-04</xbrli:startDate><xbrli:endDate>2024-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3132f94-898b-45b9-b231-38bb9e3c6785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d34cdf08-8e0e-4cba-93ee-569a80e0e67a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d383d05f-380a-46b9-b425-0ac125742038"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SyndeoTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4b33ce8-c2ef-41f9-aa40-07f4e9d94111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GARDPCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d4eb0f40-5fd8-4cae-9d09-795c67481067"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5482eb7-e694-4625-b420-b8cb85d4fcf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d5a54e09-f59e-44b6-9cef-6b6ac8a95a30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5e9003f-7e55-4b05-bab9-c11fa367b435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d616bb07-0b13-4397-853a-6fd375bf2296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d61eb3bb-dfd5-4977-b307-3cce0652657c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d68a48b8-3d2b-4af8-8344-60a112a209cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7a7bab5-9ba6-49af-9860-25a6b42523d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d84e455d-e7e3-4fbe-a104-3abc49e8a445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8ba1e61-eae2-49b5-9a4d-794567463681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CostReimbursementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d93a2eff-6ca3-4b72-bc94-7f262d74a800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d94e644a-a7b1-4e62-874d-457ce3a49fd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9b8c46c-1584-49b3-91b6-cc0e6d57dc59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9f02cfa-bf5e-4cd1-b720-fcc2c4210f0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9fc309a-2db6-4a93-97f8-d69062730902"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da7cd9c6-74d8-41bd-9505-fc9787b73b1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da892b74-d5b8-42b1-8209-9456006bda02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc46e272-bbf4-4eab-89a7-9149f700ad25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc58284d-69c1-4202-ab83-45c4db4ecabd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd617a60-08f2-42eb-9dd4-dfab3845fa6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd8d8977-0825-4ede-9687-2466de66c5ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSeniorNotes2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dec7ee2e-9d77-490d-ada1-7ee27d46f370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dedec735-1cff-4546-aac3-c4141f2f6fda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df134efd-b2f5-42e0-9b07-1a512098141d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df4709cb-5656-4808-aaeb-b3ae91bc5fa4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df4f1b43-9d3e-4a14-9590-f19507b86007"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_df8082d5-dcbb-46aa-82da-38d9db7a2979"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df9c0c3e-3b7d-4a88-ab6a-0a4e4f883405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e04b23c0-4934-4a7e-8859-cd38d15f9bd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1ad7b2e-47ad-4939-9a26-e2ea2a39b2c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1b0f380-3db6-410d-886f-3625779ce5c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e24022f1-53bf-42f3-8620-65afbf8aacaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ResearchAndDevelopmentSupportMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3289eef-c9f9-4a85-b3ce-87f3497ce8fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e593a339-fd70-42b1-8675-8d814fad602a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e63ec4f7-4b80-482a-8302-9464099a0226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonAndPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6682ffe-c7e9-4815-8a85-1e4bef9f2711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6747d6c-bd4c-45e0-a2d0-85a45a6f79e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2026-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6c84643-3ac1-485b-96c6-e0bf066aa3a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e6f36795-3f29-431e-b5be-67d9a5b96459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e78081be-df8b-41c7-9089-842b6fe1de71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7b60c9b-de37-4c35-8699-180e5b96d972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e82b4635-6ed4-4056-a68e-3a47f6f2bf52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e874e2c8-b06d-4058-bc9c-21db422ef0fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea6a953f-2b67-4ae3-af96-53ae33c766eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSeniorNotes2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb066d70-0444-4376-99ff-812e92abf2af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eba3e649-4d0f-4556-81f6-48a349c1b9b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eda262e4-057f-4998-b423-d9e9d577d4f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edb34f03-0687-4952-862d-bb3107aa1b2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edc82119-8135-4036-9cd5-7abc8eaec84c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edcdd009-7706-4509-a58c-1bface603eba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:AmendedZaiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edef9231-0188-4d5f-a4e7-cf5bc1070d0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ee82b043-3066-4252-90eb-266f31f3d243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef64ca1c-fe1e-4b9a-b5ff-0a15d056fed5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef7ae83f-f2f0-4dcb-9863-3d6a3a3a1d5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f09d870b-77a3-4a19-9ef4-c0fee32e4890"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0a0f488-206c-45bf-a6fd-b8fcfefad049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0b8d42e-b800-4698-921e-c7324bfbf8ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f112be36-1143-427f-b42f-2840c6a15d3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1250457-5420-4587-a034-747d2328f6e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2435011-c3ca-4e3e-a7fb-09a9fb137c33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f270105d-3047-4709-8eb8-f148d9149e12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f35060c4-ee1e-4ad2-ba59-f9405ab750db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginAbNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f39f8aa8-a20f-4ba5-a3cc-dabb232aa3b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3dedb00-89d6-46cf-b991-17d8708476a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3e35d02-64c1-4f38-892b-bd07f5fe2a4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3e8c321-fbbd-46fe-ad52-a5cf85e12e92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f41b7af1-e738-4a48-990d-dc1756c13b91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-10</xbrli:startDate><xbrli:endDate>2023-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f46cd1ad-fe1b-4bf9-a5a9-24eaba3fb3e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4ab2bfd-74a0-46cc-b06e-1c474c19a909"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4ddf483-cbed-4109-859d-418fd5e83000"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:BeaconMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-07</xbrli:startDate><xbrli:endDate>2025-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f4e52e0e-68f9-43ec-b6ac-caf887da2c67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f609d5f9-7bd6-42d0-b989-6627052c05d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6149710-30b2-49fb-9741-3ac89487f3da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6ee4728-a9e0-452b-8662-22a92283709d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f729f8a6-0459-456b-904e-a2336cd2e856"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7570aba-c10f-4b03-a0ca-5d70ea46865a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7d4ec88-c122-4840-9402-055ba9f5e83a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8268174-30fe-44ea-9afa-6854f75ab23e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ExternalServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f82e39f9-72f9-4bd5-b3fc-b3493d1d8807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8691cc5-0a6c-4194-a0e6-b3ab90155c90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9011696-e416-424e-81a2-652447e4d8f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9044951-f126-4cbd-81bd-331f45565190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f94f64d0-bc96-4573-be4f-370b739bbc44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f95dc6c1-8efa-49b3-a724-7a4ea46f1fbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginAbNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f96d3f3b-e048-40f2-a04c-39e52cb01dc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9ab7abf-030e-4411-a666-c1a654015dea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f9cd9435-3b1a-4e9d-ac1b-86dd50e61463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa0155b6-2f2e-4092-af25-363aa5a35539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa06863c-352c-41d4-8c55-7aa19e82ca77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa3ac63f-9ac1-406d-b258-7e778b64bfce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa5bcc25-8b49-450a-9892-dbd82bc86c2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fad3e9f3-1f85-4bfc-bf22-a300d00e3a74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-13</xbrli:startDate><xbrli:endDate>2024-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb40e1d0-39fb-4a52-b44c-a1ea5cf0b3b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fbf1519b-20bc-45f3-9a32-993d11ff1a9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc19a322-7a4a-4f36-9e91-32fa80c03ca7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fccd77c7-2dc9-4f27-8f85-1f5935f7a45a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSubordinatedNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fda3c94b-7cd8-431c-a448-eca3c92b1451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdb03ab5-f84c-4ddc-bd5f-542862b94835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fe69aeef-ca75-4945-996a-5e2bef7daf59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:FirstAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe80c249-d33c-4cd6-b2cb-331be1cd34ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fef5d651-506c-49a8-b89f-8a979f8b0712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff05dc94-b555-4348-9109-aa9b60fb068a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-27</xbrli:startDate><xbrli:endDate>2025-02-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff24ff88-61ab-4e42-8c4e-2eef4914adc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff2f5579-9b38-485b-a615-3c335d3187e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff591898-83ba-4b78-b062-c4cab6cf47a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff805685-7f62-44bb-b91d-537b589a7c39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ff91d1f1-1412-41c3-9883-093cc75f3130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_00b91c9f-9ab7-4b39-b007-fe9dae159be4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01846029-76af-4077-9228-68d2343d26d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_019d5edd-4fa8-40e3-80df-2efde6dc1a3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01c6be5d-cc54-49d6-8b11-353961389b35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02167381-4ee7-420f-9702-aa51b2304727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_034d4c49-cf20-473a-895d-63d5870c2084"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03780f91-4f1d-4cc3-9ff3-8ab31a4af745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_042d99c8-ff64-4441-b079-f3c23a00eb99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04a98a7e-c9c5-4c07-a755-8f30a3c84501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-02-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04b74a31-e5ca-4397-96ef-3eea91f0c2cf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04c59b2e-4232-4562-8d3a-6d189af3be61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_04f37986-0461-4c18-9d26-c9e485b3a1d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_057e1553-e322-46f8-92dc-4d5d487f40f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05ee92da-ae00-447e-a688-0afb8debabd7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_062943f2-bfca-4bcb-a912-8bfca3373967"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06e9c678-095e-4291-8f2b-762451638db9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07023259-2cd5-439e-8af3-725f79e6d197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0708cf2c-c327-4fd6-b98e-80fa56ca9fbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_077e2b7e-cd2f-4e0b-80c3-1c50fe7f09df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0865d3ef-f81c-4aa7-9435-994b376311c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_099aecd1-7b7a-4a20-9f80-16d10bb47ae5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_09b660d0-0222-42bb-8926-d6f07d1fabb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PrivatelyHeldHealthcareCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a0ea9ec-344f-4309-a3b8-19f6282767a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0a146130-5ab1-47b0-bf0f-7f7c0ba94af3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0aacff4b-e1cb-4189-b234-c765198bc587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0adbc8ec-6dbe-4222-bbd2-0e0eba4e778c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:BeaconMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0b8a3f4c-cf7e-42af-8db7-51c367053d7d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bd76c2e-9aae-4309-9bc2-e14f04493aff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c2b17b3-b563-4774-a444-c68ee381c769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaTRCHoldingsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0cd22ebb-1d13-4b31-83ad-8d641740a1a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ce3d616-f0eb-477a-96e3-62c320ccd76a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d289cc8-a708-4fdd-8986-e982ca8d731d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d761fab-b600-43bb-8587-3a27bbbece94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d77cda3-d1e7-4fcc-b01e-02245e7164be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-11</xbrli:startDate><xbrli:endDate>2025-08-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0df4c929-c558-43df-b2be-57f8e85bb27a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ea6bee8-0b7a-4347-b4e1-f57199a4e9f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f301d28-22f6-430f-bd52-f18b4ca91181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f3c27be-b222-4d28-80f0-06ce24daba5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1006311f-1cec-494d-8c58-386104bc8113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1087a715-1e7f-4e3f-96b3-efbc3f9782ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">inva:LyndraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10c7d0e1-daac-48c6-9186-bfc925a49e65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10e3877c-4d15-43d4-acb6-50c1c5281ab9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1178105a-9678-4a5d-807b-d01114fd7f0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_11d1f4e6-b778-4765-a18c-a66d5f46ca1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-12</xbrli:startDate><xbrli:endDate>2025-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_123df293-7632-4793-9257-bcb8b7a3e0d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SyndeoTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12c637ab-fa44-4ddd-a290-1d17a74cbbc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12cd7049-aa8a-4e80-8d0a-bdec0949c7f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12d3c44d-918f-48e8-85fa-931a2e84dfd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:DevelopmentRegulatoryAndRoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">inva:LyndraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_12d5315c-63c8-4bf3-b585-41fbafc8766c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_133b0bae-f820-43d4-8c70-d35ec0ec6a0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13e41928-9dbd-429d-b2f6-fb0ccfd61a94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13f8e3e6-05d2-4d76-8e06-db660bf31271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_147f547c-e68b-4615-a58e-a8401c3a3cb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:WalthamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_149ef97f-f1b9-4b0e-9127-348ee02e361e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesC2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-14</xbrli:startDate><xbrli:endDate>2023-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14b19da2-3f85-45b5-891e-2a495389f972"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_151edb34-8ed3-48db-aae7-373a462d2c87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_186b003f-7e82-489a-af51-10f17f0c7193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_19c66b49-0137-43c6-92ab-0b70a3008556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a3c43a6-afc9-4c65-b428-40d7849855d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:InterimSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b2e2593-a2a8-48e9-bddd-edbd0e4ece93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:TwoDirectorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b6e4f2c-7f64-4b60-808a-20645b1b5b3b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bf402f1-50ee-4c77-b54f-409f40ba6ea2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c0b66f1-46ef-4338-a79e-85c6fc2d1f95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c131411-afe9-4c15-b977-6fd724e284dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c30d3c2-8973-487f-b385-4efcc897f79b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d50a9ae-0f26-4ddd-b236-2070a1bd7766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1dcbb1f9-1291-4438-a7e7-46fd2cf48bf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSubordinatedNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e11bcae-e1f5-4912-8d5e-346484926bde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ef1ff30-e8ef-4d5c-b296-a140e0ecefb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_207224f1-5a67-4870-8fb6-e8fa25e508c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20899f10-0ff4-461b-801a-ba4175ab2431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_212cc57d-e685-4590-a4bd-6b3b410d36af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21888485-64fc-4d1a-9d3c-4e0fc17c7633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_218b6839-f930-461a-a25b-b72c22604510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_226618bc-59f6-409f-b441-d4d85c7c9b01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-02</xbrli:startDate><xbrli:endDate>2023-02-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22dbc318-90d0-4d6c-ae97-fa8f97e6f8e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_239a2a88-4dcf-4e6d-8f3b-5b1398ae730c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:WalthamMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23f06870-8557-49c9-961b-175324f1dcae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24ba47ce-629c-49d4-9f18-e4bf2ecc9008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:InterimSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24bf9896-d71a-45ca-9736-8cff19c13d9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24d3732a-a2a9-4442-b464-10be5d29362f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_257af86c-f735-4442-94a0-70da28449be7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SyndeoTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25dacf96-e93e-4daf-a92e-ed8eef93dd64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSubordinatedNotes2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_26dbc208-56e7-4883-9c81-a880c188cbbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ParatekPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2707906b-3b85-4cd4-95b1-7be4334def0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27624d2b-fd4c-438a-9721-62e1806ce67a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27718624-7715-45b9-a713-59141c2cdf0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27af781c-37f3-46f9-b219-825ba2161b60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27e7d8d1-9232-4c08-b557-38898257e2e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_280efd9d-8c7f-4e28-aa7a-2c064a232238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2840f754-c1e0-45a3-adde-c440dc45dc18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_29299cb7-d62e-4e08-9bd3-8a43b64d6f1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_298833d0-f7cb-4ad7-b8ba-9b8369ac087f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29938f9f-8929-463c-8242-1fd072e3246e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:InterimSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a02f41a-febe-490b-af61-93b34070abed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-12</xbrli:startDate><xbrli:endDate>2024-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a498a39-fd62-4604-9c70-6a29b2842bc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2026-02-10</xbrli:startDate><xbrli:endDate>2026-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2aaa98e6-3d27-48b0-aad0-9021ae880dff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2b3a7dbc-4a58-4808-a400-3b7b5bfb3e69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b4116ec-1fff-40fc-9ca2-09b0c69e59bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bdbcb89-e8cf-4578-a8fb-ed71c2c5c84c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c380213-e903-4976-8194-728662767074"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c8dee1f-3ed6-47e2-8225-b5df7bf62a8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d1f6be5-5863-4cef-a634-37c4e6881e96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2db96a8e-31d6-4b8d-831e-e5ed59bdbb06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e76908f-28df-4262-a9d3-0d9661155721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f40b780-c413-4e18-8a24-befa2c076cee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3144e120-55bf-4537-84b6-260e15c16e75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_31784cc3-872d-408e-80c1-6e43cba22130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31ec6e0a-cd1b-4e7a-af9c-54600d0d24cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-24</xbrli:startDate><xbrli:endDate>2021-11-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_320697d2-fba1-4b46-89cc-25782f7895a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_324ea22b-17bb-44c8-a2ce-76361d644371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_325eaf5e-1225-4fc5-8b0c-361313195292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:InternalExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32606254-e0d2-4b64-9791-54065180e259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_32dd02d8-2a15-4776-ae72-8afc37de465c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_330d6cb8-f79a-453a-8e56-a035cce53878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_338be7e3-2228-4533-9b23-3397a873d3d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33a0dd32-8b33-4cc0-a555-d73ff67cc33b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:Outstanding2028NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33e42f5b-3543-48dc-a026-c6016772a37c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3417b179-deaf-41ea-bd39-7e434b1db032"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ZEVTERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3429ea6d-1cb3-4c6e-8042-4861d0863d2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3495636e-7fc4-46b6-af0e-05bbaa199981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-08-01</xbrli:startDate><xbrli:endDate>2025-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_354e4e76-7396-4ce2-83c0-4f6d52adcbf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginAbNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35672b5e-10a9-4748-974c-cf69a518b68a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36784711-520b-456d-b873-8cb8b780364c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36cd9246-caa5-48b0-9537-3ae622ca29e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37077e55-6b0c-4d75-94c1-1392a17c7ed1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">inva:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_380b4395-2715-4251-a2b6-448e3fa77f25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_382677ef-0151-430b-8242-c000796ba331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_382fda11-b7da-4cb9-a380-3dfa11099b27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_392076d3-b2a9-4556-8800-6b9f6d3a290c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:BurlingameCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39ac42ec-d15a-4d4a-8811-92be23f2bc67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_39ce9270-cfd2-49c3-a23e-79c0108afb55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-11</xbrli:startDate><xbrli:endDate>2025-11-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3abf2681-e826-490a-9f8d-3f1f04055925"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3acd791d-ece0-41d0-bc86-551014479aa6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3ada3581-7aa9-4d91-ab9a-3ad5ffab6e1d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b0f0144-4aec-4d86-b2d3-8de8224c3e06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b12d761-39cf-4255-8780-b3b2751a6c1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">inva:LyndraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b886698-cb56-435a-ba7f-fa72f4cd20b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bff7c8d-4fd0-4e48-9974-ccd04b2d1f78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1AndD2PreferredStockAndCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c82e86c-b476-42ba-91a7-f0f73b075d88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d13bbf9-1c66-4a28-8180-8bf6ce3c7cf1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d42c24b-11b8-4363-8d74-c335ae153268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:NUZOLVENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3dffd990-dade-4459-b4ce-3100fb9fd1df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e7b3a72-d1b3-43e4-a867-2e38a049c660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3e958a1c-5aa6-4afc-bf9d-697d696cd0d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f151714-cd61-4ea6-ad22-1659ee2f8ad5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3fab1ccf-3d72-436d-a37b-efac6941b37d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_418a0dcc-491c-4849-aebf-ba4f6c3031b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41a7f5f8-871b-473c-8a7c-344fe2fe6e67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41adb887-7a52-48c3-afd3-50e8cb0adad6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:DevelopmentRegulatoryAndSalesMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_431e9250-fc85-45e0-9b9e-fac3bf029cec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4486e6d7-5936-40be-8a70-b6ae40d88127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44c21172-b919-4027-9bf1-950d87ebeb9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45a109c5-a8b5-4d0e-89f8-924a6b01af29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_45abe52e-ab8e-4973-995e-7e872a676421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_469092aa-cbc1-422f-9923-e5ef71f3d779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_469524bb-7a40-45d6-add1-6f69d2db9a3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">inva:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_471e4740-1ef6-4b64-a705-0ba2683dbdf6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47f20a31-1968-4d82-910b-3b3a4558e7f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_486828c2-55c2-4eca-a8e9-7c9edc91e774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_488c264e-0d44-4a7b-be6f-0dd0449e0750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4960e33b-4020-48cb-aad3-a6b5f4fac807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_49a08cdc-4904-4992-b261-91482376f0e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49e868c2-e9b1-41c3-8d56-b409dce02365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a06a460-8b26-42e1-8a9d-000242e512f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a9464c6-6ed0-4486-afcb-9d89092af626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ae30dd2-d091-4534-84e4-23090114dd52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b612ee6-394a-4ddd-9bcc-6ab2bb1b034d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b63e0ee-2b5b-49b5-91dd-4aad8b8b0682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesDWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4bf5fc18-5406-4a53-bdcc-a726e4be6261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4c9b62cc-926e-4197-953d-72eddcf7b41d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cbd448a-5be2-4867-9b30-17f58446ee15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4cc8caa7-35e9-4140-a986-58a3062ca160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">inva:MarketedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d8365a9-4d70-40de-b8a9-6b5b33f255fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d8ac49a-79f0-4d4e-96ea-3e8f524a2c51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4daceff5-03ad-4f3b-9aab-ba819d229412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4de9fb1e-acdc-4b5c-a627-40990c7b5d38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-11-01</xbrli:startDate><xbrli:endDate>2025-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4fb4788c-8450-4c40-8d91-a0ffb3b4ba73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-10</xbrli:startDate><xbrli:endDate>2023-01-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4fd4e6e2-8b75-4ad1-8522-73d454c9804c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5038c961-a52a-4d07-b20a-2ec350ef35a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51398c9e-10f3-4ea8-bf6f-402b631244a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_51b3b591-fbb0-4d6e-bbcc-a2b9316cdd48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaTRCHoldingsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonAndPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5269be09-0f8f-4632-b948-cb713105102a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaTRCHoldingsLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5328b425-8576-4d5b-b1db-1f14e4c9c1c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53386bc7-321c-4778-9d99-1014173440f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_535e864a-6312-4cf7-8e63-b685970f14e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_535f3e0c-ae46-4c2a-8349-1e7df0cae7a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54e7dc78-e88a-4740-abbe-66bd616fae5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_553bd178-313c-476a-ad6e-7c4ee1a08840"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:Outstanding2028NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_555d4978-0156-480e-84ba-fa2f5dcd4d7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5569e7b8-6eba-4eab-95a9-c63e219f2e99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_55bf4b19-2b2e-4acc-9932-1d7bd7182c58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_56003be5-dcb8-4576-a7f1-796756b2432a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-12</xbrli:startDate><xbrli:endDate>2024-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_56591878-41f9-499d-94f3-2f81c2c8216a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">inva:OptionPricingModelBacksolveValuationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_569306e7-f6a0-459f-8db9-5647b77e5c0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57143738-0b15-4679-be4b-a0bb824f5ceb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PrivatelyHeldHealthcareCompaniesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_577dc48e-2a7c-47ff-9812-6a80348a1bd8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_579c7936-813d-4e3d-9f7d-e6cfc757d33f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57a06a6f-d5cd-460f-9bf8-b3b9d0f6d3ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_57b6c234-c606-4323-ad48-c327ece76f82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58579f73-59ce-4061-ba55-4d11270a76d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5860c68c-4659-40da-819c-f9dc3f832bf9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5883bac0-e505-42e6-8df8-70275b1d4f0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a6dce6c-043b-44f3-bc89-efae60e40aff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a9347c1-884d-4675-bb79-fefe358e833d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5aa5d39a-f76b-4524-93e9-30d0fefb1a3c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b273474-f0c1-4173-8aa0-26b3ab51f2c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5df29ec0-a027-4d1e-9bcd-9baa6703c4dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e004e9c-f37b-4fd8-92e2-d31164aba4bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-03</xbrli:startDate><xbrli:endDate>2025-03-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e4ede51-f604-4176-b6c8-a3365d117e9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SyndeoTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5ec47d1f-c03d-4375-b74a-6537aa407098"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f25c1f8-433a-423e-bc21-4d71d0ad9d56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f2ad567-e08d-4636-8f55-1c301878579d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f44da0a-72da-4d0d-94ce-34a247a0ea76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f76e50f-7b05-4925-b65f-40d08587b5e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60ac9e5c-2514-4f92-bf1c-12266b1917e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_60c399b5-9347-43a0-b627-5c8557009839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:ManufacturingStageTransferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61fa56d2-4262-4f72-ae36-ba8d54b9623c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_624b9c2f-920f-4d24-9aec-1525f5843027"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62615169-458a-41ad-b0f4-aecf5d54890a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_627f6c4a-256d-48b2-9ebe-195f372836f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63c51235-4b1c-4afb-8d74-575ce49ff152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_64469642-d4d1-4b61-893c-cc3938dfe822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_647c691b-abd8-4afb-8bcb-ba9c9d68ba72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65d91678-0767-41c7-b95e-8b5037c60129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65e0e8e3-95a0-4c30-a38e-3f2f6d7a9494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65e207cc-7ebd-4bcd-bb6b-e27d80d3a005"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66187a73-ceaf-4466-bbd1-1b86eb8fc0ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_661f58ec-6b2b-444d-8088-4abba363c175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66b32c2c-80ce-44d4-8bd3-c90a4562ba4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GeorgeWashingtonUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_675639ab-20e9-408c-8ece-4bd0da8c908c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67ee3158-4444-4bb2-b548-1b1d24bb1077"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_689c9adb-8230-4574-87c7-dc46032a5878"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6975b245-2632-4293-87d4-04681539a20a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-01</xbrli:startDate><xbrli:endDate>2025-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_699a8187-6daf-4c19-b630-e6a4a350936f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_699b00df-194d-4b74-87b8-434384a664eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ab3cefd-f2b3-40bc-8f3e-a411da14524e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ad32d18-a6d7-4bbe-9f9f-6e1ebf92e327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b2a5a0e-88cb-4767-81b9-afb899aec69b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-05</xbrli:startDate><xbrli:endDate>2024-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6cf653d2-0adb-45e8-8c5c-d69aedde6497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">inva:OptionPricingModelBacksolveValuationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d3c556c-fb3c-4b80-9075-4471ffd20f1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6e51128a-27f4-498a-bddc-0169559f0163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6eab99bf-0d7f-4d97-8fbf-07f56573bf4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f8efa75-54a0-48d2-91ec-df3a956405f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_701cd6fe-36d1-47db-83fe-0af44777997c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70f1d216-d03c-43ba-a8b1-76808b9d2366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71ded7c0-3708-4f52-b6c3-6791c394800f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_71f99e54-19e3-4788-8727-45db0240d021"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_725e5a87-52ac-4ac2-b62f-1bd660bfb6b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_726df857-6023-4423-a3a4-cf7d258b67aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:BeaconMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_734a0615-eb7b-4e06-bf8d-3b288821b245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CostReimbursementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7359dc8f-bf3a-4063-889d-7a710c70a4de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7375bdeb-c66c-40d4-84b1-149ba7c7ef18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_752dd2b0-0df3-4258-a0cf-06ce4b3c92b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:LexingtonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75c1d9ea-1aaf-4126-af63-8748312d93ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75cd5b3a-0884-4009-a949-d0f1c664d036"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GeorgeWashingtonUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_768acc31-d49a-4b35-b48a-e542af02b049"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesC2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-14</xbrli:startDate><xbrli:endDate>2023-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_769493ad-88b4-4914-8b59-414f7ab2d4da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76beba6f-76b3-4d02-8823-4ee147f6a8e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76c325ef-f27e-4ba8-812a-698b1f542dd3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_772c1d45-e01c-4ce3-82b8-60c2d33c65c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7750e87c-0533-4d37-95fe-b10ee03f2aa0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77ce6bd4-4c92-464e-b740-78890313ec04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_77e3e771-6d57-4a46-9631-a87f355431a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79652bcd-01ee-4bef-9367-fe4171e3c756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a37ea45-0a90-4314-9d33-c1291075e4f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a5124fd-be46-415a-bd57-ce5d37c15986"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7a708fd2-25d5-452c-aad6-d6903d0cf646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EquityIncentivePlan2012Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b057564-e9a8-48fe-95f4-7b1c776ce39d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ba50ae3-7184-4972-bf26-f59e81848d23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCAndC2PreferredStockAndCommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7c5e8ad9-8a6d-4d11-ab0d-a7fdde037e56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d17d6ba-9603-4070-a7ab-088eeb43a446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d786c4d-9bc2-4c05-9835-fe6f2d5d9c1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d8daa92-8559-4d7e-9e07-c21e30f977fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e124fea-d3ce-4c96-a71c-c223da3547f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7e31beca-2974-46b0-a791-da8703f2803a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7f44cb79-0c20-42d0-9a50-561aefbd0d23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fba1762-844e-4c04-b43c-b15c482e2679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fd95b23-44ee-494d-bdcf-53246745fc95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001080014</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSeniorNotes2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_Director"><xbrli:measure>inva:Director</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Item"><xbrli:measure>inva:Item</xbrli:measure></xbrli:unit><xbrli:unit id="U_Customer"><xbrli:measure>inva:Customer</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_BoardMember"><xbrli:measure>inva:BoardMember</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_Installment"><xbrli:measure>inva:Installment</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_fa630cd9-d3b9-4ce5-bce3-2719848ceec9" fromRefs="F_9fb85da1-cbc3-41d4-a51d-07fc5150ec6c F_b8527f5f-0ade-4a50-82cb-a323f0a7eeff F_b904a8ef-a45a-4492-8701-2393c7419d8d F_9118e54a-a9f9-49ab-b4bd-5e6b51bfb0c2"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_30a29ac4-a358-403f-922e-b22439018a34" fromRefs="F_7e0f8737-3df8-4207-9d21-7b3dde1346c3 F_c1a4bfda-d5e2-4288-afe3-91da9698ed2f F_fe172cbb-06cd-4ace-980b-f77c69728f3c F_e7e2aa43-24df-4446-a31c-e9588f387342"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_c6ef9b64-150e-40fe-8567-e348fc66452f" fromRefs="F_caa0e40b-6bde-47a3-9868-50a819fdb087 F_7107755a-0b4b-4d35-b156-55487a5c74e5"/><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_36a39a6f-dfa4-4a07-a213-6e12c7dcf21d" fromRefs="F_9109e66c-349f-4b2b-9c9b-cdbaabe2fdff F_517fc5ee-af94-4656-b409-1fd12f23ccf1"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:3pt solid;padding-top:1pt;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc67307e-4d30-4970-8f0d-e09c2c17e6a3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:13.42%;box-sizing:content-box;"/>
     <td style="width:86.58%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Mark One)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_3ab6ec7f-ae3d-49da-a26d-0e2f401e8966" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:DocumentAnnualReport" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="2" style="padding-top:0in;text-indent:10.1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.902%;padding-left:1.867%;font-size:8pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the fiscal year ended </span><span><ix:nonNumeric id="F_4de429b5-efa3-4f5c-a253-1474f898d575" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span><ix:nonNumeric id="F_ab492e06-9ff9-417d-9ed2-9de90ff52543" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_b8c3ac37-1dff-442b-b2d2-cc894b775f93" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="2" style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="2" style="padding-top:0in;text-indent:10.1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.902%;padding-left:1.867%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">or</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_a06ec575-fc8f-46d2-aa64-5cdc831c4f68" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="2" style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">For the transition period from              to</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:3.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File No. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30dbaee1-272b-4bbd-a7e6-12950a4427b3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">000-30319</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3b3722f2-054e-430b-bac9-520fb5732a26" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"/>
     <td style="width:50%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:25.2pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10.1pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.902%;padding-left:1.867%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8d12146a-9267-4113-bb83-9692b1b241b3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Delaware</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(State or other jurisdiction of<br/>incorporation or organization)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1d2360e0-deee-4c8b-8677-9ebd1d77c778" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94-3265960</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(I.R.S. Employer<br/>Identification No.)</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2c74ebdd-835b-4f51-aecb-37342ce88810" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1350 Old Bayshore Highway, Suite 400</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/></span><span><ix:nonNumeric id="F_50a69bc0-7169-472d-a726-502e0826f71b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Burlingame</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_76bb179f-8df7-4c20-b5d8-20ca83308745" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> <br/></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2486dafd-9950-471d-86ad-db4f0bd94c51" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">94010</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/>(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6482f74-99c6-400c-b18a-73a0116e44db" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">650</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a792e13-3bb8-46a5-8783-0d349d8edeba" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">238-9600</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34.167%;box-sizing:content-box;"/>
     <td style="width:1.66%;box-sizing:content-box;"/>
     <td style="width:25.345%;box-sizing:content-box;"/>
     <td style="width:1.48%;box-sizing:content-box;"/>
     <td style="width:37.347%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title of Each Class</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">    </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Trading Symbol(s)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">    </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name of Each Exchange On Which Registered</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_84b77f46-7c0f-485d-a90c-ae93521e9dbe" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common Stock $0.01 Par Value</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:8pt;"><ix:nonNumeric id="F_f41dd007-30b0-478c-8a94-c4ca552bdf3a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INVA</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">The </span><span style="font-size:8pt;"><ix:nonNumeric id="F_4474cf7a-459d-4f29-80aa-b79fd8cce3da" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">&#160;Stock Market LLC</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT: </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NONE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is a well&#8209;known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a50ffbb7-b411-44af-a290-df0925ac9610" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityWellKnownSeasonedIssuer"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;   No &#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;   </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2d53ea1-7a2d-4155-a5c9-7091236dbebe" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityVoluntaryFilers"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8bd089f-a4b8-41d0-8e40-58bea473f48f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityCurrentReportingStatus"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;   No &#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe4b95fa-bfad-4af9-a2ae-0dccb174ee50" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityInteractiveDataCurrent"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#9746;  No &#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether registrant is a large accelerated filer, an accelerated filer or a non-accelerated filer. See definition of &#8220;accelerated filer and large accelerated filer&#8221; in Rule 12b-2 of the Exchange Act (Check One):</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:31.246%;box-sizing:content-box;"/>
     <td style="width:17.944%;box-sizing:content-box;"/>
     <td style="width:27.586%;box-sizing:content-box;"/>
     <td style="width:23.225%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:0.7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10.1pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.902%;padding-left:1.867%;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:3pt;text-align:left;"><span style="font-size:8pt;"><ix:nonNumeric id="F_58499c67-be7d-4212-9331-e1d622e776a6" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Large accelerated filer</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">&#160;&#9746;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accelerated filer &#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non&#8209;accelerated filer &#9744;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Smaller reporting company </span><span style="font-size:8pt;"><ix:nonNumeric id="F_97f21cc6-fa5c-488f-a3aa-b51a644d4eb1" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10.1pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.902%;padding-left:1.867%;font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;">Emerging growth company </span><span style="font-size:8pt;"><ix:nonNumeric id="F_d1a67592-4272-4881-8a4f-8033b4fcc28b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85ee244b-744c-4766-8ef2-56fc38d31823" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce9a96d8-2334-4e7a-991f-c502dc490a1c" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b&#8209;2 of the Exchange Act). Yes &#9744;   No </span><span style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a907693b-aec4-4a3a-90b2-ca9fcbe95673" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:EntityShellCompany" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant based upon the closing price of the registrant&#8217;s Common Stock on The Nasdaq Global Select Market on June 30, 2025 was </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b8e835b-df1a-45b5-b8cf-d0ee4e2ba250" contextRef="C_0d761fab-b600-43bb-8587-3a27bbbece94" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-7" format="ixt:num-dot-decimal">1.26</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This calculation does not reflect a determination that persons are affiliates for any other purpose.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2026, there we</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">re </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a88f43dd-4d5c-4326-ac8b-002a1c35245f" contextRef="C_04a98a7e-c9c5-4c07-a755-8f30a3c84501" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">74,073,646</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of the registrant&#8217;s Common Stock outstanding.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:8pt;font-family:Times New Roman;"><ix:nonNumeric id="F_894bfa2d-53b1-42c6-bca9-569975fe8b94" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specified portions of the registrant&#8217;s definitive Proxy Statement to be issued in conjunction with the registrant&#8217;s 2026 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant&#8217;s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="border-top:0.5pt solid;padding-top:1pt;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:3pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025 Form 10&#8209;K Annual Report</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="toc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:88%;box-sizing:content-box;"/>
     <td style="width:5%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART I</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1_business"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Business</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1A.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Risk Factors</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1B.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 1C.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_1c_cybersecurity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cybersecurity</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 2.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_2_properties"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Properties</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">78</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 3.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_3_legal_proceedings"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 4.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART II</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 5.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_5_market_for_registrant_s_common"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 6.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_6_selected_financial_data"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">[Reserved]</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">82</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7_management_s_discussion_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 7A.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 8.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_8_financial_statements_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9_changes_in_and_disagreements_with"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9A.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Controls and Procedures</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">145</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9B.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9b_other_information"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Other Information</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 9C.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_9c_disclosure_regarding_foreign_jur"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">147</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART III</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 10.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_10_directors_executive_officers_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 11.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_11_executive_compensation"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Executive Compensation</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 12.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 13.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_13_certain_relationships_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 14.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_14_principal_accounting_fees_and"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Principal Accountant Fees and Services</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PART IV</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 15.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_15_exhibits_and_financial_statement"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits and Financial Statement Schedules</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">149</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Item 16.</span></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#item_16_form_10_k_summary"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form 10&#8209;K Summary</span></a></p></td>
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">149</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#exhibits"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Exhibits</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="2" style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#signatures"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Signatures</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="special_note_regarding_forward_looking"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Note Regarding Forward&#8209;Looking Statements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">This Annual Report on Form 10&#8209;K contains forward&#8209;looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Securities Act&#8221;). Such forward&#8209;looking statements involve substantial risks, uncertainties and assumptions. All statements in this Annual Report on Form 10&#8209;K, other than statements of historical fact, including, without limitation, statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, intentions, expectations, goals and objectives may be forward&#8209;looking statements. The words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;could,&#8221; &#8220;designed,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;goal,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plans,&#8221; &#8220;projects,&#8221; &#8220;pursuing,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions (including the negatives thereof) are intended to identify forward&#8209;looking statements, although not all forward&#8209;looking statements contain these identifying words. We may not actually achieve the plans, intentions, expectations or objectives disclosed in our forward&#8209;looking statements and the assumptions underlying our forward&#8209;looking statements may prove incorrect. Therefore, you should not place undue reliance on our forward&#8209;looking statements. Actual results or events could differ materially from the plans, intentions, expectations and objectives disclosed in the forward&#8209;looking statements that we make. All written and verbal forward&#8209;looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Important factors that we believe could cause actual results or events to differ materially from our forward&#8209;looking statements include, but are not limited to, risks related to: lower than expected future royalty revenue from respiratory products partnered with GSK, the commercialization of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> and NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in the jurisdictions in which these products have been approved; the strategies, plans and objectives of the Company (including the Company&#8217;s growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company&#8217;s growth strategy and risks discussed in &#8220;Risk Factors&#8221; in Item 1A of Part I, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Item 7 of Part II and elsewhere in this Annual Report on Form 10&#8209;K. Our forward&#8209;looking statements in this Annual Report on Form 10&#8209;K are based on current expectations as of the date hereof and we do not assume any obligation to update any forward&#8209;looking statements on account of new information, future events or otherwise, except as required by law.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We encourage you to read Management&#8217;s Discussion and Analysis of our Financial Condition and Results of Operations and our consolidated financial statements contained in this Annual Report on Form 10&#8209;K. We also encourage you to read Item 1A of Part I of this Annual Report on Form 10&#8209;K, entitled &#8220;Risk Factors,&#8221; which contains a more complete discussion of the risks and uncertainties associated with our business. In addition to the risks described above and in Item 1A of this report, other unknown or unpredictable factors also could affect our results. Therefore, the information in this report should be read together with other reports and documents that we file with the Securities and Exchange Commission (&#8220;SEC&#8221;) from time to time, including on Form 10&#8209;Q and Form 8&#8209;K, which may supplement, modify, supersede or update those risk factors. As a result of these factors, we cannot assure you that the forward&#8209;looking statements in this report will prove to be accurate. Furthermore, if our forward&#8209;looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward&#8209;looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="part_i"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART I</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_1_business"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1.   BUSINESS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Innoviva, Inc. (&#8220;Innoviva&#8221;, the &#8220;Company&#8221;, the &#8220;Registrant&#8221; or &#8220;we&#8221; and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (&#8220;IST&#8221;), and a portfolio of strategic healthcare assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (umeclidinium bromide/vilanterol, &#8220;UMEC/VI&#8221;). Under the Long-Acting Beta-2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which tier upward at a range from 6.5% to 10%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our wholly owned, robust critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, commercially launched in 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(eravacycline) for the treatment of complicated intra-abdominal infections in adults;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">staphylococcus aureus bacteremia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including those with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia, licensed from Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) (&#8220;Basilea&#8221;) for U.S. commercialization and commercially launched in the third quarter of 2025; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (formerly known as zoliflodacin), approved by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we own other strategic healthcare assets, such as a significant stake in Armata Pharmaceuticals, Inc., a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies through our portfolio approach.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our disciplined focus on deploying capital in areas of significant unmet medical need with high value creation potential has driven a meaningful transformation of our company over the years from a pure-play royalty business to a diversified biopharmaceutical company with a strong, fast-growing, differentiated operating platform and multiple other assets with significant promise. We believe we are well-positioned to deliver significant long-term shareholder value.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our headquarters are located at 1350 Old Bayshore Highway, Suite 400, Burlingame, CA 94010. The Company was incorporated in Delaware in November 1996 and commenced operations in May 1997 under Advanced Medicine, Inc. The Company changed its name to Theravance, Inc. in April 2002 and to Innoviva, Inc. in January 2016.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategy</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our corporate strategy is currently focused on increasing shareholder value by, among other things, maximizing the potential value of our respiratory assets partnered with GSK, growing our critical care and infectious disease platform, efficiently allocating capital, and optimizing our operations. We continue to diversify our royalty management business by actively pursuing opportunistic investments in, and acquisitions of, promising assets in the healthcare industry to enhance the returns on our capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Royalty Product Portfolio</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Relationship with GSK</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LABA Collaboration</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2002, we entered into our LABA Collaboration Agreement with GSK to develop and commercialize once&#8209;daily products for the treatment of chronic obstructive pulmonary disease (&#8220;COPD&#8221;) and asthma. The collaboration has developed three combination products, two of which we still retain rights in. Those two are as follows:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;FF/VI&#8221;) (BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the proprietary name in the U.S. and Canada and RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the proprietary name outside the U.S. and Canada), a once-daily combination medicine consisting of a LABA, vilanterol (&#8220;VI&#8221;), and an inhaled corticosteroid (&#8220;ICS&#8221;), fluticasone furoate (&#8220;FF&#8221;), and,</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;UMEC/VI&#8221;), a once-daily medicine combining a long-acting muscarinic antagonist (&#8220;LAMA&#8221;), umeclidinium bromide (&#8220;UMEC&#8221;), with a LABA, VI.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S., Japan and Europe, in accordance with the LABA Collaboration Agreement, we paid milestone fees to GSK totaling $220.0 million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We anticipate that RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (FF/VI) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (UMEC/VI) will compete with a number of approved bronchodilator drugs alone or in combination, including each other and drug candidates under development that are designed to treat asthma and COPD. These include but are not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/Seretide&#153; Diskus</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/HFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (salmeterol and fluticasone propionate as a combination) marketed by GSK</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Symbicort</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (formoterol and budesonide as a combination) marketed by AstraZeneca</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AirDuo Respiclick</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (salmeterol and fluticasone propionate), a non-substitutable generic version of Advair, marketed by TEVA</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Spiriva</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Handihaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and Spiriva</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Respimat</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (tiotropium) marketed by Boehringer Ingelheim</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dulera</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (formoterol and mometasone as a combination) marketed by Merck</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tudorza</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pressair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (aclidinium) marketed by AstraZeneca and Seebri</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Breezehaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (glycopyrronium) marketed by Novartis outside the U.S. and Sunovion in the U.S.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Incruse</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Ellipta</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (umeclidinium) and Arnuity</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Ellipta</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (fluticasone furoate) (Innoviva is not entitled to any royalties from either product)</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foradil</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Aerolizer</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/Oxis</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Turbuhaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (formoterol) marketed by a number of companies</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Striverdi</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Respimat</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (olodaterol) marketed by Boehringer Ingelheim</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Onbrez</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Breezehaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (E.U.)/Arcapta</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Neohaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (U.S.) (indacaterol) marketed by Novartis</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ultibro</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Breezehaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (E.U.)/Utibron</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Neohaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (U.S.) (indacaterol combined with glycopyrronium bromide) developed by Novartis and approved and launched in Europe and Japan in the year ended December 31, 2013 as a once-daily treatment for COPD. In the U.S., the product was approved in October 2015 at a lower strength as a twice-daily COPD treatment, and was licensed to Sunovion in December 2016, and launched in May 2017</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stiolto (U.S.)/Spiolto (E.U.) Respimat</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (tiotropium combined with olodaterol) marketed by Boehringer Ingelheim for the treatment of COPD</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Bevespi Aerosphere</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (glycopyrronium bromide in combination with formoterol fumarate) marketed by AstraZeneca</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Duaklir</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Genuair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (aclidinium bromide in combination with formoterol fumarate) developed by AstraZeneca as a maintenance bronchodilator treatment for COPD and approved in November 2014 in the EU and March 2019 in the U.S.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Atectura</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Breezhaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (indacaterol in combination with mometasone) marketed by Novartis</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trimbow</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (a fixed-dose, twice daily combination of formoterol, beclomethasone and glycopyrronium) manufactured by Chiesi and indicated for use in COPD in the E.U.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Foster (beclomethasone dipropionate in combination with formoterol fumarate) manufactured by Chiesi and indicated for use in asthma and COPD outside the U.S.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Enerzair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Breezehaler</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (a fixed-dose combination of indacaterol, mometasone and glycopyrronium) developed by Novartis as a triple therapy/single inhaler for the treatment of asthma and approved in the E.U., Canada, and Japan</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Breztri</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Aerosphere</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (fixed dose combination of formoterol, glycopyrronium and budesonide) developed by AstraZeneca as a triple therapy single inhaler twice-daily medication for COPD and approved in the U.S. in July 2020</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Nucala</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (mepolizumab; an interleukin-5 antagonist monoclonal antibody) developed by GSK for add on maintenance treatment of severe asthma in patients 12 years and older and approved in the U.S. in June 2019</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Xolair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (omalizumab, an anti-IgE antibody) developed by Genentech for patients 6 years of age and older with moderate to severe persistent asthma uncontrolled by inhaled corticosteroids and approved in 2003. Single-dose pre-filled syringes were approved by the FDA in September 2018</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cinqair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (anti-interleukin-5 monoclonal antibody for the add-on maintenance treatment of adults with severe asthma and an eosinophilic phenotype) marketed by TEVA Pharmaceutical Industries Ltd.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dupixent</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (dupilamab, an injectable IL-4 and IL-13 inhibitor) developed by Sanofi Genzyme and approved by the FDA in October 2018 as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fasenra</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (benralizumab, an injectable anti-IL-5 monoclonal antibody) for the treatment of severe asthma in patients 12 years of age and older marketed by AstraZeneca. Fasenra Pen pre-filled auto-injector was approved by the FDA for self-administration in November 2019</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Singulair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (monteleukast), an orally active leukotriene receptor antagonist for the prophylaxis and treatment of asthma in patients 12 months of age and older marketed by Merck</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tezspire</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (tezepelumab-ekko), an injectable monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), an epithelial cytokine thought to be critical in the initiation and persistence of airway inflammation. Co-developed by Astra Zeneca and Amgen for the treatment of severe asthma. The FDA approved the Tezspire solution for subcutaneous injection in December 2021; it is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma </span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ohtuvayre</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ensifentrine), an inhaled dual phosphodiesterase inhibitor indicated for the miantenace treatment of COPD in adults with moderate-to-severe symptoms.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, several firms have developed and launched new formulations of Advair/Seretide (salmeterol /fluticasone propionate) and Symbicort (formoterol fumerate/budesonide) which may be marketed as generics or branded generics relative to the existing products from GSK and AstraZeneca, respectively. All of these efforts represent potential competition for any of our partnered products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In general, these manufacturers are required to conduct a number of clinical efficacy, pharmacokinetic and device studies to demonstrate equivalence to branded products already approved by the FDA. These studies are designed to demonstrate that the generic product has the same active ingredient(s), dosage form, strength, exposure and clinical efficacy as the branded product. These generic equivalents, which must meet the same exacting quality standards as branded products, may be significantly less costly to bring to market, and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product and products that may compete with such branded product is typically lost to the generic product. In April 2016, the FDA issued a draft guidance document covering Fluticasone Furoate/Vilanterole Trinenatate (FF/VI), the active ingredients used in RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In March 2020, the FDA issued a draft guidance on Umeclidinium Bromide/Vilanterol Trifenatate (UMEC/VI), the active ingredients used in ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Integrated Critical Care / Infectious Disease Assets</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commercial and Marketed Products</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our critical care and infectious disease portfolio was formed through the 2022 acquisitions of Entasis Therapeutics and La Jolla Pharmaceutical, and we have continued to grow it through our license agreement with Basilea. The portfolio comprises five differentiated commercial stage products. The following table summarizes our marketed products:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:22.26%;box-sizing:content-box;"/>
     <td style="width:26.22%;box-sizing:content-box;"/>
     <td style="width:27.08%;box-sizing:content-box;"/>
     <td style="width:24.44%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#000066;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Product</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Indication</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Pivotal Studies </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Regulatory Status</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-indent:5pt;border-left:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(angiotensin II)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Septic or other distributive shock</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">321-patient, multinational, double-blind, randomized, placebo-controlled study</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FDA approval Dec 2017<br/>European Commission approval Aug 2019<br/>UK authorization (post-Brexit) Jan 2021</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-indent:5pt;border-left:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(sulbactam for injection; durlobactam for injection), co-packaged for intravenous use</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">HABP/VABP caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(6)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">177-patient, active-controlled, investigator-unblinded, independent assessor-blinded, non-inferiority, phase 3 trial</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FDA approval May 2023<br/>China approval May 2024</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-indent:5pt;border-left:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(eravacycline)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Complicated intra-abdominal infections</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(3, 4, 5)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">446-patient, multi-national, double-blind, randomized, active-controlled study<br/><br/>400-patient, multi-national, double-blind, randomized, active-controlled study</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FDA approval Aug 2018<br/>European Commission approval Sep 2018<br/>Singapore approval Apr 2020<br/>UK authorization (post-Brexit) Jan 2021<br/>China approval Mar 2022<br/>Hong Kong approval Aug 2022<br/>Taiwan approval Sept 2023</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-indent:5pt;border-left:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(ceftobiprole)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Staphylococcus aureus</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;bloodstream infection, acute bacterial skin and skin structure infections, community-acquired pneumonia</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(8, 9)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">390-patient randomized, controlled, double-blind, multinational, multicenter trial<br/>679-patient randomized, controlled, double-blind, multinational, multicenter trial<br/>638-patient randomized, controlled, double-blind, multinational, multicenter study</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FDA approval April 2024</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;text-indent:5pt;border-left:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">NUZOLVENCE</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;(zoliflodacin)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Uncomplicated urogenital gonorrhea due to </span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Neisseria gonorrhoeae</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">(7)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">930-patient randomized, controlled, open-label, multinational, non-inferiority phase 3 trial</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;text-indent:5pt;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="margin-left:0.92%;text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">FDA approval Dec 2025</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For U.S. and European approval.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S.: GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">European Union: GIAPREZA is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S.: XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (&#8220;cIAI&#8221;) in patients 18 years of age and older.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(5)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">European Union: XERAVA is indicated for the treatment of cIAI in adults.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(6)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S.: XACDURO is a co-packaged product containing sulbactam, a beta-lactam antibacterial and beta lactamase inhibitor, and durlobactam, a beta lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> baumannii-calcoaceticus complex.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(7)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S.: NUZOLVENCE is a spiropyrimidinetrione bacterial type II topoisomerase inhibitor indicated for the treatment of uncomplicated urogenital gonorrhea due to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Neisseria gonorrhoeae </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in adults and pediatric patients 12 years of age and older, weighing at least 35 kg.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(8)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">U.S.: ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis, adult patients with acute bacterial skin and skin structure infections (ABSSSI), and adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP).</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(9)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">European Union: ZEVTERA is a cephalosporin antibacterial indicated for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP) in patients 18 years of age and older.</span></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (angiotensin II)</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (angiotensin II) injection is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is approved by the European Commission (&#8220;EC&#8221;) and by the Great Britain Medicines and Health Care Products Regulatory Agency (&#8220;MHRA&#8221;) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mimics the body&#8217;s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system (&#8220;RAAS&#8221;), which in turn regulates blood pressure. GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is marketed in the U.S. by La Jolla and is marketed in Europe and Great Britain by PAION Deutschland GmbH, a subsidiary of the Humanwell Healthcare Group, on behalf of La Jolla.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Angiotensin II for the Treatment of High-Output Shock (&#8220;ATHOS-3&#8221;)</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was approved by the U.S. FDA, EC and MHRA based on the results of ATHOS-3, which were published in the New England Journal of Medicine in August 2017. ATHOS-3 was a multinational, randomized, double-blind, placebo-controlled study in which 321 adults with septic or other distributive shock who remained hypotensive despite fluid and vasopressor therapy received either GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or placebo, both in addition to background vasopressor therapy. The primary endpoint was mean arterial pressure (&#8220;MAP&#8221;) response, defined as a MAP of 75 mm Hg or higher or an increase in MAP from baseline of at least 10 mm Hg without an increase in the dose of background vasopressors at Hour 3 (Khanna et al, New England Journal of Medicine 2017; 377:419&#8211;430).</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATHOS-3 Study Design</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_0.jpg" alt="img75897552_0.jpg" style="width:632px;height:261px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MAP=mean arterial pressure</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Khanna et al, New England Journal of Medicine 2017; 377:419&#8211;430</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Standard-of-care vasopressors included norepinephrine, epinephrine, dopamine and vasopressin</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> significantly improved blood pressure response. Specifically, the primary endpoint was achieved by 70% of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-treated patients compared to 23% of placebo-treated patients (p &lt;0.0001).</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATHOS-3 Primary Endpoint Results</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_1.gif" alt="img75897552_1.gif" style="width:309px;height:236px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MAP response of 75 mm Hg or higher or an increase from baseline of at least 10 mm Hg at Hour 3 without an increase in the dose of background vasopressors</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> provides the ability to rapidly achieve and adjust therapeutic response. GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rapidly increased MAP with a median time to MAP response of approximately 5 minutes. The plasma half-life of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is less than 1 minute.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, a positive survival trend was observed. Mortality through Day 28 was 46% on GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 54% on placebo (hazard ratio 0.78; 95% confidence interval 0.57&#8211;1.07).</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Positive Survival Trend Observed (N=321)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1),(2)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_2.jpg" alt="img75897552_2.jpg" style="width:530px;height:304px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Khanna et al, New England Journal of Medicine 2017; 377:419&#8211;430</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patients were treated with either GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or placebo, both in addition to background vasopressor therapy</span></div></div><p style="margin-left:4.267%;text-indent:3.482%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The most common adverse reactions that were reported in greater than 10% of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-treated patients were thromboembolic events.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adverse Reactions Occurring in &#8805;4% of Patients Treated with GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and &#8805;1.5% More Often than in Placebo-treated Patients</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_3.jpg" alt="img75897552_3.jpg" style="width:515px;height:227px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Including arterial and venous thrombotic events</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:3.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use (formerly known as sulbactam-durlobactam or SUL-DUR), was approved by the FDA on May 23, 2023, and we commenced U.S. commercial sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the third quarter of 2023. In May 2024, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was approved in China by the National Medical Products Administration (NMPA) for use in Chinese patients 18 years of age and older. XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a novel IV antibiotic. The product is a combination of sulbactam, a &#946;-lactam antibiotic, and durlobactam, a novel &#946;-lactamase inhibitor (&#8220;BLI&#8221;) with broad spectrum &#946;-lactamase coverage including Classes A, C and D, that was specifically developed for the treatment of a variety of serious infections caused by carbapenem-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In July 2024, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was named as the preferred agent for the treatment of Carbapenem-resistant Acinetobacter baumannii infections, in combination with a carbapenem, in the updated 2024 IDSA treatment guidance.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a Gram-negative, opportunistic human pathogen that predominantly infects critically ill patients often resulting in severe pneumonia and bloodstream infections but also capable of infecting other body sites as well. Once thought to be mostly benign, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is now considered a global threat in the healthcare setting due in part to its ability to acquire multidrug resistance at rates not previously seen in other bacteria. In addition, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> can remain viable for up to 100 days in dry conditions and easily spreads via air or water droplets, which explains why the pathogen can often be found in many locations in the intensive care unit, or ICU, including bedrails, bedside tables, monitors of mechanical ventilators, intravenous pumps, door handles, stethoscopes and many other locations. Of significant concern, one study reported greater than 98% of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> isolates in an ICU from non-clinical sources, such as bedrails and door handles, were determined to be multidrug resistant.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pneumonia and bloodstream infections caused by drug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> can have mortality rates up to 50%. Antibiotic resistance rates of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to current standard-of-care treatments are some of the highest reported, between 30% and 50% in the United States and greater than 90% in parts of Europe and Asia. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> resistance to &#946;-lactams is primarily driven by the expression of Class&#8239;D &#946;-lactamases, often in combination with Class&#8239;A and/or Class&#8239;C &#946;-lactamases. There are currently no effective antibiotics specifically indicated for the treatment of multidrug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> infections. Durlobactam is the first clinical-stage BLI with sufficient broad-spectrum activity against class A, C, and D &#946;-lactamases to potentially restore the efficacy of &#946;-lactam antibiotics against multidrug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sulbactam, the &#946;-lactam antibiotic used in XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has superior microbiological potency against </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> compared to other &#946;-lactam antibiotics based on </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vitro</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> analyses. Historically, physicians used sulbactam to successfully treat </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> infections before development of broad &#946;-lactamase mediated resistance rendered sulbactam on its own largely ineffective. We believe our data demonstrates that combining durlobactam with sulbactam can effectively restore the activity of sulbactam against multidrug-resistant strains of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter Treatment Trial Against Colistin (&#8220;ATTACK&#8221;)</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed ATTACK, a Phase 3 registration trial of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the treatment of patients with carbapenem-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> infections, with positive top-line data announced in October 2021 and published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The Lancet Infectious Diseases </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">in May 2023. ATTACK enrolled 207 patients at 95 clinical sites in 16 countries. This was a two-part trial with Part A being the randomized, comparative portion (XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> vs colistin) in patients with documented </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VAPB), ventilated pneumonia (VP), or bacteremia, and Part B being an open-labeled portion including </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> infections resistant to, or having previously failed colistin or polymyxin B treatment. Baseline </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> isolates tested were greater than 95% carbapenem resistant.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> met the primary efficacy endpoint of 28-day all-cause mortality compared to colistin in the CRABC m-MITT population of Part A. XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mortality was 19.0% (12/63) compared to 32.3% (20/62) in the colistin arm (treatment difference of -13.2%; 95% CI: -30.0, 3.5). Similar trends were demonstrated in 28-day and 14-day all-cause mortality favoring XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> across all study populations evaluated to date. A statistically significant difference in clinical cure at Test of Cure (TOC) was observed with 61.9% in the XACDURO arm compared to 40.3% in the colistin arm (95% CI 2.9-40.3). In Part B, the 28-day all-cause mortality was 17.9% (5/28) and consistent with that observed in Part A.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safety analyses from a total of 177 patients treated with XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> suggested that XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was generally well-tolerated with a favorable safety profile compared to colistin. XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> met the primary safety objective with a statistically significant lower incidence of nephrotoxicity as measured by the RIFLE classification for acute kidney injury. XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> nephrotoxicity was 13.2% (12/91) versus 37.6% (32/85) in the colistin arm (p = 0. 0002). Overall adverse events (AEs) in the safety population were comparable between treatment groups with 87.9% (80/91) in the XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> arm vs. 94.2% (81/86) in the colistin arm in Part A, 89.3% (25/28) in Part B. Drug related AEs were 12.1% (10.7% in Part B) with XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> compared to 30.2% with colistin. The most common non-infectious AEs (&#8805;10%) in the XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> arm were diarrhea (16.5%), allergic and hypersensitivity reactions (16.5%), anemia (13.2%) and hypokalemia (12.1%) in Part A. These AEs were also &gt;10% in the colistin arm as was acute kidney injury.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATTACK Study Design</span></p><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><img src="img75897552_4.gif" alt="img75897552_4.gif" style="width:405px;height:249px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IMI=Imipenem; TOC=Test of cure; HABP=hospital acquired bacterial pneumonia; VABP=ventilator associated bacterial pneumonia; VP=ventilated pneumonia; BSI=blood stream infection; ABC=</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter baumannii-calcoaceticus</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> complex</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2-part study, Part A being the randomized, controlled portion of the study in patients with ABC HABP / VABP or bacteremia. Part B is the single-group portion of the study and includes ABC infections that are resistant to or have failed colistin or polymyxin B treatment, as detailed in the inclusion criteria. Part B is deemed as not relevant to the HABP / VABP indication</span></div></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ATTACK Primary Endpoint Results</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_5.jpg" alt="img75897552_5.jpg" style="width:345px;height:223px;"/><img src="img75897552_6.gif" alt="img75897552_6.gif" style="width:346px;height:223px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IMI=Imipenem</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information. Kaye et al. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lancet Infect Dis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2023 May 11:S1473-3099(23)00184-6</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selected Adverse Reactions Occurring at a Frequency of &gt;5% in Trial 1</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_7.jpg" alt="img75897552_7.jpg" style="width:590px;height:259px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liver test abnormalities include the following adverse reactions: liver function test abnormal, hepatic function abnormal, increased transaminases, ALT increased, and AST increased; Acute kidney injury includes the following adverse reactions: renal impairment, blood Cr increased, toxic nephropathy, renal failure and acute kidney injury. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All-cause mortality: Kaplan-Meier analysis of time to death by day 28</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_8.gif" alt="img75897552_8.gif" style="width:665px;height:243px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Kaye et al. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Lancet Infect Dis. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023 May 11:S1473-3099(23)00184-6</span></div></div><p style="margin-left:3.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (eravacycline)</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (eravacycline) for injection is approved by the U.S. FDA and Singapore Health Sciences Authority (&#8220;HSA&#8221;) as a tetracycline class antibacterial indicated for the treatment of cIAI due to susceptible microorganisms in patients 18 years of age and older. XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is approved by the EC, MHRA, and the Hong Kong Department of Health (&#8220;DoH&#8221;) for the treatment of cIAI in adults. XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is marketed in the U.S. by our wholly owned subsidiary, Tetraphase Pharmaceuticals, Inc. (&#8220;Tetraphase&#8221;), and is marketed in Europe and Great Britain by PAION on behalf of Tetraphase and is marketed in mainland China, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines by Everest Medicines Limited (&#8220;Everest&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">cIAIs are the second most common source of severe sepsis in the ICU. cIAIs are defined as consequences of perforations of the gastrointestinal tract that result in contamination of the peritoneal space. In July 2024, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was named as a recommended agent for empiric therapy in the updated 2024 SIS treatment guidelines for the management of complicated intra-abdominal infections. SIS also recommended XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> be reserved for high-risk patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investigating Gram-negative Infections Treated with Eravacycline (&#8220;IGNITE&#8221;)</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was approved by the U.S. FDA, HSA, EC, MHRA, and DoH based on the results of IGNITE1 and IGNITE4, which were published in JAMA Surgery in March 2017 and Clinical Infectious Diseases in December 2018, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IGNITE1 was a multinational, randomized, double-blind, active-controlled study in 538 patients with clinical evidence of cIAIs requiring urgent surgical or percutaneous intervention who received either XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or ertapenem. The primary endpoint was clinical cure, defined as complete resolution or significant improvement of signs or symptoms of the index infection, at the test of cure (&#8220;TOC&#8221;) visit. The TOC visit was conducted 25 to 31 calendar days after the first dose of the study drug was administered.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IGNITE4 was a multinational, randomized, double-blind, active controlled study in 499 patients with clinical evidence of cIAIs requiring urgent surgical or percutaneous intervention who received either XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or meropenem. The primary endpoint was clinical cure, defined as complete resolution or significant improvement of signs or symptoms of the index infection, at the TOC visit. The TOC visit was conducted 25 to 31 calendar days after the first dose of the study drug was administered.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IGNITE1 and IGNITE4 Study Design</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_9.jpg" alt="img75897552_9.jpg" style="width:608px;height:330px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solomkin et al, JAMA Surgery 2017; 152(3):224-232</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Solomkin et al, Clinical Infectious Diseases 2018; 69(6):921-9</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TOC visit was conducted 25 to 31 calendar days after the first dose of the study drug was administered</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> demonstrated statistical noninferiority in clinical cure rate in the micro-ITT population, which included all randomized subjects who had baseline bacterial pathogens that caused cIAIs and against at least one of which the investigational drug has in vitro (in a test tube) antibacterial activity (N=846).</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">IGNITE1 and IGNITE4 Primary Endpoint Results</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_10.jpg" alt="img75897552_10.jpg" style="width:614px;height:296px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Noninferiority margins of 10% and 12.5% were used for IGNITE1 and IGNITE4, respectively</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical cure rates across patients with gram-negative, gram-positive and anaerobic pathogens, including those with resistant strains, are shown in the following tables.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical Cure Rates at TOC by Selected Baseline Pathogens in the Micro-ITT Population</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_11.jpg" alt="img75897552_11.jpg" style="width:516px;height:267px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">N=Number of subjects in the micro-ITT Population; N1=Number of subjects with a specific pathogen; n=Number of subjects with a clinical cure at the TOC visit</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparators included ertapenem and meropenem for IGNITE1 and IGNITE4, respectively</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Streptococcus anginosus, Streptococcus constellatus, and Streptococcus intermedius</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(4)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Clostridium perfringens, and Parabacteroides distasonis</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The most common adverse reactions that were reported in XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-treated patients in IGNITE1 and IGNITE4 were infusion site reactions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selected Adverse Reactions Reported in &#8805;1% of Patients Receiving XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_12.jpg" alt="img75897552_12.jpg" style="width:515px;height:154px;"/></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Charts, graphs and tables derived from FDA prescribing information</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparators included ertapenem and meropenem for IGNITE1 and IGNITE4, respectively</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Infusion site reactions include: catheter/vessel puncture site pain, infusion site extravasation, infusion site hypoaesthesia, infusion/injection site phlebitis, infusion site thrombosis, injection site/vessel puncture site erythema, phlebitis, phlebitis superficial, thrombophlebitis, and vessel puncture site swelling</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:3.333%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ceftobiprole) was approved by the U.S. FDA on April 4, 2024 as a cephalosporin antibacterial indicated for the treatment of: adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis, adult patients with acute bacterial skin and skin structure infections (ABSSSI), and adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP). ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is also approved by the European Commission for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP) in patients 18 years of age and older.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 14, 2024, a subsidiary of the Company entered into an exclusive distribution and license agreement with Basilea, for the commercialization of ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the United States. Under the terms of the agreement, we were granted exclusive marketing rights to ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. in exchange for Basilea receiving a $4.0 million upfront payment in addition to tiered royalties and milestones on net sales in the U.S. if certain targets are met. We commercially launched ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. in the third quarter of 2025.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The efficacy of ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the treatment of adult patients with SAB, including right-sided infective endocarditis, was demonstrated in a randomized, controlled, double-blind, multinational, multicenter trial (NCT03138733). In this trial, adult patients were randomized to either ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 667 mg (equivalent to 500 mg of ceftobiprole) IV every 6 hours from study Day 1 to Day 8, and 667 mg IV every 8 hours from study Day 9 onwards) or daptomycin (6 mg/kg up to 10 mg/kg IV every 24 hours) plus optional aztreonam for coverage of gram-negative co-infections (the comparator).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary efficacy outcome in the study was overall success at the post-treatment evaluation (PTE) visit at 70 days post-randomization in the mITT population, as assessed by the independent DRC. Overall success rates at the PTE visit in the mITT population were 69.8% (132/189) in patients treated with ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 68.7% (136/198) in patients treated with the comparator.</span></p><p style="text-indent:2.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_13.gif" alt="img75897552_13.gif" style="width:643px;height:224px;"/></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The efficacy of ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the treatment of adult patients with ABSSSI was demonstrated in a randomized, controlled, double-blind, multinational, multicenter trial (NCT03137173). Patients were randomized to either ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 667 mg (equivalent to 500 mg of ceftobiprole) IV every 8 hours or vancomycin plus aztreonam (vancomycin 1 gram or 15 mg/kg IV every 12 hours, aztreonam 1 gram IV every 12 hours). Randomization was stratified by study site and type of ABSSSI. Treatment duration was 5 to 14 days. Patients could receive concomitant metronidazole for suspected anaerobic infection. A switch to oral therapy was not allowed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary endpoint, assessed in the ITT population, was early clinical response 48&#8211;72 hours after start of treatment. Early clinical response required a reduction of the primary skin lesion by at least 20%, survival for at least 72 hours, and the absence of concomitant antibacterial treatment or additional unplanned surgery.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary and main secondary outcomes are shown below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_14.gif" alt="img75897552_14.gif" style="width:643px;height:147px;"/></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The efficacy of ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the treatment of adult patients with community-acquired bacterial pneumonia (CABP) was demonstrated in a randomized, controlled, double-blind, multinational, multicenter study (Trial 3) (NCT00326287). 638 adults hospitalized with CABP and requiring IV antibacterial treatment for at least 3 days were included in the intent-to-treat (ITT) population, comparing ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 667 mg (equivalent to 500 mg of ceftobiprole) IV every 8 hours to ceftriaxone (2 grams IV every 24 hours) with optional linezolid (600 mg IV every 12 hours) for the coverage of resistant gram-positive pathogens, including methicillin-resistant S. aureus (MRSA). Randomization was stratified by Pneumonia Outcomes Research Team (PORT) classification I to III versus IV to V, and by the need for adjunctive treatment with linezolid or matching placebo. The treatment duration was 5&#8211;14 days. No adjunctive macrolide therapy was allowed. A switch to oral cefuroxime (500 mg every 12 hours) was allowed after at least 72 hours of IV study treatment for patients who met stringent protocol-specified criteria for improvement and were candidates for hospital discharge.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results for clinical cure at the test-of-cure visit at Day 7 to 14 after end of treatment are shown below:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><img src="img75897552_15.gif" alt="img75897552_15.gif" style="width:643px;height:95px;"/></p><p style="margin-left:3.333%;font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (zoliflodacin) was approved by the U.S. FDA on December 12, 2025 as a single oral dose cure for the treatment of uncomplicated gonorrhea caused by the bacterial pathogen </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Gonorrhea is an area of significant medical need and NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the only approved novel single dose treatment that provides monotherapy oral alternative to intramuscular injections of ceftriaxone for the treatment of gonorrhea, including infections caused by drug-resistant strains. NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> targets the validated mechanism of action of the fluoroquinolone class of antibiotics but does so in a novel manner to avoid existing fluoroquinolone resistance. In November 2023, we reported positive top-line data results of a pivotal Phase 3 trial. The study demonstrated statistical non-inferiority of microbiological cure at the urogenital site when compared to treatment with intramuscular injection of ceftriaxone and oral azithromycin, a current global standard of care regimen. This trial was initiated in 2019 in collaboration with GARDP, who funded all the Phase 3 clinical trial and pharmaceutical development costs and in return received commercial rights for zoliflodacin in WHO-defined low-income and select middle-income countries. We retained commercial rights in all other countries, including the major markets in North America, Europe and Asia-Pacific.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Gonorrhea</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Uncomplicated gonorrhea is an </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N.&#8239;gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> infection of the urethra, cervix, pharynx or rectum, and is more common than complicated gonorrhea, which includes spread of the infection to other tissues and potentially the bloodstream. Gonorrhea can be associated with serious complications, including pelvic inflammatory disease, ectopic pregnancy and infertility, as well as an increased risk of human immunodeficiency virus, or HIV. Despite the continued use of effective antibiotics, it remains one of the most common sexually transmitted bacterial infections in the world with an estimated 82&#8239;million people worldwide infected each year, including over 1 million people each year in the United States. The occasional absence of symptoms, more frequent in women, is thought to be one reason for sustained levels of infection. Antibiotics remain the mainstay for treating uncomplicated gonorrhea</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the bacterial pathogen responsible for gonorrhea and has a strong propensity for uptake of chromosomal DNA from other genera of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Neisseria</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> which allows the bacteria to accumulate many mutations in chromosomal genes leading to frequent resistance of antibiotics. For example, penicillin was introduced for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">infections in 1943, and initial resistance was reported in 1945. Fluoroquinolone antibiotics were first used to treat gonorrhea in 1949 and have been one of the most successful classes of antibiotics against </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, but even so resistance was identified in 1969. One member of this class, ciprofloxacin, was introduced in 1980 and resistance was identified in 1990. More recently cephalosporin antibiotics, notably cefixime, had been widely used for the treatment of gonorrhea due to their oral administration along with a favorable efficacy and safety profile, although resistance by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has been reported since 2007. As widespread use of these antibiotics drove the emergence of drug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> strains, treatment guidelines have subsequently been amended. Ceftriaxone is currently the only CDC-recommended option for the treatment of gonorrhea and, until recently, was administered with azithromycin, a broad-spectrum antibiotic, to provide coverage against other sexually transmitted diseases that tend to occur concurrently with gonorrhea. However, rising resistance of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to azithromycin recently prompted the CDC to now recommend 500mg ceftriaxone monotherapy. Ceftriaxone is administered by intramuscular injection, which can be painful and may require patient monitoring by a healthcare administrator. Although ceftriaxone remains effective in most of the U.S., in Hawaii and Massachusetts, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> strains with resistance to azithromycin and ceftriaxone have been reported, and high numbers of resistant strains are now prevalent in many countries across the globe, prompting concerns that multidrug-resistant gonorrhea may become a major community health issue.</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Opportunity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is an immediate global public health threat with 82.4 million cases worldwide in 2020 (WHO estimate). Cases of gonorrhea in the United States are estimated at more than one million per year.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of a 2017-2018 survey of countries reporting decreased susceptibility, DS, or resistance, R, of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to current antibiotics are reflected in the table below.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><img src="img75897552_16.jpg" alt="img75897552_16.jpg" style="width:366px;height:129px;"/></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, to reduce the risk of spreading drug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the CDC has changed treatment guidelines when resistance rates to recommended first-line treatments reach 5%. Since 2015, there has only been one recommended treatment on CDC guidelines for gonorrhea: 250mg intramuscular injection of ceftriaxone plus 1g of oral azithromycin. In 2020 the CDC once again updated its treatment guideline, now recommending a 500mg intramuscular injection of ceftriaxone for treatment of uncomplicated gonorrhea. This follows a 2019 update in the United Kingdom where recommended empirical treatment of gonorrhea is now 1g intramuscular ceftriaxone monotherapy.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that as resistance to ceftriaxone continues to grow both in the US and around the world, there is an increasing unmet medical need for drugs effective against resistant strains of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">N. gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and also for an oral therapy for those patients who cannot get an in-office intramuscular injection or prefer a more convenient option.</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Completed Clinical Trials</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 3 registrational trial:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We completed a global, multi-center Phase 3 registrational trial in collaboration with GARDP who conducted and funded all Phase 3 clinical trial and pharmaceutical development costs. The Phase 3 trial enrolled a total of 930 patients with uncomplicated gonorrhea, including women, adolescents, and people living with HIV, making it the largest clinical trial ever conducted for a new treatment against gonorrhea infection, with 16 trial sites in regions with a high prevalence of gonorrhea across five countries, including Belgium, the Netherlands, South Africa, Thailand, and the U.S. The trial compared a single, oral, 3g dose of zoliflodacin to a globally recognized standard of care regimen (500mg ceftriaxone IM plus 1g oral azithromycin) for the treatment of uncomplicated gonorrhea.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Zoliflodacin met the prespecified statistical test for non-inferiority when compared to ceftriaxone and oral azithromycin (5.31% (95%CI 1.38, 8.65%)). Non inferiority of zoliflodacin was demonstrated within the pre-specified margin of 12% and, furthermore, within the margin of 10% as specified in U.S. FDA guidance.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3 trial design</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/><br/> </span><img src="img75897552_17.jpg" alt="img75897552_17.jpg" style="width:593px;height:281px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:74.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TOC=Test of Cure; IM=intra-muscular; CRO-AZI=ceftriaxone and azithromycin</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efficacy and safety results from Phase 3 trial</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img75897552_18.jpg" alt="img75897552_18.jpg" style="width:600px;height:245px;"/><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:74.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TEAE=Treatment emergent adverse event; CRO-AZI=ceftriaxone and azithromycin</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Company data, published on November 6, 2023</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase&#8239;2 clinical proof-of-concept trial: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We completed a multi-center, randomized, open-label Phase&#8239;2 clinical trial comparing a single oral dose of 2.0g or 3.0g of zoliflodacin to 500mg intramuscular ceftriaxone for the treatment of uncomplicated gonorrhea. In this trial, 179 randomized patients received treatment and zoliflodacin was generally well tolerated, with efficacy outcomes comparable to ceftriaxone. Microbiological eradication and clinical cure in urogenital infections with a single dose of zoliflodacin, the primary endpoint of the trial, was comparable to ceftriaxone, with 100% cure rate in both the 3.0g zoliflodacin and ceftriaxone groups in the per-protocol population. The results of this clinical trial were published in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The New England Journal of Medicine</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in 2018.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Phase 1 clinical trial: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated zoliflodacin in two Phase&#8239;1 clinical trials studying 72 healthy volunteers in total. In one trial, we evaluated PKs and tolerability in 48 subjects and food effects in 18 subjects, and in the second trial, we evaluated absorption, distribution, metabolism and excretion in six subjects. Zoliflodacin was generally well tolerated in these trials at doses we would expect to be clinically active for treating uncomplicated gonorrhea. Administration of a high-fat meal was associated with an increase in zoliflodacin plasma concentration, suggesting that zoliflodacin could be administered with or without food.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Preclinical Data</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We generated biochemical, microbiological and </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">in vivo</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> data on zoliflodacin. The data suggest that zoliflodacin retains potent activity against contemporary clinical isolates in the U.S., Europe, China, Thailand and South Africa that are resistant to other antibiotic classes including fluroquinolones, which was expected given its novel mechanism of action. In addition, the data show significant resistance against two of the four standard antibiotics indicated for gonorrhea, ciprofloxacin, a fluoroquinolone, and azithromycin, a macrolide.</span></p><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Competition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competes with catecholamines (primarily norepinephrine), which are available as generics and inexpensive and typically used first line to treat distributive shock, and vasopressin, including Vasostrict</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Endo International plc) and vasopressin generic drugs, which are typically used second line. In the randomized, Phase 3 study ATHOS-3, GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> demonstrated clinical benefit in patients who were not adequately responding to available vasopressors, including catecholamines and vasopressin. GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s principal competition as a treatment in patients not adequately responding to available vasopressors is the use of these same vasopressors at increased doses. If we are unable to successfully change treatment practices, the commercial prospects for GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be limited, and our business may suffer.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> competes with a number of antibiotics that are currently marketed for the treatment of cIAI and other multidrug resistant infections, including: AVYCAZ (ceftazidime and avibactam, marketed by AbbVie Inc.); MERREM IV</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (meropenem, marketed by AstraZeneca PLC); PRIMAXIN</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (imipenem and cilastatin, marketed by Merck &amp; Co., Inc.); RECARBRIO&#153; (imipenem, cilastatin, and relebactam, marketed by Merck &amp; Co., Inc.); TYGACIL</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (tigecycline, marketed by Pfizer Inc.); VABOMERE&#153; (meropenem and vaborbactam, marketed by Melinta Therapeutics, Inc.); ZERBAXA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ceftolozane and tazobactam, marketed by Merck &amp; Co., Inc.); ZOSYN</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (piperacillin and tazobactam, marketed by Pfizer Inc.); and current and future generic versions of marketed antibiotics. If we are unable to successfully change treatment practices, the commercial prospects for XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be limited, and our business may suffer.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> competes with a number of antibiotics that are used to treat carbapenem-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">infections in the absence of other products indicated for these infections, including: FETROJA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (cefiderocol, marketed by Shionogi &amp; Co., Ltd.), UNASYN</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ampicillin and sulbactam, marketed by Pfizer Inc.), colistin (polymyxin E), and other current and future generic versions of marketed antibiotics. There are at least two additional early-stage clinical programs developing investigational therapies for multidrug-resistant </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">infections. If we are unable to successfully change treatment practices, the commercial prospects for XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be limited, and our business may suffer.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a single oral dose treatment for uncomplicated gonorrhea. Gonorrhea is commonly treated with 500mg intramuscular ceftriaxone, a generically available agent. Additional generic cephalosporins and fluoroquinolones are also prescribed but not recommended as primary treatment options given current resistance rates. BLUJEPA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (gepotidacin), developed by GlaxoSmithKline&#8239;plc and approved by the U.S FDA on December 11, 2025, is the only competitive product for the treatment of uncomplicated urogenital gonorrhea that we are aware of. If we are unable to successfully change treatment practices, the commercial prospects for NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be limited, and our business may suffer.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> competes with a wide range of generic and branded antibiotics that are used to treat the various infection types for which it is indicated, including: vancomycin, daptomycin, TEFLARO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ceftaroline, marketed by Allergan Sales, LLC). If we are unable to successfully change treatment practices, the commercial prospects for ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will be limited, and our business may suffer.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory Exclusivity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are New Chemical Entities (&#8220;NCEs&#8221;) approved by the U.S. FDA. In the U.S., NCEs approved by the FDA are eligible for market exclusivity under the U.S. Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), which can prevent the approval of generic versions of the NCE for 5 to 7.5 years from the date of the initial approval of the NCE. Specifically, the FDCA provides a 5-year period of marketing exclusivity within the U.S. to the applicant that gains approval of an NDA for an NCE. A drug is an NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application (&#8220;ANDA&#8221;) or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all of the data required for approval. However, an application may be submitted 4 years after the NDA approval of the NCE if it contains a certification of patent invalidity or non-infringement. Should the NDA holder commence litigation against the ANDA filer within 45 days of receipt of the certification notice, an automatic stay of the approval of any generic competition goes into effect until the earlier of: (i) 30 months from the receipt of the certification; or (ii) a court ruling of patent invalidity or non-infringement for the relevant patents. In the absence of a court ruling, the 30-month stay will be extended by such amount of time (if any) that is required for 7.5 years to have elapsed from the date of NDA approval of the NCE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> were each provided ten years of market exclusivity by the FDA from the date of approval in April 2024 and December 2025, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#8220;Notice Letter&#8221;) from Gland Pharma Limited (&#8220;Gland&#8221;) advising that Gland had submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#8220;GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Patents&#8221;), which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;). The Notice Letter alleges that the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#8217;s ANDA.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#8217;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the Notice Letter, the FDA cannot approve Gland&#8217;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 22, 2023, La Jolla received a paragraph IV notice of certification (the &#8220;Second Notice Letter&#8221;) from Gland advising that Gland had amended its ANDA filing to include a paragraph IV certification alleging that all claims of the newly-issued and Orange Book-listed U.S. Patent No. 11,559,559 (&#8220;the &#8217;559 Patent&#8221;), which covers GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are invalid, unenforceable and/or not infringed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 22, 2023, La Jolla filed a First Amended Complaint in this litigation adding Gland&#8217;s marketing and distribution partners for its ANDA angiotensin II product, Fresenius Kabi USA LLC and Fresenius Kabi SwissBiosim GmbH (collectively, the &#8220;Fresenius Kabi Defendants&#8221;), as co-defendants. On April 7, 2023, La Jolla filed a Second Amended Complaint in response to the Second Notice Letter, adding claims that the manufacture, use, sale, offer for sale, or import of Gland&#8217;s ANDA angiotensin II product will infringe the &#8217;559 Patent. On November 14, 2023, La Jolla filed a Third Amended Complaint adding additional infringement claims against the Fresenius Kabi Defendants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 18, 2025, La Jolla, as well as The George Washington University (collectively, with the La Jolla entities, the &#8220;Plaintiffs&#8221;) entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;) with Gland and the Fresenius Kabi Defendants (collectively, &#8220;Defendants&#8221;) resolving the Hatch-Waxman Act concerning Gland&#8217;s ANDA filing. Under the terms of the Settlement Agreement, Plaintiffs granted Defendants a perpetual, royalty-free and fully paid-up, non-exclusive, non-sublicensable, non-transferable right and license solely to make, have made, use, sell, offer to sell, import, and/or distribute the product that is subject to Gland&#8217;s ANDA in the United States commencing in the early 2030s, subject to certain exceptions as is customary in these type of agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required by law, the settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Generating Antibiotic Incentives Now (&#8220;GAIN&#8221;) provisions of the FDA Safety and Innovation Act (&#8220;FDASIA&#8221;), the FDA may designate a product as a qualified infectious disease product (&#8220;QIDP&#8221;). In order to receive this designation, a drug must qualify as an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections. We obtained a QIDP designation for the IV formulation of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for cIAI in July 2013. Upon approving an application for a QIDP, the FDA will extend by an additional 5 years any non-patent marketing exclusivity period awarded, such as a 5-year exclusivity period awarded for an NCE. This extension is in addition to any pediatric exclusivity extension awarded. XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has been awarded this 5-year exclusivity under FDASIA.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Manufacturing of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (FF/VI) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (UMEC/VI) is performed by GSK.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on third-party manufacturers to produce GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and expect to continue to do so in the foreseeable future to meet our development and commercial needs. In all of our manufacturing agreements, we require that contract manufacturers produce active pharmaceutical ingredients (&#8220;APIs&#8221;) and drug products in accordance with the FDA&#8217;s current Good Manufacturing Practices (&#8220;cGMPs&#8221;) and all other applicable laws and regulations. We maintain confidentiality agreements with potential and existing manufacturers in order to protect our proprietary rights related to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The long-term commercial success of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">will depend in part on the ability of our contract manufacturers to supply cGMP-compliant API and drug product without interruption.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We exclusively license ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (pre-packaging and labeling) from Basilea for the U.S. marketing rights. Our distribution and license agreement with Basilea requires that the drug product is manufactured in accordance with the FDA&#8217;s cGMPs and all other applicable laws and regulations. The long-term commercial success of ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will depend in part on the ability of Basilea to supply the drug product without interruption.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to our product candidates, we currently rely on third-party contract manufacturers for our required raw materials, drug substance, and finished drug product for our preclinical research and clinical trials. Although we have contracts with these third parties to meet our current clinical supply needs, we do not have any current contractual relationships with these third parties for the manufacture of commercial supply of our product candidates after they are approved. As our product candidates approach potential approval by any regulatory agency, we intend to enter into agreements with third-party contract manufacturers for the commercial production of those products. We currently employ internal resources to manage our manufacturing vendor relationships and processes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government Regulation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, import and export of our products and reimbursement. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulation require the expenditure of substantial time and financial resources.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">U.S. Government Regulation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local statutes and regulations requires the expenditure of substantial time and financial resources. The failure to comply with the applicable requirements at any time during the product development process, approval process or after approval may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and untitled letters, product recalls, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement of profits or civil or criminal penalties.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Approval Processes</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, or the FDCA, the Public Health Service Act, or PHSA, and implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulation require the expenditure of substantial time and financial resources. Failure to comply with the FDCA and other applicable U.S. requirements at any time during the product development process, approval process or after approval may subject us to a variety of administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of an approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a clinical hold;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning letters, untitled letters and similar communications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizures or recalls; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">total or partial suspension of production or distribution, or injunctions, fines, restitution, disgorgement of profits or civil or criminal investigations and penalties brought by the FDA and the Department of Justice, or DOJ, or other </span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process required by the FDA before a drug may be marketed in the United States generally involves the following:</span></p><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">completion of preclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices or other applicable regulations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">submission to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed drug for its intended use, conducted in accordance with current good clinical practices, or cGCP, which are ethical and scientific quality standards and FDA requirements for conducting, recording and reporting clinical trials to assure that the rights, safety and well-being of trial participants are protected;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">preparation and submission to the FDA of an NDA;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s safety, identity, strength, quality and purity; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA review and approval of the NDA.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some preclinical or nonclinical testing may continue even after the IND is submitted. In addition to including the results of the preclinical studies, the IND will also include one or more protocols detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with cGCP. They must be conducted under protocols detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol and any amendments must be submitted to the FDA as part of the IND, and progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently in other situations, including the occurrence of serious adverse events. An IRB at each institution participating in the clinical trial must review and approve the protocol and any amendments before a clinical trial commences or continues at that institution, approve the information regarding the clinical trial and the informed consent form that must be provided to each trial subject or his or her legal representative, monitor the study until completed and otherwise comply with IRB regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on their ClinicalTrials.gov website.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1. The drug is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, distribution, metabolism and elimination. In the case of some products for severe or life-threatening diseases, such as multidrug-resistant infections, especially when the product may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients with the target disease or condition.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 2. Clinical trials are initiated in a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for regulatory approval and product labeling.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Phase 1, Phase 2 and Phase 3 testing may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points, including prior to submission of an IND, at the end of Phase 2 and before an NDA is submitted. Meetings at other times may also be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the end-of-Phase 2 meeting to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trial or trials that they believe will support approval of the new drug.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric studies for certain drugs and biologics. Specifically, PREA requires original NDAs, biologic license applications, or BLAs, and supplements thereto for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to contain a pediatric assessment unless the sponsor has received a deferral or waiver.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional animal safety studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and the manufacturer must develop methods for testing the quality, purity and potency of the final drugs. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf-life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The results of product development, preclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. The submission of an NDA is subject to the payment of user fees, but a waiver of such fees may be obtained under specified circumstances. The FDA reviews all NDAs submitted to ensure that they are sufficiently complete for substantive review before it accepts them for filing. It may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to completeness review before the FDA accepts it for filing.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once the submission is accepted for filing, the FDA begins an in-depth review. NDAs receive either standard or priority review. A drug that, if approved, would represent a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious disease or condition may receive priority review. Requests for priority review generally must be submitted at the time of NDA submission. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of new molecular entities, or NMEs, are meant to be reviewed within ten months from the date on which FDA accepts the NDA for filing, and 90% of applications for NMEs that have been designated for &#8220;priority review&#8221; are meant to be reviewed within six months of the filing date. For applications seeking approval of drugs that are not NMEs, the ten-month and six-month review periods run from the date that FDA receives the application. The review process may be extended by the FDA for three additional months to consider a major amendment to the application following the original submission.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing complies with cGMP requirements to assure and preserve the product&#8217;s safety, identity, strength, quality and purity. The FDA may refer the NDA to an advisory committee for review and recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendation.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured and tested. These pre-approval inspections may cover all facilities associated with NDA submission, including drug component manufacturing (such as active pharmaceutical ingredients), finished drug product manufacturing, and control testing laboratories. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. In addition, the FDA may require, as a condition of approval, risk evaluation and mitigation strategies, or REMS (which may include requirements for, restricted distribution and use), enhanced labeling, special packaging or labeling, expedited reporting of certain adverse events, pre-approval of promotional materials, restrictions on direct-to-consumer advertising or commitments to conduct additional research post-approval.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. If the FDA ultimately decides that the NDA does not satisfy the criteria for approval, the FDA will issue a complete response letter to indicate that the agency will not approve the NDA in its present form. The complete response letter usually describes all of the specific deficiencies in the NDA identified by the FDA. If a complete response letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Expedited Review and Approval</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA has various programs, including Fast Track and priority review, which are intended to expedite or simplify the process for developing and/or reviewing drugs. Even if a drug qualifies for one or more of these programs, the FDA may later decide that the drug no longer meets the conditions for qualification or that the time period for FDA review or approval will not be shortened. Generally, drugs that may be eligible for these programs are those for serious or life-threatening conditions, those with the potential to address unmet medical needs and those that offer meaningful benefits over existing treatments. For example, Fast Track is a process designed to facilitate the clinical development and expedite the review of drugs to treat serious diseases with the potential, based on nonclinical or clinical data, to fill an unmet medical need. Priority review is designed to give drugs that offer a significant improvement in safety or effectiveness of treatment for a serious condition an expedited review within eight months from the completed submission (six months from filing) as compared to a standard review time of twelve months from the completed submission (10 months from filing) for a standard new molecular entity NDA. Although Fast Track and priority review do not affect the standards for approval, the FDA will attempt to facilitate early and frequent meetings with a sponsor of a Fast Track designated drug and expedite review of the application for a drug designated for priority review.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Generating Antibiotic Incentives Now Act, or GAIN Act, is intended to provide incentives for the development of new QIDPs. A new drug that is designated as a QIDP after a request by the sponsor that is made before an NDA is submitted will be eligible, if approved, for an additional five years of exclusivity beyond any period of exclusivity to which it would have previously been eligible. In addition, a QIDP will receive priority review and qualify for a Fast Track designation. QIDPs are defined as antibacterial or antifungal drugs intended to treat serious or life-threatening infections, including those caused by an antibacterial or antifungal resistant pathogen or qualifying pathogens identified by the FDA. XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> have been designated by the FDA as a QIDP. Zoliflodacin has also been designated as a QIDP by the FDA for the treatment of uncomplicated gonorrhea.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent Term Restoration and Data Exclusivity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the timing, duration and specifics of FDA approval of the use of our drugs, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Amendments. As noted above, the Hatch-Waxman Amendments permit a patent restoration term of up to five years for a single patent for an approved product as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. We have applied for restoration of patent term for one U.S. Patent covering XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and, in the future, we may apply for restoration of patent term for other currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Data exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company using the drug entitled to data exclusivity as the reference listed drug, or RLD. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of data exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the use or conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent for other uses or conditions of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct its own preclinical and clinical studies in support of its application or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as described above, under the GAIN Act a new drug that is designated as a QIDP is eligible for an additional five years of exclusivity to be added to certain other exclusivity periods that the application may qualify for upon approval, specifically five-year exclusivity, three-year exclusivity, and orphan exclusivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pediatric Exclusivity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Best Pharmaceuticals for Children Act provides for an additional six months of exclusivity, which is added on to patent and exclusivity periods in effect at the time the pediatric exclusivity award is granted, if a sponsor conducts clinical trials in children in response to a written request from the FDA, or a Written Request. The FDA may request studies on approved indications in separate Written Requests. The issuance of a Written Request does not require the sponsor to undertake the described studies. To date, we have not received any Written Requests.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Post-approval Requirements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems, including safety issues, with a product may result in restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may require testing and surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs. The FDA and other authorities also strictly regulate the promotional claims that may be made about prescription products. Under the FDCA the sponsor of an approved drug in the United States may not promote that drug for unapproved, or off-label, uses, although a physician may prescribe a drug for an off-label use in accordance with the practice of medicine. If we are found to have promoted off-label uses, we may be subject to significant liability, including sanctions, civil and criminal fines and penalties, and injunctions prohibiting us from engaging in specified promotional conduct.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, any drug products manufactured or distributed pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things:</span></p><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">record-keeping requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reporting of adverse experiences with the drug;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">providing the FDA with updated safety and efficacy information;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">drug sampling and distribution requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">notifying the FDA and gaining its approval of specified manufacturing or labeling changes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complying with certain electronic records and signature requirements; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">complying with FDA promotion and advertising requirements.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMP requirements and other laws.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to comply with the FDCA and other applicable U.S. requirements at any time during the product development process, approval process or after approval may subject us to a variety of administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of an approval;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">imposition of a clinical hold;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning letters, untitled letters and similar communications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizures or recalls;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">total or partial suspension of production or distribution; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.269%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.481630819692681%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions, fines, restitution, disgorgement of profits or civil or criminal investigations and penalties brought by the FDA and DOJ, or other governmental entities.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Regulation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries or economic areas, such as the EU, before we may commence clinical trials or market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under EU regulatory systems, a company may submit marketing authorization applications under the centralized, decentralized or mutual recognition procedures, or under the purely national route of approval. The centralized procedure is compulsory for medicinal products produced by biotechnology or those medicinal products containing new active substances for specific indications such as the treatment of acquired immune deficiency syndrome, or AIDS, cancer, neurodegenerative disorders, diabetes, viral diseases, and designated orphan medicines, and is optional for other medicines that are highly innovative. Under the centralized procedure, a marketing application is submitted to the European Medicines Agency, or EMA, where it will be evaluated by the relevant scientific committee, in most cases the Committee for Medicinal Products for Human Use, and a favorable opinion typically results in the grant by the European Commission of a single marketing authorization that is valid for all EU member states and, by extension (after national implementing measures), in Norway, Iceland and Liechtenstein. In general, an initial marketing authorization is valid for five years, but once renewed is usually valid for an unlimited period. The decentralized procedure allows marketing authorization applications to be submitted simultaneously in two or more EU member states, whereas the mutual recognition procedure must be used if the product has already been authorized in at least one other EU member state. Both the decentralized and mutual recognition procedures provide for approval by one or more &#8220;concerned&#8221; member states based on an assessment of an application performed by one-member state, known as the &#8220;reference&#8221; member state.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the decentralized approval procedure, an applicant submits an application, or dossier, and related materials to the reference member state and concerned member states. The reference member state prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference member state&#8217;s assessment report, each concerned member state must approve the assessment report and related materials, unless they identify a serious risk to public health. Under the mutual recognition procedure, the concerned member states have the same 90-day period to recognize the marketing authorization in the reference member state. In either case, concerns about serious risks to public health escalate through the relevant EMA scientific committees, and the disputed points may eventually result in a consensus opinion from the Committee for Medicinal Products for Human Use that is referred to the European Commission, whose decision is binding on all member states. The purely national procedure results in a marketing authorization in a single EU member state.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following the result of a referendum in 2016, the United Kingdom left the EU on January 31, 2020, and as of January 1, 2021, the United Kingdom and EU operate separate regulatory regimes. The UK and EU announced on December 24, 2020, that they had agreed a Trade and Cooperation Agreement, or TCA, to govern their future relationship. The TCA remains provisional until formally ratified by the EU. The TCA sets out the new arrangements for trade of goods, including medicines and medical devices, which aims to ensure goods continue to flow between the EU and the UK and also has implications for product regulation and mutual recognition.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the United Kingdom&#8217;s departure from the EU, if a company wishes to sell its products in the United Kingdom, it will need to seek and maintain appropriate national marketing authorizations. The TCA does not provide for wholesale mutual recognition of the regulatory regimes and so products exported from the UK to the EU must comply with the EU&#8217;s regulatory requirements. In the pharmaceutical context, this has had a number of implications. From January 31, 2020, the UK no longer participated in EU institutions and their decision-making, including approval decisions under the centralized procedure. Moreover, the movement of finished pharmaceutical products into the EU from the UK is treated as an import from a third country. Since the TCA does not provide for mutual recognition of batch testing and release, products must be quality control tested and released in the EU. However, the UK has unilaterally waived batch testing requirements for UK imports from the EU for products placed on the market prior to January 2023. It remains to be seen how these developments will impact regulatory requirements for product candidates and products in the United Kingdom.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reimbursement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all the approved products for a particular indication. For example, in the U.S. and most major foreign markets, drugs like GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> that are administered in the hospital must be purchased by the hospital and generally are not reimbursed by third-party payors. Hospitals instead are reimbursed for patient cases based on patients&#8217; diagnosed conditions under the U.S. Medicare diagnosis-related group (&#8220;DRG&#8221;) system or other like systems for non-Medicare patients in the U.S. and in most major foreign markets. Adoption of new drugs that are administered in the hospital generally occurs more slowly than adoption of new drugs that are taken on an outpatient basis, which generally are paid for by third-party payors.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. Additionally, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a drug product does not ensure that other payors will also provide coverage for the drug product. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on investment in product development.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Health Care Laws Governing Interactions with Healthcare Providers</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws restrict our business activities, including certain marketing practices. These laws include, without limitation, anti-kickback laws, false claims laws, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item, good, facility or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration that are alleged to be intended to induce prescriptions, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the federal Anti-Kickback Statute has been violated. Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively the Affordable Care Act, or ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim for payment for items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">32</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal false claims laws, including the civil False Claims Act, and civil monetary penalties laws prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a claim paid. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, have also been alleged to violate false claims laws.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal requirements that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. As with the federal Anti-Kickback Statute, the ACA amended the intent standard for certain healthcare fraud under HIPAA such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it to have committed a violation.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we may be subject to data privacy and security regulations promulgated by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, impose certain requirements on covered entities (i.e., certain healthcare providers, health plans and healthcare clearinghouses) relating to the privacy, security and transmission of individually identifiable health information. Among other things, HIPAA&#8217;s security standards apply directly to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HIPAA's civil and criminal penalties also directly apply to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">What is more, the federal Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, require certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the children&#8217;s health insurance program (with certain exceptions) to annually report information related to certain payments or other transfers of value provided to covered recipients, including physicians, as defined by such law, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals&#8217; covered recipients and information related to certain ownership and investment interests held by physicians and their immediate family members.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The majority of states also have statutes or regulations similar to the aforementioned federal laws, some of which are broader in scope and apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government. In addition, some state laws require drug manufacturers to report information related to payments to clinicians and other healthcare providers or marketing expenditures and drug pricing. Further, some state and local laws require the licensure of pharmaceutical sales representatives. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, outside the United States, the European Union General Data Protection Regulation (2016/679) (&#8220;GDPR&#8221;) contains provisions specifically directed at the processing of health information. The GDPR provides for potentially significant sanctions and contains extraterritoriality measures intended to bring non-EU companies under the regulation. In addition, many countries around the world have enacted similar data privacy legislation. This legislation imposes increased compliance obligations and regulatory risk, including the potential for significant fines for noncompliance.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Healthcare and Other Reform</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States, there have been and continue to be significant legislative and regulatory initiatives at the federal and state levels to contain healthcare costs and reform the delivery of and payment for healthcare products and services. These initiatives include measures intended to reduce prescription drug spending and modify coverage and reimbursement under government healthcare programs.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">33</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the &#8220;ACA&#8221;), expanded healthcare coverage and implemented changes affecting pharmaceutical manufacturers, including increased Medicaid rebate obligations, expanded eligibility for the 340B drug pricing program, and discounts under Medicare Part D. Although the ACA has been subject to legislative modifications and judicial challenge, it remains in effect. Future legislative or regulatory efforts could further amend or revise its provisions, which may affect coverage, reimbursement, and net pricing for our products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">More recently, the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) introduced significant reforms to Medicare drug pricing. Among other provisions, the IRA authorizes the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) to negotiate maximum fair prices for certain high-expenditure drugs covered under Medicare Part B and Part D, imposes inflation-based rebates on certain drugs whose prices increase faster than statutory benchmarks, and redesigns the Medicare Part D benefit structure, including shifting greater financial responsibility to manufacturers. CMS has begun implementing these provisions, and additional guidance and rulemaking are ongoing. These measures, and their potential expansion in the future, may reduce reimbursement rates, increase our rebate obligations, or otherwise negatively affect net revenues.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Federal legislative proposals have also sought to address drug affordability through reference pricing models, enhanced pricing transparency requirements, rebate reforms, and importation initiatives. In addition, general federal cost-control measures, including sequestration under the Budget Control Act of 2011, as amended, have resulted in reductions to Medicare payments to providers and may continue to impact overall healthcare spending.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">State governments have likewise enacted and proposed legislation intended to control drug costs, including measures focused on price transparency, reporting requirements, limits on price increases, bulk purchasing initiatives, importation programs, and other reimbursement or patient access constraints. These state-level initiatives may increase compliance burdens and affect pricing flexibility.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With respect to anti-infective and antimicrobial products, legislative proposals have sought to create economic incentives to stimulate development and stewardship. For example, the DISARM Act and the PASTEUR Act have been introduced in Congress to encourage the development and appropriate use of novel antimicrobial drugs through reimbursement reforms and subscription-based funding mechanisms. It remains uncertain whether such legislation will be enacted or, if enacted, how it would be implemented.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cumulative impact of federal and state healthcare reform measures, including the IRA and potential future reforms, may reduce coverage, reimbursement levels, or pricing flexibility for our current or future products. We cannot predict the ultimate content, timing, or effect of ongoing or future healthcare reform efforts. Any significant changes to government healthcare programs, reimbursement methodologies, or statutory rebate and discount obligations could adversely affect our business, financial condition, and results of operations.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Laws and Regulations</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to a variety of financial disclosure and securities trading regulations as a public company in the U.S., including laws relating to the oversight activities of the SEC and the regulations of the Nasdaq Capital Market, on which our shares of common stock are traded. We are also subject to various laws and regulations relating to safe working conditions, laboratory practices and the experimental use of animals.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intellectual Property</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our product candidates, our core technologies, and other know-how. To accomplish this we rely on the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors, consultants and other contractors. To help protect our proprietary know-how that is not patentable, we rely on trade secret protection and confidentiality agreements to protect our interests. We require our employees, consultants and advisors to enter into confidentiality agreements prohibiting the disclosure of confidential information and requiring disclosure and assignment to us of the ideas, developments, discoveries and inventions important to our business. We file patent applications directed to our key product candidates to establish intellectual property positions. These patent applications are intended to protect new chemical entities relating to these product candidates as well as their manufacturing processes, intermediates and uses in the treatment of diseases.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The intellectual property portfolios for our commercial products, advanced product candidates, and various compounds are summarized below.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">34</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 13, 2026, the licensed intellectual property portfolio relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">included 12 issued U.S. patents, 2 pending U.S. patent applications, 10 issued foreign patents and 12 pending foreign patent applications. The issued U.S. patents, and patents that may issue from the pending U.S. patent applications, will expire between 2029 and 2034, absent any disclaimers, extensions, or adjustments of patent term. The foreign patents, and patents that may issue from the pending foreign patent applications, will expire in 2034, absent any disclaimers, extensions, or adjustments of patent term.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February13, 2026, the intellectual property portfolio relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> also included 4 issued U.S. patents, 7 pending U.S. patent applications, 10 issued foreign patents and 7 pending foreign patent applications. The issued U.S. patents, and patents that may issue from the pending U.S. patent applications, will expire between 2034 and 2040, absent any disclaimers, extensions, or adjustments of patent term. The foreign patents, and patents that may issue from the pending foreign patent applications, will expire between 2034 and 2040, absent any disclaimers, extensions, or adjustments of patent term.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 13, 2026, we owned 4 issued U.S. patents, 118 issued foreign patents, 2 pending foreign patent applications, 1 pending U.S. patent application, and 1 pending patent cooperation treaty (&#8220;PCT&#8221;) application relating to XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The issued U.S. patents have an expiration date of April 2, 2033 and November 17, 2035, absent any disclaimers, extensions, or adjustments of patent term. The foreign patents, and patents that may issue from the pending foreign applications, will likewise have an expiration date of April 2, 2033 and November 17, 2035, absent any disclaimers, extensions, or adjustments of patent term. An issued patent arising from the pending priority PCT application will have an expiration date of May 16, 2045, absent any disclaimers, extensions, or adjustments of patent term.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 13, 2026, we owned 2 issued U.S. patents, 1 pending U.S. patent application, 17 issued foreign patents and 3 pending foreign patent applications relating to XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The issued U.S. patents, and the patent that may issue from the pending U.S. patent application, will have an expiration date of August 7, 2029, absent any disclaimers, extensions, or adjustments of patent term. The term of one of the U.S. patents has received 315 days of patent term adjustment. The foreign patents, and patents that may issue from the pending foreign applications, will likewise have an expiration date of August 7, 2029, absent any disclaimers, extensions, or adjustments of patent term.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 13, 2026, we also filed applications for Supplementary Protection Certificates based on European Patent No. 2323972 covering the composition of matter and use of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Some applications have been granted and others are pending.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as of February 13, 2026, we also owned 3 issued U.S. patents, 1 pending U.S. patent application, 10 granted foreign patents and 5 pending foreign patent applications that relate to crystalline forms of eravacycline. The issued U.S. patents and any U.S. patent that may issue from the pending patent application will expire in 2037 absent any disclaimers, extensions, or adjustments of patent term. Likewise, the foreign patents and any foreign patents that may issue from the pending foreign patent applications will expire in 2037. We also owned 4 issued U.S. patents, 1 pending U.S. patent application, 23 issued foreign patents and 2 pending foreign patent applications relating to other tetracycline-related intellectual property.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">NUZOLVENCE&#174;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 13, 2026, we owned seven issued U.S. patents, 75 issued foreign patents as well as one pending foreign patent application. The issued foreign patents are in several jurisdictions, including Australia, Brazil, Canada, China, Eurasia, the European Union, Hong Kong, India, Israel, Japan, Mexico, New Zealand, Philippines, Singapore, South Africa, South Korea, Taiwan and the United Kingdom. Issued U.S. and foreign patents and patents issuing from pending U.S. and foreign applications have expiration dates of October 2029, January 2034 and May 2035.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">35</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Trademarks, Trade Secrets and Know-How</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our trademark portfolio currently consists of various registered trademark and service mark rights for various marks in several jurisdictions, including the United States, the European Union, Japan, Argentina, Australia, Brazil, Canada, China, Colombia, Hong Kong, India, Iceland, Indonesia, Israel, Liechtenstein, Malaysia, Mexico, New Zealand, Norway, the Russian Federation, Saudi Arabia, South Africa, South Korea, Switzerland, Taiwan, Thailand, Turkey, United Arab Emirates and the United Kingdom, and pending applications in other jurisdictions. In connection with the ongoing development and advancement of our products and services in the United States and various international jurisdictions, we routinely seek to create protection for our marks and enhance their value by pursuing trademarks and service marks where available and when appropriate. In addition to patents and trademark protection, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees, and consultants, and invention assignment agreements with our employees. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Strategic Partnership with Sarissa Capital</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Strategic Advisory Agreement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 11, 2020, we entered into a Strategic Advisory Agreement (the &#8220;Services Agreement&#8221;) with Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), pursuant to which Sarissa Capital provides a variety of strategic services to us in order to assist us in the development and execution of our acquisition strategy intended to diversify our assets and the potential sources of revenue. Sarissa Capital was considered to be a related party up until the annual stockholders meeting in May 2025 after which there were no representatives of Sarissa Capital serving on our Board of Directors.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Partnership Agreement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 11, 2020, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#8220;Strategic Partners&#8221;), entered into a subscription agreement and an Amended and Restated Limited Partnership Agreement (the &#8220;Partnership Agreement&#8221;) pursuant to which Strategic Partners became a limited partner of ISP Fund LP (the &#8220;Partnership&#8221;). The general partner of the Partnership is an affiliate of Sarissa Capital and, pursuant to an investment management agreement, Sarissa Capital acts as the investment adviser to the Partnership. Strategic Partners made a $300 million initial contribution to the Partnership. The Partnership was formed for the purposes of investing in equity securities in the healthcare, pharmaceutical and biotechnology industries.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we made an election to unwind the capital accounts in the Partnership in accordance with the terms of the Partnership Agreement. We received cash distributions of $121.0 million during the year ended December 31, 2025 and expect to receive distributions of our capital accounts through April 2026.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Human Capital</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had 159 employees, all of whom were full-time employees. None of our employees are represented by a labor union or covered by a collective bargaining agreement, and we consider our relations with our employees to be good. We also hire consultants and contract with third parties, as needed, to provide additional resources to support our business activities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our key human capital management objectives are to identify, recruit, integrate, retain and motivate our new and existing employees. We believe that our compensation and benefit programs are appropriately designed to attract and retain qualified talent. Employees receive an annual base salary and are eligible to earn performance-based cash bonuses. To create and maintain a successful work environment, we offer a comprehensive package of additional benefits that support the physical and mental health and wellness of all of our employees and their families and flexible working arrangements. Additionally, we grant equity awards in order to allow employees to share in the performance of the Company. The Chief Executive Officer regularly updates our board of directors and our committees on the operation and status of these human capital trends and activities.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">36</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have created an environment that fosters individual development while maintaining consistency in our corporate values and code of conduct. We offer seminars from external resources and promote the fair treatment and full participation of all people in our workplace.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The management team and Board of Directors are keenly aware of the importance of the Company&#8217;s need to conduct business with high standards. Our mission as an organization is to be patient-centric and develop innovative treatments to find solutions for patients suffering from rare and underserved diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our employees, partners, and investors expect us to honor our values and take action to promote a more equitable and sustainable world for future generations.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As we further build our organization behind our portfolio of royalties and innovative healthcare assets, we intend to strive to understand the perspectives of the clients and communities we will serve, and as such, we are intensifying our efforts to drive a culture of belonging throughout our organization. We will strive to comply with all applicable environmental laws, regulations and policies concerning environmental protection in all our business activities and in the selection of partners we choose to work with. We are committed to strengthening our local community by contributing through volunteerism and will continue, as we have been doing, to provide donations to parties we believe will support our goal of improving patient health and well-being. We are also committed to good corporate governance. All of our employees, officers and directors must conduct themselves according to the language and spirit of our Code of Conduct, and our Board of Directors is dedicated to providing effective corporate oversight including through oversight committees such as the Nominating and Governance Committee, the Audit Committee and the Compensation Committee. As our Company grows, we will continue to integrate policies and programs that further foster this effort.</span></p><p style="margin-left:4.267%;text-indent:-3.608%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Health, Safety and Wellness</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We strive to provide pay, benefits and other employee services that are competitive to market in the life sciences industry and create incentives to attract and retain employees. Our compensation package includes market-competitive pay, stock options and restrictive stock units, bonuses, employee spot awards, health care and retirement benefits, paid time off and family leave. We utilize third party consultants to review and update our compensation practices annually. We are also committed to the continued development of our people, providing opportunities for employees to further their career development through internal training and education programs and third party online training programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information about our Executive Officers</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth the name, age, and position of each of our executive officers as of February 13, 2026:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:80.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:54.189%;box-sizing:content-box;"/>
     <td style="width:1.84%;box-sizing:content-box;"/>
     <td style="width:9.318%;box-sizing:content-box;"/>
     <td style="width:1.84%;box-sizing:content-box;"/>
     <td style="width:32.813%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Age</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Positions Held</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pavel Raifeld</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Basso</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marianne Zhen</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Accounting Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pavel Raifeld</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, CFA, was appointed Chief Executive Officer in May 2020. Prior to his appointment, Mr. Raifeld, served on the investment team at Sarissa Capital Management LP. Earlier, he was a senior member of the healthcare investment banking team at Credit Suisse Securities (USA) LLC. Previously, Mr. Raifeld worked as a consultant, primarily specializing in advising biopharmaceutical companies, at McKinsey &amp; Company, Inc. and The Boston Consulting Group Ltd. Mr. Raifeld earned an AB degree from Harvard University and an MBA degree from Columbia University.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stephen Basso </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was appointed Chief Financial Officer of the Company in August 2023. Prior to joining Innoviva, Mr. Basso served as the Chief Financial Officer and Chief Operating Officer at Cybrexa Therapeutics and has held a variety of financial leadership positions at Inozyme Pharma, Alexion Pharmaceuticals and Pfizer. He received a BS in business from Providence College and an MBA from Boston College.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Marianne Zhen</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, CPA, was appointed Chief Accounting Officer in July 2018. Prior to joining Innoviva in October 2014, Ms. Zhen held various financial leadership roles across different industries, including at companies such as Model N and Mosys. Previously, Ms. Zhen served as a member of the board of directors of CalCPA Peninsula Silicon Valley Chapter. Ms. Zhen earned a Bachelor of Science degree in Business Administration with a concentration in Accounting from San Francisco State University. She is a member of the American Institute of Certified Public Accountants (AICPA) and a member of the California Society of Certified Public Accountants (CalCPA).</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">37</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Code of Business Conduct</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has adopted the Innoviva, Inc. Code of Business Conduct that applies to all directors, officers and employees. The Code of Business Conduct, as amended through January 24, 2023, is available on the corporate governance section of our website at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.inva.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the Company makes any substantive amendments to the Code of Business Conduct or grants a waiver from any provision of such code to any executive officer or director, the Company will promptly disclose the nature of the amendment or waiver, as required by applicable law.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Available Information</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our web page address is </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">www.inva.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our investor relations website is located at </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">http://investor.inva.com</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We make available free of charge on our investor relations website under &#8220;SEC Filings&#8221; our Annual Reports on Form 10&#8209;K, Quarterly Reports on Form 10&#8209;Q, Current Reports on Form 8&#8209;K, our directors&#8217; and officers&#8217; Section 16 Reports and any amendments to those reports after filing or furnishing such materials to the SEC. The information found on our website is not part of this or any other report that we file with or furnish to the SEC. Innoviva and the Innoviva logo are registered trademarks of Innoviva, Inc. Trademarks, tradenames or service marks of other companies appearing in this report are the property of their respective owners.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_1a_risk_factors"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1A.   RISK FACTORS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Summary of Risk Factors</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is subject to a number of risks that if realized could affect its business, financial condition, results of operations, cash flows and access to liquidity materially. The Company&#8217;s business is subject to uncertainties and risks including:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> face substantial competition for their intended uses in the targeted markets from products discovered, developed, launched and commercialized both by GSK and by other pharmaceutical companies, which could cause the royalties payable to us pursuant to the GSK Agreements to be less than expected, which in turn would harm our business and cause the price of our securities to fall.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are dependent on GSK for the successful commercialization and development of the products developed under the GSK Agreements. If GSK does not devote sufficient resources to the commercialization and development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our debt including our convertible notes are senior in capital structure and cash flow, respectively, to our common stockholders. Satisfying the obligations relating to our debt could adversely affect our liquidity or the amount or timing of potential distributions to our stockholders.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GSK has indicated to us that it believes its consent may be required before we can engage in certain royalty monetization transactions with third parties, which may inhibit our ability to engage in these transactions.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If clinical trials of our and our related parties' product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other comparable regulatory authorities, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of that product candidate.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on collaborations with third parties for the development of both our product and commercial candidates, and we may seek additional collaborations in the future. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product or commercial candidates.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if any of our product candidates receives marketing approval, such product candidate may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our operations could be disrupted by failure of our information systems or cyber-attacks.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">38</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The regulatory approval process is expensive, time-consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Business and Industry</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Currently, we derive the majority of our revenues from GSK and our near-term success depends in large part on GSK&#8217;s ability to successfully develop and commercialize the products in the respiratory programs partnered with GSK.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the GSK Agreements, GSK is responsible for the development and commercialization of products in the partnered respiratory programs. Royalty revenues from RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are expected to represent the majority of our foreseeable future revenues from GSK. The amount and timing of revenue from such royalties are unknown and highly uncertain. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have no control over GSK&#8217;s marketing and sales efforts, and GSK might not be successful, which would harm our business and cause the price of our securities to fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. The amount of royalties and milestone payments, if any, we receive will depend on many factors, including but not limited to the following:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent and effectiveness of the sales and marketing and distribution support GSK provides to our partnered products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">market acceptance and demand for our partnered products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">changes in the treatment paradigm or standard of care for COPD or asthma, for instance through changes to the GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the competitive landscape of generic and branded products and developing therapies that compete with our products owned by GSK (such as Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) but which are not partnered with us and pricing pressure in the respiratory markets targeted by our partnered products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size of the market for our partnered products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the mix of sales of our partnered products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decisions as to the timing of product launches, pricing and discounts;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reprioritization of GSK&#8217;s commercial efforts on other products owned by GSK, which are not partnered with us;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GSK&#8217;s ability to expand the indications for which our partnered products can be marketed;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a satisfactory efficacy and safety profile as demonstrated in a broad patient population;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance of, and ongoing satisfaction with, our partnered products by the medical community, patients receiving therapy and third-party payors;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">timing and amounts of payor rebate adjustments and prior period rebate adjustments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">seasonal fluctuations of demand;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability of patients to be able to afford our partnered products or obtain health care coverage that covers our partnered products;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">39</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safety concerns in the marketplace for respiratory therapies in general and with our partnered products in particular;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory developments relating to the manufacture or continued use of our partnered products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the requirement to conduct additional post&#8209;approval studies or trials for our partnered products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GSK&#8217;s ability to obtain regulatory approval of our partnered products in additional countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the unfavorable outcome of any potential litigation relating to our partnered products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">general economic conditions in the jurisdictions where our partnered products are sold, including microeconomic disruptions or slowdowns; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">if our royalty revenue or operating results fall below the expectations of investors or securities analysts or below any guidance we may provide to the market, the price of our common stock could decline substantially.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">When the FDA or other applicable regulatory authorities approve generic products, including but not limited to generic forms of Advair, that compete with RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> or a generic form of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, the royalties payable to us pursuant to the GSK Agreements will be less than anticipated, which in turn would harm our business and the price of our securities could fall.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Once an NDA or marketing authorization application outside the United States is approved, the product covered thereby becomes a &#8220;listed drug&#8221; that can, in turn, be cited by potential competitors in support of approval of an ANDA in the United States. Agency regulations and other applicable regulations and policies provide incentives to manufacturers to create modified, non-infringing versions of a drug to facilitate the approval of an ANDA or other application for generic substitutes in the United States and in nearly every pharmaceutical market around the world. Numerous companies have brought to market generic forms of the ICS/LABA drug Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> since certain patents covering the Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> delivery device expired in 2016. In general, these manufactures are required to conduct a number of clinical efficacy, pharmacokinetic and device studies to demonstrate equivalence to Advair, per FDA&#8217;s September 2013 draft guidance document. These studies are designed to demonstrate that the generic product has the same active ingredient(s), dosage form, strength, exposure and clinical efficacy as the branded product. These generic equivalents, which must meet the same exacting quality standards as branded products, may be significantly less costly to bring to market, and companies that produce generic equivalents are generally able to offer their products at lower prices. Thus, after the introduction of a generic competitor, a significant percentage of the sales of any branded product and products that may compete with such branded product is typically lost to the generic product.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2016, the FDA issued draft guidance documents covering Fluticasone Furoate/Vilanterol Trifenatate (FF/VI), the active ingredients used in RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Introduction of generic products that compete against ICS/LABA products, like RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, would materially adversely impact our future royalty revenue, profitability and cash flows. We cannot yet ascertain what impact these generic products and any future approved generic products will have on any sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> or ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, if approved.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reduced prices and reimbursement rates due to the actions of governments, payors, or competition or other healthcare cost containment initiatives such as restrictions on use, may negatively impact royalties generated under the GSK Agreements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The continuing efforts of governments, pharmaceutical benefit management organizations (&#8220;PBMs&#8221;), insurance companies, managed care organizations and other payors of health care costs to contain or reduce costs of health care has adversely affected the price, market access, and total revenues of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and may continue to adversely affect them in the future. These organizations, together with governments, have increasingly imposed utilization management tools favoring the use of generic products. As these practices expand, we may face difficulty in obtaining or maintaining timely or adequate pricing or formulary placement of our products. In addition, we have experienced and expect to continue to experience increased competitive activity, which has resulted in lower overall prices for our products.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">40</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (together, &#8220;PPACA&#8221;) and other legislative or regulatory requirements or potential legislative or regulatory actions regarding healthcare and insurance matters, along with the trend toward managed healthcare in the U.S., could adversely influence the purchase of healthcare products and reduce demand and prices for our partnered products. This could harm GSK&#8217;s ability to market our partnered products and significantly reduce future revenues. For example, when GSK launched RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the treatment of COPD in the U.S. in October 2013, GSK experienced significant challenges gaining coverage at some of the largest PBMs, healthcare payors, and providers and lower overall prices than expected. Recent actions by U.S. PBMs in particular have increased discount levels for respiratory products resulting in lower net sales pricing realized for products in our collaboration. In addition, in certain foreign markets, the pricing of prescription drugs is subject to government control and reimbursement may in some cases be unavailable. We believe that pricing pressures will continue and may increase. This may make it difficult for GSK to sell our partnered products at a price acceptable to us or GSK or to generate revenues in line with our analysts&#8217; or investors&#8217; expectations, which may cause the price of our securities to fall.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) establishes a drug price negotiation program under which the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) is authorized to negotiate maximum fair prices (&#8220;MFPs&#8221;) for certain high-expenditure, single-source drugs reimbursed under Medicare Part D and Part B. RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">has been selected for negotiation under this program, with its negotiated MFP scheduled to take effect beginning January 1, 2027, and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> has been selected in a subsequent negotiation cycle, with its negotiated MFP expected to take effect in 2028. As a result, these products will be subject to government-negotiated prices in the Medicare channel, which is expected to result in lower net realized prices relative to historical levels and may also influence pricing dynamics in the commercial market through reference pricing, formulary positioning, or other payer actions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">More recently, the presidential administration and the U.S. Congress have and may continue to take actions in an effort to modify or replace PPACA and to implement or pass other reforms to the healthcare system, including proposed legislation related to the pricing of pharmaceuticals. There is uncertainty with respect to any potential changes that may be proposed and what the impact, if any, will be on our business, including the impact on coverage and reimbursement for healthcare items and services covered by plans that were authorized by PPACA. However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that additional state and federal healthcare reform measures will be considered and potentially adopted, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures and may adversely affect our operating results.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">A portion of our current revenues are from royalties derived from sales of our respiratory products partnered with GSK, RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">. If the treatment paradigm for the indications our partnered products are approved for change or if GSK is unable to, or does not devote sufficient resources to, maintain or continue increasing sales of these products, our results of operations will be adversely affected.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently depend, in part, on royalties from sales of our products partnered with GSK to support our existing operations. The treatment paradigm for COPD and asthma constantly evolves. If the treatment paradigms were to change further, causing our partnered products to fall out of favor, or if GSK were unable, or did not devote sufficient resources, to maintain or continue increasing RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> sales, our results of operations would likely suffer, and the price of our securities could fall.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If the commercialization of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in the countries in which they have received regulatory approval encounters any delays or adverse developments, or perceived delays or adverse developments, or if sales or payor coverage does not meet investors&#8217;, analysts&#8217;, or our expectations, our business will be harmed, and the price of our securities could fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under our agreements with our collaborative partner GSK, GSK has full responsibility for commercialization of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. GSK has launched RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in a number of countries, including the United States, Canada, Japan, the United Kingdom, and Germany, among others. The commercialization of the products in countries where they are already launched and the commercialization launch in new countries are still subject to fluctuating overall pricing levels and uncertain timeframes to obtain payor coverage. Any delays or adverse developments or perceived additional delays or adverse developments with respect to the commercialization of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> including if sales or payor coverage does not meet investors&#8217;, analysts&#8217;, or our expectations, would significantly harm our business and the price of our securities could fall.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">41</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are dependent on GSK for the successful commercialization and development of products under the GSK Agreements. If GSK does not devote sufficient resources to the commercialization or development of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our royalty revenues under the GSK Agreements may not meet our, analysts&#8217;, or investors&#8217; expectations, due to a number of important factors. GSK has a substantial respiratory product portfolio in addition to the partnered products that are covered by the GSK Agreements. GSK may make respiratory product portfolio decisions or statements about its portfolio which may be, or may be perceived to be, harmful to the respiratory products partnered with us. For instance, GSK has wide discretion in determining the efforts and resources that it will apply to the development and commercialization of our partnered products. In addition, GSK may determine to focus its commercialization efforts on its own products. In the event GSK does not devote sufficient resources to the commercialization of our partnered products or chooses to reprioritize its commercial programs, our business, operations and stock price would be negatively affected.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any adverse change in FDA policy or guidance regarding the use of LABAs to treat asthma could significantly harm our royalty revenues and the price of our securities could fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 18, 2010, the FDA announced that LABAs should not be used alone in the treatment of asthma and it will require manufacturers to include this warning in the product labels of these drugs, along with taking other steps to reduce the overall use of these medicines. The FDA now requires that the product labels for LABA medicines reflect, among other things, that the use of LABAs is contraindicated without the use of an asthma controller medication such as an inhaled corticosteroid, that LABAs should only be used long term in patients whose asthma cannot be adequately controlled on asthma controller medications, and that LABAs should be used for the shortest duration of time required to achieve control of asthma symptoms and discontinued, if possible, once asthma control is achieved. In addition, in March 2010, the FDA held an Advisory Committee to discuss the design of medical research studies (known as &#8220;clinical trial design&#8221;) to evaluate serious asthma outcomes (such as hospitalizations, a procedure using a breathing tube known as intubation, or death) with the use of LABAs in the treatment of asthma in adults, adolescents, and children. Further, in April 2011, the FDA announced that to further evaluate the safety of LABAs, it required the manufacturers of currently marketed LABAs to conduct additional randomized, double blind, controlled clinical trials comparing the addition of LABAs to inhaled corticosteroids versus inhaled corticosteroids alone. These post&#8209;marketing studies have been completed and the FDA stated that treating asthma with LABAs in combination with ICS did not result in significantly more serious asthma-related side effects than treatment with ICS alone. The FDA subsequently removed the black box warning from the ICS/LABA package inserts. Although this concern appears to be resolved, it is unknown at this time what, if any, future concerns could impact the use of ICS/LABA and its potential impact on the prospects for FF/VI. Any adverse change in FDA policy or guidance regarding the use of LABAs to treat asthma could significantly harm our business and the price of our securities could fall.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any adverse developments to the regulatory status of either RELVAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> or ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> in the countries in which they have received regulatory approval, including labeling restrictions, safety findings, or any other limitation to usage, would harm our business and may cause the price of our securities to fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are approved and marketed in a number of countries, it is possible that adverse changes to the regulatory status of these products could occur in the event new safety issues are identified, treatment guidelines are changed, or new studies fail to demonstrate product benefits. A number of notable pharmaceutical products have experienced adverse developments during commercialization that have resulted in the product being withdrawn, approved uses being limited, or new warnings being included. In the event that any adverse regulatory changes were to occur to any of our products, our business would be harmed, and the price of our securities could fall.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">42</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any adverse developments or results or perceived adverse developments or results with respect to the ongoing studies for FF/VI in asthma or COPD, for UMEC/VI in COPD, or any future studies would significantly harm our business and the price of our securities could fall, and if regulatory authorities in those countries in which approval has not yet been granted determine that the ongoing studies for FF/VI in asthma or COPD or the ongoing studies for UMEC/VI for COPD do not demonstrate adequate safety and efficacy, the continued development of FF/VI or UMEC/VI or both could be significantly delayed, they might not be approved by these regulatory authorities, and even if approved they may be subject to restrictive labeling, any of which might harm our business, and the price of our securities could fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we have announced the completion of, and reported certain top&#8209;line data from, the Phase 3 registrational program for FF/VI in COPD and asthma, additional studies of FF/VI are underway or may commence in the future. Any adverse developments or perceived adverse developments with respect to any prior, current or future studies in these programs could significantly harm our business and the price of our securities could fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although the FDA, the European Medicines Agency, the Japanese Ministry of Health, Labour and Welfare and Health Canada and other jurisdictions have approved ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, it has not yet been approved in all jurisdictions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any adverse developments or results or perceived adverse developments or results with respect to other pending or future regulatory submissions for the FF/VI program or the UMEC/VI program might significantly harm our business and the price of our securities could fall. Examples of such adverse developments include, but are not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not every study, nor every dose in every study, in the Phase 3 programs for FF/VI achieved its primary endpoint and regulatory authorities may determine that additional clinical studies are required;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safety, efficacy or other concerns arising from clinical or non&#8209;clinical studies in these programs having to do with the LABA VI, which is a component of FF/VI and UMEC/VI;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analysts adjusting their sales forecasts downward from previous projections based on results or interpretations of results of prior, current or future studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">safety, efficacy or other concerns arising from clinical or non&#8209;clinical studies in these programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities determining that the Phase 3 programs in asthma or in COPD raise safety concerns or do not demonstrate adequate efficacy; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">any change in FDA (or comparable foreign regulatory agency) policy or guidance regarding the use of LABAs to treat asthma or the use of LABAs combined with a LAMA to treat COPD.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RELVAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> face substantial competition for their intended uses in the targeted markets from products discovered, developed, launched and commercialized both by GSK and by other pharmaceutical companies, which could cause the royalties payable to us pursuant to the LABA Collaboration Agreement to be less than expected, which in turn would harm our business and cause the price of our securities to fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GSK has responsibility for obtaining regulatory approval, launching and commercializing RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for their intended uses in the targeted markets around the world. While these products have received regulatory approval and have been launched and commercialized in the U.S. and certain other targeted markets, the products face substantial competition from existing products previously developed and commercialized both by GSK and by other competing pharmaceutical companies and can expect to face additional competition from new products that are discovered, developed and commercialized by the same pharmaceutical companies and other competitors going forward. For example, sales of generic Advair</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, GSK&#8217;s approved medicine for both COPD and asthma, continue to have a negative impact on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">43</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of the pharmaceutical companies competing in respiratory markets are international in scope with substantial financial, technical and personnel resources that permit them to discover, develop, obtain regulatory approval and commercialize new products in a highly efficient and low-cost manner at competitive prices to consumers. In addition, many of these competitors have substantial commercial infrastructure that facilitates commercializing their products in a highly efficient and low-cost manner at competitive prices to consumers. The market for products developed for treatment of COPD and asthma continues to experience significant innovation and reduced cost in bringing products to market over time. There can be no assurance that RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> will not be replaced by new products that are deemed more effective at lower cost to consumers. The ability of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to succeed and achieve the anticipated level of sales depends on the commercial and development performance of GSK to achieve and maintain a competitive advantage over other products with the same intended use in the targeted markets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> are less than anticipated because of existing or future competition in the markets in which they are commercialized, including competition from existing and new products that are perceived as lower cost or more effective, our royalty payments could be less than anticipated, which in turn would harm our business and cause the price of our securities to fall.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to utilize all of our net operating loss carryforwards.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have net operating loss carryforwards and other significant U.S. tax attributes that we believe could offset otherwise taxable income in the U.S. The net operating loss carryforwards available in any year to offset our net taxable income will be reduced following a more than 50% change in ownership during any period of 36 consecutive months (an &#8220;ownership change&#8221;) as determined under the Code. Transactions involving our common stock, even those outside our control, such as purchases or sales by investors, within the testing period could result in an ownership change. We have conducted an analysis to determine whether an ownership change had occurred since inception through December 31, 2025 and concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. Subsequent changes in our ownership or sale of our stock could have the effect of limiting the use of our net operating losses in the future. There may be certain annual limitations for utilization based on the above-described ownership change provisions. In addition, we may not be able to have sufficient future taxable income prior to their expiration because certain net operating losses have carryforward periods. Future changes in federal and state tax laws pertaining to net operating loss carryforwards may also cause limitations or restrictions from us claiming such net operating losses. If the net operating loss carryforwards become unavailable to us or are fully utilized, our future taxable income will not be shielded from federal and state income taxation absent certain U.S. federal and state tax credits, and the funds otherwise available for general corporate purposes would be reduced.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If any product candidates in any respiratory program partnered with GSK were not approved by regulatory authorities or are determined to be unsafe or ineffective in humans, our business would be adversely affected and the price of our securities could fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA must approve any new medicine before it can be marketed and sold in the U.S. Our partner GSK must provide the FDA and similar foreign regulatory authorities with data from preclinical and clinical studies that demonstrate that the product candidates are safe and effective for a defined indication before they can be approved for commercial distribution. GSK will not obtain this approval for a partnered product candidate unless and until the FDA approves an NDA. The processes by which regulatory approvals are obtained from the FDA to market and sell a new product are complex, require a number of years and involve the expenditure of substantial resources. In order to market medicines in foreign countries, separate regulatory approvals must be obtained in each country. The approval procedure varies among countries and can involve additional testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Conversely, failure to obtain approval in one or more country may make approval in other countries more difficult.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical studies involving product candidates partnered with GSK may reveal that those candidates are ineffective, inferior to existing approved medicines, unacceptably toxic, or that they have other unacceptable side effects. In addition, the results of preclinical studies do not necessarily predict clinical success, and larger and later&#8209;stage clinical studies may not produce the same results as earlier&#8209;stage clinical studies.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">44</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Frequently, product candidates that have shown promising results in early preclinical or clinical studies have subsequently suffered significant setbacks or failed in later clinical or non&#8209;clinical studies. In addition, clinical and non&#8209;clinical studies of potential products often reveal that it is not possible or practical to continue development efforts for these product candidates. If these studies are substantially delayed or fail to prove the safety and effectiveness of product candidates in development partnered with GSK, GSK may not receive regulatory approval for such product candidates and our business and financial condition could be materially harmed and the price of our securities might fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Several well&#8209;publicized Complete Response letters issued by the FDA and safety&#8209;related product withdrawals, suspensions, post&#8209;approval labeling revisions to include boxed warnings and changes in approved indications over the last several years, as well as growing public and governmental scrutiny of safety issues, have created a conservative regulatory environment. The implementation of new laws and regulations and revisions to FDA clinical trial design guidance have increased uncertainty regarding the approvability of a new drug. Further, there are additional requirements for approval of new drugs, including advisory committee meetings for new chemical entities, and formal risk evaluation and mitigation strategy at the FDA&#8217;s discretion. These laws, regulations, additional requirements and changes in interpretation could cause non&#8209;approval or further delays in the FDA&#8217;s review and approval of any product candidates in any respiratory program partnered with GSK.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if product candidates in any respiratory program partnered with GSK receive regulatory approval, as is the case with RELVAR</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">, commercialization of such products may be adversely affected by regulatory actions and oversight.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if GSK receives regulatory approval for product candidates in any respiratory program partnered with GSK, this approval may include limitations on the indicated uses for which GSK can market the medicines or the patient population that may utilize the medicines, which may limit the market for the medicines or put GSK at a competitive disadvantage relative to alternative therapies. These restrictions make it more difficult to market the approved products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For example, at the joint meeting of the Pulmonary&#8209;Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the FDA regarding the sNDA for BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as a treatment for asthma, the advisory committee recommended that a large LABA safety trial with BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> should be required in adults and in children ages 12&#8209;17, similar to the ongoing LABA safety trials being conducted as an FDA Post&#8209;Marketing Requirement by each of the manufacturers of LABA containing asthma treatments. The FDA did not concur with the recommendation. A pediatric program including patients 5&#8209;17 years of age is currently ongoing.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, the manufacturing, labeling, packaging, adverse event reporting, advertising, promotion and recordkeeping for the approved product remain subject to extensive and ongoing regulatory requirements. If we or GSK become aware of previously unknown problems with an approved product in the U.S. or overseas or at contract manufacturers&#8217; facilities, a regulatory authority may impose restrictions on the product, the contract manufacturers or on GSK, including requiring it to reformulate the product, conduct additional clinical studies, change the labeling of the product, withdraw the product from the market or require the contract manufacturer to implement changes to its facilities. GSK is also subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign countries in which any of the product candidates in any respiratory program partnered with GSK are approved for commercialization. The Federal Food, Drug, and Cosmetic Act, the Public Health Service Act and other federal and state statutes and regulations govern to varying degrees the research, development, manufacturing and commercial activities relating to prescription pharmaceutical products, including non&#8209;clinical and clinical testing, approval, production, labeling, sale, distribution, import, export, post&#8209;market surveillance, advertising, dissemination of information and promotion. Any failure to maintain regulatory approval would limit GSK&#8217;s ability to commercialize the product candidates in any respiratory program partnered with GSK, which could materially and adversely affect our business and financial condition, and which may cause the price of our securities to fall.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Pharmaceutical research and development are very costly and highly uncertain; we may not succeed in developing, licensing, or acquiring commercially successful products.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There are many difficulties and uncertainties inherent in pharmaceutical research and development, the introduction of new products and indications, business development activities to enhance or refine our product pipeline, and commercialization of our product.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">45</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a high rate of failure inherent in drug discovery and development. Failure can occur at any point in the process, including in later stages after substantial investment. New product candidates that appear promising in development or prior to being acquired may fail to reach the market or may have only limited commercial success because of efficacy or safety concerns, inability to obtain or maintain necessary regulatory approvals or payer reimbursement or coverage, failure to obtain placement on guidelines or recommendations published by third-party organizations that are commensurate with clinical data, the application of pricing controls, limited scope of approved uses, label changes, changes in the relevant treatment standards or the availability of newer better, or more cost-effective competitive products, difficulty or excessive costs to manufacture, insufficient infrastructure to support detection, diagnostic or other requisites for treatment, ineffectiveness in reaching healthcare professionals, including digitally given the increase in virtual engagements, or infringement of the patents or intellectual property rights of others. We may also fail to allocate research and development resources efficiently, fail to pursue or invest sufficiently in product candidates or indications that may have been successful, or fail to optimally balance trial design, conduct, and speed to accomplish desired outcomes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulatory agencies establish high hurdles for the efficacy and safety of new products and indications. Delay, uncertainty, unpredictability, and inconsistency in drug approval processes across markets and agencies can result in delays in product launches, lost market opportunities, impairment of inventories, and other negative impacts. In addition, it can be very difficult to predict revenue growth rates of, or variability in demand for, new products and indications, which in some cases leads to difficult meeting product demand or, on the other hand, excess inventory and related financial charges.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We cannot state with certainty when or whether our products now under development will be approved or launched; whether, if initially granted, such approval will be maintained; whether we will be able to develop, license, or otherwise acquire additional product candidates or products; or whether our products, once launched, will be commercially successful.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Failure to successfully develop and market new products in the short term or long term would have a material adverse effect on the Company&#8217;s business, results of operations, cash flow, financial condition and prospects.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acquisitions or strategic investments we have made or may make could turn out to be unsuccessful.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our strategy, we frequently monitor and analyze acquisition or investment opportunities that we believe will create value for our shareholders.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Existing or future acquisitions and investments could involve numerous risks that may prevent us from fully realizing the benefits that we anticipated as a result of the transaction. These risks include the failure to derive any commercial value from the acquired technology, products and intellectual property including as a result of the failure to obtain regulatory approval or to monetize products once approved, as well as risks from lengthy product development and high upfront development costs without guarantee of successful results. Patents and other intellectual property rights covering acquired technology and/or intellectual property may not be obtained, and if obtained, may not be sufficient to fully protect the technology or intellectual property. We may be subject to liabilities, including unanticipated litigation costs, that are not covered by indemnification protection we may obtain. As we pursue or consummate a strategic acquisition or investment, we may value the acquired or funded company incorrectly, fail to successfully manage our operations as our asset diversity increases, expend unforeseen costs during the acquisition or integration process, or encounter other unanticipated risks or challenges. Once an investment is made, we may fail to value it accurately, properly account for it in our consolidated financial statements, or successfully divest it or otherwise realize the value which we originally invested or have subsequently reflected in our consolidated financial statements. Any failure by us to effectively limit such risks as we implement our acquisitions or strategic investments could have a material adverse effect on our business, financial condition or results of operations and may negatively impact our net income and cause the price of our securities to fall.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have a significant amount of debt including our convertible notes that are senior in capital structure and cash flow, respectively, to our common stockholders. Satisfying the obligations relating to our debt could adversely affect our liquidity or the amount or timing of potential distributions to our stockholders.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had $261.0 million in total debt outstanding, comprised of the principal outstanding under our convertible notes due 2028 (the &#8220;2028 Notes&#8221;). The 2028 Notes are unsecured debt. Holders of the 2028 Notes may require us to purchase all or any portion of their 2028 Notes at 100% of their principal amount, plus any unpaid interest, upon a fundamental change. A fundamental change is generally defined to include a merger involving us, an acquisition of a majority of our outstanding common stock. In addition, to the extent we pursue and complete a monetization transaction or a transaction that modifies our corporate structure, the structure of such transaction may qualify as a fundamental change under the 2028 Notes, which could trigger the put rights of the holders of the 2028 Notes, in which case we would be required to use a portion of the net proceeds from such transaction to repurchase any Notes put to us.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">46</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Satisfying the obligations of this debt could adversely affect the amount or timing of any distributions to our stockholders. We may choose to satisfy, repurchase, or refinance this debt through public or private equity or debt financings if we deem such financings available on favorable terms. If any or all of the 2028 Notes are not converted into shares of our common stock before the maturity date, we will have to pay the holders the full aggregate principal amount of the 2028 Notes then outstanding. Any of the above payments could have a material adverse effect on our cash position. If we fail to satisfy these obligations, it may result in a default under the indenture, which could result in a default under certain of our other debt instruments, if any. Any such default would harm our business and the price of our securities could fall.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we lose key management personnel, or if we fail to retain our key employees, our ability to manage our business may be impaired.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our performance is substantially dependent on the continued service and performance of our management team, who have extensive experience and specialized expertise in our business.  None of our employees have employment commitments for any fixed period of time and all may leave our employment at will. If we fail to retain our qualified personnel or to replace them when they leave, our ability to manage our business may be impaired, which may cause the price of our securities to fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To continue to commercialize our products, and advance the research, development, and commercialization of additional modalities, indications, and product candidates, we have expanded, and may need to further expand, our workforce. Our failure to compete effectively for talent could negatively affect sales of our current and any future approved products, and could result in material financial, legal, commercial, or reputational harm to our business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Uneven economic growth or downturns or international trade and other global disruptions, geopolitical tensions, or disputes could adversely affect our business and operating results.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Economic slowdowns could lead to decreased utilization of our products, affecting our sales. Declining tax revenues and increased government spending on other programs attributable to uneven economic growth or downturns increase the pressure on governments to reduce healthcare spending, leading to increased control of drug prices or lower utilization. Also, if our customers, suppliers, or business partners experience financial difficulties, we could experience slower customer collections, greater bad debt expense, and performance defaults by suppliers or business partners. Similarly, uneven economic growth or downturns could limit our ability to access capital markets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, trade and other global disputes and interruptions, including related to tariffs, trade protection measures, import or export licensing requirements, the imposition of trade sanctions or similar restrictions by the U.S. or other governments, international tension and conflicts, as well as cost inflation, strains on global transportation, manufacturing, and labor markets, and public health outbreaks, epidemics, or pandemics, affect our ability to do business. For example, the financial impact of higher energy prices, defense spending, and inflation due, in part, to geopolitical and economic disruptions, has further exacerbated financial pressures on governments with single-payer or government funded healthcare systems, leading to increased impetus for increases in rebates, clawbacks, and other reforms to reimbursement systems, particularly in Europe. These and similar events have adversely affected, and may continue to adversely affect, us, our business partners, and our customers.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to developments related to our business or financial results, or those of our competitors, uneven economic growth, downturns, or other negative global developments, could also undermine our growth or result in significant and sudden declines in the trading price of our common stock and market capitalization.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we rely on third parties for several important aspects of our business. During challenging and uncertain economic times and in tight credit markets, there may be a disruption or delay in the performance of our third-party contractors, suppliers or partners. If such third parties are unable to satisfy their commitments to us, our business and results of operations would be adversely affected.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our success in preclinical studies or clinical trials may not be indicative of results in current or future clinical trials.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Certain product candidates may fail to show the necessary safety and efficacy in clinical development despite positive results in preclinical studies or having successfully advanced through initial clinical trials.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">47</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In addition, the design of a clinical trial can determine whether its results will support approval of a product, and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval. There is a high failure rate for drugs and biologic products proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections because of many factors, including to changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of the FDA, the EMA or other comparable regulatory authorities, or do not otherwise produce favorable results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of that product candidate.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We, or our potential collaborators, may not commercialize, market, promote, or sell any product candidate without obtaining marketing approval from the FDA, the EMA or other comparable regulatory authority, and we may never receive such approvals. Even if our product candidates appear sufficiently effective and/or safe in patients in well-controlled clinical trials, it is impossible to predict if or when these product candidates will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We may experience numerous unforeseen events prior to, during, or because of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, the EMA or other comparable regulatory authority may change from the views they have expressed to us as to the design, implementation, and/or interpretation of our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators or institutional review boards may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">clinical trials of product candidates may produce negative or inconclusive results;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may not be able to complete our clinical trials in a timely manner, if at all, for example because the number of patients required for clinical trials of our product candidates may be larger than we anticipate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate, or we may fail to recruit suitable patients to participate in a trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may fail to comply with regulatory requirements applicable to them, to the FDA&#8217;s or other comparable regulatory authority&#8217;s, satisfaction;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">48</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulators may issue a clinical hold, or regulators or institutional review boards may require that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, the EMA or other comparable regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with whom we enter into agreements for clinical and commercial supplies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our product candidates, once exposed to greater numbers of patients, may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or institutional review boards to suspend or terminate the clinical trials or cause regulatory authorities to refuse to approve our product candidates or approve them only with significant restrictions on distribution or use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">even if our clinical trials are successful, the FDA, the EMA or other comparable regulatory authorities may determine that the overall risk-benefit profiles of our product candidates are insufficient to support marketing authorization; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval policies or regulations of the FDA, the EMA or other comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials or other testing of those product candidates, or if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">not obtain marketing approval at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings, such as black box warnings or a REMS program;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be subject to additional post-marketing testing requirements; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">be required to remove the product from the market after obtaining marketing approval.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product development costs may also increase if we experience delays in testing and we may be required to obtain additional funds to complete clinical trials. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of a product candidate.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are not successful in discovering, developing, and commercializing additional product candidates, our ability to expand and achieve our strategic objectives would be impaired.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have chosen to devote a substantial amount of our effort on the continued clinical testing and potential regulatory approval of our product candidates. However, an element of our strategy may include the development of novel product candidates in other therapeutic areas. Our efforts to identify and develop product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including but not limited to the following:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the research methodology used may not be successful in identifying potential product candidates;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">49</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">competitors may develop alternatives that render our product candidates obsolete or less attractive;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the FDA, the EMA or other regulatory authorities may not approve or agree with the intended use of a new product candidate.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to develop and successfully generate revenue from other current and future product candidates, our future prospects may be harmed, and we will be more vulnerable to any problems that we or potential collaborators may encounter in developing and commercializing our current product candidates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we or our collaborators experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be able to initiate, continue or complete clinical trials of our product candidates that we develop if we and our collaborators are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA, the EMA or other comparable regulatory authority. We have limited experience enrolling patients in our clinical trials and cannot predict how successful we will be in enrolling patients in future clinical trials.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For instance, patients involved in our clinical trials are often in the hospital setting and the decision to participate can be made by the caregiver or doctor. Accordingly, seeking consent for patient participation may become difficult when the family and/or the patient may not be available to consider participation in a clinical trial and the providers/investigators seeking the consent often have no established relationship with the family or patient. In addition, some of our competitors have ongoing clinical trials to treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors. If we are not successful at enrolling patients in one clinical trial, it may affect when we are able to initiate the next clinical trial, which could result in significant delays in our efforts to pursue regulatory approval of and commercialize our product candidates. Patient enrollment is affected by other factors including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the size and nature of the patient population;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the severity of the disease under investigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the eligibility criteria for participation in the clinical trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the design of the clinical trial;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the perceived risks and benefits of the product candidate under study;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to recruit clinical trial investigators with appropriate experience;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of drugs approved to treat the diseases under study;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the patient referral practices of physicians;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to obtain and maintain patient consents;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to monitor patients adequately during and after treatment;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">50</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of public health epidemics, such as the COVID-19 pandemic.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in these clinical trials may result in increased development costs for our product candidates, which would reduce the capital we have available to support current and future product candidates and may result in the need to raise additional capital earlier than planned and could cause the value of our common stock to decline and limit our ability to obtain additional financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts (generally referred to as adverse events), to their doctor. We are required to report adverse events to the FDA and other regulatory authorities. Often, it is not possible to determine whether the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions or require additional testing to confirm or refute these observations, if they occur. In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical programs, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects. Many times, side effects are only detectable after investigational drugs are tested in large-scale, Phase&#8239;3 clinical trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our current product candidates or any future product candidates, have side effects or causes serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which could harm our business, prospects, operating results and financial condition.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed and our ability to generate revenue through their sale may be delayed or eliminated. Any of these occurrences may significantly harm our business, financial condition and prospects.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, if any of our product candidates receive marketing approval, regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication, or the adoption of a REMS program to ensure that the benefits outweigh its risks, which may include, among other things, a medication guide outlining the risks of the drug for distribution to patients and a communication plan to health care practitioners, and/or significant restrictions on distribution or use of the drug. Furthermore, if we or others later identify undesirable side effects caused by our product candidates, several potentially significant negative consequences could result, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">regulatory authorities may require additional warnings on the label or impose distribution or use restrictions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to change the way a product candidate is administered or conduct additional clinical trials, including one or more post-market studies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we could be sued and held liable for harm caused to patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may be required to implement a REMS, including the creation of a medication guide outlining the risks of such side effects for distribution to patients, and/or other elements to assure safe use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we may need to conduct a recall; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our reputation may suffer.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved, or could substantially increase commercialization costs and expenses, which could delay or prevent us from generating revenue from the sale of our products and harm our business and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">51</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may announce interim top-line or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our operations could be disrupted by failure of our information systems or cyber-attacks.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Our operations could be disrupted if our information systems fail, if we are unsuccessful in implementing necessary upgrades, or if we are subject to cyber-attacks. Our business depends on the efficient and uninterrupted operation of our computer and communications systems and networks, hardware and software systems and our other information technology. We collect and maintain information, which includes confidential and proprietary information as well as personal information regarding our employees and business contacts, in digital form. Data maintained in digital form is subject to risk of cyber-attacks, which are increasing in frequency and sophistication. Cyber-attacks could include the deployment of harmful malware, viruses, worms, and other means to affect service reliability and threaten data confidentiality, integrity and availability. As discussed below in Item 1C, our systems have been subject to security incidents, none of which have been material. Despite our efforts to monitor and safeguard our systems to prevent data compromise, the possibility of a future data compromise cannot be eliminated entirely, and risks associated with intrusion, tampering, and theft remain. A failure of our systems, or an inability to successfully expand the capacity of these systems, or an inability to successfully integrate new technologies into our existing systems could have a material adverse effect on our business, results of operations, financial condition, and cash flows.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The Company and its vendors&#8217; sophisticated information technology operations are spread across multiple, sometimes inconsistent, platforms, which pose difficulties in maintaining data integrity across systems. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional or improper dissemination or destruction of confidential information stored in the Company&#8217;s systems.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any breach of our security measures or the accidental loss, inadvertent disclosure, unapproved dissemination, misappropriation or misuse of trade secrets, proprietary information or other confidential information, whether as a result of theft, hacking, fraud, trickery or other forms of deception, or for any other cause, could adversely affect our business position. Further, any such interruption, security breach, loss or disclosure of confidential information could result in financial, legal, business and reputational harm to the Company and could have a material adverse effect on our business, financial condition, results of operations, cash flows and stock price.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The use or anticipated use of artificial intelligence (&#8220;AI&#8221;) technologies, including generative AI, by us or third parties, may increase or create new operational risks.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AI technologies offer numerous potential benefits, such as creating or increasing operational efficiencies, and we expect the use of AI and generative AI by us, third parties on our behalf, and other market actors, including our competitors, to increase. However, the deployment of such technologies also poses certain risks, including that the algorithms may be flawed, misused or otherwise function in an unexpected manner&#894; data sets may be insufficient, of poor quality, or contain biased information&#894; and inappropriate or controversial data practices by data scientists, engineers, and end-users could impair results. The relative newness of the technology, the speed at which it is being adopted, and the paucity of laws, regulations or standards expressly and specifically governing its use increases these risks. If the analyses that AI-based applications assist in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability and brand or reputational harm. Our competitors may also adopt AI or generative AI more quickly or more effectively than we do, which could cause competitive harm. Furthermore, use of AI-based software may lead to the release of confidential information which may impact our ability to realize the benefits of our intellectual property.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">52</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to comply with applicable data protection, privacy, and similar consumer protection laws and regulations, we could become subject to fines or penalties, or incur other costs that could harm our business.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Numerous federal and state laws and regulations in the U.S. address consumer privacy, regulating the collection, use, disclosure, and security of personal information. Such laws are evolving, many are recently enacted, and all are subject to potentially differing interpretations. For example, the California Consumer Privacy Act (&#8220;CCPA&#8221;), which initially came into effect on January 1, 2020, created new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA was then amended, and those amendments, which went into effect on January 1, 2023, included new rights and established a new agency in California, the California Privacy Protection Agency (&#8220;CPPA&#8221;), to implement and enforce the CCPA. Today, the CCPA requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches, among other things. The CPPA is currently considering rules that would potentially broaden the scope of the requirements in areas such as cybersecurity and so-called automated decision-making technologies. The CCPA may significantly impact our business activities and require substantial compliance costs that adversely affect business, operating results, prospects and financial condition. We cannot predict what new regulations CPPA might adopt, or what amendments the California legislature may enact. And while some states have already enacted very similar privacy laws, we cannot predict what other states may enact their own privacy laws, what the scope and requirements of such laws may be, or how they will affect our business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Increased scrutiny of our corporate citizenship and sustainability will likely result in additional costs and risks and may adversely impact our reputation, employee retention and willingness of customers and suppliers to do business with us.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is an increasing focus from certain customers, consumers, employees and other stakeholders concerning matters relating to corporate citizenship and sustainability. If our practices fail to meet regulatory requirements or stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, support for local communities, human capital management, employee health and safety practices and corporate governance and transparency, reputation and employee retention may be negatively impacted, and customers and suppliers may be unwilling to do business with us.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The standards for tracking and reporting on corporate citizenship and sustainability matters are relatively new, have not been harmonized and continue to evolve. The disclosure frameworks we choose to align with, if any, may change from time-to-time and may result in a lack of consistent or meaningful comparative data from period to period. Ensuring there are systems and processes in place to comply with various tracking and reporting obligations will require management time and expense. In addition, our processes and controls may not always comply with evolving standards for identifying, measuring and reporting metrics, our interpretation of reporting standards may differ from those of others and such standards may change over time, any of which could result in significant revisions to our goals or reported progress in achieving such goals.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we fail to adopt corporate citizenship and sustainability standards or practices as quickly as stakeholders desire, fail, or be perceived to fail, in our achievement of such initiatives or goals, or fail in fully and accurately reporting our progress on such initiatives and goals, our reputation, business, financial performance and growth may be adversely impacted. In addition, we could be criticized for the scope of such initiatives or goals or perceived as not acting responsibly in connection with these matters. Our business could be negatively impacted by such matters. Any such matters, or related corporate citizenship and sustainability matters, could have a material adverse effect on our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">53</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Dependence on Third Parties</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on third parties to conduct the clinical trials for our products and product candidates, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials or failing to comply with applicable regulatory requirements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have engaged contract research organizations, or CROs, to conduct our ongoing and planned clinical trials. We also expect to engage CROs for any of our other product candidates that may progress to clinical development. We expect to rely on CROs, as well as other third parties, such as clinical data management organizations, medical institutions and clinical investigators, to conduct those clinical trials. Agreements with such third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities would be delayed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with regulatory standards, commonly referred to as good clinical practices, or GCPs, for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Similar regulatory requirements apply outside the United States, including the International Council for Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use, or ICH.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also required to register certain ongoing clinical trials and post the results of certain completed clinical trials on government-sponsored, publicly accessible databases, such as ClinicalTrials.gov, within specified timeframes. Failure to do so by us or by third parties can result in FDA refusal to approve applications based on the clinical data, enforcement actions, adverse publicity and civil and criminal sanctions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Furthermore, these third parties may also have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the results of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or rejection could prevent us from commercializing our product candidates.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also expect to rely on other third parties to store and distribute product supplies for our clinical trials. Any performance failure or regulatory noncompliance on the part of our distributors could delay clinical development or marketing approval of our product candidates or commercialization of our products, resulting in additional losses and depriving us of potential product revenue.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">54</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We depend on information technology and a failure of, or significant disruption to, those systems, or a failure to adequately adopt emerging technologies such as artificial intelligence, could have a material adverse effect on our business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We rely on sophisticated software applications and complex information technology systems (including cloud services) to operate our business, which are inherently vulnerable to malicious intrusion, random attack, loss of data privacy, disruption, degradation or breakdown. Certain of these applications and systems are managed, hosted, provided or used by third parties. Data privacy or security breaches of our internal systems or those of our information technology vendors may in the future result in the failure of critical business operations. Such breaches may cause sensitive data, including intellectual property, trade secrets or personal information belonging to us, our patients, customers, employees or business partners, to be exposed to unauthorized persons or to the public. To date, neither our business nor operations have been materially impacted by such incidents, however, the healthcare industry remains a target of cyber&#8208;attacks. Cybersecurity attacks and incidents are increasing in their frequency, sophistication and intensity and, due to the nature of some of these attacks, there is a risk that they may remain undetected for a period of time. Our investments in the protection of our data and information technology and our efforts to monitor our systems on an ongoing basis may be insufficient to prevent compromises in our information technology systems that could have a material adverse effect on our business. Such adverse consequences could include loss of revenue or the loss of critical or sensitive information from our or third-party providers&#8217; databases or information technology systems and could also result in legal, financial, reputational or business harm to us and potentially substantial remediation costs. In addition, our cyber insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems or those of our third&#8208;party vendors. Additionally, we utilize artificial intelligence (AI) and other emerging technologies in select applications to support our operations. These technologies may present opportunities for our business but may also entail risks, including that AI&#8208;generated analyses utilized by us could be deficient or exacerbate regulatory, cybersecurity or other significant risks. Further, our failure to effectively implement these technologies could hinder our ability to compete, as competitors&#8217; advancements in AI may lead to more efficient operations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We rely on collaborations with third parties for the development of both our product and commercial candidates, and we may seek additional collaborations in the future. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product or commercial candidates.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited capabilities for drug development, and our product development programs and the commercialization of our product candidates will require substantial additional cash to fund expenses. As a result of these factors, we are, and expect to continue to be, dependent on collaborations relating to the development of our existing and future product candidates. We have had and will continue to have discussions on potential partnering opportunities with various pharmaceutical companies. In addition, we may seek third-party collaborators for the development and commercialization of our product candidates, particularly for the commercialization of our product candidates outside the United States. Likely collaborators for any collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies and we may face significant competition in seeking appropriate collaborators. If we fail to enter into or maintain collaborations on reasonable terms or at all, our ability to develop our existing or future product candidates could be delayed, the commercial potential of our products could change, and our costs of development and commercialization could increase. If we enter into any future collaboration arrangements with any third parties, we will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our collaborations and any future collaborations we might enter into may pose a number of risks, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators often have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not perform their obligations as expected or contractually obligated;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">55</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may not properly maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators may be subject to geo-political actions, natural disasters or other occurrences, including public health epidemics such as the COVID-19 pandemic;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">collaborators&#8217; decisions may limit the availability of the product supplies required for development, clinical and commercial activities.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaboration agreements may not lead to development or successful commercialization of product or commercial candidates in the most efficient manner or at all. If a present or future collaborator were to be involved in a business combination, the continued pursuit and emphasis on our drug development or commercialization program could be delayed, diminished or terminated.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our reliance on third parties to manufacture our product candidates and approved products increases the risk that we will not have sufficient quantities of our product candidates or approved products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We do not own or operate manufacturing facilities to produce clinical supplies of the product candidates that we are developing or evaluating or commercial supplies of our approved products. We have limited personnel with experience in drug manufacturing and lack the resources and the capabilities to manufacture any of our product candidates on a clinical scale or our approved products on a commercial scale. We currently rely on third parties for supply of our product candidates and approved products, and our strategy is to outsource all manufacturing of our product candidates and approved products, if any, to third parties.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To conduct clinical trials of our product candidates, we will need to identify suitable manufacturers with the capabilities to manufacture our compounds in large quantities in a manner consistent with existing regulations. Our third-party manufacturers may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and at any other time. If our manufacturers are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing and clinical trials of that product candidate may be delayed, or infeasible, and regulatory approval or commercial launch of that product candidate may be delayed or not obtained, which could significantly harm our business.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we can establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails risks, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reliance on the third party for regulatory compliance and quality assurance;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">56</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">supply chain disruptions due to geo-political actions, natural disasters or public healthy crises, including epidemics such as the COVID-19 pandemic.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to develop product candidates and commercialize any products that receive marketing approval on a timely and competitive basis.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to win government or non-profit contracts or grants to fund our product development activities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, we have relied in part on funding from contracts or grants from government agencies and non-profit entities and it is part of our strategy to continue to do so. Such contracts or grants can be highly attractive because they provide capital to fund the ongoing development of our product candidates without diluting our stockholders. However, there is often significant competition for these contracts or grants. Entities offering contracts or grants may have requirements to apply for or to otherwise be eligible to receive certain contracts or grants that our competitors may be able to satisfy that we cannot. In addition, such entities may make arbitrary decisions as to whether to offer contracts or make grants, to whom the contracts or grants will be awarded, and the size of the contracts or grants to each awardee. Even if we can satisfy the award requirements, there is no guarantee that we will be selected to receive any contract or grant. If we are not successful in achieving this form of funding for our clinical trials, we will need to seek alternative means of funding which may not be available to the same extent, if at all.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our and our investees' reliance on non-profit and government funding for certain of our and our investees' programs adds uncertainty to our and our investees' research, development and commercialization efforts with respect to those programs and may impose requirements that increase the costs of the research, development and commercialization of product candidates developed under those non-profit and government-funded programs.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not have the right to prohibit the U.S. government from using certain technologies developed by us and our investees, and may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the U.S. government. The U.S. government generally takes the position that it has the right to royalty-free use of technologies that are developed under U.S. government contracts.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, government contracts and grants, and subcontracts and subawards awarded in the performance of those contracts and grants, normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">specialized accounting systems unique to government awards;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adhering to stewardship principles imposed by CARB-X as a condition of the award;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">public disclosures of certain award information, which may enable competitors to gain insights into our research program; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination and affirmative action programs and environmental compliance requirements.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">57</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an organization, we are relatively new to government contracting and new to the regulatory compliance obligations that such contracting entails. If we fail to maintain compliance with those obligations, we may be subject to potential liability and termination of our contracts.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a U.S. government contractor, we are subject to financial audits and other reviews by the U.S. government of our costs and performance on our contracts, as well as our accounting and general business practices related to these contracts. Based on the results of its audits, the government may adjust our contract-related costs and fees, including allocated indirect costs.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to government funding, we receive grants and other financial support from non-profit organizations and philanthropic funders to support our research and development activities. Such funding is typically awarded for specified research programs and is subject to milestone-based payments, reporting requirements, intellectual property restrictions, stewardship obligations, and other compliance conditions similar to those imposed under government awards. If we fail to comply with these requirements, we may be required to repay funds, become ineligible for future funding, and suffer reputational harm.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reliance on non-profit and philanthropic funding subjects us to risks outside of our control, including the availability of funding, changes in the strategic priorities of funding organizations, economic downturns affecting charitable giving, and the discontinuation or reduction of grant programs. Non-profit funders may also impose restrictions on the use, licensing, pricing, or commercialization of technologies developed with their support, which could limit our flexibility in pursuing commercial opportunities or entering into strategic collaborations. Any reduction, delay, or termination of such funding could materially adversely affect our research programs, financial condition, and results of operations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to the Commercialization of Our Product Candidates</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if any of our product candidates receives marketing approval, such product candidate may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if we obtain approvals from the FDA, the EMA or other comparable regulatory agencies and can initiate commercialization of a product candidate we develop, the product candidate may not achieve market acceptance among physicians, patients, hospitals, including pharmacy directors, and third-party payors and, ultimately, may not be commercially successful. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the efficacy and potential advantages compared to alternative treatments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential and perceived advantages and disadvantages of the product candidates, including cost and clinical benefit relative to alternative treatments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">acceptance by physicians, patients, operators of hospitals, including in-hospital formularies, and treatment facilities and parties responsible for coverage and reimbursement of the product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the availability of coverage and adequate reimbursement by third-party payors and government authorities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the ability to manufacture our product in sufficient quantities and yields;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the strength and effectiveness of marketing and distribution support;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the prevalence and severity of any side effects;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">limitations or warnings, including distribution or use restrictions, contained in the product&#8217;s approved labeling or an approved REMS;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular infections;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">58</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the approval of other new products for the same indications;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing of market introduction of the approved product as well as competitive products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the emergence of bacterial resistance to the product; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the rate at which resistance to other drugs in the target infections grow.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Any failure by any of our product candidates that obtains regulatory approval to achieve market acceptance or commercial success could have a material adverse effect on our business prospects.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development and commercialization of new drug products is highly competitive. We face competition from major multi-national pharmaceutical companies, biotechnology companies, specialty pharmaceutical companies and generic drug companies with respect to our current and future product candidates. There are several large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of product candidates for the treatment of drug-resistant infections. Potential competitors also include academic institutions, government agencies and other public and private research organizations. Our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective, more effectively marketed and sold or less costly than our product candidates, which could render our product candidates non-competitive and obsolete.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If our competitors obtain marketing approval from the FDA, the EMA or other comparable regulatory authorities for their product candidates more rapidly than we do, it could result in our competitors establishing a strong market position before we are able to enter the market.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regulation of generic and biosimilar products varies around the world and such regulation is complex and subject to ongoing interpretation and implementation by regulatory agencies and courts. Particularly for biosimilars, health authority guidelines and legislative actions could make it less burdensome for competitor products to enter the market and further incentivize uptake of biosimilars. In the U.S., the FDA has issued several &#8220;interchangeability&#8221; designations for biosimilar products and is expected to continue doing so in the future. These designations could &#8211; subject to state law requirements &#8211; enable pharmacies to substitute biosimilars for innovator biological products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many of such our competitors have greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do as an organization. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Our competitors also may obtain approval from the FDA, the EMA or other comparable regulatory agencies for their product candidates more rapidly than we may obtain approval for ours, which could result in product approval delays if a competitor obtains market exclusivity from the FDA or the EMA, or our competitors establish a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic drugs. Additional drugs may become available on a generic basis over the coming years. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium over competitive generic drugs.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">59</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our industry continues to be challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet. Third parties may illegally distribute and sell counterfeit versions of our products. To distributors and patients, counterfeit products may be visually indistinguishable from the authentic version. Counterfeit medicines pose a risk to patient health and safety because of the conditions under which they are manufactured - often in unregulated, unlicensed, uninspected and unsanitary sites - as well as the lack of regulation of their contents.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The industry&#8217;s failure to mitigate the threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased threat of litigation. In addition, diversion of our products from their authorized market into other channels may result in reduced revenues and negatively affect our profitability.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Coverage and adequate reimbursement may not be available for our current or any future product candidates, which could make it difficult for us to sell profitably, if approved.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market acceptance and sales of any product candidates that we or our collaborators commercialize will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from third-party payors, including government health care programs (such as Medicare and Medicaid), government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for any product candidates that we develop will be made on a payor-by-payor basis. One payor&#8217;s determination to provide coverage for a drug does not assure that other payors will also provide coverage and adequate reimbursement for the drug. Additionally, a third-party payor&#8217;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy, and on what tier of its list of covered drugs, or formulary, it will be placed. The position on a payor&#8217;s formulary generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our drugs, and providers are unlikely to prescribe our drugs, unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our drugs and their administration.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A primary trend in the United States healthcare industry and elsewhere is cost containment. Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand, or the price of, any drug for which we obtain marketing approval for. If coverage and adequate reimbursement are not available, or are available only to limited levels, we may not be able to successfully commercialize our current and any future product candidates that we develop.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any drugs that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced resources of our management to pursue our business strategy;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">decreased demand for any product candidates or products that we may develop;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injury to our reputation and significant negative media attention;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of clinical trial participants;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">60</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">initiation of investigations by regulators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">significant costs to defend the resulting litigation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">substantial monetary awards paid to clinical trial participants or patients;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">loss of revenue; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the inability to commercialize any drugs that we may develop.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently hold product liability insurance coverage in an amount that may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">There are a variety of risks associated with marketing our product candidates internationally, which could affect our business.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We or our collaborators may seek regulatory approval for our product candidates outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">differing regulatory requirements in foreign countries;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from a foreign market with low or lower prices rather than buying them locally;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">economic weakness, including inflation, or political instability in foreign economies and markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign taxes, including withholding of payroll taxes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">difficulties staffing and managing foreign operations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">workforce uncertainty in countries where labor unrest is more common than in the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">reduced level of reimbursement, pricing and insurance regimes compared to the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods, fires, and public health epidemics, such as the COVID-19 pandemic.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These and other risks associated with our international operations may compromise our ability to achieve or maintain profitability.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">61</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Managing Our Growth</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have pursued and may continue to pursue acquisitions. Acquisitions could be difficult to integrate, divert the attention of key personnel, disrupt our business, dilute stockholder value and impair our financial results.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our business strategy, we have pursued and intend to continue to pursue acquisitions of complementary businesses, products, services or technologies that we believe could accelerate our ability to compete in our existing markets or allow us to enter new markets. Any of these transactions could be material to our financial condition and results of operations. If we fail to properly evaluate or integrate acquisitions, we may not achieve the anticipated benefits of any such acquisitions, and we may incur costs in excess of what we anticipate. The failure to successfully evaluate and execute acquisitions or otherwise adequately address these risks could materially harm our business and financial results.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Acquisitions also frequently result in the recording of goodwill and other intangible assets which are subject to potential impairments which could harm our financial results. As a result, if we fail to properly evaluate acquisitions or investments, we may not achieve the anticipated benefits of any such acquisitions, and we may incur costs in excess of what we anticipate. The failure to successfully evaluate and execute acquisitions or investments or otherwise adequately address these risks could materially harm our business and financial results.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we engage in future acquisitions or strategic collaborations, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary drugs, intellectual property rights, technologies or businesses, as deemed appropriate to carry out our business plan. Any potential acquisition or strategic collaboration may entail numerous risks, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased operating expenses and cash requirements;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the assumption of additional indebtedness or contingent liabilities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">assimilation of operations, intellectual property and drugs of an acquired company, including challenges associated with integrating new personnel;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the diversion of our management&#8217;s attention from our existing drug programs and initiatives in pursuing such a strategic partnership, merger or acquisition;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business relationships;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or drug candidates and regulatory approvals; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our inability to generate revenue from acquired technology and/or drugs sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Our Intellectual Property</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to obtain and maintain patent protection for our technology and product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and drugs similar or identical to ours, and our ability to successfully commercialize our technology and product candidates may be adversely affected.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technology and product candidates. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage that we may have, which could harm our business and ability to achieve profitability. To protect our proprietary positions, we file patent applications in the United States and abroad related to our novel technologies and product candidates that are important to our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">62</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent application and prosecution process are expensive and time-consuming. We, our current licensees, or any future licensors and licensees may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. We or our current licensees, or any future licensors or licensees may also fail to identify patentable aspects of our research and development before it is too late to obtain patent protection.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with our best interests. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If our current licensees, or any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised, and we might not be able to prevent third parties from making, using and selling competing products. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and/or unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability to prevent competition from third parties.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. For example, European patent law currently restricts the patentability of methods of treatment of the human body more than United States law does. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Furthermore, recent changes in patent laws in the United States, including the America Invents Act of 2011, may affect the scope, strength and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may not be aware of all third-party intellectual property rights potentially relating to our current and future product candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#8239;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Similarly, should we own any patents or patent applications in the future, we may not be certain that we were the first to file for patent protection for the inventions claimed in such patents or patent applications. As a result, the issuance, scope, validity and commercial value of our patent rights cannot be predicted with any certainty. Moreover, we may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in derivation, ex-parte reexamination, or inter partes review proceedings in the USPTO or similar proceedings elsewhere, challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection against competing products or processes sufficient to achieve our business objectives, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. Our competitors may seek to market generic versions of any approved products by submitting abbreviated new drug applications to the FDA in which they claim that patents owned or licensed by us are invalid, unenforceable and/or not infringed. Alternatively, our competitors may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or other agency with jurisdiction may find our patents invalid and/or unenforceable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">63</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate, a patent being held unenforceable, and/or in one or more or in patent claims being narrowed or invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products or limit the duration of the patent protection of our technology and products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest filing date of a non-provisional application to which the patent claims priority. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our candidates might expire before or shortly after our candidates are commercialized. Depending upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the European Union, as discussed above. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case, and our competitive position, business, financial condition, results of operations, and prospects could be materially harmed.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A third party may hold intellectual property rights, including patent rights, that are important or necessary to the development of our product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties. Such a license may not be available on commercially reasonable terms, or at all, and we could be forced to accept unfavorable contractual terms. If we are unable to obtain such licenses on commercially reasonable terms, our business could be harmed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could materially harm our business, financial condition, results of operations, and prospects.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">64</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors and other third parties may infringe our issued patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, trademarks, copyrights or other intellectual property. In addition, in a patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable or that one or more claims of a patent are invalid, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the basis that our patents do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In any infringement litigation, any award of monetary damages we receive may not be commercially valuable. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive because of the proceedings. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a negative impact on our ability to compete in the marketplace.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could significantly harm our business.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There is a substantial amount of intellectual property litigation in the biotechnology and pharmaceutical industries, and we may become party to, or threatened with, litigation or other adversarial proceedings regarding intellectual property rights with respect to our technology or product candidates, including interference proceedings before the USPTO. Intellectual property disputes arise in several areas including with respect to patents, use of other proprietary rights and the contractual terms of license arrangements. Third parties may assert claims against us based on existing or future intellectual property rights. The outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we are found to infringe a third-party&#8217;s intellectual property rights, we could be forced, including by court order, to cease developing, manufacturing or commercializing the infringing product candidate or product. Alternatively, we may be required to obtain a license from such third party to use the infringing technology and continue developing, manufacturing or marketing the infringing product candidate. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative effect on our business.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">65</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In some cases, we may not be able to obtain patent protection for certain licensed technology outside the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions where we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, even in jurisdictions where we do pursue patent protection or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Competitors may use our technologies in jurisdictions where we have not pursued and obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and preclinical programs and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents, if pursued and obtained, or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties prior to beginning research or disclosing proprietary information. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets. Despite these efforts and the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information due to our reliance on third parties, increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for any such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Moreover, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">66</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and uncertain and may prevent us or any future collaborators from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we, or any future collaborators, will obtain marketing approval to commercialize a product candidate.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our product candidates and the activities associated with their development and commercialization, including their design, research, testing, manufacture, safety, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import, export, and reporting of safety and other post-market information, are subject to comprehensive regulation by the FDA, the EMA and other foreign regulatory agencies. Failure to obtain marketing approval for a product candidate will prevent us or a potential collaborator from commercializing the product candidate. We will rely on third parties to assist us in the process of filing and supporting the applications necessary to gain marketing approvals. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. We may not be able to successfully manufacture our products in compliance with applicable requirements such as GMPs. If any of our product candidates receives marketing approval, the accompanying label may limit its approved use more narrowly than we anticipate, which could limit sales of the product.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive and may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. The FDA, the EMA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude us from obtaining marketing approval or prevent or limit commercial use. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. Any marketing approval that we, or any future collaborators, ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be impaired.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">67</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to obtain marketing approval in foreign jurisdictions would prevent certain of our product candidates from being marketed in these territories. Any approval we are granted for our product candidates in the United States would not assure approval of our product candidates in foreign jurisdictions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To market and sell our products in the European Union, or EU, and any other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain approval from the FDA. The regulatory approval process outside the United States generally includes all the risks associated with obtaining approval from the FDA. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, denial of approval in one jurisdiction may impact the ability to obtain approval elsewhere. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Even if we obtain marketing approvals for our product candidates, the terms of approvals and ongoing regulation of our products may limit how we or our collaborators manufacture and market our products and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Even if marketing approval of a product candidate is granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation, including the potential requirements to implement a REMS or to conduct costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the product. We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. In addition, manufacturers of approved products and those manufacturers&#8217; facilities are required to comply with extensive FDA requirements including ensuring that quality control and manufacturing procedures conform to cGMP, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation and reporting requirements, among other things. We and our contract manufacturers could be subject to periodic unannounced inspections by the FDA to monitor and ensure compliance with cGMP. We must also comply with FDA requirements for adverse event reporting for commercial products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accordingly, assuming we receive marketing approval for one or more of our product candidates, we and our contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. We could also be subject to other civil or criminal penalties. Thus, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Any product candidate for which we obtain marketing approval could be subject to post-marketing restrictions or recall or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and other federal and state agencies, including the U.S. DOJ, closely regulate compliance with all requirements governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance with the provisions of the approved labeling and manufacturing of products in accordance with cGMP requirements. The FDA and DOJ impose stringent restrictions on manufacturers&#8217; communications regarding off-label use and if we market our products for indications other than their approved indications, we may be subject to enforcement action for off-label marketing. Violations of such requirements may lead to investigations alleging violations of the Food, Drug and Cosmetic Act and other statutes, including the False Claims Act and other federal and state health care fraud and abuse laws as well as state consumer protection laws.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our failure to comply with all regulatory requirements, and later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes, may yield various results, including but not limited to:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">litigation involving patients taking our products;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">68</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on our products, manufacturers or manufacturing processes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on the labeling or marketing of a product;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restrictions on product distribution or use;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requirements to conduct post-marketing studies or clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">warning or untitled letters;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">withdrawal of the products from the market;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to approve pending applications or supplements to approve applications that we submit;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">recall of products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">fines, restitution or disgorgement of profits or revenues;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">suspension or withdrawal of marketing approvals;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">damage to relationships with any potential collaborators;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">unfavorable press coverage and damage to our reputation;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">refusal to permit the import or export of our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">product seizure; or</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">injunctions or imposition of civil or criminal penalties.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-compliance by us or any future collaborator with regulatory requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Non-compliance with U.K. and EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, also can result in significant financial penalties. Similarly, failure to comply with the U.K.&#8217;s or EU&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our current and future relationships with healthcare professionals, principal investigators, consultants, customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency, health information privacy and security and other healthcare laws and regulations, which could expose us to penalties.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our current and future arrangements with healthcare professionals, principal investigators, consultants, customers and third-party payors may expose us to broadly applicable fraud and abuse and other healthcare laws, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act, that may constrain the business or financial arrangements and relationships through which we research, sell, market and distribute any product candidates for which we obtain marketing approval. In addition, we may be subject to physician payment transparency laws and patient privacy and security regulation by the federal government and by the states and foreign jurisdictions in which we conduct our business. The applicable federal, state and foreign healthcare laws that may affect our ability to operate include the following:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">69</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">federal civil and criminal false claims laws, including the federal False Claims Act, which impose criminal and civil penalties, including through civil whistleblower or </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">qui tam</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the civil monetary penalties statute, which imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, which created additional federal criminal and civil statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">HIPAA, as amended by the HITECH Act of 2009, and their respective implementing regulations, which impose obligations on &#8220;covered entities,&#8221; including certain healthcare providers, health plans, and healthcare clearinghouses, as well as their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the federal Physician Payments Sunshine Act, created under Section&#8239;6002 of Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, and its implementing regulations, which created annual reporting requirements for manufacturers of drugs, devices, biologicals and medical supplies for certain payments and &#8220;transfers of value&#8221; provided to covered recipients, including physicians, as defined by such law, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">analogous state and foreign laws, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or to adopt compliance programs as prescribed by state laws and regulations, or that otherwise restrict payments that may be made to healthcare providers; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and drug pricing; state and local laws requiring the licensure of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, the ACA, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal statutes governing healthcare fraud. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the ACA provided that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">70</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Efforts to ensure that our future business arrangements with third parties will comply with applicable healthcare laws and regulations may involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and pursue our strategy. If any of the physicians or other healthcare providers or entities with whom we expect to do business, including future collaborators, are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in government healthcare programs, which could also affect our business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Future legislation, and/or regulations and policies adopted by the FDA, the EMA or comparable regulatory authorities, may increase the time and cost required for us or our collaborators to conduct and complete clinical trials of our current and future product candidates.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The FDA and the EMA have each established regulations to govern the product development and approval process, as have other foreign regulatory authorities. The policies of the FDA, the EMA and other regulatory authorities may change. In the U.S., Congress has enacted significant healthcare and FDA-related legislation in recent years, including the 21st Century Cures Act and subsequent user fee reauthorization acts, and may continue to consider additional reforms affecting drug development, clinical trial requirements, approval standards, manufacturing oversight and post-approval obligations. The FDA has also issued numerous guidance documents and initiatives addressing, among other topics, the use of real-world evidence, decentralized and hybrid clinical trials, diversity in clinical trial enrollment, data integrity, cybersecurity, manufacturing quality, and the development of antibacterial and antifungal therapies. We cannot predict what if any effect the Cures Act or any existing or future guidance from the FDA or other regulatory authorities will have on the development of our product candidates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently enacted and future legislation, including relevant provisions of the Inflation Reduction Act, may increase the difficulty and cost for us and our collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we may obtain.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Heightened governmental scrutiny over the manner in which drug manufacturers price their marketed products and the practices of pharmacy benefit managers and other supply chain entities has also resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, require advance notice of list price increases, establish upper payment limits or other restrictions by drug affordability review boards, allow the importation of drugs from other countries, address pharmacy benefit manager practices, and reform government program reimbursement methodologies for drug products. In particular, the Inflation Reduction Act contains provisions designed to limit the prices paid by Medicare for various prescription drugs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us or our collaborators from being able to generate revenue, attain profitability, or commercialize our drugs.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">71</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for drugs. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our business is subject to increasing government price controls and other public and private restrictions on pricing, reimbursement, and access for our drugs, which could have a material adverse effect on our results of operations, reputation or business.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Public and private payers continue to take aggressive steps to control their expenditures for pharmaceuticals by placing restrictions on pricing and reimbursement for, and patient access to, our medicines. These pressures have negatively affected, and could continue to negatively affect, our consolidated results of operations. Governments and private payers worldwide have intensified their scrutiny of, and actions intended to address, pricing, reimbursement, and access to pharmaceutical products and are demanding greater commercial and clinical value from pharmaceutical companies in the form of strong product differentiation and demonstrated value. Additional policies, regulations, legislation, or enforcement, including because of the regulatory priorities of the U.S. presidential administration and regulatory authorities worldwide, could adversely impact our business and consolidated results of operations. The effect of reducing prices and reimbursement for certain of our products would significantly impact our business and consolidated results of operations. Within the U.S., state level transparency initiatives, importation rules, reporting requirements, and mandated programs, including the establishment of drug affordability boards with the power to set upper payment limits on certain drugs in state-regulated plans, may also increase administrative costs, in some cases, compromise confidential business practices and otherwise detrimentally impact our business.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outside of the United States, particularly in the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, restrictive or unfavorable pricing, coverage, or reimbursement determinations for our medicines or product candidates by governments, regulatory agencies, courts, or private payers, including in relation to the implementation of the Inflation Reduction Act, reference pricing, and compulsory licensing, may adversely impact our business and financial results. In addition, government price reporting and payment regulations are complex, and require ongoing assessment of the methods by which we calculate and report pricing. Calculation methodologies are inherently subjective and are subject to review and challenge by government agencies. If agencies disagree with our calculations, or the methodologies and assumptions underlying them, we may need to restate previously reported data and could be subject to financial and legal liability, which may be significant. In addition, changes to calculation methodologies could adversely affect our financial position or consolidated results of operations in any given period.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risks Related to our Alliance with GSK</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because a portion of our current revenues and near-term projected revenues have historically been derived from products under the GSK Agreements, disputes with GSK could harm our business and cause the price of our securities to fall.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, much of our current and near-term projected revenues have been derived from products under the GSK Agreements. We expect royalties from such products will likely continue to comprise a portion of our revenues in the future. Any action or inaction by either GSK or us that results in a material dispute, allegation of breach, litigation, arbitration, or significant disagreement between the parties may be interpreted negatively by the market or by our investors, could harm our business and cause the price of our securities to fall. Examples of these kinds of issues include but are not limited to non&#8209;performance of contractual obligations and allegations of non&#8209;performance, disagreements over the relative marketing and sales efforts for our partnered products and other GSK respiratory products, disputes over public statements, and similar matters.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">72</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Because GSK is a strategic partner, it may take actions that in certain cases are materially harmful to our business or to our stockholders.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GSK is a strategic partner with rights and obligations under the GSK Agreements that cause its interests to differ from our interests and those of our stockholders. In particular, GSK has a substantial respiratory product portfolio in addition to the partnered products that are covered by the GSK Agreements. GSK may make respiratory product portfolio decisions or statements about its portfolio which may be, or may be perceived to be, harmful to the respiratory products partnered with us. For example, GSK could promote its non&#8209;GSK/Innoviva respiratory products or a partnered product for which we are entitled to receive a lower percentage of royalties, delay or terminate the development or commercialization of the respiratory programs covered by the GSK Agreements, or take other actions, such as making public statements, that have a negative effect on our stock price. Also, given the potential future royalty payments which GSK may be obligated to pay under the GSK Agreements, GSK may seek to acquire us in order to reduce those payment obligations. The timing of when GSK may seek to acquire us could potentially be when it possesses information regarding the status of drug programs covered by the GSK Agreements that has not been publicly disclosed and is not otherwise known to us. As a result of these differing interests, GSK may take actions that it believes are in its best interest but which might not be in our best interest or the best interest of our stockholders.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GSK has also indicated to us that it believes its consent may be required before we can engage in certain royalty monetization transactions with third parties, which may inhibit our ability to engage in these transactions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GSK indicated to us that it believes that its consent may be required before we can engage in certain transactions designed to monetize the future value of royalties that may be payable to us from GSK under the GSK Agreements. GSK has informed us that it believes that there may be certain covenants included in these types of transactions that might violate certain provisions of the GSK Agreements. Although we believe that we can structure royalty monetization transactions in a manner that fully complies with the requirements of the GSK Agreements without GSK&#8217;s consent, a third party in a proposed monetization transaction may nonetheless insist that we obtain GSK&#8217;s consent for the transaction or restructure the transaction on less favorable terms. We have obtained GSK&#8217;s agreement that (i) we may grant certain pre&#8209;agreed covenants in connection with monetization of our interests in RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and vilanterol monotherapy, and (ii) it will not unreasonably withhold its consent to our requests to grant other covenants, provided among other conditions, that in each case, the covenants are not granted in favor of a pharmaceutical or biotechnology company with a product either being developed or commercialized for the treatment of respiratory disease. If we seek GSK&#8217;s consent to grant covenants other than pre&#8209;agreed covenants, we may not be able to obtain GSK&#8217;s consent on reasonable terms, or at all. If we proceed with a royalty monetization transaction that is not otherwise covered by the GSK Agreement without GSK&#8217;s consent, GSK could request that its consent be obtained or seek to enjoin or otherwise challenge the transaction as violating or allowing it to terminate the GSK Agreements. Regardless of the merit of any claims by GSK, we would incur significant cost and diversion of resources in defending against GSK&#8217;s claims or asserting our own claims and GSK may seek concessions from us in order to provide its consent. Any uncertainty about whether or when we could engage in a royalty monetization transaction, the potential impact on the enforceability of the GSK Agreements or the loss of potential royalties from the respiratory programs partnered with GSK, could impair our ability to pursue a return of capital strategy for our stockholders ahead of our receipt of significant royalties from GSK, result in significant reduction in the market price of our securities and cause other material harm to our business.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">General Risks Factors</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Unfavorable global economic conditions, whether brought about by material global crises, health epidemics, military conflicts or war, geopolitical and trade disputes or other factors, may adversely affect our business and financial results.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our business is sensitive to global economic conditions, which can be adversely affected by epidemics and other public health crises, political and military conflict, trade and other international disputes, significant natural disasters (including as a result of climate change) or other events that disrupt macroeconomic conditions. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, us and our business partners and suppliers.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">73</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further, military conflicts or wars (such as the ongoing conflicts between Russia and Ukraine and in the Middle East) can cause exacerbated volatility and disruptions to various aspects of the global economy. The uncertain nature, magnitude, and duration of hostilities stemming from such conflicts, including the potential effects of sanctions and counter-sanctions, or retaliatory cyber-attacks on the world economy and markets, have contributed to increased market volatility and uncertainty, which could have an adverse impact on macroeconomic factors that affect our business and operations, such as worldwide supply chain issues. It is not possible to predict the short and long-term implications of military conflicts or wars or geopolitical tensions which could include further sanctions, uncertainty about economic and political stability, increases in inflation rate and energy prices, cyber-attacks, supply chain challenges and adverse effects on currency exchange rates and financial markets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, the operations of our suppliers and manufacturers may be located in areas that are prone to earthquakes, wildfires and other natural disasters. Such operations and facilities are also subject to the risk of interruption by drought, power shortages, nuclear power plant accidents and other industrial accidents, terrorist attacks and other hostile acts, ransomware and other cybersecurity attacks, labor disputes, public health crises, and other events beyond the Company&#8217;s control. Global climate change is resulting in certain types of natural disasters occurring more frequently or with more intense effects. Such events can create delays or interruptions to the Company&#8217;s development efforts and inefficiencies in the Company&#8217;s supply and manufacturing chain. Significant delays in our development efforts could materially impact our ability to obtain regulatory approval and to commercialize our products.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Without limiting the foregoing, we have experienced and/or may in the future experience:</span></p><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in receiving authorization from regulatory authorities to initiate any planned clinical trials, inspections, reviews and approvals of products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays or difficulties enrolling patients in our clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">delays in or disruptions to the conduct of preclinical programs and clinical trials;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">constraints on the movement of products and supplies through the supply chain, which can disrupt our ability to conduct clinical trials and develop and commercialize our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">price increases in raw materials and capital equipment, as well as increasing price competition in our markets;</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adverse impacts on our workforce and/or key employees; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">increased risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to fulfill their contractual obligations.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">If we fail to maintain proper and effective internal control over financial reporting or if the interpretations, estimates or judgments utilized in preparing our financial statements prove to be incorrect, our operating results and our ability to operate our business could be harmed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Sarbanes-Oxley Act requires, among other things, that we establish and maintain effective internal control over financial reporting and disclosure controls and procedures. Under the SEC&#8217;s current rules, we are required to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our independent registered public accounting firm is also required to report on our internal control over financial reporting. Our testing and our independent registered public accounting firm&#8217;s testing may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses and render our internal control over financial reporting ineffective. We have and expect to continue to incur substantial accounting and auditing expense and to expend significant management time in complying with the requirements of Section 404. If we are not able to maintain compliance with the requirements of Section 404 in a timely manner, or if we or our independent registered public accounting firm identify deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to investigations or sanctions by the SEC, FINRA, The Nasdaq Global Select Market or other regulatory authorities. In addition, we could be required to expend significant management time and financial resources to correct any material weaknesses that may be identified or to respond to any regulatory investigations or proceedings.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">74</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also subject to complex tax laws, regulations, accounting principles and interpretations thereof. The preparation of our financial statements requires us to interpret accounting principles and guidance and make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated, and expenses incurred during the reporting periods. Our interpretations, estimates and judgments are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for the preparation of our financial statements. U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) presentation is subject to interpretation by the SEC, the Financial Accounting Standards Board and various other bodies formed to interpret and create appropriate accounting principles and guidance. In the event that one of these bodies disagrees with our accounting recognition, measurement or disclosure or any of our accounting interpretations, estimates or assumptions, it may have a significant effect on our reported results and may retroactively affect previously reported results. The need to restate our financial results could, among other potential adverse effects, result in our incurring substantial costs, affect our ability to timely file our periodic reports until such restatement is completed, divert the attention of our management and employees from managing our business, result in material changes to our historical and future financial results, result in investors losing confidence in our operating results, subject us to securities class action litigation, and cause our stock price to decline.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our employees or third-party providers, or employees or third-party providers of our portfolio companies may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by employees, third party providers, or employees or third-party providers of our portfolio companies. Misconduct by employees, third party providers, or employees or third-party providers of our portfolio companies could include intentional failures to comply with applicable regulations, provide accurate information to regulatory authorities, comply with federal and state fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, the health care industry is subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. It is not always possible to identify and deter misconduct by employees, third party providers, or employees or third party providers of our portfolio companies, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We have incurred litigation and may incur additional litigation.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have been subject to various legal proceedings, and, in the future, we may be exposed to, or threatened with, litigation, claims and proceedings incident to the ordinary course of, or otherwise in connection with, our business. In addition, agreements entered into by us sometimes include indemnification provisions which may subject us to costs and damages in the event of a claim against an indemnified third party.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Regardless of the merit of particular claims, litigation may be expensive, time-consuming, disruptive to our operations and distracting to management. In recognition of these considerations, we may enter into agreements or other arrangements to settle litigation and resolve such disputes. No assurance can be given that such agreements can be obtained on acceptable terms or that litigation will not occur. These agreements may also significantly increase our operating expenses.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If one or more legal matters were resolved against us or an indemnified third party in a reporting period for amounts in excess of management&#8217;s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Further, such an outcome could result in significant compensatory, punitive or trebled monetary damages, disgorgement of revenue or profits, remedial corporate measures or injunctive relief against us that could materially adversely affect our financial condition and operating results.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">75</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Failure to comply with the U.S. Foreign Corrupt Practices Act, or &#8220;FCPA&#8221;, as well as the anti-bribery laws of the nations in which we conduct business, could subject us to penalties and other adverse consequences.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to the FCPA, which generally prohibits U.S. companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business and requires companies to maintain accurate books and records and internal controls. In addition, we are subject to the anti-bribery laws of other jurisdictions in which we conduct business. Our employees or other agents may engage in prohibited conduct without our knowledge under our policies and procedures and the FCPA and other anti-bribery laws that we may be subject to for which we may be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We are subject to evolving and complex tax laws, which may result in additional liabilities and affect our results of operations.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to income taxes in the U.S. and numerous other jurisdictions, and in the course of our business, we make judgments about the expected tax treatment of various transactions and events. Changes in tax laws, regulations, administrative practices, principles, disclosure obligations, and interpretations, as well as events that differ from our expectations, have affected and may adversely affect our effective tax rates, cash flows, and/or results of operations. In addition, tax authorities in the U.S. and other jurisdictions in which we do business routinely examine our tax returns and are intensifying their scrutiny and examinations of cross-border tax issues, which could unfavorably impact our results of operations. Further, actions taken with respect to tax-related matters by associations such as the Organisation for Economic Co-operation and Development and the European Commission could influence tax laws in countries in which we operate, such as the recent enactments by both the EU and non-EU countries of a global minimum tax. Modifications to key elements of the U.S. or international tax framework could have a significant impact on our effective tax rate, results of operations, and cash flows.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The widespread outbreak of an illness or any other communicable disease, or any other public health crisis, could adversely affect our business, results of operations and financial condition.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pandemics, such as the COVID-19 pandemic, have impacted and may in the future impact our business, operations and financial condition and results. Related risks and challenges for our business include, among others: uncertainty regarding the severity and duration of a pandemic&#894; impacts to business operations&#894; decreased demand for certain of our products&#894; increased costs of doing business&#894; manufacturing disruptions and delays&#894; supply chain disruptions and shortages, including challenges related to reliance on third-party suppliers resulting in reduced availability of materials or components used in the development, manufacturing, distribution or administration of our products&#894; evolving macroeconomic factors and conditions, including general economic uncertainty, unemployment rates and recessionary pressures&#894; changes in labor markets, including challenges related to our human capital and talent development&#894; unknown consequences on our business performance and initiatives stemming from the substantial investment of time and other resources to any potential pandemic response&#894; increased difficulty and uncertainty regarding predicting or estimating future performance&#894; pace of post-pandemic recovery, disruption and volatility within the financial or credit markets&#894; and our financial performance in general.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our investment into the Partnership, managed by Sarissa Capital, could subject us to various risks and uncertainties, any of which could impact our investment results and could materially and adversely affect our business, financial condition and results of operations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, we have invested our cash reserves in short-term investments and marketable securities, primarily corporate notes, government securities, government agencies, and commercial papers. On December 11, 2020, we entered into the Partnership Agreement and invested $300 million of our cash reserves to be managed by Sarissa Capital as the investment manager to the Partnership.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The risks associated with this investment strategy may be substantially greater than the risks associated with traditional fixed-income investment strategies or other low-yield strategies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have limited rights to remove the general partner of the Partnership and do not have any right to participate in the management of the Partnership or the investment activity of Sarissa Capital. We are solely dependent on Sarissa Capital&#8217;s management of our investment in the Partnership. We cannot provide assurance that Sarissa Capital will be successful in meeting our investment objectives. Unexpected market volatility or losses in the Partnership&#8217;s securities portfolio could significantly and negatively affect our investment in the Partnership and therefore our investment results, financial condition or results of operations.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">76</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2024, we made an election to unwind the capital accounts in the Partnership in accordance with the terms of the Partnership Agreement and we expect to receive distributions of our capital accounts through April 2026.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">The price of our securities has been volatile and may continue to be so, and purchasers of our securities could incur substantial losses.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The price of our securities has been volatile and may continue to be so. Between January 1, 2025 and December 31, 2025, the high and low sales prices of our common stock as reported on The Nasdaq Global Select Market varied between $16.67 and $22.28 per share. The stock market in general and the market for biotechnology and biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the companies&#8217; operating performance, in particular during the last several years.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">We may be unable to or elect not to return capital to our stockholders.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The payment of, or continuation of, capital returns to stockholders is at the discretion of our Board of Directors and is dependent upon our financial condition, results of operations, capital requirements, execution of our strategic initiatives, general business conditions, tax treatment of capital returns, potential future contractual restrictions contained in our credit agreement and other agreements and other factors deemed relevant by our Board of Directors. Future capital returns may also be affected by, among other factors: our views on potential future capital requirements for investments in acquisitions and our working capital and debt maintenance requirements; legal risks; stock or debt repurchase programs; changes in federal and state income tax laws or corporate laws; and changes to our business model. Our capital return programs may change from time to time, and we cannot provide assurance that we will continue to provide any particular amounts. Our announcement of future capital return programs does not obligate us to repurchase any specific dollar amount of debt or equity or number of shares of common stock. A reduction, suspension or change in our capital return programs could have a negative effect on our stock price.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti&#8209;takeover provisions in our charter and bylaws and in Delaware law could prevent or delay a change in control of our company.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Provisions of our Certificate of Incorporation and Bylaws may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">requiring supermajority stockholder voting to effect certain amendments to our Certificate of Incorporation and Bylaws;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">restricting the ability of stockholders to call special meetings of stockholders;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">prohibiting stockholder action by written consent; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted on by stockholders at meetings.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, some provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1B.   UNRESOLVED STAFF COMMENTS</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><div><ix:nonNumeric id="F_72d9685b-bcad-43f2-81bf-b2c6617ebbb3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" escape="true" continuedAt="F_72d9685b-bcad-43f2-81bf-b2c6617ebbb3_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_1c_cybersecurity"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1C.   CYBERSECURITY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><div><ix:nonNumeric id="F_592bbf51-88f6-4fd4-8d34-8a4b84b5120d" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49ec6755-9725-42b6-8ae8-44dfdc57e56f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">77</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_72d9685b-bcad-43f2-81bf-b2c6617ebbb3_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct risk assessments to identify cybersecurity threats at least annually, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We devote internal and external resources and designate high-level personnel to manage the risk assessment and mitigation process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, in collaboration with human resources, IT, legal, and management. Personnel at all levels and departments are made aware of our cybersecurity policies through trainings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1096183-9881-498c-a628-ac60842d8379" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We engage internal auditors and other third parties in connection with our risk assessment processes. These service providers assist us in designing and implementing our cybersecurity policies and procedures, as well as to monitor and test our safeguards.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8efdffc1-0972-425d-8c37-8cf9b7cd1a2b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b084be6-93b6-4b70-aeb5-e3dec83a8ac9" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, we did not identify any risks from known cybersecurity threats, including because of any prior cybersecurity incidents, that have materially affected us. However, in the future, we may face certain ongoing cybersecurity risks or threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the heading &#8220;Our operations could be disrupted by failure of our information systems or cyber-attacks.&#8221;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9bcaff1c-eea0-42d5-a8b8-ab6357c45492" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" escape="true"><div><ix:nonNumeric id="F_62e8ac27-a7bf-4380-acbb-e1c1a37f212f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1386672-e0ee-41c0-b387-0ef9f696b8d8" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" escape="true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_8b847483-46e5-4bbc-ad0c-f9144ecf3a6a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b866d93e-c989-4a68-9c46-7cbc6447580f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" escape="true"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e2ed6135-f2d1-4f9d-bb70-5b056362089d" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive team, primarily consisting of our Chief Accounting Officer, Chief Financial Officer, and Chief Executive Officer, in conjunction with our information security team and third-party consultants, is primarily responsible in assessing and managing our material risks from cybersecurity threats.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The qualifications of our executive and information security teams include a combination of formal education, current trainings and certifications in systems, network, and cybersecurity and over 50 years of combined experience in information technology and cybersecurity matters.</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc7f68a8-f441-44b8-93c0-cdee7f904a9a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">They oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.  The processes by which the executive team is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents includes the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">They provide briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, they provide briefings of any significant cybersecurity matters to the board of directors as well as an annual update of cybersecurity risks and activities.</span></div></div></ix:nonNumeric></div></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_2_properties"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 2.   PROPERTIES</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the following are the material properties that we occupy:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:34.547%;box-sizing:content-box;"/>
     <td style="width:1.8%;box-sizing:content-box;"/>
     <td style="width:15.543%;box-sizing:content-box;"/>
     <td style="width:1.34%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.742%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.8%;box-sizing:content-box;"/>
     <td style="width:13.883%;box-sizing:content-box;"/>
     <td style="width:1.8%;box-sizing:content-box;"/>
     <td style="width:15.543%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Property Description</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Location</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Square Footage</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Owned or Leased</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Lease Term End Date</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office space</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Burlingame, CA</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,111</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leased</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 2027</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office space</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Waltham, MA</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,500</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leased</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">March 2029</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Office space and laboratory facility</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lexington, MA</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,881</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leased</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">April 2036</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">78</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_3_legal_proceedings"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 3.   LEGAL PROCEEDINGS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information called for by this Item is incorporated herein by reference in Item 8. &#8220;Financial Statements and Supplementary Data,&#8221; Note 13, &#8220;Commitments and Contingencies&#8221;.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 4.   MINE SAFETY DISCLOSURES</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">79</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="part_ii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART II</span></p><p style="text-indent:-9.17%;padding-left:8.4%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_5_market_for_registrant_s_common"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 5.   MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Market Information</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our common stock was traded on Nasdaq under the symbol &#8220;THRX&#8221; from October 5, 2004 until January 8, 2016. Upon changing our corporate name to Innoviva, Inc. on January 7, 2016, we changed the stock ticker symbol to &#8220;INVA&#8221; effective January 11, 2016.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of February 13, 2026, there were 53 stockholders of record of our common stock. As many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Dividends</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not paid any cash dividends on our common stock since September 30, 2015. The payment of cash dividends in the future will be dependent upon our revenues and earnings, capital requirements and general financial condition. The payment of any cash dividends will be within the discretion of our board of directors at such time. In addition, our board of directors is not currently contemplating and does not anticipate declaring any stock dividends in the foreseeable future. Further, our ability to declare dividends may be limited by restrictive covenants contained in any of our existing or future indebtedness.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance Under Equity Compensation Plans: See Part III, Item 12 of this Form 10-K for additional information required.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Purchases of Equity Securities by the Issuer</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reflects share repurchases of our common stock for the three months ended December 31, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:38.308%;box-sizing:content-box;"/>
     <td style="width:1.38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.002%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.542%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.38%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.162%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.84%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.542%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Period</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Number of Shares Purchases</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Average Price Paid per Share</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs </span><span style="color:#000000;top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">November 3, 2025 to November 30, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,000,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">December 1, 2025 to December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,855</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.09</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,855</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,422,367</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,855</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.09</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,855</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">	On November 3, 2025, the Board of Directors of Innoviva authorized a share repurchase program under which we may repurchase up to $125.0 million of our outstanding shares of common stock. The repurchase program authorized the repurchase by the Company of its common stock in open market transactions, including pursuant to a trading plan in accordance with Rule 10b-18 promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. The authorization permitted management to repurchase shares of the Company&#8217;s common stock from time to time at management&#8217;s discretion. Repurchases may also be made pursuant to a trading plan under Rule 10b5-1 under the Exchange Act, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">80</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock Performance Graph</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The graph set forth below compares the cumulative total stockholder return on our common stock for the period commencing on December 31, 2020 and ending on December 31, 2025, with the cumulative total return of (i) the Nasdaq Composite Index, (ii) the Nasdaq S&amp;P Small Cap 600 Pharma Index and (iii) the Nasdaq Biotechnology Index over the same period. This graph assumes the investment of $100.00 on December 31, 2020 in each of (1) our common stock, (2) the Nasdaq Composite Index, (3) the Nasdaq S&amp;P Small Cap 600 Pharma Index and (4) the Nasdaq Biotechnology Index, and assumes the reinvestment of dividends.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The comparisons shown in the graph below are based upon historical data. We caution that the stock price performance shown in the graph below is not necessarily indicative of, nor is it intended to forecast, the potential future performance of our common stock. Information used in the graph was obtained from sources believed to be reliable including Nasdaq, Bloomberg and Reuters, but we are not responsible for any errors or omissions in such information.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, that might incorporate this Annual Report on Form 10&#8209;K or future filings made by us under those statutes, this Stock Performance Graph section shall not be deemed filed with the SEC and shall not be deemed incorporated by reference into any of those prior filings or into any future filings made by us under those statutes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COMPARISON OF 5 YEAR CUMULATIVE TOTAL RETURN*</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Among Innoviva, Inc., the Nasdaq Composite Index, Nasdaq Biotechnology Index, and Nasdaq S&amp;P Small Cap 600 Pharma Index.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><img src="img75897552_19.gif" alt="img75897552_19.gif" style="width:682px;height:457px;"/></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*    $100 invested on December 31, 2020 in stock or index, including reinvestment of dividends.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">81</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_6_selected_financial_data"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 6.   [</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Reserved]</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">82</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-9.17%;padding-left:8.4%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_7_management_s_discussion_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 7.   MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;) is intended to facilitate an understanding of our business and results of operations. This discussion and analysis should be read in conjunction with our consolidated financial statements and notes included in this Annual Report on Form 10&#8209;K. The information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10&#8209;K, including information with respect to our plans and strategy for our business, our operating expenses, and future payments under our collaboration agreements, includes forward&#8209;looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements are based upon current expectations that involve risks and uncertainties. You should review the section entitled &#8220;Risk Factors&#8221; in Item 1A of Part I above for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward&#8209;looking statements contained in the following discussion and analysis. See the section entitled &#8220;Special Note Regarding Forward Looking Statements&#8221; above for more information.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management Overview</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#8220;Innoviva&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar pronouns) is a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (&#8220;IST&#8221;), and a portfolio of strategic healthcare assets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(umeclidinium bromide/ vilanterol, &#8220;UMEC/VI&#8221;). Under the Long-Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion; and royalties from the sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which tier upward at a range from 6.5% to 10%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our wholly owned, robust critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, commercially launched in 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(eravacycline) for the treatment of complicated intra-abdominal infections in adults;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">staphylococcus aureus bacteremia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including those with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia, licensed from Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) (&#8220;Basilea&#8221;) for U.S. commercialization and commercially launched in the third quarter of 2025; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (formerly known as zoliflodacin), approved by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we own other strategic healthcare assets, such as a significant stake in Armata Pharmaceuticals, Inc. (&#8220;Armata&#8221;), a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies through our portfolio approach.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our disciplined focus on deploying capital in areas of significant unmet medical need with high value creation potential has driven a meaningful transformation of our company over the years from a pure-play royalty business to a diversified biopharmaceutical company with a strong, fast-growing, differentiated operating platform and multiple other assets with significant promise. We believe we are well-positioned to deliver significant long-term shareholder value.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our company structure and organization are tailored to our focused activities of managing our respiratory assets partnered with GSK, commercializing our marketed products, developing our product candidates, optimizing capital allocation, and providing for certain essential reporting and management functions of a public company. As of December 31, 2025, we had 159 employees.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">83</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Highlights</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total revenue: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total revenue for the fourth quarter 2025 was $114.6 million, representing 25% growth compared to total revenue of $91.8 million for the fourth quarter 2024. Total revenue for the full year 2025 was $411.3 million, reflecting 15% growth compared to total revenue of $358.7 million for the full year 2024.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty revenue: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fourth quarter 2025 gross royalty revenue from GSK was $58.4 million and full year was $250.3 million, compared to $66.0 million for the fourth quarter 2024 and $255.6 million for the full year 2024.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net product sales: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fourth quarter 2025 net product sales were $59.1 million, more than doubling from $28.9 million in the same quarter of 2024. Full year 2025 net product sales were $172.1 million, an increase of 77% compared to $97.5 million for the full year 2024.</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the fourth quarter 2025, U.S. net product sales were $33.9 million and ex-U.S. net product sales were $25.1 million. Fourth quarter 2025 U.S. net product sales primarily consisted of $19.3 million from GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $10.7 million from XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and $3.8 million from XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the full year 2025, U.S. net product sales were $119.2 million and ex-U.S. net product sales were $52.9 million. Full year 2025 U.S. net product sales primarily consisted of $71.8 million from GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $33.4 million from XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and $13.3 million from XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income from operations: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fourth quarter 2025 income from operations was $39.0 million, compared to $43.1 million for the fourth quarter 2024. Full year 2025 income from operations was $163.7 million, compared to $166.9 million for the full year 2024, reflecting continued investments in research and development.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Equity and long-term investments: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fourth quarter and full year 2025 net favorable changes in fair values of equity and long-term investments totaled $153.8 million and $161.6 million, respectively, and were primarily attributable to share price appreciation of Armata. Innoviva&#8217;s portfolio of strategic assets held through the Company&#8217;s various subsidiaries was valued at $614.0 million as of December 31, 2025, and consisted of $397.9 million in Armata investments, $136.4 million in other strategic equity and convertible debt investments, and $79.7 million in investments held by ISP Fund.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:12pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net income: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fourth quarter 2025 net income of $164.2 million ($2.19 basic earnings per share) and full year 2025 net income of $271.2 million ($4.02 basic earnings per share) were driven primarily by higher revenue and the positive impact of changes in the fair values of equity and long-term investments.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash and cash equivalents: </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Totaled $550.9 million. Royalty and net product sales receivables totaled $93.3 million as of December 31, 2025.</span></div></div><p style="text-indent:-4.749%;padding-left:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Key Business and R&amp;D Highlights</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUZOLVENCE&#174; (zoliflodacin): </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a first-in-class, single-dose oral medication for the treatment of uncomplicated urogenital gonorrhea due to </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Neisseria gonorrhoeae</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in adults and pediatric patients 12 years and older weighing at least 35kg, developed in partnership with The Global Antibiotic Research &amp; Development Partnership (&#8220;GARDP&#8221;).</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, IST received FDA approval of NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the treatment of uncomplicated urogenital gonorrhea. </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FDA approval was based on results from the largest Phase 3 clinical trial ever conducted for a new treatment against Neisseria gonorrhoeae infection in regions with a high prevalence of gonorrhea across five countries.</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, in December 2025, the positive NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Phase 3 data for the treatment of uncomplicated urogenital gonorrhea were published in The Lancet.</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company plans to commercialize NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the second half of 2026, either in collaboration with a commercialization partner or independently.<br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">84</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, IST delivered data from from six presentations at IDWeek 2025, including clinical data, pharmacokinetic/pharmacodynamic analyses, and microbiologic surveillance from its growing portfolio of antibiotics and critical care medicines.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Both ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ceftobiprole medocaril sodium) and XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (sulbactam for injection; durlobactam for injection) were nominated for the 2025 Prix Galien USA Award for Best Pharmaceutical Product by the Galien Foundation, one of the most prestigious honors in the biopharmaceutical and medical technology fields, celebrating groundbreaking achievements that drive meaningful progress.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capital Allocation</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the inception of the share repurchase program, the Company has repurchased 797,298 shares for $16.0 million. </span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2025, Innoviva invested $17.5 million in the Series B Preferred Stock of Beacon Biosignals, Inc., an AI-driven neurotechnology company developing treatments for neurological, psychiatric, and sleep disorders.</span></div></div><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Collaborative Arrangements with GSK</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LABA Collaboration</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2002, we entered into the LABA Collaboration Agreement with GSK to develop and commercialize once-daily LABA products for the treatment of chronic obstructive pulmonary disorder (&#8220;COPD&#8221;) and asthma (the &#8220;LABA Collaboration Agreement&#8221;). For the treatment of COPD, the collaboration has developed the following combination products:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">//BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;FF/VI&#8221;) (BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the proprietary name in the U.S. and Canada and RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is the proprietary name outside the U.S. and Canada), a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (&#8220;ICS&#8221;), fluticasone furoate (&#8220;FF&#8221;), and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (&#8220;UMEC/VI&#8221;), a once-daily medicine combining a long-acting muscarinic antagonist (&#8220;LAMA&#8221;), umeclidinium bromide (&#8220;UMEC&#8221;), with a LABA, vilanterol (VI).</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S., Japan and Europe, in accordance with the LABA Collaboration Agreement, we paid milestone fees to GSK totaling $220.0 million during the year ended December 31, 2014. Although we have no further milestone payment obligations to GSK pursuant to the LABA Collaboration Agreement, we continue to have ongoing commercialization activities under the LABA Collaboration Agreement, including participation in the joint steering committee that are expected to continue over the life of the agreement. The milestone fees paid to GSK were recognized as capitalized fees, which are being amortized over their estimated useful lives commencing upon the commercial launch of the products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as follows: 15% on the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion. On sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, royalties are upward tiering and range from 6.5% to 10%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategic Partnership with Sarissa Capital</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Strategic Advisory Agreement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 11, 2020, we entered into a Strategic Advisory Agreement (the &#8220;Services Agreement&#8221;) with Sarissa Capital Management LP (&#8220;Sarissa Capital&#8221;), pursuant to which Sarissa Capital provides a variety of strategic services to us in order to assist us in the development and execution of our acquisition strategy. The services are provided free of charge to us. Sarissa Capital was considered to be a related party up until the annual stockholders meeting in May 2025 after which there were no representatives of Sarissa Capital serving on our Board of Directors.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Partnership Agreement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On December 11, 2020, Innoviva Strategic Partners LLC (&#8220;Strategic Partners&#8221;), our wholly owned subsidiary, entered into a subscription agreement (the &#8220;Subscription Agreement&#8221;) and an Amended and Restated Limited Partnership Agreement (the &#8220;Partnership Agreement&#8221;) pursuant to which Strategic Partners became a limited partner of ISP Fund LP (the &#8220;Partnership&#8221;). The general partner of the Partnership (the &#8220;General Partner&#8221;) is an affiliate of Sarissa Capital and, pursuant to an investment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">85</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">management agreement, Sarissa Capital acts as the investment adviser to the Partnership. Strategic Partners made a $300.0 million initial contribution into the Partnership. The Partnership was formed for the purposes of investing in equity securities in the healthcare, pharmaceutical and biotechnology industries. The Partnership Agreement provides for Sarissa Capital to receive a customary one percent management fee from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners&#8217; capital account in the Partnership. In addition, the General Partner is entitled to a customary 10% annual performance allocation based on the Net Profits of the Partnership during the annual measurement period. The Partnership Agreement includes a lock-up period of thirty-six months after which Strategic Partners is entitled to make withdrawals from the Partnership as of such lock-up expiration date and each anniversary thereafter, subject to certain limitations. In 2024, the lock-up period expired, and we elected to unwind the capital accounts in the Partnership. We expect to receive distributions through April 2026.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Accounting Policies and Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition from Product Sales</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includ</span><span style="color:#252525;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">es being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span><span style="color:#252525;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to recognizing any revenue from product sales, we identify the contract, performance obligations, and transaction price, and allocate the transaction price to the performance obligations. Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#8217; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#8220;GPO&#8221;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired product. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">86</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each individual state&#8217;s guidelines regarding eligibility and services. Under the Medicaid rebate programs, we pay a rebate to each participating state, generally within three months after the quarter in which product was sold. Additionally, we may offer customer incentives and consideration in the form of volume-based or other rebates. The estimates for rebates are recorded as a reduction of revenue on delivery to our customers. </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also enter into contracts that involve a series of manufacturing processes for products and related components. For any distinct performance obligation where the manufacturing process does not create an asset with alternative use and there is an enforceable right to payment for the performance completed to date, the related revenue is recognized over time. For these performance obligations satisfied over time, we use an input method to measure progress. Specifically, we apply the cost-to-cost method, under which progress is calculated as the ratio of costs incurred to date relative to the total estimated costs of the contract. This method most accurately depicts the transfer of value to the customer because costs incurred are determined to be proportionate to our performance in satisfying the obligation. Estimated total contract costs are reassessed periodically. Changes in estimates are accounted for prospectively as changes in estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Variable Interest Entities</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary beneficiary of a variable interest entity (&#8220;VIE&#8217;) is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. To determine whether a variable interest that we hold could potentially be significant to the VIE, we consider both qualitative and quantitative factors regarding the nature, size and form of our involvement with the VIE.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#8217;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity and Other Investments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investments in Armata include a convertible note (the &#8220;Armata Convertible Note&#8221;) and term loans issued in July 2023, March 2024, March 2025 and August 2025, all of which are classified as Level 3 financial instruments. The Armata Convertible Note is measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. We measure the term loans at fair value using an income approach based on the discounted value of expected future cash flows.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">87</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Level 3 financial instruments include Syndeio Biosciences, Inc. (&#8220;Syndeio&#8221;) (formerly known as Gate Neurosciences, Inc.) convertible promissory notes issued in November 2021 and March 2025, and private placement positions held by ISP Fund LP as these securities are not publicly traded and the assumptions used in the valuation model for valuing these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies. We measure the Syndeio convertible promissory note at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Syndeio, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised. Valuation models applied for the private placement positions held by ISP Fund LP may include the Black-Scholes-Merton pricing model, the Monte Carlo simulation model and other applicable valuation models. Key assumptions involve inputs to the Black-Scholes-Merton pricing model, probability rates of certain events and scenarios applied in the Monte Carlo simulation model and discount rates, as appropriate. The Monte Carlo simulation model also incorporates assumptions made based on transaction details such as the security&#8217;s stock price, the expected term, maturity, risk-free interest rates and dividend yield, as well as volatility.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we hold a convertible note in Lyndra Therapeutics, Inc., which is classified as Level 3 financial instrument. We measure the convertible note at fair value using an income approach based on the discounted value of probability-weighted cash flow estimates.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Revenue</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Royalty Revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total royalty revenue, net, as compared to the prior years, was as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:25.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.64%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.76%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.98%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties &#8211; RELVAR/BREO</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204,021</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,925</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,042</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,904</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(117</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(0</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties &#8211; ANORO</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,281</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,631</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,627</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,350</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,004</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total royalties</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,302</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255,556</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,669</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,254</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,887</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: amortization of capitalized<br/>&#160;&#160;&#160;fees paid</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,823</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,823</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,823</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total net royalty revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">236,479</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">241,733</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,846</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,254</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,887</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*    Not Meaningful</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total royalty revenue, net, decreased to $236.5 million for the year ended December 31, 2025, compared to $241.7 million for the year ended December 31, 2024. The decrease in total net royalty revenue was primarily due to lower net sales driven by pricing pressures in the United States.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total royalty revenue, net, increased to $241.7 million for the year ended December 31, 2024, compared to $238.8 million for the year ended December 31, 2023. The increase in total net royalty revenue was primarily due to the sales growth in ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">88</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net Product Sales</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total product sales, net, as compared to the prior years, was as follows:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:28.743%;box-sizing:content-box;"/>
     <td style="width:1.201%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.968%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.201%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.968%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.201%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.968%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.201%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.727%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.446999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.201%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.727%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.446999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S.</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71,831</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,410</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,761</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,421</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,649</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,341</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,777</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,441</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">564</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">336</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,448</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,668</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,003</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,780</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">128</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,665</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">610</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">610</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total U.S.</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,230</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">80,855</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,205</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,375</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,650</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rest of the world</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,780</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,627</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">533</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">153</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,094</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,175</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,608</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,879</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,567</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,729</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,945</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,402</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34,543</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,402</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total rest of the world</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,900</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,637</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,412</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,263</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">218</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,225</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:15pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:2.773%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total net product sales</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172,130</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,492</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,617</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,638</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,875</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*    Not Meaningful</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our net product sales increased during the periods presented, driven by higher sales volume resulting from our strategic commercialization efforts and dedication to delivering our critical care products to healthcare systems. The increase in XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ex-U.S. product sales is attributable mainly to product sales under an interim supply agreement with Zai Lab, which is billed at cost.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and Other Revenue</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License and other revenue, as compared to the prior years, were as follows:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:28.743%;box-sizing:content-box;"/>
     <td style="width:1.201%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.968%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.201%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.968%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.201%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.968%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.201%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.727%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.448%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.201%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.727%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.446999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and other revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,719</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,486</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,000</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16,767</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(86</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,486</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">License revenue for the year ended December 31, 2025 was derived primarily from the continuing activities related to the Amended Zai Agreement and the Zai Manufacturing Stage Transfer Agreement, which both commenced in 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized $8.0 million in license and other revenue for the year ended December 31, 2024 as a result of the achievement of a regulatory milestone under our license agreement with Zai Lab. We also recognized $8.1 million and $3.4 million in license and other revenue under the aforementioned Amended Zai Agreement and Zai Manufacturing Stage Transfer Agreement, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized license and other revenue of $8.0 million and $3.0 million for the year ended December 31, 2023 as a result of achievement of regulatory milestones under our license agreements with Everest and Zai Lab, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Products Sold</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of products sold, as compared to the prior years, were as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:26.156%;box-sizing:content-box;"/>
     <td style="width:1.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.446%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.446%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.446%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.086%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.926%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.086%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.906%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of product sold</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,384</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,598</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,040</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,786</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">111</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,442</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(11</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">89</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The cost of products sold also includes the inventory step-up value from the acquisition of La Jolla, which is recorded upon the sale of such inventory. The step-up value included above amounted to $4.8 million, $13.8 million and $27.2 million for the years ended December 31, 2025, 2024 and 2023, respectively. Our cost of products sold increased during the year ended December 31, 2025 presented, driven by higher product sales volume. As of December 31, 2025, our total inventory included the remaining net fair value adjustments resulting from the acquisition of La Jolla of approximately $3.4 million, which will be recognized as cost of products sold when sales occur in future periods.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research &amp; Development</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses, as compared to the prior years, were as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:26.15%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.443%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.443%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.443%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.083%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.9239999999999995%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.083%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.9239999999999995%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,604</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,654</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,922</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,950</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20,268</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(60</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:26.15%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.443%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.443%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.443%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.083%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.9239999999999995%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.083%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.9239999999999995%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">External services</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,704</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,408</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,051</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,296</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">112</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(12,643</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(63</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Compensation and related personnel costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,284</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,948</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,081</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">336</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,133</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(51</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired IPR&amp;D</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,368</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,368</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Facilities related</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">733</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,483</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(680</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(93</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,750</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(70</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">195</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">565</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,307</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(370</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(65</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(742</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(57</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,604</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,654</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,922</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,950</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">124</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(20,268</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(60</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses for the year ended December 31, 2025 included $9.4 million of </span><span style="color:#242021;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">allocated cost for acquired in-process research and development (&#8220;IPR&amp;D&#8221;) related to the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Lynx&#153; long-acting drug delivery platform</span><span style="color:#242021;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as discussed in Note 14, &#8220;Asset Acquisition&#8221;, in the Consolidated Financial Statements. During the year ended December 31, 2025, we also incurred costs related to the continued advancement of NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Research and development expenses for the year ended December 31, 2024 were mainly attributable to post marketing commitments required by the FDA and ongoing product development. Research and development expenses for the year ended December 31, 2023 were mainly attributable to our product development efforts for XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General &amp; Administrative</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses, as compared to the prior years, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:26.161%;box-sizing:content-box;"/>
     <td style="width:1.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.448%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.448%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.448%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.087999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.9079999999999995%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.101%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.087999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.9079999999999995%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113,318</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">115,690</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98,232</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,372</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,458</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our selling, general and administrative expenses are primarily attributable to efforts to promote our marketed critical care products and drive revenue, maintain regulatory compliance, and support essential administrative functions. Selling, general and administrative expenses decreased by $2.4 million for the year ended December 31, 2025, compared to the year ended December 31, 2024, during which included incremental expenditures related to the September 2023 commercial launch of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general and administrative expenses increased by $17.5 million for the year ended December 31, 2024, compared to the year ended December 31, 2023. The increase was mainly due to the reallocation of resources from the research and development function, focusing on regulatory compliance since May 2023 after the FDA approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and enhanced commercial strategies resulting from our ongoing efforts to promote and deliver our marketed critical care products.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">90</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest and Dividend Income and Other Expense, Net</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest and dividend income and other expense, net, as compared to the prior years, were as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:27.375%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.218999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.218999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.218999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.899000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.699%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.899000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.678999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and dividend income</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,086</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,141</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,818</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,945</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,323</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,864</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(2,997</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,969</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">133</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,972</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(40</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest and dividend income increased for the years ended December 31, 2025 and 2024, due to higher average balances of our cash equivalents, money market funds and other interest-bearing investments.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other expense, net, primarily consisted of expenses incurred by ISP Fund LP.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense, as compared to the prior years, was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:27.375%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.218999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.218999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.218999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.899000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.699%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.899000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.678999999999999%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(16,698</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(22,209</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,157</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,511</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(25</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3,052</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
   </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The interest expense for the periods presented included the contractual interest expense and the amortization of debt issuance costs for our 2025 Notes and 2028 Notes, as well as effective interest expense on our deferred royalty obligation related to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The decrease for the year ended December 31, 2025 compared to the year ended December 31, 2024 was mainly due to lower interest expense on our deferred royalty obligation as a result of higher sales performance of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as well as the settlement of our 2025 Notes in August 2025. The year-over-year increase from 2023 to 2024 was primarily due to a higher effective interest rate on our deferred royalty obligation.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changes in Fair Values of Equity Method Investments and Equity and Long-Term Investments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in fair values of equity method investments and equity and long-term investments, net, as compared to the prior years, were as follows:</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:27.369%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.2170000000000005%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.2170000000000005%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.2170000000000005%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.2170000000000005%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:9.216%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.2170000000000005%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:9.216%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity<br/>&#160;&#160;&#160;method investments, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,433</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(64,253</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,392</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">205,686</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(141,645</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity <br/>&#160;&#160;&#160;and long-term investments, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,160</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(59,161</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,129</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,321</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(70,290</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*    Not Meaningful</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The changes in fair values of equity method investments for the year ended December 31, 2025 were favorable mainly due to the appreciation in Armata&#8217;s stock price. We recorded $141.4 million in unrealized gains, $64.3 million in unrealized losses and $77.4 million in unrealized gains associated with our equity method investments in Armata for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The changes in fair values of equity and long-term investments year over year reflect the realized gains and losses and net unrealized gains and losses in our strategic investments in Armata, InCarda, Gate, ImaginAb and Lyndra, and those investments managed by ISP Fund LP. We recorded $67.6 million in unrealized gains, $2.3 million in unrealized losses and $23.8 million in unrealized gains for the years ended December 31, 2025, 2024 and 2023, respectively, related to our other long-term investments in Armata, and unrealized gains of $10.7 million for the year ended December 31, 2025 related to our investments in Syndeio.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to Note 6, &#8220;Equity and Long-Term Investments and Fair Value Measurements&#8221;, to the Consolidated Financial Statements for more information.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">91</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income tax expense, net, as compared to the prior years, was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:27.369%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.2170000000000005%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.2170000000000005%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.2170000000000005%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.2170000000000005%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:9.216%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.897%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.697%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(55,697</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,996</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,376</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(41,701</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">*</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">380</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(3</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*    Not Meaningful</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, 2024 and 2023, we had net operating loss carryforwards for federal income taxes of $497.7 million, $520.6 million and $543.5 million, respectively. As of December 31, 2025, 2024 and 2023, we also had state net operating loss carryforwards of approximately $1,028.9 million, which will expire beginning 2030. As of December 31, 2025, we had state research and development tax credits of $33.6 million, which will expire beginning 2033.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2025, 2024 and 2023, we recognized $55.7 million, $14.0 million and $14.4 million, respectively, of income tax expense, mainly based on the income generated during those years. The increase in income tax expense for the year ended December 31, 2025 was mainly due to the significant value appreciation of our investments in Armata.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our total unrecognized tax benefits as of December 31, 2025, 2024 and 2023 were $62.7 million, $61.3 million and $19.4 million, respectively. The increase of $41.9 million in 2024 was primarily due to our strategic intercompany intellectual property alignment across different jurisdictions.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards is subject to rules, provided by the Internal Revenue Code and similar state provisions, governing annual limitations tied to ownership changes. We conducted an analysis of the Company through December 31, 2025 to determine whether an ownership change had occurred since inception. The study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. If we ever undergo an ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, $146.5 million of Entasis&#8217; federal net operating losses and $351.2 million of La Jolla&#8217;s federal operating losses from the acquisitions in 2022, both subject to annual limitations, were available for future utilization.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Liquidity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since our inception, we have financed our operations primarily through private placements and public offerings of equity and debt securities and payments received under collaborative arrangements. For the year ended December 31, 2025, we generated gross royalty revenues of $250.3 million, net product sales revenues of $172.1 million and license and other revenue of $2.7 million. Cash and cash equivalents totaled $550.9 million, royalties receivable from GSK totaled $58.4 million and accounts receivable associated with our marketed products and related arrangements totaled $35.0 million, as of December 31, 2025.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we had one outstanding convertible note, the 2028 Notes, in an aggregate principal amount of $261.0 million, which will become due in March 2028. Future interest payments associated with this note total $13.9 million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 3, 2025, our Board of Directors authorized a share repurchase program under which we may repurchase up to $125.0 million of Innoviva&#8217;s outstanding shares of common stock. As of December 31, 2025, we have repurchased Innoviva common stock in the open market for total price of approximately $4.6 million. This program has no termination date, may be suspended or discontinued at any time at our discretion and does not oblige us to acquire any amount of common stock.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2024, we elected to unwind our capital accounts in ISP Fund LP. In 2025, we received $121.0 million cash distributions and expect to continue receiving distributions through April 2026.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">92</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Adequacy of Cash Resources to Meet Future Needs</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that our cash and cash equivalents will be sufficient to meet our anticipated debt service and operating needs, as well our ongoing share repurchase program, for at least the next 12 months based upon current operating plans and financial forecasts. Our long-term capital requirements will depend on many factors including the amount of our royalty revenues, sales growth of our currently marketed products, timing of regulatory approval of our product candidates and outcome of our acquisitions and strategic investments. If our current operating plans and financial forecasts change, we may require additional funding sooner in the form of public or private equity offerings or debt financings. Furthermore, if in our view favorable financing opportunities arise, we may seek additional funding in the form of public or private equity offerings or debt financings at any time. However, future financing may not be available in amounts or on terms acceptable to us, if at all. This could leave us without adequate financial resources to fund our operations as currently planned. In addition, from time to time we may restructure or reduce our debt, including through privately negotiated repurchases, tender offers, redemptions, amendments, or otherwise, all allowable with the terms of our debt agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows, as compared to the prior years, were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:31.859%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.288%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.288%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.288%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.288%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.341%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.288%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">196,930</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">188,690</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,064</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,240</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,626</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,496</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(63,786</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(66,761</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104,282</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,975</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) financing activities</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,551</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,453</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(171,839</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,004</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">158,386</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows from Operating Activities</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2025 was $196.9 million, consisting primarily of our net income of $271.2 million adjusted for net noncash items of $50.1 million and net changes in operating assets and liabilities of $24.2 million. Noncash items included a $161.6 million net increase in fair values of equity method investments and equity and long-term investments, partially offset by $43.8 million in deferred income taxes, $26.3 million in amortization of acquired intangible assets, $14.0 million of amortization of capitalized fees and depreciation of property and equipment, $9.5 million in stock-based compensation expense, $9.4 million in acquired in-process research and development assets, $4.8 million in inventory fair value adjustments included in cost of products sold and $1.9 million in amortization of debt discount and issuance costs. The changes in operating assets and liabilities included increases in accounts receivable of $14.6 million, inventory of $12.9 million, prepaid expenses of $5.7 million and other assets of $1.1 million, and decreases in accrued personnel-related and other accrued liabilities of $5.8 million and accrued interest payable of $1.8 million, partially offset by a decrease in receivables from collaboration arrangements of $7.6 million and increases in accounts payable of $2.8 million, deferred revenue of $3.1 million and income tax payable of $4.1 million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2024 was $188.7 million, consisting primarily of our net income of $23.4 million adjusted for net noncash items of $172.2 million, partially offset by net changes in operating assets and liabilities of $6.9 million. Noncash items included a $123.4 million net decrease in fair values of equity method investments and equity and long-term investments, $25.9 million in amortization of acquired intangible assets, $14.0 million of amortization of capitalized fees and depreciation of property and equipment, $13.8 million in inventory fair value adjustments included in cost of products sold, $6.4 million in stock-based compensation expense, and $2.1 million in amortization of debt discount and issuance costs, partially offset by $12.6 million of deferred income taxes. The changes in operating assets and liabilities included increases in other assets of $38.2 million, inventory of $6.8 million, accounts receivable of $5.9 million, and a decrease in accounts payable of $4.6 million, partially offset by an increases in income tax payable of $41.5 million and accrued liabilities of $3.0 million and a decrease in receivables from collaboration arrangements of $3.6 million.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">93</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash provided by operating activities for the year ended December 31, 2023 was $141.1 million, consisting primarily of our net income of $179.7 million, partially offset by net non-cash items of $13.9 million and net changes in operating assets and liabilities of $24.8 million. Non-cash items included a $88.5 million net increase in fair values of equity method investments and equity and long-term investments, partially offset by $27.2 million in inventory fair value adjustments included in cost of products sold, $21.8 million in amortization of acquired intangible assets, $13.9 million of amortization of capitalized fees and depreciation of property and equipment, $5.8 million in stock-based compensation expense, $4.4 million of deferred income taxes and $2.1 million in amortization of debt discount and issuance costs. The changes in operating assets and liabilities included increases in receivables from collaboration arrangements of $14.9 million, inventory of $12.0 million, accounts receivable of $5.1 million, other assets of $3.0 million and a decrease in personnel-related, interest and other accrued expenses of $2.4 million, partially offset by a decrease in prepaid expenses of $7.9 million and increases in accounts payable of $3.8 million and income tax payable of $1.7 million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows from Investing Activities</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by investing activities for the year ended December 31, 2025 of $40.5 million included $92.8 million for purchases and sales of other investments managed by ISP Fund LP, net, $28.2 million for sales of equity investments managed by ISP Fund LP and $8.4 million in proceeds from trading securities. Net cash provided by investing activities was partially offset by $60.9 million for purchases of trading securities, $17.5 million for purchases of equity and long-term investments, $9.4 million in cash paid for acquired in-process research and development assets, and $1.1 million for purchases of property and equipment.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2024 of $63.8 million included $59.6 million for purchases of trading securities, $32.3 million for purchases of equity investments managed by ISP Fund LP and $43.5 million in net purchases and sales of other investments managed by ISP Fund LP. Net cash used in investing activities was partially offset by $75.8 million in sales of equity investments managed by ISP Fund LP.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in investing activities for the year ended December 31, 2023 of $66.8 million included $65.1 million for purchases trading securities, $31.2 million for purchases of equity investments managed by ISP Fund LP, $41.3 million in net purchases and sales of other investments managed by ISP Fund LP and $1.2 million for purchases of equity and long-term investments. Net cash used in investing activities was partially offset by $72.5 million in sales of equity investments managed by ISP Fund LP.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows from Financing Activities</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash provided by financing activities for the year ended December 31, 2025 of $8.6 million included $10.7 million in proceeds from the exercise of warrants and $2.6 million in net proceeds from issuances of common stock, partially offset by $4.5 million for the repurchases of our common stock under the new stock repurchase program.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in financing activities for the year ended December 31, 2024 of $13.5 million included $14.8 million for the repurchases of our common stock under the stock repurchase program, partially offset by $1.5 million in net proceeds from issuances of common stock.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net cash used in financing activities for the year ended December 31, 2023 of $171.8 million consisted mainly of the repayments of $96.2 million upon maturity of the 2023 Notes in January 2023 and $75.7 million for the repurchases of our common stock under the stock repurchase program.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Contractual Obligations</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, our notes payable obligation included $261.0 million related to our 2028 Notes, which is due in 2028. Under the terms of the 2028 Notes, we make interest payments of 2.125% of outstanding principal. Refer to Note 12, &#8220;Debt&#8221; to the Consolidated Financial Statements for more information.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our short-term and long-term obligations also include contractual payments related to our operating leases amounting to $14.9 million, with approximately $1.0 million payable in 2026, amounts ranging between $1.2 million and $1.5 million payable in each of the years 2027 to 2030, and $8.5 million payable thereafter. Refer to Note 13, &#8220;Commitments and Contingencies&#8221; to the Consolidated Financial Statements for more information.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">94</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our acquisition of La Jolla, we recognized its deferred royalty obligation in connection with the La Jolla Royalty Agreement with HCR. Under the terms of the Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The maximum royalty rate is 18% based on the terms of the agreement. The La Jolla Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $225.0 million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, we have certain contingent payment obligations under various in-license agreements which we are required to make royalty payments or milestone payments upon successful completion and achievement of certain milestones. Refer to Note 4, &#8220;License, Collaboration and Other Arrangements&#8221; to the Consolidated Financial Statements for more information.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also entered into a Commercial Supply Agreement with Corden Pharma CHEN&#212;VE SAS (&#8220;Corden&#8221;), under which we engaged Corden to manufacture and supply certain products related to XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and to perform certain services and studies. Under the agreement, we committed to minimum purchases through December 31, 2027. As of December 31, 2025, we have approximately $13.2 million U.S. dollar equivalent in outstanding purchase commitments under this agreement.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also enter into agreements in the normal course of business with vendors for manufacturing, clinical trials and pre-clinical studies, and other services and products for operating purposes.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 7A.   QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, our debt bears fixed interest rate and we had no outstanding debt with variable interest rates. Our cash flows on these debt obligations are not subject to variability as a result of changes in interest rates.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to changes in the fair value of certain of our investments in equity and debt securities. Fluctuations in the underlying fair value of the investments could result in material gains or losses. Refer to Note 6 &#8220;Equity and Long-Term Investments and Fair Value Measurements&#8221; to the Consolidated Financial Statements for more information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inflation has increased during the periods covered by this Annual Report on Form 10-K and could continue to increase for the near future. Inflationary factors, such as increases in the cost of our raw materials, supplies, interest rates and overhead costs, as well as trade and other international disputes, may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience some effect in the near future if inflation rates continue to rise. Significant adverse changes in inflation and prices in the future could result in material losses.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars, including contracts with international vendors related to raw material purchases. Our royalty revenue from RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is also indirectly exposed to foreign exchange risk as GSK also markets and sells the products outside the U.S. The majority of our cash and cash equivalents, investments, and the majority of our vendor relationships are denominated in U.S. dollars. Therefore, we do not believe that the risk of a significant impact on our operating income from foreign currency fluctuations is substantial.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">95</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="item_8_financial_statements_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 8.   FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:93.8%;box-sizing:content-box;"/>
     <td style="width:6.2%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:0.7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2025 and December 31, 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Income and Comprehensive Income for each of the three years in the period ended December 31, 2025</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_stockholders"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 2025</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2025</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#reports_of_independent_registered_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID </span><span><ix:nonNumeric id="F_f1002141-7227-47c2-b072-47d6ee4557e1" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:AuditorFirmId"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">34</span></ix:nonNumeric></span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">)</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">96</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_balance_sheets"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED BALANCE SHEETS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except per share data)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:67.313%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.843%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.5%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.843%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bda131b1-875f-4961-94b9-eaf011ae65a9" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">550,941</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06d593fa-3983-4e6c-8e11-5e684f8b6a0f" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304,964</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_836da64b-2345-4ca6-99c9-664848c7b040" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">34,966</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d4becb9-50ed-4dc1-9841-a3c5f9924923" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,392</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Receivable from collaboration arrangements</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdf07704-ca6f-45ae-975b-fc60fe89bedd" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:ReceivablesLongTermContractsOrPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">58,351</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12adb937-b0a0-47f5-861f-7aa2d3aeded2" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:ReceivablesLongTermContractsOrPrograms" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,974</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf42a752-85f6-4d27-9282-e4e5b739f971" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,172</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32ecac78-2d39-4ea7-856c-0aba6b9a62e9" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,725</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc2c6ae4-2b83-41ae-b6fb-706d651be38a" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,721</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9b66df0-a4bb-442e-a9c9-bd0dcf940869" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,063</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of ISP Fund investments (Note 5)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e6bd114-f1f8-45e4-82e0-7e5ffdcfe229" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:CurrentPortionOfISPFundInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,727</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45191efd-af54-4f7e-a38a-dd913076cd11" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:CurrentPortionOfISPFundInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,532</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_042f6b68-18b9-4ef2-af7d-cfa6fb6f9c45" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,637</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0001e971-606c-4dcf-bdf0-ab9d4598ac14" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">656</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a769caf-d515-453e-9247-513b30a1a512" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">727,515</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5d453c6-131c-45a7-8b56-a19ac7c24f1e" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">554,306</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property and equipment, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36645973-be1c-4289-b93d-291bbb4883c5" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,555</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4a7cfa5-c61b-4b40-924d-2d140d58aeb6" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">514</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity method investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f7c93b3-2ee4-4151-ad79-fd04e905a683" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:EquityMethodInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,726</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27fc7a08-d8b0-4358-8650-cc8eed5881e9" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:EquityMethodInvestment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,293</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity and long-term investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd763a46-5efa-492c-9d65-433a2d437bad" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404,497</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a60a91be-3b94-4b45-b895-75514c54047d" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">341,664</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capitalized fees paid, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f92539d-6493-4cee-b088-022fe52a9e3e" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,138</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d54e2cf-eec0-4457-85b0-4f9ab0a79cae" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,961</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Right-of-use assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fae98d4b-265e-4a21-906e-2b726bb627fb" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,929</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8a2b257-7268-43c8-af7b-f0419866986b" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,453</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Goodwill</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88287724-d84b-444f-b7b8-e3e889dbc902" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,905</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51cdeee9-1e3f-4fe4-8e27-503c03b9f22f" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,905</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49b7922b-db0f-4914-9b79-c45819fee0e1" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,156</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6905722e-5fa0-4e41-abcb-d4f7eab08910" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,433</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71c08360-efde-4530-ae13-e624ef2389bf" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb963adf-ab82-4c16-8a54-f1c379f36d5d" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredIncomeTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,054</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_123d5a32-144c-466c-95e8-439a457ffc33" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,744</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78b7e5db-8b55-426d-88fb-b71dcea2cee4" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,477</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5c53f92-0107-4f8b-ac4c-dfac503ef4fe" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,635,165</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ce92927-e4e2-4c49-ae94-c4131953a276" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,301,060</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Liabilities and Stockholders&#8217; Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05ae33cd-eecb-436d-8169-2c56521e5036" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,966</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e88c79d6-44cb-42a7-a4db-a100ee18efb5" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued personnel-related expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7153af8-24f4-40d1-a719-bc44f78c16fb" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,100</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b073105-df80-4cb0-a9f8-e4b96af068b0" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,376</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2d545b8-73c2-4ade-90f9-c9665853671d" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,618</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b04bd0d1-feba-403b-8c08-af1e0e03b8cf" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:InterestPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,422</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8429c4bb-12e7-47e4-9b05-bacb0c4377e4" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,270</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22e2950c-f994-4e95-9238-c8d834a9a584" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,126</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_991c409d-858e-4e99-8223-bcdca145b672" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">274</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be5dea84-3fff-40aa-81b7-af55d21e0ca7" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible notes, due 2025, net of issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11dd66d7-a3f2-4c90-bf85-037b6519657b" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b0968ee-dd12-417f-9723-32729f0f0627" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,028</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other accrued liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_febe2dd0-06b7-40b3-86e3-2b8db828df47" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,468</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_270632b3-3604-4830-b269-ef1f9f388baf" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,999</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6398ee21-8bf2-4411-9648-42e8f2d7ef80" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">49,696</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fb47cb6-7a08-4685-b9b2-b8ecba21a17b" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,083</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term debt, net of discount and issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c34ae4be-4b8e-4446-a1d1-11676347ed71" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,731</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97e05a48-699b-4045-8eb7-ba71ffc81e2c" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256,316</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other long-term liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c2dbc2b-be0c-4609-87e9-89cb92b0a273" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,091</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5da4192c-d52d-455e-8214-75177180679e" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,275</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74fe9b1c-f424-4464-bbd0-033f1f9887c3" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,793</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72e6ad1f-0ad7-4d7f-8d96-e107f70d4e40" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax payable, long-term</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a5cef67-d483-4ac8-a904-f6ab2235eea0" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AccruedIncomeTaxesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,013</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d68ac886-187e-4f80-89f2-4f67512d1080" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AccruedIncomeTaxesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,227</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_535b341f-6db5-401b-a3a5-8bf671fbdba5;"><span style="-sec-ix-hidden:F_ccc3aab4-a06b-4ff8-8274-4eb2a635f659;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commitments and contingencies (Note 13)</span></span></span></span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stockholders&#8217; equity:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock: $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_122f15c8-45cc-41f6-9945-fe08b5437cb1" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e4dadf41-9f5d-49e4-a0b0-a89965e4da4b" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad60b688-b51f-4fac-8de6-a78ec092ba11" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_03097ffb-874b-42f9-bf7f-db4a4b9793c8" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">230</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized,<br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5037a487-f152-4428-adeb-792cf4e228f6" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ad54e1f8-90b9-4e99-8bb7-c683ac849d2c" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a706ddba-8c13-4559-9e36-0d23a83c234a" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b5fad122-3e63-4a68-a49f-693e498e55dc" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares issued and outstanding</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ede9362d-15a3-4f12-9d28-0f1d39bca636" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad26a199-d4e0-4792-af20-aee35e0e4df4" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock: $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e06be84-8302-47de-832e-a81513766646" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal"><ix:nonFraction id="F_64f05725-c21c-449c-b4ae-807ff69cde33" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.01</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;par value, </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbc16de0-e988-4b59-9ce7-c10a1c4dc125" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_20567659-dfb3-4f87-afb6-e571678b3cd7" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">200,000</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;shares authorized, <br/>&#160;&#160;&#160;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad7e9db6-2a1e-4865-aec9-029c0207e3bc" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_201fea28-6620-4d97-b1b8-6e6d4479448a" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,636</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;and </span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4682dae-25a4-48e6-88b2-1eb93839d19e" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d28538bc-3b4a-4b02-b5ce-dfbe2cf66568" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,665</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;issued and outstanding as of<br/>&#160;&#160;&#160;December 31, 2025 and 2024 respectively</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9574bb18-14db-42cf-8c1c-5ee0fc14f4df" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">747</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0af5412e-d38b-441e-bd78-19dafd9030da" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">627</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Additional paid-in capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7353766-e812-45cd-ade0-91cb64299ece" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">902,726</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_522cce04-6628-4058-8fb0-dca327c987ec" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692,329</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Retained earnings (accumulated deficit)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2731bbc7-e3c8-4f22-bba6-f75fd4958c72" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269,368</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5567859f-378b-4872-941b-611d9c296707" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,797</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d881f102-b3d1-4f4d-992a-7951293ed26b" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,172,841</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38b54920-44df-44d9-8d90-5ef8b5337e1b" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">691,159</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total liabilities and stockholders&#8217; equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81728e74-5b2f-47c1-9fe5-29cbc3cd93af" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,635,165</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6db9ff1e-5cf5-4e32-904f-cec9ae053d85" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,301,060</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">97</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_income"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF INCOME</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> AND COMPREHENSIVE INCOME</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands, except per share data)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:51.311%;box-sizing:content-box;"/>
     <td style="width:1.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.75%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.75%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.75%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty revenue, net of amortization of <br/>&#160;&#160;&#160;capitalized fees paid of $</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30b2cc72-46c2-4ddf-b72c-523421e25c0d" contextRef="C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_87112ed2-b339-4b55-8f95-8bc52f35fa5b" contextRef="C_24d3732a-a2a9-4442-b464-10be5d29362f" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_b5a130c7-8ef4-46be-98f1-2014d3fd64e7" contextRef="C_8290bc3e-4b79-45b4-8dd5-a2d83da40c0c" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,823</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;in <br/>&#160;&#160;&#160;each of the years ended December 31,<br/>&#160;&#160;&#160;2025, 2024 and 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6d68ec7-25e9-4b6d-8f88-a6df6f0e71bc" contextRef="C_486828c2-55c2-4eca-a8e9-7c9edc91e774" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,479</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d40bcd7-d5e4-4865-8fc2-7eb6861f5519" contextRef="C_8c3d0ea3-a6a0-43b3-ad32-fa7162ce8c28" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241,733</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2929c706-5904-4132-a274-af3f6eecd92b" contextRef="C_02167381-4ee7-420f-9702-aa51b2304727" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238,846</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net product sales</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68a148be-27ee-49de-aaa5-26b93991dbb9" contextRef="C_e1b0f380-3db6-410d-886f-3625779ce5c2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,130</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cea20a73-93f6-4235-9616-3b62fd80576d" contextRef="C_0f3c27be-b222-4d28-80f0-06ce24daba5e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,492</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1910daf0-f43d-4136-92b3-07e6c90a836f" contextRef="C_d5a54e09-f59e-44b6-9cef-6b6ac8a95a30" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,617</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">License and other revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae740c85-e210-42f4-b3cc-724f8cdea377" contextRef="C_33e42f5b-3543-48dc-a026-c6016772a37c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,719</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0845b96d-6e07-4d4b-ae14-4933320518f8" contextRef="C_b0a0b85c-bd15-4eea-be59-38094513a363" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,486</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64b7b432-709d-404e-bb63-47706bcbc3f3" contextRef="C_b2be7da7-0eaa-4d69-b26f-885c2d1e7254" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57e97d1b-af9b-4475-917f-18c38f8574c3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411,328</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f33b903-f2f1-4914-bfa5-55f266bbb5b1" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">358,711</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22c25aa7-e85c-4fa6-863d-d0e521be6f93" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310,463</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of products sold (inclusive of<br/>&#160;&#160;&#160;amortization of inventory fair value<br/>&#160;&#160;&#160;adjustments, excluding amortization<br/>&#160;&#160;&#160;of intangible assets)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b9485d7-5193-4577-b5f2-6066a6ad0f6f" contextRef="C_e1b0f380-3db6-410d-886f-3625779ce5c2" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,384</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c97c0b47-693d-416c-98b3-c65dc9ec2d67" contextRef="C_0f3c27be-b222-4d28-80f0-06ce24daba5e" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,598</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d457142-8140-40c2-842d-896bf3130ced" contextRef="C_d5a54e09-f59e-44b6-9cef-6b6ac8a95a30" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,040</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of license revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f3d4a39-261c-48af-8526-47a6c471b5d8" contextRef="C_8fdc954b-b47d-4c5f-a782-7e29908c95eb" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_879d0226-a7a7-4c21-9f36-1e5301488759" contextRef="C_3144e120-55bf-4537-84b6-260e15c16e75" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87c0ac08-0b9d-4b77-89c9-4ecddf5630ce" contextRef="C_45abe52e-ab8e-4973-995e-7e872a676421" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,600</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of acquired intangible assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b780e45b-95bf-4b27-84d8-7f889ef637bb" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:AmortizationOfAcquiredIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,277</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c4298d3-f012-433f-92fb-648f253ca2b8" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:AmortizationOfAcquiredIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,902</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad8dbfd7-6078-4a90-aa8a-f41681517415" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:AmortizationOfAcquiredIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,784</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32151735-1b13-4d96-b093-0793470e8e1f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">307,667</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b874894-8085-46db-8803-7e2814847668" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">296,211</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6949fad-2280-40cf-9ea2-e5f0f03c15cd" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:GrossProfit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">246,039</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04caaed2-2b01-4188-8420-f05d7987b3b0" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,318</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffa72dbc-44bc-48c2-97bc-c48e50ade38c" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">115,690</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_743fcaac-41c4-4242-9cc7-f1d2f645e457" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,232</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8212c623-e718-4541-a338-4b3fcbf510b6" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,604</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f044d0b-d02a-4ba8-9321-c592b4482366" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,654</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d7a9508-a7e6-4689-b456-7cc7ba96cfde" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,922</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbafee88-e662-4104-bdba-13d87803f05a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,922</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e7ceb35-93d0-4cc9-81b9-5fca2ec19374" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">129,344</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4881ed19-8841-4dcb-a7c7-0443a6cc3c18" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">132,154</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income from operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c4d6ad9-c77a-4071-9dbd-6f38887b29b9" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,745</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_beb959b6-9107-4a58-a1d9-82c9329c08ae" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,867</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_811e6947-f3d3-4a92-8f7c-7563c5fd2c57" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">113,885</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity method<br/>&#160;&#160;&#160;investments, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c553fcd1-ac9a-455f-a49b-fd9723bafc20" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,433</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2f56222-55d9-42cf-a6c3-5ebd2245f841" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">64,253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a805a5e2-f2f7-49ba-b605-6eb774ab88f1" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,392</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity and<br/>&#160;&#160;&#160;long-term investments, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9a7447b-d6e5-4687-a0fe-0bafa3142627" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,160</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a4754c0-a7ad-4f00-932a-3de997197f95" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,161</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1d68301-9436-4334-9a5a-68cf4dada681" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,129</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and dividend income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_854bcba9-131c-447f-93c2-09318a93906c" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,086</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0310bf30-a9d0-4d48-93ed-945f7ee8ae55" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,141</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a61cb18b-2f7c-4c1c-96cd-f607cb9ca1f1" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,818</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6a22ea7-6887-4baf-8bc3-fe9e5cea1655" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,698</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7854109b-66e1-4a47-8767-64948c89ba84" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,209</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4bcc1756-ad52-4628-820b-b95b96478f02" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,157</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5507844-c01c-48ea-a3c6-ede5297179c8" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,864</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a1280d2-b64b-492c-a0d8-80b255289ebb" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,997</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_460f0312-9395-4b47-bff9-14ca36e2a25f" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,969</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income before income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05bf4cca-8a2d-4b02-a958-64313027ff74" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326,862</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f519e944-e841-41aa-aa90-2d06947d66ad" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,388</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed9e45c3-d1ff-4a6f-8208-5a451dc8e8aa" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194,098</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be368389-1b3e-48d2-bc65-aee985d37e63" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,697</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_746598a6-b0b8-4e5e-988b-29a5b219a3ac" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,996</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ad3f234-fb7c-48c2-92aa-0caa7caafff6" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,376</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:35pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:6.48%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income and comprehensive income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_468be4b0-0e50-4fb4-b312-7be2c79f361d" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,165</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8b9f0b8-35a9-4181-9eb8-c27fd9494e84" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,392</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82541dcd-1019-415f-a312-ed2a1bc3357d" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income per share:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_775392c1-4910-4135-b24f-fad760da67df" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.02</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d414d52-a5a2-4f81-a635-0f210232680a" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.37</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86a3a82e-7a36-4b2e-9938-deb3c438192b" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.75</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7bdea1f-3337-4edc-b0bd-4bfb30c2ddd8" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.30</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9391de5d-388d-4a42-9b5a-6b7086da17d5" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.36</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e790c25-40c7-4f1e-9004-baf95361fe7d" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.20</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shares used to compute net income per share:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a653b0b6-f7b8-4418-be84-0a1fb695bea0" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,395</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ec3a426-d068-4aa2-bada-84f047d90557" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,726</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26a384f1-5201-450f-a877-a91bd8a7d6ee" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,435</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eadcfd64-fe67-4d02-88fa-e61b0c2ea148" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,760</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f8aa9e6-f264-4890-a9b2-9ad0bf1c9cdf" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,187</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16a5a9bd-a0b5-4694-8262-669076308f06" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,876</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.21in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">98</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.3in;z-index:2;min-height:0.25in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_stockholders"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:24%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.68%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.14%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.08%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.4%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9.54%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Additional</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Retained Earnings</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Common Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Paid-In</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Accumulated</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury Stock</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Stockholders&#8217;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Deficit)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2022</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfb3d0cb-f5a0-4397-b21e-0e3c96cceb4d" contextRef="C_31784cc3-872d-408e-80c1-6e43cba22130" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,188</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05793dbd-535e-4dd7-86e0-068d2b5fade1" contextRef="C_31784cc3-872d-408e-80c1-6e43cba22130" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be83d266-7de7-49ac-8a2c-74aa80fc62a0" contextRef="C_fda3c94b-7cd8-431c-a448-eca3c92b1451" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,163,836</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13f1a051-2bd5-48c4-a3c7-c8befc1187b4" contextRef="C_7d786c4d-9bc2-4c05-9835-fe6f2d5d9c1e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">204,911</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71f03815-892f-43b9-862a-58ce0abde269" contextRef="C_0865d3ef-f81c-4aa7-9435-994b376311c7" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,005</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_843f8819-714b-484c-be44-dcf9fe9e4682" contextRef="C_0865d3ef-f81c-4aa7-9435-994b376311c7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">393,829</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f6e9242-f498-4079-bd12-297d03ca1ebe" contextRef="C_a60c1143-acae-40be-9475-53a07ff86264" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">565,788</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options and <br/>&#160;&#160;&#160;issuance of common stock units <br/>&#160;&#160;&#160;and stock awards, net of <br/>&#160;&#160;&#160;repurchase of shares to satisfy <br/>&#160;&#160;&#160;tax withholding</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf045c89-12d1-4cfd-aa5d-d09cbe7c9342" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">293</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7f50a48-17c1-4213-8ca7-d220bb88fbc8" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_107ab948-113d-4a4c-97ca-487fde9c0de1" contextRef="C_b6f9a97f-7c68-4a85-8e85-ea9cf6cc6220" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd33e5f5-6859-4ebc-8f5a-6e60d26f35ea" contextRef="C_431e9250-fc85-45e0-9b9e-fac3bf029cec" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee5120f5-cc4e-483a-af31-1b877cc63bc4" contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00335233-1983-4c04-855e-adba7bf2ac65" contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c4319ce-43fb-4b9b-8ae7-af4085895652" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">92</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchase of common stock, including accrued <br/>&#160;&#160;&#160;excise tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ad27e5c-26cb-4c83-b690-efb6803b0c5e" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">6,174</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c28e0573-5dce-4387-ba89-cf5229286f0e" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">62</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9699cf7c-7272-4d6c-a13c-5836f5344068" contextRef="C_b6f9a97f-7c68-4a85-8e85-ea9cf6cc6220" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76,422</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d028c55-e6e8-40a4-92f0-04e4cbaeff7f" contextRef="C_431e9250-fc85-45e0-9b9e-fac3bf029cec" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ddd70d7-5bab-408c-912a-c17a7ca0d7a8" contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97" name="inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0261c3c3-f9e5-4fbc-9778-d5a9aaadf3a2" contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_477dde18-020b-4612-b63f-79d8aa83b452" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76,484</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8157231-7d5c-418d-b0d6-a5001e8119c1" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7227f28e-b4fb-4af4-88ab-6e0b5cb7bd24" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44e8d0f2-c676-4e23-807f-1006faa9045b" contextRef="C_b6f9a97f-7c68-4a85-8e85-ea9cf6cc6220" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,837</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9aba897f-6891-448e-b857-08eb5279d6ef" contextRef="C_431e9250-fc85-45e0-9b9e-fac3bf029cec" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6807197-b3f4-4ad4-a163-1811f23e8e31" contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb334260-c0da-4929-8de6-bcfde0592cf8" contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2cadc34-9e18-40e5-9b04-81941daaa0b4" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,837</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_045d1f2d-0674-4687-abcd-827144f78ac0" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93686402-89b0-4ad7-a039-b18f49f6a46a" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c8eb362-ada8-4ce9-9d70-de5affd31e4f" contextRef="C_b6f9a97f-7c68-4a85-8e85-ea9cf6cc6220" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c466964e-4846-45c5-922a-d620f39548f9" contextRef="C_431e9250-fc85-45e0-9b9e-fac3bf029cec" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1a19650-56d5-4d33-9f89-48677983f87d" contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_328a3969-b3c0-4748-8875-6ce2bd4886ba" contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f9d0261-02ae-4b59-8749-d71b046565da" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c60b783b-e01b-4ed6-b1d8-2adc0cca351c" contextRef="C_c9ea7908-47f3-4091-b474-5d9827ca0b02" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,307</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0c00b01-967b-41ed-8cdf-139dc751b695" contextRef="C_c9ea7908-47f3-4091-b474-5d9827ca0b02" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">633</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c0e89ca-74a5-4a26-80da-dd1648e12f7d" contextRef="C_71f99e54-19e3-4788-8727-45db0240d021" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,093,340</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23ad3c41-e3cb-43fc-9906-48b7755596b0" contextRef="C_212cc57d-e685-4590-a4bd-6b3b410d36af" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">25,189</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a1562fe-e086-4925-9997-6bc5863942bb" contextRef="C_e874e2c8-b06d-4058-bc9c-21db422ef0fb" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,005</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bee4f42-b518-4aa0-b49a-bb09c00e2162" contextRef="C_e874e2c8-b06d-4058-bc9c-21db422ef0fb" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">393,829</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b06aa5ff-4d35-4390-9ba9-375cd8f1da7b" contextRef="C_a6f00937-2ee4-4566-bd68-45c44b998d3b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">674,955</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options and <br/>&#160;&#160;&#160;issuance of common stock units <br/>&#160;&#160;&#160;and stock awards, net of <br/>&#160;&#160;&#160;repurchase of shares to satisfy <br/>&#160;&#160;&#160;tax withholding</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87342330-ec91-4046-ac8b-5495a4ab21f0" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">345</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c28c4ce4-5aee-4675-9ab1-1d2b571f20b0" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e21c207f-fa9c-4aa3-b646-9a560ad4bc13" contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,321</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_042a8873-d6d4-43ea-b974-5d33172cef51" contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13a70b61-e406-415c-95b0-ed5749310a0a" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ee38898-3fa3-4fca-abb4-dd2972454bb4" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6255fa1-caf6-4ff9-96ae-95033ec33361" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,324</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchase of common stock, including accrued <br/>&#160;&#160;&#160;excise tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_367c648c-90cb-44b2-9ec1-1d19d2fe0c49" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">987</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d21e1e6d-3736-4363-8805-b68047a64c6e" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">9</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e778bb2b-b567-417b-9b45-f9047369b2b8" contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,916</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb220150-45ce-4754-b6cb-9334a1aa4828" contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f72ec4f-b4a8-4af9-ab49-acf6d5eb43be" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93db332c-3617-4035-8985-70c3dcaaa033" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_331ceae6-df25-4af1-8785-755d9c796d8f" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,925</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued excise tax on common stock repurchase<br/>&#160;&#160;&#160;applied against tax liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4cad5fea-1e0f-436e-a2cb-7cdc5898c2ba" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75b401da-f78e-4f14-909b-fcfa528d3a62" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc2b1282-5a41-436a-a1c4-88c74c5de479" contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c8a51e1-376f-46f0-9567-ae69f4b314f5" contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58357360-5dda-4050-9d9a-72bc42b85c26" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1942f8d1-89ec-4081-a4e6-8c6bc54c2112" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfb689f2-347d-44fb-86c0-885ea58d5b2b" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66b93687-e1d7-4fa0-93f7-6c2fa622a36e" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ec1a025-dee7-4ed5-9ae6-f7ba8b9fb35c" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0825cf4c-8553-45c1-95a7-eccad367aea7" contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,374</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7a81435-1aa9-4167-9da1-14df9eb94a40" contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb896aad-e4fc-48ea-8903-088e8a82984c" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f4258a3-0bc0-4f46-a3ae-61c55bd1182f" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b763b9e8-e948-4d4e-9707-6edfdffb66d5" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,374</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Retirement of treasury stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f52565c-c627-4282-aba2-c98daba0bebd" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be5c61ef-5952-4031-a88f-84c0f2ac5413" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09c1e40e-196d-4a22-a2b7-2219f0b6044c" contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">393,829</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_139d312d-f47f-490d-8729-12a72b710819" contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b45ea0cc-2856-419e-8465-160cad593e83" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">32,005</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a82d50cd-e3c9-4354-abb2-430e93588d34" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">393,829</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a658a40-7499-4e1f-be89-dbaf74b2ae79" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7749aa84-5e3d-4855-b374-9a44e4d8fd20" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49673229-2b29-4ef3-b47a-f07548c316e3" contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e91443c-1f1b-49c9-b6c4-936d60d95f24" contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91208728-0bbd-4ed4-80b4-ab2f289acdc2" contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,392</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5641778c-a5a3-4e73-b063-ad2bab4c2bac" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b625f2c2-0a2c-4f14-94ac-9f3ab4ccabc8" contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b7b4de5-0273-4084-a4cd-c15f261d170b" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,392</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30e11723-3401-4aa7-a2e0-8e589286daff" contextRef="C_76c325ef-f27e-4ba8-812a-698b1f542dd3" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,665</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbc78688-cabb-428a-8917-e743fd2ba102" contextRef="C_76c325ef-f27e-4ba8-812a-698b1f542dd3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">627</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8996df6-5f4f-4174-ac1c-05183bb80b33" contextRef="C_add7605c-d6b6-415c-ad09-46eb5bbbfb4b" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">692,329</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1ba2a30-2518-4594-b0a1-7b81978763ea" contextRef="C_6ab3cefd-f2b3-40bc-8f3e-a411da14524e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,797</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2bc6c9e-a32c-4788-8b5d-644bd607d133" contextRef="C_4486e6d7-5936-40be-8a70-b6ae40d88127" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21789d2c-af87-4f00-a4f8-cc5f30ccc83b" contextRef="C_4486e6d7-5936-40be-8a70-b6ae40d88127" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_314bf8b0-a495-49ef-8836-0481bb5c6391" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">691,159</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of stock options and <br/>&#160;&#160;&#160;issuance of common stock units <br/>&#160;&#160;&#160;and stock awards, net of <br/>&#160;&#160;&#160;repurchase of shares to satisfy <br/>&#160;&#160;&#160;tax withholding</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d87aa5d0-8745-43d3-998d-d17d63b024d0" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">459</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_601e9a80-34e1-4859-80ee-1225eb8f1a0f" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_353e5382-98bc-4220-b83b-23f2782e4c8f" contextRef="C_f9044951-f126-4cbd-81bd-331f45565190" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,405</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e095c2d3-062d-40af-b336-a4adb2b7729b" contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a957a5d3-ee68-45a3-a7a5-994abd954bdd" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f9c9b96-cdf3-4679-a737-2749c9592f27" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7539f36e-7214-40ce-ba6e-bb072006b5a6" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,410</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchase of common stock, including accrued <br/>&#160;&#160;&#160;excise tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30ce65fa-dd43-4e4a-b668-211b30d2b2e8" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax" unitRef="U_shares" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">228</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f105317-0ac0-4659-81e0-3576fc531e9f" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7bc165e-9352-49a5-b7f7-06339d44ac79" contextRef="C_f9044951-f126-4cbd-81bd-331f45565190" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,575</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d9dd3a3-3412-42bf-9170-40e6f2c7d9b4" contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b5fb495-2e82-4537-bb2f-6ff06fb8c5ad" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b2be2c0-7fc6-42c2-8c0a-a0c47f8e24ed" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:7pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39717bda-e9f9-46f1-bbfd-06df28a47670" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,577</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued excise tax on common stock repurchase<br/>&#160;&#160;&#160;applied against tax liability</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61ce6766-54c8-4182-90fa-72ba1b48f8cf" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_868d73a0-9157-444d-b8d2-6abdf3ef95fd" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87dadbcd-7292-4a17-a1c0-3cf632116ac9" contextRef="C_f9044951-f126-4cbd-81bd-331f45565190" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4ba9a34-846a-41f5-a739-bcf76471d3cb" contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86344fa2-4e8d-455c-a7bd-fb39a3519a80" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1554ff8a-b209-4c7c-a289-b69cf1f75c0b" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_314103a8-0698-498f-8f87-88a5745cfaf3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Conversion of 2025 Notes to common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8953fa58-0c3e-4ee6-b421-f889b8d395b3" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,149</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b30f8a92-f40f-4c25-84c0-9bd2996a7c41" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f596f949-99b2-410b-813a-f4361cea8c6f" contextRef="C_f9044951-f126-4cbd-81bd-331f45565190" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,364</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c466df5-c2e1-40cd-909e-e0f7b6a4552d" contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f69ef65f-d4ce-47a4-be5f-7caad1e7e8b8" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8296a3c3-405c-4321-aff0-005722328f22" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f3154dc-c97e-4271-98a8-944e59fb8022" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,475</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercise of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3741ff6-4aa7-4b1c-befe-a8d912efe6be" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="inva:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94cc403e-2b03-468f-8813-c1a8cc0d33fe" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="inva:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c16b028-4845-4b35-bbbc-297f3bcf3b83" contextRef="C_f9044951-f126-4cbd-81bd-331f45565190" name="inva:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,692</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42ae9744-38ce-4938-9b79-7905ab20f098" contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4" name="inva:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f7bbb24-8821-42d7-bea6-4f3400da976a" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="inva:StockIssuedDuringPeriodSharesExerciseOfWarrants" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d524011-50eb-4eee-8e14-683f403e13fb" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="inva:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16e90c84-7c25-4a96-953e-8f61b041bfeb" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:StockIssuedDuringPeriodValueExerciseOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,698</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_649c660d-d77b-4311-b04e-0f58f634a771" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6722c0a-ebde-46e5-8ffa-c5e60bcfe156" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c603895-cc56-40dd-a2cc-fc920acd9d88" contextRef="C_f9044951-f126-4cbd-81bd-331f45565190" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,452</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a98e9e8-b774-4e36-a07e-caa8c4cbfffd" contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0341ba2f-2057-4421-aeff-743ae0f4378e" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c06ce27a-862c-4d9f-b294-d914f78a865d" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78bfd34f-bd52-498d-b21b-99b51fc4faa7" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,452</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1815757d-71c4-44e9-aa2d-b94360f619f5" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a9cfd95-beaf-47a4-b47e-99a37581fe06" contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c150f09-e59d-4ef9-8f78-7f1efcf5efcd" contextRef="C_f9044951-f126-4cbd-81bd-331f45565190" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7ca43db-6282-4b61-85b5-b1f1cb07bcdf" contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,165</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9f28aff-49cf-49ca-82f5-20e0ac5720cc" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="inva:ProfitLossShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34355ba9-7ddf-422b-8349-d0275ca4d272" contextRef="C_06e9c678-095e-4291-8f2b-762451638db9" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c997fda1-3465-4e9d-93fa-8c5e75029cfa" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,165</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:7pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5566e9c4-a858-488d-bada-19c5ce677b3a" contextRef="C_577dc48e-2a7c-47ff-9812-6a80348a1bd8" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,636</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91706d0e-342d-4bb8-8bc0-0d407e263809" contextRef="C_577dc48e-2a7c-47ff-9812-6a80348a1bd8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">747</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd5b1196-c2af-4d84-8f32-dd6442848e25" contextRef="C_d93a2eff-6ca3-4b72-bc94-7f262d74a800" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">902,726</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3554d100-0d8e-4711-acf1-da5e491f6c9a" contextRef="C_edb34f03-0687-4952-862d-bb3107aa1b2e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">269,368</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c14064aa-9b71-4ca7-8f66-797b040c5c8f" contextRef="C_4cbd448a-5be2-4867-9b30-17f58446ee15" name="us-gaap:TreasuryStockCommonShares" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c419b3e-4257-4b2c-a69c-af5856595004" contextRef="C_4cbd448a-5be2-4867-9b30-17f58446ee15" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:7pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c96bc88-9a8e-4c8c-af7f-09de96b0ddfe" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,172,841</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:7pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.3in;min-height:0.22in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">99</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="consolidated_statements_of_cash_flows"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(In thousands)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:52.619%;box-sizing:content-box;"/>
     <td style="width:1.299%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.495%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.299%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.495%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.299%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.495%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from operating activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8263ac0c-a668-4a9f-9ba0-d3af6e10da6a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,165</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b4b8870-1f87-48cc-a870-46ea00d9d77c" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,392</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ca305eb-0040-4fed-85d6-a3e61d15dc93" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments to reconcile net income to net cash provided by operating activities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a24797a-6ed4-4871-878f-6ce514ebc881" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,847</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33b8aa41-5781-45cc-b9cd-ee537b49a52a" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,617</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3977d79a-c799-4fa3-a6b9-836c738fdd7e" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,400</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of capitalized fees and depreciation of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f0c8136-4b90-488c-a479-0c7231c55a3c" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,951</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78c62aca-ccbe-411e-9033-2fd7d2c5f0ee" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,951</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b0e3da3-fdb1-46c2-b422-3691905fdd5a" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,921</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of acquired intangible assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4dbb42b-5bf7-433f-8904-b9a3f2861591" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,277</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c13e1b03-7efd-4494-95f3-85ecd4491ef8" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,902</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_576d85b6-d658-4718-8af0-a236af0a5585" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,784</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory fair value step-up adjustment included in cost of products sold</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a3d3a2e-102a-4425-9b72-c1d3c523c923" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,841</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de8c5119-5a86-4be5-8546-22f8c5546a12" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,820</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_56d7358d-bc17-44b2-b1c3-80a2594ce3db" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">27,164</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock-based compensation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a4a0e39c-0876-45fa-aec4-998fd76af611" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,452</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bb2eba9-5c03-40d6-9ff7-8ffd8966fe3c" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,374</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2f253de-3ea5-46b5-8e42-7eddc557562b" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,837</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt discount and issuance costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48407010-37cd-4c56-b4fd-dc6a8d852046" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,887</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c921db62-4381-4a0f-bbb2-76c2c781b36f" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,110</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f38f0dc4-6458-438f-9924-4b1f0bec0404" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,065</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity method investments, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad6bc8ec-beec-4b6f-976f-c6063bd15033" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,433</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_324264fe-7f68-4ac5-b1f6-14a11d8bb9f2" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">64,253</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_141355d8-4323-427e-8983-1851cc415c0c" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,392</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity and long-term investments, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_962bc7af-bdf6-4785-b82b-427b14a55d00" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:UnrealizedOtherGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,160</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02714b89-5473-4f50-99f6-013ad0156692" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:UnrealizedOtherGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,161</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cad3c6eb-2c1a-4dbc-bb2e-08b6760706b3" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:UnrealizedOtherGainLossOnInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,129</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired in-process research and development assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07366f3d-117e-4169-ad15-40a74bdc1c5e" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:AcquiredIn-ProcessResearchAndDevelopmentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,368</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e7ccd13-3d85-43ba-b391-f3248dfd094e" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:AcquiredIn-ProcessResearchAndDevelopmentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eea2286e-d5e3-4042-aa72-c8eab7edfecc" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:AcquiredIn-ProcessResearchAndDevelopmentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other non-cash items</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fa0807f-2af9-4dbd-9d8a-e99048a27555" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,897</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ae4c9f8-ac48-4c7c-8fb5-3fb6602d77ad" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">722</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fabdcbbc-9cfd-4548-b72b-2d0d5573e58e" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:OtherNoncashIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">517</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts receivable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f1618ff9-d63b-45bd-884f-329f32b6a8ec" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,574</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06f829b3-59d4-4461-81c5-f6fde1b33b42" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,938</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4740c2f8-1a4c-4595-a0cc-27a79f4d032a" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,053</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Receivables from collaboration arrangements</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8b57cb6-2755-4a97-bc0a-aee1e4a4051a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,623</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1297d0b-0695-4aaf-8895-1568edbf1826" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,647</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0f24a90-51e1-4826-bdae-878480d1d504" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,949</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95f10898-1e1e-4efd-a324-dd69b93e7a1e" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,919</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0ce99aa-47a1-44ec-aa20-b2c93bf9d369" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,808</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e48c8a8-9e29-485c-94fb-eba8fa30455c" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncreaseDecreaseInInventories" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,004</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepaid expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42ee0a62-5603-4d21-96b1-2555edec0189" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,658</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee576d75-1c2b-46e8-8916-175fa8ae9964" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">567</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b5095d1-29b2-4836-812a-f43b5317d7c2" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncreaseDecreaseInPrepaidExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">7,929</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2e1ad2d-d6fd-4cf5-b6b6-934eee7da0db" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,078</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8dda26c-9342-44d3-bdf3-44a7df9c5052" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,186</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edc4445e-fe01-4c27-8bb0-0acd3ba5e89d" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,965</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accounts payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b767ae7-89fd-42f6-bdaa-1f1bc8cc04c3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,834</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c1dddcf-73a4-46b2-bbb0-22dae95a3c5f" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,585</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89c6b688-a9b5-4e20-bebd-f2e791387092" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,778</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued personnel-related expenses and other accrued liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4501536-f493-4f2c-acc0-cc106ef513d4" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,790</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ae95183-7193-47e0-a405-c13349973289" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,044</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52eb7515-9da1-49a9-bb92-444ffef68231" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,498</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18ce0725-f680-484c-a322-87a3c7dcf704" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">1,804</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2817b8f-6fb0-4f07-97a4-7ec2f1459fb5" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c8757ba-c452-4d89-b897-f4f5d21ae3fb" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncreaseDecreaseInInterestPayableNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">937</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5eaa3b76-bcfa-42ec-b444-2c7081e45713" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,144</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc43896f-58fe-4d32-ac6b-35164b5e8537" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">151</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4d31799-882e-4175-99db-057a82aa98c7" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">817</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax payable</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5789d6d0-950b-4853-912c-85ff1acacf32" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,060</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f134b829-4b33-4d97-b59a-a82b59c8379b" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,476</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7691e5ad-2d5a-44f6-997f-14d5cf3a8131" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,725</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66f26ef6-9c39-44c0-a10c-c55415cd9d47" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">196,930</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_12dd8760-c5e6-416b-b8a9-0413f48e4b31" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">188,690</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14ef2f1d-7d4f-4dd7-9e56-bd5f86c56c3a" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,064</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from investing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition of intangible asset</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1dd4981f-4d92-4641-8ead-a757ce79370a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3caad89b-a02a-43d6-887d-c45185d4dca6" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c1d3379-0ee0-4dc5-b65e-67b423afef18" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:PaymentsToAcquireIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of trading securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f1413eb-4aa8-4bb9-95f0-aaa0e2e1e558" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,899</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_597011f4-3c0a-4eb9-82d3-b34aab9234f8" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59,617</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17f4945b-57d6-4293-8db2-389e2cd2e97a" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,132</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from trading securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9db4edd1-d418-4ab8-8173-eff8d179e7b3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ProceedsFromPaymentsForTradingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,427</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e287127-f697-4c9a-9b4d-abb72e253168" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:ProceedsFromPaymentsForTradingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1498eef-06f7-476c-84b6-2ba89d2003a9" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:ProceedsFromPaymentsForTradingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of equity and long-term investments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22755102-de7d-40df-8054-9e574fc704de" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a25852f8-2fd2-4d20-8a6a-daad4e5930f5" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_294f8476-5c0b-403b-bfb5-fb6fbe87b122" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of equity investments managed by ISP Fund LP</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a6b6787-858d-42aa-80de-0ac192d6f7d3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:PurchasesOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21e38eb7-86f9-4e0d-9ec4-ec82d6dd1559" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:PurchasesOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,270</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f94917c5-9939-4dea-a472-d925811b153c" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:PurchasesOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,164</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sales of equity investments managed by ISP Fund LP</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43341ee7-dda4-4731-a8ba-0d250db8fa50" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:SaleOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,164</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef7b5253-d9b7-4acb-b94b-622df57bdf98" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:SaleOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,756</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5eb40c60-1ac7-483f-aa99-8aaa74d981f0" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:SaleOfEquityInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,500</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases and sales of other investments managed by ISP Fund LP, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61a78aaf-5308-411c-bed3-cf7f63156f3a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">92,791</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d09ad77f-9528-460c-8aa9-30c6eeea5e67" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,486</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fab50cc-a70d-4518-93e7-5f809b94b500" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,336</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for acquired in-process research and development assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc269883-79b2-4178-be37-17f050e27619" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,368</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65f41b82-9aa6-477b-abc4-7b344d7d51a3" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4446a30b-1f17-4c63-94c1-d4c11c4de983" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7943af97-abbd-4666-b76f-5d0f2a476e11" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,131</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0774587-778a-487e-b30b-e7d5e90e17dc" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">270</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8c6f7c1-3c6f-4ff7-a45c-adb7d3322f30" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sale of property and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59531326-464b-4a66-bd0f-98b2b2cd4e32" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30215e40-28ee-403d-a1c3-c6374d5c3a19" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39db054d-ff4b-49a0-b733-3726e3073e79" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_11daf70f-6ce7-48e5-85ec-ede812d80584" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,496</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46887879-f019-4127-9087-2b62a16a8308" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">63,786</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08588378-3702-4ae4-a695-2d7b7b376e42" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">66,761</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from financing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchase of common stock</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d81d5396-668c-4e57-84b3-652d35fa9035" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,532</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fab8219-dc32-4d4d-bd98-e59c26f93c27" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,777</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9493e6f-2e7e-40c4-a3a0-8637f70943ba" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,728</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repurchase of shares to satisfy tax withholding</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba219256-86ba-48b1-aaa4-b9cadd0825ed" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">143</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ab97abb-60a1-47ea-a530-315fc4f45562" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">142</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aebbb452-390b-42af-a2bf-d47eee646b29" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from issuances of common stock, net</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe376838-c9eb-45c2-b8d3-350ab4d03f41" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,553</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b52f6541-9bfc-41e2-a568-c38511bb825b" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,466</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_760090ab-a981-4671-9b01-b031ab4bc9e1" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">170</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ac71d85-424f-464d-8d49-70811d6f84be" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,698</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50abd2b6-e78d-464c-9997-3d076a32881c" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_feaccf45-7dfa-4632-b4a4-dd796ba3208d" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment for repurchase of convertible subordinated notes due 2023</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa375c2a-94c7-489f-981b-501cd9d8368a" contextRef="C_1dcbb1f9-1291-4438-a7e7-46fd2cf48bf6" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cfe903f-bab9-480d-bdfc-d01faf984507" contextRef="C_25dacf96-e93e-4daf-a92e-ed8eef93dd64" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93c6073c-44bf-4d7f-ad8d-a38b0fb153e5" contextRef="C_fccd77c7-2dc9-4f27-8f85-1f5935f7a45a" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,204</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment for repurchase of convertible senior notes due 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffe96784-af24-46e5-884d-de25bc8ac168" contextRef="C_7fd95b23-44ee-494d-bdcf-53246745fc95" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6708e6dc-b6e6-44f2-ae09-444378c2c13e" contextRef="C_ea6a953f-2b67-4ae3-af96-53ae33c766eb" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_440e7806-3f8e-4fb5-a3a0-673111d6d7b8" contextRef="C_dd8d8977-0825-4ede-9687-2466de66c5ad" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash provided by (used in) financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_329c7e6d-0d7d-4d1b-8c58-05e124ceeb48" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,551</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_386729bd-38d6-4821-b0bb-8813dfebb451" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">13,453</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_372e1ccb-3940-44f9-8a40-6063e1d1b132" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">171,839</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net increase (decrease) in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99131d8a-2408-44dd-a45b-2307aeca052b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">245,977</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b27883b6-bb55-417b-93e5-e3607bdeefbc" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">111,451</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9.5pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ef7b32c-b2ec-4073-a914-411a32c62d93" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">97,536</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at beginning of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83910247-5f26-4a41-8c6e-1b90428ebbcd" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304,964</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4103c1a8-6877-4d35-a86d-58e642a8f762" contextRef="C_a6f00937-2ee4-4566-bd68-45c44b998d3b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,513</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8531854d-64e7-4122-8d30-f08f1419cd80" contextRef="C_a60c1143-acae-40be-9475-53a07ff86264" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">291,049</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at end of period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddb4b89a-01d5-4f20-8ab2-12e20dc224a1" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">550,941</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17340a13-8530-4f1f-929e-fff401b0ea98" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">304,964</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64967c97-eb15-4b00-9e15-bc2e59c6749f" contextRef="C_a6f00937-2ee4-4566-bd68-45c44b998d3b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,513</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">100</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.2in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:52.619%;box-sizing:content-box;"/>
     <td style="width:1.359%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.435%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.359%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.435%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.359%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.435%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of Cash Flow Information:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for interest</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ded85536-fa0a-4270-8de3-afa111320fc7" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,353</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9f0d197-aedd-4276-8439-4dc5459a9235" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,359</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e4d4559-b69f-40cc-8a44-e5585c0aaec8" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,381</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for income taxes</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3290129e-a0ad-448d-a3fc-b44424e6f926" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,113</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0341845-375b-4147-b679-2acd885c3d57" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,793</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab9acae0-f0f1-4fa9-8e8a-9eaf7036dbfc" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Supplemental Disclosure of Non-cash Investing and Financing Activities:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 Notes converted to common stock</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef66e67f-f3a1-4afa-b3a8-117da2d4bfe6" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,475</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f064feae-6819-409e-a820-6dbdc7cf036f" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49d00607-effb-46aa-82d0-f5e88f3cb88f" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:StockIssued1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued interest income converted to long-term investments</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2857a8a8-463f-4a87-a9c5-d0c6aea73b53" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:AccruedInterestIncomeIncludedInLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">830</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78ed7f1c-d98c-442e-93e9-ab2424050aac" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:AccruedInterestIncomeIncludedInLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,584</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_999d6f62-a619-40fc-96e2-2ea5bde77b10" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:AccruedInterestIncomeIncludedInLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,666</ix:nonFraction></span></p></td>
     <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">See accompanying notes to consolidated financial statements.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.2in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">101</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="notes_to_consolidated_financial"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p><div><ix:nonNumeric id="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.  DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ca43962-17d8-4727-9875-76cade69ddb0" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:DescriptionOfOperationsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Operations</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#8220;Innoviva&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar pronouns) is a diversified biopharmaceutical company with a portfolio of royalties, a critical care and infectious disease platform, and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (umeclidinium bromide/ vilanterol, &#8220;UMEC/VI&#8221;). Under the Long-Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as follows: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1ae42a5-bb9c-442d-a025-2bb1ab1904f6" contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad7695e2-1a85-4669-8254-5a30a887ec6e" contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ed5a6ca-b4a1-48da-8eaf-9a5a597dceaa" contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c43f6d1b-bc48-43ab-9981-fd606a901a36" contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion; and royalties from the sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which tier upward at a range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50e49cdd-d5cf-4054-bcc8-9795395b01a3" contextRef="C_0cd22ebb-1d13-4b31-83ad-8d641740a1a8" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0f0a2a6-278a-49e2-8add-84e1d38546dc" contextRef="C_0ea6bee8-0b7a-4347-b4e1-f57199a4e9f9" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our wholly owned, critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, commercially launched in 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(eravacycline) for the treatment of complicated intra-abdominal infections in adults;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">staphylococcus aureus bacteremia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including those with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia, licensed from Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) (&#8220;Basilea&#8221;) for U.S. commercialization and commercially launched in the third quarter of 2025; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (formerly known as zoliflodacin), approved by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we own other strategic healthcare assets, such as a significant stake in Armata Pharmaceuticals, Inc., a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies through our portfolio approach.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9f87ca55-5a63-4b98-9f84-5eafe95fb52b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income and comprehensive income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1f6f43c-f3a7-497c-82b0-b2b59a0a74f3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:UseOfEstimates" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Management&#8217;s Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_d71d31c8-85bd-4d26-b283-a15e7ca1f49a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ConcentrationRiskCreditRisk" escape="true" continuedAt="F_d71d31c8-85bd-4d26-b283-a15e7ca1f49a_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">102</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_1" continuedAt="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_d71d31c8-85bd-4d26-b283-a15e7ca1f49a_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#8220;API&#8221;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currently, we derive the majority of our revenues from GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our analysts&#8217; or investors&#8217; expectations due to a number of important factors.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenues also include net product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which we commercially launched in the third quarter of 2025. In the U.S., hospitals and other healthcare organizations generally acquire our products through a network of specialty distributors, which are regarded as our customers for accounting purposes. We do not believe that the loss of any one of these distributors would significantly impact our ability to distribute our products, as we expect that the sales volume would be absorbed by either new or remaining distributors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our top three customers each account for approximately:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d8609b5-81dd-4085-9fc3-f2b7f4c3f4c5" contextRef="C_4bf5fc18-5406-4a53-bdcc-a726e4be6261" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">24</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abacd4ba-de30-476d-a577-f343f5bcae97" contextRef="C_8636f737-54f5-4f04-95a2-1c6e8e58eb52" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">22</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0783c518-7a87-4d19-9034-9309ab608305" contextRef="C_df4f1b43-9d3e-4a14-9590-f19507b86007" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">22</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our net product sales for the year ended December 31, 2025; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_052974a9-ec39-4004-955d-4c35e8f65147" contextRef="C_b772694b-7101-44aa-8dc2-322e6c88ba68" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2497c4df-10b2-4903-91a4-195f61c3faa4" contextRef="C_9bab53bf-5b1c-458d-ab5d-5fa3f3cca83c" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">24</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3087370f-a213-45cc-a34d-a5be2352bc0c" contextRef="C_699a8187-6daf-4c19-b630-e6a4a350936f" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">24</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our net product sales for the year ended December 31, 2024; and,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd5ded57-42e3-46cd-82aa-98e8b50f3af6" contextRef="C_dc46e272-bbf4-4eab-89a7-9149f700ad25" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32331d2b-4248-4ec5-842b-18a7638114a2" contextRef="C_fa5bcc25-8b49-450a-9892-dbd82bc86c2a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">27</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9f04100-f2c9-4528-8cae-18a7f11f8e98" contextRef="C_12cd7049-aa8a-4e80-8d0a-bdec0949c7f8" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">27</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our net product sales for the year ended December 31, 2023. </span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8affb29-40fc-449f-8bad-2acba4087cfc" contextRef="C_e1b0f380-3db6-410d-886f-3625779ce5c2" name="inva:NumberOfMajorCustomers" unitRef="U_Customer" decimals="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> customers for the year ended December 31, 2025 account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3bf5612-4bb1-4f6e-9c8c-2e1a2d8777ff" contextRef="C_2707906b-3b85-4cd4-95b1-7be4334def0b" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">29</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ab52b51-f33c-40c3-892b-5437f30faf0e" contextRef="C_2840f754-c1e0-45a3-adde-c440dc45dc18" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">28</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2db83414-47ae-4237-a503-f4d152b04731" contextRef="C_36784711-520b-456d-b873-8cb8b780364c" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">16</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivable&#8221; in our consolidated balance sheet as of December 31, 2025. Our top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f1254bb-91b2-4af2-b92d-6c53fb7b92e1" contextRef="C_0f3c27be-b222-4d28-80f0-06ce24daba5e" name="inva:NumberOfMajorCustomers" unitRef="U_Customer" decimals="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> customers for the year ended December 31, 2024 account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcdeaaa8-f87d-4d6e-9937-ba2055b86178" contextRef="C_cd6017c9-4e6d-48a6-b778-fdb58ebeeb24" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc64f121-b480-4a25-86c5-7ce5f61498c1" contextRef="C_aa99c31d-93ff-49a4-ada3-316eb33c9414" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">18</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aeb27cc6-9f75-4c30-9522-2b580c584c40" contextRef="C_488c264e-0d44-4a7b-be6f-0dd0449e0750" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables&#8221; in our consolidated balance sheet as of December 31, 2024.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81d7e5d1-7278-4e64-b9e4-9e0b23ed9f4e" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. Refer to Note 16, &#8220;Segment Reporting&#8221;, for more segment information.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1a8c8a23-5f93-4b7a-b22a-d7d7f9ed853b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ConsolidationVariableInterestEntityPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Variable Interest Entities</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#8217;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">103</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_2" continuedAt="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_3"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d4aa7d9-9fb0-42b9-9eb4-8cc85fde469b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80ccafe6-b9a1-4683-b2a2-ca13d8a492e0" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6bf03cb8-2dca-4f96-a253-4b1e635ab22b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:InventoryPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventory</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_43174d08-da99-419b-86e2-2c35caef3492" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our property and equipment consist of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements. </span><span><ix:nonNumeric id="F_b7e138a9-2c5b-41b2-800e-deaecefacb0b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock" escape="true" continuedAt="F_b7e138a9-2c5b-41b2-800e-deaecefacb0b_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation, and are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b7e138a9-2c5b-41b2-800e-deaecefacb0b_1" continuedAt="F_b7e138a9-2c5b-41b2-800e-deaecefacb0b_2">
         <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
          <tr style="visibility:collapse;">
           <td style="width:49.17%;box-sizing:content-box;"/>
           <td style="width:1.66%;box-sizing:content-box;"/>
           <td style="width:49.17%;box-sizing:content-box;"/>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_4cbcd9bc-16d4-4709-89fd-2ac8e89a06a3" contextRef="C_2d1f6be5-5863-4cef-a634-37c4e6881e96" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#8211; </span><span><ix:nonNumeric id="F_12b99b7d-047c-4f67-a2d3-71a4dbc1d1c7" contextRef="C_8c7fde10-e15b-46cf-8152-abd34dd01bd9" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></ix:nonNumeric></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software and computer equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_4e0027b9-d579-45b6-bed2-30b82f6aae00" contextRef="C_963ef00c-7831-40dd-b4ea-a644dc525f00" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
          </tr>
         </table></ix:continuation></div></ix:nonNumeric></div><div><ix:continuation id="F_b7e138a9-2c5b-41b2-800e-deaecefacb0b_2"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68cf4d3d-794f-47e8-b231-1cca9accc72d" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EquityMethodInvestmentsPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity and Long-Term Investments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of equity and long-term investments, net, within the consolidated statements of income and comprehensive income.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we conclude that we do not have the ability to exercise significant influence over an investee, we may elect to account for equity security without a readily determinable fair value using the measurement alternative method under ASC 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This method allows us to measure the investment at cost less impairment, if any, and adjusted for observable price changes in orderly transactions involving the same or a similar investment of the same issuer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also invest in ISP Fund LP, whose investments consist of money market funds, trading securities, and equity securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered into in December 2020, we became a limited partner of the partnership. In October 2024, we elected to unwind our capital accounts in the partnership in accordance with the terms of the Partnership Agreement and expect to receive distributions through April 2026. Accordingly, the portion of the cash balance and money market funds expected to be distributed within 12 months from the balance sheet date has been classified as &#8220;Current portion of ISP Fund investments,&#8221; while the remaining equity investments have been classified as long-term investments in the consolidated balance sheets as of December 31, 2025 and 2024.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">104</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_3" continuedAt="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_4"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85abbff2-8baa-402c-a27d-ce918af91c8e" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Quoted prices for identical instruments in active markets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Unobservable inputs and little, if any, market activity for the assets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c0c4202-1d92-4d57-a1f7-102f78c48d1b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:CapitalizedFeesPaidPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalized Fees Paid</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#8220;Capitalized Fees&#8221;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2c3c4e29-f7ca-494b-99bb-cefa49d88131" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:CapitalizedFeePaidEstimatedUsefulLife" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15 years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#8217;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_36f25b09-992e-4e2d-aa09-6545d248813b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill and Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with an indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40df869b-0e04-42be-8793-49e111ace049" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:AssetAcquisitionsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Acquisitions</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure and recognize asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost of the acquisition is allocated to the assets acquired on the basis of their relative fair values. The cost allocated to acquire in-process research and development (&#8220;IPR&amp;D&#8221;) with no alternative future use is charged to research and development expense at the acquisition date.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">105</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_4" continuedAt="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_5"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0d5da26-a399-41de-b940-3d2bc4e4d17f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_69da4ed6-62c6-479f-946b-586e3c8dbccd" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true" continuedAt="F_69da4ed6-62c6-479f-946b-586e3c8dbccd_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 606&#8221;), to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on their own methodology and assumptions for estimating rebates and returns, which they monitor and adjust regularly in light of contractual and legal obligations, historical trends, past experience, and projected market conditions. Our partner may make significant adjustments to its reported sales based on actual results, which could cause fluctuation in our royalty revenue. We have rights to conduct periodic royalty audits to evaluate the accuracy of the information provided. Royalties from GSK are recognized as the net of amortization of capitalized fees related to approval and launch milestone payments made to GSK.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Product Sales</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#8217; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#8220;GPO&#8221;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired products. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each state&#8217;s eligibility guidelines and services. Under these programs, we pay rebates to participating states, typically within three months after the quarter in which the product was sold. Additionally, we may offer customer incentives and other forms of consideration, such as volume-based or performance-based rebates. Estimated rebates are recorded as a reduction of revenue on delivery to our customers.</span></div></div></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">106</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_5" continuedAt="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_6"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_69da4ed6-62c6-479f-946b-586e3c8dbccd_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also enter into contracts that involve a series of manufacturing processes for products and related components. For any distinct performance obligation where the manufacturing process does not create an asset with alternative use and there is an enforceable right to payment for the performance completed to date, the related revenue is recognized over time. For these performance obligations satisfied over time, we use an input method to measure progress. Specifically, we apply the cost-to-cost method, under which progress is calculated as the ratio of costs incurred to date relative to the total estimated costs of the contract. This method most accurately depicts the transfer of value to the customer because costs incurred are determined to be proportionate to our performance in satisfying the obligation. Estimated total contract costs are reassessed periodically. Changes in estimates are accounted for prospectively as changes in estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of a licensing arrangement that includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price. We generally include these milestone payments in the transaction price when they are achieved because there is considerable uncertainty in the research and development processes that trigger receipt of these payments under our agreements. Similarly, we include approval milestone payments in the transaction price once the product is approved by the applicable regulatory agency. For delivery of other goods or services related to a licensing arrangement, we determine whether the performance obligation is satisfied over time or at a point in time. If the performance obligation is satisfied over time, we use judgment in determining the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize grant revenue from non-governmental entities in accordance with ASC 958-605, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition Not-for-Profit Entities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, when qualifying costs are incurred and the conditions of the grant agreement have been met. If grant funds are received after costs have been incurred, we record the amount as grant revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as grant revenue when qualifying costs are incurred. Grant revenue is included in &#8220;License and other revenue&#8221; in our consolidated statements of income and comprehensive income.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_970c751b-bb7a-46c2-9b11-1e140681551f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3101d5b-10a6-475e-b7e1-ce8c41dae2cb" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:InterestExpensePolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense on Deferred Royalty Obligation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#8220;Debt&#8221;, for more information.</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">107</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_6" continuedAt="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d20c0fad-7018-444b-b14d-f273713206cb" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Stock&#8209;Based Compensation Awards</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#8220;ESPP&#8221;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#8220;simplified&#8221; method as described in Staff Accounting Bulletin No. 107, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#8221; for the expected option term. We use our historical volatility to estimate expected stock price volatility.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) are measured based on the fair market values of the underlying stock on the dates of grant.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#8217;s best estimate as to whether it is probable that the shares awarded are expected to vest.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_42c69e8a-24fb-4174-95c1-db140a5529f1" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#8220;more likely than not&#8221; standard.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f08871f8-7439-4dec-9ce1-e1f45334c0da" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:RelatedPartyTransactionsPolicyTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related Parties</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sarissa Capital owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e955540-18be-4b42-9a94-baaf38163b40" contextRef="C_8d782d9a-b93f-45ae-a7ce-ee978ddef5a5" name="inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our outstanding common stock as of December 31, 2024. Transactions with Sarissa Capital are described in Note 5, &#8220;Consolidated Entity&#8221;. Sarissa Capital was considered to be a related party up until the annual stockholders meeting in May 2025 after which there were no representatives of Sarissa Capital serving on our Board of Directors.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_2b61e2ab-b031-4e39-bc11-06772ab1cf8d" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_2b61e2ab-b031-4e39-bc11-06772ab1cf8d_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The ASU requires the disclosure of income taxes paid disaggregated by jurisdiction and enhanced disclosures for the entity&#8217;s effective tax rate reconciliation as well as other income tax related disclosures. We adopted this guidance prospectively as of January 1, 2025, which resulted in additional disclosures in the notes to our consolidated financial statements. Accordingly, prior periods were not retrospectively adjusted. See Note 15, &#8220;Income Taxes.&#8221;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">108</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac_7"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_2b61e2ab-b031-4e39-bc11-06772ab1cf8d_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement &#8212; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires disclosures about specific types of expenses included in the expense captions presented on the face of the statement of income as well as disclosures about selling expenses. ASU 2024-03 is effective for the Company in annual reporting periods beginning after December 15, 2027, and interim reporting periods beginning after December 15, 2027. We are currently evaluating the potential impact that ASU 2024-03 may have on our financial statement disclosures.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which clarifies the assessment of whether a transaction should be accounted for as an induced conversion or extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. ASU 2024-04 is effective for annual reporting periods beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. We are currently evaluating the potential impact that ASU 2024-04 may have on our financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, the FASB issued ASU 2025-05, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses for Current Accounts Receivable and Contract Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which provides a practical expedient for estimating expected credit losses by assuming current conditions remain unchanged over the life of the asset. The amendments in ASU 2025-05 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the potential impact that ASU 2025-05 may have on our estimation methodologies.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the FASB issued Update ASU 2025-11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim Reporting (Topic 270): Narrow-Scope Improvements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ASU intends to clarify and improve existing interim reporting guidance by consolidating disclosure requirements within Topic 270 and introducing a disclosure principle requiring entities to disclose events and changes occurring after the most recent annual reporting period that are expected to have a material effect on the entity&#8217;s financial condition or results of operations. This ASU does not introduce significant changes to recognition or measurement guidance. The amendments in this Update are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the potential impact that ASU 2025-11 may have on our financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the FASB issued ASU 2025-12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Codification Improvements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which provides technical corrections, clarifications, and other minor improvements across a number of Topics. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently evaluating the potential impact of ASU 2025-12 on our consolidated financial statements and disclosures.</span></p></ix:continuation></div></ix:continuation></div><div><ix:nonNumeric id="F_a23b68a3-57dc-449f-873d-2e8c14f03054" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EarningsPerShareTextBlock" escape="true" continuedAt="F_a23b68a3-57dc-449f-873d-2e8c14f03054_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.  NET INCOME PER SHARE</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding. Diluted net income per share is computed by dividing net income by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the &#8220;2023 Notes&#8221;) up until its maturity date on January 15, 2023, our convertible senior notes due 2025 (the &#8220;2025 Notes&#8221;) up until its maturity date on August 15, 2025, and our convertible senior notes due 2028 (the &#8220;2028 Notes&#8221;) using the if-converted method. If the results are in a net loss position, diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common stock equivalents.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">109</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_a23b68a3-57dc-449f-873d-2e8c14f03054_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9329f78d-aa56-467b-aca7-5f5d06e9fbd9" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the computation of basic and diluted net income per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands except per share data)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income, basic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cd80f25-3c44-4b69-9857-7e46d713e808" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,165</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f2f0a63-c515-4e35-a360-460eec8fb980" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,392</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45d831c9-3540-40c5-95dd-f7024701b534" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: interest expense on 2023 Notes, net of tax effect</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a6c8488-0e23-483d-9f18-a1c3272b1175" contextRef="C_bc424098-7c86-48ee-a261-2e346af6f356" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4393a9ce-47f1-49cd-82c6-479b2e9d0f3b" contextRef="C_f4e52e0e-68f9-43ec-b6ac-caf887da2c67" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4d60a0a-7e20-41b7-9e0e-cce169714d7b" contextRef="C_983b3e15-da6b-4fb2-b179-654eb3026eeb" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">89</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: interest expense on 2025 Notes, net of tax effect</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f29100e-c2d6-4da6-98f6-d3780f5d834a" contextRef="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,882</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_301b2d6e-e5f0-48db-9aee-601596911d49" contextRef="C_a08b10dd-5488-446a-93cd-e5dd9322693a" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,468</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88ac724b-5d8c-4dd9-a5e5-26b423ab564b" contextRef="C_689c9adb-8230-4574-87c7-dc46032a5878" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,116</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: interest expense on 2028 Notes, net of tax effect</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_380dbeee-e551-42bd-a074-06fbe555be4a" contextRef="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,776</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7a7aad8-dba1-4045-9c2f-88f9edfecfa6" contextRef="C_9290e126-1791-4a2c-9976-a9357f71a1c8" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e68a952-ea41-4402-ba11-36edd193bcc3" contextRef="C_3e958a1c-5aa6-4afc-bf9d-697d696cd0d9" name="us-gaap:InterestOnConvertibleDebtNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,377</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income, diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70fac540-7c3a-470b-bf01-4fb4faff7988" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">279,823</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c186fc9e-b7dd-4576-a0c8-7734390671a3" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,860</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f8786295-43c8-4b24-a278-c46c9c629a51" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">191,304</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute basic net income<br/>&#160;&#160;&#160;per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27aa4759-23b3-4582-bb32-90a33e7ce4dd" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,395</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62ffe1bd-7be4-4999-ae4c-0cc586459056" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,726</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce4af715-c3c7-4625-a282-fc4ecfc98609" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,435</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of 2023 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d5eeb09-38da-456d-a55e-df149fddfa16" contextRef="C_bc424098-7c86-48ee-a261-2e346af6f356" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bf96634-ac5f-43f7-8386-cca2be7333af" contextRef="C_f4e52e0e-68f9-43ec-b6ac-caf887da2c67" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_472e7f6c-3df3-456c-aa09-41fab22f630e" contextRef="C_983b3e15-da6b-4fb2-b179-654eb3026eeb" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">187</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of 2025 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5e6c8a4-1640-41e1-a6be-94c9635451df" contextRef="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,900</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7efcc6e-0bda-436b-84e0-2d95a59707ac" contextRef="C_a08b10dd-5488-446a-93cd-e5dd9322693a" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70f6a865-6c80-4c49-b485-b34666f68188" contextRef="C_689c9adb-8230-4574-87c7-dc46032a5878" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,150</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of 2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c467c127-a83f-4385-b526-68c2ca43ea23" contextRef="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b822f15-4839-4081-aa5d-2693fb665e69" contextRef="C_9290e126-1791-4a2c-9976-a9357f71a1c8" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a6101ec5-8e03-4497-a197-4d04df062a7f" contextRef="C_3e958a1c-5aa6-4afc-bf9d-697d696cd0d9" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of options and awards granted under equity<br/>&#160;&#160;&#160;incentive plan and employee stock purchase plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bd1d9b5-2098-47b7-b22e-7230e75f0c25" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">491</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e68a9337-3df1-4099-acf8-88fb6e84f76d" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff7bbfee-6081-4b89-a645-75f89ff51d81" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">149</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of outstanding warrant</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59ef0c37-24ad-4e62-b6da-5dd477de5794" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">19</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_762852a4-1ef3-46f4-b300-2889a8796736" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc7c57d3-843b-4af5-aeb0-0ac98caf7840" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute diluted net income<br/>&#160;&#160;&#160;per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4a3a873c-fe06-4b56-acdb-9cfa278dbce9" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,760</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dcf9e8ee-f10e-42f6-b05b-ddab50061cdd" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,187</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d880542b-2890-4381-be1e-f2be43bae188" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,876</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income per share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5775455-802a-48b8-b3ca-2695f437709a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">4.02</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86136894-99ee-47f8-a85b-f4e20438f036" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.37</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69504b57-70a6-498b-9949-2ab6c910be69" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.75</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a19142ba-00a2-4a4e-8e32-1dea79f1c57a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.30</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8dcc25d-0cc7-4ce4-a3f7-cf2c0e2cb81f" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">0.36</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c115bf0f-8c0d-4bcb-a9b5-5e55ef79f36b" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.20</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti&#8209;dilutive Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5437323e-56fb-419b-a897-8a5e31db7ede" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#8209;dilutive for the periods presented:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.28%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding options and awards granted under equity incentive<br/>&#160;&#160;&#160;plan and employee stock purchase plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_801d34d2-6cfb-469f-bb15-5df48440e77c" contextRef="C_bb0d3213-3fd7-4233-90d1-9955a45217a9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,535</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08663329-8644-403a-9d07-14fbe7ac4348" contextRef="C_7750e87c-0533-4d37-95fe-b10ee03f2aa0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,196</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f35dbed5-5c86-46ad-8d3e-3d06023bbaba" contextRef="C_c7bb82e1-094a-43f1-9fb5-4b8ca5b929fa" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,333</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding stock warrant</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3abe9db-4d7f-460d-aef0-5731d7a684f0" contextRef="C_d3132f94-898b-45b9-b231-38bb9e3c6785" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1eb02ec-0d38-4486-801d-5b0a0b602c65" contextRef="C_e78081be-df8b-41c7-9089-842b6fe1de71" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79a2d2e5-044e-4691-8197-7149e5782532" contextRef="C_dc58284d-69c1-4202-ab83-45c4db4ecabd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">591</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding 2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb238373-4c89-434a-b2ba-4e98164e8a96" contextRef="C_cbc75e73-16d5-41ff-9fc0-e3415e4303d3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f37db21-f502-4ee3-b105-ae25bfdd3d80" contextRef="C_553bd178-313c-476a-ad6e-7c4ee1a08840" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d1b1658-b01e-423d-94ec-0df77fe80d0a" contextRef="C_33a0dd32-8b33-4cc0-a555-d73ff67cc33b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0f51610-a531-41cf-a37e-d59f59629836" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,535</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ba3d5ab-e72c-4c00-9a2a-d4a16c6a1c0c" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,742</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f17ced66-397c-4f35-bc21-eafec19392c1" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,924</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">110</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f199754e-2c81-44f2-a0b1-99ee701b05b5" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.  REVENUE RECOGNITION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Revenue from Collaboration Arrangement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are entitled to receive royalties from GSK with respect to RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce4ec64f-96c1-44dc-948a-f9d09239dd8c" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net revenue recognized under our GSK Agreements was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties &#8211; RELVAR/BREO</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1193fe3b-6f2c-44aa-a4f6-7abccb2384fc" contextRef="C_845eaa74-fc53-4af0-b138-f622d45b3c0f" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">204,021</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ded4573-db8f-4da8-a32f-a7c5a674b891" contextRef="C_da7cd9c6-74d8-41bd-9505-fc9787b73b1b" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">207,925</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9460e98c-78c4-49e0-ba37-e5aaac21114e" contextRef="C_f3dedb00-89d6-46cf-b991-17d8708476a1" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,042</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties &#8211; ANORO</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0718c395-e34b-4937-9340-50b90b25e7ad" contextRef="C_61fa56d2-4262-4f72-ae36-ba8d54b9623c" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,281</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b1296f2-a1f9-491e-a88e-adb8bc3b7056" contextRef="C_5883bac0-e505-42e6-8df8-70275b1d4f0a" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,631</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65c5b9b2-22a7-4ac2-88d3-4a7360f5018f" contextRef="C_0bd76c2e-9aae-4309-9bc2-e14f04493aff" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,627</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total royalties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_475134f4-7cd0-4881-a0ee-fa233e8ddfb1" contextRef="C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">250,302</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05cbe96c-44ee-46b5-a1ab-47e0ebe55863" contextRef="C_24d3732a-a2a9-4442-b464-10be5d29362f" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">255,556</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb04b8cc-ba7a-4581-b569-1f351cdf1ef4" contextRef="C_8290bc3e-4b79-45b4-8dd5-a2d83da40c0c" name="inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">252,669</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: amortization of capitalized<br/>&#160;&#160;&#160;fees paid</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abf7d19e-69c9-4a69-9d41-1c7651507518" contextRef="C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,823</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e7dd012-a2d2-4c5d-8215-45fda931ab09" contextRef="C_24d3732a-a2a9-4442-b464-10be5d29362f" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,823</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b339ec4-dc76-4922-8c46-053e3b1ea67d" contextRef="C_8290bc3e-4b79-45b4-8dd5-a2d83da40c0c" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,823</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total royalty revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cddd8fe5-0f42-4d67-ac72-a8853466b186" contextRef="C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">236,479</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a3f07a3-3b0d-40f8-baa3-af5c32c73be8" contextRef="C_24d3732a-a2a9-4442-b464-10be5d29362f" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">241,733</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a85650f4-3f8e-45c0-b16b-14c2f140b45e" contextRef="C_8290bc3e-4b79-45b4-8dd5-a2d83da40c0c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">238,846</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LABA Collaboration</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_656b75de-7cf5-4725-b9b1-2a95c80923f6" contextRef="C_80f755ab-2884-4b9f-8f1a-e93170c6f575" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">220.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization is recorded as a reduction to the royalties from GSK.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are entitled to receive annual royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as follows: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a174de5d-ce6f-4f13-84ce-93f7d7547dc4" contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddf6012b-bb3b-431c-b858-30edbd46388c" contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d730aedc-8622-466b-ab89-3b5534561be5" contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0" name="inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64034362-b47e-4f9a-a46c-041340ab5da2" contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0" name="inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" unitRef="U_USD" scale="9" decimals="-8" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. Sales of single&#8209;agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, royalties are upward tiering and range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1f37369-a891-42c9-84d8-0063676c3edf" contextRef="C_0cd22ebb-1d13-4b31-83ad-8d641740a1a8" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a800a9b9-f1b4-4db5-aaae-c82d6a2c985a" contextRef="C_0ea6bee8-0b7a-4347-b4e1-f57199a4e9f9" name="inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Product Sales</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5eaa990e-a9b6-4737-9e56-1e314cd57f49" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total net product sales were as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7604d8e5-d77a-4070-8d85-3fdb3cb367a1" contextRef="C_4b612ee6-394a-4ddd-9bcc-6ab2bb1b034d" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,611</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81679e98-bde3-4674-99fc-d360c8f55721" contextRef="C_b17848ff-54df-4b86-b3cd-386a1ff12968" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,037</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cacdba34-3fd1-4fc8-abb1-8eab5e1d73b6" contextRef="C_2db96a8e-31d6-4b8d-831e-e5ed59bdbb06" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,294</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c22794c5-4d3e-4db4-a49d-c8fcc8631ba1" contextRef="C_51398c9e-10f3-4ea8-bf6f-402b631244a3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">74,393</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3185745f-660b-431f-891e-1c119a208d2d" contextRef="C_bb1be382-95cb-4b4d-9141-588145edc4e6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,070</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a566b01-4e2b-4641-825f-d15ca7ed8425" contextRef="C_44c21172-b919-4027-9bf1-950d87ebeb9c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,003</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02e73072-f6d3-4520-8355-6948829041be" contextRef="C_8d1ae2b7-8b25-4684-9b73-d88cea1e9a93" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,516</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89da9dfe-837c-4368-875d-42975a2ad6f0" contextRef="C_d029c0a8-0421-4544-b742-f93ceeea6d0a" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,385</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de3ac594-e6d6-4b33-af65-057126e39b0a" contextRef="C_772c1d45-e01c-4ce3-82b8-60c2d33c65c7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,320</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb96c033-292f-4127-bdfa-e155de5a28f4" contextRef="C_3417b179-deaf-41ea-bd39-7e434b1db032" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">610</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60e959b7-9101-4ab7-84a3-24c5dd52c111" contextRef="C_9d19a8d1-6525-465e-9818-4f4be4f7b334" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d84e499-4493-4f36-8cd3-c84f36f0b1bf" contextRef="C_a0a9ffa5-48e7-43db-b94b-727a9650a8a7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Total net product sales</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5d69fdc-efb5-468a-aa90-026a6484a302" contextRef="C_e1b0f380-3db6-410d-886f-3625779ce5c2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,130</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8025fbe6-3ae7-493b-9388-b901dd902b70" contextRef="C_0f3c27be-b222-4d28-80f0-06ce24daba5e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">97,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_109835d3-e027-49dd-9a92-e4b395b46d38" contextRef="C_d5a54e09-f59e-44b6-9cef-6b6ac8a95a30" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,617</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We derived our net product sales:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b4e3c13-dba1-4d0b-b8d3-015ee5b10cb8" contextRef="C_8a27a178-7498-4039-b7ec-3acbc3e22557" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">69</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from customers located in the U.S. and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38532a3a-1171-4929-866c-74bd4744bcf1" contextRef="C_0a146130-5ab1-47b0-bf0f-7f7c0ba94af3" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">31</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from the rest of the world for the year ended December 31, 2025; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b7063d14-8f73-4676-8be3-4b34232ff11c" contextRef="C_9a9972fa-1809-4264-b6eb-ab4488000164" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">83</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from customers located in the U.S. and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57d3c4d9-96c0-485e-8ae0-b0f584440d8a" contextRef="C_27624d2b-fd4c-438a-9721-62e1806ce67a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">17</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from the rest of the world for the year ended December 31, 2024; and, </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55c4330e-4eac-4f6e-8ecd-3c1fc443e4a6" contextRef="C_64469642-d4d1-4b61-893c-cc3938dfe822" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">91</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from customers located in the U.S. and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6adec083-1532-4621-87be-a36f31d83bb5" contextRef="C_49a08cdc-4904-4992-b261-91482376f0e3" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from the rest of the world for the year ended December 31, 2023.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License and Other Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to the out-license agreement with Zai Lab and Everest and the Grant Agreement with Gates Foundation in Note 4, &#8220;License, Collaboration and Other Arrangements&#8221;.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">111</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_b3a40032-18e2-4488-95e9-0a8fab95bebf" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:LicenseCollaborationAndOtherArrangementsTextBlock" escape="true" continuedAt="F_b3a40032-18e2-4488-95e9-0a8fab95bebf_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. LICENSE, COLLABORATION AND OTHER ARRANGEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Out-License Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Zai Lab</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entasis Therapeutics Holdings Inc. (&#8220;Entasis&#8221;), our wholly-owned subsidiary, entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. (&#8220;Zai Lab&#8221;) (Nasdaq: ZLAB), pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR, in the Asia-Pacific region (&#8220;the Zai Agreement&#8221;). Under the terms of the Zai Agreement, Zai Lab shall fund most of the registrational clinical trial costs in China for SUL-DUR, with the exception of Phase 3 patient drug supply of licensed products. Zai Lab shall conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and shall commercialize licensed products for which it has obtained regulatory approval. We are obligated to supply Zai Lab with the licensed products for clinical development and for commercial use for a certain period unless Zai Lab notifies otherwise. Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are eligible to receive up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42bafa43-0b98-4d60-b65c-590e25d0f0f3" contextRef="C_e24022f1-53bf-42f3-8620-65afbf8aacaf" name="inva:FuturePotentialMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">91.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab shall pay us a tiered royalty ranging from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. Payments received for research support and reimbursable clinical trial costs are recorded as a reduction to research and development expense during the period in which the qualifying expenses are incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Such amounts recorded for the years ended December 31, 2025, 2024 and 2023 were not material. SUL-DUR was approved by China&#8217;s National Medical Products Administration in May 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and was launched by Zai Lab in mainland China in January 2025. Royalties under this arrangement based on the product sales was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_719289e5-635b-41b7-8553-f47c5cb07d89" contextRef="C_535f3e0c-ae46-4c2a-8349-1e7df0cae7a9" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2025. W</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3aa86a6-2a46-48ea-b0b5-2714ac57a2f0" contextRef="C_c9724995-83e8-4e3f-ac0a-df8eb2d7e801" name="inva:LicenseRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in license revenue for the year ended December 31, 2024 under this agreement as a result of the achievement of a regulatory milestone. Following the approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by the FDA in May 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3f8507c-caf4-41ac-826b-17268ab4da97" contextRef="C_32dd02d8-2a15-4776-ae72-8afc37de465c" name="inva:LicenseRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in license revenue for the year ended December 31, 2023 under this agreement.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, we entered into an amendment to the Zai Agreement (the &#8220;Amended Zai Agreement&#8221;), pursuant to which Zai Lab shall share costs associated with certain new manufacturing and technology transfer activities for XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the &#8220;Services&#8221;), which were not contemplated under the Zai Agreement and are crucial for regulatory approval in the Asia-Pacific region.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Under the Amended Zai Agreement, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8de4535c-4a32-4693-ade7-9fdbcf685b7a" contextRef="C_93087703-617b-4b4a-81e7-31843c5aa650" name="inva:LicenseRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46195adc-378f-4b4e-8917-d00a792d58d4" contextRef="C_9eb30f32-b122-4799-abad-e4b9a0d5cea5" name="inva:LicenseRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in license and other revenue for the years ended December 31, 2025 and 2024, respectively, of which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17539648-03d4-4ac7-ac36-a62129b5b10d" contextRef="C_b6b5484e-26f7-475f-aad3-d4fff0a4c327" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc235be4-6fcf-4f42-8725-d2912390a780" contextRef="C_edcdd009-7706-4509-a58c-1bface603eba" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were included in &#8220;Accounts receivable&#8221; in our consolidated balance sheets as of December 31, 2025 and 2024, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into an interim supply agreement with Zai Lab in June 2024, which was amended in February 2025 and August 2025, under which Zai Lab shall purchase XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inventory (the &#8220;Supplied Inventory&#8221;) at cost for their commercial use. We recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_722a9cb2-132a-4dcf-8eea-1cb7c849549c" contextRef="C_1a3c43a6-afc9-4c65-b428-40d7849855d1" name="inva:AmountOnNetProductSalesRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">37.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84860cba-b59d-47a7-9536-ecaf61b6589e" contextRef="C_24ba47ce-629c-49d4-9f18-e4bf2ecc9008" name="inva:AmountOnNetProductSalesRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net product sales for the cost of the Supplied Inventory for the years ended December 31, 2025 and 2024, respectively, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecf97167-4dea-4bcb-939b-0a3bb83a2a7f" contextRef="C_8714bccf-5bf2-42d4-bc52-49b4f39a126d" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bc782be-9561-4785-8545-2e9aee2490c4" contextRef="C_29938f9f-8929-463c-8242-1fd072e3246e" name="us-gaap:AccountsReceivableNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were included in &#8220;Accounts receivable&#8221; in our consolidated balance sheets as of December 31, 2025 and 2024, respectively. Advance payments received under this agreement of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9e8c47c-7ce4-4ba7-a596-657988de25c9" contextRef="C_2bdbcb89-e8cf-4578-a8fb-ed71c2c5c84c" name="us-gaap:AdvancesOnInventoryPurchases" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 was recorded as other accrued liabilities pending finalization of the February and August 2025 amendments mentioned above.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also entered into a manufacturing stage transfer agreement with Zai Lab in June 2024, which was amended in September 2024 (the &#8220;Zai Manufacturing Stage Transfer Agreement&#8221;). Pursuant to this agreement, Entasis shall provide assistance to Zai Lab for building out Zai Lab&#8217;s manufacturing site for XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and be compensated for Entasis' services and associated costs. We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73a0e1e4-e354-4699-85f1-bcaef1fba090" contextRef="C_60c399b5-9347-43a0-b627-5c8557009839" name="inva:LicenseAndOtherRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e6e563b-9a44-4a45-a96d-829de83fe955" contextRef="C_8b6e7ffc-19c9-414a-8790-449480c681de" name="inva:LicenseAndOtherRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in license and other revenue for the years ended December 31, 2025 and 2024, respectively, under the Zai Manufacturing Stage Transfer Agreement.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">112</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_b3a40032-18e2-4488-95e9-0a8fab95bebf_1" continuedAt="F_b3a40032-18e2-4488-95e9-0a8fab95bebf_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GARDP</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entasis entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership (&#8220;GARDP&#8221;) for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries (&#8220;the GARDP Collaboration Agreement&#8221;). Under the terms of the GARDP Collaboration Agreement, GARDP shall use commercially reasonable endeavors to perform and fully fund the Phase 3 registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d98aa280-9173-455d-98c7-f0a84d531684" contextRef="C_d4b33ce8-c2ef-41f9-aa40-07f4e9d94111" name="inva:ReimbursementsForResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in reimbursements from GARDP under this agreement as a reduction to research and development expense during the year ended December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We recorded immaterial reimbursements from GARDP as a reduction to research and development expense during the years ended December 31, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the GARDP Collaboration Agreement, GARDP was granted a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use our zoliflodacin technology in connection with GARDP&#8217;s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. We retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. We also retained the right to use and grant licenses to our zoliflodacin technology to perform our obligations under the GARDP Collaboration Agreement and for any purpose other than gonorrhea or community-acquired indications. If we believe that the results of the Phase 3 registrational trial of zoliflodacin would be supportive of an application for marketing approval, we are obligated to use our best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the European Medicines Agency (&#8220;EMA&#8221;). Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories. An application for marketing approval has been filed with the FDA in 2025. The FDA approved zoliflodacin, marketed as NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, on December 12, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PAION Pharma GmbH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the PAION AG and PAION Deutschland GmbH (together and individually &#8220;PAION&#8221;) License, La Jolla Pharmaceutical Company (&#8220;La Jolla&#8221;), our wholly-owned subsidiary, granted PAION an exclusive license to commercialize GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the European Economic Area, the United Kingdom and Switzerland (collectively, the &#8220;PAION Territory&#8221;). PAION is currently a subsidiary of the Humanwell Healthcare Group. We are entitled to receive potential commercial milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f0b3702-157d-4413-aa16-046f255918b6" contextRef="C_0b8a3f4c-cf7e-42af-8db7-51c367053d7d" name="inva:FuturePotentialMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">109.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and double-digit tiered royalty payments. Royalties payable in a given jurisdiction under the PAION License are subject to reduction on account of generic competition and after patent expiration in that jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the PAION Territory. We have not recognized any revenue from PAION related to commercial milestones. Royalty revenue recognized under this agreement for the year ended December 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_470845ed-1b71-4c7d-901d-7721a30ece43" contextRef="C_bb34b526-ff51-4bd5-9372-e24b00a45ea7" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08fa7c74-d972-4421-a4df-95dbd7218f7a" contextRef="C_8f658d7a-8b07-41db-8980-8e9b1025a6a3" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Royalty revenue recognized under this agreement for the year ended December 31, 2023 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a27f083-6d85-4dad-bc22-339f0bb6e565" contextRef="C_63c51235-4b1c-4afb-8d74-575ce49ff152" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">La Jolla also entered into the PAION commercial supply agreement (the &#8220;PAION Supply Agreement&#8221;) whereby La Jolla supplies PAION a minimum quantity of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until the earlier of July 13, 2027, or until a new supply agreement is executed. During the term of the supply agreement, we are reimbursed for direct and certain indirect manufacturing costs at cost. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4723af77-6680-4d98-97b1-e841ffc15e61" contextRef="C_86b41774-5017-4fc1-8e1b-cf811b6c4737" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48738bfb-fb94-4077-9f8f-c26d0fec8210" contextRef="C_734a0615-eb7b-4e06-bf8d-3b288821b245" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cost reimbursements under this agreement for the years ended December 31, 2025 and 2023, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost reimbursements recognized under this agreement for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the years ended December 31, 2024 were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8e003c4-7984-449c-a05a-694dd7d5afc9" contextRef="C_d8ba1e61-eae2-49b5-9a4d-794567463681" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Everest Medicines Limited</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Everest Medicines Limited (&#8220;Everest&#8221;) License, La Jolla granted Everest an exclusive license to develop and commercialize XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the treatment of complicated intra-abdominal infections (&#8220;cIAI&#8221;) and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the &#8220;Everest Territory&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Everest License, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2913099-388b-40c8-96df-839e923a9074" contextRef="C_3f151714-cd61-4ea6-ad22-1659ee2f8ad5" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in license revenue for the year ended December 31, 2023 as a result of an achievement of a regulatory milestone during the period. We are eligible to receive additional sales milestone payments of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_993bb486-58e7-49f8-90c0-786a9755705b" contextRef="C_471e4740-1ef6-4b64-a705-0ba2683dbdf6" name="inva:SalesMilestonePaymentsReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">113</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_b3a40032-18e2-4488-95e9-0a8fab95bebf_2" continuedAt="F_b3a40032-18e2-4488-95e9-0a8fab95bebf_3"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_06b54e57-dfec-49ed-958f-4e7efedf60b6" contextRef="C_b7886827-2301-4eae-ac39-e1b0cfe79560" name="inva:RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years after the first commercial sale of a product in such jurisdiction in the Everest Territory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Royalty revenue recognized under this agreement for the years ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02520822-f418-49ef-9597-6ee4491682f6" contextRef="C_ef7ae83f-f2f0-4dcb-9863-3d6a3a3a1d5a" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2517e088-8d37-4008-b196-68047148fc0e" contextRef="C_2b4116ec-1fff-40fc-9ca2-09b0c69e59bc" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cc37537-9387-48e1-8ccf-772f6fbd6e7c" contextRef="C_f729f8a6-0459-456b-904e-a2336cd2e856" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">La Jolla also entered into the Everest commercial supply agreement (the &#8220;Everest Supply Agreement&#8221;) whereby La Jolla will supply Everest a minimum quantity of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and will transfer to Everest certain XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-related manufacturing know-how. Under the Everest Supply Agreement, we are reimbursed for direct and certain indirect manufacturing costs at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8452d778-3937-402e-9332-f9e632e49e43" contextRef="C_a7a1c802-2b70-41a1-b1ab-0f6ea7991b5c" name="inva:PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">110</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of cost. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> W</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d15ab99a-630b-458a-b9fe-02770666cddd" contextRef="C_a7a1c802-2b70-41a1-b1ab-0f6ea7991b5c" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b246f09d-06d5-4c2d-b307-8f4eb03f1d19" contextRef="C_27e7d8d1-9232-4c08-b557-38898257e2e9" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21e73007-c5d6-495e-b857-5d4fac98bd82" contextRef="C_a2de673d-5a6d-4d89-a1af-5b182aea45da" name="us-gaap:Revenues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue under this agreement for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In-License Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basilea</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into an exclusive distribution and license agreement with Basilea, under which we were granted exclusive marketing rights to ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. The agreement will remain in effect through the expiration of ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s market exclusivity in the U.S. in 2034 (the &#8220;initial term&#8221;) and is subject to automatic renewal unless terminated by either party with prior notice. We paid an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0fdef9f-f30d-4b3a-9172-f372608bc5c8" contextRef="C_baeb567b-ccbe-4999-a205-466cd47101ba" name="inva:UpfrontPaymentUnderIntangibleAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was recognized as an intangible asset and is being amortized over the initial term of the agreement. Under the agreement, we are required to exclusively purchase ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (in pre-packaging and labeling form) from Basilea for the duration of the term. We are also obligated to pay Basilea tiered royalties ranging from the high-teens to mid-twenties, as well as tiered milestone payments based on annual net sales in the U.S. ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was commercially launched in the U.S. in July 2025. Royalty expense incurred on the sales was immaterial during the year ended December 31, 2025. There were no royalties or sales milestone payments for the year ended December 31, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">George Washington University</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the George Washington University License (the &#8220;GW License&#8221;), GW exclusively licensed to La Jolla certain intellectual property rights relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the GW License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are obligated to pay a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6876ecb8-b6ed-425f-9de0-c8f53f7ef518" contextRef="C_75cd5b3a-0884-4009-a949-d0f1c664d036" name="inva:PercentageOfRoyaltyPayableOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23ed9732-35b7-437a-adfa-731de13e9c0d" contextRef="C_75cd5b3a-0884-4009-a949-d0f1c664d036" name="inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under the GW License extends through the last-to-expire patent covering GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Royalty expense incurred under the GW License were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ffaef94-b249-4b30-be8e-8eaf29d163c0" contextRef="C_75cd5b3a-0884-4009-a949-d0f1c664d036" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33ed1543-1803-4c3a-8050-fa26610101ab" contextRef="C_66b32c2c-80ce-44d4-8bd3-c90a4562ba4a" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_478db8a7-8b20-4b2d-8607-e65003b3c610" contextRef="C_ad7b15a7-04fe-4b2d-aaa8-50707a9474c4" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Harvard University</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Harvard University (&#8220;Harvard&#8221;) License, Harvard exclusively licensed to La Jolla certain intellectual property rights relating to tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For each product covered by the Harvard License, we are obligated to make certain payments for the following: (i) up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3319f0a-9c65-4b9e-a55d-d26c2ac8e4db" contextRef="C_77ce6bd4-4c92-464e-b740-78890313ec04" name="inva:ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain clinical development and regulatory milestones; (ii) a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a1bcb62-6645-4468-b4f1-fbe8913e5f21" contextRef="C_47f20a31-1968-4d82-910b-3b3a4558e7f9" name="inva:PercentageOfRoyaltyPayableOnNetSales" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on direct U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, starting at a minimum royalty rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e776230e-fb22-44b1-8796-5ea823af7b49" contextRef="C_cbc79b2e-83c4-4eb8-a3b9-5535187253c1" name="inva:PercentageOfMinimumRoyaltyRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, with step-ups to a maximum royalty of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f45c37c3-4f34-4775-9845-aac12bf85f10" contextRef="C_cbc79b2e-83c4-4eb8-a3b9-5535187253c1" name="inva:PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% based on the achievement of annual net product sales thresholds; and (iv) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37778605-d719-4a24-857a-11a75b455fc2" contextRef="C_9d82a4f6-9c62-4ef3-a79a-b60ecce3c1dc" name="inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Royalty expense incurred under the Harvard License for each of the years ended December 31, 20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2d9f7df-a3aa-4da9-8134-3a7aff236c5b" contextRef="C_9d82a4f6-9c62-4ef3-a79a-b60ecce3c1dc" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_dffabb26-f616-470a-b92d-fb74ca0f0f33" contextRef="C_bb80b0bd-8c31-447f-bb15-56034f4a4f2d" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.4</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ion. For the year ended December 31, 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bc532c6-ca52-44da-8603-6fb0a0ef025d" contextRef="C_042d99c8-ff64-4441-b079-f3c23a00eb99" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as cost of license revenue under this agreement as a result of the license revenue we earned under the out-licensing agreement with Everest for the same period.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">114</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b3a40032-18e2-4488-95e9-0a8fab95bebf_3"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Transfer and Subscription Agreement with AstraZeneca</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entasis </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entered into a Business Transfer and Subscription Agreement with AstraZeneca, AstraZeneca UK Limited and AstraZeneca Pharmaceuticals LP (collectively, &#8220;AstraZeneca&#8221;) (the &#8220;AstraZeneca Agreement&#8221;) in 2015, which was amended and restated through 2018, pursuant to which Entasis obtained, among other things, worldwide rights to durlobactam and zoliflodacin. Under the AstraZeneca Agreement, we are obligated to pay AstraZeneca a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62a7ba1c-aaf0-4d95-bc45-2e86a4089bff" contextRef="C_a73231bb-c2af-46c2-9a92-d48cf8356bc1" name="inva:SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f1c68da8-c103-4547-8438-32a1a449b68f" contextRef="C_a73231bb-c2af-46c2-9a92-d48cf8356bc1" name="inva:TermOfMilestonePaymentForNetSales" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of achieving a specified cumulative net sales milestone for durlobactam. We are also obligated to pay AstraZeneca a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c18d6d4-d52f-41ce-a332-3766803a25da" contextRef="C_cb9d2f79-476b-4ddd-9d0f-a6df0b98ff4c" name="inva:SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a71464fd-d1e7-4e46-b669-efad14d3f1ec" contextRef="C_cb9d2f79-476b-4ddd-9d0f-a6df0b98ff4c" name="inva:TermOfMilestonePaymentForCommercialSale" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of achieving the first commercial sale of zoliflodacin. Additionally, we are obligated to pay AstraZeneca tiered, single-digit royalties on the annual worldwide net product sales of durlobactam and, the lesser of tiered, single-digit royalties on the worldwide annual net sales of zoliflodacin and a specified share of the royalties we receive from sublicensees of zoliflodacin. Royalties on sales of zoliflodacin do not include sales by GARDP in low-income and specified middle-income countries as discussed above. Our obligation to make these royalty payments expires on a country-by-country basis for each product upon the later of (i) the 10-year anniversary of the first commercial sale of a product in that country or (ii) the expiration date of the last patent right covering the product in that country.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The royalty expense in respect of durlobactam arising from our net product sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:2.68pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0ffafef-2b98-4744-a86d-5b2ffac45c7e" contextRef="C_a73231bb-c2af-46c2-9a92-d48cf8356bc1" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a2a2db98-8799-4f88-a15b-ffdcd1968709" contextRef="C_b1c1c252-d197-4e74-b2b2-f01842ca2233" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d8481489-6bf1-4114-8987-24797c8f0bbf" contextRef="C_a53dc6ea-0c8a-49d1-a28b-56b625f3832d" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2025, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Massachusetts Institute of Technology</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the asset acquisition described in Note 14, &#8220;Asset Acquisition&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in September 2025, we entered into a license agreement with Massachusetts Institute of Technology (&#8220;MIT&#8221;), under which MIT licensed to us certain patent rights relating to a drug delivery device. Under this agreement, we paid an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1affb77e-05c6-4a9b-ae47-ce99efaa4561" contextRef="C_0708cf2c-c327-4fd6-b98e-80fa56ca9fbe" name="inva:UpfrontFeePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and are obligated to pay a minimal annual maintenance fee. We are also obligated to pay MIT up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ad06b08-e44c-4f55-b71b-6e125b08c376" contextRef="C_41adb887-7a52-48c3-afd3-50e8cb0adad6" name="inva:FuturePotentialMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in development, regulatory and sales milestone payments, and pay royalties in a low single-digit percentage on future net sales related to the licensed product.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Paratek Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Paratek Pharmaceuticals, Inc. (&#8220;Paratek&#8221;) License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including non-exclusive rights to certain issued patents and patent applications covering XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We were obligated to pay Paratek a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2041b8b0-524c-4754-a9d5-e59b3342ffbe" contextRef="C_26dbc208-56e7-4883-9c81-a880c188cbbc" name="inva:PercentageOfRoyaltyPayableOnNetSales" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty based on direct U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our obligation to pay royalties with respect to the licensed product was retroactive to the date of the first commercial sale of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and continued until there were no longer any valid claims of the Paratek patents, which expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c2f8c494-a44c-4eeb-89eb-b9935d6cb9da" contextRef="C_26dbc208-56e7-4883-9c81-a880c188cbbc" name="inva:ClaimExpirationDate" format="ixt:date-monthname-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2023</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For the year ended December 31, 2023, amounts recognized under this agreement were not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Agreement with Gates Foundation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, we entered into a grant agreement with Gates Foundation, under which Gates Foundation shall fund up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a716df7-cae8-42f3-85cf-9a9c0772d2a1" contextRef="C_4de9fb1e-acdc-4b5c-a627-40990c7b5d38" name="inva:GrantFundingMaximumAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in qualifying expenses through January 2027 toward the development of a certain product candidate. We received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffec31b2-a56f-456c-aec2-1b2408e6f649" contextRef="C_5860c68c-4659-40da-819c-f9dc3f832bf9" name="inva:UpfrontFeeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, of which we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_37ec151a-dda6-4bd9-8278-0aa0aa8d77cd" contextRef="C_5860c68c-4659-40da-819c-f9dc3f832bf9" name="inva:LicenseRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as grant revenue included in &#8220;License and other revenue&#8221; in our consolidated financial statements for the year ended December 31, 2025. The remaining balance of the upfront payment is recorded as deferred revenue included in &#8220;Other accrued liabilities&#8221; in our consolidated balance sheet as of December 31, 2025.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_7af14af4-40df-4f07-abda-326e2cdadc53" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:ConsolidatedEntityTextBlock" escape="true" continuedAt="F_7af14af4-40df-4f07-abda-326e2cdadc53_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. CONSOLIDATED ENTITY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ISP Fund LP</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2020 and 2021, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#8220;Strategic Partners&#8221;), contributed a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a184cab4-796f-4de8-8e99-f959aaa9c7b3" contextRef="C_f1250457-5420-4587-a034-747d2328f6e0" name="us-gaap:LimitedPartnersContributedCapital" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">300.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to ISP Fund LP (the &#8220;Partnership&#8221;) for investing in &#8220;long&#8221; positions in the healthcare, pharmaceutical and biotechnology sectors, and became a limited partner. The general partner of the Partnership (&#8220;General Partner&#8221;) is an affiliate of Sarissa Capital.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Partnership Agreement provides for Sarissa Capital to receive management fees from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners&#8217; capital account in the Partnership. In addition, General Partner is entitled to an annual performance fee based on the Net Profits of the Partnership during the annual measurement period.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">115</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7af14af4-40df-4f07-abda-326e2cdadc53_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consolidate ISP Fund LP under the VIE model as we have determined that ISP Fund LP is a VIE and we are the primary beneficiary of the entity. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ISP Fund LP is determined to be an investment company under ASC 946, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Services &#8211; Investment Companies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as it meets all fundamental characteristics of an investment company, and its activities are consistent with those of an investment company. Since ISP Fund LP is subject to investment company industry specific guidance, we have retained the industry-specific guidance applied by the Partnership. In addition, as our investment in the Partnership is a passive investment for the Company and is not part of our main operations, the investments are presented as part of &#8220;Equity and long-term investments&#8221; in our consolidated balance sheets. In October 2024, Strategic Partners made an election to unwind its capital accounts in the Partnership in accordance with the terms of the Partnership Agreement. Accordingly, a portion of our investments, which consist of cash and money market funds that we expect to be distributed within 12 months from the balance sheet date, were classified as &#8220;Current portion of ISP Fund investments&#8221; in the consolidated balance sheets as of December 31, 2025 and 2024, and the remaining equity investments managed by ISP Fund LP are expected to be distributed through April 2026. We received cash distributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13f275f5-ca5a-4458-8d0b-235773f55391" contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2" name="inva:CashDistributions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">121.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2025. We report in our consolidated statements of income and comprehensive income any investment gains and losses by the Partnership as part of &#8220;Changes in fair value of equity and long-term investments, net&#8221;, any interest and dividend income as part of &#8220;Interest and dividend income&#8221; and any investment expenses as part of &#8220;Other expense, net&#8221;.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we continue to hold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63461a4a-92d4-40d3-a274-8b8e31c3d44a" contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2" name="inva:PercentageOfEconomicInterestInPartnership" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the economic interest of the Partnership. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, total assets of the Partnership were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b912d41-c251-4e92-a8de-633d7b64c854" contextRef="C_f1250457-5420-4587-a034-747d2328f6e0" name="us-gaap:Assets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">79.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa17e47f-0a54-414c-af1b-65a64ccfdf1e" contextRef="C_7fba1762-844e-4c04-b43c-b15c482e2679" name="us-gaap:Assets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">255.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with the majority attributable to either current portion of ISP Fund investment or to equity and long-term investments. As of December 31, 2025 and 2024, total liabilities of the Partnership were $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_95388280-97b1-46c6-ac88-562cee0f1ab0" contextRef="C_7fba1762-844e-4c04-b43c-b15c482e2679" name="us-gaap:Liabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_c0b6cffe-aa49-4b15-8c2f-db81c445146e" contextRef="C_f1250457-5420-4587-a034-747d2328f6e0" name="us-gaap:Liabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Partnership</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s assets can only be used to settle its own obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Partnership incurred</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42a36743-96df-444a-bc18-2bb100bfdc5b" contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2" name="inva:NetInvestmentRelatedIncomeExpensesEarnedInccured" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million in net investment-related expenses, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2da3659-611d-423e-aee0-8080956bedf4" contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million interest incom</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e, recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f08eea45-0a30-4b18-9073-3cfcbba945f0" contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">68.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net realized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_181dd8a0-a4a3-4716-b72b-e3bf8f4327d8" contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net unrealized gains as changes in fair values of equity and lon</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">g-term investments, net, in the consolidated statements of income and comprehensive income. During the year ended December 31, 2024, the Partnership incurred</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22e96f5a-529d-4cb0-8aec-bb27cd7ff9d4" contextRef="C_91cb662c-7d72-4446-a053-6b76cc6d61c0" name="inva:NetInvestmentRelatedIncomeExpensesEarnedInccured" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">3.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million in net investment-related expenses, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2957cbdf-74f7-4053-ac97-f0e0deec4b5f" contextRef="C_91cb662c-7d72-4446-a053-6b76cc6d61c0" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million interest income, recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3c1bd0d-b145-4e88-bd3c-405d3998cc3c" contextRef="C_91cb662c-7d72-4446-a053-6b76cc6d61c0" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net realized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0391e1a2-e464-4c30-b74a-c0ed9b3dcc71" contextRef="C_91cb662c-7d72-4446-a053-6b76cc6d61c0" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">51.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statements of income </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and comprehensive income. During the year ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Partnership incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6be2c94e-f842-40e6-b7be-b278ef21f725" contextRef="C_45a109c5-a8b5-4d0e-89f8-924a6b01af29" name="inva:NetInvestmentRelatedIncomeExpensesEarnedInccured" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net investment-related expenses, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbc4b343-6c03-4533-ace0-6bc88d70121b" contextRef="C_45a109c5-a8b5-4d0e-89f8-924a6b01af29" name="us-gaap:InvestmentIncomeInterest" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million interest income, recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fddfaaa-84ca-4841-9952-c031dcf2eb1f" contextRef="C_45a109c5-a8b5-4d0e-89f8-924a6b01af29" name="us-gaap:GainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net realized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_934b3018-01af-4c91-add0-2d6a7cef968c" contextRef="C_45a109c5-a8b5-4d0e-89f8-924a6b01af29" name="us-gaap:UnrealizedGainLossOnInvestments" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">6.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statements of income </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc5d5c59-5860-4cfc-95e7-883fcb5660ad" contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2" name="us-gaap:InvestmentTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of individual investments held by ISP Fund at each balance sheet date:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:61.232%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.603%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.603%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">In thousands</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock - Publicly traded healthcare companies</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0fbc7cb-4b6a-4ae1-a1af-e278338cfb2d" contextRef="C_5569e7b8-6eba-4eab-95a9-c63e219f2e99" name="inva:InvestmentsInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">52,392</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c648c508-b638-4d51-a8f0-0721fad17f1f" contextRef="C_7a37ea45-0a90-4314-9d33-c1291075e4f4" name="inva:InvestmentsInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,039</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3687e57-4f7b-4970-a7c1-1be4b44634c2" contextRef="C_b9d838c8-9363-4704-8fc8-ac7fe6933ce0" name="inva:InvestmentsInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,874</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be7531a0-8851-4f98-980e-47ee3c55c09c" contextRef="C_f6149710-30b2-49fb-9741-3ac89487f3da" name="inva:InvestmentsInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,989</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d82f2c4-be52-41b3-8b1a-59f0a44854f1" contextRef="C_8ff7ff5d-59d7-482d-b9ff-48452108446f" name="inva:InvestmentsInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,266</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87edf8f5-e4ff-4fb7-a97e-d8736e2b1cc8" contextRef="C_77e3e771-6d57-4a46-9631-a87f355431a8" name="inva:InvestmentsInCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,028</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock - Privately held healthcare companies</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5500bf4e-13a7-48ef-88c0-6d454f304c3b" contextRef="C_09b660d0-0222-42bb-8926-d6f07d1fabb9" name="inva:InvestmentsInPreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,748</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03ad9e84-1eab-41ea-8329-0eca4732f2ee" contextRef="C_ccbbfa18-4020-412e-b2de-ffea359a8cdd" name="inva:InvestmentsInPreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,591</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants - Privately held healthcare companies</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_96fa1451-9301-45a5-90d8-1ac260e5250f" contextRef="C_57143738-0b15-4679-be4b-a0bb824f5ceb" name="inva:InvestmentsInWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a05c84d-25a0-4c80-8f04-361e6361a5ce" contextRef="C_9de3ffb5-8381-4662-89f6-a8481e573820" name="inva:InvestmentsInWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,507</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund and cash</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39ec029e-5b5c-41cf-9e8f-f9342f94a1f6" contextRef="C_f1250457-5420-4587-a034-747d2328f6e0" name="inva:MoneyMarketFundAndCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,727</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea1af617-1046-4657-bd89-fc0ecb328f9d" contextRef="C_7fba1762-844e-4c04-b43c-b15c482e2679" name="inva:MoneyMarketFundAndCash" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,532</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total investments held by ISP Fund LP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28ceee38-b44b-44aa-b167-79ea283f70a2" contextRef="C_f1250457-5420-4587-a034-747d2328f6e0" name="us-gaap:Investments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,741</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7410f9ba-23df-4f5e-a8d8-ade5c04028c4" contextRef="C_7fba1762-844e-4c04-b43c-b15c482e2679" name="us-gaap:Investments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">255,658</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_90286cd0-ee34-465a-acf6-673b6771f4ab" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" escape="true" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity and Other Investments in Armata</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the first quarter of 2020, Innoviva and its wholly owned subsidiary, Innoviva Strategic Opportunities, LLC (&#8220;ISO&#8221;), have invested in the common stock, warrants, convertible note, and term loans of Armata Pharmaceuticals, Inc. (&#8220;Armata&#8221;), a clinical stage biotechnology company focused on development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">116</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_1" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_2"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the first quarter of 2021, Armata entered into a voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f9c400a-80e6-45fa-8afb-f8e0d055fc93" contextRef="C_555d4978-0156-480e-84ba-fa2f5dcd4d7f" name="inva:VotingAgreementMaximumVotingRightsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">49.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of Armata&#8217;s common stock for voting on the matters related to election or removal of Armata&#8217;s board members. The voting agreement will expire on the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 9, 2022, Armata entered a second amended and restated voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42fd1fe8-f937-4d11-be06-c5560f896019" contextRef="C_8f7758c5-cb43-4beb-b145-ea2ab98c407a" name="inva:VotingAgreementMaximumVotingRightsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">49.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of Armata&#8217;s common stock for voting on the matters related to election or removal of Armata&#8217;s board members or amend the bylaws of Armata to reduce the maximum number of directors or set the number of directors who may serve on the board of Armata. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12141b02-c0ec-49a9-a2c8-df5a10e5a0c0" contextRef="C_8f7758c5-cb43-4beb-b145-ea2ab98c407a" name="inva:SpecialTermReDesignatingBoardMemberToBoardOfInvestee"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0fe7361-432d-4a7b-a513-e2c2e8585e09" contextRef="C_1b2e2593-a2a8-48e9-bddd-edbd0e4ece93" name="us-gaap:VariableInterestEntityOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding shares of Armata&#8217;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#8217;s board of directors, and for so long as the Company and ISO hold at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6a51f96-cab6-4a4b-9f85-a2de04b00444" contextRef="C_bdd9c91e-8090-4b5c-afa1-5fde995c9182" name="us-gaap:VariableInterestEntityOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, but less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f6c04525-d351-45b1-b209-7e2dd2c29aaf" contextRef="C_d7a7bab5-9ba6-49af-9860-25a6b42523d6" name="us-gaap:VariableInterestEntityOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">12.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, of the outstanding shares of Armata&#8217;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#8217;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2023, Armata entered into an amendment to the amended and restated investor rights agreement with the Company and ISO, pursuant to which the Company and ISO agreed that the voting agreement will expire on the earlier of the fifth anniversary of the original agreement&#8217;s effective date, January 26, 2021, or the approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6931b723-709c-463a-b88a-dc793725825b" contextRef="C_4fb4788c-8450-4c40-8d91-a0ffb3b4ba73" name="us-gaap:DebtInstrumentDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#8220;Credit Agreement&#8221;) with Armata, under which we invested in a </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e458e759-ed06-4515-9a81-0b53167292bb" contextRef="C_4fb4788c-8450-4c40-8d91-a0ffb3b4ba73" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-year</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> convertible note (the &#8220;Armata Convertible Note&#8221;) in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99c7ded9-acc7-48a8-ab0a-11360b39d156" contextRef="C_b4075dc6-049f-43ce-ad83-c920b6727849" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e8c8dac-7ca6-485a-8a7e-34393fac456f" contextRef="C_b4075dc6-049f-43ce-ad83-c920b6727849" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">8.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pursuant to the Credit Agreement, the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, will convert into shares of Armata</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s common stock upon the occurrence of a qualified financing, as defined in the Credit Agreement. Any portion of the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, may also be converted into shares of Armata&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s common stock at our option once a registration statement covering the resale of such securities has been declared effective by the SEC. The Armata Convertible Note is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries. On July 10, 2023, ISO and Armata executed an amendment to the Armata Convertible Note extending the maturity date from January 10, 2024 to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_155b24da-c849-40bb-a1ba-9ac6d4947b22" contextRef="C_a81a0298-20b0-4919-aeae-4999deb69182" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 10, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On November 12, 2024, ISO and Armata executed an amendment to the Armata Convertible Note extending the maturity date from January 10, 2025 to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1e19e73f-9538-4c3d-a8d2-b3ff24d2b6ac" contextRef="C_56003be5-dcb8-4576-a7f1-796756b2432a" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 10, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2023, ISO and Armata entered into a Credit and Security Agreement (the &#8220;July 2023 Credit and Security Agreement"), under which we extended a term loan to Armata (the &#8220;Armata July 2023 Term Loan&#8221;) in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0717e4d-47f0-4600-9c57-ad7dd5754b74" contextRef="C_5aa5d39a-f76b-4524-93e9-30d0fefb1a3c" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Armata July 2023 Term Loan is subject to an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6e397333-088e-45e9-914f-f48f9d7d643e" contextRef="C_5aa5d39a-f76b-4524-93e9-30d0fefb1a3c" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum and is due to mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_29e6d1f0-6834-4d84-9b92-086e6e8e0bde" contextRef="C_f41b7af1-e738-4a48-990d-dc1756c13b91" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 10, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The July 2023 Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries. On November 12, 2024, ISO and Armata executed an amendment to the Armata July 2023 Term Loan extending the maturity date from January 10, 2025 to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_89282c05-ccfd-477f-ab45-05dd7af203aa" contextRef="C_2a02f41a-febe-490b-af61-93b34070abed" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 10, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 4, 2024, ISO and Armata entered into a Credit and Security Agreement (the &#8220;March 2024 Credit and Security Agreement&#8221;), under which we extended a term loan to Armata (the &#8220;Armata March 2024 Term Loan&#8221;) in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f43f8c1a-ce53-4223-9eee-bc240ed82516" contextRef="C_71ded7c0-3708-4f52-b6c3-6791c394800f" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Armata March 2024 Term Loan is subject to an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a242958a-27ed-4641-b487-abf58586e6d1" contextRef="C_71ded7c0-3708-4f52-b6c3-6791c394800f" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum and is originally set to mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a00c96cc-5ab3-41cf-9e9d-ed07c2b49fb4" contextRef="C_d2c0826f-e79a-4fce-bf90-c8a92ab2dc99" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 4, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The March 2024 Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 12, 2025, ISO and Armata entered into a Credit and Security Agreement, under which ISO extended a term loan to Armata (the &#8220;Armata March 2025 Term Loan&#8221;) in a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deebe8c1-a142-4d70-b1ae-b5529acf2ce0" contextRef="C_60ac9e5c-2514-4f92-bf1c-12266b1917e1" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Armata March 2025 Term Loan bears interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cfb8067-9265-42bb-8232-1b49de4d61d8" contextRef="C_60ac9e5c-2514-4f92-bf1c-12266b1917e1" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum and matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ea17b9e8-19d2-44a5-802d-154c03276a64" contextRef="C_11d1f4e6-b778-4765-a18c-a66d5f46ca1e" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 12, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Credit and Security Agreement is secured by substantially all assets of Armata and its domestic and foreign material subsidiaries. Concurrently, ISO extended the maturity date of the Armata Convertible Note and the Armata July 2023 Term Loan and the Armata March 2024 Term Loan to March 12, 2026.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">117</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_2" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_3"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 11, 2025, ISO and Armata entered into a Credit and Security Agreement, under which ISO extended a term loan to Armata (the &#8220;Armata August 2025 Term Loan&#8221;) in a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5d06ad8-381b-42da-8459-bf98dc2c9bda" contextRef="C_a6940b34-904b-444f-9ffb-b6b2e2a80b84" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Armata August 2025 Term Loan bears an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6020c562-46dc-4015-a949-8d8de78db88f" contextRef="C_a6940b34-904b-444f-9ffb-b6b2e2a80b84" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum and matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_078c0ce7-0e54-4702-bc51-b9dc71d9a9df" contextRef="C_0d77cda3-d1e7-4fcc-b01e-02245e7164be" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 11, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6972e287-8f9c-44d0-afa9-d0d83bc2c71a" contextRef="C_057e1553-e322-46f8-92dc-4d5d487f40f6" name="inva:NumberOfBoardOfDirectors" unitRef="U_BoardMember" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_700b2e37-a19c-425e-8f1a-eec6472d5df7" contextRef="C_5a9347c1-884d-4675-bb79-fefe358e833d" name="inva:NumberOfBoardOfDirectors" unitRef="U_BoardMember" decimals="INF" format="ixt-sec:numwordsen">seven</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> members of Armata&#8217;s board of directors are also members of the board of directors of Innoviva. As of December 31, 2025 and 2024, we collectively owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fe3e33a-42c1-4c93-a23d-5ebd16110ce1" contextRef="C_5a9347c1-884d-4675-bb79-fefe358e833d" name="inva:EquitySecuritiesOwned" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_903600b9-f219-4683-9fbb-1283f4123f65" contextRef="C_5328b425-8576-4d5b-b1db-1f14e4c9c1c0" name="inva:EquitySecuritiesOwned" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">25,076,769</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Armata's common stock, representing equity interest of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02cf6f34-236b-48ea-9d4a-b345bdd7832b" contextRef="C_675639ab-20e9-408c-8ece-4bd0da8c908c" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">68.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cb4bf4c-a45c-4b2e-a339-b1c897911f4e" contextRef="C_5038c961-a52a-4d07-b20a-2ec350ef35a7" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">69.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively. As of December 31, 2025 and 2024, we collectively hold warrants of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0311e5d-908a-4ddf-a8a8-141d6ac90562" contextRef="C_5a9347c1-884d-4675-bb79-fefe358e833d" name="inva:NumberOfWarrantsOwned" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">10,653,847</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5525e0f3-b50b-4b48-83d8-82bdc166bd89" contextRef="C_5328b425-8576-4d5b-b1db-1f14e4c9c1c0" name="inva:NumberOfWarrantsOwned" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">19,364,647</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, with exercise prices ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2994077-e3d7-45d9-922a-f3207f4af858" contextRef="C_cde889ec-684b-433c-ada2-fcc698632fea" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_778ce802-4fbf-40b9-b179-31878bd3080d" contextRef="C_3acd791d-ece0-41d0-bc86-551014479aa6" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Innoviva also held $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1871df0-7a38-4eae-b75f-e88113ad03e7" contextRef="C_057e1553-e322-46f8-92dc-4d5d487f40f6" name="inva:PrincipalAmountOfConvertibleNotesOwned" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in principal amount of the Armata Convertible Note and a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47f24e3a-ae14-4d91-85bf-cad2cda9d8ed" contextRef="C_cfe17d12-81a1-4510-9340-bf18810ec8cf" name="inva:PrincipalAmountOfTermLoansOwned" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">85.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in term loans.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investments in Armata&#8217;s common stock and warrants provide Innoviva and ISO the ability to have significant influence but not control over Armata&#8217;s operations. Armata&#8217;s business and affairs are managed under the direction of its board of directors, which Innoviva and ISO do not control. Based on our evaluation, we determined that Armata is a VIE, but Innoviva and ISO are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for Armata&#8217;s common stock and warrants under the equity method using the fair value option. The fair value of Armata&#8217;s common stock is measured based on its closing market price. The warrants purchased in 2020, 2021 and 2022 have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d86b7fae-d575-479f-8f18-08cdf4e5d10f" contextRef="C_3c82e86c-b476-42ba-91a7-f0f73b075d88" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">2.87</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ce33234-1622-4595-82b9-e1e3c38eb14f" contextRef="C_df134efd-b2f5-42e0-9b07-1a512098141d" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">3.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_389eef3d-ba0a-4ebc-9a9c-744e33397110" contextRef="C_2aaa98e6-3d27-48b0-aad0-9021ae880dff" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.00</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. All warrants are exercisable immediately within </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_80674145-95e4-49cd-91b9-019d85c4225a" contextRef="C_e6682ffe-c7e9-4815-8a85-1e4bef9f2711" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_2eea72d0-1e7c-4930-b5c7-3630f92899b7" contextRef="C_99fff56a-0af3-445d-bdc0-14b8847ce8ee" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_213df821-7137-40fd-b8c0-49a30c6dd527" contextRef="C_05ee92da-ae00-447e-a688-0afb8debabd7" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the issuance date of the warrants and include a cashless exercise option. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The warrants purchased in 2020 expired during the first quarter of 2025. We use the Black-Scholes-Merton pricing model to estimate the fair value of these warrants with the following input assumptions: Armata&#8217;s closing market price on the valuation date, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of Armata and its peer companies. We account for the Armata Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. We account for the Armata term loans as trading securities, measured at fair value using income approach based on the discounted value of expected future cash flows.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the fair values of our holdings of Armata common stock, warrants, the Armata Convertible Note, the Armata July 2023 Term Loan, the Armata March 2024 Term Loan, the Armata March 2025 Term Loan and the Armata August 2025 Term Loan were estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4914cd94-5df4-4d75-9d90-86784e8b7108" contextRef="C_65e207cc-7ebd-4bcd-bb6b-e27d80d3a005" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">157.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88bf2299-f25c-46f1-b5d3-9529589fce37" contextRef="C_820fc30b-7e3c-4f31-9d93-e486eb026d85" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">36.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd0ae110-c802-4a31-ae52-bbc63bc11f5a" contextRef="C_cfe17d12-81a1-4510-9340-bf18810ec8cf" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">101.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_531b097c-84cb-4ad0-81e4-0457922e24ec" contextRef="C_bc6304c8-3e91-4a96-bdf1-8803fdcad919" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">32.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c74d001c-c082-478a-bf91-c00432c168cb" contextRef="C_cd9cf8cd-caf0-4230-972b-b59ef42f7629" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">43.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c4c1fc4c-80a1-433b-aebd-fc5da11be8e2" contextRef="C_97c7c246-dcd0-459f-ba1c-f296e715a8bd" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a089d186-e7af-4db4-9764-28257c5cc326" contextRef="C_b335f87a-f5ca-4232-8677-8903d59dd87c" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 the fair values of our holdings of Armata common stock, warrants, the Armata Convertible Note, the Armata July 2023 Term Loan and the Armata March 2024 Term Loan were estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efb91edd-cea6-4bf9-96a2-911fde6f1eb8" contextRef="C_ce943a5c-4a0c-4116-8b1d-c757694d1ea7" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">46.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40930f16-c738-42f6-aa24-cf8a57165a11" contextRef="C_1c30d3c2-8973-487f-b385-4efcc897f79b" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea2f2a9e-f7ce-4a91-a49a-65461221b97a" contextRef="C_569306e7-f6a0-459f-8db9-5647b77e5c0a" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">42.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_109da6f2-1104-4ba2-911d-4805414bf036" contextRef="C_d34cdf08-8e0e-4cba-93ee-569a80e0e67a" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">30.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f978b26-a698-4bd9-a38a-d6a8c4d085f5" contextRef="C_21888485-64fc-4d1a-9d3c-4e0fc17c7633" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">39.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata common stock and warrants, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6ac5b3c-56c1-437e-9a89-fc0078527e47" contextRef="C_9db59475-42c5-4b23-ad54-3fcbd23354de" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">141.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b12bd9c9-7d59-4a69-ac83-ac999b3b0474" contextRef="C_ad016aed-b782-4802-bf40-a81d9aac47a4" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">64.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b71794b-75cb-4bcd-be8d-d0c452bb371e" contextRef="C_8480b31f-e5a9-455f-8428-4e043a8d826b" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">77.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as changes in fair values of equity method investments, net, in the consolidated statements of income and comprehensive income for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata Convertible Note, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f5fdf97-5c01-4534-b675-308006f4ad5d" contextRef="C_661f58ec-6b2b-444d-8088-4abba363c175" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">59.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af61ccee-4a18-4c62-8a7c-ea1bd117bdda" contextRef="C_22dbc318-90d0-4d6c-ae97-fa8f97e6f8e4" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc5a2582-07c4-49ba-8754-34f8dc4f29ae" contextRef="C_c0f46e83-20e1-4f0a-ac38-a2cdd4a209c4" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata July 2023 Term Loan, we rec</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">orded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3d4e650-7e30-4971-bf0f-2c7c2e8fb07d" contextRef="C_2b3a7dbc-4a58-4808-a400-3b7b5bfb3e69" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d0b3705b-6142-4c7a-9505-8037920bba59" contextRef="C_f0a0f488-206c-45bf-a6fd-b8fcfefad049" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31307d11-1c41-4f0e-848e-73a16de3e605" contextRef="C_8227b866-0a9c-4af9-b3ec-85e210a8c096" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata March 2024 Term Loan, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7d9696bc-3679-4145-8b8e-f8c80bc55e2c" contextRef="C_b0999027-f0c9-4ef8-ad7d-78766bc3abbe" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26c658be-6975-4de2-ae78-911e66f312be" contextRef="C_8683d1cb-18f6-4da0-8993-dbb80feae90a" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains as changes in fair values of equity and long-term investments, net, in the consolidated statements of income </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and comprehensive income for the years ended December 31, 2025 and 2024, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata March 2025 Term Loan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5656f04-3517-4906-9221-65e91f5204eb" contextRef="C_380b4395-2715-4251-a2b6-448e3fa77f25" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gain for the year ended December 31, 2025 as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata August 2025 Term Loan, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dab7a1a9-c8c0-42f5-9979-cbde20366841" contextRef="C_7d8daa92-8559-4d7e-9e07-c21e30f977fb" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gain for the year ended December 31, 2025 as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">118</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_3" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_4"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 23, 2026, we entered into various amendments to existing agreements with Armata, extending the maturities of the Armata Note, the July 2023 Term Loan, the March 2024 Term Loan and the March 2025 Term Loan to June 1, 2027. The expiration dates of all outstanding Armata warrants held by us were likewise extended to </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d22a183b-11ca-44c0-b243-d15f4cc0d300" contextRef="C_b657fd3f-8dca-44dc-a4ed-6c972e7986a9" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 26, 2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, we entered into an amendment to the amended and restated investor rights agreement, pursuant to which the Company and ISO agreed that the voting agreement will expire on the earlier of January 26, 2031 or the approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b7e4ab80-d5f0-4d7d-ba59-6907a7098999" contextRef="C_fe80c249-d33c-4cd6-b2cb-331be1cd34ee" name="inva:ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Balance Sheet Information</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.88%;box-sizing:content-box;"/>
         <td style="width:2.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.799999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.799999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_469aa03c-6e90-427d-a3de-43ec09591005" contextRef="C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,930</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7d7e485-9f96-439e-98af-d31c59b7cb22" contextRef="C_14b19da2-3f85-45b5-891e-2a495389f972" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,389</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4c3b970-9640-4b53-bb50-1b687463d0f8" contextRef="C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">72,586</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a66d4e1c-f9a3-4b12-ad83-018b3d62c74c" contextRef="C_14b19da2-3f85-45b5-891e-2a495389f972" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">75,848</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2310912-b9cc-479f-a8c8-110715777dca" contextRef="C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,950</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d962b83c-57e6-45fd-9b2b-6ccb5df31a98" contextRef="C_14b19da2-3f85-45b5-891e-2a495389f972" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,204</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f14d2ca-bd1a-49e1-a455-b965914a0bca" contextRef="C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">45,154</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85bcd7d3-38cf-438c-91fa-28e904ba4d4d" contextRef="C_14b19da2-3f85-45b5-891e-2a495389f972" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,006</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement Information</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended September 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e15a6cfb-8779-4347-984e-f2117dc238c5" contextRef="C_fdb03ab5-f84c-4ddc-bd5f-542862b94835" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,054</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53819d26-55c4-4045-97d6-4d34298547fc" contextRef="C_53386bc7-321c-4778-9d99-1014173440f8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,467</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c1eec64-8b6c-4838-97c8-cacab7cd819b" contextRef="C_ff805685-7f62-44bb-b91d-537b589a7c39" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,052</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_695d08ac-22ea-47ca-a981-4333c0b70e38" contextRef="C_fdb03ab5-f84c-4ddc-bd5f-542862b94835" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,350</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e721beac-cb1f-4ae3-bf42-e271973a5512" contextRef="C_53386bc7-321c-4778-9d99-1014173440f8" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">38,476</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5906f413-6871-4827-adbb-4fb004031573" contextRef="C_ff805685-7f62-44bb-b91d-537b589a7c39" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,639</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b8cdd05-a85d-4605-9304-8d35f021a238" contextRef="C_fdb03ab5-f84c-4ddc-bd5f-542862b94835" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">46,901</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_39866aee-04ac-4e5a-b628-07d9e612b949" contextRef="C_53386bc7-321c-4778-9d99-1014173440f8" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">41,363</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88002745-a9f6-46d8-937c-31e738c01dd3" contextRef="C_ff805685-7f62-44bb-b91d-537b589a7c39" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,512</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity and Other Investments in InCarda</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the third quarter of 2020, Innoviva TRC Holdings, LLC (&#8220;ITH&#8221;), a wholly owned subsidiary of Innoviva, has invested in the common stock, preferred stock, warrants and convertible notes of InCarda Therapeutics, Inc. (&#8220;InCarda&#8221;), a privately held biopharmaceutical company focused on developing intravenous and inhaled therapies for cardiovascular diseases.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITH has the right to designate one member to InCarda&#8217;s board of directors. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cd8c962-47f2-4a4a-8baf-957c188d481f" contextRef="C_280efd9d-8c7f-4e28-aa7a-2c064a232238" name="inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" unitRef="U_Director" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ITH designee is serving on InCarda&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23db3656-02a4-4f36-8527-bf5be20f369d" contextRef="C_280efd9d-8c7f-4e28-aa7a-2c064a232238" name="inva:NumberOfBoardMembersOfInvestee" unitRef="U_Director" decimals="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-member board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, ITH owns </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d819742b-a1b0-4016-a709-6ec1f99d0a1c" contextRef="C_51b3b591-fbb0-4d6e-bbcc-a2b9316cdd48" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0b6141d4-edd6-4786-8c30-7d814dfba0d5" contextRef="C_8e7f501b-989e-4f9f-9cee-6b92a787012e" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">36,742,250</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of InCarda&#8217;s common and preferred stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aab7a476-0519-41fa-91e9-51fe92c9fcce" contextRef="C_0c2b17b3-b563-4774-a444-c68ee381c769" name="inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal"><ix:nonFraction id="F_353e7530-771b-4d69-99f6-9eaf84468ce5" contextRef="C_5269be09-0f8f-4632-b948-cb713105102a" name="inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,490,033</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> preferred stock warrants. These represent a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22770d6a-4ccd-4b3f-bd59-fec111148c6f" contextRef="C_dec7ee2e-9d77-490d-ada1-7ee27d46f370" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8623a925-cb4d-44c9-9564-b58e1850a0af" contextRef="C_5df29ec0-a027-4d1e-9bcd-9baa6703c4dc" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% equity interest as of December 31, 2025 and 2024, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investment in InCarda does not provide us with the ability to control or have significant influence over InCarda&#8217;s operations. Based on our evaluation, we determined that InCarda is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITH also invested $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63722b30-614d-48ac-b0f8-ceba742641c6" contextRef="C_0aacff4b-e1cb-4189-b234-c765198bc587" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48320fb0-7567-4304-a23a-8e49e88bf4b1" contextRef="C_1d50a9ae-0f26-4ddd-b236-2070a1bd7766" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c896d944-0b5c-4891-a718-81d3a3d6dd3e" contextRef="C_382677ef-0151-430b-8242-c000796ba331" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in InCarda's convertible notes issued in January 2024 (the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;InCarda 2024 Convertible Note&#8221;), February 2025 (the &#8220;InCarda February 2025 Convertible Note&#8221;) and October 2025 (the &#8220;InCarda October 2025 Convertible Note&#8221;), respectively (collectively, the (the &#8220;InCarda Convertible Notes&#8221;). We account for the InCarda Convertible Notes as trading securities, measured at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the exception of the InCarda Convertible Notes and Series D Warrants, which are measured at fair value, we account for the aforementioned investments in InCarda under the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain InCarda warrants held by us expired in March 2023 and we wrote off their carrying value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87f6e7c4-1039-4220-8643-65c300300748" contextRef="C_5f44da0a-72da-4d0d-94ce-34a247a0ea76" name="inva:CarryingValueWroteOffWarrantExercise" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during 2023.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">119</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_4" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_5"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to certain changes in InCarda&#8217;s business operations during the second quarter of 2023, ITH reassessed the value of its then investments in common stock, preferred stock and preferred stock warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in InCarda using the Option Pricing Model methodology. Key assumptions used in the valuation model included an expected holding period of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d490887-4010-4153-8f84-24dc65a9a300" contextRef="C_6cf653d2-0adb-45e8-8c5c-d69aedde6497" name="inva:ExpectedHoldingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two years</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1739e484-1182-4d2a-bd56-34d52740f3ae" contextRef="C_6cf653d2-0adb-45e8-8c5c-d69aedde6497" name="inva:RiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fc66433-3d93-45b4-ba0e-cda6cbb219c3" contextRef="C_6cf653d2-0adb-45e8-8c5c-d69aedde6497" name="inva:DividendYield" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and an estimated volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88c7e093-4890-40b3-a25b-b0bf10ef59f6" contextRef="C_6cf653d2-0adb-45e8-8c5c-d69aedde6497" name="inva:PercentageOfEstimatedVolatility" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">114.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The estimated volatility was calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de43e0d4-8e9b-4a73-8f16-dc8aa8d8d4a1" contextRef="C_56591878-41f9-499d-94f3-2f81c2c8216a" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the second quarter of 2023.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, we recorded as equity and long-term investments in the consolidated balance sheets $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e301970c-a09a-42f1-8ae3-794dae3cce13" contextRef="C_29299cb7-d62e-4e08-9bd3-8a43b64d6f1b" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_8c5f58c3-ec3c-47a6-b6fc-ea79b6d750d6" contextRef="C_699b00df-194d-4b74-87b8-434384a664eb" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in carrying amount of InCarda&#8217;s Series C preferred stock and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe2206b0-2e85-4651-9c8f-695ab8d86734" contextRef="C_4b63e0ee-2b5b-49b5-91dd-4aad8b8b0682" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6b975aab-0f67-4c39-a70a-cf66de134788" contextRef="C_a549f046-b516-43a9-94af-3971494cee27" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in fair value of the InCarda Series D Warrants. As of December 31, 2025 and 2024, we recognized as equity and long-term investments in the consolidated balance sheets $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3a79f79-4634-44e3-9ecc-4ee9264f7636" contextRef="C_af50c412-1762-4092-9219-e0cb77f51b0e" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d6c1132a-e826-4568-9013-b40e4ed523c2" contextRef="C_3bff7c8d-4fd0-4e48-9974-ccd04b2d1f78" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for InCarda&#8217;s Series D-1 preferred stock, Series D-2 preferred stock, and common stock using the measurement alternative. As of December 31, 2025 and 2024, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f7fe863-0f75-4a69-a35e-401decbcf131" contextRef="C_d94e644a-a7b1-4e62-874d-457ce3a49fd3" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53105968-ea0c-47ae-af9a-981629679753" contextRef="C_d616bb07-0b13-4397-853a-6fd375bf2296" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in fair value of the InCarda Convertible Notes as equity and long-term investments in the consolidated balance sheet. During the years ended December 31, 2025 and 2024, there were immaterial changes in the carrying amount of our investments. We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2467bb39-b95b-4637-ac21-abb479d0f2a5" contextRef="C_5f44da0a-72da-4d0d-94ce-34a247a0ea76" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized loss as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity and Other Investments in ImaginAb</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since March of 2021, ITH has invested $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a1bb59b-e1d6-4290-9314-9943a73fc3d9" contextRef="C_e63ec4f7-4b80-482a-8302-9464099a0226" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea4578ed-5511-4365-8d6a-c88ec47e28d8" contextRef="C_e63ec4f7-4b80-482a-8302-9464099a0226" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">8,825,301</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common and preferred stock, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c417a43-d717-48e7-a314-49904e951ebd" contextRef="C_933e0662-5284-40a5-af01-95acd4469d1e" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in a convertible note of ImaginAb, Inc. (&#8220;ImaginAb&#8221;), a privately held biotechnology company focused on clinically managing cancer and autoimmune diseases via molecular imaging.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_59e1787c-3074-4a7c-ab6d-5fd00d609e9e" contextRef="C_ab4cbb1c-525e-4e91-8915-9c00d3a0db21" name="inva:NumberOfBoardOfDirectors" unitRef="U_BoardMember" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of ImaginAb&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83e092b8-012f-4015-8fa7-92729118ff44" contextRef="C_07023259-2cd5-439e-8af3-725f79e6d197" name="inva:NumberOfBoardOfDirectors" unitRef="U_BoardMember" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> board members was designated by ITH. As of December 31, 2025 and 2024, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d93a3e2a-9bbc-4c9d-8070-078f8770eefa" contextRef="C_6d3c556c-fb3c-4b80-9075-4471ffd20f1e" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_885be0bb-674b-4716-8664-f9486d250331" contextRef="C_d4eb0f40-5fd8-4cae-9d09-795c67481067" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">11.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of ImaginAb equity ownership.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investment in ImaginAb does not provide us with the ability to control or have significant influence over ImaginAb&#8217;s operations. Based on our evaluation, we determined that ImaginAb is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d0f2f2a-a793-40ea-952a-793c2f123caa" contextRef="C_768acc31-d49a-4b35-b48a-e542af02b049" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">270,568</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of ImaginAb Series C-2 preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1942b8d-fa3a-40c3-8163-e5772e55249b" contextRef="C_768acc31-d49a-4b35-b48a-e542af02b049" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On September 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase another </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9ee99a2-b862-4661-93d9-96f757cbc3cd" contextRef="C_149ef97f-f1b9-4b0e-9127-348ee02e361e" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">405,852</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of ImaginAb Series C-2 preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd69d869-9d52-4a50-878b-7ced1ac62b6e" contextRef="C_149ef97f-f1b9-4b0e-9127-348ee02e361e" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 23, 2024, ITH purchased a subordinated convertible promissory note (the &#8220;ImaginAb Convertible Note&#8221;) from ImaginAb for a total purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95939219-5682-4997-9e07-638f5d9432ec" contextRef="C_5f2ad567-e08d-4636-8f55-1c301878579d" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The ImaginAb Convertible Note carried an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03710a5e-8035-4ef2-a2a0-639187115ca8" contextRef="C_5f2ad567-e08d-4636-8f55-1c301878579d" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and would be due and payable upon the earlier to occur of January 31, 2025 and certain events defined in the ImaginAb Convertible Note. Under certain circumstances, the ImaginAb Convertible Note is convertible at the option of ITH into ImaginAb&#8217;s equity securities at defined conversion prices. The ImaginAb Convertible Note is subordinate to certain existing indebtedness of ImaginAb as defined in the ImaginAb Convertible Note. On October 31, 2024, ITH entered into an agreement with ImaginAb to amend the ImaginAb Convertible Note. Pursuant to the agreement, the principal amount of the ImaginAb Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05139969-d704-4b9c-a40a-cb6ca2f99850" contextRef="C_12d5315c-63c8-4bf3-b585-41fbafc8766c" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee84a6a7-93f9-4f46-8d95-eddfb699c1ad" contextRef="C_fe69aeef-ca75-4945-996a-5e2bef7daf59" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represented the principal as of February 23, 2024, accrued interest as of amendment date, commitment fees and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d2f6185-ff29-4064-8c93-d55f745f5046" contextRef="C_89c9f170-6554-4259-8589-a870931960d9" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On January 13, 2025, ITH and ImaginAb executed an amendment to the ImaginAb Convertible Note extending the maturity date from January 31, 2025 to May 30, 2025. All other material terms of the ImaginAb Convertible Note were unchanged during the aforementioned amendments to the ImaginAb Convertible Note.	</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because ImaginAb&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in ImaginAb&#8217;s Series C preferred stock, Series C-2 preferred stock and common stock using the measurement alternative. As of December 31, 2025 and 2024, our investment in ImaginAb&#8217;s Series C preferred stock, Series C-2 preferred stock and common stock amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6918cbc-c300-4ad6-a88d-f0a752f53b90" contextRef="C_807e8809-f1a2-4c0a-ac41-7942e7f10fcb" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_76ebba59-eb83-4c2c-9db7-4795cb8b25d7" contextRef="C_7ba50ae3-7184-4972-bf26-f59e81848d23" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and recorded as equity and long-term investments in the consolidated balance sheets. There was no change in the carrying amount of our equity investments in ImaginAb.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">120</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_5" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_6"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2025, ImaginAb fully settled the convertible note of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_326e6ff7-6c6d-4166-be52-907f15df2c94" contextRef="C_a13ce0ca-7bd6-470f-b4bc-7bce7c7cce0e" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a67dadbe-4b0b-4a11-9471-acc87498aa7b" contextRef="C_6975b245-2632-4293-87d4-04681539a20a" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, including $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_119a9619-18ed-4eec-b113-f20728fc8e7c" contextRef="C_6975b245-2632-4293-87d4-04681539a20a" name="inva:AccruedInterestAndCommitmentFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in accrued interest and commitment fees. Before the repayment, the ImaginAb Convertible Note was accounted for as a trading security and measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. As of December 31, 2024, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_252d92e8-99ec-4a6e-b68e-9313208588c3" contextRef="C_36cd9246-caa5-48b0-9537-3ae622ca29e0" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in fair value of the ImaginAb convertible note as equity and long-term investments in the consolidated balance sheet. Changes to the fair value of the ImaginAb convertible note in 2025 through its settlement date were immaterial. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, we recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78ea51ed-aa90-4854-9189-5f5b2770770c" contextRef="C_b0306b74-2ec2-4940-b3af-88916e13af8d" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net unrealized gain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on the ImaginAb convertible note as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Promissory Note in Syndeio Biosciences</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Syndeio Biosciences, Inc. (formerly known as Gate Neurosciences, Inc.) (&#8220;Syndeio&#8221;) is a privately held biopharmaceutical company focused on developing the next generation of targeted nervous system therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. In May 2025, Gate Neurosciences, Inc. rebranded as Syndeio.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From 2021 to 2022, ITH invested in Syndeio a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd8b6b77-960e-4b69-b4b8-1ac1e940908f" contextRef="C_75c1d9ea-1aaf-4126-af63-8748312d93ac" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in convertible notes (the &#8220;Syndeio 2021 Convertible Note&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Syndeio 2021 Convertible Note bears an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb2d74c4-240b-464c-b098-7c9859b40123" contextRef="C_f94f64d0-bc96-4573-be4f-370b739bbc44" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and will convert into shares of common stock of Syndeio upon a qualified event or into shares of shadow preferred stock of Syndeio (&#8220;Shadow Preferred&#8221;) upon a qualified financing. A qualifying event can be a qualified initial price offering, a qualified merger, or a merger with a special-purpose acquisition company (&#8220;SPAC&#8221;). Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b2ca0d4-8cd3-4b83-998c-001e480ce201" contextRef="C_31ec6e0a-cd1b-4e7a-af9c-54600d0d24cc" name="inva:NumberOfCommonStockIssuedDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#8220;Capped Conversion Price&#8221;) and the qualified event price (the &#8220;Qualified Event Price&#8221;). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Syndeio are at least $35.0 million, and (iii) the stated or implied equity valuation of Syndeio is at least $80.0 million.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 2, 2023, ITH entered into a Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Syndeio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d0d976a-1aa3-40d4-8103-911c8d870fe2" contextRef="C_f94f64d0-bc96-4573-be4f-370b739bbc44" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bda0826-e37f-4a43-94fd-f3fd701a466c" contextRef="C_27af781c-37f3-46f9-b219-825ba2161b60" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the original principal, accrued interest as of the amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0c9ff14-21ce-4c90-8c6a-45a66c10d40c" contextRef="C_226618bc-59f6-409f-b441-d4d85c7c9b01" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 6, 2023, ITH entered into a Second Note Amendment Agreement with Syndeio to amend the Note Amendment Agreement. Pursuant to the Second Note Amendment Agreement, the principal amount of the Syndeio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b0e9d14-8223-4afb-9481-6a0f3cbd2450" contextRef="C_03780f91-4f1d-4cc3-9ff3-8ab31a4af745" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7024d0c2-1627-4586-ba66-3e52b8b6ef7e" contextRef="C_c44315cf-58b6-4df1-a7fb-545a3c2a85c8" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the amended principal as of February 2, 2023, accrued interest as of the second amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee7e200f-07e9-4cb3-b2da-a8978a24c054" contextRef="C_89417c7c-4dcb-4c3c-be0a-04a18955e9b3" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2024, ITH entered into a Third Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Third Note Amendment Agreement, the principal amount of the Syndeio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_163a7dab-2021-4475-900b-eec0cccf9d16" contextRef="C_ac9f1546-4eb3-464f-9fd9-e5fcbd5159b6" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa0b0cad-1629-4407-bc6b-286c3e8062a9" contextRef="C_cffa7db5-8a40-42ec-a6b5-dae4eff5e8a2" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the principal and accrued interest as of the third amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e4b2a09-883f-4649-8155-970460ca907c" contextRef="C_9ce22bb4-5077-4fc2-a00b-d5ce7b0d778d" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 5, 2024, ITH entered into a Fourth Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Fourth Note Amendment Agreement, the principal amount of the Syndeio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ddb801d-7dbb-4ca7-a285-98c087a353d5" contextRef="C_d61eb3bb-dfd5-4977-b307-3cce0652657c" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfb20a44-ef97-4827-8f19-5e5d126731d5" contextRef="C_7375bdeb-c66c-40d4-84b1-149ba7c7ef18" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">39.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the principal and accrued interest as of the fourth amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_556aeff3-688b-4a0b-9d68-64fbeaafdf67" contextRef="C_6b2a5a0e-88cb-4767-81b9-afb899aec69b" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 13, 2024, ITH entered into a Fifth Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Fifth Note Amendment Agreement, the principal amount of the Syndeio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78014cf1-255d-44e0-ad45-f13b1efbc655" contextRef="C_8c8a8e9b-18d0-4f56-bd91-01b41b53e196" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">39.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a555b48b-05b5-4600-90ce-d3a27a3beb49" contextRef="C_a632ca34-f6ea-445b-b4f9-b800f457ca17" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the principal and accrued interest as of the fifth amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0674d5d8-cc6c-47e2-9ab5-8ae8a5cea9c3" contextRef="C_fad3e9f3-1f85-4bfc-bf22-a300d00e3a74" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">121</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_6" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_7"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 3, 2025, ITH entered into a Convertible Promissory Note Purchase Agreement with Syndeio to acquire a convertible promissory note (the &#8220;Syndeio 2025 Convertible Note&#8221;) with a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02309a1b-d87d-420d-a4ff-b2f5648f2b1c" contextRef="C_23f06870-8557-49c9-961b-175324f1dcae" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Syndeio 2025 Convertible Note bears an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a2d03d0-fe80-4596-b211-0721c43cb2b8" contextRef="C_23f06870-8557-49c9-961b-175324f1dcae" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd82bfaa-b6b9-4be1-bcc6-9abecfb6a598" contextRef="C_5e004e9c-f37b-4fd8-92e2-d31164aba4bf" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 24, 2026</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Syndeio 2025 Convertible Note will convert into shares of series seed preferred stock of Syndeio upon a qualified initial public offering (&#8220;IPO&#8221;), or into shares of shadow preferred stock of Syndeio (&#8220;Shadow Preferred&#8221;) upon a qualified financing. Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 11, 2025, ITH entered into a Note Amendment Agreement with Syndeio to amend the Syndeio 2025 Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Syndeio 2025 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e3cca5e-c717-43b9-ac85-b8d203241df0" contextRef="C_23f06870-8557-49c9-961b-175324f1dcae" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41a213ad-89fd-4691-a26b-490350bf588f" contextRef="C_f609d5f9-7bd6-42d0-b989-6627052c05d9" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the principal and accrued interest as of the amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86b0ef61-5dca-4c9e-a733-f74224259516" contextRef="C_39ce9270-cfd2-49c3-a23e-79c0108afb55" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All other material terms of the Syndeio 2021 Convertible Note and the Syndeio 2025 Convertible Note remained unchanged during the aforementioned amendments.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investments in Syndeio do not provide us with the ability to control or have significant influence over Syndeio&#8217;s operations. Based on our evaluation, we determined that Syndeio is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for both the Syndeio 2021 Convertible Note and the Syndeio 2025 Convertible Note as trading securities, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Syndeio, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the fair value of the Syndeio 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Convertible Note was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f115d07a-8930-4460-b0ea-18d4f4da5122" contextRef="C_5e4ede51-f604-4176-b6c8-a3365d117e9b" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0da46551-13e2-4ee6-9ad9-8259f3a91121" contextRef="C_b44bc8f0-aa9e-48fd-9fb8-b5701d1d6bf9" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and recorded as equity and long-term investments in the consolidated balance sheets. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdb273e4-72ab-4c41-9d5d-f7ce37586dbb" contextRef="C_d383d05f-380a-46b9-b425-0ac125742038" name="us-gaap:EquitySecuritiesFvNiUnrealizedGain" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gain for the year ended December 31, 2025, as change in fair values of equity and long-term investments, net in the consolidated statements of income and comprehensive income. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The change in fair value is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67eaf574-e6ec-4f4d-bc22-d4f1530b036c" contextRef="C_123df293-7632-4793-9257-bcb8b7a3e0d8" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material for the year ended December 31, 2024. We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_819ddb41-d393-4810-b95d-4ec3b61320d9" contextRef="C_257af86c-f735-4442-94a0-70da28449be7" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized loss as change in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the fair value of the Syndeio 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Convertible Note was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68475e1e-9113-493a-89fe-70d380d77f48" contextRef="C_218b6839-f930-461a-a25b-b72c22604510" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">24.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and recorded as equity and long-term investments in the consolidated balance sheet. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a051bbe-50e5-4e4a-8f96-9b59101ac268" contextRef="C_cdc0f154-9e15-4dde-bfd0-dcb748170232" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized loss for the year ended December 31, 2025, as change in fair values of equity and long-term investments, net in the consolidated statements of income and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2026, ITH entered into a Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Syndeio 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80b9cda5-9b5d-410e-9c1a-f19fc6e2f513" contextRef="C_a632ca34-f6ea-445b-b4f9-b800f457ca17" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">50.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81c47403-26a4-4eaa-b377-d7a40f96dcc4" contextRef="C_e6747d6c-bd4c-45e0-a2d0-85a45a6f79e0" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">60.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the principal and accrued interest as of the amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbe84417-44a7-4a9a-89a6-a35241e9445b" contextRef="C_2a498a39-fd62-4604-9c70-6a29b2842bc1" name="us-gaap:PaymentsToAcquireLongtermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Certain thresholds associated with the definition of qualified financing were likewise amended. All other material terms of the Syndeio 2021 Convertible Note remained unchanged</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Investment in Nanolive</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2022, ITC invested $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ace24080-874b-4355-9ad8-67f54727781c" contextRef="C_ff591898-83ba-4b78-b062-c4cab6cf47a9" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fed9456-6bc6-4ba1-9bee-7be20c3632a8" contextRef="C_ff591898-83ba-4b78-b062-c4cab6cf47a9" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">18,750,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock of Nanolive SA (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Nanolive&#8221;), a Swiss privately held life sciences company focused on developing breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. ITH has the right to designate one member to Nanolive&#8217;s board. ITH also has the right to designate another member, who will be mutually acceptable to ITH and another stockholder, to Nanolive&#8217;s board. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd5358b4-ed2f-4ab9-ba47-b5c64e93713c" contextRef="C_da892b74-d5b8-42b1-8209-9456006bda02" name="inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" unitRef="U_Director" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Innoviva designee is serving on Nanolive&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e72814ed-8c0c-4ed2-ba32-fe7fda79e8b0" contextRef="C_da892b74-d5b8-42b1-8209-9456006bda02" name="inva:NumberOfBoardMembersOfInvestee" unitRef="U_Director" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-member board. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d83855e-df43-432c-8478-3b666a755754" contextRef="C_3fab1ccf-3d72-436d-a37b-efac6941b37d" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e934b467-66d2-4652-b4e7-b83e7114b566" contextRef="C_2c8dee1f-3ed6-47e2-8225-b5df7bf62a8d" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">13.0</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of Nanolive equity ownership.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investment in Nanolive does not provide us with the ability to control or have significant influence over Nanolive&#8217;s operations. Based on our evaluation, we determined that Nanolive is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">122</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_7" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_8"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because Nanolive&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Nanolive&#8217;s Series C preferred stock using the measurement alternative. As of December 31, 2025 and 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52cf8d83-922a-4789-a8a1-4135d15e7e0b" contextRef="C_da892b74-d5b8-42b1-8209-9456006bda02" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_655b88a0-bf90-4475-b34d-08d8a1e99dcf" contextRef="C_f270105d-3047-4709-8eb8-f148d9149e12" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.6</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of investment in Nanolive was recorded as equity and long-term investments in the consolidated balance sheets, and there was no change to the carrying amount of our investment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Promissory Note in Lyndra</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 27, 2025, Strategic Partners entered into a note purchase agreement with Lyndra Therapeutics, Inc. (&#8220;Lyndra&#8221;) to acquire a convertible promissory note (the &#8220;Lyndra Convertible Note&#8221;) with a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49d70de7-b583-495a-9b03-c55a49f85a81" contextRef="C_00b91c9f-9ab7-4b39-b007-fe9dae159be4" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Lyndra is a clinical-stage company with a novel drug delivery platform that enables the administration of ultra-long-acting oral drugs. The Lyndra Convertible Note bears an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1d0384fd-8137-4411-8838-b76ab680fb13" contextRef="C_00b91c9f-9ab7-4b39-b007-fe9dae159be4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02f58bc3-def7-4937-b321-e4aec56b4210" contextRef="C_ff05dc94-b555-4348-9109-aa9b60fb068a" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 27, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Lyndra Convertible Note would convert into shares of preferred stock of Lyndra upon a qualified financing as defined in the agreement. Upon maturity or certain events and if no qualified financing has occurred, the principal and unpaid accrued interest may either be repaid in full in cash plus a certain premium or convert into shares of preferred stock of Lyndra as defined in the agreement.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investment in Lyndra does not provide us with the ability to control or have significant influence over Lyndra&#8217;s operations. Based on our evaluation, we determined that Lyndra is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity. We account for the Lyndra Convertible Note as a trading security, measured at fair value using an income approach based on the discounted value of expected future cash flows.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In late March of 2025, Lyndra began winding down its operations due to a lack of financing. In September 2025, Lyndra sold the majority of its assets, resulting in a change of control as defined in the Lyndra Convertible Note (Refer to Note 14, &#8220;Asset Acquisition&#8221;). Upon the consummation of the change of control, the maturity date of the Lyndra Convertible Note was accelerated, and its principal and accrued interest became due. Due to Lyndra&#8217;s inability to repay the full amount, the note went into default and became subject to a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51ad0962-7f43-4df6-8d23-c0917e3b9fe2" contextRef="C_9d514a06-f501-41ad-b742-a81bd23946be" name="inva:DebtInstrumentPercentagePremiumOnPrincipalOnDefault" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% premium on the principal balance. Interest will continue to accrue until full repayment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In October 2025, we received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20577fe1-8a54-49d3-bc4b-ad1e77cf7137" contextRef="C_9c59249e-0a1f-4f59-9c53-c8fe277b09ca" name="us-gaap:RepaymentsOfShortTermDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million partial repayment on the Lyndra Convertible Note, reducing the outstanding principal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e75d9914-3f2a-4e7c-9e0b-eccae7dfb6e7" contextRef="C_bcb70ba8-9c6a-40aa-acaa-7cbf42dfc814" name="us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the fair value of the Lyndra Convertible Note was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a21eed53-f9d6-4d6d-9708-cc1a2a5f68a0" contextRef="C_20899f10-0ff4-461b-801a-ba4175ab2431" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and recorded as equity and long-term investments in the consolidated balance sheet. We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_605aef33-a0e3-4d3b-82af-5ebbcbf5459f" contextRef="C_9d514a06-f501-41ad-b742-a81bd23946be" name="us-gaap:EquitySecuritiesFvNiUnrealizedLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized loss for the year ended December 31, 2025 as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Investment in Beacon</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beacon Biosignals, Inc. (&#8220;Beacon&#8221;) is an AI-driven neurotechnology company developing treatments for neurological, psychiatric, and sleep disorders. On October 7 2025, ITH entered into a Preferred Stock Purchase Agreement with Beacon, pursuant to which ITH acquired </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce22ab6c-dcb6-4475-bbd3-edc9e18ac677" contextRef="C_f4ddf483-cbed-4109-859d-418fd5e83000" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">1,448,303</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Beacon&#8217;s Series B Preferred Stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99b46b9f-eafc-4b11-a1b3-f6918481905d" contextRef="C_f4ddf483-cbed-4109-859d-418fd5e83000" name="inva:SecuritiesPurchaseAgreementAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c71b25c-c372-4787-ac64-61fcbb6c05aa" contextRef="C_0adbc8ec-6dbe-4222-bbd2-0e0eba4e778c" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of Beacon equity ownership.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investment in Beacon does not provide us with the ability to control or have significant influence over Beacon&#8217;s operations. Based on our evaluation, we determined that Beacon is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because Beacon&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Beacon&#8217;s Series B preferred stock using the measurement alternative. As of December 31, 2025, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60e33a6f-7fad-4396-a576-b8b8b9b0498d" contextRef="C_726df857-6023-4423-a3a4-cf7d258b67aa" name="us-gaap:EquitySecuritiesFvNi" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of investment in Beacon was recorded as equity and long-term investments in the consolidated balance sheet, and there was no change to the carrying amount of our investment.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">123</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_8" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_9"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reconciliation of Equity and Long-Term Investments Balances</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd774e5e-4315-4957-8ab1-046076fda2ba" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in balances in &#8220;Equity and Long-Term Investments&#8221; as of each balance sheet date:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.757%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity and long-term investments as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40e292bf-8751-413e-9f09-0f3304f7c00b" contextRef="C_a6f00937-2ee4-4566-bd68-45c44b998d3b" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">444,432</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of trading securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75d1781f-2f99-4c44-99db-3c2712dacb9a" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,201</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41a7b881-d5b7-4d0f-b939-13c3783b5885" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,161</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reclassification of current portion</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8651b825-3a8f-4c64-8420-f903e285d5d0" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:ReclassificationOfCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">107,532</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fcd1e4d-890b-4d1b-8793-4da7daf054f1" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:OtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">724</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity and long-term investments as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28ef20f6-4c3c-4a87-b2b8-5bd6cd35031a" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">341,664</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of trading securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd6a7635-ce74-4ef6-98dd-5aba91762b92" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,729</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from trading securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f906e999-b79a-4c87-8c92-b1a8b26648e9" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ProceedsFromPaymentsForTradingSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,427</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of equity and other long-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb567f8f-ee8c-4093-b16c-59247713f67b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:PurchasesOfEquityAndOtherLongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,533</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net sales and purchases of investments managed by ISP Fund</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50d14c73-6510-4441-97c0-025061836b8b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:NetSalesAndPurchasesOfInvestmentsManagedByISPFund" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">120,955</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecc7b719-eda0-4988-bd1d-f465e1b40daf" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,160</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reclassification of current portion</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a5ec082c-2cdc-4d1e-94e9-969357dca431" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:ReclassificationOfCurrentPortion" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91,805</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a630356a-1ee7-4686-8b56-09f22853eac4" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:OtherIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">988</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity and long-term investments as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7efd990c-f2ac-4dd9-a89a-d406252af3d3" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">404,497</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Available-for-Sale Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f5e89bb-826e-40e5-b318-6a211dc77a71" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.867%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b904a8ef-a45a-4492-8701-2393c7419d8d" contextRef="C_9ce90413-1653-4365-815b-e666974c1fc7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530,278</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fb85da1-cbc3-41d4-a51d-07fc5150ec6c" contextRef="C_9ce90413-1653-4365-815b-e666974c1fc7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9118e54a-a9f9-49ab-b4bd-5e6b51bfb0c2" contextRef="C_9ce90413-1653-4365-815b-e666974c1fc7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8527f5f-0ade-4a50-82cb-a323f0a7eeff" contextRef="C_9ce90413-1653-4365-815b-e666974c1fc7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530,278</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_579d0a3f-fa5b-4187-9a69-d9d562b35dae" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530,278</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2077ac35-fe88-4a43-a84f-969a9c99cdc0" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f9152b4-6c9c-4e14-b33a-eef7294cab19" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1db657c6-2160-4ab2-88b2-39cf189dea2c" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530,278</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_fa630cd9-d3b9-4ce5-bce3-2719848ceec9" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.867%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.222000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e0f8737-3df8-4207-9d21-7b3dde1346c3" contextRef="C_f39f8aa8-a20f-4ba5-a3cc-dabb232aa3b7" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,441</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe172cbb-06cd-4ace-980b-f77c69728f3c" contextRef="C_f39f8aa8-a20f-4ba5-a3cc-dabb232aa3b7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7e2aa43-24df-4446-a31c-e9588f387342" contextRef="C_f39f8aa8-a20f-4ba5-a3cc-dabb232aa3b7" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1a4bfda-d5e2-4288-afe3-91da9698ed2f" contextRef="C_f39f8aa8-a20f-4ba5-a3cc-dabb232aa3b7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,441</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa9b4387-6009-450c-982f-b4df5299d4ea" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,441</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c463401-3ed3-46ad-89ec-0ee19e452cff" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f5e04d02-5a3e-4846-abe4-05e098b47149" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7811a636-5103-4429-9abb-d9cc0b5c1a96" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,441</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_30a29ac4-a358-403f-922e-b22439018a34" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, all available-for-sale securities were money market funds, and there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0757825a-49f0-4a62-a20f-d1f1ca0acec4" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_2e83fa3d-a278-46a8-9cf9-8db6a6bb0dd4" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> credit loss recognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">124</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_9" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_10"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><div><ix:nonNumeric id="F_37f390bc-0ad5-495e-a717-65944cca787d" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" escape="true" continuedAt="F_37f390bc-0ad5-495e-a717-65944cca787d_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our available-for-sale securities and equity and long-term investments are measured at fair value on a recurring basis and our debt is carried at amortized cost basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:39.772%;box-sizing:content-box;"/>
         <td style="width:1.38%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.678%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.38%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.678%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.38%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.678%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.38%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.678%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2025 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Price<br/>in Active<br/>Markets for</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identical</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Observable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unobservable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Types of Instruments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3385c849-0e0e-48f4-aaf2-49a2a6f4fc2a" contextRef="C_62615169-458a-41ad-b0f4-aecf5d54890a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530,278</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba9d7e60-a84b-4e9d-ab64-38f653839f37" contextRef="C_df8082d5-dcbb-46aa-82da-38d9db7a2979" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_209a33bc-0b8a-45bb-9feb-de61d2fdbd10" contextRef="C_f6ee4728-a9e0-452b-8662-22a92283709d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a32560a-55a8-454d-9b09-1257f555bb65" contextRef="C_647c691b-abd8-4afb-8bcb-ba9c9d68ba72" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">530,278</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments held by ISP Fund LP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_854d5c73-7f01-4545-95e8-e2cf9a535941" contextRef="C_3ada3581-7aa9-4d91-ab9a-3ad5ffab6e1d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,993</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c85971a2-1083-4862-9188-16ee90c71474" contextRef="C_fa0155b6-2f2e-4092-af25-363aa5a35539" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_685aad3a-8832-4e25-96b6-cf8c3c03554a" contextRef="C_70f1d216-d03c-43ba-a8b1-76808b9d2366" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,748</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70d130c8-c8d0-4215-ab3b-e1349c288725" contextRef="C_88e66bcc-24ad-406e-bb93-f1e47d153eb0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,741</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_efe5fdd9-9a6d-440b-88d2-55e1c4429b67" contextRef="C_49e868c2-e9b1-41c3-8d56-b409dce02365" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,482</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6c90d78-9e2b-46a6-82ae-4c033587746a" contextRef="C_2c380213-e903-4976-8194-728662767074" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d52007e-a9de-4793-9983-8f2ca0c860aa" contextRef="C_24bf9896-d71a-45ca-9736-8cff19c13d9f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0a9e2cd-3474-4d80-b21c-645949a40b36" contextRef="C_13e41928-9dbd-429d-b2f6-fb0ccfd61a94" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">157,482</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c58912d4-0670-464e-9545-6c8f6e296a24" contextRef="C_1bf402f1-50ee-4c77-b54f-409f40ba6ea2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c54f1b25-6181-4ec2-97c5-5702fa834a43" contextRef="C_133b0bae-f820-43d4-8c70-d35ec0ec6a0f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,244</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23aa11d9-b8b8-4877-a256-1c5083f7c671" contextRef="C_7d17d6ba-9603-4070-a7ab-088eeb43a446" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e11949e6-ce29-42b3-ac62-528809f20ab5" contextRef="C_04f37986-0461-4c18-9d26-c9e485b3a1d5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,244</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6a3ea3f-1243-42bc-bfd2-0376d29c5ef5" contextRef="C_3e7b3a72-d1b3-43e4-a867-2e38a049c660" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a128ad2-6d19-4607-949f-f43c5fa1c1ff" contextRef="C_f96d3f3b-e048-40f2-a04c-39e52cb01dc4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4753a701-b63d-4543-a1ad-f285ac18d207" contextRef="C_fef5d651-506c-49a8-b89f-8a979f8b0712" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_94206293-9352-4579-862b-be0f954f954a" contextRef="C_5ec47d1f-c03d-4375-b74a-6537aa407098" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata July 2023 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_32cb61c0-a54f-4e9a-a515-e3777a476887" contextRef="C_eba3e649-4d0f-4556-81f6-48a349c1b9b7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ef0b0a9-c692-4398-bf4b-a31753f7e849" contextRef="C_151edb34-8ed3-48db-aae7-373a462d2c87" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17978b09-de37-4346-90ec-7460e94b02a7" contextRef="C_af76bb07-dc3c-4511-8750-d747dbdf4012" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,899</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a176a085-dad8-4d38-aa67-3313b57fb863" contextRef="C_2e76908f-28df-4262-a9d3-0d9661155721" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,899</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata March 2024 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d736cb49-4653-46b1-9b62-9c4898dce009" contextRef="C_c010fb75-cf30-4376-bfd0-a2b399f45c3f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3f59b6d-fac1-4025-9411-603052b26f36" contextRef="C_077e2b7e-cd2f-4e0b-80c3-1c50fe7f09df" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45fbc447-208b-46a0-ad6d-0c4c2f5c084b" contextRef="C_57a06a6f-d5cd-460f-9bf8-b3b9d0f6d3ca" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,290</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d15c624-845a-4574-b5e7-96ae0ed24e8b" contextRef="C_6e51128a-27f4-498a-bddc-0169559f0163" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,290</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata March 2025 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c936d40b-b6e3-409c-9013-693a9c964dc7" contextRef="C_4a9464c6-6ed0-4486-afcb-9d89092af626" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c8b5a20-fbfd-4fa2-a576-b20500f68ca7" contextRef="C_062943f2-bfca-4bcb-a912-8bfca3373967" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ba1a8ed-1f96-41ff-bcd0-bd97e20d8a6f" contextRef="C_207224f1-5a67-4870-8fb6-e8fa25e508c4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,125</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_833fd626-9e0e-4bff-a3d0-2f224ff6a388" contextRef="C_9c250d42-4b6f-46b7-8b87-dfca0a66338c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,125</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata August 2025 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f11a2501-0e6c-451a-be44-00275a9c894c" contextRef="C_324ea22b-17bb-44c8-a2ce-76361d644371" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d0eab59-9d7e-4e49-a572-2e11405f5962" contextRef="C_f112be36-1143-427f-b42f-2840c6a15d3e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c20a5ae-183c-43c4-a03c-1e7fc757836d" contextRef="C_7f44cb79-0c20-42d0-9a50-561aefbd0d23" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,534</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_422adbf4-1243-47c8-b006-5eda373adee4" contextRef="C_9ba2a047-11ad-4eed-8953-9ae11217e2fb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,534</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Armata Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf388846-54f4-4d94-a9d6-ee4a0662e4b8" contextRef="C_01846029-76af-4077-9228-68d2343d26d6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8375d0a-9805-4377-9ae4-49835397cd4c" contextRef="C_1c131411-afe9-4c15-b977-6fd724e284dd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a13e671a-c3bd-4c63-a4bd-4ec1afcd4a68" contextRef="C_10c7d0e1-daac-48c6-9186-bfc925a49e65" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,358</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd6fba17-9d58-4982-b506-7d839cd7f785" contextRef="C_9064ceea-cc8b-4413-9774-0740e1e4c1bf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,358</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda 2024 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_909081c8-86cf-4e80-b90a-e11826bb856a" contextRef="C_f3e35d02-64c1-4f38-892b-bd07f5fe2a4a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4614d736-dd34-4508-886e-709e43e8006e" contextRef="C_4c9b62cc-926e-4197-953d-72eddcf7b41d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63498d0e-d9c3-4645-9867-fc8602477d88" contextRef="C_df9c0c3e-3b7d-4a88-ab6a-0a4e4f883405" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c005982-454b-41a1-8e7a-b22c2653c409" contextRef="C_7a5124fd-be46-415a-bd57-ce5d37c15986" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda February 2025 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29fe241d-bb70-49e1-b159-478da69c07f0" contextRef="C_af252bef-3fef-4ac4-af1c-26d65e57e80a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd2ae677-7c0c-4602-bb86-2579a118ed0e" contextRef="C_c99c2a28-4992-4873-a475-9fde89e0026a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3041495-2bc1-4ef4-b2e0-5e735673dc6b" contextRef="C_b996eed8-dfe9-4e4c-91e3-6efd62f73797" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce750aa1-08d6-4155-aeef-1109da06b25e" contextRef="C_fc19a322-7a4a-4f36-9e91-32fa80c03ca7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">475</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda October 2025 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cdc5c55a-d0c1-43ac-a5c0-7400f5fbefaa" contextRef="C_3d13bbf9-1c66-4a28-8180-8bf6ce3c7cf1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fe7fba6-5300-4cac-a313-49517fa4dfd3" contextRef="C_e6f36795-3f29-431e-b5be-67d9a5b96459" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9055cbe-256b-445a-8f54-e02c884e1e77" contextRef="C_725e5a87-52ac-4ac2-b62f-1bd660bfb6b3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,225</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b81f6ba-5f89-4010-be15-91db2b0873af" contextRef="C_7c5e8ad9-8a6d-4d11-ab0d-a7fdde037e56" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,225</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Syndeio 2021 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a317afb-a289-416c-8dbd-4208f2cf89ce" contextRef="C_b59f5a94-681e-4e5c-b302-d0358109e1fc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c03b1e0e-25ef-4d96-8d3b-792903a98ce4" contextRef="C_034d4c49-cf20-473a-895d-63d5870c2084" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cb7358f-b12d-479b-bbaf-2dd509356fd9" contextRef="C_ca9df07c-03f1-4863-b309-11e88116df42" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,937</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79c81cfc-0c68-4692-aee3-7f0d689f10ed" contextRef="C_535e864a-6312-4cf7-8e63-b685970f14e7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,937</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Syndeio 2025 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8297cf80-7b8b-447b-8759-3fb6ad192ba3" contextRef="C_a94d4668-3b04-4736-b7cd-35be25a3ced1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b31e9123-6376-49c0-a3c8-8571c33a5999" contextRef="C_948f1041-1e2d-4225-b512-dbe9786f6151" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6f5607d9-c85b-49fb-90d5-830b1390d352" contextRef="C_d1a545a6-5a9b-4ad3-bbfb-5c5207b1a1f9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,490</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c96d4d58-7e46-462a-a74e-c80e4c654edb" contextRef="C_d84e455d-e7e3-4fbe-a104-3abc49e8a445" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,490</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Lyndra Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cd40079-d9a1-48b7-bd3b-0d0c0fc28be8" contextRef="C_e04b23c0-4934-4a7e-8859-cd38d15f9bd3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18474b6a-d2f8-46c1-89a8-81b40896bc02" contextRef="C_0a0ea9ec-344f-4309-a3b8-19f6282767a8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a30a4351-ff51-477d-bc48-1342f53a7b6c" contextRef="C_13f8e3e6-05d2-4d76-8e06-db660bf31271" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c2b0235f-a1ca-433a-8ecb-4df81fd125b2" contextRef="C_83fb2c06-5584-44c0-9816-0548d07c70bb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,492</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6924f6b7-c4b9-4bc7-980c-90aad54af7d4" contextRef="C_d9fc309a-2db6-4a93-97f8-d69062730902" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">764,753</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60e1f6d1-cbc6-491d-9ed5-04a659773c96" contextRef="C_be450a6d-2206-415e-accd-57ca23a7c915" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,244</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f4b274e-f185-4dce-b742-f58e44b36a01" contextRef="C_76beba6f-76b3-4d02-8823-4ee147f6a8e0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">300,052</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92928db8-b1fb-4125-a62b-dbb19f3a4ca5" contextRef="C_fa3ac63f-9ac1-406d-b258-7e778b64bfce" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,101,049</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Liability</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fddd53ee-ab09-43bb-82e9-ce1d32020e02" contextRef="C_c66f1b13-03bc-4b24-a6a3-cd400090f9ef" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f60c3796-bea8-4445-985e-a97ec89f447e" contextRef="C_abebdb2e-7b66-4a80-a391-a715e9a19b73" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267,013</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0395d39a-91bf-4696-8eba-45a41e6cbd64" contextRef="C_f4ab2bfd-74a0-46cc-b06e-1c474c19a909" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d07c4497-d553-4c26-9242-814d496a2164" contextRef="C_1006311f-1cec-494d-8c58-386104bc8113" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">267,013</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">125</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_10" continuedAt="F_90286cd0-ee34-465a-acf6-673b6771f4ab_11"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_37f390bc-0ad5-495e-a717-65944cca787d_1">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:40.468%;box-sizing:content-box;"/>
         <td style="width:1.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.402000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.402000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.402000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.48%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.402000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2024 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">in Active</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Markets for</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identical</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Observable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unobservable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Types of Instruments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19efe3fc-5064-4ba5-8f48-1360cd40afba" contextRef="C_874e94af-935a-439b-ab00-df1390a5e34b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,441</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce4cfce5-55af-4135-b112-e1983893bb4e" contextRef="C_4d8ac49a-79f0-4d4e-96ea-3e8f524a2c51" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81ec6b14-e9af-470c-b451-ceebdda3f29b" contextRef="C_58579f73-59ce-4061-ba55-4d11270a76d1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_467d8066-26e4-4971-8be0-f3a6be3b626b" contextRef="C_f2435011-c3ca-4e3e-a7fb-09a9fb137c33" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">289,441</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments held by ISP Fund LP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78c61fe2-ce4d-488c-9696-1c7788273c08" contextRef="C_04c59b2e-4232-4562-8d3a-6d189af3be61" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">193,560</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74972aa7-9db7-4fe4-b2fe-c2ede31b901b" contextRef="C_b2a12880-40dd-4a30-8ea9-b9ba0ea9cc66" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76b841fb-d0ff-4bb4-88a4-a68db0a1c672" contextRef="C_186b003f-7e82-489a-af51-10f17f0c7193" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,098</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ee6234d-dce6-4737-829f-20048ef5f29a" contextRef="C_5a6dce6c-043b-44f3-bc89-efae60e40aff" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">255,658</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ed08e95-1f1f-440c-a18e-d05df3f9b9f5" contextRef="C_d9f02cfa-bf5e-4cd1-b720-fcc2c4210f0b" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,392</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48fa713d-08a0-4dea-967d-43225d7125e6" contextRef="C_cb2b5dab-8579-446e-acf0-02b095195b73" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce39dcf7-e01f-43dd-9bfc-4a55be9a2b37" contextRef="C_1c0b66f1-46ef-4338-a79e-85c6fc2d1f95" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c90d2e95-fc96-431b-b0d9-9693a5fc92d6" contextRef="C_920caa91-234c-4ad4-9f03-0cc64046f9bf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,392</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e1c5a67-4b4e-4b9e-8768-77d07f0d5745" contextRef="C_80b69809-f556-4828-a636-e7d70a0f4529" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0d3156d-1f19-4530-b0ef-a540cb653eef" contextRef="C_41a7f5f8-871b-473c-8a7c-344fe2fe6e67" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,901</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec0f8b73-d6f5-4933-ac77-52fd4d2863b4" contextRef="C_edc82119-8135-4036-9cd5-7abc8eaec84c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b148f9a0-3623-4e17-82ac-d0a0d1356588" contextRef="C_9ce67c09-bbaa-4af5-9443-47f86c908063" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,901</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e76980d0-76b7-46b6-8a99-cc154975b57d" contextRef="C_b25d8758-99b0-4893-a9e8-7d66f0af9020" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_134757c3-8e01-46b0-a4ef-6f66e962cdd0" contextRef="C_d68a48b8-3d2b-4af8-8344-60a112a209cf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1bac985-3f87-49e7-8111-78b2f048f677" contextRef="C_c6c8e559-7887-449a-bda4-21ea384a9d5d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e1151ec-470b-407e-a8c2-77809c0547d4" contextRef="C_4a06a460-8b26-42e1-8a9d-000242e512f8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">59</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Armata Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6912d824-772a-4f68-8b0a-ab7a06786a7e" contextRef="C_8e78c83c-a602-4c9e-a0ca-fd8929e943fd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a830ba07-72df-4bc2-a671-560f980b315d" contextRef="C_df4709cb-5656-4808-aaeb-b3ae91bc5fa4" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df1a7419-35eb-4e59-a705-01702846dd78" contextRef="C_b4c7d24e-1946-466d-b882-1f82aca2913e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,095</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa914f92-9deb-42b2-91fc-de5938eb8933" contextRef="C_98398386-f407-4e2e-a939-d8ab60856a68" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,095</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata July 2023 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ac1554a-bcbb-4b90-ad8f-e0d81e8e8e78" contextRef="C_e82b4635-6ed4-4056-a68e-3a47f6f2bf52" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90c264b0-151e-40b4-baf1-f18b96933210" contextRef="C_b3f2abfb-4337-4fab-9c5b-7e5c28bbffed" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_131b6cf9-d35d-44ff-8b63-2236450225da" contextRef="C_5b273474-f0c1-4173-8aa0-26b3ab51f2c6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,197</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_72d5f8b3-1691-489d-afdd-c52cc0558656" contextRef="C_b4d781bc-915c-4c41-9106-511763a665d8" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,197</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata March 2024 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6bf19212-52aa-489c-bd57-6024cf61ccb9" contextRef="C_bf257858-aaa7-4585-83a4-5200623ef35c" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e695b5ac-d17b-4afb-97aa-0fa49e038af2" contextRef="C_d5482eb7-e694-4625-b420-b8cb85d4fcf2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fc8ccb6-74ea-4932-ab87-cf409d286ddf" contextRef="C_9dfa9bcd-fbe2-4b00-b6d2-00a31a357835" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,275</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6071f9db-47f6-4142-af6b-7da9f7265259" contextRef="C_019d5edd-4fa8-40e3-80df-2efde6dc1a3e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,275</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda 2024 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ccab1b1-9e09-4cb6-9246-a1396af324fd" contextRef="C_9c1f6269-1e70-48f2-b51f-c346e1e9651e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b5c1c9dc-e6f6-4c7b-bc99-4a249b70b8a9" contextRef="C_6eab99bf-0d7f-4d97-8fbf-07f56573bf4d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b497b768-5600-490b-90b0-db012b4de052" contextRef="C_91adb269-1218-4185-8ed5-66c8ab8bbcdb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_576141b2-d303-496e-b66c-f8969b6a493d" contextRef="C_e1ad7b2e-47ad-4939-9a26-e2ea2a39b2c6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - ImaginAb Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf6fca22-7e1e-4d33-9b57-63cdbf955b80" contextRef="C_c7ab2f82-2276-40f6-9084-327d9a8463bf" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da8dee64-e9b9-4d15-b434-f4fd9039474c" contextRef="C_f35060c4-ee1e-4ad2-ba59-f9405ab750db" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d42780db-7120-4a65-b14f-c12045dada37" contextRef="C_354e4e76-7396-4ce2-83c0-4f6d52adcbf7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,950</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba8a67a9-1065-437e-9ad5-262be17b5b6c" contextRef="C_f95dc6c1-8efa-49b3-a724-7a4ea46f1fbc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,950</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Syndeio 2021 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_653c732e-4d09-4e54-a6d6-831b299bf58e" contextRef="C_f9ab7abf-030e-4411-a666-c1a654015dea" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f2f8fa-5c1b-41e5-bd89-5351470b422b" contextRef="C_382fda11-b7da-4cb9-a380-3dfa11099b27" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98d16eaa-9414-479e-9e43-dff4be1e125f" contextRef="C_27718624-7715-45b9-a713-59141c2cdf0f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,881</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_76283d83-93b7-4f72-8c83-e908f37fa28d" contextRef="C_3429ea6d-1cb3-4c6e-8042-4861d0863d2f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">50,881</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_04851793-707d-4e81-b70e-794d659d23bb" contextRef="C_d5e9003f-7e55-4b05-bab9-c11fa367b435" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">529,393</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9974db22-e22a-482e-a51d-d6bcc950ffb8" contextRef="C_f9011696-e416-424e-81a2-652447e4d8f0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,901</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e16c2ab-05ae-40c7-acce-38e11d1f2415" contextRef="C_87678ce3-d91f-42c7-8014-482b4e96c0b6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">229,991</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4487f626-08d5-4a4b-8ca9-65ad5470be25" contextRef="C_0f301d28-22f6-430f-bd52-f18b4ca91181" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">765,285</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89d301bf-3f72-43f6-b9e9-003d327bb567" contextRef="C_4960e33b-4020-48cb-aad3-a6b5f4fac807" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c06e74e1-0fc3-4e63-ab85-62c69dd1b627" contextRef="C_7b057564-e9a8-48fe-95f4-7b1c776ce39d" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,353</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c10df1cb-8c34-4177-9103-16c0d69222b4" contextRef="C_c9dd44c1-e335-4444-826a-cca2d606205b" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a96d51cb-c30a-42dc-9d7c-ef36b34548e2" contextRef="C_3b886698-cb56-435a-ba7f-fa72f4cd20b9" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">222,353</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98bf1499-fbe9-491d-a81c-2dbf099e09d8" contextRef="C_10e3877c-4d15-43d4-acb6-50c1c5281ab9" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_167d3406-06d7-4744-9849-9604239efced" contextRef="C_edef9231-0188-4d5f-a4e7-cf5bc1070d0b" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,213</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d22a06c1-7be8-47f9-a4d5-678095c072c7" contextRef="C_8baf7a29-4878-46db-844e-4be322782050" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e357086-0c0a-4155-9bb9-bb8b7a32a972" contextRef="C_dd617a60-08f2-42eb-9dd4-dfab3845fa6f" name="us-gaap:ConvertibleDebtFairValueDisclosures" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">251,213</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fair value of debt</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4c43cab-86fa-4d7e-85ed-6a47edd3859a" contextRef="C_39ac42ec-d15a-4d4a-8811-92be23f2bc67" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0098ca04-f1c5-4f5e-8765-5a47596dfcca" contextRef="C_0d289cc8-a708-4fdd-8986-e982ca8d731d" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">473,566</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b07d18f0-f895-4531-8ca0-ec45f7c0973e" contextRef="C_55bf4b19-2b2e-4acc-9932-1d7bd7182c58" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c7caaf4-5c3a-4912-ac68-aeee76ff49dd" contextRef="C_81f83795-0714-4c71-99b4-f4a03319bbcf" name="us-gaap:DebtInstrumentFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">473,566</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_504f5e78-1164-474d-8fef-c81dfd51af2c" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:FairValueOfAssetsOrLiabilitiesTransferBetweenLevels" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_413dfdef-d7f7-4da6-b191-33bccfaa74fc" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:FairValueOfAssetsOrLiabilitiesTransferBetweenLevels" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between Level 1, Level 2 or Level 3 during the periods presented.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of our equity investments in Armata&#8217;s common stock and publicly traded investments held by ISP Fund LP are based on the quoted prices in active markets and are classified as Level 1 financial instruments. The fair values in the warrants in Armata classified within Level 2 are based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investments classified as Level 3 financial instruments are securities that are not publicly traded and the assumptions used in the valuation model of these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies. There are uncertainties on the fair value measurement of the instruments classified under Level 3 due to the use of unobservable inputs and interrelationships between these unobservable inputs, which could result in higher or lower fair value measurements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span><ix:continuation id="F_90286cd0-ee34-465a-acf6-673b6771f4ab_11"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of our 2025 Notes and 2028 Notes are based on recent trading prices of the respective instruments.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">126</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_44838ae3-e65b-462a-b753-df241229ffb1" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:CapitalizedFeesPaidDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. CAPITALIZED FEES PAID</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ba72ce08-8b98-41e2-a106-ad27b6eb974f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:CapitalizedContractCostTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:14.749%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization period</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2013-2030</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_95e341dd-7bfb-4870-bf2b-669b1d8ce094" contextRef="C_cd026123-bf98-4ceb-963d-51e954864642" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0617387-b1b4-4de6-b0da-477a9d8c3bca" contextRef="C_89cd5c2d-43bc-4a05-9084-5d42b8515c2a" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">120,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2013-2029</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aed12c6a-d60a-432e-a379-76ccb5ffcb61" contextRef="C_be14d1aa-9ffc-4de3-b4ae-142c0c538bae" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5669f72b-d352-4ec7-a91a-f152b4b6c5d7" contextRef="C_c301f3b4-0e6f-4ec9-97f7-2af4d7bc4e41" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">60,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Japan</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2013-2029</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91601a06-e544-4a0c-a69f-0bc3006ecd6a" contextRef="C_298833d0-f7cb-4ad7-b8ba-9b8369ac087f" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfe41d78-d05c-4e06-a953-59c3b96abf19" contextRef="C_0df4c929-c558-43df-b2be-57f8e85bb27a" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross carrying value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c08689e5-8e73-4bec-a6a7-a9a41245e752" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62a55d4d-3eab-4dcb-9692-4514419693b7" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CapitalizedContractCostGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">220,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a8f346c-ae45-49cb-bceb-5bd6e987668a" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CapitalizedContractCostAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">163,862</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b876b20-f656-4c9a-bd56-9782b4ed7e59" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CapitalizedContractCostAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,039</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net carrying value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4efbb3a6-c0c8-48a7-8790-b14ffd4f420f" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">56,138</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d66490f7-8bda-4230-9400-df583ce2ada5" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:CapitalizedContractCostNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">69,961</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2025, the weighted average remaining amortization perio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb93a92b-6c12-4812-b76b-59fc9094a264" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:CapitalizedFeesPaidWeightedAverageUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.2</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> y</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ears.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional information regarding these milestone fees is included in Note 3, &#8220;Revenue Recognition&#8221;. Amortization for each of the years ended December 31, 2025, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad3e61d9-22f7-4805-8095-df701f792579" contextRef="C_486828c2-55c2-4eca-a8e9-7c9edc91e774" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_90d8775b-7892-4dd6-977f-22c43af3dace" contextRef="C_8c3d0ea3-a6a0-43b3-ad32-fa7162ce8c28" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_94e7648f-d1fe-475f-b415-e0eb66b0fd71" contextRef="C_02167381-4ee7-420f-9702-aa51b2304727" name="us-gaap:CapitalizedContractCostAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.8</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The remaining estimated amortization is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bce541df-568e-4eca-b538-b8d278de7e73" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_a0755e13-9157-48a4-ada0-4cb89f2886c7" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.8</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years 2026 and 2027, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30dcad74-1282-4d9c-bd4f-8bc59d64e863" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year 2028, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fef21174-e954-4355-a304-b7b8eabab2db" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year 2029 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f719e638-3b17-4e28-ad6a-0af9ca4005e9" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year 2030.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_7d6a4308-a54e-4fe9-94c2-e65ffb173aad" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true" continuedAt="F_7d6a4308-a54e-4fe9-94c2-e65ffb173aad_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. GOODWILL AND INTANGIBLE ASSETS</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized goodwill of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9c313ae4-ca1c-4c28-9af3-4b803bdfb63c" contextRef="C_967bf8ab-5e86-4683-ac2b-d23837fdf808" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc16915a-b196-4628-bbc4-dba4d82ae4bb" contextRef="C_7e124fea-d3ce-4c96-a71c-c223da3547f2" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from our acquisitions of Entasis and La Jolla, respectively, in 2022. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amount of goodwill as of December 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ac88cb9-f9ba-4187-af17-73531171569a" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_d1df9ce0-9052-4436-bf52-eb30c0928f0b" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.9</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e1982a1-eafe-4045-9519-20a663cd5844" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_7945f361-cdd0-468f-9b54-c68ff6227156" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any impairment losses related to goodwill and intangible assets during the periods presented.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets with definite lives are amortized over their estimated useful lives. </span><span><ix:nonNumeric id="F_12d3dc73-37db-410b-aa12-1bf235409905" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" escape="true" continuedAt="F_12d3dc73-37db-410b-aa12-1bf235409905_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying basis and accumulated amortization of recognized intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 were as follows:</span></ix:nonNumeric></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_12d3dc73-37db-410b-aa12-1bf235409905_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.86%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:14.24%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketed products</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4e60471c-a6a4-4d6d-85d7-e42c02d0c63c" contextRef="C_4cc8caa7-35e9-4140-a986-58a3062ca160" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_6b206486-2d9d-471b-9b6e-3a46f95fa28f" contextRef="C_9e87c016-5304-4333-83a4-195cc836505e" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02d23618-2cb9-471b-8b78-9bc39e3eec40" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:IntangibleAssetsMarketedProductsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">226,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7f1e0af-b8f3-46f1-be30-c13719e37951" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:IntangibleAssetsMarketedProductsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,299</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb71fc8b-fafe-4ea8-ae14-e17b72634d28" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:IntangibleAssetsMarketedProductsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">156,001</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration agreement</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_832a74ac-1922-4023-bce7-a14bdbbef3e6" contextRef="C_eb066d70-0444-4376-99ff-812e92abf2af" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a433aa4-680a-44fe-bcce-a671930fef52" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:IntangibleAssetsCollaborationAgreementGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0ee6594-8afc-4889-b7c1-d97a8ec25ced" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,245</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e1aaea7-b609-4844-9d72-10f93ef7627f" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:IntangibleAssetsCollaborationAgreementNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,155</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e71149c-36f4-474b-8381-c9d58e39e295" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89e00000-0662-4a19-8c6b-4b1fcb727ef9" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">79,544</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f4af87aa-d948-42f2-a6d9-23214bf3a47d" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">182,156</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.86%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:14.24%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.56%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.22%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketed products</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8d652d9e-1bba-4dba-9744-5720a8568096" contextRef="C_469524bb-7a40-45d6-add1-6f69d2db9a3e" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><ix:nonNumeric id="F_7cfed12a-b71e-443c-8b3d-b82c624abce2" contextRef="C_37077e55-6b0c-4d75-94c1-1392a17c7ed1" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48b1f2f6-12b5-4d16-b382-482288eb1a53" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:IntangibleAssetsMarketedProductsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">223,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_697d16c3-1ded-4a54-8502-43d68b365dcf" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:IntangibleAssetsMarketedProductsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">47,559</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65f7bdbb-341e-417d-bc32-afea58f889cb" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:IntangibleAssetsMarketedProductsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,141</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In-process research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07b21d2f-500a-4f50-bd26-038155a87b69" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,600</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13d4ce30-b7fc-4507-9333-a12d4b893114" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4870ef58-cf74-4fc0-9b3d-ecdcdf2550c4" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:IntangibleAssetsInProcessResearchAndDevelopmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,600</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration agreement</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_0e4c6c69-8326-41c3-b330-8292eb49eb85" contextRef="C_7359dc8f-bf3a-4063-889d-7a710c70a4de" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98f3a623-14fa-4882-b29d-7b253e70b4a2" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:IntangibleAssetsCollaborationAgreementGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,400</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fc683bd-15e4-40f4-a947-b679f25ff303" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,708</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f6a4cea-fba8-4b32-95fc-f90298fdbd44" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:IntangibleAssetsCollaborationAgreementNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,692</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1842942-a677-4fa3-968e-86ef98c1a9e1" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,700</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c67a854-d68b-4ca8-b738-8ba790a1e14c" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,267</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5ad5eb3-c2b4-429c-85a1-36ceead11f49" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">208,433</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of Entasis amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0709cde3-1abf-4b5a-872c-c1a7cf8807fe" contextRef="C_f9cd9435-3b1a-4e9d-ac1b-86dd50e61463" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">106.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which consisted of Entasis&#8217; in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ff6d222-2be6-4718-847e-e04d37957f43" contextRef="C_1178105a-9678-4a5d-807b-d01114fd7f0f" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">71.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbcb0668-8c8d-435d-b373-9d5471a3226d" contextRef="C_65e0e8e3-95a0-4c30-a38e-3f2f6d7a9494" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Following the FDA approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in May 2023, we started amortizing $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99ee53b3-25db-414c-95df-f1fb497af612" contextRef="C_cd1ae492-3baa-4fd2-89f9-afa8f30347b3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">68.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives. Following the FDA approval of NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (formerly </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">zoliflodacin) in December 2025, we started amortizing $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b4be0731-3ffe-4920-a9f4-c2a9850416ff" contextRef="C_3d42c24b-11b8-4363-8d74-c335ae153268" name="us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the then in-process research and development as a marketed product over its estimated useful life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">127</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_7d6a4308-a54e-4fe9-94c2-e65ffb173aad_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of La Jolla amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc7dd3c8-16fc-4215-92d7-15b15ee0faa6" contextRef="C_624b9c2f-920f-4d24-9aec-1525f5843027" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">151.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million pertain to product rights and developed technologies on La Jolla&#8217;s marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in Note 4 &#8220;License and Collaboration Arrangements&#8221;, we capitalized the upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27081c65-53c5-4c65-b7d7-d7dacb1003bd" contextRef="C_c76fc58c-a666-4494-993c-5441e34ded35" name="inva:UpfrontFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that we paid to Basilea </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the exclusive commercialization right of ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. under our exclusive distribution and license agreement as an intangible asset. This amount is included in marketed products in the table above and is being amortized over the term of the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized amortization expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8e487f20-a4d2-49b9-8fba-35eaea0e929c" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbb1f632-f7e6-449b-8790-e313dff81adc" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_48ff2f17-430b-4160-85b1-d0ecb18d2442" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2025, 2024 and 2023, respectively. Future amortization expense is expected to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd56f22f-9aa7-4354-ac91-832a54924399" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_acbb6081-fba8-448c-b8bb-a3583bd33a11" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_ca260027-6ae2-450f-bf72-096cc59373b2" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_e4499451-7ad1-4477-aaa0-a644a6a5ebae" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6ca8b2d3-0546-40d1-9ef6-4ed2d26ff1c6" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">26.6</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years from 2026 to 2030 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec5eccfe-63fa-4e6d-806d-aae603bbd3ac" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">49.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million thereafter.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_14c62ab4-c6f1-47cc-8c0a-46f65124c613" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true" continuedAt="F_14c62ab4-c6f1-47cc-8c0a-46f65124c613_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. BALANCE SHEET COMPONENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventory</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_5e4c26cc-e8ea-455a-aa06-af0f12b42e55" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2832720d-a2d5-407c-8c2c-e3681e0155aa" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:InventoryRawMaterialsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,330</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c046cf95-39da-4c31-843e-cc74d92457b4" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:InventoryRawMaterialsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,113</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work-in-process</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4e1eb1b-e072-47fa-b5c0-ae70de9439ae" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:InventoryWorkInProcessNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,871</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2f373b60-676d-47bd-9ed2-083f3d0c6cee" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:InventoryWorkInProcessNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,529</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e8cdfdd-f1c7-4cf0-ad4e-c21949cd3b2b" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:InventoryFinishedGoodsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,971</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb223db6-315e-4391-802b-66d34ee69e01" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:InventoryFinishedGoodsNetOfReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,083</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventory</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_583620e2-0aa7-4dba-ac64-5e2d9428dab3" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,172</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_934f3582-ce2b-472e-813f-93792a76e578" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:InventoryNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,725</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2024, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce4a14cc-eedd-4a94-8f9d-582873f55d12" contextRef="C_099aecd1-7b7a-4a20-9f80-16d10bb47ae5" name="inva:FairValueAdjustmentsOfInventoryFromAcquistion" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0fe040f2-e358-4c33-afc8-a42e2158b422" contextRef="C_701cd6fe-36d1-47db-83fe-0af44777997c" name="inva:FairValueAdjustmentsOfInventoryFromAcquistion" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will be amortized and recognized as cost of products sold when sales occur in future periods. The fair value adjustments recorded as part of cost of products sold amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_906c3220-84b2-4dd9-aa44-592d6e734c4b" contextRef="C_fa06863c-352c-41d4-8c55-7aa19e82ca77" name="inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_22fa091e-c3b6-4447-8b82-49b4f84f2be3" contextRef="C_65d91678-0767-41c7-b95e-8b5037c60129" name="inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">13.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f6d2bce-ab3a-4ec8-86f5-1297a7708d8b" contextRef="C_4d8365a9-4d70-40de-b8a9-6b5b33f255fb" name="inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">27.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Accrued Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3c373ad-2809-4a9e-bcfa-db999123a047" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other accrued liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued contract manufacturing costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d9961a1-2bd5-413b-b436-cce4f0f9fec7" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:AccruedContractManufacturingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,220</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c0418eb-4e6f-4f47-a9c9-cc5303cb36c0" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:AccruedContractManufacturingLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,071</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical and research expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4cd8463-1c6a-4fc2-b4cc-cd34392a66c8" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:AccruedClinicalAndResearchLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">185</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d49e95e1-c9b8-42e6-a448-99f3cc0158c0" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:AccruedClinicalAndResearchLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">611</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3fac3efa-2ef3-4e3e-9fd3-a3caf77d61b6" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:AccruedProfessionalServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,845</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5a3a576-2cc5-4e02-94b9-e5aeccb2dbe3" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:AccruedProfessionalServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,682</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6a206859-f8ee-400b-9d66-43ec2846665f;"><span style="-sec-ix-hidden:F_17be60db-4ed3-4806-a6df-7a78528c373a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities</span></span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f32db5d1-2c6a-4b5b-ae37-ccdd6daf937c" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">418</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5aa0fac-f7dc-498f-9200-f0a9eaca7541" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,572</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty obligation payable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c9336df0-235b-4277-979c-d69d0f7f7aeb" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AccruedRoyaltiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,690</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4391b2a9-54a2-4f64-8aec-451f27695715" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AccruedRoyaltiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,951</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of deferred royalty obligation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78855998-5049-4a83-b4b4-209d09e74305" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:DeferredRoyaltyObligationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,124</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d2b98d6-1107-4f36-8b8d-1e94c2805f62" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:DeferredRoyaltyObligationCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,438</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued license fees and royalties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_90457a70-7c28-4c99-a666-429e4b675ee6" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:AccruedLicenseFeesAndRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,964</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce37d009-3822-409f-b4a0-41c594b97885" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:AccruedLicenseFeesAndRoyalties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,727</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7107755a-0b4b-4d35-b156-55487a5c74e5" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,022</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_caa0e40b-6bde-47a3-9868-50a819fdb087" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,947</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other accrued liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_598c0a1b-d70e-4fb5-8ad8-d045219f420f" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,468</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26319f32-b8d7-407a-9f68-0a2a3bbfc250" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">29,999</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_c6ef9b64-150e-40fe-8567-e348fc66452f" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount as of December 31, 2024 includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13fa68ce-74d2-47dc-b13e-5bc34b32b3d5" contextRef="C_2bdbcb89-e8cf-4578-a8fb-ed71c2c5c84c" name="us-gaap:AdvancesOnInventoryPurchases" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance payments received from our partner for inventory supply as discussed in Note 4, &#8220;License and Collaboration Arrangements&#8221;.</span></ix:footnote></div></div></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">128</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_14c62ab4-c6f1-47cc-8c0a-46f65124c613_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Long-Term Liabilities</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_a0499a3e-0db5-457c-b6c0-41c909b0aef0" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other long-term liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of deferred royalty obligation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35d6ad47-4e5f-43fb-a591-832347eb8594" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:DeferredRoyaltyObligationNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">54,104</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e84e633c-4b20-4f87-891d-a58194f62f47" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:DeferredRoyaltyObligationNonCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">63,096</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e88a4c0d-7875-4370-83b2-18dc892d7674;"><span style="-sec-ix-hidden:F_4bc47aec-cd74-43b5-88dc-6e2c9250c57b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of lease liabilities</span></span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02af73e0-a26f-4e17-b21b-9ebed3614e27" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,868</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8d4f8c00-744d-4b34-bc03-d8b19c8f6455" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,179</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28d185e5-6d31-4b30-8795-7e251485e438" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OtherSundryLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,119</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_343f4c05-d396-4360-8d8a-e8b433886129" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:OtherSundryLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other long-term liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3dae1fe4-ef9c-4f69-98b5-c812ea548973" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,091</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41ef06c4-0e88-4f56-897c-12c8a964b8c5" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64,275</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_9bcbfb5d-49ec-4a97-8104-1ddd440b5e64" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_9bcbfb5d-49ec-4a97-8104-1ddd440b5e64_1"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. STOCK&#8209;BASED COMPENSATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2012, we adopted the 2012 Equity Incentive Plan (the &#8220;2012 Plan&#8221;). The 2012 Plan provides for the grant of incentive stock options, nonstatutory stock options, RSAs, RSUs and Stock Appreciation Rights to employees, non-employee directors and consultants. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total shares remaining available for issuance under the 2012 Plan were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd49fbc3-9fdf-49a9-8a4d-dc0db55780a1" contextRef="C_7a708fd2-25d5-452c-aad6-d6903d0cf646" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2004 Employee Stock Purchase Plan (the &#8220;2004 ESPP&#8221;), our employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8639a926-8aae-4e58-8594-5159a54b314e" contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2004 ESPP provided for consecutive and overlapping offering periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a49317ad-8474-4b1c-834f-aefdbac75654" contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24 months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in duration, with each offering period composed of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98f3c29a-556c-45fb-ad45-340cd4c37683" contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" unitRef="U_Item" decimals="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb654271-2575-4c82-978a-5a037b5e8ab4" contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six-month</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> purchase periods. The purchase periods ended on either May 15 or November 15. The 2004 ESPP contributions were limited to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cde8b3b-5e99-450a-bcc0-96b02144db81" contextRef="C_32606254-e0d2-4b64-9791-54065180e259" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of an employee&#8217;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fdd3286-20a0-4d21-a2c0-08100e0fe75d" contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An employee may not purchase shares with a value greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_901f7ca3-a566-4a28-a22d-e1e94a08a62c" contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in any calendar year.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2023, the Board of Directors adopted the 2023 ESPP (the &#8220;2023 ESPP&#8221;). The 2023 ESPP, which supersedes the 2004 ESPP, was approved by the Company&#8217;s stockholders on May 22, 2023. Under the 2023 ESPP, eligible employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00970dc0-1f11-46e9-a878-6130f8df5342" contextRef="C_b3b3003f-d16b-4948-beec-32f75f482d34" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">85</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the stock at the beginning or end of each applicable purchase period. The 2023 ESPP provides for offering periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2b83f3e5-62fc-486e-a560-060a54ced877" contextRef="C_b3b3003f-d16b-4948-beec-32f75f482d34" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" format="ixt-sec:durwordsen"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which ends on either May 15 or November 15. The 2023 ESPP contributions are limited to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf3aff15-4236-4478-86fd-c3d14e328fcc" contextRef="C_b4464bad-246b-476e-bbdb-5189b9e3455c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of an employee&#8217;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b38e2a79-7c1d-4173-a47e-e338a3f12a88" contextRef="C_b3b3003f-d16b-4948-beec-32f75f482d34" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An employee may not purchase shares with a value greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_640b3dce-8a8d-458d-ac68-5847a8e363c6" contextRef="C_b3b3003f-d16b-4948-beec-32f75f482d34" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in any calendar year. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2082fc1d-e700-4b79-a0af-db84fd4e5546" contextRef="C_b4464bad-246b-476e-bbdb-5189b9e3455c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" scale="6" decimals="INF" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of our common stock was reserved and available for issuance under the 2023 ESPP.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total shares remaining available for issuance under the 2023 ESPP were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9020750c-0965-4d1a-9524-b560a07c0200" contextRef="C_b4464bad-246b-476e-bbdb-5189b9e3455c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">2,385,766</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director Compensation Program</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our non-employee directors receive compensation for services provided as a director. Each member of our board of directors who is not an employee receives both cash and equity compensation for services as a director, member of a committee of the board of directors, lead independent director and chairman, as applicable.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">129</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_9bcbfb5d-49ec-4a97-8104-1ddd440b5e64_1" continuedAt="F_9bcbfb5d-49ec-4a97-8104-1ddd440b5e64_2"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our independent directors receives periodic automatic grants of equity awards under a program implemented under the 2012 Plan. These grants are non&#8209;discretionary. Only our independent directors or affiliates of such directors are eligible to receive automatic grants under the 2012 Plan. Under the program, each individual who first became a non-employee director will, on the date such individual joins the board of directors, automatically be granted a one&#8209;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6aeb307c-b11e-4584-996b-93ffd499b74e" contextRef="C_f46cd1ad-fe1b-4bf9-a5a9-24eaba3fb3e3" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">125,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share (the &#8220;Initial RSUs&#8221;), plus a one&#8209;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b64d138-a650-4a3e-a25c-5f97d35e8969" contextRef="C_f46cd1ad-fe1b-4bf9-a5a9-24eaba3fb3e3" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">225,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, which would be pro-rated for the number of whole months remaining until the anniversary of the prior year&#8217;s stockholders&#8217; meeting, rounded down to the nearest whole share (the &#8220;Pro Rata RSUs&#8221;). The Initial RSUs vest in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d57c869b-5f01-4473-986d-dda2b4ef0b49" contextRef="C_0ce3d616-f0eb-477a-96e3-62c320ccd76a" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equal annual installments, while Pro Rata RSUs vest in a single installment at the sooner of the next annual stockholder meeting or the one-year grant anniversary, in each case subject to the non-employee director&#8217;s continuous service through the applicable vesting date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annually, upon his or her re&#8209;election to the board of directors at the Annual Meeting of Stockholders, each non-employee director is automatically granted an RSU covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3713e3da-e18c-4622-865f-f0247739b699" contextRef="C_f09d870b-77a3-4a19-9ef4-c0fee32e4890" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">225,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share. These RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the non-employee director&#8217;s continuous service through the applicable vesting date. Following the amendment to our non-employee director compensation program, both the annual RSUs and Initial RSUs described above remained unchanged with the exception that the number of shares of our common stock subject to each award has been reduced.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These RSUs will vest in full upon the director&#8217;s death, the occurrence of a change in control, or the director&#8217;s disability before the director&#8217;s service terminates. Director RSUs carry dividend equivalent rights to be credited with an amount equal to all cash dividends paid on the underlying shares of common stock while unvested. Dividend equivalents are subject to the same terms and conditions, including vesting, as the RSUs to which they attach and are paid in cash upon vesting.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock&#8209;Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1cadf08-9a7a-4025-b9a3-7f1c61a043ae" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;based compensation expense is included in the consolidated statements of income and comprehensive income as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.01%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.203%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.203%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.583%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1987feb-3253-494a-96cc-653e4a297f1a" contextRef="C_e593a339-fd70-42b1-8675-8d814fad602a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,930</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7259d33f-3f49-4fd7-b4ff-8740617de08c" contextRef="C_e3289eef-c9f9-4a85-b3ce-87f3497ce8fa" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,040</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e39c2d45-005b-475f-8e1b-00f143544b33" contextRef="C_79652bcd-01ee-4bef-9367-fe4171e3c756" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,645</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_323115da-6a99-4517-be53-874ea73344e8" contextRef="C_338be7e3-2228-4533-9b23-3397a873d3d9" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">522</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8152b947-4ab0-4d6f-b387-39533c0727e2" contextRef="C_6ad32d18-a6d7-4bbe-9f9f-6e1ebf92e327" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">334</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e445f0e2-1b0d-49af-9011-5868d9aa1dfb" contextRef="C_9ab9bd6f-8303-47cb-a451-087e49e1d4f2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,192</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e413f49c-ade7-401d-9a0e-b5a02f0fc6ea" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,452</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a1b874ab-b96c-4976-97e6-1ae58670e980" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,374</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb8b28fb-8ab4-4578-98a1-cbb44f6fcaab" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,837</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_386eb123-f45b-4146-9291-b81afcc59a40" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;based compensation expense included in the consolidated statements of income and comprehensive income by award type is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb16dfe0-2681-45a4-b475-4c1a602127c7" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,995</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e0228ba-ded4-47bb-8f80-f83e3db1c38b" contextRef="C_579c7936-813d-4e3d-9f7d-e6cfc757d33f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,738</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8305bd1-f547-4280-826f-6d13e1253419" contextRef="C_f8691cc5-0a6c-4194-a0e6-b3ab90155c90" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,980</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_24a1fca4-7b9c-4c21-a8b7-ee87045021d3" contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,041</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dff59639-d59e-47f3-824b-a3b6a19f34d7" contextRef="C_dedec735-1cff-4546-aac3-c4141f2f6fda" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,348</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d2ad6bb-54b8-4f39-92d4-ebe9042102c2" contextRef="C_330d6cb8-f79a-453a-8e56-a035cce53878" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,663</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSAs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff034418-16c8-4ac8-b45f-f1aa5082a891" contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a51f8ac-5771-457a-b347-dddf51633ebe" contextRef="C_57b6c234-c606-4323-ad48-c327ece76f82" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">123</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f9a7159-d729-4bc0-93dd-aeeea37ebc55" contextRef="C_c92d98ef-aaeb-428e-9c70-9239d3850fc7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">168</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98be852e-b16f-42d1-a145-a0182f418c45" contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">340</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_429cdd37-ba18-495f-a9f8-bdd375e7b06d" contextRef="C_2f40b780-c413-4e18-8a24-befa2c076cee" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">165</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53202a82-8439-40d3-a997-4cdae2927ec0" contextRef="C_b1c51e57-65da-49fa-ae45-c34168f6b7ca" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5445ee4b-5106-425f-ae93-1d116e04557b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,452</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ed194fcb-586c-43a2-a1db-74479fb80e88" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,374</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f11813a-cd87-484d-b2db-647c29a69b3c" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,837</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4737853f-89c1-48c5-92fd-738fa2ba6dc1" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.88%;box-sizing:content-box;"/>
         <td style="width:2.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.799999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrecognized Compensation Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Amortization Period (Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a07c4f09-cdf5-4e0e-87dc-6b5d18b425b9" contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,140</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_889e0ee5-9abd-429a-84a6-e5dd52ff6d12" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8699767d-61f5-43ba-93cd-347a3fab9436" contextRef="C_320697d2-fba1-4b46-89cc-25782f7895a7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,354</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_5596d9d8-58bf-4a73-9aa5-09c4bd5d50b0" contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSAs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4e69927a-8e30-4a35-aa50-d700cce434ca" contextRef="C_f7570aba-c10f-4b03-a0ca-5d70ea46865a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_0bb9a773-e7e7-4928-8c73-8535445d99df" contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe169bf1-5ee8-400a-a395-2bb80e5e3986" contextRef="C_32606254-e0d2-4b64-9791-54065180e259" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">225</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_503e5737-e9b6-485e-b4c9-f79e897c83a2" contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total unrecognized compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47a7fb8b-6f8a-4dbf-a7f4-50b836ef74e6" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,741</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">130</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_9bcbfb5d-49ec-4a97-8104-1ddd440b5e64_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation Awards</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_71428a3c-5716-478d-815f-0192b8d867d7" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:32.386%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.642%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.7219999999999995%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.642%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:7.7219999999999995%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.642%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.02%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.182%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands, except per share data)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of outstanding options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price of Outstanding Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of outstanding RSUs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of outstanding RSAs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_139997fa-08f8-4100-aa9d-c2902d8fc9d1" contextRef="C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,067</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bd26451-b2a1-4ed9-b586-c276b111aa3b" contextRef="C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.23</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80ac40ef-a020-48a9-af8c-feea1bb1c9ac" contextRef="C_e6c84643-3ac1-485b-96c6-e0bf066aa3a4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">598</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4aff13ee-3cc4-407d-907e-f63c08a40524" contextRef="C_e6c84643-3ac1-485b-96c6-e0bf066aa3a4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_504cdbc9-78c0-49e6-b8bc-000133ac316b" contextRef="C_4ae30dd2-d091-4534-84e4-23090114dd52" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d364bf56-aedc-4340-890c-f2b34064f830" contextRef="C_4ae30dd2-d091-4534-84e4-23090114dd52" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.50</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8dfefffe-6f5c-4809-ab88-6e8364f9c2d3" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">870</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dd75754-a979-4fec-9701-aed6f863660b" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.00</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ddf2a50-cb19-4c6b-a6cb-6fb8db42b1a6" contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">662</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c9a63fd-8ae6-4744-91ee-4c56abb463fa" contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.18</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38dbdad0-ad03-4d7d-990b-a928ce2b7f94" contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ea2fcc7e-18ce-4f2a-9a2e-d13a52a57228" contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbd7d669-60e7-4f23-8840-77eeabff07ec" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6534f2f-68b6-473d-870f-3dac050dd549" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.09</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Released RSUs and RSAs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d317ce33-f6e5-4ded-9a36-245a7a1600a6" contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ebfd5a3-887c-4940-aa1e-7f390fe8b95f" contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.10</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b15e368-41bf-459d-9da7-a1b33cd2a30e" contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91b628a9-c280-4f75-bc4c-bbf6895cc4f4" contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.78</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a5160d5-6395-4506-a300-0e7d1f443449" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">17</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21f9d959-0356-4f0f-9a88-b0dc24522ee5" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.87</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4fe295c8-4f42-4e69-8d92-a26c8e50ba8c" contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">36</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44636c43-e272-4bc1-92fa-971deb12fa82" contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.70</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80d920ce-e2cf-41a7-9ae4-472a2e57e013" contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" unitRef="U_shares" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2aea4196-d7d3-484e-b183-f1f592021c4b" contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fd774c45-dc64-4d14-ac62-2fafc8bde5d0" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d60dc821-6a3d-41c4-8a2e-57f7e5f9c8db" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.11</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82402064-a123-46f2-b101-5c99ea36c976" contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,834</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f51ce16f-627b-4ff8-aea2-de153d63c76c" contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.08</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e8ffd69-1a46-4a4f-9269-14300e14e8cd" contextRef="C_320697d2-fba1-4b46-89cc-25782f7895a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">924</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8c2ef59c-9b2f-4d7a-8856-a5735ed1e2fc" contextRef="C_320697d2-fba1-4b46-89cc-25782f7895a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.22</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_171b7ee8-1595-4f70-b8ff-87fbd9201306" contextRef="C_f7570aba-c10f-4b03-a0ca-5d70ea46865a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_722c23fa-91a4-41cc-b6a6-ef4d508765b5" contextRef="C_f7570aba-c10f-4b03-a0ca-5d70ea46865a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">14.77</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest <br/>&#160;&#160;&#160;as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_51870688-a6f6-45c0-9c12-fd95604e5b79" contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,834</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40165ff0-027b-432b-b471-099219d412c5" contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">16.08</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e50f1b17-c808-45ab-b688-97e2dff66fd8" contextRef="C_320697d2-fba1-4b46-89cc-25782f7895a7" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:num-dot-decimal">924</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7cb1fcb6-b36e-4957-aa14-88abcd00eba8" contextRef="C_320697d2-fba1-4b46-89cc-25782f7895a7" name="inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">17.22</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the aggregate intrinsic value of options outstanding and options exercisable was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fee90bc0-d36a-4203-875d-0ab300068b8f" contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3557f2e0-08d6-47a7-8bc1-49d34919a70c" contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the aggregate intrinsic value of options outstanding and options exercisable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_781b03b5-05fe-4152-aaa6-524ec22ce428" contextRef="C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26bbc157-35d0-4944-92e6-320a63ee388f" contextRef="C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99214317-6312-4288-8653-65c345221a4d" contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,267,886</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options were exercisable. The weighted average remaining contractual term of options outstanding was </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a056ec9-2b2c-46b0-91ab-6047222cc7c2" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.68</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_be206e0f-ef75-43c8-be3f-3f97359cf299" contextRef="C_579c7936-813d-4e3d-9f7d-e6cfc757d33f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.04</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years as of December 31, 2025 and 2024, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total intrinsic value of the options exercised was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2cc3585c-d668-432c-a8bb-83f7db2ededc" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_20d96862-65c9-483f-83d7-f42789ab5f5f" contextRef="C_579c7936-813d-4e3d-9f7d-e6cfc757d33f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d4030fea-bc79-4c8d-873c-e82b2d71b8c0" contextRef="C_f8691cc5-0a6c-4194-a0e6-b3ab90155c90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material for the years ended December 31, 2025, 2024 and 2023. The total estimated fair value of options vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28588aa3-8ef8-4f1d-8975-81adad7e544c" contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b7e03dc-a12b-4375-9301-e77c1ec6619f" contextRef="C_579c7936-813d-4e3d-9f7d-e6cfc757d33f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a54f65f2-f369-42c3-99ca-967fdb7eea9a" contextRef="C_f8691cc5-0a6c-4194-a0e6-b3ab90155c90" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total estimated fair value of RSUs vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc0b5374-e634-4599-a5b0-40987a3da4af" contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21eced27-cb3a-4eef-8678-66d922667a70" contextRef="C_dedec735-1cff-4546-aac3-c4141f2f6fda" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41c26569-b435-4489-b483-542883c927b9" contextRef="C_330d6cb8-f79a-453a-8e56-a035cce53878" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years December 31, 2025, 2024 and 2023, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total estimated fair value of RSAs vested was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aaaf9a84-7b8f-4f78-96bc-1680ff29ba6e" contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_23907c3d-3c1b-4313-8bf6-947ceda5d3b2" contextRef="C_57b6c234-c606-4323-ad48-c327ece76f82" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen"><ix:nonFraction id="F_70316d3f-ab22-4061-8cb1-a9ec1c8edec0" contextRef="C_c92d98ef-aaeb-428e-9c70-9239d3850fc7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material for the year ended December 31, 2025, 2024, and 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation Assumptions</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77d2331c-0b8b-4a4a-ae7d-6b7417ce880b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_77d2331c-0b8b-4a4a-ae7d-6b7417ce880b_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Black-Scholes-Merton weighted-average</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> assumptions used in calculating the estimated value of stock options granted by Innoviva on the dates of grant were as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.748999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.748999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.748999999999999%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05963f0c-6b15-4713-9c59-2fd216325166" contextRef="C_c10fa9b1-45fb-45df-9763-f7e84d16c427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2fc53f8d-a08a-4d59-ba45-46d09d797524" contextRef="C_ff24ff88-61ab-4e42-8c4e-2eef4914adc2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b77c682e-d167-4270-bb29-ddd627b9d59c" contextRef="C_cfb09673-608d-4b9a-af24-b826da8f9edc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">4.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_b18b67b3-24ea-4c9f-b747-d39b0327d8f1" contextRef="C_c10fa9b1-45fb-45df-9763-f7e84d16c427" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.07</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_40bc170d-ec4f-4c10-8f1b-cd2526eedfc1" contextRef="C_ff24ff88-61ab-4e42-8c4e-2eef4914adc2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.10</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><ix:nonNumeric id="F_abdd416d-b555-4ab6-937c-e735cdf30fb3" contextRef="C_cfb09673-608d-4b9a-af24-b826da8f9edc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.09</span></ix:nonNumeric></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6c2802e9-f3a4-415e-a4fa-64e1235f0df1" contextRef="C_c10fa9b1-45fb-45df-9763-f7e84d16c427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">34.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4970a789-a168-416a-9189-aaa48953225a" contextRef="C_ff24ff88-61ab-4e42-8c4e-2eef4914adc2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">35.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_62070e64-4a67-47c8-9077-10cc9f624fa7" contextRef="C_cfb09673-608d-4b9a-af24-b826da8f9edc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">37.8</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d54856b0-c4bb-4353-b8f3-5c073b4b8869" contextRef="C_1b6e4f2c-7f64-4b60-808a-20645b1b5b3b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3cd7381c-1bbc-46fb-aeb0-a07cb1fd1bff" contextRef="C_b931adf2-501a-4565-a5c0-0fce4fa655a8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ac28a052-1d5b-44ce-a5b9-e639d2550f1d" contextRef="C_c554b608-b6a5-40f5-8cdd-07a2aa79f2ec" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average estimated fair value of stock options granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_530edd5c-66e0-443d-96c9-7c98c82d04bb" contextRef="C_c10fa9b1-45fb-45df-9763-f7e84d16c427" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">7.48</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c31c49e-fc18-4534-ba3c-449809d4b1d0" contextRef="C_ff24ff88-61ab-4e42-8c4e-2eef4914adc2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">8.17</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6fc864c8-14cf-437c-8f33-c1a1238329c6" contextRef="C_cfb09673-608d-4b9a-af24-b826da8f9edc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">5.57</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:continuation></div><div><ix:continuation id="F_77d2331c-0b8b-4a4a-ae7d-6b7417ce880b_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><ix:nonNumeric id="F_c1762124-0d63-4a38-aa37-4a234e5cb527" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true" continuedAt="F_c1762124-0d63-4a38-aa37-4a234e5cb527_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2025, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_551b1ceb-4468-45e0-aa4a-d4a027ecd446" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:ClassOfWarrantOrRightExercised" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">590,703</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants were exercised into an equivalent number of our common shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65bae589-0a9a-4d21-9c8b-57f5327853ca" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">18.11</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, resulting in approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0e83ce75-e3f3-4e9f-896e-25e243300095" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ProceedsFromWarrantExercises" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in proceeds. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eef3e058-de02-4421-bb2b-a142b3c86378" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding warrants as of December 31, 2025.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 3, 2025, our board of directors authorized a new share repurchase program under which we may repurchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53135600-fed1-42b2-ad65-a311de185eb5" contextRef="C_b804b54f-6e17-4b9b-bc14-506d13cd2e58" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our outstanding shares of common stock. The timing and amount of any share repurchases under the share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">131</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_c1762124-0d63-4a38-aa37-4a234e5cb527_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">repurchase </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">program will be subject to the Securities and Exchange Commission Rule 10b-18 and Rule 10b5-1 requirements under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and will be determined by our management in its discretion based on ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions, and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at our discretion and does not oblige us to acquire any amount of common stock. From program inception through December 31, 2025, we repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a5d3300-1479-4466-8bed-e30c4d365d90" contextRef="C_d16801eb-dbe6-41b0-b0a9-f2ce69282a79" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">227,855</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2917d833-cac5-40be-8012-97bec502fe99" contextRef="C_d16801eb-dbe6-41b0-b0a9-f2ce69282a79" name="inva:CommonStockAcquiredAverageCostPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">20.09</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_244f57e9-bbba-4da4-b9a9-b3f071708e53" contextRef="C_d16801eb-dbe6-41b0-b0a9-f2ce69282a79" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">4.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> millio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n. Subsequent to December 31, 2025 and through February 13, 2026, we have repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd19fb40-ec60-42c6-8c8d-cc97fcd24a55" contextRef="C_e7b60c9b-de37-4c35-8699-180e5b96d972" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">569,443</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_639cefbc-f3a1-4198-90fe-9253a54003f5" contextRef="C_e7b60c9b-de37-4c35-8699-180e5b96d972" name="inva:CommonStockAcquiredAverageCostPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">19.88</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f5f12e4-5423-4940-b572-d0a02caf071c" contextRef="C_e7b60c9b-de37-4c35-8699-180e5b96d972" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">11.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. All repurchased shares were retired.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 31, 2022, our board of directors authorized a share repurchase program under which we may repurchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_396a2663-e72b-4650-8411-8d76deb1e330" contextRef="C_04b74a31-e5ca-4397-96ef-3eea91f0c2cf" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">100.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of our outstanding shares of common stock. The repurchase program authorized the repurchase by the Company of its common stock in open market transactions, including pursuant to a trading plan in accordance with Rule 10b-18 promulgated under the Exchange Act, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. The authorization permitted management to repurchase shares of the Company&#8217;s common stock from time to time at management&#8217;s discretion. Repurchases may also be made pursuant to a trading plan under Rule 10b5-1 under the Exchange Act, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. For the year ended December 31, 2023, we repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c29b8c1-0abe-4ed4-81c9-cd1aaff88900" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">6,173,565</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_136b7976-10a3-48fd-af3c-eba55dea16b4" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="inva:CommonStockAcquiredAverageCostPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">12.39</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e29baa3f-df8d-4a6a-9100-7a27ebb5c304" contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">76.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. From January to April 2024, we repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07a84511-9f78-4be2-84a4-413584c6309b" contextRef="C_9813ff06-8065-4d1b-980c-30aab6fdf680" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">986,928</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26e43b58-8935-488b-9b03-09d446237b12" contextRef="C_9813ff06-8065-4d1b-980c-30aab6fdf680" name="inva:CommonStockAcquiredAverageCostPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">15.12</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_680ab9e7-a25e-4b49-861b-05baaa2e48b4" contextRef="C_9813ff06-8065-4d1b-980c-30aab6fdf680" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">14.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The share repurchase program was completed in April 2024. All repurchased shares were retired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, we retired all the shares held in treasury resulting from our strategic buyback of GSK&#8217;s common shares in the Company in 2021. We recorded the corresponding cost of treasury stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fa69b4f-79a6-4202-bf8e-93b7aac1d872" contextRef="C_c8120c77-f833-4318-8b71-285654ebe1a5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">393.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional paid-in capital.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_103ad023-d365-432c-9b72-e81fa5944bfd" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:DebtDisclosureTextBlock" escape="true" continuedAt="F_103ad023-d365-432c-9b72-e81fa5944bfd_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. DEBT</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e1fe5f5-529c-43ed-ad97-a4903d98a653" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our debt consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.88%;box-sizing:content-box;"/>
         <td style="width:2.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.799999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:2.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:18.799999999999997%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ba22168-638f-4e3c-84b8-d374a70e5cb0" contextRef="C_bf1e7354-aeed-4914-83a6-37a509ddd35f" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09d1e89d-cfc4-4596-a395-b07b50fe6b97" contextRef="C_b977836a-3754-4918-ab34-119c8e6e97e3" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57664cd8-5ce6-4e71-8834-b74c97b9f4a8" contextRef="C_b9c78e4a-7998-49df-8911-c4a60d08df86" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fb5e87e-cc5c-4ee1-95f4-be2f7d82a7b5" contextRef="C_89ffeb43-b4e5-4cd3-b24e-9d0133812b42" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total debt</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_570187cc-50b5-44c6-8368-cca3d9263e33" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01808c12-5e22-4a0a-9f69-728a20079018" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">453,500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_243026fc-94b7-402b-a7f1-69225897f762" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,269</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49aca042-23fc-4693-8fb9-5e16cd6ddafb" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,156</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b11370c-9afb-4e28-8178-769b62bf5fca" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,731</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05880a9e-aff3-42a7-8fd1-2368c3b0f46c" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">448,344</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Less: Current portion of long-term debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bddb95f-50ff-4e2d-b503-d1a7a643d192" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ac43667-4247-45ec-9819-8e5205a509e8" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DebtCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,028</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4556677d-8a5e-4bea-b0d6-1abb47c8784d" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,731</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_171a6559-74c4-4267-bcee-6ab34ff8e7c2" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:LongTermDebtNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256,316</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Subordinated Notes Due 2023</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2013, we completed an underwritten public offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a745afc5-c56b-416f-964a-28ac01b44ab4" contextRef="C_f0b8d42e-b800-4698-921e-c7324bfbf8ad" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">287.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million aggregate principal amount of our 2023 Notes, which matured on January 15, 2023. The 2023 Notes carried interest at the rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de56549b-4d7c-4334-9679-3393add0ab1e" contextRef="C_f0b8d42e-b800-4698-921e-c7324bfbf8ad" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">2.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per year that was payable semi-annually in arrears in cash on January 15 and July 15 of each year.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the total face value of the 2023 Notes was reduced through partial conversion, retirement and repurchase. The remaining balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_560115b8-aeb7-4743-a962-a73ad705d6e4" contextRef="C_c6f23cff-6ae1-42a0-aeb9-137bb05864f8" name="inva:DebtInstrumentRemainingBalancePaidUponMaturation" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">96.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was fully paid in cash upon the maturity date in January 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_93261363-538d-4c1d-b8dd-fba8ea22b405" contextRef="C_bc424098-7c86-48ee-a261-2e346af6f356" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" escape="true" continuedAt="F_93261363-538d-4c1d-b8dd-fba8ea22b405_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2023 Notes for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023:</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">132</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_103ad023-d365-432c-9b72-e81fa5944bfd_1" continuedAt="F_103ad023-d365-432c-9b72-e81fa5944bfd_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_93261363-538d-4c1d-b8dd-fba8ea22b405_1">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:75.96%;box-sizing:content-box;"/>
         <td style="width:2.2%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:19.84%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65f2b891-5c7f-4f55-9638-0bc783ae2dbf" contextRef="C_98625368-01db-4a5e-b3d8-d97b38cb185c" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">85</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0f639910-cfef-4c08-83be-dec4310932e4" contextRef="C_98625368-01db-4a5e-b3d8-d97b38cb185c" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9690eeaf-b7ae-4480-8445-9d50f1bb6d66" contextRef="C_98625368-01db-4a5e-b3d8-d97b38cb185c" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">96</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:continuation></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Senior Notes Due 2025</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 7, 2017, we completed a private placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f854b81-07a3-405d-98f2-3c0ee09289a2" contextRef="C_accf2b2f-48d9-429a-b115-90bfc9822af1" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">192.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million aggregate principal amount of our 2025 Notes. The 2025 Notes were senior unsecured obligations and carried interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f46b953-8f80-478c-a87d-8b8d1bf73416" contextRef="C_accf2b2f-48d9-429a-b115-90bfc9822af1" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per year, payable semi-annually in arrears on February 15 and August 15 of each year.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2025 Notes were convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, we elected to settle the 2025 Notes in shares. Holders had the option to convert their 2025 Notes at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. During June 2025, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a639ad2-5749-4eb9-916a-18ae0b69d5fc" contextRef="C_6f8efa75-54a0-48d2-91ec-df3a956405f4" name="inva:PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the principal amount was converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_50f44a92-4a62-4613-8a79-73d151a17bb8" contextRef="C_c2aa978f-4b90-4e27-bcd0-10e52fef449d" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">28,962</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock. During August 2025, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_282d3503-2638-466a-9392-6733a8fcca1b" contextRef="C_5f76e50f-7b05-4925-b65f-40d08587b5e7" name="inva:PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">192.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the principal amount was converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ecbddee1-576f-4728-8793-f4eee9133cca" contextRef="C_3495636e-7fc4-46b6-af0e-05bbaa199981" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">11,119,956</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The remaining principal balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2e1fe63-06cc-4a8f-85cb-abec503918ff" contextRef="C_ae44ab8e-7504-455a-a5c7-18b720494066" name="inva:DebtInstrumentRemainingBalancePaidUponMaturation" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was fully paid in cash upon the maturity date in</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_905a8833-bbdb-492d-9685-a8c8b6e63aa2" contextRef="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> August 15, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The annual effective interest rate on the 2025 Notes in 2025 up to its settlement was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_887b1eaa-ebf8-4c83-9178-163987c0208d" contextRef="C_54e7dc78-e88a-4740-abbe-66bd616fae5d" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.90</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. For the years ended December 31, 2024 and 2023, the annual effective interest rate on the 2025 Notes was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d710d844-14ff-46a5-ab12-9dd51544a307" contextRef="C_b977836a-3754-4918-ab34-119c8e6e97e3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal"><ix:nonFraction id="F_6038378e-584d-44f9-ac83-4f21887804e1" contextRef="C_c43a1118-656f-4694-8c43-8a7ccd87ef7e" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.88</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1b12d0d6-0dcf-4d7b-9edf-dd85a5967014" contextRef="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1" name="us-gaap:ConvertibleDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our 2025 Notes balances consisted of the following as of December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:70.034%;box-sizing:content-box;"/>
         <td style="width:2.941%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:25.025%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4130ab61-09d1-474f-9f67-19a34d4aba4a" contextRef="C_b977836a-3754-4918-ab34-119c8e6e97e3" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,500</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_629079d0-63e3-441f-9706-e679da060568" contextRef="C_b977836a-3754-4918-ab34-119c8e6e97e3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net carrying amount</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c6a2ad5-cd14-4341-86cd-b4db43b27b2c" contextRef="C_b977836a-3754-4918-ab34-119c8e6e97e3" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">192,028</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03ddf773-2dcd-4eee-aa6d-3e946edf1f50" contextRef="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d20e2d19-7cdc-475e-823e-7513722e63a6" contextRef="C_8d85403b-c00a-43af-9139-4133780be452" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,002</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_862b80a9-cd26-4b16-8524-fadbbbdd6cba" contextRef="C_8807e583-90bb-4bf2-b789-04fcccd5635c" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,813</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d0a33cb-c476-4431-942e-a38f8ea97430" contextRef="C_f3e8c321-fbbd-46fe-ad52-a5cf85e12e92" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,813</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_692b0b21-ac79-4b8a-b733-a7cd9a23b838" contextRef="C_8d85403b-c00a-43af-9139-4133780be452" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">472</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a83fa47-ef74-45f1-a123-61f3725dd5e7" contextRef="C_8807e583-90bb-4bf2-b789-04fcccd5635c" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">733</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da519cfa-49a3-402c-9f7b-4244eca26bb7" contextRef="C_f3e8c321-fbbd-46fe-ad52-a5cf85e12e92" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">712</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bd152ee4-19e9-4663-8bdb-85c97cd7450c" contextRef="C_8d85403b-c00a-43af-9139-4133780be452" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,474</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_169a3c1a-6c7c-41df-81dc-9b0ef88614bc" contextRef="C_8807e583-90bb-4bf2-b789-04fcccd5635c" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,546</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b8860725-d3a9-4b33-9f81-19e7a667b204" contextRef="C_f3e8c321-fbbd-46fe-ad52-a5cf85e12e92" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,525</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Senior Notes Due 2028</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, we completed a private placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e529e2a-40b1-43eb-b55f-f21e932f5d39" contextRef="C_19c66b49-0137-43c6-92ab-0b70a3008556" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">261.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million aggregate principal amount of our 2028 Notes, which will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_60d2e0f8-5f4f-49aa-84db-3a9205643aed" contextRef="C_ab3f6fa0-6707-4052-910b-d4481b963aad" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 15, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We used approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17ace163-0347-4ff3-bb32-3313f06c0d41" contextRef="C_8a0737aa-6de6-4c43-ae8f-624230637866" name="inva:CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the net proceeds to fund the cost of entering into the capped call transactions described below. In addition, we used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e68b3b67-6db0-4ace-9d62-8fb077c51ef1" contextRef="C_12c637ab-fa44-4ddd-a290-1d17a74cbbc4" name="us-gaap:RepaymentsOfUnsecuredDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">165.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the remaining net proceeds to repurchase $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_25d5555d-0a76-4aa3-9ff2-9689bcace6b7" contextRef="C_b4012fc1-478c-4326-af9a-abfcc793f2a8" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">144.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million aggregate principal amount of the 2023 Notes in separate and individually negotiated transactions with certain holders of the 2023 Notes, which closed concurrently with the issuance of the 2028 Notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2028 Notes bear interest at an annual rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eeea7640-3c07-4fda-b5d6-ca05bab83005" contextRef="C_66187a73-ceaf-4466-bbd1-1b86eb8fc0ce" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="5" format="ixt:num-dot-decimal">2.125</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% that is payable semi-annually in arrears in cash on March 15 and September 15 of each year, beginning on September 15, 2022.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">133</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_103ad023-d365-432c-9b72-e81fa5944bfd_2" continuedAt="F_103ad023-d365-432c-9b72-e81fa5944bfd_3"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2028 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e0b601f4-05c7-4ebe-9d67-2a65d283b243" contextRef="C_b1909c77-5037-4101-951b-72d1da39afc1" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" unitRef="U_pure" scale="0" decimals="4" format="ixt:num-dot-decimal">38.1432</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares per $1,000 principal amount of the 2028 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a8851237-7ac0-4f5f-9ee4-c4af9406e8c6" contextRef="C_f7d4ec88-c122-4840-9402-055ba9f5e83a" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">26.22</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to September 15, 2027, the 2028 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, and will be convertible on or after September 15, 2027, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of the 2028 Notes may convert all or a portion of their 2028 Notes prior to the close of business on September 15, 2027, only under the following circumstances:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after March 31, 2022, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42e23d0a-2baa-4a8a-916a-2822716f994e" contextRef="C_ab3f6fa0-6707-4052-910b-d4481b963aad" name="inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the current conversion price of the 2028 Notes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7709e6a0-34da-4af1-a0b2-c5f61f6d9c9b" contextRef="C_ab3f6fa0-6707-4052-910b-d4481b963aad" name="inva:DebtConversionConvertedInstrumentAverageTradePricePercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the product of our closing common stock price and the conversion rate of the 2028 Notes on such day; and,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental change (as defined in the indenture governing the 2028 Notes) or a transaction resulting in our common stock converting into other securities or property or assets.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On or after September 15, 2027, holders of the 2028 Notes may convert their 2028 Notes at any time until the close of the business on the second day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2028 Notes will be redeemable, in whole or in part, at our option at any time, and from time to time, on or after March 20, 2025, and on or before the 75th scheduled trading day immediately before the maturity date but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the 2028 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any 2028 Note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the 2028 Notes) with respect to that 2028 Note, in which case the conversion rate applicable to the conversion of that 2028 Note will be increased in certain circumstances if it is converted after it is called for redemption.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we undergo a fundamental change, subject to certain conditions, holders may require us to purchase for cash all or any portion of their 2028 Notes. The fundamental change purchase price will be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7dd4f899-37da-46ed-8a36-4370691bf36e" contextRef="C_ab3f6fa0-6707-4052-910b-d4481b963aad" name="inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the principal amount of the 2028 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71d6271a-8ae4-47bb-857b-6b7d26167f8b" contextRef="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6" name="us-gaap:LineOfCreditFacilityCovenantTerms"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.</span></ix:nonNumeric></span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions. The cap price of the capped call transaction is initially $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0877ba05-3cd1-4ec0-b347-daa294b80f29" contextRef="C_35672b5e-10a9-4748-974c-cf69a518b68a" name="us-gaap:OptionIndexedToIssuersEquityStrikePrice1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">33.9850</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the 2028 Notes. The capped call transactions are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the aggregate principal amount of converted 2028 Notes, as the case may be, with such reduction or offset subject to a cap.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">134</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_103ad023-d365-432c-9b72-e81fa5944bfd_3" continuedAt="F_103ad023-d365-432c-9b72-e81fa5944bfd_4"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The annual effective interest rate on the 2028 Notes is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f45caae7-a668-4489-b19f-707cde4bceac" contextRef="C_b9c78e4a-7998-49df-8911-c4a60d08df86" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.70</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_e48d1317-a2de-45eb-af76-02b592dae487" contextRef="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6" name="us-gaap:ConvertibleDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our outstanding 2028 Notes balance consisted of th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.5%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.843%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5445b04-a36b-4817-840b-efa8d07cd5d1" contextRef="C_b9c78e4a-7998-49df-8911-c4a60d08df86" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4176cfc5-f747-41fe-a1e5-35c3bfee9aa7" contextRef="C_89ffeb43-b4e5-4cd3-b24e-9d0133812b42" name="inva:DebtInstrumentPrincipalAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93201433-5d67-4b2a-8a18-c81d95647ab4" contextRef="C_b9c78e4a-7998-49df-8911-c4a60d08df86" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,269</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_45bb28d9-1b51-42f3-ac9d-e83163ee2bc2" contextRef="C_89ffeb43-b4e5-4cd3-b24e-9d0133812b42" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,684</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net carrying amount</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d229739f-4979-49ae-a62a-daef110b69a8" contextRef="C_b9c78e4a-7998-49df-8911-c4a60d08df86" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">257,731</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_58d8cc0d-1065-45e9-ac47-3d121593e6fe" contextRef="C_89ffeb43-b4e5-4cd3-b24e-9d0133812b42" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">256,316</ix:nonFraction></span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b96d9119-1893-4ffc-b5d6-cc8ddd3e8dc7" contextRef="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2028 Notes for the years ended December 31, 2025, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.481%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.75%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8c2d339-2b3c-403c-a016-e2bb17845f0d" contextRef="C_1e11bcae-e1f5-4912-8d5e-346484926bde" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,546</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b49db20-1a18-4f22-b96f-b52bef1fc32a" contextRef="C_82023995-c0c9-4e2f-af7b-9dff1c4313ef" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,546</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b4bce4a-37e7-4f1c-9c35-29dbf38c0e71" contextRef="C_cd448608-93c9-4efb-8910-d496892f68f5" name="us-gaap:InterestExpenseDebtExcludingAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,546</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt discount and issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c0bcbd9-8c25-4161-bce3-ee4943e41d60" contextRef="C_1e11bcae-e1f5-4912-8d5e-346484926bde" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,415</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e50ea378-36ac-47dd-9dc0-dad4efadba00" contextRef="C_82023995-c0c9-4e2f-af7b-9dff1c4313ef" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,377</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1bd7b73e-770b-4413-bbcb-de0ba33feda7" contextRef="C_cd448608-93c9-4efb-8910-d496892f68f5" name="us-gaap:AmortizationOfFinancingCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,342</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_638381ee-ac23-4bb9-a286-6e90c69d9fde" contextRef="C_1e11bcae-e1f5-4912-8d5e-346484926bde" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,961</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e8ee47e-71b0-4c3c-9e19-d0bd283dc8fe" contextRef="C_82023995-c0c9-4e2f-af7b-9dff1c4313ef" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,923</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6192912f-fb71-44fe-a792-38d51e0d8ed0" contextRef="C_cd448608-93c9-4efb-8910-d496892f68f5" name="us-gaap:InterestExpenseDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,888</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Debt Maturities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd582b93-5914-46a5-b678-1e6720e0fe27" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate scheduled maturities of our convertible debt as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.757%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fee10808-8a1d-4045-b31f-af5ad55780bb" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7ba3f7a-0439-4c12-9458-88eb84f2eebe" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ea94c78-3831-4990-a562-4fb74bad3927" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebf17459-7dd5-4bc1-8ec3-f6cbfab2c418" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,000</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Royalty Obligation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our acquisition of La Jolla, we recorded the fair value of its deferred royalty obligation in connection with La Jolla&#8217;s royalty financing agreement (&#8220;La Jolla Royalty Agreement&#8221;) with HealthCare Royalty Partners (&#8220;HCR&#8221;). Under the terms of the La Jolla Royalty Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA&#174; until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The maximum royalty rate through December 31, 2023 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3a9c01c-ba71-4233-a67c-4a841295e29b" contextRef="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077" name="inva:RoyaltyAgreementMaximumPotentialPayoutPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">14</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. Starting January 1, 2024, the maximum royalty rate was increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9151546-382c-4dba-9600-24f3663d0c76" contextRef="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077" name="inva:RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">18</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% based on the terms of the Agreement. The La Jolla Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ab333c18-32e7-4bee-9c2d-d70b6491a491" contextRef="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077" name="inva:MaximumAggregateRoyaltyPaymentsDue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">225.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2025, 2024 and 2023, we recognized interest expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae38111c-eeae-4fc1-9fd1-fa58c25a51bc" contextRef="C_af13deae-2d89-4cf9-98df-3d7c55d81d4f" name="us-gaap:InterestExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8cb9846a-e43b-4968-8659-ee4b8a033808" contextRef="C_418a0dcc-491c-4849-aebf-ba4f6c3031b4" name="us-gaap:InterestExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2eaebba5-84eb-4e79-b975-c0f2217ddd1a" contextRef="C_469092aa-cbc1-422f-9923-e5ef71f3d779" name="us-gaap:InterestExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">6.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, on the deferred royalty obligation. The carrying value of the deferred royalty obligation as of December 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9cb666e3-94bc-4e12-83ab-d623bb755085" contextRef="C_ef64ca1c-fe1e-4b9a-b5ff-0a15d056fed5" name="inva:DeferredRoyaltyObligations" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">62.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d410318-bbf7-4e8c-a932-87f8f47529eb" contextRef="C_7e31beca-2974-46b0-a791-da8703f2803a" name="inva:DeferredRoyaltyObligations" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">69.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, (refer to Note 9 &#8220;Balance Sheet Components</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). During the years ended December 31, 2025, 2024 and 2023, we made royalty payments to HCR of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bac1da46-85f6-4727-a163-141a8a98226f" contextRef="C_af13deae-2d89-4cf9-98df-3d7c55d81d4f" name="inva:RoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">12.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f9d8ffa-93c1-48e1-82fd-6a7bd9a1be3a" contextRef="C_418a0dcc-491c-4849-aebf-ba4f6c3031b4" name="inva:RoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a29aa0b1-f2b2-4a0d-9c0d-bd8419d927ac" contextRef="C_469092aa-cbc1-422f-9923-e5ef71f3d779" name="inva:RoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The deferred royalty obligation was valued using Level 3 inputs, and its carrying value as of December 31, 2025 and 2024 approximates fair value. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the deferred royalty obligation was calculated as the discounted deferred royalty obligations based on risk-adjusted revenue projections for GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the annual effective interest rate of the deferred royalty obligation is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ead1629c-6073-46d2-b6d6-db781bf774fd" contextRef="C_af13deae-2d89-4cf9-98df-3d7c55d81d4f" name="inva:InterestRateOfDeferredRoyaltyObligation" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">10.03</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">135</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_103ad023-d365-432c-9b72-e81fa5944bfd_4"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the La Jolla Royalty Agreement, if we are unable to meet certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, HCR would have the right to terminate the La Jolla Royalty Agreement and demand payment of either $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_202c0632-1ed6-4cc9-a524-0239123f28ca" contextRef="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077" name="inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">125.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a2a7df80-3434-446f-9f95-6be6de4bb0af" contextRef="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077" name="inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">225.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (depending on which obligation we have failed to meet) less aggregate royalties already paid to HCR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2025, inclusive of the aggregate royalties paid to HCR by La Jolla under the La Jolla Royalty Agreement prior to our acquisition, La Jolla paid approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9a5f8d06-10a2-4443-bdad-9f318fcae74d" contextRef="C_d9b8c46c-1584-49b3-91b6-cc0e6d57dc59" name="inva:TotalPaymentsMadeForRoyaltyAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">40.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">aggregate royalties to HCR. In the event that we fail to pay such amount if and when due in a timely manner, HCR would have the right to foreclose on the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-related assets. HCR has no recourse against any asset other than GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain contract provisions within the La Jolla Royalty Agreement that could result in an acceleration of amounts due under the La Jolla Royalty Agreement are recognized as embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. We determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, we determined that the fair value of the embedded derivatives is immaterial and, therefore, not recognized as of December 31, 2025 and 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate the fair value of the embedded derivatives for each reporting period until either the features lapse or the La Jolla Royalty Agreement is terminated, whichever occurs first. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss in the consolidated statements of income and comprehensive income.</span></p></ix:continuation></div><div><ix:nonNumeric id="F_fbdd7324-426c-4165-9771-635c8167c7b3" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_fbdd7324-426c-4165-9771-635c8167c7b3_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Lease</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have operating leases for our corporate headquarters, office spaces and laboratory facilities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2019, we entered into an operating lease for our headquarters in Burlingame, California for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0c863f7-7c6d-43b0-8d86-00977435d93b" contextRef="C_392076d3-b2a9-4556-8800-6b9f6d3a290c" name="us-gaap:NetRentableArea" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">2,111</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rentable square feet. The lease commenced in November 2019 with an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a8d055de-5223-43f2-950c-df6e42a40b2d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">thirty-six</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> calendar months, which was subsequently amended to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0cf4230b-14d7-4c03-83f4-80f2b6b31b1a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2027</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our operating leases include a facility lease consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_362310dd-3335-4093-8da3-935b3e0b8dc7" contextRef="C_239a2a88-4dcf-4e6d-8f3b-5b1398ae730c" name="us-gaap:AreaOfRealEstateProperty" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">15,500</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space in Waltham, Massachusetts, which expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f563af2d-08d9-49fd-bae4-6b8f93526198;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2029</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In November 2025, we entered into an operating lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_86a71894-92d5-48fe-8c3d-32085285cb0c" contextRef="C_bd8929dd-2601-4ff3-b3c5-49946bfb7b0d" name="us-gaap:NetRentableArea" unitRef="U_sqft" decimals="INF" format="ixt:num-dot-decimal">22,881</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office and laboratory space in Lexington, Massachusetts, which expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7683dbb5-aa29-4655-8dae-71a88a149d59;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2036</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have the </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b521682f-1e2a-4476-814a-0867e26b28a6" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate" format="ixt:fixed-true"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to terminate</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this lease, for an early termination fee, before May 2029.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fab46960-5621-48fe-a145-eab943b70eeb" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease costs are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:57.863%;box-sizing:content-box;"/>
         <td style="width:1.281%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.764000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.281%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.764000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.281%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.764000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Straight line operating lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c782be48-5b54-4be6-b76e-1fc278e98a2d" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,424</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bf85fc73-8c48-4f02-8d0f-4d976e874c6a" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,200</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fedd62e8-3ee5-4bfe-9d47-0d3360b8007c" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,428</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3014efa8-cec6-4519-9723-9c1da6e34d0f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b9ffcb1-8beb-4f66-9c9d-4fc7df7a415b" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d68bcd71-cba1-4b25-9569-a261ed362a57" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">189</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63a5477f-30b6-474b-af19-07c9fdc65d93" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,515</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43eb498f-a8f3-4843-b742-5117fbeb650a" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,214</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23e927ab-12e0-4766-b147-bb300fa7f84b" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,617</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_826b395c-627d-4590-b998-cbc02ef351da" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental cash flow information related to leases are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:57.863%;box-sizing:content-box;"/>
         <td style="width:1.281%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.764000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.281%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.764000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.281%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:10.764000000000001%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of <br/>&#160;&#160;&#160;operating lease liabilities:</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d55c0b8-7328-4a5f-ad33-ec82f4344e34" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,705</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f0b1302-524a-4469-bfcb-b5e68c38dc17" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,464</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3ee024c3-089f-4093-9e69-3d787609d7b1" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,542</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange <br/>&#160;&#160;&#160;for operating lease obligations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5b4c551-f7cf-48ac-bea5-363075e26f1c" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">10,022</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5b75eb6-c9f7-40fb-8155-77d4ed51ba57" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,156</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a280a69-d6e1-4058-a54f-d4fe155a50be" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, our operating leases have weighted-average remaining term of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02133af7-cac9-4e07-b78d-a189f6ccdeb5" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.6 </span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years and the weighted-average discount rate on our operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cca661da-5c3b-4980-9104-c57aee7a7ee5" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">136</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_fbdd7324-426c-4165-9771-635c8167c7b3_1" continuedAt="F_fbdd7324-426c-4165-9771-635c8167c7b3_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3dd7dd7b-15ce-457c-8fb9-359cc0536fe9" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments on our operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 are as follows:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.757%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e32f54a6-a909-408e-8520-f139c093754d" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,005</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c0c035ea-da4b-4f6d-bce3-b2e8619f40af" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,327</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0b56be65-626d-4ffd-b508-7b09818c5f28" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,224</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c54d6845-8402-4b9a-b9c8-2c384bd215e5" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,335</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_30f80d49-f191-45de-b817-bbcf2eae5b45" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,454</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b1cf3a8-e24d-4057-9065-426f73ccc078" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,516</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70cdc319-a8d6-485f-951f-e642d88aad61" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,861</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b51d8a85-dc63-467a-a672-e5491aa42114" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,575</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f5f169b5-7b43-492f-b75e-5037a78edaec;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99ebf561-bc1e-4da8-8f87-7dcd24266b8f" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,286</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase Commitments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, we entered into a Commercial Supply Agreement with Corden Pharma CHEN&#212;VE SAS (&#8220;Corden&#8221;), under which we engaged Corden to manufacture and supply certain products related to XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and to perform certain services and studies. Under the agreement, we committed to minimum purchase commitments through December 31, 2027. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88f8deed-cdb6-4265-a464-6df08c05e5fe" contextRef="C_9e3bc0e6-f47d-404f-8fee-30b5fd642601" name="us-gaap:PurchaseObligationDueInNextTwelveMonths" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af9363e9-0f15-4bb6-8a84-b4d50d0f3fe5" contextRef="C_9e3bc0e6-f47d-404f-8fee-30b5fd642601" name="us-gaap:PurchaseObligationDueInSecondYear" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">5.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million U.S. dollar equivalent in purchase commitments under the agreement for the years 2026 and 2027, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company is involved in legal proceedings in the ordinary course of its business. We are not currently a party to any material legal proceedings except as discussed below.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#8220;First Notice Letter&#8221;) from Gland Pharma Limited (&#8220;Gland&#8221;) advising that Gland had submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#8220;GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Patents&#8221;), which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;). The First Notice Letter alleges that the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#8217;s ANDA.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#8217;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the First Notice Letter, the FDA cannot approve Gland&#8217;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 22, 2023, La Jolla received a paragraph IV notice of certification (the &#8220;Second Notice Letter&#8221;) from Gland advising that Gland had amended its ANDA filing to include a paragraph IV certification alleging that all claims of the newly-issued and Orange Book-listed U.S. Patent No. 11,559,559 (the &#8220;&#8217;559 Patent&#8221;), which covers GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are invalid, unenforceable and/or not infringed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 22, 2023, La Jolla filed a First Amended Complaint in this litigation adding Gland&#8217;s marketing and distribution partners for its ANDA angiotensin II product, Fresenius Kabi USA LLC and Fresenius Kabi SwissBiosim GmbH (collectively, the &#8220;Fresenius Kabi Defendants&#8221;), as co-defendants. On April 7, 2023, La Jolla filed a Second Amended Complaint in response to the Second Notice Letter, adding claims that the manufacture, use, sale, offer for sale, or import of Gland&#8217;s ANDA angiotensin II product will infringe the &#8217;559 Patent. On November 14, 2023, La Jolla filed a Third Amended Complaint adding additional infringement claims against the Fresenius Kabi Defendants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 18, 2025, La Jolla, as well as The George Washington University (collectively, with the La Jolla entities, the &#8220;Plaintiffs&#8221;) entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;) with Gland and the Fresenius Kabi Defendants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">137</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_fbdd7324-426c-4165-9771-635c8167c7b3_2"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(collectively, &#8220;Defendants&#8221;) resolving the Hatch-Waxman Act concerning Gland&#8217;s ANDA filing. Under the terms of the Settlement Agreement, Plaintiffs granted Defendants a perpetual, royalty-free and fully paid-up, non-exclusive, non-sublicensable, non-transferable right and license solely to make, have made, use, sell, offer to sell, import, and/or distribute the product that is subject to Gland&#8217;s ANDA in the United States commencing in the early 2030s, subject to certain exceptions as is customary in these type of agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required by law, the settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnifications and Other Contingencies</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, directors, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect on our consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not incurred any material costs and, as of December 31, 2025, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77a26267-8a9c-437a-bfd1-621398d5bf04" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:AccruedLiabilitiesIndemnificationsAndOtherContingencies" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t accrued any liabilities in the consolidated financial statements as a result of these provisions.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a83b1041-7383-43ff-8acd-36ff44c0dcd4" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:AssetAcquisitionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. ASSET ACQUISITION</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_886ab7f6-fedd-4b48-b757-553a486cfc22;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 2025</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we entered into an Asset Purchase Agreement with Lyndra to acquire the IPR&amp;D and certain fixed assets related to its Lynx&#153; long-acting drug delivery platform. We made an upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b6770e5a-064d-4294-9253-d8bc6452905c" contextRef="C_b3eec335-a345-4b7c-9e97-3ceddf99d1e9" name="inva:UpfrontCashPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">10.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a94abec-ed6e-442b-812b-9293a87da87e" contextRef="C_b3eec335-a345-4b7c-9e97-3ceddf99d1e9" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in direct transaction costs. We are also obligated to pay up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_349c11b9-6d14-42d7-a7b5-336395d67867" contextRef="C_12d3c44d-918f-48e8-85fa-931a2e84dfd8" name="inva:FuturePotentialMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">20.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain development, regulatory and sales milestone payments, as well as royalties in a low single-digit percentage on future net sales of the first approved therapeutic product.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the qualitative and quantitative assessments performed under ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we concluded that the set of assets acquired did not meet the definition of a business and, therefore, accounted for the transaction as an asset acquisition. The assets acquired in the transaction were recorded at their allocated costs based on their relative fair values. The allocated cost of the IPR&amp;D acquired was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f239bc2-368c-4e5c-bbbb-ba175bed0383" contextRef="C_3b12d761-39cf-4255-8780-b3b2751a6c1a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">9.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was charged to research and development expense as it had no alternative future use at the time of the acquisition. The allocated cost of the fixed assets, which consist of laboratory equipment, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cb33453-bb38-4c84-80bc-599e977f4aee" contextRef="C_1087a715-1e7f-4e3f-96b3-efbc3f9782ab" name="us-gaap:CapitalizedContractCostNetNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and was capitalized within property and equipment. The fixed assets have not been placed in service and, therefore, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebaa776e-54a6-438e-9444-c0ba02548846" contextRef="C_82eb691b-750a-475a-837f-1b1397fcb267" name="us-gaap:Depreciation" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> depreciation has been recognized as of December 31, 2025.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_8bb927a8-2e95-4a34-9a87-6df0598ab8c2" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_8bb927a8-2e95-4a34-9a87-6df0598ab8c2_1"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. INCOME TAXES</span></p><div><ix:nonNumeric id="F_1a7ced56-41f0-4c33-b20a-1872aca58634" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true" continuedAt="F_1a7ced56-41f0-4c33-b20a-1872aca58634_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of income before provision for income taxes are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.371%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0018f21-36e1-4754-8c78-5cb6f0413340" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">327,060</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_670382c9-0cf4-4e55-a205-c69952ea3063" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,362</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c7b11e1-521f-4061-ba4c-dc504388b5bc" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194,034</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_480b4569-3847-4f72-9875-262070abf10d" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">198</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53bb8c4d-a5cf-4755-9bbc-5468aa863863" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7408528a-bf3b-4d82-b420-618d738eec5f" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">64</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income before provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd1c17d0-eb8d-4d22-940a-0325c7fcf995" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">326,862</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd424ed8-7d49-4d08-9a89-eecfd66190b7" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,388</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_137ea0dc-f825-418e-a466-389c229f6da9" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">194,098</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">138</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_8bb927a8-2e95-4a34-9a87-6df0598ab8c2_1" continuedAt="F_8bb927a8-2e95-4a34-9a87-6df0598ab8c2_2"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_1a7ced56-41f0-4c33-b20a-1872aca58634_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33d6838d-2417-46d1-b28c-bb9918661412" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income tax expense consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.371%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca108d24-ee30-47e1-825f-cf1204030348" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,578</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_264c2d3c-9a5d-4b5f-bec4-a865195c771e" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,438</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9437d738-1a02-4013-a921-2637e64b297e" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,799</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef0d7bbb-97ac-4121-8125-d4f7a3a17614" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,477</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_140d65c1-ce3c-4c3c-83e8-b022390de17c" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,175</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9de96713-cb74-47db-8240-8e5ca01ab794" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2177</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0d9b57c9-98ca-4df6-af44-25301e479491" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,795</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_733feb5f-06b4-4daf-ad3a-9ab268ddbf89" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be98fff9-6f02-450c-9f9a-3cc7ec3d2023" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c97aa92b-850a-4cb6-ae49-af01e2bc533b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,850</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a9db334-0b4a-406f-8fb9-a66bdaf0e989" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,613</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae685665-8ae4-4184-a280-00434425f4f9" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,976</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d6d1584-bdf0-4379-8fba-2fc358b97e3c" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">42,745</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b52a30a-33df-4c51-8f8a-0cef052bc5f6" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,606</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cfa80010-73a3-4afb-8bc5-d55d5da1e327" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,594</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_16ce860b-0029-4dd4-942d-141bdb28285d" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,102</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57da6b5b-cc5f-4084-8879-c35475301bba" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66f97dbe-dbf5-4fc5-8984-6a9c835956ae" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,194</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a488ade8-6f24-4c2e-8006-b0975dd83635" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">43,847</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff527c21-3635-4309-a442-2f2679fb61de" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,617</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a6fafab-b009-49c9-a658-26f6db2f8520" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,400</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_99539bd2-1b8a-47be-b589-1ddf84c4747c" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,697</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3a874f4f-8976-4ea4-816c-7adb8f52b918" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,996</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_40c4534a-019a-446a-a18a-5475d74c9885" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,376</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We adopted ASU 2023-09 on a prospective basis beginning with the year ended December 31, 2025. The following table presents required disclosure pursuant to ASU 2023-09 and reconciles the U.S. federal statutory tax amount and rate to our actual global effective amount and rate of the year ended December 31, 2025</span><span><ix:nonNumeric id="F_298434e9-3a46-4796-b625-e5e6c7c203f7" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_298434e9-3a46-4796-b625-e5e6c7c203f7_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: </span></ix:nonNumeric></span><span style=""></span></p><div><ix:continuation id="F_298434e9-3a46-4796-b625-e5e6c7c203f7_1" continuedAt="F_298434e9-3a46-4796-b625-e5e6c7c203f7_2"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:64.447%;box-sizing:content-box;"/>
         <td style="width:1.88%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:16.537%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.4%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.738%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal tax at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1e78d809-678c-4dcc-89ca-3ecd230da355" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">68,682</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5002674f-6455-44fd-8a52-b071ae4f19ae" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local effects</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_517fc5ee-af94-4656-b409-1fd12f23ccf1" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,739</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9109e66c-349f-4b2b-9c9b-cdbaabe2fdff" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign tax effects</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other - Withholding taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_98209e3d-dd48-4e95-ab1a-7801b867aeef" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,796</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0dd9ce5-72a6-49ef-b2c1-5d37a546d152" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Enactment of new tax laws</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d4046e45-e91a-4059-8417-704db0dd9342" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97b8812e-ebcf-4706-870d-89731e495f9f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cross-border tax laws</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign-derived intangible income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bcc8c2b-aebf-46bf-a866-ffcdbac45743" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,543</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ca7eab8-bd79-45db-a4f3-21bd7f6b0b64" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">2.3</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign tax credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c8bcf0f-b4c6-4f39-ad60-a80ae537229a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,555</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e9f38f5-7b1d-47b3-971a-3bd9d116b7b5" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_428ee736-a981-406e-a79c-7bf47b20242a" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">324</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10951b3e-9023-499b-b657-f42b23bcbe10" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bc51f83-656f-4638-b5c6-4271e390e1cb" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,726</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_36fa9619-33eb-4939-b173-b769de50b29b" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">3.6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69c101cb-19c0-4b7a-b269-1f6644bbc7bc" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">407</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0e5b1d3-06b3-4d27-8739-2117604ca7cb" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_695fec17-42f3-4011-9c43-f25ef544c99f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,709</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8caf3ba6-70c1-4deb-b029-9c4d29330602" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.1</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other adjustments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_49a37162-4b30-4155-80f3-6eefc9e956de" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">488</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bc1ead2c-dabd-457f-80e4-75331b9dfafb" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d75b4103-f846-4080-a8ce-cf73317e0267" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,697</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_01c24fd1-99d9-4c53-98f4-d3a863f90abd" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">17.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	</span><ix:footnote id="FNT_36a39a6f-dfa4-4a07-a213-6e12c7dcf21d" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For tax year 2025, state taxes in Kentucky made up the majority (greater than 50 percent) of the tax effect in this category.</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">139</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_8bb927a8-2e95-4a34-9a87-6df0598ab8c2_2" continuedAt="F_8bb927a8-2e95-4a34-9a87-6df0598ab8c2_3"><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:continuation id="F_298434e9-3a46-4796-b625-e5e6c7c203f7_2"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As previously disclosed for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income tax rate as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:47.56%;box-sizing:content-box;"/>
         <td style="width:1.38%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.58%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.38%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.58%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.26%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected tax at federal statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07bf816a-4947-4a4c-a5f3-ce34db7d3178" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,846</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14d57082-6e4f-490c-ac02-5bc9f40a62d2" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4d4fd102-9300-4795-9d35-7159339cf18d" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,747</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5fa6d3a1-b8eb-473c-a92d-aba4e6a8b189" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">21.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income tax expense, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97535dbd-af98-44e4-8b10-887a950c395e" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,864</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69c864ff-7489-46c2-8f99-f7daedd166e8" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">5.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_663a5e46-b7a2-47b8-835e-4f31bc282a4f" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,433</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5d495d8d-170e-4f7b-97d9-7937a76c4f99" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.7</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state research credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c94eb1de-716f-4656-8a88-afa8501c79e9" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">90</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfbbc144-a33c-4e84-893c-bcfd88afda96" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_acd60602-f854-42d9-8785-d76163778955" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,582</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce5c873f-17db-4fab-bf6d-d8140ec153e1" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.8</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 250 deduction</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0c9514f-a315-4e34-89b5-c9973283c300" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,767</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6339f31c-5424-4060-8662-4b0ba3890d52" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">31.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31d5ce56-5bc0-4b64-9749-8bc134f25a4a" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">15,274</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2e5987a6-0b36-425b-80a8-d9970307c6f1" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">7.9</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe8eb88a-9c43-4fb7-a647-31d2d3e0dabf" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,386</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e25aa395-956a-42d4-9949-cf228e96ae0f" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">49.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f017ee22-ab74-48bb-b3ff-4383c35d1744" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">12,167</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d7d0a17e-ab99-471a-9ab4-bcf885850df8" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">6.2</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1164a2f3-6c5a-4548-87fe-6610d52e6e94" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,243</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_566092b7-0132-40de-a6c8-dde6ccb62e6c" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:num-dot-decimal">6.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2c04e4a5-5e0e-43fe-b25b-abe70c152e19" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,219</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3427f054-9596-4371-8d69-157751881585" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">0.6</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b706d5f-c857-4b69-b874-6882569c5d46" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,996</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ba5ea9f9-9cce-4751-a608-f35e00635c60" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">37.5</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09869c84-05d7-413a-9236-2b89fdad6044" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,376</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a014bcf6-9fdc-42a3-b2b8-fc6dd5e29c35" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">7.4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the income taxes paid (net of any refunds received) for the year ended December 31, 2025 in accordance with the new guidance in ASU No. 2023-09:</span></p></ix:continuation></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_128ad636-d5a4-4305-8d97-5554b754b383" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="inva:IncomeTaxesPaidNetTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.757%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddbc688e-9966-4e1c-8e0a-26a66a19a261" contextRef="C_1ef1ff30-e8ef-4d5c-b296-a140e0ecefb8" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,300</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local jurisdiction</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21086e88-3ea4-4709-93e9-2e995d8156c1" contextRef="C_a676b1bd-fe43-4060-abbc-19a8821970e5" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,377</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_715328e2-b8e6-498e-96de-e7e92b7971f1" contextRef="C_769493ad-88b4-4914-8b59-414f7ab2d4da" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">436</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash paid for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d837cacc-43b2-46b3-9011-5ea46b98cd73" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:IncomeTaxesPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,113</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span><ix:nonNumeric id="F_b0b66eaf-3a89-4bf5-af33-ae91346bdcfa" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_b0b66eaf-3a89-4bf5-af33-ae91346bdcfa_1"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of our deferred tax assets and deferred tax liabilities are as follows:</span></ix:nonNumeric></span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_b0b66eaf-3a89-4bf5-af33-ae91346bdcfa_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:61.232%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.603%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.78%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.603%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa4b3c78-2bdd-494d-a059-1edb8a2b97fd" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">172,440</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce636520-1230-4ded-ab91-bda713703523" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,989</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_edaf70d4-c68e-400c-ab69-bd2255aceb66" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,270</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_020dd3ea-a9bd-4494-8417-e41af0474885" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,359</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized losses on investment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_520c1826-e2d0-456d-9f3d-69feced8bd88" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b88b22f4-4914-4c58-9c7e-729f35325e52" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,481</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred royalty obligation, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b3c19bf-ab39-4f07-95d4-56545ead6412" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:DeferredTaxAssetsDeferredRoyaltyObligationNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,654</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_059900d8-f359-41a8-893a-91481f7563a2" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:DeferredTaxAssetsDeferredRoyaltyObligationNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,452</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_09fd6e8d-4ac7-42ec-8b66-f592b7c14a72" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,479</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_092ccbbb-45ca-48cd-9374-bd3f1a5447ec" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_832f9b21-f58d-42ea-8f47-04efb32681c9" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,942</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af3ce170-cc06-4be1-a889-9af7d502ce14" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,832</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e41f2ea1-158d-4243-8112-9935787100bd" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">217,785</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f776ebd5-40dd-4d99-801d-14a622078960" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">234,113</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3e81f64-e7f7-421a-9c99-a306deb86ce1" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">176,151</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b32db38f-65b6-4b0d-9e69-37998bb2acf7" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">187,635</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d336dab-9219-4870-9214-aedfefcbc490" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,634</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f26497a-486d-4f32-abe5-bf3db4768669" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">46,478</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fed6e15-b3e1-4cc9-a282-476a6729746b" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:DeferredTaxLiabilitiesDepreciationAndAmortization1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">32,205</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eae6c5c2-25ed-4996-b53c-a64af843ebfb" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:DeferredTaxLiabilitiesDepreciationAndAmortization1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,626</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gains on investment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff1cc3ad-8ad1-446c-9a28-b7cdae18cfea" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredTaxLiabilitiesInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">37,823</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_69cfc4ef-0d7a-48ed-97b0-c5aab0d088cc" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredTaxLiabilitiesInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory fair value adjustment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b8ad3dd-6177-4e98-ab0a-fe2c573cdc6a" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">986</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6f68ef6-5416-4995-a97a-83a701837e91" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,798</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_725a8f78-5407-49ec-b7b5-7dc445111736" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,413</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a33381c0-31bb-481f-ba9b-e82d7517a6a1" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredTaxLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_70b42814-1a60-428e-926d-11abd4227c2e" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,793</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9ecd144-3aea-4cda-b062-dd2aabf6efd3" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">12,054</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></ix:continuation></div></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">140</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_8bb927a8-2e95-4a34-9a87-6df0598ab8c2_3"><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record deferred tax assets if the realization of such assets is more likely than not to occur. Significant management judgment is required in determining whether a valuation allowance against the deferred tax assets is required. We have considered all available evidence, both positive and negative, such as our historical operating results and predictability of future taxable income, in making such determination. We are also required to exercise significant management&#8217;s judgment in forecasting future taxable income. Specifically, we evaluate the following criteria when considering a valuation allowance:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the history of tax net operating losses in recent years;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">predictability of operating results;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">profitability for a sustained period of time; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">level of profitability on a quarterly basis.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we had federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b9dff14-ed28-4d00-9be4-46a9e378f484" contextRef="C_f82e39f9-72f9-4bd5-b3fc-b3493d1d8807" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">497.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8bd2cf39-8b0f-4fc8-9514-412381d86686" contextRef="C_f82e39f9-72f9-4bd5-b3fc-b3493d1d8807" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">448.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of which do not expire. We </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">also had state net operating loss carryforwards of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a432c2f1-c1db-472a-87e8-c29638f253f9" contextRef="C_9384f77e-6605-4a4c-8810-bf720c3d9a70" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">1,028.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will expire</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> beginning </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d97c91ae-1703-4480-a2ca-20778c18458e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2030</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and state research tax credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9648c101-fb67-4346-b1f0-e8b206d08995" contextRef="C_ff2f5579-9b38-485b-a615-3c335d3187e6" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which will expire beginning </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e2ca3e4b-1265-4708-9028-4bacbb4bf6a7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2033</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted an Internal Revenue Code of 1986, as amended, Section 382 (&#8220;Section 382&#8221;) analysis through December 31, 2025 to determine whether an ownership change had occurred since inception. The Section 382 study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. However, notwithstanding the applicable annual limitations, no portion of the net operating loss or credit carryforwards is expected to expire before becoming available to reduce federal and state income tax liabilities as a result of those identified ownership changes. If we undergo an ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fec180d6-6c2e-458a-8bde-b4133ee2ad77" contextRef="C_3dffd990-dade-4459-b4ce-3100fb9fd1df" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">146.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of Entasis&#8217; federal net operating losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3752130c-0e24-49ef-afdf-baa78aa00557" contextRef="C_cdd50e55-f430-4309-b1e7-fe3c5bc72c13" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">351.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of La Jolla&#8217;s federal operating losses from the acquisitions in 2022, both subject to annual limitations, were available for future utilization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2025 and 2024, we have accrued interest or penalties of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_006bc325-8870-403e-99a3-ac97089dde54" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">3.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c41b75fd-688d-49a2-9d02-63a5dd0248ba" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">0.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Uncertain Tax Positions</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_105968db-25a0-4375-98e4-ec8cbf024860" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"/>
         <td style="width:1.8%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:15.757%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2022</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ac575bb-e99a-4e4f-9ff2-50ec2d689fc7" contextRef="C_a60c1143-acae-40be-9475-53a07ff86264" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,324</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in tax portions for 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4688d703-0e05-40d3-8c63-6198f7f249ea" contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,119</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4aa85f6-a7f2-4923-a9a7-ae3714d5d8ff" contextRef="C_a6f00937-2ee4-4566-bd68-45c44b998d3b" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,443</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in tax portions for 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d10aafd8-0dd5-4099-8d28-0f053dcd040b" contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,851</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b48941aa-17db-43d4-998e-f2739eef5cca" contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">61,294</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in tax portion for 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35561e2f-a360-426c-810a-e7bc0f45e562" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,415</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5a5b8420-28ce-497c-94fc-9661c8b9387c" contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">62,709</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to taxation in the U.S. and various state </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jurisdictions. The tax years 2006 through 2013, 2015 and forward remain open to examination by the federal and most state tax authorities due to net operating loss and overall credit carryforward positions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">141</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><a href="#toc"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Table of Contents</span></a></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_e712617a-4573-4b84-8475-52358b2a12ba" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:SegmentReportingDisclosureTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. SEGMENT REPORTING</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate as a single operating and reportable segment, focused on creating value for our stockholders. We achieve this by maximizing the value of our respiratory royalty portfolio and growing our investments in innovative healthcare assets that address critical unmet medical needs.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), evaluates the Company&#8217;s financial performance and operational efficiency using consolidated net income. This helps guide decisions related to commercial operations, product development, and regulatory compliance, ensuring resources are allocated effectively to support growth initiatives. Consolidated net income also helps inform reinvestment strategies to strengthen our market position and drive innovation.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of the segment are the same as those described in Note 1, &#8220;Description of Operations and Summary of Significant Accounting Policies&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as well as license and other revenues. Refer to Note 3, &#8220;Revenue Recognition&#8221;, for more information on our revenues for the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our long-term assets are located within the United States. The CODM does not review assets at a different level or category than the amounts disclosed in the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_648bc704-5c66-47cf-8a02-fb6d650236c8" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" escape="true" continuedAt="F_648bc704-5c66-47cf-8a02-fb6d650236c8_1"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below presents the financial information used by the CODM to assess performance, which reconcile to the consolidated net income:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.371%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:12.122%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec6e9697-1dec-487f-a01e-fc0d317535b0" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">411,328</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9b81202a-d99d-4507-91be-57206751d2ac" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">358,711</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b41d0218-0a17-4bda-8231-27cbfd962038" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">310,463</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of products sold</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9b975d3-1832-4511-9005-57ff9f43315c" contextRef="C_add7b0b6-f915-44d8-9105-5a165235bb5f" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,384</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e725f5ee-4a79-49e9-a18c-80bcae8cb560" contextRef="C_fbf1519b-20bc-45f3-9a32-993d11ff1a9a" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,598</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_93ad22c2-31e0-4369-b3ad-11c946377a22" contextRef="C_5f25c1f8-433a-423e-bc21-4d71d0ad9d56" name="us-gaap:CostOfGoodsAndServicesSold" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">41,040</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of license revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_575dcbed-a14a-48c2-9fcb-394c2d4baeda" contextRef="C_3abf2681-e826-490a-9f8d-3f1f04055925" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de22f2c3-e771-42e2-8162-18bc3d5b9b5e" contextRef="C_fb40e1d0-39fb-4a52-b44c-a1ea5cf0b3b5" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c8dc362a-6c8e-4a77-a6f9-d041424cd3b6" contextRef="C_4fd4e6e2-8b75-4ad1-8522-73d454c9804c" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,600</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of acquired intangible assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9f75fb62-cbce-4827-a043-1d7932b8d0f3" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,277</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fe1d75ce-e79e-4fb3-8f6a-e06a5077fed2" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,902</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3042e71-3c9d-4093-86ea-6d57ac118fab" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,784</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4ddb1109-045d-4cf1-b052-c78aa6c1cb38" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">36,502</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6ab699c-50bf-45a4-a935-f872627d6873" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">31,441</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5c4defac-4840-4858-8edb-5cb0daba494f" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="us-gaap:SellingAndMarketingExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">30,739</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6820cd4-f942-42d1-ac07-01b494d4325b" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">76,816</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5f1bbcd-b533-4b56-a6ee-8dcd53077dd9" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,249</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a968f83d-a4e8-4647-be56-3e052a2f809e" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,493</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - External services and expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a835d353-fb3f-458f-99bb-cf18ac2d5f14" contextRef="C_f8268174-30fe-44ea-9afa-6854f75ab23e" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,705</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_952daf13-46ae-41f4-923a-4cc0c161ebfe" contextRef="C_a16a824d-5e09-43a8-8e7c-eb26e31d2066" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,408</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d791bc24-bb4d-4b7d-a262-ce4ce184c76a" contextRef="C_bec30008-f686-4815-ac74-3fb4d99703f8" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,051</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - Internal expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ebf10f27-a1a7-40f2-9af8-945381a753d9" contextRef="C_b531a65e-a381-43b5-9fc1-7c2a415d40f1" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,531</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9d86678-bd1b-414d-bbc9-d056807104fc" contextRef="C_95f17691-1422-4df6-a2c2-e728a595c89b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">6,246</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a416e1a0-e05b-4911-aa45-3a011381b851" contextRef="C_325eaf5e-1225-4fc5-8b0c-361313195292" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,871</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - Acquired IPR&amp;D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1854cd08-7e85-4aa9-b410-3799b3ea6e27" contextRef="C_3b0f0144-4aec-4d86-b2d3-8de8224c3e06" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,368</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b39fc078-2950-4489-b3df-546a43b9f82f" contextRef="C_67ee3158-4444-4bb2-b548-1b1d24bb1077" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97607b7c-754a-4619-9f73-6e958f3f4be5" contextRef="C_ca4eb91e-0456-4f17-b035-ed0e47cc770a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity method investments, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d875dbf0-f2aa-4e5c-9423-06d297a278df" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">141,433</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c30f436f-c08b-44dc-8fbb-0daff351d607" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">64,253</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c6d86d48-c9a8-4334-848d-54d4666200c2" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="us-gaap:IncomeLossFromEquityMethodInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,392</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity and long-term investments, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee08c616-fa9f-4e0c-bb93-bfa9a908ec9f" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">20,160</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_303adb9c-906a-4ad3-a906-9e5befba8255" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">59,161</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d402515-6d17-4b04-bef0-b1b6ed26f522" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="inva:GainLossOnOtherInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,129</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and dividend income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_566884c8-9a19-455d-9792-aeef5436195c" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,086</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bf4f2fb-4953-4aea-8499-e85913ac67cb" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,141</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_82131da8-b1f8-4038-9daf-12a6dceb6239" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="us-gaap:InterestAndDividendIncomeOperating" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,818</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0aeda1aa-f6f3-4674-b559-1d1c5ce25aec" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">16,698</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a374d1be-75b2-4ed6-b9ad-682e2c99a1f8" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">22,209</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1005386f-5069-4ce5-8ad1-51673554ee10" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">19,157</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61a0e9b4-5330-4130-b40b-1e5d65a99a0c" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,864</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9582d89a-8365-4b64-9e4f-916479c39e08" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,997</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ee0a9ee-b696-40c0-9e2c-d9cf030d17ba" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,969</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_07e9e0e4-ea8e-4a43-a299-a1285269f3d6" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">55,697</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_15c03031-0ce0-435e-a47b-381776552fff" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,996</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_649d3448-124a-450b-a3c2-4f132cb84132" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">14,376</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated net income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9199d056-fe33-46bb-9c2e-be6d24c1d1aa" contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">271,165</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_812a9cf2-19e7-4dec-b0a0-b71e07099f23" contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,392</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_938810a2-66c6-4c5d-8302-5748127659cf" contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:num-dot-decimal">179,722</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_648bc704-5c66-47cf-8a02-fb6d650236c8_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">142</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="reports_of_independent_registered_1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:11pt;font-family:Arial;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Innoviva, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d6cff2a-7254-40e3-9ef6-d50be41fedf5" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:AuditorOpinionTextBlock" escape="true"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Innoviva, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and December 31, 2024, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and December 31, 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2025, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25, 2026, expressed an unqualified opinion on company&#8217;s internal control over financial reporting.</span></p></ix:nonNumeric></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Critical Audit Matter</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">143</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Consolidated Entities and Equity and Long-term Investments&#8212;Primary Beneficiary Determination for Variable Interest Entities&#8212;Refer to Notes 1, 5, and 6 to the consolidated financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Critical Audit Matter Description</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company invests in equity and debt securities of private and public companies. The Company evaluates its interests in these entities to determine whether they meet the definition of a variable interest entity (VIE) or a voting interest entity (VOE) and whether the Company is required to consolidate these entities. A VIE is consolidated by its primary beneficiary, which is the party that has both 1) the power to direct the activities that most significantly impact the economic performance of the VIE and 2) a variable interest that absorbs losses or receives benefits from the VIE that could potentially be significant to the VIE. To determine whether a variable interest that the Company holds could potentially be significant to the VIE, the Company considers both qualitative and quantitative factors regarding the nature, size and form of the Company&#8217;s involvement with the VIE. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE. The Company will reconsider whether an entity is a VIE and whether the Company is the primary beneficiary of the entity upon the occurrence of certain types of events. The determination of the primary beneficiary of a VIE requires significant management judgment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We identified the primary beneficiary determination for the Company&#8217;s VIEs as a critical audit matter due to the complexity of the accounting principles related to the determination of the primary beneficiary of a VIE and the significant judgment required by management in evaluating the Company&#8217;s role in establishing the VIE, their ongoing rights and responsibilities and identifying which party, if any, has power over those activities. This required a high degree of auditor judgment and an increased extent of effort, including the involvement of professionals with consolidation accounting expertise, when performing audit procedures to evaluate the Company&#8217;s determination of whether it is the primary beneficiary for its VIEs.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">How the Critical Audit Matter Was Addressed in the Audit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our audit procedures related to the primary beneficiary determination for VIEs included the following, among others:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;margin-right:5.083%;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We tested the effectiveness of controls over the Company&#8217;s primary beneficiary determination for its VIEs, including management&#8217;s determination of the party that has the power to direct the activities that most significantly impact the economic performance of the VIE and a variable interest that absorbs losses or receives benefits from the VIE that could potentially be significant to the VIE.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We evaluated the appropriateness of the Company&#8217;s accounting conclusions for consolidated and unconsolidated VIEs through the following:</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the investment structures and terms of the agreements, including reading the purchase agreements and other related documents which govern the formation and activities of the entity (the Contractual Arrangements).</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tested whether the Company appropriately determined the primary beneficiary by evaluating the Contractual Arrangements of the entity to determine if the Company has the power to direct activities that most significantly impact the economic performance of the VIE, and if the Company has the obligation to absorb losses of the entity or the right to receive benefits from the entity that could be significant to the VIE.</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For certain VIEs, with the assistance of professionals with expertise in consolidation accounting, evaluated the appropriateness of the Company&#8217;s determination of the primary beneficiary of the VIE.</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluated the Company&#8217;s disclosures related to the primary beneficiary determination of its consolidated entities and unconsolidated VIEs</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Jose, California</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 25, 2026</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have served as the Company&#8217;s auditor since 2022.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">144</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:-8.696%;padding-left:8%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_9_changes_in_and_disagreements_with"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9A. CONTROLS AND PROCEDURES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Evaluation of Disclosure Controls and Procedures.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted an evaluation as of December 31, 2025, under the supervision and with the participation of our management, including our chief executive officer, chief financial officer and chief accounting officer, of the effectiveness of the design and operation of our disclosure controls and procedures, which are defined under SEC rules as controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within required time periods specified in the Commission&#8217;s rules and forms and controls and procedures that are designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decision regarding required disclosure. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance levels.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Management&#8217;s Report on Internal Control over Financial Reporting</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rule 13a&#8209;15(f) of the Exchange Act. Internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on criteria established in the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Management&#8217;s assessment included evaluation of such elements as the design and operating effectiveness of key financial reporting controls, process documentation, accounting policies, and our overall control environment. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2025.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our independent registered public accounting firm, Deloitte &amp; Touche LLP, has audited our internal control over financial reporting as of December 31, 2025. Their attestation report on the audit of our internal control over financial reporting is included below.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Limitations on the Effectiveness of Controls</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our management, including our principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all frauds. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within Innoviva have been detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Changes in Internal Control over Financial Reporting</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no material changes to our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) for the year ended December 31, 2025 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">145</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6.5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To the Stockholders and the Board of Directors of Innoviva, Inc.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:9.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.324%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the internal control over financial reporting of Innoviva, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2025, based on criteria established in Internal Control&#8212;Integrated Framework (2013) issued by COSO.</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.157%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2025, of the Company and our report dated February 25, 2026, expressed an unqualified opinion over those financial statements.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basis for Opinion</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.157%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.157%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Definition and Limitations of Internal Control over Financial Reporting</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.157%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;margin-right:3.157%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f0529a2-7096-4fd0-bb5e-18121d977f1f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:AuditorName"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deloitte &amp; Touche LLP</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f114cd43-1997-4c6a-a0be-687ad92c7b9f" contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb" name="dei:AuditorLocation"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Jose, California</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 25, 2026</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">146</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_9b_other_information"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9B. OTHER INFORMATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Trading Arrangements</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None of the Company&#8217;s directors or officers </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c32b468e-c77a-4106-aca0-e007f94863d8" contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_2a476357-8882-452d-b8df-1c93bcce2793" contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">adopted</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1818786-fb0b-4267-9d3c-6ca9c7b6166c" contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b" name="inva:Rule10B51ArrModifiedFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_8d45587c-1c08-484f-abd8-754505e0fe08" contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b" name="inva:NonRule10B51ArrModifiedFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">modified</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, or </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30f27388-7eec-4973-a60f-4fd8887cf2f5" contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false"><ix:nonNumeric id="F_f8fc4b6b-633c-4946-bddf-2bc747bdedd1" contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">terminated</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company&#8217;s fiscal year ended December 31, 2025.</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_9c_disclosure_regarding_foreign_jur"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 9C. DISCL</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">OSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Not applicable.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">147</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="part_iii"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART III</span></p><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_10_directors_executive_officers_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_11_executive_compensation"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 11. EXECUTIVE COMPENSATION</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2025.</span></p><p style="text-indent:-9.012%;padding-left:8.267%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_12_security_ownership_of_certain"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than with respect to the Securities Authorized for Issuance under Equity Compensation Plans below, the information required by this Item is incorporated by reference from our proxy statement for our 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Securities Authorized for Issuance under Equity Compensation Plans</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table provides certain information with respect to all of our equity compensation plans in effect as of December 31, 2025:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:55.429%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.818%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.02%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.338000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.56%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:10.818%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:2.02%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Plan Category</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities to be issued upon exercise of outstanding options and vesting of outstanding restricted stock units and restricted stock awards</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted&#8209;average exercise price of outstanding options</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(a)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(b)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(c)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity compensation plans approved by security holders</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,758,334</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.08</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(2)</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,385,786</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#160;(3)</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes 2,833,887 shares issuable upon exercise of outstanding options and 924,447 shares issuable upon vesting of outstanding RSUs and RSAs.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(2)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Does not take into account outstanding restricted stock units as these awards have no exercise price.</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:10pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(3)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Includes 2,385,766 shares of common stock available under our Employee Stock Purchase Plan.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_13_certain_relationships_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_14_principal_accounting_fees_and"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item is incorporated by reference from our proxy statement for our 2026 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of our fiscal year ended December 31, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">148</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="part_iv"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PART IV</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_15_exhibits_and_financial_statement"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(a)   The following documents are filed as part of this Annual Report on Form 10&#8209;K:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.    Financial Statements:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following financial statements and schedules of the Registrant are contained in Part II, Item 8, &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10&#8209;K:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:93.8%;box-sizing:content-box;"/>
     <td style="width:6.2%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:0.7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:7.2pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.351%;padding-left:1.333%;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_balance_sheets"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Balance Sheets as of December 31, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_income"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Income and Comprehensive Income for each of the three years in the period ended December 31, 2025</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_stockholders"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Stockholders&#8217; Equity for each of the three years in the period ended December 31, 2025</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#consolidated_statements_of_cash_flows"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consolidated Statements of Cash Flows for each of the three years in the period ended December 31, 2025</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes_to_consolidated_financial"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to Consolidated Financial Statements</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">102</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#reports_of_independent_registered_1"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Report of Independent Registered Public Accounting Firm (PCAOB ID 34)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.    Financial Statement Schedules:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All schedules have been omitted because of the absence of conditions under which they are required or because the required information, where material, is shown in the financial statements, financial notes or supplementary financial information.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(b)   Exhibits required by Item 601 of Regulation S&#8209;K:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The information required by this Item is set forth on the exhibit index that follows the signature page of this report.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;" id="item_16_form_10_k_summary"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 16. FORM 10&#8209;K SUMMARY</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">None.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">149</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="exhibits"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibits</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7.58%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:55%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.4%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:0.7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="5" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Incorporated by Reference</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filed Herewith</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">    </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Description</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">    </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Form</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">    </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Exhibit</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">    </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Filing</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date/Period</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">End Date</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122020321/ny20004305x1_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Agreement and Plan of Merger, dated as of May 23, 2022, by and among Innoviva, Inc., Innoviva Merger Sub, Inc. and Entasis Therapeutics</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/24/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/ny20004741x1_ex2-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Agreement and Plan of Merger, dated as of July 10, 2022, by and among Innoviva, Inc., Innoviva Acquisition Sub, Inc. and La Jolla Pharmaceutical Company</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/11/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465916115299/a16-9600_1ex99d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Certificate of Incorporation</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/28/2016</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465923000897/tm231444d1_ex3-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Bylaws, amended and restated as of January 1, 2023</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/4/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465907015079/a07-1942_1ex4d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Specimen certificate representing the common stock of the registrant</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/31/2006</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913004773/a12-25051_9ex4d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Indenture, dated as of January 24, 2013 by and between Theravance, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/25/2013</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913004773/a12-25051_9ex4d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of 2.125% Convertible Subordinated Note Due 2023</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/25/2013</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465917049927/a17-18560_4ex4d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Indenture (including form of Note) with respect to Innoviva&#8217;s 2.50% Convertible Senior Notes due 2025, dated as of August 7, 2017, between Innoviva and The Bank of New York Mellon Trust Company, N.A., as trustee</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/7/2017</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465920022807/ex-4d9.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/19/2020</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465922031613/tm228653d1_ex4-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Indenture (including form of Note) with respect to Innoviva&#8217;s 2.125% Convertible Senior Notes due 2028, dated as of March 7, 2022, between Innoviva, Inc. and The Bank of New York Mellon Trust Company, N.A., as trustee</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/8/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914058343/a14-13984_1ex10d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Collaboration Agreement between the registrant and Glaxo Group Limited, dated as of November 14, 2002</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/30/2014</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746904020116/a2136994zex-10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Investors&#8217; Rights Agreement by and among the registrant and the parties listed therein, dated as of May 11, 2004</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">S&#8209;1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/10/2004</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746914001691/a2218387zex-10_13.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Strategic Alliance Agreement between the registrant and Glaxo Group Limited, dated as of March 30, 2004</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/31/2013</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746910001540/a2196645zex-10_22.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Description of Cash Bonus Program, as amended</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/31/2009</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746910001540/a2196645zex-10_47.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Change in Control Severance Plan effective December 16, 2009</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.47</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/31/2009</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746910001540/a2196645zex-10_48.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2009 Change in Control Severance Plan adopted December 16, 2009</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.48</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/31/2009</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.8</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465910060202/a10-21843_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to Amended and Restated Governance Agreement among the registrant, Glaxo Group Limited, GlaxoSmithKline plc and GlaxoSmithKline LLC, dated as of November 29, 2010</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11/29/2010</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.9</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746912001614/a2207068zex-10_34.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment to Strategic Alliance Agreement, dated October 3, 2011</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/31/2011</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.10+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465912053222/a12-11849_1ex10d38.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2012 Equity Incentive Plan, as approved by the board of directors February 8, 2012 and approved by stockholders May 16, 2012 and forms of equity award</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.38</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/30/2012</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.11</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913003879/a12-25051_8ex10d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Base Capped Call Transaction, dated January 17, 2013</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/23/2013</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.12</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465913003879/a12-25051_8ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Additional Capped Call Transaction, dated January 18, 2013</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1/23/2013</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.13</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Master Agreement by and among Theravance, Inc., Theravance Biopharma, Inc. and Glaxo Group Limited, dated March 3, 2014</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/6/2014</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.14*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Collaboration Agreement Amendment by and between Theravance, Inc. and Glaxo Group Limited, dated March 3, 2014</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/6/2014</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.15*</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914017128/a14-7412_1ex10d3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Strategic Alliance Agreement Amendment by and between Theravance, Inc. and Glaxo Group Limited, dated March 3, 2014</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K/A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/6/2014</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.16</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Transition Services Agreement between Theravance and Theravance Biopharma, dated June 2, 2014</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/5/2014</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.17</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d3.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Tax Matters Agreement between Theravance and Theravance Biopharma, dated June 2, 2014</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/5/2014</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">150</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7.58%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:55%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.4%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.18</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d4.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Employee Matters Agreement between Theravance and Theravance Biopharma, dated June 1, 2014</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.4</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/5/2014</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.19</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465914044231/a14-14482_1ex10d5.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Theravance Respiratory Company, LLC Limited Liability Company Agreement between Theravance and Theravance Biopharma, dated May 31, 2014</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.5</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6/5/2014</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.20</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465915036218/a15-7167_1ex10d64.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment/Clarification to Transition Services Agreement between Theravance and Theravance Biopharma, dated March 2, 2015</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.64</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/31/2015</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.21+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465915054328/a15-16369_1ex10d2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">First Amendment to 2009 Change In Control Severance Plan (Renamed 2009 Severance Plan)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/29/2015</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.22</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000104746918001016/a2234562zex-10_76.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Form of Notice of Performance&#8209;Based Restricted Stock Award and Restricted Stock Award Agreement under 2012 Equity Incentive Plan (director form)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.76</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/23/2018</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.23+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465918047409/a18-14089_1ex10d81.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Second Amendment to 2009 Severance Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10&#8209;Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.81</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/26/2018</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.24+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914018000502/i25948910b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter with Marianne Zhen, dated September 7, 2018</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9/11/2018</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.25+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914020000275/i35135265b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter between Innoviva, Inc. and Pavel Raifeld, dated May 20, 2020</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/26/2020</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.26+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914022000493/i5271437b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter between Innoviva, Inc. and Pavel Raifeld, dated April 29, 2022</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/2/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.27</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000119312520316331/d69428dex101.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Strategic Advisory Agreement, dated as of December 11, 2020, by and between Sarissa Capital Management LP and Innoviva, Inc.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/14/2020</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.28</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000119312520316331/d69428dex102.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Limited Partnership Agreement of ISP Fund LP, dated as of December 11, 2020, by and among ISP Fund LP, Sarissa Capital Fund GP LP, Innoviva Strategic Partners LLC and the other parties named therein</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8&#8209;K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/14/2020</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.29</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914021000501/i052021b.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Share Repurchase Agreement, dated as of May 2021, by and between Innoviva, Inc. and Glaxo Group Limited</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/20/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.30</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000089914021000501/i052021c.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Letter Agreement, dated as of May 20, 2021, by and among Innoviva Strategic Partners LLC, ISP Fund LP and Sarissa Capital Fung GP LP</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/20/2021</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.31</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465922031613/tm228653d1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Capped Call Confirmation dated March 2, 2022, by and among Innoviva, Inc., Bank of America, N.A., Goldman Sachs &amp; Co. LLC and Deutsche Bank AG, London Branch</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3/8/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.32</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122020321/ny20004305x1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amendment No. 1 to the Investor Rights Agreement, dated May 23, 2022, by and among Innoviva, Inc. and Entasis Therapeutics Holdings Inc.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/24/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.33</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025657/ny20004741x1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Support Agreement, dated July 10, 2022, by and among Innoviva, Inc., Innoviva Acquisition Sub, Inc., Tang Capital Partners, LP and Kevin C. Tang Foundation</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/11/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.34</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025945/ny20004764x1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Equity Purchase Agreement, dated July 13, 2022, by and among Innoviva, Inc., Innoviva TRC Holdings LLC and Royalty Pharma Investments 2019 ICAV</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/13/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.35</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000114036122025945/ny20004764x1_ex10-2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Third Amendment to Collaboration Agreement, dated July 13, 2022, by and among Innoviva, Inc., Glaxo Group Limited, and Theravance Respiratory Company, LLC.</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7/13/2022</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.36+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000095017023019835/inva-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Transition Agreement between Larry Edwards and Innoviva Specialty Therapeutics, Inc., dated February 23, 2023, and Release of Claims form signed by Larry Edwards, dated April 5, 2023</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-Q</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5/9/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.37</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1080014/000119312523127442/d488837ddef14a.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">2023 Employee Stock Purchase Plan</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">DEF 14A</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4/28/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.38+</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000110465923095406/tm2324789d1_ex10-1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Offer Letter between Innoviva, Inc. and Stephen Basso dated July 28, 2023</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8/25/2023</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000095017025027864/inva-ex19.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Amended and Restated Insider Trading Policy and Guidelines with Respect to Certain Transactions in Securities (effective as of March 15, 2023)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12/31/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex21_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">List of Subsidiaries</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex23_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23.3</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consent of Ernst &amp; Young LLP Independent Registered Public Accounting Firm of Armata Pharmaceuticals, Inc.**</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#power_of_attorney"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Power of Attorney (see signature page to this Annual Report on Form 10&#8209;K)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
   </table></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">151</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7.58%;box-sizing:content-box;"/>
     <td style="width:2%;box-sizing:content-box;"/>
     <td style="width:55%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:9%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:8.4%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex31_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rule 13a&#8209;14 under the Securities Exchange Act of 1934</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.2</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex31_2.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rule 13a&#8209;14 under the Securities Exchange Act of 1934</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32#</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="inva-ex32.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Certifications Pursuant to 18 U.S.C. Section 1350</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1080014/000095017024023237/inva-ex97.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Innoviva Clawback Policy (effective as of October 2, 2023)</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10-K</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2/29/2024</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Audited Consolidated Financial Statements of Armata Pharmaceuticals, Inc. at December 31, 2025, for the year ended December 31, 2025**</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.INS</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.SCH</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.CAL</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.DEF</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.LAB</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.PRE</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">X</span></p></td>
    </tr>
   </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">+     Management contract or compensatory plan or arrangement required to be filed pursuant to Item 15(b) of Form 10&#8209;K.</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">*     Confidential treatment has been granted for certain portions which are omitted in the copy of the exhibit electronically filed with the Securities and Exchange Commission. The omitted information has been filed separately with the Securities and Exchange Commission pursuant to Innoviva, Inc.&#8217;s application for confidential treatment.</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">**   To be filed by amendment to this Annual Report on Form 10-K.</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">#     Furnished herewith.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">152</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="signatures"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:47.42%;box-sizing:content-box;"/>
     <td style="width:3.42%;box-sizing:content-box;"/>
     <td style="width:49.16%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">INNOVIVA, INC.</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;text-indent:10pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-1.888%;padding-left:1.853%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 25, 2026</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ PAVEL RAIFELD</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pavel Raifeld<br/></span><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:center;" id="power_of_attorney"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">POWER OF ATTORNEY</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Pavel Raifeld, as their true and lawful attorney&#8209;in&#8209;fact and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to the Annual Report on Form 10&#8209;K, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney&#8209;in&#8209;fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she could do in person, hereby ratifying and confirming all that said attorney&#8209;in&#8209;fact and agent, or his substitutes, may lawfully do or cause to be done by virtue hereof.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:37.808%;box-sizing:content-box;"/>
     <td style="width:3.001%;box-sizing:content-box;"/>
     <td style="width:37.828%;box-sizing:content-box;"/>
     <td style="width:3.001%;box-sizing:content-box;"/>
     <td style="width:18.364%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:0.7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Signature</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">    </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Title</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">    </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Date</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ PAVEL RAIFELD</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pavel Raifeld</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Executive Officer<br/>(Principal Executive Officer)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2026</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ STEPHEN BASSO</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Basso</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chief Financial Officer (Principal<br/>Financial Officer)</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2026</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ MARK DIPAOLO</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Mark DiPaolo, Esq.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Chairman of the Board</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2026</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ JULES HAIMOVITZ</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Jules Haimovitz</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2026</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ SARAH SCHLESINGER</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Sarah Schlesinger, M.D.</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2026</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;border-bottom:0.5pt solid;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ DEREK SMALL</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Director</span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td rowspan="2" style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2026</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derek Small</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;margin-left:0;margin-right:0;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">153</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>inva-ex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T16:04:37.5058+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-21.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 21.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">LIST OF SUBSIDIARIES</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:60.552%;box-sizing:content-box;"></td>
     <td style="width:1.64%;box-sizing:content-box;"></td>
     <td style="width:21.104%;box-sizing:content-box;"></td>
     <td style="width:1.64%;box-sizing:content-box;"></td>
     <td style="width:15.063%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Name</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Jurisdiction</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ownership<br>Interest</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Advanced Medicine East, Inc</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Innoviva Strategic Partners LLC</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Innoviva Royalty Sub LLC</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Innoviva TRC Holdings LLC</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Innoviva Strategic Opportunities LLC</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISP Fund LP</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Innoviva Specialty Therapeutics Holdings LLC</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Innoviva Specialty Therapeutics Inc.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ISTx, LLC</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entasis Therapeutics Holdings Inc.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entasis Therapeutics Inc.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Entasis Therapeutics (Ireland) Limited</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Ireland</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">La Jolla Pharmaceutical Company</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">La Jolla Pharma, LLC</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tetraphase Pharmaceuticals, Inc.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">La Jolla Pharmaceutical Holdings, LLC</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nortiva Bio, Inc.</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Delaware</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</font></p></td>
    </tr>
   </table><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>inva-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T16:04:37.5046+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 23.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:12.05pt;font-family:Times New Roman;margin-bottom:0;margin-right:1.806%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consent to the incorporation by reference in Registration Statement Nos. 333-275502, 333-119559, 333-129669, 333-150753, 333-159042, 333-173923, 333-181763, and 333-197950 on Form S-8 of our reports dated February 25, 2026, relating to the financial statements of Innoviva, Inc. and the effectiveness of Innoviva, Inc.'s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December 31, 2025.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/s/ Deloitte &amp; Touche LLP</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">San Jose, California</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">February 25, 2026</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>inva-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T16:04:37.4985+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification of Principal Executive Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 302 of the Sarbanes&#x2011;Oxley Act of 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Pavel Raifeld, certify that:</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.           I have reviewed this Annual Report on Form 10&#x2011;K of Innoviva, Inc.;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.           The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15(d)&#x2011;15(f)) for the registrant and have:</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c)            Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d)           Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.            The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:5%;box-sizing:content-box;"></td>
     <td style="width:44%;box-sizing:content-box;"></td>
     <td style="width:2%;box-sizing:content-box;"></td>
     <td style="width:49%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ PAVEL RAIFELD</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0in;text-indent:3pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pavel Raifeld</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0in;text-indent:3pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td colspan="2" style="padding-top:0in;text-indent:3pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>inva-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T16:04:37.4879+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 31.2</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certification of Principal Financial Officer</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to Section 302 of the Sarbanes&#x2011;Oxley Act of 2002</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Stephen Basso, certify that:</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.           I have reviewed this Annual Report on Form 10&#x2011;K of Innoviva, Inc.;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.           The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#x2011;15(e) and 15d&#x2011;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#x2011;15(f) and 15(d)&#x2011;15(f)) for the registrant and have:</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">c)           Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d)           Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></p><p style="text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5.           The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></p><p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">b)          Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:5%;box-sizing:content-box;"></td>
     <td style="width:44.44%;box-sizing:content-box;"></td>
     <td style="width:1.78%;box-sizing:content-box;"></td>
     <td style="width:48.78%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date:</font><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">February 25, 2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ STEPHEN BASSO</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="2" style="padding-top:0in;text-indent:3pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Basso</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="2" style="padding-top:0in;text-indent:3pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="2" style="padding-top:0in;text-indent:3pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>6
<FILENAME>inva-ex32.htm
<DESCRIPTION>EX-32
<TEXT>
<!-- DFIN ActiveDisclosure (SM) HTML Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2026-02-25T16:04:37.4993+00:00 --><!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;-webkit-text-size-adjust:100%;position:relative;">
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exhibit 32</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AND PRINCIPAL FINANCIAL OFFICER</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18 U.S.C. SECTION 1350,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AS ADOPTED PURSUANT TO</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECTION 906 OF THE SARBANES&#x2011;OXLEY ACT OF 2002</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Pavel Raifeld, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, that the Annual Report of Innoviva, Inc. on Form 10&#x2011;K for the fiscal year ended December 31, 2025 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Annual Report on Form 10&#x2011;K fairly presents in all material respects the financial condition of Innoviva, Inc. at the end of the periods covered by such Annual Report on Form 10&#x2011;K and results of operations of Innoviva, Inc. for the periods covered by such Annual Report on Form 10&#x2011;K.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:47%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 25, 2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ PAVEL RAIFELD</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Pavel Raifeld</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Executive Officer</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">I, Stephen Basso, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes&#x2011;Oxley Act of 2002, that the Annual Report of Innoviva, Inc. on Form 10&#x2011;K for the fiscal year ended December 31, 2025 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended and that information contained in such Annual Report on Form 10&#x2011;K fairly presents in all material respects the financial condition of Innoviva, Inc. at the end of the periods covered by such Annual Report on Form 10&#x2011;K and results of operations of Innoviva, Inc. for the periods covered by such Annual Report on Form 10&#x2011;K.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;box-sizing:content-box;"></td>
     <td style="width:3%;box-sizing:content-box;"></td>
     <td style="width:47%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:0.7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: February 25, 2026</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ STEPHEN BASSO</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:3pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stephen Basso</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:3pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Chief Financial Officer</font></p></td>
    </tr>
    <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="padding-top:0in;text-indent:3pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:0.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</font></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A signed original of this written statement required by Section 906 has been provided to Innoviva, Inc. and will be retained by it and furnished to the Securities and Exchange Commission or its staff upon request.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;margin-left:0;margin-right:0;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</font></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img75897552_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_0.jpg
M_]C_X  02D9)1@ ! @$!( $@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ,.!V<# 2(  A$! Q$!_\0
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M\T?O_KO^?9G].=%?S&?\1<G_  1X_P"AM_:%_P##"Z__ /+.C_B+D_X(\?\
M0V_M"_\ AA=?_P#EG1_9>8_] =?_ , 8<\/YH_?_ %W_ #[,_ISHK^8S_B+D
M_P""/'_0V_M"_P#AA=?_ /EG1_Q%R?\ !'C_ *&W]H7_ ,,+K_\ \LZ/[+S'
M_H#K_P#@##GA_-'[_P"N_P"?9G].=%?S&?\ $7)_P1X_Z&W]H7_PPNO_ /RS
MH_XBY/\ @CQ_T-O[0O\ X877_P#Y9T?V7F/_ $!U_P#P!ASP_FC]_P#7?\^S
M/Z<Z*_F,_P"(N3_@CQ_T-O[0O_AA=?\ _EG1_P 1<G_!'C_H;?VA?_#"Z_\
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M *&W]H7_ ,,+K_\ \LZ/[+S'_H#K_P#@##GA_-'[_P"N_P"?9G].=%?S&?\
M$7)_P1X_Z&W]H7_PPNO_ /RSH_XBY/\ @CQ_T-O[0O\ X877_P#Y9T?V7F/_
M $!U_P#P!ASP_FC]_P#7?\^S/Z<Z*_F,_P"(N3_@CQ_T-O[0O_AA=?\ _EG1
M_P 1<G_!'C_H;?VA?_#"Z_\ _+.C^R\Q_P"@.O\ ^ ,.>'\T?O\ Z[_GV9_3
MG17\QG_$7)_P1X_Z&W]H7_PPNO\ _P LZ/\ B+D_X(\?]#;^T+_X877_ /Y9
MT?V7F/\ T!U__ &'/#^:/W_UW_/LS^G.BOYC/^(N3_@CQ_T-O[0O_AA=?_\
MEG1_Q%R?\$>/^AM_:%_\,+K_ /\ +.C^R\Q_Z Z__@##GA_-'[_Z[_GV9_3G
M17\QG_$7)_P1X_Z&W]H7_P ,+K__ ,LZ/^(N3_@CQ_T-O[0O_AA=?_\ EG1_
M9>8_] =?_P  8<\/YH_?_7?\^S/Z<Z*_F,_XBY/^"/'_ $-O[0O_ (877_\
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M.O\ ^ ,.>'\T?O\ Z[_GV9_3G17\QG_$7)_P1X_Z&W]H7_PPNO\ _P LZ/\
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MX_Z&W]H7_P ,+K__ ,LZ/^(N3_@CQ_T-O[0O_AA=?_\ EG1_9>8_] =?_P
M8<\/YH_?_7?\^S/Z<Z*_G,^$W_!TQ_P2@^-/Q4^&?P<\#^)_CQ/XT^+/Q!\&
M_#/PA#J7P1US3M-E\4>._$6G>%] BU#4)-1>.QLI-5U.U6[O'1UM;<R3LC+&
MPK^C.N>OAL1AG%5Z4Z3DFXJ<;<R6C:[VZE*2ELT_0****P&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA_96E?\ 0*TS_P %]G_\9H_LK2O^@5IG_@OL_P#XS5^BCV-'_GU2_P#!<?\
M+R7W 4/[*TK_ *!6F?\ @OL__C-']E:5_P! K3/_  7V?_QFK]%'L:/_ #ZI
M?^"X_P"7DON H?V5I7_0*TS_ ,%]G_\ &:/[*TK_ *!6F?\ @OL__C-7Z*/8
MT?\ GU2_\%Q_R\E]P%#^RM*_Z!6F?^"^S_\ C-']E:5_T"M,_P#!?9__ !FK
M]%'L:/\ SZI?^"X_Y>2^X"A_96E?] K3/_!?9_\ QFC^RM*_Z!6F?^"^S_\
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M_P O)?<!0_LK2O\ H%:9_P""^S_^,T?V5I7_ $"M,_\ !?9__&:OT4>QH_\
M/JE_X+C_ )>2^X"A_96E?] K3/\ P7V?_P 9H_LK2O\ H%:9_P""^S_^,U?H
MH]C1_P"?5+_P7'_+R7W >E_LG6EI:_\ !0?_ ()V?9;6UM?,_;._9T\S[-;P
MV_F;?C/X!V[_ "43?MR=N[.W)QC)S_LZU_C(_LJ_\I"/^"=/_9YW[.O_ *N?
MP#7^S=7\J>,,8QXH<8Q48JC2LHI)*^%PC=DK)7;;]3VLO_@O_$_S84445^3'
M<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS;G-TX5$I1YI."BXQ3=ME:[:TWV/];BOXX/^"]7_  7+_:>_9#_:MT#]F/\
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M1QRV^(P)?[;_ (7?MH:5^U9_P36U;]LCX3?;/"5]XF_9P^(_C:PL9)(;K4/
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MN2:DXIY8*<84Z]"6E2TY<MGM&G&+5]KIJ]M[:G\]?_!J7_RDB\6_]FU>,/\
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M&:^&\+)3EG?':<IM2P.*G--M\TUC*R4Y7WDE.:4GJN:6OO._5C/X>$_Q0_\
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M<Z3>Q6WQ%E^+GA"X\0PI=:%-<Z+.JW$R_/I<\MF"2D3G:<?T#_L+?\'+VJ_
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M)(56)P!R>.*_LA_X.0I8X?\ @CQ^U1)-(D4:WOP4W/(P1!GXZ_#@#+,0!DD
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M96%K;Z?<? #PA=3V:1@VTUQK%K-J.JRR1/N1SJ%]>W=U=!@5EFN)F*X<BO\
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M6;7-/TKQ/$NF:NFEV@GO[C2(Y(K[4C"MG8S132JX_<;_ (-^M)DU_P#X(T_
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M-]H\6MZGX]U":SGUEM;O9=0NVTR?0M0TJ#24$0\F\D:1Z_>C_@Y&T70O'O\
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MS5-.NK/7--UFSN&M+K2KO3)8A=QW\-TC6[6WE&1I0%C#[E)_TH/^":/[,O\
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M-2GBTS2VTZ1+B]MQ!')%(+A#(Z/^[85_HT?\$G_CQ\8OCC_P2<^#?QR^+GQ
MUGQY\7?$'PG\;:YK7CW6(=*AUC4=7TZ?Q"MC?SPZ7IVGZ6LULMI;"-8=/CB/
MDKOC<EMW\9O_  2C\7_'_P#X*Y?\%/OV7;#]N/XHZ[^TGX5^!&C^,/B<^G>/
M]*\/26<%AX?L4U72M,:R\/>'-*TRYTR_\=P^%Y]7M=:MYK2_M();)BWGB&3Q
M>!<QSO+,SX_S3,,1E]7 95B\3B<_IP6*=>OB:"S:=".3NI>G2HSQ,*D91Q/+
M)TYTDO>31>*C"<,)""FISC&-)OEY5&7LE)U+:MJ+C\.E[]#RC]E#_@WJ_P""
MD7[5_@'0/BKIW@7PE\'?A]XKTV35/#=_\8=>N?#WBK5[*2"SNM*U"+P+#I\V
MM6FCZY:W@N-.U'49;.4I"XEL$)!'AW[<W_!&?]O#_@GYX;G^(GQI^'.D^(/A
M##JD>F2?%7X9:W_PEOAS2?M4R6^G7/B^S2TM=4\(0ZG<N+>UEU""XLDEV+<W
MT/F)G^\O_@JE\#?^"MWQ_P!:\!>%O^">_P ?_AY^SC\-=(TA]1\>^)=0O9[/
MXB^*_%SZA<?9M+L[P:%KUMI_A"PTR.QE<0QVFI7VJ27D<TC6"Q"3W#]D3]G?
M]J;Q#^P_XF_9B_X*=>*?!?QZ\;^(--\9>!/$?CCP^Z26WCOX<^(K:2'26\0&
M33[//BO2X+B6"]U4:5;13W,%I=V]J3"2\1\5LZHTL)G.(QG#5?!XC%QAB.&\
M+]:_MC"8.52:=9UYI4I5HP@M'.<??A*5"*<U3?U*FVZ:592C&ZK2Y?9RE9:6
M6MF_*ZU]Y]?Y^?\ @ST_Y$/]OX?]5"^ /_J(?$.OS-_;R_X)S_M-?\%%_P#@
ML5_P4(\)_LRV_P --4\2?#CQ%X&UWQ'I/C_XBV7@:^GTC6?"&BV-O?:#:W&G
M:G=:U;65S:B#5YK>!(-+>]TM+F4/J%LK?K?_ ,&I7A*P\ :U_P %4? &DRSS
MZ3X#_:/\ ^"-*GN;G[9=3Z9X1_X6WX>T^:YO/+B^V7$MGIT,D]UY47VF5GF\
MJ/?L'P?JO[5]C^Q]_P '1GQ5\>^(=5M-%\!_$+XA:;\$/B-J%QID^IR1>&OB
M-X'\)6VD_9_L[+)8>5X]L/!UY>ZBR2P6FG6MW)<HD >X@[*>)Q]'Q#\0\;D\
M:=3'T>&*&+P5.O2G6A6E2PV0UO9.E3J4YRG6IQE3@HS35247[R5G-HO"82-2
MZBZTE)II-)RJ*]VFE;=Z;)[;G\XG[77[(GQQ_8<^-^M?L\_M#:%H^A_$G0M$
M\.^(;F/PWK#>)/#=[I'BBP&HZ7<Z/XB6QT^WU3;"3#J"6\&=/O4>SN")E(K[
MG_9L_P""%_\ P4+_ &K_ -G_ ,+_ +3OPE\*?"*+X/\ C'2M4UW0-9\<_%NQ
M\'ZE<:)H]Q=VU[J]QIEQH=ZEGI_F6-TT-S/>JDD,+3L8XL,?WB_X.T?V6?$/
MC7Q3^QA\?/ VE:QJ6J^+]0U#]F&^U"SMIKKP]I6H^+-9MM6^'<^J36L4AM[O
M7/$6LW.FV$FYFNH;66&!"Z U^G/_  53^-6A?\$P_P#@B[H7P7\-1IX7\>>,
M?A'X7_9>^'=CX?EMK:33/%6N^#6A\:Z]IHF$!9=$L(?$FN,\4#3><8Y3"Q+*
M?8J>(&;8W)."YY/2P,\\XFQU3!8FG5I5*N'P_P!3FL/C:L:,:].I"+J3IXB/
M-4DJ=!33<[QFX6%A&KB%4<U3H14DTXIRYDI1NW%KHXZ)7?;8_P VRZ@6UN[N
MU6ZL[Y;6ZN+47NG3_:M.O/L\KP_:K"ZV1_:;*XV>;:W'EQ^= R2;%W;1!354
M*JJ.  !3J_8OQ\]KG#ZA1110 4444 %%%% !1110 4444 %%%% 'J7[*O_*0
MC_@G3_V>=^SK_P"KG\ U_LW5_C(_LJ_\I"/^"=/_ &>=^SK_ .KG\ U_LW5_
M*/C'_P E3+_KS2_]1,&>UE_\%_XG^;"BBBOR4[@HHHH **** "BBB@ HHHH
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M\-^"_"?A^_>%K=[W1/#FCZ5=M;N59X&N;"SMYFA9E5FB+E&*J2I(&&ZU\/O
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MS%T/PWX=\,6KV/AK0=%\/64DS7$EGH>EV.DVLD[@!IWM[""WA:9@H#2,A=@
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MWN(XIC$[QF6-5<QNR;MK$'B_&6I^&/@=\*_B%XTT3P9&FC^!_"7BOQY=^%?
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MHH<YN7.Y2<[I\[DW*ZM9\U[W5E9WTLK#LMK:=CS7P1\&OA'\-)[NZ^'?PP\
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M_P!N"[\?:'X'U1_%?A7P!^T!K2?#_P <>+;^RN/[*^%G@KP]XP:75/$\^N7
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MT",'_AJ^XX/_ &%_#=?W1?\ !P2&/_!$GXM[3M<:7^ST5;^ZX^(/@,HW_ 6
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M>+/"'B+P/H-]!8^;>Z?\-]%\4OK.OII-S?E=;O-8TNUTZWU;3YX9OS%^)O\
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MH_LTZM<LP@\O[8#)O3^M"O\ (N_;&^)7@;XS?\%+/B_\6OAEK\'BGX>?$?\
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M>_:=U'5-:UB_>*.65;33]/M9[J=HXI'$<;;48X%?NK\=O^#NKXKP_%#7[?\
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MXE^'?C:TMK:XUCP=XCA0",WED+J"XL[^W!L]6TRYM-1MO+$\EO!_FT_MR_\
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M)$&Y?ZN/^";G_!3;]GS_ (*:_"/4/B-\&VU7PWXH\)7=CI'Q,^%7BM[4>+/
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MMFK1Z7_9HT^+P)X4-F8_,\_[4;NY#8\OR%SO'R;^T-_P<W'X#?MO_$C]C?\
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M(R".00>A![@T +17Z'?\$O\ ]@F3_@I)^U/9_LT1?$Y/A+Y_@3Q1XZN/%O\
MPCR>*IXK;PT;&/[#;Z*^I:4DTEW-?QCS9+V)(DC<_,V%KTW_ (*[?\$R(O\
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M:>)_$NKW$"1)'XGN_&>I2^+-1TZVC"6<*16<UA8VD;M!:&2:0S/_ .#O\?$
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M:LZ_U>,G6=&?[V+M!WC%)+WK.3T2:BM5>^ES^>S_ (-:OV4OA;\>/VQOB?\
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M._\ P#XHN&_8A^*D6FS/X)T)OC'X U36%BE:VM/%'BL>"-?T+3IIPA@BEO\
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M4U1P="I&%.4W.<>:<;V7-4OLTV[*RN]%T/W1_P""+/\ P1]_9;^,/ASXL_\
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M$L1ZG\0?'EH&"^*=&O-2CGBTK0M3F&@75I:7<FNZ7>)Y:-^H_P */^"A'_!
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M7Q-^!.H7<OEV]E\4_@Y?WEPY+&.WM/'7A>ZNKB1B2S;(HY)78DDX+,<DFO\
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ME3<93C3<,\/:&'KXA1C.I"48QYE=03Y+RL[:^\VW?:-M+N_VCH?[,W_!(O\
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M7_!%?_@HE\"/$O[-N@?M;>+?#^F>!OVB?VEOA;^SKX<U"Q^/6L?%J]TKQ?\
M$G4+FSM-<7PGJT,4*VVDZ;;:G-<:JFXVTDEM9/A=1&?Z6/VJ/V<_^"*W_!!O
MX _";Q]\0/V.](^/GQ6U/7[O2OAIK/B;P_I?BSXE^//&FE06>H>([^_\:>*E
MD\.>#].L;/4I+ZUM;B.+3[>%X=(TVVF6)6AG-<30J91PMP]+B3.>*\3B,3C(
M4H\-.C0GG5"A*"CA\PQU7&5?91PD%4I.JJM6\'*OB*5Z"J-P34ZU;V-*A%*-
M_;7:I.2WA#E5W)ZVLOY4];'T%\)O@+_P25_X+M?LC^*/B=\-?V8]#^&EY+KF
MI>"!XUM?AMH'PP^*_@WQMX1M@-,E@\2^#=O_  DGABVFO(95TR;4[G3-3M%E
MM=2TJSE**O\ /7_P;H?LC_!_QA_P4F_;*_9^_:-^&GPN^/NE_!3X0?$+PS#:
M_$'P/HGB[PP_B_P#^T#X5\!7?B[1-$\3V>J0:9<W]O;ZBMM.JF]@T[4)+-KA
MDDE#_P!='_!(G]N3P-^WU^SAKGQ@^%G[-T_[-'PRTOQ[JWA+PKX6?_A'FM=?
MDTR*%]9\06,OA;3]-T2>WDOI?L[36L4K/-')YUQ*XX_G!_X-W_\ E-K_ ,%1
MO^P+^TC_ .MC:/7SF78[-<'D_B;E4JF8X&CEN%P=3"8#$YC]>Q&5U)XQ4YTH
M8VDTN;D485'1<8MQ2E>47)ZRC"53!3M"3GS<THPY8SM%--Q?G>U]KGZS?M)Z
M/_P0C_X)=_'36_B%\??AI\!?"WQ:^*FB>'=6\!_#'0_@SI.OR>%/!GANQ?PX
M^I^#O!6G:1)X6\,7&NZTVO7FM^)-FCZOKYD^P/-=VFF0QC\B/^";7_!*3]FG
M_@IW^VC^VK^W!X[M)]8_8HTS]I/Q/_PH#P/X?BN?!7AKXH 36NL27>IQ6B6.
MI6'@GPPAM=.N?#UJ=(:]U$7=E>M<:5YL,OQK_P '5'/_  4Q\.$Y)'[.'@-0
M22=J_P!N>)&VKGHNYF;:,#<S-C+$G^BC_@V#\1:!JW_!)^W\.Z*MMK/B+PG\
M8/CE:>*-!%U$)'U'6M=FUS1K&Z)S]B35="O=-$?GC!CD-S@Q2"NW$T\?P[X?
M8;BC!9QF]?-\_P -EF78G$5\5[2&!P=5SK+ZE>*GAYQAA:>&5:55R_?U)J4:
MDH2C,7"MBW0E3IJG2E.:2C9SDN7X];-7FW:UM%TN>&:;_P %7?\ @WTTKX]:
MI^QGI/[,_P --+\)77C?6?ACJWQ 3]FSX9:7\#K_ ,7RZ@FA:E \KI%J<^AW
MVJ0OH]SKU[H%LDM_:.KVSV8AOI/Q[_X.*?\ @D1\*OV&-0^'?[37[,?AR3P?
M\#_BMXLO? _C?P0=8FOM*\$_$W4;74/$6@CPG;ZC-<:E;:#XITS3?$4HTJ.Y
MDTW0)=#-M816EC<VEK#]F>+O^#A3]B_P7\4M=^$.N_\ !'B^3XEZ%XZU/P*_
MAEX/A(OB;5/%6F^(;K0HX]+T>Y\(#6;^XU75+1IM*DBMYI;X21W,$DP;SCQW
M_!<K_@H?^TW^T5^Q*?@]\3O^"7O[0_[)7A<_$KP+KUU\4OC5K7A"_P##ME#I
M5OK<6GZ)H46A2FZ/B359Y1';Y:0+I5MJC/& #(O?D. S_)>)>'ZN$P&:99@,
M>_8YM2SKB?*\PAFE*<8+ZYAZ$*]*I.K2=3VJC0I5Y<[I1A:,Y1J34E2J4:JE
M.%2<?>@Z=&<'#9\KE:UG:VK2:NWMI_'%1117[\>:%%%% !1110!ZE^RK_P I
M"/\ @G3_ -GG?LZ_^KG\ U_LW5_C(_LJ_P#*0C_@G3_V>=^SK_ZN?P#7^S=7
M\H^,?_)4R_Z\TO\ U$P9[67_ ,%_XG^;"BBBOR4[@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH \/_:&_9L^!O[5WPRUGX/?M
M"?#;PW\4/A[K@9[C0O$5H9&LKX6]Q:P:SH>I6[P:IX?UZRANK@:?KNBWECJM
MB99#;7<6]L_EO\'O^#>3_@E9\&/'>C?$/1O@'J'BO7?#FHV6K>'[7XA^/O&'
MC#0--U'3[H7=I=OX>U'5?['U:2":.W>,:Y::E'&]M%+'&LV^1_VXHKU<%GN=
M9=AJV#P&;9C@L+7;=;#X7&8BA1J.2Y9.5.G4C'FE%*,G:\HI*3:5C.5*G-J4
MZ<)26SE%-K6^[7=7/R1^+O\ P0U_X)F?'3XX^+?VC?B=^S_?^(?B_P".?&FG
M?$'Q+XH3XL?%W2H[_P 5Z2-)%AJ*:)I'CBQT*SCMUT33%6QL].@L&6VVO;,)
M)0_ZV.B2(\<B+)'(K))&ZAT='!5D=6!5E920RD$$$@@@TZBL,7F>98^GA:6.
MS#&XRE@J?LL'3Q6*K8B&%I<M.'L\/&K.:HPY:5*/)348\M."M:,;.-.$')PA
M&+D[R<8J+D^[LE=ZO?N^[/Q'_:&_X-ZO^"7W[0WBN_\ '-]\$;OX8>*M7OY-
M0UF]^$'B?5_!6DZG+-O:?S/"5O-<^$K)YIW:YFGTG1-/N)IF=II9 V!]#_L:
M_P#!(3]@7]A'Q!/XV^ GP0TZV^(LR/%%\2/&NIZEXZ\::7#+"UO<6_AO5O$=
MQ>CPK!>0-Y5^GAR#2VU!%47SW&T5^F-%=];B?B+$8+^SJ^>9K6P+A[.6%J8[
M$3I2IJUJ<XRJ/GII))4Y\T$DDHI$JC14N=4J:E>_,H13OW3MH]-]PK\DOVHO
M^"'7_!-?]KCQUJ7Q/^)_P M-)^(FN7LNH>(?%GPX\1>(/A]>>)+ZYDDEO;_Q
M#IWAN_L]#U?4[^:3SKW6+S2Y-7N)4#O?DO,)?UMHK@R_,\QRJL\3EF.Q> KN
M/(ZN#Q%7#SE!M-PE*E*+E!M)N,KQ;2=BYPA-6G&,U>]I)-7[Z]3\S[;_ ((^
M_P#!.^Q_9IU[]DC3?V=]&TGX'^+-=\-^)O%VA:/XD\8Z1X@\6^(/"*&/P_J_
MB7QSINOVOC/6;O3T9UC:]UR6,B216C*NP/KG[&/_  3U_9,_X)^Z)X^\._LI
M?#2X^&^D_$[6]'\1>-+:X\9^-O&)U;5]!TV72-+N5G\:>(-?GL!;6$TD)AT^
M2V@F+>9-')(%<?:E%;5L[SG$8?$87$9MF5?"XNLL1BL/6QN)J4,373IM5J]*
M=24*M5.C2M4G&4E[.G9^Y&R5.FFI*G!2BG&+48IQ3W2:6B\EW?=GY*6'_!#C
M_@F=IO[0-O\ M0V?[/\ >Q_&RU^,!^/$'BUOBK\6Y85^*)\7/XY/B%O#\OC9
M_#KQGQ.[:@='?2VT8J?L9L/L7^CUR?[0O_! O_@F'^TI\1M?^+'C7X#W/A[Q
MSXLU.]UGQ5J7P[\:>*?!5AX@U;4',UWJ5]X?TK4E\/Q7]Q=-)=W%W8:993W5
MQ+*]V\^5"?LO175#BGB6G6IUX9_G$:U*BL-3J?VEBW.&'34E0BW5=J*DE)4U
M[BDDTKI,ET*+33I4[-\S7)'67?;?SW/FO]EG]D']G/\ 8M^&EG\)?V:_A=X?
M^&?@Z!HI[Y-,CFN]<\1ZA%%Y(UCQ;XFU&6[U[Q1K!BQ%_:6MZA>W*0A8(GC@
M1(U^?OVP_P#@E)^PM^WIXU\._$/]J3X/7?Q$\6^%/#TOA70M3M_B%\1O"*V>
MAS7CW\EFUEX.\5:%8W!:ZD>3[1<V\MP =@EV */T5HKAHYMFF'QL\RH9ECJ.
M8U'-SQ]+%UX8R;J*U1RQ,:BK2<UI.\WS+1W13IP<5!PBX*UHN*Y59W5HVMH_
M(\G^!GP1^&O[-_PF\$?!#X/Z!)X7^&OPZT=-!\(Z!+JNKZY)IFEI/-<+;MJN
MNWVI:O>D37$K^=?7UQ,=VTR%0H'PW^V1_P $=_\ @G_^W3XF3Q[\=/@?8-\2
M0NRZ^(_@35-2\!^,-918$MH5\47_ (<GLX/%GV2&-([&7Q):ZG<6**([2:&,
MLC?IY11A<US/!8R6883,,;AL=.4YU,91Q-:GB:DJLN:JZE:,U.I[23YJG/*7
M/+65V$H0E%0E",HJUHM)Q5MK+96Z6V/Q'_9]_P"#>K_@E[^SYXGTWQM8?!"]
M^)?BO1=4M]5T;4?BUXKUOQCIVG3VCI+;*OA66XM?"=ZL,Z"8/JFB7TI;"%_*
M!0_MA:6EK86MM8V-M;V=E9V\-K9V=K#';VMK:V\:PV]M;6\*I%!!!$B10PQ(
ML<<:JB*JJ +%%/,LWS7.*L:V:9CC,PJ03C3EB\15K^SB[7C34Y.-.+LKJ"BF
MU=JX0IPIJT(1CWY4E?U:U?S"BBBO.+/SN_;$_P""5'[#/[>OC+PUX_\ VI/@
M_=_$7Q7X1\/S>%] U*W^(/Q%\(K9:)/>-?RVC6?@[Q5H-E<EKIVD^T75O-<#
M.P2A %K@?C'_ ,$7?^"=/QS^#/PG^!GCKX#02>$O@9HA\-?"G5]*\5>*]/\
M'?A/P^UY<7[:(/'2ZO)XEUW1VN[NZG_LOQ+?ZQ8QRW$LT,$4Y65?U/HKV*'$
M&>X:&$I8?.<THTL!)SP-*EC\5"EA)2C.,I8>G&JH47*-2I&7)&/-&<XRNI23
MS=*DW)NG!N?Q-QBW+;=VN]EOU2>Y^9?[&W_!(']@/]A+Q7=_$'X _!&SL?B/
M=6TEC%\0O&6M:SXZ\5Z393&836OAN^\2WE]#X72ZAE%K?R^'K;3;G4K>*&+4
M9[I8UKZQ_:A_9:^"'[97P;\0? +]HCPC+XY^%?BC4/#VJ:WX<AU_Q#X9DO+W
MPMK=CXBT.4:QX6U31]9MQ9ZOIUG=&.WOXH[@1&"X66!Y(V^@Z*PKYOFN*QU/
M,\1F6.K9C2G3G2QU7%5IXNE.BU*C*E7<W4INE))T^24>1J\;,:IPC'DC"*@]
M'%12B[[W5K._6^Y\+_L7_P#!-S]CS_@GV?B*?V4/A;<_#8_%9O##^.OM'C?Q
MWXQ_MAO!R:VGAXI_PFOB/Q!_9_V%?$.K _V=]E%S]I!NO.,,/E_/?PZ_X(;_
M /!,WX4?'+P]^T?X%_9_O]'^,'A7QO<?$70_%#_%?XN:A'9^+KJ6\FGU,Z)J
M/C>ZT*X5Y+^Z865QITMBOF!5MPJ(%_6RBMEQ!GJJXRNLYS15\QIPHYA6^OXK
MVN.I4Z;HTZ6+J>UYL13A1;I0A5<XQIMP24=!>RI6C'V<+0=X+EC:+O>\=-'=
M7NMWJ?#7[9?_  3@_8^_;^7P.G[5?PNN?B0OPXEU2;P@+?QOXZ\'_P!ER:S'
M'%J+,?!?B/0#>^>D4:@7QN1%MS$$))/KO[+G[*OP-_8S^$6D? K]G;P?+X&^
M&&AZCJNK:9X>F\0>(O$TEO?:U.MQJ,QU;Q3JFLZQ,)YD5A'-?21Q8VQ(BDBO
MHBBN:>9YE4P-++*F/QL\MHU'5HX">)K2P=*HW.3J4\,YNC";E4J-RC!.\YN]
MY.]*$%)S48J;5G*RYFM%9O=JR7W'YB_M8?\ !';_ ()[_MN?%6?XU?M*?!&\
M\??$>XT#3/#$VO0?$OXG^%4;1=(B:'3[3^R_"7C#1-*!@C9@9ULA<2YS+*Y
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M>UZ[LHTTC2;*W:VM;BWLQY!G:'SGDD;^+#]@?X>V'[??_!R3\;OCKI'V2_\
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MMM(NH'CFLI[+PQ?31^$1=V%Q$MU9:C/H4^HVUP%DBND*+C]H0         ,
M <  #@ #@ =*6BKS'-LSS>M&OFF88O,*T8\L*F+Q%2NZ<7:\*?M)25.+:3<8
M*,6];7%"$*:M",8KJHI*_F[;OS9^:7[97_!(G]@?]NW69_&'Q[^!^FW?Q(EL
MX[3_ (6?X-U/5?!'CF86\$=K92:OJOAZZLH?$QL+:)+:RC\46FLPVULHAA1$
M2+R_G#]GW_@WG_X)>_L^>,]&^(%A\$[[XF>*?#\QNM'E^+WBC5?&^@VEXLWG
M6][)X/NWA\*7]Y92+"]A/J>CWK64]O%=6PBN@9C^WE%=M'B?B/#X/^SJ&>9K
M1P*@Z:PM/'8F%&--JSI0@JB4*;6CIQM!_P HG1I.7.Z<'+>[C%MON]-7YO4C
MBBB@BC@@CCAAAC2*&&)%CBBBC4)'''&@")&B *B* JJ J@  5^2]I_P0W_X)
MFV7[0,'[4-M^S_?1_&RW^,)^/47BT_%;XN-$OQ2/B]O'9\1'0&\;GP\T?_"4
M.VH?V0VEG1]I^Q_8?L?[BOULHK@P69YEEWM_[/S#&X'ZU3]EB?JF*K8;ZQ2U
M_=UO8SA[6'O2]R?-'5Z:LJ4(3MSPC*SNN:*=GW5UH].AS?C/PCH'C_P?XK\!
M^*[(ZEX7\;>&]=\(^)-.6YN;-K_0/$FEW6C:Q9+=V4UO>6INM.O;B 7-I/!<
MP&3S8)HY51U_-G]E/_@C#_P3I_8H^+NB?'7]F_X%WO@/XG>'?#NO>%=(\0S_
M !/^*GBF.UT/Q+9P:?K-F=)\5^,M:T>=KNTMH8A<3V,EQ!M+V\L3L6/ZE448
M;,\RP>'Q6$PF/QF%PF.CR8S#8?$UJ-#%PY90Y<31ISC3KQY)SC:I&2Y925K2
M=R4(2<92A&4H_"W%-QU3NFUH[I.Z['C'Q_\ V>?@O^U)\,->^#7Q\^'V@_$O
MX;^)/L[ZGX;U^&1X?M5G*)['4;"[MI;>_P!*U6PF'FV6IZ;=6M]:N6,,Z!F!
M_,+X(?\ ! #_ ()F?L]_&7PC\=?AK\)/%^G^./ 'B!/$_@DW_P 5OB#J.E>'
M-:MY2]E=064^N[]02RC:6WBMM:N-2MIH97%[%=2;9!^TE%;8//,YR_#5\'@<
MUS#!X3$J:Q&&PV+KT:%;VD%3J>TI0G&$G."4)MQO*"Y6W'04J=.<E*4(2E&U
MI.*;5G=6;5]&DUYGYX_MD?\ !*S]AS]OKQKX.^(7[5'P@N_B-XL\!>%[WP9X
M6U*W^('Q%\'KIWAW4-6.MW=BUEX,\4Z#97C2:DQN!=7EO/=(#Y23+#A*^K?@
M!\!OA=^S!\&_A_\  +X*>'9/"?PK^%^ACPYX)\.2ZOK.O2:3I"W=U?"U?6/$
M%_J>LWY^U7EQ)Y^H7]U/^\V>9L5%7V&BL:N9YE7P=#+J^/QE;+\++GPV"JXF
MM4PF'F^>\Z&'E-TJ4G[2I>4(1;YYZ^\[M0@I.:A%3E\4E%*3VT<K7:T6E^B*
MUY9VFHVEU87]K;WUC?6\]G>V5W#'<VEW:7,;0W%K<V\RO#/;SPN\4T,J/'+&
M[(ZLK$'\./CC_P &Z'_!+;XW>+]8\<GX,:Q\+M<U^[%[JEM\)?%VK>#_  P]
MR2YEDT_P;&]UX7T,7!;,\&AZ7IUJ[J)1 LSRR2?NA16F6YSFV3U)U<JS'&9?
M.HE&J\)B*M#VL4[I5(PDHU$GJE-22>UA3ITZB2G",TG=<T4[/NK['YV?L:?\
M$I_V%OV#+V3Q!^SM\$-'T+QU<V+:?>?$GQ)?ZIXR\?2V\\2Q7\-GXB\27>H7
M.A6FI!0;_3_#RZ5I]Q@*]J5&*^M_CO\  SX9?M*_"7QM\#OC)X?D\5?#/XB:
M2=$\6^'XM6UC0I-3TTW$-R8%U;0;[3=7LCYUO$_FV-];S#;MW[20?7**SQ&9
MYCB\9',<3C\7B,?"=.I#&5L15J8F$Z4E*E*%:4W4@Z4DI4W&2Y&DXV:'&$(Q
MY(PC&%FN512C9[Z)6UZ]^I^=_P"QW_P2J_8:_8)\8^)O'O[+7P?NOAUXI\8:
M!!X8\0ZE<?$#XB^+EOM%MKQ;^&T%GXR\4Z]96Q2Z19//M;>&X(&QI2A*UY!\
M1_\ @AG_ ,$ROBS\=O$W[2GCS]GZ^UGXQ^+_ (D6OQ:\0>*4^*_Q=TZ*^\>6
M6IZ?K%OK(T/3?'%IH-LB:AI=E,=.M=-ATUA"8GM#%)(C?K?177'B+/XXJMCH
MYWFT<;B:,</B,6LPQ:Q->A#EY*-:NJOM*E*/+'EISE*"Y8V6BM/L:7*H^RI\
ML7>,>2-D^Z5K)^>[(YH8;F&6WN(HI[>>*2&>":-989H95*2Q2Q.&22*1&9)(
MW5E=6*L""17X@_'[_@W@_P""77Q\\5WOC:X^">H?"WQ'JU]+?ZQ+\(?%>L>#
M=$U*28%I%'A*.:[\*:8'F9KAWT31M,DDE=S,T@*A?W"HKGRW-\UR>K.ME>8X
MS+ZE1*-26$Q%6A[2,;N,:JA)1J1BVW%34DFVTDQSA":2G",TMN9)V]+[?(_,
MG]C_ /X(^_\ !/[]AWQ%%XX^!/P+TVV^(L!NOLOQ$\9ZMJ_CGQAIJWL2V]PF
MB:CXCN[V'P^DENBPN-#M=/,B[VE9Y997?]-&575D=5='4JZ, RLK AE92"&5
M@2"""""01BG45ECLPQ^9UWBLQQF*QV):477Q5>I7J\L;\L5.I*4E&-W:*:BK
MNR5QQA&"Y81C&*Z122^Y'XM_'C_@WZ_X)<?M!?$36_BCXG^ ,WA/Q5XFO)=1
M\1CX9^,?$W@/0-7U&X$7VC4'\+:)J$/AW3[VZD26ZOKG1]-TZ34+V[N[Z_-S
M=S&:O8?%7_!&;_@G#XR_9Z\"_LM:O^SIID'P4^'?BBY\;>'_  QH7B[QUX:O
MKCQ?>62:==>)?$?BCP_XDTWQ/XLUF>QCBM9+[Q)J^IS&"&"(,(X8E3]0Z*]!
M\3\1RAA:;S[-W#!2C/"1_M'%VPTX0=.$J/[V].4*;<(.+3A!N,;1;1/L:-Y/
MV5.\OB]R/O:IZZ:ZI-]VD^A\I?LA_L3?LW?L*?#O4_A5^S#X"G^'O@;6/$5W
MXKU#1Y_%/BSQ:\^NWT44-U>#4/&&M:[J,0DCAC7[/%=);)MRD2DDGZMHHKRL
M3B<1C*]7%8NO6Q6)KR<ZV(Q%2=:M5F]'.I5J.4YR=E>4I-Z;EQBHI1BE&*5D
MDK))=$D%%%%8#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K_+?_ .#F/_E.=\7/^R#_  ._]5[;5_J05_EO_P#!S'_RG.^+G_9!
M_@=_ZKVVK[WPS_Y+'*/^O]/_ -/T3EQG\"7]?99^+]%%%?V6>"%%%% !1110
M!_0K_P $/O\ @L5\$?\ @EGX6_: T+XM_"CXN?$F\^+WBKPCKVB7'PS/@PVV
ME6GA[0Y]+N[?5D\5>)/#\IN;B>5);9[(W$0A5A*%<C'Y;_\ !0_]I?PK^V1^
MVS^T1^U!X'\.^(_"?A+XR^+]'\1Z)X<\7'2SXETFVT[P1X6\+SP:O_8M[J6E
M">6]T&YNHELK^ZC6TN+=7E,PE5?C*BO#PO#N5X/.\?Q#0HU(YIF5"&&Q=65>
MI*G.C!891C&BY.G!KZK1O**N[/\ F=]'5FZ<:3:Y(-RBK*Z;NW=[O5O[_(_=
MK_@D#_P7 ^(__!,6/6_A=XJ\$77QD_9O\7>(9/$^I^%;367L?&?@?6Y=.:UN
MM2^'TVIS_P!AF#5Y;?3O[6T&^;3K!VBGU*"Y6_DD\_\ ?K3O^#C[_@D/X<U*
M]^.?AK]D;QMIOQVO]-NM1N[G2O@W\+]*^(%YK6K.'U73[KQ_;ZG':OJ-XTDA
MU+6FUB2*]C5UDN[C<L3?P5T5XF<>'G#.=8ZMF.)P^*P^*Q22QD\#C*V%CC$M
M&L33@W"?/%)3E&,)3LI2DY7;TIXJM3BH1E%QC\*E%2Y=OA;U2[;VOI:UC]7O
M^"B/_!7C]HW]OO\ :5^'/Q_D;_A35C\!M234/@!X*\*ZS?:A#X$U*WU6VU,>
M+=1OYELXM8\8:M)IU@=1OA8P+8VBS:+ILWV!GEF_H5^$_P#P<Z?LA_'GX5:-
M\//^"BO[)=UKWB#2=.TZ\U74]"\*^%/B7\-?$/BG3HTLY-:TCPYXCN(=<\)Z
MGJ"R7%[%%%;WEOI\-Q>:8FL20[/M7\1E%=&8<"\,YC@<NP%3 2PU+*8RAEM7
M UZN&Q.$C.2G45.O&3G/VDU[2;K>U<JKE5;]I*4G,,16A*4E.[FTYJ24E-K2
M[5M&EHK6LM-DD?V@?M.?\'.GP-\ _ GQ+\$?^"9_[.>J_"GQ#>6G]G>%OB!X
MC\+>#O"'@'P2FMPR2:]XC\/> _#E]->ZKXML992-/.M6EAITVJ$ZG>R7\%NE
MO>^E?\&AEY>:EX8_;LU34KJ:_P!3U7XE_#_5M4U"Y*&YU#5-5T'4]0U/4+IH
MTCC:ZO[^YN+NY:..-&GFD9(T4A1_#K7[U_\ !%3_ (+%>!_^"6&F_'O1/'/P
M8\4?%*T^,&K>$]>T[4?"WB/3](N=(N_#FGSZ5-IUW9:C87$<UO<P3?:TO8[E
M725?LQMBI,X^9XCX#PV#X,SK*>%\OJ5\PS*M@*U:=7$*KC,;/#XW#U).KB<3
M4@FJ=.-6I&FI0@I3J2C#GF[[4L3*5>E.M-*,+I:6C&\6M(Q75V75[*]DK?T+
M?M"_\%W_ -G7]GO]OO\ :<_9H_;G_9LTSXFZ1\"?BCH]O\ /BYX9^'W@OQ?K
M/@_PQK7PU\$>+M1T;Q!8>*9?[7L]5B\57(ETS7O";RM?13P+JEK8G1[:YG_(
M[_@K[_P<3O\ MQ?!K7_V7?V9/A[XM^&/PE\8WXM/B=XT\<S:9%XN\=>'-+O[
M/4-,T7P_I^B:A>KX<T?4-2L8K[4YKR\.JW=I#;6$MO:137UO)^&__!0?]IS0
M_P!L[]M#X_\ [47AKPSJ?@W0OC'XHT77]-\,:U=6][JND0Z5X*\+^%7@O;JU
M1+::6:?0);M3"H18[A(^2A)^-Z[<@\.>'L''(\TQ.7U(YM@\!EU2IAZF)J5,
M)ALRIX6B\16AAE.5%5OK2G5ERRE1]NO:P@I)2)J8JK+VD%-.G*4M5%*4H-^Z
MG+=JVG=K1NUT_P!D_P#@D;_P6+^+W_!+[QYJ>DS:;J'Q3_9E\=WL=[\0O@__
M &A':ZAI&LPV[P0>-?AG?7S?8-$\0R)Y5MKFE7/E:+XDM8;:2ZDL=0LTO9_Z
M7;#_ (.5?^"3&G3M\>-/_9A\>Z;^T!JNE:M=:K):?!SX<6WQ-_M$P?8%TF^^
M*%M?BWNY==L0MO)?Q^()[;["D=KJ<B+'';K_  'T5Z6=^'W#6?8V>8XS#XBA
MBZT(T\55P.*J83ZY3BK<F*A#FIU+Q45*:C&I)0@I3:C9Q3Q-:E%0BXN*=TI1
M4N7_  WV\NBNW:[N?J'_ ,%3O^"IWQB_X*C?%WPWXU\:Z-%\.?AK\.]-N]'^
M&GPCTC6KC6-&T7[=J,EUJGBS5KN:TLFU'QEXAM8],L]5N3&UE9VNE65EIB1Q
M)/-=?M#^VC_P<1?LS_M-?\$V_B;^Q-X3^ WQ^\.>.?''P5\*?##3O%WB3_A7
M+>#[+5O#\WAB6?4;Z32O&=[K9TV?^PI_)^SZ-)='SH1);Q9D9/Y&Z*[J_!O#
MU:GD='ZDZ-'AS$+$Y31H5JM*%"M[6C6<ZEI.5=RJ4(3FZTIRG-SE-RE.3:6(
MJIU&I7=56FVDVUJM.VC:5MODC])?^"2W[;/@/_@GI^VYX+_:C^)/A#QEXZ\)
M^&/ /Q+\)77ASP$-#/B6XO?&^CVNF6%U;CQ%JNBZ4;2SD@>2]$NH13>6RF!)
MF!0_1W_!8?\ X*H^"?\ @H5^TS\#OVA_V?/"7Q3^#6I_!GPA::9IUWXXE\,0
M^(K7Q9IGBF;Q)I.OZ$_A;6M>M8([%S;[&N+M;C[3$S"-8R,?B917;5X=RJMG
ME+B*I1G+,Z."EE\*CJS]B\+/VO-3GA[^RG=5ZJ;E%MJ26R1"J35-TDUR.7.U
M;7F7+9WW5N5:']RW[-G_  =3?L_>)?@*?!O[<GP(\7ZI\3-+\-6^C^(CX(T'
MP[XQ^'WQADMM/6&:\?1=?OK)- U#7+NU-SJ>BZQ;3:!93W\26>J7%M%*8,;X
M;?\ !UM^SCX,\;>(M-@_9!^)_@7X Z5X:T/2?A7X!^&UO\*[34K35FNKN_\
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M_A_5M3T#7]$U"TU;1-=T6]GT[5]&U73YTN;#4],O[9DGM+VSN(XYH)XV!5U
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M32E)SLYMR;G7JU)0E.5W3:<$DE&+33TBM-XIZWVML?NO_P %Q?\ @JY\'_\
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M>>!_^AS\*?\ A1:1_P#)E'_">>!_^AS\*?\ A1:1_P#)E?AU_P 0PW_!#O\
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M3]I3_P"?#0!^XO\ PGG@?_H<_"G_ (46D?\ R91_PGG@?_H<_"G_ (46D?\
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M%_X3SP/_ -#GX4_\*+2/_DRC_A// _\ T.?A3_PHM(_^3*_#K_B&&_X(=_\
M1D5C_P"'T_:4_P#GPT?\0PW_  0[_P"C(K'_ ,/I^TI_\^&@#]Q?^$\\#_\
M0Y^%/_"BTC_Y,K8TS6M&UI)9='U;3-6CA8)-)IE_:WZ1.PW*DKVLLJQLR\A6
M()'(&*_"+_B&&_X(=_\ 1D5C_P"'T_:4_P#GPU\T_P#!#S]GSX2?LC_\%0/^
M"ZW[,/[/?ABX\ ? GX5>+/V#SX ^'P\1^)_$UAX<E\6_ GQ?XF\2SVVH^+=8
MUW6[BXU?7+^YN[FXOM2NI_+%K9K*+.QLX(0#^H:BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O\M__ (.8_P#E.=\7
M/^R#_ [_ -5[;5_J05_EO_\ !S'_ ,ISOBY_V0?X'?\ JO;:OO?#/_DL<H_Z
M_P!/_P!/T3EQG\"7]?99^+]%%%?V6>"%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
MI?LJ_P#*0C_@G3_V>=^SK_ZN?P#7^S=7^,C^RK_RD(_X)T_]GG?LZ_\ JY_
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M^HW&E:_>7MU?ZA=6=QH'C3PEJNDVNM:AJ6KZ'=?VOILNK7]H;1;;^B/]J_\
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M-LI1?* ']D<-A8VUU>7MO96D%[J+0-J%W#;0Q75^UK"+>U:\N$19;IK: ""
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MVG0FXU#5]8OK73-,L+<,JF>]O[V6"UM80S*IEGEC0,R@MDBOY(/^"87_  0
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M:3?^%IEU?7M0UK5[?1M2MM:UC2-'\*>&B\MI#;MK,\=B+>ZFNYDD>4+]5?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7^6_\ \',?_*<[XN?]D'^!W_JO;:O]2"O\M_\ X.8_^4YWQ<_[(/\  [_U
M7MM7WOAG_P ECE'_ %_I_P#I^B<N,_@2_K[+/Q?HHHK^RSP0HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ"OS(_8<_P""6/P4_8+^.O[8'Q^^&'CSXI>+/%'[9WCR#X@_$+2/'E]X6N]
M\-:K!K'B76EM/!L6@^%]!U"WT\W/BB]B9=:O]9N?(@M5%P&21I #]-Z_ 3_@
MYU_Y0R?M5?[G@3_U,M)K]^Z^-OV^?V)_AU_P4+_9<^(?[*/Q6\3^-?!_@?XD
M#1QJ^O\ P^N=$M/%=E_8NJ6VK6_]G3^(M%\0Z2OFSVJ1SBZTFY#1,P4*Q#
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MB?C-_P#.UKJC@<;)*4<'BI1:NI1P]5IKNFH-->A/-'^:/WK_ #/VRHK\3?\
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M_P!'[?#G_P (GXS?_.UH_P"(C3_@BG_T?M\.?_")^,W_ ,[6CZACO^@+%_\
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M_P#":M_\@'/#^:/_ ($O\S]LJ*_$W_B(T_X(I_\ 1^WPY_\ ")^,W_SM:/\
MB(T_X(I_]'[?#G_PB?C-_P#.UH^H8[_H"Q?_ (35O_D YX?S1_\  E_F?ME1
M7XF_\1&G_!%/_H_;X<_^$3\9O_G:T?\ $1I_P13_ .C]OAS_ .$3\9O_ )VM
M'U#'?] 6+_\ ":M_\@'/#^:/_@2_S/VRHK\3?^(C3_@BG_T?M\.?_")^,W_S
MM:/^(C3_ ((I_P#1^WPY_P#")^,W_P [6CZACO\ H"Q?_A-6_P#D YX?S1_\
M"7^9^V5%?B;_ ,1&G_!%/_H_;X<_^$3\9O\ YVM'_$1I_P $4_\ H_;X<_\
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M;*BOQ-_XB-/^"*?_ $?M\.?_  B?C-_\[6C_ (B-/^"*?_1^WPY_\(GXS?\
MSM:/J&._Z L7_P"$U;_Y .>'\T?_  )?YG[945^)O_$1I_P13_Z/V^'/_A$_
M&;_YVM'_ !$:?\$4_P#H_;X<_P#A$_&;_P"=K1]0QW_0%B__  FK?_(!SP_F
MC_X$O\S]LJ*_$W_B(T_X(I_]'[?#G_PB?C-_\[6C_B(T_P""*?\ T?M\.?\
MPB?C-_\ .UH^H8[_ * L7_X35O\ Y .>'\T?_ E_F?ME17XF_P#$1I_P13_Z
M/V^'/_A$_&;_ .=K1_Q$:?\ !%/_ */V^'/_ (1/QF_^=K1]0QW_ $!8O_PF
MK?\ R <\/YH_^!+_ #/VRHK\3?\ B(T_X(I_]'[?#G_PB?C-_P#.UH_XB-/^
M"*?_ $?M\.?_  B?C-_\[6CZACO^@+%_^$U;_P"0#GA_-'_P)?YG[945^)O_
M !$:?\$4_P#H_;X<_P#A$_&;_P"=K1_Q$:?\$4_^C]OAS_X1/QF_^=K1]0QW
M_0%B_P#PFK?_ " <\/YH_P#@2_S/VRHK\3?^(C3_ ((I_P#1^WPY_P#")^,W
M_P [6C_B(T_X(I_]'[?#G_PB?C-_\[6CZACO^@+%_P#A-6_^0#GA_-'_ ,"7
M^9^V5%?B;_Q$:?\ !%/_ */V^'/_ (1/QF_^=K1_Q$:?\$4_^C]OAS_X1/QF
M_P#G:T?4,=_T!8O_ ,)JW_R <\/YH_\ @2_S/VRHK\3?^(C3_@BG_P!'[?#G
M_P (GXS?_.UH_P"(C3_@BG_T?M\.?_")^,W_ ,[6CZACO^@+%_\ A-6_^0#G
MA_-'_P "7^9^V5%?B;_Q$:?\$4_^C]OAS_X1/QF_^=K1_P 1&G_!%/\ Z/V^
M'/\ X1/QF_\ G:T?4,=_T!8O_P )JW_R <\/YH_^!+_,_;*BOQ-_XB-/^"*?
M_1^WPY_\(GXS?_.UH_XB-/\ @BG_ -'[?#G_ ,(GXS?_ #M:/J&._P"@+%_^
M$U;_ .0#GA_-'_P)?YG[945^)O\ Q$:?\$4_^C]OAS_X1/QF_P#G:T?\1&G_
M  13_P"C]OAS_P"$3\9O_G:T?4,=_P! 6+_\)JW_ ,@'/#^:/_@2_P S]LJ*
M_$W_ (B-/^"*?_1^WPY_\(GXS?\ SM:/^(C3_@BG_P!'[?#G_P (GXS?_.UH
M^H8[_H"Q?_A-6_\ D YX?S1_\"7^9^V5%?B;_P 1&G_!%/\ Z/V^'/\ X1/Q
MF_\ G:T?\1&G_!%/_H_;X<_^$3\9O_G:T?4,=_T!8O\ \)JW_P @'/#^:/\
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M_A$_&;_YVM'U#'?] 6+_ /":M_\ (!SP_FC_ .!+_,_;*BOSH_9/_P""M?\
MP3L_;D^)>H?!W]E+]I_PC\8_B5I7A'4_'FH>%-#\.?$'2;VW\(Z/J>C:/J>M
M-<^*?"&@Z<]O9ZGXAT:TDBBO'NR]_$R6[QK*\?Z+UA4I5:,N2K3J4IVORU(2
MA*SO9\LDG9V>MNC&FGJFFNZ=PHHHK,84444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5_F1_\'"?P,_:!_:'_P""_'Q7^&_[,WPA\3?&_P"*
M4_[//P9UFW\">$K>.ZU>70=+^'MD=9U<12W=D@M=,6XMO/<S@@W$8"-NX_TW
M*_CVT7_E<H\7?]F*6W_JK_#%>]P[C\1E>.J9CA9*.)P>$K8BA)I-1JTY4W"5
MFFGRNS2::NM48UHJ<8PE\,IJ+Z:--/4_DB_X=)?\%FO^D:_QV_\ !-8__-%1
M_P .DO\ @LU_TC7^.W_@FL?_ )HJ_P!>:BOK_P#B+7&'_09#_P $8?\ ^4F'
MU##]I?\ @4O\_7^EK_D,_P##I+_@LU_TC7^.W_@FL?\ YHJ/^'27_!9K_I&O
M\=O_  36/_S15_KS44?\1:XP_P"@R'_@C#__ "D/J&'[2_\  I?Y^O\ 2U_R
M&?\ ATE_P6:_Z1K_ !V_\$UC_P#-%1_PZ2_X+-?](U_CM_X)K'_YHJ_UYJ*/
M^(M<8?\ 09#_ ,$8?_Y2'U##]I?^!2_S]?Z6O^0S_P .DO\ @LU_TC7^.W_@
MFL?_ )HJ/^'27_!9K_I&O\=O_!-8_P#S15_KS44?\1:XP_Z#(?\ @C#_ /RD
M/J&'[2_\"E_GZ_TM?\AG_ATE_P %FO\ I&O\=O\ P36/_P T5'_#I+_@LU_T
MC7^.W_@FL?\ YHJ_UYJ*/^(M<8?]!D/_  1A_P#Y2'U##]I?^!2_S]?Z6O\
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MK_2U_P AG_ATE_P6:_Z1K_';_P $UC_\T5'_  Z2_P""S7_2-?X[?^":Q_\
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M&'_09#_P1A__ )2'U##]I?\ @4O\_7^EK_D,_P##I+_@LU_TC7^.W_@FL?\
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MK'_YHJ/^'27_  6:_P"D:_QV_P#!-8__ #15_KS44?\ $6N,/^@R'_@C#_\
MRD/J&'[2_P# I?Y^O]+7_(9_X=)?\%FO^D:_QV_\$UC_ /-%1_PZ2_X+-?\
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M_P"$)\'_ /0MZ3_X#?\ V==117V/]GY?_P! &!_\),/_ /*_)?<8<TOYY_\
M@4O\_+\^[.7_ .$)\'_]"WI/_@-_]G1_PA/@_P#Z%O2?_ ;_ .SKJ**/[/R_
M_H P/_A)A_\ Y7Y+[@YI?SS_ / I?Y^7Y]V<O_PA/@__ *%O2?\ P&_^SH_X
M0GP?_P!"WI/_ (#?_9UU%%']GY?_ - &!_\ "3#_ /ROR7W!S2_GG_X%+_/R
M_/NSE_\ A"?!_P#T+>D_^ W_ -G1_P (3X/_ .A;TG_P&_\ LZZBBC^S\O\
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M$F'_ /E?DON#FE_//_P*7^?E^?=G+_\ "$^#_P#H6])_\!O_ +.C_A"?!_\
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M11_9^7_] &!_\),/_P#*_)?<'-+^>?\ X%+_ #\OS[LY?_A"?!__ $+>D_\
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M_P (3X/_ .A;TG_P&_\ LZZBBC^S\O\ ^@# _P#A)A__ )7Y+[@YI?SS_P#
MI?Y^7Y]V<O\ \(3X/_Z%O2?_  &_^SH_X0GP?_T+>D_^ W_V==111_9^7_\
M0!@?_"3#_P#ROR7W!S2_GG_X%+_/R_/NSE_^$)\'_P#0MZ3_ . W_P!G1_PA
M/@__ *%O2?\ P&_^SKJ**/[/R_\ Z ,#_P"$F'_^5^2^X.:7\\__  *7^?E^
M?=G+_P#"$^#_ /H6])_\!O\ [.C_ (0GP?\ ]"WI/_@-_P#9UU%%']GY?_T
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M,/\ _*_)?<'-+^>?_@4O\_+\^[.7_P"$)\'_ /0MZ3_X#?\ V='_  A/@_\
MZ%O2?_ ;_P"SKJ**/[/R_P#Z ,#_ .$F'_\ E?DON#FE_//_ ,"E_GY?GW9R
M_P#PA/@__H6])_\  ;_[.C_A"?!__0MZ3_X#?_9UU%%']GY?_P! &!_\),/_
M /*_)?<'-+^>?_@4O\_+\^[.7_X0GP?_ -"WI/\ X#?_ &='_"$^#_\ H6])
M_P# ;_[.NHHH_L_+_P#H P/_ (28?_Y7Y+[@YI?SS_\  I?Y^7Y]V<O_ ,(3
MX/\ ^A;TG_P&_P#LZ/\ A"?!_P#T+>D_^ W_ -G7444?V?E__0!@?_"3#_\
MROR7W!S2_GG_ .!2_P _+\^[.7_X0GP?_P!"WI/_ (#?_9T?\(3X/_Z%O2?_
M  &_^SKJ**/[/R__ * ,#_X28?\ ^5^2^X.:7\\__ I?Y^7Y]V<O_P (3X/_
M .A;TG_P&_\ LZ/^$)\'_P#0MZ3_ . W_P!G7444?V?E_P#T 8'_ ,),/_\
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MQ=B?SIF=3['_ %\C^I_831117G&@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_'O_
M ,'+G_)_O_!OA_V>U-_ZM[]E>O["*_CW_P"#ES_D_P!_X-\/^SVIO_5O?LKU
M_817K8W_ )%N3_\ 7O&_^I3(C\=3UC_Z2@HHHKR2PK^>[]HW_E9*_P""<7_9
M@7[67_I_2OZ$:_GN_:-_Y62O^"<7_9@7[67_ *?TH _H1HHHH **** "OQ)_
MX+$_\%:_%?\ P3CTWX-?#/X%_LV^.?VG?VI/VEM=D\*_!WP7I.C^((O ECK$
MEU#9:<WBSQ+I^GO;W.H:O/\ V@-(\*:7J$&K3VNCZKJ^J3Z/HMF+Z?\ ;:OP
MA_X*T_\ !9OPU^P%\2O@Q^R_\'?V>?$/[7W[;WQS@35OA3\%_"Y5(M MKV\O
M]#T3Q)XDOH+._P!0@74M4M+^UM=-T\6%Z=.M]0U:[U+3M*@:XE /SE^(O[9'
M_!TY^S=\-;[]K#XS?LB_L2^/?@_X,27Q;\3/V?\ X7W_ (FN/C'H/@"PC%[K
M]Q9W-GXRUR%[G1],@N)I+C1=0\<7\#"2Z_X1W5((G@3^A/\ 8)_;D\%?\% /
MV*?A=^V/\.= OO"FG?$?PEK.J7G@G7+VVU34?!_BKPY>:EI&O>&M0U"P6W@U
M".SU73)9+&_BALGU'1[FPOY+/3YKE[.W_G\^./QY_P"#G#X\?L__ !:O=1_9
M&_8F_9+^&S_"GQU<>-U\7^/-:\3?$&+P7J/A'4W\06]M9#6/$^FS^)-(T6/4
M%AAMH=-MI=1FAA-RR[)4]1_X--V8_P#!%*QW,S;?C'\?E7<S-M40Z(0JY)VJ
M"20JX7))QDG(!\>_L,?\%W_^"PW_  4R^"MYX6_8W_9'_9N\5_M)^&O'NO6W
MQ?\ BOXJ_P"$V\$?LV_!OP'=+9VWP^T^>QUCQMJ'B#QC\1/$D\'B/5+J#0-?
MU"#1-)L-,NM0\/2)J(C'M?P)_P""U?\ P4S_ &3?V[?@S^Q1_P %G_V;_A%X
M!T#]H[44\/\ P@_:"^!QOX_"TVO7VH2:9I4NH2S>*/$>EZOHD^L&WT6^MUMO
M#/BC0_MECJ-UHVH6EP)6Y_\ X,N+.TC_ .">G[4%_';0)?77[;?C&UN;M8U%
MQ<6UE\'_ (.2V=O-*!ODAM9+Z]DMXV)6)[NX90#*V:G_  =K +JO_!("10%D
M'[<<:B50!*J_:/AT=JR##J,_-A6 W '&0" #^@3_ (*@?\%)/@U_P2Y_9=U_
M]HOXLVE]XFU*?4(/"'PK^&>BSQ6_B'XH?$C58+B71O"NF3RI,MG;"*WN-2US
M5/L]V=*T6SO;V.SO)HXK6;\)_ _[6O\ P=9?$#X=:#^U1H'[&_[%<?PT\3+'
MXRT7]E[7;GQ-X<^/%UX NE-]IVFSMK7C6SATOQ'JFB>5-9OJVJV>IQZC=037
M_A*U4R:!'D?\'$-Q<>.?^"H/_!!OX#>.8=-N?@1XO_:>MO$7BZSUJ.QET:Z\
M06WQ ^'N@Q)J,6I.UC);C0-3U%'2Z@:%TF96?G8W]@E '\%7_!+C]KOP]^W+
M_P '27Q7_:,T/P7XK^&E]XH_89_X1_QQ\,O&^GW>G>*/AM\3? G@7X&^#/B/
MX"U:.]M-/N+FX\*>,-$U;1OM[6%D+Y;47*VL(D\L?WJU_%;^S/X1\$^#?^#R
M/]KZR\"V%OIUCK/[*FL^+M?BMFF*7'C;Q9X(^!6O>,[^03<K<7_B&^OKNX6/
M]SYTKF+Y"*_M2H _EW_X.<O%/_!1S3?V-/CCH'[/WP\_9^U_]BG5O@+KG_#3
MGC'QW<ZZOQA\./\ \)!8B,_#BVLO$NGZ.ZBR6W=Y-1T/4W$TCJK!"5KRO_@W
M#\;?\%>KK]G;]C3PO\2?A/\ LJ:;_P $XK?X*7R>!?B#X>OO$_\ PT%>V$!N
MW\)3:W9S^,KGP^9;O4FNHM3:'PS"1;I'Y?DE<M^J?_!P!_RAS_;Y_P"R&:Q_
MZ<M+IW_! '_E#I^P+_V0K1?_ $X:E0!^:7[<W_!=W]K3]EW_ (*M_%?_ ()\
M?"']F?PS^T=-<_ _P/??LX^ /!^B^)(?BGXP^.WQ#\*Z=J^DGQKXLG\5Q^$-
M(^%?ARYFU#4?%-V=!TR]M](M[>)-8@>6>_M?TK_X)?>+?^"QFO:A\7-9_P""
MK'@K]G+X?^'KG1/"NK?"G3?@M=J9] O&6\N/%.E^)ICXAU^(1V5K/:QSSRZE
M?Q)=V$K6NHRVQ>:X_&C3+6UN?^#S7Q,]S;PSO:?L1VMU:--&LC6UTOP=\.PK
M<0%@?+F$,\T0D7#".6100&-?T=?\%./&OC;X<_\ !.S]MWQW\-PQ\>>$_P!E
MWXUZYX2V_>_MRP\ ZW-8E<20G(F4$8EC.1PZGF@#\"_%'_!9+_@IU_P4/_:0
M^+?P?_X(@?L\_!?Q#\#?V<_$U_X0^(G[6G[1MYJ%S\.OB%XHAO+?3H;'X>SZ
M+JNG:;%I8>/5-5LOL+>+]6UWPY'IWB.9?#-G?Z;9:QV_P._X+0?M]?LE_M0?
M"3]E/_@M[^S#\._@=IW[0NI/X0^ _P"U)\";V]UKX6>*_',.H6&FP:)X@TR/
MQ!XNN-/&J7>JZ;:/<&70M2TVZO;&]N/"R:)??;[3\J/^"&_QZ_X+A?"?_@FS
M\$- _87_ &!/V0_BM\ ;_5/B5K.D?$OQM\1?$>D^.O&6OW/Q%\2VOB"^\7Z9
MI?C[2K:QU+3+NS7P]80_V;9N^@:/H]TT3_:!<S^K_P#!2WX*?\'$_P#P5+^$
M7P_^"OQ=_8 _97^%]CX%^+GA7XHZ#X^^&_Q2U-/&.BZIH2W=JUO97_B+QIKM
MO86%VEZESJ$EK9?;&?3K-HI!Y11P#^D__@KC_P %.]'_ ."7/[.5A\68O@_X
MY^.GQ'\=^)K?P)\*?ASX1TG6I--UCQ;=QB9&\6>)M,TK58?#6D0P9:/=;SZE
MK%V8M.TFTGN)'>'\:T_:C_X.QYOAVW[2D?['7[$-OX-GM[OQ;#^R_>W/B+_A
M>%KX02VEOK;2[A(OB!%;GQ++I:)+%:'Q$FL_VK*EO>>&+2X$OA^']+O^"F'_
M  58^''_  2C_9__ &=M!^(GPO\ $/[1G[2/Q8L_#7@?X9? GPA=65[XC\4>
M+M%T'3K+5O$-Y=7%IJ=X-(L]=D@LDO=/TB_U'5M3O8;.QC2:9I8OB'3OVJ?^
M#H?X]Z3)JO@']@3]C7]EW1]1:^FTN#XW?$;7;GQQI>G+<SQV@\06<'B'6]/6
M^D@L&EV0:);>7%JMJUS! \;FW /T5_X)K_\ !3[6O^"HW[ _Q!_:)^#/POL?
MAQ^T7X)/Q/\ AEJ?P=\;ZQ-JWASP]^T!X1\.O?\ AK1-9U:WCT+5'\*ZW>:E
MX9O[U;BVT?5]/TW4KFRE=;BU%[)_&Q;>/?\ @MX?^#BF\\4Q_!O]C,?\%(V_
M9@2WG^'TFH^,O^&>X_A<?A]9@7ZWR^.CXA_X2H:#Y)9?^$H:T_M,O&(/LV$'
M[&_\&=<6N6WP*_X**6OB:_M]3\1V_P"VYJD?B&_LX#:6-[KZ^#-*36KRSL\[
M;6WN=12>2&( %(?*0@!%59;3_E<SU3_LQN/_ -5%IU '] D?[7'CW]DS_@G8
MW[67_!3BW^'/PQ^)OPQ^'6K^*OCOH/PCNYKCP<OB2+7=2LO#7A+X;KXAU[4+
MO5M:\4V\OAO2-%TN?7;J?4/$VJ?8H)@KHB?@1\*O^"AW_!R=^WMX5NOVK/V*
M_P!C[]D[X/\ [+7B22XU'X,^!?VBM0U^;XG_ !!\+:4UI''K']ICQ#X;CU&W
M\57#7ATG58]-\&:-<64#MI5S=6J6?B#5NR_X/'/&?CGP_P#\$W?@[X6\+017
M7AWXA_M9_#O1/'EO</Y=K<:5HWASQ?XKT"VNI!-#LMYO%VBZ&DK_ #[5^;]V
M0)4[#PG^UA_P<Q^&_"OAKP]X._X)=_L(6/A+0_#^C:1X7LM)^+/C"32[3P]I
MVG6UIHMMITD/Q0DBDLH-.AMHK62.21'A5&5W4AB ?7O_  2R_P""Q'CK]J?X
MW?%#]@W]N;X"2?LE?\%$/@Q82>(O$/PJM+F?6?!7CWP.MMI]XWB_P-K<5WK-
MJD-I;:KIMQ/:_P!O:UI]]IU_8ZIHNN:C%+=0667_ ,%=?^"R'CO]CWXH?"G]
MA[]A_P""\7[3_P#P4/\ CZEI=^"_AQ=I>7'A#X=>&KZ:2*U\7_$"#3+_ $N^
MG@O1;7EQ:63ZQX>TRTTFPU+7M:\06%A8B.Z_,WX,_LF?\%F_VD?^"TW[)7_!
M0C]KO]E3X(_LX^%OA'X0UCX??$*_^#/Q$GNH?$?A5M*\4&REUVTU3Q!XAUC7
M+^2]UFPTU+-9X;)=/L+4E%:VW/UO_!/VZG^)_P#P=1?\%3_$GQ/@TRX\3?!W
MX&Z3X2^#SW\=C)J&F^%OMGPZTE9-$>=Y+N&6XT+5-46\>P,;FSO;F*Y58)&5
M@#T;4/V^_P#@OS^P-=:5\:/^"F/[+?[-/Q>_8L@&FQ_&WQU^R)=:]<_$;X"Z
M!JT\=C<?$#5-#O=5O+G7M \*O<+>>*K+3_#&HP)81M=+XBT>V@FN9/(O^#+V
M[M[_ /8>_;'OK-VDM+W]N#Q)=VLC(8VDM[GX1?"N:!VC.2C-$ZL4))4D@\BO
MZX_B?X8\'^-?AM\0?!WQ"LK?4O 7BOP3XI\.^-M/NC*MM>^$]:T.^T[Q#:SO
M K3I%/I-Q=QN\*F9%8O$#(JU_(W_ ,&7D%M:_L._MC6MFH2TMOVW_$<%J@)(
M6VA^$/PKC@4%OF(6)5 )Y('/- ']CM%%% !1110 5_/!_P $S/\ E-U_P<,_
M]C;_ ,$[?_6:_$=?T/U_/!_P3,_Y3=?\'#/_ &-O_!.W_P!9K\1T ?T/T444
M %%%% '^/[_P5&_Y3!_\%-/^SFOB!_Z>DKY!KZ^_X*C?\I@_^"FG_9S7Q _]
M/25\@U_:GA[_ ,DCE'_7NM_ZD53Y[$_QZGJO_24%%%%?:& 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !117]*O_!$3_@@_/_P4!T<_M,_M+:CKGA']E6"_OM)\#Z%X8U!-.\7?&K6]
M'U!M/UVX@U:-)I?#G@/0[NWO=(N=3LS'K>K>(+>YL["2Q@TF]EN?(SS/,MX=
MRZKF>:U_886DXP7+'GJUJT[^SH4*::=6M/EDXQ3248SJ3E"G"<XW3ISJS4(*
M\GKV22W;?1+2[\TE=M)_S4%E'!90?0D?XTZO](#Q)\ _^#:?]G3Q'X-_9D^(
M.A?L6Z=\0Y[.WT/2;+QGJ,?C#QM>307LFGEO%GQ >;5Y+?71>V\D-_<>*M>L
MM10HQO-D39/YG_\ !7S_ (-W?A%H_P &O$_[7W_!.D?9+3PQI%WXZ\:?!*PU
MS_A)?!_BGP5' MYJ7B/X2ZQ)=W1TR\TC3TEU2+P]%>76AZO813Q::;&[:)V^
M*R_Q2R7%XW"83&9=G.2T\QDHY?CLTPD:.#Q3E+DIVJQJ2Y8U)6BJB4Z,)-*I
M4A%.9T2P=2,92C.G4</BA"3<H][JVMM^CMLF?Q7$@=2!]2!_.@$$9!!'J.17
M]1__  ;)?L:?LO?MA>,_VL+/]I3X,^#OC%9^"/#WPWN?"4'B^R>^@T2;6+W6
MX]2FLHQ)&$ENTMK=9'))VQ  =Z_,S_@MU\&/A9^SW_P4U_:&^$/P5\#Z#\-_
MAIX4L?A?_P (]X.\,V@L=%TIM4^'/A_4M2DM;8%MLE]J%Q<7ERY8M)/,[L22
M37TV&XHP>*XHS#A6&'Q,<9EV!ACZN(E[+ZM.G46#:A3M4=7G7UR%^:FH^Y/7
MX;XNE)4H5KQY)R<4E?FNKZO2UM'U?0_*,D#DD >I.* RG@,"?0$&OZ/?^#;G
M_@G?\-/VV/VCOC!X^_:"^'$/Q$^!?P4^'T>DC0O$&G66H>"/$?Q+\=7 BL=+
MU=97%]'JWAKP[:2^)-*:S$2*]T&GED^6)?W_ /\ @L'_ ,$6_P!C/1?^">GQ
M_P#B#^RM^S?\.OAE\7?A7X?@^*&F^(?!NAR_VK>^&_!%]#K'CC0XQ!-+/-]O
M\*6VL"&*W#2_;8;?Y)5WQ/X^;>(N29/Q)A^&<12Q4\36JX*C5Q5/V+PF%J8Y
MP]G&NY58U/W=.I3J57"$N6,TOBBT:0PM6I2=:+CRI2:B[\TN7?ETMT:U:U70
M_P \2FEE'!90?0D?XT [DW#(RN<'@CC.#Z$=#Z&O]%W]@O\ X)L_\$L;K_@E
M[^R[^TW^TA^S3\%7FG_9?\ _$GXM_$_Q5H=Q----/X;MM1U_Q/KL]JTDTTDD
MLDD]S)%;NY& J':*]3BOBS!\)8;!XG%X3&8U8[%K!T:6"C3E5=5PE4C[M2<.
M;F47&*CS2<FDHLBC1E7E*,91CRQYFYMI632>R?>^NA_G1AE/1@?H0:6O]%+X
M4?LS_P#!L[^W1KUW\%/@#IO[-'C'QU>:+<ZG%H_PRUKQ7X$\:2Z=*!927.AZ
MD6\/WMW=V[3++%;Z7<7-_;$&\%NL<;RK_,C_ ,%N?^"-=S_P3$\8^!O'WPN\
M0>(_'?[,WQ;UZ^T30=6\21VDNO?#GQA#*NHQ> ?$6I6D=K%J=MJ6CM=3^$=4
M:T^WZA9Z'K":K-)>V37-UYN2>(.59OFD,EKX'-LDS2M!SPV$SC"?598E*$JE
MJ3YY-3<(3E&-2--5%&U*527NE5,-.$/:*5.I!63E2ES)-M+71=6MKVW=C\&=
MZ?WE_P"^A_C2AE/0@_0@U_IZ?%S_ ()P?\$1OV9?@I;?&W]HK]FS]G?X8?#G
M3=/\-0:YXU\3>']0_LRVU'6;:"*T2Y;3UO+EI[ZY+ ,EL0TA9F*@U\T?#7]@
MG_@W1_X*/6WBOP+^S%I7P9\3>(_"NGVMWK,OP'\4>*_ OC#08+B9WLM5$);2
MIM2MA.!'<.;+4; H$M+]1'(D;>!1\7LJJT)XS_5[B7^SZ-3V>(S"G@J-;"4)
M)P352M'$*E&2<X^[*I&7O15KRCS:O U$U'VM'F:O&#DU)K3IRW[WLF?YT=-W
MI_>7_OH?XU^L?_!6/_@F)XH_X)D_M1:#\-KK7H_&?P@^*5Z?$_P9\4R@QZO>
M^$[;Q%I]AJOAOQ1;+&L,>O\ AMM0M+"^GMI'AU&UN;34%2'[5LK^YSX[?\$X
M?^"'O[+/PI?XR_M%?LW?LZ?"KX;:?-HVF:EXQ\3>']1&EV^IZPGEZ?;3'3DO
M;DSWLL<@0K;E6=6+E<U[N<^(>495ALAQ=#"X_.*/$4:\LN_LRE"=6;P\L/"=
M-T:LZ=5UG4Q"I>RC"4XU:=2$DI))Y4\+4J.I%N%-TN7GYVU;FN]TFK63=W;=
M/8_S -Z?WE_[Z'^-+D8SD8]<C'Y]*_T"?^$L_P"#37_H+?L5_P#@B\7_ /RC
MK^=KX3:M_P $LD_X+B?$35O'US\&%_X)DRZE\1G\(W&HZ?JQ^#YM)O@_I">$
M5T_3X]/.J1QK\0SJ*:>KV*+'JD<K[O)\N1]<LXVEF4,RF^%^)\%_9V75\PY<
M;ETJ,L:Z'(OJ>"3;]KC*O,_94EK)1ET5V2P_)R7K4)<\XP]R=^7FM[TM-(IO
M5]FNY^#6]/[R_P#?0_QHWI_>7_OH?XU_H%?\)9_P::?]!;]BO_P1>+__ )1U
M^A'P&_X)G_\ !$K]IWX8Z)\9O@/^R_\  'XC_"_Q))J$>@>,])\*:S9Z3J_]
MEW<MC>S:?_;4.F75S:1W4,L<=]';FSN@AEM9YH2)#X&+\6,+E])5\?PIQ7@J
M,IJFJV+P%/#4G4DG)052M5A!S<8S:BFY-1DTFHN^D<%.;M&OAY.UVHS<G;2[
MLD]-7]Z/\NX$'H0?IS02!U('U./YU^D7_!6ZW_9:TS]O_P".WAK]C?P]HOAC
MX&^";W1_!%AIGAFR6R\,-XQ\-6;V7C>[\.;+BYCO='FU@^5;ZC&Z1W4MO<!8
M4\K+?LC_ ,&T/_!,OX+?M>W'[2/QX_:@^$VF_$_X6^$8/#WPL^'6A>,-.M+[
MPAJGC'4+@>(_%NOV)#KJ"^(/"%AINE:/)\T-HMGXN?*7$I5X/L\RXGP>4\-Q
MXFQV'Q5'#RPV#Q'U.481QO/C72C2PW)*:@J\757.N>T8PJ2ORQ;,(493J^QB
MXN5Y*]WRVC>\KVO;3336Z6[/Y3 RGH0?H0?Y4M?WC_\ !?#_ () ?LG_  K_
M ."??BGX[_LE_L_^!/A5XS^#/B_PKXP\7:AX)T65;S7_ (:WUQ+H&NV#B&6:
M:46^H:MH>HQ2QAH8;:"\FGC>,"2+^#@$$9!!!Y!!R"#T((X(/8CK1PKQ1@.+
M<LEF> IUJ-.&)JX2K0Q/L_;4ZM*%.I[RI3J0M.G5A.+4GH[/5,*U&=":A.S;
MBI)QO9IZ:72>C304445]*9!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ']!W_!I=_RF'^,_P#V
M9?\ $#_U9'P.K_2RK_--_P"#2[_E,/\ &?\ [,O^('_JR/@=7^EE7\7^(W_)
M79M_V$5?_3]8]_!_[M2_P1_])04445\.=(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5_'MHO_*Y1XN_[,4MO_57^&*_L)K^/;1?^5RCQ
M=_V8I;?^JO\ #%>CEVV/_P"Q=B?SIF=3['_7R/ZG]A-%%%><:!1110 4444
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M[4X'N-)LO$LEM]LT!=82(-.FCW6KVEG::K<6R275KI\]Q<6L4MQ%'&WX>_\
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M(%DDM&\8^,[:^LX_%6A:E;&,ZW+J&H/9?VE)?VVD:=I<&GZ=--+X%_P5<_8
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M )L:/^'MW_!+3_I(S^Q%_P")0?!G_P";&@#]"Z*_/3_A[=_P2T_Z2,_L1?\
MB4'P9_\ FQH_X>W?\$M/^DC/[$7_ (E!\&?_ )L: /T+K^>#_@F9_P INO\
M@X9_[&W_ ()V_P#K-?B.OT4_X>W?\$M/^DC/[$7_ (E!\&?_ )L:_*__ ((_
M?%/X9_&S_@K_ /\ !?CXH_!SX@^#/BK\-/%GBC_@GS/X7^('P\\2:3XO\&>(
M8M-_9]\7:-J3Z)XDT*ZO=(U1=.UC3]0TJ]>RNYTM]0L;JUD82PNH /Z6Z***
M "BBB@#_ !_?^"HW_*8/_@II_P!G-?$#_P!/25\@U]??\%1O^4P?_!33_LYK
MX@?^GI*^0:_M3P]_Y)'*/^O=;_U(JGSV)_CU/5?^DH****^T, HHHH ****
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M!XP\<3V[:%H,%HLUW81S7OB&2+['H]P3_6W_ ,' '_!1OPS_ ,$_?V7/"7[
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MU:S;P?XP\._#?PE+'XJ\2Z^+/Q#;QRPBVL-/BD2(VD\]Y!*ZVL$I)*_Z2/\
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MKO=-1O?57?>Y_,)1117[T><%%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P %$OC+^S[\2?AA>?"SP!+\%M+^#O@:S\+:UX=ECL8+B[?Q+?65C81ZA =
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M4=0UWQDFGZC)I/@^^2#3XXY-%GAMXG:!4ANE:Z6V&?) !_037XO?MS?MA_\
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M[UJ_NI-'U._>::SOM..I16*Z=HMAJ.;2SANFMI+MP#^R*OQ9U+_@JMXIL/\
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M=W$4$,=Q=F*. W4R1JLMP88@(H3.X:0Q1@1QEMB#:!0!/1110 4444 %%%%
M'\>__!RY_P G^_\ !OA_V>U-_P"K>_97K^PBOX]_^#ES_D_W_@WP_P"SVIO_
M %;W[*]?V$5ZV-_Y%N3_ /7O&_\ J4R(_'4]8_\ I*"BBBO)+"OFSX]_L;?L
ME_M47&@7?[2_[-/P+^/MUX4@N[7PS<_&'X6^#/B)/X?MKZ1)KVWT>7Q5H^J2
M:=#=RQ1RW$5HT232(KNK,H(^DZ* /SE_X<_?\$I?^D;_ .Q#_P"(Q_![_P"9
M&C_AS]_P2E_Z1O\ [$/_ (C'\'O_ )D:_1JB@#\Y?^'/W_!*7_I&_P#L0_\
MB,?P>_\ F1H_X<_?\$I?^D;_ .Q#_P"(Q_![_P"9&OT:HH _.7_AS]_P2E_Z
M1O\ [$/_ (C'\'O_ )D:/^'/W_!*7_I&_P#L0_\ B,?P>_\ F1K]&J* /SE_
MX<_?\$I?^D;_ .Q#_P"(Q_![_P"9&C_AS]_P2E_Z1O\ [$/_ (C'\'O_ )D:
M_1JB@#\Y?^'/W_!*7_I&_P#L0_\ B,?P>_\ F1H_X<_?\$I?^D;_ .Q#_P"(
MQ_![_P"9&OT:HH _.7_AS]_P2E_Z1O\ [$/_ (C'\'O_ )D:/^'/W_!*7_I&
M_P#L0_\ B,?P>_\ F1K]&J* /SE_X<_?\$I?^D;_ .Q#_P"(Q_![_P"9&C_A
MS]_P2E_Z1O\ [$/_ (C'\'O_ )D:_1JB@#\Y?^'/W_!*7_I&_P#L0_\ B,?P
M>_\ F1H_X<_?\$I?^D;_ .Q#_P"(Q_![_P"9&OT:HH _.7_AS]_P2E_Z1O\
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M2E_Z1O\ [$/_ (C'\'O_ )D:_1JB@#\Y?^'/W_!*7_I&_P#L0_\ B,?P>_\
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M0. OI7AG_@LM\*+'_@K3\0/^"I/C#]D?Q!XOGUSPCI>C?#OX0/\ %#PW%<>
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M&1GX7<'!(R.<$TG_ !&%^"_^D?/C;_Q(?PM_\ZZOX@Z*\_\ XA3P'_T))?\
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M("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /Z#O^#2[_E,/\9_^S+_ (@?^K(^!U?Z65?YIO\
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M5J=OXUGMM<\(74\<&@Z+XBU'Q/I&RVTR]E+:_HNE ^047<SQ>9YI_P %%_\
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M1!_8::.**-IM!^,4LS1QI&TTO_#0_P 6X_-F9%4RR^7'''YDA9_+CCCW;(T
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MT9!*_@/@;7?^#@G_ ()"^-OC9\+;#]G/7?\ @KY^S?XP\;ZU\1OA+\:]4^,
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M] U30O%\,^L?9/%NK>(]/\,_8IM/M1K%G;7VMQ7\%M<QV-TOV^*6.@#]3O\
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MX<TOPAXOTW3M.5-/UOQQ9KXETR._U"."UDCU+6[^;X;?;7AC>^TV.^G^W:@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BOXJ-&_X.:_BE^R_^V-^T/\!/VK?AE;_%
M_P""G@?X[?$3PCX:\>?#RWL= ^*_@_PSI7BK4+2QMK[0I)+3PKX\M]-LHH;*
MQMT;PGJK1JUSJ.N:C*-K?U)_LB_M]_LD_MS^$D\6?LT?&?PIX_:*T6ZUOPBM
MU_9'Q \+?ZF.>/Q)X(U46OB'3X;:ZF%B=56RGT*\NDD33-5OHU$A^HSO@WB'
M(*-'%8[ 3E@:]*E6I9AAKU\'*%:$9P52K%)X>;4DO9XB%*;:?(I1M)X4\12J
MMQC*TDVG"7NRTT=D_B7G%M'^6#_P5&_Y3!_\%-/^SFOB!_Z>DKY!KZ^_X*C?
M\I@_^"FG_9S7Q _]/25\@U_5GA[_ ,DCE'_7NM_ZD53Q<3_'J>J_])045^KW
M_!+_ /X)=:E_P4LM_P!IDZ1\6[KX9ZE^SS\.;3QW8:/8_#V7X@7_ ,0KV^@U
MN2T\-64$'B3P_/IES<3Z.EI!+;PZO<3S7L:PV3LFQ_T.\)_\$*/V1/A?;:1X
M/_;L_P""HWPC_9]_:$\2Z)IT[_!72K70+^Y^&6MZK9M?V5M\0/$.I>*+>"%1
M:7%G-=0ZG9^&+./RYQ!K%S%(L\7?C^+LARW%XC 8C%U98["^R]M@\-@<?C,3
M&-:E&O&HJ>&PU5SI1HSC4JU8.5.CS1A5E&I*,)3&A4FE)12C*]I2E&,=';=R
M5G?1)V;ULFM3^9.OT/U#_@F?\>]-_P""?.E_\%);C7? !^!6K>(+;PY;Z FH
M:@?'J7=WXED\*0W$MB;3^SA;'5(W+!;QI5MP)"@R*[?_ (*:?\$J?C+_ ,$T
M/%/@-O%7BOP_\7/@S\6+#[7\+?CAX0@2S\/>++J*S_M.ZTF;31?ZF=.U%-)D
MMM8M?)U#4-/U#3+@75C?W$:,3^U?B[_E4L\$?]E1T/\ ]79=5P9KQ-'ZMPQC
MLDQ.'Q.#SKB/+LLJUN1S4\)B7B(XB$8SY)T:\)T>22G&-2E.,H3@I)I5"E>5
M:%1.,J=&=1*]FI1<.6]KIIJ731JS3L?R'45^H'P-_P"";4GQI_X)F?M:?\%&
M5^,0\.1_LM^-E\'/\(?^$(&J'QL7B^&THU$^-3XDLO[ !_X6&%6V7PYJW.D$
MM,HO0;?\XO!OA_\ X2[QIX)\'B[_ +//C'QKX0\'C4/)^T_V<?%?B/3/#PU$
MVWF0_:18'4OM9MO.A^T>3Y/G1;_,7Z?#9C@\7+'0P];VDLMQ4L'C5[.K#V.)
MA0HXF5.\X152U&O2GSTN>#YN52<HR2R<9+ENK<\5*.JUBVTGH]-4U9V>FUK,
MYRBOT<_X*C?\$^KC_@FO^U3:_LQ+\4F^-5U>?#7P/\0+?Q6G@Y? TDEQXVUC
MQ+HUMX?70_\ A(?$J&2VF\/(R7W]JA;DZ@L;00>0S/\ JYX0_P""!G[/_P "
M_A7X%\8_\%/OV^O!?[)?Q'^*.F6FN>%/@]I-C8ZWKNA:7);)<SQ^(KNZO%O+
MW5K=IUL-4CTW1?[#TC4[.YLX->U:5R+?R<1Q9D6&P678^>+J5:&;P]IEE/#8
M/&8C%XVFH1J3G1P5*A+%N-*G*,ZLIT81I*45-Q<HIVJ-24IQY4G3=I\THQC%
MWM9R;Y;WT5F[O;N?S#T5^SW_  4>_P"".GB7]A[X-_#?]J?X2_'_ ,#_ +6O
M[)WQ(U"QT*W^,7@ZRL?#LWA_Q+KD]ROAW3;_ $*'Q'XEAU+3-86VFL[?6-*U
M6XGMM7M;FRUG2=(_<O+^,->GEF:8#.,)'&Y;B(XG#RJ5*3DH5*4Z=:C+DJT:
MU&M"G7H5J<OCI5J<*D4XR<>646XG"5-\LURNR=KIJS5TTTVFGW3:\S[J_P""
M?G_!/GXS_P#!2+XO^+?@K\#==\$>'_%7@WX;:A\4=4O/'MYJ%EI$V@:;X@T'
MPU-:VLNFVMW.VHR:AXBL&C1XEA%ND[O(I4 _#=S ]K=WMG(5,MC?7MA,5Y0S
M6-U-:2LA."4:2%BA(!*D$@'BOZ??^#396;_@H+\>E52S-^QUXJ55&,LQ^+7P
MK 49(&2< 9(&3UK,\'_\$+/V8_A9X:TS7/\ @I3_ ,%#_A[^RE\7OB'._B6P
M^ .FKH6K>+_!&D>)-9O[W2&\:75QK3W:WM_IL]LUX(]!M=$T:Z294U[5(B9(
M_E<1QAA\LXBSO+,SK-4,-A\DGEF&PF#Q&+Q]:IC:6-J8V4:.$IUJU6E3]C0<
MING&E0YHQE-2JP4M50E.G3G!:MU5-RDHQ2BZ?+K*R3?-+2^MO)L_F/HK]<O^
M"G?_  2*^+/_  3HD\$?$/2_&VD?M"_LM?%6"VD^'G[0G@RPCMM(.I7L)O;3
MP[XLTZSU+6[31[O4+%DN/#FL6NKZAHGB6&.46MW;:DK:6E7_ ()D_P#!(;XW
M_P#!2EO''C+1_&/AOX(?L^_"Z:6S^(7QQ\=V=S-H]EJ":3=ZJ^G^&;&2;2]/
M\13Z5#;1R^*9I=?TNR\,V=U;7&I7<<EQ:V\_O?ZR9'_8_P#;SS*@LIM=XM^T
M7+/G]E[&5%P^L+$JK^Z>&=+ZQ[3W%3YFD1[*I[3V7(^>_P .G:][WMRVUYKV
MMK<_)>BOZI=._P"""/[!_P 9Y;KX1?LI_P#!6SX5?$S]J*TTV2;2/!FKZ;H,
M?A?QSK.GZ1=WU[I>AR:+XEO[_P BY>VDOIKCPU)XWO-!TFVO+BXTR^B@EN(O
MYO/C5\!/B?\  #XZ>.OV</B-H#6GQ8^'WCI_AUK&B:8[WMOJ7B0WT&G6 \/7
M<D5O_:VFZW<W5K_8FH)%'%?QW$3J$)95G*>)<HSJK7P^!KUEB,/2C7JX;%X/
M%X#$+#S?+#$QHXRC0G/#RE[JJP4HJ349.,FDR=*I32<DK-M*491G&ZM=-Q;2
MDK[?,\=HK^G[X??\&^?PA^#WPS\)^.O^"G?[>WPW_9#\9_$#2;C6_#/P7LGT
M+4O%5CH\+6<POM5U'5]:LKS4=2MXIY;#7-(T#PU?Z;HNIM:P#Q+>W,C6B_(/
M_!0[_@BSXI_9 ^!^C?M=_ /X[>$?VO?V1->U62TG^*O@>ULK6;P7;WFJQZ-H
MDWB"/3M:UW3=2T^XUIW\-W&M:9?!+?7(HK:_T_3I[V&V7DPO&G#>,QE+ X?,
M'*IB*\L+A:\L)C*>!Q>)BY)T,)F%2A'!8BJY1E&$:=>7M9+EHNHVD4\/5C%R
M<-$N9KFBY1B[:R@GS):J]UIUL?%7PA_X)\?&;XT?L3?M(?MY>%]?\#V7PA_9
M?UY/#OCS0M6N]2C\9ZK>M9^$;XR>'+:"TETZ6!(/&>E9-[=6[,\5VJ@[$W?"
ME?U"?L ?\JUW_!8?_LJ4?_J-_ &OR?\ ^"9?_!-+XK?\%*_C)K/@;PMJ[_#+
MX2> ="OO$/QA^/\ J^AKJW@[X:V<-F]WIFG74=SJN@VFI^(=;6.62TTB/6+:
M2TTZWN=9U*2STN!KJHP7$,:?^M>)S?$4,/@,BSB6$IUG!Q5/"QR[+L0E-04I
MUZTZ^*G&$81E5JRG"E3A*3C%DJ3O1C33E*K34FK[R<YQTV25HIO9+5NRN?FW
M17TG^T;\'?A;\//V@]=^"O[,OQCU?]K'P]I>LV7A#1/B/HWPZF\'Q>/_ !K+
M=MI]YIG@+PU;>(?%EYK^BKJ+0:=HNNI=0GQ#<_:)M/L6TX65_??OIX._X-_?
M@)\#_A?\./%?_!3G]OCP=^R5\3_BS8VNH>'/@Q96>C:CJ_AV*60^9;:[K=UK
M#G4;V".:VMM9GL='@\/:!JD-W9KX@U38TD7=F'$V3Y70P5?&5Z\'F2YL#A:>
M!QM7,,1%0C4FXY?3H/&05*G)2K.K1IJE=1J.,Y1BYA2G-R44O=UE)RBH1UMK
M._)Z6D[]--3^7BBOZ@M*_P"#:+Q7XDU7XN>+O"7[8'@CQO\ LQ^&/@?=?&3X
M0_M#_#WP=I_C31/B?J6F/X@_M_X;:OIUCX\@M/"VNZ'#HUK<MJ>F:SXIM+RT
MU$2/!8WMM/IR?EI_P2@_X)NZA_P5(^)7Q=^&ND_%5OA%J7PP^!Z?&&QN1X+_
M .$Z/BB\G\0:=X>M/"0M1XB\--IGGW&HQ.=766^*;=@T]@2ZXT>+^'<1@\PQ
M]',HSPF50PT\QJK#XQ/"+%Z48U:<L.JOM.9.%6E"$JN'J1E"O"G.+2;H55*,
M'!\TW)05X^]RVYFG>UE?1WL_LW/S(HK^C;XU_P#!%?\ 95_9<_9C^)NM?M _
M\%%/ACI?[;?@GX<S>,!^S9X6OO"FI1:'XN6&SU"W^&FKJGB&XU[5];N;1;NP
M-TEIH<B7E_9W\%A=Z9:Q3:I\<?\ !,__ ()#_%W_ (*)Z/X\^*NI?$7PG^S;
M^S'\+5GMO'OQ^^(4,-WI=MK,.G#4;C2O#NC76J:#;:O_ &/!+:3^(M4U/7=!
MT33(KR&%=2N=1$MA&Z7%F0U<OQ>:_7)4LNP5:%"IBJ^%Q=&G6G44?9?4HU*$
M:F.C6<U&B\)"M[:7\-23BV.C54XPY;SDKJ*E%M);N6MH6W:DU9;]C\D**_J3
MN/\ @@#^R3\<XM3\)_L)?\%4_@Y\;/CKI'AS6+K3_A%XCM?#]HWCW7M#6&6_
M.BZUH_BNZU/3-#A@\^:6]TWPUXNMH(GBN9KQ+*.6Y'\^NF_LV>.K']JW1/V1
M_B9:W_PU^(,WQMT;X(^+/[4TFXGN/"VL:GXFMO#DNL)I=P^G2ZKIRI<QZSI,
MB3VUOKFE36=[9W?V6\AG.N6\39-FRQ2P>*J>UP5'ZQBL-B<)C,'BZ-!IM5WA
ML50HUIT9<K4:M*$X.7N74_=%.E4I\O/%+F?+%J491<M-%*+:NK];=]M3YVHK
M]*O^"J?_  3ND_X)D_M(Z-^SU)\6Q\9VU?X;Z-\0?^$K_P"$,'@4VPU?4=1T
M\:2=&7Q%XG60P?V?YWVP:D!()@AMXRA)]._X)U?\$II?V_O@#^UM\<X_CJGP
MI7]EG29=4?PPWP_/C ^-Q'X-U#Q;Y/\ :H\4Z#_8 ;[!_9XD%CJI#3+<&/:C
M1UI+B')X911SZ6,ME6(6&='%>PQ+YUBZT,/A_P!PJ+Q$?:5:D(6E13C?FGRQ
M3:2I5'4=)1;J)M.-XZ-+F>M^71:Z-WV5WH?D/17ZW?\ !+K_ ()2^(?^"G/@
M;]I;Q-X4^+#_  ]\1? 'PWH6L:)X0A\"GQE-\1M6\0Z3JFH:?H::@OB303X?
MWW6G16)O%L]7;_2Q.+7$+1M^E'PT_P""!G[$QUZU^#?QK_X*Z_!#2/VFM9B@
M\/#X8> 8/">HZ3X.^)BH+74O!MUXAU7QQ:KXLU&SUJ\L=)@TB6V\(:W?:E!=
MZ5!8F_<QV_%F'&/#V68K%X+%8RM]<P+I_6\-A\OS#%U:,:E*G756:PV%JQ5%
M4:L)RK<WLXW<'-5%R%0H59QC*,5RR^&4IPBF[VLN:2=[Z)6N_34_EIHK[O\
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M4DZ:WJ5F)GU*?39CI&FRWE[:Z96.7<7</YK'$5,#CI5,-A,']>Q&-J87%8?
MTL.E%S<L9B*-*A[6BIIUZ//[6B^:-2,94ZD8.=&K!Q4HVE*7*HWBY7Z>[%MV
M?1[/HW=7^ **_JP\0_\ ! W_ ()__#<M\'OC%_P5]^$WP\_:AL;/R/$VAZC8
M^$;;P;X5\2*EG>W6DZI!J_C72KBTM[&UNULA-K6M:'?7<H-^^G6LD5QI</XM
M?\%%_P#@FW\=/^";_P 6-/\ !'Q+:Q\:_#;QO9#6_@W\=?"D$K^ OBAH301W
M,BV4X>XCTKQ-I\$L<VJ>')[NXE6SE@U33+K5-(GBOV,KXNR'.,3#!X+%U?K%
M6G.KAH8K!8W!+&4::BY5L%/%X>C3Q4%&2G:C*<_9J51P4(N2)T:D%S2BK*R;
MC*,N5OI-1;<7?372^E[Z'YZ45^]?["7_  16T3XW_LU67[;_ .VG^U!X/_8Z
M_94\1R75K\/-8U6*SU/QA\072[GTNVU6S@O;ZQL=,T>YU&WNTTRWM_[;\0:N
M-.OE;1M.ME2^KT;]H?\ X(1>!IOV:_BE^UE_P3P_;4\$?MI> /@[%>:S\1/
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M@KX:Z#<Q1:E9RK=:G<RJEQ&G[YHT^B/V>_V)? _[&7_!P+^R;^R'!\5E^/\
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MF3]L/_I)5\6__$<_V3/_ )TM??-%']K8K_GUEG_AER;_ .8 ]G'O/_P94_\
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MF!N);'2;6VT^WDD,-I"D2HH^^_\ @FK_ ,$?_P#@I9^U#XU\)_%OX$:?XO\
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MH9[E]HN3E7RR3K5:"4?>:Q6$^LX9Q32FZJC+W6T9T)1C42G\%1.E+TFTD_\
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MU7Q)<R:[?^"TGO=1UGQ1<V=^SR:GXQO-*MY9IQ'?7%C)K4DB6LLEI%'7U?\
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MV[O+2?\ %S_@U?\ CYXW\3?L<_M'?L@>/-1U+Q#>?L)_'WQI\'/"OBB_OQJ
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M]M)H_BZ^\%Z7JNE>'_$,<UO*+CPY?7\>NV4?E3W^GVL-Q;R2_6G[%'_!2?\
M8F_X*'^']<\0?LB?'KPO\6!X72SD\4^'[>WUCPYXT\,Q7X(L[C7?!?BK3M%\
M3:?9W$BO;PW\VF"QEN(WACN6? ;^3'_@B7^UI_P;V?L5_L@>"-=^._[2'P;\
M3_ME?'#1['XE_M.>+/BI\,OB1X^\9:;X\\36]QJ%[\/X-8N/AAJ^G66E^#UU
M6ZTFYAT*ZEL]4UA]7U:ZOM4N+YKV3YH_;._;-_X)>_"C_@J5_P $Z/VPO^".
MOQ6^'L7CSQ;\7]/^$W[4OPI^"GA3QM\)O ?CGP/XFU_1[&WU;QCI%[X3\'Z+
M>W6O'6KW3=073XIGU&;3=/O]2@>[MH;I@#_06^(_Q'\!?"#P)XL^)_Q1\7:!
MX"^'G@70[_Q+XP\8^*-2M])T#P[H6F0M<7VIZIJ%T\<-O;P1*22S%Y'*11*\
MKHC?A=HW_!T'_P $6]=^(VG_  YLOVJ;R"74=:30HO&NK_"GXHZ%\.8+MPRB
MYOO&.L^%;'3['21,OD'6;H1:9EEN1=&P9;L_!W_!QIJ>O?M<?MH?\$K_ /@D
M=:>+O$?ASX6_M,?%M_B-^T+;^&[F>RN-4\&^%=4L+#2-/O3'/:)J=I'82>+M
M7AM)9IH-/UC3]&UA;.XO[&R,/]#:_P#!-S]A#_AGN/\ 98E_93^"5U\"D\,V
M?A4^!KSP%H-U!)86%A#I]I?S:K/9OK4OB2!((;R/Q4^HGQ$FK1IJZZD-25;H
M $_PK_X*'?L@_&W]IKXA?L@?"[XN6OB_X^?"[PMIOC7QEX3TWPUXO&E6?A;6
M+?3KO3-9TWQO<:##X(\06E[;:MI\\#:#XAU)GCN5<+@,5N^'/V_/V4_%G[8'
MB[]@[0?B9)>_M2^!?"*>.O%'PV/A#QK;QZ=X7DM[*Z741XMN?#T/@R[8P:A9
MR&SLO$%Q>KYP#6X96 _D(_X(-_LR3_L;?\' O_!0[]F:'Q)JOB?PI\(_A1?>
M&OAG>ZWKMYXAU2P^%*^*-'O?AUH-Y?WRB9)M!\*W>G:6]F&EBLVMC!'-,%,K
M_7G[/'_*W+^UI_V:5I__ *8O"= ']4WQ[^.WPN_9D^#OQ"^/GQJ\2'PA\*OA
M9X=NO%?CGQ,NDZQKAT;0K)HTN;T:1X?L-4UJ_,;2QC[/IVGW=R^[Y(6P<9G[
M/7[1OP=_:G^"7@?]HKX'^+5\7?!_XBZ(_B/PCXMN=(UOPRFHZ-'-/!)>SZ5X
MIT[1M9TQ(Y+:<2)J>GV<J+&79 F&/P3_ ,%U_P#E$-^WY_V;[XG_ /2G3Z^:
M_P#@BW\)_"OQU_X($_LO_!WQSJ_B70?!GQ)_9SU;PCXKU7P?XGO_  9XCM/#
MVKZCK5MK']F^)]+FM[[1S/8-/;75S!-'NLIKF&4F&60$ [']HK_@XZ_X)!?L
MR^/M6^&/CG]J>T\4>-- O[G3-?TWX3^!O'/Q1L-&OK/<MS;7OB3PAH.H^&6G
M@F4VTUO::Q<W$4X99(D5'9?O?]BW_@H=^QQ_P4)\"W7C_P#9(^.7A3XKZ9I0
M@'B30K-[O1/'7@][F6X@M4\7^ _$%MIGBWPXEY+:72Z==ZGI,%AJBV\LNF7=
MY"IDK\&OV<_BI_P;0_\ !&SP/J_P2T'X_P#[/OBGXAZ%=:XWC?QYX@T2'X[?
M&3QIJ=XLE])I6K>,?!/@?6=':VMK1X-'T[1]-N=*\/6+QF":.#4)M0FE_,7_
M ()>?M+?L=_$3_@YR\0>+/\ @FQH,/@K]F;]HG]E;QC9^/='L/">H^!- USQ
MUH6D#Q9XFU;P]X0G>*RTJQNO$_@_P_=S_P!G65KIT^LQ:Y>1VL=_>WTTP![_
M /\ !R;_ ,%H?A/X,\2?!;]F3]F?]J[XC?#WXY_ []JGP\_[4OAGP%I'Q2\%
MW%A\/;.PL[G4K'4/%L.@Z7HWBK3UBN_,?2?#6MZO)=-)@P.R**_IB_8!_P""
MG?[%?_!1KP]XJF_9#^,%Y\5_^%5V_AS3O'DU[X"^(_@F;2K[5K%VLE<_$#PO
MX<?4WN?LEPSRZ<]^B,A\Z4%E+?ST?\'9_P +/AGI?@+]@;Q;IOP]\%6'BGQA
M^W!X2L_%GB.S\,Z/;:YXFLYK:Q6:TU[58+1+W5K:88$D-]-.C@ $8K^F3QD/
MA%^QY^R_\7OC1X%^'G@;X>P>!_@QK_C[5F\'^$=&T)=5O/"?@VZU+3%U&+1[
M"W.H'[5!#;Q_:A-L64@D*6H ^=OVZ/\ @M#_ ,$X_P#@G/XGTOP%^U'^T)IG
MAOXCZO9IJ4'PW\(^'O$OQ%\<6.F2F V^H^(=#\%:5K,OA6SO8Y_/TR;Q-)I/
M]K0P7+Z6+SR' V?V&/\ @L'_ ,$\_P#@HSJFH>&?V5?V@M%\8>/=)LK_ %/4
M/AIXBT;Q!X#^(L.DZ9):1WVL6WA/Q?IND:CJNCVS7]EYVJ:.FH6,+3^5-/'/
M#<Q0?R _\$0OVQ_^"+_@KP_\8OVW/^"F'[1WPL\6?\%!?VGOB;XU\0^-;7XM
M^ O'_P 05^'/@J;68Y]"T3P]96OPWUWPSIE]JCPM=7U_I]S<W,>D0:-HMM+9
M65I/:2\[_P %T_VX/^"/>J6GP&_;D_X)5_&[X4:!_P %"/@E^T)X6\37EW\$
M_A[\0/A=JGQ.\ 7^F:@GB=/B%?P^"_ ]EXABL;G2/#NFO/?ZL^HS>&M5\0>'
MXUFLM5E%N ?Z*=?.G[57[5GP0_8K^"GB;]H;]HOQ/J?@SX2>#;C28/$WB?2_
M!_C#QQ)HXUK4(=+L;J[T3P-H7B+7ET_[9<0QW>H)IK65@CB:]G@A!D'J?PQ\
M5R^._AM\/O&]Q;I9S^,?!/A7Q3-:)()4MI?$&A6.K26Z2!5$B0O=M&KA5#!0
MP SBN,_:/^!_@[]I7X"_%WX">/M(TS7/"?Q8\ >)O!.JZ?J]G%?V!&MZ9<6M
MG>2VLRM'))IM^UKJ-N2-T=Q:Q2(0R@@ Z+X._%WX>?'SX6> ?C3\)O$=OXN^
M&GQ.\+Z3XR\$^);6WO;.'6?#VM6R7>GW@LM2M[/4;*1XGVSV5_:6M[9SK);7
M=O#<121K\V_M!_\ !13]D/\ 9<^/'P*_9E^-?Q3E\,?'']I*YBM?@YX"T_P7
MX[\5ZCXJ:?6!H,<\MWX3\-ZUIF@V3:IYEN;_ ,0WNEV:K;W4[3""UGDC_$7_
M (-:?V@-5M?V9_CY_P $W_BA=RQ?&G_@G5\>/'WPUGL+FPOM,>_^&.O>*];N
M]"UJVM]0GGF,9\9VGC8D(T=O%I6H^'FA$JW'VF7YR_9*T;4O^"FO_!S'^U3^
MU]<-)JO[/W_!,OPR_P"SK\*;UM2@U+3F^*EK;ZIX0U%M F6.:TN--GUF\^,/
MB:X^PF(0C6=#FCNKCSI)K@ _JC_:8_:F_9]_8Y^$VO\ QQ_:7^*GA;X1?#'P
MXNV]\1^*+QHC>7KQ2RVVBZ#I5K'<ZSXE\0WZPRC3O#^@6&HZQJ#1NMI92E6Q
M^0?P]_X.>/\ @BY\2/B!IWP\TG]K&70[S6;ZWTW2/$WCCX4?%?P1X'O+RY>.
M.-+CQ5XE\'Z=I^AP!Y-KWOB0Z-8H48-<C?#YOYB_M9> /#O_  5N_P"#COPO
M^Q;\=)+[QC^R%^P=\%X?BCK'PK.^V\->+_B;J^G:1J-]:^*8HIK6>^T^[U/4
M=(TR]R+K[7I.D7.DAH;+4K@/_1K^T9_P2_\ V&OVE?V??%/[.?C3]FGX-Z?X
M*UGPKJ?AWP[-X:^'?A/P]J_@"\NM,73]+\0^!M4TK2;:\\-:WH;V]A<:;?:9
M+!+";*"(EH08R ?>6EZIINMZ;I^LZ-J%EJVD:M96NI:7JFFW4%]IVI:=?0)<
MV5_87ML\MO=V=W;RQSVUS!))#/#(DL3LC*Q_CV_X,W@%_9B_;[   '[<NO@
M#& /A]X3P/H.P[5[%_P:I?&WXPR_ C]L+]A;XS>,-4\?ZI_P3^_::\1?!OP9
MXEU*"2'[)X&-UK&D1>%[,W;/J8TW2O%7A#Q3J>EV>J23W6D:=KMOHT<WV'3[
M.WM_'O\ @S?_ .38OV_/^SYO$'_JOO"= '])7[(O_!0']D_]NJY^,MI^R_\
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MU'QOH<=RLOB'PG8Z#<:WH5M'->ZG:6UC$]R/$OV./^"^W_!+G]NKXN6/P*^
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M/XC^&NN?%SPOHWQ!L_ OBV.:'Q'X:\*>*?&K:MX&T_5H+@":"['@VYT*5X'
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M&-(HD5%51^/G[1G_  0&_P""3?[47Q#UGXK?$[]DCP;;>/\ Q)J%CJ?B;7_
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MLSZQJ7A?4M*CUB6[BMDM;RYU6VO;R:W:0"X25A*OL?[(W_!-G]AG]A*+4O\
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M7Q!\1?#WQ!=60865]>Z!>&!=0L\\&WO[5K>[387C0S-&CNJ!S]0_\$Y/A?\
ML)?%SXV^(?"O_!0+XU>+O@9\*U\"W-_X-\3^$H;M6U3QY%JEH@T?6M4MM+U9
M-'TY=$>^OH9[JV6&\O8(K!)5EF6OU'.<IRO,<+@,TS26.SO+LMP7UB&74:/U
MNAF=2M"C[/'U<!AZ<7C<0J=YTJ5OJ\%5JS5%*]N.G.<'*$.6G.<DG.3Y7!)W
M<5-M\JON]6[6YMC^E_\ 9:_:-E_X+\?L!?MJ_"']L'X2_#'5_P!IW]E_X<7'
MQ"^&?Q_T'3K/P,UYKMWI?C+7/!%R[645S-X+;2[[09?#GB**WN[G0=8\-:A-
M<26!NQ?R+_%#LFB+0W&S[1 \EO<>4P>(W%N[0SF)Q@/$94?RG  =-K  '%?W
MH>,?@U\,?V>?^"4'[3'A_P#X(,:AX(_:(M?&L%_HO[4'Q3L_B1)XS^.UOX<3
M2);77ET;3;'2K**_OK'PIJFM0Z/I9_LRYT/1M7UC5-&2^O(A/'_!:J>6/+(<
M-&3&XEW&570E)%EW_/YJN&$N_P"?S V_YLUY'A_4PU6IQ-/+:4L!D[S6@L!D
MM=NGBLNG'!TUC*E7 RG.674L;7O6P^%M!*$92C&,.6*O$J2]BIOFJ>S?-46L
M9WDN5*=E[1P6DI:[I7'4445^C',%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_0
M=_P:7?\ *8?XS_\ 9E_Q _\ 5D? ZO\ 2RK_ #3?^#2[_E,/\9_^S+_B!_ZL
MCX'5_I95_%_B-_R5V;?]A%7_ -/UCW\'_NU+_!'_ -)04445\.=(4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5_'MHO\ RN4>+O\ LQ2V
M_P#57^&*_L)K^/;1?^5RCQ=_V8I;?^JO\,5Z.7;8_P#[%V)_.F9U/L?]?(_J
M?V$T445YQH%%%% !115.RU"PU*.2;3KZSOX8KB>UEELKF&ZCBNK9S%<6TCP/
M(J7%O*ICGA8B2)P4D56!% %RBH+BZM;-!+=W-O:QLVQ9+B:.!"Y5G"!Y652V
MQ';:#G:K-C"DB<$$ @@@C((Y!!Z$'N#0 4457@O+2Z:5;:ZM[AH2%F6">*9H
MF)=0)1&S&,DHX 8 DHX'*G !8HHHH **** "BJ]O>6EXK-:75O=*A"NUO/%.
MJL1N 8Q,P4D<@$@D<CBK% !15>:[M+>2&*>YMX9;A@L$4TT<<D[%E0+"CLK2
M,7=$ 0,=SJN,L ;% !17XO?#_P#8X_X*/:#_ ,%?_BK^UAXJ_;5OM;_8$\2?
M#VVTKP;^RZUUJLUI8:PWAK2M)AT9_"\BIX:TB3P]XFM=9\86WC:P,FMZK'K+
MZ1<J@GU"62K_ ,%&/^"I'Q$_8N_;5_X)Y?LH>"OA+X7\<:=^VGX\O?"GB#Q=
MX@U'6K>\\(6EGJVF:<7T#3]*:.+4-09+YIV2]9X5 B&SYL, ?M77A^G?LT_L
M_P"D_&W5_P!I/3_@_P##^W^/VNZ$OAC5?C"/#>G2?$&Z\.K'!$NB?\)-+"^I
MP:7Y5M#$;.WGBA:-61D*R2!_<*@N+FVM$$EU<06T98()+B6.%"Y!8*'D95+%
M58A<Y(4G& : )Z*:CI(JNC*Z.JNCHP971@"K*P)#*P(*L"0000<5^/'_  6E
M_P""F7CG_@ES^SO\-/C)X!^%OASXJ:S\0/C?X.^$\FF>*]3U;2]'TJS\2+=2
M3ZF9='*7<UZB6K)9P&1(GDW-(&13@ _8FBN=\(:O=^(/"?A?7;^WCM+[6_#N
MB:O>VL(D$-K=ZEIMM>7-O$)RTPCAFF>.,3$R!5 D);-?D!_P3Y_8Y_X*/? 3
M]LS]N#XO?M8?MJ7WQ\_9W^,'C#4=0_9Z^$EQ<ZK?6_@G2;WQ)=:OH][%INHK
M'IG@2?PSX6DL? L^B^&$:PUY;&/5;EU6UL8E /VAHHJ*">"YB6>VFBN(7W;)
MH)$EB?:Q1MLD;,C;75E;!.&4J<$$4 2T44R66.&-Y9I$BBC4M))*ZQQHHZL[
ML0JJ.Y8@#UH ?138Y$E1)8G22.1%DCDC8.DB. R.CJ2K(RD,K*2&!!!(-.H
M***AEN+> Q">>&$SRK!")94C,TS_ '(8@[+YDKX.V-,NW8&@":BBB@ HHHH
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ME,,CQNL<RJCM"[*0LJI(&C<QL0X5U9&(PP*DBOQF_P""4O['?_!1G]ESQO\
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M*>@_0S]L_P#X+(_M^_MW>&KWX>_&KXN0Z9\*+^>QGNOA=\.-$LO!7A?4/[/
M>&'7Y=+6+4O$UL;S=??9M9N;B!9O)C$9AMH4'Y==.  !V & /8 < >PI9!E.
M:4<RS?/<Y>#I8[-Z> PZP.73JU<+A<-E\*JHNIB*T*4L3BYNO-5*BHPIPA&,
M*=XR=G4G!PITZ?-RT^=\TTE*4IV;=DVHI6VO=MML****^L,0HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /Z#O\ @TN_Y3#_ !G_ .S+_B!_ZLCX'5_I95_FF_\
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M$?1-.^/_ (#\$O<MJ$TFL>$)6UF.7P+?ZG)!</)XB\.1/)=JB:#K>G7$T[R
M'YF?'+_@WC_:"_94L_AO^T#_ ,$=_P!LSX^Z+^TE\.?%?A_4=6\#?M"?&34/
M%7PN^+?A>6[M(M7LM32]C@T:VCAMP]Q=:/J=K=Z=KFARZIIMO>6.I/IL[?JW
M_P %>?\ @HK\0?\ @FO_ ,$U-3_:&N?#VCW/[2WBNW\#?"/X?>'+<0:QX;L_
MC]\0-$O)3<&W::,:UH'AB72/$6M1VD3L-4CTNUM'(ANGD7^?O]M;]C#_ (*L
M_P#!!SX(Z]^V5^Q]_P %-O'_ .T3^SS\'=8TNZ\8?L]?M.V=UXCDM/#7BZZT
MOPG(]M=ZIK^LVWB:TT[5[G3;Q-/TJZ\$7.GPM)=Z9:W=Q;W<6J=-_P '#/QJ
MUO\ :I_X([_\$N_^"@=]X&UG3_"$_P :?V?/CA\6? 6@H-?T_0;3QQX(NM5U
M"UFFNI+6"ZTFUU?3;WP]H>IZO;V]K=2:WIMO?RV%QJ20R@'KO[.'_!M?\0/V
MC_A=IW[0?_!1[]O;]K?Q5^U=\:-#@\=^)K/X=_$F^\->&OAGJWB2RAU#3-$M
M(%DDM]4OM ADLUU2"PLM$T2/4H)K+2[1;.WBNI_M/_@D)X,_X*L_L:?M-_&W
M]@S]K]/'/[3/['_AK27\4_LQ?MJ>(I)+_4+>UA2PCT_X<^)]6OKN34+OS]$2
M2.XL[Q;FXT7Q3IMP;&[NM*U\/:_OQ\&O'?A'XH?"3X9_$;P#JMCKG@KQOX$\
M*^)_"^K:9/;7-C>Z)K&BV=[82P2VDDML0()4C=(G98I4>+@H0/-=$_;#_9C\
M3?M&>(_V2/#OQI\#:[^T=X/\/+XI\5_"72-574/%7AS1&2*7[3K5O:I+!ILR
M0W%K-+975Q%>PPWEG)+;HEU"7 /YJ_@7X]\>7/\ P=P_M2^ ;GQSXTN? =C^
MQU;ZG9>![CQ7K\_@VRU%_"WP=+7UIX6EU%]!MKO=)-(+B"PCE66XN9E82W,[
MR?D-_P %E_\ @DQ\./A1_P %3_\ @GEX T_]H;]I;7[+]M+XU^,-0\5:OXE^
M(NI:QK?PQ?6?&-M<S1_"F_N[EIO#4-N^IRI:002(EM%!;1Q,$B1$_4[X"?\
M*X;^U?\ ]F66O_J+?!NM'_@O=S_P6-_X(3#(R?BUJ_&1GGQ5HH'YG@>IX'-
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M7:Y\+O%5O!XA@TRY2]N+B[>VN(=9\&6]C9WFF/80S:-JU^FIZ:\UNMR/#?\
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M &%?'-A^TQX4U_3FOH_$=EX1\+V=T/'T6B3644QCETVR&F>.7DE6%8'\%0W
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M8[.>*ZMK9;!)KV^:W$3S"437$IK\M?\ @KA_RLT_\$,_^Q6O/_4S^)E?V,T
M%?YW/_!RA_P3)\ _"']KW]B7XF:=\<OV@?$-]^WC^W)XV7Q=H?B?Q]J&L:#\
M)D\7^//AE?79^#EC<S,/")TV7QM>II,=HT<=G;Z;H]M (H-/@1?]$:OXZ/\
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MJ.BZ+XY\-W>G323/J,(_X2#0'FOK7PO;WTV)I7_!MUJ.O:7IVN:)_P %H?\
M@J!JFC:S86FJZ3J5C^T#XENK+4-,U"WCN[&]L[F+Q2T5Q:W5K+%/!/&3'+%(
MLB$JPKU/_@FC_P $@?V2/V-/^"A?Q2^-'AG_ (*%?$G]KC]K[P=\)KCX>_%/
MX??%?XH^$O'/Q/\ !GAWQO\ \(GJ>C:OX_L(]7U;Q[IT;:1I6DQ>'4UY+2T-
MC?V\EJ[0F"-P#^DROXZ/^#HW]H3XW_LX?'O_ ()2>/O@1/XAU7QIIWQRUZ[T
M7X=V'BWQ-X<\.?$/Q';W7AH>&M \66GA^_M$U?29M9DM!<6M]#<02VQN+:4"
MUN;E7_L7K^.7_@YX^('@KX4_M<?\$8/B1\1V@C\!^"?VH)/$7BR6Z>\CMH-$
MT[6?"4]]<7#Z?%->I#;Q*9I&MXGD"1DA<9H ]M3_ (-L==_:&\$:E\4_VT_^
M"A'[8/B#]M+XCZ?%XH\3^-OAW\2;K0?AE\*_'6JP1W=WH/P_\ 6EQ%IUUX3\
M*W9BTS2K>&_TB.ZM]/2:(VXF0IL_\$,_VMOVL_A;^UE^U]_P1L_X* _$]/BU
M\;OV6S:^/O@5\5]7U W?B7XH?!+7);2^MKBZNIV:\U.WMM"\2>"_$NG+?O)J
MV@V/B67PSJ3RRZ("G]15C?66J6-GJ>FWEKJ&G:C:V]]I]_93Q75E?65W"EQ:
MWEI=0.\-S:W,$D<UO/"[Q31.DD;LC G^.C]FSQ%X<_:$_P"#O']K3X@_#'4V
M\2^#?V?_ -DI_A?XY\1Z=''<Z/9_$?1M+^''A#6O"S70E!BN-,U[_A(]'N'V
M,3JWA;5K=$:$)<, ?-O[==E^V;\=_P#@Y@^)_P"QW^S!^TAXL^ MK\:_V4/
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M$23XH:%JL-M::W!#XDTS0="TJ>ZMS<2:C*UOJO@?Q)87S7"&*SOHS;K/(\K
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#VI^$=$C-U+/#86A5Q-^I'_!)_\ X(V_"_\ X)E)\4?B9K/Q3\=?M.?M;_M
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M<>*["&?^S]0L[R1+6+4O^$<\/^&M8UVWT^&RUK7;W1KB?1Z_JNHH \8^//P
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MFN^(+CXUS7]ZTNH2&XN'\R,SR !P8PJ+_;710!_)9;?\$/\ _@MW#<VTTO\
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MZ/\ Q&7BK_J%_P#!&&_^9OZN_*T_V?0_O?\ @4_+^_Y/[_(_Q<?^%"_MJ?\
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M]_D?XN/_  H7]M3_ *,1_:Z_\,%\7O\ Y@:/^%"_MJ?]&(_M=?\ A@OB]_\
M,#7^T=11_P 1EXJ_ZA?_  1AO_F;^KORL?V?0_O?^!3\O[_D_O\ (_Q<?^%"
M_MJ?]&(_M=?^&"^+W_S T?\ "A?VU/\ HQ']KK_PP7Q>_P#F!K_:.HH_XC+Q
M5_U"_P#@C#?_ #-_5WY6/[/H?WO_  *?E_?\G]_D?XN/_"A?VU/^C$?VNO\
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M4_Z,1_:Z_P##!?%[_P"8&C_A0O[:G_1B/[77_A@OB]_\P-?[1U%'_$9>*O\
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M@OB]_P#,#7^T=11_Q&7BK_J%_P#!&&_^9OZN_*Q_9]#^]_X%/R_O^3^_R/\
M%Q_X4+^VI_T8C^UU_P"&"^+W_P P-'_"A?VU/^C$?VNO_#!?%[_Y@:_VCJ*/
M^(R\5?\ 4+_X(PW_ ,S?U=^5C^SZ'][_ ,"GY?W_ "?W^1_BX_\ "A?VU/\
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MU_JVHSI:Z?IEE=:C?W4F?+MK.R@DN;J>3 )V0P122-@$[5. :_D1^-/[?O\
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M>_:RT;P7J'P]TWXMZ/>ZO;>$=4U&VU:^TA+/5+S3#%/?VD<4%P9&M&E5HXU
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M>E2Z(=5\5V<TNO6FEZ^^F:]IOB2Q"7NGQZ)J7A>QO)A<5_470 4444 %%%%
M!1110!_'O_P<N?\ )_O_  ;X?]GM3?\ JWOV5Z_L(K^/?_@Y<_Y/]_X-\/\
ML]J;_P!6]^RO7]A%>MC?^1;D_P#U[QO_ *E,B/QU/6/_ *2@HHHKR2PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX&UG_E*+\-_^S!OC
M7_ZT/\ :^^:^!M9_Y2B_#?\ [,&^-?\ ZT/\ :]/*_XF,_[%F8?^HTR)[1_Q
MP_-'WS1117F%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?Q[:+_RN4>+O^S%+;_U5_ABO[":_CVT7_E<H\7?]F*6W_JK_  Q7HY=MC_\
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M;KGC+X676D^!? &C3:]XEO[/3/&-E=ZG>6VF6Y$TUOIUHCW5VT8=XX$9E1R
MI]3U;_@GUH_[:'_!&#X:_L)?'[1]6^'^N>)?V4/A)X4NQK.FL/$/PK^+'@_P
M=H%YX:UR\TDSPL^I^"/&NE65W?Z2US$M['9W>F32B&YD- 'W)^P[X1\)> OV
M,_V4_!_@2#2K?P?H'[/'P>L?#PT1+"/2[C3E\ Z#)%?VG]E_\2^5-3:1M1>X
MLRT%U+=27*.XEWM_,W_P<A:/I?@G_@H'_P $0/CAX):PTSXVG]IP> _[6T^T
M,_BF;P-;^)O!U]!!($#F;1[6\\0^(4B1XCY4^I7KJ^TR!>"_92_;G_X+%?\
M!(7X3:9^Q+^U9_P3-^+_ .V!X,^"&DCP)^SW^T%^SBL^KZ1XC\$:3J$GA_P3
MH?B*ZAT_4;+[#IUC#IL6D"1=.\466B7NF:;JNDI)91S2^O?LA?L@_P#!1/\
MX*;_ /!3+X9?\%.O^"EWP)B_97^!G[,>AWEK^RQ^RKKNK37/C.V\9EI8(/%G
MB32)8H]0LQ%?>;XHU*X\16UC)J5_-HVGZ/9)IVC3.X!R'_!<S_E/E_P;W?\
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M!;ZU/J.F+>.[)JT'B'7=?:SDLTCO8GLVEA4H)93[7^W7^RI^TGX]_P"#E_\
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MR]E,JS:9XCU?XD:)X7U>6V,:E'>Z\%ZUXGM)(YRL1AE>0$SQ0@_G9X,^'O\
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M/XSTR71O$FA7A\0ZM/'!J>FS_OK666WEBG2.4+)Y4J%T5B5 !^-7[,L42?\
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M@\R4()&_ES_:]_X*>?\ !3S_ (*>_LX?$#]B+]EW_@CG\?\ X:>+/V@-*O\
MX3?$7XF_M$Z?;6GPU\ :#?"V3Q9=0WVJZ;I>AZ?J7E";3-,UOQ)?VD6@75]9
MZY9)<:O8V=N_]$?_  36_85O?V)/^"</P3_8L\1^*(M;\2^$_A9J>@^.O$>E
M*9].7QGXX74]6\9-X>%S%!)<:-IFNZ[J%OHCW<44UU8VMM+<QQO*Z* ?B_\
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MNZ'?:7KD&IQL55["73+JY2[4LN8#)\R]1_+E_P %*OV _P!N?]C[_@HU8_\
M!9?_ ()5?#O2OC;XO\;>#F\"_M<?LN2F2#4_B9HUG86@N=?\/B*=;S4I/$.G
M>&/"EA/IVB1/K>D^*O#FA:_8:=K*7VIPV_EW[0/_  51_P""R7[>_P +O%?[
M*7[&G_!)/X^_LY?$;XH>'6^'WC[X[?':Z/AKPM\*(O$5@#KUYH^K:EI>FZ+;
M2ZAHCWFG:;J&LW#7EE'?F^M-.N+^"!4 .9_X-G]3U2+_ ()/_P#!23P-'>O<
M^!_A_P#%[]IK1_ %O% \>F6FD77PXOKF[_LJ5US/;7-RBSD^9(8R0C$-D5]#
M?\&<EG:0_P#!(_5[R&V@BN[W]J[XQ+>7,<2+/=+:^&_ALEL)Y0 \H@21UA#D
MB-78+C<<_IM^PO\ \$YX/^">/_!*G4OV1/#1C\;_ !.D^#GQ4U/XAZWH,5S.
MWQ!^,_COPIK$FN3Z-%>!;V2UN-4GM=%T"VN")?LEM:A@LDKU\@?\&M'[-?Q_
M_93_ ."8M]\+/VDO@_X]^"/Q%/[2GQ7\2Q^#?B-H%UX;\02^'M7T'X?0Z9K4
M>G7@6X_LZ^GL+^WMKAT02RV5R%!5 S 'P]_P<X?)_P % /\ @WHD0!)3^VU/
M&944+*8S\:/V21Y;2J!(8P'?$98H/,D(4&1]W]D%?RO_ /!P;^RE^TK^T1^V
MO_P0^\;? OX'?$CXK^#_ (%_M:W'C+XQ^)O _AR[US1_AIX8'Q9_9BU9-:\8
M7=ME='T^72_#/B/4$N[A1;BUT+4Y9)$%OAOZH* /Y]_^#H/QMXU\#_\ !%_]
MJ6X\$%EG\277PU\$^)67J/!7BOQ]H>E^* ?WD?RR:=*T3<O\LA_=OTK]#/\
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M(=0\.74U];7K:<EQ<7L6A:OI%]<W]E:7E[H>KZ9);2Z?>)\9?\%8G_X+&?\
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M[5M7TG0=.NM7UW5-.T72;)%DO-4U:]MM.TZT1Y$A1[J]O)8;:W1Y9(XE:65
MTCH@)9E! -&BJ>G:CI^KV-IJFDW]GJFFW\$=U8ZCIUU!>V-Y;2J&BN+2[MGE
MM[B"12&CEAD>-U(*L1S5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCT?\(KX8_P"A<T'_ ,$^G_\ R/7![3)_^@3,O_#CA?\ YV#M5_FI_P#@$O\
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M)]/_ /D>C_A%?#'_ $+F@_\ @GT__P"1Z/:9/_T"9E_X<<+_ /.P+5?YJ?\
MX!+_ .6>O]/3Y,_X>._\$_\ _H];]EK_ ,/I\-O_ )HJ/^'CO_!/_P#Z/6_9
M:_\ #Z?#;_YHJ^L_^$5\,?\ 0N:#_P""?3__ )'H_P"$5\,?]"YH/_@GT_\
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M_P#Y'H]ID_\ T"9E_P"''"__ #L"U7^:G_X!+_Y9Z_T]/DS_ (>._P#!/_\
MZ/6_9:_\/I\-O_FBH_X>._\ !/\ _P"CUOV6O_#Z?#;_ .:*OK/_ (17PQ_T
M+F@_^"?3_P#Y'H_X17PQ_P!"YH/_ ()]/_\ D>CVF3_] F9?^''"_P#SL"U7
M^:G_ . 2_P#EGK_3T^3/^'CO_!/_ /Z/6_9:_P##Z?#;_P":*C_AX[_P3_\
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M%%%?/FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTGQWXHUGP3>V[IX(L/"/@WQ*MMJ]YK&GR7":=/::2-3M=4AM;V2XN+9+VSO
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M!I=QJ>D^&?$?V1;^S:2[_.3_ (*_6-W_ ,%1O^"T'['O_!'/6_&NJZ)^S/\
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M_P!(L!MGDEE^73["U3)D*MMW1A(RJ+^IU '\1/\ P3Y_X) :E_P6LT'XD_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K^/;1?^5RCQ=_V8I;?^JO\,5_837\>VB_\KE'B
M[_LQ2V_]5?X8KT<NVQ__ &+L3^=,SJ?8_P"OD?U/[":***\XT"BBB@ HHHH
M**** "BBB@ HHHH *Y7QWX;7QEX(\9>$&:-%\5>%?$/AMGE,@B1=<TB\TPM*
M8B)1&HNB7,9$@4'80V*ZJB@#^+C_ (-H/VF/A[^PIJW[87_!(;]JSQ+X2^!/
MQQ^#W[2GC/QW\.+#Q]JB>$[?XG>&O$UGHNAWD_AS6O$-[;Z5J,BV/AOPMKOA
M[3([A-7U;0O$7V^WBO1:7HL_H;_@ZO\ V^/@WX&_X)T_$_\ 9"\(^)[+X@?&
M_P"/UOX/O=5\%^![B+Q)>^ /A!X4\>^&?$.M_$[Q^^DV^J0^%?"TGB73?"_A
M72;C6)M(;6=9U^WATZXFCMKN-OUJ_P""A?\ P1A_8(_X*9W^A^*?VD?A;=#X
MG^%]/.E^'_BY\/==OO WQ#MM/0R/::=JFM:.T:^)-+TZ::>?3M.\00:C;V,L
MTKV@@9@1XG\(_P#@W>_X)>_"#X%?&CX#Z;\(/%'B;3/VA?#.@^#OB[\0/%OQ
M&\7:I\5O$?ACP]XG\.^,K/P[I?CQ-1M]8\(^'I_$OA70]4U#0_"LFDZ=J,MC
M&+^&Y!;(!\16O[,7C/\ :^_X-1_A!\$/AOI*:[\1-9_8'^%'B'P1HS/<))JO
MB#P;IFD^)HM.M1;9EEU"_L]-O;/3K?RIQ<W\]O;B!VD7'T)_P;R_\%(_@%^T
MQ_P3Z^"7P?U/XA>"O!W[1W[-W@U/A3\7O@[KVIV_A/Q=HTG@BYN-*T_Q%9>&
M_$-\FJWV@WFD1:?_ &AJ=I]I@TW6Q?:?J0TZX$-J?V]_9_\ @5\./V8_@I\,
M/V?/A!I5YH?PO^#W@W1? 7@31]0U;4=>O=-\-:!:K9Z9:76LZO<76IZE-# B
MJ]W?7,UQ,1NDD8\U^3?[7_\ P;P?\$POVR_B9KWQI\;?"'Q!\.?BYXJFOKOQ
M1XY^"GC?7?AM=^)]2U$QM=ZMXCTK1IQH>KZG/)%%)->SZ>MQ.R?OI) [A@#\
M@/\ @X _: \!_P#!2']JW_@G9_P2-_93\:>'OBQ\0K_]ISPK\=_C9K?@35M)
M\2^&_AKX8\':5KU@1JOB?2)]2L+77M)\):GXY\1:IHVXRV$%MHT>HK'<ZI80
MM^ZW[?\ _P %'?V*/V.O'W[-G['W[9GA#5M9\%_MA&Z\#6WBGQMX T7Q%^SG
M8:=I3VFF7-G\5]9\22R:.?M6IW&BPMHL>BZR+2'4K76=8_LO2D%Z?2?V$/\
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MR:;XD\/6NHW-O>:Q>3:K9Q/<ZE:BRC_<#]NO]F[_ (-MO^">7P;U'XR?'?\
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MAH=K#X1U:ZCC@MK?5/!VB:.^I:+H0M_#Y.EV&O:?I.EQZT'OOO;Q'_P:B_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %? VL_\I1?AO\ ]F#?&O\
M]:'^ -??-? VL_\ *47X;_\ 9@WQK_\ 6A_@#7IY7_$QG_8LS#_U&F1/:/\
MCA^:/OFBBBO,+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFU/084L?[2TO2[E;/4YVF"6]J ?K91110 4444 %%%% !1110 4444 %%%%
M!1110!_'O_P<N?\ )_O_  ;X?]GM3?\ JWOV5Z_L(K^/?_@Y<_Y/]_X-\/\
ML]J;_P!6]^RO7]A%>MC?^1;D_P#U[QO_ *E,B/QU/6/_ *2@HHHKR2PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX&UG_E*+\-_^S!OC
M7_ZT/\ :^^:^!M9_Y2B_#?\ [,&^-?\ ZT/\ :]/*_XF,_[%F8?^HTR)[1_Q
MP_-'WS1117F%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^*I4K0G7E3ARP3<$N:\FV_M#_B*P_P""D_\ TB4T3_PO_B'_ /,=1_Q%8?\
M!2?_ *1*:)_X7_Q#_P#F.KXOR?4_F:,GU/YFOT+_ (E!X _Z''$'_@6 _P#F
M7^KORM^;?\3C<:?]$KPQ_P"!YMY?]1WE^+[GVA_Q%8?\%)_^D2FB?^%_\0__
M )CJ/^(K#_@I/_TB4T3_ ,+_ .(?_P QU?%^3ZG\S1D^I_,T?\2@\ ?]#CB#
M_P "P'_S+_5WY6/^)QN-/^B5X8_\#S;R_P"H[R_%]S[0_P"(K#_@I/\ ](E-
M$_\ "_\ B'_\QU'_ !%8?\%)_P#I$IHG_A?_ !#_ /F.KXOR?4_F:,GU/YFC
M_B4'@#_H<<0?^!8#_P"9?ZN_*Q_Q.-QI_P!$KPQ_X'FWE_U'>7XON?:'_$5A
M_P %)_\ I$IHG_A?_$/_ .8ZC_B*P_X*3_\ 2)31/_"_^(?_ ,QU?%^3ZG\S
M1D^I_,T?\2@\ ?\ 0XX@_P# L!_\R_U=^5C_ (G&XT_Z)7AC_P #S;R_ZCO+
M\7W/M#_B*P_X*3_](E-$_P#"_P#B'_\ ,=1_Q%8?\%)_^D2FB?\ A?\ Q#_^
M8ZOB_)]3^9HR?4_F:/\ B4'@#_H<<0?^!8#_ .9?ZN_*Q_Q.-QI_T2O#'_@>
M;>7_ %'>7XON?:'_ !%8?\%)_P#I$IHG_A?_ !#_ /F.H_XBL/\ @I/_ -(E
M-$_\+_XA_P#S'5\7Y/J?S-&3ZG\S1_Q*#P!_T..(/_ L!_\ ,O\ 5WY6/^)Q
MN-/^B5X8_P# \V\O^H[R_%]S[0_XBL/^"D__ $B4T3_PO_B'_P#,=1_Q%8?\
M%)_^D2FB?^%_\0__ )CJ^+\GU/YFC)]3^9H_XE!X _Z''$'_ (%@/_F7^KOR
ML?\ $XW&G_1*\,?^!YMY?]1WE^+[GVA_Q%8?\%)_^D2FB?\ A?\ Q#_^8ZC_
M (BL/^"D_P#TB4T3_P +_P"(?_S'5\7Y/J?S-&3ZG\S1_P 2@\ ?]#CB#_P+
M ?\ S+_5WY6/^)QN-/\ HE>&/_ \V\O^H[R_%]S[0_XBL/\ @I/_ -(E-$_\
M+_XA_P#S'4?\16'_  4G_P"D2FB?^%_\0_\ YCJ^+\GU/YFC)]3^9H_XE!X
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ML/\ @I/_ -(E-$_\+_XA_P#S'5\7Y/J?S-&3ZG\S1_Q*#P!_T..(/_ L!_\
M,O\ 5WY6/^)QN-/^B5X8_P# \V\O^H[R_%]S[0_XBL/^"D__ $B4T3_PO_B'
M_P#,=1_Q%8?\%)_^D2FB?^%_\0__ )CJ^+\GU/YFC)]3^9H_XE!X _Z''$'_
M (%@/_F7^KORL?\ $XW&G_1*\,?^!YMY?]1WE^+[GVA_Q%8?\%)_^D2FB?\
MA?\ Q#_^8ZC_ (BL/^"D_P#TB4T3_P +_P"(?_S'5\7Y/J?S-&3ZG\S1_P 2
M@\ ?]#CB#_P+ ?\ S+_5WY6/^)QN-/\ HE>&/_ \V\O^H[R_%]S[0_XBL/\
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MKPQ_X'FWE_U'>7XON?:'_$5A_P %)_\ I$IHG_A?_$/_ .8ZC_B*P_X*3_\
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M%]S[0_XBL/\ @I/_ -(E-$_\+_XA_P#S'4?\16'_  4G_P"D2FB?^%_\0_\
MYCJ^+\GU/YFC)]3^9H_XE!X _P"AQQ!_X%@/_F7^KORL?\3C<:?]$KPQ_P"!
MYMY?]1WE^+[GVA_Q%8?\%)_^D2FB?^%_\0__ )CJ/^(K#_@I/_TB4T3_ ,+_
M .(?_P QU?%^3ZG\S1D^I_,T?\2@\ ?]#CB#_P "P'_S+_5WY6/^)QN-/^B5
MX8_\#S;R_P"H[R_%]S[0_P"(K#_@I/\ ](E-$_\ "_\ B'_\QU'_ !%8?\%)
M_P#I$IHG_A?_ !#_ /F.KXOR?4_F:,GU/YFC_B4'@#_H<<0?^!8#_P"9?ZN_
M*Q_Q.-QI_P!$KPQ_X'FWE_U'>7XON?:'_$5A_P %)_\ I$IHG_A?_$/_ .8Z
MC_B*P_X*3_\ 2)31/_"_^(?_ ,QU?%^3ZG\S1D^I_,T?\2@\ ?\ 0XX@_P#
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M'5\7Y/J?S-&3ZG\S1_Q*#P!_T..(/_ L!_\ ,O\ 5WY6/^)QN-/^B5X8_P#
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M $;Q/\/M%T_1;S1-:\/Z9;V]IJ6G^-GU,W7VDS(+:T6.*1+F1HOZFZ_SV/\
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M ^*_$'[6/QFL9]3-MH;^#M$8QQ6M[IL@6.^N=/B\+C45DW2,T&IBT@VR234
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MF3< >#?LW_\ !(W_ (*S?\%!/A;IG[6'[<W_  5I_:I_9]\>?&ZRM/B7X+^
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M$=C?WEU81V.H^4EJK:/J\@D8V%QY(!O?\'*'[87[7?[)W[0/_!+RZ_9.\?\
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M* /:?^#>#_E8'_:E_P"S,O$'_J0_L[5_H3U_GL?\&\'_ "L#_M2_]F9>(/\
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MAJ,<NEMKVG:3JK1)#=QQNUWIUJ[2HY6)4*U^A-% 'X7_  G_ ."6GQF\ ?\
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M2QBU?1M$$^I>')=8URTT+2M)T.VTW3+F7_A(;C7?$>L7+74'U'_P70_X)?\
MQC_X*E_ [X$?"[X-?$+X:?#O6/A5\?-"^+.M:A\3O^$I&F:CHNDZ5?V4FG:6
M?"NB:Y=?VH]Q=12HMW;P6CPI(C7,3LKK^X-% 'X,?\%V/^"4?QJ_X*H_LA_
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MU_H%HH _D5^)W_!-[_@XZ_;B\(:I^SW^UO\ \% _V8O@Y^SGXJ2R\(?%>X^
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M<>'+6+_A'O&WAFYE3Y;S2=1B\UK2ZC-KJFG2W>F7L?DW3E/Y_?AE_P $\O\
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MU_1O!FAV&G0>((EE@MY((M6GDN9X8&1ML(CD6:6.1&K'_P""Y.N6?AG]I/\
M98\2:CH=IXGL- \.ZIK%WX;ORPLO$$&G^+-(N7T>[*J[>1J'EBVDVH[$/@(Q
M.T_OV02SN'C]X4SS^GB*_$,/!?!SS2EB)4X8RKF:R3B"5>EB)R<80Q52O>%>
M55KEK.;K--39^!Y]'(Y^ OBM3R*IAZ'#T_&;%PRRKAXSG@Z.6RSGAU4*F'A!
M2E/"TZ+4Z,:2DI45!4DTXH_.?X$_\$P?VQ?V@?#=AXU\*?#NV\.^#=7L%U'1
MO$/CG6++PXFL6\K 6LNG:5=R+JUS;7<8>>WOEM/L;0JK&4>=$&YWX^?\$Y?V
MO/V;O#6I>-_B1\,1)X&TJZ,%YXL\)Z[I'BJQM+;>L<>J:G::1<W.HZ+ILKNJ
MK<ZI;6RH[!)-K&OW0\2_'+_@JM^TW\.O#>D_ S]FK_AEFUN;JTU%O'NM^*?#
M44MWX=AMX8K7P]:^&O$.F_V[H,;_ &B.[DNX=(CD-M9?8H7A F@G_3'X >#?
MCJ_[-">"OVPM6\*^._B5J&D>+-(\7WGAP#^R]6\.W_VVWTVVOI+>PTF&356T
M:5(M4N+&SMX1=%FMY)&07#K/?I">(?"U>AFV<S\+:^"JYXLOQ/ V2YW/.>*L
M!EZE4E+%5<RRS'XK+(5>2DZ4ZE2<O9UJE'VF6T?:.-,R+Z/WA]Q1AZ^59-3\
M4*&,I9*\PPW'&<Y+#)^%L=F#C22PE++LRP.%S.=+FJQJPIPC%SHPK.GF-7V<
M95/X-?#OA[7O%VOZ-X5\*Z+J?B/Q-XBU"WTK0M T6RGU'5M7U&[<1V]G865L
MCS7$\C$85%( RS%5!(_3S0_^",G[=NL^'VUNX\$^#]"NWMVN;/PYJWCO0$UB
M[1K6.YMXY#!=2V>FW-PTAM7MM1G@FL[F-Q>+$HS7Z*?\$/?V>/"5AK_[0WQP
MNM"M)=1\-_$#6_A/\,[RX62[F\/>']-OM1CUY;*:[A=H;Z=(M/TV6^M[J2[G
MTX36]X^VX=7^;_VQ_P#@KA^T]X9_:F\<^&?@MXNT+P[\,_A1X[G\,6N@2^%-
M,U >+Y_"\\.G>)8/%=[J]M<:H8+K6K36+*,:)<Z1Y5@T$EO)]JBCO3^DYYXF
M>(G$OB%G/ /A3@.&:7^JV6X?'Y[G?%:QM3#U<3B:>&JTLOPM/ 3:H3OB8X=\
M\*TZE:EBY>TPU+#<]3\XR/PT\/>&O#_*.//%7'<2U?\ 6C,:^!R/)>%7@85Z
M6&P]3$4JN88J>/C%UHVP\L0E"=&%.C4PL'3Q-7$.%/\ (?XW? +XO?LX^,_^
M$ ^-'@K4/!7B>2PAU2TM[F2"]T[5=.G)07NC:S8O-INK6T4RO;7$ME<2BWNH
MY()=KKBNP_9W_9&_:%_:JU#5;'X'_#R]\56V@O%%KOB"[O;+0/"VDSS .EE=
M>(M8FM=,_M-X"US%I<<[WTT,;M%"Q !_5?\ ;Y_X*&?LJ?MS? K2/AMX<\"_
M%32_CE9Z_P"';WX>:UK/A;PY:Z'I?B34;BVTS5='NM<@\0:OJ_\ PCFJ+<^7
M=1V.F+=WKV>GN4C,;1G]NHO@[\4/V?\ ]C'PU\)/V-?#O@S3OB;IWAK0K#3+
MSQ9+%9:/:ZSJ\<%QXO\ &>KRM9R-J^N_:)KN]MUU"TN#>W0MX+W]S'@>5Q+X
MZ<8<,<&\,?V[PG@.&?$'B3.,3DRH<15JN%X:P-' ?4Y8GB*M..(>*_LRI''8
M>%.@\5S4JJQ<I8FM#"TX8KU.&_ WA#B;C'B;^P^*L?Q+X?\ #F3X7./;\/4:
M6*XDQM?'?6UAN':4)8=87^TX2P6(G4KK"\M6G+"1CAJ,\3.>%_F2^)W_  2(
M_;@^&6@7/B8_#S2?'6F:?:W-WJ4/@/Q'INM:U:16^UOW'A_S8]6U1Y(R\@73
M;:Y,21.9MF4W<=_P2R5T_P""@/[.2.CQ21^)/&$<D<B-'+%(GPX\9I)%+&X5
MXY$8,DD;@,K JP!!%?TF_L2>%/\ @I1X)\>^(;3]L'QCX)^(?PZUK1))-(O]
M)N](?7_#OB:VN?.B\I-*T30XWT;4;:6ZAN(I4NI(+E;$6P@MHG4_ 'CSX.^$
M_A%_P7*^!$_A"T;3[/XI6NN_$W5M/4PBSMO$6J^"?B)IFLS6$,4$/V>+4;S3
M9-2GBD:X8WEU/(DJ1NL,?SF \9<XXDP'B;P!Q-C>$,^Q<?#7BO-LIXEX(JXJ
MIE.,A2R'&2Q>!Q,,7+GCB:,*C<9PIX=1]A.$J555:5=_1X[P;R?AW,/#/CWA
MK!<6Y#A)>)/"F4YMPWQM2PM/-L).KGN"6$QN&GA(\D\-6E3M*,JF(<O;PG"K
M3]E5HQ]+_P""PG[-OQH_:@^+'[._@/X*>#;CQ9K=EX=\7:IK$[W5KI>B>']+
M>^MK=;_7-:U"2#3]/CGE#Q6<4TRSW\T3V]I'+, E?C9\?O\ @E]^U]^SMX-N
M?B#XL\#V/B7P=I<,]SX@U?P+JMOXBD\-VD WO?ZQIEL3J4&EI"KS7&J);O96
M:J%N98WDC#?OO_P5T_;4^)/[*'A+X<:+\%;W3?#_ ,1OB3>:M'=>,+K1M-UB
M]T'PSH<<<P73[75[*]TVXFOM0G:+9>0S1VRJ\RP.SY'9_P#!*S]LSQQ^VA\'
M_B'8_&&TTF_\:?#?7-/\-:WJ^GZ=!IVG^*]#\2Z3<7-A<7>EQ.UNE^([6]M]
M6-K!::?,985M[2+$@;XO@GC_ ,6/#_P>X6XMP&2\+8KP\RC$UL%B\+BJN-_U
MBQU+%YYBJ-;'^TA*GAL'AI9AB7@<&Z4:]:%2$*^)PU?#U$U]GQIP#X4<?^+_
M !1PGC\YXHPOB%FV&HXW"XK#4L%_J[@:F$R/"U:6 5.49XG&8E8##K&XQ5)4
M*4Z<YT,-B:&(IN_\:ME9WFI7=II^FVESJ-_?W$-I8V-C!)=7E[=7#B."VM;>
M!7EGFF=E6..-69B1@5^FWP]_X(^?MS^/M%LM?G^'NA>!M/U/3K+4].@\:^*]
M(T[6WBO06^S:CX>BGEUC0[^VCV/<V>KVMK-&7$>TR*P'Z2?\$Z/V1/!7A#_@
MHE^U]>W5G97]I^SUX@-I\/+".S7^S=#;XEW>HZKI$T"3)(8[_P />&[>?1;6
M59$.9I[B- 50IPG_  4Y_P""F'[2?PC_ &I=1^$/P+\66_@'PW\,M,T%M6N!
MHFAZ[-XQUS6].M]7N_[2CUS3+S[+I^G1SKID-M9NAG\N2]$\<DB"/]HSKQ9X
MTXIXVPW ?A-@^'88F'"^ XJS3/>*UC987#X3,\%@,PP>'P^&P3YU4=#,\NA*
MI*EBY3J8N<?84(86IB'^,9-X3\&<+\%8GCOQ7QG$,\-/B?'<+97D?"KP4<5B
M,7EN,QV QF(Q&(QEX.G&MEF8SA3C5PBA3PD).O7GBJ>'7XO?M"?LI_'K]EK6
MM/T3XV^ [KPH^LF[_L/58+RSUG0-96S=5E^P:UIDMQ823!'24VC3+<I&V7B4
MJX7YXK^U>XM]'_X**?\ !-ZR\2?$3P]IMCXC\<_"S4/$MO+;6T,A\,>/-"M;
MQHM8\.3W(F>TW7U@?+?*%K6ZEMY%$9X_BDA?S8HY,8WHKX]-R@X[^M?9^#OB
M5F/'^!XAP/$&787*^*^#<YGDG$&'R^<YY=4K>TQ-.CB<'[6I7J0A4G@\71G2
ME7KVGAW5C5]G6A"'QOC!X;9?P#CN'L=P_F.)S/A7C')Z>=Y!7Q\80S&G1=/#
M5*V&QBI4Z-.<X0QF%K0JQH4/<Q"I3IJI1G.<E%%%?L9^.A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%!_^"^W_  17_:._9W\17.L>$-8\)>-O#NOZ'K-HVD^+_ 'CC0;C7O\ A(O
MWC30IF-QI/B#1_MEG+)&^ZWO+.[M+ZRFFMIU>@#^[^BO OVGOVG_ ('?L;_!
M#QS^T3^T7X\TWX=?"?X>Z<M_X@\0ZBD]S+)-/(MMIFBZ-I=E'/J.N>(=;OI(
M=.T31--M[B_U*_GBM[>)BQ9?YL[/_@ZBT?Q5X:O?BM\,_P#@EC^WQ\0OV?\
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M !1110 5\#:S_P I1?AO_P!F#?&O_P!:'^ -??-? VL_\I1?AO\ ]F#?&O\
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MC:GIVKS3>%_#FA>'+&X@T?3EU3419VTBZ78O?76H:I':V$%RURBO"&MO-?\
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M7:B,WEOC:0#J/^#4S_E"%^RY_P!CA^T9_P"M"_$JOA7_ (+0_P#*Q7_P0/\
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M5\5>'-8MH[W2=?\ #GB#3KC2=;T75+.4&*ZT_5-,N[FQO;>0%)[:>2-@58T
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M\DK_ %+12QSQQS0R)-#,B2Q2Q.LD<L<BAXY(Y$)5T=2&1U)5E(()!!K\0_\
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M/M-@ ?NE_P &[?\ RAK_ &&O^R6/_P"I!K%?M77XI_\ !NTRM_P1K_8:*L&
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MWXM^,OA[87]W*1O(L_"?@KP[I=O#N,<,=FS1JK329^$/^"P.@:+X._X.._\
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MZUO0=2\16\7VJ[AL;&Y /Z+O"7@;P=X#\&:#\._!OAC0_#7@7PQH-GX7\/\
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MMS/>^+?AN;73;<WT^A0+.-9T_2#9ZA8W[BQOY](M?$$NI+:FUBO9$ ,WP/\
M\'+G[)-CX3T3X6_L ?\ !.+]O?\ :)^&W@:PM/!/@%O@7^SQ#I_POAT_1[:&
MRLM%T,0:M>ZY +1I+*"XMKKPQ!=DWB7,AN+B8B7Y7_X-=/B1XD\?_P#!0?\
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M !1110 5\#:S_P I1?AO_P!F#?&O_P!:'^ -??-? VL_\I1?AO\ ]F#?&O\
M]:'^ ->GE?\ $QG_ &+,P_\ 4:9$]H_XX?FC[YHHHKS"PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HK'T3Q%X?\ $UK/?>&]=T?Q!96M
M_?:5<WFB:G9:K:V^J:9</::EIL]Q83W$,5_I]U&]M?6<CK<6EPCPW$<<BE1L
M4VG%N,DXR3LTTTT^S3U3]0/\OGXE_P#*:W_@L#_V7+Q%_P"II+7NU>$_$O\
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MG3G[.$ES<U6-E?\ )ZBBBOI#YP***:SHF-S*N<XW,!G'7&2,XR,_6@!U%%%
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M@#ZDT +12*RL,JP8>JD$?F*6@ HII95QN95R<#) R?09ZGZ4Z@ HHHH *.<
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MS":P^$K9AF-.MB,16Q6.J2C0P& RK!T88C'8F?M90^M86,:+C4E4I_DR&4G
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MC.&/_5)@0HHHK\M/O0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#/"WCOPS>AA=:!XOT'2_$>D3EXI("[Z?JUK=VOFB*:6-9A$)461PCKN-=<2
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MN+$J\TLB_9I(PLKF50),,/0:* &HB1HL<:JB(JHB(H5$10%5550 JJ  J@
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MX(_^7E<7_P ,4_L;?]&E?LR_^&&^%G_S*4?\,4_L;?\ 1I7[,O\ X8;X6?\
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M@C_@ZC^!/Q/.B> /VZ/!O_#/OC28VUA_PMKPQ]L\0?!S5+AFBA%[KT1C?7_
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M>+O&/Q#^((LF?5RTUWII-K>7]O<N3)J-C?W<6CZ:D=CHEI<10'S&D5S\I_\
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MM83QZI:Q1S##>*?L)Z)^P/H'A'XB?&']L'Q/I_BOQ/X4:XB\!? "1-26?Q1
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M'V+5M22WNH=#EO-3BNF16>(WZ:%I,,=MX>MWCMYI)+B[KR?XW_#/]C7]K_\
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M0R6A4]MF=3"UXXCDPE"I'$?CU=6*_M@_M.^'?"?PA^%O@CX*V/Q,\6:/X/\
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MQ.[-=Z=!J%_ISO&FI7FNWMM=SZ:]^[:5I>D6EMJKQO-=[1^,(&(V"X&-X '
M&&;''H*_=O\ ;TTW7]3_ ."7'_!.[7_#D2MX%T'1-$T_QM);SV;10:]J'@^Q
MLM#\^(%[EYIM9L=<+F!E%O*66^5&9%7]!XIX=I<+T^#N#,GSS/\  T/$/C2E
MA>*>(,1G^8U<ZQM/!Y)C,?BJ.$S#$8BK/*\9G]7 8?!?\)JPT5[1T*%."J12
M_/N%^(JO$\^+^,LWR3(<=6\/N#*F*X6R##Y#EU')L%4QF=8' 8:OB\!A\/2A
MF>$R&ECZ^,7]I/$R?LE7Q%2;A)RTOA]^U-_P3K_:T\>>&_@7\3?V*]%^$$'C
MZ:3P-X.^)_AN\T*SU#P;<ZCY:Z%'/J6F0V=WI,MS<Q1VTFLQM-96<NP7"/;S
M,1\'_%;]DNY_9H_;L\%?L_\ C==+\6>%-4^)?@6^T1I2T]MXG^&?BKQ1]FTR
M'6[5BLD5ZUI!=Z/K5N7VS7=G<W%NXM[B(+\5>"]/U#5_&O@K2M)LY]0U34/&
M7A6UTZQMH7N;BZO'UZP,$45O&#),VY=Y2,%MB,P^Z2/WW_X*C:GILW_!1?\
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M,EM8=1BGM);H/86EGIVG7-M<:EJ]S;2S:AJ5Q'I-FB.A>NI_X+!3Z=;> /\
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M6[&">UM[7Q#'I5PDMW;O/#:B]>PN;]=0(6")I!<M*:[;_@G]I3ZE_P $T/\
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MX?\ C0_LFZ)XH_9V^-W@7P]>:_)X/U4W<ND>9=S/%IJ:W!-?ZW8ZSHTTVGB
MWN@:N;G1$UE9[JTEN##9CQLTPN+X8S?.,]\0J/B#@:BXMGC<N\4.%<_J9EP_
M@<CJ9O?*\LS+AZ&-J4\JRK#48T<JS#"8G),?3E5JU).LYSH2J>SEF)PG$N4Y
M/D?A]6\/\=2?"=/!YCX8\49!#+<_QN>4\IBLTS++>(9X*%3-<TQ%:5;-<!C,
M/G67U(4Z5*"H\D:\*?R!_P $NOV3OA9\>]?^,'Q1^.MA/XF^''P!\(IXGNO
M>EW9=_%^KK;ZGJ4T&HVEJ\6H7FBVNG:1*(+6-DM=;N[T6TS8M60_0/@[]O;_
M ()Y?&;QOHWP_P#BS^Q#\// /PEU6]N-)TOX@>5I37_@J&>W>PL=:UJ/3;2"
MYL1;6FU;J>PEDN=+F*R[':)@?SV_8W_:Q^+7[&/Q%\7^,/A_X6TOQKI%]I<F
MA_%'PUJMG>MI&K>'?#VHW2JS:];6]PWAPVNIWI:+59K.]3R+M[::PE6ZPOZ;
M^'OCK_P2G_;7\>VWA/XH?LW:W\!_B7\08M+\+Z7X\\.&TT[2G\2:HZ6EM':7
M'ABZ;3=)N;6[GN)X-9UKPM!:31E7OYVN)%AC]WQ RC-X\6<29WQ'DW''$'"<
M\KP'^K6:\!<15<+C>"?88&*S>M4X=H9GE]7$XJMBIO,5F'L\QC+#4Z=*>'G1
M52C1\+P_S;*7PIPWDO#F<<$</\5PS/'_ .LF5<><.TL3@^-/;XY2RFC3XAKY
M9F%+#86CA8++OJ'/E\HXFK4JQQ$:KI5:WY5>-O@'X0\5_M9GX#_LM^-;7XH>
M"?&WC?1]#^%_BS[5]L TO7S:M,==N%AMW$7A2::^M[V]EB6:YTK38M7G DNW
M4?K'\6/&W_!/S_@FUKVE_ G1?V<;#]I7XT>']&T^7XD?$+Q8VDRS65]J]M87
M=UI\UQJ,5S%#)?6ZB^MM#TB%+/0_-BMIY&D,H' _ C]EZQ_8R_X+!_!_X27/
MB*+Q7X:N++Q)XG\&:K>QI:ZB-*\3>"?%]EX?L=91V6W;6],U>TDM?,M'==06
M&UNHHTN+E[:/\]?^"ANC^+-#_;=_:7M?&<<D6J7?Q1U_6M,$DEO*7\):W.=2
M\(3(UL!&(I= GLG2-LW$(/E77^D)(!Z"JX/Q'XKX6X7J\29QF'!M#PPP7&,)
MX;,<7D>8\7XS'YG_ &-2Q><U,M> Q<Z>#P^&>)Q6#H_5**S#'WK4O9\E%>>Z
M6,\.>%.*.)Z?#>3Y?QC6\3<;P?.&)RW"YWEW"6#P.61S>KA,GIYDL?A85,97
MQ2P^%Q=9XJL\!@6J57VCE6?Z*:[\!/V5_P#@H5^SC\2/C)^R-\*++]GKX[?!
M,S7'BOX7MJ%K:>'?%&AQ1RZ_>7ZQ:<W]GSWFK::EV-)UU((OL-_;-H^HQNV)
M*XS_ ()!?LZ_ S]HOPS^U#!\8O!/ACQ,FB>'?#[>'/$NNZ8NHW_@M-4TK6S>
MZSH;-+&MO=0+'#?(_)\^T@))0.C[?_!#RWN[/Q_^U3XHNX!%X2TWX$16FOZG
M<6SRV:R)J6H:DEEYNTP-/'917-Y-:R98VC;@A67)](_X(PW5E?>&_P!O6]TP
M*-,O?#BW>G!(/LR#3[K3?%L]D$MMJ?9D%K)$%M]B>0N(BB;=H^+XTS#.^&N&
M?&?A'+,^SJ> X5QOAUC.'<SK9EC,3G&3T^)\PRZMC<H>;UZU7&8FAAYTG/"0
MQ->I5CAL34HUY5:<TE]GP9@,EXEXE\&^+<SR')HX_BG ^(>"XBRRCEV$PN49
MO/AG+\?1P6;K*:-&G@\-7Q$*L88J>%HPI2Q6'IUJ,:-6&ORI^T#^V!^Q+=_
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MP^^&O@/XO'P)IFD^%],BTK2[O5]#\&^)=.UG5R$9DNWU/7&;[+<@*#&84C'
M=OR\^)'@[QGJW[0/Q(\#V?AW7=2\<:I\8O'6DV7AJ.UN+K7;O4M0\9:L]C:"
MV_>3&2:">"52YVI;NDC,L8R.7\!?$OQA\./B1X5^+F@:A,WC?PEXLL?&MI?3
MS;Y+W5[2^%]=PW-Q=)=MY6K*]U874SI-+';W<KQGS51A^@7QR_:<T3X6?MH6
M/[9O[+FM^#?$>I_%+P9!XWU#0O%5A=^(H/ GCOQ7HL.B^.]!U?1VDT*ZT^]L
MKNT$^A,ERDT,4DUT7DCN A_1,/E.=\*Y[@:.78>6>3J>&.'X?R_'9CB<5[/%
M<1\)XS%XNA3SG,73Q-3"T\\IYW7Q/UJK[:K4E@,5&/-4C'G_ #O$9MDG%.1X
MRMF->&20I>)F(S['X#+L/A>?#<.<5X3!X2O4R?+U/#4\3/(ZF24</]5I>QI0
MACL,Y.,)-T^X\2ZOX,_X)J_!GQ1\,]#U[1-9_;P^,WA\:/\ $/Q+I%S::C;_
M +/GPXU=(VO?!&GWOF[+7QGJ]N774+JS(N[2X^S768Q86PF^;_\ @F?;WEW^
MW?\ LS?V;ODD3QY=W<LT<3W*K9Q>%_$,U_-*8\A4DM?/4SNPC625&8DD*WI.
MI?\ !4SXUZSJ%[J^L? W]C75M6U*YDO-1U34OV=],OM1U"[F.Z:ZO;VZ\0RW
M-U<RM\TL\\CRNW+,363^Q]\:?"_PJ\9_M#?M<^+M:\):3\0M%\%^*K;X4?#+
M14@T:7Q#\2_B7<?8_M_AS0;=RNE^%O ME)<7[VC%;62*>&SLY6FM6QX7]E<4
MX'@?CJGG>1TZ_%/%65XG"8C,\/FT<VGG&=YUAGD>7X&A@Z66X=Y3D.5/&4J>
M#P\JU>A@<%'$XG%U74GCL;4]Y9KPQCN-N!:F2YY4H\+\*9IAL9A\LKY5+*J>
M3Y)DV(AG>88ZOC*N98A9KGN:_5*L\97C1HU\=C7A\-A::I0P."I_)_[1NHZ/
MJ_[0?QOU/P]]D&B7OQ3\:2Z:+&1I;,0#6KF)A;RLD;.GGQS98QJ=^X8XR?&:
MFN;FYOKJZO[V437M_=W5_?3@%1->WUQ)=W<P4EBHEN9I9-I9B-V"3C-0U^UX
M#"K X# X%3=18+!X7"*I)MRFL-0IT%.4FDY2DH<TFTFVVVKL_%,?BGCL?C<<
MX1IO&XS$XMTXI*--XFO.LX12T48N?+%*Z222/:?^#>#_ )6!_P!J7_LS+Q!_
MZD/[.U?Z$]?Y['_!O!_RL#_M2_\ 9F7B#_U(?V=J_P!">O\ (3QJ_P"3H<:_
M]E%G7_JUQI_L1X6?\FTX _[(SAC_ -4F!"BBBORT^]"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OX]M%_P"5RCQ=_P!F*6W_ *J_PQ7]
MA-?Q[:+_ ,KE'B[_ +,4MO\ U5_ABO1R[;'_ /8NQ/YTS.I]C_KY']3^PFBB
MBO.- HHHH **** /\R3_ (*@?MY_'7]B?_@X\\;?'+2O&?Q3U+X-_!/XK_"+
M5/'_ ((L/$/BBX\!#P7KOAW2=+US3-2T.#4(?#]LNJVEW?OI\5V+47FJ0IY,
MIF4D?Z6G@CQAH?Q"\%^$/'WABY-[X:\<>%] \8>'KPA5-WH?B72K36M)N2J/
M(BF>PO;>4A)'4%\*[##'^&+Q=^RUH?[;'_!>/_@M7^RQKL&GM_PN']BR7P]X
M=U'4K%-0C\-^-8M+\%WOA'Q1:0.5:/4-(U>"(V]S!)%<0Q7-RL4B^8V?UU_X
M-A?VL/$'Q<_88\2?LH?%WQ'-?_M#_L#_ !0\4_L_^/-#U66237;#P=I>KZE#
MX#NKF>=FEO[:VFTWQ)X7MYE>86=OX;M+5W6-K0, ?>'_  6V_;=LOV O^";'
M[1_QQAO5M/'6L>$[OX3?")%NK2VO)?BC\3;"_P! \/7NGB\W1W-UX6LFU?QL
M;18+II[7PQ<B2W: 3,G\]/\ P9N^./C9XKT']O+3/CEXJ^)NN^*O#GCSX=6=
MQI/Q/U?Q->ZWX=O)])U::^LFTSQ-,]YHLTDI5[BS$%J00FZ( +7L'_!474U_
MX*H?\%UOV'?^"77A77M=G^"G[%L@_:N_:[MM-GB;P_<>*+&WT/Q9X6\+ZKIE
MU;S6&J7]MH3>#O#JWD[,UAI?QD\46]@B7UG?I)ZM_P &]6P?MZ?\%V5BC$,,
M7[;&IPV\*DE8+:#6/%<-O A;DI! D<29YV(* /Z-_P!K7]HWP-^R+^S3\;?V
ME/B1>36?@[X-?#KQ-XYU4VB6TVHWAT;39[BSTS2K2[N;2&_U74[T6]CIUAYZ
M/>7<\4$>YW"G^ '_ ((G_M.?MC?L]?\ !2S]C[]I+]K/XC>)]0^!'_!:"Q_:
M0L? ^E>)?B!K,_AKP_XM_P"%F37NF7-IX5U2XET+3KB3XBVOAKPGX/BL(],N
MFT7QL\6G6D-A+:VVJ_NG_P '3/Q-\<_$CX-?LK?\$Q?@A(-0^-/[?GQ]\)>&
MSH$3I#.W@#PEJ]G?7&H7%Z6+:?IS>+'T*'4)I$2WDTR#5#/+Y$$Z-5_X+]_L
M W'PP_X(Y?L^:_\ LY6,EO\ $C_@D[KGP.^+7PSU+PYH=BUU)HWPY@TGPKXX
MUZXLITD*6<$\MK\6?$>V5I)KCPM-=WC70^T+* ?U>U_GX?M ?LM^+_\ @HO_
M ,'+_P"T[^R'XG_:I_:0^!_PLT[X9-X\C3X,_$+5="O8;_P_X'\.M96.GV5U
M<7.A65G/?:B;O4,:6\URD;QQRP2R^>G]I?\ P3]_:NT7]N']C#]G+]JK18+&
MP_X7+\+O#7BG7=%T_4(]3M_#7B][-;/QEX7-['_KIO#OB>UU72)C(L<RR6A$
M\44H>-?X[1^U?^SI^QM_P=??M8?%[]I_XL^&?@U\-A\$KOPXOBWQ6-4.FOKN
MK^#?!XTW2U_LG3M3N!<W8AG>,O D.V%PTH<HK@'VK\0O^#8'XW_#31;GQS^Q
M/_P5Y_;C\"?&WP_87U_X>?XF_$#5]9\,>(=0M(_MFF^'=3G\)ZSX7N]+TO5;
MV"&RU"ZO+7Q+81P3-+=:!J<"264WW[_P;[?\%0?C!_P4'_9_^*GPY_:JT;^R
M_P!L#]D#X@S?"'X[7]KH^GZ+IWBFZBFU*TT?Q'+8Z1(=(L?$KW.AZWI/BNQT
MBVLM'&JZ6VH:59VMCJ$5K!:^/_\ P<Q_\$@_@Y\+?&'CGPC^U/X8^.7BW1/#
M^I7_ (9^&7PQTSQ1=^)/%VNPPA-)T*WO-6\/Z=I&E)J%_+!%<:GJ%V(-.LA=
M7[PSBV$$ORS_ ,&LO[-?QM\)_ +]JS]MO]H3P9=?#GQ[^WY^T9XD^+NC>"[R
MWU'2[FR\$6>H:Q/;ZI/H&JP07^BQZKXQ\0>,1HL%X)+F]\-6>BZNTC0:C;A0
M#^J"OY%OB#\0_'EO_P '@/P/^'L?CCQ;!\/[G]B;5]3N_!*>(]6C\'W%^GPI
M^,%R+^X\."[&CR7:7%M;W(NI+,SK-;PR^8&B4C^NFO\ /X_X*S? ;XP?M1?\
M'1GPH_9V^#GQ%\4?">[^,O[)O@[P!\2_'_@MK2/Q5X?^!>O>&?B?;?&F709[
MQECMM4N_A\=;L+*ZC9;BVN+J.>'<R;6 /[,%_P""DO\ P3Z?QX/A@G[;'[+3
M>/CK'_"/#PPOQS^')U$Z_P"9Y/\ 88_XJ'[.=8-T?L(TP3F].I?\2T0?;_\
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M0!2TU[86MS:1KM9I@&4GZJK^%K_@X9_X(^?LB?\ !/O]EW0O^"D7[!7AJ_\
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M$FDZHK1-Y^E7M[;C!E##^?3_ (A1_AC_ -)//^"D_P#X=_3/_E57]8=? O\
MP4\_;B\)?\$[/V(OCI^U/XFGLWU3P5X7GTSX<:'=O%N\5?%3Q(KZ5X#T"&VD
MDB:]B;6)DU;6+>!O/3PYI.M7:#%JQ !_%G^S_P#L0>(OA]_P<-?!']D']CO]
ML7]K3XY>!/V2)M)^+O[6WC7XQ_%+4O$GAK2-2T!Y+_4/ 5K8^'_[,T^.>2/4
M-)\(7NGZY'<-/X@N[U%?[/:R1#^DG_@X(_X*/_%W]B']G#X>?![]E&&XN/VS
M_P!L[Q]8?!/X 7-K;:;>S>%;G4;W3K;Q!XLM[75+B*U.LQ6VHP:+X6N+F"\L
M;#Q'JUAJ6H6TUM9-!-YE_P &U?["'C?]GG]E;QC^U]^T3:7EU^UA^WOXIN/C
M7\0M7UUUN_$.F>!M7NKG5?!&AW-[(9+I&U:/4;CQ;J%I+,^R?5;.)N;10OR#
M_P %>K+3?B/_ ,'&7_!#GP#XF;5+/0O!5UJ_Q"TN1[M(-,U#Q-I7C.S\3Z5!
M:).JQ-(^J^$-&MM4BC>2:]@-O:JJDJ' )-'_ .#5G5?'?PVT_P")/QJ_X*=?
MMSS?MT:QX?@US5OBOIOQ'AO_  %X4^(NH0QWUU;6'ANXA'C35= T34+F^L(Q
MI_Q-\.R7\.+BS_LF)Q:#Z(_X()?\%!?VEM;^*/[2G_!)W_@H'XF7QG^UY^Q1
MJES9^'_BG<70N[WXP_"RSOQIMM?7E_\ 9;6;7=2\/12:5/%XDOH4U+6_#VLZ
M1<:Q<:AK<.I7LW]/E?Q_V%Q_PB'_  >*^((=&B-O%\2OV&K5?$\9GE6"]N+#
MP!X<:UO$@4K&9H4\-V,>TAD9S<7#?OW+4 ?V 5YMXQ^,WP?^'GBCP/X'\?\
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MJMU;0ZSH%[?V!O+-V$5[9F<75G-F&ZABE#(/0J_BN_X(?>!M*_82_P""^O\
MP56_X)I?!/6_%O\ PS!X?^%WACXP^#?!OB+55U6#PSKD47P:UR&WMI9E,^=-
M@^.6M>';2]C*7.IZ-I&F2:X]W?P1S+_:C0!_'[_P=Y?$+Q]\/_@[_P $\IO
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M1110 4444 %%%% '\>__  <N?\G^_P#!OA_V>U-_ZM[]E>O["*_CW_X.7/\
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M#$YMY/&OVC?V]OV?-$_9PUW]D7]ACX8^*?AW\./%VLRW?C[QMXHO)[3Q!KT
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MH ]I_P"#>#_E8'_:E_[,R\0?^I#^SM7^A/7^>Q_P;P?\K _[4O\ V9EX@_\
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M *3\4X+GX%7=UXDM'L;O3IO#-WX>DU27PXD$F]=)O=9OKA9X+)X=3@BLX8
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M=_!::#I5E(EIJ'DQ"XUR_P!*TVVD>6Z=4^Q-,^/7Q"_X)&_\$1/@#\4OC/\
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M_4RTBOM[X _\$POV=OV</VU/VFOV\/ .M?%.\^-'[5]O96WQ+TOQ-XGT34O
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M3?:!X.F\5+ BV\UM9>(;-KV..>]:,_0GBO\ X-#_ /@GKK#:AH'A7X\_MJ>
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M<Q66L0:#XW\/:CX9UB;2;R>VO(+34XM/U.X>PN9K2ZB@NEBEDMIT0Q-\O?\
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M:U::$!"XD6338?@3_P $X?V,M-L]=\2^(='_ &>_V3/@[8:=>^*/$4-YXO\
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M];&_\BW)_P#KWC?_ %*9$?CJ>L?_ $E!1117DEA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '^7S\2_P#E-;_P6!_[+EXB_P#4TEKW
M:O"?B7_RFM_X+ _]ER\1?^II+7NU?ZU?1U_Y-'PQ_BS;_P!6^./\K/I-_P#)
MY>)?^P3A[_UG\M"BBBOVX_ @HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]<^ WP:\1_
MM"_&#P)\%O".H:5I7B3X@:I=Z5I6HZX;@:3:366CZEK<TMZ;5)+CRS:Z7.B"
M%&<S/&-N"<>1U]X_\$P?^3_/V9?^QQU__P!5_P",*^>XNS+%9-PGQ3G&!E".
M-RGAO/<SP<JD(U:<<7E^58O%X:52G+W:D(UJ,'.G+W9Q3B]&SZ#A++L+G'%G
M"^48V,Y8+->(\BRS&1IS=.I+"X_-,+A,1&%2/O4YNC6FHSCK"34EJCQ#]IG]
MF;XH?LH?%'4?A5\4K&U75+>UMM3TC7M(:6X\.^)]&O%)M]3T>[EC1OE=7AO+
M&<+>6$RB.YC4NF? 88S-/;P*0&N+BWME8]%>XF2%6;'.U6<%L<X!QS7]<O[8
MW@WP'_P4+M/VA?V<+&TL=&_:9_9:U4>)?A?//=K!_P ))I6LZ5'=0PIM>2>7
M2M5"-H.LB:!UL=4-G=VBJKO)7\ETNF:CHGB3^Q=8LKC3=7T;Q+%I&K:;=H8K
MK3]4TS64L=0L;F,\I<6EW!-;S+R!)&V"1@GX;PC\1,1QWP[%9WAH9;Q=E>%R
MZ>>9?%1A3KT,SP5+'Y3GF!AS2_X3\XP56->FDVL/B8XG"MVI0<ONO%OP\PW
MO$3>28BIF/"6:8K'PR3'S;G4HU\MQM3 YMDF-GRQMF&48RG*A4;2>(PTL/BE
MK5G&'U)^UO\ L9_$/]CC5_ VB_$/Q)X4\17?C[09_$>DOX6&H^5;:=#.+?\
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M6VG6EM:S37+QK)YE?EQ\4OV3OV]_@MX<E\7_ !&\!_&'1?#5MAKS6;'Q'?\
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M3_9/PL_Y-IP!_P!D9PQ_ZI,"%%%%?EI]Z%%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?U/[":***\XT"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /X]_^#ES_D_W_@WP_P"S
MVIO_ %;W[*]?V$5_'O\ \'+G_)_O_!OA_P!GM3?^K>_97K^PBO6QO_(MR?\
MZ]XW_P!2F1'XZGK'_P!)04445Y)84444 %%%% !1110 4444 %%%% !1110
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MK_\  K4/_GF4?\0GOB;_ *3&?MU_^!6H?_/,H^K8#_H9K_PCK_YAS3_Y]O\
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M_P#".O\ YAS3_P"?;_\  H_UW_IZ?V$T5_'M_P 0GOB;_I,9^W7_ .!6H?\
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M!6H?_/,H_P"(3WQ-_P!)C/VZ_P#P*U#_ .>91]6P'_0S7_A'7_S#FG_S[?\
MX%'^N_\ 3T_L)HK^/;_B$]\3?])C/VZ__ K4/_GF4?\ $)[XF_Z3&?MU_P#@
M5J'_ ,\RCZM@/^AFO_".O_F'-/\ Y]O_ ,"C_7?^GI_8317\>W_$)[XF_P"D
MQG[=?_@5J'_SS*/^(3WQ-_TF,_;K_P# K4/_ )YE'U; ?]#-?^$=?_,.:?\
MS[?_ (%'^N_]/3^PFBOX]O\ B$]\3?\ 28S]NO\ \"M0_P#GF4?\0GOB;_I,
M9^W7_P"!6H?_ #S*/JV _P"AFO\ PCK_ .8<T_\ GV__  */]=_Z>G]A-%?Q
M[?\ $)[XF_Z3&?MU_P#@5J'_ ,\RC_B$]\3?])C/VZ__  *U#_YYE'U; ?\
M0S7_ (1U_P#,.:?_ #[?_@4?Z[_T]/[":*_CV_XA/?$W_28S]NO_ ,"M0_\
MGF4?\0GOB;_I,9^W7_X%:A_\\RCZM@/^AFO_  CK_P"8<T_^?;_\"C_7?^GI
M_8317\>W_$)[XF_Z3&?MU_\ @5J'_P \RC_B$]\3?])C/VZ__ K4/_GF4?5L
M!_T,U_X1U_\ ,.:?_/M_^!1_KO\ T]/[":*_CV_XA/?$W_28S]NO_P "M0_^
M>91_Q">^)O\ I,9^W7_X%:A_\\RCZM@/^AFO_".O_F'-/_GV_P#P*/\ 7?\
MIZ?V$T5_'M_Q">^)O^DQG[=?_@5J'_SS*/\ B$]\3?\ 28S]NO\ \"M0_P#G
MF4?5L!_T,U_X1U_\PYI_\^W_ .!1_KO_ $]/[":*_CV_XA/?$W_28S]NO_P*
MU#_YYE'_ !">^)O^DQG[=?\ X%:A_P#/,H^K8#_H9K_PCK_YAS3_ .?;_P#
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M]%)PC_X-SKR_ZD_F_N\SY/HKZP_XA@/^"P__ $DX^"?_ (*/B-_\Q5'_ !#
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MQ]_T4G"/_@W.O+_J3^;^[S/D^BOK#_B& _X+#_\ 23CX)_\ @H^(W_S%4?\
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M)WQ]_P!%)PC_ .#<Z\O^I/YO[O,^3Z*^L/\ B& _X+#_ /23CX)_^"CXC?\
MS%4?\0P'_!8?_I)Q\$__  4?$;_YBJ/^)NO#G_H6<2?^"<K\O^IGY_@^P?\
M$G?'W_12<(_^#<Z\O^I/YO[O,^3Z*^L/^(8#_@L/_P!)./@G_P""CXC?_,51
M_P 0P'_!8?\ Z2<?!/\ \%'Q&_\ F*H_XFZ\.?\ H6<2?^"<K\O^IGY_@^P?
M\2=\??\ 12<(_P#@W.O+_J3^;^[S/D^BOK#_ (A@/^"P_P#TDX^"?_@H^(W_
M ,Q5'_$,!_P6'_Z2<?!/_P %'Q&_^8JC_B;KPY_Z%G$G_@G*_+_J9^?X/L'_
M !)WQ]_T4G"/_@W.O+_J3^;^[S/D^BOK#_B& _X+#_\ 23CX)_\ @H^(W_S%
M4?\ $,!_P6'_ .DG'P3_ /!1\1O_ )BJ/^)NO#G_ *%G$G_@G*_+_J9^?X/L
M'_$G?'W_ $4G"/\ X-SKR_ZD_F_N\SY/HKZP_P"(8#_@L/\ ])./@G_X*/B-
M_P#,51_Q# ?\%A_^DG'P3_\ !1\1O_F*H_XFZ\.?^A9Q)_X)ROR_ZF?G^#[!
M_P 2=\??]%)PC_X-SKR_ZD_F_N\SY/HKZP_XA@/^"P__ $DX^"?_ (*/B-_\
MQ5'_ !# ?\%A_P#I)Q\$_P#P4?$;_P"8JC_B;KPY_P"A9Q)_X)ROR_ZF?G^#
M[!_Q)WQ]_P!%)PC_ .#<Z\O^I/YO[O,^3Z*^L/\ B& _X+#_ /23CX)_^"CX
MC?\ S%4?\0P'_!8?_I)Q\$__  4?$;_YBJ/^)NO#G_H6<2?^"<K\O^IGY_@^
MP?\ $G?'W_12<(_^#<Z\O^I/YO[O,^3Z*^L/^(8#_@L/_P!)./@G_P""CXC?
M_,51_P 0P'_!8?\ Z2<?!/\ \%'Q&_\ F*H_XFZ\.?\ H6<2?^"<K\O^IGY_
M@^P?\2=\??\ 12<(_P#@W.O+_J3^;^[S/D^BOK#_ (A@/^"P_P#TDX^"?_@H
M^(W_ ,Q5'_$,!_P6'_Z2<?!/_P %'Q&_^8JC_B;KPY_Z%G$G_@G*_+_J9^?X
M/L'_ !)WQ]_T4G"/_@W.O+_J3^;^[S/D^BOK#_B& _X+#_\ 23CX)_\ @H^(
MW_S%4?\ $,!_P6'_ .DG'P3_ /!1\1O_ )BJ/^)NO#G_ *%G$G_@G*_+_J9^
M?X/L'_$G?'W_ $4G"/\ X-SKR_ZD_F_N\SY/HKZP_P"(8#_@L/\ ])./@G_X
M*/B-_P#,51_Q# ?\%A_^DG'P3_\ !1\1O_F*H_XFZ\.?^A9Q)_X)ROR_ZF?G
M^#[!_P 2=\??]%)PC_X-SKR_ZD_F_N\SY/HKZP_XA@/^"P__ $DX^"?_ (*/
MB-_\Q5'_ !# ?\%A_P#I)Q\$_P#P4?$;_P"8JC_B;KPY_P"A9Q)_X)ROR_ZF
M?G^#[!_Q)WQ]_P!%)PC_ .#<Z\O^I/YO[O,^3Z*^L/\ B& _X+#_ /23CX)_
M^"CXC?\ S%4?\0P'_!8?_I)Q\$__  4?$;_YBJ/^)NO#G_H6<2?^"<K\O^IG
MY_@^P?\ $G?'W_12<(_^#<Z\O^I/YO[O,^3Z*^L/^(8#_@L/_P!)./@G_P""
MCXC?_,51_P 0P'_!8?\ Z2<?!/\ \%'Q&_\ F*H_XFZ\.?\ H6<2?^"<K\O^
MIGY_@^P?\2=\??\ 12<(_P#@W.O+_J3^;^[S/D^BOK#_ (A@/^"P_P#TDX^"
M?_@H^(W_ ,Q5'_$,!_P6'_Z2<?!/_P %'Q&_^8JC_B;KPY_Z%G$G_@G*_+_J
M9^?X/L'_ !)WQ]_T4G"/_@W.O+_J3^;^[S/D^BOK#_B& _X+#_\ 23CX)_\
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MG*_+_J9^?X/L'_$G?'W_ $4G"/\ X-SKR_ZD_F_N\SY/HKZP_P"(8#_@L/\
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M_@G*_+_J9^?X/L'_ !)WQ]_T4G"/_@W.O+_J3^;^[S/D^BOK#_B& _X+#_\
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M_P!)./@G_P""CXC?_,51_P 0P'_!8?\ Z2<?!/\ \%'Q&_\ F*H_XFZ\.?\
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MB_8(M+J&.XM;K]LR"WN;>90\,]O/\/M=CFAE0\/'+&S(ZGAE8@\&@#[EM?\
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M4X?#N8[][;4I;F\@N+.*'4)C9VYE5?W'_P"">W_!0#X%?\%)_P!F+PO^U%\
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MW]M'/%XNN_"UOX8TR>ZTN.%QJ$[+=6MJNGN&CU&5E5Y@#^KFBOQ=_P""?_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P ',EA::K_P7/\ BMI=_"+BQU)_@?87L#$J)[2\T?2;>YA+*0P$D,CH2I!
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M$Z3\._#'BE]-TR#7K/4+>R_M+5?%=Y)J$MM!#/.EM:1O.\:*B?A3-\)/AS\
M/^#I+0?A#\&_"NG_  _^&WP__P""C'@K1O!?A'0C<0Z9X:TD:]HEY%INEB6:
M6>"SMYKJ86T)F;R(BL*-L117]-7_  9-Q2P_L$?M7K-%)$Q_:]F8+)&\9*GX
M,_# 9 8#(R",CTK^>#XS6]Q_Q%JZE-]GN#%_P\J\%'S!!*4Q_:WAP;MP0C;G
MJV=H'S$[>: /ZGO^#BGXC?\ !#;P%XD\ ZE_P4H\&>,_C1^T1;_#;6[?X6?"
MSX4ZWK,'CJT\'W&HM<B^O9+;4M/\.>$+36]9BFM]'UCQ'<0C4+FPO!;1S0V%
MP\?\^_[??_!;WX/_ +7W_!/+X@?L>?LB_P#!(_7_  -\*=&\ >&[+3/BEXT\
M)Z'>6?P8\$>&=5TZX7QWH]QX1\-W%K9>(+I-)T^P.M7'B2U^U3ZIJU[?ZAJD
MJM!?XW_!V#^S5\=_A!_P4_\ !W[;'BOX67?Q&_9R\9^'_A/%HFLRZ?KNK> W
MU3X>7DPU?X6>.M5CL3IWAR^U]()[FQTE[H?VOH]]>7>GI<26NHI#]$_MH?\
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MI'A?286222&,:6(6ECDEN47Z3^'?_!;?X*>!_P!EW2?V5-"_X(&_$.3X0/\
M#:#P)J-JG@&*XD\0V5]X>_LG4?$E[?3^!)]1O]<U5;FXU(:Q<ZK-J2SW"O#J
M"%(W3[6_X.V/^"2WQV_:HM?@]^W/^S!X*U[XD>-?@QX-O?AO\6O O@W3_M7B
MW_A7VGZKK7C3P_X^T6SM9QJ6N3^'-3U76-/U6RTZTN-5@L+K3KNW$]O9RI:_
M!_P:_P"#RCXM_"+]F+3OA'\7OV/+KQ;^U#\/O!47@BQ\=/XIE\*^$=9\0:-
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M&I?!MY;J[=3,JRR%[>$PL@A:(QH=SE%(_H]_X.@4=_\ @C-^TZD:/([7GP[
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MJUI1BM[B51^SE\,@6C@E=,FYU_@.J%21CD DKD9 R,_J_P#\';L,TW_!+O\
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M:^+_ !;X4\%MML-'UO7H->UJ.X<2SV%H-3NVTNPL'9&3]<*_AK_8H_X+[?\
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MHM[2Q\87D.B:AX@L;2WO-1@ /YD/^">W_!3S]L+_ ((6? WP]^PG_P %"/\
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MH:1J6AW<E_/>VD(T.TOM8\3ZUXXUS3]/TJ>0"WU2ZCE ,9K^VROPN_X)"?\
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M$%WJ,.CI'+K#2Q6UYJ$MO<Q6:'[38C45%A)L?\$"_P!C_P#:@\=_M1_MF?\
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M%Y?QV\J1ZA+!IS7:2MIMFT,7_!R/\-_ 'BG_ (*9_P#!$Z^\3>#] \07.O\
MQH3PAKK:Q8I?Q:SX5LO'/A[6+7P_J=I<%[.]TJ'5+R[O5M9[=U:6YG$A>*1H
MSVG_  :HI(GC;_@K\7BEC#_MS^)&7S8I(MR_;?$HROF*NX9!P1D$8(X()?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /QD^(W_!>'_@C!X&\>>,/ 'Q)_
M;,^$FF^//A]XFU_P+XOT?5O WQ*U&^T+Q+X3UB]T37M$GNX/AW>VLSZ7K%G?
M6DCV=W<6;RQR26TTL3K(^0O_  <8_P#!%!555_;Y^&*JH"JJ^#_B\%50,!5
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M++_@XB_X(@Z;&\6G?MV?"73XI'\R2.R\#_%BUC>3:%WND'PVC5GVJJ[F!;:
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MN;;P!\4X+@>8"LF)HOAHD@WJS*^&^8$AL@FOUG_X9[^ ?_1#_A!_X;3P9_\
M*6C_ (9[^ ?_ $0_X0?^&T\&?_*6@#\8?C3_ ,'+W_!(CP+\(/BCXS^&?[8'
MP\^*/Q'\*_#_ ,7Z_P" /AM9>&_BK87/CWQKI6@W]YX6\'I?WO@*SM-/7Q%K
MD-CI4M_<W4$-E#=274DBK":_SK_^"F__  64_:>_X+1>/O@9X>_:#7X)_ _P
M%\.]3N].\*Z7X5TWQ1I_@7PQJOC2\LK+Q#X]\7ZYJEUXX\9W2)IEEI4-_%8F
MYL[2QTEI]-T/[9<W'G?Z]W_#/?P#_P"B'_"#_P -IX,_^4M'_#/?P#_Z(?\
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M_P""(&F(\>G?MU_"73XY&#R1V7@;XL6B2.!M#NL'PVC5F X#,"0.,XK]7_\
MAGOX!_\ 1#_A!_X;3P9_\I:/^&>_@'_T0_X0?^&T\&?_ "EH _(?Q'_P7^_X
M(0>,8X(?%W[9WP,\4Q6SK+;1>(_AG\2M;CMY$#A9(4U/X7W2Q.HEE"M&%8"2
M0 X=LZ4O_!PO_P $-Y[:WLI_VX_@]-9V8Q:6DO@'XJ26UJ-NW%O _P -#% -
MH"XB11MXZ5^LW_#/?P#_ .B'_"#_ ,-IX,_^4M'_  SW\ _^B'_"#_PVG@S_
M .4M '\E_P#P7._X+1_\$J_VFO\ @EM^TO\  ;]G;]KKX=^/?B=XPT/0+?PC
MX%T'PK\1]+NM7GM?$^EWMU!9RZKX&TK2('CMHI[AC=7MK&RQN YD*JWY!?\
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M%2W?_!P]_P $/M0BB@O_ -NGX1WL,!!@AN_ OQ7N8H2%V Q1S?#5TC(3Y1L
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M44 %4[W3M/U%$BU"QL[^..02QQWMM!=)'* 5$B).DBI(%9E#J P!(S@FKE%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#X:^$WCZ[36/L$D5U;WUS:PWEGJ'A@7]IJJV6G^)Y]"OTTK7K_7TB6\;W_\
MX.9_C)XR\2?M0?\ !-;]@'Q[\=_$/[,?[$O[6'B[7$_:;^*'A[7O^$8&M:)9
M^(= \-W'A;Q%K\DL>F6WA>VTK7)KB^LO$27'AZ:\U*PU;5K>:ST29" ?UP>'
M_B3\.O%L\EMX5\>^"_$MS$T:2V^@>*=#UF>-Y1(T2R0Z=?7,B-*L4IC#*"XB
MD*@A&QVM?R+_ !N_X-:/V)]5^#?AWXK?\$J?B;XO_9T_:A\(W^B>,/@K\?\
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MJZ8)[JU.I6 N;&$W-[;F\MQ/9VX19#/=1&3S+>$1LKF6940(RL6VD$_R(?\
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M1E='4.CJP961AE65@2&5@00P)!!R#BOY/OAO_P &A?\ P3L7X50V?Q_\:?M
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MIT<S7EI%<QNKP23PQI,IS&S8.-FOY[_^"BG_  0GU/\ :O\ VGKW]NS]EO\
M;@^/W[%'[7[^#?"W@E/%/@:\74OAYJVB>%+M;JVL-?\ #NDW7A?Q+=V>K+%;
MP:UIMQXJO_#E\UE83WGAN\2WN;6_ /Z$**_A1^-G_!8K_@L7_P $5/$NG>"?
MVY?&W[#W_!1#X?0:QK>E/JOP^^*?A;P#^TC8VMG<6ZZ3)XR\*:);:3?^&;B>
M&<P&*]^%?BLO<6]PEQXDNIK2:\OOZCO^"6W_  4H^&O_  5._9BLOVE?AIX
M\=_#.P'B34O!^M^$_'D%L]U9Z[I%O937LNBZU88T[Q'H3O=F&SU:VCM9))+>
M>.ZL;.9#%0!^D%?S6?\ !0?_ (*8?\%!?B+^U[XU_P""7_\ P2=_9VGO?CKX
M!MO"T_QY_:W^+5E&GP1^"VB>.?!7A[QII/\ 8S@7%C>^(CX?\3VUQ]HUIQ>0
MZG!#8Z!X5\32R7$UC_2G6-IOAWP_HU_KVJ:1H>D:7J?BG4;?5_$VHZ?IUG9W
MWB'5;32[#0[74M;N[>&.?5;^VT72M,TFWN[Z2>>'3=/LK&.1;:UAB0 _E%_X
M-7?C[^U3\;/#O_!0+1/VL?CMXQ^//CGX/?M$:3\.K/Q!XGUN[U:RL/[.TO5T
MUR/P\ES;6(M=,O\ 5[:2[C4V-L_E^4HBA4>4/T:_X+I_\%/O%'_!-W]E[0H_
M@;H$7C;]KW]HWQ?9?"/]F?P;-I-WKEO)XKU.:VCU3Q/>:7:*6U >'K"Z$FD:
M3*\,&M>(;C2].FE2WDN"/RM_X-0/^1B_X*Z_]GOZC_[L]/\ ^"OEA;_&+_@X
MG_X(B_"'4]4OX=#^'UUJ?Q8N-*EM(+G2;W5='\8VOBFUA,$KM'.=2'@NUTZ^
MEN(2UK:LPM@3-(2 .TS_ ((<?\%F?B1X TSX_P#CS_@MO\9?!O[8FK>'K7Q-
M!\.+'0M3MO@GX5\57T*7]OX1U;4-%U^WB2QT47EQI>HW6F_"_5(([JVQ8V=_
M:K%*?M__ ((3?\%1OCC^U0?CO^PU^W?I=AX;_P""@/[%'B"7PC\49[2*QL;3
MXG>&+74;G1K#QI;6MB_]GSZ[8W5G]C\47.B*NDZFMSI'B6TMM/@UU;*#^B>O
MX^? :6'PX_X/#_B_IOAVRBL[+XQ?L26.K>)[6UM["TMVUZV\"^ ;EM6VP6:R
MRSWC^'?M%_(\OVF\U#4+F[N+B0!8P ?U\C4M.-Q<6@U"R-U:0FXN[874'VBU
M@ !,]Q#YGF0P@$$R2*J $?-R*YO0OB)\/_%&IW>B>&?'/@_Q%K-@DTM]I.A^
M)=&U;4[.*WG%K<275A87MQ=6\<%RRV\SRQ(L4S+$Y5V53_"W\0_V>OB3^V!_
MP<P?MN_LK:#\5?&?P?\ @W\6?@SX*D_:1\4?#G5[G0OB)J_PH\(Z/X;UV7X<
M^%=?@O(GT*V^(FNQZ9X?\37J6M]M\/2:@HMF=QNR/^"R/_!*3X7_ /!"GX<_
M!7_@IG_P2P\8_$KX'?$OX4_%SP+X(\?^%->^)&O^*_"'CSPIXDBU*-GU33M5
M2XU/6FUCQ#9Z)I_BGPQ>:W!X4U'P[=:A/#I=O?V5JT@!_=YXE^(?@#P;)!#X
MO\<>$/"LUR'-O%XC\2Z-HDMP(U5W,,>IWML\H1'1G*!@JNA. RYZJWN;>\@A
MNK2>&ZM;B-)K>YMY4G@GAD4-'+#-$S1RQNI#)(C,K*05)!S7\HWPM_X-K_V4
M?VS/@EIO[1O[?_Q0^./[2'[8?[2/@73OB)XO^-J_$OQ-H-AX U7QUIQ\0Z+X
M>^&/@]KR\T:R\*_#VSU:RT'P]H^N0ZMI9M-)C6#3[&PECL(*W_!K?\4/BIX=
MT7]O?]A#XB?%#Q)\7/#O[%?[15UX)^%'B?Q0+J74;7P;</J>FW&DI<7NI:A/
M:Z:NHZ*M]INAQLUGI(N[N*R=+=T@C /ZMCK.CA+Z0ZMIHCTP9U*0WUJ$T\?,
M<WSF7;:#"M_Q\&/[K>AK%\,^/? OC5KQ/!WC3PGXL?3A"=03PUXBTC77L1<&
M00&\72[RZ:V$YBE$)F""4Q2!-Q1L?P)_L0?L4:Y_P45_X*S_ /!8[]F+XD?$
M[Q_X&_8ZM?CM<?$CX[^$_AGXDO\ PIXG^-?B#3]3UCPUX!^&6O\ B&SO!/:_
M#N$:[KOBS7["*PN'U&_T/2+))K193/"W_@JC^P3??\&_W[0?[(W[2_\ P25^
M*/C;X*6G[3WCC7?V</B#\-?'/C/6/'7@2/6/$&E:3I?@[66T?4HSJ/B'2K1]
M:\0>(;J/Q+K>J2>'_$NE:#?:#'%%<W=N@!_?)K7Q*^'/AO4X=%\1>/O!6@ZQ
M<E%M])UGQ3H>EZE.TLJP1"&QO;Z"ZD,DS+"@2(EY"$7+<5VJLK*K*P96 964
M@JRD9#*1D$$$$$'!'(K^3?XA_P#!JE^PSXT_9W\=>+/BW\4/VA/B;^V9K_@J
M_P#&WB;]KWQ+\3_$VI^)]2^*,&B'5[GQ'_PB.HZA=Z%<:%-JT!1=(U(7VJQZ
M25MHM<AO(XKR/Z _X-;_ -I3XK?'O_@G'J/A'XQ^-];^(_BC]G7XW>/O@MI/
MC+Q%)<W>LZIX,T.2TNO#4&H:G?7U]?:E-IT=S>6<$MY*T]MI\=C9--<+;K)0
M!_237\D_[0O[47[1.C?\'37[+O[,ND_&7Q[IW[/WB#X*V/B+6_A#9ZW+!X(U
M36_^%>>/+MM1OM)10ES.]U:VERWFNR>?:PR!0R<_UL5_ -_P5K_:P\*_L2?\
M'0/[/_[1_C+P-\1?B5H?@?\ 9\\,12>"?A1H<'B/QYKMQKG@[QKHUO!H>C7%
MY8I>20->F\N$%P'6UMYF53@D ']_-?RU?\%\/VIOVBO@'^W'_P $8_!/P8^,
M/C7X;^$?B[^U!9Z'\3O#WAC4(K/3/'.CKXZ^&>G?V9XBMY+>8:A8G3]6U2S:
MUE/D-%?3[HS)L=,'_B+ _9W_ .D?W_!1?_PRFF__ #15^(O_  4>_P""KW@;
M_@IM_P %$O\ @C>? '[.O[1GP/T_X4?M6^$CK%_\??!<7@[^V[_Q/\2_AP+"
MR\-1VUYJ,.HK;6VCW5QJ$TES;2V[R01);3(SS( ?W/?\%!OVV/AM_P $\OV1
M?C%^UE\48VU#1/AEH,<FB^&+:[@M-3\;^--9NX-'\(>#M*>;<WVG6=:O+9;R
M>&&ZDTO18-5UJ2VEMM,N /Y8_P!GG]FO_@NM_P %P?#$'[4_[0O[;GBK_@FU
M^S)X[OG\1? WX(_!?P]J$'C.X\,[9!H/BBYM;?4?!VLW6AZEI]PJ6>J^*_&1
MN?$2QC7K/POIMC>6SW/K/_!V-JD/CGQ)_P $A/V4=;N77P3^T)^VU8_\)C8W
M5Y-9Z#>:9H6N?##P,[ZO)]H^R)]GLOBWJ2Q7%U879M;6XU"6*6 &6.Y_K\T'
M1=,\-:%HOAW1;2"PT?0-)T[1=*L;6..&VL]-TNTAL;&UMX8E2.*"WMH(HHHX
MT5$1%5550  #^)K]H_P3_P %U?\ @@?X=T?]ISP;^UUJG_!3#]BGP7=VL7QN
M^&_Q7\/WP\:>"O#,^IV]QJOBNXGDO-;\0Z/I;VL0TV'QCI?B_7;3PU=7DEUX
MB\,R:6(KD?UR_L>?M6?"K]MO]FOX1_M0?!C58M3\"?%GPEIWB*UMOM5M=:AX
M:UB2)8O$?@S7FM'D@B\1>#]<CO\ P]K<,3M"-0T^:2V>6UD@FD_.OXR?\%J_
M^"(_BW1_B9\!_C=^V-\!O$&@ZFOBKX9?%'X=>+=(\9ZCI>H10W%YX=\5>%]=
ML)/"$MM>6YG@O+"[C5I8)@K/#+)&R2'[%_X)W:A^PEJ7[,WA^?\ X)RW7PVN
M?V8T\0^)(M"7X5IJ$'A:V\2K=Q/XFM_L>JQ0:E8ZE]J>&>\M[RW@D83PW*H8
MKB.1P#[EK(UOQ!H/AJQEU/Q%K>D:!IL"/+/J&M:E9Z790QQ@&226ZOIH((T0
M$%V:0!0021D5KU_*M\4_^#?GXZ?\%!/VU/C-\:O^"J7[7.O_ !7_ &:;/5H7
M_9K_ &=?@7K_ (E\ ^%]#T.ZG-S+IOBS3-1M[N/1HM"@CAL!/H>HZEX@\47T
MLVM7_B3388HM'8 _J&\-^,?"/C*UEO?"/BGP[XILX)6@GN_#FMZ;K=M#.N"T
M,L^F7-S%'* 03&[*X!!Q@BOE/_@H5^TIK?[)'[&'[27[0?@Z/PSJ'COX2_"7
MQ3XX\(Z%XIN?+TO5=8T>V#6D-Y;0W-K>W=IYS@RPVDL<LVT0I(C."/XTO^"@
MO[*WP(_X-_OVOOV%?VF/^":W[0'C_P  ^'?B?^TOX4^#_P"TM^R5:?%B3QUH
MWBSPA;S6EWJ,VLZ7J.MW.LM8W>E3:YH5_I_B^#5_[.UK5M%UKPOJ/AO4]/;[
M9^XG_!QE_P $X/V9_P!K#]C#XO\ [5_Q8TSQ?=?%?]EC]G[QYJ_PCNM$\5W^
MC:+975Q-:ZLQUS1;8?9=:1KI(\I='"Q@JHYY /T&_P""1_[9?C7]N?\ 8*_9
M[_:3^+LW@73?BA\6/#VIZUKOA_P5_P 2_2K*2VUS4M/@@LM)O-6U74H0EM9Q
MO*+FX>1F8R;51ES^F5?QX_\ !M5_P1\_8UT/]F7]CS_@I5I^C>/E_:=U;PEX
MHO[[59?'.J2>$'GU.^U;P]<A/"3 Z>D8TV)5C"E2LS-+R<5_8=0!_+E_P<Q?
MM,?'_P#9QLO^";4GP(^+GC;X4O\ $;]LSPYX,\=-X-U9]+/BKPM=G1Q/H6L%
M4?[3I\AED+0_+DLP)*L0?Z5K_P ?>"?"\.C6OBSQIX6\.W^IPVD5G;>(/$.D
MZ1=W]U+##B*V@U"[MY;F9VD3"1([$R)QEES_ "&?\'A3>+E^&?\ P3<;X?K9
MMX^7]L2V;P,NH[?[/;Q@-*TX^&EO]_R?8CK'V,7._P"7R2^[C-?3M]_P:R_L
M:?'[PA>>./VROC+^U)^T%^U9\0=#TC4_&_Q\UWXNS1:AH/BNXL%N-5LOA]X:
MBT@>%],\%Z?J<\UOX=T#5]*UA;'2;>UM5F&') /ZBHY$E1)8G22*1%DCDC8.
MDB. R.CJ2K(RD,K*2&!!!(-5[[4+#3(#<ZE?6>GVP8(;B^N8;2 .P)5#+.\<
M>Y@K$+NR0I('!K^2W_@VB^,7QZ^'/Q=_X*)_\$OOCG\4_$WQIM?V(OBC;67P
MN\;^)]=U+Q%/I?@DZA>^%!X7LM3UB5KV'2(X],TG4-/T:.*'3M%EEU&VTZ.&
MVD2,?+<'P=\>?\'+G_!2']J[0?C5\8OB+\/_ /@F1_P3_P#B)%\(] ^"GPT\
M41:2?B]\5]+O];TN\U[6KA8&A)O[G0=<OKGQ'=:9J>HZ9X=ET_0?!U_HDVJ:
MGJ] ']K/ASQQX+\8I/)X1\7^%_%*6LC0W+^'-?TK6UMY4"%XYFTV[N1$ZB2,
MLKE6 ="1AEST5Q<V]I!)<W<\-K;0J7FN+B5(8(D'!>261EC102 69@.>M?Q6
M_P#!0C_@@SX5_P""6GP0U[_@HE_P1_\ B)\;O@C\>_V7K;2?'OB[P#=?$'5/
M&/@SXL?#30YX5\;V6NZ7K)6>^DM;!W\0ZKI5_J,OAV^T2RUNWATJ'4O[+FA^
M^OVQ?VRK+]OK_@V3_:$_:QM--L_#VJ_%3]D#4]1\6>'M+U!K^U\-^-]-UG2]
M)\6:-;WODVTDD-IK=E=F 20QRI;2Q12J75R0#^E>VN;:\@CNK.X@NK:9=T5Q
M;2QSP2J"5+1RQ,T;J&!&58C((Z@U#)J6G17L6G2W]E'J%PAD@L)+J!+V:,"0
MF2*U:03R(!%*2R1LN(Y#GY&Q^-G_  ;P,S?\$7/V 6=F=F^$>LDL[,[$GXE>
M.>K,23Z#G & ,  5^0'[<3N/^#P#_@E<@DE"']DG7RT8ED$3$>%OVU<%HPPC
M)YYRIR50G)1"H!_8I/J%A;3V]K<WMI;W-VQ6TMY[F&*>Z8=5MX9'629AW$:L
M?:N9B^(G@&?Q</ $'C;PE-XY.GS:L/!T7B+29/%!TRVE\FXU :$EVVI_8X)0
M8YKC[-Y4; AV&#C^-W_@YK'QDG_X*)_\$=-+_9^\5MX%^,'B#QKXO\+^!_&0
MBCN3X2U3Q3KFB^'9_%,%I/+#!-?^'M-U.^U?3MSI(M[:0-#(DH1A^N__  3]
M_P"#?3]C7_@G_P#'+PS^U7X7\7?&_P"+/[4>F:3XSM/%'Q>^)_CV;5)/&>K?
M$33;C3_&&LZGX;MK6#34GOA>WLEJ6>YNH'G\ZZO;ZZ!N& /W<K\!/^"[O_!2
MO]H_]BSP?^SY^SM^Q3\,[OQW^U_^VQXUO_AO\)_$=UI;ZIX8^&D5C>^&]/U#
MQ'J5J\,EG=ZQ=S^)K6#1_P"T'CT;1;.TUKQ)K;BVTJ"WO/W[IK1HS*S(C,A)
M1F4%D)ZE202I/?&* /Y"+S_@@5_P5GU[PDOQ@UO_ (+I?M +^U@-%A\31>&;
M31=6M/@U%\1K.(W6GZ-+J6G^-;:/_A&TO!';75]%\-)(G7>_]A74"JDGVY_P
M;^?\%'_VB/VQ? ?[2G[-W[:5[X7U#]KK]B'XI+\*OB%XB\/K9V;_ ! T,/JF
MEV/BV[T_3TBTR;4+?5_#^I6&KZMHT%IINH/<:==C3=->[$+^)?\ !37_ (./
M/$7["'Q&^-WP5\'_ /!.[]ICXB^+/AG>OHNB?%SQ+HFM>%/@)K,DFBC4)/%U
MOXFL_"VM7.M>&='DN+666'3GMUU6**\@&KZ08S<)N_\ !LO^S9HWAKX ?'O]
MN+7?VB/ 7[17QQ_;O^*<OQ'^*^H_"_7K_6_!GPXN;"XUC5K'X? :W:6/B2Q\
M364GBVZFU[3]?MTDTVR30-.TU#9VK7NH ']-M%%% %*]U/3=,6)]1U"QT])Y
M/*A:]NX+19I<%O+B:>2,22;06V(2V 3C J[D$9!&,9SVQZY]*_GZ_P"#F;]E
M7_AI;_@E'\;/$FBQQ1?$#]F2;3/VD/!&IK927FI6G_"O9'N/%MCI7DR13P76
MK^$9]6M1+$S,&6,F&<+Y3>L_"+_@I)X/O?\ @A7X?_X*(7/BV*.3PO\ L7WW
MB#6-9"+)<O\ &CP%X2N_ NI:3%:W]K.@U/5?B[HDFF:7;ZA;26L\NH6,DSS6
M$XN9 #]G[/4M.U#SOL%_97WV>0Q3_8[J"Y\B4=8IO)D?RI!@Y1]K#'2B[U+3
MM/,(O[^RLC<R>5;B[NH+8SR\?NX1-(GFR<CY$W-R..17^?7_ ,&ODG[07[&G
M[>>F?!7XW3RW_A#_ (*=_L5^%OVUOAM=S>)IKP)#'JFHZMHFL7NF7#/:GQ#X
MBL=6\266IW%K</J$T.E:8UY">(-/_1'_ (*9ZS+^W1_P<4_\$W_V$K;0KCQ-
M\./V3=);]I3XQZ4=2:WTJ:[NK=?%5G=7C1>64&FZ;I/A^VELA-]IOI-26")X
MS)L(!^LG[<W_  3A^/7[3'_!07]A[]JGX?\ [=/CGX%?#7]GC7M-U#Q[\ =(
MUC5;#3_B)9Z/XBCUVZCT+3M/U"VT;4[[QM9^=X.\4R>*]/U.&QT&1)M+CEE$
MUC/S'_!P#_P4V^+G_!+?]BOP[\?OV?\ 3_AOXG^(^J?M > OA??Z#\08;O5=
M/MO#?B?P=\1/$5_?#2])UC2=12^6Y\*:5%;SR3^1'!=S,\4A>(C\QO\ @M<\
MB_\ !P/_ ,$"46214?QEK.]%D=5;'Q"\.XW*K!6]""#N'!R.*^0?^#O_ /X)
MM?LS> O@KJG_  4F\/Z7XNC_ &FOC!^T=\%_AAXRU2Y\6:A<^$)_"UI\'?&N
MD116'A.0?V?87HL_AKX85KR$F1I(;N0C-W)0!_<?\-_&=IXW\%^$M>74='N]
M3UCPIX=US5+?2;VVNHK6ZU;2K2]N%1(9YWC@6XFD2'>QRJ@;V()K^8__ (-K
M_P!J?X\_'[QG_P %;4_:!^,_C#XD:3\)/VOE\,> CX[UT7MEX'\+_P!L?%>*
M32M(EN?*CTW3#%I6FHT6\0JME %"[3G](/\ @E3_ ,$?_P!C7_@FYINJ_%/]
MF71/'FE>*?CO\+?AS8^/7\6^.=5\66-Q#IML?$,#Z;9ZB"FFR/J6KW<DIA=E
M,9CB4*B#/\C7_!%'_@G5K/\ P4E^-G_!5CX1_%KXT_%3X?\ [%GAG]L;5_%'
MQ.^&'P;\71^!=<^.'Q*?QQ\3++P]X3^(VMPZ;>:EJ?PGM_"'_"23:GX>MKBT
M:?Q!-H^I6MQ:7NGQ72 '^B5X;\:^#?&4,MQX0\6^&?%5O!(T4\_AS7=+UN*&
M5 A>.633+JZ2-U$D99'*L!(A(PZYZ:O\_;_@L)_P2X\#_P#! C1?@5_P4M_X
M)D?%#XP_"67PK\=_!/@WXI_!W6/B=KVK>$O'FA:C<:GXCTW39)#$FKZIHNI'
M0KKPWXKT#Q'JFJZ5=Z/>VUY8V]IJ5M=37W]+W_!9'_@I5XA_85_X)?:U^U+\
M,[*$?%OXK:;X#\"?!:&^%HPT3Q[\7-%EO=*U^?3[M+NVOAX4T^'4-6^Q7!>S
MEO+2UANY6@D9)0#]?=?^('@/PI+#!XH\;>$O#<UQ.EK!#KWB/1](EFN9%#I;
MQ1ZA>6[R3.A#K$H+E2&"X(-=1;W%O=PQW-K/#<V\R[XI[>5)H94R1NCEC9D=
M<@C<K$9!YK^/W]DG_@UC_9H^-7P<T7X\_P#!2_XD_'/]IK]KWX[^'[+XA?$K
MQ=/\5=;TC3_"NL>+=)COK/1]%GL'DO\ 6[SP]:W=I!/J>MW]_IT][9B#3-*L
M-%AAL6X[]C/7_CI_P0W_ ."P/PV_X)3>)_B?XW^,W_!/G]L_P]=Z[^ROKGQ5
MU^/4_$WP?\86ECJHC\):3J)AACNHU\1:3:>%=8T2PL]&T:>U\7>&?$%E;?VI
M8ZG!>@']EDNI:=#>0Z?-?V45_<J7M[&6Z@CO)T&_+PVS2":51Y<F61&'[M^?
ME;%MW2-6=V5$16=W=@JHB@EF9B0%50"68D  $DXK^.K_ (**22+_ ,':G_!'
ME%DD"/\ LS:YNC$CB-B(OVQ""4#;">F3C) 4$D*N/ZI/VG\_\,T_M#X)!_X4
M9\6L$$@@_P#" ^(.01@@CL000>10!['#JVE7%G+J-OJ>GSZ? )#-?0WMM+9P
MB)0TIEN4D:",1J0TF]QL4@M@&OP&_9__ ."KWQ@^*'_!=[]L3_@FIXDLOA/9
M?L\_ 3X"Z1\3?!/C*Q:>#QGJGB"^T/\ 9]U.:SU/6Y]=ET2^M!<?%7Q#%]DL
MM.ANH4TVT$C[H+O/P)_P:Y?!+P1^TY_P04^+O[/OQ3CU6^^'GQI^-/[27PU\
M;P:7JEQI>K3^&/%WA'P)HNL0Z=JL):XTZZ>RNIE@NH/G@E(E0;AD_C'^S?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\&O-H]_\?/^"^MC'GS+S]M/[(FT@-ON/&G[3D*X)X!W.,$\ ]:_LIK\EO\
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M-I-+97<+R6UQ''/ [-%,B2(RC^FC]GS_ )()\$/^R0_#7_U#-%KXC_X*L_\
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MS?:[EXY6D9@D,46V-0#\2O\ @ME_RGO_ ."$W_8Q>)O_ %(Z_L(K\F_VQ_\
M@E-X1_;!_;C_ &*?VW-:^,OBGP/KO[%]]J%]H7P_TCPMHNKZ+XZ?4-374G75
M]:OKZWU#1]A!MLV5K=AHF9PJ2[77]9* /Q*_X.+O^4-7[;W_ &3:T_\ 4CT>
ML_\ X-S_ -H7X>?'W_@D7^R/'X-\5>'];\2?";P&WPH^)7AW2KX3:KX)\5^$
M];UFRMM*\0:?++)>:?<ZIH*:7KU@\RK;W^GZC#<V+&'='#]_?M__ +'NB_M[
M_LC_ !D_9,\1>.-7^'&C?&'0(- OO&6A:18Z[JFBQ0ZE9ZB9K72M1N+2TNVD
M-H('26Y@(21F21752/Q!UK_@VYN?A9X8^'.M?L(?M\_';]C[X[^$_A/X.^%O
MQ'\=> M)TK3/!GQ^?P8LFGZ5XV^('@/1;NSL-,\9Q:+=WEE)J^GOJ3702V66
M*.1[F[D /G'_ (.E?'F@_&+XE_\ !,3]@CX>0OXT_: ^)'[5?AGX@OX6\-WE
MG=>(O"G@[3;_ $72H]5U+31'+=VD6M1WFL:A97,CVT4-CX6U*\GCFM_*==O_
M (+:?'/]KCXP_P#!0+]A7_@C=^SQ^T+K?[)O@#X]>#4USXN?&70]2;2O%GB_
M1P+_ $=_"FCZC;7.FW<R2:3I6H6T6@6=]$/$/B/4M/CNB]K9FUG_ $+_ .":
M/_!!CX/?L*?&SQ=^UM\8?C-\0/VT?VQ/%IOX;?XY_&2%9;OP38ZE]HBU&/P;
MIMSJ&M366J:C:3O8W.MSZ@\UKICR:1H]MI>GR313?0?_  5,_P""/G[//_!4
MOPSX&N_'7B'Q?\&_CS\(+T:A\&/VC/AE,+?Q[X E>^@O[BP,1N;%-:T2>Z@2
M^2P:_P!.NK'58K;4].U*TN(7$P!^4?Q*_P"#:;_@EW^S[\!?BU\:_P!ICXG?
MM(_&L_#/X9^(_&6L^._C1^T)XETG3EO_  YHEY>+J>I6.A7V@:5=RZG<06&F
MQ:/<-+9WI,&E6]G/+=QQ-B?\&?6N:)X9_P""2_Q/\2ZWJ-IH_ASP_P#M*_%[
M7-7U:_E6WL=*T32O"'@N_O\ 4;V=SM@M+&PMY;FXE<[8X8G=CA37KO@/_@WP
M^//Q(U^PLO\ @HC_ ,%0OVA/VSO@GX6O#?>'/@'K$$VA^ ?$E_9VTY\.7WQ)
MA_MB5_$-GX>UB'1]<3PXT4]AJMWIRQ7EW'#GS/TU_P""4'_!+7P1_P $K_V7
MO$W[+OA[XH:W\<_#7BGXB^*O'^H:SXT\):'X?9D\6:1HNCW_ (=ET33+O4]/
MN],\C1RTAN9'%R+V>!X%MU2.@#\QO'?_  1<_P""*W_!8RZ\2_MJ_LN^-]6\
M+^)_%?B?Q/I&O?&[]E'QK>>%--U/Q]IES<QZUKE]X2O;(Z+%XH.JW0U6[UE=
M%L)_$@>WU"ZEU.SN;:Z?X(^!_B;]O/\ X(P?\%C_ -D;_@G;XA_;'\0?MH_L
MI?MD2W;:5X>^*%XFJ?$7X<VFHWU[H=OK>HA[C4M4\/:CI=SI=A?P75I=0>'?
M$]BNK6Z64#6,SQ_=?CO_ (-N_$GPH^+/Q!^)_P#P3%_X*%?'G]@/0/BIXD7Q
M#XO^"WA*!O$/PWL[V_N+B;7+WPR&UBTGL$V206VB:1=Z?=QZ99P16$>K+90P
M01_4_P#P3V_X(*_"/]CK]HW5/VU_CE\??B[^VS^V9?PZU9Z5\:?C+<+;VW@_
M3]>T^/3;Z/PUX8BO]6C35%LI-4L;76+O4I5L-/UG4;32]-TX2B0 '\Y?[<7[
M#WP"^+G_  =(?$/X3?MI>*/BI\+_ (9_MH_!+P=XG^!OC?P9XZ3X>QZK\0-%
M\"^#O!NE:(/$BA(KG2=2O/A7XPT%/#[3"^N/&%]H+>6R7=A'<_L3K7_!JE_P
M3C\/Z/JVO:]\<?VN=)T+1--O]7UK5=2^/^K6NG:9I.FVLM[J.H7]S-"L-M96
M5G#-<W4\S+%#!'))(P121^L'_!3C_@E%^S+_ ,%3?AEX:\&_&Z#7?"7CSX<Z
MPWB#X2?&WP!/#IGQ'^'&K2O;O>+I>H.A2^T?4'M+.>\T>\80_;K&PU&TFM+V
MT28_CC>?\&V_[37C_08?@[\<?^"TW[8_Q$_9JTZY@MX?AG%:+IVJ^(O#16T&
MH>'_ !%KT_BV\;R=1B%Y97$DL>M026K1L]FS2RQH ?;7_!+#]F/_ ()T_LX?
ML)?M-O\ \$V/C+>_'3X0?$.3XE:OXK\<77C"Y\8QMXWT'P-?:+>:9!=W%AIO
MV5K.U6%IHEM_])\^.],DJ3QRO\1?\&:7_*);QI_V>7\8?_5<_!*OZ#?V<OV(
M?@+^R1^RI8?L@?L]>'&\!_"W2O!^O^%K6<M#J?B*^O/$FGW5EJOBWQ)JCPVK
M>(O%%]+=&\OM1O$0W4D<4(6&VBBBC^=O^"1O_!,3PI_P28_9=UK]F'P;\6O$
MGQETC6?B]XL^+;>*_%'AK2O"NH6MYXJ\.^"_#TVAQ:;I%_J5N]G:)X-AO([N
M6Z:XEFU&XC9$BAA% 'X9?\&SG_)\W_!=C_L\*]_]6#\7ZT/^#;/_ )/K_P""
MWO\ V=0__J1^,:_9G_@G-_P2A\(_\$[_ (T_MK_&;PW\9_%?Q0OOVT?BO/\
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MM:#KNCWD&H:5K&D:G;1WFGZEIU]:O);W=E>6LT5Q;7$$CQ2Q2*Z,00:_D+^
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M]FUJUAI6AZOXJT#7X+2]216EMIK[0+;Q@+>]*20*(64@7$=NK_M7_P $O?\
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M0+/P1=OJ>L:E_9FDWFEWEU/J\"_VN;87%Y':OY5K"YB,SS2. ?B__P $$?\
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M ((AV@O_ /@N'_P7UL2[1B]\;):&1" \8N?&VJPET)X#)OW*3QD#-)_P:_\
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MW_@Z2SD.J-H4]P9[O1[75!X]=8HI!%;P0R!$@@A,D:V'V9%M)/W8_P""=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH _"'_@L+_P %&?VUOV6_%/P&_9E_8!_9'\5_';]HC]I7
M4YM'T#XFZ_X;U2?X)_#247"&V36M6M_*TR^UF73K'Q#K.J1:OJ6E:3X9\/Z0
MVKZE/<_;;6W'YM_&OQ=_P=+?L7_!Z]_;#^('Q,_9!_:3\+?#2VG\;_&?]FKP
MGX%M-*U.S\ :8/M_B232?$-AIFD7%_%HUG T]U+X<U5=4L])CO\ 485O/LLE
MO-]L?\%3_P#@L[\:OV=/VJOA=_P3?_X)[_LVP?M5?MR_%CPQ;^+KC3M7UG^R
M_ ?PK\.ZE/J":9J/B:2)[:*YNOLFCZCK.M1ZOK?A?1?#?AMK/6]5UI5O;.UN
M/@W]K[P%_P '-7Q0_9(_:0\3_M#_ !H_8)_9T^$.B? [XG:G\0_A]\-_#WB3
MQ)XY\1^"'\&ZMJ'B+PWIVM>1XOT5]9.FP2^'([^7Q!HMF9+N6^MEF!!(!_07
M^R7^W1I_[9__  3B\*?MO?#_ $FW\):IXV^!OBKQRWA>XNX=?A\'>//#6AZP
M-5T&ZG00IJ-OIGB'2I#&LJP2W&GM +E(I9)%7^9K_@G-_P %/_\ @O%_P5K_
M &;](L_V6F_9Z\">+/ WC3Q)IW[0/[6/Q2\ V>E>$X&UB..?P-\.?A=\/+%M
M0MM=UG1-(CN-6\9>(TL9_LC:EHENJ6LDP,_W1_P;H #_ (-Z=*P ,^&?VJ"<
M#&2;KQ7DGW/<UQO_  9M0Q)_P23\33+%&LTO[7OQA665459)5B\%?"3REDD
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M6NW\(17 LI--MKCPUI!OM,%Q'!?K%<*S0K<$)ZA_P7F_Y0\?\%"/^S<O&/\
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MB1X<_:G^$$WPMF^QQW'B :I?3ZG!K<7A^X.9[25M.CBN+LP*PN!:V\,BG*$
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M\MK#-;$P+(_V]_P7OL=+TK_@LK_P00\5^")_)^,=_P#&+Q)H&MC1-/4^)O\
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M(;_3-7T>YFT[4!%:_O5%''#''%"B10Q(D<442JD<<:*%C2-$ 5$10%15 55
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MC_BQ<XXXX/BSPP"/H02#Z@XH ^[OA!^UK\(/B_\ LE^"OVSM-UN/0_@QXO\
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MQFN;JW.C&;P;H]VWV^W^:&]U_2YG?$#0R^J?\%=_^"C?[=_[/OQ5^!7['?\
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M)^);^72K.WA\1Z;9V]A#;V]CJFK1/J&E:_IT&K7&AM+JFC7UW%8SVL/Z&_\
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M=(U'Q'>^(?AQ+I=S=27PDMYK>\M_^$9@L%N[9D=]1DM[=TFO)*_L1H _"/\
MX(Z?\%>/$'[=6M?&K]E#]J?X<V7P$_X*!_LJ7UUIOQH^%-H]Q_8WBC0M-U*U
MT.7XB^#%N6EDCTT:E?:3#K6GFXFAM)==T:^TJ>[T?5;26/\ ,;]J;_@L?_P5
M \*_\%B_VQ_^":7[(OPT\#?'/Q#_ ,*\^&^E?LL^$M4\-:3H.G?##Q1XM^$_
MPT\<^,OC'\5_'EQ?12:OX.\"G7/$-VFBZA]ELM0OM8T#3IYH;*QN'NM2RLM,
M\/\ _!X@R?#>18[7Q9^PO<:I\:H= L4M[9O$B^%-?AM5\630*PN[I[?2/ =V
ME]<F-S.^DV62;>(-S?[+<44G_!Y/_P % WDBCD>#]BK0Y(7>-':&1OAY^QO"
MTD+,"8I##++"70JQBEEC)V2.K '[(_L&)_P4[_9P^%W[2WQ6_P""L_QK^$7Q
M1TKPYX<3XC>$U^$/AZSTM?"&A>$O"NH:KXXTZ2.QT[2H;H2K8Q&P@2&19+R.
M>:.8+=A$_'?]EW]KS_@OO_P6*TWQK^U9^QC\1?V9/V+?V1K;QGKG@KX-^'OB
M3X,3XA>+/'B>%[\P:GKVLW#Z5JFIP3R1G3H[PRBST:/4)=2T[2(98[*XNY_Z
M\?'G@S0OB/X'\8_#WQ/;F[\-^.O"VO\ @_7[52JO/HWB72KO1M3B1G5U21[*
M\F6-RC!'*MM.,5_&Y\)O^"7'_!?3_@C]J7BOP?\ \$ROCE\"_P!JO]D9_$VM
M>,/"OP ^-+67AG7[(ZO+IS:M:,NMW&@6>D>);V&-XK?4-$^(USH=VVF1:C>:
M3:7M[-ITX!^HG_!*/]NW_@I#XP_:4^/7[!O_  4X_9_BT;XM_![39?%_@_\
M:@^&GABXT;X(?%/P_=7VG-8:#:S0Q'1#K]UH^L0:QH3Z1.CSZ?HWB6TUVRT_
M6-*$=U_057\X'_!+W_@NEX]_:;_:H\0?\$[?VZ_V6O$O[(7[;_ASPWJ?BBR\
M.S27%[X-\;Z?IT;ZU+!I8O434])OQX3N+36[%W?4]&UFTL]4FL]6CGBCLF_H
M_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _E>_X*D?L _\ !0#X+_\
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MX(U[4)+:[@MITU/2+'4_#.H:I9:CIEM=#4]&U"VCTKQ'J=Q%\&ZA_P %%O\
M@YFU3P/J/P)B_P""0'@O1_V@[ZQMO#T7[0]M\3_#Q^$.E)J:R:8_CZ'P\OC:
M6S-S D-WK<%I'XTF&F7*VRW?ANY_=Z-=?UTT4 ?C7_P23_X)]?';]AG]C#QQ
MX*_:3^,VN?'W]J;XV:QXO^(WQ?\ $]WXS\3>+_#UIXIUK2Y],T;PIX.U#Q=+
M%<C3-*TY+2VN]02QT:VU34Y+B[&G6ENL*CY>_P"#;W]BG]J']B3X ?M2^#_V
MI/A/J'PF\2>/OVI?&'C_ ,(:7J'B'PAXADUKPAJ=NB66LQ3^#_$'B&TMHIW!
M5;:^GMKY<9EM8\U_1K10!^=O_!4W_@G=\.?^"H/[&WQ%_96\?ZBOAC4=9FTW
MQ9\,OB"FGQZG>?#GXG>&GFE\.>*+>RD:/[5:36]UJ?AOQ#:1R0W%YX7\0:W:
M6=Q:WLUM=P?S_? O]JW_ (.3/V"_ASH7[*OQ4_X)I>'?VZ+KP!:Z#X%^%'[1
MG@7XLZ'HEEX@\.6<*VFCP^.)9=0\W4KK3=.@CTQ]<U72O \T,=K#+K$NJ2$Z
MM?\ ]B=% '\[_P#P2P_9\_X+ >.?VJOBE^WQ_P %._BI<_!_2/&W@I/!/PK_
M &!/AKX]N==^%O@2TCNO(_X2#Q?H-MJGB/PA;>(=/M;(3Z=J6A:[K'B#7+S5
MI]2US6[:U@M]!3X?_:%_9 _X*=_\$K_^"F?[0/\ P47_ ."=GP/T+]MOX!_M
MBVR7GQ^_9ZDU?3/#/Q$\&:Y80V]U]LT/5-1NX=0N]/CU>S;4](U#0EUVY*:S
MJ6B:OX2DM[6RUN'^P"B@#^'S_@H3X3_X+S?\%J?V-/BCX0U;]B2T_8V^%7@U
M/#WBKPS\")O'OA#7_C)^U)X^@\4:?I=EHUQJWB?5/#>G>"/ _@.SC\0>*;XZ
ML/#-UKEW_9*6HUVV$#0?NIH?[#O[2WQ!_P"")'PG_8NT'XK>.OV/_P!J+1_V
M8_A]X1@\8^#O$RV6L^"?B+X4T>TD?PUK/B/P=>WDY\.:G?VIT7Q)>>$]7%X=
M,N)YM-OI2GDS_M?10!_']\)/V_/^#C7]E/X?^&OV8OBU_P $D5_:I^)'P^\/
M2^"O"W[0_A'XPZ%;>&OB/IWA.&72-'\7^(Y+:>Y@N;J]MK:RGGEU.X\%ZYKD
M*?;;[2[34[Z=U^HO^")?_!-/]M'X6?M-_M<?\%0/^"D%[X'T+]JW]L:VTC3K
M/X/?#FXM[G2?A7X.6XM]0OM'\0W.G-=:,^JVD6D>$_#.BZ=I6M>*FL-'\,R:
MAJ_C#Q#K.NW<MK_2_10!_(M^T=_P3N_X*6?\$TO^"@/Q?_X* _\ !'CP)X$^
M/OPM_:I:XU?]I+]CWQAJ^E>& /&$E_/JMWK7@ZYU+6/#5E%:3:I?ZEK>A2Z3
MK6FW>@W-[?Z)<:-KNDS6D:\O\8_CA_P<D?\ !3GPUIW[/7PR_8ML_P#@EO\
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M2\36LT&IZ7>^*;?2M:U:U5[O;:Z?J>K:S>:!<Z7I=I/IEGX/>?4+J\']C-%
M'XG?\%H/V2OV_/CM\-?@K\6/^";W[0&O?##X\_LO?$?3_BA8_!67Q1-X9^%O
M[0.E:(]MJ:>#O%]M"L>E:OJ=I>Z38KX>T7Q>TG@G5+>[U32=8&F/>VNN:;^8
M7C3_ (*5_P#!QQ\7_A_XI^!'@3_@C%I_PC^-WB'2G\#ZA\:_$7Q3\.:M\-/
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MFRXM?#WBQ?#^KZU9^(-!O)+)-"OK?Q+:^%]+TO2M0U35;'0=6U6?2KRU_J^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
4 !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img75897552_1.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_1.gif
M1TE&.#EA+@7U _<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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M?>S+0@S,4P+(QCS-L8',=+&Z$W@ HZ</L6AWO12&FD<.#@2*]MLY%2PU8&S
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MV9)MV/U:V70]VH#-V(K-V9Z=VH<QV2;<GG5'#NB #A1\CNF DO=XRN:0#N@
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MQF\$QW!,.&X4QW(TQW-$QW34)7)41_U"!/991)[8&PH$AWD(P^AK&VZ00LK
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M@(<4-P&9!^/I1@"1A^F-MO0\1?&(B/%[/?D43^-3O0?=56Z//W)Z@/=$ '<
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M/??8FQ\^^>.?K[VWSJ._OO?P@\^^__SEOW\__?C'K__\^^?_O_\"V+\!V@^
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M%EQI)/B 93;*D1A_Z*,<C$1'/O8D W(F2%BS6.0V$#$11,!R'*4TR#MNZ:6
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M&_)P#_N0#[TA'!Y0)98OV9:-)68A <E!Z?Q!$++F'=AB%H"*!>1D4,HO&V0
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M#[,O$S,P ;,P$;,Q%],Q%1,R*?,O < M+=,P*U,S,Q-5_('K3DY09B%?;+%
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M!"U300P*34)7%5<SR-BM;YG*S([9NH.D9JIMFH1##P#9HQ_6H/(S:*%2W@"
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M]#%Y_SAJ;9452N3Y6CZT:CI2-#$X=3\<_WAK!2GL$FP7 7]T%&YU5CN=T6!
MUQP=E%'9U3!ZYGQXH21TU%JPD7)RI17T1E/_9F'[\0X0)A6*\DT ($X>M$=0
M=("JIW$@]W$O*(/[-8/C<5]G X,YJ'']=4T 1A(G!Q4;. ,G2''.$5=6(@!
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MUXO_O%F\$/70T=E 9OUPO-FP#6*"TS,=TUTMTY;ZT%Y-UK4Z"[O<NU",1>J
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MBA@U;8"LF- P?"&')[.ASE,YD> 'N:N=Y$O PY- YUO"/HI YGO"JJC "[3
MRL&^E-"^$.,;DZ@'TALLF)B%>WB'.P&A<+ WDL#!<8@OD4@<5=D]O>(K'#K
MD8"'-$L'X?('HY*_SY,(?< =CT,^CU L;8 =EN@'=?_H%;%["22$0B9DQ&)R
MP@F,Q 6A/BJ<0GJR0I70/FX AV'Q!G2H!WJH!WB0 :7Z';!*BT8+A\?*OX?
M!SB,%?1;!S$<(=H!,HYP!YDIF([@!_]3E7#H@G9X!W1(LUA9E!E\E<79!G4(
M1G4H.UCY!BT<">2)&6Y AW=HAW88AZF2.)]0/IYS1'"4Q$6"Q$841W^0PDI,
MQVS!1)/0Q';@K5G(AWJHA^Z[#W[(AWM4OY1@Q2#"QWR(1J3H!W^<-*K@!WW
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M#_6PQ]>%I_0N<7K!OT3+]QBJCWS']WS(AWG0'WW1+WV67WQ1GWQ]K7Q\GZS
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M8S[H S3P@_]&K/_>0^0XZDT0JGO^1M;^[4V *P^9T]>Z9CE,)F= PWS&;6B
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M$6E%97(5=J(WXP<^@($/T( /\D"&_S^!BGFS1E9Q?QDA;6S4'9"$<RHD$UU
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M5M37-M#7ONOK5_XP"_A 6.W4,R!AI[3"</@0OS1%+N=KI>U;OW'S)OD@".^
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M^;5/^ZCO_J^?^_ O^^U?_^]O__$__[&__[BO__V/_P !0* _@04'&BQ($"$
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MUM&.=\1C'O6X1]FXL%_]*(4YPO&-;!32'._ 1S_>XH]YI ,<VBBD-]PA#WZ
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M&S#! U^86HJ<C4899O. 4V,Y^DB$I(WI6#-1/NC4Z T\@-'SL)0066-.-ML
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MD7J4I" =*4I+RKH5DE!]A!S60@"1*@/HH2"K2*0>+K<B1Y;L'5?RASIJU$X
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M,-R^63W8)A%(4&2./^#AX"@B1(DUD@=SVI&Z;*C#5@)RH:H(>A"@U@@>G0,
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M0I>T1W\R2#_T(_]C=,-&-_1F]$57-W4[[$=_7BF S+\"ACHXF#E Q&2\,K*
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M;>Y9&M^:YS*'N:Y[#G2?!_WG12<D.WW:2VB<;!R6]L?&CSV152Q9&U2\D1Y
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M<*</U*T.-:K-G6ITKUK=Y>XUN]%];G?+.][T3O>\[5WO==];W_EN=[_AC>^
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M>JF5BJF6"I&B*:E(5)H?A0\EF0V&@R"T^9:,(Q7TT*+@4#"_P0\@D@WRT(@
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M@DM")T1""<&]W1-"*IQ"*P0^'IRX!ZS Y)- +O3"+M2UY:M"+/Q!,H0^D^/
M$U1#' PT$!Q!."3!.'PP$VQ#.V3#G=(Y&EP_&73!&?Q#/PQ$&(R_.[Q!=ZD_
M#$Q$16PF_3O _^L_ $3  93$ GQ$1XQ$2TS 1=Q$^]O",/Q""OQ$401#@KI
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MU_W-;P=RN"5)(97*:0?J (<.UOKYR(<\^F?P\'X:LZ7,#@>QUWUXT ,2+0Z
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MF'=^]'/^],N%)+W',[N3P;^]QZNV#>6\J9;VP^,#.N@J[=M^[9O_?^PG[%S
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MUNN\S1WVU"OH'::V>8<B:-;1)JYT4+HG'-+02:^B?GS3QAOD-NH'GK6VD4=
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>']\9^,E'_O*5WWSF/]_YT8?^]*5??>I?O_,! 0 [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img75897552_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_2.jpg
M_]C_X  02D9)1@ ! 0$ D "0  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '( QL# 2(  A$! Q$!_\0
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M_P 'M_\ _'J[JBCGEW#E78X7_A2GA3_GEJW_ (/;_P#^/4?\*4\*?\\M6_\
M![?_ /QZNZHHYY=PY5V.%_X4IX4_YY:M_P"#V_\ _CU'_"E/"G_/+5O_  >W
M_P#\>KNJ*.>7<.5=CA?^%*>%/^>6K?\ @]O_ /X]1_PI3PI_SRU;_P 'M_\
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M_P"#V_\ _CU'_"E/"G_/+5O_  >W_P#\>KNJ*.>7<.5=CA?^%*>%/^>6K?\
M@]O_ /X]1_PI3PI_SRU;_P 'M_\ _'J[JBCGEW#E78X7_A2GA3_GEJW_ (/;
M_P#^/4?\*4\*?\\M6_\ ![?_ /QZNZHHYY=PY5V.%_X4IX4_YY:M_P"#V_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB'XU\+^*/@_>W-_IEKX!^,'@;4K.ZG2V2VM[N>=2GFR_(,^5B1B3TSWK[O\
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MG"-:ZELW?\3YV5*IAVW'[F>U12!UR#3RU?/_ .S1^T%:?$.QD\'ZVAT7Q]H
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M%:R2;N]?%?AWQAXJ_8RTG6K75_A];P?#V[\6321:S;ZJ@2TM[F8!"8%0L%0
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MWXK[=VA6)4 'UKYW\4?L@RZQJOBB/2/BAXP\,>$O%5W->ZSX9TY[=H9Y)O\
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M +#6I_\ I=/6U/J1+<]*^"G_ "3^+_L(ZE_Z7W%=U7"_!3_DG\7_ &$=2_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFOF7QYX9_:#\'^&9]6TGQ]:>*[RWDC8:1%H$-NTZ%P' =I, A=Q_"O4_@_\
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M!@>AKGN:CJ*8:533 =1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!\W!P:X,?L?Z%R?^$R\='GOXDN?\:]\91N)[_6E4TK=3KABZ]./)&3L>!_\
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M!GG)_.@#O5SM&>M+2+P!2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML=9^'$&AZ!_9%N/[837XKEL"!=A\E8P?FP.,\9H ]SHIJ<J#C'UIU !1110
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M4=CP68*!DX Y-=!10!P7Q[_Y(=\0S_U+NH_^DTE:/PF4'X5^#2>IT6RR<_\
M3!*H_'@!O@?\0P?^A=U'_P!)I*O?"/\ Y)3X+_[ ME_Z(2@#JP O X%+110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 F*-HI:*
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M_@X !_P@U@?H7_\ BJ7_ (8W^#?_ $(EA_X__P#%4O>(Y,+_ #2^Y?YGJ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH 3%&T4M% ";11M%+10 FT4;12T4 )M%&T4M% ";11M%+10 F!1M%+10
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MQAJWBOQ)XIT(ZAINNZGICVW]JHF_<[9)"280_+DGIZUV=O\ M1_#^X\8^/\
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MOA/#\0_#[ZQXET-[S^SWM]&TB>ZO8+@?>22W1=ZX')R !D>M 'MM%?/GPO\
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M\+[76K?Q1X5\ ?\ "%6T">)/!&@BYU>[NO+7=9/<K$\D(S@; 5 W9/7(X/\
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M^ OV^KCX?_LZ?##Q/\2_"'B:2\\0SV^G+J48MY&U!GBWF[CB1\^62<!,!N@
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M(Q5_;;^#=]XC_;5\->"_"^I?9M.^+5O9CQ5I=JHR8[*?>9WQT&Q,\G^$^HH
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M9OAW_P %*/C!IE_NCA\:^';/7=-D?Y1,(66)U7U(8M]-IH _.75/%OA#P_\
M"/5/'6I>)M=L?VJ-/\7,\BS37(E6%9<E7!_=B,#/'!+87IQ7U3^VAH/BW]H#
MXR?"2X/P<USXF>&+/P@-4N+'3YGL+::YN5W/&;M>$*;(SM!R<X .:W/'G[(G
M[1?Q6U+7/ 'BJ3PC?^$=6UN.ZNOB(T$*:Q/IZ.KI:$(H8X* X*\'^+;7NWQF
M\(?M'?#WXB:/K?P5O=)\4^#(=)CTR3P7KLJ6Z6TB+M6=9,J6X5?X^#N&W!!
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MV+R.TGAB[6W>YWA1B0E3D#''^]7F/_#&6O'K^T+\5_\ P<1__$5].8YSWHH
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M\P_\,8Z]_P!'"_%?_P '$?\ \11_PQCKW_1POQ7_ /!Q'_\ $5]/44 ?,/\
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M40 !5 \O@  "I/\ AC'7O^CA?BO_ .#B/_XBOIZB@#YA_P"&,=>_Z.%^*_\
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M] IH ].HJII>I0:OI]O>VLJSVUQ&LT4T?*NC %6'L00:MT %%%% !7SWI?\
MKM9_[#6I_P#I=/7T)7SWI?\ KM9_[#6I_P#I=/6U/J1+<]*^"G_)/XO^PCJ7
M_I?<5W5<+\%/^2?Q?]A'4O\ TON*[JLY?$QQV04445)04TDTZOGKXG>*?&_B
MKXJ^)/"OA'Q,GA.'PMX=BUJ2;[%'<M?74SS"*)]X^6%5@.[;AB7X(QR ?0>3
M2UY/X>\<>)_BI^S[HOB?PE_9^F>*=>TBWNK9M1W-;6TTJJ78@#+!<L0O&<*#
MC)-<[\"O%WB2^^)WCKPO>>*&\>>']"BM5'B!K2*V:'4'WFXLLQ8238HC;@93
M?M;/!H ](^-'/P>\=#_J WW_ *3O4?P..?@OX"/_ % ;'_TG2G?&5MWPA\;@
M\%M"OAM'?_1WKD?V>_BKX-UKX9^ ]%T[Q;HE_JXT.S3[!:ZA%)/E;=-PV!LY
M&#D8[4 >QT4BG*TM !1110!\R?MK6E[H,GPJ^(RV,^HZ'X%\4QZKK4-K&99(
M[)X7A>X"#EO*+JQ !(&2*P/VDOB!X2\5>!+GQOX:_:/N/",.GZ/-+:6/A[5[
M+R[^8*SQ[XW1Y&<DJFT8(],U];21K,I5E#*>"&&17"VOP'^&UCKQURV^'OA>
M#6=YD_M&/1[=9]QZMO"9S[YH ^8_!6N:SX@^(7['NJ^)[BXGUZ\\(ZG<ZA->
MKLE>=K& R,X('.<YX_*L'X>^'?BA\?/$7Q@^)/A=? ]UX0\<32^&K5?%27<D
MSZ5:B2V'E^2P58Y6:5SG)/!K[>OO"^D:IJ=KJ-]I=G>ZA:1RQ6]U/;H\L*2#
M;(J,1E0P # =0,&I-!\.:9X5T>UTK1M-M-)TNT3R[:RLH%AAA7^ZB* %'L!0
M!^;'BS7]9U#]B4_"WQ!J36OC/X>^.M(\+7=W;-^\V+>1_9+F/<. 864KD?\
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M< X%5]4\#^']8UNVUF_T'3;W5[:WDM8-0GM8WN(H9 1)$KD;@C D%0<'/(H
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M:VA01Q0PH$2-0,!5 X  ["@"<=*6BB@ HHHH **** "BBB@ HII;G&>V:-U
M#J*9N]Z-WS$9H ?13=V.XI<_+F@!:*;N'7M2>8/6@!]%,\P<G(Q^=!;:,D\4
M /HI@;/>G9H 6BBD+!>M "T4W=GZ4WS O5E_.@"2BF[N^>/I2;O4T /HIN\<
M#-.H **** "BBB@ HHHH **** &DFH;B218G,7S.!\H/3.*GZFFE%[\TD^HG
MJK'R_=?$S]J)+J=8?A-X7D@61A&[:W@LH)VDC/!(P:B_X6=^U/\ ]$C\+?\
M@\_^O7U(OZ4M>DL7!+^#%_?_ )G)[&3=^=_U\CY:_P"%G?M3_P#1(O"__@\_
M^O2'XH?M3J#CX1>%BV#@'7/;ZU]34QD#-R!^5/ZY#;V$?Q_S&Z4EJIO\#(\)
M7NKZAX9TR?7K.'3]9DMT:\M+:3S(X9L#>JMW .1FO ?VOI(=-\;? C5=<*IX
M+LO&2'4Y9R!;PS-!(MG)+GA5$Q'S'@$CD5]+CC%4?$/AW3/%FBWFD:SI]MJN
MEWD?E7-E>1++#*I[,C @BO.;N[V.I;'S#^W'XV\<> ?AQJOB6'2OA_XC\ 6
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M\PKS_7[#X[>&_CMX'^'FD_M!7_BG5+X?VOK<%UX4TV"&PTF-MK2.Z(6#RO\
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MG$3@<,25#@'H* /H]>5!/6G4B_=%+0 4444 %%%% !7SWI?^NUG_ +#6I_\
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M -D=VC@_*3$?+<8.=B'(P:]!AM(58R+"B2-]YE !/.>2.M3>6OIFE "@ =*
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M "BBB@ HHHH **** "OGO2_]=K/_ &&M3_\ 2Z>OH2OGO2_]=K/_ &&M3_\
M2Z>MJ?4B6YZ5\%/^2?Q?]A'4O_2^XKNJX7X*?\D_B_[".I?^E]Q7=5G+XF..
MR"BBBI*"OE_XH>'K;XI_'?QOH?B&\OH=+\-^#K>_TJ&VO9+98;J9[C?>?(PW
M.GDQJI.0.>.37U!7FWQ+^ _A3XK:M#?ZY#>Q7<=N;%Y]-OI;1[FU8Y>WF,9'
MF1$\[3ZG&,T 4?@OKWB'X@?LZ^#M7EO_ +'XDU;P_;RMJ+P"79<-"/WQC) ?
MYOFVYP<]JYC]D&RO]+\._$#3M2US4/$=U8>--4M3J6IRAYIMICYP %49SA0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SWI?\
MKM9_[#6I_P#I=/7T)7SWI?\ KM9_[#6I_P#I=/6U/J1+<]*^"G_)/XO^PCJ7
M_I?<5W5<+\%/^2?Q?]A'4O\ TON*[JLY?$QQV04445)04F*6B@!-HSG'-&T>
ME+10!R7Q<_Y)3XT_[ M[_P"B'K._9_\ ^2$_#O\ [%ZP_P#2=*T?BW_R2OQE
M_P!@6]_]$/6;^S[_ ,D)^'?_ &+UA_Z3I0!W]%%)0 M%%)0 M%%% !112>M
M"T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%)2T
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MA=NS/(YS7;#Q]\;5SM^$>AX[?\5<O_R-0![317B__"??&WO\(]$S_P!C<O\
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M9-9N$G66ZP4)+,H3:,N#G  .+O[2NM?$>WT'2])^'NAZA?\ ]ISM%JVJZ3+
MMWI]J!\QMUF94,KYVACG:,M@D 5Y=XCA\>Z-\+?"7@WP#\,/$OA3P[<-<1ZZ
MUI?V;:S! &SB*1IBOG3LSL9MS,N6(&[H ?0WPA^)5G\6_ .F^)[&VGL8KHR1
M26=QM,EO+%(T4L98$AMKQN-P.#C-=HO2N)^#5A!I7PUT'3[7PG/X(M;.'[/%
MH5R\;R6JH2H#-&S*Q.-V[<2=V3R37;+TH *6BB@#EOB/XTD\ ^%+[68M)O\
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M5P .!TIU% "*H48 XI:** "BBB@!K(K=1FD\I?3BGT4 -,:GJ*4#;P.E+10
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MWW[9UA9VL7B!_ OB8?#B74UTD>,W6!+;S&G^SB40&3SC$93M#A3D<XQS7/\
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M_P#_ !FBBM_91EJ9<[6@?\+K\*?\]=6_\$5__P#&:/\ A=?A3_GKJW_@BO\
M_P",T44>QB/VC#_A=?A3_GKJW_@BO_\ XS1_PNOPI_SUU;_P17__ ,9HHH]C
M$/:,/^%U^%/^>NK?^"*__P#C-'_"Z_"G_/75O_!%?_\ QFBBCV,0]HP_X77X
M4_YZZM_X(K__ .,T?\+K\*?\]=6_\$5__P#&:**/8Q#VC#_A=?A3_GKJW_@B
MO_\ XS1_PNOPI_SUU;_P17__ ,9HHH]C$/:,/^%U^%/^>NK?^"*__P#C-'_"
MZ_"G_/75O_!%?_\ QFBBCV,0]HP_X77X4_YZZM_X(K__ .,T?\+K\*?\]=6_
M\$5__P#&:**/8Q#VC#_A=?A3_GKJW_@BO_\ XS1_PNOPI_SUU;_P17__ ,9H
MHH]C$/:,/^%U^%/^>NK?^"*__P#C-'_"Z_"G_/75O_!%?_\ QFBBCV,0]HP_
MX77X4_YZZM_X(K__ .,T?\+K\*?\]=6_\$5__P#&:**/8Q#VC#_A=?A3_GKJ
MW_@BO_\ XS1_PNOPI_SUU;_P17__ ,9HHH]C$/:,/^%U^%/^>NK?^"*__P#C
M-'_"Z_"G_/75O_!%?_\ QFBBCV,0]HP_X77X4_YZZM_X(K__ .,T?\+K\*?\
M]=6_\$5__P#&:**/8Q#VC#_A=?A3_GKJW_@BO_\ XS1_PNOPI_SUU;_P17__
M ,9HHH]C$/:,/^%U^%/^>NK?^"*__P#C-'_"Z_"G_/75O_!%?_\ QFBBCV,0
M]HP_X77X4_YZZM_X(K__ .,T?\+K\*?\]=6_\$5__P#&:**/8Q#VC#_A=?A3
M_GKJW_@BO_\ XS1_PNOPI_SUU;_P17__ ,9HHH]C$/:,/^%U^%/^>NK?^"*_
M_P#C-'_"Z_"G_/75O_!%?_\ QFBBCV,0]HP_X77X4_YZZM_X(K__ .,T?\+K
M\*?\]=6_\$5__P#&:**/8Q#VC#_A=?A3_GKJW_@BO_\ XS1_PNKPI_SUU;_P
M17__ ,9HHH]C$/:,;_PNCPG_ ,]-5_\ !%?_ /QFD_X7-X3'2;5O7_D!W_\
M\9HHH]C$/:,/^%S>$MN/,U7T_P"0%?\ _P 9K#\/^+?AAX3U'6+_ $71Y=)O
MM8N/M>I7-GX8O(I+V8Y_>3,L +MR>6SUHHH]C$/:,W/^%S>$BI!EU8@_]0._
M_P#C-(?C)X2*E?,U7;C&W^PK_'_HFBBCV,0]HP_X7-X3SGS=6S_V K[_ .,4
MO_"Y_">,>;JW_@BO_P#XS111[&(>T8?\+F\)\CS=6P>W]A7^/_1-)_PN;PGG
M/FZMG_L!7_\ \9HHH]C$/:,<OQH\)JN!+JW_ ((K_P#^,TC?&;PFV?WNJ_\
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M;_D!7_\ \9H_X7+X3_Y[:M_X(K__ .,T44>QB'M&'_"YO"?_ #VU;_P17_\
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.([T45,H*FKH%)R>I_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img75897552_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_3.jpg
M_]C_X  02D9)1@ ! @$!( $@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" +.!ED# 2(  A$! Q$!_\0
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M_05UC_P2W'_Q= 'TU17S+_PUQ\&/^@KK'_@EN/\ XNC_ (:X^#'_ $%=8_\
M!+<?_%T ?35%?,O_  UQ\&/^@KK'_@EN/_BZ/^&N/@Q_T%=8_P#!+<?_ !=
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M1_Q$W_\ !*+_ **3\3__  U.M_\ R51_J3Q?_P!$UG7_ (;\3_\ *P^LX?\
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M_P#X)1?]%)^)_P#X:G6__DJC_B)O_P""47_12?B?_P"&IUO_ .2J/]2>+_\
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M  W6J_\ R31_Q!GQ8_Z-UQC_ .&',/\ Y1Y_GV8?\19\,O\ HO.%?_#U@?\
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M_P#E'G^?9A_Q%GPR_P"B\X5_\/6!_P#EQ^T5%?B[_P /\_\ @G1_T//Q _\
M#=:K_P#)-'_#_/\ X)T?]#S\0/\ PW6J_P#R31_Q!GQ8_P"C=<8_^&',/_E'
MG^?9A_Q%GPR_Z+SA7_P]8'_Y<?M%17XN_P##_/\ X)T?]#S\0/\ PW6J_P#R
M31_P_P _^"='_0\_$#_PW6J__)-'_$&?%C_HW7&/_AAS#_Y1Y_GV8?\ $6?#
M+_HO.%?_  ]8'_Y<?M%17XN_\/\ /_@G1_T//Q _\-UJO_R31_P_S_X)T?\
M0\_$#_PW6J__ "31_P 09\6/^C=<8_\ AAS#_P"4>?Y]F'_$6?#+_HO.%?\
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M1Y_GV8?\19\,O^B\X5_\/6!_^7'[145^+O\ P_S_ ."='_0\_$#_ ,-UJO\
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M_P#EQ^T5%?B[_P /\_\ @G1_T//Q _\ #=:K_P#)-'_#_/\ X)T?]#S\0/\
MPW6J_P#R31_Q!GQ8_P"C=<8_^&',/_E'G^?9A_Q%GPR_Z+SA7_P]8'_Y<?M%
M17XN_P##_/\ X)T?]#S\0/\ PW6J_P#R31_P_P _^"='_0\_$#_PW6J__)-'
M_$&?%C_HW7&/_AAS#_Y1Y_GV8?\ $6?#+_HO.%?_  ]8'_Y<?M%17XN_\/\
M/_@G1_T//Q _\-UJO_R31_P_S_X)T?\ 0\_$#_PW6J__ "31_P 09\6/^C=<
M8_\ AAS#_P"4>?Y]F'_$6?#+_HO.%?\ P]8'_P"7'[145^+O_#_/_@G1_P!#
MS\0/_#=:K_\ )-'_  _S_P""='_0\_$#_P -UJO_ ,DT?\09\6/^C=<8_P#A
MAS#_ .4>?Y]F'_$6?#+_ *+SA7_P]8'_ .7'[145^+O_  _S_P""='_0\_$#
M_P -UJO_ ,DT?\/\_P#@G1_T//Q _P##=:K_ /)-'_$&?%C_ *-UQC_X8<P_
M^4>?Y]F'_$6?#+_HO.%?_#U@?_EQ^T5%?B[_ ,/\_P#@G1_T//Q _P##=:K_
M /)-'_#_ #_X)T?]#S\0/_#=:K_\DT?\09\6/^C=<8_^&',/_E'G^?9A_P 1
M9\,O^B\X5_\ #U@?_EQ^T5%?B[_P_P _^"='_0\_$#_PW6J__)-'_#_/_@G1
M_P!#S\0/_#=:K_\ )-'_ !!GQ8_Z-UQC_P"&',/_ )1Y_GV8?\19\,O^B\X5
M_P##U@?_ )<?M%17XN_\/\_^"='_ $//Q _\-UJO_P DT?\ #_/_ ()T?]#S
M\0/_  W6J_\ R31_Q!GQ8_Z-UQC_ .&',/\ Y1Y_GV8?\19\,O\ HO.%?_#U
M@?\ Y<?M%17XN_\ #_/_ ()T?]#S\0/_  W6J_\ R31_P_S_ ."='_0\_$#_
M ,-UJO\ \DT?\09\6/\ HW7&/_AAS#_Y1Y_GV8?\19\,O^B\X5_\/6!_^7'[
M145^+O\ P_S_ ."='_0\_$#_ ,-UJO\ \DT?\/\ /_@G1_T//Q _\-UJO_R3
M1_Q!GQ8_Z-UQC_X8<P_^4>?Y]F'_ !%GPR_Z+SA7_P /6!_^7'[145^+O_#_
M #_X)T?]#S\0/_#=:K_\DU](_LM_\%1OV2/VQ/B/<?"KX(^)?%6K>,+7P_>^
M)IK76?"5[HEH-*T^6&&YE%Y<3/&TJO/&%B W,"2#P:X<Q\*_$G)\!BLTS3@;
MBC+\NP-&6(QF-Q>38VAAL-0A;FJUZU2E&%.G&ZO*3274[,!XD^'^:XW#9=EO
M&7#F.Q^,JQH87"87-<)6Q&(K3TC2I4H57.<Y/11BFWT/T1HHHKX$^V"OA;]N
M/_D7_A]_V'=9_P#3;!7W37PM^W'_ ,B_\/O^P[K/_IM@H _.BBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1NA^A_E2TC=#]#_*@#^:
M;_@ZO_Y2&?"'_LT7P#_ZGWQ'K^9FOZ9O^#J__E(9\(?^S1? /_J??$>OYF:_
MMCP__P"2,X<_[%M+_P!*F?.XG_>*_P#U\?Y(****^P,0HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _1?_@D/_P I0OV#_P#LY7X:_P#I\@K]
M-_\ @J1_RD/_ &N?^RN:C_Z:M)K\R/\ @D/_ ,I0OV#_ /LY7X:_^GR"OTW_
M ."I'_*0_P#:Y_[*YJ/_ *:M)K[?P9_Y.OF?_9NJG_K3X(_F'Z57_)#\/?\
M96+_ -4V./@FBBBOZY/X-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K]WO^#>#_ )/NUS_LBOBS_P!.&EU^$-?N]_P;P?\ )]VN?]D5\6?^
MG#2Z_)_'7_DSWB)_V3.-_.F?IO@S_P G4X$_[*'!?G(_N*HHHK_%\_UK"OA;
M]N/_ )%_X??]AW6?_3;!7W37PM^W'_R+_P /O^P[K/\ Z;8* /SHHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D;H?H?Y4M(W0_0_RH
M _FF_P"#J_\ Y2&?"'_LT7P#_P"I]\1Z_F9K^F;_ (.K_P#E(9\(?^S1? /_
M *GWQ'K^9FO[8\/_ /DC.'/^Q;2_]*F?.XG_ 'BO_P!?'^2"BBBOL#$****
M"BBB@ HHHH */08)+,J*J@LSN[!$1%4%G=W941%!9W8*H+$ E?U2?\&PW_!.
M;P+^TM\8_'_[7?QE\.P^)O!/[-^NZ)H/PQ\-ZO91W?A_6OBYJ6F2:M=:]J]C
M?VD^GZW:>"]%O-.N=)MP6%EXFO+>_DQ<:9;JOB\0YYA>',GQN<8Q2G2PE.+C
M2@TIUZU2<:5"A!M-)U*LXQ<FFH0YJC346GI2IRJU(TX[R>[V26K?R2;\]C\X
M/V8/^"#O_!3;]JK1;/Q9X6^ <WPR\$ZIIB:KH_BWXX:Q;_#>UUFVG59+%]+T
M#4([CQC>6^IV["ZL-3B\.G29K5HIC?HEQ;^;D_M2_P#!#7_@IA^R5H>M^,O'
M7[/E]XZ^'OAZWAN]6\>_!G6-/^).E6-FUO-=7NH7^A:.X\:Z7I.CPP2OJ^LZ
MKX9LM)LD42R7AB8.?ZFO^"R/_!Q'XF_8F^..L?LJ?LI> / GCKXE^$=$MIOB
M7\2?'UWJ6H>&? _BC5HHKO3/".E^$=%GTRX\0:MI^FO'?^(9K[7M*M+1K^PL
M+07-S'?FUYW_ ()3?\'+?A[]HSQ=<_!3]ONV^%/P+\5/X<:^\'_&72+_ %+P
M_P##?QYK5M=2'4_#6MZ/KUSJ<7@G6'TV>*YT2-O$&IV&KQ6&HQFX@NQ' _Y?
M#BOQ/EE\.)8\.Y35R6I3AB89;3E6EF4L#/EDL3#EQ$JS<J;4E+V,I>SE[98/
MV:<EU^PP?/['VU15$W'G=E#FT]U^ZEOV>]USIZ'\#-NINGMH[?$KW<T$%N 0
M!)+<RI!"H8X4!Y9%4LQ"KDEB "1^H_QB_P""+7_!2SX!?!/Q9^T7\6?V=(?"
MWP=\#>%X/&?BGQ:OQ7^$&M/IGANY:S6'4?[!T/QOJ'B"[+&_M<VEGID]XOF'
M= -C[?H/_@NK\&_V1O G[:_AKXJ_L3>-?A1XD^#WQY@T_P 6>)/#OPH\3Z-J
MVB^!_BW8^)H8/&-G;:!I4TO_  CFD>)+6XTCQ1:QHMOI;ZKJFLV6DVMM;V!@
M3^UW_@L3_P H2/VL?^S7=!_]'^$*]K.^/,9A9<#5<NP=&&'XJQL</C*.94:_
MUO"1^LX##U*<%3KT(PKTI8BO!RJ0JPE*$)J'*[/.EAHR^L*<G>C&\7!KEEI)
MIZQ=TTELU:[5[JZ_RUZ_27]E_P#X)#?\%$OVS/A7:_&W]G/]G>[\<_"^_P!;
MU?P]IOBG4?'WPV\#Q:KJ.A-!%JCZ3I_CCQ9X?U/4],MKB?[&-9LK.;2IK^WO
M[&"[DNM/O8H/ST\->&=?\:^)?#O@SPGI=[KGBGQ?KVC^%_#>BZ9$MQJ6K:[K
M^H6^E:5IVGV[,BSWMY>W4,%M"SJ)9G1"R@DC_5M\)WO[/W_!'+]@/]GWP-XK
MGGTCX<_#FY^#_P &;[5K.TGEFU;XE_%SQ;IVAZOXJU"%KJ]-C%XB^(?B;5?$
MFKG[5)I^BVEW<16S1:=9011]W'_&&-X8HY5A\GPN'QV<YMC)4L-A<13K5H2H
M4HI59*G0KT*CJSK5L/3HKGY97JNS<$+"T(UI3=23C3A&[DFD[MZ*\DU:RE?2
M^VJ/\Q?]K#]C+]I7]AWX@Z/\+?VH_AK+\,?''B#PU'XOT326\1^%_%5OJ?AV
M2]FTX:C:ZQX0UC7-'D6.^MYK6>W%]]IMY5 FA3<N?FJPLKK4]0T[2K&+S[_5
MM1L-)T^#>D?GW^IWD-A8P>9(RQ1^==W$,7F2ND4>_?(Z(K,/[V?^#LK]EL>.
MOV:?@E^UIX>TW[3K7P.\</X&\87MG:1SW,GP[^)*#[%<7=X")+?1]#\4V%M<
M.P9XFN-8CRH+!Q_"+X#_ .2@?#S_ +*'X"_]2[1J]3@OB67%'#>&S>I&C3Q=
M\10QM&@IQHTL5AYR]V$:E2I4C"=&5&LE*I)I5;<VFF>(I>QJRIW;BK.+=KN+
M2U=DE=.ZT26FQ^PG_$.U_P %A_\ HTJV_P##Y_ /_P">37->,/\ @@+_ ,%=
M?!'AO5_%6K_L>Z[J.FZ+97%_=V?@_P"(WPG\=>))X+:)YY(])\*>$?&VL>(]
M:O&2-A!8:5IMW>7,I2&"&261$;^_[_@L#^UQ\6OV'?V#?BO^T;\$(_",OQ%\
M&7_A&VT9/'.B7OB'PV8];\06FF7OVW2M/UC0;J=A;3N8#'J< CEVNPD *G\
M/^"0?_!Q5^U+^U;^V7X&_9@_:E\!?"K5]%^-"W^C>"/%GPH\.ZQX+U'P5XHT
M31M8U\R:_I^M>*O%,'B+0M=M;$V#M:RZ;?:->1VMPB7]M<78MOS;*N._$3-\
MDQO$.#RKABME^6SKK%4[8^CBY1PM*EB,0Z4)YA*#Y*%3GNY.3M-1ISDHQEUS
MPV%IU(TI5*ZG/EY7[CC>3M&[4$]6K?/=:-?Q$^)-&UKP;JVN:!XOT76/"^O^
M&+[4=+\1Z#K^F7NDZUH>IZ1/-:ZIINJ:7>PPWMG?:?<V\]M=6LT*S13PR1%=
MZD5^PGA[_@WX_P""N7BK0-#\4:#^RI;WVA^)-'TS7]&O3\;/@5;&[TG6+*#4
M=.NC;77Q%AN;<W%G<0RF"XBBGB+^7-&DBLH_8S_@[P_92^'GA,_ +]L'PMIE
MKHGC;XCWOB[X*_$E;"Q,47BTZ3X4OO&/@_Q#JER+DPKJVBVVFZ_I"""QCEU*
MTU,RW]W.VFVB+_3;^T5\>O'?[+W_  2DU[]H'X8IH,GC_P"%7[*O@+Q5X53Q
M1IMQJ_A]M5MO"_A6WB&JZ9::AI5S>6GEW,FZ&'4;1RVTB48(/I9MXDYG+)N$
M,RR'!8!8CB7%XO 5L/F:Q%6GAL5AJV%PRA3JX>OA6Z;KUIOVLHS<J+IODA-3
MB3#"0]IB(U93M12DG#E7-%IRO:2EK96M=:W5]F?P%ZS_ ,&^'_!7[0M+O]8O
M/V0[JYM=.M9KN>#1?BW\%=?U66*"-I'2PT;1O'][JFI73*I$-G86EQ=3R%8X
M8GD95/Y&^-_ _C;X9^*]<\!_$GP=XI^'WCGPQ=MI_B3P;XUT'4_#/BC0+]8X
MYFLM7T/5[:TU"QN5BEB=HIX%8*Z^M?UV?\$[?^#F?]L[XP?M>_ [X+_M)^!/
M@CXF^&_QJ\9Z!\,Y;OX;^$O$/@?Q/X1UOQ1?0VVF^*H;G4O&7BNRUJQLI08+
M[0Y+.SDFM[AKBWOUG@2*3[1_X.SOV:OA[K/[*7PH_:OAT>QT_P"*/PZ^+?AW
MX8W6OV=K;0:CXC\&_$2SU5$TC6[M(?M.H6F@ZGI$=]H\4LV+*:^O#&"DS*/0
MP/&/$^7<397PYQ?E>54O[:26 QF3U:[A&HW*$55AB*U=S4JL52DOW,J;G&HO
M:0T,Y4*,Z$ZU"=1^S^*-11NUHW9Q45?E?,M[[:=/Y>O@S_P0\_X*A?M!?"SP
M-\:OA'^S5!XJ^&GQ)\/VGBGP7XC?XO?!G0VUC0K_ '_9+XZ3KWCS3=8L/-V-
M_H^H6-K<ICYXER,^F_\ $.U_P6'_ .C2K;_P^?P#_P#GDU_=5_P2FUV^\+_\
M$<OV5/$NF" ZEX=_92AUW3Q=1M-;&^TG1-7O[07$*21/+!]HMX_.C66)GCW*
MLB$AA_');_\ !U-_P5+D@BD?3OV5-SQHS8^#GC #+ $X'_"VC@<^IKS,LXP\
M0.(,PSW#9)@.%Y4<ES&I@YRQT<QI5)0=?$TZ#O3QTHSDX8:3J-1IKF?NQ2:4
M=)T,+2C2=2=>]2"G:/(UM'FWA=*\M-6[7UO8_+3]K[_@F5^VY^P9X6\*^-?V
MK?@S%\+_  SXUUF]\/>&=2C^('PY\9_VEK&GV2ZC=VAM?!'BGQ!=V?E6;"83
MWL$$$G*1R-("H^COA_\ \$%/^"KWQ1\!^"?B;X%_9>M];\$_$7PCX;\=>#M9
M;XS?!#3CJ_A7Q=HUEX@\/:F=/U/X@VFHV)O])U"SNC9ZA:VU[;>;Y-U;PSI)
M&O"_\% /^"O?[7/_  4K\#^!_A]^TE:_!^W\/_#[Q%J/BCP^WPT\#ZUX4U$Z
MIJ>FKI5T-0N]5\9>*$N;3[*H,<$-O;,LW[QY7 51]?\ PI_X.6_^"DWP;^%W
MPW^$/@ZP_9G?PC\*O 7@_P"&_A9M9^$_BJ^U=O#G@?P]IWAC1&U6]M_BA8P7
MFI'3-+M3?74-E:17%T99H[6!'$2?8UZWB$LIP,\/A.&)9U*OB%F-*K/'K 0P
MRE_LLL*XXA5G5E'^-[2<HI_ HG.EAO:24I5O9<L>1KDYW+3FYO=Y;;VLN_D>
M4?\ $.U_P6'_ .C2K;_P^?P#_P#GDUX[\??^"*W_  4O_9@^$OC#XY_'']G*
M'P9\+? 5E;ZCXL\31_%?X0>(FTJRNKVVTZ&?^Q_#7CC5M:O ]Y=V\)6RL+AU
M\S>RA%9A_69_P0^_X*4?\%4O^"F?Q:\4>)_BS8? OPE^RE\*;=K;QAXK\+?!
MOQ-I6J^//'>H1,NF?#WP?X@U7XEZE8VUSI%LYU_Q9JD.F:H=)@_L?3&@%QK#
MM:?*W_!T/_P5 TL:4O\ P3:^#6N:5JFH7\VC>)OVI=7L9+U[SPS#87.C>)_
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M+?ZQKNL7D.G:/I-C$2HEO-2U&YMK.UC+*))YXT+*#D?ZK'PGM_@1_P $8O\
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M4E6V2QNNY25;&Y25()_O\_X)(_\ **SX'?\ 9./&W_IY\2U_$'\$?V;?C/\
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M1M9\>WM[I][ +G:R:1?:'=V][H]W;L;&32IK6ZL)&M&B<_UG?!G_ ((H?\$
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M(L;3O)574IR)G.,\$Y4(1IQ<DJ\([I67VM+JW+=M7Y7NK-']4W_!(V70(?\
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M'Q$O9YWCZ^9U<RQF(P\H^SJT*;JT_:?O:*=!U*V(JPI4*M>%'#0JU?;1_P!
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MK7+ZDDFI_9G@T\Z?#<R7,MG^47_!1/P-X4^$_P"V_P#"SX2^%/VIOBU^U"/
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M;B34U\.ZUKLL\<JQLJW4EWEEN721RX620.P.?\]NO] W_@DEXLTCXP?\$O\
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M_P"'\PO/"\2R@KA@8V<,"I##&1S7\=UTZ7-U=3[<K/>W5VBN 63S[F6=,YR
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MZ"LW_!3;]H)4;:[>'O@VJ-_=8_![P<%;OT.#T/2OE^#_ /E,/Q+_ .R#P_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM>3<G9=+MO09+%'-')#*@DBE1XI(V^Z\<BE71L8.&4D'D<&OO/QE_P %0_\
M@HE\0_A?JGP3\<_M@_%_Q1\)-;\-0>#=7\ :I/X5;0=1\*VL%O;6^A7/V;PQ
M;Z@UC%;VMM" M^L[)"H>9R6+?!]%&(P6#Q<J,\5A,+BIX>?M,/+$X>C7E0J7
MB_:4)583=*=X0;G3<9-PCK[JL*4E=*4DGHTFTFNS2:O\_/NS6\/:_KOA'7M#
M\4^%=9U3PWXF\,:MIVO>'/$.AWUQIFLZ%K6D7,5[IFJZ7J%I)%<V=[8W4,4T
M$T4BD,NU@T;.C?9_QF_X*:?\% OVBOAYKGPD^._[6/Q0^*_PS\2_8SKO@OQA
M#X+O-'U"33[N&_L)R;7PE9W]G=V=Y!%/;7NGWMI=Q%619Q%+-')\-44JV!P6
M)JT:^)P>$Q%?#2YL-6KX:C6JX>2E&:E0J5(2G1ES1C+FIRB^:,7>Z0*4DFE*
M23T:3:379I.S^?ZGZ ?#?_@JS_P4D^#W@/PK\+_A;^V=\9? WP[\#Z/:^'_!
M_A#1)_"/]D>'=#L@5L]+TX7_ (5O;M;6V5BL2SW4[JO&\@"NW_X?1_\ !6+_
M */Y^//_ '^\#?\ S%U^9%%<D\AR*I.52IDF3U*DY.<YSRO SG.<GS2G.4J#
ME*4I7<I2;<FVVVV[U[2HMJE16VM.22M:VE_)?<?5_P"T3^W9^V1^USH&A>%?
MVG/VC?B+\;O#?AC4[C6O#VB^-9/#[V6D:M=VOV*YU"T71M"TB7[1-:?Z.QFE
ME01DA$4DD^S^$?\ @KM_P4]\ ^%/#'@7P7^V_P#&WPWX.\%^'M%\)^$_#NG3
M>#!I^@>&O#FFVVCZ%HMA]I\(7%Q]BTK2[.UL;7S[B>;R((_-FE?<[?G316DL
MGRB="EA9Y3E<\-1E.='#SR_!RH49U'>I.E1E1=.G.H]9RA%2G]IL2G--R4YJ
M323?/*[2M9-WNTK:7_5GZ;_\/H_^"L7_ $?S\>?^_P!X&_\ F+KSKXL_\%1O
M^"BGQX^'OB7X3?&7]L/XP?$;X:>,K2&P\5>"O$,_A7^Q=?LK>[M[^"UU!=-\
M+Z?=O#%>VEM=*D=W%^^@C9LA<'X-HK.GD61TIPJTLDR>E5ISC4IU*>68&%2G
M4@U*$X3C04H3A**E&<6I1DKIIZ@ZE1JSJ5&FK-.<FFM-&F]5HC[S^%/_  5'
M_P""BOP+^'/A7X0_!S]L/XP?#GX8>!]-?1_"'@CPW/X4CT;P[I<EU<WKV6G&
M]\+WM^D37=Y=7&Z6]FE62=RLB@*%^$9YYKJXN;NXD::YO;JZO;N=\;[B\O;B
M2ZN[B3: OF7%S-+/(5509)&( !P(J*[*&"P6%J5ZN%P>$PU7$S]IB:N'PU&A
M4Q,TYR4\1.E",JT^:I4ES5'*7-4G*]YR;3E)I)RDTMDVVEHE9)O1625E;9'L
M?P*_:&^.?[,/CV/XI?L\?%/Q;\'_ (B1:/J7A]?%W@VYLX-3;0]7\@ZGI<T6
MHV6HZ=<VEVUK;.R7-C,\4D*2V[PR N>]_:,_;8_:V_:]M_"-K^U!\?\ Q[\<
M+?P#<ZS>>"HO&QT!QX:N?$4.GV^N3::^BZ'H\@.J0:5IL=RMR]Q'BSA,21MO
M9_E^BE+ X*>*AC9X+"3QM./)3QDL-0EBZ<&I1Y88EP=:$>6<X\L9I<LYJUIR
M3.:5N7FER]8W?*]4[N-[7ND[VW2"OZN_^#7_ /X*-^ _V=/B?\3/V/OC?XTT
MCP5X#^.FHV'C?X4^)?%6K/I_A_3?BOIUC#H^K^$)M0O[A='T&+QCH-K97VE&
M7[%;WVO:5>0S7+ZAJ5G%<?RB4A .,]BK \@JR,&1E(P59& 9&!#*P#*00#7G
M\19%A.),GQF3XQRA2Q<(\M:FDZF'K4YQJ4:\%*RDZ=2,6X-I3AS4W**E=72J
M2I5(U([Q>SO9IZ-.W=?<[.SM8_?;_@X9_9=\+_ ?]O;7_CU\&]?\)Z_\+/VF
M;QOBK::AX&UK2=;L_"7Q@M[F&7Q_I.I2:1=W\5AJ6L:Y'%X\T]KUX1J#:UJ,
M5C;M#H]RL7Y\?%/_ (*@?\%$/CA\-/$GP;^+_P"V!\7_ (A_"OQAIEOHOBGP
M)XAG\+/H>O:3:75I>VUAJ'V'PQ97\D$5W8V=P/+O8Y&DMXR[L-P;X7>XNI$\
MN6[O)HMXD\J>[N9X_,4,HD\N65T$@5F4.%W!690<,08:G+<DHX7+LJP>9?5L
MXQ.44:='#9ABL%1]O%4>14JE/VCKRH5HPI48SJTZJG4G2C5;4K*).HY3G*-X
M*HVY04G;75K11NKW:36B=MA" 000""""" 00>""#P01P0>".M?</@S_@I?\
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ME.<DME*4I>75O6VE]S^T_P#X-8_V>OA3\,/#?Q=_;H^+WC_X;^&?$7C.WO\
MX/?"33O$7C?POINKZ=X-T+58K[XC>()])O[^#4+"36_$>E:5I-F\T6^73] N
M)K4BVU%_._!3_@M'^WY;_P#!0S]N+QQ\3/"&I37OP2^'=G'\*O@:'@EM5O\
MP?H-U<3:MXR:UN(XIXY_''B6XU+5[9IXH+D>'(_#=K=V\5W9S _D^L]PB[([
MJ[B09Q'%=W,48R<G$<<JH-QY;"_,22<DFHZ\/ \)T\-Q3F?%>+QL\=C<91CA
M,%1E15*EEF$BHP=.D_:U74J2ITX0E52I+WL1+D_VAJ&DJS=&%!148Q?-)WNY
MRZ-Z)))W=M?LZKE"BBBOKC$**** "BBB@ HHHH **** /T7_ ."0_P#RE"_8
M/_[.5^&O_I\@K]-_^"I'_*0_]KG_ +*YJ/\ Z:M)K\R/^"0__*4+]@__ +.5
M^&O_ *?(*_3?_@J1_P I#_VN?^RN:C_Z:M)K[?P9_P"3KYG_ -FZJ?\ K3X(
M_F'Z57_)#\/?]E8O_5-CCX)HHHK^N3^#0HHHH **** "BBB@ HHHH **** $
M90ZLK#*L"K ]"",$'Z@XK[%E_P""@W[;4WPW3X/R_M+?$E_AC'X/M_ ">"C/
MH0T=?!=II,>A6WAL!=$6[_LZ+1X8M.5?M7G&V0*TS,2Q^.Z*\W,<FR?-_JW]
MK93EF:?4ZOUC!_VE@,)COJE?W?W^%^M4:OU>M[D?WM+DG[L?>T5O1P&<9ME2
MQ"RO,\PRY8NE[#%+ XS$83ZS1=_W5?V%2G[6G[TO<J<T=7IJQ%4*H51A5 4
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MJ%66'J4W4I2E&+=.;<&TFU=#554544!510JJ.@51@ >P  %.HHKT3SPHHHH
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MS/K6BODK_AQI_P %2_\ I,9JO_AG]6_^;ZC_ (<:?\%2_P#I,9JO_AG]6_\
MF^H_U=R7_HML@Z?\P?$7E_U)?-_<P]K5_P"@:KT^W1\O^GGF_N9]:T5\E?\
M#C3_ (*E_P#28S5?_#/ZM_\ -]1_PXT_X*E_])C-5_\ #/ZM_P#-]1_J[DO_
M $6V0=/^8/B+R_ZDOF_N8>UJ_P#0-5Z?;H^7_3SS?W,^M:*^2O\ AQI_P5+_
M .DQFJ_^&?U;_P";ZC_AQI_P5+_Z3&:K_P"&?U;_ .;ZC_5W)?\ HML@Z?\
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M #Z?_@4/_DO/\^S/XW:*_LB_X@__ (H?]'S^!?\ PQNO?_/&H_X@_P#XH?\
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M%_\ #&Z]_P#/&H_X@_\ XH?]'S^!?_#&Z]_\\:C_ (B?P)_T/Z7_ (0YG_\
M,7G^?9A]3Q/_ #Z?_@4/_DO/\^S/XW:*_LB_X@__ (H?]'S^!?\ PQNO?_/&
MH_X@_P#XH?\ 1\_@7_PQNO?_ #QJ/^(G\"?]#^E_X0YG_P#,7G^?9A]3Q/\
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M\^G_ .!0_P#DO/\ /LS^-VBO[(O^(/\ ^*'_ $?/X%_\,;KW_P \:C_B#_\
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M/X%_\,;KW_SQJ/\ B#_^*'_1\_@7_P ,;KW_ ,\:C_B)_ G_ $/Z7_A#F?\
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M #Z?_@4/_DO/\^S/XW:*_LB_X@__ (H?]'S^!?\ PQNO?_/&H_X@_P#XH?\
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M%_\ #&Z]_P#/&H_X@_\ XH?]'S^!?_#&Z]_\\:C_ (B?P)_T/Z7_ (0YG_\
M,7G^?9A]3Q/_ #Z?_@4/_DO/\^S/XW:*_LB_X@__ (H?]'S^!?\ PQNO?_/&
MH_X@_P#XH?\ 1\_@7_PQNO?_ #QJ/^(G\"?]#^E_X0YG_P#,7G^?9A]3Q/\
MSZ?_ (%#_P"2\_S[,_C=HK^R+_B#_P#BA_T?/X%_\,;KW_SQJ/\ B#_^*'_1
M\_@7_P ,;KW_ ,\:C_B)_ G_ $/Z7_A#F?\ \Q>?Y]F'U/$_\^G_ .!0_P#D
MO/\ /LS^-VBO[(O^(/\ ^*'_ $?/X%_\,;KW_P \:C_B#_\ BA_T?/X%_P##
M&Z]_\\:C_B)_ G_0_I?^$.9__,7G^?9A]3Q/_/I_^!0_^2\_S[,_GT_X)#_\
MI0OV#_\ LY7X:_\ I\@K]-_^"I'_ "D/_:Y_[*YJ/_IJTFOH7XU?\&X?QY_X
M)\?";XA?MO\ @;]N;P^?&7[+7A35_C/X:'ASX1ZOH6O-J_@NU?5+1=)UFY\<
MZE;Z9?-)$%@O)M/O(XG(9[=QD5UW[/W_  0>_:Y_X*%?!CX=?MK^+O\ @H=;
M6?B?]I'PY;?$C7+7Q%\*=4U_6X+Z_EFL3'J.M6OC;3(-2N5BT^(-<1:?9H1A
M!#\N]OJ^ O%G@?A3B;%\;XW-98C)\1D+X4C]6P>.=>.9SS*AG"YH5<-3_<_5
M*,KS3=IM1L?C_C-X99WXD9!E>293B<#@<3@<Y6:U*F83JJE.A]1Q&#<(/#TJ
M\O:>TKQE9Q4>52O).R?XK45_07_Q"K?M+_\ 21;PY_X9+6__ )XE'_$*M^TO
M_P!)%O#G_ADM;_\ GB5^R?\ $VOA-_T&9E_X08CR_P"G?G^#['\X?\2D\>?]
M#OAK_P &YAY?]0/G^'K;^?2BOZ"_^(5;]I?_ *2+>'/_  R6M_\ SQ*/^(5;
M]I?_ *2+>'/_  R6M_\ SQ*/^)M?";_H,S+_ ,(,1Y?]._/\'V#_ (E)X\_Z
M'?#7_@W,/+_J!\_P];?SZ45_07_Q"K?M+_\ 21;PY_X9+6__ )XE'_$*M^TO
M_P!)%O#G_ADM;_\ GB4?\3:^$W_09F7_ (08CR_Z=^?X/L'_ !*3QY_T.^&O
M_!N8>7_4#Y_AZV_GTHK^@O\ XA5OVE_^DBWAS_PR6M__ #Q*/^(5;]I?_I(M
MX<_\,EK?_P \2C_B;7PF_P"@S,O_  @Q'E_T[\_P?8/^)2>//^AWPU_X-S#R
M_P"H'S_#UM_/I17]!?\ Q"K?M+_])%O#G_ADM;_^>)1_Q"K?M+_])%O#G_AD
MM;_^>)1_Q-KX3?\ 09F7_A!B/+_IWY_@^P?\2D\>?]#OAK_P;F'E_P!0/G^'
MK;^?2BOZ"_\ B%6_:7_Z2+>'/_#):W_\\2C_ (A5OVE_^DBWAS_PR6M__/$H
M_P")M?";_H,S+_P@Q'E_T[\_P?8/^)2>//\ H=\-?^#<P\O^H'S_  ];?SZ4
M5_07_P 0JW[2_P#TD6\.?^&2UO\ ^>)1_P 0JW[2_P#TD6\.?^&2UO\ ^>)1
M_P 3:^$W_09F7_A!B/+_ *=^?X/L'_$I/'G_ $.^&O\ P;F'E_U ^?X>MOY]
M**_H+_XA5OVE_P#I(MX<_P##):W_ //$H_XA5OVE_P#I(MX<_P##):W_ //$
MH_XFU\)O^@S,O_"#$>7_ $[\_P 'V#_B4GCS_H=\-?\ @W,/+_J!\_P];?SZ
M45_07_Q"K?M+_P#21;PY_P"&2UO_ .>)1_Q"K?M+_P#21;PY_P"&2UO_ .>)
M1_Q-KX3?]!F9?^$&(\O^G?G^#[!_Q*3QY_T.^&O_  ;F'E_U ^?X>MOY]**_
MH+_XA5OVE_\ I(MX<_\ #):W_P#/$H_XA5OVE_\ I(MX<_\ #):W_P#/$H_X
MFU\)O^@S,O\ P@Q'E_T[\_P?8/\ B4GCS_H=\-?^#<P\O^H'S_#UM_/I17]!
M?_$*M^TO_P!)%O#G_ADM;_\ GB4?\0JW[2__ $D6\.?^&2UO_P">)1_Q-KX3
M?]!F9?\ A!B/+_IWY_@^P?\ $I/'G_0[X:_\&YAY?]0/G^'K;^?2BOZ"_P#B
M%6_:7_Z2+>'/_#):W_\ /$H_XA5OVE_^DBWAS_PR6M__ #Q*/^)M?";_ *#,
MR_\ "#$>7_3OS_!]@_XE)X\_Z'?#7_@W,/+_ *@?/\/6W\^E%?T%_P#$*M^T
MO_TD6\.?^&2UO_YXE'_$*M^TO_TD6\.?^&2UO_YXE'_$VOA-_P!!F9?^$&(\
MO^G?G^#[!_Q*3QY_T.^&O_!N8>7_ % ^?X>MOY]**_H+_P"(5;]I?_I(MX<_
M\,EK?_SQ*/\ B%6_:7_Z2+>'/_#):W_\\2C_ (FU\)O^@S,O_"#$>7_3OS_!
M]@_XE)X\_P"AWPU_X-S#R_Z@?/\ #UM_/I17]!?_ !"K?M+_ /21;PY_X9+6
M_P#YXE'_ !"K?M+_ /21;PY_X9+6_P#YXE'_ !-KX3?]!F9?^$&(\O\ IWY_
M@^P?\2D\>?\ 0[X:_P#!N8>7_4#Y_AZV_GTHK^@O_B%6_:7_ .DBWAS_ ,,E
MK?\ \\2C_B%6_:7_ .DBWAS_ ,,EK?\ \\2C_B;7PF_Z#,R_\(,1Y?\ 3OS_
M  ?8/^)2>//^AWPU_P"#<P\O^H'S_#UM_/I17]!?_$*M^TO_ -)%O#G_ (9+
M6_\ YXE'_$*M^TO_ -)%O#G_ (9+6_\ YXE'_$VOA-_T&9E_X08CR_Z=^?X/
ML'_$I/'G_0[X:_\ !N8>7_4#Y_AZV_GTHK^@O_B%6_:7_P"DBWAS_P ,EK?_
M ,\2C_B%6_:7_P"DBWAS_P ,EK?_ ,\2C_B;7PF_Z#,R_P#"#$>7_3OS_!]@
M_P")2>//^AWPU_X-S#R_Z@?/\/6W\^E%?T%_\0JW[2__ $D6\.?^&2UO_P">
M)1_Q"K?M+_\ 21;PY_X9+6__ )XE'_$VOA-_T&9E_P"$&(\O^G?G^#[!_P 2
MD\>?]#OAK_P;F'E_U ^?X>MOY]**_H+_ .(5;]I?_I(MX<_\,EK?_P \2C_B
M%6_:7_Z2+>'/_#):W_\ /$H_XFU\)O\ H,S+_P (,1Y?]._/\'V#_B4GCS_H
M=\-?^#<P\O\ J!\_P];?SZ45_07_ ,0JW[2__21;PY_X9+6__GB4?\0JW[2_
M_21;PY_X9+6__GB4?\3:^$W_ $&9E_X08CR_Z=^?X/L'_$I/'G_0[X:_\&YA
MY?\ 4#Y_AZV_GTHK^@O_ (A5OVE_^DBWAS_PR6M__/$H_P"(5;]I?_I(MX<_
M\,EK?_SQ*/\ B;7PF_Z#,R_\(,1Y?]._/\'V#_B4GCS_ *'?#7_@W,/+_J!\
M_P /6W\^E%?T%_\ $*M^TO\ ])%O#G_ADM;_ /GB4?\ $*M^TO\ ])%O#G_A
MDM;_ /GB4?\ $VOA-_T&9E_X08CR_P"G?G^#[!_Q*3QY_P!#OAK_ ,&YAY?]
M0/G^'K;^?2BOZ"_^(5;]I?\ Z2+>'/\ PR6M_P#SQ*/^(5;]I?\ Z2+>'/\
MPR6M_P#SQ*/^)M?";_H,S+_P@Q'E_P!._/\ !]@_XE)X\_Z'?#7_ (-S#R_Z
M@?/\/6W\^E%?T%_\0JW[2_\ TD6\.?\ ADM;_P#GB4?\0JW[2_\ TD6\.?\
MADM;_P#GB4?\3:^$W_09F7_A!B/+_IWY_@^P?\2D\>?]#OAK_P &YAY?]0/G
M^'K;^?2BOZ"_^(5;]I?_ *2+>'/_  R6M_\ SQ*/^(5;]I?_ *2+>'/_  R6
MM_\ SQ*/^)M?";_H,S+_ ,(,1Y?]._/\'V#_ (E)X\_Z'?#7_@W,/+_J!\_P
M];?SZ45_07_Q"K?M+_\ 21;PY_X9+6__ )XE'_$*M^TO_P!)%O#G_ADM;_\
MGB4?\3:^$W_09F7_ (08CR_Z=^?X/L'_ !*3QY_T.^&O_!N8>7_4#Y_AZV_G
MTHK^@O\ XA5OVE_^DBWAS_PR6M__ #Q*/^(5;]I?_I(MX<_\,EK?_P \2C_B
M;7PF_P"@S,O_  @Q'E_T[\_P?8/^)2>//^AWPU_X-S#R_P"H'S_#UM_/I17]
M!?\ Q"K?M+_])%O#G_ADM;_^>)1_Q"K?M+_])%O#G_ADM;_^>)1_Q-KX3?\
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MO$/A_4K+6=#UK2K^%+BQU/2=6TZ>YL-2T^\MY$GM+VSN)K:XA=)8971@QUZ
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M5^?/_!.']N4?MS?!GQAXC\5>!X_A)\=?@K\7?B#\!_VA_@R=7BUFX^''Q-\
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M?#F@WGQ8\::+X+UV"Y\,OK?C636?"^BW&KR6=\?*\*&)!!>6HE0 _I\_8O\
M^"Y?_!,3]OKQ]_PJK]G+]I72-7^)EPSKH_@3QQX9\6_#'Q-XG\J 7$__  BF
MG>/-%T%O$<D$9S+;Z2]S<@A@L#;6Q^MM?R=?\'(O_!)[]GC5_P!AGQI^VG^S
M7\*/"OP&_:C_ &.5\,_$[PIXV^!WAS2?AQJNL^#-"\3P#Q#H^I1^%?\ A']/
M\[PW'KEQX]TKQ(8)/$&E7'AIK2PN7AO#:GZ1^(/_  57\::+_P &X]G_ ,%(
M3?6LGQH\3?LHZ!I\&K:="+.RM/CSXHN(/A$^MQVVH2Q.T&F?$.>?5Y;>&0R3
M_9G33PP>"@#[&_;(_P""Y_\ P2\_80\;S?#+]H7]J#P[I_Q)L+G[)KO@'P%H
M7BCXI>*_"T[6\=U'%XMTKX?Z1X@D\-32PRJR6^L-:7.<JT*L5!]C_89_X*I_
ML'_\%'-,UF[_ &2OC[X<^(.L>'9&&O>!M3M-5\%_$?2;4R7$<&JW?@'Q=9:/
MXH&BWAM+DVFL0Z;+ITP@DQ< J17X\?\ !O-_P2+_ &8O /[!WPI_:>^/OP9\
M!_'#]I_]JO0[SXO_ !"^(/QC\/Z3\3]7M=+\::I/J>A:)IY\7V^M6MG)+I26
M6KZWJ$$9U+5-;U+49[V]D\QHQ\._\'&'['/@[_@FYX^_9._X++?L+>!-"^!O
MQ)^$?QZ\(^#/CCHGPST[3_!7@CQEX8U_3KB#1]7\2>']!2RM8;;4[70[CX9>
M*8=#T\?V]I/B^UDO[22ZM&U!0#^W&21(D>65TCBC1I)))&")&B L[N[$*J*H
M+,S$!0"20!7X?_M$?\'&W_!'S]F3XA:E\+_B#^UII&O^+M$NKW3]=M_A1X,\
M=?%S2M#U33;EK._TG5/$/P^\/Z]H5OJ=I<H\-Q9+J$DT4D<D;J'BD5?D#_@Y
M2_;^USX.?\$BO"FI?";Q/<>#M?\ VY[_ .''PZT3QM8W5UIDGASX?^._#<?C
MKQEJ4-Q!)%KEC]L\(POI1N=/CDO[2VU*?<F\[6\,_8#\?_\ !KY^Q9^S5X(^
M$5I\>/V)OB;XLN/"VCS?%#XE?%KPUI?COQKX[\6W=E)=:W?W]]XG\&7LFDV"
M7NHWMII6AZ9%I]II>E1V5B\,DUIYQ /Z3?V1_P!MG]EK]NSX:O\ %K]E'XS>
M$/C%X+M+]-(UJX\.7CKJ_A?6GM8[U-%\6^'+^.TU[PQJLEG-'=0V.M:?9S7%
MLXGMQ+$"XP?VCOV]_P!EO]D_XG_ +X-?'+XBMX4^)/[3OBV'P3\%_#-OX=\1
M:[=>+/$$^J:5HRP--HFF7UKI%JFH:UI\4VH:O/96<*RO+),L<,K+_%?\//CW
M_P $_P#]BS_@X$_9&\9_\$H?CAHWC?\ 9Q_;OEU#X6?M+_ SX0:_>'X9>$/&
MWB/4T\/^&]3AT>^MH(HM.CUK5[#QUI&BI'NT._TO7+?0KJTTK5I-*7Z4_P"#
MK;P=-\1OVV?^"-GPUA\0ZUX2_P"%G?&2?X8W/B;PW?3Z9X@T/3OB-\2?AMX*
MU74M%U*V(N=/U.UTW7+J2RO;9EN;6X$<]NZ3(C  _;+XQ_\ !R/_ ,$=/@=\
M6M2^"_C+]K/3]1\7:)JYT'7+_P #> ?B'X^\&:+K,6JW.BW^G:CXW\)^&=4\
M,PSZ1?VD\>KE-1EBT^)!<3R"!UD/UY^U!_P5B_X)]_L>_!;X=_M ?'+]I3P1
MHWPT^+^D0:]\)=2\--J'CK5?B;HL\5E.=4\$>'?"%GK&MZ]86T&H6LM]=VMD
M8+$2-'=R0S1R1KP/Q-_X)!?\$VKS]D'QS^S-#^R#\%=(^&Q^&.IZ!;7VC>!_
M#]C\0].?2-+%SI?B.P^)8T]_&T?BVQU'3K+54\03:U->7-]"3?F[M9[JVF_F
MC_X-+_V#_@#\9?@G\;OVC/VA/!VB?M!>+_AM\4-6_9X^#6G?%_38/'GACX3_
M  XT&V&OZS8^#_"/B9-4\,Z/=^*M?\0W.J:G=V.G)*)$S$T<UQ=S7 !_37^P
M]_P68_X)Q_\ !1+Q1>^ OV6/VB]#\7_$6RL;[55^''B70_$GP]\>ZCI&EA6U
M/5M$\+>-]*T/5-<T[38WCEU"YTF"\6R@D2>Y$4)+C\V/^#N( _\ !&+XH$@$
MCXV? ,C(Z'_A-XQD>AP2,CL2.AK\S?\ @M'\"/@Q^PE_P6K_ ."*?[0/[*GP
MP\%_!7QI\5_CK#X=^)%C\/-"LO!_A[Q=8-\1/ 7A#5)+_2=!CL[&"[USP?\
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M_P 0-(T[Q5-X8TVZ\6V&KPZ=HOA:.[M-'BBTR.&._O[34-8DDEDU.0UJWO\
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M!8X+,67@JSMI+=$ >W2QC&/LS;OZN?VMOAAXW^-G[+W[0?P>^&NK^&] \?\
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MNV%RZ0Q^%9=%T[RKRW\?>(K>+^OA$2-$CC18XXU5$1%"HB* JHBJ JJJ@!5
M      K\4?@#^U9_P1T_X)4> OA?_P $Y_#_ .U]^S_\--8^$EGI_@^X\*Z[
MX[TU_$-YXUU2]8>(]=\?:I9"XT?2?%_B3Q1-?ZKXHCUB_P!-.DWMW+%=P:=9
MP11Q?M%IFIZ;K>FZ?K.C:A8ZOH^KV-IJ>E:KIEW;W^FZGIM_;QW5CJ&GWUK)
M+:WMC>VLL5S:7=M++;W-O+'-#(\;JQ /X]OV9_&>I_\ !-O_ (.;_P!H_P#9
M#2XO4^ G_!3OPLGQS\":&MY+-I6A?&"T\-ZWXUO;[3=%L6BTW14N9-!^(GAR
M[N[RU2\O+.V\.Q&[N%ALT/\ 8O7\6W_!P)(WPJ_X+?\ _!"+XZ^&V)\7:U\6
M_!GPDOK>Y&W3W\.ZO\</#V@3W(-N8KHWZ6'Q+\01J6E:%@EFKH8TD23^TF@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
MYPO^#G;_ ),6^#__ &>+^S[_ .I+)7]'M?SA?\'.W_)BWP?_ .SQ?V??_4ED
MKZS@7_DL.'O^QE1_]N.?%_[O5_P_JC^AOPA_R*7A?_L7=$_]-EK715SOA#_D
M4O"__8NZ)_Z;+6NBKY6?QR_Q2_-F\=EZ+\@K^9?_ ()G_P#*>K_@M=_V _@9
M_P"C]4K^FBOYE_\ @F?_ ,IZO^"UW_8#^!G_ */U2OK>&O\ D4<;?]DY0_\
M6@R4QK?Q,/\ ]?7_ .FJA_311117R!N%?Q=?\$6/^5D?_@N)_P!@;4__ %:7
M@>O[1:_.;]G'_@ES^S#^RW^V'^TK^W%\+V^)!^-O[5MM=6OQ4'B3QA#K'@X1
M7>O:7XCE_P"$;\/IHUE-I+#4=(M!$T^IZAY-L9K>(*LA( /T9K^+3]E+_E<=
M_P""@G_9OWAW_P!9_P#V<:_M+K\X_ W_  2V_9@^'O\ P4,^*O\ P4W\/O\
M$G_AI;XQ>%+;P;XP6^\917/PZ_L>U\*>#?!L7]E^$%T:&6SNQH_@70_W\NL7
M06[-_<1QH+QHU /I+]L#_DTO]J+_ +-U^-O_ *K3Q-7X#?\ !H9_RAU\(_\
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M &-OANFL7,"6MQJB^"?B1\,?#@U":VB9X[>6\_L[[0\*.ZQ-(45V"[C^Q_\
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M.N7'Q=\.>([/X^77P\M[1W0R7%CXC-YX0M8[@Q2WSVL/VB."2=TC^BOV+?\
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M9I)Y))68@'\V7_!R_P#\I./^""7_ &<D/_5R? >OMO\ X.XO^4,7Q1_[+7\
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M3X?>&5L?&,5K\.SX?CTCQ9HBC4O"7]C23WMY]B\9ZR3,-9AA:X%G.;??;#>
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M1&=%C74IKD(J.ZJH 5F !/X+?"/_ (-BO^">?PP^(WPW\6Z]XM_:?^-7P_\
M@IXDB\5_!?X ?&;XV:IXO^"OP[UB&YM]1C?3O"*Z=I\-Q:QZO%+J+6)DMK._
M>58=;@U>-)#/^M_[>O[6_P ._P!A;]D7XX_M.?$G6[/1-$^&7@76+_18)KBR
MM[OQ!XSN;.6R\%^%-#M[V6&+4-;U_P 0S6&GZ?I\9>28N[^68HI2H!_+[_P2
MZM+S]HW_ (.??^"K?[2>EH]_X-^!G@N]^#%GK*Q_98%O-3O_  ?X7M[,PR?8
M)YIGD^'NO,2]C>LB0B1[E$DMY9_[0J_F[_X-GOV(_&G[/'[&?B?]J#X]>'9=
M,_:=_;O\?:S\?OB'>ZHL@\00^#?$-]=ZKX!TK4HI1&^GO=V^J:EXKGTN2".:
MSN?$30S$F)$B_I$H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB_9W_P"#EK_@L/\ L\:C ]F/C3HDGQ3\*BY8VIN]-TOQ-H_BZ&2V34_^)AJ
M-I\1KI%DL))K5A;SSL6ABB\K^K']L+XM?$[X#?LP_'#XU_!SX:6OQD^(OPI^
M'GB+Q_H'PMN=2O\ 2'\=GPK8R:SJ/AO3]0TS3M6N[?5]1TNTO(M(*:?<QR:D
M;:*9!"[NO\UG_!:KPC??\$]O^"I?[ W_  6PTWP]?:K\%K'4;7]F+]L>[TNP
MN;N3PGX1\50:EX<\,?$/5)H(+EK73;#2]?N%C\N#S+S4_"NF:)]HCFUZSC?^
ML_P_K^B>*]"T;Q/X:U;3M?\ #OB'2[#6]"US1[VVU'2M8TC5+:*]T[4]-U"S
MDFM;VQO;2:*YM;JVED@GAD26)V1@Q /RD_X)*_\ !7;X$?\ !4?]FO2OBOI&
MK>$/AO\ &30[J]T7XR_ BY\76EUXA^'&NP7]Y%I\B+J<>DZKJOAO6],AM[[2
M]?.E6UK/<&_TX@76G3K7\]?_  =$?'3X?_MQ?&3]A;_@E3^RU-:?&?\ :MN_
MVA]'^('BJW\%R2:]9?"W1;_PY<:996'B._T:TU..">\T?5;_ ,=^)H;>1Y_"
MGA#PHFM:Q;+!J5CC]9_VMO\ @V,_X)E_M6?&'Q;\?(-%^*_[/OQ0\;W(U'Q/
M>_ #QQ;>"_"^K:U=ZE)?:_K\_A*YT+5;&SUCQ)'//!JTFBW&DV$\QBU!M.:\
M^U27?UE_P3M_X(C_ /!/S_@F1J-YXN_9V^%U_JGQ7U*PN-+O?C/\4=87QO\
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M=A?V$\E?UY4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5_.%_P<[?\F+?!_\ [/%_9]_]262OZ/:_G"_X.=O^3%O@_P#]
MGB_L^_\ J2R5]9P+_P EAP]_V,J/_MQSXO\ W>K_ (?U1_0WX0_Y%+PO_P!B
M[HG_ *;+6NBKG?"'_(I>%_\ L7=$_P#39:UT5?*S^.7^*7YLWCLO1?D%?S+_
M /!,_P#Y3U?\%KO^P'\#/_1^J5_317\4GPM_X*3?LI?\$\_^"W__  5V\9_M
M-^*?%GAO0_B+J'PP\%^%9?#'@#Q1XWGN]>\)6K:IKL%U;>&[&^GL(+>TU?3W
MM[NYC2WO&DE2*3S(&4_;<'X+%YA@>,<'@<-7QF*K<.T8T</AJ4ZU:K*.>Y/4
MDH4X*4I-0A.;23M&,I/1-G/B)1A*A*4E&*JN[;LE>G-;OS:7JS^UNBOY[?\
MB)__ ."1W_15/B]_XCW\5O\ YGZ/^(G_ /X)'?\ 15/B]_XCW\5O_F?K@_U(
MXP_Z)C/?_#9B_P#Y5YK[ROK.'_Y_4O\ P./^?FOO/Z$J*_GM_P"(G_\ X)'?
M]%4^+W_B/?Q6_P#F?H_XB?\ _@D=_P!%4^+W_B/?Q6_^9^C_ %(XP_Z)C/?_
M  V8O_Y5YK[P^LX?_G]2_P# X_Y^:^\_H2HK^>W_ (B?_P#@D=_T53XO?^(]
M_%;_ .9^C_B)_P#^"1W_ $53XO?^(]_%;_YGZ/\ 4CC#_HF,]_\ #9B__E7F
MOO#ZSA_^?U+_ ,#C_GYK[S^A*BOY[?\ B)__ ."1W_15/B]_XCW\5O\ YGZ/
M^(G_ /X)'?\ 15/B]_XCW\5O_F?H_P!2.,/^B8SW_P -F+_^5>:^\/K.'_Y_
M4O\ P./^?FOO/Z$J*_GM_P"(G_\ X)'?]%4^+W_B/?Q6_P#F?H_XB?\ _@D=
M_P!%4^+W_B/?Q6_^9^C_ %(XP_Z)C/?_  V8O_Y5YK[P^LX?_G]2_P# X_Y^
M:^\_H2HK^>W_ (B?_P#@D=_T53XO?^(]_%;_ .9^C_B)_P#^"1W_ $53XO?^
M(]_%;_YGZ/\ 4CC#_HF,]_\ #9B__E7FOO#ZSA_^?U+_ ,#C_GYK[S^A*BOY
M[?\ B)__ ."1W_15/B]_XCW\5O\ YGZ/^(G_ /X)'?\ 15/B]_XCW\5O_F?H
M_P!2.,/^B8SW_P -F+_^5>:^\/K.'_Y_4O\ P./^?FOO/Z$J*_GM_P"(G_\
MX)'?]%4^+W_B/?Q6_P#F?H_XB?\ _@D=_P!%4^+W_B/?Q6_^9^C_ %(XP_Z)
MC/?_  V8O_Y5YK[P^LX?_G]2_P# X_Y^:^\_H2HK^>W_ (B?_P#@D=_T53XO
M?^(]_%;_ .9^C_B)_P#^"1W_ $53XO?^(]_%;_YGZ/\ 4CC#_HF,]_\ #9B_
M_E7FOO#ZSA_^?U+_ ,#C_GYK[S^A*BOY[?\ B)__ ."1W_15/B]_XCW\5O\
MYGZ/^(G_ /X)'?\ 15/B]_XCW\5O_F?H_P!2.,/^B8SW_P -F+_^5>:^\/K.
M'_Y_4O\ P./^?FOO/Z$J*_GM_P"(G_\ X)'?]%4^+W_B/?Q6_P#F?H_XB?\
M_@D=_P!%4^+W_B/?Q6_^9^C_ %(XP_Z)C/?_  V8O_Y5YK[P^LX?_G]2_P#
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M53XO?^(]_%;_ .9^C_B)_P#^"1W_ $53XO?^(]_%;_YGZ/\ 4CC#_HF,]_\
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M ,#C_GYK[S^A*BOY[?\ B)__ ."1W_15/B]_XCW\5O\ YGZ/^(G_ /X)'?\
M15/B]_XCW\5O_F?H_P!2.,/^B8SW_P -F+_^5>:^\/K.'_Y_4O\ P./^?FOO
M/Z$J*_GM_P"(G_\ X)'?]%4^+W_B/?Q6_P#F?H_XB?\ _@D=_P!%4^+W_B/?
MQ6_^9^C_ %(XP_Z)C/?_  V8O_Y5YK[P^LX?_G]2_P# X_Y^:^\_H2HK^>W_
M (B?_P#@D=_T53XO?^(]_%;_ .9^E'_!S]_P2-)P?BK\71[G]GOXKX'Y>'B?
MR!H_U(XP_P"B8SW_ ,-F+_\ E7FOO#ZSA_\ G]2_\#C_ )^:^\\S_P"#6O\
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M-?>'UG#_ //ZE_X''_/S7WG]"5%?SV_\1/\ _P $CO\ HJGQ>_\ $>_BM_\
M,_1_Q$__ /!([_HJGQ>_\1[^*W_S/T?ZD<8?]$QGO_ALQ?\ \J\U]X?6</\
M\_J7_@<?\_-?>?T)45_/;_Q$_P#_  2._P"BJ?%[_P 1[^*W_P S]'_$3_\
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MP_\ S^I?^!Q_S\U]Y_0E17\]O_$3_P#\$CO^BJ?%[_Q'OXK?_,_1_P 1/_\
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M'&'_ $3&>_\ ALQ?_P J\U]X?6</_P _J7_@<?\ /S7WG]"5%?SV_P#$3_\
M\$CO^BJ?%[_Q'OXK?_,_1_Q$_P#_  2._P"BJ?%[_P 1[^*W_P S]'^I'&'_
M $3&>_\ ALQ?_P J\U]X?6</_P _J7_@<?\ /S7WG]"5%?SV_P#$3_\ \$CO
M^BJ?%[_Q'OXK?_,_1_Q$_P#_  2._P"BJ?%[_P 1[^*W_P S]'^I'&'_ $3&
M>_\ ALQ?_P J\U]X?6</_P _J7_@<?\ /S7WG]"5%?SV_P#$3_\ \$CO^BJ?
M%[_Q'OXK?_,_1_Q$_P#_  2._P"BJ?%[_P 1[^*W_P S]'^I'&'_ $3&>_\
MALQ?_P J\U]X?6</_P _J7_@<?\ /S7WG]"5%?SV_P#$3_\ \$CO^BJ?%[_Q
M'OXK?_,_1_Q$_P#_  2._P"BJ?%[_P 1[^*W_P S]'^I'&'_ $3&>_\ ALQ?
M_P J\U]X?6</_P _J7_@<?\ /S7WG]"5%?SV_P#$3_\ \$CO^BJ?%[_Q'OXK
M?_,_1_Q$_P#_  2._P"BJ?%[_P 1[^*W_P S]'^I'&'_ $3&>_\ ALQ?_P J
M\U]X?6</_P _J7_@<?\ /S7WG]"5%?SV_P#$3_\ \$CO^BJ?%[_Q'OXK?_,_
M1_Q$_P#_  2._P"BJ?%[_P 1[^*W_P S]'^I'&'_ $3&>_\ ALQ?_P J\U]X
M?6</_P _J7_@<?\ /S7WG]"5%?SV_P#$3_\ \$CO^BJ?%[_Q'OXK?_,_1_Q$
M_P#_  2._P"BJ?%[_P 1[^*W_P S]'^I'&'_ $3&>_\ ALQ?_P J\U]X?6</
M_P _J7_@<?\ /S7WG]"5%?SV_P#$3_\ \$CO^BJ?%[_Q'OXK?_,_1_Q$_P#_
M  2._P"BJ?%[_P 1[^*W_P S]'^I'&'_ $3&>_\ ALQ?_P J\U]X?6</_P _
MJ7_@<?\ /S7WG]"5%?SV_P#$3_\ \$CO^BJ?%[_Q'OXK?_,_1_Q$_P#_  2.
M_P"BJ?%[_P 1[^*W_P S]'^I'&'_ $3&>_\ ALQ?_P J\U]X?6</_P _J7_@
M<?\ /S7WG]"5%?SV_P#$3_\ \$CO^BJ?%[_Q'OXK?_,_1_Q$_P#_  2._P"B
MJ?%[_P 1[^*W_P S]'^I'&'_ $3&>_\ ALQ?_P J\U]X?6</_P _J7_@<?\
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M#_\ /ZE_X''_ #\U]Y_0E17\]O\ Q$__ /!([_HJGQ>_\1[^*W_S/T?\1/\
M_P $CO\ HJGQ>_\ $>_BM_\ ,_1_J1QA_P!$QGO_ (;,7_\ *O-?>'UG#_\
M/ZE_X''_ #\U]Y_0E17\]O\ Q$__ /!([_HJGQ>_\1[^*W_S/T?\1/\ _P $
MCO\ HJGQ>_\ $>_BM_\ ,_1_J1QA_P!$QGO_ (;,7_\ *O-?>'UG#_\ /ZE_
MX''_ #\U]Y_0E17\]O\ Q$__ /!([_HJGQ>_\1[^*W_S/T?\1/\ _P $CO\
MHJGQ>_\ $>_BM_\ ,_1_J1QA_P!$QGO_ (;,7_\ *O-?>'UG#_\ /ZE_X''_
M #\U]Y_0E17\]O\ Q$__ /!([_HJGQ>_\1[^*W_S/T?\1/\ _P $CO\ HJGQ
M>_\ $>_BM_\ ,_1_J1QA_P!$QGO_ (;,7_\ *O-?>'UG#_\ /ZE_X''_ #\U
M]Y_0E5:\L[34;2ZL-0M;:^L+VWFM+VRO((KJTN[6XC:*XMKJVG5X;BWGB=XI
MH94>.6-F1U96(/\ /M_Q$_\ _!([_HJGQ>_\1[^*W_S/T?\ $3__ ,$CO^BJ
M?%[_ ,1[^*W_ ,S]'^I'&'_1,9[_ .&S%_\ RKS7WA]9P_\ S^I?^!Q_S\U]
MY^_>A>'] \+:7;:'X9T/2/#FBV7F"ST?0M-LM(TNT$LCS2BVT_3X+>T@\V:1
MY9/*A3?([NV68DZ]?SV_\1/_ /P2._Z*I\7O_$>_BM_\S]'_ !$__P#!([_H
MJGQ>_P#$>_BM_P#,_1_J1QA_T3&>_P#ALQ?_ ,J\U]X?6</_ ,_J7_@<?\_-
M?>?T)45_/;_Q$_\ _!([_HJGQ>_\1[^*W_S/T?\ $3__ ,$CO^BJ?%[_ ,1[
M^*W_ ,S]'^I'&'_1,9[_ .&S%_\ RKS7WA]9P_\ S^I?^!Q_S\U]Y_0E17\]
MO_$3_P#\$CO^BJ?%[_Q'OXK?_,_1_P 1/_\ P2._Z*I\7O\ Q'OXK?\ S/T?
MZD<8?]$QGO\ X;,7_P#*O-?>'UG#_P#/ZE_X''_/S7WG]"5%?SV_\1/_ /P2
M._Z*I\7O_$>_BM_\S]'_ !$__P#!([_HJGQ>_P#$>_BM_P#,_1_J1QA_T3&>
M_P#ALQ?_ ,J\U]X?6</_ ,_J7_@<?\_-?>?T)45_/;_Q$_\ _!([_HJGQ>_\
M1[^*W_S/T?\ $3__ ,$CO^BJ?%[_ ,1[^*W_ ,S]'^I'&'_1,9[_ .&S%_\
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M17\]O_$3_P#\$CO^BJ?%[_Q'OXK?_,_1_P 1/_\ P2._Z*I\7O\ Q'OXK?\
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M1_\ AM_!O_RFKURBCZUB?^@BO_X.J?\ R0679?<CR/\ X9_^ _\ T1/X1_\
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M _\ T1/X1_\ AM_!O_RFKURBCZUB?^@BO_X.J?\ R0679?<CR/\ X9_^ _\
MT1/X1_\ AM_!O_RFH_X9_P#@/_T1/X1_^&W\&_\ RFKURBCZUB?^@BO_ .#J
MG_R0679?<CR/_AG_ . __1$_A'_X;?P;_P#*:C_AG_X#_P#1$_A'_P"&W\&_
M_*:O7**/K6)_Z"*__@ZI_P#)!9=E]R/(_P#AG_X#_P#1$_A'_P"&W\&__*:C
M_AG_ . __1$_A'_X;?P;_P#*:O7**/K6)_Z"*_\ X.J?_)!9=E]R/(_^&?\
MX#_]$3^$?_AM_!O_ ,IJ/^&?_@/_ -$3^$?_ (;?P;_\IJ]<HH^M8G_H(K_^
M#JG_ ,D%EV7W(\C_ .&?_@/_ -$3^$?_ (;?P;_\IJ/^&?\ X#_]$3^$?_AM
M_!O_ ,IJ]<HH^M8G_H(K_P#@ZI_\D%EV7W(\C_X9_P#@/_T1/X1_^&W\&_\
MRFH_X9_^ _\ T1/X1_\ AM_!O_RFKURBCZUB?^@BO_X.J?\ R0679?<CR/\
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M  '_ .B)_"/_ ,-OX-_^4U'_  S_ / ?_HB?PC_\-OX-_P#E-7KE%'UK$_\
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M?6L3_P!!%?\ \'5/_D@LNR^Y'D?_  S_ / ?_HB?PC_\-OX-_P#E-1_PS_\
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MKE%'UK$_]!%?_P '5/\ Y(++LON1Y'_PS_\  ?\ Z(G\(_\ PV_@W_Y34?\
M#/\ \!_^B)_"/_PV_@W_ .4U>N44?6L3_P!!%?\ \'5/_D@LNR^Y'Y+?\%:/
M@M\'-!_X)G_MPZSH?PD^&.CZOIW[-_Q+N=/U33/ /A2QU&PNDT*X\NZLKVVT
MF.XM+F(G=#<021S0N!)$Z.JL,3_@CQ\&/@[X@_X)B_L6ZSKWPF^&>M:QJ'P6
MT:>_U75? ?A74-1OI_[1U1#/>7MWI,MS=3LJJ'FGE>5R,NS')KV;_@K]_P H
MO?V[O^S:?B;_ .F*>L/_ ((P_P#*+/\ 8B_[(CHW_ISU:OK5B*_^HKG[>MS?
MZVQCS>TGS<O]CS?+?FO:^MKVOJ867UE*RM[!]/\ IY$^WO\ AG_X#_\ 1$_A
M'_X;?P;_ /*:C_AG_P" _P#T1/X1_P#AM_!O_P IJ]<HKY+ZUB?^@BO_ .#J
MG_R1O9=E]R/(_P#AG_X#_P#1$_A'_P"&W\&__*:C_AG_ . __1$_A'_X;?P;
M_P#*:O7**/K6)_Z"*_\ X.J?_)!9=E]R/(_^&?\ X#_]$3^$?_AM_!O_ ,IJ
M/^&?_@/_ -$3^$?_ (;?P;_\IJ]<HH^M8G_H(K_^#JG_ ,D%EV7W(\C_ .&?
M_@/_ -$3^$?_ (;?P;_\IJ/^&?\ X#_]$3^$?_AM_!O_ ,IJ]<HH^M8G_H(K
M_P#@ZI_\D%EV7W(\C_X9_P#@/_T1/X1_^&W\&_\ RFH_X9_^ _\ T1/X1_\
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M^M8G_H(K_P#@ZI_\D%EV7W(\C_X9_P#@/_T1/X1_^&W\&_\ RFH_X9_^ _\
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MHH^M8G_H(K_^#JG_ ,D%EV7W(\C_ .&?_@/_ -$3^$?_ (;?P;_\IJ/^&?\
MX#_]$3^$?_AM_!O_ ,IJ]<HH^M8G_H(K_P#@ZI_\D%EV7W(\C_X9_P#@/_T1
M/X1_^&W\&_\ RFH_X9_^ _\ T1/X1_\ AM_!O_RFKURBCZUB?^@BO_X.J?\
MR0679?<CR/\ X9_^ _\ T1/X1_\ AM_!O_RFH_X9_P#@/_T1/X1_^&W\&_\
MRFKURBCZUB?^@BO_ .#JG_R0679?<CR/_AG_ . __1$_A'_X;?P;_P#*:C_A
MG_X#_P#1$_A'_P"&W\&__*:O7**/K6)_Z"*__@ZI_P#)!9=E]R/(_P#AG_X#
M_P#1$_A'_P"&W\&__*:C_AG_ . __1$_A'_X;?P;_P#*:O7**/K6)_Z"*_\
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M"BBB@ HHHH **** "BBB@ HHHH **** /S/_ ."OO[=?BW_@FS^P#\9_VQ?
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M!AAO]WI?X$%%%%?(FX4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS0SC^CVOQ%_X-_\ _@G;_P .[O\ @GK\._#'C#3/(^/WQQ:+XX?M :G=Q?\
M$Z/C'Q=9Q7.D^%-1NIK*ROY1X(\/R6FCO;WXGDM];DU^9)G6\)/[=4 5KV]M
M--L[O4;^YAL[&PMI[V]N[B18K>UM+6)Y[FYGE<A8X8(8WEED8A4169B #7\]
M/_!(/]N?]I'_ (*??M3?MO\ [4%GXVN='_X)W_"KXCS? /\ 92\!Z?HNC1V_
MQ)USP_9VQ\5?%'7/$4UC#XEGCN=-;1_$FE:#,MC%IT7CNPM+I9[G1':;Z@_X
M+V?M(:O^RO\ \$D?VT_B?X:OM1TSQ9J7PO/PM\*ZEI,DMOJ6F:U\8]<TKX8I
MJ]E>18:PN=%L/%-]K,%Z'CDMYK!&MV-T8$?D?^#=SX&?\*"_X([?L6^&[E+'
M^V/&OP_U#XP:Y/816T<=S=?%;Q+K'C+2VGDMT5KJ[M?"^IZ!IMS<7+RW!DL3
M$72&&&"$ _:VOPB_X+H?\%JO#G_!(;X2_#63PKX'T7XR_M(?&OQ))8_#;X3:
MKJFI:=8+X1\/S6DGC3QOXBET:"?4X]-LQ>6.@:):VQCNM4\0ZO;O L]AI.L^
M1^QOQL^,OPZ_9W^$7Q(^.GQ<\16OA/X:?"?P;K_COQKK]UEUT_0/#NGSZC>F
MVMU/G7^I7*0BSTK2[59+[5M3N+33;"&>\NH(7_A=^$/PA^(__!3/X'_\%3_^
M"^O[5_ANXTFVUS]F']H3X0?L ?#6Z"3>'?!GPI\+^"_%/A35/'UI8WYN[Q=8
MM+FVO]&TO5HYK6&[\7W_ ,0_$5M;1H^@M: ']4G_  1L_P""@/C3_@IM^PMX
M&_:T\??#SPO\+_$7BWQ?X_\ #DWA'PAJVK:UHMK:^#_$$VC6=W%?:U##?&XO
MH8Q/<PNK1PR$I%(ZC=7ZG5_-E_P:<_\ *&+X+?\ 93_C9_ZG%U7])M &'XG\
M3:!X+\-^(/&'BO5[+0/"_A71=4\1^(]=U*9;?3M&T+1+&?4M6U2^G;Y8;2PL
M+:>ZN)#G9%$[8.,5_(W=?\%^?^"B/[=_QD\>^"O^"+W[ &F_'#X$_#O5KKPG
MJO[3?QHU+4?#WA76?$EC+>W;WVEQ2:GX:TC2M&U/2H;#^R=(O+W6/%,IU&VU
M#4K#1[:ZMX1_5#\?_@AX(_:4^"_Q*^ GQ)?Q$O@#XL>%-2\%^,%\)^(M3\)>
M()_#^KHL.IVFG>(M'E@U+3&O;8/9W$MK*CRVD]Q;/F*9U/@'[/?P3_8Y_P""
M7/[.O@3]G[X?ZUX,^!7P7\/ZIKB>%8_B%XVTK3)]6US7M0N=>U>2]\2^)KRR
MN?$FNW,]S)+/=WEQ=:E);10))(T-O&% /Q3_ &+/^"\W[0NG_ME>$/\ @GU_
MP5O_ &1XOV+_ ([?%.QTR'X)^/\ 0K_4-4^&'Q)\0WJ0+9Z'/>7-SJNGV<VO
MSRFQTS5]#\0:MI%EX@2+P]K4>E75];.G] W[6'[27@']CW]FWXU?M/?%#[:_
M@7X(_#_7O'NO6NF1^;J>J)I-M_Q+]#TU2K(-1U[59;'1;"2?;;0W=_#+=216
MR2R)_'A_P6\^,WPV_P""J_\ P42_X)J?L=_\$]-;\._'WXW? +XY77Q%^+OQ
MB^'%UJ6N^!_@OX:LM<\,7.IZ-XA^(GANUU/1((K,>&-0UKQ%_9T]])HNHZ/I
MNEW3PZI?"RK^H[_@JQ^RAXE_;B_X)W?M8_LL^"[TV/C7XK_"VZM/!3&]M=-A
MOO&7A;6-(\<^$]$O=0O5>TL=-\0^(/#&G:#JEW<;(;?3M2NI7F@"&:, _GC?
M_@N-_P %CO O[+_A7_@J1\6/V ?@+:_\$[?%FH^#]6F\)>'OB'XH?]HG0_A'
MXL\4V7AW3?B5#:7$$NGRV>L6TL6K:1?:E8PZ5/9ZSI>HW5K8:-.NH0_UH^ ?
MC%\/_B+\&O"/Q\T/7K6U^%_C/X<Z-\5M.\2ZW)'H]G9>"=:\.P>*H=8UB6^>
M*+2[>ST6<7>I27<D<5DD4[S2*D3./X</'G[;_P"T!\>O^"1?@#_@ASX1_P""
M=G[:6D_M_CX/_"+]D[Q#I'BSX37.A?"'0O#GPTG\.^&-8^+EW\1Y]7:*W\(R
M>'/#,=V]_?Z?9Z79:E=W,L]XWAVSCU6[^O?VY=;^+7COPC^Q?_P;3?L=>,I=
M6^(FJ?!7X9:%^W[\;M%9=67X*? 3PII&B0^+=*GO5AMK.RU#QC+'-.MDP;49
M=#ET'PW-'&WB6Y9@#]?_ /@F)_P4V^+_ /P4S^,'[3'CGP!\$/#WA'_@GM\+
M?$EW\.?@5\>M;U'78_B/\?O'FD7-A;^(M1TGPVRG0=-\%Z#]GUA[RZ:1[N1M
M8\*6UO++>1>([;3L7_@NG^T%^V!^Q;^S1X0_;<_94\91IHO[.OQ(\+:M^T3\
M(-3\+6/B31_BK\$O$&M:=HWB)([J>-;OPOJ_AU[B.[BUVVN8DAL[JY>0"2W@
MW_J'^S#^S9\(_P!D+X#_  T_9R^!OA;3_"'PT^%OAJR\.Z#IEA;PV[W<L2^;
MJOB#5GA1!>^(/$NJRWFN^(-2D!FU#5[^\NI#NEP*/[7/P=T3]H+]ES]H7X)>
M(=,M]8TKXH?!SXA>#9=.NDN)8)[G6?#&I6VFL\=HR74AM]3-G<HENPE>2%53
M+$ @'1?L[?';P%^T]\"OA-^T+\+[V34/A_\ &/P)X>\?^%;B;RQ<KI?B&PBO
M8[6\2)Y$BO["1Y;&_@#L8+RVGA;#(0/9J_E"_P"#0/XPZ_XL_P""<?Q,^!'B
M?4+J\U3]EG]I;Q_\-[."]FB::RT37[;3?&D$%M RKJ-OIL6M:OK]O:IJ )BD
MM[FUMO+@ME@B_J]H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#\X?^"OW_ "B]_;N_[-I^)O\ Z8IZP_\ @C#_ ,HL_P!B
M+_LB.C?^G/5JW/\ @K]_RB]_;N_[-I^)O_IBGK#_ .",/_*+/]B+_LB.C?\
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MD5O%JNEWEE>VVHZ%KUK!%;:E9RO#+#::I8ZGIUE^DM?Q5?\ !,_P[9_L+?\
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M-[%=:7#<66H'3;BYU.WU?1[E]9T#6-4L+2ZDB_77]CO]GOP=^RA^RO\ L_\
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MU\8?@;I7Q*M9+WPWK/C30]3-[;"9[">WU.[T?4!'?/!:W.FJ]AK;"P'ZD?\
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MKZ9Y!=I(X!_0#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?SA?\'.W_)BWP?\ ^SQ?V??_ %)9*_H]K^<+_@YV_P"3%O@_
M_P!GB_L^_P#J2R5]9P+_ ,EAP]_V,J/_ +<<^+_W>K_A_5']#?A#_D4O"_\
MV+NB?^FRUKHJYWPA_P BEX7_ .Q=T3_TV6M=%7RL_CE_BE^;-X[+T7Y!7\R_
M_!,__E/5_P %KO\ L!_ S_T?JE?TT5_,O_P3/_Y3U?\ !:[_ + ?P,_]'ZI7
MUO#7_(HXV_[)RA_ZT&2F-;^)A_\ KZ__ $U4/Z:****^0-PHHHH **** "BB
MB@ HHHH **** "BBB@#^>3_@ZC_Y0>?M<_\ 8=_9T_\ 6D_A/7W1_P $9O\
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M/^SY\6['QA^U[XIE^-WBSX_^)([+QU:?$*&&ZNX_#MO<ZCXO\.WE]I6G:?J
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M[X'\7:=;:AX_UB[T^XOO#OB2QTW5[2"_M)([JSDN+2-;BWD2:+<C D _)O\
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MVYO+/0]'N-7\.^(?#VJ:@HM;CQ';:?>^*O#LVK*\^C0VQN)'N/UB_P""7_\
MP7NTO]LW]HWQ-^PG^U;^S9XV_8H_;D\,66LZFGPG\737=_X?\4V>@V%MJFJV
M>AZMJMAHVK6GB"#2I9M<MM)O],DM]6T&VN=3T?5;Z.VE4?FE^S/_ ,%S/^"C
M_P#P3^\'VW[*?_!4;_@F[^V;\<OC9X"\0:]H6E?M#_"CPO?^,]-^+FE37JZA
MH]VNL6>B7'A?Q??*=3^Q6VL^%->:W.DQZ5:7ND6.KV][;+J?L2? #]M__@J[
M_P %EOAS_P %A/VE?V4?$_[#/[.7[.?PTA\$_!/X?^/R=(^+?Q'U73;/Q=::
M6==TZ]T7P[XGU.QAUKQQXEUW5?%.N>&M TRY\/P^%_"?AM]=LH;R_M0"M_P4
M[_Y6I/\ @CW_ -BC'_Z!\4:_6?\ X+I?\$B?%W_!4/X7_!/Q3\"_BK:?!?\
M:K_91\;:G\1/@;XSU*.ZBT:_N]4;0+O4O#VJZIID<NIZ)=#5/"?AW6?#.O06
M]]'I&L:<R7%G]BU.^N(?SZ_X*+?L[_'_ ,9_\'*O_!*GXW>#_@A\6_%7P9^'
M_A:*W\=?%KP[\._%FM?#7P;/M^(X,/BGQOIVDW/AOP_*OVVSS'JVI6C?Z7;
M F:,-]R?\%OG_P""L_PHN/V<_P!K#_@FC?Z_\3?"/P+\3OK?[37[)>A16]UJ
M7QD\$:/J%KKT$NEZ6EM)KOB"WNM,C\1>&?$NA^$ISXPEBO\ P_J/AO3=5O--
MDB@ /S.O?^"HW_!Q5_P3G\#6VM?M^_\ !.;P5^T]\*_!5K%JWQ!^.OP'U^"/
M5]%\$:?)8Z/>ZCX@B\%3^(] 775G676+C4[CPYHFE2VEX);N#3;>WN+Q/Z3_
M /@GG^W_ / C_@I7^S-X2_:?_9_O-53POKUU?:#XA\,>)+>&S\5>!?&FB^3'
MX@\)^(+2":>(W%A/,DECJ-N[66M:7/9ZM8L;:[0+_.CXV_X.1?VGOC9\+O$/
MP;^ '_!&']MN^_:E\;>#]2\*IX<\;^ ]>G^&W@O7O$6E2Z2NO:_<R^"8+O6?
M"^GW=_;W4MKK]EX3T^\L9 FJZK86WG2-^C7_  ;K_P#!-;XN?\$VOV(-:\.?
MM"_9=-^/?Q_^*.L_&_XF^#-+U'3=2T;P!>:KI>F:)HGA2WGT93H_]IVFC:5;
MW.OKI%S>Z5!JMU-8Z?>7-K9QS. ?OI1110!_-%_P:U_\F.?M"_\ 9\OQT_\
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M7PU^"?C[6;+4/LYO&C\0W&A7>E>%8H[01S?:9+GQ-J&DVR0F*17,N)%\L.0
M?S ?\&AUO/<WW_!5W78(FET>^_:]-O::DN#;W$ZS>+[PQ1DD.6%K=VTYW(!Y
M<Z$')8#^S^OYE?\ @U _9M\0?!3_ ();:;\5O&N@WVA^-OVM?BQXT^/FH27U
M]:W/]M^&M0^Q>&_!&O6MI:O(FDVFL:%HBZG!82.)S'=K>30V\ETT2_TU4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^</
M_!7[_E%[^W=_V;3\3?\ TQ3UA_\ !&'_ )19_L1?]D1T;_TYZM6Y_P %?O\
ME%[^W=_V;3\3?_3%/6'_ ,$8?^46?[$7_9$=&_\ 3GJU?7+_ )(.7_971_\
M5-,P_P"8E?\ 7A_^G(GZ=4445\B;A1110 4444 %%%% !1110 4444 %%%%
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M&CQI<?Q8\-&\-QM=/,M=I7SHVWJ^5RC8X_H]K\[O^"LW[--]^UY_P3B_:_\
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M+BV:Z_X0?XF>'YH];\ >+A%%BYDM-+\1V=FFN6MI)!<ZIX;NM:T>.XA&H-(
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M 2"0"1T) R,]<'MGVI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
M HP  /0  <G)X'J>?K2T44 %%%% !1110 4@ &< #)R< #)]3ZGWI:* "BBB
M@!  HP  /0  <G)X'J>?K2T44 (0#C(!P<C(!P?4>A]Z6BB@ HHHH 3 !)
M)ZG R<=,GJ<4M%% !1110!_-%_P:U_\ )CG[0O\ V?+\=/\ TT^!*_I=K^:+
M_@UK_P"3'/VA?^SY?CI_Z:? E?TNU]=Q[_R6/$'_ &,*G_I$###?[O2_P(**
M**^1-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!K*KJR.JNCJ5=& 965@0RLI!#*P)!!!!!((Q7XC?L!_\$O/BS_P
M3O\ VX_VQ?'/P;^(WP]O/V!?VM=:/Q:A^!%_%XAT[X@_!OXX75Q->ZK)X%MK
M#17\#-\/K^?4M;LX]/@O=#N[31)/#.EBRG7PA:SZG^W=% !1110 4444 %(0
M",$ @]01D?D:6B@ HHHH **** #_ #^?6OQ__P""O_[ 7[07_!2OX8?"7]E_
MP-\6? OPC_9NU?XJ^&?%G[5]YJ+>*Y_B5XX^'_A34K74;7P#X L]%T]=%$>K
M3K-<ZG<Z]K^F0K<VFE@0W,"3H_[ 44 <?\/? 7A3X6>!/!OPT\":1!H/@OP!
MX8T/P=X4T6V+&#2_#_AW3;;2=)LD=RTDGV>RM88VFE9I9G#2RN\CLQ["BB@
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M67_S)TH_X)X?\%\@0?\ A\3X/X.>?A#9,/Q!\)X(]C7]*E%'^NF:?] /#?\
MXC&1?_,'E^?=A]6A_-6_\'5/_DOZN_*W\#__  1/_9/_ ."HGQH_9I^+'B/]
MD'_@H!H'[-/P]TO]I?XF>&_$W@O4O 5MXDGU[XA:98>&7\1>-([V70M1>W@U
MN&ZTZ%+)9D6(V);R4+ M^Q?_  [O_P""^7_28GPA_P"&BLO_ )DZK_\ !K7_
M ,F.?M"_]GR_'3_TT^!*_I=KZ;C+BO,,'Q1G>&I8/(ITZ&-G"$\1P_D^)KR2
MC#6I7KX.=6K+O*I.3>U[&6'H0E1IR<JJ;BG959I?)*227IW?E;^:K_AW?_P7
MR_Z3$^$/_#167_S)T?\ #N__ (+Y?])B?"'_ (:*R_\ F3K^E6BOF?\ 73-/
M^@'AO_Q&,B_^8/+\^[-?JT/YJW_@ZI_\E_5WY6_FJ_X=W_\ !?+_ *3$^$/_
M  T5E_\ ,G1_P[O_ ."^7_28GPA_X:*R_P#F3K^E6BC_ %TS3_H!X;_\1C(O
M_F#R_/NP^K0_FK?^#JG_ ,E_5WY6_FJ_X=W_ /!?+_I,3X0_\-%9?_,G1_P[
MO_X+Y?\ 28GPA_X:*R_^9.OZ5:*/]=,T_P"@'AO_ ,1C(O\ Y@\OS[L/JT/Y
MJW_@ZI_\E_5WY6_FJ_X=W_\ !?+_ *3$^$/_  T5E_\ ,G1_P[O_ ."^7_28
MGPA_X:*R_P#F3K^E6BC_ %TS3_H!X;_\1C(O_F#R_/NP^K0_FK?^#JG_ ,E_
M5WY6_FJ_X=W_ /!?+_I,3X0_\-%9?_,G1_P[O_X+Y?\ 28GPA_X:*R_^9.OZ
M5:*/]=,T_P"@'AO_ ,1C(O\ Y@\OS[L/JT/YJW_@ZI_\E_5WY6_FJ_X=W_\
M!?+_ *3$^$/_  T5E_\ ,G1_P[O_ ."^7_28GPA_X:*R_P#F3K^E6BC_ %TS
M3_H!X;_\1C(O_F#R_/NP^K0_FK?^#JG_ ,E_5WY6_FJ_X=W_ /!?+_I,3X0_
M\-%9?_,G1_P[O_X+Y?\ 28GPA_X:*R_^9.OZ5:*/]=,T_P"@'AO_ ,1C(O\
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M5:*/]=,T_P"@'AO_ ,1C(O\ Y@\OS[L/JT/YJW_@ZI_\E_5WY6_FJ_X=W_\
M!?+_ *3$^$/_  T5E_\ ,G1_P[O_ ."^7_28GPA_X:*R_P#F3K^E6BC_ %TS
M3_H!X;_\1C(O_F#R_/NP^K0_FK?^#JG_ ,E_5WY6_FJ_X=W_ /!?+_I,3X0_
M\-%9?_,G1_P[O_X+Y?\ 28GPA_X:*R_^9.OZ5:*/]=,T_P"@'AO_ ,1C(O\
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M5:*/]=,T_P"@'AO_ ,1C(O\ Y@\OS[L/JT/YJW_@ZI_\E_5WY6_FJ_X=W_\
M!?+_ *3$^$/_  T5E_\ ,G1_P[O_ ."^7_28GPA_X:*R_P#F3K^E6BC_ %TS
M3_H!X;_\1C(O_F#R_/NP^K0_FK?^#JG_ ,E_5WY6_FJ_X=W_ /!?+_I,3X0_
M\-%9?_,G1_P[O_X+Y?\ 28GPA_X:*R_^9.OZ5:*/]=,T_P"@'AO_ ,1C(O\
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M$^$/_#167_S)U_2K17S/^NF:?] /#?\ XC&1?_,'E^?=FOU:'\U;_P '5/\
MY+^KORM_-5_P[O\ ^"^7_28GPA_X:*R_^9.C_AW?_P %\O\ I,3X0_\ #167
M_P R=?TJT4?ZZ9I_T \-_P#B,9%_\P>7Y]V'U:'\U;_P=4_^2_J[\K?S5?\
M#N__ (+Y?])B?"'_ (:*R_\ F3H_X=W_ /!?+_I,3X0_\-%9?_,G7]*M%'^N
MF:?] /#?_B,9%_\ ,'E^?=A]6A_-6_\ !U3_ .2_J[\K?S5?\.[_ /@OE_TF
M)\(?^&BLO_F3H_X=W_\ !?+_ *3$^$/_  T5E_\ ,G7]*M%'^NF:?] /#?\
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MTJT4?ZZ9I_T \-_^(QD7_P P>7Y]V'U:'\U;_P '5/\ Y+^KORM_-5_P[O\
M^"^7_28GPA_X:*R_^9.C_AW?_P %\O\ I,3X0_\ #167_P R=?TJT4?ZZ9I_
MT \-_P#B,9%_\P>7Y]V'U:'\U;_P=4_^2_J[\K?S5?\ #N__ (+Y?])B?"'_
M (:*R_\ F3H_X=W_ /!?+_I,3X0_\-%9?_,G7]*M%'^NF:?] /#?_B,9%_\
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M,9%_\P>7Y]V'U:'\U;_P=4_^2_J[\K?S5?\ #N__ (+Y?])B?"'_ (:*R_\
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M /!?+_I,3X0_\-%9?_,G7]*M%'^NF:?] /#?_B,9%_\ ,'E^?=A]6A_-6_\
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M#PW_ .(QD7_S!Y?GW8?5H?S5O_!U3_Y+^KORM_-5_P .[_\ @OE_TF)\(?\
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M#\6'3CJC/I>F^!O#MP]ZITRV^RS-J!BA/F,T$K%"GX[_ +-6KZ1X=_X/!O\
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M?$3P/\0=/M9GM[F]\%>*M#\46MM/&0'AN)]$OKV.&52R[DD96&Y>.1G^%_\
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M[*'PQU+XS?M"^/\ 2OA?\+-$U'2=+USQSKT&HOH.B76N7:Z?I3:S=Z=97O\
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MBBBOD3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)@#_ $VZH:AJNEZ3$L^JZE8:9 [B-)M0O+>RB>0@L(UDN9(T9R 2%#%L G&
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MN.?%_P"[U?\ #^J/Z&_"'_(I>%_^Q=T3_P!-EK715SOA#_D4O"__ &+NB?\
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MJ$,B07<,.NZ3;6&OZ=-+;1P3P7\D-K+<+9RR5^5?_!W-^T'X9\2_LU_L_?\
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MIN@:%I=J&%MINCZ/90:=IFGVX=G<06=E;06\(=V81QKN9CDD _@!_P""9_\
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MKNKZ?!96\<L]QC1!J-ZZ0H9 EF70$KM(!^=/_!%3_@@U^R5\2?V1? /[9/\
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M=IEPNJ:_X.\&V<E[H^@ZWK&D6,DE[8#Q#XDUFV.EB[@"7>D:+X@O%V);0RR
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MH **** "BBB@ HHHH **** "BBB@ HHHH *_G"_X.=O^3%O@_P#]GB_L^_\
MJ2R5_1[7\X7_  <[?\F+?!__ +/%_9]_]262OK.!?^2PX>_[&5'_ -N.?%_[
MO5_P_JC^AOPA_P BEX7_ .Q=T3_TV6M=%7.^$/\ D4O"_P#V+NB?^FRUKHJ^
M5G\<O\4OS9O'9>B_(*_F7_X)G_\ *>K_ (+7?]@/X&?^C]4K^FBOYE_^"9__
M "GJ_P""UW_8#^!G_H_5*^MX:_Y%'&W_ &3E#_UH,E,:W\3#_P#7U_\ IJH?
MTT4445\@;A7Y+?LD_P#!)+X8_LC_ +?7[8'[?OACXM?$#Q;XW_;#M+RT\6>
MO$&F>&K;PIX26[\3:-XFW^'[W3+*'6+EH)M&BLXAJ%Q(#;3RM,)9UCD7]::*
M "OR3^&O_!(_X8_#3_@JQ\;O^"KFG?%SX@ZC\2OC?X'L_ ^L_"F\TSPQ'X!T
M:SLO!'P_\#Q7VG:E!8KXDENA9_#^SO@EQ>F'[5J=ZCJ\,=JL7ZV44 <'\5/
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M(BC5<"O=:* /RM^#/_!*KX<?!C_@J!^TA_P5$TGXK^/M:^(G[2/PLB^%6O\
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MCE_P4.^)G@R]MM3\#Z-\9M1NH? 7A_5M.U"RU'2]3N-(DU?5[[5TM+BR2?\
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ML+ZVD[,"LMO<0M%=65U%!>6<\%W;PS1]_10!_(9XA_X--?!O@WQ-KJ?LB?\
M!1[]L;]EWX1^*-1QJ/PB\.^)]0U;2=*T"]VOK&FZ5J]GXC\.W.HS7,Z^=;W6
MOVM]=+YLT=W>7:OFOU__ ."7?_!%K]CS_@E/HGB.[^"NF^(?'GQA\=V\5O\
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M7.MZ?=ZC:PO<>'8M/=M+FA86=Y<NNVZ6":+]<:* "OS?_P""IO\ P3<\ ?\
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M7[_N?+BO^?M'_P %3\O^GGK^'F?D?_Q$J_\ !(C_ *.)U+_P@/%/_P AT?\
M$2K_ ,$B/^CB=2_\(#Q3_P#(=?KA_P ,N?LT_P#1O?P3_P##6^"/_E)1_P ,
MN?LT_P#1O?P3_P##6^"/_E)1]:X'_P"A-Q+T_P"9]E_E?_F1^OW_ ''+BO\
MG[1_\%3\O^GGK^'F?D?_ ,1*O_!(C_HXG4O_  @/%/\ \AT?\1*O_!(C_HXG
M4O\ P@/%/_R'7ZX?\,N?LT_]&]_!/_PUO@C_ .4E'_#+G[-/_1O?P3_\-;X(
M_P#E)1]:X'_Z$W$O3_F?9?Y7_P"9'Z_?]QRXK_G[1_\ !4_+_IYZ_AYGY'_\
M1*O_  2(_P"CB=2_\(#Q3_\ (='_ !$J_P#!(C_HXG4O_" \4_\ R'7ZX?\
M#+G[-/\ T;W\$_\ PUO@C_Y24?\ #+G[-/\ T;W\$_\ PUO@C_Y24?6N!_\
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M ,(#Q3_\AU^N'_#+G[-/_1O?P3_\-;X(_P#E)1_PRY^S3_T;W\$__#6^"/\
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M\%3\O^GGK^'F?D?_ ,1*O_!(C_HXG4O_  @/%/\ \AT?\1*O_!(C_HXG4O\
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MN*_Y^T?_  5/R_Z>>OX>9^1__$2K_P $B/\ HXG4O_" \4__ "'1_P 1*O\
MP2(_Z.)U+_P@/%/_ ,AU^N'_  RY^S3_ -&]_!/_ ,-;X(_^4E'_  RY^S3_
M -&]_!/_ ,-;X(_^4E'UK@?_ *$W$O3_ )GV7^5_^9'Z_?\ <<N*_P"?M'_P
M5/R_Z>>OX>9^1_\ Q$J_\$B/^CB=2_\ " \4_P#R'1_Q$J_\$B/^CB=2_P#"
M \4__(=?KA_PRY^S3_T;W\$__#6^"/\ Y24?\,N?LT_]&]_!/_PUO@C_ .4E
M'UK@?_H3<2]/^9]E_E?_ )D?K]_W'+BO^?M'_P %3\O^GGK^'F?D?_Q$J_\
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M(C_HXG4O_" \4_\ R'7ZX?\ #+G[-/\ T;W\$_\ PUO@C_Y24?\ #+G[-/\
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M )GV7^5_^9'Z_?\ <<N*_P"?M'_P5/R_Z>>OX>9^1_\ Q$J_\$B/^CB=2_\
M" \4_P#R'1_Q$J_\$B/^CB=2_P#" \4__(=?KA_PRY^S3_T;W\$__#6^"/\
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M_P"CB=2_\(#Q3_\ (='_ !$J_P#!(C_HXG4O_" \4_\ R'7ZX?\ #+G[-/\
MT;W\$_\ PUO@C_Y24?\ #+G[-/\ T;W\$_\ PUO@C_Y24?6N!_\ H3<2]/\
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M/R_Z>>OX>9^1_P#Q$J_\$B/^CB=2_P#" \4__(='_$2K_P $B/\ HXG4O_"
M\4__ "'7ZX?\,N?LT_\ 1O?P3_\ #6^"/_E)1_PRY^S3_P!&]_!/_P -;X(_
M^4E'UK@?_H3<2]/^9]E_E?\ YD?K]_W'+BO^?M'_ ,%3\O\ IYZ_AYGY'_\
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M?]QRXK_G[1_\%3\O^GGK^'F?D?\ \1*O_!(C_HXG4O\ P@/%/_R'1_Q$J_\
M!(C_ *.)U+_P@/%/_P AU^N'_#+G[-/_ $;W\$__  UO@C_Y24?\,N?LT_\
M1O?P3_\ #6^"/_E)1]:X'_Z$W$O3_F?9?Y7_ .9'Z_?]QRXK_G[1_P#!4_+_
M *>>OX>9^1__ !$J_P#!(C_HXG4O_" \4_\ R'1_Q$J_\$B/^CB=2_\ " \4
M_P#R'7ZX?\,N?LT_]&]_!/\ \-;X(_\ E)1_PRY^S3_T;W\$_P#PUO@C_P"4
ME'UK@?\ Z$W$O3_F?9?Y7_YD?K]_W'+BO^?M'_P5/R_Z>>OX>9^1_P#Q$J_\
M$B/^CB=2_P#" \4__(='_$2K_P $B/\ HXG4O_" \4__ "'7ZX?\,N?LT_\
M1O?P3_\ #6^"/_E)1_PRY^S3_P!&]_!/_P -;X(_^4E'UK@?_H3<2]/^9]E_
ME?\ YD?K]_W'+BO^?M'_ ,%3\O\ IYZ_AYGY'_\ $2K_ ,$B/^CB=2_\(#Q3
M_P#(='_$2K_P2(_Z.)U+_P (#Q3_ /(=?KA_PRY^S3_T;W\$_P#PUO@C_P"4
ME'_#+G[-/_1O?P3_ /#6^"/_ )24?6N!_P#H3<2]/^9]E_E?_F1^OW_<<N*_
MY^T?_!4_+_IYZ_AYGY'_ /$2K_P2(_Z.)U+_ ,(#Q3_\AT?\1*O_  2(_P"C
MB=2_\(#Q3_\ (=?KA_PRY^S3_P!&]_!/_P -;X(_^4E'_#+G[-/_ $;W\$__
M  UO@C_Y24?6N!_^A-Q+T_YGV7^5_P#F1^OW_<<N*_Y^T?\ P5/R_P"GGK^'
MF?D?_P 1*O\ P2(_Z.)U+_P@/%/_ ,AT?\1*O_!(C_HXG4O_  @/%/\ \AU^
MN'_#+G[-/_1O?P3_ /#6^"/_ )24?\,N?LT_]&]_!/\ \-;X(_\ E)1]:X'_
M .A-Q+T_YGV7^5_^9'Z_?]QRXK_G[1_\%3\O^GGK^'F?D?\ \1*O_!(C_HXG
M4O\ P@/%/_R'1_Q$J_\ !(C_ *.)U+_P@/%/_P AU^N'_#+G[-/_ $;W\$__
M  UO@C_Y24?\,N?LT_\ 1O?P3_\ #6^"/_E)1]:X'_Z$W$O3_F?9?Y7_ .9'
MZ_?]QRXK_G[1_P#!4_+_ *>>OX>9^1__ !$J_P#!(C_HXG4O_" \4_\ R'1_
MQ$J_\$B/^CB=2_\ " \4_P#R'7ZX?\,N?LT_]&]_!/\ \-;X(_\ E)1_PRY^
MS3_T;W\$_P#PUO@C_P"4E'UK@?\ Z$W$O3_F?9?Y7_YD?K]_W'+BO^?M'_P5
M/R_Z>>OX>9^1_P#Q$J_\$B/^CB=2_P#" \4__(='_$2K_P $B/\ HXG4O_"
M\4__ "'7ZX?\,N?LT_\ 1O?P3_\ #6^"/_E)1_PRY^S3_P!&]_!/_P -;X(_
M^4E'UK@?_H3<2]/^9]E_E?\ YD?K]_W'+BO^?M'_ ,%3\O\ IYZ_AYGY'_\
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M4_+_ *>>OX>9^1__ !$J_P#!(C_HXG4O_" \4_\ R'1_Q$J_\$B/^CB=2_\
M" \4_P#R'7ZX?\,N?LT_]&]_!/\ \-;X(_\ E)1_PRY^S3_T;W\$_P#PUO@C
M_P"4E'UK@?\ Z$W$O3_F?9?Y7_YD?K]_W'+BO^?M'_P5/R_Z>>OX>9^1_P#Q
M$J_\$B/^CB=2_P#" \4__(='_$2K_P $B/\ HXG4O_" \4__ "'7ZX?\,N?L
MT_\ 1O?P3_\ #6^"/_E)1_PRY^S3_P!&]_!/_P -;X(_^4E'UK@?_H3<2]/^
M9]E_E?\ YD?K]_W'+BO^?M'_ ,%3\O\ IYZ_AYGY'_\ $2K_ ,$B/^CB=2_\
M(#Q3_P#(='_$2K_P2(_Z.)U+_P (#Q3_ /(=?KA_PRY^S3_T;W\$_P#PUO@C
M_P"4E'_#+G[-/_1O?P3_ /#6^"/_ )24?6N!_P#H3<2]/^9]E_E?_F1^OW_<
M<N*_Y^T?_!4_+_IYZ_AYGY'_ /$2K_P2(_Z.)U+_ ,(#Q3_\AT?\1*O_  2(
M_P"CB=2_\(#Q3_\ (=?KA_PRY^S3_P!&]_!/_P -;X(_^4E'_#+G[-/_ $;W
M\$__  UO@C_Y24?6N!_^A-Q+T_YGV7^5_P#F1^OW_<<N*_Y^T?\ P5/R_P"G
MGK^'F?D?_P 1*O\ P2(_Z.)U+_P@/%/_ ,AT?\1*O_!(C_HXG4O_  @/%/\
M\AU^N'_#+G[-/_1O?P3_ /#6^"/_ )24?\,N?LT_]&]_!/\ \-;X(_\ E)1]
M:X'_ .A-Q+T_YGV7^5_^9'Z_?]QRXK_G[1_\%3\O^GGK^'F?D?\ \1*O_!(C
M_HXG4O\ P@/%/_R'1_Q$J_\ !(C_ *.)U+_P@/%/_P AU^N'_#+G[-/_ $;W
M\$__  UO@C_Y24?\,N?LT_\ 1O?P3_\ #6^"/_E)1]:X'_Z$W$O3_F?9?Y7_
M .9'Z_?]QRXK_G[1_P#!4_+_ *>>OX>9^1__ !$J_P#!(C_HXG4O_" \4_\
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M4_+_ *>>OX>9^1__ !$J_P#!(C_HXG4O_" \4_\ R'1_Q$J_\$B/^CB=2_\
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MC_:NN_;Y/[/0:V9V^QS&.SN%$C1?O;0 4444 %%%% !17Y8?\%=_^"G^@?\
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MLC^]5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_-%_P:U_\F.?
MM"_]GR_'3_TT^!*_I=K^:+_@UK_Y,<_:%_[/E^.G_II\"5_2[7UW'O\ R6/$
M'_8PJ?\ I$###?[O2_P(****^1-PHHHH **** "BBB@ HHHH **** "BBB@
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M&U*/PMKMO9$7\-OXCM[>?2K:^L6%Q8ZA<V=T5E@CGAE^2?\ @CU_P4?\/?\
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MIUUK=Q937&E:!<:5-9ZC=<QX!_X+J_\ !0O]A3]I+X6? K_@O%^RA\+/V?\
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M\1>&KV;Q#IVI1VEE,K^F_$;_ (*L?'7]GG_@MU\*O^"<'QR\$?#<?LY_M0^
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M1V8 _JSHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUGD _M&HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<Z404U%E;^U"OP__ ."VW_!(P?\ !3;X1^ _%WPB\:1_"']L_P#9FUR3Q_\
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M5TCX5>"M-TK5=2BB2.7Q'XONH_M_C#Q1>; JO>>(/$5SJ&HSN%4'SE4(BJ%
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M _A/\.>+?CG_ ,&RO_!1+]K+7_&W[/7Q=^-?_!+S]M'QE#\1_"WQ ^$.C?\
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M7Q%GU";2M(U'4X;"%_'?[+026^EL;:X2TC8)(ZO<-&ICAN)0?+MYGC_LNHH
M*_C)_P""IWPH_:>_X)0?\%<O#7_!;;]F[X+^*OV@_P!G3XM> 3\,?VQOAGX!
M@>3Q+X?MH-"M+'5]::VL].OY;32-0L_"'A;QQIWBN\@GT^W\8^']1T#7;G1-
M.UO3KV?^S:B@#^4OQ)_P<G_#K]LWPWI_[-W_  3+_9T_:4^*_P"UY\=K#_A
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ME1)8I4:.2.15>.2-U*NCHP*NCJ2K*P*LI(((-*JJBJB*J(BA410%554 *JJ
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M_"]W>>/_ !'IJR#3_$'Q)\8ZSJ/B_P =ZCISSP6]W+I">(M:O=/T!KV)+Q-
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M66BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZEH*W&HP27-_H&OZ3:S>'IIGTV"\UE;>.ZN,O_@DI^SC^VE_P4<_X*F>)_\
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M?'M_%);>#? NC06%K=S)>>)-;-M8R7TL2V6E637>JZC/;V%E<3Q_DA_P0O\
MV&OBC')\3_\ @K!^W/HD=W^WA^W/=R>+[?3-6TN&";]G_P"!U_C_ (0GX:^%
M+:9#<^'1J_AV+1;C5[(>7>1:18Z!INI/+J46KR7/]&E% '\8WC_]H+PU_P $
M:/\ @X!_;'_:6_; \$_$_2/V4?VZ?@KX$;X=_M">$O!/BGXA>&_#OB_PM!X?
M?5?"NN6'A70-0U,2+=Z/K\5W9:='=ZII5O%X=O3I^H:;JDU_IWKW_!">T\7_
M +7'_!4G_@JC_P %:=$^&/Q"^&G[-'[1EGX"^$_P+N?B1HMYX:U;X@P>#K3P
MAI.L^*M.TNYLD2YL GPWL;Z::&[<Z3<^)%T6X^TW\%Z]M_61K&B:+XAL9-,U
M_2-+US39L^=I^L6%IJ5C+E'C/F6E[%/ ^8Y)(SNC.4=U^ZS WX88K>**WMXH
MX(((TAAAA18HH8HE"1Q11H%2..-%5$1%"HH"J  !0!_*[_P=T_&*_P##W_!-
M[P+^S9X-1];^*/[7'[1GPZ^'GA7P+IUO>:AXG\7Z/X;FG\0ZI:^&-*L+B.ZU
M'5!XO?X=Z5#;?9KZ.>77(;9;?[9<6<L?]"W['7P1LOV:OV3OV:_V?-/^UFV^
M"_P,^%OPT\S4$M(]1N+GP=X,T?1+V[U);!([,ZE>7MG<76H/:HL,E[-/)&-K
M"OR1^,G_  3L_:0_;0_X+)?!O]JG]I71_!_AO]B/]A/PS_:_[+G@W3_%VG^)
MO$_Q3^.=_>6&I2_$7Q?X;72GA\+:?HNHQ1W5I:W%XVH&3PCX/FM6CGFU-[;]
M_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *_G"_X.=O^3%O@_P#]GB_L^_\ J2R5_1[7\X7_  <[?\F+?!__ +/%_9]_
M]262OK.!?^2PX>_[&5'_ -N.?%_[O5_P_JC^AOPA_P BEX7_ .Q=T3_TV6M=
M%7.^$/\ D4O"_P#V+NB?^FRUKHJ^5G\<O\4OS9O'9>B_(*_F7_X)G_\ *>K_
M (+7?]@/X&?^C]4K^FBOX?O"/P:_X*(?%S_@MO\ \%;--_8(_:E^'7[-?B[1
M]8^&VI?$#6O'W@V/Q=:>*/!]_9>1X4T/3K:7PIXG2TO-#U*WU>ZN[GR;1IX]
M1AC6:X",L/W'!N&IXS!<88>KC,+@(5>'J,98O&.NL-12SW)Y*57ZO1Q%;E;B
MH+DHS?/.-TH\TH\^(DXRP[493_>OW8VN_P!W-:7:6BUU:V[VO_<#17\S/_#$
MG_!R9_TEA_9K_P##)6?_ ,Z2C_AB3_@Y,_Z2P_LU_P#ADK/_ .=)7)_JOE__
M $6G"O\ X'GGE_U)/-_=YC]O/_H&K_=3\O\ IYYO[O,_IFHK^9G_ (8D_P"#
MDS_I+#^S7_X9*S_^=)1_PQ)_P<F?])8?V:__  R5G_\ .DH_U7R__HM.%?\
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M_AB3_@Y,_P"DL/[-?_ADK/\ ^=)1_JOE_P#T6G"O_@>>>7_4D\W]WF'MY_\
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MG_!R9_TEA_9K_P##)6?_ ,Z2C_AB3_@Y,_Z2P_LU_P#ADK/_ .=)1_JOE_\
MT6G"O_@>>>7_ %)/-_=YA[>?_0-7^ZGY?]//-_=YG],U%?S,_P##$G_!R9_T
MEA_9K_\ #)6?_P Z2C_AB3_@Y,_Z2P_LU_\ ADK/_P"=)1_JOE__ $6G"O\
MX'GGE_U)/-_=YA[>?_0-7^ZGY?\ 3SS?W>9_3-17\S/_  Q)_P ')G_26']F
MO_PR5G_\Z2C_ (8D_P"#DS_I+#^S7_X9*S_^=)1_JOE__1:<*_\ @>>>7_4D
M\W]WF'MY_P#0-7^ZGY?]//-_=YG],U%?S,_\,2?\')G_ $EA_9K_ /#)6?\
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MP<F?])8?V:__  R5G_\ .DH_X8D_X.3/^DL/[-?_ (9*S_\ G25\S_JOE_\
MT6G"O_@>>>7_ %)/-_=YFWMY_P#0-7^ZGY?]//-_=YG],U%?S,_\,2?\')G_
M $EA_9K_ /#)6?\ \Z2C_AB3_@Y,_P"DL/[-?_ADK/\ ^=)1_JOE_P#T6G"O
M_@>>>7_4D\W]WF'MY_\ 0-7^ZGY?]//-_=YG],U%?S,_\,2?\')G_26']FO_
M ,,E9_\ SI*/^&)/^#DS_I+#^S7_ .&2L_\ YTE'^J^7_P#1:<*_^!YYY?\
M4D\W]WF'MY_] U?[J?E_T\\W]WF?TS45_,S_ ,,2?\')G_26']FO_P ,E9__
M #I*/^&)/^#DS_I+#^S7_P"&2L__ )TE'^J^7_\ 1:<*_P#@>>>7_4D\W]WF
M'MY_] U?[J?E_P!//-_=YG],U%?S,_\ #$G_  <F?])8?V:__#)6?_SI*/\
MAB3_ (.3/^DL/[-?_ADK/_YTE'^J^7_]%IPK_P"!YYY?]23S?W>8>WG_ - U
M?[J?E_T\\W]WF?TS45_,S_PQ)_P<F?\ 26']FO\ \,E9_P#SI*/^&)/^#DS_
M *2P_LU_^&2L_P#YTE'^J^7_ /1:<*_^!YYY?]23S?W>8>WG_P! U?[J?E_T
M\\W]WF?TS45_,S_PQ)_P<F?])8?V:_\ PR5G_P#.DH_X8D_X.3/^DL/[-?\
MX9*S_P#G24?ZKY?_ -%IPK_X'GGE_P!23S?W>8>WG_T#5_NI^7_3SS?W>9_3
M-17\S/\ PQ)_P<F?])8?V:__  R5G_\ .DH_X8D_X.3/^DL/[-?_ (9*S_\
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M_P"&)/\ @Y,_Z2P_LU_^&2L__G24?ZKY?_T6G"O_ ('GGE_U)/-_=YA[>?\
MT#5_NI^7_3SS?W>9_3-17\S/_#$G_!R9_P!)8?V:_P#PR5G_ /.DH_X8D_X.
M3/\ I+#^S7_X9*S_ /G24?ZKY?\ ]%IPK_X'GGE_U)/-_=YA[>?_ $#5_NI^
M7_3SS?W>9_3-17\S/_#$G_!R9_TEA_9K_P##)6?_ ,Z2C_AB3_@Y,_Z2P_LU
M_P#ADK/_ .=)1_JOE_\ T6G"O_@>>>7_ %)/-_=YA[>?_0-7^ZGY?]//-_=Y
MG],U%?S,_P##$G_!R9_TEA_9K_\ #)6?_P Z2C_AB3_@Y,_Z2P_LU_\ ADK/
M_P"=)1_JOE__ $6G"O\ X'GGE_U)/-_=YA[>?_0-7^ZGY?\ 3SS?W>9_3-17
M\S/_  Q)_P ')G_26']FO_PR5G_\Z2C_ (8D_P"#DS_I+#^S7_X9*S_^=)1_
MJOE__1:<*_\ @>>>7_4D\W]WF'MY_P#0-7^ZGY?]//-_=YG],U%?S,_\,2?\
M')G_ $EA_9K_ /#)6?\ \Z2C_AB3_@Y,_P"DL/[-?_ADK/\ ^=)1_JOE_P#T
M6G"O_@>>>7_4D\W]WF'MY_\ 0-7^ZGY?]//-_=YG],U%?S,_\,2?\')G_26'
M]FO_ ,,E9_\ SI*/^&)/^#DS_I+#^S7_ .&2L_\ YTE'^J^7_P#1:<*_^!YY
MY?\ 4D\W]WF'MY_] U?[J?E_T\\W]WF?TS45_,S_ ,,2?\')G_26']FO_P ,
ME9__ #I*/^&)/^#DS_I+#^S7_P"&2L__ )TE'^J^7_\ 1:<*_P#@>>>7_4D\
MW]WF'MY_] U?[J?E_P!//-_=YG],U%?S,_\ #$G_  <F?])8?V:__#)6?_SI
M*/\ AB3_ (.3/^DL/[-?_ADK/_YTE'^J^7_]%IPK_P"!YYY?]23S?W>8>WG_
M - U?[J?E_T\\W]WF?TS45_,S_PQ)_P<F?\ 26']FO\ \,E9_P#SI*/^&)/^
M#DS_ *2P_LU_^&2L_P#YTE'^J^7_ /1:<*_^!YYY?]23S?W>8>WG_P! U?[J
M?E_T\\W]WF?TS45_,S_PQ)_P<F?])8?V:_\ PR5G_P#.DH_X8D_X.3/^DL/[
M-?\ X9*S_P#G24?ZKY?_ -%IPK_X'GGE_P!23S?W>8>WG_T#5_NI^7_3SS?W
M>9_3-17\S/\ PQ)_P<F?])8?V:__  R5G_\ .DH_X8D_X.3/^DL/[-?_ (9*
MS_\ G24?ZKY?_P!%IPK_ .!YYY?]23S?W>8>WG_T#5_NI^7_ $\\W]WF?J1_
MP5^_Y1>_MW?]FT_$W_TQ3UA_\$8?^46?[$7_ &1'1O\ TYZM7X.?MZ_LD?\
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M?17\S/\ PQ)_P<F?])8?V:__  R5G_\ .DH_X8D_X.3/^DL/[-?_ (9*S_\
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MG_!R9_TEA_9K_P##)6?_ ,Z2C_AB3_@Y,_Z2P_LU_P#ADK/_ .=)1_JOE_\
MT6G"O_@>>>7_ %)/-_=YA[>?_0-7^ZGY?]//-_=YG],U%?S,_P##$G_!R9_T
MEA_9K_\ #)6?_P Z2C_AB3_@Y,_Z2P_LU_\ ADK/_P"=)1_JOE__ $6G"O\
MX'GGE_U)/-_=YA[>?_0-7^ZGY?\ 3SS?W>9_3-17\S/_  Q)_P ')G_26']F
MO_PR5G_\Z2C_ (8D_P"#DS_I+#^S7_X9*S_^=)1_JOE__1:<*_\ @>>>7_4D
M\W]WF'MY_P#0-7^ZGY?]//-_=YG],U%?S,_\,2?\')G_ $EA_9K_ /#)6?\
M\Z2C_AB3_@Y,_P"DL/[-?_ADK/\ ^=)1_JOE_P#T6G"O_@>>>7_4D\W]WF'M
MY_\ 0-7^ZGY?]//-_=YG],U%?S,_\,2?\')G_26']FO_ ,,E9_\ SI*/^&)/
M^#DS_I+#^S7_ .&2L_\ YTE'^J^7_P#1:<*_^!YYY?\ 4D\W]WF'MY_] U?[
MJ?E_T\\W]WF?TS45_,S_ ,,2?\')G_26']FO_P ,E9__ #I*/^&)/^#DS_I+
M#^S7_P"&2L__ )TE'^J^7_\ 1:<*_P#@>>>7_4D\W]WF'MY_] U?[J?E_P!/
M/-_=YG],U%?S,_\ #$G_  <F?])8?V:__#)6?_SI*/\ AB3_ (.3/^DL/[-?
M_ADK/_YTE'^J^7_]%IPK_P"!YYY?]23S?W>8>WG_ - U?[J?E_T\\W]WF?TS
M45_,S_PQ)_P<F?\ 26']FO\ \,E9_P#SI*/^&)/^#DS_ *2P_LU_^&2L_P#Y
MTE'^J^7_ /1:<*_^!YYY?]23S?W>8>WG_P! U?[J?E_T\\W]WF?TS45_,S_P
MQ)_P<F?])8?V:_\ PR5G_P#.DH_X8D_X.3/^DL/[-?\ X9*S_P#G24?ZKY?_
M -%IPK_X'GGE_P!23S?W>8>WG_T#5_NI^7_3SS?W>9_3-17\S/\ PQ)_P<F?
M])8?V:__  R5G_\ .DH_X8D_X.3/^DL/[-?_ (9*S_\ G24?ZKY?_P!%IPK_
M .!YYY?]23S?W>8>WG_T#5_NI^7_ $\\W]WF?TS45_,S_P ,2?\ !R9_TEA_
M9K_\,E9__.DH_P"&)/\ @Y,_Z2P_LU_^&2L__G24?ZKY?_T6G"O_ ('GGE_U
M)/-_=YA[>?\ T#5_NI^7_3SS?W>9_3-17\S/_#$G_!R9_P!)8?V:_P#PR5G_
M /.DH_X8D_X.3/\ I+#^S7_X9*S_ /G24?ZKY?\ ]%IPK_X'GGE_U)/-_=YA
M[>?_ $#5_NI^7_3SS?W>9_3-17\S/_#$G_!R9_TEA_9K_P##)6?_ ,Z2C_AB
M3_@Y,_Z2P_LU_P#ADK/_ .=)1_JOE_\ T6G"O_@>>>7_ %)/-_=YA[>?_0-7
M^ZGY?]//-_=YG],U%?S,_P##$G_!R9_TEA_9K_\ #)6?_P Z2C_AB3_@Y,_Z
M2P_LU_\ ADK/_P"=)1_JOE__ $6G"O\ X'GGE_U)/-_=YA[>?_0-7^ZGY?\
M3SS?W>9_3-17\S/_  Q)_P ')G_26']FO_PR5G_\Z2C_ (8D_P"#DS_I+#^S
M7_X9*S_^=)1_JOE__1:<*_\ @>>>7_4D\W]WF'MY_P#0-7^ZGY?]//-_=YG]
M,U%?S,_\,2?\')G_ $EA_9K_ /#)6?\ \Z2C_AB3_@Y,_P"DL/[-?_ADK/\
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M44 %%%% !7\X7_!SM_R8M\'_ /L\7]GW_P!262OZ/:_G"_X.=O\ DQ;X/_\
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MJV\5IH5J;UH469[@^'M'T38UXTL_V7[.J.+9;>-/V!_X*F>$].\;_P#!-_\
M;B\,ZJ+,V-_^S#\8IYA?VL=[:[]+\%ZKJ]OYEM,\<;L+FPA,+%P8IQ',F7C5
M2 >K_L5_M.^%OVSOV4?@'^U'X-@ELM"^-GPT\-^.(],G,9N=%U'4K)5UO0[H
M123(MQHVM0W^FR@2-DVV[)# GZ?K^=3_ (-4]8U'6?\ @B=^S-)J-P;A]/\
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ME;0R2?B=_P $AOA-'X*U+XI?\%TO^"KOCWP'\'/VHOVX!%IOPLT7XM^(M \
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MP\-ZC8VWAV3Q=K.H:EXAAU>PT6UA7^J>D)P"0,D D#KG Z<<_E0!_*I\9O\
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M8/$/AB#QOXA\2>'-*\1Z<SZ;JJ:#)-:2/&NX_1?_  <(>-?BI^TE_P %3O\
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M[>Z@OK?PY:O=:3K5C 4O;FWLK;5-7UN#3=/D2PL%MH($! /E[_@X3^)7A_\
M;=_X*5?\$J?^"8GP0UW1O$OQ3\%?M%Z=\9/B[?:-,^NCX7VT,NC74.E>*K73
M$G;3+V+PAI&M>)KR&Y>/[':2:8^H&TCN$=K_ /P>>KL_9:_887.=O[55VN?7
M;X*E&?TK]P?^"9'_  14_9%_X)=R^+?&/PN?QM\6/CO\0;2.Q\=?M!_&?4[+
MQ-\2=7L5N);F;3-*NK>QL[3PWI5[*\#:G;:7$+C5C8V#:M>WTEJCGJO^"JG_
M  2;^#7_  5F^'OPA^'7QF^)7Q2^&NE_!WXBS_$G0[[X6R>$8[_5-5GTA]'-
MCJY\7>&O$ML=/CA?ST%E!:W/GJN^=XMT3 'ZG0?ZB'_KE'_Z M?Q]_L1?\K9
M/_!2G_LV;2__ $'X.5_8.BA$5!DA%503U(4 #/OQ7YA_"7_@EC\(/A!_P4C^
M//\ P4RT3XC?$W5/BO\ '_P#!\/O$O@#5I/"A^'.BZ9 OA14O-"2S\.6OB=;
M[_BDK0YU#Q!>P9O+S,)'V<0 'Z?4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\T7_!K7_R8Y^T+_P!G
MR_'3_P!-/@2OZ7:_FB_X-:_^3'/VA?\ L^7XZ?\ II\"5_2[7UW'O_)8\0?]
MC"I_Z1 PPW^[TO\  @HHHKY$W"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#^*_\ X.NO^3G?^"*__9SVJ?\ J;?!>O[#_BW\/M/^
M+/PJ^)OPKU:40Z5\3/A]XS^'VIS&*.<1:?XS\.:EX<O93#*KQ3".VU*1_*D1
MXY,;'5E)!_.7_@H[_P $DO@O_P %+/B!^RG\0_BK\3/BGX!U/]DKQ_<?$/P7
M9?#J3PBEAXDU2YUCPGK#6?B@>)O#.OW#6*S>$;.!1I,^FS^1=WF9C*8)(?U;
MH _C$_X-3/VB[3]GZ']KW_@D'^T%J>B_#[]HG]F[]H7QQX@\#>"]>U&UL-6\
M6^&]1N[3P]XVTKPX\OD6OB6Y\,>*]&AUY7TV6XO-3T+QO9:E8V\NCV$EU'^E
MW_!RE^W+X"_9._X)H_&?X:GQ#9R_';]J;0&^"?P>\ Z?-:WOBW6#XMNX;'Q3
MXDM_#Y\V]GT/1- 74;:>^6W,9U>_TO3[=I+VYBA;M_\ @I;_ ,&_7[&'_!2/
MXE67[06L:Q\2OV=OVG-/L]/LO^%Z_ G6;/0?$&N1:-:3VFC/XKTF^LKO3-8O
M]/@>WLH=?MO[+\3#2;.WTE=:6S@MDM_GC]D?_@V"_8^^ GQT\)?M*_M ?&G]
MH+]N'XN> M0TK7O!-Q^T'XH@U#PCX9\2Z1.U[8ZU#X>M(Y+S6I+#4F74=,L?
M$>M:KI-C?6MC?0Z<MY:K.P!]Z?\ !#+]E/6OV,_^"6'[(OP3\5:9=:)XU3X?
M-\0O'6C7C2&YTCQC\5-6U#X@ZYI<ZR@20S:=<>(!9SV[(AMYX)8=B[,5^M-%
M% '\77_!PZLOP1_X+)_\$,?VKKO;)H3_ !2TKX17\?,\D4<'Q:\.OJ%XEK*(
M;?%IIGQ.GN#)]K\UWAC'E+Y2-)_93XFT6#Q+X;\0>'KC8;;7]#U719]X#1F#
M5;"XL9-P*N&0QSMN!5@5S\K=#^"7_!RU^PGXC_;<_P""9WCNX^&NF3ZC\9?V
M:=>M/VA?A[!IMM<3Z_JUGX0T_4(O'/AG1'L+.\U3[=JGA>ZN-6T^TTU8;F_U
MWP[HEM]HB5BP_1/_ ()B_MG^"?V_OV&OV>OVG?!=U;^=XU\!Z9I_CO08YXY;
MOP=\4/"T8\.?$3PGJ$:K'+#+I/BG3=1_L^2>WMCJ>B3Z5K5O MGJ5L6 /YAO
M^#737O!7[$/[37_!2S_@F9\;9[;X:?M&:?\ 'RU\9>!O#WB:6PT8>/\ P#HL
M5UX:TL^$)KJ2"76;B:PU/0?$FGZ;;!YKC1/$=K=VEN7CU!(/Z$_^"TO[9WP*
M_8N_X)X_M)>+?C-X@T)+_P ?_"GQW\+_ (:?#Z]O;4:Y\3O'?C?PQJFA:1X;
MT72I1-/>6T37CZEK][]FDLM*T6SO+J[=2((IO+O^"F__  0?_8O_ ."GOBK0
M?BW\09OB!\%?VBO"^G6>CZ/\??@CK-IX>\:SZ1IT[7.GZ;XCL]0L=1T3Q''I
MSO)%IM_>6<>N:7:7%S::9J]G%* GYZ? W_@TW_91T+XJ>%?BM^U]^TS^TI^W
M++X.N(+O2/ 'QB\2_9_ -S=:?>6D^F'78+:ZO_$FLZ;#;:?:6E]X?;Q#:Z%K
M$'VFWU>QO[*5+6( ^A_^#5KX,^/O@Y_P1R^"1\?1WEK+\5/&_P 2?C#X2TR^
MM/L=QIO@;QAJMI:^'<1LJRRV^L1Z)<^)K*YF!:XLM<MY8B;5H,?M)\)/VO?V
M8/CS\1/BG\)/@U\=_AG\2?B9\$M670_BIX(\)^*-/U7Q#X+U,G:\.IZ?#+YL
MD4$^;.[O;'[78V>H*^FW=S#?HUL/?]+TO3-$TW3]&T73K'2-'TFRM=-TK2M,
MM+>PTW3=.LH4MK*PT^QM8XK6SLK2WCC@M;6WBC@@AC2*)$154?B5_P $^?\
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M/AI#JC6FA^*],O8'@U:WLCK.HQVU_:76FZM]BG&EW5[=Z5!!8Q]M_P $U/\
M@D3\#O\ @F[JGQ@^)&B?$+XI_M"?M&_M :C!>_&']HOXXZS;ZY\0_%=M97ES
M>V&CPM:P0VNEZ7%/<++=I&9[K4YK2P>]NI(["RAMP#H/^"UOQ0TKX/\ _!)K
M_@H%XRUB\M;&SN/V8_B3X#CGO06A?4OBSI1^%.BV@&#_ *3J&L^-+"PLB< 7
MES;DD#D?(W_!L1\*=;^%/_!%[]E"/Q%IU_I.J?$%OB9\4/[.U*-XKF+2?%OQ
M)\3#PS>I&P 6RUSPOI^B^(=.9&=9M/U:UN"5>5XH_D[_ (.;_B-XO^/OA?\
M9'_X) ?L_P"I'4/C[^WE\;O#.H^+O#^G16U]<Z!\!OAU=7.LZQXG\26TMY9O
M9Z!%X@L%\6K/'+%+=6/PO\20I/!Y>VX_I3^ WP7\$?LY?!/X3? +X:V=QI_@
M#X-?#SPC\-/!]K>7<^H7R>'_  ;H=EH.FO?W]RSW%_J$]M9)<7][.QEN[R6:
MXD.^0T >LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'YP_\%?O^47O[=W_9M/Q-_P#3%/6'_P $8?\ E%G^Q%_V1'1O_3GJ
MU;G_  5^_P"47O[=W_9M/Q-_],4]8?\ P1A_Y19_L1?]D1T;_P!.>K5]<O\
MD@Y?]E='_P!4TS#_ )B5_P!>'_Z<B?IU1117R)N%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7!_%'XH_#OX*?#SQC\6?BSXQT#X
M??#;X?Z#?^)_&7C/Q/?PZ9H?A_0],A,UW?7UW,0  H$5O;Q++=7MU)!9V4%Q
M=W$$$G>5^?'_  4U_P""=OPW_P""H?[,%]^RO\5_B'\2/AKX,U'QQX3\<WVN
M_"Z[T*U\0W=SX1;4)++2+H>(]&U[2;G1[J>_6YNK>?3I'^TV5E/#)%) K4 ?
MRW67A'XW_P#!T=^UM)\1O'>O^*O@Q_P1&_9O^(-W8_#KPQ)<OX3\2_M4>,/#
M4PM-1U,VKSK<->ZDQE35-;NDDMOAKX;OAX;T*.3QIJ.MWT/]K_@'P[\/OAUX
M/\'_  T^'=EX?\-^#?!'AW1?!_@SPKHD]NEAHGASP[IL&EZ+HVFVXFDE%MIV
MFV<%M"K-)*8X=\CN^]S_ "9Z1_P9Q_LDZ!IUMH^A?MV?M[Z)I%F9C::7I'C7
MX::;IUJ;F:2YN#;6-G\.H;: SW$LMQ,8HE\V:225]TCLQ^C/V6_^#7C]GK]E
MC]HCX._M%^'/VV/VW_&VO?!OQUHOCO2O"7C?QSX)O/"/B&\T68RQ:5XBM=/\
M$V-[<:3=[C%>06UY;2RQ%D$JAC0!_3S1110!_%[_ ,&W4%Q\#O\ @J/_ ,%P
M/V3]6:)]0T/XUM\0K*>,^=Y]O-\1?'%M<(;N7R)Y3%:>(-%<(+0(S23R>9M"
M[O[0J_D(_;6T#3O^"7W_  <-?LQ?\%$=?LCIW[-/[?7@V?\ 96^+OBBWAFM=
M$^'WQ<U&WT/1] U_Q)+;:>NG06NNWFD>#+^;4]7U&.40?\)=J3/'::-<"3^O
M2.1)426)TDBD19(Y(V#I(C@,CHZDJR,I#*RDA@002#0!_%=_P<E?\I8_^"%'
M_9:K/_U<GPRK^T75=5TO0M,U'6]<U*PT;1M(LKK4M6U?5;RWT[3-,TZRA>YO
M;_4;^[DAM;*RM+>.2>ZNKF6*"WAC>661$5F'Y9?MX?\ !)'X+_M^?M(_L?\
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MT7Y!7\R__!,__E/5_P %KO\ L!_ S_T?JE?TT5_&K\ _V^/V3?V&_P#@N/\
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M0GQ1_P#F+H_U2XI_Z)O/O_#3C_\ Y1Y_GV8>WH?\_J7_ (,A_F?M717XJ?\
M$0__ ,$??^CPO#W_ (0GQ1_^8NC_ (B'_P#@C[_T>%X>_P#"$^*/_P Q='^J
M7%/_ $3>??\ AIQ__P H\_S[,/;T/^?U+_P9#_,_:NBOQ4_XB'_^"/O_ $>%
MX>_\(3XH_P#S%T?\1#__  1]_P"CPO#W_A"?%'_YBZ/]4N*?^B;S[_PTX_\
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M/;T/^?U+_P &0_S/VKHK\5/^(A__ ((^_P#1X7A[_P (3XH__,71_P 1#_\
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M(?YG[5T5^*G_ !$/_P#!'W_H\+P]_P"$)\4?_F+H_P"(A_\ X(^_]'A>'O\
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M?M717XJ?\1#_ /P1]_Z/"\/?^$)\4?\ YBZ/^(A__@C[_P!'A>'O_"$^*/\
M\Q='^J7%/_1-Y]_X:<?_ /*//\^S#V]#_G]2_P#!D/\ ,_:NBOQ4_P"(A_\
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M_P ^S#V]#_G]2_\ !D/\S]JZ*_%3_B(?_P""/O\ T>%X>_\ "$^*/_S%T?\
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M&W( %>IU^*G_ !$/_P#!'W_H\+P]_P"$)\4?_F+H_P"(A_\ X(^_]'A>'O\
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MY]F'MZ'_ #^I?^#(?YG[5T5^*G_$0_\ \$??^CPO#W_A"?%'_P"8NC_B(?\
M^"/O_1X7A[_PA/BC_P#,71_JEQ3_ -$WGW_AIQ__ ,H\_P ^S#V]#_G]2_\
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M_B(?_P""/O\ T>%X>_\ "$^*/_S%T?ZI<4_]$WGW_AIQ_P#\H\_S[,/;T/\
MG]2_\&0_S/VKHK\5/^(A_P#X(^_]'A>'O_"$^*/_ ,Q='_$0_P#\$??^CPO#
MW_A"?%'_ .8NC_5+BG_HF\^_\-./_P#E'G^?9A[>A_S^I?\ @R'^9^U=%?BI
M_P 1#_\ P1]_Z/"\/?\ A"?%'_YBZ/\ B(?_ ."/O_1X7A[_ ,(3XH__ #%T
M?ZI<4_\ 1-Y]_P"&G'__ "CS_/LP]O0_Y_4O_!D/\S]JZ*_%3_B(?_X(^_\
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M_:NBOQ4_XB'_ /@C[_T>%X>_\(3XH_\ S%T?\1#_ /P1]_Z/"\/?^$)\4?\
MYBZ/]4N*?^B;S[_PTX__ .4>?Y]F'MZ'_/ZE_P"#(?YG[5T5^*G_ !$/_P#!
M'W_H\+P]_P"$)\4?_F+H_P"(A_\ X(^_]'A>'O\ PA/BC_\ ,71_JEQ3_P!$
MWGW_ (:<?_\ *//\^S#V]#_G]2_\&0_S/VKHK\5/^(A__@C[_P!'A>'O_"$^
M*/\ \Q='_$0__P $??\ H\+P]_X0GQ1_^8NC_5+BG_HF\^_\-./_ /E'G^?9
MA[>A_P _J7_@R'^9^U=%?BI_Q$/_ /!'W_H\+P]_X0GQ1_\ F+H_XB'_ /@C
M[_T>%X>_\(3XH_\ S%T?ZI<4_P#1-Y]_X:<?_P#*//\ /LP]O0_Y_4O_  9#
M_,_:NBOQ4_XB'_\ @C[_ -'A>'O_  A/BC_\Q='_ !$/_P#!'W_H\+P]_P"$
M)\4?_F+H_P!4N*?^B;S[_P -./\ _E'G^?9A[>A_S^I?^#(?YG[5T5^*G_$0
M_P#\$??^CPO#W_A"?%'_ .8NC_B(?_X(^_\ 1X7A[_PA/BC_ /,71_JEQ3_T
M3>??^&G'_P#RCS_/LP]O0_Y_4O\ P9#_ #/VKHK\5/\ B(?_ ."/O_1X7A[_
M ,(3XH__ #%T?\1#_P#P1]_Z/"\/?^$)\4?_ )BZ/]4N*?\ HF\^_P##3C__
M )1Y_GV8>WH?\_J7_@R'^9^U=%?BI_Q$/_\ !'W_ */"\/?^$)\4?_F+H_XB
M'_\ @C[_ -'A>'O_  A/BC_\Q='^J7%/_1-Y]_X:<?\ _*//\^S#V]#_ )_4
MO_!D/\S]JZ_G"_X.=O\ DQ;X/_\ 9XO[/O\ ZDLE?27_ !$/_P#!'W_H\+P]
M_P"$)\4?_F+K\5?^"ZG_  5E_8 _;-_95^&'PO\ V;OV@=)^)/CK2OVG?@OX
MTO\ 0K/POXVTF6V\,>'O$(EUC57N=>\.Z79F*SCF1FACGDN9!N$4+D8/TW!G
M#7$6%XJR+$8G(<YP^'HYA2G5KU\LQM*C2@D[SJ5)T8PA%7UE)I+N88FM2E0J
M1C5IMN.B4XMO5:)7U?D?V9^$/^12\+_]B[HG_ILM:Z*N7\#W,%YX*\'W=M()
MK:Z\+>'[FWE4,%E@GTFTEBD4,%8!XV5@&56 /(!R*ZBOSJ>DYI[\TOS9UQV7
MHOR"OY2?V%_@I\'?C'_P7<_X+.:7\6OA9\/?B9IVC6/P8U/2+'QYX0T'Q7::
M7J.H-?07]]I]OK=C>PVEW>PV]O%=W$")-/'!"DCLL:@?U;5_,O\ \$S_ /E/
M5_P6N_[ ?P,_]'ZI7V'"]2I2ROC2I2J3I5(\.47&=.4H3B_[?R57C*+33LVM
M'LVMF85DG/#II->U>C5_^750_;S_ (84_8J_Z-*_9Q_\,Q\/O_F?H_X84_8J
M_P"C2OV<?_#,?#[_ .9^OJRBOFO[2S'_ *#\;_X55_\ Y8;<D/Y8_P#@*_R/
ME/\ X84_8J_Z-*_9Q_\ #,?#[_YGZ/\ AA3]BK_HTK]G'_PS'P^_^9^OJRBC
M^TLQ_P"@_&_^%5?_ .6!R0_EC_X"O\CY3_X84_8J_P"C2OV<?_#,?#[_ .9^
MC_AA3]BK_HTK]G'_ ,,Q\/O_ )GZ^K**/[2S'_H/QO\ X55__E@<D/Y8_P#@
M*_R/E/\ X84_8J_Z-*_9Q_\ #,?#[_YGZ/\ AA3]BK_HTK]G'_PS'P^_^9^O
MJRBC^TLQ_P"@_&_^%5?_ .6!R0_EC_X"O\CY3_X84_8J_P"C2OV<?_#,?#[_
M .9^C_AA3]BK_HTK]G'_ ,,Q\/O_ )GZ^K**/[2S'_H/QO\ X55__E@<D/Y8
M_P#@*_R/E/\ X84_8J_Z-*_9Q_\ #,?#[_YGZ/\ AA3]BK_HTK]G'_PS'P^_
M^9^OJRBC^TLQ_P"@_&_^%5?_ .6!R0_EC_X"O\CY3_X84_8J_P"C2OV<?_#,
M?#[_ .9^C_AA3]BK_HTK]G'_ ,,Q\/O_ )GZ^K**/[2S'_H/QO\ X55__E@<
MD/Y8_P#@*_R/E/\ X84_8J_Z-*_9Q_\ #,?#[_YGZ/\ AA3]BK_HTK]G'_PS
M'P^_^9^OJRBC^TLQ_P"@_&_^%5?_ .6!R0_EC_X"O\CY3_X84_8J_P"C2OV<
M?_#,?#[_ .9^C_AA3]BK_HTK]G'_ ,,Q\/O_ )GZ^K**/[2S'_H/QO\ X55_
M_E@<D/Y8_P#@*_R/E/\ X84_8J_Z-*_9Q_\ #,?#[_YGZ/\ AA3]BK_HTK]G
M'_PS'P^_^9^OJRBC^TLQ_P"@_&_^%5?_ .6!R0_EC_X"O\CY3_X84_8J_P"C
M2OV<?_#,?#[_ .9^C_AA3]BK_HTK]G'_ ,,Q\/O_ )GZ^K**/[2S'_H/QO\
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M'_H/QO\ X55__E@<D/Y8_P#@*_R/E/\ X84_8J_Z-*_9Q_\ #,?#[_YGZ/\
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M )GZ^K**/[2S'_H/QO\ X55__E@<D/Y8_P#@*_R/E/\ X84_8J_Z-*_9Q_\
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M_HTK]G'_ ,,Q\/O_ )GZ^K**/[2S'_H/QO\ X55__E@<D/Y8_P#@*_R/E/\
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M^IV6AZ?I?@I[#1[2]UK2[VXM],L7N+AK2RA=+>!IYC'&#(V?Z(/^&%/V*O\
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M/V*O^C2OV<?_  S'P^_^9^C_ (84_8J_Z-*_9Q_\,Q\/O_F?KZLHH_M+,?\
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M?H_X84_8J_Z-*_9Q_P##,?#[_P"9^OJRBC^TLQ_Z#\;_ .%5?_Y8')#^6/\
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M9Q_\,Q\/O_F?KZLHH_M+,?\ H/QO_A57_P#E@<D/Y8_^ K_(^4_^&%/V*O\
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M/U]645\G_:68_P#0?C?_  JK_P#RPWY(?RQ_\!7^1\I_\,*?L5?]&E?LX_\
MAF/A]_\ ,_1_PPI^Q5_T:5^SC_X9CX??_,_7U911_:68_P#0?C?_  JK_P#R
MP.2'\L?_  %?Y'RG_P ,*?L5?]&E?LX_^&8^'W_S/T?\,*?L5?\ 1I7[./\
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M  JK_P#RP.2'\L?_  %?Y'RG_P ,*?L5?]&E?LX_^&8^'W_S/T?\,*?L5?\
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M^&8^'W_S/T?\,*?L5?\ 1I7[./\ X9CX??\ S/U]644?VEF/_0?C?_"JO_\
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M644?VEF/_0?C?_"JO_\ + Y(?RQ_\!7^1\I_\,*?L5?]&E?LX_\ AF/A]_\
M,_1_PPI^Q5_T:5^SC_X9CX??_,_7U911_:68_P#0?C?_  JK_P#RP.2'\L?_
M  %?Y'RG_P ,*?L5?]&E?LX_^&8^'W_S/T?\,*?L5?\ 1I7[./\ X9CX??\
MS/U]644?VEF/_0?C?_"JO_\ + Y(?RQ_\!7^1\I_\,*?L5?]&E?LX_\ AF/A
M]_\ ,_1_PPI^Q5_T:5^SC_X9CX??_,_7U911_:68_P#0?C?_  JK_P#RP.2'
M\L?_  %?Y'RG_P ,*?L5?]&E?LX_^&8^'W_S/T?\,*?L5?\ 1I7[./\ X9CX
M??\ S/U]644?VEF/_0?C?_"JO_\ + Y(?RQ_\!7^1\I_\,*?L5?]&E?LX_\
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M.?A]]A^(>F:GJ_A[^Q/%=MXEN-3F^QZ3JVBW1OT.C6Z6LOVT11"25GBE.T
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M1ZC8:>&@M(K:WMUL88F2U+G^IZ@ HHHH **** "BBB@ HHHH **** "BBB@
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M+%(H>.2-U)5T=2&1U)5E(()!!K\)?^#D+]DSPO\ M6_\$FOVD8]4M=/7Q?\
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MZ_O-(G^V:3<S-IUU9W)ETV^6+4+,B8"&]M[:Y ,D*$>"?!?_ ()<_P#!._\
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M\.=7;1+J?Q-I^D6EE=3SP:<^B7EO=7G_ ![VMW=Z2EY]GL[B>]MP#T?]G?\
MX++?MB^"/VW?@5^PS_P50_8<\._LG>,/VK],NIOV<_BC\,OBA:_$;X>Z]XET
MW21>W?@;Q(L<VJR6FN7&J/%X;$UOJT3Z;XANM'MI=+U#1-?L_$D'](#LBH[2
M,JQJK-(SD!%0 EF<MA0H4$L2< 9)XK^*#XQ_M/Z5_P %U_\ @K3_ ,$E)OV-
MO@]\<9/@?^P-\3=7_:,^/7QP^)'P]\1_#?PSH-W=ZK\//%4/@0Q:]IRS-J]A
MJ?PCL/#RE&>'7M9\4"TTUVTW3KK5Q_5_^VW\<M#_ &:?V0?VE/CSXAUBST'3
M_A?\%_B#XHAU2_\ ,-I#K-KX=OH?#<$BQ36\KF^\13Z781117$$LLUS'''-&
M[*Z@'\L/_!H>DTFI?\%7[R!97TB;]KPI:7,0<Z9+,+CQC*5MI$_T1I1:RVTA
M$1W_ &>2!C^[,=?V@5_+G_P:4?L^Z_\ "W_@F5JWQM\8Z/KFC^+?VN?CGXZ^
M--PFLVT5M#J/AN!;+PGX6UG0E93?MH.LV^D7VJV,E_<7+3O>3WEM(;:ZC9_Z
MC* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH _.'_@K]_RB]_;N_P"S:?B;_P"F*>L/_@C#_P HL_V(O^R(Z-_Z<]6K<_X*
M_?\ *+W]N[_LVGXF_P#IBGK#_P"",/\ RBS_ &(O^R(Z-_Z<]6KZY?\ )!R_
M[*Z/_JFF8?\ ,2O^O#_].1/TZHHHKY$W"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH _B[_X+0_\K*?_  0J_P"Y2_\ 5S>*
MZ_M$K^.#_@L=X+\9ZU_P<;_\$0O$^B^#O%FL>&O#W_"(_P!O>(M)\-ZUJ6@Z
M)N^,GBJ0_P!K:Q96,^G:=Y<3+/-]KN8?L]NZ7$_EP.LA_L?H *_BT_;VVW'_
M  =V_P#!-BW\2!7T"V_9M\+7/AA=5S'IR>)CJO[1+.^D/,8X9-6\^'2B8X'D
MF\P689/FC!_M+K^-3_@Y$\/ZI^S/_P %$?\ @CG_ ,%+['36G\*_#?XY:9\&
M_B)+I#FSUR?[3XGL/%/AZWNM1N$;2X])N=!G\=V;"_D@16:2("X2[D-N ?T]
M_MZ>']3\6?L,_MG^%M%A^T:QXE_9/_:*\/Z3!ME;S]3UGX0>,=.L(=L$<TS>
M9=7,2;88993NQ'&[X4_AS_P:,>-+#Q-_P1T\#>';:ZLI;_X:_'3XX>#M:M+=
MY3>:9?WGB.V\;Q6NJQ2$^1>R:=XOLKR-(PL9L;FT<CSFEK^FUTM-1LVCD2WO
MK"_MF1XY%CN+2\M+J(JR.C!XI[>XA<JRL&CEC<@AE;G^##P=K'[5G_!KI^V[
M^T[:6_[+7Q1_:7_X)5_M3^-4^(7@SQ'\*;:XUOQ%\*M0,^KW6AZ<]]<0W%BG
MBOPKHT]_X+\2Z'XMO/#5IXQTJP\-^,-/\16SV?\ 9EZ ?UC_ /!6[QQX?^'/
M_!,C]NKQ;XH>VCT:R_9F^*NG3->.B0&[\2>&KSPUI,99X;A3++JVL6,=NGE,
MTEP\4:%'977\]O\ @UB\/ZUX=_X(E?LJ6^N:;=:9-J6N?'7Q!8172;'NM%U[
MXX^/]3T?4HAD[K74=/N(+NV?C?#*C8&<5^)7[<O_  46_:N_X.(K+P5_P3O_
M .">?[)O[0?PD_9\\=>-O"FI_M/?M%?&'PR?#MAI_@?3-72^B@*Z?J4N@VWA
M.U,$>OW-GJ'B!M=\6ZUI^D>';'2;*.;[;=_VF_LX? ;PC^R-^S/\)/V>/AE9
M7%[X2^!'PL\/> ?#%OM:*]UF+PGHD5HMU*LD]VR:AKU[!+>W'F7-RPO+Z0O<
M3',C 'T%7^<K^T[^PQ:?MK_\'8WQ1_9J^*WB#7-(^$GCO1?#/Q ^*^C:'K>M
M:3=?$+X1>&_A=X0\:Q_#N>\LI+68:7XFUO2O#<.H0[GM;6VM9+NS8WUG92I_
M11_P0^_X*[_MK?\ !1WXU_M>_#3]J3]C:[_9[\.?!75Y]0\%^*X/#_C;P_'H
MAO/$\NA6?P7\<'Q:DMKK_P 0M(L;2^U>[\0:%+I-O>PV%^)O#&EQ"QFNO"_^
M"W_[$7[67P;_ &Q/V<O^"U__  3E^'=W\5_CK\!;=?!_[1_P1T<3'4_BS\)(
M[&?1H[VVTK2[<ZEXC$?A?4]9\,^)8HSJ6I:'86WA+Q5HND7C^%[I8@#]P?%G
M_!+G_@GAXS^",G[.VM?L<?L^K\)/[#/A^S\-Z9\,_#&DW&DV02-;>XT?7]/T
M^#Q#IVJV<D-O=6FKV^J+J,-W:VUP+DR0H1_.1_P;DZ[XV_9%_P""A7_!47_@
MD1<_$'6/'7P2_9R\7R^.?@9#KM_JE[+X6LKGQ$MMJ>E:5#<R7%KI\&H:+X@\
M/W&N10M;1W>OZ;=:C'$\M[.0>*?^#NCP_P")/AKJ/AOX'_\ !.;]KS4_VM=7
MM&T?PA\,_%7A2VG\%VOBB[$5G9:IJVK>'[BX\5ZCH%OJ4SQ"PM?"UAJM]<6Q
ML9FTN&;^TH_K'_@W1_X)M?M/_LZQ_M-_M\?MYP7>E?M??MT^)8/$FO>#-5:0
M:_X$\'+J^I^(C9>*+*<3OHGB'6]<U/[0?#\=]</H&@Z9HFE:ALO[>:"V /Z:
M]5TC2M=L9]+UO3-/UC3+I=EUIVJV5MJ%C<IG.R>TNXIK>9<\[9(V&><5_(Q^
MU[J=S_P76_X*#:;_ ,$V/A!=7>B_\$T?V!O%VF>+_P!NGXB>%'TRQ\,_$SXK
M>')+]?#?P'\-ZEIVI+92:'I[VFH:3?R6EM)_9>HVGB;49K>"70=%EF_23_@N
M3^W+\=OV??@SX+_97_8H\&>*/'7[<?[:VM/\(_A V@^&M6U+3/A5X9UY9-%\
M5_&'7_$']FW/AC0IO#YOK;3_  T->O(UCU6]D\22V=YI'A?5DKZ=_P"";W_!
M-'X6_P#!/']B/2/V6/!GV?4_%OB3PWJM]\;_ (HFWAA\1_$WXH^+=,N(O$_B
M?5M4$+WMW;6$]]+I7AB.\:Y?3="L[.(*T[W+3 'XMZ+_ ,%Q?V[?C#;_ !Y\
M4_\ !+?_ ()?^%OC9^PO^QKK%_\ #"]\?^)_B=!X$\3>-[7X9I;1^((/A)X(
MC.E;K;2/!RVVJ:=H4%CKES#810QQS7NLW5MX;K]\O^"<'[>OPN_X*5_LB?#+
M]K7X4:7J7AK1_'*:MI?B+P1K5W!?ZUX!\;^&M0ETKQ-X1U/4;2&WM-3:QN8H
MKS3M4MK>V35-%U#3-1>SL)[J6PM?Y'/^"<'_  4DTK_@B#^SC^UW_P $^_VQ
MOV:OVB[3]HCP'\:OC+XM^!VD>"OAOXF\5^%_VB=+\>E8_"J^'?%^GZ6VF:1%
MJ%[8W%S%K-YYNEW?AQX+ZVF?6([G1(_V^_X-D?V/_C#^QI_P2M\"^#OCMX4U
M3P'\1/BE\4?B)\<+WP1KT4]IK_A?1_&$?A[0O#EAKNFW,$$VDZG>:'X1L=:E
MTR0RS6T6JP_:'BN7FM;8 _-S_@](*3?L6?LDZ?:E9->O_P!J-DT2SM\-K-U.
MO@?54==)BC_TZ259I[1'%F"XEEM@WS-%7]BOAD,/#?A\.&#C0])#!LA@PL+<
M,&SSN!SG/.<YYK^.?_@X2M)/VS?^"L'_  1T_P""=?AF&^\3+H_Q+/Q\^+NB
M^&X(KO4="\#W'BGP^VKZAK/VBYDT^UAM_ _@#Q+?1/J&G2?8K2\>Z'VU+Z.Q
ME_LOAB2"**&,;8X8TBC7CA(U"*. !PH X 'H!0!)1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %?SA?\'.W_ "8M\'_^SQ?V
M??\ U)9*_H]K^<+_ (.=O^3%O@__ -GB_L^_^I+)7UG O_)8</?]C*C_ .W'
M/B_]WJ_X?U1_0WX0_P"12\+_ /8NZ)_Z;+6NBKG?"'_(I>%_^Q=T3_TV6M=%
M7RL_CE_BE^;-X[+T7Y!7\R__  3/_P"4]7_!:[_L!_ S_P!'ZI7]-%?S+_\
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MWQBBE6,R_O"N_FM.B@ HHHH *_!;]N[_ ()O_M#ZG_P4?_9$_P""H/["UQX
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M:[8X88UBBC7KM2- J(N2>% %2444 %(0&!5@"I!!! (((P00>""."#P12T4
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MMTMK@VNHZ9J,6L3WUV55)8+J&,$L!7]O=?S+_P#!,_\ Y3U?\%KO^P'\#/\
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M_*__ (.GY>?E_5E;^:'_ (9J_P"#EO\ Z/O_ &1?_#3W'_RKH_X9J_X.6_\
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M]<<7_P!"7A7_ ,1S+/+_ *<^7XON'U:/_/RO_P"#I^7GY?U96_FA_P"&:O\
M@Y;_ .C[_P!D7_PT]Q_\JZ/^&:O^#EO_ */O_9%_\-/<?_*NOZ7J*/\ 7'%_
M]"7A7_Q',L\O^G/E^+[A]6C_ ,_*_P#X.GY>?E_5E;^:'_AFK_@Y;_Z/O_9%
M_P##3W'_ ,JZ/^&:O^#EO_H^_P#9%_\ #3W'_P JZ_I>HH_UQQ?_ $)>%?\
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MRO\ ^#I^7GY?U96_FA_X9J_X.6_^C[_V1?\ PT]Q_P#*NC_AFK_@Y;_Z/O\
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M_H^_]D7_ ,-/<?\ RKH_X9J_X.6_^C[_ -D7_P -/<?_ "KK^EZBC_7'%_\
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M_*__ (.GY>?E_5E;^:'_ (9J_P"#EO\ Z/O_ &1?_#3W'_RKH_X9J_X.6_\
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M]<<7_P!"7A7_ ,1S+/+_ *<^7XON'U:/_/RO_P"#I^7GY?U96_FA_P"&:O\
M@Y;_ .C[_P!D7_PT]Q_\JZ/^&:O^#EO_ */O_9%_\-/<?_*NOZ7J*/\ 7'%_
M]"7A7_Q',L\O^G/E^+[A]6C_ ,_*_P#X.GY>?E_5E;^:'_AFK_@Y;_Z/O_9%
M_P##3W'_ ,JZ/^&:O^#EO_H^_P#9%_\ #3W'_P JZ_I>HH_UQQ?_ $)>%?\
MQ',L\O\ ISY?B^X?5H_\_*__ (.GY>?E_5E;^:'_ (9J_P"#EO\ Z/O_ &1?
M_#3W'_RKH_X9J_X.6_\ H^_]D7_PT]Q_\JZ_I>HH_P!<<7_T)>%?_$<RSR_Z
M<^7XON'U:/\ S\K_ /@Z?EY^7]65OYH?^&:O^#EO_H^_]D7_ ,-/<?\ RKH_
MX9J_X.6_^C[_ -D7_P -/<?_ "KK^EZBC_7'%_\ 0EX5_P#$<RSR_P"G/E^+
M[A]6C_S\K_\ @Z?EY^7]65OYH?\ AFK_ (.6_P#H^_\ 9%_\-/<?_*NC_AFK
M_@Y;_P"C[_V1?_#3W'_RKK^EZBC_ %QQ?_0EX5_\1S+/+_ISY?B^X?5H_P#/
MRO\ ^#I^7GY?U96_FA_X9J_X.6_^C[_V1?\ PT]Q_P#*NC_AFK_@Y;_Z/O\
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ME?\ \'3\O/R_JRM_-#_PS5_P<M_]'W_LB_\ AI[C_P"5='_#-7_!RW_T??\
MLB_^&GN/_E77]+U%'^N.+_Z$O"O_ (CF6>7_ $Y\OQ?</JT?^?E?_P '3\O/
MR_JRM_-#_P ,U?\ !RW_ -'W_LB_^&GN/_E71_PS5_P<M_\ 1]_[(O\ X:>X
M_P#E77]+U%'^N.+_ .A+PK_XCF6>7_3GR_%]P^K1_P"?E?\ \'3\O/R_JRM_
M-#_PS5_P<M_]'W_LB_\ AI[C_P"5='_#-7_!RW_T??\ LB_^&GN/_E77]+U%
M'^N.+_Z$O"O_ (CF6>7_ $Y\OQ?</JT?^?E?_P '3\O/R_JRM_-#_P ,U?\
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M^?E?_P '3\O/R_JRM_-#_P ,U?\ !RW_ -'W_LB_^&GN/_E71_PS5_P<M_\
M1]_[(O\ X:>X_P#E77]+U%'^N.+_ .A+PK_XCF6>7_3GR_%]P^K1_P"?E?\
M\'3\O/R_JRM_-#_PS5_P<M_]'W_LB_\ AI[C_P"5='_#-7_!RW_T??\ LB_^
M&GN/_E77]+U%'^N.+_Z$O"O_ (CF6>7_ $Y\OQ?</JT?^?E?_P '3\O/R_JR
MM_-#_P ,U?\ !RW_ -'W_LB_^&GN/_E71_PS5_P<M_\ 1]_[(O\ X:>X_P#E
M77]+U%'^N.+_ .A+PK_XCF6>7_3GR_%]P^K1_P"?E?\ \'3\O/R_JRM_-#_P
MS5_P<M_]'W_LB_\ AI[C_P"5='_#-7_!RW_T??\ LB_^&GN/_E77]+U%'^N.
M+_Z$O"O_ (CF6>7_ $Y\OQ?</JT?^?E?_P '3\O/R_JRM_-#_P ,U?\ !RW_
M -'W_LB_^&GN/_E71_PS5_P<M_\ 1]_[(O\ X:>X_P#E77]+U%'^N.+_ .A+
MPK_XCF6>7_3GR_%]P^K1_P"?E?\ \'3\O/R_JRM_-#_PS5_P<M_]'W_LB_\
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M3\O/R_JRM_-#_P ,U?\ !RW_ -'W_LB_^&GN/_E71_PS5_P<M_\ 1]_[(O\
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M=?TO44?ZXXO_ *$O"O\ XCF6>7_3GR_%]P^K1_Y^5_\ P=/R\_+^K*W\T/\
MPS5_P<M_]'W_ +(O_AI[C_Y5T?\ #-7_  <M_P#1]_[(O_AI[C_Y5U_2]11_
MKCB_^A+PK_XCF6>7_3GR_%]P^K1_Y^5__!T_+S\OZLK?S0_\,U?\'+?_ $??
M^R+_ .&GN/\ Y5T?\,U?\'+?_1]_[(O_ (:>X_\ E77]+U%'^N.+_P"A+PK_
M .(YEGE_TY\OQ?</JT?^?E?_ ,'3\O/R_JRM_-#_ ,,U?\'+?_1]_P"R+_X:
M>X_^5='_  S5_P '+?\ T??^R+_X:>X_^5=?TO44?ZXXO_H2\*_^(YEGE_TY
M\OQ?</JT?^?E?_P=/R\_+^K*W\T/_#-7_!RW_P!'W_LB_P#AI[C_ .5='_#-
M7_!RW_T??^R+_P"&GN/_ )5U_2]11_KCB_\ H2\*_P#B.99Y?].?+\7W#ZM'
M_GY7_P#!T_+S\OZLK?S0_P##-7_!RW_T??\ LB_^&GN/_E71_P ,U?\ !RW_
M -'W_LB_^&GN/_E77]+U%'^N.+_Z$O"O_B.99Y?].?+\7W#ZM'_GY7_\'3\O
M/R_JRM_-#_PS5_P<M_\ 1]_[(O\ X:>X_P#E71_PS5_P<M_]'W_LB_\ AI[C
M_P"5=?TO44?ZXXO_ *$O"O\ XCF6>7_3GR_%]P^K1_Y^5_\ P=/R\_+^K*W\
MT/\ PS5_P<M_]'W_ +(O_AI[C_Y5T?\ #-7_  <M_P#1]_[(O_AI[C_Y5U_2
M]11_KCB_^A+PK_XCF6>7_3GR_%]P^K1_Y^5__!T_+S\OZLK?S0_\,U?\'+?_
M $??^R+_ .&GN/\ Y5T?\,U?\'+?_1]_[(O_ (:>X_\ E77]+U%'^N.+_P"A
M+PK_ .(YEGE_TY\OQ?</JT?^?E?_ ,'3\O/R_JRM_-#_ ,,U?\'+?_1]_P"R
M+_X:>X_^5='_  S5_P '+?\ T??^R+_X:>X_^5=?TO44?ZXXO_H2\*_^(YEG
ME_TY\OQ?</JT?^?E?_P=/R\_+^K*W\T/_#-7_!RW_P!'W_LB_P#AI[C_ .5=
M'_#-7_!RW_T??^R+_P"&GN/_ )5U_2]11_KCB_\ H2\*_P#B.99Y?].?+\7W
M#ZM'_GY7_P#!T_+S\OZLK?S0_P##-7_!RW_T??\ LB_^&GN/_E71_P ,U?\
M!RW_ -'W_LB_^&GN/_E77]+U%'^N.+_Z$O"O_B.99Y?].?+\7W#ZM'_GY7_\
M'3\O/R_JRM_-#_PS5_P<M_\ 1]_[(O\ X:>X_P#E71_PS5_P<M_]'W_LB_\
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M?M"_]GR_'3_TT^!*_I=K^:+_ (-:_P#DQS]H7_L^7XZ?^FGP)7]+M?7<>_\
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M\4+7_A&])TK0_B)XL\(^'Y+.;78M<U*X?5M$\/V.N3R3WB&.74VMA;0_9SN
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M-DUFVA6XN=)COK5]3M[=UC9)Y[!93=10NLT3++)$J,LL9#$.N=*O\^;XC_\
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M<;/#_A#4?#.A6FOZWXW\768%LE]HNC:9=F7;?ZWX:T.TN1%>:]KEMID,T%R
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M+.Z@E"RP7FGSR36%Y!(JR0W5M-&ZAE( ![A117\RO_!=K]O#]JBW^,'[,?\
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MYHO^#6O_ ),<_:%_[/E^.G_II\"5_2[7UW'O_)8\0?\ 8PJ?^D0,,-_N]+_
M@HHHKY$W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#^0[_@ZP^#GQ-\,:9^P%_P4B^'O@NY\?Z/^P5\>6U_XGZ)I\-]/=Z;X'\5Z
MYX(UT>(KQ;:41PZ#!KO@#3-$U34# \NF3Z[I]]+)#IL.H2)^X?P&_P""P?\
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M#//Q1>:+\#/V_/V=9I;FZTOX*?MA:T?#DOF#^S+72]:T:/1)]/T^V?-S O\
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MF.QULV=DMS;WD]GH?A'^W-5U.ZMUDALECM5N@%NXED]!_P"" 7[-FO?LJ?\
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MZ/KMUXITO4?#5H\<US>1WGB;0%>*VAUR&:$ ]R\;_#;_ (/ M"\.2_M&Z?\
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M+#!NEB>)_P"R71;5K'1M)LGR7M-,L+5B>#NM[6*)LC P<H<\#GL* -.BBB@
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M !'F_DU>[L-"T?[;J\^BZ=J6LR-J^JS:KK_B77]4OEA-]KLUM:VEK!^S5%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_-
M%_P:U_\ )CG[0O\ V?+\=/\ TT^!*_I=K^:+_@UK_P"3'/VA?^SY?CI_Z:?
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M_LVGXF_^F*>L/_@C#_RBS_8B_P"R(Z-_Z<]6K<_X*_?\HO?V[O\ LVGXF_\
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ML\UQ);6T+W$[2?3- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M"?G_ $9+^RK_ .&%^&7_ ,S5'_#N#_@GY_T9+^RK_P"&%^&7_P S5'M. _\
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MWR?W^06Q7\V'_P# *G_RSU_IZ?)__#_/_@D1_P!'K_#W_P )WXC_ /S%T?\
M#_/_ ()$?]'K_#W_ ,)WXC__ #%U]8?\.X/^"?G_ $9+^RK_ .&%^&7_ ,S5
M'_#N#_@GY_T9+^RK_P"&%^&7_P S5'M. _\ H$XM_P##AD_E_P!2WR?W^06Q
M7\V'_P# *G_RSU_IZ?)__#_/_@D1_P!'K_#W_P )WXC_ /S%T?\ #_/_ ()$
M?]'K_#W_ ,)WXC__ #%U]8?\.X/^"?G_ $9+^RK_ .&%^&7_ ,S5'_#N#_@G
MY_T9+^RK_P"&%^&7_P S5'M. _\ H$XM_P##AD_E_P!2WR?W^06Q7\V'_P#
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M"?G_ $9+^RK_ .&%^&7_ ,S5'_#N#_@GY_T9+^RK_P"&%^&7_P S5'M. _\
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MWR?W^06Q7\V'_P# *G_RSU_IZ?)__#_/_@D1_P!'K_#W_P )WXC_ /S%T?\
M#_/_ ()$?]'K_#W_ ,)WXC__ #%U]8?\.X/^"?G_ $9+^RK_ .&%^&7_ ,S5
M'_#N#_@GY_T9+^RK_P"&%^&7_P S5'M. _\ H$XM_P##AD_E_P!2WR?W^06Q
M7\V'_P# *G_RSU_IZ?)__#_/_@D1_P!'K_#W_P )WXC_ /S%T?\ #_/_ ()$
M?]'K_#W_ ,)WXC__ #%U]8?\.X/^"?G_ $9+^RK_ .&%^&7_ ,S5'_#N#_@G
MY_T9+^RK_P"&%^&7_P S5'M. _\ H$XM_P##AD_E_P!2WR?W^06Q7\V'_P#
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M#P;XOU?3O#FE:7X,?3-!L=0U[1[ZZM=(L'N[I[33H)4M8'N)FCB!<FOZ$_\
MAW!_P3\_Z,E_95_\,+\,O_F:KZ;C*?!RXHSM8[#<2SQ:QT_;RPN-RNGAW/EA
M?V,*N J5(PMHE.<I:O78QPZQ'L:?+*CR\JMS0FW;SM-*^_3MZGR?_P /\_\
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M3^7_ %+?)_?Y!;%?S8?_ , J?_+/7^GI\G_\/\_^"1'_ $>O\/?_  G?B/\
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M?_+/7^GI\G_\/\_^"1'_ $>O\/?_  G?B/\ _,71_P /\_\ @D1_T>O\/?\
MPG?B/_\ ,77UA_P[@_X)^?\ 1DO[*O\ X87X9?\ S-4?\.X/^"?G_1DO[*O_
M (87X9?_ #-4>TX#_P"@3BW_ ,.&3^7_ %+?)_?Y!;%?S8?_ , J?_+/7^GI
M\G_\/\_^"1'_ $>O\/?_  G?B/\ _,71_P /\_\ @D1_T>O\/?\ PG?B/_\
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M\/?_  G?B/\ _,71_P /\_\ @D1_T>O\/?\ PG?B/_\ ,77UA_P[@_X)^?\
M1DO[*O\ X87X9?\ S-4?\.X/^"?G_1DO[*O_ (87X9?_ #-4>TX#_P"@3BW_
M ,.&3^7_ %+?)_?Y!;%?S8?_ , J?_+/7^GI\G_\/\_^"1'_ $>O\/?_  G?
MB/\ _,71_P /\_\ @D1_T>O\/?\ PG?B/_\ ,77UA_P[@_X)^?\ 1DO[*O\
MX87X9?\ S-4?\.X/^"?G_1DO[*O_ (87X9?_ #-4>TX#_P"@3BW_ ,.&3^7_
M %+?)_?Y!;%?S8?_ , J?_+/7^GI\G_\/\_^"1'_ $>O\/?_  G?B/\ _,71
M_P /\_\ @D1_T>O\/?\ PG?B/_\ ,77UA_P[@_X)^?\ 1DO[*O\ X87X9?\
MS-4?\.X/^"?G_1DO[*O_ (87X9?_ #-4>TX#_P"@3BW_ ,.&3^7_ %+?)_?Y
M!;%?S8?_ , J?_+/7^GI\G_\/\_^"1'_ $>O\/?_  G?B/\ _,71_P /\_\
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M3^7_ %+?)_?Y!;%?S8?_ , J?_+/7^GI\G_\/\_^"1'_ $>O\/?_  G?B/\
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M?_+/7^GI\G_\/\_^"1'_ $>O\/?_  G?B/\ _,71_P /\_\ @D1_T>O\/?\
MPG?B/_\ ,77UA_P[@_X)^?\ 1DO[*O\ X87X9?\ S-4?\.X/^"?G_1DO[*O_
M (87X9?_ #-4>TX#_P"@3BW_ ,.&3^7_ %+?)_?Y!;%?S8?_ , J?_+/7^GI
M\G_\/\_^"1'_ $>O\/?_  G?B/\ _,71_P /\_\ @D1_T>O\/?\ PG?B/_\
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M\/?_  G?B/\ _,71_P /\_\ @D1_T>O\/?\ PG?B/_\ ,77UA_P[@_X)^?\
M1DO[*O\ X87X9?\ S-4?\.X/^"?G_1DO[*O_ (87X9?_ #-4>TX#_P"@3BW_
M ,.&3^7_ %+?)_?Y!;%?S8?_ , J?_+/7^GI\G_\/\_^"1'_ $>O\/?_  G?
MB/\ _,71_P /\_\ @D1_T>O\/?\ PG?B/_\ ,77UA_P[@_X)^?\ 1DO[*O\
MX87X9?\ S-4?\.X/^"?G_1DO[*O_ (87X9?_ #-4>TX#_P"@3BW_ ,.&3^7_
M %+?)_?Y!;%?S8?_ , J?_+/7^GI\G_\/\_^"1'_ $>O\/?_  G?B/\ _,71
M_P /\_\ @D1_T>O\/?\ PG?B/_\ ,77UA_P[@_X)^?\ 1DO[*O\ X87X9?\
MS-4?\.X/^"?G_1DO[*O_ (87X9?_ #-4>TX#_P"@3BW_ ,.&3^7_ %+?)_?Y
M!;%?S8?_ , J?_+/7^GI\G_\/\_^"1'_ $>O\/?_  G?B/\ _,71_P /\_\
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MGI\G_P##_/\ X)$?]'K_  ]_\)WXC_\ S%T?\/\ /_@D1_T>O\/?_"=^(_\
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M'_#_ #_X)$?]'K_#W_PG?B/_ /,77UA_P[@_X)^?]&2_LJ_^&%^&7_S-4?\
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M&7_S-4>TX#_Z!.+?_#AD_E_U+?)_?Y!;%?S8?_P"I_\ +/7^GI\G_P##_/\
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M/_H$XM_\.&3^7_4M\G]_D%L5_-A__ *G_P L]?Z>GR?_ ,/\_P#@D1_T>O\
M#W_PG?B/_P#,71_P_P _^"1'_1Z_P]_\)WXC_P#S%U]8?\.X/^"?G_1DO[*O
M_AA?AE_\S5'_  [@_P""?G_1DO[*O_AA?AE_\S5'M. _^@3BW_PX9/Y?]2WR
M?W^06Q7\V'_\ J?_ "SU_IZ?)_\ P_S_ ."1'_1Z_P /?_"=^(__ ,Q='_#_
M #_X)$?]'K_#W_PG?B/_ /,77UA_P[@_X)^?]&2_LJ_^&%^&7_S-4?\ #N#_
M ()^?]&2_LJ_^&%^&7_S-4>TX#_Z!.+?_#AD_E_U+?)_?Y!;%?S8?_P"I_\
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M(B+=V4LKV\ZJ%DC()!^DX/GP<^)\D6!PW$L,7]?I?5Y8K&Y74PZJV?*ZT*.
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M?[/EET1(SIBI]M;[66M_VLC?S(XY,8WHCXSG&Y0V,\9QG&<4 /HHHH ****
M"BBB@ HHHH **** "BBB@ HKX4_X*8_MEWG_  3X_8:^/_[8MA\/;?XJW?P1
MT+PQK,/P_N_$TG@ZW\1GQ%X_\)>"&MY?$L.A^)9-*6S3Q,VI"5-#U S-9"U\
MN,3F>+I?^"??[5=U^W!^QC^SS^UE>^!X/AM=?'3X?6/CB?P+;>('\50>&7O+
MN\MCIL7B&31] DU98Q:AQ=MHVGEO,VFW7;D@'V-1110 4444 %%%% !1110
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MOXRU?7(M!\4WVE^'_#EI?V%A!+;>'=0?4O$FM:+I2BW@FO;ZR /VKHK\S?\
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MQF&2ZT+Q)IT&I61GA;YH+J*.?R+N!OF@N8I8FY0UZG0 4444 %%%% !1110
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M3PQX(T'4KVYTZQ\2>-GTR0:@TERUEJ.H6NG23Z1I]IH^F76OZ]K.GZ.BO/\
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MR+P_??"'X;Z5XLOM,\)6/AJYO_%?@I_LNNP^'[:S:QLVG\K3]'MW\E(3++,
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M8\,:9<ZOK.HS"-7FF-O96DS16MO'+=7<WEVMI#-<S11/_!MX0^''CS_@KAX
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M'N(-"EFN[Y2TTUO=:\FOWUM:2%$MFN9G2,&X+-^H_P#P5&_X)+?#;_@JE/\
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M.SCFO[ZX>&QAM[*$QVMO#$G\CG_!4_\ 9Q\$_P#!'G_@M!_P3:_;7_8OL?\
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MJ)T^T2R22^U&*SC_ +?NM?A)_P %L/\ @H3XA_8\^&/@_P#9F_9)T"S\5?\
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M@-C^ZJJJ*J(H5$4*JJ %55&%50.     . !@4 .HHHH **** "BBB@ HHHH
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M67_!TS_T<E_P3\_\-[+_ /,;1_JG2_Z*SA#_ ,.>,_\ G:'MW_SXQ'_@$?\
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M *.2_P""?G_AO9?_ )C:/^%9?\'3/_1R7_!/S_PWLO\ \QM'^J=+_HK.$/\
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M\$_/_#>R_P#S&T?ZITO^BLX0_P##GC/_ )VA[=_\^,1_X!'_ .3_ *L_*_\
M3+17\S7_  K+_@Z9_P"CDO\ @GY_X;V7_P"8VC_A67_!TS_T<E_P3\_\-[+_
M /,;1_JG2_Z*SA#_ ,.>,_\ G:'MW_SXQ'_@$?\ Y/\ JS\K_P!,M%?S-?\
M"LO^#IG_ *.2_P""?G_AO9?_ )C:/^%9?\'3/_1R7_!/S_PWLO\ \QM'^J=+
M_HK.$/\ PYXS_P"=H>W?_/C$?^ 1_P#D_P"K/RO_ $RT5_,U_P *R_X.F?\
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M (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\
M@$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\
MT<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO
M_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+
M_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO
M^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z
M*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY
M_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^
M=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_
M (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\
M@$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\
MT<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO
M_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+
M_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO
M^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z
M*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY
M_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^
M=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_
M (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\
M@$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\
MT<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO
M_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+
M_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO
M^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z
M*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY
M_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^
M=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_
M (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\
M@$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\
MT<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO
M_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+
M_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO
M^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z
M*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY
M_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^
M=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_
M (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\
M@$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\
MT<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO
M_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+
M_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO
M^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z
M*SA#_P .>,_^=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY
M_P"&]E_^8VC_ (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^
M=H>W?_/C$?\ @$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_
M (5E_P '3/\ T<E_P3\_\-[+_P#,;1_JG2_Z*SA#_P .>,_^=H>W?_/C$?\
M@$?_ )/^K/RO_3+17\S7_"LO^#IG_HY+_@GY_P"&]E_^8VC_ (5E_P '3/\
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M_P#F-H_X5E_P=,_]')?\$_/_  WLO_S&T?ZITO\ HK.$/_#GC/\ YVA[=_\
M/C$?^ 1_^3_JS\K_ -,M%?S-?\*R_P"#IG_HY+_@GY_X;V7_ .8VC_A67_!T
MS_T<E_P3\_\ #>R__,;1_JG2_P"BLX0_\.>,_P#G:'MW_P ^,1_X!'_Y/^K/
MRO\ TRT5_,U_PK+_ (.F?^CDO^"?G_AO9?\ YC:/^%9?\'3/_1R7_!/S_P -
M[+_\QM'^J=+_ **SA#_PYXS_ .=H>W?_ #XQ'_@$?_D_ZL_*_P#3+17\S7_"
MLO\ @Z9_Z.2_X)^?^&]E_P#F-H_X5E_P=,_]')?\$_/_  WLO_S&T?ZITO\
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M_P#F-H_X5E_P=,_]')?\$_/_  WLO_S&T?ZITO\ HK.$/_#GC/\ YVA[=_\
M/C$?^ 1_^3_JS\K_ -,M%?S-?\*R_P"#IG_HY+_@GY_X;V7_ .8VC_A67_!T
MS_T<E_P3\_\ #>R__,;1_JG2_P"BLX0_\.>,_P#G:'MW_P ^,1_X!'_Y/^K/
MRO\ TRT5_,U_PK+_ (.F?^CDO^"?G_AO9?\ YC:/^%9?\'3/_1R7_!/S_P -
M[+_\QM'^J=+_ **SA#_PYXS_ .=H>W?_ #XQ'_@$?_D_ZL_*_P#3+17\S7_"
MLO\ @Z9_Z.2_X)^?^&]E_P#F-H_X5E_P=,_]')?\$_/_  WLO_S&T?ZITO\
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M_P#F-H_X5E_P=,_]')?\$_/_  WLO_S&T?ZITO\ HK.$/_#GC/\ YVA[=_\
M/C$?^ 1_^3_JS\K_ -,M%?S-?\*R_P"#IG_HY+_@GY_X;V7_ .8VC_A67_!T
MS_T<E_P3\_\ #>R__,;1_JG2_P"BLX0_\.>,_P#G:'MW_P ^,1_X!'_Y/^K/
MRO\ TRT5_,U_PK+_ (.F?^CDO^"?G_AO9?\ YC:/^%9?\'3/_1R7_!/S_P -
M[+_\QM'^J=+_ **SA#_PYXS_ .=H>W?_ #XQ'_@$?_D_ZL_*_P#3+17\S7_"
MLO\ @Z9_Z.2_X)^?^&]E_P#F-H_X5E_P=,_]')?\$_/_  WLO_S&T?ZITO\
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M_P#F-H_X5E_P=,_]')?\$_/_  WLO_S&T?ZITO\ HK.$/_#GC/\ YVA[=_\
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M=>TCX2?%GP1X_P!3T>SNVF2VN]1L/#.M:E=6EM.UO.L<\T2Q,T3C=D5\^?\
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M6'QA\9MX^UM;#PCK^A7FJ^./B!\28M>U6_U"6ZA@M]"L= M)8]0=(?[.Y?\
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M\2ZEJFFS:\W@^)O$<=W>27EM9^'84MA,L=G)%Y8=OD;]L?\ X($Q_P#!0/\
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MMXM\?^*-%\(^'=.MK:%[BXFN]8UV]L;&%(8(Y)I"\XV1([D!5)'B'P._;O\
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M@K8:_#&D>M-!YALM,\2:[9RZIJ\MR(%B\,>#M7ED?[)=N2 ?,_\ P:%?L_\
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MAJST[6'US3=*U[3[?4M%;Q-I.DZC<ZG>Z%Y>LZ)K?AZ_U6_N]%UNT6ZN[>Y
M/@3QO_P:M?\ !%/X:>#O%'Q#\>Q?'3PCX)\$Z#JGBGQ7XHUO]HOQ-8Z1H&@:
M)9S:AJFK:A=R6X6"ULK."6>5N6(3;&KR,JG[8_X)8?LZ_P#!-7X!?L-?':X_
MX)=?$*?XG? ?XD:EX_\ $OB'Q3-X[UKQV&\>Z;\/K+0K_3!<:[9Z=?:--8Z3
M9Z4USI,UC;S)+<&XF4M.,?F+XB_X-O/VZOVA[+3OA+^VK_P6O_:+^-G[,.G7
M.@?VC\--/T'4H-;\;:5HFI0WO]F^(=3\0>,=2TT:B\?V@VOB77K+QW=VEX+:
MYET^],**G]*/[//['/P+_9._9@T/]DK]G?PK;_#KX4^&O"&L^%M(MK<#4-3F
MN]?M;N/6?%GB"^E\F;Q!XHUK4;RXUG6]3NWCDU&_EDQ]GMQ##" ?S,?\&7/_
M "CG^./_ &<YK7_J%>%J_9G_ (+U_P#*'?\ X*!_]F_:_P#^G+2*7_@CC_P2
MAT7_ ()$_L^>./@'H7QOU?XZVGC3XEW?Q&?Q+K'@2Q\ 3:9+=Z)I6C-I$6EV
M/B?Q6ES$HTP77VR74$D9YWC$"HBD_87[=7[+%G^VY^R+\>_V3]0\:W?PYLOC
MIX"OO USXXL-#@\2WGAN*]N;2Y;48-!N=2T>#4W3[((_LLFIV099"PG1E&0#
M\:O^"*__ "K1?!S_ +-2_:U_]3_X^U\'?\&77[1/@?Q;^Q#\<_V;(I](L/B/
M\(OC3>^-[S2Q?6/]MZ]X-^(NDZ:;#Q(=.18]0:PT[6=(O]!ENY?M$$<J6L2S
MQF98%_>+X'?L8V'_  3U_P""1>O?L<:7\0;[XJ6'P3_9N_:*TJV\?:EX<MO"
M5[XA3Q.GQ.\=M+-X>M-7UZWTW[#)XI?2XT35[TSQ6,=U)(LD[Q1_R&?\$!_^
M"2_A[]N#_@FCI7Q^^"?QT^(W[%7[;/PM_:(^(?A_P;^U%\%[V_T_7M9\!R?\
M(AJ=_P##GXF:+IFK:&OCKP>\\<ES8V%]J$/D7#_9;X:IHC2:2P!_3[_P<<_M
M(?#[]G;_ ()"_M<P^--:TRRUOXX_#_4/@%\.M#N[Z.WU+Q/XO^),3Z4]KHUG
MO%SJ$VB^'UUKQ+?I;HZ6NFZ1<W-T4@1MWQC\+OA7XG^#7_!IW=>!_&6FWNC^
M)$_X)]^//$NHZ7J$?E75DGC<:]XRTV*2,QQ/&'TG7+"=4D4NJR@,[D;CB_"3
M_@VE\3_$WXU^"_CG_P %6/\ @H#\;/\ @H)=?#+Q NN>!/A)KAU/0/A;'-:W
M\6JV[>((-3US69Y]-O+UKA=4\->&M,\+6]W;16UM<ZQ>Z>SZ='_0[^UK^S;I
M?[4O[*GQM_9:7Q&WPWT?XQ?"[7OA?'XET?0K35CX0L-:T[^S8;W3?#LEWI5E
M>)ID(06VFF\L;<HBQ++$@& #\=/^#57_ )0>?LF?]C)^T=_ZTE\5J^'/^#J[
M_DHO_!&'_L_?P_\ ^GWX<5_0%_P2\_8+TS_@F?\ L5?"O]C;1_B9?_%[3_AA
MJ/Q#U"#Q]J?A:V\&7FL'Q_\ $7Q1\0989?#MKKGB2"R&ER^)GTN-UUBZ-W'9
MK=L(&F-O%XG_ ,%1O^"4NB?\%,_$/['>OZQ\;=7^#[?LC_'.R^-MA:Z7X%L?
M&B^.;JROO#EZOA^[EO/$_AQM B8^'EC&I0IJQ47CLUA(84# 'XB_\'D'P-MO
M&7[/?["GQY\7IXEN?@S\$_VG+WPA\:K?PM;M<ZE9^!_C-I_AHWNO0C<D-K>6
M4'PVO-%TF\O);>S&L>(["P>YBN-0MEE^BOAY_P &L?\ P1+^*_@3P?\ $SX<
M)\<?&/@+QYX<T?Q7X0\5:#^T7XEOM'U_P]KEC#J&EZI87,5N4D@N[6>.4+\K
MQ,S12I'(CHO]''[0W[/GPA_:K^"WQ#_9[^//@S3?B!\)?BEH$GAWQCX5U3S4
MAOK/[1;WUE=VMU;O%=Z;J^C:K9V&M:'J]C-!?Z1K.GV.I6,T5U:Q2+_+S9?\
M&W?[9_[.$OB;P5_P3V_X++?M&?L\_L]:_K%Y=:+\%O$5CK6O6G@+1M0O)KZX
MT_P_JVF^,(-.?4EG96DU_2/#/@_4=45BNJ//-$US<@'IO[,G_!(W_@@A^Q__
M ,%(/A3X*^$GQ4\46_[>_P (7'Q'\"_!_P 3_'?Q/XCUJ%+KPWJ\BW-UH5SI
MZ:7J!70+J_U:31FU(7L=F(K^YLA:NC2_+7_!<7_E8?\ ^""'_90?!W_J]-"K
M]??^"6?_  0I_9^_X)L>./&_[0FM_$?QU^U3^V)\34UB#QK^TE\6(88-92RU
MW47U#5[3PEH)U#7I]!FUPBUC\2ZQ?^)->UC7#91*+S3]/9M,'=?ML?\ !(C0
M_P!LO_@H#^PK^WE?_';6?A_J?[$>OZ+KNF_#.Q\ 6'B*P^(C:/XYLO&OV6]\
M4W'BK2;GPTMV]D-,DE@T/6C%%(;F-!*OEL ?L=7\%OP?^%_QU_X.'/\ @J-_
MP4$^'O[4/[7'QG^"O[+?["?Q,TSPEX*_9J^#&M7'@*[\2VH\<^.?"VD7.I17
M-Q>):R'2O ^M#X@:_-I^H:_)JOBK1+71K_1+:TM@/[TJ_FF_;7_X-XHOB?\
MM9>,/V^/V!/VQ_BO^P+^U7\0KF>_^(M[X+M#K'P_\=ZEJTNG#Q'J-[8:=J6@
MZMI<_B)[1]=\1V=[+XKT+7_$B17TFBZ=/(]Y$ ?EO_P6P_X(N_\ !'S_ ()K
M?\$UOVB?C+X<\#:W#^T+XST_PSX#^"GBSXI_%GQGX_\ %NH?$*]\0:?.H\-:
M5K.KFS-Y;>&+;67U.]L]**6.DVB2WKI'"CM^ZG_!-?\ Y5Z?V=/^T<U[_P"J
MLU^O@:^_X-D_%'[1/@'XQ:A_P4-_X*%?%K]KK]HSQOX#B\!?!SXE^+O#5SJ/
M@7]FJ&76+6^USQ1X%^&FH>,;72];\6:_IMG'I!U)I?#$6D075_<6]M>:E-'J
M$/[U_LY_L86'[/?[ /P^_80M/B%?>*--\!?L]7'P"A^)=QX<MM)U#4K6?PQ?
M^&O^$G?PO'J^H6MK<1I?&[72AK=S&6B6%K\AS* #\$?^#-7_ )1/_$'_ +/5
M^,G_ *K7X'5_637Y6?\ !'[_ ()@:/\ \$E/V6/$'[,6A_&75?CE9Z]\9O%W
MQ@;QCK'@FR\!75I/XL\->"/#DF@IHMCXC\412P62^"TO5U!]262>34I8?LL,
M=M&9/U3H _B]_P""Z'_*PA_P0(_[*=X)_P#5^>&J_I _;S^*O_!.^/P[X._9
M;_X*!>(/A+)X9_:=UW3/!_@;X:?%S3+V^TOXA^)I-9L+'2+31)XM-N;>QUNR
MUN^TT6>I)?Z9=Z5<W5K<+>6JRK*WSI^V[_P2)T/]M#]OK]A']NR_^.^L_#W4
MOV'_ !+H?B/3?AK8^ +#Q'8?$5]%\>Z;XY%I>^*+GQ3I%SX96[?3AI4DT&B:
MVT4,QNHX_-01MZ[_ ,%0_P#@EA^SK_P57^!^F_"7XX3^)/"?B;P3JMYXI^$'
MQ<\#W,5MXR^&/C&XL3:#5+*&Z5K'6M&NVCLVUOP_>_9QJ45E!]BU+1]0AMM3
MMP#\6?CI_P &F_[*'AW1-5\;?L&?M)?M*_L6?%+PY9ZIXF\)W6F_%35O$GP[
M?QA8&"_\/ZCXL74F@\6VVE:,+2:T^TZ3XHM;J&TNWN;MM1^RK!)Z]_P;3?M^
M?M#_ +?W['_[1/PF_:@\8-\2?B/^S%\19/@K#\?M,N+74;7XE>%/$'A_4K?1
M]2AU^UM;2'Q3K.A2Z+J%S+XHD47>O:5J_A[4;[-S/+--X6G_  ;R_P#!2_Q)
MX2C^ 7Q'_P""\'[2.K?LQC1AX>OO"^C>&M>@\9ZSX:^SFSN/"NH:O=_$4W<V
MB7^GRW.EW-MJGB+6]/:P=+>ZTC4+1?L=?T)_\$__ -@']GC_ ()K_LY^'OV:
M?V;=$U6Q\'Z7J.H>(M?\0^)M035_&/CKQAK"VZ:MXK\5:I#;65K/J-S!:65C
M;VNG6&GZ9IVFV-G9V5E$L4DDP!_-'_P:D>+M+^!/Q*_X*C?\$\?B"9]#^/'P
MQ_:L\2?$^;2-8N%MK_7_  H\=I\/;V]T_3YXX[B>32[WPUINH:G.CR8M/%.D
M2&*.,^;)_5+^UA^UI\!?V)/@GXE_:%_:3\=6?P]^%7A2YTFRU;7[F&>^N&O=
M;OX=.TRPTS2+)9M4UK4KJYF'DZ9I-K>ZC-%'-+#:R+#(5_)+_@H]_P $!_A%
M^VM\?=)_;+^!'Q]^*W[#7[9NDVMC:W7QK^"S,UKXP72HC#877BSP_9ZOX8U!
MM=%M':Z7/K^D>)+#[;I5O%!K>DZXT49'QAX1_P"#:CXO?'CXA?#WQ9_P57_X
M*9?'7]NGP!\*=7TG4_"?P&N5UKP_\.=5DT>57AF\4R:AXFO_ #)M2M9+[2/$
M%UI.A6/B;6M+NOLUUXO\B-;<@'U[_P %POC;\/\ ]I#_ (-[OVMOCM\*K[5-
M4^''Q3^"7P\\7>"]3UG0=9\,:CJ/A_4OC+\.387\^A>(+/3]8T]+R)!<6R7M
MG \UK)#<QJT$T3M] ?\ !OO_ ,H;/V!/^R(6/_I]UNOJO]O/]B#PQ^VS^PQ\
M7_V&['Q6OP3\(_$_P7X5\"Z9XC\->%+'78/ VB>$?$_A;Q!IEII'A)M3\/V$
M]C%:^%K;1+>PCU/3HK.SF#V[@VT<3=-^P1^R98_L+?L@? C]DO3?'%Y\2;'X
M'^"XO!UMXXO]!@\,7?B*.*_OKX7T^@VVJ:U!IC?Z:81;IJM\ L0<SLS' !_-
MI_P7[_Y3%?\ !!/_ +++K_\ ZF_@2O'_ /@[>^!'@'5OC)_P2D_:#^/\WBI/
MV3-+^/%S\%/VD[_PU]L@O/"W@CQ/XD\&>+-0U#2[^R_?6FNZUX+T7XA?89(F
MBN4E\,P/:^?)N$/[[?MY?\$HM%_;D_:\_85_:QU'XX:S\-KW]B/Q??>+-.\#
M:?X$T_Q-9_$62^US0-:-G?:]=>)='N/#2QG0Q:>?;Z9K.Z.\DE\A9(HZ^Y?V
ML?V3?@/^VY\"/&_[-_[2/@>T\??"OQY:P1ZII4T\UCJ.FZE83K=Z-XD\.:Q:
M,E]H?B30K]([W2M4LY%>*17M[F.ZT^YO+.X /P,T3_@T_P#^",WB?1M)\2>&
M]-^.VO>'M?TVRUK0M<T;]H[Q#JFD:QI&IVT=[INJ:7J5G'/::AIU_9S0W5G>
MVLTMO=6\L<T,CQNK$_82_P""7'_!";]DG_@I+;^%_P!E?XM>(-1_;V^ ?AS7
MO$.H_"O5_C9XB\9ZCHF@Z_X;;0-;;5M,N]-30]0N[#1O$EN]]I,.K3ZMH+W5
ME/J-A:82O#M&_P"#<?\ ;X^ ^GS?"?\ 8^_X+>?M)_"G]FRZM]5TVR^'/B#1
M-6U#5?!.@ZE<%ET7PM>Z3XVMM,B>"V2%!JVA6?@B993,UM96HEE:7]5O^"4?
M_!$K]FO_ ()86WBWQOX:\2>+_CM^TW\4M/CL_BS^T;\3WCF\3>(%.HW.JWEA
MX6TII]2?PAHNIWT\%WK4+ZWKNLZ_>V-G=:WKM\MK96]F ?B;^WO_ ,K?/_!-
M;_LUGP;_ .I%^U)7],'_  5$_P"4<'[=?_9I_P >/_5;^(:^6OCM_P $A-#^
M-_\ P5I_9Q_X*J7'QYUKPWK7[/7PRT?X;6OP4M_A_I^IZ3XK@TB^^)]\-5NO
M',WBJTO=(>X;XE2HUG#X8OO+_L:%ENV%[*D'Z0_M-_!2W_:2_9U^./[/MUXC
MN/!]M\:OA7XY^&%QXJM--AUFZ\.0^-O#NH>'Y-:M])N+NQ@U*;35OS=QV,U[
M:1W+1"%[B%7+J ?BC_P:K_\ *#S]DO\ [&+]HW_UI+XK5^9?[=W_ "MT?\$W
MO^R)Z/\ ^FCXT5_2E_P2]_8,TS_@FA^Q5\*OV-M'^)E_\7M/^%^H_$/4(/'V
MI^%K;P9>:P?'_P 1?%/Q!EBD\.VFN>(X+(:7+XF?2XW76+HW<=FMVP@:<V\7
MS5\<O^"0&A_&O_@K'^SM_P %3KCX]ZWX=UG]G[P;8^$+7X*6_P /M-U+2/%,
M=E9^-;3[=<^.)?%%I?Z2TW_"8M*]O%X;OMC:9"J3A;F;: ?BO_P=D_\ )?O^
M"'G_ &=GX^_]2S]F.OKG_@Y__;C_ &G?V5_@'^R_\&_V7_B'>_!;Q)^U[\<H
M?A-XK^,VFV\]OK'@SPRD6F,\&@>(XKF$>'[S4;O4HGU:Z@5=2?P_9ZA#87=E
MYL\P^^O^"JG_  2*T/\ X*@>//V*?'&L?';6?@U)^QM\4]?^)^GZ;I7@#3_&
MT?C^?7=6^&>JG2+VZO?%/AQO#J6I^'$=NE[!#JYE769I'M%:SB$WT)_P4I_X
M)J_L\?\ !4C]G>?]GG]H6'7["PT_7K3QCX$\<^#[BQL_&/P_\::?:W5G:Z[H
M<^HV6HV4L5S97MWIFM:;<VQBU32;NYM!/9SM#>6X!^/OPF_X-1_^"?%MX3TF
M7]J7XD_M,?M=^/YF@UKQ1XP\??&_Q;H6@:QK$R6EY>R67A_PU?6>S1_[02]N
M+$:EJNJ:B]I>LNHZE?3(DX_-G_@@AX=_9A\&_P#!Q?\ \%3/!/[&]EX?T_\
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MJR31:K%XOO/!NBW'B--4BN+:SGAU(:Q)>"^AFM;>6&Z\V*2&-T*C\ ?V//\
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M'_U33,/^8E?]>'_Z<B?IU1117R)N%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7\,?\ P4._9K_X+D>+/^"V4G[=/PP_X)]>$/VL
MOA!^S"B>%/V-]'\?_%3X;>'?AWIFG_V/:WJ?$1_#L?QO\$>+9_%5MXJU/7=0
M4:[!:6K:C;:7<OILJ:1I<B_W.44 ?PF?\%'_ -MC_@Y&\=?L'?M8^#_VF?\
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M$GO^CZ/@5_X4<_\ \A4?\/O_ /@D]_T?1\"O_"CG_P#D*C_5OB+_ *$.<_\
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M_P"'W_\ P2>_Z/H^!7_A1S__ "%1_JWQ%_T(<Y_\-F-\O^G'F@]M1_Y^TO\
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M_P#R%1_JWQ%_T(<Y_P##9C?+_IQYH/;4?^?M+_P9'_/S7WGZJT5^57_#[_\
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M_P"'W_\ P2>_Z/H^!7_A1S__ "%1_JWQ%_T(<Y_\-F-\O^G'F@]M1_Y^TO\
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MS\U]Y^JM%?E5_P /O_\ @D]_T?1\"O\ PHY__D*C_A]__P $GO\ H^CX%?\
MA1S_ /R%1_JWQ%_T(<Y_\-F-\O\ IQYH/;4?^?M+_P &1_S\U]Y^JM%?E5_P
M^_\ ^"3W_1]'P*_\*.?_ .0J/^'W_P#P2>_Z/H^!7_A1S_\ R%1_JWQ%_P!"
M'.?_  V8WR_Z<>:#VU'_ )^TO_!D?\_-?>?JK17Y5?\ #[__ ()/?]'T? K_
M ,*.?_Y"H_X??_\ !)[_ */H^!7_ (4<_P#\A4?ZM\1?]"'.?_#9C?+_ *<>
M:#VU'_G[2_\ !D?\_-?>?JK17Y5?\/O_ /@D]_T?1\"O_"CG_P#D*C_A]_\
M\$GO^CZ/@5_X4<__ ,A4?ZM\1?\ 0ASG_P -F-\O^G'F@]M1_P"?M+_P9'_/
MS7WGZJT5^57_  ^__P""3W_1]'P*_P#"CG_^0J/^'W__  2>_P"CZ/@5_P"%
M'/\ _(5'^K?$7_0ASG_PV8WR_P"G'F@]M1_Y^TO_  9'_/S7WGZJT5^57_#[
M_P#X)/?]'T? K_PHY_\ Y"H_X??_ /!)[_H^CX%?^%'/_P#(5'^K?$7_ $(<
MY_\ #9C?+_IQYH/;4?\ G[2_\&1_S\U]Y^JM%?E5_P /O_\ @D]_T?1\"O\
MPHY__D*C_A]__P $GO\ H^CX%?\ A1S_ /R%1_JWQ%_T(<Y_\-F-\O\ IQYH
M/;4?^?M+_P &1_S\U]Y^JM%?E5_P^_\ ^"3W_1]'P*_\*.?_ .0J/^'W_P#P
M2>_Z/H^!7_A1S_\ R%1_JWQ%_P!"'.?_  V8WR_Z<>:#VU'_ )^TO_!D?\_-
M?>?JK17Y5?\ #[__ ()/?]'T? K_ ,*.?_Y"H_X??_\ !)[_ */H^!7_ (4<
M_P#\A4?ZM\1?]"'.?_#9C?+_ *<>:#VU'_G[2_\ !D?\_-?>?JK17Y5?\/O_
M /@D]_T?1\"O_"CG_P#D*C_A]_\ \$GO^CZ/@5_X4<__ ,A4?ZM\1?\ 0ASG
M_P -F-\O^G'F@]M1_P"?M+_P9'_/S7WGZJU\Y6/[(O[-6F?M):M^V#I?P<\'
M:7^TSK_A"/P%X@^,FF6EQI_B_P 0>$88;.VAT37Y[.Z@LM;MX;?3=-MX9=4L
M[NZA@TS3(H[A8].LE@^-_P#A]_\ \$GO^CZ/@5_X4<__ ,A4?\/O_P#@D]_T
M?1\"O_"CG_\ D*C_ %;XB_Z$.<_^&S&^7_3CS0>VH_\ /VE_X,C_ )^:^\_5
M6BORJ_X??_\ !)[_ */H^!7_ (4<_P#\A4?\/O\ _@D]_P!'T? K_P *.?\
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M>?V?.U#VEN7G:C>^AC[6E]83]I3M[%J_/&UW.+2O>UVM4C^E&BORJ_X??_\
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MS&^7_3CS0>VH_P#/VE_X,C_GYK[S]5:*_*K_ (??_P#!)[_H^CX%?^%'/_\
M(5'_  ^__P""3W_1]'P*_P#"CG_^0J/]6^(O^A#G/_ALQOE_TX\T'MJ/_/VE
M_P"#(_Y^:^\_56BORJ_X??\ _!)[_H^CX%?^%'/_ /(5'_#[_P#X)/?]'T?
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M_P"'W_\ P2>_Z/H^!7_A1S__ "%1_JWQ%_T(<Y_\-F-\O^G'F@]M1_Y^TO\
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MJ/\ S]I?^#(_Y^:^\_56BORJ_P"'W_\ P2>_Z/H^!7_A1S__ "%1_P /O_\
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M-![:C_S]I?\ @R/^?FOO/U5HK\JO^'W_ /P2>_Z/H^!7_A1S_P#R%1_P^_\
M^"3W_1]'P*_\*.?_ .0J/]6^(O\ H0YS_P"&S&^7_3CS0>VH_P#/VE_X,C_G
MYK[S]5:*_*K_ (??_P#!)[_H^CX%?^%'/_\ (5'_  ^__P""3W_1]'P*_P#"
MCG_^0J/]6^(O^A#G/_ALQOE_TX\T'MJ/_/VE_P"#(_Y^:^\_56BORJ_X??\
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M4?VYG7_0XS3_ ,.&+_\ EP>RI?\ /NG_ . 1_P O)?<?GQ_PZ@_X)M_]&6?
M#_PA-.H_X=0?\$V_^C+/@!_X0FG5^@]%']N9U_T.,T_\.&+_ /EP>RI?\^Z?
M_@$?\O)?<?GQ_P .H/\ @FW_ -&6? #_ ,(33J/^'4'_  3;_P"C+/@!_P"$
M)IU?H/11_;F=?]#C-/\ PX8O_P"7![*E_P ^Z?\ X!'_ "\E]Q^?'_#J#_@F
MW_T99\ /_"$TZC_AU!_P3;_Z,L^ '_A":=7Z#T4?VYG7_0XS3_PX8O\ ^7![
M*E_S[I_^ 1_R\E]Q^?'_  Z@_P"";?\ T99\ /\ PA-.H_X=0?\ !-O_ *,L
M^ '_ (0FG5^@]%']N9U_T.,T_P##AB__ )<'LJ7_ #[I_P#@$?\ +R7W'Y\?
M\.H/^";?_1EGP _\(33J/^'4'_!-O_HRSX ?^$)IU?H/11_;F=?]#C-/_#AB
M_P#Y<'LJ7_/NG_X!'_+R7W'Y\?\ #J#_ ()M_P#1EGP _P#"$TZC_AU!_P $
MV_\ HRSX ?\ A":=7Z#T4?VYG7_0XS3_ ,.&+_\ EP>RI?\ /NG_ . 1_P O
M)?<?GQ_PZ@_X)M_]&6? #_PA-.H_X=0?\$V_^C+/@!_X0FG5^@]%']N9U_T.
M,T_\.&+_ /EP>RI?\^Z?_@$?\O)?<?GQ_P .H/\ @FW_ -&6? #_ ,(33J/^
M'4'_  3;_P"C+/@!_P"$)IU?H/11_;F=?]#C-/\ PX8O_P"7![*E_P ^Z?\
MX!'_ "\E]Q^?'_#J#_@FW_T99\ /_"$TZC_AU!_P3;_Z,L^ '_A":=7Z#T4?
MVYG7_0XS3_PX8O\ ^7![*E_S[I_^ 1_R\E]Q^?'_  Z@_P"";?\ T99\ /\
MPA-.H_X=0?\ !-O_ *,L^ '_ (0FG5^@]%']N9U_T.,T_P##AB__ )<'LJ7_
M #[I_P#@$?\ +R7W'Y\?\.H/^";?_1EGP _\(33J/^'4'_!-O_HRSX ?^$)I
MU?H/11_;F=?]#C-/_#AB_P#Y<'LJ7_/NG_X!'_+R7W'Y\?\ #J#_ ()M_P#1
MEGP _P#"$TZC_AU!_P $V_\ HRSX ?\ A":=7Z#T4?VYG7_0XS3_ ,.&+_\
MEP>RI?\ /NG_ . 1_P O)?<?GQ_PZ@_X)M_]&6? #_PA-.H_X=0?\$V_^C+/
M@!_X0FG5^@]%']N9U_T.,T_\.&+_ /EP>RI?\^Z?_@$?\O)?<?GQ_P .H/\
M@FW_ -&6? #_ ,(33J/^'4'_  3;_P"C+/@!_P"$)IU?H/11_;F=?]#C-/\
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M4?VYG7_0XS3_ ,.&+_\ EP>RI?\ /NG_ . 1_P O)?<?GQ_PZ@_X)M_]&6?
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M'4'_  3;_P"C+/@!_P"$)IU?H/11_;F=?]#C-/\ PX8O_P"7![*E_P ^Z?\
MX!'_ "\E]Q^?'_#J#_@FW_T99\ /_"$TZC_AU!_P3;_Z,L^ '_A":=7Z#T4?
MVYG7_0XS3_PX8O\ ^7![*E_S[I_^ 1_R\E]Q^?'_  Z@_P"";?\ T99\ /\
MPA-.H_X=0?\ !-O_ *,L^ '_ (0FG5^@]%']N9U_T.,T_P##AB__ )<'LJ7_
M #[I_P#@$?\ +R7W'Y\?\.H/^";?_1EGP _\(33J/^'4'_!-O_HRSX ?^$)I
MU?H/11_;F=?]#C-/_#AB_P#Y<'LJ7_/NG_X!'_+R7W'Y\?\ #J#_ ()M_P#1
MEGP _P#"$TZC_AU!_P $V_\ HRSX ?\ A":=7Z#T4?VYG7_0XS3_ ,.&+_\
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IVACM[:VMXTA@MX(46.&""&-5CBABC58XXXU5$1555"@"I:**\LT/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img75897552_4.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_4.gif
M1TE&.#EAP 3J O<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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M4W,P:D=H1R>D &I()-8..LN\GY<E?EO!MQ.]'\DS1Q9D@O!8"1,Q2)EC]O-
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M8CI6R?*+ .30#L<\6 ^T*#3]7>CS9&$T:VSH*/ PC KG+H$LU/10#R1V#X@
M#Y=YR?YBR'&6-KX&0!.\*#(GNMTV<J8;2*(Z ^T@9*:7?J8W/I$2>DX]UF2(
M!23FKRIE,$%6FIB3>5J6T5D-<+KCFJ9@<8AP#W@-;6O9UZ7K(&G#9RUC;JY9
MTOBC'CD-S[MB, -8U$@W,4/T#EPJ*2\%=Y MV9L79,.C2W')>K0W/C_'U][&
MI:C-S?",N=UYT$ AKQ,=TBP5/_ 2-F"-P$DYE(B8/GJ76+K\W'OF>$!XD_<
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M)?[(_T=ZR53#W,(P'XD,KASIP4,(>V%>LQAN #=YQQDV$8>_O+"8"$(54,Z
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MVRE[XL;IXU#KLTP3/S( +0K.KAJC,CRI6TSSVRWY-+C0HC[;H=:)+D%X -K
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M).R.14: %2IS:@>10K)Q:N;*F@?\R@=J,VQQ$>QPI->)ZEA4>6676T21TH<
M[N?KV9UI"M&@"Z=V"Y]_]%C*[&R(S<R]/F7J#.C_@:33!6[JO/P?NXSJ FH4
M&U*DC);J,<'6* 03(XIH%J:3(T)D7(WC;T63%_LF'NY!.NK*@FGN-M&!J3Q"
MXA[NNY3K='W4I+[-I?;5@G9OSPW2GZWK2JJM&B7NWYYO^21EB(!03355 \YM
MO?9GK<F>V)9FTD4?[8EM +=,MA/P_WYP5-[M\O3M"L]O27UJ^#9OX)Y4('YO
M_$9-];9/1,7/#[=P] 9QND;Q$U?Q%H^4_7Z(_HYP!L=M!)_Q&P_P'+=Q':]Q
MW)[PWK[P%0]R%S?Q(3_J%$=7$3=2$D=2%C]R)R]R(9=R(M?P)85QAY!Q'A]P
M'-_Q+N_Q+==R" _S?^[2_Q\?Z"E_<B./<BI'\C5/<_H,'$-=[]5HC6R@$=?(
M$CP/G#OG\SSO\SWW\T ']$'7\T+_<T,7=$0G]$-G]$1O]$5W]$B']$E7]$J_
M<P&HC#VG]$>W=$GO]$WW=$X7]5 G=5 W]4]']5$/ #M?SHEHA718=4XY -?P
MAEF7=5JW]5K']5V_]5[7=5_/]6#G]5\G=F$']F$W]F)']F4_]F97=F=/]FAG
M]F<O@=% @!*8]0-X]FV7=FB?]F[G]F\7=V\G]W O=W!']W'WAEC_3-[&\U$_
M=7A/]5*?]WBG=WG']WO7]TG']'VO]W_/=WL7>(#W]X G>%"/$EU5"%Y%C8:'
M"?^!( B&=_B)I_B*'PQ_P =!N O%L/B.]_B/)PJ;P F%!_F2QPB)-_F4=PB(
M+PB5=_F7AWF5P'B-;P>.C_F;Q_F;%WG3R/F>/V.?]WF61WF@)_JBG_B9WW@'
M-?JE9_K!V'F2;_J/'_JH;WBAI_JKQWK'0/J:5_JL]_JOYXFG!WNI'_N.-S>9
M1/NX5?N+3GNT#Z2UC]NW;WNY7WNZ=_NVCWN\9WNXW_NYUWN[SWN^!_R^K_N_
M-WS!/WRTIX<K8($9, 6_1_S(A_S)+WS)KWS*OWO+SWS,#WS.)_S-O_S0!_W1
M[WS1+WW2__S35_W4_WS0FOJRA_W8QPBQE_VCK_W;C_W_?&#\*Y OW/?]WP?^
MX%<(VA=^S7C]XD=^D-=]G.C]Y'?^YX?^GB?^Z ^,XZ?^ZU^,F8R"KQ +IQ"+
MJ!"$YL?^\2?_\F<+HPBDD3*%W:<'MN\KZS?_F(#_^*=_M!!Y ?#^=A#(^N?_
M_O=_F0 (?[-,73$AX*")&8):^0/@\"'$B!(G4JQH\2+&C!HW<NSH\6/%AA7K
ME0L00(#!@P(0J&S)LN7!ES!ENH09T^9*G#15[KQILV?.GSJ'"BTZD^A1HS65
M\D2Z-"G4IU*;,O49E>I5JU.U8MT:-&M0$S*!DG7:]2S7M%^]EJVZ%NU;M6W!
MSF5K5N[=N'KKPN6+UZW?O7D#_Q,>;!CP8;J)[2)NK-@QX\>2(S,6NS(EY+Z+
M-6?^.YGS9\^4J9H,8 [?19$4$94,@$ L[-<H7],V&!OV[-NY:^_&?5OV;]NU
M@0\7KCMX;^+'BR<WSALY=.;1EU-_+OUZ==_8K6=7SOV[]N[.PX/W3OZ\^?3C
MU3=O/[W\^OCNMZ.7_[[^?/'YX>_'?Y_]?_;1!^"  NH78'\$'EA@@@;RAR"$
M#$:X((4/2GAAA?YA:&&&"G+XH88=.A@BB!Z2>)M)5Z!FD6H3L692<2;*..*,
M#=HX88DTZGCCAB?6B*./.P+Y8X]$BLCCD4,*6>2220ZW$A2"Z,.//JWD8V4K
M^+12)?^7B%S! D(L0''%._5<664^B+0S Q0MK#?F.XAHB68]\EP1A9LQ!HED
MCGSNJ:2?1O8)**%,!MKDH(86ZB2CB3;ZIZ*1BO=:BBN&9-&+KBWJ**>0/BJH
MIYV".BJBH9I*ZJ&I;GIJJ:BNZNIU",W0SCT-^2-(%"JEA, 5K3C$CQ=@^I;
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MIW[AQX+KQV\/)@B(, ]W9B5?,P_CM7DP^((NR'\_.'K[-WY&5WY-UGA0%H1
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MCM8%.3&S7H_)#WNJ3@ES$4YDKRLV*&.$COF!K $$ /2@,H::G4O4C%@R9EX
M-C#122>RG-A*7I&A+P(! ;_JJ1W#IN?ZB $I*H?(B8K(>,68JJ!;KZE;?:?[
M1#5HE^R49ANS99%X!62P80IFESD2@]''+G8V:*H:EEQK40#XG@;IB?M:M?0Y
MI<I+=NZ0ABMK%(0U'U!!'YPQ#XRCE59[BH=Q%'J#.G;C->_PB<]+@HCA._?
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M;& =:8?L5^R<EO>P$]R!!SYLE9PLG#0*V8%BK3\5T (17C&)!P)5V)8LITU
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M!MBB18G/Y9.4S67*21G_I&W>09LJO41'(L0[P%LK8W)9HEQP:<ELE16;,.2
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M"],\Q3,]X7,]WY,^X[,^Y],^??,[[9,_\=,_Y1- [S- ^W- _U-]VK- $U1
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M*YT#/#CU4TMU3T&55!/C*+ )>D[55%,55E$U.?L!P5SD567U5G/557?54V:
MR7!U5V-55X7U-E<UB5J56),56)5U6-FP'S#%5H-U6:>U6:NU.$453ZA56JV5
M6;=U+8U5B5ZI6\=56\F56Y__M20XL%S7E5O9U5M+SA^@A![OH4CR#*4,A!_:
M55_?U5W--5RD"7*H2CX"]7$B15/[%6'WU5\WU!]J%4\3EE\5%F*9M2MJY;I*
MHA7^(F(W=F$G-D1GP4J,Z\(L@F,]5F)/%C\/!7%Z<0\7XFCRU61+%F4[]E7;
M:._(PF<.=F9CEF9E=CZ-[C6R;K)XEFAWUFAQDTJBI6_R3E-]MF>?MFB!4TPR
MJ)".%FJM-FKE,T4!A1[VTVFS%FRQ=C%;86WLZ6O%EC01(1T.P!L0P!N^H03<
M]@#B]FWI=F[=%F[EEF[SUAONMF[U%F_M=F\%-W !]V_[=G -EV_]=G$3%W$+
M]W$/_Y=Q"5=R'7=R%9=R&Q=R+S=RX?8 N(%M-]=R1U=T2[=R35=S3U=U4Y=U
M,]=U,1=V._=U93=V.==V+=<;6  >Q/7D9B$IVO8;/#=XXW9X#V!X$:!XCS=Y
M\W9YB5=XF?=YG;<$C!=ZIU=YHQ=YL;=YL]=ZJY=ZI?=[N3=\MY=\M==\NQ=\
MKQ=]Q;=YQ_=\W7=]RS=^WU=]X==^ZQ=_O3=_TU=_^Y=__Y=]_3> TY=M66 =
M2(0PE@T<O*%M:=>!;Q=U9Q>"5U>"29>":]>"6Q>#(WB#+SARYW9N^5:#'SB#
M*YB#2?B$)WB$5=B$/9B%.SAUO:$$H-,)'48 $N !'@"'=_]8AWN8AW_8AX,8
MB(=8B(N8B(_8B),8B9=8B9N8B9_8B:,8BJ=8BJN8BJ_8BK,8B[=8B[LX 1)@
M(=J!=S6M%=#A ,)A'=KA'=;!'=K!'=C8C>'XC=MXCN.8CN48C^]8C^V8C^O8
MC_.XCP'YC_=XD .9D 49D0]9D0V9D0O9D1.YD2'YD1=YDB.9DB49DR]9DRV9
MDRO9DS$Y^=0A' X '8"%,*+",KQ8E;F8E5?9E5L9EE]9EF.9EF?9EFL9EX58
M(3RO VWXEG\YEX,9F(=9F(N9F(_9F)/9BK/,'<88AEIA;4M '=QXFM-8'=ZX
M':HYF[%9FZ_9FMO!FKD9G+?YF\/_N9S).9O'V9O3V9S9&9V[69S;&9[/>9WG
MV9WK69WC^9WSF9[U&9_EF9_OV9\'NI\+6J -VIX3.J 5&J ;>I\=^I\?6J(C
MFJ()^J O^IJS>91+V3!0N2F0&:256:1#FJ1'VJ1+&J6Y& $XB9>%T)=/&J93
M6J9CFJ9GVJ9K>HJ9V9D+JHRY09JI69V#FIZ%^IZ)NIN-&JF'6JF+>JF/NJF3
MFJFCVJFE&JJGVJJK&JN?6JNI>JNONJNSFJO#VJO%&JS'&I[;(1W @91-&3 \
M&@%N&JYQ.J[G6J[KFJZ[>*6/0UWO\#D$X*[M&K#_6K #F[!G6J<O#9KG=IK=
M@:$GVJ(;_[NB$7JA)QNB'YNR'5NR*SNS,1NC+SNR.UNS09NS(=NR0YNT-_NS
M3UNT4[N-17FM._H*4KFP9WNP:YNV;]NVJSBO6YJO)R*W<1NX?UNX@YNP#]OB
M>OJG&;NLE_NKFYNLG=NLF?NYISNZH5NZJYNZKUN[K9N[L[N[SSJM7_N48_NC
MB7NXS]N\TQN]?WFW]_K27GJ]U5N^XYN^YWN)C?OD$CNY5=NL2WNT/=N_4QO
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M#@Q"+M3"+A1#+RS#,]P^Z1M ,R3#-AS#-V1#.+3""(S#.D1#.+Q#.\0_(/3
M//1#-]1#/ 1$+%S"-?Q#043$0%3$0^2^.5S$083$1&3$2>R]WPO#2'Q$2<1$
M2M1$TY,^>6C"3LS_Q%'D1%+$1$<LQ53<Q%44Q53DPU9D15.$Q5E4Q%:X@A9@
M@1EPO*3;Q1DHAQG@16#T16'LQ5\,QJ0S1ET4QF0L1F)<1F=$1F@<QF.<1F6,
M1FIDQF?$1FG,QFNTQFILQFWD1:3#Q180QV_L1G#41G3DQG8\QW!DQW=<1WBD
MQWFT1V^L1WR\1W74QW[DQW],QX!TQW@4QK# .E6D1824Q85D03#LPUA4R(B$
MR(E,2(ID2(G1!XR[ GZ0R(KTR(O\R(X$R9'<PE<D28L4R91$R94,22K,R/ES
M$)8\R9:DR9FT296L2<YSR)R429R\R9X$2I[4O9>\@I@4RI\\2I]4RJ!$_TJ&
M-,FE3$JFA,JFG,JJG N--$JJE,JMC,JNU$JO),*=_,JQM$JPY$JR/$*BY,BS
M+$NT-,NW=,NXU,EVF+^'A,NVQ$NVU,N[Q#]^@!%!F(?4FX%<A(>]N;I6Z+N\
MY,O%E,N];,RD%$O%?,S)E,S*=$R=;(4]: $!$  30 #/- '.;($]0$S&M$S3
MO,S41$V/A)=W0#I@9 &V2SK@<X=Z6,O5I$S5S$W<Q,G6;('0!,X9> <#.<W=
M-,[B1$[=G,1^$(0HB,W._$P$@ (O<+GDY$WEQ,[KC,I6@(?!G#Y>T<[CS$[Q
M#$_K=+_8B$T$B )!N$WR=$]\,(< V(8 H,\ ./^ ^KQ/^LQ/^\3/_M1/_^3/
M_Q30 "70_310 #W0 4W0 D70!E50!V70!Y70"*70!;50"+W0"<W0"L70#M50
M#^70#Q71$.70^]S0$P51%!U1%251%G71%(71%8W1%IW1%Y71&Z51'+71'.71
M'?71&@52'0W2'AW2'Q72(R52)+U0Q4& $E#2(H72)Y72)*52(R70*ZA.SZN8
M (A.T.S2+_72, 73,173,B73,S73-$73-573-F73-W73.(73.973.J73.[73
M/,73/=73/N73/_730 7401740B740S741$7415741F741W742(7429742J74
M2[743,74314 ^@0JV-O_TDW5U%$5U5(EU5,UU51%U555U59EU5=UU5B%U5F5
MU5JEU5NUU5S%U5W5U5+MU/+2O%#EU6'M56(UUF)%UF-5UF1EUF5UUF:%UF>5
MUFBEUFFUUFH=TU_]5"U]"BZ]UF_%5G 5UW EUW$UUR]E 7,$1G6% G9U5Q;H
M4NA,U]E<5\_DS#*55W=M5W@%SG+UUW,%V'\5V( EV%355KM4PFX=V(4MV(9E
MV(=UV(B-3HF* KZ;"'\X$*3(#Y4X',WDS/7D2 O!6+2@B'P0A"M @'M5S\*
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M4X]4UOQ1M&#9J _-3?+-B)/.%2>99U)JJ!U0^$^GOYRC^@T8$9#^]*'3C6A
M#GHFA5XWO-7]1W"_-LFK)9Y_ L""T=9C!MPE[Y'S823S=?>YZ2(@+-4&HGZ(
M,*'C:MZC$1$ZF0KBM:TN_S9[+2W&.EZA'?1HQ60!E _H24^\LN1D;P$TK6IR
MW,SB+BE[$:>/5B@NFB#OI%,%,7),U]%XH=:'/A!AYU([MJZMT*%,]V!NWK9
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M(1(_!N0^#N3&D,X,I!IH$:1""B1#.I(_RM@#+:1$WA]S(8U\%50^SETFSHP
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M6_N[RWN]G_N]IWN\X_N^Z[N]]SN[_[O \_O ^SO!'WRS,[HY<-!B;P0]B'L
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MZM%''MS@"W*U&904,TD?41,R1P]K;(A')8$<,K\C_W-3$T*(SL2,-3+C;+-
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MRLPI<M).Y<DK$> ;_(:  5B'!3B  W59[610#76(8X]P?WB'_9>'C[B'E7B
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M3T>- >B.2U<@$  +\/BC%SY=": B-/W4T]%#,[;C$846=N=%/@#D \]X)LP
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M$"%04@(9Q!.:(@_TX$/G\SU&I$YC]DK/IH-H CDJR#8R 7/-(A/RX'IQ1@\
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M)/\T%SD!#PL1:AWB#MYVCZ"7EO1%-1-5?%]#@%A)#V9&CM'G#IFB'2WP)EY
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M+H&".Q04GGHX9YA$U,L,W+4V<XV$FHA$F"$553 L70%S[]#1HJ @3+PHQF0
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M1+T@'[D;T D?O6F2)^E5<S(.<X$"(*,'&(N*+O@Z>#$3S/''G^&.>Z15_]>
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M*R2L4]</G J:0 25H,7D7!&),G]^G;CQM[?J;'[8U@]<\EN08[AR!=B#)2V
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M^83G/L&I3GWVLYWXY*<YZSE0?QHTH/\DZ#%+X#V!D0^,$/7B1,\7D8D4LZ
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M'>D1'^]1'^V1'^O1'_.Q'P'R'_=Q( .2( 42(0]2(0V2(0O2(1.R(=T16*Y
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M(J! ,^;T68GU[;K42KGU2H_.'S@T1Z" O;C47+<47;_46]?U7-5U(6A1'F8
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MU".?T."'/H9)#WB\XW1KF=U>X(&/I.)#'GIX!SWZX0]_Y(,>/8P<@0IS1G<
MHHP]E.$[\-$/ /#C'F2$JE0+-R#_=] CJ7"EW#KDD5!HU*.'67&'/%9!37Y
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M:I_%@/AE80J%"/H56<X4@ \03025:A4Q V?G?82V$WYW!0I6$K\46?0$0#I
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M$G6$)A&_5V>"1GV>9F6H%F-PAF?M) _5=WT$@7PS0 :/!@"S( \I./]UTT:
M7B!M]L</]$ &+]5JTN=,$D%UA:)2+T4/CH80;+<2-,@/\( 1*#5N!^9ICJ=A
M$R%@.H!=L $/@N8%_54W,Q!Z!!E,0?==F(>"((B1B, /LX!KU[A@.?" ;$.#
ML[!/!"1D_*!FKM=JL9< TU6.P>(1V8-+/YA+W\-[7=)GU/A1"!EG4F<103:3
M8@9E<%9W(JEUZ.==F>1W@O!I<19@-# /",%ZYR-)-'!V]F>39^8/:29[+@5G
MHK=]R<&6'8126!9T(>D%;B>6FH1,<R<0B> .^6,M,R /_L!Z,X,^VH=,B,>
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M2 7#FQ!.!+IMCQ]$X!&W"R^\]0P1)Z$K]4%\9JFGUE-QS)+''^G_T4E-1;N
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MNQ="(;>*F2I^@(<WRX%W&)%9TCAZV L &A&2N B5_XDTZ&"!9VD7'4 _I\G
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MU@&/? RTG$55ICN2R.5U./&$,%S'#0%TL@<>&*E@K%@, UK.,BNYATF42CJ
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MU#QY\Y8.+CP9J]2=Z[!6M2MW)_/(1IVO?MY<-63ITMNY0Q?NF[I[(_6E.Q"
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M><BQ',WQ'-$Q'=5Q'=FQ'=WQ'>$Q'N5Q'N>1!>CQ'O$Q'_5Q'_FQ']DQ  +
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MV],?X--,W'-;Z%,^[3,^YU,_\[,^X=,_MP5 [W,_!90__Q,_#Y1 $31 %W1
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M6'GU5SFU-N:A"SJ#0XE56(%U6)EU69TU6IMU6J&56I_U6J6U6K555OWA'5I
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M^NBOKW[[*>/Y],* 0IV7H(0:6J^_ >\_K\#R_I\__P60?P#,EP -2, !]@]
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MG<G3GDHXFA/60P:#\@:+'F.9Q;@P,C&DS PO\\+*R! S,-0A#FG(PQKN\(9
M[*$-<RC$'R+QB$HT(A-G X4O(4A!EBD(0IYXGW3,Z$4FD('1\-$%:4V'1C22
M 8T$QJS?_01I%#F4#-X!HGR\0P8SL1(_]%2]7AV,@@C@2,W>$P"@\8<?<;00
M_&8AIIUQ)8Y5; ?_POR'D7-U81Y"F8',KC"/_F Q #O3"AS)4<"LZ*-=^NJ(
MT.!#$O,])5 "@1\ =I<2*NK0'/4  #3@,3F&S$<>\VM@Y2K2CO2!A3X\,1QZ
MDMC$(OIPB<D\9A"92<1F+C.:R)PF-*GYS&L.,9O&E&8UNXE-8VJ&,YXY(3GY
M!)H]R8TU 0,A.SWHSG;"\YWRC&<[!U<X\O"&!>6X0A?>P;&;\&,>7O#G.DQY
MK'?<(TP)1,\,KJ N]2'B'O68Q_B*(ASS004?[FC!;0Y"GY_P;D)&:HK/LD@2
M;K6C1P"X!R5))"Z+?=%#VVL' J@UTO1-D(QBM)P83YG2>S"%'NBH*0LH_Y8/
MC2Y$9C0+I?M*P,7BT4-)[L#.=W0BCRG!KQ_PD!1O2K _%#DREQ]!A ,3I3D$
MM&-[X[O"/9(7TA#&S*+SG"L]Z6K7NN+UKGI%B)WP=$ZXM:UM@1I4H;QVML-J
M#;&&32QC%^O8JZ'ML5V#K&(IVUC+2E9LD<4L9R?KV4HEI$!+><^8* 4%[^6#
M*_XHS1NC,I6:<DXI-VNI"6; R'JD+G4><\<M6^54>  4=/$Q:PD^6H_QM6B/
MQ/N<@@:WO9^XQR< J$=+<WD?09!C!E?:'19G(@.*+:4IT,B'ZQQGE"N\ [=.
M 5%XR4K4CJ16D1H3%U.E%0 97"E+T#@=3IX[7O]1PH\?[F !M9ZFOY:]K+<=
M6@=0ZK$\PNB3</B S^^N2[X(.4B+G=5L93]+M@YS^+(>WNR(0?QA$8<XLR=6
M,8E3O&&PB9!MY PLW-))M[WB.*\ZSC&/=^QCXLR1</HP7%',.KISS8 H(\W'
M.LY%C@K!MAVI);*]3DJC"JV3-DY-RDVJES\3?-2+%TX(.H[$W)( MW;N2/(I
M"8? A_0J'_[IT9D[%$8H)+D[ 10E; :BCND];$K<<J/QAJI)(QUUH^?AAE&6
M*DH(X1<G#TLR&2D-99K@0X#, TYQZP/6(C,D:'6^B+5\0MJB@@@?3;Z(G^F!
M#T2T T";_C&M>VSK6N/_^M86C#$) 5O.T*1PA2W<IC6UJ<QB$]N;QG;FLKGY
MS6,K.]G/9K:TFXUL:.-P()T[D.N\^4<67!(?#BPP+BW9/@+VLI<P.8I1F?HS
M<O>EML ]W>V^;<E^V#$E5Z"'?<BZFCVZ<;H)[!U-^).]>R1M(NJ0!Y__V*LZ
M1FG,]EK'3?3Q#@*S9M_S0T0F-QE?6<\$'J-UWWW=H;JM_G$@YBC8:XL[K@'#
M.Y:S1%%O%V+/^34<X&T53Y.K2#-_0*,>:]8,-UB0#GE\!C^OG+:SK1UM;#N=
MZ=>F-M2K;?6J8YWJ6F_ZU;4>SLY\YM=O^RMJ5*/.TN8Z[;I6.]O7[O;AD&X6
M_T-.&7-F$DEW2+Q#ULHTZ(Q<'!)U(4^MA.CLH!4Z0TWGHZ?KU_3D%\6K**4?
MKZ:'[+*T4DKB$BF(P/>0QVR5D?X$$93'%C0.J:L]FIPIY!5$/4 D/U5JDLMP
MQ'SB2X<E?/1/(Y8$:#WH@;VD$],$@>^'.V;=U1G< P"=E^M8"CX_FZDOM?91
M%@'/=2W6\>/5[0$?>>'C][:#_^WB#S_Y<=S77I/=G' #E* (U<(7MWC%\#=Q
M_.M/__NC6/XESK_]^8]_%O\?9\W$#%S'%<B:_/54G^W,B712!8W-P+1#/[T#
M/ @"P\E#!<K#JFD9 C :M\"#Z-&#/"S)CI3, 5J/P?_HUCM<003B#XQ843\,
M$HSHDSIT@9/T"SRX@SJ0T8*X"+?(0^K<P\=P1T&1ST:0H",9H3O  SR A<9T
MRSR('L),4)%]%W(Y(%=]7A<H#+I!T+[  Q3.@SS 0Q>L0^8\2!)ZR[<(0L*@
MPPY>80#N'P#ZWQS*81W.'QW>H1W&81[RX1[ZH8M]5HP=R(SY28V9W8V57R*.
MWR(J8B/^C8 T3IH05XE(SSM,R?<AQWFDG !PHB9&HFZP *.YB-K("(8QB/^4
MXI696U0P#G$5TXA@(B1:185 R"<&BY;E3(1P8D%8B"UB8H D5_Y,R,\0C=\1
M346D'",JHR,RXS(ZH]WP6OK_F9#8!5L L)!K=!W799TV;MW4<>,W>F,X/ETW
MCB,XEJ,X2MTYJF,/W8LID6,Z)H9&\- WI!L4F!Q/<,]P/0JHF2,\1MT_8D:I
MK"- ;B,Z$N0['F0_)J1!9B-#%N1 -B1$+M'7C9/8^5K9S4V6->-&/F-'<N1'
M=M O>N1*T,0\T,/0C21(JF1*LN1*NN1(GI\TKI_ZL1]AO=\?ZA\@ZF1.\F3_
MZ>%.^F0? B4<#B4>XF10'B51]J128J%1%N5/+J531B54(N53"N547F558F52
M2J56>B53@F7:U!38M4WZR21&JM-+JF5+LN5:?AF.983>B&2NS:5=U24'44XS
MWF5;__*E6_9E1T:C^DWCKU7C-?IC1![F0R8F0B+F0DHD8RJF8RYFTVE,3Z%=
M8T)& D:FS<FC9'HF9FYF BZD0!J&9=8(/SKD,?$BC?2%:9K19*:F0H(F9-*F
M;&[F;=9F;.IF,U%DV%FD8(:&C6GD7_IE<1+G^-W+'JB+Z G"D*!=!AV+("3)
M%AH?F5B%.@C"FNVE<:*)W8D@P#RGWY0 .;B#]/B>NM##&"+A.]W+!_:>>C+?
MP#B4)$45$W+A<7(G?NIGV\4D<)HE34Y7^Q565H8E518H@7;E@7*E@29H@S+H
MU"2$\]A$]AT5= G%X=RB Z;;J6B;;+U#L<Q:4^Y*1L!#/_^\1[SQ8(9NZ :B
MZ!NRJ%] $*Z$*''Q2B!]:/71Z(@JA <*0L^9T?O,$E-HQ;CX!%3P68["*&A]
MRKD@%'1E&E"\6I,QVGR<3U<D5%,(W90L*((^*)=ZZ9:"J56&Z5:*:9G"V%C*
MV G16/H)9WZZZ7[":5T%67\,23GD&=+-SU;E98KN2DE<8C#V&0<:A0S8:8VD
M6XRB!1240SF 7$)HDBY-6"SN:!/2Z$E1JI8AV7I248?@&5$<8Z!R"Q3L8%[*
M ,GH8T7(S R\RZF2Y P0BV:4P^9IU>'E3TF(*KI9Q=[!$8'E!H3 CS^(2)*Y
M*E8 !3\<*:AU*FH.A"B^J&[LF]S_:92PIL.UF&A+]0JVW(,7I(,,^. ;#=AV
MQFFXONFXIDE@#F99CD9A#AMNVF9N/F:[PNMNPN:[RNMGLBO Q<\]=,&[Y<R-
M@,4II0M*3L<,<(R4D$0Z3" \R,/LA(B[U"#>Q80/WL^]J&"%8(4@Q-J*E(1W
MW.AY+6RF:44]R(/P=(@NG>B&YI*KC8OZR$-%A='180]0J \3$@6UY%+J9)]K
MZ9$FV:.KM0?J?(SWA1I61-3VN,?(4@F[+6Q_W0,BV*<3OH,DZ<-^->W3*MS2
MCE=475*>FF'$ZMF39%KOJ:!F.%<_N(Q0_*NGO$]"%=\?\565Z!(_!-^Y>$?1
MHDY4C83,_]3@R+KA*;V#DC1J 6$%N)"<_O ; CG<E_ #/ !(SI094##NO=+K
MY,YKY=JKNUKN;,8KY1YD;_[F6<;-(0XGN9*NN)HNFZ!9Q;7+D'CJM'#B'CV+
M/R"0M-@=4,WNS&2)S:QA#LY YV")/"R,._B$@%4'?\ :271!_.0#<FU.T,P"
M:5D)5.!'.Z0+MN #[SRJY%V!D4$24.V./WT@4&@+B2"4>^"@NFR/[1A$&^5#
MT(5+>V1+<WT4>;U#%\ #]LCN@/F.&T$#/@C4WR+/B28.B)QDNCR)/B!"D\5>
MIH4)QGK!/&34'LACG,V"_[K# X^+_,Q>1^V,@01%=GI'*L&'!_^"B.0U)[QL
MJECXJD]<W.;$:(&<CO#,;TCDR+7(KH(XK_J:"SH( K?17@BQYDJ40X]H2775
MQ.ED)[YX0<PF,%>5[A.?;A2327^>:R&*QF"YWV4JJ)E^I8-^*1=O,9F*<1=W
M:;/,T0]:J=.BA,WMV[F56T(=TO,P!<RYKO/MSKBA$7X0!>1 PSWTG RX U3<
M0\<)[_8,V(U,H=M&;_:M U'I$@+QQ;UP!_G8K#!!P[X"#>' 8"B:RQ7\JP'Q
M#\;M$;ZH""!#17WY[4VHVE6T%5C!%K>H ^85"%.L&D,1X;G$[O6")POL'4R5
MQ#SPQ#P8&D,9#=?B*H.D QFJ2,X\45/_ *]F0 %]75PRNL7[C,O% 48']H@^
MV"<!HD3OU-:5(/!(H%DJX3%P9=_M9!CES!'QR%G23*DY !>^?<0@:@G$CBD9
M?_$8A[$^YW,_ [07AZD@HNN:JE^;2G%"0_%"UQVDJ4/!B!Z(Z&Y*D,ZYR8@!
M184I!?+UPL?H:)Y[7(&SU P]8%XZM!XB[(&LL4 /+VZE29@7B$Q)>+([1&U$
MS8^J.;+%;"]O< L__2T4@L>$F8 FP8Z<$6[:#FIY-D62Z,BJZL^5Z(3Z](OO
M 17UP(?FR:R2>#*1?)N))$](D"&E6D_%R!GE,1Z(Z(X@[%/ID+1$"  Y'(D@
MT6J@4D=/=X%R_P*5D<*+KF)SK[J<(/$J! '--D?+*9U$.S1)ZZ6UT,*P/APR
M?<R"[11A5YT7!-_'?Q1031R5QU0@ZVVVCS)T:"OT:.^&N5XD8:J0-:XKYE[N
MYF:NY+XV:VMNO<XVO5J9H6Z(]7B$/VQ510LP,;)5_)+$\USO2-#C09"(B822
M_;8O/M1;;/5QK%U(&U\O36.+// JMT!P4Z".[%PIPN7TR3:*/>:U/C3MM\2/
M4'-J#:+.?61?$]NL;4G/<Z66B.#7_*2/Z-7#5$\4N*2$0&A>ZW%%PV(C1WP'
MD5J,/)B##/S9@?3O5$N4QX0@?'S4/"15C7Y$M(2H<DN>\8C>*8O2N?_\(#=?
M^%VL+6!3CCH0Z0"U\4VHS[IX;Q-/!\_40\+(0T[ 7&,X(50;JRF%42 '#ZC1
M!%"1EFS#=FO3]I'7=FR[-I)S;M=Y[N<.IG"&)VE;N6B3J]U17K2XKMU==^B$
MV>U<=/*>V\R<#CS0W>CLVU&Q3[;6+ +\F9S%VL^8 #GLP8=0:/TH, +<%/#F
M]K,@<$AG;Z36!AJ9MZ";RP(M+]F>2X/H4P^OE"F5T73S6Y@0R_.\\X7?MDE!
MA'8QA7/#BX:,#/'XP^I>2X@<WD10AVOLCQ=I1B?N3,5]Z&W88\W,[GQEVC/S
MLJ]8G!,3Q H+6$TU#MVVE7-?Q;@X=E*52/O_)H@<#4SY9A_J3"PF;JR :_B$
ME(0\V,<\D$.+K&TK6>*5BSN6BSL5G_9_8O& _K- @S&[\[.[^W.[E[&\7R7J
MW8/NJ!&-T-'\7%Q!%+/%W2F6/!X+I)D@Z-&1J8-2@(: 7;B*UX["/,0"ZDG\
M4C+G>([K&)#\X(,Z./(-\P5&7;8\J@,$T]+ I<,\1"F-'!WR)(@Y1)+XD*WW
M;!Q1\'!.)$B%S #-7&\1KOG-7X4X^P>^1-0A,;B!"+=V'4TLDP0/:T6(%S(W
MPPLZ?,?"7_LCD0/LB)G?^@2PFE(T8XO/L^IT+X6N<\LZ_"!/:)1.)3Q4%'8Y
MU$2_^>A!00-H],.1_W+*43S+3CQ,Q%Q942 +MW7!E/#R4ADKB ;TO+\[XL=[
MXN_SXCO^X5<-01/BV!VTZ)+[Y8^[Z4[$M&)+4VB/Z7S%F UQS>Q$:CUI/BY[
MDJ1Y"+%5>+Q'[VC;21L@ =T;3WSKC)B/1+]1]O4'QVN2T;!4I6H<EJ1::@&
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M%EACF>V5V&$1M)6\,*.:_U6T88>T=MELN;W6K\22Q2I#PL952H!CE?T66J=
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&VM<E(  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img75897552_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_5.jpg
M_]C_X  02D9)1@ ! @$!( $@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *<! P# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBZ6:ZKYV/])K3[M;^PLKY056\M+:[52,%5N(4F ([$!P"/6K=?@[_P %/?\
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M7W6O0_3*BOY*OBM_P<977P*_:]^)WP1\;_#^XN_#G@1[NWM#;I))<:I.K-%
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M>/VJ=7^,'[%\7[2EYI1L]3E\!W_BO^S#U$MIIC7HAQ[LN/Q_"ORA_P""7O\
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MO&OQO_9=^)_PT^'MO;W?BWQ+HTUGI,%TXCADG>WN(U#N2 HW2+R3TS7X4?\
M!"[_ ()F?M;_ +%&F_M.V_[0&@Z)I4OQ)T[6;?PI_9EVDXGDO+:YB@$VV1]F
M6D4')'?FM,OSS XG@[C#ZQ6P."QN8YI@,10R^G.--RC&M1E4^KT=W3@HMNVR
MOZ@Z4XXK#M*4H0A).;UUTW?F_P!/4_$;_@AUX)\(>/O^"Y/[1^E>-_#VE^*-
M+TZV\3ZG8Z?K-I%>VEOJ,"7TD%TD$RM'YD<BJX)4@D<Y'%?0O_!VG\*OA_X
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M_L70^,?$?P^\+^(?$VI?9$N=5UG2+34+CRXE0JJM<QR <A<,!N!7@C-?<?\
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M:%^!_C[]GS0-#U;PUX+2P77YM3O([>:(P-&9/*5I%+8"G'!''&<U]4?MP_\
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M^B$]G=B+4V9!-"P*N!C'(/%?Z)/A+X9?#SP&%'@OP7X:\+[8%M@=#TBSTYC
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M32BUU/33=ZSX4O-J_N-<$4?V?=(?F16>%!D'AL=,Y'\?WAK_ ()\_P#!>O\
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MU:E_?_\ !M3R_O>7XON?SW?\.J/^"B'_ $E5^)__ (*[S_X_1_PZH_X*(?\
M257XG_\ @KO/_C]?T(T4?ZX9U_U*_P#PR91_\Q>2^X/JU+^__P"#:GE_>\OQ
M?<_GN_X=4?\ !1#_ *2J_$__ ,%=Y_\ 'Z/^'5'_  40_P"DJOQ/_P#!7>?_
M !^OZ$:*/]<,Z_ZE?_ADRC_YB\E]P?5J7]__ ,&U/+^]Y?B^Y_/=_P .J/\
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M /!M3R_O>7XON?SW?\.J/^"B'_257XG_ /@KO/\ X_1_PZH_X*(?])5?B?\
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M9,H_^8O)?<'U:E_?_P#!M3R_O>7XON?SW?\ #JC_ (*(?])5?B?_ ."N\_\
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MGN_X=4?\%$/^DJOQ/_\ !7>?_'Z/^'5'_!1#_I*K\3__  5WG_Q^OZ$:*/\
M7#.O^I7_ .&3*/\ YB\E]P?5J7]__P &U/+^]Y?B^Y_/=_PZH_X*(?\ 257X
MG_\ @KO/_C]'_#JC_@HA_P!)5?B?_P""N\_^/U_0C11_KAG7_4K_ /#)E'_S
M%Y+[@^K4O[__ (-J>7][R_%]S^>[_AU1_P %$/\ I*K\3_\ P5WG_P ?H_X=
M4?\ !1#_ *2J_$__ ,%=Y_\ 'Z_H1HH_UPSK_J5_^&3*/_F+R7W!]6I?W_\
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M0_Z2J_$__P %=Y_\?H_X=4?\%$/^DJOQ/_\ !7>?_'Z_H1HH_P!<,Z_ZE?\
MX9,H_P#F+R7W!]6I?W__  ;4\O[WE^+[G\]W_#JC_@HA_P!)5?B?_P""N\_^
M/T?\.J/^"B'_ $E5^)__ (*[S_X_7]"-%'^N&=?]2O\ \,F4?_,7DON#ZM2_
MO_\ @VIY?WO+\7W/Y[O^'5'_  40_P"DJOQ/_P#!7>?_ !^C_AU1_P %$/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*'CDC971T895D=2592.002".E/H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]DC5K+X[BVG^*WP0\9:I\+M:U6T(==9L?#;+866HW4H'[V\F$+&5R68@*"<
M5[M_P6ZT36-=_P""?_Q6MM%E>&X@B2ZFD0D;;:*WN3+NQ_#CDGMB@#^;SX3_
M /!,BW_:-_X)E?$+_@HK\0/'GQ"?]N76M:U_QOX3\:VGB_4K?0M"CT?6;?\
MLZQ;1U<1/";.:X\QMPVE$78XD+)^B^N_MS_%OXD_\$:_"_B6PU2Z;QHL<'P;
M^)GB:T>5KB>&.-=,U#5%GBS);R/""3,67;P21UKVK]BRY@/_  0BF<7<3J/
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MJ'H\;JZ'Z,I(/X&@!]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD?\ @GM_T7;2O_ 27_XNC_A\C_P3V_Z+MI7_ ("2_P#Q='_$+_$C_HA.+?\
MPP9G_P#,P?\ $1N ?^BSX8_\/>7?_-!^H=%?EY_P^1_X)[?]%VTK_P !)?\
MXNC_ (?(_P#!/;_HNVE?^ DO_P 71_Q"_P 2/^B$XM_\,&9__,P?\1&X!_Z+
M/AC_ ,/>7?\ S0?J'17Y>?\ #Y'_ ()[?]%VTK_P$E_^+H_X?(_\$]O^B[:5
M_P" DO\ \71_Q"_Q(_Z(3BW_ ,,&9_\ S,'_ !$;@'_HL^&/_#WEW_S0?J'1
M7Y>?\/D?^">W_1=M*_\  27_ .+H_P"'R/\ P3V_Z+MI7_@)+_\ %T?\0O\
M$C_HA.+?_#!F?_S,'_$1N ?^BSX8_P##WEW_ ,T'ZAT5^7G_  ^1_P"">W_1
M=M*_\!)?_BZ] ^%7_!4+]BKXU?$#0?AA\.?C!IVO^-?$TQ@T;1X;:1);N4=5
M5BY /UK'$>&_B#A,/7Q>*X*XIP^&PU*I7Q&(K9'F-.C0H4HN=6M5J3PZA3IT
MX)RG.348Q3;:2-L/Q]P1BJ]+#8;B[AS$8BO4A1H4*.<8"I5JU:DE"G3IPC7<
MISG-J,8Q3<I-))MGZ!T445\4?6A1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!S'C7Q$_A'PCXF\41:;=:S)X>
MT/4]8CTFQ7=>:D^GVDMRME:J 29[EHQ%&,'YV'!K^<'QAXO_ ."SW[=E^?$G
M[.%WX6_9C^"TNHWNEZGH?Q!LTM/%MS;6T[0^9;RR0"Y99XU#IC<.=QZ9']*N
MK7,EGIFH7<,/VB6VL[B>. C/G-%$SB/'?>5VX]Z^$/@C_P %&/V>_BW\3_%?
MP/N=9;P#\4/!ERUG?>'_ !>(=!M]5F$_D@^'Y[V6(7X<G<$C7/! 9F(! /RU
MT3_@EG^WS+X7OCXH_:C-QXSN@TL=W::G<+91SMD@@# V!NV/6N*T?X,_\%S?
MV2-2_P"$LMOB]\/_ (S?!/PS;3:CKW@I8H[_ ,7:A!;!I'AT_P Z)IO.EC7R
MU:+.&*@D$BOTU_X*>_MZ^*/V+? WP^T_X6^%M*\9_&7XQ>)H_"/PUT'79S;:
M+?ZS.8X[>.YN1(@"O+*H(##"X;HPKY)_8^_X*+?MRK^U;X6_9-_X*#_ _P
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M*10\<D;!XW1AE61U)5E(Y!!((I] !1110 4444 %%%% !1110 4444 %%%%
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M\_<D?Y;'Q.T#0K;XM?%2VM-(L;6TL_'_ (D@L[6"!4@M((]3N!%! @&(XHU
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M^..$4Y2:?$F2IIMM-?VEAM&KZG^BU1117^'!_L,%%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]AA_ZU\9XC_\F]XY_P"R2X@_]5>)/L/#[_DN>$/^RDR7_P!66&/]%JBBBO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"1?E__ & 8+_U%I'^+.9?\C#&_]A-;_P!+D%%%%=9Q!1110 4444 %%%%
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M!S@GI0!]LT5G:1J4.L:78:K;I+'!J%K#=Q1SILF2.9 ZK*AY5P#AE['(K1H
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M=FT)(DD$$H241C&#N4\Y.0.!^IU !1110 4444 %%%% !1110 4444 %%%%
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M%JWP[_X)V_#CQ!';_$WQV\JVS?%G[)>VD=YI&AW"[&OLLA<Q1[PL>]B!&K$
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MYH8;;4KR1G+SE4&_YVRPYZ5_1O0 4444 %%%% !1110 4444 %%%% !1110
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M$(]+MVL-6M[M[D;;6%L216[+$6E="'8X)VD?7?\ P2B_X+J?L]?M%6/P=_9
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M_P#A:^&O_EG7^,]_PFGQ/_Z*U\2__"NU3_X_1_PFGQ/_ .BM?$O_ ,*[5/\
MX_1_Q B'_13+_P -DO\ YJ]?Z>A_:<O^?'_DZ_R/]F'_ (6]\)O^BH?#O_PM
M?#7_ ,LZ/^%O?";_ **A\.__  M?#7_RSK_&>_X33XG_ /16OB7_ .%=JG_Q
M^C_A-/B?_P!%:^)?_A7:I_\ 'Z/^($0_Z*9?^&R7_P U>O\ 3T/[3E_SX_\
M)U_D?[,/_"WOA-_T5#X=_P#A:^&O_EG1_P +>^$W_14/AW_X6OAK_P"6=?XS
MW_":?$__ **U\2__  KM4_\ C]'_  FGQ/\ ^BM?$O\ \*[5/_C]'_$"(?\
M13+_ ,-DO_FKU_IZ']IR_P"?'_DZ_P C_9A_X6]\)O\ HJ'P[_\ "U\-?_+.
MC_A;WPF_Z*A\._\ PM?#7_RSK_&>_P"$T^)__16OB7_X5VJ?_'Z/^$T^)_\
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M$5_H:?\ !V3_ ,H\/#G_ &4ZR_\ 1%O7^>7#_JHO^N:?^@BOZV\'?^2)H_\
M8TS'\Z!X./\ ][E_U[@24445^I'*%%%% !1110 4444 %%%% !1110 4444
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M>_M5>,]5T'0/A+^S;K'P/U,6/P/T*9H(;7Q'+93!M3_LW>"@W,6\P1CUR :
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MW*#@$4 ?V=6=U97EO'/I]Q:W5JP BFLYHI[=E X$<D+-&0!C&TXQ5JOYP_\
M@A?\2?B#X?\ %G[3W[*6O^,-9^(?@SX'_$G5?#_@KQ)K]Y)J6LP:58/-##:Z
MC>R-(7F*HH?$C98 ]J_H\H **** "BBB@ HHHH **** "BBB@ HHHH ****
M/Y;_ /@[)_Y1X>'/^RG67_HBWK_/+A_U47_7-/\ T$5_H:?\'9/_ "CP\.?]
ME.LO_1%O7^>7#_JHO^N:?^@BOZV\'?\ DB:/_8TS'\Z!X./_ -[E_P!>X$E%
M%%?J1RA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-?[C?[K?R-
M.IK_ '&_W6_D:<=UZK\P/[]O^#1?_DR3XM_]E6'_ *(U"OZQ;J'[3;7%ONV^
M?!-#N_N^;&R;OPW9K^3K_@T7_P"3)/BW_P!E6'_HC4*_K,K^+?$C_DN>)/\
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MNX'EJ><8KWZB@#^9?Q=_P;>>"-8\7^(M+\*_M6?%OP3^S3XK\3)XDUW]FC2
MR^!+V3[0;JXM'C74(T$-Q*%9P(>2H)!K^B3X3?"_PE\%_AQX.^%W@73H=*\*
M^"=!T_0-'LX8UC5+33[=($9@H ,DFS>YY.3C)Q7HE% 'YGZ]_P $UO!/C']M
MWPA^VMXW\>^(_%'B+P!:75IX-\&ZB@ET#0TN&DDW6Z/,Z9261G!\G.>A%<%_
MP44_X)5:%^W%JW@;QOX'^,_C/]FGXJ^#M2O+FY^(WPY0IKFOV%U9FU73-1D6
MZM6:&'<SI\Y7I\H()/ZVT4 ?G]_P3^_X)^_#_P#8)^'.K>$_#OB'5?'WB[Q5
MJKZYXT^(GB) -?\ $NJRAO.NKU_,E8M*[L[YD;)QZ5^@-%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!_+?_P=D_\ */#PY_V4ZR_]$6]?YY</^JB_
MZYI_Z"*_T-/^#LG_ )1X>'/^RG67_HBWK_/+A_U47_7-/_017];>#O\ R1-'
M_L:9C^= \''_ .]R_P"O<"2BBBOU(Y0HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "FO]QO]UOY&G4U_N-_NM_(TX[KU7Y@?W[?\&B__ "9)\6_^
MRK#_ -$:A7]9E?R9_P#!HO\ \F2?%O\ [*L/_1&H5_697\6^)'_)<\2?]A__
M +@HGOX/_=:/^!?FPHHHKX@Z0KF/&GB_0O 'A/Q#XU\3WBZ?X>\,:5=ZSK%Z
M^-MK8641EN)FR0,(BD\D5T]?,_[9?P^U_P"*_P"RI\?_ (;^%5D;Q'XU^%WB
MKP_HJPDK*VH:AITD5N(V7D,7( (YSTH _&Y?^"BW_!0SX^S?%OQE^S#^S9X-
M\5_LY^'8M<B\-^.M8OI(;[Q!IEA:WIOKJS1KE8[F5(;>0Q)'&P=P%VG.#\X_
MLZ_M-:-I/_!+3]MG]I/Q%\-(O','A&?47\6_"CQ*)(],US4EORE_I\RS'BVC
ME9A$P&TCD>W9?\$YO^"AW[-G[(O[$1_9/_:!\22^ OC)\"?#_B[PQKNA:AI&
MH27'B/4+DZQ=6CPRQP,+FYO'ECM0SD*VZ,$J%Y^8M(\?3_$G_@B!_P %'_&W
M_"$WWA"VUE]3N]*TA-+G@N-0TZ;4V:VU"&S6(2R?:8R)#M0GUH \(_X+0?&/
MXV^.O^"8/_!/#7/@9\%O#7@SX!_%+Q=\+_$-_P"'+"[>)-(\2:E<W$FE^#(E
M21"=+O)A="0X"L!@YP /IS_@M+K_ .V)X _X(Z6N@Z'\$?!W@#0=8L_ 47Q4
MAT.]6.3P]YLUBMO%8^3*K,+^9(8;AL$KDKG#G/CO[?US/%_P0F_X)/-'9ZJQ
MD^)W[/I>V@L;M[F(K=:AAKBVCC,L(CR<M(H"9YQFOUC_ .#@V>:/_@CG\194
MBO;B1Q\(-\5I;SW-U)NO[!FS#"K2O\P#/E3@@%N: -;]CGX_ZE^QQ_P33^'_
M ,5_VA/A?X6^%.K6_P +?"3^$=*T*=&/B]IO#MG/IUQ>,&W_ &K4(Y[2[FW$
MN3,V?O;AX?'_ ,%7/VZO!N@^%/CS\6?@;\*]&_9F\5ZKI<5IKNF^(1-XIATK
M5;NX@AN); WC,LJQV[NZF/Y=RDC!%='^W3\!?&'QX_X)9?LBZGX=M]0OK/X8
M_#/X:>,O%.DQ"87%]HUIX*\,Q36\L.TR,8Q;.OE,N1G&.*^([/Q?_P $V/%O
MP0^'NDZW\6?$OB+Q5<W>D:?=_!R2'5##INMRSRVWV$6T@\I!;S0@A@@"^>3Q
MF@#] ?VUO^"POQ/^&7Q,_9E^&'[*'PFTSXNZO^TG]BBT"XU*66.WL[FY$;2Q
MS/#,BJ(O,VY)Y*DX'0>^?M#_ /!1OXF_LB?L[>#]?^/_ (#\/:1^T9\2_$47
MA3P+\/\ 2[WSM(N-4NI%BMI;VX$S-%:^8RAI#(%Y.2,5^;WQ*\)Z-X"_;X_X
M)S>'M \,7NDZ-!J5K=:5:SV4TYL;64QO"[7(C*V^Z/;U9<=Z]>_X+N?!?6KK
MQ+\!_C?J6BZEXF^&6A>+M+T_QJUFDT__  A&EPO ;GQ*L,:L4\E-\Q= "2.N
M000#TCPS_P %._VN/@Y\3_AKI7[;/PJ^&/P_^&?Q#NK;3X?$G@[7DU.]LKS4
M9S!IZ20B[D&7)1F5@"0<9%7_ -HK_@J5^TYX?_;)U7]DO]G#X':%\1-4N?">
ME^(_"FKZE/-%'>G4[>.>);LQSHL47S_>XX[]Z^0KS_AVY\<?B)\(_ 7@'XG^
M)OV@=?U+Q!H=_I&ARKJ+?8[C3+R./SO,N"RQ)%)%O*G&<U[O\+H8['_@N!X^
MTV+3;F*VTKX:>'+&P::RE,5G;P6MO'';I=E/+WHF%;8^3SF@#WG]CK_@I'^T
MIX@_:HU;]C_]MWX-^'_A#\5(_ US\1=(N?#-T][H<_AJ&W>Y$TUXT\T8DV*%
M?#X5MP(R*X7Q[_P4@_;K^,'QA\>^&?V"/V=O"?Q6^&/PSU4Z5XC\9>*;R6Q^
MVSQ221RKI#"YBCNI#Y+E(X]['H <9K0^./AR;QG_ ,%?;[P;8V\MMJWB?]DK
M6='T_64M)!]DEN-,N#\E^$VHR@EO+#@Y'3FO$OV"_P!N/X$?L"6'Q7_9@_:K
MU-OA;XW\">+M1GM-8OM(O9V\;P75Y=2+-'<P0L+BY0,@AWL%(=@9%[@'Z)?#
MS_@HW'IW[*'CWX\?M">#+OX;^+?AC;:D/%/AB2"6&WGOK(!(X=,>=BTZR3AA
ME"V4P1CK7Y[0?\%6?V\[CX?Z5^TBGP*^%*_LU:Y?6VHZ=K#^(0/%"^#Y+F>.
M74+BP-X&2YCAMW<H8QC*_+7H7[7OCF]_X*)?L(?$_P :_!/X;ZA'X?\ #=UJ
M6I:7:K9FTG^(%K9&(R1K"D$;RK)&HE"NK$ER0V:_.3X8^-/^"=A_9:\">#O'
M?Q>\36WQ).D6_A[Q;\$#!JBQZ1X@O9KFUDT$6_\ JE\MH@=P3://![T ?UD?
ML]_'7P5^TA\)O"OQ=\ 7@OO#GB>T62&48(2[BCC%[;A@6#""=VC#9&X+G KV
MJOD?]AOX>^$OAA^S3\/?"?@;P[<^%O"]O9RWFE:1=D^?'!?>7,)GW<CS\AP#
MR*^N* "BBB@ KG?%_P#R*7BC_L7=;_\ 39=5T5<[XO\ ^12\4?\ 8NZW_P"F
MRZK?"_[SA_\ K_1_].1,J_\  K?]>JG_ *1(_P N[XI_\E@^+G_90_$__ITN
M:XJNU^*?_)8/BY_V4/Q/_P"G2YKBJ_WFR_\ Y%^7_P#8!@O_ %%I'^+.9?\
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MNM_(TX[KU7Y@?W[?\&B__)DGQ;_[*L/_ $1J%?UF5_)G_P &B_\ R9)\6_\
MLJP_]$:A7]9E?Q;XD?\ )<\2?]A__N"B>_@_]UH_X%^;"BBBOB#I"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG?%__ "*7BC_L
M7=;_ /39=5T5<[XO_P"12\4?]B[K?_ILNJWPO^\X?_K_ $?_ $Y$RK_P*W_7
MJI_Z1(_R[OBG_P E@^+G_90_$_\ Z=+FN*KM?BG_ ,E@^+G_ &4/Q/\ ^G2Y
MKBJ_WFR__D7Y?_V 8+_U%I'^+.9?\C#&_P#836_]+D%%%%=9Q!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?H=_P $D_\ E(K^S[_V&'_K7YXU
M^AW_  23_P"4BO[/O_88?^M?&>(__)O>.?\ LDN(/_57B3[#P^_Y+GA#_LI,
ME_\ 5EAC_1:HHHK_  Z/]B HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/QIT^*VFNET;0KOQ#<1PJSN+?3+.ZEE?:H)(53S@=^* /R,_8\_9A^%.K?\
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M^@BOZV\'?^2)H_\ 8TS'\Z!X./\ ][E_U[@24445^I'*%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4U_N-_NM_(TZFO]QO]UOY&G'=>J_,#^_;
M_@T7_P"3)/BW_P!E6'_HC4*_K,K^3/\ X-%_^3)/BW_V58?^B-0K^LROXM\2
M/^2YXD_[#_\ W!1/?P?^ZT?\"_-A1117Q!TA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5SOB_\ Y%+Q1_V+NM_^FRZKHJYWQ?\
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MQ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME)DO_JRPQ_HM4445_AT?[$!1110 4444 %%%% !1110 4444 %%%% !1110
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MS_LIUE_Z(MZ_SRX?]5%_US3_ -!%?UMX._\ )$T?^QIF/YT#P<?_ +W+_KW
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M-_[":W_I<@HHHKK.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"RK#_T1J%?UF5_)G_P:+_\F2?%O_LJP_\ 1&H5_697\6^)'_)<\2?]A_\
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MTDCL2S020[,E21TW*" #^G^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH _EO_P"#LG_E'AX<_P"RG67_
M *(MZ_SRX?\ 51?]<T_]!%?Z&G_!V3_RCP\.?]E.LO\ T1;U_GEP_P"JB_ZY
MI_Z"*_K;P=_Y(FC_ -C3,?SH'@X__>Y?]>X$E%%%?J1RA1110 4444 %%%%
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M "7/$G_8?_[@HGOX/_=:/^!?FPHHHKX@Z0HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YWQ?_P BEXH_[%W6_P#TV75=%7.^+_\
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M -6?E<O4_EC_ .!/R_N^O];^G?;K+_G\M?\ P(B_^+H^W67_ #^6O_@1%_\
M%UYC_P *>\,_\_6L?^!S_P"%'_"GO#/_ #]:Q_X'/_A1['+/^@W$_P#A&O\
MY?\ U9^5R]3^6/\ X$_+^[Z_UOZ=]NLO^?RU_P# B+_XNC[=9?\ /Y:_^!$7
M_P 77F/_  I[PS_S]:Q_X'/_ (4?\*>\,_\ /UK'_@<_^%'L<L_Z#<3_ .$:
M_P#E_P#5GY7+U/Y8_P#@3\O[OK_6_IWVZR_Y_+7_ ,"(O_BZ/MUE_P _EK_X
M$1?_ !=>8_\ "GO#/_/UK'_@<_\ A1_PI[PS_P _6L?^!S_X4>QRS_H-Q/\
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M .-4?\,<?LO?]$/^'G_A.V'_ ,:H_P"(Y91_T),?_P"#J'_R8?V;5_Y^P_\
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MTFLZ=?Z#<-\5@4M=;MI--N9$\C4#YD<-T(W>/H-X&,D<\U_6']NLO^?RU_\
M B+_ .+KQ?0_V<_A-X3MGLO!7A>R\%V$K^;/8>&8H]+M)YN?WTD,"*C28)^8
MC/)]:VO^%/>&?^?K6/\ P.?_  K\5XDS/*^(<]S+.E5Q6$688CVZPTL/&JZ/
M[N$.5U(UHJ?PWNDO\_1HPJ4J4*=HRY$ES7:OJM;6=MW_ %OZ=]NLO^?RU_\
M B+_ .+H^W67_/Y:_P#@1%_\77F/_"GO#/\ S]:Q_P"!S_X4?\*>\,_\_6L?
M^!S_ .%>)['+/^@W$_\ A&O_ )?_ %9^5]+U/Y8_^!/R_N^O];^G?;K+_G\M
M?_ B+_XNC[=9?\_EK_X$1?\ Q=>8_P#"GO#/_/UK'_@<_P#A1_PI[PS_ ,_6
ML?\ @<_^%'L<L_Z#<3_X1K_Y?_5GY7+U/Y8_^!/R_N^O];^G?;K+_G\M?_ B
M+_XNC[=9?\_EK_X$1?\ Q=>8_P#"GO#/_/UK'_@<_P#A1_PI[PS_ ,_6L?\
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M1K_Y?_5GY7+U/Y8_^!/R_N^O];^G?;K+_G\M?_ B+_XNC[=9?\_EK_X$1?\
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M^!/R_N^O];^G?;K+_G\M?_ B+_XNN>\77MFWA/Q.!=VQ)\/:T !/$22=-N0
M 'R23P .M<E_PI[PS_S]:Q_X'/\ X4C?!SPNZE)+C5I$8%71[UBCHPPR,"N"
MK D,#P02*NE#*Z=2G4^NXE^SG"=OJ<;OEDI6UKVZ6_I7BHJDX3A:*YX2C?F;
MMS*U[6Z7?W??_F7_ !2TOQ WQ>^++IX:\0NC_$+Q.4==(O2K+_:ESAE9865E
M8<JP)!&"#7%?V5XB_P"A7\1?^"B^_P#C%?Z:S_LG_L]2R/--\+/"<L\KM)//
M)I5JTLTK'+R2N8LN[$DLQY))IO\ PR9^SO\ ]$H\(_\ @IM/_C5?WQA_IL9)
M0P^'H?ZC9A+V%"A0YO[5H+F]C2IT^:WL-+\K=KMK:[T9_%>)^B#B,1B*U?\
MUXPT?:U)5.7^QJSMS23:O]=\Y;?+H?YE?]E>(O\ H5_$7_@HOO\ XQ1_97B+
M_H5_$7_@HOO_ (Q7^FI_PR9^SO\ ]$H\(_\ @IM/_C5'_#)G[.__ $2CPC_X
M*;3_ .-5M_Q.[DG_ $0F8]/^9K0\O^G'K^/=6P_XD\Q'_1<X;I_S):W]V_\
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M(O\ H5_$7_@HOO\ XQ1_97B+_H5_$7_@HOO_ (Q7^FI_PR9^SO\ ]$H\(_\
M@IM/_C5'_#)G[.__ $2CPC_X*;3_ .-4?\3NY)_T0F8]/^9K0\O^G'K^/=6/
M^)/,1_T7.&Z?\R6M_=O_ ,QW^+^K'^97_97B+_H5_$7_ (*+[_XQ1_97B+_H
M5_$7_@HOO_C%?Z:G_#)G[.__ $2CPC_X*;3_ .-4?\,F?L[_ /1*/"/_ (*;
M3_XU1_Q.[DG_ $0F8]/^9K0\O^G'K^/=6/\ B3S$?]%SANG_ #):W]V__,=_
MB_JQ_F5_V5XB_P"A7\1?^"B^_P#C%']E>(O^A7\1?^"B^_\ C%?Z:G_#)G[.
M_P#T2CPC_P""FT_^-4?\,F?L[_\ 1*/"/_@IM/\ XU1_Q.[DG_1"9CT_YFM#
MR_Z<>OX]U8_XD\Q'_1<X;I_S):W]V_\ S'?XOZL?YE?]E>(O^A7\1?\ @HOO
M_C%']E>(O^A7\1?^"B^_^,5_IJ?\,F?L[_\ 1*/"/_@IM/\ XU1_PR9^SO\
M]$H\(_\ @IM/_C5'_$[N2?\ 1"9CT_YFM#R_Z<>OX]U8_P")/,1_T7.&Z?\
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MS+!9A[!916INM]3Q%'$>S4WC)*#G[.45)QDE>[32L>[?;K+_ )_+7_P(B_\
MBZ/MUE_S^6O_ ($1?_%UYC_PI[PS_P _6L?^!S_X4?\ "GO#/_/UK'_@<_\
MA7\,>QRS_H-Q/_A&O_E_]6?E?^QKU/Y8_P#@3\O[OK_6_IWVZR_Y_+7_ ,"(
MO_BZ/MUE_P _EK_X$1?_ !=>8_\ "GO#/_/UK'_@<_\ A1_PI[PS_P _6L?^
M!S_X4>QRS_H-Q/\ X1K_ .7_ -6?E<O4_EC_ .!/R_N^O];^G?;K+_G\M?\
MP(B_^+H^W67_ #^6O_@1%_\ %UYC_P *>\,_\_6L?^!S_P"%'_"GO#/_ #]:
MQ_X'/_A1['+/^@W$_P#A&O\ Y?\ U9^5R]3^6/\ X$_+^[Z_UOZ=]NLO^?RU
M_P# B+_XNC[=9?\ /Y:_^!$7_P 77F/_  I[PS_S]:Q_X'/_ (4?\*>\,_\
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MKQHQJ-4*DZM.RM.=/V<F^ON<T[?^!%*]M4D_)W_1?UU"BBBLAA1110 4444
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M7BS4+[X4:5=:=H?POEV3>";J>?S&2_N[=[C:UQ!(_F(?L[$,.&!K-_X*$_\
M!,CX;_M\Z)X06]\>>+O@QX[\#7C77AOXC_#S9!XDL$*HJV\<OVBV*Q($(4"3
M #=!CG]-** /S@_X)Y?\$W?AY_P3_P#!>OZ)I/CCQ3\8/&_BG7+G6]=^)_C\
M)-XLOGN5D5K5[D7%RWD?O6R#(<X7@8.?T?HHH **** "BBB@ HHHH **** "
MBBB@ HHHH **^+_"O_!03]E#QE^T9JO[*.B_%+36^.NCPW,]UX)O8)K&ZDCM
M YF-I-<!(KHCRW"B$L6(P.>*^D_B?\3O _P;\">(_B5\1]?LO#'@OPG82:GK
MNM7\@CM[*TC(#.Q)&YB2-J+EFYP.* .]HKYM_9@_:T^!7[8O@.Y^)?[/_C!?
M&W@RUU271Y-8CLKFRB:]AW%TB6Y56ECPI*RIE&'(/-<A^T?^WE^RO^R7XK\
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M^W=^V,[_ !,MO WQ*U7X?_"CX8^)%35_ MGHJO?&TU231KL26KW-ND"E2T3
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MO^":?P"^'UQ%K?B?X9^-;_6/'4&GLMS/X>AO[F%XSJ*1Y>T38%YEP"2<?>H
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MOH3_  3\=W7B3X@:F08XKC24U)3MNI <$;-P&X\9/3-?L%_P4H_Y6 OV(_\
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MO^SGX]\+ZOI6I+>?#O1X-8MM,O(+IM&U>$3+=:7?1PNQM;N# +P2JC -TX.
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M2.?6O%,=S GD1Z1;_8[AY75=JMA7^;\JY[]C[_@O+\&OVG_CY;_LZ^-/@/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOB/;>+=+^,]K<VT7AE+6:(Z4MQ<I,PD>2-4D!0-&P#-G)K]=J* /YVOV*_\
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M%.FSZ3K>E7D:207=E<KMDC82*Z@\ JVTE6 -?S.:9_P12_;X_91\8?$33/\
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M"4GA#P]XU\77_CCQ!9R7AO3=^(M2+M=W@<PP[!(7;Y-K8S]XU]6444 ?B/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img75897552_6.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_6.gif
M1TE&.#EA#02> O<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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MG(5"*8&'+V:L)-$*V*0.%JJNL_\:KS<[KSE;KSO[KCU+KSX+I<#J8,G&:8A
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M0;M7^/!=_-'?" -8P'SU*S)_JUU<S>._5Q"$W)##0_J>]PKH1?&PSF4*][:
M!1Q9_W +MFL*HM5*$!T.,)!QI0_[>+?$+C[Q_ZA<32N;V+[:;<<\_ H $49X
M!D=6, N4[(4*$[2\"$@SUIRY8B+_V,=7@&^B1.2<$6HWRAGFZW+P:&8T)WG
M!6YESP2QCA\W^@KNR/%G5BR(=D3!R'!>\ S@J\-G\B/"+& N"Z[ 9&*V AXS
M""YSKW /^-##T026'@#T<>4K8 '6SVHQ? 5!ZRN(>5.M8*&CP<Q9&XE(KI5&
MKQ?8:,M\M)C&113A?^OJN.O50QXG_G*>B;4I^IU8$/JIQQ58P (%FV#<2HXO
M;W?;6]JJ==VO9'=MVRU;>7=3'UZ  J:CD&Y@"I9N (MN1_^H:UU!L* CQ#W+
M+ 31@E!CP122[E2"%SSJ]-QC#PF>[K?[$6XTMX!/S]SSK+T\@_"..[@"0,"^
M WA@B3/8P1E)A#M0W9$9F +DPKS'%3J2\F]G),(<$36I5BN(<I ; 5>HAWU:
M(>YR+S@!XU:SR>$\ T$4.R&MN+BYJ7N/*B^GO1)6LX([(NI[S<3344#R%:KD
MW788'.4F>#JYC6STX5[A>/X@,CGH?N[PXO@>V^8E=A"!X0 ;.0'E%@ +O("\
M65]AN0)0>S[[\?,TK]J5D[^"Q--\;JAC6M3ONF[FFY[F-0OB[W),A+B9"P69
MF#,?7D"[@O=M7(4S//%(_\SK#1[_@ 2X0T/ !-_,33 #=Q#MG!"*GL_=CG 5
M1\T+'==P9DPA;CBWH/@?$D3LX<QY<C_=\SHC9S^(;' 3()T?TS\RV<>,]02S
M@+KXR$QY+]UT%@0XOX@FLZO=/@._S"3<:=8TXZ,W=[NM>B/ >?.J>#M  QS
M!D2HU9*_DQ, YJ+ 3"LN"XNN4*NN-O*"5%.RA"NX4*,X^&B%MAL[BMNX*TB
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M2JF;^B*6/NF_>2F07@9KN=$[],Y3R8!6U$-8K%Y6M$.-P0,YW,65\0-? )5
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ML#"ATEU+@?@$1=$JP(16J&1GM+M7TQ\_>EFCEGTJ=::^@?[N[9EA @&++OA
MSGH+Y2S?IUM97(%G5&"B* ("((C2$V')*% E]YRE3Q#ALE#VDFU1MU6]K @,
MMYC;]TJ]67<UMLIJ^ KAH5[J\<MGLC +WUM-C,X]:UYMU,?Y0JGK;U;)D\#[
MC@U^!5$_F_?<>>X[ \I8E=39:A1L7 !JWZC1+O;7SW1WON5IRVL%V^/5V:Q-
MC?372MYIPV;+@\*+>_H9J)^\0@L."M7.6@F?5DSQ0BR^*&2M*.LVX@>1=EJ
M[C"R,LOG-7WZ.PRSSUJK"J+Q5KN",8GZX?_/"YGDLRHHR$8C$*%\O!!J.@)G
M,>VP%A8$+JVU6H''O[XZ3"E$%25JR[2M!)CA';L*HF<&J6:@J1]]VA&JKRY,
MF>5 O2@DDL'R5JJGP/&HO*+,>3I$[KB5?!+)(SU!&FE//_O\4]! ">734$ /
M'31111%ME-%'"W4T4D@7K;31?+)#;;3J)A6H%9QTXLDGH(02H(6B!)IG!IT2
M<],@V3 3\)[U9*N3!<TPM2VQ%V?9;0^9U*JJGWQ*J\>45O319[?+(ILLSU;0
M[,L+P*)D[PHJNRRP()ADVD.0EO:[ C($ZD((J"O,FXF?S<(ZCJ?P .!''J=8
M>^<>?5K)IYY?::/_QY^0H+7U"GJ@M K?>XQ%EA]\W6G2A(%5= Z!R%Q<""@H
MAIKIV&3OD5"KT5J),4Q6%4M$']V*/19#\?)!&)$']9D%K)-N6YDS9LE]45(-
M[TLL/X=B=&<OUN9!-ME$&KXMYGO@^DX0?))M!>&-M;4VJ9T0H2\CYYK$,Z$#
MLV)U6IMXU'6/@BN:19"A$R,84E)3:D$MZPCB\; C^YF%:5TK9BBO.I6;!^I6
M9@Y-0' Q"IKM=D0$ZC*^J"NH%0Z3ZTKF:\E*[&EDI4Z8+193:@TAII]BP<KY
M)+64TM197]WU3E6'O?5.97\]]MMGQ]WVW!OE.N-[,MJOGAEEHLDF4'>B_PQN
M4_?(4U6Q"31(GVAEI?4Y!$1E45-4^^3L)-],OZ*=7TO-C"UHV?XK>/2!$]U0
MV<95UURL-%67W<<3RYHA:#$+7Z;_]T"\*PSH7[&A'/;<4::#[.<=IS%=%*X0
MP-E\QVT N-G$R)4/@_@C0N6#H 0C2+P "F(M GF)(-9QA2C0BT(L$!"U$H<5
MLX2O"^VH3:E68K-VE<=%;Y,A;7[V$/O,\']%[);XGO8:"R8"'EUHRF_N=(5W
MA.PGIKD:%/0GDK*YRW@;1 KT_M4K+V!,)6?;4Y#(0ZXL3H0?^U*A8ABS/+GI
MJ&X]0DU:0J8WXP1G,0OL3*R,V"T14D8D%X/*J?\$T;"MB$HADP-<.Q08+T0H
MZ8EF,<P,W#$?T E 3J-SX S4P[O=C;)VI=2=*46)RD&IDI6G=&4J7TG*#/TP
M<\KY'W>D,X.BW.4F.4G>J&[$/*/XXWDJ&9"V , ^[!$P1M>[59Y(IQ2F".(=
M,Y*.G-!(EST@XA[T*!%FG.6I:#GH(YS13F("V$#"B.U9Z(+/:+Q@PR+5CR;L
M\DS^Z.,/'I$#,S.I1R+H81*GC.9;( E8Y2)IH&!JKAX(,TG7($80RTSL._!
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M02Y\)TBK+WG=9#M]SW7-*#^-U[7M:0=LU'^MS'[]:TD=U\'Y.K<7#F?XAMQ
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MC17I!UC?5XYTJ ,=\J")0NHA$G!H<,,"Z0<BWM?F/@/@'E/9(GQYLNCQEA<
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MB3D*!VU8J?7Y-GVXH.D+P;5#(QG30VUTF*2XN7NX"*18B1U$!##:!ADXH8.
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M9EE&7A1K(W<0!+9\B%\^BGK0(SO"WD);!RSF8H,N6\-*W,G-W,O-Z#OEAWN
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M>=CAIT=VG5:+<L?Y_G:'S5_[[[TCLP=AF=]]N&<!JXI]@  @$$ _?>]8!$
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M<H8$,.=\D2M_L2N_TBO#<NB"40*Q$B3&0P;> 1J=41K7TBW_8Q C \F(RRO
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MA_^CA<O8E\EX7ZLN==DXC7=YC8TY4_=JB_P!&N8!B$OA'F;)&OCA2::YNJI
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MZ4O-A\&B A4^YN'%;&!W'EF+Y>NB1X)Q,&9JGA['DQO_0L2J;6,=4/3'/?2
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M(AI%>4S["9.A#N! 0WW$$M;T#8-U,.'@#=G4$%B6#N4P#C 5@?)5+_101^B
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M..#PM>:IOK)Z5>U9+_(09TXKGN @380C%K.D#I682VS88HUQ.,Q3K!N5#WK
ME?WE:\(8@56 #O_<4PY5^:$<G+Z?&*$7&L(9*L(;2L*!6,(CG,(=9#3@U<&=
M^L+:Z<$@&B3/>[B+:\.,>\.-B\,\O,,^K,- G,-"?+B/RZDQ#,.?.BCGNQ9O
M6 H4&8$9/ X9/&?RDG;+0G8.=C?GA1#Y8#C<(P/I &H.X0\X5: -"4J1E0ZF
M)H&ME';V\0Z<2X.Y5%6FYF1;N+R!&1'4>KQ\C+R)I+S-N\3N^+R!.[[B&[[1
MZ[V(3+V&G,B-S,B+C+WD.\D=^[+FB\<&%KF:O,F_1[9L^\DG&<HNN;:BS))G
M&S3/Q\FJK!EUV\-![,I#_,.Q_,JR#,NV7,N(6\2K_!F"#!]AY7:KTIC_KW(?
M]1/(F'S,/U6\?KS,?:QXXEB O9S'=TG(D$S)CAS)BFS-U7S(VBS)W/S-U]S-
MV0RS,BO-ZB;#+HQ:#?8$8W@/F15+4:-ZN1@2Z9S$2*R^^-R@,0S"*GS"_FR(
M%&K" *VA_XR(+/Q!^FS/1[S0"FU:-8S+M!S1LSS1MRS1%4W1N*S+#)W/,TQ
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M*I5P(%,:H'?XAFT(!WF ADJYE'&8!Y*:'K 1&F&J"7(PO':BB'< I:WX0=9
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MU <OZ[?-1=W455W6J$_^_$\!]<_[A-T =5W9K=W][,\\(U QI(=R^(9VB$C
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M3U#EP /1/.HX1!0_\QSU4#[MC:-./@59MV%Z_WG(H7H?=@BBB"&2:!U7+ C
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M.EXZ:(B.>G"D($5K'SF4=I#PD(,<GU*//^CQNU]=+6ON,,<3U$$4% F(/_.
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M.G##./]T!W*H SB  S/MCG,8)SIX SC(@Q$-5CA@R#;EAU-T#3_(PW[@3-O
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M)1+[B<M<BA^^I9/DH9_0@:G4C]" ZQ99L2#E!^BP,BOW:)*F1B++@1SLD.#
MHPJ\H>N>X.;*@:=TC*OF3J9^C=D$)P(GT$RVCAR 2WE*0;_"L$QB:EK$C^[.
MZ@F":6; P;BBSS5*2P4_K4S(CCQ:+1M)R1V&$"SI!!W: 1#<X6;@TC6TC=N\
M[1W,:QWX0;G6I>3<0P7*X3Y*(?,6\*N2T/_=X$TK95--5L\$VV4S&<*:]*$=
M5 #:2$T@%!%XNBRBEDNISL_YVJ4_=BG'O%+31&N1E*,&NZSQ$.7O<$DE)0S
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B79NV9?NU31NV9_NG.7NT>SNT@?NWA1NTA]NWB;NC P( .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img75897552_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_7.jpg
M_]C_X  02D9)1@ ! @$!( $@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ,)!ND# 2(  A$! Q$!_\0
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M#]L/^%A^$/\ H,VW_?0_QH_X6'X0_P"@S;?]]#_&OQ/_ .$KUS_G^G_[^/\
MXT?\)7KG_/\ 3_\ ?Q_\: /VP_X6'X0_Z#-M_P!]#_&C_A8?A#_H,VW_ 'T/
M\:_$_P#X2O7/^?Z?_OX_^-'_  E>N?\ /]/_ -_'_P : /VP_P"%A^$/^@S;
M?]]#_&C_ (6'X0_Z#-M_WT/\:_$__A*]<_Y_I_\ OX_^-'_"5ZY_S_3_ /?Q
M_P#&@#]L/^%A^$/^@S;?]]#_ !H_X6'X0_Z#-M_WT/\ &OQ/_P"$KUS_ )_I
M_P#OX_\ C1_PE>N?\_T__?Q_\: /VP_X6'X0_P"@S;?]]#_&C_A8?A#_ *#-
MM_WT/\:_$_\ X2O7/^?Z?_OX_P#C1_PE>N?\_P!/_P!_'_QH _;#_A8?A#_H
M,VW_ 'T/\:/^%A^$/^@S;?\ ?0_QK\3_ /A*]<_Y_I_^_C_XT?\ "5ZY_P _
MT_\ W\?_ !H _;#_ (6'X0_Z#-M_WT/\:/\ A8?A#_H,VW_?0_QK\3_^$KUS
M_G^G_P"_C_XT?\)7KG_/]/\ ]_'_ ,: /VP_X6'X0_Z#-M_WT/\ &C_A8?A#
M_H,VW_?0_P :_$__ (2O7/\ G^G_ ._C_P"-'_"5ZY_S_3_]_'_QH _;#_A8
M?A#_ *#-M_WT/\:/^%A^$/\ H,VW_?0_QK\3_P#A*]<_Y_I_^_C_ .-'_"5Z
MY_S_ $__ '\?_&@#]L/^%A^$/^@S;?\ ?0_QH_X6'X0_Z#-M_P!]#_&OQ/\
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M_P : /VP_P"%A^$/^@S;?]]#_&C_ (6'X0_Z#-M_WT/\:_$__A*]<_Y_I_\
MOX_^-'_"5ZY_S_3_ /?Q_P#&@#]L/^%A^$/^@S;?]]#_ !H_X6'X0_Z#-M_W
MT/\ &OQ/_P"$KUS_ )_I_P#OX_\ C1_PE>N?\_T__?Q_\: /VP_X6'X0_P"@
MS;?]]#_&C_A8?A#_ *#-M_WT/\:_$_\ X2O7/^?Z?_OX_P#C1_PE>N?\_P!/
M_P!_'_QH _;#_A8?A#_H,VW_ 'T/\:/^%A^$/^@S;?\ ?0_QK\3_ /A*]<_Y
M_I_^_C_XT?\ "5ZY_P _T_\ W\?_ !H _;#_ (6'X0_Z#-M_WT/\:/\ A8?A
M#_H,VW_?0_QK\3_^$KUS_G^G_P"_C_XT?\)7KG_/]/\ ]_'_ ,: /VP_X6'X
M0_Z#-M_WT/\ &C_A8?A#_H,VW_?0_P :_$__ (2O7/\ G^G_ ._C_P"-'_"5
MZY_S_3_]_'_QH _;#_A8?A#_ *#-M_WT/\:/^%A^$/\ H,VW_?0_QK\3_P#A
M*]<_Y_I_^_C_ .-'_"5ZY_S_ $__ '\?_&@#]L/^%A^$/^@S;?\ ?0_QH_X6
M'X0_Z#-M_P!]#_&OQ/\ ^$KUS_G^G_[^/_C1_P )7KG_ #_3_P#?Q_\ &@#]
ML/\ A8?A#_H,VW_?0_QH_P"%A^$/^@S;?]]#_&OQ/_X2O7/^?Z?_ +^/_C1_
MPE>N?\_T_P#W\?\ QH _;#_A8?A#_H,VW_?0_P :/^%A^$/^@S;?]]#_ !K\
M3_\ A*]<_P"?Z?\ [^/_ (T?\)7KG_/]/_W\?_&@#]L/^%A^$/\ H,VW_?0_
MQH_X6'X0_P"@S;?]]#_&OQ/_ .$KUS_G^G_[^/\ XT?\)7KG_/\ 3_\ ?Q_\
M: /VP_X6'X0_Z#-M_P!]#_&C_A8?A#_H,VW_ 'T/\:_$_P#X2O7/^?Z?_OX_
M^-'_  E>N?\ /]/_ -_'_P : /VP_P"%A^$/^@S;?]]#_&C_ (6'X0_Z#-M_
MWT/\:_$__A*]<_Y_I_\ OX_^-'_"5ZY_S_3_ /?Q_P#&@#]L/^%A^$/^@S;?
M]]#_ !H_X6'X0_Z#-M_WT/\ &OQ/_P"$KUS_ )_I_P#OX_\ C1_PE>N?\_T_
M_?Q_\: /VP_X6'X0_P"@S;?]]#_&C_A8?A#_ *#-M_WT/\:_$_\ X2O7/^?Z
M?_OX_P#C1_PE>N?\_P!/_P!_'_QH _;#_A8?A#_H,VW_ 'T/\:/^%A^$/^@S
M;?\ ?0_QK\3_ /A*]<_Y_I_^_C_XT?\ "5ZY_P _T_\ W\?_ !H _;#_ (6'
MX0_Z#-M_WT/\:/\ A8?A#_H,VW_?0_QK\3_^$KUS_G^G_P"_C_XT?\)7KG_/
M]/\ ]_'_ ,: /VP_X6'X0_Z#-M_WT/\ &C_A8?A#_H,VW_?0_P :_$__ (2O
M7/\ G^G_ ._C_P"-'_"5ZY_S_3_]_'_QH _;#_A8?A#_ *#-M_WT/\:/^%A^
M$/\ H,VW_?0_QK\3_P#A*]<_Y_I_^_C_ .-'_"5ZY_S_ $__ '\?_&@#]L/^
M%A^$/^@S;?\ ?0_QH_X6'X0_Z#-M_P!]#_&OQ/\ ^$KUS_G^G_[^/_C1_P )
M7KG_ #_3_P#?Q_\ &@#]L/\ A8?A#_H,VW_?0_QINJ?$7P?HVGOJFHZU:VUB
MB%VN'=0@4#)))8#I7XF2^*]<PO\ I\XRZ_\ +1O?CK57]K+Q5KMC^S;K%Y:W
M]U#<+I$S"5'<.&,+<AMQ(//;'KGBNK 8=8S'X3!N7(L36C2Y[7Y>:25_Q)D^
M6+>]D?J5>?MK_LT:?<O9W?Q0T&&Y0E6B>XB# @X(QYGJ,?6H/^&X/V8O^BIZ
M!_X$Q?\ QVO\H_XZ_M!_%JU^+.NV\'C+78XEO[I51;R?: LC8&-V.!@#([>N
M:\Y_X:(^+W_0Z:[_ .!DO_Q5?T!2\#J-2E2J?VO53J0C-KV4';FMINMM?ZL>
M4\S:;3IK3S?E_P '[O,_UMO^&X/V8O\ HJ>@?^!,7_QVC_AN#]F+_HJ>@?\
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M,7_14] _\"8O_CM?Y)/_  T1\7O^ATUW_P #)?\ XJC_ (:(^+W_ $.FN_\
M@9+_ /%4?\0+H_\ 0XJ]/^74?+S]?Q[JQ_:G_3N/WR_R]?Z>G^MM_P -P?LQ
M?]%3T#_P)B_^.T?\-P?LQ?\ 14] _P# F+_X[7^23_PT1\7O^ATUW_P,E_\
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M ([7^23_ ,-$?%[_ *'37?\ P,E_^*H_X:(^+W_0Z:[_ .!DO_Q5'_$"Z/\
MT.*O3_EU'R\_7\>ZL?VI_P!.X_?+_+U_IZ?ZVW_#<'[,7_14] _\"8O_ ([1
M_P -P?LQ?]%3T#_P)B_^.U_DD_\ #1'Q>_Z'37?_  ,E_P#BJ/\ AHCXO?\
M0Z:[_P"!DO\ \51_Q NC_P!#BKT_Y=1\O/U_'NK']J?].X_?+_+U_IZ?ZVW_
M  W!^S%_T5/0/_ F+_X[1_PW!^S%_P!%3T#_ ,"8O_CM?Y)/_#1'Q>_Z'37?
M_ R7_P"*H_X:(^+W_0Z:[_X&2_\ Q5'_ ! NC_T.*O3_ )=1\O/U_'NK']J?
M].X_?+_+U_IZ?ZVW_#<'[,7_ $5/0/\ P)B_^.T?\-P?LQ?]%3T#_P "8O\
MX[7^23_PT1\7O^ATUW_P,E_^*H_X:(^+W_0Z:[_X&2__ !5'_$"Z/_0XJ]/^
M74?+S]?Q[JQ_:G_3N/WR_P O7^GI_K;?\-P?LQ?]%3T#_P "8O\ X[1_PW!^
MS%_T5/0/_ F+_P".U_DD_P##1'Q>_P"ATUW_ ,#)?_BJ/^&B/B]_T.FN_P#@
M9+_\51_Q NC_ -#BKT_Y=1\O/U_'NK']J?\ 3N/WR_R]?Z>G^MM_PW!^S%_T
M5/0/_ F+_P".T?\ #<'[,7_14] _\"8O_CM?Y)/_  T1\7O^ATUW_P #)?\
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M1_Q NC_T.*O3_EU'R\_7\>ZL?VI_T[C]\O\ +U_IZ?ZVW_#<'[,7_14] _\
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M0/\ P)B_^.U_DD_\-$?%[_H=-=_\#)?_ (JC_AHCXO?]#IKO_@9+_P#%4?\
M$"Z/_0XJ]/\ EU'R\_7\>ZL?VI_T[C]\O\O7^GI_K;?\-P?LQ?\ 14] _P#
MF+_X[2']N']F%02?BIH  Y)^TQ?_ !VO\DK_ (:(^+W_ $.FN_\ @9+_ /%5
M!=?M%?%];>8CQIKO$;=+R;N,=FS^5"\"Z+LO[8JZV_Y=0\O/U_IJQ_:G_3N/
MWR_R]?Z>G^O7X4_:F^!7C?S/^$8\?:1JOE??^SSQMMQUSAST[U-JG[3WP0T:
M8V^H^.])MI5;:4>:,$'IC[]?YXG_  1P^,WQ&\1#Q'_:_B?5[S:DQ4SW,SX^
M4]W<G@C\J[;]K/XP_$.Q\=W\5IXEU6%!=R@+'<S  !V' #C\/Y9KW> _HYX?
MC'/\UR:>>UL*LMC3DJL:,).HYI/5-:;M:+S9^3>+7BY6\-L%EF*I973S!Y@Y
M+DG4E#DM;9IJ_7[K^1_?G_PUK\ #_P U#T;_ +_Q?_'*/^&M/@!_T4/1O_ B
M+_XY7^;6OQP^)F!_Q5.L=!_R]3>G^]2_\+P^)G_0TZQ_X%2__%5^O?\ $DV#
MO_R5F)_\)Z?]W^[Z_CV/PA?2]QFG_&+X?I_S$3_N_P";^_[O])/_ (:T^ '_
M $4/1O\ P(B_^.4?\-:? #_HH>C?^!$7_P <K_-L_P"%X?$S_H:=8_\  J7_
M .*H_P"%X?$S_H:=8_\  J7_ .*H_P"))L)_T5F)Z?\ ,-3_ +O]WU_'L"^E
M[C-/^,7P_3_F(G_=_P W]_W?Z2?_  UI\ /^BAZ-_P"!$7_QRC_AK3X ?]%#
MT;_P(B_^.5_FV?\ "\/B9_T-.L?^!4O_ ,51_P +P^)G_0TZQ_X%2_\ Q5'_
M !)-A/\ HK,3T_YAJ?\ =_N^OX]@7TO<9I_QB^'Z?\Q$_P"[_F_O^[_23_X:
MT^ '_10]&_\  B+_ ..4?\-:? #_ **'HW_@1%_\<K_-L_X7A\3/^AIUC_P*
ME_\ BJ/^%X?$S_H:=8_\"I?_ (JC_B2;"?\ 168GI_S#4_[O]WU_'L"^E[C-
M/^,7P_3_ )B)_P!W_-_?]W^DG_PUI\ /^BAZ-_X$1?\ QRC_ (:T^ '_ $4/
M1O\ P(B_^.5_FV?\+P^)G_0TZQ_X%2__ !5'_"\/B9_T-.L?^!4O_P 51_Q)
M-A/^BLQ/3_F&I_W?[OK^/8%]+W&:?\8OA^G_ #$3_N_YO[_N_P!)/_AK3X ?
M]%#T;_P(B_\ CE'_  UI\ /^BAZ-_P"!$7_QRO\ -L_X7A\3/^AIUC_P*E_^
M*H_X7A\3/^AIUC_P*E_^*H_XDFPG_168GI_S#4_[O]WU_'L"^E[C-/\ C%\/
MT_YB)_W?\W]_W?Z2?_#6GP _Z*'HW_@1%_\ '*/^&M/@!_T4/1O_  (B_P#C
ME?YMG_"\/B9_T-.L?^!4O_Q5'_"\/B9_T-.L?^!4O_Q5'_$DV$_Z*S$]/^8:
MG_=_N^OX]@7TO<9I_P 8OA^G_,1/^[_F_O\ N_TD_P#AK3X ?]%#T;_P(B_^
M.4?\-:? #_HH>C?^!$7_ ,<K_-L_X7A\3/\ H:=8_P# J7_XJC_A>'Q,_P"A
MIUC_ ,"I?_BJ/^))L)_T5F)Z?\PU/^[_ '?7\>P+Z7N,T_XQ?#]/^8B?]W_-
M_?\ =_I)_P##6GP _P"BAZ-_X$1?_'*/^&M/@!_T4/1O_ B+_P".5_FV?\+P
M^)G_ $-.L?\ @5+_ /%4?\+P^)G_ $-.L?\ @5+_ /%4?\2383_HK,3T_P"8
M:G_=_N^OX]@7TO<9I_QB^'Z?\Q$_[O\ F_O^[_23_P"&M/@!_P!%#T;_ ,"(
MO_CE'_#6GP _Z*'HW_@1%_\ '*_S;/\ A>'Q,_Z&G6/_  *E_P#BJ/\ A>'Q
M,_Z&G6/_  *E_P#BJ/\ B2;"?]%9B>G_ ##4_P"[_=]?Q[ OI>XS3_C%\/T_
MYB)_W?\ -_?]W^DG_P -:? #_HH>C?\ @1%_\<H_X:T^ '_10]&_\"(O_CE?
MYMG_  O#XF?]#3K'_@5+_P#%4?\ "\/B9_T-.L?^!4O_ ,51_P 2383_ **S
M$]/^8:G_ '?[OK^/8%]+W&:?\8OA^G_,1/\ N_YO[_N_TD_^&M/@!_T4/1O_
M  (B_P#CE'_#6GP _P"BAZ-_X$1?_'*_S;/^%X?$S_H:=8_\"I?_ (JC_A>'
MQ,_Z&G6/_ J7_P"*H_XDFPG_ $5F)Z?\PU/^[_=]?Q[ OI>XS3_C%\/T_P"8
MB?\ =_S?W_=_I)_\-:? #_HH>C?^!$7_ ,<H_P"&M/@!_P!%#T;_ ,"(O_CE
M?YMG_"\/B9_T-.L?^!4O_P 51_PO#XF?]#3K'_@5+_\ %4?\2383_HK,3T_Y
MAJ?]W^[Z_CV!?2]QFG_&+X?I_P Q$_[O^;^_[O\ 23_X:T^ '_10]&_\"(O_
M (Y1_P -:? #_HH>C?\ @1%_\<K_ #;/^%X?$S_H:=8_\"I?_BJ/^%X?$S_H
M:=8_\"I?_BJ/^))L)_T5F)Z?\PU/^[_=]?Q[ OI>XS3_ (Q?#]/^8B?]W_-_
M?]W^DG_PUI\ /^BAZ-_X$1?_ !RC_AK3X ?]%#T;_P "(O\ XY7^;9_PO#XF
M?]#3K'_@5+_\51_PO#XF?]#3K'_@5+_\51_Q)-A/^BLQ/3_F&I_W?[OK^/8%
M]+W&:?\ &+X?I_S$3_N_YO[_ +O])/\ X:T^ '_10]&_\"(O_CE'_#6GP _Z
M*'HW_@1%_P#'*_S;/^%X?$S_ *&G6/\ P*E_^*H_X7A\3/\ H:=8_P# J7_X
MJC_B2;"?]%9B>G_,-3_N_P!WU_'L"^E[C-/^,7P_3_F(G_=_S?W_ '?Z2?\
MPUI\ /\ HH>C?^!$7_QRC_AK3X ?]%#T;_P(B_\ CE?YMG_"\/B9_P!#3K'_
M (%2_P#Q5'_"\/B9_P!#3K'_ (%2_P#Q5'_$DV$_Z*S$]/\ F&I_W?[OK^/8
M%]+W&:?\8OA^G_,1/^[_ )O[_N_TD_\ AK3X ?\ 10]&_P# B+_XY1_PUI\
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M'Z?\Q$_[O^;^_P"[_23_ .&M/@!_T4/1O_ B+_XY1_PUI\ /^BAZ-_X$1?\
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ML?\ @5+_ /%4?\2383_HK,3T_P"8:G_=_N^OX]@7TO<9I_QB^'Z?\Q$_[O\
MF_O^[_23_P"&M/@!_P!%#T;_ ,"(O_CE'_#6GP _Z*'HW_@1%_\ '*_S;/\
MA>'Q,_Z&G6/_  *E_P#BJ/\ A>'Q,_Z&G6/_  *E_P#BJ/\ B2;"?]%9B>G_
M ##4_P"[_=]?Q[ OI>XS3_C%\/T_YB)_W?\ -_?]W^DG_P -:? #_HH>C?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4O1?\ ?7^1JI^UW_R;
M+K/_ &!Y?_1+5;EZ+_OK_(U4_:[_ .39=9_[ \O_ *):O3R/_D>93_V%T_\
MTN)%3X)>A_G,_'O_ )*_K_\ V$+O_P!&-7FM>E?'O_DK^O\ _80N_P#T8U>:
MU_>&'_W;#?\ 7BE_Z2CYE;R]?T04445J,**** "BBB@ HHHH **** "BD+*H
MW,<*.IKI]#^&_P 3/&REO WAF\UT#.3;022C_P <5C_G\*3E&*YISA3CUE4D
MH16V\GIU$WY-^2U>OD<S173Z[\*_B_X'A^V>.O!^H:#98W>?=6L\2[?7<Z #
M/3K^=<O;17.JM'!HT9O;F9@D,<8WL\A. H"@\YXQ@G(HC*$US4ZE.I#K.$XR
M@GUO*+:T_P""%^Z:?9K7Y+YBT5WP^ '[12V']NR_#G5UT';YAU V-R(A'C.[
M>8MN-IR1VQVKA;B"XL)'MK^,V]S$3'+$XVLLH."I!P>#P1C.:4:E*I?V5:E5
MMHU2J1FXOJI<K=FGI9V?D%WU32Z-JW;_ #(Z*Z#1_AS\3_&#;?!?A>]ULMC;
M]FMI9<YZ#,:-U[?Y%:.J_!;X[>%8C<^+/ >IZ3; ;FEGL[B-57KNR\8QQ_DT
M.I04N26(H1J/:G*K!5'M]AOFZOIT%S/?EE;O8XZB@AHV,4@VS+PZ'@@CL1U!
MZYJ&6>.( .P#,<*.Y8]!WZFKLW\]AW^7?R]2:BNKT;X0?&SQ= M]X1\$:EK%
MB_,<]O:3R(P/0[DC(.>V#TYYK4N/V>_VDM/B:YU#X:ZQ;VT8+22/870"J!R3
MF+' K)UL,GRRQ6&C/;DE6IJ=]-.5R3OKM;=6W8KR_DETZ=[6\NOY=]. HIEY
M'=Z),UIX@B.G7:'8\4JM&ROG !#!2.?;T/(S7::-\&_C=XSMAJ?@?P/J6NZ4
M1N%W;6EQ*FWUW1QD>G)..>*N4J<$I5*M.G![5)SC&#VVE)I-Z[7'?LFWU26J
M]4<=17HW_#-_[3N,_P#"L-:QW/V"ZP/_ "'_ /KKE-=^'WQ.\$C=XV\,7FAH
M.K75M+%^KH!Q_P#7]JF-7#S:C3Q.'J2>T85H3D]ME%M[O]>HKOK"2^3\OU?]
M=,2BH[1CJ3B#3O\ 2;DG:(D^9BW90!SGM]:[B#X)_':]M?[6L? >ISZ0%\PW
M:V<YC$77=N$>#P<Y_$9%5*5.&M2K2I=O:3C"^VBYFKO78+]DY7[*_6WW^7R.
M+HJ6ZM;O2YGL]7A:SO8B1+ XVLC+PP*L 1@]NM;>A?#SXE>/&,?P]\-7GB*3
MH5M+>6<@XSC]TC<^WOT/2ARA%<TYPA#?GG)1A;OS-\MNN]AW\FWIHE=J_='/
MT5O:CX ^(WAR^70_$WAN[TS7Y"$BT^>"2.5W)P $= QY]JZ&#]GO]I"_C6XT
M_P"&VL7%O( T<B6-R593]T@B/'(YI.K024I8G#QC)7C*5:"C)::QDY)25G>Z
M;0KOI&3?:S_K^NAP%%>BM^SA^TX@+-\,-:"+R6-A=# [_P#+/ _/WKA-;\/^
M*?!5P++QSI4^AWC$*L-S$\3%NP^=5R31&I1J-*EB*%63^S3JPG+9=(R;Z_@%
MWUC*/FU9=.]NK_7TJT5!)<11JK%P!)@1_P"T3]W'7KD5V6C?"#XU^+X!>^$/
M!.HZQ9/RD]M:3R(P/0[DC(.>.0>_>G*4()2J5*=*+=N:I)0C?M>32OUWZ,;?
M9-OK;6VJW^_3N<I17?W/[/7[2.GQ-<ZA\-=8M[:,;I)'L;H!5'))S'CC_/OY
M_=V^H:/.UEKENUC>HVQX)49&5@<$$, >#UX]/K2A.E4O[*M1K62;]E4A4[?R
M-[7_ %"[ZIQ]59=/NW^?X"T4=0#V(R/<4A(4$DX &23V JABT5T7AKX:?%;X
MD.T7PT\*7WB:2/)D6RMIIRH7EL^4C=!SVXYZ8-3ZS\+OBOX1U"/P_P"+_"=]
MH_B.<A+?3;BVECFDD8X 6-T5CDX[?A4NI14N1UZ*J)7=)U(^TC'3WI0OS):Z
MMI);[$W_ +LFNZ6GR[_UT.6HKKM7^#GQP\*V(UOQ7X&U+2=#D421WT]I<1Q-
M$V"'#-&%P5.<@X]^M<;%+'.!Y3!V8[5 [MT(]>N*:E":YJ=2G5C>SE3G&<4^
MJ;BVKKUZ#OW33[-6?]:DE%=9I?PC^,WBF'[5X3\&:AJUF 6,T%K/(NW&<[DC
M(QCI_D5AZIX=\2^%YC9>+-,FTB^4[6@GB:)PW(QAP.XP?I0ITY-QC5I3FMX1
MJ1E-;;Q3;6_5(+^37FU9??<SZ***8PHH ).!3+2.[UF^71]"B-_K$C!8[.)&
MDD9CT4*@)R?H<T[;O9)7;>B2[M[)>;$W;]%U8^BO1(?V<_VF;I%FMOACK,L,
M@W(ZV%T0RGD$$1XP017,^(/AU\4/ 6UO'_A>]\/HY^4W=M+#GIP#(B_EGGJ*
MSC5P\VHPQ.'G-Z*$*T)2Z?9C)RWNGII;4+O^627=IVZ&#1566]MH4$DDJJK?
M=)/7/3\Z[#0?A5\8O&\!O?!'@[4-=L@,^?:VL\J[>>24C(Z?7_&Y.$%S59PI
M1O;FJ24(W]967X@WV3?IKV_/IW.9HKHM6^'/Q.\(R1P^,_#%[HLL[;($N;>6
M)G<G"J-ZKDD\ =2>U=(G[.O[25YIB^)-/^&NLW'AID\Y=36PN6@,.,[PXCVD
M8P<YQS4.MATDY8G#QC+2$I58*,W_ "Q;>K\E=WM;=!=O[,K]K>FOXZ=_(\YH
MI\UI?Z?-)9ZI UK?0$I/ ZE6C<$AE((!&".X!IE7Z--=UJGZ#"BBB@ HHHH
M**** "BBB@ HHHH *KW?_'M/_P!<V_E5BJ]W_P >T_\ US;^5..Z]5^8I;/T
M?Y'[F_\ !%G_ )F7_<F_] -=O^U__P CYJ/_ %^2?^AO7$?\$6?^9E_W)O\
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M*%>C5HS:NHU:<Z<FNZ4XQ=OD2T5>T?P[XH\67!M/"FE76KW X,5K"TK@G'&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX^_9_P#&FL^'? V@Z=J.CZ-=S^9I]G"OR0PMAEPK-D$ -R<'! Y JU\*]/\
M#W_!/+]B7P[I_D^3 NBVLO[M=CAWM%;! QSMEQT'Y9KM/V5_VA--_:U^'/C/
MPR%:6UUC3[ZS*S'=\DJ%6XS_ +(QZXZXK^>\US3-<7G>,XFP]?$++\/F2C2E
MSS4%1C5C[O+S6^%;6U?8]:G"G&G"C)+G<%?36[2ZVT_3IY?Y2?Q5^S^'OC/X
M\\-H&CAT?5+NW"$% NRXD4  @=, ?YQ7Z3_\$S?^"=_C']M3XMZ/IMQ82_\
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M$\/>,/&/@/P[%;+X>M+JXN9[*U#$"TC=FWL@YZDDGGCCG(_F!_X+(G_C:O\
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M=3M*PQ2.-V<=40CJ1W_6O4=3_9)_:$T6REU+4?"6I16<*EI)##.0H R?X/\
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M_P"NC?S%<)V$E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2CRRNE:[2ZJW?3N4<5">*JW:4)+EC+H]KJ_RO_2/Y4/^"E7P^^)^C?M;>/\
M2(_!&L7,;:EJ:17*6LY27,[J"&"XYX(QG.>N<U_5E_P:G?"OQUX:M?$FO>)M
M O\ 1K9=-O=IO()(@_G0O$NTNH!R9%QS^E?O9\1OA+_P3!^.>N1^--<UKX?7
M6M3L+RXNH+R$R2>81*WFI+"Q1R2=Q65@,_*.YM^.?VL_V'/V)/A)K4OPF\0^
M#(+VTL)%@LM&N(Y+F9D0MFY9EB!<,B[1'#C))R, 'DSWC[$\1\,T.&,+D&/I
MXRO3P^'J59TJB@I4^6+EJK)2UMHK==QTL)&C6=>5:#BKM)-7Z>?W_D?SA?\
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M9"".X_TT"O\ 2B\2RVOQW_X)H3:G8Q)?WEY\,/ML42@22?;40H4"KDAC',I
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MW%_W5_D*=34^XO\ NK_(4ZOZU/X>"BBB@ HHHH **** "BBB@ HHHH ****
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M<7.$O=DFXST3NKZ*Q_&G^R)_P3#^,O[9%A/JFB6E]HEO"K.9)XVB3:N2"2^
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M_P"P#]O.3Q#>_LJSCP5YLEL^@!)#8Y"NBVOS;?+P/3IZX%?Q-?LB6_Q5T?\
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M8*I"FL#B<CQ4X_6:O,KQJ5*#:E!*]DW9O2]]#U0?L5_\%,B>/&.NY_Z^I_\
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M_!"OX2>(=8_:<B\4-93#26U&"=KAHV"!?.\TL&P< >8.O4=J_5O"G)LUX/\
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M_HQJ\UK^\,/_ +MAO^O%+_TE'S*WEZ_H@HHHK484444 %%%% !1110 4444
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M.),VQN<9G5E6Q>-K5*U23;:CSSE*,(WUY*:ERP72*"BBBO:/&"BBB@ HHHH
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MT_:@_P"A?U?_ +\7'_Q%'^IU;_H8X3I_R^AY?WO/^KH/K"_DG]WI_G_5U?\
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M_+Z'E_>\_P"KH/K"_DG]WI_G_5U?](_[3T+_ *"=O_WV/_BJ/[3T+_H)V_\
MWV/_ (JOS<_X5I^U!_T+^K_]^+C_ .(H_P"%:?M0?]"_J_\ WXN/_B*/]3JW
M_0QPG3_E]#R_O>?]70?6%_)/[O3_ #_JZO\ I'_:>A?]!.W_ .^Q_P#%4?VG
MH7_03M_^^Q_\57YN?\*T_:@_Z%_5_P#OQ<?_ !%'_"M/VH/^A?U?_OQ<?_$4
M?ZG5O^ACA.G_ "^AY?WO/^KH/K"_DG]WI_G_ %=7_2/^T]"_Z"=O_P!]C_XJ
MC^T]"_Z"=O\ ]]C_ .*K\W/^%:?M0?\ 0OZO_P!^+C_XBC_A6G[4'_0OZO\
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M]75_TC_M/0O^@G;_ /?8_P#BJ/[3T+_H)V__ 'V/_BJ_-S_A6G[4'_0OZO\
M]^+C_P"(H_X5I^U!_P!"_J__ 'XN/_B*/]3JW_0QPG3_ )?0\O[WG_5T'UA?
MR3^[T_S_ *NK_I'_ &GH7_03M_\ OL?_ !5']IZ%_P!!.W_[['_Q5?FY_P *
MT_:@_P"A?U?_ +\7'_Q%'_"M/VH/^A?U?_OQ<?\ Q%'^IU;_ *&.$Z?\OH>7
M][S_ *N@^L+^2?W>G^?]75_TC_M/0O\ H)V__?8_^*H_M/0O^@G;_P#?8_\
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M?YH_ 7[;:?\ />/\Z/MMI_SWC_.OWZ_X<*_&S_H!:A_X#R_X4?\ #A7XV?\
M0"U#_P !Y?\ "C_7'AG_ *&E#_P./^?FOO#V&(_Y]_@_+_-'X"_;;3_GO'^=
M'VVT_P">\?YU^_7_  X5^-G_ $ M0_\  >7_  H_X<*_&S_H!:A_X#R_X4?Z
MX\,_]#2A_P"!Q_S\U]X>PQ'_ #[_  ?E_FC\!?MMI_SWC_.C[;:?\]X_SK]^
MO^'"OQL_Z 6H?^ \O^%'_#A7XV?] +4/_ >7_"C_ %QX9_Z&E#_P./\ GYK[
MP]AB/^??X/R_S1^ OVVT_P">\?YT?;;3_GO'^=?OU_PX5^-G_0"U#_P'E_PH
M_P"'"OQL_P"@%J'_ (#R_P"%'^N/#/\ T-*'_@<?\_-?>'L,1_S[_!^7^:/P
M%^VVG_/>/\Z/MMI_SWC_ #K]^O\ APK\;/\ H!:A_P" \O\ A1_PX5^-G_0"
MU#_P'E_PH_UQX9_Z&E#_ ,#C_GYK[P]AB/\ GW^#\O\ -'X"_;;3_GO'^='V
MVT_Y[Q_G7[]?\.%?C9_T M0_\!Y?\*/^'"OQL_Z 6H?^ \O^%'^N/#/_ $-*
M'_@<?\_-?>'L,1_S[_!^7^:/P%^VVG_/>/\ .C[;:?\ />/\Z_?K_APK\;/^
M@%J'_@/+_A1_PX5^-G_0"U#_ ,!Y?\*/]<>&?^AI0_\  X_Y^:^\/88C_GW^
M#\O\T?@+]MM/^>\?YT?;;3_GO'^=?OU_PX5^-G_0"U#_ ,!Y?\*/^'"OQL_Z
M 6H?^ \O^%'^N/#/_0TH?^!Q_P _-?>'L,1_S[_!^7^:/P%^VVG_ #WC_.C[
M;:?\]X_SK]^O^'"OQL_Z 6H?^ \O^%'_  X5^-G_ $ M0_\  >7_  H_UQX9
M_P"AI0_\#C_GYK[P]AB/^??X/R_S1^ OVVT_Y[Q_G1]MM/\ GO'^=?OU_P .
M%?C9_P! +4/_  'E_P */^'"OQL_Z 6H?^ \O^%'^N/#/_0TH?\ @<?\_-?>
M'L,1_P ^_P 'Y?YH_ 7[;:?\]X_SH^VVG_/>/\Z_?K_APK\;/^@%J'_@/+_A
M1_PX5^-G_0"U#_P'E_PH_P!<>&?^AI0_\#C_ )^:^\/88C_GW^#\O\T?@+]M
MM/\ GO'^='VVT_Y[Q_G7[]?\.%?C9_T M0_\!Y?\*/\ APK\;/\ H!:A_P"
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MC_GW^#\O\T?@+]MM/^>\?YT?;;3_ )[Q_G7[]?\ #A7XV?\ 0"U#_P !Y?\
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MSK]^O^'"OQL_Z 6H?^ \O^%'_#A7XV?] +4/_ >7_"C_ %QX9_Z&E#_P./\
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M/B'.,]S7,:<,OS*-..%JIIJ3IJ,9*]^CTZ[??^%^.?ASQ!X@9?DV$R.E&=3
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M^*K]&_\ AT7\>O\ H":E_P" TW_Q%'_#HOX]?] 34O\ P&F_^(H_XF)\,O\
MH<4^G5>7GZ_CW5C_ (ED\1O^@:ET^W'R_N^;_'MK^<G]H6'_ #]Q?]]+_P#%
M4?VA8?\ /W%_WTO_ ,57Z-_\.B_CU_T!-2_\!IO_ (BC_AT7\>O^@)J7_@--
M_P#$4?\ $Q/AE_T.*?3JO+S]?Q[JQ_Q+)XC?] U+I]N/E_=\W^/;7\Y/[0L/
M^?N+_OI?_BJ/[0L/^?N+_OI?_BJ_1O\ X=%_'K_H":E_X#3?_$4?\.B_CU_T
M!-2_\!IO_B*/^)B?#+_H<4^G5>7GZ_CW5C_B63Q&_P"@:ET^W'R_N^;_ ![:
M_G)_:%A_S]Q?]]+_ /%4?VA8?\_<7_?2_P#Q5?HW_P .B_CU_P! 34O_  &F
M_P#B*/\ AT7\>O\ H":E_P" TW_Q%'_$Q/AE_P!#BGTZKR\_7\>ZL?\ $LGB
M-_T#4NGVX^7]WS?X]M?SD_M"P_Y^XO\ OI?_ (JC^T+#_G[B_P"^E_\ BJ_1
MO_AT7\>O^@)J7_@--_\ $4?\.B_CU_T!-2_\!IO_ (BC_B8GPR_Z'%/IU7EY
M^OX]U8_XED\1O^@:ET^W'R_N^;_'MK^<G]H6'_/W%_WTO_Q5']H6'_/W%_WT
MO_Q5?HW_ ,.B_CU_T!-2_P# :;_XBC_AT7\>O^@)J7_@--_\11_Q,3X9?]#B
MGTZKR\_7\>ZL?\2R>(W_ $#4NGVX^7]WS?X]M?SD_M"P_P"?N+_OI?\ XJC^
MT+#_ )^XO^^E_P#BJ_1O_AT7\>O^@)J7_@--_P#$4?\ #HOX]?\ 0$U+_P !
MIO\ XBC_ (F)\,O^AQ3Z=5Y>?K^/=6/^)9/$;_H&I=/MQ\O[OF_Q[:_G)_:%
MA_S]Q?\ ?2__ !5']H6'_/W%_P!]+_\ %5^C?_#HOX]?] 34O_ :;_XBC_AT
M7\>O^@)J7_@--_\ $4?\3$^&7_0XI].J\O/U_'NK'_$LGB-_T#4NGVX^7]WS
M?X]M?SD_M"P_Y^XO^^E_^*H_M"P_Y^XO^^E_^*K]&_\ AT7\>O\ H":E_P"
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M?\_<7_?2_P#Q5?HW_P .B_CU_P! 34O_  &F_P#B*/\ AT7\>O\ H":E_P"
MTW_Q%'_$Q/AE_P!#BGTZKR\_7\>ZL?\ $LGB-_T#4NGVX^7]WS?X]M?SD_M"
MP_Y^XO\ OI?_ (JC^T+#_G[B_P"^E_\ BJ_1O_AT7\>O^@)J7_@--_\ $4?\
M.B_CU_T!-2_\!IO_ (BC_B8GPR_Z'%/IU7EY^OX]U8_XED\1O^@:ET^W'R_N
M^;_'MK^<G]H6'_/W%_WTO_Q5']H6'_/W%_WTO_Q5?HW_ ,.B_CU_T!-2_P#
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MFBG3IOAD25,^FY&8?K1SS_FE_P"!/_,++LOZ_P"&7W&9_P (]H'_ $!-)_\
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M_#+[C'_X1[0/^@)I/_@NM/\ XS1_PCV@?] 32?\ P76G_P 9K8HHYY_S2_\
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M/7=$[C]:MD@ DG '))Z >IHN^[^]@9W]CZ3_ - O3O\ P"MO_C5']CZ3_P!
MO3O_  "MO_C51OKNB12_9Y-9TJ.<G A?4+1)2>F/+:8/G/;;6FK*ZAT975@"
MK*0RL#T(8$@@]B#BB[[O[V!0_L?2?^@7IW_@%;?_ !JC^Q])_P"@7IW_ (!6
MW_QJK<MQ;P#,\\,(]994C'YNRBN?\0>*M,\.VB7U[(IM&R6G1U,:(.K%QE<
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MNC?] G3/_ "U_P#C5']BZ-_T"=,_\ +7_P"-5HNZ1J7D=411EG=@JJ/4LQ
M^IJO#?6-R2MO>6MPR\$0W$,I!]"(W8C\:+ON_P"O^&7W!=]W][*W]BZ-_P!
MG3/_   M?_C5']BZ-_T"=,_\ +7_ .-5IT47?=_U_P ,ON"[[O[V9G]BZ-_T
M"=,_\ +7_P"-4?V+HW_0)TS_ , +7_XU5B^OK73;2>^O9X[>UMHVDFFE8(B*
MHR22>/85SWACQKX>\8+<OH-_;WR6CE)F@E20*P;:0=I..:+ON_Z_X9?<%WW?
MWLV?[%T;_H$Z9_X 6O\ \:H_L71O^@3IG_@!:_\ QJK=S>6EFGF7EU;6L?\
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M[@N^[^]F9_8NC?\ 0)TS_P  +7_XU1_8NC?] G3/_ "U_P#C5:=%%WW?]?\
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M"KC?NP>>#U';K7Z__P#!4_\ ;O@_8:^"T'BJVV2:[KS75KI\.0)<@+'&R?Q
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MMWQ#X[^&NAQ1>#]-UV>[&KVT85)[>.Z=A)YB  @K@YR>M ']=/[3G[1?AO\
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M1FOY=OA]I?[>O_!1OQ/XF\4?#KQ7KOA#PW#<SW-BXNKJWAD@60F(*0Z*0P(
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MUX9O_&?P8^)GA32]W]HZ_P"#]8TRSVY#?:+FV9(\$<YSZ5_$/_P3C\<>#/\
M@D]^U[\48?VIY(=*L_'6OZE_9VJZB%S;B\NI!'(C3C'R!PPZ#\.: /H/XMZ)
M^W;_ ,$V/#^E_'GXD>,-;\4^'#+:RW=E)=W,R1!B)'1E9V ^7L0#CK7]'_\
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M /PD_8H^+7_!33PE\(+*Q^'7P[F_L-VB>.>PL&VN/+;&YHX]N2"2<DU\N?\
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MY^#5MXQ^!WVQ]2TJ5I[^&T\PM)%"_F,I"=0R'&#UK\LO@S_P<!?#2X^&-O\
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MV7HOR"BBBN<84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MATKXL^%;F;Q+X5?5;;RK^]#/(8'E5D;=)EE)3!QP0>"!7]CW[$7[15I^U/\
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MC*4:P\*Z%:%2,%3!IMO&01VQMH [:BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSG_X*D?\
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M)0.@XR?KS7U=X+\#>%OA[HL/A[PAI%MHNCV^##96B!(DP-HPH '0 ?A76T4
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M10 5_.!^V]_R<98_]A6+_P!'"OZ/Z_G%_;?A<?M&V(./^0K%W]9ABOK.#_\
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MFV=AYGW_ ++ D6[G/S%0">?6M2@ HHHH **** "BBB@ HHHH **** "BBB@
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MZMD,#Z&LO1_#>@^'Q,-$TBPTL3G=,+*WC@$ASG+A ,G//UH \,^+?[)G[/\
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M/IUIIMKNW>19PI!%N_O;4 &?>@#3HHHH **** "BBB@ HHHH **** "BBB@
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M?Q[GQ=_P][\"?\^=]_WZ>C_A[WX$_P"?.^_[]/7VC_P[F_9?_P"A+3_R#_\
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M_(/_ ,9H_P"'<W[+_P#T):?^0?\ XS0L9P=I_L&/Z?;A_<\_)ARXC^:'3O\
MW?\ @_CW/B[_ (>]^!/^?.^_[]/1_P />_ G_/G??]^GK[1_X=S?LO\ _0EI
M_P"0?_C-'_#N;]E__H2T_P#(/_QFA8S@[3_8,?T^W#^YY^3#EQ'\T.G?^[_P
M?Q[GQ=_P][\"?\^=]_WZ>C_A[WX$_P"?.^_[]/7VC_P[F_9?_P"A+3_R#_\
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MW/B[_A[WX$_Y\[[_ +]/1_P][\"?\^=]_P!^GK[1_P"'<W[+_P#T):?^0?\
MXS1_P[F_9?\ ^A+3_P @_P#QFA8S@[3_ &#']/MP_N>?DPY<1_-#IW_N_P#!
M_'N?%W_#WOP)_P ^=]_WZ>C_ (>]^!/^?.^_[]/7VC_P[F_9?_Z$M/\ R#_\
M9H_X=S?LO_\ 0EI_Y!_^,T+&<':?[!C^GVX?W//R8<N(_FAT[_W?^#^/<^+O
M^'O?@3_GSOO^_3T?\/>_ G_/G??]^GK[1_X=S?LO_P#0EI_Y!_\ C-'_  [F
M_9?_ .A+3_R#_P#&:%C.#M/]@Q_3[</[GGY,.7$?S0Z=_P"[_P '\>Y\7?\
M#WOP)_SYWW_?IZ/^'O?@3_GSOO\ OT]?:/\ P[F_9?\ ^A+3_P @_P#QFC_A
MW-^R_P#]"6G_ )!_^,T+&<':?[!C^GVX?W//R8<N(_FAT[_W?^#^/<^+O^'O
M?@3_ )\[[_OT]'_#WOP)_P ^=]_WZ>OM'_AW-^R__P!"6G_D'_XS1_P[F_9?
M_P"A+3_R#_\ &:%C.#M/]@Q_3[</[GGY,.7$?S0Z=_[O_!_'N?%W_#WOP)_S
MYWW_ 'Z>C_A[WX$_Y\[[_OT]?:/_  [F_9?_ .A+3_R#_P#&:/\ AW-^R_\
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M>?DPY<1_-#IW_N_\'\>Y\7?\/>_ G_/G??\ ?IZ/^'O?@3_GSOO^_3U]H_\
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M^'O?@3_GSOO^_3U]H_\ #N;]E_\ Z$M/_(/_ ,9H_P"'<W[+_P#T):?^0?\
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M>?DPY<1_-#IW_N_\'\>Y\7?\/>_ G_/G??\ ?IZ/^'O?@3_GSOO^_3U]H_\
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MQK?]@M7\C"O\"]5_Z5$_=/\ 9Y_Y)-X7_P"O5?\ T5%7ME>)_L\_\DF\+_\
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M?"MR!@ \\ D4 ?TKT5!;7,-Y;Q7-NXD@G021.O(9#T8$=C4] !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X8_P#!
M7;_CY\"_[UO_ .CQ7WE^PM_R2'1O^P?;_P#H,5?!O_!7;_CY\"_[UO\ ^CQ7
MWE^PM_R2'1O^P?;_ /H,5?:8[_DD<L_Z_5?_ $Y$YX?[Q5_PQ_*)]N4445\6
M= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M  5-^(/P.\5VO@?]G[2_^$H\02S+;M#;0"Z<R!Q&3L57(W,2<9X_EW/["/\
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MV]_IUC<L\;!@LEQ;1RLA()Y5BPY]/7- '74444 %%%% !1110 4444 %%%%
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M);>V[GOSWS0!^E_[,7_!7;2;7XDZ9\!?CHEU8^.=0N(;.*6\#0L)Y'6,?-(
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M*TI@C=]DB*20FT,%8M@*H/!.,D#D?L)10!_G9?$7]G?P;^S#_P %\OAMX+\
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MGX3:-:_"JZ^/$UE";_PG"DB7GE*98FM(U96$FW<.@P<CD'TKTK_@AY^T%/\
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M&/\ @FM_P2H^#O\ P35TWQ9I_P ++U[T>+@?M\LD)B;+7$=P3RH)R\8KS/\
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MG[<%O"TH$G_"1D8QW^UCBOZ*_P!JJ:./]@'QC,[8C'PWMF+8/3REYKF?%_\
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MBZ'+&L[Z);6(CB6U"']YY21J !&S<[>YQ7S;\./V@?\ @E]^UIHTNL?$W2O
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MQIXAMGBN-VI+)<B*=&WX22<?PG )'!(X..:_=BSM(+&UMK*VC6*WM8(K>&-
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M_P#>L1_U^J?^ELVCLO1?D%%%%<XPHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,3Q,<>'==)[:/J)_*TEK^-S5-4LA^W0L/F
M_O/^$A Q@]?M1K^S2^M4OK*[LI/]7=VT]L_^Y-&T;?HQK\UY_P#@F7\)I_BJ
M/BLUTW]LB\^V;/*./,\PR=<>I_SU(!]X67B71O"/PYTGQ!K][%I^E6'A^QN+
MFZF8*B(MDLN"3@9*J<#UK^+?X[?'CQ5_P4#_ ."DL/[/UC!/KWPFL?$8C,RI
M)+9!8Y\DEOFB XZ>@YK^S'XH?"JP^)7PROOAK<WDMA8WMA;Z>;J+(D2.W@,
M(V\C*GM7Q;^S'_P3*^"W[-7C.Y\>Z)%'JGB:YNVNVU*>W7[0)&8OQ*R[^I]?
MI0!]H? _X3Z)\$OAKX>^''AZ&.#2]!MQ##'$H5 =D:,0% '_ "S%>MT44 %?
MQP?M\> ;CX0_MPVGQ=U;=IVFWFOATNW'EHP>X!&'; .3[^E?V/U_/3_P7^_9
MR\8_%'X :%XD^%VGS2>*]*UM9KI[*)FG^SP>6^X^6-V#N.23C(QP* /V@_9K
M\4VWC/X,>"?$5I.MS;W^EPO',K!PX$<?.X$@]:3]IAUC^"?CMW.%&D3DG_@#
M5\"_\$?_ (H3ZK^RQX$^''BF2>/QKX5LA;:A!<*RRDK&H?<'PPVM&<#GJ<U^
MHWC?PG9>./"^K>%]0.VSU:V>VF.,X1P0>/QH _DD_P""?NJ6<W[7]_"DFYV\
M0.I&,8S=$>]?L%_P5\_:;^*/[*?PAT'XA_#G0[OQ LMZ]IK5I;023[+.,HSO
M(B!L*4=N6';VKV;X0_\ !-_X6?"#XCR_$?0[EGU26\-X5,17$AD\SKCU[YY_
M6OMGXI?"WP=\7_"&J^#/&NCV6KZ5J=K/;F.\@2<0M-&4\V,." PX[=* /Q _
M9@_:4_X)@_M4?"+PQX[^-.E?">V^)<=D'\46?C"WD&HVU_DO(R?9V!"J>&61
M ZN"=S @+^6G[>/[2'P>^(/[1_@CX _L;Z'I&J^#+JZT[3M=F\+6I;3(V#1Q
M7'E>69&6%6W>696+E0"P4G:/N'Q=_P &WGPFO_&?B3Q1X5^)FK:!:>))[B2;
M2K9[JWM[07#LQ\J.-?+PN[ "\\=,<5]E?L-_\$7?@=^QMKTOBB/4G\<:[))Y
MZWNJ0M-)%+NW[DDN$W\'H<#Z>@!]W?LC?"#3/@)\%=#TQUCL!<:79:EJ08!!
M#*8-\F\8^7;N).<8[XZ#\._^"E7[95Y^T-XXT?\ 9C^!VMO+J\>M-9:Y#ITC
ML\D+W BF67RCR-B@$'T ZU_2[K^APZYH5]H9;[/!>6CV@:,;?*C>,QC8!T"J
M> /2OS&^"O\ P2J^$?PA_:#U7]H%=1DUSQ!J5Y+>_9;R)GCBEDD,G!<8X8]0
M<_0\T ?!WQ5_9XO?V3?V3+'6?">E-IVO:MHJ2^+]0AB*RL9K?=<O.Z@-R6;=
MD^]?GIXR\1?LC:C_ ,$UOC!KGAVYT;4/VA#'>RP31M"^J1Z@58C&T^>&\T]!
MT..U?V"?%WX5^'?C!\/?$7P\\06\)TS7]/EL&;RE/V<2*5#Q@+\NU20 !CGI
MQ7X7^$/^" ?PE\&^*-;U"T\9W=]H'B"_DO;S1[@S_9T,DK2,AA9"A'. %##'
MI0 W_@VPU;XE:Q^PY?W7Q,>[?5!XK5+'[7YH?[%Y=[LV^;SM "=,"O@+_@Y3
MN)?C?JWP3^&NBQB:?P_XFMGF,7S'F^,S9"Y/1@.1Z=Q7]2/P@^$'@+]E;X6O
MX6\*VT-CH>F0/<%88EB626""0J2J@#+'(SCOFOYEO!G@_P 4?MF?\% =?T;Q
M1IUQ-X0\/:[<S64]S"Q@V079VE7<%?N+GCMG% ']('["6@S>&/V1_@1H-PI6
M;3? >F6TBL,$,GF9!!Y'7I_^JOK6N;\(>&K+P=X9T;PQIP"V6C6,5E;@# \N
M($# XP.?2NDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH _#'_@KM_P ?/@7_ 'K?_P!'BOO+]A;_ ))#HW_8/M__
M $&*O@W_ (*[?\?/@7_>M_\ T>*^\OV%O^20Z-_V#[?_ -!BK[3'?\DCEG_7
MZK_Z<B<\/]XJ_P"&/Y1/MRBBBOBSH"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /X#/VQ]9T^+_@XP\"6+SA;D^++(
M!"#R?MB]^E?UX?\ !2'P9XJ\:?L]ZU8^$TFEOK>#4IY8( Q::+[*AV$)DD':
MPZ'J:\-^)7_!(CX)_$K]L[2?VS]5O73QYI.H1ZA##Y)(,L4@D7Y]N/O#DY']
M:_6N]LK34;::SO;>*YMKB*2&:&9%='CE4HZD,#U4D9'/I0!_&Y_P1Q_:\^"/
MP ^,GC_P/\:IM,^&OB*634+./4]41+3[3,973+O)L=ED(()&Y@&)PV,'];/^
M"FO[>'[).K?LB?$[PS9?$[PQXIUW7M*$&BZ)97,<\]S=/'+Y;A#R1M8H @)+
M.*X_]KC_ ((+_ G]IOQY-\0+/Q'<^!]9FN&N6.EQ20!Y&<N=S6ZDG))YYY-?
M/&F?\&VGPJG\2Z+KOBCXIZSJMKHLENR:9-)=3PW*V[*R^8KKLPP7!!YYY% '
MB/\ P;N?!KQV-,\2^/[JTN=%\.7>K37-I;,DD,,T$DQD0A6 4[DYX!X'%?US
M5XC\!/@/X*_9[\!Z;X#\$V$%II]A!#"TD4*Q-,84"*S;0#D\D^I(ST%>W4 ?
MD#_P5X^&5WXJ^ VO>*[6)G'AK2IKR>103Y44(8[R>P!P,G Y]:^7/^" 'Q4L
MOB#\+?'NGV]\MW+H%P+:90X9HS'=Q1$$9)')QS7[4_M.^ '^*'P%^*'@.& 7
M%UXE\*WVF6JE S+/,8]K(,'D $?C^-?R\_\ !*;2]>_X)\_'_P =?!OQ>EY'
M_P )[KUP+9)HI!&!<7WF(!N '&!^76@#^AC]O+]M?P%^Q/\ !W5?B3XPU*UM
M6@BN!!'.RC#)"6#X8CHS+@\\@U_%Y^RO\;/V9OV_/VN]4^+O[1WQLTZW\$V6
ML7-_INC:IJ42V\:)<&6-5CGE* 8(& .F:_L+_;\_X)X^ ?\ @H'\/?\ A!_'
M>M7.EZ5=6RD^2'8$2QCG:H(Y5AV[5^%5M_P:3_LW:0N/#?Q7\0:$Q^\UE]KA
M)]?]6!U__70!^\OPS_;J_P""?_A73- ^'7P\^-WP^MK:UB@TW2M*L[]&FD**
M%C1V5%$DK=21\N2=H4$"OOC1-=TGQ'IUOJVBWL.H:?=1K+;W4#;HY$895E/<
M$<U_*Y\.?^#7#X0_#[QMX>\9VWQR\5WEQH&HPZA';RS7Q29HCG:^[@@]\U_3
MI\*_A]:_##P7HW@ZSNY+Z#2+2&U2YER7D$*; S%N<D4 ?S,_\%_M1M+*R\)_
M:)?+SK, '!//FIZ5^V__  30FCN/V-OA'+$=R/I(*GU'DVU0?M>_L!?#;]KZ
M/3X_&]RT(T^Y6YCQ&7RZL'&>#W&/I7U%\$/A+HOP/^&OAWX:>'W,FE>'+;[-
M:N5VDIM1>F!V0=A0!\<_\%$/VU_ _P"R_P#"'Q-$=?MHOB!?V$L.A:2) +F6
M=D;8JIN#LSOL"A1^>>/RH_X)E_L_^*/VD[CQ1^UI\7M(FB\31O>SZ#]NB<2S
M9BN)[<QB5=QW;%(Q[]\5^G7[6/\ P3,^'G[67Q1\/?$?QEK]U -!N()QI $C
MVUQY+JX5T *$-MP<^IK] _AW\//#'PR\):5X.\+:;:Z?I.EV<-JL5O"D2S&*
M,1F215&"6 .<\8..YH _C=^$7BGX9>(O^"D/Q:@_:8O;5_#5C;ZI;Z9INJE1
M#&81*D81)B4&-JXP!]...F_X)T>((Y?^"B'Q)T_X-2;_ (>+K%T((;+>;6.U
M^T.6P(\Q@",$=.G>OV)_:(_X(T?"GXU_%+5/BS9:Y+H.OZM-+)=I;*\&\3EB
MXW1K@@;CU8$_6O=OV)_^":GPL_8KU76?%6@78U?7-6AF-[>SQ%F4S*PD(>1
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MA'F_>VJN/7CC]*]UKP7_ (:=^!7_ $4?P[_X'0__ !='_#3OP*_Z*/X=_P#
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MFSX8_##Q'>>*O#.D1V^L7K2-/=&*-9&:4DL2ZC<3DGO4O_#3OP*_Z*/X=_\
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M#_\ %T?4\7_T"XC_ ,$U/+^[YH.:/\T?O7]=5]Y[U17@O_#3OP*_Z*/X=_\
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MX)J>7]WS0<T?YH_>OZZK[SWJBO!?^&G?@5_T4?P[_P"!T/\ \71_PT[\"O\
MHH_AW_P.A_\ BZ/J>+_Z!<1_X)J>7]WS0<T?YH_>OZZK[SWJBO!?^&G?@5_T
M4?P[_P"!T/\ \71_PT[\"O\ HH_AW_P.A_\ BZ/J>+_Z!<1_X)J>7]WS0<T?
MYH_>OZZK[SWJBO!?^&G?@5_T4?P[_P"!T/\ \71_PT[\"O\ HH_AW_P.A_\
MBZ/J>+_Z!<1_X)J>7]WS0<T?YH_>OZZK[SWJBO!?^&G?@5_T4?P[_P"!T/\
M\71_PT[\"O\ HH_AW_P.A_\ BZ/J>+_Z!<1_X)J>7]WS0<T?YH_>OZZK[SWJ
MBO!?^&G?@5_T4?P[_P"!T/\ \71_PT[\"O\ HH_AW_P.A_\ BZ/J>+_Z!<1_
MX)J>7]WS0<T?YH_>OZZK[SWJBO!?^&G?@5_T4?P[_P"!T/\ \71_PT[\"O\
MHH_AW_P.A_\ BZ/J>+_Z!<1_X)J>7]WS0<T?YH_>OZZK[SWJBO!?^&G?@5_T
M4?P[_P"!T/\ \71_PT[\"O\ HH_AW_P.A_\ BZ/J>+_Z!<1_X)J>7]WS0<T?
MYH_>OZZK[SWJBO!?^&G?@5_T4?P[_P"!T/\ \71_PT[\"O\ HH_AW_P.A_\
MBZ/J>+_Z!<1_X)J>7]WS0<T?YH_>OZZK[SWJBO!?^&G?@5_T4?P[_P"!T/\
M\71_PT[\"O\ HH_AW_P.A_\ BZ/J>+_Z!<1_X)J>7]WS0<T?YH_>OZZK[SWJ
MBO!?^&G?@5_T4?P[_P"!T/\ \71_PT[\"O\ HH_AW_P.A_\ BZ/J>+_Z!<1_
MX)J>7]WS0<T?YH_>OZZK[SWJBO!?^&G?@5_T4?P[_P"!T/\ \71_PT[\"O\
MHH_AW_P.A_\ BZ/J>+_Z!<1_X)J>7]WS0<T?YH_>OZZK[SWJBO!?^&G?@5_T
M4?P[_P"!T/\ \71_PT[\"O\ HH_AW_P.A_\ BZ/J>+_Z!<1_X)J>7]WS0<T?
MYH_>OZZK[SWJBO!?^&G?@5_T4?P[_P"!T/\ \71_PT[\"O\ HH_AW_P.A_\
MBZ/J>+_Z!<1_X)J>7]WS0<T?YH_>OZZK[SWJBO!?^&G?@5_T4?P[_P"!T/\
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MX=_\#H?_ (NC_AIWX%?]%'\._P#@=#_\71]3Q?\ T"XC_P $U/+^[YH.:/\
M-'[U_75?>>]45X+_ ,-._ K_ **/X=_\#H?_ (NC_AIWX%?]%'\._P#@=#_\
M71]3Q?\ T"XC_P $U/+^[YH.:/\ -'[U_75?>>]45X+_ ,-._ K_ **/X=_\
M#H?_ (NC_AIWX%?]%'\._P#@=#_\71]3Q?\ T"XC_P $U/+^[YH.:/\ -'[U
M_75?>>]45X+_ ,-._ K_ **/X=_\#H?_ (NC_AIWX%?]%'\._P#@=#_\71]3
MQ?\ T"XC_P $U/+^[YH.:/\ -'[U_75?>>]45X+_ ,-._ K_ **/X=_\#H?_
M (NC_AIWX%?]%'\._P#@=#_\71]3Q?\ T"XC_P $U/+^[YH.:/\ -'[U_75?
M>>]45X+_ ,-._ K_ **/X=_\#H?_ (NC_AIWX%?]%'\._P#@=#_\71]3Q?\
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M_P!!E/\ \)J'_P AY?GW8?5J/\GXOR\_+^K*W\XG_#D/QK_T6F__ / Z[_\
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M/_PFH?\ R'E^?=A]6H_R?B_+S\OZLK?SB?\ #D/QK_T6F_\ _ Z[_P#BJ/\
MAR'XU_Z+3?\ _@==_P#Q5?T=T4?ZZ\0_]!E/_P )J'_R'E^?=A]6H_R?B_+S
M\OZLK?SB?\.0_&O_ $6F_P#_  .N_P#XJC_AR'XU_P"BTW__ ('7?_Q5?T=T
M4?ZZ\0_]!E/_ ,)J'_R'E^?=A]6H_P GXOR\_+^K*W\XG_#D/QK_ -%IO_\
MP.N__BJ/^'(?C7_HM-__ .!UW_\ %5_1W11_KKQ#_P!!E/\ \)J'_P AY?GW
M8?5J/\GXOR\_+^K*W\XG_#D/QK_T6F__ / Z[_\ BJ/^'(?C7_HM-_\ ^!UW
M_P#%5_1W11_KKQ#_ -!E/_PFH?\ R'E^?=A]6H_R?B_+S\OZLK?SB?\ #D/Q
MK_T6F_\ _ Z[_P#BJ/\ AR'XU_Z+3?\ _@==_P#Q5?T=T4?ZZ\0_]!E/_P )
MJ'_R'E^?=A]6H_R?B_+S\OZLK?SB?\.0_&O_ $6F_P#_  .N_P#XJC_AR'XU
M_P"BTW__ ('7?_Q5?T=T4?ZZ\0_]!E/_ ,)J'_R'E^?=A]6H_P GXOR\_+^K
M*W\XG_#D/QK_ -%IO_\ P.N__BJ/^'(?C7_HM-__ .!UW_\ %5_1W11_KKQ#
M_P!!E/\ \)J'_P AY?GW8?5J/\GXOR\_+^K*W\XG_#D/QK_T6F__ / Z[_\
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M/_PFH?\ R'E^?=A]6H_R?B_+S\OZLK?SB?\ #D/QK_T6F_\ _ Z[_P#BJ/\
MAR'XU_Z+3?\ _@==_P#Q5?T=T4?ZZ\0_]!E/_P )J'_R'E^?=A]6H_R?B_+S
M\OZLK?SB?\.0_&O_ $6F_P#_  .N_P#XJC_AR'XU_P"BTW__ ('7?_Q5?T=T
M4?ZZ\0_]!E/_ ,)J'_R'E^?=A]6H_P GXOR\_+^K*W\XG_#D/QK_ -%IO_\
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M_P!!E/\ \)J'_P AY?GW8?5J/\GXOR\_+^K*W\XG_#D/QK_T6F__ / Z[_\
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M/_PFH?\ R'E^?=A]6H_R?B_+S\OZLK?SB?\ #D/QK_T6F_\ _ Z[_P#BJ/\
MAR'XU_Z+3?\ _@==_P#Q5?T=T4?ZZ\0_]!E/_P )J'_R'E^?=A]6H_R?B_+S
M\OZLK?SB?\.0_&O_ $6F_P#_  .N_P#XJC_AR'XU_P"BTW__ ('7?_Q5?T=T
M4?ZZ\0_]!E/_ ,)J'_R'E^?=A]6H_P GXOR\_+^K*W\XG_#D/QK_ -%IO_\
MP.N__BJ/^'(?C7_HM-__ .!UW_\ %5_1W11_KKQ#_P!!E/\ \)J'_P AY?GW
M8?5J/\GXOR\_+^K*W\XR?\$1O'"$E?C5?@D%3_IUWT/4?>K\BOVF?^"87C+P
M%\8+7PS<_$"\O)I;Z.);AKJ1F):3:#DR9(Y '('0U_==7\XW[<%S.W[1MB6F
MD)_M6+DL3TF%?2<,<6Y[BL=4A5Q5.45AJDDO84E[RM;6,4]U?_AW?&M0I1BF
MHV=UU?>*_+^MK>??"S_@BOX[U;P)H>HO\8-0LA?VJ3K;_;;D 1D?*?E<@#.X
M#OQ]*[__ (<A^-?^BTW_ /X'7?\ \57[I?L^222?"CPLTCLY%HJ@L22 (XCC
M)[9)/U)KVFO!Q/&G$,<16C];I^[5FE_LU&VDFEO!OI_5V:QPU&R]V^BZOR\_
M+^M+?SB?\.0_&O\ T6F__P# Z[_^*H_X<A^-?^BTW_\ X'7?_P 57]'=%8_Z
MZ\0_]!E/_P )J'_R'E^?=C^K4?Y/Q?EY^7]65OYQ/^'(?C7_ *+3?_\ @==_
M_%4?\.0_&O\ T6F__P# Z[_^*K^CNBC_ %UXA_Z#*?\ X34/_D/+\^[#ZM1_
MD_%^7GY?U96_G$_X<A^-?^BTW_\ X'7?_P 51_PY#\:_]%IO_P#P.N__ (JO
MZ.Z*/]=>(?\ H,I_^$U#_P"0\OS[L/JU'^3\7Y>?E_5E;^<3_AR'XU_Z+3?_
M /@==_\ Q5'_  Y#\:_]%IO_ /P.N_\ XJOZ.Z*/]=>(?^@RG_X34/\ Y#R_
M/NP^K4?Y/Q?EY^7]65OYQ/\ AR'XU_Z+3?\ _@==_P#Q5'_#D/QK_P!%IO\
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MB'_H,I_^$U#_ .0\OS[L/JU'^3\7Y>?E_5E;^<3_ (<A^-?^BTW_ /X'7?\
M\51_PY#\:_\ 1:;_ /\  Z[_ /BJ_H[HH_UUXA_Z#*?_ (34/_D/+\^[#ZM1
M_D_%^7GY?U96_G$_X<A^-?\ HM-__P"!UW_\51_PY#\:_P#1:;__ ,#KO_XJ
MOZ.Z*/\ 77B'_H,I_P#A-0_^0\OS[L/JU'^3\7Y>?E_5E;^<3_AR'XU_Z+3?
M_P#@==__ !5'_#D/QK_T6F__ / Z[_\ BJ_H[HH_UUXA_P"@RG_X34/_ )#R
M_/NP^K4?Y/Q?EY^7]65OYQ/^'(?C7_HM-_\ ^!UW_P#%4?\ #D/QK_T6F_\
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M(?\ H,I_^$U#_P"0\OS[L/JU'^3\7Y>?E_5E;^<3_AR'XU_Z+3?_ /@==_\
MQ5'_  Y#\:_]%IO_ /P.N_\ XJOZ.Z*/]=>(?^@RG_X34/\ Y#R_/NP^K4?Y
M/Q?EY^7]65OYQ/\ AR'XU_Z+3?\ _@==_P#Q5'_#D/QK_P!%IO\ _P #KO\
M^*K^CNBC_77B'_H,I_\ A-0_^0\OS[L/JU'^3\7Y>?E_5E;^<3_AR'XU_P"B
MTW__ ('7?_Q5'_#D/QK_ -%IO_\ P.N__BJ_H[HH_P!=>(?^@RG_ .$U#_Y#
MR_/NP^K4?Y/Q?EY^7]65OYQ/^'(?C7_HM-__ .!UW_\ %4?\.0_&O_1:;_\
M\#KO_P"*K^CNBC_77B'_ *#*?_A-0_\ D/+\^[#ZM1_D_%^7GY?U96_G$_X<
MA^-?^BTW_P#X'7?_ ,51_P .0_&O_1:;_P#\#KO_ .*K^CNBC_77B'_H,I_^
M$U#_ .0\OS[L/JU'^3\7Y>?E_5E;^<3_ (<A^-?^BTW_ /X'7?\ \51_PY#\
M:_\ 1:;_ /\  Z[_ /BJ_H[HH_UUXA_Z#*?_ (34/_D/+\^[#ZM1_D_%^7GY
M?U96_G$_X<A^-?\ HM-__P"!UW_\51_PY#\:_P#1:;__ ,#KO_XJOZ.Z*/\
M77B'_H,I_P#A-0_^0\OS[L/JU'^3\7Y>?E_5E;^<3_AR'XU_Z+3?_P#@==__
M !5'_#D/QK_T6F__ / Z[_\ BJ_H[HH_UUXA_P"@RG_X34/_ )#R_/NP^K4?
MY/Q?EY^7]65OYQ/^'(?C7_HM-_\ ^!UW_P#%4?\ #D/QK_T6F_\ _ Z[_P#B
MJ_H[HH_UUXA_Z#*?_A-0_P#D/+\^[#ZM1_D_%^7GY?U96_G$_P"'(?C7_HM-
M_P#^!UW_ /%4?\.0_&O_ $6F_P#_  .N_P#XJOZ.Z*/]=>(?^@RG_P"$U#_Y
M#R_/NP^K4?Y/Q?EY^7]65OYQ/^'(?C7_ *+3?_\ @==__%4?\.0_&O\ T6F_
M_P# Z[_^*K^CNBC_ %UXA_Z#*?\ X34/_D/+\^[#ZM1_D_%^7GY?U96_G$_X
M<A^-?^BTW_\ X'7?_P 51_PY#\:_]%IO_P#P.N__ (JOZ.Z*/]=>(?\ H,I_
M^$U#_P"0\OS[L/JU'^3\7Y>?E_5E;^<3_AR'XU_Z+3?_ /@==_\ Q5'_  Y#
M\:_]%IO_ /P.N_\ XJOZ.Z*/]=>(?^@RG_X34/\ Y#R_/NP^K4?Y/Q?EY^7]
M65OYQ/\ AR'XU_Z+3?\ _@==_P#Q5'_#D/QK_P!%IO\ _P #KO\ ^*K^CNBC
M_77B'_H,I_\ A-0_^0\OS[L/JU'^3\7Y>?E_5E;^<3_AR'XU_P"BTW__ ('7
M?_Q5'_#D/QK_ -%IO_\ P.N__BJ_H[HH_P!=>(?^@RG_ .$U#_Y#R_/NP^K4
M?Y/Q?EY^7]65OYQ/^'(?C7_HM-__ .!UW_\ %4?\.0_&O_1:;_\ \#KO_P"*
MK^CNBC_77B'_ *#*?_A-0_\ D/+\^[#ZM1_D_%^7GY?U96_G$_X<A^-?^BTW
M_P#X'7?_ ,51_P .0_&O_1:;_P#\#KO_ .*K^CNBC_77B'_H,I_^$U#_ .0\
MOS[L/JU'^3\7Y>?E_5E;^<3_ (<A^-?^BTW_ /X'7?\ \51_PY#\:_\ 1:;_
M /\  Z[_ /BJ_H[HH_UUXA_Z#*?_ (34/_D/+\^[#ZM1_D_%^7GY?U96_G$_
MX<A^-?\ HM-__P"!UW_\51_PY#\:_P#1:;__ ,#KO_XJOZ.Z*/\ 77B'_H,I
M_P#A-0_^0\OS[L/JU'^3\7Y>?E_5E;^<3_AR'XU_Z+3?_P#@==__ !5*O_!$
M3QLK*P^-5_E2"/\ 3KOJ#G^]7]'5%+_77B'_ *#(?^$]#_Y#R_J[#ZM1_D_%
M^7GY?U96_B<_;]_X)7^,_A-)X6GN_B3>ZRFK/'Y;O=RMM;SO*.-[Y7#(1R.W
MOS]0?LT?\$;O'7C#X>Z9KR_%B^TV*YM862,7LX&9$#%0J.>V<G&.G.37WU_P
M5UFF6?P&@D<*K0;5#$ 9N,G ]R2?J37WE^PS-*_P?T5'D=E%A;$*Q) (2, _
M4 D?B:^KQ?%>>4^&<OQ,<3356I6J*4O84G>,9J,=.7E32?;IY&$:%)UYQ<6U
M&,6M7O:+/R;_ .'(GC8_\UIO_P#P.N__ (JC_AR'XU_Z+3?_ /@==_\ Q5?T
M=T5\K_KKQ#_T&4__  FH?_(>7Y]V;_5J/\GXOR\_+^K*W\XG_#D/QK_T6F__
M / Z[_\ BJ/^'(?C7_HM-_\ ^!UW_P#%5_1W11_KKQ#_ -!E/_PFH?\ R'E^
M?=A]6H_R?B_+S\OZLK?SB?\ #D/QK_T6F_\ _ Z[_P#BJ/\ AR'XU_Z+3?\
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M?=A]6H_R?B_+S\OZLK?SB?\ #D/QK_T6F_\ _ Z[_P#BJ/\ AR'XU_Z+3?\
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M?=A]6H_R?B_+S\OZLK?SB?\ #D/QK_T6F_\ _ Z[_P#BJ/\ AR'XU_Z+3?\
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M>3^(OB5X!^$_PZL/%'BK6K+0O#=EHUI)#<7<JQ1F%;5&C1&8A>%P#SP/7O\
MEGXW_P""PGPWT_5)H/ >FV_B_3+>=HI[^R=YXXU5B&<M$Q7@#)SP/I0!^TE%
M?#O[,'[<_P +/VD$-AIFJV%CXC0'?I/VA?.#J 6CV,Y<$<@<')&/<=?^T/\
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M=X:L_#6BQ)#8V4*01(F  B  8Q@8PH[9H ]+JM>745E:75Y,P2&UMYKB5F(
M$<$;2.23CHJFK-?!_P#P4)_:#B_9Z^!&L>)&G%O)J,-YI\3EMGS26^S .1SB
M0_GUH \B\'?\%%?"/QB^.>J_ WP,@;5]"OY;6^DA<N28)6B<M@DC&TDX( Y
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M .2&2_\ 7S+_ .AO7[*U^-7_  1O_P"2&2_]?,O_ *&]?LK73Q/_ ,C[,O\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYP/VWO\
MDXRQ_P"PK%_Z.%?T?U_.!^V]_P G&6/_ &%8O_1PKZS@_P#Y&-;_ +!:OY&%
M?X%ZK_TJ)^Z?[//_ "2;PO\ ]>J_^BHJ]LKQ/]GG_DDWA?\ Z]5_]%15[97S
M>+_WK$?]?JG_ *6S:.R]%^04445SC"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ H(R"#T/!HHH Y?6-,TZPTCQ!>VEE;V]U)I&I&
M2XBB59F;[),02^,YW 'K7\?^LSS3_MRJTLC.Q\0#))_Z>FK^PWQ+_P B[KO_
M &"-1_\ 226OXZ]49?\ AN11N7/_  D XR,_\?34 ?T@_MH_#_6/BG^QEXC\
M&>'[5KW5-5\,:/':VZJ7+O'II0X YX)XQ7\H/[.W_!-W]J^_LO$/@UI]:\(6
M<VH7,D,T'VFV4HTC$'*;>/\ ]5?V%?&WXY^'OV;/V<G^+/BFV%WHWAS0M'DN
MH"H<.+BR\Q?EZ' 0UP'[$W[:'PA_;/\ A]<^//A]'I=@;2\:UN; &U2XX+@R
MK'@2A5*8<DMRP[ T ?R2?$;XI?MF?\$D?B#X0=[S7_%GA;7-3MX+RYG:ZN(D
M@DE"2%F<LN -P.3CCWR?['_V3/VA-*_:,^#'@GX@6\T0U;6M%M;O5+--H>WN
M7C5G#*OW<DXQ@<@U^4__  75\?\ PB\(?!WPS:^,[+2+[6-2N)4TQ0EM+?1L
MSE8R%7,@!?)4D9.21D8KK?\ @BWHWB2'X3+K=X+M- U&P232HK@.J1Q.%:,(
M&X VD8P* /W(K^:S_@YM^(5_\/?V-?#E]I[LLM[XI>U.TD9#+;C''^\:_I3K
M^:G_ (.;_!&H>-OV-O#-GIT$D\MKXJ>X*QH7("K;')P#@<=?YT ?6W_!#7PB
MD/[#?PQ\;7,0%[XFTX2N2/F91#"Y)[]9>YK]DH--T^VF:Y@L[>*=\[IDC42-
MN^]E\9Y[\\U^0G_!#[7FF_80^%OA>[=4O/#^G10^1D;PKP('++U&/*7L*_8F
M@#^";]M::2?_ (.(? 'FNSA/$]DJ!N0JB\   Z   #';M7]ZZ?<7_=7^0K^"
M']M%T'_!Q#X"!90?^$HL^-PS_P ?H[9S7][,DT=M;27$S!(H(&FE=B %CBC+
MNQ)P  JDDGCB@#YM_:V^,.F_!GX&_$#Q/-?I::M;^'+]M'C\P)+)=F-A&4!(
M)Z,..<U_-'_P2;^&WB+]M?XZ^//C;\9=-DN#X4UBXN="O-1B9VQ%=G[.8FD5
MB<L5P5X]< 4__@LK^U1XL^,OQG\!? KX'W\VI6L>JVVG^)(=-E,P:,W"I.)T
MB9AC+-D,, <<=:_H@_89_9]\/? KX(>#+?3].@LM<UKPYIUUKK10K$[W4L:S
M.)"%!+;L$T ?1?Q'^&7ASXF>";SP/X@LX;K2KFU6W6*9 Z)LA,*':0>BG'2O
MYXOBK_P0)TWQE\0KCQM8_$N7PQX:T^[EU4Z-!=3Q6\T$+&>2-HXAY2*$5L^;
MM4#.2.:_ID) &20 .I/ 'XU^*7_!4O\ ;DO?A5X1M?AG\)]1-YXQ\53S:+J,
M>G2A[J""[;[.R[8F+J  2<@?>.0: /PA^/'@6/Q!\5O#'P/^ -ZVH:'X0O;>
MP\=W=BVZ.>"UE6&[:X>+*L"J.6+GIGIW_I$_9A^-?[&7[/WA3PS\*/#WB[P_
MHGC*XTVP77[2,PBXN-6:)//25UD7&)2>"NXMDDG@#\B?AY\$KC]D'X(ZQ\:M
M:@FU+Q=\4[":\O)KU#)/:3ZC&\S'?(-R%6E/.1[U\J^/?V/]"TK]CCXI?MSM
MX^G/CO1Y;O6-.TN'4F,R,A:X2-(1)N !P  ,8&* /[5=)U?3M<L8-2TJ[BO+
M*YC62&>%@Z.CC*D$$CD>]?QY?\'4]E)X9TO]GWQ7I4IM;R_\26,<YB.PMY-^
M8><8ZJ@)P>IK]2_^" /[3?C+]J/]C:7QAXT:\>_T?Q!'HT#WA<R/!''=A6!<
MG((A%?EY_P '3]U'XTT+]GWPGH+&YU?3O%%LUU%%\[(&U)G VKD_=8'GI^5
M'])G_!/:[FO_ -C']GN[N&+S3_#W2GD<DDLQ\SDD\YK[+KXU_P"">]A<:9^Q
ME^SY87:%+BV^'VE1RJPP0P\PG(/3K7V50 4444 %%%% !1110 4444 %%%%
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M:I\1_MF_'GPI^S?^SQ?:A.NC:VFG^)CI\SO#+ +D+<^<86V,""X.X8VC&..
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MP%;2V?@OPQ:S B6#1K&.0$8(985!&*ZZ@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\Y_\ @J1_R:=XP_ZZ1?\
MH#5^C%?G/_P5(_Y-.\8?]=(O_0&KU<C_ .1SEG_8;A__ $Y$BI\$O0\"_P""
M-_\ R0R7_KYE_P#0WK]E:_&K_@C?_P D,E_Z^9?_ $-Z_96NGB?_ )'V9?\
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M! P,:@;2!Q&>G?GUK^XNF>7'YGF[$\W;L\S:-^W.=N[&<9YQG% '\>7[,?\
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M4$,1^L<:J?U%3T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5_.!^V]_R<98_P#85B_]'"OZ/Z_G _;>_P"3C+'_
M +"L7_HX5]9P?_R,:W_8+5_(PK_ O5?^E1/W3_9Y_P"23>%_^O5?_145>V5X
MG^SS_P DF\+_ /7JO_HJ*O;*^;Q?^]8C_K]4_P#2V;1V7HOR"BBBN<84444
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MP/ZQ**_D[_X2S_@L9_SZZY_WS+_C1_PEG_!8S_GUUS_OF7_&C_4N?_0]R/\
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M'_X5^G]WS_+OH?65_P ^JO3[*Z\OG_>_ _K$HK^3O_A+/^"QG_/KKG_?,O\
MC1_PEG_!8S_GUUS_ +YE_P :/]2Y_P#0]R/_ ,*_3^[Y_EWT/K*_Y]5>GV5U
MY?/^]^!_6)17\G?_  EG_!8S_GUUS_OF7_&C_A+/^"QG_/KKG_?,O^-'^I<_
M^A[D?_A7Z?W?/\N^A]97_/JKT^RNO+Y_WOP/ZQ*_G7_;CT:ZB_:.L$9X26U6
M+&)%[S+UYXQGD'D=QGBOFF'Q-_P6-F+ 6NN?*NX_++ZCWK\I?VA==_X*$3?%
M2V?QG#J:Z_\ ;%V>8K[O.#Y],_>Y'KQC/4?1<,\)SPV.J3_MG)ZM\/4BXTL3
MSR7,DU)JRLEKT=U9V,:V(3BOW=1:K=)+>+[_ -6/[M_@+9RV/PJ\*1RLC,]@
MDH\M@X"LJI@D$X.4/'7&#WKV&OY OA?XD_X*Z#P1I3>'[;6CI4<"&VVK+C85
M0>N.@&,5W/\ PEG_  6,_P"?77/^^9?\:\/$<&5)5ZS>>Y'=U:C:>+LU>6S5
MM'KMZ=S58E62]E5V2^'_  ^?][\#^L2BOY._^$L_X+&?\^NN?]\R_P"-'_"6
M?\%C/^?77/\ OF7_ !K'_4N?_0]R/_PK]/[OG^7?1_65_P ^JO3[*Z\OG_>_
M _K$HK^3O_A+/^"QG_/KKG_?,O\ C1_PEG_!8S_GUUS_ +YE_P :/]2Y_P#0
M]R/_ ,*_3^[Y_EWT/K*_Y]5>GV5UY?/^]^!_6)17\G?_  EG_!8S_GUUS_OF
M7_&C_A+/^"QG_/KKG_?,O^-'^I<_^A[D?_A7Z?W?/\N^A]97_/JKT^RNO+Y_
MWOP/ZQ**_D[_ .$L_P""QG_/KKG_ 'S+_C1_PEG_  6,_P"?77/^^9?\:/\
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M .$L_P""QG_/KKG_ 'S+_C1_PEG_  6,_P"?77/^^9?\:/\ 4N?_ $/<C_\
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M #ZJ]/LKKR^?][\#^L2BOY._^$L_X+&?\^NN?]\R_P"-'_"6?\%C/^?77/\
MOF7_ !H_U+G_ -#W(_\ PK]/[OG^7?0^LK_GU5Z?977E\_[WX']8E%?R=_\
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MS+_C1_J7/_H>Y'_X5^G]WS_+OH?65_SZJ]/LKKR^?][\#^L2BOY._P#A+/\
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M];_^CQ7WE^PM_P DAT;_ +!]O_Z#%7V>-27".6.W_+^J_G[2/^;.>'^\5?\
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M&6.>))H7$D4BAD=3E64]"#Z&I* "BN$\0?$[P#X6NUL/$'BK2-*O'8(MM=W
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M/Q?>7W['W@?Q?>3O=WL?A2YU"661BSR2V]FLG))))W+WY.:_DR_:U_8RTO\
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M#PM%XO\ V&?C1I$B!GET8M"V 61_*N!E?0G(SCT]J_&W_@VQO]6\&?##QKX
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M?%O0O#/P>U'Q/I'C37+UTU Z3/=0F*>Z+AB3$R$=#G)P0"I!% '(_P#!:O\
M8'_X* _"[]GF+QW\6_BI>Z[X M?$:+>:6=4:ZB=F1<;E69T&05P#@_*2.AK^
ML/\ X(%36LW_  3<^#OV5-B1QS1O[R);68<_B0?ZU_-#_P %?_VO?VZ/V\?V
M;=!^'_A+X0:O:V-WJEK<7]E9:/<1(SM(F^618XAN8(, MG &. *_J%_X(<?#
M;QG\*?\ @GO\)O"/CW29]%\2VB327UA<1-#+$TEO:?>1P&'*MP10!^OE%%%
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M2UBOK5FQ*C>3 1E#\PP0P.:^T?VB--U#5O@]XVT_2X6N+ZYTJ9((44LSN58
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M 4444 %%%% 'X8_\%=O^/GP+_O6__H\5]Y?L+?\ )(=&_P"P?;_^@Q5\&_\
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M1VJO)NZ$@9('X\9KYF_X(%_M(6WQL^&7CO0O.'VCPC<FQ$).&"V]VL! 4Y/
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M_P G*^#O^PE:?^C8Z_I\TG_D%:9_V#[+_P!)HJ_F%='?]I;P<%5F_P")E:]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "OYP/VWO^3C+'_L*Q?^CA7]']?SB_MOPS+^T98@QN#_ &M$,%2#
MGS@.GXU]9P>U_:-77_F%JF%?X%ZK_P!*B?N=^SS_ ,DF\+_]>J_^BHJ]LKQ7
M]GM'3X3^%@ZLI-HI 8$$CRXAD9[9!&?8U[57S>+_ -ZQ'_7ZI_Z6S:.R]%^0
M4445SC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ !P ,UIT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO&'_ %TB_P#0&K]&*_.K_@J,CO\ LG>,BJLP62+) )QE'QG'K@X]<&O5R/\
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M -"/$?\ A5/R\_+\?6YR5_\ GXNGV5_=_P"#^/<_)C_A]G<?]$DO?^_%W_\
M%4?\/L[C_HDE[_WXN_\ XJOUG_X8Z^ ?_0BZ/_X!0?\ Q-'_  QU\ _^A%T?
M_P  H/\ XFC^TN$?^A'B/_"J?EY^7X^MSDK_ //Q=/LK^[_P?Q[GY,?\/L[C
M_HDE[_WXN_\ XJC_ (?9W'_1)+W_ +\7?_Q5?K/_ ,,=? /_ *$71_\ P"@_
M^)H_X8Z^ ?\ T(NC_P#@%!_\31_:7"/_ $(\1_X53\O/R_'UN<E?_GXNGV5_
M=_X/X]S\F/\ A]G<?]$DO?\ OQ=__%4?\/L[C_HDE[_WXN__ (JOUG_X8Z^
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M5?K/_P ,=? /_H1='_\  *#_ .)H_P"&.O@'_P!"+H__ (!0?_$UC_:7"/\
MT(\1_P"%4_+S\OQ];ODK_P#/Q=/LK^[_ ,'\>Y^3'_#[.X_Z))>_]^+O_P"*
MH_X?9W'_ $22]_[\7?\ \57ZS_\ #'7P#_Z$71__  "@_P#B:/\ ACKX!_\
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M_+S\OQ];G)7_ .?BZ?97]W_@_CW/R8_X?9W'_1)+W_OQ=_\ Q5'_  ^SN/\
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M_%5^L_\ PQU\ _\ H1='_P# *#_XFC_ACKX!_P#0BZ/_ . 4'_Q-']I<(_\
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M *$71_\ P"@_^)H_M+A'_H1XC_PJGY>?E^/K<Y*__/Q=/LK^[_P?Q[GY,?\
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M +\7?_Q5'_#[.X_Z))>_]^+O_P"*K]9_^&.O@'_T(NC_ /@%!_\ $T?\,=?
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MQ_T22]_[\7?_ ,51_P /L[C_ *))>_\ ?B[_ /BJ_6?_ (8Z^ ?_ $(NC_\
M@%!_\31_PQU\ _\ H1='_P# *#_XFC^TN$?^A'B/_"J?EY^7X^MSDK_\_%T^
MRO[O_!_'N?DQ_P /L[C_ *))>_\ ?B[_ /BJ/^'V=Q_T22]_[\7?_P 57ZS_
M /#'7P#_ .A%T?\ \ H/_B:/^&.O@'_T(NC_ /@%!_\ $T?VEPC_ -"/$?\
MA5/R\_+\?6YR5_\ GXNGV5_=_P"#^/<_)C_A]G<?]$DO?^_%W_\ %4?\/L[C
M_HDE[_WXN_\ XJOUG_X8Z^ ?_0BZ/_X!0?\ Q-'_  QU\ _^A%T?_P  H/\
MXFC^TN$?^A'B/_"J?EY^7X^MSDK_ //Q=/LK^[_P?Q[GY,?\/L[C_HDE[_WX
MN_\ XJC_ (?9W'_1)+W_ +\7?_Q5?K/_ ,,=? /_ *$71_\ P"@_^)H_X8Z^
M ?\ T(NC_P#@%!_\31_:7"/_ $(\1_X53\O/R_'UN<E?_GXNGV5_=_X/X]S\
MF/\ A]G<?]$DO?\ OQ=__%4?\/L[C_HDE[_WXN__ (JOUG_X8Z^ ?_0BZ/\
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M_/Q=/LK^[_P?Q[GY,?\ #[.X_P"B27O_ 'XN_P#XJC_A]G<?]$DO?^_%W_\
M%5^L_P#PQU\ _P#H1='_ / *#_XFC_ACKX!_]"+H_P#X!0?_ !-']I<(_P#0
MCQ'_ (53\O/R_'UN<E?_ )^+I]E?W?\ @_CW/R8_X?9W'_1)+W_OQ=__ !5'
M_#[.X_Z))>_]^+O_ .*K]9_^&.O@'_T(NC_^ 4'_ ,31_P ,=? /_H1='_\
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MSN/^B27O_?B[_P#BJ/\ A]G<?]$DO?\ OQ=__%5^L_\ PQU\ _\ H1='_P#
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M /%4?\/L[C_HDE[_ -^+O_XJOUG_ .&.O@'_ -"+H_\ X!0?_$T?\,=? /\
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M22]_[\7?_P 57ZS_ /#'7P#_ .A%T?\ \ H/_B:/^&.O@'_T(NC_ /@%!_\
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M@Q3:A:12 ^A1YE8'VQ0!J45#!<V]T@EMIX;B(])()4F0_1XV93^=34 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?S@_MO$_\-&6/)_Y"L7<_P#/85_1
M]7\X'[;W_)QEC_V%8O\ T<*^LX/_ .1C6_[!:OY&%?X%ZK_TJ)^Z?[/))^$_
MA?)S_HJ_^BXJ]LKQ/]GG_DDWA?\ Z]5_]%15[97S>+_WK$?]?JG_ *6S:.R]
M%^04445SC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **^;_P!I7]I+PG^S3X,D\8^*XFGMMDIBA1MK2/&#A0.IR<#@Y_,5
M_'I^U_\ \%W?B]KO[1'A'PI\+;#5] \-:CJEM;N_[Z&&6%IT0X.0K J>.3GZ
MT ?W-T5\N_LK?$;4?&_P&\+>./$MP3=W.AP7UY+*^<L+<RR$L3DGC&?\,U^*
MG_!1#_@M%:?"O4=5^$OPNT#4KCQ3"\\,FJ6JR.HDBW*-LB<*HZX&,D\D\4 ?
MTFT5_,A_P1G_ ."@_P 5_P!J/XD:YX4^(=[<R/9-=,L%S*S.JH6*C:Q+#' Y
MK^F^@ JI>7]EIT)N+ZZ@M(0<&6XE2),^@+$9/L,FK=?SX?\ !6_]K;Q<EMH7
MP:^!FLO;>/#K*1W\5I<%;G#2^6PQ&=X&U0 /4GUH _?C3M<T[5BWV"=+A!G$
MD;!D;'<,"01[C/:M>OAC]D_5=>^'/[)'A?QA\4Y9I/$FF>'I=4UUKF0^?)L2
M+Y<O\Q8G..O7/>OP#_X*2?\ !</Q!I'@7Q8/@5H6L6,O@]IHKS4H5FVO)$Q$
MCF5<#&5(&,  #OR0#^N.BOPE_P""#7[:7CG]M;]FO5O'_CR]EO-5LM0@MB9I
M#(Z%C(&4DDD8VXQG@YKW#_@IG_P4:T#]C/P/);6L+7OB?6#)8V4<!WRQ3O\
M(F%4Y!W]3UZ4 ?K1N4'!9<^F1G\LTZOXJ=,\4?\ !4?XN^'Y_P!HGPCK?B&U
M^'T\<NIV^G+<72@VI)F55C!Q@1\#UZ5^I7_!-O\ X*<W7CF^E^#GQI>:U\>6
MLT=HC7TA6:2Y1UA;F4[B"=^0.IP>PH _H,I,@G (R.HR,C\*_,C_ (*?_M?M
M^RG\ Y_$NDS^5KFM($TMU?:X,J,L14@@\N0<@\\?2OYVO"?[7?[<OPET+PG^
MTQ\2M<U:Y^%GB_58A9V\T\[0"VN9P8^&.S'EL.G^. #^UV@D#J0/K7RW\+_V
MC/#OB?\ 9HTCX\7]U FG'PH^NWBO*BL6A0$I@MN)8O&..<$XZ9K\<OA/^V+\
M;/VQOVGI&^%,M]9_#GPUK/V74TB>1;:2&"XV.,*=I! ]><T ?T':MXKT30Y%
M35;V*R5C@23NJ)DG &YB!R>G/3M6S9WMIJ%O'=V5Q%<VTH#1S0NKHP(!X921
MW%?F!_P55\-?%34/V;9[_P"#\UY!XPTZZ-S+):/(DIMXK>-WR8\-@,CD_E7A
M/_!(_P#;,N?B?X)MO@QX_P!2%Y\2_#ADBOUEFWW*M!^[E#JS%S]S/([=N00#
M]OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /PR_X*[$_:? O)^];]_\ IO7WE^PN2?A#HV23_P 2^W[_ .S'
M7P9_P5V_X^? O^];_P#H\5]Y?L+?\DAT;_L'V_\ Z#%7VF._Y)'+/^OU7_TY
M$YX?[Q5_PQ_*)]N4445\6= 4444 %%%% !1110 4444 %%%% !1110 4444
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MVGPW$\[1+;WDJE  YP %<8Q_]>@#^T>C(]17S1;_ +1/AG3_ -F^Q^/.J74
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M.>>:_K1^"W@+P?HWPC\$Z)I_AW2[?38_#MC";1;2$Q.!&0V]0N&R<]>V!VH
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MPCP(XMI5D(((XQ7X]_\ !OGXW\=?%'_@KI\2O&?Q-TN3PWXLO+_4YKO19(S
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M'HP!R!I6G 'U LX1G\>M &K1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M\X'[;W_)QEC_ -A6+_T<*_H_K^<#]M[_ ).,L?\ L*Q?^CA7UG!__(QK?]@M
M7\C"O\"]5_Z5$_=/]GG_ ))-X7_Z]5_]%15[97B?[//_ "2;PO\ ]>J_^BHJ
M]LKYO%_[UB/^OU3_ -+9M'9>B_(****YQA1110 4444 %%%% !1110 4444
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M)-Q9I:Q3=P2BJ$!&.GO],?"+_@L;^T5/\;;3PC\4/ DF@> =0OHH=)U*;3Q
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MF66"WCB9I!(-SY10>6&??^7[I_\ !,ZR;5_V%/ &E%L&^T+4;!6)^ZMWIUO
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M-FVGZYIEGJMD^=UK?0)<0MD8)*2 C..,]:_)3_@HA\6OV?OV7_A^_AB'X?\
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M#X=;Q&=5B\8^'/"\-OJ5D5(CEU"V0J/E,1<[C@N _)!P1FOS^_:X\&6OCO\
M:];P[XDTAKS0]3UMK:\WP[U,$ESM;DC&"N>GKS7Z]Z)_P1,_8N\3^$O#&I6W
MA4V[:E8V5[JA50$N?-C5Y55 1@J^Y"IX)R<X/ !_/A\)])^*7_!4'_@I5HW[
M2'AW3]5B^&.CZW$\C3Q3+ ;6*XW?Q +]PC_/-?I-_P %LOV2_%_PYT'PC\:_
M@AI,UQ>Z ()=7-E 3*%L65I2=@SR@!'J"#C/%?T*_L[_ +*'P6_9>\/GP[\)
M/"]MH5FZ*LL@2(S2%0H+;UC4KN(R1D]<9/?V/QOX&\,_$3P_>^&/%FF0:KH]
M_$\5Q;3(C K(I1MN]7 )4X/'- '\VW[%'_!>G]F?0?@;X5\#?%AM:TWX@^$=
M/>RUR'9Y>]K=4W,RRQ,WF;_,!.[! 4;002?RV_:?\:^-O^"M_P"WA\,O%?P"
MT[5F^&G@[5]*BU29HI/*-K8SQ*S.VT*28XR20 ,Y-?T7^.?^"'O[$_BG7)_$
M.G>"AI&H:A,SZEL*F.X65V:0CRTCP?F^Z5(P.O:OMC]F;]B3X!?LG:?)9_"3
MPI!I,TZ!;B]D2)IY6Y#.I"%HV;VD;'KZ 'Y!_P#!P-HLGP[_ ."4%QX:TZSN
M;MM"M]%TDV]K&TDK>7I_^D_(@)(\[=GUSCO7RU_P2K_8@^&7[7'_  2*T.SU
MOPM!IGBZ6UU8:3>/8I%?KJ%K:13VYD<JLH+.VU.N7P..H_IZ^-WP*^''[0O@
MFY^'WQ1T.+Q!X7NY!+/I\NS:[@8!.])%Z?[-2_!7X(_#O]G_ ,$6?P\^&.B1
MZ!X6L)'EMM/BV;(W<*K$;$C7D*/X: /X^/V#/VMOBK_P3=_:0NOV>/V@K?79
MO 6JZK-I/A>6=)FA6WEN/(MS&S*57:-I!Y Z@>OR3_P7'T/QYJO[>7P6_:3O
M!KTGP6?4M'U6[M;=9WLC8K<QSNLJ*"A'E=01C'7/?^U[XS_L/_L[_'GQ5I'C
M/XA>"K;4?$.BSQW-C?1"*%TFB<.CG$))(89/S>N,5=^+O[%_P$^-O@RQ\#>/
M/"%MJ>C:;:+960=(FE@A1/+4!FCR2!CH1TH _*WX:_\ !9/]A>T^$%EI?A70
MHIKOPYX*M(3I8TNR,-SJ5KI$<<J3,;8S2&6X5S)N)D*DQJZ@ K_-]_P0Y^*T
M/QP_X+7?%KQ[HOAJ\T/1+W6=;FA'V-[:S\MWN70)\BH  1C'\J_K"\(?\$5?
MV._!VJW%WI_AEFL;@NTEF5"[MY.Y",E I!QGG'H>E?3'[/\ _P $Z?V5_P!F
M7QI=^/\ X2?#^V\/>*+XNUSJ*>29)#)G>24@C;G)ZL: /Y7O^#G?4KW3OVQO
MV-Y+;2K^_7^T_#N^6T@DE2+_ (FQ^^44X[9]*_7/_@HQ^S%JOQ6_8?\ A7\0
M/!VE&^\6^%_!&@:EY!@\R41'2;6Y1=N"<Y# C@@\$=Z_6OX[_L9? +]I#Q'X
M;\5?%CP=;^(M:\*/#)HEU-Y6ZT:WD,L17S(I#\KG/!'M7T(?".@OX7B\&RV$
M4OA^'3(=(2QD5606,$2P118*D#;&BJ"%X';% '\HG_!.S_@LO^SO\$/A@/@C
M^T%X:ET/Q_X<OGA>=-,MPUW'$&B*S>?;L6V>6&C*L-N^3(;(*^Q^+O\ @M_X
M"^-_Q:\._"O]F+P#%JMT=4AM]1U*YTR"2;:\J)(WF1VT:J@'** 2N3EFY)_1
M3XN?\$9/V,/BGKMWXMG\#)IOB>[FDGEOH2FR5Y2"X98TB*YYP?FY."!UKT#]
MGO\ X)3_ +)'[.6LV_BGP3X(B'BB)Q+)JLHCRTORDE49'; (.&+@D<X!H \*
M_P""G=WJE[^PM/K&JZ?(NN77A\/>V5M$=R2M &90B XY[ =C7SQ_P;R3SS_
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M DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM^(?ASX8>#+S7SKWB2Y2RTV.:.-(0Y9(U4A;=0%&]0 ",# 'MWEY_P $"/\
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MS/<>?%LN0TH#L26 8\R=?7M0!^X5K;I:6\-M%_JX(UC3/]U1@5/110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
M&/\ P5V_X^? O^];_P#H\5]Y?L+?\DAT;_L'V_\ Z#%7P;_P5V_X^? O^];_
M /H\5]Y?L+?\DAT;_L'V_P#Z#%7VF._Y)'+/^OU7_P!.1.>'^\5?\,?RB?;E
M%%%?%G0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <CXZTRZU;POK%G8EA>O97'V4J2&\_RG$>".^[&/YBOY#[C_@H
MM\7?V&_VTM?M/VH_#VI:K\$KC4KVVLY[JU-Q%!;R2.B30&:*6(21*=\996 =
M5+*1Q7]CU?'W[1W["W[.7[5%M]G^+W@FVUL_-B:,112[B"-Q;R6)()SUY_+
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M_$KQC^TCJFFR6FH^/&OKLBXB*R+)>^8P(W<@[I![\'TH _H#\/:<-(T/2M+
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M J9P!^=?*7_#=W[-G_0]0?\ ?M/_ (]1_P -W?LV?]#U!_W[3_X]1_9>8_\
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M/YH_?_7?\^S/L.BOCS_AN[]FS_H>H/\ OVG_ ,>H_P"&[OV;/^AZ@_[]I_\
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M\.>'\T?O_KO^?9GV'17QY_PW=^S9_P!#U!_W[3_X]1_PW=^S9_T/4'_?M/\
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M#_OVG_QZC^R\Q_Z <7_X(J?_ "/FOO#GA_-'[_Z[_GV9]AT5\>?\-W?LV?\
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M9>8_] .+_P#!%3_Y'S7WASP_FC]_]=_S[,^PZ*^//^&[OV;/^AZ@_P"_:?\
MQZC_ (;N_9L_Z'J#_OVG_P >H_LO,?\ H!Q?_@BI_P#(^:^\.>'\T?O_ *[_
M )]F?8=%?'G_  W=^S9_T/4'_?M/_CU'_#=W[-G_ $/4'_?M/_CU']EYC_T
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M ,CYK[PYX?S1^_\ KO\ GV9]AT5\>?\ #=W[-G_0]0?]^T_^/4?\-W?LV?\
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M_D?-?>'/#^:/W_UW_/LS[#HKX\_X;N_9L_Z'J#_OVG_QZC_AN[]FS_H>H/\
MOVG_ ,>H_LO,?^@'%_\ @BI_\CYK[PYX?S1^_P#KO^?9GV'17QY_PW=^S9_T
M/4'_ '[3_P"/4?\ #=W[-G_0]0?]^T_^/4?V7F/_ $ XO_P14_\ D?-?>'/#
M^:/W_P!=_P ^S/L.BOCS_AN[]FS_ *'J#_OVG_QZC_AN[]FS_H>H/^_:?_'J
M/[+S'_H!Q?\ X(J?_(^:^\.>'\T?O_KO^?9GV'17QY_PW=^S9_T/4'_?M/\
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M_P"&[OV;/^AZ@_[]I_\ 'J/^&[OV;/\ H>H/^_:?_'J/[+S'_H!Q?_@BI_\
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MW=^S9_T/4'_?M/\ X]1_PW=^S9_T/4'_ '[3_P"/4?V7F/\ T XO_P $5/\
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M)5+^%#_"C^-;]IGX&K\;/V@?"^GO--$)[^!,PL5QNE3ICM@C_P"OFOT^LO\
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MEJ"M<V\;@"23C$8S@=A@COGBO1/^'3MM_P!!34O^_LE?K_\ L^R&3X4>%BP
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M[;?]!34O^_LE?O111_K9G?\ T%/[O3_+\?6Y["E_*?@O_P .G;;_ *"FI?\
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M  48_P""?UO\-;[PP8[Z\D2]>(KOD<X#2A>,GJ>O_P!;K]5?LI_\$R[?Q?\
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MT_R_'UN>PI?RGX+_ /#IVV_Z"FI?]_9*/^'3MM_T%-2_[^R5^]%%'^MF=_\
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M_P"_LE'_  Z=MO\ H*:E_P!_9*_>BBC_ %LSO_H*?W>G^7X^MSV%+^4_!?\
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M*_G1\#?\%O/!_C_XH^/_ (0:'/'=>+/#=W>65G;P$22-/ \D2@JF6'S*/?\
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M7Q/XXT+]B;XB0^&Y+RTTVYMX5U"]LA()85*3*#N3Y@"&<Y![5\1?\&W7P/\
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M[(?[ /P8^$7[/.B^ ;_PWHNOW.HZ4ANM7GM(+B<^= JATF()+[BQ;)/IU)P
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MX_M!^BXQTR/KVZ9_T8_AAX1L/ _P_P#"_A^PMTMQ8>']+AG5$";[B.PB$K,
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\DAT;_L'V_\ Z#%7VF._Y)'+/^OU7_TY$YX?[Q5_PQ_*)]N4445\6= 4444
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M_!G5/V(/V;_ARF@:=*WC+Q!#:#Q?JZ1MYI%PJ&Y::4#=T9LECW- 'W#\,O\
M@K9^RO\ #;6?#'[..GZ;<V5[X;MK703<VS106!F@(MVF91!R[LH9W:0EL8X
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M@#SSG->B444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 7Q%XT\1?$OXM?$;3I;6[@UF:?2&NH&4RJUZ A0N,D>6Q88.,#UXK^B7XS?
M/PS\:X;6U\232"UMP%:!5W)*H.<.I(!SR.:Z;X5_"#P?\(=&_L7PCI\%C;,J
MB7R8EB\PK@[F"]22,\]* /4E4*JJ.BJ%'T P/T%+110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?AC_P %
M=O\ CY\"_P"];_\ H\5]Y?L+?\DAT;_L'V__ *#%7P;_ ,%=O^/GP+_O6_\
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M<?XT?ZI0_P"AM@_O?^?K_2U/;_\ 3N73\>7R_O?@?TS?VQI/_04T[_P-MO\
MX[1_;&D_]!33O_ VV_\ CM?S,_8_VNO^?_6_^_EQ_C1]C_:Z_P"?_6_^_EQ_
MC1_JE#_H;8/[W_GZ_P!+4]O_ -.Y=/QY?+^]^!_3-_;&D_\ 04T[_P #;;_X
M[1_;&D_]!33O_ VV_P#CM?S,_8_VNO\ G_UO_OY<?XT?8_VNO^?_ %O_ +^7
M'^-'^J4/^AM@_O?^?K_2U/;_ /3N73\>7R_O?@?TS?VQI/\ T%-._P# VV_^
M.T?VQI/_ $%-._\  VV_^.U_,S]C_:Z_Y_\ 6_\ OY<?XT?8_P!KK_G_ -;_
M ._EQ_C1_JE#_H;8/[W_ )^O]+4]O_T[ET_'E\O[WX'],W]L:3_T%-._\#;;
M_P".T?VQI/\ T%-._P# VV_^.U_,S]C_ &NO^?\ UO\ [^7'^-'V/]KK_G_U
MO_OY<?XT?ZI0_P"AM@_O?^?K_2U/;_\ 3N73\>7R_O?@?TS?VQI/_04T[_P-
MMO\ X[1_;&D_]!33O_ VV_\ CM?S,_8_VNO^?_6_^_EQ_C1]C_:Z_P"?_6_^
M_EQ_C1_JE#_H;8/[W_GZ_P!+4]O_ -.Y=/QY?+^]^!_3-_;&D_\ 04T[_P #
M;;_X[1_;&D_]!33O_ VV_P#CM?S,_8_VNO\ G_UO_OY<?XT?8_VNO^?_ %O_
M +^7'^-'^J4/^AM@_O?^?K_2U/;_ /3N73\>7R_O?@?TS?VQI/\ T%-._P#
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M_P"?_6_^_EQ_C1_JE#_H;8/[W_GZ_P!+4]O_ -.Y=/QY?+^]^!_3-_;&D_\
M04T[_P #;;_X[1_;&D_]!33O_ VV_P#CM?S,_8_VNO\ G_UO_OY<?XT?8_VN
MO^?_ %O_ +^7'^-'^J4/^AM@_O?^?K_2U/;_ /3N73\>7R_O?@?TS?VQI/\
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M,W]L:3_T%-._\#;;_P".T?VQI/\ T%-._P# VV_^.U_,S]C_ &NO^?\ UO\
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MS?VQI/\ T%-._P# VV_^.T?VQI/_ $%-._\  VV_^.U_,S]C_:Z_Y_\ 6_\
MOY<?XT?8_P!KK_G_ -;_ ._EQ_C1_JE#_H;8/[W_ )^O]+4]O_T[ET_'E\O[
MWX'],W]L:3_T%-._\#;;_P".T?VQI/\ T%-._P# VV_^.U_,S]C_ &NO^?\
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M?@?TS?VQI/\ T%-._P# VV_^.T?VQI/_ $%-._\  VV_^.U_,S]C_:Z_Y_\
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M<?XT?ZI0_P"AM@_O?^?K_2U/;_\ 3N73\>7R_O?@?TS?VQI/_04T[_P-MO\
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M +^7'^-'^J4/^AM@_O?^?K_2U/;_ /3N73\>7R_O?@?TS?VQI/\ T%-._P#
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M_P"?_6_^_EQ_C1_JE#_H;8/[W_GZ_P!+4]O_ -.Y=/QY?+^]^!_3-_;&D_\
M04T[_P #;;_X[1_;&D_]!33O_ VV_P#CM?S,_8_VNO\ G_UO_OY<?XT?8_VN
MO^?_ %O_ +^7'^-'^J4/^AM@_O?^?K_2U/;_ /3N73\>7R_O?@?TS?VQI/\
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M,W]L:3_T%-._\#;;_P".T?VQI/\ T%-._P# VV_^.U_,S]C_ &NO^?\ UO\
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MS?VQI/\ T%-._P# VV_^.T?VQI/_ $%-._\  VV_^.U_,S]C_:Z_Y_\ 6_\
MOY<?XT?8_P!KK_G_ -;_ ._EQ_C1_JE#_H;8/[W_ )^O]+4]O_T[ET_'E\O[
MWX'],W]L:3_T%-._\#;;_P".T?VQI/\ T%-._P# VV_^.U_,S]C_ &NO^?\
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M3\>7R_O?@?TS?VQI/_04T[_P-MO_ ([1_;&D_P#04T[_ ,#;;_X[7\S/V/\
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M]C_:Z_Y_];_[^7'^-'V/]KK_ )_];_[^7'^-'^J4/^AM@_O?^?K_ $M3V_\
MT[ET_'E\O[WX'],W]L:3_P!!33O_  -MO_CM']L:3_T%-._\#;;_ ..U_,S]
MC_:Z_P"?_6_^_EQ_C1]C_:Z_Y_\ 6_\ OY<?XT?ZI0_Z&V#^]_Y^O]+4]O\
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M[7\S/V/]KK_G_P!;_P"_EQ_C1]C_ &NO^?\ UO\ [^7'^-'^J4/^AM@_O?\
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M&V#^]_Y^O]+4]O\ ].Y=/QY?+^]^!_3-_;&D_P#04T[_ ,#;;_X[1_;&D_\
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M\%/]0T>?]D[QFIU:Q$GF0>4BW,+M)F.4M@([?=POUW<="1^4_P!C_:Z_Y_\
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M_P">?_@3_P _)?<%EV7]?\,ON,#_ (17PY_T!=._\!H_\*/^$5\.?] 73O\
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M1=.'_;M'_A7\ZG[;NB^'8_VB[%(=*MXXSJL0*") "//&> ,8Z\>G2OZ2:_G
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M(KX<_P"@+IW_ (#1_P"%;]%'M)_SS_\  G_GY+[@LNR_K_AE]Q@?\(KX<_Z
MNG?^ T?^%'_"*^'/^@+IW_@-'_A6_11[2?\ //\ \"?^?DON"R[+^O\ AE]Q
M@?\ "*^'/^@+IW_@-'_A1_PBOAS_ * NG?\ @-'_ (5OT4>TG_//_P "?^?D
MON"R[+^O^&7W&!_PBOAS_H"Z=_X#1_X4?\(KX<_Z NG?^ T?^%;]%'M)_P \
M_P#P)_Y^2^X++LOZ_P"&7W&!_P (KX<_Z NG?^ T?^%'_"*^'/\ H"Z=_P"
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MOQ[J?Q+^,4?A3PMX!UR\1=(O-3-O%<065RWR"-Y54AE0KTYR?I0!_5[\+/\
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M  3]\<> ?L/QU^--]/J?B'Q(+C48[*_F:2:(7";XG\N0E@N^0@' !VG!R#@
M[K_@H3\!OV5/''Q6^&7C'XN2VMKXFDO+"?24GD6-WF,Z-'M5B"<O@#KT^@K]
M?O"#^&?!GPW\-F.^M=/\,Z3X?L!;7ES*L5O%9"W62)VD8XP4;(QDD=,U_'1_
MP<E^-_'7A;]KC]D;1/"&K7&F:=>ZKX=2[MX)GC24-J";@0I .5..<\5^G'_!
M3O\ :;UCP/\ L'^ /AOX5UQ]*\>^-_!'ABUM[R&9HKD21Z0EL^'4AAOE<'C&
M2!GW /NWXM?\%/\ X(_#7Q.OARQN(?$S?:EM9+K3[D2QQL7",282P&#G@GBO
MR'_X+1_M3^$OB=\*_A=<^"/$<%MJ,UU!)-IT%V!=)YUR9 KJK!N%(&"/RJO_
M ,$D_P#@FIKGB_X(WOC[XZ:K)XEUW7IY);&?4)FGDC,XDE5U,A)&PE.0>,CD
M5^,G_!=_]C7XN_LC_$/X<?$/2=>N]3\$:UK-L;?2XKB26W@C%V(]@C#%1LVE
M2,#&,'% ']@?_!-?Q"^B?LH>'?%6O3.UO::+%-<S32$\)$K,2S>P'4YYZU[?
M?_MY_ ZTT75=3A\0Z?<W6E/*DVGI=QF<O%N#+L4[LDKC&/\ "OA+]E7Q#='_
M ()*MXFCS;ZC+X'GG)&5>.06D6/0C!9ORK^?/_@FA^RQ\7/VG_CSXZUO6?&%
MY+X4A\1W8DTN2[E,1B-PX92C/MQ@]"/RS0!_47\/O^"J_P "O&7BM?"^H3Q>
M'Y9+G[-%<WMR(HW8MM!'F$ @]1@G/:OTST+7](\2Z7:ZUHE];ZAIMY&)8+JW
MD5XG0J&^\"1P#SSCWK^/O_@M-_P3YU+X+?!_PO\ $[X2ZLWA_5['5(8+JXLI
MVA>22W,$C$E&4DMOSSUSS7ZO_P#!-#XVZ[HW_!.&[\7>.-9:\U[P=X8OKDW5
MQ*6EF:&Q?80[$DD.@/7W'- 'Z2?'O]JOX5?L_P"FFZ\6^(--%^5W1Z:+R(7#
M C*C:&)W-Z 9'?GBOE;X7?\ !4KX*?$3Q*N@3[="BDF6*/4+V?RX'W,%#!I,
M*<YSUZ<]*_E&^ GC^/\ X*?_ +6GQ N?B5\84\*>%? &NWJ+I5YJ9MXKB&QG
MDP@C:100PCQT[^N!7Z;?\% OV>?V6/"O[.']H?![XPZ+H_C70H85:[LM2BBG
MGFA0,3NCE#,2Z'G/?Z4 ?T[^*/BMX7\/>$U\907]KJNBM%YXN[.=)8?)*[@Y
M="0N1V;!&.1CFN2^$?[1/P]^,MQ=6?A+5;6\O;,.;FVAG21XO+SNW*"2,!3G
M/I7\]G_!*3X^:E\=OV:?'_P0U[Q(WBO6]'T'4H+#4VG:=V>&WE6(K(2QR2%Q
M@GFODO\ X(V_$CXG_";_ (*%_&/X8_%*^NX?#]]JNL:?HBWTD@A'GR3QP%!*
M0ORET((]O7@ _L/^('CK0?AOX5U3Q?XDNXK+2M*B\VXFF=8T ]-S$ < G\*\
MY^"?[0/@OXZZ?=:IX+NXKZQM9&B>X@E$J;U.,;E.!G!]>E?C?_P6Y_:7ET#X
M<GX"^&M8^P>)/&\45O9^3+LEE:Y10FTJ0QY;C!Z5[A_P10^!OC7X,?LQFV\>
MS7%UK.MWL&HPSW+.[M;S)*^5:3G!+*: /V9K\1_^"BWP!_97\8?%SX;>(/B_
M+:V_B?[?9RZ2)Y51GF$ZF/:&9=V64=CR1[5^W%?Q5_\ !RQX_P#'7A/]JW]D
MNR\+:Q<:=9WNL:"+R*&5XUE5KV,,&"D Y![B@#^M"Z^(O@+X&_"CPE>:A>06
M7A:RT.S@L+B658XA;11*4PY.W&&!Z]*^9_%/_!2KX(Z)HTNLZ5?6^O0PDB1;
M*Y$I7;][/ED\#UK\_O\ @J_J7BA_^"97PWET#49;'7;[PCI.Z]CD,<GF2:59
M@G>"#DOENOKUS7Q%_P $5/\ @G]XC^)?[/VL>-OBIX@DUY-8NY[2VCO+AIMA
MF69LJ)&8_)A<^F1ZB@#^A/\ 9[_;Z^"O[0-Y_9>AZU8V&K%O+%C-=)YOF;MH
M4JQ#<GCZ\U1_;B^%/PY^)7@6;_A831_V(MN!+(S@1E%Y^]G!X)Z$_K7\FO[4
MW[/OQ*_X)[_M=>&?&7A;Q/=6WAK7_$<"C3(KF01K%+= [?+5MH&TC^'@?K_0
M]^W1XWUO6O\ @G7IOCFTNG@U;4O#4%RUP'(<O)9AB2PY.3U]<4 ?1?[ G@GX
M/_#'X9ZS!\*9(7T>/=+>-&X8 P@.V2"<<#U'XXS7OWA+]J7X<^,/'LGP]TO4
M+>378IC UNLZM('5MI&P'.0>/\X/XW?\$.O$WB/Q%^S)\4[G7[Z6]N8;;4S%
M)*Y<J0CXP6.>/R_*O@']B7QEXPO/^"JNM:1=ZI/)I*^)+A5MFE=DVB]V@!2<
M=.G']: /Z]/''C?2? >BW&N:S(L5G;1O+([MM4*@RQ)/3 KS'X:?M&>!/BEI
MVKZCX;O8;F'1A*;ORY0^P1 EMQ'3&#FO"O\ @HK>WMA^SKXQN;"5H;F/1]0:
M.16*E6$#$'(YX/I_6OQ$_P"",?C/Q/J/PW^/UQKFH37AMEUH0&21F,>TS[<;
MCQV_*@#]S_%W[??P)\(27MGJ'B331JEF\D;Z>;V(3F2,D%1'G=G(Q]>*\J\#
M_P#!3;X7^./$5QH5AI<\:V[,)+LN_E;%.#)NQMVXYSG_ .O_ "6^#?V2/C-^
MTW^WEJMXGC:]@\)KXIE,FE?;)1"8?MAROE[]N"HY  XX^O\ 6#H'_!/+P1\.
M_A_XG_L^V@?Q"/"NH+#>1D&1KRWL)9$8-R<O(G&,DD^] 'VK\+?V@OA]\6[^
M[TSPIJUK>W]DKM<V\,Z2/%Y:DON522,8/7I^%>@^/O'&A?#GPMJ?BWQ'=Q66
ME:7%YMQ-,XC0#DX+,0!P#^5?QR?\$;OBQ\4OAM_P40^,7P\^*=_=Q>'=1U;6
M=-T1;V201#S9YX("@E(7"Y4C'-?J9_P6W_:8E\-?#4_ KPWK L/$?CF&*WLC
M#+LEE>Z0!"I4AB/G &.W3F@#]A_@I^T'X*^.MC=:EX+NX;ZRM97BDG@E$R;U
M8C&Y> 3CIUKWJOQ=_P"")?P-\;?!G]FF2'Q]-<76L:[=V^I0SW+.[F"9))"0
M7YP=RD=17[14 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7\X'[;W_)QEC_ -A6+_T<*_H_K^<#]M[_ ).,L?\ L*Q?^CA7UG!_
M_(QK?]@M7\C"O\"]5_Z5$_=/]GG_ ))-X7_Z]5_]%15[97B?[//_ "2;PO\
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MV_X^? O^];_^CQ7WE^PM_P DAT;_ +!]O_Z#%7P;_P %=O\ CY\"_P"];_\
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MC=NX_2OZ:/\ @FU^Q&/V5/@V=&U^\O+SQ)XAM'CUC[4[.ZBXAVSJ2[$@EF(
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M<;"U?T__ /!-C]FCQG\!_@UI=G\2;R^NO&#B&2\-[))(XD,>9<F0D_?X^OZ
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MVOC]^V=^T/\ LY^._A-;7,VC> =4T>XUMH$+*L=K=)))NP.,+G]?I0!]!?\
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MC _;>^&?@KX0_P#!3SP!-\1+6-X=9\46,L4-U$##(LM\A&XN"N""/:OZBO\
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MNV6FV>G31R;)'P9$1 TC2 .N,,</G(QM_ G_ ((Y?%#Q/HO[86N?![1M;O\
M6/ .GZO=6]HS/++:)''<%$5&)*8"X P<8 Q7@7C[P+_P6X^/FAQ>!O$@\20^
M&M0GMTU-AYZYBP8Y<D?[#-G^5?T!?\$NO^"<^G_LN>"=-\7^-;9G^)]Z8[G4
M+F:,&X$Y4/,9)&P_,AX/))!]* /U4^*O_)./&?\ V ;W_P! %?R-_ 3_ )/;
MN?\ L8#_ .E=?UZ?$#2KG7/!7B;2+($W6HZ1=VMN!U,DB87]:_G4^$?_  3U
M^.?A?]J2?XD:C;7 T!]9-T&*,%$?VCS!STQCW[]30!_2=IO_ "#K#_KRM?\
MT1'5?783<:+J\"C+3:9?1*/4O;2J/U-6[&-H;*SA?[\5K;QM_O)$BM^H-664
M.K*W*LI4CU##!_0T ?Q:_'6]F^$_[<^CKJ4?D+JOB.,1M(-F[S+P $%@,Y![
M?SK^P_PEJ2Q_#GPYJH(*#PSIEV2.1L-E%(Q_(GG\J_DI_P"#@#X9^+O"7[07
MP(^(GP\T^Z^R)JFF76NSVD;;4 NE,K2L@PH.TG)/0BOZ:_V3OB)HOQ8_9^\
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MI.B:IJ*H9'M+*XF1!DEG6-BH ').<5LU%/!#<Q203QK+#*I62-N593U!'<4
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M]HKYO%_[UB/^OU3_ -+9M'9>B_(****YQA1110 4444 %%%% !1110 4444
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M .G(G/#_ 'BK_AC^43[5HHHKXLZ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!  !@  >@&!Z_SI:** "BBB@ HHHH
M ^6?VI_V9O"7[1G@#6-"U?3H)M=^Q,NCWTB1L]O.JL$"LRDJ<L"&#<;>F3FO
M$O\ @G_^S#X[_9G\->)/#WB_49+ZVNY_^)6KR^8(85G5D51D[0(UQ@?2OT3H
MH *3 !)  )QDXY..F3WQVS2T4 %%%%  0#P1D>AHHHH **** "D"JI)"J"QR
MQ  +'U)'4_6EHH ^</VJ/AAXB^+_ ,(/$'@;PS=/::CJ\+1+,CE" 5VCY@1Z
MGO7SQ^P9^QH/V:_!=_;^*XXM0\4WFH_:1?2;))4CRY/[TY;)++CD9ZU^BU%
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M /GRN/\ OQ1_P\[U_P#Y\KC_ +\5]]_\,&_ O_H$O_WZB_QH_P"&#?@7_P!
ME_\ OU%_C7SO]H<*_P#0OK?<O+_+^K*VO)7_ )X_C_7_  S\K_ G_#SO7_\
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M  )_P\[U_P#Y\KC_ +\4?\/.]?\ ^?*X_P"_%???_#!OP+_Z!+_]^HO\:/\
MA@WX%_\ 0)?_ +]1?XT?VAPK_P!"^M]R\O\ +^K*QR5_YX_C_7_#/RO\"?\
M#SO7_P#GRN/^_%'_  \[U_\ Y\KC_OQ7WW_PP;\"_P#H$O\ ]^HO\:/^&#?@
M7_T"7_[]1?XT?VAPK_T+ZWW+R_R_JRL<E?\ GC^/]?\ #/RO\"?\/.]?_P"?
M*X_[\4?\/.]?_P"?*X_[\5]]_P##!OP+_P"@2_\ WZB_QH_X8-^!?_0)?_OU
M%_C1_:'"O_0OK?<O+_+^K*QR5_YX_C_7_#/RO\"?\/.]?_Y\KC_OQ1_P\[U_
M_GRN/^_%???_  P;\"_^@2__ 'ZB_P :/^&#?@7_ - E_P#OU%_C1_:'"O\
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MU_PS\K_ G_#SO7_^?*X_[\4?\/.]?_Y\KC_OQ7WW_P ,&_ O_H$O_P!^HO\
M&C_A@WX%_P#0)?\ []1?XT?VAPK_ -"^M]R\O\OZLK')7_GC^/\ 7_#/RO\
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M/]H<*_\ 0OK?<O+_ "_JRL^2O_/'\?Z_X9^5_@3_ (>=Z_\ \^5Q_P!^*/\
MAYWK_P#SY7'_ 'XK[[_X8-^!?_0)?_OU%_C1_P ,&_ O_H$O_P!^HO\ &C^T
M.%?^A?6^Y>7^7]65CDK_ ,\?Q_K_ (9^5_@3_AYWK_\ SY7'_?BC_AYWK_\
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M5Q_WXH_X>=Z__P ^5Q_WXK[[_P"&#?@7_P! E_\ OU%_C1_PP;\"_P#H$O\
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M7]65CDK_ ,\?Q_K_ (9^5_@3_AYWK_\ SY7'_?BC_AYWK_\ SY7'_?BOOO\
MX8-^!?\ T"7_ ._47^-'_#!OP+_Z!+_]^HO\:/[0X5_Z%];[EY?Y?U96.2O_
M #Q_'^O^&?E?X$_X>=Z__P ^5Q_WXH_X>=Z__P ^5Q_WXK[[_P"&#?@7_P!
ME_\ OU%_C1_PP;\"_P#H$O\ ]^HO\:/[0X5_Z%];[EY?Y?U96.2O_/'\?Z_X
M9^5_@3_AYWK_ /SY7'_?BC_AYWK_ /SY7'_?BOOO_A@WX%_] E_^_47^-'_#
M!OP+_P"@2_\ WZB_QH_M#A7_ *%];[EY?Y?U96.2O_/'\?Z_X9^5_@3_ (>=
MZ_\ \^5Q_P!^*/\ AYWK_P#SY7'_ 'XK[[_X8-^!?_0)?_OU%_C1_P ,&_ O
M_H$O_P!^HO\ &C^T.%?^A?6^Y>7^7]65CDK_ ,\?Q_K_ (9^5_@3_AYWK_\
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M )X_C_7_  S\K_ G_#SO7_\ GRN/^_%'_#SO7_\ GRN/^_%???\ PP;\"_\
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M%???_#!OP+_Z!+_]^HO\:/\ A@WX%_\ 0)?_ +]1?XT?VAPK_P!"^M]R\O\
M+^K*QR5_YX_C_7_#/RO\"?\ #SO7_P#GRN/^_%'_  \[U_\ Y\KC_OQ7WW_P
MP;\"_P#H$O\ ]^HO\:/^&#?@7_T"7_[]1?XT?VAPK_T+ZWW+R_R_JRL<E?\
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M $"7_P"_47^-']H<*_\ 0OK?<O+_ "_JRL<E?^>/X_U_PS\K_ G_  \[U_\
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M_P#Y\KC_ +\4?\/.]?\ ^?*X_P"_%???_#!OP+_Z!+_]^HO\:/\ A@WX%_\
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M -^HO\:/^&#?@7_T"7_[]1?XT?VAPK_T+ZWW+R_R_JRL<E?^>/X_U_PS\K_
MG_#SO7_^?*X_[\4?\/.]?_Y\KC_OQ7WW_P ,&_ O_H$O_P!^HO\ &C_A@WX%
M_P#0)?\ []1?XT?VAPK_ -"^M]R\O\OZLK')7_GC^/\ 7_#/RO\  G_#SO7_
M /GRN/\ OQ1_P\[U_P#Y\KC_ +\5]]_\,&_ O_H$O_WZB_QH_P"&#?@7_P!
ME_\ OU%_C1_:'"O_ $+ZWW+R_P OZLK')7_GC^/]?\,_*_P)_P /.]?_ .?*
MX_[\4?\ #SO7_P#GRN/^_%???_#!OP+_ .@2_P#WZB_QH_X8-^!?_0)?_OU%
M_C1_:'"O_0OK?<O+_+^K*QR5_P">/X_U_P ,_*_P)_P\[U__ )\KC_OQ1_P\
M[U__ )\KC_OQ7WW_ ,,&_ O_ *!+_P#?J+_&C_A@WX%_] E_^_47^-']H<*_
M]"^M]R\O\OZLK')7_GC^/]?\,_*_P)_P\[U__GRN/^_%'_#SO7_^?*X_[\5]
M]_\ #!OP+_Z!+_\ ?J+_ !H_X8-^!?\ T"7_ ._47^-']H<*_P#0OK?<O+_+
M^K*QR5_YX_C_ %_PS\K_  )_P\[U_P#Y\KC_ +\4?\/.]?\ ^?*X_P"_%???
M_#!OP+_Z!+_]^HO\:/\ A@WX%_\ 0)?_ +]1?XT?VAPK_P!"^M]R\O\ +^K*
MQR5_YX_C_7_#/RO\"?\ #SO7_P#GRN/^_%'_  \[U_\ Y\KC_OQ7WW_PP;\"
M_P#H$O\ ]^HO\:/^&#?@7_T"7_[]1?XT?VAPK_T+ZWW+R_R_JRL<E?\ GC^/
M]?\ #/RO\"?\/.]?_P"?*X_[\4?\/.]?_P"?*X_[\5]]_P##!OP+_P"@2_\
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M["5I_P"C8Z_I\TG_ )!6F?\ 8/LO_2:*O3XN^#*O^P:I_P"E1(P^T_\ $O\
MTE&A12$X!/H"?R%?BU_P4)_X*-_%3]E"]BM? W@1_$V]MN5L!==.I_U4F.?_
M -=?&'0?M-17\>FN?\'''Q1\"VT=QXY^&4>DJR@MY^EI#@GI]ZW&/?Z@UH:#
M_P '#GQL\<P0:EX)^$XU72Y)41[B'2%E559@-VY;<CH<Y_6@#^ONBOR*^ ?_
M  4(\9_$+X9WWCKQIX5&AO9:>][)#):+ !LC+D$&->,#I7JG[%?[>&G?M8^*
M?&'A_3[:"'_A%VG61HE0$^2[(<[5!/S #KWH _2&BBB@ HHHH **** "BBB@
M HHHH ***^._VO/VH;7]F/P1=^+KN".:*VCWD2*K#[H;HP(]J /L2BOC_P#8
MP_:>M?VJ_AC)\0K*&*&".\2T*Q*JKN978<* .B&OL"@ HHHH **** "BBB@
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M=>*=3T7P)\-TUJUL+R:V$\&F)."(I&0G>L#@]!Z]?7J ?UKT5_)GX<_X+O\
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M^33O&'_72+_T!J]7(_\ D<Y9_P!AN'_].1(J?!+T/ O^"-__ "0R7_KYE_\
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ML<H<9VD$$@9YP#BOQ]^+_P#P6/\  7PP\=7WPOO)P?%K7,EI8P(07:7S#'&
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MD<L_Z_5?_3D3GA_O%7_#'\HGVY1117Q9T!1110 4444 %%%% !1110 4444
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M-7_!&_\ Y(9+_P!?,O\ Z&]?LK73Q/\ \C[,O^PA_P#I,14OX4/\*/Y<Y?\
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M>Z/XUTGQS\8_B9=^*K73[F&=/#^IW-Q=QLL3 DF)Q)&I)4?>VDY!&1R?Z4/
M7P\\,?#GPAIW@KPUIEK8Z)I]HMJMI#$J12+Y8CD+(H4$,HQTZ>Y- '\0_P#P
M15\;:-_P3_\ VP/CWX3^,LT7A;2_'FNZC%97>I'[/'MFOF>-D>78..&ZD'&#
MQQ7]8?Q__P""A7[.7P4^%>M?$6'XC^$_$ES80P/9:+8:FDUW=27"ET!B1D<
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M7?M;:+H?@/\ 9A\5>&?#>G6^E:#9^'KNVCT^TC6.#R(;4* 44!2S; 6..3R
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M?[//_))O"_\ UZK_ .BHJ]LKYO%_[UB/^OU3_P!+9M'9>B_(****YQA1110
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MC?,;32M*5^:(+P6['Z$5^K^I:5'>:/=:5;D6Z3VKVR,G&P,A0'CTR#^M 'X
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M98G-OY:7193N8%/NCC']*_L&\.:%:^&M%L-$LE"VUA D$048&$ ' P,#CTH
MVZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3RJ5*A4J1^K35XQ;5^:.ET94)17.FTGS)_>DOS/K:BOE'_AL'X2_]!RQ_P#
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M]/\ -'U=17RC_P -@_"7_H.6/_@7'1_PV#\)?^@Y8_\ @7'1_9V/_P"@2O\
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M"7_H.6/_ (%QT?V=C_\ H$K_ /@N0<\?YE]_I_FCZNHKY1_X;!^$O_0<L?\
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MZ/[.Q_\ T"5__!<@YX_S+[_3_-'U=17RC_PV#\)?^@Y8_P#@7'1_PV#\)?\
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M'X2_]!RQ_P# N.C^SL?_ - E?_P7(.>/\R^_T_S1]745\H_\-@_"7_H.6/\
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M_P#H$K_^"Y!SQ_F7W^G^:/JZBOE'_AL'X2_]!RQ_\"XZ/^&P?A+_ -!RQ_\
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M $_S1]745\H_\-@_"7_H.6/_ (%QT?\ #8/PE_Z#EC_X%QT?V=C_ /H$K_\
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M_AL'X2_]!RQ_\"XZ/^&P?A+_ -!RQ_\  N.C^SL?_P! E?\ \%R#GC_,OO\
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M?OY11_K=G?\ S_I?^"*?EY>2#ZO2_E?W_P!=OS[L_ /_ (=,_$S_ *'_ /\
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M$4_+R\D'U>E_*_O_ *[?GW9^ ?\ PZ9^)G_0_P#_ )4C_P#'J/\ ATS\3/\
MH?\ _P J1_\ CU?OY11_K=G?_/\ I?\ @BGY>7D@^KTOY7]_]=OS[L_ /_AT
MS\3/^A__ /*D?_CU'_#IGXF?]#__ .5(_P#QZOW\HH_UNSO_ )_TO_!%/R\O
M)!]7I?RO[_Z[?GW9^ ?_  Z9^)G_ $/_ /Y4C_\ 'J/^'3/Q,_Z'_P#\J1_^
M/5^_E%'^MV=_\_Z7_@BGY>7D@^KTOY7]_P#7;\^[/P#_ .'3/Q,_Z'__ ,J1
M_P#CU'_#IGXF?]#_ /\ E2/_ ,>K]_**/];L[_Y_TO\ P13\O+R0?5Z7\K^_
M^NWY]V?@'_PZ9^)G_0__ /E2/_QZC_ATS\3/^A__ /*D?_CU?OY11_K=G?\
MS_I?^"*?EY>2#ZO2_E?W_P!=OS[L_ /_ (=,_$S_ *'_ /\ *D?_ (]1_P .
MF?B9_P!#_P#^5(__ !ZOW\HH_P!;L[_Y_P!+_P $4_+R\D'U>E_*_O\ Z[?G
MW9^ ?_#IGXF?]#__ .5(_P#QZC_ATS\3/^A__P#*D?\ X]7[^44?ZW9W_P _
MZ7_@BGY>7D@^KTOY7]_]=OS[L_ /_ATS\3/^A_\ _*D?_CU'_#IGXF?]#_\
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MQ+U3X?:)>KXVDMDO+9)%BDOFC(&Q?F"M(IVDDC(X)4\\&O1?^'3/Q,_Z'_\
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M$4_+R\D'U>E_*_O_ *[?GW9^ ?\ PZ9^)G_0_P#_ )4C_P#'J/\ ATS\3/\
MH?\ _P J1_\ CU?OY11_K=G?_/\ I?\ @BGY>7D@^KTOY7]_]=OS[L_ /_AT
MS\3/^A__ /*D?_CU'_#IGXF?]#__ .5(_P#QZOW\HH_UNSO_ )_TO_!%/R\O
M)!]7I?RO[_Z[?GW9^ ?_  Z9^)G_ $/_ /Y4C_\ 'J/^'3/Q,_Z'_P#\J1_^
M/5^_E%'^MV=_\_Z7_@BGY>7D@^KTOY7]_P#7;\^[/P#_ .'3/Q,_Z'__ ,J1
M_P#CU'_#IGXF?]#_ /\ E2/_ ,>K]_**/];L[_Y_TO\ P13\O+R0?5Z7\K^_
M^NWY]V?@'_PZ9^)G_0__ /E2/_QZC_ATS\3/^A__ /*D?_CU?OY11_K=G?\
MS_I?^"*?EY>2#ZO2_E?W_P!=OS[L_ /_ (=,_$S_ *'_ /\ *D?_ (]1_P .
MF?B9_P!#_P#^5(__ !ZOW\HH_P!;L[_Y_P!+_P $4_+R\D'U>E_*_O\ Z[?G
MW9^ ?_#IGXF?]#__ .5(_P#QZC_ATS\3/^A__P#*D?\ X]7[^44?ZW9W_P _
MZ7_@BGY>7D@^KTOY7]_]=OS[L_ /_ATS\3/^A_\ _*D?_CU'_#IGXF?]#_\
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M*_O_ *[?GW9^ ?\ PZ9^)G_0_P#_ )4C_P#'J/\ ATS\3/\ H?\ _P J1_\
MCU?OY11_K=G?_/\ I?\ @BGY>7D@^KTOY7]_]=OS[L_ /_ATS\3/^A__ /*D
M?_CU'_#IGXF?]#__ .5(_P#QZOW\HH_UNSO_ )_TO_!%/R\O)!]7I?RO[_Z[
M?GW9^ ?_  Z9^)G_ $/_ /Y4C_\ 'J/^'3/Q,_Z'_P#\J1_^/5^_E%'^MV=_
M\_Z7_@BGY>7D@^KTOY7]_P#7;\^[/P#_ .'3/Q,_Z'__ ,J1_P#CU'_#IGXF
M?]#_ /\ E2/_ ,>K]_**/];L[_Y_TO\ P13\O+R0?5Z7\K^_^NWY]V?@'_PZ
M9^)G_0__ /E2/_QZC_ATS\3/^A__ /*D?_CU?OY11_K=G?\ S_I?^"*?EY>2
M#ZO2_E?W_P!=OS[L_ /_ (=,_$S_ *'_ /\ *D?_ (]1_P .F?B9_P!#_P#^
M5(__ !ZOW\HH_P!;L[_Y_P!+_P $4_+R\D'U>E_*_O\ Z[?GW9^ ?_#IGXF?
M]#__ .5(_P#QZC_ATS\3/^A__P#*D?\ X]7[^44?ZW9W_P _Z7_@BGY>7D@^
MKTOY7]_]=OS[L_ /_ATS\3/^A_\ _*D?_CU'_#IGXF?]#_\ ^5(__'J_?RBC
M_6[._P#G_2_\$4_+R\D'U>E_*_O_ *[?GW9^ ?\ PZ9^)G_0_P#_ )4C_P#'
MJ/\ ATS\3/\ H?\ _P J1_\ CU?OY11_K=G?_/\ I?\ @BGY>7D@^KTOY7]_
M]=OS[L_ /_ATS\3/^A__ /*D?_CU.3_@DU\3%96_X3[.T@_\A(]O^VU?OU11
M_K=G?_/^E_X(I^7EY(/J]+^5_?\ UV_/NS^,;_@H;_P3U\??#BY\+S:AXGFO
MQJ+1&-Q<M*@_>^7\K!R."I!P3@AAQSCZH_9:_P""8/Q(\5?#W2]8A\836D$U
MI"RJ]XT2Y=%.%S(H)ZG'' X'!Q]D_P#!76XF6?P'&)&"*T&U<\#-QDX'N23^
M)K[R_8:N)I?@_HJ22,Z"PMF"D\ A(P#]0"1^)KZS%\39O#AC+\0JU+VDZU5-
M^QB_=4TDK;+=&,*%/V\U9VC%-:O=J+^9^;)_X),_$PDG_A/^O_42/_QZC_AT
MS\3/^A__ /*D?_CU?OY17R?^MV=_\_Z7_@BGY>7DC;ZO2_E?W_UV_/NS\ _^
M'3/Q,_Z'_P#\J1_^/4?\.F?B9_T/_P#Y4C_\>K]_**/];L[_ .?]+_P13\O+
MR0?5Z7\K^_\ KM^?=GX!_P##IGXF?]#_ /\ E2/_ ,>H_P"'3/Q,_P"A_P#_
M "I'_P"/5^_E%'^MV=_\_P"E_P""*?EY>2#ZO2_E?W_UV_/NS\ _^'3/Q,_Z
M'_\ \J1_^/4?\.F?B9_T/_\ Y4C_ /'J_?RBC_6[._\ G_2_\$4_+R\D'U>E
M_*_O_KM^?=GX!_\ #IGXF?\ 0_\ _E2/_P >H_X=,_$S_H?_ /RI'_X]7[^4
M4?ZW9W_S_I?^"*?EY>2#ZO2_E?W_ -=OS[L_ /\ X=,_$S_H?_\ RI'_ ./4
M?\.F?B9_T/\ _P"5(_\ QZOW\HH_UNSO_G_2_P#!%/R\O)!]7I?RO[_Z[?GW
M9^ ?_#IGXF?]#_\ ^5(__'J/^'3/Q,_Z'_\ \J1_^/5^_E%'^MV=_P#/^E_X
M(I^7EY(/J]+^5_?_ %V_/NS\ _\ ATS\3/\ H?\ _P J1_\ CU'_  Z9^)G_
M $/_ /Y4C_\ 'J_?RBC_ %NSO_G_ $O_  13\O+R0?5Z7\K^_P#KM^?=GX!_
M\.F?B9_T/_\ Y4C_ /'J/^'3/Q,_Z'__ ,J1_P#CU?OY11_K=G?_ #_I?^"*
M?EY>2#ZO2_E?W_UV_/NS\ _^'3/Q,_Z'_P#\J1_^/4?\.F?B9_T/_P#Y4C_\
M>K]_**/];L[_ .?]+_P13\O+R0?5Z7\K^_\ KM^?=GX!_P##IGXF?]#_ /\
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M_P#!%/R\O)!]7I?RO[_Z[?GW9^ ?_#IGXF?]#_\ ^5(__'J/^'3/Q,_Z'_\
M\J1_^/5^_E%'^MV=_P#/^E_X(I^7EY(/J]+^5_?_ %V_/NS\ _\ ATS\3/\
MH?\ _P J1_\ CU'_  Z9^)G_ $/_ /Y4C_\ 'J_?RBC_ %NSO_G_ $O_  13
M\O+R0?5Z7\K^_P#KM^?=GX!_\.F?B9_T/_\ Y4C_ /'J/^'3/Q,_Z'__ ,J1
M_P#CU?OY11_K=G?_ #_I?^"*?EY>2#ZO2_E?W_UV_/NS\ _^'3/Q,_Z'_P#\
MJ1_^/4?\.F?B9_T/_P#Y4C_\>K]_**/];L[_ .?]+_P13\O+R0?5Z7\K^_\
MKM^?=GX!_P##IGXF?]#_ /\ E2/_ ,>H_P"'3/Q,_P"A_P#_ "I'_P"/5^_E
M%'^MV=_\_P"E_P""*?EY>2#ZO2_E?W_UV_/NS\ _^'3/Q,_Z'_\ \J1_^/4?
M\.F?B9_T/_\ Y4C_ /'J_?RBC_6[._\ G_2_\$4_+R\D'U>E_*_O_KM^?=GX
M!_\ #IGXF?\ 0_\ _E2/_P >H_X=,_$S_H?_ /RI'_X]7[^44?ZW9W_S_I?^
M"*?EY>2#ZO2_E?W_ -=OS[L_ /\ X=,_$S_H?_\ RI'_ ./4?\.F?B9_T/\
M_P"5(_\ QZOW\HH_UNSO_G_2_P#!%/R\O)!]7I?RO[_Z[?GW9^ ?_#IGXF?]
M#_\ ^5(__'J/^'3/Q,_Z'_\ \J1_^/5^_E%'^MV=_P#/^E_X(I^7EY(/J]+^
M5_?_ %V_/NS\ _\ ATS\3/\ H?\ _P J1_\ CU'_  Z9^)G_ $/_ /Y4C_\
M'J_?RBC_ %NSO_G_ $O_  13\O+R0?5Z7\K^_P#KM^?=GX!_\.F?B9_T/_\
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M^MV=_P#/^E_X(I^7EY(/J]+^5_?_ %V_/NS\ _\ ATS\3/\ H?\ _P J1_\
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MC:P))90!@<Y]: /Z(?"/B[0?&^@:?XD\.W]OJ&EZE L]O-!*DHPP#;&*$@.
M02#S@@]#72U_()_P2B_:R_:4^%G[4&L?LG?&#1M>N]#\/WUQIMEJ5XEP\!2.
M4P*RR/E?NHN#NZ8]*_JU^(?Q7\"_"W0+GQ!XU\1:7H=M;VQG2*^O(8)IVV%D
MBBC=@[%B",XP "<YP" >C45^0,O_  5[^#<?B2;15T_?80W7V?\ M432?9V&
M_9Y@<-LVGKD9&*_2OX5?&#P1\7_#5EXD\(ZU87\%TBL\$%S')+$[#<%*!MQX
M/8$@@YQ0!ZG17S9^T-^T_P##K]FVQTC4?B#J5MIMKK$@CMY;F984R93%G+$
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\X'[;W_ "<98_\
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MO[:/P<\4_%^]^"NCZDUUXNL+A[6=(Y(WB$B/L(PJDXS[U^;?QF_X*!R_#O\
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MZW_]'BOO+]A;_DD.C?\ 8/M__08J^#?^"NW_ !\^!?\ >M__ $>*^\OV%O\
MDD.C?]@^W_\ 08J^TQW_ "2.6?\ 7ZK_ .G(G/#_ 'BK_AC^43[<HHHKXLZ
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M ]3CI_1[9?\ !%;]D[4=5;4?"&KV.K/',)4CM+N*4IL(89\J1T&,9.&( [T
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M@-7JY'_R.<L_[#</_P"G(D5/@EZ'@7_!&_\ Y(9+_P!?,O\ Z&]?LK7XU?\
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M_P!OR"3XK7,EGJ/B+Q(ILQ=9B4-/=J4P9, #+#G_ .MD _<_PG_P2$\+W'P
MT3PI?W<"^,;K0K.2YUAW_?BZGM4<NTI^;<';)R<COR,5^-_['GQ]^,/[%?\
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M[!?\$IEUI/V2OAK_ &BT\EI+X?LFL9)]V3$(8\ ;NW.>,<D]A0!^F5?R'?\
M!:6^?XT_%/P]\+]0C-S96.O1".-@2H"7 [-QZ_Y-?UXU_(Q_P5IL;OP!\>=&
M\8W,)2SN==B*S.NU"'G&?F(P<^IZ^_< _H#_ &,?#"?#K]C'P3H-FOD+HW@^
M\,"J-NPK9Y4@#IAEZU_%W^WS^UU-X4_;$2TBT0^(/%MKKGEZ5((FFGCE%T5B
M\OAF!!(QCOW-?VT_LD:A'XU_93\&7$)#+JWA>X@0J006EM H&1G^)QZU_&-^
MW'\./!GP9_X*=_#^X^(-HCPZSXIL9(XKJ)3 ZS7T;<EQMP0PY/Y>H!]3:G\"
M_P!NW]H;PSH_QCT_Q'XBT :=IUOJ-OHZ27<(:&WMTE@B$0(X,:JH&.F*]M_X
M)B?\%1_$.J?M$R_LH_'/PW)%KFD7ATT:YJ-N5DDFAD\GS/-F4,3D;LY/-?U2
M^!++PH? 7AFYT?3](@T*Y\,Z3<Q"&"U%H+-M-@;]XZKY96- 1*S'AE<N00U?
MQ8?M$^)/A9??\%+9M/\ @M:VD/C1?$LBWATF.-F#K=D.6>#WSR3]* /Z;OV\
M?V"O!/[;N@:"^I&T;4- C$VC7C;/DE1F>)XG8#&"5QR.GTK\1/B=_P $=_'O
MPIU&T^/OCWXIS7GA#X;Q)/;^'IM1+Q+;6VYHD,#2%0&6+ 7&<=L$5_3W\*+^
M[T/X0^'M2\7S?99].T-;K59[@[3$D40D=Y"Y&#CH"1R0*_G5_;S_ &L/B#^U
M?^T)HW[+GP)N[W4OA_>7D>G>)[O3C));#:PBN9)C"SQJ6PQ.2<#Y<D 4 ?'O
MP&^&:_M._M+Z9\2_&.J?8O@3X1O(H+NWGE,>G/'9R*K.5<^2?E0GI@_I7]8G
MPA^+W[.M_9V7@/X2>-/"EY;Z/$MI;:1HUT&,)B58BI4JNZ4[!O(X+= !@#^9
MGXG>'K'X&ZGI7[&WAN[?3K_Q7;01ZAJL;>3)'<7:A92TH(PRNYSDY./K7@'C
MKX2^+?\ @EYXD\&_$33O'VH>(Y_%6IVDLUH+Z2Y"B[D5V!19&Q@L!T[=Z /[
M2_%]C'J?AC7+"4!H[K3IXG!Y!!7//Y5_%OXXEOOAS_P4W\-:+I,YM[._\26_
MFQ(2JL&O1G(&!R!W]>:_KB^"WQ+?XB_LZ>%/B3JY,3:YX074[LR94KF)E8MG
MD'*]Z_DA^+"MXV_X*@>%-3\. WEG:>)+;SY8OWBJ%O.<E<@8% ']K.EL7TS3
MG/5K&T8_5K>,G]35ZJ&E KI>FJ>"+"S!]B+>,&K] !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^&/\ P5V_
MX^? O^];_P#H\5]Y?L+?\DAT;_L'V_\ Z#%7P;_P5V_X^? O^];_ /H\5]Y?
ML+?\DAT;_L'V_P#Z#%7VF._Y)'+/^OU7_P!.1.>'^\5?\,?RB?;E%%%?%G0%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?,O[6VBZEX@^#'BK2]*M'O+RYTV]CBAC4LS.\!"@  G)(Q^-?35>.?&K
MXJ^'?A'X5F\2^)HTETR%)6F20 J4106# \8(_K[4 ?PR_ G]B#]L&]^/OQ"F
M\.1ZYX0T_6+[4%BNHDN;9'2:9\$. HP5;KGI^=>ZP?M"_MD_\$Q_BM82?$>X
MUSQ+X$N=0CCO=2O!<SVL$+R#?ODD+1J AYR0".*_K"_9I_::^!7[1D^K?\*V
MM-(CU/2 [WR1PV(G8I(L;E?+C64X+;CG. "2>N/AO_@NC:_#"+]A'XL#7-.T
M5O&<FG!_#,@@MQJL=RT<P:2,J!*RG"  ACE05*C.X _0']D/]I_PM^U=\*=.
M^)'A>>":">.V6Z6W966.>6(NRG:2 0RL,#&.F*^J:_F8_P"#7R+Q?%^Q9XC7
MQ:]XTO\ PE$?V(7:R*RVV+K8$$G.T+MQCCFOZ9Z /Q/_ ."S/C^ZT?X*W_@R
M,L;?Q'8-!-&"<.)5=,$=#D$UY7_P01^#]E\+_@_XTN+2V6W_ +>N(;J3: -S
M27 E)..3R#USZ\=_0/\ @LWX5OM0^&,7B"W@:2'2K3S96"DA1%O8Y(SQC/H*
MB_X(A^.H?&'P<\0PQ,A;36@BD56#%2LP4Y[@Y/XT ?@9_P %GOVM]:^!O[;+
MV]O8R:]%<:XT,-@$:95=KA@I$8R.#QP,]*]C\'_#O]L3]KWX4Z?X\\':IKGA
M#2[&S6ZT_3;=KFV1@L*OM5%*YR @Z>]4_P#@LC\$- \+?M=:9\8OB'9++X8E
M\1I,DEQ"&AP;C<,LRE0/7\2:_J9_82N_A]XC_9E^'>L>!M/TM-#O-+1 +:*!
MU:1880ZR%5/.TI\AZ#D#F@#^7']FW_@I#\0?V7/CGX7_ &??VJ-&N;^:]OK?
M3M)U36878R(TRPQ.DER#U!4@@^AZ<U_6%\:?A!X/_:G^ <G@;4(K>;PWXPT>
MQO($8*T*Q7%H7C &"OR^=@<<8/;BOY%O^#B34/A3J/[7?[/>D^$H].M_'%CJ
M.D0W<NC10!YKA;J'"N+48#(-D;''S,I<DELG^N;]D'^WT_9_^&UOXB21;V#P
MOI 4RA@[1/9QO&3NY^XRXH _GS^)/_!!?QY?:+-X5\%_$J3PMX#TNZDU8Z9;
MZA]G@GCA+3M$(D=58;%;)VX'0D'&?A;XB_#[7O'/B/PC^RU\,]7D\OP%?V]E
MXMU.TE8"YM[-UCNC-)&<,&"L3N/KGBOW3_X*K?MZWWPE\*0?"?X*:E)J'Q/\
M0WK:7?6FG/ON8(9Y!;F+9"S2;1RQ/&=P&, &OS*;P!?_ +''PGT/XX^-UGD^
M(OQ<17OOM"-]HMY-2PQ8EAN4@RGGC!'/K0!^[G[*/B']D_\ 9_\  GA7X8>&
M_&WA#3?&KZ79P^(+8W:C5KW4]JB99U5=FT3+\HR6)Y8G@+^B%O<07<$5S;2I
M/;SHLD,L;!DDC895E8=01TK^*WQO^QCXE\-^#+O]M%?B3?BY*C7H-(34G.!D
M7(C$(DS@'C 'Y5^_/_!)/]J'7?VFO@1>ZMKOG//X9N[?2DEF#;I%"RID%N3G
MR<_Y% 'X;_MI>$+?P;^W1;^-=* @U&ZU_=),GRL2UR,Y*X)Z^IZ 5_6#^S[J
MESK'PB\&:A=N9)Y]+A9W)))(1>I.23]:_E<_;J\0Z3XE_;/M/#.BSI<:Q;^(
M-DEO$P=U*W0!!C!)YP>,>]?U-?LYV-SIWP<\$VEXACGBTJ'>C J1E%/0\T >
MWT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %?G/\ \%2/^33O&'_72+_T!J_1BOSG_P""I'_)IWC#_KI%_P"@
M-7JY'_R.<L_[#</_ .G(D5/@EZ'@7_!&_P#Y(9+_ -?,O_H;U^RM?C5_P1O_
M .2&2_\ 7S+_ .AO7[*UT\3_ /(^S+_L(?\ Z3$5+^%#_"C^7.7_ ).5\'?]
MA*T_]&QU_3YI/_(*TS_L'V7_ *315_,'+_R<KX._["5I_P"C8Z_I\TG_ )!6
MF?\ 8/LO_2:*O5XN^#*O^P:I_P"E1,\/M/\ Q+_TE&A7DGQL^#GA/XY_#_7O
MA]XOLX;G3-<L9K-WDC61HA*C)N7() ^;)QSW%>MT5\8=!_#Y^T7_ ,$L/V[O
MV+_'GB'Q-^P/=ZXNF:S>RW,L5BT_E*))&D 58\*!R1P.@YS7BVB_";_@OU\7
M[FV\-?$2[\41^$;Z=8=4+&[4>1*P27.3_P \]PX_#W_OLHH _&3_ ()D_P#!
M,OP_^RG8+\2?%<+W'Q1UR)9M5FN8PTJW,B9F9V<;@=['&<DD>V:\@_X*^_\
M!,+5OVJHK'XI?"B*6U^)V@H+FPDLE*3/>V_SQ.3& 2695.<\GCGI7[]44 ?P
MR:#8?\%NO _AZ3X6W$GB5C;0)HNCO_I6?L !A3#=.(R>GX>E?K;_ ,$M_P#@
ME7K?PV\:1?M0?M'6\]U\;YKM+XO?1EYA<,QE+$R#<%5^ISGD8YK^B:2TM99H
MKF2WADN(<B&9XD:6//\ <<@LO4D8/!)(P2:L4 ?S;?\ !P)_P3L^-O[>6G?
MFW^#\5S(W@?6+>[U86Z,P$::K+='=M!QB,C\*_;W]D?X>ZU\*?V;/@[\.O$0
M9=;\(^"]-T;4@X(875MYGF9!YS\PS7T910!_)=^V)_P2P_:(^+7_  6!\ _M
M:^&8+IOAOH>MZ?=WLB1L81##=+(Y+8VX"C!Y]?>OU:_X*S?L>^._VE_@S9)\
M);K4+3QYH1D6Q:P=TD,44,?V8?NSN.'5_ID=:_7>B@#^(KP=X<_X+)_"WP*_
MPM$GB.]L;6RNM,L/M!NY T,JF)0=Q(.%_P FOMG_ ()B?\$W?C__ ,++E^,G
M[5EC+!KT=T+^R:: HQ._S5P649.1QG/.*_J6DMK>9TDE@AE>/E'DB1W3_=9E
M)7\".>:FH _'+_@K=^P9J7[6'[/]WI7P\MF?Q[I-O*NCM''NE+1P+]F"[<MD
M2)^&1BOR6_X(U_LZ?\%4/V??&%_\-OV@'U@?""R@EBTN.Y$XA'G+)"V-_P O
M,80=/H>E?U[44 ?SE^(_^">/QDN_VN;+XJ6D4_\ PC<.M1WK,$;9Y:SB1N<8
M'I[#GTK\YO\ @OUX/;QK\7?A/\.!(8M2,6F1;E.V02,(P@&#G.['Y5_:;7\T
MG_!5']D;QW\8_P!JSX=>//#EG=7%CI%QI3SO%&[QJ('C+;MJD#A#G/:@#\H?
M /PX_P""LGP)\+Z)X?\ @3<>()? ,\%K=PF(W#)M\K"8*X &QSTQVQ@U]A_L
M!_\ !,#]HWXH?'6W^-W[8L>H7ZPZDNI0PZHDDJJ\<BSD(LV1DG(&".>,BOZB
M?@%HUQI'PK\+Z/J=K"MQ8Z;:6\BO"H)V01K\X8')!4XR.,D5[8 % 50%4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** /PQ_X*[?\ 'SX%_P!ZW_\
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MHU& B.BJ .G /:I?M]E_S]0?]_%_QK^6S_A/_P#@I'_T+^M?]^9_\*/^$_\
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MH^WV7_/U!_W\7_&OY;/^$_\ ^"D?_0OZU_WYG_PH_P"$_P#^"D?_ $+^M?\
M?F?_  H_U-J?]#;*^G_,1#^[_>\W]WDP^L+^2?W>G^?]75_ZD_M]E_S]0?\
M?Q?\:/M]E_S]0?\ ?Q?\:_EL_P"$_P#^"D?_ $+^M?\ ?F?_  H_X3__ (*1
M_P#0OZU_WYG_ ,*/]3:G_0VROI_S$0_N_P![S?W>3#ZPOY)_=Z?Y_P!75_ZD
M_M]E_P _4'_?Q?\ &C[?9?\ /U!_W\7_ !K^6S_A/_\ @I'_ -"_K7_?F?\
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M_=Z?Y_U=7_J3^WV7_/U!_P!_%_QH^WV7_/U!_P!_%_QK^6S_ (3_ /X*1_\
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MTI)J^JMHW]WDS2.(5E^[GLNC\O\ /^M+_P!2?V^R_P"?J#_OXO\ C1]OLO\
MGZ@_[^+_ (U_+9_PG_\ P4C_ .A?UK_OS/\ X4?\)_\ \%(_^A?UK_OS/_A6
M7^IM3_H;97T_YB(?W?[WF_N\F/ZPOY)_=Z?Y_P!75_ZD_M]E_P _4'_?Q?\
M&C[?9?\ /U!_W\7_ !K^6S_A/_\ @I'_ -"_K7_?F?\ PH_X3_\ X*1_]"_K
M7_?F?_"C_4VI_P!#;*^G_,1#^[_>\W]WDP^L+^2?W>G^?]75_P"I/[?9?\_4
M'_?Q?\:/M]E_S]0?]_%_QK^6S_A/_P#@I'_T+^M?]^9_\*/^$_\ ^"D?_0OZ
MU_WYG_PH_P!3:G_0VROI_P Q$/[O][S?W>3#ZPOY)_=Z?Y_U=7_J3^WV7_/U
M!_W\7_&C[?9?\_4'_?Q?\:_EL_X3_P#X*1_]"_K7_?F?_"C_ (3_ /X*1_\
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M,/K"_DG]WI_G_5U?^I/[?9?\_4'_ '\7_&C[?9?\_4'_ '\7_&OY;/\ A/\
M_@I'_P!"_K7_ 'YG_P */^$__P""D?\ T+^M?]^9_P#"C_4VI_T-LKZ?\Q$/
M[O\ >\W]WDP^L+^2?W>G^?\ 5U?^I/[?9?\ /U!_W\7_ !H^WV7_ #]0?]_%
M_P :_EL_X3__ (*1_P#0OZU_WYG_ ,*/^$__ ."D?_0OZU_WYG_PH_U-J?\
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M4'_?Q?\ &C[?9?\ /U!_W\7_ !K^6S_A/_\ @I'_ -"_K7_?F?\ PH_X3_\
MX*1_]"_K7_?F?_"C_4VI_P!#;*^G_,1#^[_>\W]WDP^L+^2?W>G^?]75_P"I
M/[?9?\_4'_?Q?\:/M]E_S]0?]_%_QK^6S_A/_P#@I'_T+^M?]^9_\*/^$_\
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MH^WV7_/U!_W\7_&OY;/^$_\ ^"D?_0OZU_WYG_PH_P"$_P#^"D?_ $+^M?\
M?F?_  H_U-J?]#;*^G_,1#^[_>\W]WDP^L+^2?W>G^?]75_ZD_M]E_S]0?\
M?Q?\:/M]E_S]0?\ ?Q?\:_EL_P"$_P#^"D?_ $+^M?\ ?F?_  H_X3__ (*1
M_P#0OZU_WYG_ ,*/]3:G_0VROI_S$0_N_P![S?W>3#ZPOY)_=Z?Y_P!75_ZD
M_M]E_P _4'_?Q?\ &C[?9?\ /U!_W\7_ !K^6S_A/_\ @I'_ -"_K7_?F?\
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M_=Z?Y_U=7_J3^WV7_/U!_P!_%_QH^WV7_/U!_P!_%_QK^6S_ (3_ /X*1_\
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M^WV7_/U!_P!_%_QH^WV7_/U!_P!_%_QK^6S_ (3_ /X*1_\ 0OZU_P!^9_\
M"C_A/_\ @I'_ -"_K7_?F?\ PH_U-J?]#;*^G_,1#^[_ 'O-_=Y,/K"_DG]W
MI_G_ %=7_J3^WV7_ #]0?]_%_P :/M]E_P _4'_?Q?\ &OY;/^$__P""D?\
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M-_=Y,/K"_DG]WI_G_5U?^I/[?9?\_4'_ '\7_&C[?9?\_4'_ '\7_&OY;/\
MA/\ _@I'_P!"_K7_ 'YG_P */^$__P""D?\ T+^M?]^9_P#"C_4VI_T-LKZ?
M\Q$/[O\ >\W]WDP^L+^2?W>G^?\ 5U?^I/[?9?\ /U!_W\7_ !H^WV7_ #]0
M?]_%_P :_EL_X3__ (*1_P#0OZU_WYG_ ,*/^$__ ."D?_0OZU_WYG_PH_U-
MJ?\ 0VROI_S$0_N_WO-_=Y,/K"_DG]WI_G_5U?\ J3^WV7_/U!_W\7_&C[?9
M?\_4'_?Q?\:_EL_X3_\ X*1_]"_K7_?F?_"C_A/_ /@I'_T+^M?]^9_\*/\
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M 'O-_=Y,/K"_DG]WI_G_ %=7_J3^WV7_ #]0?]_%_P :/M]E_P _4'_?Q?\
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MD_M]E_S]0?\ ?Q?\:_.[_@J-<V@_9.\7[YDS(\1BPZ_-\CYQSSU'TYK\??\
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M"/R8O^>4?_?"_P"%'DQ?\\H_^^%_PJ2B@"/R8O\ GE'_ -\+_A1Y,7_/*/\
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M"/R8O^>4?_?"_P"%'DQ?\\H_^^%_PJ2B@"/R8O\ GE'_ -\+_A1Y,7_/*/\
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;>5%_SSC_ .^%_P *DHH   . ,#T%%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img75897552_8.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_8.gif
M1TE&.#EAR@?8 O<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
MS#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F_S.9 #.9
M,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_9C/_F3/_
MS#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S_V9F &9F
M,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,9F;,F6;,
MS&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D _YDS )DS
M,YDS9IDSF9DSS)DS_YEF )EF,YEF9IEFF9EFS)EF_YF9 )F9,YF99IF9F9F9
MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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M- "KM"JKM4JKLQJKN'JKMJJKO7JKN0JLO$H?PQJLNFJLN^JKQ*JLL_H "?
M?;D9##B IU4*=9ASP$(MW'D7HZJJWLI(]B-*WSJNCB$($( %V]H9CQJIYC00
M!'@\;0(/?;-OSY&;CM&MY)JO^KJO"FBNZ&HMQQ-&DSJM DA?Y? $ 34B"6N0
M(YJN=8&O_!JQXU,/P":Q%DL49?  #Y"LR]JQP?JQ' NRORJR'ANMI4.IUE8Q
M5:*GIC=CLV*!HEJH%SNSYV,_GO^PIC1+KOY !E7RHKN$LM<6',/E1?"0"$N*
M&!";LTJ[M$S;.CO;L^@$M+UFJ853%F>57W/V!()2>OV#)_3A5E:1M$WK;_Y
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MEE3)%B%VR"=(I\:(V5([4L<KD01Y0G38TR/N5K";3(8<ZB!'.,#QRGTJ!1J
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MB.\K/8P!(CUHI524 >)@$[$XL==I'B)#'DE3,X@)L&](Q5X,"Z J!7=8OG+
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M3RGN0)%R(JTG3M'EX*!,J$;6Z*/'_Q6H#>?WU/B7O?_:^O</]MO\Y[;\ 9"
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M:X\4"6D8JA]]DM'CFP.N X<Z<+C9KL4O6B%1OQX7_ Q%@P"! @'V=)S%'WV
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MY2A?N<M;/E[UVCFS+,\SS^AD#BNM12KE4/!JA=?:XJ#5/4Q)QY__\]L/^\T
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M5&X" /H E4D5E5-).VQ)0C0155K)5!=1E6B)E6C)E<?TD4R)34=$"EX&$8)
M#UY4+_UP*="@;P\V8$,1;(\#B'PDDQ+7(8RYE$V9E*2)FJ99FJ?)-ETU4JMY
ME(NIFCN59,?F&99I.#"9FJS)F["YF[XYF\'9F[])G(4EF\.Y3*&3#_CX7/KP
M"7L #RVI#_4 #^L@"#69FZ^%G-L)G-Q9G-XIG-TIGG$E#)<@#.#96,<YGC:%
M*54U%>H0C@+H1O+2;=FCF]#A;N647SYR1"N"_T.)81$8XD7WY$7D5D*8@B'\
MP&@6H2"U@23RX"5SP20<D0][(E&AL2((HJ"F81%N,J!^\I\E<9<'PB D6J"M
MHQBA@YOAT:$X-# ^TB-C9(9,Y44KVDWNL ?L]IWKB9X\ZJ,["J2159[#T*.,
MI9Y!*D'] 0T"F [D( /H@)#[I@ZE<SH+6DG:F1V!<71Q)!#T58I^81'S 8!$
M07&K &M24CLQMB#(<*:FX6[]-W)I!"($\PQP8FP>MJ6*L2+X@(^P:!1)\)"1
M 13K((Q+T0]+JHTLD /HQCJI=*CW@&[;I:"9\0P/YA#A\"HIYB"E9@Y/@ "]
M0Q:826X,RGA;,:FER/]M@!:>2/JCJ^JJ1?JJK0JKV'2DL4I,_[1 7> .JM8%
M[>!DB=&@^YF=U>4<JFA L)@,YF D/D9Z*"&,8NI[^.%-7B (#;(.V+@.#7=R
MCV$6SLH3H/$G<PHZ_- )I&-%7=DB6[&BIN&0]@$:0*$.&$89+%(EAE>*9=<Z
ML,,FYYH9_]<"O)0:5]=*FH&#.><%Y.:H'EA"LLJPK.JPM@JQL_I+Y7F>#=M;
MM2JQQE,6VM<;&[HXG^D;_P<%[3!\L)A/"F$.Z:"R3Q OH&82ZA8\4^&D%/%,
M[5DC^.!VA5@**+D.74" P@8[_,6LH".G\#1X)Y$24F9AF<0/= (%5WA&9)'_
M$>C D(D!%/P58D]$16DW$ZHX#N2@M%*[#O CK#WAKP#+%.] .I86IJ0TL!"9
M#Y[ .T-X&((&!:SVL!D;L1:KMWW+MUPS#)WPFGG[5QC[M];331"Z:3-@.O=0
M(PPR0/IP;EX&!0E7#RA*-_<I&ZH890L[&3AG#GC;KR Q [@$&=:@#WLP%$IQ
M#YZ0?T7A#E<P"-J'*<A@C<)30OT1KD8KJ'9J=B\XM+GV#%6VNIUQM7G2&1F2
MKA(B@V Z)_0!JOVZ"G20J0'KML&62D2R#NM !H4&D57X9[7IMX1+OGM;ON-K
MOL5B0^B[4H9[OLFC0_R #_AP#PM7(YB;.2!K'&*Z_[H,RB#UDA_E  7T$Z"4
MV9Y[,L#X!1F*!CK\>:H<>I<F(29^4B]LM*Z:L2+00,$<Z@\"VI\UHJ'U A0V
MT0H#T\$FP4;[.: K8J4 BB0E*J#W2S !BL(>;* ^TL$F:J(B)BZ  )_8^;Y!
MG+[L>[A#7,3@D@S",+A&;*1\>,0\VIX'H@_X\+^6P4;WE ]3+,4/?!N:VQL#
M1 H-MY_BNQ3XR\3[$CKT\ XYZKEG3,1"_,9N_,1PG!O"(+AQ3*M.3,<85#[P
M<&9I%D?X8 HE/"!BXI+0]1(-92"D@($7AQ[ZB\=S+,=[/,F5',F4C$U)=<D4
MY;Z6W#QLL0XT0!3/0 ]=</^NUN . *BJN.)A7*B\5S!ZX7%HL"7)FVS+M8S+
MF)S+D ,-GD +C:3$/J%4*"0,I4#,0U02]4#,QHQ"4B5LR=!(S"P,C83,53G-
MQ/P)2LR7T$S,U P9@='-VGP86X5"QNP)P\!7@)'$V=S,<DD3UXQ"0!6BPQS/
MXIQ*RAS-S9QKXE+.UUP/)63-P%S,(^7)<=7)MQPVH5,[I)80XR #"]%WV'LK
M9?%]I'A :BR4Z_ $"N$%E\L8^A 7[P /02G2[B /)?T.YL)@S6$2]-0"01"U
M$33"9Z)W 9,A8T85:%:VQ_9M*4N35KJD*^86OOI,JN0.5)&RW$8/^^E]ZX#4
M+,;_=/6)T 5-U5-MU;M\U;J<-P>-U82#F7N !9:VHM8P#WMPG3NM'&4!=_"Y
M+JU!1D\@73'--P!"R[[1THTGU\*+6N6PT?7!MH !93-+!O*P!SE:FQF"B>F&
MHXC@?>KPM0Y-$?F02LD0NUVPLPM1:81<IU5B=AGB#JG*:('1<*H3H0)%+[GA
M;N00%A:&#J9:MD Q>6+M%1;"'S@'$W]':4Y7AJ8%$J54/^I  UF;U57=U5I-
MW-^9E=)4W,<=65QMW$*SR.3@#0?H#0>G8-8=#M^  %L!Q-:A(.3&1C;<(QF:
MPF+"/Y6&UJ0!R6Y-@7@-.DX+!>[W+TA[!>@'")*&CJ0$_T]YG4,LXB(BUQB=
MM*\LH2EI<2=^,1\X@@Z?S9EE^DZ=.6.29ID*,N$+TCILERC,.F,;-L8B @5@
MVVI^JA\Z0B2#@6.N%D5A:R#N.3IJ"-NYQR/BN]S#3>,S;N.,U<N[H)8U_MP1
MY-S,C3=,10\Z2C[/X\6N<=<S(M>=Q (<.!:B4PXYL&)Y87NM#$]9UW/9+0.T
MA',ZAQ&.)F[W0 ^Z&"(Y:'LCG"?S$7KAH*QP)!EO>J$640UPLA6)@ _Y<.?U
MF^=9+,+W+<H\C$!Q(B5 H0=1H@^/AQ0AGBFM3< 9DHFBE1 E *<+W""J0L@N
M7%7N$BDMW..=#N0W_NF>SN.A7O\M/S[J'K/(G1H.T^T-!P .!_BI$@T]ZXWD
M%)@E.0 /]W9N@F *'N$@O",/\("$3MUM1E8AY0 7]& [62([_.UJH\"#74L[
MG6J$\[!O+!@I_NV !Y[F09$ 6* G:U+?H^H3G93=C&OM[G 0H(H;/>P6[J#&
MZT '.DV)_),.<"$//EP5C>H95%*U_V+;I&@9:MY$-7WJH'[PHH[PYX$D2&55
M0752/I*51H54/Y2%1X7Q2!6B/X3Q1F7Q9-&7R6!5]#!5"Z_PZZ7'I*X\S[ *
M\<H3UJ#L]&,-[:#*Z2TW1SXRXB<[,NXS<-Z91Z-?U9E.D+AI7B#<^2%@7*80
M YQ+3.'_#GK0!>0T%0)'MR:O\E:?\%=_\EK/]=IAZEAO-#6"L( -D/!)IB^)
MI2F3'_S$3\I*6F._-W(4.S\/]EN?]7=?][P%#;O@"<J ]W9OD5\/^!IC#?F@
M!_W[0CC_]UV?]XOO^(TO,ODPS5,Y^(P_D8)O^3VCBD_ #09G<-EM<"Q@)YM#
MZYG_^)5_^J8/^3/#\ZJ/^BV'^:F_<HJ_^JYO^[)?^[@_+?HPS7Z?^[^?9[$/
M_&CL#\O)Q1Q4^KI_^\.O_,U_E(<:EB0!S;Q0SVEY&"?42,#\ESV1Q,&0_<5<
MU$D,S-Z?#)W7_8UD_<RO_MTE_*\O+0<$H0:)#DE-I0">OW3M__SNO_SZG_\1
MV\O! !#0  #P-Y"@P8(#$QY4B-!A0X@,)2ZD^'"BQ8H1,U[4B-%C1Y <16XD
M^7&DR9(A4YY4B=)E2Y@L9:ZD^7*FS9HQ<][4B=-G3Z 'LPT=JBWH3J0_>2Y-
M>E1I4Z9/I0;MU^_>/#WIS)E3U^6=O*SIO"2:Y=1L5)6SUHUK-Q7M6ZAQW<H]
M2Q?N7+QU\][5VY?O7[N!]PKV2QCP8,2%$Q]6W)CQ8\.1%TMV3!FR1VC"=@F\
M7'GR9\^A.X^V7!HTZ=.F1:N.2K3HZM2Q8<]&+;K:*G(LRGFY-\M?68+^^ODK
M"&V5'B^"?,N&K#9<6]JLI3.?'IWZ=?_KV6MOK\X=NW?MW<5_'Q^>_'GSA:'M
M\L09_/OR\-'+3T_??GS\\_-[=IW-Z'W] JQOOY/XT>>9>:!HX8I$\M$'GU;R
MR6<5=:!@$#@" U.++0$!'+###$$4\4,2/30QQ!)1/''$%5-D4<7 H.%%&/="
MS&PS%W-L<4<87_11QQZ!]*B__X+D\<<CSQHN'WQ*@2>=&=I!Y)Y[ZL&G'BIG
MX>>Q?O@I19TGR EGG'!DN&*0?# $ )I2]"AG3'*B3&3+HYR#+DD\C=03R3V%
M]#-//@/]LT] !Q6T4.YD;$]$:#S!$5%"(SU44D,KA=1'(BVE]%(A"^)GEGX.
M(N[3X4CUA]3_Y43K9Y5.RIFAC.&>T0.*L8"KBA1RH"BCK*3:X5#328,%=EA.
MB]WT6&&-31998IGE,1]A+MDEF5#[H4<8;#W!-AA/D@DNF6RQ%4;;>CP%5]MP
MA?$6@'Z207=<>/-I=EEZY[57V7N=K2A3?/O5-[8N2TD.U'Y*:4<==]9I9YV$
M%^["G3G5;,P?9-39K17?K"&E'!:\F 5#?Y[)HQP:$$DU'W<67CCEE=M1.9QP
MW*G7WYG_S;=FG&_6F>:=;>;YY\@4K3%GH(GV^6BCDS:OG@=F:(4_UXI4NNB>
M3>J2%'.^"0><K<?A&ARON_Z:!7*\P-@Q!/6XPHM'"DHHY%DO'*@?_XVA0&=7
MIC:\$^FJ^Z;Z;[X!GSIPP@<WW.\89QP:\<,%9_QQQR,OZ!X:KGCZ,GX+AUQS
MF?H!]510^8&FGGDB]LN:X\#AYH!PR'F"3!E>W;*XX\KA.LZQZ,Q[G><:Y_QW
MWX/?7'C)B0=^>.0A$]IXYI,_OGCG1:3<::B)DCIZ[/LU3@\6KIB'E'7*R0$>
ML+H8BW"]FX=^_>?;5]_][.%G__V:UZ.1_OCQGS]^+?O_]'__!1"  Q1@ 0EX
M0 ,F$($+5& # 8@(&LP@$:&23.;T)[]-&:<=5U"./^ZAMG7, Q#IH!59>F:G
M"Z8P?RO<7PLQJ,)+G>H9T% &-&8X0_= P_^&.ZRA,D+%+G[<D(;02(8.#Z+#
M(M:PB- @#KOTD<0=SI!._M"A$&O(Q('H(Q]"?$8^="><*@X1BT<DXA"3P0\*
M$J0?,U2B$1<21C:BT2!=:B,.'8+$(3YC. ?IQQ/-Z$:%Z+"-3"Q('Z$H1'T$
M,H\['*,6K4A$?K@-AB]D(24C)P@(>,R22:&<Y:KW&A=.DE[\(*7$@):^2HHR
ME:L,)2LWJ4K&)&,7GTBC*V'Y2EOFLI6[Q*0F;^F03EZN@E'3)2YWA+ITM$ Y
M$8%&.^@@MU/R;F^_+"8U=VE,;%J3DK*DY36U^<UJAM.;]^IEJL9YDND)$S$6
M%&<V:5,5@VUE'+K_.=@ZTG$P=:QC8.A;RS3;"<YSNC.@ !5H00EZT'\F=* *
M74DY#=J1>D10G8IAYT(M&A]HY*,4@NB-\U#(4(1>-*0/%2E(LP.N4M2RI"LE
M:4M'^E+'.!2FAZFH2TWZEUN9(T[K@,=7W@$/=\!#$*:+YJ]8.E.;'O6F265J
M8F294J5&M:E+16JR/*>/66!5'ZW0:E:SRE6O:A6L7=TJ6;]JUK*&]:M>R*0Y
MIXHY8DJUJDZ19*F6(TE^]HZJ>Y4K7]_ZU[GV5;" ]6M@R^.%&7BAL,.KJ6&1
M&C) S*$<Y4"'.=(Q67/,0!"MX*=1"3M8QRX6M**%WQ/S(4G2AG:TJ_TL_V$0
MZP74LM9PC4TM7Y^QBG;L(!$6*9@>(&9*?7U4MK4=;G%;JUJ;/56EQR4N<XV+
MW(^\-K;.+1QMGUM8-NE!3*X3TSQKU5E_7E>\U(5N<\L+'BKND;SF9>]XYRI=
M]U;-NNLM;B3UH44#&:A+33RA-,]+7P#_5\#M)4PR@D&M^"8XP 1&*'P77+3Y
M#GBEQN'8%<A #](A L/SF!)G$5.0^]9#'GDP1PO,-D=^;$QK8WK=/!FT7)2@
M4L$2?G"-T4-%T>4XD0LA)31R#(T]*H2*^O Q-(CL$ ,5F<AO4Z.2?3P[@Q3Y
MQTT$XX]SK#LI.WF._3"RDZMR1");62"%%+/HOO],D"S_V" ]_O&2W3;D+".Y
MS804%9>M#.6!I)G.<^-RF)]\1UDBV,8,[MLLKM"T"$)@!HE>] P4S6A(.[K1
MCY9TI"E]Z4EGVM*:KG2G,;UI4'N:TY\6=:A)?>I1I]K4JBYUJU&]:EB[FM6O
M%K6B$S%=&@<JPH1>:9?>P4'@?L9 ]VA%59!A#AGHX') ),4,L+!;P AWT#/F
M];2MG>MJ8YMGL\ "#>I!;7!?.W^[#C<LKV:.,(V#'.,HA[KG&04O?"HT*39'
MQY;-CU7D89Y1"BHBL)H1?;QC90QK1\)2UC"8R2S;"R\WP^5"Q60DLN$3%S?%
M\\)M"'R[XAO7=G7CRG'_A:+.'5@81+!A<RJLL4#9)GE&*9[0O0E&Q5?A!;G%
M'=YQA_CCJ;B^><]M_O.$<-O;0,>YSY%%[IH;$W5Z^ 8)#L UK7T#'-]@@;U-
M'A5_6",9>GB=-[[A#:[-X,46L8:L8 [CM/2SZ$0W>M&IR.2VQYWM#<>XQM>>
M]+OK^N-YE_M.V*1OL(6#;%XP65RDS?>YX[UJR9"6HSJQ"VDAN%V0W\7C'=4M
MA0CC\8^/_ _7)$MI67Y=!.%'M-@#^6!\._&(5[S@\J$#23=-T;*? >UM'WO<
MSS[WM=_][14-@03HX!ZK[SOK X1TX^>/YX"3<>N=GWSB1__YQ1<2/F /[>E+
M_Q_ZV40^]=<'3ZZ[+G9EV!(TWD$'LUW]6(?W?O;=SR=_1&OT[V__]E]J?0G6
M7__:'_?>]V])XU@'&E".:J@'=R"_=JF0].LOS[*__W/ ^XB_3I@_"*0__I,K
M_,.^"MS !Y0O_[O 5Q*.58"'=5@'/4"'<KB"=K@UYO.O#@1!#I0/'5H<&'Q!
M"S2H#+3!&+S!I.F^&OR;EDL'&B@Y:RB%.>B>>7 '!3R;HJ*Y'7Q"'=0+<*'
M*/Q!'DRE'+1"*-3">?'!*_R;JZD"L/N&Q&J;-3F_S5*_26$_+FQ#&RN54WD[
ME8HD.CR5B8C#.O2\0L)#.Q2R.HRD+PS$O)N>"0(50__T'$0\1$5,1$9<1$=L
M1$A\1$F,1$J<1$M,1$&LPDRD&2_<PDW\#;731$]4K4;9!7KXQ%$41;U()U5T
MPU1TQ8[HQ%;,H.,8AV\@$[%I'<WRL/[2*UC\1?HJQ61 Q5E\14Z*( TL1F4$
MQ@V416;<F57Q+1-J0F.LQF4DQF<L-U;,1FSLQE%T1F^TE.VQQ; !F]O9Q;QR
MPFNTQ@ESE&%DQW#D1F!"QG6L1WDL/G"$1R2I%N$@F-&A!Z(ZFN;31WM$D<RP
MO%W0C$L0!HE[!L=+R,K;A5(8L\R0%LUP/&'8(W<YO8<L(H( O<V(1Y$DR(/8
MQI$L2)+$NWQ$R1+9GNZ1!T#_L)@<^"D],!\6] Q/N2N+L*]26CZ:8,.3O$</
MT8=Q\9:@/,J4#!!"9$FA1,J;6\FF[! - C8/ B%Z< <2JA7%R"Z=*@=O.#N#
M0!U/, <&*8B6RRR/J9-0C$I1+$5Y:1%]X!:C3$JF=$KO,$FZ9$N]M#&HM$L"
M&8ZMTD, Z#%\@)#?\ S4.<*QRSI20 >K4XA^( 42TX'=ZI4&K,L-;)1@>$N_
MS,O.S)^EW$O/',W4ZDO2?(_;$L*28R9W>*9IE(S$!$O&=,P%5"-D<!/*9(B
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M=O&-?D0CK!H.S_')91G(,Y6[JC"P8) X,,U3,V6(,2W3/_\-U$(51#4%5*B
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MDQ$N9&<I.^ZI7IVX7D5V"(?\U!918N$[9!(>9$R.9$Y6ED3>9/OX.Z\A$Q:
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M.3Q4.2BD(H*#-WS#/@&-994"P+*B_&3+=\S .YC59T54N2 D*\(-6Z1)/;)
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MG_WP7__\W1]_^]-?_O4GK;)II(W^_[]& '!M!-#_ M  !_  "Q !%U !&Y
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MO]O>P)FL,,8VZ\W66KX OV-H]2:34F3P">$(!PO,X06<> 80Z$!X.&2@CI%
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M5N[0C*O0">9 : 9"#^;PDT\P#HNYF.' F.,0#M[P#?"P(1B7!^3PF.! #NA
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MV$@&N'J4<B:LRPQ>K47%A;G(SV!LB.89<;L.5E@%YL!P^*J$C-%.V$B3\AS
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MU$"]?+.L'#E:4*>Q2+@+M$.9H;]A8S:DVE+Y!-] #O[ZPZL+F_R<$IKM#0G
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MZ#/%ITH<J']^78I>J(,:*(+JYRYDEUTT:'T&PS2AYWI"I(\&:4,.Z6N(IA<
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MWC.2S\QI3A!Q!2_,1J=$]:D_C[I3I!95J49-JE.7^M2F0G6J=['D,?^OJL
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M;5<[V^/V=KB[7>Y*AT/;YB8WN-TM[G>W>][IEG>]XXUO=-L;W.N^M[[S_6V
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M6@H[ZAENF9YP*:9O2:;ZR&+RD ?E4&,,]F'6H ^_A0[KL Z"D ]GIIYC&J:
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MA8>/^@6"%&#DP (&C<PUW:\_2U5QQZJ/()&7*Z?S\%MZX.-3<;JI"^67\=M
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MO?(^YQ9OU5"5\9<L#QYP[Q$;?V^Z_08$0$#Q,KKXUG,%(P4YD'_Z[Z]J.#J
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M=%,W=%OW=%^W=,MHG5+57M?U=_NU=X<W7^<U>?_UVP**-97_K7@'-EH7B:E
MQ>G89'F#]UT7":_$=[L(]G[3MX;Q2CHX%C6W]U_SM]?^!2FL TNU:WT7.'LW
MN'D[>'\/>(03N(0_.(-;>(97^(93^'ZA=Y?$VH6/-X;'1NSDMRZ+^(1/KI8
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5F[ +V[ /&[$36[$7F[$;6[$# @ [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img75897552_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_9.jpg
M_]C_X  02D9)1@ ! @$!( $@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" /?!R$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+REQ%=,'@(P=GWE4CN>QZ?3/UJ2Q25(L.Z-%Q]G"CE8NP9NY_/Z]J +M%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 (3@$^E1ER1P,>^:D8;@1TSW'6
MH=H08!)/7M@#T_K^-"5]$3*48_%V[=/Z0WIZ\_4_XXIPSD8Z]J7(!/&1VSCK
M3&D"8/()R#@<?E_D9Z8H:MN#Q$;-*W72WIVOW_!CG0X/OWS]/7U]OK6=(KH^
M1WZXP,]ZNR23  QA3D#[^!C--RS 9"[^^",8]L=_8=,>AP6EM>Z7Z>7?Y7.:
MK*56$H0^)_#9.Z?K_70BC9R.IXQQU ]?K@?XTYY,#)., _GCD_AU]J9-))&5
M\CR=J9-P\K;50=L$\#\<C(/UKP/XE_'[P9X&26S6>XU/7&!6"SL(C>(TW( ?
MRMQV[^IQTJ)J-GK97T?6U_3JCJP&$F^53O/:Z?V;VM=N_P!_H>U33K]G<W$Z
MRH-S%G95V*#GN0<#^@_#Q/QA\>_A=X"CN(]9\06GVN-6Q98=F9P"=F4!Y]QG
M\Z^9&T7X^_'Z[%S?,?!WAUI/EDTF[EL[AK4$;6>,E27=.6!S\WKV]8\.?LD_
M#ZPEBFU+5-3\4ZK$0TPUI5NH3)U.7D# @G/.?P%<TVU:RLMD_P#@=^^^ZVT/
M>BL/02C4D[Z<T8_9O9I-JS2T^)<O3U/([[]M6ZN[N6#P%X$FUBVWE6G@DD0.
M_.TD,@'/;\2,5@WWQL_:J\43!O#/PBU:WA=04GBNA\H/\6".F/45^@VC> /!
M.A6\5I:>$_#]J8P 6M[&W!8KP&<A,[B1Z_3W[."WMK8C[+#';J%VA(0$3 Z?
M*.#CW!_6L^6K-IINRMHMTM^UGUZFD.(<'A5*E'+\+5DM/:58N4I;:R;NVOOT
MTM=)'Y06=Q^VSJ&M[M0T_7M+TZ211<0M(C((^XR#GO[<_C7<>)-*_:P730^B
M:GK<<P7Y8XRN21U'/^1V]*_27SITE).'5\*P8D@ <\#M]"/7ZU.,;MW)!Y"Y
MXQ_GV_"E[*H];R].VBWUMMVZC7%E#_H68%;7M3:3T2>EMUT;O9*^K1^4VA^*
M_P!M'PY;2-J'AC7?$95GV^9*B;N./PX_+/)JA)^V'\;O!=[#%X_^$>HZ?"D@
M\Z[FN&90H)RQ"*V<#GCCH,5^MH92,,HQZ<X_3%<MKWAOPWK#VZZGX?TS5MSX
M<7UK',,$=]ZL#U).5(XYQC%*5.K"S4FO>Z7757T^?E>UD=-'BC#252+RG!-5
M(M-^RBVEI[R;5U9:7373H?$GP]_;U^"WBO5$TGQ#K%KH6I,Q0V\XG^60]069
M5'4\G)SZ8%?:GA?Q'X?\16K:KX?URVU"PE1O+\IXR"2,J1\V[&#W'M[5\R?%
MW]B[X/?$MPT&CVGA2_E20_:]!L[>TG60]&$BHIW9/;GZ9X_-_P <_LZ_M5?L
MI:K)XE^!.MZGX\TN F:72/$NISR6B6H.^1H[=&P75!A %)QQFNF>)E1HMU'>
M/?[OEHK:6O?T=NF."RC-:"5/%U,+B:D4UAY*U*RDMK_-<REYZJQ^Q_Q2NC!X
M)U+7$N6CO/#]M-J"HOWI"G1>#D9P /Y]*PO@C\5M+^)GA5+G39TN-6TF-(;^
M%6!DBG8D%7!YZ<\\<=:_/'X!?M]:!\6[^Z^$_P 6K%_"/Q$:,66LV5]:/I^C
M2>9E$6UNKO:DS-QN52<9' Q7*? ;QU?_  8_:E\6^!S>02>"?&FMW5TE_P">
MK6]I#;H[1K;R*?*5&.!P<8QCIFN.EG-%).34E*:@];.+LK)K;;?NKKH=5;@W
M%X3+ZSC0<W[.GB(5*<>?GHS487C.*7,U4T:>JYKL_9U6$"A[IMSLXP#U0DXV
M\>A../<^E6I)H8MA>Y6)9" J$K@]..3].<?2OF#PS\?-.U*]\0W&IW.G0>'=
M%DU!_MLLT:RR"S9F C+MARZCY0OWB0!DX%>#>$OCGJ?[2_Q*GTKX>C4+;POX
M?N$FOM1GAELHI8$D\N;R)B!'*VX9 !_.NY8B-91DE%J6R2N^FNGJ[;)?>?-+
MAG&9:I5*U.<*:@JG.]$U))I6DOC5O>OK'2^CU_1E"VXD,64\@\],=L_4=.O6
MK:;B.Y]/7'^>GY5C:5]GM+86$,LUP]D%CDGF!)=L $AR?F]R#^-;$<F[!Q@]
M_?GD?YS^!K6$$TY+MU_K3;?NM.IXE;%P]I[*VM[76[M;?2WS7W]Y@QR,GC(]
M.E2U7<_/QMP<=Q_D\^QR<YJ<<@'U JVDDFG>ZU\GI_F:-647W7]?F+1114DA
M1110 4444 5W1I3M=<(.3G')'(/^';UZU3-Q!-*]J)@)K=?-<]-J#N3T 'KG
M%.NQ$)%+RS*W4+&"0?3./\_K7Q?^W=^TKX:_9/\ @'XS^)6L7:6FNZMHNI:%
MX2B<JJ7/B!K-WL8LDAMS.T8;;R,@@<4 ?9R+'('DEG6\@<= RLL0]?D/U!YR
M#R<56*W(<06\6V-QO2ZSQ"G3:,^H]_IVK\DO^"1%S\<_'GP7OOCY\;M8NI$^
M*=M)>:1H\NH27-KI=O;7<FY[>"5B;97A0C=@!FR,YXK\NO\ @MG_ ,' 'A+]
MF;P;XE^ '[+EKKGBS]H2XNUT\7$6EW<VBZ7'%,8;]9M3LRZ6LT2EG59&5F*Y
M&!D4 ?U<Q+("-I6[;C-T'4]",H=I(!'U' Z4WR9Y;DM]O!6,YEL@R-A0#\K[
M22,G'4 5^'G_  ;Z_&?XJ_'W]@FS\??&;7+O5_%>K^--9>XNKF_DN[BV$Y21
MK-9I6=XT@D(2-#C:,C'!(\5_:A_:/^./[$'_  4&^&$_B/5+S4/V>_C?XRM]
M)N;O4;V:9-)TZ!4\^6",OY,7S.5R0 <=^30!_1S))' HD8^7#C##' 8\#('.
M<D8'%2VZ.B?/*9<DLK$8PIY4#V Z5SVAZ]I/B72M+U[1+N+4M#\1VD>HZ?=@
MYBEMI$5DE0G@!@P(&>#D=JWH655PA+*"1\WJ.H'MZ<8]!0!:HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*^UV,3Z=X6OUU.UMY!E+DG!:, @J^>!AAC'IQ7YI_P#!3GQ%=Z!J7P_M]-U
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M']&_@/XJ^"OB98ZMK'@&_P#[4&CZC]@N)MRO DI/*12(6#1XZ8.,9[5^2O\
MP75_9"\0_M(_LW^$O'7@^Q@/BKX%^*X_BC/<0X2YEL_#\/VL0!T'F2+NC("
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M@]_P6T\6:A^U-\9_V?OV&OAZ;F[E\2>,9=$^)IAW&VM;&\$+1&65,HL?R?\
M+48!SWZ?TT/% D)EMF9CMPV')+..JKS]XGC%?+>B?LE? K1_C#J'QRF\-7=[
M\1=?NHKBYU&YG-PNE36YQ'-Y<A8VXP!ADP??%!F>C?LZ?"#3OV?_ (!_"[X+
M0R-Y7@'PIIWAY'M2&0FQ0+NW( I4X&,<'!/?GWRS\WR0)1R#\ISDE.Q/OZU5
MDN4BN8H4MY9UN59S<KAXT(& &;!Z]L'ZU<MUF5")W21MQVE!@!?X5/N!UH L
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*K9Z;L@8[8!/7GIT)(KR;XD?%7PU\%O#EWK'BJYAAM$25K2:9DWR3J"PC!?
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M36ZZ:K7L.+Y6GV=S];HHXUM[>YB.Y[I$D#D<[)U#K@G.  W'Z^M?B%_P6O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH_N&^<_9RBEE2.-L@C#9&  >F>,^]?RY_P#!P+=QVVK?#>ZFE6%H]+O/]&)
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MDDAB'EKD;P,8&>.OT&:8C^H'7/%_ASPW:JWB+Q%IVBM<*=D%],D4DAR!M7+
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MPB[0^'?[^OS_ ")R,@CU&*:H(X)'M_G%.HI$C<-GKQZ8_P _SIU%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\'>,-%\17^F7LZW-SIEXDT99@JCA"<%2-O3G!XK]-_@5_P %5/V;?VX-/O\
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MW8P=H'OQC_/M4U=T(RBK2WW?W(^8;3U7E]]M?Q&,I)R,=,<T8?U'^?PI]%4
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MS[XUB58HSL13D J?Q_3''8<9J[10!A3O=03?8[&%)=ZF9C/DQ@'[RKDX_P"
M^N/QM1,[1?-$$N""%11^Z5NQ4=L^O/'Y5IT4 5D)2,O*#O4?O0GW68\9QW],
M_P!:A6V5E*,@,#-YV"6W!P=P &<#!_EZBK]% &7(7G#M*&$$8R57.X[<YXYR
M<9]_;I4#>6\(>:-OL[<VY529D7/<#E3W[?J:VZ3 Z8&/3% &>T++"ABFGQ\I
M +L#L&,@\^G;G\J<JESN@A2-'^5Y,%9",\\C!/XY.1^=^B@"BL15F2%Y!@_/
MN9NIQ]TD_KV_#E4C10Q4L3N.[=]TMCT[\]#_ (5=IKGY?J<?U_I36Z]5^9,X
M\\7!:<VGXF7):!R7E8@-P O3(![<#TQ^1[XHW.GQW,84AW6/C:^2.O\ "#CO
MV]_3IN4Y0N".!TQ^OY^]7-*2?,EHVMNCMY]K=/N,Z+J87%4JD6TXQLFM]DFK
M]$[_ *^O,PZ=)#"P@1(HLY<)\I9O7;CG/?IQGGK6A:PYQ*V<IC('0X/IQGUZ
M8ZBM-AD%>/KU!Z?IQ^M(J[1BB"2BVEJVONT7RMJ]O/URQ$*F*S..)DWI3Y;M
MMWLT]7=N_>^_FD11 M))*,A7/ /7CN1[<_SJRGWA2IU/T_J*EJ96YG;;1?<C
MLEO;M9?<D@HHHJ1!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %,*#<6'WOT_'^M/HH K3_:=N8%B+@<;NGT
MYZ?_ %ZH3)>-L>(@7@(!4DB Q<;^>A..GU%;%% %/RHV91\T;+@E4^5<XYX'
M'Z=Q5>*&5+BY,_S+.W[@CYB@QR#UV^_K^-:E% 'AGQ>^ /PP^..ER:3XY\/6
M&H#;L^TO9P2W*H.H621#@'N.N0.]?G-XE_X(F_L;>+-9DUR;2]3MY@-RP006
MJ0)(ISOV&-202,$!1Z@FOV#V,=QB/EG/)89SWR/\_P!*:N5)!7S7[E, 8_H>
MQ]30!^-6B?\ !#K]C?1M:/B.2SU6XO)&61H;B.S-JK+QB.-U) XP3CUXQ5_Q
M_P#\$:_V/_B#:R366DW]AJ.G6LUE;BWMK:**64IM1G7R5+@GG<I;'((P17Z]
M7-J]PDWFH5PN8FWKB,#DLP#<\9)KYU^.'[3WP5_9^\+W_B3QKXY\/:5>Z99R
MK!IMW>QQ75Y<[&V(D1()9GP ><EL#)S@ _AU_:\_9>\0_P#!//\ :>\-0>%I
M7AM+G6]-N=,2W<B>3S[E7@&(P&.X8Z9S[#!/]O\ ^R#XK\1>.?V<OASXIU\2
M)KVK:5"][]IW+(I52BA]YW#Y54Y;U^E?S267@7XI?\%8/VPM.^*M[X=OM%^$
M/A#4+&73-4OK0G3;YM&NEV);S*@1A+$H* Y&,8&:_K$\.Z'IO@/POHGA/2HT
M6&TM8;54B"JBE(D5B    2N>F?SX .L+L[QK%&AN4&&9@,$C.XAN_?G)_+@W
M%,X+$K'Y2IG"CDN!D\?_ %^M-@\I!"@($GE_4YQ^O7\AUXJQ"K*A#G)W,<^Q
MZ4 4I8GN_(=<HB,2P'#8]AP<U FGQ+*T\<T[2*2=LC-MXZC&.W3WZ>E;-% &
M*RRW$@NK4%=OR2(_RY"_>(4XY]/4<]<5=6-/*DDPZF1,-@?,,8R!WZU=P!T&
M** ,U[>-H5?,B!0!\G#/[OCJ>>_:JYTTQR"6&5]@ 8H6/)')XZ9/?VXY-;5%
M &)(8'.\B<2'A0%.Q2.,CT_S[T]('2VE29I)!.P9026( P0,<X['&1[YK7P/
M0?D*6@#,:*:0(ACBPJJ5;&& ' !/;..1FG002_:)GG2/8ZJ%"@$9'YCI_GTT
M:* ,H6TEN\\H9O+=LA5)RH/'R@9QVX[>N*'LU)4J6F=@'\N<[HL'DD@C&?0<
M^F?75HH R3:HQE#H(=B;CY V@^W &2?Q'ZU7%C#$T3QR7!:7)"ECM]PWICW_
M ,:WJ,#TZ=/:B]M>VOW$SCS1E'NK&+=6[80@9&Y=V,Y)!'\NO?MTX%/ETZ&2
M3S)&<%T5/E)[#M]/S[_76) ZU$S9/MV]:%74DG?\'TVW3VL%.3H0Y8RMI;1)
M/IM_GV]$4?LQ18XD9C&G&23DC_:/^<\#H"*E1"&6/G;@GK]?;V/J:GHINM%+
MSM9.]WT\OO\ ^ <ZIRJU>:3;UZOH]_F]=?/8<A'F,@YPH.?KC_/Z<U-4$9;(
MX()//';(_3Z_RQ4]2I<VOR_!>IU./+[JZ?\ #A1113 **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **JSR2J%:
M( KN ?/IW([]/\BH/[042LACD*<!6"DC/?)':@#1HJ(2'(+%55AE03@XQ[_U
MI-[$ED*M&H.2.3D#./\ /M0!-150SNXB:,!5+?O=_&U>_7I_]?\ .V"#R#D>
MHH **09R<XQVQG/XTC':-W8<GUQ[>_MWH =15:.5R69P-C',8498#_;'8G(-
M2LX5=S,JY. 2<#)Z D]_ZT 245&K,,!F3)/3/)] /7(^M5/M3EIXPA#(0$+#
M"GZGZ?YSQ0!?HJ*$R,F9"I;/\)R![''&:EH **#GMC/O1]: "BBJ_G;)-DA'
MS'"E>0O^_P"G/&3Q0!8HJC=7T=K \[*TJ*XCQ"I=MS'"Y /3U(J-;J>.W4W"
M@W$N?*5%R &_U>\=B.-U &@RY''4?K4+1,QST_+_ !HB=Q$GV@HDS Y&<#/M
M4?GR-N5<*X8!6;A"O?DX'T]?RH I7NH6.DPL]Y.8% )9@NX[<9Z '_.,U\W_
M !'_ &O_ ($?"B">7Q9XI>WE@#$QFRFD)89SRJ>O!P#D?G7TK=V%K<J?M">:
M64!@P#+SUP",8/;_ !Z_.WQ#_91^$?Q.G^T^)M,>=B2S(D<(1MW4%7B;.?<G
MUYH _.SXK?\ !:#X.^';*ZL_AAIDOC?Q-(&BTW3GL]2@229\I&2Z1A?E<@X8
M;2>&R,BOS=M_@+^V]_P4]\86NI_&:'7/AU\'X=434X-+CNS<6-S;QS!EC:"1
M@P$L+!2".F>,FOZ(O!W[&?[//@>XCO;#P!X?O)X""DFHZ/8SN&'((<P CD9S
M^.>*^D-/TW3M.MH[71[&VTNRAQM@L(4MHMJ<;-D01< 8&,<_I0!XC^S=\ /
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MGM0"",B@!:*C=F3YL J.H[X_SD_AS4+O,)8F!C2V()E,A"OG'RXSTYZ_A[T
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MQYL9VR8Z;O;VJ>@ HII)!'N<4Z@ HHJDURS7!MD&UT 9V<$(RG'",>K#TZT
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M# (]">?KP=:B@"N)"05\F0 # RI[<#J/ZG//-0R/(OW89#]%)^@^Z?Y5>HH
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MP:L44 57GD! 6&3'<[&_3BCSI/\ GG)_WP?_ (FK5% %<2O@DQR=.!L(.?\
MOD?U_"A9GP=\4F?9&_H*L44 5VE?'RQR _[C?U'^??I5)X)GD$R!HI^ TI4L
MK1CJ@3. << XZUJT4 9\ID4CRHY&9L"5S&RAA@#N./>DAB\E]\4;HKY:56!9
MF;L1D''?I[#TK1HH JN\A'"/R>/E)P/RZ_7_ .N'QLP&&5_^^3_A_G\34]%
M%:25N0L<A'J$8_T__41U--1Y-OW'!SW4C^:_T_\ KVZ* *4DDP**(W)<X#!"
M0A_O.0, ?7'M[TI6>5_LUU9SS1D\W"*VP8Y!X'<CH.AQ6U10!4("QKM61XTP
MHC\MU?CH<, Q ''3W!J:-RP^9&7_ '@1GZY'7_/6I:* $(!ZBEHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** &$MN&.G';\\U#,7!^56;/
MHI/8=P#5FB@#.DEE2:)5MI7W*<R@'8GLW&.:E92SD,\O"[F18'"GO@28V,W^
MR&+>O>KE% &/.D*A$6RN9([P[)V5'W0*.C.@!<9]A[BK(@41*(M\1@ 2)S&[
M-L[CR\!SUQG&?R-7Z* ,]B$195MYI&+!2-I#9Z&0KDD+GGD=>?K:#L!RKMD<
M$(1CZ@C/?GZ&IJ* *VYP<[&SST4GK[;:SM2FD6!'%A<7K+*I$,2L'!'1^ !@
M5M44 9 (O(X;F>VN()8#O%NT3ELCHN0 &S[=JE>>=(7F2&9Y'P4@$+AU'0AC
MM(![\D?XZ5% &1=OBUAEETZ>=S+'FWB!=T)(S(VS/"]3T_E4YANC<--]I*VY
M5=D'DEG0@<YP3S]!GZGFM"B@#.C=]TVVWE3YO]8R,/._V@",@>Q QGD8J17E
M!R8Y/^^3_@/ZU=HH J-++N0>7(1D9(1B!]2% _SU%2.S9R%8^G!X_3OZ?_6J
M>B@"L9)!_ Y^BD_^RUGNUS+=!)8)/(4@JXC;@^^T=O?\ZV:* ,ZXE:)7DALI
M9Y(_N*H*[\\<;@!QUYJJ\LQ51)!<3+)AC&L$B>2YZ MMPP0\D@X_"MNB@"FJ
M2")5F9I),Y#+&> >B$\=,\DD?I56ZEDA$>+.:\R>!&A'E?4XY]\<=ZUJ* *T
M4SLBEH9$) .QE;*_[))'4?Y]H'$A8E4<#TV''YXZ?C^/>M"B@"ODH(\(['N
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M[_P4]_:L_P""< _9"/[,>M^#-'_X7*?C]_PF_P#PEW@S3_%WVG_A7G_"E/\
MA&_[/^WRQ_V?Y/\ PG.O_:_*W?:_-MO,Q]F3/9D62XSB'-<+D^ =&.+QGM_9
M/$3E3HKZOAJV*J<\XPJ2C^ZH34;0=Y<J=DVU-6I&E"525^6-KV5WJU%;M=6N
MI_2I17XH>%O^"G'C'X4?\$5O /\ P4O^-GA"'XL^-8OAS\._$WC3PIX6N['X
M?6_B'5/'WQDT'X5HVF7']EZY9:)!I@\36FJ-"--NQ<QZ=):AHI;K[3%Z9_P2
M=_X*I>'O^"J'P]^+7CS0/@UK7P9'PI\9Z)X1NM*U?QG8^-3K)US1'UF#4+>]
MLO#WAO[&(?*EMI;62TGSB.9+D[VBCWQ'#6<X?!YEF,L*IY?E.95<IQN,IUJ+
MI4\=1J4Z<J<:<IPQ$XN5:DXU(T.1JHKM-244JU-RA#FM.I!5(Q:=W%IN][66
MSTO?0_6.BOY9_P#@KO\ #3_@N7XE_P""@/P U[]@SQE\1-,_9_CTSPA'X73P
M+XXC\/?"KPWXTM=?@;QQ??M->&/,M;7Q5X?<G3-0CMO%^C>.- N_"$=YIGA7
M3YM<;Q-HTG]3 Z#/7O66991#+\#D^-CF>7XUYMAZM>>%P=;VF(RYTIPC[''0
MLO95)\]HKK.G6C9QIJ<W"HYRJ1Y)Q]G)+FDK*=U>\>Z7Y-/K9%%%%>,:!111
M0 45\S_MD?M(Z?\ L@?LO_&G]IC5?"EYXXL/@YX,N?%UQX2T_58-$O-?$-W9
MV4>GPZO<V6HPZ<9)KV-GNGL+SRHU=EMIFVH?@'_@D?\ \%@?#O\ P5</[0(T
M#X%:U\%?^%"CX4F[_MCQ[8^./^$E_P"%H_\ "R?(^S_8O"OAG^S/[&_X5U-Y
MWF_;?MO]JQ;/LWV1_/\ 5H9)FF)RG&9Y1PDIY5E]:E0QF+]K0C&C6K3HTZ<'
M2E5C7FY3Q%%7ITIQ7.G)I*34.I!3C3<K3DFXQL]4KMN]K+9[OH?LM17\W7_!
M?;X>_P#!73QI>?LWW/\ P3D\0_%VS\ 6&H:W#\1=&^ 'CR3P#X^;Q]++%)X8
MU/QI>V>I^'-2U/X;MHJZA:+:2:W>>$;?64GE\8:5!/+X7NY?WR^!=K\5['X)
M?!VR^/&HZ-K'QQM/A9\/K7XRZMX<2WC\/:I\5K?PGI$7Q#U'0H[.QTNTCT:]
M\7)J]SIB6NF:=;I92P+!8VD06WCTQF40PN497FL<SR_$SS*>*A/+Z%;FQV!^
MK5.12Q=*W[M5E[T+V]UP<7-2;BHU.:I.')-<EO?:M&5U?W7UL>IT445XQH%%
M%% !1110 445_*Y_P<#_ /!67]L/_@G7\9O@!X*_9IU_P-I&@_$3X8^(O%'B
M6'Q;X%TSQ9<2ZOIGBI])MI;.YOI8I+2'['A)($+([J).&SGVN'\AQW$F9T<I
MRZ5".*KPK5(/$U)4J7+0I2JSYIPIU))\D'R^X[NR;6YG5J1I0=25^56O97>K
MLMVNK/ZHZ*^:/V+OBAXK^-_['?[*'QH\>3V5SXX^+O[-?P,^)_C.YTVRCTW3
MKCQ7X]^&'A?Q5XAGL-.A+16%E+J^JWDEK91,T=K R0(2J U]+UY>(HSPU>OA
MZG+[2A6J49\KO'GI3E3ERMI-QYHNS:5UT1::DE);-)KT:N%%%%8C"BBB@ HH
MHH **** "BBOYT_^#A'_ (*5_M0?\$Y?!?[,.K_LSZKX-TC4/BMXG^*&F^+9
M_%WA"S\6B2S\(Z5X*N=)BT^*]N(H;(F;Q#?O=2+'))-MMU5XUC<2^KDF3XO/
M\TPF48%T5B\9*K&BZ\Y4Z*=&A5Q$^><85)17LZ4[6A*\K+2]UG5J1I0E4E?E
MC:]E=ZM16[75KJ?T645\,_\ !-'X\_$/]I_]A']F?X_?%>[TR_\ B+\4?AW#
MXE\67>C:7!HNES:I+J^JVC-9:7;%H+* 06D*K#&S#*EB2S$U]S5QXS"U<#B\
M5@JSBZV#Q-?"U7!N4'5P]65*HX2:BY1YH/E;BFU9M+8N,E*,9+:24E?>S5U<
M****YAA1110 445_+/\ MW_#3_@N5K__  6$^$OB/]F#QE\1-,_8]CU+X3/X
M7.@^.(]&^ >A>#;+1[ ?&>R^/W@U98M,\1Z]=:Y'X\O[&XU[PWXMUZXT'5?!
M=CX%OQX@L-+TO1?9R/*(9SB<1AYYGE^5*A@<3C57S*LZ-&J\.H6PU.23O6J<
M_-&-K^SA5DE*45"6=2HZ<4U"<[RC&T%=J_5^2V]6EI>Z_J8HI!G SUP,XZ9[
MTM>,:!1110 4444 %%%?QV?L._\ !:C]N+]H#_@M#;_L4_$#7?ANWP%N_C;^
MU1X+.BZ+\/=/TW7H?#WPJ\$?&;Q!X.M(?$K7ESJ7FV=_X*T$7=U,\UQ?P0W$
M=S(YN9'/O9/P[F&>8;.<7@I8=4LCR^IF6-]O4E3F\/2IUJDE04:<U4J<M&=H
MR<$W9.2O=95*T*<J<97O5ERQLDU>Z6NJLM5W/[$Z***\$U"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5I"6$7B#4)X-1\;>,-.\2^*(O$ND:3K/AKQ!^5G_  =X?\G)?LC?]D/\9?\
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MEC_U1O@6OMJOB7_@FC_RCD_8!_[,I_98_P#5&^!:^VJ_F;-O^1KF?_8PQO\
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M_2RHHHK^;SU@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5^LRITVJDE!595/:MM151RT4F=%.=OK_ #2M:4^6\MOXB5KO3HE;R\C\QO\
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MFI[+#NS6'H2=>I&>'A[DH*,&K12*H047C6G*]/VL8^\]O?5WW:Y5KW/Y[O\
M@W6_:K_:A^-WP7_X*IZK\9_VD?CW\7=3^'GP5^&^J^ -2^)_QA^(?CZ_\#:I
M?>%/VD+F^U+P=>>*_$6K7'AF_O+C0M$GNKS19+*XN)M'TJ6:1WT^T:'\@O\
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M  38_P""DNK_ +87[7FL_&_XD7?[.7QD\>?!/QSX<^/WQU^)7B'X8?\ "+_
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M%?6;77+E=.N+);B.2-?XO/\ @U(F6X_X*8_%:= 0L_[(OQ3F4'J%D^+WP*<
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M-RE4J?5:56I93YN>4)I\W*_=3G%M-VLGKN[N[L?+/_!8GPO_ ,%.?V>/A[\
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MX>ZM9ZGZQT445^)GHA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXMG_ ))'_P +3_X2S_A:?_"LO^JG?#C^PO["_P"%<_\ 49_M/^V?^8=_9_\
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M\)'Y6H7]_P#VA_PC7]O>)_['W?;O*^R?V_JF/*W_ &D[]B?C3^P[_P &_/\
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MP?V3_:WV/[-J?V#[5>?MC^VO^S5_PV'^RG\;OV8_^$T_X5W_ ,+D\%S>$/\
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M@;>&VU[4"]JLZ132-$TH81!3[[\// /A#X4^ ? _PN^'VBP>&_ 7PW\(>&O
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M_P#!23_AK;^V_P"T_P!HSXR_'_\ X4Q_PH7^S?(_X6YJ7CG4/^$2_P"%B_\
M"Y[_ ,S_ (1__A-/)_M[_A!8_P"UO[-\S^QM-^V;+7(_;1_X-XO^&O?^"A'B
M3]N__AK[_A7O_"0^,?@OXL_X57_PH#_A+/L?_"H?!/P\\'?8/^$X_P"%V>&?
MM'_"0_\ "!?VC]J_X0^#^R?[5^R?9M3^P_:KS^E2BO8AQSQ33QE/,(9I;%TL
MJ624ZOU'+GRY6JL:RPOLWA'2?[V$9>VE!XC3E]KRMIY_5J'*X<GNN?M&N:?Q
MV:O?FOL]KV\C\'?^"O'_  1-N/\ @JMX_P#@YXU;]J*;X%6OPC\&Z_X4AT!O
M@X_Q1M]9N/$&M0:M<ZS%<GXM?#R/1YC':6EE/ EAJ#W:6MO))>(L,<*_D#_Q
M!X?]9$__ #4?_P#*<K^V"BM\L\0N,,GP.'RW+<W^K8+"QE"A0_L_*ZOLXSJ3
MJR7M*^"JU9WJ3G*\ZDGK9.R22GA:%23G.G>4MWS35[*VRDELNB/QX_X)(_\
M!)FT_P""7/PT^-?PVO\ XX6_[0MC\9O%.B^(;VXN_A/'\.+32[32] N=!N-&
MNM)F^(?Q'AURWU*&Z=YI);FPC6/=;26EPKF0?E-^TS_P:H_#;Q'\4[CXH_L8
M_M,^(?V9X+O7;G6(/ &N>&M5\::9X-:Y@0JOP_\ &VF>,?#GC#2+.SNUN1;Z
M=K;>(KLVNH+%'X@M8],2#4/ZX**YL-QOQ1A,TQV<4,UG''9DJ:Q\OJ^$>'Q:
MI4U1I>VP3P_U-NG37)"4:$9P4I\LDZDW)RPU&4(TW#W87Y-97C=W=I7YM7OK
MV[(_EO\ V%?^#8OX._L^?&3PQ\?OVIOCKJW[5?C'P9K-GXD\,>"'\''PG\.H
M_$.C/C0-3\:/K'B;QCXA^(,>CO;:=JNGZ3+/X8T1+^S@T_6].\2Z+#-:7W[>
M?MZ?L&_ K_@HC\ ]5^ ?QTL=2@TYM1L_$7@[QMX9;3K?QI\._%VG;TM/$/A:
M^U.PU.RC>XLYKO1M:T^\LKBRU?0]0OK*18+HV6H6/VI17+F'%?$.9YEA<WQF
M:5YX_ N+P5:FJ>'CA.27-%8>CAX4Z%--VY^6G>JDE5<T5&A2A"5.,%R2^).[
MYO5MM^FNG2Q_%W\*_P#@T)T#3?'4-]\9OVTK_P 5?#G3M7M)6\/?#WX.)X0\
M5>*=&BOB]U;7/B/7?B#XKT_P?=76GQ)"&M-"\6^1<7LLD<^-/C.H?=O[&?\
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MX*/?\&_W_#P3]L>V_:T_X:T_X5)]GT/X>Z-_P@'_  H;_A/=_P#P@9!^T_\
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MOB!]J^Q?\(-_9_\ 97]B6_VC^U/M?]I0?8OLUW_1!17/7XQXCQ/]LJOF//\
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MG?9K/[+]ON/E_P#X)1?\$$?^'8?[2_BW]HG_ (:M_P"%W_\ "4_"#Q3\*?\
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M'_#K7]G_ ,>? O\ X75_PO3_ (3?XQ:O\6?^$I_X5Q_PK'^S/[5\%>!?!_\
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M\Q=I/A?_ ((]_P#!&[_AT_??M WO_#1O_"_/^%ZVGPPM?*_X5#_PJS_A%O\
MA6\WC^7S-_\ PM#XC?VW_;/_  G.W;LTC^SO[+SNOOMN+3]NZ*\6EQ!G%'*\
MPR:&-E_9V:XB&*S"A.EAZL\3B*=2C5C5GB:E*>*C+VE"E.7LZ\%-Q?.I*4^;
M1TJ;G&HX^_!<L6FTDM=.5-1ZO='\\?[2_P#P06_X:)_X*@>'_P#@I%_PU9_P
MA_\ 87Q6_9U^)W_"F?\ A1G_  D'VK_A06G_  ZL?[$_X6)_PN'1/(_X2S_A
M ?-_M+_A!9O["_M;9_9^L_8-]Y]Q_P#!6'_@G'_P] _9L\-?L]?\+D_X4?\
M\([\8?#/Q8_X2_\ X5Y_PLO[9_PCGA/QWX7_ + _L#_A./A_]G^V?\)M]N_M
M7^VY_L_]F?9O[-G^V_:+3].:*Z'Q5GTJ^2XEX^];AZA2PV3S^JX+_8Z%&$84
MH<JP_)B.6,(KFQ4:\Y6O*3;;:]A2M47+I5;E47-+WFW>^^FO\MD?A?X1_P""
M+7_"*_\ !)'Q]_P2S_X:4^W_ /"<:T=7_P"%Z_\ "G/LO]EY^,?AWXM?9_\
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M_"AOC]\#?CE_PWI_PE?_  ICXP_#/XL?\(O_ ,,N?V%_PDG_  KKQIHGB_\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y]_P#!2O\ X*">#O\
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MH)\-?A_X;\.>-/&B?#<^-?!/@_Q=X$\9_";XA76H#P_9Z=X]\):SKGB&/4M
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M5*?/.--V4HQG*,923G#FQIXFE4ER+F4FKQ4HN/,NZONM^VS/UCHK^./]N/\
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M/@/;>(O%_B3P/\5-;^*5MX(\??#7X7^/OB!J,5YX>^+NB^'[S6-)C\7^(?\
MA'([;P68T@M-+M[RPU:Y2XFO>Z_X)L?\%I_V]OV]?V^? /@[Q+^SMH?PH_8M
M\?GXI'PWKMC\-/B#=WDD'A[P1XN\6>#-/U?XRZUJC^$-9\43C3[ :JWA_1-
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MJQ4G3E44)N/-4QBDZ2HR:YJL8RYH6YHMVNKIZ>:U77='^FA1117XP>@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 445^7_ /P5>_X*:> O^"8/[.L'Q3UOPZ?'WQ,\=ZQ<>#_@
MY\.%OTTRW\0^)(+%K_4M<\1:@!)=V/@SPG9M;7.NSZ;:W>H7=]J.A:#;+8G6
MVUG2^S+\OQF:XW#9=@*$L1C,755&A1@XISF[MWE)QA"$8J4ZDYRC"G",ISDH
MQ;4SG&$93D[1BKM_UN^B75Z'Z@5^!7[/7_!?3X0_M$?\%#8_^"?'A_X _$C0
M/$\_Q*^,OPXM_B1K/B7PQ+H+3_!WP_X]\0WVJS:%9)-J$4.MV_@.Y@M;5+V9
M[2;4(#-/,D,C-^)OP0_X.-_^"L'BS5+S]H?Q%^PYI/Q0_8T\+ZKJ%O\ %'5_
M@Y\#?C9#X?\ !FA:1:6=SK<]M\;Y=?\ &'A/0O$OAVRN++6-4_X3$7&C307D
ML%Q8>'K?4M-U'1_SZ_X) >.O#_Q0_P"#ACX;?$KPE//=>%OB!\<_VO?&GANY
MNK::RN;C0O%'P=^/NM:3-<6=PJ7%K-+8WL#RV\Z)+"[-'(JNI _6<M\-*F!R
M[BO$<18>A7J9=D&,QF75<%F'M:>&S##8;$UI4<2J$X-5J7+1FZ->+ISBVX.H
ME/EX9XOFG05)M*=51FI1LW%N*35UL[O5:^FA_I645_.S_P %E?\ @O/X9_X)
MP:[%\ ?@MX%T;XM?M2:AHFD>(]2C\83ZC#\+OA7HFL-]KTR;QA:Z%?Z7XC\5
M^(];TV(7&G^$='UGPNEGI>IV'B34?$R(MGH.M_C=XD_X.#O^"TW[-M]X2^)_
M[5/[$GA#PW\&?'4BOHMKXI^!'QH^$&A:VFL6EQJ^F:7X.^(^N>*-:@M-<M[&
MV:Z@T[6H/%&I'1$N9K_2I)9(-5MOE,J\.N)LWP.'Q]"C@Z%+&QG/+Z6-QM'"
MXG,(PBI<V$HU'S2C).\)5'3C*-JB?LI0G+>>+HPDXMR;C\3C%R4=;>\U^E^V
M^A_=O17P#^SU_P % ?A9^U[^Q#XA_;%_9ZG-W::3\/O'>KW?A7Q99SQZCX-^
M(O@CPM=:UJ?@7QE965U;-+-IE\EHMQ/I.I"TUC1[NTU31M3:RU"TO#^*G_!$
M;_@N1^UE_P %)_VN?'/P#^.?P]_9W\*>#_#/P$\8_%.PU+X3^$_B5H7B6;Q!
MX>\?_##PK96=Y>>,/BWX[TN31I=.\:ZK-=6\.C6]Z][;Z?)%J$$$5S;W?D4.
M%,ZKX3/,9]7C0APZU'-:6(FJ6(HS;G'DC2:;G).G*]G;9IM-,T=>FI4XWO[7
M6#2NGMUZ;H_JIK\Y_P#@IU_P45\'?\$R/V?_  S\?O&_PW\3?%#2?$WQ:\/?
M":#P]X5U?2]%U&UU#Q!X3\<^+(=7EN]7BFMGL[>W\#W5I);HHG>:_MY%8)%(
M#^;7_!=W_@L!^TM_P2_\5_L[:%\ O _P,\7VGQ<\/>/]6\22?%_PUX^U^YLK
MGPKJ7ANST]-$?P7\3/A_%;031:Q<M>K?PZE)))' 8)+=5D67X)_X+J_'SQA^
MU)_P05_89_:&^(&F^&M'\:?&#XZ_ OQSXETOP=9ZII_A>QU;7/@9\?;J[M]"
MLM:UGQ#JUMIT<C%;>&_UO4[E$P);N9OFKW>'.#,1B<5PKCLTHTJF1\09F\%"
M-/$RC7J>S^L*I&4:?+4I+FP\[24KNRZ,RK8A1C6C!M5:45)W6BNX]]'\1_2=
M_P $[?VX/#G_  4-_9E\/?M->$_ 6M?#C0?$OB/Q;X?LO#/B'5['6M7A/A+6
MKC0KJ[NKK3;6VLD%W=VD\D$$/G%;;R7DE$LCPQ?<M?YW/[ O_!6K]MK]GK]@
MSX:?LQ?\$]/V4/$'QV\:^ M1^)/CWXY?$E/A!\5?B]I/@&T\3?$'Q%JVC>'[
M/P]\/HM.L]-E'A^'3]:U7Q;XAU?4M)-GK;:3:Z1::GIL^IQ?J]_P20_X../'
M?[2_Q_\ #W[)O[;7P^\%^$/'OQ#UV_\ #WPT^*/P_L-5\*:1_P ):L;2Z?\
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M?@WXE:7;VZVTT4SPW,/@KQA<2SSV0M],\&:@8IYIY([&[_,C_@IO_P $@?\
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M\LI?BIX9^'OPMTRT:\ECB/\ :%]J;ZW\0KJROX98X3%;:BQBE^U1-!^Z?_!
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M:5^&/!&K?MM_M >)=:BTJZ\=>%?V<KD^"8+Z6REU"RT_7/B#X1L/&&N:/87
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MIC,MF\EH\$C>?_\ !-?_ )5EO^"I/_9;OB=_ZJO]EBOWZ_X+#_L ?$CXO_\
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M<*MJ;J*<8+EJQ4JC:E%-7U7DM+:I.ZYG]N[_ ()R?\'"/_!1H_#:;]IKX&?
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M@$J52E'!RY)3]DY.<8KF:YI*5M.UVNUU:]G<^H?^#OO_ )*+^Q)_V)7QD_\
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M9.I"'L^:-6[NIV[*E.3QD9*+Y70E%SY7RJ3YU9RM:]K:7O:Q^'7_  :3^'/
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MQ%2DU7?L52E*K"H^3]ZL-/#>PJN:DFY*-XVYU*]UJWT22>FM[)G]6G_!#O\
MY14?L8_]DL7_ -/^LU^KM?BE\#T^,W_!-[_@APT_Q(T&U\ ?'C]FW]E'XC:B
MNA7VH^$O&%CH/Q*L-/\ $EQX*AOKS0M?U/PKKUB/$E[H+WD&G:Y>Q7EL\MI
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M53J2J3I1^K.*A'WIU86Y&DE:FVM=5;HWHVDDS^73]J3_ )65-+_[22_LZ_\
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M*7,L2L1)JI5]DHUIJ%YQE-67-IU1PT8SY_:5F[M\KJ7CKY6V737MV1_G$?\
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MI_S=_P %Y?\ @D/_ ,%#_P!L_P#;SU7XT?LU?L]_\+)^&ES\,?A]X>@\2_\
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M'?MG_MY:I\9_V:OV>_\ A9/PTN/AC\/_  ]#XD_X6Q\#_!V_6-$T^>#5+/\
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MK'?=)NSLKMV2/VNHHHK\:.\**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\=?_ )L*/^(*\3?]!67?^#)?Y>O]/0_M"CVG]W]?TGY7_P!B*BO\=W_AO/\
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M*^.O_P V%'_#>?\ P4:_Z27?\%$O_$ROCK_\V%>__P 05XF_Z"LN_P#!DO\
M+U_IZ9?VA1[3^[^OZ3\K_P"Q%17^.[_PWG_P4:_Z27?\%$O_ !,KXZ__ #84
M?\-Y_P#!1K_I)=_P42_\3*^.O_S84?\ $%>)O^@K+O\ P9+_ "]?Z>A_:%'M
M/[OZ_I/RO_L145_CN_\ #>?_  4:_P"DEW_!1+_Q,KXZ_P#S84?\-Y_\%&O^
MDEW_  42_P#$ROCK_P#-A1_Q!7B;_H*R[_P9+_+U_IZ']H4>T_N_K^D_*_\
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M !!7B;_H*R[_ ,&2_P O7^GH?VA1[3^[^OZ3\K_[$5%?X[O_  WG_P %&O\
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M_P O7^GH?VA1[3^[^OZ3\K_[$5%?X[O_  WG_P %&O\ I)=_P42_\3*^.O\
M\V%'_#>?_!1K_I)=_P %$O\ Q,KXZ_\ S84?\05XF_Z"LN_\&2_R]?Z>A_:%
M'M/[OZ_I/RO_ +$5%?X[O_#>?_!1K_I)=_P42_\ $ROCK_\ -A1_PWG_ ,%&
MO^DEW_!1+_Q,KXZ__-A1_P 05XF_Z"LN_P#!DO\ +U_IZ']H4>T_N_K^D_*_
M^Q%17^.[_P -Y_\ !1K_ *27?\%$O_$ROCK_ /-A1_PWG_P4:_Z27?\ !1+_
M ,3*^.O_ ,V%'_$%>)O^@K+O_!DO\O7^GH?VA1[3^[^OZ3\K_P"Q%17^.[_P
MWG_P4:_Z27?\%$O_ !,KXZ__ #84?\-Y_P#!1K_I)=_P42_\3*^.O_S84?\
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M_-A1_P 05XF_Z"LN_P#!DO\ +U_IZ']H4>T_N_K^D_*_^Q%17^.[_P -Y_\
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M$5%?X[O_  WG_P %&O\ I)=_P42_\3*^.O\ \V%'_#>?_!1K_I)=_P %$O\
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M  WG_P %&O\ I)=_P42_\3*^.O\ \V%'_#>?_!1K_I)=_P %$O\ Q,KXZ_\
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M[Z_@;-?^1IF7_8?C/_4BH?2T_P"'3_P1_P#24%%%%<!84444 %%%% !1110
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M*K3J5,/.:;A&M",G*E*23<8U%%R2;2:0VFDFTTGLVFD_1]?D%%%%;B"BBB@
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _AM_X/+?\
MD:/^"6G_ %^?MI_^F;]FFOXT:_LN_P"#RW_D:/\ @EI_U^?MI_\ IF_9IK^-
M&OZS\&_^2,A_V,\?^=$\3'_[Q_VY']0HHHK]5.(**** "BBB@ HHHH ****
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M[\,O'?[5W]N^!_B+^T5\$_ GC+1/^%%_LUZ9_;'A3Q=\2_#/A_Q#I7]I:/\
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M:Q2Y?K5%Q4;Q=?25*FYUJ'L8QA3I<\:MGS\R2=Y2OJFV]/)^=OR3_P""?_\
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M$5Y2ITN6E&-Y5.;E3DE:4HQNYO=)>ZK+O8^)OV_/^"'O[$'C7]@R^_X*-?\
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M4I4X0IQTA"$*^'E",%[6E-OEC*,4U%2YH*3O&][6?V>EW<_..Q_9)_X)<?M
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MXJ/LZ=5-+F2:JR<>5\RVDVEU3=[G6_M7?\&_/_!([]E_Q'\&/B]\9OCSXO\
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M445^JG$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_1S_P:U_\
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M#FJ>*[/P-INH/<1Q^)_'"W<NIW,$UO9W<-[C0X?Q1_85M_V@/AE_P5U_8_\
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M@>VM/$]KI>HZEJ,EKX=N?$UZ=+L[VWT>STO36UF?3SXA\/KJGR^+S3.*U/Q
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M#X4\8>&?B9X:MOB1X5UK5K*SO+7PKK6CJ=$OKJ6)WT_5;.3^T+;YD_X(-_\
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M5+EE!5$D[7]ZS>MK]W\S?L@?\$3O^"(VO:IJ?[*/Q$_:+M_VA_VUO#<>K/\
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MZ^(J8BJITH2ISE1EM4Y)8JMSTTU&$>6;ISG#F<8M2JJ+U2^%/1)+757/D?\
M;#_X)2?\$H?C?^Q#XZ_;:_X)=_M*PZ-_PJ/0M<U/Q%\./B!XUU>XTKQ9%X+:
MYO\ Q5H-QX?^)6FZ7\7/ OQ.?2[RUNO#D5\M[X:\5V-MX=@TG0+:V\51>-9?
MY.+![&.^LY-3M[N\TU+NW?4+2PO(=.OKJQ69&N[>SU"XL-4@L+N> 216]Y/I
MFHPVLS)/+87B(UO)_?M\4OV#/^"5'_!3O_@FS\4?VS_@!^RFW[''BK0/A?\
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M.K[*G22IJ+LXU*=:GM?FYE:=]=[::W;M?^-6BBBOWT\T**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K^C'_ (-1_P#E+GXX_P"S$OBI_P"KG^"%
M?SG5_1C_ ,&H_P#RES\<?]F)?%3_ -7/\$*_/?%+_DB\U_[@?^G$=6"_WBG\
M_P F?Z1]%%%?QR>\%%%% !1110 4444 %%%% !7^.[^WG_RD:_X*7?\ :1+]
MLK_U>OC"O]B*O\=W]O/_ )2-?\%+O^TB7[97_J]?&%?L/@M_R4^)_P"Q=5_]
M*B<.8?P5_B7YH^8:***_J<\4**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K]?/B%_P6H_:F^)/_  3RL/\ @FGKO@'X 6GP*T[P/\,? ,'BS2?"
MWQ%@^+3Z/\*/&?A/QSX=N9==O/BI?^#FU.]U;P=IEOK4R> TM;C3I[^&QL].
MN9;>[M?R#HK@QN68#,9X.IC<+2Q,\OQ5/&X*51-O#XNBU*E7IV:M.#2:;NM-
M45&<H<RBVN:+C*W6+W3\GU/1?@_\3=>^"GQ:^%WQE\*VFD:AXG^$GQ%\$_$W
MPY8>(+>]NM!O=>\!>)=,\5:/::W:Z=?Z5J%SI%SJ&E6\.I6]AJFFWLUF\T=K
M?V<[)<1_?_\ P4F_X*U?M&_\%2/^%,?\- >"O@GX/_X49_PL7_A$O^%.^'/'
M?A_^T?\ A9O_  @O]O?\)%_PFOQ(^(/VO[)_PK[1O[(_LS^R/L_VK5/MGV_S
MK3[%^7=%%;*\OQ&/PF:5L+2J9A@(5J>#Q4D_:X>&(A*G6C3=[)5*<Y1E=/23
MM8%.2C*"DU&5N:/1V::OZ-(_HC_8X_X.6?V[/V5/AAX;^#GB;0/AG^T3X*\%
M>'X?#W@_4_B?'XLMOB+I%A8W.=)T^\\;:)XA@7Q!I.EZ8[Z1:6^N:'>ZM%96
MNCQ0Z[#;Z=+;7_Q__P %%_\ @LQ^V1_P4ICT_P *_%G6/#/P_P#@QH>H)JFC
M_!+X5:?J.C^#KK6+2ZU)].\3>,M1UK5=<\3>,_$UKI][;Z>KZCJ\'A2QDL%U
M/PUX/\.:CJ&K3W_Y.45YF'X2X:PF9/-\/DN I9BYRJK$PHZPJS;<ZM.FVZ-*
MK)MMU:5.$[RE[WO.]NO6E#V;J2<-K7Z=F]VO)NQ^X_\ P3\_X+]_ML?L!?#O
M2?@IH=MX"^-OP6T&?5)?#O@SXL6WB.YUCP=;:C$LJ:3X)\8:'K^F7VC:#:ZI
M'_:$.@ZG8Z_I-NM]J]OIEGIDM]#=V7;?MK?\''/[>G[8OPS\:_!*UL?A7\!?
MA1\0M'NO"_C32_A?H&KWOC'Q9X.UC1;G2?$_@[7_ !KXSUSQ"8=!\1_;;D:D
M/".A^$-4N-*6'P_=ZG=Z5<Z[%KGX!45$^#N%ZF9/-IY'E\LP=7V[Q$J-TZZF
MJGMW1O[!U^=*?MG2=7G][FYM05>LH<BJ24$K63Z6M:^]K=+V/]!C_@DWXM\2
M> /^#:CXW^._!NL7?A[Q?X*^!O[?OBWPIK^GLB7^A^)/#>E_%'6=#UBR>1)(
MUN],U2RM;VV9XW19H$+(P!4_C7<_\'7_ /P4"?X7:?X2L_AA^SC!\2(K1[#5
M?BW<^%_%]W<7J&.^CCU;3_!$7C*R\,Z9XB3S--G>>Y75O#<ES:7Q7PI%:ZA!
M::9^&G@O]O3]L7X<_ K5OV9/ O[0OQ%\*_ +7M!\9^&-;^%6C:G!:>$]5T#X
MB+JL?C?3-0LTM/,NH/$L6MZI#J;33O++!=M LB0QPI'\C5\[E_AYELLPS_&Y
M_@\NS7^T<\Q&:Y?>%653"T:\I-T:SE&FIWO%SI7JT)2C=IM)FTL5-0I1I2E#
MDIJ$MK2:MJM[;.ST>OFS]&?V)O\ @J%^TG^PQ^T[\5/VN? =I\/OBI\9?C1X
M5\<^&/B%JGQPTKQ7XEL-;F^(OQ \*?$SQ9XJEB\&^-/ &I-XJU+Q3X1L[A[Z
M;59[ PZAJRR:7+//:W-GX[\<_P!M3XT_'7]L/6OVY;^3PS\/?CMJ?Q&\&_%?
M3+WX<:7?V7ASPGXX\ Q^'?\ A%=7\-Z5XNU?QE>)_9EYX7TG4U@UK5=:BEOH
MY3*KVD@M4^2**^UCD^5PQE7,(X'#QQE?!QP%:NJ:YJF"CR\N%E'X'17)!*'+
M:T4MM#G]I-Q4>9\JESI?WG]J^]S^AC]J#_@XY_:K_:X_9!\7_LG?%[X&_LXZ
MO;?$?P[I_AKQ]\04T3QU%J.I)H^HV^M:/XIT#PS#XV@T/PYXYTWQ#I'AOQ+:
MZH3JOARVU[2KBXL?"%G97=EI^D=;^S=_P<]_MX? CX'Z5\%_%_@KX+_M R>$
M/"EIX2\$_$+XHZ9XMC\8KI>F:;/I>DVOQ$F\,>*-&L?B-#IUC'I%F^H3VV@>
M+M=M[&^NO%GBSQ#K^L7&O0_S=45XSX'X3E@W@'D6"^J/%RQRHVJ)0Q4XPA.K
M2DJBG2YX4Z<)PI2A3G"G3A*#C"*5_6:_-S>TES<O+?39:V>EGKK=ZW;[G[\?
M$?\ X./_ /@H!\7?@%\=_P!GGXD>'_V>?%?AC]H#1OBEX9\3^)[WP3\0;7QE
MX9\+_%&SU#2I?#?@672_BO8>%-'TKP5HE]'H_@P:GX2UN\$%C;ZCXNO/%NOW
M>L:QJG@?P\_X+4?M3?#7_@GGJ'_!-/0O /P N_@5J/@CXF^ 9_%FK>%OB+/\
M6DT?XK>,_%?CGQ%<Q:[9_%2P\'KJ5EJWC#4[?19G\!O:V^G06,-]9ZC<Q7%W
M=?D'1733X2X;I4E0I9-@J=&./HYG&E3IN%../P\)4Z&)C&,DHU*5.<H044HJ
M,FN43KUF[NI)OE<+MW?*VFU?LVE<_7SX>?\ !:C]J;X:_P#!//4/^":>A> ?
M@!=_ K4?!'Q-\ S^+-6\+?$6?XM)H_Q6\9^*_'/B*YBUVS^*EAX/74K+5O&&
MIV^BS/X#>UM].@L8;ZSU&YBN+NZ]J_8O_P"#A[]M3]A?]FKX;_LL?"3X8?LN
M^(OA]\+O^$Q_X1_6/B+X*^+&K^,KS_A-O'WBGXBZK_;&H>&?C9X1T2X^SZWX
MNU*UT_[%X>T_RM*@L8+G[7=QSWUS^#-%/$<)\.8NEB:&(RC"5J.,S&6;8FG.
M,W&MF,XU(2Q<TIK]]*-:K%M634Y::@J]6+3522<8J$7II!6]U:;:+[C^GS4?
M^#L;_@HKJ>GWVFS_  8_8K2#4+.ZLIGA^'7QS658KN!X)&B9_P!HV1%D5)"4
M+QNH8 LC#(/XQ?L)?\%#/VF_^"=/Q4U'XJ?LW^*["PF\1Z3_ &%XY\!^++&Z
MU[X;_$'2X/M,NDQ>+O#5MJ.E37%]X<OKJ?4/#>O:3J>D>(M%EN-3L;+5H]%U
M_P 1Z7K'Q!11A.%.',#A<;@L)D^"HX3,H4X8[#JESTL3&CS^R56%1S3=-U)R
M@U9QD^>+4DFB5>K*492J2<H:Q=]8WM>WK97[]3^I/XC?\'8O[>/BOX<W7A?P
M1\(OV>?A9X]U+3$L+GXGZ-HWB[Q1<Z+=2:?+#>:UX/\ "'C'Q-K'ARQU--2:
M&_TF+QC'X]T>SMHI+#4])UUIA>Q?A!\!_P!N']IK]G+]J/\ X;&^&_Q+U.'X
M[W_BOQ+XM\8^)M<5-7L_B1=>.-3N-6\>Z7\0])D,5KXDT7QK>W=S=:W:R^1<
M0ZB]MKVB7FC^(]*T;6-.^2Z*>7\*<.950Q>&P&3X*A0Q\'2QL/9>U^LT9)Q=
M&M*LZDYT;2E:BY>S3E)J*;;9.O5FXRE4DW%WB[VL^ZM;7SW/Z;_C%_P=3_M\
M?$GP1H_A/PE\-OV?OA/J33Z1/XU\3^'-$\;ZU?>)H-/O-+O-3\/Z1:^(?&MY
M%X3\,^*HK75=&U](I=7\6PZ%JXB\->,O#NMV,>OS?FI_P4F_X*U?M&_\%2!\
M&!^T!X*^"?@__A1G_"Q?^$2_X4[X<\=^'_[1_P"%F?\ ""_V]_PD7_":_$CX
M@_:_LG_"OM&_LC^S/[(\C[3J?VS[?YUK]B_+NBL\NX/X9RG$8?%Y=DV#PF)P
MLJ\L/B*<9NM3EB:;HUK5)SE*2G2E*FE)R4(2<8**;"=>M-.,ZDI*22:=K.SN
MM+6T:O\ F?K9_P $)?\ E+5^Q5_V43Q)_P"JR\<U_41_P6B_X+'?M._\$P?^
M"B_@3PY\+-+\$_$/X4>/_P!D#X<^)/%'PP^(%IJ0T]?%4'Q<_:-T>#Q/X;UW
M0[[3]5T'5Y[6VTBUU@/_ &GINKZ;H]G:3:?%=06NHVG\*'PF^+7Q(^!7Q#\-
M?%CX1>+]6\ _$?P=<W=YX6\7Z#)#%K&A7=]IM[H]U=:?-/#/'#</IVHWELLX
MC,D(G,L#1S)'(G7_ +07[37Q]_:K\9:9\0OVB_BMXN^,'C;1O#-GX,TKQ+XT
MOUU'5+'PMI^JZSK=EH=O.L4(2PMM6\0ZW?Q1;25N-3NGW'?@>1G7!E'/>*<)
MF^8T\%B\II9)4RRO@*\:CK5*TL37KTZU-QBHP5-U(.,XU858R3<;:-Z4\0Z5
M&4(\T9NHIJ2M9))*S[WL[JUK;GWA_P %)/\ @LE^UE_P4XL?"WA'XQP> ? O
MPI\#>)[WQ;X8^%_PPTG6M/T23Q!):7^D:7XC\5ZEXCU_Q%JOB3Q-HWA_4]3T
M>ROXY](TFWBU?6Y=.T#33JMS'7UU^QM_P<G?ML_LG_!KP;\ -<\#?!CX\?#3
MX<^#M/\  G@0^.]&\0:'XST+PMH5I9:1X:\,SZ_X5UVPT;6O#F@>'K0Z)9VV
MJ^$[C79K9+'[5XCFCLY(+O\ GAHKV:O"7#5?+:&3U<FP4LNPU257#X;V;BJ-
M6;;G5IU(RC6C4GS/VE15.>:=IN22,U7K*;J*I+G:LWO=+9-/2R[6/Z(;W_@Y
MM_X**ZUX2^.O@OQ5X<_9P\7Z-\=KOQ;]L77O _Q)$OPV\.>+O >C^ )O!'PN
M31_C!I%EH_A72+'29M>TJ/Q)9^+-;F\5Z]XAUK7M;UMM2^SP_GU_P3@_X*@_
MM(?\$QOB/XH\:_ L>$?$'AKXC6_A_3_BE\-/'FDW%_X7\;V/AB;6'\/W)OM)
MO=)\1Z#K_AU/$?B%O#^K:5JR6L$^KW']M:1X@T\MIDGYQT55+A7ARA@\;E]+
M)\#3P68QHQQN%C2M1Q"PZ2H.<+V4J+2E3G#EG"HE4C)5$I(=:JY1DZDG*#;B
M[ZJ^]O7JMFM-C]R_C/\ \%Y_VCOBQ^W9\ ?V_;/X'?LX^%?BQ^S=X.\9> O
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M(KG5-3ND.N)I,&EZ5IW\W%S.]U<7%S(%$EQ-+.X0$('FD:1@@8LP4,Q"@LQ
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M:I'=V>KV^A^+O$VOWFG^&(+[3+E+2*^T7PS;>*M*N%FU'2/%-C=/;&R^-/\
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MI3YY<TERRE?5QLE9^5DON/TZ_P"";O\ P5E_:E_X)B^(_%MU\$I?"7B_X?\
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M6R'ZS]=^HYW_ *S=/XSL/"VE>*-9TWP7KNH>)_#%C>/:Z3XAU328M!O-:@@
MC;4GT:'4=733([N57FM[,ZG?R00/&DMU+(&<\Q117ZC0A.E1I4ZE:>(J4Z4(
M5,14C3A4KSC%1E6G"C"G2C.I).<HTJ<*<7)J$(Q22_/,34I5L17JT,/#"T:M
M:K4HX6$ZM6&&I3G*5.A"I7G4K5(T8-4XSJSG4FHJ4Y2DVV4445J8A1110 44
M44 %%%% !1110 4444 %%%% !1110 5_1C_P:C_\I<_''_9B7Q4_]7/\$*_G
M.K^C'_@U'_Y2Y^./^S$OBI_ZN?X(5^>^*7_)%YK_ -P/_3B.K!?[Q3^?Y,_T
MCZ***_CD]X**** "BBB@ HHHH **** "O\=W]O/_ )2-?\%+O^TB7[97_J]?
M&%?[$5?X[O[>?_*1K_@I=_VD2_;*_P#5Z^,*_8?!;_DI\3_V+JO_ *5$X<P_
M@K_$OS1\PT445_4YXH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]U^9_'I17]\/_$&5_P $O_\ HN_[>O\ X=#]GK_Z%RC_ (@RO^"7_P#T7?\
M;U_\.A^SU_\ 0N5^N?\ $;LG_P"A7B/_  HE_P#,?]6?E?A_LZ?\Z_\  ?\
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MZ_\ AT/V>O\ Z%RC_B#*_P""7_\ T7?]O7_PZ'[/7_T+E'_$;LG_ .A7B/\
MPHE_\Q_U9^5S^SI_SK_P'_[8_@>HK^^'_B#*_P""7_\ T7?]O7_PZ'[/7_T+
ME'_$&5_P2_\ ^B[_ +>O_AT/V>O_ *%RC_B-V3_]"O$?^%$O_F/^K/RN?V=/
M^=?^ _\ VQ_ ]17]\/\ Q!E?\$O_ /HN_P"WK_X=#]GK_P"A<H_X@RO^"7__
M $7?]O7_ ,.A^SU_]"Y1_P 1NR?_ *%>(_\ "B7_ ,Q_U9^5S^SI_P Z_P#
M?_MC^!ZBO[X?^(,K_@E__P!%W_;U_P##H?L]?_0N4?\ $&5_P2__ .B[_MZ_
M^'0_9Z_^A<H_XC=D_P#T*\1_X42_^8_ZL_*Y_9T_YU_X#_\ ;'\#U%?WP_\
M$&5_P2__ .B[_MZ_^'0_9Z_^A<H_X@RO^"7_ /T7?]O7_P .A^SU_P#0N4?\
M1NR?_H5XC_PHE_\ ,?\ 5GY7/[.G_.O_  '_ .V/X'J*_OA_X@RO^"7_ /T7
M?]O7_P .A^SU_P#0N4?\097_  2__P"B[_MZ_P#AT/V>O_H7*/\ B-V3_P#0
MKQ'_ (42_P#F/^K/RN?V=/\ G7_@/_VQ_ ]17]\/_$&5_P $O_\ HN_[>O\
MX=#]GK_Z%RC_ (@RO^"7_P#T7?\ ;U_\.A^SU_\ 0N4?\1NR?_H5XC_PHE_\
MQ_U9^5S^SI_SK_P'_P"V/X'J*_OA_P"(,K_@E_\ ]%W_ &]?_#H?L]?_ $+E
M'_$&5_P2_P#^B[_MZ_\ AT/V>O\ Z%RC_B-V3_\ 0KQ'_A1+_P"8_P"K/RN?
MV=/^=?\ @/\ ]L?P/45_?#_Q!E?\$O\ _HN_[>O_ (=#]GK_ .A<H_X@RO\
M@E__ -%W_;U_\.A^SU_]"Y1_Q&[)_P#H5XC_ ,*)?_,?]6?E<_LZ?\Z_\!_^
MV/X'J*_OA_X@RO\ @E__ -%W_;U_\.A^SU_]"Y1_Q!E?\$O_ /HN_P"WK_X=
M#]GK_P"A<H_XC=D__0KQ'_A1+_YC_JS\KG]G3_G7_@/_ -L?P/45_?#_ ,09
M7_!+_P#Z+O\ MZ_^'0_9Z_\ H7*/^(,K_@E__P!%W_;U_P##H?L]?_0N4?\
M$;LG_P"A7B/_  HE_P#,?]6?E<_LZ?\ .O\ P'_[8_@>HK^^'_B#*_X)?_\
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M )U_X#_]L?P/45_?#_Q!E?\ !+__ *+O^WK_ .'0_9Z_^A<H_P"(,K_@E_\
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M&[)_^A7B/_"B7_S'_5GY7/[.G_.O_ ?_ +8_@>HK^^'_ (@RO^"7_P#T7?\
M;U_\.A^SU_\ 0N4?\097_!+_ /Z+O^WK_P"'0_9Z_P#H7*/^(W9/_P!"O$?^
M%$O_ )C_ *L_*Y_9T_YU_P" _P#VQ_ ]17]\/_$&5_P2_P#^B[_MZ_\ AT/V
M>O\ Z%RC_B#*_P""7_\ T7?]O7_PZ'[/7_T+E'_$;LG_ .A7B/\ PHE_\Q_U
M9^5S^SI_SK_P'_[8_@>HK^^'_B#*_P""7_\ T7?]O7_PZ'[/7_T+E'_$&5_P
M2_\ ^B[_ +>O_AT/V>O_ *%RC_B-V3_]"O$?^%$O_F/^K/RN?V=/^=?^ _\
MVQ_ ]17]\/\ Q!E?\$O_ /HN_P"WK_X=#]GK_P"A<H_X@RO^"7__ $7?]O7_
M ,.A^SU_]"Y1_P 1NR?_ *%>(_\ "B7_ ,Q_U9^5S^SI_P Z_P# ?_MC^!ZB
MO[X?^(,K_@E__P!%W_;U_P##H?L]?_0N4?\ $&5_P2__ .B[_MZ_^'0_9Z_^
MA<H_XC=D_P#T*\1_X42_^8_ZL_*Y_9T_YU_X#_\ ;'\#U%?WP_\ $&5_P2__
M .B[_MZ_^'0_9Z_^A<H_X@RO^"7_ /T7?]O7_P .A^SU_P#0N4?\1NR?_H5X
MC_PHE_\ ,?\ 5GY7/[.G_.O_  '_ .V/X'J*_OA_X@RO^"7_ /T7?]O7_P .
MA^SU_P#0N4?\097_  2__P"B[_MZ_P#AT/V>O_H7*/\ B-V3_P#0KQ'_ (42
M_P#F/^K/RN?V=/\ G7_@/_VQ_ ]17]\/_$&5_P $O_\ HN_[>O\ X=#]GK_Z
M%RC_ (@RO^"7_P#T7?\ ;U_\.A^SU_\ 0N4?\1NR?_H5XC_PHE_\Q_U9^5S^
MSI_SK_P'_P"V/X'J*_OA_P"(,K_@E_\ ]%W_ &]?_#H?L]?_ $+E'_$&5_P2
M_P#^B[_MZ_\ AT/V>O\ Z%RC_B-V3_\ 0KQ'_A1+_P"8_P"K/RN?V=/^=?\
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M7B/_  HE_P#,?]6?E<_LZ?\ .O\ P'_[8_@>HK^^'_B#*_X)?_\ 1=_V]?\
MPZ'[/7_T+E'_ !!E?\$O_P#HN_[>O_AT/V>O_H7*/^(W9/\ ]"O$?^%$O_F/
M^K/RN?V=/^=?^ __ &Q_ ]17]\/_ !!E?\$O_P#HN_[>O_AT/V>O_H7*/^(,
MK_@E_P#]%W_;U_\ #H?L]?\ T+E'_$;LG_Z%>(_\*)?_ #'_ %9^5S^SI_SK
M_P !_P#MC^!ZBO[X?^(,K_@E_P#]%W_;U_\ #H?L]?\ T+E'_$&5_P $O_\
MHN_[>O\ X=#]GK_Z%RC_ (C=D_\ T*\1_P"%$O\ YC_JS\KG]G3_ )U_X#_]
ML?P/45_?#_Q!E?\ !+__ *+O^WK_ .'0_9Z_^A<H_P"(,K_@E_\ ]%W_ &]?
M_#H?L]?_ $+E'_$;LG_Z%>(_\*)?_,?]6?E<_LZ?\Z_\!_\ MC^!ZBO[X?\
MB#*_X)?_ /1=_P!O7_PZ'[/7_P!"Y1_Q!E?\$O\ _HN_[>O_ (=#]GK_ .A<
MH_XC=D__ $*\1_X42_\ F/\ JS\KG]G3_G7_ (#_ /;'\#U%?WP_\097_!+_
M /Z+O^WK_P"'0_9Z_P#H7*/^(,K_ ()?_P#1=_V]?_#H?L]?_0N4?\1NR?\
MZ%>(_P#"B7_S'_5GY7/[.G_.O_ ?_MC^!ZBO[X?^(,K_ ()?_P#1=_V]?_#H
M?L]?_0N4?\097_!+_P#Z+O\ MZ_^'0_9Z_\ H7*/^(W9/_T*\1_X42_^8_ZL
M_*Y_9T_YU_X#_P#;'\#U%?WP_P#$&5_P2_\ ^B[_ +>O_AT/V>O_ *%RC_B#
M*_X)?_\ 1=_V]?\ PZ'[/7_T+E'_ !&[)_\ H5XC_P *)?\ S'_5GY7/[.G_
M #K_ ,!_^V/X'J*_OA_X@RO^"7__ $7?]O7_ ,.A^SU_]"Y1_P 097_!+_\
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M6?E?#^SI_P Z_P# ?_MC^!ZBO[X?^(,K_@E__P!%W_;U_P##H?L]?_0N4?\
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M>(_\*)?_ #'_ %9^5S^SI_SK_P !_P#MC^!ZBO[X?^(,K_@E_P#]%W_;U_\
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M[X?^(,K_ ()?_P#1=_V]?_#H?L]?_0N4?\097_!+_P#Z+O\ MZ_^'0_9Z_\
MH7*/^(W9/_T*\1_X42_^8_ZL_*Y_9T_YU_X#_P#;'\#U%?WP_P#$&5_P2_\
M^B[_ +>O_AT/V>O_ *%RC_B#*_X)?_\ 1=_V]?\ PZ'[/7_T+E'_ !&[)_\
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M^"7_ /T7?]O7_P .A^SU_P#0N4?\097_  2__P"B[_MZ_P#AT/V>O_H7*/\
MB-V3_P#0KQ'_ (42_P#F/^K/RN?V=/\ G7_@/_VQ_ ]17]\/_$&5_P $O_\
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M #'_ %9^5S^SI_SK_P !_P#MC^!ZBO[X?^(,K_@E_P#]%W_;U_\ #H?L]?\
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MG3_G7_@/_P!L?P/45_?#_P 097_!+_\ Z+O^WK_X=#]GK_Z%RC_B#*_X)?\
M_1=_V]?_  Z'[/7_ -"Y1_Q&[)_^A7B/_"B7_P Q_P!6?E<_LZ?\Z_\  ?\
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MZ_\ AT/V>O\ Z%RC_B#*_P""7_\ T7?]O7_PZ'[/7_T+E'_$;LG_ .A7B/\
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M #F7_P"T]7_!1#_WC]=^'_W',?3"?^GR7\4?^WOR/WJHHHK@*"BBB@ HHHH
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ML&O]*O#)#)!>Z;J,%KJ6DZOI=_;WFD:WHVI6MMJ.CZQ87VF7]O!=VDT2^S4
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MO>>&+3XK^ ?#_CNV\/76K06EA#JESHL.O)IL^HPV-E%>RVS7,=I;I*(4]XH
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MWO=%N9/L20179^UM+:_I10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'X*_P#!L?\ \H1_V-/^O[]I?_UK;X[U^]5?@K_P;'_\H1_V-/\ K^_:
M7_\ 6MOCO7[U5W9I_P C+,?^P[%_^I%0F'P1_P ,?R04445PE!1110 4444
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M1110 445\O?MJ_M-Z7^QE^RC\>/VI]:\)W_CK2_@;\/=7\>W?@_2]3M]%O\
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M1110 45_-]XP_P""K'_!1?\ :$_;S_:;_9._X)I?L@? SXB_#O\ 8G\2>$/
M_P"T)\4_VCOB)KG@V\UKQCK]UJBZGIGPVTO1M4T:TQIRZ!X@L;,7DNN?:#I]
MGK>K3:#::YI6FS?T=V[3-;P-<HD=PT,33QQMN2.8HIE1&R=R*^Y5;)R #DT
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M$WC"S\#7NBV6MWM[K46G_$7^RG\0^,?N_P#X+U_M>?'+]@+_ ()5_M ?'O\
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MOX@EUKPYH^@37&JR:OJVK^(WUO0;G2-.\.:UX*;Q?QK^T'_P57_:<_X+F_\
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M'^#GPE\4>--0M;ZPTFUUW5+C6M=UC5+]CKVJZJMBU_<P:8ME:R&"OG?XO_\
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M4\-:AXET9_"NL6.B^&/B#\-](T9O#NO6FL>-?$H!ZUX9^,'_  4>_P""5?\
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M\*_BM>ZYX@T^TU;PSIFNZAXS\%:3K_\ 9?C*S\.Z5X/\#>._%-UX?;5C<_\
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M^#+/[>_X+.?\ID_^#;?_ ++Q^V9_ZBW[-] 'I_\ P5=_;F_:Z\0?MF?LU_\
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MK,H^MOA1_P $2_\ @EI\:O@-I'[37P\_X*/_ +?FM? S4_"UCXNNOB/_ ,/
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M\:>'#XJT/6==O=7LW\4W6MZ1K.EZ1^J/_! __E#C_P $]?\ LWGP[_Z<M7H
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MK^S#X.^T^;Y'V?\ X2?X<_M0:)Y_G?9;[R?)^W>9YOV*\\O;O^RW&/*?K_\
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MNK:X^KZE>3W4TNMFSBMK6*Q,MY_/'_P<+_#76/@S_P $3?V$/@_XAG@N=?\
MA5^T1^P3\-];N;4*+:XU?P/\/O$7AG4I[<++.H@EO-,FDB"S3+Y;+B60?.?Z
MWX_]7'_N+_Z"* .=\:>,/#7P\\'>+/'_ (TU>WT#P=X&\-:[XP\6:]=K.]IH
MGAKPSI=UK6NZO=);13W+V^FZ7975Y,MO!-.T<+"**20JA_D\_9(U?_@KU_P7
M-\,>)?VVO"7[?FK_ /!-/]B;Q5XV\>>'/V5/@Q\&/A%X)\<_%'Q-X;\!>+M1
M\&77COXH>-M?N+*^EN[O4=)UO0M4T^T\4ZCH4_B?0M0N=!\+>%]+M[:ZU_\
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M_$7P8GB33M(&IVVE1RZS+X:\8QZWK'BK4]'7QMXL^.?^#6S_ )-O_P""D?\
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MC]/L-9TG3-.O=/QHESI_@.!/ S:N8;73KA/%7C_6+4P*]G=Z/X<_-7_@DO\
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M]ZJ[L7_N^5_]@-3_ -668DQWG_B7_I$0HHHKA*"BBB@ HHHH **** "BBB@
MHHHH *\0_::_Y-N_:#_[(A\5_P#U ]?KV^O$/VFO^3;OV@_^R(?%?_U ]?H
M_#?_ (-C_B/\//"__!#_ /9%@\3>/?!?AV;2[_\ :=NM3AUWQ3H>D2Z=:C]J
MSXY7IN;Z/4+ZW>T@%FRW9FN!'&+9EG+>40]?*GQU^(?PQ_;(_P"#H+_@G@W[
M*?B'P]\2M5_8J_9W^,FM?M3?%CP#IVE>+O"_A/P]XP\'_$[0_"GPYU+QUI1N
M[/4=3@U'XC6MM+9->'2?"MY\2KA=,OY?&,/B;0].^8O^"#'_  09_P""4/[:
MO_!*[]FO]I7]IK]E3_A9?QK^(>I_':+QCXT_X7E^TCX-_MA/!_[1/Q7\#>'%
M_P"$<^'_ ,8?"OA/3_[.\+>&]%TO.EZ#9&[^Q?;;XW6HW-W=S_U?_L=?L"?L
M=_L >"=8^'O['WP%\'?!'PUXCO;'4?$S:%+KFN>)/%-[IEJ]GID_BKQOXQU?
MQ'XV\3G3+>6Y334U[Q#J$>GM>ZC+9I#-J-])< 'YW?MW?##_ (+.?M3_ +7'
MA_X"?LL?&'PY_P $_OV$/#?@.T\3^//VOO#=M\./B_\ &KXP>-KNXL+M_AQX
M6^'>NW-CXJ^'1\/WEI'9#4[:;P[I5[I,NMZYJ/C7Q9'?6?PP@^*]#^+W_!2#
M_@E-_P %*/V$_P!DW]I/]M34/^"B?[,'_!0R?XE^"?"NL_$CX5>"/A?\7/@I
M\2_AS9:%JFJ:G9^(/"=SJ]_XRT&Z_P"$I\++):>(]5%@-.U74+31M*TK4/#K
M:AXE\M^(MM\;_P#@K)_P6F_;9_8+^-?[=GQV_8M_9R_8S\'?"A_ /[+'[,/Q
M-3X2_%']J/2/'7A:T\4>(OB1XG\9)]HO/$?A?3)-1\.W_B+17\+:S8:/X:\=
M?#_2M)_L'7;;5?&/B'X8_:'_ &+?^"?W["__  7&_P""+_PB_93^(GC+XC?M
M"W/QM^*'B#]J'4/B7\;/%GQH^).FZ-=>'O"<'PALO%]SJ=X_A?PK>7VL6_Q?
M\0+HNEZ7H_B6XFUFZU7Q#;'0[WP8(P#V/_@N'^RK^UEJ/_!77_@D>-,_X*#_
M ! T1?V@OVC_ -HJ?]G1(?@WX"NU_8P&A:3\%+_7QX*DGU1;OXHOXNMK_3[.
M[C\>W2Z=IIT> 66FG3;FXTD_HS_P6:^+'[;?_!,G_@BG+XN\*?MH>./B?^U/
MX"^+'@W2=0_:EU+X=_#GPCXH\6Z1XX^(OB6[&G:AX LM*USP%:6^C^%M5TWP
M? (M-G:ZM]!L]9D,6K322IR__!<W7]"\&?\ !4__ (-V_&_C#6M)\*>"]#_:
M/_:CLM;\7>)=1L]"\,:/>:[X>_9_LM$M-4U_5)K72M/N=8O$>TTJ"[NX9=0N
M4>"T2:52@W?^#M"\M-0_X(O?$6_L+JWOK&]^,'P*NK.\LYXKFTN[6X\22RP7
M-M<0L\,\$\3K)#-$[QR1LKHS*02 ?;__  6 _P""AGQ2_8A^ ?P5\)_LT^$=
M"^)'[:_[9?Q>\&?LX_LM^$/% _XIJW\:^+OLT>L_$3Q4KW6EV3^&_!45[ID-
MPMYJMC86VM^)?#^I:TDWA73_ !%Y7Y__ !$_8-_X+W? KX2ZE^U1X6_X+(7O
M[0W[2WPS\)ZO\4?$O[,?B[]G#P%X=_9N^)VH:+X3U?4O$/PF\-Q^&=1T*: :
M@470O!VN2>'O!D&I:Q'9ZU<P_#Z>\6]\/^-?\'2'P,TCQ3:_\$HOVD/B9J7Q
M8\)?LV? 7]IJ^\"?M(?%#X,ZN^C>,_A-\._C^/A792^.8M6M;&\OO#=I;-\-
M[K2O^$NW1V6EW^J:?HOE7NN^)?#UG-Z)X]_X(E?\$L_AM\ ->_:D\4_\%(/V
M^[?X!>'_  OJGBZ?XHV7_!0.+4O!^I:5I5O=S21>']>L]!ETKQ!JM[/8SZ9I
M.DZ3>75_JVLA-(L()]0D2 @'<_M<?\%<OB7\:/\ @VZ^(W_!4']EK5[[]GSX
MUW7AGX8QV_\ 9KZ#XNO_ (9>/[']JWX>?!?XIZ%9GQ+H5YI>JZ?-GQ7I^CWV
ML>'8;B^\.:KI^LQ65G<W%M+%A>!/V/\ _@M]^VY^SM\.OVI[G_@JQK_[%/Q2
M\=_"7PMXJ^%O[,O@GX2^%_'OPY\,:9+HEMKG@BR^-GQ U#^P]=\5>/O%RW27
M?Q0\0VO@:_LO#-YJTFCZ5X>\6Z5X8M;'6/E/]N'X._L5_!W_ (--?VE;;_@G
MYXA^*/BW]F#Q[)\+OB-X(\3?&'3_ !/I/CC6[K7_ -M/X,VNO7MYIWB[P7X
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MU'2;6[T7P]J-[IFG+X>MF)U)+_4H;C]#_P#@UX_Y(5_P4R_[2[?M2_\ J _
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MJ6BG4XK2ZMKC5M!^'U];?$7Q#8Z!?Q7]E<>*]=T2ZTMM,U^&Q.I@'R[\;O\
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MR9\ /^"W?_!2KX/>'O\ @H%XO_X*L:Q^PTOQ\TO3?BE^SI^R]\%_@+X.\?\
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M &E@_9$_]1GXTT ?4W_!:#_@HK\;?V2O#/[,7[-_[%^E>$==_;F_;T^+-O\
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MU*X\NSFYS]C/X;_\%:_^"NG[,^F_M\:;_P %DM7_ &4=4^+6J>,KSX4_L[_
M'X'?"WQK\(?@MI7AWQ]J%GHG@OQ[J$^N:=XG\;:]!8V&H6GB2'Q=</XMT:XU
M'3]/U^\U>/PW/HFI=?\ \&QWQ(^'WP=_X(I_$SXL?%G4#I/PM^&WQ=_:D\<?
M$?5O^$>USQ7'I7@7PQJ5[K'BO4[GPWX:TG7M>UFST_0[.^O+ZQTO1M2NIK.&
M<)9S ,IH^#/^"-/_  2Q_:L^$\O_  4+_P""7?[8?[2W_!.CPY\5O#7B?Q]X
MD^)G[(W[0VN_#/X>V8CM-4U'7+?XH^#-:UAYOA];_#35GU@Z_P" M!\8_#G0
M_!D'_"2>'VL-&M4M)M' /W=_X)T:C^W?=?LQ^&],_P""COAWP)I7[4'AG7O%
M'AWQ+XC^&VJ>'KWPE\1_#NGZQ<_\(?X^LM,\-S36'AN]UGP_+8PZUHQ6R8:S
M9WVH0:1H=G?VVCV/W77\_?\ P;F_MQ?M#_MM?L;?$^X_:,\9Z?\ &/Q#^SS^
MT7XW_9[\)_M$Z9I<>E1?'OP1X0T'PGK&B^/-21)T34=;?_A(9],O-:M-+LK7
M5;6RL+F^N-1\2MX@N*_H$H **** "BBB@ HHHH **** "BBB@ HHHH *_!7Q
M'_RLS_#?_M"OXP_];,@K]ZJ_!7Q'_P K,_PW_P"T*_C#_P!;,@KOP&^,_P"P
M#$_E$F7V?\2_4_>JBBBN H**** "BBB@ HHHH **** "OP5_X(/?\YE_^T]7
M_!1#_P!X_7[U5^"O_!![_G,O_P!IZO\ @HA_[Q^N_#_[CF/IA/\ T^2_BC_V
M]^1^]5%%%<!04444 %%%% !1110 4444 %%%% !1110!\Q?&;]C;]F[]H/XS
M?LV?M!_%_P"''_"7?%[]D/7O&GB;]G?Q=_PE_CS0/^%>ZW\0K7PU9>,+W^P/
M#'BC1?#'BS^U[7PAX=B^S>.-%\2VFG_V=OTNWLI+N^>Y^G:** .0^('@#P/\
M5O _BSX:?$OPGX?\>?#[QYX?U7PIXS\&>*]*L];\-^)_#>MV<MAJVB:WI-_%
M/9ZAIVH6<\MO<VUQ$Z.CG@$ C\3?@M_P;2_\$;?@+\9O#GQR\#?LJ2WOBGP7
MK-AXC\$Z'XY^+/Q<^(7@7POXBTO4)]0TW6H?"7C'QIK&G^([JP>6WCL[;QQ_
MPE6EVS:=IVI0V":Y;G57_>&B@#YB_9$_8V_9N_80^#.G?L^?LI_#C_A5?PAT
MK7M>\36'A'_A+_'GCCR-;\3W2WNN7O\ ;_Q'\4>,/$\OVZZ19?LTVM26EMC9
M9V]O&2A^<M5_X)"_\$]=1_;8\+_\%#K/]GS3?"W[6?A?7-1\4#XD>!O%OCKP
M19>(_$^J:3J>C7WB7QAX'\+^)=+\">)O$-_9:UJHUK6]1\.2:IXJDOI3XNNM
M?1((XOTJHH ^8O ?[&W[-WPS_:<^.?[9'@CX<?V)^TA^TIH/@7PS\:_B-_PE
M_CS4O^$TT3X:^'M$\*^";+_A$-7\47_@/PY_8N@^'-&L/M/A/POH5WJ/V/[5
MJUQ?WMQ=W$_A'[=__!*']@?_ (*4P^%)?VP/@#HWQ'\1^!87L_!_CW2M?\5^
M /B%H>E2W,UW-X?7QGX"USP[K>K>%Y+BZOKE?"OB"ZU?PY::AJ%YK%AI=IK4
MHU)/T4HH _-/]A;_ () ?\$[?^";^J>(/$_[)'[.'A[P%X]\4Z?_ &1KOQ,\
M0:[XM^)'Q'FT0W#7,N@:3XP^(FO>)M6\)^'KV1;)M9\/^#9O#VC>(I](T2^\
M16.K:EH^GWL'T?X$_8V_9N^&?[3GQS_;(\$?#C^Q/VD/VD]!\"^&?C5\1O\
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ML1D:.9_"&E?$RUTNRM0Q@:31=(33?#]R+2..ZTF>*YU*.^_?*B@#D/A_\/\
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M"Z<?"N@Z+::/8QWMCI-I90:OJZWWT/\ LB?L:_LW?L(?!K3_ -GW]E/X<?\
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M+;X?CI3Y^3DH?Q.?VGL/WWM/K>8_73_7V,OXG!' %3F_B_\ &/U:'M>?^/\
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M_>JN[-/^1EF/_8=B_P#U(J$P^"/^&/Y(****X2@HHHH **** "BBB@ HHHH
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MU\7Z?K\6@7<^H#1ULK76M=MM3P/@C_P0U_X):?LZWW[/NM?"/]E;1_"WB?\
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M\8_\)+I%L;&QO8M-75K<:BW[QT4 ?!/P[_X)B?L-_"C]D;QW^PEX ^!X\/\
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MJ?!CQM^SQX3\,_ [2? G[/\ \./@5\,?#$VC^"])^"GA_6_"UGJMUJ-[;ZC
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MX"@HHHH **** "BBB@ HHHH *_!7_@@]_P YE_\ M/5_P40_]X_7[U5^"O\
MP0>_YS+_ /:>K_@HA_[Q^N_#_P"XYCZ83_T^2_BC_P!O?D?O51117 4%%%%
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M_$UAIFMV'V3Q5X3URQB^VV,'VJ&VCO;;S;2Y@FDY/X5?MT?LT?&G]J+]H?\
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M9/\ B-X8UBXTZ^BBCBL8_%7CKQOX?A&EF32([G0+RWL&2.$P0_V5_L$_LV_
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MH>BZG;>*_$VL>+/'.@:/9^#M%:Z\2A7U'6+C38/#^DZCJ]O[;^PA^WM\ ?\
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MP5@_8S_;PBTO7_BQKO[+'PG^"?C&?]H_Q1=>"_'WPTO;KX5W/A;Q[JOB+6?
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M2]"U;XHZ7X:^)GBK0].B:[O!966C^*O%NLZ=;:9%)%;Z7#;)I]O9V$%M'90
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MZ)H6K0ZCI=EXZ\3WUP9=,\):R)_KG_@NY=75]_P29_X)$7E[<SWEY=?MV?\
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MD6?A[0IM+N=!TB7PNMM87WA1X-*,7A_5-*TK4-/@BGT^V*?P>^"?&'C?4O\
M@T-_X*'_  M\7>*+KQ7I7[.G[0B?!+X?7]]$R7MKX&T+]K/X ^(=.TN626XN
MYWM=/U'Q-JD&D6LEU-%HVBKIVA6)CT[3+.*, _JH\$_\%X?^"<7Q._:N\!_L
M8?#'XH>+?B)\;_'>H:;H26GA7X=^)+OP;X3\6ZCX;UKQ;+X*\8^.[R"Q\,Z9
MXLT?0?#^K3:[I-C?ZJVDZG8:AX;NI5\3Z3K.C:=^QM?!G_!,;X!_"/\ 9O\
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M(UGY>A^$_$%]_;M_X1M?#3?V?]F366O+JRM[G]UJ* /PH_X+Y?L;?M(_MJ_
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MF?L$?&[]G#]G_P#X*(?"#]L;X1V_A32OVF/V\_VD_B3H/A>[\8^"?%MKX\^
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M#XO_  R\5ZG\$_AMH7Q3^$7C#Q?\:OBE\5M?\?\ A_3OB=XPUO2?#-[H^G>
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M?VR_&'PX_L?]FW]H+X*?LQ^$?A#\1_\ A+_ >H?\)=XA^'GPN^'OASQAI_\
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MJ^FA.D:K=C1-4U#2=.U&ZU?1K.;6+&P6OY_=-_;%_P"#C7P-\(M._9R\4_\
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M(?#.I[(YHV^T:/K.H6C;L+.6# ?I510!_.5^V[_P3B_;B^#O_!0"Y_X*J_\
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M#VNV@OK&PU30=:_76B@#^7GQK^V%_P '*?Q-^&6O?LZ>#?\ @DM\+?@'\?\
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M]=^'_P!QS'TPG_I\E_%'_M[\C]ZJ***X"@HHHH **** "BBB@ HHHH ****
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MPIXBT#P#XLUIY+GQE\/]<T75];U)]1FL+'4/#UK)H)L=8\.^);_PUJM_X?\
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M\9?AE\'/V7+WXH?M+V'[.7P<UCQ3\=].\6?"+X0ZQX3T77? &H7B>!?"5O\
M#_1[FR\.6-[H=G<ZCJ]OI5O>W%U9S7>IPWH!_>M17X0_\%<_V[/VKOA]\8_V
M2_\ @FW_ ,$YG\$Z?^W+^VQ<^,];@^*GQ#TRSUKP?^S;\#/AWIEUJ'BSXN:K
MHNLV6HZ#JNM7G]GZZWA2UU71O%VG7*^"O$NC/X2UGQ)KG@VPO_AW]J3X.?\
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M (JL/$5[L\.:!KKK_-?_ ,'&_P"S7^T[JO[=O_!*_P =Z3^W1XY\/^ _C?\
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MEII]]XZ\0VB7%A'J.E>%YM4T+1[336U"$3^+O&'A2:_M+_P[;:_"OPA\0/\
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MX^%GPUMM:^%MYK]Y=>-?&7PS^(T?B&0>&O$NE>'ELM-T31D6&<ZK)-KUU?\
MB/3%7P2@!_277YG?ML?M9_MD? #]H3]BKX8_LZ_L-^)_VE_A-\?OBQI_@GX_
M_&K1_$%Q:Z5^SQX4N=8TBUO_ !1K.E:1I>KW-I:Z/X;N-?\ %LNN>*3HOA;4
M)-#L_!VFZE/XE\06L=I^EZ%F1&=/+=D4O'N#[&(!9-PX;:<KN'!QD<&OP4_X
M*K?M7_M"_ G_ (**?\$2_@M\)?B;J_@GX8_M/_'+]H'PU\>/"NFZ?H%Q;_$3
M0O!&A?![4O"^FZCJ&IZ3?:QIMOIEYK^LR?\ $@U#29+U+^>WU![NVV0H ?O;
M17\M'_!2?]K?_@I5HO\ P7"_9?\ V$/V(/B;H_ACPU\<OV()?&>IVGC?1] U
M3X<_"[Q5)\4_C-I7B3]H7Q%I;^&-1\1^.=0\(^!_"%KI7ACX</X@T7PQXE\7
MS^&(M5N=.@-[?'Y\_;DD_P""M_\ P0^TOX0?MO:[_P %.?%?[>O[+<'QE^'_
M ,//VI?@K\;?@YX(\*:MHW@+Q7K):\\6^ -9T?6-9U WILK2_P!#M/[#:PUC
M0=>O?#VI76C>._#4^NV'A\ _J2_:O_:G^"W[%'[/_P 0OVG?VA_$=]X2^#GP
MN@\.W'C/Q#IOA[7/%5]IT7BGQ=H'@?16@T#PW8ZEK6H&Y\1^)M'LY%L;*<V\
M5P]W.([6WGE3V3P;XN\/^/\ PEX8\=>$[\ZKX7\8Z!I'B?P[J9M+VQ.H:)KM
MA!J6EWILM1M[34+0W-E<PS&VO;6VNX=_EW$$4JLB_P R7_!U'\(/C7XV_P""
M8/QT^.'@_P#:B\4_#OX*^!/ GPH@^)7[,NG^ ?"^M^&_CC>^(?VB/A;;>']5
MU_QUJUS_ ,)'X0E\(ZAK&EZU9P^%[&%M5N-"AL]6N)[*Y$5K]G_\$Z_!/QE_
M8#_84\1?M'?MF?M\^/\ ]JCX/>'OV5OAS\5M*T#Q)\'O ?@,? GP7\-?AMKO
MBOQ9I?A"?PE?7>N^/[WQ#H]WH^DV5MXEO[G5KB[\+Z7!9SSW^M7;. ?N%17\
MFW[+WP\_X+4?\%?_ (.1?MJ>)_\ @H_JG_!-;X3?%N\UKQ'^RK^SS^S_ /!G
MP-\1[C2OA-J3O'X6\8?%?QOK6J>$/$_BO5M>M[73]0L]*N=8\HZ4KZQ96_@F
MZ\3WOAG1?MS_ ()0_MO?M7ZG^T;^U'_P2V_X*"7OA'QO^U9^QOHW@?Q7X?\
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MH_BKP3\8+KQ[\!V\1ZWX9UJSLY[WQMX1M?"S>*M-T6QUBTNM.BOK1+-FGLV
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M9_X)V>%O%/[7?[%7_!SY^UA\&?#/B#6?AY_P4%\9_ML>&?V48-2T?4?#=_\
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M-UX=T+29=8U(W(!^./\ P1I_Y3-_\'(O_9</V,__ %&?VD*3_@L]_P ID/\
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MX>\-6GG^59:-;0Q0QQ_3M !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'X*_\ !L?_ ,H1_P!C3_K^_:7_ /6MOCO7
M[U5^"O\ P;'_ /*$?]C3_K^_:7_]:V^.]?O57=FG_(RS'_L.Q?\ ZD5"8?!'
M_#'\D%%%%<)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZGI6EV]W-)%X?UZST&72M?U6]GLI],TG2=*O+J_U;60FD6$$]_(D!_J#\>>
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MV/C%^QG_ ,$K?VA?VGOV5+G1-4\?Z5#X-\*Z!\0[>33O$6C_  YL_'WCK1?
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MP:SXO\0ZWJ5II-GI^CVEU!I6G6%G;@'X7_\ !K__ ,D;_P""G7_:6W]IC_U
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M/!NN>$[N2.,:;<Z;<6>B?\)-X4'A^RL&BU+X7:@=7U"UEC?PK;^L_P#!RO\
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M%'I_<\_P?8.;^[+[C]ZJ*_!7_CJ _P"L"O\ YT)H_P".H#_K K_YT)H^H?\
M4;@/_"CT_N>?X/L'-_=E]Q^]5%?@K_QU ?\ 6!7_ ,Z$T?\ '4!_U@5_\Z$T
M?4/^HW ?^%'I_<\_P?8.;^[+[C]ZJ*_!7_CJ _ZP*_\ G0FC_CJ _P"L"O\
MYT)H^H?]1N _\*/3^YY_@^P<W]V7W'[U45^"O_'4!_U@5_\ .A-'_'4!_P!8
M%?\ SH31]0_ZC<!_X4>G]SS_  ?8.;^[+[C]X[JUM;ZUN;&^MK>\LKRWFM;R
MSNH8[BUNK6XC:&XMKFWF5XI[>>)WBFAE1HY8V9'5E8@EK:VMC:VUC8VUO9V5
MG;PVMG9VL,=O:VMK;QK#;VUM;PJD4%O!$B10PQ(L<4:JB*JJ /P<_P".H#_K
M K_YT)H_XZ@/^L"O_G0FCZA_U&X#_P */3^YY_@^P<W]V7W'[U45^"O_ !U
M?]8%?_.A-'_'4!_U@5_\Z$T?4/\ J-P'_A1Z?W//\'V#F_NR^X_>JBOP5_XZ
M@/\ K K_ .=":/\ CJ _ZP*_^=":/J'_ %&X#_PH]/[GG^#[!S?W9?<?O517
MX*_\=0'_ %@5_P#.A-'_ !U ?]8%?_.A-'U#_J-P'_A1Z?W//\'V#F_NR^X_
M>JBOP5_XZ@/^L"O_ )T)H_XZ@/\ K K_ .=":/J'_4;@/_"CT_N>?X/L'-_=
ME]Q^]5%?@K_QU ?]8%?_ #H31_QU ?\ 6!7_ ,Z$T?4/^HW ?^%'I_<\_P '
MV#F_NR^X_>JBOP5_XZ@/^L"O_G0FC_CJ _ZP*_\ G0FCZA_U&X#_ ,*/3^YY
M_@^P<W]V7W'[U45^"O\ QU ?]8%?_.A-'_'4!_U@5_\ .A-'U#_J-P'_ (4>
MG]SS_!]@YO[LON/WJHK\%?\ CJ _ZP*_^=":/^.H#_K K_YT)H^H?]1N _\
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M?_.A-'_'4!_U@5_\Z$T?4/\ J-P'_A1Z?W//\'V#F_NR^X_>JBOP5_XZ@/\
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MT?\ '4!_U@5_\Z$T?4/^HW ?^%'I_<\_P?8.;^[+[C]ZJ*_!7_CJ _ZP*_\
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MG&%*MSSE.:CRI1Y5^?1B;O;27Q)ZH_?*BBBO(+"BBB@ HHHH **** "BBB@
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M *K\49U?@_[>I_\ IR)^HM%%%>,:!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQE^TQHNAP7^I3J8;"TEOEN+R4&.WCD<$5C_!?_@W^_X-H_VD-$O_ !-^SO\
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M_P!7Y=?\$<_^3&/#W_9?_P!LS_UL#XXU\C?\0N/_  0H_P"C&?\ S9G]L/\
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M[;^*?"O[/GPQTOP1J'A'POX@6XN+FPFT!?$7A;7=3\06_B/0?&'B#3?[5DC
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M74S8:<+.W%C9'1]6T"YTDVEIY?V>V.EW-G:7&G&&-#93VMO+;>5)!$R^V_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /P!_X(.?\ (Q_\%LO^T['[=?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD_\ 7AXK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<_B[I/[/W[;?[&?CS_A.?V??C#XG\/?\)7X9O[2_;3O^$A\#?$?3D@NKS5-
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M5/A/I7@?4]3G\<_VQX@TC5(K#53X]TF"PET"QUJXB%KJ,MQ:KY=M%=??5?Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUKD7FC6ES#K6I6/B>36],T37M$\)^'K:V\8@']I-%?R-?LQ_%7Q3_P $J?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH _ '_ ((.?\C'_P %LO\ M.Q^W7_Z0?">OW^K\ ?^
M"#G_ ",?_!;+_M.Q^W7_ .D'PGK]_J "BBB@ K^"/]GSP'_P38_:Z_X*#_\
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M]-U/3;^"2UOM/U"QNHY;6]L;VUEEMKNTN8I(+B"22&:-XW92 ?QB_'3X>?\
M!G1\$OV?_$?Q^@\._L>?%N'2M%DO] ^$_P 'OVAO&?CCXW^,M8FBG_LGPUIG
MPLTWXR-XPT6\U.\B2SGU7Q;I6@>'M 69+_Q%JVEV'^D'=_X*S:E8? 7_ ((I
M?L&^'_V6?AO\=_\ @G?_ ,$_?C)^T!\'8_VN/"WAO3M>D_:"^ /[,_QRUG7/
MB!XUM]8%CK7Q*U;PO'JNNZ_JFJ^)=/O[VYU*Y\67'A'X;:I;6<?B75O FK_T
M:^ ?^"6/_!-7X5_$+2_BO\./V"OV1?!/Q&T'5T\0>'/&'AS]G_X9:7K/A?7H
M;V/4;76_"EQ;>&T7POJ]A>1)-IFI>'TTV]TS!CT^:VB=T;[1\8^#/!_Q$\*^
M(? GQ \*>&O'7@?Q=I%]X?\ %?@WQCH6E^)_"OB?0=3@>UU+1/$/A[6[6^TC
M6M(U"VDDM[[3=2L[FSNX'>&XADC9E(!_$1^UI\&_^#6O]E?]@#X]77[,EO\
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M>Z3;[+;3I[:WCCB7[*CCCACCAAC2**)$CBBC14CCC10J1QHH"HB* J(H"JH
M   % #Z*** "OP;_ .#F_P#Y0;?MV_\ 8%^!7_K4/P1K]Y*_!O\ X.;_ /E!
MM^W;_P!@7X%?^M0_!&@#]RO#?_(NZ!_V!=*_](8*VJQ?#?\ R+N@?]@72O\
MTA@K:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ_X(4?\ 1C/_ )LS^V'_ /1!4?\ $+C_ ,$*/^C&?_-F?VP__H@J_?ZB@#\
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M_1C/_FS/[8?_ -$%1_Q"X_\ !"C_ *,9_P#-F?VP_P#Z(*OW^HH _,O]B?\
MX(Y_\$WO^"=7Q%\3_%K]CG]FRT^$'Q%\8^"[CX=^(?%3_%'XV?$2_N_!=WKF
MB^)+S0+:+XK?$GQS9:5:7NN>'-!U&]DTBUL+J\FTBP6YGEBMHXQ^FE%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XH
M_&O_ (-UO^"-O[1'Q;^(WQT^+W[&MIXG^*7Q:\8:[X^^(7B6R^.O[37A&+Q%
MXP\3ZA/JWB'7I/#W@KXT>'?"^G7>L:G<W.H7RZ1HNGV\][<3W+0^;-([>7_\
M0N/_  0H_P"C&?\ S9G]L/\ ^B"K]_J* /P!_P"(7'_@A1_T8S_YLS^V'_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ K\NO\ @CG_ ,F,>'O^R_\ [9G_
M *V!\<:_46ORZ_X(Y_\ )C'A[_LO_P"V9_ZV!\<:]G#_ /(@S7_L:Y'_ .HN
M?&;_ (L/^O=7_P!*HGZBT445XQH%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'Q/\1/V@/VC?^&C?&?[/_P"S_P# CX)_$/\ X5Y\$_@O\8O%OBWXQ?M+>._@
ME_R6WQW^T%X*T'P[X=T'P5^RM^T%_:W]D_\ #/NLZGJ^KZGK/A__ )&#3+*S
MTNY^S7=W1_PGG_!1K_HU7]B?_P 3^^.O_P!+3H\!_P#*1K]JK_LR?]@'_P!7
MK_P4LK[8KV<54PF$G2HQRS!U?]BR^M*I5JYE[2=3$X##8FK*7LLPI4U>I5G9
M0IPBHM)+2Y"4G=\\E[TE9*%DE)I;Q;V7?J_*WQ/_ ,)Y_P %&O\ HU7]B?\
M\3^^.O\ ]+3H_P"$\_X*-?\ 1JO[$_\ XG]\=?\ Z6G7VQ17/]=PW_0HR[_P
M;FW_ ,\_ZN_*QRO_ )^3^Z'_ ,A_5WY6^)_^$\_X*-?]&J_L3_\ B?WQU_\
MI:='_">?\%&O^C5?V)__ !/[XZ__ $M.OMBBCZ[AO^A1EW_@W-O_ )Y_U=^5
MCE?_ #\G]T/_ )#^KORM\3_\)Y_P4:_Z-5_8G_\ $_OCK_\ 2TZ/^$\_X*-?
M]&J_L3_^)_?'7_Z6G7VQ11]=PW_0HR[_ ,&YM_\ //\ J[\K'*_^?D_NA_\
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M_5WY6.5_\_)_=#_Y#^KORM\3_P#">?\ !1K_ *-5_8G_ /$_OCK_ /2TZ/\
MA//^"C7_ $:K^Q/_ .)_?'7_ .EIU]L44?7<-_T*,N_\&YM_\\_ZN_*QRO\
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M1K_HU7]B?_Q/[XZ__2TZ/^$\_P""C7_1JO[$_P#XG]\=?_I:=?;%%'UW#?\
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MC5?V)_\ Q/[XZ_\ TM.OMBBCZ[AO^A1EW_@W-O\ YY_U=^5CE?\ S\G]T/\
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M?_8/B!\9O'7_  DO_#;?QU\*^;_PMSXP>.?BO_9?]C?\.\?$GE_\(]_PF?\
M8'V[^U7_ +6_LW^U/L>F_;/[.M?UZHK:.:PAAZN%CE>7*A7JT*]6GSYF^>KA
MHUX49<SS+GCR1Q-=<L9*,O:-R4G&#BN352YYW2:3]S9N+:^"VKBOQM8^)_\
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MZN_*WQ/_ ,)Y_P %&O\ HU7]B?\ \3^^.O\ ]+3H_P"$\_X*-?\ 1JO[$_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445Q_C#XA>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW2:4DG9M-)[:/L4FGLT_1W"BBBH&%%%% !1110 4444 %%%% !1110 4444
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MU%-MV2U;/UHHK^&7_B,N\;?](K?_ #>+2?\ Z%VC_B,N\;?](K?_ #>+2?\
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M_P#HG,R_\%1_^3#ZSA_^?L/O/[FJ*_AE_P"(R[QM_P!(K?\ S>+2?_H7:/\
MB,N\;?\ 2*W_ ,WBTG_Z%VC_ % XS_Z)S,O_  5'_P"3#ZSA_P#G[#[S^YJB
MOX9?^(R[QM_TBM_\WBTG_P"A=H_XC+O&W_2*W_S>+2?_ *%VC_4#C/\ Z)S,
MO_!4?_DP^LX?_G[#[S^YJBOX9?\ B,N\;?\ 2*W_ ,WBTG_Z%VC_ (C+O&W_
M $BM_P#-XM)_^A=H_P!0.,_^B<S+_P %1_\ DP^LX?\ Y^P^\_N:HK^&7_B,
MN\;?](K?_-XM)_\ H7:/^(R[QM_TBM_\WBTG_P"A=H_U XS_ .B<S+_P5'_Y
M,/K.'_Y^P^\_N:HK^&7_ (C+O&W_ $BM_P#-XM)_^A=H_P"(R[QM_P!(K?\
MS>+2?_H7:/\ 4#C/_HG,R_\ !4?_ ),/K.'_ .?L/O/[FJ*_AE_XC+O&W_2*
MW_S>+2?_ *%VC_B,N\;?](K?_-XM)_\ H7:/]0.,_P#HG,R_\%1_^3#ZSA_^
M?L/O/[FJ_+3_ (+&?L)6W_!0+]A?XH_"72--@N_BUX0@_P"%J_ NZ98Q<I\3
M/!UC?2VGA^*=]HB@\>:'=:UX%N&E<6MM)X@MM5F1Y-+MRG\V'_$9=XV_Z16_
M^;Q:3_\ 0NT?\1EWC;_I%;_YO%I/_P!"[7;EW!_'F5X_!YC@^'\RIXG!8BEB
M:,O9*W/2FIJ,DIKFA.SA4A>TX2E%Z-DSKX:<90E5@XR335^C_)]4^CU/Y"/"
M'@'QGX]\>^&/A;X0\-ZIKGQ#\9^+]%\ ^&/"%M;F/6]8\9^(M:MO#NB^&[>U
MN3 4U34-<O+;3(K>X:$K=S+'*8\,1_KC?\$_/V/O"O["'[(?P6_9C\,-8WUU
MX!\+PR^.O$ME$Z)XS^)WB"637?B)XM#W$4=^]CJOBJ_U$>'K;4FGO-&\*6^@
M^'?/:VT>V5/\V[X7?\%6/AE\+/\ @I[XM_X*4Z=_P3IDU&+6]5\7^-?"/[.3
M?M/:!9Z!X!^,'C/2;#3_ !!\34\>M\#+V#7[.[NM3\>Z[HG@X_#W27\->*/$
M.F:[I_B2-O"FE6][^X7_ !&7>-O^D5O_ )O%I/\ ]"[7Z=XF4^+.*:63X'+.
M'\T6!I8>EF&-@Z-FLRKTW%8:?,XJ;R^E*</:0]R=3$54KJG%G'@_8T74E.K#
MF;<(N_V4_B7^)Z^B1_<U17\,O_$9=XV_Z16_^;Q:3_\ 0NT?\1EWC;_I%;_Y
MO%I/_P!"[7Y)_J!QG_T3F9?^"H__ "9W?6</_P _8?>?W-45_#+_ ,1EWC;_
M *16_P#F\6D__0NT?\1EWC;_ *16_P#F\6D__0NT?Z@<9_\ 1.9E_P""H_\
MR8?6</\ \_8?>?W-45_#+_Q&7>-O^D5O_F\6D_\ T+M'_$9=XV_Z16_^;Q:3
M_P#0NT?Z@<9_]$YF7_@J/_R8?6</_P _8?>?W-45_#+_ ,1EWC;_ *16_P#F
M\6D__0NT?\1EWC;_ *16_P#F\6D__0NT?Z@<9_\ 1.9E_P""H_\ R8?6</\
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MWXJ_]&^XL_\ #+C/_E1R?\13\,O^CB<#_P#B5Y%_\W']AU%?QX_\1/7[6_\
MTAN_\Z&?#/\ ^<#1_P 1/7[6_P#TAN_\Z&?#/_YP-'_$&_%7_HWW%G_AEQG_
M ,J#_B*?AE_T<3@?_P 2O(O_ )N/[#J*_CQ_XB>OVM_^D-W_ )T,^&?_ ,X&
MC_B)Z_:W_P"D-W_G0SX9_P#S@:/^(-^*O_1ON+/_  RXS_Y4'_$4_#+_ *.)
MP/\ ^)7D7_S<?V'45_'C_P 1/7[6_P#TAN_\Z&?#/_YP-'_$3U^UO_TAN_\
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M.)P/_P")7D7_ ,W']AU%?QX_\1/7[6__ $AN_P#.AGPS_P#G T?\1/7[6_\
MTAN_\Z&?#/\ ^<#1_P 0;\5?^C?<6?\ AEQG_P J#_B*?AE_T<3@?_Q*\B_^
M;C^PZBOX\?\ B)Z_:W_Z0W?^=#/AG_\ .!H_XB>OVM_^D-W_ )T,^&?_ ,X&
MC_B#?BK_ -&^XL_\,N,_^5!_Q%/PR_Z.)P/_ .)7D7_S<?V'45_'C_Q$]?M;
M_P#2&[_SH9\,_P#YP-'_ !$]?M;_ /2&[_SH9\,__G T?\0;\5?^C?<6?^&7
M&?\ RH/^(I^&7_1Q.!__ !*\B_\ FX_L.HK^/'_B)Z_:W_Z0W?\ G0SX9_\
MS@:/^(GK]K?_ *0W?^=#/AG_ /.!H_X@WXJ_]&^XL_\ #+C/_E0?\13\,O\
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MC^&2Q3J?\1"X']E\<?\ C*LBLY_R_P"_?9;YO).*ZG]Y=%?QX_\ $3U^UO\
M](;O_.AGPS_^<#1_Q$]?M;_](;O_ #H9\,__ )P-?BG_ !!OQ5_Z-]Q9_P"&
M7&?_ "H]#_B*?AE_T<3@?_Q*\B_^;C^PZBOX\?\ B)Z_:W_Z0W?^=#/AG_\
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M_HXG _\ XE>1?_-Q_8=17\>/_$3U^UO_ -(;O_.AGPS_ /G T?\ $3U^UO\
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M3G)13T3>S?8_NDHK^&7_ (C+O&W_ $BM_P#-XM)_^A=H_P"(R[QM_P!(K?\
MS>+2?_H7:]K_ % XS_Z)S,O_  5'_P"3,_K.'_Y^P^\_N:HK^&7_ (C+O&W_
M $BM_P#-XM)_^A=H_P"(R[QM_P!(K?\ S>+2?_H7:/\ 4#C/_HG,R_\ !4?_
M ),/K.'_ .?L/O/[FJ*_AE_XC+O&W_2*W_S>+2?_ *%VC_B,N\;?](K?_-XM
M)_\ H7:/]0.,_P#HG,R_\%1_^3#ZSA_^?L/O/[FJ*_AE_P"(R[QM_P!(K?\
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M\%1_^3#ZSA_^?L/O/[FJ*_AE_P"(R[QM_P!(K?\ S>+2?_H7:/\ B,N\;?\
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M[7SG^H'&?_1.9E_X*C_\F:_6</\ \_8?>?W-45_#+_Q&7>-O^D5O_F\6D_\
MT+M'_$9=XV_Z16_^;Q:3_P#0NT?Z@<9_]$YF7_@J/_R8?6</_P _8?>?W-45
M_#+_ ,1EWC;_ *16_P#F\6D__0NT?\1EWC;_ *16_P#F\6D__0NT?Z@<9_\
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ME.I.<FHPIPBG*4Y-1C%.3:2N?J=17\>/_$3U^UO_ -(;O_.AGPS_ /G T?\
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MXS_Y4'_$4_#+_HXG _\ XE>1?_-Q_8=17\>/_$3U^UO_ -(;O_.AGPS_ /G
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M,_\ E0?\13\,O^CB<#_^)7D7_P W']AU%?QX_P#$3U^UO_TAN_\ .AGPS_\
MG T?\1/7[6__ $AN_P#.AGPS_P#G T?\0;\5?^C?<6?^&7&?_*@_XBGX9?\
M1Q.!_P#Q*\B_^;C^PZBOX\?^(GK]K?\ Z0W?^=#/AG_\X&C_ (B>OVM_^D-W
M_G0SX9__ #@:/^(-^*O_ $;[BS_PRXS_ .5!_P 13\,O^CB<#_\ B5Y%_P#-
MQ_8=17\>/_$3U^UO_P!(;O\ SH9\,_\ YP-'_$3U^UO_ -(;O_.AGPS_ /G
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MJV@36FKJWA/3;K5_W?\ ^(GK]K?_ *0W?^=#/AG_ /.!K]/\3>%_$WBBEE&
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M)Z_:W_Z0W?\ G0SX9_\ S@:/^(-^*O\ T;[BS_PRXS_Y4'_$4_#+_HXG _\
MXE>1?_-Q_8=17\>/_$3U^UO_ -(;O_.AGPS_ /G T?\ $3U^UO\ ](;O_.AG
MPS_^<#1_Q!OQ5_Z-]Q9_X9<9_P#*@_XBGX9?]'$X'_\ $KR+_P";C^PZBOXW
M->_X.EOVH_#.AZSXDUO_ ((\?8M%\/Z5J.MZO>_\/!OAW<_9-+TJSFO[^Z^S
MVG[/=Q=W'V>TMY9?)M8)KB79Y<,4DC*C?U,?L@_'[_AJS]E;]G3]IG_A$_\
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MH9X._P#)K^"/^Q#A?SF?Y,>./_)VN._^QY5_],4 HHHK]*/RD**** "BBB@
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MHK^ESR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBVW14I:TX49XITHTTX4X2CK=.<XV3D[OO=+IUZGQ1_PY._X-]/\ I,!X?_\
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M4FJ=6-"3@XRDIS2H4Y48PDE[:M&I.G+K'EMRJVFC6MWYZG\.?_!-WX%_ /\
M:=_;,^"O[.O[1WB+Q[X.^'_QJ\0/\/-.\7_#GQ#X7T#7] \?Z]:RQ_#X2)XN
M\(^+M*UNP\2>*H].\%R:/'#I%_\ :_$UEJ]GJL[Z2= US[1_X+??\$I?#?\
MP2W^,WPBT/X8^+_&_COX._&?P#JVM>&]>^(?]BR>*+/QMX+UF'3O'?AN>[\.
M:'H&B:A86&FZ]X'UJQNX-.M+Q!XDGT^\M2MA;ZCJ?Y(:A8_$?]GWXO7VF7J7
M?@?XN?!'XD7-C=QQS:=>W_@_XC_#;Q.]O.B7%M)J.DW=WX?\3:*ZK-;RWVG3
MS6@>*2ZMG5G_ +Y?^"V/A?1/^"DG_!$+X8_MG^ ],$GB#X?Z!\+_ -J*PL+-
MD6\TW0/$FCP^%/C/X-G,\EU#Y'@]/$=[K>NQQ7K2FZ^&:K8ZC? "UU3[#B+.
M,?DO%?"6*CC)RX>SR53*,7AU*$L-'&UE? 8N,VI<CK2K4_>A-4W1PU232YY2
MEA2A&I0KQY5[6FE.,NO*G[\;>23Z7N]^A_,__P $-O\ @D]X+_X*D?%+XZZ=
M\6O&/C;P1\)_@IX!\,WM_JOPVU+0[#QC<?$/Q_XBN(/!.GA?$_@[Q;H<WAJ7
MPWX/^)%SK)*V&JQ:I:^'!8&YM)=5$'P[_P %*_V??@=^RE^VM\</V;_V>O&'
MBOQ_\._@UK>E>"I?&'C/Q!X7\1:YJGC6Q\.Z3<?$*PN9O"'ASPSH^FOX2\:7
M>M^"+K1_LEU?V.H^&KTZE=Q7LTVF:=_:K_P1ML_"7_!+[_@A?XJ_;"^*$$D%
M[XYT[Q]^U-KND:CKOAQ!JHU);#X?_ _P3H.HP306-J_Q$TSP[X%ET32=1U"\
MUR+Q;\1;K2KD6NHR1>'=,_@Y\&^%OB[^V9^TOH?A:PN6\7?&[]ICXQQ6T^K7
MMI)!!JOC[XI>+&GU?Q)K-OX;TBX_LW25U;6+W7M?GTC0WMM(TJ*^N[?3EM;0
M0+GP[G689OQ5Q?CZF-G#AK)&LJPM%RC]5EB\.HRQV,4U%.3I?5ZDW)SY%1Q=
M-Q4[*:=6G&%&A%13K5??;Z\K^&.^E[KSO%[;']0__!*G_@V_^!W[9G[%7PU_
M:<_:,^*7[0/@#Q;\6M1\5ZWX7\)>!8/!7A;3=.^'FF:]=>&O"^H7D'C7P1XN
MU;5[CQ4VB:AXQTO7[>;2=)U+PKX@\.'3=+G@B&O:W_/1_P %*/V,M3_8%_;/
M^-/[,\TOB/4O#'A#7+;5?AGXG\3645MJ'B[X8>*;"WU[P9K;WEE:V>D:U>6^
MG7I\/>(=5T.VM=+?Q;H7B&Q2PTFZL;O1]/\ [B_^"LG[<^A?\$BO"7_!+'X
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M .F^XK_7F_X)4_\ *+[_ ()O_P#9AG[(/_K/OP]K_(9\4?\ (L^(O^P%J_\
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MO4=?AM[&&YN]6T*'PG::=I-T\T;1:9>W-G=1SK!8?9/YKJ_6?#;CS!>)/"6
MXJP6"Q&6QQ53%8;$8#$SC6J83%X.M*A7I*O"%..(I7BITJRITG.G.//2I5%.
MG'\F\2.!,9X<<68_A;&8W#YD\+2PN)P^/PT)4J>+PF,H1KT*KH3G4E0J<LG"
MK1=2JH3A+DJU:;C4D4445]X?"A1110 4444 %%%% !1110 4444 %?=O_!!W
M_E.!XZ_[19>-O_6K_A!7PE7W;_P0=_Y3@>.O^T67C;_UJ_X05_/?TH/^30YU
M_P!AV5_^I)_1WT5O^3N8#_L2YU_ZCP/[HZ***_RK/]0@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K_$.\!?\BO9?]?>L_P#IZU"O]O&O
M\0[P%_R*]E_U]ZS_ .GK4*_<? W_ )'.=_\ 8LH_^I4#SLQ_AT_\;_\ 26=C
M1117]+GD!1110 4444 %%%% !1110 4444 %%%% !1110!_5U\"_^"$/[)G[
M;G_!,V]_:U_8H^,7QT\7?M)VO@.3[3\&/%?B;X5ZIX>T?XY^$(=)U#Q_\(-6
M@TSP'X7UNVN]5L7O!\.K[5-=T)]0T[Q)X%\7ZG"-$U5K:?\ -C_@C7_P2@U_
M_@IW\>?$6@^+K_Q=X#_9X^%NB7.H_%7XC^&(=-CU8Z_?HUIX2\ >%+W6M/U?
M21XHU>[,^NWLMUI&IV.F^&=!U0W@M=0U7P\M[]8_\&SW[;OQ#^ ?[<6B?LP0
MZ?K_ (O^$W[5[WVB:OX<TV?5;T^"_'?A7PUK7B31/B7I>@VMO?6TD2Z5HM[X
M>\=S)%I83PQ-:>)]6UAK'P%;Z;=_UY?\%%/B7X,_X),_L(?M7?M#?LS_  <T
M_3_B%\3?B+>^+M4N]%L)!HX^-/QLUC3_  [??%SQW*LI-MI^B+]FGM;6U@6T
MU7Q#;>'/#LB6*Z_>ZS;_ (9GO$G%7#F;9EPG2Q%3,,9Q#7P=3A3,L1.A[3 4
M<PKO"UJ-=V2?U>4)4\-.<;QJ0>(G&I&JHQ]*G1H5:<*[2C&DI*O!7?,XI--=
M=4[OO>W1G\;/Q3_X)H_L(?\ #W?X*?\ !-;X!_&/XY^,O"5UXBO_  7^T)\4
M=7\4?#36=3T/X@66A^(->U3P%X!BT#X<Z7HMGJ7@N'0[;1O%VIZZ=?DM_%NH
M:SX9F\/Z3>>#;N76_P!@_BW_ ,&[G_!&#X ^(;'PC\=_^"C_ (S^"GBS5-%@
M\1Z9X8^+?[17[*?PX\0ZCX>NK[4-,MM>L=%\8^ -&U*[T6XU+2=5T^#5+>VD
ML9K[3-0M(YVN+*YCC_G<_P"")&J:EKG_  5T_8]UK6+Z[U35M7^*OB?4M3U+
M4+F:\OM0U"^\ >.+F\O;R[N7EN+JZNKB62:XN)Y))II7>21V=BQ_LF_X*\_\
M$(-:_P""HW[17@3X[Z;^TUI?P6A\&?!70OA(_AB^^$MWX^EU&71O'/Q"\9'7
MEU>#XB^$$M8[A/'*:>-..G3M$VFM<F]D%V(+=\59MC<BS_(<EQ_&6993E_\
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MI>BSZHEA;^%-&UW6X;G2M/\ $WB/0O/T[6IIK?1-2_;C_@ZG_;%M_BW^UEX
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M2YTF/3=6\-^,-9N+J&+1/"FB7BWT=SX=M(X6>\D@$$UP'@>0Q21?AW7];O\
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MP^%-/N_&6DR^%M&N[SP/KFH>'],U))K30[=KOP_HUQK5I7KOP:\ ?LM>&O\
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M6>?9K7P5#&5J>'RFG56(PV&PDJM7#UL56KRC&6%Q-:I"G0I3J1_DYHK]Y_\
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MM<GP-9MJWB/Q-I'AC==)XG\07NHQIX?\*Z5)8B[M=5TB_-NEQ/J=C+:Z4OI
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M273KN632[FWMO[,L9+.\!CL[FSL9/D+_ (*?_LF_"SXA_LLZ'^V[\.?A//\
M WQ]!%X7U_XF>#-2T-_!>H7^B>-[V&QNE\4^%;+1S;'XA:/XKUG2UGUB3^QF
MU2PN]8EUB_U2Z@T.W3SN'?I"8/.LWX>HXWA/'9/P[Q?F<\HX9X@K9UD^,KXO
M&NHZ.%CF60X6H\QR>EC:J]EAZU=U8U)RIN'/2<ZM/T.(?H^8W)LIX@K8/BO
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M\1'EJRH8>C.,S^-6BO[.?V7/B7^R=_P4<^"7Q.\ Z5^SYIG@7P+X6EMO ?\
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M ((OM8^(/Q&UG6[[P3XQM_L4VL:6=0U*TB\)NU[K_C/38X;33;$W$MC\<_\
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M_P 0?&3P!_P01_X(V_L^V?C+X::3\2_%FD:/X'\ :A\*;7Q9K&BZ5\1?C/\
M%5-6\>?%Y!XOU7P9XUN=.T*&9_B'XA@FUOPG%I4MEI^G>%(;30_[2TG3X/\
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M&[;X"> /[;'B/QC_ &)X7A@?Q18/:S:XM];QZA<6T>F7OY0_\'4/[+:?"/\
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MFHG3?SX_X*#^&?VTOAA^Q]=W'[3W[<GA_P 7CXC/X6T&^^!>D? 7X::8-?\
M$D&L:?XENM)TWXA>'K#2==&E>%UT==8NO$<&BZ7;75S9V6C7,$*ZU;"X_#CX
M8?M2?M'?!>P72/A9\;OB;X(T-$N4B\/:)XNUB'PW";NZ-[<S0>');J;0X+N:
MZ:2=[V'3TNS)/<D3@75P)>!^(WQ2^)'Q>\1S>+_BEXZ\5_$'Q--$+<ZUXNUS
M4-=OH;-9IIXM/LY-0GG%AIEO+<3M::98K;Z?:>:ZVMM$AVU\?PAX#YWPUFO#
MU&IB_#JKD'#69?VA1S:CX?9-5XZSBG0Q;Q6!PF99OF&%Q=/!U</)4U'-<MG3
MS.FJ:=.M[7V=>E]?Q=X[Y+Q)E7$%:EA/$.EG_$F6_P!GULJK>(&<TN!\GJ5\
M*L+C<7EN49?BL)4QE/$1=1RRK,H5,MJ.H_:472=2A5_IR_X+#?\ *.KX(_\
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M-X?&83&8/#XFOB</0EB\)C</AL1A:E2IA:UJ%>G3KJG[*O*DJ&(P]2KZN?\
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MB#X=_#_7+"+Q@-'@A9A<Z/8V6O>)!?W5Q<[+.TM=0.C07MPXMK*^N+_99/\
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M?C^TTZ!98+KPU\./!_B'Q\^DZW+)8:C!:^'_ !3JGAS2_!^KRSQ0&XM_$/\
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ML]*UZ[O=;BT6*\31X;70/$%P=2DM3#H&N2!=*N_GG_@N4(OV??@O_P $LO\
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M_P#[,,_9!_\ 6??A[7\_^.?QY#_AQ/YQ/4R[:IZK\D?P9W?_ ">#_P %4?\
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M7[&GB'Q!#%XDOM.MM6=_AAXKUJRN+FP@\.:[<2VGA[2M0UK4;"VU?3M*&O\
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MU=8KB:,+(WZ3Z-\=?^"=?Q^^%OP@\'?M.?#;XJ?!;XB?"#P5'X2/C[]F[1_
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M>.O^T67C;_UJ_P"$%?SW]*#_ )-#G7_8=E?_ *DG]'?16_Y.Y@/^Q+G7_J/
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M8(=.O?L^D:8I\N_X)^_&/_@@C_P3U^(7Q'\:?#[_ (*'_M'?$'0OBW\*M?\
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MNFT/08]#33M8U.RN[>SU&#3[_P ')!>R7*/J/BJ[L+%_#=S^6G@?QEK'P_\
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MO?'O[+__  3'_8*_9O\ VAM9DF_MCX]:)\--)U[Q-!'J5C>KKUWX8M-+\/\
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MAHK] OVTOV*]&_9XT'X7_&3X/?$1_B_^SA\:]-6\\!^.;S33HNNV.IB![M]
M\0:7+':3">:PC:\M+M]-T>[2>WU?1]5T/2K[1]^H?G[7T'#_ !!E7%&58?.<
MFQ$L1@L1*O2_>T*^%Q.'Q.%KU,-C,'C,'BJ=+$X3&83$TJN'Q.&Q%*G5I5:<
MDXV<9/P.(.'\UX8S2OD^<8>.'QM"%"K^ZKT,7AL1AL70IXG"8S!XS"U*N&Q>
M#Q>&JTJ^'Q.'JU*52G--2YE******]H\4**** "BBB@ HHHH **** "BBB@
MHHHH **** "ONW_@@[_RG \=?]HLO&W_ *U?\(*^$J^[?^"#O_*<#QU_VBR\
M;?\ K5_P@K^>_I0?\FASK_L.RO\ ]23^COHK?\G<P'_8ESK_ -1X']T=%%%?
MY5G^H04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_B'>
MO^17LO\ K[UG_P!/6H5_MXU_B'> O^17LO\ K[UG_P!/6H5^X^!O_(YSO_L6
M4?\ U*@>=F/\.G_C?_I+.QHHHK^ESR HHHH **** "BBB@ HHHH *_1W_@G]
M_P %0OVDO^"=^J^++#X8#P=\0?@_\2VME^*WP"^+6AMXI^%_CJ.&VETYKY[!
M+FSU#0/$)TN>6R.K:/>PVNJ1P:7;^+=)\4Z7HVG:7!^<5%<F.P.#S+"U<'C\
M-2Q6%K)*I1K14H2Y9*4)+K&<)QC.G4BXSISC&<)1E%-5&4H24HMQDMFG9_\
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M%?M-U[_"O_)1Y+_V,<-_Z<1G5_A3_P +/X :***_ND^;"BBB@ HHHH ****
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M\FD>%--UCX1_"G3[[Q)JJ1O'(^FZ':W$NJ7R))&[6MK*%=&(8>OK_P $=/\
M@G654M_P7D_9*5BH)7_A75F=I(R1G_A>PS@\9P,^@KR;_@N=<^"[/_@MM^T-
M=_$BPUC5?AW:_$+X"W/CW2_#KQ1^(-2\%P?"?X3R^*;#0I)[W388]8O-#6^M
M],>;4;");V2!I+VU0&>/UH?'[_@VEP-W[#'[?9.!DCXG:2 3CD@?\-!\#->_
M1K9K2X;X0675.(:<7P[E;J_V)EN1X^#:P&#Y?K$LW:G3G;F5-4/=DG)SU43"
MT'5K<ZI/][*WM)U(_:=[>S^YW\K'Q7^W-^PA^R=^RQ\,?#7C3X&_\%*_@O\
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MI:P*L^KZM,/M^MWXFU+4IV=HTA^8_P#@EA_P3\^%/_!1+5/VF/@WJWQ6\0>
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MXPQ="K0Q6$A1TE*I"GB+151+Z?\ ^'>7[(G_ $E)^ G_ (2-K_\ /2K\Y?\
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MM=RSLMI>3^$%%G;7FB^([&\S?^"B\CS?L<_\$PY96+R2_!#59)'8Y9W?P_\
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M_DQXX_\ )VN._P#L>5?_ $Q0"BBBOTH_*0HHHH **** "BBB@ HHHH ****
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M^H\#^Z.BBBO\JS_4(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT:[4?=3JPD^73;0****[S@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \J^.W_)$/C)_P!DJ^(?_J(ZQ7]YW_!(/_E%9_P3H_[,L_9N_P#53^%J
M_@Q^.W_)$/C)_P!DJ^(?_J(ZQ7]YW_!(/_E%9_P3H_[,L_9N_P#53^%J_@CZ
M9_\ OW!/_8)F?_IZD?W_ /0T_P"1#QM_V-\K_P#4*N?HO1117\/']HA1110
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MW1_R/\07_A97@G_H-?\ E.U;_P"0*/\ A97@G_H-?^4[5O\ Y K_ &^J*/\
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M"?\ H-?^4[5O_D"O]OJBC_B.><?]"/+?_!^*_P P_LZG_P _)_='_(_Q!?\
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MI_X;^_9(_P"BL_\ EA_$S_YC*/\ AO[]DC_HK/\ Y8?Q,_\ F,K_ %5J*/\
MB<KCK_HEN$__  './_GF'_$GGAM_T/N./_#CD/\ ]#9_E4_\-_?LD?\ 16?_
M "P_B9_\QE'_  W]^R1_T5G_ ,L/XF?_ #&5_JK44?\ $Y7'7_1+<)_^ YQ_
M\\P_XD\\-O\ H?<<?^''(?\ Z&S_ "J?^&_OV2/^BL_^6'\3/_F,H_X;^_9(
M_P"BL_\ EA_$S_YC*_U5J*/^)RN.O^B6X3_\!SC_ .>8?\2>>&W_ $/N./\
MPXY#_P#0V?Y5/_#?W[)'_16?_+#^)G_S&4?\-_?LD?\ 16?_ "P_B9_\QE?Z
MJU%'_$Y7'7_1+<)_^ YQ_P#/,/\ B3SPV_Z'W''_ (<<A_\ H;/\JG_AO[]D
MC_HK/_EA_$S_ .8RC_AO[]DC_HK/_EA_$S_YC*_U5J*/^)RN.O\ HEN$_P#P
M'./_ )YA_P 2>>&W_0^XX_\ #CD/_P!#9_E4_P##?W[)'_16?_+#^)G_ ,QE
M'_#?W[)'_16?_+#^)G_S&5_JK44?\3E<=?\ 1+<)_P#@.<?_ #S#_B3SPV_Z
M'W''_AQR'_Z&S_*I_P"&_OV2/^BL_P#EA_$S_P"8RC_AO[]DC_HK/_EA_$S_
M .8RO]5:BC_B<KCK_HEN$_\ P'./_GF'_$GGAM_T/N./_#CD/_T-G^53_P -
M_?LD?]%9_P#+#^)G_P QE'_#?W[)'_16?_+#^)G_ ,QE?ZJU%'_$Y7'7_1+<
M)_\ @.<?_/,/^)//#;_H?<<?^''(?_H;/\JG_AO[]DC_ **S_P"6'\3/_F,H
M_P"&_OV2/^BL_P#EA_$S_P"8RO\ 56HH_P")RN.O^B6X3_\  <X_^>8?\2>>
M&W_0^XX_\..0_P#T-G^53_PW]^R1_P!%9_\ +#^)G_S&5^M'_!N5\8/AS\:_
M^"T/Q'\4?#+Q%_PDVA:?_P $RO'N@WE]_9&NZ-Y.K6W[47P1U":T^S>(-,TJ
M\DV6>IV,WGQ6[VS>?Y:3-+%,D?\ ?=17Q?B!])+BCQ$X9QG"^:Y#D."PF+J4
M*TL1E_\ :$<3">'J>TA;ZSC,12<&])Q=--K:43[;P_\ H\<&>''$='B?),UX
MGQ>/HX7%82-'-<7E5;".GBX*%24H83)L%6YXI)P:KJ*?Q1DM HHHK^<S]Z"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O\./PIXW\+Z/H
MD&G:CJGV:\M[O5?.A^Q:C-L\[5;V>/\ >06DL3;HI$;Y7;&[:V&! _W'**^R
MX-XQQ/!N*QF*PN"H8RIC*%/#N.(J5(0A"%3VC:5-<TI2DHI-R2BE+23DG'"O
M0CB(QC*3BHMO1*[=K=3_ !!?^%E>"?\ H-?^4[5O_D"C_A97@G_H-?\ E.U;
M_P"0*_V^J*_0/^(YYQ_T(\M_\'XK_,Y?[.I_\_)_='_(_P 07_A97@G_ *#7
M_E.U;_Y H_X65X)_Z#7_ )3M6_\ D"O]OJBC_B.><?\ 0CRW_P 'XK_,/[.I
M_P#/R?W1_P C_$%_X65X)_Z#7_E.U;_Y H_X65X)_P"@U_Y3M6_^0*_V^J*/
M^(YYQ_T(\M_\'XK_ ##^SJ?_ #\G]T?\C_$%_P"%E>"?^@U_Y3M6_P#D"C_A
M97@G_H-?^4[5O_D"O]OJBC_B.><?]"/+?_!^*_S#^SJ?_/R?W1_R/\07_A97
M@G_H-?\ E.U;_P"0*/\ A97@G_H-?^4[5O\ Y K_ &^J*/\ B.><?]"/+?\
MP?BO\P_LZG_S\G]T?\C_ !!?^%E>"?\ H-?^4[5O_D"C_A97@G_H-?\ E.U;
M_P"0*_V^J*/^(YYQ_P!"/+?_  ?BO\P_LZG_ ,_)_='_ "/\07_A97@G_H-?
M^4[5O_D"C_A97@G_ *#7_E.U;_Y K_;ZHH_XCGG'_0CRW_P?BO\ ,/[.I_\
M/R?W1_R/\07_ (65X)_Z#7_E.U;_ .0*/^%E>"?^@U_Y3M6_^0*_V^J*/^(Y
MYQ_T(\M_\'XK_,/[.I_\_)_='_(_Q!?^%E>"?^@U_P"4[5O_ ) H_P"%E>"?
M^@U_Y3M6_P#D"O\ ;ZHH_P"(YYQ_T(\M_P#!^*_S#^SJ?_/R?W1_R/\ $%_X
M65X)_P"@U_Y3M6_^0*/^%E>"?^@U_P"4[5O_ ) K_;ZHH_XCGG'_ $(\M_\
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M.I_\_)_='_(_Q!?^%E>"?^@U_P"4[5O_ ) H_P"%E>"?^@U_Y3M6_P#D"O\
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MRN.O^B6X3_\  <X_^>8?\2>>&W_0^XX_\..0_P#T-G^53_PW]^R1_P!%9_\
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M<<?^''(?_H;/\JG_ (;^_9(_Z*S_ .6'\3/_ )C*/^&_OV2/^BL_^6'\3/\
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MJG_AO[]DC_HK/_EA_$S_ .8RC_AO[]DC_HK/_EA_$S_YC*_U5J*/^)RN.O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQT;X5VGBBQ>/0=?O?&J1W::5XVU:!_RK_P""GWQ=_P"#>OQC^SSX%B_X)8?
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M/Q2EU/7/"UGXWT33H_!]SJ$6KO?ZQX2U"P\0:59K;&XU#3;ZSGM(YA<PA_\
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M//I/B6;[;X3U:-_B?XPU744\5Q&YL]#TWX?_ &[_ /E9N_X(8_\ 9#/VYO\
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M]FOXW:9;>(]!O(98)K36M$FNDU/2[F*:&6"^M8)8Y8V0. #^E+X;_P#!0/\
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M^,+Z?Q#X ^).I2WGBR"\O2NJ_#&&Y@U%OAKX2E\,@'7?\%V/^"J7P_\ &O\
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M_!/'6_VD?CW\$?AW^T3\1OB1\1?B3\*[0_';P=H/Q6\.^ /A)X.UV6:#X=>
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MYL+?Q/\ #G]F76X;.XEBQ%+/:QWJP2R1@1NZ,R *17QA_P %O/VK?V8O%_\
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MK2/%F@O>0)&UYI5W=Z1=7(TS7=,:9(-8T#4UL]:T:[W66JV%G=QR0+_DQ_\
M!+7XU?\ !#S1]%^-_P 3/^"R7PX_:@_:?_:(^(OQ'UF[\/1Z!J7B^_\ "5GX
M5U?1;:]UKQSK/B+PS\8OAEXP\0?%'QCXO\0>+?[;OO%&I>((--M]%\-Z]H3V
M'B.[U'4'_1#_ (-O_P!K/P%\(O\ @N_XH_9__8OU?XIP_L,_M=S?&KPUX/\
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M6_$?AB"_ENH--O/$?A9+B/Q)H>GZK-8WT6DZCJFE6MAJKV5XNG7%R;6X\O\
MG8_X+D_L3_ _]I?_ (*9_L!_$KX@_P#!6SX<_L/^-?A3H/@1?#WP+\5^.?\
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M/B%I?![Z#H5M.+JQ@\/K;7,36@!_8Y_P56_;W\$?\$\_V*?C/\>=2^(_PO\
M!OQ0M_ 'C"']GG0?B3=M<6?Q(^,%OX?NKWPGX6TGPS8:GIFN>*VFOA:SZC::
M/<PI:6!:\U*]L; 27(_(O_@WS_X+RZC_ ,%&O GB_P +_MJ?%G]ESP#^T[JO
MQIU/P9\$?A#X*OHO /C+Q_X-TSX<^'O%E[J.F>!/$GCKQ/K^N&WOG\2B+5;"
M.WM+E-+O[.!;BXTN[$7YX_"/X<?#7_@HA_P:;:/\4?VL_"E_\5/B/^QS\$/V
MI=2^!_BW4_'GQ"TZ^\-^)O@_?^/O"/P\\0W$7A_Q/HT/B%M!\':3H&@+HGC
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M_FZ8%;]*_P!C#_@AW_P3O_9[_8V\ ?LZ>-_V3OV??C'K%_X'TF3XR>/?B/\
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MHEG_ &7X@O8H)(-'U379)AX:T[4%:YAMKJVO=9@DL=09M,O1;ZA'+:I\M?\
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M$,]Q'*0E?@+X)^#WA#_@JW_P<)?MFZA^U/X<T+XG? #_ ()4?#SX1?#7X%?
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MW^FV6G?\)UX-TK2/%5Y8V,L\.M64=SJTDMGXCT[3M>MIHM2MO/< _H"\>_\
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M_NU31+."32KSP?HFE:)>PW,6C*TGLW_!*#]E+]ES6?\ @M!_P7=\(ZQ^S9\
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M>'_\%U_^E=7_ ,ZY?L>?_,31_P /#_\ @NO_ -*ZO_G7+]CS_P"8F@#\&?\
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MCX1?%WP/X3UTW.G^,VT;4VM/#WCOP%;*SW>EZ1X9U?2_#FKB?QQ>Q_._Q/\
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MX<O^"IO[5_[97_!7CP-^Q$_[-'_!+K]N#P%^RU\)_P#@H5^S5\3/%OCWXX_
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M9;>#(_%-M;_#WX>V_AJ_N'O9[_1?%WA_4)[72K3P;XM\77FK^)KKX<^X6O\
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M 7]FW7B/Q;X='A[1%OK(66IPZ99_\)[\6;OQ+<>&](\&>#3JG]6E% '\%_\
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M[.ZTJ[DAO[>:W3]YO^'A_P#P77_Z5U?_ #KE^QY_\Q-'_#P__@NO_P!*ZO\
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MMO$J?U'?\/#_ /@NO_TKJ_\ G7+]CS_YB:/^'A__  77_P"E=7_SKE^QY_\
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M^'-OXD/B'Q'\/]#\7:'\7=43P.?%HDN--U/Q=I7AB]\0Q6TEO)#*TVEZ2UB
M?V=_\&X_[$UC^Q/_ ,$IOV=M(U'0#H_Q2^/.AQ_M'_%R>\TF?1==F\0?%6VM
M=9\*Z)KNGWDL]]8:AX)^&P\&>#+VQN6MW34M#U"\ETW2[R_N[&']4OVL_P!G
M'P?^U]^S-\=?V8/'UYJ&E^%/CI\,?%OPXU36M(9AJOAY_$>E3VFF^)=,03V\
M5UJ'AK56L=>LK&]=],U"YTZ*QU6WNM-N+NUF_'O3_P#@H!_P7+TJQLM,TW_@
MW+@LM/TZTM[&QL[7_@K;^QS!;6EG:1)!;6UO#'X(6.*&"&-(HHT541%55
MJW_P\/\ ^"Z__2NK_P"=<OV//_F)H _FA_89^(O_  69_P"#;+5OVB/V5-9_
MX)H_$?\ ;@_9X\<?$75/&_P^\<_!S1_'<GA"7XC7&A>'O#</Q"T;XG> ?A7\
M4)KGP_XO\$>%?#J:I\*_&^A^&O$^GWVA)+IUYX9O;7Q7:ZQ^Y/\ P1C^/?\
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M;P,GB+0_&>FZ+K6A:-XBN;W2C'K5WIY@ATJ_768(;ZWC2*?\F?\ @VF\>_\
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M,<D<BE'C=+:)71T8!E=6!5E8 J000"*_BW_88_95_:@\(_\ !KO^V?\ L_\
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M][=Z];VT7@C7(=7GO-,T=;:X6T%J+Z&X\]/SD_X)H_\ !3?]ICQO^UG\:/\
M@EO_ ,%+OA[\*/AQ^W=\#O NG?$_PMX[^"&L:E<?!;]IOX0RS:=8OXX\%6'B
M*0ZOHGB6"'5M$UR]T*9K*]UFQO?$E^O@7X>CP3K_ (<L/GC_ ((R_P#*9?\
MX.2_^R[?L8?^HM^TG0!_3I17XP?\$1_V]?CG_P % O@K^UMXY^/4'@>'7_@5
M^W[\>OV8?!TG@7P_>^';6\^'?PQ\)_"?6/#]]X@MKS6M:6]\57%[XSUAM5U*
MP.EZ=<1BSCM='LA QEP==_X**?'G3/\ @OAX-_X)GP:5\.'_ &>/$7[$%U\?
M[W4YO#^MM\3(O'T'B/Q79H;7Q(GBB/14T0V>A6ELVFS>%IW*27,@NA</%-"
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M](TN9-.FMEDTZQ<-;1 '>T5^._\ P5H_X*-_%O\ 8MF_9/\ V??V5_A5X/\
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M8]6UF*\\+W5SXPTK3FBN_!?AW6/"FOW4>I+XDL;&OTNK\7_VG/V]OCG\'_\
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M_'CQ+^PSXIT?X@>(OC=\,O@5X?\ #]WXDU[0?'?Q&MK/PUIFO?$OPUX3T_\
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MX@^*O[3GC+1?"&GZA\2O'?A^ST"#7-"^&GP\^)?C"#7-.^ 7A75/%5EXBO\
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M]-2>XB.JZ?'Y9EO+=)/Y^O@+_P %!/\ @J%^R1_P4F_9_P#^">W_  58T?\
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MV]L[626YB /I2BOY;?A3\6_^#F7]M?X,>#_VNO@U#_P3@_9+\"_$W0K#QO\
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M+H"Z_P"-0#^A6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4#V'B'1C/K6L6/A?1[:;PC%K^I:Q9@']8%%?SW?\%H?^"IO[2O\ P3]^.O\
MP3+\ ?LY_"_2_C':?MC>//C/X/\ $WPXCT&&_P#B%XRUSPO9_!VV^%GA?P-K
MFI>+?#/AOP<NO>*OB.UAXP\0Z^NI6NE>'GGU6'[++I9>?Y-_;!_:@_X.//\
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M2 /Z9:*_F7_X)O\ _!97]H7]MK_@E[_P5$_;KU[PS\/_  YXM_9<\5?M9?\
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MT/@-#\5?"7Q+\'?!36_@Q>>'[GQ9X>U_PE\0W\5:OJ^O>+OBY\5-4USP9?\
MQ5\??&OQ9JNM7$^N^-M:^)LEO/;VNE:7;:)::1I&G6%L ?#7Q=_Y6VOV6_\
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M]-TJ\T9--M/M-WJ'VXV5KI^ISSQZ==>Y?L%?L4_"S_@G;^R=\*?V.O@IK_Q
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M[7O_  4 _P""CMW\%M?OO%'PP^&O[<7[1$OQC^"OAGQ'=_V/)%X@_P"$!O\
MPW#=:CJ<%UHUK+=V-]XDE\(>(+>&SLO%'A/6K>P@% 'A?[<MS'>_\',__!"B
M\A6X2*[^ 7[<%S$EU:W5C=)'/^SS\:Y46YLKV&WO;.X57 FM;NW@NK>0-#<0
MQ2HZ+R?P:\6>$OV>?^#K+]MS2_C>UOX5U7]M;]C?X%/^RCXU\;06VDV?B0^
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M[U&ZU_3=*O-&CTVT^TW>H?;C96NGZG<3QZ==?T7_ /!!KXO_  O^-'_!(/\
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M=?B\:Z=H.G03^&M"T^Q\)Q>'M!\-@'Q=_P $3/A1#\#?^"]/_!9#X2K^T?\
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MO[?7_!.C]F7_ (*0_"G2/AA^T3H'B""_\&>((O&/PF^+OPXUQ/!GQJ^"?CB
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MS5\ O@?^SGX%U#Q!JW@CX!?"#X:_!7P=JGBV[TZ_\5:EX6^%G@S1? WA^_\
M$M]H^E:#I%YX@O-)T*TN-9NM+T/1M.N-1DN9K+2M.MGBM(?G3_@G1_P3X^#/
M_!,C]FC2/V5_@-XF^)WBWX>Z-XM\7>,[76/B[K7A77O&4FJ>,]034M4@N-0\
M&^"_ .B/803H$L(H_#T5Q%$2MQ=73XD !^&?_!,3PYJ_C'_@J+_P=*>$?#]W
M/8:]XI\7_LS^'-$O[618;JRU?7/AI^U#IFFW=M*UW8+%/;7MU#-#(U]9*DB*
MQN[8 S)^:7_!O]^PE^V-^TI_P3WT&?X(?\%B/VA_V0$^$_Q9^+_PN^(G[+G@
MOX,^#-57X/>/M/\ &VI^(M0T_7)/%&JZ!XBCUKQ)IOB/3/%=]%J=E,UE=:O<
M:.ET)-)GT_3_ .OC]F;_ ()\?!C]E7]IK]MO]JSX>^)OB?K/Q#_;T\5?#+Q?
M\7]&\9ZUX4U'P9X;U/X4V'C;3O#T'PVT[0_!?AW7-'L;R#QYJ[:U%XG\1>,;
MBXEMM-:QN=.2&Z2\^)/VK_\ @@Y^SQ^T#^T+XE_:M^"'[1'[8'_!/WX^?$41
M-\8O&/[#OQEF^#%G\9;V&*ZCB\1^/]%M-(O5N/%P%W<_:==T.]T1-;EU#6M2
M\3:?KNOZO<ZTH!\C?L\_\$Q;;X5?\%</V;_C)^TC_P %H/$G[6W[87P(^$/Q
M+U?PA^SC\1_!_P -O!OQ*\1_!3XA>#_B%\/[JY:S\/\ CR?Q'-X-T7Q)XJO_
M !A:K+X?U:U_M?0Y)XTM(VN-0@N?\$:?^4S?_!R+_P!EP_8S_P#49_:0K](/
M^">O_!(#]E__ ()W>+_B;\9O!_B+XT_M _M2_&NV.G?%K]K+]J'XB7'Q4^._
MC#0GFT;4)O"9\1'3]&TW2_"\VM:%INL7<5KI#^(]?NM.T)/&/B;Q1'X5\*#1
M?:?V9_\ @GQ\&/V5?VFOVVOVK/A[XF^)^L_$/]O/Q5\,O%_Q?T;QGK7A34?!
MGAS4OA58^-M/\/0?#;3M#\%^'=<T>QO(?'FL-K47B?Q%XPN+B6VTUK&YTY(;
MI+P _';_ (+._P#*9'_@VW_[+U^V3_ZBW[-])_P6>_Y3(?\ !MQ_V7G]LK_U
M%OV;Z_8K]IO_ ()\?!C]JW]I;]B3]JCXA^)OB?HWQ"_8+\7?$OQG\(-'\%ZU
MX4T[P;XDU3XJ6'@G3O$,'Q)T_7/!?B+6]8L+.#P'H[Z-%X7\0^#KBWEN=2:^
MNM12:U2SP/\ @HG_ ,$R?V9/^"G'PW\%> /VAHO'^@:O\+?&">/_ (1_%KX/
M^+E\"?%SX4^,!#%!-K7@KQ//I>O:; ]VEM8RW5CK6@:UI<E]I>C:LMBFKZ)I
M%_9 'Z%5_.G_ ,'57@3Q=XX_X(K?M(2^$K;6+_\ X0CQ=\$_'?B;3M%MKB]F
MNO"6D?%3PU8ZS<WUK:S),VCZ"=6MO%&K7/V>^@TRRT.75KV"VL;"YU33_P!G
MOV1_V?;[]E;]G?X:_ #4?C7\8?VB)_AM8:SI<7Q?^/GB.W\7?%GQ58:AXFUO
M7M+@\6>([:RTZ/5#X8TS5;3PCHDS6J3Q^'-!TB"ZEN;J&:YF]WU_0-!\6:#K
M?A;Q3HFD>)?#'B72-2T#Q'X<U_3;/6=!U_0=9LYM.U?1-;TC48;G3]5TC5=/
MN;BQU+3;ZWGL[ZSGFM;J&6"5T8 \F_9E^*OPY^.G[.?P(^,WP@AL+3X6?%/X
M0_#KQ]\/+#3+---L=+\'>*O">DZSX?TB'2TM-/&D_P!D:9>6^F2Z0^GZ?+I,
MUI)IT]A936SVL7\[G_!&'5/#'QB_X+'_ /!??]I#X2:GH'B;X(:[\2OV9OAI
MX=\<^&;W3M1\-^+O&O@SP;XPLO'<WAO4]%EO-)UFSL]7T][Z]UFWO#'J0U_2
M]0MWO#?73VWIFJ?\&S_[/&E:CXY\-_ ?]O+_ (*@?LH_LX?$8^(AXC_90_9W
M_:LF\*?!&TLO%<6K)X@\.:%H.O>#_%&?".KOJ]Z^I:%XO7QFUY%J.M64E^+'
M48;:P_:G]C[]CG]G?]A#X$>$_P!G']F'X>Z=\._ACX2^T72V<$DM_KGB7Q#J
M B.M>,O&GB*\:35/%/B[79((#J.M:G/)(EK;6&CZ=%I^@Z3I.E6 !^$__!M7
M_P ?'_!9/_M,!^U!_+P_7].U?"?[$'_!/?X,?L#/^TO)\'O$WQ/\2']JG]I#
MQY^U#\0A\2]:\*:P-&\?_$,68UK2/!O_  B_@KP:=/\ !]K]AB_LO3];/B+6
MH-TGVOQ!>Y79]V4 ?A'_ ,% O^">_P"R)_P4._:^\,ZI\-?VVOB1^R?_ ,%0
M_P!F/X.+%I'C7]ESXN:9I_Q=\(_!CQ)K[W^DZ?\ %[X=070U>X\!7%[XVU^7
M2;"UUCX?W^NVWQ NUUG4_$7A>^L]*/Q-X&_:@_X*E?\ !+O_ (*0_L2_L0_M
MT?M5_#__ (**_L^_MY_\);\//A)\2K#X1^'O@O\ 'GX2>+/AS%X;M8]<\6^&
MO >DZK'XA\.7Z>(- AU;4_%?B;Q;J6LR:CXC\1W'C+1_^$&U.W\4?J;^W-_P
M1P_9I_;?^+_A;]ID?$3]H[]E+]K+P5X0O? WA_\ :?\ V//BY>_!;XN2^%[F
M.[B@T+Q%JMMIFL66N:9;V^HZII;RBQL->N?#VJ7GA]]?33(M,BTW@_V-?^"'
M/[-G[*G[0=I^UW\1?C1^U1^W/^U=HWAB;P;X,^.O[;OQ=;XV^*?AEX<EEOO]
M!^&BWFB:=_PCDXL]2U&RCU6^N=<UC3K?6O$UMH%_HNG>)]:T^[ /B_\ 86_Y
M6<_^"XG_ &07]AO_ -9_^"M</_P;@>,/"7PI^,G_  6&_8O^(SP^&OVJO!__
M  4I^,_Q?UK2O&-M'H'Q"^(7PF^(-IIFF>!O%6DV^J#^U?%WA=)_!7B'Q?;Z
MCI.I^(=*LM*^(^A>(DN(=.\<Z/JOB#]P?A1_P3X^#'P=_;K_ &J?^"@WAGQ-
M\3[[XS?M>^$?A5X,^)7AG7=:\*77PQT/2_A!X/\ "_@GPU/X'T73_!>F>*M-
MO[[2O">G7&NRZ_XT\36]SJ$U[+86NF6TD%I;?AY^WII7_!!']M#_ (*(?$'X
M+_M6_$7Q9^Q7^WG^SOIO@S2K?]H@^.Y?V,==^+6C^./"MF]CIW@KXM>(9[+0
M/BE_8OA^ZM/!MM?>*=)M]7O=(UEM(^&6H^)?";SW5J <1_P<,?''X47O_!1W
M_@@)^SI9:]X>U/XTZ'_P4B_9]^+>N^'[>;S_ !+X/^'NL_&WX3^%M#O=11+&
M5+#3?&^N:?J8LX9M3M+B\D\&/<#3KRWACN[3W']O3_E9H_X(8_\ 9$_VW_\
MUG_XUU^2WQ]^#/\ P3MT?]O'_@C-^Q!_P2N\=>'_ -IWXO:'_P %$O"/[7G[
M7'Q;T7XSI\?_ !I-X<_9_P!<\)^*-2UKXU?%RRNM6T&_\167@ZR\>QZ)X=TJ
M]T]/#B^%9]+U'0M*U+Q-ILNK?UY?%O\ X)\?!CXS?MS_ +*7_!0+Q1XF^)]A
M\9?V/O"WQ4\)?#/PSH&M>%+7X9:YIOQ>\'^*/!7B6?QUHVH^"]4\5:G?6.E>
M+=2N-#DT#QGX8@MM0@LI;^VU.VCGM+D _/'_ (.B/^4%7[<__7+]FW_UKWX
MUW_[5'[.O[!_[9?_  3^_8E_9%_;@^*MM\+Y_B_IG[/5[^S;>:!\3=#^'/QG
MD^._ACX>:58Z+JGP2&M6NM0:[XLL-'\5ZIH-]!=>$_%.DV>F^+F-Y86NHW>B
MW]O]^_MY_L6?"S_@H?\ LG_%?]COXU:_X_\ #'PR^,*^"%\3:[\+M5\.Z+X[
ML1X"^(_A#XGZ/_86I^+/"OC;P_;&YU_P5I5GJ7]H>&-3\[1[C4+>U^QWLMMJ
M%IY;^UO_ ,$O?V3?VW/V8_AU^RQ^T!X;\3:_X1^$$7@V;X5>/=#\1GPO\7?A
M[K_@?1;?P]I7BOPQXTT>QMXK+6[S2;<VVM6\FCS^'=5:1+BXT'[3I^D2Z< ?
MS]_ME:%_P6-_X(2_ B;]L#PU_P %/S_P4 _9%^#GCOP GQ*_9R_:_P#AQH%E
M\9/$'A'QYXP\-_#\Z=X?_:*\WQU\2_%/B6&^U/2GM;IM<\/:;H5M>:UXLN/!
M_B1-$U#2=?\ ZU/A1X_L?BQ\+OAO\4M,T^_TG3?B3X#\(>/=/TK58)[75-,L
MO%_A_3_$%KI^I6UU!:W-O?V<&H1V]W!<6UO-%<1R)+!$ZM&OX-Z5_P &XGP
M\6>.O!OB']KO]N#_ (*4?\% OA[\-_&UAX^\#? /]LO]J&Z^+/P7A\1Z4;N/
M3]1\6>$Y_"]B?$]Q%8W!TVZAMKO0-'UG3+G6-'\0:1JV@ZU=:2O]#=I:6FGV
MEK86%K;V5C96\-I9V=I#';6MI:VT:PV]M;6\*I#!;P0HD4,,2)'%&BHBJJ@
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M=,\,Z19Z+83ZE/9VMC:37\UK9127<MK96=O)<-(\-K;QE8D .NHHHH ****
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M6B:SX5\+^%= \/\ C"[UO2IK[3K^R/AG1O#4EA--)X@;3=#AU/4(/YHO@O\
MLA?\&N/QV\'S_M'_  ^_;.'P.^"'B[4;3XF_%3]CKQ)^W'9? SX;V&L:U+!<
MZCX0^*WP \0>)[7Q9I2W5S9VWA9]"T/Q!_8&K0Z)9Z+X(U'4M'@LGG /?O\
M@WV^-'PQ_:%_X*K?\'"'QB^#>K:+XA^&?C7XS?LTWOA+Q+X=\PZ+XITZRU']
MIW2F\5:?)+8::\\'B:ZL;C71<FV87+7[7"W=^L@OKCVK_@UX_P"2%?\ !3+_
M +2[?M2_^H#\#J\R_P"#<Y/"7Q1_;#_X+4?M8_ 3PU:Z5^QU\4OCS\$O@O\
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M#-K+=7=B^CV@DTZ7Q GA'6;2"ST_Q#X5U>UL8$H P?\ @J-^VK^W%XP_;?\
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M6&E^'K*?0;37M*\2:E:W\MU+J.K:I;O%:P 'P7_P:X?\H0?V0_\ L8/VG/\
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MN+QC%XN.H>#M,A-_/X\N=&^QSW\8T 3RV]Q:_P S'[,W[ 7P2_;\_P""O/\
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MA"]T;R'AT]73E_VMM>^'W_!)S_@OK\)_VT_$,UC\/?V8_P#@I!^S1\4OAO\
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MZ%\,_#GA[6O"EI\-M<M/BCX5\1^$/$$GCK1]2\%ZMXGU.YL]-\3W\^COX?\
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MH'Q ^'7C'0SG1?''PZ\86L+W_A7Q7IP,L*W]HCVU_87-[I&K66HZ/?WMA/\
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MM C\*^(H8(Y[O1O$OB+4I[?PMH.H::9!:ZO;ZMK=H^C:G'<:3JHL]4M;FSB
M.W_9L_X)H_\ !/\ _8^\47'CK]F?]D#X"_!WQY<VMU8'Q[X3^'VB)X[MM,OX
M4M]1TG3?&FH07WB?2='U***(:GH^EZK9Z9J+11R7MK/)&CK]Q5!:W5K?6MM?
M6-S;WEE>6\-U9WEK-'<6MU:W$:S6]S;7$+/%/;SQ.DL,T3M'+&RNC,K G\]O
MCI_P5L_X)G?LT^/=4^%OQP_;@_9S\ _$C09Y;/Q)X&O?B-HVJ^*?"M_"(FDT
MSQ=HOA^75[_PGJPBGAG72?$<.F:E);2QW4=J]NZRD _1"BL'PMXJ\+^.?#NC
M>+_!7B30/&'A+Q'I]OJWA[Q1X6UC3O$'AW7=+NT\RUU+1M;TFXN],U33[F,A
M[>\L;F>WF0[HY&'-6-?TN37-"UK1(=7U;0)=8TG4M+BU[0)K6VUW1)-0LYK1
M-7T6XO;/4+.#5M-:87FFS7=A?6L5Y#"\]G<Q*\+@&M17XT_\$:_A=\'OV8OV
M*/B/>>!_^"B7B7_@HE\++[XW?&'XN7?[3'C3Q5-XOM?#>DKHWAFVU/P%IVNC
MQ5XVBN].\$Z7X776?$]]8:NMMJ_CS7?&FOQ:'X>DU:30-/\ H7Q]_P %;/\
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M7EE<0W$)958QR*653D  UJ*_&K_@M?\ L^?#G]HCX _!?PG\2O\ @HQ\0O\
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M=(^,7[.OQ7\#?&;X8:[<7UGIGC7X?Z_8^(=$EO\ 3)S;:GID]Q9R.]AJVFW
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M6@17D<>G^$K/Q%-8Z[?7_A^SD\2F'20#^H2BOYR?^"4/[>'[7GA/]LOX^_\
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M\2=$34/%.HV\R0MIGA*:_FL[#Q9JLQ<S66E^'+S5-0U&SANK^PMKFQM+JXA
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M  <Q?L'?LI_![X,?\$[?B;^SE\&? 7[*7Q4F_P""BGP&_9UL?BC^RSX-\'_
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M6OCKQ?X.GCN]#\7Z+#X;\:+H_B+2O$$T6D7[_#GP1HMUX6US0M6\7OJ'0?\
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M'Q#?:A+=:AJ/BF]\(>'M!C\5:WJ%]?7_ (D\1P:IXEO;A;K6);:W_7SXW?\
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M4)M0TNU\.:-?Z3H5ITG['G[.'[>7_!3/_@H1\*/^"J/_  41^"FH?L>_ ?\
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M%9$^&O@CP8OA2[U#]5_^"3WP2^,_PY_X*U?\%^OB1\0OA'\3_ GP[^,GQ?\
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M/WFI>$= ^)OQJ\.> =-:RCTB_P#$-K9:KXIT[0-&;4HO#]A_0]7(^+OA_P"
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M+:XO#HFIWVGW%K8:O]DM-1TBZNO[-NI8KW[-;:MI=Q/Y/E0ZC92,MS%_!?\
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MB)\(OB'9:_X.U+Q/X>4:B][X#\5ZMX6LK+4=4TN'59T\+ZYJDVF6A\2:7##
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M= BM)_'J:.OBJ:VBT&SM-$C@DU9HDTBUMM-5!9P10K_0Y\5O!]S\0OA=\2?
M%E>0:=>>./ /C'P?::A=1R2VUC<^)O#NHZ+!>7$47[V2"VEO4GFCB_>/&C*G
MS$5_-5_P;T?%;]H3]E+X=^"/^"//[4'["O[4WP>^)O[/T'Q]\4Q_M'7O@J3Q
M!^RU\0-&\1_&?Q!\1],;P[\5]*C_ +!:[OT^(UYI.EOI]YKFBW\WAB=3KEMK
M5_)X>TP ^5?^#<O]@K]F#X\ZC_P4?_:-^/GPL\)?'3Q/X6_X*/\ [2GPG^'7
MA7XOZ#IWQ%^'?PSLSI/PV\3>+_%_@CP'XLAU;PCHOC_XA+K>@^'_ !9XUMM$
M7Q/=^&? WAOP_#J\.D+?65UZW;?L\?##]@W_ (.COV?-._96\*^'?A!\/_VX
M?V)OBAJ/QM^%_A#0--T3P++XB\*:AXKU8ZYX5\.Z9'::+X7FU;4/A;X)U*\B
MT?2[5EU5?%M\MPX\9:I;I]>_\&Y/P2^,_P #_@S_ ,%"]+^-7PC^)_P@U/QK
M_P %1_VD/B#X-T[XH^ ?%?P_O_%O@+7?!/P<M-$\;^&;/Q9I.DW&O>$-8NM+
MU.VTKQ+I4=WHVH7&G7T-I>S26EPL<G[4/P3^,WB#_@XV_P""</QPT'X1_$[6
M_@KX&_8^^-_AGQK\7](\!>*M2^%W@_Q)JR?%P:5X>\4_$"RTF;PGX?US4SJ6
MG#3])U;5K2_O?M]E]FMY/M4'F 'XX_\ !4C]LK]C;QK_ ,%_[_X1?\%,="^(
M_P 2/V3/V _@1X)U'X2_L[^#_AKKWQ8\&_$?]H/XK^'_ (?_ !/U'XB?$[P/
MH\>I0>(/"^E^$_&NG^'-4T;6X+70M9O?"W@ZPU"QO=';Q+I_BKYF_P""KW[>
MG_!*CXF_##X>?';_ ()A_ KXL_LV_P#!0S]F[XH> ?'WP0^(7PO_ &._%7P&
MC\0:#9:O=:;XT^'GC74O"F@:3HVL>$]3T'Q#J6KWNGZU;>=J,>E3>&5U!=#\
M2:_HNM_OE^WK\$/VL_V$O^"F5I_P6&_9)^ ?C7]LSX=_%7X%V/[.G[8/[+WP
MQMQ??'*UM_#QM;KP/\6/A#8KI>JW?B.PM4\->$]'U[P?H]C+K,-U8WMYY>I6
M'BF;4? F+J__  65_;W_ &T/'?PP^"7_  3*_P""9/[6/P>\6WOC3P_JOQD^
M/?\ P4F^ ,_PJ^ _PR^%T6H"P\1M)I'A[XGP7WCC6+E+Z'4M/T+0/B-X9\<7
M]OHNJ0>'/#^L@7]_HP!_1O\ #'Q=)X_^&_@#QU-I5_H<WC+P9X9\42Z+JB>7
MJ>DR:]HUEJCZ;J";(]E[9-=&VNEV)MFC<;5Q@?SB?\%J_P#E+A_P;D_]G%?M
M9?\ J*_ "OZ<8O,$<8F*&;8GFF)66,R;1O,:LS,J%LE%9F8+@%B<D_SN_P#!
M7;X)?&?XE?\ !4+_ (((?$#X<_"/XG^/_ ?P=^//[3FL?%SQMX*\ ^*_%7A'
MX6:1K_AKX(0:%JGQ'\2:%I-_HW@?3M:GTG58=)OO$U[I=MJ4NF:A'9RS/97*
MQ@'Q'_P43_9>^&G[7?\ P=!?L3?"+XS0ZIK?PI7_ ()K2>,_'/P_MM4U'3O#
M_P 4]/\ !WQT_:!U;2? 7Q M].O+,^(/ %WXH30=>\1>$]1^UZ'XG3P];:-K
MNGWVDW=W;N__ (.<OV,/V5OV<?V%_ /[;?[.WP"^$WP#_:6_98_:2^"/B_X7
M?$OX+_#_ ,(_#'6&D7Q.]Q#H7BN3P;HVCR>)-!LM;M=)\3Z/'=2QZKX?\0:3
M%=>']6TNVU7Q+9Z[]L_&7X)?&?5/^#FO]E7X]Z9\(_B?J/P+\._\$Q_%'@'Q
M!\:+'P#XKN_A-H7CJX^,'QHU.#P7K'Q&M])D\'Z9XMGTW5=+U"'PY>ZQ!K$M
MCJ5A=I9M!>6\DFA_P<^_!7XR?'[_ ()-_$?X<? CX2_$SXU_$*^^*_P?U&R\
M!_"3P'XI^)'C.\T_3/$<L^I7]KX7\':5K.N7%GI\!$U]=0V+P6D1$D[QH<T
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M7_X+.?M>_M/^!M8_99^!'_!(?_@H9\&_VT?B1H]]\/[OQ)^T3\)-(\&_LN_
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M?%7XLZ]\:=)CUSXX^#]"^*T?PW\#>!_C[\4/#6F?#KX6:?XZL]?TSP!X/O\
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MW!:>'-1 /M?_ (+1V0TW_@I__P &X^G"]N]2%C^T5^TG9C4+YK9[V]6V\&_
MN$7=V]I;VEJ]S<!!+,]O:V\+2,S1PQJ0@\\_X.//@7\$M1^/?_!'CQMJ'P=^
M%E_XS^)/_!3_ /9V\$_$7Q=>?#[PE=>)_'W@R?Q7X T:;PCXUU^?2'U7Q3X8
MFTBSM-*ET#7;N_TJ33;6VL7M#:P11+Z5_P %"?V5OVA(?VO/^#<*P\/^!/BI
M\;M,_9A\>_%;2?CQ\6_!_@+Q3XM\->$!;_#CX&:#;>,/B3XC\/Z ^C>"M/\
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M=SIFFWVN0P3P72F^:-8);C]F*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *_.;4OV"!K_\ P5)T/_@HYXF^(<FN
M6G@G]D2;]F;X;_"=]*^RVG@O5]7^(]_XV\5?$%=36>=-6U'7-/NUT&W_ -'T
MR?3[.34;>\?6X)M(&@_HS10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
@% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img75897552_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_10.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" && R@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.TEK9-13UUZ?T^T445^ GJA1110 4444 %%%% !1110 4444 %%%% !1110
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M:?#_ /\ "-\.?_*VNC_8O^HK_P I$^__ '?Q&_\ "W/A3_T4[X>_^%IX;_\
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M%3?"O_HFGP__ /"-\.?_ "MH_P"%3?"O_HFGP_\ _"-\.?\ RMH_V+_J*_\
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M_"IOA7_T33X?_P#A&^'/_E;7?(B1HD<:+''&JHB(H5$10%5$50%554 *H
M   %95?8>[['VO7F]KR>5N7E^=[^5AJ_6WRO^HZBBBLAA1110 4444 <5J/Q
M*^'6CWUSIFK>/O!6EZE9R>5=Z?J/BK0K*^M9=JOY=S:7-_%/!)L96V2QJVUE
M;&"":7_"W/A3_P!%.^'O_A:>&_\ Y95?U'X<?#S5[VXU+5O ?@S5-1O'\V[O
M]1\+Z'>WMU(%5!)<75S8RSSOL55WRR,VU57.  *7_"IOA7_T33X?_P#A&^'/
M_E;72OJ=ES?6>:RYK>RM>VMKZVOM?6VY/O=.7\1O_"W/A3_T4[X>_P#A:>&_
M_EE1_P +<^%/_13OA[_X6GAO_P"65._X5-\*_P#HFGP__P#"-\.?_*VC_A4W
MPK_Z)I\/_P#PC?#G_P K:?\ L7_45_Y2#W_[OXC?^%N?"G_HIWP]_P#"T\-_
M_+*C_A;GPI_Z*=\/?_"T\-__ "RIW_"IOA7_ -$T^'__ (1OAS_Y6T?\*F^%
M?_1-/A__ .$;X<_^5M'^Q?\ 45_Y2#W_ .[^(W_A;GPI_P"BG?#W_P +3PW_
M /+*C_A;GPI_Z*=\/?\ PM/#?_RRIW_"IOA7_P!$T^'_ /X1OAS_ .5M'_"I
MOA7_ -$T^'__ (1OAS_Y6T?[%_U%?^4@]_\ N_B-_P"%N?"G_HIWP]_\+3PW
M_P#+*C_A;GPI_P"BG?#W_P +3PW_ /+*G?\ "IOA7_T33X?_ /A&^'/_ )6T
M?\*F^%?_ $33X?\ _A&^'/\ Y6T?[%_U%?\ E(/?_N_B-_X6Y\*?^BG?#W_P
MM/#?_P LJ/\ A;GPI_Z*=\/?_"T\-_\ RRIW_"IOA7_T33X?_P#A&^'/_E;1
M_P *F^%?_1-/A_\ ^$;X<_\ E;1_L7_45_Y2#W_[OXC?^%N?"G_HIWP]_P#"
MT\-__+*C_A;GPI_Z*=\/?_"T\-__ "RIW_"IOA7_ -$T^'__ (1OAS_Y6T?\
M*F^%?_1-/A__ .$;X<_^5M'^Q?\ 45_Y2#W_ .[^(W_A;GPI_P"BG?#W_P +
M3PW_ /+*C_A;GPI_Z*=\/?\ PM/#?_RRIW_"IOA7_P!$T^'_ /X1OAS_ .5M
M'_"IOA7_ -$T^'__ (1OAS_Y6T?[%_U%?^4@]_\ N_B-_P"%N?"G_HIWP]_\
M+3PW_P#+*C_A;GPI_P"BG?#W_P +3PW_ /+*G?\ "IOA7_T33X?_ /A&^'/_
M )6T?\*F^%?_ $33X?\ _A&^'/\ Y6T?[%_U%?\ E(/?_N_B-_X6Y\*?^BG?
M#W_PM/#?_P LJ/\ A;GPI_Z*=\/?_"T\-_\ RRIW_"IOA7_T33X?_P#A&^'/
M_E;1_P *F^%?_1-/A_\ ^$;X<_\ E;1_L7_45_Y2#W_[OXC?^%N?"G_HIWP]
M_P#"T\-__+*C_A;GPI_Z*=\/?_"T\-__ "RIW_"IOA7_ -$T^'__ (1OAS_Y
M6T?\*F^%?_1-/A__ .$;X<_^5M'^Q?\ 45_Y2#W_ .[^(W_A;GPI_P"BG?#W
M_P +3PW_ /+*C_A;GPI_Z*=\/?\ PM/#?_RRIW_"IOA7_P!$T^'_ /X1OAS_
M .5M'_"IOA7_ -$T^'__ (1OAS_Y6T?[%_U%?^4@]_\ N_B-_P"%N?"G_HIW
MP]_\+3PW_P#+*C_A;GPI_P"BG?#W_P +3PW_ /+*G?\ "IOA7_T33X?_ /A&
M^'/_ )6T?\*F^%?_ $33X?\ _A&^'/\ Y6T?[%_U%?\ E(/?_N_B-_X6Y\*?
M^BG?#W_PM/#?_P LJ/\ A;GPI_Z*=\/?_"T\-_\ RRIW_"IOA7_T33X?_P#A
M&^'/_E;1_P *F^%?_1-/A_\ ^$;X<_\ E;1_L7_45_Y2#W_[OXC?^%N?"G_H
MIWP]_P#"T\-__+*C_A;GPI_Z*=\/?_"T\-__ "RIW_"IOA7_ -$T^'__ (1O
MAS_Y6T?\*F^%?_1-/A__ .$;X<_^5M'^Q?\ 45_Y2#W_ .[^(W_A;GPI_P"B
MG?#W_P +3PW_ /+*C_A;GPI_Z*=\/?\ PM/#?_RRIW_"IOA7_P!$T^'_ /X1
MOAS_ .5M'_"IOA7_ -$T^'__ (1OAS_Y6T?[%_U%?^4@]_\ N_B-_P"%N?"G
M_HIWP]_\+3PW_P#+*C_A;GPI_P"BG?#W_P +3PW_ /+*G?\ "IOA7_T33X?_
M /A&^'/_ )6T?\*F^%?_ $33X?\ _A&^'/\ Y6T?[%_U%?\ E(/?_N_B-_X6
MY\*?^BG?#W_PM/#?_P LJ/\ A;GPI_Z*=\/?_"T\-_\ RRIW_"IOA7_T33X?
M_P#A&^'/_E;1_P *F^%?_1-/A_\ ^$;X<_\ E;1_L7_45_Y2#W_[OXC?^%N?
M"G_HIWP]_P#"T\-__+*C_A;GPI_Z*=\/?_"T\-__ "RIW_"IOA7_ -$T^'__
M (1OAS_Y6T?\*F^%?_1-/A__ .$;X<_^5M'^Q?\ 45_Y2#W_ .[^(W_A;GPI
M_P"BG?#W_P +3PW_ /+*C_A;GPI_Z*=\/?\ PM/#?_RRIW_"IOA7_P!$T^'_
M /X1OAS_ .5M'_"IOA7_ -$T^'__ (1OAS_Y6T?[%_U%?^4@]_\ N_B-_P"%
MN?"G_HIWP]_\+3PW_P#+*C_A;GPI_P"BG?#W_P +3PW_ /+*G?\ "IOA7_T3
M3X?_ /A&^'/_ )6T?\*F^%?_ $33X?\ _A&^'/\ Y6T?[%_U%?\ E(/?_N_B
M-_X6Y\*?^BG?#W_PM/#?_P LJ/\ A;GPI_Z*=\/?_"T\-_\ RRIW_"IOA7_T
M33X?_P#A&^'/_E;1_P *F^%?_1-/A_\ ^$;X<_\ E;1_L7_45_Y2#W_[OXC?
M^%N?"G_HIWP]_P#"T\-__+*M_0O&'A'Q2URGACQ3X<\1O9+$UXFA:WIFKM:+
M.7$+7*Z?=7!@68QR"(RA!(8W"$[6QA?\*F^%?_1-/A__ .$;X<_^5M;VA>$/
M"?A=KE_#7A?P[X=>\6);Q]"T33=(:Z6$N85N6T^VMS.L)DD,0E+B,R.4QN;,
MS^J\K]G]8Y].7G]GR[J]^77:]K=;= 7-?7EMY7N=%1117.4%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%?(/[3W[4^L? C7OA?\ #CX;
M? _QO^T?\;/BW#X[UWPK\*_ ^O>$/"-Q#X#^%FG:-??$/QSKOB[Q[JNC>%=&
MTS1KSQ3X,\,:59W=\M_XB\7>-/#ND6,<=M)J>IZ8[5/VTOA/9?L:Q?MN:=9>
M*];^&=_\-=&^(>C>&K32[:V\>ZE>^(GL=,T7X?2:1?7UOI^E>.)_%VI6?@C4
M+/5=6M=*T3Q&;E-6U:UT^RNK^( ^O**_*S6/^"F>H^%? 'Q D\9_LN^/_"O[
M07PQ^*GAGX7>+/V?=1^)/PGDVR^+/A)K/QZT;Q3I'Q>M_$,GPXU'P]??"KPS
MXFO+,RWUEJ4GC719O!%S865S<6NIR_8GP)_:5\,?M#:SXW3P#X>\1#P=X(TO
MX;K=>-]9@AT^RU#QKX]\&VGQ"U3P!9Z<7ENFUOX?^$?$7@6?QE=K))IUAK_B
MN3PFD\FN>&?$5M8@'T?17P7\9OV\/#7PC\2?'/PQ:_#?Q7\0=6^#U]^S=\/]
M&T?PIJ.B0ZW\3OC_ /M1:_>Z/\/?@QX=BURXTS1=&O+'3[OP/XF\4>*_$NO:
M=HVB>'?&UOJMS$+32;N6;S36O^"C/B73/A=!?V?[)_Q)U+]I>V_:7T7]E+Q%
M^RFWQ!^%NE^)M'^)FN^ ;CXMZ=JEI\3-3U^#X<ZQX!U+X2):?$;2/%D6I6L=
M]H5W):7%C8:[INJZ39 'Z?T5^=7B#]O/Q#\/_$_[.O@;XK_LU^,_A_XV^,::
M9=?$;P]/\2?A7X@?X':;XJ^,_A/X$>!;[4-1T7Q#/IGQ(_MWQQXZ\+7>L6_@
M*ZOY?"?A2[O]<U7?+IS:=/\ 5WP#^,VG?'_X;6'Q8\/Z!JVB>#/$^K^)#X O
M]9,:3^-_ >F:Y?:5X7^)>GVBJLUEX9^(NFV4?B_P?'>A+Z[\):MHFJ745M)J
M'V6  ]GHK\T/ ?\ P49F\<>.? =^/V8/C-HG[*GQ?^(*?"GX/_M<W>H^!-0\
M(^-/&NH:M?>'_"6IZA\,=(\0WWQ3\'?"WXE>(--FT3X;?$_Q!H$.D>(+S4?#
M%WJ5CH&B>*=&U>Y^J?V;/VC_  9^TI\+? GQ(T",>&K[QWX=U+Q5:> M9U?1
M[GQ?IV@Z=XKUCP@VK7FGZ?=2NVF7&JZ-/%#J,,;67G.MH9OM221J ?0U%<%\
M4?$OC/P?\/\ Q3XF^'OPXO\ XN^--&TUKOP]\-=+\2^&O!VH>+[\3PQC2K3Q
M/XQO=.\,:/*T+RW N]9OK:TQ 8C*))$!^7/V0?VMO'_[27BG]H+P-\2?V9?&
M/[-_BW]GGQ1X%\'^)+#Q'\1?AG\3]*UG7O&W@BT^(7]E:7XC^%^MZYHT6J^'
M/"NM^$=3U_2[JX2[LH?&&A[EW2RI& ?<%%?ES9_\%.]"\1>&OCKK'A']GGXP
M_P!N_"GX[?"+X#>"O"/Q*;PY\']7^+>K_&C1/">O>#O&=L/&NH6\GPX\$:EI
MOB:34-/N?B-:Z'XAO=,LK6ZD\.6=QK>FV+_3'[.W[6?A3]IO4)#\//"OB>+P
MQ8?"7X-_$;7O%&MK9V=MH/B?XU>$K;XA:%\)+NV@FNEN?'7ASX?:IX:\6>,T
MT^\N],T*T\8>%;7[7<W.J,ML ?5U%?*WA3]M;]F/QC\9/VBO@/I/Q>\%1?$?
M]E31]#\0_'#2M2\3>'=/A\&:!K/A^#Q+<:[J$\^K![71?#.G7=DGC'5K^&RT
M_P ,7M]:6>J7,,TP4>X?#GXG_#;XP>%+'QW\)OB#X)^)W@G4Y+B'3O%_P^\4
MZ'XQ\,WTUI(8;N"UUWP]?:CID\]I,&@NX([EI;:96AG2.12H .YHKX,_9A_:
M]^+7[2GC3Q T7[(OC;X?_L_VGB'XM^&_"'[1.N_%GX/ZUHWCN]^%7Q(UKX:F
M?3OAOX>\1WGQ'TC3_%FH^'-:U30[S6M&MHH]+M8);TQ-?6H=?B)^UY\6M'_:
M?U#]G'X-_LC>-OCO9>#O"_PB\6?%CXIZ/\6/@_X"\.?#?3_B]XB\<Z3I5O<:
M#X]\1:3XG\4:CI&C^ =8\4:E9^&K&]E;3KC3;:W#WMY%$P!]Y45^9W_#ROPH
MOBSXT^#Y/@]XX?5O GC&/X??"*VL=?\ !NI7OQ^\:_\ "\_&/[-MQX<T32[+
M59=1\"7\/Q9\"^(R#XSM[:V?X;Z?>_$R2X@T/2==@TKU[XG?M<OX!\6?'?X:
M)X,@/Q!^&?A+X >*? -M?:XSZ5\0K']HWQUJOPB\'7UQ]GTZ*YT6TT/XLZ%J
M_AWQ%;Q2:C<?V7%INK020OJT5I;@'VG17P1!^U9\4=#^)WB/P/\ $/X9^#='
MT[1OB]\%_!:7OA/QIJ/BR]T_PQ\>?$?Q \&>!K;Q2\WA_1-)TKXC6U_H/P_\
M;Z_X>TF^\065AX(^)&GQFY^UVEMJ6J_>] !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%_$CQ
M_P"&OA1\._'GQ1\9W4MCX0^&W@SQ1X]\57L,)N)K3PYX0T2^\0:W<PVX93<3
M0:;I]S)% K*TTBK&""P-?&G[*O[87Q3^,GCU?AG\>OV=D_9V\8>+_@QH?[1_
MP@TZT^)MO\35\5?"'6-<M] U73O&+Q^#O!K>"/BW\.M0UOP5;_$/P99IXL\-
MV4GC;1O^$=\=>(E@U$VA^T#^PAI_QBM_VF-9L_CA^T1%KOQ_^!7Q6^#\7PY\
M1?&WQOJW[./AR?XB?"Z\^'5OJ^G?!1KP>%].DT]Y(-;,VGPQ70U:74=2BD6[
MO96/S/\ "?5OVN_$7Q1T+]IOX@_L:?$SP=K'[-W[)4'[.%C\'[OQS\%I/%GQ
MH^+_ ,5_B7\'];^,'BKX:Z]I?Q)U+P@_PA^'^C?"C0K[PUXB\<:IX+\0>+QJ
MNNPVWA.PO-+AM[H ]]\,?MA_'/XA?MC?$[]G_P"'WP.^"FI_!WX.?$C1_AOX
MY^*OB+]J3_A'_BW->R_"7X>?%+Q3JWA#]GBT^#6NS>(-*\+'XE:#X;EN[SXE
MZ);7NI1:@WVFT>TDMAYG\ _^"G-[\=-4T_P=IGP;T8?$7Q;\7?"?A'P3X:\,
M?%BT\86=O\-=8TG4_&/CGQC\3]3M?!]A=?#?QQ\%_!&AWA^)OPWN=)UB+3/'
MGB3X8>![;Q=+<?$33]0L/-/C%\"/%_CS]L7PI)X6_8!\,> /B?X;_:Z^$'QR
MM?\ @H9X/B^$MCI>M_ +PII&AI\1]+\9^,(=;T_X[7GQ3\<>%=,\2_L]:G\*
MI?!VK^"[[P_K^C>+G\2_V+9R"PX_X[_!K]MG3?BUJ/[1WP"^&VJ^!?%OC3XI
M>,/A]X:\*?#2W^#,%[HG@#0M3T>3P-XN^,[^*9!I4O@?]H#XD0>*?BA^T/K/
MA1]0^)[^!]$^ GA.2>"^\'ZRH /U;_:+^.%S\%-)^%<.C:';^)/%_P 8OCM\
M+?@CX0T>[NI;.U:Z\:ZS+>^*]<N)84DFDA\%_#30/'/CA[2((U\/#7V(S6ZW
M#3Q_)GPQ_P""@7C'QQ\6O \.O? 6P\)?LO?&OXX?%_\ 9M^!'QW_ .%K66I^
M,?$_Q:^#5U\2+.^_X3;X/R^$=+/@SP7\1+OX/_$RT^&^LZ?XZ\5Z[<7'AW2E
M\5>&/#:^+M--IW_[<=I<:5XI_87^*+VGVCP[\*_VVO D_C&Z=&:WT/1?BS\*
M_C%^S[I.O7,@1TM8;/QW\6O!EI->3-#;VMMJ%Q+--&@)K\^?"7[&/Q U[]N/
MX?ZL?V?_ (Z?";P5\$_VJ?C+^TU=ZUK'[0.E>+OV+KF3Q'X6^)6C^%M?_9R^
M$]IXME\8Z!\4_C9XB^(]IXR^+MAXJ\":7X>^&6I6GQ;M/"4TG_"?65_KP![W
M\(?^"DGQT^('P ^,?[4_B7]FSX,:+\$O!'PL\2_$;X?W'@?]K0?$CXA^)9[;
M5C!X+TWXE^#(O@=X;TWX1:5XG\-I+XNU;77\6>,IO#&DQMG1M7*320_1G[,/
M[;%[^TIXA\)>$=(^'FB0ZM8^#OB)XD^.&O\ A3XAQ>./AY\/K[PM\6_%?P;\
M 6/@KQA9^&--A^)%E\:-8^'WQ \:^"+Z2S\*7%I\-_#47B#6=/M[G7M#T^^^
M)_V:/@GXK\-?'F#XI^&?^":VC_L>67PI_9?^-OPX_:!\)_#V'X'Z7X*_:X^(
MGB+Q+X*U_P"'WA/X46G@CQ+Y'Q!\)Z1)X3\>:YHOQ$^-6B^ M:TP_%*W\-W-
ME;S:MXWBT[;_ &=/@A^VE\#OVG?A=;2:%>:7\-_B3I^E_$G]H*+P';?"ZT^
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M^A;^.W_B,'[27_SJ*/\ AHKP%_T+?QV_\1@_:2_^=11]2QG_ $"8G_P15_\
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MZ%OX[?\ B,'[27_SJ*/^&BO 7_0M_';_ ,1@_:2_^=11]2QG_0)B?_!%7_Y
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MJR/\ _V@'1E*LK>#?#;*RL,,K*?&9!4@D$$$$'!XKZ"HH]MAO^@./_@ZM_\
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MYK'AV#_A'C%JOAS5[7Q+;2OH27-_!D,^XZ*** "BBB@ HHHH **** "BBB@
MHHHH *\@^/'P*^&G[2WPK\3_  4^,6BWGB7X9>-O['A\8>&;37=<\.Q>)M*T
MC7--UYO#NKW_ (=U#2]4N/#FM3Z7#IWB715O8[+Q#H-QJ&@ZK'<Z5J-Y:S>O
MT4 ?S"_L Z/IVGZ?_P $%=+^P6MAX.T#1/\ @IE:>$],@2.VT?2_'&FOK>F>
M#[73+!"EO%>Z?\,S\4[/2$AA+6>BC6HH#%"TH;>_X)YB&_\ V\_AW/>M:77P
M[TR+_@N'!^S_ "[H1HT<(_X*4?"B#Q6_A>(!(71+">ZLTN[:+;_97VRVM9FL
M4F0?LGXH_P""?_[)/C'X">"OV9]<^%)/PA^&WB2?QE\.M)TGQQ\1?#?BKP#X
MMNM2\1ZI<>)O!?Q-\.>+=)^)WA?79Y_%WBBUFU/1/&%E=RZ1KVJZ#)*^B7L^
MGO1^('_!.G]C#XF?!_X3? ?Q-\#M&M?A?\"HY8/A#HG@WQ'XX^'&J> +.]TV
M?1M<T[0/&/P]\3^%_&L&F>+M)NKO3?'6FR^(9K'QW:7=U'XO@UHSR,P!^0MO
M+JVH?\&UGQ=_L:>>?1&^ 7[35IH4]G(T$$OP&MOC=\3+/2#ITJFW/_".-\"8
M;8:8T.R.;PY]F-L&BDC5O;OVD/@UK_QJ_P""B<'@3X#^(_"7A3Q/X-_8/_9B
M^-^ARZUI]]?^ '\4?L__ +=-C\2O@!H7CRU\.26NIQ>$O%%EH'Q:\,6=SI5P
M=2T[2[_7M6T>SO)=+%G<?JYI7[*'[/6AZA;7FD_##0[&QM/V?[7]EFV\)PW&
MK?\ "O(O@%97DUY;_#A?AH^HMX .E W$UG)>MX;.M7&D.=$N-2ET@"R'._LU
M_L3_ +,O[(6F^+],_9Z^&@\!CQW_ &/#XHU2X\7^._&?B74--\-6=WIWA+P]
M%XL\>^)_%'B;3?"?@K3K^\T_P1X0TO5K/PQX.LKFXM_#>DZ9'/*' /Y^OA1\
M:OB=^Q?K^M^/=-\)>"/CS:?!WX:?M6ZAJWB_5=>U[P'X?;X-_!+]HKPKXX_;
MQ\0_ 73(=+\87EUXG\>_M4_M#R?#WX9Z?XHNK'0[OX=?LJ:!+K.MF^\06D\/
M]5H((!'0@$?0\U\>>*_V _V1_&_A#X(> _$WP>T^_P#"G[.R16WPJTF'Q+XU
MTM=+TS[3HM_J'A_Q+=:3XDL;WXB^%?$>K>'/#VN>,O"GQ%N?%7AOQMK^AZ5K
MOBW2]9U6QM[M/L2@ HHHH **** "BBB@ J&YN;>SM[B\O+B&UM+6&6YNKJYE
MC@M[:W@1I9[BXGE9(H888E:2661ECC16=V"@D35\V_ME>$;'Q_\ LA_M3^!-
M4\=VOPNTSQG^SI\:_"NH_$N^DGBL?A]8>(/AMXETF\\:W\EJDES'8^%[>[DU
MN\>W1IUMK*4Q*9 HH \6_9C_ ."I7_!/G]LOXH^,/@M^S%^U5\,/C!\4? MK
MJ6H:[X/\-W>KV^H3Z5H^H)I6J:WX7N-;TG2M.\=:!I]]+!#=Z_X(O/$.C0K=
M6=P]\+>\M995^'O_  5*_P""?'Q7_:?U_P#8R^'7[5OPL\6?M,>&K[7=*U/X
M6Z9?ZF;Z36O"Z2R>)- T;Q#<:7!X/\2>(M 2WO#K/A[PYXAU76M-.G:H+RQA
M;2M1%K_'!\!=1_:9M?C+_P $ ?AQI/P:_97^''B+X*> _P!JWP-\'?B=^S!\
M:?"/QC\0_M3_  ^T?]F?Q3'KWQJNU^'VDVLG@/X6Z[>Z9I/FZ=XQU2\\1^)O
MB9XA\4ZD;?P_>6$UH+WPJT#X)6'_  1X_P"#?GQM\++/PK;?M<S_ /!5_P"#
MEO'KVD6M@GQ:U/XA:C\=?BG9?'NQ\5W(MF\6:A!_9=AH<7BY+]9X$L['PB]Q
MNM1I+. ?V_\ [1O[17[-/[&W@#Q/^T7^TI\2_!'P5\"V\6@^'==\?>+KM[7^
MTI+2;6KKPUX:T^TLX;S6/$>L&74]>GT?P]H.G:EK%UY^HR6EC,J3%/"+'_@J
M=^P-K?[*>H?MK^%OVB_"_C/]G+3O$^G^!9O&?@[1_%WB/6Y?'^KZUIOA[2/A
M];_#K3?#TWQ(E\>ZKJNLZ3#I_@X>$U\0W5OJ-GJ,6GG3)X[P_E__ ,%__%NB
M>//#/_!.CX>?!BZ\*>,_VH]6_P""F'PM3]F8^(]4\/ZI^S_HWQM^&EAXAB\2
MZ-^TEO74I9?"FGZ)KU]8ZAX/T..'Q]<:_+I\>C)!<6ERC_&?[!'[.%K\?_"7
M_!6?X3?'SXIZ?^S%^W'^SY_P4F^'/[9'QH^./P+TWPOK?[-7PK^(W@31M.^(
M_P '?%WPC\.>-M/2PU'P1I7A;PKXC@^)_AKXDLWB4ZA<ZC<>)M4$SQ) VV]6
MVW9+5WT222]$DDET226@']0'PT_:Z_9P^,-G\";[X:?%CPYXNC_:8\ >(/BC
M\$H=*34Y+WQOX!\)0:'+XJ\2Q6+V"7>B6'AN?Q+H6E:Y_P ))#H\VF>(-4M/
M#EU%'KL@TX?1]?R.?\$GOVB_A+^R]\;_ (?_  ;UOX5?M!>+A\5K'X,?L[_!
MWX^^)]-\!VWASX-?";XIZ3\8/CK^S+X'\=^'(==T_P 9:/\ $/\ :\_X1[XE
M?M0_$BZ\+^#CX8\(W7C_ .&/PX\226<O@?36A_KCI %%%% !1110 4444 %%
M%% !1110 4444 %<_P"+?%?ASP'X5\2^./&.LV/ASPCX-T#6/%7BGQ!JDPM]
M-T+P[X?TZXU;6M8U"<@B&RTW3;2YO+J4@^7!#(^#C%=!7S;^V3X(\)?$O]D;
M]J'X>>/G\5Q>!_'/[/GQC\)^,)? FCW'B+QM#X9U_P"'WB'3-<G\(^'[-DN]
M>\2P:;<W,NB:+;,)]5U)+:PB^>X6@#\__P!D?_@NC^Q!^V%\3K7X7^$[/X\_
M".[\4^!/'7Q2^#GC+]HGX/ZI\)/AU^T+\,_AJ;B;QSXZ^"?B[5-2O;/Q3H?A
MO2;6?Q#J<6J1>']8MO#\%WJ<NE+%IVI+9^_?L&_\%2/V2_\ @I+K/Q^T[]E/
M7_%_B_2?V=O$WA;PQXJ\8:YX0O/"WA?Q3)XRLM;U#P_K?@&75;B/6=;\.W]I
MH%]<0:GJ.BZ)]IMI+&]LX+FQO;>Y?^0+]ACQGXX_:F_;)_X(2_ BW_:__9E_
M;0^'G[+?A/\ :#DT?PI^SW\,/&/A?7?AQ^R[I/P&?X='7OVQ[7QU.\GA[XE>
M.0WA3X7K\,[+3K+1;6TL+B?5#XBN/%=MJ5Y^V'[#OQ@^!7[)7[?_ /P<-_%#
MXN>+O!OP3^!OPK^+_P"PG9ZMXAU-(="\'>#=%F_9UL/"_AW3X;33;4PV-DU_
M>Z7HNE:?86>Q9)K:UMH H"J ?9/[6/\ P6S_ &'/V+_VA_&_P=^('AKX]^+_
M !)\.]$^&UU^TQ\6?@Q\$=6^(GPK_9IT+QM<7,GPY/[0WCO3;ZUG\+0ZA::S
M<ZUIEEIFE^);J#3]3>3[-'=W7V1_8_$W_!5;]GSPW^V5X"_8ZC\,?%/Q#>>.
M;GX7>'6^._AWP]I.H_ CPO\ $;XY^ O'/Q0^"WPT\0^)1K\6OKXE^)7@#X>>
M(O$>A7>E^&=2\/P6QTN+5-8L9=041?BY_P %A?VS/V/_ (@?'?Q/_P $F_AQ
M\7?V7_V6=1_:LTCPIXY_X*:_M?\ B^^^&_P]D\-_ W3M/T&]T/X?V'B'6$TP
M?%3]H/XF^"[O3-&\*+JUUK1\"^ M<M-39HK&^EN="]%_X*=?LN?LA:3>_"7X
MI? ,_$?5/C%XK_9S'Q!2]^&/Q=\2+X!T?]D+]D;X&^)['7/VF9O"=A=7?A;6
MOC!IOP2^(FH_L\?LX_$.^LYGL_&7QNT37K*"]7PS>7=DVV]VWHEKKHE9+T22
M2[)6 _HH^ 'Q\\"?M+?#P?%;X8IKUQX!OO%7C7PUX8\1ZUI0TJS\<67@CQ3J
MGA&X\;^$%-S<3:IX"\1ZEHU]>>#?$4L=FGB70OLFNV-L=+U"PN;GVNOR1_X)
M#?MA^(/VG_@SXS\">)O@Q\)O@G>_LUR_!CP+X=\-? ;XC7GQ/^$8^&7Q$_9\
M^&/QF^%&F^'?$.I:!X;U"TUOPGX"\=Z+X3\8Z#<:?)#I>O:1.;&^O+&Y@<?K
M=2 **** "BBB@ HHHH **** "BBD8$J0#M)! 8 $J2.#@Y!P><$8/>@#P'P'
M^U;^S+\4OBMX\^!?PW^/_P '_'?QF^&#7"_$+X7>$_B%X7U[QUX/:RN(+345
MUWPUINI7&JV+:3>W=K8:R)+;.C:A=6UAJGV2\N(8'M?!O]I_]G']HB_\=:5\
M!OCK\)OC'J7PRUF/P_\ $&Q^&OCWPUXSNO!VL3?:!;V?B"#0=1OI-.-VUG>Q
MV<\ZK;7DUAJ$-K--+87:0_R"?'2R_:#_ &;?V1_V0/A!X7_9]L/ OC_]G^;_
M (*#:'8_M@^#O'7PE\4:7^TR_BK]AW]MKQG>^+_@I=>!_%6O_$'6X?B?J>EZ
M1\6?C1-X[T?PA+X0^('A70=-9=<UN'3+[3OVU^!WA/P/\*_VU/\ @F7X9^#F
MC>'] \-:]_P2A^,_ACQ%:^'K6QMCJ'@'X:>*/V,KSX1S:FMJL,]U::)J?C#Q
MFOA^^O$E$4_BGQ,MLR3:IJ+2 'ZC>/\ ]I_]G'X4_$SX>?!CXF?'7X3> ?BU
M\6I4@^&?PW\7^/?#7A_QKXXEFN9K&U3PWX=U/4;;5-3.H:A;SZ7I9M[9EU75
M89=+TXW6H1M;#?T[XZ_!?5_BYX@^ >E_%3P!J'QM\*^'K'Q9XE^$]GXKT:X^
M(&A^&M2%LUEK6I^%8[QM8L]/GCOM/F$\UHJQV^IZ5<R[(-4T^2Y_GW_:[T+1
M-4\ _P#!R!X_\5:?ILOC_P "^&?@_!\-=?UB&U.J>'--^%'[%OPM^,'P/D\,
MWMV#)IIT;X]^)?&/BKPU)I\UO,OC6[N[NT*:D$D&O^T]\"?VD/A;\9I_BAIW
MBCP'X<TWXW_%WXI>(_@SXPT+5_$5S\<+;XE_M0_LJ_#3X-?$[3-8\'/X>M=&
ML?"/[,'PL^#WQ>_:1LO$L'C;79/$$/@CX=^"8O"FD2:-/?70!_0]X*\<>#_B
M1X9TWQIX!\3:)XQ\):S]M_LCQ)X<U&VU;1-473M0N]*O7T_4;.26UNXK?4;&
M\M'E@DDB,UO(%=@,GJ:_-O\ X)M_M*Z%\9/AA;?"W1/@1J'[/FC_  ;^$O[.
M^N_#'P?<^-M*\?V^I_LZ?%_X=S:Q\!?$%SJ^FZ9H[:-XMF\-^%]4TOQSX,O+
M747\,^(-)FCM/%/BNPO;76KC])* "BBB@ HHHH **** "OY+_P#@OKI'@;X@
M?M[?L!?#KXD? OXE_P#!0GP+'\%?VFO$OB3_ ()R?!?Q%XYTGQ]J-T^GZ?;^
M%/VF;^P\/2Z3X5O_  WX7U/2[[P;;R>*_$^E:K;:S/'+X,TWQ%?)J>G#^M"O
MRD_;C_X)C:O^U#\?_A3^UW\ _P!K'XJ_L5?M6?"OX9>+/@A!\6_AOX2\#?$6
MQ\6?!OQAJDFOW_@;Q3X%^(5G<Z)>+IOB&:YUS0-6@GM[G2]1NY;WR;B_M-%O
M-) /Y!(/$/C7]H/]E7_@@;^P=K^D>/O^"A'P_P#B1X<_;,^)WC3]G3P=\8-?
M^$D7Q+^(7P>\0:E:?"C]F_XS?%CQ7_PC6O\ @KP=^RGI6L:A8^/M9U>TENY[
M?PM##X<TJ\@N_"M_/_4)_P &]FO>!S^PAXE^%W@W3/CCX$N_V>_VF_CO\$?&
M_P !_CWX^T7XI>(_V:?&OA/7K&]UGX&>#OB'H^CZ&?%OPO\ ":ZQ;7_@K5-5
MLY-6C@UJ^TZYO;R.P@F/-W'_  0*^$_@W]G;]E7X;?LX_M,?'']G[]HO]D+Q
MU\5_B5\-/VR-(MO"OB[XI:QXN_:!26/X]/XZ\.:S9VOA?Q)H/Q)C:TBGT%UM
M8M)@T;1[:*ZO((M2CU7W[]FC_@D_'^RIX._9V\+?"_\ :Z_:#@O?AU^TM\3?
MVJ/VE_$NH7>D2ZI^VW\2/BWX?O\ 2?%R?&N.!(+>+1C?2Z3?:78VRZFMG:Z-
M!'.;W7S;>*+$ _D$^#B>%#^V;\"OCA:Z9\2=+^(FK_\ !<#Q5IFK?\%L[WQ=
M\5[W]G?XX?!BZ\2>)'A_9+T>/6+:*WMY_&L8M_@W:6=SX?T_X466I:1J]QI7
MCS4-":\-M^FO[2_[/'Q=_8+_ &V?CK\:_%WQ.^!_P5T;]K+5OVS;1/VG_"7B
M'QK>_',?LY?M!^/O@%XU\??$OXU^'QX0BL-.7]B'P+X0U#X._LTV^G>(?%][
MXO\ C?\ '3X2:!X6\/6$=[J5E-^B7AC_ (-Y? _A[Q5X%\!W'[9O[0&L_L"_
M"_\ :;E_:U^'G[!-WX>^'D7@;0/BLOB6]\9Z;IUQ\5H=*_X6%J_PWTSQ1J>I
M:A#X&NV%M*EY</-J#:M=:AK-]]Y_M/?\$U-!_:=G_:7\4^(?C!XFT7XI?&73
M/@!H7PC\<1>&]'U:S_9Q\/\ [-GQ&\,?''P'X?\ "_AB\NX[7Q5I?B/X[^'I
M/B'\44U6^TZ;QU:RZ'X6GET^Q\'^'[NV /J?]C_QE^S?XZ_9E^"^M?LB>(O#
MWBC]F^R\#Z5X4^$NJ>&)=0DTR+PQX'1O!L6D2IK,-OKMIJ^@76A7.B:_8^(;
M:V\166MV&H6VNP1:K%=H/I*ODS]B7]E^7]D+]G[1?@]J?Q N?BKXMN?&OQ8^
M*GQ%^(]QX<T[P;%XQ^)WQO\ BAXM^+WQ#UK2_!^DW-[IWA309?%OC/58?#_A
MVVOM0_LG18+&TGU'4+F.>\G^LZ "BBB@ HHHH **** "BBB@ HHHH **** "
MOX<O^"JVE_&GXJ_MV?\ !:>+]C+P[\%-0LO '_!-SX9>"/\ @H'>?M1FPCU2
M+PG>^!_$WC#0KG]CIH[*:?1?&=O\)Y-7;4M<\<.W@1_'=IX=EV6^J0:/J%?W
M&U^:/[6O_!'_ /X)W_MP_%/3?C5^TG^SS8>-?B79Z)IWA?5?$VC>./B1\/9_
M&WA32;J.]TSPO\1[/X>>+_"VG_$+0K">&$6EEXOM-7^SVT,5C#(EA&ML #\2
M?VQ==^"'[17_  35_P""4'["W[)GA)X/%7_!4/PG^SS\$_!'BWQ]X9\-W_QL
M^'G[''PL\ >%O$GQY^(7B364TV>:36_#/PTT.Q\+7MWI\D6FWR^(M1N?#TZ6
M\-HI^\/^"])T7X,_\$0/VQ_@Q\"[K3=!E^&G[.WPM\(6O@#P]J5N^O\ AWX&
M/\0? OP\U!)-)@FDU:S\,W/@:RU_09=7GM19RV5KJP:9_LUWY?ZH:3^Q7^S%
MH/QQ^%_[1>B?"C2-)^*OP3^"4_[.GPAU33M1U^R\.?#7X.W-U;W5QX1\%_#^
MWU:/P!X?$RVMMI[ZWI_AF'Q"=%ACT$:L-&7[#2:_^Q5^S!XL^,7Q;^/'BKX2
M:!XE^)?QW^!=C^S7\6]4U^?5=7TCQQ\%+"_U344\#:QX4OM0G\+/874^K7,>
MH7<.CPZEJ%K':6EW>2V]I!&@!_,'^RA\$K[4/V\+7]B7]I;PO^QWXXT;]M/_
M ((T^,=.\#?$K]D'X8I\+/'?[-OP!\1W&F^"=5^ NIZU;:[K=K\3/ <^D^);
M>Z\'_$_QII\VN^(/$FCZ=J-K8:/:/=Z;)Q_@GXC>!/\ @G7^T[KOC;XDWG[0
M_P"WSX ^"'B[XM>,;KXD>&_"'PF\*1ZE\1_V;?@M\%_V?OVE?VF]0\)+K_A'
MP]J'@S]B#X%R?#+]G;PM:>&XO$'C'QA\8/&O[1^LZ=BZT6SAM/Z0?V,_^"4W
M[!7_  3^UGQ]XF_9/^ UA\,O%7Q*TV/0/$_BR7Q?X]\9>*?^$6MYX[FR\'Z#
MX@\<>*/$>J>%O"EA<06UQ:Z#X<N=,L//LM.GGBGFTW3Y+:M\7?\ @E%^PW\:
M_AI\$/A#XP^%&J6?@+]GYO$=MX"TKPG\1OB)X3O+WPYXZO;34_B;X)\?:[HG
MB>UUWXE^#/BUJMA9:Q\5-"\=:EKT7C[6;9=7\12WNI2W-U. ?H=87UMJ=C9:
ME92>;9ZA:6U]:2[63S;:[A2>"38X5TWQ2(VUU5ESA@""*MU'##%;PQ6\$:0P
M01I###$H2.**)0D<<:* J(B*%15 "J   !4E !1110 4444 %%%% !1110 4
M444 %%%% 'E'QI^._P %_P!G+P)>_$_X]_%3P%\'?AYI][8:9=>,OB-XHTCP
MEX?34]5F^SZ9IB:CK-U:07&IZA,&2RT^W:6\NBDAA@=8Y"O ^//VS/V2?A=\
M,O!'QI^(O[2WP-\%_"/XF3:?!\._B5XC^)_@_2_!'CF35(3<V7_")^)+G5TT
MK7TEM5DNY)=+N;F*VLXI[NY>&V@FE3Y"_P""BO@GQB_QA_8"^._A7X5+^T9;
M?L[_ !Q^)OB?6/V<M*\1?#G1OB)XU'C'X$^.?!>G?$3X3:3\4_$_A#PCXN\=
M_!JYU%_$7]A7&O:=J$/A35/%&M:5>0:AI5OO_)W_ ()>:+=_$G]O?XA>&OC7
M\+O"OASP5X(\-?\ !4>7X6?!FX;PWXM\!_"N/XB_MM_"VQ^,/@C19M,AF\(7
MFHZ%%>0>$/'#: )M!M-2U;Q5H>BW5WX=ND:0 _J??7=$31&\3/K.E)X;32CK
MK^('U&T71%T1;0Z@VLMJQF%@NE+8 WIU$W M!: W)F\GYZ^?/!7[9_[)'Q'^
M%GCOXX> /VE?@AXR^#WPPN-3M?B+\3/#7Q*\)ZQX*\$7.D017-_!XG\06.J3
M:=HTL=K/;74*7T\+7MM=V=Q9"XAN[9Y?P^N]=\4:O_P;0:6+F_OIX+W]G?PM
M\-;V_MIG,MQ\"W^-&E?"^_D^UPNS2:7<? 43K/?1,4FT=Y+N-?+<1U[5^T+\
M"/$'C?\ ;O\ V@_@M^SKI/P[\-ZE<_L2_L!?'23PIJ:'PW\/_$?Q"_9A_;A\
M?^+_ (:>&_'4OAO2-6NM'T_QEX&\%:M\-5UO_A'-<FTS0++2[F#2=3L_"T&F
M2@'[.Z)\;_@]XFTOX7:WX<^)W@;7M'^-LDT/P@U/1O$VDZG8_$J6U\/:MXMN
MT\%W-E=31>(&L_#6@ZUK=X-.:?['I^EWT]SY2VTNWU*OY:_AM\<O'?[(_P 0
M]5\:>,OA+I_QTU#]G_2?VYO$5UHGP_\ B);^'O 'PTLKSXNV/[4O_!0CQ5\-
MM>\7>&UF^)>O?""Z^,7P/_9K^'.A3:-X&N?&>O\ P_\ C&9=2\#VE_>V<G]1
M5C>6^HV5IJ%I)YMI?6MO>6LNUE\RWNHDG@DVN R[XW5MK ,,X(!!% %JBBB@
M HHHH ***_C+_;%_X.A_CA^S)^U=^T7^SMHG[)7PI\6:/\$?C#XX^&>F>)M5
M^)OB_3-2U^R\)ZS<:7;ZK?Z?:>&+JULKJ\2$336UO<30Q.Q5)' R??X?X8SG
MBBOB,-DV&AB:V&HJO6C/$8?#J-*52--24L14IQD^>27+%N5M;6,JM:G12=1M
M*3LFHN6N_1.WJ]#^S2H+JUM;ZUN;&^MK>\LKRWFM;RSNH8[BUNK6XC:&XMKF
MWF5XI[>>)WBFAE1HY8V9'5E8@_P@_P#$7S^T)_T95\&O_#M^-_\ YD:/^(OG
M]H3_ *,J^#7_ (=OQO\ _,C7U?\ Q"3CK_H5X?\ \.>6_P#S5_5GY7P^O8;^
M>7_@$_\ Y'S_ #[,_JD_9-_X)%_\$ZOV'/B]XV^.W[+G[,?@_P"%GQ2\=V6H
M:5J7B:SU3Q9K[Z'HNK7ZZIJ^@^!=.\5>(-<TOX?:%JE\D4M]I/@NST.QFA@M
MK#R5TVUMK.+!^%O_  1I_P"";GP6_:UU/]MSX:_LS>&O#?[06H:QXD\36NO1
M:YXMO/"GAKQ?XRBE@\6^,_!WPXU#7KKP%X2\5^(()YH;W6=!\/6-Q"DTQT[[
M"\\[R?R\_P#$7S^T)_T95\&O_#M^-_\ YD:/^(OG]H3_ *,J^#7_ (=OQO\
M_,C1_P 0DXZ_Z%>'_P##GEO_ ,U?U9^5SZ]AOYY?^ 3_ /D?/\^S/ZK/&'_!
M);_@GQX^^#/Q'^ /B[]G+P]K/PO^*?[0/BS]J?Q5H\GB/QQ:ZO#^T#XUNA=Z
M_P#$_P *^,+#Q-:^+_ _B&X8&WMSX/UW1+.RT]Y],M+6+3[FYMI>A^#W_!,/
M]AWX"_LX?$#]D_X6? W3_#7P2^+FH7.J_%S0E\5^.K_Q'\5K^_FLI-5F^(WQ
M#U#Q-<_$'Q?'K-M80Z/K%GK/B:ZL=2\.RWWANZMI-"U&_P!/N?Y,O^(OG]H3
M_HRKX-?^';\;_P#S(T?\1?/[0G_1E7P:_P##M^-__F1H_P"(2<=?]"O#_P#A
MSRW_ .:OZL_*Y]>PW\\O_ )__(^?Y]F?UT^)_P#@G=^RAXN_:L\#_MFZO\/M
M07XW?#^R\/PZ-/IOC'Q=I/@&_P!5\&>'_%'A/P!XM\2?"[3M8M_ 'B/QM\._
M"WC?QAX<\">+=6\/W.M^&-%\1ZA8:==QP+9K:_;E?P=?\1?/[0G_ $95\&O_
M  [?C?\ ^9&C_B+Y_:$_Z,J^#7_AV_&__P R-'_$)..O^A7A_P#PYY;_ /-7
M]6?E<^O8;^>7_@$__D?/\^S/[Q:*_@Z_XB^?VA/^C*O@U_X=OQO_ /,C7['_
M /!%_P#X+?\ Q-_X*D?&WXN_"GQS\ O GPCL/AM\*[/XA66L>$_&OB#Q/=ZK
M=W7BW2_#;:;=6NL:)I<-M;)#J#W0N(I9)3+$L9C",6'GYIX;\79-@,3F>89?
M1HX/!P53$5(X_ UI0A*<*::ITL1.I+WYQ5HQ;W>RN7#%T*DHPC)N4G9)PFM;
M7W<;+Y^A_1M1117PITA1110 4444 %%%% !161X@O)].T'6]0MBHN;'2-2O+
M<NN]!/:V<T\1=,C>HD12RY&X9&1FOX7&_P""_P!_P47#.!XF^$. [*/^+46/
M16(_Z#'M7ZSX8^#/%WBU'.I\+5<FIK(99?''?VMC:^$;>9+&/#^P]A@\7[1)
M8&O[3F]GRWA;FYGR_F7B)XL<+>&,LHAQ)3S6;SJ..E@_[-PE'%)++WA%B/;>
MUQ6&Y'_MM'V?*I\R4[\O*N;^[JBOX0_^'_\ _P %&/\ H9OA#_X:BQ_^7%'_
M  __ /\ @HQ_T,WPA_\ #46/_P N*_5?^)./%K_H*X/_ /#SC_\ YSGYK_Q-
M;X7_ //CBG_PTX3_ .>G]6?E?^T_X8_LT_LZ_!/Q+XU\9_!SX#?!SX4>+OB1
M="^^('B?X<?#3P;X)U_QM>?:);LW/BK5O#>C:;?:[,UY//>R/J4]RTE]//>.
M6NIY97DUW]F[]GGQ1;_%.T\1_ GX.Z[;?'*;0KGXU0ZM\-?!NH)\7;GPM#!;
M^&;GXFBZT:7_ (3NX\.6]K;0:#/XH.J2Z1#;P1:>]ND4:K_%9_P__P#^"C'_
M $,WPA_\-18__+BC_A__ /\ !1C_ *&;X0_^&HL?_EQ1_P 2<>+7_05P?_X>
M<?\ _.</^)K?"_\ Y\<4_P#AIPG_ ,]/ZL_*_P#8=\0?V#OV'?BUXLU3Q[\5
M/V-?V5?B7XYUS[$-:\9^/_V>_A+XQ\5ZQ_9MA;:5IW]J>(?$/A'4=7U#[!I=
ME9Z;9?:[R7[+86EM9P;+>"*-/<=-^%?PPT:[2_TCX<^!-*OH_ FE?"Z.\T[P
MCH%E=1_#/0GNI-%^':7%MI\<J>!M(DOKU],\)JXT&Q>[N6MK")IY"W\0'_#_
M /\ ^"C'_0S?"'_PU%C_ /+BC_A__P#\%&/^AF^$/_AJ+'_Y<4?\2<>+7_05
MP?\ ^'G'_P#SG#_B:WPO_P"?'%/_ (:<)_\ /3^K/RO_ &K? W]G7X#?LR>#
M[OX?_L\?![X<_!/P1?\ B'5O%E[X4^&7A+1?!N@W?B379(Y-6UNXTW0[2SM9
M=0O?)@BDN'C+I:VUK9Q>7:VMO#%[-7\(?_#_ /\ ^"C'_0S?"'_PU%C_ /+B
MC_A__P#\%&/^AF^$/_AJ+'_Y<4?\2<>+7_05P?\ ^'G'_P#SG#_B:WPO_P"?
M'%/_ (:<)_\ /3^K/RO_ '>45_"'_P /_P#_ (*,?]#-\(?_  U%C_\ +BOZ
M+O\ @C%^VK\=?VW?@K\6_'/QYU#PQJ.O^#OBK#X2T23PMX;A\-6L>C/X/T#6
MF2YM8;JZ6XN/MVHW+"<LK",I'MP@-?&<??1R\0/#GAO%<5<05^':F682OA,/
M5CEV98K$XIU,;7AAZ/)2JY=AH.*J37.W53C&[2D]#ZW@KQZX'X]S_#\-Y'2S
MV&8XFABL13>/R_#X?#\F$HRKU5*K3QU>2ER1:@E3:<E9M+4_8ZBBBOP0_:@H
MHHH **** "BBB@#X"^%G_!-#]E?X1_%;5?BMX?T/QSKDCZ;\3](\#?#;QW\1
MO%?CCX,_!?3OC=JT^N?&:T^"GPO\0W][X8^'47Q/U*YNCXI72;4@:7>7OAS1
M?['\,WMWHT]/X+_\$S/V</@'IGQ-L?A[J_QTBU'XB?".X^ &B>+?$7QV^(_B
MOQK\$?@8$U(Z)\*/V?/%&OZU?:I\)/"?A.]U(ZMX<'AV9=9M]6TSP]?:AJ^I
M2^&M!_L[[1T?XF_#;Q#XR\2_#K0/B%X'USX@^#+:RO?&'@31_%F@ZGXR\*6>
MI!3IUWXE\,65_/K>A6U^&4V4^J6-K%=!E,#R C,GA'XD?#OX@7'B:S\!^/?!
M?C:[\%ZY+X9\8VOA'Q3H?B2X\)^)+>-99_#WB:#1KZ]ET'7(8G6272=46UOX
MXV5WMU4@D ^+OB=_P3,_9C^+_C_PM\0O'7_"VM2OM+\/_"OPU\0?#5M\8O'F
MF^!/VA]/^!^I#6_A)+^TEX.L=6@T;XQW_@?7&N-5LKWQ+ \VLR7<VG>*CK^A
MI:Z5;_5GBCX*> _&GQ0\#?%KQ18WFL^)/ASX1^(7@[PCI][>-+X8TVS^*/\
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MT*'[6?\ X:7P5_\ /9K_ #HJ*/\ B#?!G\F:?^%Z\O\ IQY/[_(/K^([T_\
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M *-4^&G_ (<GQ3_\S5'_ !$Q?&+_ *-4^&G_ (<GQ3_\S5?S+44?\2V^"/\
MT0.!_P##KQ#_ //CR_/NP_XF \7_ /HM,7_X;<D_^=G]7?E;^FG_ (B8OC%_
MT:I\-/\ PY/BG_YFJ/\ B)B^,7_1JGPT_P##D^*?_F:K^9:BC_B6WP1_Z('
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M.Z!K/Q4\-ZCXF\5_$JPUOQ?\&/AY';Z3\,7N](TJ/]O/V8?@U\*OV7OVR_\
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M:> -*L6U'1=7M_#VLR>-/B38?$#QEXCO?!?@U/%6MZU9Z&EM. ?EM^V9\/\
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M3_QO_P!)9^?E%%%?TN>0%%%% !1110 4444 %?UE?\&BW_)XG[4__9M.D_\
MJT?#=?R:U_65_P &BW_)XG[4_P#V;3I/_JT?#=?$^(__ "0_$7_8'2_]3,,=
M&$_WBE_B_1G]^U%%%?Q:?0!1110 4444 %%%% '/>+O^14\3_P#8O:U_Z;;F
MO\KI_P#62?\ 723_ -#:O]47Q=_R*GB?_L7M:_\ 3;<U_E=/_K)/^NDG_H;5
M_H#]!S^!XE_]?>$O_2.)#^'OIC?Q_#W_ *]<4_\ I?#PVBBBO[W/XH"BBB@
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MT%?^#MW_ ),3_9[_ .SL]#_]4_\ %VO\^JOZX\'_ /DB<+_V'9A_Z?/#Q_\
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MB@?L?:7XM@U/XP>)?C5KVN^'/A+\,]$\1^(_#7AWPG/X<^"_P \*7G@SX,^
MY-/\- 66M:UX?TC5=;N_$_CBY6UOO&&N:Q=7[:7HUE#8Z7:_=-%% !1110 4
M444 ?RJ?\';O_)B?[/?_ &=GH?\ ZI_XNU_GU5_H*_\ !V[_ ,F)_L]_]G9Z
M'_ZI_P"+M?Y]5?UQX/\ _)$X7_L.S#_T^>'C_P#>)?X8?D%%%%?J!QA1110
M4444 %%%% $%U_Q[7'_7";_T6U?[0?PA_P"23?"__LG?@G_U&M,K_%\NO^/:
MX_ZX3?\ HMJ_V@_A#_R2;X7_ /9._!/_ *C6F5^ ^._^[\,?]?LW_P#2,M/3
MRW>MZ0_.1Z)1117\ZGJA1110 4444 %%%% '\=7_  <N?\E__9F_[(]XO_\
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M %3_ ,7:_P ^JOZX\'_^2)PO_8=F'_I\\/'_ .\2_P ,/R"BBBOU XPHHHH
M**** "BBB@""Z_X]KC_KA-_Z+:O]H/X0_P#))OA?_P!D[\$_^HUIE?XOEU_Q
M[7'_ %PF_P#1;5_M!_"'_DDWPO\ ^R=^"?\ U&M,K\!\=_\ =^&/^OV;_P#I
M&6GIY;O6](?G(]$HHHK^=3U0HHHH **** "BBB@#^.K_ (.7/^2__LS?]D>\
M7_\ J:P5_-97]*?_  <N?\E__9F_[(]XO_\ 4U@K^:RO]C/HY?\ )D^ /^Q;
MC_\ U=YH?Y3^/O\ R=[C7_L.P/\ ZI\N"BBBOVP_'PHHHH **** "BBB@#ZW
M_8#_ .3Y?V/?^SE?@S_ZGFB5_I8U_FG?L!_\GR_L>_\ 9ROP9_\ 4\T2O]+&
MO\XOIM_\E7P3_P!D]C__ %9']]?1 _Y)CB__ +'V#_\ 5?$****_B0_KX***
M* "BBB@ HHHH **** /QY_X*U_'C4_A\_P"QY\#(/%7Q_P#"/AW]I?XY^*]
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MUC%IFGV&FPO+)#I]E:V,4D[^9/)%:0)!&\S@+OE98PTC[1N<DX&<4 7****
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M &A[#]H[QMX=^&0^*_P0^&WQ7_:DN_V?OVN]:TRX\(_#S1_"+:%X!\%Z5/\
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MD_\ JT?#=?$^(_\ R0_$7_8'2_\ 4S#'1A/]XI?XOT9_?M1117\6GT 4444
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M444 %%%% !7]97_!HM_R>)^U/_V;3I/_ *M'PW7\FM?UE?\ !HM_R>)^U/\
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M )*O@G_LGL?_ .K(_OKZ('_),<7_ /8^P?\ ZKXA1117\2']?!1110 4444
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M>6[UO2'YR/1****_G4]4**** "BBB@ HHHH _CJ_X.7/^2__ +,W_9'O%_\
MZFL%?S65_2G_ ,'+G_)?_P!F;_LCWB__ -36"OYK*_V,^CE_R9/@#_L6X_\
M]7>:'^4_C[_R=[C7_L.P/_JGRX****_;#\?"BBB@ HHHH **** /K?\ 8#_Y
M/E_8]_[.5^#/_J>:)7^EC7^:=^P'_P GR_L>_P#9ROP9_P#4\T2O]+&O\XOI
MM_\ )5\$_P#9/8__ -61_?7T0/\ DF.+_P#L?8/_ -5\0HHHK^)#^O@HHHH
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ME7P3_P!D]C__ %9']]?1 _Y)CB__ +'V#_\ 5?$****_B0_KX**** "BBB@
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M444 %%%% !7]97_!HM_R>)^U/_V;3I/_ *M'PW7\FM?UE?\ !HM_R>)^U/\
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ME]X-D'PAU3Q+#XGO?A>C:%+)<7'[-4 %%%% !1110!_*I_P=N_\ )B?[/?\
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MO] ?H.?P/$O_ *^\)?\ I'$A_#WTQOX_A[_UZXI_]+X>&T445_>Y_% 4444
M%%%% !1110 5_9/_ ,&U/_)LW[0G_9>[?_U7/A*OXV*_LG_X-J?^39OVA/\
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M[\+_ !QX"T[PG\"?"6N_&+P#8_'B;QR]WJ=Q\1/V>_@3X0_:*^+D?B+X<?\
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MG_U/-$K_ $L:_P T[]@/_D^7]CW_ +.5^#/_ *GFB5_I8U_G%]-O_DJ^"?\
MLGL?_P"K(_OKZ('_ "3'%_\ V/L'_P"J^(4445_$A_7P4444 %%%% !1110
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M %]X2_\ 2.)#^'OIC?Q_#W_KUQ3_ .E\/#:***_O<_B@**** "BBB@ HHHH
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M[%N/_P#5WFA_E/X^_P#)WN-?^P[ _P#JGRX****_;#\?"BBB@ HHHH ****
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M_&3_ -2V^K]Q\#/^1UGG_8JI?^IE(\[,?X=/_&__ $EGY^4445_2YY 4444
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MV'QK_P!#'X?_ /"5O?\ YJ*/8T_^@K#_ /@.*_\ F;^K/RN7?9_A_F?S ?\
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M8&C_ (B[P/\ ]!^,_P##=B__ )#U_IZ'U'$_R1_\#CY?YO[O,_SW:*_T(O\
MB$N_8+_Z+5^T]_X4O@+_ .8&C_B$N_8+_P"BU?M/?^%+X"_^8&C_ (B[P/\
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M*_M'_P"(;K]D;_HKGQY_\&O@_P#^92C_ (ANOV1O^BN?'G_P:^#_ /YE*/\
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MTP^+PRP6+CBX.C3PBHSYY*-/DDIJRC9W6MSK**Y/[#XU_P"AC\/_ /A*WO\
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M7E[2.(IU7S1]A&RY8O6[UT\SCQE&I6A"-.-VI7=Y):6MIJ[^A_F_T5_H1?\
M$)=^P7_T6K]I[_PI? 7_ ,P-'_$)=^P7_P!%J_:>_P#"E\!?_,#7[1_Q%W@?
M_H/QG_ANQ?\ \AZ_T]//^HXG^2/_ (''R_S?W>9_GNT5_H1?\0EW[!?_ $6K
M]I[_ ,*7P%_\P-'_ !"7?L%_]%J_:>_\*7P%_P#,#1_Q%W@?_H/QG_ANQ?\
M\AZ_T]#ZCB?Y(_\ @<?+_-_=YG^>[17^A%_Q"7?L%_\ 1:OVGO\ PI? 7_S
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MRW#8+,Z%66$S*&)KJIBL'.C24:2I0NG4FE)\WNI7U/OVBN3^P^-?^AC\/_\
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MP,]UX)UFTL_V<O@Q-HVAW\%O'?/?3ZSJUE->65K#=:8N$NHO3?AM/X@^.O\
MP5:_9B\)>(_V(_!'_!/+XA_LB_#GXI_M":Q/=^.?A7KGQ"_:5^%'Q:\%Z_\
M!!? WPRE^".F77AGQ/\ #;P=X_UC0O%GQC_X2?Q3%?>$_%&A_#*&U\+2-XEL
MM>A /Z"K3QYX&O\ QEK/PZL?&?A2]^(/AS1-)\2^(? MIXBTBY\9:#X<U^XO
MK30M?UGPQ#>/K>EZ)K5UIFI6VDZK?6,%CJ-QI]]#9SS26DZQUK3XD?#N_P#
MDOQ2L/'O@N]^&4.AZAXGF^(MIXIT.Y\"1>&M)AN;G5?$,OBZ&^?P_'H>F6]G
M>3ZAJS:@+"RAM;F6YN(T@E9/Y,_V;_VU?A-=_P#!3_P7^UOI^O>+Y?$/[87[
M8'[2?[&WC>YN/@_\7=#^'[_LVVVB^$?A[^Q'KNG?&+Q!\/['X/>(K34/B?\
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M_LI;C^P1'25$DC=9(Y%5XY$8.CHX#(Z,I*LK*0RLI(8$$$@T .HHHH ****
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M26'[6/PO_9CEUV_^)?B^W\3>&O$>BZ[\#O&W[0#:MI?AW2M,TZ\\1W/AC6M
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M6BQ:X/V!H **** "BBB@ HHHH **** "BBB@ KYT_:U_9E\#_MC_ +.WQ/\
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M7%CXT^$$_CG7?B]\0O$=_;_#_6+OQ?H,,?@3PIKOBAM$U?4)]-T=P#[*MO\
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M:NTL8;.RMK318+A7^RRN_P"SE% 'Y[?&+X>>.]9_X*4?L2?$K2?"6MZC\/\
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M_P#"3>+)_!_P[TV1]&^'^@W%SM_ "']H_P"./B+_ ()O_ GQQ^R[\8/A1?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img75897552_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_11.jpg
M_]C_X  02D9)1@ ! @$!( $@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ,A!@P# 2(  A$! Q$!_\0
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M $/0_P#":\8?_,_0![_17@'_  U'\"?^AZ'_ (37C#_YGZ/^&H_@3_T/0_\
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M )GZ/^&H_@3_ -#T/_":\8?_ #/T >_T5X!_PU'\"?\ H>A_X37C#_YGZ/\
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MS] 'O]%> ?\ #4?P)_Z'H?\ A->,/_F?H_X:C^!/_0]#_P )KQA_\S] 'O\
M17@'_#4?P)_Z'H?^$UXP_P#F?H_X:C^!/_0]#_PFO&'_ ,S] 'O]%> ?\-1_
M G_H>A_X37C#_P"9^C_AJ/X$_P#0]#_PFO&'_P S] 'O]%> ?\-1_ G_ *'H
M?^$UXP_^9^C_ (:C^!/_ $/0_P#":\8?_,_0![_17@'_  U'\"?^AZ'_ (37
MC#_YGZ/^&H_@3_T/0_\ ":\8?_,_0![_ $5X!_PU'\"?^AZ'_A->,/\ YGZ/
M^&H_@3_T/0_\)KQA_P#,_0![_17@'_#4?P)_Z'H?^$UXP_\ F?H_X:C^!/\
MT/0_\)KQA_\ ,_0![_17@'_#4?P)_P"AZ'_A->,/_F?H_P"&H_@3_P!#T/\
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M_5+BO_HF>(?_  RYE_\ ,WFOO#V]#_G]2_\ !D/\S]K:*_%+_B(F_P""./\
MT>&G_A@?VH?_ )R='_$1-_P1Q_Z/#3_PP/[4/_SDZ/\ 5+BO_HF>(?\ PRYE
M_P#,WFOO#V]#_G]2_P#!D/\ ,_:VBOQ2_P"(B;_@CC_T>&G_ (8']J'_ .<G
M1_Q$3?\ !''_ */#3_PP/[4/_P Y.C_5+BO_ *)GB'_PRYE_\S>:^\/;T/\
MG]2_\&0_S/VMHK\4O^(B;_@CC_T>&G_A@?VH?_G)T?\ $1-_P1Q_Z/#3_P ,
M#^U#_P#.3H_U2XK_ .B9XA_\,N9?_,WFOO#V]#_G]2_\&0_S/VMHK\4O^(B;
M_@CC_P!'AI_X8']J'_YR='_$1-_P1Q_Z/#3_ ,,#^U#_ /.3H_U2XK_Z)GB'
M_P ,N9?_ #-YK[P]O0_Y_4O_  9#_,_:VBOQ2_XB)O\ @CC_ -'AI_X8']J'
M_P"<G1_Q$3?\$<?^CPT_\,#^U#_\Y.C_ %2XK_Z)GB'_ ,,N9?\ S-YK[P]O
M0_Y_4O\ P9#_ #/VMHK\4O\ B(F_X(X_]'AI_P"&!_:A_P#G)T?\1$W_  1Q
M_P"CPT_\,#^U#_\ .3H_U2XK_P"B9XA_\,N9?_,WFOO#V]#_ )_4O_!D/\S]
MK:*_%+_B(F_X(X_]'AI_X8']J'_YR='_ !$3?\$<?^CPT_\ # _M0_\ SDZ/
M]4N*_P#HF>(?_#+F7_S-YK[P]O0_Y_4O_!D/\S]K:*_%+_B(F_X(X_\ 1X:?
M^&!_:A_^<G1_Q$3?\$<?^CPT_P## _M0_P#SDZ/]4N*_^B9XA_\ #+F7_P S
M>:^\/;T/^?U+_P &0_S/VMHK\4O^(B;_ ((X_P#1X:?^&!_:A_\ G)T?\1$W
M_!''_H\-/_# _M0__.3H_P!4N*_^B9XA_P##+F7_ ,S>:^\/;T/^?U+_ ,&0
M_P S]K:*_%+_ (B)O^"./_1X:?\ A@?VH?\ YR='_$1-_P $<?\ H\-/_# _
MM0__ #DZ/]4N*_\ HF>(?_#+F7_S-YK[P]O0_P"?U+_P9#_,_:VBOQ2_XB)O
M^"./_1X:?^&!_:A_^<G1_P 1$W_!''_H\-/_  P/[4/_ ,Y.C_5+BO\ Z)GB
M'_PRYE_\S>:^\/;T/^?U+_P9#_,_:VBOQ2_XB)O^"./_ $>&G_A@?VH?_G)T
M?\1$W_!''_H\-/\ PP/[4/\ \Y.C_5+BO_HF>(?_  RYE_\ ,WFOO#V]#_G]
M2_\ !D/\S]K:*_%+_B(F_P""./\ T>&G_A@?VH?_ )R='_$1-_P1Q_Z/#3_P
MP/[4/_SDZ/\ 5+BO_HF>(?\ PRYE_P#,WFOO#V]#_G]2_P#!D/\ ,_:VBOQ2
M_P"(B;_@CC_T>&G_ (8']J'_ .<G1_Q$3?\ !''_ */#3_PP/[4/_P Y.C_5
M+BO_ *)GB'_PRYE_\S>:^\/;T/\ G]2_\&0_S/VMHK\4O^(B;_@CC_T>&G_A
M@?VH?_G)T?\ $1-_P1Q_Z/#3_P ,#^U#_P#.3H_U2XK_ .B9XA_\,N9?_,WF
MOO#V]#_G]2_\&0_S/VMHK\4O^(B;_@CC_P!'AI_X8']J'_YR='_$1-_P1Q_Z
M/#3_ ,,#^U#_ /.3H_U2XK_Z)GB'_P ,N9?_ #-YK[P]O0_Y_4O_  9#_,_:
MVBOQ2_XB)O\ @CC_ -'AI_X8']J'_P"<G1_Q$3?\$<?^CPT_\,#^U#_\Y.C_
M %2XK_Z)GB'_ ,,N9?\ S-YK[P]O0_Y_4O\ P9#_ #/VMHK\4O\ B(F_X(X_
M]'AI_P"&!_:A_P#G)T?\1$W_  1Q_P"CPT_\,#^U#_\ .3H_U2XK_P"B9XA_
M\,N9?_,WFOO#V]#_ )_4O_!D/\S]K:*_%+_B(F_X(X_]'AI_X8']J'_YR='_
M !$3?\$<?^CPT_\ # _M0_\ SDZ/]4N*_P#HF>(?_#+F7_S-YK[P]O0_Y_4O
M_!D/\S]K:*_%+_B(F_X(X_\ 1X:?^&!_:A_^<G1_Q$3?\$<?^CPT_P## _M0
M_P#SDZ/]4N*_^B9XA_\ #+F7_P S>:^\/;T/^?U+_P &0_S/VMHK\4O^(B;_
M ((X_P#1X:?^&!_:A_\ G)T?\1$W_!''_H\-/_# _M0__.3H_P!4N*_^B9XA
M_P##+F7_ ,S>:^\/;T/^?U+_ ,&0_P S]K:*_%+_ (B)O^"./_1X:?\ A@?V
MH?\ YR='_$1-_P $<?\ H\-/_# _M0__ #DZ/]4N*_\ HF>(?_#+F7_S-YK[
MP]O0_P"?U+_P9#_,_:VBOQ2_XB)O^"./_1X:?^&!_:A_^<G1_P 1$W_!''_H
M\-/_  P/[4/_ ,Y.C_5+BO\ Z)GB'_PRYE_\S>:^\/;T/^?U+_P9#_,_:VBO
MQ2_XB)O^"./_ $>&G_A@?VH?_G)T?\1$W_!''_H\-/\ PP/[4/\ \Y.C_5+B
MO_HF>(?_  RYE_\ ,WFOO#V]#_G]2_\ !D/\S]K:*_-[]G;_ (*Y?\$\_P!J
M^[^)-C\ /VA%\?77PB^'&M_%KXAQ#X5_&WPO_P (]\/O#C0KK/B#?XT^&_AR
M/5A9&>(?V5H;ZEK=QOS:Z;.%8CB/^'W/_!,$?\W.+_X9K]H+_P"=177E_ 7'
M6;3Q-/*N"^+,SJ8-THXR&7\.9QC9X65>#J4(XF.&P=25!UH)SI*JH.I!.4.9
M)L\7-N*^%L@E0AGO$N09+/%1G/#0S;.<NRZ6(A3E&-2=".,Q-%U8TY2C&<J:
MDHRE%2:;2/U8HK\I_P#A]S_P3 _Z.<7_ ,,U^T%_\ZBC_A]S_P $P/\ HYQ?
M_#-?M!?_ #J*]/\ XA1XI?\ 1M>/_P#Q#N(O_G=YK[SQ_P#B)GAQ_P!' X(_
M\2O(?_F_S7WGZL45^4__  ^Y_P""8'_1SB_^&:_:"_\ G44?\/N?^"8'_1SB
M_P#AFOV@O_G44?\ $*/%+_HVO'__ (AW$7_SN\U]X?\ $3/#C_HX'!'_ (E>
M0_\ S?YK[S]6**_*?_A]S_P3 _Z.<7_PS7[07_SJ*/\ A]S_ ,$P/^CG%_\
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M/_!,#_HYQ?\ PS7[07_SJ*/^'W/_  3 _P"CG%_\,U^T%_\ .HH_XA1XI?\
M1M>/_P#Q#N(O_G=YK[P_XB9X<?\ 1P."/_$KR'_YO\U]Y^K%%?E/_P /N?\
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M ,ZBC_A]S_P3 _Z.<7_PS7[07_SJ*/\ B%'BE_T;7C__ ,0[B+_YW>:^\/\
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M'_1SB_\ AFOV@O\ YU%'_#[G_@F!_P!'.+_X9K]H+_YU%'_$*/%+_HVO'_\
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M=UZ].5-5J%!+WG6K4X4U%J;ERM-_FW1117Z ?$!1110 4444 %%%% !1110
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M69SF&58W"95G*J/*LPK4)PPF/5&WM/J]:W)/EYD[7NU=I-1E;FZ*_1[]CO\
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MKDL?*S:>)+JU$@)-R(_WE?EO^T3^RQ\?_P!D[Q?:>!?V@OAKK'PZ\1:CI_\
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M,U^<W_!)/_E'9^RW_P!D^'_IXU2OT9K_  Z\1O\ DX/'/_97\2?^KC&'^QG
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ML157MYXB,I5(TZ2I?FC\*/\ @VNFUKX::;JGQ=_:0O\ PA\3M7TT7LV@^$_
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MTL?CZ.-RA5\=5PM2E&MAL7AIXJIAWA<2\-#'2K1E2G16)5:I&5:?\]W[;O\
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M6[Q]_P!?^F_^F'2J^,/K#PZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-&ZKN-&5&,4E-WG.[YI;:>2TM;M?NV_]"#_@E'_P5<_9%_;2_P""=6N_LO\
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MG&7L/90JJ,:4TG&44K<LGIO>IXJ,^9O#TN:5[RM=W?6[6^_X=M?]!3_@@?\
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M/AUX>OO['N;PV&O^'M9TW4;XWUI-INE>=?\ !N1I?[.?AW]O&7]H3]IGXW_
MOX+^$OV?_A[KVL>")OC1\5_ OPV_X2/XH^.H)_!>BQ^'['QMK^A1>(H="\)7
MWCG5=2NK(:A_PCFKKX4N);>"\U'3+VV_ &BMH<+4*'"?^J>$Q=;#8=Y?+ 2Q
MD(0=>4*[<L95Y&U!3Q3J5^97M#VSM>RNO;-U_;R2D^=3Y;NVGPJ^]HV5O0_K
MA_X+L?\ !;3XT1?M>Z/\-OV ?VMY=*^#?PV^&GAVW\0^,?@+XVT3Q#X4\>_$
M;Q6]QXFUB[M_&7A^35-!\0V/A[PY>^%/#Z0Z7?7D6B^(;/Q38W=TNHF\T_3O
M*/\ @C)_P6T_:6L?V[_ /AC]MS]K#Q!XJ_9_^(_A;QOX)U_6_C9\1=$\.^ O
MAKKG]C_\)9X7\=7^J:[;V>DV\[ZQX4@\$(]]JNCPPVWC2[NOMLKVZZ;?_P N
MM%<=/@+AZGP]_8'U+"S;R^I@WF4L'AOK_M:D))XU5E34U65:7MHKG<4U&FVX
M*SKZS5]K[7F?Q<W)S/ELFO=M?:R2[]=S^J+_ (.A-5_9;^-/QB_9X_:<_9M_
M:-^!7QOU76O FM?!_P"*FC?"/XY?"7XBW'AMO!FKR>)_A[K]]X9\(>(M4\50
M?\)):>,/&&D7VO21W7A^VC\(Z#I]P='U&^M/[?\ Y7:**]OA[)_[ R?!9/'%
M5<;# PG2I8BM",*LJ3JSJ0A*,&XVI1G[*#5OW<()IR3D\ZM3VM253E47*S:3
MNKV2;5^]K^K/]-#]E:XE_P""DW_!OQX>^'_A*66?QSXQ_8T\1?L]PR^-9&NI
M;CXP?![PW?\ PRT_5]>O(F\1WC6?B'QKX*TWQ/%K"17NN+I.L6NK?V=;ZT#I
ML'\E'_!MW\8OA%\"?^"C5QXU^-WQ5^&_P=\&#X"?$[1/^$O^*?CGPQ\/O"YU
MB]UGP3)9:4/$'BW5-(THZE>QVEU):6/VO[5<QVUP\,3K#(5;_P $4?\ @M7+
M_P $OE^*GPW^)_@GQ;\4O@%\2;V#QK8^&O!EUX>L_$'@[XHV]E8:)?>)-/&M
MBPAU*Q\5^&]+T;2->M;K6X!:-X9T*\TR#S#J<=[^7_[=7Q6^!OQW_:L^,WQM
M_9X\+^./ _PX^+?B_4OB''X*^($6D#7/#'B?Q7.^K>,=/M[S1-?\066H:)<>
M);G4M6T67S-/DT^PU&'0SI_EZ5'?WWYYDW"./PN*XZX:Q-&M2R#B"53&Y;FE
M%4IQI?6N95\,X.;FJU*G5ITXNI",)?5:DDVJL$^JI7A)8:LFG5I6C.#NF^5I
MIWMLW?9M^]Y,_6G_ (.9?C9\&?CS_P % / OC/X&_%OX8_&?P?9_LP_#_0+O
MQ7\)_'OA7XB^&K77;+X@_%B]O-$N-=\(:MK&EP:O:6>HZ?=W.FRW2WD%M?V4
M\L*174#R?I%_P;D?\%F/!WP_\'ZK^P_^V3\7=!\$^$?"-C<^)/V=_B]\6/&'
MAGPIX/\ #/AJV2(:Y\%_$/C/Q5K&CV]A:V%PZZ[\+X]0DO\ %K=^)/"*:EIN
MF:-X$\/M_%[17U.+X'RS'<*87A3%5*E6C@Z%*GA<=R4UBJ%:BVX8FFM81FU*
M5.<5[LZ4YP>DKK&.)G&LZT4DY-N4=>5I[Q_R?1V9_1!_P<R_&SX,_'G_ (*
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M5/FY8SIN+E./.Z=2I"=4L1*GSIPC.%1WE"6U[WNGT?G9]':Z1_HP_#GXQ_\
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M %%%% ']&G_!NQ_R-G_!2/\ [1Q_&_\ ]':37Q(W4_4_SK[;_P"#=C_D;/\
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M/I%U+)X2\,7LU_9Z5??PNT5_-M+Z+6#E#!Y)F?B9Q[F_ 6 Q-.OA^"<7CW'
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MUF\\+W%U9Z)X-\*WM]:Q'Q'I%MJ:-K][XGT</X>U,VGA^3P[K&L6,EY*/O\
M^%O[5?[+VG_\$9YOA=?_ +2/P$L?B8?V%?B#X1'PZO/C#\/+;QT?%E[\)/$F
MFV?A@>$9O$2>(#XAN]1G@L+;11I_]I3WLT5K%;//(D9_BAHKGQ7T<N$Y<(<(
M\'9;F69Y=@N%>)(<42QKAA<5CLXS3E<:U3,)N%&DO:Q5.E'V-."HT*-&C"+5
M.[WPWCYQ/'BGBCBK'Y?EV/Q?$N02X<6$4\3A\'E67*2E2IX&*G5J/V<N>I+V
MU2?M:U:M5DTYV7IWP6\:^&OAS\6?AYXX\9^"=$^(_@_PUXLT?4_%?@3Q%8PZ
MEI/BKPU%=HFNZ--:7,D5N]Q=Z7)=)ITL[^3:ZC]DNI5D2%HV_K4\5?LW?\$4
M?^"AGPZ\ WGPB^)WPE_9NUW0(-0U>73/AW<_#+X._$62TO/[/T[5=*^(_@GQ
MAI,.K:Y!H]]8V\6G:R8I[."YNI;W1]<U#2]?6?4/XW:*^VX_\-\1QEC<GSG*
M.,^)."\^R-5Z>$QV2UXUL%B*.(C.,Z>891B&L+BY052HJ-5RIRC"M5A45:+I
M*E\CP/X@4.$\'FN4YIPEP_Q=DN<.C4Q.#S>C*EC*-6A*+C/ YI03Q.%C/D@Z
MM-1G&4Z5*=-TI*I[7^XSQU^V3^Q?_P $K/V-;3]G_P"&?QU/[1'CWPGX?U_0
M_ GA:U\=>%/'OC-M:\82:[K^GWGC"Z\-BWT/P=X)T.YU.-;.Q>SCOK7PVFCV
M=C8:W=7'V^Z_B8\.>,?%?@SQ+9^,O!7B7Q!X-\5:9<W-WI/B3PKK6I>']?TF
M>ZAGMIY--UG2;FSU&QDEM;FXM99+6XB>2VGFA<F*5U;FJ*Q\-?"?*?#O#\13
M>98WB3.>+\=+,>)\XS6G0@\SKR>)DX+ T(_5J&'=3&XRI*E^]E.6)JJ=25-4
MZ=/3Q \3<SX\KY#!8#"9!E/"N#6!X=RK+*E>2RZBEAH\[QE:7UBM74,'A(1J
M_NHPCAZ;A3C-U)SW?$WBCQ-XUUW4O%/C+Q%KOBWQ-K-P;O6/$7B;5]0U[7=5
MNBJH;G4M7U6XN]0OK@HB(9KJXED*JJEL* ,*BBOU.G3A2A"E2A"G2IPC3ITZ
M<5"%.$$HPA"$4HQA&*48QBDHI)))(_-ISG5G.I4G*I4J2E.=2<G.<YR;E*<Y
M2;E*4FVY2;;;;;;9V]Y\3?B3J/@72?A=J'Q!\<7WPST'4Y-:T/X=7GBS7KKP
M+HVL32:E--JVD^$9[]_#^G:G++K.L2R7]GI\-T\FJZD[2EKZZ,O$445-*A0H
M*HJ%&E156K4KU52IPIJI7K2YZM:HH*//5JR;E4J2O.<M9-O4JK6K5W!UJM6L
MZ=*G1INK4E4=.C2CRTJ4'-OEI4XI1ITXVC".D4EH?6?["7QGT[]GO]L+]GGX
MOZT8H]!\)?$K15\27,UT;.*P\,>(A/X5\2ZJ\X9%QI.A:YJ&IB&62*WN3:"V
MN98K>:61?Z>O^#CKX*W_ (V_9S^"WQUT=);B+X0>.M8T#788! %3P[\5=/TD
M0ZS=N\?FO!IVN^#M&TN!(;C*3^)BWV:9&DGM?XTJ_H>\#?\ !9KX6^//V"M3
M_8V_:_\ AE\3_'VM7?@>?X;#XD>#[SPQJ\VH:/HXL[GX>^,-5MO%.JZ/=R^-
M/".H6&D7-R]S<ZFFO:CX=M=>O=46[UB\L[+^>/%O@OB1^(GA?XH\)996SC&<
M,9A/)^(LOPTZ*Q=3AO,'6A6Q6%IXBM1I5983#XW-J<Z<9^VG5QF%E&+ITJDZ
M?[MX7\6\/_ZB>(OAOQ1F-+*L)Q%@H9KD..Q$*KPL,_P*HRI8?$U*%*K4IK$U
M\'EE2-24?8QIX3$1E)3J0C4^R_\ @@#^TI^SI\&OV2?BGX;^+_Q]^"OPI\1:
MC^T7XCUS3] ^)/Q4\"^!M:OM%G^&GPKL(-7L]+\4:[I=]<Z7-?:=J%E%J$$#
MVDEW8WELDQFMIT3^8#XB>-=0T#]H?QG\1/ /B+[)JNB?&#7/&?@SQ9H%[!.;
M74M+\87&M^'O$&C:A;M-;RM;W4%IJ.GW<+2PNR131ET()\7?9O;R]Q3<VPN
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M8SBJG5H\19QE-.<L=CJ5>-:-=4FJ>'6'G45>M^\F\2Z3K5ZM%4\15]O'U_\
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M.:+-8VVIZO>:KXIUC0M$L[2VNM4TZTW76I0M-=WUI:VZ2W$\<;>)>(O#NO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =@?\
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MON?$7C"SN=(L6N?$FI+>7SU^B?Q _P"5:G2O^T37PJ_]9T\'U_+E_P &LO\
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M -':37Q(W4_4_P Z^V_^#=C_ )&S_@I'_P!HX_C?_P"CM)KXD;J?J?YU^M^
M'_(W\2?^POA7_P!56+/XK^EI_P C+@?_ +%N=?\ J9@Q****_I4_D,**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O;_V9?\ DY']
MGS_LM_PH_P#4\T"O$*]O_9E_Y.1_9\_[+?\ "C_U/- KR\\_Y$N<?]BO,/\
MU$K'I9-_R.,J_P"QE@?_ %*I']X'_!6']L/Q=^Q'^RBGQ:^'.C:)J7Q'\0^/
MO#GPS\%ZGXATQ-7TOPQ?^(M'\1:_J6O7%@;NRDNFBT'PEJEG90K.T']K7FFS
MW]I?:?!=6<WS9_P1&_X*"?&G]MCP!\9?#'Q]U"R\4_$#X-ZSX4NT\>V6@:%X
M8;Q'X:^(G_"4RZ58:II'AJUTO0EU7P_>>%-6M!>:7H>D6]SHT^BI=0WFK0:G
MJ=]QO_!QM_R8E\./^SGO /\ ZJ_XR5\>_P#!L?\ \A#]M/\ Z\_V>O\ T?\
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MW%?_ $.\9_Y2_P#E7DON*^K4/^?<?Q_S\OS[L_G/_P"(9?\ 8J_Z.1_;^_\
M#_\ @W_YSU'_ !#+_L5?]'(_M_?^'_\ !O\ \YZOZ,**/]=N*_\ H=XS_P I
M?_*O)?<'U:A_S[C^/^?E^?=G\Y__ !#+_L5?]'(_M_?^'_\ !O\ \YZC_B&7
M_8J_Z.1_;^_\/_X-_P#G/5_1A11_KMQ7_P!#O&?^4O\ Y5Y+[@^K4/\ GW'\
M?\_+\^[/YS_^(9?]BK_HY']O[_P__@W_ .<]1_Q#+_L5?]'(_M_?^'_\&_\
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M -#O&?\ E+_Y5Y+[@^K4/^?<?Q_S\OS[L_G/_P"(9?\ 8J_Z.1_;^_\ #_\
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MC^/^?E^?=G\Y_P#Q#+_L5?\ 1R/[?W_A_P#P;_\ .>H_XAE_V*O^CD?V_O\
MP_\ X-_^<]7]&%%'^NW%?_0[QG_E+_Y5Y+[@^K4/^?<?Q_S\OS[L_G/_ .(9
M?]BK_HY']O[_ ,/_ .#?_G/4?\0R_P"Q5_T<C^W]_P"'_P#!O_SGJ_HPHH_U
MVXK_ .AWC/\ RE_\J\E]P?5J'_/N/X_Y^7Y]V?SG_P#$,O\ L5?]'(_M_?\
MA_\ P;_\YZC_ (AE_P!BK_HY']O[_P /_P"#?_G/5_1A11_KMQ7_ -#O&?\
ME+_Y5Y+[@^K4/^?<?Q_S\OS[L_G/_P"(9?\ 8J_Z.1_;^_\ #_\ @W_YSU'_
M !#+_L5?]'(_M_?^'_\ !O\ \YZOZ,**/]=N*_\ H=XS_P I?_*O)?<'U:A_
MS[C^/^?E^?=G\Y__ !#+_L5?]'(_M_?^'_\ !O\ \YZC_B&7_8J_Z.1_;^_\
M/_X-_P#G/5_1A11_KMQ7_P!#O&?^4O\ Y5Y+[@^K4/\ GW'\?\_+\^[/YS_^
M(9?]BK_HY']O[_P__@W_ .<]1_Q#+_L5?]'(_M_?^'_\&_\ SGJ_HPHH_P!=
MN*_^AWC/_*7_ ,J\E]P?5J'_ #[C^/\ GY?GW9_.?_Q#+_L5?]'(_M_?^'_\
M&_\ SGJ/^(9?]BK_ *.1_;^_\/\ ^#?_ )SU?T844?Z[<5_]#O&?^4O_ )5Y
M+[@^K4/^?<?Q_P _+\^[/YS_ /B&7_8J_P"CD?V_O_#_ /@W_P"<]1_Q#+_L
M5?\ 1R/[?W_A_P#P;_\ .>K^C"BC_7;BO_H=XS_RE_\ *O)?<'U:A_S[C^/^
M?E^?=G\Y_P#Q#+_L5?\ 1R/[?W_A_P#P;_\ .>H_XAE_V*O^CD?V_O\ P_\
MX-_^<]7]&%%'^NW%?_0[QG_E+_Y5Y+[@^K4/^?<?Q_S\OS[L_G/_ .(9?]BK
M_HY']O[_ ,/_ .#?_G/4?\0R_P"Q5_T<C^W]_P"'_P#!O_SGJ_HPHH_UVXK_
M .AWC/\ RE_\J\E]P?5J'_/N/X_Y^7Y]V?SG_P#$,O\ L5?]'(_M_?\ A_\
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MAWC/_*7_ ,J\E]P?5J'_ #[C^/\ GY?GW9_.?_Q#+_L5?]'(_M_?^'_\&_\
MSGJ/^(9?]BK_ *.1_;^_\/\ ^#?_ )SU?T844?Z[<5_]#O&?^4O_ )5Y+[@^
MK4/^?<?Q_P _+\^[/X?/^"I7_!'/X$?L6Z7^QZOPG^/W[8VJP_M)_MB_"O\
M9L^(UKXY^-.D:O:GX<_$.+5T\0G1X-&\!>'4BUEDLHH[:;5AK&DA'E2[T:[#
M +^B8_X-0/\ @FN0#_PL;]K_ ) _YJ;\*_\ YQM>M_\ !P)_R"_^"7W_ &E%
M_9Q_]%^(Z_H47H/H/Y5]+C^,N)\-P_PWB</G6,HU\8\X^M5:<H0E7^KXRE3H
M^T<8+F]E!N,.R;1E'#T75JITXM1]GRIW=KQN^O5K7N?S(_\ $)__ ,$U_P#H
MH_[7_P#X<WX5_P#SC*/^(3__ ()K_P#11_VO_P#PYOPK_P#G&5_3?17@?Z_\
M9_\ 11YE_P"#8_\ R!I]5P__ #ZA]S_S\OS[L_F0_P"(3_\ X)K_ /11_P!K
M_P#\.;\*_P#YQE'_ !"?_P#!-?\ Z*/^U_\ ^'-^%?\ \XROZ;Z*/]?^,_\
MHH\R_P#!L?\ Y /JN'_Y]0^Y_P"?E^?=G\R'_$)__P $U_\ HH_[7_\ X<WX
M5_\ SC*/^(3_ /X)K_\ 11_VO_\ PYOPK_\ G&5_3?11_K_QG_T4>9?^#8__
M " ?5</_ ,^H?<_\_+\^[/YD/^(3_P#X)K_]%'_:_P#_  YOPK_^<91_Q"?_
M /!-?_HH_P"U_P#^'-^%?_SC*_IOHH_U_P",_P#HH\R_\&Q_^0#ZKA_^?4/N
M?^?E^?=G\R'_ !"?_P#!-?\ Z*/^U_\ ^'-^%?\ \XRC_B$__P"":_\ T4?]
MK_\ \.;\*_\ YQE?TWT4?Z_\9_\ 11YE_P"#8_\ R ?5</\ \^H?<_\ /R_/
MNS^9#_B$_P#^":__ $4?]K__ ,.;\*__ )QE'_$)_P#\$U_^BC_M?_\ AS?A
M7_\ .,K^F^BC_7_C/_HH\R_\&Q_^0#ZKA_\ GU#[G_GY?GW9_,A_Q"?_ /!-
M?_HH_P"U_P#^'-^%?_SC*/\ B$__ .":_P#T4?\ :_\ _#F_"O\ ^<97]-]%
M'^O_ !G_ -%'F7_@V/\ \@'U7#_\^H?<_P#/R_/NS^9#_B$__P"":_\ T4?]
MK_\ \.;\*_\ YQE'_$)__P $U_\ HH_[7_\ X<WX5_\ SC*_IOHH_P!?^,_^
MBCS+_P &Q_\ D ^JX?\ Y]0^Y_Y^7Y]V?S(?\0G_ /P37_Z*/^U__P"'-^%?
M_P XRC_B$_\ ^":__11_VO\ _P .;\*__G&5_3?11_K_ ,9_]%'F7_@V/_R
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MA7_\XROZ;Z*/]?\ C/\ Z*/,O_!L?_D ^JX?_GU#[G_GY?GW9_,A_P 0G_\
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M,_\ HH\R_P#!L?\ Y /JN'_Y]0^Y_P"?E^?=G\R'_$)__P $U_\ HH_[7_\
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M_#3_ .<C7]+U%'_$2.//^BJSG_PJE_EY+[@_L;*?^A;@O_":EY?W?)'\T/\
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M?TO44?\ $2.//^BJSG_PJE_EY+[@_L;*?^A;@O\ PFI>7]WR1_-#_P 0J_\
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M/[&RG_H6X+_PFI>7]WR1_-#_ ,0J_P#P3M_Z*W^VA_X=OX:?_.1H_P"(5?\
MX)V_]%;_ &T/_#M_#3_YR-?TO44?\1(X\_Z*K.?_  JE_EY+[@_L;*?^A;@O
M_":EY?W?)'\T/_$*O_P3M_Z*W^VA_P"';^&G_P Y&C_B%7_X)V_]%;_;0_\
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M_P *I?Y>2^X/[&RG_H6X+_PFI>7]WR1_-#_Q"K_\$[?^BM_MH?\ AV_AI_\
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M>9_8J_X+ ?\ !+/P-^QM^R7X*\7_ /!0+]DOPYXM\'_LR_ ;PMXH\/:M\;O
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M/AV[@OY[H7_BN[&HK>JET;E8(U !_5A17\L?[7/[??\ P4G_ &\?^"@WQ/\
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M.O _BJ37'N/#OACP3\/?&VJ:PUNP!^]U%?QG?M?1?\'&?_!(GX):Q^W!KO\
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MX<T?Q=KFGO?>/-)N=*TGPKIS6UIXP\&:_P"$/!'B?PCING^*0#^CRBOYB?\
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MV3_V[-!^&VD?MD_L _%C1OAA\3-<^&!2S\-_$/1M;?Q5H^G>*8]*M[BZT?\
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M^#_A%\)O ^G'4O$WCGQOK%MHVBV,3L(K*RMVG;[3JVNZS=O#I?AWPWH]O?\
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MB5[V:%&ECMA(\:LZJ" ?CU^S]_P4#^-O[9__  6<_:8_9G^!WBS1/#W[%/\
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MSJ^H07=U/JLVE/=6\!N=3DA23[)_X(-Z[\(==_X)!?L!-\%[G1I_#NE_LY^
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M\.7_ %]K?^G9GS/^VG_R9Q^UG_V;/\>/_56^*J^&?^""'_*(O]B__L3?'O\
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M2RNKWQ3X\UW1=#\5ZM8#7M675-9O++POX7FT70I=031?"?AO1O#5AI>D:?\
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M->F3PMHGP)AAM=5VZ/XCT#4XC:V !#_P:\_V;JWQE_X+C^-/A^U_<_ OQ/\
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M\'7$6FZIH&F7-A=>'FETJTT[5-)U#17NM-N/QF_X)%_L3_\ !9/_ ()\^,/
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M$E_@[_P59^,W[7W_  6/\*?L0_\ !1[X:?LA_$3P=^W/\0]5_:-\(^/OV;_
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MU&^N[R::>0 Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^>K_@X$_Y!?_!+[_M*+^SC
M_P"B_$=?T*+T'T'\J_GK_P"#@3_D%_\ !+[_ +2B_LX_^B_$=?T*+T'T'\J^
MIS;_ ))GA/US[_U/HF,/XU?_ +A_^DL6BBBOEC8**** "BBB@ HHHH ****
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M&LX=.TC1-$TC3OV(+;3]*TG2M/MK>QT[3K&W@L[*S@AMK:&*&)$4 _K-
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MC6? .@>&-+$B0.+?_A'_ !?XH+N5$@B!+  _="-Q(B2 $!T5P&&& 8!@& )
M(!P1DX/<U\6_\%*/"^K>-_\ @G1^WWX+T&(3ZYXO_8J_:G\+Z+ 8[F43:MK_
M ,#/'>DZ=$8K*WN[R027EW"ACM+6YN7SM@MYI2D;?:M4=4TO3-<TS4=%UK3K
M'5]'U>QN]+U;2=4M+?4-,U33-0MY+2_T[4;"[CFM;VQO;6:6VN[2YBEM[FWE
MDAFC>-V4@'\]7_!JMXBTS6O^"'W[)VE6,OF7G@WQ+^T?X=UM-]NWD:G=?M*?
M%CQ7%%MAGEEBSH_B;2IMEW':W!\WS%@:UDMKFX^%_P#@KL_C?_@H?_P7&_8C
M_P""-?Q*\;^)O"7["FJ_!N?]I7X\^!? /B/5?"VN?'+6_#\/Q4\5Z;X;\8:M
M8!Q>>%;._P#A?X,TK2M'BCT^[T)=7\9>,--UY/%J>#)_#'<?\&TECXI_8H^+
M7_!2K_@CQ\596'BO]F#X^#XX?"/6=0T2^T;4?B7\&/BE86/AM/&%@KV]O:SZ
M)%;>%O 'B02O%YB7GQ->QL=1U;3[!8](^_\ _@L!_P $9W_X*'>)?@I^T]^S
MM\<-0_9/_;[_ &870?!KX]Z99WE[IVK>'K/4-2\0:;X!\;II<\&L6FDZ;XEU
M34]2T/7M-35X]'@\2^---U;PAXNT[Q-)9V0!W?Q,_P"#?'_@CO\ $WX2:I\'
M[C]A?X->"--O= AT/3O'7PST>3P3\6_#MQ8VBV^D^(M+^)VF3GQ5J&OZ=/';
MZC/-XJOO$>F^)KN%HO&VE^)].O-2L+W\I_\ @W;^,_QQ^,?P=_X*K?\ !+'X
MH_%;5?BS_P ,)_$;Q5^SO\(?C1XRU+Q'XBU2Y^'?Q"E^-WPP\-:)<ZCX@G37
M;KPOX-OOA'>W_A;2Y](TB70/"^N6/AFQM;;3=)TW2M)Z?7_V?_\ @[C^).B7
MWPB\1?M??\$[_A=X<\30+X3\1_';X9Z3XFC^(^B>'9'CMM=\5>"T?X,6S6?B
MG5=)CO$T>>RT?PIJ>GW^HPW.CZMX!U2"S\1:#^PG_!)C_@EM\*/^"4_[-0^#
M?@KQ'K7Q(^)GCO6A\0?V@?C-XCFO1JGQ3^*5[90VNHZS::3<WU_%X;\-:=%&
M--\-:%!/<W4.GQ_;]?U37O$VH:UKNH@'\^?_  9<_ 7X)>'/V4_VJ/CI!IFD
MW/[4&J_M$ZK\&OB%>:C;30>,O GPS\&>$?!/B'PGX)33]1E>ZT72M=\4>(/%
M7B'6=1TRTTR#Q7J=AINB:VVIWOPRT]=)^R_^#N?X>?"[7O\ @DQK7Q0\5VFD
M6GQ4^#'QN^$6N_ ?Q:U]!H_BW1O%OB7Q/;>'/$^D^%]422WU:[CU;P3/K6M:
MKX<L)WM[J;PEI'BJZLY+GP5IM]ILO[4__!%G]M3X)_ML_$__ (*&_P#!%7]I
M[X?_ +._Q0_:%&L:W^T]^SW\>XM?USX)?%_QIJ6N7'B75?%=I);^&_'HM-3\
M2:QJ&K:V+'4- M+OPQXHU37KCPCXY\+^&_&.KZ%IWC?AO_@B_P#\%2_^"BG[
M0/PV^(O_  77_:H^#7CS]FOX">+],\<?#O\ 8W_9JT^:'X??$#Q5;Z:EM>R_
M$*>3P/X&C@\/RSVEJ+RYUZZ^)_B[6-)USQUX0\/:A\,/#^K+-J0!_3+^R;XD
M\8^,OV6OV;?%WQ$E\[Q_XI^ WPB\1>.)O,2;S?%VM> = U'Q')YL=Q=QR[]8
MN;QO,CNKE'SN6XF4B1O>KJZM;&UN;V]N8+.SLX)KJ[N[J:.WM;6UMXVFGN;F
MXF9(H(((D>6::5UCBC5G=E521\:_M]_ ;XX_'[]B'X__ +/O[)WQ;@_9Q^-G
MCSX:R>$/A5\3+.:ZT.P\'W<=YICS:4=4T/1=<UGPGI'B3P]9ZCX)O/$WA31;
MSQ1X.TS7I_$/A&"/Q#I.E21^9?\ !)[]G/\ :X_94_8<^$GP3_;<^/O_  T9
M\?O"_P#PD$FN^./[8USQ7_9.B:EK5W?>&_!'_">>*K6Q\5^/O^$5TJ6&R_X2
M;Q%96U[\W]BV:S:+HVEW4X!ZGHWBW]A+_@I]\"_%^B:%KG[/W[:W[/$OBVW\
M)^-=.L;KPM\6OAP?&WA0>'/&EMH>LPH=3TI-?T-=2\,>(8[:4+=VD=]IMV J
M7$9?^87_ (+Q_P#!.GX ?\$MO@1X<_X*L_\ !,RQL_V'/VG?V>?B=\.M%O+/
MX2W-QH?PY^+O@/QUXJO--UGP/X@^&C71\,:I--K6KZ/JFI6ALI-"UKP+H&L^
M&->\/:G:1Z#>>&_<_$G_  14_P""F?\ P3X^/'Q;^+'_  0M_:X^#WPS^ _Q
MU\83>._'O[%'[2NA75W\,O#/B*[L9[%G^'6JVG@OQ]''8V5S?_:=+_LV+X7>
M(['PWH/AKPGXA\5?$/3/#]A97%>Y_P""-'_!6C_@I'X_^'=Y_P %K/VU_A'>
M_LQ_#?Q1HGC>V_9$_9$TO4;'PO\ $+Q'X8U!#9+\1=4UCP-X/M$M=7LI]8M+
M^]EG\?:M9:+J,MAX8N/"%]JEY=Z: ?T\?L\?%,_'+X _!#XU'3SI!^+OPD^'
M/Q-.E'!.FGQUX0T?Q.; D2S@_8SJGV?B:8?N^)9/O'\.?^"W?[87QK\4>)/A
M-_P1Z_8-U&$?MK?MU:1J\7CWQP4\01Z5^S#^RL\&IZ;XV^*_B/7_  Y(NH>&
M=7\3"TU71O#-[:6NKW-II&D>*7%MI?BC6?AO+K/] ,^G7'A;P9/I/PZ\-^&A
M=^'?#,NG^!?"-U?R>"_!_P!ITG2VM_#/AVYU31/#GB6;PIX;,T%EIL^H:1X2
M\02Z%IF^YL/#NJO:Q:9<?CY_P2B_X)D?%3]E#QA^T?\ MC?MM?$?P9\=?^"B
M_P"V#XPOK_XR_$OX?W7B34/AOX)^&NA:@++X;_"#X33^+]"\+Z_%X2TCP[I7
MA^:]6[\,Z$+)-.\.>"+.VO\ 0_A]H>NZL ?F;XGD^.'P,_:Q_9D_X-XO^"3?
MQHT7]AKPE\*?V3/$GQ_^.W[4.K_!?PW\?_'U]>ZMJ\C-#X>\+?$7Q-INB7FM
M>-O$VL#Q'XRU]+F#4=.O/&L*^$KG0]/\&C2KS[A_X)*?M@?M;7'[6/[>?_!+
M;]N?XG>'_P!HCXW?L-W?PK\4^"OVH-!\$:/\-=0^-/PA^,WAJ'QAX?/CKX?>
M%UE\*^&?%OA/2-9\(HTVDZC>S:I!K\VF:O+JFM>%=1\8>+KO[>W_  3L_;%B
M_;\^%/\ P51_X)J>)_V>A^TEH'P;N_V;/C7\%_VI8?%]E\)OBK\)+S6;K7+'
MQ)H?BCX>6-QXMT'XCZ)?2Z=92+/<VNC:AI&@^'KB.[@_L36O#'Q![3_@EI_P
M3O\ VF_@9\??VQ/^"@'[?GQ ^#_C?]MC]M>]^'>F>)_#W[/-GXHT_P""7PC^
M&/PK\/P^'/!G@GPG)XIMM+US7]2DT>R\/:=K>I^(++5;VTA\(Z1';^)_$6H7
M_B;Q+XC /R__ .#N2[E\2_#7_@F-\$](A$_BWXH_M[^%+CPXC+?2"2;1M)B\
M*-"8K+3KUY1-J7Q(T92L3F^(&VQT_4"\QM?Z]+=2L$"GJL,:GZA%!ZX/45_(
MS^W%I6O_ /!1?_@Y<_80_9:\*S6G_"L_^"5/PZC_ &O_ (U:G?:?I<\FC>/O
M%FL>!?'&BZ'IHDCE?4;S7I=/_9D6Q@O;VSOM)L[_ ,7^*-$TXOX<>XU?^NR@
M HHHH **** "BBB@ HHHH **** /YZO^"_?3_@EK_P!I/?V=_P#TJOZ_H33[
MB_[J_P A7\]G_!?OI_P2U_[2>_L[_P#I5?U_0FGW%_W5_D*^IS;_ ))GA/US
M[_U/HF,/XU?_ +A_^DL=1117RQL%%%% !1110 4444 %%%% !7)^//'G@KX7
M>"O%7Q'^(_BK0? W@'P-H.J>*?&/C'Q3JEIHOAWPSX=T6TEO]6UK6M6OY8;.
MPT^PLX9;BYN;B5(XXT))S@'K*_GU_P"#@[_@F_\ M_\ _!4+X#_"/]G+]CKX
MT? CX6_"P^*/$OBC]I#P_P#&G7_'/AD_$.YT=O"%S\&[+1=3\!_"7XGZC<:3
MX<U2'QOK'B#2;V;0+&ZU5O!]^8]7N-*A.E@'Y?:CX=^*7_!TK^U':ZXNI_$;
MX1_\$,OV6?&[:;9V$EW<^$O$_P"W-\8O#5U<MJFN:=IL%M8:[H'A&*QO;;1O
M[7UFYNK_ ,%^&VN;/PM%H/Q0\:>-/^%<?V4>#_"/AKP!X3\,^!?!FBV'AOPA
MX,T#2/"WA;P]I4"VVF:'X>T"PM]+T;2-/MU^6"RT[3[6WM+6%?ECAA1!P*_D
M:^"?[ 7_  =3_LX_"GP-\#_@;^V)_P $FOAI\*/AMH-KX;\%^"?#/@+Q+:Z3
MHNE6I=R 9/V*IKN_U"^NI;C4=8UG4[F]UG7=7N[[6-9O[_5+Z[O)OVH_X)C?
M#;_@L+\/I_C4?^"K7[07[+7QS@U:+X=CX%)^S9HNI:0_AB:Q?QP?B6WC(ZA\
M$?@[]H764O/ 0\/^2WB'RCI>M>8NE>8AU$ _GV_87^ WA/\ X+F_\%8O^"E7
MQO\ ^"B]K-\:?A1^P!\;I?@%^RG^S%J&NZXGP1\'6!\9^/M&OO$'B'P7'-#;
M>(]:O-(^%_A>\U^2[O3H7CKQ%K?B*Z\4^%Y=*TCP5I.A?9__  62_P""(W[
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M;C7FM-,TG0=2?QGXWL]9BTN#Q#J7BJTM_ASKWB+Q-)XLL_%JWO\ 9/7X0?\
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M%M  ?LM1110 4444 %%%% !1110 4444 %%%% '\]'_!+K_E+C_P7-_['_\
M9G_]-WQCK^A>OYZ/^"77_*7'_@N;_P!C_P#LS_\ IN^,=?T+U]1QA_R.H_\
M8EX8_P#6:RDPP_\ #E_U]K?^G9GS/^VG_P F<?M9_P#9L_QX_P#56^*J^&?^
M""'_ "B+_8O_ .Q-\>_^KD^(]?;G[<-]:Z9^Q7^U_J5]*(++3_V7/V@+Z\G*
M22"&UM/A/XMGN)2D2O*XCBC=]D:/(V-J*S$ _P [_P#P2'_X+0_\$S_V9O\
M@G)^S#\#/CA^TW9^!OBI\/O#/B[3_%_A27X5_''7Y-'N]3^)GC;7[&%M7\+?
M#/7- O?/TC5M/O ^G:K>1QBX$,KI<1S0Q]V6Y;F.9\'8^CEN QN858<3994G
M2P6%KXNI&G'*LUC*I*%"G4E&"E.$7-I14IP3=Y).9SA#$0<Y1@O8S5Y245?G
MINUVTKV3T\F?UA45^+__ !$+_P#!'G_H\?3_ /PR?[2/_P YVC_B(7_X(\_]
M'CZ?_P"&3_:1_P#G.UY/^J?%7_1,\0?^&;,?_F8T]O0_Y_4O_!D/\S]H**_%
M_P#XB%_^"//_ $>/I_\ X9/]I'_YSM'_ !$+_P#!'G_H\?3_ /PR?[2/_P Y
MVC_5/BK_ *)GB#_PS9C_ /,P>WH?\_J7_@R'^9^T%%?B_P#\1"__  1Y_P"C
MQ]/_ /#)_M(__.=H_P"(A?\ X(\_]'CZ?_X9/]I'_P"<[1_JGQ5_T3/$'_AF
MS'_YF#V]#_G]2_\ !D/\S]H**_%__B(7_P""//\ T>/I_P#X9/\ :1_^<[1_
MQ$+_ /!'G_H\?3__  R?[2/_ ,YVC_5/BK_HF>(/_#-F/_S,'MZ'_/ZE_P"#
M(?YG[045^+__ !$+_P#!'G_H\?3_ /PR?[2/_P YVC_B(7_X(\_]'CZ?_P"&
M3_:1_P#G.T?ZI\5?]$SQ!_X9LQ_^9@]O0_Y_4O\ P9#_ #/V@HK\7_\ B(7_
M ."//_1X^G_^&3_:1_\ G.T?\1"__!'G_H\?3_\ PR?[2/\ \YVC_5/BK_HF
M>(/_  S9C_\ ,P>WH?\ /ZE_X,A_F?M!17XO_P#$0O\ \$>?^CQ]/_\ #)_M
M(_\ SG:/^(A?_@CS_P!'CZ?_ .&3_:1_^<[1_JGQ5_T3/$'_ (9LQ_\ F8/;
MT/\ G]2_\&0_S/V@HK\7_P#B(7_X(\_]'CZ?_P"&3_:1_P#G.T?\1"__  1Y
M_P"CQ]/_ /#)_M(__.=H_P!4^*O^B9X@_P##-F/_ ,S![>A_S^I?^#(?YG[0
M45^+_P#Q$+_\$>?^CQ]/_P##)_M(_P#SG:/^(A?_ ((\_P#1X^G_ /AD_P!I
M'_YSM'^J?%7_ $3/$'_AFS'_ .9@]O0_Y_4O_!D/\S]H**_%_P#XB%_^"//_
M $>/I_\ X9/]I'_YSM'_ !$+_P#!'G_H\?3_ /PR?[2/_P YVC_5/BK_ *)G
MB#_PS9C_ /,P>WH?\_J7_@R'^9^T%%?B_P#\1"__  1Y_P"CQ]/_ /#)_M(_
M_.=H_P"(A?\ X(\_]'CZ?_X9/]I'_P"<[1_JGQ5_T3/$'_AFS'_YF#V]#_G]
M2_\ !D/\S]H**_%__B(7_P""//\ T>/I_P#X9/\ :1_^<[1_Q$+_ /!'G_H\
M?3__  R?[2/_ ,YVC_5/BK_HF>(/_#-F/_S,'MZ'_/ZE_P"#(?YG[045^+__
M !$+_P#!'G_H\?3_ /PR?[2/_P YVC_B(7_X(\_]'CZ?_P"&3_:1_P#G.T?Z
MI\5?]$SQ!_X9LQ_^9@]O0_Y_4O\ P9#_ #/V@HK\7_\ B(7_ ."//_1X^G_^
M&3_:1_\ G.T?\1"__!'G_H\?3_\ PR?[2/\ \YVC_5/BK_HF>(/_  S9C_\
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M>WH?\_J7_@R'^9^T%%?B_P#\1"__  1Y_P"CQ]/_ /#)_M(__.=H_P"(A?\
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M&3_:1_\ G.T?\1"__!'G_H\?3_\ PR?[2/\ \YVC_5/BK_HF>(/_  S9C_\
M,P>WH?\ /ZE_X,A_F?M!17XO_P#$0O\ \$>?^CQ]/_\ #)_M(_\ SG:/^(A?
M_@CS_P!'CZ?_ .&3_:1_^<[1_JGQ5_T3/$'_ (9LQ_\ F8/;T/\ G]2_\&0_
MS/V@HK\7_P#B(7_X(\_]'CZ?_P"&3_:1_P#G.T?\1"__  1Y_P"CQ]/_ /#)
M_M(__.=H_P!4^*O^B9X@_P##-F/_ ,S![>A_S^I?^#(?YG[045^+_P#Q$+_\
M$>?^CQ]/_P##)_M(_P#SG:/^(A?_ ((\_P#1X^G_ /AD_P!I'_YSM'^J?%7_
M $3/$'_AFS'_ .9@]O0_Y_4O_!D/\S]H**_%_P#XB%_^"//_ $>/I_\ X9/]
MI'_YSM'_ !$+_P#!'G_H\?3_ /PR?[2/_P YVC_5/BK_ *)GB#_PS9C_ /,P
M>WH?\_J7_@R'^9]VZU^Q!^S;K7[7_@_]N]O D^D_M0^#OASK/PD3XC>'?$GB
M30!XK^'6LB1V\+_$#PWI>J6WACQS::7=2+?:'=>(](O]2TJ[M-+>VO1'HNCQ
M6'UG7XO_ /$0O_P1Y_Z/'T__ ,,G^TC_ /.=H_XB%_\ @CS_ -'CZ?\ ^&3_
M &D?_G.T?ZI\5?\ 1,\0?^&;,?\ YF#V]#_G]2_\&0_S/V@HK\7_ /B(7_X(
M\_\ 1X^G_P#AD_VD?_G.T?\ $0O_ ,$>?^CQ]/\ _#)_M(__ #G:/]4^*O\
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M_P"&3_:1_P#G.T?ZI\5?]$SQ!_X9LQ_^9@]O0_Y_4O\ P9#_ #/V@HK\7_\
MB(7_ ."//_1X^G_^&3_:1_\ G.T?\1"__!'G_H\?3_\ PR?[2/\ \YVC_5/B
MK_HF>(/_  S9C_\ ,P>WH?\ /ZE_X,A_F?M!17XO_P#$0O\ \$>?^CQ]/_\
M#)_M(_\ SG:/^(A?_@CS_P!'CZ?_ .&3_:1_^<[1_JGQ5_T3/$'_ (9LQ_\
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MOF_]4^*O^B9X@_\ #-F/_P S&OMZ'_/ZE_X,A_F?M!17XO\ _$0O_P $>?\
MH\?3_P#PR?[2/_SG:/\ B(7_ ."//_1X^G_^&3_:1_\ G.T?ZI\5?]$SQ!_X
M9LQ_^9@]O0_Y_4O_  9#_,_:"BOQ?_XB%_\ @CS_ -'CZ?\ ^&3_ &D?_G.T
M?\1"_P#P1Y_Z/'T__P ,G^TC_P#.=H_U3XJ_Z)GB#_PS9C_\S![>A_S^I?\
M@R'^9^T%%?B__P 1"_\ P1Y_Z/'T_P#\,G^TC_\ .=H_XB%_^"//_1X^G_\
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MT%%?B_\ \1"__!'G_H\?3_\ PR?[2/\ \YVC_B(7_P""//\ T>/I_P#X9/\
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M8/;T/^?U+_P9#_,_:"BOQ?\ ^(A?_@CS_P!'CZ?_ .&3_:1_^<[1_P 1"_\
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M/_\ #)_M(_\ SG:/]4^*O^B9X@_\,V8__,P>WH?\_J7_ (,A_F?M!17XO_\
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MY_Z/'T__ ,,G^TC_ /.=H_XB%_\ @CS_ -'CZ?\ ^&3_ &D?_G.T?ZI\5?\
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M $;K\"O_  T?@#_YGZ/^&7?V9O\ HW7X%?\ AH_ '_S/U[K11]=QG_07B?\
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M ,F'+'^6/W+^NB^X\*_X9=_9F_Z-U^!7_AH_ '_S/T?\,N_LS?\ 1NOP*_\
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MOFPOM&/WP'[+O[,V!_QCM\"N@_YI'X _^9^OQ@_X.!/^07_P2^_[2B_LX_\
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MP!_\S]>ZT4?7<9_T%XG_ ,'U?_DPY8_RQ^Y?UT7W'A7_  R[^S-_T;K\"O\
MPT?@#_YGZ/\ AEW]F;_HW7X%?^&C\ ?_ #/U[K11]=QG_07B?_!]7_Y,.6/\
ML?N7]=%]QX5_PR[^S-_T;K\"O_#1^ /_ )GZ/^&7?V9O^C=?@5_X:/P!_P#,
M_7NM%'UW&?\ 07B?_!]7_P"3#EC_ "Q^Y?UT7W'A7_#+O[,W_1NOP*_\-'X
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MP!_\S]>ZT4?7<9_T%XG_ ,'U?_DPY8_RQ^Y?UT7W'A7_  R[^S-_T;K\"O\
MPT?@#_YGZ/\ AEW]F;_HW7X%?^&C\ ?_ #/U[K7)>.O'_@3X7^%=5\=?$SQK
MX2^'?@C0A9'6_&/CKQ)H_A'PKHPU+4;32-..J^(=?O=/TC3A?ZM?V.F61N[R
M$76HWMI90>9<W,,3GUW&?]!>)_\ !]7_ .3#EC_+'[E_71?<>;_\,N_LS?\
M1NOP*_\ #1^ /_F?H_X9=_9F_P"C=?@5_P"&C\ ?_,_7KOA[Q#H'B[0-$\5>
M%-<T?Q/X7\2Z3IVO^'/$GA[4[+6M \0:%J]I#J&DZUHFL:;/<Z=JNDZI87$%
M[IVHV%Q/9WMI/#<VTTL,J.VQ1]=QG_07B?\ P?5_^3#EC_+'[E_71?<>%?\
M#+O[,W_1NOP*_P##1^ /_F?H_P"&7?V9O^C=?@5_X:/P!_\ ,_7NM%'UW&?]
M!>)_\'U?_DPY8_RQ^Y?UT7W'A7_#+O[,W_1NOP*_\-'X _\ F?H_X9=_9F_Z
M-U^!7_AH_ '_ ,S]>ZT4?7<9_P!!>)_\'U?_ ),.6/\ +'[E_71?<>%?\,N_
MLS?]&Z_ K_PT?@#_ .9^C_AEW]F;_HW7X%?^&C\ ?_,_7NM%'UW&?]!>)_\
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M@5_X:/P!_P#,_1_PR[^S-_T;K\"O_#1^ /\ YGZ]UHH^NXS_ *"\3_X/J_\
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M_7NM%'UW&?\ 07B?_!]7_P"3#EC_ "Q^Y?UT7W'A7_#+O[,W_1NOP*_\-'X
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MRSP30QQZQ96;/+#+&H+QN!Z)1]=QG_07B?\ P?5_^3#EC_+'[E_71?<>%?\
M#+O[,W_1NOP*_P##1^ /_F?H_P"&7?V9O^C=?@5_X:/P!_\ ,_7NM%'UW&?]
M!>)_\'U?_DPY8_RQ^Y?UT7W'A7_#+O[,W_1NOP*_\-'X _\ F?H_X9=_9F_Z
M-U^!7_AH_ '_ ,S]>ZT4?7<9_P!!>)_\'U?_ ),.6/\ +'[E_71?<>%?\,N_
MLS?]&Z_ K_PT?@#_ .9^C_AEW]F;_HW7X%?^&C\ ?_,_7NM%'UW&?]!>)_\
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MK\"O_#1^ /\ YGZ/^&7?V9O^C=?@5_X:/P!_\S]>ZT4?7<9_T%XG_P 'U?\
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MQ+!X,T^Z7XLS>(4\!-;7WC"ZMO"EG.-?,5UXEN(-"@=]4FCM6\<^*7_!2?\
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MCV5Z\,UQ:13+')>6JS?S+^,OA5XE_P"#C#_@KS^TW\(?BUXT\<Z7_P $G/\
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M0S3VUW?^']'UBYUJUL+J*UO#:ZA+8K8W+6&H1P7$DFGWJ0?5E?PA_P#!Q_\
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M0]9&K^#_ !-X?U'7/$P!]6_\%NO^"J_PU_X)U?L9?M!ZMX#^/GP8T']M?3O
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M?0?$'A74[AU5-.\6V6H>(86\*7\:O%<7-IXB.F7%G9307]W'!97$-Q)^"/\
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M?#O4M)_:(^!?AO\ ;$^-WQ VZU\</VF?CW!J&M_%CXF>.;NW@BU77M$OX-7
M^#_AZ%8(-,\)^!/A9<>'-#\*>'+#3-,1]4U&'4-=U3\E/^#331_$OPCO/^"O
M?P3M?&0U/]EWX"?MC'PA\%_[2\02W=KI-_X?U#XK:-\0M>"W-_<Z=IVFZWX.
M\._"+4)=2@D$6HW-KJ%U<W5SY'G* ?UN_%+XP?"7X&^$;OX@?&SXH_#KX/>
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M-XBOVB5/$.OZ/XM^$GQ"LU\3O)'J6L>%W\+?V];7.O6NI>(_$?W+_P %>_\
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MI27XB>'K70_&MIXS/CW^Q+0Z#H_@>RM_$.I?#NPO/B+JWA.WT_P@ >F?MI?
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M\-?#/P^6?5K?Q)KWC^TNOFK_ (,L_P#E&3^T=_V?_P#%#_UG_P#9DH ^A/\
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MX ?$?_@JK_P34\*_$7Q->_"WXD?'OX9_\,T1^$/%^K:Y-?:UHOPV^(>L^/\
M3-.\9:-/8W%KJ7B?1=6\/>'?$UWK&HV7C-OAI\($US4='\3?1'_!/7XC>)/V
MK?\ @O7HOQ._X+2W'CG]G?\ ;^^&'@O5=!_8C_8G\0?!6\\,? *VT632O&['
MQ3\,OBNWC7QM:_$2]T;2(/B'KUO>^)+"ST[Q#XSU6/7O OC[7KSPAI7A?PR
M?W8ZGJ>FZ)INH:SK.H6.DZ/I-C=ZGJNJZG=V]AINF:;80275]J&H7UU)%:V5
MC96L4MS=W=S+%;VT$4DTTB1HS#^5'_@W>U_Q%XO^%/\ P54_X*W_ !$5-4N_
MVO?VG?BMX_T#0](LS;13?";]GRS\5W/AFPT;6-6CBU<V%KJGB7QAX,T33=8C
MD_LFQ\-6=Y-/)?:IJ<<7Z2?\' O[4FG_ +)G_!)']L/QJVJMIOB?XC?#F\^
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MFWO?$OASQ#X>T/P;JW@3P_IOA>3Q'<^*_$)X']J[]FC]IW_@V*\6?!K]M_\
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MCOQ__8=_X-EOV7_A)JGQO^-?P5_8)\(?#RPL-9N].U%O$.BZGJ?C*]T.PO\
M4;OPU\._#^E^*[O6_B#XQG@TR]33_"7@^QUC7[^XMY8;:P=XY-GW=^UG\"(_
MVZOA3=?!/]K7_@GMX$^-GPXGO[;2;72/$OQ3TNRU;P]\5[7*0_%/P5XQ\/2:
M)XU\"?!P6LESIDWQ)\&>(O#_ ,?;C1K_ %30Y_@U-I&JZC97?Y/_  9_X-W/
M^"?GP6\>:?\ $.Q_X)86GQ&U?1M9NM,T71?C+^U!X@^)_@.Q\?7"HD'B*_\
MAWXCUB;P1XS_ &8=/B\]+;5_B%H/BSXORM</<:A\#;^[M]/N+,_MG"?\^,T_
M\,V;?_,8?\0VS_\ Z&? O_BR?#__ .B7S_/LS[F_8.TC]C+2O^";'QG_ &P/
M^"7_ .QAXA_90B^/OP,\=^//"WA;6_AO8?"?XK_$'6/AYX-\<GX4:A>I%KGC
M2TO=(GU34]1O/ASK=EKFM^&;RR\23^(M!>[T_6VNKW\E?^#27]KO]B[X6_\
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MY#^)?[!O[*/Q@_:G^"G[:WQ%^%7_  D7[37[.VA:CX:^#GQ+_P"$Y^)&D_\
M"'Z+JL?B6*_LO^$-T+QAIGP_\0?:$\7^(E^T^*?"FMW<7]HYAGC-I8FV /'O
M^"K_ .UM\=?V%/V(/BO^UC\ ?A#X;^./B+X+MH?B?QCX!\2W^L:;!-\,GU%-
M,\9>([*]T207MO/X.@O[3Q3J,K6U];Q^&])UV26V0(M[:?&W[/?Q$_X(6_\
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M^&C_ -K>^_LW7_#NI6VKZ/?_ &+4OCU>:=>?8]1L[:X^RW]I=65QY?E75M/
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M_P#Z(*ON#]B'_@DA_P $]O\ @G%XH\<>-/V,OV?O^%-^)?B1H.F^&?&FI?\
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M.GA^%[*#4S\-/V==)CUZSN#-K-A)I5W9Z]X6M_CHFGZ;<S7UM<:_X8TZ6_\
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MRTO=)UG2-0MI)+>^TS4[.YL[J!WAN()(V92 ?+?PH_X*"?L-_%_X5>&OB_\
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M[G5;ZRNM6DGOY0#\;_\ @[T^(<GA[_@E7HGPLTFZ@E\4?M _M0_!_P"'&D:
MNHVEI?ZO:V%GXN\;7$ZV]QJVF^9I=EK/AGPY:W]]+#J&GZ=?:MHRWL-K)>6E
M_:_T9?LX_#2/X,_L^_!#X10RV\\7PP^$WP]\ QS6K736TJ>$O"FE:$LENU[+
M/>-"XL0T1NII;@H09I'DW,?YU/VR_@'\0?\ @J3_ ,%SOV4/A;KWPO\ B"O[
M"O\ P3&\.7GQS^*GC;QGX-U[PQ\,?BQ^T=XDU'3=3\+^ OA[XDN-)GTGXGPZ
M-J7A_P"&TWB:TN99=!M[+P=\6_"5XEB^IVDGBG^I%555554*J@*JJ %50,!5
M P     !@#@4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?ST?
M\$NO^4N/_!<W_L?_ -F?_P!-WQCK^A>OYZ/^"77_ "EQ_P""YO\ V/\ ^S/_
M .F[XQU_0O7U'&'_ ".H_P#8EX8_]9K*3##_ ,.7_7VM_P"G9GS/^VG_ ,F<
M?M9_]FS_ !X_]5;XJKX9_P"""'_*(O\ 8O\ ^Q-\>_\ JY/B/7VW^W%-=6_[
M%7[8%Q8V?]HWL'[+G[0$UGI_VB.T^W747PG\6O;V?VJ8-#;?:9E2#[1*ICAW
M^8X*J17\P?\ P2I_;0_X*O\ PS_X)_?LW^!OV?O^"5=K\??@]X?\.^*K?P3\
M7I/VCO O@I_&ME<_$7QC?ZA>MX7U;_B8:3]@UJ[U+1A%<_-.--%VG[JX2O1R
MG+,1FG!^84<-5P-*<.)<LJN6.S' Y;3<5E>:0:C5Q^(P].<[U(M4XR<Y14Y1
MBU";4SFH8B#:DTZ,U[L)3>M2GT@F[>=K=-VD_P"Q^BOYZ/\ AX5_P7#_ .D)
M=E_XEO\ #3_"C_AX5_P7#_Z0EV7_ (EO\-/\*\__ %0S3_H+X=_\2KASR_ZF
MGG_5U>_;P_EJ_P#@FMY?W//^KJ_]"]%?ST?\/"O^"X?_ $A+LO\ Q+?X:?X4
M?\/"O^"X?_2$NR_\2W^&G^%'^J&:?]!?#O\ XE7#GE_U-//^KJY[>'\M7_P3
M6\O[GG_5U?\ H7HK^>C_ (>%?\%P_P#I"79?^);_  T_PH_X>%?\%P_^D)=E
M_P");_#3_"C_ %0S3_H+X=_\2KASR_ZFGG_5U<]O#^6K_P"":WE_<\_ZNK_T
M+T5_/1_P\*_X+A_](2[+_P 2W^&G^%'_  \*_P""X?\ TA+LO_$M_AI_A1_J
MAFG_ $%\._\ B5<.>7_4T\_ZNKGMX?RU?_!-;R_N>?\ 5U?^A>BOYZ/^'A7_
M  7#_P"D)=E_XEO\-/\ "C_AX5_P7#_Z0EV7_B6_PT_PH_U0S3_H+X=_\2KA
MSR_ZFGG_ %=7/;P_EJ_^":WE_<\_ZNK_ -"]%?ST?\/"O^"X?_2$NR_\2W^&
MG^%'_#PK_@N'_P!(2[+_ ,2W^&G^%'^J&:?]!?#O_B5<.>7_ %-//^KJY[>'
M\M7_ ,$UO+^YY_U=7_H7HK^>C_AX5_P7#_Z0EV7_ (EO\-/\*/\ AX5_P7#_
M .D)=E_XEO\ #3_"C_5#-/\ H+X=_P#$JX<\O^IIY_U=7/;P_EJ_^":WE_<\
M_P"KJ_\ 0O17\]'_  \*_P""X?\ TA+LO_$M_AI_A1_P\*_X+A_](2[+_P 2
MW^&G^%'^J&:?]!?#O_B5<.>7_4T\_P"KJY[>'\M7_P $UO+^YY_U=7_H7HK^
M>C_AX5_P7#_Z0EV7_B6_PT_PH_X>%?\ !</_ *0EV7_B6_PT_P */]4,T_Z"
M^'?_ !*N'/+_ *FGG_5U<]O#^6K_ .":WE_<\_ZNK_T+T5_/1_P\*_X+A_\
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M7P[_ .)5PYY?]33S_JZN>WA_+5_\$UO+^YY_U=7_ *%Z*_GH_P"'A7_!</\
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M%P_^D)=E_P");_#3_"C_ (>%?\%P_P#I"79?^);_  T_PH_U0S3_ *"^'?\
MQ*N'/+_J:>?]75SV\/Y:O_@FMY?W//\ JZO_ $+T5_/1_P /"O\ @N'_ -(2
M[+_Q+?X:?X4?\/"O^"X?_2$NR_\ $M_AI_A1_JAFG_07P[_XE7#GE_U-//\
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M:?\ 07P[_P")5PYY?]33S_JZN>WA_+5_\$UO+^YY_P!75_Z%Z*_GH_X>%?\
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MC_AX5_P7#_Z0EV7_ (EO\-/\*/\ AX5_P7#_ .D)=E_XEO\ #3_"C_5#-/\
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MV7_B6_PT_P */^'A7_!</_I"79?^);_#3_"C_5#-/^@OAW_Q*N'/+_J:>?\
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MY_U=7_H7HK^>C_AX5_P7#_Z0EV7_ (EO\-/\*/\ AX5_P7#_ .D)=E_XEO\
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M\/"O^"X?_2$NR_\ $M_AI_A1_JAFG_07P[_XE7#GE_U-//\ JZN>WA_+5_\
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M_P#$JX<\O^IIY_U=7/;P_EJ_^":WE_<\_P"KJ_\ 0O17\]'_  \*_P""X?\
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MD3C?^RIRO_U4YP-_[S'_ *\5/_3E,_7ZBBBOEC<**** "BBB@ HHHH ****
M"BN8\;^-?"/PU\%^+OB+X_\ $>C^#O ?@'PQK_C7QMXN\17]OI?A_P *^$?"
MNE7>N^)/$>NZG=/':Z=H^AZ-87NIZG?W,B6]G96L]Q,ZQQLP_+'_ (?V_P#!
M'+_I(7^SM_X4NH?_ "IH _76BOS1^$7_  6/_P""7WQ[^)7@_P"#OP;_ &V/
M@C\1/B?\0-630O!G@GPYKM]=:YXBU>2":Y2PTZW?3(DEG-O;SS8:1%$<3L6
M%?I=0 4444 %%%% !1110 4444 %%%% !17S[-^U;^SC!^T=:_LAO\9/ [?M
M,WG@=OB3#\%H=66X\<IX&5KE3XBNM,MTE6QLRMK+.L=]-;W3VK6UXENUK>6<
MT_T%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%?.O@3]K7]G+XF_
M'7XI?LS> OBOX=\4?'CX)6%GJ?Q:^&>FQZJWB#X?V.I?V8VE3^)3-IT5AI_]
MKQ:QI]UHT;WIEU>RFDOM-CNK.UNYX #Z*HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKYTTC]K7]G+7_ -I+Q3^Q
M_HOQ8\.:G^TQX)\'V_Q!\7?!RSCU6;Q;X=\#7=MX<N;;Q=JL2:<;&T\/3KXO
M\,6T>K27HLFU'7=-TH3?VG<I:$ ^BZ*** "BBB@ HHHH _GJ_P"#@3_D%_\
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M^SN8H;BY,H29[:YCMM0M+ZRM0#[<HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _GJ_P""_?3_ ():_P#:3W]G?_TJOZ_H33[B_P"ZO\A7\]G_  7[Z?\
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MOV$_V9OVG_VJ/V4_C%_PM[PSXX_9(^&'@SXA^./$T?A#PSJ7@SQUXA^).@^
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MQ]H_A_2=.U;2M<NK>&#I_#?[1OQ"_P""8G_!H5\'OB1\/O$6LK\8/%GP!L-
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MU:MK%E+?:?IWB#PY8?#&_L[[0]6FT.3X:_&_3H);>P\>V]W7]D( 4!0,
M=  , #Z"@#^5;_@N%!HW[8W_  5,_P""+'_!,*9]7UGP_>_%_P 3?MK?'SP<
M+KR?"VI?#;X3:=J]QX..NP0/]I9O$%EX ^.'@N/47ETI]/AU^73]'N[S5/$
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M3_QQ_P"KC^(U '[?5_-A_P '4/[3_C3X'?\ !,6]^"OPJW7/Q4_;?^+?@O\
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MA[X6^&M!\3R,+&6:$SR^)--U66Z>1UO'N7E?4(H+]KF&, _G!_;7_9[\)_\
M!!7_ (*Z?\$_/VO?V'_#5O\ "O\ 98_;M^)L/[+7[6?P!T/6[;2_A=!?^(/$
M?AO3K+Q-HF@:M>R'0HK2S\7O\1?"VF>'X].T'PQXD^%NHZ,VJ^&_"GQ!O]$U
M#[Y_X.N-6O-*_P"">'P$NM7BU^;X)/\ \%!OV8C^T\NEZ/KNMZ!_PH*VT[XE
MZGKO_"P+;P_97]VO@Y_&ECX#C7?$!>>+)/"NE6/GZSJ.EV=UX=_P=R7-Y/\
M 7_@G-X;T"YN(O&6M?\ !0WX;7'A>&TGDL;I[RQ\+^);&.XMM4+V]MI]Q;:I
MK>CK#//>VKQR7"W$3B.VN)8/ZJ/'_P -_ 'Q?^'WB/X8?%7P9X9^(GP[\;Z#
M-X?\8>"?&6C6'B+PQXDT:]B5;K3=9T;4X+FQOK60A7"3POY<T<4\12:*.10#
M^4?_ (*2:9^S#/\ \%5O^#>J+]B6#X*7'Q2A^-_Q!:]T[]G"3P9/+9?LSP>%
M?!GBO7KO4M'^'\CZ'I_@27P5JWCO7](U"^M(!>Z%-XOO_#-Q/:V^M20^D?\
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M>TJ!+73-"\.Z!I]OI6BZ/IUL@"6]CING6EM9VD" +%!#&B\**_DK^$.M1_\
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M5WX=L;W4+#P_H9M_"FA^-X- T71-"TW1=1^%>H>)YY_[/\3:QCYC_P"";/\
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M3##_ ,.7_7VM_P"G9GS/^VG_ ,F<?M9_]FS_ !X_]5;XJKX9_P"""'_*(O\
M8O\ ^Q-\>_\ JY/B/7W-^VG_ ,F<?M9_]FS_ !X_]5;XJKX9_P"""'_*(O\
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M3+>UM8_+M;6VMDV1#9;V\$*XCAC5=Z@#_/4_X(*?\%0_ '_!%#]E?P9\"?\
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M\6:7X1M#8ZVC^'OAUX>\:ZOI^E:Q?VNCWGCFS\(1:I(G@_6O$L=OI/9?!/\
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M_#WBS5OB-K6H3>%O!'BJWM/[1_$WA;PSXTT2]\,^,?#FA>+/#>I_9O[1\/\
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M^?\ 8?LF[3_*^T_:9/(_5VB@#\S/^"SW_*)K_@HK_P!F@?'/_P!035Z^=/\
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MQA_&K_\ </\ ])8ZBBBOEC8**** "BBB@ HHHH **** "BBB@ HHHH _S?\
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M00Q*L<4,2+'&BJB*%  _->/_ ()PZ9J'_!4Z\_X*?^+?C!K7B+Q!HW[-UO\
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M$MO@]X1DDDM+'1()9VU9FM_+O8XK;_2'HH 9%&L4<<2DE8T2-2V"Q5%"@D@
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M,V?_ ,^RC_AT5_P4E_Z3Q_M._P#AF;/_ .?91_8F0_\ 19Y5_P"&OB/_ .=
M>TJ_] ]3_P #H_\ RSU_IZ?T*T5_/5_PZ*_X*2_])X_VG?\ PS-G_P#/LH_X
M=%?\%)?^D\?[3O\ X9FS_P#GV4?V)D/_ $6>5?\ AKXC_P#G0'M*O_0/4_\
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M ,,S9_\ S[*/^'17_!27_I/'^T[_ .&9L_\ Y]E']B9#_P!%GE7_ (:^(_\
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M)X_VG?\ PS-G_P#/LH_X=%?\%)?^D\?[3O\ X9FS_P#GV4?V)D/_ $6>5?\
MAKXC_P#G0'M*O_0/4_\  Z/_ ,L]?Z>G]"M%?SU?\.BO^"DO_2>/]IW_ ,,S
M9_\ S[*/^'17_!27_I/'^T[_ .&9L_\ Y]E']B9#_P!%GE7_ (:^(_\ YT![
M2K_T#U/_  .C_P#+/7^GI_0K17\]7_#HK_@I+_TGC_:=_P##,V?_ ,^RC_AT
M5_P4E_Z3Q_M._P#AF;/_ .?91_8F0_\ 19Y5_P"&OB/_ .= >TJ_] ]3_P #
MH_\ RSU_IZ?T*T5_/5_PZ*_X*2_])X_VG?\ PS-G_P#/LH_X=%?\%)?^D\?[
M3O\ X9FS_P#GV4?V)D/_ $6>5?\ AKXC_P#G0'M*O_0/4_\  Z/_ ,L]?Z>G
M]"M%?SU?\.BO^"DO_2>/]IW_ ,,S9_\ S[*/^'17_!27_I/'^T[_ .&9L_\
MY]E']B9#_P!%GE7_ (:^(_\ YT![2K_T#U/_  .C_P#+/7^GI_0K17\]7_#H
MK_@I+_TGC_:=_P##,V?_ ,^RC_AT5_P4E_Z3Q_M._P#AF;/_ .?91_8F0_\
M19Y5_P"&OB/_ .= >TJ_] ]3_P #H_\ RSU_IZ?T*T5_/5_PZ*_X*2_])X_V
MG?\ PS-G_P#/LH_X=%?\%)?^D\?[3O\ X9FS_P#GV4?V)D/_ $6>5?\ AKXC
M_P#G0'M*O_0/4_\  Z/_ ,L]?Z>G]"M%?SU?\.BO^"DO_2>/]IW_ ,,S9_\
MS[*/^'17_!27_I/'^T[_ .&9L_\ Y]E']B9#_P!%GE7_ (:^(_\ YT![2K_T
M#U/_  .C_P#+/7^GI_0K17\]7_#HK_@I+_TGC_:=_P##,V?_ ,^RC_AT5_P4
ME_Z3Q_M._P#AF;/_ .?91_8F0_\ 19Y5_P"&OB/_ .= >TJ_] ]3_P #H_\
MRSU_IZ?T*T5_/5_PZ*_X*2_])X_VG?\ PS-G_P#/LH_X=%?\%)?^D\?[3O\
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M[6J_83;?L[KGI77N];SL[ZM6;\[']"U%?SU?\.BO^"DO_2>/]IW_ ,,S9_\
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M=_\ #,V?_P ^RC_AT5_P4E_Z3Q_M._\ AF;/_P"?91_8F0_]%GE7_AKXC_\
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M=_\ #,V?_P ^RC_AT5_P4E_Z3Q_M._\ AF;/_P"?91_8F0_]%GE7_AKXC_\
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M=_\ #,V?_P ^RC_AT5_P4E_Z3Q_M._\ AF;/_P"?91_8F0_]%GE7_AKXC_\
MG0'M*O\ T#U/_ Z/_P L]?Z>G]"M%?SU?\.BO^"DO_2>/]IW_P ,S9__ #[*
M/^'17_!27_I/'^T[_P"&9L__ )]E']B9#_T6>5?^&OB/_P"= >TJ_P#0/4_\
M#H__ "SU_IZ?T*T5_/5_PZ*_X*2_])X_VG?_  S-G_\ /LH_X=%?\%)?^D\?
M[3O_ (9FS_\ GV4?V)D/_19Y5_X:^(__ )T![2K_ - ]3_P.C_\ +/7^GI_0
MK17\]7_#HK_@I+_TGC_:=_\ #,V?_P ^RC_AT5_P4E_Z3Q_M._\ AF;/_P"?
M91_8F0_]%GE7_AKXC_\ G0'M*O\ T#U/_ Z/_P L]?Z>G]"M%?SU?\.BO^"D
MO_2>/]IW_P ,S9__ #[*/^'17_!27_I/'^T[_P"&9L__ )]E']B9#_T6>5?^
M&OB/_P"= >TJ_P#0/4_\#H__ "SU_IZ'_!?OI_P2U_[2>_L[_P#I5?U_0FGW
M%_W5_D*_A[_X*O\ _!/W]LOX)#]AO_A:W_!4[XV_M'?\+'_;;^$7PZ\#CQ=\
M.;?0?^%1^-M>GNETCXLZ#Y?Q+\0?VGKOAED=[/3&_LI;@R$'5+;&3^N"_P#!
M(K_@I(54C_@O%^TZ 0,#_A3-GQQT_P"2V5]'F649-+A_AJG/BO+:=*D\Y]EB
M)9=GTH8GGQM*53V<(99*K3]C)*$O;0I\[=Z?/%-F4*E3VM5^PFV_9W7/2NO=
MZWG9WU:LWYV/Z%J*_GJ_X=%?\%)?^D\?[3O_ (9FS_\ GV4?\.BO^"DO_2>/
M]IW_ ,,S9_\ S[*^<_L3(?\ HL\J_P##7Q'_ /.@U]I5_P"@>I_X'1_^6>O]
M/3^A6BOYZO\ AT5_P4E_Z3Q_M._^&9L__GV4?\.BO^"DO_2>/]IW_P ,S9__
M #[*/[$R'_HL\J_\-?$?_P Z ]I5_P"@>I_X'1_^6>O]/3^A6BOYZO\ AT5_
MP4E_Z3Q_M._^&9L__GV4?\.BO^"DO_2>/]IW_P ,S9__ #[*/[$R'_HL\J_\
M-?$?_P Z ]I5_P"@>I_X'1_^6>O]/3^A6BOYZO\ AT5_P4E_Z3Q_M._^&9L_
M_GV4?\.BO^"DO_2>/]IW_P ,S9__ #[*/[$R'_HL\J_\-?$?_P Z ]I5_P"@
M>I_X'1_^6>O]/3^A6BOYZO\ AT5_P4E_Z3Q_M._^&9L__GV4?\.BO^"DO_2>
M/]IW_P ,S9__ #[*/[$R'_HL\J_\-?$?_P Z ]I5_P"@>I_X'1_^6>O]/3^A
M6BOYZO\ AT5_P4E_Z3Q_M._^&9L__GV4?\.BO^"DO_2>/]IW_P ,S9__ #[*
M/[$R'_HL\J_\-?$?_P Z ]I5_P"@>I_X'1_^6>O]/3^A6BOYZO\ AT5_P4E_
MZ3Q_M._^&9L__GV4?\.BO^"DO_2>/]IW_P ,S9__ #[*/[$R'_HL\J_\-?$?
M_P Z ]I5_P"@>I_X'1_^6>O]/3^A6BOYZO\ AT5_P4E_Z3Q_M._^&9L__GV4
M?\.BO^"DO_2>/]IW_P ,S9__ #[*/[$R'_HL\J_\-?$?_P Z ]I5_P"@>I_X
M'1_^6>O]/3^A6BOYZO\ AT5_P4E_Z3Q_M._^&9L__GV4?\.BO^"DO_2>/]IW
M_P ,S9__ #[*/[$R'_HL\J_\-?$?_P Z ]I5_P"@>I_X'1_^6>O]/3^A6BOY
MZO\ AT5_P4E_Z3Q_M._^&9L__GV4?\.BO^"DO_2>/]IW_P ,S9__ #[*/[$R
M'_HL\J_\-?$?_P Z ]I5_P"@>I_X'1_^6>O]/3^A6BOYZO\ AT5_P4E_Z3Q_
MM._^&9L__GV4?\.BO^"DO_2>/]IW_P ,S9__ #[*/[$R'_HL\J_\-?$?_P Z
M ]I5_P"@>I_X'1_^6>O]/3^A6BOYZO\ AT5_P4E_Z3Q_M._^&9L__GV4?\.B
MO^"DO_2>/]IW_P ,S9__ #[*/[$R'_HL\J_\-?$?_P Z ]I5_P"@>I_X'1_^
M6>O]/3^A6BOYZO\ AT5_P4E_Z3Q_M._^&9L__GV4?\.BO^"DO_2>/]IW_P ,
MS9__ #[*/[$R'_HL\J_\-?$?_P Z ]I5_P"@>I_X'1_^6>O]/3^A6BOYZO\
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MS9__ #[*/[$R'_HL\J_\-?$?_P Z ]I5_P"@>I_X'1_^6>O]/3^A6BOYZO\
MAT5_P4E_Z3Q_M._^&9L__GV4?\.BO^"DO_2>/]IW_P ,S9__ #[*/[$R'_HL
M\J_\-?$?_P Z ]I5_P"@>I_X'1_^6>O]/1O_  2Z_P"4N/\ P7-_['_]F?\
M]-WQCK^A>OY?/^"%_P ,_'GP=_X*$?\ !8[X;?$WXQ>(/C_XZ\)^)?V9=-\1
M_%_Q3I2Z)K_CF_%O\:YCK&I:6FK:ZMG<-%-%;F)=5O1MMU;S?FVK_4'5\;0A
M3S^=.G5C7IPRGAN%.O"-2$*T(\.94HU8PJQA5C&I%*:C4A"<4[2C&2:2PVM-
MMJS=2K=.UU^\EH[76FVC:['S/^VG_P F<?M9_P#9L_QX_P#56^*J^&?^""'_
M "B+_8O_ .Q-\>_^KD^(]?<W[:?_ "9Q^UG_ -FS_'C_ -5;XJKX9_X((?\
M*(O]B_\ [$WQ[_ZN3XCU%+_DB<;_ -E3E?\ ZJ<X&_\ >8_]>*G_ *<IGZ_4
M445\L;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY'@NK.YAGB=HY%) .IHK^7#XL_\ !S;H/@C]IS]IK]F+X6?\$W_VQOVG]?\
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MM9+SP]XCT/4[SP]J_P#9>K:%JD]W!!!%;^*M&\*:]++H-O\ JC0 445^/_\
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M_P""77_*7'_@N;_V/_[,_P#Z;OC'7]"]?4<8?\CJ/_8EX8_]9K*3##_PY?\
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MU?!7X;WW[5\%U8?LS?M$_LT7.M:OX+\3>,P]NEEX9\4Z0?&7C^>2WO-?O(O
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M_3M/LX);BYN;B5(XXT/)) /7=*_E[_X.W/BY\0/ ?_!+KPO\*_AWJU_H5_\
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M]6\4KXLU;QCIFHZQHE_8Z!=66FZ9%#HVF:G;ZI"?VSK\4?\ @W3^#][\$O\
M@B]^P?X8U/3S8:EXH^%^M?&&<R+#]HOK+XY_$'QA\8/#VH7$L-G9&<3^%O&V
MAK9--'--!I<5A9&\O4M4NI?VNH _GJ_X.!/^07_P2^_[2B_LX_\ HOQ'7]"B
M]!]!_*OYZ_\ @X$_Y!?_  2^_P"THO[./_HOQ'7]"B]!]!_*OJ<V_P"29X3]
M<^_]3Z)C#^-7_P"X?_I+%HHHKY8V"BBB@ HHHH **** "OG[]J_X'ZE^TS^S
M-\>?V=]*^(NL_"2Z^./PI\;_  ID^(_A[2+#7=;\)Z=X[T&]\-ZQJ6F:7J4U
MK;7%V=(U&^M8WCO=.OK7[0;O2]3TS4X+/4+;Z!HH ^(_^"=7[$'@7_@G5^R!
M\(OV2? .I6/B33?ACIVJ1ZKXWMO"EIX.U#Q_XBUK6M0UG5O&/B+2+34];!\0
M:G)>QPWUS+J]^TB6EO%;M:V$%I86G\X^O:AI/QN_X/"_A7XA_9=;3M8T7]G3
M]C#Q/X9_;J\2>%;G2;G26\40^%OC+X9L-(\2ZIIESJ$5]XBT+6_'?[.G@_4-
M)O7T[7]*U7P==:1=6*1>%+S?^@/_  66_P""IGQ.^#VL^%?^"<7_  3>MA\6
M/^"IO[20L])\)>&_#^FV'B*R_9R\!:S:M<:K\7?B/=WUW%X?\)ZS;>'VFU[P
MC%XKCN]'T/28)?B/XWTY/"-KHMGXN^G?^".G_!*GPO\ \$M_V?\ Q+H&M^-;
MGXT?M1_'SQ/%\4_VK_V@-8,][K/Q'^)%Q%=S+I%AKFKP_P#"5ZKX)\(WNK^(
MI] N/%E[=ZWK'B#Q/XT\;W\.D7_C.]T33@#9_;P_X)8^&/V]OVIOV$_V@_B1
M\6+NU\#?L0^.M=^(5C^S[JGP^T7Q=X"^*/B36]2\*:@VH^)+^YUK2+VTN;#_
M (0[18K!+ZS\3:7:M;%X-*BCO]=M]9^Y/VHOB1\$OA!^SE\;?B/^TA>^'K+X
M#^%OAGXNNOBI'XHN-*M]%U?P;=:/<Z9JOA>6/6[[3=,U"\\7Q7H\*Z/H<][
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MBYO&>KP:0Z> ]!T?5-=^(EQINCZKJ/BK3I/$VN7>K)I@U'1_#>JZAH_]>G[
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M'_B^[2>>V.F7>@Z-J>EROJD,4VG_ -9'A'PGX<\!>%/#/@?P=HUAX<\(^#=
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MP[X=\+Z7IO\ :2C!U5QG#JK#/7# $9QD9P>>37^=Q^W?_P $Q?B3\$/VZ?\
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M?#_@+5?%]Y?ZT]U<RV&CZ4;*"Z\:^$O@YXX\7:4FBOKVAQ^+DUG7O$G]B5%
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M\'Z+%IUM<R_;[F+4O%.@6MXEH;-]5L_M F7Z*HH _P ]+_@F]^R5_P '(?\
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M+G6_BO\ MM_&?X2_LA_#_2K!= FOKF_^(.KW?BC5H%@\0W=O:16VO:)X'O?
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ME6=K86%G B16]K;Q11JJ(!7] 7[!7CW]M3XP?LWV>N_\%$?V<_ /[./Q_O\
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MI[VTF^,O^#;#]I[2?VF?^"0_[,$4$MK'XI_9ZT2Z_9?\=Z1!K/\ ;4VB:O\
M!@P>'_#4=[*Y6XL+C7/AN_@?Q9'I$\,*Z7:>(;:SLOM.FQ65[<_O#7Y^?LD?
M\$ZOA/\ L7?'G]L3XT?!OQI\2+;0?VS?B99_&7QK\%-8U/1[_P"%O@GXI7,>
MH/XT\8_#^V;1E\2Z3>>/=0U WFM:=<>(;K1+&"RTO2-%TW3](TC2K.R /PG^
M.'_!.;_@J-_P3/\ V^?CU^WK_P $?-!\ ?M)?!3]K/6[_P =?M)?L0?$?QII
MW@F\_P"%@ZK?ZOKNN>)?!.H^(]:\+^'7L[76M4U?7?"MWI'BC3?$.B)XBO\
MP+'X)\4:%9Z=<2>:?M#W_P#P<K?\%7/AUJ/[&GB?]BGX,?\ !-OX$_$]K71?
MV@_CKK7Q5\-_$+Q-J7PVU#4M.M=7\'^$M)T;QWJ^MRB_TMM7OM<TG2_#<,GB
MFVL;3PS>_$#P+I.J:A%XE_LFHH _.KX;_P#!,O\ 9Y^&G_!-F/\ X)@Z7#JM
M]\"I/@AXF^#.J:M=1Z7:>)]6F\8V^J7/B7X@W9T2QTG2U\9:GXNUC4/',]W;
M6,$,GB29KN:.0M(7_GA_9M\.?\'&O_!&_P"'T7[%/PK_ &._@I_P4O\ V:O
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MX5_X6%_8'_">?\([HW_":?\ "*_;O^$8_P"$I_LZW_M__A'O[3_XF/\ 8O\
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M3_T$<4_^$>4^7_4=Z_AYA_M/:A_X%4_^1]?Z6OO_ /P\;_X)Z?\ 1^'[&?\
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M_P##QO\ X)Z?]'X?L9_^)0?!'_YN*/\ AXW_ ,$]/^C\/V,__$H/@C_\W%>
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MP:_\!?$/_P OZ/\ AR9_P2F_Z,A^#7_@+XA_^7]')P3_ -!'%/\ X1Y3Y?\
M4=Z_AYA_M/:A_P"!5/\ Y'U_I:^__P##QO\ X)Z?]'X?L9_^)0?!'_YN*/\
MAXW_ ,$]/^C\/V,__$H/@C_\W%> ?\.3/^"4W_1D/P:_\!?$/_R_H_X<F?\
M!*;_ *,A^#7_ ("^(?\ Y?T<G!/_ $$<4_\ A'E/E_U'>OX>8?[3VH?^!5/_
M )'U_I:^_P#_  \;_P"">G_1^'[&?_B4'P1_^;BC_AXW_P $]/\ H_#]C/\
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M/^'C?_!/3_H_#]C/_P 2@^"/_P W%> ?\.3/^"4W_1D/P:_\!?$/_P OZ/\
MAR9_P2F_Z,A^#7_@+XA_^7]')P3_ -!'%/\ X1Y3Y?\ 4=Z_AYA_M/:A_P"!
M5/\ Y'U_I:^__P##QO\ X)Z?]'X?L9_^)0?!'_YN*/\ AXW_ ,$]/^C\/V,_
M_$H/@C_\W%> ?\.3/^"4W_1D/P:_\!?$/_R_H_X<F?\ !*;_ *,A^#7_ ("^
M(?\ Y?T<G!/_ $$<4_\ A'E/E_U'>OX>8?[3VH?^!5/_ )'U_I:^_P#_  \;
M_P"">G_1^'[&?_B4'P1_^;BC_AXW_P $]/\ H_#]C/\ \2@^"/\ \W%> ?\
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M^C(?@U_X"^(?_E_1R<$_]!'%/_A'E/E_U'>OX>8?[3VH?^!5/_D?7^EK[_\
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M_P"7]')P3_T$<4_^$>4^7_4=Z_AYA_M/:A_X%4_^1]?Z6OO_ /P\;_X)Z?\
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MGA74_M6JW(;3-2-M ;A81#,?+79,G.?VN'_!$S_@E.0/^,(?@UT'_+KXA_\
ME_7T>91X2_U?X9]K7XC6'3SGZLZ>%RQUF_KM+V_MXRQBA&T_X7LY2YHZSY7H
M\H>W]K5LJ-_W=[RG;X=+>[VOOU/H#_AXW_P3T_Z/P_8S_P#$H/@C_P#-Q1_P
M\;_X)Z?]'X?L9_\ B4'P1_\ FXKP#_AR9_P2F_Z,A^#7_@+XA_\ E_1_PY,_
MX)3?]&0_!K_P%\0__+^OG.3@G_H(XI_\(\I\O^H[U_#S-?\ :>U#_P "J?\
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M_"/*?+_J.]?P\P_VGM0_\"J?_(^O]+7W_P#X>-_\$]/^C\/V,_\ Q*#X(_\
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M"/\ \W%'_#QO_@GI_P!'X?L9_P#B4'P1_P#FXKP#_AR9_P $IO\ HR'X-?\
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MM??_ /AXW_P3T_Z/P_8S_P#$H/@C_P#-Q1_P\;_X)Z?]'X?L9_\ B4'P1_\
MFXKP#_AR9_P2F_Z,A^#7_@+XA_\ E_1_PY,_X)3?]&0_!K_P%\0__+^CDX)_
MZ".*?_"/*?+_ *CO7\/,/]I[4/\ P*I_\CZ_TM??_P#AXW_P3T_Z/P_8S_\
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M]'_#DS_@E-_T9#\&O_ 7Q#_\OZ.3@G_H(XI_\(\I\O\ J.]?P\P_VGM0_P#
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M\$IO^C(?@U_X"^(?_E_7SG)P3_T$<4_^$>4^7_4=Z_AYFO\ M/:A_P"!5/\
MY'U_I:^__P##QO\ X)Z?]'X?L9_^)0?!'_YN*/\ AXW_ ,$]/^C\/V,__$H/
M@C_\W%> ?\.3/^"4W_1D/P:_\!?$/_R_H_X<F?\ !*;_ *,A^#7_ ("^(?\
MY?T<G!/_ $$<4_\ A'E/E_U'>OX>8?[3VH?^!5/_ )'U_I:^_P#_  \;_P""
M>G_1^'[&?_B4'P1_^;BC_AXW_P $]/\ H_#]C/\ \2@^"/\ \W%> ?\ #DS_
M ()3?]&0_!K_ ,!?$/\ \OZ/^')G_!*;_HR'X-?^ OB'_P"7]')P3_T$<4_^
M$>4^7_4=Z_AYA_M/:A_X%4_^1]?Z6OO_ /P\;_X)Z?\ 1^'[&?\ XE!\$?\
MYN*/^'C?_!/3_H_#]C/_ ,2@^"/_ ,W%> ?\.3/^"4W_ $9#\&O_  %\0_\
MR_H_X<F?\$IO^C(?@U_X"^(?_E_1R<$_]!'%/_A'E/E_U'>OX>8?[3VH?^!5
M/_D?7^EK[_\ \/&_^">G_1^'[&?_ (E!\$?_ )N*/^'C?_!/3_H_#]C/_P 2
M@^"/_P W%> ?\.3/^"4W_1D/P:_\!?$/_P OZ/\ AR9_P2F_Z,A^#7_@+XA_
M^7]')P3_ -!'%/\ X1Y3Y?\ 4=Z_AYA_M/:A_P"!5/\ Y'U_I:^__P##QO\
MX)Z?]'X?L9_^)0?!'_YN*/\ AXW_ ,$]/^C\/V,__$H/@C_\W%> ?\.3/^"4
MW_1D/P:_\!?$/_R_H_X<F?\ !*;_ *,A^#7_ ("^(?\ Y?T<G!/_ $$<4_\
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M^"4W_1D/P:_\!?$/_P OZ/\ AR9_P2F_Z,A^#7_@+XA_^7]')P3_ -!'%/\
MX1Y3Y?\ 4=Z_AYA_M/:A_P"!5/\ Y'U_I:^__P##QO\ X)Z?]'X?L9_^)0?!
M'_YN*/\ AXW_ ,$]/^C\/V,__$H/@C_\W%> ?\.3/^"4W_1D/P:_\!?$/_R_
MH_X<F?\ !*;_ *,A^#7_ ("^(?\ Y?T<G!/_ $$<4_\ A'E/E_U'>OX>8?[3
MVH?^!5/_ )'U_I:^_P#_  \;_P"">G_1^'[&?_B4'P1_^;BC_AXW_P $]/\
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M_P#_  \;_P"">G_1^'[&?_B4'P1_^;BC_AXW_P $]/\ H_#]C/\ \2@^"/\
M\W%> ?\ #DS_ ()3?]&0_!K_ ,!?$/\ \OZ/^')G_!*;_HR'X-?^ OB'_P"7
M]')P3_T$<4_^$>4^7_4=Z_AYA_M/:A_X%4_^1]?Z6OO_ /P\;_X)Z?\ 1^'[
M&?\ XE!\$?\ YN*/^'C?_!/3_H_#]C/_ ,2@^"/_ ,W%> ?\.3/^"4W_ $9#
M\&O_  %\0_\ R_H_X<F?\$IO^C(?@U_X"^(?_E_1R<$_]!'%/_A'E/E_U'>O
MX>8?[3VH?^!5/_D?7^EK[_\ \/&_^">G_1^'[&?_ (E!\$?_ )N*/^'C?_!/
M3_H_#]C/_P 2@^"/_P W%> ?\.3/^"4W_1D/P:_\!?$/_P OZ/\ AR9_P2F_
MZ,A^#7_@+XA_^7]')P3_ -!'%/\ X1Y3Y?\ 4=Z_AYA_M/:A_P"!5/\ Y'U_
MI:^__P##QO\ X)Z?]'X?L9_^)0?!'_YN*/\ AXW_ ,$]/^C\/V,__$H/@C_\
MW%> ?\.3/^"4W_1D/P:_\!?$/_R_H_X<F?\ !*;_ *,A^#7_ ("^(?\ Y?T<
MG!/_ $$<4_\ A'E/E_U'>OX>8?[3VH?^!5/_ )'U_I:^_P#_  \;_P"">G_1
M^'[&?_B4'P1_^;BC_AXW_P $]/\ H_#]C/\ \2@^"/\ \W%> ?\ #DS_ ()3
M?]&0_!K_ ,!?$/\ \OZ/^')G_!*;_HR'X-?^ OB'_P"7]')P3_T$<4_^$>4^
M7_4=Z_AYA_M/:A_X%4_^1]?Z6OO_ /P\;_X)Z?\ 1^'[&?\ XE!\$?\ YN*/
M^'C?_!/3_H_#]C/_ ,2@^"/_ ,W%> ?\.3/^"4W_ $9#\&O_  %\0_\ R_H_
MX<F?\$IO^C(?@U_X"^(?_E_1R<$_]!'%/_A'E/E_U'>OX>8?[3VH?^!5/_D?
M7^EK[_\ \/&_^">G_1^'[&?_ (E!\$?_ )N*/^'C?_!/3_H_#]C/_P 2@^"/
M_P W%> ?\.3/^"4W_1D/P:_\!?$/_P OZ/\ AR9_P2F_Z,A^#7_@+XA_^7]'
M)P3_ -!'%/\ X1Y3Y?\ 4=Z_AYA_M/:A_P"!5/\ Y'U_I:^__P##QO\ X)Z?
M]'X?L9_^)0?!'_YN*/\ AXW_ ,$]/^C\/V,__$H/@C_\W%> ?\.3/^"4W_1D
M/P:_\!?$/_R_H_X<F?\ !*;_ *,A^#7_ ("^(?\ Y?T<G!/_ $$<4_\ A'E/
ME_U'>OX>8?[3VH?^!5/_ )'U_I:^_P#_  \;_P"">G_1^'[&?_B4'P1_^;BC
M_AXW_P $]/\ H_#]C/\ \2@^"/\ \W%> ?\ #DS_ ()3?]&0_!K_ ,!?$/\
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M]!_*OJ<V_P"29X3]<^_]3Z)C#^-7_P"X?_I+%HHHKY8V"BBB@ HHHH ****
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M%^^G_!+7_M)[^SO_ .E5_7]":?<7_=7^0KZG-O\ DF>$_7/O_4^B8P_C5_\
MN'_Z2QU%%%?+&P4444 %%%% !1110 4444 %%%% !1110 45\-_\%%/VZO!'
M_!.C]ESQ;^TQXV\ ?$#XK?V5K7ACP3X,^&7PQL;2^\7^/?B-X]U2/P_X'\+V
M1O;B&*PM-4UVXMX=4U.&#5]2L=/^T3:-X=\3:R+#P_J7\A'C;_@H)_P7<D_X
M*;?\$M-6_:[O;']BWX"_MI?M Z;H/@W]BOX=WBIXCTWX6>%?B#X6MKT?'>YU
M'2[[7+SQ-XLTSQ7I%O>^=XFTN>\2RU-;GX<?#>VN%\/S@'][=%<YXQ\7>&_A
M_P"$?%7CSQCJUOH/A'P3X<USQ=XJUR[69[71O#?AO3+K6=<U:Y2VBGN'M].T
MRRNKR98(9IFCA8112.50_P ?7PGUW_@KY_P<$ZQX[_:5^ '[;'B#_@E3_P $
M\O"WCOQOX'_9F;X<^!_$?BKXR_'=_"6HZ=X?U3Q]XN>V\3_"9=5\+WE]:Z[9
MM=6_CXZ5X2\7:1J_@:R\&ZS>Z1J_C:Z /[***_C[^#'[6?\ P4Q_X(\_\%(_
MV;OV#/\ @I+^TC:_ML_L>?MOZS#X!_9D_:NUWP.VD?%K2OBTK^&_#=AX3UG2
M]$U[Q!XBL[>Y\=>,/"/AGQ;:^,[[XBV<-IXQ\&^-]%^(.A6%GX\T.#^P2@ H
MK^7S_@B]XA\=_M>?\%1?^"S_ .WQXF<O\.-#^.&C?L2? FTGUN]UU=(TCX%V
MT=EXS?18T\OP[X?L/%NA:9\(/&&L66AMJ']H^(=5O9KR\E>PBU?7_P T?^"@
M'_!:'_@K)^V5^S+^T9^TS_P37^$>M?L9_P#!/;]G;3='U'7/VK?C%;6VB_'?
MX\7J^+-"TEK?X-Z1/9^(=%T?0CJNJV5I=Q>'[;Q%%)IMC>/KOQ/T2]UFY^'M
MB ?W8T5^=_\ P25^)_Q ^-7_  32_8C^+?Q6\6:OXZ^)/Q'_ &<_AGXR\<>,
M->G%SJ_B/Q-K_AVSU'5]6OY42*(37EY<2RF*"*&V@5EAMH88(XXE_G-\2?M4
M_P#!5#_@NW^VA^T9\"?^";_[3UI^PC_P3\_9&^(/_" >*?VE_#NA>?\ %3XL
M^,;*ZM=*N;C339>(;?Q?J]E>S:;XK\3^!_#OA[6OA7X??P5/I'_"T]0;Q1J6
MAV&F@']H5%?Q>?';X@?\%D_^#?'6OA/\?_C]^V1KO_!5;_@G=XF\?Z)X#_:#
MN_'/PVF\*?%[X*MXEEGCL?%MCJ+>(?B9XET[36GEF71-3U#QQK?@[6-9T^P^
M'^M:1X/UCQ?X-UB7^R;POXET7QEX:\/^+O#=_#JGA[Q1HNF>(=#U*W+&WU#2
M-8LH=0TZ]@+*K&*YM+B&:,LJL5<94'B@#=HHK^6C_@J7\6_$G[<?_!7/]A#_
M ((X^!M6UL?!CP=>V'[9O[=J>&]0NM!.L>$O EGJNM?#[X3>+-3@U2UN]6\%
M>))AH4'C+PM:Z3>VNIM\3? VJP:E9ZIX;DOO#@!_4O17Y2_\%F/^"D-G_P $
MJ?V#_'7[3.F^'M(\5?$.;6]!^%OP2\*>(H[F;PMK'Q3\5VFKWVAIXJAL-<\/
M:Q<^&M%T'PYXC\2:Q9:)JUGK&I6>B/IUG>:<]VVJ6/XY_#W_ ()A?\'"?[0?
M@[PQ^TW\5_\ @N3XI^ 'QR\6^']"\6Z;^SQX)^ ,0^$G@V/4]%L+^P\(^+=+
ML?$WP]\,6^L:(+ZZTCQ#!=_!GQA++?:<EW?ZUXBOIY;R( _KFHK^=G_@AE_P
M4K_:G_:5\:_MB?L&_P#!0*T\,W'[:?[!7CVW\(>+_B/X2T.+PKH'QL\(W>K^
M(O#UOXULO#MMI/AW3TN;?5O#,E^VNZ#X6\)>%_$GA3Q;X'U?1/#]G)<ZCG^B
M:@ HK^!__@X?_P""TW[:UE\?/BC\'_\ @FM\5O%/PR^$/_!/^UT32_VP/C=\
M.+K1+RPU?XV?%G7['PYX=^$^HZM>Z)K%O8ZEX#N=#\1:5#H5G?6.H7OB;3?B
MK;:S:S-X$L_LW]N'[,OB+6_%_P"SE\!O%?B74KG6?$7B7X._#?7M=U>\96N]
M3UC5O"&D7VI:A<LBHK7%Y>3S7$Q5%4R2,0H&  #W"BBOY6_V^?VO/^"@?[>W
M_!1[Q+_P2%_X)B?&/1/V5O#OP&\)^&O'?[:W[9$$=CXH\6>'K+Q1::'?VOP_
M^&]C%&MS9:UHT&O6*W5IX>U_PUXKU[Q?::IX<U#QE\/O#_ACQ&_B( _JDHK^
M)_\ :[\#?\%R_P#@A#\-K']N*S_X*:7G_!33]FCP+XH\,6O[2?P<_:&^'M]X
M*UVR\.>*O%/A[PMH]WX0U;4?&'QFU:PM-1U/4+?0)O$>C^-O#5SX5U[6="OG
M\#>/M)N]<@L/ZG/&/[87A"Q_8#\8_M\> ]-G\7>!=*_9&\4?M:>$=(FF@L[C
MQ-X8TGX0:A\7-%TR2XMY[JWM9M8TRUM[1IH;BXAA>X,B2R(H8@'V)17\*$FO
M_P#!5_0?^"3:_P#!=A?^"J7QF\1?&.>R\'?'F?\ 98UCPSX5T_\ 9,/PSOOB
M=IOA:[^&5S\/M+TLB:YN]"N-(,^J^'U\'72D:W:0ZC'JFHIXMB_I[^-O_!3?
MX1?LR_\ !,S1?^"C?QM2VT;0=:^!?@#XDZ!X 34%T_6/&_Q$^)7A/3M9\&?"
MCPN1%K5R^K^(-;U&.PDN[>SUF/PYH-MK7B_5XF\/^'=8O;< _32BOQ__ ."-
M/A#]NR]_9TU;]I#_ (*$?%KQ7XF^-W[5&O2?%O2O@;/-86_PY_9H^'.NW>IZ
MUX(^''@G0DTX:SHVJ'1]<BF\4VFM>(M?N-,2#0_#!F-UX<O=1U7\R_\ @L9X
MVO?^"77_  4\_8"_X*I>']1N/#?P1^._B&X_8S_;IN;R+Q+J'@Z#PKK8\-7G
M@SX@:G8V.H7%LGB+1_#'AW4=8232M+AU>32/@O:6UO9^)!=WUA& ?U:45%!-
M%<PPW$#B2&>*.:&0 @/%*@DC<!@" R,& (!P>0#4M !1110 4444 %%%% !1
M110 4444 %%%% !1110!_/1_P2Z_Y2X_\%S?^Q__ &9__3=\8Z_H7K^>C_@E
MU_REQ_X+F_\ 8_\ [,__ *;OC'7]"]?4<8?\CJ/_ &)>&/\ UFLI,,/_  Y?
M]?:W_IV9\S_MI_\ )G'[6?\ V;/\>/\ U5OBJOAG_@@A_P HB_V+_P#L3?'O
M_JY/B/7W-^VG_P F<?M9_P#9L_QX_P#56^*J^&?^""'_ "B+_8O_ .Q-\>_^
MKD^(].E_R1.-_P"RIRO_ -5.< _]YC_UXJ?^G*9^OU%%%?+&X4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<UXS\6:1X"\'^+/'/B![B/0?!GAK7?%FMR6L#7-TFD>'=
M+NM8U)[:V4JUQ<+96<S0P*RM+(%C!!;-=+7Y7?\ !<#XPP_ K_@D;_P4'\?2
M7]OI<US^S+\0OAOINH3WMUI[VFN?&NRC^"_A^:PO+(BY@UE=<\?Z>-!,;('U
MHV$<DD43O(H!_G@?L#?\%N?$O_!.W_@GC^UU#^S7IE]XE_X*&_M9?M*>*/B5
MX^^(]UX1G\2?#[]FCX):?H_@/0?#/Q,UI?%/A_4+#Q?X]\2?%+XA^-]$\&:+
MX@U?Q=X%TF[U#1-6\;*VJ7EOX,^(7]W/_!"3]@7]G_\ 9V_9D\/?M>^'/BFW
M[6?[3/[<WA#0/C=\<OVSO$@U.]\4_$:3Q_!:^,'\(>''\311^*?"G@W0=6N?
M+UG0=<M],\7:UXOTV?4?B!INEZII.B^$?!GR_P#\$!O^"5_[+.B?\$5?!WAO
MXA_!33[W7_\ @HC\#-0\1?M/:]K4>HP^,/B#X(^)(\0_\*]TVQUZYM=-UKPQ
MX>\/?#G6="UGX?)X8:PM-%UZ^F^(7AZ_N_$6KR^*M0^2?^"!'Q8\=_\ !+[]
MM/\ :5_X("_M9:[<)+HWB;6OCE^PK\0=8/V'PW\3O WB>WBU[6O"WA2ZU 67
MVR\\5:#_ ,7$T_1] M=0TG2/'7AK]H'PQJ>KP^(]#MM/OP#]3?\ @Y>^,][\
M%/\ @BS^V9J6D2VL>N?$/0? 'P9TU+QY4AGL_BG\3_!WA7QC$JVVJ:5>270^
M'MYXOFL4@DO8A?0V\FJ:7J.AQZI;MY5XG_:ZTK_@B%_P;]?LE>/+CPM8>-?C
M'H'[./[,_P (?A-\++W4M9OM/^(W[3OQ2\":9K>IZ!#J6AZ=/>76@Z)>#XB?
M$2XT^&31IM;\)>"[WPQHFM:=KVJ:-,?EG_@[>U-OB+\ _P#@GK^Q;8^*KG0-
M3_:V_;\^'.A7FG:5J]K8ZSKOA30-'U+P;J1&FW6KV4&LZ+HGBKXO>!M8N8M2
MTZ^T*Q\26_A"]U"]TJ[CTK[=R'_!VC\-O"FK_!O_ ()9>%_B+J<OA']E=?V\
M? ?PV^,^M'4KC3+7PQX4\1^%Y-.BU.?Q/>WUQ;:3+HWPYT7XF7<.I:EI6K3Q
M16MUJ'VZT2SO;?5P#M_@?_P;7>'_ -L+P[9?M0?\%KOCA\?/VG_VQ?BQI^I^
M)/$7@/1_BEJ7@[X.?L_6'BT'5-*^&OP\T31]+M-4L+WP2UWMU&RT;5=*^&MG
MJL$>A:'X*O-*T>7Q#XJ\Q_X)9> _&?\ P2:_X+E_&3_@D!\,OC3XP^*/[$/Q
M4_9J'[3_ ,)_ OQ#UA?%GB?X->,$GMIKW38[VTC\.Z)X;NM7N$\;RZ\NA^'6
M7Q=H,_PUU76X&UZUOM6KZEM/^#1__@B]?VMM?6/@;XWWEE>V\-W9WEK\?_$M
MQ:W=K<1K-;W-M<0P/%/;SQ.DL,T3M'+&ZNC,K GHO^".?_!/#_@AA\,OVC_C
M/\<?^"9/C?Q%\5OB_P#LXW.O? 'XG:Q+\2OB+XM\)^#M5\7^7+?Q:-<ZWI&B
M^$O',&IVOAK4+'2_%_A/4?&'@ZXCBU9=.U*74;:.>S /S*_X*\:)^T-^U9_P
M<W_L!_L]_LK^*=.\#^._@Q^R[!KVI_$WQ%I5_JME\$%\8ZE\;-1^(?QBT#0F
MU2WTCQ+XP\#?#S4/!FO?"[2-1MT\.>(_B[9^%?#/C]-4\&-J5M!]N?&C_@TT
M_86\1_!CQQJ?P]^(_P"T_/\ MO/I\_C/P7^V!X_^.'B'Q5\1]0^-&CPQ:MX?
M\1>*["2;1O"MY9ZGXFL+4ZI<V=EH_BBQM+F6?2/&&F:I:V>J0?(O_!/;]JKX
M8^-?^#NC_@J%)XI\4^&-,UGQ7\$_$_[-'PEN-0\736L6J>+?@%J_[-'A/Q;\
M,/">DZG)%!JOB?51\(_&7C35=+L?](TZ[\%>+IM-@N+:YU"XK^F3_@J!_P %
M _A!_P $UOV//BG^T?\ %/Q3I^CZS8Z!JWA[X.^%F>RN/$/Q(^,6JZ5>KX'\
M(^&=$NIXGUB0ZDB:QXBDC26WT'PCIFN^(M3"Z;I=RU 'YC?\&MW[</QH_;0_
MX)J2Z9^T1K>M>*?B]^RU\:?%G[.&J>,/%ESJ-[XX\8>$M \,^#/&?@K5_'5Y
MJ%G;23^*-#L/&EW\-[N>ZFOM>U.T\ V/B'Q7>WOB37-2O[S\:?\ @FQ\ _@O
M_P ''?QV_;*_:+_X*D_&'XE^)O$7PS^/?B+X=? /_@G8/C;JGPSM?@'\-;;2
M+>]L]>U3X4Z%;Z'XKM=1LX=W@=?%.A:MH[^(?%G@KXG7_P 1=/UK67L+NS_5
MG_@A7X5\#_\ !'S_ ((:6'[2/[<OB[6/@WI?Q-\;:]^UO\=M8\9Z!XSU[6/!
M<WQKUWP+\*?AC;ZCH&@:;XF\;:EKGBKPGH7PHO;S2[3PY_;5MXF\6W>F7VF&
M[L[R_N.I^,O_  0"_P""-'_!530=(_;9^#NG>+_AGJO[1OA_1_C#X4^/7[+_
M (MU'X=+XCU'Q3>V_C.T^(=U\-_&?A_5_#6B^,M3NYIX?&=E?^!?#'BZ#4[K
M6H/$-OHOCVT;4]+ .H_89_X(@>//^"8__!0^^^*W[$'[0-SX-_X)P?$OX<7M
MM\;?V0OB-XC\:>/M=NOBN-,UFRT/Q%\.[F\MH]%TN'1[_3O FIP^,_$^M:]X
MX_LJ?X@>"7:;0=6T2;2ODG6)K_\ :5_X/#_"=C%<V+Z=_P $]?\ @GWJ6J2V
M<=Y<H;>X^(/A;4;"[O)+2/7I[=]?O!^V-HEO<-+IMB9_#MCI+2:/*VGV/B*;
MD?\ @WQ^+O[1_P -?^"E'_!2;_@FAJ7[6'Q _;@_9'_9/T+3KCX:_&?XA:O<
M>(M2\#>.8/%VD:1=?#VVUMSXK/F7!UOQOX;UO39?'UGI,.O_  =U'4_"7@K3
MHM6\0VN@=1_P0M>V_:&_X+5_\' 7[8$^L7&OQ>&?C1X4_9G\!Z_%K$6L:5KG
MA+P]XO\ B!X8N)M/NH]=UC[1I%AH/P$^&@\+7D3?V7-H&H0Q:(NFV=O+I%H
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MZ7KW@+PCX0TGP?K'LK?\$$_CE_P38_X*)?LD?M3?\$8-;U7PW^SYXF\;>%_
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M48KK^U=7UKQ!<VT_D6>GZE<Z9I.GZMXDELFT[0K^:#Y0_P"#93X<_$OX8?\
M!%/]C30OB;I$^@7FNZ7\3_B/X.T>[2!+R+X:_%7XQ>/?B1X"U:8V\2J]OXO\
M/>*;3QKI+R3W<YT/Q'I@FDMI VG60!^]5?R$^&;RT_:"_P"#QOXD6FMZ5?ZC
M+^P[_P $_P"P@\(75]=6!M]"O/%GA#X<ZC<ZKHT+!;@6,ME^UOXFT:6U4O??
MVGK&J7N1II8)_7M7\A7P_MY/@7_P>.?'2XUJVOX$_;*_X)^Z._A&6\T^^>VO
M4\+^$?@K:7-QI-R;73K>*Q27]EOQ+:2WZS:[8_VG:ZCI9N8=2D-EI !]-_\
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MOI_P2U_[2>_L[_\ I5?U_0FGW%_W5_D*^IS;_DF>$_7/O_4^B8P_C5_^X?\
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MS6O#.DZ3XKTJ'Q)+_0Q10!^=G_!2#_@F1^S]_P %2/AO\)_A+^TCXA^*NF>
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M1>@^@_E7V.;?\DSPGZY]_P"I]$\.'\:O_P!P_P#TEBT445\L;!1110 4444
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M_P#\IQ_S/YZ/^'^FK?\ 2)O_ (*D_P#B.]S_ /)M'_#_ $U;_I$W_P %2?\
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M?\/]-6_Z1-_\%2?_ !'>Y_\ DVOZ%Z*/[6X:_P"B2C_X?<Q_^1]?Z6IR5O\
MG_\ ^4X_YG\]'_#_ $U;_I$W_P %2?\ Q'>Y_P#DVC_A_IJW_2)O_@J3_P"(
M[W/_ ,FU_0O11_:W#7_1)1_\/N8__(^O]+4Y*W_/_P#\IQ_S/YZ/^'^FK?\
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M_P#\IQ_S/YZ/^'^FK?\ 2)O_ (*D_P#B.]S_ /)M'_#_ $U;_I$W_P %2?\
MQ'>Y_P#DVOZ%Z*/[6X:_Z)*/_A]S'_Y'U_I:G)6_Y_\ _E./^9_/1_P_TU;_
M *1-_P#!4G_Q'>Y_^3:/^'^FK?\ 2)O_ (*D_P#B.]S_ /)M?T+T4?VMPU_T
M24?_  ^YC_\ (^O]+4Y*W_/_ /\ *<?\S^>C_A_IJW_2)O\ X*D_^([W/_R;
M1_P_TU;_ *1-_P#!4G_Q'>Y_^3:_H7HH_M;AK_HDH_\ A]S'_P"1]?Z6IR5O
M^?\ _P"4X_YG\]'_  _TU;_I$W_P5)_\1WN?_DVC_A_IJW_2)O\ X*D_^([W
M/_R;7]"]%']K<-?]$E'_ ,/N8_\ R/K_ $M3DK?\_P#_ ,IQ_P S^>C_ (?Z
M:M_TB;_X*D_^([W/_P FT?\ #_35O^D3?_!4G_Q'>Y_^3:_H7HH_M;AK_HDH
M_P#A]S'_ .1]?Z6IR5O^?_\ Y3C_ )G\]'_#_35O^D3?_!4G_P 1WN?_ )-H
M_P"'^FK?](F_^"I/_B.]S_\ )M?T+T4?VMPU_P!$E'_P^YC_ /(^O]+4Y*W_
M #__ /*<?\S^>C_A_IJW_2)O_@J3_P"([W/_ ,FT?\/]-6_Z1-_\%2?_ !'>
MY_\ DVOZ%Z*/[6X:_P"B2C_X?<Q_^1]?Z6IR5O\ G_\ ^4X_YG\]'_#_ $U;
M_I$W_P %2?\ Q'>Y_P#DVC_A_IJW_2)O_@J3_P"([W/_ ,FU_0O11_:W#7_1
M)1_\/N8__(^O]+4Y*W_/_P#\IQ_S/X>/^"LG_!5J_P#VE;']B&&?]@G]N3X*
MCX1?MP_!WXO1R?&+X0S>%X_B%)X636 OP\\!%[F3^VO'VN_:B=$T5=C78@GP
MXV5^MX_X+Z:M@?\ &IO_ (*D]!_S;O<__)M/_P"#@3_D%_\ !+[_ +2B_LX_
M^B_$=?T*+T'T'\J^BS+,\@CP_P ,SGPRJE*H\Y]C1_MC'1]AR8VDJO[Q1YJO
MM9>_[Z_=VM&Z,H0J^UK)5;->SN_9QU]UVTOI;\3^>G_A_IJW_2)O_@J3_P"(
M[W/_ ,FT?\/]-6_Z1-_\%2?_ !'>Y_\ DVOZ%Z*^=_M;AK_HDH_^'W,?_D?7
M^EKKR5O^?_\ Y3C_ )G\]'_#_35O^D3?_!4G_P 1WN?_ )-H_P"'^FK?](F_
M^"I/_B.]S_\ )M?T+T4?VMPU_P!$E'_P^YC_ /(^O]+4Y*W_ #__ /*<?\S^
M>C_A_IJW_2)O_@J3_P"([W/_ ,FT?\/]-6_Z1-_\%2?_ !'>Y_\ DVOZ%Z*/
M[6X:_P"B2C_X?<Q_^1]?Z6IR5O\ G_\ ^4X_YG\]'_#_ $U;_I$W_P %2?\
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M]?Z6IR5O^?\ _P"4X_YG\]'_  _TU;_I$W_P5)_\1WN?_DVC_A_IJW_2)O\
MX*D_^([W/_R;7]"]%']K<-?]$E'_ ,/N8_\ R/K_ $M3DK?\_P#_ ,IQ_P S
M^>C_ (?Z:M_TB;_X*D_^([W/_P FT?\ #_35O^D3?_!4G_Q'>Y_^3:_H7HH_
MM;AK_HDH_P#A]S'_ .1]?Z6IR5O^?_\ Y3C_ )G\]'_#_35O^D3?_!4G_P 1
MWN?_ )-H_P"'^FK?](F_^"I/_B.]S_\ )M?T+T4?VMPU_P!$E'_P^YC_ /(^
MO]+4Y*W_ #__ /*<?\S^>C_A_IJW_2)O_@J3_P"([W/_ ,FT?\/]-6_Z1-_\
M%2?_ !'>Y_\ DVOZ%Z*/[6X:_P"B2C_X?<Q_^1]?Z6IR5O\ G_\ ^4X_YG\]
M'_#_ $U;_I$W_P %2?\ Q'>Y_P#DVC_A_IJW_2)O_@J3_P"([W/_ ,FU_0O1
M1_:W#7_1)1_\/N8__(^O]+4Y*W_/_P#\IQ_S/YZ/^'^FK?\ 2)O_ (*D_P#B
M.]S_ /)M'_#_ $U;_I$W_P %2?\ Q'>Y_P#DVOZ%Z*/[6X:_Z)*/_A]S'_Y'
MU_I:G)6_Y_\ _E./^9_/1_P_TU;_ *1-_P#!4G_Q'>Y_^3:/^'^FK?\ 2)O_
M (*D_P#B.]S_ /)M?T+T4?VMPU_T24?_  ^YC_\ (^O]+4Y*W_/_ /\ *<?\
MS^>C_A_IJW_2)O\ X*D_^([W/_R;1_P_TU;_ *1-_P#!4G_Q'>Y_^3:_H7HH
M_M;AK_HDH_\ A]S'_P"1]?Z6IR5O^?\ _P"4X_YG\]'_  _TU;_I$W_P5)_\
M1WN?_DVC_A_IJW_2)O\ X*D_^([W/_R;7]"]%']K<-?]$E'_ ,/N8_\ R/K_
M $M3DK?\_P#_ ,IQ_P S^>C_ (?Z:M_TB;_X*D_^([W/_P FT?\ #_35O^D3
M?_!4G_Q'>Y_^3:_H7HH_M;AK_HDH_P#A]S'_ .1]?Z6IR5O^?_\ Y3C_ )G\
M]'_#_35O^D3?_!4G_P 1WN?_ )-H_P"'^FK?](F_^"I/_B.]S_\ )M?T+T4?
MVMPU_P!$E'_P^YC_ /(^O]+4Y*W_ #__ /*<?\S^>C_A_IJW_2)O_@J3_P"(
M[W/_ ,FT?\/]-6_Z1-_\%2?_ !'>Y_\ DVOZ%Z*/[6X:_P"B2C_X?<Q_^1]?
MZ6IR5O\ G_\ ^4X_YG\]'_#_ $U;_I$W_P %2?\ Q'>Y_P#DVC_A_IJW_2)O
M_@J3_P"([W/_ ,FU_0O11_:W#7_1)1_\/N8__(^O]+4Y*W_/_P#\IQ_S/YZ/
M^'^FK?\ 2)O_ (*D_P#B.]S_ /)M'_#_ $U;_I$W_P %2?\ Q'>Y_P#DVOZ%
MZ*/[6X:_Z)*/_A]S'_Y'U_I:G)6_Y_\ _E./^9_/1_P_TU;_ *1-_P#!4G_Q
M'>Y_^3:/^'^FK?\ 2)O_ (*D_P#B.]S_ /)M?T+T4?VMPU_T24?_  ^YC_\
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M?_$=[G_Y-K^A>BC^UN&O^B2C_P"'W,?_ )'U_I:G)6_Y_P#_ )3C_F?ST?\
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MCO<__)M?T+T4?VMPU_T24?\ P^YC_P#(^O\ 2U.2M_S_ /\ RG'_ #/YZ/\
MA_IJW_2)O_@J3_XCO<__ ";1_P /]-6_Z1-_\%2?_$=[G_Y-K^A>BC^UN&O^
MB2C_ .'W,?\ Y'U_I:G)6_Y__P#E./\ F?ST?\/]-6_Z1-_\%2?_ !'>Y_\
MDVC_ (?Z:M_TB;_X*D_^([W/_P FU_0O11_:W#7_ $24?_#[F/\ \CZ_TM3D
MK?\ /_\ \IQ_S/YZ/^'^FK?](F_^"I/_ (CO<_\ R;1_P_TU;_I$W_P5)_\
M$=[G_P"3:_H7HH_M;AK_ *)*/_A]S'_Y'U_I:G)6_P"?_P#Y3C_F?ST?\/\
M35O^D3?_  5)_P#$=[G_ .3:/^'^FK?](F_^"I/_ (CO<_\ R;7]"]%']K<-
M?]$E'_P^YC_\CZ_TM3DK?\__ /RG'_,_GH_X?Z:M_P!(F_\ @J3_ .([W/\
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M $24?_#[F/\ \CZ_TM3DK?\ /_\ \IQ_S/YZ/^'^FK?](F_^"I/_ (CO<_\
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M?_$=[G_Y-K^A>BC^UN&O^B2C_P"'W,?_ )'U_I:G)6_Y_P#_ )3C_F?ST?\
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MIH;%XQ96MS=%A!!+(IJOQ(^'>A^*M(\":WX]\%Z/XWU^"&ZT'P;JOBG0]/\
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M[4YBA?6=8M=.T"TN+FSM[W5;>>]M(YOS9^.'_!R7_P $;?V?/C#XF^"'C_\
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M)?5M)\7^*M ^)7Q-N_A1<Z%=ZMIT%WXYM;?1O!"KHLVJIX5\3_#F]&G>(=%
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M'[76D^ M8O-+UCXQ7>JI\+/'<&FZO;W6J6&@:U9:?#\0_@QX<\!_:M#\4O\
M#_Q#K?C7Q\+/7)X[;2]! /ZQ_AM^T_\ LT_&76)_#WP@_:'^!GQ5U^U@^TW.
MA_#;XM> ?'.L6]MME;[1/IGACQ!JE[#!M@F;S9(%CVPRG=B-\>YU_*E^U3_P
M:H_\$_+7]GGQ#JG[!'ASXC_LL_MD?#7PQ<>*O@G\=-!^.7QUU_4M8^)'A;2S
M=Z-9^,K+5/%WBB/1[3Q=>VC6%_KOPK\.>'M?\,7VK#7/#VDZI;Z9'X/U/[N_
MX-[/^"AWC+_@I)_P3:^'_P 6OBOJP\0?'+X6^,/$WP!^-WB%=/735\2>.O M
MGH6MZ=XHDM[;2])TK^T/%'P^\7^!_$.N_P!A6QT>+Q!J>JVMH+1K>73K( _;
M^N$U[XI?#+PMXET?P7XG^(O@3PYXQ\1?8/\ A'_">O>+O#^D>)==_M74)=*T
MO^Q]"U#4+?5-3_M+5()]-L/L5K/]LU"&6SM_,N(WC'(?M'?M!_"O]E'X%?%+
M]HWXV^(1X6^%?P>\'ZIXT\9:R(&N[J/3=.15AL-+L(V674]=UO4)K/1/#^DP
M,+C5M;U'3]-MSYUTE?YG?Q+T?]I[X^_\%1?^"-__  5B_:<FNM ?_@I/_P %
M,/AYJ7[/WPJNY(FD^'7[+?P&^/7[*>A_!=!;VT4-KIR:[I/CZ_>&."/?XEM]
M,A^(^H2W&K^/-1N)0#_4NHHKF_&7BK2? GA#Q5XWU]YX]"\&^&]<\5:U):P&
MYNDTGP]IEUJ^I/;6RE6N)UL[.9H8%93+(%C!!;- &!\2/B]\)_@WHT7B/XO?
M$_X=_"KP]/.+6#7?B1XU\->!M&FN2T2"WBU3Q/J>EV,DY>:%!"DYD+2Q*%S(
M@,WPX^*OPO\ C%X=/B_X1?$CP#\4_"8O[G2SXH^''C#P]XX\.C4[)8FO-..M
M^&=1U33?M]HL\#7-I]I^T0+-$98T$B%OX>?^"6/_  3JT#_@X>\6?'3_ (*O
M?\%4]8^('Q'\!^(_B[XL^%O[-'[*VC?$_P 8:'\-OAY\/_"<NCZC>QZ9KGAK
MQ39>,-'\+V.I:G=>$=,\+Z#/\/KC4=?TCQG\1?$<>O7_ (UTJ_LNK_X*<_L$
M^%_^#=GQG\#O^"JW_!+;5_''P@^#VE?%/P'\)?VM_P!DRX\=^//'_@7XK?#[
M7I[NXADMK_Q_J'C#54_M&WL/$&D7<OC?Q'J</ACQ7K?A/Q-\/;CPWJMC<6FH
M@']S%>.Z3^T3^S]K_P 2;_X-:%\=/@YK7Q?TN?4;;4_A5I/Q-\%:E\2=.N='
MB:?5K>_\#6>MS>)[2?2X%:;48KC2XY+*)6DN5B0$CX8_X*M?M :_X*_X)'?M
MA_M#? WQ3<:3K$_[*OB7Q3\//&=G;7=EJ%A9^-M M;33O$6F0W\%IJ&F:M!I
M&OG4-*ENK:WOM+U%;6XDMX[FV,0_D>_:\_8-_8O_ &9/^#;7]C3_ (*!_LP^
M#=%^$O[9G@WPE^Q?\>=%_:;^'/BFXM?BWJ?QN^)*^%!\4=.U'QNM_>:M>VFC
MZ_XD\575KX*M;JUM_!.J>$[*RL+33;/0]2TZX /]"JN3\+>/O OCDZLO@KQI
MX2\8-H-\VF:Z/"WB/1_$!T74EW[M.U8:3>79TZ^78^ZTO/)N!L?,?RG'X=_\
M%AO^"C7Q<_9W^ /P*_9;_9?T/6O$'_!3#_@H7:6?PN_9R\&^&K62WO\ X:7F
MJ6&C6WQ$^-/B234HKV#PAHGPY@UN5]*U/Q/+!;:?J4-_XJU&>7PQ\//'5[I?
MW1_P3%_X)[?#+_@FG^R9X"_9V\#2P>)O&"0MXL^./Q<N=-MK+Q-\:?C/XA5;
MSQOX_P#$-RHFU&X@GU%WTKPE8:QJ6M:AX;\%:;X>\-SZUJTFEOJ5V >V_!W]
MLC]FGX^_%[X\_ 3X3?%+3O%7QB_9CUO3?#WQS^'[Z'XL\/Z]X!U/6;O7++21
M=1>*- T6WUG3]3E\.:K)8:SX:N-:T:[LDL=1@OWT_5]'NK_Z;K^2?_@J5X@U
M7_@F]_P7A_X)K_\ !0C0(+N#X/?MLZ</V%_VH].TW7]0T?3KS56UK3- \$>/
MO%XD@N["XC\.6?CGP1XFLK&*WNQ?Z1\#-7T^&WT+5=1BUV[_ *UP00"#D$ @
M^H/(- "T444 %%%% !1110 4444 %%%% !1110!_/5_P7[Z?\$M?^TGO[.__
M *57]?T)I]Q?]U?Y"OY[/^"_?3_@EK_VD]_9W_\ 2J_K^A-/N+_NK_(5]3FW
M_),\)^N??^I]$QA_&K_]P_\ TECJ***^6-@HHHH **** "BBB@ HHHH ****
M "BBB@ KA->^*7PR\*^)-'\&^*/B+X$\-^+_ !%]@_X1_P *:]XN\/Z/XDUW
M^U+^72M,_L?0M0U"WU34_P"T=4@FTVP^Q6L_VR_AEL[?S+B-XQR7[1?[0'PM
M_95^!OQ1_:+^-?B%?"WPL^#_ (0U3QIXRUD0M=7,6FZ;&HBL=,L499=2US6;
M^6TT70=*A83ZKK6H6&G0'SKI*_S-OBQI7[3G[0?_  4Y_P""/O\ P5D_:8FN
MM 3_ (*._P#!2SX>W7[/7PKNY(6D^'O[+_P)^.G[+FC?!W%M;10VVG)KNE^.
MKYXDAC\SQ)!IL/Q#U"6XU7QO?SR '^IC7DOQ/^/OP*^"2:?)\9_C5\)?A$FK
MDKI3_$_XC^#O *:FP\W*Z>WBO6=)%Z1Y$V1;&4CR9<_ZM\:7QD\9^(/AS\(?
MBK\0O"?@K7_B3XI\!_#?QSXS\-?#KPI8_P!I^*/'WB#POX8U36]&\%>&]-^T
MV?\ :&O^*=1L;;0M'L?MEK]KU&_MH/M,'F>:G\D__!.#_@@;X+_;V\ >-/V]
M_P#@NC\/_C/\:_VS?VD?'/BV_NOA)\4?%7Q2^!=K\!? _@_Q-JWA#PAX>T_P
MM\,/%7@37$FUO3='_M[2+:ZU?_A"M&^'^H^"- \*^#M'N=*UC7_$X!_7SX,\
M;^#/B-X9TGQI\/?%WACQYX.UZ![G0_%G@S7]*\4>&=9MHYI;:2XTG7M$N[[2
M]1@2XAF@>6SNIHUFBEB9@\;*.GK^)/PG^SYI7_!!_P#X+S_L<_L__L<>./B+
M9?L5?\%(]#\;VGQ&_9I\6^+M5\8^'_!/C/3T\2VV@ZQX.O=;G:[:/PUJ5AX&
MCT7Q%XHN_%'Q 'A=?&7AS5_$^L0ZK8W%M_;+=75M8VUQ>WMQ!:6=I!-=7=W=
M31V]M:VUO&TL]Q<3RLD4$$$2/+--*ZQQQJSNRJI( /GOPU^UI^SQXQ_:3^(O
M[(7A?XF:;KO[1GPC\(:#X[^)WPUTW2/$MQ=^!O#'BBUT2^\-7GB3Q NB_P#"
M(Z;>Z_I_B+2-2T?0I]?&O:CIEU)J5IIDMC9WMQ;=IXG^//P-\$ZW>>&O&7QG
M^$_A+Q'IPMCJ&@>)_B+X0T'6[$7EK#?6AO-*U76+2_MA=65S;WEL9H$$]K<0
MW$6Z*5';^;G_ (-Q;&Z_:1^+7_!5[_@J5K.O:QXB3]KO]LCQ!\._A/?:A8MH
MEA+\"O@BU]+X"O\ 2M#>TM[VUA6P\<V_@IQKL]YJT$?P^MXKA8;YM4O]9_/&
M']@_]F7_ (*__P#!R7_P5)\.?M;>#=>\8_"C]GSX1_"3PQX6\(Z?XV\0>!;V
M#Q=H_ACX6^$!KQU7P++HVK:C8R3:%XVO8+34-;\N"+Q-;PW%G?O:64FD@']G
MEM^TU^S=>W-O9V?[0?P0N[R[GBMK6UMOBOX#GN;FYGD6*"WMX(M?>6:>:5TC
MBBC5I))&5$5F8 ^W@@@$$$$9!'((/0@]P:_GL\$_\&N'_!&+X?\ C/PCX\\-
M_LX^-8?$/@GQ/H/B[09KK]H'XY7=M%K7AO5;36=+EN+63QYY=S!'?64#S6\G
MR31AHV^5C7W%_P %??VY+G_@G%_P3M_:*_:F\.V%CJGC[P=X7T[PM\)M)U&6
M,6=Q\3O'^M:=X)\'ZC=P7%O=1:KI_@^[UE_'>LZ'+]G.OZ)X6U+1H[^PGOXK
MV  ^T/B+^T/\ /@_K>B>&?BU\<_@[\+O$GB6%+CPYX?^(OQ-\%>"=;\002W9
MT^.?1-*\2ZWIE_JL,E^K6226%O.CW:FV5C,"E>HZ3JVE:]I>G:YH>IZ?K.BZ
MQ8VNIZ3J^DWEMJ.EZIIM] ES9:AIVH6<DUI>V-Y;2QW%K=VTTMO<02)+#(\;
MJQ_D*_X)Q?\ !MI^R5^T5^RUX0_:G_X*HZ#\1OVL?VSOVL?#VF?&[X@^,O%W
MQR^-'A^Z^'J^/],76?#7A73E\$>+/!,VJ>(-"\-7^B0>+)O&;>,[&W\5V5]I
MWAJ=/"5I86T_)_L(V'Q,_P""&?\ P6;\,_\ !)6W\<_$KXI_\$]_VW_ &O?$
M[]DU/'DUUKE[\$?B+I\'B_Q+KF@6>MPQV>B1VMW?>$/&>C>-=&T#2$GU2]\1
M_"WQ_J=KH$NI>)KK7 #^S&BBO&OVB_C7X<_9M^ 'QM_:$\7Q?:/#'P0^%'Q!
M^*^N62W2V4VI:=X \*ZKXHN-*M;EH+HQWVK+IG]FV 2TNYI+VZMXH+2ZF>."
M0 P-!_:L_9[\4_M'^.OV1_#7Q.T;7OVBOAAX)T3XA_$?X9Z19:WJ&H>!/"OB
M4:9)X<NO%VM6NER^%_#^IZ_::SIFJ:+X:U37+;Q-JNB7<>NV.CSZ,LE\GNVI
MZGINBZ;J&LZSJ%CI.D:38W>IZKJNIW<%AINF:;80275]J&H7UU)%:V5C96L4
MMS=W=S+'!;P1R332)&C,/YG_ /@UX^'?CCQA^R3\=?\ @HG\:KO^W/CI_P %
M'/VC/B!\7/$.OW5G>1:E!X \"Z_K/@+P3X32\UC4=6URY\-:+K]EX_UGP9;7
ME\ECI?AOQ18V.E6IM8_[2U/XP_;T\&:W_P %@O\ @X#G_P""4'Q^\>?$'P)^
MQ!^RC^SE8?'CQ'\,/!GC/6? 4/Q^\::OX:^'&M6FM2E!JNE>)]6T#4OC!I>C
M:;=R:5:W7AWP]X0\>6^@7^F:EJNKW>H ']</PQ_: ^ WQL;45^#/QM^$?Q;;
M2"!JR_#'XD^#?'K:63Y>!J(\*ZUJILB?.AP+D1']['_?7/KE?Q:_\%?O^#?W
M]@W]B']BCXI?MT_\$\]*\>_L9_M.?LEVOAKXK> _'/A;]H+XR7]AJ;Z?XLTC
M1]<TV^O/B+XJ^(>L:=K.HZ!KFH1^&#X5OO#S:CXGM]$T349AHFK:PLW]*_\
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M,VJZKX8\*:+XJ\/ZS<R)%:W^FR^(_!6JZ5J^N?VOXT\4_#W0_B'X2N3XEOM
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M (<O^OM;_P!.S/F?]M/_ ),X_:S_ .S9_CQ_ZJWQ57PS_P $$/\ E$7^Q?\
M]B;X]_\ 5R?$>ON;]M/_ ),X_:S_ .S9_CQ_ZJWQ57PS_P $$/\ E$7^Q?\
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M%'PW\.:JVA6&GW;:SX,OKV+PMX:GTGP!X1NM#TNR\31>(OUB_84_80\>^/\
M_@TQF_9L^&UE/KOQ@_:)_9=^-'Q=\*Z-9L?#=UXM\8>//'7B;XJ_#KP?;7<]
MSH2_:/$6A6/@[P9'?Z]J@T'4I;D2:E>'P?<?9(N3_P""-?\ P4[_ ."(-K_P
M3S_9U^%/[07B7]EWX&_M ? #X3Z3\-?C3X,_:$^&OA/PEXON?%_@&-]$UGQ%
M8ZQXA\+?8O',OBZ6T_X2*&+1=6UCQ0LVI2Z?KVFVFOVM_9Q@'YC_ /!6W_@H
M/_P2&_:0_:N_X)A?M ?\$PO'^A3?M@?#_P#;7^','Q$\5_"_X'_%K]GV?7_A
M1X@\1:$+Y/B+KWB;X8?"J]\;WCZY;6>AZ.EGK>H7]MX;\3>/=-OE33];&/V@
M_P"#O?QOKB_\$U_A/^SUX*@M]6\>_M5_MC_!GX5Z'X:?5DTBZU6STS3/&7C-
M)H)KNXLM'DAC\<:%\/\ 1KDZY>VNEV;^(;;4YIHGL8YX?H[]B?\ X*3?L3?M
MW?MVZK\#OV"OV&_"_P 7OV??@UX/@\9?$O\ X*":1\-_"WPQ\ _#;XJQ2RW_
M (+\%>$_"WB_X:Z!XP\37^IWUB(-+\2Z9K.BZ]'JUAJ6N^'_  GK?@31;GQZ
MOY3?\'5GQ/\ BKJ7[;'_  2.^#_P0\)>*?B-XT^"NJ?&S]N#6/AOX0GT2[US
MQ5H_P1D\&_$=M0TK0]18RW>M>$O /P0^,NHZ5:-%=/XB^VWFC:+IFLZPB:;*
M ?TE?L'_ /!*_P#97_8A^!VB_#W3_AKX+^)WQ8U_PQIEM^T!^T'\1O#6E>-O
MBQ\>_&,EGN\1ZQXY\;^*K/4_$VK>'9=4NM2'A?P??:C/H7A?1;A--T^S61[V
MYO/YYOV;?@IH'[#7_!VS\4/@_P#LRZ?I7@CX&_M4?L?ZM\6?B1\)/!=S9:7X
M)\&W]YHUOKEVR>%I8YK6QN9_BEX"/BW1-,T)+";PQIWQ1U+3O#ATKP-=7WAV
M7]=[K_@Y&_X(YV?[.J?M%3?M?^$6MG\+V>O#X+6ME?W_ .T2-<OM-@O(/ +?
M"2QCN-73Q0FHW$?A^\U1[I?AYIVI+/J&H>.K7PM:W/B*'X8_X()?"#XW_MA?
MM<_ME_\ !>K]IKX9M\)[K]L+3]*^$_['7PWU<ZP=<\/?LQ^';?PC;V?C(VU]
M,-/?3_%VA^ OAOI&D^+(=.TNZ\;ZSH/Q(\=Z#HGA[P)X_P!#/B, _/W_ (*6
M_&;X0_LF_P#!RGH?[2G_  5D^&/B7X@_L-6/[,WA;PY^QIXBD^$S?%/X5^ /
M'$>B:!J%_JWBKP[KGAZ_TOQ!X@\,_$J'XUZV(/!$.O>.?"^J>)OA%XN\N"ST
MH+8?LOXQ^'__  0O_P""_ND_"^Q^&GQH^'WC/QW\#/&&E?%KPCJ_[/NMVWP'
M_:9\.V=K;WT<FE7UCXA\'Z%\8]#\"7VH/I^M:M;VFB:)<67B?P[X9U6WU?2M
M2TV!I>-_96_X.$OV%/VJY/VB?@E_P46\$_"__@G[\8_@!\8M1\#:S\ /VL?B
M'X6\7:=XATW0Q':VGBBVU_Q3X%\%>%1XMTWQ+;>(](UWP9IUKK\GA^VLM$\0
M:=XHUS3/$T3Z?^(:^%?V&/VL?^#@S_@GGK7_  0Q^$WAWP[X0_9OUV3XD?ML
M_'']GGX>:IX!_9ZM_"JZE>W=QX933I_#D?@319-:\%6/C+X>?V[X9\(:#9>-
M[_XEZ-X8\/\ BBXU/P]'J?A, _2;_@YI>V^-W[4'_!#/]A.36+B32?CY^W=I
M/C#Q_H&FZQ%#<Z?X5\*>*/A7X!7Q1?Z9_;MAY=Q#X=^*/Q''A:]N-.EN;V33
M/%&GZ#JEI=1W]CJ7*?\ !S_^WQX5\+?$W]D#_@F%XY_:)\0?LK? #]IAD^)O
M[<WQH\'VGB'7/%FG_LM0:]K'AB/P!I?ASP7X"\=^,KL?$S5/"_C#3U?2=.N-
M-U'4-#T_0/&6E:KX U/Q=;CK/VEKF']H_P#X.Y?V%?AU;6<VL^&/V*_V-/&7
MQ)\:6%Q''=VFF^,_%7AGXS7NE:OMM]?=-.@LKOX@_ Z^M+R?2K35I=;M(K:[
ML;W1)M(U2'AO^"T5S\*OV*/^"[7_  3@_P""EW[8'@H>(_V'=?\ @!XP_95\
M?^+=1\(/\4M(^&OQ-MK?X]:KHNN7_@=[?Q%J4]@^G?%72-4_LOPUX?&J3:/H
M/C[7_#5AXG\26-]H>H@'H7P;_P""L/\ P:6? ;X(VO[.WPY\4?L]V7PE&C6N
MC:]X:US]@W]HSQ6WCXV_AT>%+G6OB?J7B3]F+5-2^)/B?6- \S3-?\2^-;G6
M]:UNTN+BVU&\GMYGB/D__!IS\0OA)J_QS_X+8?#7]EC7]>U']BWPI^T_\+?B
M%^S+IFKGQ'I]I;^$_B9JG[0^@1Z_IOACQ!'IEQH47B'P9\*_AU;VIU7PUH?C
M:;P_H7AW3_&\;:EHUM8:5]\_M ?\%E?^#>/X#?"35/BC!XZ_9%^,>I+8:R?"
M?PN^"GPG\(>/_B1XQ\0:987]W9>'%T72O![P>"?[:GL38V7B?XDWG@_P;'/<
M6C76OQ)=6OG_ &'\,?VH;CPI_P $F_BY^W;XV_8R'[ GB.R_9I^,/Q]UCX V
M-QX2E\9:9:^"OA_XD\0^#[F_N]!T7X5$^*/%%AI]A/X?T#Q)I_@WQ;ID^JZ?
MHNNVWAO6S<V=D ?DO_P;&7$'QO\ VA_^"XG[< \0GQ?!^T'^WIJ'A?PMKO\
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MOXL^$'C?4;?1M1F\3>#?%/AKP[J96VTBPM-0_1/_ ()>?\%D_P!@3X1?L*?
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MU#38?$WCOX@>&K/XA137%E%J?AC6?%NA^([.VTO5]7T,@'T1\&/C#_P:Y?\
M!(CQW\;M3_X:C^'OQ[^/WQ'^(.M^-O&WQ:\?VGB#]N7XNV^I:]?3>*_^$"\/
M_%CX:_"WQEI.DZ;9>(+22\UF:]UO_A*]1\7K87/Q?\9:YXDTW1;G3OAW]DS]
MI_\ 9>_X*"?\'47[.'[0G_!/SP/XP^&GPH\'?L?>/+G]H.YG^&EA\(T^,/B2
M?X=_%NPC\:Z[X=TK68[W6_#MQ:_%/X!:5:>(/%FDP:AJOB'P%H\UIHESHUAX
M:\7W/Z9?L:_MJ_\ !M#^Q-^Q+\'+_P #_%/]B[2SH/PP\%:_XH8>!='\7_M-
M>+?'D.@Q:GJVK>._#*^'O$OQFU#X@RZ^VH(MKK:3IX7E>TT#1Y=)\.V&D6MM
M\L?\$#/C1XE_X*(_\%SO^"O7_!1/7/AUXD^$$'AGX8?#3]G#3OA5X[.I6/CS
MX?Z-JNO:'X:\/Z!XJ\/7EZT7A[Q=-8_LEW&L_$3P_%:W5OX>\=ZIK.G6%['"
MTTFI@'@W_!7;]O[]C+]IG_@M"G[%7_!1S]H[7_@M_P $R_V%?#OA?Q3XT^&6
M@:)\5?%^E_M4_M4W6EZ+XJ&E>)K;X+?#7Q7XIT[PSX8T?QM#X*U6UUZ>)-)3
MP)XW_P"$.U_1M6^)DMUIOV+^T=_P5A_X-4?B_P#LG?$W]FE/%7P*M_ ^K?#G
MQMHO@OPA\/OV#?C;X)N_"7B/5/#=U9:-K7PONU_9ATG0_ ?C:PU&+3+CP]XE
MMYM*BTS5+/3[F]O([.VD*^(:#\2OV1?^"8/_  <%?\%)[7_@I?H'A/PS\,?V
MZO#7PN^-'[+_ ,<?BMX'@^(_P[DM(S>GQ9H4NIW5AXQUCP29O%5_X@\*R2W]
MGH^@V$_PT2*[_LKP_J?@.34?O;]K;_@M%_P1E^#6F:+X*_9*^#_[/O\ P43_
M &KOB!XE\,^$/A!^S1^S5\-?"^L2>.->\2ZA!:1)J?Q9T?X6^,/!7ANVM8Y=
MGV*QB\4^+KS5+BQLK/PE+8?VWK.@@'>_\&G_ (Z\4^-_^",WP5@\4:UJ6N?\
M(1\2OC1X&\.W&JZCJ.I7-EX5TGQQ>7VBZ-%+J-Y=FVT[18]5ETS2-.L5M-.T
M[2K:RLK6SB6%GD_I(KSKX1Z;#I7PQ\"V\7POTKX*3W/AG2M7U7X2Z*?#+Z?\
M//$&O6R:WXD\*)=>#%7PIJ-SI&OZAJ5K?ZOX?,FE:S?I=:K9S3Q7BS2>BT ?
MSU?\' G_ ""_^"7W_:47]G'_ -%^(Z_H47H/H/Y5_/7_ ,' G_(+_P""7W_:
M47]G'_T7XCK^A1>@^@_E7U.;?\DSPGZY]_ZGT3&'\:O_ -P__26+1117RQL%
M%%% !1110 4444 %%%% !1110 5_&)_P5<^$?_!T=\2?"?[17ASPAX@^"_B_
M]D#7?&'CN";X4?L?:OHWA+]I_P ??LX7_C-;?3_A_:^)O'/P]U'Q!8>)-1^'
MMPD&KKX(O+_6=5@M]>TC4;#QC9ZC_P (GXB_17_@K!_P5-_:I_X):?MJ?LC^
M/?B3\/\ P[K?_!)'XI6;>"/CU\4?"GPY\2>*?BW\+_B[<Q^.;6T_M#5K+Q7'
MI6G>&U2[^'GC/3K5?#%[KGBWP]X:^)^@>&-,U+Q'I5DM]ZO\0O\ @Y*_X(Q>
M ?A7<_%6W_;1\(>/K8:/9:OI/@+X>^&?&^L_%37I-3MDNK#1[;P'J?AW1-5T
M+6)5D6&]M_&A\+6^@7.^W\2W>C2Q2J@!T?\ P0#^+W[ _P 4_P#@F_\ "O3O
M^">NB^(/!WPL^&VH:QX,\>> /'W]G3?%CPA\7)&M_$GB^/XGZSI5I::;XN\0
MZX-=L=>L?&>EH=*UOP_?Z3!:0:-)IMSX:T+]$OVS?VJOAO\ L0?LL?'3]K#X
MLS[/ _P/\ :OXROM/2[@L+SQ/K*&'3/!W@71[NZ5K2#Q#\0O&>H^'_ WAMKL
M+:'7_$.FK=/' TDB_P ^W_!K;\"?C?H'PI_;B_;&^*7@;5/A'X+_ &]/VI-=
M^,_P9^$^OZ7J_A_6]"\&6^K^,KJ7Q-)X>U"WM[?3-%\2S^*K?2O#4]L)&UG1
M?"-KK$4UQHE[H-S/Y-_P6UU[7_\ @JE_P4M_8Y_X(2_"G5M77X5>$M8T?]K3
M_@HOXC\+W5[;R^%_AQH5C#J/AGP+JFKZ98:I-X:U67P7K:W.CGQ#HVJ^$;_X
MB_'']GG4;IK:XT29X0#W+_@V@_9&^)O_  JWXW?\%9?VK(_[0_:N_P""G7C'
M5?BQ#+?Z=JNGWG@_X$7WB'4M9\':=H]EK",^C>'?B+>S+XX\,Z;HU[J'AYOA
M/;_!J'3KF-=+-E:?I-_P7,_:A_X9!_X)0_MK?%^T?4H_$=[\']6^$W@J?28E
MDU#3_&GQRN;3X0>'=?@>66"VMQX4O?&@\63SW,NQ;?0Y4@MM1O'M=+O?U+\.
M>'- \'^'M"\)^%-$TCPUX7\,:/IGA[PWX<T#3;+1M"T#0=&LH=.TC1=%TC38
M+;3]+TK2["VM[+3].L+:WL[*T@AMK:&*&-$7^7?_ (..H;?]JCXS?\$EO^"5
MD.N:C!IW[7/[8%G\2/C/HFG7&K6%O?? SX*V$:^*K/6M0\/W<>M9U32?%?BK
M4O"NFQ6<FE7'B3P=#K6KZWX5D\.:9JQ /U@_X(N_LQ']D'_@ES^Q9\$;[PM_
MPAWBO3O@GX:\:_$?0I+[^T[ZS^*'Q46;XF?$:'4]1$DR7-_;>+_%FKV4D5M<
MW>FZ9#:PZ/HMS-HNGZ>U?;W[0T/QPN/@3\7X/V9[KP18_M"3_#GQ=#\%KWXE
M+>OX"L_B5)HEXGA"Z\6)IUO>7C:+;ZTUI+>+':72LB8GMYX#+$WL*((T2-?N
MHJH/HH 'KV%?RV:/_P %W/'O[$O_  4J_:G_ &-?^"R"^#/@#\(M6UW3O$?[
M!?QZ\$_"KQ_'\//&OPKU/QAXEL=+E^(?B.QUCQ[=2:GJOA[5?!=GJ'B"ST>P
M\&^ O%7@SXF:3XX\0:7Y6E3S 'XP_P#!2WP3_P %?/#_ (K^"'Q9_P""_NC7
MO[0?_!+#X:?$31M9^*?@[_@G_P")?!'AGP5X,\3WUSX?\-^$/&WQ8T'4_ VD
M>-/'&A7WB#Q%#X9L](\3ZKI]I]MOM7TKPEXM\&7_ (BM[3QG_7S^V%^SG\'?
M^"J__!*WXC? ;X)^*O")^$_[3O[/_A35OV?_ !CIL&K:+X$L9M+;PS\2_@/K
MDFFZ+:V&LZ3X3TCQ5X9\&76JZ##I*7EEH]I>:/=^'YVCN-&E_%W_ (+.?\%V
MO^"=GQ=_88^.O[(G[*GQ23]LC]H[]J_X=:U\'OAC\,?@5X+\4_$1H=4\6RVV
ME2:WK-[!I5K96U[I%I)=ZIX=TC29-9\5WVO66F/9Z UD9]1M?TF_8\_9L_;7
M_8\_X(8_#+X ?#;5?#T'[<GPC_9AUC4_ UEK-JGB?P_;?%![_6?B+H/PKU6W
MUJ(V]Y%%#?V_PLO9D$-E9SB2YT:\M;6VL;V( _$?]A7_ (.!_#__  2A^"OA
M3_@FS_P5^_9\_:!^!?Q__9'\#Q_#KP%XN\'^"(/&O@7XQ?![P$T?A+X8:EX>
MO+OQ/IM[<W5[I>E77AS0/$_A^'7?A3XFT[P?+KD'C?P_>7I\*V'YG?\ !2;]
MJ#]K#_@I-^WS_P $F_VRO%'[.GC[]FG]C>/]N+X,? _]B_X=?&.2\TOXX?&.
MYU?XO?#7Q?X\^-P^&\*W=G8Z5XDLH?AUX?N+_P /WFIZ ]Q:>&M!\/\ BCQ[
M)I^IZO8_T,_\$V/^#D?]C+XN?LZ:#I/_  48^-?@K]EO]N/X/>(/$/@SX\_#
MCXK^$?$'P^BMO&NCZUXDT"#Q'X*CN_#PLK3[;HD4^F>)?"WGVWB[P!X@&N^&
M/$>GG39]#\0>*?FKX>?&N?\ X+__ /!:']GWXN_ S1/&]K_P39_X)(ZSXV\7
MV/QNOK671?#_ .T#^TOK1\/'0++PE'<6%GJ%O;_;-)\)>*++3M576+VT^&?A
M'4[[7;7X?ZK\8-"TRX /[&5X5<_W1_*OC3_@H[XQUKX=_P#!//\ ;Q^('AM[
M:/Q%X%_8R_:A\8Z!)>6ZW=I'K7ACX(>.=;TI[JU9E6YMDOK&!I[=F59H@T98
M!B:^S:\7_:1^%"?'C]G?X]_ Z0V C^,WP7^*7PHD.J$#3 GQ$\#Z[X0<ZB6T
M[6%%@%U@F\+:1J@%OYF=.OA_HTH!^'O_  :H>&[;1/\ @B'^RSJ\)MS-XU\6
M?M&^)+[R;..UD%U:_M%_%#PBHNITD=M0G^R>%[4K=RK%)';&WL ABLHY)/B?
M_@J5\,OVDO\ @E5_P5FT[_@N[\!_@GKO[0_[-7Q-^#^F?!?]OCP/X"DUO4/B
M/X(\*>'M%\-Z5J/Q,ATPRRZ9I_A/3?!OPL^&>M6>M2K;^#+'Q%\/]2TOQ[<>
M#AXOTKQL_M__  :'?%V+QI_P2?7X07MU#;^)OV9_VB?C-\,]7\-7%U>+KVAV
MGB;6K;XMV<NJ:)J"0W&D07NJ?$+7[2U^S0+IUS>:3JJ"4ZS::Y;VOH/_  4G
M_P""KG[17_!*_P#X*7?LYW_[2422?\$C_P!H'PC<>'==^)OAWX8W_B'Q)\&/
MC39Z1K$$UIK.M>'-(OM9UK3!<:9H?C ^%;:&Z\5ZMX7UKQGJOA&'Q%-X#E\(
MW(!\S_$W_@YB\,_MO_#Z7]FW_@CU^S1^U)\>/VR?C?X7C\,Z/J/B3P/:_#_P
M+^S*/&]A<:)=_$/XG^--$\5^(8]-U/X=WM];WL%_975O\.(KVTGU6[^)\-MI
MEM8Z[S__  9M>!M9^'G['O[;_A'5[G3=7F\)?MW^,O!-UXC\/3W.H>%=;UCP
ME\+?AAIVK7'AW6)[2R.IZ?(S6U]:S-;6]P^GZAI]U<6MM]KC0_7/[=O_  <D
M?L ?!+]GKQ!'^Q)\6O#7[7/[5GQ)U"7X?_ /X,_ FQO?$&KW/Q2\>R75OH_B
MSQ!;'PS?6KZ=IWB'4(=1.BPZ7K7B'Q[XHN]-\,:=I$S:SJ>LZ-]B?\$'OV#O
M&O\ P3V_X)P?"+X1_%NXU&3XZ_$'4?$'Q[^.]GJ5^FHS>'OB=\59+35;WP=)
M<Q7.H03ZCX)\/6OASPCXDO[35-5T_6_%NB:_X@TV^DT_5K6.( _)O_@HMK&O
M_P#!<G_@IUX4_P""/GPTU+7M+_8;_8JUW1OC9_P4E^)/AR_M[.3QIX^L[2^3
MP1\!M O;62*["V-W=2>&;UQJT4D'BW5?'/B>?PO=:C\!?#5SKG-?\'$'ASP_
MX/\ ^"C'_!L#X2\)Z)I'AGPMX8_;GB\/>&_#F@:;9Z/H6@:#HWQU_8(T[2-%
MT;2-.AMM/TO2M+L+:WLM/T^QMX+.RM((K:VABAC1%9\*_P#@U-^-?P(U'QSJ
MOP+_ ."W_P"V_P#!34/B;K@\2_$6\^$MEXL^'5WX]\0+-?W$6M^-+KP?\?\
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M;X?? SPA=2:CJ'A?1[[7- GM=9U6TN-0TKQ-%JLDNCZ3+\2]&^'_ ,-]/O\
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M]+IVK1Z!K&J?V5J!M_P3_P""C&K>'?@=_P ''G_!([XR?M#>)O#_ ,,OV0-
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M;6:^U6#3-,L/^%/2:]%#;Z3?[#9ZE^T!9PV%K+=V\VK7+SI8:5KATZ^DT?\
MKTTVQM=,T^PTVRMX+.ST^SMK*TM+6&.VMK6VM84@@M[>WB5(H((8HUCBAC1(
MXHU5$554  %VBBB@ HHHH **** "BBB@ HHHH **** /YZO^"_?3_@EK_P!I
M/?V=_P#TJOZ_H33[B_[J_P A7\]G_!?OI_P2U_[2>_L[_P#I5?U_0FGW%_W5
M_D*^IS;_ ))GA/US[_U/HF,/XU?_ +A_^DL=1117RQL%%%% !1110 4444 %
M%%% !1110 4444 ?R(?\%&]:\0?\%PO^"FOA+_@CQ\,=2UW2_P!B/]C37-&^
M-?\ P4D^)7AV_MK.3Q?XWLK6]7P5\"=!O;62.['V*ZN9/#=ZPU:"2'Q7JOC;
MQ)/X9NM0^!GARYUKE?\ @XF\,^'O!?\ P4 _X-C_  ?X1T/2?#/A7PM^W-;>
M'?#?AS0=.L](T/0=!T;XV?L*Z=I.CZ/I6G0VUAIFF:;86\%G8V%E;P6EI;0Q
M06\,<4:('_##_@U/^-7P-U;QYK7P+_X+>_MO?!/4?BAKI\3?$2\^$MEXL^'5
MYXZUX7%_<Q:QXSN_!_Q_T6?Q5JL$NJ:B\6I:X]]>(]_>NLRM=SF3\9O^"PG_
M  2G_:6_9@_; _X(\?##XB_\%8_VS/VI/$7[4'[5$_PZ^'/Q1^+WBKQ]J?B_
M]EK7D^*'[-/AX_$?X076N_&'Q;?:7XI>^\>Z)XB:XT+5O"5[_:?@#PW(=4,U
MO:7.G '^E?7SA^UQ^U?\%/V(?V>/B9^T_P#M">)9?"_PK^%FBIJNN75E9/JF
MM:K>WU[;:3X?\,>&M)B>)]5\2^*->OM.T+1+-Y[2R^W7T=QJNH:7I%O?ZG9_
M/G[(7P3U_P#X)K?L<>,M-_:C_;4^+?[5FD?"6#XF_&3QU^TE^T#=>+M>\;:-
M\.=(TJ?Q9KL&KSZMXN^)7B+4-'\%:-I.JW5G#87\TGV!?LMCI'VA +G^)R3_
M (*F_L;?\%B_^"A$GQ;_ ."H7[2G@3X!?\$SOV3_ !7=7_[-/[%NOVWQ'UV?
M]H3QO;M+;:+\3?C'I?@[P=JMGJUDVGNVJ:]8>(;BRL+.TN[#X6^'])US0=0^
M*FM>) #]DO\ @D/\#OCC_P %2?VZ_$O_  7G_;.^'VM_#CP9IGAN7X8_\$U_
M@IXEM-%=_#7P:G_X2(#XEW5U%IFF:OJ\,L/BKQ2?">OZMI]M_P )/JOC;Q?X
MMT5?^$33P#./V(_X+@_M0#]D+_@E3^VG\8;9M13Q!/\ ![6/A;X-FTF)9-0L
M?&7QKGM?A+X>UR!Y98+:W'A>]\8KXJFGN9@B0:)*L-OJ%X]MIE[QGPJ_X+U?
M\$=/B3XV^''P6^$_[:/PWUGQEX_\5>$/AA\-?!>C^"/BMIHU;Q/XKU?3_"O@
M_P ,:7]J^'=AI5A]OU:_T[2K+[3<V6GVIFC,\]O;HTB?GA_P<?)!^U!\5O\
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M_P .>)[[Q1?Z9<2:5IVJ_M9_P4U_X)G^(OVB?^"*7C+]@7X9:Q/XA^)/PN^
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M5QJW@Z[\>>&+VRT34O$?A.XN=ES?>#/$K6\VJZ?IVK&"]FTF<:!XC$<MAK8
M.<_X(M6OAJS_ ."2W_!.>+PI;06NG2?L=? *ZOH[>&X@1_$M[\.= N_%URZ7
M*J[3W?BB;5[FYF0&WGN)99K5GMY(F/XN_P#!W)<RV?[.O_!/N\T18'\;6O\
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MM$U:6#Q/^U+J/A^XAFM;;QOK^O64L^C:F(KW4=)UL2:7:^)-8TOX9_#_ %=
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M%_Q'UCPUH^F:CXX\476H:UK-]<:_XFN=4U::\U;4[J2[:>_NGE]7HH \*_:
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M_P XZC_A1W_!RI_T>C_P3S_\-MXK_P#G'5_0M17G_P"M5?\ Z$G"W_B/9?\
M_*_+\^[*]@O^?M?_ ,&R_K_AWY6_GI_X4=_P<J?]'H_\$\__  VWBO\ ^<=1
M_P *._X.5/\ H]'_ ()Y_P#AMO%?_P XZOZ%J*/]:J__ $).%O\ Q'LO_P#E
M?E^?=A[!?\_:_P#X-E_7_#ORM_/3_P *._X.5/\ H]'_ ()Y_P#AMO%?_P X
MZC_A1W_!RI_T>C_P3S_\-MXK_P#G'5_0M11_K57_ .A)PM_XCV7_ /ROR_/N
MP]@O^?M?_P &R_K_ (=^5OYZ?^%'?\'*G_1Z/_!//_PVWBO_ .<=1_PH[_@Y
M4_Z/1_X)Y_\ AMO%?_SCJ_H6HH_UJK_]"3A;_P 1[+__ )7Y?GW8>P7_ #]K
M_P#@V7]?\._*W\]/_"CO^#E3_H]'_@GG_P"&V\5__..H_P"%'?\ !RI_T>C_
M ,$\_P#PVWBO_P"<=7]"U%'^M5?_ *$G"W_B/9?_ /*_+\^[#V"_Y^U__!LO
MZ_X=^5OYZ?\ A1W_  <J?]'H_P#!//\ \-MXK_\ G'4?\*._X.5/^CT?^">?
M_AMO%?\ \XZOZ%J*/]:J_P#T).%O_$>R_P#^5^7Y]V'L%_S]K_\ @V7]?\._
M*W\]/_"CO^#E3_H]'_@GG_X;;Q7_ /..H_X4=_P<J?\ 1Z/_  3S_P##;>*_
M_G'5_0M11_K57_Z$G"W_ (CV7_\ ROR_/NP]@O\ G[7_ /!LOZ_X=^5OYZ?^
M%'?\'*G_ $>C_P $\_\ PVWBO_YQU'_"CO\ @Y4_Z/1_X)Y_^&V\5_\ SCJ_
MH6HH_P!:J_\ T).%O_$>R_\ ^5^7Y]V'L%_S]K_^#9?U_P ._*W\]/\ PH[_
M (.5/^CT?^">?_AMO%?_ ,XZC_A1W_!RI_T>C_P3S_\ #;>*_P#YQU?T+44?
MZU5_^A)PM_XCV7__ "OR_/NP]@O^?M?_ ,&R_K_AWY6_GI_X4=_P<J?]'H_\
M$\__  VWBO\ ^<=1_P *._X.5/\ H]'_ ()Y_P#AMO%?_P XZOZ%J*/]:J__
M $).%O\ Q'LO_P#E?E^?=A[!?\_:_P#X-E_7_#ORM_/3_P *._X.5/\ H]'_
M ()Y_P#AMO%?_P XZC_A1W_!RI_T>C_P3S_\-MXK_P#G'5_0M11_K57_ .A)
MPM_XCV7_ /ROR_/NP]@O^?M?_P &R_K_ (=^5OYZ?^%'?\'*G_1Z/_!//_PV
MWBO_ .<=1_PH[_@Y4_Z/1_X)Y_\ AMO%?_SCJ_H6HH_UJK_]"3A;_P 1[+__
M )7Y?GW8>P7_ #]K_P#@V7]?\._*W\]/_"CO^#E3_H]'_@GG_P"&V\5__..H
M_P"%'?\ !RI_T>C_ ,$\_P#PVWBO_P"<=7]"U%'^M5?_ *$G"W_B/9?_ /*_
M+\^[#V"_Y^U__!LOZ_X=^5OYZ?\ A1W_  <J?]'H_P#!//\ \-MXK_\ G'4?
M\*._X.5/^CT?^">?_AMO%?\ \XZOZ%J*/]:J_P#T).%O_$>R_P#^5^7Y]V'L
M%_S]K_\ @V7]?\._*W\]/_"CO^#E3_H]'_@GG_X;;Q7_ /..H_X4=_P<J?\
M1Z/_  3S_P##;>*__G'5_0M11_K57_Z$G"W_ (CV7_\ ROR_/NP]@O\ G[7_
M /!LOZ_X=^5OYZ?^%'?\'*G_ $>C_P $\_\ PVWBO_YQU'_"CO\ @Y4_Z/1_
MX)Y_^&V\5_\ SCJ_H6HH_P!:J_\ T).%O_$>R_\ ^5^7Y]V'L%_S]K_^#9?U
M_P ._*W\]/\ PH[_ (.5/^CT?^">?_AMO%?_ ,XZC_A1W_!RI_T>C_P3S_\
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M /..H_X4=_P<J?\ 1Z/_  3S_P##;>*__G'5_0M11_K57_Z$G"W_ (CV7_\
MROR_/NP]@O\ G[7_ /!LOZ_X=^5OYZ?^%'?\'*G_ $>C_P $\_\ PVWBO_YQ
MU'_"CO\ @Y4_Z/1_X)Y_^&V\5_\ SCJ_H6HH_P!:J_\ T).%O_$>R_\ ^5^7
MY]V'L%_S]K_^#9?U_P ._*W\]/\ PH[_ (.5/^CT?^">?_AMO%?_ ,XZC_A1
MW_!RI_T>C_P3S_\ #;>*_P#YQU?T+44?ZU5_^A)PM_XCV7__ "OR_/NP]@O^
M?M?_ ,&R_K_AWY6_GI_X4=_P<J?]'H_\$\__  VWBO\ ^<=1_P *._X.5/\
MH]'_ ()Y_P#AMO%?_P XZOZ%J*/]:J__ $).%O\ Q'LO_P#E?E^?=A[!?\_:
M_P#X-E_7_#ORM_/3_P *._X.5/\ H]'_ ()Y_P#AMO%?_P XZC_A1W_!RI_T
M>C_P3S_\-MXK_P#G'5_0M11_K57_ .A)PM_XCV7_ /ROR_/NP]@O^?M?_P &
MR_K_ (=^5OYZ?^%'?\'*G_1Z/_!//_PVWBO_ .<=1_PH[_@Y4_Z/1_X)Y_\
MAMO%?_SCJ_H6HH_UJK_]"3A;_P 1[+__ )7Y?GW8>P7_ #]K_P#@V7]?\._*
MW\]/_"CO^#E3_H]'_@GG_P"&V\5__..H_P"%'?\ !RI_T>C_ ,$\_P#PVWBO
M_P"<=7]"U%'^M5?_ *$G"W_B/9?_ /*_+\^[#V"_Y^U__!LOZ_X=^5OYZ?\
MA1W_  <J?]'H_P#!//\ \-MXK_\ G'4?\*._X.5/^CT?^">?_AMO%?\ \XZO
MZ%J*/]:J_P#T).%O_$>R_P#^5^7Y]V'L%_S]K_\ @V7]?\._*W\]/_"CO^#E
M3_H]'_@GG_X;;Q7_ /..H_X4=_P<J?\ 1Z/_  3S_P##;>*__G'5_0M11_K5
M7_Z$G"W_ (CV7_\ ROR_/NP]@O\ G[7_ /!LOZ_X=^5OYZ?^%'?\'*G_ $>C
M_P $\_\ PVWBO_YQU'_"CO\ @Y4_Z/1_X)Y_^&V\5_\ SCJ_H6HH_P!:J_\
MT).%O_$>R_\ ^5^7Y]V'L%_S]K_^#9?U_P ._*W\]/\ PH[_ (.5/^CT?^">
M?_AMO%?_ ,XZC_A1W_!RI_T>C_P3S_\ #;>*_P#YQU?T+44?ZU5_^A)PM_XC
MV7__ "OR_/NP]@O^?M?_ ,&R_K_AWY6_GI_X4=_P<J?]'H_\$\__  VWBO\
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M^#E3_H]'_@GG_P"&V\5__..K^A:BC_6JO_T).%O_ !'LO_\ E?E^?=A[!?\
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MT?\ @GG_ .&V\5__ #CJ/^%'?\'*G_1Z/_!//_PVWBO_ .<=7]"U%'^M5?\
MZ$G"W_B/9?\ _*_+\^[#V"_Y^U__  ;+^O\ AWY6_GI_X4=_P<J?]'H_\$\_
M_#;>*_\ YQU'_"CO^#E3_H]'_@GG_P"&V\5__..K^A:BC_6JO_T).%O_ !'L
MO_\ E?E^?=A[!?\ /VO_ .#9?U_P[\K?ST_\*._X.5/^CT?^">?_ (;;Q7_\
MXZC_ (4=_P '*G_1Z/\ P3S_ /#;>*__ )QU?T+44?ZU5_\ H2<+?^(]E_\
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M%_S]K_\ @V7]?\._*W\]/_"CO^#E3_H]'_@GG_X;;Q7_ /..H_X4=_P<J?\
M1Z/_  3S_P##;>*__G'5_0M11_K57_Z$G"W_ (CV7_\ ROR_/NP]@O\ G[7_
M /!LOZ_X=^5OYZ?^%'?\'*G_ $>C_P $\_\ PVWBO_YQU'_"CO\ @Y4_Z/1_
MX)Y_^&V\5_\ SCJ_H6HH_P!:J_\ T).%O_$>R_\ ^5^7Y]V'L%_S]K_^#9?U
M_P ._*W\]/\ PH[_ (.5/^CT?^">?_AMO%?_ ,XZC_A1W_!RI_T>C_P3S_\
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M /..H_X4=_P<J?\ 1Z/_  3S_P##;>*__G'5_0M11_K57_Z$G"W_ (CV7_\
MROR_/NP]@O\ G[7_ /!LOZ_X=^5OYZ?^%'?\'*G_ $>C_P $\_\ PVWBO_YQ
MU'_"CO\ @Y4_Z/1_X)Y_^&V\5_\ SCJ_H6HH_P!:J_\ T).%O_$>R_\ ^5^7
MY]V'L%_S]K_^#9?U_P ._*W\]/\ PH[_ (.5/^CT?^">?_AMO%?_ ,XZC_A1
MW_!RI_T>C_P3S_\ #;>*_P#YQU?T+44?ZU5_^A)PM_XCV7__ "OR_/NP]@O^
M?M?_ ,&R_K_AWY6_GI_X4=_P<J?]'H_\$\__  VWBO\ ^<=1_P *._X.5/\
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ME+?V206GB/PSKNBZII^L>%?%^GVUO8ZQ;2WNFW-KI7B;0?$OA_1>$_X)>_\
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M_$?7XKRYTGP9X,TFYO--T]KQM/TW4]7U'4=7U/3=+T_2]-N?])N=6N=(TC5
M#[SHK^4+XB?\%Y/^"K/P:\!7?[3'QB_X(#_&CX?_ +).A6]CXF\9^)M0_:#T
MFX^+O@KX<3F--0\7>*?AB?A=:^*O#5YH=JTFO:]HWBSPQX<L?#MK!-IWBCQ'
MH-E!<^*K?^CC]E#]J+X/_MI_LZ?";]J3X":]-XC^%'QD\+Q^)O"U]>6\=GJM
MD\%]>Z+X@\->(+&&XO(=.\4>#O%&E:UX2\5:;!>WMOI_B/1-4LH+Z\A@2ZE
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MX]_&'Q'!X2^%WP?\#^(_B%XZ\0SQ371T[PYX7TRXU74#9V%JDM]JVJW,5O\
M8]&T/3(+G5M=U>XLM'TFTN]2O;6VE_S0_P#@I!\)?B=^WO\ L"?M?_\ !?;]
MJ;0=7\(:_P#'3XT?"#X)_L*?!N]CNX[#X3_LJ^'O&TMC'XJEN;[$NO:SXS:S
M73;+6;&RT'2=0O4^)7CJPTZXTGXHZ#8>%0#_ $Z?!/B[1O'_ (-\)^._#KW$
MGA_QIX:T+Q9H<EW UK=2:1XBTRUU?37N;9BS6]PUG>0F:!F9HI"T9)*YK\.O
MVL/^#D?_ ()B_L6?M"?$O]F'X\>+?C!HOQ8^$^JZ?I'B_3M"^$6M^)-(AN=5
MT+2O$NG26&M:;>/9WT%UHVM:==AD*20M.UO<Q0W,4L2?KA^RI_R:_P#LX_\
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M\)PS_9+G2]<U;P=?:=I?C;0+&2YGAM[+6[W1;.R.KV]YID-W_:VF7]K:_?-
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M'5E8@^H_\*L^&/\ T3CP'_X2'A[_ .5U '\[WA__ (.T/^".?B77M$\.:?\
M$3XWI?Z_J^FZ)8O<_ GQ9';+>:K>PV-LUQ)'+*\<"S3H972*1UC#,L;D!3_2
MU%(DT4<T9)26-)$)!!*.H920>02".#R*_BS_ &BO#'AG_@LI_P %_OAY^QWX
M'\/:"?V&_P#@E$P^)/[2S^'=*T^R\,?$C]H>VU.U:?P3KQTM+6UU<Z9XKT_1
MOA>?#_B&QDNM+M_ _P ?6T>Z-EXDD\W^R/QQXQ\._#3P+XO^('BFZ73/"?P_
M\)^(/&/B.]PFW3_#OA31[O6M7NL2/%'MM--L+B;#R1IB/YG1<L #\^_@-_P4
MB\/?M"_\%%/VPOV"?!/PRNQ9?L8^$/AQJGQ"^-=SXTLFL-<\:?$K3--U73O!
M7A[P)#H+7QAT2-O$FF^(?$-]XDMS9ZWX<-E;:+>6NIPZC;_-_P"VW_P<)?\
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M2RZ9+IB0?)__  75G\(/_P %V/\ @B_IG[:.JZ=8?\$]KG1_%FH)!XVEMO\
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M7*:WX<F_9XT^'Q!I#0WSKJ6B2W]E%JMF9K"2[MEN#,GDO[2FG?MJ_P#!%O\
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MX;\(PVUU-?6]I?2W,$>CK%/+>6MM=22HS7%O#,7C4 _F1_;M\#Z7_P %%O\
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M%H(O/#7Q TC2/$MMI$VHZ=XGUS1[B^.K27XU^\OCK5T;C[+8@'U+_P %<_\
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M$:=^SW_P0!^,/[1A^.,]W\8_&W[64?[3'ACP3KG[1,_BC4-2U'PGXENM/O\
MX!>(]<MO#6B>&]0@TSPEIFH^)M;@CBEU7Q';W'VWQ5JT]U_1C^S7_P $X[CQ
M?_P;_?"K_@G+XQ;7OA1XP^)O[!FF>#/%A\5:1?'7/A7\:/BMX,?Q[KR>)/#<
ME]97]P?A[\7/$UW'K'A@ZAIDU[::+<Z)Y^E^=FV_&W]C+_@L%^VQ_P $K/V?
M/AS_ ,$__P!N;_@D+^V;XH^(/[,_A?1_@]\.OBE^S;X/F^(/PV^+F@Z;;M'\
M-5L-<M;&;PE=W3^'TMM$U'7/ _C3QR=1U72-1>Y\/:'K\&L>&-) /+?^"AOC
M'_@K]_P5>^('[ _AG5_^"(_Q8_91C_9U_;'^&7QEN/B]J/QR\'_$S5-/T:#6
M](L-8L+;5)/ /PH?P5H,2I:>)O$&H#5KZ"ZN/#&A7$\%L='AN1]8_MQZ##_P
M41_X.;/V+/V+/B3%HOBK]FC]@_\ 9RUW]J?QI\,-9L/#6L:5XI^)WB:.74%E
M\0V%_:7T>LZ9=7LG[.UO/X7\2V>H1P^'](\62Z3;Z=#XUOM1?]!/^"=_QY_X
M+&_MM?M4:E^TK^T5\$1_P3M_X)]^'OA_=>&? W['_P 3_#FA>*OVA/C3XZU'
M[4D7Q&\8>(M8\-^$OB3\*CX;N4^VR:7J.C^%-)GTY])\*V7@KQE<3ZO\3[#X
M8_X+#_ G]O#]BC_@J!\"_P#@MO\ L*_ ?Q/^UOX5T7X*3? 7]K7]G'P;;WEW
MXNU/P=:ZC=V5KJ>G0:%;>)_'-QI'B#3_ !%H&I0:IX(^'_B5/A=XG^$5KXT\
M<V.O>!]>UK2( #^MVOSTTSX>_P#!/?\ X(X?LR?'SXL>%?!7P\_9,_9PT?7]
M6^./Q@N?#EMJJZ--XKUZ/P]X2MSI&BM<ZI=?VEK]W:^%O!O@;X?>$;:WL+C6
M[W2O#WA'P[%J&KBWNOPA^*'_  68_P""G?\ P4.\!WW[./\ P2Z_X)>?M>?L
M]_%_Q_,_@CQC^U=^U=X5B^%_PJ_9UC4V4'CR_P!+\1ZMI\OAV_\ &_AO3-7M
M;[2[>YU!O'5I;/+JGAKX5>*M>ATS2G^CO^"SG_!.O]M+XV?\$+4_9.^&WQ6\
M:?M8_M*?#5OAG\1/BWXC\3BQM_'?[3$O@?4=3\5_$32O"NE6EK!:P7(\3:A;
M>(_AIX%$USJYT#P7X?\  MKJWB;Q0]K<:T >$_!K_@MO\<?BEX=UNX_X)!?\
M$!_CI\0?@UXC\7ZWXD?XK>))OA[^R#\*O'6L7HL[7_A.=&2P\%:SX2^(6N^(
MM-\-WUEXAOH?',&L>'O[/\'6VM7-_<ZO8:1;_$?[&?CS]KG]M3_@ZJ\,>.OV
MY?@-X'_9R^-_[&?[$7C"2P^!OP\^(NF?%$_"KP?KVBZKI'AB'X@_$#P;J?B/
MPEXN\4^(]/\ VMM4\4^=87FD:39:%XR\&V$UI9^(=+DL+K[<_9;_ ."^W[2W
MC3X9^$?V:_@__P $,?VZ&_:D^'_@[0/AE8?#.;PQ9?"S]G7PAKWA#2K/PO';
M>-_BUXZT'P=:_!GP?IL^DWMK';^+/".F6NES65EX6_M&*ZN%N[;E/^#>;]F_
M]NVS_P""CG_!7']K_P#;]^%?C7P=\4_B!K?@'X<Z7X_\0_"7Q=\*_A_\3;NW
M\4>-/^$PD_9]3QMX?T_5_%?P5\+6G@#P%I7@KQ3'?+-KG@V;P1JVOV]UK]]=
MIHX!I_M+7,/[1_\ P=R_L*_#JVLYM9\,?L5_L:>,OB3XTL+B..[M--\9^*O#
M/QFO=*U?;;Z^Z:=!97?Q!^!U]:7D^E6FK2ZW:16UW8WNB3:1JD+/^"J5W8_M
M$?\ !RK_ ,$/_P!EU-+NO$"? /PMX_\ VK-=1H(K[0M"N);SQ7XRT2^G*Z[&
M-.UG3-5_9=T#5)'O--TUHY+_ ,&RVMQXEN+^ST>T]G_X)S? #]HSQ7_P<.?\
M%A/VX?C!\%_BE\,_AO:_#WP#^S-\$/%GC[P!X\\%>$OB;X4M;KX>Z,VM_"/5
MO$[GP]XX\/-!^SAI_B/Q%K'A.XU33XM2\8Z9JBKX<C\4QZ7=K\"O@)^TI\4/
M^#H[]KS]JKXA_!;XE^#/V;/@+^QWX5^"GP*^+'BKX?\ CSP[X*^).N:]HOPC
MOM3M/!/C#5F'@SQF;'7_ !!\:WU";PI>W%GI=I8Z3;:IH%MXBN;[5HP#0_X+
M\?L _MJ_&'XY_P#!/_\ X*(_L)_#OP5^T)\5_P!@'QGX@\7:M^S?\1-6TF*Q
M\9V:>(O!/C/PWXA\#Z/KDV@:7>^(M%O_  OK#ZXEOXQTSQI-/%X#O_AM9W7B
MOP]'#=>)0?\ !R1X.\-^*_#_ .S)_P %G?\ @E]\=/V)M&^)%GIOASQ#XM^)
MWA,_&']G?7]5:^/FZMJ>D^*/ _AJXU?X:37&ERZA'J7@^T^+TNBZG;'3+F+4
M;?1M0\40>J_M;?M]_P#!7#_@FK_P4:^-7CGXN?LW_&K]N_\ X)4_$?P/HFH_
M!*T_9:^#GA74_%_[.GB&WM_"B:ZOC75?#?A=_%LDEE?V'C:VU.'XH>*I_#7B
MJW\1>"_$/A#Q9X6N;37OA_8?"'[<_CK]OK_@Y*TWX9_L7_ __@GQ\?/V)_V1
M?!'QE^'WQ6_:%_:9_;-T2;X9>)[D:=8^)="3PG\-_!&H:5+;^(+K1-'\0ZSX
MBFMO"6J>,M7U77/^$-L_%$GPN\,R3WWC( _MDT'0=!\+Z/I_A_PQHND^'= T
MJW6UTO1-"TVSTC1]-M0S.MO8:;I\-O96< 9V80V\$<89F(7)).O6#X5\-Z9X
M-\+^&_"&B1>1HWA70='\-Z1#Y=O%Y.F:'I]OIEA%Y=I!:VD?EVMK$NRVMK>W
M3&V&"*,+&N]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?SU?\ !P)_R"_^"7W_ &E%_9Q_]%^(Z_H47H/H
M/Y5_/7_P<"?\@O\ X)??]I1?V<?_ $7XCK^A1>@^@_E7U.;?\DSPGZY]_P"I
M]$QA_&K_ /</_P!)8M%%%?+&P4444 %%%% !1110 4444 %%%% '\5W_  6Y
M_;.^"_[=?_!1WX'?\$8_&'[3_P 'OV>/V-_A;K_ASXU_\%&OBG\3OB1X7^%.
MB^*+SPF=.\9:!^SAX=\=^,?$WA+2;K7[G2;W0H;B#P]J>J7>B^-_%]IK=[87
M&H_!7Q'H8L_\')_[7_\ P3H\:?\ !&6__9Q_9%_:M_8V\>3>#/'?[/7AWX??
M!7X _'WX,>-=4T'P!X"OX]*L-.\-^!? ?B[5M2MO#7A30;*RLT2RTT6&DZ=;
MP(YAA1<?O'\:_P#@A?\ \$H/VC/BMXY^-_QL_8X\%?$'XJ_$G7)_$GC?QEJ_
MC+XL6^H:_K5S'%%+>W%OI?C^PTVVQ###!%;6-E:VEO!%'#;P11(J#\%_^"\O
M_! S]CKX6?\ !/#QIXI_X)S_ /!/76-3_:8'Q&^&.G:/:_ S0OC9\8?B'_PB
M=WX@W>+)-.\'VVM^-[HV*64,7]J:I;:(9+*S9U>[MX)YA( ?TP?\$]OVG/V;
M/V@OV=/A7H7P$_:%^!WQOUOX7_!?X*Z9\2]&^$/Q9\!?$K5?AWJ6J^"HK33-
M.\=:=X,U_6KOPE?:E=^&_$5K86FOPZ?<7EQH.M0V\<DFEWRP?(O@;_@WH_X)
M"^"OBC\5_B_>?L>>"_B9XN^,'B'5O$OB"+XU:MXD^+_AS1=0UW59-<UG_A$?
M#'CW5M;T703J&L33WLM^EG<ZU"D\NFVFJ6^CM_9P]T_X)@_\$Z/V4?V!_@CH
M-Y^SQ\ +3X&>.OC%\*_@E-\=@VI^/+WQ!XE\4^"O"NH2V:^)[/QUX@UN[TS5
M]$U?QGXP%W;P0:=<"\U6\BU&*22"!+?^>OX6?%__ (*W_P#!!CXZ?M*?"OXO
M?LP_M=?\%3OV!_B=\2-3^(7[.GQG^&_B/Q9\=OBS\,X+]++3M.\/^,=0O[#Q
MCXOT:TF\/V_AKPUXC\.^,AX:\*VWC?0[[Q+\-M0U>+Q5K3:R >,?\%]O^"??
MP?\ ^"/NK?LO?\%?O^":_A_3/V8OB#\)OCWX/\!?$CX2^ ;W4_#GPT^)6B^)
M+?Q-XA18_#VFI)#I-IXAL-"U?P!\1/#EG<V7A?Q+X*UNU$&D66IZ5=3:W_5;
M_P %(_VKXOV5_P#@F[^U9^UCX:U_1-+U7P+^SMXK\3_#/6_$,]UIFDR?$+Q5
MH::!\(TG1C97[S:MX_\ $?A2PT_2$ET[4-4U"]M='@NM/N[Q+F#^93XX>'/^
M"@/_  <O?&7]G7X5?$3]A[XL_L#?\$L/@)\6]%^+?QD\0_M%KJWA3XQ?'7Q1
MH6F7.E7OAOP1X;U"P\):[!+=^'/$7C'X?^&==\*:7KOA7P@VK>*_&GBKQW=^
M)(O#GPLB^V?^#G37'^(/P7_8$_X)B>!M)U%_$G_!0?\ ;*^&7P^;2_#-EJ,%
MQIGP:^$VL>%Y_'NI:1<V%A>>'M#D\+ZWXX^&>KR7OB33]5T/1_#FGZ[K$GA^
MY@T>;4]# /MS_@W2_9UE_9L_X(Z_L7:!?7T&I:Q\4_AV_P"T;JMY;6EK9QF/
M]H75+WXL>&[%EMY;B2>?1?!?B?PSH5U=WEU-=7-SIDLOEZ=;M;Z3I_HOQL_X
M(8?\$Q?VDOVOO$?[;_Q]_9QM/B]\</%UMHD7B2/QSXR\;:O\-M:NO#'@KPK\
M._#>HZI\+6UZ/P1J4^B>#O"-AI5K8W^D7.AW$]S=ZWJ.DWWB"+2]5TW]6/#?
MA_2/"?A[0?"WA^P@TK0?#6C:9H.B:7:@BVT[2=(LH=/TZPMPS,P@M+.WAMX@
MS,1'&H))YK^5']N.S_X*O?\ !,;_ (*<^.O^"B'[/?PW^.__  4+_8$^/7A3
MP]HGQC_9H\+^-O$'CWQM\ M8M/\ A&-.UO5/AA\-)[;Q%X@T;2530I_%>@WW
MP^T*Z\(K;7FO>'/B=)X3TS2O"'B&8 QO^"[7_!"G]B#0_P!A3XH_M8_L?_"3
MP9^QO^TE^QGX>O/V@? GCKX"6+?"^WUVR^'UQ:>)O$&A^(;/PC! DFN6^F:9
M/K7P]\6Z=%IOBGPQXXTO0FM_$5EX?N]>L[S]0/V1?^"G7A>Q_P""(WP:_P""
MF/[5GB:U@L_#_P"S3I7BWXM:[:0W%K+XJ^(/AR_;X:SZ=I=I<0*1XF^)/Q+L
M;30=&LHT_LZ;Q-XEL[6SN&TV2&Z/XD_M@?MR?\%1O^"X/P>U+]@/]C[_ ()>
M_M'?LA?#SXUZIH/A[]HO]I_]K_1=8\ >%O!WPUMM=TW5-<T7PW_:GAW0++4+
MJ[%OIESXDCT"_P#&'C.\\+MJ7A_1/ +SZY;^(M-_I3\ ?\$S_P!EGP[_ ,$]
M/AU_P31\?^!K;XM?LV^#?AO\/_ 7B3P]XDN=7T<_$/4/ VO:'XYE\8:[+X:U
M?3-0L-8\1?$S1(_B#J5MH^I6EA%K-S-9V\*:3BQ(!_-+_P $+/VD?V+?&?Q'
M_:&_X+$_\%%OV[/V&_"O[<?[8'B;5]$^'WPO\?\ [2WP-\'Z[^RO^SYX7U&Z
M\.:'X#T+PIXE^(-GKWA>Y\3:;I&BZ<G_  D.G/XI_P"%?^$_"5W>ZM/K'C/Q
M[<Z[P/[+/[;O[%_A[_@[ _X*2_M&:_\ M=_LP:'^SYXZ_8@\"^$_!'QVUCX^
M_"G3/@UXQ\56?@W]@>UN_#/A7XGWOBR#P3XA\06MSX.\76]QHVD:Y>:C!/X5
M\20RVRR:'J:VO[R_\0XO_!$[_HP;X<?^%O\ &;_YY5?@-\ O^""W[-NJ?\'"
M?[;OPJ^(_P#P3S\9Q?\ !-'PW^ROX3UOX ZIKWA;XZ:/^S]<?&"?PS^R)-K,
M/@KXROJEE8^*O%*ZMKWQK%WX?A\<ZQ+;W,'BV Z;$?#<L>E@']T&DZMI>O:7
MINN:'J6GZSHNLV%GJND:QI-Y;:CI>JZ9J%O'=V&I:;J%G)-:7UA?6LL5S9WE
MK-+;W-O+'-#(\;JQT*P/"GA?0O!'A?PYX,\+V/\ 9?AKPEH.D>&?#VF_:;R]
M_L_1-"L+?2]*L?MFH7%W?W7V6QM8(/M-[=7-W/Y?FW,\TS/(V_0!_'[_ ,&8
MEL%_X)]_M87FM-='QY/^WS\1+;Q6FK75V_B!5M?@E\!);9M9L;Z9KJWN6UB[
M\2"2ZNK>.[N[U+Z&YFGDLMEO]!_\'!O[6/Q)\7^-_P!EW_@C/^SE\-O@]XL^
M//\ P4+U.WNM:\=_M$_#?0/BK\*OA/\ "K0]4U8/XITKP5XET7Q3HFH_$"SU
M?POJGB6T\2:IX5\1IX#T+PA?WVAZ'/XQUWPUXE\&^&?\&_T%U^Q[_P %0?\
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M_B.R\*Z5JB7TDNIW_AJUOH])LVGU2UTD_:9;/Z"_X('_ /!-_P#:@^ /B?\
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M:E:76F-:3_!KP%XT\4 'S#^SSXM\9_\ !&#PO\)/AD?@9K'_  4*_P""[_\
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MOX/\7>+?')\&P:CJ!\):1X-OOA@VAW-K+>:[I^M_\)3HU[HOB.YN;#Q%I.C
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MX+%_\%!=%_X)G?\ !/\ ^-W[3+W>GCXCQZ6OPZ^ >BZ@MM.GB+XZ>.K6_LO
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M544 *JA5 Z!5& ![ #%?QR^*?'W_  5G_P"")7[=7[3_ ,1=4^ 7[3__  5
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M*RV2P6ZP""/\I_\ @MG\1/B5_P %//V\?AI_P0/^ 7ASX.^$$'@T?'G]I?\
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MV,<PLYPOW+_P2A_8#\)?\$U?V&O@M^R_H(L[[Q9HF@P^*/C+XKLY9;F+QO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBV2R(DC"2<2S$AI"!_4-^VG_ ,F<?M9_]FS_ !X_]5;XJKX9_P"""'_*(O\
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MW9_/3_Q#%_\ !+K_ * GQZ_\/7K'_P K*/\ B&+_ ."77_0$^/7_ (>O6/\
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MM;_Y+R_/NP^K4/\ GS3_ / 5_73\^[/YZ?\ B&+_ ."77_0$^/7_ (>O6/\
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M_/NP^K4/^?-/_P !7]=/S[L_GI_XAB_^"77_ $!/CU_X>O6/_E91_P 0Q?\
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M ,$NO^@)\>O_  ]>L?\ RLH_XAB_^"77_0$^/7_AZ]8_^5E?T+44?Z[<7?\
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M7_0$^/7_ (>O6/\ Y65_0M11_KMQ=_T4><?^%M;_ .2\OS[L/JU#_GS3_P#
M5_73\^[/YZ?^(8O_ ()=?] 3X]?^'KUC_P"5E'_$,7_P2Z_Z GQZ_P##UZQ_
M\K*_H6HH_P!=N+O^BCSC_P +:W_R7E^?=A]6H?\ /FG_ . K^NGY]V?P\_\
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M_A;6_P#DO+\^[#ZM0_Y\T_\ P%?UT_/NS^>G_B&+_P""77_0$^/7_AZ]8_\
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ME"E[22E>?LXMQC>]HMK9F4*%%U:J=*#4?9V7*K*\;O[[:_\ !9_/7_Q#%_\
M!+K_ * GQZ_\/7K'_P K*/\ B&+_ ."77_0$^/7_ (>O6/\ Y65_0M17SO\
MKMQ=_P!%'G'_ (6UO_DO+\^[-?JU#_GS3_\  5_73\^[/YZ?^(8O_@EU_P!
M3X]?^'KUC_Y64?\ $,7_ ,$NO^@)\>O_  ]>L?\ RLK^A:BC_7;B[_HH\X_\
M+:W_ ,EY?GW8?5J'_/FG_P" K^NGY]V?ST_\0Q?_  2Z_P"@)\>O_#UZQ_\
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M_A;6_P#DO+\^[#ZM0_Y\T_\ P%?UT_/NS^>G_B&+_P""77_0$^/7_AZ]8_\
ME91_Q#%_\$NO^@)\>O\ P]>L?_*ROZ%J*/\ 7;B[_HH\X_\ "VM_\EY?GW8?
M5J'_ #YI_P#@*_KI^?=G\]/_ !#%_P#!+K_H"?'K_P /7K'_ ,K*/^(8O_@E
MU_T!/CU_X>O6/_E97]"U%'^NW%W_ $4><?\ A;6_^2\OS[L/JU#_ )\T_P#P
M%?UT_/NS^7S_ ((7_ #X>_LM_P#!0C_@L=\!/A5#K,'P_P#AKXE_9ET#PQ%X
M@U:77-833UM_C7=A;[59HXI;V;SKJ4F5XU.TJN,**_J#K^>C_@EU_P I<?\
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MX\!_#'Q?\>M$^#'P$\8^*OA9^R/\*%\!>&[WQM>_!KP5HW@+7/"^N7XTW1M
MM/".G?&F'3-!\3^(-6TVU\=>,_#'B35[J[27S;_@F7X<_P""I/\ P7B_83^$
MGQ)_:&_;^^,_[&WP.^']MKGP<BU#]E:2S\)?'K]L;Q3X.\3W5OXB^-?Q'^*-
ME-I\_@GPMI_AJXLOA"O@/2K+6(?'GC[PSX\^(_B>WT[2[O0= U, _M*HK^,[
M_@DYXB_;;_8/_P""YOQ\_P""2GQ?_;0^)W[:O[.]S^SYJ_QU\"ZK\4]9U[Q[
MXQ^']U=2^"==\*MK>K>*M6UG5_A[J,6D:UK.B>)=!T#7+SP-XJOM:\.>,(-
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M:UX:?<WFGKKWAJ]FN=!UM;"\O+%=5TZ[6SO+JV$5Q)_-!K7_  5$_P""M_\
MP51_:)_:(^#'_!%+PW^RY\(_V<OV8?B!%\-O&7[9'[2-]K.MWGCSQI8QZ]/-
M_P (EX8/A3Q.-$\)ZV=-DL;/3(?A%\0-;^SPZ#XHU'QKX2M/$[>'],_>#_@E
ME^QS>_L _P#!/W]F']DC5M9T[7_$/PC\ 2P>+]6TBQ@T_2KKQQXQ\1:Y\0/'
M TV*W=UN+"W\7>*]:M;35)2+O6;>&/5KY$O;V=%_D=_8:_;I\ ?\&P_[2/[6
MG_!-?]M?25UC]G'XB_'+Q9^T1^SM\8_@EXK\"?%7QKX>T7Q'X7\*:+H-E\;O
MA'I?BZ3XG> !XK^'OA7P'#8Q>(M+@U>U\86&J7&A:;XU^'FNQ_$C3 #]&OAA
M_P %5_\ @J;_ ,$]OVU_V6?V+?\ @M/X$_9K\9?#_P#;)U]_AU\!OVN/V9;G
M5M.@F^),6N:!X7^S>-- U*'0[>\T0^(?&7P^T[6I?^%:_"S_ (12R\;6OBE[
M_P 1:=8:KI.C_P!8_7I7\('QL_; \/\ _!S-_P %%OV(?V>/V0;6/P+^R7^Q
MC\5K;]I3XU?%#XI>+/AQX-^,OCQ?#FI^'+N_C^%_P1O?$^I_$.Y\.6]AIMKX
M.TSQ=!X=UNPL_%/Q!AU3QUHOA_2O#>GQ>(_[J-<UO2/"V@ZQXDU^_@TO0?#F
MD:AK>M:I=%EMM.TC2+.:_P!2O[ED5F$%G96\UQ,51F$<;%5)P* /YXOAS^TU
M\?\ ]IK_ (.0?C;\"O!OCCXFZ-^R)^P!^R#X=TSXE>!]/\47?AWX:>,/VD/B
MNVFZ]X>U[7_#%E>>?XWO&\&?$/7-&TJ/Q!8IH>F:E\*)M=L(X+ZVT+4M?_HT
MK^7G_@V \/>(?BW\'OVY?^"E?CR;[1XU_P""BW[9WQ*\?:>;F_DU+5M-^%OP
MVUW7]#\%^&M5FDRFG#POXK\2?$K1="\/V4MSI6C^%K;0ETR:&VN!I]C]T_\
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M71?';>%-0\:^-+C4=<O==\4:=IWC^+_A&O"J>%U$.I'Q?%KFD_O/^P__ ,'
MOCCQG^V?IG_!.C_@IM^QSXC_ & _VK_&RVLOPD:Z\07'BWX:?$JXUA3)X<\/
MV>K'3PEAJ'B/[-J]CX6\1Z7K?BKP1XDUW1=1\+?V]H_BT6/A_4 #^FBBBN;\
M9>*M)\">$/%7C?7WGCT+P;X;USQ5K4EK ;FZ32?#VF76KZD]M;*5:XG6SLYF
MA@5E,L@6,$%LT ?SS?"[]KSXR_MY_P#!??XJ? _X0?%3QGX5_8F_X)8?"G4]
M'^,NE_#SQ!?1>$_V@/VL?B:Z^'#X0^*KV,&G+)H7PQN;7QEIFB^%;ZXO)K#X
MA_ OQ7>PSZCH/B_5].T[Z-_X+.?\%9=;_P"";7A'X _#/X$?"G2?C_\ ML_M
ME_$<_"']E_X/Z]JUYHOABX\1W5QHWAZ'Q?XROK5M/BN]%L?''C/X?>&[7PC-
MXM\!7OC"X\27;:=XPT.P\.^(-6TS\XO^#0SPU>>)OV*/VJ?VL?&)FOOBI^U7
M^VO\3_%OC+7Y-/DL8M5M-"T7PS-;)9R323R:A:Q>,?$_Q!OS=B<Q0W6JW6F>
M7]HT^YN;KIO^#C_X'_%_X7>/?V#/^"O_ ,#4^&VNZQ_P3K^)-]<_%7X??%'X
ME^#_ (5:3XV^&WC'6/#MQI]MH7B[Q[K.C>'[36GO[+Q!X,32].&L^,M9U#XA
M:!>>%?#^M7OAN32[X X;QSXF_P"#MO\ 9Z\)^(OVJ/&&K_\ !-CXW^#/!^@:
M[XR\8?LF>%;'Q'::[IGA;1M"U'5]=;2M8;PK\/[V^U/1M/TJ>XTNUT[X]^*K
MZ\U:\L8$T?Q-;^?ID?[D?\$JO^"B7@7_ (*B_L7?#7]K#P;X=N/ VJ:]<:UX
M1^)?PYN[Y=6G^'WQ.\(7G]G^)_#L6L1P6\6L:/=(^G^)?"VJ^1:W=_X3\0:%
M<:OIVC:V^I:+IWX%_&/_ (/&/V#;G]GR\O\ ]FWP-\9/$7[4WC+2;7P]X ^&
M7Q/T#PE\._ W@?Q[XBAEL;+7OBG\4]9\8R^"+/P+X2U%H[[5+W2=0U(ZHGV"
MUO&\-Z/=ZWXG\,?HY_P;=?\ !/SQM_P3S_X)H>$O!WQ.U[0-8^)?[07Q!\0?
MM0^,[#P?XK\,>/?!7A:3XA^&/!7AGPCX?\*>._!MUJ/ACQA8_P#"NO ?@W6]
M5U[P_K&O^';CQ1K.OP^%_$?B'PQ!HVLWP!^^%?PR?&O_ (.3/VKO&_\ P6+^
M 7[.'[)UCX#M_P!@/QI^W#\(/V+)/B+X@\!P:_J_Q@\0Z9\3_A;X8_:(USPG
MXK.LR6^EV]I!\5-,M/"$FG).C^$[GP;XSN+>UU'Q)=Z79_K%_P ' G[;GQ=\
M,^#_ (3?\$M?V'FF\0?M_P#_  47N;OP+X9TW1-4EL-6^$W[/T\&M6WQ'^+F
MK:CI=T=8\)V^H6>C:_HVD^)I-/;3]-\*>'?B]XQAU*TU'X=0P7GXY?\ !47]
MBKX8?\$]OV@O^#3K]D_X4QP7.B_##]M=[/7_ !6-(M=&U/XB^.[[X_\ [!M[
MXV^(NOVEM/>>7K'B_P 0S7NJ26TNH:E_95G)9:':WLVGZ79A0#^\:BBB@ K^
M&3XV?\')O[5WC;_@L5\ _P!G#]DZQ\!V_P"P)XT_;@^$'[%LOQ%\0^ X-?U?
MXP>(=,^)WPM\,?M#ZWX3\5_VS);Z7;VMO\4],M/"$FGI.C^$[GP;XRN+>TU'
MQ'=Z79_K%_P<"?MN?%WPQX.^$W_!+;]A\S>(/V__ /@HO<W?@7PSINB:I)8:
MM\)OV?YX-:MOB/\ %O5=1TRZ.K^$[?4+/1M>T;2O$TFG-I^F^%/#OQ>\81:E
M9ZC\.X(+S\<O^"HW[%7PP_X)[?M ?\&GG[*'PIC@NM%^&/[:[V?B#Q6-(M=&
MU/XB^/+[X_?L'WOC;XBZ_:6T]YLUCQ?XAEO=4DMY=0U+^RK*2RT.UO9M/TNS
MV@']M?Q^^,7AS]G?X$?&O]H'QC;7]YX1^!?PD^)'QB\56>E1K+JEUX<^&7@[
M6?&NN6VFQ-A9;^?3-$NHK.-B%>X>-3P37\AS_P#!1+_@N]X9_P""?=G_ ,%L
MO$?Q+_8_\1?LVWUWX-^)5Q^P?H/PJNM*U*V^ FN_$6Q\#WLMO\<-2U&3Q5H_
MC-[5[#4;=9KWQU%;)K][J;Z=<3Z1;^"W_KI_:*^"V@?M)?L^_'7]G;Q7JNL:
M%X7^/?P;^)WP6\2:WX>:R77]'T#XI^"=;\#:QJNAMJ5K?Z<NL:?IVNW-WIC7
M]C>60O88#=6MQ!YD+_R6C_@F[_P7,UG_ ()^6G_!$36?"?['-M^S(LL7@"Y_
MX*"2_$;5[GQ+#\ -#^+NF_$70])LO@!8:+::Q-\2;?1=)/A>W6[MTT35-+N-
M/TS5/%VC>((=1^*$P!_3CX^_;B^!GPE_8>G_ &_OBEK4OA#X%V'P,\,_':_N
M+AK4:Q)HWC'0-'U?PKX4T>WU2XT:WU+QGXLU7Q!H?@[PGHMQ<:;)KOB[6M(T
M:-[>XOHPORE_P1V^-W[>7[57[/&M_M9?MM:=X5^&^D_M"^)[GQQ^S/\ L]Z)
MX/BTK7_A%\!;N_UB\\%W/C;QLUY'J'CG6O&FA:CHMY83:AX;\.7%MX?TG2-:
MN;2+4?%.HZ5H_P"-TOPS\/\ _!9?]MOX;_L%> X-?O\ _@CG_P $;V\)^$_C
M+XADU--2T+]LG]IKP)X9TWPKX$^$$^NV]U'I7B7PA\,M-TBZ?Q;=:/IUY))I
MUSXNAU@:9#\5_A5X@T7^OFRLK/3K.UT_3[6WL;"QMH+.RLK2&.WM;2TMHEAM
M[:VMX52*"W@A1(H88D6..-%1%"J  #^:S]HG]J?XS_\ !.G_ (+Q_LV^$_B-
M\:/&7B;]@_\ X*A_#S7/ ^@^#OBK\3+^[\(?L\?M.> )K2WDN_A7:^(;66TT
M?PSXTU+5/AIHTWA7_A(HU?Q#\9-9DTU=-T7PCX+\*77]+G7I7\J/_!W[\/=7
MU/\ X)D?#OXZ>$;G^QO&W[,?[6_PA^)FD^)[>TN)]4TC3]7TOQCX*:/3KB,/
M;:<S^,M>\!ZRUW?Q/;//X?M+-3]HNH4D_IB^"WCZU^*WP>^%/Q0LGMY;/XC?
M#CP3XZM)+1HWM)+;Q9X:TW7H'MGAO-1A:W:._4PM%J%]&8RI2[N5Q,X!Z911
M10 4444 %%%% !1110 4444 %%%% '\]7_!?OI_P2U_[2>_L[_\ I5?U_0FG
MW%_W5_D*_GL_X+]]/^"6O_:3W]G?_P!*K^OZ$T^XO^ZO\A7U.;?\DSPGZY]_
MZGT3&'\:O_W#_P#26.HHHKY8V"BBB@ HHHH **** "BBB@ HHHH **** "OX
M9/CM_P ')O[5WC#_ (+!_ C]G']DNQ\!V_[!/B[]MKX1?L8W/Q%\0^ X/$&K
M?%[Q)IWQ,^&/AK]H/6/"?BK^V7M],M[2V^)^G6GA&33TF63PK<>$/&%Q;VFH
M>(;K3+3]9O\ @X"_;>^+?A+P7\*/^"7W[$1E\0_M_?\ !12ZNO ?A33-$U.2
MQU;X5? 2XAUBU^(WQ:U6_P!,NO[8\*V][9Z1KNCZ5XE?3GT_3O#'A_XL^+HM
M1M-0^'T,%W^-7_!4G]BCX9?\$]?C;_P:E_LI?"V."ZTKX:_MLFV\2>+!I-KH
M^I_$3Q[?_';]AJ]\;?$+7K6VGO"NK>+/$$MYJ3P2ZAJ)TNS>ST6VO9;#3;0*
M ?WAW5U;6-M<7M[<06EG:0375W=W4T=O;6MM;QM+/<7$\K)%!!!$CRS32NL<
M<:L[LJJ2/Y!O!O\ P4Z_X+/_ /!8GQY\;]0_X(U^'?V3?V>?V.?@K\3-5^$>
MF?M-_M.2>)-:\7_%;Q;H*IKL^HZ7X</@SQ?<^%--U;P?JW@W6%\(ZE\%[S4/
M#T7B>V6_\>W^H7%UIOAG^M[QAX6TGQSX2\4^"M>2>30_&'AS6_"VLQVLQMKE
M])\0:9=:3J*6]PH9K>=K.[F6&95)BD*N 2N*_A#_ .";G_!4'P'_ ,&Z_B'X
M\_\ !*C_ (*-VL>J:#X!^+GB_P ?_!KXX_L^ZUX$^+!O?#OC 65__9'Q3^&?
MACQC>>//ACJ&N6Z:?XR\+V?BJP7Q0;/Q3-IFM:!I6FZ1I>MZR ?I[^S!_P %
M6?\ @I-^R=^WS\!_^":W_!9CX<? *^UC]I73=7M/V>OVM?V<KV]A\.^-_$UE
M?ZK:Z1:>-O#ERUA L'BG4].;PQID^F>!/AMK.B:KJG@U=:\$7&F:[J?B72/Z
MH:_A=L/VC;/_ (.4O^"P7[$WBS]G/3H?AU^Q=_P2S\>WWQWU7QC\0/&_PTT'
MX]_$OQ=8^*/ASXPMK_P_\!X_$>L_$&+X=>*O&OPY^&7A>UUVZT@Z-I/A<>*-
M4\0>(_"_C[5M#^'H_L(_;1^/UG^RO^R-^TO^T?>R0H?@G\#_ (F?$?3HIQ&R
MZAK_ (8\):IJ7AG1T2<&![C7/$4.EZ/:QW&+=[F^A2=DA9W4 _&7_@E?^TU\
M?_VU/^"JG_!7GXJZKXX^)LG[(G[._P 0?"/[)7P!^'6K>*+NS^&]AXY\!"[T
MCXP^(=&^'UM>36DNN:Q?^#=!\8+XF\0VT&N66F?$/^S-/%K'?ZWHVD_)'[4O
M_!0'_@LW\9O^"QW[5'_!.S_@F+XM_9<T[PO^SI\*?AI\1M:O/V@O#-HVGV<O
MB'P/\+=1U_2].\3Z%!X@UK4[YM?^(2A+&^T.(:;/I^O65W?6JVFE07OW5_P;
M,?L^ZO\ !+_@D[\'?&OB[4%UGXA_M7^*?''[6/CW7'U&ZUF_UO4/BSJ40\*:
MGK>LWX%]J?B*Y^&NA>"/^$AGNS+-#K*WME]JODM4OKG\$_@[\:_^"D/[-O\
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MP52_X*__ +5'@']KWP#_ ,$L_P#@E1\&/!WQX_;F\8:%IWC'XH>+/&TM_?>
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MO@NV\(^'=.U6XTOX=:-KOPKUWQ/\/+&"]T?1O'5QH_B2XM-'^]/^"??_  1
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MF7/@^VU/2+3Q+:@'XK?MZ_LT?\%8_P#@W[^!5S^V3^S7_P %=_B%^T=^SO\
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MXB6PU;7?$.H+K>H>(K;S?[4*)H]M<B^OM2_7>@ HHHH **** "BBB@ HHHH
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M)^ _[4.G_MZ?MQ_M<?%?_@HU^VGH&CMH_@#XA_%?2QX=\ ?"6UDBN8X7\">
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M??\ "X?.^(/P&\=_\(M_PD/_  L7P7_PK[;_ ,*2_LK^V_[#\;Y_X2;[=_9
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M-8+X!\#07_P%^*5[J1O- TOP?H%QXC6\T"\DT[P[="2SEE\3:X]QX7_P5_\
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MHOM!M/$7A#POJ_B!+B6TU+]HCX=ZHVGV^CZO;MX@_K?1!&B1KG:BJBYY.%
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MLH]?ATG^QI[RUGLK>^EO;6]MK;[BK^<?]MG_ (( W'Q1_:M\0?MZ_P#!/?\
M;1^+'_!.W]K3Q[-(_P 6]5\&Z4?&_P *_BF]Y8W&FZKK&J>"4\0>$[K2?%&K
MQW0O]:NKC5?$WA/4]5TZTUJ#P1I7B^ZU'QC< 'E/_!WK-\'XO^"1.O)\1;71
M;CQY<?'3X3P_ N6]:-=8LO'@O=3F\176B@7,%PZ-\,8?&]IJ2B.[L_)NX&N;
M87*V%U;?KE;_ +5W@C]AG_@FG\(/VE?VU[WQ)\.-"^&WP'^ ,/QHN8?"'C#Q
M=K?A;Q?XHTOP3X,N+'4M T&R\1>(EE3QOKUKI%Y-="?[-<S*MY>-,RF3\LO@
M%_P;Q>*O$/[17PN_:F_X*H?M_P#Q@_X*5>/O@9J2:S\&/AOXO\-+X$^"7@G6
M+>Y@N[;4M2\*3^*_&1\22C4M-T3Q#-9Z5'X'TO5=7TC3H/&%AXRTZQ2&?^B;
MXK_"?X<?'+X9>./@U\6_!^C^._AA\2?#&J^#?&W@W7(7DTK7O#FM6CV=_83&
MWDM[JTD\I_,LM0T^YM-2TN\BMM1TN\L]0M;:YB .*^&7C;X%_M?_  2^%WQN
M\)V/AOXH?"3XP?#[0_'W@'4O$_A:WNDU'P=X^T.QU:T-UH?B73VO=(N+[3+F
MV@UK1-2L[6^M+B*33M5M(KFUD@C_ ),/VY_AQ\-/^"='_!Q1_P $O?'/[%.D
M6_PBU[]MN3Q#X'_:N^"WPRB;P]X$\?\ AG7?%]YI1^(GB/PAI-NVFO=ZE=ZS
MJ/B"^6&UM](36OA/IGB5+73]:;6]:O\ W71?^#=+]MK]E>\UGPC_ ,$U/^"U
MG[1G[,_[.FJZA=ZEH_P%^(/@N3XIZ3X"N+K4+_5KH>%=1@\=^'?"]LNJZEK&
MI76JSZ/\.O"NJ:E(EG/XCU/Q/>QQ7EI]Z_\ !.+_ ((4_#3]B;XZZ[^V1\=_
MVC/C%^W;^W#XAT[5M%?]HKXU7.H6">&]%UVTM;75[/P9X*NO%/C232;J]BCN
M[$:GJOBSQ!=:;H-]/X?T$:/IMSJ46I '[NU^9/\ P6@\(WWC;_@D]_P4)T33
MGV7$'[*7Q?\ $SMMA;_0_ _A:]\:ZBN)[FT3Y]/\/W29$S2KNW06]W.([2;]
M-JYWQAX7TKQQX2\4>"M>2>30_&'AW6_"^LI:S&VN7TKQ!IEUI.HI;W"AF@G:
MSNYA#,JL8I"K@$KB@#\7_P#@W \?Z+\1/^"+_P"P_J6BSV\B^'O 7B3P#J<$
M-P\TMIK/@#X@^+?"&HQ722V]I-;333Z.;U('A*?9KJ"6UN;ZSEM[ZY\K_;V\
M&_\ !)O_ (*^?M3>*_\ @DE^U)X=^(>E_M;_  .\#R_%KP5XYT;38? 'C/PA
MX=UBR\":M>WGP=^*M[#XA\+>,8_$GA_Q=HEWK'@'6_#WB[1)K?3=6U35_"UI
MXG\"17^@?,?_  ;<ZAXN_9$^(G_!1'_@C;\8-8NY_&_[&'Q^O?B3\'&UAO#\
M-SXK_9X^,T4.K>'O$6A6VC:A=7#Z??S)I7Q+U6'4X5O]$;XSZ)I=Y/%<[]%T
M7]!_^"GO_!%7X8?\%#/B/\+OVF? 'QU^*W[&G[;/P1TQM$^&/[4/P7E>XUBV
MT/[1?W%KHWC#PS%K7AB[\06&EG6O$4.G3:#XP\&:O)9>(M7T?6M5UG0);?2+
M8 _.GQ-_P0V_X):?\$F_ /Q(_P""C7Q\^)7[0O[3_B;]E?X::QXF^"T_[8WQ
MC\&^,M \#^*O",6NZE\)O#/PX\+VOA#X>>&-?\<:GXGU#2M!\"Z!XZ?Q/X87
MQW=Z9KWAKPSX>UO[->6?=_\ !OQ^QAK<'_! &Z^%WCCPS?\ AS5/VV_!'[27
MC2YTK4VL;R>_\(?'S2?$'@WX?ZY'8:A_Q)8+#Q7\,(O"7B'3;*XGET^YT_5;
M:ZU(VTMY>VEMQ^F?\&Z7[2W[2?Q"^'-S_P %9O\ @JK\7OV\?@#\)?$"^-O#
M'[.NG^!V^%?AKQ/XT62TA2[\=:W#XRU][O01H]O?:+=V.F:+;>*IK'7M2AT+
MQQX3AGU>'Q!_5'HNBZ/X;T?2O#WA_2]/T30=#TZRTC1=&TJT@L-,TK2M.MX[
M2PT[3K&U2*VL[*RM88K>UMH(XX8(8TCC144  '\N/_!I%\:=-UK_ ()T>-/V
M4->?4?#OQE_8U_:#^*O@/XB?"[Q3 ^C>-/!FG>.O%FL>/=$O=3\*WU_+K.AZ
M;J'B+5/'/AQ/[3TCP[(WBOP;XRTT:;+/I%UJ-ZS_ (.WOC=H^C?\$Z?"/[)G
MARZ'B#X[?MA?'_X7>!OAO\+M'DM+GQ=XHTOPUKB^(M2U6QTJ6.2YGTZW\6V_
M@3PN)+1[:ZFUSQ9H]M#)-;'4HU]D_;)_X-_;_P >?M7^,?V[?^"<W[:OQ/\
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M#H_Q'^+8_:3L;6+3+?Q;!\8;KQOJK6EQXX2PCCEN+N;X8Q?#ZV\*7M\9KL^
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MUXN-N-7UZ?3$U/7[C0M%C2V5].\/S>)->^SW]WK.L7&I7>JZ[JEW<@'X3?\
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M_P S]\**_ __ (B7/^"27_1:OB!_X8_XI?\ S.4?\1+G_!)+_HM7Q _\,?\
M%+_YG*/]2^+O^B:SS_PV8O\ ^5!]8H?\_J?_ (&O\S]\**_ _P#XB7/^"27_
M $6KX@?^&/\ BE_\SE'_ !$N?\$DO^BU?$#_ ,,?\4O_ )G*/]2^+O\ HFL\
M_P##9B__ )4'UBA_S^I_^!K_ #/WPHK\#_\ B)<_X))?]%J^('_AC_BE_P#,
MY1_Q$N?\$DO^BU?$#_PQ_P 4O_F<H_U+XN_Z)K//_#9B_P#Y4'UBA_S^I_\
M@:_S/WPHK\#_ /B)<_X))?\ 1:OB!_X8_P"*7_S.4?\ $2Y_P22_Z+5\0/\
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M_P#Y4'UBA_S^I_\ @:_S/WPHK\#_ /B)<_X))?\ 1:OB!_X8_P"*7_S.4?\
M$2Y_P22_Z+5\0/\ PQ_Q2_\ F<H_U+XN_P"B:SS_ ,-F+_\ E0?6*'_/ZG_X
M&O\ ,_?"BOP/_P"(ES_@DE_T6KX@?^&/^*7_ ,SE'_$2Y_P22_Z+5\0/_#'_
M !2_^9RC_4OB[_HFL\_\-F+_ /E0?6*'_/ZG_P"!K_,_?"BOP/\ ^(ES_@DE
M_P!%J^('_AC_ (I?_,Y1_P 1+G_!)+_HM7Q _P##'_%+_P"9RC_4OB[_ *)K
M//\ PV8O_P"5!]8H?\_J?_@:_P S]\**_ __ (B7/^"27_1:OB!_X8_XI?\
MS.4?\1+G_!)+_HM7Q _\,?\ %+_YG*/]2^+O^B:SS_PV8O\ ^5!]8H?\_J?_
M (&O\S]\**_ _P#XB7/^"27_ $6KX@?^&/\ BE_\SE'_ !$N?\$DO^BU?$#_
M ,,?\4O_ )G*/]2^+O\ HFL\_P##9B__ )4'UBA_S^I_^!K_ #/WPHK\#_\
MB)<_X))?]%J^('_AC_BE_P#,Y1_Q$N?\$DO^BU?$#_PQ_P 4O_F<H_U+XN_Z
M)K//_#9B_P#Y4'UBA_S^I_\ @:_S/WPHK\#_ /B)<_X))?\ 1:OB!_X8_P"*
M7_S.4?\ $2Y_P22_Z+5\0/\ PQ_Q2_\ F<H_U+XN_P"B:SS_ ,-F+_\ E0?6
M*'_/ZG_X&O\ ,_?"BOP/_P"(ES_@DE_T6KX@?^&/^*7_ ,SE'_$2Y_P22_Z+
M5\0/_#'_ !2_^9RC_4OB[_HFL\_\-F+_ /E0?6*'_/ZG_P"!K_,_?"BOP/\
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M_@:_S/WPHK\#_P#B)<_X))?]%J^('_AC_BE_\SE'_$2Y_P $DO\ HM7Q _\
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M_@:_S/WPHK\#_P#B)<_X))?]%J^('_AC_BE_\SE'_$2Y_P $DO\ HM7Q _\
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M?\4O_F<H_P!2^+O^B:SS_P -F+_^5!]8H?\ /ZG_ .!K_,_?"BOP/_XB7/\
M@DE_T6KX@?\ AC_BE_\ ,Y1_Q$N?\$DO^BU?$#_PQ_Q2_P#F<H_U+XN_Z)K/
M/_#9B_\ Y4'UBA_S^I_^!K_,_?"BOP/_ .(ES_@DE_T6KX@?^&/^*7_S.4?\
M1+G_  22_P"BU?$#_P ,?\4O_F<H_P!2^+O^B:SS_P -F+_^5!]8H?\ /ZG_
M .!K_,_?"BOP/_XB7/\ @DE_T6KX@?\ AC_BE_\ ,Y1_Q$N?\$DO^BU?$#_P
MQ_Q2_P#F<H_U+XN_Z)K//_#9B_\ Y4'UBA_S^I_^!K_,_?"BOP/_ .(ES_@D
ME_T6KX@?^&/^*7_S.4?\1+G_  22_P"BU?$#_P ,?\4O_F<H_P!2^+O^B:SS
M_P -F+_^5!]8H?\ /ZG_ .!K_,_?"BOP/_XB7/\ @DE_T6KX@?\ AC_BE_\
M,Y1_Q$N?\$DO^BU?$#_PQ_Q2_P#F<H_U+XN_Z)K//_#9B_\ Y4'UBA_S^I_^
M!K_,_?"BOP/_ .(ES_@DE_T6KX@?^&/^*7_S.4?\1+G_  22_P"BU?$#_P ,
M?\4O_F<H_P!2^+O^B:SS_P -F+_^5!]8H?\ /ZG_ .!K_,YK_@OWT_X):_\
M:3W]G?\ ]*K^OZ$T^XO^ZO\ (5_$K_P5I_X+1?L!_M8C]A3_ (4I\2?%FO\
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M@?\ AC_BE_\ ,Y1_Q$N?\$DO^BU?$#_PQ_Q2_P#F<H_U+XN_Z)K//_#9B_\
MY4'UBA_S^I_^!K_,_?"BOP/_ .(ES_@DE_T6KX@?^&/^*7_S.4?\1+G_  22
M_P"BU?$#_P ,?\4O_F<H_P!2^+O^B:SS_P -F+_^5!]8H?\ /ZG_ .!K_,_?
M"BOP/_XB7/\ @DE_T6KX@?\ AC_BE_\ ,Y1_Q$N?\$DO^BU?$#_PQ_Q2_P#F
M<H_U+XN_Z)K//_#9B_\ Y4'UBA_S^I_^!K_,_?"BOP/_ .(ES_@DE_T6KX@?
M^&/^*7_S.4?\1+G_  22_P"BU?$#_P ,?\4O_F<H_P!2^+O^B:SS_P -F+_^
M5!]8H?\ /ZG_ .!K_,_?"BOP/_XB7/\ @DE_T6KX@?\ AC_BE_\ ,Y1_Q$N?
M\$DO^BU?$#_PQ_Q2_P#F<H_U+XN_Z)K//_#9B_\ Y4'UBA_S^I_^!K_,_?"B
MOP/_ .(ES_@DE_T6KX@?^&/^*7_S.4?\1+G_  22_P"BU?$#_P ,?\4O_F<H
M_P!2^+O^B:SS_P -F+_^5!]8H?\ /ZG_ .!K_,_?"BOP/_XB7/\ @DE_T6KX
M@?\ AC_BE_\ ,Y1_Q$N?\$DO^BU?$#_PQ_Q2_P#F<H_U+XN_Z)K//_#9B_\
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M _\ #'_%+_YG*/\ B)<_X))?]%J^('_AC_BE_P#,Y1_J7Q=_T36>?^&S%_\
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M6KX@?^&/^*7_ ,SE'^I?%W_1-9Y_X;,7_P#*@^L4/^?U/_P-?YG[X45^!_\
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MZ%'PQ_X(-*_^1*Z>BCVE3_GY/_P*7^8679?U_P ,ON.8_P"$)\&?]"CX8_\
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M"#2O_D2NGHH]I4_Y^3_\"E_F%EV7]?\ #+[CF/\ A"?!G_0H^&/_  0:5_\
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M8_\ !!I7_P B4?\ "$^#/^A1\,?^"#2O_D2NGHH]I4_Y^3_\"E_F%EV7]?\
M#+[CF/\ A"?!G_0H^&/_  0:5_\ (E'_  A/@S_H4?#'_@@TK_Y$KIZ*/:5/
M^?D__ I?YA9=E_7_  R^XYC_ (0GP9_T*/AC_P $&E?_ ")1_P (3X,_Z%'P
MQ_X(-*_^1*Z>BCVE3_GY/_P*7^8679?U_P ,ON.8_P"$)\&?]"CX8_\ !!I7
M_P B4?\ "$^#/^A1\,?^"#2O_D2NGHH]I4_Y^3_\"E_F%EV7]?\ #+[CF/\
MA"?!G_0H^&/_  0:5_\ (E'_  A/@S_H4?#'_@@TK_Y$KIZ*/:5/^?D__ I?
MYA9=E_7_  R^XYC_ (0GP9_T*/AC_P $&E?_ ")1_P (3X,_Z%'PQ_X(-*_^
M1*Z>BCVE3_GY/_P*7^8679?U_P ,ON.8_P"$)\&?]"CX8_\ !!I7_P B4?\
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M6I/_ %9X3?/.[>?7?,[NV/HVOKT,H)>VK:?\^_\ TEG,_P#"$^#/^A1\,?\
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ME]QS'_"$^#/^A1\,?^"#2O\ Y$H_X0GP9_T*/AC_ ,$&E?\ R)73T4>TJ?\
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MDBKS1[2I_P _)_\ @4O\PLNR_K_AE]Q5_P"$)\&?]"CX8_\ !!I7_P B4?\
M"$^#/^A1\,?^"#2O_D2KWAWQ%X?\7Z!HGBOPGKNC>*/"WB72M/U[PYXE\.ZI
M9:WH&OZ'JUK%?:5K.B:QIL]SIVJZ5J5E/!>:?J-C<SV=Y:S17%M-)#(CG9H]
MI4_Y^3_\"E_F%EV7]?\ #+[CF/\ A"?!G_0H^&/_  0:5_\ (E'_  A/@S_H
M4?#'_@@TK_Y$KIZ*/:5/^?D__ I?YA9=E_7_  R^XYC_ (0GP9_T*/AC_P $
M&E?_ ")1_P (3X,_Z%'PQ_X(-*_^1*Z>BCVE3_GY/_P*7^8679?U_P ,ON.8
M_P"$)\&?]"CX8_\ !!I7_P B4?\ "$^#/^A1\,?^"#2O_D2NGHH]I4_Y^3_\
M"E_F%EV7]?\ #+[CF/\ A"?!G_0H^&/_  0:5_\ (E'_  A/@S_H4?#'_@@T
MK_Y$KIZ*/:5/^?D__ I?YA9=E_7_  R^XYC_ (0GP9_T*/AC_P $&E?_ ")1
M_P (3X,_Z%'PQ_X(-*_^1*Z>BCVE3_GY/_P*7^8679?U_P ,ON.8_P"$)\&?
M]"CX8_\ !!I7_P B4?\ "$^#/^A1\,?^"#2O_D2NGKSOX??%_P"$WQ;BUV?X
M5?%#X=_$V'POJTF@>)IOA]XV\->,XO#NNPHLDVBZ[)X<U/4DTC5HHW6233=0
M-O>(C*[0A6!)[2I_S\G_ .!2_P PLNR_K_AE]QN_\(3X,_Z%'PQ_X(-*_P#D
M2C_A"?!G_0H^&/\ P0:5_P#(E=/11[2I_P _)_\ @4O\PLNR_K_AE]QS'_"$
M^#/^A1\,?^"#2O\ Y$H_X0GP9_T*/AC_ ,$&E?\ R)73T4>TJ?\ /R?_ (%+
M_,++LOZ_X9?<<Q_PA/@S_H4?#'_@@TK_ .1*/^$)\&?]"CX8_P#!!I7_ ,B5
MT]%'M*G_ #\G_P"!2_S"R[+^O^&7W',?\(3X,_Z%'PQ_X(-*_P#D2C_A"?!G
M_0H^&/\ P0:5_P#(E=/11[2I_P _)_\ @4O\PLNR_K_AE]QS'_"$^#/^A1\,
M?^"#2O\ Y$H_X0GP9_T*/AC_ ,$&E?\ R)73T4>TJ?\ /R?_ (%+_,++LOZ_
MX9?<<Q_PA/@S_H4?#'_@@TK_ .1*/^$)\&?]"CX8_P#!!I7_ ,B5T]%'M*G_
M #\G_P"!2_S"R[+^O^&7W',?\(3X,_Z%'PQ_X(-*_P#D2C_A"?!G_0H^&/\
MP0:5_P#(E=/11[2I_P _)_\ @4O\PLNR_K_AE]QS'_"$^#/^A1\,?^"#2O\
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M&J1:9\7/B9I4?B2\_M.\FT_X?NR^(X]!U*VTJQXC_@UXG^(/[-WQ]_X*]_\
M!+?6?B3K_P 1_@[^Q)^TAI(^ <VN1V\LVC:3XF\8?&3PQXRG:<B&71_^$OM?
M _P\\47O@_1X/^$3TKQM=>/]<TI4O_$VJZCK?QO_ ,$D_P#@G_X*_P""KO\
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MH-+\1+X<U/4)M U&YMD-[9V.L165S>6#17]K%-9313O_  B_\$?O%7_!,/\
M:^_:C_;W^-?_  7*\5_ 2_\ ^"A_B']IOQ-X%T+X0_MB>,$L?AQ\-/AYI,4>
MEP>!_AO<>//%4/P:\37/A_Q?9ZS\,]$\/F#4O$G@70_ /AJ'PO=0V/CF5=0_
MIB_9J_X(G_LN?LY?\%#M"_X*-?L-?$QO@1\*/%7P@U3P%\0?V7_@MIVDWWP'
M^,USJEOKEK%XJ.LKX@U&PT'1+&^_X0KQ%8^%?!.AZ?IL/C#P#;ZU!J42>(O$
MVGWX!^ZM%%?FO_P5=_8RU#]O#]D'QA^S[)^U]XT_8T\#>(;^RN/BOX\\)V'A
M6ZT[QA\.8H;J#6?AYXVN?$5]X?N[#P?KUU<:?+K)T;Q?X=35K:S?P]XB77?#
M.KZKHEX ;GB?_@K;_P $N/!GBJX\$^)_^"A_[%^C^*++49='U32KG]I'X2L^
MB:M;:C<:3>Z7XANH?%4MCX>U'3=0M;BVU:RUNYL+G23$TFI16L)$A^]?#_B#
M0?%N@Z)XJ\*ZWI'B;PQXFTC3?$'ASQ'X?U*RUG0?$&@ZS9PZCI&MZ)K&G37.
MGZKI&JZ?<V]_INI6%Q<6=]9SPW5K-+!*CM_)'\0/V<_^#1_]E_\ 9T\<_ 7Q
MOXL_88UV;P7X!\4Z#XO\5:?\5_"GQH_:XEURUMK_ $OQ#J6G>*O"FK>*?B+:
M_&!-<M+RZL/"OA>STJ+PYKAATS0?!>@^'4L]&B]-_P"#2+Q]X]M?^",MUXA^
M,WBL2_#_ .'OQ[^.<?PRU#4M4O-03PE\$_#N@^#-:U:RNA/+<MIEEI7Q#F^*
M6HP:=:I';P:9<6T\%N&N&+@'])_PZ^/'P.^+^O?$?PK\)?C-\*/BCXH^#OBF
MX\#_ !=\-_#KXB>$/&VO?"SQK9WFIZ==^#_B/H_AK6-3U#P/XIM=0T36;"X\
M/^)K?2]6@O-(U.UEM%GL+I(CXO?'CX'?L^:#HOBKX]_&;X4?!#PQXD\4Z=X'
M\.^(_B]\1/"'PUT'7O&NL6>IZCI'@_1=8\9ZQHNGZIXIU33]%UB_T[P_8W$^
MK7UGI.IW5M:2P6%T\7\P?_!HGX=U;QA^R3^V9^V)XHMDLO%/[7G[<?Q+\7W-
MHD=S<^7I&@:1HFI*QUW4;:+4=9">,_'/CNR622XOK:(67GB=-5O=9MH*7_!R
M7!9_'S]LC_@A=^PS!>B:7XN_MK1_$KQOIJV4VIKIO@;P5KWPV\/W.L7FG;KB
MRNC<>'_$WQ#.FPWVDWEG+_8NJ+J.I:'I@O)+\ _J ^-?[0OP"_9K\*Z?XZ_:
M+^./P?\ @%X(U;Q!:>$]+\8_&OXE^"_A7X5U+Q3?Z=JNL6/AK3_$/CK6M"TB
M\\07FDZ%KFJ6FC6]Y)J-QIVC:K?0VSVVG7<L/DOB[]OO]BCP)\>/#'[+WBS]
MJ7X'Z/\ M%>,M=T;PSX=^"DOQ"\/W'Q)OO$'B(W2Z'I$WA2RO+G5=-OM5>TD
MCLH-4M[)II);*-?GU'3UN?YI/^#M&+6OCW=_\$F/^">_@B[>#QY^U9^VI%J>
MC7$ND6/B;0M D\,6_AGX2V/B#Q3X<O-6M[>_L+*?]H&[U..VU/2)]'O]%T+Q
M='?:WHMI:7<6I_LK^RK_ ,$/_P#@FO\ L::EX0^+6@_!>U\=?M"^!]8G^)'B
M']K/XV^,/%?CWXU^*_B=<::$\8_%?Q-XO\3^(+G3]*U?Q+<C4->URRT'3]#\
M*0:EJ>L:E;Z-;7.HZC<W0!^H7Q-^*WPN^"G@W5?B+\9?B3X!^$GP^T)8FUOQ
MW\3?&/AWP%X-T=9G\N%M5\3^*M1TK1-/6:0A(C=WT(D?Y4RW%> _ 3_@H!^P
MW^U+KDWA;]G+]KS]G#XV>+(!,\OA#X;_ !C\!^*O& @M[1[Z:\7PGI>N3^(9
M-/CM(;B<ZC'IK6.RTO<7!:QNQ#_&S\"_CY^P+_P7+_;(^,7[97_!5C]M+]F_
MX??L=_LT_%/Q!\)?V%OV!?B_^TCX*^!NE^*-,TZQT'5KC]H?XB^'/%OC'X=^
M-O$6G^,+>[T:^N(;C2$L_%'B./4/A]KVJ3^"/AE/X(UOS_\ X+U?"#_@BA\+
MOV:_#'[8O_!*3]HC]BSX/_MM_L^?%WX:^(O!VF?L5?M+?"H^+?%.AWVNVFBW
MMSI?PT^&GCC5&&N>"[^?2?&<'BCP_HFG7UAINE:__;5Y>V-XZ1@']\?Q1^+'
MPL^!W@37?BE\:OB7\/\ X/\ PR\+_P!F?\)-\1?BCXR\._#_ ,">'?[:UC3_
M  ]HW]N^+O%FI:1X?TC^UO$&K:5H>F?VAJ%O]OUC4]/TRU\V]O;:"3J/#_B#
M0?%N@Z)XJ\*ZWI'B;PQXFTC3?$'ASQ'X?U*RUG0?$&@ZS9PZCI&MZ)K&G37.
MGZKI&JZ?<V]_INI6%Q<6=]9SPW5K-+!*CM_(O_P=!?'/Q7\2/^"-?[(_@>"P
MT_3OBA^W3\=?V6-%N_"$4NHP?8GU?P#K?Q2U=;&PT>[\3-J%EHOC^P\$:#)8
M#4?$.P:S:W5C<:Q>VMI<2?UA?"KP!I?PH^%_PW^%NAR"71?AKX"\(> =(E%K
M;V(DTOP=X>T[P]8.+*S5+2S#VFG1,+6U5;>W!\F%1&B@ &+HGQX^!WB;XL^,
M_@)X;^,WPH\0?'3X<Z1IGB#XA?!;1/B)X0U7XL^ ]!UNST;4-&UOQG\.;#6+
MCQAX7TC5[#Q%X?OM,U+6]&L;*_L]=T:YM9I8=3LGGH?'#]HOX ?LS>$/^$__
M &B_C;\*/@5X*:X:R@\4_%OX@>%OA[HE[J A:==+TV_\5:II<&IZO-&C&UTC
M3VN=2NWVQ6MK-*Z(W\PO_!!RWLOC]_P5\_X+Z_MI6M\-3T)/V@="_9Q\ :L+
M*=TUG0O"7B?QOI^J7MKJ=X;MX]..C?#7X<7.GV5EJ0%S9:A;7&HZ-HD=MHMD
MOYS>&O'W[!_[2?\ P<$_\%)(_P#@NKXT^&>@C]GOQ)IWPH_87^$/[27BW4='
M_9WT_P"&FF:YJ]I8>)Y]4O?$^G_"K3;SQ#X E\#?$EO!7Q$^TZ1XAUWXO^+?
M%ATZV\0>#O,T\ _M4_9V_;@_8Y_:XNO$&G_LP?M0_ ?X^:IX3@@O/%&B_"GX
MH^#_ !KKOAZPNY$AM-3UG0M$U:[U?3=)O+AC:V>K7=E%IMW>1W%G;W4MU;7$
M47U+7\]>E_\ !#K]A'Q%^V!^R%_P41_X)V_$3PE^RF?@3K=Y=>---_9(LO"N
MM?"S]I/PC<3:0S^"=7DT;Q'+X)\,Z=JOAR;Q5X5\8:KX<T#4-6\5>'?&437%
MQ9:IX=\/:K;?T*4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 ?SU?\' G_(+_ ."7W_:47]G'_P!%^(Z_H47H/H/Y
M5_/7_P ' G_(+_X)??\ :47]G'_T7XCK^A1>@^@_E7U.;?\ ),\)^N??^I]$
MQA_&K_\ </\ ])8M%%%?+&P4444 %%%% !1110 4444 %?R??\%(_%O[8'_!
M3W_@J]H__!&W]G[XY_$']D7]EKX(?"+2/VA/VSOC?\-+/Q=X;^)OQ -Y!X5O
M[7X5>"/&*#2-&U.TETCXG_#&TM-+LM7E\.V6I>)_%WC#QE8^/+KX9Z3\.W_K
M!HH _B _;M_X(D_$C_@CG^SMXY_X*)_\$PO^"BG[:GAOXE?LVZ9!XX^)7PZ^
M/WQ"\*?$;P1\8? %OXA\/6E]X?O]/\,^#/AKX;FLM M;O5O$5[X<\>^%OB-I
M'BJ6UL;72X/"NM65IK$W]9'[!/[3J?MH?L7_ +,?[5)T6W\-W_QU^#'@7X@Z
M_P"&[-[F6P\.^*]9T2U;Q=H.F7-X%N[W2=&\3QZMINE:A<(DVH:=;6U[)'&T
MY1?YS?\ @N-^VQXD_;[^+6B_\$!O^"?.L0^,/C/\<?$NC:=^VS\7-$L-=UGP
M=^S5\(?"GB/0O$GB;1=8\1^%M4M5@UJTNM.T^#XJV-TMQHUMI%]#\';V:3QS
MX[NM(\/?TX_LO?L\^ _V3/V=O@M^S3\,H;B/P)\$/AQX5^''AV6]?S-0U"T\
M,Z5;Z?+K.J2;F$NK:Y=Q7&L:K*I"2:A?7+QJB,J* >/?\%$?VY/A1_P3H_9"
M^,'[5WQ;U*QAT[P!X?G@\%^&+BY:+4OB3\4=8BFL_A]\.- MH1)?7FH^)]?,
M$=_-96\Z^'O#-MX@\8:O]D\.^&]9U&R_BE_X(D:_^W_9_P#!>_PE<?MS?$CX
MD_\ "Q/VFOV4_BE^UWXC^#.N^+/&">&_AY#\;)I/%?@[PRWP\U?6[W3/!=SH
MOAN73I[#P1]AL[OX;V-_;^!KNRTW4O#]]9P_I3?*W_!P[_P5NLK>TN)]:_X)
M,_\ !)CQRTNKK-:Z_9^%_P!J_P#:XNX+I([6SFCO+?P_XJ\,^"-3T&RN6NIX
M=6?3?AW!=V:V5GI'[2,5_;[]P /^#Q2S & /^">1  Z #0< 4 ?UUU_++X7?
M6?VS/^#J#QQXBAUK1[OX6_\ !*3]CJP\(:9_8T2ZQ;M\9?VA="N!JECJ%Y<;
M[?2O$DGA[XG>-])UN[T2Y9[&+X9Z;X6O+.+4;CQ.;;^G7QGXP\-?#SP?XK\?
M^,]6M] \'^!_#6N^,/%FNW:SO:Z+X:\,Z7=:UKNK7*6T4]R]OINEV5U>3+;P
M33M'"PBBDD*H?YGO^#7CPO=_%#X'_MO_ /!2/Q7HVOZ?X]_X*+?MN?%WXE17
MNM00PVUW\+O!'B37;/P=IFBR1M.UYI_AGQWXL^+N@^=#=)IEE+9MH6FZ?:QZ
M-+=:@ >,?MJ6G[5W_!9S_@J]\5O^"7WA3X^?%/\ 9#_X)^_L=^#?"7C']H?Q
M-\*(O$/@KXG?M/>*_$=GX6NM4\&Z1K^J0VVGZCX;T"Y\1R:!I"ZCI.O?#_2=
M7T&^\?ZOX>^(T]Y\/8-*^2O^"AW_  2T^-__  0,_9^NO^"D7_!-#_@H-^UI
M=Z9\"/%G@*?X[? /]I_QKH?Q0^'_ ,6?#/CKXB^"_ .F&XL/".@_##0)K*#7
M-;T;1?$.AZGX2UCQ%?Z+K,^N>%/'O@35O#%O_:W]T5?QO?\ !8']J/6_^"R7
M[4?@O_@@W^P;KX\0>"O^$]TOQ7_P4=_:/T+3=6UWP-\(O!GPP\1Z3K[^"--U
MK1]1&@Z_K'AK7M,,FMZ7K-J- U'XRV_PO^'=GXIT77+3QM+X> /ZM_V;/C7H
MO[2?[.WP&_:)\-V%QI7A[X\_!KX9?&70M,NY'FNM.T?XG>"]%\::98W,KVUD
M\L]I9:U#!-(]G:,\D;,UM 28E^2_^"JW_!0SP/\ \$T/V-_B/^T1KQTC6OB-
M+;/X)_9[^&FH_;;FY^+'QT\1VMS#X%\'6VE:3-;ZSJ6FQ7<4FO\ BQ=*GMKV
MW\):/K,EI=PZ@;%9?M7X7?#GP'\ OA#\/?A+X'M+?PQ\,O@Q\.O"OP]\(V-S
M=!;3P]X&^'OANQ\.Z%:SWMTZA;?2M!TBUBENKB0 10-+*X 9J_E%_9PL[W_@
MX#_X*SWG[;NNIJ5W_P $M_\ @F#XQ;P/^R1X:UBQU>R\.?M,_M)6,MSJ.K?&
MM;&:X"SZ7X:UFV\-^-(WNSH]P_A[2O@5X=U?PJUYJ'Q9TM #X+_X-S(?VX_A
MO_P77_:L^!_[</Q<^*7C/XMQ_L#77QJ^(W@_QOXXU[7-/\->/_CGXI_8V^-,
MME=>')]3N?#>D>*_#%C\5;GPWK"Z)9P6>G:@NLZ?I7E:=((V_OWK^0+]D'C_
M (/)/^"IV./^, /AY_Z@W_!..OZ_: "OY._@AXSOO^"H'_!R7\<?%VJ+'K_[
M,_\ P1:^'NN_"KX8:)J<L=W9V'[6/Q6NV\$^.?&D>DVMG]@%ZUUX-^*GA^.7
M6=6U2YL;CX2^ /$.F:=I^M"3_A&/ZQ*_D)_X,_K^;XI_LU_\%!/VHM9TS3K+
MQ;\>/^"@7CZ[\17$5W?7^IM+:_#_ , _$ :9=WMZIDO-.TS4OBSK$FFW4TTE
M[<7%_JDMXB%HVE /T"_X*D?M,?\ !5/Q-^T9X,_X)V_\$M?@]X?\,>+?'?PD
M\%_%WXS_ +>GQ'>+4?A]^S?X$\;^./BGX+L=)TGP_J&CWNC2_$+4)OA1JM_8
M75W:^/=2N-(O+FST+X=IJ"#QOX8_+#_@VJTKX_?#O_@I/_P65^ /[0?[1_Q"
M_:<\6_ SQ1\/?"-[\1O'6M^)KV/7?$3>/?BZOBSQ+HV@^(O$7B7_ (1I?$VH
MV4%U>6EG?MYZVMF+AF^S0QP_VAU_(;_P0T_Y3F_\'$7_ &7#PE_ZLGXUT ?:
M_P#P<$_\%$_V@OV4OAK^S=^R+^Q LR?MT_\ !0WXKQ_!CX)>((H]$,7P]\/6
MVI^%]&\6^+4O=<>XTS1/$5_K'CGP?X9\-ZQKFF'1-%TG4?&_C:35]*O_  +9
MFX^)]0_X-5]9C^'TWQ'\._\ !67_ (*$V?[?MYI<.OZK^T#J/Q<N&^'^M_%"
M&:+6&U.?P_IUI;_&:QTN?6[+3FAU2?XYZ]K^FS6<6O#^TKJ"WTQ&_P#!19;3
MQA_P=<?\$9/ ?BV'4;7P?H'[-WQ%\?:/J<NJ3V6DW7C6VT?]K36-,TVR6:%+
M%=1AUWX>^"1J<5O<RWFLVVJ:3I<\$*_87N?Z]: /YZ_^#?W_ (*7_&K]L_X9
M_M$?LN?ME-:+^W9^P!\5[_X*?'K4[2"QM(?'^F6^L>)?#F@>.IK?2]/TO18/
M$T'B3P1XV\&>,K'0+>;3_M?AK2/%K'35\=6NB:;\9?\ !23X\?M<_P#!3K_@
MJS9_\$3_ -C'XZ_$#]ESX'_!'X9VWQ4_X*!_M _#2ZAT;QS>Z9X@TGPYK5I\
M._">OZ?KFF:M<:/)H_C?P%X0FT?2-9TVXUKQ1X[\:?\ ";>%_$'@SX87D&HK
M_P $S]3G\/?\'/7_  6V\"Z2HMO#WB3X5_"KQMJMMY]](9O$&F:=\(Y(KL+)
M=M;D23^/_$DQ66WE:V-V(-.>QM#/;SY7_!!I;3Q=_P %L/\ @XT\=^)(=1T_
MQMX:_:1\,^ ?#MCJFJ3RW-QX*C^+'[1ND7&I165Y#;W%QIUS9_#WP)>:1+%&
M]GH^E:C96%K/<6MW:W$P!XK^V)_P1$^/O_!(7X)^+/\ @H#_ ,$I_P#@H%^V
M-<^-?V7= USXL_%+X(_M'>/] ^)/@#XK_"_0;6'4/B3#>Z3X7\*_#GPM>V6C
M>$=*F\1:KX?\7>%O$C:G:^'8M1\/:[X9\7:'X9OXOZ?/^";G[;G@[_@HK^Q/
M\ _VO_!FFC0(?BSX1,WBKPD;F6\;P3\1_#.IW_A+XD^#DO+BVL;K4;#P]XXT
M/7=/T/6KG3M.?Q'H$6E>(HK"UMM6@B7Z;^,FFV6L_"'XJZ/J4/VG3M5^&_CG
M3;^W\R6'S[*^\,:I:W4/G6\D4\7FP2R)YD,L<J;MT<B.%8?S7_\ !G]XEU37
M/^"14>DW\HDL_!?[3GQM\.:&@>Y?R-,NU\)^+YHBL]Q-%&3K/BG5IMEI':VY
M$HD>!KM[FYN #^IBOXR/BGK7[3G_  <(?\%.OVJ_V-?AY^T?\:?V6?\ @EI^
MP%JL7PN^.NJ?!#6],\(>/?VBOC-!KFL>'M8T!]:2ZOX=4T/4/$OA;QO)X8FU
M6R\>?#_0O"7P^\,>+-8\#6WB_P"(FE?8O[-Z_D*_X,\%M/$?[(W[=/Q4U:'4
M;#XD>//^"@?Q$C\8Z1K&J3WNK:;9V/PP^%7B'2XM3M[R&VOQJ"Z[XS\86UYJ
M=Y;6\VIW%I)')%'-831H ?,?[:/["?[4O_!N'X9\,_\ !1?_ ()__MC?M*_'
MS]F7X<^+/ WA7]JK]DS]J7Q_8>+M$\2_#_QCXOM-&M]:L=8T'PWX?\(Z;)=>
M+M=L_#6E:]IWPUMO''@36?&*:SI>MZ]HFI^+O#]__1[^VC^W8NE?\$?/C;_P
M4$_9?U5;L:W^R!/\;O@GKNK6CVUSIC>/O"%C>>#];U/2F=WM=;\,MXAM-2O-
M"NVW6^LZ9)I.HA"EPJZG_!:W3++5O^"2?_!1&TU"#[1;Q_LG?&#44C\R:+;>
MZ/X7O-7TV;?!)&Y^S:C8VMQY98Q3>5Y4\<L#R1/\J_\ !$?P+X0_:K_X(%?L
MD?"7XX^'M.\;?#_XC_LY>*OA%XN\.ZE&]W::EX-TWQ9XS\!V-NIOY+U[:]LM
M$TG3Y=.O+=HVTC4[2UO='33S9V4=L ?SM?M$_L=:K^P]_P $8OV6O^"V_P "
MOVJ_VLC_ ,%#;CPW^RE^TO\ $7XO?$?XV>,OB38?%.7]I:Q\)7'B_P"&GC#P
M?XDU6;PQJG@NPN?'UG;H=7TS6-1\1:'X?DTCQ?/KK:W<7UI_3M_P5@_X*CQ_
ML*_L=>!_$WPZTE/%G[9_[6T>A_"_]BKX&V%E_P )7X@\=?&GQQ;^'[&UO8/#
ML'V.ZU_P]X!O?%NA7&K>7;16^K:_JW@[PBZVUYXRTY3\%>(O^""OP8^!?P<7
M0/VL_P#@I)^U#\0/^"6'[*'B"]_:#T?]D/XB1^#K7X:^%_!OPZGU;QJ/"OQ5
M\=:5HFJ>.?BK\.=!@-PEMX)L-,T)9+=/L'AS3K74;BR\KSC]@/Q!H?[47QW^
M(_\ P<*_\%+O%OA']G3]GG35O?A-_P $Q/AY^T7K.C_#3P]\$_@?<O<:=#\9
M9)?%FM0^'Y?B9\<K1KK^QM0T[4-;O?$<VK^*;CP=?7_@N^^&]EHX!^T'_!)W
M]ASQE^PK^R;X8\$_&?XG^*OC1^TQ\1+A_B?^TI\2?$OC+Q7XNL]3^*OB=?MV
MK>'?!B^)M3NX-'\#>!HIHO"7AZ/0]+\,6?B"+2IO&%]X<TG6O$6HV</XQ?MA
M^)G_ ."6?_!Q!^R-^TCHT%_X8_9F_P""LWA*T_9H_:%L/#VGZ!_8^I?M&>&-
M9M_"_P /_'.LV@73H]-D@U;QQ\'IM6\1ZA<0:J='U#XKZ[;:EKH&J: G].7P
M0_:#^!'[3'@B/XE?L[?&7X7_ !S^'\E_-I!\9?"7QUX9^('ARWUJUMK.\O-"
MO=6\+ZEJ=II^O6%MJ%C-J.AWTMOJVG+=VXOK.W:5 ?Y@_P#@\5\.W6F_\$^_
MV;_CWX?G6U\:? 7]MKX::[H5Q->W]M"EGK/@7XD33K%#IQAGEOU\2^'/!UU#
M.E_ILUI8VNJ-:WJ74L*N ?UN=>E%8'A76[;Q+X8\.>(K-)XK37M"TG6;6.Z6
M-+J.WU.PM[V%+A(I9XDG6.=5E6.>9%D#!)9% <[] !1110 4444 %%%% !11
M10 4444 ?SU?\%^^G_!+7_M)[^SO_P"E5_7]":?<7_=7^0K^>S_@OWT_X):_
M]I/?V=__ $JOZ_H33[B_[J_R%?4YM_R3/"?KGW_J?1,8?QJ__</_ -)8ZBBB
MOEC8**** "BBB@ HHHH **** "BBB@ HHHH \8_:/^+_ /PSY^SQ\>?CY_PB
MVH^.?^%(?!CXH_%__A"=(N?L6K>,?^%:^!]=\9_\(MIEY]CU'[)J/B#^Q?[)
MLKG^S[_R+F[BE^QW6SR'_P ^#_@M;XC_ ."Y_P 4?V+#_P %#_VQ/BMJ/[#7
MP?N_CEX0\'? S_@G_P#"75/$'AWQCX<T;Q1H_B[^RO'/Q<\8Z%JVDZS<>+$T
MC2)A-:^*[S5=0N;[5]5GL_!/PFL)(?"Z?Z0U?RL_\'B'_*(>W_[.H^#?_J.?
M$R@#^D;X:ZW8>'?@+X%\2:S-<1:7H7PG\.ZWJL]O97^J74=AIGA.TO[Z:#3M
M,MKW4]1N$MX)7BLM/M+N_NY L%I;3W$D<3_QN?LJ?L0?M!_\'(FL?%W]N3]O
MK]JO]IW]G?\ 9OT[XD>+/AG^RU^R!^SCXJA^&<_P_P!(\*W&G >,/%H\;^'?
M'7AUM<U73[V2RUW49/!<_B_QEJ>W5AXHT#P7I7A;P>G]F_P6_P"2/_"O_LG?
M@S_U'=.KH/'GCSP5\+O!7BKXC_$?Q5H/@?P#X'T'5/%/C#QAXIU2TT7P[X:\
M.Z+:2W^JZSK6JW\L-G8:?86<,MQ<W-Q*B(B'DD@$ _C)L?#'[2'_  ;S?\%1
M?V OV>_#W[8OQL_:A_X)V?\ !1/QYJ?P2T+X1?M#ZP/&'CGX0^/$OOA[X'TR
M^T'Q'8+!I4$^G^-/B+\/=436/#'A#P1X>U?PGK'B;PKK?@Z35M%TKQ]%_;%7
M\9'[..K:[_P</?\ !7?P9^V[;Z#KFA?\$Q/^"7'B&6/]F+5/$7A[Q)HE_P#M
M _M"2WFBZW_PE5G:ZE>OI=G!I/B;PYH7C_5KBT73-?T;PWX6^"_AGQ1X6_M?
MQ-K\_A_^H[]N/]I+1/V/_P!CW]I3]IO7KR"SM_@O\'/'/C;2Q<1&9-1\66.B
MW,/@?0$B,<L;W/B7QG<Z#X>LQ<*MF+O5(3>RP6@GGC /P/\ ^"3;:S^UU_P6
MZ_X+'_M]7NM:/J?@7X0:SX>_X)__  9FT")=3T34-%^']]ILOC>YTK7[C=.D
M$EW\.O!OBF[_ ++N+S1O$.J^.=0O[.6/2].T,S_"7_!1[XN?\%K_ /@HQ\ ?
MVT_C/X/OYO\ @FC_ ,$VOV9/!GQL\2>&#I=WJ=Q^T/\ MBR?!LSSZ1J:^(+0
M>$O%?A_X<>,[OP_=7^FZCX>N_!_@Z'1=;-M-'\>(;"SU>']A?^#9/]G4_ ;_
M ()'_ KQ/JUAKUKX[_:?UKQI^U'\0+SQ%$(K_7=0^*&K^3X+U^/>9;JYL]4^
M$V@?#R>TU&]N[NXU>';JRO:V][!I]G]K_P#!9+_E%)_P4-_[-%^./_J"ZO0!
M\]_\&Z_B7Q'XP_X(V_L5>)?%NOZWXI\1ZOX2\>7>K>(/$>JWVMZWJETWQ;\>
MJUSJ.JZG/=7][<,JJIFN9Y9"JJ"V *_9G7M>T/PMH>L^)_$^LZ5X<\->'-*U
M'7O$/B'7M1L](T/0=#TBSFU#5M9UG5M0FM[#2]*TNPM[B^U'4;ZX@L[*S@FN
M;F:*&)W7\2_^#;7_ )0I?L,_]B5XZ_\ 5N>/Z^-/^"['[1GQ5_:\^+_PJ_X(
M+_L5>)KC1_CA^U1;V?BC]KWXF66G:Y=Z7\ /V6M-6+Q)J8U_4]#O=.:SN?&]
MI81#5M$O-1TRU\3Z!?>'_AO?7J1_&*QR ?S2?\%&?VY/VP_VZOVRO@O_ ,%!
M/A[\0?BA\+O^"?<W[;GPU_8P_9-TK0_$?CWX>Z=\:?#?@/QFOB'Q[\3[KPDN
MIZ0NK1:YJ6IK#J^OZIH:F;^TK?X:33RW_P +]:L;'_3HM23:VQ)))MX22>22
M8UR2>Y-?Q7?\'$'[./PK_9%_9E_X(H?LV_!/0!X:^&'P@_;8^&G@_P *Z8TS
MW5V]M8_V&]YJNJWT@$VHZYKNI2WFM:[J<_[_ %+5[^]OI\RW#FO[4+3_ (]+
M7_KWA_\ 1:T 6*_E0_X.#OB=XD_:?_:@_P""<?\ P1*\!:A=P6'[9WQ4\/\
MQ>_:ILH=0?3DU;]F7X7^)KGQ+-X=\S3;:YUV3^U%^&OQ(\6PRV5YX>%IK_PV
M\,*-4>&\OKO0_P"J^OY"OAQ?R_&'_@\8_:$T_6]+TZ6']EK]@+0XO"-U>7=]
M<7$"^(/"7P U6YU/3(662"QU$7'Q^\1Z2UM$8;.33)K^]9S?W3I* ?T??M>?
M'GPU^PG^Q7\=OV@=/\(6.HZ#^S;\#_$_BSPQX!TP+H&DZI<^$/#LD/@WP=#)
MIUC=)X>T;4M7CTC0YKZSTR[CT+3;B6]AT^Y2S%M)_*!^PE_P2"^-/_!;+]F?
MP/\ \% /^"GO_!1+]N&7Q)^T)<:]XT^'GP2^ ?Q'\$?#;X:_"[P18ZU?>&/!
M[:1X=NO"GQ&\"V#^(-"T@^)7M/"GA#P9=P1>((8O$\=WXMC\17^H_P!>G[66
MA? _Q3^R_P#M#>&?VF-7T[P_^SUXC^#'Q)T+XU:]JNI#1K/1/AGJ_A+5=/\
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ME$IU*XU_2["+4=/N](C26U /*T_X-5_AJ54O_P %3/\ @J6'*J6 ^/'A_ ;
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M$TOPSHUSX@U2ZU6;2_#VFS>%[V73]%L)+IK73+*6\NI+:RBAA>XF9#(W]/\
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MKQ3J<.O/INC:S#<7/ZX?\%TOVT/%W[-/_!'K]JS]IK]F#QO]H\7-X=\'^!?
M/Q4^&^L:=J]KX4N/B9\7/"/PAUSQEI/BC2Y=0M-.U#PU:^(M;M]&UG3Y'O=+
M\;0Z1;VT^GZDB7ME]A_MR?\ !-G]BG_@I!X0\+>#/VR/@;HOQ=L/ =QKMYX
MUA]=\6>#_%_@:]\30Z5%KTWA?QAX&U[PWXCTZWUDZ#H$VLZ.VHS:#KLV@Z,=
M<TK4DTVUCCZ_X(_L+?LK?L]_LD:3^PK\.?A)H_\ PRMI7ACQKX.?X2>-=0US
MXE:+K7A_XD>(?$?BSQ[I_B.Z^(&I^)-4UZV\4^(_%_B35+^TU*^GLK4ZH^GZ
M3:Z=I%II^GV8!_-I_P $N?\ @DW_ ,$&;#]A;X0_M??'+6_@!^U/X\^)'PN\
M-_&?]H+]HW]ICXW:5XAT/1O'7B'2M.\9_$?0_$_A_7O&]M\/? )\ ^++[5]
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MJ&D6<>L6.F>(;*VU[23?>']<BU#0-4U33+P _FI_X))_LK^/'_X-5O&GP?\
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MI:V'AR.>ZT[1/'GBK4+NU\(V]W9?;_$&@6VE^,='AO\ PWXH\/7U]YK\'/\
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MO;>(?#4JPZQJOBW6WT_5OH7]A+X=^*?V;/\ @T[U4_#"WUJ]^(>L_P#!.?\
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M86MC_P )O\/_ !#:_M!1^!_AO^TA\)HM)FO],N](\6>*?AY\0;WQ!X4M-2T
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M,+SQ%HVI?$G1;N?3-%%WHUKJ\-II^N:3'K^KZCIW[Q !0% P%  'H , ?@*
M/Y1_^"ZW_!:/QQ\,?BQX4_X)1_\ !/\ \?\ PX\+?MF?'2WM-)^)_P"T1XX^
M)O@[P'\/OV2_!WB"SU"\NQJ/C/6M5CL_"/Q4E\)V-YXLNK_4XEUOP-X.NM%U
M3P3H?B;XA^+_  ='HGW7_P $S?!O_!(__@E]^S]:_!KX-_MG_LH>(_&/B2XM
M_$_QR^.'B?\ :)^"S_$;XX_$9XI3?^*O%5^?'%W/:Z5:3W=]#X1\(PWUUIGA
M73;JX5;C5->U3Q'XCU[M/V@O^#?'_@D)^U/\9OB!^T%\>?V1O^$[^+WQ2UQO
M$GCOQ=_POO\ :=\,?V[K36MM9->_V!X-^-/A[PQIF;:TMXOL^C:+I]H/+WB
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M>$?!/P=OM \/76G2G3[C2]/GLO.@FU.UF_H__9._8K_9D_8>\#^)?AY^R_\
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MFF$%GI]I%:6T/G7$DL\OEPPHGF32R2OMW22.Y+'6HHH **** "BBB@ HHHH
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M<?9;ZTNK.X\ORKJWF@=XVK_M>?L%_'W]J?\ X+1_\$[_ -H;7_ >F:A^Q/\
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MGUKR3:P?\2OQ"VK:-)L_>Z=)N?=];(BQHJ(,*BJBC).%4 *,DDG  &223W-
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M.K:GJGB;Q#XH:';IL&EV=U%;6*WFOZI+9>'M)U;5++\:_P#@TM^"?QD\!?\
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MEA:2RB&*ZO4^$WBUK6WEF8JL4<TXCC>4D"-6+D@#-?S"?\$J?V@?^"VG@_\
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M_P!(POV5O_$D?!W_ ,^BC_5/%_\ 0WX6_P#$GR7R_P"HSS_!]@]O'_GW7_\
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M  <7_P#2,+]E;_Q)'P=_\^BC_AJ;_@XO_P"D87[*W_B2/@[_ .?11_JGB_\
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M_@^P>WC_ ,^Z_P#X(J__ "/]6?E?^A>BOYZ/^&IO^#B__I&%^RM_XDCX._\
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M?_D?ZL_*_P#0O17\]'_#4W_!Q?\ ](POV5O_ !)'P=_\^BC_ (:F_P"#B_\
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MJ_\ R/\ 5GY7_H7HK^>C_AJ;_@XO_P"D87[*W_B2/@[_ .?11_PU-_P<7_\
M2,+]E;_Q)'P=_P#/HH_U3Q?_ $-^%O\ Q)\E\O\ J,\_P?8/;Q_Y]U__  15
M_P#D?ZL_*_\ 0O17\]'_  U-_P '%_\ TC"_96_\21\'?_/HH_X:F_X.+_\
MI&%^RM_XDCX._P#GT4?ZIXO_ *&_"W_B3Y+Y?]1GG^#[![>/_/NO_P""*O\
M\C_5GY7_ *%Z*_GH_P"&IO\ @XO_ .D87[*W_B2/@[_Y]%'_  U-_P '%_\
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M87[*W_B2/@[_ .?11_PU-_P<7_\ 2,+]E;_Q)'P=_P#/HH_U3Q?_ $-^%O\
MQ)\E\O\ J,\_P?8/;Q_Y]U__  15_P#D?ZL_*_\ 0O17\]'_  U-_P '%_\
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M_$D?!W_SZ*/]4\7_ -#?A;_Q)\E\O^HSS_!]@]O'_GW7_P#!%7_Y'^K/RO\
MT+T5_/1_PU-_P<7_ /2,+]E;_P 21\'?_/HH_P"&IO\ @XO_ .D87[*W_B2/
M@[_Y]%'^J>+_ .AOPM_XD^2^7_49Y_@^P>WC_P ^Z_\ X(J__(_U9^5_Z%Z*
M_GH_X:F_X.+_ /I&%^RM_P")(^#O_GT4?\-3?\'%_P#TC"_96_\ $D?!W_SZ
M*/\ 5/%_]#?A;_Q)\E\O^HSS_!]@]O'_ )]U_P#P15_^1_JS\K_T+T5_/1_P
MU-_P<7_](POV5O\ Q)'P=_\ /HH_X:F_X.+_ /I&%^RM_P")(^#O_GT4?ZIX
MO_H;\+?^)/DOE_U&>?X/L'MX_P#/NO\ ^"*O_P C_5GY7_H7HK^>C_AJ;_@X
MO_Z1A?LK?^)(^#O_ )]%'_#4W_!Q?_TC"_96_P#$D?!W_P ^BC_5/%_]#?A;
M_P 2?)?+_J,\_P 'V#V\?^?=?_P15_\ D?ZL_*_]"]%?ST?\-3?\'%__ $C"
M_96_\21\'?\ SZ*/^&IO^#B__I&%^RM_XDCX._\ GT4?ZIXO_H;\+?\ B3Y+
MY?\ 49Y_@^P>WC_S[K_^"*O_ ,C_ %9^5_Z%Z*_GH_X:F_X.+_\ I&%^RM_X
MDCX._P#GT4?\-3?\'%__ $C"_96_\21\'?\ SZ*/]4\7_P!#?A;_ ,2?)?+_
M *C//\'V#V\?^?=?_P $5?\ Y'^K/RO_ $+T5_/1_P -3?\ !Q?_ -(POV5O
M_$D?!W_SZ*/^&IO^#B__ *1A?LK?^)(^#O\ Y]%'^J>+_P"AOPM_XD^2^7_4
M9Y_@^P>WC_S[K_\ @BK_ /(_U9^5_P"A>BOYZ/\ AJ;_ (.+_P#I&%^RM_XD
MCX._^?11_P -3?\ !Q?_ -(POV5O_$D?!W_SZ*/]4\7_ -#?A;_Q)\E\O^HS
MS_!]@]O'_GW7_P#!%7_Y'^K/RO\ T+T5_/1_PU-_P<7_ /2,+]E;_P 21\'?
M_/HH_P"&IO\ @XO_ .D87[*W_B2/@[_Y]%'^J>+_ .AOPM_XD^2^7_49Y_@^
MP>WC_P ^Z_\ X(J__(_U9^5_Z%Z*_GH_X:F_X.+_ /I&%^RM_P")(^#O_GT4
M?\-3?\'%_P#TC"_96_\ $D?!W_SZ*/\ 5/%_]#?A;_Q)\E\O^HSS_!]@]O'_
M )]U_P#P15_^1_JS\K_T+T5_/1_PU-_P<7_](POV5O\ Q)'P=_\ /HH_X:F_
MX.+_ /I&%^RM_P")(^#O_GT4?ZIXO_H;\+?^)/DOE_U&>?X/L'MX_P#/NO\
M^"*O_P C_5GY7_H7HK^>C_AJ;_@XO_Z1A?LK?^)(^#O_ )]%'_#4W_!Q?_TC
M"_96_P#$D?!W_P ^BC_5/%_]#?A;_P 2?)?+_J,\_P 'V#V\?^?=?_P15_\
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MX:F_X.+_ /I&%^RM_P")(^#O_GT4?\-3?\'%_P#TC"_96_\ $D?!W_SZ*/\
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M\21\'?\ SZ*/^&IO^#B__I&%^RM_XDCX._\ GT4?ZIXO_H;\+?\ B3Y+Y?\
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M_P#/HH_U3Q?_ $-^%O\ Q)\E\O\ J,\_P?8/;Q_Y]U__  15_P#D?ZL_*_\
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M /!%7_Y'^K/RO_0O17\]'_#4W_!Q?_TC"_96_P#$D?!W_P ^BC_AJ;_@XO\
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MHO-/NX)9++4+2SU&QE:2TU"TM;R">WC ._HHHH **** "BBB@ HHHH ****
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M?MF? M8?VA/AU:_ SQ#\>_ 5GX(U-;"Z^*/AC0?"5]XRBT7PU<ZI9?\ $O\
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M=NO$MSX>TTS76M:1>Z397>K:AI6D/<HL\^IV^G,;Y0#V2BOB/]A']O[X#?\
M!0[X8>,/B=\#(?'V@?\ "N?B?XK^#GQ*^'GQ:\)_\(%\4_AS\1O!K6AUGPSX
MV\%R:CJ=SH5^D%_9W,4-Q<F4)*]M<QVVH6E]9VOVY0 4444 %%%% !1110 4
M444 %%%% !1110!_/5_P7[Z?\$M?^TGO[.__ *57]?T)I]Q?]U?Y"OY[/^"_
M?3_@EK_VD]_9W_\ 2J_K^A-/N+_NK_(5]3FW_),\)^N??^I]$QA_&K_]P_\
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MDU"2]6PATSP9J7C_ $_POH_C?5;JX8&STOPAJ&MZA>6VZ^M;::R5K@?J$""
M0000""#D$'D$$<$$=#0 M%%?&UK_ ,%"_P!B6^_:B'[%5C^TO\++_P#:J-_?
M:4?@=8Z]]M\;KJFE^$KOQWJFFO:6L$MI'?Z9X3L+[6=1LWO%N+&&SNH+J.&\
MMY;= #[)HHKS[XK?%;X=? [X=>+_ (N?%OQ=I'@+X:^ ='G\0>,O&.OS20:-
MX=T6V>-+C4M2FBCFDBM86EC$CK&^W<"1C) !Z#17Y%?\/[?^".7_ $D+_9V_
M\*74/_E37=_#'_@L_P#\$K_C/\0O!_PI^%O[<GP'\:?$7Q_KMCX8\&>$M'\2
M73:KXC\0ZG*(-.T?38[C3H(I;Z^G*P6L#2HT\[I#'ND=%8 _3JBOG?\ ::_:
MU_9H_8T^',OQ:_:E^-GP^^!WP_6^CTFTU[QYKMOICZWK,T4MQ'H7A?1T\_7?
M%OB![2WNKY=!\,:9J^L'3[.^U#[%]BLKN>'C_P!D?]O+]C[]O#PMXB\8_LB_
M'WP)\<=#\(:I!HWBP^%KC4+36?#.H7D4D^GIK_ACQ!I^C>)M(M]4B@N7TB_O
M](M[#5Q9WW]F75V;&[$(!]<45X/^T9^T_P#L_?LC?#F3XN_M+?%GP?\ !CX:
MQZWIOAMO&/C?4#INCG7M82ZDTS28Y4BGEFOKV*QO)88(HG<PVMQ*0(X9&6O\
M=OVC/"/P(_9S\=?M.WWACX@_$KP#X!\#K\2-3T7X3^&X?$GCO5/!D26E[J>M
M:#X:U;4_#GV^/1-!N+CQ/JMK-?6E[%H>EZE+;6UU?0PV%P ?0%%>!_LN?M*?
M"O\ ;"_9]^$_[3'P4U6ZU?X9?&/P?IGC'PO-J4%O::S8P7\96\T+Q#86EYJ%
MOIOB7P[J45YH7B/2XK^\73-;T^_L?M,YMS(WOE !1110 4444 %%%% !1110
M 4444 %%%% !1110!_/1_P $NO\ E+C_ ,%S?^Q__9G_ /3=\8Z_H7K^>C_@
MEU_REQ_X+F_]C_\ LS_^F[XQU_0O7U'&'_(ZC_V)>&/_ %FLI,,/_#E_U]K?
M^G9GS/\ MI_\F<?M9_\ 9L_QX_\ 56^*J^&?^""'_*(O]B__ +$WQ[_ZN3XC
MU]S?MI_\F<?M9_\ 9L_QX_\ 56^*J^&?^""'_*(O]B__ +$WQ[_ZN3XCTZ7_
M "1.-_[*G*__ %4YP#_WF/\ UXJ?^G*9^OU?"O\ P4X_:<\2?L9_\$^_VO/V
MG?!5JMWXY^$'P-\;>(O *S:3+KMC:_$"ZT\Z%X%U36-(B1S?^'M&\6ZMHVK^
M(X)#!;'0;+46N[NRM5FNX/NJN8\;^"O"/Q*\%^+OAUX_\.:/XQ\!^/O#&O\
M@KQMX1\16%OJGA_Q5X1\5:5=Z%XD\.:[IETDEKJ.CZYHU_>Z9J=A<QO;WEE=
M3V\R-'(RGY8W/Y2O^"!?_!)[]@OX\_L4_#_]OG]IWP-\-/V_/VI/VN9/$OQ,
M^,GQ2_:(T?0?CE9Z-XMN_%7B:TU3P7#X7\:7OC7PK8>)O#D\DVG^,-8N]/B\
M4:GK]L9=0AT>.PTS1M+]-_X*#_\ !O+IVO?M)_LA_MI_\$C-&_9Y_8=_:0^
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M!U?X*>!M0T'4MHF\074%_=:KK4\FH0ZM=T ?UA_L9?M6^ OVXOV8?A!^U?\
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M^*OC_KND?:D$,M]HUU\>/B';6>I) 6\Z*VO7LYY;-ITC-U:&"^MQ+975K<3
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M]YXEO/$MWXID?Q5?Z-J%I:0?&W[27P:^&O\ P0@_X+K?\$]OBG^R5#??"?\
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M33+[3-3TG7M!U;6/#VL:5JUZ ?SI?"'6H_\ @G1_P=1?'']GW2&\/:;\)/\
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M@W.NV&A#QKHWAW5IM2O)_%6CZ7KB2ZQ=2?:K#4M$E,IE_*[_ (*/_P#!L?\
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MHRZ1XW\8Z5JTUO#=-<ZZ]FVG6-VMY?V\Z@'Y3?\ !OQ;Z+^UI^V3_P %@_\
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M;.UUBYL?^$Q\ ^(KGQ+X9\=^'M2O(1IVGW.B6MKJ_P#1;\8_@WX(_P""Y/\
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MJ+>*\U*>*U1D:5+9(DFFGE5YI/Q5_P""YM[:?\%4?^"B/PC_ ."57[%OP3\
M:]^VU^S3HD7QI\??MN^-O'/Q'^'(_8]\*W*>$O$OD^"[SX;:OH.L^+_$EGJ/
MB#X7:S!?RV_C[2?"?BOQ%IVC:1X6M/$4OB_Q+X- /NS_ (+0?\$??^"5>E_\
M$R/VKO'^C_LH?LR?LX>,/@?\"?&WCSX9_%;X6_"KPE\+?$=CXY\,Z;;:CX1\
M/ZKJW@:#PI/XQF\?Z_I>D_#ZWB\9W'B)8[OQ9+>6EK+J=PQN/M#_ (-_?C9\
M7/V@_P#@D%^Q1\3/CC/XAOOB'<_#W7?"5YK7BQM0F\1>)_#OPW\>^+/AWX'\
M7:OJ&JPPZEK=YXM\$^%_#_B23Q%>O>7/B+^TQK<NIZJ]^=1NOYS/^"AW_!#C
M_@LB_P  M,^('QC_ ."A-O\ \%4OA1^SM-/\4?&?[&'QDO\ XP_!+PW\3/"_
MA31I9-8FBUOX=_%+3=6\;^--&TB"\O-%EUWQCX3\16L']M2>&O$MWK6LW/A?
MQ1_3W_P21_;H_9U_;4_X)[?"'X[_  2\%^'_ ( ?#7P'X4;X;>)?@Y'J4"^&
M?V>;WX3Z5:Z7J?P_AU^?1O"VE3^$_"?A^VTV]T/78M*TBPE\)7&F7MQ9Z7)]
MIL;0 =_P5Z_X*2>#?^"8/[''C/XZ:A:Q>)_BQXDE'PZ_9Y^&D,T#ZKX^^+WB
M.VG@\/QQZ8S&\OM \,'/B3Q5]C@EE?3+%-(MRNJZUI4<W\7/[$'[#'Q3_8;_
M .#BW_@D=:?M">-=6\>?M.?M/_L_?&[]KC]I76M8O+K4;JW^,'Q?\"?MNKK.
MC3ZA>22W.I:GHVC^']#L/$NK.YCUGQ7#KFK6X6VO847]COV,].OO^"]'_!5K
MQ?\ \%%?B19R7G_!/C_@FWXWU3X3_L%^!9KO4&TOXB_'G1M2T'7=7_:#U"">
M+^S[MH9;'1_&42V-KI%U;W:_!O0;F^U6X^%VNS:\G[<__*W_ /\ !(C_ +,I
M^(/_ *BW_!0"@#^OZN%^)OPQ^'WQG\!>)_A=\5O!^@^/_AUXUTUM'\7>"_%%
MA%JGAWQ)I#S0SRZ7K.FSAK?4-/GD@B^TV5PKV]S&IAN(Y(7>-NZHH _,3_AR
MO_P21_Z1R?L>?^&*\!__ "HK^7_]E+]D7]E[]NO_ (.(/%OB3]D/]G[X2? O
M]A[_ (),R6-CJ6L?!/P'H'@/3_C-^T[I>I:I:6=[J>M^&],LKO7K:R\=V?B"
M31GM];U3PS=^"OA-H>HVEG:+\2-6.H?T-_\ !>K_ (*(S_\ !.7_ ()Y?$WQ
M]X(U&>']H;XQR)\!?V;-/TLRR:_'\3/'UC>VTWC/2K:TCNKQ9_AOX8AUOQ?I
M5VVGWFF2^,K'P?X<U)4'B6V$F[_P0W_X)Q6?_!,[]@'X7_!_7;2 _'#Q_%'\
M8?VC=55=,EFF^+WC;3=/N-8\-1ZEI-]J=AJNE?#S3X--\!:1JEE?-9:W;>'C
MXABMK.;6;BW0 _-3_@LMJ/P^M_\ @M7_ ,$-X?VI8]";]D./5OVA6U,_%?2X
M[KX'GXTZGX&U:Q^'']M3ZS:3>%)?%D?CN/X8OHJZI(\FDWQT742+.VEDNGI?
M!6S^%6G?\'37QO\ $/[,Q\$P_#VW_P"":MO<?M3:K\,[K2'\!:5\26\?^"ET
M-?'-QIDS^&=$\9R^%=&\,7<%M ;+69],M-6U*2)T;Q1<O_1Y^TG^RM^SI^V#
M\-=0^$'[3GP=\#_&CX=:C+%<R>'?&NDI?"QOH)8Y8=3T+58'MM;\-ZO&T2HF
MK^'M2TS4U@:6V%W]GFFBD_F"_;Z^&OP/\!^,O"'_  ;]_P#!'SX4_"W]G+XO
M_MDV%OXD_;F^)7@+1]9TW4_@_P#LA:'I@N-=/C;QG#9ZEK_BOQ;\3M#U*Y\,
MZ-9>)/$>MQP>'M;G\+:SIEC9?&#3_$FF '<_!>VU;_@O7_P4[3]J/Q)H^I?\
M.L/^"9?Q!UGPY^R_97.IS)X8_:Z_:KT'53%?_&Y;"UDN+;7OA_X N=.L]9\-
MW33::)#'X$T]S=RZA\7?!]E_5KJ6EZ9K.F7^BZOIUCJNCZK8W6EZII.I6EO?
M:9J6F7UO):7NG7]A=1RVMY8WEK++;75I<126]Q;R20S1O&[*?YG-"_X+'?L&
M_P#!-KPE=_L<?LM?L?\ [>G[0?[-7[!]I>_"+XX_M ?LR_L]7?Q+^!/P1\1>
M"+9KGQO:_$#XG:OXC\,6^I^)]'OI+SQ)\3/$$\=II;MJ%QK^EZMXB:[>%?Z)
M/@S\9/AE^T+\*O 7QM^#/C#2?'WPN^)OAG2_%_@GQ=HLDC6&M:#K%LEU9W"Q
M7$<%Y97**Y@O]-U"WM=2TR^BN-/U&TM;VVG@C /Y:?\ @W#\5:K^RK^U5_P5
M0_X(_:[J6G:GX9_9=_: UCXM? +4B\[:]J'PX\=:U>Z)K5E>QMJ5U:VFGZ;9
MZ=\.?$D=C%'=W]GXB\>^*+;4=7NX8M,2'^N.OY O@/=6G@[_ (/$?VSM*\+W
ML/V;XC?L+^%KKQSH\-Q%]DL]=M?!?[+]]:W)T_3FM8[?5I;72K/4C-K$=]>.
MGB/5KR-ECU>)X_Z_: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^>C_
M ()=?\I<?^"YO_8__LS_ /IN^,=?T+U_/1_P2Z_Y2X_\%S?^Q_\ V9__ $W?
M&.OZ%Z^HXP_Y'4?^Q+PQ_P"LUE)AA_X<O^OM;_T[,^9_VT_^3./VL_\ LV?X
M\?\ JK?%5?#/_!!#_E$7^Q?_ -B;X]_]7)\1Z^YOVT_^3./VL_\ LV?X\?\
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M>*?#2^._V@OBG\(_%?AO]G7]G+X>RWL=UJ7BSX@R>(+*UU"U@U**RU'1S?\
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M]XV^%NC?#'_@F]\"/CW^T5\?G\-2:3\'_P!D3X;? '5OAKI'AA[*V%O:W7Q
M\7_8[?X3?"GX-^"[FZTB;XB>.-+UO6M&\#>'=076IK1].M[RXM/Z&OBA\*;S
MXD3Z.UI\2_B)X LHH;W1_%=AX'UM=*3QEX2U)[:XO]"FNGAFO?#&J27%E;PV
M7COP?/HGCK0]*O-=L?#^OZ5<ZK%J.G^$>&_V,+'PE;W]IX>^-GQ=T&T\0:G=
M6_C"U\-7_A[PK;^*/ TNSR_#ES#X:T+2H].\:W'V>/\ M[X]:4MI\=->_M#7
M?M'CVW\_P]_PB_G5L5CJ=6<*.63KTTTHUEB\-3C.\8MODG)5(J,I*+O&_N57
M%.U)5OL<LR/A7%X'#XG,>.,/E.+J*;KY=/A_.L;5P_)5G&,7B,+2>%JSJTJ4
MJL%"KR)XC TZE2FZF.EEO\Z'_!H/9^*/B?\ !S_@H_\ MJ^/X--OOB#^U7^W
M)XAO/%7C/2M.U2PT[QCJ'AW0S\1=4OM$_MVX_MR7PW#XL^.GBJ724U.QANK2
M>^U*TO+V[U.+4;;3>B_X-C3??&[]HG_@N+^W9/IAAT3]HS]O2_\ "/A"ZD\F
M<:=IG@'7/BEX^?PY971T#0[QSIOAOXU^ K?4[NXAM9]9^QZ3>:CI-C?P2277
M]&'_  S!K\W_ !_?M*_M 7OVS_BG==_XJNQL?[7^%MM_R#? L/\ 9VF6G]A^
M(HMG_$S^-6A_8/C3JW]I^(-WCBT^T^'_ /A%S_AF#7YO^/[]I7]H&]^V?\4[
MKO\ Q5=C9?VO\+;;_D&^!8?[.TRT_L/Q%%L_XF?QJT/[!\:=6_M/Q!N\;VGV
MGP__ ,(OE]=S+_H35?GCL'I>UKVJ.UN:/-;FMRU>7FY:7MN__5K@A;^).#=M
M^3A;B1WM\7)SX:GS<WLZWLN?V?-[3 >U]A[?&_V9_/1_P=Y^(+[Q3^Q/^R7^
MR;X3O9_^%A?M8?MU?"CP9HNBVL4EU>:QH&C>'/&-I?&TLH]4TQ-0N+/Q[XM^
M%Z165ZTMC-)>+ODLKU;"]@^\O^"_/_!./XA?MY?\$L/%O[-W[,VFZ>GQ(^$V
MN?#GXG_"'X<M=6NE:=XS3X66FH:%+\-;/5M2E%KI.H7O@?7-;7PA+?S0V%YX
MKTWP]HVL:GHVDZGJ&NZ;^DO_  S!K\W_ !_?M*_M WOVS_BG==_XJNQLO[7^
M%MM_R#? L/\ 9VF6G]A^(HMG_$S^-6A_8/C3JW]I^(-WC>T^T^'_ /A%_P I
MO^"LWA[_ (*B_LU?!?PI\8O^"?I^('[75QH7B&;1?VC?A-JOB;Q(_P 7/$?[
M/-E>>'[OP_X5^#/AOP)#I<M_XI6RL/%>@^-_BAX4M;[]IR_NO&-GKWA;5=2M
M=-?3_#I]=S+_ *$U7YX[!Z7M:]JCM;FCS6YK<M7EYN6E[8_U:X(6_B3@W;?D
MX6XD=[?%R<^&I\W-[.M[+G]GS>TP'M?8>WQO]F?$G[-7_!S5XN'P[^'7P(^.
MO_!+'_@IAKW[=NC^&/#W@WQ5X"\ ? B&Y\/^.?'WAZPT?POXK\427/C/Q-X;
M^(/@:SUCQG#K<^H:1JG@+Q*?!X:#3]4\2:M<+>7<'QK_ ,$O[?\ :O\ VI?^
M#H?]H'XX?ML^ ]"\+_%S]GW]CZ3Q$W@+PU*/&?@/]F.;XC^%/A#IWPX^!.@?
M$$V^JZ???$;0/A=\;O$5O\2=1TV?PHVM_$>;XX#08)_"T$T>L>EM_P %Y?$G
MC'X<M;_##]AC_@N5\0OVCM6\/G0;WX8M\+[.+X<ZIX86$VNA?#>/XA^"%U;Q
MW9F'79=,L=5^/WASX,Z'\>_$$.O>("FOZ9>77A>T\/?J+_P2<_8+_;QL? 'Q
M#_:#_P""@?Q6U;X/_'S]I/6=)N/&_P !?@C<^%-)TSP]X TVSEMM7?QOXP\/
MQZQJ5Q\=OBO/!H"^,?BKHGC/7/B9H7@/PAX,\.V_Q(B\7#6K_23Z[F7_ $)J
MOSQV#TO:U[5':W-'FMS6Y:O+S<M+VQ_JUP0M_$G!NV_)PMQ&[V^+DY\-3YN;
MV=;V7/[/F]I@?:^P]OC?[-^0/@N=4_:._P"#NW]J3QC'X?=O!O[#W[#OAWX9
MVGBF4Q26LOBKQ?X>^&.K+:VZ3Z!;W-CJ<DOQL^(VE1VZ7=R]QIWA?4=3C\0_
MV7J=GX?<^*T>I?M(?\'??[.&CV6D27/AS]@_]@[Q/XI\1!UBN++^U_&GAGXB
MV?\ PD$YNO#Z-NM[O]IKX86%M96VIW<6GZGINEZW:ZK:7UU?:+7]%O\ PS!K
M\W_']^TK^T#>_;/^*=UW_BJ[&R_M?X6VW_(-\"P_V=IEI_8?B*+9_P 3/XU:
M']@^-.K?VGX@W>-[3[3X?_X1<_X9@U^;_C^_:5_:!O?MG_%.Z[_Q5=C9?VO\
M+;;_ )!O@6'^SM,M/[#\11;/^)G\:M#^P?&G5O[3\0;O&]I]I\/_ /"+GUW,
MO^A-5^>.P>E[6O:H[6YH\UN:W+5Y>;EI>V/]6N"5OXDX-VWY.%N(W>WQ<G/A
MZ?-S<E;V7/[/F]I@?:^P]OC?[-\M_P""L/Q<M_@7_P $S/V\OB=)?MIVH:%^
MRI\;--\+W*FX5SX\\7^!=8\%_#RT1K.[L+U7U#QUXA\.V"-8WEO?!KD&RD%T
M(@?RE_X(N_L;7/C;_@VG\#?LO[H?!_B3]KK]E;]JG3]1\1W=L]F4F_:EU#XN
MV'A'Q5?I$=9:2&P\"^+?!ZV]U#;3R7>DZ79W1TN.>5[%?VL_X9@U^;_C^_:5
M_: O?MG_ !3NN_\ %5V5E_:_PMMO^0;X%A_L[3+3^P_$,>S_ (F?QJT/[#\:
M=6_M/7]WCBT^T^'_ /A&#_AF#7YO^/[]I7]H"]^V?\4[KO\ Q5=E9?VM\+;;
M_D&^!8?[.TRU_L/Q#%L_XF?QJT/[#\:=6_M/7]WCBT^T^'_^$8/KN9?]":K\
M\=@]+VM>U1VMS1YK<UN6KR\W+2]L?ZM<$K?Q)P;MOR<+<1N]K<W)SX>GS7Y*
MWLN?V?-[3 ^U]C[?&_V;_)I_P2=_X+3_  O_ ."0W[/<'_!+7_@K=X%^*G[,
M/QV_9-\1^+/#/@'Q!;?#'Q5X^\*_&#X<^+/&WB'Q=HFJZ#?> M+UA]0?3-0U
M_4M+TCQ%I6G7/@_Q=X.A\+ZWIGB75->N]>MK:YXL\0_%S_@Z!_;2_9=D\)_
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M?_N'_P"DL6BBBOEC8**** "BBB@ HHHH **** "BBB@#\N/^"R?_  4)T?\
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MC:X^)&B-YKPWUI>^&;^PGLTM;6PO=0X#_@M3\,OVHOV'/^"IO[)__!<?X(?
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M]]/^"6O_ &D]_9W_ /2J_K^A-/N+_NK_ "%?4YM_R3/"?KGW_J?1,8?QJ_\
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MV<_VD_V<O%?Q4^(EUJOQ T.\^(L7B?1M$_:IU"S3P[XGB\$VNG:9IAG^#?A
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M ,.7_7VM_P"G9GS/^VG_ ,F<?M9_]FS_ !X_]5;XJKX9_P"""'_*(O\ 8O\
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MZ_X*??\ AZ?&?_S>T?\ #D#]I#_I-U_P4^_\/3XS_P#F]H_L?AW_ **_#?\
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M]I5_Z!Y?^#*?^?K_ $]/Z%J*_GI_X<@?M(?])NO^"GW_ (>GQG_\WM'_  Y
M_:0_Z3=?\%/O_#T^,_\ YO:/['X=_P"BOPW_ (9<W_\ E']6?E<]I5_Z!Y?^
M#*?^?K_3T_H6HK^>G_AR!^TA_P!)NO\ @I]_X>GQG_\ -[1_PY _:0_Z3=?\
M%/O_  ]/C/\ ^;VC^Q^'?^BOPW_AES?_ .4?U9^5SVE7_H'E_P"#*?\ GZ_T
M]/Z%J*_GI_X<@?M(?])NO^"GW_AZ?&?_ ,WM'_#D#]I#_I-U_P %/O\ P]/C
M/_YO:/['X=_Z*_#?^&7-_P#Y1_5GY7/:5?\ H'E_X,I_Y^O]/3^A:BOYZ?\
MAR!^TA_TFZ_X*??^'I\9_P#S>T?\.0/VD/\ I-U_P4^_\/3XS_\ F]H_L?AW
M_HK\-_X9<W_^4?U9^5SVE7_H'E_X,I_Y^O\ 3T_H6HK^>G_AR!^TA_TFZ_X*
M??\ AZ?&?_S>T?\ #D#]I#_I-U_P4^_\/3XS_P#F]H_L?AW_ **_#?\ AES?
M_P"4?U9^5SVE7_H'E_X,I_Y^O]/3^A:BOYZ?^'('[2'_ $FZ_P""GW_AZ?&?
M_P WM'_#D#]I#_I-U_P4^_\ #T^,_P#YO:/['X=_Z*_#?^&7-_\ Y1_5GY7/
M:5?^@>7_ (,I_P"?K_3T_H6HK^>G_AR!^TA_TFZ_X*??^'I\9_\ S>T?\.0/
MVD/^DW7_  4^_P##T^,__F]H_L?AW_HK\-_X9<W_ /E']6?E<]I5_P"@>7_@
MRG_GZ_T]/Z%J*_GI_P"'('[2'_2;K_@I]_X>GQG_ /-[1_PY _:0_P"DW7_!
M3[_P]/C/_P";VC^Q^'?^BOPW_AES?_Y1_5GY7/:5?^@>7_@RG_GZ_P!/3^A:
MBOYZ?^'('[2'_2;K_@I]_P"'I\9__-[1_P .0/VD/^DW7_!3[_P]/C/_ .;V
MC^Q^'?\ HK\-_P"&7-__ )1_5GY7/:5?^@>7_@RG_GZ_T]/Z%J*_GI_X<@?M
M(?\ 2;K_ (*??^'I\9__ #>T?\.0/VD/^DW7_!3[_P /3XS_ /F]H_L?AW_H
MK\-_X9<W_P#E']6?E<]I5_Z!Y?\ @RG_ )^O]/3^A:BOYZ?^'('[2'_2;K_@
MI]_X>GQG_P#-[1_PY _:0_Z3=?\ !3[_ ,/3XS_^;VC^Q^'?^BOPW_AES?\
M^4?U9^5SVE7_ *!Y?^#*?^?K_3T_H6HK^>G_ (<@?M(?])NO^"GW_AZ?&?\
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M-_X9<W_^4?U9^5SVE7_H'E_X,I_Y^O\ 3T_H6HK^>G_AR!^TA_TFZ_X*??\
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M'?\ HK\-_P"&7-__ )1_5GY7/:5?^@>7_@RG_GZ_T]/Z%J*_GI_X<@?M(?\
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M/VD/^DW7_!3[_P /3XS_ /F]H_L?AW_HK\-_X9<W_P#E']6?E<]I5_Z!Y?\
M@RG_ )^O]/3^A:BOYZ?^'('[2'_2;K_@I]_X>GQG_P#-[1_PY _:0_Z3=?\
M!3[_ ,/3XS_^;VC^Q^'?^BOPW_AES?\ ^4?U9^5SVE7_ *!Y?^#*?^?K_3T_
MH6HK^>G_ (<@?M(?])NO^"GW_AZ?&?\ \WM'_#D#]I#_ *3=?\%/O_#T^,__
M )O:/['X=_Z*_#?^&7-__E']6?E<]I5_Z!Y?^#*?^?K_ $]/Z%J*_GI_X<@?
MM(?])NO^"GW_ (>GQG_\WM'_  Y _:0_Z3=?\%/O_#T^,_\ YO:/['X=_P"B
MOPW_ (9<W_\ E']6?E<]I5_Z!Y?^#*?^?K_3T_H6HK^>G_AR!^TA_P!)NO\
M@I]_X>GQG_\ -[1_PY _:0_Z3=?\%/O_  ]/C/\ ^;VC^Q^'?^BOPW_AES?_
M .4?U9^5SVE7_H'E_P"#*?\ GZ_T]/Z%J*_GI_X<@?M(?])NO^"GW_AZ?&?_
M ,WM'_#D#]I#_I-U_P %/O\ P]/C/_YO:/['X=_Z*_#?^&7-_P#Y1_5GY7/:
M5?\ H'E_X,I_Y^O]/3^A:BOYZ?\ AR!^TA_TFZ_X*??^'I\9_P#S>T?\.0/V
MD/\ I-U_P4^_\/3XS_\ F]H_L?AW_HK\-_X9<W_^4?U9^5SVE7_H'E_X,I_Y
M^O\ 3T_H6HK^>G_AR!^TA_TFZ_X*??\ AZ?&?_S>T?\ #D#]I#_I-U_P4^_\
M/3XS_P#F]H_L?AW_ **_#?\ AES?_P"4?U9^5SVE7_H'E_X,I_Y^O]/3^A:B
MOYZ?^'('[2'_ $FZ_P""GW_AZ?&?_P WM'_#D#]I#_I-U_P4^_\ #T^,_P#Y
MO:/['X=_Z*_#?^&7-_\ Y1_5GY7/:5?^@>7_ (,I_P"?K_3T_H6HK^>G_AR!
M^TA_TFZ_X*??^'I\9_\ S>T?\.0/VD/^DW7_  4^_P##T^,__F]H_L?AW_HK
M\-_X9<W_ /E']6?E<]I5_P"@>7_@RG_GZ_T]/Z%J*_GI_P"'('[2'_2;K_@I
M]_X>GQG_ /-[1_PY _:0_P"DW7_!3[_P]/C/_P";VC^Q^'?^BOPW_AES?_Y1
M_5GY7/:5?^@>7_@RG_GZ_P!/3^A:BOYZ?^'('[2'_2;K_@I]_P"'I\9__-[1
M_P .0/VD/^DW7_!3[_P]/C/_ .;VC^Q^'?\ HK\-_P"&7-__ )1_5GY7/:5?
M^@>7_@RG_GZ_T]/Z%J*_GI_X<@?M(?\ 2;K_ (*??^'I\9__ #>T?\.0/VD/
M^DW7_!3[_P /3XS_ /F]H_L?AW_HK\-_X9<W_P#E']6?E<]I5_Z!Y?\ @RG_
M )^O]/3^A:BOYZ?^'('[2'_2;K_@I]_X>GQG_P#-[1_PY _:0_Z3=?\ !3[_
M ,/3XS_^;VC^Q^'?^BOPW_AES?\ ^4?U9^5SVE7_ *!Y?^#*?^?K_3T_H6HK
M^>G_ (<@?M(?])NO^"GW_AZ?&?\ \WM'_#D#]I#_ *3=?\%/O_#T^,__ )O:
M/['X=_Z*_#?^&7-__E']6?E<]I5_Z!Y?^#*?^?K_ $]/Z%J*_GI_X<@?M(?]
M)NO^"GW_ (>GQG_\WM'_  Y _:0_Z3=?\%/O_#T^,_\ YO:/['X=_P"BOPW_
M (9<W_\ E']6?E<]I5_Z!Y?^#*?^?K_3T_H6HK^>G_AR!^TA_P!)NO\ @I]_
MX>GQG_\ -[1_PY _:0_Z3=?\%/O_  ]/C/\ ^;VC^Q^'?^BOPW_AES?_ .4?
MU9^5SVE7_H'E_P"#*?\ GZ_T]/Z%J*_GI_X<@?M(?])NO^"GW_AZ?&?_ ,WM
M'_#D#]I#_I-U_P %/O\ P]/C/_YO:/['X=_Z*_#?^&7-_P#Y1_5GY7/:5?\
MH'E_X,I_Y^O]/3^A:BOYZ?\ AR!^TA_TFZ_X*??^'I\9_P#S>T?\.0/VD/\
MI-U_P4^_\/3XS_\ F]H_L?AW_HK\-_X9<W_^4?U9^5SVE7_H'E_X,I_Y^O\
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MCU__ (55K?B.>Z2T^*/@+[?XJU+^R_'7APQL^C:G:_8[FW:1C'=Q9Y_6]?\
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M_8_#O_17X;_PRYO_ /*/ZL_*Y[2K_P! \O\ P93_ ,_7^GI_0M17\]/_  Y
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M_P#!E/\ S]?Z>G]"U%?ST_\ #D#]I#_I-U_P4^_\/3XS_P#F]H_X<@?M(?\
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MM17\]/\ PY _:0_Z3=?\%/O_  ]/C/\ ^;VC_AR!^TA_TFZ_X*??^'I\9_\
MS>T?V/P[_P!%?AO_  RYO_\ */ZL_*Y[2K_T#R_\&4_\_7^GI_0M17\]/_#D
M#]I#_I-U_P %/O\ P]/C/_YO:/\ AR!^TA_TFZ_X*??^'I\9_P#S>T?V/P[_
M -%?AO\ PRYO_P#*/ZL_*Y[2K_T#R_\ !E/_ #]?Z>G]"U%?ST_\.0/VD/\
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MZL_*Y[2K_P! \O\ P93_ ,_7^GI_0M17\]/_  Y _:0_Z3=?\%/O_#T^,_\
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M9_[=_P"T=JO_  4"_P""@?\ P2X_;7\9K\3/C?\ LYZY8?&KX#_%2U\$>!O
M%O\ $#]E?Q=IG@6/0UU+0? L=AH[>(/#MQXP\):AJ^I6=G=>;JOC75-#OYM+
MG\-P:6/WTH **** "BBB@ HHHH **** "BBB@#^>K_@OWT_X):_]I/?V=_\
MTJOZ_H33[B_[J_R%?SV?\%^^G_!+7_M)[^SO_P"E5_7]":?<7_=7^0KZG-O^
M29X3]<^_]3Z)C#^-7_[A_P#I+'4445\L;!1110 4444 %%%% !1110 4444
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M$_BK1=%\!6/AK4UM#IFM3^*;^]@T9;#5&O["'2YQ>,NI7-]96MC]HN+NWBD
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MQA;>#=6N8+FU3Q-HEM8Z]-IVS4-,BLKJ2V ![A17X7?\$2?^"@?QQ_:MT/\
M:R_9C_;!N[;5/VT/V#?V@/%WPA^-?B+2_#OAKPKH7C3P_J7BOQA%\.?%^D:#
MX6:+2M/MKBS\,ZYX=C:PM/[/U2W\-6^O6NI:F^K3RQ_NC0 4444 %%%% !11
M10 4444 %%%% !1110!_/1_P2Z_Y2X_\%S?^Q_\ V9__ $W?&.OZ%Z_GH_X)
M=?\ *7'_ (+F_P#8_P#[,_\ Z;OC'7]"]?4<8?\ (ZC_ -B7AC_UFLI,,/\
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MA[4M5TZ)[31O%NJQV_P[\*V,FJ+I/A#2/&6K:+KGB.T /5/@5^V9_P %7_\
M@FO_ ,%0_P!ES_@G;_P4O^.?P?\ VT/V>_VY%\70_ ;]J+2/"&B?#+XH^$_&
M>B:;=1V?@[6/#7AFPT"R=9O&K>'="U30_$6E>+!<V'Q,\)ZYX,^+TLOA?Q/\
M,++]'/\ @M+_ ,%1?B;^P-X-^ WP4_9+^%5C\?/V^_VT/']U\-OV9/A1J=GJ
ME]H-M%HK:0OC+XB>*H-.N]%MIM+\/3>(O#FDV&FZMXM\'V,]UKMWXKO]8;PG
MX"\9QQ_S.?M??LH?M;?LM?\ !:W_ ((4V?[87_!0_P 7_M]_$#Q]^T9'KVE7
M/B+X9:'\)])^$FDV?Q%^%T5[I/AGPSHGB[Q3%<V?B?6[W4))-;:'P]!=6WAS
M3=/M-$M5TJ5%^DO^"[&A_M/:[_P<5_\ !*C1OV??VCO#/[+WC;Q7^S5X@\(_
M 7XQ>.OAUI'Q3\(^!?C#KFN_M&:/XG5_!'BGPEXI\,ZUJ_Q%T?6?A[\.M)FN
MM/U.3P_KFL:#XB9- ETW3]:8 ^OS^Q1_P=4?#KP7;?%SPQ_P5>_9W^-'Q?M]
M'GU_Q'^S=XX^!WPYT+X>Z[?/I-KK&H>"/#GCVR^$5C:KJLVNB]T'P_>QZ9\+
M=#_<:=+=^*_"^A:IJD6F?K5_P1R_X*?Z-_P50_93N/BYJ/@&[^#_ ,<?A5XY
MU/X*?M(?"#4&>&3P;\6_#.D:-J6K7F@Z=J5P_B>S\%>(8-8CGT.'Q39VNL:/
MJ]EXG\%WMQK5_P"#[[7-1_.S_AA'_@YQ_P"DYOP)_P#$%_V?/_G(U]+_ /!$
MO_@D]\<?^"95Q^V;XJ_:"_:$\%_M#?$?]L#XN>'OB[XD\2>"_!%SX'M8/$EJ
M_CG4O%.H7NFL8-,CG\1Z]XXO+^/3]"TK2M(TJ. P65LEO)#;6H!^%_[$_P"W
M9_P7Z_X*D>*?VQ?V8OV9_P!HGX8_"U?@!^UUX]M/B#^V-\3?AK\)4O\ X>?!
M35)O$'A7X3? /X6?#_PS\)Y=,\7>([K4/!'CSQ+XI\9:[H>H>*M-M5\(QM\0
M/"C74(\0?M/^U)^V]\;O^"'O_!([P-XL_:Z^*5E^W!^V\WB+5?@S\-=>30]3
M\/V?QV^+WCWQGX]\3?#F#6M+\/:6FI6F@?#CX3VUL?%%T4TN]\6R>!DT"W\0
M6GB_QQHVH3_#?_!J-_SEZ_[2)>-/_=@JI_P<YZNOA?\ :Y_X-_?&'CK71HO[
M/7A;_@H/8ZO\9);G^U%TJU6P^)O[,FJ:;KNH3:99RSQC1/!&F_%-D^S7D&J&
MVO;U]-L[UXYI;$ Z#P7^R!_P=7?%_P "1_'7Q;_P50^ 7[-GQ<\5:=?>)_#G
M[+D7[/?PL\1^!/AQ#X@M-8U;2OAUXP\61_!_QE'#>^&+C4=.\,WE_+IWQKU7
M3K2%[^3QOXTU70K2?5ON?_@B]_P5B^*7[:NO_M'_ +&W[:?PZT;X-?\ !0W]
MBKQ5=>%/C+X2\+V]X/!?Q#\*:1=6/A9OBMX4FEGO;2T:Z\7+=P:MINF7]_X8
MO='UKP1XS\$:QJ/A_P 7G2_#/[W5_(W^SS_8^O\ _!X1^W%JOPW74;J#PQ_P
M3Y\*:/\ ''4[1+>VT>/Q?+I/[+,6EZ9<WMJL$>L$:(G@&'[)>2W^I0ZSHFI0
M*D=MX6D32P#X"_X*1_M%_'S]G#_@Z$O-6_9/^$EO\;/VJ/BI^Q1X*^!O[._@
M;5[JVL/!Z?$SXCZ;/;6_C#X@W]QJ.EFU\"_#[PWI_B/QSXA6*[MEOH?#\6EW
M^I^'-)OM1\4Z'][_ !E_9L_X.C?V7_A-X@_:J\*?\%+O@M^U7\0_ VCW_P 0
MOB%^Q[9_L[^!;/P/XBTRTNH=9\4>#/ACXIU#P9X7\1^)K;2-/2_GT:&U3X2^
M,]8TO2O[%\.W8UW5;;1K[C/%&H>$K+_@\V^'-MXCL=-N]8U;]B"^T_P#/?6V
MF3W6F>+8O@YX\U6\OM&EOW2ZLM2D\":9XUTV6YT59=3?2-0U6SE0:/=ZM)'_
M &+75U:V-K<WU]<V]G96=O-=7EY=31V]K:VMO&TUQ<W-Q,R106\$2/+--*ZQ
MQ1JSNRJI( /S,_X)P_\ !4'X._\ !0#_ ()]>'?V]1:_\*H\.Z1X?\<2_';P
MQJ]Y+K*?"'Q5\*+>ZNOB/93:K8V:OKGA^VTBU@\:>&]4MK"/4=2\&:YH5QJ6
MD:3X@DU+0-._![X(?'K_ (+K_P#!<?5O'?[2O[&_[1W@?_@F)_P3XTGQQJG@
MC]G>_P!5^$?AOXF_$K]H32O"OB+7/#_B3XDZA/XLT#5-7N)M-N[.\TW4K?2-
M3\"^ +/78HO 6GV/BKQ-X(\8>.:_._\ X)?7?B;Q+_P0(_X.,/$7P8US4&^$
M.O?%;]K35_AD\%MX@AAD\(/\%?#>K_$BXCBU723JL7_"0?!>Z\,6.J1:H1J=
MM8QQ'Q!%HRYO9/H/_@CE^S/_ ,%R_C1_P39_9<\=?L7_ /!8?X'?!W]G2X\)
M>(-$\#?".]_8W^#'BG5OAK=>&?'/BC0/%GA+7/$/B?X.7_B'6]8L?%^GZY<7
MFM:I?7\FNF[36[34=3TW4;+4;H _0+]FG_@H#_P4K_X)V_MW_ #_ ()T?\%C
M_%?PL_:$\(?MC_;_  [^QS^VO\)M+TCP5_:_C[1_$\ND0?#KXMZ%-X>^'6E7
M'B+5X?$7P^T"6W\/^'9M7T#Q+XI\"6*:U\5&\9ZMXF\/^W_\%G?^"C?[9'PO
M_:A_8K_X)=_\$Z+CX?>!OVL?VVVUO7[[X^?%31;/Q!X?^"GPW\/WUULUKPOX
M>UFPUSPQKOB*_@\*>/M1UV3Q+X:\60:5X<\,#2-!\&Z]XI\:Z-J_A'Y%^(__
M  0U_P""P?[5OQ\_8X^*'[=G_!4_X,?M ^$/V1OV@O!'QK\,>&]*_9B\'?#;
M4X$T?QGX+\0^+K/3KOX9^$/ *ZA?Z]IG@RPL+-?$=U?6%E<1QRP+:":ZDE_3
MC_@L'_P1O\'_ /!3I_@7\3/"/[1OQ"_9"_:[_9TU'5W_ &>OCS\/9I99[&\U
M6^T?Q/?:5JNE:7KO@[Q;<7VGQ^$[S4_"&O\ @GQUX7U[P7?W6K>(9(_$EA!<
M:'. ?FK\7OA9_P ',W_!.[0_!7[1G@[]L7P[_P %9_#&C^,/"UE\;/V1+7]G
M3P5X$\9:KX1U&]M;*\U#X<Z]X9T&Y\;:A):W%Y<Z?>:IX<GL+[P]%=:;XSUK
MP'XR\-:+KUCHGVE_P<BZ_P"(?%?_  0!_:_\4V.@^*/"NL^)?!'[,.OZEX7N
MK>^M/$WANRUC]ICX ZCXHT'7[6&*"[MI-'T:YU73O%5O/####:6^J1ZC%':K
M<H/S/_: ^/G_  <B_P#!%/X<77Q]_:&^(7[-W_!3S]C7X;:EI:>/M=BTO_A7
MGQM\/>'_ !9;:;X;TZY\27VD^#/#&I:=I6A_$"ZLX(O$D<'QGU"6UUV.[\2R
M6&CS-#X)_H_UO2OA!_P5T_X)H2V3CQ5X3^$7[>?[*UCJ-A)=1Q6_C;P!9?%[
MP-;:OHMY<VUG?/I=UXJ^'NL:A97DUDE_J/A?5]7T)K66;6?#MXYO #Y._P""
MW/[:_P 2?V/_ -C/PSH?[,>F^,[#XG?M*^,_"GP-\"?&+X9?"OQ3\7="_9L^
M'^O-92?$+X_W?A+X<VE]K6J)X!^&_P#:<_P[TSP_9WL]WXTN_#=W::9K%AIE
MWI%]_/Q\>/VZO^"<_P #=<_X(1_!S]F;PU^T9HGP>_8=_::FN==TO6?V._VA
M_ OB76]#O?A3XITWQ'XVT?0]=^&6BS?$+QQXI\;:QJ7CCQ[8^%8]5\4ZKK7B
M+6?$0TR^>>\E7^L/_@F$O[0^E?L,?L^_#_\ :O\ !%_X&_:$^"_@Z/X#_$J&
MZEAO;#Q?J7P5N[CX;Z5\4/#NL6]W=P:]X>^*?ASPYHWCZPUJ);!;U_$%QC1]
M'\O^S;7O_P!HO]C'X7_M.?%;]DOXP>/=>\>Z1XE_8V^,&H_&OX8V/A#5/#UA
MH6N^*M3\*:AX/GT_QY;:SX6U_4-4\/IIFI3SPVOA_4_"^HK?)%*^JR6ZO:R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 ?SU?\' G_(+_ ."7W_:47]G'_P!%
M^(Z_H47H/H/Y5_/7_P ' G_(+_X)??\ :47]G'_T7XCK^A1>@^@_E7U.;?\
M),\)^N??^I]$QA_&K_\ </\ ])8M%%%?+&P4444 %%%% !1110 4444 ?'?B
MK]@K]EGQ[^V)X;_;N\?_  NT;QW^T?X$^%/A/X0?#3Q9XN@M];L?A?X=\)^+
M/B7XQCUGP%HUU;-:Z)XUUG4_BEK=MJWBUS=ZM#I>F:+8Z#+H:?VV^M_SI?\
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M<OVSOV]_VZ/B'\,?@U^SO\"?!MAXO^,O_"J? 7A?1/B;H)\/#Q%K&EZUX/\
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M]!\2>+],\0^);:VC:[G\.Z5JD5H/M+1$ 'X7_P#!87XN?$7_ (*:_MU?!O\
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MMW\$^*;/2=0N]5G2>VU'08]93QO\/[O5=%B\'0_$BR^(VL:/_P )CI/]=E%
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M\%Q7;2>(]&AUW7O#;Z'XUU'QQ##X?T3Q#\0+#P%HTWPON?ZIZ*        #
M X  Z #L!1110!_(W_P0ET#4_P#@GI_P5#_X*M_\$F_&-CINBZ!KGC#3OVW/
MV7+BQ\)7GA73O%?PH\73V6BZ]_8$\=I;^&=0TOPUH7B+X4>$XM)\."&TT7Q3
MX1^)FF6 OHM"U6W\/?J+_P %@O\ @CYX5_X*@>&?@WXY\%_%C6?V:?VP_P!E
MKQ6OCS]FO]HOPUIT^IW'AK68-6T/Q&/#_BC3+'5-#U"_T=O$'AC0M;\-:_I^
MJ0^(/AQXGLQXC\/1ZA9WWBGPMXK^Z_B+^P]^S7\4OVJO@;^VOXL\!S_\-+?L
M\>&O%?@OX<_$O0?$OB3POJ1\&^+[35K74?"'C"V\/:IIMEX\\+6+^(/$.H:%
MX?\ %T&KZ3H>J>(-=U#3K2&YU:_>?ZTH _DUL_@5_P '>-_X=M/A7??M;?\
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M[N&3Q5J?BOQ_XDT"U.OZ1X \.>!+_P 5R^-[#^OVB@#YE_:*^#7CSQ3^R/\
M%OX#?LL>-K#]FWXA:I\$O$GPV^!'C3POIMKHNC?"76U\*S:'X%ET>RTC2[H>
M&M#T)H[#3X+CPSI7]J^&-+7[=X5AM]7T[3&B^,?^"+?[)'[;7[%G[%EA\&?V
M]OVD;?\ :7^,Y^)'C/Q=I6OVWB/Q3XZC\ >!/$<>CRZ5\-V^)'CG3=(\8_$"
MXLM=M_$OBVZUK7=/B&C7/C"7P3H4^H>%_"FAZE=_K110!_)AXQ_X(I?\%)OV
M#/VIOC_^TM_P1"_:D^!W@/X>?M/^()_%7Q4_9._:8\/ZDO@/0=>N]1O-42?P
M#J>@>%/%VG7MEHFKZ[KT_A6WFT_P#J?A;PM=MX6N->\9P00K<=1\&O\ @C%_
MP4+_ &R/VKO@S^U[_P %QOVIOA;\6=(_9D\1V/BG]G_]CC]G+2-0M/@I9>+-
M'NM)U/3O&/CW4K_P]X+BNVD\1Z-#KFN^&WT/QKJ'CB&'P_HGB#Q_I_@+1YOA
MA<_U3T4 <5\1YOB):_#_ ,9S?"'2_!6L?%*'PQK+?#O2OB/KFN>&?A_>^,18
M3CP[;^,]>\,>'O%GB+2O##:G]F_MF[T/PWK&J1V G%C927!C*_E3_P $@O\
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M;8^,+.S\/^,I;"[M],>/P]JD5QX-\6Z)K.C0:'>PZ3HOB3PM9:SJ'P%\0O\
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M=02P2R1M\+1?\$H_^"9\,44*?L&?LH,D4:1(9?@=\/[B4K&H13+//H<D\TA
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MVG_IQ]U3_/U_I:X/_#WK_@F!_P!'V?LU?^'-T+_X_1_P]Z_X)@?]'V?LU?\
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MC_T87^R9_P"&)^'7_P H*/\ AU1_P31_Z,+_ &3/_#$_#K_Y047X*_EXI_\
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M_P!'V?LU?^'-T+_X_1_P]Z_X)@?]'V?LU?\ AS="_P#C];W_  ZH_P"":/\
MT87^R9_X8GX=?_*"C_AU1_P31_Z,+_9,_P##$_#K_P"4%%^"OY>*?_ \I_\
ME?K_ $M3_:?^G'W5/\_7^EK@_P##WK_@F!_T?9^S5_X<W0O_ (_1_P />O\
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M_P />O\ @F!_T?9^S5_X<W0O_C];W_#JC_@FC_T87^R9_P"&)^'7_P H*/\
MAU1_P31_Z,+_ &3/_#$_#K_Y047X*_EXI_\  \I_^5^O]+4_VG_IQ]U3_/U_
MI:X/_#WK_@F!_P!'V?LU?^'-T+_X_1_P]Z_X)@?]'V?LU?\ AS="_P#C];W_
M  ZH_P"":/\ T87^R9_X8GX=?_*"C_AU1_P31_Z,+_9,_P##$_#K_P"4%%^"
MOY>*?_ \I_\ E?K_ $M3_:?^G'W5/\_7^EK@_P##WK_@F!_T?9^S5_X<W0O_
M (_1_P />O\ @F!_T?9^S5_X<W0O_C];W_#JC_@FC_T87^R9_P"&)^'7_P H
M*/\ AU1_P31_Z,+_ &3/_#$_#K_Y047X*_EXI_\  \I_^5^O]+4_VG_IQ]U3
M_/U_I:X/_#WK_@F!_P!'V?LU?^'-T+_X_1_P]Z_X)@?]'V?LU?\ AS="_P#C
M];W_  ZH_P"":/\ T87^R9_X8GX=?_*"C_AU1_P31_Z,+_9,_P##$_#K_P"4
M%%^"OY>*?_ \I_\ E?K_ $M3_:?^G'W5/\_7^EK@_P##WK_@F!_T?9^S5_X<
MW0O_ (_1_P />O\ @F!_T?9^S5_X<W0O_C];W_#JC_@FC_T87^R9_P"&)^'7
M_P H*/\ AU1_P31_Z,+_ &3/_#$_#K_Y047X*_EXI_\  \I_^5^O]+4_VG_I
MQ]U3_/U_I:X/_#WK_@F!_P!'V?LU?^'-T+_X_1_P]Z_X)@?]'V?LU?\ AS="
M_P#C];W_  ZH_P"":/\ T87^R9_X8GX=?_*"C_AU1_P31_Z,+_9,_P##$_#K
M_P"4%%^"OY>*?_ \I_\ E?K_ $M3_:?^G'W5/\_7^EK@_P##WK_@F!_T?9^S
M5_X<W0O_ (_1_P />O\ @F!_T?9^S5_X<W0O_C];W_#JC_@FC_T87^R9_P"&
M)^'7_P H*/\ AU1_P31_Z,+_ &3/_#$_#K_Y047X*_EXI_\  \I_^5^O]+4_
MVG_IQ]U3_/U_I:X/_#WK_@F!_P!'V?LU?^'-T+_X_1_P]Z_X)@?]'V?LU?\
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MG_AB?AU_\H*/^'5'_!-'_HPO]DS_ ,,3\.O_ )047X*_EXI_\#RG_P"5^O\
M2U/]I_Z<?=4_S]?Z6N#_ ,/>O^"8'_1]G[-7_AS="_\ C]'_  ]Z_P""8'_1
M]G[-7_AS="_^/UO?\.J/^":/_1A?[)G_ (8GX=?_ "@H_P"'5'_!-'_HPO\
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M_2U/]I_Z<?=4_P _7^EK@_\ #WK_ ()@?]'V?LU?^'-T+_X_1_P]Z_X)@?\
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M)@?]'V?LU?\ AS="_P#C]'_#WK_@F!_T?9^S5_X<W0O_ (_6]_PZH_X)H_\
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M"8'_ $?9^S5_X<W0O_C];W_#JC_@FC_T87^R9_X8GX=?_*"C_AU1_P $T?\
MHPO]DS_PQ/PZ_P#E!1?@K^7BG_P/*?\ Y7Z_TM3_ &G_ *<?=4_S]?Z6N#_P
M]Z_X)@?]'V?LU?\ AS="_P#C]'_#WK_@F!_T?9^S5_X<W0O_ (_6]_PZH_X)
MH_\ 1A?[)G_AB?AU_P#*"C_AU1_P31_Z,+_9,_\ #$_#K_Y047X*_EXI_P#
M\I_^5^O]+4_VG_IQ]U3_ #]?Z6N#_P />O\ @F!_T?9^S5_X<W0O_C]'_#WK
M_@F!_P!'V?LU?^'-T+_X_6]_PZH_X)H_]&%_LF?^&)^'7_R@H_X=4?\ !-'_
M *,+_9,_\,3\.O\ Y047X*_EXI_\#RG_ .5^O]+4_P!I_P"G'W5/\_7^EK@_
M\/>O^"8'_1]G[-7_ (<W0O\ X_1_P]Z_X)@?]'V?LU?^'-T+_P"/UO?\.J/^
M":/_ $87^R9_X8GX=?\ R@H_X=4?\$T?^C"_V3/_  Q/PZ_^4%%^"OY>*?\
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M_#WK_@F!_P!'V?LU?^'-T+_X_6]_PZH_X)H_]&%_LF?^&)^'7_R@H_X=4?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img75897552_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_12.jpg
M_]C_X  02D9)1@ ! @$!( $@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '/!@D# 2(  A$! Q$!_\0
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M0*6#J"I^&?\ AM?XI?\ 0O\ @#_P5^(O_FIH _3^BOS _P"&U_BE_P!"_P"
M/_!7XB_^:FC_ (;7^*7_ $+_ ( _\%?B+_YJ: /T_HK\P/\ AM?XI?\ 0O\
M@#_P5^(O_FIH_P"&U_BE_P!"_P" /_!7XB_^:F@#]/Z*_,#_ (;7^*7_ $+_
M ( _\%?B+_YJ:/\ AM?XI?\ 0O\ @#_P5^(O_FIH _3^BOS _P"&U_BE_P!"
M_P" /_!7XB_^:FC_ (;7^*7_ $+_ ( _\%?B+_YJ: /T_HK\P/\ AM?XI?\
M0O\ @#_P5^(O_FIH_P"&U_BE_P!"_P" /_!7XB_^:F@#]/Z*_,#_ (;7^*7_
M $+_ ( _\%?B+_YJ:/\ AM?XI?\ 0O\ @#_P5^(O_FIH _3^BOS _P"&U_BE
M_P!"_P" /_!7XB_^:FC_ (;7^*7_ $+_ ( _\%?B+_YJ: /T_HK\P/\ AM?X
MI?\ 0O\ @#_P5^(O_FIH_P"&U_BE_P!"_P" /_!7XB_^:F@#]/Z*_,#_ (;7
M^*7_ $+_ ( _\%?B+_YJ:/\ AM?XI?\ 0O\ @#_P5^(O_FIH _3^BOS _P"&
MU_BE_P!"_P" /_!7XB_^:FC_ (;7^*7_ $+_ ( _\%?B+_YJ: /T_HK\P/\
MAM?XI?\ 0O\ @#_P5^(O_FIH_P"&U_BE_P!"_P" /_!7XB_^:F@#]/Z*_,#_
M (;7^*7_ $+_ ( _\%?B+_YJ:/\ AM?XI?\ 0O\ @#_P5^(O_FIH _3^BOS
M_P"&U_BE_P!"_P" /_!7XB_^:FC_ (;7^*7_ $+_ ( _\%?B+_YJ: /T_HK\
MP/\ AM?XI?\ 0O\ @#_P5^(O_FIH_P"&U_BE_P!"_P" /_!7XB_^:F@#]/Z*
M_,#_ (;7^*7_ $+_ ( _\%?B+_YJ:/\ AM?XI?\ 0O\ @#_P5^(O_FIH _3^
MBOS _P"&U_BE_P!"_P" /_!7XB_^:FC_ (;7^*7_ $+_ ( _\%?B+_YJ: /T
M_HK\P/\ AM?XI?\ 0O\ @#_P5^(O_FIH_P"&U_BE_P!"_P" /_!7XB_^:F@#
M]/Z*_,#_ (;7^*7_ $+_ ( _\%?B+_YJ:/\ AM?XI?\ 0O\ @#_P5^(O_FIH
M _3^BOS _P"&U_BE_P!"_P" /_!7XB_^:FC_ (;7^*7_ $+_ ( _\%?B+_YJ
M: /T_HK\P/\ AM?XI?\ 0O\ @#_P5^(O_FIH_P"&U_BE_P!"_P" /_!7XB_^
M:F@#]/Z*_,#_ (;7^*7_ $+_ ( _\%?B+_YJ:/\ AM?XI?\ 0O\ @#_P5^(O
M_FIH _3^BOS _P"&U_BE_P!"_P" /_!7XB_^:FC_ (;7^*7_ $+_ ( _\%?B
M+_YJ: /T_HK\P/\ AM?XI?\ 0O\ @#_P5^(O_FIH_P"&U_BE_P!"_P" /_!7
MXB_^:F@#]/Z*_,#_ (;7^*7_ $+_ ( _\%?B+_YJ:/\ AM?XI?\ 0O\ @#_P
M5^(O_FIH _3^BOS _P"&U_BE_P!"_P" /_!7XB_^:FC_ (;7^*7_ $+_ ( _
M\%?B+_YJ: /T_HK\P/\ AM?XI?\ 0O\ @#_P5^(O_FIH_P"&U_BE_P!"_P"
M/_!7XB_^:F@#]/Z*_,#_ (;7^*7_ $+_ ( _\%?B+_YJ:/\ AM?XI?\ 0O\
M@#_P5^(O_FIH _3^BOS _P"&U_BE_P!"_P" /_!7XB_^:FC_ (;7^*7_ $+_
M ( _\%?B+_YJ: /T_HK\P/\ AM?XI?\ 0O\ @#_P5^(O_FIH_P"&U_BE_P!"
M_P" /_!7XB_^:F@#]/Z*_,#_ (;7^*7_ $+_ ( _\%?B+_YJ:/\ AM?XI?\
M0O\ @#_P5^(O_FIH _3^BOS _P"&U_BE_P!"_P" /_!7XB_^:FC_ (;7^*7_
M $+_ ( _\%?B+_YJ: /T_HK\P/\ AM?XI?\ 0O\ @#_P5^(O_FIH_P"&U_BE
M_P!"_P" /_!7XB_^:F@#]/Z*_,#_ (;7^*7_ $+_ ( _\%?B+_YJ:/\ AM?X
MI?\ 0O\ @#_P5^(O_FIH _3^BOS _P"&U_BE_P!"_P" /_!7XB_^:FC_ (;7
M^*7_ $+_ ( _\%?B+_YJ: /T_HK\P/\ AM?XI?\ 0O\ @#_P5^(O_FIH_P"&
MU_BE_P!"_P" /_!7XB_^:F@#]/Z*_,#_ (;7^*7_ $+_ ( _\%?B+_YJ:/\
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M_K_AGY7_ -#6BO\ /*_XBU/^"BW_ $1/]BK_ ,-Y\<__ *(RC_B+4_X*+?\
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MO_\ 1*?V5/\ PB?B[_\ /QH_XE%\9/\ H!R#_P /N'_^5A_Q-%X4?]!F=_\
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M7Z*_B@_XB1/VW_\ HE/[*G_A$_%W_P"?C1_Q$B?MO_\ 1*?V5/\ PB?B[_\
M/QH_XE%\9/\ H!R#_P /N'_^5A_Q-%X4?]!F=_\ AEK_ /RP_M?HK^*#_B)$
M_;?_ .B4_LJ?^$3\7?\ Y^-'_$2)^V__ -$I_94_\(GXN_\ S\:/^)1?&3_H
M!R#_ ,/N'_\ E8?\31>%'_09G?\ X9:__P L/[7Z*_B@_P"(D3]M_P#Z)3^R
MI_X1/Q=_^?C1_P 1(G[;_P#T2G]E3_PB?B[_ //QH_XE%\9/^@'(/_#[A_\
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M ,_&C_B47QD_Z <@_P##[A__ )6'_$T7A1_T&9W_ .&6O_\ +#^U^BOXH/\
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MS^E^BBBOYY/W4^</VL/^2(^)?^O_ ,._^GZPK\CJ_7']K#_DB/B7_K_\._\
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MH **** "BBB@ HHHH **** "BBB@ HHHH _KB_X*S_\ (I_\$S_^T<?P"_\
M2?5*_'6OV*_X*S_\BG_P3/\ ^T<?P"_])]4K\=:_I?P,_P"34<'_ /8)C_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXE^-5W^UQ8FRN91IUOK7QUUC6HOBCI>BZ7J=]?:MIF@67B'1?#VJZ?;)>ZI
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M$S1/$V@ZA8^(_ <4L/\ )M7^EU_P;GZ#H?PU_P""-GPM\?6&GZ3IUUXMUO\
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M_@JK\+/C)H%Q^R!^SI\/_C)\!++PKI.K^([C4#ID_BS4/$(U+4$\0^'A:O\
M$OP]XAA:/3(M-ETFXT;PI>QF2^9Q+JTMO=6%MEQ1X[<=Y!G_  ]P/4X=X*R?
MB[$\.4\]S[$\5<1QRGAR&)JUL13AE638QXGV5:K.-"+I8BMF%3VU>=7#JA#Z
MO.K+7ASP8X+SO),]XQIY]Q=FO"]#/ZF2Y)A^&L@EF>?3H4Z6'G/,LUPBPWM:
M5.,J\O:4*6"INE1A3KNM/V\*<?X,/&/@KQE\._$FJ>#?B!X2\3>!?%^B2QP:
MUX5\8Z#JOACQ)I$\T$5U##JFAZW:6.J6$LMM/#<1QW=K$[P313*#'(C'^F#X
MRZ?_ ,,9_P#! 7X2^&_"R0+XJ_:_UGP-J?C/Q1H2_P#"+ZI)I7Q1M-5^+A_M
M&YTY+RXUXV?@KPQX<^%NH07VI6AU;0;FY\Q8--CET!O!?^"S7[='PS_:D\*>
M O 6L?LG_'/X#?'WP/XHMM:LO$'QR\$Z;X)\0S?#&]T_Q+8:OH4=C)>S>(9+
M#4?$\>DZA8QRQS:5;W.DZN(+D74D_G>]?\% 8D^+7_!#3]@OXA>!I/[9T#X8
M6WP=\,^+Y8# W]EW7A_X<ZY\+M?GF=;AE$.E>/-%'AZ:)=]U]JO[?S((1%<B
M+IXEXCSKC#"^ ^)XJX?EPQ1S3Q/P<LVRJ>-P^88&OCLLP..Q.05*.8867)6P
MF.QD%7PN%J2O*K#V56.(>&C5GS\/9!E'"N)\:,/PWG<>(JN7>'6*CE>91PE?
M XRC@\QQN!H9U3JX'$QYZ6*P>%FZ&)Q%.-E2FZM.5#V\J4/CCX??\%<-._9B
M_87\#?LX_L:_#[4?A'\='U2UU;XM?&K6M%\%^((==U"X6YN/$FKZ%:Z@NK?V
MCKNJSQZ/H>FZAXMT>]B\.^#;!]'TJSBO(=%U+1OO3_@KMK6M^(/^"7'[(NM_
MM>Z98:;^V?K'BC1;BQ5M(\(:5XQEMH?#VLGX@3W]GI2"+2-!O;"Z\$ZAXRT?
MPS'IUM:>,[OPA!<Z1IL-N;"T]3_X(K?\$OO"G@KX<>$/VV_B3:^'OB%\4_&/
MAW_A*?@9X2U"YG@\*^!+*\MI7T?7=8O_ .RM4D'C#5F\L+J=OH^JQ^#=/F:X
MTVSU+6F)MOAW_@KM^Q%_P4#U.R\;_MI?M3?%+X!Z[X/\-:AH_A_PY\//AKXN
M^)6I)X'\/^(-<ATS1]!\*:1XD^%WAG2V@@N;N*YUS5+S5X=2U:X^T:C<FYN&
MCMT^(H9GX6YIXWY5E7#N)RO)<5P[QKC<YSSBO,<17K<4<9<6YG[?+H\)Y+B*
ML*F,ED6'Q-65/'_6:RP$^2.&RZA3A_M6+^PK9=XCY=X/YEF>?8?,<WP^>\'X
M/*<FX9P.'HTN'.%.%\N]ACWQ-F]"G.GA8YU7PU-3P7U>E+&P4I5\=6J2_P!F
MPOLOQUTA?VR/^""/P:^-NO6#WWQ/_97GL-)MM9^S2ZKKUWX=\-^+X_@WKUM_
M:+64MY)9Z[X<'A'QMXIF+Q?Z9X5AN=0U"Y&FRR7/\NU?U)^#;^/X$?\ !N?X
MIO-=AA\/>(?CCKVJ:?X9T[Q-'<6$_B.3Q=\7H;6"72+*[O;6YO);WX:^%M7\
M5:')8Q""[TVPCUQ;._TL7%U<_P ME?M/@4YTJ/BCEU"_]B95XO<9X/(8K2E0
MPDJF#Q6*PN%2<H_5*&8XC%NE*,FI5*E:_+*,HK\D\9U"I5\.,=7M_;&9>%O"
M>+SJ3_B5L2J6)PV&Q.);49?6JV!H895(RBG&$*5KQ:;_ % _X)$?LCZ3^U[^
MV/X3\,^,M*BU?X9?#C2[KXH?$+3KZPDO-(US3=!OM.LM(\*ZBPN;6#RO$&O:
MG8+<64SW']H:/9:S$UC<VJ7AB_4W_@XP_:?OD\1_"O\ 8[\)78L?#6AZ#8_$
M_P ?VFG/<6L%QJM]-J.D^#/#EW#!=Q6TEOHVD6=QKHLYM/EA4ZWI-Q!<B:V>
M*'U+_@VA\"65MX'_ &HOB:P234=9\6> O L>_P EY+2S\,:/K&ORFWS9K/;K
MJ$WB^(796_EBNSIMF&L[=[-9KG\+O^"K_C@_$#_@H?\ M4ZT;Q+[^ROB9>^!
M_.2"YMQ$/AS86'@$692[59'?3QX<%B\\8-M<O;M<6;-:RPL?@L+4EQ[]*G,J
M&/<J^3^%'#-.>4862<\-#.\QI9=*MBY4VO9PQ'/F>(4:KO4D\KP4H:4DZ?VN
M)IQX*^C7@*N"4:.:^)G$,H9IB8M1Q$LGP%3'>RPL:B;G*@X9=0<J:Y81698N
M,M:C]I_;9X__ &//@O\ M._L?6OP9\5^$="TBU\9?"_PM'8>(M#TBPTO6_#O
MB.ST?3K_ $#Q#8WMC;PW#2Z9J\%K=7%I([6NJ6BW.FWT4UG>3Q/_ )]/[0?P
M*\?_ +-'QE\?_ WXG6$.G^-/A[KDNCZF+22>;3M1MI(8;[1]>T>XNK6RN;K1
M/$6C7=AKFBW5Q96<]UI>H6D\MI;R2-"G]^O[3_[2>N_LB_L'Z'^T#H&EV6N3
M> ]*^!+:KHM_"TT>K>&=>\3^"O#GBFQMBEW8M;ZK+X?U;46T2\:Y6"SUA+"Y
MO(;RRBN;*Y_.K_@K!^R3X*_X**_LH>!_VW_V9X[[Q9\0_!_@&V\1:'9Z%IL;
M:G\3_A1?7,>I:MX:O=-O&M=1@\5?#^2XUG7M*TZ%CJKR+XJ\+'1M8US4-!AT
MW\0^CKXCYQP+FTZ7$E2J_#SC7BO,N'\-FF(K3GA\CXPPE+ UJ4\1.?-'"X;,
ML)C<+AZ\JCA3DJ<,8ZE.AEN,;_8/'C@'*N-,KIU,@A37'G"/#.7YW7RVC2A#
M$9SPKBJF*HU(T81M/$U\OQ.$Q%>@H*4XNI/"JG.MF&%MZQ_P50\&^$-(_P""
M17C;4=)\*^&]+U >#O@0HO\ 3M#TRRO LOCKX?>:HNK:UBGQ)_RT&_#_ ,6:
M_ACK^\'_ (*QJR_\$?\ QPK*59?"'P&5E8$,K#QW\/P58'!!!!!!&01@U^&/
M_!*GXK_\$GO ?P&\<:5^WEI?PUOOBM=?%W5]0\+R^,_@S\0OB-J2_#V3P;X'
MMM/CM]9\(^!?%&GV=B/$EKXG9-,N+Z"\BN&N+I[1(+R":?\ 2OH\\6XWA7P@
MXNSVCP]Q'QCB*7B9F>&CE/#N$JYGFU2%?+<@@ZU/#Q4YNAA[N=:25H1=]+GY
M]XZ<,83B7Q2X7R:MGV0\*4*GA[EV(EFF?8JEE^64YT<?G,E2G7DX05:O\%*+
M=YR5C\#**_LL_P"&C?\ @W!_Z%[X#_\ B+/QL_\ G0U^4'_!5_XI_P#!+SQY
M\.OA7I_[ VE_#BQ\66?C#6;OQ])X,^#OCGX<7KZ =(ABTE+K4_&'@?PO'?6W
MV]KDBRL+NX<2!9KB !(77]EX6\9LWXDS_+<CQ'@_XH\.T<PJU*53.L^X=Q6"
MRG *G0JU_:8W%3I*%*$W25&#DTI5JE.%[R/RCB3PFROA_),PSBAXJ>'&?5<#
M2A4AE&2Y]A\7F>-<ZU*C[/"8>%5RJS@JCJS23:I4YRMH[?KE_P $#/AYX&\+
M_L$?$/XI>-?#?A_6(]7^*_Q \6SZGK'A?1Y+VT\-^$?"OAO1Y;"VU;5MRWVG
MVUSX>UB_A=[BRL+.]U"_MV6.2.ZNYJ$O_!?;_@FS%+)$?V;OCLQCD>,LGP>^
M I1BC%25)^,@)4D94D#(P<"N>_X)+?M=_L1^#_\ @G+:? KXN_M&^!/AMXP-
MM\9+/XB^'O$FKOX4U_3[#QAXD\5&TF\-R^(K%M-\3W]SX2O],O[!?#$.O*E]
M.NFW%A+JEM>61W_V8O&?_!![]I;Q9<?LK_#7]GKP99ZWJ]IJ6A>%M3^(OPWO
M=,USX@0Q:2MS?3^#_BKJ&LZI\1+36UM?MCV=QK6N>%O%C76GWEWI",ZVMU/_
M "9Q)DV7XCQ \7\^X]X \5,^P&!XGQ%;"8WANEBLLR[+N'\'4Q-&KF-?$8AX
M>EBJ-;#4<+B,'+#J=&>#HUL95Q%*BU5G_3N09MCL/P1X5Y+P3QOX;9)C<9P[
MAZ>*PG$%7#9AC\?G>+AAJU/ 4:%!5ZN'K4L15Q-#%1K.%6.*JTL+3H5:R]G#
M\+_^"A/[1OP<_P""B?[8/P=U#]G_ ,,^*?AGX7U[P]\/?@V;?QUX7\+:!=V?
MB+5O'VO+-K2Z/X*\4>)M.N=,CB\56,A<ZG;WUQ+;7436\2K#-+_4#^Q/^P=^
MP5^P]XPT3X,6^M^#_BO^UQXN\$GQ+KFL^.+/3]7\<7/AO3Q''J>H^&O!>=9T
M_P"%W@JXU"ZD2U0S?VKKBB"QU;Q1XKDT>T>S_FE_X*U_L VG_!/3X\^"_$WP
M<U[6K'X5?%"75?%OPLWZG>KXH^'/B7PAJ.F7&L>&+3Q"+MM6U"'PU-JWA_5?
M#'B6XGBUN.SU&ULM0N=0U?2+G7M4]1_X('ZWK7B;_@HW?^(O$>KZIX@\0:[\
M)_B?J^MZ[K>H7>JZSK.K:CK'A>[U#4]5U._FN+W4-1OKJ66YO+V[GFN;FXDD
MFGE>1V8_KW'V183B?P(P&<< \:9UE?ASP_P9FN/IY+25LRS[&X.HUAL'G>8S
MDJT:.5XNCBZ&/P<?;T<3BH7C*]&ABH_EG!&=8KAWQHQF5<;\)91F7'N><6Y9
M@:F;U&G@,EP>+@OK&+R? 0C[&5;,<+5PU;!8MJA5P^'G:4;5:V'EUO\ P<8Z
M'HF@?MB_"*TT+1]*T6UE_9H\-W$MMI.GVFFV\EPWQ2^+433R0V<,,;S-'%%&
MTK*7*1QH6VHH'Z/V/_!?3_@FW;V5G;R_LW?'=Y8+6WAD=?@]\!F5I(HD1V5F
M^,:LP9E)!90Q!R0#D5^>G_!R1_R>;\'O^S8O#/\ ZM7XNU^ WA7PQKOC;Q1X
M;\&>%]/?5O$WB[7M'\,>'=*CFMK>34]=U_4+?2M(T^.XO)K:S@>\U"[M[99K
MJX@MHFD#SS11*SK[W!'AAPGXF>"_A96XOJ9FH9#D..K8>M@\VK9;&$<=B82Q
M=3%U8W52$8Y?1E&5225&*J.Z4FUXW&/B+Q/X>>+?B11X5IY<YYUG. I5Z.+R
MRECW.6#PS6%AAJ<K.$I2QU:,HTTW5<H*UXH_T*OV'OVMOV:/V^O#_C;Q;\(/
M@!XJ\+^%O VLV7AV_P!>^)W@#X2:/::IK]U8IJ=QI.C6WA3QOXTU.6XTS3KG
M3KS4)]1L-,L?+U2R2RN[VX6]AL_YX_B3^V[H7[.7_!<[Q]\1_A?KNF:?\'-4
M\=^ ?@/\8-/$<'A3PE)HFD^%O!WPX^(%Y??VAID=K:P_#WQQH^H>*[/7;*.S
M@U-O#TRVVN+X=\0:A<W?[&?&#Q%X>_X([?\ !*K3_#/A&^0?$^#P[!X \%ZE
M%%=+)K7QV^(EMJ&IZ_XU6"]A\;6%BGAUU\3^.[72]6:?PQ<-X?L/"*W5K%JN
MGH?X2Y99)Y9)I6WRS2/+(^ -TDC%W;"@*-S$G   S@ "OSWP \-.'^*LT\5.
M(L'0QR\.LUPN9^'W#>#S+$5L;4S/ 5:F#K9CG-2>*2J0K0E@LOKX.I2Y5A\5
MB<31ISA6R]2/N?&_Q!SSAK+?#;(L56P;X\RW$9=QQQ!B\OH4L'#+\;2IXFE@
M<JA'#-TY4IQQ>.H8NG4O[?#8?#U9PE2QKB?U8?\ !P_^QEHJ6'@W]MWP'ITL
M-_?WVC?#?XP6NDZ5%)9:@D]E?W'@KXA:I=6%D)X+I(;/_A"]7U;5[V6RN8AX
M%TRR6UNQ(=2_E+K^]W]JIH_VF?\ @BMK7B_Q.DFB7GB[]E+X9_&.6'3)%F%C
MK>C:/X1^)$.GQ/+%%'-9SWFG?V7<.]NC?8[F6:&.*X6%H_X(J_5/HK<09EF/
MA_F/#F;UY5\=P+Q)F'#%.<WSM9=0IT*V#I>U5XU(X>I4Q6$HI2E[/#8>A!/D
M4#\U^DGD>7X#CC 9_E5*-'!\:9!@>(IQ@G"+QU>=6EBJOLG:4)8BG##8FJW&
M//7KUI-<[F%%%%?TR?SR%?LW_P $%/\ E(GX'_[)]\1__3/#7XR5^S?_  04
M_P"4B?@?_LGWQ'_],\-?FGC+_P FH\1/^R0SW_U K'Z%X3?\G-X#_P"RJR7_
M -3J)_>;1117^*1_KL?.'[6'_)$?$O\ U_\ AW_T_6%?D=7ZX_M8?\D1\2_]
M?_AW_P!/UA7Y'4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]AZ_KNL>!=,T;0O[>_MO5M%M-2;5=,TG5+VXT'X!_:(_X+R?\%1?VE?"6K>
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MTO6;IO#UOHK2W-BEJC1:3/>:=<_OV?>&?&U+QMR'Q0X5QG#E7+JF4X'A[B;
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M_"@O'7_#=G_"I/\ A:?_  N#6/\ A&/^$^_X2S^UO^%?_P#"%^!?[/\ LO\
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M'_\ 3/#7XR5^S?\ P04_Y2)^!_\ LGWQ'_\ 3/#7YIXR_P#)J/$3_LD,]_\
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M+KNOZ_X=?>=/17,?\)MX,_Z&[PQ_X/\ 2O\ Y+H_X3;P9_T-WAC_ ,'^E?\
MR71[&K_SZJ?^ 2_R"Z[K^O\ AU]YT]%<Q_PFW@S_ *&[PQ_X/]*_^2Z/^$V\
M&?\ 0W>&/_!_I7_R71[&K_SZJ?\ @$O\@NNZ_K_AU]YT]%<Q_P )MX,_Z&[P
MQ_X/]*_^2Z/^$V\&?]#=X8_\'^E?_)='L:O_ #ZJ?^ 2_P @NNZ_K_AU]YT]
M%<Q_PFW@S_H;O#'_ (/]*_\ DNC_ (3;P9_T-WAC_P '^E?_ "71[&K_ ,^J
MG_@$O\@NNZ_K_AU]YT]%<Q_PFW@S_H;O#'_@_P!*_P#DNC_A-O!G_0W>&/\
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M,?\ ";>#/^AN\,?^#_2O_DNC_A-O!G_0W>&/_!_I7_R71[&K_P ^JG_@$O\
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MUG_X$P?_ !=']HZ?_P _UG_X$P?_ !='MJ7_ #]I_P#@<?\ ,/JV)_Z!Z_\
MX*J?_(^:^\N453_M'3_^?ZS_ / F#_XNC^T=/_Y_K/\ \"8/_BZ/;4O^?M/_
M ,#C_F'U;$_] ]?_ ,%5/_D?-?>7**I_VCI__/\ 6?\ X$P?_%T?VCI__/\
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M^1\U]Y<HJG_:.G_\_P!9_P#@3!_\71_:.G_\_P!9_P#@3!_\71[:E_S]I_\
M@<?\P^K8G_H'K_\ @JI_\CYK[RY15/\ M'3_ /G^L_\ P)@_^+H_M'3_ /G^
ML_\ P)@_^+H]M2_Y^T__  ./^8?5L3_T#U__  54_P#D?-?>7**I_P!HZ?\
M\_UG_P"!,'_Q=']HZ?\ \_UG_P"!,'_Q='MJ7_/VG_X''_,/JV)_Z!Z__@JI
M_P#(^:^\N453_M'3_P#G^L__  )@_P#BZ/[1T_\ Y_K/_P "8/\ XNCVU+_G
M[3_\#C_F'U;$_P#0/7_\%5/_ )'S7WERBJ?]HZ?_ ,_UG_X$P?\ Q=']HZ?_
M ,_UG_X$P?\ Q='MJ7_/VG_X''_,/JV)_P"@>O\ ^"JG_P CYK[RY15/^T=/
M_P"?ZS_\"8/_ (NC^T=/_P"?ZS_\"8/_ (NCVU+_ )^T_P#P./\ F'U;$_\
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M_+O+\^[#ZO0_Y\TO_ (_Y>7Y]V?A#_Q#8_\ !(G_ *-\\7?^'U^-/_S<4?\
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M #<5^[U%'^N7%O\ T4V??^'7&_\ R[R_/NP^KT/^?-+_ , C_EY?GW9^$/\
MQ#8_\$B?^C?/%W_A]?C3_P#-Q1_Q#8_\$B?^C?/%W_A]?C3_ /-Q7[O44?ZY
M<6_]%-GW_AUQO_R[R_/NP^KT/^?-+_P"/^7E^?=GX0_\0V/_  2)_P"C?/%W
M_A]?C3_\W%'_ !#8_P#!(G_HWSQ=_P"'U^-/_P W%?N]11_KEQ;_ -%-GW_A
MUQO_ ,N\OS[L/J]#_GS2_P# (_Y>7Y]V?A#_ ,0V/_!(G_HWSQ=_X?7XT_\
MS<4?\0V/_!(G_HWSQ=_X?7XT_P#S<5^[U%'^N7%O_139]_X=<;_\N\OS[L/J
M]#_GS2_\ C_EY?GW9^$/_$-C_P $B?\ HWSQ=_X?7XT__-Q1_P 0V/\ P2)_
MZ-\\7?\ A]?C3_\ -Q7[O44?ZY<6_P#139]_X=<;_P#+O+\^[#ZO0_Y\TO\
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M C_EY?GW9^$/_$-C_P $B?\ HWSQ=_X?7XT__-Q1_P 0V/\ P2)_Z-\\7?\
MA]?C3_\ -Q7[O44?ZY<6_P#139]_X=<;_P#+O+\^[#ZO0_Y\TO\ P"/^7E^?
M=GX0_P#$-C_P2)_Z-\\7?^'U^-/_ ,W%'_$-C_P2)_Z-\\7?^'U^-/\ \W%?
MN]11_KEQ;_T4V??^'7&__+O+\^[#ZO0_Y\TO_ (_Y>7Y]V?A#_Q#8_\ !(G_
M *-\\7?^'U^-/_S<4?\ $-C_ ,$B?^C?/%W_ (?7XT__ #<5^[U%'^N7%O\
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MXW_Y=Y?GW9K]7H?\^:7_ (!'_+R_/NS\(?\ B&Q_X)$_]&^>+O\ P^OQI_\
MFXH_XAL?^"1/_1OGB[_P^OQI_P#FXK]WJ*/]<N+?^BFS[_PZXW_Y=Y?GW8?5
MZ'_/FE_X!'_+R_/NS\(?^(;'_@D3_P!&^>+O_#Z_&G_YN*/^(;'_ ()$_P#1
MOGB[_P /K\:?_FXK]WJ*/]<N+?\ HIL^_P##KC?_ )=Y?GW8?5Z'_/FE_P"
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M=ZBC_7+BW_HIL^_\.N-_^7>7Y]V'U>A_SYI?^ 1_R\OS[L_"'_B&Q_X)$_\
M1OGB[_P^OQI_^;BC_B&Q_P""1/\ T;YXN_\ #Z_&G_YN*_=ZBC_7+BW_ **;
M/O\ PZXW_P"7>7Y]V'U>A_SYI?\ @$?\O+\^[/PA_P"(;'_@D3_T;YXN_P##
MZ_&G_P";BC_B&Q_X)$_]&^>+O_#Z_&G_ .;BOW>HH_URXM_Z*;/O_#KC?_EW
ME^?=A]7H?\^:7_@$?\O+\^[/PA_XAL?^"1/_ $;YXN_\/K\:?_FXH_XAL?\
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M7>7Y]V'U>A_SYI?^ 1_R\OS[L_"'_B&Q_P""1/\ T;YXN_\ #Z_&G_YN*/\
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MXAL?^"1/_1OGB[_P^OQI_P#FXH_XAL?^"1/_ $;YXN_\/K\:?_FXK]WJ*/\
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M+O\ P^OQI_\ FXK]WJ*/]<N+?^BFS[_PZXW_ .7>7Y]V'U>A_P ^:7_@$?\
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M\)77Q"O==LO"^O>+8;J:YU?Q!=_$F?2M.NK#4)O"'B;5M$,>K_H7_P $(_\
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MX56>O7Z:_)X7\.Z_=^-/ABEG?67P[\1:3IOAN^U3QC8_L_\ \$4O^"@?C/\
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M>"_^"6/C_P #VMS@2^)?!OA/]FWQKX#\1^(=."[@]AI'B_\ XD%VTACD6_\
ME2-X_P!Y7VK\0_$'[&'_  4SUC]I7]A75/B!X]O_ !1^R[X]^':?'?P=X"\;
M?$?X$^//#^O:QH<WBGP>]EXC\-:AX0\<ZCX1OK2Y$W_"0>&[O_A$=?NK<Z=;
M:QJ\-MJ%J #Y-_X)'_&OXO:;^TE_P4A_X)W>.?C]XQ_;&^'?[ /CSX%:5\(_
MVJ?B1K&E^)OBYJ>D?&KP!K/B7Q!\"/C=XTTJSTS3_B'\4O@=XA\-7NAZYXXM
MH;_6]3N;^^L_',7A#6M/L/"5EI_\$S?'_P 0/@]^V]_P4W_X)M>-[S5-<\!_
M!'XF^$/VL/V4O$.L^)M%U:[TOX ?M@PZSXSUOX-:7I-I9V>LZ9X/^"/Q<T_Q
M?HW@Z37KC5M5BT;Q(F@M)9>&= \&76O?/'_!([PWH7[$/_!13]O7_@E+\#/B
M+J_Q>_96^%7PZ^&'[4_A2?7=#\(:EXT_9]^,/QH\0ZU'\3O@U\5OB_X6TK2M
M9^)_B?Q=;R:!X[\$ZA\34NO'.D_#[3;#PG)?:I%X3O->UOU?X;76F^)?^#EC
M]IC4/#DA6+X:?\$E?@G\/?B)#;:A:74$GCKQ9^TAKGQ \.RZG:75L-4T_48?
M <NG)96NCW0T<V$[:AJZ3:EJ>G"S /WTHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#^>G_ ((&?\A7_@J__P!I1/VA
M/_1FF5_0M7\]/_! S_D*_P#!5_\ [2B?M"?^C-,K^A:OJ>-?^2FS+TP/_JNP
MACA_X,/^WO\ TJ04445\L;!1110 4444 %%%% !1110 4444 %%%% !1110
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M%'Q ^ -_\)1/XON;Z74/$FA7/PH^,,=[9:A>65M-X@MK[2M<F6&1O*/])_\
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ME'_P3H^(/P7_ &?/$GA?]FFX_:M_:,_:,^,?PWNOBAJV@^%'\8:-X.T'P?\
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MK_Q/^&5SJOAZROKQM2?2+C0O@EX):%WL4BATNYT"7^T+W^T(DMP#^ORBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /YY_\ @@)]_P#X*F_]
MI//V@?\ TG\.U_0Q7\\__! 3[_\ P5-_[2>?M _^D_AVOZ&*^IXU_P"2FS+T
MP/\ ZKL(8X?^##_M[_TJ04445\L;!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?Q@?\%"/^#F/XY>*_!'Q]U/_ ((Z?LY:O\9?A#^S-;:+>?'W
M]O3XF^&+S3_@OX.N+K7=)LCX?^'W@[Q%-X<N/%-WJ$FI:?I*WWB.[L/$%R+O
M5K[0/AS?Z!:Z5XZNO[/Z_ 3_ (+=? WX0_LX_P#!!#]LWX._ OX>>&/A=\,_
M!?P?\&Z5X<\(>$].CT_3;.WMOBI\.8?M%S)F2]U;5KSRQ/JNNZQ=7^MZU?/-
MJ.KZA>W\\]S( ?HI_P $S/CS\0_VHOV /V1?VB?BS>:;?_$GXT? GP!\1O&M
MUHVEV^BZ0_B'Q5H=KJNHKI>DVN8;#3XI[EHK.VWS21VZ1K-<7$V^9_R>_P""
MDO\ P5N_:NM/VW_!?_!*7_@DW\-/A1\7?VQM;\$R^/\ XR_$[XK:N\_PM_9R
M\.9BNXK+Q#INEZC9S-XFMM"ET_7]<FU<W5GI=GXL\#Z3HWA[QCXE\23:3HGW
MY_P1$_Y1&?\ !.W_ +--^#?_ *A^FU^+7_!N3:7?Q>_X*"_\%XOVNO$FJV'B
M'5_&G[7_ /PJWPO=BSOK:_T7POX3\9_%K6/L5I]K8/%H5YH6K^ ]*T^RND?4
M;6+P?"+R9W;<X!R?Q4_;X_X.!?\ @CMK'P[^-W_!4/P_^R]^VE^PSXE\;>'_
M  ?\8_B7^RMI][I'C7X$Q>*;[^S;#5VAF^'_ ,*+YWM$MKK4K"/6OAUK?@GQ
M1JK:9\/;[XG^ O$WB_PS=+_71\-OB+X*^+WP]\#?%;X;>(=/\7?#SXE^$?#O
MCSP-XJTJ1I=,\2>$?%ND6FN^'==T^5E1I++5=)OK2^M79%9H9T)4$XKY"_X*
MD?##PS\9/^";W[=/P[\6V5O>Z1K?[*?QRO8/M44\\6G^(?#7P]U[Q5X0UX6]
MO=V$ES/X:\6Z)HGB&UMC=PPW-UID,%R6MY)4;\\/^#7[X@7OC_\ X(I?LCG4
MGGEU#P9+\8_A]+-*96BDL?"/QL^(&F^'Q:M<7U].88/#2Z/:NK&VAANH+B"R
ML[>PBM4H _H!K^<[_@MY^V3\9X?CA^P5_P $I_V0?B;XH^%G[1O[=?Q?T'6?
MB=\4/AAJLEI\5?@E^RSX%US^TO&?BWPK;P63W%EJGBNV\/>-;_3=?6^2QBT3
MX2>._#VLV;Z=XC>_T[^C&OY#OV9IK7]IO_@[3_;B^(&LR7NK:#^QC^R;X9^&
M/PR672)88O#_ (CU;1OA9I/B,S:A)--%"QUKQ+\8X],CCB@?6+#69+N)XX["
MZ2\ /W@_X*%?\%'_ -FG_@E?\ M#^*W[0VI>.=:;7=4L_A_\*_A_X)T/5_''
MQ,^+GCI;$2VWAO1'NIEL(;][*&74=3\0^-/$6CZ:$C: :EJ'B'4-(TC5?Y\/
MV'/^"UW_  5)_:0_X+%_ 3]ES]IO]G+PO^QU^S_^T!\(?%OQL\#? C6])@\0
M?&"'X=VO@3QI>>#=7\8>-M2?3?$&GZKJWB/PO>7UYI>I>!/AYJJVEI:(WABR
MTZZCN=4_K-\=_!#X1_$_Q=\,?'?Q%^'OACQMXL^"^MZKXF^%6K^)M-CU=O ?
MB?6;"+2[[Q/X=M+PRZ?8^)1IL1L;'Q MHVL:3:W%_#I5[91ZEJ"W/\K_ ,??
M^5P7]CC_ +,2\1?^H[\?J /Z\Z\O^-OQE^'/[._P@^)?QV^+OB*W\)_#'X1^
M"O$7C_QQXAN(YKC^SO#OAG3;C5-0:TL;9);W5=3N(K?[)I&BZ=!<ZIK>JW%G
MI.EVMUJ-[;6TOJ%?C?\ \'!/PI^(GQH_X(W_ +=_@3X60SW/C _"[P_XS2TM
M9=1CNKSPS\+OB=X$^*'CVSM5TJUO+VYN;SP%X.\2VT&GI T.IRRII]Y)!9W5
MQ/$ ?BM\$?VW/^#D7_@K\=6_:,_8 \.?LK?L%?L<37NK:-\);W]I"PO/$^N_
M$^#1+BSM+_7FUZY^%/Q,U[Q+)/J,VH0VNM^&?ASX%\ 6JZ;?^&EU#7M?T*]U
M;4_MS_@G_P#\%<?VQ?#'[=C_ /!*+_@KS\(OAS\,/VK/$'A%_&_[/_QL^#D]
MS!\'_P!H3PY;V^N:A-]AM=7OW,.H7FGZ!K;:#JNBQ6EGJ.J>%_%WA77O#/@[
MQ3H,>G:O];_\&^G[17P,^/\ _P $F_V.++X+Z[X8NK[X*_!/X>?!'XM>%M#:
MUMM6\'?%KX>^%=+T3QG!XIT:*VLKO3=5\3ZG;R^-8;N]M WB'3_$5KXBM[W5
M+?4TU&Y_G=_X.%/VX?A-XJ_X+0?\$=?A-\!_'&D^(/B_^RC^TQX1D^,.N>#_
M !7=WMKX>U7XF?'#X0Z-_P *>\2C1)[>"QUC3M(\'>((O'6BPZJ;^;2?'#>&
MO$-M9/;S6K ']&W_  6?_P""@'QH_8>^#_P \'_LN:!X"US]JK]LS]I;X;_L
MK? B\^*]IJ]W\,/"'B/XC:E%I,_C7QA'HE_87\L&C3W^E6VG0(;V"*_U*+5M
M0T;7],TB^T'4_C#X1?MB?\%.?V(?^"EW[*G["?\ P44^+'P4_:U^&_[=_@?Q
MQ>?"GXU_##X8V/P6\0?";XI?##P[K/B3Q+X1U+PMH7VR+Q7X6O;:QTO38=4U
M#3K*[N+WQ/H^K6VJ:9:Z+XBT23['_P""S?\ P3S^,O[=_P (?V?_ !C^S+XY
M\,>"_P!J3]C;X_>#/VH_@/;?$!/-^&GBWQKX#E@UJR\+>+TATV^O85O]5TG1
MCI=X+BVTN.6.YM-;'V&^-_IOYP?$/P/^V3K'[2/P@_X+"_\ !8KP7\ OV,OV
M=_\ @EQ\&/BOXG\)?"3X0?%D?%[XA_$SXJ?$72CX)GN=6UY[?1/"%II_B2XU
M#1].^''@RR\4#6M1\>3^$O#5U<7T&MZM)& ?HW_P6+_X*.?$;]C7P/\ ![X"
M?LE>%['XI_\ !0;]L;Q]IGPQ_9?^&DT5GJMEI!&H6;^+?BKX\TF6>-[?X?\
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M,G_**OX@_P#95?A+_P"GVYKZ?@K_ )*[AO\ ['.7_P#J1 QQ'\"M_P!>Y_\
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MH_;F_P"[9O\ UL/]GVOH#X-_\$I/^%2?\%DOVL?^"MG_  OK_A(/^&H/V?\
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MZ+[1]F@ /Y\/^#4;_G+U_P!I$O&G_NP5\G?\' ?P:UWQ5_P< _\ !)[4-?\
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MXJTJ[T+Q)X<UW3+I)+74='US1K^]TS4["YC>"[LKJ>WF1HY&4_RQ:7_P;O\
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M3XK\4^([^'4? 5WXD\<VME82VOB>71;S3+GQ%K=O?V\$DLS+'=M:0_A_>?\
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MRV=]"\-P;:W,T;+(8(BVQ?PR_P"#CO\ ;N\3_LF_L,)\!_@?<3W?[7'_  4
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MJV\U6V(\,WW]G>)-$U&?_A&/%?A[2O JV]WI>K?V#J7PK^,NGR*^B^/!Y_\
M4CX+^#OC#X7?LM>%O@!\//B_X@NO'_P]^ FC_"'P-\>_BUI:_%/Q3-XP\+?#
MZW\'>&?BY\2]$?5_"R?$;76UJQLO&/C#26U[PXOBZ_\ [0LVU?2!J!O;?XC_
M ."1'_!++PM_P2H_9]\7_"J+XJZC\?\ XJ_%/XH^)_BS\9?CUK?AK5/!^M_$
MCQ-K<_DZ5+?>'-4\?_$J33VT31(K:QFFC\4W;:UJKZKXCNTBO]9NHU /U;
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MHH **** "BBB@ K\6?\ @XE_Y0M_M[_]DQ\*_P#JVOA[7[35\6?\%$_V0/\
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M .:&C_4CB[_HG<U_\)*G^0?6:'_/ZG_X$OZZ_GV9_0M17\]/_$35_P $U_\
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M3_(/K-#_ )_4_P#P)?UU_/LS^A:BOYZ?^(FK_@FO_P ^/[37_AC+S_YH:/\
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MR#ZS0_Y_4_\ P)?UU_/LS^A:BOYZ?^(FK_@FO_SX_M-?^&,O/_FAH_XB:O\
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MT+45_/3_ ,1-7_!-?_GQ_::_\,9>?_-#1_Q$U?\ !-?_ )\?VFO_  QEY_\
M-#1_J1Q=_P!$[FO_ (25/\@^LT/^?U/_ ,"7]=?S[,_H6HK^>G_B)J_X)K_\
M^/[37_AC+S_YH:/^(FK_ ()K_P#/C^TU_P"&,O/_ )H:/]2.+O\ HG<U_P#"
M2I_D'UFA_P _J?\ X$OZZ_GV9_0M17\]/_$35_P37_Y\?VFO_#&7G_S0T?\
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M9_0M17\]/_$35_P37_Y\?VFO_#&7G_S0T?\ $35_P37_ .?']IK_ ,,9>?\
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M2I_D'UFA_P _J?\ X$OZZ_GV9_0M17\]/_$35_P37_Y\?VFO_#&7G_S0T?\
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MTTW6#I&JPW%F]_8VVJ:A%:SO$S0"[F,>UF##VM55%55 55 55 P%4#  '8
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M?_"2I_D'UFA_S^I_^!+^NOY]F?T+45_/3_Q$U?\ !-?_ )\?VFO_  QEY_\
M-#1_Q$U?\$U_^?']IK_PQEY_\T-'^I'%W_1.YK_X25/\@^LT/^?U/_P)?UU_
M/LS^A:BOYZ?^(FK_ ()K_P#/C^TU_P"&,O/_ )H:/^(FK_@FO_SX_M-?^&,O
M/_FAH_U(XN_Z)W-?_"2I_D'UFA_S^I_^!+^NOY]F?T+45_/3_P 1-7_!-?\
MY\?VFO\ PQEY_P#-#1_Q$U?\$U_^?']IK_PQEY_\T-'^I'%W_1.YK_X25/\
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MS^A:BOYZ?^(FK_@FO_SX_M-?^&,O/_FAH_XB:O\ @FO_ ,^/[37_ (8R\_\
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M?_-#1_J1Q=_T3N:_^$E3_(/K-#_G]3_\"7]=?S[,_H6HK^>G_B)J_P"":_\
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M .:&C_4CB[_HG<U_\)*G^0?6:'_/ZG_X$OZZ_GV9_0M17\]/_$35_P $U_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\
M]/\ P0,_Y"O_  5?_P"THG[0G_HS3*_H6K^>G_@@9_R%?^"K_P#VE$_:$_\
M1FF5_0M7U/&O_)39EZ8'_P!5V$,</_!A_P!O?^E2"BBBOEC8**** "BBB@ H
MHHH **** "BBB@ HHHH **** /RY_P""Q'[3O[7'[)_[#GC[XB?L-?L^^/OV
MB_VF-?UO0OAY\/?#GP]^&OBKXN:EX%F\4Q:F^I?%;4O '@_1==U+7].\%Z?I
ML[V5M>V1\/GQ1J'AP>(DOM&:\TG4?Q1^%_\ P:\:S\<_!'A[XU_\%$_^"D?_
M  4$\9?MO^,+"U\4^/\ Q#\*?CAX8TGP'X#\2W<$6H:;X,\-0^+OA]X^UW4=
M-^'E](=)LM0T#Q+X1\/W5M80IX3\+^#M,CL[6+^O2OP=_P""I'[:7_!9?]G?
MXG'PE_P3P_X)J^$/VI_AI-\,/#^N#XS>)_&T%U'I?Q'U/Q#XAT_5?#<_PPT?
MQ[X$\5ZQI^C:59Z!>2)8ZC923?VI/>_VK':0/'  ?&__  0C_:'_ &O_ (-?
MMP_M_P#_  1H_;1^/VO_ +4WB']C[3?!/Q$^ ?QN\2Z)XK_X2O6/A'KEMH!F
MLO&'B37WU2Y1KWPY\0?A!XA\/>&/$7B+Q%K&B:IJGQ TOP]XX^(G@S1])U71
M_P"JJOX_/^#8>7X%_$_XD_MI_M-?%GXN^,/%_P#P5L^+VOF?]L+X3_%KX9_\
M*0\;_!70E\1S3G0O _P^75;FUUWX?7^N)H,>H>)K6QTR]T.?2_"7AW7?"_@B
M:;3K#6?TW_X+M_\ !1_Q;^Q)^S;X?^"O[-=CJ_C']OS]MS6;OX"?LB^!/"ML
M][XFTW7_ !"+/0_$GQ;A475E;V+?#Z'Q!ID7A*XNYYXIOB1KO@^>_P!'U/P?
MI?C6YTD _FJ_X.2?V[OVE/VP?%?[1?@C]B/XD>*O"W[('_!*/1/!VN_M0_&'
MX:>*O$7AG3_'W[3OQ?\ BSX,^"&D?"Z/Q-H.J6*ZS<?#6V\6:I%ING:>/L\&
MIZ?\7)=;FODM_!TEO_9;_P $K=9U?Q%_P3%_X)TZ_P"(-5U+7=>US]AC]DW5
M]:UO6+ZZU/5]8U;4O@/X#O-1U35-2O99[S4-1O[N::ZO;V[FFN;JYEDGGEDE
M=F/\WO\ P4/_ .";WA7_ ()??\&L'[6G[/\ ;:I9>,_BSKMU\ ?B9^T7\58#
MJ$LWQ.^-7B[]KK]GR7Q'K*7.J[+^70O#]E;Z7X+\)FXM--N;KPYX<T_6-8T]
M/$VK:]=WG]&'_!)7_E%=_P $U?\ LP?]D#_UG[X?4 ?H-7\^W_!RI^VWXY_9
M$_X)P>(/ OP5GUJ']H?]L[QQH7[)WPBG\.26*:YHZ?$*WOIOB%KMB;W9)!<W
M/@73]6\!Z)JVDW%KKWASQCX^\*^)-)NK2?23>VO]!-?R'_\ !=QYOBI_P6I_
MX-\/@%J=A8W7A30_CIXG^,EY:ZA>Z@FGZWJ&G^//A;K"V^J:=;A[6\.C6WPH
M+:.EQ#)#=S:]J.F:B4TJ\NPX!_1M^P1^RIX6_8@_8T_9O_93\)6FDV]C\%OA
M5X8\*ZU=Z)'+'8>(_'3VG]K_ !)\; 3P6LKWGCWXA:EXG\::G,]I9F?4]>NY
MOL=H)!;Q?RU_#GX>?'[_ (.>_CE^T/\ %+QU^TY\</V9/^"1_P"SW\7;[X-?
M /X7_L^:GX>\(>/?VB?&_A/1[V[U?XH>)_%6I3>,--MI])_X2+PKK,=]JO@W
MQAX7GTC7X_!7@VWT7Q-X>\9>+;S^GC_@I3XHU7P/_P $Y_V_/&F@2BWUSPA^
MQ3^U1XHT68O<Q"#5?#_P+\=ZMITIDLKBTO(Q'>6D+[[2ZMKE NZ"XAE"2+_$
MA_P0KM?^"N?[</[ OP=_9;_8*^+/A#_@G/\ LN?LY>(?B'IGQ^_:UN/ >E^/
M/BE^T?\ %CXD?&3Q3\47L/AOIEWH$+M%\)?AWK'@?P]K M_&7@>_U"1[?1=6
M\=:IX?U"V\,^& #[P^+7[!?[?/\ P0'^.?[.?[0__!./XI?MY_M\_L2^,/'^
MA_#C]JW]B_5M*U+]ICXOQ:/J!USQ%K/CSP5X:\"_#S3?"^DZ:VD:7>_V7XUT
M[P_\.M:\,>/K;PWX6\1^,_$?A3XF:EING_VIHV]$<JR;E5MK##+N .UAV9<X
M([$$5_&-XZ_:A_X*X_\ ! 'X\_L^S_\ !0']JG1/^"B7_!,WX[_$C1_@KJ7Q
MR\0^#+3P+\7/@9XDU.W>]B\3>(KF&WUKQ$VH1Z-9ZWXJCT#7/'_Q;TOQ;X5\
M"^+;73K[P1XE,-]=?V<HZNBNIRKJKJ?56 (/X@B@#G?&7BK2? GA#Q5XWU]Y
MX]"\&^&]<\5:U):P&YNDTGP]IEUJ^I/;6RE6N)UL[.9H8%93+(%C!!;-?Y^?
M_!$K_@C[XC_X*N_L@>(OVO\ XZ_\% /V\/A+KWB;X\_$WPSX8\'?!3XS-I/@
MFS\(>'5T 0O;V/B=?&.J6\\?B.^\26,,+7FGP6^DV6EVT.G.(#JNI_W8?M8^
M!?B%\4/V6/VEOAI\([K1['XK?$3]G_XR>!?AC>^(M0U#2?#]G\0O%OPZ\1Z!
MX+NM=U32(YM5TW1[?Q)J&FS:GJ&F12ZA9V23W%E&]S'$I_D5_8G_ ."$W_!>
M#X,?LQ>"O@#IO_!4WX9_L.^"?AMXH\9ZEX:^'/[.O@"]^(]_XKO/$?CB\\5Z
MIX[^)GQ'N;?X:ZWJFL:Q>+9:;H_AK[;KWAZP^'^G:-IUW8Z3J^K>,]*NP#]E
M/^"?_P#P0L\"_L"?M"V?[0NC_MP_MS_'[4M/\(^)?"EMX ^/'Q6T?Q5\/7/B
M5;*&76;O1K7PQ8SW&I:=!:RKIDD=Y;^1-<M*S2(K02_/G_!??QA\0_B5\?O^
M"2G_  3BT?XH?$CX0_!O]OO]H;XKZ;^T/XH^#_BW4/!/Q#\0?#SX.>&_ ,DG
MPUM=>L2R1^&?&J?$[46\06M[;WUG)=Z+H5Q/I]_%:26DOSE_P3]_X*(?\%(?
MV*?^"F>B_P#!('_@KCXI\/?'+_A<V@7OB']D/]KK1=.L-(NO'%K:Q>)-0TO3
M_$ T?1]-CU>R\31^'M:\-F/Q'8:9XS\$^.]!71[_ %#QMX:\4^'_ !):_N-_
MP4B_X)D_!;_@I-X'^%NG>._$WC;X1_&']GWXCZ7\6_V<_P!HSX47&F:=\6/@
MKX]TR_TC4I+_ ,+ZGJ=C>Q/I.L7GA_P]>ZUHS"!+O5/#/A;6X+JSUGPWHU]:
M 'XG_L]_":\_X)4?\%Y_V?\ ]A7]F_XL?&+6/V0?VP/V-_%_Q"\4?!;XL?$/
MQ%\3M/\ !WQ.^%L_Q N+;QWX3USQG>ZWJNE7_B#_ (1>Z;6M/T)_#^GWD_B+
M4&OXM0L],\,V.A^H_P#!3CXZ?%#_ (*3_MR?#7_@BI^QK\2O$?@?P7X(OO#O
MQS_X*<_M"?#RXU6QO?AO\./#.K6.L>%/V=O#OC?1;N";1?B#XSU&/3M3UM-/
M>TO+/4KGP78QZY/I^@_%_P )P^,_M7?"6Y_X(W6FO_MO^./VC?CS_P %-_\
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M>-?^2FS+TP/_ *KL(8X?^##_ +>_]*D%%%%?+&P4444 %%%% !1110 4444
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M7+6S-I8/:WOA.32?$;^!K31/ 6J6OC.#QMK_ (!\'7$,^IVG[[?\%-?VD/\
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M#/\ P0Q_X) 65M\*OV(/#7Q'"_#SX+?%;XE_"^WM_"UW^TGJ>K^,;_3M F\
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M,@MOAC>ZC\.[4)YEY?-]F6V\,1"T FBC%J(A'9Z?&%L;?]A: "BBB@ HHHH
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M\0:=>0_MXZS_ ,$\]$_X+Y_\$5_@/_P3[^'7[/7@O1O@K^T+X9B^-&I_LT^
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M/&O_ "4V9>F!_P#5=A#'#_P8?]O?^E2"BBBOEC8**** "BBB@ HHHH ****
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M&_\ %.HW]S>W^M>*UT&'Q)XCOKVXO/$FJ:O<K;RP 'XS?M9_''PM_P %2_\
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MCZ2 ?TD4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_//\
M\$!/O_\ !4W_ +2>?M _^D_AVOZ&*_GG_P"" GW_ /@J;_VD\_:!_P#2?P[7
M]#%?4\:_\E-F7I@?_5=A#'#_ ,&'_;W_ *5(****^6-@HHHH **** "BBB@
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M7A*_U?3K+3?'?@?4;_3+VWL/%_@^\UG1)2EM))=10ZGI4E]_-9\/_BG\,/\
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M<\%SZ[IMR;?4=$UO5O#^I:KX<U>PT_6O#EWI.K6D=[7[?          8  X
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M!WXK_P#!2W]JK]@3_@EIX%\ ?$ZY_9\_X6G;?M0_MQ_%J+POXET3X3:#\,/
M]M/I_A_X>0?%G3M-N8!\1O%.B:CXXTZR\,6DP?3-<\8?"_Q'?0W%G'>:CX8
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M )]5_P#P5+^O^&?E?^A:BOYZ?^%O_P#!S#_T:G_P31_\+'XE_P#S]:/^%O\
M_!S#_P!&I_\ !-'_ ,+'XE__ #]:/]5:O_0]X6_\/^"\O[WG^#[![=?\^J__
M (*E_7_#/RO_ $+45_/3_P +?_X.8?\ HU/_ ()H_P#A8_$O_P"?K1_PM_\
MX.8?^C4_^":/_A8_$O\ ^?K1_JK5_P"A[PM_X?\ !>7][S_!]@]NO^?5?_P5
M+^O^&?E?^A:BOYZ?^%O_ /!S#_T:G_P31_\ "Q^)?_S]:/\ A;__  <P_P#1
MJ?\ P31_\+'XE_\ S]:/]5:O_0]X6_\ #_@O+^]Y_@^P>W7_ #ZK_P#@J7]?
M\,_*_P#0M17\]/\ PM__ (.8?^C4_P#@FC_X6/Q+_P#GZT?\+?\ ^#F'_HU/
M_@FC_P"%C\2__GZT?ZJU?^A[PM_X?\%Y?WO/\'V#VZ_Y]5__  5+^O\ AGY7
M_H6HK^>G_A;_ /P<P_\ 1J?_  31_P#"Q^)?_P _6C_A;_\ P<P_]&I_\$T?
M_"Q^)?\ \_6C_56K_P!#WA;_ ,/^"\O[WG^#[![=?\^J_P#X*E_7_#/RO_0M
M17\]/_"W_P#@YA_Z-3_X)H_^%C\2_P#Y^M'_  M__@YA_P"C4_\ @FC_ .%C
M\2__ )^M'^JM7_H>\+?^'_!>7][S_!]@]NO^?5?_ ,%2_K_AGY7_ *%J*_GI
M_P"%O_\ !S#_ -&I_P#!-'_PL?B7_P#/UH_X6_\ \',/_1J?_!-'_P +'XE_
M_/UH_P!5:O\ T/>%O_#_ (+R_O>?X/L'MU_SZK_^"I?U_P ,_*_]"U%?ST_\
M+?\ ^#F'_HU/_@FC_P"%C\2__GZT?\+?_P"#F'_HU/\ X)H_^%C\2_\ Y^M'
M^JM7_H>\+?\ A_P7E_>\_P 'V#VZ_P"?5?\ \%2_K_AGY7_H6HK^>G_A;_\
MP<P_]&I_\$T?_"Q^)?\ \_6C_A;_ /P<P_\ 1J?_  31_P#"Q^)?_P _6C_5
M6K_T/>%O_#_@O+^]Y_@^P>W7_/JO_P""I?U_PS\K_P!"U%?ST_\ "W_^#F'_
M *-3_P"":/\ X6/Q+_\ GZT?\+?_ .#F'_HU/_@FC_X6/Q+_ /GZT?ZJU?\
MH>\+?^'_  7E_>\_P?8/;K_GU7_\%2_K_AGY7_H6HK^>G_A;_P#P<P_]&I_\
M$T?_  L?B7_\_6C_ (6__P ',/\ T:G_ ,$T?_"Q^)?_ ,_6C_56K_T/>%O_
M  _X+R_O>?X/L'MU_P ^J_\ X*E_7_#/RO\ T+45_/3_ ,+?_P"#F'_HU/\
MX)H_^%C\2_\ Y^M'_"W_ /@YA_Z-3_X)H_\ A8_$O_Y^M'^JM7_H>\+?^'_!
M>7][S_!]@]NO^?5?_P %2_K_ (9^5_Z%J*_GI_X6_P#\',/_ $:G_P $T?\
MPL?B7_\ /UH_X6__ ,',/_1J?_!-'_PL?B7_ //UH_U5J_\ 0]X6_P##_@O+
M^]Y_@^P>W7_/JO\ ^"I?U_PS\K_T+45_/3_PM_\ X.8?^C4_^":/_A8_$O\
M^?K1_P +?_X.8?\ HU/_ ()H_P#A8_$O_P"?K1_JK5_Z'O"W_A_P7E_>\_P?
M8/;K_GU7_P#!4OZ_X9^5_P"A:BOYZ?\ A;__  <P_P#1J?\ P31_\+'XE_\
MS]:/^%O_ /!S#_T:G_P31_\ "Q^)?_S]:/\ 56K_ -#WA;_P_P""\O[WG^#[
M![=?\^J__@J7]?\ #/RO_0M17\]/_"W_ /@YA_Z-3_X)H_\ A8_$O_Y^M'_"
MW_\ @YA_Z-3_ .":/_A8_$O_ .?K1_JK5_Z'O"W_ (?\%Y?WO/\ !]@]NO\
MGU7_ /!4OZ_X9^5_Z%J*_GI_X6__ ,',/_1J?_!-'_PL?B7_ //UH_X6_P#\
M',/_ $:G_P $T?\ PL?B7_\ /UH_U5J_]#WA;_P_X+R_O>?X/L'MU_SZK_\
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MO_0]X6_\/^"\O[WG^#[![=?\^J__ (*E_7_#/RO_ $+45_/3_P +?_X.8?\
MHU/_ ()H_P#A8_$O_P"?K1_PM_\ X.8?^C4_^":/_A8_$O\ ^?K1_JK5_P"A
M[PM_X?\ !>7][S_!]@]NO^?5?_P5+^O^&?E?^A:BOYZ?^%O_ /!S#_T:G_P3
M1_\ "Q^)?_S]:/\ A;__  <P_P#1J?\ P31_\+'XE_\ S]:/]5:O_0]X6_\
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M_P %Y?WO/\'V-?;K_GU7_P#!4OZ_X9^5_P"A:BOYZ?\ A;__  <P_P#1J?\
MP31_\+'XE_\ S]:/^%O_ /!S#_T:G_P31_\ "Q^)?_S]:/\ 56K_ -#WA;_P
M_P""\O[WG^#[![=?\^J__@J7]?\ #/RO_0M17\]/_"W_ /@YA_Z-3_X)H_\
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MO_\ !S#_ -&I_P#!-'_PL?B7_P#/UH_U5J_]#WA;_P /^"\O[WG^#[![=?\
M/JO_ ."I?U_PS\K_ -"U%?ST_P#"W_\ @YA_Z-3_ .":/_A8_$O_ .?K1_PM
M_P#X.8?^C4_^":/_ (6/Q+_^?K1_JK5_Z'O"W_A_P7E_>\_P?8/;K_GU7_\
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M_P +?_X.8?\ HU/_ ()H_P#A8_$O_P"?K1_PM_\ X.8?^C4_^":/_A8_$O\
M^?K1_JK5_P"A[PM_X?\ !>7][S_!]@]NO^?5?_P5+^O^&?E?^A:BOYZ?^%O_
M /!S#_T:G_P31_\ "Q^)?_S]:/\ A;__  <P_P#1J?\ P31_\+'XE_\ S]:/
M]5:O_0]X6_\ #_@O+^]Y_@^P>W7_ #ZK_P#@J7]?\,_*_P#0M17\]/\ PM__
M (.8?^C4_P#@FC_X6/Q+_P#GZT?\+?\ ^#F'_HU/_@FC_P"%C\2__GZT?ZJU
M?^A[PM_X?\%Y?WO/\'V#VZ_Y]5__  5+^O\ AGY7_H6HK^>G_A;_ /P<P_\
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M_P 'V#VZ_P"?5?\ \%2_K_AGY7_H6HK^>G_A;_\ P<P_]&I_\$T?_"Q^)?\
M\_6C_A;_ /P<P_\ 1J?_  31_P#"Q^)?_P _6C_56K_T/>%O_#_@O+^]Y_@^
MP>W7_/JO_P""I?U_PS\K_P!"U%?ST_\ "W_^#F'_ *-3_P"":/\ X6/Q+_\
MGZT?\+?_ .#F'_HU/_@FC_X6/Q+_ /GZT?ZJU?\ H>\+?^'_  7E_>\_P?8/
M;K_GU7_\%2_K_AGY7_H6HK^>G_A;_P#P<P_]&I_\$T?_  L?B7_\_6C_ (6_
M_P ',/\ T:G_ ,$T?_"Q^)?_ ,_6C_56K_T/>%O_  _X+R_O>?X/L'MU_P ^
MJ_\ X*E_7_#/RO\ T+45_/3_ ,+?_P"#F'_HU/\ X)H_^%C\2_\ Y^M'_"W_
M /@YA_Z-3_X)H_\ A8_$O_Y^M'^JM7_H>\+?^'_!>7][S_!]@]NO^?5?_P %
M2_K_ (9^5_Z%J*_GI_X6_P#\',/_ $:G_P $T?\ PL?B7_\ /UH_X6__ ,',
M/_1J?_!-'_PL?B7_ //UH_U5J_\ 0]X6_P##_@O+^]Y_@^P>W7_/JO\ ^"I?
MU_PS\K_T+45_/3_PM_\ X.8?^C4_^":/_A8_$O\ ^?K1_P +?_X.8?\ HU/_
M ()H_P#A8_$O_P"?K1_JK5_Z'O"W_A_P7E_>\_P?8/;K_GU7_P#!4OZ_X9^5
M_P"A:BOYZ?\ A;__  <P_P#1J?\ P31_\+'XE_\ S]:/^%O_ /!S#_T:G_P3
M1_\ "Q^)?_S]:/\ 56K_ -#WA;_P_P""\O[WG^#[![=?\^J__@J7]?\ #/RO
M_0M17\]/_"W_ /@YA_Z-3_X)H_\ A8_$O_Y^M'_"W_\ @YA_Z-3_ .":/_A8
M_$O_ .?K1_JK5_Z'O"W_ (?\%Y?WO/\ !]@]NO\ GU7_ /!4OZ_X9^5V_P#!
M 3[_ /P5-_[2>?M _P#I/X=K^ABOX=O^"4'Q"_X+2:&W[<W_  R;\"/V+_&9
MU+]MKXLZE\=?^%L^(?&=B/#WQPGBTC_A+O#_ (%_LGXH^'?M/@BR1;,Z3<WW
M]KWTC/-YNK7.%"?KG_PM_P#X.8?^C4_^":/_ (6/Q+_^?K7T?%G#=7$\08^L
MLXX<HJ:P?[O$9UA*-:/+@<+#WZ<Y<T;VYHW^*#4EHT94*R5**]G6?Q:JG)KX
MGU^?X/RO_0M17\]/_"W_ /@YA_Z-3_X)H_\ A8_$O_Y^M'_"W_\ @YA_Z-3_
M .":/_A8_$O_ .?K7SG^JM7_ *'O"W_A_P %Y?WO/\'V-?;K_GU7_P#!4OZ_
MX9^5_P"A:BOYZ?\ A;__  <P_P#1J?\ P31_\+'XE_\ S]:/^%O_ /!S#_T:
MG_P31_\ "Q^)?_S]:/\ 56K_ -#WA;_P_P""\O[WG^#[![=?\^J__@J7]?\
M#/RO_0M17\]/_"W_ /@YA_Z-3_X)H_\ A8_$O_Y^M'_"W_\ @YA_Z-3_ .":
M/_A8_$O_ .?K1_JK5_Z'O"W_ (?\%Y?WO/\ !]@]NO\ GU7_ /!4OZ_X9^5_
MZ%J*_GI_X6__ ,',/_1J?_!-'_PL?B7_ //UH_X6_P#\',/_ $:G_P $T?\
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M]@]NO^?5?_P5+^O^&?E?^A:BOYZ?^%O_ /!S#_T:G_P31_\ "Q^)?_S]:/\
MA;__  <P_P#1J?\ P31_\+'XE_\ S]:/]5:O_0]X6_\ #_@O+^]Y_@^P>W7_
M #ZK_P#@J7]?\,_*_P#0M17\]/\ PM__ (.8?^C4_P#@FC_X6/Q+_P#GZT?\
M+?\ ^#F'_HU/_@FC_P"%C\2__GZT?ZJU?^A[PM_X?\%Y?WO/\'V#VZ_Y]5__
M  5+^O\ AGY7_H6HK^>G_A;_ /P<P_\ 1J?_  31_P#"Q^)?_P _6C_A;_\
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M $:G_P $T?\ PL?B7_\ /UH_X6__ ,',/_1J?_!-'_PL?B7_ //UH_U5J_\
M0]X6_P##_@O+^]Y_@^P>W7_/JO\ ^"I?U_PS\K_T+45_/3_PM_\ X.8?^C4_
M^":/_A8_$O\ ^?K1_P +?_X.8?\ HU/_ ()H_P#A8_$O_P"?K1_JK5_Z'O"W
M_A_P7E_>\_P?8/;K_GU7_P#!4OZ_X9^5_P"A:BOYZ?\ A;__  <P_P#1J?\
MP31_\+'XE_\ S]:/^%O_ /!S#_T:G_P31_\ "Q^)?_S]:/\ 56K_ -#WA;_P
M_P""\O[WG^#[![=?\^J__@J7]?\ #/RO_0M17\]/_"W_ /@YA_Z-3_X)H_\
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MZ+4RKUDZ-5>SK*].2NZ<DEIU>R7GY/RO_;%H'_("T7_L$Z=_Z1PUK5DZ!_R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_"?["^H_LS_#31/AQJ7Q]_:3_:^^-_AKX*? KX">&_%6G>$]7U=M5G2/Q/\
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MQ!')8.#+';Q6UPQV7* ?"/\ Q%U?\$:/^BA?';_PPWBG_P"2: /Z=**^ O\
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MN%T:T\13Q2ZAX6TF2  _0[_@L-_P5'L_^"3'[/?PB^/NH?!NV^-5A\4/VFO
M/[/%]HUY\48OA+9^$K/QKX(^)WC2Y\?7?B.?P'\08;ZVT&'X;O:SZ'-IFDQ7
M,6JO?2>(+%---O>_F1\:_P#@OK^W/HOA[6OVF/V;/^",OQX^.O\ P3ZT*XN-
M1L/VD[_X@6_AGQ9\1?AOHFM7MOK7QF\%_![0_!WC'QC:?"?5?#MFWBOPGXVU
M:QET.X\(M%XTUZ]T;0I9Q8_"G_!TQXY\1?$__@W_ /\ @G#\2O%]V-0\6?$/
MX[?L@>.?%%^ ZB]\1>+?V*_VA-?UN["R22R 7.I:A<S 22RN-^&D=LL?[8;7
MP;X4L_!]M\/H?#VDOX'M?#4/@V+PI=64-]H3>%(-+71$\/7.G7RW%O>:2VD*
M--FLKQ)X;BS+07"RH[A@#^;V3_@XM/[3WACX8:7_ ,$E/V'OB]_P4"^-7BWX
M7Z'\7/BUX.E\5>&?@[X*_9@T+4O$/BWPE<^"/C+X]U==?L+/XQ2>)?!NI0^'
M_ JQ:;I7BWP?<VOQ(\)^,=?\/O86FK^L_P#!,W_@N?K7[7W[5_Q"_P""?W[8
M/['OCC]@W]M3P3X7N_'.B_#?Q=XMC\6Z!\0/"ME9Z5K%VNC:E?\ AOP9JUCX
MGB\/:U!XET_2;32_$VA^(/"&EZWXJT[Q7$ME-H\'P3_P93VMJG_!+S]H*^2V
MMUO;C]OCXE6MQ>+#&MU/:V?[//[,$UG;37 42RV]K+?7TMM"[M'!)>73Q*C7
M$Q?0_;!O+RU_X/(/^"54%M=7-O#J/_!/?XB6>H0P3RPQ7]FGA'_@I#J"6MY'
M&ZI=6R7]A8WR03AXEO+.UN0@FMX70 _4[]J'_@HOX$^"/_!8/]@G]@[5?V4O
M"7Q!\?\ [2GPQ\=>(O"G[4FH>+=&TWQA\%=*%I\29-=\,^'O#ES\+]?UK5-/
M\31_#.*'5CIOQ*\(6UTFJ1_;-/O5TM5O?YO?^#QC]IK]IGQ1\*;#]EWQ1^Q'
MXL\"_LO?#C]K'X+>,_AQ^W/>?$ZPU3PA\9O&=]^S'\3KR^^&VE?"V/P18ZAX
M;O\ 2[OQYX\TZ36I_'6LQ3O\*=1F&FQ#7H8])^]O^"D?_*U/_P $5?\ L@?Q
M'_\ 3=^TU53_ (/5O^467P#_ .S_ /X6?^LZ_M54 ?N'_P $XOVS?VS/VNO^
M%R?\-<_\$VO'?_!/7_A7W_"O/^%??\)M\9]*^+W_  MW_A+/^$Y_X2O^S/[,
M^&WP]_X1[_A ?^$:\-?;?/\ [7_M;_A-;3R_[/\ [,D^V^)_\$3/^"B_@3_@
MHU\(/VD?&WP__92\)?LE:9\)/VH_''PPUCPIX.\6Z-XLL?'WB@:)X<\4:[\3
MM2FT3X7_  LM[+7O$MSKJIJT5UIFN:A=3V8O+SQ!>23".']IJ_D-_P"#/O\
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M7R>(-82^TJ!_$^E0:;I-SX4UBT>WT[2O'MYIEU:^,IN:_P"#H6+4?BU^T/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0T[XG>'=,A2Z\5>*[2PD\2V,7BO6I9_%5AJ'PW\6:7K&K^.]*O/#_BU/Z[:
M.:UGP7X.\1W4=[XA\)^&M>O(H%M8KO6="TO5+J*U2269+:.XOK6>5($EGFE6
M%7$:R32N%#2.3^'W_!?3]L#X=?\ !.7_ ()X?$KQOX"\%^"X/VC?C;.G[/\
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M],TV7P=I5@=3UO30#<_X.7_V<K#]H3_@D#^T?J237UCXR_9QG\)_M0?#C5K
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M+>*/%.D6.NVG@>3P#<ZEJ?C#PI8>%_#>F_V=U_!]H'[-WC7_ (-9?VT_@?\
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M!%=M<S)K"76@VENMY TTOV"X.@VNBNMJL=L)+9K>],+/>-<3@'U]_P %$_\
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MR\+S7?A#Q1J\D%S'&T5QJFMZ#?7]TD(:S6YN)18RS6?D2OB_\%&/V@?V/_\
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M:K;P+ X:(0QA=@ /K2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "OY_O\ @YD_Y15_$'_LJOPE_P#3[<U_0#7\_P!_P<R?\HJ_B#_V57X2
M_P#I]N:^GX*_Y*[AO_L<Y?\ ^I$#'$?P*W_7N?\ Z2S]Z] _Y 6B_P#8)T[_
M -(X:UJR= _Y 6B_]@G3O_2.&M:OF9;OU?YFL=EZ+\C^>G]I3_E8[_X)S?\
M9FOQY_\ 3;\:Z_H6K^>G]I3_ )6._P#@G-_V9K\>?_3;\:Z_H6KZCB7_ ';A
M/_LEL-_ZMLY,:/Q8C_K_ "_]-TPKYT_:Y_9F^'W[97[,WQM_9=^*5OY_@?XV
M_#_6_!&K3JMS)-H]W>PK<:!XFLXK2_TN>;4?"?B.UTGQ-IL U"UBGO\ 2;:&
MXD^SO*K?1=%?+&Y_ ;_P;P_L)?\ !07Q/_P4"^$?CC_@H/\  GXN_#/X9_\
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ME_=#_@IO\'OVX/CC^R7XQ\$_\$]/VC=&_9D_:5&K:-K&@>,_$&A:;J6E>*-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _GI_X(&?\A7_ (*O_P#:43]H3_T9
MIE?T+5_/3_P0,_Y"O_!5_P#[2B?M"?\ HS3*_H6KZGC7_DILR],#_P"J["&.
M'_@P_P"WO_2I!1117RQL%%%% !1110 4444 %%%% !1110 4444 %%%% !7Y
M"_\ !>OX:?$?XP_\$B?VV?AK\(_A_P"-OBG\1O%?P^\*67A;P!\.?"NN^-_&
MWB6\MOBKX!U&XM- \*^&;#4]=UBY@T^SO+Z:#3K"YEBL[6YNG18()73]>J*
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M^)/"AO;.;QE\)_&UA!JOAK7Y_"WB6.RA:"2R\0"+2WEUB)-+G?7I[VR ,?\
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MX=D;PQ%H5U%KNF3>,]+U*Y9=<T^XT?\ 6X    8   'H!P!0 M%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?SS_P#! 3[_ /P5-_[2>?M
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M9OAS<VVERZ]'_:710!_%/\5?!O\ P48_X.,?C_\ LQ:'\6_V&_B3_P $]_\
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M)XPU.WCDD@M]5\7^(I]4\2ZI;VA2QM[_ %2XAL8;>T2&&/\ "SP3^S]\>_\
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M%.NHT^=>V>O.HZ^SIZ6?R=_,_H7HK^>C_B'YTO\ Z2B?\%2?_$CK?_YEZ/\
MB'YTO_I*)_P5)_\ $CK?_P"9>O%_LGAG_HK'_P"&''__ "XUYZW_ #X_\J1_
MR/Z%Z*_GH_XA^=+_ .DHG_!4G_Q(ZW_^9>C_ (A^=+_Z2B?\%2?_ !(ZW_\
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M?_$CK?\ ^9>C^R>&?^BL?_AAQ_\ \N#GK?\ /C_RI'_(_H7HK^>C_B'YTO\
MZ2B?\%2?_$CK?_YEZ/\ B'YTO_I*)_P5)_\ $CK?_P"9>C^R>&?^BL?_ (8<
M?_\ +@YZW_/C_P J1_R/Z%Z*_GH_XA^=+_Z2B?\ !4G_ ,2.M_\ YEZ/^(?G
M2_\ I*)_P5)_\2.M_P#YEZ/[)X9_Z*Q_^&''_P#RX.>M_P ^/_*D?\C^A>BO
MYZ/^(?G2_P#I*)_P5)_\2.M__F7H_P"(?G2_^DHG_!4G_P 2.M__ )EZ/[)X
M9_Z*Q_\ AAQ__P N#GK?\^/_ "I'_(_H7HK^>C_B'YTO_I*)_P %2?\ Q(ZW
M_P#F7H_XA^=+_P"DHG_!4G_Q(ZW_ /F7H_LGAG_HK'_X8<?_ /+@YZW_ #X_
M\J1_R/Z%Z*_GH_XA^=+_ .DHG_!4G_Q(ZW_^9>C_ (A^=+_Z2B?\%2?_ !(Z
MW_\ F7H_LGAG_HK'_P"&''__ "X.>M_SX_\ *D?\C^A>BOYZ/^(?G2_^DHG_
M  5)_P#$CK?_ .9>C_B'YTO_ *2B?\%2?_$CK?\ ^9>C^R>&?^BL?_AAQ_\
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M/[)X9_Z*Q_\ AAQ__P N#GK?\^/_ "I'_(_H7HK^>C_B'YTO_I*)_P %2?\
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MBL?_ (8<?_\ +@YZW_/C_P J1_R/Z%Z*_GH_XA^=+_Z2B?\ !4G_ ,2.M_\
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MM(J_O/HT?T+T5_/1_P 0_.E_])1/^"I/_B1UO_\ ,O1_Q#\Z7_TE$_X*D_\
MB1UO_P#,O7SG]D\,_P#16/\ \,./_P#EQKSUO^?'_E2/^1_0O17\]'_$/SI?
M_243_@J3_P")'6__ ,R]'_$/SI?_ $E$_P""I/\ XD=;_P#S+T?V3PS_ -%8
M_P#PPX__ .7!SUO^?'_E2/\ D?T+T5_/1_Q#\Z7_ -)1/^"I/_B1UO\ _,O1
M_P 0_.E_])1/^"I/_B1UO_\ ,O1_9/#/_16/_P ,./\ _EP<];_GQ_Y4C_D?
MT+T5_/1_Q#\Z7_TE$_X*D_\ B1UO_P#,O1_Q#\Z7_P!)1/\ @J3_ .)'6_\
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M_E2/^1_0O17\]'_$/SI?_243_@J3_P")'6__ ,R]'_$/SI?_ $E$_P""I/\
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MT+T5_/1_Q#\Z7_TE$_X*D_\ B1UO_P#,O1_Q#\Z7_P!)1/\ @J3_ .)'6_\
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M!SUO^?'_ )4C_D?T+T5_/1_Q#\Z7_P!)1/\ @J3_ .)'6_\ \R]'_$/SI?\
MTE$_X*D_^)'6_P#\R]']D\,_]%8__##C_P#Y<'/6_P"?'_E2/^1_0O17\]'_
M !#\Z7_TE$_X*D_^)'6__P R]'_$/SI?_243_@J3_P")'6__ ,R]']D\,_\
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M!SUO^?'_ )4C_D?T+T5_/1_Q#\Z7_P!)1/\ @J3_ .)'6_\ \R]'_$/SI?\
MTE$_X*D_^)'6_P#\R]']D\,_]%8__##C_P#Y<'/6_P"?'_E2/^1_0O17\]'_
M !#\Z7_TE$_X*D_^)'6__P R]'_$/SI?_243_@J3_P")'6__ ,R]']D\,_\
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M<*?.[1YY)J-[M6,J\ZKHU4Z-DX2N_:1=E;5VMK;>Q_;'H'_("T7_ +!.G?\
MI'#6M63H'_("T7_L$Z=_Z1PUK5^;2W?J_P SJCLO1?D?ST_M*?\ *QW_ ,$Y
MO^S-?CS_ .FWXUU_0M7\]/[2G_*QW_P3F_[,U^//_IM^-=?T+5]1Q+_NW"?_
M &2V&_\ 5MG)C1^+$?\ 7^7_ *;IA117\C/Q@_X+T_\ !2[5O^"D/[6O_!/[
M]A[_ ()O?#[]J76OV7]3O[G4-4;XI7O@_59O!5C)X2L&\0ZU+X@O=#\,VER^
ML^,--T^#2[/59K^\4S7=I92VMCJ,MI\L;G]<U%?R*^,O^"]?_!7']D6)OB!^
MWW_P0O\ B9X3^ %C;QZAXS^)_P "?B2?'@^&GA^WG<:KXG\32Z-HWCOP=#:0
M1*L5O:>,?&/PQT][F6#SO$T8N;>*7^C[]B[]M3]GC]O[X >$OVD_V9/&H\:?
M#?Q2!9W N;.72_$7A#Q5;6&G7VN^!/&>C2M(='\7^&#J=I:ZU8P7-_I[2217
MFD:IJVD7=AJ=V ?5E%?D!X+_ &C_ /@J/JG_  5]^*7[.'BG]DOP-I7_  3+
M\/\ PETGQ%X)_:?C?6(_$NL>*I_"6@ZE&]IXDF\4MH>MZI>>/=1\2>!M=^&2
M> =-UKP_I6@:?XQC\0/HT<=]XY_7^@ HHHH **** "BO/?BYXSNOAQ\*/B=\
M0[&RM]2O? ?P\\:>,[/3KJ22*UO[KPOX;U+7+>RN98?WL=O=2V*0321?O$CD
M9D^8"OSB_P""+W_!1+QA_P %1OV'/#?[67CGX<>&OA7KVN_$/XA^#)/"'A/5
M]4US2+>U\%:M#IMM>IJ&L107LEQ?+(TL\;1+'$V$CR 6(!^K]%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% '\]/_! S_D*_P#!5_\ [2B?M"?^
MC-,K^A:OYZ?^"!G_ "%?^"K_ /VE$_:$_P#1FF5_0M7U/&O_ "4V9>F!_P#5
M=A#'#_P8?]O?^E2"BBBOEC8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M=A#'#_P8?]O?^E2"BBBOEC8**** "BBB@ HHHH **** "BBB@ HHHH ****
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M<^)?LNY-$\%^#O#UC_;7C/Q;J:P7.HGP[X,\/74]MI]OJ.KS6.GZ#I>H7MD
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M\.7MMX@B^+-4_9K_ &F_V8?^#F/_ ()(>$?VNOV[?$W[>7QD\4_#?X@^.?\
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M9^)KQKCQ!XR\3WQ+/?>(/$FHZEJD^1%]H2VBA@B_K)K^<S_@ZU_Y0E?M+_\
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M;>VT>P\;W7B6.VEUB8W'B+6?R!_9RT/_ (*0?\$@-2_X*'?LA^&/^"<_Q?\
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MM;FZBD59+>WFE5(V_A(_X(3_ /!:?2/V&/\ @GAX4^"'PD_8&_;+_;2\?O\
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MJ_B#_P!E5^$O_I]N:^GX*_Y*[AO_ +'.7_\ J1 QQ'\"M_U[G_Z2S]Z] _Y
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M_GI_X(&?\A7_ (*O_P#:43]H3_T9IE?T+5_/3_P0,_Y"O_!5_P#[2B?M"?\
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MN[.2#2-486LSK+J*@16T7R'_ ,$Y_P!@;_@IM^SE_P %$OV\/VC/VK?VX_\
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M\_:!_P#2?P[7]#%?SS_\$!/O_P#!4W_M)Y^T#_Z3^':_H8KZGC7_ )*;,O3
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MZO;R>>YFD:21C7LE%% '\C?[?.@:I_P3\_X.-/V"?^"@$]AIL/P)_;W\+/\
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M:_#:+4-&\*SW=S=>'M3U'0].;3_ W@+2](L?$/C2>]TGQ)X@\6ZAXB7]4_\
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M>Y\%+\/- U+PQXQ\$:59O;W7@^W\4:=XFFMQI.CV&M>%-1_L?6KGXD_U#T4
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M/?\ 1[7PI_\  3QK_P#,I1_P_%_X)/?]'M?"G_P$\:__ #*5]0?\._?V#/\
MHR3]D7_Q&WX-?_,91_P[]_8,_P"C)/V1?_$;?@U_\QE>)S\$_P#0-Q3_ .%V
M4^7_ %+O7\/,T_VGO0_\!J?_ "7K_3T^7_\ A^+_ ,$GO^CVOA3_ . GC7_Y
ME*/^'XO_  2>_P"CVOA3_P" GC7_ .92OJ#_ (=^_L&?]&2?LB_^(V_!K_YC
M*/\ AW[^P9_T9)^R+_XC;\&O_F,HY^"?^@;BG_PNRGR_ZEWK^'F'^T]Z'_@-
M3_Y+U_IZ?+__  _%_P""3W_1[7PI_P# 3QK_ /,I1_P_%_X)/?\ 1[7PI_\
M 3QK_P#,I7U!_P ._?V#/^C)/V1?_$;?@U_\QE'_  []_8,_Z,D_9%_\1M^#
M7_S&4<_!/_0-Q3_X793Y?]2[U_#S#_:>]#_P&I_\EZ_T]/E__A^+_P $GO\
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M[!G_ $9)^R+_ .(V_!K_ .8RC_AW[^P9_P!&2?LB_P#B-OP:_P#F,HY^"?\
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M_0-Q3_X793Y?]2[U_#S#_:>]#_P&I_\ )>O]/3Y?_P"'XO\ P2>_Z/:^%/\
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M'M?"G_P$\:__ #*4?\/Q?^"3W_1[7PI_\!/&O_S*5]0?\._?V#/^C)/V1?\
MQ&WX-?\ S&4?\._?V#/^C)/V1?\ Q&WX-?\ S&4<_!/_ $#<4_\ A=E/E_U+
MO7\/,/\ :>]#_P !J?\ R7K_ $]/E_\ X?B_\$GO^CVOA3_X">-?_F4H_P"'
MXO\ P2>_Z/:^%/\ X">-?_F4KZ@_X=^_L&?]&2?LB_\ B-OP:_\ F,H_X=^_
ML&?]&2?LB_\ B-OP:_\ F,HY^"?^@;BG_P +LI\O^I=Z_AYA_M/>A_X#4_\
MDO7^GI\O_P##\7_@D]_T>U\*?_ 3QK_\RE'_  _%_P""3W_1[7PI_P# 3QK_
M /,I7U!_P[]_8,_Z,D_9%_\ $;?@U_\ ,91_P[]_8,_Z,D_9%_\ $;?@U_\
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MW]@S_HR3]D7_ ,1M^#7_ ,QE'_#OW]@S_HR3]D7_ ,1M^#7_ ,QE'/P3_P!
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M^8RCGX)_Z!N*?_"[*?+_ *EWK^'F'^T]Z'_@-3_Y+U_IZ?+_ /P_%_X)/?\
M1[7PI_\  3QK_P#,I1_P_%_X)/?]'M?"G_P$\:__ #*5]0?\._?V#/\ HR3]
MD7_Q&WX-?_,91_P[]_8,_P"C)/V1?_$;?@U_\QE'/P3_ - W%/\ X793Y?\
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M/3Y?_P"'XO\ P2>_Z/:^%/\ X">-?_F4H_X?B_\ !)[_ */:^%/_ (">-?\
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M/?\ 1[7PI_\  3QK_P#,I1_P_%_X)/?]'M?"G_P$\:__ #*5]0?\._?V#/\
MHR3]D7_Q&WX-?_,91_P[]_8,_P"C)/V1?_$;?@U_\QE'/P3_ - W%/\ X793
MY?\ 4N]?P\P_VGO0_P# :G_R7K_3T^7_ /A^+_P2>_Z/:^%/_@)XU_\ F4H_
MX?B_\$GO^CVOA3_X">-?_F4KZ@_X=^_L&?\ 1DG[(O\ XC;\&O\ YC*/^'?O
M[!G_ $9)^R+_ .(V_!K_ .8RCGX)_P"@;BG_ ,+LI\O^I=Z_AYA_M/>A_P"
MU/\ Y+U_IZ?+_P#P_%_X)/?]'M?"G_P$\:__ #*4?\/Q?^"3W_1[7PI_\!/&
MO_S*5]0?\._?V#/^C)/V1?\ Q&WX-?\ S&4?\._?V#/^C)/V1?\ Q&WX-?\
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M_P EZ_T]/E__ (?B_P#!)[_H]KX4_P#@)XU_^92C_A^+_P $GO\ H]KX4_\
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M?LB_^(V_!K_YC*.?@G_H&XI_\+LI\O\ J7>OX>8?[3WH?^ U/_DO7^GI\O\
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M_#S#_:>]#_P&I_\ )>O]/3Y?_P"'XO\ P2>_Z/:^%/\ X">-?_F4H_X?B_\
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MG[(O_B-OP:_^8RCGX)_Z!N*?_"[*?+_J7>OX>8?[3WH?^ U/_DO7^GI\O_\
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M:^%/_@)XU_\ F4H_X?B_\$GO^CVOA3_X">-?_F4KZ@_X=^_L&?\ 1DG[(O\
MXC;\&O\ YC*/^'?O[!G_ $9)^R+_ .(V_!K_ .8RCGX)_P"@;BG_ ,+LI\O^
MI=Z_AYA_M/>A_P" U/\ Y+U_IZ?+_P#P_%_X)/?]'M?"G_P$\:__ #*4?\/Q
M?^"3W_1[7PI_\!/&O_S*5]0?\._?V#/^C)/V1?\ Q&WX-?\ S&4?\._?V#/^
MC)/V1?\ Q&WX-?\ S&4<_!/_ $#<4_\ A=E/E_U+O7\/,/\ :>]#_P !J?\
MR7K_ $]/E_\ X?B_\$GO^CVOA3_X">-?_F4H_P"'XO\ P2>_Z/:^%/\ X">-
M?_F4KZ@_X=^_L&?]&2?LB_\ B-OP:_\ F,H_X=^_L&?]&2?LB_\ B-OP:_\
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M>GR__P /Q?\ @D]_T>U\*?\ P$\:_P#S*4?\/Q?^"3W_ $>U\*?_  $\:_\
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M2?LB_P#B-OP:_P#F,H_X=^_L&?\ 1DG[(O\ XC;\&O\ YC*.?@G_ *!N*?\
MPNRGR_ZEWK^'F'^T]Z'_ (#4_P#DO7^GI\O_ /#\7_@D]_T>U\*?_ 3QK_\
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M3_Y+U_IZ?+__  _%_P""3W_1[7PI_P# 3QK_ /,I1_P_%_X)/?\ 1[7PI_\
M 3QK_P#,I7U!_P ._?V#/^C)/V1?_$;?@U_\QE'_  []_8,_Z,D_9%_\1M^#
M7_S&4<_!/_0-Q3_X793Y?]2[U_#S#_:>]#_P&I_\EZ_T]/E__A^+_P $GO\
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MCE^SA^UYKO\ P2B_X)X>!O'^I?#GX+R^$OA_:^-/CC\5]8T"VTV\U/6-=O\
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M&NS76M3W]S+_ #Z_\$\/'EQ_P3?_ ."Y7[9/_!)O7-4N-'_9V_:ST6+]M/\
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MX-;O^"87Q._9E@\>?\$SOC-XP^'O[0>GZ98>+?V>_P!LCP5^TAXB^)OA^_\
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M#L'ALRW5I_HNK3>-M%\):'J'A[P#X*MM?M/"C^!9]2T_Q!J.M6O#/A'XE?\
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M^$_BAHW@F?7;]4UG6X_"L.J^()]6UZ[U/7M6_HSK^0+_ (,J?^467Q\_[/\
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MH;6*8 _1S_@F+\4[OXV_\$Z?V'?BQJ5W/?:SX\_95^!7B+7[FZD>:Y?Q'?\
MPX\/2>(4N+A[/3_M4T.L_;8I+N*SM[>[=#<6R""2,G[HKX'_ ."6'PIUOX'_
M /!-O]A;X4>)[>:S\4^"/V5O@=HOBJRFE68V/BB'X>Z#)XBLHI!;6A-M9ZS)
M>VUJ)(%F6VBB69I)0\C_ 'Q0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5_/]_P<R?\ **OX@_\ 95?A+_Z?;FOZ :_G^_X.9/\ E%7\
M0?\ LJOPE_\ 3[<U]/P5_P E=PW_ -CG+_\ U(@8XC^!6_Z]S_\ 26?O7H'_
M " M%_[!.G?^D<-:U9.@?\@+1?\ L$Z=_P"D<-:U?,RW?J_S-8[+T7Y'\]/[
M2G_*QW_P3F_[,U^//_IM^-=?T+5_/3^TI_RL=_\ !.;_ +,U^//_ *;?C77]
M"U?4<2_[MPG_ -DMAO\ U;9R8T?BQ'_7^7_INF%?F?\ L\?\$J_V>OV:?V\_
MVIO^"A_@3QC\9M6^-7[7.C2:'\2/#'BWQ#X(O_A=HEI)JWA;66D\$:+H_P .
M]!\6:;<"Z\(Z;&'U[QMXEB\B>^4PF22"6V_3"BOEC<*_.3PU_P $P_@)X6_X
M*5_$'_@J=I_B[XO3?M!?$CX-V7P0USP=>:_X,D^#=IX3L=/\$:;#J&D^'H/
M%OXV@\0M!X"T=Y+N\^(=]IIEN=29=)1)K6.S_1NB@#\^/^"E?[6O['G[,'[)
M/[1%_P#M>>-_ $7@75?@IXUT77?A%K_B#2D\6?%O1/'NB:WX)M? 7A[P@UIK
MFMZT?B#>W%[X2BNH/"^LZ39(^JZGK42Z)HNM7%I^0W_!I=^Q5J'[+?\ P2WT
M7XO>,O#=SH/Q'_;-\;ZA\<IQJEKJ%CK:?".SLX/"?P4M;BUNX;>W.C:YH.G:
MS\5_"E_:)=+JOA[XJV.H'49H+BULM._2[]HS_@BE_P $T_VN/VH(OVO_ -I3
M]G"U^,GQGBT7PSH9F\9_$+XHWO@*YM/!\2VOA\7_ ,+8/&EM\/=2MK2R#6ES
MHFH>'+GPSJIFNM0U?0[_ %B[N=2F_4NUM;6QM;:QL;:WL[*SMX;6SL[6&.WM
M;6UMXUAM[:VMX52*"W@B1(H88D6.*-51%55  !_,E_P=U?\ *&CXA?\ 9=O@
M-_ZE-S6,_P#P;H?LY?'/P?\ #_XX_ G]J#]L3]A#5_CC\&?@OK?QQ^'_ .R5
M\4K7X??"#XG^*5\#:&FL^.-7\!PZ-Y5KXQ\3Z9?:I;>(+NWU-_#]_JMV?$LO
MADZUJ'BNX\5?NU^VI^Q)^SU_P4#^!][^SK^T_P"%]7\8_";4O$OA[Q9J/A_1
MO%.O^#KJ]U?PM-/=:(\FN>&+[3=:AM[6\G%T\%I?6RW$D,4=P9;8S02_2WA;
MPSHG@KPQX<\'>&;+^S?#?A+0=(\,^'].^TW=Y_9^B:#I]OI>E67VS4+BZO[K
M[+86MO!]IO;JYNY_+\VYN)IG>1@#\]_^";/_  2?_8T_X)5?#/6?A[^RMX)U
M>+6?&-Q:W?Q*^+_Q#U:U\5?&#XG7&FR7?]B)XL\2V>E:#H]II'A^VO)K;1/"
MO@WPWX3\'V$LM]K*>'V\2:YXAUO5U_X*1?\ !*#]C3_@JE\._#W@/]JOP1JU
MUJG@B?6+OX=?%3P!JUMX4^*_P\N==TZ33]47PWXGGTO6;*YTF];[#J=[X5\3
MZ+XB\':EK.BZ%J>J^'KZYTBR:+])** /Y@_!G_!JY^QYJ'C;PWXF_:P_:I_;
ML_;C\+>!+FRD\#_";]H7XZRWWPZTRTM+)(19:M!H&D:;XJNX8KKSY;.V\-^*
M?!^EKI\[:3JFEZO;M-+/_3+X?\/Z#X3T'1/"OA71-(\,^&/#.D:;X?\ #GAS
MP_IMEHV@^']!T:SAT[1]$T31].AMM/TK2-*T^VM[#3=-L+>WLK&SMX;6UAB@
MB1%UZ* /P8_;4_X-Z/V//VP/VG+C]L+PW\5OVHOV/?C_ .)H[&T^*?CC]D+X
MH:9\,KGXJ6MD^CLNH^(8M4\)^*!I?BP#P]H3?V]X<?2K+4;W38-:\4:#XE\0
M)!JUO^H?[6O[&O[/G[<W[/OB7]FC]J3P/:_%3X:^)[>QDN#J;1Z;XET?Q+I4
M4BZ/X\\*:_HL&G7'A3QMI4TUQ/9ZQH$5A$8;W4M%NK*Y\-ZMJNBWOU)10!_*
MFO\ P:<?LN"SF^&[_M[_ /!2UOV8VGMKB#]FQ?CWX77P)%&J70N](F@/PY?0
MI]#G5[*RMH4\)V^LVNDV]U:RZ]>7UY#JMC_0_P#LH?LF?L__ +$7P,\'_LX_
MLR?#S3_AG\)/!"ZA)I&@6=YJ>KWMWJ>L7TVIZWKWB#Q!KM[J6O>(M?UC4+B6
MXOM6UG4;RZ,8M["V:WTRQL+*U^C:* /S@_X)?_\ !+_X!?\ !)GX!>+_ -G/
M]G/Q?\8/&G@GQI\8-?\ C7JFJ?&O7_!?B/Q5;^*O$?@OX?\ @6^T_3[[P+\/
M_AQI$7A^+2/AQH=Q:VMQH=UJ*:C=:K--JL]M/9V=B?MK?\$O_@%^W?\ 'W]A
M7]HSXN^+_C!X<\;?\$^OC!-\:_@SI?PXU_P7I'A7Q-XJG\:?"#QT^G_$ZQ\3
M_#_QAJ^L^'QJ_P %?"MNMKX5USP7J(T[4/$$)U4W-UIUYI7Z/T4 ?"?_  4(
M_P""</[*O_!3GX&2_ 7]JKP9J&NZ#8ZA<^(/ _C+PKJ[>&OB-\+_ !A-I-_H
MT/C#P)XB%M?VD&IVUIJ$IET;Q)H_B7P5K<D-DOBCPKKL%C:P1?BA:?\ !JM^
MSYXQU?2M/_::_P""@'_!1[]J;X.^';G2+S0O@?\ $[X]1MX-E?35M1)8^(+F
M/1+S4)=)G%M&EM'X+/@'6=.BBM4MM=+6PD?^INB@#Y#^(7[#_P  O&_[$WB[
M_@G]H>A:A\)OV<O%/P.U7]GNST/X67&G:5K7@[X>:KX>E\-.OA74O$NE>*[/
M^WK>QFDN1K7B32O$EQJ.K23:KKJ:O>W5W+<:_P"Q3^R/\-_V$/V7?A%^R5\(
MM;\;^(_AQ\%]$U70?"VM?$?4M!U?QM?V>K^)]<\5W,FOZEX8\->#]"NKE-1U
M^\A@?3O#>E1+916T<D,LZ2W,WU+10!_-U\>/^#8O]BOQW\:_%_[07[,OQN_:
MR_8 ^(OQ!UY]:\:V7[(WQ2LO 7@'5%U&X^T>(H=,\*MX?GU#PL=4EEU"XL-/
M\.>)=.\':'=:I>BS\'R:=]FTRW^TO^";/_!%']B?_@F%J/BOQ_\ !W1_''Q.
M_:'^(=OJ-M\1/VG/COXG3QW\8_$]GK.K-K^L:5:WUKIVB>&O"VDZGK;_ &_5
M_P#A&?#FFZ[XKDMM*D\>^(/&%[HNE7MK^N=% 'YP?MK?\$O_ (!?MW_'W]A7
M]HSXN^+_ (P>'/&W_!/KXP3?&OX,Z7\.-?\ !>D>%?$WBJ?QI\(/'3Z?\3K'
MQ/\ #_QAJ^L^'QJ_P5\*VZVOA77/!>HC3M0\00G53<W6G7FE?H_110!^<'_!
M+_\ X)?_  "_X),_ +Q?^SG^SGXO^,'C3P3XT^,&O_&O5-4^->O^"_$?BJW\
M5>(_!?P_\"WVGZ??>!?A_P##C2(O#\6D?#C0[BUM;C0[K44U&ZU6:;59[:>S
ML[']'Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH _GI_X(&?\A7_ (*O_P#:43]H3_T9IE?T+5_/3_P0,_Y"O_!5
M_P#[2B?M"?\ HS3*_H6KZGC7_DILR],#_P"J["&.'_@P_P"WO_2I!1117RQL
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^;O\ P44_X)>_ G_@
MIU8_L_\ AK]HWQS\9;'X;_ #XLVOQF@^$GP_UKX?V'PX^+7BW3H[.STF#XQZ
M1XS^&OCK4O$.B:5H9\4>&[33_#6L^#Y7T+X@>-+6]N[N>^TJZT;]&;.SM-.L
M[73["VM[*QL;:"SLK.TACMK6TM;:-8;>VMK>%4A@@@B1(H88D2..-51%55 %
MFB@ HHHH _E7_P"#AOX/>(_V<?CO_P $_P#_ (+=_"O1]5O=>_87^+'A3X?_
M +2T?A]]:;6=9_95\;^)[RSU:-1I.E:BMCIFF0>-OB7X2U'4;F2.V5/BW&+O
M3]9MXC9K_4/X1\6>'/'GA3PSXX\'ZS8>(O"7C+P_H_BGPOX@TJX6[TO7/#WB
M#3[?5M&U?3KI/DN;'4M.N[:\M)T^6:WFCD7AA6U=6MK?6MS97MM!>6=Y!-:W
M=I=0QW%K=6MQ&T,]M<V\RO%/!/$[Q30RHT<L;,CJRL04M+2UL+6VL;&VM[*R
MLX(;6TL[2&.WM;6UMXUB@MK:WA5(H(((D2.&&)%CCC541550  ?G9\<?^"8?
MP$^/W[?/[+__  46\8^+OB]IOQM_9,\*ZSX0^'/A?PSK_@RS^%FM:9KD7C>&
M[G\;:)JG@#6?%NHWT:^/=8-O+H7C?PW;HUMIIEMIA#="\]*_X*!_L*?!K_@I
M!^RO\1/V3/CI<^*-*\$>/I- U*'Q+X)O=.T_QAX3\2>%=;LO$'A_Q#X?NM7T
MO6M*^TVU[8BSOK;4-*O+;4-&OM3TYE@>[2Z@^T:* /E7]B3]CGX._L _LN?"
M7]D7X"+XH/PL^#NDZQI^@7GC;7$\1>+M8O\ Q-XGUSQMXK\1>(]6@L=*L)]7
M\2>+_$NNZ]?0:-H^B:!83ZB^G^']#T71+6PTNT_(S]KW_@V@_P""?_[3WQV\
M0_M._#[Q5^T3^Q?\<_&-QJ^I>./%/[)/Q'TSP%HGCCQ!X@NK2;7?$FO^%]?\
M*^*[?2M7U>*WG;51\/+[P'INOZO?7OB3Q3IVOZ_>7U_=_P!#M% 'X*_L,?\
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M_0Q7U/&O_)39EZ8'_P!5V$,</_!A_P!O?^E2"BBBOEC8**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KY/\ VX_V/?AU^WW^RO\ %G]D7XM>*/B/
MX,^'7QDL?#.F^*/$7PEUO0O#OC^RLO#'C?PSXZ@M]#U?Q+X8\9:';PZK?^%[
M32-;BU'PUJD5]X?O]5L$CMYKJ*\M_K"B@#^3?2/^#/+_ ()[^']/@TG0?VNO
M^"FFB:5:F4VVF:1\?/@CINGVYGFDN)S!967[,D-M"9KB66>4QQKYDTLDKY=V
M8_7/[%'_  ;A?LD_L*_M._"_]JOX:?M/?M[_ ! \;?"B;Q9/H?A#XR_&GX9^
M*_AKK#>,/ OB?X?WZ^)M T#X&^$-7U!++2_%=]J6E"S\1:<;;7+/3+R8W5O;
MS65S_0?10 5POQ1^&_A#XR?#/XB?"'X@Z8-;\!?%3P+XN^&_C?1FD>%=7\(>
M.- U#PQXETQIH\21"_T;5+VU,B$/&)=R_,!7=44 ?RX?\&XFI>+_ -DC4OVV
MO^".'QJU2<_$;]BGXX:]X]^#:ZA-JL$7B[]FKXPW4>NZ+XD\(6.K:5I9NM"'
MBZ?4_%.IZGIL4-D;KXEZ9&]A;SNUYJ/ZY?\ !1W_ ()3_L;_ /!4[X<:#\/_
M -JOP/JE]?\ @RYU2]^'OQ.\":K;^%?BI\/;O6;"2PU$^&?%$VFZO:S:9>-]
MCU"]\,>(]'\0>$M3U72-%U#5= OI]+M#'^AQTK2SJ8ULZ;8'65L3I@U<V=O_
M &F--,_VHZ<+_P O[4+$W/\ I)M!+]G,_P"^\OS/FJ_0!_+[\*?^#4;]@[0/
MBYX,^+'[1GQS_; _;9B^'MQ%=>%_AI^TK\4]$\1?#666&5[J*#Q+IFB^$-'\
M1Z]H\.H1V.H-X73Q1IOA367M)=.\7Z'XHT*_O-(D_I%^)GPT\&_%[X8?$'X.
M^/-)35_A]\3_  %XK^&GC/0@[6\>I^#?&OAZ_P#"WB+21)%AX$O=$U.\LP\>
M&C67<F"HKO:* /R__P""6_\ P28_9H_X)*?"SXA?"W]G/6?B?XKM_B;X^N/'
M?BOQ7\6?$6CZYXEO)8;.+2O#^BPQ>%_#G@_PQ9Z=H&D0);I-9>'+:_U*]N+V
M]O[F2)[&RT[]0*** /S@_;>_X)?_  "_;X^-/[$GQV^,/B_XP>&_%W[!7Q@?
MXU_!_3OAKK_@O1_#GB3Q5)XL^%GC$Z?\2;3Q1\/_ !CJ>L>'QJ?PB\-P"U\+
MZOX.U'[!?:Y$=5-Q<V%UIOZ/T44 ?GG^SE_P32^ 7[.7[6?[3G[<-GK_ ,3/
MBU^T]^U5<V5KXT^*/QCU3P7K6K^#/ >E1:7;Z/\ "3X6Q>#_  'X&MO"OPVT
MVT\/^%[(:7=Q:WKFIVOA'PI'KOB'5CX>TQK?KOV]/^"?G[/W_!17X0:7\)?C
MM%XST*Y\(>,M"^(_PL^+?PH\1Q>"/C1\&?B)X<NX[G2_&WPN\;R:9K,>@:[&
MB-;2_;=(U?3)D:"\?3CJVF:-J.F_;U% 'X\?L2?\$9_@]^R!^T7XE_:]\:_M
M$_M6_MH?M/ZUX*OOAEH7QB_:[^*2?$S7/A]\-]2U*RUJ]\)>!;.'1]*L-"MI
M]4M)9(KF.)Y-+T^_U/1] CT?3-8URWU7\L/^"YWAY?\ @J%_P4)_X)]_\$;/
M!-Z_B#P7X3\7W/[9/[==IH37B:GX#^$?ABVTSP]X22ZU=-0TJRT+4?$N@>+O
M%WANVFMGU?7=,OOB=X%UV'3H;-A!K7]:U9,6@:%!K%SXAAT32(=?O+=;6[UR
M+3;./6+JU58%6VN=32$7L]NJVMJJPRSM&%MH % AC"@%C3--L=&TW3](TRUA
MLM-TNRM=/L+.VBCAM[6SLX4M[:WAAB5(HHH88TCCCC1415"JH  J]110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_/]_P<R?\ **OX
M@_\ 95?A+_Z?;FOZ :_G^_X.9/\ E%7\0?\ LJOPE_\ 3[<U]/P5_P E=PW_
M -CG+_\ U(@8XC^!6_Z]S_\ 26?O7H'_ " M%_[!.G?^D<-:U9.@?\@+1?\
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M2?\ YP]'_#VC_@J'_P!($_C[_P")'Z3_ /.'K^A>BC^W,B_Z(O)__#IQ-_\
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M?K_2U_GH_P"'M'_!4/\ Z0)_'W_Q(_2?_G#T?\/:/^"H?_2!/X^_^)'Z3_\
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M)O\ Y]?U=^5CV=7_ *"*G_@%'_Y7Z_TM?YZ/^'M'_!4/_I G\??_ !(_2?\
MYP]'_#VC_@J'_P!($_C[_P")'Z3_ /.'K^A>BC^W,B_Z(O)__#IQ-_\ /K^K
MORL>SJ_]!%3_ , H_P#ROU_I:_ST?\/:/^"H?_2!/X^_^)'Z3_\ .'H_X>T?
M\%0_^D"?Q]_\2/TG_P"</7]"]%']N9%_T1>3_P#ATXF_^?7]7?E8]G5_Z"*G
M_@%'_P"5^O\ 2U_GH_X>T?\ !4/_ *0)_'W_ ,2/TG_YP]'_  ]H_P""H?\
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MZ3_\X>C_ (>T?\%0_P#I G\??_$C])_^</7]"]%']N9%_P!$7D__ (=.)O\
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M^O\ 2U_GH_X>T?\ !4/_ *0)_'W_ ,2/TG_YP]'_  ]H_P""H?\ T@3^/O\
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M .'3B;_Y]?U=^5CV=7_H(J?^ 4?_ )7Z_P!+7^>C_A[1_P %0_\ I G\??\
MQ(_2?_G#T?\ #VC_ (*A_P#2!/X^_P#B1^D__.'K^A>BC^W,B_Z(O)__  Z<
M3?\ SZ_J[\K'LZO_ $$5/_ */_ROU_I:_P ]'_#VC_@J'_T@3^/O_B1^D_\
MSAZ/^'M'_!4/_I G\??_ !(_2?\ YP]?T+T4?VYD7_1%Y/\ ^'3B;_Y]?U=^
M5CV=7_H(J?\ @%'_ .5^O]+7^>C_ (>T?\%0_P#I G\??_$C])_^</1_P]H_
MX*A_]($_C[_XD?I/_P X>OZ%Z*/[<R+_ *(O)_\ PZ<3?_/K^KORL>SJ_P#0
M14_\ H__ "OU_I:_ST?\/:/^"H?_ $@3^/O_ (D?I/\ \X>C_A[1_P %0_\
MI G\??\ Q(_2?_G#U_0O11_;F1?]$7D__ATXF_\ GU_5WY6/9U?^@BI_X!1_
M^5^O]+7^>C_A[1_P5#_Z0)_'W_Q(_2?_ )P]'_#VC_@J'_T@3^/O_B1^D_\
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M?_G#T?\ #VC_ (*A_P#2!/X^_P#B1^D__.'K^A>BC^W,B_Z(O)__  Z<3?\
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M4*5E[S[P;[]>OD?ST?\ #VC_ (*A_P#2!/X^_P#B1^D__.'H_P"'M'_!4/\
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M*/[<R+_HB\G_ /#IQ-_\^OZN_*Q[.K_T$5/_  "C_P#*_7^EK_/1_P /:/\
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M-_\ /K^KORL>SJ_]!%3_ , H_P#ROU_I:_ST?\/:/^"H?_2!/X^_^)'Z3_\
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M .D_AVOZ&*^IXU_Y*;,O3 _^J["&.'_@P_[>_P#2I!1117RQL%%%% !1110
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MB1Y)%4_RX_M<:5\";C_@X=_X(L:E^Q[;_#&X\<V_PK_:&?XV'X(2>')[>Q^
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M]1U1XM+^&LNEZA8+I%K;6>I 'ZN?\&H7PV\8>(_V4/VK?^"@OQ*L=+@\>_\
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M+X@T?P[K\MC>P7%O-?\ AN3Q%<:]X=NMB76B>*=.T/Q%IL]MJ>CV4\?Z^_\
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MNF:G-ILGCC3(Y]"\9>)]"\*R60U'7_#'PMBUGQ%XJ_T70M#UC0[*^U7QMX4
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MNK6]WINIV%U&=EQ9WMM/;S(2LD;#BOX7_P#@HO\ MOZY_P ',L7P;_X)T_\
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M_P 5ZCXIO_!GVW^PQXJ\.^*M,\'7WB?X6:U=KH8\8>$=9\,:S/#I(U5HK?\
M@@^#7_!;?]D+]JC_ (*4ZM_P4-_X*XW_ ,7?&?A+X&:I>V?["?[(7PX^%^E>
M-OA9\*[=[V*[TOQ]XM3Q!XZT72;[QGI"6MAJ4UV;#6]2\1^/HK3Q1/?^'](\
M"> ?#UL ?U$?\$5OV(OVG?C=^T)\2?\ @M;_ ,%,?#-SX>_:?^/.C_V)^R[\
M$]2U#7FM_P!F/]GW5+>0V^G6WA+7I;J?P3K/B+3;A;?3- GNY-<T70K[7=1\
M3Q67C'Q[XNTVQ_H^^+OP<^%7Q]^'GB7X3?&OX>>$?BE\-O&&GSZ7XD\%^-]#
ML/$&@:I:3Q/$3+8W\,R0W=N)&EL-1M3!J.FW2QWFGW5K=PQ3I_/#\#_^#L'_
M ():_'[XT?"#X#> M(_:BB\;_&OXG^ /A%X,?7?A)X7T[0HO%7Q(\5Z3X-\.
MMK%_;_$R^GL-)35]9LSJ%W!97DMK9B::.UN'187_ '2_;"_:L^$W[$7[-7Q>
M_:C^-FKKI?P_^$/@_4_$U]:Q7-C;ZOXHU:*(P^&_ WAA=2N;.RNO%GC?7Y=.
M\+^&K2ZN[6UFUC5+3[;=6=BMS=P '\[_ .W[X9_94_X).^%_!?[$_P#P2'_9
MM^$7PB_X*:?\%'[I/@A\'_$/ANR\2'QM\-OACXAU.=/B!\;?%'Q.G7Q)XWTC
MPMX'@LKVZ\.6D?B.!=-\0Z?_ ,)[INA^(;/X8ZGH=QM_!#]L/]C[_@ASX \.
M_P#!,3]G#]F+]MO]N[XS? G0- \?_MBZE^Q?\ ]1^,TW@CQO\2-+M_$6N>//
MBUKESK'AVTT_6/%T"F^\)>'[62ZTS1_"VEVGAS4]=T.XT%;,^R?\$2_V4OC+
M\4O'?QB_X+-_MS^&+W0?VL_VUK5;3X+_  OU>_U"[A_9A_9'BGMKCP'X TC2
M[Z.-M%UOQO9V&C>(M<CN7N+^'0;'PNU[9>&/&.K_ !&TR^_/#]F;]KK]GK_@
MB?\ \%0_^"T9_P""D?B_Q-\%3^US\;=%_:6_9T\?7_PR^('C?2?C'\(M6\6?
M%'5=*T#P;K?@'0O&5UJ%WX'N/'MKX9?1[T6%AHMY!KD1.FC2=>@TP _JC_8V
M_;&^ W[>7[/G@3]IC]G+Q5)XG^&_CNTF,<6HV@TOQ1X5U_3IFL_$'@OQKH1G
MN7T+Q;X9U*.;3M8T_P"T7=H\D27^D:AJNBWFG:I>?S1_\%#[JS\%_P#!US_P
M2 \3^';V&#Q+XM_9J\:>%?%NE1W,44=_X<N-/_:KTW3[_5+&Q:UO[J29[^]2
MRNM3N+FQDNO#&E+!;L=%EC?[$_X-C?AG\0_"?[$/QY^*WB[P;XC^'O@?]J?]
MM[X^?M%_ 7P;XOTVX\.^)]&^"OBBW\'>%?#C:MX0G41>%%U;6?!GB+6])T_3
MI;O2=3T+4M+\2Z7>WECKL%Q)\:Z:VG?M>?\ !WI>Z_HUMXDU?0/^"=/[',V@
MWWB*WMYAX8TOQUXC\.WNE2Z'+J!U2:W 9?VC/&=C%ITEKIUW>:_X<\0W-GHM
M[::->>(I0#^P2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M  E/AS1_$/\ 8VIKLVZCI/\ :UG=_P!G7Z^6FV[L_)N!L3$@VC'644 %%%%
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MW%SJ^IVEK#>ZE/<+I]@LTUY/-)*+&T#LPMH=G2T44 <UXD\%^#O&4=G#XO\
M"?AKQ5%I\\=U81>)-"TO7([&ZBNK2]BN;--3M;I;:>.\L+"[CFA"2)=65I<*
MPEMH73I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _GI_X(&?\ (5_X*O\
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M /YI:_H6HH_UOS;_ *!^'_\ Q%N&O_G5Y+[@^KT^]7_P=5_^3_J[\K?ST_\
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M_/3_ ,.W?^"TG_2<;5/_ !$KX?\ _P TM'_#MW_@M)_TG&U3_P 1*^'_ /\
M-+7]"U%'^M^;?] _#_\ XBW#7_SJ\E]P?5Z?>K_X.J__ "?]7?E;^>G_ (=N
M_P#!:3_I.-JG_B)7P_\ _FEH_P"';O\ P6D_Z3C:I_XB5\/_ /YI:_H6HH_U
MOS;_ *!^'_\ Q%N&O_G5Y+[@^KT^]7_P=5_^3_J[\K?ST_\ #MW_ (+2?])Q
MM4_\1*^'_P#\TM'_  [=_P""TG_2<;5/_$2OA_\ _-+7]"U%'^M^;?\ 0/P_
M_P"(MPU_\ZO)?<'U>GWJ_P#@ZK_\G_5WY6_GI_X=N_\ !:3_ *3C:I_XB5\/
M_P#YI:/^';O_  6D_P"DXVJ?^(E?#_\ ^:6OZ%J*/];\V_Z!^'__ !%N&O\
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M_B)7P_\ _FEH_P"';O\ P6D_Z3C:I_XB5\/_ /YI:_H6HH_UOS;_ *!^'_\
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M2?\ 2<;5/_$2OA__ /-+7]"U%'^M^;?] _#_ /XBW#7_ ,ZO)?<'U>GWJ_\
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M (B5\/\ _P":6C_AV[_P6D_Z3C:I_P"(E?#_ /\ FEK^A:BC_6_-O^@?A_\
M\1;AK_YU>2^X/J]/O5_\'5?_ )/^KORM_/3_ ,.W?^"TG_2<;5/_ !$KX?\
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M_P#)_P!7?E;^>G_AV[_P6D_Z3C:I_P"(E?#_ /\ FEH_X=N_\%I/^DXVJ?\
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MJG_B)7P__P#FEK^A:BC_ %OS;_H'X?\ _$6X:_\ G5Y+[@^KT^]7_P '5?\
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M ,1;AK_YU>2^X/J]/O5_\'5?_D_ZN_*W\]/_  [=_P""TG_2<;5/_$2OA_\
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MX/J]/O5_\'5?_D_ZN_*W\]/_  [=_P""TG_2<;5/_$2OA_\ _-+1_P .W?\
M@M)_TG&U3_Q$KX?_ /S2U_0M11_K?FW_ $#\/_\ B+<-?_.KR7W!]7I]ZO\
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M5/\ Q$KX?_\ S2T?\.W?^"TG_2<;5/\ Q$KX?_\ S2U_0M11_K?FW_0/P_\
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)E%%?);F^Q__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img75897552_13.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_13.gif
M1TE&.#EA902( ?<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
MS#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F_S.9 #.9
M,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_9C/_F3/_
MS#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S_V9F &9F
M,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,9F;,F6;,
MS&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D _YDS )DS
M,YDS9IDSF9DSS)DS_YEF )EF,YEF9IEFF9EFS)EF_YF9 )F9,YF99IF9F9F9
MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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M=Q[\D"=8IRS!HAX'I'0TD$+^4 8?*#]!)W"_A077$T#!YBC]\'+VL4#HL4$
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MQIS:N;S*8I[;UO[ *L[M2EKJ\"[$M&[CHAS*C$[4^5[&F6VT=BW(2\[1[7[
M[S[OF[KM!O_"S9[P)_SH-ESP#-^?\A[QU][!'A[B&#_B&8_A&W_Q&O_Q' _R
M'A_R)#_R)M_A*-_?/=SQ*<_A$7[R+]_R(O]>\C+/\C%_\RZ?\S,/\SIO\SU/
M$S4O\D%/\SB_\T//\T9?]#Z?]#]/]$UO\H9%;3_6&%._&%4O3:-Q]7VA];J1
M]5X/8E]/]6%O]6./]6!_]F*/]F2O]F:?]FZ_]F_?]G _]W)?]UM?]G?/]GD?
M]WM/][H!#W.R*"EI'(/ODFA5^# I^(>_^(K?^-:!^)#/^(\O^=T1^8Y?^<AQ
MC;K2+!3"^0_B^9O?^:+_^:,?^J1_^J:?^J"_^J7/^JCO^JK?^K+_^K,?^[1/
M^E*)]UVO][O/][WO][]O]\'?]\+/]<:O^\?/^\GO^\L/_,U?_,@?_<HO_<Q/
M_<Y?]KN1P/3P_,3_W_W#__W<#_[6#_W37_[5;_[7C_[D?_[LG_[MO_[N'QCT
M /C'6/_4*''5:/_)J/_3N/_%2'$  4$@! 4##18T*!!APH4'$RI\2#!BPX$4
M(3ZT*!'C1(X;/3+L"/*CPY$50Y(4F1+E2I,E+U;4 0]1O7OU9M:C-[/FS9PT
M;=;#J?-G4)\\A1HM"K3G3J5'FR8ERC3JT*54G4Y%*K5J5JM0MS[5>O4K5K!=
MPWH5FQ;MVK-MS;[E&K>L7+)UQ]X]2D\>/'CSY-'#RQ;N7,)VG=:$IRU;-G0T
M>^*;)^.;.IGWYFW+MBW<XFP!Y"&2MYES-FW?WMF\)P]SMG6HWRW6YLYF_[G%
MX;R-#J#NILW;Y&:F@YUN*;UY\.3-F^D.-CS4ZA9[DY?ZVV)RTSES6R>TR^K:
MY3!_DPDO0&?1V;C1LPQ.\>AP[W:*7]QNIW+S[NFQ6 SNP.AM[08;%HRNP-R:
MB1YXNC !@01-$&!!!15L\,$%(W20P00%: $?  !H!0H!!$" G@WK82%"$"L4
MX(H- =CC0P41V;"?%BI4T(L-\9F10D%&9,'!$Q],<4-^9OC1A!GX < ?+R9D
MH15_9KE"10#TF8%&"R6$T$H*'V3AG7=.:DFE,%EZR2$; 9B%!HT@\&*6#049
M2! WD]QP%GH&HL'-65J9\\E6="BH%3I7_$(@.?]7K!-.@?+<4)\YT?3B"R0W
M]"<1@00%H-"!1 3 4H&^Z =1 /KQ% (=*/6BH$$V;$50?RA5=$V4%-@AU%;
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M]FC[0 Q%C.^H1BN[$M!B O!+QF?)\B7=XFW=^$SS#(>FA"K45&33O._[YL[
M+"5-_X:*D@:%_KH,\PY(\^8KI0)ME[I-!%7/5DI&V##L]&IK]B@/LL(M %-*
M6<8MN3Z"^Y:/=4#BW&@*<#SPP7QP^N*J>0K-M,8/POS/C1@MU[),QYQOS#[0
M\T+PUPIK1S+,V4+&2TB(D/"E7K(0 ;]GNP9KLVK&D#Z&O5AO:SH%<4I-#5DL
M#==L6KJO.%@I!WWLO;A0"MML#Y,L5$1G"]U/A<8F\"*O"Y7%[QAC"6W"$A%B
M\>0"$VF"$W_#\0*K""_1S7ZB!^G-\"0Q/A(O+Q(1W(+O(#21+D@1)@HQ.4#Q
M)%JQ-69QVB(Q%9=C%8,H%GV1*FYQ&+.'EQAJH1QJ&1NJ&?^5T1F3,1J9\1FI
M41JA<1JML1JQ<1NOL1NUT1NS,1RY\1E!8QS%$1S-,1W1<1V_L1W/T1V3":*@
MT!@GT2AL21CI42F*,1^?!Q7Y$3@HT9/P\1\7:/@(4HMZ\2!Q QAI:" 5\B;V
M\2%1QL/RD/,H,#P:<#SZZB)#,1</\171RZ\RLB;,1[^^J_0@#--F)$_:YXZJ
M+P+A1 ]!<B)JJ=3FB@FE;0QIBQ&S96A.$"8OR-]:4B>?I(",; C'IMS^[U(&
M4:Q^QB<AY _+R (E+/52!'T:1/(VYP*E!6"(3_;,<+A2SZQBQ "C:_,(#8Z6
MJ_78AOA6"O3 XP(A#"X[T&58TOG_"NRG[!%&W@S&WFR%4J^EB#)SMG+4PJ.+
M:K$BR*C]S/!O'/.)7.CX'A,RZ^\O1S)^Y@W6<)!?>E(4ETP%?S!$DLUTB&H!
MGT@%9U*!*+)X8 @"[T_)4-(1QTO[X"]\;))=*F<.H\0U7^S,TJ\R_9+\LF:$
M9#+'6O$G9:S_D"PQ 6"6'A'&2A HK^8Y_8^_8'+#:L\D\BO-JJT,:[.T=NT[
M*8<QF2PUE2<S_Z>QTM,MARU@4NT[8XLTN[,!R9,)18DJ5["]!DTFE2R,,F3]
M=B8[_ZN-SC(_7T@0 10LI4B\^-!=/JT&6V]NS KZ:J9 #T=ON"5#$6LOMVH'
M0\P$4=.!_^0L8EJR+M&R0P>,.6FRVQ*(#,.(,CDL^2:M,QETR\I(*#F&*&/M
MM781P*I+%)'PUHP0RBK-0__N"87C-H>1(<T-*%W1(S_"(6>"(\?#2>LG(GOJ
MP*Y"2R=)16DH(5MCK/*129''/$W",RN#1;L"36&B1_'-(+W"36N#314/2272
M%@.RDJ3T3F4"2_F41\#4K^CT)G33,3V1WLCT@O;T3[<(3AF5?J"MCK OM+1L
M4IV&_::&_R!FQRC+)>^/S?@M455331]U*ORT5)/#SC33+N,,<Q0T;KK/1ORR
M/L\G<@BH0P)/5.MG45'U,1RU5ZVGHQRF#9W(.X>5$>\$#6>5V?\6!/WH\%+-
MU)3R%)5(%5B%XE2MU3<B<2V5K%M?3()&R\'6THJHZD ;,UF;;U!S25<AM5JS
M]2>P]5UQPQ_E=3+8-7YXM5X)XU?U=78"M5\9XU[))U\!=LCXM6#CA5X1]C $
M5GO*\1T6MB"Q)V)G!QG[XI@N%BXRMB@V5B,Z5AX^-F2-261]B60Q=F11MF13
M]F15MF59]F4U=F5CUF5G%F8Y5F9OEF9SUF8]%F=[5F=_EF>OR61KMFAWUFB#
M%FE!UF>7%FB;5FB)]FBE-FFG]FF5-FJI-FNMMFJQ=FNUMFO!EFG#UFG'%FK%
M]FS)=F5S0N#*]FK1UFS3-F[A=F[=5F[_ZY9NN?9M[W9O\]9N^Q9OOU9O5V(>
M*;9P#?=PAU$=X9$=W[%Q%==Q&?=Q)3=R*7=Q+1=R+W=R,[=R,;=S-==S.?=S
M13=T27=S3?><C$(>Z.$>Z*$>ZN$>5N$>7K=U7S=V9]=U85=V61=W;7=W:U=W
M:3=W;_=WAU=X?==X@[=WDQ=X>9=YB?=XE;=YBS=ZGW=YI]=YD5=ZH1=[J3=[
MJU=[K7=[KW=\Q;=\P_=\P3=]OW=]O3=WZ6$>UH$%3( %2@ !3,!^[9=^\?=^
MY[=^^3=__7=_]?=_^W=_ =B "YB !UB  YA_%]B!&_B %3B"$YB!$?B!)=B"
M)_B"2X %<F(&_R @A!\@A"%@A$68A$VXA%%XA4^XA578A5,XAEGXA6E8AF%X
MAFVXAG%XAV^XAW78AW,XB'GXAXE8B(%XB(VXB)%XA:] 'DI!?=NW>Z68>ZF8
M?-&7?:?8BJ$XB\UWBZNXB['XBZ\XBL78B[4XC,^8C-.8B\>8C<T8>NN!;3%B
M'H"WCF?7CED7CU?WCODXC_MXC_TXD %YD/6XD/_8D 49D0GYD!DYD1MYD1TY
MDB%YDA6YDA_9DB49DRGYDCDYDE6B'3"8@!%XE$6YE$GYE$TYE5%YE56YE5GY
ME5TYEEG '>3AA$=8AF]YA7/9EG5XEU78EW,9EWMYF(6YF'69F(_9F/]Y69E_
M&9F7.9FA^9FEN9F9.9BCF9JOV9JG.9>;F(XW.9,[^9O%69/).9S+&9S1>9S-
M>9W3^9S5N9W9^9WEV9WIV74]MA14UWA707OW^7G[69_Y.:#]6: !>J -NJ 1
MNG?_6:$)FJ$/VJ$36G<76J(;FJ(?VJ(CNG8K6J,OFJ,S&G8W&J0[6J0_.G;?
M-W[OUW\76*4#F*7QUZ53.H-A&@%FNJ9E^J8KV*9S&J=7FJ=;VJ=?.H/G]X.7
M^(B-6HF/.HF5NJB1NJF7.JF9^JF=.JJI&JJM6H6;N!0P&J*Y>JN]VJ.[&JR_
MFJ3#FJS'>J+%.JW-6JW1>JW=NJWA.J3C>J3_Y[JDY?JNZ1JO[3JO_9D>Y%@E
M[!@1%EFP WNP#;NP$9N/"5NQ#YNQ$]N/%QNR&UNR'WN/(]NR)QNS*UMV+YNS
M,]NS-[L>.ENT/YNT0WNT4;NT4SNT\>&30QF683N68WNV9;NV:?NV:WN6Y^&&
M@;F9M]FWL?FW>WNXG3FXC5N;CQNXD7NYE;NYB;N:G;NXF?NYLSFZH=N7NYFR
M'7N[M;N[-9N[O]N[01N\QUN\39N\S]N\5QN]UUN]5?N]3QN^V5N^W3N^[7N^
M\=AC-6)UV[B,T1B,U1C W?B_^WN-_3O "US #WS $?R-$_S!'3S"?_>DY3>4
M+9R"+YR#-7R#.5R#_ST<@C?\PX5ZQ"L8Q#O<Q!G8@^<!A*]:JEV\JJ>ZQ6'\
MQ66\QF/\QFD<QZDZJR6\P0F\QQD\R!=\R V\R!7<R"'\QY7<QYE<R)$<R!<\
MCD%VCNL9GJU\GN.YRK'\RK6\R[/\R[D<S+?\G5V;@G'[S&T[S=%\S=6\S6>Y
MEI.;NH5;NJV[NN4\SNG\SJ<[S_G\NOO<SO]\SOT\N\?<R\/\T M=S T]T1%]
MT1U=T2&]T;^\'NXYG\NZKB]=K\,:'U;!'<IA')Y@',AA'>B8K_?ZU+F:'M!A
M'-#!=?'A'N"A',@AU$==J^_AK:47'TK!',)A'-SAK#4=V$T]TX==V%']K/]9
M%W[EEZ:!.J8KV(//>[$1P1WDMPN^6]JA0 ;H0;#?@068W8'E0; %@06NX-HM
M6QY8H!VD7;/IX0KJ%QW6G;/G 92__=O+G;/3H=F_O:=+7,597,=M7*EU !\2
MX1X2@> -'A&\(,>E>@:\@ 8 /N(9'@)TH. 100<D?H=[.^!G?(FSVJM9-]1[
M7>1!G1S4876-W79UW1WHF-B/G:V#'>:+7>9?'M=K%QU&?AQR/AWFX75_=QU
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M?DM\I5:]JF,9:S'&7LPQ7OG*6 ;Y(\4L]JH50V &B1!P+SN<B%<]0 >(3(1
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M08"/J8RF(+A='^7[(<,CH_CQOB; CYP?1W^N5ZD58 VJM9];V8\&L\B5[![
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M95(^95-.PRW.XBY>95?68EANY5AF95I^95F^Y5J>95O.95S>95_696!F-GB
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M<$BO]5UG<R ']CA/]$+7[N5F\#['<<W@\EY/]I@P=C^7=F&/\:.^=#4_S+N
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MDE67A?L$XH_CDK4^<C,SKR6FNL%Y26Q/S-S_YLGUU!TQ>?_,W@77:"7UO>U
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M1V19K-&AG/S5']&4W(^A&+]4;+B>:XG=;;;F[;,J*]H!BFQX2)<>V '_!6:
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+$ \1$1-13P(" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img75897552_14.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_14.gif
M1TE&.#EA900" ?<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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M+,BCIYZS0"'(HGE>@8  5T"Z9RM18,?"HW(*(H!RWX4Z7GD42FAJJ>[M8"@
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MP/@0O#X(L>KQ?8]ZDBNOWA?!ZB!A>N%['Q;R0P/YQ0=9K5B6#K0'@!V\9P>
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M>SP?])JCY>_C?"G%X)FC' _. @$0]#WO; # #SKU&RV0#W)2;/C(*?Z0#XF
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M/MKH>M<D%^FEB7::Z:+_DZ:ZS3FO!A6[K$VXQQ\ \N$4@2L \&>6*P*]HA\
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M18L[PKNWOS,]@D,]M+.WNTO"GU,X:L-"PLN[B"NYT3N\VYN]VT,R'>Q"+T3
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MAE7$;6(M[E4+""58<J?;>29L2IYH08_S*1[S^.'TT0'B*9MBR:9^ )_-&1"
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M^-PL],$WM+7";Q$ZVSWLA@"Q&:1M_D#$"]%VCP_-H';^F$&$XG:D>MB.!5<
M0#U8P"%3H$T06=L5QEJ4N\&]SG-'6LCH " ["+0BA;/H8MN::('$V; 5][
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M1N$33J$34B$67J$60N$66B$7?J$7AN$0=N$8@F$9BJ$/PL,\E ( MN'_O>$
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M'@9/W"*+V%J.X):I':1PZZRC1W[D:#9IC]CG&#6)DS@N\O^<$9C2@;CN 1V
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M$P#Z02U/K<J^ )_JH2J<TA_*H"NPPBLRL*DVD +ASP51[:G4PBG-LBHL(/M
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M 'S1,"P(8R77&!H60(.)3KS"<]SACNBH0P NA88,2&/2+E!18!'C*44AMKX
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MV,$7CA'T]MW"B,/P>Q/GH,2U5_$+7ISB&.\XQS]N\8RG+S#]<U_\[,<^1P)
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M VS7';YA:7;'=H,BLK&!=W=EE.9!0>KJK>G*/<XR??'T7+86FOFQGK@7%.W
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&QNF    [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img75897552_15.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_15.gif
M1TE&.#EA902F /<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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M#TRG='+D+0%P3$FB#07CP'OQQD"==K9$2&CDA )#@C/S#>002-D0 -P 1XA
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MSW'04T ,3GRA8WSHG%D)!P#ZH^( H0!" AW\ /C; 0&"0 @T] & *$@AA(<
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M'_F8%WW-!3#_+M&?_D"R/_W?9/\CS5_^_N\__LL_(AG ^=N_+BF2 MR_G#-
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MU(WA!F]8F#&<!]=X4H^$.+!\0K(<R]-\.$I-PZ)DB[C\U&^E!S;%RWF0#N.
MF7P@U,!<U'58/X7\ALJDC"'%![FX#G])4WSAR=)0U69-/\/LS.:0A__05 =T
MM5AU#;G4'$8FN8*42 3NA)M&_%BU<< A84V(V /DO =5',[I-,XD45E+I#E:
MG('Y.]G87!,D80%=Y)1IU(<\V5A (3U",<879<>)J(?^W$^C^P)^6,^&.-%9
MT(<2E=I9D @(2$\=: I4^<9=Z168F)3Y) FG]8)FY(<"98ENE,>)<(IK2;M[
M^!5) 9-YI &# ("LT('GG%K:G!-]N(GPA( !O5K;&PEJC(F>$!7#I4<87=R)
MF%&+J]%LX 9_Y4BKG X4I%*V/("VW ;M< N%%-.<60?*&(?\P$P9D%QTF(Q"
MC4O*V :U[-QN[=S>F8ZTW%S;Y=/,*-/M<(O_>4!8=X 9B 6-=JA6_^ +-IU3
MA3P >!BX)/754IV+Z,@&*44$O32/@?L-K,0'46T,=_A*U/W+BDM)RJC4GU35
M;:#<3;V,>[#)-%Q3GNR.9:T9V#T V3T Z_@.R74'-53(8:7?;I52Y+A1;:#,
MA'S>>P#?<) -B;3#SVB,__6&SHW4I=S);:A8B3/,/O6& <Z&+(W5UR!7PC#7
M="W-$OXXLP2-AYD.V(#7ORP%YYC7NTS#>:!2%8[7?5Q4SDSA<C!8&J89FL%*
MS)A,AB4.;V@''(18<VB.DM%A;3A7C(5B[--8U=S9Q+7BC8 " 8!-2!D54:D'
M)FD!N!457H02XGQ9_R%!SBOF8BJ910D-QB2I!T6<19+H!R\H60&XV3UXDZ 5
MDN]L7, %3PY56T[9B 6% %94XZ_=@91P487(T"[6 :_M"*0+6_[4$B^ VZ"@
MT/Z$T&Y\"0XE9$*>A??D3_*D6[O]VV-18P# AQ6UQZ@;1ZQEE (U6D#^8QG-
M1QKE1QWFY4=-S'L82!4>V/V]!P?F3/787AW5!L-#A"8-A^;]C!^>CC[%AWGX
MC5XV7GPH4^;H782U%Q5,!X3E3!N5TT&M#>Z CW805E[FAM4H#7@(31N.UNW-
M86DVAXM<5VE.87],/RWMC_6%6//@C.0@#O60C>'0Y_1HBU:=WF_-UW8@Y_\4
M9AE<U54"?L'B'=/*C-,4AAC9:(V$YN:EK(?-U(9G/KA\@%-PD(W1=1?T^%7Q
M< UN8%Z0&^&+-6&;)F&W$\P.ONDHSFF<AKLIYN.A[DZB-NJBMKFA-3W&?>6C
MO>48A>JGENJFMF6J%L&JKN6K'KO'!6J?MNE[<$KM2 =S2 =TH%)N@-Z?YEYM
M<-.?]NJW=KQD7HX]W(R"W8ONPPL<_LMVI6GTL3ZW[NG !NR[P&O![FK#AFN#
M$VJD/NK&9NS'YF,_MNJHGNRISFK*OFS+9NK,KNS.YNQZ/,$43.S#'D(@W Q\
M!NK,\$G$9NW!/KXBW+LE_+B:'NW:;FW2QFW;=NW_/W0YR/9M0 % G0ONFRM9
MQS;N(E'JHMWL#XQEI_;LY7;NS^; =/2ZYCY/Z,;JJ>-JW;98U$9MX_ONA OO
M=)54I*3(\VZ^H72[\<[MVZ;MV^;N^(;O^=YM^%[LX]Y85@1% <C.E.#%NS(3
MFBM%X82"IQ"$[.1-(,E.X41N*9D%D/WMGI-LZ;Z]MGU'EH#E0)YNJK9N"*"5
MP06[6,Z) .7L7=D!!N7B3U:(!H6(1I:]4 G0[&R%,NB*:@2* $V[#L44K<9L
MM<OE^B9O>3B8^W4+8R9GXF@'OI:X-7RX4BU5D7:.?)#?<9 'N_Y(\;9(?/"9
M()8XZ77=?VF.--S)PZR9_^D]XF7UAG5(#7-@"WDH:6EM.WQ0AQP^<LE-S'H(
M9AXN6-I87A@&AW2 TT(EAY9I[Y]^;R O]$27;T1?](N][P@_&V0! '[@!U')
MAR(AHI55\)I(B4U$@+NZAYJ;@8< 1B I<&],6GT010"HAS,&E"_Q1DC7N>3&
M;JW>E*LMW'XX<4ONSZF%E *U<!3EE*@H@[Z=A3L1%4H)E5X_4;3]\!6/SYG@
ME'ZHS2[&\:ZCB>?,![7U J,;B5YY %CA%4U."TMQ<:T8T)!0"!E/4,.=6K1E
MO6QL!1J@<,#=;OKV0P?^AHP+9M8=PXF5W+!,!W%5![A WC0<CK.,8)JA\FK.
MX?_ZE8YPR M\Z%\[W0::X>&) ^NSK-A\H <P]09YJ ??E6C7%53^:.?40 =$
M.!C*A3OOL-$+%M\\YVM/E=,T_ ZTSGF15_2;/O2>9W1\;_2A%WK%>W3\%A):
M<4T@(9-^2 <X2<16R.)-UT068('Q[(=,#O R;L46*.XA80%]Z(<K8 %$&-O,
M$P!X !,(1_JSF?!:GST+QW4ZWO4.G7?4LP!2WXG"Y>*^WU"D396A@Y4ZAHEE
M_]MGAX#"58D$,-NO(#HQ)O&RR'9*48A,#M!06="\C<V$* -1:7< .'>D(U&H
M<#J-D(C_U!*80 IJ[/ >-\%[#WKIT\G)" V(5(=\D>G_-ZQ3RB@'[XAGT$CS
M=L47XNA2-\\&$HA)>L@'ZQ7Y#19FSOR&>O!1R;6.'\Q>.$?(-R4'<""'=ZC6
M;1#Y%729>AC=Z1U3A9-SFR'_185*D]/7PYQ@@L-3Y<\+FG<.BO<7;RUOHI^^
MG^=_H >(>_00U1-(T&#!@0D/*D3HL"%$AA(74GPXT6+%B!DO:L3HL2-(CB(W
MDOPX\F,]>5=,(&#ILB7,ES)CTIQILV4K  #HP;PR"T"_* @$ <@WXR4] /X2
ML8!)U)_.>S=-7.D'@-_1FEX "!)0%<"5KU<$L$P*H-[4FFK3LD7  MX[" H@
MT*T+X8'=NGCSWN7;E^]>NC^Y_]+5 ;7?#KQ/6]&X:T&?TC)TMT8M(VB6OUF"
MZ";2F=F+%T%E0#?>"E7?%T$YE7ZINWHS!,.LYPY2>M8+HL%+ =>E/ M+W7LZ
M$\6&ZD7O#IV(Z3[0P<\V !V![=)XK;<NC5G\:#SHG(B&][JR^^E(X'?Z==[J
M\T[7 8]>R)+Q3<H_.;_A/!G9LI7#5W >.?ME(T,ZZ9B3#CKKS,/1.^-LLPT\
M^.1SCSK:9 ,./??4PXV%Z="#CSK[:0-..N4<(. X\N #SXG9<(-@.-D<0(X\
M]2!2CHCAJ$,.-P*6DV%'YEBXS3CJ]"BCBO3(<^0!!WZSGS<1)H3//.!H(\\]
MYB")CO^,\]!'3S@69O,-@N5H(V8Z_M5#CH4_^G>/F=F,,\^;]]EW9WUYTK?G
M///  X\\\-2CIYV$XKEGH8@>FBBCBSIJ**2*1MKHI(]**E!**ZVU:5N=MB0
MJ#*!2A8"H=(T*JDNH9JJ6E'PXT\K3;T4EJPMM1"64"ZY Y4@G/KJ*5MPL7<>
ML>O9A1YS<OT%@7E\-9O7LW:9-U=@>,WU[+3+6LML>L/2]6RU=6';[;'*ACM7
MN<[ZE6VZ?2&BU'%VZ>"%#GG-ZT5C=&4':[[D^INLL?_*Y1Y\EE)ZZ<$-V9C.
M?NK<HV$^$MX3\801XS-?/11/7-'$^%Q\4,82^X?/Q@B1K''_G2"CG'')(4W\
MLD<A3YAR0?70H\Y[;]8#CSKKJ CIR2)7%/+'][23C3;F#&HPTY4Z[5&??P8Z
M*,)-5_UTPE9GC;7677/]]=5A@Y0IL+^:73;:9]/$P@RYJLT2VU"4^C;=;;T5
M%[K>ZMTNWP(CNVS? ._M=[&#"QXXX(0'?+CB>M.P0V-_2PX!#?4VCOCDQA*\
MM=A>[REUYV!S/KKGI$^*CSSOO%,ZZZ*?%#6@@KH^>^BUFVY[Z[C3?COOBY)=
M-_!I"Q\\\<,;OY:PF!>N_.*),_Z\\]%G;KCTRU]^/?33,T^]]MA7SY<"F^?>
M^^[CFU\^^KJK3_[ZA\(>*#WS*!G___SRRT/__?;CO[_^_=?_?_X R#\!^B^
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M)H4[8097^,4JMB]:*7S5$P,WQ2".*GJMVF'TMO>6VT5P5Q\I7QPWE;DN[BI
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M$9(.;WR#&]X !SPV> #XXN/CC%+B,_,EQIUD65NK.*-"ENC!BT"9)PJ!!ZG
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M88,\;$S @@28<2[<24\ *2W, 1[6H2#*H1TRHB04XDOR"!USXDS$2!M(8!X
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M\N(;M6$(W".32>QW+^U9O'6,3@[^M&'TB)6GKU^8L.$K\N:A_-]2@"P-N)!
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M[:NZYFN]L)R_&/R]M'S+\ZO'H]RT,)S M1S#2QJRP7S!)PO#&?R]^_N^*WS
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CQ.PE/=Q(/VA&4YK3I&8UK7E-;&93F]OD9C>]^4UP?B\@ #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img75897552_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_16.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $$ N,# 2(  A$! Q$!_\0
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M N"N$7MPQDS],#3?Y'*\176^(JKUG_P#^@?_ (B;O^"KO_0Q?"?_ ,)"U_\
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M5R<FI-4M-0T":2T\1Z;?^';Z%%EFL-;MGT^\BB;[LKP3A76-OX7(P>,=:/\
M4OA"]O\ 5G)+M-I?4J5VDTFTMVDVDVE9"^L5_P#H(J_^!:??:R/WQ_XB;O\
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M$_\ X2%K_P#&*/\ B)N_X*N_]#%\)_\ PD+7_P",5^!-%'^I?"'_ $3.2_\
MA#3#V^(_Y_U?_ O^ ?OM_P 1-W_!5W_H8OA/_P"$A:__ !BC_B)N_P""KO\
MT,7PG_\ "0M?_C%?@311_J7PA_T3.2_^$-,/;XC_ )_U?_ O^ ?OM_Q$W?\
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MPUDTI2PU"4I2P5-N4I4H-MOJVVVR7B,1=_OZJ]Z2TEV;1^^W_$3=_P %7?\
MH8OA/_X2%K_\8H_XB;O^"KO_ $,7PG_\)"U_^,5^!-%;_P"I?"'_ $3.2_\
MA#3#V^(_Y_U?_ O^ ?OM_P 1-W_!5W_H8OA/_P"$A:__ !BC_B)N_P""KO\
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M$W?\%7?^AB^$_P#X2%K_ /&*_ FBC_4OA#_HF<E_\(:8>WQ'_/\ J_\ @7_
M/WV_XB;O^"KO_0Q?"?\ \)"U_P#C%'_$3=_P5=_Z&+X3_P#A(6O_ ,8K\"&9
M5!9B%4#))(  ]R>*9'-%,"8I$D .#M8'!]\4?ZE<(;_ZL9+;O]1IA]8K_P#/
M^K_X'_P#]^O^(F[_ (*N_P#0Q?"?_P )"U_^,4?\1-W_  5=_P"AB^$__A(6
MO_QBOP)JY8Z9K&KSBTT/1M4UV](+"RTBSEOKLJ 26\F%6?: ,DXP!DT/@O@]
M:OAG)$NK>"I)+U;T0?6,1_S_ *O_ (%_P#]ZO^(F[_@J[_T,7PG_ /"0M?\
MXQ1_Q$W?\%7?^AB^$_\ X2%K_P#&*_ MXYH9)(+B&:VN(7:*XMKB-HI[>5#A
MXIHFPT<B'AE8 @]:;1_J7PA_T3.2_P#A%3#ZQ7?_ "_J_P#@7_ /WV_XB;O^
M"KO_ $,7PG_\)"U_^,4?\1-W_!5W_H8OA/\ ^$A:_P#QBOP)HH_U+X0_Z)G)
M?_"&F'M\1_S_ *O_ (%_P#]]O^(F[_@J[_T,7PG_ /"0M?\ XQ1_Q$W?\%7?
M^AB^$_\ X2%K_P#&*_ FBC_4OA#_ *)G)?\ PAIA[?$?\_ZO_@7_  #]]O\
MB)N_X*N_]#%\)_\ PD+7_P",4?\ $3=_P5=_Z&+X3_\ A(6O_P 8K\":*/\
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M9!@<$&XC!!],;J2X)X1>W"^3/TP--_D@^L5UOB*B_P"WS^@O_B)N_P""KO\
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MN)_"?A*Y3QSJFI+$TEG:7/A^87D,,[ %0TGE@*K'GH <XK^Z7]L#2?VY[/\
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M/M"\.>)+_P $Z'IB?#4:C;PS2^'=3>>-)[UH=NR-<9(<H#G!YQBOL;P%J_\
MP4#M/VJM2\1_%;XZ_LQ:E^R3</?V4W@?3;FQ;Q=!:&1XH(3;LQD,JQ_)*&4D
MG(<$$@\]?Q,Q&7TL#@,NPF7M9?DF7XK%_P!I8O%.IBJM7#PJ_4<%*G2JSG65
M-J/M*[C*52]G97*C@E.4I2E/WZDE'DBK12:7-+5*S?37TW/\N>U\*^,-0UX^
M$=-\)Z[J/C,7"V9\(VEC++KPO&;8+4V(7S1-NRI7;D$'TK[WO_\ @DS_ ,%
M]-^'<'Q.F_9]\:RZ'/IJZH-+@T:Z?7([=E\SRY;,+O68("Q7;T_"OZ?==\)_
ML4?LG_\ !?OP]\0/%&H>$K/P!\9OA_J.H:0]U;)<>'])^(LY;[!Y421210R^
M>^59XUPQ# =C^T?QCT7_ (*27G[2D?Q>_9A^*OP:\8_LWW'AY8;KX9:R\$^I
MSA(@XFLTCSB:1  BY67+9(YX]'-O$O&X>IE7U' 8'"X?'Y33S5XG.JF(H4*U
M23<9Y=AZM.E.,:T)PG'VDVDW;FLFKQ3P:DI\TYRE";IVI)-K9J;5]5;IMN?Y
M;NKZ1K?AR^N=)\3:+J/AS6K%GCU#1]7MWM-0LI8\B2*XMY KHZ$$,".U?5/P
M?_84_:;^/GPZUSXK?"GP)?>)O!?ANTNK[6+ZRMY)S;6UG&\]P[;,[0D,;R$G
M'RJ3V->__P#!8SQ1XR\9_MZ?$/6/B%\(U^"GBI[)(-1\)16/V"TU1E<*WB*U
MC1(XW@U YD5U&2&]J_<W_@U&^+WVC4OVGOV<?%6N?;-,\=:6TGAK0+QXFCAB
M6PGMKV*TB?YC'-;W,HE7!4G!(.!7V&><0X[+^$8\1X7"X>6(AA\%BZ^$E4^L
M4HT*TZ:KJE6I.U3V<)N<:J]WEB[G/3IQG7]BY/E;E%2^%W233:W5WHUO<_F6
M_9S_ &-_VB/VM)?$4?P'\"ZEXP7PG=7%CK\]E:RS0V-Y:N\4UM*R#Y)1(C(%
M;!SQSS65\/?V4?CS\5?C/XD_9[\"^"-4UKXL^#[F6U\2^&K:TEDNM)EA)\PW
M42C?$JX/+< =>17^A=_P32_9M\ _\$R;S]JK6O%TT'ACPE\6_C[96GA6*94B
MBBN]8N;DI:0-)CY9I[A7*H=IVCCH:Z7]GG]@SPW^S[_P5)_:8_;%M(X+/3?B
M+\.KW4=0'E)':?:I%^V/?(Q 1))(0R[HP,AB,\C/P^)\6%2Q.>1I82C/"X?
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M^ GB4N;>Z\67\NH2^&(YU6:PMT=I9$6V>&2$6SJ &CV].5'B'_!O'\ /A_\
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M:N,/^?63?^$$_P#YI#^SL/WJ_P#@?_ /\T3_ (AA/^"JW_0/^$'_ (5=M_\
M)%'_ !#"?\%5O^@?\(/_  J[;_Y(K_2[HH_XC5QA_P ^LF_\()__ #2']G8?
MO5_\#_X!_FB?\0PG_!5;_H'_  @_\*NV_P#DBC_B&$_X*K?] _X0?^%7;?\
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M>K_X'_P#_-$_XAA/^"JW_0/^$'_A5VW_ ,D4?\0PG_!5;_H'_"#_ ,*NV_\
MDBO]+NBC_B-7&'_/K)O_  @G_P#-(?V=A^]7_P #_P" ?YHG_$,)_P %5O\
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M\#_X!_FB?\0PG_!5;_H'_"#_ ,*NV_\ DBC_ (AA/^"JW_0/^$'_ (5=M_\
M)%?Z7=%'_$:N,/\ GUDW_A!/_P":0_L[#]ZO_@?_  #_ #1/^(83_@JM_P!
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M\*NV_P#DBC_B&$_X*K?] _X0?^%7;?\ R17^EW11_P 1JXP_Y]9-_P"$$_\
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MS_\ #KQ)\5_BWXJTWP;X%\*6,VH:SKFJ3+%!!%%&\@CC!(::XEV%884!>1\
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MLLWFLZ>_P8T7]F./QMI^DI:*-0C\0FYA4SO=@;VB"MQ'G&1ZT ?OE17\DGP
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MANH(;JVE2>WN(HYX)HF#QS0RH)(I8V'#)(C*RL."I!%?BC_P7Y^!WAGXK?\
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MW&L?@+X]_"SP=>WVBPCR[;3=>M+:&\N-0BB4!%:XN%+OM +9P2: /Z:Z***
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M^%OQK\#:'\0? FNJJZEX?UZV^T6DS(&$<J,I26&:/>Q22)U92<YX%?!OPO\
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M\0?'O]HJ?2#K>IHL5V/AQX/T%U%_K.ISC<=,O&M5>X1G:-V4 9'-?MM^RO\
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M4E^-G_!1KQ7!<:C\"O@?J=S\-OV7X+L-+8Q:_H\W]F>)-8L1)NB82;'E6:,
MLQ4YP<5^V/\ P4F^"^O?'S]BKX^?#SPHCS>*KSP'KNH^&[6-6=[W6=,TZYN;
M.S55R6:XD78@ R7*CJ:^D?@U\#_A1^SYX*MOAU\&? ^A?#[P5:7M[J,'A_P_
M:_9;%;[49?.O;HJ69GFN)!OD=V8D^@KU8@$$$ @C!!Y!!Z@CN#0!_.;_ ,$@
MO^"G'[,/A?\ 8,\&_#;]H#XJ>%_@S\8_V;]%O_!_Q5\#_$'5+3P[K\-_I5]?
MNEQI6FW\T5SJ45U&$2%;='<R%,_*^X>5_P#!((ZU^UI^WK^V7_P4ODT74M+^
M'>L6MY\'/AQJFJVKV3>)?#6@WBW4&L6:R +-930VY=)T)4AEYP:_5KXY_P#!
M(+_@G=^T;\0Y?BK\6?V;/!OB#QU=WL5_J>N0B\TV35[B)PZG5(+*>*WNE9P&
M<&)2Q_B&37U7JOP7TWP+\!->^$/[/>A:!\.HD\+WN@^$;#3+9+#2]*DNH#;+
M(1'\Y*QLV979I"<9:@#\4/\ @E/9)^T?^WW^W/\ MYH5N])\07=M\$= N%<R
M6]J? E^EG=0VW6-6V6Y1]A!VGD=Z]T_X+E?MEZC^SU^S/#\%/A==K??M _M.
M:M9?"SP)X:LY-VLMHOB>631_$.N6T"'SO+TZVN&=I4 V8/(S7UK_ ,$U/V*(
MOV$?V=Y?A%)J4.L:UK7CGQ3\0/$>J0L76[UOQ5=K=WA$ARSJD@(7).,G!YKZ
M2\?_ +,_P*^*7Q'\"?%SX@_#7PYXL^(GPR$X\"^)]8M6NK[PW]I8O.=/#/Y*
M-(QW%VB9@>A% '@/_!-C]C[1?V(OV1?A7\$;)(KCQ#IVB0ZKXWUK;F\USQ3J
MI:^U"ZOIR/,GEADN#;JTA9@$(SS@?BY_P4CUG_AA_P#X*_?LU_\ !0+X@66J
M_P#"E/&W@73_ ($>)O$>GV<EU8^%)GN06U/7)E!CL+%!-N:XE95"@FOZE0
M !@   #H . /PKS'XO\ P7^%OQ[\$:K\./C!X)T+Q]X*UJ)HM1T'7[-+NTF5
ME*DJ3B6&3!($D,B/[\"@#^>S_@MM_P %!_@]\5?V3IOV3_V3?B-X8^-'Q_\
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M^-M7.MWFDMYL*^ ['4!/X5M))&+,)T@">:@;"[ * /U^HHHH **** "BBB@
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MFHZ2;F[RO9)6MR4U6M/DE32]I/249-[K=J2_)'RC_P /G_\ @FM_T<]X1_\
M #7O_E71_P /G_\ @FM_T<]X1_\  #7O_E77U=_PQC^R7_T;?\%__#>>&?\
MY74?\,8_LE_]&W_!?_PWGAG_ .5U>-[7A#_H#XB_\+\N\O\ J7^O];:6Q'\U
M'_P"?_R7]7?E;Y1_X?/_ /!-;_HY[PC_ . &O?\ RKH_X?/_ /!-;_HY[PC_
M . &O?\ RKKZN_X8Q_9+_P"C;_@O_P"&\\,__*ZC_AC']DO_ *-O^"__ (;S
MPS_\KJ/:\(?] ?$7_A?EWE_U+_7^MBV(_FH_^ 3_ /DOZN_*WRC_ ,/G_P#@
MFM_T<]X1_P# #7O_ )5T?\/G_P#@FM_T<]X1_P# #7O_ )5U]7?\,8_LE_\
M1M_P7_\ #>>&?_E=1_PQC^R7_P!&W_!?_P -YX9_^5U'M>$/^@/B+_POR[R_
MZE_K_6Q;$?S4?_ )_P#R7]7?E;Y1_P"'S_\ P36_Z.>\(_\ @!KW_P JZ/\
MA\__ ,$UO^CGO"/_ ( :]_\ *NOJ[_AC']DO_HV_X+_^&\\,_P#RNH_X8Q_9
M+_Z-O^"__AO/#/\ \KJ/:\(?] ?$7_A?EWE_U+_7^MBV(_FH_P#@$_\ Y+^K
MORM\H_\ #Y__ ()K?]'/>$?_   U[_Y5T?\ #Y__ ()K?]'/>$?_   U[_Y5
MU]7?\,8_LE_]&W_!?_PWGAG_ .5U'_#&/[)?_1M_P7_\-YX9_P#E=1[7A#_H
M#XB_\+\N\O\ J7^O];%L1_-1_P# )_\ R7]7?E;Y1_X?/_\ !-;_ *.>\(_^
M &O?_*NC_A\__P $UO\ HY[PC_X :]_\JZ^KO^&,?V2_^C;_ (+_ /AO/#/_
M ,KJ/^&,?V2_^C;_ (+_ /AO/#/_ ,KJ/:\(?] ?$7_A?EWE_P!2_P!?ZV+8
MC^:C_P" 3_\ DOZN_*WRC_P^?_X)K?\ 1SWA'_P U[_Y5T?\/G_^":W_ $<]
MX1_\ ->_^5=?5W_#&/[)?_1M_P %_P#PWGAG_P"5U'_#&/[)?_1M_P %_P#P
MWGAG_P"5U'M>$/\ H#XB_P#"_+O+_J7^O];%L1_-1_\  )__ "7]7?E;Y1_X
M?/\ _!-;_HY[PC_X :]_\JZ/^'S_ /P36_Z.>\(_^ &O?_*NOJ[_ (8Q_9+_
M .C;_@O_ .&\\,__ "NH_P"&,?V2_P#HV_X+_P#AO/#/_P KJ/:\(?\ 0'Q%
M_P"%^7>7_4O]?ZV+8C^:C_X!/_Y+^KORM\H_\/G_ /@FM_T<]X1_\ ->_P#E
M71_P^?\ ^":W_1SWA'_P U[_ .5=?5W_  QC^R7_ -&W_!?_ ,-YX9_^5U'_
M  QC^R7_ -&W_!?_ ,-YX9_^5U'M>$/^@/B+_P +\N\O^I?Z_P!;%L1_-1_\
M G_\E_5WY6^4?^'S_P#P36_Z.>\(_P#@!KW_ ,JZ/^'S_P#P36_Z.>\(_P#@
M!KW_ ,JZ^KO^&,?V2_\ HV_X+_\ AO/#/_RNH_X8Q_9+_P"C;_@O_P"&\\,_
M_*ZCVO"'_0'Q%_X7Y=Y?]2_U_K8MB/YJ/_@$_P#Y+^KORM\H_P##Y_\ X)K?
M]'/>$?\ P U[_P"5='_#Y_\ X)K?]'/>$?\ P U[_P"5=?5W_#&/[)?_ $;?
M\%__  WGAG_Y74?\,8_LE_\ 1M_P7_\ #>>&?_E=1[7A#_H#XB_\+\N\O^I?
MZ_UL6Q'\U'_P"?\ \E_5WY6^4?\ A\__ ,$UO^CGO"/_ ( :]_\ *NC_ (?/
M_P#!-;_HY[PC_P" &O?_ "KKZN_X8Q_9+_Z-O^"__AO/#/\ \KJ/^&,?V2_^
MC;_@O_X;SPS_ /*ZCVO"'_0'Q%_X7Y=Y?]2_U_K8MB/YJ/\ X!/_ .2_J[\K
M?*/_  ^?_P"":W_1SWA'_P  ->_^5='_  ^?_P"":W_1SWA'_P  ->_^5=?5
MW_#&/[)?_1M_P7_\-YX9_P#E=1_PQC^R7_T;?\%__#>>&?\ Y74>UX0_Z ^(
MO_"_+O+_ *E_K_6Q;$?S4?\ P"?_ ,E_5WY6^4?^'S__  36_P"CGO"/_@!K
MW_RKH_X?/_\ !-;_ *.>\(_^ &O?_*NOJ[_AC']DO_HV_P""_P#X;SPS_P#*
MZC_AC']DO_HV_P""_P#X;SPS_P#*ZCVO"'_0'Q%_X7Y=Y?\ 4O\ 7^MBV(_F
MH_\ @$__ )+^KORM\H_\/G_^":W_ $<]X1_\ ->_^5='_#Y__@FM_P!'/>$?
M_ #7O_E77U=_PQC^R7_T;?\ !?\ \-YX9_\ E=1_PQC^R7_T;?\ !?\ \-YX
M9_\ E=1[7A#_ * ^(O\ POR[R_ZE_K_6Q;$?S4?_  "?_P E_5WY6^4?^'S_
M /P36_Z.>\(_^ &O?_*NC_A\_P#\$UO^CGO"/_@!KW_RKKZN_P"&,?V2_P#H
MV_X+_P#AO/#/_P KJ/\ AC']DO\ Z-O^"_\ X;SPS_\ *ZCVO"'_ $!\1?\
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M+\N\O^I?Z_UL6Q'\U'_P"?\ \E_5WY6^4?\ A\__ ,$UO^CGO"/_ ( :]_\
M*NC_ (?/_P#!-;_HY[PC_P" &O?_ "KKZN_X8Q_9+_Z-O^"__AO/#/\ \KJ/
M^&,?V2_^C;_@O_X;SPS_ /*ZCVO"'_0'Q%_X7Y=Y?]2_U_K8MB/YJ/\ X!/_
M .2_J[\K?*/_  ^?_P"":W_1SWA'_P  ->_^5='_  ^?_P"":W_1SWA'_P
M->_^5=?5W_#&/[)?_1M_P7_\-YX9_P#E=1_PQC^R7_T;?\%__#>>&?\ Y74>
MUX0_Z ^(O_"_+O+_ *E_K_6Q;$?S4?\ P"?_ ,E_5WY6^4?^'S__  36_P"C
MGO"/_@!KW_RKH_X?/_\ !-;_ *.>\(_^ &O?_*NOJ[_AC']DO_HV_P""_P#X
M;SPS_P#*ZC_AC']DO_HV_P""_P#X;SPS_P#*ZCVO"'_0'Q%_X7Y=Y?\ 4O\
M7^MBV(_FH_\ @$__ )+^KORM\H_\/G_^":W_ $<]X1_\ ->_^5='_#Y__@FM
M_P!'/>$?_ #7O_E77U=_PQC^R7_T;?\ !?\ \-YX9_\ E=1_PQC^R7_T;?\
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M"/\ X :]_P#*NOJ[_AC']DO_ *-O^"__ (;SPS_\KJ/^&,?V2_\ HV_X+_\
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M8MB/YJ/_ (!/_P"2_J[\K?*/_#Y__@FM_P!'/>$?_ #7O_E71_P^?_X)K?\
M1SWA'_P U[_Y5U]7?\,8_LE_]&W_  7_ /#>>&?_ )74?\,8_LE_]&W_  7_
M /#>>&?_ )74>UX0_P"@/B+_ ,+\N\O^I?Z_UL6Q'\U'_P  G_\ )?U=^5OE
M'_A\_P#\$UO^CGO"/_@!KW_RKH_X?/\ _!-;_HY[PC_X :]_\JZ^KO\ AC']
MDO\ Z-O^"_\ X;SPS_\ *ZC_ (8Q_9+_ .C;_@O_ .&\\,__ "NH]KPA_P!
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MFM_T<]X1_P# #7O_ )5T?\/G_P#@FM_T<]X1_P# #7O_ )5U]7?\,8_LE_\
M1M_P7_\ #>>&?_E=1_PQC^R7_P!&W_!?_P -YX9_^5U'M>$/^@/B+_POR[R_
MZE_K_6Q;$?S4?_ )_P#R7]7?E;Y1_P"'S_\ P36_Z.>\(_\ @!KW_P JZ/\
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MOX=?$/\ 8\_:0^&GB+XI:_9^'?!5GXP\)7FG3:[?W5S%;%+&*2)7E\EI5:3
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MI[?]CIH/_HQZ]KAS_D?93_V'8?\ ]+1G5_A3_P +/N7]F#_DWKX/?]B)H?\
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M6\)?!!VAR>1ZBL[P%\6?A?\ %.VNKSX:?$/P7X^M;)Q'>7'A#Q)I'B&*U<G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ K\,_\ @J3_ ,G%_L?_ /8W6_\
MZ<%K]S*_#/\ X*D_\G%_L?\ _8W6_P#Z<%KZ/A7_ )'-+_L&QW_J)6,JW\.7
MK#_TN)^XMK_Q[6__ %PA_P#1:T46O_'M;_\ 7"'_ -%K17SAJ?A=\$_^4YW[
M3O\ V;GX6_\ 3C9U^[%?A/\ !/\ Y3G?M._]FY^%O_3C9U^[%?2<3?[QE?\
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M-_87E\6_%#Q?XPU/XQ_M,_$[S&^(OQ<UZ:>YN[R*602MIFE?:AY]IIJR9*0
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M[47[-/Q1LO@M^U[^SR]W_P *T\<ZO9R:AH+V%\6:]TS5;&-)/.CNE9H29$9
MC_-@ U^:_P <O^".?_!3S]O3PS\,)?VUOVQOA[)XB^%/Q:\,^//#>A^!?#4U
MAX9FTG0KJ.>[MM2L;6W6WN-1O?+8Q7+!C$&7<PQP ?T(^.OC_P##G]F;]E>W
M^-OQ6UF#2O"/@GX;Z-JU]-<2QK<WK0:-:F&QLDD.9[RZ?;''&@9LDG!Q@_BI
M_P $Z_@C\3O^"B7[0^I?\%//VNM!$?@C3KZ>P_8_^%&KV,0T_P +>&K24#3_
M !W':R0AQJ.HVX#F>7+RR-NRV#CVS_@K[_P2O_:0_P""AWPF^"GPE^#W[1VD
M?!GP]\,9-(O?$%CJ>EWNH:?XQOM*L[>WC74K:U0B>S\RW65;>8-'V=&0E#\[
M?"K_ ()T?\%Q?AT? /AQ?^"B7PA3X<>"CI6G1>%M*^'^H6:'P[I\D8?3K4+9
M+'"7@1D!R "V<X% $?\ P6(5?^'KG_!&\X&1XV\> ' X&(>!Z?A5C]O^XE3_
M (+]?\$NDC\C*_"CXE%5>&W8L)-0N@^X2(?,/0+NW%/X-M?>W[8'_!.'QS^U
M#^U3^P+^T<OQ1TS01^R)=ZG?^+=%ET^:>7QS=ZI:6T4[V4JH5LQ]HBEE_>%3
MB0#L:X__ (*>?\$OOB-^UY\4?@;^T_\ LV_&2S^!_P"U'^S[;WVE^!?&&M6$
M^J^'_P"QM5N3<:A:WNGP1R-,TA>15)0@;ATYH \<_P"#BO3--UK]DSX4Z-J]
ME#J&DZC\=O"5O?Z?.,V]W;F2/=#*HQE#W%?9OQV\"^#+S_@EIXC\&3>&M)'A
M/_AGVQM8]"%I";"&&'2+>2)8XMF%9)$$@D $F_+;LDD\)^UQ^P'\=_VR?V1/
M@1\&OB?\9/#<?QF^'_B;PSXL^(?Q!TW198-#\5:MHSN;UM.TQ80]G'>*(MJM
M&FU@Q(YQ7V[X\^ NI>,/V6=3_9]@U^"SU._^'4/@E?$+P,\$=Q%8QVAOC !N
M*%D+[-N<'&,T ?R-_%A3<?\ !KWXRTN[DDO+"V^)>D:/#;W+M(BZ5'\0-*MX
M[$;RQ$"P$Q!<\+P,<5_3Y\ =-@^'7_!.#P+_ ,*QT.TT*[T3]FRVU'P]I^D0
M+'LU=/!AN8)(@JAGGDN]K[VW.6P,G KX+\7_ /!'7QUXE_X).^(/^"=4/QDT
MFV\4ZSXUL_%*?$=M*F:PAAMO$]GKS6C6 C,K,T5L;<-LX9MQ.!7[.?!'X:R_
M"SX,?#GX5ZI>P:[+X+\$Z'X2OK\0[;?4SI>FPV$\_DN.(KGRV;RV'W6P1UH
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MFT'3I-8MOAQ=B"_,""2-O[*=?-V!1&TV!D3,ID#?-NW<U^S/[+O_  3J\5_
M'_@HA^V%^VKJOQ(L/$6@_M,^'O#&C:5X*@L)8+SPS+H%Q%/+/<WCH$N%N!&5
M4(QVD] *X/P]_P $NO&&B_\ !6#Q%_P43D^*>FS^%M;\,3:!'\.5TZ9;^"66
MT:W%PU]Y?E,H9MV-_0=* /R[_P""D]Q/HG_!Q+_P3CO]%D.E7U]\(->MM1NK
M("";4+?^V;M!#=M&%,ZA,(/,+X0!1\H 'T#_ ,%9- O_ -DS_@H#^Q;_ ,%
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MUM^[]%?A!_PZV_;I_P"DK_QW_P#!)8?_ !^C_AUM^W3_ -)7_CO_ ."2P_\
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MY?WO/\/6W[OT5^$'_#K;]NG_ *2O_'?_ ,$EA_\ 'Z/^'6W[=/\ TE?^._\
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M'K;]WZ_*G_@L)#++^R=,8XWD">,] +E5)"YE;&['3.#C/7!KYV_X=;?MT_\
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M **K+O\ PAS?R_Z@O/\ #UL>TJ?\^)_^!4_+^]Y_AZV_=^BOP@_X=;?MT_\
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M,:@*D<:@*JJ  !@5<K\(/^'6W[=/_25_X[_^"2P_^/T?\.MOVZ?^DK_QW_\
M!)8?_'Z/['R?_HJLN_\ "'-_+_J"\_P];'M*G_/B?_@5/R_O>?X>MOW?HK\(
M/^'6W[=/_25_X[_^"2P_^/T?\.MOVZ?^DK_QW_\ !)8?_'Z/['R?_HJLN_\
M"'-_+_J"\_P];'M*G_/B?_@5/R_O>?X>MOW?HK\(/^'6W[=/_25_X[_^"2P_
M^/T?\.MOVZ?^DK_QW_\ !)8?_'Z/['R?_HJLN_\ "'-_+_J"\_P];'M*G_/B
M?_@5/R_O>?X>MOW?HK\(/^'6W[=/_25_X[_^"2P_^/T?\.MOVZ?^DK_QW_\
M!)8?_'Z/['R?_HJLN_\ "'-_+_J"\_P];'M*G_/B?_@5/R_O>?X>MOW?HK\(
M/^'6W[=/_25_X[_^"2P_^/T?\.MOVZ?^DK_QW_\ !)8?_'Z/['R?_HJLN_\
M"'-_+_J"\_P];'M*G_/B?_@5/R_O>?X>MOW?HK\(/^'6W[=/_25_X[_^"2P_
M^/T?\.MOVZ?^DK_QW_\ !)8?_'Z/['R?_HJLN_\ "'-_+_J"\_P];'M*G_/B
M?_@5/R_O>?X>MOW?HK\(/^'6W[=/_25_X[_^"2P_^/T?\.MOVZ?^DK_QW_\
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M6)M:^*?B/PGI7B3QO<2LY2#7-8M(KNZLX%?!2&V:3RPF  0W':ORG_X+H?\
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MQOX2\7S7OC>__P"$L\;Z1:B_NK#5M,FB6VFMM:U!'40J[B(,J ."6'ZJ?\%
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M/0?_ $:Q_I7M<.?\C[*?^P[#_P#I:,ZO\*?^%GW'^R__ ,F\_!W_ +$/0O\
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MG:?:+XH#L:20.V7()YQWX_ITK^9/_@FOIK_'C_@L!^W;^USH\LMUX9T'1O\
MA0S74:%K+^U_#VI1M/"DXRC2*(22H.>"2!QG^FR@ HHHH **** "BBB@ HHH
MH **** "BBB@ K\-?^"I/_)QG['G_8W6_P#Z<EK]RJ_#3_@J2?\ C(O]CWV\
M76__ *<5-?1\*_\ (YI?]@V._P#42L95OX<O6'_I<3]P[3_CTM?^O>'_ -%K
M11:<6ML/2WA_]%K17SAJ?A?\$_\ E.=^T[_V;GX6_P#3C9U^[%?RK_$[]JOQ
M_P#LU?\ !:+X^Z[X'_9D^)7[0NH:_P# S0=+GT3X>&(ZEHEM9WEO/_:MT)D>
M/[+<+"47*Y!;"\E:^Q_^'P'[17_2+?\ :I_[]6'_ ,BU]]G7#V:X]Y3B<+1H
M3HRR#)XQE/'X"C)N&$C%_NZV)IU$K[-Q2>ZNCDI5J<%.,FT_:3VA-]>ZBT?O
M#6%=^%O#-_>PZC?>'=#O-0M\^1?76DV%Q>0YZ^5<RV[S1YZ_*XYYZU^'?_#X
M#]HK_I%O^U3_ -^K#_Y%H_X? ?M%?](M_P!JG_OU8?\ R+7C?ZI9[_T#X7_P
MZ97_ /-GFOO-/K%+^:7_ (+J?_(>:^\_=]$2-0D:*B*,*B*%51Z!5  'L!31
M#")#,(HQ*PPTH11(1Z%P-Q'L3BOPB_X? ?M%?](M_P!JG_OU8?\ R+1_P^ _
M:*_Z1;_M4_\ ?JP_^1:/]4L]_P"@?"_^'3*__FSS7WA]8I?S2_\ !=3_ .0\
MU]Y^[LT,-Q&\,\4<\,BE9(ID62-U/!5T<,K*1P0P(-9&G>&?#>C^=_9'A_1-
M+^T.9+C^SM*L;+SY&ZO-]F@C\QSW9\GWK\.?^'P'[17_ $BW_:I_[]6'_P B
MT?\ #X#]HK_I%O\ M4_]^K#_ .1:/]4L]_Z!\+_X=,K_ /FSS7WA]8I?S2_\
M%U/_ )#S7WG[N-!"RJC0Q,B8*(T:%5(Z%5((7'; &*D      '  & !Z #I7
MX/\ _#X#]HK_ *1;_M4_]^K#_P"1:/\ A\!^T5_TBW_:I_[]6'_R+1_JEGO_
M $#X7_PZ97_\V>:^\/K%+^:7_@NI_P#(>:^\_=]T2161U5T8%61U#*RGJ&4@
M@@]P00:Q=-\,^&]'N+FZTCP_HNEW5[+Y]W<:?I=C93W4Q&#+/+;P1R2R$#[S
MLQZG.22?PZ_X? ?M%?\ 2+?]JG_OU8?_ "+1_P /@/VBO^D6_P"U3_WZL/\
MY%H_U2SW_H'PO_ATRO\ ^;/-?>'UBE_-+_P74_\ D/-?>?N^RJZLCJKHP(96
M 96!ZAE(((/<$8-8EEX7\,Z;>3:CIWA[0["_N2#<7MEI-A:W<Y'0RW$%NDTA
MYSEG///6OP[_ .'P'[17_2+?]JG_ +]6'_R+1_P^ _:*_P"D6_[5/_?JP_\
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M ?M%?](M_P!JG_OU8?\ R+1_JEGO_0/A?_#IE?\ \V>:^\/K%+^:7_@NI_\
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M@/VBO^D6_P"U3_WZL/\ Y%H_U2SW_H'PO_ATRO\ ^;/-?>'UBE_-+_P74_\
MD/-?>?O#17X/?\/@/VBO^D6_[5/_ 'ZL/_D6C_A\!^T5_P!(M_VJ?^_5A_\
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MW_:I_P"_5A_\BT?\/@/VBO\ I%O^U3_WZL/_ )%H_P!4L]_Z!\+_ .'3*_\
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MF8J_"_\ X? ?M%?](M_VJ?\ OU8?_(M'_#X#]HK_ *1;_M4_]^K#_P"1:/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXET75-:^"7B/P+<F[\'?$32].MII7N/M)E9/,CVJSM%SD$,,DL/P<^+^F_\
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M//#7@?\ :'^"%V%AU/P=(\V@^*](_>.M]%(SE#)Y"JY:,#=U;).:\G_X(%7
ME\0?MG)&RF,?&?Q.P5=A*G^W90 2HW< D8)_#BOG/X,ZK>1_\'+WQLTN*_DB
MM+GX<ZBTUFCJ(Y)H]+D9))(P069 N 6!]Z /K;]I#_@HQ^VI\<_VKO%/[(7_
M  3"^'G@/Q=J'PB+Q?'3XJ?$2[^R>&O">I1.5.@VER)5B&HRD".-"&D9B ,
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M+G4+N0$EI9226)8\FN\_X:<_9S_Z+K\)?_#@>%__ )9T?\-.?LY_]%U^$O\
MX<#PO_\ +.CZGB_^@7$_^"*O_P CYK[PYH_S1^]?UU7WGG/[,'[$_P "_P!D
M2Z^(-Y\&]'U/2YOB9K]WXE\4G4-1>_%QJE[<M=SR0AT3R4:9B0@S@<9KCM!_
MX)W?LW>'/VP]?_;ETS0M7C^/?B32I='U/67U:1],DLIH3;NB:;Y8C1C&Q&X/
MG/->[_\ #3G[.?\ T77X2_\ AP/"_P#\LZ/^&G/V<_\ HNOPE_\ #@>%_P#Y
M9T?4\7_T"XG_ ,$5?_D?-?>'-'^:/WK^NJ^\^0/VX/\ @E/^S'^W9?Z3XF^(
M*^,? /Q"T*":#3/B+\*M?E\'>*MDI)$=_J%@B37\"DD&*610RG:6Z$<;^Q#_
M ,$<?V3_ -AWQE??%#PC_P )M\3OBQJ-FEE/\1/BUXAF\8:_:Q+CY=+GOUDD
ML%P-J^7*S <@@XQ]X_\ #3G[.?\ T77X2_\ AP/"_P#\LZ/^&G/V<_\ HNOP
ME_\ #@>%_P#Y9T?4\7_T"XG_ ,$5?_D?-?>'-'^:/WK^NJ^\]RHKPW_AIS]G
M/_HNOPE_\.!X7_\ EG1_PTY^SG_T77X2_P#AP/"__P LZ/J>+_Z!<3_X(J__
M "/FOO#FC_-'[U_75?>>Y45X;_PTY^SG_P!%U^$O_AP/"_\ \LZ/^&G/V<_^
MBZ_"7_PX'A?_ .6='U/%_P#0+B?_  15_P#D?-?>'-'^:/WK^NJ^\]RHKPW_
M (:<_9S_ .BZ_"7_ ,.!X7_^6='_  TY^SG_ -%U^$O_ (<#PO\ _+.CZGB_
M^@7$_P#@BK_\CYK[PYH_S1^]?UU7WGN5%>&_\-.?LY_]%U^$O_AP/"__ ,LZ
M/^&G/V<_^BZ_"7_PX'A?_P"6='U/%_\ 0+B?_!%7_P"1\U]X<T?YH_>OZZK[
MSW*BO#?^&G/V<_\ HNOPE_\ #@>%_P#Y9T?\-.?LY_\ 1=?A+_X<#PO_ /+.
MCZGB_P#H%Q/_ ((J_P#R/FOO#FC_ #1^]?UU7WGN5%>&_P##3G[.?_1=?A+_
M .' \+__ "SH_P"&G/V<_P#HNOPE_P##@>%__EG1]3Q?_0+B?_!%7_Y'S7WA
MS1_FC]Z_KJOO/<J*\-_X:<_9S_Z+K\)?_#@>%_\ Y9T?\-.?LY_]%U^$O_AP
M/"__ ,LZ/J>+_P"@7$_^"*O_ ,CYK[PYH_S1^]?UU7WGN5%>&_\ #3G[.?\
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MQ36%Q#3Q-=K]Q5ZU96^SYK[T5"4>6/O1^&/5=EY^:^]'N5%>&_\ #3G[.?\
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M_-'[U_75?>>U6EI:V%K;V5E;PVMG:0QV]K;6\:Q0000H(XH8HT 5(XT4*JJ
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M?_+@5&EI^ZI]/L1_Z=^0?\./?^";/_1!4_\ "I\1?_)U'_#CW_@FS_T05/\
MPJ?$7_R=111_;^>_]#K-O_#CC/\ Y<"HTM/W5/I]B/\ T[\@_P"''O\ P39_
MZ(*G_A4^(O\ Y.H_X<>_\$V?^B"I_P"%3XB_^3J**/[?SW_H=9M_X<<9_P#+
M@5&EI^ZI]/L1_P"G?D'_  X]_P"";/\ T05/_"I\1?\ R=1_PX]_X)L_]$%3
M_P *GQ%_\G444?V_GO\ T.LV_P##CC/_ )<"HTM/W5/I]B/_ $[\@_X<>_\
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MI:?NJ?3[$?\ IWY!_P ./?\ @FS_ -$%3_PJ?$7_ ,G4?\./?^";/_1!4_\
M"I\1?_)U%%']OY[_ -#K-O\ PXXS_P"7 J-+3]U3Z?8C_P!._(/^''O_  39
M_P"B"I_X5/B+_P"3J/\ AQ[_ ,$V?^B"I_X5/B+_ .3J**/[?SW_ *'6;?\
MAQQG_P N!4:6G[JGT^Q'_IWY!_PX]_X)L_\ 1!4_\*GQ%_\ )U'_  X]_P""
M;/\ T05/_"I\1?\ R=111_;^>_\ 0ZS;_P ..,_^7 J-+3]U3Z?8C_T[\@_X
M<>_\$V?^B"I_X5/B+_Y.H_X<>_\ !-G_ *(*G_A4^(O_ ).HHH_M_/?^AUFW
M_AQQG_RX%1I:?NJ?3[$?^G?D'_#CW_@FS_T05/\ PJ?$7_R=1_PX]_X)L_\
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M$7_R=111_;^>_P#0ZS;_ ,..,_\ EP*C2T_=4^GV(_\ 3OR#_AQ[_P $V?\
MH@J?^%3XB_\ DZC_ (<>_P#!-G_H@J?^%3XB_P#DZBBC^W\]_P"AUFW_ (<<
M9_\ +@5&EI^ZI]/L1_Z=^0?\./?^";/_ $05/_"I\1?_ "=76^ _^"./_!//
MX;^,-#\=^&/@)ID/B;PW>PZCHFH7VL:QJ!T^]MW$D-S ES=NJR1N RGD9Z@T
M45G5SW.Y4IQEG.:RC*+C*+S'%M2C)6<6G6LTTVFGHT[,%2I*S5.FGIJH1_Z=
<^1^GB(L:)&@VHBJB@= J@*H_  "BBBOE3H/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img75897552_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_17.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &X YX# 2(  A$! Q$!_\0
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MK\.?!_7K;3]$TSX1>// FL1ZCXA7XD:BD]W?SZG;1'3+.*.V@\Z:<<I_8O\
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M $4G_@B]_P"&2_;B_P#H@:_:&B@#\7O[%_X.(?\ HI/_  1>_P##)?MQ?_1
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M9PE"5HRY9Q<7RRBI1=FD[2BU*+V<6FKIH$T]G?T/Q>_L7_@XA_Z*3_P1>_\
M#)?MQ?\ T0-']B_\'$/_ $4G_@B]_P"&2_;B_P#H@:_:&BI _%[^Q?\ @XA_
MZ*3_ ,$7O_#)?MQ?_1 T?V+_ ,'$/_12?^"+W_ADOVXO_H@:_91=2TY[Z32T
MO[)M2AA2YETY;J!KZ*WD.U+B2T$AN$A<\)*T8C8\!B:NTVFMTUHGKV>S]'T
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M .B!H_L7_@XA_P"BD_\ !%[_ ,,E^W%_]$#7[0T4 ?B]_8O_  <0_P#12?\
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M:OX8\6:#<3>.?B/H6K6AM)=5\2^)-3O[);B[AB$'G3\?M-_P2<^ ?QJ^$/\
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MC\5O#OPFG^(U[<77BC5=8MYDU2+PA)H,BS/_ *;);BR*N+8$MN_<;]GSP/\
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MK_Z.Q_9V_P##P^ __E[1_P -V?L5_P#1V/[.W_AX? ?_ ,O:/[.S#_H QO\
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MT?\ #=G[%?\ T=C^SM_X>'P'_P#+VC^SLP_Z ,;_ .$M?_Y7YK[PYX?S1_\
M E_F?5M%?*7_  W9^Q7_ -'8_L[?^'A\!_\ R]H_X;L_8K_Z.Q_9V_\ #P^
M_P#Y>T?V=F'_ $ 8W_PEK_\ ROS7WASP_FC_ .!+_,^K:*^4O^&[/V*_^CL?
MV=O_  \/@/\ ^7M'_#=G[%?_ $=C^SM_X>'P'_\ +VC^SLP_Z ,;_P"$M?\
M^5^:^\.>'\T?_ E_F?5M%?*7_#=G[%?_ $=C^SM_X>'P'_\ +VC_ (;L_8K_
M .CL?V=O_#P^ _\ Y>T?V=F'_0!C?_"6O_\ *_-?>'/#^:/_ ($O\SZMHKY2
M_P"&[/V*_P#H[']G;_P\/@/_ .7M'_#=G[%?_1V/[.W_ (>'P'_\O:/[.S#_
M * ,;_X2U_\ Y7YK[PYX?S1_\"7^9]6T5\I?\-V?L5_]'8_L[?\ AX? ?_R]
MH_X;L_8K_P"CL?V=O_#P^ __ )>T?V=F'_0!C?\ PEK_ /ROS7WASP_FC_X$
MO\SZMHKY2_X;L_8K_P"CL?V=O_#P^ __ )>T?\-V?L5_]'8_L[?^'A\!_P#R
M]H_L[,/^@#&_^$M?_P"5^:^\.>'\T?\ P)?YGU;17RE_PW9^Q7_T=C^SM_X>
M'P'_ /+VC_ANS]BO_H[']G;_ ,/#X#_^7M']G9A_T 8W_P ):_\ \K\U]X<\
M/YH_^!+_ #/JVBOE+_ANS]BO_H[']G;_ ,/#X#_^7M'_  W9^Q7_ -'8_L[?
M^'A\!_\ R]H_L[,/^@#&_P#A+7_^5^:^\.>'\T?_  )?YGU;17RE_P -V?L5
M_P#1V/[.W_AX? ?_ ,O:/^&[/V*_^CL?V=O_  \/@/\ ^7M']G9A_P! &-_\
M):__ ,K\U]X<\/YH_P#@2_S/JVBOE+_ANS]BO_H[']G;_P /#X#_ /E[1_PW
M9^Q7_P!'8_L[?^'A\!__ "]H_L[,/^@#&_\ A+7_ /E?FOO#GA_-'_P)?YGU
M;17C/PU_:,^ 7QDU._T7X2_&GX7?$O5]*M%O]3TSP+XY\.>*;_3[%Y!"EY>6
MNBZC>36UL\I$2S2HD;2'8&+<5[-7-4I5:,W3K4ZE*:2;A4A*G-)JZ;C))I-:
MIVU6J&FGJFFNZ=S^+[_@C!_RLJ?\%U_IXL_]7/X3K^S;4/\ CQO?^O2Y_P#1
M+U_&1_P1>_Y64_\ @NM_N^*__5S>$J_M!95965@&5@592 0RD8((/!!!P0>"
M*A.S3[.XS^(K_@DTOPGD^)>L3>,KK_@F,TB?MP_&YP/C%J=RO[9:7L7CZ]_L
MU? UN8CIQNENU1_":23DEUN P5^#Z+X$_;'_ &]$L/@O^U+K/[:'BS7_  ]K
M'_!6GQ!^QI>_ V^\)^![?P)JGPGG\;7.EK;:OJ%AIMKJUWK]G9JEO8WB2QSV
MR11_,\F]V_J5M?V*?V/+'Q3!XXLOV6?V>[3QG;:T?$EOXKMO@_X!@\10>(&N
M&NVUN+68M!74(]6-T[W)U!+@71G9I3+O)8]Y'^SW\!X=*LM"B^#/PNBT73?'
M#?$W3](C\">&4TVQ^(SSFZ?QY:62Z:+>W\8/<DW#>(XHTU=IB93=E_FK]*QG
M&V5XK%XC%3RFIB?K2HPE3QL,%B50HQABXUZ6&E6I572==UZ,G6I*C47L(]DU
MQQPTXQC%34>5MWCS*[?+9NS5[<KT=UJ?R[0?M@?M]:%^SE_P5:_;2TK]H_Q3
M\0[G]F7]K/X\_LW?!WX*77@[PS<>#_ OA6S^(OA/PZWQ U:XT;3[;5]?O/AO
MX;UVXU;1[;41+#;1:5=OJ4MXERY3Q?X\_M)?%&\^#G_!0G]EM_VP+C]O'X#O
M_P $]_"W[0ES\<-2B\+W%U\-?BUK'C+1=+O_ (<-K_A&"UTD:;XFLYI/$VE:
M!?;M2T:T\NSR!$^?[$M$^%'PO\-:7XOT/P[\._!&AZ+\0-9UOQ%X[TC2?"^B
MV&F>,M>\2J$\1:UXHL;6RBM==U374 35[[4XKFYU%0%NY)0,5P'A+]E/]F7P
M%X.\6?#SP5^S_P#!WPMX$\>2F;QMX/T/X=>%-.\-^+7,AE'_  D>CVVEQV.L
MI&YS#%J$-Q% H"0I&@"C##\8931J2JO(J*G#&X7$8;V-#+Z+A1P\LNE3C*K#
M"JM3K8:I@\55HSH3A]9J9A56+<X049-X>H]/:NSC)2NY/67.MF[--2BG?917
M+:^G\:6K?';XN?L^^-O^"@/COX"_$J7X6?$74/ ?_!%_P1;^,[+3]&UJ?3='
M\:?#AM&U.,Z;K=O=V$\=U:3LI5HDED (BFC)+#U;X\?M(?\ !07X$2_M_P!G
M;?\ !0?XE>*(OV#OBO\ LR:]X6EUCP=\/K2Y^(-I\?KG25U[PGX]EM=-0+X3
MT:.ZG&B:79+ ^9G+SLHA6+^NJ\_9M_9ZU!M9>_\ @=\);Q_$0\'C7VNOA]X5
MG;6A\/8A!X#&JF72V-^/!D $/A<77FC0HQLTS[,O%7=:_9^^!/B,^-#X@^#?
MPOUL_$>70Y_B =6\"^&=0/C>?PQL_P"$<F\6&ZTV4^()=!,<9T=]4^U-IQ1#
M:&':,='^O&5RJ4IULAHXCEA@(5GB,/EV(JU(X2ED&&E%5J^$JU8PGA<MS.A"
M*FHP69<Z2G!R$\-4LTJK7Q6LYI*_M'>R:5^:4&]->2ST9_*)^U9^WY_P4$U3
M]JG]IJT^'7Q6@^$47[-&L_!S3_A5X!U[XE_!7X6_"OQI8^*]*\/ZK>Z]\2]/
M^)4L'C/Q[IOQ >_O=.TN7P:7MM!8P10,+I9&$G[8G[6W[>L5U_P5=^+O@C]L
MCQ5\*]'_ & =-^"'Q%\#_"3PSX:\#ZIX9UG5O%&B^';CQ#X1\0Z]>:;)JMYX
M-N;V_ND@B$\L]RKK<+<-&T2I_5!XT_9?_9P^(WC+PW\0_'WP)^$WC/QUX/AM
M[;PQXM\3> ?#.LZ_HEO9[?L4%AJ5_IT]S%#8%$:PC\PI8LJM:B%@#6YJWP%^
M"&NP?$&UUOX0?#35[;XM16<'Q1M]2\$>&[V'XBP:<(UL(?&\5SITB>*(K)8H
MA:QZTMZD C01!0BXYZ/%^2T?[/Y.',%?"X;"T*R>%P=3VGL\3E53%WE7IUE5
M>*H8+'1565.G6I3S&JE*5I5*C>'J/G_?3]Z3:]Z2M[LU'9IJSE'2[34$^R7\
M[7[.^H^+M6_X+S:_XD\8?M(>(]'?XC?L,_ [XD:;\-[V30;'0?&Q\2:9;W=]
M\/?#]C<VR2W>D>&=0DNO$=M<:6S:S&\S0WUU-"BK7DG_  5Y_P""A7QX^%WQ
MR_:&3]G+]HKXK^$KW]E#PI\+M1UOP-:Q_"'P1\+M)UWQ7?023S:U;^,+B^^(
MOQR&O6$[6T^G^&=*L=,\.1L98[N256E']1EU\%?@_?>+_"7Q!O/A;\/KKQWX
M"TH:'X(\9W'@_0)?%'A'11&(1I/AO7GL#J>C::(0(A9:?<V]L(_D$87BN3\<
M_LM?LU_$[Q=/X^^(WP%^$7COQK=:(?#5UXH\7?#[POXAUN[T LC_ -D7=_JF
MF74]U8*R)Y=O</(D84+&%7(KGPW%.5K-<#F&-RGZU0P>38/+/J<J>"E2E/"5
M*474<94$I0K86G.ES2:K4IU=95J,'1J.5"?LY0A4Y7*I*?->5_>5[7O_ #:M
M;-=F[K^6K]J[]K?]NOQ)J_\ P4O^(?P__;+\7?!_P]^Q9^S+\"/VC?!7PZ\)
M>%/!%WI.N>*?$/P]TKQ/K.@:YJ>IZ;-JT7A#5[^>4W%@9II6,R[)Q$@B.7^U
MS^V7\=OC7XK_ &A?!?Q'_;,L?V7/ OP[_P"":7PN^,/A'X6C1/#D>B?M,^+/
MC!\,X-6\;7.JG6HQJ&N:,]W?3:)INE>%[N.]TIY%N$.%D<?UCW?P"^!M_!XU
MMK[X/?#*\M_B1H-AX6^(4%UX'\-SP^./#6E6B6&F>'_%L<NFLGB'1M/LHTM+
M/3=5%U9VULBP0PI&H49?BK]F?]G3QU>>&M0\:? CX0>+;_P;HD7AKPE>^)/A
MSX2UJZ\->'8+<6L&@Z%/J.DW$NEZ/#;*MO%IMFT-G'"!&D(08KHP_%^347AK
MY!1B\+2A3HU:6&RWVU-QPN4TZD[U,'.-:=:O@<9-U,0JE6E#,*DZ4U5A>2>'
MJ._[UOF;YDW.SUG9?$K)*4=%9/E2M;;^?SQ?^TK\7_V6/^#>;]F/XF_ G7H_
M!7BW4? WP&\!W/Q+_LV+7(OA=X5\=^,;3P_XD\?I9RQ7-JTN@:9=S2VMU>12
MV5E/)'<W*[(B1^?D'[07Q+_9I_:?_P""F?QA^"7[3%G^VO\ $SX4_P#!/GX+
MP^%OCG=:?HFK75O;:GX[TZVU'7/$-KX6#:-XDF\ V>J76N/-;11P2VD%M:WH
M+6\Y;^SEOA9\,W^'_P#PJA_A]X+?X7_V1_8'_"NW\,Z,_@G^P^?^)/\ \(NU
MF=%_LP9.++[%]G!Y$8-<AX,_9L_9Y^'*WZ> /@9\(_!2ZIX;/@W4U\+?#OPG
MH*ZEX2::6Y;PQ?C3-*MA>: 9YYICI-SYE@9)9',&78G/!<7Y9AJ>9*MDRQ$\
MPS+&XNJI?5;8G"XK'Y=C(87$UI8>>*4:,,'7H*G2JJA4^N3J3I.4/?)8>;]G
M:I90A&*^+W91A*+E%*2CJVGJKKELGJ?S!^#OVUOVI/ VL?M$_"+X0?M^>$_V
MG]"O_P#@G_HW[2EG^T;\4W\(0^&?V>_CEK.KV^FS^&;[Q1X<LD\.Z1I'B2"[
MFN?#GA[Q#%++H-Y+8O=HMI;SAOF[6OV^OC_8_L$_M[>'/$W[0'Q(\<?&?X2^
M'/V8/&#Z;\8- ^!_QF\%^')?'WQ7\%:;K.L>"/BCX9MM6\(^+="\20:A<3V'
MA7Q/X?34?#Z26US87 F@#1_V!^!/V7_V;_AAX<\5^$/AU\!_A%X)\*^.UN(_
M&OA[PU\/O"VD:/XMBNO.\Z#Q)I]GID5MK5LRW$R+;:C'<01Q2-%'&D6$&;X>
M_9'_ &6O"?@GQ)\-O#7[.WP6T3X?>,;ZTU/Q9X+T[X;>$K?PQXEO]/O8]1TZ
MZUW14TH6&JRZ=?10W6G&]@F%A-#"UF(?*CV[PXOR*%1S_L"G4<<9E>)51X?+
MJ5:O]1K86I7=;V6'5&C[>G1JTG0P]*,)>T4Y58MUUB$\/6:_C6]V:M>;4>:+
M2M>5W9M.[=UT6UOY6_VI?VN_V\='T7_@IQ\?_ W[:'BWP)X<_8(^,_P'M?AW
M\(-,\(>!9_"OB/2_'<G@C2M:\.^,=3ETM-5E\/LFNW%Q;V22^<LLDG[\H85A
MZ3]M/]N[]JFS^+'_  4/\06_[<=[^RCKO[*WPF^%%Y^SG^S_  >%?"EUI?QE
MA\<^%-,UKQ!XYD3Q)87-_P")[R\U"Z>#2Y-&>:'P\!;FXB,*S;_ZJ-1_9]^!
M.L:;XYT;5O@W\,-3TCXG7>FW_P 1]+O_  +X:N[#QY?:.UN^DWGC"TGTV2#Q
M'<Z8]G:-83ZO'=R6C6T!@9#$FW\U_P!LC_@D_-^UQ\1O%WB.Y_:0\0^!O 'Q
M"\):%X%\4^!8/A;\-/$NKZ'X6TLPQZGI7PO^(.KZ2/%7@&W\1VD(AU6*TN+V
M,,S-;+%'MA7HROBCAVKB</''Y9@L%1P]*,%B9Y?@Z[=*,>'U5H.E2RW$^WJ8
MB>7YK-U<13=10S.I&&(I2^(G1K*+Y:DY-[I3DM;U;2NYQ:45*G9)VO"_*S]
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M_:&OQ>_X.(/^4+7[?_\ V2+1_P#U97@:OVAH _%_]L7_ )32?\$5_P#LD/\
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MJ[^BCVU;_G[5_P#!DO\ /R7W!9=E]R. _P"%4?"W_HFO@#_PC?#O_P KJ/\
MA5'PM_Z)KX _\(WP[_\ *ZN_HH]M6_Y^U?\ P9+_ #\E]P679?<C@/\ A5'P
MM_Z)KX _\(WP[_\ *ZC_ (51\+?^B:^ /_"-\.__ "NKOZ*/;5O^?M7_ ,&2
M_P _)?<%EV7W(X#_ (51\+?^B:^ /_"-\.__ "NH_P"%4?"W_HFO@#_PC?#O
M_P KJ[^BCVU;_G[5_P#!DO\ /R7W!9=E]R. _P"%4?"W_HFO@#_PC?#O_P K
MJ/\ A5'PM_Z)KX _\(WP[_\ *ZN_HH]M6_Y^U?\ P9+_ #\E]P679?<C@/\
MA5'PM_Z)KX _\(WP[_\ *ZC_ (51\+?^B:^ /_"-\.__ "NKOZ_@N_X.GOV@
M?CY\,_VW_@3X4^&?QO\ BY\-_#,O[-46O7&@_#_XA^*O!FEW6M77Q%\36,^J
M7EKX<U33H[R]>RL[6U$]T)62&%$0J,Y^EX2R'%\5YS2R>EF#P4JE#$5_;U%5
MK1C'#T^=Q]G"I!MRLDO>26^MDGC7J1H4W4<%*SBK*R^)I;V>U^Q_<E_PJCX6
M_P#1-? '_A&^'?\ Y74?\*H^%O\ T37P!_X1OAW_ .5U?Y G_#7O[77_ $=?
M^TQ_X?;XG_\ S3T?\->_M=?]'7_M,?\ A]OB?_\ -/7ZK_Q!#,_^BHH=/^8/
M$^7_ %%=/_;?0X?[1C_T#O\ \"C_ /(_U9^5_P#7[_X51\+?^B:^ /\ PC?#
MO_RNH_X51\+?^B:^ /\ PC?#O_RNK_($_P"&O?VNO^CK_P!IC_P^WQ/_ /FG
MH_X:]_:Z_P"CK_VF/_#[?$__ .:>C_B"&9_]%10Z?\P>)\O^HKI_[;Z!_:,?
M^@=_^!1_^1_JS\K_ .OW_P *H^%O_1-? '_A&^'?_E=1_P *H^%O_1-? '_A
M&^'?_E=7^0)_PU[^UU_T=?\ M,?^'V^)_P#\T]'_  U[^UU_T=?^TQ_X?;XG
M_P#S3T?\00S/_HJ*'3_F#Q/E_P!173_VWT#^T8_] [_\"C_\C_5GY7_U^_\
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M4GJT[W=NB1]1?\*H^%O_ $37P!_X1OAW_P"5U'_"J/A;_P!$U\ ?^$;X=_\
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M<K+D#<I&17\8/_!%[_E93_X+K?[OBO\ ]7-X2K^T$D*"S$!0"220  !DDD\
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M)#_VK_\ P5_ +_YSM'_#''QP_P"DA_[5_P#X*_@%_P#.=K[G_M_0O^@UI/\
MX,;/_P"/4?V_H7_0:TG_ ,&-G_\ 'J/[6S#MA?\ PUY=Y?\ 4'Z??YZG)#O+
MI_R\GY6^UY+^F?#'_#''QP_Z2'_M7_\ @K^ 7_SG:/\ ACCXX?\ 20_]J_\
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M?VQCO^H/_P -N6__ #)Y?GW8>SC_ 'O_  .?E_>\D? 7_#''QP_Z2'_M7_\
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M^#&S_P#CU']OZ%_T&M)_\&-G_P#'J/[6S#MA?_#7EWE_U!^GW^>IR0[RZ?\
M+R?E;[7DOZ9\,?\ #''QP_Z2'_M7_P#@K^ 7_P YVC_ACCXX?])#_P!J_P#\
M%?P"_P#G.U]S_P!OZ%_T&M)_\&-G_P#'J/[?T+_H-:3_ .#&S_\ CU']K9AV
MPO\ X:\N\O\ J#]/O\]3DAWET_Y>3\K?:\E_3/AC_ACCXX?])#_VK_\ P5_
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M\GY6^UY+^F?"_P#PQQ\</^DA_P"U?_X*_@%_\YVC_ACCXX?])#_VK_\ P5_
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M\%6/_5;?LM5^T%?B_P#MB_\ *:3_ ((K_P#9(?\ @JQ_ZK;]EJOV@H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^'7_@X._9)^(?[;?_  5P
M_9Q^ ?POU_P9X7\4ZI^Q=XE\7'7/']WJMEX8L=%\#>,?'7B379;R?1=.U;4C
M,FF65P]M#;V,S32J$XR*_N*K^3+_ (*6?''X2?L[?\%[?V9/B?\ &WQMX6\
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M+'_P%?Y'RZV7HC;_ .$H\7?]#IXW_P#"T\4__+:C_A*/%W_0Z>-__"T\4_\
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M.+'_ .[2_P =/_TI'\KG_"4>+O\ H=/&_P#X6GBG_P"6U'_"4>+O^AT\;_\
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MR3!E2A\EH]IBRI*GRRN5)!X.*8MK;(Z2+;PJ\2E(W$2!T1B2RHP7<JL220"
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MTK256%M?EN;.[N8M(%O;ZI=/LVI_!G]FMBTCFW@+2QB*5C$FZ2(=(Y#MRZ#
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M/F<DEB3S7R>*X#ABZ[KU<S5)NC@Z?)A<NIX>$%@OJ,:="DEBIN&7*&!IU*>
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M_P#4"\"U_GW5_H(_\&D'_)B7Q\_[.I\2_P#J!>!:^2\7_P#DB,7_ -A^7?\
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M-3=(#&_]^G_!*O\ Y1L_L,_]FO\ P=_]0S2J_+_%6MGE;A[+I9[A:>%K+/\
M$+"0IRH3YL(\LH3]^5"M6A*5/$RQ%)2?LY3A3A.5-7YI=N!5-59^SDY+V2YF
MTU[W.]KI;KE?5)Z7T9]^4445^"'J!1110 4444 %%%% !1110 4444 %%%%
M!1110!_%[_P1>_Y64O\ @NM]/%@_[Y^-'A-3^H./:OZ__B[_ ,DG^)__ &3S
MQK_ZC>IU_(!_P1>_Y64O^"ZW_<W_ /JZ_"M?U_\ Q=_Y)/\ $_\ [)YXU_\
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MS.T?><(W<HU.:_710:C9MWY=K6/<_P#@I;HFB^&_V_/VK]#\.Z/I?A_1-/\
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M6VH-QP,G)K[Q\.?\%$OCUX4^&_A[P)HOAWX+6_BCPA\,=6^"WA'X^'X9V/\
MPT%X9^%>N+=)J?@[2?B%'?1K';2Q7MU:0:C/I,^JVMC<2VEO>)&Y-?""J$4*
MO0?F23DDGN2223W))->AD668[ 8C-*F+J1E2Q-2F\/"-1U)R<*V-J5,57FTE
M.OB*>(P].I4Y:<G'#0IRI1C2A*:J2C)044URIIWTW4+17]V+4FE=V<GJ[M)U
M%%%?1F85_H(_\&D'_)B7Q\_[.I\2_P#J!>!:_P ^ZO\ 01_X-(/^3$OCY_V=
M3XE_]0+P+7YAXO\ _)$8O_L/R[_T^SKP/^]0_P %3\D?U7T445_(Q[I^+W_!
MQ!_RA:_;_P#^R1:/_P"K*\#5^T-?B]_P<0?\H6OV_P#_ +)%H_\ ZLKP-7[0
MT ?B_P#MB_\ *:3_ ((K_P#9(?\ @JQ_ZK;]EJOV@K\7_P!L7_E-)_P17_[)
M#_P58_\ 5;?LM5^T% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %?YYW_!VM+$G_!0#X#!Y$0_\,J69P[JO_-4/%_J17^AC7S!\=?V*?V2/VG=
M<T7Q-^T+^SI\(OC+XA\.Z;+H^A:U\0O!6C>)-3TK2IKAKN73K*\U"VEGALWN
M7><VZOY?FNT@4,Q)^OX'XDP_"N?T<WQ6'K8JC3PV*H2I8>4(U6Z]/DC).HU"
MT7NFUIM=Z/#$T77I.FFHMRB[N]O=:?3O8_QV/M%O_P ]X?\ OZG_ ,51]HM_
M^>\/_?U/_BJ_UM?^'2/_  3'_P"C%/V9/_#4^&/_ )"H_P"'2/\ P3'_ .C%
M/V9/_#4^&/\ Y"K]K_XCED?_ $)<V_\ !F#_ /EOK_2U\[^SJO\ S\I_=+^N
M_P#2U_R2OM%O_P ]X?\ OZG_ ,51]HM_^>\/_?U/_BJ_UM?^'2/_  3'_P"C
M%/V9/_#4^&/_ )"H_P"'2/\ P3'_ .C%/V9/_#4^&/\ Y"H_XCED?_0ES;_P
M9@__ );Z_P!+4_LZK_S\I_=+^N_]+7_))-Q;$$&> @C!!DC((/4$;N0:!/;*
M JS0*H& !)& !Z  X ^E?ZVW_#I'_@F/_P!&*?LR?^&I\,?_ "%1_P .D?\
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M\/\ W]3_ .*IADLV8.7MBXQART188Z88G/';FO\ 6X_X=(_\$Q_^C%/V9/\
MPU/AC_Y"H_X=(_\ !,?_ *,4_9D_\-3X8_\ D*L/^(Y9'_T)<V_\&8/R_P"G
MO]:=M7_9M3_GY3^Z7E_P?P[:_P"25]HM_P#GO#_W]3_XJC[1;_\ />'_ +^I
M_P#%5_K:_P##I'_@F/\ ]&*?LR?^&I\,?_(5'_#I'_@F/_T8I^S)_P"&I\,?
M_(5'_$<LC_Z$N;?^#,'_ /+?7^EJ?V=5_P"?E/[I?UW_ *6O^25]HM_^>\/_
M ']3_P"*H^T6_P#SWA_[^I_\57^MK_PZ1_X)C_\ 1BG[,G_AJ?#'_P A4?\
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M /CE?[&G_#%7['?_ $:I^SI_X9?X=?\ S.T?\,5?L=_]&J?LZ?\ AE_AU_\
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MFS_Y^P_\ ?\ \EZ_TM?\<O\ M72_^@E8?^!EO_\ '*/[5TO_ *"5A_X&6_\
M\<K_ &-/^&*OV._^C5/V=/\ PR_PZ_\ F=H_X8J_8[_Z-4_9T_\ #+_#K_YG
M:/\ B.N7_P#1.XW_ ,.%#_YF]?Z>A_9L_P#G[#_P!_\ R7K_ $M?\<P:GII!
M(U&Q(49)%W;D 9QDGS.!GCGO2?VKI?\ T$K#_P #+?\ ^.5_JQ?M,_LP?LS>
M&/CQ^PIH&@?LW_ #2]&\=_'?QOH7B_3[;X,_#E8->TBR^!/Q+URTT^_4^'#Y
MEO!J^F6&H1KD8N+2%_X:^TO^&*OV._\ HU3]G3_PR_PZ_P#F=KHK>-F HTL)
M5?#^+:Q=&=:*6/HW@H8FMAG&5\+9MRHRDFFU:23L[V2R^;<E[6/NM)^X]?=C
M+^;L_P"K:_XY?]JZ7_T$K#_P,M__ (Y1_:NE_P#02L/_  ,M_P#XY7^QI_PQ
M5^QW_P!&J?LZ?^&7^'7_ ,SM'_#%7['?_1JG[.G_ (9?X=?_ #.US_\ $=<O
M_P"B=QO_ (<*'_S-Z_T]'_9L_P#G[#_P!_\ R7K_ $M?\<O^U=+_ .@E8?\
M@9;_ /QRC^U=+_Z"5A_X&6__ ,<K_8T_X8J_8[_Z-4_9T_\ #+_#K_YG:/\
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M  ,M_P#XY1_:NE_]!*P_\#+?_P".5_L:?\,5?L=_]&J?LZ?^&7^'7_S.T?\
M#%7['?\ T:I^SI_X9?X=?_,[1_Q'7+_^B=QO_APH?_,WK_3T/[-G_P _8?\
M@#_^2]?Z6O\ CE_VKI?_ $$K#_P,M_\ XY1_:NE_]!*P_P# RW_^.5_L:?\
M#%7['?\ T:I^SI_X9?X=?_,[1_PQ5^QW_P!&J?LZ?^&7^'7_ ,SM'_$=<O\
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MZ!^+W_!Q!_RA:_;_ /\ LD6C_P#JRO U?M#7XO?\'$'_ "A:_;__ .R1:/\
M^K*\#5^T- 'XO_MB_P#*:3_@BO\ ]DA_X*L?^JV_9:K]H*_%_P#;%_Y32?\
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MM+?\)YX'_P"AS\*?^%%I'_R91_PGG@?_ *'/PI_X46D?_)E?XZGP5^ GQO\
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M\6_[3>?]!+5__!SJW_R;1]IO/^@EJ_\ X.=6_P#DVC_B!%/_ **B?_AFC_\
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M!0>&S7$8V%."A"G2J5\33I)1BXQ["BBBO] #^$PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /XO?^"+W_*RE_P76_[F_P#]
M77X5K^T*OXO?^"+W_*RE_P %UO\ N;__ %=?A6O[0J "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O\_[_@[J_P"3S_V4O^S:/$O_ *LZ
M]K_0!K_/^_X.ZO\ D\_]E+_LVCQ+_P"K.O:_3_!__DN,#_V!9I_Z@UCCQ_\
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M/?#M8&E TK2?#-GIT.H6UQ=75S!J$<S/(%E4'\F?V?/^3A?V>O\ LO?P8_\
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MEU1Q4HJ*Y$^517QM?#&"]W1N%^3WDK\W-)?:9_=S_P $[_C+^S9JGP\_:/\
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M+)KEE=;9;NX6.W-PR.L D\UD8(0?+:];_9\_Y.%_9Z_[+W\&/_5E>&:PQ/\
MNV(TO^XJZ.]G^[EH[-/[FGYC6Z]5^9_J":C^V!_P4GM=0O[6T_X)83W]I;7M
MW;VE^G[67PVB2^MH)Y(K>]2)_"I>)+J)4G6)SOC$@1OF4U3_ .&Q_P#@IA_T
MBEN?_$M?AI_\RE?K;17\-+-< DK\-Y.W;5_6,^U\],ZMKY'T?)/_ )_5/_ :
M7_ROU_I:_B3X8\8_\%)?&_[5&G?'Z_\ ^"?GA'P':>&_@-K_ ,)5T7QC^U5X
M9']J7/B#Q]X?\6KJECJ/A_P!K>TV<.B26DUE<Z?&'^TK.MV/+\IOK[_A</\
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M'W6-:_9F^''[,,WA_1H/#OPV^*?Q ^*VG^+(KR[;7=4U/X@VVGVU]H]]8O\
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M*[:#7-1U2Z\-:]+-H^I:$NOQ2PP:Y:7#W\4;&"*5_P ;_A/\<-6^%OQR\/\
MQUG\,>#/'^K:7XHO?$FM>#_&.EPS>#O%::N;@:WI-_IUHD8TZVOH[J=;6YTU
M(I](E,5SIXCE@CQ]7?$?]O[1O'<GP>\)6W[.7AJP_9_^%OQ2G^,NO_ CQ/\
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M?_!D_P#,_>+_ (B5_P#@KW_T6[X6_P#AA? W^%'_ !$K_P#!7O\ Z+=\+?\
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M_HFLB_\ #7@__E/DON'[>O\ \_JO_@R?^9^\7_$2O_P5[_Z+=\+?_#"^!O\
M"C_B)7_X*]_]%N^%O_AA? W^%?@[11_J;PE_T361?^&O!_\ RGR7W![>O_S^
MJ_\ @R?^9^\7_$2O_P %>_\ HMWPM_\ #"^!O\*/^(E?_@KW_P!%N^%O_AA?
M W^%?@[11_J;PE_T361?^&O!_P#RGR7W![>O_P _JO\ X,G_ )G]!G@/_@Y.
M_P""M5]X^\ Z=K'Q?^%>J:1JGCKP;I&K::WP.\&V8O\ 2]7\2Z7IFH6OVRU*
MW5JTUI=S*EQ;LLT3[70@BO['O^"Z'[9_QW_86_X)_:K\>_V=M7\/Z!\3W^*'
MPK\&VFK^(O#MGXITZPTOQ?J5S!J\L>C:B19W%T8;<1VS7 9(M[/M+ 8_S OA
M[_R4;X:?]E+^'?\ ZFFAU_HI?\'1_P#RB<O_ /LOOP#_ /3OJ-?E_&G#N0X3
MB_P\PN%R?+<-ALPS.O2QV'H8.A2HXNG#$98HPQ%.$(PJQ4:M2*4TURSDMG8Z
MZ%6J\/BY.I-RC"+BW)MQ;4[M-MM;+;L?RQ?\1*__  5[_P"BW?"W_P ,+X&_
MPH_XB5_^"O?_ $6[X6_^&%\#?X5^#M%?J'^IO"7_ $361?\ AKP?_P I\E]Q
MR>WK_P#/ZK_X,G_F?O%_Q$K_ /!7O_HMWPM_\,+X&_PH_P"(E?\ X*]_]%N^
M%O\ X87P-_A7X1VUK=7US;6-C:75_?7MS!9V-A8V\MW>WUY=2I!:V=G:P*\U
MS=7,\D<-O!$C22RNJ*"37W+\2?\ @G%^T]\)O#WC?5O&<'P@M_$_PP\*>'O'
M'Q.^#FF_&KP+J'QV^'7A;Q,MF]CJGB_X6?;;?6M.:RCO[277-.@EO-4T>*8/
M=60"OMY:_#7 ^&G2I8C(^'*%2N[485<!@(2J6G2IMP4J2;2J5:,')>ZIU*46
MU*<4VJN(:;56LTMVIS=M]]?)OT3?1GWO_P 1*_\ P5[_ .BW?"W_ ,,+X&_P
MH_XB5_\ @KW_ -%N^%O_ (87P-_A7X5>'=.OO%WB'1?"7AFW?7/$WB/6--\/
MZ%HFGLDVH:GK6L7L&G:9IUM &#-<7=[<0P1JV/F<9Z5]-_M!_L7?M#?LR>(O
MB'X;^)_A32KF;X0OX7LOBWK?@'Q'I_COPE\,/$/C.1XO#O@OQSXGT@+I>B>-
M[XJKMX8>6;4((I[>655CF5A=3A;@JE6I8>KD/#M.O6BYTJ,\OP$*M2,:E*DY
M0A*DI2BJM6C232LZE2G!7E**:]M7:<E5K-+=J<VEI?5IV6B;]$WLC].O^(E?
M_@KW_P!%N^%O_AA? W^%'_$2O_P5[_Z+=\+?_#"^!O\ "OQX^%_P4\:?&#P;
M\8_'G@F\\$/X?^!'A73?&?C]?$'CKPYX:UA]$U;46TJS7P?HNK7D%_XUU7[6
MC&YTC0(KF]M;;;<RQB-ESXPFH6,BNR7=LRQ)OE(FC/E)G&Z3#?( >"6P >#5
MPX1X/G.K3AP[D,JE"4(5H1RS!.5*<Z<*L(S2HWBY4YTYQ3LW&49+1H/;U[)^
MVJV:;3]I.S2=FT[ZI/1]F?K1\&/^"U?[?W[/?C/XV_$#X0>+O@]X/\6_M$^.
M4^(WQ:U2U^!7@>7_ (2'Q7'81Z<MS:P-&D>D6'DHTYTNRVVC:A<7E^RFYNIG
M;Z&_XB5_^"O?_1;OA;_X87P-_A7X*_:[7$A^TP8B57E/FIB-' *LYW?(K @J
M6P#VS3?MUGY0F^UV_DE_+$OG1^69/[@?=MW?[.<^U=-;A/AK$5'5Q'#^3UZK
MC3@ZE;+L+4FXTJ<*=*#E.DY6ITX0A"-[1A",8I**22K54K1K5$M795)):ZMV
M3ZMW?K?J?O9_Q$K_ /!7O_HMWPM_\,+X&_PH_P"(E?\ X*]_]%N^%O\ X87P
M-_A7X*?;;,P_:/M5OY ;9YWG1^5OSC9YF[;NSQMSG/:NY^&W@3Q)\6_'_@7X
M9>!;>TU/Q?\ $CQ5H?@SPC:7-_;Z?8WWB#Q'?0Z;I-O<:G<'[+96T]W/&DMY
M,?)@0F1_E!K"?!_"-.$JE3AO(80IQ<ISEEF"C&$8KFE*3=%)*,5=MZ)*^R'[
M>L[6K5==OWD]?377=?>?ME_Q$K_\%>_^BW?"W_PPO@;_  H_XB5_^"O?_1;O
MA;_X87P-_A7Q1\5_^"6/[;'P6^"WQB_:!\=?#70D^%_P#^+&I_!7XJ:MX=\;
MZ)XDU/P[XZT:\TNPU-(]$TTM>:AX?L[K6=-CF\0VV;$"Y#C*JV//?VL_V!OV
MGOV(;#X1ZE^T=X/T#PG;?''PT_B[X=+HWC#1_%-SJ&B1VMC>22ZK;:6QDT2Z
M2'4;7=:7@\T2-)$?GB<#SZ&2^'F*G2IX;+.%*]2O4K4:%.CA<LJ3JU</1IXB
MO3IQC!RG.C0JTJU2,4W"E.$Y)1DF4ZF)2;<ZZ2LVW*HDDW9-MO2[32[M66I^
MC/\ Q$K_ /!7O_HMWPM_\,+X&_PH_P"(E?\ X*]_]%N^%O\ X87P-_A7X.T5
MZ7^IO"7_ $361?\ AKP?_P I\E]Q/MZ__/ZK_P"#)_YG]I/_  1'_P""VW_!
M0K]LO_@H3\/OV=_VB?B%X \7_#'Q=X ^*.M7]AHOPM\.>$-5MM5\(^'!K&DW
M5KJVCD7&W[0#%<V\NZ&6%CP' -?V[U_F1_\ !M/_ ,I>?@G_ -DM^//_ *@Q
MK_3<K^;/%S+,NRKB?#X?+,#A<!AYY-A:TJ&$H4\/2=66*QT)5'3I1C#GE"G"
M+E:[45?8]; 3G.C)SE*35223DW)VY8.UW=VNW]X4445^7':%%%% !1110 44
M44 ?Q>_\$7O^5E/_ (+K?[OBO_U<WA*O[0J_B]_X(O?\K*?_  76_P!WQ7_Z
MN;PE7]H5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q
MI^TI_P $\_V*?VP_%/AWQM^TY^SE\._C/XK\)Z#/X8\-ZYXRLK^ZOM'T"YOW
MU2?2K1[34+1%M9=0D>[961V\UB0P!Q7V7171AL7BL%66(P>)Q&$KQ4HQK8:M
M4H5HQFG&454I2A-*46U)*5FFT[H4HQDK2BI+M))K35:/31ZGY4?\.._^"2W_
M $8C\#/_  4ZS_\ +JC_ (<=_P#!);_HQ'X&?^"G6?\ Y=5^J]%>E_K)Q%_T
M/\Z_\.F._P#EYG[&C_SZI?\ @N/^7DON/RH_X<=_\$EO^C$?@9_X*=9_^75'
M_#CO_@DM_P!&(_ S_P %.L__ "ZK]5Z*/]9.(O\ H?YU_P"'3'?_ "\/8T?^
M?5+_ ,%Q_P O)?<?E1_PX[_X)+?]&(_ S_P4ZS_\NJ/^''?_  26_P"C$?@9
M_P""G6?_ )=5^J]%'^LG$7_0_P Z_P##ICO_ )>'L:/_ #ZI?^"X_P"7DON/
MRH_X<=_\$EO^C$?@9_X*=9_^75'_  X[_P""2W_1B/P,_P#!3K/_ ,NJ_5>B
MC_63B+_H?YU_X=,=_P#+P]C1_P"?5+_P7'_+R7W'Y4?\.._^"2W_ $8C\#/_
M  4ZS_\ +JC_ (<=_P#!);_HQ'X&?^"G6?\ Y=5^J]%'^LG$7_0_SK_PZ8[_
M .7A[&C_ ,^J7_@N/^7DON/RH_X<=_\ !);_ *,1^!G_ (*=9_\ EU1_PX[_
M ."2W_1B/P,_\%.L_P#RZK]5Z*/]9.(O^A_G7_ATQW_R\/8T?^?5+_P7'_+R
M7W'Y4?\ #CO_ ()+?]&(_ S_ ,%.L_\ RZK3T7_@BI_P2J\.:WHOB/0_V'O@
MEINN>'-8TOQ!H>IVVE:PMSINM:)?0:GI6HVS-K+*MQ8W]K;W4!9642Q*65AD
M']1**3XCXA::>?9RTTTT\TQS33T::=>S36C3W'[&C_SZI_\ @N/EY>2^Y!11
M17C&@4444 5[RTMK^TNK&\A2XM+VWGM+JWD!,<]M<Q-#/"X!!*2Q.R, 0=K'
M!%?ED_\ P0]_X),.\LK_ +"7P-:2:6:>5CI.LY>:>5YII&_XG7WI)9'=O5F)
MK]5:*[<'F>99>JBP&88W JKRNJL'BZ^&55PYN1U/8U(<_)SRY>:_+S2M:[O,
MH0G;GA&5MN:*E;;:Z=ME]R/RH_X<=_\ !);_ *,1^!G_ (*=9_\ EU1_PX[_
M ."2W_1B/P,_\%.L_P#RZK]5Z*[?]9.(O^A_G7_ATQW_ ,O(]C1_Y]4O_!<?
M\O)?<?E1_P .._\ @DM_T8C\#/\ P4ZS_P#+JC_AQW_P26_Z,1^!G_@IUG_Y
M=5^J]%'^LG$7_0_SK_PZ8[_Y>'L:/_/JE_X+C_EY+[C\J/\ AQW_ ,$EO^C$
M?@9_X*=9_P#EU1_PX[_X)+?]&(_ S_P4ZS_\NJ_5>BC_ %DXB_Z'^=?^'3'?
M_+P]C1_Y]4O_  7'_+R7W'Y4?\.._P#@DM_T8C\#/_!3K/\ \NJ/^''?_!);
M_HQ'X&?^"G6?_EU7ZKT4?ZR<1?\ 0_SK_P .F._^7A[&C_SZI?\ @N/^7DON
M/RH_X<=_\$EO^C$?@9_X*=9_^75'_#CO_@DM_P!&(_ S_P %.L__ "ZK]5Z*
M/]9.(O\ H?YU_P"'3'?_ "\/8T?^?5+_ ,%Q_P O)?<?E1_PX[_X)+?]&(_
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M"J_]>Y_^DL_S,_@1^QQ\2?CI\+/B-\=1XP^$_P '?@5\*-:T#PGXN^,7QO\
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M+>,ZDD,WD'Q5_:H_9[T?4-7U'XU?&C]F?]H3QAJ/_!3+PM\8OV(;P:S9>/O
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M,);,,6H59QE*N\+5=6GA%2E85"-M:L>9R235K)>_S*W/=R]V.B^'F5G*^O\
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M .43E_\ ]E]^ ?\ Z=]1K^0O_@H%\6?A[\</$_\ P2G^('A_XD>&OB3\5_\
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M&95NI_L=O*\<!8>:R;!R17Z#_MY?LQ#QU^TY^U3^UNWQU^!7BS]FCQ;\3_\
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M\.ZOK%]XU\8Z6ZZOX3T#PY9ZJ-0M 85<70\JN;^ W_!+KQ;^T/)XUO\ X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.M^':JOQ(^&A50"WQ-^'18@ 9/\ PFNA<G'4^YYK_10_X.D?^43E[_V7_P"
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M&7X7P_$SPAIVKW_P\O/#^HI<M%J-K;"*YO;6\TN6XA>,J_TKXE_X*'_\$_\
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M1FFK-5I)KLU&":^\****_)3N"BBB@ HHHH **** /XO?^"+W_*RE_P %UO\
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MB=-^ _[0WQ)M_#OP@;Q3\*O^"KEU^Q%X:TR>PUQ;6\^$<?BC0-'M];U.R'B
M7TWC5['4[N1KZVD@TLS0AETT)'(IZ9<%9VI0ARX23G5I8>7+BHR5+$U*JH2P
MU5I>[5H5)05;EYJ<5.+A4FKM3]9IVO[RT;5XO5)7NO)K;KIJEI?^CQ)8I=_E
M21R>6YCDV.K[)%^\C[2=KKW5L,.XH2:&1I$CEC=XCME5'5FC;^[(JDE#[, :
M_D+^$/[;W[1_P*L/VIOA]\$]0\-Z_P#&K]I7_@MU\9OV>OAQXH^->H:OJ_P\
M^%OA^;1_#.JWUU-9)?03S6]C"K0:%X=M+FUMGEN)61&9-C_>/_!(WQ9\:M?_
M &G_ /@JSIOQS\1Z/K?CKPO\:O">C:I%X.UG5M0^'UGJ%MX.F6]N/!-EJLTT
M^@:9J4R_;9-&+/+I\[M;RRRO'NJ\=P?BL!A,?C:N+P[I82C0K48)/V^*A5Q.
M"PLZBI<S5*C3K8N4%.4Y2G.A->SC&49LAB(SE&*B[R;3?2+M*25^K:CMYG]
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M='TWQ1K#ZKHNBP3V&K78LG\^-8"&T=*_X*N? &?XN?L'>//&O[//C'Q1X?\
MV2OV/O&G[-WB2QU ^ =;U:;Q_P")%$^@?&#X:6.OQ7WAY;SP1JR1ZMH=EXJ@
M5_M<<;N%>,-7X38/H?R-&#Z'\C7W$N%,EG*<Y4*[E.GB:*?UO$ITZ&*AC8U*
M%*U3W*2>8XV=.*O[.=>3B[1A&/.JU1?:6\7\,=7'DLWIJW[.-]KI?,_H0^(_
M_!8;X(>)M:N-2TCP!^TEXIE'_!,7XN?\$^QXE^+'B7P+JWC7Q%XG\?\ BIO$
M^D_%[Q7J6F7;030^=<7:>(=+M 9H<6T.DHT"87Y<_P"":G[?OP,_8L\!^.?#
MOQ%^&'Q0N_'VO?%3X5^/M!^,GP0G\"6/Q#@\&^ Y/-\5?!VXUSQL@OO#/A'X
MB&.VM==U#PG<0:G/8I+;W"RHP%?DE@^A_(T8/H?R-./"V3PP.(RZ-&LL+BI8
M>=>*Q-;FG+#595J?O<VD?:3ES0MR2B^646DDCVM3F4VTY132;BK)-)/3T6C=
MVN^]_P"@CXC_ /!5#]D'XB_#']O[PEI/PS_:C^#?Q!_X* _'C7/B3\4OBSX#
M;X1Z[XFG^%8,;>%?@JD^LZOI5SHV@^9;PS>*9--N;E+]YM1CB6:WU"6"/G-8
M_P""LOP/\8?#'Q#\&O$WPL^,NF>"O%W_  3 \&_L"ZUJ/AV[\!WFN6GC;P9X
MH_X2&S^)>G6.JW<.GS>&;F!(["32KFYAU*+S)I%C8K&1^#6#Z'\C1@^A_(UG
M#A')81C!4\0U"M2Q%/GQ5:<J=:C2PU"E.,Y2<G[.E@\+3IPFYTZ<*$(PC&/,
MI/VU2][K:S]U6:;;::VU;DVTEJ[N]C]]_B#_ ,%@?@YXRMOVE[6U^"?Q)@C^
M.G[ /[/G[&^AG4=2\)2G0_$_P4EBDO?&FLK%<.LGAW5S!"^G6ECYFI02JS7$
M,>5*8WQ%_P""MOP=^)G[5/Q[^*.N_!/XF0? _P#:>_88\,_L4?%'0M/\0>%[
M?XL^']-T'1]%B;QOX'OF:;PS<7 UW0[6YATK6+B&&YTV2:"X>.5N/PAP?0_D
M:,'T/Y&BGPCD=)MPP]9/V/L$_K6(O&')@(1E%NH[5(?V9@Y0GK*,Z7-]J:DO
M;5>LD]4W[L=;<VFVSYI779^1^Z>M?\%7O@O8_L]?$7]E?P#\&_BE!\*X?V$_
M"W[&GP3U[Q9K?A6Y\;K>6'Q4E^*?BCQW\4XM.E&CI::GJ<\EEH^C^%7NS8VB
MI%*7R9%Z?XS?\%=/AQ\9X_VY-'\%_!+XE:;XG_;"^"W[)?PA^&#:EK/@V0>"
M_''[/-O96L6N^()#=QP2V&L:Q;6UUH*V4RO9,%;4'M_F9?P%P3T!/X4A7((*
MY!!!!&00>""",$$<$'K37"621G[18>JZOMEB7.>)Q$N?$?6,NQ<JM1>U7-*I
MB<KP=6JM%-QJ1LHU9IGMJFW,K62LHI62C*-EH[*TI)=DUV/ZU_\ @HS_ ,%,
MA^SS\>O^"76KZ1H/P_\ &_Q*^!&GZ/\ M7_M:^%_!?BO3=1M/$OQ^^(7@*Q^
M&_B;3=>U_P .7.I:')XL?P?:7U]-)%=72Z9KAMH)-L*-*?S;_9V_;R_8&_9%
M_:#UCXX? [X$_M6ZO=>-?!7[2?AWQQ/\2?B%\/Y[E;CXW6.JV_A?2_"_A?15
M70K72_"$NK3#6O$-YJ1US788HG6P23<M?B1#;Q6Z"."%(8P2PCBC6- S<L=J
M #)[G&3WJ7!]#^1K#!<'95A<OC@)O$5(RPM7"8N5&O7PD,91JXC%XGV=6C3K
M27LZ-7&XCZM!SFZ4904IU'3BU4J]1SY]+W4DFE)Q:45HVENH*^FOEL?T,Z9_
MP6>^#=E9^';:?X'?%"X;1?\ @F3K?[!\S#6?".RX\:ZI+YL7CV,/.2OA"%L&
M33W UDL RQ%@"?DK]@;QEH.N?L(?\%3_ -E34O$N@>&O%WCOX*?"WXV^ +CQ
M#>VFDV'B&7X">.;35O&?A>TOKVY@6[\1:IH-^D_AS0[<2WE_-:W)ACD\MQ7Y
M-X/H?R-,>%)=OF1+)L=9$WH&V2+]UUW [77LPP1V-=4>&<NH8:M0P:J8:5;%
M9=C)57.IB&JV5XZ./PS4*M395E*,XJ4>:$W&ZM%J?:S<DY/FLIQ2LEI./))7
M2[6L^EEYW_6/]EW]O&W^'7P6_84_9_\ !G@ZVB^)_P"S_P#\%$=1_:JL_%WC
MO7=(T#X4:OIOC?0M*\'V7A35;^1GO] GMW6:74==O[8:38I,ETSL(Y%3]F?V
MK/"OP=G^%.F?!FTN$^%WQ'_:V_X+0^!/COKGA[QE\=O@[\2+<>$;#0;./QI\
M0_"OB7X=Z_?:)IGPH\+6]V+6Q\0>+[K2M9UV2&:[-A&Z^0/Y!2I8$%20P(((
MR"",$$'J""00>HZU633[.)9$CL[>-)5"RJEO&JR*.0K@( P!Y 8$ \USX[A:
MAB<91QF'Q,L'.G6KXFKRTZM:5>O5Q,\93<I2Q5.FJ5+%S=;V+HSNFX4YT+\R
M<:LHQ<6E--**NTK)147:T6[N*M>ZLM;-[_UP_P#!.OXX>&OVCO\ @Z#^(WQ@
M\%R0W/@_Q#_PT3H_AC4K:X2ZM-=T/P1\.['P9IWB*RGC 62RU^WT--6M3U$-
MT@)S7]]%?YD7_!M, O\ P5Y^"2X"C_A57QY"C&!@>"%X ] .PZ"O]-VOYW\7
M\+3P/$.4X&C?V.#X8RS"4N9WDZ>'Q&/HP<GUDXP5WWN>K@&Y4JDGO*M.3]7&
M#?YA1117Y2=P4444 %%%% !1110!_%[_ ,$7O^5E+_@NM_W-_P#ZNOPK7]H)
M (((!!!!!&00>""#P01P0>M?Q??\$7O^5E+_ (+K?]S?_P"KK\*U_9]*)3%*
M(&19C&XA:12T:RE3Y;2*I5F0/@NJLI*Y (/- 'Y?/_P1J_X)Y/\ %]_C.?@;
MMUN3Q^_Q5F\'1^,O&,?PFG^),EZ-1D\:S_"M-:'@F;7)+T"Z>232&M7N?](:
MU,^)1Z%XM_X)=?L2^-_ /Q/^&GB3X0?;?"OQ>^-Q_:,\9PQ^+?&%GJDGQE,D
M3_\ ";:'KEGKD&K^&;]1$L20Z!>:?9I 7A6W$;LIT;_PK_P4J>_OGTWXR?L=
MPZ:UY<MIT-Y\$_BS->0V#3.;2*[FB^+L44UU' 8UGEBBBCDE#.D:*0HJ_P#"
M)_\ !3?_ *+1^QG_ .&.^+G_ ,^&OJ7C\WFZ4Y\67E15)47+,<T<J2HRC4I*
M+^KOE=.<8RBT_=E%-.Z3,.6FK_[/O>_N0UO9.^O;3T3\KY7Q5_X)8?L8_&3Q
MOIOQ!\:^ /$Q\10:'X0\.>(W\/\ Q*\?^%['XDZ1X"BAB\(0?%.QT'Q!80?$
M"?0UMH!;7WB,7E_*(ECNKFXBW1F/XA_\$J/V(/BE\6I/C'XS^%%]J7B"]U+P
MKK>N^&XO''C2R^&WBG6_! @'A/6/%'PYM=<C\(ZWJ&AK;QK:S7>ELLO+7:7+
MA679_P"$3_X*;_\ 1:/V,_\ PQWQ<_\ GPT?\(G_ ,%-_P#HM'[&?_ACOBY_
M\^&E#&9K35-0XKC!4J4J%)1Q^9Q]G1GR.5.%L,N6#]E2]U62]E3M;V<.4M!W
MO0>K3?N0U:V;][=7?X]]?7/VH?V./V?/VQ/ ^B> ?COX(/B'2O"VL6_B'P=J
MNC:QJ_A/Q7X,URUA-O#JGA/Q5X<O-.UO0KGR,0S"RO(X+J%$BNH9HT51Y5HO
M_!,S]B[P_P##3X/_  DTCX006?@KX&_%BQ^.?@*TC\2>)_[3C^+6GSRW,7CK
MQ'KAU?\ M?Q;K<TTSM=S>([S48[H;(YHVCCC18/^$3_X*;_]%H_8S_\ #'?%
MS_Y\-'_")_\ !3?_ *+1^QG_ .&.^+G_ ,^&L:53'4*%/"T>):-+#4JLJU*A
M3QN90HTZTXRA.I"G'#*,9RC.<9223:G--^]*[?*VY.@W)I)MQ@VUIHWS;;?=
MY(^@_BY^S/\ !GXY^-/@G\0OB;X4/B'Q9^SQXVNOB'\)-3&K:OIW_",>+;W3
M&TBXU,VNFWMK:ZH'T]V@^RZK#>6JYWK"'^:O!_#_ /P31_8U\+>!_A9\.=$^
M%+V?A#X+_''Q!^T;\.=+_P"$L\73'0?B_P"*-=U'Q)K?B@W4VM/=WXN]8U6^
MNO[*U":YTF+SO*BLTB1$6I_PB?\ P4W_ .BT?L9_^&.^+G_SX:/^$3_X*;_]
M%H_8S_\ #'?%S_Y\-*G+&4:4*%'B.A2HTOX=*GC,QA3IZXA^Y".%48ZXO%/1
M+_>*_P#S]GS#Y6[NC)ONXP;UY=_>_NQ_\!79'5/_ ,$]OV1I_!/[07P[O?A+
MI^I>$/VH?'][\4OC-I.IZOKVH+XC^(%[';(WBG3[FZU*2Z\,ZI:M9VMQIT_A
MR;3#IUU EQ9"&4;CP?AS_@EE^Q;H'PA^*/P2OOAOK7CGP=\9I]'N_B->_$GX
M@>./'WB_7;SPWM_X1B]B\7^)-=OM=T:\\,;(O[ N=#N].ETUHDD@82EW?2_X
M1/\ X*;_ /1:/V,__#'?%S_Y\-'_  B?_!3?_HM'[&?_ (8[XN?_ #X:TCB,
MRBG&/%%.*E5HUY)8[,U>MAU25"J[8;^)25"@J<_BC[&C9KV4.4M#3]P]$X_!
M#1/=?%MJ[KU[ZX/A3_@E!^PUX2^ OQ6_9P@^$=SKWPW^-^IZ=K7Q4D\6^,_&
M'B;QCXPUC1/*_L#5-0\<:IK4WB>"]\/K#"NAS6&HVATP1@VP1R[-NV'_  3"
M_8IL[7XBV5W\(%\10?%CX0^%O@9X_'BWQ7XN\52>(?ASX)N)+OPKI=Q-KFMW
MLT.I:)=2?:;'Q!:O#KD,\<,JW^^*,JO_  B?_!3?_HM'[&?_ (8[XN?_ #X:
M/^$3_P""F_\ T6C]C/\ \,=\7/\ Y\-6\7FLG4D^*XMU:JKU'_:&:7G67L+5
M9?[-K-?5L-:6Z^KT;->RARJT-/W#T5E[D-%V7O;:O\>^O(^"?^"1W["/@/X2
M_%KX+Z5\)-0U+PA\<H=$L_BA?>)O'GC?Q)XR\4:5X9NH+SPYH<_C?5M=N/$]
MGH6AS6UO_9VDZ?J5K91"%2\4DA=V^E_"?[(_P$\$?'2']I'PUX+;3_C!!\$/
M#?[.D7BG^V]<N%7X1>$M5&M:#X8_LJXU"722UEJ(\_\ M4V9U6?_ %<]Y)'\
MM>+?\(G_ ,%-_P#HM'[&?_ACOBY_\^&C_A$_^"F__1:/V,__  QWQ<_^?#6=
M:MF&)=5XCB>E6]LIJM[7&YE/VJJPH4ZBFI89J2G3PV'A-.ZE"A2B[QIP2:Y5
M:U!JUK6C#2VJ^UT<F_6_?7YZ_:W_ ."9GB;XO?%O]I_XX_!WXGZ=X/UO]I_]
MB3X@?LK?$3X?^(='N+GP]XC\1ZAIE_!\.OB"-<L[L7.BWGAR:Z6QU-/[+U,7
MNEAEA2*;);7_ &,O^"0O[*_[-O@/X=ZEXF^%^B>)?CE:_LWZ!\!_B5XEN/$7
MBSQ%X5O[.Y\)6.A?$2W\(^'-?U.;1O#>F>+[R/4)]0?1])TNYOHKR4W(#RR"
MO;O^$3_X*;_]%H_8S_\ #'?%S_Y\-'_")_\ !3?_ *+1^QG_ .&.^+G_ ,^&
MNMYGFKP,<NCQ'@:6&C&E3:H5,90J5*5"C["C1K5*.#A*O2ITDH1C5<VHQA&_
M+"$5/)3YW/V,W)WW46DVTVTG)I-O5VZW[Z^>^!?^"/'[!7P]P=$^%OB.\:#X
M=?$/X0Z:_B#XH?$77_["^%WQ0TN;1O%?@/0(]2\230Z-X;ETRXFM=,LK"*$Z
M0)'GL)(;EVF;V_X@?\$^_P!D_P")_P"S%\/?V/O&OPQ75O@-\*(/ \7PY\,+
MXC\36.J^$)_AQ"MOX,U+1/%MCJUOXHM-7T2%3';ZHFK?;7624332>8^>2_X1
M/_@IO_T6C]C/_P ,=\7/_GPT?\(G_P %-_\ HM'[&?\ X8[XN?\ SX:YZF+S
M2M5I5ZO%4*E:A5A7HU9X_,Y5*5:FYN%6G)X:\*D74J.,XM23G.S]YW:4$FE0
M:35FN2%FM-'[VJT5[WV]"'5_^"7O[$_B#PS\:/">O?"'^V],^/\ J'@S6_B;
M/JWBOQ;J&L:KXB^'UDEAX.\3:9K5WK4NJ>'?$FAP1J;76]"NK"_:8O-/-*[N
M6Q?!O_!)_P#8<\#>!/#?P^TCX47]YI?ACXU>'?VA[?6-=\<^--:\7:O\8/"8
M1?#_ (P\2^*[[6Y=9U^?38XXX8-/U*YFTD0HL9L2H(/0?\(G_P %-_\ HM'[
M&?\ X8[XN?\ SX:/^$3_ ."F_P#T6C]C/_PQWQ<_^?#36+S50=-<5Q4'.%1P
M689IRNI3I0H4YM?5K<T*-.G2B]U3IP@O=A%(M"]_8.^WP0ZN[Z]VWZW?77X>
M_8U_X(F_!OX::AK'Q$_:@\*^'/B?\7]._:@^)?Q[\"ZKH?B?QE#X0MD\1>*K
MCQ!X*N_$?@S[;IWAK7O%'AB.<QVU]JND:BUDP1+2?9&M?6>O?\$D/V%?$GQ(
M\0?%#5OA9K$FN>(_BMH7QQO=&M?B%XZT[P3;?%OP_J,>JVOCW3/!>GZ];>'M
M.U^ZO(8WU2XM[%4U*-?)NHGB9D;KO^$3_P""F_\ T6C]C/\ \,=\7/\ Y\-'
M_")_\%-_^BT?L9_^&.^+G_SX:Z<3FV=8K$U,5/BJE3J5(NGRT,9F5&E"DYJ?
MLJ5.&&4:=+G2FJ<4HJ5W:[9,84XQ450DTFGK&#=]%=OFU=M/EZ7LZ_\ \$S_
M -C3Q-X&^(_PWUGX4O=^#_BQ\>="_:8\=Z7_ ,);XNA.L_&7PWKECXCT?Q6+
MJ'6DN[(6NKZ=9W1TFQFM](E\KRI;)XF9#<\2?\$W?V.?%GQ*^/'Q8UOX3+/X
MO_::\*0>#_C@]OXI\7:?HGC[3[6U@LK/4M3\.V&MVVBP^)K*UMK:&T\46-E:
MZ[;)!$(KY=HK*_X1/_@IO_T6C]C/_P ,=\7/_GPT?\(G_P %-_\ HM'[&?\
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M'G_X(_?]&=>&_P#PO?BM_P#-S7[244?ZV<4_]%)GW_AWS#_YH#V%#_GS2_\
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M_P#A>_%;_P";FOOS_AN7]C/_ *.I_9__ /#L^"?_ )<T?\-R_L9_]'4_L_\
M_AV?!/\ \N:X_P"VN.O^AKQ7_P"%N;__ "P?L\+_ "8?_P !I_Y>:^\^ _\
MB'G_ ."/W_1G7AO_ ,+WXK?_ #<T?\0\_P#P1^_Z,Z\-_P#A>_%;_P";FOOS
M_AN7]C/_ *.I_9__ /#L^"?_ )<T?\-R_L9_]'4_L_\ _AV?!/\ \N:/[:XZ
M_P"AKQ7_ .%N;_\ RP/9X7^3#_\ @-/_ "\U]Y\!_P#$//\ \$?O^C.O#?\
MX7OQ6_\ FYH_XAY_^"/W_1G7AO\ \+WXK?\ S<U]^?\ #<O[&?\ T=3^S_\
M^'9\$_\ RYH_X;E_8S_Z.I_9_P#_  [/@G_Y<T?VUQU_T->*_P#PMS?_ .6!
M[/"_R8?_ ,!I_P"7FOO/AC0O^" /_!([PWKNB>)-)_8^\+0ZMX>U?3==TF>?
MQG\3;V&WU32+R&_T^XDL[SQI/:7(M[NWAF$-S!- Y0"2-UR*_0W]I?\ 99^
MO[8/PHOO@A^T;\/-,^)GPPU'5-'UNY\+:G>:KIT']K>'YS<Z/?PWNB7^FZE;
M7-A,S-#);WD1P[*VY6(KF?\ AN7]C/\ Z.I_9_\ _#L^"?\ Y<TP?MT_L7&1
MHA^U=^ST9D4.\(^+O@4S(C<*\D(ULRI&Y!"2.@1R"%8D&N/$8KBO%U\-B<57
MX@Q.)P4G4PF(KU,QK5L+-RC)SP]6HY3H2<H0;E3E%N48N]TK5%4$G&*HI27O
M**@E)>:6C5GU[^9\#?\ $//_ ,$?O^C.O#?_ (7OQ6_^;FC_ (AY_P#@C]_T
M9UX;_P#"]^*W_P W-??G_#<O[&?_ $=3^S__ .'9\$__ "YH_P"&Y?V,_P#H
MZG]G_P#\.SX)_P#ES79_;7'7_0UXK_\ "W-__EA/L\+_ "8?_P !I_Y>:^\^
M _\ B'G_ ."/W_1G7AO_ ,+WXK?_ #<T?\0\_P#P1^_Z,Z\-_P#A>_%;_P";
MFOOS_AN7]C/_ *.I_9__ /#L^"?_ )<T?\-R_L9_]'4_L_\ _AV?!/\ \N:/
M[:XZ_P"AKQ7_ .%N;_\ RP/9X7^3#_\ @-/_ "\U]Y\!_P#$//\ \$?O^C.O
M#?\ X7OQ6_\ FYH_XAY_^"/W_1G7AO\ \+WXK?\ S<U]^?\ #<O[&?\ T=3^
MS_\ ^'9\$_\ RYH_X;E_8S_Z.I_9_P#_  [/@G_Y<T?VUQU_T->*_P#PMS?_
M .6![/"_R8?_ ,!I_P"7FOO/@/\ XAY_^"/W_1G7AO\ \+WXK?\ S<T#_@WG
M_P""/P/_ "9SX;/L?'GQ6Q^/_%<U]^?\-R_L9_\ 1U/[/_\ X=GP3_\ +FC_
M (;E_8S_ .CJ?V?_ /P[/@G_ .7-']M<=?\ 0UXK_P#"W-__ )8'L\+_ "8?
M_P !I_Y>:^\_%_\ 9+_X(6_\$K/B9X&\=ZOXR_9/T#6-0T;XV_%CPEIUQ-XW
M^)<+V^@>'/$\UAHNGA;3QA;1LEC9JD"22(\\@&Z:61SFOJ3_ (AY_P#@C]_T
M9UX;_P#"]^*W_P W-?67_!/'7=$\4?!KQYXC\-:OIVO^'M;_ &A?C=J.BZYH
M]W#?Z3JVGW'C"X:WOM-O[=GM[RSG7YH;B"1XI!RC$<U]Y56:<4<44LPQ=)<0
MY[24*TH^S6:X^"@U9./(JZY;.Z:LK.^@4Z-%PB_8TGIO[.'^1^+?_$//_P $
M?O\ HSKPW_X7OQ6_^;FC_B'G_P""/W_1G7AO_P +WXK?_-S7[245P?ZV<4_]
M%)GW_AWS#_YH+]A0_P"?-+_P7#_(_%O_ (AY_P#@C]_T9UX;_P#"]^*W_P W
M-'_$//\ \$?O^C.O#?\ X7OQ6_\ FYK]I**/];.*?^BDS[_P[YA_\T!["A_S
MYI?^"X?Y'XM_\0\__!'[_HSKPW_X7OQ6_P#FYH_XAY_^"/W_ $9UX;_\+WXK
M?_-S7[244?ZV<4_]%)GW_AWS#_YH#V%#_GS2_P#!</\ (_-O]F;_ ()%?\$\
M/V//BI9?&S]G7]G#P_\ #OXGZ;H^KZ!I_BRW\1^-];O;'2M>@6VU>VM8/$?B
M75K& WUNH@GFCM5G,64$@4D'])***\K&X_'9E66(S#&XK'5U"--5\9B*N)JJ
MG%R<::J5ISFH1<I.,;\J<I-*[9<8Q@K0C&*O>T4HJ_>R25PHHHKD*"BBB@ H
MHHH **** /XO?^"+W_*RE_P76_[F_P#]77X5K^R+Q9J\^@>%?$VO6L44]SHG
MA_6=7MX9RX@FGTW3KF\ABF,9#B*22%4D*$.$)VD'!K^-W_@B]_RLI?\ !=;_
M +F__P!77X5K^PWXE?\ ).O'W_8E>*O_ $Q7]=&$A&IBL-":4H3Q%&$HO:49
M5(J2?DTVC#$RE##8B<6XRC0JRC)6NI1A)IJ]U=-)ZJQ_'H/^#D_]K [O^+#_
M  $X>1/^/SQ[_ [)_P!!?_9Z\9ZX'0+_ ,1)W[6'_1!_@)_X&>//_EO7\ZB]
M9/\ KM/_ .CI*=7^Q?\ Q+UX+_\ 1OLF_P#!V9__ #?Y?GW9_E9+QW\6E*27
M&N964FE^YP'1K_J$\OQ?<_HI_P"(D[]K#_H@_P !/_ SQY_\MZ/^(D[]K#_H
M@_P$_P# SQY_\MZ_G6I-RXSD8]<C'Y]*/^)>O!?_ *-]DW_@[,__ )O\OS[L
MG_B._BU_T6N9?^"<!Y?]0GE^+[G]%7_$2=^UA_T0?X"?^!GCS_Y;T?\ $2=^
MUA_T0?X"?^!GCS_Y;U_.M11_Q+UX+_\ 1OLF_P#!V9__ #?Y?GW8?\1W\6O^
MBUS+_P $X#R_ZA/+\7W/Z*?^(D[]K#_H@_P$_P# SQY_\MZ/^(D[]K#_ *(/
M\!/_  ,\>?\ RWK^=:BC_B7KP7_Z-]DW_@[,_P#YO\OS[L/^([^+7_1:YE_X
M)P'E_P!0GE^+[G]%/_$2=^UA_P!$'^ G_@9X\_\ EO1_Q$G?M8?]$'^ G_@9
MX\_^6]?SK4@((R""/4'(_2C_ (EZ\%_^C?9-_P"#LS_^;_+\^[#_ (COXM?]
M%KF7_@G >7_4)Y?B^Y_15_Q$G?M8?]$'^ G_ (&>//\ Y;T?\1)W[6'_ $0?
MX"?^!GCS_P"6]?SK4@(/0@\XX.>1U''>C_B7KP7_ .C?9-_X.S/_ .;_ "_/
MNP_XCOXM?]%KF7_@G >7_4)Y?B^Y_15_Q$G?M8?]$'^ G_@9X\_^6]'_ !$G
M?M8?]$'^ G_@9X\_^6]?SK44?\2]>"__ $;[)O\ P=F?_P W^7Y]V'_$=_%K
M_HM<R_\ !. \O^H3R_%]S_0U_P""57[;7Q!_;R_9X\0_&#XD>$O"/@[7='^)
M_B+P/!IG@R75Y=+ET[1]+T&^@NY3K-S=70O))=4G24)((?+CB*HK%J_3.OY_
M_P#@W'_Y,=\<?]G">./_ %'_  ?7] %?Y;>,6399P_XG\;9+DV#I9?E66YYB
M,-@<%1=1TL-0A"FXTX.K.I4<4VW[\Y/7<_T>\+<US#//#WA+-LUQ53&YCF&3
MT,1C,554%4KUIRGS3DH1A!-I)>[%+0****_-3[X*_'__ (*Y?\%$/BC_ ,$^
M/"/P2\0_#'P/X&\:W/Q-\5^+- U>#QM-KD4.GV^@:+8:G:S:?_8EU:N99I;N
M1)_M#.@1$V*&)-?L!7\P'_!S4?\ BV7[)(_ZJ3\2#^7A/1?\:_7/ C(<GXG\
M6.#\BS_ 4<SRC,,3F4,9@:[J*CB(T<DS/$TE-TITZB4*]&E47+./O05[JZ?Y
MCXR9WFG#OAIQ5G62XRI@,TP&&P53"8NDH2J49U,UP%";BJD9P?-2JU(/FBU:
M3ZV:^/\ _B)._:P_Z(/\!/\ P,\>?_+>C_B)._:P_P"B#_ 3_P #/'G_ ,MZ
M_G6HK_3?_B7KP7_Z-]DW_@[,_P#YO\OS[L_SQ_XCOXM?]%KF7_@G >7_ %">
M7XON?T4_\1)W[6'_ $0?X"?^!GCS_P"6]'_$2=^UA_T0?X"?^!GCS_Y;U_.M
M11_Q+UX+_P#1OLF_\'9G_P#-_E^?=A_Q'?Q:_P"BUS+_ ,$X#R_ZA/+\7W/Z
M*?\ B)._:P_Z(/\  3_P,\>?_+>C_B)._:P_Z(/\!/\ P,\>?_+>OYU2RC@L
M ?0D"EH_XEZ\%_\ HWV3?^#LS_\ F_R_/NP_XCOXM?\ 1:YE_P""<!Y?]0GE
M^+[G]%/_ !$G?M8?]$'^ G_@9X\_^6]'_$2=^UA_T0?X"?\ @9X\_P#EO7\Z
MU%'_ !+UX+_]&^R;_P '9G_\W^7Y]V'_ !'?Q:_Z+7,O_!. \O\ J$\OQ?<_
MHI_XB3OVL/\ H@_P$_\  SQY_P#+>C_B)._:P_Z(/\!/_ SQY_\ +>OYUJ0$
M'D$$>H.:/^)>O!?_ *-]DW_@[,__ )O\OS[L/^([^+7_ $6N9?\ @G >7_4)
MY?B^Y_15_P 1)W[6'_1!_@)_X&>//_EO1_Q$G?M8?]$'^ G_ (&>//\ Y;U_
M.M11_P 2]>"__1OLF_\ !V9__-_E^?=A_P 1W\6O^BUS+_P3@/+_ *A/+\7W
M/Z*?^(D[]K#_ *(/\!/_  ,\>?\ RWJ*?_@Y2_:PAAEE'P&^ A,:,X!O/'N"
M5!.#_P 3<?S%?SMU5OO^/.Y_ZXR?^@FA?1Z\%KK_ (U]DVZ_Y?9GY?\ 4?\
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M$'^ G_@9X\_^6]'_ !$G?M8?]$'^ G_@9X\_^6]?SK44?\2]>"__ $;[)O\
MP=F?_P W^7Y]V'_$=_%K_HM<R_\ !. \O^H3R_%]S^BG_B)._:P_Z(/\!/\
MP,\>?_+>C_B)._:P_P"B#_ 3_P #/'G_ ,MZ_G6HH_XEZ\%_^C?9-_X.S/\
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M)2YJ<W3PT)V?*K\LD][,_M_HHHK_ "T/]'#\7O\ @X@_Y0M?M_\ _9(M'_\
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MX51\+?\ HFO@#_PC?#O_ ,KJ/^%4?"W_ *)KX _\(WP[_P#*ZOY__P#B*?\
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M?^B:^ /_  C?#O\ \KJ/^%4?"W_HFO@#_P (WP[_ /*ZOY__ /B*?_X)7?\
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M*+G5JU)M:1A"+E*3V2;94<10DU&-6FVVDDI*[;M9)?-?>?M51117S!L%%%%
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MM((W\1>';Z1;JQU>PENXY;9@_DNL@S'NC8-_."P"R3*.B7%PBCT5)Y%4?@H
M_"OV9F_X+,^/XO%/@C7]'^ '@:PL/A]\$_B5\"M TB\\=>,]:FE\-?$>ZLIY
M]6U/6M4-SJ=[K.E)8I&C332I?/--+/)&?+6/\9B2S2.>LDDLA Z RR-(0/4
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MC#3?'NE^-?@A;:E9ZM\7_C%\8?AII_A/X\_%GX8:1X&U+XS:6EMJOAGQS9^
M+G1;KXQ^&O#FMQKXC\.6^M:AH%Q;7.ZSEFDMI)-W/_"+_@M#K/PVT+X;:AXD
M_96^'WQ"^-WPP_9;\;?L@:)\:9/B'XJ\+RWWP?\ %O\ :(T^'5?!%EI>H:5=
M>(?"T6I3VNGZPVI&6\M9+I;I!<7;7,4XM<?XG!8FBZ5##UJRY8O U<#3JT[T
M\4XNAB9XR,H4E+ZG'$N2^M0K*J\+.KAZEJ+B\*I)WDTMU*,VGK%.Z4=7;F<;
M>[:W,E*U_P 1+5VEMX9'.6= 6. ,GUP, ?A7[C_\&Y/_ "E^_9J_[%?XX?\
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MV4CXD_\ J)Z+7]0%?R__ /!S5_R3/]DD?]5(^)/Z^$]%_P *_<_HU?\ )[^
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M_P#ZO>'C^6OI;?\ )N\G_P"RMP/_ *JLX/RXHHHK_3@_SL"BBHY06C< 9)'
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M4?!3_DZO W_8]PW_ *3,_M_HHHK_ !A/]9S\7O\ @X@_Y0M?M_\ _9(M'_\
M5E>!J_:&OQ>_X.(/^4+7[?\ _P!DBT?_ -65X&K]H: /Q?\ VQ?^4TG_  17
M_P"R0_\ !5C_ -5M^RU7[05^+_[8O_*:3_@BO_V2'_@JQ_ZK;]EJOV@H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""Z_X]KC_ *X3?^BVK_%Y
M^)7_ "4[XI?]E1^)/_J;Z]7^T-=?\>UQ_P!<)O\ T6U?XO/Q*_Y*=\4O^RH_
M$G_U-]>K^@? G^)Q-_@RG_TK,3R\R_Y<_P#<3_W&<91117]#GEA7NO[,/P0N
M?VE_VBO@K^SY9^)(/!UU\9?B+X;^'L'BNYTV76+?P]+XBOH[)=6GTJ&XM)=0
MBLR_FO:QW5NTH&T2IG->%5Z%\)/B?XM^"/Q4^''QE\ W4%EXW^%7C;PYX_\
M"=S=Q-<64>O^%]3M]5TT7]LDD375A+<6Z17MKYL8N;9Y82ZA\C#%*O+#8B.%
MG&&*E0K+#3FDXPKNG)49R3C).,:G*Y)QDFD[Q:T;C;FCS?#S+F7]VZO^%_\
M-;GZE^$_^"0NN>*_$?PX\.0_'O1[2;XA_P#!2WXE_P#!.&*<^!;R8:3J_P .
M/#]_KTGQ;DC_ +=C^TZ?K"V7V6+PD)(;FT:999-7D52#TMC_ ,$9-<^(GB3]
MG33_ -G[]HK1OB?X5^-_Q=_:.^$7BOQ;XD^'&K?#UOA1>?LJRW#?%GQ)=Z-+
MKFNS>*=%CL;6:;PVMA<6EWK%Z]I9/#:),]S%Y?KW_!8S]I35?$'PB\1:-\+_
M -G#P'/\&OVK?$'[:.@:?X+\#>)+#3O$'QV\5Z7JFE>)=:\8"^\8:A>:MIFL
MIK%[=W-G!=65Q%<BUCM;R"SL[>VC\N\&_P#!43]JSX=Q_!4>!=3\&^%[GX$?
M'[XY?M$^$KW3M N6FUKQ3^T9=7,WQ4\(^,8;K4KBRUOX>ZS:WEUI=OH2VMK=
MVUA,"=1DNK>VN8OC_8<<RC[2.+P5*HJ==1HU5A)TO:3HYFJ,JSIX1U'[.L\J
MDE2J*-HXA3A67,I;WPU_ADU=-V<D[7I72O+JE53NNJM:YU?PR_8%^"_QNU_X
MAZM\)?VR-/UWX)_ KX&>._CE^T9XT\0?!;Q/X<^)OP@L/!'B>3PM!X8E^%PU
MS4-+\4ZSXTNGL-0\(R:1X[^SS:9=3RZL=,GM&@D]VT3_ ((]Z!J?A+QE\:[K
M]K73H?V9M+_9&\-?MD^ OBKIGP?UG4O%?CCX=ZSXVE^'VK^'=1^&T_B>PG\*
M^,?#_B:"33WLVUW5K*^D\J2*\CMG>X3Y=\.?\%)_BGX'\4RZK\._@C^S!\/?
M 6L?"SQU\&_'WP1\,?#*^3X:_%GP3\2->F\3^+(?B=>:EXBO_B!XHU*XUN2W
MNM)OYO&<4GAR.PL[70A86PFBET_$/_!4_P#:4U_PY\5? T&@_"+PS\-OB?\
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M])3/^";/_AZ;_P#^5%'_ !&CPQ_Z*S#?^&_.>MO^I;YH/^((>*O_ $1>:?\
M@>#_ /FKS7WGYMTF "2  3C)P,G'3)ZG';-?I+_PP%\(O^DIG_!-G_P]-_\
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M\DT_9)_[*/\ $C_U$]&K^H&OP%_X+S_ KPG\</ G[-]CXK_::_9W_9KB\/\
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M5^DG_# 7PB_Z2F?\$V?_  ]-_P#_ "HH_P"& OA%_P!)3/\ @FS_ .'IO_\
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M<,/#+LSI2JOVM2G'E52M2BTFW>:TM>W\[-%?I)_PP%\(O^DIG_!-G_P]-_\
M_*BC_A@+X1?])3/^";/_ (>F_P#_ )45_H-_Q&CPQ_Z*S#?^&_.?+_J6^:/X
MA_X@AXJ_]$7FG_@>#_\ FKS7WGYMT5^DG_# 7PB_Z2F?\$V?_#TW_P#\J*/^
M& OA%_TE,_X)L_\ AZ;_ /\ E11_Q&CPQ_Z*S#?^&_.?+_J6^:#_ (@AXJ_]
M$7FG_@>#_P#FKS7WGYL[5QC:N,YQ@8SZXQU]^M.K])/^& OA%_TE,_X)L_\
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M4:&_ASQ+HM]/I>L>'M;T^/3M9TK4K5S'=:?J&GW,:7-K>6\@,<UO(@DC<%6
M(JUHOA#5O$L'B*Z\.^&+O7K;PAI#^(/%D^DZ4+Z+PSH,<J02:UKC01.--TN.
M>2.%[RYV0K(ZJ6!(K^E?Q)?_ +/'BWQ_X@\3Z-)^RKXN^ >O_%C]KF]_;:\4
M^/M1^&U[\;6NKR[UJ7X4ZQ\(=2UNZ7Q?<:-/8+HS> I_AP;A;S5Y)1K@D4RU
M7^W?!/1?@W\<-&^&/BG]E'P?^R7\0OV1/@IX3^#&MWU]X M_CYK/CG4?&.@)
M\48?B?9V5U;_ !7US7].=M1OO&^C^(O+T9]+M53PR\;%9!I_K54Y*2_LZM&K
M.6'C-SG)4X2GB8X>K2<8TW46+Y5+%4,(US5<#R8IU4KTQ>P2O[\;+:R5W9)I
MVT5KVBY+:2LEH?S((NER!V1-.=8QF1D2U81@=2Y (0#U; KJM(\#:SK_ (5\
M7^.-'\/)J'A#P"FC2>,?$,$-F=-T!?$.HKI.BB]F)!WZAJ+I;0I&KL&;?)L0
M;J_J8^*/A;]B32/%7P.A\767[,,7B33_ (K?$W1OAU>O+\$]-\#>*6M_@M>'
MX/\ B+QQX=^%]Q=0Z9\&=;^(-K!?6C?%75=6OC>3P0>([R)3<05XE^SY#\)+
M772O[9EA^P39_$__ (3G]DNXUS3/A[<?#V+PY=^%4\=ZW/XG7QI8>%KG_A6+
MZE-HJVX\8Q>"0VG)H;:?)K7EW3*U"XM]IAGB*>78A.*HS]FZBG4JPGBY4)/#
MP4(.K"$*;=6LW'ZM4J4(RI5+M![&S2YH]F[62=HO7LM=-[\NC5C^:R.+3I@3
M##82A3AC'%;2!3Z$JIP>#P:E^R6G_/I:_P#@-#_\17Z$_MF_$CP=\5OAW\&_
M%&FZ%\%]!\;V/Q<_:F\*ZW;_  ?\(>%/ _F_#G0O%WAA?A*_B+1?"=O:6]W!
M'I-SJL?AWQ!?0->ZQ9">22ZN3$SC\_J^GP>)GBL/&M.C+#S<ZU.5*4^?EE0K
MU*+:GRPYHS]ESP?)%N$HW29DTD[:.UM;6O>,7MTMM\C_ $.?^#3"*.+_ ()P
M_$E8HXXU/[5OQ-)6-%0$_P#",> ADA0!G &3U.*_J'K^7O\ X-,_^4<?Q(_[
M.L^)O_J,^ J_J$K^,?$'_DM>)/\ L9UOR@?083_=J'_7N/Y!1117QQT!7\:_
M_!X5%%+\(OV%!+%%*%^+WQ<P)(TD SX"T7) <$ G R17]E%?QM_\'@W_ "2+
M]A7_ +*]\7/_ % M&K[WPP_Y+O(/^ON-_P#59C3EQO\ NU7_ +<_].0/X6_L
MEI_SZ6O_ (#0_P#Q%:.D>'+KQ!JNG:%H.A-K&M:Q>0:?I6DZ=81W-_J5_<N(
M[:SL[=$WS7$\A"11KRS$ 56J:VBNY[JU@L&VWUQ<V]M9,;M;!5N[B9(;9GOW
MDACL8Q,Z>9>23116R;II)$1&8?V6V[.S2=G9O9/HVKQT5E?5:+=;G@V7;^M/
M\E]R/>M<_8W_ &I/#%YX5T_Q%^S!\8M%OO'7B"7PGX*M;_X<:G%-XL\4063Z
ME/X>T +;.NHZQ!IL<FH3V4+&2&S1KB3;&"P\M^(OPH\=_"#Q(?!OQ8^'/B'X
M:^+19VFHCPWXU\//H.LOI]^KM97T5G=Q*TUI=K'(;>XA,D<GEOM;*D#]P?A9
M\?-#^"_[1O[./[)'@#XC^!_%?PQ^$GP@^)WAOXI>-?$_Q7NO"_A'XE?''X_>
M#D?XJZUX-^*<S^(=(\->(M"TR2S\$?#;Q-=.GARTO;'4K>[N[:TO3)67^V;X
MN^'1\ ?#GX*? K2OA%XA_P"%!?L6^)/#7Q.U?XT_$_P)\5/B!H.D^)?B0_B#
M0+'P!\1-+NK;0O%?QJT&W>>.2S\#"_?2]&U 6L"2!)V'RE'/LQ^N83#U\%2=
M'%4G6C7@ZE#EP\ZF*CA\35C6JU)8>,X4<(E0E&I)U<9"#KTYTW3EI[.'(Y*5
MG%V::37,E"ZT2O9\VJMI&_*UJOP6D33(F"2QZ?&YP0DD=JC$'H0K*"<]N.>U
M:.D:*_B#6=.\.:#I"ZUX@UB]MM,TG0],LHKS5M3U&\D6&TL+&QA1I[B[NI72
M*""-"\KLJJ"2*_8?]A6UO_#/[(WQ\^)$-E^R5\3/$=POB;P%\'/@I\9C\ -/
M\;6OBO6M#9M?^,WB/7?B9-:>,AX6\$6*HO@KPWHUSY>M^*IX3"HAAES]F?""
M;]FCP_+X)\0^(W_93T;]E;2OA9^S9J_P"\7^&+WP'8_M%V'[4-AXH\+R>/)_
MB+>2W"?%6![;Q-_PELGBEM>C'@JT\$1Z7+8R)^Z)VQG$;PM7&488*==X:M["
M$J=?F=6KRTG[.-+V*J>V3JP<**O&M&CC'2KMX2<61I<RB[I<UFKK1+36_;2U
M[73Y+QU1^$_AS]D']HCQ7K&DZ!HGP1\3RZQK,'CB[M;*]TJUTQ[:T^&DOD>/
MKO6&OFA70[;PG<_Z+K$^JFUCMKK$!8R$ ^(^)_">I^"-431/&?ANX\*:S)I^
MEZM%I?B#34TN^ETG7+"#5-#U6&WNHT>73M9TNYMM2TJ\0&&^L+B"Z@9HI48_
MU/:[^T-\#?A_X0_:,UWX?>.?V>QXV^(_P _X*&2>(-6E'@;Q'KWC+Q9J/QIW
M_#C3+FXU$W5UJ,_B#P_<7%SX>TB/Y->T]8[I(;J."-U\MTO6/A!XZO\ PEK7
MPSU#]DOQK\4UOOV'M&_:%N_CSJ/PUU&RMOV:-!_9B\"Z=XGTSP)/\0K@:7:S
MZ%X@M/$^F>.[?P2X\=:3J5GI=G"D30A1YV'XIQ[=2IB<MY,-%3A"2]M1DJE*
MO&G*=>I5C.%*C)2C&E)*4IU(QNH*LH4:=&*LHRN[^3TLG9)6;:MKT2MJW%M_
MS9^'/".J^,==M/"_A'PQ=>*/$VH17<]AX?T+2QJ6LWL%A:S7U]-:Z?;QO<31
MV=C;SWERZ(1#;0RS.0B,1A>5IWFR6_DV'GQ,Z2P^5;>;&\;%)%>,+N5D8%7!
M VD$&OZ=_P!GG5?@!X*\2>"/%O[,VK_LF^'OV:+2;]LB/XR^*?B7JW@[3?V@
M])U^_?QSI?P>M/#^H^-9XOB'9^&+_P '2>$K?P;#X(#07E]-JZ:V'5Y 72^!
MOV)-)_9(\(Q_%W4/@-XD\.0Z=^S'XBM?''A9/A/X;\1:S#>^/M*/QBT_1-/\
M.75W\==;\1:1X=O]4LOB'<^,;BVLKB>.2?1-'AABC\O>?%O)7]F\MQ3C*KAZ
M-.$6WBU4J8G$X>I&K1]G[.G6IJC2KQPOM?:2PU55E-KW8I4+JZE#9N_V=%"2
MM*^JU:YK*S25M#^;3P5\/?$'Q'N==L_ GA@^*;OPQX;U3QAK]OI,%G/+I?AC
M1!&VK:S<J2N+2P6:-I]NZ0*V51@#CCX1I=QCR$TZ8E0X$4=LYV'HV%4G;[XQ
M7]#VNP:#;:Q^T1'^T#9?\$^-'T,_!?\ :13]G27X%W?P\M?$-_IDESX(/PY=
M_P#A"[H6<\+Z,9QX3/B[_BX]QK/_  D)NH7M%!'SW^VY\6O@[\0M!_;2\!^%
M/!O[,_A_1OA!\9/V=+7]FW6OA'X+\&^%_$NM>$=1T&?2_B.++Q#X=CBO?'FD
M3/:6VH^()[B2]AT[5)9)D>W$VP]F%S^MB<33I1P,I4JGL6Z]*MSTJ4:N(PF&
MNJO(HXAQJ8N$IQC"BZ,*-=MU'32:=)1BWS*ZO[O+9NR;VOII&RU=WRVMU_&S
M[):?\^EK_P" T/\ \15#5;.T_LV__P!$M?\ CTN/^7:'_GDW^Q6O5#5?^0;?
M_P#7I<?^BFKZ6+=UJ]U^:_R7W(RLNR^[^NR^X_V7_P!F0 ?LV_L^   #X'_"
M<  8  \!Z   !P !T%>X5XA^S+_R;=^SY_V1#X4?^H'H%>WU_G[B_P#>\5_V
M$5O_ $Y(^GA\$?\ #'\D%%%%<Y05_EF_\'!EM;/_ ,%@/VO7>W@=S<?"?+O#
M&[''PH\*@99E). ,#)X'2O\ 4RK_ "T_^#@K_E+]^UY_U\?"?_U5'A6OV;P0
M_P"2GS+_ +$-?_U89:>?F/\ "A_U\7_I,C\8_LEI_P ^EK_X#0__ !%>F?#3
MX%_%;XT7>KV'P@^$7C'XGWOA^SAU#7K;P/X5GU^31+&XE\BWO-5-I"4L;:><
MB&&:X>-))3L0LW%>=U^G7_!.KQ[\0O#GA[]HOP7X)T3]E?QKI7C^T^&D?C?X
M;_M,?$O5/A7/XP\/Z/KUZ7D\ ^([;Q1X/T>>71#>M?Z]I^K:T+@JMA=Z99W,
MMM)L_I3,L57P>"K8BA&E.K3=&T:T^2DHSKTJ<Y3DYTTN2G*4X\U2G!RC%3J0
MBW)>1&,7))Z+R5WHKI;/=I+9M=%HCXN\*_LK_M#>.I_&%MX)_9Z^)WBZX^'V
MIW.B>.H?#O@2^U1_".M6<3SW>CZ[]FMV%GJ=M!&\\]CE[B.)?,:/:03X<]G:
M1RSV\EI:QSVLLD%S"]O"LMO-"[1RPSQE-T4D<B,CHX#*RLI (-?T&_LZ^$_A
M9\./VRO$GBWX7?$GX:?$/]DSX=_M.7LFB>!_%?[4C?"O6/@UJ_\ 9NCRWO[0
MF@V6NZQ8V7Q@T?P^D<^G:#)"_B6Y\70:!#INJZ=Y-Q$TWY<_M(Q:D9/AHVCW
M/P8\1>%KOQ?\5Y_AYXX\(CPS8>/?'EE>_%+5KFV\0?'?2+:\FFT:_O99TGT&
MV\0PVENOA=XV51;$@>?@<YJXK&2P\J<(TI4,+6I3:GAZD)5J->K4H5J52=5J
MM35&$I4VJ+C"HY4WB:=*59MTU&-]+WDGLU[K@DTTDK-MV>MVDFHNT3XP4:4^
M[8NFML!9]J6K;%!P6; .T \$G !XKMO!WPU\6_$--1F\"^"-3\6VNC7&A6VN
M7^AZ0M]IV@R>)]6BT+P\=<OXHS:Z5#K.LS1:983WDD44UXWE!P02/Z.=6TWX
M4>&?&?[+OPR^+UK^PWXVT/PWX2\6>(_$/QX\%/\ L\V.@>-?VG/%'@.ZE^%W
MP\\7:/X#N+?4XO@E\/\ 4!;6&L:IXITV&PUGQ:!>ZW<"P9E-;P9XB^$OA7X>
M:OX?^->L_LO>$/V@?''@3]G'3/VD?#?PDUOP!IWPS\4VVC_M=:5=^&XGT[P3
M>'P%=>(+;X3O>ZA\0K?PN3;6VG[;S54B8LX\^?%4W2A*AE\ZDJDZ"IN%9UHN
ME5Q=2@ZRA&G2J.G3HT74J.?LIT*N(P5&M2BZTG3OV*ZR2MNN6SNHQ=M6UK=)
M;W49-/W5?\)X?V0/VB[KP[J?BJS^!7B^_P!%TCQ1XK\&WLNGZ'#?7@\0^ XW
ME\;VMMIMMYE[>6OA!$9O$>I6L4MAI7RBZG0NH/SFB:9(Q2./3W<#<42.V9@H
M&=Q4+N QSD@8'6OZ<OAI^U!X$TW6O@WX!A^(/P3\.>!O"/AG_@K[I5@^FQ>"
M="N='M]7\?:K:_!NPN/$ELD.HB/QMH,\<GAR.[NV/C&VCM+M3?"VAD7DM"TS
M]B_^PW7XW6?[,=E^P_-\//V96_9[UKX8R^"E_:,?XH'5]!C^)%O\3/L,I^+C
MR#57\2+\24\3V_\ PCMOX9^QMI+K)Y512XFQM.518S+9R3E?#K"*K[2I!8_$
M8)4XTZJ:K8R<*%/%4\/3E'FH.O-3Y:$?:#I1TY9KI?FMI[L)7;5DHJ[C>VC4
M=.W\Z$?AVZF\.W7B^'0GE\)V.M6WAJ]\31Z?&^A6?B.\L9M3M-!N=36,VT.K
MW6FVUQJ$%C(ZSR6<$MPJF-":R,:4(Q,4TX1%MHEV6OEENNT/C:6QVSGVK^I>
M'3/!6N7'@+P%\8_%W[!/@S1KC]NGQUX[^&6C?#B+X1ZMX?\ $WPF\._"3Q38
M_"X>/?#OAO5].\*W7]L37&G>'_!6M_$&X62'5;J=/&2S2%8'Y#XH:+\!;?XB
M?$2V^!NB?LOP?M8R?LP? A_!V@_%FZ_9UO/AG!XI'Q3\46_QE@UB+2TLO@-;
M_%^'PI#HB7%A91I);^&E=K7=K&)#5/BU2FJ;P,VY14XU(5[T*=.5>&'C4K5Y
M48Q5"G+FJ8G$0C-8>$+2IMV;/8=>:/:UO>;LI62N]7HDG:^CO9'\X-YX%UK3
M_!.B?$B]\.K;^ _$>NZQX8T3Q3)#9C2[_P 0:!#:7.KZ3%+G<MW96]_:3.LB
MJLB3!HF<*V.:2WL9$$D=O9R(V=KI! R-@X.&5"#@\'!ZU_13X \3?LZ^"/A/
M\9_%7B6P_8IO/C?X8\-_MU:OH.D>';#P[XL^'$/Q)M3\&C\-Y? WA?QD;N'6
M+>+4#XK_ .$'LS9W.D7LBZY%H"7&D*H'Y9?MUZE\.O$/Q4^'WC#X>6?P]T^3
MQI\ /@]XD^(=E\+[/2=(\)P?$^[\*6D7C#R_#N@A-&\,:I)?PF75]#TZWLX+
M6_>9C:QN[5Z67YU4QN)EAY8*M1@G74<0W:#=*:Y8<K3O&5)Q<:ZG:I*.E&":
MM$J:C%2YD[\NB6U[+?UZ/5=]#XE^R6G_ #Z6O_@-#_\ $5_3#_P:C6\$7_!3
M'QVT4$,;?\,J>.1NCBC0X/CKP'QE5!QP..E?S35_2]_P:E?\I,/'?_9JOCG_
M -3KP)7G<??\D9Q)_P!BNM_Z5 TPR7UBCHOC1_HQ4445_$I]$?B]_P '$'_*
M%K]O_P#[)%H__JRO U?M#7XO?\'$'_*%K]O_ /[)%H__ *LKP-7[0T ?B_\
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M.!^SO^R0,9..!\13P,X'WCVZD^IS[)_P\ ^%?_1)?VMO_$4?C?\ _,C7P?\
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M:0,"?V._:-3XQ^+?C!X[_:=^$?[6'PR\$?LHZK^R]IVD>'-3NOB'X=O-)L/
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M'XG:"-4ETU]6\"> -=\5Z8=;C"&>P-UI-C=1/JD8D0RP M<CS%+#YQG]D_\
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M+]YSU*2_>/EM*_-&T;2\K]O\T?T_45_,#_Q%C?\ !.+_ *)W^U5_X;'PW_\
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M._VJO_#8^&__ )NZ/^(L;_@G%_T3O]JK_P -CX;_ /F[H_XA]QK_ -$WF?\
MX)7_ ,D'UK#_ //ZG_X%_7=?>?T_45_,#_Q%C?\ !.+_ *)W^U5_X;'PW_\
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ME>SJQJ*%X*,I9T<52Y7[2I2C+GG91G=.+DVG=][W7DUWL?T_45_,#_Q%C?\
M!.+_ *)W^U5_X;'PW_\ -W1_Q%C?\$XO^B=_M5?^&Q\-_P#S=UXG_$/N-?\
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M /F[H_XA]QK_ -$WF?\ X)7_ ,D'UK#_ //ZG_X%_7=?>?T_45_,#_Q%C?\
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M_!6]58']AWXFY\V=O^0[\/>C32,I_P"1O[J0?QJ7_AQM_P %;O\ HQ[XF_\
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M^4@/^"%?_!603?:!^PK\11<9)\\:O\.?.R1@GS?^$MWY()!.[.#BGC_@A?\
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ME>ZNGG5IJM3E3DVE*UW&UU:2DK736ZZH_P IC_AQM_P5N_Z,>^)O_@]^'O\
M\U]'_#C;_@K=_P!&/?$W_P 'OP]_^:^O]6>BOU+_ (CCQ'_T*<C_ / ,P_\
MF\XO[-I?\_:O_E/_ .0/\I9_^"&?_!6N1&23]AOXENC@JZ/K?P\9&4]596\7
M$,#W!!!J ?\ !"G_ (*Q+$T"_L)_$00.0S0C5OAP(F8=&:,>+-C$=B037^KA
M13_XCEQ'_P!"G(__  #,/_F\/[-I?\_:O_E/_P"0/\I)/^"%O_!6:/R]G["W
MQ'3R598=FL?#I?*5_OK'CQ:-BM_$%P&[YILO_!"O_@K).RO/^PK\1IG0 (\N
MK_#F1E .0%9_%K%0#R,$<\U_JWT4?\1RXD_Z%62?^ 9A_P#-X?V;2_Y^5?\
MRG_\@?Y2;?\ !"[_ (*SMYF[]A?XD-YV/.W:S\.CYNT87S,^+?GVC@;LX'2F
M-_P0J_X*QO*LS_L*?$5IEV[96U;X<M*NS[NV0^+"PV_PX/';%?ZM]%'_ !'+
MB3_H59)_X!F'_P W^2#^S:7_ #]J_P#E/_Y _P I9_\ @AE_P5KD4I)^PW\2
MY$;&4?6_AXZG!R,JWBX@X/(R.#S4<O\ P0N_X*S3#$W["_Q'E 4H!+K'PZD
M0X)7Y_%I^4E5RO0X'' K_5MHI?\ $<N(_P#H4Y'_ . 9A_\ -X?V;2_Y^U?_
M "G_ /('^4>G_!"G_@K%'_J_V$_B)'\RO\FK?#A/G7.UOE\6#YER=K=1DX(R
M:L_\.-O^"MW_ $8]\3?_  >_#W_YKZ_U9Z*;\<N(WOE.1OUAF'_S>']FTO\
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M4*,*%?\ X2S<NT<+@C X%?ZN%%/_ (CEQ)_T*LD_\ S#_P";P_LVE_S\J_\
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ME4:C:6$S#PQ::7);V^B7:C4$,]T[Y]@UG_@EK_P38TO7[_2U_9J^)$T.F?\
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M?B"O@+QKX._:F_9R^'?[%7Q5U^^A\:^-?&_A_4+CX\?$'0;*6/Q#KL^FZ/\
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MX+T*_M++5=#\+XU#6]3,[:9)';J*]I^-_P#P3;\$:-\+_!VB>,?BOK$GP/\
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MVT;I%5+_ (*,_!/2O@/^RC_P3\^'EM9>&KWQ;X6\2?MI^ /%/C31=$M-&O\
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M+>:+:63WMM/=:6\UE<Q2'\R/V(_V3OV??&OP*^'OQG^-O@3XE_'&;XT_MD^
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M#HWQ:U7Q3XVFT[P_>27FH>$;'PU-H.DQ3>(E:RMA,^IWCN!M:4* 6"J2./\
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M.N_!;P]I?]C:9\.?B!\/]4TV70?%>G6]AA)U\1:?/>2W2)=S/]JC5UZ[0_\
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MD0W&GO'%;ZGX=U[5;%-"15TJQEN%NK:VCN88W67X)_\ !2']K/\ 9Q\'^&?
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MAS-VW=M]7_.->_MF?M=:E'\/8K_]IGXU7*?";4]/UOX9[_'.J(_@K6M(TO\
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M^T7PE<^+-0.K>*;C0;*=F2PG\1:JS:CK,L9+WUXQGF)<DUQ,W^JE_P"N;_\
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MG4&^',,UN8M&TZUTZVN-+MGALXRUO;$7'Z]5\W_LT_'F\_:'\/>/O&</A/\
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M#J_Q!1#X@F\-Z#?M?6CJLVM1QRSIG]K=9\.Z#K?[0WQKL="T+X<^(OC5X?\
M^"3'[-,W_!/CPS\2M.\#ZEX?U77Y/"/A2Y\5S:#X;\=>=\/-:\7Q6EQXVN-*
MLO$$4ULVJMJ4ELKWJK(.RIC\+@</@ZE/"Y97I5UBJE:MA,-'"8:M#!8W#T:-
M6#DIJE3CB<72Q]7$R>*I4*&'Q6)H.LG3KDJ,I<UY33BXI*;;DFX7:W3;:BX)
M6BY2<8R2=T?D9X[^-7[?_P"RA\0_#VJ^-OC/\3?AK\1/&7P0^&/]A:E_PF.A
M:Q<:Q\"I=.@U;X4::Y1=5TDZ-I6GK!<^';"[@&J:$5'EFVF+YX#1OV]?VR_#
M^@:MX:T7]J?XO6/A_6-1\2ZKK%BOBU;O[9J'CL2CQ?+/J%];W>IQQ>+1<2_V
MW8Q7T5AJ7F;I;5F"%?ZG?$_A/P;XQ_:HOOB?XSUCX!:[K/A+X)?\$[_!'Q&^
M'/AOP)^SY\3[G1-$O-)NY?BGJ&E7/Q1\2V_P[^'?PNTIK*31_B9J7A#3_$'B
M_1T @T.RT^.&/SOD[QQ\//V5-!T']N?XW6'@/X+M/_P3E^*_[47@#PUX$30/
M#%UX6^+'AG]J6$R?LUWMQJ-A#>:?XPN/AUXEGUB#PSJ!-Y+I&E3:;:1",6L;
M1^'A>)<MKPI0Q&082MB94,"ZSH8>BZ2KXF%&&$H<M;#MJ$L1C,)@\/556K3C
M]9]HW3A&4#5TIK156HIRMS2:?+&UWH][1E*4;)^[:S9^$'PO\/\ [77[6OQ4
MC\8>"/$GB3QC\2OA#X.\*ZE)\4O%/C[1? UK\+?!/P^^Q:!X&FU+XD^)M1T+
M0O"6G>'F:PT7PL+W4K>5Y?)LK3SY/EKH_P!H/]HK]O7P_P"//B)\*/VAOC9\
M5X?&FG:%XF^%'Q$\-:EXBTA['4O"OBY['4/$^B7<OAJWCT+Q#H/C-;;3-3GU
MZTDNSXBLX["\BU6>W,9/T_\ \$R-9TZX_9]_X*!_!S3?AWX ^-_Q7^)?@K]G
MN^^'WP3^)>ORZ'H?Q/TSP/\ $F\N/'5G-Y'B7P?<ZTNAZ?J]CK\NC0>*-*G=
M[*'4LW4.G26LOC/[57P9^".C?\%$/B#\%_V>_!FI_&_X31>)-"TW2OACX(^+
M,.G7.H>(;SP9I=_X\^&O@[XO:Q%JD%OI?@SQK-K7AK0]9O/[35-.TJ"W^UWI
M N9/H88JA/.\;@,1@<(J&685U<'-X/#<\:%/#Y97J5(XBMB80PU*57&SH4:<
ML/0H5'A:TOK:>'KPCERM4XS4I7F[27,[<S<E9I1;D_=3OS2E[R]UW1X]H_[=
M7[:?@[Q3?>-](_:4^,&@>+]0\,^%?"VI:X^J0QZC?^%_!$"Q^";*\AU'2I(+
MN/PQ;1HOAW5I;635+.%$-KJ15$(^D;3P[_P5+\-_LZ>,/$VG?$?Q_#\#_&?A
MRY^+/Q%\-6WQD\$ZOXRA\$?&+5+31]8^*7B_P3)K%_\ $_P5X'\=WUS8GQ)X
MM>#1-%O+:YAU+59UM;AIV^D?^"Y'@CP[I/Q8^%OC/P[\#=<\%V=W\$/@1X0F
M^)B?&WPK\2?"^LWOA?X8:;9WOPU@\)^'+*-]+\5>!KA&T_Q%XEGO&&NWJ,[6
MML[%:QM)_9X^+W[%7[#'Q9\?:5X'7XF_%;]LKX!C0?B5XMT?QGX+U;X?_LR_
MLJWU]::YJ.AZX\7BUM8\3?&+QV;&QDO/#UGILEC\._#Z)"\5SJ]VUO!PK'X'
M$9;D^.P^!R?"XC-,1@Z<,'BJ&!K>T]E4A&<(8FC7I4J,L%0=6I3J5%4G"7L\
M/##1Q%:%&=<LE*<)2FU33;E&4E;1.]I1;:FTDUHFKRYFDV?"/@SQ=XW_ &,O
M$'[2'[/GQL^'-WJ.@_&7X2M\-/B=X$L]>TVUN1+=1:?XV^%7Q \+>*[./5=)
MO8M UA],U^QO=.:[L-=T*_U&RM[E)+J.>'FQ^W/^V<WA'PYX%F_:<^+4GA7P
MHG@P:%HBZ_$EI8/\.KRSU'P&XG^Q'4KX^#-0T^QNO##:K?7\FCM:PI:ND2LC
M>Z?\%!C;S^%?^"?FI:Y)>2?%S4OV$?ABWQ1_M0.FL&SL_$'B:S^&$^JQ2;66
M>;P1% MM(Z+--816K2[@L9K\XZ]S T<)F&'IX[$X/#3Q%:5ZSG156F\3A)2P
MCQ%"%;VGLU4C0BZ51/VD\/'#J<YJG"V;;BW%2=EM9V=I6GRNUKV;]Y/3FYK)
M)GT!\/?VK_VF?A-XF\?^,_AI\=/B+X*\5_%749]9^)6NZ)K,:7OC76[G4;K5
MY==UQ;NUNK677?[4OKR_BUJVM[;5+:YN97MKN$-M'W5^QE_P4^_X9"^'KZ?8
M^$OC-XE^)EGJ7Q=UR":W^-4<?P4\>>(?BCX7E\/V?B+XI_#WQ#X?UKQ!#K/A
M:XN)M0N)OAMXG\)P^,%@L(O$L5Y)'.\WY*T5MC,GRS'TJE#%8.C.G5=-UE!.
MC*LJ,)4J<:TZ+ISJPITYRA"%24HTTTX*,HPE$C.<6G&335[=4KM-M)W2;:3;
MMOZL^B]._:^_:ITKX50_ [3OV@OB?9?"&"$6T/P^M/$#0Z!!8KK \0II4+"#
M^U4T2/7%35(]$.I'2A=HDK6;%:;%^UU^U+!X@\2^+(?C_P#$^+Q/XR\:^#?B
M3XLU]/$+#4_$7Q ^';;O ?C+5I_(_P!)U_PBW.A7I539GHC5\[45T_4<#>;^
MI8.]64IU']6H7J3G*$YSJ?N_?G*=*E.4I7E*=.G)MRA%I<TM/>EI9+WI:):)
M+7333YON[_4FB?MO?M@^&QX?&A_M(?%/3T\*3>-9O#L*:S:7%OI;?$F[FO\
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M.SE4T=FVW=M)IG#?$O\ X*$^*_'/[/7BK]G/PE\$OA=\&/"_Q%3X=P?$W5O
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MYSG*,4YS<U"E7H0ND^5:R:Y9W3;GS7CRWCR\DF[V7X7_ *-J*_$']G3]N/\
M:T^*G_!5_P"/_P"S/KGPXTB']FKPE\(/ 'COPS>?VYHR:]X5L/%6F+J6B>+K
M[R--%_K#^-)94L7\//>?\4Z1YQFG&5'[?5\YF>5XG*JN'HXF5"4\3@L)CX>P
MK0K*-'&48UJ4:C@WR58QDE.G+5.SBY0E&4MH3C43<;VC*47=-:Q=G:_3S"BB
MBO.+"BBB@ KY9^-/[('P?^/WBZ_\6?$VQO\ 7#J/PAU[X-RZ.9K:/3[;0]>U
MVU\1MKVF3"U.IZ5XLTO5;*UN-(UG3[ZWDLW@C81NPS7U-16U#$5\+4]KAZLZ
M-5)Q52F^6:3WM):IZ+56:Z,32DK-)KL]4?G;KW_!/FVO+W3]<\*_M)?'7P-X
MNO?A_P"'/AG\3/&FCR^ ]1\3_%KPWX/6YMO"M[XHU#7/!VHC3?%NA:7>76DV
MGBSPU#I.JR6MQ++=//>,+D<W\8/V2=8^,W[7O[*/B'4/"=U8?"?]E#1I?$5Y
M\0M5\5QWNK?%C738)!X-\#WVA1K+=7]IX1\3:=9>.M6UC6S%'<ZN(6L5><RN
M/TVIK-M5FP6VJ6VKC<< G R0,GH,D#/4@<UZ$,[S"$U4=6,ZD:&)P].;IPA*
ME#%47AZDHRI*FYRC0DZ-%574A0ARQI0BH4^6'3@U:VEXR:WNXM-;WW:O*UN9
M[WN[^5_&;X87/Q<\$3^$[#X@>-_AAJ:ZGI>L:7XR\ 7UC::]IM]I-TMS#');
MZM8:IHVL:3> /:ZKHFLZ;>Z;J5G(\%Q 059?BRP_X)H?#_1/#EO/X=^+/Q-T
M'XSP_%?Q-\9Y_CO90>"V\3WGC/QEH5MX8\3P3>$)_#,GP\C\+ZMH%E96$GAN
MV\-0V<4EG!J$<@U)6NWXWPC_ ,%(]2O_ -H>Q^"OBKP1\,(+;Q>_QCMO"$/@
M/XT:1\0/'GAN_P#@[X7U7Q=>VOQ:\/:-I3:1X2E\1Z/I4TMA;V>NZE=:7<2P
MVFH0/(TC1;'P4_;T^+'C_6O@KJ'Q _9[TSP-\._VDO ?C+Q5\(+_ $OXD6NO
M^+X]8\"Z#/XCO]!\;Z/<Z+I&E:1!KNEVT]QHFKVFK7%M!MB34UA:5C#Z5+!<
M19?1E"DX4*/(L6TJV!?MZ<X8GFBN:<I8FE[/!XIU<-^\HM49RG3=XN4N5&;N
M]7?EVEO>'9:.\H6EH]4K[H]1UO\ 85T_4O"GPQCTWX]_&O1?C%\)]:\5:WX8
M_:!34/"VI>/YSXX65/%FA:QI>H>&Y?!E_P"$]6B:WB3PXGAZWL=-%A8R:;]E
MFMQ*:.M?L$VT]E\/=6\)_M'?'WP;\7? ^@>+/"NH_'"#7/#GB3QWX[\-^.-9
M'B#Q#I'BV#Q3X>U7P[<6\6L 7OA@6&CV2^$F2.WT9(;16MW^0-4_X*3^,_B#
MX4_:*^'*Z9\-O"7Q"TC]E[XG?'/X?^*/@Q\7].^+D/A>#P;JFG^&KOP_XWO]
M/TBPTK2/'.FZAK.GW0ATB]U?3F*W5N)E>U$DWONJ_P#!0!_A?X3^)6@^+/ =
M[K?Q$^&OPR_9W\3?#^P_M^.&;X[W/QUMK+PYX=_LZ8Z9)_8U\_Q 2_T+5H5C
MU9K*-8=0E"1W*1#HEA.)J7LX\T)576ER44L%44H8F=.%[N,J-3"3KYA*#H<T
MJ%*=2M4=*$>>9/-0=WTLE=\R^'5>?,E#>UW9*[>A]%?##]C'X4?"/6?AGK/A
M"\\4Q2_##X6^+_A;ID-_JD5\FN6OCO7;+Q+XK\4^(YI;3[5J'BO5]<LVU"YO
MUG@MS-=W.+0*T:Q^3O\ \$Z_!NB:?\/X?A?\8_B_\)];\&?#S4?A#K?BKPK?
M^&KG7/B#\+M0US4O$8\*>*&UGP]?V44FEZOJ^I7>A:[HUIIVKZ0][<FVN-TF
M5P8/VZ/&NI_M6:I^SO;_  X\!:/8>&M9T7PWXDL_%OQ4MO"?Q?U4:OX4M/$5
M[X[^&?@35M&@LO'W@#1;R\_L*74-'UE]0NKRUO9X[:#[*;:3P<?M\>(/A)\)
M?@7;>$_#5KK=_P#%C6?C'=0>,OVF?C$OA;PE9MX(\97-A'X(N/BBOANXTL>,
MO$[W!@\#Z+JL&FV\6FVC++=71M'5HI87B24X.-9RK8F-"K&$ZV%JPJTJ]',,
M5&I7]I.5-)4_K551JQ=W4<U::@-RHV>FD;JZ35FG"-HV2>[BKKMKH>RV7_!+
MCX>>%/!WP;\)?##XS_%[X>S?"3X5ZU\$)O$ULW@SQ)XA\:_"_7];O/$-_HVM
M7'B;POJ-IIFMIJM_=W%KXK\/6>F:S")W5Y)B(VC^DO@9^R!\.O@#X@\)^(_"
M6M>+]3O?!W[/_A3]G33D\0:C9WL5SX-\(>*=:\6Z?JM^8;"UEN/$MSJ.N7<=
M]?"2.WFMTB5;2.0/(_T7X.UN[\2^%/#?B&_TU-&OM;T33-4O-)CU&SU>+3KF
M]M(KB>SBU73WDL=2BMY)&CBO[1S;W<:K/%A' '25XV)S?-*\:M#$8N=2,YU?
M;)JDW4E.I.<W4J0CS55SU*CBY3E&*DU3M%V-%3@FFHI-)6WT22223VT2NNO7
M4_-[]CS]F#Q!X*_:"_:L_:I\>^#(_A[XB^/7BFPT[P;\/QXB@\2-X2\&: K?
MVSK$\UDITS3]6^)WBE)/&>K6&FRR1P&2TCN7>Y23;^D-%%<V-QM;'U_K%>W,
MJ5"A",>=QIT<-1IX>C3CSRG-J%*G%.4YRG.5YSE*4FVXQ459=V_5R;;?S;?D
MMEH%%%%<A04444 %%%% $<T2S0RPL2%EC>)BIPP612A*GL0#D'UKX0T'_@GA
M\$/#-SX$O-#U#Q?I]SX4T3XC>#?%+6]]ID4/Q=^'7Q/O=4U/Q%X!^*%K%I4=
MMXAT2UU/5);_ $&\BCL]<T6=#]BU1$N+I)OO.BNG#XS%86-2.'KU*,:MO:1@
M[*=H5::YEUM"M42[<UU[RBTG&,K72=MK]-4_S2?R/AGX.?LA7G[/.HQ^)=+^
M-'QH^+.B> ?!>O>'?A=\(?$NH>"]-\.:1IUQ$DEEI4]YHWAK1-0\5:G:V]G;
M:#H.L^,M3U&32K$AG=[AKB[EY?\ X)[_ +*^J?L\^'OC7XW\7^'8/"'CK]H;
MXR^*/BE>^![?75\36OPT\)W;QVG@SX=:=JZQI!]ET/3(GN[RSTT_V5%JNHWI
MM=^6D;]#J^<_VH?C7K/P%^&+>-=!TCP1JFI3Z]I.@Q7'Q)^(VC?"WP'H:ZI)
M(C:UXF\6:O'<M%8V?E@+I^E6%_JVHSR16UI;@L\L??#,,QQWML$I0G5S.>&I
M59/DH.HJ%2=6E3ERNEAU%UINM4J3A[2=1<SJ>]-3CDA"TK64$[;NUTDWUDW9
M62O:W3:WE?[0?[$>C_M&>)]1NO%WQF^+.F_#CQ-_PB9\;?![2[KPS<>#M?D\
M&ZA:ZEILNE7^L>'M1\3^");^XLK3^WI/!VLZ1)JPMXW=XI]\KYEM^P?H>A_$
MO4?%W@;XV?%WX??#[7?B%;?%/Q#\%O"MQX3MO!^J^-$-H^I7,>NW7ANZ\;Z9
MHWB">QMKK7M T[Q%;Z??7*.X6)9I4?PCP=_P4G\8?$?P!\-[CX=_!CPYXP^*
M'C_X]_$+]G<V.G?$D#X96/B7P!IK:I<>-[+QFWAQK_6/ >HV:B:WFMM%CU/<
MZVZPRL1+743_ +>WQ C^!<GC2^^&OPJ\$?%#PY\<?''P"^(NG?$WXWZ/X-^$
M_A/Q7\/;DPZUJUAXYOM+_M;Q/I>JQR6C^'M/TGP^VK74ER8KJ.V6!I7]18;B
M6A"&%YJ=.$9RPD</*KE]DW)TO:RI2DW?FPBIPQDX^T_=4X4ZNM-..:B[RLV_
MBO:=]$G:Z\I)N*TU=UN>M:+^PYIOA;XHW?C'P=\=OC=X0^&FI?%*X^,^K? /
MP[KNB:?\/=1^(-\Z7&ISR:C'HG_"96_A35M01=4U/P3:>(8/#UY?;VDMOL\D
MEN^#H7_!//P/H7CC0;^+XK?%2[^"_A'XIS_&SPA^S;<W?AS_ (5=X=^)4NK7
MGB*#5[:YBT%/%UUI&G^)M0OO$FG>&;[Q!<:-:ZS<O<B!D5(5^:O"/[=WCWXM
MZW\'OB[X'\.74VFW7P!_:2\3:Y\&M,\1QW&B^,/&WPDU6"T2+1/$[Z9&UY:W
MT-M/-X;U*72H&N$NX(Y[1&9F'M6J?\%'=)N=!UWQ3\//A-XE^(VA^%?V1]$_
M:>\2GP_>F?5=+U/Q=?06?A7X7C2;?3;FXN-=N8DUK4]7O$*_V9IN@W\J6-U(
MHB%5,-Q-3E[-3YIRI_5ZR3PD?8U*=:MA(JM.2BEB>93ITL9S.M-5)4Z>(;YX
MI*5!]K7NM]4U&6B_EV;C:RM=JSN_<_#G[%_PR\->#?@SX'M=9\7W>D?!'XI>
M*/BSX<>_O[">YU77O%WB#Q7XBU33_$##34BO-%^U>+]3MX;6"*VE6TCMHY+B
M1D=Y/$[+_@FAX&M/%WPOU!_C;\;KCX:?!'XP-\;/A'\%6UCPY'X'\'^*Y]1U
M'4[G3VNT\/?\)+KGAA+C5]372]$U;6)XM&BO94L94V6Y@\[T/]K[Q)\7_!_P
M6\2>*(/"^G_VM^U=\)O 6CZ]^S1\>M.\9>"]?MO$L=[/):>++Y]"M-56STB5
M&T[Q=X)U;3-.NKZ1(Y;.\CC!">F_L[?MR>+OCO\ 'SQ;\,F^'W@/PSX8T#7?
M'GAZ32KSXH6T/Q[\,2>"-7O-(M->\>?!W5-)TZ^L?#/C=K%]0\,ZGH>H:O"-
M+NM.O+F1H[LF")4N(L-#%UO;M>RC7JXQNKA9*#G.K[24)2E*]:;Q&(5Z2C6C
M[2K133J.$G>C+ETW:4;)]DUMLE9;Z:)[:JKX1_X)H>!?"7CGPGK\/QC^+%YX
M$^'/Q&\=_$_X;_"=CX.M/#7AGQ'\1K+Q+:>)%U#6[3PU'XM\6V2R>+=:NM(@
M\0ZU=-IDMPBI),D,033_ &B_V8];L?V%+O\ 9!^"/A.^^($NM^%XOA=X>UOQ
M-XHT_0[KP-%?-<2V7Q-U76$M899KKP=?_9]6MHM%LQJ,UY!;BV1<.P_1BBO*
M_MO,95\-7KUOK#PM:CB*<*B48.M0G5J4YS5'V4I3]I7JU)S<N>I.I.524G)L
MT]G!)I*W,FGU=FDFE>]E9)6V5M$>3_ GX3:)\"?@W\,_@]X>>2?2OASX+\/^
M$X;V=M]UJ<VD:=!:WFK7TQ >XO\ 5;R.?4+VYES-<7-Q++*S2.Q/K%%%>95J
M3K5*E:K)SJ59SJ5)O5RG.3E.3\Y2;;\V4DDDEHDK)=D@HHHJ!GXO?\'$'_*%
MK]O_ /[)%H__ *LKP-7[0U^+W_!Q!_RA:_;_ /\ LD6C_P#JRO U?M#0!^+_
M .V+_P II/\ @BO_ -DA_P""K'_JMOV6J_:"OQ?_ &Q?^4TG_!%?_LD/_!5C
M_P!5M^RU7[04 %%%% '\HW_!W)_R8[^SO_V=/H__ *K?Q]7^?J\:2!1(BN%9
M74, 0'4Y5AGHP/0]17^K7_P5M_X)C6W_  5,^"'P\^#5U\9+[X*IX"^*5I\2
MU\06/@ZS\:2:F]IX<U[P^-(?3[S6M$CMD<:XUT;M;B5E-N(O)(D+I^ 7_$'O
MI/\ T?OXA_\ #":%_P#-_7]%>'''G"N0<+8?+<US-X7&T\7C:LJ*P6/K6A5J
MJ5.7M,/A:M-\RULIMK9I,\K%X:O5K.<(<T7&*OS06J6NCDG^!_$?+!#/CSHH
MY=IROF(K$'D$@D$C()SBAH(6C$+11M$  (RBE %Y7"XP,'D8'!Z5_;A_Q![Z
M3_T?OXA_\,)H7_S?T?\ $'OI/_1^_B'_ ,,)H7_S?U]Y_P 16X$_Z'DO_#;F
MW_S"<WU+$_\ /K_R>G_\F?Q(1PQ0J4BC2-"22JJ I)ZD@#!SWSUKT[Q[\6_&
MWQ.\'_"GP/XVO-/UO2/@OX<U/P?X#O9M+MU\16OA74M6?6XO#VKZ]EKW6])T
M*_FNV\,VMZ2NA6]]>VMF1#<%1_9#_P 0>^D_]'[^(?\ PPFA?_-_1_Q![Z3_
M -'[^(?_  PFA?\ S?U$O%+@&<Z<YYRI3I2<Z4Y99FKE3E*$J<I0D\#>+=.<
MX-IJ\9-/1A]2Q-K>RTVMST[6WM\?=+[C^(K[%:;57[-!M1F91Y285F.6(&."
MQ +>O>O:X/CIX\L?@1>?LXZ1'X6T+X9ZSXWL/B!XJ_L3PS9Z?XM\<:]HMM-;
M>'+?QIXJ1WO=>T+PL+BXN/#FBR1PVNF7L\ETIED((_L*_P"(/?2?^C]_$/\
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MT?0]'T3PYI-IH>@>'O#NBV[-:Z+H&BZ596]IIVF6I\FW1789>1V;S&O[:_\
MB#WTG_H_?Q#_ .&$T+_YOZ/^(/?2?^C]_$/_ (830O\ YOZSI^*/ %*G"E2S
MA4Z=.$:=.G#+,UC"$()1C",5@4HQC%)))6222']2Q3WI_P#D]/\ ^3/XE**_
MMK_X@]])_P"C]_$/_AA-"_\ F_H_X@]])_Z/W\0_^&$T+_YOZO\ XBKP)_T.
MW_X;<U_^80^I8G_GU_Y/3_\ DS^)2BO[:_\ B#WTG_H_?Q#_ .&$T+_YOZ/^
M(/?2?^C]_$/_ (830O\ YOZ/^(J\"?\ 0[?_ (;<U_\ F$/J6)_Y]?\ D]/_
M .3/XE**_MK_ .(/?2?^C]_$/_AA-"_^;^C_ (@]])_Z/W\0_P#AA-"_^;^C
M_B*O G_0[?\ X;<U_P#F$/J6)_Y]?^3T_P#Y,_B4HK^VO_B#WTG_ */W\0_^
M&$T+_P";^C_B#WTG_H_?Q#_X830O_F_H_P"(J\"?]#M_^&W-?_F$/J6)_P"?
M7_D]/_Y,_B4I5ZCZC^=?VU?\0>^D_P#1^_B'_P ,)H7_ ,W]'_$'OI/_ $?O
MXA_\,+H7_P W]'_$5>!/^AV__#;FO_S"'U+$_P#/K_R>G_\ )G["?\&W?_*(
M#]F/_K_^+O\ ZMWQI7[HU\-?\$X?V+H/^"??[(7PR_93M_B%<_%*+X<S^+IU
M\;W?AZW\+7&K_P#"4^+=:\4E7T2VU'58;3[$=7-DI2^F\Y8!,VQI"B_<M?RI
MQ)B\/C^(<\QV$J>UPN,S;,,3AZO+.'M*%?%5:E*?)4C"I#FA*+Y9QC)7M**=
MT>U1BX4:4)*THTZ<9+>SC%)JZT>JZ'\4/_!X3_QZ_L"?]AC]H'_TS_#FOY2/
M#O[3^K:'^S5X?^!T=MX@TSQC\*/CU%\>OV?OBEX5UB'0M3^'&M:U806/C_2K
MYXHO[4OX-<GT[1]<T6:QN[8Z9K.G[KE9[25XF_T:_P#@L!_P1[M/^"KL7P#C
MNOCYJ/P0_P"%'7GC^[C-AX#L?&__  DA\<VGAVU9)1>^(-"&FC31H =6C^U?
M:?M15A%Y0+?BI_Q![Z3_ -'[^(?_  PFA?\ S?U^Y\#\<<&Y;PED^5YSF/L<
M9@:N*K3HO!9C5]E4GCL95IOVF'PM2E-5,/7Y:D5.49TJM2C434IP/,Q.&Q$Z
M]6=.%XSY4GS05TH03T<DU:4;K3=)KHS^5C5O^"A'[;VN^(?"'BG5?VF?B1=:
MYX!F\8S^#KA3X<M+'0W^(FG1Z3X^$6@V.@6WAZ^A\::=%';^)K;5=*O[?6&7
M[3>Q2WA:X/J7P1_X*)?%'X?_ !+\4?'_ .*7BGXH_%_X]:5\!O'_ ,"?@9XB
MOM?\.Z;X8\!Z)\2-)U+0]83Q)9PZ/;ZO?:%HECK&J77AC0?#L^G6]C?W"(=E
MC#' G]*O_$'OI/\ T?OXA_\ #":%_P#-_1_Q![Z3_P!'[^(?_#":%_\ -_7T
MU3CWPOJ4I47B\)"G.G*C)4<ES"A)T)RE.K14Z.70G&E6<ZGM81DHU%5J\Z?M
M)WR6%QB::C*Z::O5B]5:SLYM-JRLWM96V1_%IX+\6^+/AUXF\.^-O WB;6_"
MOC/PEJ=IK?ASQ7HE_-9:[I&L6,@EM]2M;Y&,GV@2 M+YOFQ7(:2.ZCGBDD1N
M]^+OQ^^-/Q\\1:+XK^,WQ)\1?$/7_#>FPZ/X=N]:_LZWM- TJ"^FU1;#1-$T
M:PTS0=*MY-2N)[^Z6QTR WUY-)<7K7$K%J_L._X@]])_Z/W\0_\ AA-"_P#F
M_H_X@]])_P"C]_$/_AA-"_\ F_KNEXG^'LJL:\LUI2KPA*G"N\HS)UH4Y_'"
M%5Y?SPA*[YH1DHN[NG<GZEB4K>ST[>TA;2UFUSZM65F]4?RA^//VZ?VOOBA\
M,W^#'Q"^/'BCQ5\)WMQ:KX!OM$\#6WA^UB\VUG<Z?%IGA2QN]+N+B:RM)+R]
MTVZM+V^:!/MMQ< L&@^''[</[6_PA^'>E?"/X:_'3Q-X6^&&AZKJ>NZ/X$CT
M7P3K'A[3=<UD_P#$VUFTM?$?A;69(M4U%0L=U?\ FFYDA2.#S!#&D:_UA_\
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MZ';_ /#;FO\ \PB^I8G_ )]?^3T__DS^)2BO[:_^(/?2?^C]_$/_ (830O\
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M,WB6\CNTTNTT^\,4-N(KJ,B0OS]M_P $?/@7;>$?#?@]/B1\57L/#'[?EO\
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MSJ5)RJ5)R=Y3G.3E*4GU<I-MOJV4DDDEHDK)=D@HHHJ!A1110 4444 %%%%
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img75897552_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_18.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %_ ZH# 2(  A$! Q$!_\0
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M-/\ @L!_T<OX:_\ #(?"O_YGJ_$*BM/]3^%/^B;R+_PU8'_Y1_5WY6/;U_\
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MI>WNH(IE#*60!@2_]4.$N;E_U<R'FMS<O]EX#F<4TF[>PO:]DWM=V[![>O\
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MJZRO -73LUI0W33371W730]O7_Y_5?\ P9/_ #/V]_XB-/\ @L!_T<OX:_\
M#(?"O_YGJ/\ B(T_X+ ?]'+^&O\ PR'PK_\ F>K\0J*?^I_"G_1-Y%_X:L#_
M /*/ZN_*Q[>O_P _JO\ X,G_ )G[>_\ $1I_P6 _Z.7\-?\ AD/A7_\ ,]1_
MQ$:?\%@/^CE_#7_AD/A7_P#,]7XA44?ZG\*?]$WD7_AJP/\ \H_J[\K'MZ__
M #^J_P#@R?\ F?M[_P 1&G_!8#_HY?PU_P"&0^%?_P SU'_$1I_P6 _Z.7\-
M?^&0^%?_ ,SU?B%3/,C\PQ;U\T*',>X;PA. VWKM)[XQ1_J?PI_T3>1?^&K
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M  6 _P"CE_#7_AD/A7_\SU?B%11_J?PI_P!$WD7_ (:L#_\ */ZN_*Q[>O\
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M$7*4%P[D+G&,92@LKP#E&,FU&4HJA=1DX346TDW&23O'0]O7_P"?U7_P9/\
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M_F?M[_Q$:?\ !8#_ *.7\-?^&0^%?_S/4?\ $1I_P6 _Z.7\-?\ AD/A7_\
M,]7XA44?ZG\*?]$WD7_AJP/_ ,H_J[\K'MZ__/ZK_P"#)_YG[>_\1&G_  6
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M_#'[$W[=7QU\ ^"-%^%7@BY\/Z?<_"3X]>+]">Z\<1ZG>6TGQ'UWPWH26*>
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M6_QO^-?QL_:'^*-S^R_X%\.?LK^)_A/?> ?AIINH_%SQ:_[5\=QJ/@:R\?\
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MC^S^*-5N8+]KFX6;4U>*V>"3\C?^"A?[*?AO]C+]I_7?@IX+\<:K\1/ ]QX
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M0+]/2?\ !8G_ (*%2_ L_L^M\;K/_A$F^'__  J=O&(\">#Q\96^&'D_9O\
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M2\!ZEJ,'BC5K?3K_ $":]M'-E]DU>\N[6VO]2N+>>\T_36NIM,\N[$+#Y_\
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M8:O9?$^U\50:#'\;M1ECTHW-UH4FC2Q63_"N2^7P[;RP/?QS^:^Q?R?^#?\
MP6(_;Y^ G@'X4_#SX;?$OP3:Z=\#[;4-,^%7B+Q+\(?AYXP\=>#O#FK-/)J7
MA+3?&?B#1;S74\+WDMPSS:0+I86"0Q%O+A11XWH__!0S]JW1?@;\;/V<(?'6
MA7_P@^/_ ([UGXG^/_#.M>!O"^K36OQ!\0ZG;ZQK/BWP/JUW8/J/@35[[4;6
MWN&N?#EQ9O \*?9S%@YXWPWQ16QTZ^)S"$\+1SC 8_!X=9OFLE"GA<5F,9S2
MJPFZ<_J6)P;EA8S>&KUL-.,U34_:.O:TE%*,&FZ<X2ER03?,J;2T=FN:,O>L
MI)-6OL?T _M@_P#!*?\ X)L?!SP%^U%\%]"U_P +_#WXZ_LV_!K3/&O@WXM7
MW[2M]XV^)WQ7^(.G:!::_KOAGXD?L\1Z+_9/P]\/^)89I+?PQJ6GW,+/<2V3
M--&C'?\ F)_P2R_9-^"'QB^&/QQ^._[1_P !9/B7\/O FO\ @3P;I'BOX@_M
M(:5^S'\!O"FK>)I5?4X/$OB^!Y?''B7QLUNZ?\(]X=\+:=>V\C,JWT8>5"/#
M/B7_ ,%=/V\OB[\'-9^"/COXI^&M2\.^*O"^E>"/&WC"T^%_@'2_B[X\\':'
M'#%I?ASQG\5+'1(O&&O6$,4$<5P;O46FOHQLN9'7BO)_V9O^"@?[3_[(_@+Q
MY\+_ (->*/",?P^^(NK:5XEU[PCX]^'/@_XDZ):>+M!C,6B>,?#UCXPTS4X-
M"\3:6NUK34[)%E6:*"9@9(4(ZL'DG%E'(L;@L1F<<1F-?%8.4*\\TS#W:%/Z
MNL=.ABZ="CC,'+%.G5J4L-3E4H47+DAR4YRI*95*/M(RC!J$8M<JA#=WY4XM
MN,N6Z3>C>[3=F?U(?"O]E+]C#]A3X_?\%D?@;!\!;KXT> O"'[#W@CXZ:)+X
ML^(%U_:5I\-_%4=TVI_"31=8.BW,VEW*ZWYVK:9\4+14\21::+6QDCD,/V@_
MDU_P;N7GP0UK]O7XC:9XW^!]CXYM-=_9M^._B'P%;:WXDEO-/\ Z+H>C1:KJ
M^ASV%WIMW;>*K[7-"EMO#]GXBO8X+W1)()-6M(VN+F2.OBW2_P#@KO\ M\:5
M^T=XQ_:M3XM>'[WXR?$3X::7\(/'][J7PT\$7OA#QE\/-%7&E:#X@\"3Z4_A
MF^%E(3<1W;V/V@W#22.Q\Q@?EW]GS]JSXY?LL?'6S_:0^!7BNS\#_%>RG\2,
MFIP>']'O]"FL?%QE'B/0[KPM>VTNB7'A_4HY3$^CO;"TACC@6!(Q!'MQH<+9
MW+*N(<)CL9"OC\YRC+*$<7_:>8.+S#!Y;#"UW4C[*/L:53$4HU77HQ<\12JS
MA7H6CR3J5:'M*4HQM"G4G+EY(74)34E;75I724M(M)J6KM_0/^RC^P+_ ,$\
MO'7[,FG?MK?&7X;^%8/"W[1_[57C?X;?#SX5_$/]K?5OA%X>^!7PT\/:M<V=
MXOA[QC#I,FK_ !8^)ZM'=ZAIV@ZM%!!>VPLX%BC!=FL?L^_\$X/^"9MI\3OV
MP_ .K>(O#_[3GC#P'\=_!_@S]G/P5\3?CQK_ .S5X+\7_"GQ5INEZQ<W6C_%
M*PTBVTCQ)\6-(_M230$T+4[W3K"YU:PMQ+!%'J G7\E?A5_P5R_;@^#>H_$N
MZ\&^,OAM-I'Q4^)-_P#&'7/!'BGX+?#?Q9\/O#_Q0U-E:[\:_#[P;KFA7>B^
M M7E=(Y)#X;M[*"62*-WB++DYGPE_P""L'[</P=UKXJZYH_Q(\*^-I/C1XZC
M^*'C[2_BW\,/ ?Q.T&[^(]LT;6/C31M&\4:+>67AS6]/,-LMG)H\5K#%%:6D
M*Q".VC RK</\82EFCAFU2,,1*E+!4HYWF$(TZ<<5AZM/#RE]4E5H+#8:%7"U
M:V$K4*V8J3JUZD*M3VE(56@O9KV:]VZD_9Q;?NM-KWK.[=TI)J%K136C_=#P
M1\*/V8?V7/V)?^"XOPP\=_L4>,+>?X)_$'X0+-H/Q2^*FFS_ !&&@?$32I[O
MX;V-AXT\*6&J:=HEAX'N'DUFUUWPQ?2?\+#T>^LHM:,+I)N_(K_@FM^RO^SG
M\1_@;^W=^V/^U!X1\6?%WX<?L4_#SPOK]C\"/!OB^\\!W_Q$\1^-;V\M[&?6
M_%FEP7&KZ3X9T2&T/VVYT]8I(YI4GEE=$^SR>(^$O^"IO[</A'QE^TCXZ3XN
M6?BC7/VN--BTOX_0>/?!7A7QIH/C6WL].GT?1WC\/ZYIMSI6B3^'=*N9M-\.
MR:7;P?V18^7;6H18HROC7[*?[9G[0_[%?C'7_&O[/?C2T\-7?C#09/"OC;P[
MK_AW1?&?@;QMX;DF^T?V-XK\&>);2_T+6;6"?,MF;JU:6T<DPNH9E/=A\@S[
M#X'.Z<<9!9AF6(R;%1Q%/,\Q4:GU;!Y;0S3"QJU(5*^ 6)>$Q=*CC*'M:ZI8
MFC*482PU."EU*;E3?*^6"G&SA#K*;A)VLIVYHMQE9-Q:O[S9_6#_ ,$_/V;O
MV1?V;?V_OV,_VA/@C\(?&.D^&/VT?V!/C1\?/AEX"\9?$G4M2\0?LV^)_!GA
M:&[\:6>G:G-8->>+],\8Z/?1:5X:US6#%J&A3B[UBPEG+1PI^"_[*?P:\%_\
M%5O^"M7_  @_C>\\=>!?AW\6/''Q*\=^*+'5/'FH?$/XB#PIX TS4-9O/"5K
M\0?$%L-1UK7-9CTY=.T_5+RR:>UMYO)@@9K>$CPO4_\ @J;^W#JW[2FG_M:7
MGQ:L'^-&A_#C7_A#X6O!X'\*)X+\'?#/Q-IDNCZOX0\(_#Y-.3PKH&FS6,\H
MB-AI\4T%RYNTD\[!'Q_\+OB_\2_@I\4?#'QI^%/B_5/!'Q0\&^(F\5>&_%NC
M.D5]INM23333RB)E:WGM+O[1/!>:?/%)9W5I-);31-$VT++^&LZPRS?%U<PC
M_:^.R"CEF#QLL7B\7+!XBG7S2K34I5X1]K3P\,1E\%B?9^VKU:&(Q,Z4:M:I
M[5RK0;IQ4/W<:KG*-DN9-4ULMF^6=U>R3BD[)6_>?X2?L^_\$QOVO?VB_P!E
MCP9\)/V3/VE/@1HFJ_MIZO\ L[_%S0_$/C?Q;XW^$GQ'\ Z=I_B#R+H?%*Z-
MEJG@KXI2ZAIEI<W?A32;V/R+%[F-,EHYEI?#[_@G5^S1K/PH_P""AOBWQ!\/
M_$Z:M^SY_P %#_@7^SK\*[R;Q/XHL8='^&WC3XNZ5X4\6>'[J(W$5OK6IR^'
MM0$#:IJ"7&IV+7%O=PRPRLCM^?WQN_X*U_MX_'W6/A3K/C'XNZ7X<F^"OQ @
M^+/P_L/A9X"\(?"_1K+XI0;U_P"%A:OI/A#3-.LO$/BB6.6X@DU#5X[IC;7=
MY!C9<R9ZGXN_\%G?^"A_QRT#7?"OQ#^+WA2\\,^)/%7@#QQK&A:+\)/AYX=L
M;KQC\-/$5IXK\,>)/^)/HEK,=6?7K"RO-=O)99IO$$5G;6>I/+:01Q+B\EXM
M3PZHXV-&C+ZHJU*KGV9XRKAHX;-EC*WLL35P,:N,EC,&Y8:I[=TG3@HT?:5:
M2@HGM*-G>+O[UK4X13O!15XJ5H<LES+EYKW;T9^PNK_\$T?^";7Q._X*H^+O
MV!?AC\*/B/\ ##P=^S)X=\?_ !?^-WC77?C+J5Y<_%O1=+\*Z?K>B_##PRNK
M"]7P5X>T2_NT34O%Q>[U^?2/MES/(KQ1N/SF_P""G_[*G[%'PW^ ?P0^/O[*
M6I^!/!'C#Q=XZ\3_  \^)/P.^'7Q[U#]I3P?8V=E;WU_X9\>>'?B/J>F6-S]
MIE@LFL?%.B32S16&I75O#;QH(Y'?X/E_;^_:S;]K74/VY;7XI-I/[3.K7[7^
MK>.M#\.Z%I.F:HLVE1Z'>:7J/@^ULU\-WF@ZEI$2V&IZ+<6,EC?0%A/&S-NI
M_P"U9^WO^TM^V;:>#='^-OB+P>/"GP^EU*\\(^!OAQ\.?!WPN\%Z5JNM,'UC
M7#X>\&:7IEE>:WJ3@FYU*[26?:[QQE48@[Y?D/$V$S')JU;.*V(P>%P.$AF%
M.IF>-K.KC(T<4LP<J&(H5*>-I8G$UJ-6A5K3H5<+"C&%"-*%.-.HI5:4H5$J
M:4I2;B^2*M&\>5737*U%.Z2:DVV[MW7[A_LX?\$O?V,OC]X)_8B_;$B\%Z[I
MO[)2?LN_M ^-OVZ]#A\=^)4CT_XP? .T^SFWM_$\]ZVI>&H?&FNWUC%::9IU
MQ:QFSM9)+2%5D+M<TW]F?]C[XH?";_@B7-^T/XQ^+?@[]G'XS6O[7^NZYX=U
M+XB>-M>\*^"[#0KW2]4\ ^$=&1H];/PU\/:I=7-CIGC'Q+HMC'-*JF[O+F)@
MD\7X1?#S]N_]JCX4_LO_ !3_ &-/ ?Q,.B_L[?&C4+K4_B%X*;0-&O;W4Y[^
M'3X-2@T[Q+=VTFMZ'I^J1:79+J6GZ9=06UZ4E:9"T\I;K/!7_!27]LGX=V7[
M,>G>#?BG9:)8_L>V?C73/@-;P>#/"\R:!I'Q%CMH/&VB^)1<Z?,OCC2/$%O:
M0VUW8^)5O8E@#)%LW$UA7X<XFJ5:T_[8<XTL7CUEW^WXJG5I8&ME^>4\+4G4
MGAL1&&84\9FN'HRK*G5Y<'EV'J*52I%46U5I)+]WJXQY_=C9R4Z3EHG'W'&G
M)VNO>FUHO>/Z1?@Y_P $[O@9X-_;R_8M\2_!WX0>.O@#\.OBMX._:MTNY^*/
M[/'[7MQ\7?A5XWN/!_PUUZ]\.3> /BKI-[;?$;PIXBN;&.9?&GA;7[>TL[N
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M1110 4444 %%%% !1110 5ZW^S[_ ,G!_L_?]EW^#?\ ZLGPS7DE>M_L^_\
M)P?[/W_9=_@W_P"K)\,UABO]VQ'_ %XK?^FY#CNO5?F?[,M?E3_P6U_Y19?M
MT'_JVWQY^EYX?_QK]5J_*K_@MK_RBQ_;G_[-N\>_^EGAZOX6X=_Y*#(?^QUE
M7_J?ASZ.M_"J_P#7N?\ Z2S_ "DUZ#Z#^5+2+T'T'\J6O[P/FPHHHH ****
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MUB"ON;X_?\F1_P#!/#_KK^V ?P/Q2\$#^8KX9K[G^/W_ "9'_P $\/\ ?_;
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MM3#/A[%3>'G.@YK,*45-T9.FY)/"MI2<6TFW:Z5W;7-9=)I/VL=4G\#ZV?\
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M+4_LV?\ S^C_ . /R_O>OX>9_C??;['_ )_+;_O_ !__ !5'V^Q_Y_+;_O\
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M7[*7_1M?P)_\-1X'_P#E'1_PR%^RE_T;7\"?_#4>!_\ Y1T?\1UP/_1.8O\
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M_@3_ .&H\#__ "CH_P"&0OV4O^C:_@3_ .&H\#__ "CH_P"(ZX'_ *)S%_\
MAQH__,GK_2U/[-G_ ,_H_P#@#\O[WK^'F?XWWV^Q_P"?RV_[_P ?_P 51]OL
M?^?RV_[_ ,?_ ,57^R#_ ,,A?LI?]&U_ G_PU'@?_P"4='_#(7[*7_1M?P)_
M\-1X'_\ E'1_Q'7 _P#1.8O_ ,.-'_YD]?Z6I_9L_P#G]'_P!^7][U_#S/\
M&^^WV/\ S^6W_?\ C_\ BJ/M]C_S^6W_ '_C_P#BJ_V0?^&0OV4O^C:_@3_X
M:CP/_P#*.C_AD+]E+_HVOX$_^&H\#_\ RCH_XCK@?^B<Q?\ X<:/_P R>O\
M2U/[-G_S^C_X _+^]Z_AYG^-]]OL?^?RV_[_ ,?_ ,51]OL?^?RV_P"_\?\
M\57^R#_PR%^RE_T;7\"?_#4>!_\ Y1T?\,A?LI?]&U_ G_PU'@?_ .4='_$=
M<#_T3F+_ /#C1_\ F3U_I:G]FS_Y_1_\ ?E_>]?P\S_&^^WV/_/Y;?\ ?^/_
M .*H^WV/_/Y;?]_X_P#XJO\ 9!_X9"_92_Z-K^!/_AJ/ _\ \HZ/^&0OV4O^
MC:_@3_X:CP/_ /*.C_B.N!_Z)S%_^'&C_P#,GK_2U/[-G_S^C_X _+^]Z_AY
MG^-]]OL?^?RV_P"_\?\ \51]OL?^?RV_[_Q__%5_L@_\,A?LI?\ 1M?P)_\
M#4>!_P#Y1T?\,A?LI?\ 1M?P)_\ #4>!_P#Y1T?\1UP/_1.8O_PXT?\ YD]?
MZ6I_9L_^?T?_  !^7][U_#S/\;[[?8_\_EM_W_C_ /BJ/M]C_P _EM_W_C_^
M*K_9!_X9"_92_P"C:_@3_P"&H\#_ /RCH_X9"_92_P"C:_@3_P"&H\#_ /RC
MH_XCK@?^B<Q?_AQH_P#S)Z_TM3^S9_\ /Z/_ ( _+^]Z_AYG^-]]OL?^?RV_
M[_Q__%4?;['_ )_+;_O_ !__ !5?[(/_  R%^RE_T;7\"?\ PU'@?_Y1T?\
M#(7[*7_1M?P)_P##4>!__E'1_P 1UP/_ $3F+_\ #C1_^9/7^EJ?V;/_ )_1
M_P# 'Y?WO7\/,_QOOM]C_P _EM_W_C_^*H^WV/\ S^6W_?\ C_\ BJ_V0?\
MAD+]E+_HVOX$_P#AJ/ __P HZ/\ AD+]E+_HVOX$_P#AJ/ __P HZ/\ B.N!
M_P"B<Q?_ (<:/_S)Z_TM3^S9_P#/Z/\ X _+^]Z_AYG^-]]OL?\ G\MO^_\
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M.-'_ .9/7^EJ?V;/_G]'_P  ?E_>]?P\S_&^^WV/_/Y;?]_X_P#XJC[?8_\
M/Y;?]_X__BJ_V0?^&0OV4O\ HVOX$_\ AJ/ _P#\HZ/^&0OV4O\ HVOX$_\
MAJ/ _P#\HZ/^(ZX'_HG,7_X<:/\ \R>O]+4_LV?_ #^C_P" /R_O>OX>9_C?
M?;['_G\MO^_\?_Q5'V^Q_P"?RV_[_P ?_P 57^R#_P ,A?LI?]&U_ G_ ,-1
MX'_^4='_  R%^RE_T;7\"?\ PU'@?_Y1T?\ $=<#_P!$YB__  XT?_F3U_I:
MG]FS_P"?T?\ P!^7][U_#S/\;[[?8_\ /Y;?]_X__BJ/M]C_ ,_EM_W_ (__
M (JO]D'_ (9"_92_Z-K^!/\ X:CP/_\ *.C_ (9"_92_Z-K^!/\ X:CP/_\
M*.C_ (CK@?\ HG,7_P"'&C_\R>O]+4_LV?\ S^C_ . /R_O>OX>9_C??;['_
M )_+;_O_ !__ !5'V^Q_Y_+;_O\ Q_\ Q5?[(/\ PR%^RE_T;7\"?_#4>!__
M )1T?\,A?LI?]&U_ G_PU'@?_P"4='_$=<#_ -$YB_\ PXT?_F3U_I:G]FS_
M .?T?_ 'Y?WO7\/,_P ;[[?8_P#/Y;?]_P"/_P"*H^WV/_/Y;?\ ?^/_ .*K
M_9!_X9"_92_Z-K^!/_AJ/ __ ,HZ/^&0OV4O^C:_@3_X:CP/_P#*.C_B.N!_
MZ)S%_P#AQH__ #)Z_P!+4_LV?_/Z/_@#\O[WK^'F?XWWV^Q_Y_+;_O\ Q_\
MQ5'V^Q_Y_+;_ +_Q_P#Q5?[(/_#(7[*7_1M?P)_\-1X'_P#E'1_PR%^RE_T;
M7\"?_#4>!_\ Y1T?\1UP/_1.8O\ \.-'_P"9/7^EJ?V;/_G]'_P!^7][U_#S
M/\;[[?8_\_EM_P!_X_\ XJO7/V?+ZS;]H3]GU5NK=F/QX^#0 $T9))^)/AG
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M+PMI93!A;3O#U[J4^D6?E<>0(+.,6XX@$8)%<C44((BC!&T[ =O]W(SM_P"
MYQ^%2U][&$()J$8P3;DU&*BG*3O*3223;>K>[>K.<****H#TCX,_\EE^#_\
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MK>+O"-[I(T.W\-7?EQVS-;FYDU+3_@H[\8] ^,^C:F+R/XN_ WXC:7^U;?\
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MZC]\O\_+\^[/Q;_XA>/V!/\ H^;XV?\ @D\"_P#RCH_XA>/V!/\ H^;XV?\
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M $?-\;/_  2>!?\ Y1U[IX:_;&\7>,OCT^A:5XH\&Z-\.X/CKJWP-B\)Z_\
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M6ZM-Z7LT?5<.M/9+5:ZRULXM7U[I/U7FS\)_^(7C]@3_ */F^-G_ ()/ O\
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M3=][N-^RDF]SX8_XA>/V!/\ H^;XV?\ @D\"_P#RCH_XA>/V!/\ H^;XV?\
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MB"]UOP[XT30=606=UJE]:WSZ%K5M.1:WNG06CG$]M&:_:+^PO"G_ $)OA?\
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M<M.$8)59M04I*2/94[I\JNK:]7RM-7>[UC'5ZZ+4^0:*^P/["\*?]";X7_\
M!8?_ (]1_87A3_H3?"__ (+#_P#'J\_V\?Y9?^2^7GYO[O,T/E'1O^0QI'_8
M4T__ -+(:_1Z[_X^[K_KXF_]&-7C-CH7A87UF5\'^&487=N5==-PR,)D*LI\
MXX92 5.#@@&O8+UC]LN^2/\ 29^ 3C_6O7-7FIN+2:LGO;K;LWL!PO[%G_)J
MGP+_ .Q#T[_T=<U]05\O_L6?\FJ? O\ [$/3O_1US7U!6F8_\C#'?]AF*_\
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M"'UF&'KRE*4:*I3Q,XPK4HJ4ZDSA5UY9-J^BYI)I-/5OF5^5M=7=+5/9</\
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MLPI))//=ZA?37'G7^IW]W-/?:E?S?OKV]N)[F7YY&KM/[(U+_GT/_?\ M/\
MY(KP<?B*>)QN,Q-+W:=?$UZT(R<5)0JU93CS)-Q4K27,D^5.Z6B-H)J$4]U%
M)^J23,ZBM'^R-2_Y]#_W_M/_ )(H_LC4O^?0_P#?^T_^2*Y;KO'_ ,"7^?G^
M?9E&=6U??\@?0?\ N*_^E4-5O[(U+_GT/_?^T_\ DBMB]TO4&TG0T%L2Z?VI
MO7SK8;=US$5R3,%.0,_*3CO@TFU>.JW[KL]]=-P.6HK1_LC4O^?0_P#?^T_^
M2*/[(U+_ )]#_P!_[3_Y(IW7>/\ X$O\_/\ /LP,\$J0RD@J001U!!R"/<'F
MORPOO@/\'_&7[;_]O_"/X6>%=#U']E71];^*WQ(\:^'+>XMM4\;?M%_$'P]J
M'_"N?AYJ-Y!>%+Z+0-#N+OQUXJTV0>6]_J_A:"YBP\J+^K_]D:E_SZ'_ ,"+
M3_Y(K-T[P=!H\NJ7&C^'=,TF?7-2DUK6Y],M]*L9M9UF6**"75]6EM7BDU'4
MY(((('O[MIKIH8(8FE*1HH[\!CYX'ZU*G.:G7PU3#I0K.%.U:U.JZT(R7M8_
M5YUH0C+2%6I&LGS4DG$X*?+=*T9*6J3>FJ2NM-4FWV5NI^"W[!-S=:7\2?V4
M/'GB^T^%^M?$C]H[P+\:;OQ9K/PZ\9^+;WXR:=XAT1H=5\27G[2>FZE?7&D^
M);%[_P#XEEC!-INDGX;>(UBT+0VFLI&4_>'CJ'1_%O[8OQ6T3XA^*K[P3X+\
M!_L-VMWH^OVNN_\ "-R>'M.^)GQ \5Z?\5/&^FZY*?)T:_T[1/"6B:;-K:*9
M=,MX-RO&9?F^S_#WP4\ ^$O%'B+QQX4^%G@3PQXT\7DGQ7XN\/\ AKPQI'B7
MQ(6D\USK>M6$,&H:EYDP\Z47-Q()IL32AY &&?XG^!/A'QCXTTSQYXD\,1:M
MK5AX(\3_  WN[2]FTZ[\/^)? WBZZL;_ %?PSXMT&[-QI_B+2UO].@O;"VOX
MFCLKB6\9%9;R9&];%YWAL7CZN+Y*M%5,%5P\91G"52C.6)GB(*C&4G"$(49+
M *S2E3YJ\H1G.=-9QI.,%&Z?OJ3\[12N_.ZYO71;)GY(_"3QUX:^#/PT_:0_
M:<_97^'MU)\+]?\ "WPZ^'_P!^#7@*#5_'WB+QWKND7VH:#_ ,-1^// GAV7
M7/$.BZ9XENM6AU"]N4TU=<U[PGX;76=7B:^U>SBB[S_@F;X\\"^'-._:R\,W
M7CGQ]>OI7[4JW.H>-/C3X>\8> ;SQ%XP^(/@7X?SWT5M'\0;'26T_5/$'C:X
MU>72? UHL5WIEC>Z7%;Z;%:W=F9?TX\!? ;X9_"FZO[[X6_!_P"''PTO=5MX
MK/5+SP!X0\(^#[G4;2!_,@M;Z?P_;6$EU;02?/#!.SQ1-\R*IKH-0^&GA_5T
MO(]5\#>&=3CU'Q'8>,=12_TG0;M=0\7Z7]D_LSQ7?"<.+OQ+IPL+ 6.N7'F:
MG:BRM%@N46WB"O%9W@\12Q]#V&(DL;/"VQ53$4GB%2POU6-&%=2C4=>I3IT:
MR]M[>FZM3$U*E2%H0A C2E%Q=X^[S>[9V]Z[DUJK7;6G+9)*SWO^:7@K]G#X
M">/?VYM=\0?#SX5>$?#/A#]FG2O$&D_$3Q%X=MKFU;XE?M ?&32I1K?A?69X
MKMH]4TWX?^ ]2N+S7;"96@_X2KQ9 DB)=:1M'OW[ FKZEJ_[)_PS&I7UUJB:
M!?\ C_P;HFJ7LKSW.H^%/!OQ \2>'/"MW+<R%GNB^A:?9(ERSNTT<:.7;@U]
M:_\ " 6L&E>(M)TC1H/#4/BE];NM9N_#(TO1-1N-7\0P/!JOB,7=D49O$EQO
M%P=;G6:]-W%!<2R2-$HJA\/_ (6Z5\+_  /X4^'7@K1#I/A/P7HEGX?T#3S>
M6T\D&GV2%4:XN7G$EU=W$C27-Y=R_O;FZFEF?YG('%C,U6,P;P]2=:<J<LOA
MAW6J^U<*6%HXU8B4JDY.7-B,3C'5C!>Y3A>FGRTJ=JC3Y9<R45=3YK*VLG"V
MG91C:_5ZVNS>HK1_LC4O^?0_]_[3_P"2*/[(U+_GT/\ W_M/_DBO&NN\?_ E
M_GY_GV9J06/_ !^V?_7U;_\ HY*]/O?^/R[_ .OF?_T:]<!9Z5J*WEHS6I"K
M<P$GS[4X E0DX$Y)^@!)[ FN_O?^/R[_ .OF?_T:]9SZ6:>^SOV X;]BS_DU
M3X%_]B'IW_HZYKZ@KY?_ &+/^35/@7_V(>G?^CKFOJ"NC,?^1ACO^PS%?^GY
MDP^"/^&/Y(^4_ G[:O[.WQ-_:&\4_LO^ _&EQXE^+'@OPOJ_BSQ+9V/A_74\
M.:=9:#KVG^&M:L$\675A;Z#J.M:5J^J6=MJ.EZ7>7MQ8-)_I8A8;3PO@S_@H
MC^S5X\^)>@_#C0]7\8K;>,_'?B;X6_#WXFZEX%\1:=\'_B-\2O!WVP>(_ _@
MCXBW-HFA:YKME)IVI06T<4L=IJ]SIFH6VCW5_/:NA\Q^('AW4;S_ (*;^!X-
M&LKG3[>^_8&^.&FP:Q;6%Q#I=GKFK_&#P"T32W\$ M(M1ED8WIC:87DZQ27"
MHX1G'Y;^$=<T[QY^Q_\ L(?L(^$+36-)_:W^%W[3W@BS^(7@T^']4MO$GPE;
MX0^,O%VM^/\ XK>)9?L872O#.HZ9)'?Z9XC$_D^(!XGM8M.ENI9G1?IL+DF6
MXJE"K&.+4:F'P4JC^L4Y_4HUZ>:/$9A7<<-%2PU&I@:%Z?+3485I4Y5G4E2J
M/&52:;7NW4I)>ZUS6=.T5J[-J;6[U5TK)I?LKX1_X*)_LT>-?B5HGPZT?6?%
M\=GXM\>>)OA7X$^*&I^!O$6F_!SQ_P#$SP<+W_A)/ W@WXCW5HF@ZSKM@^FZ
MG;P(DT=GJMWIFH6NDW=]/:NAZ'X<?MS? SXD:Q=6%K<^)O"VC3>"_&/Q)\)>
M,_&GA^Z\/>$/'_P\^'NIQZ3XV\8^$]8NF*W&C^'KN:"2[.H1:?=2Z=<6^JVM
MO/I\JSU^+?@/Q/HOB[]E;]@K]AWP]I6K6_[5?PG_ &O?AU_PLKX?/X<U&#Q#
M\-K/X.?%#Q)XK^(_Q-\3F2T6#3?"FM^'B;S3_$4DYM/$2>*;:"QEN99Y(T]4
M_:A_9\T'PQK_ ,0O!?P#\.?$?Q_X7_9O^$NN>,OB'X:\2:[KVO>"M(\,^*==
MLO'&@_LO_#O38((+H:/XUU;2K3QS\4(+.[U'4;;X;>&-,\'07$*^(88%Z:N0
M93'$/"R^NX><ZF)A1G5JTI0>&PV)GAZ.8\TH48*GCZE3"PP\9-T9R5=4ZMZE
M%PE59\O-[LE9-I)KWG%2<-V[P7,Y=5I=:._[I_"CXDZ-\8/AYX5^)OANPUS3
MO#GC/3$UOP_'XCTV31]6NM$NI)/[,U.;3)V:XLX-6LUBU*P2Y$<[V%U;3211
MF7:/0Z^!?V(_CKXS^+-[\6?#.J^*_#/Q7\$?#R;P!#X*^,?@WPE)X*\/^()?
M$OA"VUGQ%X-BT< :>]QX%U!H[);C3 JP:?>V-AJ:#5K6[)^]+B0PV\\R@%HH
M99%!S@E$9@#CG!(P<<XZ5\?C\-+"8NM0E%1Y7&<(\TI.-.M"-:E&3G3I5.>-
M.I!352E2FI)J=.$DXKHB^:*>_3YIV>S:W71M=FT345YW\)O&-_\ $#X=>%?&
M6IVEI8W^O6$EW<VEB9FM('2\N;<)"9V>8KL@5CO8G<6[8%>B5R%!1110 45Y
M-\>O%?C3P)\$OBWXU^''A\^*_'_A/X<^,?$/@SPT(I+@ZWXFTC0+^^T;3?LT
M)$US]JOX((_LL)$MSGR(R'D6OP6^!7[8L_P\^*/[#6IZ7^W1XO\ VL-8_:QM
M?$.F_M!_"'Q&?#VI:=\.=>3X::YX^;6_"FBZ%H^GWWP:F\*>*]$NO!9\%:[<
M2-JMA]H#0O>Z7<7!]G+LDQ.98?$XBA.'^SJK:GR5YRFZ.%K8RHI2I4JE.A'V
M%"I[.>(G3A5J>Y!M1J2IYSJ1@XI];:Z:7DHK=IO5K17:1_2%17\]OA[XJ?M1
M>'?V?_@?_P %+=<_:/\ 'FO0_%'XV> T\?\ [-]W#HC?!+3?@5\7/BS;_"[1
M/"_@[1(M-CU?3/&_@_3M8T#7T\8/J\MUK&JPZG!J%L;6=$3[W_X*6_%KQW\*
MOA7\)X/#'Q'U'X'^#/B/\>_ GPW^,WQ]TC3K>_U+X.?#'7K;6Y]1\265S>VU
MYIOARXU;6K#1?"D?B_5;6;3O#+:[_:-PH*1NNU3(*\,9A<'#$X>M+$8G$X.5
M2G'$<M'%X)Q^MT)0=%5:LJ:J4W3="G5^L>TA&BI5'R)*JG&4K-6496=KN,OA
M>CLKZWN]+-O34_1NBOY_OA7^T+\:/&,_[?\ ^RA^R]^T1XJ_:DU?X0> /A5X
M[^"?QHU?5/#.K>.(3\0+J_L_B#\.M,^(<5CIGA3QAXBT&VT2_N?!WB*ZC,6F
M:KJUGIVI74OV19(NS_9P^,G[0OC/QGX7_9U\:_%#Q=\.=#^&'QDUGQ7\0?&O
MQ8\6>#)/C-JO@C49X-3^!'[,6MZ]97<NDZY\5?$MHU[XH^* T<W>K:-X'C\/
MZ/<&'4]><)K5X:Q-&.(E/%8:/U>-&M.G/VT*ZPE?!T<92Q+P\Z:KP4U7I4(T
MY04GB7*ETC*259-I*,KNZOHX\RDXN*DG9[-W_EU\E^YU%%%?-FP4444 %%%%
M 'PI_P %)? WQ%^(_P"Q_P#$SPE\,3-=Z[?WW@>?5_"MEXFM_!FJ_$7P1IWC
MCP_J'COX9Z)XHNKW3H=(UOQ]X4MM5\,Z7(U]:M=W>H1Z<DRM>BOQKM_B7-\#
M_CS\<]>_94_99^(_[(7@!O\ @F;\=_B!K/@OQ;X:MO =QXD^*'PHNK6+P9XZ
ML_AC!J6H+I6H>$YKRZ\//XUO;>T;QJ9BD,NIP:<UT_\ 1C\9?@[\._C]\,_%
MGPB^*OA^+Q/X$\::>NGZWI4EQ<V<Q\BY@OK"_P!/U"RE@OM,U;2M2M;34])U
M.QGAO-/U"TM[JWE62(&O%_@A^Q9\&O@;<^.]6LKGQ_\ %#Q7\2O#]CX-\8>.
M/CCXYU?XJ>,-4\":9;W%KIW@,:OXA+_9?!UI%=W1.B6MO%;WD]Q+=:B;RZ;S
MA]7E&=X/ 996PN)ISQ$G6KSCA>2<:%:.(C@HN5>:Q*I5'2^JN=)5<+4E1FE[
M.4G6<\-A4IRE-23MHKRTNN5MZ:75[ZV:OUM;7\8/V/\ P(OP3^(__!/7XD_%
M+]FOP!\,)?C]HMSH?@#XN_"+XK>*=5^,FN^./&7PTN?&M]IO[5XOK2'1_BW8
M^/K*UU3Q"U]:75[#X.\4P6RVKFW"S'];?VY? 7[,=]X1\,?&K]K2>?6OA5\!
M[G6_$5O\,]1W:OX/^('B_P 1:>F@>&[#4O 2QR#XA^+$NYOL?@#P[)#=AM?U
M(316;S!9H8/@[_P3G_9T^"7Q \,?$+PT_P 3_$-U\.K#7M+^#WA;X@?$[Q1X
MV\"?!'3O$RO#K%K\)O"NLW,MAX4$UD[:9;7"F\O--TD_V9IMS:67[FL#Q[_P
M3+_9[^(W@#X*?#KQ'XJ_:!;2?V?O&GB/XA?#;5[3X[>.X_%5EXQ\2:AJ.HRZ
MYK/B*YO[J^\17FC2ZK>0>%VUEKL>&K1T@T@6HAB*[XS-LMQF;83&O'9CAXT8
MSI5:V'HU/;NC5JX^K*&'=?'XB>'G&E5H8:4XU)1]I6KXF$&Z26)4:<XTY1Y8
M2O9I-I*Z4%[W+%*6J<MMDHWL_=^(?#W[$WCW5_V&M";QO)\/O@MHWAGXZ?$S
M]I_0_@+\<;?4_&/P>^$_P8\4V/B$Z)\(_B!86^HVT@3X?:'JK>,+>SM[B;2?
M"WBM9--LX/LMA#)%D_\ !/SXG?"^P^*/PGL?C+XO\;:Q\0- ^&_A'X _LO6O
MB/P=XJ3P_P"$_ U]X=EUO3->\9>)9[:YT#P[\;_VDM(T9_&>G^&-4U,^(-+^
M&MCX8T$,LD]['<_J7:_L9?#&3X-7_P "?%OB[XS_ !-\!:QXRTWQEKJ?$[XK
M^)_&.O:^VF7^FZG#X5UG7]0G&H7_ (%N+S2K22_\)RR?V7?H;B"ZCD@NIXY)
M-4_8K^!^K?'K3/VAKBT\5P>*]-U7P_XF/A6R\5:C9_#/4?&WA+PY>>$/"GC[
M5/ L.W2[OQCX;\,7T^AZ/J^Z,6UB(5-O))!%*CEG^%KT,RPV+K8F<<34QM;#
M3PU"E2]E*KRRIPYJLZM9QQ+J5X8F<ZCJNG!4YU:L<36Y#V4DX2CRWBHJ7,V[
MVZZ)*\4ERZ6NVTDXJ_UG1117QAT!1110 4444 %%%% !7Y(_M?:!XDT/]N7]
MG[XN^"_ GPW_ &D?$^F? ?XH^"H?V;/%7Q"\'>"?'^FZ7JOB;0-0U#XT?#*#
MQZI\.ZI;V306_A+Q\5>WU2TT6[L);62XA\^U;];J\"^._P"RY\ /VFK#0-.^
M.GPQT#X@Q^%;RZOO#5WJ#ZEIVL:#<:A;BTU(:3KVA7^E:W86^IV@%MJ=G;ZA
M'::C;JL5[!.B*%]/*<92P6,]K74Y4)T,3AZL80=23AB*%2BUR1Q&$FXWDN94
M\5AZG+?EJK5.)Q<HV6Z<6M;?"T][2[=8M>1_,UX,M/C9KOP?_95\#6%G\%O"
M?A/QQ_P5B_:6AT&RUG[7XQ_9X\&VEEI/C?5O -CH]@9-*T[QQI'ACQJFO7?P
M^T4O8^&]=\<Z19BU062VBU^PO["/B%? _P ;?VU_A5\2;?X-R_$KP!XW^$MU
MX\^._P *]!@^&_A;XLW'CCP6DWA6V\:^$4U6\\.^'OBQX:M(4T'7+?295?5[
M671KJ5&GF5*^Z/$?[,G[/_BSX,V/[/.O_"7P7?\ P5TJPTO3M(^'0TF.S\/Z
M-;Z)*EQI$NC1V+6USI%_IMR@NK/5=-N;74X+HO<I=B>221N+T;]B']D_P_\
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M491FHJ491E*+BTTVK,Z$[I-JS:3:VM=;:Z_>/\R7_GK+_P!_9/\ XJCS)?\
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M5'F2_P#/67_O[)_\53**++LOZ_X9?< _S)?^>LO_ ']D_P#BJ/,E_P">LO\
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MC?D<G3;YH,FG)RC>6]WK9QNN]GJNWG:X_P R7_GK+_W]D_\ BJ/,E_YZR_\
M?V3_ .*IE%<-EV7]?\,ON+'^9+_SUE_[^R?_ !5'F2_\]9?^_LG_ ,53**++
MLOZ_X9?<!J:/+)_;&DYEEQ_:>G_\M9/^?N'_ &J_1R[_ ./NZ_Z^)O\ T8U?
MG!H__(7TG_L)Z?\ ^E<-?H_=_P#'W=?]?$W_ *,:N+%)7AIT?YH#S_\ 8L_Y
M-4^!?_8AZ=_Z.N:^H*^7_P!BS_DU3X%_]B'IW_HZYKZ@IYC_ ,C#'?\ 89BO
M_3\R8?!'_#'\D)@9S@9QC..<=<9ZXSVJG&FG?;KAXELO[2\F(73QK!]N\@DF
M$7#*/M'DD@F(2'9D'9WJQ.)F@F6W=(YVBD$$DB[T28H1&[H""Z*^UF4$;@",
MC-?RNZ%?_$3]GG5?V2-7UWX4?M":+^VI=?MM:EX-^/WQ9\07?BB^^'7QC\&>
M/-2\?S3:;9^*KG5I_!WC7PGXHT"+P\?!_AWPS:R7_@I])5I+72&LIY)^[*,H
M_M6.*4<3&C5HJ"ITN6$G5<J.*K.I4YZU%T\/3>&C2JU81K2A5Q%!>R?,34J>
MS<=+IWN[VM9Q5EH[R?-=)V32>NA_4TB:<+Z=XDLAJ1AB%RZ+!]N-OD^2)V4?
M:##D'RA(=F0=O.:2UN=-FGOH;*XL9;FWF1=2BM98))X+AXP46^CB8R13/$JE
M!<!7:-01E0*_FG\ >'IO"7[+O["?[=^C>,/&E]^T_P#&3]K?P OQ1\6R^+-=
MO[CXBZ%\<_B7XB\&>,/A;J^@7&H2Z)/X8\*Z'):0^']#@TR%- E\*0W%D()O
MM#R=%XU\._&K]BW5O#L5WK/ACP3X^U3X3_&CP;XN^*NA^-/$/CC6/B%H6J^-
M=(\2Z[^U5\0?"$^GVTND#X3>&C-8^&++4)]3U35_B1XNT7P?H\W]CMY;>H^&
M(2JSH4LRC.LJ^)PD(5*'LW4Q&!G4AB^6/MYU)X:GR4O9U:<)U9JLG/#T8TJK
MC'MG9-P:349-IWLI<O+T2YM7=-I>[92;:/Z.;(6(@ TX6@MA)* ++R1 )1(P
MF $'[L2"7<)1]X2;M_S9I;[_ (\KS_KUN/\ T2]?)?['?COX77?@(_!CX?Z!
M\0/!>I?!'2_#&CZ_X0^*NGR6'CY;3Q-I"^(-#\8:S,U]J<6K/XU@GN=:NM2@
MOYV759-1L;R*RO+26SB^M+[_ (\KS_KUN/\ T2]?,8FA+#5ZM&2FN27NNI%0
MG.G)*=*HXJ4TO:TY0J+EG.+C).,Y1:D]HOFBGIJNCNK]5?39Z;+S2/%_V:O^
M2&?#G_L"S?\ ITOZ]RKPW]FK_DAGPZ_[ ]Q_Z==0KW*L!A17S)^V=^T0_P"R
M7^RO\=OVDT\+?\)L_P &/A[K/CI?"8U)='_M\Z2L;?V=_:C6]VMCY_F8^T&V
MF"8_U;9K^2=/^#P2_=%;_AA@C<JMC_A<UOQN ./^11]Z^GR+@WB+B3#UL5DV
M 6+H8>M["K/ZUA*'+5Y(U.7EQ%>E)^Y.+YHIQUM>Z:6-7$4J+4:DG%M77NRE
MI>V\8M?K97/[5?%.BS^)/#/B#P];:WK'AJYUS1=3TFW\1>'[B.UUW09]0LYK
M6'6-&N9HIX8=3TV25;RQDF@FB6YAC,L4D>Y&_,KX)_L#?%?2/BQ\//'_ .T5
M\5_A3\2=,^#+Z_J?@Z/X;_!33?A=XJ^*/CO7-"O_  @OQ7_:"UVSU.]@\7>-
M=.\(ZKJNGV]OHMGI6C2:IK.J:W+!Y\L4$7\\/_$8%?\ _1C!_P##S0?_ #)4
M?\1@5_\ ]&,'_P /-!_\R5?587P[\1,'1Q%##Y/2A'%0<*DGBLFG5490G3FJ
M5:>(E5I*=.I.$_9SBI)W^*,91PEB\))INI+39<E5+>+U7+9V=M^S6U[_ +Z>
M%_\ @G%\8],3X=? CQ!^T-X>UK]B+X1_&:S^,G@OX80_#V>T^+.I0^'_ !;<
M>/O _P *?%_CYM>ET+4/A[X/\8SQ:A!-9^&K77M6L-.TS2[^Y$5L97^F/B[\
M _VHOB=X+^)>AVW[2/AC0=7N?C#9>.?A! /A-IFH>#+7X8V-A#:S_!'XV^&K
M_4KI?BCX7\022ZI)KFJ6TWA[5"9=-DLVBDTT>?\ RY_\1@5__P!&,'_P\T'_
M ,R5'_$8%?\ _1C!_P##S0?_ #)5TU.!O$JM5IUJN386<Z4G4CS2R!Q=656-
M:K6G#VO+.MB)PC]8JR3G6@E3J2=-**E8G!I-*I/6RVK72LDE>VBC?1;)IM:G
M].'[.O[(WQ%^"VE?&_QYJGCCX97'[1/Q@T73-"TG5O WPR_X0SX+?"S0O"&D
M7^G^ /"O@WX=6VK27\GA_1M0U&]\0:VU_K?]H>(=5NYWFFMHA&B_,'Q4_P""
M3,OBO0_ACI/A3XG>'7U.Q\-^)-%^,7C3XD>"I_%OB_Q+XO\ '7C?P[\0/&OQ
MT\ :C;:SI_\ PAWQGU'6-#?2]+URY.HVFC>&Y-/T>TC6UTF"*3\+O^(P*_\
M^C&#_P"'F@_^9*C_ (C K_\ Z,8/_AYH/_F2JJ7!/B=1Q,\72RRG"M.5.4G'
M$Y*HOV-!X:C#D^L<JIT:+<:=-+DBWSV<_>!XG!.*BY.WG"K?5IMM\N[;U>^C
M[']M=O"+>W@MP[R""&*$22'=)((D5 \C?Q.VW<Y[L2:FK^([_B,"O_\ HQ@_
M^'F@_P#F2I1_P>!7Y>)/^&&"/,FABS_PN6W^7S94BW8_X1+G;OW8[XQ7C?\
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M/_AQM7_^*H_X>4?\%!O^CSOVB?\ PXVK_P#Q5?$U%']CY1_T*LM_\(,+Y?\
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MQMXF\9:_IVBVES<_\)#=PVDZ/$^I2O8Z=;6*2K),:'AK]OG1?%OQ"\(RZ1X
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MU:-6G"M.E5J*G/E2JQ=M]9\BT3U>U[-V736S3:NE='U+_P *;T7_ *&_4_\
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M@D=A_;_ES+H,+O.;N]M9)-\1U51#Y10*N'D\P$L=F #V%;=__P @;0/KJ_\
MZ504G4J>[[S^*^RZ1:[=>OJP/#_^%-Z+_P!#?J?_ (3=O_\ +FC_ (4WHO\
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M*TH.=.G.UXRA)2A%J49JUK-J,E)75UT:>Z?G9M>>C9Y5_P *;T7_ *&_4_\
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M:)X4O]2O="O?"EYX^T^_D\!>*;.'5]2TR37-+BO(KRQN(S=:=)<6=O*/8O\
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MFNVEF$I$FU=@_&;QT,?O?#_(R/\ BF=)_P#C-)_PN;QU_P ]?#__ (3.D_\
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MPN;QU_SU\/\ _A,Z3_\ &:/8U/[OWOR_N^;^[S ]\HKP/_A<WCK_ )Z^'_\
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MI_=^]^7]WS?W>8SWRBO _P#A<WCK_GKX?_\ "9TG_P",T?\ "YO'7_/7P_\
M^$SI/_QFCV-3^[][\O[OF_N\P/H6R_X_+3_KY@_]&I7J-]_Q^WG_ %]7'_HY
MZ^-]+^,7CB;4]-A>70-DVH643[?#>E*VR2YB1L,(<J=K'##D'D<BOLV\4&[N
MB1R;F<GD]3*U85H2@XJ5M4VK._:_1 <!^Q9_R:I\"_\ L0]._P#1US7U!7R_
M^Q9_R:I\"_\ L0]._P#1US7U!6V8_P#(PQW_ &&8K_T_,F'P1_PQ_)$<L:S1
M2PL6"RQO&Q1BCA74J2C#E6 )*L.0<$<BOQP^'W_!-GXP^'+?]G[X-^)_B_\
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M/7LM>-?LZ?\ )OWP._[)%\./_40T>O9:_P _\7_O>*_["*W_ *<D?30^"/\
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MO'_%/\PK_.R_X*^_\I*/VK_^QU\/_P#J >$J_P!$VO\ .R_X*^_\I*/VK_\
ML=?#_P#Z@'A*OWGZ%'_)Q>*/^R)Q/_J^R(_E_P"ES_R060?]E9A__53FQ^;E
M%%%?Z8'^>84444 %%%% !1110!_7W_P;-_\ )(_VHO\ LI/@G_U&M2K^G6OY
MBO\ @V;_ .21_M1?]E)\$_\ J-:E7].M?X]?24_Y/;QW_P!A>5?^J#*3_57Z
M/_\ R:#@O_L$S#_U<YD%%%%?AA^QA7B'[1__ "1;QO\ ]<-%_P#4DT:O;Z\0
M_:/_ .2+>-_^N&B_^I)HU=."_P!\PG_830_].P%+9^C_ "/;Z\?^-G_(B^)/
M^Q7U_P#]QU>P5X_\;/\ D1?$G_8KZ_\ ^XZL(?''_%'\T,_#S]KOP]JNN_L_
M>.M1\.M<IXH^'QT+XL^&6M)Y8)Y-6^&&N6/C V2F%E,J:KIVF:AI,UO)NAG@
MOI(Y593Q^2S>//%'C'7?$OC/2?$&NR:!_P %5=7A\(?"N(7EY':>&M)\ _$7
M1?#;7NA1JX.BG4?A--KNO2R0B)[FWT^:[4@H*_?>X6W>WN$NU@:T:"9;M;KR
MS:M:M&RW"W(F_<FW:$N)Q+^Z,182?(37(VNB?#>VTCPU?V6D^ ;;P]X,WR^#
MM0M;/PW#H7A#S(9--DE\,7T*+IOA_?;SRV$CZ5-:;H9I+5B4D:-OM<KSF. P
M\J$\)]8;KRJ1FY)6BX4JM.BTX2=HYA@\OQ7NM<T*->C;]^YQPJ4N>7-S<ONV
M^:>LEKOR2E'RNGTL?E[X0U/Q++^T!\*=-T'XB'X8^"[+]K#]M?P'>^&O#^GZ
M+9:)XOM_ _AK?H%GXADOV/\ :NOZC;6HT\7$KO?M./M]DGV]!)7*?!/XN?&S
MX'_!OX$>(!XS@^)GAGXA_"W]IC6-)^&=WX;@@D\/:S\*K?5/%?A>32?$EM<7
M.OZVU[F:R\0P:AYOVB,JUB+3R55_T\\+S? _XLV>HSZ#H'@WQ';>%OB=XJ:Y
MCO?"^FQRV/Q0\):LVE^)_$]C;WMFLTNL0:J3&_C"S1VU%I%ECU"=)59NWMM(
M\ 6/_",16>F^";(6+:E#X*BM[;0+86C:DC1ZS#X3CC5!$VHQL\>IQ:,H-VA=
M+I9%+"NFKG-'E]A7RU227+6H5J5%2?LUFLZ<G5='V\*JJX^E*55-581PKC&?
M+5E&,JEM*-2UTK-.77V=].:S7NM6VO+R1^,_C;XO_%GP7XLUCXE:=^T5X2^*
M7CE/^"?NM_$WPW>Z?X>T*#2O!.O>*_BO\++0F70M'U&XL=4\-P_VE<0:-#K/
MEZ[%'#=0W5R3*K+Z[^U1^T7\9?V?]/U33?#_ ,6=5\7^+?A!\(-)^+7CK[5X
M$^'F@>'-='B/Q)=1:3_PE>KZYX@L+A=%O;6QU#0--\.>!-+OM:@,,%]?ZDMU
M)##-^A>D?"OX!>%QX@L]#^'7P=T#^U+;49O%5MI_AGP;IS7MA->6MSJQ\00Q
MVL;/IS:A:6-Q?I?J+-;VVM))U6>&$K>\8?#OX*>-Y=&\6?$#P5\+/%SZ=;_8
M= \2^,-%\*ZU%;VFH_*MEINK:O#/ ]K>$D16L,[PRN28HRY)JUG.72KX.57*
MXUJ%!SYXRPN!C/$*7L?94G"G1A"G3A'ZQ%0HSBE.O'$VG4IN%1.E.TK5$FTO
MM2TZN5VV[_"[M/16V9^;'Q(_;5^+?PJ^)OB#P[K=WI5WX:^ _BQ_BK\>+B31
MTCFF_9F^).E^';;X2R:<T:!K6\LO$.K^(_M^I)F6>T\)JD@9[EP<+XN_M8?'
MWP#\.]!U]/&UU%\0?!WP+\*?''XC>&(O!W@73_"<"?$'Q3?7/AG3_%GB+Q5K
M^G:E/I[^&8DT&#0?!&DWFLP:C;S:A?WZ3S06I_6_4/!G@W43K4NK^$?"VH-K
MVCVFA^))=3T'2;HZWX>TLR2V&C:[)=6K_P!I:)II>62ST[4&FL++?(\,,09B
M>5U_X;_!?XB7OA[7O%'@;X7^/+_3[:XL?"VK:UH'A;Q-/;V46?M-CH=W=6]Y
MOM+?:S26EF[PVK*SF.)@6K.AF^4Q>%E/):4E1]G]8DHT*BQ#4$YJ4)TE&,:M
M6IC&G&494J7U-1]I]3Y:K=*IK^]U;TW5M5UOJTE"UU9N]_BNOS)N/BK\6O#D
M?QCO?AQXFBT>+7?VN/B5JGC2VTR\\%W_ ,28_#NE_ GX5>(8(OAMX?\ B/K.
MCZ!KECHVI73W?BS2H;^WU)-&*/IP2>YDDKZ\^(WQ^UK2_P!CS0_CEX%U[2]1
MU3Q1H'PW%GXZUCPY/IFB:/#XXUG1]!U3X@ZOX5GN6>PL- CO[G6+G2+B]-K;
MM"L4MX]FIG;W?Q3\./@EXGTI].\:^!_A7KFB3^)!J$EIXDT+PI=Z;/XP^SP:
M=]L=+^ P2^)6L[2VTZ20DZE):6T%C+O@ACA7L+RU\(O8#P7J$'A=M+O;(>'U
M\'WRZ.+&[T]K0(-#3P[<$0W%HUB J::EF\1M -D/E 8YL1F."KO S>7KFP]>
ME.NE&DOK%"BH*=*K4Y)3JN481A'FY*=*$>64*O/>G4:<USKVF\;+5^ZWU2T2
MOKMJV[IKK^2^F?%7QK\)?CS\=#=?'30/B7#%\:_V&OAWXJ\?7%GH.G6-CX(\
M;Z;\0_[;T_6X]+O)_"^DZA)+)8QC6K!K1?L\^GBX(NMS'<\7_M;_ !=U_P 3
M/X)^'7B$3Z1KW[1?[0G@C3OB#X,L_ 6IW=EX9^$/ACP/J&D>$M#NO&>M:/X0
MN=2N=3U[5KK5+Z\O;C4+C3-.GM].MY6$L\/W=X4\+?LP7VC?$;X;^$/"/P5/
MASPW?P>&/BGX.TSPYX1@T.RO+2RM]=M=/\7Z8MHEE.EG::S#?6\NHI)!9R7L
M@CEBG,JCL)_A!\%M>\&Q>#IOAC\,=7^']Q=0ZS;^&D\)>&;SPC-?K#%!#K%K
MIT%D^EO>FVAA@74H$-P\$:1>>T:JH[)YKERK0JXC*I3J1I8>BG6H8:$'"GE^
M'H4\0\/"$*?/SP6)IX>+5!TW&'.U)S<JG.UHU$E=MI-O7G;:3=W:SY7)ZWUM
MLCYCUSQM\4_B!_P3W\<^.];URV\&?%.Z^!OQ#U2X\2> ;O2=6@34-!L-=2WU
MC0KK2[S4]*AFU:TTZ&><:;?W:Z3?3W4=G<LUM&]>+ZM\9OBOI6B2:'I7[1OA
MCPS;_!_]D/X=?'&U\5^)] \+ZO-\=/$GB#3M1FO=,U">2]MK7_A'/#QT:V\.
M:JGA8R:_/JVMVEU/*EP!#-^H-GHNC:=I$'A_3]'TNP\/VM@-*MM"LM/M+71K
M?2Q";?\ LV#2X(DLHK#[.S0&S2 6YB9HS&58@\%=_!'X+W]EX5TR]^$?PUO-
M-\#3R7/@K3[GP3X=GLO"4\MQ]KE?PY:R:>T.D"6ZQ=2)9)#&]PJS,AD56'%A
M\SP=-UE4P5-TIXZMBJ4(X?"U51A5]G:E&.(A.\84Z3H1A.4Z<8UYUHQ]M1I-
MW*G)VM-W45%MN2NUUTVN];I)W26S9TO@3Q!?>+/ W@KQ7J>ER:'J7B?PEX=\
M0ZAHLN\2Z1>ZSI-IJ%UIL@D"R!K.>X> B15D&P!P&S754?Y_+@#Z < =A17B
M3<93E*,>2+E)Q@FVHQ;;44WJ^5:7>KM=FRVWOY]_,****D HHHH ZOP9_P A
MJ7_L":]_Z;9JY)/N+_NK_(5UO@S_ )#4O_8$U[_TVS5R2?<7_=7^0J5\4O\
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MFU<FG'DC9VW;LME?HOS?G<****X2PHHHH TM&_Y#&D?]A33_ /TLAK]'KO\
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MJ4G6JQLFKU*,:F&DY>[[/$5/M<MB23Y;NR4D[=VD[+Y.TM.J72Y_/AX \/\
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M?_\ 4 \)5_HFU_G9?\%??^4E'[5__8Z^'_\ U /"5?O/T*/^3B\4?]D3B?\
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MMXGXF^#?QRUSPE\&-0\3?"#5]-^''AV#X\Z+<_#GP7\(8/%U\VL>*O$-G<^
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M_P#'J/\ A2</_0\Z=_X(]3_^/4>UI_S?A+_(#PBBO=_^%)P_]#SIW_@CU/\
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M=T,=+F<=?25O:N3$RC)PY7>R?1KMW2 X+]BS_DU3X%_]B'IW_HZYKZ@KY?\
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MO[*7_)T'[.W_ &6OX:_^I7IE>!5[[^RE_P G0?L[?]EK^&O_ *E>F5Y.?_\
M(ASO_L3YI_Z@USU<B_Y'F3?]C7+O_4NB?Z>=%%%?X.G^T84444 %?YVG_!U]
M_P I%/A>/^K9O#OZ>-/%'^-?Z)=?YV?_  =?_P#*17X7?]FR^'O_ %-/$]?J
M?@[_ ,EI1_[%V/\ _2('#F'^[_\ <2G^9_,71117]:GBA1110 4444 %%%%
M']6G_!I-_P GH?M%>_[/]A^GC6R_Q%?Z!E?Y^?\ P:3?\GH?M$_]F_V/_J:V
M%?Z!E?R+XO?\EOC?^P/+OPPL$>W@/]W7E.7YI_J%?YV7_!7[C_@I1^U>/^IT
M\.G\&^'_ (2(_P#KU_HFU_G9_P#!7_\ Y25?M7_]CEX;_P#5?>$J_>?H4_\
M)QN*%_U1&)_#/LA_S/Y@^ES_ ,D%D'_968?_ -5.;'YMT445_IB?YYA1110
M4444 %%%% ']??\ P;-_\DC_ &HO^RD>"3_Y;>IC^E?TZU_,5_P;-_\ ))/V
MHO\ LH_@C_U'-4K^G6O\>?I)N_C;QYY8S*U_Y@,I/]5?H_\ _)H."_\ L$S#
M_P!7.9!1117X:?L85XA^TAQ\%?')[+;:.Q^B^(M'8X]\#CWKV^O#_P!I'_DB
M?CO_ *\]*_\ 4@TFNG!?[YA/^PFA_P"G8"EL_1_D>X5PGCK_ (\9!_U"M8_4
M67^%=W7!^.O^/&3_ +!.K_RLZYX[KU7YC/DWQU;?$&[\,W]O\+=6\&:)XW=K
M?^R=2^(&A:SXD\*0*LH:[&I:1X?UGP_JMRTEN'2V-MJMN(IRLDHDC!0_EK:?
MMC?M4:/^Q[;_ +3_ ([UC]E_2F\5_%7P?\+_  [%%X)^)ECX9\#QZC\==1^$
M7B7Q=XXGN?'UY>Z[IL&G6!US3;#1Y-&FMKF3R+NYNHDR?UZ5MK!@,XS^H(KX
M9U;]BYI?V5?#/[-/A[XI/I5[X.^*6D_%?0OB%K/@33?$L!UK1OC'?_&&STW5
M_!$^LV5AJ>E-?7YT*YB;5X&FLX1=Y69S$/H\IQ&7TXPI8ZGAW%YGETY3J8=S
MG' KZP\<O:0I59J/-'"WBHSFTYJG"<95(O&I&;=X-_PYJR=ESWCR:-KIS=4M
MKO8SM3_:9\<>%OV8?&WQ6L_&WP)_:!^)4_C#3?AU\'HOA#HOB_PQ\/\ Q+\0
M_%U_I7A_P;X.URW\0>(_$6NO>+K5]/J>NWFGW]O&GA^WD^SV\=Q \K^=^//V
MW/&MC\"_V4/B#I&H?!WX6>*/CA\2;WX4_%?5OBU8>)]>\"?"7QGX3\/>,&\>
MZ0+'P[KNAZS=RZ?XW\'W?AS3&NM23?;7-O=S)(67=ZWXE_8]U#XQ6WPWT?\
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M*^+NI_&;5_ =M8Z-X[\7^)%U.T\6ZEXHU*SCURXUC7-'UFST_4]*MO$*7_\
M:_AV![**Q.@7%@NF23V<22M]+WW_ !Y7G_7K<?\ HEZ^:?V?_P!G;5/A#XD^
M)/Q \:?$B[^*?Q(^*"^#+'7_ !&WA;1O!.EVVA> -"_L#PSI>G>&]"EGLHI4
M@DNKS4=0EGEGN[N[:.);:SM[:VC^EK[_ (\KS_KUN/\ T2]?(8]T'BZTL-5E
M6I3<9^TDN6]2<(SK**]CA[PA6E4A3?L*/-",7[*%^5=$+\JYE9[6\D].LM;6
MO[SUZO<\7_9J_P"2&?#K_L#W'_IVU"O<J\-_9J_Y(9\.?^P+-_Z=+^O<JXRC
M\S_^"R?_ "BT_;G_ .S??&7_ *+MJ_R:X?\ 51?]<T_]!%?ZRG_!9/\ Y1:?
MMS_]F^^,O_1=M7^37#_JHO\ KFG_ *"*_IOP._Y$.<?]C=?^H6'/(S'^)3_P
M/_TIDE%%%?MIYP4444 %%%% !2I_K;;_ *^[/_TJAI*5/];;?]?=G_Z50T ?
M[+7[.G_)OWP._P"R1?#C_P!1#1Z]EKQG]G/_ )-^^!W_ &2/X=?^HCI%>S5_
MG]BM,5B5VKUO_3DCZ>.R]%^1^&7_  <-_P#*/"[_ .RW_"G_ -'ZY7\+E?W2
M?\'#/_*/*Y_[+A\*O_1VNU_"W7^I/T.W_P :@FO^JNSQ_?A<I_R/\WOI6+_C
M9U'SX:RM_P#E?'+] HHHK^J#^:0HHHH **** "O??V4O^3H/V=O^RU_#7_U*
M],KP*O?OV4?^3H?V=?\ LMGPU_\ 4LTRO)S_ /Y$.=_]B?-/_4&N>KD7_(\R
M;_L:Y=_ZET3_ $\J*0=!]!2U_@Z?[1A1110 5_G9_P#!U_\ \I%?A=_V;+X>
M_P#4T\3U_HF5_G:?\'7W_*13X7_]FS>'?_4T\45^I^#O_):4?^Q=C_\ TB!P
MYA_N_P#W$I_F?S%4445_6IXH4444 %%%% !1110!_5I_P:3?\GH?M$_]F_V/
M_J:V%?Z!E?Y^?_!I+_R>A^T9[?L_Z;CVSXUM<_G@9]<#TK_0,K^1?%_3C?&_
M]@>7?CA8,]O +_9UYSD_QM^@5_G9_P#!7_\ Y25?M7_]CEX;_P#5?>$J_P!$
MRO\ .R_X*^_\I)_VKCW_ .$UT 9[X'@+PH /P' ]!Q7[U]"E?\;%XH?_ %1&
M)7WY]D/^1_+_ -+IVX"X?\^+<.O_ #$9L_T/S<HHHK_3 _ST"BBB@ HHHH *
M*** /Z^_^#9O_DDG[47_ &4?P1_ZCFJ5_3K7\Q7_  ;-_P#)(_VH?^RD^"_T
M\-ZAC\LG\SZU_3K7^//TDU_QNWCSSQN5O_S 94OT/]5?H_\ _)H."_\ L$S#
M_P!7.9!1117X:?L85X?^TC_R1/QW_P!>>E?^I!I->X5XA^T?_P D6\;#L8=$
M!'J#XET8$'U!!((Z$$@UTX+_ 'S"?]A-#_T[ 4MGZ/\ (]OK@?'=_8Z9:)>Z
MI+:0:9#9:A_:%Q?RB"SM[1S:+)+<SET2&)25!D=U4$@$C(KO1T'T%?EI_P %
MJ+V]TW_@EW^W#?:;>WFG7UM^SCX\EM;[3[J>RO;:5;OP\%EMKNUDBN+>5<G;
M)#(CKDX85>783Z_F& P//[+Z[C<)A/:6YO9_6<13H>TY;KFY.?FY;J]K75[B
MG+DA.5K\L92MWY4W;YV/I_\ X3WX1_\ 0S^ O_"AM/\ Y/H_X3WX1_\ 0S^
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M2FI:"?%&GZ#??'*ZM_!U[X=7PU>^+6UJW\>2:LNB2:>-%TZ_D:?("W=G<63
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MK;_B!?\ U4D__#>O+_J*\G]_D+^TG_SY7_@;_P#D3_7C_P"$]^$?_0S^ O\
MPH;3_P"3Z/\ A/?A'_T,_@+_ ,*&T_\ D^O\AS_A8GQ$_P"BA^/O_"U\3_\
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M_HH?C[_PM?$__P M:/\ B!?_ %4D_P#PWKR_ZBO)_?Y!_:3_ .?*_P# W_\
M(G^O'_PGOPC_ .AG\!?^%#:?_)]'_">_"/\ Z&?P%_X4-I_\GU_D.?\ "Q/B
M)_T4/Q]_X6OB?_Y:T?\ "Q/B)_T4/Q]_X6OB?_Y:T?\ $"_^JDG_ .&]>7_4
M5Y/[_(/[2?\ SY7_ (&__D3_ %X_^$]^$?\ T,_@+_PH;3_Y/H_X3WX1_P#0
MS^ O_"AM/_D^O\AS_A8GQ$_Z*'X^_P#"U\3_ /RUH_X6)\1/^BA^/O\ PM?$
M_P#\M:/^(%_]5)/_ ,-Z\O\ J*\G]_D']I/_ )\K_P #?_R)_KQ_\)[\(_\
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M?6M.7V#=[N_/TY=3^TG9?N5=N2^/LH/^7^]^!_KU?\)[\(_^AG\!?^%#:?\
MR?1_PGOPC_Z&?P%_X4-I_P#)]?Y#G_"Q/B)_T4/Q]_X6OB?_ .6M'_"Q/B)_
MT4/Q]_X6OB?_ .6M;_\ $"_^JDG_ .&]>7_45Y/[_(/[2?\ SY7_ (&__D3_
M %X_^$]^$?\ T,_@+_PH;3_Y/H_X3WX1_P#0S^ O_"AM/_D^O\C3P[XH^*'B
M?Q#H/AG3OB3XLMM0\1:QINAV-SK/Q&U[1]'M[S5+N*RMY]6U>]U=+/2M-BEF
M1[W4;MTMK.W$D\S+&C$?H'\9_P#@GE^WA\"?@)XJ_::\7_%3X:>(?@SX,\0:
M-X4U_P 4?"[]L'0/B9+!XFUZX@@TW0+73_#'B&YEOM7D6YCO)]/MW:[MM-$N
MH2PBUADD''B/!O 8.MAZ&*XPI8>MBYQI8:E6P<*<Z]2<X4XTZ2EBTYSG.2C&
M,;MRDDDV4LPG)-QH745>34FTEW=H:?TS_3(_X3WX1_\ 0S^ O_"AM/\ Y/H_
MX3WX1_\ 0S^ O_"AM/\ Y/K_ "B_@]\-OVJ/CG\7?A9\#O FH?$R'XA_&G4T
MTKX:V7C'QEXO\%:1XDGDM;F]2XMM=U^[MK Z:UO:3,-1C::UW!$W[I%S]6_"
M/_@GY^V[\;O'_P //AOX"^)MM?Z_XV\%?$SX@>(KF7XM^,5T3X1>&?A-XHU+
MPEXMN_B=JT9>VTR5M4TNX;1+?33J,FLP/%]D#2[XTSQ/A!EN"YOK7&5&AR4O
M;S]I@X+EHI5G[67^UOE@_JV(49/24J<X1O./*"Q]27PT+ZVTD]]-/@W]Y.W9
MI[,_TQ_^$]^$?_0S^ O_  H;3_Y/H_X3WX1_]#/X"_\ "AM/_D^O\K/XT_ S
M]K'X$W?PCMO%GB7Q?KR_'KP7>?$7X02?#_XB>*O&=SXS\%6GB'5O#*ZU!I.E
M73ZMI\EUJ.B7TD&F7MFE^+)8KF6*-9-J^#:;K7QMUG6)_#^DZ[\7]1URSD:/
M4-(LM:\=W.HZ4(KB.UN9M7LH+J2ZTNVLII%6_N;Z&"*R&6N6C"G'31\%<-7I
MJM1XLC5I-2?M(8*#C:$W3FVUB[+EJ0J4Y7^&:E%V<6A/,9)V="S[.;3V3VY>
MS3]&NY_KB_\ ">_"/_H9_ 7_ (4-I_\ )]'_  GOPC_Z&?P%_P"%#:?_ "?7
M^5#\;_@U^UU^SW\7O&?P+^(EU\2[CXD?#[2]&UKQ?I?@;QKXN\?:?HVDZ]HU
MIKVG:A=:MX;N[NUCM#IE[;RW-Q+Y4-K*7AE</&U>'V?B;XR:EI6K:[IGB+XO
M:IHF@HDFN:SIFM>.K_2=%67_ %1U?4K6[ELM,$IXC-]/ '/0TZ/@IAZ]*G7H
M\5QJT:L*52G5IX*$H3A6C&5*<9+%M.-6+3IM/WE).-]!/,9)M.BDT[-.;336
MZ:Y=&C_7._X3WX1_]#/X"_\ "AM/_D^C_A/?A'_T,_@+_P *&T_^3Z_RD?B%
M\/?V@O %O\.+F+XB>+O'Z_$KX:^&/B?91?#CQ=\0?%,WAG2_%M[<:?I&A^+T
MM=O]D^(Y;N 6XL@9H9IY8X+6XGE^4^*7WC7XIZ7>W6FZIXT^)FEZE8SO:WVF
MZGXI\7Z?J%C<Q'$MM>65WJ$-U:W$9XDAGBCD0\,H-.CX)4:\5.EQ2ZD7>ULO
M5_=ERR?*\4I)<R:NUUTTL#S&2WHK_P #?_R)_KL_\)[\(_\ H9_ 7_A0VG_R
M?1_PGOPC_P"AG\!?^%#:?_)]?Y#G_"Q/B)_T4/Q]_P"%KXG_ /EK1_PL3XB?
M]%#\??\ A:^)_P#Y:UK_ ,0+_P"JDG_X;UY?]17D_O\ (/[2?_/E?^!O_P"1
M/]>/_A/?A'_T,_@+_P *&T_^3ZOW'CKX9BQTY[GQ!X*CL7-Y_9L\FMVZ6]QM
ME07HMI3>!9C#-L6?8S>4[*K;20#_ )!O_"Q/B)_T4/Q]_P"%KXG_ /EK7W!\
M>_'?CN+]BK_@GQ<Q>.O&T5S=O^UU]KN8O%WB*.XNO(^*/@I(/M4Z:DLMQY",
MR0><[^2C,D>U6(/-7\$U0JX&D^(IR^MXJ>'YOJ"7)R8+%XOGM]:UO]5=.UU;
MVG-=\MFUF+:D_9+W4G\>]YQC_+_>O\C_ % _^$]^$?\ T,_@+_PH;3_Y/H_X
M3WX1_P#0S^ O_"AM/_D^O\AS_A8GQ$_Z*'X^_P#"U\3_ /RUH_X6)\1/^BA^
M/O\ PM?$_P#\M:Z?^(%_]5)/_P -Z\O^HKR?W^0O[2?_ #Y7_@;_ /D3_7C_
M .$]^$?_ $,_@+_PH;3_ .3Z/^$]^$?_ $,_@+_PH;3_ .3Z_P AL_$7XAJ"
MS?$3QZ%4$DGQMXG   R23_:O  Y)K]-/ G_!,G_@I?\ $?X0:'\8_#8O5L_%
MW@?4_B;X$^&6M?M"6NA_';X@_#S1X)KJ^\8^"?@]J/B2'Q?KVCBUMYKNSDM[
M,2ZA;1O+:Q.  W'C/!O 9?&G/'\84<'"K-4Z<L3A:5&-2I;F<8NIC(IM1C*4
MK:1C>4K)7*CF$Y.T:',UK92;_*'R]=#_ $L/^$]^$?\ T,_@+_PH;3_Y/H_X
M3WX1_P#0S^ O_"AM/_D^O\U3P-_P3%_X*4?$GX2^!_C%X,U?2M7T?XF> M?^
M)?P\\"M^T_I=A\9?&OA#PM+>0>(;WPU\*=0\0VOBC5[O29M/O([S3[*&:YA>
M%D=5?Y1E? K_ ()N_P#!1[]HGX6^&?BW\/KR2PT'X@'71\*/#GC_ /:*L?A_
M\1?C(?#;3QZP?A3X#\2^);37O&207%M<6=O)86X2^OH9+6U:1UR>27A7D4(U
M9SX\P$8T*RP]9RIX=>RKWJKV4[XZ\9_[/B+IVLJ-9O2C-Q?UZKI_LTM5=:RU
M6FJ]S5>]'[UW1_I@?\)[\(_^AG\!?^%#:?\ R?1_PGOPC_Z&?P%_X4-I_P#)
M]?Y%NL>+?BUX>U?5?#^O>,?B7HVNZ%J5]HVM:/J7BWQ7::CI6K:9=2V6HZ=?
M6LNJ+);W=E=PRV]Q$X!22-AR,$_5_B;]E+]N3PA^QWX/_;SUZ7QI;?LS>._$
MJ>%?#?BZ'XIZQ<Z[<ZC-?:MIEM>7/A&/5/[8LM#N]1T/4[*UUF=1:37,*1J1
MY\)?OK>"V$P_U?V_%M.E];KT\-AO:8.G#ZQB*L7.G0H\V,7M*M2,)RA"%Y2B
MFTFD2LQF[VH7LKNTF[);MVAHM5J]-3_4C_X3WX1_]#/X"_\ "AM/_D^C_A/?
MA'_T,_@+_P *&T_^3Z_S5/!__!-']O[X@?"O7_C'X+^+GP>\2>#?"7PPF^,7
MBZ'2OVUO"MYXH\)> K?2_P"UI]1\4>%[?Q)+J>@WD4)6S;3=26WN1JS+I?\
MQ]-LKX[^/OPT_:=_9EU[P+X:^+_BOQ3HVK_$?X5>"?C3X4@TGXIZSX@BN_A_
M\0K2>^\+ZA>3V&K&.PU&ZM[>5KO29_\ 2K%P$F^8US8;PBRO%UI8;"\:8?$8
MB$I1G0I8:E.K&4(QE-2IK&.:<8M2DFM%)/:PWCZB5WAVD[.[E*VNVO)8_P!6
M_P#X3WX1_P#0S^ O_"AM/_D^C_A/?A'_ -#/X"_\*&T_^3Z_R'/^%B?$3_HH
M?C[_ ,+7Q/\ _+6C_A8GQ$_Z*'X^_P#"U\3_ /RUKT?^(%_]5)/_ ,-Z\O\
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M@V[&8?I2/^#7[_@GL !_PVW^T1P,?\@SX:__ #$T?\0O_P#P3V_Z/;_:(_\
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M_P"CV_VB/_!9\-?_ )B:/^(L\%_]!F-_\-F-\O\ IUY_U=7/J.)_D7_@</\
M,_AQHK^X[_B%_P#^">W_ $>W^T1_X+/AK_\ ,31_Q"__ /!/;_H]O]HC_P %
MGPU_^8FC_B+/!?\ T&8W_P -F-\O^G7G_5U<^HXG^1?^!P_S/X<:*_N._P"(
M7_\ X)[?]'M_M$?^"SX:_P#S$T?\0O\ _P $]O\ H]O]HC_P6?#7_P"8FC_B
M+/!?_09C?_#9C?+_ *=>?]75SZCB?Y%_X'#_ #/X<:*_N._XA?\ _@GM_P!'
MM_M$?^"SX:__ #$T?\0O_P#P3V_Z/;_:(_\ !9\-?_F)H_XBSP7_ -!F-_\
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ML-"\/W?B72)?B3<264\(OM+TY?%*::RZFRK=2 _4W_$+_P#\$]O^CV_VB/\
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MJ6G4HR=.HX5:7).G!L=+&-6]E3WD])V=Y24GJJB:U25D[-73O<_/Z^_X*7_
M#X=_LP^/$^!GQ\TOPM^T#;_\$OOV4/@E\/)M$\,:O:Z]8?'3P%\7]7UWQSX:
MTZ[N_#C:59>(/#_A:^%Y)J[SC3D#JNF:G-<0Q;?R;_X*S_'CX6?M+_MCW7QE
M^$?BO2?&^B>)O@5^SQ:^+O%.CZ/<Z)#JWQ7T3X8Z3IGQ0FOK.[TW299=97Q7
M#>)JM\MGY-[<@S0SW"8D/],O_$+_ /\ !/;_ */;_:(_\%GPU_\ F)H_XA?_
M /@GM_T>W^T1_P""SX:__,37L97QAX=Y3C98_#YAFL\1-8F,I5LMK2<H8J&
MC*G*=/!TYRITG@:<Z,')J$ZU>34G4CRQ/#XN<>5TXV7+9*4=XN3OK-J[YG=]
M4E\_X<:*_N._XA?_ /@GM_T>W^T1_P""SX:__,31_P 0O_\ P3V_Z/;_ &B/
M_!9\-?\ YB:^E_XBSP7_ -!F-_\ #9C?+_IUY_U=7R^HXG^1?^!P_P S^'&O
MN?X_?\F1_P#!/#_?_; _]6IX)K^J?_B%_P#^">W_ $>W^T1_X+/AK_\ ,37M
MOCO_ (-U?V&?%_P7_9_^%NI_M??'73_#WP:;XM'PMKEKIWP_;4O$7_"Q_$^B
MZ_KHU59?"$EJ@T>]TRVM;#['!;EH9Y#<&9PK+PXOQ3X/JXC+)PQF,Y<-CJE:
MJWEN,35.66X_#II>RO)NKB*2M&[LW+X4V-8+$<LUR+6,4O?CNJD)=^T6?P"4
M5_<=_P 0O_\ P3V_Z/;_ &B/_!9\-?\ YB:/^(7_ /X)[?\ 1[?[1'_@L^&O
M_P Q-=W_ !%G@O\ Z#,;_P"&S&^7_3KS_JZNOJ.)_D7_ ('#_,_AINH3<6MS
M "%,\$T(8C(!DC9 2.X!.2.XXK^C3XR?$G]@']KKQC\#_P!MKQC^WEXQ_9S\
M3?"S]E;P%\)O&O[-W@GP=XT'[1-K\0OA5X&_X1'2]-^"7C33H$\$VGA+QU<6
M\%[?ZC?:C9_9H;N]:Z@WOMK]8O\ B%__ .">W_1[?[1'_@L^&O\ \Q-'_$+_
M /\ !/;_ */;_:(_\%GPT_\ F)KRLR\1.",QGAJRS?-\%7PT<32A6PN5U)2E
MA\;&E#%4)QQ6!Q-/EJJE2:G&$:M.4$X32E*,[CA,3%->RA).SM*:W5[-<LXN
MZN^MM=4?&W[/W_!3']AKP7\/OV%_!&K:E\-M&^,_PU_8?_:$^'NA?M=>+/#/
MC3Q/XO\ V1/CIXKUGQ!-X/T+7-#M[+^R?$.C>+M*U25M:U?1M/UJXL=5N$E2
MY6VEFB/@7@_XX?L-_M#WO_!-+]H[XO\ [:>G_LZ^._\ @GKX(\/^!/BG\%[K
MX?\ COQ%XG^)4OPS\;:AXPTCQ7\ ]=\/6+:%$_Q*>9+:^777TR:VFN))+U$3
M)/ZC?\0O_P#P3V_Z/;_:(_\ !9\-?_F)H_XA?_\ @GM_T>W^T1_X+/AK_P#,
M37A1XD\.Z<ZU7#YUG^'KUYUY2K1P%2M.,<6\Q6)HTUB<!7A3HU89K7BJ<8*-
M*4(5Z2C7J8BIB-'1Q;LG2IM)15N9+X>3E;Y9IMKD5WN[M/112_F1^/O[7W[/
M7[0/BW]IK5;S]CGX;6'CS]HKXV>/_&GAG]I'Q!\0?B5IWC+X3Z'X[\817NEW
M3>!=!U!O M\?#&B>;]HBETJ[DE%S=LR75Q'%N_;?XI?\%$/^"8OQ ^'GQS_8
M"TCQ3\0]+^#%M^P[X.^ OPE_:"UO6KJY_9_U;XD_!BSM?'_@KQ#X>^%5EX13
MQUX<\5^,/B1>:AINO^+K[,>I+9%+FVM[:Y6=_K?_ (A?_P#@GM_T>W^T1_X+
M/AK_ /,31_Q"_P#_  3W_P"CW/VB/_!9\-?_ )B:ZL9Q;X<XR."C_:>?489>
MU4P<:=+-)QH8F#P?L,3!5X5N66&6$A&C0ARX1*K6<L/.5124QP^,CS?NX/GT
ME=T]5K=.S5^:[NW>6UFEH?C--:?L5>%O^"9>C?LX_ ;_ (*&?L^?#CXH?%_3
MW^+/[:4GB#X=_&5_B)\6/%^BZ6]_X _9X\.:OHO@HZ9IO@/PK>E[:ZBO-4-C
MKWBN8:E>N+ ,TGR'_P %4/CY\(_VAOBK^S7XD^#OC*S\:Z/X(_8C_9T^%GBR
M[L[+5+%=$^(7@K0]1M?%7AB=-6L;"6>ZT:YGBBFN;2.>PF+@VMU,N6']*W_$
M,!_P3WZ?\-N?M$X]/[,^&O\ \Q-)_P 0O_\ P3V_Z/;_ &B/_!9\-?\ YB:Z
M,%QSP-A,9''2SK.L77C7Q^(3Q&5M7J9BJ$:W/+#Y?1J5(TZ="A1PZG.7L*%&
ME1A:G"$12PV*<>7V4$G&$=)](7M;FJ-)MMN5EJVV]6?PXT5_<=_Q"_\ _!/;
M_H]O]HC_ ,%GPU_^8FC_ (A?_P#@GM_T>W^T1_X+/AK_ /,37T'_ !%G@O\
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M5\O_ +%G_)JGP+_[$/3O_1US7U!7YEF/_(PQW_89BO\ T_,[(?!'_#'\D%>
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M *I\W/S<HHHK_3 _ST"BBB@ HHHH **** /Z^_\ @V;_ .21_M0_]E)\%_\
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M\OS[L"C_ &%X1_Z$CPG_ ."R3_Y*H_L+PC_T)'A/_P %DG_R55ZBB[[R_P#
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M82M@6\Z(*K&6$"[)EB"LK&2/<@5E.[!!/QE^VU-JFE_LP:-X7/B*[O+?Q?\
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M,B;G_P!A>$?^A(\)_P#@LD_^2J_%KX#ZUJ.C?#7]B34+:[GMO&O@O]NSXO\
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MG^85_G9?\%?O^4E/[5Y_ZG3PZ/R\ >$\U_HFU_G9?\%??^4E'[5__8Z^'_\
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M>_\ /%?_  (M?_C]']FWO_/%?_ BU_\ C]?#^Q?3]3_C1L7T_4_XT>P_O_\
MDO\ ]L!]YZ1I]XMXQ:$8^QWHXGMCRUNX'28GGUZ#O66--O<#]RO0?\O%K_\
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M4_XT>P_O_P#DO_VP'W!_9M[_ ,\5_P# BU_^/ULWVGWATC0T$2ED.J[AY]N
M-US"5Y,P!R 3\I..^#Q7P-L7T_4_XUVFN*O_  AG@'CI_P )7CKWU.R-)T-8
M^]O*WP_W9/OY"OK;R;^ZW^9]6?V;>_\ /%?_  (M?_C]']FWO_/%?_ BU_\
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M.0)86^C1>&Y-.;2#H5OI\$L=O;:4FENVGQ65ND<,-IB&%415 _*?P?\ M/>
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MS_\ 2J&@#_9:_9T_Y-^^!W_9(OAQ_P"HAH]>RUXU^SI_R;]\#O\ LD7PX_\
M40T>O9:_S_Q?^]XK_L(K?^G)'TT/@C_AC^2/PT_X.&/^4>-Y_P!EO^%'_I3K
M5?PM5_=+_P '#'_*/&\_[+?\*/\ TIUJOX6J_P!1OH=?\FBJ_P#979W_ .HF
M4G^;_P!*S_DY]+_LF\K_ /3^."BBBOZJ/YI"BBB@ HHHH *]]_92_P"3H/V=
MO^RU_#7_ -2O3*\"KWW]E+_DZ#]G;_LM?PU_]2O3*\G/_P#D0YW_ -B?-/\
MU!KGJY%_R/,F_P"QKEW_ *ET3_3SHHHK_!T_VC"BBB@ K_.T_P"#K[_E(I\+
M_P#LV;PY_P"IIXHK_1+K_.T_X.OO^4BGPO\ ^S9O#G_J:>**_4_!W_DM*/\
MV+L?_P"D0.',/]W_ .XE/\S^8JBBBOZU/%"BBB@ HHHH **** /ZM/\ @TF_
MY/0_:+_[-_T__P!36SK_ $#*_P _/_@TF_Y/0_:+_P"S?]/_ /4ULZ_T#*_D
M;Q?_ .2WQO\ V!9;_P"HE,]S ?[O'_%/\PK_ #LO^"OO_*2C]J__ +'7P_\
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M6M.N4DF;4;"WFGLHL_M5_P *=\.?]#9J_P#X(+?_ .6='_"G?#G_ $-FK_\
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MZKJCI)RY^9W]V][6TE"3LE:S?LXJ_P">EOGVBOH/_A3OAS_H;-7_ /!!;_\
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MX^TJ3AS)PIU$X\T%S)TZE*HFKWA4A+X9IL6&PSVI4W;LD[=.GFK?+R/Y,?\
MB$;_ &0?^CE/C]_X">$O_D:C_B$;_9!_Z.4^/W_@)X2_^1J_K.HK/_7_ (T_
MZ*3-?_"A_P"7E^?=A]5P_P#SYI_^ _UV7W'\F/\ Q"-_L@_]'*?'[_P$\)?_
M "-2C_@T<_9"5D<?M)_'[,<D<J@V?A(@M%(LB@C[-RI91N'&1D9'6OZ7?%/[
M2GP(\%IXX?Q-\3_"^E_\*UUSP_X:\>QO<S74_A/7O%>GG5O#FE:U;65O<W%I
M=ZQIH-[9(\1$EOB0D C/F>@?M[_L=^*K/6-0\-?'_P ":[8Z!97NH:S=Z5<:
MC>V^GVNFWUOINH/<30:>Z+)97]W;6EU;AC<03RB.2)65]O7#B_Q"J0]I3S?B
M"=-<EYP5>4/?C"=.\E3:]^$X2CK[T9QDKJ2;3H81.SITD^SLGI\^EOE;R.W\
M'?"WXK^"/"/A;P9I'Q>T632O"7AW1?#.F27GPRMI+N33]"TZVTRS>ZDB\511
MR7+6]K&T\B11J\I9@B@XKH_^$5^-'_17/#O_ (;"'_YKJ\^^'G[:_P"RI\6/
M%=IX&^&_QP\%>,O%M]J%UI5OH6B7%]<WO]IV5I)?W>GS@V*16E[;V<3W$MM=
MR0S)& 2GS(&^HZ^,Q-#%4*C6+HUZ-6=ZCCB*4Z4Y*3?O\M2,6U)W]ZUF[F\7
M%KW6FEIHTTK=-/(_/G]K_P#8=UO]M?X/R?!+XM?&J?3O",OBC0/%K7/@_P
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MX2_^1J/^(1O]D'_HY3X_?^ GA+_Y&K^LZN)\&?$?P-\0IO%]OX*\2Z=XBF\
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M%+_B//C'_P!'%XF_\+5Y?]._+^K*Q_Q!;PJ_Z(3A_P#\)'Y?W_)'Y>_L2_\
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M_P /2WFC"WUS4H;26.VOSJ=WYM?9?[.?QX^+OPV\9_ME_"+PQH/Q1_:Y\$?
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M#276UMO,TN)?L$K6\+RV[O&K#53]F;]G>/14\-Q_!#X6Q^'XO!6M_#>+1(_
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M7D-]"(YT@=?VR\*_L>_LM>"++Q)I_A7X _"O1[7QAX1N_ 'BM8/!^DRS>)/
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M;\)-&^,>K^ M:/P@\5_ 71M1\/:QX=\1V&G2W^E-?#4=0U"YNEN=;M+"V=(
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MB>(O#GBGX0?#[6]$\6^,C\1/$EA>^&-,:/6/'QB@@/C6\>.!)G\5>1:V\/\
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M1+T'A3XQ_%B+X'_L^_MF#]H#X@:M^T#\4?VY])^$'C3X-77B<7/P^F\'Z_\
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M^(+GP=IGP]GUG3]!TVSU&7P)HLDTND>#VNK>WCE/AO3)+B=[#1MPL+1I9#!
MF]L\U;B/ .&)>'P+IU:JA]63H83DR^4)/VLZ$N64IRQKDJU9N--T:M.$:;J*
MTX5&C.\>:5TM]9>_M\6OV;-1U::=VNA\Y?\ !/3XB^,?BU^Q'^S)\1?B#KL_
MBCQKXH^$_AR\\2^)+I85O->U2WBEL)M7O?LZ10-?:@+1;J]DBCCCDNI99%10
MVT?9-<[X2\(>%O 7AO1O!W@GP]H_A/PGX>LDT[0O#GA_3[;2M%T>PB9FCL].
MTZSCAM;.V1G<I#!$D:EB0HR:Z*OEL95IU\7BJ]&FJ-&MB:]6E12BE2IU*LIP
MII1M%*G&2BE%**M9:6-HIJ,4W=J*3?=I6;"BBBN8H**** "O#_VD?^2)^._^
MO/2O_4@TFO<*\/\ VD?^2)^._P#KSTK_ -2#2:Z<%_OF$_[":'_IV I;/T?Y
M'N%<'XZ_X\9/^P3J_P#*SKO*X7QNCO9NJ*SL=)U<!54LQ.+/@  DGZ"N>.Z]
M5^8S\[OVK?BYXB^"/P1UWQUX1@T1O$\WB3X?>"=#U'Q2LS>$_#6H?$7QSH/@
MF'Q;XJ6WFMYGT#PS_;9U>^@2XMQ=?9HK1[B!)VE3\QO%?[0G[0_P!^-'[4/A
MJ^\;:-\9/B/K/Q)_8_\ @UX>\2>$?"=S>Z%X-A\<^"/$FJ7VM?\ "J1XF72(
MO&;P6$EG'I-KJ^EV.NZM>Z)/?AR6BF_;+Q+X-TCQGX?UGPGXO\,6?B;POXBT
M^XTK7O#VN:8-0TC5]-NEV7%EJ%E/&T5Q!(,$JPRK*KH5=58>-Z-^R-^SIX>\
M&^)?A[HGP ^'VG>"_&:::GB[P_!X7#6GB9M%.[19];GF,M]?WFCMAM*OIKLW
MFGD+]EGB"J!]/E699;@\-4I8O!/$3JS2J6HT)JI26)R_$0YJM22JP5'ZI77U
M>"]EBGB+5IP5-7RG"<I)QERI+N]'::>EK:\RUO>-M$[GPSX*_:4_:J^(6K_#
MOX&WMQX1^#OQ)\3>+_CA:S?%KQWX%LGDUWP?\(M*T+4M*@MOA7;^*KFP\/>/
M==E\0"/Q)H]]KDG]EZ;H.KZE8:?$LT!AN:_^U'^T-X>U_P",6OR^)OA!XK\$
M_LW?LD^&OCWXMT+X;Z%>Z_;_ !C\::IIOC2WN-,\'>++C4#+H'A"74-"L-31
MDM=2U%&2ZTR.[,&;AOMF^_9%_9UU+X=Z5\);[X">!+CX;Z%JUQK^C^$7\..-
M/T[7KWS/M^MVTZ.FI+J^HK+*FI:@U\UUJ$4KPWDDT3;*]'T#X1^ ?"IN#X:^
M&WAK01=^%-'\"72:5X;M;.*Z\$^'H;BWT+PG<0Q6XAF\/Z3!>7<5EILD;6\2
M74XVGS7)UGFF47E*GEL+2YX^QEA</"/O8M5)U8UO:5JE*57"7P\:$%*G@IKV
MN%G>;Y9]G4T3J-;>]S2;TC:W+HG:7O7>LEI)'Y2>&_VR?VE-'\%>.+SXFBST
M5]7\#_"+7OA=X]U?X+W-E=IX]^*OBN+PU;?#[P_\+/#WC75M9^(>FZHMS;R?
M#OQ+-=Z3;7UZ)[?7KJ6.%R*^C_M?_M8^)_AKKMOH^CHOB_X;_M-_$'X._$;Q
M!9_#?0-6^*L'@7PA\-/#OC[3/$>F_ -/&T=OJVMPW_B.+2?'>F^'=6U*^\/Z
M)9MJJ:7!<S2+!^B6D?L<?LTZ#X9\9>#=&_9Y^'FG>%OB";'_ (331+?PN?LG
MB!-*N7O='BNVD:2XAM]&O9'O-&M[*:U@TJZ8SV$<$AW5#/\ L8?LQ7/@R+X>
MR_LZ_#K_ (0N'Q'+XQCT"+PPT%N/%MSI=KHE[XF:Y@DCU!]<U'1K&STG5-1>
M\:XU+3[>*UOFGB7%=/\ :V0<TY?V7K+$0J1;P6%Y(4XT*5-R]BL2ESN2JR>'
M=26%J3<*TE&7/3FO9UM/?VBU\<M7>^KY=K6UMS6NKO=?G)XR_;T_: \1:PR?
M 73]*\;:-X$^!'P;^+>J:WHGPRN;WP?\7-6^)D=Y<W]KJ&M>)O%>@7WP?\'6
M4.EW>EPWLT6JZCI_B"1HM0N'ALVMI8_V@/CM\=_B%X<\0>,K+Q_X*^&GPX\%
M?MR?!CX /\)([6\M/B7>FP\:^%3J>K7GCRQURVF&I^(+C4)Y;+PO;Z5+HFL>
M$8]TS3&?[2/TY\5?LI?L^^.)/!<GB[X"_#_7S\.M.LM&\#I?>%(O(\.:+IDL
M<^FZ)96T"PV\NC6%Q#%<6FE7L5U8P7$:SI )-S--X@_9:^ GBSQ^OQ4\3_ O
MP'KWQ%632IQXOU3PM%<ZO]LT(PG1-29F46SZKI MX(]-U5[9M1M(HHX8KE8E
M"!4\XR2C4P]2EECI.@FW)X?#5JLY*="7+*<ZL83=;V=6?UE4:=;!NJZ6'C.B
MH*(Z=5IIS3NUI>5NO2UTEI[MVI6NVFSV^[ %U<@  "XF     $C   < #I@<
M#I5>K36EZS,S6MTS,2S,8)22Q.22=O)).2:3[%>?\^ES_P!^)?\ XBODELNI
MT%:BK/V*\_Y]+G_OQ+_\11]BO/\ GTN?^_$O_P 10!6HJS]BO/\ GTN?^_$O
M_P 11]BO/^?2Y_[\2_\ Q% %:BK/V*\_Y]+G_OQ+_P#$4?8KS_GTN?\ OQ+_
M /$4 5J*L_8KS_GTN?\ OQ+_ /$4?8KS_GTN?^_$O_Q% %:BK/V*\_Y]+G_O
MQ+_\11]BO/\ GTN?^_$O_P 10!<T;_C]?_KROO\ TF>LE>@^@_E6]H]I=B\<
MFUN /L5\,F&0#)MW '*]STK*6RO,#_1+GH/^6$OI_N4 5Z*L_8KS_GTN?^_$
MO_Q%'V*\_P"?2Y_[\2__ !% %:BK/V*\_P"?2Y_[\2__ !%'V*\_Y]+G_OQ+
M_P#$4 5J*L_8KS_GTN?^_$O_ ,11]BO/^?2Y_P"_$O\ \10!6HJS]BO/^?2Y
M_P"_$O\ \11]BO/^?2Y_[\2__$4 5J*L_8KS_GTN?^_$O_Q%'V*\_P"?2Y_[
M\2__ !% %:BK/V*\_P"?2Y_[\2__ !%'V*\_Y]+G_OQ+_P#$4 5J*L_8KS_G
MTN?^_$O_ ,11]BO/^?2Y_P"_$O\ \10!6K:OO^0/H/\ W%?_ $JAK.^Q7G_/
MI<_]^)?_ (BMF^M+HZ1H8%M<$K_:FX"&0E=UU$1D;<C(Y&1S2>\?7]&!SM%6
M?L5Y_P ^ES_WXE_^(H^Q7G_/I<_]^)?_ (BF!6HJS]BO/^?2Y_[\2_\ Q%'V
M*\_Y]+G_ +\2_P#Q% %:BK/V*\_Y]+G_ +\2_P#Q%'V*\_Y]+G_OQ+_\10!6
MHJS]BO/^?2Y_[\2__$4?8KS_ )]+G_OQ+_\ $4 5J*L_8KS_ )]+G_OQ+_\
M$4?8KS_GTN?^_$O_ ,10!6HJS]BO/^?2Y_[\2_\ Q%'V*\_Y]+G_ +\2_P#Q
M% "V/_'[9_\ 7U;_ /HY*]/O?^/R[_Z^9_\ T:]><V5G=B\M";6Y %U 23!*
M  )4R2=O %>C7O\ Q^7?_7S/_P"C7K.IT^?Z <-^Q9_R:I\"_P#L0]._]'7-
M?4%?+_[%G_)JGP+_ .Q#T[_T=<U]05T9C_R,,=_V&8K_ -/S)A\$?\,?R044
M45QE!1110 4444 %%%% !TZU!]JMO^?B#_O]'_\ %5S'Q 9E\!^-F5F5E\(^
M)&5E)5E8:->D,K @JP/((((/(.:_SU[?Q'XF\F/_ (JCQ1]W_H9-<]3_ -/]
M3*7+;2]S:E1=7F?-RVMTO>_S1_HG_:K;_GX@_P"_T?\ \51]JMO^?B#_ +_1
M_P#Q5?YVW_"1^)O^AH\4?^%)KG_R?1_PD?B;_H:/%'_A2:Y_\GU/M/+\?^ ;
M?5'_ #K_ ,!_^V]?Z>G^B3]JMO\ GX@_[_1__%4?:K;_ )^(/^_T?_Q5?YVW
M_"1^)O\ H:/%'_A2:Y_\GT?\)'XG)POB;Q6QQG">(=?? ]]EZV/QH]IY?C_P
M ^J/^=?^ _\ VWK_ $]/]$G[5;?\_$'_ '^C_P#BJ/M5M_S\0?\ ?Z/_ .*K
M_.V/B/Q,.OB?Q2.V#XCUT'/3&/M^<YXQC.>,9I[:]XK600MXA\7K.2@$#Z]X
MA6<F3!C"P->"4EP04 0EP05R*/:>7X_\ /JC_G7_ (#_ /;>O]/3_1&^U6W_
M #\0?]_H_P#XJC[5;?\ /Q!_W^C_ /BJ_P [?_A(O$^6'_"3>*P4X<'Q%KP*
M')7#@WPV'<"N&P<@C&12?\)'XF_Z&CQ1^'B37"?R%_D_04>T\OQ_X ?5'_.O
M_ ?_ +;U_IZ?Z)/VJV_Y^(/^_P!'_P#%4?:K;_GX@_[_ $?_ ,57^=['K/C"
M8VZPZ[XSF:\E^SV:Q:WXCD:\N-RH8+14O";F<.RH880\BNRJ5#, ;$M]X[AC
MO9I]3\=PPZ;<I9:C--JOB>*+3[V3=LL[Z5[I8[2[?8X6VN&CF8HP"9!H]IY?
MC_P!?5?^GB_\!]/[WG^7?3_0Z^U6W_/Q!_W^C_\ BJ/M5M_S\0?]_H__ (JO
M\[;_ (2/Q-_T-'BC_P *37/_ )/H_P"$C\3?]#1XH_\ "DUS_P"3Z/:>7X_\
M ?U1_P Z_P# ?_MO7^GI_HD_:K;_ )^(/^_T?_Q5'VJV_P"?B#_O]'_\57^=
MM_PD?B;_ *&CQ1_X4FN?_)]'_"1^)O\ H:/%'_A2:Y_\GT>T\OQ_X ?5'_.O
M_ ?_ +;U_IZ?Z)/VJV_Y^(/^_P!'_P#%4?:K;_GX@_[_ $?_ ,57^=M_PD?B
M;_H:/%'_ (4FN?\ R?1_PD?B;_H:/%'_ (4FN?\ R?1[3R_'_@!]4?\ .O\
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MX4FN?_)]'M/+\?\ @!]4?\Z_\!_^V]?Z>G^B3]JMO^?B#_O]'_\ %4HN;<D
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MT;Q='+.EPECXBMM56W%P_P!@?\+IUK_H6_"O_@+?_P#R?1_PNG6O^A;\*_\
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M6K[";XSZXAVMX9\+*< X:TU '!&0<&_!P001Z@YIO_"Z=:_Z%OPK_P" M_\
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MPO\ @-^RYHW[/?PGFOM1M[W7_$%_K?B.R\0>._$.KVUO''_9RP1^&]!L;1)
M$NI;^_-M%%;VT6[UU/C/KLC!(_#'A=W/14L]09CWX5;\D\<\"F#XUZP2RCP[
MX3+(=KJ+>^+(Q&0KJ-0+(2.0& )'(R*IYEF,J4J$I4G"5.=*T:.'I2C"IS)I
M2HPIMJ%.=6A1C/GA0H5JM*A&G%KE/9PO>VMT]6WJK6W;ZI-M6<FDY-GMM%>)
M_P#"Z=:_Z%OPK_X"W_\ \GT?\+IUK_H6_"O_ ("W_P#\GUYOLJG\OXQ_S+/;
M**\3_P"%TZU_T+?A7_P%O_\ Y/H_X73K7_0M^%?_  %O_P#Y/H]E4_E_&/\
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M7Q%6;LE%*2C&,8I).,5%-+9V_"*BE\E%>?F>V45XG_PNG6O^A;\*_P#@+?\
M_P GT?\ "Z=:_P"A;\*_^ M__P#)]<OLJG\OXQ_S*/=;+_C\M/\ KY@_]&I7
MJ-]_Q^WG_7U<?^CGKY&TSXRZS-J6G0MX<\+JLU]9Q,R6M\'427$:%ES?D;@&
MR,@C(&017U[>(#>71.>;F<_G*Y]*QJQE'EYE:]^J?;LV!P/[%G_)JGP+_P"Q
M#T[_ -'7-?4%?&_P*C^,_P (/A!X ^&6J?!2_P!:U#P5H$&A76K:7X^\"QZ=
MJ,EK-.1>64=[JEO>);SHZ2)'<P13QAMDB!E)/K/_  L3XL?]$!UW_P .%\._
M_ES77C:,JN,Q=6G4P\H5,37G"2Q>%2E"=6<HRLZR:NFGJD^Z(B[1BFI744G[
MLM[+R_K7LSV^BO$/^%B?%C_H@.N_^'"^'?\ \N:/^%B?%C_H@.N_^'"^'?\
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M?_#A?#O_ .7-'_"Q/BQ_T0'7?_#A?#O_ .7-'U:I_-A__"O"?_+@YE_>_P#
M9?Y>?Y]F>WT5XA_PL3XL?]$!UW_PX7P[_P#ES1_PL3XL?]$!UW_PX7P[_P#E
MS1]6J?S8?_PKPG_RX.9?WO\ P&7^7G^?9GM]%>(?\+$^+'_1 ==_\.%\._\
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M,RBM/^QM3_Y]3_W^MO\ X]1_8VI_\^I_[_6W_P >KCNNZ^]%F916G_8VI_\
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M35"E2@Y7YDO9S]ISN2=W#37W>5MM*[LTT[:):N[1UU%:?]C:G_SZG_O];?\
MQZC^QM3_ .?4_P#?ZV_^/5X-UW7WHW,RBM/^QM3_ .?4_P#?ZV_^/4?V-J?_
M #ZG_O\ 6W_QZBZ[K[T!F5VNN?\ (E^ /KXL_P#3E8USO]C:G_SZG_O];?\
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M?_/J?^_UM_\ 'J/[&U/_ )]3_P!_K;_X]7!==U]Z-!NC_P#(7TG_ +">G_\
MI7#7Z/W?_'W=?]?$W_HQJ_/+2-'U(:MI1-J0!J5@2?.MN@NX2?\ EM7Z&W?_
6 !]W7_7Q-_Z,:N+%M7AJMI=5W0'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img75897552_19.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img75897552_19.gif
M1TE&.#EA&PMP!_<  /___P  ,P  9@  F0  S   _P S   S,P S9@ SF0 S
MS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9_P#,  #,
M,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S, 9C, F3,
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MS)F9_YG, )G,,YG,9IG,F9G,S)G,_YG_ )G_,YG_9IG_F9G_S)G__\P  ,P
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M"46WX8<@ABCBB"26:.*)**:HXHHLMNCBBS#&*..,--9HXXTXYJCCCCSZU^%
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M=OFTDC.)'](&D"3C#^;WE* DDHEX(&JGDV68#-.'CB6%#/:G(($X<G0WDH.
MAJNP=K97(FM84TP)4$YIE?#1C:JUD!&4@'3I) 6Y6JI7+37I6G_X'\\ EF/X
M5$&I(7VY6MI(']!@4I9U#"EY(?JH4W%Y4'.YE^@A@K!%0[/0@IJ))(N96G_)
M+ XYCNMQ5D=GF!.IDY WEB,RFBWG'^ZH6)-Y(&^95)?I4)D9FN!!>W&6F#.D
ME[XI)+*96E_X*<^0@R"U"MH1F 7@ E% !Y[ G*YY4\CP5O#!C'V%#&UY(GV
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MYD@;Y07OVJ.@LPROZ?4Q#Q7?7SBMNQV>'32/=NQ1WK;NX*N@>7(]PN)^*OQ
MZ")/\;R;\E3B#WQEYU4"G80-(H$HSQ9"@7[W(K5I<J=,Z7LHZCZ?)*Q-VT9_
M):O@X'1M(AN_]S@.,X7NOK"-'<,LX$L?5U6O).] -&EO'5W?_-)Q]N9 <]@A
M#WDC0M)/_==A_3K_<_S1'V#;(0] LT!S?V';,0]4<]\9<@7!\ ==W0[O,+?R
M'^4=# C,S?DDC?^)'_PWO?GY__\  6^>/'GP!!&$1P_ 0H8-%_;+4D#B1(H2
M4R1RF%'C1HX=/69<-68+ERUB1I8\:9*D2I0K3\KZ&%/F3)HU;=[$F5-G37H%
M![IK&50,()\($?7;F53I4J9*DP7K%&P45*E2H37%FE6KS5DO*DZLL77KJ:]?
MOXA%FW8AV;(36ZF%"^ 9U:E1ZU8E=37NPCYM*2XXM5?P8,*%#1]&G%CQ8L:-
M'3^&S# ?2\KY(E]6J\_E9D"S,'><!6BS4$#^$O,3B/!@T8*K+1\^)#1E_TE]
MGVW?CMQ*GS[=M7$KSI>NG(QRYH:;,T[<G#I^'),7/_X\N;EV&?NI&PY=!O+L
M\$QOO)Y]^G/O&M]M-^XYXRQUX\4/?\>QWSKMW)67@_<;JQ?5" >.'JHU_PC:
M8X&:9ADD"Z_\8K#!BE[H(Y'O=&IEC]52$Y U@P9LK<$7D-*/IM@HVX*>54@$
M<+84UUE%O1!?A P?V5*DL20NVGF'H SE:0Y&'SMZQBZZJ-+K1Q]K:"L%%P]K
M98$&LXC&2,=::7"0P:!Y2D@A27D&@'Z0J4K+,(,A!<2XOG#P(BG79+---]^$
M,\Z9^NG/I]?DO&U$%3O#$T]^4+1Q0L7Z 010E?_X7*P?1.K$<$,-+QQ(GCL'
M%:G&0P3M,U/,>NM-4T\_!354CA#\8D$'3T7U5 -%A6N6>PR9,=9#$>F15<=<
MU;-&0U5L:159>+T4 'YD6>600GG=55=DD37DD%7XP72P7U=:Y3)_QKQK%&1L
M5:ROMFK-*AI3V_J0V\7\&?>K+)8B94@QLW6WJE&B%<M;!A=XRUQ]]^6W7W\+
MTR>?GAQM=#5Y(C5HTG^QFH6+% ]9F$U_3 )T2:UD<5A6B!NKI^ !ZS%34WZ4
MW3ABDS_B=+>35V:YY<723;6L55T6#)]YDM4X9'/[.7%995?BXA"%;9ME8$C[
MNX=>AV;!AYYC?Y;5YZC_5ZKU$ "K?:S==Z7RC>:F!O$K7YK\B>A>L;U6#&:*
MUJ4I&7BWACO,;9D"VT&,T,8;QG[RP4?GO/]F<^]ZCL[0XT<1JH?1>=X9K0O%
M%:<'7+3Q,;1KP&'TIU+9+)_IGJD58LR??#@D^"B7*9=ZZ,L_39GSU5^''6^U
M8_XK]L;TL1IJ$H6^J6>2$-E)%JNGGAH01%SOUY]%#_>)'J75.@1%0&+[&5'(
M@L26*M5MWVAVVBL*C/O+RB;WH7C?SGYK9"2GJ>X&PQ<_?L7H0?CH>9Z7/W^.
M_&&:'L/_K]^ Z'$/B^T$'P R! "*U:QB\0IX#N''\@@6P(/Y352Y:@D@]"<E
M_PSBS%!88TP^)MB?>2#/=JO0%1?,]"O*@'"#D&G="V4X0QK6L%4H)!Z*_B"+
M?LA"'AZ4FA@,40_VV7 A-GM<06@UF.C-)E@-P2'.'IB8:Z%/6S/TWO=F9L3%
MN.U\=(D"_I3B/@99B8MG9$H_C$8ZPHVP< &<!SWR440T/F9@<(Q6/_ AP3;V
MD72(N(<^Q+B7?#PMAX<P%A!U=Q(N ,(=[^CC/.CXHH8]K(ZW^:$3_4&]&1F2
M8H?IQT#<F+!+:L1SR>K,\%I82K7$D)6OA&4L9]C!+21R))*Z!P)EJ11]R,./
M!#&A8C:90WP01FO9(\4D+Y=%VFUQETOQ!YBL2!5,D?_Q>]<L@!F?^<S1_1*
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MT0/+NE^=P'A=L#&S*L4-/]ICH2_RQV_?^]\'_S;UP74_%_TFFJ]ER/-*_)5
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MCJ_]4.PBQQ)W9M%G"S5E4+,,W2.?0=L.M=.4)1-T+T,47S3K+.WH9,XZPP)
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M1/ ID*I,1,OL$*B0G6*(UD&8U*;)AUYEB.\\_] 8'572-8]5U,1 T)"F#9(
M)<N%8(1N^""VE4SN44ER*=% U$.4<5_'-,4//8J,M0-@S 5%<14F/95(.,5.
MZ8:%Z$3_;1-AB*'>J<."?&$8CI%7_=LN(9D[@$H_*(]WC5%Z40D<"L*2#(9.
M;!Z=#9M/>,0ZU .#Y ]*;-L@F19=89 ,P,.2%**C3!> 302>E XB' 4B;$_I
M28RU:"(L>40[T$;QH(2IA5&K343R/<B2'&%UL9E.W"!#3%\Z(,)FH$ZG&: R
M!@D!+J,S/L8)OL38*!@BP5TK6L_U0:+(.,\O(46'K9[(8) @(,7/55X:P1TX
M[LF!.94P(84(]DJ (?_-2^@#SI6-9AD14HS>3@@C%ZT9O\A8"7;,+%!C2^1#
MV-773H@<151,/PV:.R9)]I',0,[32Y"AX(53@D1DTA3%\=F,3ESCH1"&"XH1
MC]UB2WC511+3<6ADC/Q:1R(,$A551&B/O*71S&2A3^"&3,J.6?#C0QR0&Z81
M$@7DT63,,QXEB30C4BYE=K2%4ZS#-&VA9CV-5<R25^E</YU<V=3=0*A''7+1
M_KW<;^RD54%=3V429ES1$G(%)T[6%.E$?HBA0_:3LF7@ ,$B(LW"%)D%7*(,
M+.V3/_E.X[0@6/T7VOF3WCW-.NRD4I4.5WJ,]PQ1MUR$-@I/6KZ<9H@$/(;_
MTP<YI8MXFTR98QJUPG TCD_.A7S8I=$PV&DR! +ZF/WPI3GHWARQI,@@8^/\
M7;'MC3]-GVMP7$3$E4).ESIE9DN$4J)UE5C"I7Q!Q :6 U%*3$I=IHN8)1-^
MX%)FY\>X%AAIYS/^!#_RF! >"D$:S5 HY$0.EVM$4T:FD;0$4IU%S2S<@R$2
MW'A\I!AU%U8Z!*2TPUCQ51;EU6-"2SZ@0S<^!'^9 UVU9QA13!_]1#IHG4ZD
M@[EP6CK&BU7EBHS10SZ\R?9$WQ.6RA@M"V]U5X&:UL'031@!REI^UJP-)4N]
M6\& Q'+FF[XQ5!J)5 DM5-E,1WJTA9E)5,9UT8T<_VA#*,OW=%CP44WZC<S<
MX&2%&-]$4%E<G-J0,@2@J .$)9>Y;*#HB!%U#8MZH(S<=1BR,40TAI&0042(
M"28@G0I&V2<7P4Z7*4_) 8"7OJ2N5(E)%9&,V9Y#:%Z.&H2;,97<U8,'RL"X
M'-6%<HMP;MDG=LZ0V908-<5P[H5WK(2@>B>GGHA2=NIJH>3X)05A[,GR#"A!
M.4]EAI'*'))#9-*JKI8[A9'?O"3Z]$A*F056B5E;>9GWQ9UCH41T#I2$J&:\
M_&<RDJI%* 2>+2/+ 2AL(:N5*4^L#I0_$$<7\1=#H>J-X"J:@21KQ8=%#.OH
M9)I)*D3RX:4 ADEKQDN'$?^54@C(%RZ',[J,L::1X.S40P!:M0K41!IIR?S8
M5R@%U;"'JF$(J":L%W%GHRILR<2*QNC4J$I$^*&JPUYLP#+F-JD#K%W/3KA#
M)\+#KF(LR<[IR/:2#&C,7B5KPGUER;ZLT6@$(MD&K,7'L;A5 X(KS.YL]YVL
MQ^ 'M,D8O$X$(K@LSQ[MOO #N4*+LK@@Y VL#M(8TDYM:X5(=U)M;$W5_6 M
MUW;MAG : 'JMV(XM:7C@2)(MVJ;M2US8E:JMV[[MD>SE&\$MW=:MS\"AQ=HM
MUGZJWO:MW_XMX :NX XNX1:NX1XNXB:NXBXNXSXCWS8NY$:NY$XNY5:NY5XN
MYF;_KN9N+N=VKN<VQ.-^KNB.+NF6KNF>+NJFKNJN+NNVKNO";>B^KNS.+NW6
MKNW>+N[FKN[N+N_V[N'&KN\&K_ .+_$6K_$>+_(FK_(N;_$"+_,^+_1&K_1.
M+_56K_5>+_9FK\@XK_9VK_=^+_B&K_B.+_F6K_E2+O>>K_JN+_NVK_N^+_S&
MK_S.[Y.D;^4.P@L4@/[N+__VK__J[PM\ 8E4!T\Y(-U)!&;$#%RV:[Z,HA]1
M)P,?:3NL0Q>TPP2[@P5?'R!A\ 17< </8W)1L 6O Y7R93KDK9CYPS.4 C*0
M C(D0S(L+6E0U\M!:;;0*TN@37XTZ>*D)3P(2Y9TWI>._P=?K@,'4S"2B64$
M-S!5 FRN4>7WS(.PF-@(O=R=3D13UC \Q!BAX([:4M0K=<Z]D@8]C+ '&S&2
M/841F[$%4XO GG$%2^AA)NQJX(/&D@AUVO"M.3%$')R48C%5OD/3R</*INC+
M7+ %4YYSB>%")*99U)9GNH,\I%R!#::^+L73R,-RG1@%6[*$"5US_.<8;TCY
M73&QE/)J\>4=.\<-(5RHT,,9'W&BLC$B=U);Q'([J%/CF+(!ZL,A'$+#AL?$
M@<0\?!P]P,.RA"VQ1=E()JI+M!XBY_)ECG)ME!<=<>A4D)=.^*R?*%: DA5$
M?(U8IH,[F-@[J.=.?)M8OL,]5/_?QR&"TX HK3DE/. #/NC#/.CRFSY$E*"0
MRDU%%4H;4FC=.HCP!$L.7[[2K8TGR>;#",ORGQ8T+K>#&=7C!SYT+O.E13 T
MVMKOY/XO2(=T_W8( 5],?E!(G$*K0B2P0\C3N#YP><)$^MRGKC[&<+5KY^16
M:*+4,B;#* 1#)P3#3P?U4 LU4!LU41_U*"!#A]#P49BIJ]")/"<;C\";4T!I
MP&"&9 :94ZQR%5\JG9B1WEVJY5Q$0")C"2K<PBF%."OF.]"#.^BS*S=R,,+E
M! =T.51@%5[!!&OTV0X/7*J#.R1JJ/VD-2,$/,Q#1C^-^^B-<K6"^PG51U@,
M*J^2!CO_%V:<4UL/S%L+1KY&H5CTLSFLRP%GFUGTJY<A@B8G]FH+@B;SLGB4
M-HFM]1?:(M'FQS@.R(0>R?;044"^W'%Y()0RF!FA#I0V4SD\IEJO\D(\#>%8
M9'(_!-J\$KOX=6+G\F R36_#Y=-LCL<.C#ND'#U(]F92=5NH X&M0Y3)@**4
M'_PL3Q?(;4P/!-H@FD0O)^%P31'+PSRXPY;6B717M:3 C3!M\3ML]U]YHCK,
M@V#D<Q%C<)]TSE3OR6Z[A"IK'TJ<(N[T=5H6ET;+@#L(U>[$Y4-\-SF+-WE7
M#0LUCL88V-FVA%7)0$NTQ2-I'4<SW"J(P19PP1;H.!<  H,<_T*/[_B04S-D
MV ]PO@1:(I4^M+(P=>1PK-11S;5$)/%B/M.]A)PTOQS( IJ+5#!WG^M ).HZ
M;#$5NX:8S^M&LU!^>#=F<#-ZW3)KE_'3L"&9H,3D:5<[('-:7BI$;$]T1OE$
MP&4#"4S;.L1ZO(36K52,8\ZMK4,52M4(-8[5R!C4O'5PJ:>=OYE%@)YGV@F#
MO5\+M@/.W7)G#DPGPR4@=J56S_F?;CHF>P2KY8=U H#>^#G9>K37MH)(][JO
M_SJP![NP[V^ME[1#.*#[W-U*>T5 Q5LAR2UA:9U,PI"?B<5-LT1.-P025:G1
M0(-2?WM2ASM2CWM1ESNXD_NYF[NXJ_\[NJ_[N:\"',&EJX#M84BU<R[/<_@=
M4OA#YU!DC%RXCKA&2SMP0_395(\@4B C<W,.7X;%]A#6<YK;=-_[1UPJ7))?
M@8")=3"$!A,6#/4:Z%&E.FA998/P15C7<-2H9^K$PK?TTY"V))I$6[3\J_B#
M/+@V(;L7(>,\:^_\:NL\// \T M]:_]\T>?\T?=\T!N]SR-]TRN]T.]D:5M/
M6X#''M.*15RJ!]IF;:SL$"L$<+,$,CI6"T;$L^93P6,&4GBI,J^$<R-&!S7$
MQ"]$IGD;7#R@:XI&1'0=9ELR7_H*V%QHR3M$GRUIQMM+32[Z1/"H$P_^A#$[
M(,NK)Y7PX]3_(O9!1)_92H(J:%( ?//TEZ9X1">ULNZ1?D/P_<KW/6@'2R _
M1HS/>$RS'.2[V)#SN(_7/N[?ONX3^>[;/N__ON\'?^X#__ +?^_G?L.:J9RJ
M^4[XRJT-C*_46:5!\QJW0WC3O$N$V)HN!.KTGY".-D0(.JK,@T53)Z8XA#=S
M?YL#UM0O13_TA_FSM.X 782@! ^O>.Q$!+4K1'RP_$0H/D   *"OG(QRYO0)
M5+A0H;J#Y5HQE"@Q7<%RZ]9U:=<N8SU^$QG6,VCN'4B!\RS. ]D/43IS%E_*
M,!>S7#Z)]6*6-*E0Y$R=$_O%-+?3X<N(0.FE&UEP)DR(.Z$NI-DO_RJ HD\9
MRI/Y$E%5KU_!AA4[EFQ9@:WTZ4.;T&Q;MV_AQI4;M4!=NW?QYM5;8*[7=UOE
M@83WD!Y400^WEF,+U9U%=$SO15T'^*O6A[/,3IY9S^M@@RI-TIO:EW3IL/Q(
M!1L5K)-JUJY;KXZM&IKIJ$$M4MU9<:F,=A)G-96A.^HL=#'A*9SW4ET]?Q+[
M>3[X4V$_IN8^2L0GZ/CUR!+U+<5<U9_+EX$9^KLJ YWSB??6(4[WO*P[FN;<
M'5W8+VE,A@1'4F>\A?0QKYPK0%JN(- FPF>D=7:B:2(%$RML/W-&0F? A?@1
M3AWZ".3-' @7"DX>XA:Z)T")4)*)P87R@?\I.Y#N@:F=#1FZYQT<Q\I'J*KX
M28S'A92:B43;D$P2 $3DD0>>>9J$1Y HH71R2B>KE+))"Y5D2,B=U!/N('2@
MNV[&J- 9Z2?+TJ&'QWX$$>[(A1!#42%]YDD3L>\8PLT@.W=C*CF)'!K)G*X:
M+'3,(;T2"E"!DD*,RX4H?/$LQ-0!M$#''@6@%>$6FRBXF-P!42)$WC%5('QH
M:L?.Z JR23FF+&7HG9@X8S&F6A>"IRE$85SJ"D!G<:D@=!YMT9Q:]:%IG3,%
MXB?-F<SAT3*A7KIBHW7HH:=3AKH0\R5&O3)SHFO1$\PB/A5BE2GJ )CE5J>
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M]_=[]9=[_3=_!5C*H"$UG#=^8?<9^N$9D!>!#_B!+Q<9GH%^[Y?*[/=_*SB
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M<34V6&*'/9;.>9:$-+![9BDVP%EB(W1$+@XM"L@4NUW1VY%$$DI799%=EEP
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MW_[Z3[_\^U]_UT./5_$_]N._ MP_!/P_^EM _$O  U3 !H1  R1 "@3 ![S
M"F3 "7RU\\- "\S "/1 #71 $-S $91 $OQ %3Q!$0S!$DQ!%GQ!%)Q!L>M
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MAZ$&22CW-S:7 8W&&I9<A[<S]99\<JU <7HHN5E@RY+D<I24\1D;N"N?270
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M3D2F16J("DD]$&9@H"A'M-!R$!N))-)0E4,[>!62L@4TRDU"H*.<T(4^=*2
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MH_NYJSNWKWNXL_N[NWN\;[N\>WN[S_N]USN\,Z*VYSN]@SN^_WN_ [RYZ[O
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MM5,]V[,\L1,^UU,^V=,^ZQ,_PW,^]_,^];,_W_,_W5- X],_\Q- #?0OQW-
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MS9=\SU=]TY=]WW=]X]=]Y;=]K9=P#9=^X7=^][=^];=_\Q> ^==_!SB _U>
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MO;N\P=N\TQN]U[LE1ON\QUN]X9N]WYN^X[N^Y]N^\QN_]UN^WYF[[[N_ 5S
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M@A^4'68.]AZ<GG9<7N5;WNI/_NJK'NNW7NN[7IX%7I2#ZX"<ON!#MA]$AAQ
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MT7?-$WU(UT*4AWHH6&_UR3>]6(B-*M)ZFCKUB_>;57753XKE T2H!WS !WW
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M^C4H5SG+$:.4?!C,+XNIW#J8XO"_Z/#72UFTQLF3""EXP7B*')M_*[<'+!3
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M99+B4C1HL<A=[?6%+*"?%AX"=LI+_]1ILTFL=GRKMX1KS;Y=!0ZF)Z! 1+R
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MX?N]Y7N]Z=NQRQN]ZSN^\WN^\;N_>9B[_9N_]3O ][O "7Q#[WO %5S &=S
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MKRZENO6KUJYAHXKE"I:LVK1LQ[;_1>LV+MRY9^N:O>L5;]F\?/?Z72O7;E_
M=/42%OSW+>+#AA4W#ORX\&#'DR%7EIS8<F;,C"\OIKSYL^;.H2.+Y@R:M.K4
MK$>W1NTZ-NS9IVN;ONT9=^G<O'?[7BW;=F_@M'43%_[[-?+CQI4W#_Z\^'#G
MTZ%7EY[<>G;LS*\OI[[]N_;NX:.+YPZ>O/KT[,>W1^\^/OSYYWOVFVFS)O[]
M^OO3_)\?@/P)Z%^  "15E($#*EC@@@XV""&!$C(XX8,5TM-0.1*Y,U Y^BC(
M3T/K5+B.# /A Z _Y9C8SD3MK%A./O[U0Y ,(T9(88X6ZHCCCC[V"&2%0?(H
M9)%$'OFC_Y%)(CGDDDXV":6243(I99547OFDE5EB.>667G8)II9A<BEFF62>
M^:69::(YYIINM@FGFG&R*6>==-[YIIUYXCGGGG[V":B>@?(I:*&$'OJGH8DB
M.NBBCC8*J:*1,BIII91>^JBE2Q:5%*:39NIIA?HT9(Y&YIQ44DTJ"H0.D!G>
M-U,_Z'14ZD?E-/1A?K.<2DXZ"7T*K*;!ADHLJ,8.>ZRPRA:+;+/+)LOLL\Y&
M2RVTUDY[K;3:5HMMM]MFR^VWWH9++KCFCGNNN.J6BVZ[ZZ;+[KONQDLOO* B
MV%.]\V;;3SHPGM2AB0ZUD\]^)5J4H<#D'*32+ '#@Y\[+=6(\/] \_S7#L 4
M US/OA[+"[*^(=O[L<@FDSQRR2B?K'++*;_,,LPKS^QRS#;3+'/-.-^L<\\Y
M_\PST#L/[7/01A.]+J<Y'5VTF^X(=$_34@L]-=-47VUUUDAK7?767G<--M9?
MBQTVUV2?;7;:8ZM=]MINMPTWVF_+'3?;=%N);TESV\WWWG[7_??=?0-.N."!
M#VYXX8@O?GCCBCN>>.2,/TZYY)!/;GGEF&]^>><3*:VWYIYG3CKGHI]>^NBF
MIX[ZZJZK#GOKL;-.^^NRWU[[[+;GCOONONL._+!Y_]Y[\+P?3SSRQB?/_/+.
M%P^]\M$W/_WSTE]//?;69\_]]MY7KSG_Z-V#KSWYXY>/_OGJ?Y\^^^N;[W[\
M\,_?/OWOUX___?K+G[_JP_._/_L!<( "+&#_#!C  RHP@0PDX (=V$ $0G""
M$JS@ RT800")CX(7[& &/\A!$&(PA"0<H0D]6$(4GI!*]" A3QB(#[U1<!87
MD^ ]T%'##OKC:1B9H3G>(4%YH*.%*SS<_XJ(Q/3I T;I@(<^YO$BA<GC5^AC
M2$OF44!$="@='Q+@P<PQHOO1Z(H"S$?"*N8.\\GC7Q-;T3WD-XMT:.Q?Z.AA
M]6X8,#2:[QULS%"+X,BK,YKC8MV;AR!IU0_R^2.*%2.(.]37#EK5J!T$=-C&
MR(&(]<G#1+,2_X@Z9&B^=4AR192$'Q[-4<?[[1!&\"C@KDZ"(@$*<2!A3.'B
M-IA$$:*/5W:4R2G) 3'KR3$= *@'P.@!/WP(I&-\) @7 0B/COB#'ZBDI0)/
M-2)CM@29^'L'0>01('><A(K$:TC!;!*B@3R2>??HB#KP4X];>2AZ&2L'PV(B
M3G*\TWMF+,<Z]"//1*9/'ATAHD;NX<CLG:H<O5S(B\S1PN;A$8@R:<D VR&0
M1,:1(.@H)?[\X9!USM(AF91?/"&*$%%Z$I3M6P=*_$$CCGKT=]!H2"KWHX\7
M]FZ- J&H@?01P^2A Y;\F<5.6/JZ4Q(31(B0AXQ4*+@C0E67YZ-'C?_>V"!X
M"*P4TJ/1'S.B38%@L7VE&*)*..3,+E9Q'0P-"34%5DOH[2J-&@EK.<;*O'H@
M%23X6-&-RM</@X:3I,W3*X@\4L5ZP H_]R#E]_@1RXW HX]Y[)CRZ-%0A,QB
MJ&U4&#H*AKI^X$,_&,JCQO89/'ZD2B.+I"S%6EF^R9KCG)J5XXHXBT/OK>B=
M']FD12J"RLRBSJJ8S(@_5%H05D*OF:"D9HT"&5G7S6-B+>0'2P3BCGKHXQZ1
M;$A$@S<+==0H'8G4HC/AD0]\&/.Y+U'>+X/YQ70@(A_Y<(?"@MFZZ7H7 "&B
M%7I%V]V!?#>7*\/E5&WI/9W,XQ[0D,FH.A3_4?_(@R#O6%P_ZH$(M1+)KMP$
M@'Z)&;=\T.,>PB50,PO2Q? 2Y)Z&ZT<^YJ&/(5%31! YY5ZK]L1Z@+9(')Y(
M--'Q5[N)F,1(&HF&8**/A>:J;9"E1XR+E(]OVN1I!:D;/^815""MT1PHRHAU
M.P).N,WB'O10+)(Z F*)F+<<H3,</Q!!#WXTJ+1X5<D2"5(Z?<CCR06*Y#/U
M0V78#F[,.B903./*VI,<!'#JA?&<H=:??'2(=/[0,Y__XTURP"HA\SC)0COJ
M.4+3MC\"^2=$^O'0:A*V<_FH1]0*U%BS3B36MVK))TD'67ED&=,.Z67&1@EJ
MPEWX'KG"CW[-(=  _V5ZG8RF1W0;)MYR5)@_^T6<:.?19IN<\HT&BN=+,Y?C
M+AL;S>T=+#F8?>":296J"%8<0SB);7[<4&!+34EI";*.9_M#MO4.&W'1D8Y[
MX*.^' N27>L,MH>6 QX#IP=;G7D?(*$5Q4:$$3I*P9,U"BR8.WJK->T&CY.L
M0Q_\T$<^!?+4#0,L:BT&;CF<FH]2^(L@E'00.DSTDB@3I ODW%M?390.)^.#
MCP(;\'^B?&Z%V'<@X+3;R=V17D3(D5;EYH]L#_+EH<K9S3,W1X;Y00^7U[Q!
M-S_RFGE^N'B::!W:O0>'!,9M']U#8 UFVT8[\@Z@(@*W:3Z2Q(#<N%-ZG?^^
M[\@0(8'TRG*4M&R3-9$[\#&+H?^K[CZ:!R=O3+;-GF3/^+"JR/&C\9.'62*S
M2&/;[BW?]%*9((LW%2H??M./S"/"=VNMB=Y![+!;?*]X9*2@([+#4=,MIKV*
MLS[6VY%'UD3CXNV(OOD!L;;!HR'J&#@^7-JA)0OII.B(G#\J8B*&ZX,>_C*1
M.IJD#A,AG&Z2=H@ZG'R/+1<T26;LR&K5AM&!M$,?+L8^04K,(/,P$/V6;D!C
M8.Q&8&'3?)NV$16!#EA%$_I03PWA#@#H-KW7']PW(>TD$!UV.'ST@/N1#AT8
M(='V9XEC2:42($EV*_>W'\KT<8U36E-$$R=%@ ;_0E"0)CEL]5G[44TLIR#^
M5PYH)V8#^!\(=2L]%Q/4)$_FT'2-,WWVU!_-M$[\00\(8PY;QS?^@@X1)Q/5
M-%H"8F0[IX1T8UXU-Q-6-80,,@ORX("T9(%-@WUAF!]=8#$"D@\3YFF693=,
M>'[XP0\652#U((3KX()@<U(<%Q.=5@YC1Q.S4'A-.&V-8V1:J!+ %7=(!H&8
M$V5KB!_X0"O[,0]QF#A;9G09(4YW%2#\P(>P@TJU0A,S)VXPH1.SHX9-MWP=
M$63XT0_P,'-#6(9<8X=<]A]#I7@4(GG5=CB!"'#[@4>M(B#]('4G05YQ,V'V
MA(,=,5/XH0^1^$W!V&XP_[-NX8B RB-/'&1,JDA!P$5Y]I,/[L1!UTA[[R,P
M",2!%69 ZT 0VD>/2>A!^C5Z]V-;I-@\^, B"/1C@N5 D[8_]& B-*@_W:5A
ME300W;<_OM6*]C-.%'2&*+1T0$B.EW. (9F !CB&;<1-#4)E3Z80IX1H9M-I
M;51JPK>"(142/U8.(-DU_*!P#=$1T4<@ HA2"[%1Y7!K98,/JC8QZ-!E#5)-
M]D:!D1-R,NE/-#D32(>+*44K*><W^O!P30AF#]),LYAD9)AV8-D0S^0@M])W
M +!Z3P@VI3='/85Y&4%<M)=U6=@V^/"+/HD. <D?: 5*9P>.17.%?CD0M[8@
M2_^$#O@($?YWBF^C8E0I#XOE'YFF?:."9LGF-_60(3Y9?0_B23!QA5(6./X
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M9PS-KK4B)DTW:#6HS:2"*=$/S=19#QW)@!H3_E!^0-PO05VCD7.-__QO PH
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M$123"9LLCV@F)>R*U6M" ("<)D&(VO"^+\P,,YNB%A/"EA"O^DL''6L([L%
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M.6/FP"]J$LBQ8A]C'*^;3]2YS9XKAQ0THR81W4M47N:D6_TARYH*5D;E&9]
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MK_XOAX?I%G_T)W]Y5?'T]W[W#U)P;?[V'__W%TQ]Z&;ZS__YS\OJKG_U1SR
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MBM]!@-..T=T#0)4K( U=YXZ*G*^"W_N;.Z97/\K@(X$Z'%W@5A*](;8.'?X
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M#$P]\N\F_SQ<_P;5&KD%.X1PD0OS3DP'Z(FX5'.4#8GUE(MC.I,DN>581U)
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MD*)%!!7IU%V+@9>^K55;G9D/T@XTE4*3^,,A& +"+9Q= :1 +MS!!:3"$>1
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M92=JSGF)1**A R**A#HP#EG=CWDEQ8:>!*[M%X&"74ETTEDM%I+*Q+>-'48
MJD,DF)^NQ)!A%H.QCILZ_T2CE<._0>7HQ-9<OA13J">B72I*:)M!102KW0Y)
M3!PZVBF><H2>VN:F$9'F_*2^\1M-?,]QKJC,#2B+)!Q !JO"#6O"&:2Q/F2Q
M$FNR4B2R"FNS+NNS'NL6[,0]\*?IN-P>PE+A'(]5U@X8,D2+92E"9!P@A0]9
M!!&P095F<5/:J=E)9%P)PD2\CB-G1D3.M>M$K&8T%@9F"A?KD-U(,&K U@2[
MKN1(T)/M.(24#EI+7"NJ^@-[7IA+3!QPLF4@[1 \[*38$:RC=NC6D>.]W9Q,
MH&''WB;H')ZC%44.+>93&%Y)Y- ZJ.@16=JXRL[C=:9DH"9U85<F8:H*BAY(
MM/^#7Y[>-J5>29B?QY%05L%$) Y1+:J35,H7*7UI2L @1RA/)G'BC*R"]"$?
M]'WM](&M\HTM\Y6M\XGM,[3D;5HF1A@B+GDG1VCB SYM_$PH3_B#;[K:0[C?
M.N'$52H;W2X/U(I.DMH=0;DE2>1C.:S73\A@)H$K4%B@QKV$_ TCH1Z.E2I$
MPG(I1A"4 V;N2GQH?&6M#"B@2P)7V@G/1RH4,6Y;MMD: D&3O.Z%#I8##VX3
MIY)<?J8+1\WH%48A2 &'& *>?D%E&VZ$.1#N1PKNCR+%56;E0MBA3+C/-JUJ
MJ/DF/ UN!=$I0\C2-ED5[Q25RVHG2G#=KP( 7L97B\'_JJG9JD=XXFM.A"VU
M+TWX4CS]Z<?Z4^0,:@92(DE0$"BYVVXI8V A+ROJ+T+<;_BZ7?\-I> "$%EN
MSCF]8>+*!#?R8G9U1$-!+$*8E<5ZA%FA(_V&!6+"$PC3(S39H^'H[EJ%:*\<
M D7:50?7U4-R@2'@AYYFTL6)93+6:SG07$(('E5:!+V^Q@;QYKUN4YRF)RF9
MA!%'Q &>(DB-:4'(TDC>6P-N$5%J!$5M$PH+143-U#L@ B.2*5QZV+\2ETK0
M ^-L+2C6XTH4UD) UBI]KD3$3_U*A)EI75*TI524;("FD%ZZ3CK 0SV0Z9C^
M,6"Z%\F2DLDNQ$S>+LR6W&,:_\XOD?';G'$E=T7;(A<G5X0X01.$0AYT?2:9
M--)T[2PE81?@Z%]$;-<GB@2;JH._K@2^:2G@K.U$Y"THHX3$1B[E,$[5;G "
M5P3#AI*V/(-U5B<IU(8D[V1"F$ZLV6<&CA]-<!K%#47>CL[U1MBHB@1SO2]%
ML-JMB@2]$:+[*0^G8H0T 8X>*UGVOO!.6>S#E>)%L%Q=@JXY:"X ?"\Z=&Y&
M+"CF_DT!0^KHR"5#?* O:T0;GZ3$(1XQ7AE&K X<GH3<E2]DF"B*LG!*A!@Y
MM&ZTL%F.DK2,RIEK0%KRN'&>-?0!FZI&/L7Y6@24FD0PAO1#T%X2PP2NF0-%
M^$/HH/]B362S.?0OF&Z?29AH!UMSZ"[C]S!P2W/KX'#Q2/!Q.0QF4( <%N/$
MHVZ$H.YS/P/ H;J;Q,*S/U3TQ#8$5_MSZ,PS5,Z41K0H5S@T0".F.?,$.#=E
MJ5KMYBBU.&FU;WT/.E;U52>%MF7EM=YT5.#GX?1;1Q?S--DL#$-KL.*P#&UI
M1"PV/TM=[:#BO/XU:? G2&ZQSI'DNX+09\\7/$,Q4(ZL$I.V1<1:.2AU2-29
M;4TP):OL&7Z/_.)T[>QRC:FDXFK.WN*8Z\RV0^SN6#*$%[=;2CPN6OIQR#(%
MQPKRZSK$Q#UU0W!=.6)1I1(FXT R0LSDB<)L1-OVW_@5#IG_]U>\;$BP;$J<
M]6]K#<Z&YF"DP"I?%VM\WL^&==#>,MT>+4O,;2.C1$7WX65J3N,R!>[E4NQV
MA#LGMJ_T S*8K=@6$RF8X3-[\DC(*OA1!!IW+TP\7 3I P0+KCE$7-_6[>FT
MPZ&99)MB=1UG']<M[_*J0S +A;253HW35!=+FO;N.#$OM6:+!.>BQ!U?Q)#!
M0VA#<!#&S0;MN [U;P]'^=]$+P(7HTC,==3>JC_P') #N)@--"\1[QI>LBSC
MR@1M(18"[YI[%(Y'1IF#A#K4(B$B\7$C;%758/8R;V(2MO2:>-3R$/PM1#KH
M8T\88OWV4I4SNN&<75,$.IB'=_K^_V_V(7&-'TY1KYR-6T3>-?KF&/0LF">8
M)U28N6"@\F]?,C4G;1,Z%EEL8[JK)\2IHU.'"WKIX/FC1?HVH8,V;L3D L[=
M*@4&3X0WOG*B_LUQBSJID](\9#6BMA-CW;I/280^H)[[1@XI%T4/K_"F0IEO
M\K:SQ/#!5;9T 'N@HX.\SH*M,_L&+I$L:6]N0L1JCT7U8KH!M>Q+YNM'].T3
M?S:#]3D\J4,I_#N#:?&]3C6%?CI-1A9#9"28I\/2IG'8N7$ U^TK3L7=1?I4
M2M:/!WS'O<2EUZTW1_??6#!+!')*J#4 $/RT'PXZR!]WM_9)9=*D2W*D,30
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MO9,[QW,[S5,]R?,[TY,]S[,\WW,]W9,^P[,^T3.*EO,ZJQ,[^=,_J1- ]S-
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M*K=TLW=Z?_AZJ5>(@=B'@YB(U<Y>@Y1MS>%L;TEM3=9\#8)N;9:&E+9J+18
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M9JBFBF"F:^S_W6O-2$]C\0=2,%C2$-7'\@=^73WP#&S-L.B\%MMC3FAHKNR
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M/(P?/)(FD"U\K:$ZFS-=2A%]#W:6OC7#;A-_S3=8M%3>Q'> R?=\\_> _Y>
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M4K7U2UZVTI>7="67<YGE,'?YRUZV#W$_F1WPCI(Q>FR,-./H#WKH<,X^W.'
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MJ\S(YJ6)/,V)7Z2>(?#_R+$]_NHO(,5=X3 ,$/[*F:NR#L!!A/X0+E2(L-_
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MA#H4DFP)*<#^%7#Z@$?WJHD.8/KK5*DZ&31=>RE;UT16MZY-KBUV#V%MLU3
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M.;K:/56#2*Q2&I:B%V1XR(Q4GCTBD$0 R97YJ?R@+Y-<R9/A0JFS*9:4F7Y
MAHZ,F\BX*7^8PORH@832R-3SR9C\R9 42J(,2J,$2J0<RJ.,ELTQG391RJ2$
MJ<]SRJB$EKP"O8WY'+*:JWSLF6VZJJLL.#' QJHL2Z@\2VZ"E,(2M5)3E,.R
M$:"@B'F0K/$)#W@(BGIPBN$C"/)IB+NDB+QLBKVL@KZDCW?@'GH8C.1;/@"
MAY!(S*4PB7+@"+=D2T 1D2FX@E6"!T! KG8 _P0^*;F<"08] "33-(LI^()3
M( H1L89^Z$37A,U\B!-H<!0>NX=[ *_<U*Y[H+_F8B\I(HF<1!&>K$SCG)!)
M"C#B^J\_@*BV'+5$@<ZWE$[+?(GKR R*E"#05!,'8C^2NLSC?$[Q!$_=P"+U
MX"+J#$_R'$]!&<ZL(;7UA(]9T,G0F +XO,_H9,_@X(>TV8_T_$\ >+$.&="Z
M^*#JM)2D&Z-9B$_\G$[]=% &S<\(A= &/5 *E= *5<\,!= )M5 /#4]HD,$+
M'=$/Y=#E2,XP&242U5 ,;=$5/0CF%(/.*-$D\8>#C-'O<=$LH0=*^\T48M$@
MZ0>U8,XPT$H@I=$./?]2)351'44(6RS*JFR'=(B]2]F>5C&'AO!%6M,4=%B6
MQ)R4>_A%=?B4+@V5+[V(,!V(,9T4>'"'=8 >24F'5BD']I&4;$(5_^D(<Y 5
MR%0*RVJ5G%C*XYF">.R9SE3(XAJ8=X 0GVB%0<@"^CQ-L<F"0?#/J9+($"LW
MRR"I?DA0T7B!G8+2E&F\=3D$M((GBD(70[B'IS%+47W5J.DG>:!(C;F,[82@
MDL,9>B!+M!14RE$I>X$7EW)57PT<3RV H#+*_TN; R%6I&R%_H35H_ ',NRZ
MN1&+C[0HE"20_>A59_56<)76<"W6<?U6*.7*Q8#,<EU7?CE5"&)7<L6K@CO_
MA&+5A\V9UYAD07?;U]OYJ\EC* F4!7@UUWA]J=4+3EID(U;AGCUU+(UHV#ZU
MB.UYV,=BV/7QB'8(B3UUAU)P!W5@6--"BHQE6([U6) UBK\<B"Y:B'78T_.A
MAW9H6>XA)Z-P!XHMAW:8AW<HQH:EV80%(3Y Q<7H1O2C/R\@(^IIA2^8@C22
MU+U)@1?H@T3($R)J!=^\VB;J,A2QU)^-GL93C2 " %"2H%=Z056@VJY-VT.J
MA^S4*[)]P>Y<+V%36[JMO@S:D(^LV]:#5@*!240"FQ,I3KTM)/Z4.JYEHV=X
MA@["EY[PP;LUPV-P(2N"(8H97,N]7,S-7,W=W-;C_]'T^U'.Q21-<EM5"-W+
MI4!-5%%%HI((5-U"^HCZP[_Y(Z&01:313:NUH%?3W5U(>M*"U<A[\%AA^<5U
MF#=/V=-6&=Y7&][EDY1YZ![E-8=TR(=H>=Y>^L7IS90[+8<\K0UX$*=?3%YU
M(*A-\8?GE9572X=8&UBAP0)^/-2%Y$<L4)&@<51(=5K33 %*3029X0-Z_%][
M#!L".1#VG19214AT&;!M0V &W@+G_-T"9LE'5"<)2M4&3I<&>H>0$E$(%E>C
MH;F.I+X.'F&EZ(>F#8T^*,A3..'\$$ /_EU^8.'0:%;1\0<0-BHRK*>:I)>Z
MF2K /1'[).$()E@B'F(C?O_A(D9BA;"=?YK;(R[8Y$152WKB)"X:>WVKSUG)
M0T/51_M)6>5'  8I=44]&Z4\,8@L)4YC(>::@WW1!T72E^">)F52-TY2.H;C
M+1D$^HR"=O $;!D%3]"#*)!A0;J4]>R'5NB#&@! _$V;U#R%67B*=_!12G:N
MJ ,-@L3C.MZ-&R6N+%Z(?K AY70T0ZB'E=W0-U[25)8M6?A71WOE48[EKC $
M4R7%5;YE.S82:+"REMKD.<;E!CVH3[UCBSA6LWB!!47E7%YF5#9A$SG<.79<
M&-,@ J7F@R'F)80CM/UE9N9F9?YF;PYG7QYG32YG5>YF<CYG<+[04Y2NVDUG
M8H[_Y\&8X#4Y8W@&9G$VYR$EKN\TY]8A4M<XY7PFCY#KT>BBY#XU9]G88@!;
M*W16:'R^YX<F#]^M8ER<O7:@8HU68XN^%/N-U$;^U"D8!)N: BR8Y'@3*#L1
M!*V="L'MZ*DY8-?X9$WQ!UFX50M&5;Z:/H[>Z)>QAH%#5"X>:JPTXYR&H#\P
MA%60A>_Q:;92&JY;FKQU:J7<5K,XO9,:21-)8:K^26<.0,?QAVN-%VRIN;%>
MJ5$8UN(ALOGBWYY^ZS6.:YB6ZZZF:YAJ&)6>CE:M:UP$'BXV4KL.;+.9)-"+
MJZUR5^$IF=2;A55Z-WGC5W,#)JAD78HR;+Z^;*YJ8]XU_R)]< <]"+[-#FW1
MUJ,OR (9#FG4[MO1CIY8>,#2+2!^:+2W=<6/R='5?J1G<, (%,50$B#"5@T,
M+EO:=EOBAIT)7&J!1B3^.@3;9B3S?%STO.TYBN$!]B)CGHJ:DNY"^NKJ'J(7
MJSEX^4&^<(;DGB(I1)$4UF[U7F_V;F_WKB)^N ?YFZ[WIJ+?;@W7K6]:<IW9
MSN\C$M+9_@I#V.9"PH?979A=-=UGN%=(]&_]?G G;91;$FS,IG"XGNNJ_.C4
MWO"^L?"8Y =7%FJX$E@,'U<0[\:C-KA"<,ZP,NJXNA1^J ?4^+84!U@;KTBE
MWM4L-:?[5BM1!=::5.L+#]=(K?^!RA'(!\F"O1YR)%:JK?:;'<;A'9X3T9D%
M87X0(R]Q)O=P+>?R"N_R;_6'?$"$Q@9C>Z2'GOSRS G%O5+S+:<9!G\=AL2<
M-$'4IT2]?M = *;>-X\6%$=@Q79S+^^I-H;HB9;G0X]H0U_G11]H1,]0?TCD
M1=[PO:%?=79T12</F]YG6,:A5<#J3'_T)K5I50 7@%9.0XB%Y%:(1V3.+)X1
M?["=S#@$<93EY;SU3@^#"52%6""6^$11XG)H1G<1CJSF8,A;3$]T9<<1L4O)
M2 [/;$Y)OQUV49=H%G'R!TGO!)%F8^]VOD#V"VUV$P'59*?V4#_W92]W=;?V
M=6]T=G__=W='$GW !UDWZ$QEKE+X3G-/]TWV!T +@]=&]WT?^'7/M-40]C)I
MQ0"+I7CGO4I6#)ZN=D,'=N0:2X%O]TN'=Q"5<%0;=(\'<T$'>:[BAT'H Y!N
MY X7^7K]VAMWI^9LZCX_GGYH!,J^8+%<:I5A<VYY<:[AASK)ZWE8ZAEO^1JO
MR)9/ZE7855"7E!Y/R+[Z29KC.A%6>:1TR?RP*:293R".><'&=@+1]I2AR6"U
MIZAFFN5983:D8:ZG^I!O^[5W>[M^S0\#>LU[[)0&8]2!^\G9XN"9XK?_>XOI
M!QJ_$LN92H3\ [\'R5C75-[)>\ _&B%%5,!F^\<W'LV&<,S/_WS-+Z,K1VVD
MW7SX+G5-Q-T?VJ%.NNU03CCA#O#F7(73SY[)TUTBT@<H\L[HL896-@0V9WW2
M[_W1IR1#4 66%Y.#H.=O$?9$VF4- D+0-R)&-HLU(B"K!HT%@.;F-Z,?)A""
MQ!YI+L/P7O[Q-B*M/Y%!NG[S/W_T3_\BZ@=\:.?/E5VA/7#,J/4M: ?YK_T6
M4G_C[YA/5G]:<B6 "+,ES!^!8OXT J!P(<.&#OD5'!CQH, PAOPYS*AQ(\>.
M^>3-@R</9*F1(>?IZZAR)<N6+E\V7$51HL&"A?C!S*ES)\^>/G\"=0A-7[Y\
M_* MQ*A0*0"F3I-"71JUZ=2G4J]2Q?]J-2O7K5ZK@M4:MNO8KV+/DD5K-BW;
MM6[+PE4;M^W<MW+OTL5K-R_?O6NG% @L>##APH53U$VL5W%?QGX=P_5'SU!-
M@P.WS!1S^:"A5?X>+P[=6+1363(G;D9=&?/FSOU&PP8-^]X\D/!JG[1-#^=>
M:*8/4<:L6KCEU9J-IRXNO+._X)E7028-M]^Q8-6O6P^&3#KWV-&]=[>;Q7"!
M%XG]O2 ON,;K\-]EPW\OOWN_&NH+9*GK+SOV_OS_^_>,>PKU,]Y]!4PQ2WP#
M@M?@@@[.!R&##U(8(3^XP=->A1-&N*&$'WH88H<C=I<//O/DEN)MMF'8(HOS
MY),2/2K. TC_9I>ULR*-+-IVSVLB<AAD@_UH=AQQT $)(HE*"IGD4_X8F=D?
M&D9VR'"9I=0D8_W4PZ.*]V#DY))BBD5D<JP)= B93+*YIIMC0F44-$/EPQ5#
M3-V9$9Y3Y>G0GECUV="?=O)9**"&$GJHHHDR.JBC>D+J9Z2"3AJHI8@^*JFF
ME&YZZ:*9<AJJIXU6BFFIGYY*:J=0 7:@JX*9!^JHLIJZ*JJVJBIJK;K>2JD^
M5E84$4'!$BO1(>WM.FNJM/;*D#6Q4":LM,4.2Q-FJLAB3:[*XLKLME7=8YM)
M(HE+#Y[>[FG-;]%2.ZVUU<+KKB'!P0M=M\OBRQ RHP!3';_^!J,M_Z_?-INL
MP04C3#"I@ZCWP@M3U##%PQ%/+'%Z!PZ";KX#:WROQQQOS"W(2]FG7GZK/G-,
MO\'\R_+*+</\<K_;B1PHPP<NT,K(.]=\L,(=\^PST#TG/+30(1_M)S_B@H34
MQT3_C'314D?]=-)!3VUUUE@3VH\^](P;-M,AB4UVC_E\YA ^Y)(-2+S%YE@V
MVW.#I(_16T-]]\^RO!N1+'E3K;?@@1.N==4+K?+V0/;JL\HAO#5$I+O5JGDU
MX$)A6'8I60YN>.=<,]O(Y!$9(O#AEX->>.J>JXYZH'3*":>6L[<I>^VTOXF[
M[;G?WKMLK;[J*F*Z$^_[[G4U'N655V);O/^'O_YQ(W+3;]$93L8[7Y9D*HY;
MFX^VJ^NXVV@21[[TY2M/$/:Q/0/@RL<(F+W\Z^]E8/#W!_:"@L?/S[O_4]7G
M/B<CBS-4YA\#NN^ *WO&@A*1@@.E8!#]XQ_]*/B_"4Y0']R3A]TLZ$$,5A"$
M%W00/_!1#QW-+7->2J$\Z%$/?H2I+/I@D8U44T/EQ TD] ";V38X#W.)\(-T
M,43Z,#/"(PH1B6KQ1R&*F#XD 8"(RR.(+)3(%;"MT"3S4(H5NZ@864SD2O8*
M(1F]&,3%R(E.05DC&]OHQC?",8YRG",=ZVC'-@(/?^0QSQW[Z,<^/JL@82S6
M3*K%')Y XQ#- PK_/U9A"&L5<I"0M,DALO3'2VJ$'_0HR=@X.0^G_9%=Y:M6
M)%=3.4QNQ!K7D5EUG('*5_8QCWJ\CP1A:<M; L5^AIE"0Y"!P);]\GVLM,[*
MD($LF/"C9/?I RZ;Z<QG0O,G_6";)T52IVAB,YO:K",T:#./:IH$G"317 N-
M\I/3$,L0# %6^1)RIWKT4)S?A-$VY6@-*55$%?7<)S\=$HM12G)8T7,71?2)
MRW[(TY.@[&<TZ170BS0$C 89(T,K:DO8'26)&CUC&3?:48Z:\:,BE>4L!\-'
MD88TI8QQI/FFB*9"-,)T:TD<^4[9&'_(0A5%<JD3!V((>LC4HRH% #]*_^&B
M%&UN@H>0'G1DTM+B_,&F(?4E@+*3-I *=4DD+2FL((?5KZ+T/;HLS!2@457_
M(..L575&?,9JF!<@:ZAA!:M<Z\H8#:X00YS+*EWY.M>_/H4?&CPJ"@E[U%+@
M(R4B0B>:#,'.GJ;)*@@U+(_N<3W \H]OR/D;9OOJV385Z4R0%8X8O!I6?ZR-
MLO6(JU_MBA=][%0Y!_F;9M$W1M=V-K=O22-13F>YW^(-N+X-+G&':]S/N4ZX
MR%5NZYC+.@ ,XF)<+4 *OA##YZXNN\DM[G(1EM/CC*Y=8L#6H&BJ.'I<JA^-
M&)_BVBNMSG"6N\V5+W89 @VY=<^TVR65*MZV"O^)]HU:$#UNX: QS'\)J+L$
MKJ]S0;95KL9JO@O6;H/WJV \N;4 >W"9OX:YT'Y  QEI;24RGF&ZHMWL/BEH
MQ84EW&(&TY?",;:PBT.VM![2#23WJ#"/9]SC"=,8QO[PI"7UU@]^W(,>.<8Q
M?IE6#VA<ML?L=&^[B!7555R/*?T(%Y,[N5<8 _EJ#@V6&'QLYC"?^<4RS@J
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M@D(HC]3#(H9G1_%#/^!#DM7?@4:HB@#>O2&:/J D[!E"/O^V12Q$#\1I"3\
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M2#96\RYO;. #AQZ<M'UGJ%5.DA!L?ZBC\THOHW&J3X(>OD9?,- N:22L?"[
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MLFS*KJPW2RPWDXO\%47_?A1>J6PXMU#NK<G<?7!9JA\V+\375+,.40E.L10
M5O#B>*#YR+,P@Q67I#.81#- %_22/FWQ*O1",W1#._1#WY$16FX\D2XNS=WK
M#@0@\)Q/' /= @Q$1RUDWL8M*9U'<QBA]@09RR=<@G1+KX0^B"YBOI!#"]8J
MN"MB)J[FYK1(FX0B&L7=HNW^A2W>Q0)03RUJ[?3@9I).G>X6I,1R)J5+]^W6
M;N9/2O550VTJ'_0_;[4T&S17@[57=S5>8&S]>:Q4J&EMP+%&02^,EA:(F"^
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M-^80CC>L(1)Q*$-\4 D:9_''><260WJ8L8PYPE -\3''+HV(BH%,Y"+)R$A
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M2(LV2(V6:(]6:9.6:8MT:9VV:8$T:HE4:J'6_VGS@89DQT>1EEID(9]*U'*
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M[+@TD!^(:[ANYYI$,-K^E/\BQY&-W&&-_0T0Y.&L?3.MDPI.(JNRYDU6XWK
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M'N_S7N]!E92 /!5C+H#@W,K/&#A3'8372:5:%>E;XRRT[,&_W,O!7,PA3R$
M'O(_?2) ^,GY#LRQ//(_'\/Y?<P-HL[C:;'"=LJOG)]J?5K=7/ MYX/W7O9G
MG_9KW_89 N7G/N[IGO=WW_?A?INYNM&)PJN#$>'^KQVVQ,#SK\#E@>& OU?<
M6F8OW>M9[9YJ5B!ZGC*2Y]4=7^R[_N<K/9<'DM,;Y"#],2%Y@AZ^MOH#4":3
M-:(-3-8W:]=U'_I[__Y_W_[W'___I6NQ,QX@  #P)["@0((&#R94N!!A0H<&
M(1:4R/#APH$7*6)LF+$CQX\604;T&++D2)$329XTF1)EQ94P6[)\*3,FS9L;
M9^:TN;.F3YP:@ZK\V1/H4*,NBRH5FI2I3J<\H1*5BO3IT:57J6)MFK4KUZ]6
MP4;U&K;L6+%3R1;L!T^>O'EMW\:%ZY:NW+IM\YE-B[;JV9#ZYKD5\R?,EC"%
MM[0#9!AQ8T!NZ=WCN]<OY;^8+VNVS+FG-5FK#AER?#@QZ=.F4S=677JUH=:P
M4:^>'9NU[-JT$8LQ=&A5+'[ZM KW>,BVH<O]0MM>GMNTH5C6ME:6GKGS<(/\
MBC??7EK_S*I^UZ>'KTY]<WGK:LV/5Y\>?=_S\->[%]\^?GWY]M_CWW^_OW[_
M]/TG8( $DL??@ 8"F"""[#$XWX(%-ACA@S)!HT\^^? #C4P.=<CAAQ5Y&"*(
M.8E8(HDFIHCBBB.V>**+*L+(XHLTQECCC#;FB...,O9XHX\Z LGCCT0&6>20
M1B:)Y))"-GFDDTI"R>235$99Y9169HGEEE)V>:676H+)99'WR"6877"=.1<\
M:M8USYAA?BDG0H<<M@5AAHEAYVYP]BGFGW/Z&6A%_(!F2&)ZYHGHGHLJFB>C
MCSIZ)Z232IKHG8UBFB=OJ\C"3S^ QAFC=G<>)Z8_AE:JJ:IX_[*ZJ"&=BBJH
MK"/Z4\]HJU[:JJZ%&2(+K8,&"^RPLQ8;JK'"(DOLL<PFV^RRSD8+[;3*5ONL
MM=)B2^VUW&;;[;;>A@NNK!E"8Z%>%Z6K[KKLMNONN_#&*^^\]-9K[[WXYJOO
MOOSVZ^^_  <L\, $%VSPP0@GK/#"##?L\+SXT/-6*7C51?%=$UN,S\,<&T0J
M:7QV+/+() /0CS6-J/):JR"SQC*B+L?LFB&-K*)/="7GS*XUL8P&,VTO2^I8
M(;V!JO.]LJB2Z,^P!0U((S@?+?745%=M]=589ZWUUEQW[?778(<M]KOGEJOM
MV=^B+:[:X[+M=MIPKQUWVW._+??==/_C;7?>?._M=]V Z\UMG9O^+?CA?==]
MR*Z4\AIIJ37+$G7BB!ONCS^A,99KXYSG^32HE$>)^<J9,BYI;Y:G'GCHJE>^
M>NNLORZ[Z[3'7COLN,]N^^ZYWZY[ZN6>F]^$PT-HO(3'4ZA\\<@WO_R!Q$.?
M////*^@\]=A+?[WVU3N8O?7=1P_^]]YS3[[XY8]O_OKJMY_^^^C'/_UPJLBV
M"@#6W"P+:X>P#__\[@M0JFY#P.7 ZE?.VU]C[M>9[!2&.;BYTRKX\;_M!1"
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MU 4O=\4+7>^&][SC16]YR6M=CXJT-333W&Y641M3;7>]ZFUO>O>+7_[JM[\
M_J^ L\M> N?7P/Y%<( 5/.#['I2TQ8VP<B6<W H;U\(4OK"&,\SA"7L8PQ]^
M9FXA=3]4;<X0! EQAT',X@VK^,4M7K&+8PQC)0Y6M#C.L8YWS.,>^_C'0 ZR
MD .F-%>::LA(3K*2E\SD)CL9D1"NL8RG+.4JT_C*,\XRE;&\92U;V<M<;MN(
MPXCB+IOYRV<.LYK_P<SF-+<9S7 & '/-FV ',_C.=LXSG1>LYP+W^<!_KO.>
M&SQH/!<ZT'P^M*+]O&A -UK0%7PO8NS[Z$0S^M*.QC2D,\WI37O:TIT&]:<)
MK6E1FYK4H0Y?E-?LYE;'^<VL?K6K8TUK6-MZUK>6M9@)DT5=UQK7P/9UKG\M
M[& 3^]@*N?&3E\WL9CO[V=".MK2G3>UJ6_O:V,ZVMK>MLU4/^]O&!G>QQXWL
M<)N;W.(N-[K/K>YVI_O=[(;WNN?M[GC;FUP:$AZB43UJ0Y>:WZ?V=ZH%WN]]
M$SS@!D]XI0'.\(,W7.'_=KC$(3YPBA=\X1/'N,41KO&.1WSC#_=XQ45^__&/
MDYSC$?7VO>M-;WFS_.4NC_G*9=[RF=N\YCB'^<UUGG.:\_SG/K^PLKE-]*(;
M_>A(3[K2E\[TICO]Z5"/NM0MJ?*>[SSH5\^ZU;<.=*UWG>M8![O7P_[ULI/]
M[&-/N]BM/&>3NWWD;R\YW.<N][JCG.YWMWO(XY[WON\=[W_7>\;Y'GB_#Q[P
MAQ<\R!-O^,4[_N2%CSSC)?]XPD_^\M"KNMG5OOFU=_[S:/=\Z$'/^=&;OO2H
M%WWJ2:_ZUK.>JD.?NNQG3_O:V_[VN,^][G?/^][[_O?]TOSI73_\UQ?_^*M'
M/O&3S_SE.]_XS8?^\Y4O_>I3O^V(KWSV(8]Y[O]K7_'>#[_EO]]X\6]__.8'
M/_K7?_[VJ]_]Y6?_^^<??_A3/OWUI__]Y9___N\_?L(7?=0W@ )8@--G@-:'
M@ 1X@ R8@ VX@ X8@1 X@0I8.;$'?!B8@1JX@1S8@1[X@2 8@B(X@B3(+@'X
M@!6(@BHH@2G(@BM(@2_8@C#H@C0X@S8H@S@8@UB%??K7??SW?SU(?D#H?SYH
M?T48A/@WA$IXA$0HA$RXA$X8A4GXA%0HA3]8A5-HA4:HA4AXA5S8A%D(("=8
M@SE(ACIHAFAX@V>HAFE8AFSXAFX8AVLHAVV8<Q=8@GB8AWJXAWS8AW[XAX 8
MB((XB 4SAG XAXA8AXK_>(B+2(>,^(B.&(F)"(F3*(F-6(EQQ(-@Z(5AR(F>
MN(6="(J?V(6B6(JD>(J;:(JIB(I0&(JLB(6CN(JRV(JQ2(NJ:(NO^(6X.(NP
M2""&:(F4>(G"&(S$"(S&B(G#>(S)B(S%R(S*V(R?=X>$.(W46(W6>(W8F(W:
MN(W<V(VZ](O.&([+.([06([/>([B:([IB([DR([JV([KF(GY5DBZV(NYZ(J\
M6(_ZB(^[V(_VF(_\^(_^N(^U*) &29"W>) !B9#W6) ,"9 .N9 2&9$4Z8L7
M8C;OF)'NN)'Q"(\>J9$="9(?R9$C&9(D*9(H>2+2Z(TLV9(N^9(P&9,R.9,T
M_UF3' B.)9F3*6F2/*F3)_F3/;F3/AF40#F41BF4SZ2) SF1"?F02UF1#=F4
M3!F55 F14@F55EF53WF57*F5"HF56^F53OF579F59AF69TF6*X&32%F4;4F4
M<'F4;CF7<?F6<EF7='F7>FF74K*2-OF7@!F8@CF8A%F8AGF8B*E(;)F7?,F8
MCHF7D+F7CRF9D=F8E3F9EDF9KZ>4:IF68_F94^F9H8F6I-F9I0F:8&F:JHF:
M97F:H[F:K\F:8AF;M)F:LBF:MEF; 'B1.I29OHF9P'F9PJF9OSF<Q4F<P8F<
MQIF<P^:7B?F<T!F=TCF=U%F=UGF=A+B8R[F=RMF=Q__YG<P9GMP)GN,IGMYI
MGN39)YQYFZZ9F^[9FK#YGK,IG[@)G^P9G_:IF_.9G_39GOSYG_L9H/4IH/Y)
MH/AIH!6EG>=9G@RZH Z:GA"*GA+:H!%*H1/ZH'3HG-BYH1S:H1[ZH2 :HB(Z
MHIVEH!6*H1::HBBZHB?:HA?JHBH*HRSZHL:VGOHYH#A:H#EZH#MZGSYZHSH:
MI#PJI#_:GT-ZI$4*H#T*I$C*I$F*H$X:I0-BHC0:HU4ZHU::I5BZI3+:I5?J
MI5H*ID.DH21:IF9ZIFB:IFJZIFS:IK[$FYD5IE\ZIW):IUQ*IW=JIV*ZIWC*
MIWJZ-C9JI$^ZI((JI4I*I(;_"J6%NJB'VJ2,JJB-.JB(^JB$&JF)6JF0FJF8
MNJFJ!J=Y^JE^"JI].JI_6JJB:JJAFJJD:I1DZJ:N^JJP&JNR.JNT6JM\2*6H
MNJJJFJN\>JJ^NJN_JJO"VJO 2G:!:JF4.JG(NJR:JJS-ZJC,RJG0^JR2.JW2
M6JW8>JG.>JW::JW;^JW>VHNX&JS$.JSD>J[%:J[I6J[LBJ[J^J[NU*JV.J_T
M6J_V>J_XFJ_ZVF/CNJ[NVJ[^&K#P^J\$*[  .[ &6[" .H_]U*W9FJSA^K#1
M"JX22ZT.>[$06['<FK$8.[$1V[$6R[$BZ[$:2[&-UJ\(F[('N[(*R[()^[(J
MV[(R_PNSO2JO^WJS.)NS.KNS/-NS/CLR*.NR,4NS,SNT1BNT2%NT24NT3#N9
MQQJR) NR&QNU(PNU5CNU5VNR58NU7*NU5/NU6?NQ6^NU85NR8@NVE!&T2KNV
M3;NT1\NV;]NV<.NV=#NWM&:S/YNW>KNW?-NW?ONWL*JV<CNX<5NX=4NXAVNX
M=HNXBZNX/O>T77NV92NU9!NY9GNYE"NYEINYF#NVFENYH/NYHMNY:!NZI#NY
M*>>IC+NZCMNZB?NZC0N[K"N[KAN[%8:W@)N[NKN[O-N[OON[U"BXM3N[MDN\
MQCN\R$N[REN\R<N\Q *YILNYTNNYI[NYU#N]I3NZV(NZV?];O=%[O>#;O=MK
MO>(;OMS[?L*[O,>KOLV[OL[[ONX;O^T[O\N+N\![O_B;O_J[O_S;O]>6OO!+
MOP',O@0\P 8LOP6,P =<E-"KO>9+ON<+P1+\O>5;P1%,P1?LP!8\P1J<P=[;
MP1S\P2(\OIV*(;TIP J<PBB\P@G,P@O<PC#\PBMJO_Y;PS9\PSB<PSJ\P[0$
MP"H<PS\LPT$\Q"Y,Q$!<Q$A\A@T\P@^,P2%,PB#LQ%(<Q53,Q!L\Q5;LP5"<
MQ4_<Q%6\Q6#,?CX<;OZP#NWP)D><QD*<Q&NLQD;<QG#\QG)+PYY5#^5@#N_
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M>8S69JW697W<Q(W<QIW<S+TD%NU827W2H)P.I6!*%]$/J2S=V?_-UQ'QRE4
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MZ^=2X>"9J1YSYMGT4'W<&:Z<=*R1*9]4S2F%-G[:2?6=1/EY=3R,\&&NG))
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M*WY1C&$T8QK+N$8KMM&+;'RC&\DHQS'6$8UPG&,<]9A'/MKQC']4(QWO*$A
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M?;:)$3V(B[3AF]5OAYM(??^[01S25X>\I_N[YWW=Q_O=#]6LWUA_J'SD,!X
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M6CRCY.3?^@FX!C?"&UH"Y_JDU&40 \  0[&YV'I\*W#X,D<:5Q?]1GJ_W)1
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MC0A FMYI2#5LP;TV*GUP!&G2U]:JYYV"PC76W;&B94F>K-#R9QYAQ?]]MUT
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M=" %\F7D9$-^0A/)NH>QO7V]RTK=D-#+:F^VWTH,@Z=6M/.^9ES;-T)*??&
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M#FL+MW%CY41SLB-5$B<G5W)KTADM%X04E9INAXDN]G)O4GTH)C-J,3J"IW(
MZ^<H%W0/(A_JH1X:D.L S"%#YXY((X%8MW*S9AY8+B]*3"-O)Y .,'>)EW(.
M114=)R/S-G.9UWTP QK$45J;]'1:34DQUR:OIU?HH7?Q0M5"LW?VYEZ;]WI1
MAQ]*X1Y <MB:)'ELL!PJKWC'=WVFD/)LYT%V-'2QUW&LX1Y@-X$2$3AO1PK)
M%W\IR'SQ 20G[X229W,C-W^K)VOHX:8D0I]D2'<>45,KUX%MY_+_K*N#$@?
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M&"_^Y$^G@SDNORKG!=GX)_XD_Y!@]R+PT75@A(?0:BV1C2I;OP,I9CJR4W*
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M5_\J!X%BBL@KAW:(-810A]9#1SP"$5"SB=&C"I@CB%E;&IS<(=-0R9' B=4
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MJ$BS_"-R ,SZ?1$4@EBUP!J99%N@-8V+_1 .\MH/J@>J\%C9@ 9.^E #7HX
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MD29'I0UM#6IHXQ+FK+$GZ[S+28 D)J%BM)X)J0^M1AH1?]A);*PQT<Q2.E0
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M%%*7JM2@)A6J38WJ4YU75:LRCZE/E>K_5I]J*4SY-';94F<5PJ?54(T*(OU
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MP1!3!Q_WZ!J:!1XM09+)]!CH4%<-<2/+I1(XUB>_X1IZ8)-(YQ$4B1.&8A
MZ1 >6 4. 5\H"7'7MI00$1Q>$A)'>5*ZXAP=87$*0BQU)A"5QG(,T0]VH3$Z
M$48'X23_#Y=:A%83\)65UH(26UD3+ $8(-D0E(*6(=F7U0(-%N842B&84J&3
M?5EJ)0%8GO)B#(%>*(03>VD.=04DCI81'Z9P#)$91(D:'F&8 L$@$&D3=&D0
M7GF9Z4"4 ,!5!W%N<T$9)F$-2H*09.89%,$K>N!5^20E![&2)G8H-:$H!/D@
MIS:1)C$[@]66B=$;G$&;)G%F%*&;YK .)-D/\-5O#N=76@82#E@2_E!I/0D
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M,DHH$/GPK0/\C-RT2]]$-$EG/.G01>L C/XD$%#W,NI ,O?0#I&Z3H%$6O+
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:KYYVMJ_=[5S_>MS#+G>TOUWL:H>[O@," #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>27
<FILENAME>inva-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2026-02-25T16:04:42.9344+00:00 -->
<!-- Copyright (c) 2026 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.inva.com/20251231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:inva="http://www.inva.com/20251231" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" namespace="http://xbrl.sec.gov/ecd/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" namespace="http://fasb.org/us-gaap/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" namespace="http://xbrl.sec.gov/country/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" namespace="http://fasb.org/srt-types/2025"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" namespace="http://fasb.org/srt/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" namespace="http://xbrl.sec.gov/ecd-sub/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd" namespace="http://xbrl.sec.gov/cyd/2025"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>75000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>75010 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1" id="StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1">
        <link:definition>75030 - Statement - CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical" id="StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical">
        <link:definition>75040 - Statement - CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>75050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>75060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" id="DisclosureCybersecurityRiskManagementStrategyAndGovernance">
        <link:definition>75070 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies1" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies1">
        <link:definition>995455 - Disclosure - Description of Operations and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShare1" id="DisclosureNetIncomePerShare1">
        <link:definition>995465 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognition1" id="DisclosureRevenueRecognition1">
        <link:definition>995475 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangements" id="DisclosureLicenseCollaborationAndOtherArrangements">
        <link:definition>995485 - Disclosure - License, Collaboration and Other Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions3" id="DisclosureConsolidatedEntitiesAndAcquisitions3">
        <link:definition>995495 - Disclosure - Consolidated Entities and Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements2" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements2">
        <link:definition>995505 - Disclosure - Equity and Long-term Investments and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaid1" id="DisclosureCapitalizedFeesPaid1">
        <link:definition>995515 - Disclosure - Capitalized Fees Paid</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets3" id="DisclosureGoodwillAndIntangibleAssets3">
        <link:definition>995525 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1" id="DisclosureBalanceSheetComponents1">
        <link:definition>995535 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation" id="DisclosureStockbasedCompensation">
        <link:definition>995545 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquity1" id="DisclosureStockholdersEquity1">
        <link:definition>995555 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebt4" id="DisclosureDebt4">
        <link:definition>995565 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies3" id="DisclosureCommitmentsAndContingencies3">
        <link:definition>995575 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisition1" id="DisclosureAssetAcquisition1">
        <link:definition>995585 - Disclosure - Asset Acquisition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxes3" id="DisclosureIncomeTaxes3">
        <link:definition>995595 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReporting1" id="DisclosureSegmentReporting1">
        <link:definition>995605 - Disclosure - Segment Reporting</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureSubsequentEvent" id="DisclosureSubsequentEvent">
        <link:definition>995615 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>995625 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>995635 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareTables" id="DisclosureNetIncomePerShareTables">
        <link:definition>995645 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionTables" id="DisclosureRevenueRecognitionTables">
        <link:definition>995655 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables" id="DisclosureConsolidatedEntitiesAndAcquisitionsTables">
        <link:definition>995665 - Disclosure - Consolidated Entities and Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables">
        <link:definition>995675 - Disclosure - Equity and Long-term Investments and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidTables" id="DisclosureCapitalizedFeesPaidTables">
        <link:definition>995685 - Disclosure - Capitalized Fees Paid (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" id="DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>995695 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="DisclosureBalanceSheetComponentsTables">
        <link:definition>995705 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" id="DisclosureStockbasedCompensationTables">
        <link:definition>995715 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>995725 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>995735 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>995745 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingTables" id="DisclosureSegmentReportingTables">
        <link:definition>995755 - Disclosure - Segment Reporting (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails">
        <link:definition>995765 - Disclosure - Description of Operations and Summary of Significant Accounting Policies - Description of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <link:definition>995775 - Disclosure - Description of Operations and Summary of Significant Accounting Policies - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" id="DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails">
        <link:definition>995785 - Disclosure - Description of Operations and Summary of Significant Accounting Policies - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" id="DisclosureNetIncomePerShareBasicAndDilutedEpsDetails">
        <link:definition>995795 - Disclosure - Net Income Per Share - Basic and Diluted EPS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails" id="DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails">
        <link:definition>995805 - Disclosure - Net Income Per Share - Anti-Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails" id="DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails">
        <link:definition>995815 - Disclosure - Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails" id="DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails">
        <link:definition>995825 - Disclosure - Revenue Recognition - Schedule of net product sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails" id="DisclosureRevenueRecognitionDetails">
        <link:definition>995835 - Disclosure - Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails" id="DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails">
        <link:definition>995845 - Disclosure - License, Collaboration and Other Arrangements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails" id="DisclosureConsolidatedEntityIspFundLpDetails">
        <link:definition>995855 - Disclosure - Consolidated Entity - ISP Fund LP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails" id="DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails">
        <link:definition>995865 - Disclosure - Consolidated Entity - Summary of Individual Investments Held by ISP Fund (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails">
        <link:definition>995875 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Armata (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails">
        <link:definition>995885 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Summarized Financial Data (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails">
        <link:definition>995895 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in InCarda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails">
        <link:definition>995905 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in ImaginAb (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails">
        <link:definition>995915 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Syndeio Biosciences (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails">
        <link:definition>995925 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Nanolive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails">
        <link:definition>995935 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Lyndra (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails">
        <link:definition>995945 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Beacon (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails">
        <link:definition>995955 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Reconciliation of Equity and Long - Term Investments Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails">
        <link:definition>995965 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Available-for-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2">
        <link:definition>995975 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet3" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet3">
        <link:definition>995985 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAdditionalInformationDetails" id="DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>995995 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" id="DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails">
        <link:definition>996005 - Disclosure - Capitalized Fees Paid - Schedule of Capitalized Fees Paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>996015 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3" id="DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3">
        <link:definition>996025 - Disclosure - Goodwill and Intangible Assets - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2" id="DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2">
        <link:definition>996035 - Disclosure - Goodwill and Intangible Assets - Summary of Accumulated Amortization of Recognized Intangible Assets (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" id="DisclosureBalanceSheetComponentsScheduleOfInventoryDetails">
        <link:definition>996045 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>996055 - Disclosure - Balance Sheet Components (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails">
        <link:definition>996065 - Disclosure - Balance Sheet Components - Schedule Of Other Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" id="DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails">
        <link:definition>996075 - Disclosure - Balance Sheet Components -Schedule of Other Long-term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails" id="DisclosureStockbasedCompensation2012PlanAndEsppDetails">
        <link:definition>996085 - Disclosure - Stock-based Compensation - 2012 Plan and ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails" id="DisclosureStockbasedCompensationDirectorCompensationProgramDetails">
        <link:definition>996095 - Disclosure - Stock-based Compensation - Director Compensation Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" id="DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>996105 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails" id="DisclosureStockbasedCompensationCompensationAwardsDetails">
        <link:definition>996115 - Disclosure - Stock-based Compensation - Compensation Awards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails" id="DisclosureStockbasedCompensationValuationAssumptionsDetails">
        <link:definition>996125 - Disclosure - Stock-based Compensation - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>996135 - Disclosure - Stockholders' Equity (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3" id="DisclosureDebtScheduleOfDebtDetails3">
        <link:definition>996145 - Disclosure - Debt - Schedule of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2" id="DisclosureDebtScheduleOfDebtDetails2">
        <link:definition>996155 - Disclosure - Debt - Schedule of Debt (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4" id="DisclosureDebtConvertibleSubordinatedNotesDetails4">
        <link:definition>996165 - Disclosure - Debt - Convertible Subordinated Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails2" id="DisclosureDebtConvertibleSubordinatedNotesDetails2">
        <link:definition>996175 - Disclosure - Debt - Convertible Subordinated Notes (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails3" id="DisclosureDebtConvertibleSubordinatedNotesDetails3">
        <link:definition>996185 - Disclosure - Debt - Convertible Subordinated Notes (Details) 3</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3" id="DisclosureDebtConvertibleSeniorNotesDetails3">
        <link:definition>996195 - Disclosure - Debt - Convertible Senior Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails2" id="DisclosureDebtConvertibleSeniorNotesDetails2">
        <link:definition>996205 - Disclosure - Debt - Convertible Senior Notes (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails" id="DisclosureDebtDebtMaturitiesDetails">
        <link:definition>996215 - Disclosure - Debt - Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>996225 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails">
        <link:definition>996235 - Disclosure - Commitments and Contingencies - Schedule of Components of Least Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails">
        <link:definition>996245 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Lease (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3">
        <link:definition>996255 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2" id="DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2">
        <link:definition>996265 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails" id="DisclosureAssetAcquisitionAdditionalInformationDetails">
        <link:definition>996275 - Disclosure - ASSET ACQUISITION (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails" id="DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails">
        <link:definition>996285 - Disclosure - Income Taxes - Income loss before income tax expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" id="DisclosureIncomeTaxesIncomeTaxExpenseDetails">
        <link:definition>996295 - Disclosure - Income Taxes - Income tax expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>996305 - Disclosure - Income Taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails" id="DisclosureIncomeTaxesNetIncomeTaxesPaidDetails">
        <link:definition>996315 - Disclosure - Income taxes - Net income taxes paid (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3" id="DisclosureIncomeTaxesDeferredTaxesDetails3">
        <link:definition>996325 - Disclosure - Income Taxes - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>996335 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefitsDetails" id="DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefitsDetails">
        <link:definition>996345 - Disclosure - Income Taxes - Summary of Changes in Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails" id="DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails">
        <link:definition>996355 - Disclosure - Segment Reporting - Schedule of Reconciliation to the Consolidated Net Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" id="DisclosureSegmentReportingAdditionalInformationDetails">
        <link:definition>996365 - Disclosure - Segment Reporting (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="inva-20251231.xsd#StatementConsolidatedBalanceSheets" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2" xlink:href="inva-20251231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails2" xlink:href="inva-20251231.xsd#DisclosureDebtConvertibleSubordinatedNotesDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2" xlink:href="inva-20251231.xsd#DisclosureDebtScheduleOfDebtDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet3" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2" xlink:href="inva-20251231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails3" xlink:href="inva-20251231.xsd#DisclosureDebtConvertibleSubordinatedNotesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1" xlink:href="inva-20251231.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="inva-20251231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:href="inva-20251231.xsd#DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails" xlink:href="inva-20251231.xsd#DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:href="inva-20251231.xsd#DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3" xlink:href="inva-20251231.xsd#DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" xlink:href="inva-20251231.xsd#DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:href="inva-20251231.xsd#DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:href="inva-20251231.xsd#DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3" xlink:href="inva-20251231.xsd#DisclosureDebtScheduleOfDebtDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails" xlink:href="inva-20251231.xsd#DisclosureDebtDebtMaturitiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:href="inva-20251231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3" xlink:href="inva-20251231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails" xlink:href="inva-20251231.xsd#DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:href="inva-20251231.xsd#DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails" xlink:href="inva-20251231.xsd#DisclosureIncomeTaxesReconciliationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3" xlink:href="inva-20251231.xsd#DisclosureIncomeTaxesDeferredTaxesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical" xlink:href="inva-20251231.xsd#StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="inva-20251231.xsd#StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:href="inva-20251231.xsd#DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:href="inva-20251231.xsd#DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables" xlink:href="inva-20251231.xsd#DisclosureDebtTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:href="inva-20251231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:href="inva-20251231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:href="inva-20251231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails" xlink:href="inva-20251231.xsd#DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails" xlink:href="inva-20251231.xsd#DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails" xlink:href="inva-20251231.xsd#DisclosureRevenueRecognitionDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails" xlink:href="inva-20251231.xsd#DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails" xlink:href="inva-20251231.xsd#DisclosureConsolidatedEntityIspFundLpDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails" xlink:href="inva-20251231.xsd#DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="inva-20251231.xsd#DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="inva-20251231.xsd#DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails" xlink:href="inva-20251231.xsd#DisclosureStockbasedCompensation2012PlanAndEsppDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails" xlink:href="inva-20251231.xsd#DisclosureStockbasedCompensationDirectorCompensationProgramDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" xlink:href="inva-20251231.xsd#DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails" xlink:href="inva-20251231.xsd#DisclosureStockbasedCompensationCompensationAwardsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails" xlink:href="inva-20251231.xsd#DisclosureStockbasedCompensationValuationAssumptionsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="inva-20251231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4" xlink:href="inva-20251231.xsd#DisclosureDebtConvertibleSubordinatedNotesDetails4" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3" xlink:href="inva-20251231.xsd#DisclosureDebtConvertibleSeniorNotesDetails3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="inva-20251231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails" xlink:href="inva-20251231.xsd#DisclosureAssetAcquisitionAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails" xlink:href="inva-20251231.xsd#DisclosureIncomeTaxesNetIncomeTaxesPaidDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="inva-20251231.xsd#DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails" xlink:href="inva-20251231.xsd#DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="inva-20251231.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="inva-20251231.xsd#StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies1" xlink:href="inva-20251231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShare1" xlink:href="inva-20251231.xsd#DisclosureNetIncomePerShare1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognition1" xlink:href="inva-20251231.xsd#DisclosureRevenueRecognition1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangements" xlink:href="inva-20251231.xsd#DisclosureLicenseCollaborationAndOtherArrangements" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions3" xlink:href="inva-20251231.xsd#DisclosureConsolidatedEntitiesAndAcquisitions3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements2" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements2" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaid1" xlink:href="inva-20251231.xsd#DisclosureCapitalizedFeesPaid1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets3" xlink:href="inva-20251231.xsd#DisclosureGoodwillAndIntangibleAssets3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1" xlink:href="inva-20251231.xsd#DisclosureBalanceSheetComponents1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation" xlink:href="inva-20251231.xsd#DisclosureStockbasedCompensation" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquity1" xlink:href="inva-20251231.xsd#DisclosureStockholdersEquity1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDebt4" xlink:href="inva-20251231.xsd#DisclosureDebt4" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies3" xlink:href="inva-20251231.xsd#DisclosureCommitmentsAndContingencies3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisition1" xlink:href="inva-20251231.xsd#DisclosureAssetAcquisition1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxes3" xlink:href="inva-20251231.xsd#DisclosureIncomeTaxes3" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReporting1" xlink:href="inva-20251231.xsd#DisclosureSegmentReporting1" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureSubsequentEvent" xlink:href="inva-20251231.xsd#DisclosureSubsequentEvent" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="inva-20251231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="inva-20251231.xsd#DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareTables" xlink:href="inva-20251231.xsd#DisclosureNetIncomePerShareTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionTables" xlink:href="inva-20251231.xsd#DisclosureRevenueRecognitionTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidTables" xlink:href="inva-20251231.xsd#DisclosureCapitalizedFeesPaidTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="inva-20251231.xsd#DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="inva-20251231.xsd#DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:href="inva-20251231.xsd#DisclosureStockbasedCompensationTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="inva-20251231.xsd#DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="inva-20251231.xsd#DisclosureIncomeTaxesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingTables" xlink:href="inva-20251231.xsd#DisclosureSegmentReportingTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:href="inva-20251231.xsd#DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:href="inva-20251231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefitsDetails" xlink:href="inva-20251231.xsd#DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:href="inva-20251231.xsd#DisclosureSegmentReportingAdditionalInformationDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncreaseToConvertibleNotes" xlink:label="inva_IncreaseToConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostTableTextBlock" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CurrentPortionOfISPFundInvestments" xlink:label="inva_CurrentPortionOfISPFundInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityMethodInvestment" xlink:label="inva_EquityMethodInvestment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CustomerTwoMember" xlink:label="inva_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NetInvestmentRelatedIncomeExpensesEarnedInccured" xlink:label="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock" xlink:label="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember" xlink:label="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InvestmentsInPreferredStock" xlink:label="inva_InvestmentsInPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RelatedPartyTransactionsPolicyTextBlock" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxesTable" xlink:label="inva_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" xlink:label="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RiskFreeInterestRate" xlink:label="inva_RiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CashDistributions" xlink:label="inva_CashDistributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredRoyaltyObligations" xlink:label="inva_DeferredRoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfDerivativeInstrumentsPurchased" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ClaimExpirationDate" xlink:label="inva_ClaimExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NetIncomeLossPerShareAbstract" xlink:label="inva_NetIncomeLossPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_HealthCareRoyaltyPartnersMember" xlink:label="inva_HealthCareRoyaltyPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NonCashActivity" xlink:label="inva_NonCashActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ReductionToAdditionalPaidInCapital" xlink:label="inva_ReductionToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD1PreferredStockMember" xlink:label="inva_SeriesD1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DescriptionOfOperationsPolicyTextBlock" xlink:label="inva_DescriptionOfOperationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:label="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DividendYield" xlink:label="inva_DividendYield"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BurlingameCaliforniaMember" xlink:label="inva_BurlingameCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AstrazenecaMember" xlink:label="inva_AstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ReclassificationOfCurrentPortion" xlink:label="inva_ReclassificationOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfEstimatedVolatility" xlink:label="inva_PercentageOfEstimatedVolatility"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNetNoncurrent" xlink:label="us-gaap_CapitalizedContractCostNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RightOfUseAssetsObtainedThroughAcquistions" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoDirectorsMember" xlink:label="inva_TwoDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfAcquiredIntangibleAssets" xlink:label="inva_AmortizationOfAcquiredIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontFee" xlink:label="inva_UpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfBoardOfDirectors" xlink:label="inva_NumberOfBoardOfDirectors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EverestMedicinesLimitedMember" xlink:label="inva_EverestMedicinesLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WalthamMassachusettsMember" xlink:label="inva_WalthamMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OtherAccruedLiabilitiesMember" xlink:label="inva_OtherAccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseAndOtherRevenue" xlink:label="inva_LicenseAndOtherRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontCashPayments" xlink:label="inva_UpfrontCashPayments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MassachusettsInstituteOfTechnologyMember" xlink:label="inva_MassachusettsInstituteOfTechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DevelopmentRegulatoryAndSalesMilestoneMember" xlink:label="inva_DevelopmentRegulatoryAndSalesMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleNoteAndWarrantsMember" xlink:label="inva_ConvertibleNoteAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommercialSupplyAgreementMember" xlink:label="inva_CommercialSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="inva_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RegulatoryMilestonePaymentsReceivable" xlink:label="inva_RegulatoryMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentConvertibleConversionPremium" xlink:label="inva_DebtInstrumentConvertibleConversionPremium"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedInterestAndCommitmentFees" xlink:label="inva_AccruedInterestAndCommitmentFees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSubordinatedNotes2023Member" xlink:label="inva_ConvertibleSubordinatedNotes2023Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ImaginabConvertibleNoteMember" xlink:label="inva_ImaginabConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD2PreferredStockMember" xlink:label="inva_SeriesD2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyPayments" xlink:label="inva_RoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontPaymentUnderIntangibleAsset" xlink:label="inva_UpfrontPaymentUnderIntangibleAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes" xlink:label="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontFeeReceived" xlink:label="inva_UpfrontFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember" xlink:label="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedContractManufacturingLiability" xlink:label="inva_AccruedContractManufacturingLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataConvertibleNoteMember" xlink:label="inva_ArmataConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock" xlink:label="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfMinimumRoyaltyRate" xlink:label="inva_PercentageOfMinimumRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedInterestIncomeIncludedInLongTermInvestments" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD1WarrantMember" xlink:label="inva_SeriesD1WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MarketedProductsMember" xlink:label="inva_MarketedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund" xlink:label="inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GrantFundingMaximumAmount" xlink:label="inva_GrantFundingMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember" xlink:label="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AssetAcquisitionsPolicyTextBlock" xlink:label="inva_AssetAcquisitionsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralPartnerMember" xlink:label="us-gaap_GeneralPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD2WarrantMember" xlink:label="inva_SeriesD2WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InterimSupplyAgreementMember" xlink:label="inva_InterimSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfWarrantsOwned" xlink:label="inva_NumberOfWarrantsOwned"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LyndraMember" xlink:label="inva_LyndraMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaTRCHoldingsLLCMember" xlink:label="inva_InnovivaTRCHoldingsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyHeldHealthcareCompaniesMember" xlink:label="inva_PrivatelyHeldHealthcareCompaniesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CreditAndSecurityAgreementMember" xlink:label="inva_CreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxesPaidNetTableTextBlock" xlink:label="inva_IncomeTaxesPaidNetTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WarrantsPurchasedIn2022Member" xlink:label="inva_WarrantsPurchasedIn2022Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseBorrowingsAbstract" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesA1PreferredStockMember" xlink:label="inva_SeriesA1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisLeaseMember" xlink:label="inva_EntasisLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OutstandingStockWarrantMember" xlink:label="inva_OutstandingStockWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmendedZaiAgreementMember" xlink:label="inva_AmendedZaiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontFeePayment" xlink:label="inva_UpfrontFeePayment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseCollaborationAndOtherArrangementsTextBlock" xlink:label="inva_LicenseCollaborationAndOtherArrangementsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CordenPharmaMember" xlink:label="inva_CordenPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DevelopmentRegulatoryAndRoyaltyMember" xlink:label="inva_DevelopmentRegulatoryAndRoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedProfessionalServices" xlink:label="inva_AccruedProfessionalServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DurlobactamMember" xlink:label="inva_DurlobactamMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredRoyaltyObligationCurrent" xlink:label="inva_DeferredRoyaltyObligationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioBiosciencesMember" xlink:label="inva_SyndeioBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WarrantsPurchasedIn2020Member" xlink:label="inva_WarrantsPurchasedIn2020Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesDWarrantsMember" xlink:label="inva_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember" xlink:label="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ResearchAndDevelopmentSupportMember" xlink:label="inva_ResearchAndDevelopmentSupportMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CarryingValueWroteOffWarrantExercise" xlink:label="inva_CarryingValueWroteOffWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault" xlink:label="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityIncentivePlansAndESPPMember" xlink:label="inva_EquityIncentivePlansAndESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock" xlink:label="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TermLoanInvestmentMember" xlink:label="inva_TermLoanInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DecreaseToAccumulatedDeficit" xlink:label="inva_DecreaseToAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedLicenseFeesAndRoyalties" xlink:label="inva_AccruedLicenseFeesAndRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesCWarrantsMember" xlink:label="inva_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GARDPCollaborationAgreementMember" xlink:label="inva_GARDPCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrincipalAmountOfConvertibleNotesOwned" xlink:label="inva_PrincipalAmountOfConvertibleNotesOwned"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_Rule10B51ArrModifiedFlag" xlink:label="inva_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfEconomicInterestInPartnership" xlink:label="inva_PercentageOfEconomicInterestInPartnership"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZEVTERAMember" xlink:label="inva_ZEVTERAMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedEntityTextBlock" xlink:label="inva_ConsolidatedEntityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OptionPricingModelBacksolveValuationMember" xlink:label="inva_OptionPricingModelBacksolveValuationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" xlink:label="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LyndraConvertibleNoteMember" xlink:label="inva_LyndraConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedClinicalAndResearchLiability" xlink:label="inva_AccruedClinicalAndResearchLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_Percent2.50ConvertibleDebtMember" xlink:label="inva_Percent2.50ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BeaconMember" xlink:label="inva_BeaconMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WarrantsPurchasedIn2021Member" xlink:label="inva_WarrantsPurchasedIn2021Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TermOfMilestonePaymentForNetSales" xlink:label="inva_TermOfMilestonePaymentForNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TechnologyTransferAgreementMember" xlink:label="inva_TechnologyTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember" xlink:label="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForTradingSecurities" xlink:label="us-gaap_ProceedsFromPaymentsForTradingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization1" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InternalExpensesMember" xlink:label="inva_InternalExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ImaginAbNoteMember" xlink:label="inva_ImaginAbNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PaionAgMember" xlink:label="inva_PaionAgMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZoliflodacinMember" xlink:label="inva_ZoliflodacinMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityIncentivePlan2012Member" xlink:label="inva_EquityIncentivePlan2012Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PreferredStockWarrantsMember" xlink:label="inva_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRepurchasePercentage" xlink:label="inva_DebtInstrumentRepurchasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ClassOfWarrantOrRightExercised" xlink:label="inva_ClassOfWarrantOrRightExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TotalPaymentsMadeForRoyaltyAgreement" xlink:label="inva_TotalPaymentsMadeForRoyaltyAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OneOfImaginabsCommonStockholderMember" xlink:label="inva_OneOfImaginabsCommonStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CustomerThreeMember" xlink:label="inva_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" xlink:label="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NanoliveMember" xlink:label="inva_NanoliveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxesLineItems" xlink:label="inva_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DenominatorAbstract" xlink:label="inva_DenominatorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity" xlink:label="us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ExpectedHoldingPeriod" xlink:label="inva_ExpectedHoldingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncreaseInDeferredTaxAssets" xlink:label="inva_IncreaseInDeferredTaxAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_VotingAgreementMaximumVotingRightsPercent" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredRoyaltyObligationNonCurrent" xlink:label="inva_DeferredRoyaltyObligationNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquitySecuritiesOwned" xlink:label="inva_EquitySecuritiesOwned"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InvestmentsInCommonStock" xlink:label="inva_InvestmentsInCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="us-gaap_InvestmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmountOfInventoryPurchasesNotBilled" xlink:label="inva_AmountOfInventoryPurchasesNotBilled"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PresentationReclassificationPolicyTextBlock" xlink:label="inva_PresentationReclassificationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRemainingBalancePaidUponMaturation" xlink:label="inva_DebtInstrumentRemainingBalancePaidUponMaturation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PubliclyTradedHealthcareCompaniesMember" xlink:label="inva_PubliclyTradedHealthcareCompaniesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NonRule10B51ArrModifiedFlag" xlink:label="inva_NonRule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ManufacturingStageTransferAgreementMember" xlink:label="inva_ManufacturingStageTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AcquiredIn-ProcessResearchAndDevelopmentAssets" xlink:label="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InvestmentsInWarrants" xlink:label="inva_InvestmentsInWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FirstAmendmentMember" xlink:label="inva_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonStockAcquiredAverageCostPerShare" xlink:label="inva_CommonStockAcquiredAverageCostPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesC2PreferredStockMember" xlink:label="inva_SeriesC2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrincipalAmountOfTermLoansOwned" xlink:label="inva_PrincipalAmountOfTermLoansOwned"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_Outstanding2028NotesMember" xlink:label="inva_Outstanding2028NotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfInventoryFairValueAdjustmentsMember" xlink:label="inva_AmortizationOfInventoryFairValueAdjustmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InterestRateOfDeferredRoyaltyObligation" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostLineItems" xlink:label="us-gaap_CapitalizedContractCostLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" xlink:label="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseAndOtherRevenueMember" xlink:label="inva_LicenseAndOtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies" xlink:label="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SalesMilestonePaymentsReceivable" xlink:label="inva_SalesMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyFinancingAgreementMember" xlink:label="inva_RoyaltyFinancingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesCAndC2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesCAndC2PreferredStockAndCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GatesFoundationMember" xlink:label="inva_GatesFoundationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseRevenueRecognized" xlink:label="inva_LicenseRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfRoyaltyPayableOnNetSales" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MoneyMarketFundAndCash" xlink:label="inva_MoneyMarketFundAndCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember" xlink:label="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:label="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax" xlink:label="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BasileaMember" xlink:label="inva_BasileaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OneDirectorMember" xlink:label="inva_OneDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LexingtonMassachusettsMember" xlink:label="inva_LexingtonMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataTermLoanMember" xlink:label="inva_ArmataTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfMajorCustomers" xlink:label="inva_NumberOfMajorCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidDisclosureTextBlock" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ProfitLossShares" xlink:label="inva_ProfitLossShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember" xlink:label="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNetAbstract" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumeratorAbstract" xlink:label="inva_NumeratorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RegulatoryStartingMaterialMember" xlink:label="inva_RegulatoryStartingMaterialMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NUZOLVENCEMember" xlink:label="inva_NUZOLVENCEMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XacduroMember" xlink:label="inva_XacduroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ImaginabMember" xlink:label="inva_ImaginabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SummaryOfSignificantAccountingPoliciesTable" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCommonStockIssuedDescription" xlink:label="inva_NumberOfCommonStockIssuedDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UnrealizedOtherGainLossOnInvestments" xlink:label="inva_UnrealizedOtherGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ReimbursementsForResearchAndDevelopmentExpense" xlink:label="inva_ReimbursementsForResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SulbactamDurlobactamMember" xlink:label="inva_SulbactamDurlobactamMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WithdrawalFromInvestment" xlink:label="inva_WithdrawalFromInvestment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StrategicAllianceMabaProgram" xlink:label="inva_StrategicAllianceMabaProgram"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_QualifiedFinancingMember" xlink:label="inva_QualifiedFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels" xlink:label="inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" xlink:label="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BusinessCombinationDeferredConsideration" xlink:label="inva_BusinessCombinationDeferredConsideration"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ParatekPharmaceuticalsIncMember" xlink:label="inva_ParatekPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostTable" xlink:label="us-gaap_CapitalizedContractCostTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FactorsAffectingComparabilityPolicyTextBlock" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonAndPreferredStockMember" xlink:label="inva_CommonAndPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaCommonStockMember" xlink:label="inva_InnovivaCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommitmentsFor2024ToBeUtilizedIn2025Member" xlink:label="inva_CommitmentsFor2024ToBeUtilizedIn2025Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCustomers" xlink:label="inva_NumberOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmountOnNetProductSalesRecognized" xlink:label="inva_AmountOnNetProductSalesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SoftwareAndComputerEquipmentMember" xlink:label="inva_SoftwareAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CustomerOneMember" xlink:label="inva_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PurchasesOfEquityAndOtherLongTermInvestments" xlink:label="inva_PurchasesOfEquityAndOtherLongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSeniorNotes2025Member" xlink:label="inva_ConvertibleSeniorNotes2025Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NameOfEventAxis" xlink:label="inva_NameOfEventAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ExternalServicesMember" xlink:label="inva_ExternalServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock" xlink:label="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" xlink:label="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GeorgeWashingtonUniversityMember" xlink:label="inva_GeorgeWashingtonUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyNegotiatedCapPriceMember" xlink:label="inva_PrivatelyNegotiatedCapPriceMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" xlink:label="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaMember" xlink:label="inva_InnovivaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TermOfMilestonePaymentForCommercialSale" xlink:label="inva_TermOfMilestonePaymentForCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MaximumAggregateRoyaltyPaymentsDue" xlink:label="inva_MaximumAggregateRoyaltyPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CostReimbursementMember" xlink:label="inva_CostReimbursementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_HarvardUniversityMember" xlink:label="inva_HarvardUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseToConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase to convertible notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseToConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase To Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseToConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Capitalized Fees Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Released RSUs and RSAs (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The average trading price per $1,000 of Notes with respect to product of the closing common stock price and the conversion rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Average Trade Price Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average trading price percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Interest Payable, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale of Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale of Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Royalty Rate Defined, Level Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate for sales above first level of annual global net sales (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt, net of discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Excluding Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total long-term debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total long-term debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect of outstanding warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CurrentPortionOfISPFundInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Portion Of ISP Fund Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CurrentPortionOfISPFundInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of ISP Fund investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CurrentPortionOfISPFundInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of ISP Fund investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Warrant Exercises</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JP_lbl" xlink:role="http://www.xbrl.org/2003/role/label">JAPAN</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_JP_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Japan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment of Notes Receivable from Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Other Observable Inputs, Level 2</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price of Outstanding Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">COMMITMENTS AND CONTINGENCIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gross carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, after Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Purchase Agreement Fourth Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note purchase agreement fourth amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note Purchase Agreement Fourth Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument, Ratio of repurchase price to the principal amount of debt instrument to be repurchased in the event of default or a fundamental change.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Ratio of repurchase price to the principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ratio of repurchase price to the principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Noncurrent Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other Long Term Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Stated Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt Instrument, annual interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, annual interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Inventory, Gross, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible debt investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityMethodInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityMethodInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityMethodInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity method investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Two [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Scheduled Maturities of Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net investment-related income (expense) earned (incurred)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Investment Related Income Expenses Earned Inccured</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net investment related income expenses earned inccured.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Reconciliation of Equity and Long-Term Investments Balance [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of reconciliation of equity and long-term investments balance.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Equity and Long-Term Investments Balances</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Convertible Promissory Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one convertible promissory note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InvestmentsInPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InvestmentsInPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InvestmentsInPreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investments in preferred stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Describes the entity's accounting policies for transactions entered with related parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory fair value step-up adjustment included in cost of products sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inventory fair value step-up adjustment included in cost of product sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross amount of In-process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets In-process Research and Development, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development, gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of income taxes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets obtained in exchange for operating lease obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Syndeio Two Thousand Twenty Five Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Syndeio two thousand twenty five convertible note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Syndeio 2025 Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Changes in Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax Reconciliation Changes in Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards beginning date of expiry</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average estimated fair value of shares granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">InCarda October Two Thousand Twenty Five Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">InCarda October Two Thousand Twenty Five Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">InCarda October 2025 Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risk free interest rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price as a percentage of fair market value of stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDistributions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash distribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDistributions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Distributions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CashDistributions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash distributions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized fees paid, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PutOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Put Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PutOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock prices above $38.00 per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expired (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Royalty Obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred royalty obligations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Royalty obligations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intangible assets pertain to product rights and developed technologies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of derivative instruments purchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Derivative Instruments Purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of derivative instruments purchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Current Maturities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Carrying Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClaimExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Claim expiration date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClaimExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Claim Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClaimExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Claim expiration date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Unrecognized Stock-based Compensation Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of trading securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetIncomeLossPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HealthCareRoyaltyPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Health care royalty partners member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HealthCareRoyaltyPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Royalty Partners [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HealthCareRoyaltyPartnersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HealthCare Royalty Partners</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to common stock and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock And Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonCashActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonCashActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonCashActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adoption of ASU 2020-06</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital share based compensation requisite service period recognition shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction to additional paid in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction to Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReductionToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction to Additional Paid in Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D 1 preferred stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D 1 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D 1 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of net product sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DescriptionOfOperationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DescriptionOfOperationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of Operations [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DescriptionOfOperationsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of operations.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Purchase of Securities, Operating Activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of trading securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax at statutory rate, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Dividend yield.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividend Yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DividendYield_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or nondeductible items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Noncash Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-cash items</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement, maximum potential payout, percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Maximum Potential Payout Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum potential royalty payout</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Name Of Event [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Event [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income, Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment income, interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BurlingameCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Burlingame, California.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BurlingameCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Burlingame California [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BurlingameCaliforniaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Burlingame, California</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Convertible Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible notes, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards do not expire</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of intangible asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AstrazenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AstraZeneca</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AstrazenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AstraZeneca [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AstrazenecaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">AstraZeneca.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss from fair value changes in equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized loss from fair value changes in equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReclassificationOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of current portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReclassificationOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification of Current Portion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReclassificationOfCurrentPortion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of current portion.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of reconciliation to the consolidated net income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Inventory, Current [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedInvesteesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated investees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedInvesteesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Investees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedInvesteesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Investees [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedInvesteesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Consolidated Investees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEstimatedVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of estimated volatility.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEstimatedVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Estimated Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEstimatedVolatility_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Net, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostNetNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized cost of fixed assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right of Use Assets Obtained Through Acquistions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right of Use Assets Obtained Through Acquistions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained through acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized gains on investment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Balance sheet Information Related To Operating Lease Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Balance sheet Information Related To Operating Lease Table Text Block</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Information Presented In Balance Sheet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Directors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoDirectorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Two Directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Exercise of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, equipment and leasehold improvements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ShareRepurchaseProgramAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfAcquiredIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Acquired Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfAcquiredIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of acquired intangible assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfAcquiredIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of acquired intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of computation of basic and diluted net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Purchase Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note purchase agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note Purchase Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the consecutive and overlapping offering period for the offering of share-based payment awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Consecutive and Overlapping Offering Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total duration of consecutive and overlapping offering periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Basic net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of net revenue from collaboration arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Covenant Terms</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, covenant terms description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardOfDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Board of Directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardOfDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of board of directors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardOfDirectors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total number of directors</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Released RSUs/RSAs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Notes converted to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONSOLIDATED ENTITIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment, furniture and fixtures.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment, Furniture And Fixtures [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment furniture and fixtures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EverestMedicinesLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Everest Medicines Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EverestMedicinesLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Everest Medicines Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EverestMedicinesLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Everest Medicines Limited</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Cross-Border, Other, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Purchase Agreement Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note purchase agreement amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note Purchase Agreement Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WalthamMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Waltham Massachusetts Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WalthamMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Waltham Massachusetts Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Finished Goods, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finished goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other Accrued Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OtherAccruedLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndOtherRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and Other Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndOtherRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and other revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndOtherRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and other revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInSecondYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum purchase commitments, 2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ShareRepurchaseProgramDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt, Excluding Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net increase in tax portions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Strike Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strike price for the underlying number of shares (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontCashPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Cash Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontCashPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront cash payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontCashPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MassachusettsInstituteOfTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Massachusetts Institute of Technology [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MassachusettsInstituteOfTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Massachusetts institute of technology.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MassachusettsInstituteOfTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts Institute of Technology</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stockholders' equity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued personnel-related expenses and other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities inventory fair value adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Inventory Fair Value Adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory fair value adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory fair value adjustment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Retained earnings (accumulated deficit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Unsecured Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for repurchase of debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment upon maturity of debt instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment for repurchase of convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Purchase Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Duration of purchase period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for reporting prior period immaterial correction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prior Period Immaterial Correction [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior Period Immaterial Correction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographic Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographic Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DevelopmentRegulatoryAndSalesMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory and Sales Milestone [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DevelopmentRegulatoryAndSalesMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development regulatory and sales milestone.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DevelopmentRegulatoryAndSalesMilestoneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development Regulatory and Sales Milestone</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Retired, Cost Method, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of treasury stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible note and warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Note and Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In Carda Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleNoteAndWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible note and warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Investee's Board members currently representing the Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of the Company's Board Members Currently Serving on the Board of Investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of the Company's Board members currently serving on the Investee's Board.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">STOCK-BASED COMPENSATION</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Conversion of Debt Securities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommercialSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial supply agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommercialSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommercialSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Exercise of Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value exercise of warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loans Payable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payments receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payments Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional regulatory milestone payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated amortization amount of Marketed Products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Marketed Products, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Marketed products, Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Products and Services [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentConvertibleConversionPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage above the last reported sale price of the Company's common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentConvertibleConversionPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Premium</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentConvertibleConversionPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion premium (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax at statutory rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedInterestAndCommitmentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and commitment fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedInterestAndCommitmentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest and Commitment Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedInterestAndCommitmentFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">accrued interest and commitment fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Liabilities and Stockholders Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of reimbursed for direct and certain indirect manufacturing costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Reimbursed For Direct And Certain Indirect Manufacturing Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reimbursed for direct and certain indirect manufacturing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Long-Acting Beta2 Agonist, RELVAR/BREO, which is being developed and commercialized by entering into a strategic alliance with GSK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Acting Beta2 Agonist Relvar Breo [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RELVAR/BREO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Role of Management [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Discount (Premium)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the variable interest entity, Theravance Respiratory Company, LLC ("TRC").</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Theravance Respiratory Company Llc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Theravance Respiratory Company, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of purchase periods having duration of six months each.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of offering periods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Paid, by Individual Jurisdiction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedNotes2023Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible subordinated notes due 2023 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedNotes2023Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Subordinated Notes 2023 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedNotes2023Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Subordinated Notes 2023 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effective interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt Instrument, Interest Rate, Effective Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ImaginAb Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ImaginAb Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ImaginAb Convertible Note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred tax (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Weighted-Average Assumptions used to Calculate Estimated Value of Stock Options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Cash Flow Information:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D 2 preferred stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D 2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D 2 Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Purchase Agreement, Note Amendment Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible Promissory Note Purchase Agreement, Note Amendment Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note Purchase Agreement, Note Amendment Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GOODWILL AND INTANGIBLE ASSETS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontPaymentUnderIntangibleAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Under Intangible Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontPaymentUnderIntangibleAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment under intangible asset.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontPaymentUnderIntangibleAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment under intangible asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Right-of-use assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares an employee may purchase during any purchase period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets before valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of capped calls in connection with convertible senior notes due 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost To Enter Into Capped Calls Sales In Connection With Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost to enter into capped calls sales in connection with convertible senior notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee received.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">August Two Thousand Twenty Five Credit and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">August two thousand twenty five credit and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August 2025 Credit and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedContractManufacturingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contract manufacturing liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedContractManufacturingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contract Manufacturing Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedContractManufacturingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued contract manufacturing costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash paid for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross amount of Marketed products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Marketed Products, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest on Convertible Debt, Net of Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Add: interest expense on Notes, net of tax effect</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Arrangements and Non-arrangement Transactions [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CIK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The percentage of ownership of common stock in the reporting entity owned by related parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Common Stock Ownership Percentage By Related Party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of common stock owned by a related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Amortized Cost and Estimated Fair Values for Available-for-Sale Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Purchase Agreement Second Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note purchase agreement second amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note Purchase Agreement Second Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Armata convertible note member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share repurchase agreement with GSK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Agreement With Glaxo Group Limited [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to share repurchase agreement with Glaxo Group Limited.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchased and retired during period, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Retirement of treasury stock (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount of debt converted into shares of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Principal Amount of Debt Converted into Shares of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Principal amount of debt converted into shares of common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Short-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfShortTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term of options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deconsolidation, Gain (Loss), Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net gain on sale of TRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net gain on sale of TRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeconsolidationGainOrLossAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Gain on sale of Theravance Respiratory Company, LLC ("TRC")</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of deferred tax assets and deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMinimumRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minimum royalty rate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMinimumRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minimum Royalty Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMinimumRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of minimum royalty rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Specified Sales Level for Determining Royalty Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual global sales level used to determine royalty rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Financial Statement Error Correction [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Call Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock prices below $27.79 per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the number of shares payable to the entity on settlement of derivative instruments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Shares Receivable on Settlement of Derivative Instrument</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net shares settlement payable to the entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Sundry Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Income Included in Long-term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest income included in long-term investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest income converted to long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D1 Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D1 Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D1 Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Long-Term Debt Instruments [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Long-term Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MarketedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MarketedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketed Products [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MarketedProductsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketed products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net sales and purchases of investments managed by ISP Fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Sales and Purchases of Investments Managed by ISP Fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Sales and Purchases of Investments Managed by ISP Fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">InCarda February TwoThousand Twenty Five Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">InCarda February TwoThousand Twenty Five Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">InCarda February 2025 Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of 2025 Notes to common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XeravaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">XERAVA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XeravaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">XERAVA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XeravaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">XERAVA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrantFundingMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Funding Maximum Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrantFundingMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Funding Maximum Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrantFundingMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant funding maximum amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Syndeo Two Thousand Twenty One Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Syndeo two thousand twenty one convertible note member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Syndeio 2021 Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LabaCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the collaboration with GSK to develop and commercialize once-daily LABA products and combination products RELVAR.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LabaCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laba Collaboration [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LabaCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Acting Beta2 Agonist (LABA) Collaboration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cross-border tax laws</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Share-based Payment Arrangements, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata outstanding shares percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AssetAcquisitionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisitions [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AssetAcquisitionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for asset acquisitions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AssetAcquisitionsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Acquisitions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General Partner [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralPartnerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General Partner</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Unrealized Gain</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain from fair value changes in equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and local effects</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Stock-Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of deferred tax assets and deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D2 Warrant.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D2 Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD2WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D2 Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterimSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interim Supply Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterimSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interim Supply Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterimSupplyAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interim supply agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfWarrantsOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Warrants Owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfWarrantsOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants owned.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfWarrantsOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credit carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeCapPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative, Cap Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeCapPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cap price for the underlying number of shares (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Unamortized debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt discount and issuance costs, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Debt discount and issuance costs, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued excise tax on common stock repurchase applied against tax liability, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Excise Tax On Common Stock Repurchase Applied Against Tax Liability Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued excise tax on common stock repurchase applied against tax liability shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LyndraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lyndra</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LyndraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lyndra [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LyndraMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lyndra.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Expired (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaTRCHoldingsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innoviva TRC Holdings, LLC [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaTRCHoldingsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Innoviva TRC Holdings, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaTRCHoldingsLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innoviva TRC Holdings, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total estimated fair value of equity instruments vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata Pharmaceuticals Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest and amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to equity investments and money market funds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Investments And Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity investments and Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyHeldHealthcareCompaniesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Privately Held Healthcare Companies [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyHeldHealthcareCompaniesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Privately held healthcare companies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyHeldHealthcareCompaniesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Privately Held Healthcare Companies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription Agreement One-time Milestone Payment on Commercial Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription agreement one-time milestone payment on commercial sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time milestone payment on commercial sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Unamortized Discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unamortized Debt discount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">State and local jurisdiction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock-based Compensation Expense Included in the Consolidated Statements of Income and Comprehensive Income by Award Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury stock, shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common, Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Treasury stock balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Treasury stock balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation Assumptions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill, impairment losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (Decrease) in Stockholders' Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Credit and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesPaidNetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesPaidNetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of income taxes paid, net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesPaidNetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of net income taxes paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Purchase Agreement Third Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note purchase agreement third amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note Purchase Agreement Third Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument maturity date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants purchased in 2022 member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Purchased In 2022 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2022Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants purchased in 2022</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfTreasuryStockTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Treasury Stock [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardMembersOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of the Investee's Board members</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardMembersOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Board Members of the Investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfBoardMembersOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The total number of Board members of the Investee.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of acquired intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Unobservable Inputs, Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value, Inputs, Level 3</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonrecurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Nonrecurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair value of equity and long-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain loss on other investments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Other Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Changes in fair value, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GainLossOnOtherInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair values of equity and long-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrealized Gain (Loss) on Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrealized loss on other equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrealizedGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of other equity and long-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net product sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Product [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Borrowings [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A1 preferred stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 preferred stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A1 preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entasis Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entasis Lease [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entasis Lease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased and Retired During Period, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock repurchased and retired during period, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Retirement of treasury stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of consolidated entities and business acquisitions by acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Consolidated Entities and Business Acquisitions by Acquisition [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fees paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OutstandingStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding stock warrant member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OutstandingStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Stock Warrant [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OutstandingStockWarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Stock Warrant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmendedZaiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended Zai Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmendedZaiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended Zai Agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmendedZaiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended Zai Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Commitments and contingencies (Note 13)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UpfrontFeePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the strategic alliance with GSK for initiating three new full discovery programs and giving GSK option to license exclusive development and commercialization rights of products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Strategic Alliance Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic alliance - MABA program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Work in Process, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Work-in-process</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the capped call option entered in connection with the offering of convertible debt.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Privately Negotiated Capped Call Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Privately-negotiated capped call option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Entasis Therapeutics Holdings Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entasis Therapeutics Holdings Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entasis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entasis Therapeutics Holdings Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseCollaborationAndOtherArrangementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Collaboration and Other Arrangements [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseCollaborationAndOtherArrangementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure of license collaboration and other arrangements .</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseCollaborationAndOtherArrangementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LICENSE, COLLABORATION AND OTHER ARRANGEMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CordenPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corden Pharma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CordenPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Corden Pharma.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CordenPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corden Pharma [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets deferred royalty obligation, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Royalty Obligation, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred royalty obligation, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DevelopmentRegulatoryAndRoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development, Regulatory and Royalty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DevelopmentRegulatoryAndRoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development, regulatory and royalty.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DevelopmentRegulatoryAndRoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development, Regulatory and Royalty</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Professional Services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedProfessionalServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets collaboration agreement net.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Collaboration Agreement Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and dividend income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Dividend Income, Operating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Dividend Income, Operating, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndDividendIncomeOperating_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest and dividend income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum number of additional shares into which warrants may be converted under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Warrants, Number of Warrants Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants purchased under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DurlobactamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Durlobactam [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DurlobactamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Durlobactam.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DurlobactamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Durlobactam</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income and comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets collaboration agreement gross.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Collaboration Agreement Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Examination, Penalties and Interest Accrued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination, Penalties and Interest Accrued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and penalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of deferred royalty obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Royalty Obligation, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of deferred royalty obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares used to compute basic net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeioBiosciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Syndeio Biosciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeioBiosciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Syndeio Biosciences.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeioBiosciencesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Syndeio Biosciences</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to warrants purchased in 2020.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Purchased In2020 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2020Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants purchased in 2020</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued excise tax on common stock repurchase applied against tax liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Excise Tax On Common Stock Repurchase Applied Against Tax Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued excise tax on common stock repurchase applied against tax liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of differences between expected U.S. federal statutory income tax to income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Syndeio Two Thousand Twenty One Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Syndeio two thousand twenty one convertible note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Syndeio 2021 Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Raw Materials, Net of Reserves</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raw materials</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Consideration Transferred, Transaction Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ResearchAndDevelopmentSupportMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and Development Support [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ResearchAndDevelopmentSupportMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Support [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ResearchAndDevelopmentSupportMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Support</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Attributable to Parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Equity, Attributable to Parent, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Equity, Attributable to Parent, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Balance Sheets and Income Statements of VIE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Variable Interest Entities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Interest Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan, Held-in-Portfolio, Principal Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loan, Held-in-Portfolio, Principal Outstanding, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CarryingValueWroteOffWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value wrote off warrant exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CarryingValueWroteOffWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Carrying Value Wrote off Warrant Exercise</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CarryingValueWroteOffWarrantExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value wrote off warrant exercise.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Repurchase Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Portion of debt retired, carrying value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The additional value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation, Arrangement by Share Based Payment Award, Additional Equity Grant Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pro rata shares grant, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument percentage premium on principal on default</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Percentage Premium on Principal on Default</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument percentage premium on principal on default.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross Revenue from Contract with Customer, Excluding Assessed Tax, Before Amortization Of Capitalized Fees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Special Terms on amended and restated investor rights agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Special Term Re Designating Board Member To Board Of Investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Special terms on re-designating board member to board of investee</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Long-Term and Short-Term, Combined Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, remainder of 2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationTechniqueDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Approach and Technique [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Management's Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlansAndESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to options, Equity Incentive Plans and Employee Stock Purchase Plans.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlansAndESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plans And E S P P [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlansAndESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity incentive plans and ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock, Common [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amount of In-process research and development.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets In-process Research and Development, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development, net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Finite-Lived Intangible Asset, Residual Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Information of TRC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Financial Information on Consolidated Entity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of financial Information on consolidated entity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermLoanInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan Investment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermLoanInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermLoanInvestmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing and Financing Items [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Non-cash Investing and Financing Activities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Equity Method Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair values of equity method investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of equity method investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DecreaseToAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Decrease to accumulated deficit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DecreaseToAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Decrease to Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DecreaseToAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease to accumulated deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryCurrentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Current [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of changes in unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLicenseFeesAndRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued license fees and royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLicenseFeesAndRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued License Fees and Royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLicenseFeesAndRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued license fees and royalties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Operating Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt Instrument Principal Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Principal Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentPrincipalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Operating and Nonoperating</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">All Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stocks - Privately held healthcare companies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity investment ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Product and Service Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cost of products sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GARDPCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GARDP Collaboration Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GARDPCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GARDP Collaboration Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GARDPCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GARDP collaboration agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of equity investments managed by ISP FUND LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of equity investments managed by ISP FUND LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales of equity investments managed by ISP Fund LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Income Taxes Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSET ACQUISITION</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt, Fair Value Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Jurisdiction [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to the Company's Employee Stock Purchase Plan (the "ESPP").</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Old debt instrument interest rate before repurchase of notes member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Old Debt Instrument Interest Rate Before Repurchase Of Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Old Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Real Estate Property</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease space</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrincipalAmountOfConvertibleNotesOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount of convertible notes owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrincipalAmountOfConvertibleNotesOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Principal Amount of Convertible Notes Owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrincipalAmountOfConvertibleNotesOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Principal amount of convertible notes owned.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Europe [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Europe</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rule 10b51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rule 10b51 Arr Modified Flag.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Rule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rule 10b51Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Gross</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total purchase price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Total debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee exercised the right during the reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other adjustments, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement increase in maximum potential payout percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Increase In Maximum Potential Payout Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in maximum potential payout percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of net fair value adjustment of inventory resulting from the acquisition.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustments Of Inventory From Acquistion</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net fair value adjustment of inventory from acquisition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TrelegyElliptaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Trelegy Ellipta.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TrelegyElliptaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trelegy Ellipta [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TrelegyElliptaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TRELEGY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income before provision for income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestInPartnership_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Economic interest of the Partnership (in percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestInPartnership_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of economic interest held in Partnership.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestInPartnership_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Economic Interest In Partnership</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZEVTERAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ZEVTERA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZEVTERAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ZEVTERA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value portion of subordinated debt obligations which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Subordinated Debt, Fair Value Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for consolidated entity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CONSOLIDATED ENTITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligation payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Royalties, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OptionPricingModelBacksolveValuationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option Pricing Model Backsolve valuation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OptionPricingModelBacksolveValuationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Pricing Model Backsolve Valuation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OptionPricingModelBacksolveValuationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Backsolve Valuation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign tax effects Other - Withholding taxes , Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables, Long-Term Contracts or Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivable from collaboration arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">InCarda Two Thousand Twenty Four Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">InCarda two thousand twenty four convertible note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">InCarda 2024 Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash, cash equivalents and restricted cash at end of period shown in the consolidated statements of cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid, Excluding Capitalized Interest, Operating Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PartnershipAgreementLockUpPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PartnershipAgreementLockUpPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partnership Agreement, Lock-Up Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PartnershipAgreementLockUpPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lock-up period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise price of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Debt, Fair Value Disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercisable option</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetRentableArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rentable square feet</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LyndraConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lyndra Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LyndraConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lyndra convertible note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LyndraConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lyndra Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative effect period of adoption adjustment member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedClinicalAndResearchLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical and research expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedClinicalAndResearchLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical and Research Liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedClinicalAndResearchLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical and research liability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Existence of Option to Terminate [true false]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GiaprezaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GIAPREZA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GiaprezaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">GIAPREZA [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GiaprezaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GIAPREZA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award number of annual installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of annual installments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The number of annual installments that RSUs granted to newly appointed independent directors will vest.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost, Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of capitalized fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: amortization of capitalized fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management, Strategy, and Governance [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Enactment of new tax laws, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Percent2.50ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the information pertaining to 2.50% convertible senior notes due 2025.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Percent2.50ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percent2.50 Convertible Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Percent2.50ConvertibleDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase and sale of other investments managed by ISP FUND LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase and sale of other investments managed by ISP FUND LP, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase and sales of other investments managed by ISP Fund LP, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases and sales of other investments managed by ISP Fund LP, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investments [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign tax effects Other - Withholding taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BeaconMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beacon [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BeaconMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beacon [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BeaconMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beacon</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSAs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants purchased in 2021</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Purchased In2021 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WarrantsPurchasedIn2021Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to warrants purchased in 2021.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of the milestone payment on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term of Milestone Payment for Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of milestone payment for net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of maximum royalty based on achievement of annual net product sales thresholds.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Maximum Royalty Based On Achievement Of Annual Net Product Sales Thresholds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum royalty based on achievement of annual net product sales thresholds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares used to compute diluted net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TechnologyTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Technology Transfer Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TechnologyTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Technology transfer agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TechnologyTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Stage Transfer Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of shares granted annually to independent directors upon re-election the to Board.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award, Annual Equity Grant, Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual grant of shares, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IspFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to ISP Fund LP, an investment managed by Sarissa Capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IspFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Isp Fund Lp [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IspFundLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ISP Fund LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 2025 Credit and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">March Two Thousand Twenty Five Credit and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">March two thousand twenty five credit and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentValueRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentValueRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent value rights liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentValueRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights liability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ContingentValueRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contingent value rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuredConvertibleCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Secured convertible credit agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuredConvertibleCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Secured Convertible Credit Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuredConvertibleCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Secured Convertible Credit Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuredConvertibleCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">January 2023 Secured Convertible Credit Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from (Payments for) Trading Securities, Short-Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from trading securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForTradingSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Proceeds from trading securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Depreciation And Amortization 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities depreciation and amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Depreciation and amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BALANCE SHEET COMPONENTS</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of common stock price as a percentage of conversion price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Common Stock Price to Conversion Price Ratio, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price to current conversion price ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Benchmark [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Product Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InternalExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Internal Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InternalExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Internal Expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InternalExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Internal expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginAbNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ImaginAb Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginAbNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ImaginAb Note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginAbNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ImaginAb Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaionAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PAION AG [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaionAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">PAION AG [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PaionAgMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PAION AG</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZoliflodacinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zoliflodacin [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZoliflodacinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zoliflodacin.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZoliflodacinMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Zoliflodacin</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SEGMENT REPORTING</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlan2012Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the 2012 Equity Incentive Plan as approved by shareowners.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlan2012Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan2012 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquityIncentivePlan2012Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2012 Equity Incentive Plan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty On Payments Received From Sublicensees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty on payments received from sublicensees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty payable as a percentage of payments received from sublicensees.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization YearThree</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Released RSUs/RSAs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrants Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRepurchasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Portion of debt Instrument, repurchased.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRepurchasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Repurchase Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRepurchasePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of notes repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClassOfWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClassOfWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClassOfWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant or right, exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TotalPaymentsMadeForRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for royalty agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TotalPaymentsMadeForRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Total Payments Made For Royalty Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TotalPaymentsMadeForRoyaltyAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total payments made for royalty agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price (dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Conversion price of convertible notes into common stock (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneOfImaginabsCommonStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One of ImaginAb's Common Stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneOfImaginabsCommonStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Of Imaginabs Common Stockholder [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneOfImaginabsCommonStockholderMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to one of ImaginAb's common stockholders.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Gross (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Enactment of new tax laws</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Extinguishment of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Loss on extinguishment of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata March Two Thousand Twenty Four Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Armata march two thousand twenty four term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata March Two Thousand Twenty Four Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Armata March 2024 Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NanoliveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nanolive [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NanoliveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nanolive [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NanoliveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nanolive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in dollars per shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements Not Yet Adopted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign tax credit, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-Dilutive Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets unrealized losses on investment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Unrealized Losses On Investment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses on investment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncomeTaxesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Denominator [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DenominatorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible subordinated notes due 2023 (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment for Purchase, Investment, Operating Activity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of equity and long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExpectedHoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Expected holding period of equity method investment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExpectedHoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expected Holding Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExpectedHoldingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected holding period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Promissory Note Purchase Agreement Fifth Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible promissory note purchase agreement fifth amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Promissory Note Purchase Agreement Fifth Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payment of Financing and Stock Issuance Costs, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Financing and Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Subordinated Debt [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible subordinated notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Differences between the expected U.S. federal statutory income tax to income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Carrying Amount of Equity Component</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity component, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in deferred tax assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncreaseInDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in Deferred Tax Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of economic interest in any future payments made under the agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Economic Interest on Future Payments Under Agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of economic interest in any future payments made under the agreements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of maximum voting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Voting Agreement, Maximum Voting Rights, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the percentage of maximum voting rights under voting agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of lease liabilities included within Other accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current portion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of license revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long-term portion of deferred royalty obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Royalty Obligation, Non Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DeferredRoyaltyObligationNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of deferred royalty obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of components of the income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Changes In Unrecognized Tax Benefits Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Changes In Unrecognized Tax Benefits Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in unrecognized tax benefits, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Fair Value per Share at Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C warrants and Series D warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C warrants and Series D warrants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Warrants and Series D Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquitySecuritiesOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquitySecuritiesOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EquitySecuritiesOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity securities owned.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InvestmentsInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InvestmentsInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investments In Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InvestmentsInCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS' EQUITY</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">NET INCOME PER SHARE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Individual Investments Held by ISP Fund</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Inventories, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustments for change in value of Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Change in inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmountOfInventoryPurchasesNotBilled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount of Inventory Purchases Not Billed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmountOfInventoryPurchasesNotBilled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of inventory purchases not billed.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmountOfInventoryPurchasesNotBilled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of inventory purchases not yet received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Useful Life [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of property, equipment and leasehold improvements useful lives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PresentationReclassificationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Presentation reclassification.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PresentationReclassificationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Presentation Reclassification [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PresentationReclassificationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Presentation Reclassification</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">La Jolla</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">La Jolla [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">La Jolla [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">La Jolla [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Purchase Agreement, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SecuritiesPurchaseAgreementAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payments for acquire variable interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyEightNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty eight notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyEightNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Eight Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyEightNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Straight line operating lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRemainingBalancePaidUponMaturation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Remaining Balance Paid upon Maturation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRemainingBalancePaidUponMaturation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument remaining balance paid upon maturation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_DebtInstrumentRemainingBalancePaidUponMaturation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining balance paid upon maturation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional disclosures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants and Rights Outstanding, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Term of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Dividend yield</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of royalty payments not entitled to receive</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments the company is not entitled to receive.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of operating lease liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, FDII, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign-derived intangible income, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PubliclyTradedHealthcareCompaniesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Publicly Traded Healthcare Companies [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PubliclyTradedHealthcareCompaniesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Publicly traded healthcare companies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PubliclyTradedHealthcareCompaniesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Publicly Held Healthcare Companies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Settlement of convertible note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Debt Issuance Costs and Discounts, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs and Discounts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt discount and issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Rule 10B51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Rule 10B51 Arr Modified Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NonRule10B51ArrModifiedFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Rule 10b51 Arrangement Modified</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtByMaturityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term debt maturities for years ending December 31:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated entities and acquisitions disclosure abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities and Acquisitions Disclosure Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ManufacturingStageTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Manufacturing Stage Transfer Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ManufacturingStageTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Manufacturing Stage Transfer Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ManufacturingStageTransferAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing Stage Transfer Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Conversion, Converted Instrument, Shares Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Principal amount converted in to shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired in-process research and development assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acquired In-Process Research and Development Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acquired in-process research and development assets.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement, Royalty Rate Defined, Level One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate for first level of annual global net sales (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InvestmentsInWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InvestmentsInWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InvestmentsInWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Investments In Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total estimated fair value of options vested</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Amendment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Amendment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First amendment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade Accounts Receivable [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TradeAccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables from Net Product Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of components of income before income tax expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Acquired Average Cost Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Acquired Average Cost Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonStockAcquiredAverageCostPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares repurchased average price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition, Date of Acquisition Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Date of acquisition agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Reconciliation Section Two Fifty Deduction Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax reconciliation section two fifty deduction amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 250 deduction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Tax Credit Carryforward [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research tax credit carryforward</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesC2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C-2 Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesC2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C-2 Preferred Stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesC2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C-2 preferred stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrincipalAmountOfTermLoansOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Principal Amount of Term Loans Owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrincipalAmountOfTermLoansOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Principal amount of term loans owned.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrincipalAmountOfTermLoansOwned_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount of term loans owned</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Outstanding2028NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding 2028 Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Outstanding2028NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding 2028 notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_Outstanding2028NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding 2028 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Assets [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notes converted into common stock, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">InCarda Convertible note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Carda Convertible Note [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InCardaConvertibleNoteMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">InCarda Convertible Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward beginning date of expiry</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future minimum purchase commitments, 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2020-06</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2020-06 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FuturePotentialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Future potential milestone payment receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FuturePotentialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Future Potential Milestone Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FuturePotentialMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future potential milestone payment receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding RSUs and PSUs/RSAs and PSAs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfInventoryFairValueAdjustmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of inventory fair value adjustments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfInventoryFairValueAdjustmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Inventory Fair Value Adjustments[Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfInventoryFairValueAdjustmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of inventory fair value adjustments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to noncontrolling interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income attributable to Innoviva stockholders</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income, basic</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest rate of deferred royalty obligation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Rate of Deferred Royalty Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Rate of Deferred Royalty Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Pro Forma Information [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pro Forma Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets measured at estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net amount of Marketed Products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Marketed Products, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsMarketedProductsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketed products, net carrying amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk, Percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata March Two Thousand Twenty Five Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Armata march two thousand twenty five term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata March 2025 Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndOtherRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License And Other Revenue [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndOtherRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and other revenue member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseAndOtherRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and other revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total fair value of debt</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 ESPP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Twenty Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Stock Purchase Plan Twenty Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities to provide for indemnifications and other contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Indemnifications And Other Contingencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued liabilities to provide for indemnifications and other contingencies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SalesMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestone payments receivable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SalesMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone Payments Receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SalesMilestonePaymentsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestone payments receivable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrivatePlacementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program, Remaining Authorized, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of shares repurchased</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowing which takes priority over other debt securities and can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Senior Unsecured Convertible Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement required payment for breach of agreement payment two.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Required Payment For Breach Of Agreement Payment Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related and Nonrelated Parties [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">INCOME TAXES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Credit loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty financing agreement member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Financing Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyFinancingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Financing Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCAndC2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C and C 2 Preferred Stock and Common Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCAndC2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C and C 2 preferred stock and common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesCAndC2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C preferred stock, Series C-2 preferred stock and common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other long-term liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gates Foundation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gates Foundation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gates Foundation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License revenue recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Revenue Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LicenseRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License revenue recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty payable, as a percentage of net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payable On Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payable on net sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Placement Positions And Convertible Notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Private Placement Positions And Convertible Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Placement Positions And Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innoviva Strategic Opportunities, LLC</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innoviva Strategic Opportunities Limited Liability Corporation [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to Innoviva Strategic Opportunities, LLC.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Portion of debt instrument face amount, exercised.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion of Debt Instrument Face Amount, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Portion of debt instrument face amount, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED KINGDOM</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_GB_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United Kingdom</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development, accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets In Process Research And Development Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible sssets in process research and development accumulated amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New debt instrument interest rate after repurchase of notes member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Debt Instrument Interest Rate After Repurchase Of Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Limited Partners' Contributed Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contributed to partnership for investing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LimitedPartnersContributedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Capital contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Asset, Finite-Lived [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities, FV-NI, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and long-term investments at fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesFvNi_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nontaxable or nondeductible items, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_DirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-employee director</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accumulated Amortization of Recognized Intangible Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series D 1 and D 2 preferred stock and common stock.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D 1 And D 2 Preferred Stock And Common Stock Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D 1 And D 2 Preferred Stock And Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MoneyMarketFundAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Fund and Cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MoneyMarketFundAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Money market fund and cash.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MoneyMarketFundAndCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market fund and cash</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued personnel-related expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recurring basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">March Two Thousand Twenty Four Credit and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">March two thousand twenty four credit and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 2024 Credit and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research credits , percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal and state research and development credit, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling and marketing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling and Marketing Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling and Marketing Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum contributions as a percentage of employee's eligible compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreement, accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Collaboration Agreement Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Intangible assets collaboration agreement accumulated amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Collaboration agreement, accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Equity Award Activity and Related Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total investments held by ISP Fund LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of capitalized fees and depreciation of property and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Capitalized Fees and Depreciation of Property and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of capitalized fees and depreciation of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GateNeuroscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gate Neuroscience [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GateNeuroscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gate Neuroscience [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GateNeuroscienceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gate Neurosciences [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Expected Amortization After Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finite lived intangible asset expected amortization after year four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, thereafter</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Shares Acquired Including Accrued Excise Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury stock shares acquired including accrued excise tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock, including accrued excise tax (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fees paid weighted average useful life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Weighted Average Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining amortization period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BasileaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basilea [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BasileaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basilea.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BasileaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basilea</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Income Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional cash investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Long-Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Initial contribution</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Purchases of equity and long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">One Director.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">One Director [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_OneDirectorMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One Director</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets Abstract</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Other-than-Temporary Impairment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LexingtonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lexington Massachusetts [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LexingtonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lexington Massachusetts.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LexingtonMassachusettsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lexington, Massachusetts</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Armata term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Convertible, Conversion Ratio</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion rate for shares of common stock per $1,000 principal</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities measured at estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities at estimated fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercised (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents GSK, with whom the entity has agreements and arrangements, such as those for developing and commercializing different products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">G S K [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GSKMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Accumulated amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock: $0.01 par value, 200,000 shares authorized, 74,636 and 62,665 issued and outstanding as of December 31, 2025 and 2024 respectively</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income, diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfMajorCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Major Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfMajorCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of major customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfMajorCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of major customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Royalty revenue from a related party</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaPharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">La jolla pharmaceutical company member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaPharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">La Jolla Pharmaceutical Company [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LaJollaPharmaceuticalCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">La Jolla Pharmaceutical Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The entire disclosure for information about capitalized fees paid.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CAPITALIZED FEES PAID</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProfitLossShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProfitLossShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ProfitLossShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit Loss Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Long-Term Receivables, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivables from collaboration arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accrued Liabilities, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State and local effects, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Debt Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of debt issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">July Two Thousand Twenty Three Credit and Security Agreement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">July two thousand twenty three credit and security agreement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">July 2023 Credit and Security Agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid, Net [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Payable, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued interest payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repurchase of shares to satisfy tax withholding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation, Arrangement by Share Based Payment Award, Initial Equity Grant Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One time grant of shares, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">REVENUE RECOGNITION</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">DEBT</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense on Deferred Royalty Obligation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Income Taxes, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payable, long-term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire in Process Research and Development</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cash paid for in-process research and development assets acquired</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other income, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Numerator [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumeratorAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax expense, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryStartingMaterialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory Starting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryStartingMaterialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Starting Material [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RegulatoryStartingMaterialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory starting material.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NUZOLVENCEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NUZOLVENCE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NUZOLVENCEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NUZOLVENCE [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NUZOLVENCEMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">NUZOLVENCE.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of common stock, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advances on Inventory Purchases</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance payments received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdvancesOnInventoryPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment received for additional inventory purchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and of Significant Suppliers and Partners</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XacduroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">XACDURO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XacduroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">XACDURO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_XacduroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">XACDURO [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Imaginab [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ImaginAb</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ImaginabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to ImaginAb.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense, Debt [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistAnoroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents Long-Acting Beta2 Agonist, ANORO, which is being developed and commercialized by entering into a strategic alliance with GSK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistAnoroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Acting Beta2 Agonist Anoro [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_LongActingBeta2AgonistAnoroMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ANORO</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Items [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Liability and Equity Components of Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Information related to various accounting policies of the entity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCommonStockIssuedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock issued description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCommonStockIssuedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Common Stock Issued Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCommonStockIssuedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock issued description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents the royalty rate for combination products.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Annual Royalties as Percentage of Net Sales for Combination Products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty rate for combination products (as a percent)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized gain on equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Investments, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Realized gain on equity investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Changes in fair values of equity and long-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual term of options exercisable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Cross-Border, Other, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net decrease in tax portions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Stock-Based Compensation Awards</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Expense (Benefit), Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expenses [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares to be purchased under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares purchased under the securities purchase agreement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Released RSUs and RSAs (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fee paid estimated useful life.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fee Paid Estimated Useful Life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized fees paid, estimated useful life</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Diluted net income per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Segments [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrealizedOtherGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Changes in fair values of equity and long-term investments, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrealizedOtherGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrealized other gain loss on investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrealizedOtherGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrealized Other Gain Loss on Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_UnrealizedOtherGainLossOnInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Future amortization expense, 2030</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title and Position [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Relationship to Entity [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign tax credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReimbursementsForResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursements for Research and Development Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReimbursementsForResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursements for research and development expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ReimbursementsForResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SulbactamDurlobactamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sulbactam-Durlobactam [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SulbactamDurlobactamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sulbactam-Durlobactam.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SulbactamDurlobactamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sulbactam Durlobactam</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes face value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loan amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan facility in aggregate amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Interest Entity, Not Primary Beneficiary [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Interest Entity, Not Primary Beneficiary</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WithdrawalFromInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Withdrawal from investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WithdrawalFromInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Withdrawal From Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_WithdrawalFromInvestment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Withdrawal From Investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted Average Fair Value per Share of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Weighted-Average Fair Value per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal and state research credits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Federal and state research and development credit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">No definition available.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceMabaProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">strategic alliance - MABA program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceMabaProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">strategic alliance - MABA program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_StrategicAllianceMabaProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Strategic alliance - MABA program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyThreeNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty three notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyThreeNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Three Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyThreeNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for capitalized fees paid to a related party.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid To A Related Party [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees Paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, Weighted average remaining lease term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties payable period after first commercial sale of product.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties Payable Period After First Commercial Sale Of Product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties payable period after first commercial sale of product</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_QualifiedFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Qualified Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_QualifiedFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Qualified Financing [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_QualifiedFinancingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualified Financing</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration, date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Next Twelve Months</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount the employee may contribute of employee's eligible compensation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement By Share-Based Payment Award Maximum Amount As A Contribution Of Eligible Compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum value of shares an employee may purchase in a calendar year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Assets Or Liabilities Transfer Between Levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair Value Of Assets Or Liabilities Transfer Between Levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of assets or liabilities transfer between levels</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Stock Value Acquired Cost Method Including Accrued Excise Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury stock value acquired cost method including accrued excise tax.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock, including accrued excise tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Net, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationDeferredConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination deferred consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationDeferredConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Deferred Consideration</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_BusinessCombinationDeferredConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination deferred consideration.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ParatekPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Paratek Pharmaceuticals, Inc.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ParatekPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Paratek Pharmaceuticals, Inc [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ParatekPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Paratek Pharmaceuticals, Inc</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Loss from operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalizedContractCostTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Contract Cost [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of Equity Investments Managed by Isp Fund Lp</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases of Equity Investments Managed by Isp Fund Lp</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of equity investments managed by ISP Fund LP</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: Current portion of long-term debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt, Current, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt, Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Current portion of long-term debt, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible notes, due 2025, net of issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Factors affecting comparability.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Factors Affecting Comparability Policy [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Factors Affecting Comparability</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs to acquire equity securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity issuance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonAndPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common and Preferred Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonAndPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common and Preferred Stock [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommonAndPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common and preferred stock member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Innoviva's Common Stock Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innoviva Common Stock Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innoviva's Common Stock</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommitmentsFor2024ToBeUtilizedIn2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments for 2024 to be utilized in 2025 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommitmentsFor2024ToBeUtilizedIn2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments for 2024 to be utilized in 2025 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CommitmentsFor2024ToBeUtilizedIn2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments for 2024 to be utilized in 2025.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmountOnNetProductSalesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount on net product sales recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmountOnNetProductSalesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount on Net Product Sales Recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmountOnNetProductSalesRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount on net product sales recognized.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Liabilities, Noncurrent, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncurrent liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SarissaCapitalManagementLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">This member stands for Sarissa Capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SarissaCapitalManagementLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sarissa Capital Management Lp [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SarissaCapitalManagementLpMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sarissa Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term portion of lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quoted Price in Active Markets for Identical Assets, Level 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SoftwareAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Software and computer equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SoftwareAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software And Computer Equipment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SoftwareAndComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software and computer equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customer one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer One [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CustomerOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityAndOtherLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchases of Equity and Other Long Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityAndOtherLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchases of Equity and Other Long Term Investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PurchasesOfEquityAndOtherLongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of equity and other long-term investments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Lease Cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unamortized Debt Issuance Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized debt issuance cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities, net</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax (liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, FDII, Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Foreign-derived intangible income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorNotes2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Notes 2025 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorNotes2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible senior notes 2025.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConvertibleSeniorNotes2025Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes due 2025 [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Capitalized fees paid future amortization.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Future Amortization [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized Fees paid, Future amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfGoodwillTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-US [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rest of the world</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-US</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of anti-dilutive securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Jurisdiction [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Name Of Event [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_NameOfEventAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Event [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty five notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Five Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Two Thousand Twenty Five Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TwoThousandTwentyFiveNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Income Location, Balance [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExternalServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">External Services [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExternalServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">External Services.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ExternalServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">External services</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Financial Information Of Variable Interest Entities [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of financial information of variable interest entities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Balance Sheets and Income Statements of VIE</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Represents information pertaining to InCarda.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incarda [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_IncardaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">InCarda</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata August Two Thousand Twenty Five Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Armata august two thousand twenty five term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata August 2025 Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of Deferred Tax Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect, Period of Adoption [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GeorgeWashingtonUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">George Washington University.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GeorgeWashingtonUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">George Washington University [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_GeorgeWashingtonUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">George Washington University</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCapPriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Privately Negotiated Cap Price [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCapPriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Privately negotiated cap price.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_PrivatelyNegotiatedCapPriceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Privately-negotiated cap price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, term</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical development and regulatory milestones amount payable.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development And Regulatory Milestones Amount Payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical development and regulatory milestones amount payable</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Armata July Two Thousand Twenty Three Term Loan [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Armata july two thousand twenty three term loan.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Armata July Two Thousand Twenty Three Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Armata July 2023 Term Loan</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subscription Agreement One-time Milestone Payment on Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Subscription agreement one-time milestone payment on net sales.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time Milestone Payment on Net Sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Innoviva [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Innoviva [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_InnovivaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Innoviva [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term of Milestone Payment for Commercial Sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of milestone payment for commercial sale.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_TermOfMilestonePaymentForCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of milestone payment for commercial sale</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute net income per share:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorOpinionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Opinion [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited (in shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Reconciliation Section Two Fifty Deduction Percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax reconciliation section two fifty deduction percent.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Section 250 deduction, percent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capitalized Fees Paid Remaining Estimated Amortization Year Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of estimated amortization for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated amortization for the year 2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock - Publicly traded healthcare companies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of fair value adjustments of cost of products sold.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization of Fair Value Adjustments of Cost of Products Sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of fair value adjustments of Cost of products sold</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation of Revenue [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition and Collaborative Arrangements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MaximumAggregateRoyaltyPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Royalty Payments Due</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MaximumAggregateRoyaltyPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate royalty payments due.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_MaximumAggregateRoyaltyPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total royalty revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">License revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total net revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostReimbursementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost Reimbursement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostReimbursementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost Reimbursement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_CostReimbursementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost reimbursement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2029</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty agreement required payment for breach of agreement payment one.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Agreement Required Payment For Breach Of Agreement Payment One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required payment for breach of agreement, payment one</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Repurchased Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Repurchased Face Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Portion of debt retired, face value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Consolidated entities and acquisitions.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities and Acquisitions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities and Acquisitions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares remaining available for issuance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Amortization Period (Years)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZaiLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Zai Lab.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZaiLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Zai Lab [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_ZaiLabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Zai Lab</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HarvardUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard University.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HarvardUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard University [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="inva_HarvardUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard University</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite-Lived Intangible Assets [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name [Domain]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncreaseToConvertibleNotes" xlink:to="inva_IncreaseToConvertibleNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostTableTextBlock" xlink:to="us-gaap_CapitalizedContractCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:to="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CurrentPortionOfISPFundInvestments" xlink:to="inva_CurrentPortionOfISPFundInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_JP" xlink:to="country_JP_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostGross" xlink:to="us-gaap_CapitalizedContractCostGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:to="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityMethodInvestment" xlink:to="inva_EquityMethodInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CustomerTwoMember" xlink:to="inva_CustomerTwoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured" xlink:to="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock" xlink:to="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember" xlink:to="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InvestmentsInPreferredStock" xlink:to="inva_InvestmentsInPreferredStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RelatedPartyTransactionsPolicyTextBlock" xlink:to="inva_RelatedPartyTransactionsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" xlink:to="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeTaxesTable" xlink:to="inva_IncomeTaxesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" xlink:to="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" xlink:to="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" xlink:to="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RiskFreeInterestRate" xlink:to="inva_RiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CashDistributions" xlink:to="inva_CashDistributions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PutOptionMember" xlink:to="us-gaap_PutOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredRoyaltyObligations" xlink:to="inva_DeferredRoyaltyObligations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfDerivativeInstrumentsPurchased" xlink:to="inva_NumberOfDerivativeInstrumentsPurchased_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ClaimExpirationDate" xlink:to="inva_ClaimExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="inva_NetIncomeLossPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_HealthCareRoyaltyPartnersMember" xlink:to="inva_HealthCareRoyaltyPartnersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommonStockAndWarrantsMember" xlink:to="inva_CommonStockAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NonCashActivity" xlink:to="inva_NonCashActivity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ReductionToAdditionalPaidInCapital" xlink:to="inva_ReductionToAdditionalPaidInCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD1PreferredStockMember" xlink:to="inva_SeriesD1PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DescriptionOfOperationsPolicyTextBlock" xlink:to="inva_DescriptionOfOperationsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:to="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DividendYield" xlink:to="inva_DividendYield_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:to="inva_RoyaltyAgreementMaximumPotentialPayoutPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NameOfEventDomain" xlink:to="inva_NameOfEventDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BurlingameCaliforniaMember" xlink:to="inva_BurlingameCaliforniaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AstrazenecaMember" xlink:to="inva_AstrazenecaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ReclassificationOfCurrentPortion" xlink:to="inva_ReclassificationOfCurrentPortion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedInvesteesMember" xlink:to="inva_ConsolidatedInvesteesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfEstimatedVolatility" xlink:to="inva_PercentageOfEstimatedVolatility_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostNetNoncurrent" xlink:to="us-gaap_CapitalizedContractCostNetNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RightOfUseAssetsObtainedThroughAcquistions" xlink:to="inva_RightOfUseAssetsObtainedThroughAcquistions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesInvestments" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:to="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoDirectorsMember" xlink:to="inva_TwoDirectorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmortizationOfAcquiredIntangibleAssets" xlink:to="inva_AmortizationOfAcquiredIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UpfrontFee" xlink:to="inva_UpfrontFee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesMember" xlink:to="us-gaap_EquitySecuritiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCovenantTerms" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfBoardOfDirectors" xlink:to="inva_NumberOfBoardOfDirectors_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_VariableInterestEntityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:to="inva_LaboratoryEquipmentFurnitureAndFixturesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EverestMedicinesLimitedMember" xlink:to="inva_EverestMedicinesLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WalthamMassachusettsMember" xlink:to="inva_WalthamMassachusettsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OtherAccruedLiabilitiesMember" xlink:to="inva_OtherAccruedLiabilitiesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LicenseAndOtherRevenue" xlink:to="inva_LicenseAndOtherRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondYear" xlink:to="us-gaap_PurchaseObligationDueInSecondYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ShareRepurchaseProgramDomain" xlink:to="srt_ShareRepurchaseProgramDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UpfrontCashPayments" xlink:to="inva_UpfrontCashPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MassachusettsInstituteOfTechnologyMember" xlink:to="inva_MassachusettsInstituteOfTechnologyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfUnsecuredDebt" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_IncomeStatementRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" xlink:to="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicConcentrationRiskMember" xlink:to="us-gaap_GeographicConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DevelopmentRegulatoryAndSalesMilestoneMember" xlink:to="inva_DevelopmentRegulatoryAndSalesMilestoneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleNoteAndWarrantsMember" xlink:to="inva_ConvertibleNoteAndWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommercialSupplyAgreementMember" xlink:to="inva_CommercialSupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:to="inva_StockIssuedDuringPeriodValueExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="us-gaap_LoansPayableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RegulatoryMilestonePaymentsReceivable" xlink:to="inva_RegulatoryMilestonePaymentsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentConvertibleConversionPremium" xlink:to="inva_DebtInstrumentConvertibleConversionPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedInterestAndCommitmentFees" xlink:to="inva_AccruedInterestAndCommitmentFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:to="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LongActingBeta2AgonistRelvarBreoMember" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TheravanceRespiratoryCompanyLlcMember" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleSubordinatedNotes2023Member" xlink:to="inva_ConvertibleSubordinatedNotes2023Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ImaginabConvertibleNoteMember" xlink:to="inva_ImaginabConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD2PreferredStockMember" xlink:to="inva_SeriesD2PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyPayments" xlink:to="inva_RoyaltyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UpfrontPaymentUnderIntangibleAsset" xlink:to="inva_UpfrontPaymentUnderIntangibleAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes" xlink:to="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UpfrontFeeReceived" xlink:to="inva_UpfrontFeeReceived_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember" xlink:to="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedContractManufacturingLiability" xlink:to="inva_AccruedContractManufacturingLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsMarketedProductsGross" xlink:to="inva_IntangibleAssetsMarketedProductsGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataConvertibleNoteMember" xlink:to="inva_ArmataConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:to="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock" xlink:to="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfShortTermDebt" xlink:to="us-gaap_RepaymentsOfShortTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeconsolidationGainOrLossAmount" xlink:to="us-gaap_DeconsolidationGainOrLossAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfMinimumRoyaltyRate" xlink:to="inva_PercentageOfMinimumRoyaltyRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CallOptionMember" xlink:to="us-gaap_CallOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:to="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedInterestIncomeIncludedInLongTermInvestments" xlink:to="inva_AccruedInterestIncomeIncludedInLongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD1WarrantMember" xlink:to="inva_SeriesD1WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MarketedProductsMember" xlink:to="inva_MarketedProductsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund" xlink:to="inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" xlink:to="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_XeravaMember" xlink:to="inva_XeravaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GrantFundingMaximumAmount" xlink:to="inva_GrantFundingMaximumAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember" xlink:to="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LabaCollaborationMember" xlink:to="inva_LabaCollaborationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AssetAcquisitionsPolicyTextBlock" xlink:to="inva_AssetAcquisitionsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralPartnerMember" xlink:to="us-gaap_GeneralPartnerMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD2WarrantMember" xlink:to="inva_SeriesD2WarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InterimSupplyAgreementMember" xlink:to="inva_InterimSupplyAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfWarrantsOwned" xlink:to="inva_NumberOfWarrantsOwned_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeCapPrice" xlink:to="us-gaap_DerivativeCapPrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" xlink:to="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LyndraMember" xlink:to="inva_LyndraMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InnovivaTRCHoldingsLLCMember" xlink:to="inva_InnovivaTRCHoldingsLLCMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataPharmaceuticalsIncMember" xlink:to="inva_ArmataPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:to="inva_EquityInvestmentsAndMoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrivatelyHeldHealthcareCompaniesMember" xlink:to="inva_PrivatelyHeldHealthcareCompaniesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CreditAndSecurityAgreementMember" xlink:to="inva_CreditAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeTaxesPaidNetTableTextBlock" xlink:to="inva_IncomeTaxesPaidNetTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsPurchasedIn2022Member" xlink:to="inva_WarrantsPurchasedIn2022Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ClassOfTreasuryStockTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfBoardMembersOfInvestee" xlink:to="inva_NumberOfBoardMembersOfInvestee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GainLossOnOtherInvestments" xlink:to="inva_GainLossOnOtherInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnInvestments" xlink:to="us-gaap_UnrealizedGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseBorrowingsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesA1PreferredStockMember" xlink:to="inva_SeriesA1PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EntasisLeaseMember" xlink:to="inva_EntasisLeaseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidPolicyTextBlock" xlink:to="inva_CapitalizedFeesPaidPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OutstandingStockWarrantMember" xlink:to="inva_OutstandingStockWarrantMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmendedZaiAgreementMember" xlink:to="inva_AmendedZaiAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UpfrontFeePayment" xlink:to="inva_UpfrontFeePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_StrategicAllianceAgreementMember" xlink:to="inva_StrategicAllianceAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EntasisTherapeuticsHoldingsIncMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LicenseCollaborationAndOtherArrangementsTextBlock" xlink:to="inva_LicenseCollaborationAndOtherArrangementsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CordenPharmaMember" xlink:to="inva_CordenPharmaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DevelopmentRegulatoryAndRoyaltyMember" xlink:to="inva_DevelopmentRegulatoryAndRoyaltyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedProfessionalServices" xlink:to="inva_AccruedProfessionalServices_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsCollaborationAgreementNet" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeOperating" xlink:to="us-gaap_InterestAndDividendIncomeOperating_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DurlobactamMember" xlink:to="inva_DurlobactamMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsCollaborationAgreementGross" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredRoyaltyObligationCurrent" xlink:to="inva_DeferredRoyaltyObligationCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SyndeioBiosciencesMember" xlink:to="inva_SyndeioBiosciencesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsPurchasedIn2020Member" xlink:to="inva_WarrantsPurchasedIn2020Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" xlink:to="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesDWarrantsMember" xlink:to="inva_SeriesDWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember" xlink:to="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ResearchAndDevelopmentSupportMember" xlink:to="inva_ResearchAndDevelopmentSupportMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:to="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CarryingValueWroteOffWarrantExercise" xlink:to="inva_CarryingValueWroteOffWarrantExercise_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault" xlink:to="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:to="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="us-gaap_ValuationTechniqueDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityIncentivePlansAndESPPMember" xlink:to="inva_EquityIncentivePlansAndESPPMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock" xlink:to="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TermLoanInvestmentMember" xlink:to="inva_TermLoanInvestmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DecreaseToAccumulatedDeficit" xlink:to="inva_DecreaseToAccumulatedDeficit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryCurrentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedLicenseFeesAndRoyalties" xlink:to="inva_AccruedLicenseFeesAndRoyalties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentPrincipalAmount" xlink:to="inva_DebtInstrumentPrincipalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesCWarrantsMember" xlink:to="inva_SeriesCWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GARDPCollaborationAgreementMember" xlink:to="inva_GARDPCollaborationAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:to="inva_SaleOfEquityInvestmentsManagedByIspFundLp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTextBlock" xlink:to="us-gaap_AssetAcquisitionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EmployeeStockPurchasePlanMember" xlink:to="inva_EmployeeStockPurchasePlanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:to="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtMember" xlink:to="us-gaap_DebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrincipalAmountOfConvertibleNotesOwned" xlink:to="inva_PrincipalAmountOfConvertibleNotesOwned_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_Rule10B51ArrModifiedFlag" xlink:to="inva_Rule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:to="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:to="inva_FairValueAdjustmentsOfInventoryFromAcquistion_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TrelegyElliptaMember" xlink:to="inva_TrelegyElliptaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfEconomicInterestInPartnership" xlink:to="inva_PercentageOfEconomicInterestInPartnership_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ZEVTERAMember" xlink:to="inva_ZEVTERAMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntityTextBlock" xlink:to="inva_ConsolidatedEntityTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OptionPricingModelBacksolveValuationMember" xlink:to="inva_OptionPricingModelBacksolveValuationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" xlink:to="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PartnershipAgreementLockUpPeriod" xlink:to="inva_PartnershipAgreementLockUpPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LyndraConvertibleNoteMember" xlink:to="inva_LyndraConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedClinicalAndResearchLiability" xlink:to="inva_AccruedClinicalAndResearchLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GiaprezaMember" xlink:to="inva_GiaprezaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAmortization" xlink:to="us-gaap_CapitalizedContractCostAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="us-gaap_CapitalizedContractCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_Percent2.50ConvertibleDebtMember" xlink:to="inva_Percent2.50ConvertibleDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:to="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsPolicy" xlink:to="us-gaap_EquityMethodInvestmentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BeaconMember" xlink:to="inva_BeaconMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WarrantsPurchasedIn2021Member" xlink:to="inva_WarrantsPurchasedIn2021Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TermOfMilestonePaymentForNetSales" xlink:to="inva_TermOfMilestonePaymentForNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:to="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TechnologyTransferAgreementMember" xlink:to="inva_TechnologyTransferAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IspFundLpMember" xlink:to="inva_IspFundLpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember" xlink:to="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ContingentValueRightsLiability" xlink:to="inva_ContingentValueRightsLiability_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuredConvertibleCreditAgreementMember" xlink:to="inva_SecuredConvertibleCreditAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForTradingSecurities" xlink:to="us-gaap_ProceedsFromPaymentsForTradingSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:to="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InternalExpensesMember" xlink:to="inva_InternalExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ImaginAbNoteMember" xlink:to="inva_ImaginAbNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PaionAgMember" xlink:to="inva_PaionAgMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ZoliflodacinMember" xlink:to="inva_ZoliflodacinMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquityIncentivePlan2012Member" xlink:to="inva_EquityIncentivePlan2012Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:to="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PreferredStockWarrantsMember" xlink:to="inva_PreferredStockWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentRepurchasePercentage" xlink:to="inva_DebtInstrumentRepurchasePercentage_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ClassOfWarrantOrRightExercised" xlink:to="inva_ClassOfWarrantOrRightExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TotalPaymentsMadeForRoyaltyAgreement" xlink:to="inva_TotalPaymentsMadeForRoyaltyAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OneOfImaginabsCommonStockholderMember" xlink:to="inva_OneOfImaginabsCommonStockholderMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CustomerThreeMember" xlink:to="inva_CustomerThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" xlink:to="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NanoliveMember" xlink:to="inva_NanoliveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_IncomeTaxesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DenominatorAbstract" xlink:to="inva_DenominatorAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity" xlink:to="us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ExpectedHoldingPeriod" xlink:to="inva_ExpectedHoldingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleSubordinatedDebtMember" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncreaseInDeferredTaxAssets" xlink:to="inva_IncreaseInDeferredTaxAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:to="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_VotingAgreementMaximumVotingRightsPercent" xlink:to="inva_VotingAgreementMaximumVotingRightsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DeferredRoyaltyObligationNonCurrent" xlink:to="inva_DeferredRoyaltyObligationNonCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:to="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:to="inva_SeriesCWarrantsAndSeriesDWarrantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EquitySecuritiesOwned" xlink:to="inva_EquitySecuritiesOwned_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InvestmentsInCommonStock" xlink:to="inva_InvestmentsInCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTableTextBlock" xlink:to="us-gaap_InvestmentTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmountOfInventoryPurchasesNotBilled" xlink:to="inva_AmountOfInventoryPurchasesNotBilled_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PresentationReclassificationPolicyTextBlock" xlink:to="inva_PresentationReclassificationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LaJollaMember" xlink:to="inva_LaJollaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SecuritiesPurchaseAgreementAmount" xlink:to="inva_SecuritiesPurchaseAgreementAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoThousandTwentyEightNotesMember" xlink:to="inva_TwoThousandTwentyEightNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_DebtInstrumentRemainingBalancePaidUponMaturation" xlink:to="inva_DebtInstrumentRemainingBalancePaidUponMaturation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:to="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PubliclyTradedHealthcareCompaniesMember" xlink:to="inva_PubliclyTradedHealthcareCompaniesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NonRule10B51ArrModifiedFlag" xlink:to="inva_NonRule10B51ArrModifiedFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ManufacturingStageTransferAgreementMember" xlink:to="inva_ManufacturingStageTransferAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets" xlink:to="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InvestmentsInWarrants" xlink:to="inva_InvestmentsInWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FirstAmendmentMember" xlink:to="inva_FirstAmendmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAccountsReceivableMember" xlink:to="us-gaap_TradeAccountsReceivableMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommonStockAcquiredAverageCostPerShare" xlink:to="inva_CommonStockAcquiredAverageCostPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:to="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount" xlink:to="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesC2PreferredStockMember" xlink:to="inva_SeriesC2PreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrincipalAmountOfTermLoansOwned" xlink:to="inva_PrincipalAmountOfTermLoansOwned_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_Outstanding2028NotesMember" xlink:to="inva_Outstanding2028NotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InCardaConvertibleNoteMember" xlink:to="inva_InCardaConvertibleNoteMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FuturePotentialMilestonePayment" xlink:to="inva_FuturePotentialMilestonePayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmortizationOfInventoryFairValueAdjustmentsMember" xlink:to="inva_AmortizationOfInventoryFairValueAdjustmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InterestRateOfDeferredRoyaltyObligation" xlink:to="inva_InterestRateOfDeferredRoyaltyObligation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsMarketedProductsNet" xlink:to="inva_IntangibleAssetsMarketedProductsNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" xlink:to="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LicenseAndOtherRevenueMember" xlink:to="inva_LicenseAndOtherRevenueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_DebtInstrumentFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" xlink:to="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies" xlink:to="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SalesMilestonePaymentsReceivable" xlink:to="inva_SalesMilestonePaymentsReceivable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeniorUnsecuredConvertibleNotesMember" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyFinancingAgreementMember" xlink:to="inva_RoyaltyFinancingAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesCAndC2PreferredStockAndCommonStockMember" xlink:to="inva_SeriesCAndC2PreferredStockAndCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GatesFoundationMember" xlink:to="inva_GatesFoundationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LicenseRevenueRecognized" xlink:to="inva_LicenseRevenueRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PercentageOfRoyaltyPayableOnNetSales" xlink:to="inva_PercentageOfRoyaltyPayableOnNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:to="inva_PrivatePlacementPositionsAndConvertibleNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:to="inva_PortionOfDebtInstrumentFaceAmountExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:to="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LimitedPartnersContributedCapital" xlink:to="us-gaap_LimitedPartnersContributedCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesFvNi" xlink:to="us-gaap_EquitySecuritiesFvNi_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:to="inva_SeriesD1AndD2PreferredStockAndCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MoneyMarketFundAndCash" xlink:to="inva_MoneyMarketFundAndCash_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember" xlink:to="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" xlink:to="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:to="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GateNeuroscienceMember" xlink:to="inva_GateNeuroscienceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax" xlink:to="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:to="inva_CapitalizedFeesPaidWeightedAverageUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BasileaMember" xlink:to="inva_BasileaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_EarningsPerShareDilutedLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_OneDirectorMember" xlink:to="inva_OneDirectorMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LexingtonMassachusettsMember" xlink:to="inva_LexingtonMassachusettsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataTermLoanMember" xlink:to="inva_ArmataTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GSKMember" xlink:to="inva_GSKMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfMajorCustomers" xlink:to="inva_NumberOfMajorCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LaJollaPharmaceuticalCompanyMember" xlink:to="inva_LaJollaPharmaceuticalCompanyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidDisclosureTextBlock" xlink:to="inva_CapitalizedFeesPaidDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ProfitLossShares" xlink:to="inva_ProfitLossShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:to="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember" xlink:to="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_IncomeTaxesPaidNetAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpensePolicyTextBlock" xlink:to="us-gaap_InterestExpensePolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumeratorAbstract" xlink:to="inva_NumeratorAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RegulatoryStartingMaterialMember" xlink:to="inva_RegulatoryStartingMaterialMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NUZOLVENCEMember" xlink:to="inva_NUZOLVENCEMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvancesOnInventoryPurchases" xlink:to="us-gaap_AdvancesOnInventoryPurchases_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_XacduroMember" xlink:to="inva_XacduroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ImaginabMember" xlink:to="inva_ImaginabMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_LongActingBeta2AgonistAnoroMember" xlink:to="inva_LongActingBeta2AgonistAnoroMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="inva_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfCommonStockIssuedDescription" xlink:to="inva_NumberOfCommonStockIssuedDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:to="inva_CapitalizedFeePaidEstimatedUsefulLife_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_UnrealizedOtherGainLossOnInvestments" xlink:to="inva_UnrealizedOtherGainLossOnInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ReimbursementsForResearchAndDevelopmentExpense" xlink:to="inva_ReimbursementsForResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SulbactamDurlobactamMember" xlink:to="inva_SulbactamDurlobactamMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_WithdrawalFromInvestment" xlink:to="inva_WithdrawalFromInvestment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="inva_ConsolidatedEntitiesDisclosureAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_StrategicAllianceMabaProgram" xlink:to="inva_StrategicAllianceMabaProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoThousandTwentyThreeNotesMember" xlink:to="inva_TwoThousandTwentyThreeNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" xlink:to="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:to="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_QualifiedFinancingMember" xlink:to="inva_QualifiedFinancingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_InvestmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels" xlink:to="inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" xlink:to="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_BusinessCombinationDeferredConsideration" xlink:to="inva_BusinessCombinationDeferredConsideration_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ParatekPharmaceuticalsIncMember" xlink:to="inva_ParatekPharmaceuticalsIncMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_CapitalizedContractCostTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:to="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_FactorsAffectingComparabilityPolicyTextBlock" xlink:to="inva_FactorsAffectingComparabilityPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommonAndPreferredStockMember" xlink:to="inva_CommonAndPreferredStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InnovivaCommonStockMember" xlink:to="inva_InnovivaCommonStockMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CommitmentsFor2024ToBeUtilizedIn2025Member" xlink:to="inva_CommitmentsFor2024ToBeUtilizedIn2025Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NumberOfCustomers" xlink:to="inva_NumberOfCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmountOnNetProductSalesRecognized" xlink:to="inva_AmountOnNetProductSalesRecognized_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SarissaCapitalManagementLpMember" xlink:to="inva_SarissaCapitalManagementLpMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SoftwareAndComputerEquipmentMember" xlink:to="inva_SoftwareAndComputerEquipmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CustomerOneMember" xlink:to="inva_CustomerOneMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PurchasesOfEquityAndOtherLongTermInvestments" xlink:to="inva_PurchasesOfEquityAndOtherLongTermInvestments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnamortizedDebtIssuanceExpense" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConvertibleSeniorNotes2025Member" xlink:to="inva_ConvertibleSeniorNotes2025Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidFutureAmortizationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_ScheduleOfGoodwillTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TwoThousandTwentyFiveNotesMember" xlink:to="inva_TwoThousandTwentyFiveNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ExternalServicesMember" xlink:to="inva_ExternalServicesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock" xlink:to="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_SegmentReportingRevenueReconcilingItemLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_IncardaMember" xlink:to="inva_IncardaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" xlink:to="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_GeorgeWashingtonUniversityMember" xlink:to="inva_GeorgeWashingtonUniversityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_PrivatelyNegotiatedCapPriceMember" xlink:to="inva_PrivatelyNegotiatedCapPriceMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:to="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" xlink:to="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_InnovivaMember" xlink:to="inva_InnovivaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_TermOfMilestonePaymentForCommercialSale" xlink:to="inva_TermOfMilestonePaymentForCommercialSale_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorOpinionTextBlock" xlink:to="dei_AuditorOpinionTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent" xlink:to="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:to="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_MaximumAggregateRoyaltyPaymentsDue" xlink:to="inva_MaximumAggregateRoyaltyPaymentsDue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_CostReimbursementMember" xlink:to="inva_CostReimbursementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_ZaiLabMember" xlink:to="inva_ZaiLabMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="inva_HarvardUniversityMember" xlink:to="inva_HarvardUniversityMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorOpinionTextBlock" xlink:label="dei_AuditorOpinionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorOpinionTextBlock" order="87.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityMethodInvestment" xlink:label="inva_EquityMethodInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CurrentPortionOfISPFundInvestments" xlink:label="inva_CurrentPortionOfISPFundInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_InterestPayableCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="inva_EquityMethodInvestment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CapitalizedContractCostNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="inva_CurrentPortionOfISPFundInvestments" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DebtCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockCommonShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseAndOtherRevenueMember" xlink:label="inva_LicenseAndOtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfAcquiredIntangibleAssets" xlink:label="inva_AmortizationOfAcquiredIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LicenseAndOtherRevenueMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_AmortizationOfAcquiredIntangibleAssets" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_GainLossOnOtherInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestAndDividendIncomeOperating" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="inva_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" xlink:label="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax" xlink:label="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ProfitLossShares" xlink:label="inva_ProfitLossShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_21"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares_22"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockCommonShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_StockIssuedDuringPeriodValueExerciseOfWarrants" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ProfitLoss" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_ProfitLossShares" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding_21" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockCommonShares_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSubordinatedNotes2023Member" xlink:label="inva_ConvertibleSubordinatedNotes2023Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSeniorNotes2025Member" xlink:label="inva_ConvertibleSeniorNotes2025Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedInterestIncomeIncludedInLongTermInvestments" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NonCashActivity" xlink:label="inva_NonCashActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForTradingSecurities" xlink:label="us-gaap_ProceedsFromPaymentsForTradingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UnrealizedOtherGainLossOnInvestments" xlink:label="inva_UnrealizedOtherGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AcquiredIn-ProcessResearchAndDevelopmentAssets" xlink:label="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_ConvertibleSubordinatedNotes2023Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_ConvertibleSeniorNotes2025Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="inva_AccruedInterestIncomeIncludedInLongTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="inva_NonCashActivity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForTradingSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_SaleOfEquityInvestmentsManagedByIspFundLp" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_UnrealizedOtherGainLossOnInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_Rule10B51ArrModifiedFlag" xlink:label="inva_Rule10B51ArrModifiedFlag"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NonRule10B51ArrModifiedFlag" xlink:label="inva_NonRule10B51ArrModifiedFlag"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="inva_Rule10B51ArrModifiedFlag" order="14.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="inva_NonRule10B51ArrModifiedFlag" order="15.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShare1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognition1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseCollaborationAndOtherArrangementsTextBlock" xlink:label="inva_LicenseCollaborationAndOtherArrangementsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_LicenseCollaborationAndOtherArrangementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedEntityTextBlock" xlink:label="inva_ConsolidatedEntityTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="inva_ConsolidatedEntityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaid1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidDisclosureTextBlock" xlink:label="inva_CapitalizedFeesPaidDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="inva_CapitalizedFeesPaidDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquity1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebt4" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisition1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTextBlock" xlink:label="us-gaap_AssetAcquisitionTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxes3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReporting1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureSubsequentEvent" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DescriptionOfOperationsPolicyTextBlock" xlink:label="inva_DescriptionOfOperationsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" xlink:label="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PresentationReclassificationPolicyTextBlock" xlink:label="inva_PresentationReclassificationPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FactorsAffectingComparabilityPolicyTextBlock" xlink:label="inva_FactorsAffectingComparabilityPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:label="us-gaap_ConsolidationVariableInterestEntityPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy" xlink:label="us-gaap_EquityMethodInvestmentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidPolicyTextBlock" xlink:label="inva_CapitalizedFeesPaidPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AssetAcquisitionsPolicyTextBlock" xlink:label="inva_AssetAcquisitionsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RelatedPartyTransactionsPolicyTextBlock" xlink:label="inva_RelatedPartyTransactionsPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_DescriptionOfOperationsPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_PresentationReclassificationPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_FactorsAffectingComparabilityPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_UseOfEstimates" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ConsolidationVariableInterestEntityPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_EquityMethodInvestmentsPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_CapitalizedFeesPaidPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_AssetAcquisitionsPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_InterestExpensePolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_RelatedPartyTransactionsPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock" xlink:label="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="us-gaap_InvestmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" xlink:to="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_IspFundLpMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_InvestmentTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock" xlink:label="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock" xlink:label="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostTableTextBlock" xlink:label="us-gaap_CapitalizedContractCostTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="us-gaap_CapitalizedContractCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_Percent2.50ConvertibleDebtMember" xlink:label="inva_Percent2.50ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_Percent2.50ConvertibleDebtMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" xlink:label="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxesPaidNetTableTextBlock" xlink:label="inva_IncomeTaxesPaidNetTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="inva_IncomeTaxesPaidNetTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SummaryOfSignificantAccountingPoliciesTable" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CustomerOneMember" xlink:label="inva_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CustomerTwoMember" xlink:label="inva_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CustomerThreeMember" xlink:label="inva_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCustomers" xlink:label="inva_NumberOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfMajorCustomers" xlink:label="inva_NumberOfMajorCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DecreaseToAccumulatedDeficit" xlink:label="inva_DecreaseToAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ReductionToAdditionalPaidInCapital" xlink:label="inva_ReductionToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncreaseToConvertibleNotes" xlink:label="inva_IncreaseToConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncreaseInDeferredTaxAssets" xlink:label="inva_IncreaseInDeferredTaxAssets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="inva_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_LaJollaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_SarissaCapitalManagementLpMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_NumberOfCustomers" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_NumberOfMajorCustomers" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CapitalizedFeePaidEstimatedUsefulLife" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="inva_SummaryOfSignificantAccountingPoliciesLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_DecreaseToAccumulatedDeficit" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_ReductionToAdditionalPaidInCapital" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseToConvertibleNotes" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseInDeferredTaxAssets" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SoftwareAndComputerEquipmentMember" xlink:label="inva_SoftwareAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_LaboratoryEquipmentFurnitureAndFixturesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_SoftwareAndComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_SarissaCapitalManagementLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NetIncomeLossPerShareAbstract" xlink:label="inva_NetIncomeLossPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DenominatorAbstract" xlink:label="inva_DenominatorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumeratorAbstract" xlink:label="inva_NumeratorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NumeratorAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_EarningsPerShareDilutedLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_DenominatorAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NetIncomeLossPerShareAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityIncentivePlansAndESPPMember" xlink:label="inva_EquityIncentivePlansAndESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OutstandingStockWarrantMember" xlink:label="inva_OutstandingStockWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_Outstanding2028NotesMember" xlink:label="inva_Outstanding2028NotesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_EquityIncentivePlansAndESPPMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_OutstandingStockWarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_Outstanding2028NotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StrategicAllianceMabaProgram" xlink:label="inva_StrategicAllianceMabaProgram"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_TrelegyElliptaMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_StrategicAllianceMabaProgram" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XacduroMember" xlink:label="inva_XacduroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZEVTERAMember" xlink:label="inva_ZEVTERAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_GiaprezaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_XeravaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_XacduroMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ZEVTERAMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SulbactamDurlobactamMember" xlink:label="inva_SulbactamDurlobactamMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommercialSupplyAgreementMember" xlink:label="inva_CommercialSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XacduroMember" xlink:label="inva_XacduroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmendedZaiAgreementMember" xlink:label="inva_AmendedZaiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PaionAgMember" xlink:label="inva_PaionAgMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ResearchAndDevelopmentSupportMember" xlink:label="inva_ResearchAndDevelopmentSupportMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InterimSupplyAgreementMember" xlink:label="inva_InterimSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RegulatoryMilestonePaymentsReceivable" xlink:label="inva_RegulatoryMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EverestMedicinesLimitedMember" xlink:label="inva_EverestMedicinesLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TechnologyTransferAgreementMember" xlink:label="inva_TechnologyTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SalesMilestonePaymentsReceivable" xlink:label="inva_SalesMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GARDPCollaborationAgreementMember" xlink:label="inva_GARDPCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ManufacturingStageTransferAgreementMember" xlink:label="inva_ManufacturingStageTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BasileaMember" xlink:label="inva_BasileaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CostReimbursementMember" xlink:label="inva_CostReimbursementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RegulatoryStartingMaterialMember" xlink:label="inva_RegulatoryStartingMaterialMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GrantFundingMaximumAmount" xlink:label="inva_GrantFundingMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GeorgeWashingtonUniversityMember" xlink:label="inva_GeorgeWashingtonUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DurlobactamMember" xlink:label="inva_DurlobactamMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseRevenueRecognized" xlink:label="inva_LicenseRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_HarvardUniversityMember" xlink:label="inva_HarvardUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZoliflodacinMember" xlink:label="inva_ZoliflodacinMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ParatekPharmaceuticalsIncMember" xlink:label="inva_ParatekPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseAndOtherRevenueMember" xlink:label="inva_LicenseAndOtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ReimbursementsForResearchAndDevelopmentExpense" xlink:label="inva_ReimbursementsForResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MassachusettsInstituteOfTechnologyMember" xlink:label="inva_MassachusettsInstituteOfTechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseAndOtherRevenue" xlink:label="inva_LicenseAndOtherRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AstrazenecaMember" xlink:label="inva_AstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DevelopmentRegulatoryAndSalesMilestoneMember" xlink:label="inva_DevelopmentRegulatoryAndSalesMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GatesFoundationMember" xlink:label="inva_GatesFoundationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BusinessCombinationDeferredConsideration" xlink:label="inva_BusinessCombinationDeferredConsideration"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmountOnNetProductSalesRecognized" xlink:label="inva_AmountOnNetProductSalesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontPaymentUnderIntangibleAsset" xlink:label="inva_UpfrontPaymentUnderIntangibleAsset"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontFeePayment" xlink:label="inva_UpfrontFeePayment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontFeeReceived" xlink:label="inva_UpfrontFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfRoyaltyPayableOnNetSales" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfMinimumRoyaltyRate" xlink:label="inva_PercentageOfMinimumRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ClaimExpirationDate" xlink:label="inva_ClaimExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TermOfMilestonePaymentForNetSales" xlink:label="inva_TermOfMilestonePaymentForNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TermOfMilestonePaymentForCommercialSale" xlink:label="inva_TermOfMilestonePaymentForCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_SulbactamDurlobactamMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_CommercialSupplyAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ZaiLabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_XacduroMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_AmendedZaiAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_FuturePotentialMilestonePayment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_PaionAgMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ResearchAndDevelopmentSupportMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_InterimSupplyAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RegulatoryMilestonePaymentsReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_EverestMedicinesLimitedMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_TechnologyTransferAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SalesMilestonePaymentsReceivable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_GARDPCollaborationAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_GiaprezaMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_ManufacturingStageTransferAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_BasileaMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CostReimbursementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_RegulatoryStartingMaterialMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_GrantFundingMaximumAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_GeorgeWashingtonUniversityMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_DurlobactamMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_LicenseRevenueRecognized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HarvardUniversityMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ZoliflodacinMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ParatekPharmaceuticalsIncMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LicenseAndOtherRevenueMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ReimbursementsForResearchAndDevelopmentExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_MassachusettsInstituteOfTechnologyMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_XeravaMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_LicenseAndOtherRevenue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_AstrazenecaMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_DevelopmentRegulatoryAndSalesMilestoneMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_GatesFoundationMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_BusinessCombinationDeferredConsideration" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_AmountOnNetProductSalesRecognized" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfRevenue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_UpfrontPaymentUnderIntangibleAsset" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_UpfrontFeePayment" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_UpfrontFeeReceived" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyPayableOnNetSales" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMinimumRoyaltyRate" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClaimExpirationDate" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_TermOfMilestonePaymentForNetSales" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_TermOfMilestonePaymentForCommercialSale" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralPartnerMember" xlink:label="us-gaap_GeneralPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedEntitiesDisclosureAbstract" xlink:label="inva_ConsolidatedEntitiesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfEconomicInterestInPartnership" xlink:label="inva_PercentageOfEconomicInterestInPartnership"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CashDistributions" xlink:label="inva_CashDistributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NetInvestmentRelatedIncomeExpensesEarnedInccured" xlink:label="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_IspFundLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_GeneralPartnerMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_ConsolidatedEntitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PercentageOfEconomicInterestInPartnership" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_VariableInterestEntityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_CashDistributions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_GainLossOnInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Assets" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PubliclyTradedHealthcareCompaniesMember" xlink:label="inva_PubliclyTradedHealthcareCompaniesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InvestmentsInPreferredStock" xlink:label="inva_InvestmentsInPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsAbstract" xlink:label="us-gaap_InvestmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InvestmentsInCommonStock" xlink:label="inva_InvestmentsInCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyHeldHealthcareCompaniesMember" xlink:label="inva_PrivatelyHeldHealthcareCompaniesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InvestmentsInWarrants" xlink:label="inva_InvestmentsInWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MoneyMarketFundAndCash" xlink:label="inva_MoneyMarketFundAndCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_PubliclyTradedHealthcareCompaniesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="inva_InvestmentsInPreferredStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_IspFundLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAbstract" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="inva_InvestmentsInCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_PrivatelyHeldHealthcareCompaniesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_InvestmentsInWarrants" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_MoneyMarketFundAndCash" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_StatementLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Investments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CreditAndSecurityAgreementMember" xlink:label="inva_CreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrincipalAmountOfTermLoansOwned" xlink:label="inva_PrincipalAmountOfTermLoansOwned"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OneDirectorMember" xlink:label="inva_OneDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember" xlink:label="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WarrantsPurchasedIn2020Member" xlink:label="inva_WarrantsPurchasedIn2020Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfWarrantsOwned" xlink:label="inva_NumberOfWarrantsOwned"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoDirectorsMember" xlink:label="inva_TwoDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember" xlink:label="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WarrantsPurchasedIn2021Member" xlink:label="inva_WarrantsPurchasedIn2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember" xlink:label="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WarrantsPurchasedIn2022Member" xlink:label="inva_WarrantsPurchasedIn2022Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfBoardOfDirectors" xlink:label="inva_NumberOfBoardOfDirectors"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember" xlink:label="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquitySecuritiesOwned" xlink:label="inva_EquitySecuritiesOwned"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataConvertibleNoteMember" xlink:label="inva_ArmataConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataTermLoanMember" xlink:label="inva_ArmataTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" xlink:label="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrincipalAmountOfConvertibleNotesOwned" xlink:label="inva_PrincipalAmountOfConvertibleNotesOwned"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" xlink:label="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" xlink:label="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" xlink:label="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_VotingAgreementMaximumVotingRightsPercent" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SecuredConvertibleCreditAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_CreditAndSecurityAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonStockAndWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_PrincipalAmountOfTermLoansOwned" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_OneDirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2020Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfWarrantsOwned" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_TwoDirectorsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2021Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2022Member" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardOfDirectors" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_TitleOfIndividualAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_EquitySecuritiesOwned" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataConvertibleNoteMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataTermLoanMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_PrincipalAmountOfConvertibleNotesOwned" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_VotingAgreementMaximumVotingRightsPercent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncomeStatementRelatedDisclosuresAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_ProfitLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_QualifiedFinancingMember" xlink:label="inva_QualifiedFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OptionPricingModelBacksolveValuationMember" xlink:label="inva_OptionPricingModelBacksolveValuationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaTRCHoldingsLLCMember" xlink:label="inva_InnovivaTRCHoldingsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonAndPreferredStockMember" xlink:label="inva_CommonAndPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NameOfEventAxis" xlink:label="inva_NameOfEventAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleNoteAndWarrantsMember" xlink:label="inva_ConvertibleNoteAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" xlink:label="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesA1PreferredStockMember" xlink:label="inva_SeriesA1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD1PreferredStockMember" xlink:label="inva_SeriesD1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD2PreferredStockMember" xlink:label="inva_SeriesD2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD1WarrantMember" xlink:label="inva_SeriesD1WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ExpectedHoldingPeriod" xlink:label="inva_ExpectedHoldingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD2WarrantMember" xlink:label="inva_SeriesD2WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RiskFreeInterestRate" xlink:label="inva_RiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DividendYield" xlink:label="inva_DividendYield"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfEstimatedVolatility" xlink:label="inva_PercentageOfEstimatedVolatility"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesCWarrantsMember" xlink:label="inva_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesDWarrantsMember" xlink:label="inva_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CarryingValueWroteOffWarrantExercise" xlink:label="inva_CarryingValueWroteOffWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NameOfEventDomain" xlink:to="inva_QualifiedFinancingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="inva_OptionPricingModelBacksolveValuationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaTRCHoldingsLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonAndPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_IncardaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ValuationTechniqueAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ConvertibleNoteAndWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaConvertibleNoteMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesA1PreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1PreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="inva_NameOfEventAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2PreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1WarrantMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_ExpectedHoldingPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2WarrantMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_RiskFreeInterestRate" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DividendYield" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCWarrantsAndSeriesDWarrantsMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_PercentageOfEstimatedVolatility" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCWarrantsMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesDWarrantsMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_CarryingValueWroteOffWarrantExercise" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FirstAmendmentMember" xlink:label="inva_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaTRCHoldingsLLCMember" xlink:label="inva_InnovivaTRCHoldingsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ImaginabMember" xlink:label="inva_ImaginabMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OneOfImaginabsCommonStockholderMember" xlink:label="inva_OneOfImaginabsCommonStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonAndPreferredStockMember" xlink:label="inva_CommonAndPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedInterestAndCommitmentFees" xlink:label="inva_AccruedInterestAndCommitmentFees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesC2PreferredStockMember" xlink:label="inva_SeriesC2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesCAndC2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesCAndC2PreferredStockAndCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ImaginabConvertibleNoteMember" xlink:label="inva_ImaginabConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfBoardOfDirectors" xlink:label="inva_NumberOfBoardOfDirectors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_FirstAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaTRCHoldingsLLCMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_ImaginabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_OneOfImaginabsCommonStockholderMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonAndPreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_AccruedInterestAndCommitmentFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesC2PreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCAndC2PreferredStockAndCommonStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ImaginabConvertibleNoteMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardOfDirectors" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember" xlink:label="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioBiosciencesMember" xlink:label="inva_SyndeioBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember" xlink:label="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCommonStockIssuedDescription" xlink:label="inva_NumberOfCommonStockIssuedDescription"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_GateNeuroscienceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_SyndeioBiosciencesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCommonStockIssuedDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NanoliveMember" xlink:label="inva_NanoliveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_NanoliveMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LyndraConvertibleNoteMember" xlink:label="inva_LyndraConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LyndraMember" xlink:label="inva_LyndraMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault" xlink:label="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_LyndraConvertibleNoteMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_LyndraMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BeaconMember" xlink:label="inva_BeaconMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_BeaconMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" xlink:label="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity" xlink:label="us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForTradingSecurities" xlink:label="us-gaap_ProceedsFromPaymentsForTradingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PurchasesOfEquityAndOtherLongTermInvestments" xlink:label="inva_PurchasesOfEquityAndOtherLongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund" xlink:label="inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ReclassificationOfCurrentPortion" xlink:label="inva_ReclassificationOfCurrentPortion"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForTradingSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="inva_GainLossOnOtherInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="inva_PurchasesOfEquityAndOtherLongTermInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="inva_ReclassificationOfCurrentPortion" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_OtherIncome" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_LongTermInvestments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataTermLoanMember" xlink:label="inva_ArmataTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TermLoanInvestmentMember" xlink:label="inva_TermLoanInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ImaginAbNoteMember" xlink:label="inva_ImaginAbNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" xlink:label="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PreferredStockWarrantsMember" xlink:label="inva_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" xlink:label="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember" xlink:label="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" xlink:label="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" xlink:label="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LyndraConvertibleNoteMember" xlink:label="inva_LyndraConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WithdrawalFromInvestment" xlink:label="inva_WithdrawalFromInvestment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" xlink:label="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ArmataPharmaceuticalsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_EquityInvestmentsAndMoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_IspFundLpMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_IncardaMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataTermLoanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_TermLoanInvestmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ImaginAbNoteMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ContingentValueRightsLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_PrivatePlacementPositionsAndConvertibleNotesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_PreferredStockWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_PartnershipAgreementLockUpPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_LyndraConvertibleNoteMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_WithdrawalFromInvestment" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels" xlink:label="inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAbstract" xlink:label="us-gaap_CapitalizedContractCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostTable" xlink:label="us-gaap_CapitalizedContractCostTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostLineItems" xlink:label="us-gaap_CapitalizedContractCostLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostAbstract" xlink:to="us-gaap_CapitalizedContractCostTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_CapitalizedContractCostLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidFutureAmortizationAbstract" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XacduroMember" xlink:label="inva_XacduroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BasileaMember" xlink:label="inva_BasileaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NUZOLVENCEMember" xlink:label="inva_NUZOLVENCEMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontFee" xlink:label="inva_UpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:label="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_XacduroMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfGoodwillTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_BasileaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_NUZOLVENCEMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="inva_UpfrontFee" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_CounterpartyNameAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_GoodwillLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MarketedProductsMember" xlink:label="inva_MarketedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="inva_MarketedProductsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CollaborativeArrangementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BusinessCombinationDeferredConsideration" xlink:label="inva_BusinessCombinationDeferredConsideration"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmountOfInventoryPurchasesNotBilled" xlink:label="inva_AmountOfInventoryPurchasesNotBilled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_InventoryCurrentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ZaiLabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_FairValueAdjustmentsOfInventoryFromAcquistion" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_InventoryLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_BusinessCombinationDeferredConsideration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_AmountOfInventoryPurchasesNotBilled" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedContractManufacturingLiability" xlink:label="inva_AccruedContractManufacturingLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedClinicalAndResearchLiability" xlink:label="inva_AccruedClinicalAndResearchLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedProfessionalServices" xlink:label="inva_AccruedProfessionalServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredRoyaltyObligationCurrent" xlink:label="inva_DeferredRoyaltyObligationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedLicenseFeesAndRoyalties" xlink:label="inva_AccruedLicenseFeesAndRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedContractManufacturingLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedClinicalAndResearchLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedProfessionalServices" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_DeferredRoyaltyObligationCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_AccruedLicenseFeesAndRoyalties" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredRoyaltyObligationNonCurrent" xlink:label="inva_DeferredRoyaltyObligationNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="inva_DeferredRoyaltyObligationNonCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityIncentivePlan2012Member" xlink:label="inva_EquityIncentivePlan2012Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EquityIncentivePlan2012Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="4.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="5.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaMember" xlink:label="inva_InnovivaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="8.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ClassOfWarrantOrRightExercised" xlink:label="inva_ClassOfWarrantOrRightExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonStockAcquiredAverageCostPerShare" xlink:label="inva_CommonStockAcquiredAverageCostPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfTreasuryStockTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_ClassOfWarrantOrRightExercised" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ShareRepurchaseProgramDomain" xlink:to="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="srt_ShareRepurchaseProgramAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_CommonStockAcquiredAverageCostPerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_HealthCareRoyaltyPartnersMember" xlink:label="inva_HealthCareRoyaltyPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OtherAccruedLiabilitiesMember" xlink:label="inva_OtherAccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyFinancingAgreementMember" xlink:label="inva_RoyaltyFinancingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MaximumAggregateRoyaltyPaymentsDue" xlink:label="inva_MaximumAggregateRoyaltyPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredRoyaltyObligations" xlink:label="inva_DeferredRoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyPayments" xlink:label="inva_RoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InterestRateOfDeferredRoyaltyObligation" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TotalPaymentsMadeForRoyaltyAgreement" xlink:label="inva_TotalPaymentsMadeForRoyaltyAgreement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HealthCareRoyaltyPartnersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="inva_OtherAccruedLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_RoyaltyFinancingAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_MaximumAggregateRoyaltyPaymentsDue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DeferredRoyaltyObligations" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyPayments" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_InterestRateOfDeferredRoyaltyObligation" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_TotalPaymentsMadeForRoyaltyAgreement" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaCommonStockMember" xlink:label="inva_InnovivaCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRemainingBalancePaidUponMaturation" xlink:label="inva_DebtInstrumentRemainingBalancePaidUponMaturation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyNegotiatedCapPriceMember" xlink:label="inva_PrivatelyNegotiatedCapPriceMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfDerivativeInstrumentsPurchased" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRepurchasePercentage" xlink:label="inva_DebtInstrumentRepurchasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_CallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inva_InnovivaCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRemainingBalancePaidUponMaturation" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_PutOptionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCapPriceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfDerivativeInstrumentsPurchased" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="7.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRepurchasePercentage" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtAbstract" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseBorrowingsAbstract" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock" xlink:label="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes" xlink:label="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentConvertibleConversionPremium" xlink:label="inva_DebtInstrumentConvertibleConversionPremium"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRemainingBalancePaidUponMaturation" xlink:label="inva_DebtInstrumentRemainingBalancePaidUponMaturation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebt" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentConvertibleConversionPremium" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRemainingBalancePaidUponMaturation" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PortionOfDebtInstrumentFaceAmountExercised" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowingsAbstract" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtByMaturityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BurlingameCaliforniaMember" xlink:label="inva_BurlingameCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisLeaseMember" xlink:label="inva_EntasisLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CordenPharmaMember" xlink:label="inva_CordenPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WalthamMassachusettsMember" xlink:label="inva_WalthamMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommitmentsFor2024ToBeUtilizedIn2025Member" xlink:label="inva_CommitmentsFor2024ToBeUtilizedIn2025Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LexingtonMassachusettsMember" xlink:label="inva_LexingtonMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies" xlink:label="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_BurlingameCaliforniaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="inva_EntasisLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_CordenPharmaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_WalthamMassachusettsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="inva_CommitmentsFor2024ToBeUtilizedIn2025Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_LexingtonMassachusettsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RightOfUseAssetsObtainedThroughAcquistions" xlink:label="inva_RightOfUseAssetsObtainedThroughAcquistions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="inva_RightOfUseAssetsObtainedThroughAcquistions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DevelopmentRegulatoryAndRoyaltyMember" xlink:label="inva_DevelopmentRegulatoryAndRoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LyndraMember" xlink:label="inva_LyndraMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAbstract" xlink:label="us-gaap_AssetAcquisitionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontCashPayments" xlink:label="inva_UpfrontCashPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNetNoncurrent" xlink:label="us-gaap_CapitalizedContractCostNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_DevelopmentRegulatoryAndRoyaltyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="inva_LyndraMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAbstract" xlink:to="us-gaap_AssetAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="2.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="inva_UpfrontCashPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_CapitalizedContractCostNetNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="inva_FuturePotentialMilestonePayment" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="6.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_Depreciation" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" xlink:label="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNetAbstract" xlink:label="us-gaap_IncomeTaxesPaidNetAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxesPaidNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxesPaidNetAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization1" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxesTable" xlink:label="inva_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxesLineItems" xlink:label="inva_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="inva_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesTable" xlink:to="inva_IncomeTaxesLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfInventoryFairValueAdjustmentsMember" xlink:label="inva_AmortizationOfInventoryFairValueAdjustmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ExternalServicesMember" xlink:label="inva_ExternalServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InternalExpensesMember" xlink:label="inva_InternalExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="inva_AmortizationOfInventoryFairValueAdjustmentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ExternalServicesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="srt_StatementGeographicalAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_InternalExpensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_CostOfRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="inva_GainLossOnOtherInvestments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_InterestAndDividendIncomeOperating" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_InterestExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_ProfitLoss" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_NumberOfReportableSegments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseAndOtherRevenueMember" xlink:label="inva_LicenseAndOtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfAcquiredIntangibleAssets" xlink:label="inva_AmortizationOfAcquiredIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LicenseAndOtherRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_AmortizationOfAcquiredIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GrossProfit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_GainLossOnOtherInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestAndDividendIncomeOperating" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares" xlink:label="us-gaap_TreasuryStockCommonShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember" xlink:label="us-gaap_TreasuryStockCommonMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:label="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StockIssuedDuringPeriodValueExerciseOfWarrants" xlink:label="inva_StockIssuedDuringPeriodValueExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" xlink:label="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax" xlink:label="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" xlink:label="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" xlink:label="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ProfitLossShares" xlink:label="inva_ProfitLossShares"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockCommonShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_StockIssuedDuringPeriodValueExerciseOfWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="inva_ProfitLossShares" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSubordinatedNotes2023Member" xlink:label="inva_ConvertibleSubordinatedNotes2023Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSeniorNotes2025Member" xlink:label="inva_ConvertibleSeniorNotes2025Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedInterestIncomeIncludedInLongTermInvestments" xlink:label="inva_AccruedInterestIncomeIncludedInLongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NonCashActivity" xlink:label="inva_NonCashActivity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForTradingSecurities" xlink:label="us-gaap_ProceedsFromPaymentsForTradingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UnrealizedOtherGainLossOnInvestments" xlink:label="inva_UnrealizedOtherGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AcquiredIn-ProcessResearchAndDevelopmentAssets" xlink:label="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_ConvertibleSubordinatedNotes2023Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_StockIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_ConvertibleSeniorNotes2025Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="inva_AccruedInterestIncomeIncludedInLongTermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="inva_NonCashActivity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForTradingSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_SaleOfEquityInvestmentsManagedByIspFundLp" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_UnrealizedOtherGainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables">
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:label="inva_ConsolidatedEntitiesAndAcquisitionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:label="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TheravanceRespiratoryCompanyLlcMember" xlink:label="inva_TheravanceRespiratoryCompanyLlcMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock" xlink:label="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTableTextBlock" xlink:label="us-gaap_InvestmentTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_TheravanceRespiratoryCompanyLlcMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_IspFundLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_InvestmentTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock" xlink:label="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock" xlink:label="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_Percent2.50ConvertibleDebtMember" xlink:label="inva_Percent2.50ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_Percent2.50ConvertibleDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails">
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="inva_SummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SummaryOfSignificantAccountingPoliciesTable" xlink:label="inva_SummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CustomerOneMember" xlink:label="inva_CustomerOneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaMember" xlink:label="inva_LaJollaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CustomerTwoMember" xlink:label="inva_CustomerTwoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAccountsReceivableMember" xlink:label="us-gaap_TradeAccountsReceivableMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CustomerThreeMember" xlink:label="inva_CustomerThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCustomers" xlink:label="inva_NumberOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfMajorCustomers" xlink:label="inva_NumberOfMajorCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeePaidEstimatedUsefulLife" xlink:label="inva_CapitalizedFeePaidEstimatedUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DecreaseToAccumulatedDeficit" xlink:label="inva_DecreaseToAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ReductionToAdditionalPaidInCapital" xlink:label="inva_ReductionToAdditionalPaidInCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncreaseToConvertibleNotes" xlink:label="inva_IncreaseToConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncreaseInDeferredTaxAssets" xlink:label="inva_IncreaseInDeferredTaxAssets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerOneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_LaJollaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerTwoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_TradeAccountsReceivableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_SarissaCapitalManagementLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="inva_CustomerThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_NumberOfCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_NumberOfMajorCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_CapitalizedFeePaidEstimatedUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_DecreaseToAccumulatedDeficit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_ReductionToAdditionalPaidInCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseToConvertibleNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="inva_IncreaseInDeferredTaxAssets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaboratoryEquipmentFurnitureAndFixturesMember" xlink:label="inva_LaboratoryEquipmentFurnitureAndFixturesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SoftwareAndComputerEquipmentMember" xlink:label="inva_SoftwareAndComputerEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_LaboratoryEquipmentFurnitureAndFixturesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="inva_SoftwareAndComputerEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SarissaCapitalManagementLpMember" xlink:label="inva_SarissaCapitalManagementLpMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" xlink:label="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_SarissaCapitalManagementLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDilutedLineItems" xlink:label="us-gaap_EarningsPerShareDilutedLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NetIncomeLossPerShareAbstract" xlink:label="inva_NetIncomeLossPerShareAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DenominatorAbstract" xlink:label="inva_DenominatorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumeratorAbstract" xlink:label="inva_NumeratorAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NumeratorAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NetIncomeLossPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_DenominatorAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedLineItems" xlink:to="inva_NetIncomeLossPerShareAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NumeratorAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_DenominatorAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityIncentivePlansAndESPPMember" xlink:label="inva_EquityIncentivePlansAndESPPMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OutstandingStockWarrantMember" xlink:label="inva_OutstandingStockWarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_Outstanding2028NotesMember" xlink:label="inva_Outstanding2028NotesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_EquityIncentivePlansAndESPPMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_OutstandingStockWarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="inva_Outstanding2028NotesMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TrelegyElliptaMember" xlink:label="inva_TrelegyElliptaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StrategicAllianceMabaProgram" xlink:label="inva_StrategicAllianceMabaProgram"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_TrelegyElliptaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_StrategicAllianceMabaProgram" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XacduroMember" xlink:label="inva_XacduroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZEVTERAMember" xlink:label="inva_ZEVTERAMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_GiaprezaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_XeravaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_XacduroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ZEVTERAMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistRelvarBreoMember" xlink:label="inva_LongActingBeta2AgonistRelvarBreoMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_StrategicAllianceAgreementMember" xlink:label="inva_StrategicAllianceAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" xlink:label="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LongActingBeta2AgonistAnoroMember" xlink:label="inva_LongActingBeta2AgonistAnoroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LabaCollaborationMember" xlink:label="inva_LabaCollaborationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" xlink:label="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" xlink:label="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" xlink:label="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" xlink:label="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistRelvarBreoMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_StrategicAllianceAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LongActingBeta2AgonistAnoroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_LabaCollaborationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SulbactamDurlobactamMember" xlink:label="inva_SulbactamDurlobactamMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommercialSupplyAgreementMember" xlink:label="inva_CommercialSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XacduroMember" xlink:label="inva_XacduroMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmendedZaiAgreementMember" xlink:label="inva_AmendedZaiAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PaionAgMember" xlink:label="inva_PaionAgMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ResearchAndDevelopmentSupportMember" xlink:label="inva_ResearchAndDevelopmentSupportMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InterimSupplyAgreementMember" xlink:label="inva_InterimSupplyAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RegulatoryMilestonePaymentsReceivable" xlink:label="inva_RegulatoryMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EverestMedicinesLimitedMember" xlink:label="inva_EverestMedicinesLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TechnologyTransferAgreementMember" xlink:label="inva_TechnologyTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SalesMilestonePaymentsReceivable" xlink:label="inva_SalesMilestonePaymentsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GARDPCollaborationAgreementMember" xlink:label="inva_GARDPCollaborationAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GiaprezaMember" xlink:label="inva_GiaprezaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ManufacturingStageTransferAgreementMember" xlink:label="inva_ManufacturingStageTransferAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BasileaMember" xlink:label="inva_BasileaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CostReimbursementMember" xlink:label="inva_CostReimbursementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RegulatoryStartingMaterialMember" xlink:label="inva_RegulatoryStartingMaterialMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GrantFundingMaximumAmount" xlink:label="inva_GrantFundingMaximumAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GeorgeWashingtonUniversityMember" xlink:label="inva_GeorgeWashingtonUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DurlobactamMember" xlink:label="inva_DurlobactamMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseRevenueRecognized" xlink:label="inva_LicenseRevenueRecognized"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_HarvardUniversityMember" xlink:label="inva_HarvardUniversityMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZoliflodacinMember" xlink:label="inva_ZoliflodacinMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ParatekPharmaceuticalsIncMember" xlink:label="inva_ParatekPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseAndOtherRevenueMember" xlink:label="inva_LicenseAndOtherRevenueMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ReimbursementsForResearchAndDevelopmentExpense" xlink:label="inva_ReimbursementsForResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MassachusettsInstituteOfTechnologyMember" xlink:label="inva_MassachusettsInstituteOfTechnologyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XeravaMember" xlink:label="inva_XeravaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LicenseAndOtherRevenue" xlink:label="inva_LicenseAndOtherRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AstrazenecaMember" xlink:label="inva_AstrazenecaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DevelopmentRegulatoryAndSalesMilestoneMember" xlink:label="inva_DevelopmentRegulatoryAndSalesMilestoneMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GatesFoundationMember" xlink:label="inva_GatesFoundationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BusinessCombinationDeferredConsideration" xlink:label="inva_BusinessCombinationDeferredConsideration"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmountOnNetProductSalesRecognized" xlink:label="inva_AmountOnNetProductSalesRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" xlink:label="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" xlink:label="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontPaymentUnderIntangibleAsset" xlink:label="inva_UpfrontPaymentUnderIntangibleAsset"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontFeePayment" xlink:label="inva_UpfrontFeePayment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontFeeReceived" xlink:label="inva_UpfrontFeeReceived"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfRoyaltyPayableOnNetSales" xlink:label="inva_PercentageOfRoyaltyPayableOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" xlink:label="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" xlink:label="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfMinimumRoyaltyRate" xlink:label="inva_PercentageOfMinimumRoyaltyRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" xlink:label="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ClaimExpirationDate" xlink:label="inva_ClaimExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TermOfMilestonePaymentForNetSales" xlink:label="inva_TermOfMilestonePaymentForNetSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" xlink:label="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TermOfMilestonePaymentForCommercialSale" xlink:label="inva_TermOfMilestonePaymentForCommercialSale"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_SulbactamDurlobactamMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_CommercialSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ZaiLabMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_XacduroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_AmendedZaiAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_FuturePotentialMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_PaionAgMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ResearchAndDevelopmentSupportMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_InterimSupplyAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RegulatoryMilestonePaymentsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_EverestMedicinesLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_TechnologyTransferAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SalesMilestonePaymentsReceivable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_GARDPCollaborationAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_GiaprezaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_ManufacturingStageTransferAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_BasileaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_CostReimbursementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="inva_RegulatoryStartingMaterialMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_GrantFundingMaximumAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_GeorgeWashingtonUniversityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_DurlobactamMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_LicenseRevenueRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HarvardUniversityMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ZoliflodacinMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ParatekPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_LicenseAndOtherRevenueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ReimbursementsForResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_MassachusettsInstituteOfTechnologyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_XeravaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_LicenseAndOtherRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_AstrazenecaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_DevelopmentRegulatoryAndSalesMilestoneMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_GatesFoundationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_BusinessCombinationDeferredConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_AmountOnNetProductSalesRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_UpfrontPaymentUnderIntangibleAsset" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_UpfrontFeePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_UpfrontFeeReceived" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyPayableOnNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMinimumRoyaltyRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_ClaimExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_TermOfMilestonePaymentForNetSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="inva_TermOfMilestonePaymentForCommercialSale" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityLineItems" xlink:label="us-gaap_VariableInterestEntityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralPartnerMember" xlink:label="us-gaap_GeneralPartnerMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfEconomicInterestInPartnership" xlink:label="inva_PercentageOfEconomicInterestInPartnership"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CashDistributions" xlink:label="inva_CashDistributions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NetInvestmentRelatedIncomeExpensesEarnedInccured" xlink:label="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="us-gaap_UnrealizedGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestments" xlink:label="us-gaap_GainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="inva_IspFundLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_GeneralPartnerMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_PercentageOfEconomicInterestInPartnership" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_CashDistributions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_UnrealizedGainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_GainLossOnInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityLineItems" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:label="us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PubliclyTradedHealthcareCompaniesMember" xlink:label="inva_PubliclyTradedHealthcareCompaniesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InvestmentsInPreferredStock" xlink:label="inva_InvestmentsInPreferredStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InvestmentsInCommonStock" xlink:label="inva_InvestmentsInCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_GB" xlink:label="country_GB"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyHeldHealthcareCompaniesMember" xlink:label="inva_PrivatelyHeldHealthcareCompaniesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InvestmentsInWarrants" xlink:label="inva_InvestmentsInWarrants"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MoneyMarketFundAndCash" xlink:label="inva_MoneyMarketFundAndCash"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfVariableInterestEntitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_PubliclyTradedHealthcareCompaniesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="inva_InvestmentsInPreferredStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_IspFundLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="inva_InvestmentsInCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_GB" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_PrivatelyHeldHealthcareCompaniesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_InvestmentsInWarrants" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_MoneyMarketFundAndCash" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Investments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuredConvertibleCreditAgreementMember" xlink:label="inva_SecuredConvertibleCreditAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CreditAndSecurityAgreementMember" xlink:label="inva_CreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" xlink:label="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonStockAndWarrantsMember" xlink:label="inva_CommonStockAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrincipalAmountOfTermLoansOwned" xlink:label="inva_PrincipalAmountOfTermLoansOwned"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OneDirectorMember" xlink:label="inva_OneDirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember" xlink:label="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WarrantsPurchasedIn2020Member" xlink:label="inva_WarrantsPurchasedIn2020Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfWarrantsOwned" xlink:label="inva_NumberOfWarrantsOwned"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoDirectorsMember" xlink:label="inva_TwoDirectorsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember" xlink:label="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WarrantsPurchasedIn2021Member" xlink:label="inva_WarrantsPurchasedIn2021Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember" xlink:label="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WarrantsPurchasedIn2022Member" xlink:label="inva_WarrantsPurchasedIn2022Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfBoardOfDirectors" xlink:label="inva_NumberOfBoardOfDirectors"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember" xlink:label="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquitySecuritiesOwned" xlink:label="inva_EquitySecuritiesOwned"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataConvertibleNoteMember" xlink:label="inva_ArmataConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataTermLoanMember" xlink:label="inva_ArmataTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" xlink:label="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrincipalAmountOfConvertibleNotesOwned" xlink:label="inva_PrincipalAmountOfConvertibleNotesOwned"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" xlink:label="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" xlink:label="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" xlink:label="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_VotingAgreementMaximumVotingRightsPercent" xlink:label="inva_VotingAgreementMaximumVotingRightsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityOwnershipPercentage" xlink:label="us-gaap_VariableInterestEntityOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" xlink:label="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SecuredConvertibleCreditAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_CreditAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonStockAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_PrincipalAmountOfTermLoansOwned" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_OneDirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2020Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfWarrantsOwned" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="inva_TwoDirectorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2021Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_WarrantsPurchasedIn2022Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardOfDirectors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_EquitySecuritiesOwned" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_PrincipalAmountOfConvertibleNotesOwned" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_VotingAgreementMaximumVotingRightsPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_VariableInterestEntityOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:label="us-gaap_IncomeStatementRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AssetsNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncomeStatementRelatedDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementRelatedDisclosuresAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_QualifiedFinancingMember" xlink:label="inva_QualifiedFinancingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="us-gaap_ValuationTechniqueAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="us-gaap_ValuationTechniqueDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OptionPricingModelBacksolveValuationMember" xlink:label="inva_OptionPricingModelBacksolveValuationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaTRCHoldingsLLCMember" xlink:label="inva_InnovivaTRCHoldingsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonAndPreferredStockMember" xlink:label="inva_CommonAndPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NameOfEventAxis" xlink:label="inva_NameOfEventAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NameOfEventDomain" xlink:label="inva_NameOfEventDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" xlink:label="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleNoteAndWarrantsMember" xlink:label="inva_ConvertibleNoteAndWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" xlink:label="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaConvertibleNoteMember" xlink:label="inva_InCardaConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesA1PreferredStockMember" xlink:label="inva_SeriesA1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD1PreferredStockMember" xlink:label="inva_SeriesD1PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD2PreferredStockMember" xlink:label="inva_SeriesD2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD1WarrantMember" xlink:label="inva_SeriesD1WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ExpectedHoldingPeriod" xlink:label="inva_ExpectedHoldingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD2WarrantMember" xlink:label="inva_SeriesD2WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RiskFreeInterestRate" xlink:label="inva_RiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DividendYield" xlink:label="inva_DividendYield"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesCWarrantsAndSeriesDWarrantsMember" xlink:label="inva_SeriesCWarrantsAndSeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PercentageOfEstimatedVolatility" xlink:label="inva_PercentageOfEstimatedVolatility"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesCWarrantsMember" xlink:label="inva_SeriesCWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:label="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesDWarrantsMember" xlink:label="inva_SeriesDWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CarryingValueWroteOffWarrantExercise" xlink:label="inva_CarryingValueWroteOffWarrantExercise"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesD1AndD2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesD1AndD2PreferredStockAndCommonStockMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_NameOfEventDomain" xlink:to="inva_QualifiedFinancingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationTechniqueAxis" xlink:to="us-gaap_ValuationTechniqueDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationTechniqueDomain" xlink:to="inva_OptionPricingModelBacksolveValuationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaTRCHoldingsLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonAndPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_IncardaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="inva_NameOfEventAxis" xlink:to="inva_NameOfEventDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_ValuationTechniqueAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ConvertibleNoteAndWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesA1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="inva_NameOfEventAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_ExpectedHoldingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD2WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_RiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DividendYield" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCWarrantsAndSeriesDWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_PercentageOfEstimatedVolatility" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesDWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_CarryingValueWroteOffWarrantExercise" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FirstAmendmentMember" xlink:label="inva_FirstAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaTRCHoldingsLLCMember" xlink:label="inva_InnovivaTRCHoldingsLLCMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ImaginabMember" xlink:label="inva_ImaginabMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OneOfImaginabsCommonStockholderMember" xlink:label="inva_OneOfImaginabsCommonStockholderMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonAndPreferredStockMember" xlink:label="inva_CommonAndPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedInterestAndCommitmentFees" xlink:label="inva_AccruedInterestAndCommitmentFees"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesC2PreferredStockMember" xlink:label="inva_SeriesC2PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeriesCAndC2PreferredStockAndCommonStockMember" xlink:label="inva_SeriesCAndC2PreferredStockAndCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ImaginabConvertibleNoteMember" xlink:label="inva_ImaginabConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfBoardOfDirectors" xlink:label="inva_NumberOfBoardOfDirectors"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_FirstAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaTRCHoldingsLLCMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_ImaginabMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_OneOfImaginabsCommonStockholderMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_CommonAndPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_AccruedInterestAndCommitmentFees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesC2PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_SeriesCAndC2PreferredStockAndCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ImaginabConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardOfDirectors" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember" xlink:label="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GateNeuroscienceMember" xlink:label="inva_GateNeuroscienceMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioBiosciencesMember" xlink:label="inva_SyndeioBiosciencesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember" xlink:label="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCommonStockIssuedDescription" xlink:label="inva_NumberOfCommonStockIssuedDescription"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGain" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedGain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember" xlink:label="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_GateNeuroscienceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_SyndeioBiosciencesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCommonStockIssuedDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedGain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NanoliveMember" xlink:label="inva_NanoliveMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" xlink:label="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfBoardMembersOfInvestee" xlink:label="inva_NumberOfBoardMembersOfInvestee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_NanoliveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_NumberOfBoardMembersOfInvestee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LyndraConvertibleNoteMember" xlink:label="inva_LyndraConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LyndraMember" xlink:label="inva_LyndraMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault" xlink:label="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedLoss" xlink:label="us-gaap_EquitySecuritiesFvNiUnrealizedLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentOfNotesReceivableFromRelatedParties" xlink:label="us-gaap_RepaymentOfNotesReceivableFromRelatedParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="us-gaap_RepaymentsOfShortTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" xlink:label="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_LyndraConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_LyndraMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNiUnrealizedLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_RepaymentOfNotesReceivableFromRelatedParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_RepaymentsOfShortTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConsolidatedInvesteesMember" xlink:label="inva_ConsolidatedInvesteesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BeaconMember" xlink:label="inva_BeaconMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SecuritiesPurchaseAgreementAmount" xlink:label="inva_SecuritiesPurchaseAgreementAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="us-gaap_EquitySecuritiesFvNi"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ConsolidatedInvesteesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_BeaconMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="inva_SecuritiesPurchaseAgreementAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_EquitySecuritiesFvNi" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="srt_EquityMethodInvesteeNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataPharmaceuticalsIncMember" xlink:label="inva_ArmataPharmaceuticalsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityInvestmentsAndMoneyMarketFundsMember" xlink:label="inva_EquityInvestmentsAndMoneyMarketFundsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" xlink:label="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IspFundLpMember" xlink:label="inva_IspFundLpMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesMember" xlink:label="us-gaap_EquitySecuritiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncardaMember" xlink:label="inva_IncardaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataTermLoanMember" xlink:label="inva_ArmataTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TermLoanInvestmentMember" xlink:label="inva_TermLoanInvestmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ImaginAbNoteMember" xlink:label="inva_ImaginAbNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatePlacementPositionsAndConvertibleNotesMember" xlink:label="inva_PrivatePlacementPositionsAndConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" xlink:label="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtMember" xlink:label="us-gaap_DebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PreferredStockWarrantsMember" xlink:label="inva_PreferredStockWarrantsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" xlink:label="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember" xlink:label="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PartnershipAgreementLockUpPeriod" xlink:label="inva_PartnershipAgreementLockUpPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" xlink:label="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" xlink:label="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="us-gaap_LimitedPartnersContributedCapital"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" xlink:label="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LyndraConvertibleNoteMember" xlink:label="inva_LyndraConvertibleNoteMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WithdrawalFromInvestment" xlink:label="inva_WithdrawalFromInvestment"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" xlink:label="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ArmataPharmaceuticalsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_EquityInvestmentsAndMoneyMarketFundsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_IspFundLpMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_EquitySecuritiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_IncardaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_TermLoanInvestmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_ImaginAbNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_ContingentValueRightsLiability" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="inva_PrivatePlacementPositionsAndConvertibleNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtInstrumentFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_PreferredStockWarrantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_PartnershipAgreementLockUpPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LimitedPartnersContributedCapital" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="inva_LyndraConvertibleNoteMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="inva_WithdrawalFromInvestment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostLineItems" xlink:label="us-gaap_CapitalizedContractCostLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostTable" xlink:label="us-gaap_CapitalizedContractCostTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:label="inva_CapitalizedFeesPaidFutureAmortizationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_JP" xlink:label="country_JP"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidWeightedAverageUsefulLife" xlink:label="inva_CapitalizedFeesPaidWeightedAverageUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" xlink:label="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_EuropeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_JP" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_CapitalizedContractCostTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_CapitalizedFeesPaidFutureAmortizationAbstract" xlink:to="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CapitalizedContractCostLineItems" xlink:to="inva_CapitalizedFeesPaidFutureAmortizationAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems" xlink:label="us-gaap_GoodwillLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="us-gaap_ScheduleOfGoodwillTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_XacduroMember" xlink:label="inva_XacduroMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BasileaMember" xlink:label="inva_BasileaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NUZOLVENCEMember" xlink:label="inva_NUZOLVENCEMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontFee" xlink:label="inva_UpfrontFee"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:label="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_ScheduleOfGoodwillTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_XacduroMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_BasileaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_ConsolidatedEntitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_NUZOLVENCEMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="inva_UpfrontFee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfGoodwillTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GoodwillLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MarketedProductsMember" xlink:label="inva_MarketedProductsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="inva_MarketedProductsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_CollaborativeArrangementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsMarketedProductsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems" xlink:label="us-gaap_InventoryLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable" xlink:label="us-gaap_InventoryCurrentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ZaiLabMember" xlink:label="inva_ZaiLabMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FairValueAdjustmentsOfInventoryFromAcquistion" xlink:label="inva_FairValueAdjustmentsOfInventoryFromAcquistion"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" xlink:label="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BusinessCombinationDeferredConsideration" xlink:label="inva_BusinessCombinationDeferredConsideration"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmountOfInventoryPurchasesNotBilled" xlink:label="inva_AmountOfInventoryPurchasesNotBilled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdvancesOnInventoryPurchases" xlink:label="us-gaap_AdvancesOnInventoryPurchases"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryCurrentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_InventoryGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_ZaiLabMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_InventoryCurrentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_FairValueAdjustmentsOfInventoryFromAcquistion" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_BusinessCombinationDeferredConsideration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="inva_AmountOfInventoryPurchasesNotBilled" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InventoryLineItems" xlink:to="us-gaap_AdvancesOnInventoryPurchases" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityIncentivePlan2012Member" xlink:label="inva_EquityIncentivePlan2012Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" xlink:label="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EquityIncentivePlan2012Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EmployeeStockPurchasePlanMember" xlink:label="inva_EmployeeStockPurchasePlanMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="inva_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" xlink:label="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaMember" xlink:label="inva_InnovivaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="inva_InnovivaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ClassOfWarrantOrRightExercised" xlink:label="inva_ClassOfWarrantOrRightExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis" xlink:label="srt_ShareRepurchaseProgramAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain" xlink:label="srt_ShareRepurchaseProgramDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" xlink:label="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GSKMember" xlink:label="inva_GSKMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommonStockAcquiredAverageCostPerShare" xlink:label="inva_CommonStockAcquiredAverageCostPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfTreasuryStockTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_ClassOfWarrantOrRightExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ShareRepurchaseProgramAxis" xlink:to="srt_ShareRepurchaseProgramDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ShareRepurchaseProgramDomain" xlink:to="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="srt_ShareRepurchaseProgramAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="inva_GSKMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="inva_CommonStockAcquiredAverageCostPerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_HealthCareRoyaltyPartnersMember" xlink:label="inva_HealthCareRoyaltyPartnersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OtherAccruedLiabilitiesMember" xlink:label="inva_OtherAccruedLiabilitiesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyFinancingAgreementMember" xlink:label="inva_RoyaltyFinancingAgreementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" xlink:label="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_MaximumAggregateRoyaltyPaymentsDue" xlink:label="inva_MaximumAggregateRoyaltyPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredRoyaltyObligations" xlink:label="inva_DeferredRoyaltyObligations"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyPayments" xlink:label="inva_RoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InterestRateOfDeferredRoyaltyObligation" xlink:label="inva_InterestRateOfDeferredRoyaltyObligation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" xlink:label="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TotalPaymentsMadeForRoyaltyAgreement" xlink:label="inva_TotalPaymentsMadeForRoyaltyAgreement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_HealthCareRoyaltyPartnersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="inva_OtherAccruedLiabilitiesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_RoyaltyFinancingAgreementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_MaximumAggregateRoyaltyPaymentsDue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DeferredRoyaltyObligations" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_InterestRateOfDeferredRoyaltyObligation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_TotalPaymentsMadeForRoyaltyAgreement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CallOptionMember" xlink:label="us-gaap_CallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" xlink:label="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InnovivaCommonStockMember" xlink:label="inva_InnovivaCommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtAbstract" xlink:label="us-gaap_InterestExpenseDebtAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRemainingBalancePaidUponMaturation" xlink:label="inva_DebtInstrumentRemainingBalancePaidUponMaturation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PutOptionMember" xlink:label="us-gaap_PutOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" xlink:label="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyNegotiatedCapPriceMember" xlink:label="inva_PrivatelyNegotiatedCapPriceMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfDerivativeInstrumentsPurchased" xlink:label="inva_NumberOfDerivativeInstrumentsPurchased"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="us-gaap_DebtInstrumentRepurchaseAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" xlink:label="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRepurchasePercentage" xlink:label="inva_DebtInstrumentRepurchasePercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnamortizedDebtIssuanceExpense" xlink:label="us-gaap_UnamortizedDebtIssuanceExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_CallOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="inva_InnovivaCommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRemainingBalancePaidUponMaturation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:to="us-gaap_PutOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCapPriceMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfDerivativeInstrumentsPurchased" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseDebtAbstract" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchaseAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRepurchasePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_UnamortizedDebtIssuanceExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebtAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseBorrowingsAbstract" xlink:label="us-gaap_InterestExpenseBorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SeniorUnsecuredConvertibleNotesMember" xlink:label="inva_SeniorUnsecuredConvertibleNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyThreeNotesMember" xlink:label="inva_TwoThousandTwentyThreeNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrivatelyNegotiatedCappedCallOptionMember" xlink:label="inva_PrivatelyNegotiatedCappedCallOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock" xlink:label="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleSubordinatedDebtMember" xlink:label="us-gaap_ConvertibleSubordinatedDebtMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyFiveNotesMember" xlink:label="inva_TwoThousandTwentyFiveNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_TwoThousandTwentyEightNotesMember" xlink:label="inva_TwoThousandTwentyEightNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeCapPrice" xlink:label="us-gaap_DerivativeCapPrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OptionIndexedToIssuersEquityStrikePrice1" xlink:label="us-gaap_OptionIndexedToIssuersEquityStrikePrice1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes" xlink:label="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentConvertibleConversionPremium" xlink:label="inva_DebtInstrumentConvertibleConversionPremium"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRemainingBalancePaidUponMaturation" xlink:label="inva_DebtInstrumentRemainingBalancePaidUponMaturation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" xlink:label="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" xlink:label="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" xlink:label="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCovenantTerms" xlink:label="us-gaap_LineOfCreditFacilityCovenantTerms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PortionOfDebtInstrumentFaceAmountExercised" xlink:label="inva_PortionOfDebtInstrumentFaceAmountExercised"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="inva_SeniorUnsecuredConvertibleNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyThreeNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="inva_PrivatelyNegotiatedCappedCallOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleSubordinatedDebtMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyFiveNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="inva_TwoThousandTwentyEightNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestExpenseBorrowingsAbstract" xlink:to="us-gaap_InterestExpenseDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DerivativeCapPrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityStrikePrice1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentConvertibleConversionPremium" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRemainingBalancePaidUponMaturation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCovenantTerms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_PortionOfDebtInstrumentFaceAmountExercised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="inva_DebtInstrumentPrincipalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseBorrowingsAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_BurlingameCaliforniaMember" xlink:label="inva_BurlingameCaliforniaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetRentableArea" xlink:label="us-gaap_NetRentableArea"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisLeaseMember" xlink:label="inva_EntasisLeaseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CordenPharmaMember" xlink:label="inva_CordenPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_WalthamMassachusettsMember" xlink:label="inva_WalthamMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CommitmentsFor2024ToBeUtilizedIn2025Member" xlink:label="inva_CommitmentsFor2024ToBeUtilizedIn2025Member"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LexingtonMassachusettsMember" xlink:label="inva_LexingtonMassachusettsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PurchaseObligationDueInSecondYear" xlink:label="us-gaap_PurchaseObligationDueInSecondYear"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies" xlink:label="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_BurlingameCaliforniaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_NetRentableArea" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="inva_EntasisLeaseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="inva_CordenPharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_WalthamMassachusettsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="inva_CommitmentsFor2024ToBeUtilizedIn2025Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="inva_LexingtonMassachusettsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PurchaseObligationDueInSecondYear" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionLineItems" xlink:label="us-gaap_AssetAcquisitionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionTable" xlink:label="us-gaap_AssetAcquisitionTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DevelopmentRegulatoryAndRoyaltyMember" xlink:label="inva_DevelopmentRegulatoryAndRoyaltyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LyndraMember" xlink:label="inva_LyndraMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" xlink:label="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UpfrontCashPayments" xlink:label="inva_UpfrontCashPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNetNoncurrent" xlink:label="us-gaap_CapitalizedContractCostNetNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_FuturePotentialMilestonePayment" xlink:label="inva_FuturePotentialMilestonePayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_DevelopmentRegulatoryAndRoyaltyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_AssetAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="inva_LyndraMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionDateOfAcquisitionAgreement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="inva_UpfrontCashPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_AssetAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_CapitalizedContractCostNetNoncurrent" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="inva_FuturePotentialMilestonePayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:label="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="us-gaap_IncomeTaxesPaidNet" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxesLineItems" xlink:label="inva_IncomeTaxesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxesTable" xlink:label="inva_IncomeTaxesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EntasisTherapeuticsHoldingsIncMember" xlink:label="inva_EntasisTherapeuticsHoldingsIncMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_LaJollaPharmaceuticalCompanyMember" xlink:label="inva_LaJollaPharmaceuticalCompanyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="inva_IncomeTaxesLineItems" xlink:to="inva_IncomeTaxesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_EntasisTherapeuticsHoldingsIncMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="inva_LaJollaPharmaceuticalCompanyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="inva_IncomeTaxesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="inva_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:label="us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:label="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US" xlink:label="country_US"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingSegmentsMember" xlink:label="us-gaap_OperatingSegmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfInventoryFairValueAdjustmentsMember" xlink:label="inva_AmortizationOfInventoryFairValueAdjustmentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ExternalServicesMember" xlink:label="inva_ExternalServicesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InternalExpensesMember" xlink:label="inva_InternalExpensesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="us-gaap_SellingAndMarketingExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="us-gaap_DeconsolidationGainOrLossAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidationItemsDomain" xlink:to="us-gaap_OperatingSegmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="inva_AmortizationOfInventoryFairValueAdjustmentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_ExternalServicesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_CostOfGoodsAndServicesSold" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="inva_InternalExpensesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_SellingAndMarketingExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="srt_ConsolidationItemsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="inva_GainLossOnOtherInvestments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_InterestAndDividendIncomeOperating" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_InterestExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_DeconsolidationGainOrLossAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesLongTermContractsOrPrograms" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="inva_EquityMethodInvestment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_CapitalizedContractCostNet" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_AccruedIncomeTaxesNoncurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DebtCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="inva_CurrentPortionOfISPFundInvestments" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReceivablesLongTermContractsOrPrograms" xlink:label="us-gaap_ReceivablesLongTermContractsOrPrograms"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EquityMethodInvestment" xlink:label="inva_EquityMethodInvestment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesNoncurrent" xlink:label="us-gaap_AccruedIncomeTaxesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_CurrentPortionOfISPFundInvestments" xlink:label="inva_CurrentPortionOfISPFundInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="inva_DebtInstrumentPrincipalAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_LongTermDebtNoncurrent" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="inva_ContingentValueRightsLiability" order="0" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ContingentValueRightsLiability" xlink:label="inva_ContingentValueRightsLiability"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="inva_IntangibleAssetsMarketedProductsNet" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="inva_IntangibleAssetsCollaborationAgreementNet" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsNet" xlink:label="inva_IntangibleAssetsMarketedProductsNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementNet" xlink:label="inva_IntangibleAssetsCollaborationAgreementNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GrossProfit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="inva_AmortizationOfAcquiredIntangibleAssets" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="inva_GainLossOnOtherInvestments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestAndDividendIncomeOperating" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfAcquiredIntangibleAssets" xlink:label="inva_AmortizationOfAcquiredIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GainLossOnOtherInvestments" xlink:label="inva_GainLossOnOtherInvestments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForTradingSecurities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="3" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="4" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireLongtermInvestments" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfUnsecuredDebt" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="inva_UnrealizedOtherGainLossOnInvestments" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_SaleOfEquityInvestmentsManagedByIspFundLp" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" order="13" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="14" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="20" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="24" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="25" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" order="28" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="29" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="32" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="34" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="35" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="36" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInterestPayableNet" order="37" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" xlink:label="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForTradingSecurities" xlink:label="us-gaap_ProceedsFromPaymentsForTradingSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" xlink:label="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireLongtermInvestments" xlink:label="us-gaap_PaymentsToAcquireLongtermInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfUnsecuredDebt" xlink:label="us-gaap_RepaymentsOfUnsecuredDebt"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AcquiredIn-ProcessResearchAndDevelopmentAssets" xlink:label="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:label="us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_UnrealizedOtherGainLossOnInvestments" xlink:label="inva_UnrealizedOtherGainLossOnInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_SaleOfEquityInvestmentsManagedByIspFundLp" xlink:label="inva_SaleOfEquityInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" xlink:label="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent" xlink:label="us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:label="us-gaap_IncreaseDecreaseInInterestPayableNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_InterestOnConvertibleDebtNetOfTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestOnConvertibleDebtNetOfTax" xlink:label="us-gaap_InterestOnConvertibleDebtNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_CapitalizedContractCostAmortization" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" xlink:label="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="inva_ConvertibleSubordinatedDebtFairValueDisclosures" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="inva_ConvertibleSeniorDebtFairValueDisclosures" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentFairValue" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFairValue" xlink:label="us-gaap_DebtInstrumentFairValue"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSubordinatedDebtFairValueDisclosures" xlink:label="inva_ConvertibleSubordinatedDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_ConvertibleSeniorDebtFairValueDisclosures" xlink:label="inva_ConvertibleSeniorDebtFairValueDisclosures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CapitalizedContractCostNet" xlink:to="us-gaap_CapitalizedContractCostAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostNet" xlink:label="us-gaap_CapitalizedContractCostNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross" xlink:label="us-gaap_CapitalizedContractCostGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAccumulatedAmortization" xlink:label="us-gaap_CapitalizedContractCostAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="inva_IntangibleAssetsCollaborationAgreementGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="inva_IntangibleAssetsMarketedProductsGross" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementGross" xlink:label="inva_IntangibleAssetsCollaborationAgreementGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" xlink:label="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" xlink:label="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsMarketedProductsGross" xlink:label="inva_IntangibleAssetsMarketedProductsGross"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" xlink:label="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedContractManufacturingLiability" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedClinicalAndResearchLiability" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedProfessionalServices" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_DeferredRoyaltyObligationCurrent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="inva_AccruedLicenseFeesAndRoyalties" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherLiabilities" order="9" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedContractManufacturingLiability" xlink:label="inva_AccruedContractManufacturingLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedClinicalAndResearchLiability" xlink:label="inva_AccruedClinicalAndResearchLiability"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedProfessionalServices" xlink:label="inva_AccruedProfessionalServices"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredRoyaltyObligationCurrent" xlink:label="inva_DeferredRoyaltyObligationCurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_AccruedLicenseFeesAndRoyalties" xlink:label="inva_AccruedLicenseFeesAndRoyalties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="inva_DeferredRoyaltyObligationNonCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherSundryLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredRoyaltyObligationNonCurrent" xlink:label="inva_DeferredRoyaltyObligationNonCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:label="us-gaap_OtherSundryLiabilitiesNoncurrent"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="inva_DebtInstrumentPrincipalAmount" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" weight="-1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DebtInstrumentPrincipalAmount" xlink:label="inva_DebtInstrumentPrincipalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" order="5" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" order="6" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsForeign" order="7" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="8" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount" order="9" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="10" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" order="12" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="17" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount" xlink:label="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" xlink:label="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" xlink:label="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesInvestments" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxLiabilitiesDepreciationAndAmortization1" xlink:label="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="us-gaap_DeferredTaxLiabilitiesOther"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" xlink:label="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesInvestments" xlink:label="us-gaap_DeferredTaxLiabilitiesInvestments"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" xlink:label="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet"/>
          <link:loc xlink:type="locator" xlink:href="inva-20251231.xsd#inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" xlink:label="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="inva_CustomerTwoMember" name="CustomerTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" name="OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AccruedContractManufacturingLiability" name="AccruedContractManufacturingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_EntasisLeaseMember" name="EntasisLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InCardaConvertibleNoteMember" name="InCardaConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DenominatorAbstract" name="DenominatorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes" name="CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SeriesD2PreferredStockMember" name="SeriesD2PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" name="DeferredTaxAssetsUnrealizedLossesOnInvestmentNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_MaximumAggregateRoyaltyPaymentsDue" name="MaximumAggregateRoyaltyPaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ConvertibleSeniorNotes2025Member" name="ConvertibleSeniorNotes2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_UpfrontFeeReceived" name="UpfrontFeeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ReductionToAdditionalPaidInCapital" name="ReductionToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_TechnologyTransferAgreementMember" name="TechnologyTransferAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ArmataConvertibleNoteMember" name="ArmataConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_BusinessCombinationDeferredConsideration" name="BusinessCombinationDeferredConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ProfitLossShares" name="ProfitLossShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ConvertibleSeniorDebtFairValueDisclosures" name="ConvertibleSeniorDebtFairValueDisclosures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ResearchAndDevelopmentSupportMember" name="ResearchAndDevelopmentSupportMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SarissaCapitalManagementLpMember" name="SarissaCapitalManagementLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember" name="SyndeioTwoThousandTwentyOneConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncomeTaxesPaidNetTableTextBlock" name="IncomeTaxesPaidNetTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CostReimbursementMember" name="CostReimbursementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ManufacturingStageTransferAgreementMember" name="ManufacturingStageTransferAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo" name="CollaborativeArrangementRoyaltyRateDefinedLevelTwo" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NonRule10B51ArrModifiedFlag" name="NonRule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent" name="EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_IntangibleAssetsInProcessResearchAndDevelopmentNet" name="IntangibleAssetsInProcessResearchAndDevelopmentNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_WalthamMassachusettsMember" name="WalthamMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SaleOfEquityInvestmentsManagedByIspFundLp" name="SaleOfEquityInvestmentsManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CapitalizedFeePaidEstimatedUsefulLife" name="CapitalizedFeePaidEstimatedUsefulLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_ReclassificationOfCurrentPortion" name="ReclassificationOfCurrentPortion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RoyaltyFinancingAgreementMember" name="RoyaltyFinancingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" name="NumberOfSharesReceivableOnSettlementOfDerivativeInstrument" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ImaginabMember" name="ImaginabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" name="DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" name="IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DecreaseToAccumulatedDeficit" name="DecreaseToAccumulatedDeficit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_InterestRateOfDeferredRoyaltyObligation" name="InterestRateOfDeferredRoyaltyObligation" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund" name="NetSalesAndPurchasesOfInvestmentsManagedByISPFund" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" name="CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_OtherAccruedLiabilitiesMember" name="OtherAccruedLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault" name="DebtInstrumentPercentagePremiumOnPrincipalOnDefault" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" name="InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidFutureAmortizationAbstract" name="CapitalizedFeesPaidFutureAmortizationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InvestmentsInWarrants" name="InvestmentsInWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ConvertiblePromissoryNotePurchaseAgreementMember" name="ConvertiblePromissoryNotePurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InterimSupplyAgreementMember" name="InterimSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_BeaconMember" name="BeaconMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConsolidatedEntityTextBlock" name="ConsolidatedEntityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_AcquiredIn-ProcessResearchAndDevelopmentAssets" name="AcquiredIn-ProcessResearchAndDevelopmentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" name="AmortizationOfFairValueAdjustmentsOfCostOfProductsSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NumberOfCustomers" name="NumberOfCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_FuturePotentialMilestonePayment" name="FuturePotentialMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DevelopmentRegulatoryAndSalesMilestoneMember" name="DevelopmentRegulatoryAndSalesMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PrivatelyHeldHealthcareCompaniesMember" name="PrivatelyHeldHealthcareCompaniesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RegulatoryStartingMaterialMember" name="RegulatoryStartingMaterialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NonCashActivity" name="NonCashActivity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember" name="SyndeoTwoThousandTwentyOneConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CommitmentsFor2024ToBeUtilizedIn2025Member" name="CommitmentsFor2024ToBeUtilizedIn2025Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" name="PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_ZEVTERAMember" name="ZEVTERAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LicenseAndOtherRevenue" name="LicenseAndOtherRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_NumberOfBoardOfDirectors" name="NumberOfBoardOfDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_WarrantsPurchasedIn2022Member" name="WarrantsPurchasedIn2022Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_UpfrontPaymentUnderIntangibleAsset" name="UpfrontPaymentUnderIntangibleAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_InnovivaMember" name="InnovivaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InnovivaTRCHoldingsLLCMember" name="InnovivaTRCHoldingsLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" name="SubscriptionAgreementOneTimeMilestonePaymentOnNetSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ReimbursementsForResearchAndDevelopmentExpense" name="ReimbursementsForResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_TwoThousandTwentyThreeNotesMember" name="TwoThousandTwentyThreeNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LaboratoryEquipmentFurnitureAndFixturesMember" name="LaboratoryEquipmentFurnitureAndFixturesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TwoThousandTwentyEightNotesMember" name="TwoThousandTwentyEightNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" name="RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PresentationReclassificationPolicyTextBlock" name="PresentationReclassificationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_LyndraConvertibleNoteMember" name="LyndraConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AccruedProfessionalServices" name="AccruedProfessionalServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ConvertibleNoteAndWarrantsMember" name="ConvertibleNoteAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TrelegyElliptaMember" name="TrelegyElliptaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" name="AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_EquityMethodInvestment" name="EquityMethodInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_MoneyMarketFundAndCash" name="MoneyMarketFundAndCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_AstrazenecaMember" name="AstrazenecaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock" name="PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PrivatelyNegotiatedCappedCallOptionMember" name="PrivatelyNegotiatedCappedCallOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RoyaltyPayments" name="RoyaltyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_HarvardUniversityMember" name="HarvardUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GateNeuroscienceMember" name="GateNeuroscienceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ClaimExpirationDate" name="ClaimExpirationDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock" name="ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_LexingtonMassachusettsMember" name="LexingtonMassachusettsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EquityIncentivePlansAndESPPMember" name="EquityIncentivePlansAndESPPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PubliclyTradedHealthcareCompaniesMember" name="PubliclyTradedHealthcareCompaniesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PercentageOfEconomicInterestInPartnership" name="PercentageOfEconomicInterestInPartnership" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SeriesD1AndD2PreferredStockAndCommonStockMember" name="SeriesD1AndD2PreferredStockAndCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TermOfMilestonePaymentForNetSales" name="TermOfMilestonePaymentForNetSales" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_SalesMilestonePaymentsReceivable" name="SalesMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_LongActingBeta2AgonistAnoroMember" name="LongActingBeta2AgonistAnoroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_Percent2.50ConvertibleDebtMember" name="Percent2.50ConvertibleDebtMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" name="PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_AccruedLicenseFeesAndRoyalties" name="AccruedLicenseFeesAndRoyalties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember" name="ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OneOfImaginabsCommonStockholderMember" name="OneOfImaginabsCommonStockholderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CordenPharmaMember" name="CordenPharmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock" name="ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" name="PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ImaginAbNoteMember" name="ImaginAbNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" name="SaleOfWarrantsNumberOfWarrantsIssuedInTransaction" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_BurlingameCaliforniaMember" name="BurlingameCaliforniaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GARDPCollaborationAgreementMember" name="GARDPCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GSKMember" name="GSKMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IntangibleAssetsMarketedProductsNet" name="IntangibleAssetsMarketedProductsNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" name="SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_IntangibleAssetsMarketedProductsGross" name="IntangibleAssetsMarketedProductsGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_OutstandingStockWarrantMember" name="OutstandingStockWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" name="RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember" name="ArmataMarchTwoThousandTwentyFiveTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SoftwareAndComputerEquipmentMember" name="SoftwareAndComputerEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" name="GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember" name="ArmataAugustTwoThousandTwentyFiveTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember" name="AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" name="RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_SeriesCWarrantsMember" name="SeriesCWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_UpfrontCashPayments" name="UpfrontCashPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SeriesCAndC2PreferredStockAndCommonStockMember" name="SeriesCAndC2PreferredStockAndCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee" name="SpecialTermReDesignatingBoardMemberToBoardOfInvestee" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_Outstanding2028NotesMember" name="Outstanding2028NotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ArmataMarchTwoThousandTwentyFourTermLoanMember" name="ArmataMarchTwoThousandTwentyFourTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TheravanceRespiratoryCompanyLlcMember" name="TheravanceRespiratoryCompanyLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TwoDirectorsMember" name="TwoDirectorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ExpectedHoldingPeriod" name="ExpectedHoldingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_AmortizationOfAcquiredIntangibleAssets" name="AmortizationOfAcquiredIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AccruedInterestAndCommitmentFees" name="AccruedInterestAndCommitmentFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" name="CapitalizedFeesPaidToRelatedPartyPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_GiaprezaMember" name="GiaprezaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember" name="MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IntangibleAssetsCollaborationAgreementNet" name="IntangibleAssetsCollaborationAgreementNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_WithdrawalFromInvestment" name="WithdrawalFromInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_DurlobactamMember" name="DurlobactamMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AmortizationOfInventoryFairValueAdjustmentsMember" name="AmortizationOfInventoryFairValueAdjustmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment" name="DeferredTaxLiabilitiesInventoryFairValueAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember" name="ArmataJulyTwoThousandTwentyThreeTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DividendYield" name="DividendYield" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" name="NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_InnovivaCommonStockMember" name="InnovivaCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_UpfrontFee" name="UpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NetInvestmentRelatedIncomeExpensesEarnedInccured" name="NetInvestmentRelatedIncomeExpensesEarnedInccured" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" name="CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfEstimatedVolatility" name="PercentageOfEstimatedVolatility" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember" name="JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TermOfMilestonePaymentForCommercialSale" name="TermOfMilestonePaymentForCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DebtInstrumentPrincipalAmount" name="DebtInstrumentPrincipalAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_InvestmentsInPreferredStock" name="InvestmentsInPreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_OptionPricingModelBacksolveValuationMember" name="OptionPricingModelBacksolveValuationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AssetAcquisitionsPolicyTextBlock" name="AssetAcquisitionsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_AmountOnNetProductSalesRecognized" name="AmountOnNetProductSalesRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_UpfrontFeePayment" name="UpfrontFeePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_LaJollaPharmaceuticalCompanyMember" name="LaJollaPharmaceuticalCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DescriptionOfOperationsPolicyTextBlock" name="DescriptionOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_AccruedClinicalAndResearchLiability" name="AccruedClinicalAndResearchLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PriorPeriodImmaterialCorrectionPolicyTextBlock" name="PriorPeriodImmaterialCorrectionPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_IspFundLpMember" name="IspFundLpMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_FirstAmendmentMember" name="FirstAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage" name="DebtConversionCommonStockPriceToConversionPriceRatioPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels" name="FairValueOfAssetsOrLiabilitiesTransferBetweenLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_CommercialSupplyAgreementMember" name="CommercialSupplyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_StrategicAllianceAgreementMember" name="StrategicAllianceAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ZoliflodacinMember" name="ZoliflodacinMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ExternalServicesMember" name="ExternalServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" name="PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CarryingValueWroteOffWarrantExercise" name="CarryingValueWroteOffWarrantExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" name="ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DevelopmentRegulatoryAndRoyaltyMember" name="DevelopmentRegulatoryAndRoyaltyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidWeightedAverageUsefulLife" name="CapitalizedFeesPaidWeightedAverageUsefulLife" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CurrentPortionOfISPFundInvestments" name="CurrentPortionOfISPFundInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_EquityInvestmentsAndMoneyMarketFundsMember" name="EquityInvestmentsAndMoneyMarketFundsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NumeratorAbstract" name="NumeratorAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" name="AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_VotingAgreementMaximumVotingRightsPercent" name="VotingAgreementMaximumVotingRightsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" name="ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_StockIssuedDuringPeriodValueExerciseOfWarrants" name="StockIssuedDuringPeriodValueExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CustomerOneMember" name="CustomerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember" name="ConvertiblePromissoryNotePurchaseAgreementAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncardaMember" name="IncardaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_WarrantsPurchasedIn2020Member" name="WarrantsPurchasedIn2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertibleSubordinatedNotes2023Member" name="ConvertibleSubordinatedNotes2023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" name="AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_InCardaTwoThousandTwentyFourConvertibleNoteMember" name="InCardaTwoThousandTwentyFourConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidDisclosureTextBlock" name="CapitalizedFeesPaidDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DebtInstrumentRemainingBalancePaidUponMaturation" name="DebtInstrumentRemainingBalancePaidUponMaturation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CustomerThreeMember" name="CustomerThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_XacduroMember" name="XacduroMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PrincipalAmountOfTermLoansOwned" name="PrincipalAmountOfTermLoansOwned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_NumberOfWarrantsOwned" name="NumberOfWarrantsOwned" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_AmountOfInventoryPurchasesNotBilled" name="AmountOfInventoryPurchasesNotBilled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_UnrealizedOtherGainLossOnInvestments" name="UnrealizedOtherGainLossOnInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_LongActingBeta2AgonistRelvarBreoMember" name="LongActingBeta2AgonistRelvarBreoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GrantFundingMaximumAmount" name="GrantFundingMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" name="InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_LicenseAndOtherRevenueMember" name="LicenseAndOtherRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_MassachusettsInstituteOfTechnologyMember" name="MassachusettsInstituteOfTechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EquityIncentivePlan2012Member" name="EquityIncentivePlan2012Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NumberOfDerivativeInstrumentsPurchased" name="NumberOfDerivativeInstrumentsPurchased" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_ParatekPharmaceuticalsIncMember" name="ParatekPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GeorgeWashingtonUniversityMember" name="GeorgeWashingtonUniversityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock" name="ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PortionOfDebtInstrumentFaceAmountExercised" name="PortionOfDebtInstrumentFaceAmountExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_MarketedProductsMember" name="MarketedProductsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_BasileaMember" name="BasileaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" name="PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" name="CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NanoliveMember" name="NanoliveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AmendedZaiAgreementMember" name="AmendedZaiAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DeferredRoyaltyObligations" name="DeferredRoyaltyObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_IncreaseToConvertibleNotes" name="IncreaseToConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount" name="EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_NUZOLVENCEMember" name="NUZOLVENCEMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CommonStockAndWarrantsMember" name="CommonStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_HealthCareRoyaltyPartnersMember" name="HealthCareRoyaltyPartnersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_EverestMedicinesLimitedMember" name="EverestMedicinesLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TwoThousandTwentyFiveNotesMember" name="TwoThousandTwentyFiveNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ContingentValueRightsLiability" name="ContingentValueRightsLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SeriesD2WarrantMember" name="SeriesD2WarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ClassOfWarrantOrRightExercised" name="ClassOfWarrantOrRightExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_IntangibleAssetsMarketedProductsAccumulatedAmortization" name="IntangibleAssetsMarketedProductsAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" name="RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CreditAndSecurityAgreementMember" name="CreditAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InternalExpensesMember" name="InternalExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesD1WarrantMember" name="SeriesD1WarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PartnershipAgreementLockUpPeriod" name="PartnershipAgreementLockUpPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ArmataPharmaceuticalsIncMember" name="ArmataPharmaceuticalsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PrivatePlacementPositionsAndConvertibleNotesMember" name="PrivatePlacementPositionsAndConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertibleSubordinatedDebtFairValueDisclosures" name="ConvertibleSubordinatedDebtFairValueDisclosures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_SeriesD1PreferredStockMember" name="SeriesD1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PurchasesOfEquityInvestmentsManagedByIspFundLp" name="PurchasesOfEquityInvestmentsManagedByIspFundLp" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" name="ShareRepurchaseAgreementWithGlaxoGroupLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CommonAndPreferredStockMember" name="CommonAndPreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesC2PreferredStockMember" name="SeriesC2PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization" name="IntangibleAssetsCollaborationAgreementAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_XeravaMember" name="XeravaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DeferredRoyaltyObligationCurrent" name="DeferredRoyaltyObligationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_TermLoanInvestmentMember" name="TermLoanInvestmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LicenseCollaborationAndOtherArrangementsTextBlock" name="LicenseCollaborationAndOtherArrangementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_StockIssuedDuringPeriodSharesExerciseOfWarrants" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PurchasesOfEquityAndOtherLongTermInvestments" name="PurchasesOfEquityAndOtherLongTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IntangibleAssetsCollaborationAgreementGross" name="IntangibleAssetsCollaborationAgreementGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SecuritiesPurchaseAgreementAmount" name="SecuritiesPurchaseAgreementAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PrivatelyNegotiatedCapPriceMember" name="PrivatelyNegotiatedCapPriceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_RiskFreeInterestRate" name="RiskFreeInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive" name="PercentageOfRoyaltyPaymentsNotEntitledToReceive" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_AccruedInterestIncomeIncludedInLongTermInvestments" name="AccruedInterestIncomeIncludedInLongTermInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_WarrantsPurchasedIn2021Member" name="WarrantsPurchasedIn2021Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" name="ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DeferredRoyaltyObligationNonCurrent" name="DeferredRoyaltyObligationNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_TotalPaymentsMadeForRoyaltyAgreement" name="TotalPaymentsMadeForRoyaltyAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" name="IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_PercentageOfMinimumRoyaltyRate" name="PercentageOfMinimumRoyaltyRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_IntangibleAssetsInProcessResearchAndDevelopmentGross" name="IntangibleAssetsInProcessResearchAndDevelopmentGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember" name="ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SecuredConvertibleCreditAgreementMember" name="SecuredConvertibleCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeriesDWarrantsMember" name="SeriesDWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_LabaCollaborationMember" name="LabaCollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ArmataTermLoanMember" name="ArmataTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_EntasisTherapeuticsHoldingsIncMember" name="EntasisTherapeuticsHoldingsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_StrategicAllianceMabaProgram" name="StrategicAllianceMabaProgram" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_LyndraMember" name="LyndraMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" name="RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_QualifiedFinancingMember" name="QualifiedFinancingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" name="InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConsolidatedEntitiesDisclosureAbstract" name="ConsolidatedEntitiesDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_FactorsAffectingComparabilityPolicyTextBlock" name="FactorsAffectingComparabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_RelatedPartyTransactionsPolicyTextBlock" name="RelatedPartyTransactionsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_DebtInstrumentConvertibleConversionPremium" name="DebtInstrumentConvertibleConversionPremium" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_LicenseRevenueRecognized" name="LicenseRevenueRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_CashDistributions" name="CashDistributions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember" name="EmployeeStockPurchasePlanTwentyTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_OneDirectorMember" name="OneDirectorMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember" name="ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SyndeioBiosciencesMember" name="SyndeioBiosciencesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DeferredTaxLiabilitiesDepreciationAndAmortization1" name="DeferredTaxLiabilitiesDepreciationAndAmortization1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" name="InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_RegulatoryMilestonePaymentsReceivable" name="RegulatoryMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ConsolidatedEntitiesAndAcquisitionsLineItems" name="ConsolidatedEntitiesAndAcquisitionsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NetIncomeLossPerShareAbstract" name="NetIncomeLossPerShareAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_InvestmentsInCommonStock" name="InvestmentsInCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember" name="ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_NameOfEventDomain" name="NameOfEventDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne" name="CollaborativeArrangementRoyaltyRateDefinedLevelOne" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PercentageOfRoyaltyPayableOnNetSales" name="PercentageOfRoyaltyPayableOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" name="ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember" name="MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_IncreaseInDeferredTaxAssets" name="IncreaseInDeferredTaxAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_RoyaltyAgreementMaximumPotentialPayoutPercent" name="RoyaltyAgreementMaximumPotentialPayoutPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CommonStockAcquiredAverageCostPerShare" name="CommonStockAcquiredAverageCostPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" name="NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_GatesFoundationMember" name="GatesFoundationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ConsolidatedInvesteesMember" name="ConsolidatedInvesteesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies" name="AccruedLiabilitiesIndemnificationsAndOtherContingencies" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_GainLossOnOtherInvestments" name="GainLossOnOtherInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_LaJollaMember" name="LaJollaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_DeferredTaxAssetsDeferredRoyaltyObligationNet" name="DeferredTaxAssetsDeferredRoyaltyObligationNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_RightOfUseAssetsObtainedThroughAcquistions" name="RightOfUseAssetsObtainedThroughAcquistions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_SeriesCWarrantsAndSeriesDWarrantsMember" name="SeriesCWarrantsAndSeriesDWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_EquitySecuritiesOwned" name="EquitySecuritiesOwned" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfMajorCustomers" name="NumberOfMajorCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember" name="ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_PrincipalAmountOfConvertibleNotesOwned" name="PrincipalAmountOfConvertibleNotesOwned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax" name="TreasuryStockSharesAcquiredIncludingAccruedExciseTax" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfBoardMembersOfInvestee" name="NumberOfBoardMembersOfInvestee" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="inva_Rule10B51ArrModifiedFlag" name="Rule10B51ArrModifiedFlag" type="xbrli:booleanItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NameOfEventAxis" name="NameOfEventAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_ZaiLabMember" name="ZaiLabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtConversionConvertedInstrumentAverageTradePricePercentage" name="DebtConversionConvertedInstrumentAverageTradePricePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" name="EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_PaionAgMember" name="PaionAgMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SulbactamDurlobactamMember" name="SulbactamDurlobactamMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" name="TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_ImaginabConvertibleNoteMember" name="ImaginabConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SeniorUnsecuredConvertibleNotesMember" name="SeniorUnsecuredConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember" name="SyndeioTwoThousandTwentyFiveConvertibleNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_DebtInstrumentRepurchasePercentage" name="DebtInstrumentRepurchasePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_NumberOfCommonStockIssuedDescription" name="NumberOfCommonStockIssuedDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" name="CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_FairValueAdjustmentsOfInventoryFromAcquistion" name="FairValueAdjustmentsOfInventoryFromAcquistion" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember" name="TwoThousandTwentyOneConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="inva_CapitalizedFeesPaidPolicyTextBlock" name="CapitalizedFeesPaidPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 13, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INNOVIVA, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3265960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1350 Old Bayshore Highway, Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Burlingame<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-9600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.01 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INVA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,073,646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001080014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Specified portions of the registrant&#8217;s definitive Proxy Statement to be issued in conjunction with the registrant&#8217;s 2026 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant&#8217;s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Jose, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorOpinionTextBlock', window );">Auditor Opinion [Text Block]</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Opinion on the Financial Statements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Innoviva, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2025 and December 31, 2024, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and December 31, 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2025, based on criteria established in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25, 2026, expressed an unqualified opinion on company&#8217;s internal control over financial reporting.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorOpinionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X<br> -Number 210<br> -Section 2<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorOpinionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 550,941<span></span>
</td>
<td class="nump">$ 304,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="nump">34,966<span></span>
</td>
<td class="nump">20,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesLongTermContractsOrPrograms', window );">Receivable from collaboration arrangements</a></td>
<td class="nump">58,351<span></span>
</td>
<td class="nump">65,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">39,172<span></span>
</td>
<td class="nump">33,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses</a></td>
<td class="nump">26,721<span></span>
</td>
<td class="nump">21,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CurrentPortionOfISPFundInvestments', window );">Current portion of ISP Fund investments</a></td>
<td class="nump">15,727<span></span>
</td>
<td class="nump">107,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,637<span></span>
</td>
<td class="nump">656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">727,515<span></span>
</td>
<td class="nump">554,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,555<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_EquityMethodInvestment', window );">Equity method investments</a></td>
<td class="nump">193,726<span></span>
</td>
<td class="nump">52,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity and long-term investments</a></td>
<td class="nump">404,497<span></span>
</td>
<td class="nump">341,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Capitalized fees paid, net</a></td>
<td class="nump">56,138<span></span>
</td>
<td class="nump">69,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">10,929<span></span>
</td>
<td class="nump">2,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">17,905<span></span>
</td>
<td class="nump">17,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">182,156<span></span>
</td>
<td class="nump">208,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">40,744<span></span>
</td>
<td class="nump">41,477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,635,165<span></span>
</td>
<td class="nump">1,301,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,966<span></span>
</td>
<td class="nump">2,132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued personnel-related expenses</a></td>
<td class="nump">9,100<span></span>
</td>
<td class="nump">7,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">3,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Convertible notes, due 2025, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">192,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">29,468<span></span>
</td>
<td class="nump">29,999<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">49,696<span></span>
</td>
<td class="nump">236,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discount and issuance costs</a></td>
<td class="nump">257,731<span></span>
</td>
<td class="nump">256,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">66,091<span></span>
</td>
<td class="nump">64,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities, net</a></td>
<td class="nump">31,793<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Income tax payable, long-term</a></td>
<td class="nump">57,013<span></span>
</td>
<td class="nump">53,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.01 par value, 200,000 shares authorized, 74,636 and 62,665 issued and outstanding as of December 31, 2025 and 2024 respectively</a></td>
<td class="nump">747<span></span>
</td>
<td class="nump">627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">902,726<span></span>
</td>
<td class="nump">692,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="nump">269,368<span></span>
</td>
<td class="num">(1,797)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">1,172,841<span></span>
</td>
<td class="nump">691,159<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 1,635,165<span></span>
</td>
<td class="nump">$ 1,301,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CurrentPortionOfISPFundInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of ISP Fund investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CurrentPortionOfISPFundInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_EquityMethodInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_EquityMethodInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesLongTermContractsOrPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesLongTermContractsOrPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">74,636<span></span>
</td>
<td class="nump">62,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">74,636<span></span>
</td>
<td class="nump">62,665<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 411,328<span></span>
</td>
<td class="nump">$ 358,711<span></span>
</td>
<td class="nump">$ 310,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AmortizationOfAcquiredIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">26,277<span></span>
</td>
<td class="nump">25,902<span></span>
</td>
<td class="nump">21,784<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">307,667<span></span>
</td>
<td class="nump">296,211<span></span>
</td>
<td class="nump">246,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">113,318<span></span>
</td>
<td class="nump">115,690<span></span>
</td>
<td class="nump">98,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">30,604<span></span>
</td>
<td class="nump">13,654<span></span>
</td>
<td class="nump">33,922<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">143,922<span></span>
</td>
<td class="nump">129,344<span></span>
</td>
<td class="nump">132,154<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">163,745<span></span>
</td>
<td class="nump">166,867<span></span>
</td>
<td class="nump">113,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Changes in fair values of equity method investments, net</a></td>
<td class="nump">141,433<span></span>
</td>
<td class="num">(64,253)<span></span>
</td>
<td class="nump">77,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GainLossOnOtherInvestments', window );">Changes in fair values of equity and long-term investments, net</a></td>
<td class="nump">20,160<span></span>
</td>
<td class="num">(59,161)<span></span>
</td>
<td class="nump">11,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Interest and dividend income</a></td>
<td class="nump">21,086<span></span>
</td>
<td class="nump">19,141<span></span>
</td>
<td class="nump">15,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(16,698)<span></span>
</td>
<td class="num">(22,209)<span></span>
</td>
<td class="num">(19,157)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(2,864)<span></span>
</td>
<td class="num">(2,997)<span></span>
</td>
<td class="num">(4,969)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">326,862<span></span>
</td>
<td class="nump">37,388<span></span>
</td>
<td class="nump">194,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense, net</a></td>
<td class="num">(55,697)<span></span>
</td>
<td class="num">(13,996)<span></span>
</td>
<td class="num">(14,376)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income and comprehensive income</a></td>
<td class="nump">$ 271,165<span></span>
</td>
<td class="nump">$ 23,392<span></span>
</td>
<td class="nump">$ 179,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ 4.02<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used to compute net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">67,395<span></span>
</td>
<td class="nump">62,726<span></span>
</td>
<td class="nump">65,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">84,760<span></span>
</td>
<td class="nump">74,187<span></span>
</td>
<td class="nump">86,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 236,479<span></span>
</td>
<td class="nump">$ 241,733<span></span>
</td>
<td class="nump">$ 238,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">172,130<span></span>
</td>
<td class="nump">97,492<span></span>
</td>
<td class="nump">60,617<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)</a></td>
<td class="nump">77,384<span></span>
</td>
<td class="nump">36,598<span></span>
</td>
<td class="nump">41,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_LicenseAndOtherRevenueMember', window );">License and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,719<span></span>
</td>
<td class="nump">19,486<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of license revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AmortizationOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of acquired intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AmortizationOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_GainLossOnOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_GainLossOnOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LicenseAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LicenseAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Parenthetical) - Royalty Revenue - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of capitalized fees paid</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of capitalized fees paid</a></td>
<td class="nump">$ 13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 565,788<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 1,163,836<span></span>
</td>
<td class="num">$ (204,911)<span></span>
</td>
<td class="num">$ (393,829)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,005,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax', window );">Repurchase of common stock, including accrued excise tax</a></td>
<td class="num">(76,484)<span></span>
</td>
<td class="num">$ (62)<span></span>
</td>
<td class="num">(76,422)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax', window );">Repurchase of common stock, including accrued excise tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,174,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,837<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,837<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of treasury stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,173,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">179,722<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">179,722<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ProfitLossShares', window );">Net income (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">674,955<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
<td class="nump">1,093,340<span></span>
</td>
<td class="num">(25,189)<span></span>
</td>
<td class="num">$ (393,829)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,307,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,005,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</a></td>
<td class="nump">1,324<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,321<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax', window );">Repurchase of common stock, including accrued excise tax</a></td>
<td class="num">(14,925)<span></span>
</td>
<td class="num">$ (9)<span></span>
</td>
<td class="num">(14,916)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax', window );">Repurchase of common stock, including accrued excise tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(987,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability', window );">Accrued excise tax on common stock repurchase applied against tax liability</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares', window );">Accrued excise tax on common stock repurchase applied against tax liability, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">6,374<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,374<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(393,829)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 393,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,005,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">23,392<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,392<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ProfitLossShares', window );">Net income (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 691,159<span></span>
</td>
<td class="nump">$ 627<span></span>
</td>
<td class="nump">692,329<span></span>
</td>
<td class="num">(1,797)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">62,665,000<span></span>
</td>
<td class="nump">62,665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding</a></td>
<td class="nump">$ 2,410<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">2,405<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of 2025 Notes to common stock</a></td>
<td class="nump">192,475<span></span>
</td>
<td class="nump">$ 111<span></span>
</td>
<td class="nump">192,364<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible subordinated notes due 2023 (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">591,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_StockIssuedDuringPeriodValueExerciseOfWarrants', window );">Exercise of warrants</a></td>
<td class="nump">10,698<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">10,692<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax', window );">Repurchase of common stock, including accrued excise tax</a></td>
<td class="nump">4,577<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">4,575<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax', window );">Repurchase of common stock, including accrued excise tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(228,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability', window );">Accrued excise tax on common stock repurchase applied against tax liability</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares', window );">Accrued excise tax on common stock repurchase applied against tax liability, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,452<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,452<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares', window );">Stock-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">271,165<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">271,165<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ProfitLossShares', window );">Net income (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2025</a></td>
<td class="nump">$ 1,172,841<span></span>
</td>
<td class="nump">$ 747<span></span>
</td>
<td class="nump">$ 902,726<span></span>
</td>
<td class="nump">$ 269,368<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">74,636,000<span></span>
</td>
<td class="nump">74,636,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock balance (in shares) at Dec. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued excise tax on common stock repurchase applied against tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued excise tax on common stock repurchase applied against tax liability shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital share based compensation requisite service period recognition shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ProfitLossShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit Loss Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ProfitLossShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_StockIssuedDuringPeriodValueExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_StockIssuedDuringPeriodValueExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury stock shares acquired including accrued excise tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury stock value acquired cost method including accrued excise tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 271,165<span></span>
</td>
<td class="nump">$ 23,392<span></span>
</td>
<td class="nump">$ 179,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">43,847<span></span>
</td>
<td class="num">(12,617)<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment', window );">Amortization of capitalized fees and depreciation of property and equipment</a></td>
<td class="nump">13,951<span></span>
</td>
<td class="nump">13,951<span></span>
</td>
<td class="nump">13,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">26,277<span></span>
</td>
<td class="nump">25,902<span></span>
</td>
<td class="nump">21,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales', window );">Inventory fair value step-up adjustment included in cost of products sold</a></td>
<td class="nump">4,841<span></span>
</td>
<td class="nump">13,820<span></span>
</td>
<td class="nump">27,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,452<span></span>
</td>
<td class="nump">6,374<span></span>
</td>
<td class="nump">5,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">1,887<span></span>
</td>
<td class="nump">2,110<span></span>
</td>
<td class="nump">2,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Changes in fair values of equity method investments, net</a></td>
<td class="num">(141,433)<span></span>
</td>
<td class="nump">64,253<span></span>
</td>
<td class="num">(77,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_UnrealizedOtherGainLossOnInvestments', window );">Changes in fair values of equity and long-term investments, net</a></td>
<td class="num">(20,160)<span></span>
</td>
<td class="nump">59,161<span></span>
</td>
<td class="num">(11,129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AcquiredIn-ProcessResearchAndDevelopmentAssets', window );">Acquired in-process research and development assets</a></td>
<td class="nump">9,368<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">1,897<span></span>
</td>
<td class="num">(722)<span></span>
</td>
<td class="num">(517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(14,574)<span></span>
</td>
<td class="num">(5,938)<span></span>
</td>
<td class="num">(5,053)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent', window );">Receivables from collaboration arrangements</a></td>
<td class="nump">7,623<span></span>
</td>
<td class="nump">3,647<span></span>
</td>
<td class="num">(14,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(12,919)<span></span>
</td>
<td class="num">(6,808)<span></span>
</td>
<td class="num">(12,004)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="num">(5,658)<span></span>
</td>
<td class="nump">567<span></span>
</td>
<td class="nump">7,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(1,078)<span></span>
</td>
<td class="num">(38,186)<span></span>
</td>
<td class="num">(2,965)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,834<span></span>
</td>
<td class="num">(4,585)<span></span>
</td>
<td class="nump">3,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued personnel-related expenses and other accrued liabilities</a></td>
<td class="num">(5,790)<span></span>
</td>
<td class="nump">3,044<span></span>
</td>
<td class="num">(1,498)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest payable</a></td>
<td class="num">(1,804)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(937)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">3,144<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="num">(817)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payable</a></td>
<td class="nump">4,060<span></span>
</td>
<td class="nump">41,476<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">196,930<span></span>
</td>
<td class="nump">188,690<span></span>
</td>
<td class="nump">141,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of trading securities</a></td>
<td class="num">(60,899)<span></span>
</td>
<td class="num">(59,617)<span></span>
</td>
<td class="num">(65,132)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForTradingSecurities', window );">Proceeds from trading securities</a></td>
<td class="nump">8,427<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchases of equity and long-term investments</a></td>
<td class="num">(17,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchasesOfEquityInvestmentsManagedByIspFundLp', window );">Purchases of equity investments managed by ISP Fund LP</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(32,270)<span></span>
</td>
<td class="num">(31,164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SaleOfEquityInvestmentsManagedByIspFundLp', window );">Sales of equity investments managed by ISP Fund LP</a></td>
<td class="nump">28,164<span></span>
</td>
<td class="nump">75,756<span></span>
</td>
<td class="nump">72,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp', window );">Purchases and sales of other investments managed by ISP Fund LP, net</a></td>
<td class="nump">92,791<span></span>
</td>
<td class="num">(43,486)<span></span>
</td>
<td class="num">(41,336)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Cash paid for in-process research and development assets acquired</a></td>
<td class="num">(9,368)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,131)<span></span>
</td>
<td class="num">(270)<span></span>
</td>
<td class="num">(411)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sale of property and equipment</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">40,496<span></span>
</td>
<td class="num">(63,786)<span></span>
</td>
<td class="num">(66,761)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(4,532)<span></span>
</td>
<td class="num">(14,777)<span></span>
</td>
<td class="num">(75,728)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase of shares to satisfy tax withholding</a></td>
<td class="num">(143)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuances of common stock, net</a></td>
<td class="nump">2,553<span></span>
</td>
<td class="nump">1,466<span></span>
</td>
<td class="nump">170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">10,698<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">8,551<span></span>
</td>
<td class="num">(13,453)<span></span>
</td>
<td class="num">(171,839)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">245,977<span></span>
</td>
<td class="nump">111,451<span></span>
</td>
<td class="num">(97,536)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">304,964<span></span>
</td>
<td class="nump">193,513<span></span>
</td>
<td class="nump">291,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">550,941<span></span>
</td>
<td class="nump">304,964<span></span>
</td>
<td class="nump">193,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow Information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">10,353<span></span>
</td>
<td class="nump">10,359<span></span>
</td>
<td class="nump">11,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">19,113<span></span>
</td>
<td class="nump">11,793<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">2025 Notes converted to common stock</a></td>
<td class="nump">192,475<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedInterestIncomeIncludedInLongTermInvestments', window );">Accrued interest income converted to long-term investments</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">3,584<span></span>
</td>
<td class="nump">2,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_ConvertibleSubordinatedNotes2023Member', window );">Convertible subordinated notes due 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(96,204)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_ConvertibleSeniorNotes2025Member', window );">Convertible senior notes due 2025 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of convertible notes</a></td>
<td class="num">$ (25)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedInterestIncomeIncludedInLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest income included in long-term investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedInterestIncomeIncludedInLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AcquiredIn-ProcessResearchAndDevelopmentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in-process research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AcquiredIn-ProcessResearchAndDevelopmentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of capitalized fees and depreciation of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory fair value step-up adjustment included in cost of product sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase and sale of other investments managed by ISP FUND LP, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchasesOfEquityInvestmentsManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of Equity Investments Managed by Isp Fund Lp</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchasesOfEquityInvestmentsManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SaleOfEquityInvestmentsManagedByIspFundLp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of equity investments managed by ISP FUND LP</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SaleOfEquityInvestmentsManagedByIspFundLp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_UnrealizedOtherGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized other gain loss on investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_UnrealizedOtherGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due within one year (or one business cycle) of receivables that were originally due beyond one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from sales and purchases of trading securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_ConvertibleSubordinatedNotes2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_ConvertibleSubordinatedNotes2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_ConvertibleSeniorNotes2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_ConvertibleSeniorNotes2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management, Strategy and Governance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITEM 1C.   CYBERSECURITY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Risk Management and Strategy</span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conduct risk assessments to identify cybersecurity threats at least annually, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We devote internal and external resources and designate high-level personnel to manage the risk assessment and mitigation process.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, in collaboration with human resources, IT, legal, and management. Personnel at all levels and departments are made aware of our cybersecurity policies through trainings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We engage internal auditors and other third parties in connection with our risk assessment processes. These service providers assist us in designing and implementing our cybersecurity policies and procedures, as well as to monitor and test our safeguards.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, we did not identify any risks from known cybersecurity threats, including because of any prior cybersecurity incidents, that have materially affected us. However, in the future, we may face certain ongoing cybersecurity risks or threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the heading &#8220;Our operations could be disrupted by failure of our information systems or cyber-attacks.&#8221;</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Governance</span></p><div style="font-size:10pt;font-family:Times New Roman;"><div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive team, primarily consisting of our Chief Accounting Officer, Chief Financial Officer, and Chief Executive Officer, in conjunction with our information security team and third-party consultants, is primarily responsible in assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The qualifications of our executive and information security teams include a combination of formal education, current trainings and certifications in systems, network, and cybersecurity and over 50 years of combined experience in information technology and cybersecurity matters.</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">They oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.  The processes by which the executive team is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents includes the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">They provide briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, they provide briefings of any significant cybersecurity matters to the board of directors as well as an annual update of cybersecurity risks and activities.</span></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, we did not identify any risks from known cybersecurity threats, including because of any prior cybersecurity incidents, that have materially affected us. However, in the future, we may face certain ongoing cybersecurity risks or threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#8220;Risk Factors,&#8221; under the heading &#8220;Our operations could be disrupted by failure of our information systems or cyber-attacks.&#8221;</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive team, primarily consisting of our Chief Accounting Officer, Chief Financial Officer, and Chief Executive Officer, in conjunction with our information security team and third-party consultants, is primarily responsible in assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The qualifications of our executive and information security teams include a combination of formal education, current trainings and certifications in systems, network, and cybersecurity and over 50 years of combined experience in information technology and cybersecurity matters.</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">They oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.  The processes by which the executive team is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents includes the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">They provide briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, they provide briefings of any significant cybersecurity matters to the board of directors as well as an annual update of cybersecurity risks and activities.</span></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive team, primarily consisting of our Chief Accounting Officer, Chief Financial Officer, and Chief Executive Officer, in conjunction with our information security team and third-party consultants, is primarily responsible in assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The qualifications of our executive and information security teams include a combination of formal education, current trainings and certifications in systems, network, and cybersecurity and over 50 years of combined experience in information technology and cybersecurity matters.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our executive team, primarily consisting of our Chief Accounting Officer, Chief Financial Officer, and Chief Executive Officer, in conjunction with our information security team and third-party consultants, is primarily responsible in assessing and managing our material risks from cybersecurity threats.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">They oversee our cybersecurity policies and processes, including those described in &#8220;Risk Management and Strategy&#8221; above.  The processes by which the executive team is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents includes the following:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">They provide briefings to the audit committee regarding our company&#8217;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, they provide briefings of any significant cybersecurity matters to the board of directors as well as an annual update of cybersecurity risks and activities.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_Rule10B51ArrModifiedFlag', window );">Rule 10b51Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NonRule10B51ArrModifiedFlag', window );">Non Rule 10b51 Arrangement Modified</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NonRule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non Rule 10B51 Arr Modified Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NonRule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_Rule10B51ArrModifiedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rule 10b51 Arr Modified Flag.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_Rule10B51ArrModifiedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Operations and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1.  DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Operations</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#8220;Innoviva&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar pronouns) is a diversified biopharmaceutical company with a portfolio of royalties, a critical care and infectious disease platform, and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (umeclidinium bromide/ vilanterol, &#8220;UMEC/VI&#8221;). Under the Long-Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as follows: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion; and royalties from the sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which tier upward at a range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our wholly owned, critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, commercially launched in 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(eravacycline) for the treatment of complicated intra-abdominal infections in adults;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">staphylococcus aureus bacteremia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including those with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia, licensed from Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) (&#8220;Basilea&#8221;) for U.S. commercialization and commercially launched in the third quarter of 2025; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (formerly known as zoliflodacin), approved by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we own other strategic healthcare assets, such as a significant stake in Armata Pharmaceuticals, Inc., a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies through our portfolio approach.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income and comprehensive income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Management&#8217;s Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#8220;API&#8221;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currently, we derive the majority of our revenues from GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our analysts&#8217; or investors&#8217; expectations due to a number of important factors.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenues also include net product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which we commercially launched in the third quarter of 2025. In the U.S., hospitals and other healthcare organizations generally acquire our products through a network of specialty distributors, which are regarded as our customers for accounting purposes. We do not believe that the loss of any one of these distributors would significantly impact our ability to distribute our products, as we expect that the sales volume would be absorbed by either new or remaining distributors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our top three customers each account for approximately:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our net product sales for the year ended December 31, 2025; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our net product sales for the year ended December 31, 2024; and,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our net product sales for the year ended December 31, 2023. </span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> customers for the year ended December 31, 2025 account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivable&#8221; in our consolidated balance sheet as of December 31, 2025. Our top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> customers for the year ended December 31, 2024 account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables&#8221; in our consolidated balance sheet as of December 31, 2024.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. Refer to Note 16, &#8220;Segment Reporting&#8221;, for more segment information.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Variable Interest Entities</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#8217;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventory</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.</span></p></div><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our property and equipment consist of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation, and are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
         <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
          <tr style="visibility:collapse;">
           <td style="width:49.17%;box-sizing:content-box;"></td>
           <td style="width:1.66%;box-sizing:content-box;"></td>
           <td style="width:49.17%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software and computer equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span></p></td>
          </tr>
         </table></div></div><div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity and Long-Term Investments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of equity and long-term investments, net, within the consolidated statements of income and comprehensive income.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we conclude that we do not have the ability to exercise significant influence over an investee, we may elect to account for equity security without a readily determinable fair value using the measurement alternative method under ASC 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This method allows us to measure the investment at cost less impairment, if any, and adjusted for observable price changes in orderly transactions involving the same or a similar investment of the same issuer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also invest in ISP Fund LP, whose investments consist of money market funds, trading securities, and equity securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered into in December 2020, we became a limited partner of the partnership. In October 2024, we elected to unwind our capital accounts in the partnership in accordance with the terms of the Partnership Agreement and expect to receive distributions through April 2026. Accordingly, the portion of the cash balance and money market funds expected to be distributed within 12 months from the balance sheet date has been classified as &#8220;Current portion of ISP Fund investments,&#8221; while the remaining equity investments have been classified as long-term investments in the consolidated balance sheets as of December 31, 2025 and 2024.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Quoted prices for identical instruments in active markets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Unobservable inputs and little, if any, market activity for the assets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalized Fees Paid</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#8220;Capitalized Fees&#8221;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#8217;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill and Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with an indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Acquisitions</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure and recognize asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost of the acquisition is allocated to the assets acquired on the basis of their relative fair values. The cost allocated to acquire in-process research and development (&#8220;IPR&amp;D&#8221;) with no alternative future use is charged to research and development expense at the acquisition date.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p></div><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 606&#8221;), to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on their own methodology and assumptions for estimating rebates and returns, which they monitor and adjust regularly in light of contractual and legal obligations, historical trends, past experience, and projected market conditions. Our partner may make significant adjustments to its reported sales based on actual results, which could cause fluctuation in our royalty revenue. We have rights to conduct periodic royalty audits to evaluate the accuracy of the information provided. Royalties from GSK are recognized as the net of amortization of capitalized fees related to approval and launch milestone payments made to GSK.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Product Sales</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#8217; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#8220;GPO&#8221;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired products. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each state&#8217;s eligibility guidelines and services. Under these programs, we pay rebates to participating states, typically within three months after the quarter in which the product was sold. Additionally, we may offer customer incentives and other forms of consideration, such as volume-based or performance-based rebates. Estimated rebates are recorded as a reduction of revenue on delivery to our customers.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also enter into contracts that involve a series of manufacturing processes for products and related components. For any distinct performance obligation where the manufacturing process does not create an asset with alternative use and there is an enforceable right to payment for the performance completed to date, the related revenue is recognized over time. For these performance obligations satisfied over time, we use an input method to measure progress. Specifically, we apply the cost-to-cost method, under which progress is calculated as the ratio of costs incurred to date relative to the total estimated costs of the contract. This method most accurately depicts the transfer of value to the customer because costs incurred are determined to be proportionate to our performance in satisfying the obligation. Estimated total contract costs are reassessed periodically. Changes in estimates are accounted for prospectively as changes in estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of a licensing arrangement that includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price. We generally include these milestone payments in the transaction price when they are achieved because there is considerable uncertainty in the research and development processes that trigger receipt of these payments under our agreements. Similarly, we include approval milestone payments in the transaction price once the product is approved by the applicable regulatory agency. For delivery of other goods or services related to a licensing arrangement, we determine whether the performance obligation is satisfied over time or at a point in time. If the performance obligation is satisfied over time, we use judgment in determining the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize grant revenue from non-governmental entities in accordance with ASC 958-605, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition Not-for-Profit Entities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, when qualifying costs are incurred and the conditions of the grant agreement have been met. If grant funds are received after costs have been incurred, we record the amount as grant revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as grant revenue when qualifying costs are incurred. Grant revenue is included in &#8220;License and other revenue&#8221; in our consolidated statements of income and comprehensive income.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense on Deferred Royalty Obligation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#8220;Debt&#8221;, for more information.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Stock&#8209;Based Compensation Awards</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#8220;ESPP&#8221;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#8220;simplified&#8221; method as described in Staff Accounting Bulletin No. 107, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#8221; for the expected option term. We use our historical volatility to estimate expected stock price volatility.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) are measured based on the fair market values of the underlying stock on the dates of grant.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#8217;s best estimate as to whether it is probable that the shares awarded are expected to vest.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#8220;more likely than not&#8221; standard.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related Parties</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sarissa Capital owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our outstanding common stock as of December 31, 2024. Transactions with Sarissa Capital are described in Note 5, &#8220;Consolidated Entity&#8221;. Sarissa Capital was considered to be a related party up until the annual stockholders meeting in May 2025 after which there were no representatives of Sarissa Capital serving on our Board of Directors.</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The ASU requires the disclosure of income taxes paid disaggregated by jurisdiction and enhanced disclosures for the entity&#8217;s effective tax rate reconciliation as well as other income tax related disclosures. We adopted this guidance prospectively as of January 1, 2025, which resulted in additional disclosures in the notes to our consolidated financial statements. Accordingly, prior periods were not retrospectively adjusted. See Note 15, &#8220;Income Taxes.&#8221;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement &#8212; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires disclosures about specific types of expenses included in the expense captions presented on the face of the statement of income as well as disclosures about selling expenses. ASU 2024-03 is effective for the Company in annual reporting periods beginning after December 15, 2027, and interim reporting periods beginning after December 15, 2027. We are currently evaluating the potential impact that ASU 2024-03 may have on our financial statement disclosures.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which clarifies the assessment of whether a transaction should be accounted for as an induced conversion or extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. ASU 2024-04 is effective for annual reporting periods beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. We are currently evaluating the potential impact that ASU 2024-04 may have on our financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, the FASB issued ASU 2025-05, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses for Current Accounts Receivable and Contract Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which provides a practical expedient for estimating expected credit losses by assuming current conditions remain unchanged over the life of the asset. The amendments in ASU 2025-05 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the potential impact that ASU 2025-05 may have on our estimation methodologies.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the FASB issued Update ASU 2025-11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim Reporting (Topic 270): Narrow-Scope Improvements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ASU intends to clarify and improve existing interim reporting guidance by consolidating disclosure requirements within Topic 270 and introducing a disclosure principle requiring entities to disclose events and changes occurring after the most recent annual reporting period that are expected to have a material effect on the entity&#8217;s financial condition or results of operations. This ASU does not introduce significant changes to recognition or measurement guidance. The amendments in this Update are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the potential impact that ASU 2025-11 may have on our financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the FASB issued ASU 2025-12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Codification Improvements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which provides technical corrections, clarifications, and other minor improvements across a number of Topics. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently evaluating the potential impact of ASU 2025-12 on our consolidated financial statements and disclosures.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2.  NET INCOME PER SHARE</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding. Diluted net income per share is computed by dividing net income by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the &#8220;2023 Notes&#8221;) up until its maturity date on January 15, 2023, our convertible senior notes due 2025 (the &#8220;2025 Notes&#8221;) up until its maturity date on August 15, 2025, and our convertible senior notes due 2028 (the &#8220;2028 Notes&#8221;) using the if-converted method. If the results are in a net loss position, diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common stock equivalents.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the computation of basic and diluted net income per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands except per share data)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income, basic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,165</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">179,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: interest expense on 2023 Notes, net of tax effect</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: interest expense on 2025 Notes, net of tax effect</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,882</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,468</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,116</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: interest expense on 2028 Notes, net of tax effect</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,776</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income, diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">279,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,860</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191,304</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute basic net income<br/>&#160;&#160;&#160;per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,395</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,726</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,435</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of 2023 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of 2025 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,900</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of 2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of options and awards granted under equity<br/>&#160;&#160;&#160;incentive plan and employee stock purchase plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">149</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of outstanding warrant</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute diluted net income<br/>&#160;&#160;&#160;per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,760</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,187</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income per share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.02</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.37</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.75</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.30</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.36</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.20</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Anti&#8209;dilutive Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#8209;dilutive for the periods presented:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.28%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding options and awards granted under equity incentive<br/>&#160;&#160;&#160;plan and employee stock purchase plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,535</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,196</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,333</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding stock warrant</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding 2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,535</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,742</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3.  REVENUE RECOGNITION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Revenue from Collaboration Arrangement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are entitled to receive royalties from GSK with respect to RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net revenue recognized under our GSK Agreements was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties &#8211; RELVAR/BREO</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204,021</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,925</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,042</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties &#8211; ANORO</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,281</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,631</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total royalties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,302</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255,556</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,669</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: amortization of capitalized<br/>&#160;&#160;&#160;fees paid</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total royalty revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">236,479</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">241,733</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,846</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">LABA Collaboration</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As a result of the launch and approval of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization is recorded as a reduction to the royalties from GSK.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are entitled to receive annual royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as follows: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion. Sales of single&#8209;agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, royalties are upward tiering and range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Net Product Sales</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total net product sales were as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,611</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,037</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,294</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,393</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,070</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,003</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,516</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,385</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,320</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">610</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Total net product sales</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172,130</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,617</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We derived our net product sales:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from customers located in the U.S. and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from the rest of the world for the year ended December 31, 2025; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from customers located in the U.S. and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from the rest of the world for the year ended December 31, 2024; and, </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from customers located in the U.S. and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% from the rest of the world for the year ended December 31, 2023.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License and Other Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Refer to the out-license agreement with Zai Lab and Everest and the Grant Agreement with Gates Foundation in Note 4, &#8220;License, Collaboration and Other Arrangements&#8221;.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LicenseCollaborationAndOtherArrangementsTextBlock', window );">LICENSE, COLLABORATION AND OTHER ARRANGEMENTS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4. LICENSE, COLLABORATION AND OTHER ARRANGEMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Out-License Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Zai Lab</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entasis Therapeutics Holdings Inc. (&#8220;Entasis&#8221;), our wholly-owned subsidiary, entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. (&#8220;Zai Lab&#8221;) (Nasdaq: ZLAB), pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR, in the Asia-Pacific region (&#8220;the Zai Agreement&#8221;). Under the terms of the Zai Agreement, Zai Lab shall fund most of the registrational clinical trial costs in China for SUL-DUR, with the exception of Phase 3 patient drug supply of licensed products. Zai Lab shall conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and shall commercialize licensed products for which it has obtained regulatory approval. We are obligated to supply Zai Lab with the licensed products for clinical development and for commercial use for a certain period unless Zai Lab notifies otherwise. Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">are eligible to receive up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab shall pay us a tiered royalty ranging from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. Payments received for research support and reimbursable clinical trial costs are recorded as a reduction to research and development expense during the period in which the qualifying expenses are incurred.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Such amounts recorded for the years ended December 31, 2025, 2024 and 2023 were not material. SUL-DUR was approved by China&#8217;s National Medical Products Administration in May 2024, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and was launched by Zai Lab in mainland China in January 2025. Royalties under this arrangement based on the product sales was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year ended December 31, 2025. W</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in license revenue for the year ended December 31, 2024 under this agreement as a result of the achievement of a regulatory milestone. Following the approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> by the FDA in May 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in license revenue for the year ended December 31, 2023 under this agreement.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, we entered into an amendment to the Zai Agreement (the &#8220;Amended Zai Agreement&#8221;), pursuant to which Zai Lab shall share costs associated with certain new manufacturing and technology transfer activities for XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(the &#8220;Services&#8221;), which were not contemplated under the Zai Agreement and are crucial for regulatory approval in the Asia-Pacific region.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Under the Amended Zai Agreement, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in license and other revenue for the years ended December 31, 2025 and 2024, respectively, of which </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were included in &#8220;Accounts receivable&#8221; in our consolidated balance sheets as of December 31, 2025 and 2024, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into an interim supply agreement with Zai Lab in June 2024, which was amended in February 2025 and August 2025, under which Zai Lab shall purchase XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inventory (the &#8220;Supplied Inventory&#8221;) at cost for their commercial use. We recognized </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mil</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">lion and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net product sales for the cost of the Supplied Inventory for the years ended December 31, 2025 and 2024, respectively, of which $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million were included in &#8220;Accounts receivable&#8221; in our consolidated balance sheets as of December 31, 2025 and 2024, respectively. Advance payments received under this agreement of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as of December 31, 2024 was recorded as other accrued liabilities pending finalization of the February and August 2025 amendments mentioned above.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also entered into a manufacturing stage transfer agreement with Zai Lab in June 2024, which was amended in September 2024 (the &#8220;Zai Manufacturing Stage Transfer Agreement&#8221;). Pursuant to this agreement, Entasis shall provide assistance to Zai Lab for building out Zai Lab&#8217;s manufacturing site for XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and be compensated for Entasis' services and associated costs. We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in license and other revenue for the years ended December 31, 2025 and 2024, respectively, under the Zai Manufacturing Stage Transfer Agreement.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">GARDP</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entasis entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership (&#8220;GARDP&#8221;) for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries (&#8220;the GARDP Collaboration Agreement&#8221;). Under the terms of the GARDP Collaboration Agreement, GARDP shall use commercially reasonable endeavors to perform and fully fund the Phase 3 registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in reimbursements from GARDP under this agreement as a reduction to research and development expense during the year ended December 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We recorded immaterial reimbursements from GARDP as a reduction to research and development expense during the years ended December 31, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, under the GARDP Collaboration Agreement, GARDP was granted a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use our zoliflodacin technology in connection with GARDP&#8217;s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. We retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. We also retained the right to use and grant licenses to our zoliflodacin technology to perform our obligations under the GARDP Collaboration Agreement and for any purpose other than gonorrhea or community-acquired indications. If we believe that the results of the Phase 3 registrational trial of zoliflodacin would be supportive of an application for marketing approval, we are obligated to use our best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the European Medicines Agency (&#8220;EMA&#8221;). Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories. An application for marketing approval has been filed with the FDA in 2025. The FDA approved zoliflodacin, marketed as NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, on December 12, 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PAION Pharma GmbH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the PAION AG and PAION Deutschland GmbH (together and individually &#8220;PAION&#8221;) License, La Jolla Pharmaceutical Company (&#8220;La Jolla&#8221;), our wholly-owned subsidiary, granted PAION an exclusive license to commercialize GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the European Economic Area, the United Kingdom and Switzerland (collectively, the &#8220;PAION Territory&#8221;). PAION is currently a subsidiary of the Humanwell Healthcare Group. We are entitled to receive potential commercial milestone payments of up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">109.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and double-digit tiered royalty payments. Royalties payable in a given jurisdiction under the PAION License are subject to reduction on account of generic competition and after patent expiration in that jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the PAION Territory. We have not recognized any revenue from PAION related to commercial milestones. Royalty revenue recognized under this agreement for the year ended December 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Royalty revenue recognized under this agreement for the year ended December 31, 2023 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">La Jolla also entered into the PAION commercial supply agreement (the &#8220;PAION Supply Agreement&#8221;) whereby La Jolla supplies PAION a minimum quantity of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> until the earlier of July 13, 2027, or until a new supply agreement is executed. During the term of the supply agreement, we are reimbursed for direct and certain indirect manufacturing costs at cost. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in cost reimbursements under this agreement for the years ended December 31, 2025 and 2023, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost reimbursements recognized under this agreement for </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the years ended December 31, 2024 were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Everest Medicines Limited</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Everest Medicines Limited (&#8220;Everest&#8221;) License, La Jolla granted Everest an exclusive license to develop and commercialize XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the treatment of complicated intra-abdominal infections (&#8220;cIAI&#8221;) and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the &#8220;Everest Territory&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Everest License, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in license revenue for the year ended December 31, 2023 as a result of an achievement of a regulatory milestone during the period. We are eligible to receive additional sales milestone payments of up to an aggregate of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years after the first commercial sale of a product in such jurisdiction in the Everest Territory.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Royalty revenue recognized under this agreement for the years ended December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, 2024 and 2023 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">La Jolla also entered into the Everest commercial supply agreement (the &#8220;Everest Supply Agreement&#8221;) whereby La Jolla will supply Everest a minimum quantity of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and will transfer to Everest certain XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-related manufacturing know-how. Under the Everest Supply Agreement, we are reimbursed for direct and certain indirect manufacturing costs at </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">110</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of cost. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> W</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in revenue under this agreement for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">In-License Agreements</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basilea</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we entered into an exclusive distribution and license agreement with Basilea, under which we were granted exclusive marketing rights to ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. The agreement will remain in effect through the expiration of ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s market exclusivity in the U.S. in 2034 (the &#8220;initial term&#8221;) and is subject to automatic renewal unless terminated by either party with prior notice. We paid an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was recognized as an intangible asset and is being amortized over the initial term of the agreement. Under the agreement, we are required to exclusively purchase ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (in pre-packaging and labeling form) from Basilea for the duration of the term. We are also obligated to pay Basilea tiered royalties ranging from the high-teens to mid-twenties, as well as tiered milestone payments based on annual net sales in the U.S. ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was commercially launched in the U.S. in July 2025. Royalty expense incurred on the sales was immaterial during the year ended December 31, 2025. There were no royalties or sales milestone payments for the year ended December 31, 2024.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">George Washington University</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the George Washington University License (the &#8220;GW License&#8221;), GW exclusively licensed to La Jolla certain intellectual property rights relating to GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Under the GW License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We are obligated to pay a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under the GW License extends through the last-to-expire patent covering GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Royalty expense incurred under the GW License were </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> m</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">illion, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Harvard University</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Harvard University (&#8220;Harvard&#8221;) License, Harvard exclusively licensed to La Jolla certain intellectual property rights relating to tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For each product covered by the Harvard License, we are obligated to make certain payments for the following: (i) up to approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain clinical development and regulatory milestones; (ii) a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on direct U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, starting at a minimum royalty rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, with step-ups to a maximum royalty of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% based on the achievement of annual net product sales thresholds; and (iv) </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Royalty expense incurred under the Harvard License for each of the years ended December 31, 20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> mill</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ion. For the year ended December 31, 2023, we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as cost of license revenue under this agreement as a result of the license revenue we earned under the out-licensing agreement with Everest for the same period.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Transfer and Subscription Agreement with AstraZeneca</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Entasis </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">entered into a Business Transfer and Subscription Agreement with AstraZeneca, AstraZeneca UK Limited and AstraZeneca Pharmaceuticals LP (collectively, &#8220;AstraZeneca&#8221;) (the &#8220;AstraZeneca Agreement&#8221;) in 2015, which was amended and restated through 2018, pursuant to which Entasis obtained, among other things, worldwide rights to durlobactam and zoliflodacin. Under the AstraZeneca Agreement, we are obligated to pay AstraZeneca a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">three months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of achieving a specified cumulative net sales milestone for durlobactam. We are also obligated to pay AstraZeneca a one-time milestone payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of achieving the first commercial sale of zoliflodacin. Additionally, we are obligated to pay AstraZeneca tiered, single-digit royalties on the annual worldwide net product sales of durlobactam and, the lesser of tiered, single-digit royalties on the worldwide annual net sales of zoliflodacin and a specified share of the royalties we receive from sublicensees of zoliflodacin. Royalties on sales of zoliflodacin do not include sales by GARDP in low-income and specified middle-income countries as discussed above. Our obligation to make these royalty payments expires on a country-by-country basis for each product upon the later of (i) the 10-year anniversary of the first commercial sale of a product in that country or (ii) the expiration date of the last patent right covering the product in that country.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The royalty expense in respect of durlobactam arising from our net product sales of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:2.68pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> for the years ended December 31, 2025, 2024 and 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Massachusetts Institute of Technology</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the asset acquisition described in Note 14, &#8220;Asset Acquisition&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, in September 2025, we entered into a license agreement with Massachusetts Institute of Technology (&#8220;MIT&#8221;), under which MIT licensed to us certain patent rights relating to a drug delivery device. Under this agreement, we paid an upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and are obligated to pay a minimal annual maintenance fee. We are also obligated to pay MIT up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in development, regulatory and sales milestone payments, and pay royalties in a low single-digit percentage on future net sales related to the licensed product.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Paratek Pharmaceuticals, Inc.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the Paratek Pharmaceuticals, Inc. (&#8220;Paratek&#8221;) License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including non-exclusive rights to certain issued patents and patent applications covering XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We were obligated to pay Paratek a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty based on direct U.S. net sales of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our obligation to pay royalties with respect to the licensed product was retroactive to the date of the first commercial sale of XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and continued until there were no longer any valid claims of the Paratek patents, which expired in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">October 2023</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. For the year ended December 31, 2023, amounts recognized under this agreement were not material.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Agreement with Gates Foundation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2025, we entered into a grant agreement with Gates Foundation, under which Gates Foundation shall fund up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in qualifying expenses through January 2027 toward the development of a certain product candidate. We received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, of which we recognized $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million as grant revenue included in &#8220;License and other revenue&#8221; in our consolidated financial statements for the year ended December 31, 2025. The remaining balance of the upfront payment is recorded as deferred revenue included in &#8220;Other accrued liabilities&#8221; in our consolidated balance sheet as of December 31, 2025.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_LicenseCollaborationAndOtherArrangementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of license collaboration and other arrangements .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_LicenseCollaborationAndOtherArrangementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Entities and Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesDisclosureAbstract', window );"><strong>Consolidated Entities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntityTextBlock', window );">CONSOLIDATED ENTITY</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5. CONSOLIDATED ENTITY</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ISP Fund LP</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2020 and 2021, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#8220;Strategic Partners&#8221;), contributed a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to ISP Fund LP (the &#8220;Partnership&#8221;) for investing in &#8220;long&#8221; positions in the healthcare, pharmaceutical and biotechnology sectors, and became a limited partner. The general partner of the Partnership (&#8220;General Partner&#8221;) is an affiliate of Sarissa Capital.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Partnership Agreement provides for Sarissa Capital to receive management fees from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners&#8217; capital account in the Partnership. In addition, General Partner is entitled to an annual performance fee based on the Net Profits of the Partnership during the annual measurement period.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consolidate ISP Fund LP under the VIE model as we have determined that ISP Fund LP is a VIE and we are the primary beneficiary of the entity. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ISP Fund LP is determined to be an investment company under ASC 946, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Services &#8211; Investment Companies</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as it meets all fundamental characteristics of an investment company, and its activities are consistent with those of an investment company. Since ISP Fund LP is subject to investment company industry specific guidance, we have retained the industry-specific guidance applied by the Partnership. In addition, as our investment in the Partnership is a passive investment for the Company and is not part of our main operations, the investments are presented as part of &#8220;Equity and long-term investments&#8221; in our consolidated balance sheets. In October 2024, Strategic Partners made an election to unwind its capital accounts in the Partnership in accordance with the terms of the Partnership Agreement. Accordingly, a portion of our investments, which consist of cash and money market funds that we expect to be distributed within 12 months from the balance sheet date, were classified as &#8220;Current portion of ISP Fund investments&#8221; in the consolidated balance sheets as of December 31, 2025 and 2024, and the remaining equity investments managed by ISP Fund LP are expected to be distributed through April 2026. We received cash distributions of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">121.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the year ended December 31, 2025. We report in our consolidated statements of income and comprehensive income any investment gains and losses by the Partnership as part of &#8220;Changes in fair value of equity and long-term investments, net&#8221;, any interest and dividend income as part of &#8220;Interest and dividend income&#8221; and any investment expenses as part of &#8220;Other expense, net&#8221;.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we continue to hold </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the economic interest of the Partnership. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, total assets of the Partnership were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">with the majority attributable to either current portion of ISP Fund investment or to equity and long-term investments. As of December 31, 2025 and 2024, total liabilities of the Partnership were $</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">0.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Partnership</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s assets can only be used to settle its own obligations.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2025, the Partnership incurred</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million in net investment-related expenses, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million interest incom</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e, recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net realized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net unrealized gains as changes in fair values of equity and lon</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">g-term investments, net, in the consolidated statements of income and comprehensive income. During the year ended December 31, 2024, the Partnership incurred</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million in net investment-related expenses, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million interest income, recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net realized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statements of income </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and comprehensive income. During the year ended December 31, 2023, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the Partnership incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net investment-related expenses, generated $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million interest income, recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net realized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statements of income </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of individual investments held by ISP Fund at each balance sheet date:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:61.232%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.603%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.603%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">In thousands</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock - Publicly traded healthcare companies</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,039</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,874</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,989</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,266</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock - Privately held healthcare companies</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,748</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants - Privately held healthcare companies</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,507</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund and cash</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,727</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,532</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total investments held by ISP Fund LP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,741</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255,658</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConsolidatedEntitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConsolidatedEntitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConsolidatedEntityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConsolidatedEntityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6. EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity and Other Investments in Armata</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the first quarter of 2020, Innoviva and its wholly owned subsidiary, Innoviva Strategic Opportunities, LLC (&#8220;ISO&#8221;), have invested in the common stock, warrants, convertible note, and term loans of Armata Pharmaceuticals, Inc. (&#8220;Armata&#8221;), a clinical stage biotechnology company focused on development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the first quarter of 2021, Armata entered into a voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of Armata&#8217;s common stock for voting on the matters related to election or removal of Armata&#8217;s board members. The voting agreement will expire on the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 9, 2022, Armata entered a second amended and restated voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the total number of shares of Armata&#8217;s common stock for voting on the matters related to election or removal of Armata&#8217;s board members or amend the bylaws of Armata to reduce the maximum number of directors or set the number of directors who may serve on the board of Armata. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the outstanding shares of Armata&#8217;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#8217;s board of directors, and for so long as the Company and ISO hold at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, but less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, of the outstanding shares of Armata&#8217;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#8217;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2023, Armata entered into an amendment to the amended and restated investor rights agreement with the Company and ISO, pursuant to which the Company and ISO agreed that the voting agreement will expire on the earlier of the fifth anniversary of the original agreement&#8217;s effective date, January 26, 2021, or the approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#8220;Credit Agreement&#8221;) with Armata, under which we invested in a </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">one-year</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> convertible note (the &#8220;Armata Convertible Note&#8221;) in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million at an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Pursuant to the Credit Agreement, the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, will convert into shares of Armata</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8217;s common stock upon the occurrence of a qualified financing, as defined in the Credit Agreement. Any portion of the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, may also be converted into shares of Armata&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s common stock at our option once a registration statement covering the resale of such securities has been declared effective by the SEC. The Armata Convertible Note is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries. On July 10, 2023, ISO and Armata executed an amendment to the Armata Convertible Note extending the maturity date from January 10, 2024 to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 10, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. On November 12, 2024, ISO and Armata executed an amendment to the Armata Convertible Note extending the maturity date from January 10, 2025 to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 10, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On July 10, 2023, ISO and Armata entered into a Credit and Security Agreement (the &#8220;July 2023 Credit and Security Agreement"), under which we extended a term loan to Armata (the &#8220;Armata July 2023 Term Loan&#8221;) in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Armata July 2023 Term Loan is subject to an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum and is due to mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 10, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The July 2023 Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries. On November 12, 2024, ISO and Armata executed an amendment to the Armata July 2023 Term Loan extending the maturity date from January 10, 2025 to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 10, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 4, 2024, ISO and Armata entered into a Credit and Security Agreement (the &#8220;March 2024 Credit and Security Agreement&#8221;), under which we extended a term loan to Armata (the &#8220;Armata March 2024 Term Loan&#8221;) in an aggregate amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Armata March 2024 Term Loan is subject to an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum and is originally set to mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">June 4, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The March 2024 Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 12, 2025, ISO and Armata entered into a Credit and Security Agreement, under which ISO extended a term loan to Armata (the &#8220;Armata March 2025 Term Loan&#8221;) in a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Armata March 2025 Term Loan bears interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum and matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 12, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Credit and Security Agreement is secured by substantially all assets of Armata and its domestic and foreign material subsidiaries. Concurrently, ISO extended the maturity date of the Armata Convertible Note and the Armata July 2023 Term Loan and the Armata March 2024 Term Loan to March 12, 2026.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 11, 2025, ISO and Armata entered into a Credit and Security Agreement, under which ISO extended a term loan to Armata (the &#8220;Armata August 2025 Term Loan&#8221;) in a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Armata August 2025 Term Loan bears an interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum and matures on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 11, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">seven</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> members of Armata&#8217;s board of directors are also members of the board of directors of Innoviva. As of December 31, 2025 and 2024, we collectively owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,076,769</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Armata's common stock, representing equity interest of approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively. As of December 31, 2025 and 2024, we collectively hold warrants of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,653,847</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,364,647</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, respectively, with exercise prices ranging from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share. Innoviva also held $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in principal amount of the Armata Convertible Note and a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in term loans.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investments in Armata&#8217;s common stock and warrants provide Innoviva and ISO the ability to have significant influence but not control over Armata&#8217;s operations. Armata&#8217;s business and affairs are managed under the direction of its board of directors, which Innoviva and ISO do not control. Based on our evaluation, we determined that Armata is a VIE, but Innoviva and ISO are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for Armata&#8217;s common stock and warrants under the equity method using the fair value option. The fair value of Armata&#8217;s common stock is measured based on its closing market price. The warrants purchased in 2020, 2021 and 2022 have an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.87</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.00</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, respectively. All warrants are exercisable immediately within </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">five years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from the issuance date of the warrants and include a cashless exercise option. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The warrants purchased in 2020 expired during the first quarter of 2025. We use the Black-Scholes-Merton pricing model to estimate the fair value of these warrants with the following input assumptions: Armata&#8217;s closing market price on the valuation date, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of Armata and its peer companies. We account for the Armata Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. We account for the Armata term loans as trading securities, measured at fair value using income approach based on the discounted value of expected future cash flows.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the fair values of our holdings of Armata common stock, warrants, the Armata Convertible Note, the Armata July 2023 Term Loan, the Armata March 2024 Term Loan, the Armata March 2025 Term Loan and the Armata August 2025 Term Loan were estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2024 the fair values of our holdings of Armata common stock, warrants, the Armata Convertible Note, the Armata July 2023 Term Loan and the Armata March 2024 Term Loan were estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata common stock and warrants, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as changes in fair values of equity method investments, net, in the consolidated statements of income and comprehensive income for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata Convertible Note, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata July 2023 Term Loan, we rec</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">orded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata March 2024 Term Loan, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gains as changes in fair values of equity and long-term investments, net, in the consolidated statements of income </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and comprehensive income for the years ended December 31, 2025 and 2024, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata March 2025 Term Loan</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gain for the year ended December 31, 2025 as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the Armata August 2025 Term Loan, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gain for the year ended December 31, 2025 as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 23, 2026, we entered into various amendments to existing agreements with Armata, extending the maturities of the Armata Note, the July 2023 Term Loan, the March 2024 Term Loan and the March 2025 Term Loan to June 1, 2027. The expiration dates of all outstanding Armata warrants held by us were likewise extended to </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 26, 2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In addition, we entered into an amendment to the amended and restated investor rights agreement, pursuant to which the Company and ISO agreed that the voting agreement will expire on the earlier of January 26, 2031 or the approval by the FDA of any of Armata&#8217;s product candidates for marketing and commercial distribution.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Balance Sheet Information</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.88%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.799999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.799999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,930</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,389</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,586</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,848</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,950</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,204</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,154</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,006</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement Information</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended September 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,054</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,467</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,052</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,350</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,476</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,639</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,363</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity and Other Investments in InCarda</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the third quarter of 2020, Innoviva TRC Holdings, LLC (&#8220;ITH&#8221;), a wholly owned subsidiary of Innoviva, has invested in the common stock, preferred stock, warrants and convertible notes of InCarda Therapeutics, Inc. (&#8220;InCarda&#8221;), a privately held biopharmaceutical company focused on developing intravenous and inhaled therapies for cardiovascular diseases.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITH has the right to designate one member to InCarda&#8217;s board of directors. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ITH designee is serving on InCarda&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">six</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-member board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, ITH owns </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,742,250</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of InCarda&#8217;s common and preferred stock and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,490,033</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> preferred stock warrants. These represent a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% equity interest as of December 31, 2025 and 2024, respectively. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investment in InCarda does not provide us with the ability to control or have significant influence over InCarda&#8217;s operations. Based on our evaluation, we determined that InCarda is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ITH also invested $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in InCarda's convertible notes issued in January 2024 (the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;InCarda 2024 Convertible Note&#8221;), February 2025 (the &#8220;InCarda February 2025 Convertible Note&#8221;) and October 2025 (the &#8220;InCarda October 2025 Convertible Note&#8221;), respectively (collectively, the (the &#8220;InCarda Convertible Notes&#8221;). We account for the InCarda Convertible Notes as trading securities, measured at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">With the exception of the InCarda Convertible Notes and Series D Warrants, which are measured at fair value, we account for the aforementioned investments in InCarda under the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain InCarda warrants held by us expired in March 2023 and we wrote off their carrying value of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during 2023.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Due to certain changes in InCarda&#8217;s business operations during the second quarter of 2023, ITH reassessed the value of its then investments in common stock, preferred stock and preferred stock warrants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in InCarda using the Option Pricing Model methodology. Key assumptions used in the valuation model included an expected holding period of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">two years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a risk-free interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, a dividend yield of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and an estimated volatility of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">114.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. The estimated volatility was calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million during the second quarter of 2023.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, we recorded as equity and long-term investments in the consolidated balance sheets $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in carrying amount of InCarda&#8217;s Series C preferred stock and approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in fair value of the InCarda Series D Warrants. As of December 31, 2025 and 2024, we recognized as equity and long-term investments in the consolidated balance sheets $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, for InCarda&#8217;s Series D-1 preferred stock, Series D-2 preferred stock, and common stock using the measurement alternative. As of December 31, 2025 and 2024, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, in fair value of the InCarda Convertible Notes as equity and long-term investments in the consolidated balance sheet. During the years ended December 31, 2025 and 2024, there were immaterial changes in the carrying amount of our investments. We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized loss as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the year ended December 31, 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity and Other Investments in ImaginAb</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since March of 2021, ITH has invested $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,825,301</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of common and preferred stock, and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in a convertible note of ImaginAb, Inc. (&#8220;ImaginAb&#8221;), a privately held biotechnology company focused on clinically managing cancer and autoimmune diseases via molecular imaging.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of ImaginAb&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">six</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> board members was designated by ITH. As of December 31, 2025 and 2024, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of ImaginAb equity ownership.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investment in ImaginAb does not provide us with the ability to control or have significant influence over ImaginAb&#8217;s operations. Based on our evaluation, we determined that ImaginAb is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">270,568</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of ImaginAb Series C-2 preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On September 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase another </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">405,852</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of ImaginAb Series C-2 preferred stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 23, 2024, ITH purchased a subordinated convertible promissory note (the &#8220;ImaginAb Convertible Note&#8221;) from ImaginAb for a total purchase price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The ImaginAb Convertible Note carried an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and would be due and payable upon the earlier to occur of January 31, 2025 and certain events defined in the ImaginAb Convertible Note. Under certain circumstances, the ImaginAb Convertible Note is convertible at the option of ITH into ImaginAb&#8217;s equity securities at defined conversion prices. The ImaginAb Convertible Note is subordinate to certain existing indebtedness of ImaginAb as defined in the ImaginAb Convertible Note. On October 31, 2024, ITH entered into an agreement with ImaginAb to amend the ImaginAb Convertible Note. Pursuant to the agreement, the principal amount of the ImaginAb Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represented the principal as of February 23, 2024, accrued interest as of amendment date, commitment fees and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. On January 13, 2025, ITH and ImaginAb executed an amendment to the ImaginAb Convertible Note extending the maturity date from January 31, 2025 to May 30, 2025. All other material terms of the ImaginAb Convertible Note were unchanged during the aforementioned amendments to the ImaginAb Convertible Note.	</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because ImaginAb&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in ImaginAb&#8217;s Series C preferred stock, Series C-2 preferred stock and common stock using the measurement alternative. As of December 31, 2025 and 2024, our investment in ImaginAb&#8217;s Series C preferred stock, Series C-2 preferred stock and common stock amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and recorded as equity and long-term investments in the consolidated balance sheets. There was no change in the carrying amount of our equity investments in ImaginAb.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2025, ImaginAb fully settled the convertible note of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, including $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in accrued interest and commitment fees. Before the repayment, the ImaginAb Convertible Note was accounted for as a trading security and measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. As of December 31, 2024, we recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in fair value of the ImaginAb convertible note as equity and long-term investments in the consolidated balance sheet. Changes to the fair value of the ImaginAb convertible note in 2025 through its settlement date were immaterial. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the year ended December 31, 2024, we recorded </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in net unrealized gain</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> on the ImaginAb convertible note as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Promissory Note in Syndeio Biosciences</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Syndeio Biosciences, Inc. (formerly known as Gate Neurosciences, Inc.) (&#8220;Syndeio&#8221;) is a privately held biopharmaceutical company focused on developing the next generation of targeted nervous system therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. In May 2025, Gate Neurosciences, Inc. rebranded as Syndeio.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From 2021 to 2022, ITH invested in Syndeio a total of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in convertible notes (the &#8220;Syndeio 2021 Convertible Note&#8221;). </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Syndeio 2021 Convertible Note bears an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and will convert into shares of common stock of Syndeio upon a qualified event or into shares of shadow preferred stock of Syndeio (&#8220;Shadow Preferred&#8221;) upon a qualified financing. A qualifying event can be a qualified initial price offering, a qualified merger, or a merger with a special-purpose acquisition company (&#8220;SPAC&#8221;). Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#8220;Capped Conversion Price&#8221;) and the qualified event price (the &#8220;Qualified Event Price&#8221;). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Syndeio are at least $35.0 million, and (iii) the stated or implied equity valuation of Syndeio is at least $80.0 million.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 2, 2023, ITH entered into a Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Syndeio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the original principal, accrued interest as of the amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 6, 2023, ITH entered into a Second Note Amendment Agreement with Syndeio to amend the Note Amendment Agreement. Pursuant to the Second Note Amendment Agreement, the principal amount of the Syndeio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the amended principal as of February 2, 2023, accrued interest as of the second amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 13, 2024, ITH entered into a Third Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Third Note Amendment Agreement, the principal amount of the Syndeio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the principal and accrued interest as of the third amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 5, 2024, ITH entered into a Fourth Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Fourth Note Amendment Agreement, the principal amount of the Syndeio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the principal and accrued interest as of the fourth amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 13, 2024, ITH entered into a Fifth Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Fifth Note Amendment Agreement, the principal amount of the Syndeio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the principal and accrued interest as of the fifth amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 3, 2025, ITH entered into a Convertible Promissory Note Purchase Agreement with Syndeio to acquire a convertible promissory note (the &#8220;Syndeio 2025 Convertible Note&#8221;) with a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The Syndeio 2025 Convertible Note bears an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 24, 2026</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Syndeio 2025 Convertible Note will convert into shares of series seed preferred stock of Syndeio upon a qualified initial public offering (&#8220;IPO&#8221;), or into shares of shadow preferred stock of Syndeio (&#8220;Shadow Preferred&#8221;) upon a qualified financing. Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 11, 2025, ITH entered into a Note Amendment Agreement with Syndeio to amend the Syndeio 2025 Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Syndeio 2025 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the principal and accrued interest as of the amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">All other material terms of the Syndeio 2021 Convertible Note and the Syndeio 2025 Convertible Note remained unchanged during the aforementioned amendments.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investments in Syndeio do not provide us with the ability to control or have significant influence over Syndeio&#8217;s operations. Based on our evaluation, we determined that Syndeio is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We account for both the Syndeio 2021 Convertible Note and the Syndeio 2025 Convertible Note as trading securities, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Syndeio, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, the fair value of the Syndeio 2021</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Convertible Note was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, and recorded as equity and long-term investments in the consolidated balance sheets. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized gain for the year ended December 31, 2025, as change in fair values of equity and long-term investments, net in the consolidated statements of income and comprehensive income. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The change in fair value is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material for the year ended December 31, 2024. We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized loss as change in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the year ended December 31, 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the fair value of the Syndeio 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Convertible Note was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and recorded as equity and long-term investments in the consolidated balance sheet. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized loss for the year ended December 31, 2025, as change in fair values of equity and long-term investments, net in the consolidated statements of income and comprehensive income.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 10, 2026, ITH entered into a Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Syndeio 2021 Convertible Note was increased from $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which represents the principal and accrued interest as of the amendment date and an additional cash investment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Certain thresholds associated with the definition of qualified financing were likewise amended. All other material terms of the Syndeio 2021 Convertible Note remained unchanged</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Investment in Nanolive</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2022, ITC invested $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,750,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of preferred stock of Nanolive SA (</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Nanolive&#8221;), a Swiss privately held life sciences company focused on developing breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. ITH has the right to designate one member to Nanolive&#8217;s board. ITH also has the right to designate another member, who will be mutually acceptable to ITH and another stockholder, to Nanolive&#8217;s board. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Innoviva designee is serving on Nanolive&#8217;s </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">six</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-member board. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of Nanolive equity ownership.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investment in Nanolive does not provide us with the ability to control or have significant influence over Nanolive&#8217;s operations. Based on our evaluation, we determined that Nanolive is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because Nanolive&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Nanolive&#8217;s Series C preferred stock using the measurement alternative. As of December 31, 2025 and 2024,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of investment in Nanolive was recorded as equity and long-term investments in the consolidated balance sheets, and there was no change to the carrying amount of our investment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Promissory Note in Lyndra</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 27, 2025, Strategic Partners entered into a note purchase agreement with Lyndra Therapeutics, Inc. (&#8220;Lyndra&#8221;) to acquire a convertible promissory note (the &#8220;Lyndra Convertible Note&#8221;) with a principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Lyndra is a clinical-stage company with a novel drug delivery platform that enables the administration of ultra-long-acting oral drugs. The Lyndra Convertible Note bears an annual interest rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">November 27, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The Lyndra Convertible Note would convert into shares of preferred stock of Lyndra upon a qualified financing as defined in the agreement. Upon maturity or certain events and if no qualified financing has occurred, the principal and unpaid accrued interest may either be repaid in full in cash plus a certain premium or convert into shares of preferred stock of Lyndra as defined in the agreement.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investment in Lyndra does not provide us with the ability to control or have significant influence over Lyndra&#8217;s operations. Based on our evaluation, we determined that Lyndra is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity. We account for the Lyndra Convertible Note as a trading security, measured at fair value using an income approach based on the discounted value of expected future cash flows.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In late March of 2025, Lyndra began winding down its operations due to a lack of financing. In September 2025, Lyndra sold the majority of its assets, resulting in a change of control as defined in the Lyndra Convertible Note (Refer to Note 14, &#8220;Asset Acquisition&#8221;). Upon the consummation of the change of control, the maturity date of the Lyndra Convertible Note was accelerated, and its principal and accrued interest became due. Due to Lyndra&#8217;s inability to repay the full amount, the note went into default and became subject to a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% premium on the principal balance. Interest will continue to accrue until full repayment.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> In October 2025, we received a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million partial repayment on the Lyndra Convertible Note, reducing the outstanding principal to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the fair value of the Lyndra Convertible Note was estimated at $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and recorded as equity and long-term investments in the consolidated balance sheet. We recorded $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in unrealized loss for the year ended December 31, 2025 as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Investment in Beacon</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beacon Biosignals, Inc. (&#8220;Beacon&#8221;) is an AI-driven neurotechnology company developing treatments for neurological, psychiatric, and sleep disorders. On October 7 2025, ITH entered into a Preferred Stock Purchase Agreement with Beacon, pursuant to which ITH acquired </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,448,303</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of Beacon&#8217;s Series B Preferred Stock for $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, we held </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of Beacon equity ownership.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our investment in Beacon does not provide us with the ability to control or have significant influence over Beacon&#8217;s operations. Based on our evaluation, we determined that Beacon is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because Beacon&#8217;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Beacon&#8217;s Series B preferred stock using the measurement alternative. As of December 31, 2025, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of investment in Beacon was recorded as equity and long-term investments in the consolidated balance sheet, and there was no change to the carrying amount of our investment.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Reconciliation of Equity and Long-Term Investments Balances</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in balances in &#8220;Equity and Long-Term Investments&#8221; as of each balance sheet date:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity and long-term investments as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">444,432</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of trading securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,201</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reclassification of current portion</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,532</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">724</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity and long-term investments as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">341,664</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of trading securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,729</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from trading securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of equity and other long-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,533</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net sales and purchases of investments managed by ISP Fund</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,160</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reclassification of current portion</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,805</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">988</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity and long-term investments as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404,497</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Available-for-Sale Securities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.867%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.867%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></div></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025 and 2024, all available-for-sale securities were money market funds, and there was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> credit loss recognized.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurements</span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our available-for-sale securities and equity and long-term investments are measured at fair value on a recurring basis and our debt is carried at amortized cost basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:39.772%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.678%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.678%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.678%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.678%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2025 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Price<br/>in Active<br/>Markets for</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identical</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Observable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unobservable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Types of Instruments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments held by ISP Fund LP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,993</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,748</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,741</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,482</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,482</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,244</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,244</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata July 2023 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,899</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,899</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata March 2024 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata March 2025 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,125</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,125</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata August 2025 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,534</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,534</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Armata Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,358</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,358</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda 2024 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda February 2025 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda October 2025 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Syndeio 2021 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,937</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,937</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Syndeio 2025 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,490</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,490</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Lyndra Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">764,753</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,244</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,052</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,101,049</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Liability</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">267,013</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">267,013</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:40.468%;box-sizing:content-box;"></td>
         <td style="width:1.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.402000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.402000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.402000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.402000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2024 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">in Active</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Markets for</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identical</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Observable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unobservable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Types of Instruments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments held by ISP Fund LP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193,560</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,098</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255,658</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Armata Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,095</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,095</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata July 2023 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,197</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,197</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata March 2024 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,275</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,275</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda 2024 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - ImaginAb Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,950</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,950</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Syndeio 2021 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,881</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,881</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">529,393</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">229,991</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">765,285</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,353</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,353</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,213</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,213</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fair value of debt</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">473,566</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">473,566</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> transfers between Level 1, Level 2 or Level 3 during the periods presented.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of our equity investments in Armata&#8217;s common stock and publicly traded investments held by ISP Fund LP are based on the quoted prices in active markets and are classified as Level 1 financial instruments. The fair values in the warrants in Armata classified within Level 2 are based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The investments classified as Level 3 financial instruments are securities that are not publicly traded and the assumptions used in the valuation model of these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies. There are uncertainties on the fair value measurement of the instruments classified under Level 3 due to the use of unobservable inputs and interrelationships between these unobservable inputs, which could result in higher or lower fair value measurements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair values of our 2025 Notes and 2028 Notes are based on recent trading prices of the respective instruments.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/825/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalized Fees Paid<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAbstract', window );"><strong>Capitalized Contract Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidDisclosureTextBlock', window );">CAPITALIZED FEES PAID</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7. CAPITALIZED FEES PAID</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:14.749%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization period</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2013-2030</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2013-2029</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Japan</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2013-2029</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross carrying value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163,862</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,039</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net carrying value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,138</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,961</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2025, the weighted average remaining amortization perio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">d was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4.2</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> y</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ears.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional information regarding these milestone fees is included in Note 3, &#8220;Revenue Recognition&#8221;. Amortization for each of the years ended December 31, 2025, 2024 and 2023 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The remaining estimated amortization is $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years 2026 and 2027, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year 2028, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year 2029 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the year 2030.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about capitalized fees paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8. GOODWILL AND INTANGIBLE ASSETS</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized goodwill of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million from our acquisitions of Entasis and La Jolla, respectively, in 2022. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying amount of goodwill as of December 31, 2025 and 2024 was </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t recognized any impairment losses related to goodwill and intangible assets during the periods presented.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets with definite lives are amortized over their estimated useful lives. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying basis and accumulated amortization of recognized intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 were as follows:</span></span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.86%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:14.24%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketed products</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">226,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,299</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration agreement</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,400</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,245</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,155</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,544</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.86%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:14.24%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketed products</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223,700</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,559</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,141</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In-process research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,600</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,600</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration agreement</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,400</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,708</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,692</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,700</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,267</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,433</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of Entasis amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">106.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which consisted of Entasis&#8217; in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">71.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. Following the FDA approval of XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in May 2023, we started amortizing $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives. Following the FDA approval of NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (formerly </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">zoliflodacin) in December 2025, we started amortizing $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the then in-process research and development as a marketed product over its estimated useful life.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Intangible assets recognized as a result of the acquisition of La Jolla amounting to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">151.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million pertain to product rights and developed technologies on La Jolla&#8217;s marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As discussed in Note 4 &#8220;License and Collaboration Arrangements&#8221;, we capitalized the upfront fee of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million that we paid to Basilea </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for the exclusive commercialization right of ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. under our exclusive distribution and license agreement as an intangible asset. This amount is included in marketed products in the table above and is being amortized over the term of the agreement.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognized amortization expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years ended December 31, 2025, 2024 and 2023, respectively. Future amortization expense is expected to be $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for each of the years from 2026 to 2030 and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million thereafter.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9. BALANCE SHEET COMPONENTS</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventory</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,330</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,113</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work-in-process</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,871</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,529</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,971</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,083</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventory</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,172</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,725</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and 2024, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will be amortized and recognized as cost of products sold when sales occur in future periods. The fair value adjustments recorded as part of cost of products sold amounted to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million for the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Accrued Liabilities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other accrued liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued contract manufacturing costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,220</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,071</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical and research expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">611</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,845</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,682</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6a206859-f8ee-400b-9d66-43ec2846665f;"><span style="-sec-ix-hidden:F_17be60db-4ed3-4806-a6df-7a78528c373a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities</span></span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">418</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,572</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty obligation payable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,690</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,951</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of deferred royalty obligation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,124</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,438</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued license fees and royalties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,727</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other accrued liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,468</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,999</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount as of December 31, 2024 includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance payments received from our partner for inventory supply as discussed in Note 4, &#8220;License and Collaboration Arrangements&#8221;.</span></div></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Long-Term Liabilities</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other long-term liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of deferred royalty obligation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,104</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,096</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e88a4c0d-7875-4370-83b2-18dc892d7674;"><span style="-sec-ix-hidden:F_4bc47aec-cd74-43b5-88dc-6e2c9250c57b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of lease liabilities</span></span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,868</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,179</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,119</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other long-term liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,091</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,275</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text"><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10. STOCK&#8209;BASED COMPENSATION</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Incentive Plans</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2012, we adopted the 2012 Equity Incentive Plan (the &#8220;2012 Plan&#8221;). The 2012 Plan provides for the grant of incentive stock options, nonstatutory stock options, RSAs, RSUs and Stock Appreciation Rights to employees, non-employee directors and consultants. As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total shares remaining available for issuance under the 2012 Plan were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Employee Stock Purchase Plan</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the 2004 Employee Stock Purchase Plan (the &#8220;2004 ESPP&#8221;), our employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2004 ESPP provided for consecutive and overlapping offering periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24 months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in duration, with each offering period composed of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six-month</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> purchase periods. The purchase periods ended on either May 15 or November 15. The 2004 ESPP contributions were limited to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of an employee&#8217;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An employee may not purchase shares with a value greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in any calendar year.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 13, 2023, the Board of Directors adopted the 2023 ESPP (the &#8220;2023 ESPP&#8221;). The 2023 ESPP, which supersedes the 2004 ESPP, was approved by the Company&#8217;s stockholders on May 22, 2023. Under the 2023 ESPP, eligible employees may purchase common stock through payroll deductions at a price equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the lower of the fair market value of the stock at the beginning or end of each applicable purchase period. The 2023 ESPP provides for offering periods of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">six months</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which ends on either May 15 or November 15. The 2023 ESPP contributions are limited to a maximum of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of an employee&#8217;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. An employee may not purchase shares with a value greater than $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in any calendar year. A total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million shares of our common stock was reserved and available for issuance under the 2023 ESPP.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, total shares remaining available for issuance under the 2023 ESPP were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,385,766</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Director Compensation Program</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our non-employee directors receive compensation for services provided as a director. Each member of our board of directors who is not an employee receives both cash and equity compensation for services as a director, member of a committee of the board of directors, lead independent director and chairman, as applicable.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Each of our independent directors receives periodic automatic grants of equity awards under a program implemented under the 2012 Plan. These grants are non&#8209;discretionary. Only our independent directors or affiliates of such directors are eligible to receive automatic grants under the 2012 Plan. Under the program, each individual who first became a non-employee director will, on the date such individual joins the board of directors, automatically be granted a one&#8209;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share (the &#8220;Initial RSUs&#8221;), plus a one&#8209;time grant of RSUs covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, which would be pro-rated for the number of whole months remaining until the anniversary of the prior year&#8217;s stockholders&#8217; meeting, rounded down to the nearest whole share (the &#8220;Pro Rata RSUs&#8221;). The Initial RSUs vest in </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">two</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> equal annual installments, while Pro Rata RSUs vest in a single installment at the sooner of the next annual stockholder meeting or the one-year grant anniversary, in each case subject to the non-employee director&#8217;s continuous service through the applicable vesting date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Annually, upon his or her re&#8209;election to the board of directors at the Annual Meeting of Stockholders, each non-employee director is automatically granted an RSU covering a number of shares of our common stock calculated as $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share. These RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the non-employee director&#8217;s continuous service through the applicable vesting date. Following the amendment to our non-employee director compensation program, both the annual RSUs and Initial RSUs described above remained unchanged with the exception that the number of shares of our common stock subject to each award has been reduced.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These RSUs will vest in full upon the director&#8217;s death, the occurrence of a change in control, or the director&#8217;s disability before the director&#8217;s service terminates. Director RSUs carry dividend equivalent rights to be credited with an amount equal to all cash dividends paid on the underlying shares of common stock while unvested. Dividend equivalents are subject to the same terms and conditions, including vesting, as the RSUs to which they attach and are paid in cash upon vesting.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Stock&#8209;Based Compensation Expense</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;based compensation expense is included in the consolidated statements of income and comprehensive income as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.01%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.203%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.203%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.583%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,930</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,040</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,645</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">522</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">334</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,192</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,452</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,374</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,837</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;based compensation expense included in the consolidated statements of income and comprehensive income by award type is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,995</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,738</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,980</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,041</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,348</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,663</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSAs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">340</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,452</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,374</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,837</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.88%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.799999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrecognized Compensation Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Amortization Period (Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,140</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,354</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSAs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total unrecognized compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,741</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Compensation Awards</span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:32.386%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.642%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.7219999999999995%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.642%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.7219999999999995%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.642%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.182%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands, except per share data)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of outstanding options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price of Outstanding Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of outstanding RSUs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of outstanding RSAs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,067</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">598</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">870</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">662</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.18</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.09</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Released RSUs and RSAs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.10</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.78</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.87</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.70</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,834</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.08</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.22</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.77</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest <br/>&#160;&#160;&#160;as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,834</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.08</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.22</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the aggregate intrinsic value of options outstanding and options exercisable was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2024, the aggregate intrinsic value of options outstanding and options exercisable </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. As of December 31, 2025, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,267,886</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> options were exercisable. The weighted average remaining contractual term of options outstanding was </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7.68</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8.04</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> years as of December 31, 2025 and 2024, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total intrinsic value of the options exercised was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material for the years ended December 31, 2025, 2024 and 2023. The total estimated fair value of options vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million the years ended December 31, 2025, 2024 and 2023, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total estimated fair value of RSUs vested was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million for the years December 31, 2025, 2024 and 2023, respectively.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The total estimated fair value of RSAs vested was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t material for the year ended December 31, 2025, 2024, and 2023.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Valuation Assumptions</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Black-Scholes-Merton weighted-average</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> assumptions used in calculating the estimated value of stock options granted by Innoviva on the dates of grant were as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.748999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.748999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.748999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.07</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.10</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.09</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average estimated fair value of stock options granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.48</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.57</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11. </span><span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stockholders&#8217; Equity</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the year ended December 31, 2025, a total of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">590,703</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants were exercised into an equivalent number of our common shares at an exercise price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.11</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share, resulting in approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in proceeds. There were </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> outstanding warrants as of December 31, 2025.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On November 3, 2025, our board of directors authorized a new share repurchase program under which we may repurchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">of our outstanding shares of common stock. The timing and amount of any share repurchases under the share</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">repurchase </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">program will be subject to the Securities and Exchange Commission Rule 10b-18 and Rule 10b5-1 requirements under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and will be determined by our management in its discretion based on ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions, and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at our discretion and does not oblige us to acquire any amount of common stock. From program inception through December 31, 2025, we repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">227,855</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.09</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> millio</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">n. Subsequent to December 31, 2025 and through February 13, 2026, we have repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">569,443</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. All repurchased shares were retired.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On October 31, 2022, our board of directors authorized a share repurchase program under which we may repurchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of our outstanding shares of common stock. The repurchase program authorized the repurchase by the Company of its common stock in open market transactions, including pursuant to a trading plan in accordance with Rule 10b-18 promulgated under the Exchange Act, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. The authorization permitted management to repurchase shares of the Company&#8217;s common stock from time to time at management&#8217;s discretion. Repurchases may also be made pursuant to a trading plan under Rule 10b5-1 under the Exchange Act, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. For the year ended December 31, 2023, we repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,173,565</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.39</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. From January to April 2024, we repurchased </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">986,928</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares in the open market at an average price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.12</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share for a total amount of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. The share repurchase program was completed in April 2024. All repurchased shares were retired.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, we retired all the shares held in treasury resulting from our strategic buyback of GSK&#8217;s common shares in the Company in 2021. We recorded the corresponding cost of treasury stock of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">393.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in additional paid-in capital.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12. DEBT</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our debt consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.88%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.799999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.799999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total debt</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,269</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,731</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">448,344</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Less: Current portion of long-term debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,731</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256,316</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Subordinated Notes Due 2023</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2013, we completed an underwritten public offering of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">287.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million aggregate principal amount of our 2023 Notes, which matured on January 15, 2023. The 2023 Notes carried interest at the rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per year that was payable semi-annually in arrears in cash on January 15 and July 15 of each year.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the total face value of the 2023 Notes was reduced through partial conversion, retirement and repurchase. The remaining balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was fully paid in cash upon the maturity date in January 2023.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2023 Notes for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023:</span></p></div><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:75.96%;box-sizing:content-box;"></td>
         <td style="width:2.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Senior Notes Due 2025</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On August 7, 2017, we completed a private placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million aggregate principal amount of our 2025 Notes. The 2025 Notes were senior unsecured obligations and carried interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per year, payable semi-annually in arrears on February 15 and August 15 of each year.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2025 Notes were convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2025, we elected to settle the 2025 Notes in shares. Holders had the option to convert their 2025 Notes at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. During June 2025, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the principal amount was converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,962</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock. During August 2025, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the principal amount was converted into </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,119,956</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares of our common stock.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> The remaining principal balance of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was fully paid in cash upon the maturity date in</span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> August 15, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The annual effective interest rate on the 2025 Notes in 2025 up to its settlement was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.90</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. For the years ended December 31, 2024 and 2023, the annual effective interest rate on the 2025 Notes was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.88</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our 2025 Notes balances consisted of the following as of December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:70.034%;box-sizing:content-box;"></td>
         <td style="width:2.941%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:25.025%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">472</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net carrying amount</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,002</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,813</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,813</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">472</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">733</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">712</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,474</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,525</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Senior Notes Due 2028</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, we completed a private placement of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million aggregate principal amount of our 2028 Notes, which will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 15, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We used approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the net proceeds to fund the cost of entering into the capped call transactions described below. In addition, we used $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the remaining net proceeds to repurchase $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">144.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million aggregate principal amount of the 2023 Notes in separate and individually negotiated transactions with certain holders of the 2023 Notes, which closed concurrently with the issuance of the 2028 Notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2028 Notes bear interest at an annual rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.125</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% that is payable semi-annually in arrears in cash on March 15 and September 15 of each year, beginning on September 15, 2022.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2028 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38.1432</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> shares per $1,000 principal amount of the 2028 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26.22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Prior to September 15, 2027, the 2028 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, and will be convertible on or after September 15, 2027, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Holders of the 2028 Notes may convert all or a portion of their 2028 Notes prior to the close of business on September 15, 2027, only under the following circumstances:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">after March 31, 2022, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the current conversion price of the 2028 Notes;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the product of our closing common stock price and the conversion rate of the 2028 Notes on such day; and,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental change (as defined in the indenture governing the 2028 Notes) or a transaction resulting in our common stock converting into other securities or property or assets.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On or after September 15, 2027, holders of the 2028 Notes may convert their 2028 Notes at any time until the close of the business on the second day immediately preceding the maturity date of the 2028 Notes.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2028 Notes will be redeemable, in whole or in part, at our option at any time, and from time to time, on or after March 20, 2025, and on or before the 75th scheduled trading day immediately before the maturity date but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the 2028 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any 2028 Note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the 2028 Notes) with respect to that 2028 Note, in which case the conversion rate applicable to the conversion of that 2028 Note will be increased in certain circumstances if it is converted after it is called for redemption.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we undergo a fundamental change, subject to certain conditions, holders may require us to purchase for cash all or any portion of their 2028 Notes. The fundamental change purchase price will be </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the principal amount of the 2028 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.</span></span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions. The cap price of the capped call transaction is initially $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.9850</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per share and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the 2028 Notes. The capped call transactions are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the aggregate principal amount of converted 2028 Notes, as the case may be, with such reduction or offset subject to a cap.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The annual effective interest rate on the 2028 Notes is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.70</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our outstanding 2028 Notes balance consisted of th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,269</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,684</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net carrying amount</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,731</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256,316</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2028 Notes for the years ended December 31, 2025, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt discount and issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,415</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,342</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,961</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,923</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,888</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Debt Maturities</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate scheduled maturities of our convertible debt as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Deferred Royalty Obligation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As part of our acquisition of La Jolla, we recorded the fair value of its deferred royalty obligation in connection with La Jolla&#8217;s royalty financing agreement (&#8220;La Jolla Royalty Agreement&#8221;) with HealthCare Royalty Partners (&#8220;HCR&#8221;). Under the terms of the La Jolla Royalty Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA&#174; until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The maximum royalty rate through December 31, 2023 was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%. Starting January 1, 2024, the maximum royalty rate was increased to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% based on the terms of the Agreement. The La Jolla Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the years ended December 31, 2025, 2024 and 2023, we recognized interest expense of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, on the deferred royalty obligation. The carrying value of the deferred royalty obligation as of December 31, 2025 and 2024 was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively, (refer to Note 9 &#8220;Balance Sheet Components</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">). During the years ended December 31, 2025, 2024 and 2023, we made royalty payments to HCR of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively. The deferred royalty obligation was valued using Level 3 inputs, and its carrying value as of December 31, 2025 and 2024 approximates fair value. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The fair value of the deferred royalty obligation was calculated as the discounted deferred royalty obligations based on risk-adjusted revenue projections for GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, the annual effective interest rate of the deferred royalty obligation is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.03</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the La Jolla Royalty Agreement, if we are unable to meet certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, HCR would have the right to terminate the La Jolla Royalty Agreement and demand payment of either $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">125.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million or $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (depending on which obligation we have failed to meet) less aggregate royalties already paid to HCR.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> As of December 31, 2025, inclusive of the aggregate royalties paid to HCR by La Jolla under the La Jolla Royalty Agreement prior to our acquisition, La Jolla paid approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">aggregate royalties to HCR. In the event that we fail to pay such amount if and when due in a timely manner, HCR would have the right to foreclose on the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">-related assets. HCR has no recourse against any asset other than GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Certain contract provisions within the La Jolla Royalty Agreement that could result in an acceleration of amounts due under the La Jolla Royalty Agreement are recognized as embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. We determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, we determined that the fair value of the embedded derivatives is immaterial and, therefore, not recognized as of December 31, 2025 and 2024. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate the fair value of the embedded derivatives for each reporting period until either the features lapse or the La Jolla Royalty Agreement is terminated, whichever occurs first. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss in the consolidated statements of income and comprehensive income.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13. COMMITMENTS AND CONTINGENCIES</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Lease</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have operating leases for our corporate headquarters, office spaces and laboratory facilities.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2019, we entered into an operating lease for our headquarters in Burlingame, California for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,111</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> rentable square feet. The lease commenced in November 2019 with an initial term of </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a8d055de-5223-43f2-950c-df6e42a40b2d;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">thirty-six</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> calendar months, which was subsequently amended to expire in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0cf4230b-14d7-4c03-83f4-80f2b6b31b1a;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 2027</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our operating leases include a facility lease consisting of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,500</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office space in Waltham, Massachusetts, which expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f563af2d-08d9-49fd-bae4-6b8f93526198;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 2029</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In November 2025, we entered into an operating lease for approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,881</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> square feet of office and laboratory space in Lexington, Massachusetts, which expires in </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7683dbb5-aa29-4655-8dae-71a88a149d59;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 2036</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. We have the </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">option to terminate</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> this lease, for an early termination fee, before May 2029.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease costs are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:57.863%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Straight line operating lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,424</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,200</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,428</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,515</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,214</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,617</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental cash flow information related to leases are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:57.863%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of <br/>&#160;&#160;&#160;operating lease liabilities:</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,705</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,464</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,542</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange <br/>&#160;&#160;&#160;for operating lease obligations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, our operating leases have weighted-average remaining term of approximately </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9.6 </span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">years and the weighted-average discount rate on our operating lease liabilities was </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments on our operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 are as follows:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,005</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,327</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,335</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,454</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,516</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,861</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,575</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f5f169b5-7b43-492f-b75e-5037a78edaec;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,286</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Purchase Commitments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, we entered into a Commercial Supply Agreement with Corden Pharma CHEN&#212;VE SAS (&#8220;Corden&#8221;), under which we engaged Corden to manufacture and supply certain products related to XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and to perform certain services and studies. Under the agreement, we committed to minimum purchase commitments through December 31, 2027. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million U.S. dollar equivalent in purchase commitments under the agreement for the years 2026 and 2027, respectively.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Legal Proceedings</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">From time to time, the Company is involved in legal proceedings in the ordinary course of its business. We are not currently a party to any material legal proceedings except as discussed below.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#8220;First Notice Letter&#8221;) from Gland Pharma Limited (&#8220;Gland&#8221;) advising that Gland had submitted an Abbreviated New Drug Application (&#8220;ANDA&#8221;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#8220;GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Patents&#8221;), which are listed in the FDA&#8217;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#8220;Orange Book&#8221;). The First Notice Letter alleges that the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#8217;s ANDA.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#8217;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the First Notice Letter, the FDA cannot approve Gland&#8217;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 22, 2023, La Jolla received a paragraph IV notice of certification (the &#8220;Second Notice Letter&#8221;) from Gland advising that Gland had amended its ANDA filing to include a paragraph IV certification alleging that all claims of the newly-issued and Orange Book-listed U.S. Patent No. 11,559,559 (the &#8220;&#8217;559 Patent&#8221;), which covers GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, are invalid, unenforceable and/or not infringed.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 22, 2023, La Jolla filed a First Amended Complaint in this litigation adding Gland&#8217;s marketing and distribution partners for its ANDA angiotensin II product, Fresenius Kabi USA LLC and Fresenius Kabi SwissBiosim GmbH (collectively, the &#8220;Fresenius Kabi Defendants&#8221;), as co-defendants. On April 7, 2023, La Jolla filed a Second Amended Complaint in response to the Second Notice Letter, adding claims that the manufacture, use, sale, offer for sale, or import of Gland&#8217;s ANDA angiotensin II product will infringe the &#8217;559 Patent. On November 14, 2023, La Jolla filed a Third Amended Complaint adding additional infringement claims against the Fresenius Kabi Defendants.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 18, 2025, La Jolla, as well as The George Washington University (collectively, with the La Jolla entities, the &#8220;Plaintiffs&#8221;) entered into a settlement agreement (the &#8220;Settlement Agreement&#8221;) with Gland and the Fresenius Kabi Defendants</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(collectively, &#8220;Defendants&#8221;) resolving the Hatch-Waxman Act concerning Gland&#8217;s ANDA filing. Under the terms of the Settlement Agreement, Plaintiffs granted Defendants a perpetual, royalty-free and fully paid-up, non-exclusive, non-sublicensable, non-transferable right and license solely to make, have made, use, sell, offer to sell, import, and/or distribute the product that is subject to Gland&#8217;s ANDA in the United States commencing in the early 2030s, subject to certain exceptions as is customary in these type of agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As required by law, the settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Indemnifications and Other Contingencies</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, directors, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect on our consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To date, we have not incurred any material costs and, as of December 31, 2025, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">t accrued any liabilities in the consolidated financial statements as a result of these provisions.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Asset Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAbstract', window );"><strong>Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">ASSET ACQUISITION</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14. ASSET ACQUISITION</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_886ab7f6-fedd-4b48-b757-553a486cfc22;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">September 2025</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we entered into an Asset Purchase Agreement with Lyndra to acquire the IPR&amp;D and certain fixed assets related to its Lynx&#153; long-acting drug delivery platform. We made an upfront cash payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and incurred $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million in direct transaction costs. We are also obligated to pay up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million upon the achievement of certain development, regulatory and sales milestone payments, as well as royalties in a low single-digit percentage on future net sales of the first approved therapeutic product.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on the qualitative and quantitative assessments performed under ASC 805, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Business Combinations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we concluded that the set of assets acquired did not meet the definition of a business and, therefore, accounted for the transaction as an asset acquisition. The assets acquired in the transaction were recorded at their allocated costs based on their relative fair values. The allocated cost of the IPR&amp;D acquired was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which was charged to research and development expense as it had no alternative future use at the time of the acquisition. The allocated cost of the fixed assets, which consist of laboratory equipment, was $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and was capitalized within property and equipment. The fixed assets have not been placed in service and, therefore, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> depreciation has been recognized as of December 31, 2025.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-50/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15. INCOME TAXES</span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of income before provision for income taxes are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.371%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">327,060</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,362</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194,034</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income before provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">326,862</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,388</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194,098</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income tax expense consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.371%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,578</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,438</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,799</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,477</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,175</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2177</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,795</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,850</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,613</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,976</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,745</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,606</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,594</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,194</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,847</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,617</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,400</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,697</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,376</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We adopted ASU 2023-09 on a prospective basis beginning with the year ended December 31, 2025. The following table presents required disclosure pursuant to ASU 2023-09 and reconciles the U.S. federal statutory tax amount and rate to our actual global effective amount and rate of the year ended December 31, 2025</span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: </span></span><span style=""></span></p><div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:64.447%;box-sizing:content-box;"></td>
         <td style="width:1.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.738%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal tax at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,682</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local effects</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,739</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign tax effects</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other - Withholding taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,796</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Enactment of new tax laws</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cross-border tax laws</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign-derived intangible income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,543</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign tax credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,555</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">324</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,726</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,709</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other adjustments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">488</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,697</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For tax year 2025, state taxes in Kentucky made up the majority (greater than 50 percent) of the tax effect in this category.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As previously disclosed for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income tax rate as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:47.56%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected tax at federal statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,846</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,747</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income tax expense, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,864</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,433</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state research credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,582</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 250 deduction</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,767</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,274</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,386</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,243</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,219</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,376</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the income taxes paid (net of any refunds received) for the year ended December 31, 2025 in accordance with the new guidance in ASU No. 2023-09:</span></p></div><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local jurisdiction</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash paid for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of our deferred tax assets and deferred tax liabilities are as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:61.232%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.603%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.603%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172,440</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,989</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,270</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,359</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized losses on investment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,481</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred royalty obligation, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,654</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,452</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,479</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,942</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,832</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,785</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,151</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187,635</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,478</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,205</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,626</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gains on investment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory fair value adjustment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">986</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,798</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,413</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,793</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,054</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We record deferred tax assets if the realization of such assets is more likely than not to occur. Significant management judgment is required in determining whether a valuation allowance against the deferred tax assets is required. We have considered all available evidence, both positive and negative, such as our historical operating results and predictability of future taxable income, in making such determination. We are also required to exercise significant management&#8217;s judgment in forecasting future taxable income. Specifically, we evaluate the following criteria when considering a valuation allowance:</span></p><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the history of tax net operating losses in recent years;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">predictability of operating results;</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">profitability for a sustained period of time; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">level of profitability on a quarterly basis.</span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, we had federal net operating loss carryforwards of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">497.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">448.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of which do not expire. We </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">also had state net operating loss carryforwards of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,028.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which will expire</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> beginning </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d97c91ae-1703-4480-a2ca-20778c18458e;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2030</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and state research tax credits of approximately $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, which will expire beginning </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e2ca3e4b-1265-4708-9028-4bacbb4bf6a7;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2033</span></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Utilization of net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We conducted an Internal Revenue Code of 1986, as amended, Section 382 (&#8220;Section 382&#8221;) analysis through December 31, 2025 to determine whether an ownership change had occurred since inception. The Section 382 study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. However, notwithstanding the applicable annual limitations, no portion of the net operating loss or credit carryforwards is expected to expire before becoming available to reduce federal and state income tax liabilities as a result of those identified ownership changes. If we undergo an ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of December 31, 2025, $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of Entasis&#8217; federal net operating losses and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">351.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of La Jolla&#8217;s federal operating losses from the acquisitions in 2022, both subject to annual limitations, were available for future utilization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2025 and 2024, we have accrued interest or penalties of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Uncertain Tax Positions</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2022</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,324</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in tax portions for 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,119</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,443</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in tax portions for 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,851</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,294</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in tax portion for 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,415</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,709</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to taxation in the U.S. and various state </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">jurisdictions. The tax years 2006 through 2013, 2015 and forward remain open to examination by the federal and most state tax authorities due to net operating loss and overall credit carryforward positions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16. SEGMENT REPORTING</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We operate as a single operating and reportable segment, focused on creating value for our stockholders. We achieve this by maximizing the value of our respiratory royalty portfolio and growing our investments in innovative healthcare assets that address critical unmet medical needs.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Chief Executive Officer, as the chief operating decision-maker (&#8220;CODM&#8221;), evaluates the Company&#8217;s financial performance and operational efficiency using consolidated net income. This helps guide decisions related to commercial operations, product development, and regulatory compliance, ensuring resources are allocated effectively to support growth initiatives. Consolidated net income also helps inform reinvestment strategies to strengthen our market position and drive innovation.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies of the segment are the same as those described in Note 1, &#8220;Description of Operations and Summary of Significant Accounting Policies&#8221;.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, as well as license and other revenues. Refer to Note 3, &#8220;Revenue Recognition&#8221;, for more information on our revenues for the periods presented.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our long-term assets are located within the United States. The CODM does not review assets at a different level or category than the amounts disclosed in the consolidated balance sheets.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below presents the financial information used by the CODM to assess performance, which reconcile to the consolidated net income:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.371%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">411,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">358,711</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310,463</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of products sold</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,384</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,598</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,040</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of license revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,600</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of acquired intangible assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,277</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,902</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,784</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,502</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,441</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,739</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,816</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,493</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - External services and expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,705</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,408</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,051</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - Internal expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,531</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,246</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,871</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - Acquired IPR&amp;D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,368</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity method investments, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,433</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,253</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity and long-term investments, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,160</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and dividend income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,086</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,141</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,818</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,698</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,209</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,864</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,997</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,969</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,697</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,376</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated net income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,165</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">179,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Operations and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DescriptionOfOperationsPolicyTextBlock', window );">Description of Operations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Description of Operations</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#8220;Innoviva&#8221;, the &#8220;Company&#8221;, or &#8220;we&#8221; and other similar pronouns) is a diversified biopharmaceutical company with a portfolio of royalties, a critical care and infectious disease platform, and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#8220;GSK&#8221;), including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (fluticasone furoate/vilanterol, &#8220;FF/VI&#8221;) and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (umeclidinium bromide/ vilanterol, &#8220;UMEC/VI&#8221;). Under the Long-Acting Beta2 Agonist (&#8220;LABA&#8221;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">as follows: </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% on the first $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion of annual global net sales and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% for all annual global net sales above $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> billion; and royalties from the sales of ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which tier upward at a range from </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our wholly owned, critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Acinetobacter</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, commercially launched in 2023</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(eravacycline) for the treatment of complicated intra-abdominal infections in adults;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">staphylococcus aureus bacteremia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, including those with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia, licensed from Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) (&#8220;Basilea&#8221;) for U.S. commercialization and commercially launched in the third quarter of 2025; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">NUZOLVENCE</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (formerly known as zoliflodacin), approved by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, we own other strategic healthcare assets, such as a significant stake in Armata Pharmaceuticals, Inc., a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies through our portfolio approach.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#8220;VIE&#8221;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income and comprehensive income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Management's Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Use of Management&#8217;s Estimates</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#8220;U.S. GAAP&#8221;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and of Significant Suppliers and Partners</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Concentrations of Credit Risk and of Significant Suppliers and Partners</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#8220;API&#8221;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Currently, we derive the majority of our revenues from GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If GSK does not devote sufficient resources to the commercialization of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/BREO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and ANORO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ELLIPTA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our analysts&#8217; or investors&#8217; expectations due to a number of important factors.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our revenues also include net product sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XERAVA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, XACDURO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, and ZEVTERA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which we commercially launched in the third quarter of 2025. In the U.S., hospitals and other healthcare organizations generally acquire our products through a network of specialty distributors, which are regarded as our customers for accounting purposes. We do not believe that the loss of any one of these distributors would significantly impact our ability to distribute our products, as we expect that the sales volume would be absorbed by either new or remaining distributors.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our top three customers each account for approximately:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our net product sales for the year ended December 31, 2025; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our net product sales for the year ended December 31, 2024; and,</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%; </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">27</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our net product sales for the year ended December 31, 2023. </span></div></div><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> customers for the year ended December 31, 2025 account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivable&#8221; in our consolidated balance sheet as of December 31, 2025. Our top </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">three</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> customers for the year ended December 31, 2024 account for </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, respectively, of our receivables from net product sales, which are included in &#8220;Accounts receivables&#8221; in our consolidated balance sheet as of December 31, 2024.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Segment Reporting</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. Refer to Note 16, &#8220;Segment Reporting&#8221;, for more segment information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Variable Interest Entities</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#8217;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#8217;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Accounts Receivable</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inventory</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Property and Equipment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our property and equipment consist of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements. </span><span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation, and are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:</span></span></p><div style="font-size:10pt;font-family:Times New Roman;">
         <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
          <tr style="visibility:collapse;">
           <td style="width:49.17%;box-sizing:content-box;"></td>
           <td style="width:1.66%;box-sizing:content-box;"></td>
           <td style="width:49.17%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software and computer equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span></p></td>
          </tr>
         </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity and Long-Term Investments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity and Long-Term Investments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 825, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of equity and long-term investments, net, within the consolidated statements of income and comprehensive income.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If we conclude that we do not have the ability to exercise significant influence over an investee, we may elect to account for equity security without a readily determinable fair value using the measurement alternative method under ASC 321, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Investments - Equity Securities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. This method allows us to measure the investment at cost less impairment, if any, and adjusted for observable price changes in orderly transactions involving the same or a similar investment of the same issuer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also invest in ISP Fund LP, whose investments consist of money market funds, trading securities, and equity securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered into in December 2020, we became a limited partner of the partnership. In October 2024, we elected to unwind our capital accounts in the partnership in accordance with the terms of the Partnership Agreement and expect to receive distributions through April 2026. Accordingly, the portion of the cash balance and money market funds expected to be distributed within 12 months from the balance sheet date has been classified as &#8220;Current portion of ISP Fund investments,&#8221; while the remaining equity investments have been classified as long-term investments in the consolidated balance sheets as of December 31, 2025 and 2024.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Quoted prices for identical instruments in active markets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Level 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8212;Unobservable inputs and little, if any, market activity for the assets.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidPolicyTextBlock', window );">Capitalized Fees Paid</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Capitalized Fees Paid</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#8220;Capitalized Fees&#8221;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15 years</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#8217;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#8217;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Goodwill and Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with an indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#8217;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AssetAcquisitionsPolicyTextBlock', window );">Asset Acquisitions</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Asset Acquisitions</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We measure and recognize asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost of the acquisition is allocated to the assets acquired on the basis of their relative fair values. The cost allocated to acquire in-process research and development (&#8220;IPR&amp;D&#8221;) with no alternative future use is charged to research and development expense at the acquisition date.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We apply the guidance on principal versus agent considerations under ASC Topic 606, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Contracts with Customers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(&#8220;ASC 606&#8221;), to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on their own methodology and assumptions for estimating rebates and returns, which they monitor and adjust regularly in light of contractual and legal obligations, historical trends, past experience, and projected market conditions. Our partner may make significant adjustments to its reported sales based on actual results, which could cause fluctuation in our royalty revenue. We have rights to conduct periodic royalty audits to evaluate the accuracy of the information provided. Royalties from GSK are recognized as the net of amortization of capitalized fees related to approval and launch milestone payments made to GSK.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Product Sales</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#8217; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#8220;GPO&#8221;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Returns: We offer customers a limited right of return, generally for damaged or expired products. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each state&#8217;s eligibility guidelines and services. Under these programs, we pay rebates to participating states, typically within three months after the quarter in which the product was sold. Additionally, we may offer customer incentives and other forms of consideration, such as volume-based or performance-based rebates. Estimated rebates are recorded as a reduction of revenue on delivery to our customers.</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We may also enter into contracts that involve a series of manufacturing processes for products and related components. For any distinct performance obligation where the manufacturing process does not create an asset with alternative use and there is an enforceable right to payment for the performance completed to date, the related revenue is recognized over time. For these performance obligations satisfied over time, we use an input method to measure progress. Specifically, we apply the cost-to-cost method, under which progress is calculated as the ratio of costs incurred to date relative to the total estimated costs of the contract. This method most accurately depicts the transfer of value to the customer because costs incurred are determined to be proportionate to our performance in satisfying the obligation. Estimated total contract costs are reassessed periodically. Changes in estimates are accounted for prospectively as changes in estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">License Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">At the inception of a licensing arrangement that includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price. We generally include these milestone payments in the transaction price when they are achieved because there is considerable uncertainty in the research and development processes that trigger receipt of these payments under our agreements. Similarly, we include approval milestone payments in the transaction price once the product is approved by the applicable regulatory agency. For delivery of other goods or services related to a licensing arrangement, we determine whether the performance obligation is satisfied over time or at a point in time. If the performance obligation is satisfied over time, we use judgment in determining the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Grant Revenue</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We recognize grant revenue from non-governmental entities in accordance with ASC 958-605, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue Recognition Not-for-Profit Entities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, when qualifying costs are incurred and the conditions of the grant agreement have been met. If grant funds are received after costs have been incurred, we record the amount as grant revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as grant revenue when qualifying costs are incurred. Grant revenue is included in &#8220;License and other revenue&#8221; in our consolidated statements of income and comprehensive income.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense on Deferred Royalty Obligation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Expense on Deferred Royalty Obligation</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#8220;Debt&#8221;, for more information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Fair Value of Stock-Based Compensation Awards</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value of Stock&#8209;Based Compensation Awards</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#8220;ESPP&#8221;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#8220;simplified&#8221; method as described in Staff Accounting Bulletin No. 107, &#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share-Based Payment</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">,&#8221; for the expected option term. We use our historical volatility to estimate expected stock price volatility.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted stock units (&#8220;RSUs&#8221;) and restricted stock awards (&#8220;RSAs&#8221;) are measured based on the fair market values of the underlying stock on the dates of grant.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#8217;s best estimate as to whether it is probable that the shares awarded are expected to vest.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#8220;more likely than not&#8221; standard.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#8217;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RelatedPartyTransactionsPolicyTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Related Parties</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sarissa Capital owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of our outstanding common stock as of December 31, 2024. Transactions with Sarissa Capital are described in Note 5, &#8220;Consolidated Entity&#8221;. Sarissa Capital was considered to be a related party up until the annual stockholders meeting in May 2025 after which there were no representatives of Sarissa Capital serving on our Board of Directors.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Adopted Accounting Pronouncement</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Improvements to Income Tax Disclosures (Topic 740)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The ASU requires the disclosure of income taxes paid disaggregated by jurisdiction and enhanced disclosures for the entity&#8217;s effective tax rate reconciliation as well as other income tax related disclosures. We adopted this guidance prospectively as of January 1, 2025, which resulted in additional disclosures in the notes to our consolidated financial statements. Accordingly, prior periods were not retrospectively adjusted. See Note 15, &#8220;Income Taxes.&#8221;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Recently Issued Accounting Pronouncements Not Yet Adopted</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement &#8212; Reporting Comprehensive Income &#8211; Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which requires disclosures about specific types of expenses included in the expense captions presented on the face of the statement of income as well as disclosures about selling expenses. ASU 2024-03 is effective for the Company in annual reporting periods beginning after December 15, 2027, and interim reporting periods beginning after December 15, 2027. We are currently evaluating the potential impact that ASU 2024-03 may have on our financial statement disclosures.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, the FASB issued ASU 2024-04, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Debt &#8212; Debt with Conversion and Other Options (Subtopic 470-20), </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">which clarifies the assessment of whether a transaction should be accounted for as an induced conversion or extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. ASU 2024-04 is effective for annual reporting periods beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. We are currently evaluating the potential impact that ASU 2024-04 may have on our financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2025, the FASB issued ASU 2025-05, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Financial Instruments &#8212; Credit Losses (Topic 326): Measurement of Credit Losses for Current Accounts Receivable and Contract Assets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which provides a practical expedient for estimating expected credit losses by assuming current conditions remain unchanged over the life of the asset. The amendments in ASU 2025-05 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the potential impact that ASU 2025-05 may have on our estimation methodologies.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the FASB issued Update ASU 2025-11, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interim Reporting (Topic 270): Narrow-Scope Improvements. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ASU intends to clarify and improve existing interim reporting guidance by consolidating disclosure requirements within Topic 270 and introducing a disclosure principle requiring entities to disclose events and changes occurring after the most recent annual reporting period that are expected to have a material effect on the entity&#8217;s financial condition or results of operations. This ASU does not introduce significant changes to recognition or measurement guidance. The amendments in this Update are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the potential impact that ASU 2025-11 may have on our financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2025, the FASB issued ASU 2025-12, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Codification Improvements</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, which provides technical corrections, clarifications, and other minor improvements across a number of Topics. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently evaluating the potential impact of ASU 2025-12 on our consolidated financial statements and disclosures.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AssetAcquisitionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for asset acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AssetAcquisitionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fees paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DescriptionOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DescriptionOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RelatedPartyTransactionsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the entity's accounting policies for transactions entered with related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RelatedPartyTransactionsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Paragraph 2AA<br> -Subparagraph (a)<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-2AA<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Operations and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of property, equipment and leasehold improvements useful lives</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation, and are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:</span>
         <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
          <tr style="visibility:collapse;">
           <td style="width:49.17%;box-sizing:content-box;"></td>
           <td style="width:1.66%;box-sizing:content-box;"></td>
           <td style="width:49.17%;box-sizing:content-box;"></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Leasehold improvements</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Shorter of remaining lease terms or useful life</span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Laboratory equipment, furniture and fixtures</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#8211; </span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7 years</span></span></p></td>
          </tr>
          <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Software and computer equipment</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
           <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3 years</span></span></p></td>
          </tr>
         </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computation of basic and diluted net income per share</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table shows the computation of basic and diluted net income per share for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands except per share data)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Numerator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income, basic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,165</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">179,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: interest expense on 2023 Notes, net of tax effect</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">89</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: interest expense on 2025 Notes, net of tax effect</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,882</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,468</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,116</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Add: interest expense on 2028 Notes, net of tax effect</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,776</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income, diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">279,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,860</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">191,304</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Denominator:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute basic net income<br/>&#160;&#160;&#160;per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,395</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,726</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,435</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of 2023 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of 2025 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,900</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,150</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of 2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of options and awards granted under equity<br/>&#160;&#160;&#160;incentive plan and employee stock purchase plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">491</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">149</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dilutive effect of outstanding warrant</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average shares used to compute diluted net income<br/>&#160;&#160;&#160;per share</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,760</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,187</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,876</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net income per share</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.02</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.37</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.75</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Diluted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.30</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.36</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.20</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of anti-dilutive securities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#8209;dilutive for the periods presented:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.28%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding options and awards granted under equity incentive<br/>&#160;&#160;&#160;plan and employee stock purchase plan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,535</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,196</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,333</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding stock warrant</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Outstanding 2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,535</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,742</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of net revenue from collaboration arrangement</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Net revenue recognized under our GSK Agreements was as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties &#8211; RELVAR/BREO</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">204,021</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">207,925</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,042</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalties &#8211; ANORO</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,281</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,631</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,627</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total royalties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">250,302</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255,556</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">252,669</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: amortization of capitalized<br/>&#160;&#160;&#160;fees paid</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total royalty revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">236,479</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">241,733</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">238,846</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of net product sales</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total net product sales were as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">GIAPREZA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,611</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,037</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,294</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XACDURO</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74,393</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,070</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,003</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">XERAVA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,516</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,385</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,320</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ZEVTERA</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">610</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;Total net product sales</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172,130</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">97,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,617</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Entities and Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember', window );">ISP Fund LP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems', window );"><strong>Consolidated Entities and Acquisitions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Summary of Individual Investments Held by ISP Fund</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following is a summary of individual investments held by ISP Fund at each balance sheet date:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:61.232%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.603%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.603%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">In thousands</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Common stock - Publicly traded healthcare companies</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,039</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United Kingdom</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,874</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,989</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total common stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,266</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Preferred stock - Privately held healthcare companies</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,748</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,591</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Warrants - Privately held healthcare companies</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,507</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market fund and cash</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,727</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,532</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;&#160;&#160;Total investments held by ISP Fund LP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,741</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255,658</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ConsolidatedEntitiesAndAcquisitionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consolidated entities and acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ConsolidatedEntitiesAndAcquisitionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org/325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock', window );">Reconciliation of Equity and Long-Term Investments Balances</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table reconciles the change in balances in &#8220;Equity and Long-Term Investments&#8221; as of each balance sheet date:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity and long-term investments as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">444,432</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of trading securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,201</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reclassification of current portion</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,532</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">724</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity and long-term investments as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">341,664</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of trading securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,729</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from trading securities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,427</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Purchases of equity and other long-term investments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,533</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net sales and purchases of investments managed by ISP Fund</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,955</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair value, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,160</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reclassification of current portion</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91,805</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">988</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity and long-term investments as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">404,497</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Amortized Cost and Estimated Fair Values for Available-for-Sale Securities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.867%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></div></div>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.867%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.222000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrealized</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cost</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gains</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Losses</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair Value</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our available-for-sale securities and equity and long-term investments are measured at fair value on a recurring basis and our debt is carried at amortized cost basis.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:39.772%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.678%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.678%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.678%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.678%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2025 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Price<br/>in Active<br/>Markets for</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant<br/>Other</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identical</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Observable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unobservable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Types of Instruments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">530,278</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments held by ISP Fund LP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,993</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,748</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,741</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,482</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">157,482</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,244</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,244</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata July 2023 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,899</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,899</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata March 2024 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,290</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata March 2025 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,125</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,125</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata August 2025 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,534</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,534</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Armata Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,358</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">101,358</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda 2024 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda February 2025 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">475</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda October 2025 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Syndeio 2021 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,937</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,937</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Syndeio 2025 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,490</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,490</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Lyndra Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,492</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">764,753</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,244</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300,052</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,101,049</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Liability</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">267,013</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">267,013</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:40.468%;box-sizing:content-box;"></td>
         <td style="width:1.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.402000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.402000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.402000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.48%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.402000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Estimated Fair Value Measurements as of December 31, 2024 Using:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Quoted Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">in Active</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Markets for</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Significant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Identical</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Observable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unobservable</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Types of Instruments</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Inputs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 1</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 2</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Level 3</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Money market funds</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">289,441</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments held by ISP Fund LP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">193,560</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,098</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">255,658</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Common Stock</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - Armata Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Equity investment - InCarda Warrants</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Armata Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,095</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,095</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata July 2023 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,197</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,197</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Term loan investment - Armata March 2024 Term Loan</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,275</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,275</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - InCarda 2024 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - ImaginAb Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,950</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,950</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible debt investment - Syndeio 2021 Convertible Note</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,881</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,881</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total assets measured at estimated fair value</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">529,393</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">229,991</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">765,285</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,353</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">222,353</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,213</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">251,213</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total fair value of debt</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">473,566</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">473,566</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock', window );">Schedule of Balance Sheets and Income Statements of VIE</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Balance Sheet Information</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.88%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.799999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.799999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">September 30,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,930</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,389</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent assets</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">72,586</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,848</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">139,950</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">118,204</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Noncurrent liabilities</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,154</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,006</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Income Statement Information</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Twelve Months Ended September 30,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,054</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,467</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,052</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Loss from operations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,350</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38,476</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,639</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,901</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,363</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of financial information of variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of reconciliation of equity and long-term investments balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalized Fees Paid (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAbstract', window );"><strong>Capitalized Contract Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostTableTextBlock', window );">Schedule of Capitalized Fees Paid</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:</span></p><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:14.749%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization period</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">United States</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2013-2030</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">120,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2013-2029</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Japan</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2013-2029</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross carrying value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">220,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accumulated amortization</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">163,862</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,039</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net carrying value</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">56,138</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">69,961</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost capitalized in obtaining or fulfilling contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Accumulated Amortization of Recognized Intangible Assets</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The carrying basis and accumulated amortization of recognized intangible assets as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 and 2024 were as follows:</span><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.86%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:14.24%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketed products</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">226,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">70,299</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,001</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration agreement</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,400</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,245</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,155</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,700</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">79,544</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">182,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:36.86%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:14.24%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.56%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.22%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="12" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Useful Life</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net Carrying</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Years)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Marketed products</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8</span></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">223,700</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47,559</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,141</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">In-process research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,600</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,600</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Collaboration agreement</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span></span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,400</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,708</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,692</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,700</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,267</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">208,433</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inventory consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Raw materials</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,330</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,113</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Work-in-process</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,871</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,529</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finished goods</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,971</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,083</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total inventory</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,172</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,725</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other accrued liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued contract manufacturing costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,220</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,071</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued clinical and research expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">185</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">611</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued professional services</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,845</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,682</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_6a206859-f8ee-400b-9d66-43ec2846665f;"><span style="-sec-ix-hidden:F_17be60db-4ed3-4806-a6df-7a78528c373a;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of lease liabilities</span></span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">418</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,572</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty obligation payable</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,690</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,951</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current portion of deferred royalty obligation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,124</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,438</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accrued license fees and royalties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,727</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,947</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other accrued liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,468</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,999</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount as of December 31, 2024 includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance payments received from our partner for inventory supply as discussed in Note 4, &#8220;License and Collaboration Arrangements&#8221;.</span></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long-term Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other long-term liabilities consisted of the following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of deferred royalty obligation</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,104</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">63,096</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_e88a4c0d-7875-4370-83b2-18dc892d7674;"><span style="-sec-ix-hidden:F_4bc47aec-cd74-43b5-88dc-6e2c9250c57b;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Long-term portion of lease liabilities</span></span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,868</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,179</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,119</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total other long-term liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,091</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,275</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;based compensation expense is included in the consolidated statements of income and comprehensive income as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.01%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.203%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.203%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.583%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general and administrative</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,930</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,040</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,645</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">522</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">334</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,192</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,452</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,374</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,837</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-based Compensation Expense Included in the Consolidated Statements of Income and Comprehensive Income by Award Type</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Stock&#8209;based compensation expense included in the consolidated statements of income and comprehensive income by award type is as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,995</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,738</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,980</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,041</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,348</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,663</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSAs</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">123</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">168</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">340</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">165</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,452</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,374</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,837</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Schedule of Unrecognized Stock-based Compensation Cost</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.88%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.799999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Unrecognized Compensation Cost</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Amortization Period (Years)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Stock options</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,140</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.6</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSUs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,354</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.8</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">RSAs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">ESPP</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">225</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.4</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total unrecognized compensation expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,741</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Equity Award Activity and Related Information</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:32.386%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.642%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.7219999999999995%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.642%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:7.7219999999999995%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.642%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.02%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.182%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands, except per share data)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of outstanding options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Exercise Price of Outstanding Options</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of outstanding RSUs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Number of outstanding RSAs</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted-Average Fair Value per Share at Grant</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,067</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.23</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">598</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.50</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">870</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.00</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">662</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.18</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.09</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Released RSUs and RSAs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.10</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.78</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.87</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.70</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expired</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Balance as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,834</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.08</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.22</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14.77</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Vested and expected to vest <br/>&#160;&#160;&#160;as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,834</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16.08</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">924</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.22</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted-Average Assumptions used to Calculate Estimated Value of Stock Options</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Black-Scholes-Merton weighted-average</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> assumptions used in calculating the estimated value of stock options granted by Innoviva on the dates of grant were as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.748999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.748999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.748999999999999%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Risk-free interest rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected term (in years)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.07</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.10</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.09</span></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Volatility</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">34.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Dividend yield</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Weighted-average estimated fair value of stock options granted</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.48</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8.17</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.57</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (i)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our debt consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.88%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.799999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:2.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:18.799999999999997%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2025 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028 Notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total debt</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">453,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,269</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,731</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">448,344</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;&#160;&#160;Less: Current portion of long-term debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total long-term debt, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,731</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256,316</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate Scheduled Maturities of Convertible Debt</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The aggregate scheduled maturities of our convertible debt as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2023 Notes for the year ended December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2023:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:75.96%;box-sizing:content-box;"></td>
         <td style="width:2.2%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:19.84%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">85</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Liability and Equity Components of Convertible Notes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our 2025 Notes balances consisted of the following as of December 31, 2024:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:70.034%;box-sizing:content-box;"></td>
         <td style="width:2.941%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:25.025%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,500</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">472</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net carrying amount</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">192,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,002</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,813</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,813</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">472</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">733</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">712</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,474</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,525</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Summary of Liability and Equity Components of Convertible Notes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our outstanding 2028 Notes balance consisted of th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">e following:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:67.313%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.5%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.843%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Principal</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">261,000</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Debt discount and issuance costs, net</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,269</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,684</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net carrying amount</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">257,731</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">256,316</span></p></td>
         <td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of Components of Interest Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table sets forth total interest expense recognized related to the 2028 Notes for the years ended December 31, 2025, 2024 and 2023:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:51.311%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.481%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.75%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contractual interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,546</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of debt discount and issuance costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,415</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,342</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total interest and amortization expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,961</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,923</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,888</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Cost</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of lease costs are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:57.863%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Straight line operating lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,424</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,200</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,428</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Variable lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">91</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total lease costs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,515</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,214</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,617</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Supplemental cash flow information related to leases are as follows:</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:57.863%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.281%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:10.764000000000001%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash paid for amounts included in the measurement of <br/>&#160;&#160;&#160;operating lease liabilities:</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,705</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,464</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,542</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating lease right-of-use assets obtained in exchange <br/>&#160;&#160;&#160;for operating lease obligations</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,022</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,156</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Future minimum lease payments on our operating leases as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2025 are as follows:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Year ending December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,005</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,327</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,224</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2029</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,335</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2030</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,454</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Thereafter</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">8,516</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total undiscounted lease payments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,861</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less: imputed interest</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,575</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><span style="-sec-ix-hidden:F_f5f169b5-7b43-492f-b75e-5037a78edaec;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total operating lease liabilities</span></span></span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,286</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of income before income tax expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The components of income before provision for income taxes are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.371%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Domestic</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">327,060</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,362</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194,034</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">198</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income before provision for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">326,862</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,388</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">194,098</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of the income tax expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income tax expense consists of the following:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.371%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,578</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,438</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,799</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,477</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,175</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2177</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,795</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total current</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,850</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,613</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,976</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42,745</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,606</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,594</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,102</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,194</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,847</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,617</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,400</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,697</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,376</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of differences between expected U.S. federal statutory income tax to income tax expense</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: </span><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:64.447%;box-sizing:content-box;"></td>
         <td style="width:1.88%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:16.537%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.4%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.738%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">U.S. federal tax at statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68,682</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local effects</span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,739</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign tax effects</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other - Withholding taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,796</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Enactment of new tax laws</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cross-border tax laws</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign-derived intangible income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,543</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Tax credits</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign tax credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,555</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development credit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">324</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,726</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Nontaxable or nondeductible items</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">407</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in unrecognized tax benefits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,709</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.1</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other adjustments</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">488</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effective tax rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,697</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(1)	</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For tax year 2025, state taxes in Kentucky made up the majority (greater than 50 percent) of the tax effect in this category.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As previously disclosed for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income tax rate as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:47.56%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.38%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.58%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.26%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Expected tax at federal statutory rate</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,846</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40,747</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State income tax expense, net of federal benefit</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,864</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,433</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.7</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal and state research credits</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">90</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,582</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.8</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Section 250 deduction</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,767</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,274</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.9</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Change in valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,386</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,167</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.2</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,243</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,219</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0.6</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total income tax expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37.5</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,376</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table presents the income taxes paid (net of any refunds received) for the year ended December 31, 2025 in accordance with the new guidance in ASU No. 2023-09:</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesPaidNetTableTextBlock', window );">Schedule of net income taxes paid</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">&#160;</p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Federal</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,300</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">State and local jurisdiction</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,377</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Foreign</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">436</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net cash paid for income taxes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and deferred tax liabilities</a></td>
<td class="text"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Significant components of our deferred tax assets and deferred tax liabilities are as follows:</span><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:61.232%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.603%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.78%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.603%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">172,440</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,989</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development tax credit carryforwards</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,270</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,359</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized losses on investment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,481</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred royalty obligation, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,654</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">17,452</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Accruals and reserves</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,479</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,942</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,832</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets before valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">217,785</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">234,113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Valuation allowance</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">176,151</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187,635</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total deferred tax assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,634</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,478</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation and amortization</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,205</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,626</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrealized gains on investment, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,823</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventory fair value adjustment</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">986</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,798</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,413</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net deferred tax assets (liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,793</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,054</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of changes in unrecognized tax benefits</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:80.444%;box-sizing:content-box;"></td>
         <td style="width:1.8%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:15.757%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2022</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,324</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in tax portions for 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,119</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2023</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,443</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in tax portions for 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,851</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61,294</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net increase in tax portion for 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,415</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Unrecognized tax benefits as of December 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62,709</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncomeTaxesPaidNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income taxes paid, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncomeTaxesPaidNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of reconciliation to the consolidated net income</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The table below presents the financial information used by the CODM to assess performance, which reconcile to the consolidated net income:</span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:53.371%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:12.122%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Year Ended December 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(In thousands)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2023</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">411,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">358,711</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">310,463</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Less:</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of products sold</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,384</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,598</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41,040</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of license revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,600</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization of acquired intangible assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">26,277</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,902</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,784</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling and marketing</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,502</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,441</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,739</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">General and administrative</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">76,816</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,249</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">67,493</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - External services and expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,705</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,408</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,051</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - Internal expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,531</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,246</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,871</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development - Acquired IPR&amp;D</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9,368</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity method investments, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">141,433</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64,253</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">77,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in fair values of equity and long-term investments, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20,160</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59,161</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest and dividend income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,086</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,141</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,818</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Interest expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,698</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">22,209</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,864</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,997</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,969</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax expense, net</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">55,697</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,996</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14,376</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Consolidated net income</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">271,165</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">$</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">179,722</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Operations and Summary of Significant Accounting Policies - Description of Operations (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>Customer</div>
</th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeePaidEstimatedUsefulLife', window );">Capitalized fees paid, estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Net Product Sales | La Jolla [Member] | Customer Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfMajorCustomers', window );">Number of major customers | Customer</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Customer Concentration Risk | Receivables from Net Product Sales | Customer One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Customer Concentration Risk | Receivables from Net Product Sales | Customer Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Customer Concentration Risk | Receivables from Net Product Sales | Customer Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember', window );">Sarissa Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty', window );">Percentage of common stock owned by a related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember', window );">Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne', window );">Royalty rate for first level of annual global net sales (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate', window );">Annual global sales level used to determine royalty rate | $</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo', window );">Royalty rate for sales above first level of annual global net sales (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember', window );">Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember', window );">Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeePaidEstimatedUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fee paid estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeePaidEstimatedUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate for combination products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock in the reporting entity owned by related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_LaJollaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_LaJollaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inva_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inva_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inva_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inva_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=inva_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=inva_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Operations and Summary of Significant Accounting Policies - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember', window );">Laboratory equipment furniture and fixtures | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember', window );">Laboratory equipment furniture and fixtures | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_SoftwareAndComputerEquipmentMember', window );">Software and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_LaboratoryEquipmentFurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_SoftwareAndComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=inva_SoftwareAndComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Operations and Summary of Significant Accounting Policies - Related Party Transactions (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember', window );">Sarissa Capital</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty', window );">Percentage of common stock owned by a related party</a></td>
<td class="nump">11.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock in the reporting entity owned by related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_SarissaCapitalManagementLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Basic and Diluted EPS (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income, basic</a></td>
<td class="nump">$ 271,165<span></span>
</td>
<td class="nump">$ 23,392<span></span>
</td>
<td class="nump">$ 179,722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income, diluted</a></td>
<td class="nump">$ 279,823<span></span>
</td>
<td class="nump">$ 26,860<span></span>
</td>
<td class="nump">$ 191,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute basic net income per share</a></td>
<td class="nump">67,395<span></span>
</td>
<td class="nump">62,726<span></span>
</td>
<td class="nump">65,435<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Dilutive effect of outstanding warrant</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute diluted net income per share</a></td>
<td class="nump">84,760<span></span>
</td>
<td class="nump">74,187<span></span>
</td>
<td class="nump">86,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NetIncomeLossPerShareAbstract', window );"><strong>Net income per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ 4.02<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: interest expense on Notes, net of tax effect</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: interest expense on Notes, net of tax effect</a></td>
<td class="nump">$ 2,882<span></span>
</td>
<td class="nump">$ 3,468<span></span>
</td>
<td class="nump">$ 5,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect</a></td>
<td class="nump">6,900<span></span>
</td>
<td class="nump">11,150<span></span>
</td>
<td class="nump">11,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestOnConvertibleDebtNetOfTax', window );">Add: interest expense on Notes, net of tax effect</a></td>
<td class="nump">$ 5,776<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Dilutive effect</a></td>
<td class="nump">9,955<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NetIncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NetIncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-26<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestOnConvertibleDebtNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestOnConvertibleDebtNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Anti-Dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">11,742<span></span>
</td>
<td class="nump">1,924<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_EquityIncentivePlansAndESPPMember', window );">Equity incentive plans and ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,196<span></span>
</td>
<td class="nump">1,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_OutstandingStockWarrantMember', window );">Outstanding Stock Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">591<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_Outstanding2028NotesMember', window );">Outstanding 2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Anti-Dilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,955<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_EquityIncentivePlansAndESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_EquityIncentivePlansAndESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_OutstandingStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_OutstandingStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_Outstanding2028NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=inva_Outstanding2028NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total royalty revenue</a></td>
<td class="nump">$ 411,328<span></span>
</td>
<td class="nump">$ 358,711<span></span>
</td>
<td class="nump">$ 310,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Less: amortization of capitalized fees paid</a></td>
<td class="num">(13,800)<span></span>
</td>
<td class="num">(13,800)<span></span>
</td>
<td class="num">(13,800)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total royalty revenue</a></td>
<td class="nump">236,479<span></span>
</td>
<td class="nump">241,733<span></span>
</td>
<td class="nump">238,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | Royalty Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Total royalties</a></td>
<td class="nump">250,302<span></span>
</td>
<td class="nump">255,556<span></span>
</td>
<td class="nump">252,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Less: amortization of capitalized fees paid</a></td>
<td class="num">(13,823)<span></span>
</td>
<td class="num">(13,823)<span></span>
</td>
<td class="num">(13,823)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total royalty revenue</a></td>
<td class="nump">236,479<span></span>
</td>
<td class="nump">241,733<span></span>
</td>
<td class="nump">238,846<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | RELVAR/BREO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Total royalties</a></td>
<td class="nump">204,021<span></span>
</td>
<td class="nump">207,925<span></span>
</td>
<td class="nump">208,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | ANORO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Revenue Recognition and Collaborative Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees', window );">Total royalties</a></td>
<td class="nump">$ 46,281<span></span>
</td>
<td class="nump">$ 47,631<span></span>
</td>
<td class="nump">$ 44,627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of net product sales (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 411,328<span></span>
</td>
<td class="nump">$ 358,711<span></span>
</td>
<td class="nump">$ 310,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_GiaprezaMember', window );">GIAPREZA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">73,611<span></span>
</td>
<td class="nump">55,037<span></span>
</td>
<td class="nump">41,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_XeravaMember', window );">XERAVA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">23,516<span></span>
</td>
<td class="nump">21,385<span></span>
</td>
<td class="nump">17,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_XacduroMember', window );">XACDURO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">74,393<span></span>
</td>
<td class="nump">21,070<span></span>
</td>
<td class="nump">2,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_ZEVTERAMember', window );">ZEVTERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 172,130<span></span>
</td>
<td class="nump">$ 97,492<span></span>
</td>
<td class="nump">$ 60,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_GiaprezaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_GiaprezaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_XeravaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_XeravaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_XacduroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_XacduroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_ZEVTERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_ZEVTERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">$ 411,328<span></span>
</td>
<td class="nump">$ 358,711<span></span>
</td>
<td class="nump">$ 310,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Milestone fees paid</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenue</a></td>
<td class="nump">172,130<span></span>
</td>
<td class="nump">97,492<span></span>
</td>
<td class="nump">$ 60,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Milestone fees paid</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Product Sales | Geographic Concentration Risk | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Product Sales | Geographic Concentration Risk | Rest of the world</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk, Percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | Long-Acting Beta2 Agonist (LABA) Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Milestone fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | RELVAR/BREO | Long-Acting Beta2 Agonist (LABA) Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne', window );">Royalty rate for first level of annual global net sales (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate', window );">Annual global sales level used to determine royalty rate</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo', window );">Royalty rate for sales above first level of annual global net sales (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | ANORO | Long-Acting Beta2 Agonist (LABA) Collaboration | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts', window );">Royalty rate for combination products (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate for combination products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_LabaCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Other Arrangements (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (411,328)<span></span>
</td>
<td class="num">$ (358,711)<span></span>
</td>
<td class="num">$ (310,463)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,604<span></span>
</td>
<td class="nump">13,654<span></span>
</td>
<td class="nump">33,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,966<span></span>
</td>
<td class="nump">20,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_XacduroMember', window );">XACDURO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,393)<span></span>
</td>
<td class="num">(21,070)<span></span>
</td>
<td class="num">(2,003)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236,479)<span></span>
</td>
<td class="num">(241,733)<span></span>
</td>
<td class="num">(238,846)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_GiaprezaMember', window );">GIAPREZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,611)<span></span>
</td>
<td class="num">(55,037)<span></span>
</td>
<td class="num">(41,294)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_LicenseAndOtherRevenueMember', window );">License and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,719)<span></span>
</td>
<td class="num">(19,486)<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_XeravaMember', window );">XERAVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,516)<span></span>
</td>
<td class="num">(21,385)<span></span>
</td>
<td class="num">(17,320)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ZaiLabMember', window );">Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LicenseRevenueRecognized', window );">License revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Advance payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ZaiLabMember', window );">Zai Lab | Amended Zai Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LicenseRevenueRecognized', window );">License revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ZaiLabMember', window );">Zai Lab | Interim Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AmountOnNetProductSalesRecognized', window );">Amount on net product sales recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,900<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ZaiLabMember', window );">Zai Lab | Manufacturing Stage Transfer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LicenseAndOtherRevenue', window );">License and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ZaiLabMember', window );">Zai Lab | XACDURO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LicenseRevenueRecognized', window );">License revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ZaiLabMember', window );">Zai Lab | Research and Development Support | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FuturePotentialMilestonePayment', window );">Future potential milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ZaiLabMember', window );">Zai Lab | Royalty Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_PaionAgMember', window );">PAION AG | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FuturePotentialMilestonePayment', window );">Future potential milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_PaionAgMember', window );">PAION AG | Royalty Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_PaionAgMember', window );">PAION AG | Cost Reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember', window );">Everest Medicines Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct', window );">Royalties payable period after first commercial sale of product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember', window );">Everest Medicines Limited | Commercial Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts', window );">Percentage of reimbursed for direct and certain indirect manufacturing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember', window );">Everest Medicines Limited | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SalesMilestonePaymentsReceivable', window );">Sales milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember', window );">Everest Medicines Limited | Royalty Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember', window );">Everest Medicines Limited | License and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_GARDPCollaborationAgreementMember', window );">GARDP Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ReimbursementsForResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_BasileaMember', window );">Basilea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_UpfrontPaymentUnderIntangibleAsset', window );">Upfront payment under intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_GeorgeWashingtonUniversityMember', window );">George Washington University | GIAPREZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPayableOnNetSales', window );">Percentage of royalty payable on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees', window );">Percentage of royalty on payments received from sublicensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_HarvardUniversityMember', window );">Harvard University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of license revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees', window );">Percentage of royalty on payments received from sublicensees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_HarvardUniversityMember', window );">Harvard University | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPayableOnNetSales', window );">Percentage of royalty payable on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_HarvardUniversityMember', window );">Harvard University | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfMinimumRoyaltyRate', window );">Percentage of minimum royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds', window );">Percentage of maximum royalty based on achievement of annual net product sales thresholds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_HarvardUniversityMember', window );">Harvard University | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable', window );">Clinical development and regulatory milestones amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ParatekPharmaceuticalsIncMember', window );">Paratek Pharmaceuticals, Inc | XERAVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfRoyaltyPayableOnNetSales', window );">Percentage of royalty payable on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ClaimExpirationDate', window );">Claim expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023-10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_UpfrontFeePayment', window );">Upfront fee payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_MassachusettsInstituteOfTechnologyMember', window );">Massachusetts Institute of Technology | Development Regulatory and Sales Milestone | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FuturePotentialMilestonePayment', window );">Future potential milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_AstrazenecaMember', window );">AstraZeneca | Durlobactam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales', window );">One-time Milestone Payment on Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TermOfMilestonePaymentForNetSales', window );">Term of the milestone payment on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_AstrazenecaMember', window );">AstraZeneca | Zoliflodacin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales', window );">One-time milestone payment on commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TermOfMilestonePaymentForCommercialSale', window );">Term of milestone payment for commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_GatesFoundationMember', window );">Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GrantFundingMaximumAmount', window );">Grant Funding Maximum Amount</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_LicenseRevenueRecognized', window );">License revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_UpfrontFeeReceived', window );">Upfront fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AmountOnNetProductSalesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount on net product sales recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AmountOnNetProductSalesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ClaimExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Claim expiration date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ClaimExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical development and regulatory milestones amount payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FuturePotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future potential milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FuturePotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_GrantFundingMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant funding maximum amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_GrantFundingMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_LicenseAndOtherRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and other revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_LicenseAndOtherRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_LicenseRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_LicenseRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of maximum royalty based on achievement of annual net product sales thresholds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfMinimumRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum royalty rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfMinimumRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimbursed for direct and certain indirect manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payable as a percentage of payments received from sublicensees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfRoyaltyPayableOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the royalty payable, as a percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfRoyaltyPayableOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ReimbursementsForResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursements for research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ReimbursementsForResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties payable period after first commercial sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SalesMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SalesMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement one-time milestone payment on commercial sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Subscription agreement one-time milestone payment on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_TermOfMilestonePaymentForCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of milestone payment for commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_TermOfMilestonePaymentForCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_TermOfMilestonePaymentForNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of milestone payment for net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_TermOfMilestonePaymentForNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_UpfrontFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_UpfrontFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_UpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fee received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_UpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_UpfrontPaymentUnderIntangibleAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront payment under intangible asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_UpfrontPaymentUnderIntangibleAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_XacduroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_XacduroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_GiaprezaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_GiaprezaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_LicenseAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_LicenseAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_XeravaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_XeravaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_AmendedZaiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_AmendedZaiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_InterimSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_InterimSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_ManufacturingStageTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_ManufacturingStageTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_ResearchAndDevelopmentSupportMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_ResearchAndDevelopmentSupportMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_PaionAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_PaionAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_CostReimbursementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_CostReimbursementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_EverestMedicinesLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=inva_CommercialSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=inva_CommercialSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_GARDPCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_GARDPCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_BasileaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_BasileaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_GeorgeWashingtonUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_GeorgeWashingtonUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_HarvardUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_HarvardUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_ParatekPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_ParatekPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_MassachusettsInstituteOfTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_MassachusettsInstituteOfTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_DevelopmentRegulatoryAndSalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_DevelopmentRegulatoryAndSalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_DurlobactamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_DurlobactamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_ZoliflodacinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_ZoliflodacinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_GatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_GatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Entity - ISP Fund LP (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>CONSOLIDATED ENTITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 1,635,165<span></span>
</td>
<td class="nump">$ 1,301,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember', window );">ISP Fund LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>CONSOLIDATED ENTITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LimitedPartnersContributedCapital', window );">Capital contribution</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfEconomicInterestInPartnership', window );">Economic interest of the Partnership (in percent)</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CashDistributions', window );">Cash distribution</a></td>
<td class="nump">$ 121,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NetInvestmentRelatedIncomeExpensesEarnedInccured', window );">Net investment-related income (expense) earned (incurred)</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="num">(3,700)<span></span>
</td>
<td class="num">$ (4,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Investment income, interest</a></td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">6,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss on other equity investments</a></td>
<td class="nump">12,700<span></span>
</td>
<td class="num">(51,500)<span></span>
</td>
<td class="num">(6,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Realized gain on equity investments</a></td>
<td class="num">(68,700)<span></span>
</td>
<td class="num">(5,300)<span></span>
</td>
<td class="num">$ (2,400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 79,700<span></span>
</td>
<td class="nump">$ 255,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CashDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash distributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CashDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NetInvestmentRelatedIncomeExpensesEarnedInccured">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net investment related income expenses earned inccured.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NetInvestmentRelatedIncomeExpensesEarnedInccured</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfEconomicInterestInPartnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of economic interest held in Partnership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfEconomicInterestInPartnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of capital contributed by the limited partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 860<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481420/860-30-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Entity - Summary of Individual Investments Held by ISP Fund (Details) - Isp Fund Lp [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stocks - Privately held healthcare companies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_MoneyMarketFundAndCash', window );">Money market fund and cash</a></td>
<td class="nump">$ 15,727<span></span>
</td>
<td class="nump">$ 107,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Total investments held by ISP Fund LP</a></td>
<td class="nump">79,741<span></span>
</td>
<td class="nump">255,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember', window );">Publicly Held Healthcare Companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock - Publicly traded healthcare companies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_InvestmentsInCommonStock', window );">Common stock</a></td>
<td class="nump">61,266<span></span>
</td>
<td class="nump">86,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember', window );">Privately Held Healthcare Companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stocks - Privately held healthcare companies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_InvestmentsInWarrants', window );">Warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Publicly Held Healthcare Companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock - Publicly traded healthcare companies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_InvestmentsInCommonStock', window );">Common stock</a></td>
<td class="nump">52,392<span></span>
</td>
<td class="nump">84,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Privately Held Healthcare Companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stocks - Privately held healthcare companies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_InvestmentsInPreferredStock', window );">Preferred stock</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">53,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom | Publicly Held Healthcare Companies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock - Publicly traded healthcare companies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_InvestmentsInCommonStock', window );">Common stock</a></td>
<td class="nump">$ 8,874<span></span>
</td>
<td class="nump">$ 1,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_InvestmentsInCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_InvestmentsInCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_InvestmentsInPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments in preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_InvestmentsInPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_InvestmentsInWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_InvestmentsInWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_MoneyMarketFundAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Money market fund and cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_MoneyMarketFundAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_IspFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_PubliclyTradedHealthcareCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_PubliclyTradedHealthcareCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_PrivatelyHeldHealthcareCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_PrivatelyHeldHealthcareCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Armata (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 23, 2026</div></th>
<th class="th">
<div>Aug. 11, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 12, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Nov. 12, 2024</div></th>
<th class="th">
<div>Mar. 04, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 10, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 10, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 09, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>BoardMember </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_ArmataConvertibleNoteMember', window );">Armata Convertible Note | Secured Convertible Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility in aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 10,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 10,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfWarrantsOwned', window );">Number of Warrants Owned | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,653,847<span></span>
</td>
<td class="nump">19,364,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardOfDirectors', window );">Total number of directors | BoardMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_EquitySecuritiesOwned', window );">Number of shares owned | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,076,769<span></span>
</td>
<td class="nump">25,076,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">Jan. 26,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_VotingAgreementMaximumVotingRightsPercent', window );">Percentage of maximum voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee', window );">Special terms on re-designating board member to board of investee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least 12.5% of the outstanding shares of Armata&#8217;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#8217;s board of directors, and for so long as the Company and ISO hold at least 8%, but less than 12.5%, of the outstanding shares of Armata&#8217;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#8217;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | July 2023 Credit and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility in aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 10,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 10,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | March 2024 Credit and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility in aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  04,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Secured Convertible Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#8220;Credit Agreement&#8221;) with Armata, under which we invested in a one-year convertible note (the &#8220;Armata Convertible Note&#8221;) in an aggregate amount of $30.0 million at an interest rate of 8.0% per annum.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Consolidated Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.80%<span></span>
</td>
<td class="nump">69.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Two Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Armata outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Common stock and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Warrants purchased in 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Warrants purchased in 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Warrants purchased in 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.2<span></span>
</td>
<td class="nump">5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157.5<span></span>
</td>
<td class="nump">46.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Armata Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PrincipalAmountOfTermLoansOwned', window );">Principal amount of term loans owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.4<span></span>
</td>
<td class="nump">42.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.3<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Armata July 2023 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.9<span></span>
</td>
<td class="nump">30.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Armata March 2024 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
<td class="nump">39.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Armata March 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Armata August 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Armata | One Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Armata outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Armata | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Armata | One Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Armata outstanding shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Armata | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember', window );">Innoviva Strategic Opportunities, LLC | Armata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardOfDirectors', window );">Total number of directors | BoardMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PrincipalAmountOfConvertibleNotesOwned', window );">Principal amount of convertible notes owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember', window );">Innoviva Strategic Opportunities, LLC | Armata | March 2025 Credit and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility in aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 12,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember', window );">Innoviva Strategic Opportunities, LLC | Armata | August 2025 Credit and Security Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Term loan facility in aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 11,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_EquitySecuritiesOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity securities owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_EquitySecuritiesOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of board of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfWarrantsOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfWarrantsOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PrincipalAmountOfConvertibleNotesOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal amount of convertible notes owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PrincipalAmountOfConvertibleNotesOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PrincipalAmountOfTermLoansOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal amount of term loans owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PrincipalAmountOfTermLoansOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special Terms on amended and restated investor rights agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_VotingAgreementMaximumVotingRightsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of maximum voting rights under voting agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_VotingAgreementMaximumVotingRightsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_SecuredConvertibleCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_SecuredConvertibleCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=inva_TwoDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=inva_TwoDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_CommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_CommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_WarrantsPurchasedIn2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataMarchTwoThousandTwentyFourTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataMarchTwoThousandTwentyFourTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=inva_OneDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=inva_OneDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Summarized Financial Data (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="nump">$ 727,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 554,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">49,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Income Statement Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">411,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">163,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="nump">$ 271,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract', window );"><strong>Income Statement Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,639)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (46,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (41,363)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (59,512)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Equity Investment in InCarda (Details) - InCarda<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Director </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee', window );">Number of Investee's Board members currently representing the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardMembersOfInvestee', window );">Number of the Investee's Board members | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CarryingValueWroteOffWarrantExercise', window );">Carrying value wrote off warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_IncardaMember', window );">Innoviva TRC Holdings, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction', window );">Maximum number of additional shares into which warrants may be converted under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,490,033<span></span>
</td>
<td class="nump">2,490,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember', window );">Consolidated Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="nump">9.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember', window );">InCarda October 2025 Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember', window );">InCarda February 2025 Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaTwoThousandTwentyFourConvertibleNoteMember', window );">InCarda 2024 Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaConvertibleNoteMember', window );">InCarda Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_CommonAndPreferredStockMember', window );">Common and Preferred Stock | Innoviva TRC Holdings, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,742,250<span></span>
</td>
<td class="nump">36,742,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesDWarrantsMember', window );">Series D Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1AndD2PreferredStockAndCommonStockMember', window );">Series D 1 And D 2 Preferred Stock And Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=inva_OptionPricingModelBacksolveValuationMember', window );">Backsolve Valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity investments</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Backsolve Valuation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ExpectedHoldingPeriod', window );">Expected holding period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DividendYield', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PercentageOfEstimatedVolatility', window );">Estimated volatility</a></td>
<td class="nump">114.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CarryingValueWroteOffWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value wrote off warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CarryingValueWroteOffWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DividendYield">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividend yield.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DividendYield</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ExpectedHoldingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected holding period of equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ExpectedHoldingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfBoardMembersOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of Board members of the Investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfBoardMembersOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's Board members currently serving on the Investee's Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PercentageOfEstimatedVolatility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of estimated volatility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PercentageOfEstimatedVolatility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk free interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_IncardaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_IncardaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inva_InnovivaTRCHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inva_InnovivaTRCHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaTwoThousandTwentyFourConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaTwoThousandTwentyFourConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_CommonAndPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_CommonAndPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesD1AndD2PreferredStockAndCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesD1AndD2PreferredStockAndCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=inva_OptionPricingModelBacksolveValuationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=inva_OptionPricingModelBacksolveValuationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Equity Investment in ImaginAb (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 14, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 14, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>BoardMember</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 23, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000<span></span>
</td>
<td class="nump">$ 453,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Payments to Acquire Long-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember', window );">ImaginAb</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardOfDirectors', window );">Total number of directors | BoardMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember', window );">ImaginAb | Consolidated Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.80%<span></span>
</td>
<td class="nump">11.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember', window );">ImaginAb | Common and Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,825,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember', window );">ImaginAb | Series C-2 preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares purchased under the securities purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,852<span></span>
</td>
<td class="nump">270,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember', window );">ImaginAb | Series C preferred stock, Series C-2 preferred stock and common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember', window );">ImaginAb | ImaginAb Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedInterestAndCommitmentFees', window );">Accrued interest and commitment fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Settlement of convertible note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember', window );">ImaginAb | ImaginAb Convertible Note | First Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Payments to Acquire Long-Term Investments</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember', window );">ImaginAb | Innoviva TRC Holdings, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardOfDirectors', window );">Total number of directors | BoardMember</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedInterestAndCommitmentFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>accrued interest and commitment fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedInterestAndCommitmentFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of board of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_ImaginabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_ImaginabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_CommonAndPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_CommonAndPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesC2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesC2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_SeriesCAndC2PreferredStockAndCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_SeriesCAndC2PreferredStockAndCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ImaginabConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ImaginabConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_FirstAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_FirstAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inva_InnovivaTRCHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inva_InnovivaTRCHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Syndeio Biosciences (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 10, 2026</div></th>
<th class="th"><div>Nov. 11, 2025</div></th>
<th class="th"><div>Mar. 03, 2025</div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
<th class="th"><div>Aug. 05, 2024</div></th>
<th class="th"><div>Feb. 13, 2024</div></th>
<th class="th"><div>Oct. 06, 2023</div></th>
<th class="th"><div>Feb. 02, 2023</div></th>
<th class="th"><div>Nov. 24, 2021</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_SyndeioBiosciencesMember', window );">Syndeio Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCommonStockIssuedDescription', window );">Number of common stock issued description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#8220;Capped Conversion Price&#8221;) and the qualified event price (the &#8220;Qualified Event Price&#8221;). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Syndeio are at least $35.0 million, and (iii) the stated or implied equity valuation of Syndeio is at least $80.0 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_SyndeioBiosciencesMember', window );">Syndeio Biosciences | Syndeio 2025 Convertible Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember', window );">Syndeio 2021 Convertible Note | Syndeio Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,900<span></span>
</td>
<td class="nump">50,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain', window );">Unrealized gain from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember', window );">Convertible Promissory Note Purchase Agreement | Syndeio Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 24,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,800<span></span>
</td>
<td class="nump">$ 33,500<span></span>
</td>
<td class="nump">$ 27,700<span></span>
</td>
<td class="nump">$ 21,500<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember', window );">2021 Convertible Note | Syndeio Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember', window );">Convertible Promissory Note Purchase Agreement Amendment | Syndeio Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember', window );">Convertible Promissory Note Purchase Agreement Second Amendment | Syndeio Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember', window );">Convertible Promissory Note Purchase Agreement Third Amendment | Syndeio Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember', window );">Convertible Promissory Note Purchase Agreement Fourth Amendment | Syndeio Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember', window );">Convertible Promissory Note Purchase Agreement Fifth Amendment | Syndeio Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Additional cash investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember', window );">Convertible Promissory Note Purchase Agreement, Note Amendment Agreement | Syndeio Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="nump">$ 60,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCommonStockIssuedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common stock issued description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCommonStockIssuedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_SyndeioBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_SyndeioBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Nanolive (Details) - Nanolive<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee', window );">Number of Investee's Board members currently representing the Company | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NumberOfBoardMembersOfInvestee', window );">Number of the Investee's Board members | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair value of equity securities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_NanoliveMember', window );">Consolidated Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_NanoliveMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Equity Investment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares to be purchased under the securities purchase agreement | shares</a></td>
<td class="nump">18,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement | $</a></td>
<td class="nump">$ 9.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfBoardMembersOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of Board members of the Investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfBoardMembersOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's Board members currently serving on the Investee's Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_NanoliveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_NanoliveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Lyndra (Details) - Lyndra - Lyndra Convertible Note - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 27, 2025</div></th>
<th class="th"><div>Oct. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible notes face value</a></td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">Nov. 27,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault', window );">Debt instrument percentage premium on principal on default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss', window );">Unrealized loss from fair value changes in equity investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio', window );">Outstanding principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument percentage premium on principal on default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (a)<br> -Paragraph 4<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_LyndraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_LyndraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_LyndraConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_LyndraConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Beacon (Details) - Beacon - Series B Preferred Stock - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 07, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares purchased under the securities purchase agreement</a></td>
<td class="nump">1,448,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_SecuritiesPurchaseAgreementAmount', window );">Amount of securities purchase agreement</a></td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity and long-term investments at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_BeaconMember', window );">Consolidated Investees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_SecuritiesPurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_SecuritiesPurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_BeaconMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_BeaconMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ConsolidatedInvesteesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Reconciliation of Equity and Long - Term Investments Balances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities', window );">Purchases of trading securities</a></td>
<td class="nump">$ 61,729<span></span>
</td>
<td class="nump">$ 63,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForTradingSecurities', window );">Proceeds from trading securities</a></td>
<td class="num">(8,427)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GainLossOnOtherInvestments', window );">Changes in fair value, net</a></td>
<td class="nump">20,160<span></span>
</td>
<td class="num">(59,161)<span></span>
</td>
<td class="nump">11,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PurchasesOfEquityAndOtherLongTermInvestments', window );">Purchases of equity and other long-term investments</a></td>
<td class="nump">17,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund', window );">Net sales and purchases of investments managed by ISP Fund</a></td>
<td class="num">(120,955)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ReclassificationOfCurrentPortion', window );">Reclassification of current portion</a></td>
<td class="nump">91,805<span></span>
</td>
<td class="num">(107,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other</a></td>
<td class="nump">988<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Equity and long-term investments</a></td>
<td class="nump">$ 404,497<span></span>
</td>
<td class="nump">$ 341,664<span></span>
</td>
<td class="nump">$ 444,432<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_GainLossOnOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_GainLossOnOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Sales and Purchases of Investments Managed by ISP Fund</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PurchasesOfEquityAndOtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of Equity and Other Long Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PurchasesOfEquityAndOtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ReclassificationOfCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ReclassificationOfCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid to purchase debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForTradingSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from sales and purchases of trading securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForTradingSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Available-for-Sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 530,278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 289,441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">530,278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">289,441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Credit loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">530,278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">289,441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 530,278<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 289,441<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">$ 1,101,049<span></span>
</td>
<td class="nump">$ 765,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">530,278<span></span>
</td>
<td class="nump">289,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">79,741<span></span>
</td>
<td class="nump">255,658<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Term loan investment | Armata July 2023 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">32,899<span></span>
</td>
<td class="nump">30,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Term loan investment | Armata March 2024 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">43,290<span></span>
</td>
<td class="nump">39,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Term loan investment | Armata March 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">11,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Term loan investment | Armata August 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">15,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">764,753<span></span>
</td>
<td class="nump">529,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">530,278<span></span>
</td>
<td class="nump">289,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">76,993<span></span>
</td>
<td class="nump">193,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Term loan investment | Armata July 2023 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Term loan investment | Armata March 2024 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Term loan investment | Armata March 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Term loan investment | Armata August 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">36,244<span></span>
</td>
<td class="nump">5,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2 | Term loan investment | Armata July 2023 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2 | Term loan investment | Armata March 2024 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2 | Term loan investment | Armata March 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs, Level 2 | Term loan investment | Armata August 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">300,052<span></span>
</td>
<td class="nump">229,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investments and Money market funds | ISP Fund LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="nump">62,098<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3 | Term loan investment | Armata July 2023 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">32,899<span></span>
</td>
<td class="nump">30,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3 | Term loan investment | Armata March 2024 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">43,290<span></span>
</td>
<td class="nump">39,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3 | Term loan investment | Armata March 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">11,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs, Level 3 | Term loan investment | Armata August 2025 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">15,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="nump">267,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Quoted Price in Active Markets for Identical Assets, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Significant Other Observable Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="nump">267,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">473,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | Significant Unobservable Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Total fair value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | 2025 Notes | Quoted Price in Active Markets for Identical Assets, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | 2025 Notes | Significant Other Observable Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | 2025 Notes | Significant Unobservable Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | 2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | 2028 Notes | Quoted Price in Active Markets for Identical Assets, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | 2028 Notes | Significant Other Observable Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Nonrecurring basis | 2028 Notes | Significant Unobservable Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">101,358<span></span>
</td>
<td class="nump">42,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Equity investment | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">157,482<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Equity investment | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">36,244<span></span>
</td>
<td class="nump">5,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">157,482<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">36,244<span></span>
</td>
<td class="nump">5,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">101,358<span></span>
</td>
<td class="nump">42,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember', window );">Armata | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda | Recurring basis | Equity investment | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Equity investment | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda | Recurring basis | Significant Other Observable Inputs, Level 2 | Equity investment | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember', window );">InCarda | Recurring basis | Significant Unobservable Inputs, Level 3 | Equity investment | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginAbNoteMember', window );">ImaginAb Note | Recurring basis | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginAbNoteMember', window );">ImaginAb Note | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginAbNoteMember', window );">ImaginAb Note | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginAbNoteMember', window );">ImaginAb Note | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaTwoThousandTwentyFourConvertibleNoteMember', window );">InCarda 2024 Convertible Note | Recurring basis | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaTwoThousandTwentyFourConvertibleNoteMember', window );">InCarda 2024 Convertible Note | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaTwoThousandTwentyFourConvertibleNoteMember', window );">InCarda 2024 Convertible Note | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaTwoThousandTwentyFourConvertibleNoteMember', window );">InCarda 2024 Convertible Note | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember', window );">InCarda February 2025 Convertible Note | Recurring basis | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember', window );">InCarda February 2025 Convertible Note | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember', window );">InCarda February 2025 Convertible Note | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember', window );">InCarda February 2025 Convertible Note | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember', window );">InCarda October 2025 Convertible Note | Recurring basis | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember', window );">InCarda October 2025 Convertible Note | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember', window );">InCarda October 2025 Convertible Note | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember', window );">InCarda October 2025 Convertible Note | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember', window );">Syndeio 2021 Convertible Note | Recurring basis | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">62,937<span></span>
</td>
<td class="nump">50,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember', window );">Syndeio 2021 Convertible Note | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember', window );">Syndeio 2021 Convertible Note | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember', window );">Syndeio 2021 Convertible Note | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">62,937<span></span>
</td>
<td class="nump">$ 50,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember', window );">Syndeio 2025 Convertible Note | Recurring basis | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">24,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember', window );">Syndeio 2025 Convertible Note | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember', window );">Syndeio 2025 Convertible Note | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember', window );">Syndeio 2025 Convertible Note | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">24,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_LyndraConvertibleNoteMember', window );">Lyndra Convertible Note | Recurring basis | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">3,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_LyndraConvertibleNoteMember', window );">Lyndra Convertible Note | Recurring basis | Quoted Price in Active Markets for Identical Assets, Level 1 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_LyndraConvertibleNoteMember', window );">Lyndra Convertible Note | Recurring basis | Significant Other Observable Inputs, Level 2 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_LyndraConvertibleNoteMember', window );">Lyndra Convertible Note | Recurring basis | Significant Unobservable Inputs, Level 3 | Convertible debt investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at estimated fair value</a></td>
<td class="nump">$ 3,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=inva_EquityInvestmentsAndMoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=inva_EquityInvestmentsAndMoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_IspFundLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_IspFundLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=inva_TermLoanInvestmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=inva_TermLoanInvestmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataMarchTwoThousandTwentyFourTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataMarchTwoThousandTwentyFourTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ArmataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_IncardaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginAbNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_ImaginAbNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaTwoThousandTwentyFourConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaTwoThousandTwentyFourConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_LyndraConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=inva_LyndraConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity and Long-term Investments and Fair Value Measurements - (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels', window );">Fair value of assets or liabilities transfer between levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Assets Or Liabilities Transfer Between Levels</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capitalized Fees Paid - Schedule of Capitalized Fees Paid (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="nump">$ 220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(163,862)<span></span>
</td>
<td class="num">(150,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNet', window );">Net carrying value</a></td>
<td class="nump">$ 56,138<span></span>
</td>
<td class="nump">69,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidWeightedAverageUsefulLife', window );">Weighted average remaining amortization period</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidFutureAmortizationAbstract', window );"><strong>Capitalized Fees paid, Future amortization</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths', window );">Estimated amortization for the year 2026</a></td>
<td class="nump">$ 13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo', window );">Estimated amortization for the year 2027</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree', window );">Estimated amortization for the year 2028</a></td>
<td class="nump">13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour', window );">Estimated amortization for the year 2029</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive', window );">Estimated amortization for the year 2030</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization expense</a></td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="nump">$ 13,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Gross carrying value</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember', window );">GSK | Royalty Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostLineItems', window );"><strong>Capitalized Fees paid</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization expense</a></td>
<td class="nump">$ 13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
<td class="nump">$ 13,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidFutureAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fees paid future amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidFutureAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated amortization for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CapitalizedFeesPaidWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized fees paid weighted average useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CapitalizedFeesPaidWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Aug. 22, 2022</div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 17,905,000<span></span>
</td>
<td class="nump">$ 17,905,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future amortization expense, 2026</a></td>
<td class="nump">26,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Future amortization expense, 2027</a></td>
<td class="nump">26,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Future amortization expense, 2028</a></td>
<td class="nump">26,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Future amortization expense, 2029</a></td>
<td class="nump">26,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Future amortization expense, 2030</a></td>
<td class="nump">26,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Future amortization expense, thereafter</a></td>
<td class="nump">49,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">26,277,000<span></span>
</td>
<td class="nump">$ 25,902,000<span></span>
</td>
<td class="nump">$ 21,784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_BasileaMember', window );">Basilea</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_UpfrontFee', window );">Upfront fee</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | XACDURO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets pertain to product rights and developed technologies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | NUZOLVENCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue', window );">Acquired Finite-Lived Intangible Asset, Residual Value</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets pertain to product rights and developed technologies</a></td>
<td class="nump">151,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets pertain to product rights and developed technologies</a></td>
<td class="nump">106,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis | Collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets pertain to product rights and developed technologies</a></td>
<td class="nump">35,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember', window );">Entasis | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Intangible assets pertain to product rights and developed technologies</a></td>
<td class="nump">$ 71,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_UpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_UpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of residual value of finite-lived asset acquired in business combination, asset acquisition, and from joint venture formation. Excludes financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of identifiable indefinite-lived intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_BasileaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_BasileaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_XacduroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_XacduroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_NUZOLVENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_NUZOLVENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Summary of Accumulated Amortization of Recognized Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsMarketedProductsGross', window );">Marketed products, gross carrying amount</a></td>
<td class="nump">$ 226,300<span></span>
</td>
<td class="nump">$ 223,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentGross', window );">In-process research and development, gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsCollaborationAgreementGross', window );">Collaboration agreement, gross carrying amount</a></td>
<td class="nump">35,400<span></span>
</td>
<td class="nump">35,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total gross carrying amount</a></td>
<td class="nump">261,700<span></span>
</td>
<td class="nump">261,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsMarketedProductsAccumulatedAmortization', window );">Marketed products, Accumulated amortization</a></td>
<td class="num">(70,299)<span></span>
</td>
<td class="num">(47,559)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization', window );">In-process research and development, accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization', window );">Collaboration agreement, accumulated amortization</a></td>
<td class="num">(9,245)<span></span>
</td>
<td class="num">(5,708)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(79,544)<span></span>
</td>
<td class="num">(53,267)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsMarketedProductsNet', window );">Marketed products, net carrying amount</a></td>
<td class="nump">156,001<span></span>
</td>
<td class="nump">176,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentNet', window );">In-process research and development, net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IntangibleAssetsCollaborationAgreementNet', window );">Collaboration agreement, net carrying amount</a></td>
<td class="nump">26,155<span></span>
</td>
<td class="nump">29,692<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net carrying amount</a></td>
<td class="nump">$ 182,156<span></span>
</td>
<td class="nump">$ 208,433<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Marketed products, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Marketed products, Useful Life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Marketed products, Useful Life</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets collaboration agreement accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsCollaborationAgreementGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets collaboration agreement gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsCollaborationAgreementGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsCollaborationAgreementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets collaboration agreement net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsCollaborationAgreementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible sssets in process research and development accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsInProcessResearchAndDevelopmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsInProcessResearchAndDevelopmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of In-process research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsInProcessResearchAndDevelopmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsMarketedProductsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amortization amount of Marketed Products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsMarketedProductsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsMarketedProductsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of Marketed products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsMarketedProductsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IntangibleAssetsMarketedProductsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net amount of Marketed Products.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IntangibleAssetsMarketedProductsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=inva_MarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=inva_MarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 16,330<span></span>
</td>
<td class="nump">$ 11,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">17,871<span></span>
</td>
<td class="nump">20,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,971<span></span>
</td>
<td class="nump">2,083<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 39,172<span></span>
</td>
<td class="nump">$ 33,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Additional Information) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_ZaiLabMember', window );">Zai Lab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvancesOnInventoryPurchases', window );">Payment received for additional inventory purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaPharmaceuticalCompanyMember', window );">La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FairValueAdjustmentsOfInventoryFromAcquistion', window );">Net fair value adjustment of inventory from acquisition</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold', window );">Amortization of fair value adjustments of Cost of products sold</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 13.8<span></span>
</td>
<td class="nump">$ 27.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of fair value adjustments of cost of products sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FairValueAdjustmentsOfInventoryFromAcquistion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of net fair value adjustment of inventory resulting from the acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FairValueAdjustmentsOfInventoryFromAcquistion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesOnInventoryPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesOnInventoryPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule Of Other Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedContractManufacturingLiability', window );">Accrued contract manufacturing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,220<span></span>
</td>
<td class="nump">$ 1,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedClinicalAndResearchLiability', window );">Accrued clinical and research expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">185<span></span>
</td>
<td class="nump">611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedProfessionalServices', window );">Accrued professional services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,845<span></span>
</td>
<td class="nump">$ 8,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Total other accrued liabilities<span></span>
</td>
<td class="text">Total other accrued liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">$ 1,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalty obligation payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,690<span></span>
</td>
<td class="nump">2,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredRoyaltyObligationCurrent', window );">Current portion of deferred royalty obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,124<span></span>
</td>
<td class="nump">6,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedLicenseFeesAndRoyalties', window );">Accrued license fees and royalties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,964<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,022<span></span>
</td>
<td class="nump">6,947<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total other accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 29,468<span></span>
</td>
<td class="nump">$ 29,999<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount as of December 31, 2024 includes $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance payments received from our partner for inventory supply as discussed in Note 4, &#8220;License and Collaboration Arrangements&#8221;.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedClinicalAndResearchLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical and research liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedClinicalAndResearchLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedContractManufacturingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedContractManufacturingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedLicenseFeesAndRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued license fees and royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedLicenseFeesAndRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Professional Services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredRoyaltyObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredRoyaltyObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components -Schedule of Other Long-term Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredRoyaltyObligationNonCurrent', window );">Long-term portion of deferred royalty obligation</a></td>
<td class="nump">$ 54,104<span></span>
</td>
<td class="nump">$ 63,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total other long-term liabilities<span></span>
</td>
<td class="text">Total other long-term liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">$ 10,868<span></span>
</td>
<td class="nump">$ 1,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">1,119<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 66,091<span></span>
</td>
<td class="nump">$ 64,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredRoyaltyObligationNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term portion of deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredRoyaltyObligationNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - 2012 Plan and ESPP (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>Item </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EquityIncentivePlan2012Member', window );">2012 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for issuance</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price as a percentage of fair market value of stock</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod', window );">Total duration of consecutive and overlapping offering periods</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods', window );">Number of offering periods | Item</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod', window );">Duration of purchase period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum contributions as a percentage of employee's eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares an employee may purchase during any purchase period</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation', window );">Maximum value of shares an employee may purchase in a calendar year | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember', window );">2023 ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price as a percentage of fair market value of stock</a></td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod', window );">Total duration of consecutive and overlapping offering periods</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum contributions as a percentage of employee's eligible compensation</a></td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Maximum number of shares an employee may purchase during any purchase period</a></td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation', window );">Maximum value of shares an employee may purchase in a calendar year | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares remaining available for issuance</a></td>
<td class="nump">2,385,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the consecutive and overlapping offering period for the offering of share-based payment awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute of employee's eligible compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of purchase periods having duration of six months each.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EquityIncentivePlan2012Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EquityIncentivePlan2012Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Director Compensation Program (Details) - RSUs - Non-employee director<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>Installment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue', window );">One time grant of shares, value</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue', window );">Pro rata shares grant, value</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments', window );">Number of annual installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue', window );">Annual grant of shares, value</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The additional value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares granted annually to independent directors upon re-election the to Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of annual installments that RSUs granted to newly appointed independent directors will vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,452<span></span>
</td>
<td class="nump">$ 6,374<span></span>
</td>
<td class="nump">$ 5,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">22,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">165<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Amortization Period (Years)</a></td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,995<span></span>
</td>
<td class="nump">2,738<span></span>
</td>
<td class="nump">1,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 9,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Amortization Period (Years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,041<span></span>
</td>
<td class="nump">3,348<span></span>
</td>
<td class="nump">3,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 13,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Amortization Period (Years)</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-Average Amortization Period (Years)</a></td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 8,930<span></span>
</td>
<td class="nump">6,040<span></span>
</td>
<td class="nump">4,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 522<span></span>
</td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 1,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=inva_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Compensation Awards (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of outstanding options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">2,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(85,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(17,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">2,834,000<span></span>
</td>
<td class="nump">2,067,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">2,834,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price of Outstanding Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 15.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">15.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">15.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">14.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">16.08<span></span>
</td>
<td class="nump">$ 15.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per shares)</a></td>
<td class="nump">$ 16.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">$ 11.1<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable option</a></td>
<td class="nump">1,267,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term of options exercisable</a></td>
<td class="text">7 years 8 months 4 days<span></span>
</td>
<td class="text">8 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total estimated fair value of options vested</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of outstanding RSUs and PSUs/RSAs and PSAs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">598,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="nump">662,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released RSUs and RSAs (in shares)</a></td>
<td class="num">(300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited (in shares)</a></td>
<td class="num">(36,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">924,000<span></span>
</td>
<td class="nump">598,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">924,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value per Share at Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">18.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released RSUs and RSAs (in dollars per share)</a></td>
<td class="nump">15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">17.22<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 17.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total estimated fair value of equity instruments vested</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSAs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Number of outstanding RSUs and PSUs/RSAs and PSAs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released RSUs and RSAs (in shares)</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value per Share at Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released RSUs and RSAs (in dollars per share)</a></td>
<td class="nump">15.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 14.77<span></span>
</td>
<td class="nump">$ 15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total estimated fair value of equity instruments vested</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value per Share of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Valuation Assumptions (Details) - Employee Stock Option - Innoviva [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Volatility</a></td>
<td class="nump">34.50%<span></span>
</td>
<td class="nump">35.50%<span></span>
</td>
<td class="nump">37.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average estimated fair value of shares granted (in dollars per share)</a></td>
<td class="nump">$ 7.48<span></span>
</td>
<td class="nump">$ 8.17<span></span>
</td>
<td class="nump">$ 5.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Weighted-average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Valuation Assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=inva_InnovivaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=inva_InnovivaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Feb. 13, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 03, 2025</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_ClassOfWarrantOrRightExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,698<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchased and retired during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount of shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock repurchased and retired during period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,855<span></span>
</td>
<td class="nump">986,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,173,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CommonStockAcquiredAverageCostPerShare', window );">Shares repurchased average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.09<span></span>
</td>
<td class="nump">$ 15.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchased and retired during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 76,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Stock repurchased and retired during period, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">569,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CommonStockAcquiredAverageCostPerShare', window );">Shares repurchased average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchased and retired during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Stock repurchased and retired during period, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393,829)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-In Capital | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Cost of treasury stock</a></td>
<td class="nump">$ 393,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CommonStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Acquired Average Cost Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CommonStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Schedule of Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 261,000<span></span>
</td>
<td class="nump">$ 453,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="num">(3,269)<span></span>
</td>
<td class="num">(5,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Net carrying amount</a></td>
<td class="nump">257,731<span></span>
</td>
<td class="nump">448,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Less: Current portion of long-term debt, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(192,028)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, net</a></td>
<td class="nump">257,731<span></span>
</td>
<td class="nump">256,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">$ 16,698<span></span>
</td>
<td class="nump">22,209<span></span>
</td>
<td class="nump">$ 19,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_HealthCareRoyaltyPartnersMember', window );">HealthCare Royalty Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementMaximumPotentialPayoutPercent', window );">Maximum potential royalty payout</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent', window );">Increase in maximum potential payout percent</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo', window );">Maximum aggregate royalty payments</a></td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_MaximumAggregateRoyaltyPaymentsDue', window );">Maximum aggregate royalty payments</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne', window );">Required payment for breach of agreement, payment one</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_TotalPaymentsMadeForRoyaltyAgreement', window );">Payment for royalty agreement</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Total debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">192,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(472)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes | Convertible senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Total debt</a></td>
<td class="nump">261,000<span></span>
</td>
<td class="nump">261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized debt discount and issuance costs</a></td>
<td class="num">(3,269)<span></span>
</td>
<td class="num">(4,684)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Net carrying amount</a></td>
<td class="nump">257,731<span></span>
</td>
<td class="nump">256,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember', window );">Royalty Financing Agreement | Loans Payable [Member] | HealthCare Royalty Partners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">6,300<span></span>
</td>
<td class="nump">9,800<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredRoyaltyObligations', window );">Deferred Royalty obligations</a></td>
<td class="nump">62,200<span></span>
</td>
<td class="nump">69,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_RoyaltyPayments', window );">Royalty Payments</a></td>
<td class="nump">$ 12,800<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_InterestRateOfDeferredRoyaltyObligation', window );">Interest Rate of Deferred Royalty Obligation</a></td>
<td class="nump">10.03%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredRoyaltyObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred royalty obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredRoyaltyObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_InterestRateOfDeferredRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest rate of deferred royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_InterestRateOfDeferredRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_MaximumAggregateRoyaltyPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate royalty payments due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_MaximumAggregateRoyaltyPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement increase in maximum potential payout percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementMaximumPotentialPayoutPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement, maximum potential payout, percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementMaximumPotentialPayoutPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement required payment for breach of agreement payment one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty agreement required payment for breach of agreement payment two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_RoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_RoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_TotalPaymentsMadeForRoyaltyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total payments made for royalty agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_TotalPaymentsMadeForRoyaltyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_HealthCareRoyaltyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_HealthCareRoyaltyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_RoyaltyFinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Convertible Subordinated Notes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Jan. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,618<span></span>
</td>
<td class="nump">$ 3,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,269<span></span>
</td>
<td class="nump">$ 5,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember', window );">2023 Notes | Convertible subordinated notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentRemainingBalancePaidUponMaturation', window );">Remaining balance paid upon maturation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Portion of debt retired, face value</a></td>
<td class="nump">$ 144,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment for repurchase of debt instrument</a></td>
<td class="nump">$ 165,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentRemainingBalancePaidUponMaturation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument remaining balance paid upon maturation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentRemainingBalancePaidUponMaturation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Convertible Senior Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 15, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 07, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,269,000)<span></span>
</td>
<td class="num">$ (5,156,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 257,731,000<span></span>
</td>
<td class="nump">$ 448,344,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember', window );">2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 15,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentRemainingBalancePaidUponMaturation', window );">Remaining balance paid upon maturation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember', window );">2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCovenantTerms', window );">Debt instrument, covenant terms description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock', window );">Principal Amount of Debt Converted into Shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,000,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.88%<span></span>
</td>
<td class="nump">2.88%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 192,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(472,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,028,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowingsAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,002,000<span></span>
</td>
<td class="nump">4,813,000<span></span>
</td>
<td class="nump">$ 4,813,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">472,000<span></span>
</td>
<td class="nump">733,000<span></span>
</td>
<td class="nump">712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,474,000<span></span>
</td>
<td class="nump">5,546,000<span></span>
</td>
<td class="nump">5,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2025 Notes | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Principal amount converted in to shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,119,956<span></span>
</td>
<td class="nump">28,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="nump">$ 261,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 15,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage', window );">Common stock price to current conversion price ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtConversionConvertedInstrumentAverageTradePricePercentage', window );">Average trading price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount', window );">Ratio of repurchase price to the principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentPrincipalAmount', window );">Principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,000,000<span></span>
</td>
<td class="nump">261,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt discount and issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,269,000)<span></span>
</td>
<td class="num">(4,684,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Net carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,731,000<span></span>
</td>
<td class="nump">256,316,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowingsAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,546,000<span></span>
</td>
<td class="nump">5,546,000<span></span>
</td>
<td class="nump">5,546,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415,000<span></span>
</td>
<td class="nump">1,377,000<span></span>
</td>
<td class="nump">1,342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,961,000<span></span>
</td>
<td class="nump">$ 6,923,000<span></span>
</td>
<td class="nump">6,888,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Privately-negotiated capped call option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1', window );">Strike price for the underlying number of shares (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes', window );">Purchases of capped calls in connection with convertible senior notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember', window );">Convertible senior notes | 2028 Notes | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion rate for shares of common stock per $1,000 principal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.1432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (dollars per share) | $ / shares</a></td>
<td class="nump">$ 26.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember', window );">Convertible subordinated notes | 2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 287,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, annual interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.125%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DebtInstrumentRemainingBalancePaidUponMaturation', window );">Remaining balance paid upon maturation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt Instrument, Repurchased Face Amount</a></td>
<td class="nump">$ 144,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfUnsecuredDebt', window );">Payment upon maturity of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowingsAbstract', window );"><strong>Interest expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total interest and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost to enter into capped calls sales in connection with convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock price as a percentage of conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtConversionConvertedInstrumentAverageTradePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average trading price per $1,000 of Notes with respect to product of the closing common stock price and the conversion rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtConversionConvertedInstrumentAverageTradePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Principal Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Ratio of repurchase price to the principal amount of debt instrument to be repurchased in the event of default or a fundamental change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DebtInstrumentRemainingBalancePaidUponMaturation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument remaining balance paid upon maturation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DebtInstrumentRemainingBalancePaidUponMaturation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal amount of debt converted into shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCovenantTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the conditions for borrowing under the credit facility including the nature of any restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCovenantTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityStrikePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise or strike price stated in the contract for options indexed to the issuer's equity shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)(2)<br> -SubTopic 40<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityStrikePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyFiveNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyEightNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=inva_SeniorUnsecuredConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=inva_PrivatelyNegotiatedCappedCallOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=inva_PrivatelyNegotiatedCappedCallOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleSubordinatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=inva_TwoThousandTwentyThreeNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Debt Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Long-term debt maturities for years ending December 31:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total</a></td>
<td class="nump">$ 261,000<span></span>
</td>
<td class="nump">$ 453,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 30, 2025 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, Weighted average remaining lease term</a></td>
<td class="text">9 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate', window );">Lessee, Operating Lease, Existence of Option to Terminate [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies', window );">Accrued liabilities to provide for indemnifications and other contingencies | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=inva_CordenPharmaMember', window );">Corden Pharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Future minimum purchase commitments, 2026 | $</a></td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondYear', window );">Future minimum purchase commitments, 2027 | $</a></td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=inva_BurlingameCaliforniaMember', window );">Burlingame, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration, date</a></td>
<td class="text">Dec. 31,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=inva_WalthamMassachusettsMember', window );">Waltham Massachusetts Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Lease space | ft&#178;</a></td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration, date</a></td>
<td class="text">Mar. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=inva_LexingtonMassachusettsMember', window );">Lexington, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration, date</a></td>
<td class="text">Mar. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued liabilities to provide for indemnifications and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to terminate operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=inva_CordenPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=inva_CordenPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=inva_BurlingameCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=inva_BurlingameCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=inva_WalthamMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=inva_WalthamMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=inva_LexingtonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=inva_LexingtonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Components of Least Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Straight line operating lease costs</a></td>
<td class="nump">$ 1,424<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 1,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 1,515<span></span>
</td>
<td class="nump">$ 1,214<span></span>
</td>
<td class="nump">$ 1,617<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Lease (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of operating lease liabilities:</a></td>
<td class="nump">$ 1,705<span></span>
</td>
<td class="nump">$ 1,464<span></span>
</td>
<td class="nump">$ 1,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease obligations</a></td>
<td class="nump">$ 10,022<span></span>
</td>
<td class="nump">$ 1,156<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 1,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">1,327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">1,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">1,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2030</a></td>
<td class="nump">1,454<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">8,516<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">14,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">$ (3,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Liabilities and Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 11,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET ACQUISITION (Additional Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,604<span></span>
</td>
<td class="nump">$ 13,654<span></span>
</td>
<td class="nump">$ 33,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=inva_LyndraMember', window );">Lyndra [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionDateOfAcquisitionAgreement', window );">Date of acquisition agreement</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_UpfrontCashPayments', window );">Upfront cash payment</a></td>
<td class="nump">$ 10,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost', window );">Asset Acquisition, Consideration Transferred, Transaction Cost</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=inva_LyndraMember', window );">Lyndra [Member] | In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=inva_LyndraMember', window );">Lyndra [Member] | Maximum | Development, Regulatory and Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_FuturePotentialMilestonePayment', window );">Future Potential Milestone Payment</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=inva_LyndraMember', window );">Lyndra [Member] | Property Plant And Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostNetNoncurrent', window );">Capitalized cost of fixed assets</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_FuturePotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future potential milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_FuturePotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_UpfrontCashPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_UpfrontCashPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionDateOfAcquisitionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when asset acquisition agreement is executed, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionDateOfAcquisitionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=inva_LyndraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=inva_LyndraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_DevelopmentRegulatoryAndRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_DevelopmentRegulatoryAndRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income loss before income tax expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="nump">$ 327,060<span></span>
</td>
<td class="nump">$ 37,362<span></span>
</td>
<td class="nump">$ 194,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(198)<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">$ 326,862<span></span>
</td>
<td class="nump">$ 37,388<span></span>
</td>
<td class="nump">$ 194,098<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income tax expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 6,578<span></span>
</td>
<td class="nump">$ 23,438<span></span>
</td>
<td class="nump">$ 7,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">3,477<span></span>
</td>
<td class="nump">3,175<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,795<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">11,850<span></span>
</td>
<td class="nump">26,613<span></span>
</td>
<td class="nump">9,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">42,745<span></span>
</td>
<td class="num">(12,606)<span></span>
</td>
<td class="nump">6,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(2,194)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">43,847<span></span>
</td>
<td class="num">(12,617)<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense, net</a></td>
<td class="nump">$ 55,697<span></span>
</td>
<td class="nump">$ 13,996<span></span>
</td>
<td class="nump">$ 14,376<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Differences between the expected U.S. federal statutory income tax to income tax expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rate</a></td>
<td class="nump">$ 68,682<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 7,846<span></span>
</td>
<td class="nump">$ 40,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rate, percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local effects</a></td>
<td class="nump">$ 2,739<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,864<span></span>
</td>
<td class="nump">$ 1,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local effects, percent</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects Other - Withholding taxes</a></td>
<td class="nump">$ 1,796<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax effects Other - Withholding taxes , Percent</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Enactment of new tax laws</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Enactment of new tax laws, percent</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract', window );"><strong>Cross-border tax laws</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount', window );">Foreign-derived intangible income</a></td>
<td class="num">$ (7,543)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent', window );">Foreign-derived intangible income, percent</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">Foreign tax credit</a></td>
<td class="num">$ (1,555)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">Foreign tax credit, percent</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Federal and state research and development credit</a></td>
<td class="num">$ (324)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (90)<span></span>
</td>
<td class="num">$ (1,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Federal and state research and development credit, percent</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount', window );">Section 250 deduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (11,767)<span></span>
</td>
<td class="num">$ (15,274)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent', window );">Section 250 deduction, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(31.50%)<span></span>
</td>
<td class="num">(7.90%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">$ (11,726)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 18,386<span></span>
</td>
<td class="num">$ (12,167)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, percent</a></td>
<td class="num">(3.60%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">49.20%<span></span>
</td>
<td class="num">(6.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nontaxable or nondeductible items</a></td>
<td class="nump">$ 407<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nontaxable or nondeductible items, percent</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits', window );">Changes in unrecognized tax benefits</a></td>
<td class="nump">$ 3,709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent', window );">Changes in unrecognized tax benefits, percent</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">$ (488)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">$ (2,243)<span></span>
</td>
<td class="nump">$ 1,219<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments, percent</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6.00%)<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37.50%<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense, net</a></td>
<td class="nump">$ 55,697<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 13,996<span></span>
</td>
<td class="nump">$ 14,376<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For tax year 2025, state taxes in Kentucky made up the majority (greater than 50 percent) of the tax effect in this category.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Changes In Unrecognized Tax Benefits Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation section two fifty deduction amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax reconciliation section two fifty deduction percent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation Changes in Unrecognized Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Net income taxes paid (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Net cash paid for income taxes</a></td>
<td class="nump">$ 19,113<span></span>
</td>
<td class="nump">$ 11,793<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Net cash paid for income taxes</a></td>
<td class="nump">17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and local jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Net cash paid for income taxes</a></td>
<td class="nump">1,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Net cash paid for income taxes</a></td>
<td class="nump">$ 436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 172,440<span></span>
</td>
<td class="nump">$ 176,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">21,270<span></span>
</td>
<td class="nump">21,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet', window );">Unrealized losses on investment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxAssetsDeferredRoyaltyObligationNet', window );">Deferred royalty obligation, net</a></td>
<td class="nump">15,654<span></span>
</td>
<td class="nump">17,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves', window );">Accruals and reserves</a></td>
<td class="nump">2,479<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5,942<span></span>
</td>
<td class="nump">6,832<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets before valuation allowance</a></td>
<td class="nump">217,785<span></span>
</td>
<td class="nump">234,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(176,151)<span></span>
</td>
<td class="num">(187,635)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">41,634<span></span>
</td>
<td class="nump">46,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxLiabilitiesDepreciationAndAmortization1', window );">Depreciation and amortization</a></td>
<td class="num">(32,205)<span></span>
</td>
<td class="num">(31,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestments', window );">Unrealized gains on investment, net</a></td>
<td class="num">(37,823)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment', window );">Inventory fair value adjustment</a></td>
<td class="num">(986)<span></span>
</td>
<td class="num">(2,798)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(2,413)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,054<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax (liabilities)</a></td>
<td class="num">$ (31,793)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxAssetsDeferredRoyaltyObligationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets deferred royalty obligation, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxAssetsDeferredRoyaltyObligationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets unrealized losses on investment, net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxLiabilitiesDepreciationAndAmortization1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxLiabilitiesDepreciationAndAmortization1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities inventory fair value adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">497.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Net operating loss carryforwards do not expire</a></td>
<td class="nump">448.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Entasis Therapeutics Holdings Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">146.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | La Jolla Pharmaceutical Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">351.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 1,028.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating loss carryforwards beginning date of expiry</a></td>
<td class="text">Jan.  01,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research tax credit carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_IncomeTaxesLineItems', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward amount</a></td>
<td class="nump">$ 33.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Tax credit carryforward beginning date of expiry</a></td>
<td class="text">Jan.  01,  2033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_EntasisTherapeuticsHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=inva_LaJollaPharmaceuticalCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Changes in Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 62,709<span></span>
</td>
<td class="nump">$ 61,294<span></span>
</td>
<td class="nump">$ 19,443<span></span>
</td>
<td class="nump">$ 16,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Net increase in tax portions</a></td>
<td class="nump">$ 1,415<span></span>
</td>
<td class="nump">$ 41,851<span></span>
</td>
<td class="nump">$ 3,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Reporting - Schedule of Reconciliation to the Consolidated Net Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 411,328<span></span>
</td>
<td class="nump">$ 358,711<span></span>
</td>
<td class="nump">$ 310,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">30,604<span></span>
</td>
<td class="nump">13,654<span></span>
</td>
<td class="nump">33,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">26,277<span></span>
</td>
<td class="nump">25,902<span></span>
</td>
<td class="nump">21,784<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Changes in fair values of equity method investments, net</a></td>
<td class="num">(141,433)<span></span>
</td>
<td class="nump">64,253<span></span>
</td>
<td class="num">(77,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GainLossOnOtherInvestments', window );">Changes in fair value of equity and long-term investments, net</a></td>
<td class="num">(20,160)<span></span>
</td>
<td class="nump">59,161<span></span>
</td>
<td class="num">(11,129)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Interest and dividend income</a></td>
<td class="num">(21,086)<span></span>
</td>
<td class="num">(19,141)<span></span>
</td>
<td class="num">(15,818)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">16,698<span></span>
</td>
<td class="nump">22,209<span></span>
</td>
<td class="nump">19,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">2,864<span></span>
</td>
<td class="nump">2,997<span></span>
</td>
<td class="nump">4,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense, net</a></td>
<td class="nump">55,697<span></span>
</td>
<td class="nump">13,996<span></span>
</td>
<td class="nump">14,376<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income and comprehensive income</a></td>
<td class="nump">271,165<span></span>
</td>
<td class="nump">23,392<span></span>
</td>
<td class="nump">179,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">411,328<span></span>
</td>
<td class="nump">358,711<span></span>
</td>
<td class="nump">310,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing</a></td>
<td class="nump">36,502<span></span>
</td>
<td class="nump">31,441<span></span>
</td>
<td class="nump">30,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">76,816<span></span>
</td>
<td class="nump">84,249<span></span>
</td>
<td class="nump">67,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of acquired intangible assets</a></td>
<td class="nump">26,277<span></span>
</td>
<td class="nump">25,902<span></span>
</td>
<td class="nump">21,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Changes in fair values of equity method investments, net</a></td>
<td class="num">(141,433)<span></span>
</td>
<td class="nump">64,253<span></span>
</td>
<td class="num">(77,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_inva_GainLossOnOtherInvestments', window );">Changes in fair value of equity and long-term investments, net</a></td>
<td class="num">(20,160)<span></span>
</td>
<td class="nump">59,161<span></span>
</td>
<td class="num">(11,129)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Interest and dividend income</a></td>
<td class="num">(21,086)<span></span>
</td>
<td class="num">(19,141)<span></span>
</td>
<td class="num">(15,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">16,698<span></span>
</td>
<td class="nump">22,209<span></span>
</td>
<td class="nump">19,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="nump">2,864<span></span>
</td>
<td class="nump">2,997<span></span>
</td>
<td class="nump">4,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense, net</a></td>
<td class="nump">55,697<span></span>
</td>
<td class="nump">13,996<span></span>
</td>
<td class="nump">14,376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income and comprehensive income</a></td>
<td class="nump">271,165<span></span>
</td>
<td class="nump">23,392<span></span>
</td>
<td class="nump">179,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,368<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">77,384<span></span>
</td>
<td class="nump">36,598<span></span>
</td>
<td class="nump">41,040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of license revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of license revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_ExternalServicesMember', window );">External services | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">15,705<span></span>
</td>
<td class="nump">7,408<span></span>
</td>
<td class="nump">20,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=inva_InternalExpensesMember', window );">Internal expenses | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,531<span></span>
</td>
<td class="nump">$ 6,246<span></span>
</td>
<td class="nump">$ 13,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_inva_GainLossOnOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain loss on other investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">inva_GainLossOnOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>inva_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_ExternalServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_ExternalServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=inva_InternalExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=inva_InternalExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>615</ContextCount>
  <ElementCount>590</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>178</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>75000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>75010 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>75030 - Statement - CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>75040 - Statement - CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>75050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>75060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>75070 - Disclosure - Cybersecurity Risk Management, Strategy and Governance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance</Role>
      <ShortName>Cybersecurity Risk Management, Strategy and Governance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995455 - Disclosure - Description of Operations and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies1</Role>
      <ShortName>Description of Operations and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995465 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShare1</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995475 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognition1</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995485 - Disclosure - License, Collaboration and Other Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangements</Role>
      <ShortName>License, Collaboration and Other Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995495 - Disclosure - Consolidated Entities and Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions3</Role>
      <ShortName>Consolidated Entities and Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995505 - Disclosure - Equity and Long-term Investments and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements2</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995515 - Disclosure - Capitalized Fees Paid</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaid1</Role>
      <ShortName>Capitalized Fees Paid</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995525 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets3</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995535 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995545 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995555 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquity1</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995565 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDebt4</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995575 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies3</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995585 - Disclosure - Asset Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisition1</Role>
      <ShortName>Asset Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995595 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxes3</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995605 - Disclosure - Segment Reporting</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReporting1</Role>
      <ShortName>Segment Reporting</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Operations and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies1</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Operations and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies1</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShare1</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognition1</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995665 - Disclosure - Consolidated Entities and Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables</Role>
      <ShortName>Consolidated Entities and Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions3</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995675 - Disclosure - Equity and Long-term Investments and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements2</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995685 - Disclosure - Capitalized Fees Paid (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidTables</Role>
      <ShortName>Capitalized Fees Paid (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaid1</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995695 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets3</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995705 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995715 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995725 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureDebt4</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995735 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies3</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995745 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxes3</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995755 - Disclosure - Segment Reporting (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingTables</Role>
      <ShortName>Segment Reporting (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReporting1</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995765 - Disclosure - Description of Operations and Summary of Significant Accounting Policies - Description of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails</Role>
      <ShortName>Description of Operations and Summary of Significant Accounting Policies - Description of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995775 - Disclosure - Description of Operations and Summary of Significant Accounting Policies - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>Description of Operations and Summary of Significant Accounting Policies - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995785 - Disclosure - Description of Operations and Summary of Significant Accounting Policies - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails</Role>
      <ShortName>Description of Operations and Summary of Significant Accounting Policies - Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995795 - Disclosure - Net Income Per Share - Basic and Diluted EPS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails</Role>
      <ShortName>Net Income Per Share - Basic and Diluted EPS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995805 - Disclosure - Net Income Per Share - Anti-Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails</Role>
      <ShortName>Net Income Per Share - Anti-Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995815 - Disclosure - Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails</Role>
      <ShortName>Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995825 - Disclosure - Revenue Recognition - Schedule of net product sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails</Role>
      <ShortName>Revenue Recognition - Schedule of net product sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995835 - Disclosure - Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails</Role>
      <ShortName>Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995845 - Disclosure - License, Collaboration and Other Arrangements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails</Role>
      <ShortName>License, Collaboration and Other Arrangements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995855 - Disclosure - Consolidated Entity - ISP Fund LP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails</Role>
      <ShortName>Consolidated Entity - ISP Fund LP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995865 - Disclosure - Consolidated Entity - Summary of Individual Investments Held by ISP Fund (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails</Role>
      <ShortName>Consolidated Entity - Summary of Individual Investments Held by ISP Fund (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995875 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Armata (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Armata (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995885 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Summarized Financial Data (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Summarized Financial Data (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995895 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in InCarda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Equity Investment in InCarda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995905 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in ImaginAb (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Equity Investment in ImaginAb (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995915 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Syndeio Biosciences (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Syndeio Biosciences (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995925 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Nanolive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Nanolive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995935 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Lyndra (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Lyndra (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995945 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Beacon (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Beacon (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995955 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Reconciliation of Equity and Long - Term Investments Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Reconciliation of Equity and Long - Term Investments Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995965 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>995975 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>995995 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Equity and Long-term Investments and Fair Value Measurements - (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Capitalized Fees Paid - Schedule of Capitalized Fees Paid (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails</Role>
      <ShortName>Capitalized Fees Paid - Schedule of Capitalized Fees Paid (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Goodwill and Intangible Assets - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3</Role>
      <ShortName>Goodwill and Intangible Assets - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Balance Sheet Components (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996065 - Disclosure - Balance Sheet Components - Schedule Of Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule Of Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996075 - Disclosure - Balance Sheet Components -Schedule of Other Long-term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components -Schedule of Other Long-term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996085 - Disclosure - Stock-based Compensation - 2012 Plan and ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails</Role>
      <ShortName>Stock-based Compensation - 2012 Plan and ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996095 - Disclosure - Stock-based Compensation - Director Compensation Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails</Role>
      <ShortName>Stock-based Compensation - Director Compensation Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996105 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996115 - Disclosure - Stock-based Compensation - Compensation Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails</Role>
      <ShortName>Stock-based Compensation - Compensation Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996125 - Disclosure - Stock-based Compensation - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails</Role>
      <ShortName>Stock-based Compensation - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996135 - Disclosure - Stockholders' Equity (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquity1</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996145 - Disclosure - Debt - Schedule of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3</Role>
      <ShortName>Debt - Schedule of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996165 - Disclosure - Debt - Convertible Subordinated Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4</Role>
      <ShortName>Debt - Convertible Subordinated Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996195 - Disclosure - Debt - Convertible Senior Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3</Role>
      <ShortName>Debt - Convertible Senior Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996215 - Disclosure - Debt - Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails</Role>
      <ShortName>Debt - Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996225 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996235 - Disclosure - Commitments and Contingencies - Schedule of Components of Least Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Components of Least Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996245 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Lease (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Lease (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996255 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996275 - Disclosure - ASSET ACQUISITION (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails</Role>
      <ShortName>ASSET ACQUISITION (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996285 - Disclosure - Income Taxes - Income loss before income tax expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Income loss before income tax expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>996295 - Disclosure - Income Taxes - Income tax expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Income tax expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>996305 - Disclosure - Income Taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>Income Taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>996315 - Disclosure - Income taxes - Net income taxes paid (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails</Role>
      <ShortName>Income taxes - Net income taxes paid (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>996325 - Disclosure - Income Taxes - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3</Role>
      <ShortName>Income Taxes - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>996335 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>996345 - Disclosure - Income Taxes - Summary of Changes in Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Changes in Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="inva-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>996355 - Disclosure - Segment Reporting - Schedule of Reconciliation to the Consolidated Net Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails</Role>
      <ShortName>Segment Reporting - Schedule of Reconciliation to the Consolidated Net Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="inva-20251231.htm">inva-20251231.htm</File>
    <File>inva-20251231.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img75897552_0.jpg</File>
    <File>img75897552_1.gif</File>
    <File>img75897552_10.jpg</File>
    <File>img75897552_11.jpg</File>
    <File>img75897552_12.jpg</File>
    <File>img75897552_13.gif</File>
    <File>img75897552_14.gif</File>
    <File>img75897552_15.gif</File>
    <File>img75897552_16.jpg</File>
    <File>img75897552_17.jpg</File>
    <File>img75897552_18.jpg</File>
    <File>img75897552_19.gif</File>
    <File>img75897552_2.jpg</File>
    <File>img75897552_3.jpg</File>
    <File>img75897552_4.gif</File>
    <File>img75897552_5.jpg</File>
    <File>img75897552_6.gif</File>
    <File>img75897552_7.jpg</File>
    <File>img75897552_8.gif</File>
    <File>img75897552_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1355">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>127
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "inva-20251231.htm": {
   "nsprefix": "inva",
   "nsuri": "http://www.inva.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "inva-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "inva-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    }
   },
   "keyStandard": 435,
   "keyCustom": 155,
   "axisStandard": 39,
   "axisCustom": 0,
   "memberStandard": 49,
   "memberCustom": 119,
   "hidden": {
    "total": 17,
    "http://fasb.org/us-gaap/2025": 14,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 615,
   "entityCount": 1,
   "segmentCount": 178,
   "elementCount": 1191,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1355,
    "http://xbrl.sec.gov/dei/2025": 39,
    "http://xbrl.sec.gov/cyd/2025": 13,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "75000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "longName": "75010 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "longName": "75020 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1",
     "longName": "75030 - Statement - CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:AmortizationOfAcquiredIntangibleAssets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical",
     "longName": "75040 - Statement - CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_486828c2-55c2-4eca-a8e9-7c9edc91e774",
      "name": "us-gaap:CapitalizedContractCostAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "longName": "75050 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_a60c1143-acae-40be-9475-53a07ff86264",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a60c1143-acae-40be-9475-53a07ff86264",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "longName": "75060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance",
     "longName": "75070 - Disclosure - Cybersecurity Risk Management, Strategy and Governance",
     "shortName": "Cybersecurity Risk Management, Strategy and Governance",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies1",
     "longName": "995455 - Disclosure - Description of Operations and Summary of Significant Accounting Policies",
     "shortName": "Description of Operations and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShare1",
     "longName": "995465 - Disclosure - Net Income Per Share",
     "shortName": "Net Income Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognition1",
     "longName": "995475 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangements",
     "longName": "995485 - Disclosure - License, Collaboration and Other Arrangements",
     "shortName": "License, Collaboration and Other Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:LicenseCollaborationAndOtherArrangementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:LicenseCollaborationAndOtherArrangementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions3",
     "longName": "995495 - Disclosure - Consolidated Entities and Acquisitions",
     "shortName": "Consolidated Entities and Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:ConsolidatedEntityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:ConsolidatedEntityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements2",
     "longName": "995505 - Disclosure - Equity and Long-term Investments and Fair Value Measurements",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaid1",
     "longName": "995515 - Disclosure - Capitalized Fees Paid",
     "shortName": "Capitalized Fees Paid",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:CapitalizedFeesPaidDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:CapitalizedFeesPaidDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets3",
     "longName": "995525 - Disclosure - Goodwill and Intangible Assets",
     "shortName": "Goodwill and Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1",
     "longName": "995535 - Disclosure - Balance Sheet Components",
     "shortName": "Balance Sheet Components",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation",
     "longName": "995545 - Disclosure - Stock-based Compensation",
     "shortName": "Stock-based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquity1",
     "longName": "995555 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDebt4",
     "longName": "995565 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies3",
     "longName": "995575 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisition1",
     "longName": "995585 - Disclosure - Asset Acquisition",
     "shortName": "Asset Acquisition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxes3",
     "longName": "995595 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReporting1",
     "longName": "995605 - Disclosure - Segment Reporting",
     "shortName": "Segment Reporting",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "995625 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Description of Operations and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:DescriptionOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:DescriptionOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables",
     "longName": "995635 - Disclosure - Description of Operations and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Description of Operations and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareTables",
     "longName": "995645 - Disclosure - Net Income Per Share (Tables)",
     "shortName": "Net Income Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionTables",
     "longName": "995655 - Disclosure - Revenue Recognition (Tables)",
     "shortName": "Revenue Recognition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
     "longName": "995665 - Disclosure - Consolidated Entities and Acquisitions (Tables)",
     "shortName": "Consolidated Entities and Acquisitions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2",
      "name": "us-gaap:InvestmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2",
      "name": "us-gaap:InvestmentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
     "longName": "995675 - Disclosure - Equity and Long-term Investments and Fair Value Measurements (Tables)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidTables",
     "longName": "995685 - Disclosure - Capitalized Fees Paid (Tables)",
     "shortName": "Capitalized Fees Paid (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:CapitalizedContractCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:CapitalizedContractCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables",
     "longName": "995695 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables",
     "longName": "995705 - Disclosure - Balance Sheet Components (Tables)",
     "shortName": "Balance Sheet Components (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables",
     "longName": "995715 - Disclosure - Stock-based Compensation (Tables)",
     "shortName": "Stock-based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables",
     "longName": "995725 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables",
     "longName": "995735 - Disclosure - Commitments and Contingencies (Tables)",
     "shortName": "Commitments and Contingencies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables",
     "longName": "995745 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingTables",
     "longName": "995755 - Disclosure - Segment Reporting (Tables)",
     "shortName": "Segment Reporting (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
     "longName": "995765 - Disclosure - Description of Operations and Summary of Significant Accounting Policies - Description of Operations (Details)",
     "shortName": "Description of Operations and Summary of Significant Accounting Policies - Description of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "inva:CapitalizedFeePaidEstimatedUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "inva:CapitalizedFeesPaidPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "inva:CapitalizedFeePaidEstimatedUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "inva:CapitalizedFeesPaidPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "995775 - Disclosure - Description of Operations and Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "shortName": "Description of Operations and Summary of Significant Accounting Policies - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "C_2d1f6be5-5863-4cef-a634-37c4e6881e96",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2d1f6be5-5863-4cef-a634-37c4e6881e96",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails",
     "longName": "995785 - Disclosure - Description of Operations and Summary of Significant Accounting Policies - Related Party Transactions (Details)",
     "shortName": "Description of Operations and Summary of Significant Accounting Policies - Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "C_8d782d9a-b93f-45ae-a7ce-ee978ddef5a5",
      "name": "inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "inva:RelatedPartyTransactionsPolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
     "longName": "995795 - Disclosure - Net Income Per Share - Basic and Diluted EPS (Details)",
     "shortName": "Net Income Per Share - Basic and Diluted EPS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails",
     "longName": "995805 - Disclosure - Net Income Per Share - Anti-Dilutive Securities (Details)",
     "shortName": "Net Income Per Share - Anti-Dilutive Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails",
     "longName": "995815 - Disclosure - Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details)",
     "shortName": "Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054",
      "name": "inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails",
     "longName": "995825 - Disclosure - Revenue Recognition - Schedule of net product sales (Details)",
     "shortName": "Revenue Recognition - Schedule of net product sales (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_3417b179-deaf-41ea-bd39-7e434b1db032",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
     "longName": "995835 - Disclosure - Revenue Recognition (Details)",
     "shortName": "Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8a27a178-7498-4039-b7ec-3acbc3e22557",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
     "longName": "995845 - Disclosure - License, Collaboration and Other Arrangements (Additional Information) (Details)",
     "shortName": "License, Collaboration and Other Arrangements (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c9724995-83e8-4e3f-ac0a-df8eb2d7e801",
      "name": "inva:LicenseRevenueRecognized",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "inva:LicenseCollaborationAndOtherArrangementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails",
     "longName": "995855 - Disclosure - Consolidated Entity - ISP Fund LP (Details)",
     "shortName": "Consolidated Entity - ISP Fund LP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:Assets",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1250457-5420-4587-a034-747d2328f6e0",
      "name": "us-gaap:LimitedPartnersContributedCapital",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "inva:ConsolidatedEntityTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails",
     "longName": "995865 - Disclosure - Consolidated Entity - Summary of Individual Investments Held by ISP Fund (Details)",
     "shortName": "Consolidated Entity - Summary of Individual Investments Held by ISP Fund (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "C_f1250457-5420-4587-a034-747d2328f6e0",
      "name": "inva:MoneyMarketFundAndCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f1250457-5420-4587-a034-747d2328f6e0",
      "name": "inva:MoneyMarketFundAndCash",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
     "longName": "995875 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Armata (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Armata (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b4075dc6-049f-43ce-ad83-c920b6727849",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "us-gaap:DebtInstrumentDescription",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
     "longName": "995885 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Summarized Financial Data (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Summarized Financial Data (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88",
      "name": "us-gaap:AssetsCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inva:ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
     "longName": "995895 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in InCarda (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Equity Investment in InCarda (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "C_280efd9d-8c7f-4e28-aa7a-2c064a232238",
      "name": "inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
      "unitRef": "U_Director",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_280efd9d-8c7f-4e28-aa7a-2c064a232238",
      "name": "inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
      "unitRef": "U_Director",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
     "longName": "995905 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in ImaginAb (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Equity Investment in ImaginAb (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_07023259-2cd5-439e-8af3-725f79e6d197",
      "name": "inva:NumberOfBoardOfDirectors",
      "unitRef": "U_BoardMember",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
     "longName": "995915 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Syndeio Biosciences (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Syndeio Biosciences (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:PaymentsToAcquireLongtermInvestments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_31ec6e0a-cd1b-4e7a-af9c-54600d0d24cc",
      "name": "inva:NumberOfCommonStockIssuedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
     "longName": "995925 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Nanolive (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Nanolive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "C_da892b74-d5b8-42b1-8209-9456006bda02",
      "name": "inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
      "unitRef": "U_Director",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_da892b74-d5b8-42b1-8209-9456006bda02",
      "name": "inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
      "unitRef": "U_Director",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
     "longName": "995935 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Lyndra (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Convertible Promissory Note in Lyndra (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "C_00b91c9f-9ab7-4b39-b007-fe9dae159be4",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_00b91c9f-9ab7-4b39-b007-fe9dae159be4",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
     "longName": "995945 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Beacon (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Equity Investment in Beacon (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "C_f4ddf483-cbed-4109-859d-418fd5e83000",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f4ddf483-cbed-4109-859d-418fd5e83000",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails",
     "longName": "995955 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Reconciliation of Equity and Long - Term Investments Balances (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Reconciliation of Equity and Long - Term Investments Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inva:ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inva:ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
     "longName": "995965 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Available-for-Sale Securities (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Available-for-Sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
     "longName": "995975 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "C_fa3ac63f-9ac1-406d-b258-7e778b64bfce",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_fa3ac63f-9ac1-406d-b258-7e778b64bfce",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAdditionalInformationDetails",
     "longName": "995995 - Disclosure - Equity and Long-term Investments and Fair Value Measurements - (Additional Information) (Details)",
     "shortName": "Equity and Long-term Investments and Fair Value Measurements - (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:FairValueOfAssetsOrLiabilitiesTransferBetweenLevels",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:FairValueOfAssetsOrLiabilitiesTransferBetweenLevels",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
     "longName": "996005 - Disclosure - Capitalized Fees Paid - Schedule of Capitalized Fees Paid (Details)",
     "shortName": "Capitalized Fees Paid - Schedule of Capitalized Fees Paid (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:CapitalizedContractCostGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CapitalizedContractCostTableTextBlock",
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:CapitalizedContractCostAccumulatedAmortization",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:CapitalizedContractCostTableTextBlock",
       "div",
       "inva:CapitalizedFeesPaidDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "longName": "996015 - Disclosure - Goodwill and Intangible Assets (Additional Information) (Details)",
     "shortName": "Goodwill and Intangible Assets (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:Goodwill",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3",
     "longName": "996025 - Disclosure - Goodwill and Intangible Assets - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)",
     "shortName": "Goodwill and Intangible Assets - Summary of Accumulated Amortization of Recognized Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "inva:IntangibleAssetsMarketedProductsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "inva:IntangibleAssetsMarketedProductsGross",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails",
     "longName": "996045 - Disclosure - Balance Sheet Components - Schedule of Inventory (Details)",
     "shortName": "Balance Sheet Components - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "longName": "996055 - Disclosure - Balance Sheet Components (Additional Information) (Details)",
     "shortName": "Balance Sheet Components (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "C_2bdbcb89-e8cf-4578-a8fb-ed71c2c5c84c",
      "name": "us-gaap:AdvancesOnInventoryPurchases",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "inva:LicenseCollaborationAndOtherArrangementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_099aecd1-7b7a-4a20-9f80-16d10bb47ae5",
      "name": "inva:FairValueAdjustmentsOfInventoryFromAcquistion",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails",
     "longName": "996065 - Disclosure - Balance Sheet Components - Schedule Of Other Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Components - Schedule Of Other Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "inva:AccruedContractManufacturingLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "inva:AccruedContractManufacturingLiability",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails",
     "longName": "996075 - Disclosure - Balance Sheet Components -Schedule of Other Long-term Liabilities (Details)",
     "shortName": "Balance Sheet Components -Schedule of Other Long-term Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "inva:DeferredRoyaltyObligationNonCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "inva:DeferredRoyaltyObligationNonCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails",
     "longName": "996085 - Disclosure - Stock-based Compensation - 2012 Plan and ESPP (Details)",
     "shortName": "Stock-based Compensation - 2012 Plan and ESPP (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "C_7a708fd2-25d5-452c-aad6-d6903d0cf646",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7a708fd2-25d5-452c-aad6-d6903d0cf646",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails",
     "longName": "996095 - Disclosure - Stock-based Compensation - Director Compensation Program (Details)",
     "shortName": "Stock-based Compensation - Director Compensation Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "C_f46cd1ad-fe1b-4bf9-a5a9-24eaba3fb3e3",
      "name": "inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_f46cd1ad-fe1b-4bf9-a5a9-24eaba3fb3e3",
      "name": "inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
     "longName": "996105 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "shortName": "Stock-based Compensation - Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails",
     "longName": "996115 - Disclosure - Stock-based Compensation - Compensation Awards (Details)",
     "shortName": "Stock-based Compensation - Compensation Awards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4daceff5-03ad-4f3b-9aab-ba819d229412",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails",
     "longName": "996125 - Disclosure - Stock-based Compensation - Valuation Assumptions (Details)",
     "shortName": "Stock-based Compensation - Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "C_c10fa9b1-45fb-45df-9763-f7e84d16c427",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c10fa9b1-45fb-45df-9763-f7e84d16c427",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "longName": "996135 - Disclosure - Stockholders' Equity (Additional Information) (Details)",
     "shortName": "Stockholders' Equity (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:ClassOfWarrantOrRightExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "inva:ClassOfWarrantOrRightExercised",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
     "longName": "996145 - Disclosure - Debt - Schedule of Debt (Details)",
     "shortName": "Debt - Schedule of Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077",
      "name": "inva:RoyaltyAgreementMaximumPotentialPayoutPercent",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
     "longName": "996165 - Disclosure - Debt - Convertible Subordinated Notes (Details)",
     "shortName": "Debt - Convertible Subordinated Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:InterestPayableCurrent",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R78": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
     "longName": "996195 - Disclosure - Debt - Convertible Senior Notes (Details)",
     "shortName": "Debt - Convertible Senior Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_2ff1d571-1f1e-4d04-9274-1397b426e2d1",
      "name": "us-gaap:DebtInstrumentMaturityDate",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails",
     "longName": "996215 - Disclosure - Debt - Debt Maturities (Details)",
     "shortName": "Debt - Debt Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "996225 - Disclosure - Commitments and Contingencies (Additional Information) (Details)",
     "shortName": "Commitments and Contingencies (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails",
     "longName": "996235 - Disclosure - Commitments and Contingencies - Schedule of Components of Least Cost (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Components of Least Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails",
     "longName": "996245 - Disclosure - Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Lease (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Lease (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3",
     "longName": "996255 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)",
     "shortName": "Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
     "longName": "996275 - Disclosure - ASSET ACQUISITION (Additional Information) (Details)",
     "shortName": "ASSET ACQUISITION (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_b3eec335-a345-4b7c-9e97-3ceddf99d1e9",
      "name": "inva:UpfrontCashPayments",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "us-gaap:AssetAcquisitionTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails",
     "longName": "996285 - Disclosure - Income Taxes - Income loss before income tax expense (Details)",
     "shortName": "Income Taxes - Income loss before income tax expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
     "longName": "996295 - Disclosure - Income Taxes - Income tax expense (Details)",
     "shortName": "Income Taxes - Income tax expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails",
     "longName": "996305 - Disclosure - Income Taxes - Reconciliation (Details)",
     "shortName": "Income Taxes - Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails",
     "longName": "996315 - Disclosure - Income taxes - Net income taxes paid (Details)",
     "shortName": "Income taxes - Net income taxes paid (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:IncomeTaxesPaidNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_1ef1ff30-e8ef-4d5c-b296-a140e0ecefb8",
      "name": "us-gaap:IncomeTaxesPaidNet",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "inva:IncomeTaxesPaidNetTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3",
     "longName": "996325 - Disclosure - Income Taxes - Deferred Taxes (Details)",
     "shortName": "Income Taxes - Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "longName": "996335 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefitsDetails",
     "longName": "996345 - Disclosure - Income Taxes - Summary of Changes in Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Summary of Changes in Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aac97a17-df6e-4461-927e-d6634b600e0e",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
     "longName": "996355 - Disclosure - Segment Reporting - Schedule of Reconciliation to the Consolidated Net Income (Details)",
     "shortName": "Segment Reporting - Schedule of Reconciliation to the Consolidated Net Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_01c6be5d-cc54-49d6-8b11-353961389b35",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "inva-20251231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASU 2020-06",
        "label": "Accounting Standards Update 2020-06 [Member]",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768"
     ]
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r213",
      "r214",
      "r215",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r329",
      "r330",
      "r368",
      "r369",
      "r370",
      "r418",
      "r419",
      "r427",
      "r480",
      "r481",
      "r482",
      "r483",
      "r578",
      "r579",
      "r580",
      "r581",
      "r632",
      "r633",
      "r634",
      "r635",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r690",
      "r691",
      "r692",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r742",
      "r743",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r786",
      "r787",
      "r812",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Payable, Current, Total",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r1250"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Total",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r1031",
      "r1104",
      "r1275",
      "r1682",
      "r1683"
     ]
    },
    "inva_AccruedClinicalAndResearchLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AccruedClinicalAndResearchLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued clinical and research expenses",
        "label": "Accrued Clinical and Research Liability",
        "documentation": "Accrued clinical and research liability."
       }
      }
     },
     "auth_ref": []
    },
    "inva_AccruedContractManufacturingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AccruedContractManufacturingLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued contract manufacturing liability.",
        "label": "Accrued Contract Manufacturing Liability",
        "terseLabel": "Accrued contract manufacturing costs"
       }
      }
     },
     "auth_ref": []
    },
    "inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued excise tax on common stock repurchase applied against tax liability",
        "label": "Accrued Excise Tax On Common Stock Repurchase Applied Against Tax Liability",
        "documentation": "Accrued excise tax on common stock repurchase applied against tax liability."
       }
      }
     },
     "auth_ref": []
    },
    "inva_AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued excise tax on common stock repurchase applied against tax liability, shares",
        "label": "Accrued Excise Tax On Common Stock Repurchase Applied Against Tax Liability Shares",
        "documentation": "Accrued excise tax on common stock repurchase applied against tax liability shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r137"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Income tax payable, long-term",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r137"
     ]
    },
    "inva_AccruedInterestAndCommitmentFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AccruedInterestAndCommitmentFees",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest and commitment fees",
        "label": "Accrued Interest and Commitment Fees",
        "documentation": "accrued interest and commitment fees."
       }
      }
     },
     "auth_ref": []
    },
    "inva_AccruedInterestIncomeIncludedInLongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AccruedInterestIncomeIncludedInLongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Interest Income Included in Long-term Investments",
        "documentation": "Accrued interest income included in long-term investments.",
        "terseLabel": "Accrued interest income converted to long-term investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities",
        "totalLabel": "Total other accrued liabilities",
        "terseLabel": "Other accrued liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities",
        "totalLabel": "Accrued Liabilities, Total",
        "terseLabel": "Accrued liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "inva_AccruedLiabilitiesIndemnificationsAndOtherContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AccruedLiabilitiesIndemnificationsAndOtherContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities to provide for indemnifications and other contingencies",
        "label": "Accrued Liabilities Indemnifications And Other Contingencies",
        "documentation": "Accrued liabilities to provide for indemnifications and other contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "inva_AccruedLicenseFeesAndRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AccruedLicenseFeesAndRoyalties",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued license fees and royalties",
        "label": "Accrued License Fees and Royalties",
        "terseLabel": "Accrued license fees and royalties"
       }
      }
     },
     "auth_ref": []
    },
    "inva_AccruedProfessionalServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AccruedProfessionalServices",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Professional Services",
        "documentation": "Accrued Professional Services",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty obligation payable",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r1128"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetResidualValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AcquiredFiniteLivedIntangibleAssetResidualValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acquired Finite-Lived Intangible Asset, Residual Value",
        "documentation": "Amount of residual value of finite-lived asset acquired in business combination, asset acquisition, and from joint venture formation. Excludes financial asset."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r1119"
     ]
    },
    "inva_AcquiredIn-ProcessResearchAndDevelopmentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AcquiredIn-ProcessResearchAndDevelopmentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development assets",
        "label": "Acquired In-Process Research and Development Assets",
        "documentation": "Acquired in-process research and development assets."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1336"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1643",
      "r1719"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r1349"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r1349"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r1349"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1349"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r213",
      "r214",
      "r215",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r255",
      "r329",
      "r330",
      "r368",
      "r369",
      "r370",
      "r371",
      "r418",
      "r419",
      "r427",
      "r480",
      "r481",
      "r482",
      "r483",
      "r578",
      "r579",
      "r580",
      "r581",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r690",
      "r691",
      "r692",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r786",
      "r787",
      "r812",
      "r813",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "inva_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation (in shares)",
        "documentation": "Adjustments to additional paid in capital share based compensation requisite service period recognition shares.",
        "label": "Adjustments To Additional Paid In Capital Share based Compensation Requisite Service Period Recognition Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvancesOnInventoryPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdvancesOnInventoryPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advances on Inventory Purchases",
        "terseLabel": "Advance payments received",
        "verboseLabel": "Payment received for additional inventory purchase",
        "documentation": "Carrying value of capitalized payments made in advance for inventory that is expected to be received within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1428"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1394"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1307",
      "r1318",
      "r1328",
      "r1361"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r1310",
      "r1321",
      "r1331",
      "r1364"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1395"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r1349"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r1311",
      "r1322",
      "r1332",
      "r1356",
      "r1365",
      "r1369",
      "r1377"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r1375"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r582",
      "r591"
     ]
    },
    "inva_AmendedZaiAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AmendedZaiAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amended Zai Agreement [Member]",
        "documentation": "Amended Zai Agreement.",
        "terseLabel": "Amended Zai Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "inva_AmortizationOfAcquiredIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AmortizationOfAcquiredIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Acquired Intangible Assets",
        "documentation": "Amortization of acquired intangible assets.",
        "terseLabel": "Amortization of acquired intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "inva_AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of capitalized fees and depreciation of property and equipment.",
        "label": "Amortization of Capitalized Fees and Depreciation of Property and Equipment",
        "terseLabel": "Amortization of capitalized fees and depreciation of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r102",
      "r470",
      "r1663"
     ]
    },
    "inva_AmortizationOfFairValueAdjustmentsOfCostOfProductsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AmortizationOfFairValueAdjustmentsOfCostOfProductsSold",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of fair value adjustments of cost of products sold.",
        "label": "Amortization of Fair Value Adjustments of Cost of Products Sold",
        "terseLabel": "Amortization of fair value adjustments of Cost of products sold"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails3": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r470",
      "r1489",
      "r1663"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortization of Debt Issuance Costs and Discounts, Total",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and issuance costs",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r1169",
      "r1170",
      "r1489",
      "r1663"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of acquired intangible assets",
        "verboseLabel": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r212",
      "r405",
      "r412",
      "r1124",
      "r1135",
      "r1136",
      "r1138",
      "r1140"
     ]
    },
    "inva_AmortizationOfInventoryFairValueAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AmortizationOfInventoryFairValueAdjustmentsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of inventory fair value adjustments",
        "label": "Amortization of Inventory Fair Value Adjustments[Member]",
        "documentation": "Amortization of inventory fair value adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "inva_AmountOfInventoryPurchasesNotBilled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AmountOfInventoryPurchasesNotBilled",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Inventory Purchases Not Billed",
        "documentation": "Amount of inventory purchases not billed.",
        "terseLabel": "Amount of inventory purchases not yet received"
       }
      }
     },
     "auth_ref": []
    },
    "inva_AmountOnNetProductSalesRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AmountOnNetProductSalesRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount on net product sales recognized",
        "label": "Amount on Net Product Sales Recognized",
        "documentation": "Amount on net product sales recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Anti-Dilutive Securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Lease space",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ArmataAugustTwoThousandTwentyFiveTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ArmataAugustTwoThousandTwentyFiveTermLoanMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Armata August Two Thousand Twenty Five Term Loan [Member]",
        "documentation": "Armata august two thousand twenty five term loan.",
        "terseLabel": "Armata August 2025 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ArmataConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ArmataConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Armata Convertible Note",
        "label": "Armata Convertible Note [Member]",
        "documentation": "Armata convertible note member."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ArmataJulyTwoThousandTwentyThreeTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ArmataJulyTwoThousandTwentyThreeTermLoanMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Armata July Two Thousand Twenty Three Term Loan [Member]",
        "documentation": "Armata july two thousand twenty three term loan.",
        "terseLabel": "Armata July Two Thousand Twenty Three Term Loan",
        "verboseLabel": "Armata July 2023 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ArmataMarchTwoThousandTwentyFiveTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ArmataMarchTwoThousandTwentyFiveTermLoanMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Armata March Two Thousand Twenty Five Term Loan [Member]",
        "documentation": "Armata march two thousand twenty five term loan.",
        "terseLabel": "Armata March 2025 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ArmataMarchTwoThousandTwentyFourTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ArmataMarchTwoThousandTwentyFourTermLoanMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Armata March Two Thousand Twenty Four Term Loan [Member]",
        "documentation": "Armata march two thousand twenty four term loan.",
        "terseLabel": "Armata March Two Thousand Twenty Four Term Loan",
        "verboseLabel": "Armata March 2024 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ArmataPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ArmataPharmaceuticalsIncMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections.",
        "label": "Armata Pharmaceuticals Inc [Member]",
        "terseLabel": "Armata"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ArmataTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ArmataTermLoanMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Armata Term Loan",
        "label": "Armata Term Loan [Member]",
        "documentation": "Armata term loan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_AssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r979",
      "r1634"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferredTransactionCost",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred, Transaction Cost",
        "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1228",
      "r1635",
      "r1636",
      "r1637"
     ]
    },
    "us-gaap_AssetAcquisitionDateOfAcquisitionAgreement": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDateOfAcquisitionAgreement",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Date of Acquisition Agreement",
        "terseLabel": "Date of acquisition agreement",
        "documentation": "Date when asset acquisition agreement is executed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1634"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r979",
      "r1634"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r1634"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r1634"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisition1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Text Block]",
        "terseLabel": "ASSET ACQUISITION",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r710",
      "r1634"
     ]
    },
    "inva_AssetAcquisitionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AssetAcquisitionsPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisitions [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for asset acquisitions.",
        "terseLabel": "Asset Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r155",
      "r186",
      "r224",
      "r227",
      "r228",
      "r281",
      "r296",
      "r316",
      "r320",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r718",
      "r723",
      "r797",
      "r922",
      "r923",
      "r933",
      "r1036",
      "r1155",
      "r1156",
      "r1171",
      "r1250",
      "r1267",
      "r1268",
      "r1285",
      "r1571",
      "r1572",
      "r1670"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "terseLabel": "Current assets",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r198",
      "r224",
      "r227",
      "r228",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r718",
      "r723",
      "r797",
      "r1250",
      "r1571",
      "r1572",
      "r1670"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets measured at estimated fair value",
        "totalLabel": "Assets, Fair Value Disclosure, Total",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r1236"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Assets, Noncurrent, Total",
        "label": "Assets, Noncurrent",
        "terseLabel": "Noncurrent assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r227",
      "r228",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r718",
      "r723",
      "r797",
      "r1571",
      "r1572",
      "r1670"
     ]
    },
    "inva_AstrazenecaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AstrazenecaMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AstraZeneca",
        "label": "AstraZeneca [Member]",
        "documentation": "AstraZeneca."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1290",
      "r1291",
      "r1314"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1290",
      "r1291",
      "r1314"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1290",
      "r1291",
      "r1314"
     ]
    },
    "dei_AuditorOpinionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorOpinionTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Opinion [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1398"
     ]
    },
    "inva_AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "August Two Thousand Twenty Five Credit and Security Agreement [Member]",
        "documentation": "August two thousand twenty five credit and security agreement.",
        "terseLabel": "August 2025 Credit and Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r377",
      "r932"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r377",
      "r770",
      "r789",
      "r790",
      "r791",
      "r792",
      "r920",
      "r1121",
      "r1236",
      "r1240",
      "r1247",
      "r1524",
      "r1647",
      "r1648",
      "r1649"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1372"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r1373"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r1371"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1370"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r1369"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r1369"
     ]
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r725",
      "r727",
      "r728",
      "r729",
      "r730",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r796",
      "r1233",
      "r1234",
      "r1409",
      "r1685"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r725",
      "r727",
      "r728",
      "r729",
      "r730",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r796",
      "r1233",
      "r1234",
      "r1409",
      "r1685"
     ]
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]",
        "terseLabel": "Balance Sheet Information"
       }
      }
     },
     "auth_ref": []
    },
    "inva_BasileaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "BasileaMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basilea [Member]",
        "documentation": "Basilea.",
        "terseLabel": "Basilea"
       }
      }
     },
     "auth_ref": []
    },
    "inva_BeaconMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "BeaconMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beacon [Member]",
        "documentation": "Beacon [Member]",
        "terseLabel": "Beacon"
       }
      }
     },
     "auth_ref": []
    },
    "inva_BurlingameCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "BurlingameCaliforniaMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Burlingame, California.",
        "label": "Burlingame California [Member]",
        "terseLabel": "Burlingame, California"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r979",
      "r1186",
      "r1187",
      "r1627",
      "r1629",
      "r1631"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r402",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r979",
      "r1186",
      "r1187",
      "r1627",
      "r1629",
      "r1631"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Pro Forma Information [Table Text Block]",
        "terseLabel": "Pro Forma Information",
        "documentation": "Tabular disclosure of pro forma revenue and earnings for business combination or aggregate of series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r1192",
      "r1198",
      "r1405",
      "r1406",
      "r1628"
     ]
    },
    "inva_BusinessCombinationDeferredConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "BusinessCombinationDeferredConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business combination deferred consideration",
        "label": "Business Combination Deferred Consideration",
        "documentation": "Business combination deferred consideration."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived",
        "terseLabel": "Intangible assets",
        "verboseLabel": "Intangible assets pertain to product rights and developed technologies",
        "documentation": "Amount of identifiable indefinite-lived intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset."
       }
      }
     },
     "auth_ref": [
      "r1630",
      "r1632"
     ]
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Policy Text Block]",
        "terseLabel": "Business Combination",
        "documentation": "Disclosure of accounting policy for business combination."
       }
      }
     },
     "auth_ref": [
      "r652",
      "r653",
      "r659",
      "r661",
      "r672",
      "r680",
      "r684",
      "r1192",
      "r1195",
      "r1226",
      "r1227"
     ]
    },
    "us-gaap_CallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CallOptionMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Call Option [Member]",
        "terseLabel": "Stock prices below $27.79 per share",
        "documentation": "Financial contract between two parties, the buyer and the seller of the option, where the buyer has the right but not the obligation to buy an agreed quantity of a particular commodity or financial instrument (the underlying instrument) from the seller of the option for a certain price (the strike price). Seller is obligated to sell the asset to the buyer, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r1080",
      "r1081"
     ]
    },
    "us-gaap_CapitalizedContractCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails": {
       "parentTag": "us-gaap_CapitalizedContractCostNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization",
        "documentation": "Amount of accumulated amortization of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1544"
     ]
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails": {
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Amortization",
        "verboseLabel": "Amortization expense",
        "terseLabel": "Amortization of capitalized fees paid",
        "negatedLabel": "Less: amortization of capitalized fees paid",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r387"
     ]
    },
    "us-gaap_CapitalizedContractCostGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails": {
       "parentTag": "us-gaap_CapitalizedContractCostNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Gross",
        "terseLabel": "Milestone fees paid",
        "verboseLabel": "Gross carrying value",
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1544"
     ]
    },
    "us-gaap_CapitalizedContractCostLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Line Items]",
        "terseLabel": "Capitalized Fees paid",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_CapitalizedContractCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Net",
        "totalLabel": "Net carrying value",
        "terseLabel": "Capitalized fees paid, net",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_CapitalizedContractCostNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost, Net, Noncurrent",
        "terseLabel": "Capitalized cost of fixed assets",
        "documentation": "Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_CapitalizedContractCostTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Table]",
        "documentation": "Disclosure of information about cost capitalized in obtaining or fulfilling contract with customer."
       }
      }
     },
     "auth_ref": [
      "r386"
     ]
    },
    "us-gaap_CapitalizedContractCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Contract Cost [Table Text Block]",
        "terseLabel": "Schedule of Capitalized Fees Paid",
        "documentation": "Tabular disclosure of cost capitalized in obtaining or fulfilling contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1543"
     ]
    },
    "inva_CapitalizedFeePaidEstimatedUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeePaidEstimatedUsefulLife",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fee paid estimated useful life.",
        "label": "Capitalized Fee Paid Estimated Useful Life",
        "terseLabel": "Capitalized fees paid, estimated useful life"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeesPaidDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaid1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about capitalized fees paid.",
        "label": "Capitalized Fees Paid Disclosure [Text Block]",
        "terseLabel": "CAPITALIZED FEES PAID"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidFutureAmortizationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeesPaidFutureAmortizationAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fees paid future amortization.",
        "label": "Capitalized Fees Paid Future Amortization [Abstract]",
        "terseLabel": "Capitalized Fees paid, Future amortization"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeesPaidPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fees paid.",
        "label": "Capitalized Fees Paid [Policy Text Block]",
        "terseLabel": "Capitalized Fees Paid"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Next Twelve Months",
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "terseLabel": "Estimated amortization for the year 2026"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Year Five",
        "terseLabel": "Estimated amortization for the year 2030"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Year Four",
        "terseLabel": "Estimated amortization for the year 2029"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capitalized Fees Paid Remaining Estimated Amortization Year Two",
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "terseLabel": "Estimated amortization for the year 2027"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated amortization for assets expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Capitalized Fees Paid Remaining Estimated Amortization YearThree",
        "terseLabel": "Estimated amortization for the year 2028"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidToRelatedPartyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeesPaidToRelatedPartyPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for capitalized fees paid to a related party.",
        "label": "Capitalized Fees Paid To A Related Party [Policy Text Block]",
        "terseLabel": "Capitalized Fees Paid"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CapitalizedFeesPaidWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CapitalizedFeesPaidWeightedAverageUsefulLife",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitalized fees paid weighted average useful life.",
        "label": "Capitalized Fees Paid Weighted Average Useful Life",
        "terseLabel": "Weighted average remaining amortization period"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CarryingValueWroteOffWarrantExercise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CarryingValueWroteOffWarrantExercise",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying value wrote off warrant exercise",
        "label": "Carrying Value Wrote off Warrant Exercise",
        "documentation": "Carrying value wrote off warrant exercise."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "label": "Cash and Cash Equivalent",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash balance",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r181",
      "r1125"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Total cash, cash equivalents and restricted cash at end of period shown in the consolidated statements of cash flows",
        "totalLabel": "Total cash, cash equivalents and restricted cash at end of period shown in the condensed consolidated statements of cash flows",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r109",
      "r223"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r109"
     ]
    },
    "inva_CashDistributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CashDistributions",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash distribution",
        "label": "Cash Distributions",
        "documentation": "Cash distributions."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1347"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1342"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ClaimExpirationDate": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ClaimExpirationDate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Claim expiration date.",
        "label": "Claim Expiration Date",
        "terseLabel": "Claim expiration date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r192",
      "r193",
      "r194",
      "r224",
      "r228",
      "r260",
      "r265",
      "r274",
      "r276",
      "r283",
      "r284",
      "r367",
      "r437",
      "r440",
      "r441",
      "r442",
      "r446",
      "r447",
      "r484",
      "r485",
      "r487",
      "r488",
      "r490",
      "r493",
      "r496",
      "r497",
      "r500",
      "r503",
      "r510",
      "r797",
      "r984",
      "r985",
      "r986",
      "r987",
      "r992",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1023",
      "r1044",
      "r1065",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1401",
      "r1494",
      "r1496",
      "r1505"
     ]
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfTreasuryStockTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Treasury Stock [Table]",
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants",
        "verboseLabel": "Exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r231",
      "r511"
     ]
    },
    "inva_ClassOfWarrantOrRightExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ClassOfWarrantOrRightExercised",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised",
        "label": "Class of Warrant or Right, Exercised",
        "documentation": "Class of warrant or right, exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Outstanding warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical development and regulatory milestones amount payable.",
        "label": "Clinical Development And Regulatory Milestones Amount Payable",
        "terseLabel": "Clinical development and regulatory milestones amount payable"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1348"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1348"
     ]
    },
    "inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty rate for combination products.",
        "label": "Collaborative Arrangement Annual Royalties as Percentage of Net Sales for Combination Products",
        "terseLabel": "Royalty rate for combination products (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration agreement",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CollaborativeArrangementRoyaltyRateDefinedLevelOne",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.",
        "label": "Collaborative Arrangement, Royalty Rate Defined, Level One",
        "terseLabel": "Royalty rate for first level of annual global net sales (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CollaborativeArrangementRoyaltyRateDefinedLevelTwo",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.",
        "label": "Collaborative Arrangement, Royalty Rate Defined, Level Two",
        "terseLabel": "Royalty rate for sales above first level of annual global net sales (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.",
        "label": "Collaborative Arrangement, Specified Sales Level for Determining Royalty Rate",
        "terseLabel": "Annual global sales level used to determine royalty rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "inva_CommercialSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CommercialSupplyAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial supply agreement.",
        "label": "Commercial Supply Agreement [Member]",
        "terseLabel": "Commercial Supply Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 13)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r142",
      "r937",
      "r1022"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingencies3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r429",
      "r430",
      "r1106",
      "r1561",
      "r1566"
     ]
    },
    "inva_CommitmentsFor2024ToBeUtilizedIn2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CommitmentsFor2024ToBeUtilizedIn2025Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments for 2024 to be utilized in 2025 [Member]",
        "label": "Commitments for 2024 to be utilized in 2025 [Member]",
        "documentation": "Commitments for 2024 to be utilized in 2025."
       }
      }
     },
     "auth_ref": []
    },
    "inva_CommonAndPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CommonAndPreferredStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common and Preferred Stock",
        "label": "Common and Preferred Stock [Member]",
        "documentation": "Common and preferred stock member."
       }
      }
     },
     "auth_ref": []
    },
    "inva_CommonStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CommonStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Acquired Average Cost Per Share",
        "label": "Common Stock Acquired Average Cost Per Share",
        "terseLabel": "Shares repurchased average price per share"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CommonStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CommonStockAndWarrantsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to common stock and warrants.",
        "label": "Common Stock And Warrants [Member]",
        "terseLabel": "Common stock and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1272",
      "r1273",
      "r1274",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1501",
      "r1502",
      "r1504",
      "r1643",
      "r1715",
      "r1719"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Common stock - Publicly traded healthcare companies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1023"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r83",
      "r1023",
      "r1042",
      "r1719",
      "r1720"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock",
        "terseLabel": "Common stock: $0.01 par value, 200,000 shares authorized, 74,636 and 62,665 issued and outstanding as of December 31, 2025 and 2024 respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r485",
      "r492",
      "r939",
      "r1250"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r1353"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r1352"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r1354"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r1351"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of deferred tax assets and deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r328",
      "r980",
      "r981",
      "r1105",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r328",
      "r980",
      "r981",
      "r1105",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r328",
      "r980",
      "r981",
      "r1105",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk and of Significant Suppliers and Partners",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r794"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r328",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r328",
      "r980",
      "r981",
      "r1105",
      "r1509",
      "r1510",
      "r1511",
      "r1512",
      "r1513"
     ]
    },
    "inva_ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConsolidatedEntitiesAndAcquisitionsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated entities and acquisitions disclosure abstract.",
        "label": "Consolidated Entities and Acquisitions Disclosure Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConsolidatedEntitiesAndAcquisitionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConsolidatedEntitiesAndAcquisitionsLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated entities and acquisitions.",
        "label": "Consolidated Entities and Acquisitions [Line Items]",
        "terseLabel": "Consolidated Entities and Acquisitions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r236",
      "r718",
      "r719",
      "r722",
      "r723",
      "r724",
      "r841",
      "r926",
      "r1111",
      "r1570",
      "r1573",
      "r1574"
     ]
    },
    "inva_ConsolidatedEntitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConsolidatedEntitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Consolidated Entities"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r225",
      "r236",
      "r718",
      "r719",
      "r722",
      "r723",
      "r724",
      "r841",
      "r926",
      "r1111",
      "r1570",
      "r1573",
      "r1574"
     ]
    },
    "inva_ConsolidatedEntityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConsolidatedEntityTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitions3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entity [Text Block]",
        "documentation": "The entire disclosure for consolidated entity.",
        "terseLabel": "CONSOLIDATED ENTITY"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConsolidatedInvesteesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConsolidatedInvesteesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated investees.",
        "label": "Consolidated Investees [Member]",
        "terseLabel": "Consolidated Investees [Member]",
        "verboseLabel": "Consolidated Investees"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r224",
      "r225",
      "r233",
      "r236",
      "r281",
      "r298",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r926",
      "r1155",
      "r1156",
      "r1571",
      "r1572"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r224",
      "r225",
      "r233",
      "r236",
      "r281",
      "r298",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r320",
      "r321",
      "r322",
      "r437",
      "r438",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r926",
      "r1155",
      "r1156",
      "r1571",
      "r1572"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r1142"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "terseLabel": "Variable Interest Entities",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r56",
      "r58"
     ]
    },
    "inva_ContingentValueRightsLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ContingentValueRightsLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet3": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights liability",
        "label": "Contingent value rights liability",
        "terseLabel": "Contingent value rights liability",
        "verboseLabel": "Contingent value rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtFairValueDisclosures",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2": {
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "2028 Notes",
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1654",
      "r1655",
      "r1656",
      "r1658"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt investment",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r449",
      "r450",
      "r460",
      "r461",
      "r462",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Summary of Liability and Equity Components of Convertible Notes",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertibleNoteAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertibleNoteAndWarrantsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible note and warrants.",
        "label": "Convertible Note and Warrants [Member]",
        "terseLabel": "In Carda Convertible Note",
        "verboseLabel": "Convertible note and warrants"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertiblePromissoryNotePurchaseAgreementAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertiblePromissoryNotePurchaseAgreementAmendmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Purchase Agreement Amendment [Member]",
        "documentation": "Convertible promissory note purchase agreement amendment.",
        "terseLabel": "Convertible Promissory Note Purchase Agreement Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Purchase Agreement Fifth Amendment [Member]",
        "documentation": "Convertible promissory note purchase agreement fifth amendment.",
        "terseLabel": "Convertible Promissory Note Purchase Agreement Fifth Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Purchase Agreement Fourth Amendment [Member]",
        "documentation": "Convertible promissory note purchase agreement fourth amendment.",
        "terseLabel": "Convertible Promissory Note Purchase Agreement Fourth Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertiblePromissoryNotePurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertiblePromissoryNotePurchaseAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Purchase Agreement [Member]",
        "documentation": "Convertible promissory note purchase agreement [Member]",
        "terseLabel": "Convertible Promissory Note Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Purchase Agreement, Note Amendment Agreement [Member]",
        "documentation": "Convertible Promissory Note Purchase Agreement, Note Amendment Agreement.",
        "terseLabel": "Convertible Promissory Note Purchase Agreement, Note Amendment Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Purchase Agreement Second Amendment [Member]",
        "documentation": "Convertible promissory note purchase agreement second amendment.",
        "terseLabel": "Convertible Promissory Note Purchase Agreement Second Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Purchase Agreement Third Amendment [Member]",
        "documentation": "Convertible promissory note purchase agreement third amendment.",
        "terseLabel": "Convertible Promissory Note Purchase Agreement Third Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertibleSeniorDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertibleSeniorDebtFairValueDisclosures",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2": {
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of long-term notes which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. Senior debt has the highest claim on the assets of the issuer in case of bankruptcy or liquidation, due within one year or the normal operating cycle, if longer. Senior note holders are paid off in full before any payments are made to debt holders having a lesser priority of repayment.",
        "label": "Convertible Senior Debt, Fair Value Disclosures",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertibleSeniorNotes2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertibleSeniorNotes2025Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Senior Notes 2025 [Member]",
        "documentation": "Convertible senior notes 2025.",
        "terseLabel": "Convertible senior notes due 2025 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ConvertibleSubordinatedDebtFairValueDisclosures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertibleSubordinatedDebtFairValueDisclosures",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2": {
       "parentTag": "us-gaap_DebtInstrumentFairValue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of subordinated debt obligations which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Subordinated Debt, Fair Value Disclosures",
        "terseLabel": "2023 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleSubordinatedDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleSubordinatedDebtMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Subordinated Debt [Member]",
        "terseLabel": "Convertible subordinated notes",
        "documentation": "Debt that places a lender in a lien position behind debt having a higher priority of repayment in liquidation of the entity's assets which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "inva_ConvertibleSubordinatedNotes2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ConvertibleSubordinatedNotes2023Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible subordinated notes due 2023 [Member]",
        "label": "Convertible Subordinated Notes 2023 [Member]",
        "documentation": "Convertible Subordinated Notes 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CordenPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CordenPharmaMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corden Pharma [Member]",
        "documentation": "Corden Pharma.",
        "terseLabel": "Corden Pharma [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding amortization of intangible assets)",
        "label": "Cost of Product and Service Sold",
        "totalLabel": "Cost of products sold (inclusive of amortization of inventory fair value adjustments, excluding depreciation and amortization of intangible assets)",
        "verboseLabel": "Cost of products sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r882",
      "r1136",
      "r1141",
      "r1232",
      "r1479"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of license revenue",
        "label": "Cost of Revenue",
        "totalLabel": "Cost of Revenue, Total",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r224",
      "r227",
      "r228",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r797",
      "r1155",
      "r1571"
     ]
    },
    "inva_CostReimbursementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CostReimbursementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost Reimbursement",
        "label": "Cost Reimbursement [Member]",
        "documentation": "Cost reimbursement."
       }
      }
     },
     "auth_ref": []
    },
    "inva_CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of capped calls in connection with convertible senior notes due 2028",
        "label": "Cost To Enter Into Capped Calls Sales In Connection With Convertible Senior Notes",
        "documentation": "Cost to enter into capped calls sales in connection with convertible senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r234",
      "r235",
      "r452",
      "r498",
      "r840",
      "r864",
      "r930",
      "r1132",
      "r1133",
      "r1134",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435",
      "r1436",
      "r1437",
      "r1438",
      "r1439",
      "r1638",
      "r1639",
      "r1640",
      "r1641"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "inva_CreditAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CreditAndSecurityAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit and Security Agreement",
        "label": "Credit and Security Agreement [Member]",
        "documentation": "Credit and security agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative effect period of adoption adjustment member"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r240",
      "r248",
      "r255",
      "r368",
      "r371",
      "r419",
      "r631",
      "r632",
      "r646",
      "r648",
      "r744",
      "r746",
      "r747",
      "r749",
      "r750",
      "r751",
      "r761",
      "r764",
      "r766",
      "r767",
      "r835"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r240",
      "r248",
      "r255",
      "r368",
      "r371",
      "r419",
      "r631",
      "r632",
      "r646",
      "r648",
      "r744",
      "r746",
      "r747",
      "r749",
      "r750",
      "r751",
      "r761",
      "r764",
      "r766",
      "r767",
      "r835"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r240",
      "r248",
      "r255",
      "r368",
      "r371",
      "r419",
      "r631",
      "r632",
      "r646",
      "r648",
      "r744",
      "r746",
      "r747",
      "r749",
      "r750",
      "r751",
      "r761",
      "r764",
      "r766",
      "r767",
      "r835"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1410",
      "r1492",
      "r1498",
      "r1621"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1410",
      "r1492",
      "r1498"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r1492",
      "r1498"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Current"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CurrentPortionOfISPFundInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CurrentPortionOfISPFundInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Portion Of ISP Fund Investments",
        "documentation": "Current portion of ISP Fund investments",
        "terseLabel": "Current portion of ISP Fund investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1410",
      "r1492",
      "r1498",
      "r1621"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r1510"
     ]
    },
    "inva_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer one.",
        "label": "Customer One [Member]",
        "terseLabel": "Customer One"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer three.",
        "label": "Customer Three [Member]",
        "terseLabel": "Customer Three"
       }
      }
     },
     "auth_ref": []
    },
    "inva_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer two.",
        "label": "Customer Two [Member]",
        "terseLabel": "Customer Two"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1299",
      "r1388"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1299",
      "r1388"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1390"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1390"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1303",
      "r1392"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1390"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1294",
      "r1383"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1295",
      "r1384"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1295",
      "r1384"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1293",
      "r1382"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1293",
      "r1382"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1293",
      "r1382"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1296",
      "r1385"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1298",
      "r1387"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1298",
      "r1387"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1299",
      "r1388"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1302",
      "r1391"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1389"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCybersecurityRiskManagementStrategyAndGovernance"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1297",
      "r1386"
     ]
    },
    "inva_DebtConversionCommonStockPriceToConversionPriceRatioPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DebtConversionCommonStockPriceToConversionPriceRatioPercentage",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of common stock price as a percentage of conversion price.",
        "label": "Debt Conversion, Common Stock Price to Conversion Price Ratio, Percentage",
        "terseLabel": "Common stock price to current conversion price ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Notes converted into common stock, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r27"
     ]
    },
    "inva_DebtConversionConvertedInstrumentAverageTradePricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DebtConversionConvertedInstrumentAverageTradePricePercentage",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average trading price per $1,000 of Notes with respect to product of the closing common stock price and the conversion rate",
        "label": "Debt Conversion, Converted Instrument, Average Trade Price Percentage",
        "terseLabel": "Average trading price percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Debt Conversion, Converted Instrument, Shares Issued",
        "verboseLabel": "Principal amount converted in to shares",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r27"
     ]
    },
    "us-gaap_DebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Current portion of long-term debt, net",
        "totalLabel": "Debt, Current, Total",
        "label": "Debt, Current",
        "negatedLabel": "Less: Current portion of long-term debt, net",
        "verboseLabel": "Convertible notes, due 2025, net of issuance costs",
        "documentation": "Amount of debt and lease obligation, classified as current."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebt4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "DEBT",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r224",
      "r226",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r435",
      "r436",
      "r448",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r464",
      "r471",
      "r472",
      "r474",
      "r741",
      "r810"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r70",
      "r71",
      "r136",
      "r141",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1248",
      "r1492",
      "r1493",
      "r1495",
      "r1500",
      "r1562",
      "r1563",
      "r1564",
      "r1662",
      "r1664",
      "r1679"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3": {
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Gross",
        "totalLabel": "Total",
        "verboseLabel": "Principal amount",
        "terseLabel": "Total purchase price",
        "netLabel": "Total debt",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r141",
      "r475"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Carrying Amount of Equity Component",
        "terseLabel": "Equity component, net",
        "documentation": "The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "inva_DebtInstrumentConvertibleConversionPremium": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DebtInstrumentConvertibleConversionPremium",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage above the last reported sale price of the Company's common stock.",
        "label": "Debt Instrument, Convertible, Conversion Premium",
        "terseLabel": "Conversion premium (as a percent)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Conversion price (dollars per share)",
        "verboseLabel": "Conversion price of convertible notes into common stock (in dollars per share)",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r451"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Conversion rate for shares of common stock per $1,000 principal",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r74",
      "r122",
      "r123",
      "r451"
     ]
    },
    "us-gaap_DebtInstrumentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentDescription",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, description",
        "label": "Debt Instrument, Description",
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r67",
      "r70",
      "r136",
      "r141",
      "r810"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Convertible notes face value",
        "verboseLabel": "Loan amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r810",
      "r811",
      "r1167",
      "r1168",
      "r1248"
     ]
    },
    "us-gaap_DebtInstrumentFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFairValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fair Value Disclosure",
        "totalLabel": "Total fair value of debt",
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r790",
      "r791",
      "r792",
      "r795",
      "r1167",
      "r1168",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate",
        "verboseLabel": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r478",
      "r810",
      "r811",
      "r1248"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Debt Instrument, annual interest rate",
        "terseLabel": "Debt Instrument, annual interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r450"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r741",
      "r926",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1248",
      "r1492",
      "r1493",
      "r1495",
      "r1500",
      "r1662",
      "r1664"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument maturity date",
        "label": "Debt Instrument, Maturity Date",
        "verboseLabel": "Debt instrument maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r1166",
      "r1648",
      "r1649"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1248",
      "r1492",
      "r1493",
      "r1495",
      "r1500",
      "r1562",
      "r1563",
      "r1564",
      "r1662",
      "r1664",
      "r1679"
     ]
    },
    "inva_DebtInstrumentPercentagePremiumOnPrincipalOnDefault": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DebtInstrumentPercentagePremiumOnPrincipalOnDefault",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument percentage premium on principal on default",
        "label": "Debt Instrument Percentage Premium on Principal on Default",
        "documentation": "Debt instrument percentage premium on principal on default."
       }
      }
     },
     "auth_ref": []
    },
    "inva_DebtInstrumentPrincipalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DebtInstrumentPrincipalAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails2": {
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument Principal Amount",
        "label": "Debt Instrument Principal Amount",
        "terseLabel": "Total debt",
        "verboseLabel": "Principal"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Ratio of repurchase price to the principal amount of debt instrument to be repurchased in the event of default or a fundamental change.",
        "label": "Debt Instrument, Ratio of repurchase price to the principal amount",
        "terseLabel": "Ratio of repurchase price to the principal amount"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DebtInstrumentRemainingBalancePaidUponMaturation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DebtInstrumentRemainingBalancePaidUponMaturation",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Remaining Balance Paid upon Maturation",
        "documentation": "Debt instrument remaining balance paid upon maturation.",
        "terseLabel": "Remaining balance paid upon maturation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRepurchaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Portion of debt retired, carrying value",
        "documentation": "Fair value amount of debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "inva_DebtInstrumentRepurchasePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DebtInstrumentRepurchasePercentage",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of debt Instrument, repurchased.",
        "label": "Debt Instrument, Repurchase Percentage",
        "terseLabel": "Percentage of notes repurchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Debt Instrument, Repurchased Face Amount",
        "verboseLabel": "Portion of debt retired, face value",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r40",
      "r66",
      "r121",
      "r123",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r741",
      "r926",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1248",
      "r1492",
      "r1493",
      "r1495",
      "r1500",
      "r1662",
      "r1664"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Instrument, Unamortized Discount, Total",
        "label": "Debt Instrument, Unamortized Discount",
        "verboseLabel": "Unamortized Debt discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r1576",
      "r1661",
      "r1662",
      "r1664"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails2": {
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3": {
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized debt discount and issuance costs",
        "terseLabel": "Debt discount and issuance costs, net",
        "negatedTerseLabel": "Debt discount and issuance costs, net",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r476",
      "r809",
      "r810",
      "r811",
      "r1167",
      "r1168",
      "r1248"
     ]
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Long-Term and Short-Term, Combined Amount",
        "terseLabel": "Total debt, net",
        "totalLabel": "Net carrying amount",
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt [Member]",
        "terseLabel": "Debt",
        "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance",
        "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "verboseLabel": "Credit loss",
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r377",
      "r381",
      "r382"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of Amortized Cost and Estimated Fair Values for Available-for-Sale Securities",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1526",
      "r1527",
      "r1528",
      "r1529",
      "r1530",
      "r1531",
      "r1532",
      "r1533",
      "r1534",
      "r1535",
      "r1536",
      "r1537"
     ]
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeconsolidationGainOrLossAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deconsolidation, Gain (Loss), Amount",
        "terseLabel": "Net gain on sale of TRC",
        "negatedLabel": "Net gain on sale of TRC",
        "negatedTerseLabel": "Gain on sale of Theravance Respiratory Company, LLC (\"TRC\")",
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r208"
     ]
    },
    "inva_DecreaseToAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DecreaseToAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease to accumulated deficit.",
        "label": "Decrease to Accumulated Deficit",
        "terseLabel": "Decrease to accumulated deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "negatedLabel": "Federal",
        "terseLabel": "Federal",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1492",
      "r1498",
      "r1620",
      "r1621"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "negatedTotalLabel": "Total",
        "totalLabel": "Total deferred",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1611"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Income Tax Expense (Benefit), Total",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r162",
      "r1492",
      "r1498"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Deferred"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Net deferred tax (liabilities)",
        "negatedTotalLabel": "Net deferred tax (liabilities)",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r138",
      "r621"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities, net",
        "totalLabel": "Net deferred tax (liabilities)",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r600",
      "r601",
      "r934"
     ]
    },
    "us-gaap_DeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Total",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1423"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Revenue, Current, Total",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1422"
     ]
    },
    "inva_DeferredRoyaltyObligationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DeferredRoyaltyObligationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of deferred royalty obligation.",
        "label": "Deferred Royalty Obligation, Current",
        "terseLabel": "Current portion of deferred royalty obligation"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DeferredRoyaltyObligationNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DeferredRoyaltyObligationNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term portion of deferred royalty obligation.",
        "label": "Deferred Royalty Obligation, Non Current",
        "terseLabel": "Long-term portion of deferred royalty obligation"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DeferredRoyaltyObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DeferredRoyaltyObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Royalty Obligations",
        "documentation": "Deferred royalty obligations.",
        "terseLabel": "Deferred Royalty obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "negatedLabel": "State",
        "terseLabel": "State",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1492",
      "r1498",
      "r1620",
      "r1621"
     ]
    },
    "inva_DeferredTaxAssetsDeferredRoyaltyObligationNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DeferredTaxAssetsDeferredRoyaltyObligationNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets deferred royalty obligation, net",
        "label": "Deferred Tax Assets Deferred Royalty Obligation, Net",
        "terseLabel": "Deferred royalty obligation, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets before valuation allowance",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1616"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1616"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1618"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards do not expire",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1618"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1618"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credit carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1618"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Reserves",
        "terseLabel": "Accruals and reserves",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1618"
     ]
    },
    "inva_DeferredTaxAssetsUnrealizedLossesOnInvestmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DeferredTaxAssetsUnrealizedLossesOnInvestmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets unrealized losses on investment, net",
        "label": "Deferred Tax Assets Unrealized Losses On Investment, Net",
        "terseLabel": "Unrealized losses on investment, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "inva_DeferredTaxLiabilitiesDepreciationAndAmortization1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization1",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities Depreciation And Amortization 1",
        "documentation": "Deferred tax liabilities depreciation and amortization.",
        "terseLabel": "Depreciation and amortization",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DeferredTaxLiabilitiesInventoryFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DeferredTaxLiabilitiesInventoryFairValueAdjustment",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities inventory fair value adjustment",
        "label": "Deferred Tax Liabilities Inventory Fair Value Adjustment",
        "terseLabel": "Inventory fair value adjustment",
        "negatedLabel": "Inventory fair value adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Investments",
        "negatedLabel": "Unrealized gains on investment, net",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments (excludes investments in subsidiaries and equity method investments)."
       }
      }
     },
     "auth_ref": [
      "r1618"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesDeferredTaxesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "terseLabel": "Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1618"
     ]
    },
    "inva_DenominatorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DenominatorAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Depreciation, Total",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r34",
      "r211",
      "r1135",
      "r1136",
      "r1138",
      "r1140"
     ]
    },
    "us-gaap_DerivativeCapPrice": {
     "xbrltype": "perUnitItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeCapPrice",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative, Cap Price",
        "terseLabel": "Cap price for the underlying number of shares (in dollars per share)",
        "documentation": "The cap rate on a price risk derivative such as a cap or collar. A payment or receipt is triggered if the market rate exceeds the cap rate on the contract."
       }
      }
     },
     "auth_ref": []
    },
    "inva_DescriptionOfOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DescriptionOfOperationsPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Operations",
        "label": "Description of Operations [Policy Text Block]",
        "documentation": "Description of operations."
       }
      }
     },
     "auth_ref": []
    },
    "inva_DevelopmentRegulatoryAndRoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DevelopmentRegulatoryAndRoyaltyMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development, Regulatory and Royalty [Member]",
        "documentation": "Development, regulatory and royalty.",
        "terseLabel": "Development, Regulatory and Royalty"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DevelopmentRegulatoryAndSalesMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DevelopmentRegulatoryAndSalesMilestoneMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Development Regulatory and Sales Milestone [Member]",
        "documentation": "Development regulatory and sales milestone.",
        "terseLabel": "Development Regulatory and Sales Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Non-employee director"
       }
      }
     },
     "auth_ref": [
      "r1519",
      "r1716"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Revenue Recognition and Collaborative Arrangements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r523",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r523",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of net revenue from collaboration arrangement",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1580"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "STOCK-BASED COMPENSATION",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r543",
      "r574",
      "r575",
      "r577",
      "r1189"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_DividendYield": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DividendYield",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend yield.",
        "label": "Dividend Yield",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1290",
      "r1291",
      "r1314"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1290",
      "r1291",
      "r1314",
      "r1357"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "inva_DurlobactamMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "DurlobactamMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Durlobactam [Member]",
        "documentation": "Durlobactam.",
        "terseLabel": "Durlobactam"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1346"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Basic, Total",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic net income per share",
        "terseLabel": "Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r206",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r257",
      "r260",
      "r274",
      "r275",
      "r276",
      "r280",
      "r483",
      "r580",
      "r650",
      "r715",
      "r767",
      "r768",
      "r921",
      "r951",
      "r1144"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted net income per share",
        "terseLabel": "Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r206",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r260",
      "r274",
      "r275",
      "r276",
      "r280",
      "r483",
      "r580",
      "r650",
      "r715",
      "r767",
      "r768",
      "r921",
      "r951",
      "r1144"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "verboseLabel": "Net Income Per Share",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r265",
      "r274",
      "r276"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShare1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "NET INCOME PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r277",
      "r278",
      "r279"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r1191"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax at statutory rate, percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r230",
      "r604",
      "r636",
      "r1191"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r1191",
      "r1492",
      "r1499",
      "r1612"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Enactment of new tax laws, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r1191",
      "r1492",
      "r1499",
      "r1612"
     ]
    },
    "inva_EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation Changes In Unrecognized Tax Benefits Percent",
        "documentation": "Effective Income Tax Rate Reconciliation Changes In Unrecognized Tax Benefits Percent",
        "terseLabel": "Changes in unrecognized tax benefits, percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border, Other, Amount",
        "terseLabel": "Other",
        "documentation": "Amount of reported income tax expense (benefit) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law classified as other."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1614"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, percent",
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border, Other, Percent",
        "documentation": "Percentage of reported income tax expense (benefit) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to cross-border tax law classified as other."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1614"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationCrossBorderTaxEffectPercentAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Cross-Border Tax Effect, Percent [Abstract]",
        "terseLabel": "Cross-border tax laws"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, FDII, Amount",
        "negatedLabel": "Foreign-derived intangible income",
        "documentation": "Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1612",
      "r1614"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, FDII, Percent",
        "negatedLabel": "Foreign-derived intangible income, percent",
        "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1612",
      "r1614"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax effects Other - Withholding taxes , Percent",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r608",
      "r1191",
      "r1492",
      "r1499",
      "r1612"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent, Total",
        "terseLabel": "Nontaxable or nondeductible items, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r612",
      "r1492",
      "r1499",
      "r1612"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other adjustments, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1492",
      "r1499",
      "r1612",
      "r1613"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State and local effects, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1191",
      "r1492",
      "r1499",
      "r1612"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r605",
      "r1191"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "negatedLabel": "Foreign tax credit, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r1492",
      "r1499",
      "r1612",
      "r1614"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state research credits , percent",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "negatedLabel": "Federal and state research and development credit, percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1492",
      "r1499",
      "r1612",
      "r1614"
     ]
    },
    "inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Reconciliation Section Two Fifty Deduction Amount",
        "documentation": "Effective income tax reconciliation section two fifty deduction amount",
        "terseLabel": "Section 250 deduction"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Reconciliation Section Two Fifty Deduction Percent",
        "documentation": "Effective income tax reconciliation section two fifty deduction percent.",
        "terseLabel": "Section 250 deduction, percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Employee-related Liabilities, Current, Total",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued personnel-related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-Average Amortization Period (Years)",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Stock options",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600",
      "r1601",
      "r1602",
      "r1603",
      "r1604",
      "r1605",
      "r1606",
      "r1607",
      "r1608",
      "r1609"
     ]
    },
    "inva_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the Company's Employee Stock Purchase Plan (the \"ESPP\").",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EmployeeStockPurchasePlanTwentyTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EmployeeStockPurchasePlanTwentyTwentyThreeMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 ESPP",
        "label": "Employee Stock Purchase Plan Twenty Twenty Three [Member]",
        "documentation": "Employee Stock Purchase Plan Twenty Twenty Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EntasisLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EntasisLeaseMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entasis Lease [Member]",
        "label": "Entasis Lease [Member]",
        "terseLabel": "Entasis Lease"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EntasisTherapeuticsHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EntasisTherapeuticsHoldingsIncMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Entasis Therapeutics Holdings Inc.",
        "label": "Entasis Therapeutics Holdings Inc [Member]",
        "terseLabel": "Entasis",
        "verboseLabel": "Entasis Therapeutics Holdings Inc"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CIK",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Entities",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1397"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1399"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1340"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1393"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r1393"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r1393"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r168",
      "r175",
      "r176",
      "r202",
      "r203",
      "r204",
      "r237",
      "r238",
      "r239",
      "r242",
      "r250",
      "r252",
      "r254",
      "r282",
      "r368",
      "r371",
      "r419",
      "r482",
      "r512",
      "r580",
      "r631",
      "r632",
      "r646",
      "r647",
      "r648",
      "r651",
      "r714",
      "r715",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r766",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r812",
      "r814",
      "r837",
      "r949",
      "r967",
      "r968",
      "r969",
      "r992",
      "r1065"
     ]
    },
    "inva_EquityIncentivePlan2012Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EquityIncentivePlan2012Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2012 Equity Incentive Plan as approved by shareowners.",
        "label": "Equity Incentive Plan2012 [Member]",
        "terseLabel": "2012 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EquityIncentivePlansAndESPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EquityIncentivePlansAndESPPMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to options, Equity Incentive Plans and Employee Stock Purchase Plans.",
        "label": "Equity Incentive Plans And E S P P [Member]",
        "terseLabel": "Equity incentive plans and ESPP"
       }
      }
     },
     "auth_ref": []
    },
    "inva_EquityInvestmentsAndMoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EquityInvestmentsAndMoneyMarketFundsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to equity investments and money market funds.",
        "label": "Equity Investments And Money Market Funds [Member]",
        "terseLabel": "Equity investments and Money market funds"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r642",
      "r797",
      "r1402",
      "r1403",
      "r1404",
      "r1622",
      "r1623",
      "r1624",
      "r1625"
     ]
    },
    "inva_EquityMethodInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EquityMethodInvestment",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments",
        "label": "Equity Method Investment",
        "documentation": "Equity method investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Other-than-Temporary Impairment",
        "terseLabel": "Impairment of equity investments",
        "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r1541"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investment, Ownership Percentage",
        "verboseLabel": "Equity investment ownership percentage",
        "terseLabel": "Equity method investment ownership percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r797"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Method Investments [Policy Text Block]",
        "terseLabel": "Equity and Long-Term Investments",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r365",
      "r797"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity and long-term investments at fair value",
        "verboseLabel": "Fair value of equity securities",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r789",
      "r1127"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gain",
        "label": "Equity Securities, FV-NI, Unrealized Gain",
        "terseLabel": "Unrealized gain from fair value changes in equity investments",
        "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized loss from fair value changes in equity investments",
        "negatedLabel": "Unrealized loss from fair value changes in equity investments",
        "label": "Equity Securities, FV-NI, Unrealized Loss",
        "verboseLabel": "Unrealized loss",
        "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity investment",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r1251",
      "r1280",
      "r1281",
      "r1282",
      "r1723"
     ]
    },
    "inva_EquitySecuritiesOwned": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EquitySecuritiesOwned",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares owned",
        "label": "Equity Securities Owned",
        "documentation": "Equity securities owned."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1350"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r1307",
      "r1318",
      "r1328",
      "r1361"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r1304",
      "r1315",
      "r1325",
      "r1358"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "auth_ref": [
      "r1722",
      "r1724",
      "r1725",
      "r1726"
     ]
    },
    "inva_EverestMedicinesLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "EverestMedicinesLimitedMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Everest Medicines Limited [Member]",
        "label": "Everest Medicines Limited [Member]",
        "terseLabel": "Everest Medicines Limited"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "inva_ExpectedHoldingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ExpectedHoldingPeriod",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected holding period of equity method investment.",
        "label": "Expected Holding Period",
        "terseLabel": "Expected holding period"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ExternalServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ExternalServicesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "External Services [Member]",
        "documentation": "External Services.",
        "terseLabel": "External services"
       }
      }
     },
     "auth_ref": []
    },
    "inva_FactorsAffectingComparabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "FactorsAffectingComparabilityPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Factors affecting comparability.",
        "label": "Factors Affecting Comparability Policy [Text Block]",
        "terseLabel": "Factors Affecting Comparability"
       }
      }
     },
     "auth_ref": []
    },
    "inva_FairValueAdjustmentsOfInventoryFromAcquistion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "FairValueAdjustmentsOfInventoryFromAcquistion",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of net fair value adjustment of inventory resulting from the acquisition.",
        "label": "Fair Value Adjustments Of Inventory From Acquistion",
        "terseLabel": "Net fair value adjustment of inventory from acquisition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements",
        "verboseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r782",
      "r1236"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r782",
      "r1236"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of Available-for-Sale Securities Measured at Fair Value on a Recurring Basis",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1645",
      "r1646",
      "r1651"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r783",
      "r1121",
      "r1238",
      "r1247"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Equity Investment",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r792",
      "r1121",
      "r1247",
      "r1657"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r783",
      "r1121",
      "r1238",
      "r1247"
     ]
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r792",
      "r1121",
      "r1247",
      "r1655",
      "r1657"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r534",
      "r769",
      "r771",
      "r772",
      "r773",
      "r774",
      "r781",
      "r782",
      "r784",
      "r790",
      "r848",
      "r849",
      "r850",
      "r1121",
      "r1167",
      "r1168",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1236",
      "r1240",
      "r1247"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772",
      "r774",
      "r1236",
      "r1648",
      "r1652"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Price in Active Markets for Identical Assets, Level 1",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r526",
      "r531",
      "r533",
      "r771",
      "r782",
      "r790",
      "r848",
      "r1121",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1236",
      "r1247"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs, Level 2",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r526",
      "r531",
      "r533",
      "r535",
      "r771",
      "r772",
      "r782",
      "r790",
      "r849",
      "r1121",
      "r1167",
      "r1168",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1236",
      "r1247"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs, Level 3",
        "verboseLabel": "Fair Value, Inputs, Level 3",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r534",
      "r771",
      "r772",
      "r773",
      "r774",
      "r782",
      "r790",
      "r850",
      "r1121",
      "r1167",
      "r1168",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1236",
      "r1240",
      "r1247"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772",
      "r774",
      "r1236",
      "r1648",
      "r1652"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r534",
      "r769",
      "r771",
      "r772",
      "r773",
      "r774",
      "r781",
      "r782",
      "r784",
      "r790",
      "r848",
      "r849",
      "r850",
      "r1121",
      "r1167",
      "r1168",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1236",
      "r1240",
      "r1247"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrecurring basis",
        "label": "Fair Value, Nonrecurring [Member]",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r770",
      "r771",
      "r772",
      "r774",
      "r1236",
      "r1648"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1652"
     ]
    },
    "inva_FairValueOfAssetsOrLiabilitiesTransferBetweenLevels": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "FairValueOfAssetsOrLiabilitiesTransferBetweenLevels",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Of Assets Or Liabilities Transfer Between Levels",
        "documentation": "Fair Value Of Assets Or Liabilities Transfer Between Levels",
        "terseLabel": "Fair value of assets or liabilities transfer between levels"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1653"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r378",
      "r379",
      "r380",
      "r473",
      "r508",
      "r741",
      "r756",
      "r785",
      "r796",
      "r799",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r862",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r929",
      "r950",
      "r1164",
      "r1236",
      "r1238",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1251",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1537",
      "r1538",
      "r1539",
      "r1540",
      "r1644",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1652",
      "r1654",
      "r1655"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurements2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "inva_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Asset Expected Amortization After Year Four",
        "documentation": "Finite lived intangible asset expected amortization after year four.",
        "terseLabel": "Future amortization expense, thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Marketed products, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization",
        "negatedTotalLabel": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r388",
      "r411",
      "r1124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "terseLabel": "Future amortization expense, thereafter",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1557",
      "r1728"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Future amortization expense, 2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r1119",
      "r1124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future amortization expense, remainder of 2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1728"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Future amortization expense, 2030",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r1119",
      "r1124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Future amortization expense, 2029",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r1119",
      "r1124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Future amortization expense, 2028",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r1119",
      "r1124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Future amortization expense, 2027",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r1119",
      "r1124"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r415",
      "r416",
      "r883",
      "r884",
      "r979",
      "r1119",
      "r1124",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r411",
      "r415",
      "r416",
      "r417",
      "r883",
      "r1119",
      "r1124",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r406",
      "r407",
      "r408",
      "r410",
      "r411",
      "r415",
      "r416",
      "r979",
      "r1119",
      "r1124",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225"
     ]
    },
    "inva_FirstAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "FirstAmendmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Amendment",
        "label": "First Amendment [Member]",
        "documentation": "First amendment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Tax Jurisdiction [Member]",
        "terseLabel": "Foreign",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r605"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1311",
      "r1322",
      "r1332",
      "r1365"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1311",
      "r1322",
      "r1332",
      "r1365"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1311",
      "r1322",
      "r1332",
      "r1365"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r1311",
      "r1322",
      "r1332",
      "r1365"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1311",
      "r1322",
      "r1332",
      "r1365"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1345"
     ]
    },
    "inva_FuturePotentialMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "FuturePotentialMilestonePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future potential milestone payment receivable.",
        "label": "Future Potential Milestone Payment",
        "terseLabel": "Future potential milestone payment receivable"
       }
      }
     },
     "auth_ref": []
    },
    "inva_GARDPCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "GARDPCollaborationAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GARDP Collaboration Agreement",
        "label": "GARDP Collaboration Agreement [Member]",
        "documentation": "GARDP collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "country_GB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "GB",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED KINGDOM",
        "terseLabel": "United Kingdom"
       }
      }
     },
     "auth_ref": []
    },
    "inva_GSKMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "GSKMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents GSK, with whom the entity has agreements and arrangements, such as those for developing and commercializing different products.",
        "label": "G S K [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Realized gain on equity investments",
        "totalLabel": "Gain (Loss) on Investments, Total",
        "label": "Gain (Loss) on Investments",
        "negatedLabel": "Realized gain on equity investments",
        "verboseLabel": "Changes in fair values of equity and long-term investments, net",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r103",
      "r1400"
     ]
    },
    "inva_GainLossOnOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "GainLossOnOtherInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in fair value of equity and long-term investments, net",
        "documentation": "Gain loss on other investments.",
        "label": "Gain (Loss) on Other Investments",
        "verboseLabel": "Changes in fair value, net",
        "terseLabel": "Changes in fair values of equity and long-term investments, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "terseLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r37",
      "r38"
     ]
    },
    "inva_GateNeuroscienceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "GateNeuroscienceMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gate Neuroscience [Member]",
        "documentation": "Gate Neuroscience [Member]",
        "terseLabel": "Gate Neurosciences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_GatesFoundationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "GatesFoundationMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gates Foundation",
        "label": "Gates Foundation [Member]",
        "documentation": "Gates Foundation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "totalLabel": "General and Administrative Expense, Total",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r1047"
     ]
    },
    "us-gaap_GeneralPartnerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralPartnerMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Partner [Member]",
        "terseLabel": "General Partner",
        "documentation": "Party to a partnership business who has unlimited liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeographicConcentrationRiskMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk",
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)."
       }
      }
     },
     "auth_ref": [
      "r1105",
      "r1513"
     ]
    },
    "inva_GeorgeWashingtonUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "GeorgeWashingtonUniversityMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "George Washington University.",
        "label": "George Washington University [Member]",
        "terseLabel": "George Washington University"
       }
      }
     },
     "auth_ref": []
    },
    "inva_GiaprezaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "GiaprezaMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GIAPREZA.",
        "label": "GIAPREZA [Member]",
        "terseLabel": "GIAPREZA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Goodwill, Total",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "periodEndLabel": "Goodwill, Ending Balance",
        "label": "Goodwill",
        "terseLabel": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r389",
      "r919",
      "r1156",
      "r1165",
      "r1192",
      "r1193",
      "r1194",
      "r1229",
      "r1237",
      "r1250",
      "r1546",
      "r1547",
      "r1633"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "GOODWILL AND INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1545",
      "r1548"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1545",
      "r1548"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, impairment losses",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r390",
      "r396",
      "r401",
      "r403",
      "r709",
      "r1165",
      "r1237"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r1165"
     ]
    },
    "inva_GrantFundingMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "GrantFundingMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Grant Funding Maximum Amount",
        "terseLabel": "Grant Funding Maximum Amount",
        "documentation": "Grant funding maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Profit",
        "totalLabel": "Gross profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r97",
      "r154",
      "r224",
      "r227",
      "r228",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r797",
      "r1148",
      "r1155",
      "r1508",
      "r1515",
      "r1516",
      "r1517",
      "r1518",
      "r1571"
     ]
    },
    "inva_GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails": {
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer before amortization of capitalized fees.",
        "label": "Gross Revenue from Contract with Customer, Excluding Assessed Tax, Before Amortization Of Capitalized Fees",
        "terseLabel": "Royalties",
        "totalLabel": "Total royalties"
       }
      }
     },
     "auth_ref": []
    },
    "inva_HarvardUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "HarvardUniversityMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard University.",
        "label": "Harvard University [Member]",
        "terseLabel": "Harvard University"
       }
      }
     },
     "auth_ref": []
    },
    "inva_HealthCareRoyaltyPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "HealthCareRoyaltyPartnersMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health care royalty partners member.",
        "label": "Health Care Royalty Partners [Member]",
        "terseLabel": "HealthCare Royalty Partners"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1290",
      "r1291",
      "r1314"
     ]
    },
    "inva_ImaginAbNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ImaginAbNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ImaginAb Note [Member]",
        "documentation": "ImaginAb Note.",
        "terseLabel": "ImaginAb Note"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ImaginabConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ImaginabConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ImaginAb Convertible Note",
        "label": "ImaginAb Convertible Note [Member]",
        "documentation": "ImaginAb Convertible Note."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ImaginabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ImaginabMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Imaginab [Member]",
        "terseLabel": "ImaginAb",
        "documentation": "Represents information pertaining to ImaginAb."
       }
      }
     },
     "auth_ref": []
    },
    "inva_InCardaConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InCardaConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "InCarda Convertible note.",
        "label": "In Carda Convertible Note [Member]",
        "terseLabel": "InCarda Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "InCarda February TwoThousand Twenty Five Convertible Note [Member]",
        "documentation": "InCarda February TwoThousand Twenty Five Convertible Note [Member]",
        "terseLabel": "InCarda February 2025 Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "InCarda October Two Thousand Twenty Five Convertible Note [Member]",
        "documentation": "InCarda October Two Thousand Twenty Five Convertible Note [Member]",
        "terseLabel": "InCarda October 2025 Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InCardaTwoThousandTwentyFourConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InCardaTwoThousandTwentyFourConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "InCarda Two Thousand Twenty Four Convertible Note [Member]",
        "documentation": "InCarda two thousand twenty four convertible note.",
        "terseLabel": "InCarda 2024 Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1549",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1556",
      "r1558",
      "r1559",
      "r1560"
     ]
    },
    "inva_IncardaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IncardaMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to InCarda.",
        "label": "Incarda [Member]",
        "terseLabel": "InCarda"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r229",
      "r603"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before provision for income taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r146",
      "r154",
      "r922",
      "r924",
      "r946",
      "r1137",
      "r1139",
      "r1141",
      "r1148",
      "r1155",
      "r1508",
      "r1515",
      "r1516",
      "r1517",
      "r1518"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeLossBeforeIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r229",
      "r603"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Equity Method Investments",
        "terseLabel": "Changes in fair values of equity method investments, net",
        "negatedLabel": "Changes in fair values of equity method investments, net",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r94",
      "r145",
      "r281",
      "r301",
      "r320",
      "r363",
      "r945"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r426",
      "r428",
      "r726",
      "r731",
      "r732",
      "r740",
      "r776",
      "r780",
      "r783",
      "r798",
      "r799",
      "r800",
      "r962",
      "r964",
      "r1050",
      "r1119",
      "r1121",
      "r1192",
      "r1194",
      "r1234",
      "r1235",
      "r1239",
      "r1247",
      "r1626",
      "r1628",
      "r1686"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "terseLabel": "Income Statement Location [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r428",
      "r726",
      "r731",
      "r732",
      "r740",
      "r776",
      "r780",
      "r783",
      "r798",
      "r799",
      "r800",
      "r962",
      "r964",
      "r1050",
      "r1119",
      "r1121",
      "r1192",
      "r1194",
      "r1234",
      "r1235",
      "r1239",
      "r1247",
      "r1626",
      "r1628",
      "r1686"
     ]
    },
    "us-gaap_IncomeStatementRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementRelatedDisclosuresAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Related Disclosures [Abstract]",
        "terseLabel": "Income Statement Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r604",
      "r605",
      "r616",
      "r627",
      "r1191",
      "r1617"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "terseLabel": "Income Tax Authority [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r604",
      "r605",
      "r616",
      "r627",
      "r1191",
      "r1617"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxes3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r230",
      "r595",
      "r604",
      "r613",
      "r614",
      "r615",
      "r619",
      "r625",
      "r637",
      "r639",
      "r640",
      "r641",
      "r928",
      "r978",
      "r989",
      "r1191"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1615"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesIncomeTaxExpenseDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total income tax expense, net",
        "negatedTerseLabel": "Income tax expense, net",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense, net",
        "terseLabel": "Income tax expense, net",
        "totalLabel": "Total income tax expense, net",
        "negatedLabel": "Income tax expense, net",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r163",
      "r224",
      "r253",
      "r254",
      "r281",
      "r302",
      "r320",
      "r602",
      "r604",
      "r638",
      "r953",
      "r1137",
      "r1139",
      "r1141",
      "r1191"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "verboseLabel": "Differences between the expected U.S. federal statutory income tax to income tax expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Paid, by Individual Jurisdiction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r627"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r598",
      "r599",
      "r619",
      "r620",
      "r624",
      "r629",
      "r983"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r1191",
      "r1612"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "terseLabel": "Enactment of new tax laws",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r604",
      "r609",
      "r1191"
     ]
    },
    "inva_IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Reconciliation Changes in Unrecognized Tax Benefits",
        "documentation": "Income Tax Reconciliation Changes in Unrecognized Tax Benefits",
        "terseLabel": "Changes in unrecognized tax benefits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign tax effects Other - Withholding taxes",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r605",
      "r608",
      "r1191",
      "r1612"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Federal tax at statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r1191"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "totalLabel": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount, Total",
        "terseLabel": "Nontaxable or nondeductible items",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r612",
      "r1612"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other adjustments",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1612",
      "r1613"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State and local effects",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r607",
      "r1191",
      "r1612"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "negatedLabel": "Foreign tax credit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r1612",
      "r1614"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state research credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Federal and state research and development credit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1191",
      "r1612",
      "r1614"
     ]
    },
    "inva_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes",
        "totalLabel": "Net cash paid for income taxes",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r222",
      "r626",
      "r627"
     ]
    },
    "us-gaap_IncomeTaxesPaidNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IncomeTaxesPaidNetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IncomeTaxesPaidNetTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net [Table Text Block]",
        "documentation": "Tabular disclosure of income taxes paid, net.",
        "terseLabel": "Schedule of net income taxes paid"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of income taxes.",
        "label": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 34.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "terseLabel": "Accounts receivable, net",
        "negatedLabel": "Accounts receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 35.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 36.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued personnel-related expenses and other accrued liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "terseLabel": "Income tax expense recognized",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 32.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r1120"
     ]
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 37.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Accrued interest payable",
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 28.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Inventories, Total",
        "label": "Increase (Decrease) in Inventories",
        "terseLabel": "Measurement period adjustments for change in value of Inventory",
        "negatedLabel": "Inventory",
        "verboseLabel": "Change in inventory",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInLongTermReceivablesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInLongTermReceivablesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Long-Term Receivables, Current",
        "negatedLabel": "Receivables from collaboration arrangements",
        "documentation": "The increase (decrease) during the reporting period in the amount due within one year (or one business cycle) of receivables that were originally due beyond one year (or one business cycle)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 29.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "terseLabel": "Prepaid expenses",
        "negatedLabel": "Prepaid expenses",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "inva_IncreaseInDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IncreaseInDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in deferred tax assets.",
        "label": "Increase in Deferred Tax Assets",
        "terseLabel": "Increase in Deferred Tax Assets"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IncreaseToConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IncreaseToConvertibleNotes",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase to convertible notes.",
        "label": "Increase To Convertible Notes",
        "terseLabel": "Increase in convertible notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToCallOptionsAndWarrants",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive effect of outstanding warrant",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r276"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Incremental Common Shares Attributable to Conversion of Debt Securities, Total",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Dilutive effect",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r271",
      "r276"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive effect of options and awards granted under equity incentive plan and employee stock purchase plan",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r264",
      "r276",
      "r542"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r409",
      "r414",
      "r1124",
      "r1199",
      "r1200",
      "r1201",
      "r1210",
      "r1211",
      "r1225"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r409",
      "r414",
      "r1124",
      "r1199",
      "r1200",
      "r1201",
      "r1210",
      "r1211",
      "r1225"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r1311",
      "r1322",
      "r1332",
      "r1356",
      "r1365",
      "r1369",
      "r1377"
     ]
    },
    "inva_InnovivaCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InnovivaCommonStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innoviva's Common Stock Member",
        "label": "Innoviva Common Stock Member",
        "terseLabel": "Innoviva's Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InnovivaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InnovivaMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Innoviva [Member]",
        "label": "Innoviva [Member]",
        "terseLabel": "Innoviva [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Innoviva Strategic Opportunities, LLC",
        "label": "Innoviva Strategic Opportunities Limited Liability Corporation [Member]",
        "documentation": "Represents information pertaining to Innoviva Strategic Opportunities, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "inva_InnovivaTRCHoldingsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InnovivaTRCHoldingsLLCMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Innoviva TRC Holdings, LLC [Member]",
        "documentation": "Innoviva TRC Holdings, LLC.",
        "terseLabel": "Innoviva TRC Holdings, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r1375"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r1292",
      "r1381"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r1292",
      "r1381"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r1292",
      "r1381"
     ]
    },
    "inva_IntangibleAssetsCollaborationAgreementAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IntangibleAssetsCollaborationAgreementAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement, accumulated amortization",
        "label": "Intangible Assets Collaboration Agreement Accumulated Amortization",
        "documentation": "Intangible assets collaboration agreement accumulated amortization.",
        "negatedLabel": "Collaboration agreement, accumulated amortization"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsCollaborationAgreementGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IntangibleAssetsCollaborationAgreementGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets collaboration agreement gross.",
        "label": "Intangible Assets Collaboration Agreement Gross",
        "terseLabel": "Collaboration agreement, gross carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsCollaborationAgreementNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IntangibleAssetsCollaborationAgreementNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets collaboration agreement net.",
        "label": "Intangible Assets Collaboration Agreement Net",
        "terseLabel": "Collaboration agreement, net carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total gross carrying amount",
        "totalLabel": "Total gross carrying amount",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "inva_IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development, accumulated amortization",
        "label": "Intangible Assets In Process Research And Development Accumulated Amortization",
        "documentation": "Intangible sssets in process research and development accumulated amortization."
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsInProcessResearchAndDevelopmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IntangibleAssetsInProcessResearchAndDevelopmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of In-process research and development.",
        "label": "Intangible Assets In-process Research and Development, Gross",
        "terseLabel": "In-process research and development, gross carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsInProcessResearchAndDevelopmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IntangibleAssetsInProcessResearchAndDevelopmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of In-process research and development.",
        "label": "Intangible Assets In-process Research and Development, Net",
        "terseLabel": "In-process research and development, net carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsMarketedProductsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IntangibleAssetsMarketedProductsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amortization amount of Marketed Products.",
        "label": "Intangible Assets Marketed Products, Accumulated Amortization",
        "terseLabel": "Marketed products, Accumulated amortization",
        "negatedLabel": "Marketed products, Accumulated amortization"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsMarketedProductsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IntangibleAssetsMarketedProductsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3": {
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of Marketed products.",
        "label": "Intangible Assets Marketed Products, Gross",
        "terseLabel": "Marketed products, gross carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IntangibleAssetsMarketedProductsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IntangibleAssetsMarketedProductsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net amount of Marketed Products.",
        "label": "Intangible Assets Marketed Products, Net",
        "terseLabel": "Marketed products, net carrying amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Net carrying amount",
        "terseLabel": "Intangible assets",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r1556",
      "r1558"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "terseLabel": "Intangible Assets Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestAndDividendIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and dividend income",
        "label": "Interest and Dividend Income, Operating",
        "totalLabel": "Interest and Dividend Income, Operating, Total",
        "negatedLabel": "Interest and dividend income",
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r147",
      "r149",
      "r150",
      "r151",
      "r1139",
      "r1727"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Interest Expense, Total",
        "label": "Interest Expense, Operating and Nonoperating",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r296",
      "r300",
      "r303",
      "r320",
      "r808",
      "r1155",
      "r1156",
      "r1718"
     ]
    },
    "us-gaap_InterestExpenseBorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseBorrowingsAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Borrowings [Abstract]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt",
        "totalLabel": "Total interest and amortization expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r468",
      "r479",
      "r1169",
      "r1170",
      "r1718"
     ]
    },
    "us-gaap_InterestExpenseDebtAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebtAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt [Abstract]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails3": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r469",
      "r1169",
      "r1170"
     ]
    },
    "us-gaap_InterestExpensePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpensePolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Policy [Policy Text Block]",
        "terseLabel": "Interest Expense on Deferred Royalty Obligation",
        "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r1660",
      "r1664"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of Components of Interest Expense",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestOnConvertibleDebtNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestOnConvertibleDebtNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest on Convertible Debt, Net of Tax",
        "terseLabel": "Add: interest expense on Notes, net of tax effect",
        "documentation": "Amount, after tax, of interest recognized on convertible debt instrument excluding interest on principal required to be paid in cash."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r267",
      "r276"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "terseLabel": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r220",
      "r221"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Payable, Current",
        "verboseLabel": "Accrued interest payable",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "inva_InterestRateOfDeferredRoyaltyObligation": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InterestRateOfDeferredRoyaltyObligation",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate of deferred royalty obligation.",
        "label": "Interest Rate of Deferred Royalty Obligation",
        "terseLabel": "Interest Rate of Deferred Royalty Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InterimSupplyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InterimSupplyAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interim Supply Agreement",
        "label": "Interim Supply Agreement [Member]",
        "documentation": "Interim supply agreement member."
       }
      }
     },
     "auth_ref": []
    },
    "inva_InternalExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InternalExpensesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internal Expenses [Member]",
        "documentation": "Internal Expenses.",
        "terseLabel": "Internal expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory fair value step-up adjustment included in cost of products sold",
        "label": "Inventory Fair Value Step Up Adjustment Included In Cost Of Product Sales",
        "documentation": "Inventory fair value step-up adjustment included in cost of product sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r1129"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryGross",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, Gross, Total",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "totalLabel": "Total inventory",
        "terseLabel": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r1126",
      "r1250"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r180",
      "r195",
      "r383",
      "r384",
      "r385",
      "r881",
      "r1143"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r1131"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r1130"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Investment income, interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r299",
      "r320",
      "r1155",
      "r1441"
     ]
    },
    "us-gaap_InvestmentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment [Table Text Block]",
        "terseLabel": "Summary of Individual Investments Held by ISP Fund",
        "documentation": "Tabular disclosure of investment."
       }
      }
     },
     "auth_ref": [
      "r1411",
      "r1412",
      "r1523"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1007",
      "r1008",
      "r1010",
      "r1012",
      "r1071",
      "r1073",
      "r1075",
      "r1078",
      "r1079",
      "r1082",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1274"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1007",
      "r1008",
      "r1010",
      "r1012",
      "r1071",
      "r1073",
      "r1075",
      "r1078",
      "r1079",
      "r1082",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1274"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Investments",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments",
        "totalLabel": "Investments, Total",
        "terseLabel": "Total investments held by ISP Fund LP",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r930",
      "r931",
      "r1267",
      "r1268",
      "r1269",
      "r1271"
     ]
    },
    "us-gaap_InvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InvestmentsInCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InvestmentsInCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments In Common Stock",
        "documentation": "Investments In Common Stock",
        "terseLabel": "Common stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_InvestmentsInPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InvestmentsInPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Investments in Preferred Stock",
        "documentation": "Investments in preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "inva_InvestmentsInWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "InvestmentsInWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Investments In Warrants",
        "documentation": "Investments In Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "inva_IspFundLpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "IspFundLpMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to ISP Fund LP, an investment managed by Sarissa Capital.",
        "label": "Isp Fund Lp [Member]",
        "terseLabel": "ISP Fund LP"
       }
      }
     },
     "auth_ref": []
    },
    "country_JP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "JP",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "auth_ref": []
    },
    "inva_JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July Two Thousand Twenty Three Credit and Security Agreement [Member]",
        "documentation": "July two thousand twenty three credit and security agreement.",
        "terseLabel": "July 2023 Credit and Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LaJollaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LaJollaMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "La Jolla",
        "documentation": "La Jolla [Member]",
        "label": "La Jolla [Member]",
        "terseLabel": "La Jolla [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LaJollaPharmaceuticalCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LaJollaPharmaceuticalCompanyMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "La jolla pharmaceutical company member.",
        "label": "La Jolla Pharmaceutical Company [Member]",
        "terseLabel": "La Jolla Pharmaceutical Company"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LabaCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LabaCollaborationMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the collaboration with GSK to develop and commercialize once-daily LABA products and combination products RELVAR.",
        "label": "Laba Collaboration [Member]",
        "terseLabel": "Long-Acting Beta2 Agonist (LABA) Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LaboratoryEquipmentFurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LaboratoryEquipmentFurnitureAndFixturesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment, furniture and fixtures.",
        "label": "Laboratory Equipment, Furniture And Fixtures [Member]",
        "terseLabel": "Laboratory equipment furniture and fixtures"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1408"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r1408"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r1249"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Components of Lease Cost",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1666"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease expiration, date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity:",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Operating Lease",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r831"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r820",
      "r831"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]",
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1667"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total",
        "totalLabel": "Total undiscounted lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r1493",
      "r1500",
      "r1679"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r1493",
      "r1500",
      "r1679"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r1493",
      "r1500",
      "r1679"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2030",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r1493",
      "r1500",
      "r1679"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r1493",
      "r1500",
      "r1679"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r1493",
      "r1500",
      "r1679"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r829",
      "r1493",
      "r1500",
      "r1679"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest",
        "negatedLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1665"
     ]
    },
    "inva_LexingtonMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LexingtonMassachusettsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lexington Massachusetts [Member]",
        "documentation": "Lexington Massachusetts.",
        "terseLabel": "Lexington, Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Liabilities, Total",
        "label": "Liabilities",
        "verboseLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r70",
      "r71",
      "r72",
      "r76",
      "r77",
      "r78",
      "r81",
      "r224",
      "r227",
      "r228",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r719",
      "r723",
      "r724",
      "r797",
      "r1021",
      "r1147",
      "r1171",
      "r1285",
      "r1571",
      "r1670",
      "r1671"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r143",
      "r941",
      "r1250",
      "r1267",
      "r1268",
      "r1492",
      "r1497",
      "r1542",
      "r1659"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities and Stockholders Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities",
        "verboseLabel": "Current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r179",
      "r224",
      "r227",
      "r228",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r719",
      "r723",
      "r724",
      "r797",
      "r1250",
      "r1571",
      "r1670",
      "r1671"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Total liabilities measured at estimated fair value",
        "totalLabel": "Total liabilities at estimated fair value",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1645"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Liabilities, Noncurrent, Total",
        "label": "Liabilities, Noncurrent",
        "terseLabel": "Noncurrent liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r76",
      "r77",
      "r78",
      "r81",
      "r224",
      "r227",
      "r228",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r719",
      "r723",
      "r724",
      "r797",
      "r1571",
      "r1670",
      "r1671"
     ]
    },
    "inva_LicenseAndOtherRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LicenseAndOtherRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Other Revenue",
        "documentation": "License and other revenue.",
        "terseLabel": "License and other revenue"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LicenseAndOtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LicenseAndOtherRevenueMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License And Other Revenue [Member]",
        "documentation": "License and other revenue member.",
        "terseLabel": "License and other revenue"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LicenseCollaborationAndOtherArrangementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LicenseCollaborationAndOtherArrangementsTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License Collaboration and Other Arrangements [Text Block]",
        "documentation": "The entire disclosure of license collaboration and other arrangements .",
        "terseLabel": "LICENSE, COLLABORATION AND OTHER ARRANGEMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1580",
      "r1581"
     ]
    },
    "inva_LicenseRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LicenseRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License revenue recognized",
        "label": "License Revenue Recognized",
        "documentation": "License revenue recognized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LimitedPartnersContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LimitedPartnersContributedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Limited Partners' Contributed Capital",
        "terseLabel": "Contributed to partnership for investing",
        "verboseLabel": "Capital contribution",
        "documentation": "The amount of capital contributed by the limited partners."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_LineOfCreditFacilityCovenantTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityCovenantTerms",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Covenant Terms",
        "terseLabel": "Debt instrument, covenant terms description",
        "documentation": "Description of the conditions for borrowing under the credit facility including the nature of any restrictions."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r75"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Term loan facility in aggregate amount",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r75"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans Payable [Member]",
        "terseLabel": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "inva_LongActingBeta2AgonistAnoroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LongActingBeta2AgonistAnoroMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Long-Acting Beta2 Agonist, ANORO, which is being developed and commercialized by entering into a strategic alliance with GSK",
        "label": "Long Acting Beta2 Agonist Anoro [Member]",
        "terseLabel": "ANORO"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LongActingBeta2AgonistRelvarBreoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LongActingBeta2AgonistRelvarBreoMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Long-Acting Beta2 Agonist, RELVAR/BREO, which is being developed and commercialized by entering into a strategic alliance with GSK",
        "label": "Long Acting Beta2 Agonist Relvar Breo [Member]",
        "terseLabel": "RELVAR/BREO"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "totalLabel": "Net carrying amount",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r141",
      "r225",
      "r236",
      "r461",
      "r477",
      "r926",
      "r1167",
      "r1168",
      "r1248",
      "r1680"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtByMaturityAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Long-term debt maturities for years ending December 31:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Current Maturities",
        "totalLabel": "Net Carrying Amount",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2026",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r225",
      "r236",
      "r466",
      "r926"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2028",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r225",
      "r236",
      "r466",
      "r926"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails": {
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtDebtMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2027",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r225",
      "r236",
      "r466",
      "r926"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails2": {
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, net of discount and issuance costs",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "totalLabel": "Total long-term debt, net",
        "verboseLabel": "Total long-term debt, net",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and long-term investments",
        "totalLabel": "Long-term Investments, Total",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r1562",
      "r1563",
      "r1564"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r35",
      "r1562",
      "r1563",
      "r1564"
     ]
    },
    "inva_LyndraConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LyndraConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lyndra Convertible Note [Member]",
        "documentation": "Lyndra convertible note.",
        "terseLabel": "Lyndra Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "inva_LyndraMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "LyndraMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lyndra",
        "label": "Lyndra [Member]",
        "documentation": "Lyndra."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r328",
      "r1173",
      "r1176",
      "r1261",
      "r1265",
      "r1684",
      "r1687",
      "r1688",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714"
     ]
    },
    "inva_ManufacturingStageTransferAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ManufacturingStageTransferAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing Stage Transfer Agreement [Member]",
        "documentation": "Manufacturing Stage Transfer Agreement",
        "terseLabel": "Manufacturing Stage Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "March 2025 Credit and Security Agreement",
        "label": "March Two Thousand Twenty Five Credit and Security Agreement [Member]",
        "documentation": "March two thousand twenty five credit and security agreement."
       }
      }
     },
     "auth_ref": []
    },
    "inva_MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "March Two Thousand Twenty Four Credit and Security Agreement [Member]",
        "documentation": "March two thousand twenty four credit and security agreement.",
        "terseLabel": "March 2024 Credit and Security Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments in Marketable Securities",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "inva_MarketedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "MarketedProductsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketed products",
        "label": "Marketed Products [Member]",
        "documentation": "Marketed products."
       }
      }
     },
     "auth_ref": []
    },
    "inva_MassachusettsInstituteOfTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "MassachusettsInstituteOfTechnologyMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Massachusetts Institute of Technology [Member]",
        "documentation": "Massachusetts institute of technology.",
        "terseLabel": "Massachusetts Institute of Technology"
       }
      }
     },
     "auth_ref": []
    },
    "inva_MaximumAggregateRoyaltyPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "MaximumAggregateRoyaltyPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Royalty Payments Due",
        "documentation": "Maximum aggregate royalty payments due.",
        "terseLabel": "Maximum aggregate royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r431",
      "r432",
      "r433",
      "r434",
      "r537",
      "r569",
      "r570",
      "r571",
      "r592",
      "r774",
      "r880",
      "r961",
      "r963",
      "r977",
      "r1013",
      "r1014",
      "r1072",
      "r1074",
      "r1076",
      "r1077",
      "r1083",
      "r1099",
      "r1100",
      "r1102",
      "r1103",
      "r1117",
      "r1118",
      "r1163",
      "r1172",
      "r1188",
      "r1192",
      "r1196",
      "r1197",
      "r1240",
      "r1241",
      "r1245",
      "r1246",
      "r1262",
      "r1575",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r1348"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1348"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r431",
      "r432",
      "r433",
      "r434",
      "r537",
      "r569",
      "r570",
      "r571",
      "r592",
      "r774",
      "r880",
      "r961",
      "r963",
      "r977",
      "r1013",
      "r1014",
      "r1072",
      "r1074",
      "r1076",
      "r1077",
      "r1083",
      "r1099",
      "r1100",
      "r1102",
      "r1103",
      "r1117",
      "r1118",
      "r1163",
      "r1172",
      "r1188",
      "r1192",
      "r1196",
      "r1197",
      "r1240",
      "r1241",
      "r1245",
      "r1262",
      "r1575",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "inva_MoneyMarketFundAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "MoneyMarketFundAndCash",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Fund and Cash",
        "documentation": "Money market fund and cash.",
        "terseLabel": "Money market fund and cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1582",
      "r1583"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r1376"
     ]
    },
    "inva_NUZOLVENCEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NUZOLVENCEMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NUZOLVENCE",
        "label": "NUZOLVENCE [Member]",
        "documentation": "NUZOLVENCE."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NameOfEventAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NameOfEventAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name Of Event [Axis]",
        "label": "Name Of Event [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NameOfEventDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NameOfEventDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name Of Event [Domain]",
        "label": "Name Of Event [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r328",
      "r1173",
      "r1176",
      "r1261",
      "r1265",
      "r1684",
      "r1687",
      "r1688",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1349"
     ]
    },
    "inva_NanoliveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NanoliveMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nanolive [Member]",
        "label": "Nanolive [Member]",
        "terseLabel": "Nanolive"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "totalLabel": "Net cash provided by operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r111",
      "r148",
      "r176",
      "r177",
      "r199",
      "r200",
      "r204",
      "r224",
      "r227",
      "r228",
      "r233",
      "r241",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r272",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r483",
      "r486",
      "r489",
      "r494",
      "r580",
      "r650",
      "r715",
      "r768",
      "r797",
      "r948",
      "r1043",
      "r1063",
      "r1064",
      "r1137",
      "r1139",
      "r1141",
      "r1283",
      "r1571"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to noncontrolling interest",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Innoviva stockholders",
        "verboseLabel": "Net income, basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r207",
      "r246",
      "r247",
      "r248",
      "r249",
      "r257",
      "r258",
      "r273",
      "r276",
      "r486",
      "r489",
      "r494",
      "r715"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income, diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r259",
      "r266",
      "r267",
      "r268",
      "r269",
      "r273",
      "r276"
     ]
    },
    "inva_NetIncomeLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NetIncomeLossPerShareAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Net Income (Loss) Per Share [Abstract]",
        "terseLabel": "Net income per share"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NetInvestmentRelatedIncomeExpensesEarnedInccured": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NetInvestmentRelatedIncomeExpensesEarnedInccured",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net investment-related income (expense) earned (incurred)",
        "label": "Net Investment Related Income Expenses Earned Inccured",
        "documentation": "Net investment related income expenses earned inccured."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetRentableArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetRentableArea",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Rentable Area",
        "terseLabel": "Rentable square feet",
        "documentation": "Net rentable area for properties owned."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NetSalesAndPurchasesOfInvestmentsManagedByISPFund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NetSalesAndPurchasesOfInvestmentsManagedByISPFund",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales and purchases of investments managed by ISP Fund",
        "label": "Net Sales and Purchases of Investments Managed by ISP Fund",
        "documentation": "Net Sales and Purchases of Investments Managed by ISP Fund"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NewDebtInstrumentInterestRateAfterRepurchaseOfNotesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New debt instrument interest rate after repurchase of notes member.",
        "label": "New Debt Instrument Interest Rate After Repurchase Of Notes [Member]",
        "terseLabel": "New Rate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NonCashActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NonCashActivity",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non cash activity.",
        "label": "Non Cash Activity",
        "terseLabel": "Adoption of ASU 2020-06"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r1348"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r1311",
      "r1322",
      "r1332",
      "r1356",
      "r1365"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "inva_NonRule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NonRule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Rule 10B51 Arr Modified Flag",
        "documentation": "Non Rule 10B51 Arr Modified Flag",
        "terseLabel": "Non Rule 10b51 Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1376"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1376"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-US [Member]",
        "terseLabel": "Rest of the world",
        "verboseLabel": "Non-US",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1722",
      "r1724",
      "r1725",
      "r1726"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-cash Investing and Financing Activities:"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfBoardMembersOfInvestee": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NumberOfBoardMembersOfInvestee",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of the Investee's Board members",
        "label": "Number of Board Members of the Investee",
        "documentation": "The total number of Board members of the Investee."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfBoardOfDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NumberOfBoardOfDirectors",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Board of Directors",
        "documentation": "Number of board of directors.",
        "terseLabel": "Total number of directors"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfCommonStockIssuedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NumberOfCommonStockIssuedDescription",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common stock issued description",
        "label": "Number Of Common Stock Issued Description",
        "documentation": "Number of common stock issued description."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Investee's Board members currently representing the Company",
        "label": "Number of the Company's Board Members Currently Serving on the Board of Investee",
        "documentation": "The number of the Company's Board members currently serving on the Investee's Board."
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NumberOfCustomers",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number Of Customers",
        "terseLabel": "Number of customers"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfDerivativeInstrumentsPurchased": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NumberOfDerivativeInstrumentsPurchased",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of derivative instruments purchased.",
        "label": "Number of Derivative Instruments Purchased",
        "terseLabel": "Number of derivative instruments purchased"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfMajorCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NumberOfMajorCustomers",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Major Customers",
        "documentation": "Number of major customers.",
        "terseLabel": "Number of major customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1156",
      "r1514"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1149",
      "r1161",
      "r1514"
     ]
    },
    "inva_NumberOfSharesReceivableOnSettlementOfDerivativeInstrument": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NumberOfSharesReceivableOnSettlementOfDerivativeInstrument",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares payable to the entity on settlement of derivative instruments.",
        "label": "Number of Shares Receivable on Settlement of Derivative Instrument",
        "terseLabel": "Net shares settlement payable to the entity"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumberOfWarrantsOwned": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NumberOfWarrantsOwned",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants Owned",
        "documentation": "Number of warrants owned.",
        "terseLabel": "Number of warrants owned"
       }
      }
     },
     "auth_ref": []
    },
    "inva_NumeratorAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "NumeratorAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "inva_OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "OldDebtInstrumentInterestRateBeforeRepurchaseOfNotesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Old debt instrument interest rate before repurchase of notes member.",
        "label": "Old Debt Instrument Interest Rate Before Repurchase Of Notes [Member]",
        "terseLabel": "Old Rate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_OneDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "OneDirectorMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Director.",
        "label": "One Director [Member]",
        "terseLabel": "One Director"
       }
      }
     },
     "auth_ref": []
    },
    "inva_OneOfImaginabsCommonStockholderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "OneOfImaginabsCommonStockholderMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One of ImaginAb's Common Stockholders",
        "label": "One Of Imaginabs Common Stockholder [Member]",
        "documentation": "Represents information pertaining to one of ImaginAb's common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "terseLabel": "Operating expenses",
        "verboseLabel": "Operating expenses",
        "negatedLabel": "Operating expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations",
        "verboseLabel": "Loss from operations",
        "terseLabel": "Operating expenses",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r1137",
      "r1141",
      "r1148",
      "r1508",
      "r1515",
      "r1516",
      "r1517",
      "r1518"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Straight line operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r823",
      "r1249"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Total operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of lease liabilities included within Other accrued liabilities",
        "verboseLabel": "Current portion of lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities:",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r818",
      "r825"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Weighted Average Discount Rate, Percent",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r828",
      "r1249"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, Weighted average remaining lease term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r1249"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss Carryforwards, Total",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards, Expiration Date",
        "terseLabel": "Net operating loss carryforwards beginning date of expiry",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r321",
      "r1155",
      "r1156"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityStrikePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OptionIndexedToIssuersEquityStrikePrice1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Strike Price",
        "terseLabel": "Strike price for the underlying number of shares (in dollars per share)",
        "documentation": "Exercise or strike price stated in the contract for options indexed to the issuer's equity shares."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Axis]",
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r134"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "inva_OptionPricingModelBacksolveValuationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "OptionPricingModelBacksolveValuationMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Pricing Model Backsolve valuation.",
        "label": "Option Pricing Model Backsolve Valuation [Member]",
        "terseLabel": "Backsolve Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPolicies1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "verboseLabel": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r1420",
      "r1491"
     ]
    },
    "inva_OtherAccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "OtherAccruedLiabilitiesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accrued Liabilities [Member]",
        "label": "Other Accrued Liabilities [Member]",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r1250"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Assets, Noncurrent, Total",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r1045",
      "r1084",
      "r1085",
      "r1086",
      "r1267",
      "r1268"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Liabilities, Total",
        "label": "Other Liabilities",
        "terseLabel": "Other",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r935",
      "r1017",
      "r1018",
      "r1171",
      "r1267",
      "r1268",
      "r1285",
      "r1681",
      "r1716"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other Noncash Income (Expense), Total",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities",
        "verboseLabel": "Other Long Term Liabilities",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Long-term Liabilities",
        "documentation": "Tabular disclosure of other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income, net",
        "terseLabel": "Other expense, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expense, net",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r1232"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1348"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Noncurrent",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r140"
     ]
    },
    "inva_Outstanding2028NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "Outstanding2028NotesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding 2028 Notes [Member]",
        "documentation": "Outstanding 2028 notes.",
        "terseLabel": "Outstanding 2028 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1309",
      "r1320",
      "r1330",
      "r1363"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1312",
      "r1323",
      "r1333",
      "r1366"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1312",
      "r1323",
      "r1333",
      "r1366"
     ]
    },
    "inva_OutstandingStockWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "OutstandingStockWarrantMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock warrant member",
        "label": "Outstanding Stock Warrant [Member]",
        "terseLabel": "Outstanding Stock Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "inva_PaionAgMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PaionAgMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PAION AG [Member]",
        "label": "PAION AG [Member]",
        "terseLabel": "PAION AG"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ParatekPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ParatekPharmaceuticalsIncMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Paratek Pharmaceuticals, Inc.",
        "label": "Paratek Pharmaceuticals, Inc [Member]",
        "terseLabel": "Paratek Pharmaceuticals, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PartnershipAgreementLockUpPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PartnershipAgreementLockUpPeriod",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time in which contributors to an investment fund have waived the right of redemption, as defined in the partnership agreement.",
        "label": "Partnership Agreement, Lock-Up Period",
        "terseLabel": "Lock-up period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payment of Financing and Stock Issuance Costs, Total",
        "label": "Payment of Financing and Stock Issuance Costs",
        "terseLabel": "Total issuance costs",
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsForPurchaseOfInvestmentOperatingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForPurchaseOfInvestmentOperatingActivity",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment for Purchase, Investment, Operating Activity",
        "terseLabel": "Purchases of equity and long-term investments",
        "documentation": "Amount of cash outflow for acquisition of investment, classified as operating activity. Includes, but is not limited to, funding, origination, drawdown, and participation in investment."
       }
      }
     },
     "auth_ref": [
      "r1721"
     ]
    },
    "us-gaap_PaymentsForPurchaseOfSecuritiesOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForPurchaseOfSecuritiesOperatingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Purchase of Securities, Operating Activities",
        "terseLabel": "Purchases of trading securities",
        "documentation": "Cash paid to purchase debt and equity securities, classified as operating activities, during the period; includes trading securities and any other investments classified as operating."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Debt Issuance Costs",
        "terseLabel": "Liability issuance costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs to acquire equity securities",
        "label": "Payments of Stock Issuance Costs",
        "verboseLabel": "Equity issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Repurchase of shares to satisfy tax withholding",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire in Process Research and Development",
        "negatedLabel": "Cash paid for in-process research and development assets acquired",
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Acquisition of intangible asset",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireLongtermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional cash investment",
        "label": "Payments to Acquire Long-Term Investments",
        "verboseLabel": "Initial contribution",
        "negatedTerseLabel": "Purchases of equity and long-term investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term."
       }
      }
     },
     "auth_ref": [
      "r1485"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of trading securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1525"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1347"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1347"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1349"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "inva_Percent2.50ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "Percent2.50ConvertibleDebtMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to 2.50% convertible senior notes due 2025.",
        "label": "Percent2.50 Convertible Debt [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfEconomicInterestInPartnership": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PercentageOfEconomicInterestInPartnership",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Economic interest of the Partnership (in percent)",
        "documentation": "Percentage of economic interest held in Partnership.",
        "label": "Percentage of Economic Interest In Partnership"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of economic interest in any future payments made under the agreements.",
        "label": "Percentage of Economic Interest on Future Payments Under Agreements",
        "terseLabel": "Percentage of economic interest in any future payments made under the agreements"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfEstimatedVolatility": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PercentageOfEstimatedVolatility",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of estimated volatility.",
        "label": "Percentage of Estimated Volatility",
        "terseLabel": "Estimated volatility"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of maximum royalty based on achievement of annual net product sales thresholds.",
        "label": "Percentage Of Maximum Royalty Based On Achievement Of Annual Net Product Sales Thresholds",
        "terseLabel": "Percentage of maximum royalty based on achievement of annual net product sales thresholds"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfMinimumRoyaltyRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PercentageOfMinimumRoyaltyRate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of minimum royalty rate.",
        "label": "Percentage Of Minimum Royalty Rate",
        "terseLabel": "Percentage of minimum royalty rate"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of reimbursed for direct and certain indirect manufacturing costs.",
        "label": "Percentage Of Reimbursed For Direct And Certain Indirect Manufacturing Costs",
        "terseLabel": "Percentage of reimbursed for direct and certain indirect manufacturing costs"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Royalty On Payments Received From Sublicensees",
        "terseLabel": "Percentage of royalty on payments received from sublicensees",
        "documentation": "Represents the royalty payable as a percentage of payments received from sublicensees."
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfRoyaltyPayableOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PercentageOfRoyaltyPayableOnNetSales",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the royalty payable, as a percentage of net sales.",
        "label": "Percentage Of Royalty Payable On Net Sales",
        "terseLabel": "Percentage of royalty payable on net sales"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PercentageOfRoyaltyPaymentsNotEntitledToReceive": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PercentageOfRoyaltyPaymentsNotEntitledToReceive",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of royalty payments not entitled to receive",
        "documentation": "Percentage of royalty payments the company is not entitled to receive."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600",
      "r1601",
      "r1602",
      "r1603",
      "r1604",
      "r1605",
      "r1606",
      "r1607",
      "r1608",
      "r1609"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600",
      "r1601",
      "r1602",
      "r1603",
      "r1604",
      "r1605",
      "r1606",
      "r1607",
      "r1608",
      "r1609"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1340"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r1396"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "inva_PortionOfDebtInstrumentFaceAmountExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PortionOfDebtInstrumentFaceAmountExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of debt instrument face amount, exercised.",
        "label": "Portion of Debt Instrument Face Amount, Exercised",
        "terseLabel": "Portion of debt instrument face amount, Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r1272",
      "r1273",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1715",
      "r1719"
     ]
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosure [Abstract]",
        "terseLabel": "Preferred stocks - Privately held healthcare companies"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r496"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r1023"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r496"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r1023",
      "r1042",
      "r1719",
      "r1720"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock: $0.01 par value, 230 shares authorized, no shares issued and outstanding",
        "verboseLabel": "Preferred stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r485",
      "r491",
      "r938",
      "r1250"
     ]
    },
    "inva_PreferredStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PreferredStockWarrantsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrants.",
        "label": "Preferred Stock Warrants Member",
        "terseLabel": "Preferred Stock Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1429"
     ]
    },
    "inva_PresentationReclassificationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PresentationReclassificationPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Presentation reclassification.",
        "label": "Presentation Reclassification [Policy Text Block]",
        "terseLabel": "Presentation Reclassification"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PrincipalAmountOfConvertibleNotesOwned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PrincipalAmountOfConvertibleNotesOwned",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of convertible notes owned",
        "label": "Principal Amount of Convertible Notes Owned",
        "documentation": "Principal amount of convertible notes owned."
       }
      }
     },
     "auth_ref": []
    },
    "inva_PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of debt converted into shares of common stock",
        "label": "Principal Amount of Debt Converted into Shares of Common Stock",
        "documentation": "Principal amount of debt converted into shares of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "inva_PrincipalAmountOfTermLoansOwned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PrincipalAmountOfTermLoansOwned",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal Amount of Term Loans Owned",
        "documentation": "Principal amount of term loans owned.",
        "terseLabel": "Principal amount of term loans owned"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrincipalAmountOutstandingOfLoansHeldInPortfolio",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding principal",
        "label": "Loan, Held-in-Portfolio, Principal Outstanding",
        "totalLabel": "Loan, Held-in-Portfolio, Principal Outstanding, Total",
        "documentation": "This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "inva_PriorPeriodImmaterialCorrectionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PriorPeriodImmaterialCorrectionPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting prior period immaterial correction.",
        "label": "Prior Period Immaterial Correction [Policy Text Block]",
        "terseLabel": "Prior Period Immaterial Correction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "inva_PrivatePlacementPositionsAndConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PrivatePlacementPositionsAndConvertibleNotesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Placement Positions And Convertible Notes.",
        "label": "Private Placement Positions And Convertible Notes [Member]",
        "terseLabel": "Private Placement Positions And Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PrivatelyHeldHealthcareCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PrivatelyHeldHealthcareCompaniesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Privately Held Healthcare Companies [Member]",
        "documentation": "Privately held healthcare companies.",
        "terseLabel": "Privately Held Healthcare Companies"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PrivatelyNegotiatedCapPriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PrivatelyNegotiatedCapPriceMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Privately Negotiated Cap Price [Member]",
        "documentation": "Privately negotiated cap price.",
        "terseLabel": "Privately-negotiated cap price"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PrivatelyNegotiatedCappedCallOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PrivatelyNegotiatedCappedCallOptionMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the capped call option entered in connection with the offering of convertible debt.",
        "label": "Privately Negotiated Capped Call Option [Member]",
        "terseLabel": "Privately-negotiated capped call option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes, net of issuance costs",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuances of common stock, net",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForTradingSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromPaymentsForTradingSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from (Payments for) Trading Securities, Short-Term",
        "terseLabel": "Proceeds from trading securities",
        "negatedLabel": "Proceeds from trading securities",
        "documentation": "Amount of cash inflow (outflow) from sales and purchases of trading securities."
       }
      }
     },
     "auth_ref": [
      "r1484",
      "r1486",
      "r1490"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "totalLabel": "Proceeds from Sale of Property, Plant, and Equipment, Total",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of warrants",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r1487"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "Net product sales",
        "verboseLabel": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1141",
      "r1173",
      "r1174"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r882",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r1122",
      "r1136",
      "r1139",
      "r1141",
      "r1173",
      "r1174",
      "r1260",
      "r1262",
      "r1263",
      "r1266",
      "r1270",
      "r1407",
      "r1442",
      "r1443",
      "r1444",
      "r1445",
      "r1446",
      "r1447",
      "r1448",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453",
      "r1454",
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1567",
      "r1568",
      "r1684",
      "r1687",
      "r1688",
      "r1689",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "auth_ref": [
      "r324",
      "r882",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r1122",
      "r1136",
      "r1139",
      "r1141",
      "r1173",
      "r1174",
      "r1260",
      "r1262",
      "r1263",
      "r1266",
      "r1270",
      "r1407",
      "r1442",
      "r1443",
      "r1444",
      "r1445",
      "r1446",
      "r1447",
      "r1448",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453",
      "r1454",
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1567",
      "r1568",
      "r1684",
      "r1687",
      "r1688",
      "r1689",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income and comprehensive income",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r177",
      "r199",
      "r200",
      "r218",
      "r224",
      "r227",
      "r228",
      "r233",
      "r241",
      "r250",
      "r253",
      "r254",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r483",
      "r580",
      "r650",
      "r715",
      "r717",
      "r720",
      "r721",
      "r768",
      "r797",
      "r922",
      "r924",
      "r947",
      "r991",
      "r1043",
      "r1063",
      "r1064",
      "r1230",
      "r1231",
      "r1284",
      "r1440",
      "r1571"
     ]
    },
    "inva_ProfitLossShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ProfitLossShares",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (in shares)",
        "label": "Profit Loss Shares",
        "documentation": "Profit Loss Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r830"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, equipment and leasehold improvements",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property Plant And Equipment",
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "totalLabel": "Property, Plant and Equipment, Net, Total",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r830",
      "r927",
      "r944",
      "r1250"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r160",
      "r161",
      "r943"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r830"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "inva_PropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment Useful Life [Table Text Block]",
        "terseLabel": "Schedule of property, equipment and leasehold improvements useful lives"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PubliclyTradedHealthcareCompaniesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PubliclyTradedHealthcareCompaniesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Publicly Traded Healthcare Companies [Member]",
        "documentation": "Publicly traded healthcare companies.",
        "terseLabel": "Publicly Held Healthcare Companies"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase and sale of other investments managed by ISP FUND LP",
        "documentation": "Purchase and sale of other investments managed by ISP FUND LP, net",
        "terseLabel": "Purchase and sales of other investments managed by ISP Fund LP, net",
        "negatedLabel": "Purchases and sales of other investments managed by ISP Fund LP, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PurchaseObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation, to be Paid, Year One",
        "terseLabel": "Future minimum purchase commitments, 2026",
        "documentation": "Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1493",
      "r1500",
      "r1679"
     ]
    },
    "us-gaap_PurchaseObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PurchaseObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase Obligation, to be Paid, Year Two",
        "terseLabel": "Future minimum purchase commitments, 2027",
        "documentation": "Amount of purchase arrangement to be paid in second fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1493",
      "r1500",
      "r1679"
     ]
    },
    "inva_PurchasesOfEquityAndOtherLongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PurchasesOfEquityAndOtherLongTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchases of Equity and Other Long Term Investments",
        "documentation": "Purchases of Equity and Other Long Term Investments",
        "terseLabel": "Purchases of equity and other long-term investments"
       }
      }
     },
     "auth_ref": []
    },
    "inva_PurchasesOfEquityInvestmentsManagedByIspFundLp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "PurchasesOfEquityInvestmentsManagedByIspFundLp",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases of Equity Investments Managed by Isp Fund Lp",
        "label": "Purchases of Equity Investments Managed by Isp Fund Lp",
        "negatedLabel": "Purchases of equity investments managed by ISP Fund LP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PutOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PutOptionMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Put Option [Member]",
        "terseLabel": "Stock prices above $38.00 per share",
        "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option."
       }
      }
     },
     "auth_ref": [
      "r1080",
      "r1081"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "inva_QualifiedFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "QualifiedFinancingMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qualified Financing [Member]",
        "label": "Qualified Financing [Member]",
        "terseLabel": "Qualified Financing"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r431",
      "r432",
      "r433",
      "r434",
      "r525",
      "r537",
      "r569",
      "r570",
      "r571",
      "r577",
      "r592",
      "r774",
      "r851",
      "r863",
      "r880",
      "r961",
      "r963",
      "r977",
      "r1013",
      "r1014",
      "r1072",
      "r1074",
      "r1076",
      "r1077",
      "r1083",
      "r1099",
      "r1100",
      "r1102",
      "r1103",
      "r1117",
      "r1118",
      "r1163",
      "r1172",
      "r1188",
      "r1192",
      "r1196",
      "r1197",
      "r1240",
      "r1241",
      "r1245",
      "r1246",
      "r1262",
      "r1274",
      "r1565",
      "r1575",
      "r1648",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r290",
      "r431",
      "r432",
      "r433",
      "r434",
      "r525",
      "r537",
      "r569",
      "r570",
      "r571",
      "r577",
      "r592",
      "r774",
      "r851",
      "r863",
      "r880",
      "r961",
      "r963",
      "r977",
      "r1013",
      "r1014",
      "r1072",
      "r1074",
      "r1076",
      "r1077",
      "r1083",
      "r1099",
      "r1100",
      "r1102",
      "r1103",
      "r1117",
      "r1118",
      "r1163",
      "r1172",
      "r1188",
      "r1192",
      "r1196",
      "r1197",
      "r1240",
      "r1241",
      "r1245",
      "r1246",
      "r1262",
      "r1274",
      "r1565",
      "r1575",
      "r1648",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677"
     ]
    },
    "us-gaap_ReceivablesLongTermContractsOrPrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReceivablesLongTermContractsOrPrograms",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables, Long-Term Contracts or Programs",
        "terseLabel": "Receivable from collaboration arrangements",
        "documentation": "Amount to be collected within one year of the balance sheet date (or one operating cycle, if longer) from customers in accordance with the contractual provisions of long-term contracts or programs including amounts billed and unbilled as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1426"
     ]
    },
    "inva_ReclassificationOfCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ReclassificationOfCurrentPortion",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsReconciliationOfEquityAndLongTermInvestmentsBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of current portion",
        "label": "Reclassification of Current Portion",
        "documentation": "Reclassification of current portion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of reconciliation to the consolidated net income",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31"
     ]
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r31"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1304",
      "r1315",
      "r1325",
      "r1358"
     ]
    },
    "inva_ReductionToAdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ReductionToAdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction to additional paid in capital",
        "label": "Reduction to Additional Paid in Capital",
        "terseLabel": "Reduction to Additional Paid in Capital"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RegulatoryMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RegulatoryMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payments receivable.",
        "label": "Regulatory Milestone Payments Receivable",
        "terseLabel": "Additional regulatory milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RegulatoryStartingMaterialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RegulatoryStartingMaterialMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Starting Material",
        "label": "Regulatory Starting Material [Member]",
        "documentation": "Regulatory starting material."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ReimbursementsForResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ReimbursementsForResearchAndDevelopmentExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursements for Research and Development Expense",
        "documentation": "Reimbursements for research and development expense.",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "terseLabel": "Related Party [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r232",
      "r233",
      "r331",
      "r532",
      "r536",
      "r838",
      "r839",
      "r936",
      "r942",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1041",
      "r1070",
      "r1717"
     ]
    },
    "inva_RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock in the reporting entity owned by related parties.",
        "label": "Related Party Transaction, Common Stock Ownership Percentage By Related Party",
        "terseLabel": "Percentage of common stock owned by a related party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Parties",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r232",
      "r233",
      "r331",
      "r838",
      "r839",
      "r840",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r232",
      "r233",
      "r331",
      "r532",
      "r536",
      "r838",
      "r839",
      "r936",
      "r942",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1041",
      "r1070",
      "r1669",
      "r1717"
     ]
    },
    "inva_RelatedPartyTransactionsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RelatedPartyTransactionsPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the entity's accounting policies for transactions entered with related parties.",
        "label": "Related Party Transactions [Policy Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentOfNotesReceivableFromRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentOfNotesReceivableFromRelatedParties",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of Notes Receivable from Related Parties",
        "terseLabel": "Repayment of notes",
        "documentation": "The cash inflow from a loan, supported by a promissory note, granted to related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payments",
        "label": "Repayments of Debt",
        "verboseLabel": "Settlement of convertible note",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1488"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInLyndraDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Short-Term Debt",
        "terseLabel": "Repayments of notes",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_RepaymentsOfUnsecuredDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfUnsecuredDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Unsecured Debt",
        "terseLabel": "Payment for repurchase of debt instrument",
        "verboseLabel": "Payment upon maturity of debt instrument",
        "negatedLabel": "Payment for repurchase of convertible notes",
        "documentation": "The cash outflow to repay long-term debt that is not secured by collateral. Excludes repayments of tax exempt unsecured debt."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r224",
      "r234",
      "r235",
      "r452",
      "r498",
      "r840",
      "r864",
      "r930",
      "r1132",
      "r1133",
      "r1134",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435",
      "r1436",
      "r1437",
      "r1438",
      "r1439",
      "r1638",
      "r1639",
      "r1640",
      "r1641"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Research and Development Expense, Total",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r1119",
      "r1137",
      "r1138",
      "r1155",
      "r1678"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r593"
     ]
    },
    "inva_ResearchAndDevelopmentSupportMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ResearchAndDevelopmentSupportMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Support [Member]",
        "label": "Research and Development Support [Member]",
        "terseLabel": "Research and Development Support"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research tax credit carryforward",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1617"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r1305",
      "r1316",
      "r1326",
      "r1359"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1306",
      "r1317",
      "r1327",
      "r1360"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r1313",
      "r1324",
      "r1334",
      "r1367"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "terseLabel": "RSAs",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1507",
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600",
      "r1601",
      "r1602",
      "r1603",
      "r1604",
      "r1605",
      "r1606",
      "r1607",
      "r1608",
      "r1609"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600",
      "r1601",
      "r1602",
      "r1603",
      "r1604",
      "r1605",
      "r1606",
      "r1607",
      "r1608",
      "r1609"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r124",
      "r940",
      "r971",
      "r976",
      "r988",
      "r1024",
      "r1250"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r175",
      "r176",
      "r237",
      "r238",
      "r239",
      "r242",
      "r250",
      "r252",
      "r254",
      "r368",
      "r371",
      "r419",
      "r482",
      "r580",
      "r631",
      "r632",
      "r646",
      "r647",
      "r648",
      "r651",
      "r714",
      "r715",
      "r744",
      "r747",
      "r748",
      "r751",
      "r766",
      "r812",
      "r814",
      "r967",
      "r969",
      "r992",
      "r1719"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      },
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total royalty revenue",
        "negatedTerseLabel": "License revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "verboseLabel": "Total net revenue",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r281",
      "r297",
      "r298",
      "r314",
      "r320",
      "r324",
      "r326",
      "r328",
      "r521",
      "r522",
      "r523",
      "r882",
      "r1137",
      "r1141"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognition1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Text Block]",
        "verboseLabel": "REVENUE RECOGNITION",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r523",
      "r524"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "totalLabel": "Revenues, Total",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r205",
      "r224",
      "r227",
      "r228",
      "r281",
      "r297",
      "r298",
      "r314",
      "r320",
      "r324",
      "r326",
      "r328",
      "r367",
      "r437",
      "r438",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r446",
      "r447",
      "r797",
      "r922",
      "r924",
      "r1155",
      "r1232",
      "r1267",
      "r1268",
      "r1571"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets obtained in exchange for operating lease obligations",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r1249"
     ]
    },
    "inva_RightOfUseAssetsObtainedThroughAcquistions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RightOfUseAssetsObtainedThroughAcquistions",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSupplementalCashFlowInformationRelatedToLeaseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of Use Assets Obtained Through Acquistions",
        "label": "Right of Use Assets Obtained Through Acquistions",
        "terseLabel": "Right-of-use assets obtained through acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RiskFreeInterestRate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk free interest rate.",
        "label": "Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties payable period after first commercial sale of product.",
        "label": "Royalties Payable Period After First Commercial Sale Of Product",
        "terseLabel": "Royalties payable period after first commercial sale of product"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement increase in maximum potential payout percent.",
        "label": "Royalty Agreement Increase In Maximum Potential Payout Percent",
        "terseLabel": "Increase in maximum potential payout percent"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltyAgreementMaximumPotentialPayoutPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RoyaltyAgreementMaximumPotentialPayoutPercent",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement, maximum potential payout, percent.",
        "label": "Royalty Agreement Maximum Potential Payout Percent",
        "terseLabel": "Maximum potential royalty payout"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement required payment for breach of agreement payment one.",
        "label": "Royalty Agreement Required Payment For Breach Of Agreement Payment One",
        "terseLabel": "Required payment for breach of agreement, payment one"
       }
      }
     },
     "auth_ref": []
    },
    "inva_RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty agreement required payment for breach of agreement payment two.",
        "label": "Royalty Agreement Required Payment For Breach Of Agreement Payment Two",
        "terseLabel": "Maximum aggregate royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "inva_RoyaltyFinancingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RoyaltyFinancingAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty financing agreement member.",
        "label": "Royalty Financing Agreement [Member]",
        "terseLabel": "Royalty Financing Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty [Member]",
        "verboseLabel": "Royalty revenue from a related party",
        "terseLabel": "Royalty Revenue",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1580",
      "r1581"
     ]
    },
    "inva_RoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "RoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Payments",
        "label": "Royalty Payments",
        "terseLabel": "Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "inva_Rule10B51ArrModifiedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "Rule10B51ArrModifiedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b51 Arr Modified Flag",
        "documentation": "Rule 10b51 Arr Modified Flag.",
        "terseLabel": "Rule 10b51Arrangement Modified"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r1376"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r1376"
     ]
    },
    "inva_SaleOfEquityInvestmentsManagedByIspFundLp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SaleOfEquityInvestmentsManagedByIspFundLp",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of equity investments managed by ISP FUND LP",
        "documentation": "Sale of equity investments managed by ISP FUND LP",
        "terseLabel": "Sales of equity investments managed by ISP Fund LP"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Number of shares to be purchased under the securities purchase agreement",
        "terseLabel": "Number of shares purchased under the securities purchase agreement",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SaleOfWarrantsNumberOfWarrantsIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SaleOfWarrantsNumberOfWarrantsIssuedInTransaction",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Maximum number of additional shares into which warrants may be converted under the securities purchase agreement",
        "label": "Sale of Warrants, Number of Warrants Issued in Transaction",
        "documentation": "The number of warrants issued or sold by the subsidiary or equity method investee per stock transaction.",
        "terseLabel": "Number of warrants purchased under the securities purchase agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SalesMilestonePaymentsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SalesMilestonePaymentsReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone payments receivable.",
        "label": "Sales Milestone Payments Receivable",
        "terseLabel": "Sales milestone payments receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Net Product Sales",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r1510",
      "r1511"
     ]
    },
    "inva_SarissaCapitalManagementLpMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SarissaCapitalManagementLpMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Sarissa Capital.",
        "label": "Sarissa Capital Management Lp [Member]",
        "terseLabel": "Sarissa Capital"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Accrued Liabilities",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareAntidilutiveSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of anti-dilutive securities",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Available-for-Sale Securities",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343"
     ]
    },
    "inva_ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ScheduleOfBalanceSheetInformationRelatedToOperatingLeaseTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Balance sheet Information Related To Operating Lease Table Text Block",
        "label": "Schedule Of Balance sheet Information Related To Operating Lease Table Text Block",
        "terseLabel": "Schedule of Operating Lease Information Presented In Balance Sheet"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense Included in the Consolidated Statements of Income and Comprehensive Income by Award Type",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "verboseLabel": "Schedule of components of the income tax expense",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1619"
     ]
    },
    "inva_ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ScheduleOfConsolidatedEntitiesAndBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of consolidated entities and business acquisitions by acquisition.",
        "label": "Schedule of Consolidated Entities and Business Acquisitions by Acquisition [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Debt",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r39",
      "r40",
      "r66",
      "r121",
      "r123",
      "r1167",
      "r1169",
      "r1493",
      "r1500",
      "r1662",
      "r1679"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and deferred tax liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1616"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computation of basic and diluted net income per share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1506"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r265",
      "r274",
      "r276"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of differences between expected U.S. federal statutory income tax to income tax expense",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r1191",
      "r1612"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of net product sales",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r364",
      "r365",
      "r366",
      "r642",
      "r797",
      "r1402",
      "r1403",
      "r1404",
      "r1622",
      "r1623",
      "r1624",
      "r1625"
     ]
    },
    "inva_ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Financial Information Of Variable Interest Entities [Table Text Block]",
        "documentation": "Schedule of financial information of variable interest entities.",
        "terseLabel": "Schedule of Balance Sheets and Income Statements of VIE"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ScheduleOfFinancialInformationOnConsolidatedEntityTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Financial Information of TRC",
        "label": "Schedule of Financial Information on Consolidated Entity [Table Text Block]",
        "documentation": "Schedule of financial Information on consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfAccumulatedAmortizationOfRecognizedIntangibleAssetsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r411",
      "r415",
      "r416",
      "r417",
      "r883",
      "r1119",
      "r1124",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219",
      "r1220",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Accumulated Amortization of Recognized Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r1124",
      "r1555"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r1165"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of income before income tax expense",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1492",
      "r1498"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r89",
      "r90",
      "r91"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Scheduled Maturities of Convertible Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r830"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]",
        "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed",
        "documentation": "Tabular disclosure of asset acquired and liability assumed in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1630",
      "r1632"
     ]
    },
    "inva_ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Reconciliation of Equity and Long-Term Investments Balance [Table Text Block]",
        "documentation": "Schedule of reconciliation of equity and long-term investments balance.",
        "terseLabel": "Reconciliation of Equity and Long-Term Investments Balances"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r232",
      "r233",
      "r838",
      "r839",
      "r840",
      "r1048",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Equity Award Activity and Related Information",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r129"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r541",
      "r544",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r577"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Summary of Weighted-Average Assumptions used to Calculate Estimated Value of Stock Options",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r131"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "verboseLabel": "Schedule of Unrecognized Stock-based Compensation Cost",
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Summary of changes in unrecognized tax benefits",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r1190"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity [Table]",
        "documentation": "Disclosure of information about variable interest held, whether or not such variable interest entity (VIE) is included in consolidated financial statements."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r57",
      "r60",
      "r61",
      "r718",
      "r719",
      "r723",
      "r724",
      "r859",
      "r860",
      "r861"
     ]
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheets and Income Statements of VIE",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r57",
      "r60",
      "r61"
     ]
    },
    "inva_SecuredConvertibleCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SecuredConvertibleCreditAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Secured convertible credit agreement.",
        "label": "Secured Convertible Credit Agreement [Member]",
        "terseLabel": "Secured Convertible Credit Agreement",
        "verboseLabel": "January 2023 Secured Convertible Credit Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SecuritiesPurchaseAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SecuritiesPurchaseAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the Company agreed to pay for common stock and warrants upon satisfaction of certain closing conditions under the terms of the securities purchase agreement.",
        "label": "Securities Purchase Agreement, Amount",
        "terseLabel": "Amount of securities purchase agreement",
        "verboseLabel": "Payments for acquire variable interest"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r326",
      "r327",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r922",
      "r923",
      "r924",
      "r925",
      "r1006",
      "r1009",
      "r1011",
      "r1073",
      "r1075",
      "r1079",
      "r1087",
      "r1099",
      "r1101",
      "r1102",
      "r1103",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1123",
      "r1145",
      "r1173",
      "r1175",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1264",
      "r1274",
      "r1684",
      "r1687",
      "r1688",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r1154",
      "r1162"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r1151",
      "r1159"
     ]
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReporting1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT REPORTING",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r281",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r304",
      "r305",
      "r306",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r325",
      "r328",
      "r1149",
      "r1152",
      "r1153",
      "r1155",
      "r1157",
      "r1160",
      "r1161"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r323",
      "r326",
      "r1150",
      "r1151",
      "r1158"
     ]
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and marketing",
        "label": "Selling and Marketing Expense",
        "totalLabel": "Selling and Marketing Expense, Total",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Selling, General and Administrative Expense, Total",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r1136",
      "r1137",
      "r1138",
      "r1141",
      "r1479"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r1192",
      "r1194"
     ]
    },
    "inva_SeniorUnsecuredConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeniorUnsecuredConvertibleNotesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which takes priority over other debt securities and can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Senior Unsecured Convertible Notes [Member]",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesA1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesA1PreferredStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A1 preferred stock member.",
        "label": "Series A1 preferred stock [Member]",
        "terseLabel": "Series A1 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Preferred Stock",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1424",
      "r1425",
      "r1577",
      "r1578"
     ]
    },
    "inva_SeriesC2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesC2PreferredStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C-2 Preferred Stock [Member]",
        "documentation": "Series C-2 Preferred Stock member.",
        "terseLabel": "Series C-2 preferred stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesCAndC2PreferredStockAndCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesCAndC2PreferredStockAndCommonStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C and C 2 Preferred Stock and Common Stock [Member]",
        "documentation": "Series C and C 2 preferred stock and common stock.",
        "terseLabel": "Series C preferred stock, Series C-2 preferred stock and common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C preferred stock",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1424",
      "r1425",
      "r1577",
      "r1578"
     ]
    },
    "inva_SeriesCWarrantsAndSeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesCWarrantsAndSeriesDWarrantsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C warrants and Series D warrants.",
        "label": "Series C warrants and Series D warrants [Member]",
        "terseLabel": "Series C Warrants and Series D Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesCWarrantsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C warrants",
        "label": "Series C Warrants [Member]",
        "documentation": "Series C Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesD1AndD2PreferredStockAndCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesD1AndD2PreferredStockAndCommonStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D 1 and D 2 preferred stock and common stock.",
        "label": "Series D 1 And D 2 Preferred Stock And Common Stock Member",
        "terseLabel": "Series D 1 And D 2 Preferred Stock And Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesD1PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesD1PreferredStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D 1 preferred stock member.",
        "label": "Series D 1 Preferred Stock [Member]",
        "terseLabel": "Series D 1 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesD1WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesD1WarrantMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D1 Warrant [Member]",
        "label": "Series D1 Warrant [Member]",
        "terseLabel": "Series D1 Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesD2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesD2PreferredStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D 2 preferred stock member.",
        "label": "Series D 2 Preferred Stock [Member]",
        "terseLabel": "Series D 2 Preferred Stock"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SeriesD2WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesD2WarrantMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D2 Warrant.",
        "label": "Series D2 Warrant [Member]",
        "terseLabel": "Series D2 Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Preferred Stock",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1424",
      "r1425",
      "r1577",
      "r1578"
     ]
    },
    "inva_SeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SeriesDWarrantsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Warrants",
        "label": "Series D Warrants [Member]",
        "documentation": "Series D warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The additional value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Additional Equity Grant Value",
        "terseLabel": "Pro rata shares grant, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Additional disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of shares granted annually to independent directors upon re-election the to Board.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Annual Equity Grant, Value",
        "terseLabel": "Annual grant of shares, value"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the consecutive and overlapping offering period for the offering of share-based payment awards.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Consecutive and Overlapping Offering Period",
        "terseLabel": "Total duration of consecutive and overlapping offering periods"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee exercised the right during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r557"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Fair Value per Share at Grant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Released RSUs and RSAs (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total estimated fair value of equity instruments vested",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released RSUs and RSAs (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Valuation Assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r571"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Volatility",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of shares granted to newly appointed non-employee director on the date that such individual joins the Board.",
        "label": "Share Based Compensation, Arrangement by Share Based Payment Award, Initial Equity Grant Value",
        "terseLabel": "One time grant of shares, value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-based compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r541",
      "r544",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r577"
     ]
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute of employee's eligible compensation.",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award Maximum Amount As A Contribution Of Eligible Compensation",
        "terseLabel": "Maximum value of shares an employee may purchase in a calendar year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate",
        "terseLabel": "Maximum contributions as a percentage of employee's eligible compensation",
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "terseLabel": "Maximum number of shares an employee may purchase during any purchase period",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Granted (in shares)",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r127"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Number of outstanding RSUs and PSUs/RSAs and PSAs",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Fair Value per Share of fully vested and expected to vest non-option equity instruments outstanding that can be converted into shares under award activity.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Vested And Expected To Vest Outstanding, Weighted-Average Fair Value per Share",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award number of annual installments",
        "terseLabel": "Number of annual installments",
        "documentation": "The number of annual installments that RSUs granted to newly appointed independent directors will vest."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of purchase periods having duration of six months each.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Number of Purchase Periods",
        "terseLabel": "Number of offering periods"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares remaining available for issuance",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable option",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average estimated fair value of shares granted (in dollars per share)",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of outstanding options",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price of Outstanding Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per shares)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "inva_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the duration of each purchase period within each consecutive and overlapping purchase period for offering of share-based payment awards.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Purchase Period",
        "terseLabel": "Duration of purchase period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationStockbasedCompensationExpenseDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r545",
      "r546",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "verboseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r553"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r554"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Fair Value of Stock-Based Compensation Awards",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r538",
      "r547",
      "r566",
      "r567",
      "r568",
      "r569",
      "r572",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ShareRepurchaseAgreementWithGlaxoGroupLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ShareRepurchaseAgreementWithGlaxoGroupLimitedMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase agreement with GSK",
        "label": "Share Repurchase Agreement With Glaxo Group Limited [Member]",
        "documentation": "Represents information pertaining to share repurchase agreement with Glaxo Group Limited."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1579"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program [Domain]"
       }
      }
     },
     "auth_ref": [
      "r1579"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term of options exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term of options outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total estimated fair value of options vested",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Released RSUs/RSAs (in shares)",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r1610"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Released RSUs/RSAs (in shares)",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": [
      "r1610"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensation2012PlanAndEsppDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price as a percentage of fair market value of stock",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": [
      "r1610"
     ]
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r1562",
      "r1563",
      "r1564"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r1562",
      "r1563",
      "r1564"
     ]
    },
    "inva_SoftwareAndComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SoftwareAndComputerEquipmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Software and computer equipment",
        "label": "Software And Computer Equipment [Member]",
        "terseLabel": "Software and computer equipment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SpecialTermReDesignatingBoardMemberToBoardOfInvestee": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SpecialTermReDesignatingBoardMemberToBoardOfInvestee",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Special Terms on amended and restated investor rights agreement.",
        "label": "Special Term Re Designating Board Member To Board Of Investee",
        "terseLabel": "Special terms on re-designating board member to board of investee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesNetIncomeTaxesPaidDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State",
        "verboseLabel": "State and local jurisdiction",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r604"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInBeaconDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r192",
      "r193",
      "r194",
      "r224",
      "r228",
      "r260",
      "r265",
      "r274",
      "r276",
      "r283",
      "r284",
      "r367",
      "r437",
      "r440",
      "r441",
      "r442",
      "r446",
      "r447",
      "r484",
      "r485",
      "r487",
      "r488",
      "r490",
      "r493",
      "r496",
      "r497",
      "r500",
      "r503",
      "r510",
      "r797",
      "r984",
      "r985",
      "r986",
      "r987",
      "r992",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1023",
      "r1044",
      "r1065",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1401",
      "r1494",
      "r1496",
      "r1505"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r83",
      "r86",
      "r87",
      "r168",
      "r175",
      "r176",
      "r202",
      "r203",
      "r204",
      "r237",
      "r238",
      "r239",
      "r242",
      "r250",
      "r252",
      "r254",
      "r282",
      "r368",
      "r371",
      "r419",
      "r482",
      "r512",
      "r580",
      "r631",
      "r632",
      "r646",
      "r647",
      "r648",
      "r651",
      "r714",
      "r715",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r766",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r812",
      "r814",
      "r837",
      "r949",
      "r967",
      "r968",
      "r969",
      "r992",
      "r1065"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r287",
      "r326",
      "r327",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r922",
      "r923",
      "r924",
      "r925",
      "r1006",
      "r1009",
      "r1011",
      "r1073",
      "r1075",
      "r1079",
      "r1087",
      "r1099",
      "r1101",
      "r1102",
      "r1103",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1123",
      "r1145",
      "r1173",
      "r1175",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1264",
      "r1274",
      "r1684",
      "r1687",
      "r1688",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "terseLabel": "Statement",
        "verboseLabel": "Subsequent Events",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r282",
      "r484",
      "r485",
      "r487",
      "r490",
      "r814",
      "r882",
      "r982",
      "r993",
      "r1004",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1023",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1046",
      "r1047",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1065",
      "r1139",
      "r1141",
      "r1275",
      "r1717"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncomeParenthetical",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r282",
      "r331",
      "r484",
      "r485",
      "r487",
      "r490",
      "r814",
      "r882",
      "r982",
      "r993",
      "r1004",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1023",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1046",
      "r1047",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1065",
      "r1139",
      "r1141",
      "r1275",
      "r1717"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r1308",
      "r1319",
      "r1329",
      "r1362"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1584",
      "r1585",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593",
      "r1594",
      "r1595",
      "r1596",
      "r1597",
      "r1598",
      "r1599",
      "r1600",
      "r1601",
      "r1602",
      "r1603",
      "r1604",
      "r1605",
      "r1606",
      "r1607",
      "r1608",
      "r1609"
     ]
    },
    "us-gaap_StockIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Notes converted to common stock",
        "label": "Stock Issued",
        "documentation": "The fair value of stock issued in noncash financing activities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of convertible subordinated notes due 2023 (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r39",
      "r83",
      "r86",
      "r124",
      "r465"
     ]
    },
    "inva_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Shares Exercise of Warrants",
        "documentation": "Stock issued during period shares exercise of warrants.",
        "terseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture, Total",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding (in shares)",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r82",
      "r83",
      "r124"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationCompensationAwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r82",
      "r83",
      "r124",
      "r553"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of 2025 Notes to common stock",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r83",
      "r86",
      "r87",
      "r124"
     ]
    },
    "inva_StockIssuedDuringPeriodValueExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "StockIssuedDuringPeriodValueExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Stock Issued During Period Value Exercise of Warrants",
        "documentation": "Stock issued during period value exercise of warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture, Total",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Exercise of stock options, and issuance of common stock units and stock awards, net of repurchase of shares to satisfy tax withholding",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r82",
      "r83",
      "r124"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "terseLabel": "Amount of shares repurchased",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased and Retired During Period, Shares",
        "terseLabel": "Stock repurchased and retired during period, shares",
        "verboseLabel": "Retirement of treasury stock (in shares)",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r82",
      "r83",
      "r124"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchased and Retired During Period, Value",
        "terseLabel": "Stock repurchased and retired during period, value",
        "verboseLabel": "Retirement of treasury stock",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r82",
      "r83",
      "r124"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Equity, Attributable to Parent, Ending Balance",
        "periodStartLabel": "Equity, Attributable to Parent, Beginning Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r86",
      "r87",
      "r112",
      "r1025",
      "r1042",
      "r1066",
      "r1067",
      "r1250",
      "r1285",
      "r1492",
      "r1496",
      "r1497",
      "r1542",
      "r1659",
      "r1719"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "verboseLabel": "Stockholders' equity:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r62",
      "r168",
      "r169",
      "r175",
      "r176",
      "r203",
      "r237",
      "r238",
      "r239",
      "r242",
      "r250",
      "r252",
      "r368",
      "r371",
      "r419",
      "r482",
      "r512",
      "r580",
      "r631",
      "r632",
      "r646",
      "r647",
      "r648",
      "r651",
      "r714",
      "r715",
      "r744",
      "r746",
      "r747",
      "r748",
      "r749",
      "r751",
      "r766",
      "r801",
      "r802",
      "r806",
      "r813",
      "r837",
      "r968",
      "r969",
      "r990",
      "r1025",
      "r1042",
      "r1066",
      "r1067",
      "r1097",
      "r1267",
      "r1268",
      "r1284",
      "r1492",
      "r1496",
      "r1497",
      "r1542",
      "r1659",
      "r1719"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquity1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r495",
      "r497",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r509",
      "r512",
      "r741",
      "r757",
      "r1068",
      "r1069",
      "r1098"
     ]
    },
    "inva_StrategicAllianceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "StrategicAllianceAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the strategic alliance with GSK for initiating three new full discovery programs and giving GSK option to license exclusive development and commercialization rights of products.",
        "label": "Strategic Alliance Agreement [Member]",
        "terseLabel": "Strategic alliance - MABA program"
       }
      }
     },
     "auth_ref": []
    },
    "inva_StrategicAllianceMabaProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "StrategicAllianceMabaProgram",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "strategic alliance - MABA program",
        "documentation": "strategic alliance - MABA program",
        "terseLabel": "Strategic alliance - MABA program"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement One-time Milestone Payment on Commercial Sales",
        "documentation": "Subscription agreement one-time milestone payment on commercial sales.",
        "terseLabel": "One-time milestone payment on commercial sales"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SubscriptionAgreementOneTimeMilestonePaymentOnNetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SubscriptionAgreementOneTimeMilestonePaymentOnNetSales",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subscription Agreement One-time Milestone Payment on Net Sales",
        "documentation": "Subscription agreement one-time milestone payment on net sales.",
        "terseLabel": "One-time Milestone Payment on Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r843"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r843"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r843"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r842",
      "r844"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "inva_SulbactamDurlobactamMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SulbactamDurlobactamMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sulbactam-Durlobactam [Member]",
        "documentation": "Sulbactam-Durlobactam.",
        "terseLabel": "Sulbactam Durlobactam"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "terseLabel": "DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to various accounting policies of the entity.",
        "label": "Summary of Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponents1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "BALANCE SHEET COMPONENTS",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1421"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Disclosure of Cash Flow Information:"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SyndeioBiosciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SyndeioBiosciencesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Syndeio Biosciences [Member]",
        "documentation": "Syndeio Biosciences.",
        "terseLabel": "Syndeio Biosciences"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SyndeioTwoThousandTwentyFiveConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SyndeioTwoThousandTwentyFiveConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Syndeio Two Thousand Twenty Five Convertible Note [Member]",
        "documentation": "Syndeio two thousand twenty five convertible note.",
        "terseLabel": "Syndeio 2025 Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SyndeioTwoThousandTwentyOneConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SyndeioTwoThousandTwentyOneConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Syndeio Two Thousand Twenty One Convertible Note [Member]",
        "documentation": "Syndeio two thousand twenty one convertible note.",
        "terseLabel": "Syndeio 2021 Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "inva_SyndeoTwoThousandTwentyOneConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "SyndeoTwoThousandTwentyOneConvertibleNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Syndeo Two Thousand Twenty One Convertible Note [Member]",
        "documentation": "Syndeo two thousand twenty one convertible note member.",
        "terseLabel": "Syndeio 2021 Convertible Note"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r1355"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardExpirationDate",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Expiration Date",
        "terseLabel": "Tax credit carryforward beginning date of expiry",
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "inva_TechnologyTransferAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TechnologyTransferAgreementMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Technology Transfer Agreement [Member]",
        "documentation": "Technology transfer agreement member.",
        "terseLabel": "Manufacturing Stage Transfer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TermLoanInvestmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TermLoanInvestmentMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan Investment [Member]",
        "documentation": "Term loan investment.",
        "terseLabel": "Term loan investment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TermOfMilestonePaymentForCommercialSale": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TermOfMilestonePaymentForCommercialSale",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term of Milestone Payment for Commercial Sale",
        "documentation": "Term of milestone payment for commercial sale.",
        "terseLabel": "Term of milestone payment for commercial sale"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TermOfMilestonePaymentForNetSales": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TermOfMilestonePaymentForNetSales",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of the milestone payment on net sales",
        "label": "Term of Milestone Payment for Net Sales",
        "documentation": "Term of milestone payment for net sales."
       }
      }
     },
     "auth_ref": []
    },
    "inva_TheravanceRespiratoryCompanyLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TheravanceRespiratoryCompanyLlcMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitiesAndAcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to the variable interest entity, Theravance Respiratory Company, LLC (\"TRC\").",
        "label": "Theravance Respiratory Company Llc [Member]",
        "terseLabel": "Theravance Respiratory Company, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1519",
      "r1668"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationDirectorCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TotalPaymentsMadeForRoyaltyAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TotalPaymentsMadeForRoyaltyAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for royalty agreement",
        "label": "Total Payments Made For Royalty Agreement",
        "documentation": "Total payments made for royalty agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1347"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r1354"
     ]
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAccountsReceivableMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Receivables from Net Product Sales",
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1520",
      "r1521",
      "r1522"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r1375"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r1377"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsAvailableforsaleSecuritiesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInImaginabDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInNanoliveDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r473",
      "r508",
      "r741",
      "r756",
      "r785",
      "r796",
      "r799",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r862",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r929",
      "r950",
      "r1236",
      "r1238",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1251",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1537",
      "r1538",
      "r1539",
      "r1540",
      "r1644",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1652",
      "r1654",
      "r1655"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1378"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1379"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1379"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r1377"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r1377"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r1380"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1378"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares",
        "label": "Treasury Stock, Common, Shares",
        "periodStartLabel": "Treasury stock balance (in shares)",
        "periodEndLabel": "Treasury stock balance (in shares)",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "terseLabel": "Cost of treasury stock",
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r41",
      "r83"
     ]
    },
    "inva_TreasuryStockSharesAcquiredIncludingAccruedExciseTax": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TreasuryStockSharesAcquiredIncludingAccruedExciseTax",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock Shares Acquired Including Accrued Excise Tax",
        "documentation": "Treasury stock shares acquired including accrued excise tax.",
        "terseLabel": "Repurchase of common stock, including accrued excise tax (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stock Value Acquired Cost Method Including Accrued Excise Tax",
        "documentation": "Treasury stock value acquired cost method including accrued excise tax.",
        "terseLabel": "Repurchase of common stock, including accrued excise tax"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TrelegyElliptaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TrelegyElliptaMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Trelegy Ellipta.",
        "label": "Trelegy Ellipta [Member]",
        "terseLabel": "TRELEGY"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TwoDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TwoDirectorsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Directors.",
        "label": "Two Directors [Member]",
        "terseLabel": "Two Directors"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TwoThousandTwentyEightNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TwoThousandTwentyEightNotesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty eight notes.",
        "label": "Two Thousand Twenty Eight Notes [Member]",
        "terseLabel": "2028 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TwoThousandTwentyFiveNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TwoThousandTwentyFiveNotesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtScheduleOfDebtDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty five notes.",
        "label": "Two Thousand Twenty Five Notes [Member]",
        "verboseLabel": "Two Thousand Twenty Five Notes [Member]",
        "terseLabel": "2025 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "inva_TwoThousandTwentyOneConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TwoThousandTwentyOneConvertiblePromissoryNoteMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsConvertiblePromissoryNoteInSyndeioBiosciencesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Convertible Note",
        "label": "Two Thousand Twenty One Convertible Promissory Note [Member]",
        "documentation": "Two thousand twenty one convertible promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "inva_TwoThousandTwentyThreeNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "TwoThousandTwentyThreeNotesMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtTables",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty three notes.",
        "label": "Two Thousand Twenty Three Notes [Member]",
        "terseLabel": "2023 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSeniorNotesDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r213",
      "r214",
      "r215",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r255",
      "r329",
      "r330",
      "r368",
      "r369",
      "r370",
      "r371",
      "r418",
      "r419",
      "r427",
      "r480",
      "r481",
      "r482",
      "r483",
      "r578",
      "r579",
      "r580",
      "r581",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r690",
      "r691",
      "r692",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r786",
      "r787",
      "r812",
      "r813",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesDescriptionOfOperationsDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetRevenueFromCollaborationArrangementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCapitalizedFeesPaidScheduleOfCapitalizedFeesPaidDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntitySummaryOfIndividualInvestmentsHeldByIspFundDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureSegmentReportingScheduleOfReconciliationToTheConsolidatedNetIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnamortizedDebtIssuanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnamortizedDebtIssuanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Debt Issuance Expense",
        "terseLabel": "Unamortized debt issuance cost",
        "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r1374"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Unrealized Gain (Loss) on Investments, Total",
        "label": "Unrealized Gain (Loss) on Investments",
        "verboseLabel": "Unrealized loss on other equity investments",
        "negatedLabel": "Changes in fair values of other equity and long-term investments, net",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "inva_UnrealizedOtherGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "UnrealizedOtherGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in fair values of equity and long-term investments, net",
        "documentation": "Unrealized other gain loss on investments",
        "label": "Unrealized Other Gain Loss on Investments",
        "terseLabel": "Changes in fair value, net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r617",
      "r1190"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Net decrease in tax portions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r1190"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net increase in tax portions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r1190"
     ]
    },
    "inva_UpfrontCashPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "UpfrontCashPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureAssetAcquisitionAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Cash Payments",
        "documentation": "Upfront cash payments.",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_UpfrontFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "UpfrontFee",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront fee",
        "label": "Upfront Fee",
        "documentation": "Upfront fee."
       }
      }
     },
     "auth_ref": []
    },
    "inva_UpfrontFeePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "UpfrontFeePayment",
     "crdr": "debit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront fee payment",
        "label": "Upfront Fee Payment",
        "documentation": "Upfront fee payment."
       }
      }
     },
     "auth_ref": []
    },
    "inva_UpfrontFeeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "UpfrontFeeReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Fee Received",
        "terseLabel": "Upfront fee received",
        "documentation": "Upfront fee received."
       }
      }
     },
     "auth_ref": []
    },
    "inva_UpfrontPaymentUnderIntangibleAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "UpfrontPaymentUnderIntangibleAsset",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Upfront Payment Under Intangible Asset",
        "documentation": "Upfront payment under intangible asset.",
        "terseLabel": "Upfront payment under intangible asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDescriptionOfOperationsAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Management's Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r285",
      "r288",
      "r289",
      "r290",
      "r922",
      "r924",
      "r1146"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r773",
      "r1192",
      "r1197",
      "r1240",
      "r1649"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r772",
      "r773",
      "r1192",
      "r1197",
      "r1240",
      "r1649"
     ]
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityLineItems",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "CONSOLIDATED ENTITIES",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r723",
      "r724",
      "r859",
      "r860",
      "r861"
     ]
    },
    "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsSummarizedFinancialDataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity, Not Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Not Primary Beneficiary",
        "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityOwnershipPercentage",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "terseLabel": "Armata outstanding shares percentage",
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly)."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureConsolidatedEntityIspFundLpDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity",
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r718",
      "r719",
      "r723",
      "r724"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfComponentsOfLeastCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r824",
      "r1249"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": [
      "r1430",
      "r1569",
      "r1642"
     ]
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureDebtConvertibleSubordinatedNotesDetails4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": [
      "r1430",
      "r1569",
      "r1642"
     ]
    },
    "inva_VotingAgreementMaximumVotingRightsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "VotingAgreementMaximumVotingRightsPercent",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of maximum voting rights",
        "label": "Voting Agreement, Maximum Voting Rights, Percent",
        "documentation": "Represents the percentage of maximum voting rights under voting agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "inva_WalthamMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "WalthamMassachusettsMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waltham Massachusetts Member",
        "label": "Waltham Massachusetts Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInIncardaDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "terseLabel": "Warrants",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1272",
      "r1273",
      "r1276",
      "r1277",
      "r1278",
      "r1279"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrants",
        "verboseLabel": "Term of warrants",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1647",
      "r1648",
      "r1649"
     ]
    },
    "inva_WarrantsPurchasedIn2020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "WarrantsPurchasedIn2020Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants purchased in 2020.",
        "label": "Warrants Purchased In2020 [Member]",
        "terseLabel": "Warrants purchased in 2020"
       }
      }
     },
     "auth_ref": []
    },
    "inva_WarrantsPurchasedIn2021Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "WarrantsPurchasedIn2021Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants purchased in 2021",
        "label": "Warrants Purchased In2021 [Member]",
        "documentation": "Represents information pertaining to warrants purchased in 2021."
       }
      }
     },
     "auth_ref": []
    },
    "inva_WarrantsPurchasedIn2022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "WarrantsPurchasedIn2022Member",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsEquityInvestmentInArmataDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants purchased in 2022 member.",
        "label": "Warrants Purchased In 2022 [Member]",
        "terseLabel": "Warrants purchased in 2022"
       }
      }
     },
     "auth_ref": []
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureStockbasedCompensationValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted-average"
       }
      }
     },
     "auth_ref": [
      "r569",
      "r570",
      "r774",
      "r863",
      "r1117",
      "r1118",
      "r1240",
      "r1672",
      "r1674",
      "r1677"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted",
        "totalLabel": "Weighted-average shares used to compute diluted net income per share",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r276"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used to compute net income per share:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureNetIncomePerShareBasicAndDilutedEpsDetails",
      "http://www.inva.com/20251231/taxonomy/role/StatementConsolidatedStatementsOfIncomeAndComprehensiveIncome1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic",
        "verboseLabel": "Weighted-average shares used to compute basic net income per share",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r276"
     ]
    },
    "inva_WithdrawalFromInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "WithdrawalFromInvestment",
     "crdr": "credit",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureEquityAndLongtermInvestmentsAndFairValueMeasurementsScheduleOfAvailableforsaleSecuritiesMeasuredAtFairValueOnARecurringBasisDet2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Withdrawal from investment",
        "label": "Withdrawal From Investment",
        "documentation": "Withdrawal From Investment"
       }
      }
     },
     "auth_ref": []
    },
    "inva_XacduroMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "XacduroMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "XACDURO",
        "label": "XACDURO [Member]",
        "documentation": "XACDURO [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "inva_XeravaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "XeravaMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XERAVA.",
        "label": "XERAVA [Member]",
        "terseLabel": "XERAVA"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r1341"
     ]
    },
    "inva_ZEVTERAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ZEVTERAMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfNetProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ZEVTERA [Member]",
        "documentation": "ZEVTERA."
       }
      }
     },
     "auth_ref": []
    },
    "inva_ZaiLabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ZaiLabMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Zai Lab.",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Lab"
       }
      }
     },
     "auth_ref": []
    },
    "inva_ZoliflodacinMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.inva.com/20251231",
     "localname": "ZoliflodacinMember",
     "presentation": [
      "http://www.inva.com/20251231/taxonomy/role/DisclosureLicenseCollaborationAndOtherArrangementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Zoliflodacin [Member]",
        "documentation": "Zoliflodacin.",
        "terseLabel": "Zoliflodacin"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)(2)",
   "SubTopic": "40",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(a)",
   "Paragraph": "4",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Paragraph": "2AA",
   "Subparagraph": "(a)",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AA"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-4"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-5A"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-6"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-9"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-11"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-26"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-50/tableOfContent"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/825/tableOfContent"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-42"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-49"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-X",
   "Number": "210",
   "Section": "2",
   "Subsection": "2"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/321/tableOfContent"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "325",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/325/tableOfContent"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-9"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r1612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-13"
  },
  "r1658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r1661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477867/946-230-45-1"
  },
  "r1722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  },
  "r1728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>128
<FILENAME>0001193125-26-071776-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-26-071776-xbrl.zip
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M<RW,A1?U=2:\\ST*P?*2V \F] <$YNM@$M&0#'&[K3D_BAZ!Z,;W]$%SCW@
MCZ,AEO+*X*RY:O$QTIR]3?0A8DR :JERTMF7A;99UD7&G-C7$%^BF;".V@%L
M&.O(P+X+QI#9\!/[-(J+6<F"?T6(-_[]PW)%;Y.8:BZ%J?;[Y(^5*7WX&Z?&
MV/8LC]Y0ZX2,05.54Y5F9]/O$'E# M<.>H0?UI/N^Z*FTCU9GO#>?</CY?!=
M.:&G?;=\;\L4)J+O_;XY6H(2.F7=^V#$:'_\B]_&VY;RZ=AKTVMI*R\ZBLX6
M% J=6@].+PW][%]32X,SQ#/WM;%=]E'\K(\D27W3?0='QBU Y+US#8_;>M09
MH'F -\HB[ 8-WR^JF23>YN?<G:%2M>''N?C<]UR^:C/ETT+#_%=_O%G]_IW,
M5)<Y[*T0QA5L5QL)L.&;Q],[F>\8AL 0/869C[&C(=YGP \RD)2* -Z-&2?)
MJE1?^L/^!&_?,N')AGG'N:4GW\E6Q]HNDI_*&@62 -0VJ+!&W=R7@^;L%4TV
M+(943Z#"*=MQ>+Z![K$#OG26Z*3R#Z4*'K_;MI/9U-G[6ODE+I_EB'>2[V:H
M*RFDYV9Z^15&/P61ERG^EWL][-;^7 H2]="X,(&6IZRO;,3*3Q8*?BY#\NO_
M_NM%L<)D8./KHL(CQ;:^$_FQSV8;<RZ7JG4,KH7[+GY0DUO%ADPY_-K$0$3]
M23ZV*Q#KASWNA+%B)F(X]BW1 O3;H"_95^7D#C2?L0>=?![BDW[BCWB%3H)K
M P;J-/O\$M>JX=G9"ZX^-MYBG-'K61;YWZM67A$-W1*@W+M#A.XQPN<.LY@E
MQAIFPYKB>WE(R7A> PVP8.!]GA281,GFU1VB\$&=*HF.HZH$ZU4%W*QKG%3Y
MB3CJLOCR!]62R!J<\>.6T:XUEY;Y:+IB#Q0^5?! MW?GJ2OTW3JOL>(@FNY>
M:UV!Z^GG?[%B67G;=#SNK,:R0NO)-R6_/$X%6<AW".LFY=P>LC*V',\I>.&Z
ME>80%N@W_^I<I^7:[I!1%*2!NOX@+)7,H(#KA+G^@8$LD6@Y$$?#42P;@Y:@
MU'0>_QZ0?<W5>O&O19]%)=KO]!/(^WE2P'1[1M7EJA:1A\E,%MZ3/X6K[5TS
MZ[?.8ZP)"-@>(!F"H6HB#"\(NN4Q;O%=3G?SW\RY?@#V$(<QYT$_J?+2JYF[
M45) .OYI0[*QJXUU_1.T2L;,(FO#H>5.4T9 PRO8]P?'#P[7#S>%C[A$V:6N
M7'CSU6;@+E@:7^Q6>2=??L(J9OZ9!SIHI,LL\(7[*-G 59&2;^:3]6S#<C:P
MI'IBTB&T56\=J^>*8HKZ4FI ^0#JJV)L%X)P!Y<(;XQJA#K6'BPL8:AG=M5^
M1DL;SM[3UR[?Y.IC:0/;3PJT]D9+O2,]O)3/T0[ZG$RHNK-#;DP]-"?S9I,1
MB.U2)RPM;<\CR7"J]A)J+HP.3OL;G$,+.-$8*&Z,*P4G]K4I2Z0?'ANEW#8E
M;A)O2^-DQ@C?1\=-##A]]].LTMI$/OFFYWB(Z!U^@._'+$."#8N$QIR0!;:O
MR>!8TM\3^YMH% ]&&IN4YCCG;0$P,-?8L-B:2LV"C=TQ_NGE3M8\CCSSB9SN
M-_)AH@N5N[-)UM?I_Z.E3?Y#4.NO@*G:U.)G<6=N;=ATK[Y4O)EUHR:FV]ZJ
MV/&V;W?4:+*X37:ZF;]  UD[I_9Y^M%TA?(=DX65%<L;+S)24]M<*D)_FA&K
MQO?A4/7F0BU!!)&LHZ7+;%A2U$%@>VN3 GV6AI$':N+;K8+*P;2!12E:C-B7
MJ-/3:@V]=8U-XPV1%YUU5)QZ1V0FV\O/_E666&RJ#V=(V  U]!]@\_YI4*V'
M4'O(0'_F=#Q%:9$1!L3W\/REP89)H#/?G_B:>='[ZN 7DO?LCA?1N..DCQCK
M58FKYFBAS]M>/]7I0[?!>]#Y_7R@$-GD:O>Q84(J;-C22SI60!43&$&V.,.2
MLP!(9A,AHE4,/5]L*$:_M9TX;./L9*15KDGZ9"<P_"Y+X3=$JPZK&SJNG=#D
M0$W?EV%UDVJQO0%Q"$&,#1"PC$S"6!1Z8876)K:"RZI#),U0\?R+FUEW*TI1
MCB3GWAGBCZ#1Y_,O3GP^3!Q]Z;3G,AF]#NP^%3U)GDV]=*O6ZJ9^*3RA=]E-
MK.K8,9^I\E<V^*;>B=*G.6]LNVV?K<F/GB_GE/H]XWRO;HM3YRS13<GI^;/;
MPSF5[Z2>8YK-S ;WJI#OL$O1\*-LF!\I!O4V+II,F$]EPWJ3ELUQ(KY9^)X:
M;G#3QB^ PO4D2O1S<=FX!E)H ^O7<;,X-?A=QV2#5I9S\O'!D"<;H5E!G,U4
M(ZP!%O!WH'KL7V5! JP6WXM*P#?4]/%Z4C*?_<"G&,@!?7$=U8:E3D,>9*:V
MV81GX]N4R[HSHPNW$LU???$,5NVK&WD$8Z"AP-=#6-%/:)"!-_ ELV$>-:!<
M>ZM6-!EW:',28S!C<''>2XVR+8FY2NNU)G[:% OHB3QGJY6EBL\'GXA7\5R?
ML2;9M]-D*D)"_'QY8YH$"']16DP0%#?-L;H-C0=$=.NIUL8=L4_^& .;Z&<K
M(F@=FQ"7.U\*CR@&U=B;%9L:]6OZF*!GBTUXS2Q&^KKD%1RG4LVKR[V:9X9^
M;X5_SA5BW<<*L&$^6% '3N?YJ*^T_SL& Z;1UBR PU414NF><GU^\*Y%74"R
MI+3BBN1JKO<RZO@Z40NOA;O<G9^$=#7;FU'7=2&*'GJTO%<-N2L/N7M+ PDJ
MD'KP B!J8,\@>@E)C"!K%L?.XC#P?&3PGEJBOD(HS7LOK!=[3'9I9^GME*9L
MZJ3C1-)@JU2Y1NB?8Y?;GU_3J=_F"W+)5 Z?/A9JE[MBNZ%X\]E=9$+&N5-.
M*3[X[1?E/9_M9(^8!:]H<H\J%L1K.+^YV6*+K[]?;N;G:EP4'E 0ZK2]D;Y%
M#=K5363Q8)=:"8!MS?PV_29TC4D,0] ($*&_H&7VC,6U!L082/IJN0E-WOO!
M4Z&DU.%@G!AI1\UCP\Q;6JZ$TAHJD]7ETQ?B./X(EZ/R0J!S&3*Q&C6GJSDV
MH/9I]SVJ8;=[>T[I_4,^>@@^I5,0?7+F)^-J'L]$(588)/5W*DT%M\U.U03D
MWIUNY%$10.K>S>08\/.5'7OQG5 8#=3H]"W5Y?0[YIG'O%_]=/.6^],^RIN/
M*9(SL0H?>Z9M7G>4G",T^N3J'G\3U5_QP-0D2S:E5'14(EU6WCQC/#&LZ;O3
MNE#Q?-/:GO XJHL-8_#+L7A^[5MLHAKP/7B(XHW11@;ZL8<PWK/2 /8Q2QZ,
M&T#6T7:?,,++E">];X"9MK5-D]00_+%-/@[O"6;UZ,2:8>N^WN\3":N)A$(L
MJ-S,$%)4 \\AWZN(N 'Q3XK 9-H8I;.X#)KQ#G&KS83,WR9D)[?Z1NN7 X0;
M8TY^-BWPXA_Q$]0-:3,Q**]P^^2L\=R16>W%N#[["(Q6I!R3.VZ6K&RO?=X,
M?;3E83*Y5B,[*]?.NM)[\(77OFY*:\41W<#HW!P)617WQ&)=ZZJP4SVFY<Y9
M:N9*YR8[IBL7MOV^96Y9"+&""%P(+R2H T&M4"%8LTS:VJ49+IL"O!WT>O\=
M-"]&")@D,T=+BPH6-W3Y'OW(C3 B9-MWU#F7J4C7-W2VWGW9=]=?C"PS,$X"
MS + 2PCZ>P!'U0&VZ=;,=DT;FEJ7@1HM"W-N"A-$21:>OP(V I,#VNJY<N8M
M-(N^9UH9+.GZS-X3?86;]K-BD8T_<[)BPNQ]UB7>7![VC-49.:9J4"V@^5?]
M=3<')'%5]"Z'J'6)'I\0MR6D_#X^H2=<Q32LDA53CFM,E2R+O B<^ER0H]BM
M'AJS(C2D8MTQ^=!U8WIBH0W> @<"Y:B[^];0&,9ZXN=VH4E7UYS\0XT#73I
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M(,T56"TO]#&0;&^="B[E"0@L]='U6$G)O]SKE)S[18ZJ53U>FBZ7J<N&62"
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M^+/?'_#\C6?X%8X0![DH@'A\A/'>OI?:W,T4359<I%3VL_]<B<:E_>II&,$
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MEZ3S$[%>TVRYLMF%!628=V!UE?'97S^S+!%:EO+BWQMM]SSV=#G#'''@%Y=
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M;RE$>IS9^O7?YJ8X_:'ZE9W;^<Z4):.3A']K\/P,:J*A\8KFJ:^RPHSTY&H
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M!&:6F7GD8>S==7C5%DH[DFX0[7:X$BBAJYJ'K(R%;#XS(ZAJ7;4JR]Q'LKT
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M]DW$D=^\<^AJ-50Q+0L],:1?DU!1]:[6VQ4O7X*K@7]0'S <0D@O[<X[S*A
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MU,;+L-T:&>CRT!+_'8D',^U= R]"BY?*B_"KSHM:NE>77ID+JAM(TLF@)4W
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M"JI5\A_F67PP;YTS#\@/D7_QNF4LL+7T430OS4:&,PQNA@V<L\(1T@A_X,_
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M0VIV*ET/98^;W?EX Q3,VMJ!SFDR>B<O3OR>MV&\85?MG#/8#F:Z=_)M91^
MA#9?-V)*?MP+CLL,[+I)&SFBQ#MV*ROYKV,/+G-G)0 -0\VEDG8?JT%$$ KL
M1E2 9LKB*>V&N#5C+?)N(D0N^!$XJ85I96U>,Q'R^G>PN=/LB;#J=^^*5K5!
M%K\L1H:E]B[E65Z^ZN<7K=B@U>3GL^J:?C<NSPH!YJ=%?&@.5?X4WOR>ZHWV
MLSR7G/!BV?ZD8%@V1LFA,"C:'N5:4UHU&UK:V:9,=".T))\P*X%\/)LW]='Z
MBWF#<;'J8GL;N:[%!>%,SAP562_N>PJT]17CU8)?_>@R[S(J86>/ILML*TT%
ME_[W?=R$Z=$G91G^,/NB:9[E>:<#D"-J3KP7UI*Z\0<WF,M?(F& _/1 V F6
M(;TM@Z5(ZU@CMV5M;*6D5EO17M[_3:W[R9&<'"RL^T#NOK[;IU(D=;]W<)QI
M72A%W'AD-:[]Y0!4$!)?S33XGZ?4H; 9S;XV"#^[_  4.)H!$^@2CHB(02*$
M_+'?@B""N(FMI;:2 Y 3D06MPXWDH.L62BWAFV'JLNE+;;G_G3?]=(I..$'5
M+ZJQS!JFNQBX?,H7M1>RX7_VI4A18T"E,>EYN A9LFU81<BC43C[ED4X(F?D
MWT>KN2UV6<^#3$S>05Q-IR=A5J6K):W%>/3/D]P)6K%3H2&",W\.4073#D!A
MFK,V+L P'465DQ'.[RT_-H54  @4W'3?* ]</4H"NQ7*LJ0,UR6LNC%J*=*&
M<</\9_3&,1?'U4],1JEF%B?>YMR$DIJ0<D2CP\XYR_31K)T/5-R8T3GZ,L.7
M'HV+TDJK:!UC:<61K&(<VHN<]NYF\/'QI5<]Q3O<U/AV!/;\#:K'%!K6"4U;
MN )TUB!GP"VFF715"G]W=G%6EW<%RV(Z<L39@ZC]3"'?;&Q3:B%<Q V2Y5^H
M7::[H(]Y7>$M$HQS!NLB;@,OZ8I4F^PH;#I4PBB6<K@)XG37K9#<-$0(-=MK
M&4;7;;V_4=G<PB%.:DHN=S)UJFSGKLO)R9UHRBWXP\/#L,>UT;,_M@95\D,R
M6L&UT7&'M^7*NASMP4M=6M"$TKN.\)<6Y=(SO=;6&.>@R8NU5P<,WJ59%RA?
M%\Y(VLM_7E ZQK+>?1AJA<_TK<[=.74 2NA!]D,,N-_ER+X[B N $!5V-,#K
MPF27(TDP RDRU>4/J08GZ\P;6O WN+D-UP5$2PW,/W?#E:W;N2_VU"Z:/BGL
MJC7]!I5$D8C0HVNH4UM<_*CE8K+1[=9A"BP5+ TY#1SIS_2]_*Y)YCS-DS (
MY5^[_I%4Y4?Y$N06,CI3>WG0+W'XG\'DUMPE<5(82Y2'P\O#U(4?@XBQQ-@-
M$%6X'GFG*9^IVCO<:%Z_LB#C6EETM8(VNXH.S+^18/IL4XI//$<3M][NZ)Q]
M^3N*EW#_ #2[2W)JH!_Q!%29UHA0P![#<ID>RN HK7*.TC>Q9+8913'CV& M
MMYJ?%,_2>/W=5:?[WGRPV\ '?(?ZY5('_#]ETX)H83[R8'PJ^3XSJ;IT"?=
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M! .Z?7@?L18:C3/A<52,"9#OM-J2ZUC--Q+(4,+^E/W$JU3Q^/]U&%LR' ]
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M$;]!3@0A( PP;!BBL_Z:6(=R4V4F[GT)NL\];H#X6_ TXN&4D:-XAI'3T>F
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M*;!4I&Y+:^N[*:-S%/T[)T:6_NE(H'SF?),V=K_=WC(1TM5D5$1#E=IL#!^
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MN'86Z19TANQ5H/*WF(6)_*OQI6GM\O )A<DEEEMA>+[W?[WKZ'KG#0A=DTD
M[,O9P9PBHX=!C-/4F.8W@;->.;1J:\5N SG)R%WQ]8*(ZN 6=(IVD:ASVJR7
MB9+:[P!&[TE/>MOSG%!N$('NH0B<W>D6GB,S$_%TOW2N!!!%'<2NYS$DF8D
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MI4]TB#!N39B0F7G9S)"#^4E]Y*4^0N >R+!$'DW9%$Y9[LT[QOW,$XDX8C@
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M?[H'<I1KB+QD.DZX@XLC2/X,4]<C@E4R]D D!0GZ4,T;MBKO-\432KI)]O"
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M]@ER_9S FUOYLG,_7WV?XTQ(^_Z(^7%%&./R/QGO/95[_PE^;W2RQI:)W;O
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MB(R(DF83:K'EG[.B6Y:[[=Q[3DW\5,9WUXC)JNX:\9K[POU8TM"[P6.? X6
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MKH"C3>%P_5KM82ES79>O7BZDM[UJ4V>8"]!SF:M);$D5KL DW8RYQ"G2)L_
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M4=/MF)L47 \K,X4LI',FPUK6!"#16U@N$\I6F\*P%[EC</B\I%/;F.8]<FC
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M%9,)#9*D03X[>D8[RP89=W6"+4R]$FK#'9X.VP,E%DN.+S6-Z7!,I;,W<AG
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M+UN:[BL3?==&RK W6NJBC8ST\OT*D1E]U?I&I#OZ(?_:G>SR.>>GL6]3CIX
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MWX74DUG"U0QI]A.T#Q4IQQF&\_[H.HXJ'Y ^("=)/U(:0M]/U4[,9IHU=WB
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M*$6GOE]^07)]<4<JHL$5[24BYB+H\I58M7XIV=9\42VD4O6#;K%]Z(A:@M:
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M[VQ[M#=.WJW#_^8+UOMSMTG0.&!J-41BBNO=N@=Q@-WF5R(U[NDT0X?]; 7
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M_H2#.?7E3-JKV\Y-6/6]E?*]#O.\M#&N3)&XTH3B?((VZ3\N TL!%P=V BP
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MW1-0_.J%F-5+]K, &"^C:M=WFO,*OY/"E!:O3?Y.7/<\>_5-R^$JOTY"9[:
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M//I'RD.=]W_^4&13<'?I1-U$(E&.8?:]QW,]9"8B\"8:/5;6#5VB3Q-C,G>
M,LS=;=<D32O?^SP_ZZL9!5\W.QX[:1MT_5S:D9BTV+8_FB$J6J?"F-PD9G&N
M<%:R@+Q5^@2%E0)Q%3FXW5*_D-3! \9GP(N JO^<?AT0@\=:XOF5B<"9[A_D
M'4\\W6Q?P/M%N8FE'&5&-7W@_>H.$J7?MB/^G>I'O1[F!>$B9!FJPI?,2".G
ML+W-39X[VH"+Q/Y1[> ZFC*R8'1.**;GC*0J#X[>"!R_'JK^S-WC^QRE@&S
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M5(99@^MS09R4T.E'AU7\29H!3 =#2YE]%<S[9"\9)CF'./TM%7GZ&RO &%%
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MHJ0G2Y.&ZY=V&P0$F%:65MZ[F/P;-@:MO[VM!^N/H(WJ43Z:O\R_&8"*L0N
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M+<-(7,E&YL;C7A+M[YY;VZ9I"<XP&>0T,K4@(B%907JH%L&^1I%<'WKC9_^
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M>YC5O]5 9(9L0*7=G2TR3)N$O%>&J=,7F,DP%FYX_D8"M($FQ977T^ -E%W
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M8C_LW/_U#[F\/8]W9BY:&+Y@*3.+ ^T>1N0Y8(>X5YK%V$Z2B.] 5[$-A-O
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M$]?22E-"KP_LH_[$#-(&B9+O0**1S:Y[U+-W*>$&TH4 ;QO*[ [ =T/)_*:
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M//G*UMJI<J9T<2[Y=M79WRKMNZ[=XQT_:QM4&N(S$O/\!J5Z#661/<T27)C
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M17K@>,3[0Z&YFU&0"RPIB<QT-:3MX?1%R0? @@U;2O1:G-5^$AE$5_D2(D4
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M'0OWXWX1-5H+H$')=0Z5W=.%IGLP;9-(E>CVB_/*^:> N+<^"_>48ROA*L7
M,V<E%"U8]4YCS-M%U;S5Q J3YB2!'EJ+=,;BO1O>D\*<I4PX\-*$9$H ,3&:
M4-,3AVZYRG?%2@)3+(*FX%CB6:YIG(@"R'DNT%N+YA): J,+0D%=+B2AQ5)\
M:L&L9MIW:M'C>W'"1.ZNG(V39\6PMJ*^BG-(^'JH0"$=W#TILCQZ9*6XC3.7
M9F4\C?N,$(MJSCU@1'@'6'3(!<]UWJM/CKJU)TL.WW&*!8E_<Y7D]L(;2 "E
M&A[UF43#UU>B13A["]^.H"R/_#$6PK H(AT"'" L>\Q")I1!R6R^N2CRR+?
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M??T)B>O*&_F):'306X/ALZS^6]V_P(TIZY&"P2C"'LR#R/=1Y_\]!9V*YHG
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MB%*(OWX3J7IL#?$8OPMMI3GM<,/(N)B+%7$9"B\\]U9%AF??7=;ZN/;[?--
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M(@_3+;^N!3-AQY\I3WD63TL_[COD&L%X>;HM6BV*O#9D@C\UXC&OLU6]6'*
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MW^/L/AUQ"9=]WGB-?LNN(<;0,/ .WN"R1S&@S!SH0B3CE4F0?W&2'*>:*FP
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M9?32&R5]YTJU79+5=&8'OCF4".OFRW7ICJBHO'N6^'.V+SPH,<W1FFN(G$.
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M1W,6.4WS=S<<?0U_L09A]_A=&J7]3L4+[$ FZD"='<@-;5&G80+@'PH#/B$
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MO4K-\C7,G<%[.:N2 RG#Q<9[>?UXLAE';IUO0XW<'&-=G .P]HD61Y/R'-[
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M' S.5QM-2UP<?GF,)(,D0*VL=?S/EIPJ/C68^/UH&EBP,IP:G;<T>L$C<5N
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MX97HS6>RGO"!P8E/0 <2/$X0')F(E57FFBVPUN:.OEY/]K,8N *DI!#:\Q2
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M_\O)& U=0BP[# <F'%L]L+#T\-+S@+RHJ%[[!JA 63A !FS6(5^PW%0!F>#
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MG  ]7=U"NB'/%T4\;;WDWR0:@(L69 U/K]73O!X*VW5&N]8A[^NUUR$4_+3
M^I;E3/$"3*"Y;;>=N]6-_ZL-ZRU8Y.\7'B)Y<:]/B[2WDBV$C$T; D8UZY!#
M%B!N'7);BB/"/5<84^IAB ?G*)FK^Q&YHGP+Y;,.281E(/[EQ.I\U/U_F]#_
M?JU#8-/@86-^ 52X$R,*-0PY6]8A*"N/?6/_Y_K'2R@HZ=OS'N3")$YPH83
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MD8]'+]> 83D%C %!_O9!X0(FZ+0@C'Y@RV;QK3+AT'T1PS)N6XFZG%N(/0W
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M7[#]E1[B'7CC.>OXGLD70C^"GF@\H2+1D\0)03B.7#NYRK*CM$]FCC&#73N
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MHT\8J=(16;4VU;DV^ZV,;GC<M7[H2/I/!CW;4DU,*P52GISY5G>%6]=*9=E
MQTOI<]WPW>C!Z3V;N:A==(TTT&%(LA,\118TO1DF4E7\'>E$+XY_&5'@"IB;
M#P1H7^5I!Y2:%B_(C)9<+M3^4; <X=,8\</OJL"?@2V(0#C%7]9IJ8\KPK/Z
M,$AT00FP^C@C+,>Z&:KXA+-5E!<]0"]*PK#X6V7_7H3S2GQ6])X7&:?;#7_8
M3@@Z+OP</45&J9&.\ON@+%OH^/89!: \FMB"S,#:82FN,AVBL;+4]J9>[[;(
MM83$)2TUFR[2[KPQT^>>M<074^,OHB81,P$1!R1>Q)ON4TX;03< A:PZ>G=7
M'P3 T7T[^W8#00R-=OSA^5H_Q5.LH)30I@#ORZ.K?P\K_=:X'_ALYF[R/<:'
M^EP==U</$^&1RG??VR7+?C<L18"6,;J9!+ME9<Y0K. >_T^:>6L*.=FF& >"
MX:U%Q=/#MT;45NWUYW5L)Y&Q'B.T.L*[[&5.5"@Q_92TY>>1XGO7@\UV\+#@
MQ_:@PL'F>(!4(6J[%N8M3*L-6A3=AQ,BW\<_ALJ@?(N1OF[ &NM/6Z0\3+)9
M(N)(<ZVL4VJSU>W,C:K-U,S(O"HOG<(HP9%FU;=^X=F([Y<1I^"#?9,JG)]@
M<_+\K^2#Z#T\"<"<J\SOP]7CN_O2<5(&AJRYJX ^5QLI0T](-C!_XXS(RM*[
MP;:N>GLB)[CPK.SW1XV..6],D8V9%4ICX4^65IGG%I;)ON3[HH R>4F8&S$]
MO@@CVBP-T$23C4X-J=$(0\V(X+V%;Y"CHX,3'FI+U$Y%6?*@-H(KAYS-U(^&
M.7P@U32X''[3D'XI_?784@HXYJ3MFL_H-OZ1E"Y,G?E2#6OE(_G@L:$C@UL0
M^FW/SC*@KFOQP#&Z56=F$Z/%Q#GK"NF#945B4)"!ON(S[5D"WN_!H"M."8).
MGJ]IE<[UDB+^,Q106$NTC+[HE3YU_ZBSV.U::?8.R9TC.S\>3=PW([9T2<K4
M8WO;JB295D&6PO'W@1.^!S<&H[W)$QQ8D\,G0+=K'(O.!,7S[ LF.S'EDYCV
M*TB5]FP_ULBGNF?Y V^&UC!R?M"]U7BU0%>;FOEU3YV19W+??KMQ<'SAHLUG
M!I9<-4SK63X4R&)8YY2!L>8PQA\C#91R<H"\L+?'L8[9*PRI#DU >[E(O[H(
M@4V@P..(IP9G_RCFOX77FA]ZUH N1X]BWC4LO>2&(7W;\H0WJT@"@,T,)KY9
ME"&(LJ=;J7;:(S('[C6N<B3\0JB4WC<+%,.A5TOJRO79TXR(*F6S ZSS18%D
M>S]*6/PS+Y]B/T?'QL!7)12W<3]*=*J8ZX3S..7*/ZX45[=+9<(M1()8T5D3
M\3/!9LF)^0Z0'3PO/H5\, A&P\)8#[KCR4$KJ1N&:]@E<^X#U)EWVQU):M2(
M5]?6%TV8UAT*C=:W>-9L@=DM89C;F==0/)^GTF)IL]IBTC8V%F(B/#2?9=O-
M7>1>W<[%P]!>P^JP2^L5Z/[(!J8]*ZHK4HLD1&8[/49IT#3D?RDJLQ,Z<HA#
MBNNF_09J^7[KX3*E]J,_=3B<&;N8;W*VJNZ>A+,FJAI4G"QI#TI^LY"DN C;
M;Z3/TV9A.C$)L@"<&20 4$T)HZN(5]X6WO',(XUF""OC"95_7?UU[-RHE,-W
M$(A_7R7!,LE@<)_& <?[VO")-U"6K(8E6];R#'QHY3Y13;R[4Q:7TNQ%S]V_
MT14Q%\_H;O=49N\M+7+/\GNIG.)2/Q(PK1_UX)BCDQ_$2!P,>^Y&.W@.0V1?
M'"6'\QOH*?97E&<'\201G!=L7'>N1'ODZ_"#GI.  G%%S'V^<6JJI>/&RR Q
M9$J'T:F6H6II+;?-_88J-U(/J=.]_Y!YA\E;D!.=7#1FX@\R=@MR<_WI(G?_
MT"I7^$1;][7!RONKO1K70:6S.J5K4Q__I=WF76V<6N72_?O,#-4H2WU+9&$,
MA;)O)GZ?]]6"*U=N0L]MEZZH@2W5<,61X5V>$ILOT0< !*T[ 7T466^C@.RY
MQNH=;0H)PB-KW>0"=*S\?RPVDO!G['/D+*.\A(LR.>7/=F8N=/[[&*.(8UW&
M4_[0='D2< X3]-RW:!"*Z[/25K<@CZE2Z!/\X<BL#IN="+11,'T+L@M(L:X=
M-G#1TKMO=(3\FWE_3<WM*MOL5?6ON\M7:D<(0P\# E-'^>YD TSK*)7E 'V,
MJ7=JQ3R%U8TM%5;J=JTD4 7(]X(. -TS-MTX ;?/T:R*-JK8FH8 SXHU]]A(
M8@)9G)\N[-9)J<8&@&3?]:EL2(\/HO278^_<=X/V3_P>&&(+ BBK\"1F.+_9
M(KDS&I12SFV6:*>HO)_>?3TCW$P.E@G21I*"NJ"=<R@W+:IMHR0MHMSUBL3G
MAECG:&-]Y\,%!.>]@\W3^2!6!8,C]EX@UW7'D7T,33@7 1O81QL!Y*!HXH;&
MXX+ZL?O',8J3?OSC@_GL0")^/GLD*]G HJJS!&CJR!3S0":X#G?H1!([BS2[
M S/9QCO^]H"A$60V7T31&IAQ$UH6OTC/ _WA/WGB/SZ2O;%<78VGU(V$^;!%
M#$%WJ8DEP,$#)F6HW9OY_,/WX)*D@_Y_[C7(8I\0_Q*=M2I>\?2#I::35*V*
M_&4#"S+\QLZ::C>91C[5.Q4]I3K4O(.FL0^EQC*/,Y)'P?HK>1HTS*Y?LKYQ
M/!7ZE&$I0D'BTD"5=\W@:H]98S:#-CE!,9$7.SR7:9>H^ZDWXQ(L@PP<%>"5
MY/"%P [ZG+^R!1FN<*C2 /2]^19]/ E]?E]3&W1#Y3I^_CQM;,F>>X;?AY$F
M:?+" $V6;[LB!&C@7H:;EJ'NL+NP1@WJ%3.3OS14AH_A'+&V(T'WC]YI:7S?
M*%0R,=YU-]OLCG*:!=<*W4FM76$^]V9QK39+C420",8FMHU\Z/+,%B1AE*_T
M?I0YU,;7K$\[EN#Q3D^]HKAI2LFV\JY^_8?Z4#G/O;MC=O ^8%I[,+N;34$^
MN07A283P]^=N0?;CKP-]K"B.(WOO<UH01;4U$AM7Q;OI$\":<QN]-<)<BPZQ
M^"!^^>V]6F'[#IVSFR7*M8-KI4.!@257&D6A"Z+MN%0,*P@TH=@;J C6[!A/
M8F.,3A^\O^9AO=CA*MH.$UG,4]!U+ M1SV*('EC(?(#(1M>4:D997?OH<IW3
M\(^5R+Q.0M!WO!C2I(VDSB)5T+!20+@96S=V;>I8M( ;JXM<ZKJP(8TOF'++
M<<O5L!_2WE>MIE'IVW#B<,#R[<R+$O'VHV19;="P=37X^WH8,-F&= WR;2AD
M<NJK0O6J@FJ'HL&@@4I4N/*,IT6T;@+HFY*3%-/@XYI/9FIU,LVH/[@G?OK>
M.@ %CJ\PL[ABZ FTX6;96M!X%$<''@L3-A(!&D7C,T&>&O^<9B,(V+3B%*55
M7\W];E8.+IB@^#/WE+M=KK8L]O?*HUX?)JARG^WIW*"T<O&>/JQ8&KD-#E*S
MCZX:;2LQ<!$4%*1:*PD%S@3L=LG(=RQ^DO^5&Q_7A?V\#A@O\!GZ2-/I8N28
M;-RB6:W'][XC5,^<_[.,X']=T&XR3QXT/A7N=D5?S 33:@M2$<5QPB\=(V,Q
MP,40OLTZ7Q@D8764G"V(X_H2'CYN&CE._2O]8PNRMB*W!2F[GL@+,_3>@A2]
M*4A6_?P_R@!1I07X\NU26%3^5[D9.)\ ^RC+_4G:.XJ9/4D6WH(LM9+ E5@T
MX>W VZCR3YSG=[Y*X!=>3V)"V>U_S*E:MJ81<7'_EP']'P.< 4>VQVP+\F([
MA]H*MO23= 0S/Z_Z0W:#R]\/4O!38#"(R<9,]*(N;4&&!IT^:6^6T5=X&1?-
M-Z.JP.%)V>1U;$$42\NW((,W;$VE./'_;2[-?YMKTZ_+DU.6?PAVR-% O+93
ML@+T(&\&7>B,W^E8CL>^O4+'WCD=UG>'].!>)//1B U!,!J",SRKZ@G>U6JR
M05YK$7KZ+UIG"Y)AG@1;LDD'NRZAG<^+A*V!A"E+8F4%N-#$%URA01,1,QK
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M1Q5^DM^P69-\X6M*HH GK.'QYP4GAKK A^ZVWP\,GQ@]'J/I,B_Z< U<41%
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MP!MQX"S$\#'-:7:=:2KNCFF]QE>?_/Q<H9M9)B^^YXAF>E"*GH'UCB./KWV
M_&,6&3M(LDRHI5S4D)U;/376.:.B+O>EQKG245_,P$Q5)BE/]U#Y:(6=8ZK[
MR 4SK7GCW-,/4KWW^ZD]JM#5D\PME"R_:9MJ9YOJX#>A1-9]-%V%ZR]>P:($
MMT$?_1%:5YJ$ED/IL3!8&*T04[_^)!!]_#O*@3T6'Z2^BGV:)X@SKFMV(2Q&
MVSHRNA;;!H"Z=M=0],'PFH2.[![$NFQSPO6ASAI0%=\6!302$F#W \([<;6E
M/&G$=4"4+<&)!(A%WRGC/*<FEG4*;444=6YD-4HNS74:*CDYSWQ;Z9C=.95J
M>P]]M 818'^-K3E(/Z>6VU$)<]V"T.J>;7,W\ATRY7@KKGZ,V4I;.<@?@8NM
M]260A  7KC;ZR['?_4!(FQW*8(QWF8&1XGEF71W6SE$[30]<"2.+_,JNXI?>
MWWCH-ME>HG#<[0,YCK#22YTHG='@B8?PA6++/="?R=)D;XU]Z XRT2D1I<:X
M RBP=>E[1C,:O?WU3#\,JU6B#*.\2I%6VCAQU_E'HI4+TW)LW7C%2;>!2NTH
M*WWG&!\$$6B6<F_0^>0_-U$JXNL\SYASDGL5'"_M'(G\7M)0_WJ^YT2I'2'X
M=^N=9ZDG'?+$7SR8IR_"?%QS[OW*R-4K?Z%JGXP]XY60\3S-]%XI4];:8"V0
M8A? [7%8QFCDG0)<6'8]G+91OO OF#Q/NQS][1TO7%$,Q)E[_W8LTA&XI^&*
M1Y_\9/_8>V@ZC$!@K:Y+<_X46>^9+7=_F2&?R<^ (:B &J:-"J@LXUA<CBEH
MBZ?GX3LGZ0DQS3)OJ,@&3F;TWAZ&)/\\6_G[\VB\<;S^>]#HF55VT_N4FMCP
M1.T/Q5E<DYN$^@%Q.83ETZ#9=<X30)71-]$T@]_.@>=VV[G9S(C&P@^B3%GK
M'3*.E^->KBT_0=[R,.XSD(OB.C8T6<7-F)PW2U]XTC<,8UG;Q&U!WF5U]J61
MCK+P/$FA&:<4TEZ4*GSG=RJ@V\$7CV>Z.;!_N!87"$-=1]0(+2Y:T1=#S4FD
M^*@*G_C?G'V5XC<S??##(:]+5;\^>']@2"M37[^G]KO,Z-$LV\*UQL.YU_H+
ME]AK#PY%!B._&Y=&#!8'5;3>K- V59U,?STG<-(D\_6<TNL??]W%PX/M WY7
M+*\%COX<YX.H[(.GZ, !C>ZE/5Q_WM'-=VAQGN;(%L2/.H&A=W9W:,1CH*L*
M>GT?>R.JI^;1Y\8,Q!XR?:2^3@L%J',O9[7G'4N>7IZ[/&J@_=8J6/E)D\QO
M#;9)[;T4D^ ZYD&#S'5%>X'$[VY-)A>3NG9U^)C_?@U1T'D'D7=:SY^!QL(/
M8'QQ@+( 4Q/4>L"1KGP:EG)LK.L=_!>9*-"I#TL21_;-$,D)$E<SQSP]Y*QJ
M!BL+R*0:5DE9E4GAO"_WW)S) #':VV$@8^/W45 "^I=F&M3*:]WI8GATW0Q5
M5G()Y_']WWNI;T%P7X7)/WLC%*'#[3?+.H9Z_"QW/&\>C?EXASA9FMQ3*J^@
MG5KFM.O4-Y>P,P%1H^WT@-WYAZ]IIEZ\C1<O:DG.^5FV1-4VK?2-4'<H]6'*
M2V=D-A4'#]N:HE-#_B>\[+_E;?WA_]?]A%L0+2J@U<2W%V7C^%_)# %^)?;)
M"#_S)@_.T.6]G&C8?'H3)$1K6(P GVG)$_LOYL::NVIK*@GY[RXG-K, #-VS
MBN <U4G6;T%&X/1D?AOB_]A^&'GQT?@6A"MS&Z-W-\RH>Q.%7<!X;9/3KB?_
M87I2UCTWW@T79@3H;7SC'ZI6(6:ZJ?X;6)B\,/'527K00/18<6=SN7>>]+&K
MKR6?W7PBN>-A<@QC8;1W=T.X#J>F[KZ+^HGTW>HW7Q^)<'&H[WA$$7E4H7.V
M**EU]\[M;=47=RL^5:3U@X_Q%.JQ+'D94%VU+"LN[1.#++GW;]8-9;&Z0Y]/
MTO9",M(%3C_8<?N_=G#N3,8'1?@A*T>S'->O/54E-K.MRSL"=Z1>;[60?WQ5
MZ>&%"G 2;OYL(C1D'"K]T!#O%B^TV]Y*_J%UY\N=;>E?!C7#K^S8I?"M(O7=
MWDZ(I!-CO7T+,C[#WV_X!D1I./\T?U3Q]"8QB$@>E^C B080\'OY/55AY;U^
M7I6Z\82J$PJ'>1K'2N,)20:&#(2';Y?TM,Z[<XC(RLB>>9G3,='&+N#BMIK!
M:&50,=CME4DGON L]R12E:X1QPLN15/0!BVLTD0##X:PN6M#,RNN.*^JQ*]S
M51AV[1YC6'NOY<_<C+4\J9U'ZWZV0] C8PGSU#J;)5":\ *V_=<01MN"M',Q
M6,KR4]*A$?19K/#\(.IR(VNA>[=E :;-ZHQ&66OQ7\?^COO,N63I-)?#^S\?
MP3QXJZX>4'70(BQX#\$G1E!=.5U2_?*M_!\^=ITW$]U_Q*D<VOM8I2 [/>-T
MX[E&O8K"PKU.9I *U9TFJCOWOU,Z>%E "F"#_+@81-Q7R#F^8 A7GZ<%?*9!
MXTCR0%DE[Q) I:T\_>V7ISJ\%J!A/EC)N]I@9U/V*O1A5HAG@6NMR\<[5_.L
M>H_<L7\L.IZMFLN*QX<S1 4!N >Y(7V0Z\9:3JJ8IK0I':1,+;@&$&=[FXT?
M#NVC9_NF:VJ>VW-#2;D._@^498,;GP.7B27!^;KYWD@#/0JM+U[O[IN@S@BD
M:BN8@"':(CBDG.H&J%BTL)5'\873G24+JHJO:!:\\W2_,R@AHQ3Z4X1PQ'WO
MD4 /Q]$N9<AF?D%RLB#M0Y)O?;9J(OS1YS?/E),X-6:32O<_37JXN.VFORAK
MW7UC-\'V>J8S/6TV^TKRR6%"QK5%^7N%%?HU^\OU,X^(ND*B)<=_6-@J)PU>
M_6&:<?'XK?EC%PZDIQ=5'#]UH+(H?O?!JUH+H&;,SV1,[SJ8A_0Z_^6=L?++
MX^>O;T$>'HJM_9M!$AD?4I]Z\D;P[?\C,,O'9#(S2S3#P@+N^RA=45=)ECAJ
ME__TMIG=K.6;HR$Q7T2G#]==4H32;29*.1B6;F>?' K%PH+R$'(/*LM7<C/W
MF<$G9V,2M(#F<$;.R5Q%535X1_R)X>7[,YK&XF-,H<"R R>/3QSP)]%-'3R,
M6U?@5FZ39L/>C]T_WVHXFS/.3#DFE$ 4\;TJ]%DVR57SL*_I5";DL5M!,L]L
MNP@*:. WT4<QK3I&1\!;6/-A&OPI7QS($6!BN<8-K3BQ*0#G,$J8YQTMJ6Y@
MS5R3+8E5_.=+0V-1V4Q*F7<,3[M^TTCY]!7L)6B#EB,L,? $H5^[IRE<T]WU
MUT9NA[A(3:_PB]]79@Q\%&XFO,?/6?*%R9MUH/5C)O7IYDP<GC](E=2V2=IH
M:+>A='="19LE(LI=G5TM\I%F;4()]0,TZ8-NE>\ZC\5@SS7G&Q=>Y88?%)V7
M3HX7RD$4^:E5'_F0YM[5M[OF:\JQQRZ'"^_N&#ZK;/%]QV'YY.S'^T\W3;N:
M&CRJ]7#K#CDI+-74)VYSK.96R067I^F"YI#R?ZZ=A88R0."P-85(.IS[/MG&
MZM;NT+1XT'DDW<4[;2XXM>CDDJR97-;I)XG?+_QP& 8!V2'VQKO&O(714<[@
MSX7.0K?)>^I>V5$Z69@7#3>ZF,I-%K,6LTDOA?X&$132'@N%.IS_/DGI_CEE
M(TQPB_G[_,L_W1]("RO/7H;KB.Q]&/RQ3&S0P>)X6,9%*<^+8K&%A8\__?IR
MK;;VGR]?KMZZO#OVDLA_=H87OO1@O#S^HOUXUZ+\E[=,H=I_:LNORNIJUHA(
MC3Q+;-]9E,R["RZE';\;U(*XB1!0YQ*KB=P0]$0#G+ >AU9!6;T?10LB'S+^
M.(T4L![%-&:61:DW($[45Z@\?>Y*& [0FF,9I0_>V\!PKH=;JGYBTW9Q'B4C
M&LVP2NDUW;)U34U[KICN>37U;]S-F[OKQ"&0C$N2XW?C&5K9@MYY,KN+WC5^
MEGM\55E!2!5R>7=,Q.XPR1W*_PF<-ZZ"_PJY\_PC)$R)LQ-<$*&H"K>.<Q3W
MR2FSJIJBANR+_1=N/HQCW+TQJ2#G=Y'R9;Q]IR\8%>)__IS^-AW5](%.)!#C
MW7)R<E[9"44AD&+%V1$_7V9>\(K7WBX#X) FE3M^4@DCZQK$5 5!;?OE+8L7
M"8R%@))]9;-@"4;#8=[)+*W-6+G12V+96*XRZC);8,:F R;R=6!J054Z;]25
MV)52[OH]^D/HI-KM=F,6/[O1F"KLZ]'RB@[A?_V%GSG&Y;2 [;X'O4,$XP^=
MP'Z$LFS)6+[8Y@>85Q EB*'XG)5-G9F\]P#P9:BTXPXM] @VM9#^-#/A@?$:
M$C?U NO*$;*8Q&;#XD4!RP^#VJH>A5Q=<)"\[5,O"M#3)"'P=Q"_"RI-]L-+
MJM67,A2$KBE" 2?:V(=DN14%G@/[L%Y0+.JBUZ[*#(^3P\JRU17RFOK5::7P
M6F;T*WXPF3:)G=R"\/=;<:WX4[AZ_,>@R75&>)+!Y;<\90#V!EE.I9,^%,WK
M.1CM9<,2FX,+OI]Y5,^1?K2NTZ:VRR/]F[Y^V=VH*,=X0<TSN_L%.+'_]69(
M@+VR70(<\YD/CIT$Y4398Q:F-U\N<O?A9ZA\$?<MR//-[?WIL"5."<A+6KBJ
M8QPQSWI=OND'V&84:(4+]L=@"C;._Y58\=MR_\F"Q__M!<BY;$%>%/!T0;ZS
M%QC;@E2)LO:2_N*?$'%_KVFT8[AG@](P&_T@/B*&OFQ!DE*W(#5WO;8@;X>.
M19GS'O &UGLE;3V]_D=E9K8'"6R/SI8\>Q;#LK?A7L0G0C<BK_W=2R*!JU*(
M^7(+%'TE.$X(_"!L=?7E;V&,/S)J"Z*4;KL%\5S$+)C:S]7 NLL6R*LO0!B)
MSG_\/^%T_Y]\;U4"E,'=(.5S; ;O[G@S5O@9OV[RN$Z#L%HL,X ]R5$&R-YL
M*B>8K8.E:R11'CVI NX.N8P9J!8 7]H,Y3IL)[LK+H5:H85R+_[,5?,2\SC4
MS+U=G.]SQ@KYW31KK+=6GGJF_=J+X$,\LD1<X>G!%Z?,BOWMGBI8&$NI'/*H
M]I4-\0N0J0G]D6_WFA)@_.#YM3'"G1PBQ:EV&1L*3DI]UW-,JPTLZ%/1#?9G
MKB7 OWAP]4[8T,@+KI22+#\51LN $[#M.$!5=VF$C@-.C#&#\./WR 3H4DTU
M(,,@+R6Q[=PJ#JUM0<3GH<)XYK)::!B!;*J77D=/.R'#ZDLD,,]95(-_3LB.
M&UG5G-=5A.K68H[A#J/5@3\S6Y!.?")5'GW*_U'D6 <NF:\ZC J8R85;#U:&
MJ@I;=D3B7W(6FPQEKJ>KZ5O&V)PPS'2T-0^2%NF42X>SO&>@'9B)%0;Y,5J7
M=X2M-"T&Y+!Z.AP]3[&"$KT:8MCWM=UDOI=%E$ZI4OPC?;[[,,,,3[.5:H<K
MBS,'ER\>>3;\]R+^0'-?PCD><20>JO/EG;-*YD_)[]EM=YT-E/5$@I\G:+&(
MWU5,Q 3MT4.BM@TV%+/]NON;7_KH>TH\MX_EWGA1/8+W42Y,(:4%/O==O;C]
M8BX&1BO<@HCL./Y@,]- 4E#^ %8!"=S9E7=^,9N%GUB<$>7)$0M1PH!-$7H0
M7B?#?,[ 8AN#GJ!@OFQ,1]Z^#%'@"I$*;?>6!; .+!8F5?:4K-5H_L^61/[G
MH>"@V5@_H9VJOR<YK=N;\.[U3?8PT"_96$XN.S!I!I8HJ_'T/DJHU+]1-)8@
MNGNBDYZK;SM,1.A?U,*+3$ZZV 0K</"8X_!K:2%*#[N%8%D'_(T<RKZ\OUVE
M>/CS.?=',(6G'3[_(HVK[C\_BX^]>=K4ZD+C0*EUL:MJ]L+Y4JEO+ZH*!$>L
MB:[/4N^4JA;;[7?T7+$DX)H&ZC8<H0HPVF@_YL< )NCXTIWZ;G!E9;Z0]X+4
M(-J))O*!/</PQ'//($.Z%,4V\U;69G/H0?&D(UH!,VI0D.7?JG-1"^.D.(P6
MZF(HEE''I$:"R /3\KVORX$ J46?5PH&U<1K_5__?$6464[H193XP:%F0MGB
M<Z76Y;-Q-S\5,F5:/LTJ%'UZ\3W#_45AX+N2-YQKO=79GM.YV%]8OG 8"$&5
MOW"<0*HL>34H5O5W%*=_I"^!'(2GP#JN/;\Z+;=99F##T%0@&0T<96U!TH^,
M[GXTFVC[X&?/_3WI Z>,J>J(%YO/80@J%O-NO1,PTN?WDDX.\*!L'6J[WDHL
M8S2L;_^OO',U'KLZTFYM=)8-A 'J6G^TV_TR[ZJ2S]@$'@]+>ORRE8U+1!NR
MS3MM%($>AF\:/F ->O@_.23X%)3]6Y FS3]J:%PF/AR+3.NMS[GS;&+<Y,QR
MKT)QI=_NTX_,\B])]9J<[!ABO.[3>_VV65'W1,_OA=#AGXOEX^[6IXDNUB+9
M,45TU]/B:2X6GRTNF"I-AEB_.#7QQRSD>:1+F9F@R_2ZM?JZY3"_$4-KAN\D
MJ6R+(?Z.;9IAAYW0M1CC7^2=K0.L0;J82Q?=&\\.3R-!%QI;IK/>"MLVJ] [
MA@-5+ T]B&IRW9A;?S0(%LQ5!+=':M!S@=-#7P&.R/ D5CAYHQC:&]Q^T#2#
MY'BG0&G2)AH+KW,>XQ\'NKNWLS/DJI J[1M/ZP!O.(N32Z^2_M/!NK?XENJN
M<.V/W7#@*CO*+]^/XO '(7I/O9*W!?D*&\_A[X_@^H*]-;H[HD:^BTOV-F9A
M$XE15KX=H*/Q; J=D76MLK-3A*#=&<)01XO"@14-M2*D>IC:\:6&2H,/J'8E
MS7<;&IP/(-HM8UI!GGP?FS!&%D2%L.TM@"A6CTO\2905'?[4"$IDN?-5DXPH
MSYV1L1V9MQ!C>5!R/,NT#(E@^A5YMA3G?NTG],?CLQ)$V9X"I_!M+JA:EQ\O
MO5):Z2$H4_?KP<"9.KF+C03_65;^Z0NO/0XYX:_%.3/\AMZVO%[H$K>S"?(S
MOBGE5YXW<.&+PV#*TU(I.6V=%4F*5:G<"N+70QQQO</FR1:D?HXG?9Q1FLAS
M8^M1VV!UF$XJ)0RUCWRH6;^0^G[(2-[T89[D0+.OXLLR,_623 ^K(Y8?JH\T
MU.O\;OF;/#UP/;8>'&D6.&&RF'OP\:"95",)P(V&2\$1X!]Q4DB$!5MW^V0W
MTD$@I P9:]6B&USN3Y(?4V(%LX6K<\KGPS6"U(HH*7XI>&>J>5C1I/ME1/ Y
MOG: 1Y/F[YG <Y'>ASY=Y(7D_>U%MVUO5&!Y4(%3\*5GM%X)>E8,6FL<X-)Q
M"78,-;DVF$SS^1+D<O3I@:KCQ'>#H3BIA:M\I<%584D328IG'"+RC-J4AW'$
MPT]ROX*1![8@:NDW^=5.;;<??'@$EV^LM\UVR%3,/"WI=>W0?8\S 0>T_0G!
M+T8T?"]\@3I66&.$3YF__G*NU CC7U1\\0\H *S5FKZHG\MH5EBN*F_P$-^,
M /G,7?)=*L62$PZT<DW1HW %E-P,Y@FTUC.-"T,VF+#S:MCFUB,HF0)DCL<
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MICS$5<-9]OCQ<+[@=@';BV26RM)+K@O0T*Y#)2B\C/_ L(GAH(6!E (@BI/
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M)*O[W2YO7=E?^(HVV'>8'4<&+]KS6'-I;;S:M'O2SF7(.]Q<6[SNQ=2!C\[
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M]2B-!9J2Z.FMK \Y7,+Z;@8VB*5'T"]HXBREW72TFT&2Q2&_O-M%$!Y<3KO
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M@JZN*K?V5;()VZ.7SB6<,G7XYE+:O-"[N16'?^LNC(?\P#9$YW<4NO$J+-P
MN0W7<%FPM7,"8[7J)-Q^[:D?W1F.S:8OA39"Z4EQ.<5NI8<?R1.V$&P[@.O=
M8RM,DN)_F&__!W,Y8$F2N@K5T.OS-:KELQA$.U*GHQ*E#=QF\JK0=7%2K=R;
MB!ZMZ-SKI87F>X<1(Z]-:_Q2"GYYT^)ML!XWUM[D<X']!/;@.1 3;/,ABX9<
M.,JIQY:CNXLS@//OF[ 14OS<?"AD.Z#"KC!*G]]!'7'_]/ MXU)&9%9<(L8*
MBE)HWM21*)SR I7^N +6'- BTR]WJT+R&(*(,M]1-,&QIB^*S":K"-^KU'H^
MGO70I2&KOA"5R_SK^WQB8W@S6W1>I?]V-P=YW_7_HSKGGPI0JSNA1J6G.*,Z
M*T$W;!\]2((?,%(\A$9BZ63E0?J>!G2%"2HKD"A-84O4 8="3IROZ;-)OGH(
MC,O.'Q-$OY\O]/N VOBVL][Y8:=)/ Z8#8209K;B!..:9PDM<N0T19WSE-W]
MG:W_(L;RU9GO$_J709[DR?#A;04'J$.I?V<\.*B76I\1\27(+^\\Y0IIWL'<
MOS]]$EX?>!WQ-3?MM1IQAE^@+BA6747\V@Q0V*I?R4:<GS=S$'V\K' 6<\!<
MZ0=(;L&H WVK U2&&WQ%*<5Y*7L&903<E53D E*J*B$.3!+1/[A):E<B)/EW
M8DO;O_MOW+^7/0<QQQL O7AD,0_X83\5^3E 28B?YH";?@+ _VOQ]('_JW#%
M0.![9!I90,3+?Q(Y_\QBC'#P$4YU@7HE4X9RE#AMZ?0LYE<;X+]-P5:D/&'"
M=^M/S&*.<&!S%!YO17VB!\R)&=S0+.95P6<UBM[IGSCI,,HIC32'^G)TU:4<
MD$OWG\5\6<C\-[/8(EV]* 7234_DC*&9ZOPSG)\9,W7?R]2L?4H1K*_B<#XA
MLQASU2E LA<1L";/$JOXR$I\DDCUJNO?3L(1."02I=L@+_5>E#G<M9_%; >\
M&)[$BJ] U"QF+BM]6L42?0*2F*J-9*$'<M=943N+X2V T%_^94S\;Y/PE<Y'
MG54'_%$.^)2LTD63WR_4,?F;-D4T5@Z(/;ZCPJ4J54SH"LIMM)7!0%<"PB?#
MIQOQP(]YSO]N"I3*CFU$$=[>0I[2E#_X5:3J4/O]]$8ZL]5RU1(&6?0= .XA
M6XC_'1H7_\T<9)FI$PY:12M"LM'D'/4!#SE%'"O<?]#W'_3]!WW_0=]_T/<?
M]/T'??]!WW_0]Q_T_>^&OATLV':[V%EF)";!OZ2W$'$J+W4FP4&U%FPM4:ZA
M[^F2A7/N %HJ0-RPQ/VTRAG>OM[XD(_\3KU]SFAJ<*1GOWUD1+\643!24U67
MMO%<2K\$A=^!X(WL=U>+AQJO_>7YMNS7NU92G*V_V^]O0H_]F7__[O%K>18_
M PP,RETOAO?D%^[]U==I?<,*U\@)?32/M;CYO_0\T@+& 81+!$]TZB ?9S'5
MBU3Z.(5;%[)BO'$>BNW3K#L4<.0D%%%0.CJ3R6S6ZDPAK(,WCET_'YM[]&/0
MD8>(V4?R9GN2U5_A*P/6N^HEJG]G_ZA7W^)0F (/A>:0;P/ C2(8,UJ "D=.
M%586"(D4^=!9NAU86B,U)7+1G7?4E5 QJM_A+XT[X S(OKDV+B<OO:L>'SE,
M7=1&D;C;'^F98NFCP!4YY0<O/Q4DU7Z.G=SWA).,2\:!WGAX"Z!:P6M&YD-R
ME8&EPD7]EPI0;H)'6FN!F'#RG5E,1<3+TJ"K-)Q'7ZG+K1WA5C)J\XIY"S.H
M3X/3'!@OQ2\\3ADFG\'>*<%[[R/WM3$Y0:08XM)93& (5?$,2D^V&3071\2"
M7 ;>#W[WY?BM;NI\D@16N16(3N:UOPJL[:L<E7D=+/N8.C3D)_0YT!CV9N.\
MP:?LX4X)265@CRR;H[G0RY.RDP'07?2!HZ# .Y5KW$L'O>D;H!&9%\#FI##6
MC<[\(A*2@^U^_T K<N\IE55IUUV\RQEH7.*PY<'3CVW9'V@]S>X%%",HFHUZ
M*4U3W4Y5*,27^6K*(MFAGJ:0.(=NJ[1 /J8)SE)$R[Z U<4]] WPYQSWX)F[
M1V&+X2/]JMTA4Z\K>Z/4#DW"YMHQRG*AB(M31)04^(T>O0$<J/02QZOTXY$E
M3&A:L1N=X6^ :PT$X.*&]&"O$OI6=;4JU-$><CL%I3"E27+CKYY$D$4C-W7@
M;T[IF+<\VI)<X*>STZ?V+[NJ; ID^_'RUCOKO%)(0X4?6^9W;]%VUD^9\_7@
MVC-9?Y^[VH%Q<V(L1B7GL,#C5"8+/$$>&%;<@BN4>V@D"?DVW0DL4/S1WXB%
M&9T2 E,:;>)2!W[)% ,+:6DF'9XX?;BBA1]IS"/3$A6;MH2$3H28]5N=]UW\
MV75#^G>L(A(5'@T%7%]B:!C<HMS%:&65R;F<A%E,%?$6PY&6LZ\19EH\D (Z
MC$[B0F0>#!QO -4I;,CL1_,L9GGN"SYA YSD6ZU3X/WU>KUGUT7HE*A%4G)X
MV,[N%4YXP@!^^0P9(E:25'I"1.N$E"/0U#<ODK#GM4/3DC]]BJ]/WT*6^#DO
MC!T. 9K]?W''2@)C)WU;0XZ)#M?QMTSY6;GU5FU=T%)][[S!.W8DQ4'@Y\A)
M(R\C7L+!#H&*.-B=HO2CFZK3.*<[EZAP4']\%&0B(;\B):0W;D^7*LK &:3?
MSXU;W;.K)FDR@1K> .Q/:YK%D%CH'J^9>? 6<K^:2[NN?2^O:8Z:=I2<B@.=
MY?"FE+Q9S(*MZLRJ3E/XAYB5" 3*DSE+Z&>N@NW#>!YK^4F1<'0KK>U0=:)O
M"9EK=+W8<^8!&B?9VI4AIA]UKCP9N^+WM<;HT>TT5@AK*NO&$JN?G:B>,U$]
MH]XE2'Z34\6\"8@S6>!AU@?Y234Z&Z5S-1R!,_P(,]MF(CB/5?I@2L+INI>]
M2P4L 1UOE+ H?H+LU*=R+W62=ICSC#<[]*<_,?64-]?>&HT0Z="#-3=7 2Z7
M QX*T4/75TE5Z9-0^TXCV#)>IU]/R<RC'V(ISO2'RXAMP!)?[S_W%0R-S<1E
M/PON3POH>%#2G&YFUE]O'QE%I>3YTPIX-<8/,@<_+%)8.3'"&0.BZNH<,![1
M2H)J%).P5I!$M&+,S$#]"$_81=]6!E7ER>3QX>97)./N@%,E9)T26QP4V?UJ
M7;U+N(G?SE,5#P-37)XT^C6>4>G#"U#%GD>%_8SJPK41M4,X'C72[^K[P 5K
M>[<R\-1E>B#\$ZJ=;LDR@Z.DK+L*#[\A&O,5>:YJ593TGG1AEXI88!=;< I.
M)V<T^[@C-4_'[(Z,78\:E:]?@_NPP$"%KAZU17$EBF!V,T<8U2H"#Q'A7P(G
MQB4DU')>=-5;V2<UFE(0C/*2F1;,+!CM3Q,\Z,_:+'=TDA:=I(83L:AS;W*3
MJ '>]:EO\87"40'"BCS_>,PA+,(CFH4N($GCJX-0'T74HMO#D6"%)'-:IJT,
M8G0)4N&KB@A8.S?I=<;Q^ON?@F):LBQC#NH4NTG:W3V]BTLF99O.UO/Q_12;
M7ING:U[VAKPB!H]_MT2TVM!Q3X-\E;Z5(D[-:<1\!19/R>/M1<_C6_5AUV(X
MWHL?)O/I:>/CATF)C3H(OUMV*<>U\L5\D78IN[$SHGM'C&>U^]"Y[7-^GK"7
M:>X$VC#::^WN* \P^CAE-1.94(4BHGMR$B*WDF-%%?DY;!XT(IF^V53RK2XJ
MWX<D=?<W=2.#^5G?/YX*<MA5P$R>]#0R[/IV#P73DY\YB(XSG"G!)P/5D2HC
M\K#EC=!2-ET;"E3<!TG-G(7^9!_7,U'A$K(IG:0NK#\J42:UKP*B L/M4I_Y
MN%ZA6,K7/,BRY&W2GZ,N.^K$L >X9XGBHFD<> B( Y:E2E!*BC=#ND25B]H
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MB.UL9,6A]Q-',#3S)-]!]"XG_@;>F 4\.]&MN_"8,Z.U=(7 L?N;6LM\@E^
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M-]:]55YBFHM4;""9GT)WO-D:0H#[5]0G&1P26D,C1)T\*R27E(I2GJ'30"E
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MWC[^J[3/WJ?]41K'43W?1,K3/;V24Y0<$CO!+"<UKUQ<!)X-<&?^V+(8S/3
MJHLN--+2"K*]S"(C7^QNB$[.V,6W/< 9L(/H5K?6 7XIL0>J*5N#VLKV^?YV
MM^S5E:?1+I>.'FB+.;QE#_U/2?(B#-WM1; KBHW%L)]@:S&=_QZ-B/P 8S8K
MKL*0N%_D*JGL9;2,W #*?,4J$^P:MN,IUU+,F)=+@TH#5L[5ZYC;1-[R_JGF
M&+MZGQ_<O$)4YIL6OSQ\S=,33W*KKXO1F3+XV4^]UKOU4"7?WN#1BY2I/[?]
M6B?Z$[93"LIXP4=XHX=N$"#$$4Y,*(BJ= D:'&5+[1VGWA7N'R\ZD$A]>,%*
M",F=:QZ1Y""2 )?Y-00RE;E,YF7P-_\\A3VPOSY0,(ULS'74/-=E8X93D/]R
M]M2EJ+=;+@7-DT!3A@ K+B+Y4B:<!64 A:<-.'#-X:"G"#/B1C[E$>%( <$.
M^ 5I#--8LH&:2D!W2T5+B<>U(]8?L@VG6D8*/8VTT[G,Z_+XCC?_8(!;"0OE
M0EOH/5JRY./'B0/TC>@]HAT-8(;0>S[?!#"E=F'EIO!$)Q7P[)*=O_:8B?]B
MCZF<X6=-++. %?(EIHC>_P )0ZM8V]I<#0?!;7%]JWY0N$L.M9N22*_S>XSB
MHJG[AK!>/W^]R7=0CSKCX3T&,/O"7LS5UV76WS+,M%_TZCX7F2B6A9O($!D"
M*]T8X QJTIJH;7-3X*4)4.,(SAR/W"9J=20JT=W\,>&87G1)=4.*@FQ?.='#
M<[^AS8' )W-'9H\LUM-SS$5]8!*\"(3_Z]:>%ND6]A&VMEZD(-M&W"P9-0PS
MJZO>RQ"L$:J!C_^QLH(V\_]T6]H-FW.8Z3)M/N!M:&BD2ES9K.J8N< E*ZM1
ML[+$/MB(@J?L)+5?I4"R$GT:R8UU B$2K!*&BI! O4CQF^"\.!_:"7-)96<V
M)4%TS>HB'S6SU&.,G!-D:FX9$@5F#9TN]4?+ ,L]Q6L(:<.6U)&'*LS'U.=7
M^V^MF--O1EY #M#C/E- D_@]1(EH,!'_(/]3]E+2ZAULJ*3^_FI(7@FI?2?)
M)V[HEJ&!RDH'I#-<N>FY?)O1LOJ2:I"S%^O3/X%6\TVEYX5)K,-VXP:]&U!Z
MQ \HI%44WP>2<P&HG:1XXC:^%!F]&QP3R(_4.FT!]3LM(EE@2E?CB&B%Y3UD
M$FRU8WIQ<6$-T=L<V&9W\$JBUMAWC&B['_M;-_8!%CA+F;#EF/<P$J;W@S!C
MZD KC1HT.[)Q:@%W_%OW#AC=X!N5AVYU?YP;*IQWS6%>K="V/]F0?/GFE;TO
M$"*)K'7G :IHET2/6S=-V2?=@>>FDVEZ]4NF*;]CTV.W"P;I/06?#MB]3]9H
M0UAN$$I4>ZQ!2?%29Y!FWGX'_MB0F-JZ@_CA]^_V,P/\5/0>O$5G]V%\G>,I
MT!;:;CNXMW4@+,T[1VT"3\/-/-[G.!0X>O[&GN']HE'XNY]#?:A:<K<3:%0O
MDN^<873B8E#RHE  RVZ!GJTA5-!Z>%QGO3LYEHC:"QUTZ,KH=G^/_;YZ5O:T
MT-Y\D\-)FS-[=\>L(2X.KQ.]PMM*\M)C*;]8*GB/BWQ7D5*&X-:8E3$5S#C9
MRM=-P0'4X_44UX^&I@X.J7X.\6' *4>EK-6[X69)6IE[RO?M.27L7,VN_YG:
MO/GS@4\[O']V/'FG.][J[[+.9E]4V_:_M[0C[I:^^#^E7) S<!2_MH;(@*E;
M+ &S("A90XRT"/7A:<3^W^<<M=S"B5)NDU978$@[7'**:)%?M888O'#QM/+G
MS/^*P(DR8 83Q_VG01S,BN3XE6L(=Q1;+NHG=D,0YL<?6!C="GYCP9A_N0!"
MC%&?POY'DO/UOA,>HY)3 C+(^:=H*6=?87/'?TFMYK_[\Y^D$@D4_[/J"0-]
M=;UKB/$FQ7^&CI0*,/.?2<Y"Z<)D_0\F,OL*'_SGSTN>A^O@70V+>=>Q,$?+
MTX.WTFXTCY@&309;GJ^U3=MMV]C2G*D>=#?BQF.= -_C@Q9:.MDG$ .%I;/,
MQY2R<69@CJ,XO[2$U:XQ\KB(ZGDBTB<B^$!\,G=P<>)+_>N8T[N+,G=JFE^2
MJ=HU\N[_,1_MO_YD[TWK5._3?QYZ*G5ONEV[PM$!!\NF*ID7R;)'#JT[OO?)
M)@0Z&: _0-7VMN&8E([[+#+&CYP$J8'U[$HDOO,:L(W*I6]Q"(O@\+D,.?&?
M0?<]X\M-RULRJS/E(D+(+[X/86<OO>%IM/RJ5/H[?_9_I7DI]X.5/>CM@&8J
M)E$4RJV4 X]TC@[:R'UHX;;<.0<LIN(,.V_%[%]V])K[T+-?CY2NE!X6H/[E
M>&\RN8-X%,"2[R[QR!OP] [(9'##'@WG#J+6(.$T%9=NFFDJO$<.CPANX/JF
MJ?;WG7DW)_/$?\.+PN1]B,+7=#6"/1@.< >9:P@NBMRLRM97?TMD^$7,."E]
M)ZK4-E$J,X)#*[#CG5:OM5="+>F8>[4B0^Z2-/CM=!U?+X;@Q%G:@;^W7.Q@
M'=G!',WERJGPV$^Z+2;AN>N?>L3;^O? NZKS7X\I%<7]=AIQUT12"MZ(7OL>
M _R.73@B]!'YBPOH?HZH#@S@[#2Q809=B?O[*L2X_Z&^6&0)1@-'' <-'UG8
M)A"T0S0[+/T-<U8]]H?1D4R0^ZW;+//"G)?NP-V6BXY\<$90(3E-AG%+>VBS
MCI]0'=\GV/F1Q,[!5H<G6UUAYU8RI;AZCUOU9K';FUW+_=6VO<[?XXDY$6W0
MK/]R7B4E@CJ[^N1C+4INK_G]DC0?ZCRT?^A7RUE_76C8_QE2$XZBTJ"M(!A4
M!,(%48#,!RM5P)5#C8%VX*\O/O3^$:7>CD:] L2I4[.)&R/GW]Q265R]F)FS
M&%!\+_S>/8':?UQYR)DB:-OMD;O]&P0PVH[9C,_P'#;XA4/B_03MHP1;KO4=
MY]>/^^P_$C %HHOBK###H&LC2]]NU _]*M<[7_>Z=1A7<>/Q]."@M%_VH,E-
MU*"YR"H<DEZ#R9UMN="0Q/D%!J\A^I5)1UG [1_/*?5C(O7978GIML:\RM!=
M578I>R_!G%25Y!N6OM_G][=[+^W?+RD5_;"L]-()J G#409ZQ;(Y2$@:'E'(
MMK*@W&#C[>8"[Q?><XP,=3\;Y3,/%5:'!GI*D/*ZPM:[],9'Y>B('Z^+\4LJ
MK(XF^PB*+JFSE\2FK"%^W6=5CT$HIWB6: "F^$@-";)<0PS,PYP+C$*KDWZ>
MQKJM(3KT.>1551.42'%V#2$BVXKVM.Y80Q3<.0%/*!INYLUR.^\P:77C>SHP
M$[>&^/8;S_6?4IC<**PAON33AX8^,T#\DD@1?EFRA\!]#=$Y"\".*^< AC-#
M!V#(O6J-FPB"OY[:B8/\R^8QX&G"H37$R:^Q\.M$8=80DGR5AZZ=J%]&_AA0
M;V@-\8\F.2!C#?%1UQ=&Y+M@&&FY?H240X'6&4-N\V)K]#GXWX_AEX,_^WV9
M[ELI0E/DZ/\4%D&:EC BD,Q#T:@XDPZL$LS6$%^36VO^8_O_\1T$V1CQ^IM8
M,+1C#?'SE>'_=/%_NO@_7?Q_W<7*?+0&]!&[OA7^?_MY@MX+D1S8"S"X8G(\
MZ3HRI<Y+NPD,FL$BP<')$TTC&'_C:.?93&8SA*+34YPH%^+?"3R.5G@=,]*N
M:<"/9.IJ_YJ'Y+%;21\;8%S.IL =^7P?]/KI.%3+ @^@.E__XJ%[G>Q)OY%3
MG0Z,3TPRI=U(_K@'!TJP-;VH/R\H*!)YN900\[K(5T?Z*&.9*&0JU55X!-5G
M,?Y.N;1X.>+.'>?XS0_S9N[FE*K;EPRGA][1P81GMU?@OQ<.387=)F5]HWXW
M5;J(1=_Z_UIB\/\/C[(HTI_^H\$VA;[0;4A?=@6]Z:]R(.M:[#_7BKI9 N],
MUFJ9Z)#78\\Z#-0]3OF0G><$TPRL]BIEW%'IHE?HL_]<,M(;S/!Z!=0GA"TI
MSE5'N/LEF'@Z>PT7O]'TC$_S01=$Z#IM\&UI3LUHZS59]Z.2=QUF@>O$C^C7
MRU!(+VAD#5%KVTF.2>BN/ SZG.??K.BK".J[U1YB9#(EY10O=,W_L/E3-2LJ
MZ=;3F71,;415-;(+ QK4BY04!3;B.@P[ 0-<E",)3HB+FJ7Y,=C-H WG,G$/
MN:UQN0N]!YC\)"* %W9G71ST<\1<JZYM>/2'1V>@@9_]5MU[/]6. +VB[3."
MLR"\1C9%B)^1;J% _25>.]6=.##FBD&)K@-!@IL BFQX<Q2M#DJU$962IP5,
MKK%,X"&'@D"%<= /"TQG%TPH4\Z_RIGINM_]-4^WZF5WQ+9*T:XFV%,\%.>C
MY:$.U@Y,L/$XJ\W":6%FAB75S:%O(WYL-.Z8+03(T= A$9*?]5BT/R"\$%_9
M#AR>5;T?'\M7F.1 #06MJ4'7#Z1XM(?+#5\\+GB ^H@5R>MRN4N0-(P)-BXV
M-.8'E66O(7Q1#ZO[0^\89#!,R)P^;X;!8,U;[:JY#UW"L3"A ZG]*HG]%[UJ
M)=6H51T:H-.6VAGQ6'F#6J'UI9]M.=1$CPM\S[Q4\7M!9O7T]T:=.FJX]X^^
MX-^G3\]Y?#(X9-IY:O>-<!$--!>ZS5%>K8C4UP'&@FS@2_<CS2-@F'"=R#2K
MS>;"(T><^6/3<JGS'YL/EZQ_4T-K+7K12]A]4V;>O[W>Z/(_*-'V2FA+IU!O
MCE(MU4F?Q A>@YX%T!"+1N8%4YWXU-YI:Y!#=9K966M)4@T<G&-B$WY%H;J\
MHOXZ7?ZL:C@LRN7'(%=XJ>6/YZ[RLVGM(6VHC[T+O4(_Z!V]+CRNLME/:$B(
M $/Y]$[FE0[WP!6O3?Q-K45A1=?>),]NKGG^1FOD%_7W26>>P&Q>^WE:SWN^
M7=D"5J%5CV )'F.3Y6%07SZ#VTJP!) /?TVV8+N(1OSX&I]GWRW.Y/G@#$?Z
MNZ<+7CANE''9HN//<8E,FB"4X8N?/D7R)0;M)\YMUH%GY)"X<0WQVQ*X'[4@
M5P*CLO5$%9$/V/<<8F!HI';D5I(_93U^WF9T63W8ZRO$Z(C_ZF"W:(K;@MRQ
MM+UOJSLJ^2Y&>CY')RO/J%*YMQ9VP9/W\U]9K8-;9H^U[G8')UW%\4Z\?:;&
M3.IQ@.#^1$A\DL31<#@..__4ER?^(7'4R;WR(/$P_VQC$MTC7'BW3FZ'%"\K
MFL1N8@%VI,1I@R&"/ <[R6!?Z4U<+O?J/#EP:]DPZ-+'X.4H9^=6M;"X\LSB
MB@!W8DY_V#V^K;ICN(QR_G[9C=Y]JP,; <\3<B,O!ZY-7NO>)5C9;I=QPDI1
M*WU_0::9_Y?DJQ->Q^2S-78<KKHD1SJ8N898AV%_J@0/,!;J[P"R OPP_09N
M*X-KK>KTT4JZ5&11!5 Z64Q9#C6Q(*[<ZLB+[H)Y'QO^U(<J9/J['+\D3FL=
M?Z.<E6O0O1\FI0)SWGYNL!.T)0\>" <P+Y1#2B'N!LNYN(EP]LT"-MQ[C *D
MW]&8WU0*3G;GO 88'1SNU73HU(CA79(*OM+NU1#,+O;U)/F4?"\\H4'/9Z,N
M0D-8P(4%ZB$7PF=&0 _A&6@,(XU6%YV!&(Z7OK6[-G;WE',U#O=XI)1=O3EZ
MRT36VL5QY]?758W)^IX7F)YOKH?;;<7?^85=F!)Z0N^Q=5(/%T5WA =%=R0F
MV,&,&G0+=*=VKB'D)^:Q$^&W=^-YRQY[;PS?;?"]P-6AU]8?-G'>$X+7O0Q9
M262'X- ._XAF;<7XXF0(0>+7F"#,>,9,+Z]4>&[V'FD'VGH>6TON(<43M?FN
M,833,T&6J9><$F)/\,_339B:I1S0-"E8Y&96%!(VSU"J*]#Y7,>?F!6XH*7Y
M0FZ]2+$3DH;QQ"8O<;2DZB&H7<F3!X)< %7>3KY,+YO$PPE-B!\PJK4X-?P1
MMX$P3V+'F"-?LZ;$/0B]NQ80J:4R$D<]MNPX5<?LB?GYG>KDT/<]Y#CFX_G6
M '$Q_19N(E)P]*-H/Q?'3)D)CR9*X<-[-25:GDX=.=_(R_M-4O7=^7H3.G2H
MAT8_Z'"KOJ='-J5=Z8=-;E!D=ONAR?=O?]&(MJ3V.W1OGIY 4DO*FSC$VD(Y
M73U"N,-QVCB'V@EM_W2M-\QP.H-OSG%,74KZ53*0.;P(C?)U$Z02FZ50N;M>
M65-3*J__<:;Z'SZ"2)O\9!..VS126VK:\O[0-8_^G9_2.P\;I)U-:+17UR]=
MW&+ZTW&%1Q'JS])KZW*%N["$NX <G7>Z['L0U]&<'3OWDA 17H#."*\THFIF
M/CF<@EOPD.V_D)5W[>KDV]\OG]F 8E! K34$K[<0FB !#J0'%"6K$]RC(5;A
M0$9[*9 R\Q<S3MC_(H!H!CJ7=!8'KO:TCEW-&5D6JXWV=I=]J_F;&9CL$G!%
MEO(6"6I1XZULA7<DB(O.+B8!KG2U6>8?K;*M_ _UPF/$_I_XF \]LR]K#=6@
MZ;$K69WNM4Z['T^>!EHSJ/X9Y<_VV(D<0G>-G3^5MATYRQ)DBVM(OJ3QR8XJ
MD"%X!O*!&79)]._%+W7Y],3@NT*QJV)W4"KJ]"/&R[GQAGSU>Q9A<>^>#Q;:
MO7%OWB"0Y ^^EA2 I >1=MH"\X(H\:M6.=%Q_G)'S03>C-5E6(1/N73:7_M#
M1@D8/WF6<N5FYM=]Z1I'KWWXD9XBKS7V=8D'<\V-DE/ND"GB%!-FIDHID,Q%
MX843,T@I:D)Y,$$6T!-D@W$<G"QA.Q@:_MR&JM/R-7FEL2[I3BD^R#&=^?-R
M2D?]A37$332MU!2J#RVS56 ZBOXAM</(69'.CG>E( @HO@<D_66&,E$W*>""
MGOPLSM<J=A16X-)$J\*,6_A.%]PIFYK7:]]NR_%HLE;Y9CMD_$OL>"-^;EHT
MT1\<=0"[[\\-XNT5(<$+O$5C8Z/=M%I:O$=N65FV3\PT<WIC@-_KU_DN=@7Q
M.YX^SW3;Z9.JG#>^;R_Q'+X3DFV!^Y< H%*7L0GYNN)F:.,$F'MRU.B77*"^
MYYT+([4MQE>'EBI,YH7J+9'V0\:U%P2NF=6==PQ<?TR>/![^Y^Y/:"]X=/KQ
ME8(X$,;O&V5 ZDQES$H.C=R%4B5^H,A:.<_4<&9(Z*8PMG6D S"UANB:M];U
MV*26E/_3KJ79(>DW6?V GE_VB?G'2::PVWBL>6 -$8MK/4SL6D-(0^NG\)$"
MEZ%6LT#4UG+",3Z]G5X;DLT1R\[H)5I%J#P<))P8OD6PG[%[:4P+.F9$'3;Z
MU>_1MOKWY$1 RM;?[3>-YMW60D#T5G7".3"23VZ#=H%90%E/OCH8!ZPANIF$
M^Y7Q!!^.AA?C&@#57]<^+)LB=[;'K?SKY:=[XV]LTZE_G>P1,7BL,-T4(#%3
M!'-B,MV['-.Y2N&Y"4^)#H*JP=R&"BU@F&C)WVI!+*AH>7FI_W>F5\9ZS\#Z
M)UU/SJIQU77K?UYHTSF2MO,?14A:,D8LT%Z2ZP2>YG=V4F2(:/PW+F:!/U.I
M-H]1$ZD_ YD_&%<^0MOQW@ZR99/]QAWW1RF1X=O*"_N>]P9%1I5V!WF'1?;9
MT[++IW]>>'T/(DC.>$G54AU+H*$Q3TZ(E:C_8G!+<GJ];A@./HBTA>Z'?-AZ
MR"*/T8E"@-H=TELSL^XQ-V;I.0U_R T(]2D):(S(^69?-TSB:(TLE8>$!9]S
M0D@MKQ,:PBU=Q+ I]#I*8H5(0W@(&J%($_7!#ST#2XL$]<+Y?E]NU8UTJ^ [
MN&=!+JLWBZ.V;/EQ9!;PW!CGY<I,>^/\W9BI+<@!-PEU1,=>@TU">X(+0&ZG
MQV<VUF477,,S>L9X5/^T(+7A_LU/J;2.TT>B2E9]_=DG=GZZ4GU\X]A/B?Z3
M1+?G',2@;UI#W.B/A&0TA+(B#%"Y4"1T@7K<,Z/Y) <^JT,_'+ B[@9("14+
M"[0IQ<N#OX(;+Z^86=R%W19.A;)ANE_Y0V[9-2=JH.M9*UM(-D-X/A!39RM2
M5P6."/+']M2G=%%40^!ERE  7[J[:5ATBX*#RJ_Y3QLW#/WZ&H#N+/F$K[0?
M":F==SKL6U^5.;W;Y%V,+0)*@T/0&@*$;5:D6"2P&[GKN$$0)ZY ;R<<Y>LE
M_M+0[U8SCS?5N.=HTQ6>KS'*XS8/AF4-F 1YVEZH?C5L4!+_8S#JI.SI_%%_
MOQ3"[2[L+&EB1?"7F(()9*V?%)T3_X4^",K.F$>':&C#(2BAC:A5,\H++DGS
M+*H;_BVN>_'IO?E=C^IR\LJ+WV[Y?/KA+>)A>,X,Z.S'V&I*/,G7*9ZUDQY(
MBO.2$<,,/8C$M&S+D>K&DEEJK68@R9$_32\%$[B;HZF!_6RQM.D?S8._<-)X
ME-/K.H >OV?0P.2;IZ63_:"E:::^OM,[G@.[_@&=#?M$ ,N8<)+4MY$>:]86
M[B6UGZM5AV$2R&!K/HV\<X>#W !"AN=9)P?#/#4_K"$N-S1D. S1WM9.W>^P
MC5NZ&^GHX#%@4)+?<24.@2DG)U-HU(4) ,--Z$#&T%711_#_)NE@R6,KJW[M
ME1OP&9>%VYKX"FL(A]=#O#!9[+;CWOZ+OK6O1^Y^OZG@()/0]'#][="?:X@.
M%'B@4J3X;6:)IQPIW$]0%;_X=^7/4WNY/4V WT-<I>EO&> >KBQ.T<VFW,9/
MG! 17M(\6-/K^^+:WJH);/-A.\-<S'N*2$,*>/=M!B=2ZH6VA -G)[O=EV(4
M9VS)K7M$>X>MKG!23WIJ=UD8I?)17+\VDM2\ZWUT&6Y7O47PBL"E*F*7:MV;
M$,,)T1N[L,UT*F4B")(.%VX@=@_BG2^(<^DWG>+7$-L(%]D\M9\V@X1PWY+^
M%WB!A^/%T)=O2_'UEU\WCYK*IGJ?_(G-7CRG0WE7%\,</1K,12RS8!?$$&=B
MO.F;)@G'Q:6MQ_ ;V-2XI:6B(9,RQLZ@0\SI((M';ZW2)KXS3:L]@RQ>%@=_
M.6R:^A"8C.M__ZIT*\%#X >O)TE99(LUQ"V,<B_;>*)3T !:\RU[[^P=] #U
M'/BR 9!^D]W&QSR?@OG,55_HF=6+Y]G$=KFW_NFV&U9N;X2.8VXZ/2(!CD[@
M?J1(654P)(;#++L,13-?^,>7C8O&*(491U.JJ LS? :7%-\LQRXE2'$$C30:
M7Y2OP#=J";2RQ<G57C#M&GTU.7N?\2@$1\L[JU]J:/B2)_:!9(]PG$"M>+K0
M /]3\%@<@PFH'*]AU_-8P#J"-1_#]DNBWS1.U92%1XZ;ZM=N7K>8O^450(XE
MG*UCMGRMHK[]/>>N(,=NF!=F%XR[\?IUG<.D91MR,6=N;K1G].OJZM?I#^\^
M3 >5]?65%M73:+3ZU)+7#0VOL]/W&;*3--U*GHX>+7()][VRE^B(;X)D&V!G
MG008D\-8\=/[Q,W$3;/3^X$/-2_PD=AD:]R%X;MY1]P'_1IHP[=T^9NS2[S\
M;[_U"P\R?3[(G%.<-'PC+YWBA\JBU)%YQD)'X@0*"-(L@AWAX:PN,Y(:49?X
MGB6W!.W[A \BM.J-B2R?@2LG@83>5->S4'===+!B=S[JH^AB99!+YCU^<27L
M2H+.UHO9\38_Z2+YR1X,$"+50Q[WX2 75O[^CJE^FM"C"%#L!HD6> =!\N O
MY#:"YUBKUIR:WE.^^H5:?GBJXOGAY3?/1Z[37]<-$Z1?IF+L7V5V"JT"9OI.
MPW$2^C_BY+0ZF"V)DVK_QLD>-<^Z&@YY!][6M6;,1 YWKBG5-V:N]V)5IK_.
M)H];59ENY5^0F[I"'=5[Z-K$$0K@S!A'"?:,_7*2AH8I-&2'Y/J? 5^N>:71
M-2ZLWRN(H>#@$_*JMG[,W2@EN!0[.YK ,^/N7-YAJ/#M@\VMFY[=!%=(VAD>
M^ [),<;&=C"8[\19:5M#I$)68"E YM:3%R$=\$AG_L'FVN%:9(+*ZL/;!FKF
MT94&QHOEGP<J@C\G>Y[DR>\=K?1VO,06_VV?@_T,-]G)CX2DNX$B2"9%DL@M
M.3(:98(6QLRA;FQM9M-S@@&_EW>"4THCQPDH<KV)!-O NM&LZ3TUC0#Y(3O+
M-J$=61C8JON8R8+D=YB,F^2='-4WM-=!0#,87]+DF."HN-X@3+@T82M(!OWX
M[81]!HRD!9%R1?%H^3.C J7;S-:RPBG;@#)W&ZW,HZE=F20_ATRA_KMZ5%-E
M :1%L 'T.LA206N([:VZ^,[._ V >=S=^3QLEY<^WZO2M^"[.SK/3Y81&A;U
M8D[Q!$[F>6C592/?[+9DI727RY@$U"82.YT$.$WY"59 2::ZN3@6?<B?).<'
ME,1&<5@:HL/BG&7ZUCGL!DC?L2Q U8R'2;G+V#;7[TLU8.K2BJ?1J=03F[-"
M2V?1._FH"16H_WF32'(\1;\Z)<$"='8MJFI)),_PX%>4%1+?PTS/2LZ<9R@\
M!V([P]TSL\KP@XN#/3/8H5IUWJ4N1HCA9&=0X>FB%.'.W0-+M-Q^]YV# @>5
M!QL$11TLP',)W*OWJ-G3ETU"0BS,.J/F$Z5S[B'D8ML[E:S9G'NEI7,K!]W&
M)\;G+?*S_9X[[*T//SB9/E:J]J:KYJ%MF-BG!I[[8,/*7\*RH'GU-WL::EIJ
M\O5S'<H"/MK+==.ZM@*,C0/5S9>ZEG8EMJ<E/PGZX<K%BK870=).?&WVO5)@
MYQK"!Q4+*0'O(<UA$T<I+X"88A0G4>N]UG8ZL^4YGBF;9&5O5%D\;=@BKEUM
M+?C;QN1CA*M@)3/CVJ3C/U?6$)L["'= %L>2,CD$28?RQWI6L/)+&'8>24T'
M2.A8VHDM[EJ!Z<,VD0V7H3D[=%7N)/?KW/=9%V9O_!#VX]VI,VY&OZ+,NU,*
M/=[?NOMG\*T'F-LT$GB +%*L/ X@NQC):@Q>+.!T'D"VLQ*+.*@NNJ(GOOA2
M;P=%T3[;*;K2>>'KXK>NP.!OK)+9T96,,[O3_CI0),]#58_Q2$(+B(F2,H30
M4#]+X1<I"26C!U.V3<UNWEGW5.XUTN/WVBWWZ8\OVQE\K4UO]XV/<+]Q%>JW
M.I)PJ-66+]D ,OQ7Q?0#I5Z/)\D;/<EG\-PXE\%>V"&P_7@!W E(7;2+KUE:
M1DX8)<E;.7"=%.4B>U>7XE\N!K\TY3D+%1T^WBTWYE4,>.@\;6NH:TKV'S3^
M[@?)[@=4A *8(L;HP_Y0;@WQ&VY= &8SNQ9P*:\,]%(&G8L<BYI !_>1A1M@
ME6Z"3R&5.3-"(V^-:C'2JY;%3'1-GBU\@D!'\QDB51](>B<PT^O>VTE6@:91
MZQ<(5S@\[_G.51XMOR'JY2SS?-7U*'0NR2>\XGMC,)2L^6YQ^NKB\WC(?X_,
MW@!"32/]+*0JN@SB^#5M^;O  H#<J[D#) ,_NT?U80;7X[5MU&"9A9QW.<?;
MF2/Q>%?W'GJ7?L+J=&90Q$RZ],QC_RE5\*>D+S"=DNL%RX2*HCV@?#E,6UR'
M,/ZRK(1#^#LSE0\Q 8YZQP?0AOA<KHS_4/_,O-BXBV@>WQ/L<_[I-WKC8!AR
M0V"*9F[1\X/:DZQ9<XJ?> YN]#*\Z@X2=Y#:#XDT^%D=F'7$H^!/+JF-\H@N
MKP,6 3/MF@=:JD9^(>/<0ZA*'=:J[3F\N.7W%A^R(WUU,J[-%3+?+@>E7"R]
M9JO3_[YZ.W)4!B+"L_?%>)+4C:J"S<RCQP+7Z>AP80 Z1!S6/#  (^"E^,:>
MC(A0W[_]L]"F\8OSW3FC>:89AJO8";RQX]CNH1NTW44CQ@8.Z>55:XAG9R$K
M#'LF^.3/7DE=#Q2H5;DP$>E3[ 4Z];)H5RC)ICN6<;7] >@B'[XQQRGN-UHS
M+;'VTM6W/ES+(<LM.3.[+VXYR7F *62 NO4+V<^)G917E(5.H7% X[TLZAQ*
M%E(";S-Z*I\S92T]G;E>]2$$!_Z1:_LF<NQ-R1KS:N(U1.[=']=,[IQ)-W^C
M3/P#].57<E1[4JR]UQ <3!=ED\BF#A!41CS#1S?K<.4LW;).CB[H')P.L.BG
M_?7CVNS]N-K_C;TW#6LBB]I%XXB($ $!!2$MBM@BT J(,E4KK8B(46EE$M*(
MRB2D49$@(:4BDPAIL06%AJ@(B(B1(429(G/;B,P@0<E *S($JEH():E4;J6_
M>Y[GGN?K[]S[W!_GQW?Z1P5X@)U::^^UUOM6]G[7_4=5W*Z&[S9.:W9<C@,M
M@$H<RQNTC)*7H&?@((E2JYLI9V/&C%92Y5@*YT-T"[8-BDZQB15HHT3DCIBD
M^;YE9^T")[F"E[/'[BGY22U,"3:R[)V.,C_0OM['.C(EGX#E/TDL*7X7G.U?
M\'0BZ\B[\>Q]"9^*'H^\_]V86U'VG)LQ,3T1X_LQW2"6]BC3,T)3\RYD]G4?
M1$;UFJ1E\BNU[B)F/ 7R)[Z;;.8M\CU9Q_P!ZI2D0K8'L]HHA-JPQP9N'TX$
M1)\1#:>%;K%1<W08OS4R/J+:3W<K\7:UYMH-)EY<\>M#AAB/MG5T,YB$J<;)
M3M O(AN>>=$/044I"L*IF?1Z>^1"*>)Q)"/,4L^[ TIM\4ED;KX%GB[]F1FS
M==/*[F]J."\%!ONS-*U#%Z$E6!NE@HS_HW#,DN\LS9)S@'#+]70_: ;5GA=%
M-^=2A?-3;)D-8M_F.;*ZJF^TI_1^]I@7K-ES+],^QW'G:)-/U<O2\9&+V6,W
MV5%UQB,3@^Y=;W9TR.(8KS \[\3_C+I -=A*/,4N'498\%EP:/@@/!^/&3+Z
M0+QJ-P-K)[ =4-5+H=^E\8W<VG0I=5:68]8^'&/^9C"9RUC;?S@UMG#"R7G$
MIWT!7Z;+LX,9I%Y F$I:S''?&!@Z8H)DP3@O@0-+VP^/^50B/'&=5H?)S0QS
M/_KN@N!#WQ#TO'4_9T3L6LC!-#;VSLI=L!7=LBCUO2N*=,&5]_NV-9<[,$X\
M"!''+9,$N6>XU'O]EG&K:C9P/O_<2H+\% ZGG9LH!O7:="ODM;#U)565?AS2
MNUZ_ :%*RF+TBA\B;7O+!F<_L^^WQ^@]YPM:U-]ON+OO?$;KNFM_#B'LT<>8
M'MT<N0WO\#/PA-=0-&J7C)(,77%.1'Q'?C*Y,,70A*;SQ2K=E8X[^FS>YI=,
MA!7EF.]L_. 3VSXDXEY?M^DH)1</QQ\H6F%&RBQ^B-%@-UUCFE/\GM')6%-Y
M1_KF7KQKMH)PX+E!4(8WP\^IL7_'Z:W#T?NU=CSF%?<M0G]0;KL A;_H9Z&Z
M%7N0V\H^S/@X#4C%Z$"%F)<ZX@0')3&T&&]/V+6EUJN- RJHFC#N<KC!@4SW
M52:E\I<O98[O]7?F+M7TWOEKX #5(DJ=?#3#:S?QAJ B73D?G_ W<.<%.%*D
M^Y!NV-=3G@J$"VX,@"J8.?86T*238\4?-C9]:SZ=^LA@1KW=OG4A8>Y7GSD%
M(>6BG\]7[>/E_0_#=TQ/S+N]V)<J"T$>P #NG09J4MYVI SV;,FVO,I8CP)=
M-D1MI*UE9$-M>M/^+FOS'=HV'^5S?8^V&F]171^J[YLR8D;;F!$3F,9+5Q"&
MLJFZ8$,S"SK.7,EX[\-+H._#><AF%JI=T:PUS.CH0E*=^ZR+ZQWIWHD+ W).
M28-C^SN_AJ"GXY?!%,Y:X^OO@R^O]R$E<I:[R3V.''@%5/[Q7^Z,>W@%^"^E
MUT C?.K.CZ&L&=0 -RJ(8XN5S@SY\Y[?F"OC_66.E^+)$5L%X=@]363B,IYU
M7??L6^.9X?7/'VC^SY?G*WXG6J GXLGOVK;RY,'@%9OY#KHZ3@?_.,K "?Q0
M/!T'GP-)R!+_/$_T4) \U8HHWW]/FP^,)GUBU@<_O/%%[;_>[O=_T/6?/FFF
MO'/_STIM+A;#)#RW3I''#KTM>J<@L&_)R5.;;VQA[^KZ1\F\.[ @<;#5?P6<
M=7U=_C[8,X'N+*J*.71MD]^% [6]:@=/&1_53WUXLO6'JWO>.9^J?K)EB;+;
M5WPP$,),XCTO+)4%@ T;>*&=6HB;D-Q&BA=4%MU$HR%Q4QO_(>VP0!R=6.L>
M]/!S]&WD@@^L+JF_\_CW*B<#J*I&)-EA?[U_+ERMF4+EWICU\4\%'O"$.  9
M'A4*KO*$N8"V@G#:<@62URY6:540F ,8L:Z?KB>,3:YUC142KQNM@6<2Z<ZE
MZ&%8-KYSX9&3#E299])+MQ3Y;1[URCD0'N0]*!'U/L.9T_1.N;)US=\]Q\"?
MF,BWN5B2F,5W$85W(2Q1G,,X@X2\A.;]ZB';9OMPQU7,D*+0[('T;G:*=9U=
M2!'K<&_MGN7YU,!M/77WK][5%(,K\"KT808QF6DD7J7H.RT9YZUP."H.MY(F
M0&_CA3.IO-4.OK!!"[^HA:J)!#:-F$(S-Y^B]@4(;&,0%]CH9,1JKM?IFG-W
M=H:>9A_.?=P>N):7^*?N[RK-)W@52NVNL!G$AB12:2 F+AP,XVG:L-Z11"[)
M=,U\J_>;LMG)#@:%(4Z;4P]S=(<R_?9BG>YU%;VE:'%+!RJ5BE5"]$A[P89:
M'G0,N$*I;$.U)X59#7*R6.]:K:',A=$QHDY. /3J-2;YN;SKJ%^^JS U)\V,
M#.MD):+.].Q2:7S,HWU%"D)PZ"562+S[0(N45:QN)W0.!:E@D()PE:(!G 6N
ML58!09W7]8]_2H)XPOGXBY1%-&V7/IMP%_^Z7KK-?9_2O'LA44\GYO5\\@JL
MOS,N^2 XV1&YW>#1+:;-5]N_GQC7DJ!#EL.6XK-U<%&K8 5]#S0F'KM16%\#
MNZ0S5M($?DAXM#C.[>AVSDBIV-%L_V_!E^N+'&[MVS18,3X9:6\Z\^@7^T0"
M>@5?CU> 8.(B?,@#8*@ ,0U"M6RE'G!14OTV^EZ>O,C!#!:,GN4*W7U=8<M$
M3!\);."?J/MI?XDXSCCN8..@?P_=I!@9:_8I3'O1'K"L*LWH8=G[B<S5W&FN
M1+E;:9FA_ 80R"8Q.EAE\Y)[(G5?;X@BN1Y1JQXN9AG0ENR#]:;& HI"R"&%
M)X=0SP&ZZ[;LW;(319$/&_G;+EN4FV_H*XW*#919'MQS.<Y4NAI?BZ[*%F_N
M<_TSX!GJU6I*@L,9L9KWE U>;$8V]<T!!BAYP'KXWOWJESW/Z.%BWU2)O[IQ
M;#MM9E//Q:_G*D<CO\3]NK4U9895I3+E*;-BC  J<\!5%L>EL4Y%S&J2?<4^
MA(07/QVX+$CD7%U:54:+;\ V]_Y9-4C_5KS"?"QO!2=.8^$MY+SME\HT;1RD
MCZEA*Y4[+L*432G&@7)F"X5/=:Y!*++UM,%7V I8[Z:3/GH*,8$WS+H#1^$[
MS^X]#LW3[+DH6#QN)Y>FCJK.I5&GND+XT=<O)M-=[2HCQSW+AH>3>U_QSI*3
M6)Q.=,TDINZ Y$+S8FML"Y(/WYC?!Y<*&MQXNFZ/_9$2,7"]?C$B^QYNNS([
M&>[OS<<!UV7.IU*AG(*'"Z_OV1D]SZJ==N&SI6'G_F3<1/0P]2-*-]*<6W49
MFP=0-3A)['\K'TGL]>^J)Z'.2.>H^H57EUQ/C9M4,1\'IUP(I>]YM/CI;7Z8
MK9Y9#'53)C<OKC(#QQQ=\U=1=:$@D4&$!IMFDO)TN^C:0NKRSP-.1E#1=;IE
MP=#G/"-(FE3X?>: _HE;!5[[EN6FW7FZHJQEJ:8Q06VU][UD%;@4=YTIHA1!
MM)17 Z<LK^L#S7AIRY=ZI$IY"%DT24T0D%"UT=2PN"7B$_FCI.5/L\FHJ:V^
M14W)T(3=%,.J]UQI[9XGH0N';$^<X$M&2@K]U)W^>NN[PJD15DE49AORT+ 4
MEF<#IP5)I'+31G(RCV/;S-;VG:C78$GC(/\TV.P0XE(:')TX>G" L25T@7)S
M!13;$G-V_I?]"Y=*HHJ<0VW\CKUM;'I= Y8#82!BB]/8"[( E RKM';JH_J#
M]8:H+WRV1%XA9AK0=>#.9(8^6>RX7QP;$Q4K"=O7->W1-,A/KWJ^8\(G/R2D
MV-VA9T3M0=2F<M=9O:F-N.G*%!N+Q^#NJ ZW5K ">"6+LQ3[L\.B D XL$U_
MN@Q6$5.DC >&M9<S[P6(>=KO1T8^5_L72(/]9>[="0FY?<GZP;_=_H78=UD)
M5CK:1MO:_,C8"E>X#5-3/IB30A?Y4R.&\C+ZL@<T!4%JVYO1?F) XI*"61&G
M_,#]B6W[>TL'XDXBSLT^2=<EIM?,UC!_A.XD/,Y$'*L!:0$^1+C\E_OR))XP
MAU4^]LI[]IWUC*X7ZMA;&P2O;2LPU)_X(B8RC]+=Q=]&^:I:1>J6GAX<X)O/
M\(>FX\</9MS9LO%PCK08-].#T:0@5#$E*I"S]+[\(4.;/,I,54*J\4C4=L"C
M)<^T^V))\$6R-G#3.AD/:HW/"[EY:6*:]<SJUYL?A.AR0VAE#AD_ .<EZ^2Z
M]XE?%N3)3HL9?U @#PIB'H2N6?B"K83%7G0R# JC6[Z(F$-%TF D9S3NPJN1
MY3PDY@'"]>W:%E5JL"<N[)#?"7/M)B-#).R\P[J0$G6SYJ:V:FY*%$5]HKO#
M8:".C:['P9V"@*D&R(RQQFK;J:\R,_H:^3T&">L5:&(;:(!_^J!PYBJZB:5M
M38EGK$M'$?9)F)QJK;YCOEF??'W./(!N_JBM:)+?G\9*YJCF3?/MARI+JBCC
ME/]0_G14GM("&P[0O8-@^U%>D[LO'G]%(9D^-NQ6RX01DSY4930GS:)Q["VG
M?##BXCT],KSM1)=K=-#IA;FT6:GN_'GSW[KN"K?3V/& <)B%F'A>YP4)UF-O
M!UDJ:*!8LD0<G>Q $I.3C7;#EBU$?7?8H]DS;ZG,%Z$>(AMY35SR&4@1^=KG
MR(:''$P?=!1]MLWB'O,3>+]_?^[6]XYC8A?)&)2*J;;@M]HJ9RD((91T)QTD
M5\Q+RE;VN[R"K>\WQW21PT3=":DVDM1@IU-0F%\R[#>1O2\O1_3Y]-)0'\X'
MX8WWUI$NZAU]4FDOG0F[8*HX15FJ/!,<CZKWXH.JAXFBI[I%;%74K:L4,V:E
M :KTR'QT74WOL[F2Y7D*PI'^.>K*"6Q]-\ QMYB)\/#OK3V>_Q;@&F?Z!;KK
M5]H_E+?6(T3HM@]B2IH:%S.7!#.L$ L'E2+4J@XBIIEKM]@950A+K0Y6=8=7
MNE\2>.L%>ET?E_[BXI#5&E)TR^'K^HXO@T(+/(\OOZ\\0,YAZ;J6^M)L1R]=
M%=G7N1WOXU@F\%7:+ U"L&75X<<N5<N6%3S\4%7P*&1GEM;!@0&[L_D16GJZ
MD\9MZ_<0 )R+#4H"6_.,81ZJDRK=#?':J.L9W>!S:B-E38@_09[+,*95Q\H]
M79GDP8](BDAU Y17?'Z@U=[1]U4UD!0QYZBV-]9QY?+GO9Q24W+WJ<$^01C8
MP&%5"N+!4Z1UV" /.L#FSS3[:R(;9<ZHI3R_UD],2;Q,264S$R_.I/!5DHW6
M4D]!;<ETY\B00B1=/BV1V#!7-01*8VJ=16FG6F4'DCR\+(I(_6U3'-E&["VE
MC-)8"@BY4PU03B-K!</0ZV15_N844:SFTNI6CDUI0:X 'ZOX4,^$CX*0;"DL
MX[A) H]75]>]6+V_U*)Y'^4.0"4C&\>FU/":;\SKIKO*R.@ZIC>2(&IW<P3V
M(L7"CEA/B-2<HVY%SIOXU'Z0N@:Y)%:JEKM5O:A]D6UFZ&[Y3=J0CXWSJN7?
M$3L4!&2W);;2%+(7CJ':@E&]J1H10$(\V\#*)$GX(^XKR\7H%HC!?8BP6KI]
M:7S?</MF_8&7#T,&!VT7-')T;T7:Y.7&/O;=2YV+';8W=W#[^4TW0WD&,HAW
MME,+^QV$PLA3\[)=2/_O<%;C.$[<'.U;GE>F6$K!&U%D30%2Y-^-]AW(.)H?
MNM Q\DOY$\DOWBK+OQ_.F=>36N.H*0X0WN65F3;[68V:-G5>XR<QL>\^1V\?
M04 QT-JI&T;1GF.O"M4=M-7V"LW3+8=7?0G.,^J?"GBQ\Y=)_;/W- H#CG1>
M[ D_@W1B&I,*PJ_V- '6'MU E1_X=)_8C5N_:1!=XR(%Y96\ ,%5P6JZ([RQ
M49^:7OLMU-N8IX4,0C.^\,[4(J1-Q&PFJ09+,1)\^+8X34M26>I"+K.KOQ.W
M,^6I7XA=5"*WX*NG].#JU^LI5T@<EU;R"K#A1T XRGRG)@*G2O$P\T64IRG_
MT@.T,'O4!\HLH3Y##"VT/3F#4>96[K#1O4O6D[_/YB#6@(9:JEK."RI]3VS4
MLM\&(X<.IR[8/P$;"*#P-PHWJ9$Y]&5TK(6$TWK(I65&F_&6M[1R9BW"$PXR
MHSH3FUHG']',?O -=VM9V)QJ_#G[4_TYUYZ/@]/;/(^SR&[!$1%!,IU[\7/1
MTG5X9HADM('08<ND:F83.+11B-V&1MT&J4X",6LU.3I.#!C2&B6;7V3VH\='
M_2[%"E9/'@UI_.1E76)?TAM8Z*NY+*URQ7?? [^!R"X2YG%4*=F"HXHWMA@;
M''K+*WN"4*69^+M<9/PAX/#:6$.@]#8B$'Z(;09T>8&=NNRT^J5AEREIM1ZB
M&J(ZDD!W%5%UU4H]G+MM[!W-FI\K".&([9[<4IOVL.&@1+ZO9UKI]+.-X,LM
M2U"\[MP%RGFH-DNH@JX!I9A2%Q1L.,Y83E]&6LUF6(8"VL!98C)O?>G'GDKF
M.AK)LZ;O- <O,PET;_;$3I\?[<Z6/GA=B-QN&JA.ZZC[5!:SLR1(^_W$B8=_
M .^)PVQIA+(=#D^81UD^1[K),E00SE"',J1K3_>$HX[0F.@M2R30H?O '2.<
M"X:<FTYJD"^MS>UEOS%?$AWUQ#TZ,/_=T#Z3CI'\Q3$XYO !(G VYC)EB<?M
MQG)H"N1D-3C:MNG/7/\IN[=QQ+Z;XT=IX*V^J&:0DO$I?&=3JQ.>E3FL*6Y-
MNGU%X<GW)[W4$G:H@2-O-B$>TAC\SL[BD.LVI6*&20=@:W0M3&ZEKD5\ B+O
M=\ "L5Z*TR8DVKTZ463QE&H,72HY7[\N^XM[MD'(.0OJQ6$N)YN_^\%?'PIV
M$.+4X4#IK/P6(+S'@PXQ$P'.X53(0"RXCIL;2UR%+"8M0HV1*.@/-9(.8OH#
M<N_;&NB-DRG46E8ZGDV].CMD8WAL[5S.!ZKW\:I^FUA?:SU^X8.0H,B_>"T
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MF*@1"N#,YTR.1(-X_?*)>Z(2=TNOWL ^&YHD8GGITZ:-G24,T8T']S9N=76
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M(\X%A$CF#*D> Q86U(=SX#L5Z3LY%Q2R<%3E9XFMZ%>>$T/83[$^.V(K=16
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MFB$B-3"Y\/<KL$?LS5PO2CQ#6A0QX>4:Q CB(V(79?37!Z4<4@A<JV<0M&0
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M5TY:1.8D^I<&+FWSP:;8<$ #7C36Q[(ZH7VRA^)8F_!E/FW)4B*]JN_5!2I
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M-RFQ1WPY_XA/F^2<S-'KO_F]V__"CY*4XIQ^^(=]'T.6ZVY2IFKG!H5H@J\
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MWCRS.MQG?]WGZK$K2\> [CCU6QOZ>6$1^F-F7!SO^.U$OV_&MM>+?QO(]:1
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M"_39T6^"AWV]V%E8UI- O(Q^N.A@DB3E4-.$FV46RB3FUU2_'5$X?27Y*'Q
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MIWD6_@>[UH)*V8:XV(4M5')"MTRW(1\+J>F,P*6MYG[E+T'C2*XCC$>Z/FM
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M7.K-)]UI,:];+O?:F7\S\M FT(4MS.U+;87.OSDW;/,HU/U+UW@TUK_P]S.
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M?&BXE(ZQY!1NM*O<K?G>J0JF,/;]&'0FIOLZ)G"-W^60[OD5_H,9CKF2/^>
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M/&,]KT@;O 8<R=UB/5=UM+%U6, 1/O?J/7F&+:G,+&QEZ.<7HX)(RHU?6QM
M"?<\ZMKOR@[;]W=R<N\\K(:I3:JZA,30X(+S2WY_,P=J4R_7X';#R)3+:UA*
MH3)P7CEM&Z),#.:XTQ'O%VR[6K.SZ*MZ@C")926=F9+1ZVRCBA!I8_*%YNF+
MX1LN[K4=<6(8YD>U*N;/)+U\=RLYY:'/:IZ*GL_H41DF-M=0_Z8^[%>]7F1@
MIU#1:BKZ847NW#\BL70*#-3"KQ.!52M+Q;'.DZOW:K*?<O*&T9Y72L"TC0OW
M5<\]"]F<N:$V&2*;<HQ38)_MEHU\D;@+\\T">)C\4^E8=^3(HY8^N^ROT 3
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MH"URJ=O]GDP\F?Q3Z]+7J:B_UL\C?8H*/*2/:=X<S-C%GBAE2_MS]^\H;LR
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M'-B5KUYZR[\(17<8C4X_L$QV2\1*M0XUQ*;8$1C/K=:EZVF.HJ>F?WFV(V_
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M%6&OW=B&5*1P6TJY<3K@SI%,")F\P1S=N?MSNO-DAB.Y:5WU;'1X'_<(H^K
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M*HRMF,K;X ^,H/=S"#GVQ4F,)ML W"SUZBT$"YFA.=2EQ]$CBL.,W4*HMYW
MYB-DU%R(8:Q?']TG<,)PKMIFPW:2/=0;4S@WW\-0_H#C;42/8SI.EDCYN@U)
M5CX(#X$E NQ#C&U(/VX6R5N#M#D<R YKL.P -JEI1.J22!= )UGJV(5'+5,8
MT?A'X8V5&V+>]LBOI)BR[)R/(9CA_?R;ZP@(MNM"$2\78,F8C]QC4SOW.YN4
M#Q"@LUB;R=^Q5E[-8#JR?,%CD(9:C*3.8:%SW_7S5%L9KD,E7Q75)TC#G/*;
M\K034_F_ZC8Y6&T$<!NZ1F=,T&%K+UDGV"Y@  4FRD: WJSC:$P36,BR9JL
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MKN6&2YH.ZPJP2L,@ Z#ENBV!]CI?HCGXQJV)GC86[,K'-5ZE"1O^H6SS#F&
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M2DO9Z7UXW==_0)QV"#6+B9+ZPWG49"%::J/Q(-CNVD'L5"*%I+!TK+J&O$E
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MUF)U?;)5YVIN@<JRXFC#);TWLVM,UT0<7EX0#//AO?[7IY-ADD'YN,D(PTJ
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MZ5.T_HWF9DJ+:SC3Z+6ZPC;L>/.?.?=_!17YS*">GYE?:OW;Z;]Y+WE4(B4
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MGKY=3TH6(_3A:I8JK#^O'Y:*=8^Q'"N\^8*_?;RU%_"$W@Q4L.,X</9RX#U
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M=?"T(> $O@MW$*WW>6-5QI5/---#H0.V0/MYUJ4>U"##+5#C#TJZYS'$W.[
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MS(L6<G.+-[+2;N.W6Q:^PWR"-\!7%X42M8*=N_J%K4D3&A62;";#3\-C3O+
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M"\Z1:00LRP4R[<^I$=XN'(T$--@B E%M]@].  N27,<3#V6LIY&E(]I3UZ4
M!^MAT\!72TZ4%3: N.)$'HLHB-&U(@36S<JZOTUNR8)I,_D$X!$7&81EP7"
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MI "F*TQKD^I@[#(T!]=.9EF DR&2 A%S=GMOT6$@>8^@A;&^+X!E3@?OY1D
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MM/CWXK?6QL>$S*E_6_C:;!'>02CG.K!.#Y:YLGW6/^8=Z0A;I \B/AG8G,E
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MYT/7B_-9E\CU!@2-OE/2] Z]BRP/W4M<Z+UZRJT6ROMQJ&0H8<4D(%1T#Q+
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M"28X'XB]6[1:8"_@F5EB(KKDQ'A)$"4YD]"("=)L74S$?A2TTF8U#,BT!7T
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M=_-&G1#.']VD(POP@ UQPOLSOF(]FN3OCI3 N+>W* ]%*(,WNXR![?+_&*D
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M$F *!97J5@G,FQSRS#X? -\1= "#H\'(T$@Y'C",;D\->V%@YO4>4]<J=P:
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MLQFJ[C$9D9E"7*]HC)EMJ&RN^F2F]KOLSK^OJ#G3F&FEFP_,A%)>Z'YX)[B
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MC_3.E#*&%'$:^)_>N""-(R<'O1Q)B_C?D'9]O7?V*C"2[SRYZ\ QRG>N<7+
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MNAE>NQYW_[[+SJ;3B@+[,RY%E3W\D1Z1[9QZP@ &7Y#4*8 M8^_?U"FQR#2
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ML/TA!3\N\K,*U[^!HD&D-Y+18':QQ*R+$H"7(=8&>OIDE/B,:YE6/!T&LPX
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M-.A_K/]R4HKBT>HD;#WM<,U.+>\>6]'[#/?NQZ>T]4RGX^I3Z=^1D'RP."B
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M6GNDDC;Q"%ICKC9CY&W CUO\;,WI,S]-<0>%RQ_B2P(_A"X?_>F/=ZD^]()
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MW4?:TT#Y6EROI=D2HG;K3E%ZV,/@NLZ4FM#T'_@2%YN2(\C9.\SJN.EAQ9)
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MJ/&_JKMG'1J0V)4.Z0_3GK)MGAU8$W Z)/5$:L!9C[B [A.743<X50:2=2X
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MUJ"/*I":4.%53Z=/D/<+EM5B@_'+ZC0T,@:N5*7_.DSK-,U>Z H-?;K&N2%
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MJ]A9MX2ANEUUROR]2W_\U&^,QI[) V]3KT205^U'9LG!+4G'NK3/_^EK9OH
M<K(1*-/UJ(^C#.FM/>7@XU*?AI 9;>"O$S_:9<DZUZ,?KAGKRH.1I)AN;UO?
MFP_JFD?S %ZVK_;W6M)]ME3(S5O^;DMO"G9.>0+L]F"LNPFU,<LG2I=XJB/!
M299VW*HU.W$7=^J%GQ_0K\'VWE[=?0O">>9QY<$_UL*T]>4+DSACU8V"0\R
ML9UM!.)VJG87$G _[5-H#A$)X6<A\>9)'>/,SLD#1RS."$3=O!?=*ZA1#7F\
M:=@*>5MBXJGEOIK4K3L8H=CXHX?41,X(:1UP[.B@_7,+.'EQWRZN&<;;[$N0
MW>-FC>BZ  G+X5:#8HYV]7"YR=GBA88'S2HYS^%1GHTI?S8,WXBZHSXR3-T0
MN?56!*]Q0OZC=/'ON]!]K"H/I;##(#M%^53OB[0<Q@<B8\4*%S* S@#/8FZQ
MK8^WFS5&/4DMB5Y=\^2/</-]CF_[A"T2(KE7%H@_+VD9GMF&13WT[Q7'?W-+
M20P>;'3E.1!IPW6IIH+X3HL+J=92R$:)9'FAFVGJ'\D&MT[^CF^)ECCT]ZZ/
M_QQ7@SWLXRAFTU#"57U(4,NNF[H<:L'J&6>&E("RG','+W\(A4<%#4J!4^Z1
M%^M?SIZDN-F4+F;",UE3'U,7I3N+]2F7* '9Y^$<Y12 VJ%Z%.H$%#N=,E6M
M-C0N7S?<:!O6^P2(;J;TQ*-ZRD''_CY35;(V%EE"N0:O;1O.'=/5674DAX8X
M9LS=VX\I\!F$]./>-P5QLVA0DX4I3$0R!QD6J--'U:>) :PC'W>:?JY3@?]Z
MLN"A;1APS^1O)&<?@2?X]X=]-<=P0U?A/HPT\W.0EK*,LG!/=3XRCSRAO!?=
M7&XFL%:RA?9]= U2DMY,RX)KOH\"/C_%>Q/B&[RMFD>8.D$-=0D=E"YS/TH0
M\.$6>RA/O8_/[*99K.S>L3X&BJ/H@'_X$$HS?] )'7SO(+! E./INTQ8T'=3
M*,2$;VT^ZI32!_I?OXYUSK@DIC=]3=RU%;5U)P+O2:7$PJR0L':MZT>T(,[^
MY( K#29TD V3#G6B%W,4+5(0'*E!^K"5<FHSQPO\(MROU#N-R3)]T%QR+/2X
MDO/?!?$P7E89YQ?>%S$YSD[@OB'2%E 4!!VUW+=U&1+SY\&X8."&_DN<-NCZ
MT8T;>%;D$AB2_P%/W_)1QQ"#RS\<J@NQ_651@E9.;/DFE8_/?8Z70^X>ADPD
M$,?!/>TYGL@;H"S&_7DR-@XACC6\>^CH]PWYW^V>3T\ZA,,V+7G*.].KT[9A
M!1N<8(@9W_ZU#<L(_BW$TF"?X1;_!S% 0V.>X'HN;XS00$A&!J"5P,'+;6/8
ML[,2BKX_%WYBC+N:O093M&:!L<0K,]=6K=9]@[6O^,H>F!X_4O[Y\A_XW)[_
MG#;N%)1*I'TC@OOSRZ_4''Y<!4^]F9K_)YC)@/TN<#A2?/"6'#_?N\3[9@K0
M=QV3Y*CL1BAQ8I"TYX1J:H^-C-TXCQ]K K27L:KL@>CRC4PCW<3ZM:;1]8?)
M9<7RBA\Q-%.%83WVX];^T'[]IH:V#,.Y$RG+<DL7AJKJ_ GB'@N*7O,Q57H?
MZJS;A!>[R+,6S4.5VJZ]LQ>;AN?BEKU'-*I#:K.ZG!7);H[^(7&Y-V-^ET*A
M#N Z"?7H6%,=7C\"<+";$+!,[R/4:RR?"SY#YHE-+SI)4;"7P:NRZ^0F?+'/
MIDUY!ER17,W?^.A594FN9?GYPTUY'@^-< 1\">5<P'UZ%IRC F?HQN'DT-$H
M823M&;&QO7'+=W%&58@.Q<XX4DR*I^R&*?K+VG),?Q5.@B)2*(= L]&UW[+I
MX=7? U9T=7H'HJ8F5G)"[24R(;2CICPV%>)"&4G;.3S/A?J8*C9V X _]DK6
M%?)E377Z[XW)]2=*Z6*MBL';PTJ^AV*=00\Q=Q/DS>_=M2X+;P?N*5]M3=5@
M;Z"Z8CA*GC1\TC9,'+I:+0)P3!'E#6^N)#"0%"F. =0^&<[M,:SA+:-=8-(L
M06%@UDYV87/_TVK>^Z'ZL$?S%T<N>"\O>7L)NQTSJW[#6_K!MW.88L3P0@.R
M'LV!6_($?V])82^,H%Q A<*O_GA%K#^-Z^B?"8PG![NI7''K=PO]:BJ+T2'W
MVP']"\.%HP'*9$H%L[S&''WO\.H2;Z;WX^>/8J>'/Y/';>OKXWLI73,S1[0J
MEE_'78_^+.*<>CV:+"][(W[&D'R$X9 DJ2:,S*2"AOYL0V[1-];\\F,HS-VX
M"5B#,HXE"/%J_FT8RW7)5 >$L *E8MF'%Q*O#V"<O;J%N#1R,_TR:\_ J^_E
ME =-]*U=VN1"^BOORVEBQHY9'^[<ZAPATE9UP<,QG&/9[B'=JI+< CUTR@?E
M+-OJK1,:72U+52K.&,94V*OQZ#R6TK4IT-0'Y1I7KJTS/Z:M?UZD>V-3+#IW
M?N%N. ;-D:[JE,-7-W*48Z#F.7"?FLI2=!X#U@PD*44,&QK3:8_BR\.@W<8S
MN]K/UB20FFUROAK;U-8C]@6''1N>^"/3Z$$"NMC7=B4C%KZS']TY#*+K/U1F
M)S0:/73)=2H&5UD:CW7USYCL+YVAN$U_Q>#P4N"LQ8A^]BL=W[R'=RJKZD#S
MQ$:YP7T5OH=Z6DZ9&Y=L0GR;Q\W ^Z)B\:K(.U10"\ZL $A.X!E6"GN0I>R*
M[+*+\E ?J0P:\.Q$[=5KRLN9^1EFX/072SQ=M4A;+TS$NIY\O:ZI;8ACL+=!
M.V/*H6Z*C@ LWGU#@894GDC_ ?-C?8=&C57R@RVG6$K6 OXU4>C+$7^?45#^
M(L#6-)?]A)DR'S6QH@W",2%68X>&]-WQ)$5>0I&_O97>U07%Z))"]XE)OZ?]
M=UC3YCJ$^R9.]S[PQYTT.9<7?+<<ALRTV]F1 BHSM#3$VT:F%:N?'K-\?DL=
M7&+'< M-/!DG!)B[[FTI8-5& CW))B[TV.%>3;&K/9DROLV.-4%#W%QNOD9,
M(N6"4>'SW\UI\RZ^-KA#.VOX\+0\9-T\,VIV%3P\'L^!B"@_$US?D@"M.Z@-
M\"A]8A1*'J<_.;6@JL,JH STQK) /(D>M/20%J&IY%S/_-/EZ_2$R(L@;J_5
M!9UVB*OPA^X(!]QG(G!.S)M=Q$U THJ1@B;!6T98S*BICK^'R5N0Z0W\<F+-
M$%B-G2&-N@&Y??Y5&+0=D8RN<S?IN_<&@UL9J+<3^]KWAOII(\/U2UL=6@BZ
M*!W?:?T->L_&D'A""RPX.PRT8_%9<V--$;P)4P6 ^H1GR#'[4LG1#6&ESQ[Z
MNO+R<)- 1*OVPYWE^X=H1 D7;K8]N3C[U))BL^LU5Y>S-4)F2 \B;>VN!$=&
MA!9N$KEU!VO$'XJ()*J<JUHDT&(B34X JY"*(NS&:%I4 QM/6O<#JYWMJL!<
M3-'4.5_/P@5%IYBU+6LE8_]0G]P(O7C!9PB=@Z);_[S1\O\-5>W(+[-I=N!A
MC8[U^*->:# @)>96^>76<AAHS!I-N^#7K2O_ 19XK&GZH\3Z<QKJM[2)RA3O
M*$HBF+8->Z\^^.:UQ#<^GF!V@:\'E-B1T7A:,U*\%5X\";IUN&(S**]2(M<,
M#XQPSOJ^,>@6D[9H;1A1<VAL_*>]K.3X\;PC6\%=I5%>#KR/_N B9+6S_QFZ
M_( "W(M]"O]*(T]YU@6^V<*&T>T?--E7,"/??U" 9?%Z?&!Y\4?^7WSQL=(9
M!AQX#$^PDX96Q9 Z$-+X.X-/LM II@A,-@K035@+<^N@2M<K,46ZVV7(ND$V
MH1=R5B1B0AIJ33/+7:BN%]DA(7)HK;^M O2JC=[_%H'8BCQD\GVR#D[LW^#-
MTM?'2D$D W"P/RYK!OZ],^^>#W97<_WO#9I=!_,2>^GR:+L8YRAQ5%^D+*%_
M:8D:DR/9W-;>UIRZHE-96>D]]"UG;G'..RTT;BXDPU?A>^KDRQ?D;5AT*"BP
M#;N I OPE.SVXG]FA",U\8P#2% ]A8N@DG0Y!TUUMV&_FLJSJT!#)YZ@?]B9
MIC;N.YRXQ[6W]N-PE 3OZ+1MI\4^A=O@[9^2^5%[WJF<0%4@@$$\;!OV(X8#
M(2_)ES;(NS*T#1/= "1XL?@N"<[I'-%MV'=M&,YQ&]9M@0?,I4;86Z 75.]C
M>K9AO!#]= 1'61-" _WX'RCSK;L<Y>3U6Z=$WO,0G*O6N9K>)Q.BP-N'I)7_
M>1?6IZ&1_O_CAM8[>SAW$8'S;I,#8_-,$O#WRO>&E:8F$,^R??B9VO*R$.J'
MRCNEOZ<]$QV6H#X7\P130ODH,[P9E' ELW!JSNTK1I/QM5LZX/I2^U&<4BNZ
M?LP]Y"CIR(V(755C5: W,1R_=IXGB:?7 9#"/^KS7VU\1(M(8^B"ZN+92CW%
MN*\$H2"P '_RXG*K!.LFV2#=QWWE*?9TD@N[M')N3T/XJ?!C35 *1Q%IT0,A
M;#;W7;MX_38LZ_"6+R#0<RID7E3*@&)'LC,>X-]]D-IZ_3ZJ'"(^_](@MGY$
MX"Z5([GJ44VP'D<&XI\8?7X9E*3R^54I*,&HS/>\IY1OL7"V<)[D4O'=,NFK
MPJVDYZF3%X]U*P?P\41V]CE3 BI>S1'H^"E-FEV,EKX<]8WS#Z2HZ<$%N9#!
MMY;M/Z?L0'>T6/_#ZX<74C]WP(TM--=_\116:0BN).1P!!A@ O';CZY(>@YO
MUS9L2 *$B'KT2">!4_A:XL.4+F@8PA,,+8J#VW*;3:6<M29^9?1W$&0K+KSC
MESA^#B"?.+Q++?#S+L.ERV[X_WC67_-QB/?6/:Q*78L[V-0 F<A01^"%\(>X
M/- G36SQ4U7T[\?[:X2JR/A_Z2QYW,Y!!OU4X&+*;HX:F#^+C,8W") &XY%2
M'$U@&]:SN0T+-U5RP: 9%5&#*5C_0A^#C1PYX!%J!A3^/&*'DO)_.K%PA3K]
M]9S8,X,K[E;JY8>)GXD\833$<)YQBXFT.@]34(&^2A'#"7$D #BIS7;5%JC,
MI+L;]"CB'V-/E(+#/S_V=YN>9>&:2MTQL[TA%[.\,IZ+<1P/SWT>[K/R7?LJ
MP<PT4 W9W,"3SG+XMF%Y""!R&R96'(G\;6W).47M0&[NWX8)(@$*YM0V[%G=
M+LXJOO,LDE9!!/X8G)!AGP8EMC0PWCQA!:#?/8&N$<'42[K?'=-)D&6D=\]H
MMV4$7.TQ6@K+IH>EF3@UCWVG3+1,F2/9=QRM[HJ^7]Z9MQ6;"-&+>.0:'B]*
M!)Z"Q&W8YSGB7\3_Z]7\_^)\&*<""=S+Y$A=B)!@K@/=$9!G8WH8@F?/(8#*
MAWM;MV%7H2+$Q'<2*>2"X"1/=C7WG_6 :R^<%[,RNR14J7Z'*K+#6I2FJJ).
M3J?S88=D#GNJ[>O59%O_VT#["(E,QBJH?N=$GRBRD=@%WHB3,\Q+Z*3"/9,-
MO^RYD"1#?__7!7M9![.=)4^R+Z"D*>9(CNFT3Q,:)3J[VWZYXAMT2=NP>/_@
M^2:M7V&OL:=D'I9_^C2,GNE.LSHXOIB.5>2^=')0E,$> Z6;)U,&%(TQ2G1P
M[,]S-^^KC7S.9-?*6^6&,51:;L?5QDF^0O_?V.3[F;'$$]^9K'& ^@=YG-B8
MTE76'](+ZK3*LOP8\,[W7_<1Q;XJ":0^-S2)C^_GB4,.CU#SC64M4!M17>ZF
M9^1-4B<Q2HR>O(NT /$E 9+/V MQON,'Q4_%<U'_)?!3_EL3$-UX +4*[A=(
M](Q P'&35#Z3J[*UY0U#F!0ZH;LBT/BAI*'+?AL[>MAP]^*A9YH6LN%I9N(J
MM86Z'&6HD/ ;Y%!F/N*G4FAKY >><AEIH "C((.<'SCMU@&%JZB]V&L==7,E
MS *JG/HO$0R_,RAR;1741D#2@9T%]=D--[P-VT7T1E.6Z-04G :&=/Z+-N<
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M2+9?5@M;-U(H:)[8-@RLA<@IBV77E4*9Y0F>8B#B515!(BU%Q?<+UHJ;9>+
MLE_$2YCJ8N"77R47!"NM*B_)/1 1>UYN^>?HVL!-=P>T5I7VZEK4R'J8UK7/
MN[BQ,ZB)A2&A=9$I:WF1\IO^_2\";IXT^'KNX$JL.S'JW'0HW[7/32R)#E/Y
ML36D!)C2.R/]19\J@^HK!.^;D['F!;[-E2TEUHA7LM&IQ3/NI) W7S_(J1J'
M7O1Z/I;N]VJ)\#V&)TXBM_KN;,T6"SHQ5/ 6,5W;,,E G.'_1]R;_T.Y_O'C
MTU%)DITBIK)5MDY9.K8Y)21)47:FDF6(.269,LW=L>^24!PF9,LR8<:4;;)7
MDK*;B5FT689[E.G.+#ZW]_?[-WP^O\RC7[KOZWHMS]?S>;NNUTNX=6R5*4-G
M&I4$/X&Z.'V<'Q<^E-(R>BQRZ_/KK/CRTQ%_^O7^\7[GQ-9V6;XIK-9Q! D<
MPQ>2^M^<'8K8$']=5(J*T AVA8P%I^<)!T;;KMV4W0RI]]$-J8GXZVP: N?3
MK7;F2/]U%E$B5"7/0B:C75QR77FIL,(^;WPM_"GSZCG9^:UKXGZGII>C498,
M9TN7II1OK1T=+Q.'WX]OWGV[/B)"\]C>%$EC[?JJL@==+VDRPN.@:GIZ#1L)
M9TVOH<2ALQU[>)I9=62C-U\/O35A#.2HFP3?24(\_)VT9V+%6(#YSMR]<=N;
M"'K(IJ+!,^VJLWII';) IPWJ,K #A_(4U=;::.)B_5"^$'<64'3"5!O'FVXE
M4S-WE5#'ZKZ"O>5YU,B:N34+'-J=9UWQ8*WWI^19FL ?Z&PD-@TMMH(>_4@*
MG!F*G$KN)L%A\1C0M!P;A4HA;&EOA)J>A8H5>7TEK&.!/-.OV;.[*#$Q&:>W
MK<+LXR4EXZ?HA(:&WHI]94EH'M:ZZ1YP6?D=[.$.&1!_,)+#5(&"N_@KI^[W
MHY(IT\9VB8[E.P)2M$?KZ[(_W]=2LM-YI"^WS=7A"U*HH,[_ >7"3C'<N-4C
MM!*5<2O X@2!7:B%9(98$U?/%W338Z&M$[,.<9K?SI G C]<6SUE3+*RK'9
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M4Z-WY76>0,LS#+052PUM%'HDZ">[;>/2Z'D8Q^I02@0CX=FDV>"4-@_S1:X
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M?'U94S.I]\Z.%O;C $43V]-._(X?)PT:'PDS.$?VU,^$O2!]EN8GPFS">^/
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MY)3)A'1$XSG)GSGH-RBNM. \X:.%N5##5& D?M?BTH?6G&,V_4JVV3X)I?E
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MIO[SAWA[$FRHRZ)"%*N2RS)6Q[7V%!^#=@M.X@\8$&5H(<QXU>MS:+DVU)7
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M<'>C8K5HD(/&3+9QW7L_ U53-SRD>W?VU#L+&-ZJY==QZL%6[S;D/YL:>-O
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MN!;KAO+8"6!3F@[1)2I@EWK[]4:#;#O'\#UE)D/.+V-XOX*:"6#H?JDOE"_
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MAK(,6XS(JX6PZ7HDE#N!3@IH;30"OV0*8AQM*K2'*;2/,5NO=^Y<1IUF6;*
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MLE?7]!XQ+1_<E^-=T'Y?%?1-X_W/IK'_KU=%.Q[:"T@UT2T$A#S&$U!4 (E
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MSQ6J&7E\-DC,!1F#2>YMZ0[H6-/P44RS_W9 R2A59\ZD [+?-$\]=%6X^L'
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MISPYJ\)Z%CI35L2*Q_6E0=N=9J<E@7"_/P82@'@Q+,MALF\A2,R?:1*.D-=
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M05:@T=M?N:VMC;%1PEE_1?*5\%0:::=+B?FL\<E;<$<0V="UA&1UP^-.IM;
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M#"OZ 2ME"G#0;JQ43R AP_WL:E.Z$(."V*Z0U01^-:6WR7_;PZ[IQI4B.\9
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M6^HRXB#/?B&ST7':[8[>?R:*#3%G5>WPL_X!"%^'FX+.)26H9!=++7 QDW7
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M0H/LT0KCA^%0G71.M79Z'#?\0[9'F>FN-?XV1I3#M?,2SR4;=(8[0L7E4?$
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M9N[7=?V!R0/3=2YZ[TS)S\F?JK^/_I'J46*(")0.2"MDZDN:U4 +&A"6XQB
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M@.W."]HGQ'R:D-DHG[B'$*0&K9S:IVD9.9GN85*_ML&Z ^63\>R=S#Y&5?!
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M[@9) 6GI[NYNV ^^]\=]GKDS<^:<,^]]KJ2T!#?/-T:T"Y0K  "!0   ;
M! "  P #3R^>(S8V !L$P 8'L T V!#/20@;  (!0.  R   @GBNA;,!X!
M' Z #P#@B.?6 3;   0P  <,#  &$$](  0;  $!(.  Q,#3I&?@9^@GK*?F
MIVK$\YSG V%C@[.Q#;"Q(9['/D40"!L$S@898(,@GED\)>$0-CB<#3[ !D<\
MDWJJ'8"P#<#9!@;8!A!/')]:V1 0-@2<#3' AD \4W[6\$3ZB>43+<2S@N=)
M3]!/6$_-B&=!S_'3@4,@ Q (XEG?T]BG" Z'P <@<,2SW"<63\D!.&1@ #*
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M5B;FS(/?>7X0T9A\G9#83,.>WB"MN8FP@\>MY, WO[;&_S4@/;2![K$Z 5P
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M-J&.GU$4>KAD^$&.;6MD"K3!@HT&X=;8KB0?AWJ<HCI47;-12&A DKSKMFN
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MFO:[9S%V&V)7.]_545@UG( &6L$ZG,:ULTP6:;E9UM;[PE=%T<Q&] PBNF6
MI1N2N99'0\"3(:.?^!0VD 6_-N0RHS])DQNB M9'^/Y\G&&7>D6AW7J?2L>,
M2FT<U8)FT81,<W?>U/4JY "[<G?=;8Z/)J$?N@]>R/G?E,+HIU%$L/TGTM"<
M7A2)>[_$3_2A& :>:&_7YL)<U(A>"Z'_J=UZ.83>SZGZ<L@(?UFZY]$*G&?K
MQ[V+^/IY.UEJ*S;19V[C5.?2=Q9TUA,(12TWQ*6S!Z O!M%:>^*C>BY#+ZF/
MWY3IYN)/:-H H[P- ,NK6)"%B*3Q=2MTNK8]5S(C7*"W>YO)Y((-'=-+JW@@
M,:V=Z &0 6C)M&QQC&\/4S25/(#*?4=*N?R+CPXP?]07O[:@RP?*G^ED!98G
M?3#PQ?8_F'4D@.C2YVZ*0RXT(>B2DGLI GMCNE/M:3#H8M +I[V=L.#$<$M1
MH>_3>DM("9*:0DZH,&L X;Y$GHK']7J@"\18UM\M'ZBL<>"5>"R79WRR$,3)
M9?//*L ==N5<QY(Q_2T$ABPUM.# >-2\^&-BTL)]PQ QKW">>FTY D%:.7RY
MN@A;4U"1^GEX);:0-X2+LQ6T!]JA>]%\\PE=9TNEY?&*Z."EZS1,%1$$_6Y]
ME7;H-EGM?FPK4VHM3V.@K^!-;PH5./:EUP#^T@<R4-RFIL/HI"8 "3L_/MD4
M;EY61Z\[.QFI;P"5A?W=ZJ'=G'885XORPZY88*<T;^@;+B0X<&U' A %W0FK
M/>?_? *#G;@+W+SYLJ;< EQ0M8H0LG/SOA('. ,,7$O5#_2N"O\&6B+!?*=W
MH&K>5RWQSO)^R1$&2%$$/T8X8557C6Q?+$2'G)7RC'] 5'\"S)AH':I&@3\E
M48FM7>31'OP,W,NBG6:=BQ!.QR:LX2J>@.O?+^Y3>Z&E4&=Q=#:6/2!Z^IK3
M2&'!3RM4KOL33O1%Z"91XDK%]R\EKU''8-]EOL/<)%0JILZKK@K%L3VZ>BY#
MU)V"Z(C'WX>A,:IZ8=^76J/]001=GD&]RG]*.PH]U)F'(\/<+TX'D0V.,UK]
M7CS<['$5I8L"7E++9-.=?.OTQ?N@$#K]=472'U^,D<0LFHJ'B,$X-$;$+JLG
MAH6G#Y5G%#,$GT>SO'X4(YN"CA=ZZZ%IW:V0JBZ7N@\$?\#$1=>04S67R9('
M',B]&IRQHM7X"2L]'@\2-A^BTSOTT:6C"U9(4]84QHG%)I\I9:.(Y^>6'<'+
M5/F'.$WY5THF%,6.5-WX.F%W&?]KZ4AG8?TG;W=7YR&#V7\JZJELY[HOF.EE
M9E)AMX:;4PK'(\[W4I<QSAN7>$W,6).8@X;G5OXEBY:"?'5Y&6I,[VMG4>)L
MOBB_0J,9;.BQ:QF4V4/[OL]M]D;$@P4E'UCGUM050GUZANR^A><!G,N9W EP
M5 L8S#S,+N(K$CKEYU)55=0Y&?K"9H:OY4(:-4[HA]C9(OD2>5(][G!4<QPN
M\?*?GXJZNDU"NOP#ZA\*[9P"C>B@M[?BJR:/[TYUD?TFI!((+C1J=>B]G_[!
MKQH^Y2E2':)"\!T:%M:6I:J:QR8"#MXE1C@)5'#@"+T!H04@"'8="71";*5-
M1+\UN/*\DS0*Z#:1 OW>F,/+;AG7"W@9JFF$"?'BB1*Z;HY+LC5SI=3W<D<W
MZ,A$1V<6$[UOUEQ1D=4,3+=9HM1<SG ?.OWFJ)Z=3^@O'4?]3?+AW2D(YC=H
M0N'+')\]G.43'T<LLM?0^%V>?M6\J-0TNFZO[/?BQWV1#R7CKRMB/V+NES<P
M)C-4M? 2'U2-B;J7U,R<:AW4CKN%6-8MOR@ZJ%^)GBMNV(EO8FS<ERFR:CKY
MO<=8=^[E?MA\.EETU'*\>7?T&W#UHZS^'M\#G@F3J=EV 0+OC]M>K&%6=.)@
MZK!TXVHW%U<P-&3;=C\JO6+]2V7M88?H14THKOS[07;^M(^IBK]J@$.?Y&R0
M>4_.?H@_HKEJ4.@NE'5(%"C//B) ?E Y*D]\P#XJQO; WO/1E=]Q7)8@E6-<
MP[WE8DI:>?!B^ILL%N>L84Q+[8Q6T8+3E%GZ0^V\U;!GW8)KCSS7DLO1@?,,
MOF.HQ<+//5*7)6B5+O>J-U-:_4H45RGW?(SL8_U:G)$"SUJR?BG/=BH4U+"1
MXVYUNXV#]<BRD]>4QKM5TOG8L%W3;^6^6=^3=G?0<O9X=]@^=MATG+\GR'_<
M2X"XG2P:MN(_Z9,%>YZ.,R'XS_YI"WE>3CC_?#B9"T$(7$TGDPO>K*67M=0-
M9;7^OCKV&_Z-N-]H_2GT<-U3AKB_VT*T(I"G6Y%FP=ZH*N0(U$U!%'Q%;RQ^
M@ULJ#2%4UDA?4#4%ZGNZ=E3#8Q^R?0IT+@T1'+UC8TR&S!?*O2*O(38!'TE6
M,+]N=Q!U1 :R%E."K/,[\3<CH>%\F6"_:Q%\$$N@Z*M,G!#33NK7.$&R*H;@
MS'JQ#ZPL00HJQ-@%^7_H%:)"5#U^$=1-=[%H184:L!N]Z<R78'>*"M/O^C6!
MGB#!%5P1ZL2_1KJ5V,-Y>!+FT45-<4'8*X11&;G8OXKWX!-NP6Q'<DR(+GCZ
M#V3-;$=\:CHM.M[>:^&/@A,U *3JKI"VCWQ!6=76PU6)!#J\-L(_0$Q+<(+:
M9 (&#,EB8Y$R=[FEA$Z5$@+W-][>;<N*OL9-='BUR0@UDRNFC/8_X@90MR.!
M/<_]R$O7)3BK*\+<N.EB0U6@*1+1( ES([*79CE\Y3<L8!_JY-/Z7JJJ%9#Q
MHQ+\,OL[RY'K@"<&;GJ_7*[0Q<P7+^1SV4'V)8;>=BE\';-WU]XFG'U1A#^W
MLTA"Q24%+]^AV-%*:51IK'-BL^"(M]F1Y+#W\EGMY'A7QF9<6.P(&VDIPG^/
MY]SX[\C9:XWYD+WY^6@#9"?ZBV77G$7*NAS(V;L#DGLK3B82ML&[&!5N8W$*
M.$+'%Q0O" L][):6KBD4NLX,S_8RXN"JV4$(.1>.58W&EOR0+]*>^#A5/XI7
M&KRWHW/P<:3ND*/,LV1/_R)8N16$7QZ QZ"%4D3?_):S JJZ;R3; [;OS2#9
MD HR87&?Z;.ZK-S&-G.^MP6[1OH1SZ&W<=:N8!'U!DJS[T!YE9JD+5V,2-/-
ME04&VGT=;' KPQ\LM7&(=99 7)5M&T4BA/0ZZV0)Y8.I<,'2R/&OFY5Q1XF'
MM$W,:0$#R&1(T^^H:XAQ7 W8B.>QNT0;%1<M1L2H;BDDE?[B*&SA7S7TYS#9
M[Q4MW9_6.?;16/TD;M*_5WI'OH;*]$'2%WT_29TLIE#*F^[EHF,Q)MGTJS;U
M5]%@D?JLSEM39>\C!/TR-DIB&S5G!4RYN(V[\K"+4:W"%O@J/MB7ZY?.GSBA
MR?9E0,9:-J 7RF>>@N5@D:"D:6+,+3@1@?*=FI0TVHIZ@]J(<*ZNBZF6-2XO
M=..3^H'&IR'6(".2S8]<0Y2O6)+%;K\. G]H#M!MLL+7YB$\$0V_$:I+#).4
MZP)3W"1*N1O\XR=8,$@,R8XW,!G,&A%F94>\9UI6>9NI*-MXV6=5RYZZY&'&
M_(-W+#&-+7^/?Y,O)I*<%Y+]*GB^#^7]C>R- 3L7;Q_8PJGRW:,+D/JO3T30
M>%;JXG5Y/A^I^3?@W=B?S>J*H))]8S9WUVS.= HE.!:1L0//XD W+RWO:P0F
MFQ+9E@-^:8U/>)>%S.R2< _W[STLYW=N,V87T ^HE-:NO=K8YVG.+4>61QYG
MQ$N/BU>M%Y^.O5":EU' W.U@JV-_-I(5D/YU)Q[C2:!8\RIN!/<?)JN34/O[
ME?>D3E4KK^R,8W36>_080F*FP<[O5(D/\JOEO0I5HN?%.E:X8Z3/,Z5=65$I
MS^KS319]!E'F7<9H@0 A#9M\\; =!CFN\(Z,P_/<B)T=U;S;\1PRQT)M@3V=
MGMO)S,6+<GW=/2,AONE_5I?559X'5HC;N3^+3O5CNH>V3.X+)^$ %Q*!=0E$
M4YXLZ#I*_W#F/?G]REW<><[PPJ'K5>,:==G57S%$VJEQ&?\F4YEKC9#765@=
M_Q9-^LV(W^-9%I?G]$VXB_.5[K&/M<"^NC539Y7>92EP:E7@Y]78D=Y5ZGN!
MHY\1;LMW>N=_F#R/@LKN5]B$#@M_MAP8@1]V< 5O)[E,^W#U/7<3&*[ZOWB=
M!8 ?3T):[[L1OV^BTA^7TX7N#YQ_G]<Q_3P8:[V<3Z<^>/#Z^9#U]^Y0'7%7
MLG1200[ IT B6P;04MRB4:"\-3@16+J?T4<]U7_XFH'ZZ\OC@AZ:.<7HAU3D
M1W)DQ@R48 -TWV5@M#Y*/ 5&N,&:R/*+[B5,O254NPPT,J5+70K0)$7C]1)&
M808@>OGE8\9+9$H<4";.)6(9I<, -$J!^S$3Q$N):D+Q1B'SU5M4, ;E:_QO
M^&24^$[?,%ZL$)AG$C0NOU9:>>3XAA?_[>UL1D++2(&M'X\FJB"S5HFJ>-G&
M;*FM.)_P&-?\)(-B-*<.GG][)]>%F.1ZYQ!/XEO.*;Q 2@+>57R)7P25&>]$
M5]_=4J!$K^"64KY-RR0:6G[/.8SU2U%0^ V700QG;QOU/S&!;+]J$S^>^40-
MV.M:,V))FV1.ESF)=4)N@P1.;S$^4U1!8>4B(G&A;3&!D4Y^.NC[1DUJI54:
M7TIV+2H.A2P.PU4.&>H[,\/WOE3O U>IW(S8:H?I:K$%A'&Y!SK3JD5=_P*<
M:SII"Q!KLB,HG^)1]#/^EH@H^Q)1\QL2.\%>DUC]DA6@YL3/YB3+)E3+$J$U
MYF1=Y_3-$@[.$N]>YE9X)Q.;13@A1I"!PA/::=4NQM@@(T2(Q^.0_:H:14 8
M4R ;A:<YIO1<C"!VG;NXDR' B +GG:B@H=CNNNBIL8+:JH(:%9>H,9=2]F>)
M[*^T:6^\J)47R15XU[](4*LHY'Q1HE&\S+9]9:),9O)U-EN=*N?AD\EG6AH?
M 1/5M U5B1S10A-%&1HMF0"U\ UU)QJ-21K=QC0-.YJOEW&:N3FJC3GZOS>T
M'C<,&O5U=C?4HG-T#TT,G;3T/F[JGN8 7T.T\2$&>K0&D%R3< 2E4=^&(>?F
M=S?(>\%-'2<(V44.1"W7W-#$O'(3\IL60$9KG+1IX0LQGLVUCH*84M&^S:2U
M:-PTKZ2Q >79X'_?_@LQ6\VU"Z:UI-VRWLE=&/A&[:HD*/Y:<+E30&7+T0F&
ME]1)&^<G>"S&L2'&;^)7RM.;J_@:LU?:65?#W=,_QB.!M_B-/2C>^L5[D]??
MO=[F&:SF?>/<LIJ$>(+HK$_?2.CA\$M-6V1.NID]70>Q3AWMVH._0QNK/(/(
MKB:=;FK^RB9B@%XC49.87;QM>07(S]VMH-/WD,?<8'-:NQ?Y]M&FH1CYH8\C
M/J?*0B[?&5J4-7;H:@[^^IB)24Z("VD@8KGF-02ZU'W953_"WX0NCGC^V@Z^
MW8J5,?M1:TJ+O&WYFB[,:2=T=2FL8YA?<8+6TX\W P4.B>'JHOPQCH+)GL23
MC\+CH4XMHE5&X5N&52 Z@L)@Z<>[+"9@$<O9.Y4@6A"D]B%>:2?N\'U6[K:M
M^8=LQN]A5CO9(!P'B8\)JXJQM(5QE:995+MYC72Y:H79;CLQ2A]?!!84_"K4
ML33/=RO,ZOZ8W_?Q.V>.(.H'?@]B]S9U3HNQUM!W/(/?S08ZADPZSSZA4DVG
M\&MU)6Z^57?L$H@LX*HW5IL7XS/IY Z%B;@H?^S^)I!A2/#F8U':;K[34$Y\
M8;UH5-'HQ^*APB9&Q,<FA;401JQ &6U&?$WI7C$^-,!2YE^I/F_?#BI^?OK/
M(V(?;3OYF.,D*7RK=9'$T64%Z50X'9 \H\4%(W<$D=MXVZ(YY]5BVL24T-KX
MY5$I695D^OPUO/?<KCOK(,KUT?2-'1:YE2L3Q>8-M;N9'7M-M45#EPS#C_O-
M3O(MW:-\Y_.&.NIEFYVRYYW\WIUN[52"U],)]9W.:-ZUO_V'*.&:./W\4L0U
M2L$#)IU<^6LBQYUXW'M5&:^I2SH[&<6%HOUJ-WNBV@V;I,7[S3O[PXL6%XL'
M6&,*<W\,Y$XT'A;_>K18(;/*Z_MQ\ZI$E>6@9G(:J5KL'X^<T#H*6]\![SEB
M-0WN1S74Y:ZJQ#SJ+UCM-W9(A/FJN.RZ4T:0T24H67,!0R!?+&DRD4=%HB7_
MT$$7:7EH?_$%XU4*_='IP?VKTF$JQCRRHZ*W1UFKFM#@XG^7)8.WI><OK)61
MK><HD.$OA/^,*O%%HF2RC'*%^O&.E_"56XG;PBJW450]Q:SECS!QRE9H2^^I
MK)N'CDZ5F!ZCS1\ECAX[OA+[1@DEBBF%B4E([R.I[$M2:HKA)7Z^,/\0@,?I
MTSDI@UK:_FOTK?^G@FC*TZ.[38O[4::56>L'W_(;M)([.V:,H]+'T]R+:#D!
M13RN?#$;0IL_,OF?W%#K3/P87X<(M65QEI>8K3/SM"'$>(65 =QPC#7P_<<C
M]/=EZ%#F^"0;A*CU:W46/"@$4PR$U>,O%&O!F>]7:)+O^K%8?MW/66O4"EVT
M]":1K^WU/]V38S=F7+$*W)ACX-3)F/0)1AXS"689N?K1TN7)RQ^%)$*V)V]/
M2;DJJ+YOD'^Q/>*UHSXZ^?Q8AB=T:H9?23I\0OF=E>K'Z>)G5G)M.SJ_2GM(
M!848ZRJ#[?LRUO=UK&2(+8KTRG?]IW1,>1]"[&B.PCXVG5)9G]*/L3!D53(/
MLS*.V7T VK&\KVHT/&6ZLV-ZS\I<ED\V=<JLS,828V>TP,I)?S:\;\<F5L4F
M:<^=<,R98,]@;\_!](LSO8J''D'&)E3UOH>-_F?5:F650%X5R]:9*575PSG*
M)]_.%\K^_!:O>6WRVEF5>'28/[>AD.M]$E(<Y6S>YU%E)A0KRIC]P%L6P=5Y
MQF_/SA1R]G[IC".DFB/!0>.4[361!K<_RJ=N)9[FSIZ9X[3E51 Y*C]@G]96
MC&? 3V*^TYGF7(1BC:^XDY>B ^M[]8$%NU3_F60$&[?D(OL6J[0LAR!UC7W)
M6=U AT#&!][C;:ERZEE:\4B6T4H,!SXS/P$[6;"1,F^LC%#@H<@XBG"T)1\T
M3(F/0WG,7M+/067/7I>:0 "5@<<,1>DEG+.W7+[Y.,W,CW/$+"S3K_2MO^#(
M*F=VIX4#@D \H'/]U*\ZK!/Y[D)EF$PF[TMZ6R=O=2>O0SO?N-\X8S^_0[N9
MY 0_W7G9/(K%S[ZT$3&+?K$:./O1_(7R5HWD7@WI58VJW^4C"[M+R8>!.$MZ
M\5$!B@Y>=,XH1R@A)MRE18G312R0\DHJ><3T9YU+'I8-YI72$8<>=:4M@D.U
M7P,J6.NF$IH\.<WMGQV\+J:(4RZR31>--4MK4N1\=UEB<.%2=R4=R^4&=/9-
MKALN=38E=PYVQ4N7KU>L( ZI[J17XK[&/T@8E^B79O\4M\49*<;#K\K=9:E:
M=56&7>]=Q>7+5>/;R>V'4A(LYA*V=.T7@A-"S!TQW!6"RQ4)1M1%8M*$Y[F$
MDS=$"7UWJ>..A@Y$@%W=^J]]FW+]WKOZ %TBYJZO][GCB<]BTNMBH:Z1N*XQ
MRE44PH"D/!Y4.N^G9W+=35*G:TKG37*=:VK136I30\H63]+93<K<31J0-Q63
M-P/<F$G ^VN-)Y/^-I/-[=>>:Y;8;=;5S2_9QBSZV^CXAI^?7(\\&*G_K'8.
M(0NA+]!2GDC(<5*CM5WKT?5_'OMK1U"7H_79H83/<:*@ 05F<G/LX1H;X5HF
MQL.A=A/GO J7Y,TAODO7;\QANJOXXE;)=E?%U50IRU=]UU"CSEOSW;W:^JZ&
MVKV.[Z[N"U\=T"U7NZ'!SNWEH)BB-(*Y<G05CX1#5!@>H-?%/_*6*W-LI&6+
M01'O;?(=XM@M],ZM#<5=X.[N P%?O=%=O7M3!]2]ANL_ "U TK\\Q#.\Q"?\
MQ(N[PVO[Q2\\Q2=\N0][X:'[\LC#FR+9>S9)/+' GW'$@6W# ]=$*X@2.& %
M/2!TIM,#51V U'I\*K\SF O\C/^\>A>Y_B*\Q4?\QA=]Q3]\TF.\T2/]T2O]
MTS/]TFN\TQ=]QS/YVG#YL!#K]VK# 9SB-GR]:8G]8;/&JX%7.)3#-V 7+@6+
M/% 20%-*S>4:/)2OAZ8#ONH\T@ \T(LYP4]Y$FKZP3<]U%=]X1^^U$<]U2/^
MXB>^X3L^XV>\Y!,^I5__O:Z;CM8+?0KS/>#[?.?_?>II_NX2?>13?N.?_N1/
M?>HK_NH_/NJ;?NN7_J!;?I<?3>8+OE5SOM_W/.A[?NCC?B.3/N0/_^NK/NP?
MO_$G/^LC__(KO]77_L=3,O0#_\XS'N]?_Z]C_\ S,O4+L_ 7?_.'O^O'/O&3
M/_B//_.CO_,_/.UK>=:#O.A/_T;HON_7?^\_L[!C_?9]O_GW?_K+/D! $"A0
MP4"#!0T23*AP(<*$#@\NA !Q($6&#R5:G)B18\..&#V&!#DR8BL )T_Z0[E2
MY<J4+E_";.ER)DN8 &JBS!F3YLV=.'T&E2FTYU"C15V2D\%"QC@9/Z$2M7ET
M_RK2JE=U2LU*=:O5KEAY@@7*->Q7LV71CO6:-BI9M6+;KAW+CX4 $W81F,B;
M%Z]>OWWWWO4;&/#?P88#\SVL.+'@QH49'X;L6/)BRH0M3]:<F?/CSI4]AP8]
M&K/HTJ01HXZ, -[9MZ[CPM7*=O9KVFYCPZZ=^[9<WK:!__XIZ&-$D<9)5BRN
M_#CSY!>11W<N'?ITZ]6Q;VR>76/WY=R_:W\NGOI&D[)Q[U:?GKWO]>[;BU7*
MU*GP]^CAY\>_7W?\_OK_XZ\W 8.[+\#^Z+)K,]-2.\W!!B%<+<++)EQ0-0HE
MS!###2U\4,,.*_S,0PY%#-&TU@8\,,45"_2/1?M<;/\1P!<-I-$MXK8C[SH=
MP<O1.Q_#^W$\(<LC<D<C>QPRR"6!;!*C\U24D4 89Y0R2BJGO&F^IIZJT4H;
MB_+''6ZR 6<>J5HQQYMLV&QS&V_(R<>H?M()H$TVOTEG%K3P^2:;<?29"<LK
MO1P4S"QCA#%!$AG\L$1'&V7T0A AG?1124>D%%,3+8U4TT\'0_'+40TEM=!3
M$T6URE)9K0U')9TLDDE8:94UUB-GM;567&]-4M=?<87R4$)3+79551%-:BDN
M6S6V*GI8V(8<=?H!H!]UMLDF''I\:J4<-L>Y!SA]9&!3&WU2XB?;;Q!YJ1]W
MV$PGT)/>X4:;<?QI]EAGB=W_U]]DIUH45$\O';C3@S,M6&&"&4:8TX0;AMCA
MU435%^!^+QY68U/YW=ABE%X%UE=>=QW99!Y11C+E7$D6>>5>7RXY9EF%Y?A?
MC''V&-DHMZQO9YWGQ%9;;F5"9!PVU^$G.'C(U$8>E7*[-IMMWE%IEG:RW48=
M?-YA(1MMR$'W9J#'MCECLQ&L:]-*)6[[X;?9AGOMN0UV.^Z[Z5X8X8I_1IOL
MLS_^.V>_"1^.Y9-53OSPF5MN'/'%%8<Y<IDG+ZGLP OO&_-2>^ZRX\R#SG;;
MH/R11QLVS1$;)7[:.3T;<P0-ZIYPLCF@GK<$83.<=E%JO7;5!0\>],LU%TI@
MO>W._SMBN>MF'GGGE\>[>>F?IWCPS8O_''OMLR<>II =9_QQR2$OG_SS*3<_
M??1I]MY]P+N'WZW.MW__^OCOYUY_^X5OZ_CHE3>Q "9O>@.$G@ +F,#J#9!O
M^Y,?_X;W0 GFKVS@&]_Z,.BRRH5O@Q?4H/H^R+Y@0;!^$^Q?W^B'OQ,ZD((F
MC& +8;C"_R%P@0H$H UI>,,:[E"'/=Q;#%^X0A*J,(A%_(T%Q9?$#BH1A!QL
MH@>=*$(H3G%E-2LA$*\H1 *ED(5:Q"(1LVA$,(X1 #,D( ]SF,8S^G"-:CQ@
M&^'XL 8.L8MBK&,8\>@E)"Z1CT]DHA3_F,$H"I**??2(%?_)2$=%NO G7%SD
M%^^82$9*$I+[,N,;,4D]-F;2@)ITHR?C"$HY5G*2D33E([W(HCWZT9"$#&0(
M7=E*6,YRD!]$Y"E+B4H[*HL^GM-E'G%)2F&F<I?HN:0HD=E)9>(PE,M$8S.9
M.4IB O.7E)PF$5<)2%G6DIN%9.4WM0E.)=VRFL&\YN<<F4MU#K.8[*3F.F]S
M3&=N,IG1K.<S.6G/>:IQCO!LYSG+&="S93.6XJ2E-\.9T((J]*#F$:@[K5G$
M=$+4G/^TZ#LI2D=YZI.C^+PG/?<)38^&M$']S*@_,0I0E.K1H-U\I4NWB="%
MSK2A?23G2BN:4L)-5*7WF\>:LB'_KY_0@W;?(!I.^$$F;J (:N^(%S]F0H^C
M<4-<.8VH3K>WT9%V%*1<_21)/_I59IJTIV6]Z%71>J.6RK2F:WTI6V'JUI@Z
M%*</-2OGEN4SJVK/:$A3&E28]K6GJ:4>[: =F\"Q-934XW3R0LD]NH .<HQ#
M'OC(5UKM>M9B)4@ "NKL73[;6<^.%K2D%6UI47M:U8:6M:9M;6I?NUK7SA:V
MM)5M;7%[6]W&EK>V[6UN?[M;WPX7N+YES4F1>U?,UE4LKW+(<YT#W8M(5SS4
MM6YTL3O=[%9WN]?5[G>Y"U[OAI>\XS5O=]$KWO26=[W0O6ER-9O9W_ TOO"#
MAYVR(0_@_[SC %\K1[5:1*?3K6,F_6@'F]RQI\5.]4S,A2]6E_O@""MWK_*=
M<'TE7&$'4]C"&LYPAT&\80P3D[X0_AP^$#$/>LP#$?B :FWR@0AZ  \J^5#Q
M/%P\8AV;.,0?%C&/?WQA(/N8R!P.LH>-7.0="YG)2%XR3$K<Y!XGF<I/GK*5
MCWSE(5=YRUA6<I?!+.4LC_G+8BZSDZ/LY#"KV<Q<;K.7W<QF.6OYS6NF\YS)
M'.<[[SG/</9S(_/JRS[;>=!U_ID_VH%?;;  'I>%23VBQ::EVJ8>;4J=:_#1
MWV^, [_E4/!59O&.-6T#'37)B3[< =1LJ$/!*KG'T<ID6:+0(_\=;;(=31 !
M#C;) %WUNT>YV$2.VX%Z'N *1[:RT0Y'@[@?P"Y3U:8R#S^QR1N\LXD^UM&F
M;ZRC9CB9Q3R^I;NC3D4?A]6&-ZX X*ST0]2N,\>GS\SG>#,2$6U"QU]],@MX
M3#L;84,)N[/E#4'@63?Y0 >;RI$/0E.0'OV=FCJ&G16#(_MU\$[)MZ<-MG'K
M9!;K(-/7U $\CJNC3=Q AYQ@P@]!D,-UXU"XH0ENUC3+6\^%CKF,]$$.2:L[
M9Y5&G>IJ4@]=]QOE)]$'K,&!CZ^$>M3HX/E/VN'P<?#.U; .Q\N'P@]YI,/A
MV7 ZKH<N@VI]3!Y#]SK02?>.;&GCWBO_0<2T!>TW?.@\&^]0-Y7\08^/LRD
MWV !.NA!CZ*;Y5W(-L?=9S,/9)\<)67'D]@67O-Y?[G>;$)'KX4BCX]OHZK6
M4GLV!.Z2>WS<&^W AS[X@?I[U*M-"5Z)@9$= '4@@A^ISX?00$^/EO1C'0[?
M1A?ND?I9X&,>L,[&.EH- (/?:1ONF$<^^-&*>F0;L?1(/@#6X3IOH(/VMH?'
M8;-1#J4/RQR[5EJR^.%L28-#!NX(/,_+P@^@?J,>L>,*/T@NV)/P8]KTMS_-
M_^S-9L[F ##R I J:DVP<B(NY*%-VN'1+ WM\L'X[J0"O^9.PD'64(+IIJ;4
MLN35$.L>H&(6_\(-].K/)W)MUS O1N3!X;3!L7YC'KK.=2S0 M]-8^:.3:"-
M1OPA]5#/2D P&[YA_   'X#J (XJ-Q"M3<;-'_(O&[H :K2B'F@G'>3A_"0O
M"P^0A"K/Z_"M/0 .] 9N)? /O\QE&[3A +CA&\CAL,"!=_JA"SY.'18PW]IA
M\[[!&P[@&_)P#_N0#[TA'!Y0)98OV9:-)68A <E!Z?Q!$++F'=AB%H"*!>1D
M4,HO&V0 "WE0'_ A'\9.*_)/&]QA]Q+P=1"/*^H!UM+A_/PAL,(/"^/"'[QF
M'-8!_K:0 /UI "=/"PVP%_.ML%0M&P+ &_)P[]K$&V1 \&S1YUY';/\FL$W@
MX?JL0MK8I/E.@@-)[>G4(PC!002UXJ?:) -U(@7;Y'30T!RU 1U/YW3,H:I<
MT5S2<6KB\1SE<1W-Q!\0X0B)\#;6 =F\8>-Z2A[H[D[BT0SC9?"ZHA^^[TZ&
M\0"\@0:S@1O2@5MB0Q\6\DX<\AL@,AS>X<5NSA<_$HRZ\/)L)@Q#3R<.K!PS
M,AS=X0H^SMI0 A\.[@SS\$Y@<"7RH02%40\ISN0BCA!G4AU*D1C-\ #:8?"B
M"AUZ\AN,\0#2 2F7JQ76(1CKT0+!0?>(XAYP3]+TT!LH3EOF807#!-PJD!NZ
M\DZ^@21O<1=U3!=Y$>8*$"YQD2U!,BY#\B[_[3(OY_(M\7(OUY(O]9)G JTN
M_9(PZ5(N#[,O$S,P ;,P$;,Q%],Q%1,R*?,O < M+=,P*U,S,Q-5_('K3DY0
M9B%?;+% 2',T+:H?1G/98G$6:D\?^@'^E+ ?],$U:T\:5T(?NB <$NL\./,W
M'[,S)_.%[@$=O($.:6(6^L'4B,(?5E,U3<D?5%,*94(YI?,YL?,T<<,V:Y,Z
M:2(?T@$<P*$+/G$X@=,\B0@SSY,QA9,]-=,?9O( .F\F^,$=UDX-=>=VHF(>
ME&H0?T8?2.!/WD%LX&'M&NTK^ _D-%$M_*$+VB0*7R_<OJ'H=F+TOL8#>0(>
M'([5T+-#W3,XU],F_^AAZ&KQ)_CK:_10T@"R)L@Q'63S5/R!=L:A'>9%Z)!F
M.6^"J*9&3UYD%@Z+$H$C'V3@=':')Q"M:09+,C_40\]&/4'T29DT,B-3WYI.
M&_?//K_F 6.2[K:A'6 1 /@S(OUS \VN!FOP'\FB0+_F0&."'](AX("*&\P!
M$2H1$<IA[\P!(<M"'W2R&M5!3]]B%O)/V):T4)7T4.D2V+9AV$RTO[3A!KU-
M*3O0(T^B1>%/0\TT4\?A%'MB1&]T)_R!T[;A3;J@'O#A'O*!^,B!XG@-*? 1
M'2"R',D!*[$"'[Z%[6@,2@U52EG$2:-T,W45424/'VCG4:VTC+!4&[2T*O]D
M$$]D;$VX84ROT1SR$!R^P5JMM5JO=5O9$";10DVU@4W5(A_LY 6E(A]TC00@
M]/5<DSEA(A^\IM\ K";R@>YDH/. ]5?;4UCW52>Z(&NH[B9.]%%Q\R3P8>B6
M*A\.RT5=8AYD8%NSU1NPE5LE-BW_3T1)%$=A0C7Y06-?PQ_"] 75#1_B];\B
M\0YK9Q1S@AI?,%?U-41Y=51\=5?SE6;[U:SF@42ED1_VS2PAT3?2Q!NX 1P@
M,8O*SB&3-#CT#1V^(0!&51NX@1O(83Z%(N_2@2FA=AN<%AS0 1X6E"=FDJJ"
M-69AMF8=4TRHC59=0AY8@!N<LF!Y O^$UAO6]8O_[H$<W%9EA>)=P.%IN6$;
MUM#T9$0ZVT$C_S8 LA8<S$$>7G3_K,[B;C9RRW:G!G-LS99L+5=R.<X[^;7+
MIM-=;79R13=S/1=R1S>GVI53.Y=T67=^*O=E6S=T8W=U8;=V9==V:?=V=3=W
M>1=S<1<E9K9W+W=X-?=WB?=T=]=WD_=X9U=YA;=X 3!XG7=ZF==XH?=YD1=[
MF[=ZE_=ZJ==[N5?$.F=+E,(IR)=+SM=\EZ5\92!]VW=]T1=^U9<IV-=][5=^
MWY=^XU=_Y_=]^[=^\?=^^3=__9>  7B !;B $_B %3B '1B!'[B!(7B");B"
M&?B"]]>",QB#_W>#/;B#_T'8@#]8A$-X@4?8A$LX@CF8A%D8A5M8A4\8AE.8
M@E?8A6U8AE^8AF-8AV=8@WNXAG'XAGDXAWV8B(%XB(6XB)/XB)4XB)T8B9^X
MB:%XBJ6XBIGXBG?8BK,8BW]XB[VXB\'8B+]8C,/X?)4"@,\X?M-8?=?X?=LX
MC=&X@=_8C=58CNTXCO&XCO.8C>]8C_V8C_>8C@,9CO]8D N9D 'YD.DXD1G9
MD!L9D1TYDB%YDA=9DBN9DN<XD_OXD2^YDS5YD#UYDRWYDQ69E#G9E$=9E#%9
ME4,9E%%YE5V9E5^YE4M9EFTYEG&YEG/YE&]9EWV9EW<YE8,9EG]9F(N9F('Y
MF/]I.9F9V9B;&9F=.9JA>9J769JKF9IG.9M[62F,M"O^[YN].9R[>9P95)S+
MF9S!&9W-.9W/N9W9^9W7.9[5>9[=69[KF9[A&9_M.9_ON9_Y^9_W.:#U>:#]
M6: +FJ !&J$-.J$/NJ$9^J$7.J(5>J(=6J(KFJ(A&J,M.J,ONJ,Y^J,W.J0U
M>J0]6J1+FJ1!&J5-&J()6:5=^J1A.J5C>J5I^J5E^J9K>J9M.J=Q>J=]6J>!
MNJ>#FJ>)^J>%^JB+>JB-.JF1>JF=6JFANJFCFJFI^JF1NJ6GVJJK.JNY6JJ]
M>JN_6JO%NJO!NJS'.JS)^JS-.JW9&JW=>JW?6JWENJW_X;JNYSJN2QJK\7JO
M[9JN[[JO^?JO!=NO"3NP"QNP$7NP#7NQ$_NP%;NQ&?NQ)=NQ*1ND]1JR,7NR
M([NR,YNS-;NS-SNT07NT/[NT/?NT1=NT4QNU29NU53N>+_NU9=NU:7NU;;NU
M;WNV<[NV<;NW==NW>?NWA3NXB7NW;SNVBQNXC5NYF7NXE]NYFSNYH7NZI;NZ
MG]NZH_NZM3N[ QJYMYNZOQN[P9N[Q[N\Q?N\PSN]R1N]UUN]S=N]>=N[VWN^
MW[NW_4$?\J$5RI.]Z[N_^1NF]:$5/!&^"9R^_[O _1O!&QH?KJ"S B#=&%0?
MWF$&6* %*MP44"(?9D"T9J 2_R-:'Z[@+@*@!210$*Z PCL+ :"@'>X!\G!"
M$.HB  1@#Z1QN^6[M*] QD5+ %C &Q/<P%/;'_8  02 ,/:@KT%\QW><!=06
MGAM<R04@ !  [7[<II\<RJ6<0H'<HOO!"]0F,+S@I^>!R)<\"<V9'T(<RM5<
MM%@ "JY@0!4\SC,;QJ-\S:%<Q:_@"@*VR@^\M^NA!?QB!E2G'Y[\+J" !0:#
M:D%\,/2+H/.AP?.B!?3S) 3A+Z! $/0!OQ'A"A"=R"5]'/_B"N8%NF_<M2'=
MTEM!SOD\M&<A'TQ<$#Q\KA>],?8""FI\*Q22R&F=QZF\SW>Z$5F U@UC#)':
M'0KCT_]ONQ]:@1[>'!\X5:;I = #X]/IF1^Z@$0F(S%$7=5]W;$1 0J$73&R
M_2Y80!"\D]O1O:^[_,NO@#65$RCP8<-UG6K+Z H"H]T+&MA3' I\,UW>/79F
MW02H'=[W0@ D_=9?N]13^]3Y@AQ2_=],? :B0.*O0![VA!_V@-,1(-@%?@\>
M_IU=T\2EW2]:8 ]HCS5UP@O<?.(G7K_\X1ZB("\0W0OV&VKZH1ZN -P'@P6Z
M0!#T6Y[](1^\( HZ?3 NO1Y0,YUOW@NN -"+O@6B(,\_?IV'+^>+/B\J?NH)
MVA2N(.I9?@8:#-YSGN+=7&E4CM/]HLW!'N7I.>##O6K .=K_+:/@6:#76R+H
M3?SJ66 &KJ >GKTK^ $1W&'D-W[CKX#&SQTEF+T<NE[B:?3%3UPO@IT%KL#Z
M4/IJ&H/$NZ#(0[V?]X#B)_[2G?,>0KS3:?S1W9SC$\/K9T!:1?/L";_C:<^=
M-[WQ)][C\P4>1KX%!LX?6N'$63[GB;TK]$'P8]_P$;^=HYWS(_TGS]P+!J/(
M66#/Q^+W4UPO>#SB^('I)7X&&-_B?=_>)?\*OA H>K >5#XQ]GY _SXF\J[Q
M55\OW!P>$"'Q8Z(5Y&'H]9[BHS'Q^T$0 "+*C"A7H%P1U,\?@(4*%\Z[4NZ*
MP"CN]"T$X*]5NX(#!R+RY\_4#!,(_TCNP7BQ(8!^K=Y=85$2 4PH@NK-4J@R
M9\J= !!!$4 RZ)5^/#'.FL<B:$D!5_CI9+BRU9Z7,F/2K)>PJ,Y^@@1"B4F2
MQ8R#^;0"F-=B8D$O"EE> <LBBI=\(,U"]=</GY<H2<$>O$<4JN"S$B4.K(A1
MT)61,5E<L3E89\:I45J8Z&NBQ95V\V9%+LI2,4RE!N_=1#DX'P(!)6?<0PU;
M(3[&)%^G7MVZ7FRS_5JP%L!"D.?=@OF]-0'TBL6M[5@ =3S\*?'ITJO;I;Z3
MG SMVC][Q_[=>GB>5U@'%0"EE<I^7IPK99%4@'SY2DDCBMS*/5CY59'71^!.
M70R5!]=H2__1UP51"AEG7DRLL= "? T*Q0]/]QA(TH,M0!$A;N=!$=U"_>P!
M5F,S</C5A$!]!!M7*H8%GV5 .3@#/N#!=L\,#0(WST[UE BA?_/15R))]-RH
MDCY7U,?"5$H!=^1@[-5W8HG 6707(A@NE1E\R$V(0(^"^0./AUQNV.&+7>!T
M$3TZ%KC:D#,R>=)XW^5#H%)77#2/F0*T4-9WY;V'&5#SG71/D8HB!\4].>4W
M9X$11LJ:(+$A0DZD01[X7(\9_71><&.6^>*)'?YG ENPT6,96"WH9B< _'3A
M7V/W32=/D4T.QT][FA9*7U,H];.DE3)%&%]]RO'$#XG_B86BF6'_W8K3/5\]
M:RI,*D818C_-17J%>D6A->$,IJ0TRW&NGC<? E<("( IONT'H[;[!<>FG3X5
M.919^#A78K@YS5(/P.S&N"5R^.ZDY(LL0#$#.:U2&2A*[D0:EH.+XF;I5H+4
MFF%)R*+*@CPA.C1Q2? =&"?)\NR4D7XA0WMJP"<#4 ]M7,JT,L@R60I;/A//
MH)MUL_V&@&VPZ8.; #.4)=ZPM)5\,TZ"R'P%U+RYH]\>55\7==A@C\W==C+$
M*C;:8WN7YU+DB"NBK_5Y$=DL,K=V9$,%\XLE;/C$B32L&+5-X73\Z$R2F+N]
M R30./&3CS[YW$-/*W4[ZV +%;;U[7N"_SS52CVMY#-Z*PHN5*R>\*I4CV]S
MOKLV /?,&Y2H4/WXWU Z&?>? )_'KN1_7A>L['(8:1FII;@[R$+?_B ?,A2)
M?,8@C5HO1/KD]"!R.E3XI$Q24RJQFGO55P1PKZIIH^3/U9$&("Q#^=&+T'2#
MVCS>Q4^^2MR%0,+=HM2)[%P,V=>36. IK;0"5(UQW$6R1SGN[>9[N7-*FV@G
M,L%%K5?U 0Y"^L&/69#.%%TI$E "=!$.[H<IUX,-@V;$&J]]YD+F 4K]&G*^
M>]4#=-O+GNE0DJ/_1 $?6[F'Z'P(%6_=36#C A__&)(N18G/+'VBDO$$TX\H
ME"@]:?,)QA! D/\KB/$*Y$@6O;RP.3X5:0;.2TDKM!@]RQGE;B;(V@0%88K2
MZ2-$^@M85@1SM2*U@("# Q,+Z+8;02CJ<RHAEX.8<C-BH2]4OU-(/@P6DRD*
MIAZ5R]YI%$(^+M6(.,3B#W*B $ 5GO*/$]29TAJ"CVO)!)$#NX<@*L>F]NF'
M!=-#C?L:!"U300P*34)7%5<SR-BM;YG*S([9NH.D9JIMFH1##P#9HQ_6H/(S
M:*%2W@" #P&&SX+3+.1^]N2=9F%FA8:2DY6>=JG%P,= 1.J=YF CDGJR,RP#
M^1T4K]8[.7WIB\#1X'5RM",$^DA1+6P(/Q+FSQL%KT0R]$>N:FB"SRW_,%+;
MQ)F5FI="#+)+H//)76QF(9I3E?2+)F&EF\IE4/G!<2D+6^8LW"'%6R)B'CJ5
MQSJ1P\3!W"]#L,L?QOBGDW"BBJ1#>A("9'B\3%$R7['9*"7KEE)ZPE!1[7"I
M$V-J.%JQ=&-!:4%G!M.K)<I1.KE:*GWD!*;,%*U-F'R2H2X#H<<\94326J&)
MLL8<M4K'D4$Q%[K4%10T4B<1,[7K0)M:)"\$!CP&5)0^W^.%*Z*F'K+L(%Q]
MEMA<N@-57)H1A!S34 #T,4,SH*I*^('!& Y''N K&6\^1B\ =M-58/4'8^]5
M21$AUH3T@<\,VD'..1*4J2SM%Q3?@9EE?<8?__K 1RNL.UF%3)0U+XM,>8##
MHO&-!"A$0PT_\FA=TJ7WNJ6SKO,0(23E,+.<\XUFV:!9W_Q*$S75?-MZY!:3
MCNIDMX7]9C]H=2]]5&<6_6@P@UGICVJBDSC^Z-.$LG::?GSRD^SCL" PQ@)W
M\$/#;)H'I>YI'9#P Q$N$0AHW26NV9W'!.7U1X8W?)=H+F1V$[(=2I:GE-3*
MBHX1C=I$E0)5&T=AK$&)*#T^VC?>[<=D.+FQ:SF,)R$*8H]L.G),UI'<4)8U
M2E5MK ==>YTLDW7-&6H!F54RU-44%3NK1>9<D]B._[@C(58V2BXOU=DS4\>J
M#82*FI42!4&$L,OB1/] 5\<GTB?>2)6X84%X839I+^1NK45I'9'^Q.65;/C/
M-AX/7DR!"$%TH;/GI,Y-_)$/06RD,I<-<5:4""X J@1S9=5@%&<LK.JT8J@>
M) J)_<P^9'>1@4(9&+-C\@[B#'M.Q1ZUJ$G]-2CRHQ[U4 SXP$)+U5)J!MU#
M386E)0#%Y;/5GSET@!7,ITCW]K=3=35UZ\%BJI V;[\&2R7[+)GIY.PR=4QC
MK(B%UV4]Q1][<(X=VZWOA^N8?8*X%@*S/7']TM>99=NXQS-.'A5Q\2+8W*J
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M5CN=T6! UQP=E%'9U3!ZYGQXH21TU%JPD7)RI17T1E/_9F'[\0X0)A6*\DT
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MMZUY#^-P -D N9&;#=S@#6!F%_E #H\KN9![ .0P?Y'1#^BP#=F@#9%[ .@
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M#J1]#[6M#2/8\5!D\$/O]D4/]V\O]W%/]W-O]T>_]&N?]TE/F$W_DRM6#_?
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MG#2!(9@18QK%>H+PTP=D(8'X MN:$-N>3<NR15N@75PW5=NH<$6NHD5S,$T
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M=9I>FD 8;U J52G%KWR'>BR^)I8JF5D?,OV(0^2&[QH)+06AFO7!<"5A];7
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M+NW7/FW6%NW6ANW95FW:SFW<WNW8KFW9=NW;[FW=%F[>#F[C!F[4#LO%;6O
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MY_*.T/>85WF9OWJKSWJ"U_J4WWJO3WF:3UN;5PU]2!3O]+C?0ON!0="U !U
MXK_W+I,02'. ]Q KAW=(R/IE&SE^$7QHEH$9A^$;XY"O][&-^G0V^:^O^L-W
M>:Y'_*YO?,9_?,4/];#'UX6G]"YQ>L&_1,OW&*J/?,?W?,B'>= ??=$O?99?
M?%&??'VM?'R?K,!_^IXE_+\V_,\W?:Q/?-M'_=S'_=/G?6U7^+'??%5^_<SW
M5N&7EL[?_=KO_>6__>;7?>8/_=-7?4;_9?T.-Q7BAWU<E?VDIGWI=_[OAW[P
M)_WH)__Q%WWJ'U?KEWISP7SM[[7C'Y?D+W_E#W_?%W_\OW_]?_[T#];UCW^
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M>GR]W$'FQQ64;@*T$X0>,RA[ZVV.*)#4 PI*AQEC_.$.I9= $ ?)1Q=F#P7
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M[=F_-Q]_O7SW].'/QU\__WW]_UF3B@XJ0*)2$K HH0PLD, !>5K0IP:!>O!
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M/@FL0 QDO^0"HW,I/_"#/BP)K[&"I!,TP12$,W<@NY=XAW#@AEZZI0#[AG6
M*ZW@AW7HL!FLNG4PLX-@+F^ I'10MQ$</R,,P2,4P1>2ONQSPN?(!VB:P2FD
M0FYP.8= ,RK4PG)PMH+HAVKK+'FH!WD@)FTP!V?SAW:HL3Y[PC9TPS><H^U#
MPCE<0LK@!WAHAW=H!W?(PSWL0W=PAXZ"+&MBP8;(MK&"K&^ AWK AT!"1'OK
MM*J0A['R!B,#@,W2I% KB'O(+F[X+"4$Q204_T4Z#$7E:3T*5#]4M, ,5$4"
MJH=,TJ1?:@I\& <I+*1OX+9-M+@+FSR!F,1(ZC&!H =8S 9_8BYHDL4.9,4-
M7,949$9EA$8-=,9I7$5E++Y1K$-LS ^"NR6QDPA^B*A;VH9FL@IBTB0NG$6V
M\RAU@#]]4$>/&JI^>#./0BIMM$=2O,=LQ$<X A X]$=!035-X@8-0XA@HSH;
M) U_2 <#N*5OZ$4 .$2JD\%O\+> -(=/_,>,U,B-C!XYU,>/+$7!\(=[2"9(
M$KL6]#$9K+IK(PMX""C(@@>I\(=20 =O^+IP((=U^"X @ <+PZ9]!,E\#,FA
M%,KE.3]JY$!IK$:E3/]*FBF%&>2&K)N(59!!:^HDCG#)&?0F#ND'8BH'?QL(
M?_A!I&S&I6S%LFS*9V1*M&3+:#S+)+I&H"1*N<P+>= &&>2&K;R*>K!%7W('
M@7N)K+PE%AP+P1P'N-(Q<O &;[ Z<% 'QRM*NI3,H)S,N22/)N3(S/0-P>2G
MG20-:+BH6^JWTGB' [@EMU,-RH*DCP. L]+";!@'P]/,V:3-VFP4C[3,W(Q,
M )BS0:S$LP#''82D<* KE/"'DBPD=,0*?%!'<#"U233)=YB%?L"'1[*F[:K,
MW=3-[.1.RFR;HS1+M7S+M73+])N'J_,H>>"_BO ')[LESUH(BZI*;V##F9C_
MAV1"!R\\N4+RP8+(PFP A\PBSP$=SP(5SP,ER_),4 )%T$G[0*SISNWT3H80
MJV[\2;H8QAG<!G.X!WQHQ'2(P5OJ)['0A_.RIGEH",H:JW0 S'(XP</4SAB-
M4!F=4!IE",RTS1QM#7GH2Q(@S-5HLM>DPG"0S8D8IE8#2X.X!P#;!H2Z!QU$
MJ_K4T2FETBIE#MRTT2R5.U8;Q&MZ#'YX!P6C.JK+R^+T"C"\.4^Z+HM3R4K$
M-PF%4RVMT1FERU-LT+1<4 /-4T6S"B?A!WJ AW<(5'I(4A/I4XG(!W>H G30
M)3W(K/#<TTB%U$G%4TIM2P:5U$K5U!R)RSGUU#BE_]-/E5-0%=50K1@<M=)4
M5=559=56%2$L-=51E=58I=52M552Q54? A!"ZX=ZB#Q=2CQ@30=A%=:_M(E>
M;8=T2+QU2"0+N8= '-:Q@XEZ0 =T\,Q+U5-+55!MQ51NS=9-W59P[59Q_59L
MO=/?ZE10Z0=X$,XQ1<%!Q"6#8PA_X,RON[J3M(H,W8:U$T)<,M.=*(5J4H=9
MO56"S=5:/=B"1=CV0%7DH#_\DS_Z>[\[U"1S*%0 "#GM*D"",#F44SF&.,]L
M> *-ZDW6- AK:(>ERCE79=F6==F7Y3Q871=V,TEV5"AB2KF7X*B[](9@(@BV
M(L2=X-)VT#JILRR6--BD7?_8I578IDW8I\T+.YU&?N L7_I8AF"Y;)@IB] '
M6R(!HBV(8H/->2,[@)LK)#LY;2C$<@U7<\U4M_76<VW;N1U7N"57N:U;NF5;
MBTA7BUG20N*TJ[@'J +02(P*?S"')WLU?3#-WU0(>;2V!ALU;>A/IU5:RV5:
MJ,W<R]7<@6C8YZB'9$+-J62S(C6(>=R&8 19RWH"M3):7YJI?L SU879VK7=
MV\5=%9/94JD' #L -G2*'YLH(7N*J=L&2X0UF[.FNTPU4V,K44)1) .Q%N3<
MZMW<Z\7<[.U<HI3::H0&,A-0FE(P%M6)![,FX/5"?( '>"B%>V@P\_*H>8,'
M<MC_05\:AWK<V_S%6_U]6[W=W__MW[P58/Z-VP NU[X-E768KK6="N'%SJGH
MKFU@K;CH6FM"A)\U4;?SATNJIF\@1^RE"WV0@0!  !,H800H@1,V81-.X14^
MX196812.81:>81EV81J^81N.81AV81Y^X1KV81S>82 FXAP.8AWNX2(>8B-6
MXB1FXB=>XBAV8BG^82B>XBNNXAT6!.VU7BX&8=/[W.4(W>3$*=. AHY:ID>=
MB-#BAHLUXXL*AR1]RFRPV)QZI&_HPLWCAQEH81: X3[^XQ+VXRH>9!PN9!L^
M9$ FY$ V@4069$9VY$:&Y$E>Y$HV9$J^9$M&9$S>9$U6_^1,!N5.#N5/%N52
M)N53?N1*9H$MSMU6=N6%V5U*Z0>;\P;7?0I0TJ2KC KYI.,;I(I^N(=' JMY
M50=( B:-0 1;V@9-]&*WT <^KN$<EN9HIN9IMN9JQN9KUN9LYN9M]N9N!N=O
M%N=P)N=Q-F=P7N5FWMXN7N?2Z]X+I ?3I%P&"3F;C8AMNC#K.A!:#"KW&HC]
M9,F">$5?PLB[-> )>>8@/N057NA4ON&&EN09ANB)5NB*EFB+?FB,5F&*ONB.
MSFB/WFB-9FB1=NB0!NF1/NF21NF/9FF3;ND59F6[E6G_/>B:+N";-FB<1M<'
MS1A^<-%L. #5-0MF"["MA37K]/\&U H+>N@P&)6(7_PHC8@W(F5GLTCH<L;J
M<];JK.;JK?;JK@;KKQ;KL$9G5J[J+T9K=?:K,$:.?-BG5,OCTLB'T$0O<ZA:
M97H"QSL-)8MCTK@'"S.'>9@'6YHH-^:\/4;EB![EDD[L2'9L3FYLR&;LR59L
M4Z;LQ_;DRY;LRH[LS.9LS?9LS%[LSX[H='[ETT9M@8GE+N$P8PX,YE)>;=B&
M<D#(N@C=;9@VK^ '6NRE;WB')#UKK[CJL29NLB[NXS;NY$;NY59NK#;MX&YG
MM4[KPGKGF1Y@ #;+X7;I[5YI[E;I[Z[L[A9O\.;HER9OD@[O\T[I]&;O\O;N
M]D9O]Q[_;_A>;XB.:9K6:?S.Z?VV;@+F;_UV()Z6;NW5;N8V\.8^\ 1'\ 57
M\ -_[NF&[@B'<%.,HSQ);8=!;- >;=&V;-+F\,[>\,W^< WO\!'W<!%'\=!.
M\1!7<56^[PN'\1@'E-4>\*$L< ;'\0;/\1W7\1[G\1-^\!J7<"&?</"I;@!'
M\NM>M!NG;_-N\O>6;_5V\BA_\OFF\BN/[RRO;RV?<BZ'\B"^;R7/;S'_;S+O
M;^PN\P,6\.AF<R;_<1^'\S>7\SBG\QH.<C8?<CPO\AUB:QD_E P_\19G\4$O
M\14O=$$_=$('\41G]$5W=!)_]$ W;3^G]$IO#AK7<Y!T\SKG__0Y]_1.!W6P
MOO,\)_4]+W5_.7(S3W+_UB(FQ_(MA_4NC_4OGW4K]W);KW4IIW59Y_5=]W68
M'G-67W4T/W.;3G-B;UL$)O()W?1/=_90A_9GE_9K'G53M_9ESW3"Z7-+%Q1
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MGOPUCCWXNY_^W:N__>Q___<=2G?1TS_T]N\\Z/'?W[\S?O&%![S_'1X #MX
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M AP\SA_>X5*\X1X0 Q,OQ5DP^.<>6((C.(YQ$-8TN(WK^(XO&(]_C'H?5R%
MCAN\;2,X;2#<X3">YU1<\"#P8>/ X2:@87ZV ;HXXMJR81T*:W^F8QUF,GXY
MN8^-8GO%MWO'-W%)^7L9UY1CUGPM-WT[^7P]F95?&7YC67Y=N98Y% )]RL;\
M(1]^R!LFSS#HH86A3R+@(3Q6;C'RX3U(()M&CN)NI2+<H1*E\%=>Q1PBQ8Y;
M[XWE>)OA^-7R^)LS&)RQ.9QKT77-BA].)ANZ#  ..1M<XD;Z8>.VH6N@ 53
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MF=]<KB3\3=U WL<Z'N!M[MP^GN9,+BX)GN1';N<.WN!#CN2CMN1Q3EH5/N,
M: [:8(&NX0]\^00:<B[N4#VD@3CAH W^9XIWX:,DP UYFN'%'>B?P>&QW>$D
M[M.S[>FC'N(28>*:GN*;GNJ4X^5A[NI@#NO"C>JS7M,;.4<^-@^* PYGB1SY
M$##?6 [D8 Z0F T64QSJH"'A\ [RH X'$)LM)!<"B#QJ+G=LSN/7[M%PCN/;
M_VX[UDWD=Z[GX&[D>/[M?$[M%-[)XL0/@$#L^7*65$$/C1(.@$H0@_.-[H 0
M_= .)# A!I$/?K,W".&O",.O9D[7Y83E JWE69[P>[WP"H]A"&WP8-CJL2[F
M%__J$(W8$]\D:"Y-^H" I4("5+?KS'$/D&@.D\X;_*<-WJ!_ * /@,$-^-X4
M[8JGD0)"@YX-,WKNU6;M;@[T:ZSM/4_TUT'G>3[NX4[N>U[N0R[A<A[>.ZSB
M<'$/C;(-Y5 /$\,J9KD7]1(8''(8^N"$IB(J!#&%Q?[N W&%-GJ!,.^-VR"*
MJD[K%VYHPOOI(H[WH7[W>D_JH+Y)=#_WF5[KR%7Q8_]N^!AO\84MXZL>^,]K
MX]N$#^D@@52T#IE1\JOI-^. B;ZA\]S0]OI@(N/#$/Q EB.2*BSR#?10]-3V
M\]CN^FH\]%"_^LTIY$EO^W6^].*.^VO=Y]S>Y.FN3UKO[D"2EN:RED(""!HR
ML 9Q\K7G#H$##;(*L 1A#8 !#@7/\0?O\ W/UQ!OY0S__=Z_Y=D_FH6/^(>?
M\>>?O1M/_DGB\:!;^=IP^;V1GJ[I&[#)DE*A*N'@[-\(#GP*$ #\Y=NF[4D^
M  +[W:/W3AZ^6?X2"IPH,:%%BA<K;M38,>-'C"$Y@APITJ-)DB=+KE39,N5+
ME!CUS2B!P(1-G#=UYN2YTV?_3Z _A08E.M1H4:1'E29ENM1I4ZA/I4:ENI2%
M()<Q6<+<JC5K5[!?Q7(=ZY7L6;-IPZ)=&S/1 PAP(<2E*[<NW;EP]<Z]:W>O
MW[MY _?E^[?P8,."]RK&2Y@QX,6.)2>>C-AR9,J9+S?6C'DS9,Z?#WN&\$AM
MV;:I4:]FR_IT:[0RR,DH1_OCQ-LC<6/<C5OW;X^]^;7+EBU</=X3Z8W+IBT=
MO^ 3W7'+MJW4[W[^LN.F!\XX/H'\S!DHKDU;\W+ZDD=GG[O]>O?QX<_W_;Z^
M_/OTZ^OWS;_WS)I\8B' G ;LR4 !"=0)P0(5M(G!!1TT <('):1P0@LS/%##
M!#?T_[!#$!O\4,00(QS1Q!(K/%'%%#%<T02L@,-OO_QJI/'&_FS,$<?>>)31
MOQ]U['%'(H<T,D@?[4O2O;<.$^S)T* $3$HGH[1RRBNKQ')++;ND\LLLP>12
M3"_#-'/,,\M$<TTUH2L2R3>5C'/&.8&4\\@[X<33/=IDL\TUU6 S2Y]US@.G
M'I7J(:<Y=;9329UMLN$&T=/J\28;<-0# )]%MVE4HGN8XT8>00-][5134P5T
M5=@ K.K5J6*%=599:Z7U5EMSQ777FZYB%=5?52TU6&*'-1;88X7UI\G.0O/L
M66>C!6W:T:2MEMK'KM4V6VXK@Q9;;ZWMMEEPR=TVW'(#,_]-67:+1?;==I,]
MJ<_:RKGO7GSSU7???(<CP3A$[[,FG>)4N"=?=(K[!AI^$UKEFVSLG>B=XM!A
M>*)0LR%!GX8[]OACD$,6>622Z^.')A81")#!E0EL&:>7;XI9Y91GMKEFG%V4
M.6>6>7;99YB!WEEGFHF^V6BAB^X9:::7=OKGIJ%^&@%?2[;Z:JRSUGIKKKON
MN$DRPTY3;#;)5O-LL],>>^VRV4;;;;7;1A,"-[VV^VZ\\P: WC_E]?LU0LT[
M5"5_W"DN&WIBJ@><\\SAV"Q^X"G('(O\\:?0;-SI)R-\GF@N\7CA=3=TTD?W
MR%5=4^=U==5;9_UUUV-?O6K1_R[_W7;3<=>]=M[;8O9<<\<53?AO@1\>7>.+
M)UY<Y)=/5_GFHP]>^KG6S;WWZV_'_F\_ZZ5S3SN_#W*XXHZ;KQ]URJ?4-W[*
M*<X;?%#:S1]Y+C4'(8P,SZ:=N@&8!^*-+2E\ Q22G@R8)P2*+X'T01V)'(BB
M!Z8,@A.48 6)1L$+6O!"&^10!#/X00Z^*(0M&J$'2XC!$UHP1@LL( L%V$(%
MQI" +Z1AG6 X0QO6$$]@@UL/Y?:V'\8-B$,48A%]2,0C&E%N_7-A#IT(OAM&
M48<'E&$+^S0;B>U.>Q,)'*8"AA)HN$]CZM#'++*3#_UE8QSS (L_*):-3VV$
M'M3)QCHH_](/<U0L(EO,7A^UZ$>9H$QV@X1=(0EY2$,F$I%#H1T?__C([472
MD9($Y.^@-SU,'B^3E]1D)SGY2>9M,I2>'"4HGR<NZT%RDJL$9.CXED6]98U\
M -.7&R]5'&YX@X[9\(;F&J8'\SSG7OH(Q_O&08Y_@0-TL61F,YW9+T%.;6C2
M5)K4K!FTJ&&3FD?;9M*X><UI@K.:VA3G-\EYSG"B<YSI9.<ZW?FRJCU3GO.D
M9SWUQL,@)E&?^>0G$ONI1'\&%* #[2'=['E0A&[ME:S4'3_F@0YTK ,A9XF<
M.=!1#G2D QX!0\L]TH&.ZWS%'1>-:#XHJ<I6IO21#5RD(EW:4O^8OE2F,>U5
MC$YZ4X;B5*4Z12E,?N>\Y)52J*<D:E"+"E2D4L^41F5J4D69KM+P5*HYI:IK
MNF<;'$)QBDW4ZA.IF-6O2M&K7 WK5JOX0I9JL(,H7*M:1=A6$,(UA7%]:UU)
M*%>\VM6$>6W1"L\ZUK]V5;!E!2Q8R7K8P!)V(O@4Z#X;^T_'$A2RDWUL927;
M)K,:-K&(U6QGQ8JG*_9MJCNM:D]':]K2;B^M-)UI:UG[6M?&EI$V36UM27M;
MU.(V))8<:E.5VENGDO*HOQWN4WUKW. NE5NI/&US;9M;@2PTH=.E;G6M6\^3
MF;.=VGVG-[V;S>U^MYO@[2YYN7M>\9;_,[WJ-&<\K_M>^,:7:XR];'TC>U_*
MVC>_^+7L?0TJ7P!75[K0=:YNGUM@ C]WM;)E,&P=W& (JZZ1!J9P@BN,X)O^
ME+C'%2Z'E;OAY (7Q"-&+HD[&=4#I_C"KL0B5C^K6!AS]L4RSNR,-WMCS]88
MK8+<JU[9ZF.WWA7(=!5RD7MLY!\C.<A'9C(&_9KCPMH8RH.E<91U;&4L[W"_
M6^XOE_7;93!_6<P^9"*.I7SF*U/9S%L-;18QK&(+Q_G-*R[6@A]\YPCG&<][
M1LJ$Y0SG.?^9SFCA;7$['&)#?[C$BSZTB17=:$8OAKF IO2@TS+@ &=:TYNV
M;G;7&U[S?KJ\_^,EM7I#?>I2LU?4Z$6UJ5/M7D['6M;PI2]_Q^QE6^<:U[L.
MLS[_.VM@WVW @29VI05][&*?CL=\9K:>G=UL//LYV<@V]K0QK.%(BSC;B=8V
MI+W]:'!W.]Q0G;2EJWWNBUS57E..\9JSW&YV5UG-\7;WO&NTVKGFFZ]-7G*2
M^4WD?^M[R )7,L#]?7";/!G-[Y8WO!=N[S0[/.+LJ36O;]UKB^L:XQN_N)C*
M3&^0/USB#%=@F]%-;7.G'.70M?.S70[ME\=<5](^N;5K?G/7%-K#XN8YMWV^
M\Y\C&NA#%SI2R[URFZL\))@.=M.=_O2/>;K5JIXZJ%-M=5=GG>I7'_^UUK&^
M=:]W'>SGA#74S7[VK56<XQKO.-O=GG&X]_?7:*=[QX:-<Z3C/>EY'TO+8?YW
MF0<>\$^AN=+U?GC#9P7;W^XYT1W=^*(_/NB2=[QF4)QXOF?>'^JN]\@A3O*0
M3[SS#2?]Z"F"[WTCW.#]9OWJ74_P@*>^];!7/>U;KW#1AQ[T(B^][C__>^"H
MO>UQ'_[:B?]VXP/QX[PWO>\]__R]U0:+B-<\]?=^?2XN6_#;'SSWMU_XZF,>
M^^+WG6$FO^W*,_[\ZD__N-L/^:.//_QR9GK=[7__3$N=ZZS>_ZK]7W6Q^SH!
M#$ "Y+^P,T"R\RO\6T &K _A0[[BBT (G,#_X\NXN6M !KP[\MO ^9,_^?,[
M[^L^$0S!/ ,_#[0^%+2TQ7._R$._%F2_%V1!RHO!;KN\#DQ!T^(\Y^L]YMO!
MYNM!(,P]($2]@9.]US-"VSO"(ES"@DM")T1""<&]W1-"*IQ"*P0^'IRX!ZS
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MC4DE/^^X1R2@/)4"9RD P).1.I7.=$]PV;0C)C_K_ 6?HH>^]V@^53"DC3M
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M/\@Z6$2"#XM1'T+"^FN_HDP'O_;H0+<*U=8E+#)SYX#P*U-F7@:N+"Z3/?2
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MN'+#.)?;9"!BMRY]-EXH&I5A5%B0MAN>MC:-PSA((B*X1VM[!:/@!=SEASY
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M26X[_?8W]CYC_WKV.6/_OG_.. WCS1AD)>]\Y[.>.><SL]X5S4N-"&%R<'_
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M\^Z)^^5+N]K"6ZX<>9+#VZ(X27& GS*U<=4D-*::O",8J#?.$JQ<@7C2N$M
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M$\JY9@WB2C89B[[:XAW#!@V[RO9G,TP_\6S@+GL2'IZ_ .%['2R',($*GR3
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MPWV*H.C9R-YYG5IRF]SM:;& :@7?K(&C"*J?N.83Y!;"FG<H"[4G.5_B4U?
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M+?<]"VT-UXAKZ5DI#:0>;QI]7=N \KR8F>MYG:]!&%X2 *R5M^Z3)Z7('J>
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M^67OL-:ME^QXYM,7Q[+<@2M3-N#=W :ROXB1RT);)5'-.,,IK]*"29,_P*_
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M*%8J>W_W]_L9]MZUJX&4/+",UT2?7W'364HR8WNJ^ 2D:F0/[%!T4L6<A09
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M*[@\,6$4Q=CB$MLSOKA_V&(HF'(K9W]1*1*F#FD[7>HE#9[-2UB]X,T(-D<
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MHL]!3]HD?TD(EFE/XGDYV@O;B4F+V49* \$$.?SIHQ?=:NK)^S'E$.4;='?
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MNW0F,J_GJ.#_<_=;\=R[EB7Z0$O!$R</;\Q+>B?ONHQ_2)1'1W!N^TH"9.7
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MV6X7L/KD;+?A0B,)W49HP=K>D$/F>@?!VY7R)-14Y5?!8,Y'9)(P#Z@K0QG
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M)4.8';>15.$\^E6Y7@G8B._'3&XIE-QD;"WG-O9=*4<2@SH/S)CTTWVW\*(
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M*?B>6=XN. M)Z[ Y#_6W!)%*NE5^M<;Y%CL>R8Q6\.<,]_&E_-F<GLF/UU5
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M\AM2=$393HF3,:S-,Q!F"3&+VDR4F:.CO /-4/>;S"VMXE6G8&!S#>R-9.^
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M)RZ4G-VQ%3OXP3]FZ@:'/Q1NG_9&F"W6./R6>^JW;<:/_Y.0^=^:D"%<$UX
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ME?)A&AS1()^![M2%L&A0T?!1-;^7K@YHHLU#&8BO8L2:M:X+]5-3IZ+?(F%
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MEH6Y4D[^.1<S4/<_E^>\R_Z7N[S7LU-Y#3 9$T!YV/EF#C3>Z8!@N)B2EN+
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M@K>[>[Z6R8-Z!CJ%B=%7B ,T;2$2K-L6.TZ"MK6=!LR$D=RL@I4=H*(DG(@
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M!P;YCE)/Y<F-5[*(<?!BL1?8W%HR]43@ANX#95"S[/U#,^V%_5J&9H/."J7
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MUL)NGT!BY@C;KC!ZQZ.C1W6K_U,%\F]2!4+4T.$([4_0?-(,U%3GPEH\6=/
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MZV\ONL?("F[6E#1?.NO5Y?3%I93*A^O+-AN+*^CFWUT]AL=0W$\<^+T.6-:
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M[OZT\UGNBV\=MKS[%5%1"S96\^Z[KXJ X]6_K]R\MIM%.IN;:R!\572;_\Y
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M6"(;8ZY;X^@\!%QF5GU[..IC.Z;W$]Z$8_F)A)@ %5P^=D6WG(F&XC5=M-7
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M,/\3L,_FV>]'7F+>2Y0QX+, $QD3-N6I.[/#6FJ'<%C*N.[:N$1]&G3*U(V
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MJ#]'ST_0<2 +X \=G711M>=9A0>DJ1.A$9W+#N WS:A<V-<;.5BDO1]QHN)
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M&QRE;0?+1^CG(0SOSC^V1VI(");;ZWP%O1?MW!:SKN)GW%: H)P#,1T8X$2
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M-[."5PU@\ WJ#O;$_%!1&,YISZ+>3P1QXDE("8S+4_)Q-E49L/4E*5M<I:Z
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M&CM3Q966X>M$.?!&30QD(U_5=!.WTU>32DI55^F4'K_,96"VA6L:&>=*V]P
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M)WCX)R=$K[Z76EA\9$*,NZ=.NWOE'P: 1=9^!:WD$MA8$J1ES3&SRC8 1&4
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M>.;24I+V*TM>@X9UQ(M^W5<9@%(FDI[K@J3<'5Y=I$X9JO?W] X@K*24=&R
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M3LLBGC981K[AX2,S;+G-B@B;,BNR"62>ZE/M[+>2JO(EP)$#MD.+>N>3 +P
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M!9+Z[@S.*H@N]84WV7F#Q]C /MZB'NI%*ZD2#H16L;R _F!H"ACI(&Y.5FV
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M0Q>_SH+3!728 EWL)#XD\)$]A&3^7/Q//O+[&[.)$%*MSZ#%_\^BAAQ64^;
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M4,"(^E$0VUG;LG\HO9.@0OX6+%O^W<L53C\Z/S4P2AFON@]U2$\PW8K[WJA
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M!%,9NCYD_J;0EA.6,AL4I$@02F@"%]A.Y"5H>;F>'+A&Q"ZGX )154!+47C
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M$Y#(L/$V_2BXDBTZXH^LPH?1B'&U;(%J"7),<"^&DBA?Z5WN;7O)WD'13UU
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M)8S0.B]C?G5C%6HV+S5[_Q>F[2SA:%'F;&#V^:[;CLA#1*]YO6,'9%^<T^7
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MPK,#6>TZO+,/M2,T?'!':1?'!E)1X[BNQKGO6L)6W+>_]B260WK5!>+I>\S
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MG<2[_![_?#Y_0/E1Y^37VYJ^13S\X\F%P.>\9@>VG'1R*R?)5 8;G!OL];'
MT@^</'@WIL:5[?BXV;]@N"RMXECO$<[CBM2N@3SU[UY?4&,Z:54K3'20(0NN
M>LY/Q;];C;HOR"HA 2@Z\/C=[>?YJI8?YGO0&47*5S.^RWS+NJ!UHTZ]?-Y
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M\EH]^R.Y$<8>?_8XVS^VL_GDD>[9#L3N2;R[OQFRL[XG(7G*5]0UUXQXAY/
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MQS[(/Z\^@_*^)AJB,DM Y!]KJ?SKN*Z+T7.?V]EX^LP^YF!6TT:B->&=V#P
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MM$$IN-'5-Z[)M_:TS:GZR_M<P-3)Q.9W#-4'I"&"2[3-H_*0V?YLRYE6O<.
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M=?0$T'BT0:4F:@?/?;Z;ZU;+FXC7(ZMS(K!2$(/#;%:W%*.\7I8W] ]<#IE
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MQ7;A8-/JEPS?L&=5V=GY>=X?CN[J\/08?>UC<'@3]N[$Q$1 S5!F3F%$6&&
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MAP,OQW4/URA(:93U"$V5EL$0V+;4_9E@F=7L^Q3)$O''MA5WMQ'"2PY'JSS
M=E^*0$JQ@]-2V99,_5:W4(L>U&L>6%I&64W4LMZP941+W&'N M!I<'G$ G?:
M6D%8[0M;*O*G R!QZ_,/W-4XI '3@D($N<NKH_R#5A:%*;N(;;)WQ?-CY+[+
ML94.K8TQP4%,L:@ -SUYG0I<-=X(9GX+E/SA^,]2/ZX47-??X:D!=XG]FD4]
MG*#?] 1%FZO(=M!G%2"6KT(8[<+Z_.E2-<W8(:.6-LSW@O=$"+;TLYR4T6Z2
MH%WE2FOY^C'$VZ]75<"L!:WI5N]>J,]#W:EAD FN!BMD1$QS95V#J>B7'GC
MQD ^[#=R:X!.2P8@OYDW2YUL*Y0VGAH.0G5H;3%2!K1331!/B>4"F(IZJ1C+
MHD(W0,9%DY&V-BT#T;8A5]5M"X/U*?7=;052\4KHWZ'[FONN \\+'#\+56G3
M72KC<,SP=\+TJ-8,-8 [IAE5K.\0)X4\DZLO,&(&^=K*V\:V%JILBG_9]<LY
M5=9^WXN?? )1@GUU'WH$>I]Z.6[&+/+3TA&2LQ7[6_P':FDIH.&BWD4BXD[3
M/$9B+F@/LPXN]8=GV>I2FY/4'L AF'0=/%^T5W,%\DZ/Y2P?-XYFQ)1' F8,
M%_ER)-<?RD]GE.V=")*FQF5Q;A<("AF)*[-5P:-[L+'/HE!K/:QA.^\5$=G,
M1<VX&J[N.0^XU#T,:*9ZV-:1Q'KJE#X<=A Y!^\]B_QPLEL,KIV-CD9/EXR/
M[> <X;]L[%W4J[L/6UXG'ROHPA/KZ_P'OA>>()%I*63'F'VU3?^D:?!RN80R
MY/PTU,Q:!:*F=MBJ?U2@/LL0XD_Q(\M_UT:R1T-=H3AN=@ED<#LNRRG*FGA+
M8-Z#!M^GAQ+K&AL$SP=B-XQ0H;$&-=646?']T SJ4H68M@(FS7XJ8Y;^PK\?
M"G.$.41KH:*9"WE.$@C8H+#><GH;U(2MOJ9=-HPT*=_=T'X_+B.(00)K)S(/
MI1*LSXXB)T$SIO-XL2DTQMEU@Z&JI+9:A?X2IR)936J*M\/;QK*5G9S5J'.R
M)*$\>S/&9R]UNN"TS:01"=A.%!B<;CZ@ #)M#2&>!%@^.>0W\G9XDKT>KDHY
MIZ(:3VCR77//!KT-C@JBE(9?6ZZ1FHYTFOV^=:^/M>-S \;_Z7/;GP?__[:;
M@1X@]),#NG2H4[Y<\RMMN&-1SPO)$3[P^D!)_B=@X)W\TU&(6X7_YY/9H^=0
M',#-$Q;U#O_8ZV7^J5WTO\[U5SQJSL-6#T)RS# >DBO_^AHEP\"TD=:/W2-P
MX+RB5<]/M2BVS[G!\6U<R\-//A1X2>Z<C5@@9K@8&=N*C\/V*:6RH,@$DP85
M:(%P@WM0DC+:Y!.]R\^O!]Q,V02*PD"%$*RFW,"3O):.YP-SEG68=NN' .(E
M)/DQBX!(E4)+EA]$O'5Y^O*< WR9'ZXD98 ;2,Z5CJWN'J6XYV7442W0?1 G
M):6KV=V_1<59YO,T..2 ]N\E;B2&]-4.T^/:_:#H^V;&4Y3:@HQJ24Q3"649
M<EH9P0H)7]1;??6/SC8KAB2$% BO+%4X=JV<>P_'#?(EA9\6,&YE9/YZ'R5O
M>3/\)]GE4O7/0BB *NM4R*<N_/?4UB?L72B]N7_D^P%L'3*O++]%WL'FF\C7
M8_8L+R@\G>6A8*0./8DNI=]Q0+<E/,/C>=!E8VRV)[6'[&%2I_+]\>V'!0_M
M=H-'3"/-'WA(11'?6,UH!G7ISIOAU^IV^3(R"#LJB&)=T(14'%#LBA0J>00D
MQXFH6-3+W,4][HICO=7HL9X+2*3J'39TI^. -#KN=(@_G;X[ 8]*$/I,0_9Y
M8__R5-#0P]05X&>0M@3,:X4U8%OW, <S--*Z,SW5!PL?,^/;BMV$\/MV)T D
MJPT8DO&2T<TPT.8VMA7*RWUZAO;(+S(A[\%#*EV5I=L^,G*X;)1Y,WC_&U._
M5"W0U%CVI"PBX6)))3TH.X=3$J%Q2RBKK(C*O[K OE<Z7I#4G!^_D%,"QF]U
MK?=W]7_>&1,?'[/37S,$'W;NVQKQIQZ0T\7 3+Y8ZB'',M)5+!T'.,S5X"7]
MIC_JAFQ[PAZ26Z+6"J+1F7&Y=4"'K4L3]+I<+31D^K2-;>N+)2R/"OVZH=;*
MAI?1-L2-X04&1<KN=A4M!-;-)E"JZVD"(G1B!G&D3D7C5A-"'CE\K2?R3GT*
M*52]=!(J_;'70A.GZ>;3L%15-#CW]^NB"PYI9*O\O)(CD%I^9L*";^L&1\^D
MH9ORZTT_^"<('JB:*NW$C>6*<'2]_I$!/-J> U  0]:)&=%@ U]!HZX8#,^:
ME \'8(;SCR:' M:*3?(?G9$'A3*'_A"?K,O\["O@X[P\#MPXZ7Y!/.99QOH6
M6=13)3I1(.!6=!YA/+F-]CQ@JD8M'S$5@_QXCL R8LQ=5X(:0.6MX"J*%;.F
M[7GPY%7 "-VO!"Q8/O#MH.[KM?2*BW6]9/JS"="LKBDZN.W9Y;F(V!8WKQ<]
M%WI-M=%SSPF_"Y$M?-2"KR:BYI[J[NE<B*=*F^)':W>)M'L)!F<CV69#<T2S
M4=:QT[ 01\/G(A^BW_4W>SY"XIQ]P0/]Y!V7&I]9+#@];QI@E#'O/^?S<PR%
M#S,Q3U"1"G[ZMQ#YAH-UYM\2SEU@1?,^Y&*K';4^P%2<UA ;HM6.EH[6%3=!
M,0JJA&2.[ K^S_3%VGS5]I[+M?+4>K?=H6T>CYY'A0(#9+=RGR\UTA.-(7OJ
MBL;87=L-WN.T0:M90#[C4'#E?Y'LDU#7(=;)QIFI1&B_IK!:QP7.Q_8WKU..
MFAYN21;Y8UO ](39XJ_Y_='H"55%U]56,"UT>W5_W>_*?'$!D%FYHJLY-^KY
MR'@H21L&BJX*OB+()ML!B$I%MLJG;L3C\WRAJ\ V!$<!4&/<>'/8.87PAGQ%
M7.46+,0Z&.K(0*F/0SX47"RM8H:=S:7VLD)VE:BI^DC,=[#Y,!2%9!V'LXOY
M#R.XWX.B!GG-L0;M7E!D!UX8(5@%G1U!#R(CI<QDS6^PKFVV^'+YXPG QF5$
M:(4<FSP3GI=8.G0?"8M7>+B=R3IQKVY[G1/EG2/RK.J.CQ&M"C72NN$1C ,:
M15Z"P72 ]C@2UHJ9Z I0 ,YM4ZM)TWYPO$2P%V[G,U3$]2'TA>:\@M=-3Q&U
M1+ C__M^.]B!XR*<HAHQSSESC=]$%>\0AA ]^5R_7P\M0S*4 $(*F/Y'2T19
M"  E8T9A>,#(:W2Y B*[!]O2UTR"I)I,Q$X]ZJ"BBH5KZ++B^S*R>WB.G[AX
M+U*A[!SE7W+QO6KCICJ8JP97(U'F4C]E1T9MUT'9 G&\4%W>(;\IKW%HY5FP
M?M+=9]LC@-*RE:$_WG$2=LMA,9X%1\B<;A]K=71TO%HDZ*^@-W:-B$N1>'&"
M1\NB7CK+IS+DS <VL6_.Z<>%U^V@.A\S>J"-6=HI?G,0T5>\1]<W88;GXAVF
MDV!>!U"+HY-K,$E%36$YP*N!FT0]U$#939CL(66RSL'[9EM(7IG6A;P-;[H>
M3P:%I''('B4?W!VRG:U'Z&#Z9Z:?#S#(FR9H":PUNBI,GZFOB=.5QV;[J;K%
M5 -FEI*755=IX#\T%Z% TJK0W<GLV\7[!'F:>8G[6'92Q:JZ[$1J88B6FA[.
M]W%*/#DPV]02VN&GAUU! ;R"'^5R +YTBJMU9_])K/;.J@(N +)@=<Y=*$ ,
MUGFW:TFFR#;!UI!A9*A#3"'#!)PIKPD,.OQ(_D%@6S\0V^#4'P(3T6VN/T\6
M!,)XKB:R@[\M7-#RU$V8$5T)&#%-,2-<+RL5S/TB6ZL>LHV29,+Z&3:YJYPQ
M0H*]^YL!Y:B13RW"@0[N#W'S[HTM3/1U._J\_O;RFWU_R(R8OT;GN'P9H+'[
MUG:'UIO= ^)H_P+Q!LT,!_WR;,%F6PLD $H4+91GDR\\2[?Z..&Q_YC7F5C=
M5ZVN@7$>\<$#]C6]9.!1:VM2</! K,Y5_WW(-A#@0M^!N(.U<1#'CG:AS%19
M+B$,-XF$RV:YMT ">1ML(.Z/H.R$21EQ13]VMKO_-51PUJJ07G PZ_)05XFU
MQ\&1D]4O^%E^/H\_5BI2A\[\BEBB9K0V 4XN;TJ7;JZB*W!_O8H<?AHUHR5@
M_PDJ2X%'L-7Q:B?]D])9#U('97M/W&,U))T:=DB?#;;VUGH]JQX).E 6Q'QH
M6$>PF&#OAK\/.NH^,Z4.>]J1C8]U&<+3/A$WV!I0]%.S@]*#< CJ3FG>?9^U
M$YI/1??=CZQ/H*3<CW!W>9U;'FFU*^M19,](Y$)H;NFX9DCC?K4HC+&B].ZC
MM2/!GF:['VXWT!AZF?\EM\5V1,KUV2O02$1:T5DN>H3:(KZPM2KOB6NE<_W"
M*?=X\8S!),6I)=^O>#24Z8Q,UV:$:B).E.:\.017N#_>1.30:N91,X*:,<W%
M4]6_=67 1?#&V,Y>LH?6;&GAF&(UC'AK4C^Q]BEY:Y%\' 6%J(O")0GV1<K?
M6(%?1?$IZR$W\0=G@D50R)L/\Z$V\'$D!>H^TS]7.Q1K?-6'2$ARQ =>.HOR
M*;H%?SV#;H:\LYJ#%: ERD#ZX::VSZBK[M_ Q46]5*G%#EA?;2E949WY?6WM
MX;"!.CK!,'*AOE09K2\1;,79?DHS_5FD.S^;;%<>*5@KG?--/-9?!> S*'HY
MJ>%'\/'/(TV:%&F</TR4D&2=F@=(%^S7'KJI\82NW+E@9>D%2&5,^?1]YH92
M_T%TFXIDYKAEGV7HSA;;'ZB[QN3_PKE_%D9 SR$,[4G\\G<*%8\Q F*CILKH
M"NF4"\PX(]3=QRR9CN(^9K>$L@Z2R.9OD<-*6">7A+MCJ,QY?P@G?YD?J991
M>R,3O%-8-&5WJM]$0NDM2ZXL*&(%;3T^;*A0H0!O)KB6:K]'V;C,&R)^POX(
MVL5]0L>V]0J(+#;TC@=WM[(M7O3QXO;/K)WT#W+(0!-5W^QL=KM0%F757F=?
M"=F)AYS"U[C&%W#2@CX:^PH?$-^X:=XB2]I>J\L3;,"&@&6D. >(),DR^IM[
M %Z^-I!9([)U[(FSKB2T%1O 5XN6S^\.G!RSENZ\//57GBRQB!3T7&N0C@*)
M3Y#XP#Z7_=U_T'(6]:"?.>AZ/Q]=05VW#6LO(B]A]U, 6)HZ(N8:"R]P#1'3
M]L9NR4P&]@V<G?WZWGUT'^QPPP5<$_2[<MK-3_@KSO0:X2.RR,D?^B,7@N@+
M'RN57?HT!: 8 88#U/FH:2%F:*Z*IFE*H)GT9H)J4<\&_1X1:D\+6X$-D8U5
MR6I""F4%0Q_Q^;87M5-5VO[M8J0S.#LTBWN,&W%MU2PP51$2)A9W[/X@V 3-
M<;-B=0SJ<<+2O9+KN++#!4XL%]T3;]2T S/,U6Z=Y/(YTYTEXQ:"K<B+1Y2'
M8Z:( V3P[<#L[LJ(:7AOAS2_T3:+7B$/ED=8KN]XAI2+0DVK%_5N)7_?<QZN
M+78=_ %Z1K-G6F-&P]JK[-^)M>$BW@TB%,Q '%+SM5N0 $W^4&VW,?HEHH5H
M*E(J91-K7R_+\YK*9J_XYS?H]_F^2 9L*5X7Z<Y:>!8DS*QS E0>G*QFTP<X
MJH_*IQG7C5I*+!;><?_9C.>-B*5;-.Q.\#E_ZCT<K[F'E"BZB>Q!$#K)0';,
M3X-PD^K"^U?4X60E=D\%WEZ'T+X7-@GY(>#TV.9&:2TW#8><C4BVRF/9NWQ_
MZ1R]>UW4UQ]"C8>FFC>K9BR"L6<32TP$L>>@YM2V!0?45!];W:%=Q^[C5AMD
M8YN9DV+!%B0)*M2\K(8[1)4$B>RM+YMK1'J W%#2UJ$DA*/@63!?7([SV'NP
M/R[)VAO*:P!!@Y18W@:DXOA09>WOUX'*;SWU_CBP9MGRV$VW;WJDO\MK6-0S
M1&@'(""EV4TA-#J#7S@SO-7=Y!<EUV1<&-4LP+I[9AV-DDA'JK672Z[$@_&:
M8.LSF[2^<Z-=;[7DD<*,LO!?&E?K8>? 2 )"(DT3X !-.9*M70HN"^&/ORWJ
M,;A9-/UW>4 .N)$5H YQ>R6LD=^(\W"?^-1Q BHNXD4UOK]9Z_2S)N1@AU_O
M%.MP)7H4"N4^G2RV'7K6;%S"\NQ7)5V4<O\;3FK="VPY>PA<!H1QD)U"U'2,
M^J:[#:AS2W>>6;UTECDD;%^(EX#)!3.9=467^\6-C+2ZQ!9]"7%MK=G7=-G,
MK5B:*2V":.K217V5B]2($^0YJ*.29TBO']O$UR4@UR  ,\0+\_)PQ!S.4AG<
MJN7I8[^#R\F!L*U<%=!.M$;X';;[82=!N7I1;^/;#Y0U_1_G".O1[V%2-MG'
MIN7O\;XI9] HTO(Y$G.DJ65@SF;O]\^YIZ6,R\("$N+8/1T,23&C#CA&XX+[
MT]*]]%UQI+7LGJ#\5I[,KQ4@"B.H,H:(_252I!2FR&ODJ<Y,%X[!^&>AY%&6
MN.]>:3)M$#VX,)]:.SD8[7D0$A0IJ!N ]/.P1?[Y9;J+[%%BG?0Z^(-\V%K=
M,1T/?]67%-"*BV]\176Q)YID>:P1IJ7/&6D)QDQK45Y!H8S65CK*E'98O4]C
M[8A^VG7A&J/,]UD'Z%$I<9TQQ0QDN("1H*)47I-7I-V)]8+0"=(;3T5^*_<-
M5].(AX PK=@6)HDXF0OS68*]J%$]\J+D+5VX)FY1[[:5?VV'*%X6-_WO(3KO
M,/TQXG/B1?(A>.>GB+R$-[TLA\<8'Q2= W#Z:H-/\ZU044"K(TZE09VT7M0#
MKYW@+18Q7H%3Q[4'9Q[*D1)EFD2HCP;UHFY/SAH5AI6.,/_0OOH).3SWCZV*
M9&+S$WW>PNJ1>VQ!M/SS",QM%4(G9Y"O^%.?EYJ#.F.;0)&+8#?V>P!17["3
M_2>V5\<#HX",L2W0:;[(AM@JU"<#SY@Q;0' LH=U\,J*)ZQ#0^0?2,]<P-41
M!9=+>-T/)W"G;B6I#,-[2@8$]N.;B(.6TUQM*$K4I0 7"5G".K##YF0B(0TT
M).^@M,1<*'_V\Z1@IW37HS1?B'.#18IV_B7X+9/;86O?TL?:_<"H,\OW*US!
M?IF+>F<'8BM-^D\.[D1QN%L):S5<W1/P/#>-5NLP38-H(F[-? [F%,RQ8E*5
MM!07AGE48WX:MF'2PBJN(_D]K$+X1_IXSAQK^HDZ3=VU!T';N@1W'\H_^$MS
MVRJK>&'AR%'(&X<\!J#H2% OR27:$T_TN)<_1[+"S;MJMJF889IV71.+(MUY
M_D;?V(CO(.5+=!?TL=PLWL?C77DLR^-)L$M1+?:E[C[O/,2?^^VI^7>/EYU:
M<?P;O677]6;U;WQ+O &^F)]6:@\S/;'5__QWK1 /V$N )4GR6\?-69XL7K,)
MX5O>9!DJ(N/D-X(R^DND;&NDL5N4[,L)A.-OD>*ZIX(!4R(A$J]SN6.H.Y);
M]78823S:"!7_<D4[2>M8U$._/'V!-#6#)X(=>/"886."]?VU3<:)!W2E?R'+
MX/V29_X>M%/(-1ZS6ZE[G:N\H=F_8\ZGB (8(2-JU;/[<L_2483S)[_O??[Q
MEYE+Q^S[KWDJ+ME^;M;.6:_V?]-C!O3 E2_@0CXT[>&9I8E+ ^9TAN5O:?,!
M_ZS&$@&%, E0Y DUN?)A^:+>$=[D@BGUI? C[Y/YW#X^FDMVF.2"$TFF&T K
MH4Z\J-=W9F+[0\&9-_]K?P''SY/8:IR7K=B$&.-6>:G+;SZL]4'C\A;U3AV:
M\6L%UV V$4>?J!B90E,7I_TG!IQ)*S[,[_&\0B\)ZHPNE4^P-\&44M-QS*8G
M5JM5,IY.E!_IB0-[@A!+31>NJ2NL9;HFRA8\D:VG?#,A-!V:U[@@0CHL5*:E
MH$35I(?EJ[$M<%=JBX*S-O(SZRC4_N#^I+_@Z^?]'\E&X>?.Z>4>;:SMBYNQ
M.',@(8-W=H\>VQ"_7%&@4/&7,4%TA=U7T(VNY;5F:UU%99'L;P;(AA?@!$,@
M<K."KHX(%34;1*JC_51C^:HW)8V!<]:.W<-WU('0Z-.0$+K Z.:([X!]VGP-
M9O@"UX Y@OOEBF]Q#>S34EFKK%[GEIV==.?>1!,5)-.LW2IY*G$]&5B1\KI%
MP5UOXYY8:%AU[OE@;%+B(6'=;]X52%AH3UUJ??_?PEQJW4*8YCHR!Y5K@A%'
MV$Z3C,A5%8SE+ ?$1TF?L62.2/@6TO@2:M\EULL[CA[[J3>7#K[S/:A)]'4\
MV.<\2<_V]!_D7:H=L;Y6]?%!AK 00)SGE6Z2:4?-<=UC811A T)1*WG7P4LS
MLHIV<"-FA%)>TE_HN(K=RX-.3FJN=)5]J.]^%"7+#(FTLGT073(^61DQMO'%
MT \W8IMT3FOU)X7(=B%JP9?(:\!IX $HH@C/<8<=VHE\X;3\&?-(9T>Q Q*C
MY)B/AYHMG7F\<L+5TBJ[K!P&)+#XF3RR8"IO#Q)^AD:@YQ4;]0B5UC _)2Z1
M0PP*G2PP2:M$]S_&C70-5)0!SU.;E#9^F!%><Y8_!J\3:Q;U..1@9?<:;ZTW
M]GI1;WTM-6/, HE8^*OQUFIRI'()%=2H;5+Y5_V."8:(1^KAF5MH4,&NN\P%
MAV0T,/%:>5"G$D>9<SQT72%F8JY[@L<Z8\1(^3[;3G<;K_E@*ML4FL%!WZ5.
MHO[DF"LT(^*8>G!O;AV@$!%U:$]L]I&95IG3^TRR,?@P!(DY1M<%11./(0&J
M>[7WG#>X.(ZNE**6B=CJ+.TN4'1(>+ZP&[%/0TT3]L\@VRVG?;6^S%SE(/;+
M(W0-Y-^BFK93O$]!"3!17+QM@+*)CNUIZ=M92UHS%M)5@N?L'8E,/BQC!H@6
MYC/(!V!]?XB36N7<R5FK!_Z0T"WI3A/8(M$5K!^E^*57.BK]DQ5%GJIC-;#)
MYS,OLD0+X=>=*U<S3"="]S1+4759F[*32 CNKCP[\4XQ[%WV_7PJ8[./]%.T
MDHN0\E%S'PT&\V[7\1"[-'3]PTYUP%2W(NFD5FRG!J;MU"U&2C53*K$ZFW!*
M=J]_ZR#; 25!MC=B(G4O(EXP 2K<(0'6=96V\--=#&/]&YM[8CDO0,4SVC+*
MWJ6-;,D1%$?L-<5&^K$Y'O93!$R%:[]AN<#Y6<Z!E#_&''H$Z^CRE;.\;(&]
M)R_$Y55_'"%-8 V_YCT^$!]'J7#]==X?LBXZ=N@DM1I4)"?,M-K$8X8KM,O<
M1(E%5J#).%C#O>Y,-6][*&\#;;AMHZ0CF7*UE^!^6(N0[GL.^XI@,3J1M_?P
M\CQ^_AZ'-\_"/DW_J/?/_/]$;MT $$63>;8+GQ.GGVCW,,LU&W3"YA4EAU7K
MH"Q)@@CV3L8<F&Q9SP1_@2_FFGN%19OE6P1]F1>ZR>J4U*HTIT;96;;4))!A
M%KEP]>4",%,)KN-"/[WOZ$X3K@$5]7+(LR58&5I:=D#KPP(0GC*1D,5/.&IK
MX3Z,[( !->DZ>;>2] 6]\57M0-SDF;HN8@ R;F856G-Y2&:?KXXD>RI_^T$@
MY?&V82(@$LA.($VIM?O06-T#EM=?X(\L4\0#ME2UEZP0?YWS4?Z*O7:P^7CL
MWZO@3N>%K/$GY^C1EUO??7RGLJ8?EZZ7/-+_9(<9PEHVZYJN#B>]3XG0*49:
M8WCFBNXI'^V&";8>8@EU^#R'=J5=**>#5FDCM<*LH,IY27"+/<F,67BBA^6G
M $SM[Y9'R!Y ;;P4-. 1+31H+*M[#=VMF82:X:PF5R6\!=8Y\5#3$LRP04N:
M /'$,.-:I"M1D]:<03)):UAVB'74N9KF/:S#L%]=:=&@KJA2\QO9DYZH8N@A
M?JT<E;&%/ 1)BU;YY[?Z&J#6!"BX?6P%7A(B M$DI&K7+O8N[*W0FN+(EE+V
M#[F8][^NK"*D6TFLB"DNG;EE6\Z,!#.YK:'FO<V1X66!SRPT /3KL?,OG@^$
M"^LXL^I6877:E(-V-?)>P]<UUC*6,\,5TML"YT YBZI[BGV#Y+:SOQFZ/^ L
M- 32R:>?TO>(U40S9K(GY)J[O+&^\LE$ 54\[2 .8M<X)_P8.MYXJY&2;)YN
MH* (<8_"B?S-W]BO*(Y()(C_B$?RS;.![&YBC;2-8SF".![3W5_4"^>ERQS:
MG(Q>%;2UEK[*:FND)J,Q,.=(<W/(KI&S\!J*56Y[J 5<U:2<-J )(&HJ.<0M
MK6[_$8Q7Q[!&? Y _N4P,1 VN5N&F'I!+?/9<0SST=#O"VRY2@^W(_EG!\@'
M8M@;[_ONZCYT,_I@8DO[UMKL=V^/7Q1R",@N #6;UUS$Y2K&_O0#121 46#5
M]7Y:I*6R^RA[$3 F)AQ*:Z7L&V01H9)7Q?KPU1OJI( .MCT\4.].2OTANZJV
MTWC+WY7<MJ"K*25O)^>+MZ>)^9/*PJR9\3!/7?:L?.G6#YE,TAJ@$7!\5IW3
M%JWF#%0^-0)[M]NNAMD-YU1=":U2Y= ]!6T#;;SX:VG 2>GEK? :BWEX+ 1)
M=3J2]&,[-B&G\84Y&HWA=6#9,Z&B@0B=EH^4M-/6L7SQ@K#4$/LL,Q[G,U.%
MT*1DGKVJ7QA!DEFK['^!JH"L@I9?Y[\>I6,K>M$XV%J1?;>*LV8H?VWG@\B%
M\ASTP"-9?6ZBVE/1%19,-7R3),4';,4''*+3Z@VF#>&]FG5+C;$N\#:RQ2"_
MO'6IUP'O%.*C&OTN*;@5E\"I;,)UR#T_G6*-9,X?ZQN;BWXP,!L=]?JU@]19
M:,;T\\MJM]6' VZ3]UVHI$42*X35Q"D>)-38Z_XML, ZN2M-!/(UV-H/,0B(
MNWMAU]X3L%E]@'LI]L)9UE[R*&+!..\!Z/2Q-&9;VZ?QJY]'FZRSVE\VWTF\
M)\RO- VIQT6] 8JD C.D4[OG4!SC%A$ZNJ@WS),0#<!(>8;[4?=';$LIMC5*
MPR6RMD4KKKD0IT9=99_/IK4)32_TS;[993\X.WIQ1%&>Z9)M>J*IIN]9UV.#
MJ3348@G2J0%DF_=4BI(AVZN<%P,FK! X+8OBP;14U&<H2.O?(CE_C 0VP)Q4
M<I)J?;TE>R._49#EGPFL:!I^!!VF7Q7$W7DB:*CF=6T7*LH!Z.?87F]G&O0=
M\$7MS^UWVN50']LHY/<MJ0?%3.3K/_[UTZMU/=>9/#R\DULP)\3N50$#75_2
M*EP79U@[LWP"K#<I@7W:8[(IBWJA=7R(VNJ&,.BX(4"CD>###-6.2\Z<]#O-
M5K'YQ\=&M^:[)Z6T],G'/'@\NA"*"T]F6W<1,P6.X!*N5^"Q: 1<1!BU/B[(
M9S4CY3C"_F/DX)"+X27G+L;)WKC3+Z ZWDCT^=ZJ9[63I SW?^=++><3KG(]
MWN9=]:/K$87$YY9M,SCY48-3<V5,K69,5Q#+&0;4*>\SFGW.Q4"<@W#Q774%
MG60<R9=?Z(EK<*FT.S-4.904M3SO[V=_->8P[=:]N!&6YY8[G0"1AM,T7,1:
M&X:NA9;6G?<ABWJ'D%\@KFK7KP7E:<U>I7L[=IZTJ[7*2:L:CS>R+5'.F'ZP
MA-]&4K9 [WB,R(H/"76E0T6/9:*8Y>D>FNL4"]PM?L5&L*7]_;%+CW" =*YE
MH%?E[U!':R'+5+ECU^8;*!W>*Y$."38B\<H?;35_C,^.S."T++H[\[+S4N=@
M<&4@DR-Q34C21AI';P,0>X?T1;THPI?L5EH-*.&..+07,+(7]2)P4$]P%F:R
MOVGL1>T>,.U\H;^(:]%N"X3VJA<!Q3(V-\SD@0)<'25S2)G33ITM"I8$7:Q\
MZOE-35,]/QFRQDSB&FN1>>T!/%-L !7%0=E8(2E9&#$SXDV%N6TA6SX&IS'1
MO4I?QJOBY7WE=T1.?Z5.QW$(Z"&DHGQ<%1CF+WA!CRP>D[T+?@SB9'L#<I@<
MJ""9(>L]3LY[<B2"M5+RUH*AWZY&N;O3W5V&<AK+BN/+.D<]+GN-/A@K#$_=
MVW+E7\O0#F02,_I=&X4-<C<(=J%+]^\=<(F^D6MZH?A7<HM0)J%]4:^.))%G
M4DPAPJM11GO"Z>E/$^[AXLFL;G,$$-O:]WQTSO+Q"#\ +Q=:7G+I\J,.S8[\
M@QJ4C?.#G&;2D[(T]OBH?['H,&'ZFH*&.,2CYI::33!AREI[!CW2&U<QDT*Q
MJX?CRK,IJU@7!V+=ANQ?]C<[/1O)_J[3DZX-(0360:,?N>KN]+&-L"WOX=O(
MX\RGG6>'6/ON3]!^ Z'OA".@@HNNXXB +W$GOR>$_+J^HKTI5Y-2*/O1 TCN
MTAI]\7Z(D3XKOR6O9:3&U?;5!L !:92MPQ\(YU0^+4XL%\:Y1TC:"8N%@TV*
M&J61A_ZI%D%_G0?Q< W.9W[L 16-(!3(1>QQQ'R3B22VA;HA2RL<:J0I!G;3
MI.L::F?TF/D'$=^X*Z7,$B4.&+BWW..SXQQ]3=[3;OY#L?52R UESVY--I9+
MY&9(B7C!O@%Z[S.(!B0LTUW 9,1Z!Q'PQE$3C=S5GL1ZW-L^WH/DRKR[-M-_
MYZ07G.[.(I^ND)_M"'N [!>Y^]=4?'"UZLYB>3WV-<_[I?SLQ$)TU5%I8\Z#
M\DC_@(44WN<2)0?9:8!::M5#G')V+[&&@:Z5>C7H?G4I--X? KTN@DGJ]ZFS
MM&S!'JCE8Q']\1F$\]V+(?0T7KQ#"[HE5X-24BM*ZK,AOS;7=<$^+D5E%2J[
M:->'PG.X<^#<] 6C@S"2B!E&J@DKV-T46]@[1["-98]4*H@Y]> :EN4*_(\R
MV0X1Q6;]S8%*8!TS^+N>Z2UY:HFL-#57W<2Q.H-<['%]4A6"'+$V_F+D%&S6
M>)#S6,U^381^)J'KK[[7_ C),]@[T<A>O QQ\!@T1DF$6Y@#ULEVAHC9L:0,
MFC$Y6M%%D?I(R09*H7YDJ&5COB0HKFAJ2[<X!OEQ?P6C^EH"NW+EC:K( BSM
MX?4D#FZPXO_N;'#"7\M0%R3[<23-&#VG!; >8!DY@( SGXB9X1J53<<(^1Q4
MTA;O^\0KK.B@KX-8VLC#X<<H01+DF_K@&9/6&B2CLRUA^[M/F>%'7_;]SIW+
M%-X!$;<2I7<[[3:QOAPUU\=65ZH(-XMWZ0HH>FP9L#9V!CDN-VZ^HO3A&C#+
M52:_V I5!(M0U']PUI4>_!UI.JYRSP3-]$U;5:1@%YR6T1Q'N5=9ZWY46B"?
M>_$M<6DE(8"+['1KY2'; /%,6D\W--E&K+6<=H3?!^6V<FMFIJ85CIV'6 ?4
M-K$A9][L>J+:^*-O@,2*FO*Z]/%P1,'Y8AN(FX6S25.D[)-87&"?J9R+#OL.
MO0L340LJ9C2O_8;IKM84ZWB@(I-BU@^<)Q(<Z<2U#D@(G.75@'0KN"NI.U-I
M9E%LJUHD [:3#%TM-G^>$T*56%+L$%]ED?']^M<U5<B6U@]10\T=TX% :C-I
M4<\@#I.$;M(]M+ F&4XNZE4?7;"<:JM"\D_6UT%=0DY5+?>VU>DR+OUG%^MH
MBM-)K21 OG8VVM)3.I0X*=S +!1_BG0_59#W0NGX#FND;)D<6P[QQ3,V3*XJ
MKT398J?DI)&M54F)*M=*M<,+3JM5^ WG[/7:XS"[1/7$Y5M9%/-RIUBSD/+Z
MY4*ZJV.95ZSTAY&,%7I,SA1#2T,)NB8<C@*I>):SG()5CIQUZ-?(O=*N:V7U
MI>=EH<('4;+HO]MS5<!J)O?P-7NL"W9(=>ETU%D&\%-5GT0?I\8FCPS$>7RE
MZCS1B/X+F<<A[P%=L^ K]MM%/5OP'(ALXTSQ(5.U;8W6CADL*I!.[X#YFCM(
MN8JXBFG@!3,DOKNTIR!>ZXP10F_-:V2W7.%UF>0_\<39O.%@7/26:+^C4N>N
M8]UB_P6/JA=5[' \!(N$&_'0P(,56[T/4HL V9!P1?-N[<EAE@]RXN'D[@_U
M\PDFV3#UR. 46%/0X<5/=')IOZNP64FO!'P&=[$ <S3_YW%7_VIJ4OR3),=$
M)7$$Q Q/X+('Z)J!R$6]+S )S1)@$(?YV.K]EF)C\.@@&$Y O.4JMU9&!FWU
M[/3/(T<AWFUT=Q4='HD<6S=@#W\4&B_JY<1MG)J=YS_OF[/>?B>B+LEV$V&(
MB&SM0,WND) =M*G/*J$MDJL\5@DYJ/-%Q$S,0<?%HZX[>:%N-N$VVQAI4A1Z
M;)D/IA)"?_]K(K]XH[!NZ-G%ZB0:]06>D)V'R/OW1YW\\'.4="SL(2@ZQ@+A
M3FSU$Q4'<7@_]0#BX]B4;8EU40@U4N%E@LRTS;T\8W9TK]([:ZZB$"'OA[BO
MKGQHC,9R50SB1/1ENSO=P<V]S^[G>\%_'8YSD=_D7:K",1*9 .MKGN%)P@N3
M<#?.9H<IM1] R)^ .('3E7!6N[#&8:I)Z43SANM+M8 </9WLW>.=30Y6.>TQ
MCA<7_ JNBKY0#Z=,?S;V/!H=)K$U[XO+7O5AS!9)>Q()],K1]1S,L%=)0NRY
M4Z4/4*MZ>(5<0KUMNV>HCI3)K>6T)_U(;VI)5+UOG[%,OTP.4 4W%<XGUO7%
MSF5*Q<4;ZKBZW<[&6]IG@KA^L--'?F74#[:6N.DZ=(^$].XWA9H B#]=JMV%
M5(VR'+7N:""TLD5[#-W:" 4DLXY0G- 5, DWG%*^+C!2-I_^K*INQF#2W6NT
MK:J(\93I>X<9RS.?#!IZM!X@!-'&%_6> LLINQ!OG&F(>"F #7G9%1?Y#<%N
M%EY1)3,&HV=W&EZYHN1^B8!4V#[#N3/Z2OSEZM_+H_QG-MV<4*V5I+^_^_7T
M?[!!^8I8C@S0A.GN"Y9-%GCDM)2CYQ WF*CL[7=9R<\<"\;A!/5TGW/3K::&
M5.;LR(CQR7?=Q_OCXM*[2Z)<ZQLK*[QCPM=DH2@N1PEQHPLI X .%]+2%NZ.
MA(+B;]@]\@T"XS>''4=]8RP*K\67H&=K:HI5[U;=^OV"9=NZR/-.[YOJZ_K/
MU53GG*'\.>1ZG3C@]/_1)Y78[8VNG\1.XE>\5,=>+.II\*#KCV]WQU(F__F
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M /'$'L"K>; FM$89[;Y_U$W1D2DP9?J<@ +$=@9I'TOU R!VH=+)[P1TC/_
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MSX@USP:-ZJN,X_M^U]?^&@3:9>$<M3#8AUE'-\IPZDB/WKE%V+,>G/23C.V
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M *<TYU;=Z!2]\0^FN,"T!H/0#9%&0?<&CHN:N'2_YNRPW/L^XF,X9IRT#^Q
M*PWAY!2"<S#4Q%_Y',F035US'A92!S-DE 0Y\9J(="520U@YQMX.*>\4,*ME
MZP6N)$/[-O"YU<H.^ZSA<OA"EO&73'KCT)9*^L_D6Y-Y25^M?X9,R4Z)6A09
M.(&ELI8B$7/QJ9%0-:9[$)?4>?)%)=*2/<H=WP_1;M!X2^/"<M<U1J][EP.%
M!*Y)$XJ-*89(0;/_L8&)-&E.6ND+V5>1^MEF;I?GSYV'R%?1;9"XGD)$+DIJ
MUXB%&!&RB9LFZC"]O^%=S.G?#8GC(XJ\S'9UA>6\HR<G5';S6FWI>_TNOKN3
M%[?_R:]O?T&E4EH2I\P&-?:41C61"4QJ,X< T@77;H7:0;-RLZO%,T1=EC>4
M75IDR._-@_IOLK9O[%$4S^A?E/!Z)K[K/2M]QN_9?+*V+'AJ6NPH'L_$?"A.
M8+T)*+G+>0(J@N ,93WN&TMV/[B$,M^/W6VUIAKF*/15UNQ.YW4XB73W@P_/
M1G.O\^VBGE?V498@MPV2Z8%K!'=XP-+"N!K#!\Q%=OZ-SD'Q=1M?(42?A.=5
M7^ND:+N2X]Y*$S^)FMBALF2V8'I'\%R*0.K4B96J(UA+W6K()A6UDY.OB&ZW
M7W7]4IX---%,6"82-?7Y$!DJ:KLD]5?YWZGQ-.F+S6_)-0 ":RIBGT>KX_.E
M7M&RW_KGO-3:Y65V="57?1T\U2[R;NPSG:,EL;]BMX.Z=>N0<FIYXHGN"=17
M)E@8/,=-E'3)?<_8WB^H/O_ P/;WTW=X4^7V\,XO?URA(?S"P+_4KQ9(*FB0
M]QMO8> \W" "]FOQHAI=[2T56@<?-&*_%)<%9H.%8^#*+?:7LMJ.467B9:$Y
M"Z%>?I+P0<H\^PQX:1YLYMYMTW6J+X(Q#XEJO)".K>T5%',^0T@-I"4U1A(-
M(1Z7D#7;\Q"7YVP"5!<KX2YDN@O['.<"KTA!7<1_'[_3U46J,/+B[55$J*UW
M=VT^.ZUP;A9])>&55\0O/G@RY3 !M"%! 1K"1Z\$U )G&4'S91RU+[" KJ1A
M^KZJLTR54GNG/0*-1!10<H-?RPW*5IIO"&<)Q7!@!*H5CE!<D-2_S!FDWN3:
M22MKJZLK$+"@KDB^U[[5RWEZW*\TH6 D(R5_-/HV5GM?VX>"B^DFPE/*7_&3
M)H#UFP Z+9ZR!7&[Q_I*'<_>,![HB/!SD0\T."=#SE@VZI>:7&=)A_Q1YVX6
M("$:!_M5W$UG&_;DII.7(VD-CJWA.Y+6#39M_N#/'N_0^?@>K#<')4\%C\FH
MD8[RZ^XZ(X2KW*]]Y8'UM3J/O8Y9Y(?4JKQ9@=WLA2Q7V)AFB'V!9'>2@[I9
M.V5BD<U^V XW*FM[WF!(U=+K<S=OY[YX=-P_%/NRQ]Z3N!RI;J2&?ZB<V(@S
M4XGZCN",AJ!]@QHU%BM;8,[$1U40?4A'7;JY9F.XA)C UD<.XK+Q,%Y,/;VL
MICQKGE8CMZ1V/C(L[G[PT7+ACH=\SF[8/?'D3T,#&<$_RAR!40]:'.=Q/VID
M(>^?:,,O<A(?^6WLS9 K'-5@YR\U4]PBQ:5I%]19<YDO-009Y5J$YZ!_E@"A
MVJ<$/7?6B;<O6_.U3(P9:@AFR-WJV\L77]E, "*LSZ]9>WF9I<GS$_'S+G^W
MXK.O/U]EF!;[NK])@*L__;$A;6*-8(O9^AW?&XWGD-5)@E!0?^3QBLG31J$B
M7/BV6XXZ1^RQM;U4_6)!1L9?[MWLZGOW]D.%_L7\C18Q18<CO<C:-7#NN_MX
MXY8T]]Z)<].U_AZ]=G8S!ML.=SOH7[0C3ROV-$QN+V&<982=21=-=KW;&#89
M]O;'E7G,-S]=UKX0&EIYG==&QQ;'J&Q"CF[]F)%C ),5).F;,*?!REL/W["[
M.*:N/L;^)W)\OW^9*@O;%)9Q7O2:Y/3[,?,^3WI6:AR>'$K;Y2"R 43-+)36
M^(0<T'VP(+%FG4HO5+!H&"=,KHC9<XIU+\NNE/5#'PH0FZ@FHW46<'S)=ZL"
MF4=Q<TK!6/L26_>D'92I;P)HS8%?=$?^ 8<RMX)+HDA0V+K4)/#[U&0:=(B+
M6+<T^1YC<I7?(0CE*Y9U7Z3!<M6>'O8Z= 62?^*DE ?'7:VMK2V>6WMTR!32
M25S -?LY@V,4V-QRL)>G6IBZ5Z4A_+T3?Q ^XJA$MIZVR7MEBX&;DJKM!GC&
M;"=$EP_=";IXJ3!TR*J\QX&\+*1N'EP5$EY?[!?BS$B,]*(>ZIA1.#@PIYFN
MGG(OIZ-00C)ORL@CZ-2\-R@.^%@6*+F)RU/V\E".SB1P HP-7-S-B%@<L<.E
MA;9D^J*K$<P05IHZ)C/N(\F>2';! =:1!S@O@0?'MK7)BJ8,1^O65\?EPA49
MLACG#X<>UZ*XYHN]@&U#SR,MVKOK)?CHRY \V/\(4JXA++&!+9IHY8(&4HK5
MUIX:=YG=H6&IN'$CVXGU!=27&/X N1K1?ZZ&+!F<NA95B9EV#7?9)T80]<?3
M*2O+^!7=$=E.^[JB8T EB%_E*;9V)$.\N&:WB@;6NV!FS/#&#O(UU!T>Q.NA
M+!BS'LFQO"6OZ&<=D?# 6-.V(%FVC\=-V/[B! _4"XV.P?(,7J86,74.7VUO
M]"-.V*#+3V*Z85 >IDM5.1!CV7JP%1^VE@7=G+D'ZRBO(&VR[=P]#V&J[+;B
M)\>JF^4A]U^+:4U2@4%(YQY[L4'PM]3PR*4<TN",VCL0=KQ70J^ZKO-A6$-8
M=!Q=B*R3M@]0E0^0T45W[K_&>LRY"J-'J#D2=_'!H)?.C1I=J+T^QQ"B7F?9
M2'[JGED9.+Z[BR\V9L8V!:[NB[3<VKT_MBDZ.SXKEQ[V< C=VMWOH2)C2X>1
MBU!U( [B_72:L:M/R'T_UF'D2[A::EH-D9I*8A:ERMY8--6M@W=4)KA2[R.T
MPQYV,_2G,XP%[25T/V["9IM+EQ[6K+O/?#3VTI.S,*12=%; !U##(&4/8J,Z
MJ^W0?S5>VT<0#)E*T!#*!4U$D3'=7*S8H=J!7DJF]5-T632X(+_T.#/C"!QP
M/QVS@$=X/:A'<:AY1<7F2(//NJ:$5AMZ'<93%R/##?C_WN3>"QERD@J0-5HB
M1<;T-JJ^1AV19#R)]:L?40R8'Y1T1%>FWM9"6HH3+G"@B)I)2A O<SW"*,CG
M3PB6%:8]QQ;=)!);=^0_J'G67UIG@U0?ZXILMV2Z"44)0B)QK-7Q_CSU5NQ%
MW5HX]8;@-'>@LDELN.Y##2CC7-:B19Y8TYC5!E_@2RSG'X17Y9R-,CO?*CCV
MK(:QU:7H)]:D?^)/B19#I:4E9\/.,1CGOBLO+[]*+ZJN?IA7R>?S*U,*<MZ]
MDYW9>_?JXEMO,T,"3B8Y!%TX<LB]65 I?LZX"9 $WY-2<5M-363#YX@#+?*@
M5(KY"RDQCF:T^5U5QX0K*<KRW<\?0MP/=TP'A/M".;=D5*+O&$6W!G:*L_=O
M-V:Z[.\OA(G7ODMM=#YP>RU;VQHQ1_V+AD!/'?!6KD(\(*KR-8*G!H.5L J7
MQ]!?/4H1N>KD<9BF/)#XD.X3-60!N:,V.9OX93 M52 UZ<J/;\66,PQ]_0-1
M\:L*NF-R7DB4]^7HG!29^)4GIA<#D9OFUL>5LMO%%943,#DY#+61!S@WCS>(
M3>M6D2R8WS+#F]-%5N5ZEM1]7J!;@*?0:O5-T;>5%VZ)0RJ_VW1\#^TCGEFO
MPCA4G-D$L-ZN;@$S'-/# W[![V7EZ@0@1#PP+(L2EIB^;Y?:M34G0,.RJ<MH
MI*RHS<D7 JY3S!TZH>:']J(^;MY8YNU[3]*^Z:O1OTNGK.BOV?%0Y'YWB,EX
MC7K@I],^"KFCO4U(<67Y(V7XO]BI2RE$UC:$"/<W&S&G6@1E[@K;>P$!Z%:H
M_7KI1%!9$!+Y2,0DMW2VG#P=#BJSR2I'<MR0=1DT%"OEZB()3;1ET^W$5[['
M?9[]_7&H'RZTV  2=1$'9;&:CQD.8;^#!NC!7.;0H'*7^I9][9X6W.[+:MRE
M*3L-?D1W]SJDSF=2.NTB+VV<2?94#03!RI+3N6-;7S&_ES>8B?+?#F7.4[NR
MVTG&[2WDR\ "BH.EZZB.;*J!F@ 8'?CI+P<R69%2 U+CN^>W-DO4-\8X0;*0
MA$DDG5H#+@4EE6"%6;/ F)DF=4(-QY4&/2=(%96*WONA,'.V9:'K3JO;JB^P
MW]H7%18@@S+!]1D-8>G>JH3X2-!(W\MG#]2FR"_EAH?<#[':>#XL'\GS11A;
MRM6$]L+C3/_ZM%%@:8V3]%Z45+RDM1 Q:W#R><\DX\0\I"NBHA)J3S@7Z64D
MS%F7U9!CL6WGZ8+V!R%6R^$%5:9WZMX)A55%HJ:"XVP*6+]!(+E#,@%.$U>P
M.S6$"B<%'R;5<RQ!22[^$_$&F8MM13T1,%+FY2857&6;C_A=?H(PH%BI/4;N
MJ"%SFZ1VUL(JGX1WM?Z")2/?O+"?6LI<\Q+G%&Y(S+WQJL<Z[QB)?R!2:)NR
M3'T'D R1D;7BYA0SI3F4T< 9V-;((6$N[!YG03WN)Q">F9DL*?JUC9A08P>;
M-8K.)5XL80XVBI[#I!O\Z6>Q![NYKG0]9-^P6S=J;E_4_A24_,BIT%&$G5<=
MPX9 R),QR)%%X?DN.#5%_/B-N$%@C-@J[W:P#/-0AQZ*/;H::9,^8)V0?I!S
M$X;,?%FV4HXI0MW;QUJ3XICV8*CMT4YN6T'H^[',_KA(T@IFU91"@0-U0EWV
MO5I T;Y4>AB49.;8J',2%.ONLBRJU5D4!]1,_? $')/1P$@2Z)(=LDI^:&G,
M)"51K(Z]9E;N1%)S:9Z%OGO+7XM&1/&W[B+1,I>G0)D#=PEKIP*0I'.@ QJ"
MB"$):A$/&F%Z\U1LUM<(( <'3RK[:Y&H B9'*"YOXR39XPBG+<96H+802EFE
M;?YO8Y,4QJL-I_7<[YRHV5%(C^9<W\SW']S+LK[OSI"!AJ%FV'J8?/TY0,:I
MTZ3G,Y8GU(_IID#4O==P)9($5 KBMKA^=:.R2W=])^_GF@T=/Q?SQOM_\GK(
MVMOY4_$!QG6+LQ'JKVN:^^>F*P\]_KKPD="<\V"W3BGQ(.W7=D53/EV[_ M$
MMH<KEZG3:VP="E%; %E'%3[XVT:L*7[92DY^^_H4^90IW6HAW)Q\;S1W[]N8
M/1\",ZCJ.Z;-^H.#+HKU."EKPC9TVLNP59=2:',3=S]+VO /!W&X"-.?[<9T
M\?.&[%!G:PC3CS#!/7M5,C:F(:RFM0?];S8^_2=WWBQW&_NT6OS#ZO,?V*[P
M\-4Z,Z9M$ZX<K)&BG9#399;!W;&<C7A-8GD_\@NNL\2C*\+?@S$31O?KY;Z-
M?RFD/BZ/]T_.RDH\])7\&X^7\\9M/^+!'!LKD&1I")7:>JDO 1J @5:E,]()
M64L9#4)9ZG(D3_E7;0/X;+"%LA)8-AEQ 8IKKZ^V,_.&2 VTQ+F4YC1IVR&2
MQ;C5YUV,,QV;S_&/0C$?4WV>=MUS/J;S5IDG%2?1H BNPIU>NJ40MI"2T&6M
M2E^X.J3BPO* UXAG(WYQIV:R0<#QBH>E(:*SIGWFDU>D*XH983R&(N;,.]QX
M]6P+>A:@O_LN^BU<F )(CX.GK8A0:GS-/"FP!#&KS[1+B$=72]KF[X4JXVIV
MY']=(3J3(%5\UB#V[.2E4-ZPCVWF*2A]0UU])A]/QAOO?,[]@R[A3.""4L<;
M>PGHL0P@0,)0).)1E(F$0'G2BEBZ5+ 0L1%2/H/M2M-R1X_FO[Y\2IU44"WH
M(9?F/^V)3 GR?E;;%_DF<%)UK(\Q->,Y7OU"$ I(?A8;""2/!<1"I >4%-%X
M9A-\^*6!'SGAI.00NRUS2_Y]('Y]&;B*E!@FMW[ ,D1<E'%]ASX\=Q-BGLR$
MWYP#^>^VW'ZWNN=K@,-X19,X:5=S/Q- 1\G(1I]F7.=MJ"T6F[.-V<])%OG(
M0M5&['>_^.I2FWJ2SC'22D2UIP[6N<XR6]4QR$SUJ^FBF"&!'V@_3DZ/!#K#
MII4R6ZXQ$AA@NQ<ZFG8O1KO*Z4<\8*W9SW/TU-?9#EBO^$EA ]D :_S;7B,3
M5Z#91C&ICH@&JS//1;;'FM?FE$"R9JI)P$AT"5?X2L[K.<=O#7#T!)8RKX54
M!&Z 6A*!LDF>> 42]0UHZ/X@#.L'H%UXYL!%392B7J[=2PHO,AQE%@*JMN,4
MOB.C4L!S>DY*\0LLB8)LY<3K#B[)V9Z-.38_?MC=44/[8XR]H=<W4I5MX0>Q
MWOLC,I4?O"=5/J6_L_CU:)^&0$&/XA/ &4Q](P =BK$XH,[!:P('9QE<R$T)
MU/;Q8GQDPPG@J5J2;YK,J>G-IE:_KLGV:Y.G>UCS<@=W%_H.^(XY7; Y"E/1
M-1#S9HS1D7YTH;P[/Z3U+H&M;;&R52"Y2S%5%P*29-)"01AC,.@05'!;ZL60
M4E-<[52[D-@FD?58W9*^8E0'GM]$^\SUI PP&SE#6E9__BY3Q%A*?81D#DWV
MA5ENYE</]X1MMK_V]&K_^WZI&%WF<NA9SPQ#9(,MSL==<0L1JU9@OW)XOYMG
MW, -=H1);)@3-TW%=1U'DCP?3+&.0*(HI!IJ[K2[6]GEZB3EZ@?0,<N>NM5(
M^.[N*30U*:/OA_K<_NF'4NJK%N4%*&@BCJ[2&V%_=@4XDT6+K11_)I N$ CJ
M>D5RJ;+P[G$DZA"OMG<F9"K2Y<TA9=?[=V,QH6/OPG;S?;,.&>G??4)\ERH-
M0I>WX%D-#XSZ;CYG8 K3C54%8ZV<%>!),WC1,QDGWFJ)NJ3F2_ ^^C6RP^DZ
MO\T[H-_5Z7M[\@)F>L.D\'!-;[J&<*B'QS41!9O/)J[IJSE8B#H@%T'N&#3^
M'8E#JG!'EX=+2!-IJDNXN5<!ISGST9T(5W60/4CC92C*@U3>6(^8U])T@=-,
MLW3UD9"N90KB7-UB8DSS0?"'.G/(:SI:IXEJV!9R_I+<CNW/-0AE?PYS$QW>
M=MCK^Z<.XJ!SILOW/)-PD?6K<.)<*&R!3<3-Q,$H>4(#<:!06G=%2E?9;3O2
M']13<S!(;A!$K:FKJ>YN-%_TC!AWEF54M-GL5DP%8V7(W)F"$NF@XFQA :CM
M67E3; *<$8C,9/VH,<YR#7!ZZJ4N$DAR!:LBVMR%T85)K&V+BLP:2%?K%M76
ME?U(6X2NK^SG*?3F5(JCF5N23RRMP)9!7H5QKG9TL\NLU=*4;?LH:_M801^(
MJ/$BN9]V.W.)3("LZY^X1+^8]YI%5M^H,T+:E>^1C!.70.73<S6,R*)09^)5
MN]-0_E"&8T:,+'7Q>)TQXL-E!AU[5GVI3<<3%ER/3-$+L_5^?+KW.9!''*B4
M9,3BTEXP,"LIG%!#6*L*J*<MQ-6MA903'_;S;]T&UO4YJ[IY%MO/O<N13;Y[
M-_?.UO \>#$J*NKBQ8N;9WVBHIR6OW"!**N0-ZI5;-$7**C.8=G!-I($Q>HP
MR:X:Y+3* [7IBIPR8.VL@+J8Z;3ER+D/]>+EZ/8%_=# EC(@ON9(OB/G44.N
M+,#L<*)Q[2_5E$?<=R1E+1[+=FP125]P=BJ1 QTD(6O$"G])ZD"R'&BY\WD/
M7E>!RZ05TQZ1U"LT<X>9OK7PHEJ93PY9CXD-"7WA"W?/G>.&3=4L=R@!&@.M
MX?AJ*2-Q:'%RDWG<_<]7N:.FWMCB<M42=!5NQR\P$:=,("S149JIBX!3)-TQ
MVBIL.?J=.F<+@V*ZH=?59GUR9!$SW+^3Y72Q8-0OEIDF%.&))@'=?IYNQ7D0
MPE[7EUMK)'XU9HXE<K$6L'ZUAA#:O@I'+>35/F"KO(/\TD'%Y;U[P[B;7/&-
MJ*%U7T4?&B0-\SX$,1)KW!@%(=41:F>B(9U"JNF3/7Z2--372>X;TO<_EN?/
M%"RA?(Z'@QT@$8BA0V'.[1(!:MRBG%;G4/38O_9G_)7;*(@7E.4D/G*ZB6UZ
MY=NVM(1QLGB(3B/6N!08N(9>R SUVUW,+/+O4)RSN]_+92U\%' L1'%1K8_N
M5/_B>@G*4AK -A.XQ1>\[V'I0C8RF]BZQ8(&;7N,0'@_D1A;,Z]$%'(PQ-SF
M^DQ?=\U&V6AA#8_&"YWURT+<&[W%]"EU_H/1JAMIKQ,)@ D@*1;@-"L%X(F;
M1T$\54(>W.741^Q7.0"_BL0W4^A+2T)MB3KL%KSD%I\KMI\BN3]BEK[L_K;Z
M"=Q07W(LA+)6 ,GKN<CR<9\N=)UT8)*RF1G?>@ 2C(.HD0ZF6PC98+JG55^,
M@.6%]=X/Z)6ST;%,H:R]47'Q C-#)FA4N!WHGE8SFN:R'[6'A^6^L@AS;/6$
MIN(C/IXJ[^#9ZMN&E/(# F8"HHY@/N )&K(Z 5UU0OMR/@_YB?.D4N&O?28*
MY?!AL/%+9IJ,G,*BGH2)^'B7N5(CPQ;?;#_0X\J0$U_U'X4M1DR=MM+&TJ,7
M]RS*8!2/.P\563ZNZV6LSU 2E8<1,WR.7S&#E F(=RG63ZL(0HU:9*2)_@+D
MSAE$(!'$YYC"!AFI#AJ"GD/<Q"$_IM\8=<#S>:>P:-UTNL\7]G6;.U?;SB^N
MI*ZD7[P,!->163^H?ZHQ@ETDLPW$%($AQ2"$9(;9C'\&7A$OK8EZB(32K)!*
MWRX'.^<_:(B.,)K#*3G^>C2SI"";Z;!C2^_N[*$L2\FSE.G*],&!FHL28"%Z
M$*(EU:U"]T"EL?+4>4SYSAZ4+"?J('G[>7TU+C+:TO&C/[X:JW(LSZ?M=LC'
M.&"(_>/C_NU&>7DY\PBI+SC(9A]TN;7VYL#AJ7A\'J4U.V#O;]4Y@I"I@<IF
M=QEY0@&+/3J^A^=!?75;(K+WC LQZV[KVJY(%PYQ+#,C@6>YI_M@5V2RET]#
MSN==$>)E X/C1SM"<\S[!;8SQ $=;&DM(I3X D%$G)15^DQ\"7&EI65WW254
M"ZR#ML2>:S*$,GI9&](3[]&=V^/?52!NTCM2.#7QK%7 [AD#1[F4?6^AL-WQ
MC@S0'5)G;YB/T_'8 ^>FVQ=K",)>09 X?BZGMAAK!Q=I"&$Q@>2KF?'YC]H?
MC3+NA@J@OX[H949,G0@YQUC?X6J"1^S1S-Y<_V<.MO1G]H,VO[1>4E_U&1:C
M1F1,MQWRQW2C5)N8WLH3R+;S#YA7PO@6XI4L3R2EU+\^2$9.$ACSQP,H_8UU
M+GW%BE,Y8JJ3H^CH[=R1Z%U13H5N4$7BO>#RT&C>'*LJ?WAD'0%< T#'5WH_
MQTU[7(!\3FP,8*FSA.:S340SEDOWY(MEB:Y>,3*Q;O %94[,**_[==T]V$SX
MY?7/Z[*^9?#/>IIEQE LID8&E1\16,8=N*1<JRX&@KF?O1HUSTC!]-GM8A.V
M-=.QG99T*46/:L*DU8LJ"J7#?0J[,_QG@BZ[&>;F21Q(0^^;8_:\W%C\?8_]
MQRVF2NWV?8@S0WD>29 #KP12'<5#*&A/-U^<)(8.D%.MC-2Y/#5EN"&<F:L$
M%SA62E^Y^FS>6-#L\.NT'9'6Z:HC)UF(!@,&0LB2=OUQO[YGX6%F"6&,,(#)
M-F:*I41%FVH-0FH!!J*C;E)TL%YPGGTV]2 T660\5<A,E8J;-(3Y>QPX2\;3
MP]U/7UI."_93O$LN'IW]8H#FO^V-[^MZ>OBJ6\WST%:P7D<@^4GP)$IQ2V6)
MA&-ZNU4@NJ,+=W*[:%CY:R]Z40Y8(N/*I'1&8I5[ F\'J26Z/[;&5BI8C/@?
M3P*6AGC0I1K"XE&GY4.M]P-#1;LJH]BF$,8-D90 >SL5V%F\1@VQ?Q?@N)%<
M(QD)3HF130FH4>K>I^K,F9*3\N94*$$9I^90+)&$IDSW^JF;['DU'7S0]+CO
M$+J=5U,)-=W,B6C7'3,_RKT[&#IGD[#T6;A$;#;"7H%_?@]7%C[-O2R0I'(@
M/PZR[N4SF*A=N$ <=%'&P!D3./4U"Z78=; 78J_\ NOF-(0&3_6!=[(+L4*G
M.9]8U#<O-$2Y^VK[\?Z($I]Z0^;-#[_V3+D2R%CG0YM<=#,^]BW:+;,$8:FB
M0LFPPNMO[X,_I)BRO"%PXFT1V. .N2MWJ3.M^WE 7#KEBZ[)",\WI*:<+;V
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M!_M<O\2SZH$$5MF8:?26+ 9L4+/5SM>JW3-+J,@M5CP<S>375DZ/JW:QV$B
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MY3T- 7@(2GX%[ZAV[F;C]OKS"?VI8["'L(_:R!5G7?%G6S2$.[&#'1H"IT<
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M<\<'4[(>?9R.>?;+&=5(_(/Q\GM/%GXY0UL5\1?5&]F%>]EMMC$9UL[=4HV
M$$VO-F93-["_',OM51V":#>P'>BN;E%(^;O05CV3[4HR+Q+7O:W?_LXU8,*:
M=SX>:KW,6/9F54YV&>4+64=.#L4C*NDFH!8 U:I&4F:H*_PV!R\UO\^V5!Q1
M024"L0/JJ4!W:^R=]"G&0@V>/(.);N-GYZ?W%%?#Q%3TQUQ^>K0I2Z*QA$RN
M8Z0^]C87"X-N0REL=FQZ"C.;CQ]L!7ZPGWSP#["QE/H=Q\:8RS$SN*%AQM_
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M'%2#RY$O>XV_3V;N$)VL.,VVT8$M9H/S& [+N]V\R*_J%$DLSV7B;9*."W!
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M<*RCXFODE2G9"T;YLBLFNY<PFON:;W5>]E"@=H60[!5]D>=NR!&G<1#N:^7
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M0%IZ0=S 6I?BD_I]AJ_9LDZ$:*-&CDU8GIJIQRAI%+&'.[A(N5+]B_![8$$
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M1Z9:M:*;DB)CK0YV/9P!DL3XJ!T/X*R3@JK.:LJJ-IDN2_XM6)BN+KF+IB&
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ML8;APR*,LUQ;2QYX%&$Q5AWGS7;KW_C8TU4,7AR(GQFVD@8A!I7*7P?X!C+
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M@S._C[V<E4">R7[^W5<:7%.6.K94@RLZQ^Q0A6APS_YD]0/*\QJ<&7GF)/Q
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M2[U#\V8K>1]">>#0\3M1@BS?:0%[>L=_;FSFZ+^  Y?[Q:&^.-27B/X%@%\
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M[98_[M)_&*4^W',P;VW4[D(_9=[K S]6\M<@;,5\38:=ZFOD0+Q9,*:PR*&
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M"( L#?@K/CR2LK\MGINR7E*A1H2+RCY$."J/JOK["Z&!7O:8S]$5?72)[=K
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MSQ*2*L6_$%>PUT#^7-$2MI6^<N[*0_B3.$/@@0.E<EC"7\BZJR9>9V]3DDR
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M[VQ\181\'A F71K.60Z+GBLU[H'./0(\K@M92<UQ%Y[DNH\&Q&J'DA]_^%Q
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MD.5L>]NE4!KR"V4]3@!0]L^VUIUBY8)9P@VBSAHSD2-[0.4*G06*_Q=*!YN
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M9NY=S]G_JL/T9.#$F@$CJE:[^6\D^5^.1=S][GL/? 0;PW$O*Y)7$YMI&37
MW([OC=FW+ZFY@_%J:?(U1 ['2X;L\GPZQ+_2;M1U.U@-E58BY1*W.Q&<^; P
MUZREIJ*",?/'E?Z"91 OC>(R2UA2<E?%3:.O$%J<+\;>XE#A"OS"3:9#ON"
M@9(Y7@X]61]K<&-2V\<&5=^G78MA"U6!V*Q>FB6,+:-<VU]ZJO>'K\X9YG^&
M<:R>=:! U%M&44/8@N]7YHHOXZU9<G:PS^MS <4#^MS6!5RU:JS5I"RQ)=62
M;:HO88?HUG/>!IO!"Q!0D3/^1MF^\Z>OLP2E0-*HT'9.OJ6WQG%N/V1%@"8C
M!3:UM= _KYZ.O(F%#8*1^L?5N1(.;I#:6<+79.)[MSG4R *F+J'[^',+@57R
MK^DXB>#K<PW: /UNE[COW9@1KN)^W\QI%&MIZ*590CE7Y4+@R/WGMN0:',&Z
M,6?$!I_VEGK$'BJ/D;;0!D&5'%<?Y_,-#K^XN7KJ-7<94F#CUQSLX;O)OC;P
M)SQAL:Y(E!7C5=Z49X&HYS>'.UV3@:.RT$D>_;]NZ!I!3!F#5"M'K?.@=T'^
M1P10:A9NAWWJ9O?(W__=ZB0P(JMIXY$//L\\NO\@_^0L87\W.U05YK"!]7<R
M(*@\U'%HV9-KX"'Y\[;Q$:5TP$+KIR\ +@#+#DW'V35(;]C.1QC&I5MN?1C+
M*;" -"GYY4C6]T<U+Y*G2":CD)Q1E]%X_OP">82%D5'^4R]'-;9+K/@H'?@_
M=I__AS6-+2/K?@,;O3@FJ).^"+AX'[AH$]MHNQX)A=N:ZNR:=]KCB1+').O2
MFNS"ACC91\3XJ^2HN ?U5)"(-<6*-_N2(J&X7HI'S$7MEVSQ(/V6D*[DIQ88
MP_Y<=FAYX&=;8\@M12"U0/A!PM-#_5Y0?TKTZXK0H-[*.[(M7X+EA[O&*_EV
MN%C*+TR^<?3 NN-  W^\76>']>'$XA1O,$2;\7^6"G%B^RKER/J)<9V*26+O
M@]8BO4K0E'T(]F^1#QHVMQVYCGJK^6ESK)\2% Z5R!Q_TZR%4V]6O\2I[=+/
M,F*ST3G[_PXC4MAP?S]G8[C"=I: 0\=C?<XL(92&;/)&5S&P)2.ZPV C!9VG
MX ^T:Z\A/-TQ3TC2*E^ +63%8B:^]NI0206CE60TZ;OO'2EU:%4VV?ASMGMF
MSBVV-]0=((#D2>?JX8ND%='_T53^(H:"?S>8G'MG?5*?!S+)LND&T  (G7C?
MK[W[2G];:*KFK1F-U/FCD=#T0+?**0>*I746WAEL HTV"EPQ!P'L?Y/B>6E^
M!M=PK&"YW:&NB7$\7UG*PG)R@JUA_Z_%<* B]G_NY,5!,#&5(Y7/;1G<VEJF
M9");+1HGTD2N'9QE+%#['B>15(<1T!+XE6\^9G7A(2LG+K311[J"5=MHD6N<
MJH!AOQ9;,XB;(MRHRBL?<,X//0G);U*M$,'3:- 4?+ H4U-0?#[\\<CTC\'O
MZ8.[X\]?93A<'@R2!>VM&OPP*#6E^.VF.-UI<;CX9L/%REO'DW:1&F/'<8FW
M<!*9A__&PS*)-TLXQQ^XJ[V2U&+*"N[66LWMCSBA8EHQIN-F"3<IL?"" ,B[
M;:=;L^WVOM5_N5-O7WXR&!9W9OU>J/+>0^2W)NN?WY9DUUZF!P>#\3%H"AHY
M2[C7/%<^2?<CR00<W:[S\I_ZM(NT%FS<!418BL^)W_.T#_5/.&^+Z*/@ FPY
M2]XZ9-8EW*WEC=O$MM7D'NH#C5&/BH2;WV@B[ ULD<6G>#P<W=2DE:$!$:;6
M6TZ.O>$/^V-&,[AQ#V!O 2LPI!U -M,U&BA'&:MYJ#N)?<1P%VOEF2-\;09D
MD"PBCXC,(%&5ZNU!DG&XN_%U-8.Y MDG#^P/Z3X/B^I5"8 D;E,]T^VF]/I)
MSP=(0/-'SN]@XW]EH>E33.0'?\U(N-)B:;FW@IXBRWSC*HWE&<T1>\QL%-M.
MV^+ 'SA48/R\_\@92Y.+[8:UPNX[BWL<.??P[CDSW,U?XW;.P__^UQ!RY><?
MGM7J,\#0G5:?(N^\7>\^D2HR1QB[8<HMA_.YIA31ANZ8TU$%WH%MKZ[2C]PT
MU+Y*^9$X;*#MUQ?,+<XMG-M740<V @!#_AZ4X*BT# = [F"MZB+PHE\3"AEX
M]FFJQ<D=]+F2JM;=3X6^C\*L!..I>VYV25LF8(LF66BJNKN:M)QU5QE56.A:
MKA0O8^\6=[H01:!B+#/@VT'\"UCLA76]JOY_D UXJ!]A#J1AW>W%GV>^U#X
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MH338(EUX&=:I_5L!@P&LP]96!)/37,8^[K/Q:#!0,V_\+:YY+GB1+8N\W!+
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M$Q_2VX!7-NJ+;8WAVR#[!<DP3J+@KH3/?O"#R&DN!69BVV6I&BOC>-]G:.M
M;7M60FU]7:1D:M&^1[_ND>7GDL!H>\2LJ(6P0N".'($A%5M*T5R1L)R9NR'[
M%EA@#=<H_T!-P+RK2)!R./C#L7Y>MYO( :\_%K86,O1/B"N31L\([E?[%/EK
M0@K<O_RSNXQRDP(>9L/VXQPPAM\R<1D  [ @LR[P.KJ&$2!W&A 3#9#UNG+2
M:<Y26*IJF7&[UK"M@EQ)JZ9V1]NN:<C]T.*NG\XDE8Y)E]\J2X^)Z\!R5M:)
M;H1ZES82\W?[_<L \]97##:&J[BVS(VZ7!*5GL$Q=):I.1DRDUD<%GRN%;K#
MYXO^.8K]5S1&!4@F#;Y*_"*JP/]O-_.<Q.<MEJP"VKO0G=L;"L^^5-RT^W-D
MN"@ZMW[D1LF8Z]:F\Y$5U/[@6R7B1]#;(3(],<;FKRU#;W_H7 :^M'[8W6%5
M^\LJDVL_)H=MP_AIM]!0>(IRF6!.HE*RW4L^8V1!+DN>(JR$GXSY5<>0 PM[
M_FS3R\VY/]H<$BL8<%$??2_R[G:*K']2RSG2>T;5(*BNI3Y6X-!#@%Q*ANTI
MX\NU/Z)-TX2Z//5FT%>>ID[4!C!CX6[H];0J,$/@Q3 4<5;0&VRX(4QO 8\/
M_B759Z^&B"F/7 I"]D@FV>DUM#J6=0]/F]Z0L&;I<,>)[U8B$TK9"V$R!]PO
M@[=5H 83"HPD?4XI1AR[A#3ZU<)579@"!]F*B-(BNF)O[,):^+? UD"6375C
MKR-&[^\ BZ-8;LD[NF/]#?V[XP@IE](R/G"TI!9IJU?X7#LVS.8W8<BJ2%AG
M?@_R1A>OTBZ<*]-&EDQK3NO*>8;J< 7_!3[9RPZ^!W%1,_7"H1;WWZH8$ZU>
MBR#[+&<9[N,!R<NX2(4_V?L)>/6H*TFJ"3/"?&:LZ5(!'UD35J"UA^V5!&1)
M&Y;ZP/=MZ.)S"N$"5A]K;K!YUAC&'(U9<RU- ]9!$^+$\\KLZ\_./X@JM*D'
MW=A>MHR!8.ALSOW&]]R'R&HP6SV1-@G@Q7*B,2.'?![:*A88I1WO0;;,F\%8
MK/[V:$M_=C))CC$GL&YUI"XG#UT<"B[%H/T#5";9.(5/\564<AX-%AP@98J=
M-L:V@KV%*Y]"N3JW8QUU)='UOV?V?PKYR>XK6?K!#S8]ATF<:V%C[D)Z,R-3
M9+==CT$M6%UTZ &"SQ'E#+U!])(5[(R?8."BJIUHN <E2!H<OT2CZVK NJ*'
M0T,=\?%>.>&E;_WC]5-79<UDP\\P]$9NFT@K7 ,?@BH4$U>]-B NT/4"K]M*
MTD+&D'<5A$^;"O%(+W1LCP",NL5QN%_;3SR0_NYB[/ZW[\6RX9!0\;)1Y!4J
M$ZS0_89M68[  HP<QYQS0;KN#LN4:8<I-!]H\GV<(V<WS>*6,,ZVMW# .TPW
M.%)I<X"!?LN,@4@M0RD0,;N6;<BP-708XIH,BI4.L1+FSK)97//%TH^%W];"
M$>51\;CE))JQ=S F<1Q3P5[,2N0<+X.L@#NHP6WL"Q%H)%LE&RI2AF4];J<J
MA%*BZG7.,@LO*]WOM33=NHNO*XI@^J&;7_V@CBH_PSMFI?#,9/0E<RX-O!.*
M4?J*[1X'JGJ<M38.?C5\R>2P:\^(B%Q5F_$M[\F3VI1O>;RZI$W5H@5+6F_X
M6*[_T>?(01SW71OF36E: M!DPIRGD,'KB.,J[69T". #K<"52PN3H?D:<:\P
M''_Y$KOU(F*JHF=8'K>U&_"\"$4>?];OZ4$M&[/=F.(_<;76,&AC[3"A61I:
MEA;G'__#TZ[<OU"$U2JK<WM!'VK7,$&BFJC=QGA(-D.^A_J*6[^/L]I9 A<U
MYZ,%6X/@Y":62]>U:>(]!E_D_MMYJE3 T60]][WI+.B),P[8W2#A^;W OQ>A
M!M./]L[5+V-Y]3JFO7O"*O^<* P,+@#.$@R&6&]DAF=BU&C3>84LXY<FFG(X
MOADE]#A.Y.W'*% %Q9RYO_HYSW7 9"901%EX?-2\?NVUF93;: /MGV^P34D?
M#F8041,^]B>)P1'QJX;@/+&PAI[MZ: <WNB1?O_ZW*AR<P)O]YTR672=JQ,-
MB/W2J%,&A4;'6[AN.0Y'[COF].9C3^LL;D#]__?AZ1W_@W]VIWS9I0+&RU_-
MXJ8"_I@_B[O(UC'*L>_<P.'V'O)A5C\]Y+,,]W_ZG8>X DU= (_<1$^1@3^R
M83LT _IP##+F-A,'\UHN#:CC(?(><&UC*T]E$[CK&5PB]P4;;S+BIHSMFN,&
M7"B#T\'@:_:#[ .O-*]M(L6'2Z:2FG-(0T)HQ32RE(A>%O+:T)5L ^!K/_>3
M-!.'O-3E"N4/.3B,>[^)QSBP6@UZB AF,8(ES'55L/ 7C6RY)RE"7D!K^<*T
M!/=[;8%L^F^8)#]DJ%.O./AOO&+^J.JX;".W9&QSV[VW)07/!$@!9F([4<LQ
MP0I,)P?'2.8-_F<I1W6E6/:<N$Y:H>HO3GJUDE=)\L]J)BS:N"[CS*1V03(Y
M3<PQ; CY^YA#:$BPK..A?Y2F>\0EFSNU&=OSU4*0,NK$P@!V4Z!0+F._>=^Q
MN[Z&U7N)K]:#2,U.1@.'AF%\TX@K[ >$;Q]^&-V_R963J&#/8T;5]&XLX]_\
MW/Q*JE3MSSU,G!R3/<;,'X.M>DPJ-(V8EJGZKX"1S:Q5T%UV&Z 7UYEI:9^B
MJ.]UN06'*#K39UR?ET=#4>Z)J??*:1I+?%;L+&[A6/!PX[6?@9-1%]SSKKE8
M/8BE&$<G".]?6C\?\D47S?7F(^MND>1%0,T%MAP8?"UIK;?()$40DCDUG"1T
M$^PA+ER:):KS,NWW]%7@31D)NS (6WYL>/CCB%W/X3%%8.;A_HE]KI"H5%2R
M]US$"9?1JCIDF>XZAH?3".!9O#I<>XG52L#<383/+-2#;;3>:%^ABZX$B"!)
MZ2\ _!2PC+D5XEY&CD3>%V],V7ZK(#4[;NV'),_-Y^1^>+,AQ%/B^5/A"JAV
MQ!X4E-!H)R(5E906PMLCJ;=*1H$8]"_)&><)M94V._"@5J^@D3,TY=?!H?5R
M69W60+2P_HM*Z_,W&M&"!E]\XMHGQIO"(2+;S9*UW9ZAB@Y]L;NS%E&O;KFT
MF_.8FG.Q[JMT[_LWT1>FCSZYF,L/=.T4K!:,*!DAFSOLJO2_KBX#FIJ]/'6-
MJ!M"U!4*Y9F<)].90!1ME+6&:JC=P>J9N]AUN8$&?M4<AP/ 7#VW2^HV36?:
MU!!IY3%8>%1R\TN,.;"<&NS?P1.7I*2E"@A(0'^<HNCC/QPPGMOB1)][$13*
MV"JG7YT,89O"SS5ENDK4@$GHGDS8>]3A&5#S$Q39,D1UVB6-&6Y\)Q[(]#10
MD/$[R[)]O9]=9.[@CP+;"^\ I2.SN$/NYE?N,4+V5(&SN-384'M1_<);.%[/
MY'9#_YH>YVS7OJ""F$?.PUY6"0[?S_?8E#JR2&7TUP]_WXQ[,+_3:PF\6**@
M- .I!,/QI5(/0NHLS@19+G=PKCG6W^WD25!4;A7UCT97#8YV53X1E7U[Y:1D
M/-Q4SR R^NX.3IL,"XW9EFW($F_4\*+V& N+;K46S9S,D8US-XLPQ_#S=) _
MSX/'Y [>RA38&PIORG?]G3Y),(^R/..:FQ< - ?/C%O:WBX79%5TR-DKWD2'
M+>MMB'C("&B5'NG4L ^&!DMEP6_?R$)"1H+"0CIH%R/CC.+-^4?YIK5NY@.N
M7QW$VQL@#['SEB)?QS-_?GK5L@2OJM!T85\/#\]5_K"LX&G-'-.T9=K $]I=
M3 #6*BZB-C!7<T4(1@PTTZ^2YGM9PQ,[(1]^-N\EDZ*R(>\<8+JI1(J"U4$2
M3[=*1I$_N/M*R<BG#5P&21QF#UW/.*&PFL7UTX#+J!DF>BO0M AU8JX'R]*=
M=9?&-,=TUTA1^"4=JH5I 6 +88G F1:V#&J[1N==3@[HG\I>PI IV])1\?V0
MC=P$UROA0/&HJ\62(&KNN1#T+\;YYI$5X(7;YAD*@DF4EWGWW<&_1VVM>YQU
M^/UIK_A)/:3O1/OY/!Z['0, =?XWC',UX ]/KZ_HBW\P'YDBR9,XX(\D'-"T
MC!0!+&0:8(]W#8YLE>%10];@T> \=;OV.U:WK7$/\Q#DUS3S.$.91<<CZR"@
M&6\:Q;+M+NME;E5VFE 0)XGG&6E\6DZ+'XT.F5AU6G@K;E3"9[^V<(Z@W;+:
M>#$9=K=7D9NX;\8T)#@42E!PD:5EB@'V)#>3Q.M44R#[)KK"&;[W@+%Q-)LC
M8J?=Y'7TU;K=:(I?>_W*_:$QB["-C9!]NAW$R6QP4,@6,[?1LN.U)R%"2L-F
ME<V64#/QB'47,Z"(+'S=X^E;3)UY?]OM#GU[<6%,:AD]CF9_FQ9W_HQ6Z:'^
M;)]28]WC0)-*I6^D0\?>#(4,#@8-B6B1D32C"YJZNCKHD:NFOQ]\Z*/78&KG
M8[39KFU9](/,AW=Q>.40:K(]$:^9NZ^3A)G+MZ1H#D8-+_5Z.0!-Q%G<Z6=,
MBJ+3@D%O]C+I8?HJ.(;(/FB!9N+$O4\C2^H%/0U$V_SZR&2!.2.M&37OIY"[
M/4^< ,=:"JWY60%IY&<];3V<VD#$6J)U0WQT>:S-0T"3DX# /*6[Q]H">\ME
M60V^C^ D>G+A-C@.]-;X@@?2%!YJW\/P<TC66E_**6DJ^EAHTNVL/CW6Q%H&
M'AYS+VL!+*,LXT5<H] 06IA=E^WT3&5?;.76XQ(7&[,0R2.7;*MC50T]O,35
M1VKXO<X= ?M[G?ZN%4IX5H9/W_,$50)>?@BMW>/W$OXS?NZ>T]FJ"P$Y"@Q9
MDUX$_\  7HR8@0/)SBL^V]>S=X&%*25P_!Z_BE+C\[_DGV73(D_Q+8P>2OZJ
MRE@;L7#W23T<L!DC$6?PX^W%<\ZFY\Q>!"?OL5R>IX[GHKWN'S(^K^VI_/M9
M7VRG^:=ZX8NHJ:'GAJ.?5_7IM:5X$:@WCNGJI:^'#G6KG=^9\RV9OWZRF,7-
ML9(];-A!F 3(4PH-X&0,"V*?)=4RO3#J3Q1SOD'7,?= ;DVR:V$KX1@E=SES
M&YP&JL2L[WK/V@N>),G(=5!GNC-Q">/]D'CD6S@2(HI0T]X&!Z5L\2?_(IJ#
M7$UK^DNP#IVBY4#QEYF&T#<OG3MM&<3F,%=)^/"[470C^)ZM]%L_W1'SL];)
MY8['&XM8S='S=6]:1RN=BK<Q[$[AT%]($13XNP'U+2RIGM ]95G.79A#X0 N
M<Q7VK$>1#7[# 9HDW4/4B[FNT"90<[5__#-&1IHKX>74!]&;C@U1"LA^7A9]
M+L;$P[TN%/TH:5NZ9[C*(6;UD5H8D,O,&7C$9H@@=B)H(G1I7AL^RDP0;\A*
M3GHQBQL*;P;,O;93I<9"S2/+V+"5H. )9HR0[:_.8V]BF-O+J7Q;+_#O$<=^
MC&.]SWHX%KP[[:'S=)A33Q%AP'C9O'\X6@+ZEO"$CYB'8Y[;IL(/#AV"_IC%
M+?;<&P<9:J(A/F(_LI@MDG[&H&+XW,D\>2EUXJXL]-.ELY7T$PIAIONZ445#
M8_?$A/&[W\Z_#7GQY24BQO;?'I _%NH!\E2.O@L77JN/+"<I9G%BV:!*.3 ^
M#;DI!45R6<8,2<2V8*@4@:WDM+#-T(?TJ<:M;0+39T]Z'C50$Q2ZR);PEER6
M&612('\^8<1($VFDH?_T.^LBXH;QONB[V X'OV['GR3.,:ZB/9*8!ED-=2:B
MH#$E6UC@G&=VT3RW6DRWN'/.L:;]7:O@5,]+AXCAWQ6,YR^\]. KI_(CV9X6
M"J(5M?KSE\FYMVOG?:&UOR6\KWN:F)O?43!N6)_@L&WH3'AL?VZ/=8/I%AS@
M*7LR@9B/J?*093*- -XK)\/KN..WE4YDC0WX^-ZC,-8 J0ZO]E,0S1CS13U4
M\U]\Z'0%:;"?8@C?G,61&Z&9VCI),!5UY/7S"DZ^U]!"PYMLYX-U:0"T&/A=
M*'_W3QP^&^#Y(DLD&JON6J+Z/2S3_B)%]D#[:II723RW@BH*?$(1,CCA1)^K
MIQW>CCA!#FW2_A+'P%\>%YQ0^/W6"'ZNB_/W')S%A5S PIUK7;^K:[_FPM$+
MH'1P4"JR::RLK&R@&3?R> W?W=A)7[#GAK?1GFJQY4.[AP^^N?3O%6IT"P8_
M'WLYP-PYHHS9<#^".6-2)[^)8HZ$ZZZQ'%B=A]#7%)X/ANXH)MG>8J$)MS+.
MD(X/D<FBW0Y1O99T<:>H),6!:(()G4E3%GC)E,88'F'&@$T\HD%>E^>.0@6D
M0DT # 5\:*H 2>BB43!/%:_.T9YG'I:H)[EIMN8$O88C13!1<4I:7$V=R6O!
M9_P"7W%N<KTAW]W(:^RU7TA*JWOR$I-[S?/\/?CDP,$&X)/F4W__3/_[UAGI
MR)=77T9H(>T>#\*?\NIY3[/O/:U[QK\=MD'](6-DP[U;EMO"3_L>/?JM' YO
M8IF /H_O1<B%!C"MV36XKC*.&UU7N**KMO&;@8 !>A$_51O<ZS19$;*'ZT+[
ML]+I9'WOV<-^[>GJRAYJP8EKZ_6_RC#?OPG?UOZ ON: 9SO55@_0/L%ZD-["
MEB:+Y]Y*VX!%RKH*\.LN6SRX9L0=UD$6S2,+H--Y"BOO\,HB.$$QD-9 JQB=
M.5H-T(I&&.\[FTVC;]HG3W&7MM&+-90%L[B?V);((8RXG!78L)HOV8V.F,#E
M&)@W&+P_ZGZDE+^%.G,@!SJOQ%\)AW,BBAD/O[3MO54[9N#U[=AF:ABQ-\:Y
MXZBFU8 7\M$JM#%E(UUXUWW]?'CN7G@XYJY-PIHRQ$RDV0W2QPVQQ1P$\S!?
MC=14ZK)B!U$#LN(T[*>4+1N5F2)X^5CV[K87[M-I&QL<(BO>A(2)[P8?@T_/
MX@XW]MYI]MKT3*+V!!2$Y108$&\Y!I^5B4))*CYBC3%?/8>Y"[_X9<R%< Z(
M/;NA%F,J_!;@2CS!/#:;Z--/HN&S+K#62.)L2"W!K!L72X=%7)@< I&2&RRH
MRN>&\9#P2BQ^(>(!Q2?]!)V^K>*FSZCK[NBR&!R%4"2T&J9.CVP%+9*0T(3B
M3FI<21B#TRRU%<:5'G^S]YQ+=BOGW,,WP^V1V__@QQ^6^I^!7M+7=HB:_Y3L
M":F]BU<4H8LY4(6B<WSU7!$SLD;')\F+2=\@_M!\C4N][K=:82KGR0?VI/";
M0<0'0]C)@F\9B8]=8@*.Y?GT3EDE;AD3V^I!0"9K59A_44M>V.JN,YZ)"KKU
M1^F: ;^RZ',: #Q&@+^G*"C_]BB0Z<H;,,RX0 4#4+QRXC(2 &K&%!SU2NU1
MADC!OLY:B>C!J^7L3(M<$IY'PHDJ&;FB/0.>5*A=&<MRZF&N51!QH^Z4-^/(
M=F5'B-*5]\!?05_ >#@BT?I";BD-6U7^2Z=%7IO!]RG*3N-/P&FT>^[20FTV
M*:S;!5\]W 10-<,./_+KJYYKG725E6H^AVY_(SY&[Z^0TZEN09-.\W\ ZVZ<
MF"MB^EA/3HLU_FX>K>3C)?,[D<54RYB'->Y#QZCU3%?-T9\77CAAW&#:NO+W
ME)=K+@,>A!K]\7F/F)&8BL(%YJ@(72FII2]F?%#1Q_47/E?0"$NEV5MW/X%Y
MT-GF#ZJ!U#)HSZ:Q/'?/0-G2AKTG$I2AASVLLB-]<S_-XH[RN]6\A#V33TD8
M!I/?HH#GVL8E6@/T9:'!O[U4"K^!/VB=4(FP.BU%S5H:-FK);A(NBW8-<P$+
MDZUO(MN2;/#^?ISE#')KW<BB.SNJ^Q70:789(Z!E?3WE>H.'<JR )#X?5;@"
ME=%N#C#GRRG+HO.]^$JZ'L.O);@SC5ZK"Q#-")XK.@B!?7-=R)[F3^SKC4W0
M_?!:.;%?(-GX>>/&6NWS#3\]??*TD%I9G+DW]/?Y8#AJ4*UEH3(.&- IE;62
M:O%764MDZ%__(II%#'=_HL)Z%K>2965%R);QA-G<RL^K)9YTA9^V<:>9".-=
M3JH^?#H1V:D8@/33%J"6X$12;*5OB_M(#;3X*Y;Y4Y^PWI!P0ODM&7C.'ED6
MJ)(AR^/E$UFU:F_5I)=![RPNG"Y=*%$4,?=T,YW LEV\:O!Q'I=!>_6LON]$
MSF&0E.:Y2JZFM'@9]/"$2QBT$)"4P;2*,\DQ1DLBS^LF NU5A'D,"^6ZVPLS
MH/E-6!+NSZ8!YN4QQ8PV43XI8[(]\8!A0L6>N!6.+L\]QO;0%;S&QKK,+]_G
M*CT2GC\XO-.FY:&<\*(3L29A?E\C$=*);_0$9JP68)& 2.,\B10#61P3IH5J
M%B?E*TDBH06R'8P4LVT^YC=PEC!7@U::BUTN62$44Z8WM*Y 2<*%PGG*"\+$
MXC=1K 5>AMU,-T>W8%D+66_X+3J#A;!PH3Q_Q$-W3RA/.8RV<>8A#M1R)EGW
M!\L,F3\@6,[TJJ[:ZO_X+?KZDDE*\:>1!>"M.HY%^N.VC"E*6B[+H8MI7#H:
M<%SP3$F-I1CY5325TMSJ_P"Z>%C"S*[D96?S&@MN%32XUEVX4-5&I]%H=$L1
M/2:&OKCX8$C3TC4'14L=S^U^F/[P(:[P,BF'>(4 7F C9I$BTGQGF_F:VUW"
M*/)E4FU\<Z?1J-="N S$'X8]E,;GCS^!;\C'YFZYX?$P+; NWV;C]\ZZ^/V-
M_$QB>CP!/S5V\+XDN+M6O=NP(DKH!\ASA?P!=1FFTB60K(V8+7#1W5#I\H1R
MSFG9;@GIU!TL'UK&9R!;M4>1P-Z!\3Q+839"5N3VN] 7<-(L2V]M;I1P:QUH
M#C9N1Y[5=GEN4\HRJX(8:2WNQ+'31:!,,<)5AKJU7N)?;K!XR!#M?JH]>D/9
MX=LLM9G(B*W@VAE2:D?KU1W7ZDNRVP8K8V(:QD(>%']QNIL6GV<4W5B"6X[D
M DUB(5X8A1\LTY3,W<3%]B;2:P%SK0 >5@C?G&]A;08'U/9R+G[4,AN+1HY>
MQF-5G14C\/V02GN?WNL9"BOZHC#D>-<4VY8F<4T#.UND$TDN@Y.)E .]4^_J
MT-J/=_'O_%H!\ )G?)6*E-+O"E0#(CS&U?)U7,&JJ"=!S#6Z6\X326'?)8MK
MD!\:GFRECA"@[.FT-9#YG0<AU.P/([1-R(9>@1TE+'B4_W/4N#**MT+H+]!'
MENH:A=&$N<NXXHDD&7B(8L[TZA;2\%*)'-_&QC'2]H*$5$=/-P7WR@RYE9,Z
M([OLN5;>>."#SW/(IBS#TT>18'.89 I+CE<E?7HM:;G46JE(M&'Z%L\UHUW8
M.).GZ,3!%DW3TM=E"J(>3&Z6YF$(JT:H6-7KN0T+,;L$ \(G=H7&]MK3$_MK
M>)P?T?:D3^]M/-0]9,WZQ_;7AU[M+3XZAB7NA+F32TRS-('9OUPULNF_)B4E
M/6-L5<://X<&-+L'&@+OP?8MFQ WB,3V=( B%>RLAA@EW2+JTGMV@MS?[6A"
MK23.F'*L9Q(P&Y7&HD80D#R.;*L<9:WK<QE$O.G4$F6G*3,$"^-W@1CB8!RR
M%B0HXT5$V$XV7@*9M0C-D%"(HGQ\I8AJRNJ3+4%L$A]\S&<5*(RM GM<UD]E
MKPYZQJ/,^V1KPVOH=?(DRCLHR@LEJE!O?TC$H#<MF<5%C7P'XJ\PXW2_><;,
M ;"6J,#VAU'AXC#K;L1;EUW^N*/^^BU=962\KH I"(YY7O/E[,*6EN2HMKU4
M*NT$+28\/(8>&1&Y8,XO?_UOOQ3_MU_N_+^@6]S\?U;/C4+5/==<^>_;!D+.
M$_.<4JLID-Y*-F/UA7W'6[=2V3>)7\C@-Q6Z;!H>"H597Y97=3=LTWHRT)C=
MB^*LKO:?B4O("OVATU=K?J>"K*5AGI@+"V- !PPE87]_ V=M)=N(A>-<B-XD
M==1TB<^M+<OT6@^?_*J(OTH,-E!SG=XGM8F]MG1__ESTC']S4/W3[;.N.T[=
M /PPNQ918%>57,=NXL!VT^/^I2%OK+;[M14:0H&MQI<4+?=51P08ZC,4LS9+
MB)\]QSR6[F*9]S9L+PU:H?Z+,I@?EY[Y-6"'BT?G:_P;]T/:?=@:>V7@$>+U
MFB9:G(([&*#Y!8P?5RFB2FB-!T+MQ8$?%!M3'GS*K?_-XOQH<(R(PM!7Z?V1
MO\,O2-"A]$@O?N)>6E Y_%(7V[V#\"$-0T%\N :DHR9SC<K3Y]H?Q9*2ZJ?%
M$YA@,\A>A!_,T_"JP# ZD@BV*[#@A/&&YM^!3(%Y56&G"*)5*&09'(,IM@5M
M)@;JM7'V&.HP'YDA&K>=AU8W$RI(/#9B+0:%FIOPN8>LN5R)H:2T69P5@&EY
MZ+SJR%74&-S1[67&W VRKH#)>P9NQEB$PC65E#%SP<H^^3/PL.S8,%7:V))/
MN-+@D !0500K1ON!KH9M0$GT"!9L%K8@)G!WR:@,#)@8(JBF180,TF+6*A9&
ME_B1UY@!"[.@0$5:NL""<:<E;%G7G6 X.4(5X^$'^28C*Q]$VUKT(4>@]M;\
M[2E]UV_%W ^FL:PAVX*(,FI@77W!7?0/II.<\ V\XE-;DY<AF)?\NI$I+7W*
M=,(<6_0AN'>(I?8]ZNY?4*;)_GJ17?_YZ^NG'K(M-FW?$OZZQ1_/OHAY\%SC
MSK.D,YW?P)Q0/I361EB*04"%"L@6.%7U1O36WNF4$C0WP+H\,%GKZ]-+9[JL
MU3POAC?SB'JCKO&L53W[1S90#'DCE>?N!T6_CF6?P#9J'TOLQG+!!&.Q OVS
M_GX0X_Q173DIG'A=N3WRQR2#FZT4Z2=R!NH,!F9QPYQL1@**/\K,/+<^',W3
M]^\EQFJ=//9G&KBL=/RVD/Y1B?'#;_\+B(5R!BM0 S_M%@:&Y%,PV_> +T(2
M3>!<]ZE3VT-:"_4$O5RO97"9V,L 3E8XQ;?9.D/<%&:D8JH[YG/#";W*]P6/
M0H*:F,RM%Q44\]$\+QMH(-G3KSRJ<(U PEP[P]>:_IO7HSKA[^S5\8K?22<F
M!@G!723Y[1&#;B20T(:73FLXX$"&)_XQ\@-44%B66/S1UDKW^WB#FW([613\
MMF[ ,C8^_UU9ND5@7Z5SY=&]#3'A8-'1G@;2/2R\3$&!EYF&*N[X/14="\:M
MJW\0A 9XVWXW=^A#&(_QOQ#3&\M5TSR$XV/OODABACDY/[NN6V.UV]W/SR_$
M,(1F945+\'#X?A6OIJ8VU2,A)"2$T>^00*,QCM@E+;+;E;GBI,_U]7V'EA_9
M@2.TRQ!S0/,>[M3N0RZ ><@2#FH@K,207*U,O;)XOY WW3JD)YF:,$3;@1K;
MRN+H&\R=/<C.<Y'QCB.64+]0D7#';SC8GZQU^%'20%3B#>' IOL32B)&+_6B
M;5<B<\?<Y7/US0);H.F;-7-S]8"F_< )CL'K>M(X716#UR3J'E7>:ZCJ0A*T
MNV'#MJ5C[H]&-D%B38ZB'3 :9I2U7K 0FGO9P&6M];R"=YH[;ME>1M1@VPQB
MJL!F-/<2<3K>!_>SS,AK#6RO(HHH:4(+U)*F&?D./@\%--DN@]ER_+*@IH08
MJI*DQY#]4 414WAC(3'[^ML/\>OZ)K<?:#N89*7U\/OS_M,?Z^N2XA@YS^:.
M&_Z_+ __]WS#&Y#_(?S""T3,S\_5>2H^H!AJ.OU*-S=__"7V&#_$ O"Z0,1L
M0A6OWK1Q4@%M&BT'!S2)W7'+ZIZR6TBVG@G4!T$,&Y,"1O<0S1U(EM?V"^P9
M1;LOJM_U(A9RTE)I\'[BJ;I G>_]RR1CDEQ&@NT_5VL7 DTDIK7,3'+HN:X$
MH!;L(TO=--G]O'9M04#+%GBHK:YJ9-3+NC]N98./,H2F\VX.LTHD[>^+<[!Z
M<[_?<]?,9[ZG84+YVQI6)4M"L6U8C?&>US)K(&H69],POYDRG[6<,:;,Y<6X
MWC/)E58*DY!M#VC54>:!.3X_EU<P,C^]-M;W27((::_HH!QZ4E/SI/'YTZ1^
M^CEN)DE^G_-$;UH-::V94;H;3EY.T90%3EZNU$OZ:;R)]'IB2B5RXM&HP$K"
M#+D+YX7TQ.K,OX:"4W]PP-_>?+S)H!PN?*_Q2?/IFR+9O1UNY(F?ZO_-12S%
MH#F0*@3W=2YFGH<.AX8RC^EJ!4[(<5TQNF8LOY5#,VDLWUL.MQ\&[:_:)AY8
M>3KO4(\+Q0"V]X?Z;YN&6(5X=%K3B OOZ'4,3_5-<L!?_KW3C"$_/_Q@8%.8
M%6QCI*'4?E 'GE<)#9FKH<:1K(A'C/.*O#1D/EU!@(.\//.MAM[(GT*%>71H
MOLA<B*\=&R8&=E."A$_[I]H]VO%XKXQ*] MS ;P3LYS!KW)Z$_>R8.G3PHEF
MV0)T.>(%^RDJ*BIH#AYW"N8K!JY.<A9%?7T;3*T*'NVOZ2@;-?_B1S\10X\P
MNM8M;5JV^ ;W49?^/Y^ )H)0_I0#^M#AM;.X%Z$!^P8VDFB$:Q1>7FOC22 =
MX-'5:\L1\RX7@AER$$ZI.#X<'6\9RDUO\(9.JL2!@L6@^'T1*W]S_^/PQH&I
M.Q-+X*^!DMIA0%Q?<HL_53!7FCMGJZP_.>#1/'B(,,Z-@"YT".8116G0 .)$
MTANU-5V*S_1MHRDXXZM+&#4M&,O2PXN$2P#J/[.X$]IU:M(K+5EZZ@LI,.HN
M_J].V'$:N4]#%SM@CG %ZIS%'?0/$\1B.8,^BWNWF%!%U^7,XJR!3RHXF\+O
M/3B/\I*-V/ 5Q"6PGR9*ER:, 1:/2E/+'Z"M!+Z^B+,B>C2B2%"QD*U@F^V0
M\I$UE^[E!59)BJK2V@ 3 8%QTB-D+-(RMTS9X=KG$FJW]>=\]E0!Q0/M%]:0
M11-#5AHJ/* E(H?KOB)XB/O"\D.2"S7I;8/4OV/2+E&_)?><E$+-Z7C "&QQ
ME09FQ+[1TSTZ3QD]VDVV__5+.>Z9*M0,@\.\LO%&Y2S.F!$I?@;BU430HL72
MY(JJ<EW'8T!Y VX#9[X>D'@&E5*G,8TD7(M"[=(":VH:M%;^VJ=G/9,Z:V#A
M7!^9N<&W5JCQ/W",$@^OQ6AVC=Q"3$D^S'2$!EHFEC,7Z.YB,7-U&,05$;-'
MC"!2IJ/GSDO,[0_\UE; SRPHT+IG%:.%6\"&)=0+P4;]7HN@MC1/&\A0=.D/
M#$9-$;#-9.L*9W'1E$%[S0J8K'5B]=</B";,&1.:!'0 #I"SK9#O(?MTIL]]
MN$W.3R5Z<J[.9/_-LN^:="*+I(79BFUG$-L1:]=I5RD&O0O<:0EW\TZ_EDQ2
M@KJ<B:;2$G9Z;*A]Z)/,V/KKG4&2,U-^QSX773]V\YW3Q+W"-05VA5$]$3OM
MVIP?K'"\OD@?Y& )9:Z2-I4"-/UYR;>9#:_#@F^%?%H,F,&D,+@< W% K;W:
M%PILGFD33:00C#RWR2NLNFGAY94EK27G7#DT4GI.6'](B^F;3X'2NAL*C@G#
M3.3E-.#I34LH!GX1FB#+2Q%74#_)R^;C@,7 )=_+R&I%Y\+1P. _ZKY^"G2/
M3XU-V&[^*O$'FE^(51#]=-V3ZW[E,8\JO[UYX4)F_Z)7+07FMTNHE]9><S^=
M7?J&:AG#OZ/! F4-OZJ:_[7DII*^KJ?G^[M9'85!I_/:LYDO3]W<W?Y\LW '
MX4]ZJ^R?XV2-+\:YYD$6:!&I]@BK&V@*!^3%EFW(4K[&88 4K3.4A]5 VH,2
M=!4#_\)/D>7T"\D0CA=U,UJ_0&L@@,W<[QB7,(QOUH@.V-H^>29Q=CK[Y6OK
MR!J0Q78J>%Q03ODT$_DI96<<C99(.Q^1$*/WKN!OL^!A::BWC;BRK[(EQDCS
M[^MJ3[.6B65=K[*MJVM65S@LV>&U 'S7>15#5Q4 Z/\]H/ $22W %12O>P9$
M='COARRNNG#M.I7VHDHWY732QMK!Q[%C=YXO?]*[<3*\_/$SA1/E4'>XA.ES
MPO;&P^@PV^MMAYYV#_QS"MO,&*#I)QX17D41V82@!N>P+<Z" R&.XGVU=CN6
M^,TI-4 ;=S[L$03G@$-*87.VW[$Z:%>P[2VE1\'N@<.04;#QQ#5;;5.P+"VV
MOWM2B(NV=,-,]"/%! F2QTH\R;K7DZ-![J^OW&-<[W-D>M\?=5?_%E#2>^'2
MZSN1#X/;XJQ_:<G;0$\T@M:,+ONZ.^<[ _-M)3N:3OV\@Y0!I,J6>6'4K.F5
M$#Q"'_1335_Q,F7ZP>&89W"Q9Z<Q2K7*TC25,&/$(O0;()M"B)69PI30&K"O
MH)7S@(9:029E#V@8 (G'(+IIZO0A]@N.<2UYF5MFG+%5&)RG&+8(0EOGNJNP
M*8:SN(C.*[+EI"CV-71U'<AIEB47+AI@7E1MCX[G!X7WQ#ILV+C[3O'0<?(9
M%XKI&/_DT$Z0FZ8N0;L@0H:+D\/.'B7G<&_EMSG]:B>G,TXQC\[$5(X_>B1/
M[>]YW;-"K8Z)B5$=NUM7QT\YO/[;I#5[%*EKCJFRCY@>^7'>R<NDVP"\FOZ"
MG$6HXZLQQH0:-FE/,[ PT(QZPM,*2$Z?Z]KA%!X@$&3)\>/'Q^+M4UT>.')7
M[PF'"&(_XWT?0D,OO+*RLKG0WL)RA-YGEU*#(\6WG9\3;B!.VGU,#"\G>0)-
M%P#Y VR)\ON%&P90(X2HXR-X,$UI,5X#27Z$XU03-@QBVXR%2*=/6L(T*(Z>
MQ>$G\99C^?'IS%6)Y6\8%U2BP$L1MPO)1M1KJ_AI+223DQ!)L_/_W?[>H<.N
M0Z)"1\@WE20O(=0M%R8CA^2DP6G-WW,L$J'K[@HC.BQ:+WFBY@,\X55;N[[/
MW%K VOYJ7J?$.9$0G/QC35?L/^,NAO> \XKMOG]^C?4(U?^QCW5<]\"^1O<8
MD*N!-UR%:Y)+8[A(6$48KZQ@DN%J>IEHJX^"8TFKM[C>$')OA'+<N\*/7A85
MKZ_DCW_A6_2,7AC(FTDMSM?K#30/K _5<:<^/"0G4$NCW8)/<W25#Z1O0CO+
M1BG1J2+M/HW5Q36U$G3XYTJ]O"'[8VI!WY9:5S2RP.ZWW<MA+& N2,66<A:)
MU-WR3-3&H&]D=:[EX(<P72WI["SN>C#W.D*G@16'>Q%O4*:(;&ZT"NC?B-HB
MFT!7OC)[_EYH?W6P/_>3A.86\%<7Y6,^(%+;:JP: YHD8Y<>Z*MU_YORT']+
M1#L#__=5I\+"3I@H(\-KN;KB:4W\+*ZG8@:]*OE,U%8@*8D'8F9Q:SH-9C[(
M9CB[6@FMF*_]/(N;S'6?F]#I^G^?T/F_)G5BB!DUS/GWA5>(-@QH\IF8Q?U$
M9+.\L(P*H 8WM-\QP_H:-FOWP70%Z:I=K\"!U2-<+EC"*$TDBKVLZDUAR2Y>
MUHM?&45[GG9[FIZ+KQC5U'NZ3@O-N).A\>(+Z.)N)DGK!'Y 33!:GK0>L</0
M(6L%<Q-\3KL?QBLF+C>02C#R(S &^2\H\S\*;$%96FW(GD>QC:OW](RSUHNH
M$1&1-*-SWD:;[5*._WKL)O#XX?KY\HGTD<WP#2VVZ"9W.FL]*B*8N;"39&9
ME&SPN0BP$)[&IX>M[7&F)9)%^;)L3X<B9!=,CU$9;T0E8JG7+?KCM:T%"NZ*
M[ZNA35V3:LJ1ANK:OL]G*A5/T5AA!!'>QM^AN^$YKXR%A;$0? J)9_%B8BA!
ML< BWSZ[@5K.M,.@K1%RJB<FSJ_":7Z;U-EKJ9?UAG4U,73/\ !P.H5'3F.M
MK96<@,@I#?&5/H]=4N_HV$</U-R-"K/C^1&61-4?>!YA/1IG4UA3%O3I0O7;
MUIN[\@SH"4;@H]%EDCF76[[VQGR]&U=PZ"IT+1(-9\SB]+\#FGX@_>3OK2'#
M>*A(04?,IC6&\& ")%(2U!$0K7DF,FUR(C.X[H92:!!]XZ/M-UWO&W,W%/>Z
M$*^6-:$$?X>6^@_ID]4J?U\Q90EB?,]7$57KP.63Y$*N@B(=T'R<Z[N J?0[
M[DJ7,5*FL/:1D(=O92_ZX-\??D?AUC1,.![B%QK9[!86U"AAGE,T;E6QKKH,
MM3]P= [QMPJ]Y0PLKSD^VD_I.U)24I+R7^?LMV[]81HL#9)ZV_ J*VL75>^D
MSQWG;=IIM*]:;+2GNC7S0>8R',E%-7>X/)J?ABQW_XHN!I2R:Y8#Z0T[BU@=
M_5AZ]\4"^SF8M+\*G+[,=-K(Q6>X=)P=$^==$E0_I-6WEBD=A,M&I-E;]X*W
M!)P():W 2QZ=NO+QQ&62GUW&JLSOPP]6BRU]+*_ARBVO'L']A%N&VX13"O^:
M1A>G8;9?"AMJ$X FLB.Z$'U3N X>E /P6L)X&N0U0Q,F40P]EY=]&MFJ*T7M
MD2W]3K79 :CY52?5L(D5R8A1%)+5$LQBE_N6"^XIV*D'_</O?PRSA*^H8B+%
M[H$SX9A3OXQ/%<HG./!J<K*GQSV&=[/M(MT#3Z*";/AQAIZ&N"BX>$0?=&7?
MA8&=W>,*R62!U>X>#*YGNFK<3^>5'AMJBCQQ8NY0-+=*O,#4=UETD:9(H]0E
M Q$8TH\?+P>?*SK;0CHSJIB$7F:@G")U:+:PQ0W48BMC//8_R+ 0N_NFI9:=
M>QCEM2[%<6Z,@FE<I$"BE_\7,:4H2QQ"7<V9+,68]&% :4* UU!T"X4T-N*)
M+IW%?0B@I,C W01XE6S\A'8?T+07D#\B&;*^C>98CB-8@%HPI'OL::]@#[X>
M$]ENZW)6AXX[$Z_-XFIM;Y1U0M^\QXPIF%>6,;%T2#Y]]=1-/S^;I0:1,4'Y
MLO;&ZP[TR;3[EU<NHRT[UU)\*WNIBU.2^- /27MPD?/_P&WM6OP/7?,.)I[3
M[F9A_(B7]H*VBJ0I:\4/2E1$4:.)7\C>.,,[P!*X0J$1%C,N?)$=R#K4$Q)0
MV'Z\7O)9(2$$5*4=NJE7_;0^<^2B=2+9!P>X4,!H8FL[.8, [L7/8SHV"+<P
M5)HPN!I*D^==CZ4UVB6:'>TBDA0NO2P[F"4Z6/MT#ZOW),AAQ_K%]<;(]^0K
MI1/^#;FJD)ZIB^2MF'ZC="48P+O+ ?=W#DGD;/4'1:6#JE,]US+\B0!T^9!*
MHI&N4 P?V4&.G(4-.T^41N=?A,LB2_WB:;;))]9FPG1*35_#SH1BQ+.^?Y*]
ME!'9<DEV=:IS)7R^)4YC,4[_]X5RY[]'9X> L_3L6=SB.#*N0VN OJTGIZ&;
M:2/SZB&WK)^@B6:,%-X4!33DB'/@<)%%;O! *A=Q4FFYI@R1V/)Q&<:E0[1;
MI%^;PXRJNU[GR&-<_3J'\G'H#H#*A=TM%"2U _CZJV;N-OL.YG?P/]I]Z%NA
MM;@3,Y?4>FNA$7.OP@.?9EX_4A!'?\P\U"A(#DB"/C-71F[H=20::[(5;*-.
M*UC2RK*7>&Y55 R%AFA4Z"*,AR^8248-BK3?(-:Z.RY^6<8!RLMU0C@#&J!(
M-D8T2*:XUP2>M^,X*]I*1O;J<89J"8;/@^#5(LMDJC3B=8F"8T2U3"V)L*V(
M8T[,'+H/!XILK6BEX$2:L\T\;@.WKBZK:'0F(.SBP@!]:79VPT+5RZU_G?SJ
M]\]IZK[POY@3!_6AVV .:NC][]3V;X&H3JF')@1;I&H(B8-O@]Q#<%8%(TNS
M5\=S)ES-=])DJ2@+_ED2\@8..R'W(!HQ @Y+)IP]_(DMOPY^S,W/N]9@H1P.
M%!?:0,U.3WOR?$#"4(6F?@"S@@\R&^8\W66AO)"S"/U>RFIE&<"#"F*FD#>A
MSE%Q##KE='W&A<Y=W1./3F$@U$@4^(338AF9PHQX',J(;Q:LSQ\*@]K8%-_\
M@>8+M@O!W"+H&_IG=D#/9$=T:^+68Y)'<3&N'W=OC-4=Z!E!6^4^WY&7%/9\
MVO;3[[Z>ASI6W'0==*3:*;KWG,TK'OV73665CL[LOG/VE.L,*R\RINS-B].W
M/OPNHE*M-^V**-R[[M=BFB#(=G=[S=)Y_X1BMARA$SXFR6\ 53%MZI5RV15+
M65L48J&D8&C(<%*X:'#L@TB*3XM5GRN5W(/(;,\C+G7\\H_HBB?\GJ(NIXDS
ML=D)!QL@=KJG?4E'S/+<HL0**C+11C!A)*.&F*\L^ FZ?EM!,H#3Y/AKP!GA
M8-;<03S3"G)W2QIK+G0N<.98P[X_0+;W;)(.H$O[F7OO4_,O0G&"]+SSL/<1
M\K)@!N-X;?!VEB T>"ALZ'A0V%!3?&3\@CK^A;Q#ON=BXF+.6?EL;VQ96B%V
M-MLU85V])]OZQK],[#3NOWZ,</HXW/<XDZ3+I P*;.^+6)N"=U"#;*T;0Q\U
MP"Q5+Q0V@#YH#NONDTYU+AXE&4[61(+/CT/ZJ>@&AN%.07\MW8 AW)GM8I7U
MI/P>QE0%]Y0Q[F-'0?OKCX<;@N0V/WVLO]$U::NO2=+=;<!TJK\5?0M4DT3T
M-V7R"3'=D-4LK&:+AXDJ?AM=RE&6WKHH]U_=,NTZL@[LS4-7@@?RS5HL=PE6
MN9-2B+'$>4/1FS\5KFL8:-A9&7UI(!79JL ;?9)>+]>UTECF8&=&2A5$2',F
M+C%<O;G&<N1&V:?[76\O_G#^#%']><'"<T9>Y[(B[[SS$<;G_MY76UM;Q:NK
MKN+QGSRI27((\?/8$U['X]5=,5_OI*Y4_)BZ:%7VT>_O9YA_WWW$](?+Z^=C
MD5LZH2F#_;0FZ%\R<R%5ENW^5.)EBUB#8?>4#NVGZJOX_9Z''H:$Z#BBL$5@
M5^]9QT=G&T)4B9?\/3 7K7WVC,>[<ZS/R?]=1T'FV^&=,!9(%NS7_89N8?X(
M3;028$>9ND.1-:ROJ=+QG(YVRKG-NK!9W,'Z+,T)W4V[PA'5B\)O>F*??U3%
M6(1 XH)4MM+F%X^\PAF;Q>VBA9IVD=>F/M2.RI=U\Y;-0T+1#@)O8*Z7V (R
MYMSW,5^/NH,N]E'.35];CH6P9_# ?;1'6%/&YJ(KF3L@00[$5MA6*(49,Z6W
M%'-%%JQY7<R(N >AL-V'MMP1RQS?1G-S2Z>_+=_ZU'87CW51A?=(X!FZB)3.
M,M.EH]N9@5!\,M,7U+[ DA-)W0A-:#)A0_F$Q2C?U@;RR@9#6C2H">;H(4?
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MV8%==NS. FZBXAO+__LFL?\O/TP<T')0*!<LX(P6</(B,D]V57BFD*CQU94
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MEAS+>I,EG^YT@E=J'1&?>BL;;(O3H2Y_\&(F+1':KUS]-+HZ9#A"2KLZ;3O
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MQ'O!OPJ<U?F1@1_**DY:5I+Z_N(J7$4 _ W=1TD<FFLC\,P1DT9-F8XE/+>
MDXJ49CG@F"915X':1H:82AB>2C]J>\/12";N*<2^6K_>!@*28Q=P%B>[2U^4
M1QZVRYQ)-9^+[ZIZ"P/[!N.&#^/'K6Y\I-X"-@K,T&[A<H$- L!BY8A["]F
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MQ.N 5EKT/(;QE_KK"I%=6B+0LD-XFI;*-$\>6KJ JY-<%=C2B_Z2^E:I^OD
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MG:6(1()/E_[(.'AK6JE_O09Q"%-RUXO*)\PEXY%.!5WG^^/\\)]8RNFI_1A
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MR\E?P,<.:O>?#+<R P5WHTO#F\X:CXKCDV(T09;?A_[R$?TP?9C_J^? [,C
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M.=J]'OL$Q]Y%98;:R;R6%0SP6FDCZ;J]R/?Z:^(3BAL487A#VA7"%=%,YM1
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M"_A][R(G67)1\5%UI@A\[W[QUUJQH%7@O'JK^T1 34AEU\3P8MU!9!4FDSQ
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MU-\W-VO2?Q?>E+FK!:.QXQ&L+>'+&D8X QQC5R;3Q3I?U@6X4Q>$2H!JGM2
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MPQ$3,?0SW4MY"TJ<:R\X)3N7?3[2ON85B-Y\M'F>,&>84C9WMPET3;>(%63
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M:5Y6\(@9Z..73I$40=92&88+$1,-WJKI_B'@^%)B3Y#[%<2O..*.AMJ!!);
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M,N#,BGL681(*^"M09Z^BP0=I[XA@+E#GF0_488EO)K]'K,+@_]5"G8="9[P
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M8*MAB$KB3>E'*&$4Q'B\"'D?>!F09E"4ORC&CE-FB$%"/041YZ,+[V*J>VC
MY2\VMNFZ+%ILP'W0+_S-VH#;O' ?%G(O4#/UOA=1AZ-HNYR#3L=>NCF.WA$9
MAV+@[?Z^H=(*LQL!^!?B-."OI_FH@SNVWABV'JB_;L!!*\@S#;BO9T.G8(:/
MP8Z$?4#KOXS-]U[2YAAP7U N_',X8I6-7N<H9>AWQHYYF6,_GZ'JIYVEHI8?
MR+1Q^R'X D='C2+"\ZBHKVPR"+,TQ(OQ=RMS7Y5N 4:Y=[,L#;B/:B[,5"#6
M[2A7:MR1JK\'8ZFUN8%I@ORP 9WE;\!MW0+2#;@IK"T&W.M)BNH5#]S!F%Q/
M3*3!9FHB2FM]):&,63908-]?_@(ZXOBJC\1O*OZFXF\J_J;B;RK^IN)O*OZF
MXF\J_J;B;RK^IN)O*OZFXF\J_@\5_[7'@)O>I"^G' =2:QB(]2U*D@$G=!_^
M "U&"-BOB/!T#6U^X661.[(!2H2IDIH?Z9H B'$M4]KGU+$K496SIGEF1^S(
M_J"!@*T'T?8XF_&6S\96Y'_KZ0Q%XT4)(R>BI__31I !0!(!*+-H3[C#ND+C
M?<D/\#K=>N0'^))3 Q%>07FI2!+/(6Y.#-RBYG'ZEOJ?&<J=UX%V/GZ?W.[F
M&#WEZ<&?-A"=S^_\[9/V*2"QQK3^)QZN(R:&F" U?TMY?.S"+TP_/4W%H]-2
MNNR]/@V^R26LB<V>'"$Q1C1KCEV-IJ@N_>"7Y=%RN_\+IUHK//5(,1%76\C@
M^%UZP1?OZ\?_H[B)_^@'(/X?U/Q?C9'_VY]*WN1,-0]Q_)TE'O24@5\QDXP<
MP33V79$!]^]) \Z/!ORC;>_Y1VODX_[)K?[1('[XW@E-^!Z3],PO/-+DC7'$
M2ZHO%.(14^PEQR&]<[P!]]^8MN\_FV/MU']VK7]R_O_RV'AM;@<%7,5#N/PQ
MX80!]S\OZ_R,!*#?,14 N2N_&'"/1FG2/RCR2[LQQWP,?"&+VV0*+.S\0_2:
M"_Q#O%G]\A_\Z9\=_L:N60;<O1LK#;@ZK\+7:/X+ +_VFXZ_Z?B;CK_I^)N.
MO^GXFXZ_Z?B;CK_I^/^ CA$C_5*@[W@5[@W&<UOO#;BD,-T^]AN:I5@URWA#
MGS43*L0^D6HJK !;&C"2GP)[;G_V(CJP(=?)>+JQ?I*K-4D^UQ#KD?SBL3[#
MKV+VPX^#B[8"L034U/A,XZ;/]+68,&LH'_O),R>!=Q#M#0^QH:.S"G0ST1;-
MWX]G2M>>@&- '6K#0^9.57+K#+@4VKNU4=BO9M$N>_F<968IDH04852UIZ#9
M)VSSF2=_;9B3?_P5S=BZ8YJ_4=VW]P+'B/^+O3>/:B)MVP?CBH 8!00%(>V*
MBIA665J6Q*45%3$J*IN0MFEEB9BV 8D04BI+6(2\:@NOT!!EB\H2D27*DAC"
MTK:-84= R-:*+)$JA5!-*L44[\R<,W/F^\[YSLS\_NL_ZI #.<7SW,MU7]?S
M5#UWO.]V/!(#L[M0R?\K<<?L^U4-CM*O:0-G_$)?3N'_EZCLOK?_#W6?/8?[
M9TWCGV6K?US\CXO_<?$_+O['Q?^X^!\7_^/B?US\CXO_<?'_V,5B*GB$N@ZV
M47HCJS>BAC05ATW:!0HXB+F28('^V3=,@(!;]0<+X9+&V0]W*N"VE?4=R/Y'
M ;)1Y]PGF7LWFIMY1S3^E-[%^NL'<J$!&@K(;W/UT76($>:-+"Q(0H6FR&8P
M\[Z<RF8MAX")MB*&?V/,]K?9@6D\.VY+2G-1]ONVJ]\E>[H^__%H8?A;F>.W
M>E/5WBW#K5H6X!UEA9_(L]3L?'X[K)8Z]O'LQ)"/^ ^#@O27W9NW/@DX5'UI
MAX,NIX&OWCX\2!TXIA'6"%O_G,/5<)$'K6K,C)>DD&H.=Y:>6J+@PM^PD7RB
MACB'JW!J%<V^)&WL>R_['WZS^_0<[JX-%H\73WC/X9[^)J?K/I*GE3STMV*6
MZ-2AU5]:%(=,3R[X_WP!NP'0G3*HIWFLJ\#2KH0,^B^ %JGHJ:X4[2[6&X*%
M/99#U,7"U9[%G\ZABSOIX:3US!/@#0B?2(\L<SY7^[*J@V3@T*S[O>_#/1^*
MM;A\K(9 Z[83-H^+0!\IO$-3H27 7#'Y6>N$G3P6& A&#5*T^\^'UMI(* D6
MGH^A%7= -J5/3BNA6C-/50F$SP1II[CN'KG1DD"SGFI/PHD*<+I:UB1+SLY,
M <<]JJWM<&C\)WX3)7[^%<LP#FQ#04QB-3FZ0H!.';11\M4!VB,,;PT-+H"X
MRAU9SEGLJCE<XAS.J%JZF&'28KW'>A%LJ"@C>,#7[E$V#XRB!.N-D%E)<)PR
ME^[950RV"21EMJ?BECI3P2N<9OH 636#&&?)Z>I%6B_D'!3=/(=+Y5JX^D+L
MYN"F8<?K;U_2%.%ZRN@4EB4CR./;*K/,<[.QH^ABBX__MD]S"7?^_,:??7KP
M:FQ<[/5?%FCO'/IIW!E-5+SQF:P_6#9J8?2KP)"V^F/E$]_1:\\#7'_Y,[/C
M/=5S,>5G:+]KB<'+.P5)W@;GG#;HRGK*ILNJI]/;&C[<_U#O="XZL]+]*BV*
M=M6BC1X1?M70U6M0:E+XK,VDZI>6/S[]6:J/RTM%:61Y';=:IG8#L_[35&L/
MZS7Y^61+;JR\MTC[(^L=^9W,K!HP](6O??5Z"0<I #/$ A3R:"5&?F,#R"=*
M,7(*VODTTF,M9D'X6+FKR^8JOR)A09&ON]/4=4?1(_\Q39[UB]ZI9 ?M^+7:
MY^T?NTN5O<3P4U=\/X='MCZ@7['KN3RYMCA)+_U<[U^9"_6/W:!U'#K9/1U
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M6V)T][$[%7<E]OS^_-XIVH6KWW+^_ 'ODY^*8A55KJ /[%&2,^I]M9@>$A.
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MM>_ GI%XTC=AUQR=$YN?,]+<P59VE-6%39U5+Z*NVW-N:3)[-:Q-YM&]JVX
MYWX]<])S]9_?OM^G/!*<NO?1OQ8N:MZNO_'G-0L7;5R*N_'S=5QWU7]W@M3_
MHE.DR&K>'&[+U?E*W5^),.9P/?[*IW PNFS]'&YKFBX-NY,G-(F68U1YQNE_
M_-VI4>"U2?H<[CG/%OO6B9_Q_[]O")WONXWX%C(,Q>@.2)ILK733$^=9]#%]
MRU[3%IT?VG)',;1SW*<[;Z#_6'5S8[_OG^VO2LMVW Q:;-866?UW .;85[ $
M_XH/;\("E-#:21T<C3B/_BE:*;0<K4V8$?C%#M"X%A,%,%'Q=REQ1_++>-^
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M2/RK*[][!')33S?7W-N9#HX<@A]$KRAZ$NI7!1VB13V.J^W8,1D^_?,*F1Q
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M[N'=V)!]I&WS.Y P_97HV0RR;KT60Q QF?P#YW8VNYG^3J\9J#P%*Y04]KE
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M>%V%U:SWQ+EB"RA89=O O<:=+5I(YR01S)A;0-M&NHG#X2'9,8(U%*,.<VY
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M26PWY37)XH]P@M;LJ1WN&OPU\U@T<*_WS7"_E\$"NJKE[H%NJHCV3#PDT6^
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M%-KWC]]'M\6>472?RYZS*'CD,JHAYN2W]XCJ#E0JA9@5K%=3.U1 ]QCQ?]A
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ML+@B3DYC[2S2B,=3X/KF68)UP_;24ZVG-4G4YMVTO3#_:LVNS)K%3@(EB07
M^]-RAFE&IR+-(]Q_SU^MT*6?.ZV),MD<7[0T),K=<>^C5_-T+G.4SE8?A[T2
M/PUH(?</J.E:(SB$F#X$&"K0"PG01Y5U>E SE0KOPW;!(05)ZNA=?L);GYO8
MEC#ICMK)=O]SF)\Z< H.NT%AN:AWFW?[^7KZR[>,._%CHL4[1'/'RW20H?W\
M:X!%@R=4UJ*L&1VMF[[&VIN@YEB,A2Q"\$FW#QEW3>6X_5!TN->^&N9>8Y,C
M%=99XW'_1@\ER#R("9HDFYG^VX)LPX%HZ)[1I!^3>VWN-)S^S^W@2FP=)B4M
M1>20I)5LART?F3G/@]U46/IP\/RC"$<5[7A2V%TET-):"HFUHMQ3W<[_JF5Q
MO\AS^YT:ZT=GCKOM\'0M#EMMF)3,$C)(1@A?!1JCAY$PC9*(?%9/<SR $J2B
MJ7 G5%H>P4,8+9BM3+M.W!7/L_;_(R]JEX&*O0FO<II8\S\(GH:&6G!TO^"K
MM)NUQU '1D\.C.F6R>*5ME@7#_;2$)OYBF/^UG3K+^!\Q%%#SZY)<@Q&RDN0
M8Q+1-]!TF@=0562#O&ZN1E[[P:[IL<-)QC5W:7X,X[' L/1)9\/7??.G\[/0
M$L-34"4$(1]IGV.;]2S!5!Q!5$B:\HFMN]?WE3Z!A$TV0#:VA3DM^1QIUGXI
M*DHS:*+FI*/^0T:-N3[Y=N=W46QIZH'G7[+O4F=DJS2] HYPAC*^%L^9/QJN
MBE4EVYF/R7VSA&%=#DQN82]*97C054X!>V#Z%>K:\/SCW&T*3\U\E9(T=Z+Z
M%,/DY87XT)^PS9"AEJ\>\/T.DWJ)>[0NY4=^OT)^( B8C]]XF8263"7 7JV,
MZR%4*!U';EKADNZT"HV2A$RWN--3&QS4@[NKUCS-^N@OCR\HV.W>$<.HXCGK
MG?/C\Z:_KQ?\(?#F;^6I<J$).;8L#3>P?0AS9N#%-JSOE_7<Q![WI2';ZI -
M\*CDQ>:DG\=B<M\A#_1J7DUC7I;PS98/\(:_MS$O]L^/E-L\#"%YR5;,G_GJ
MP1-TM\9N?JMB4:9&O"0JWRNS@:*)MO>%C=)0;[7AD/1D)VOOO3'7GT?=#P@?
M1-G$R=W9%0\CZY(Z&G4%Y2?>T<*2PCS<7+M]EC[2/OG_N>WI0I9!#2BDN@!X
M,CO@!6F1H10(F[1A:JNV.EDWA5@@KZ&/+6RGJ IOF6RTG^56C-SZ?-+-2KZE
M=MHLF[)C5?_IF_[?68DM 54-\&027<'!EFR&JW4G#=GL)6.!\B8ILI%_XTQ/
M/$XI*X:%R1X75$[$M@3HY+NH'R10[; DD)_U(XP[C',TS?,MS]E@0>MLL-30
MY@\QI>V)!VI@&_FQ3M3J=+<'1Y>)A\-CH.I7(;F:PQ$H4T!3CU#]M^AY2'EE
M,KYH ;M+!I!$3F-U\E2/,+7=AJEHAU;LZT[J!I9O/7(T]G[PJ"+.FOUMC?!M
M@UG%@X['9:DL&O3A2\30VK=[@$>V%15!MD$% P._;1FO5.6/3DR,AFNUT='1
MPQ%56V-B-I[-6KPFDW2R]+;LFV+_A'-^ZYGIJ(O#^.M9@I<UY("3M#FWQ\*C
MH,^8Z3-#"74=6SG7K]37XH"AN$:Y$IEL&3*&R7-;$$-;@>4>1Q_W#S*+- XI
MSGH36S%Q])^HB\*$_-OO==DJ@!Q!G<>EPRM<L4V]-<#B4V/Y3;(8/JA>+Y\_
M2UAT?ZZ[O/=ZK$/DL?Z6-P[^3&2LYQ_PP^5[Q'<5=$64+D;T7/CTJ>&>:'%(
M2 C-E%=2PF\%Y[T[-7CJW<$G>QF,!8'ZUQZ?7XVLV-:2L_[6C@>..PE)8OZA
M6<(WDP,!V&)8_U5D$702[&O_[XOA!>\1WRJF;:O(*LE1=\7P#',ZQ:(A.3#I
MLYHO"7+K8@4_1':\DK2)'&4"P)1Y!?G:)#C1I]%3,I,\.B-MY:18772_?9N/
MKJ]CEV Y%N\"1V2QP2'OFB+.A49O:!U\_^[MP$"@0M%RMO##ATLGUR4O/N.5
M%_$P[L:FWKO]?MX$,A4)U0D,A1X1>F_TD.'7ALWP3E_Y+"%<G%)HADOG&Z+-
MJ$MW',?\73!"E(0XUG3RT>WQ&KK9UBP/^U(EDN(+;\U^'*Y8*EI#6M,35_'<
M99?OUB 31WTVXSS,R?&P@SY+W,4Y'J!&:LJT;1HB"X,Z+K<6;I?'B9<B8?L$
MES2U/CQZB*RJ4M#H.E@5ECP8UE"7MK$P_,'2LS=7S!*VX8L<W9LJUY)A>VS)
M<SSJ'9'5#(:U>.I>&00-WBJ<5BARLL,O[D 7(C:,]TC"HXA "T502+_$< ?^
M2OYBHFY\.K]5 )IJ[S\_P1CP[W%I(%\G0P<G%0/8DG;\<GL1^3 #^;J$G\5R
MPU?CI>'W^%W1.W7;#7=1(APF422D8KNS[TSMWD$G(?E*-2=GBFR''!H-WM$V
M%@C7EFM.-!C!E.^Y;21+J"QEJG%7<Z&E+"Z# )3@R"$+C%Z .6(% )5275GV
M2+WAUSV]8O4)UD&(P1$_?;G<S(6,['>Y&S2^+U-EKZ7Z[WL;:C@3)G=$YLX[
M& :;5LX2SG*0#6[CY?CEF@Z)5;\%\EO(?>FZ=,-OV'KTVSP9L 0] T_FQ#&R
M$NDW/*(?,$-\;3Z\'G;C>-!Y+ZO"N=-U"1G 4X&C(:"Y<"UTY,YPCE%[D6D#
M[>&HMX:V"#P U@+HBNP PUVQ*B>$,M?6.X)*3).T!0!/I<WB+/82*"PSU/>[
M]KT(%]9)7XCLD$NE2.G WIZ:Q36['23LW4BN6@<[Y>7R5[HXN1T1"ZKA#;\'
M&//VS)LAPH NUW"7NG@T,28;+AZ>;*)?"VRK/J,HO?D0I2%E*@9A-+'J-ZYY
M(+6XM(_)#^Z*X5?^,+HY.G]"MCE:IOEV[0[CY?])+)QC=:V!N],S6-MY(R3[
M3I<3"V7<JG#WVWE/BD?]__KK@49RK/O#LZ<-5YX^S>1]O+7CU0O7O?.17OQF
M?L"M5E?T5*H%]=M9WQH:<:[WV VP!*/)BE#=:R@@7>0^:AWBCKR% 4E=0AIK
MU;#!1#(CEARD!R+1\'Q/&,QB[1,MRC[T/'^:#O\P$D@MX#6I]/1%$;[JH*#R
M;0T4J!T?(^6B6/5TEO#4^@4Y&5S!8CR:VQ,)J,H3&Z<ET6256TY-D06SC98B
M)FFG[IHT)^YO3ZTQT3H>5T:R8F$+=4T#:5UM[QI9#64I,GRJ2[2IZ6+A(BC]
M1OPVHC8QZVN3_RERCO\_(V?9\^?/[MS:M"9Y_:7S^0$G-#DG!V\?_W6>*F2]
MH0(($QNSWXJ)X-GH!,W%G&C]0?08Y/\<MF^B+];^5-,8U#*M)#:X*P2!13DU
MC/&<K;,$7Z@H->=#:F5$X/EZS9C!Q%<>W^$ZN;=SPL7N_,8G_(N]+KX[/;M=
M[*(">WZ*RR$??%+?ZQ(==+Q>V/VE@W*X6_MWO;@GWE;_?&W-TR=/:]*""NKK
M[YP1U@JSO$MOVA\XC=[#[5)O,]&HO\SN+8*.DY$M81Q_31S2#M\$SH']0EKO
MCZ+":?4LX04M[><1]K9GD"Z[?,S-?+"*PX]02)M=Y)5?D@!\/@VQ*O'R2.UI
MW9B\6S#75R"YH \]@O_Y"Q^!$4=&UHVBQV!A,ZWOM>XXXG0?ZR37R')53F<^
M^\BHVX-'RZ'J]I\CZAH;9>6G[T7Y![( ,VPI,_8%&-F)XNM)1#UYB+R]67JJ
M<%<T92\!>X+9LKMG"=6TMN S()&UQG ?6\3RDVM_U/N^28<&-/(KK-C*H('H
MVZ*WU#MJCEDD]X^F6N."CEL+.3_MN-N7 T_$H^7L7@"*Y* 6_\AUE^!EY?H%
MS%@-,%ZM/\MR@5K;LT3&:%PG^UM6O'S**53CE2JH3B@^B;QZ?1Q.R+)_J_4(
MOAPNLYZ9;!8O8UZF0ZVZ2A<I,<*]1'2'G#(%U(M50U)D4\)UL>IA$>3+3Y\E
M6(D<1R4MY-4B*T32HB2PW9BI<5/= 2V%[I!382IO9&C3K:$!GZXXOI:X@D6%
MP:NH9]4LX720'8EB%IG(X]T31%V*&UM#')A1NTQFT9<V.&F"R4UL!R1;15O&
M;&^A_SA+N 8V)TYG-P /F=Q@K+=G0Y= /)YD\GV/TY0O3>]S/#G)53+N7VVH
M_CXM:!>X0^-V_1>R($%K!/%U1Q%+V$>7@PQHEJL9J:!1 _DQL[LM\,^K51/%
MW7%_^Z5)?/[(R0NF!<NFC"N_T(@CV[8]ZZUI]*)U1TOOQMW&PD#S+Z#B\O#<
MTPAL,4X%%IXQE&VLZR1C2VCXEVW(I7*V5+FDZN_,ATB\W@E=A$SI-W\"%W8&
M#>PWK?H]?R)W>&PZ[1M[I28H:0<Y8^::T$;,<;'-W /TU&4Y%L#<+$'15TS/
MUA W^1#S"V41PC@%^]=LJ%ST8<2YB!C!#10]U,E>^54Y!.WZ-G^EY7]>KSG1
MM+!ZSTJR.97"<D#<BO=K@&RE!6:'?@U]^9Q]PD6927*!Y%<%$54^^Y*'G(ZU
MS!1R0]>__Y"Z8/.WOPJ>;#KUYY4.:%C#Q^GV]1 [*@79#]N_ %:@&RD3<=4:
M3CII&S1]P\/=9=>&3+[S, \).]KKK!0JMD N'64*]MNO.I;G.9NO9:@_8L:A
M>!X;[014ZDDK5ASN%'RPZ?@4)X.\'#7")R7:@@3IG=FO%&XMLX25X:"I"->?
MT.]UU.++I#M5S*A6UY!M;U%*:'ED0LCR;@_*/2DT,WQ4_H6S"MT/KT[$R7%.
M7(5^*Q];$JM?@- QTWZXZ,4D\K40-1\(@-N;B2F*@%9@'KK!P,.SUVN.'?*Y
M'5N(\"!]2.&$9I43'P4?,25^-*WM9:)9A/4OB+(E\7?J2CA$J 8L6+N?04,5
MH1<B'ET!8RV'ZVA:"SV LR1S!F8:3K>C+HO"]=CS*=MHFMH_%W9K"N2VW'7_
MZ)59ULN;1$W#>!V:R]Y?GEF6]IQYUC5\Z]6&B*W^ZQ=PT@!5!5VP2*SB(^L3
MM.EZ3Y8I[-N66TG3?XUP6P&B1UA8=,*Y1R=.(@-[:@3=#?M+/<&%I?=+(SLC
M;/[M<2Z/X?$F!8W[HV/6"V]\Z&L!;DXJ/NM,#=FSA/,TQ%6N<\:-?!7[BVKZ
MEFV.]1>:0MQQ.OQQOZ$46XV4:N2:H3*X7G,(^9YUM+N&;,LS?.!=CB@>P];#
M?KW\9%X,+QJU>,P\\NI5<[=O=>>4D[MJOF%)12XDY#28#.=64)(;(M24E:XI
M+,7Y.@\GS6YRB]'^'BY;N\O?QO=]?S>?&SHA:/@G9E'[7^#F=K42M;+%EKC
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M^"6JCGZ#7[@^#=C9\FO$'ZAGSX9GO2P&Z'&%/!H:X@,#PY,O^,G>92_AHN&
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M%S.Z#"Z//-9'O0L''.P%GJ(N:OBQ;_$G*E6.NIS6@.8GE.&)&4;W6;;X-?_
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M\]4BQA@EHGFHX)R=@:PK,Q58'<8>*.8AU6J-<O0*(4F3[]S*7L4X?:L"]E)
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MXVR/"@_V\\V]"D,@Y]8$]^BZ<*%DE#7G8_=QZI]G=R:4-&1U,!I9>JA1;!R
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M[ :Z/OWWG=#@$!U][3_B@(.]ODB-_R*FT%H/4+CE+&(^"_"B!NR/@M$I +;
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M5Z7[W&M6+2U:5KRTXK<'SWIDC\^4'0Q]7!=UI;=)\)@4H:^9P;U[2::3=6Y
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MX_?J+V.S?!00'T!Q@/@@BJ.RC\/NX2KBU_#C)TVK9W"_&@P!8CPA\2(^%5C
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M37IN5UOY[;"="1&WX>8VR?[:Q:-]'KFC!,1\#%VX'=1HEU%?2Q4SN$QR!-X
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M: XV[.O8<*_!:J:03OR:O3?@=8XVIJGG1(..E P.B*?U*GI]:$KZ>QOBC@;
MB.T);^.'9=!]F2\K51K+#E=%O=1UX 5@@)K\5:AF8 4AIX]L&><?X:N_B'U#
M]IYNX%3:Y#_,*ZV3?2(8.*L4WVW^[2W-,H>".%?K;\4Y;1XX6-V8H[;8?/0(
M9>^#,-Q7DZVYB(UD!C?W6#V<D:"X@:Y'HKJ]7.F)WG<(EAK.5[ J@$NYNOBI
ME4]9/ZW^%(7;>K6R/IAVTW^G,C'E=J5DY:-N]=_?[").;@>Y0P;-\FRY,9L
M92@$V6PB1%;&9T^F3G48L,;$]<+[=<JW"?Y7CC &0SS'?&+-9&';3Y>.'MJ2
MRISD!W9]\NM1\UVM/<LC&TZW%5KH,\+U5Z;H 2M8\=JX@-?7I<HSMU29^P8"
MNT@$P;B:"6;O[[P_E:]9(E[D-O3D9WB'[ML>C>OAJ<1M%LWON_=?F>Y2HGUK
M<_YIP<J$=WNZ>@;WDTC6'O JORU>7CV/IRX:@G2;QIH\%N;=+U>&*[,7B@7"
M7]>>ZO+>%C:PHZ&77#G)<)>0P8(H6]>0Q3(9ZTI?RYS/==I/V.+]@;:20?^
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MI[5I8V7N 9#<3#:(_#SH!@N'/!<XWZG)#>I"UM[)S".=KQZ0A[2K1,M'PRS
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MIJUGI=U Y'!0S^HK+V(Q?<.$UV>/5V.#7%@-IS% (@6ZG@3A%6@U[2;[*$R
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M"Y2&,5+IU8QXMC$*0*04)V>Y6Q[=!5@Y0]0*&R2GGX(3&RB)_%CK0P_[G/;
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M>&%/LU%;G92\KE5Z,X*W@O5]'RM5J=F9)@";<,=+B^C:[(U8JV:X#EW5J:Q
M=LBG.$)MF/9W?#,%0I]9M)"7HUH01S;;$K88LA,]&/7->Y<DH!2(4MZ^0'=4
M#(_FI+5?*^>#*TQ,9LIUFTRI.;H-SINUYG#$Q)UBO\XWQM\YFOG+!3A%HJQ@
MGF%^B1YY87L2;X$5Q?5-$"/=R5@>'M:(V4'3T2G\A_FS!VM@^Z3([1$6JL>.
M!Q_U.@'4S/M/ L]0LK;-9K+ML*?TJJA6FF:,:U4W<%E2W9D@4Q>+@N<)EP M
MJAFZHT=@8:DL4V?"00I,.+(1X<@M=<4_C<YYY58$(,<1\=''72P=68.[XSX8
M2$:!XF!?L[<%0?(\W]D6K?OXPUJQ7TKJ7/!T;'B4%8#_/Y[];)9<[=TVBG>P
MSAU=-<;<90A']E<^@(0'FG) &2>Y ^IL\QQ&&AKM9J-RBNMDNO[V](9'V2T7
M1E:DRI=D;H!FKT4P%03U$O4=-M&/_0)<**2P=!_#O#1L_0#JCT3*IY*BV(Y(
M>%G[;62V^<*(91?#QF>F4P=/$P%[3I0?W</\Y--I6=,UY9^></0Z2F,/BB \
MY*6((-?=#,2",5$"SQY6\U%_U98!2IK0# ^,CP4DG.7VYW^-G#AQ_D[(7&V1
MC+RV,^2$54(Y"^CY8#M/6*MWN)FR N'NZ]IZ*J-I9%.2U\/L77#2 -TPDHQ8
MT-!5,4I472H*YBY@+5/?!:7W-0F///BI)0=,[XQ';6'C=@Q 'JN^#IV2\_01
MSF%H*IZUSH:\<L:9U#RRLA:.2@T_$7\ \F7N:F.OKD+"B2E4,Z;U,>AYB>Y%
M[F0@#O5UN'N+-(N),!WFD-) 4R[S!KTF:$)VF\5^,<4V91U7%P)G_,CZK&\A
M[\L"\KVU9]$=Q>_[ZP(,NR(NGN6[KQ@,![Q^YWC"!VOK+U1$#%LW.B3>N1^2
M?7^!^J &<_R@*Z*SY %S*7$R4)JV!20&D]<+UP>S[>C+AT,-Y_C]";9XU^QI
M$:Y^U!M^G!_O^3M4E[)UAD%\=L\EZ"3%K"='.N!3DSA(P<.3M(3.-Y_ -?VB
M,L1, 0[6B<G54V+Z:G8_?1W_+^041&X>T48"92E4"OL%MX:4=KRA&F*GWG^-
M_&QB+"=>B]AGZ_;;#-'8M7@L.QJM=^PH>M\1*?<_O^NA:.Z=4D^=@6Y3+<!:
M)0M$IV@KPGQ%5R,XE^DKPJ<=YPDK7_MU@J7,U("LF*G5S/:C53T1*NL+QWL%
M'O?'O>OM4D)"SD6%!3IG99*&S!-.YL)!2D<UKK>#R<A7='1-3QL(_4 ?RI!R
MTMAZK 7J&[;<-2SRWT7=GH'&3EIRT4+DS=50SU8Y<;!=3A;SUH]23?ILB*O&
ME94^H0'+JV#3^)AS016A7MF^@;XT**PQP ;^7OM/H+HSE16$^^,X)&JF);I(
M3U=J=AOA%\;I?%. ;>=:]@N)@9-1OBVDW>27$5L27%_"$>S!0Z,QN@_>TRI)
M0LE2(,'K(])'7O%J-&=OWAVFHF50N\4M54N:]ZWD0$T/>/)_!@Y^8!AH"NF3
MA,[L/[A\XD2#G/BJ0/F7.M=&LHQ9("<UQGK**4G4;YF, .2\PI*R3_!"^ 6B
M+\^.KU$1]<:C6=G1_+S:ZH+!\NGH=;TUWY6S]LB-4]-\;!AQ@+047"JT83\#
M(6_>*QJFJRVC#<PJHB9W0-:RH$:N,=9!-T%U57;,_6 *?2UF,C#6 2<=@T0M
M0Y3$K)7B^TA&<S[8:G(86$T?"%TU&'Q!:#)\S[UDF/Z^=FZ&@FRQ2H$;E)HE
M#V*LEPMYJ6.4IY!9E1G[^:RDROX*<!*(9Q/5]UCK2)<P"GJT=S,LBD?]Y9+U
MW"5-]\:TFWU=XAG"M79)Y\,LWS:4C(/0K^_[ZRG)'\Z><=I3^+[1A(.:9*IQ
M>*[P163JLGD"60+54+7 9GO\G^!'//HF9!=\EL"3*NYGDJA.A&<.M;Y*-"H)
MY W27_F.^PHU7SYI+%EMV<R\.J7\$2&>KRAZDS,Z&_* !C4T?QQS.W_\%S_+
MS.81F^:P/767P__26YFX(9?TN1FG P\%.TI9/VG*V"R:P2T,0NTK&V!B&V7(
M0MD&552&W'V??8%2.L D-T:'S\;Q=?.\1F*M#U/)W11;26KTZ<?D:Y2<]@/=
MTU-)V->/&E1GKY>$O17//87:DVJX.DR&&#-XL177EX!><'W Y8*0"W<2*O**
M@I7?A,S%IOU^^O1*7U^_UD4[;B:GVW;H/R.<_0\%*Q:@,_^Y!,;GB?]^Y.%_
M&@X,O'?WZN? XW>O?DGX-R\MI J_H@0;)"^9)YP%D"^YC5/()O+5>4+(5#RN
M$MLG+D.* .A=&XA\6==*2Y&L0K=!O%WP&J%!.-!FI#TQ?ILYWF9J!F5EG.<-
MCWI';XVRP\B]MHZ/R6T!6VOZ*%N#7E)7(/&[#472ORB#LYA.AQR_P992E;VF
MAT1-A"E*6>L4E$M4$R0&\I.2V_''P6Q[(X %B.%GFPX31W'^$L@\E>]_D$AD
MTG?55/-U3Q6G6EHU+SWRYS?W^Z>TVR3(QFQT=:HR'2E7:'B\L2B0NYBU$RF#
MR;ZY+0%V<!9/0;FJG$M\_("V_J<G%YV%V0HUX%Z[<.V)1(L88PL_-^:/Z6LW
MI-L<(<>#D/\\ =E GPB'&C =A8*KF:]VT,R.UPM+5 <H',QH=,Z2USBIKPAJ
M(R8'-?='PXPU3XH1ZM QF-_C4W1K&Q@RYC6W\<;3%_6/7ZZD??.+UIQF$5\D
MUL.M#II<H+)#S:#91G"0)(UJ>P;*P"9:W!RCY3%11F[%$]B^/JK)F ,W?F-U
MSQFGR&*F/;V/P3*+N>>/Q-#YE?Q^:<^[AD<O9I(WI+M&=/3&/\,%+ @=\B=A
M.II"1?BC#ZL./![)IVYJ+^*)>9>BK6[7]I0D"QV88WU81R.41H4+:GLG6%\9
M5/!@\Y9ZQT[&EB+IE!:2WM=WXJ)9?0T7<N,BYO83):K%K!70VP(5P.[L$VE1
M-Z G$ _(!W/\G)/-.8OND=/T$4<QJ<>W79Y*-F'&^]9WS\22O&$PE=T?KB?,
M_;DN)^\OWRL'H9V_L'=A Y+J=KQ=D:]Y*,E%^1-B 5M+Z6UD'=RWMH#T5LY7
MR#LY;3W>9/X*^G(665V"45W-$_DQH![BV"+\$KJ"+4(*[@Z$99LN@H0%M^E^
M(Z/]IBL@H/U4M^W+:KCOIIE4>X@,,>BH?IV7.FZ><%RB-SY/,)R(3%0_ $-5
MN,H,!@?#O.$#];<PRQH8N%:0<1CB7;)]VU\S;L+N/ (1$V9T_<BDD)P'<V7M
ML.,A)+YT,+3.SI?_>SH%V>ZIO%6O_@V0<@ ^M:0@S&A+AKPS+?ITDLH>^='Y
M]$>W"WV;D*9[8" R3]C7-7DB:R3<TS=7IE?2$M80]MV'36XQ,1:/?<<<ATR^
M'3\H4$N/_'!D-_YWV?W;7]^_UWS_7N,R@N;/\7/TI[.HX8T/$J5F$K 6]\Y:
M0)IK-[BEB/=^D-+RC*[\@ R%!S'*7!AA4GKBM^.Z4AU;YT.#_LS0?C$NC2")
M'$AD[3*8%,P]_BNG+_YNB$-) H^OLB@_IC4;@^G JNVNJDT:NE%5,M$;&;ND
M]#YK'6( *1JQ#;WAX99GPOF,-2&FZWH4\-XR1DB06<LW.TJ9E\;L*_>>G7JK
MXZ N\7AIM;RN&CT*2B429//S(I4+ZX3ZOM,YU9?,\W)1*R>=:@%'I;-^8ELQ
M,UHEJP0K1BCP[%5;D(1TM!BYB+GZ85$C.CTS>N>/]J9:Y*V6.R_K?CK2TPR_
M/W=L3.&ISL(]LX?P];TC6K>/K"7$$+;1VRE769KU;)J]X6;L87K-/*'%WU-*
MF@3P#[_'/SS/?IGO6 ]W7HZD+6"6M8#KA!24T,M?)W!YX(,X3\?D$M<@'6+?
M@]=+0_M&#/,M X8.(B?NOW^WLP^UEW^',L[Q$-_OB>9XBD@$I;_B 4\RL0JB
MR691@_.83I<LC:BT5=\&3W)3)"N*7N)WC^^B23L7(0IQ@#F\)F!=319M6;!'
M:XD?,Z?=M^],Q+"OFWG7M&@="O0)Z#*)T2[>G:X-M>HYS:ST?4Q+?4TDS<QA
MH&O(K8'?<UNX*ZE$IO81Q$):!I=992NFTK@& KQ7Z% NH4:_?-4S4]+5E7$8
M)B=G=/9$[G,BR40K7[<Z/U8+=HH6@J&BM6#3?E#ZEPZVFOT'6U\=3W4$->?=
M'4\#Y-Y)V 9V-]<4#^/E7W]J'G&$3W$3O68L(XA)5"/8,$$&E^L:<KU3#U9"
M'_(48<Z[VDK$4<*M?0+]N\%&OSIDS^R"AS"=<=5Z3=AZ)^8,T!7O<*5&9.U'
M=*"LJ:;!)!Q%2='%Y?)GE/W0VSM2LL[8R!(H;[CH71)K1\'XMT*.+#S&N_OX
MU4^>C^+V40IOR+=_V)08W CD:>)K22N F'M/5$(D7-+QZ9-TO#7-U%<$N_!W
M;74#:P?03A_T;AWY5ETF"C(Q;S==F=IZ SS[GKSDW4-ZLMTOR$4G:[.9D3IY
MN6''_F[WNFLSCSUW9Y&Z!!19C+/%6S*R(6B2H]J(XBB)*P.;0-1%T3E8HF1
MM"11,#"T:\=+ZL*P$2M$ ;6+H^W;5+I3Z2)^:V_F;+.)IP^\)Y/34N;8P3!
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M9GFFZ&;#KE\4[)+VL"]J1:!0^A^PYO9NOUVH^7MC Q:LRSLA;PT>(<3K]3T
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M&OS0WOOL!\$0T,:R&=N6,S5_-ULM5<D([V!_O_X&8@G;\S1]Q01]V;0['G]
M$W]> NG0QY=C"^'(^1&(EU(EV #[ME%6RN]?=Z.N8U\) :LK[4O;%7_-""RC
MLX.//<F:6[F^;)3A59NU_J?#Z5^7+W%.1RW_'>0#GB0NP5ZQ#MT(?\2R[!GF
MZ$Q%Q_,HRA*X%FN=1,06UAHHDV&?PB]8'"_MDO. \1Y$4PM2R1'7M;+4/:FU
MEW* .PVD2$W),FA_)714<4'T2W3PI7L%DS=^,QF?GFK&G+E87!]P7REK9$T
MO+D&L8E0=S0YZR+T/_7&QM,&)Q?%G(6L<' Z$_$[#SQ7C-OD>8!_=9[>]X)=
MY-_[2&I[;CXRD6+'V+.YY#G;/5;XZ9GHG ]%FE#'^<="]36I/G-12>@_$M4+
M^DO/#&KDWCU$'OUE'+)&UE&CM)^EKT/V01*IGXE6V2HAG(;SU;([+D*$"CI0
M5T]2+<_"L1JA+?(5?%X='WIM\M >CP?JRYI,_U8'1U#"%S'QZC&TA<HD\@>
M"LE4IL$7[9ZK^)JG$C0MX-($JV?&BE973-@NX%+)FY['A*WO[G9:;O*KG'S
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M@F-;U@*N@I](IBS@3+B?PH_.@/W->]RG^1N[9W^].FT9<N9T5WR1LN,)QF^
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M6L5'K+V;1CX1G($$Z5P<MV<!MU24J*$/:O5%,&/I*ZTL95XQ,CB1P8@/9Y;
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M0R)7E(7*?/-A0$6NT^/FPS[[.@[K<=_[G6IITI(&)[<6M3V/7''C+;^PP$Y
MRZ%8ED7)X142Q$S<']B A^VY(VPH_!D5#!J%5[.?24R8N^#52@KA-9, VT*B
M^FQS^ #X;K@>;.(-DRQ -GN,;AL<*8LKOE$D'_J&6NA644HI--WV8:A+]N&T
M@C-9!^.U]AA1)VLMF<MU*9Z^M'O, S 5'-5$@N$CSU6//?V4122I#YRGQ.,1
MEW9T(7P7L(!W^C\8O"M766;2'_0RKF^[-K!'D,4OT-)2"UJ77V]"WC)HJ.DG
MPP$D]/? T*6PX35T$_:Q!0F$IV@=:!F=S7(VRX@9 ,>$0^N&E:PLU8855=!/
M<'#(]4#ZG.;\-[2?0F@!09QDS[E@ _K1?^_^+M>%XP5^$G/XW%=Y*2)%GQZ7
M3%JKR]'CPD4X%,N@X&%BCY\F#<X"!^K/X-4+,6.,UMTFD6"@,=NMRX7R%>/F
MJ^CP>M0$/@N9U&?;0Z8WTS8.FL/Q@5##>67"4[_9S='QGO>M^&OARR$FAPT'
M #RG$^J?]FP,QO(]4+.1MT27KN@DOJ \&!:$$J"T!E&8LB>AR*W#CY%M#06J
M31]0CMQ_,_1MI,9#D[\R9R$647T?Z39@L_X1J+&HMD;%>IRE9[#V(/,$_!DZ
MJAG352+Q.?7*9IJF0'?GV+6)PZ"(?92?[I_I#>]1-@<>AF[>43C8^FQSJS0=
MDV:[0@$%T<JF58BC4NTG1LV%G>6V/N[H+,,&/G_0"K'X= #VA<3/N(L\3VJ7
MLF1 V<L94H5$O19\U?BJ*]KE,>(5K:+A\8SR")D@44B/BU06[1^>3!<746OE
M9LRU#Q 29'7%TT]E$^$*\QV]O3MPY"/5JYE[X3C03RF]@B'K8 CS;#O$!4Y0
MZKSK2:X0[W+<S-@J(W'EG'3C[$^[.XCV2P[,__;RS&7S0D)#?*??^-7**M[,
MR_Z='J>&M,<0#RF@P+12$:A.T*Y'MK8*3RJ:*1H?6(^+ S-55/81]\D5$RG%
M3%<5CUUI^?1^S]"DH[HZ+_H>_/;GPJ"KO[AQ\ET35[2GK52.&KT]AZW062RM
MD665 ^)0"TS-)5@HHK)<6%U &2<1\0\K((YT@T^?G0%JSDY5[60MR&[X5'N&
M72>R&91U"*R23^\J"E?9.GK:Y,.E)I&*#J8C1-\L%6;M$(_+T5GNF%I[L""O
M?H[]\1YB(^8YRCQ..= =KGPGRF$NP#B#*V4.0BR%I&P$KR!?8*T'B5>81$6S
MR3,S6*!$+"<W"<GX,4>3G9Q=D-NURDTWA%^M_Z!>FK[K"0[Y!1,W=/ 3*@9
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MI%4)N28]EA;_%8?:VB/SC[\8UEPU["DE*Y*!4G7=.W]S!7"1M!A]O6[;Y,[
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MEKN50,-UJ#TU20X6SCBOR]7EQ-"5:^DQD+GJ5)%JQ:-.OMQLR*1HR&YIQ2>
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ML'Y# +^UX27UK0>;,8KH2NFAUQ#*T].<8HO\"^GV(I#=V&Q?9V<* \4^1QX
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M>6+_.D[4XVX8=:T")$, C 4YYXG:RPA>CTM))RNN4<>"JA<#2@Z<J\>]?$N
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MQ;]=F,M4<T=LMNI%J&.X&/R>!=N]KL+_3'9&KD!.Z<7<$8J%"]4H]@P8.SD
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MT&;O"V8*])%:>TU$<DS5XUIMU7E6'6EHAEF9 F\4ZZ@)^4!&30N[I_"S[B>
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MV@/,UOJ5C!+,^(D/D:BM'U_UNM$-M9Y(J0RT1?Z.7G=K<<]=Z&W&E+_49N3
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MH.5:KL[D!;7S'[#^'YL:*R*BZ5IGK.LD?XR> HN "Q,.7^+JG^%EI9T"1$&
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ML'6,4CVN9 V'^^]3-$\"J0M1#,![B0/;U*L$W5. I$1=BGA"5'%896%\V:C
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M*WH]\"TW^-SKYJ$HY96YTT/?FEU/#W[3'1GA+,/C+9K\%SR';LS$5L.P1KI
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M)+^7;8L-2NJ*\Z\';OPRK=#L0O0HVYFJUK+2D(BP(1#*\A^;;-1/""J_>/5
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M5PA.$BI"26LP<X0G_"H,;>2KS7\<NO9M8W^=1UQ;2#GKC,8!>P<2J=)&*A0
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M8D+A01E_4_5]0^:OP\Z/ 0\2=):#[.*\42$[2=/E"HX84$1UJA_Y[DHX@L1
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MTIR<DJV#4JETL.7QX*"_?T/14G-P;]+2+4TI*X\\NK_QT14<V8(L'^)>[\-
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M+2^+8EB,:#**%,5#/VA]LOO)\M_)Y3)U':32@/ [# CUO6]^1[:5ZW)%ZY
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MTX 6OUE<JL M2*U6_R*9Q,@D&X-L,$> 6'+C5XEG<=?_3'D:/BG'U[$M6#O
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M2U3/D?V$%HGX5E-->4%T+']IU4.1/RN^7C-LVM(UXP8+?.7=4VXSZ^6]+>Y
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M@(*MH SP902TX2/PM+[A/<(_.XUVO(/>G?M4HDBZHKWI_K]=G+MJ7,24V%H
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MOJ60_L6,0PO,R)8Q?Q(YA0HH\?5Z/?:Z%@->4'*+T%AKIM;5S+LG<G9?>7
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M,C[1Q5*/KV+)-=J_[[8WZWG>P^UMGV6-!^J].MSC]VUW0867#NMW%AYS@Q.
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M,6I<9\D\>JUKDJ@L01(!5S9(J<=R6HIR_]3XE!I72)Y5:16_H<R1/VG/WQU
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MX-CC3T0N6\OA-!2O35?ZBDY#Q"3>\:6W9<+ENI:[P'-U<K;IL)A_C>D!+[3
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M6KN#MY-97,!XI&/OX)HGD.98W?_TX*[_U0MPI8 _6"'Q"]%%HOB%TM^JQGG
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MT$(@3H@T8D149M-**X2(:1N1*"&E(D1 2"L_I866.#')$!$"RI (2:!M1(0
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MG+0_"8H$5XE??O)> ?03P43DH2P! W#<9Z- %C4K\6^ER"*4$,X30P\+D5<
MST&3HPW6W3(\G;P;W@PL(4;CT_)0+LXQ@K> Q%:<;/GG*9&WD_87,%^#%=;1
MM+8MS)5O)O*!)7]]Z52VQW#C)OY:*^G#?=+KC%"<R1:<9 ^8J2?98VPM1S'>
M.OXV2/=0^I[' X.%1)G_OKJN<QS[6*G;WU$@-PT.)%QTNT]1.V;JDP](]KTA
MD)7$16PSZW,#1!,YU7M]CUQXE%@%5+NWT?J)NAO@^'7F9G0IER&+&1%@AS3K
M3*.G6FX/6_<RMG*'I^1+72IL]_8Z3W2:CP[9_. TE5Z.JE*,^\VVTG<!P/S\
MQ\-?EC^)\&GXEH3.LXTQ!ZQKX3RU&GNICQPNHRG&96U*O,9/@5O(L(3NWEM?
MP<H.VO<<Q14V<Q4YICOV]Y".TL%/0]92V+8(:MOE[GXP!***KH2>/E77H/5Z
M7U0YQW#]Z-&F2HJ]]9M)SO+1*9 2AF75W/6-Z)OT?- >5TRQ"?A3.GW+(%S3
ML&#+F.;#LS\>5R]0GS#_TXC<(KLU5*WD+!FUFHYK92<__G3QZ,.D1Y%W3/MR
M$Y*BYG6T<GX[55?SG\Z36[BTK;?[9*0?W.1S _Z0ID'CRD$2ZN$;(3] ))_,
MSCX""2Q6X5CG_G"+\/\8>U%ZU37+K06_N=LDOY307O9'SDD>3RS\>/I[_]4A
M;XV^):(+L6^"RDF?P<P!:)T#G6)!%)#!J:5IVM4:6NOR 4)=D#-'F;^ 0#D9
M=P$@N'V)",!=YV^%]SQ+_XYPHOOST*=7SK0S<7')9LB2LX8\O@?4YH=J:CPR
M()C/7T)OT.5T$14<'.]DKIASG5P]GG*.*K D0^W*HD(N8YLVK51EM[NY]KQ-
M:MLU%]/Y0(J6'BXZ).L?,8NQP8J<2)$]YR1*?YQY[/0/J/WC\!VZ$^30NOUA
MWISO;^M?S&!JY*WRQ51MNA-G3,:30:36[UL.F:077:UEJ3ILU.U-&=W_I(M*
MS_3])AN,^,:&K1K$'',B%0]M0I7!$UD@(8I(YO!6PRU![/UD;;0N"V!YO)>G
M,4YJ=_N A7)V$8DUS:\V=Z_] AV2^('SBY.*8ZRFS]^_-P2U!W<Q BJ'<Z6(
M"5CQ^C]SIKS+9KL+HK-<Y22(+F'^""7JL@$K*#\0_'O$WMZ0/T&:3Z]&;' A
MVD=='7$G00&R-+0FE2<AD,YR=S&\ZWMU3POF7+ Q/=/>:C5DW21):!A'42TE
M; ;S"Y$MJ,X=2]?.8%32-FZ:NP#C3*1R9"0QSH9OS^ST8+%XV(5#C&T0XUR[
MJ=6^O/&6^NMA)SM3@3KGGYMX;V!/;Y1M[5;<-6H)$Y)<^75QQ</$\R-$D/81
M7B8(A(+<FY7Z.0R3)^ _!7:9PK-T]H'NR21:1E]MK8I8/7(0/N4AXEB<U)K_
MMGOE4RAM2CQUD7]OS^\CN8E]=>Y'OR*SI9*?$ZV86QA6AL?_QE*!^[C6\"&M
M>^MXBOQ)G?A'E>$.@:H.H(9*X7 E/NTHLDX*?^=M$_LOGZ+&/8J9Y5/4++S0
M&^53MY3DQ?02>#<)&S'"_)=/7<+=(H,_S8;&C+'TW[\#FGT 11'1KH9KR?C-
M4"V@ 0,/53@A+H5<+7C!F?^6+E#CX<V<.73R'BC_'@>+74:U.<93S&"N6M47
MBYVL6FPJ.J9-HT*)6(+[^MNI6J,0\/Q]BI+;2[-&G^0,^@0<7-VM<=B3BBSZ
MJC=&>N55EI?UNT8*[&R<6?KP3][?0WX*_'+@.'W 5\K''8N5+W-QBE("8B++
MRB/WVD3%DB/2\HE\FE'8LM(8_D;MQ#'<\^>(])L#LOB;(0=9#'^O+8;-62)D
M#6D)Q-9506;:(5)_]4%^05\(PT_!3NU;/A*WX7[1<&YW?H=1 /10S5X$I<DT
MQ35I.@UB4U0PM<5%_\QX# ?;84&A$B?"0FOQFMV5<("$0'1N NO)::@>^JA,
MPR*])4=!J8@-A?*7@>_PRLQVQ;Z>1E]E5I*HP(POT?3Y37I9A?=4:-3^/%Y#
M#<;0 ?F"W!=$(V]SV 7:!!;OLK>"CH.L%]Y8* K\*-Q]N"^A63F#^0XR$TX#
MJ;## U.J*"R[2F4:00E;DGO\A*M7_-&>2=2\KM6$W;Y_X<(6Z?*+=HQYJ"-7
MK,UE>Z\!FK<1?\;;,P[T.+NR[2"ASMM0P/!5.?VF^ZC)8UT[PV.G%ECS6:*+
MA5+9F>LH_IW^4->7$&JSYWP/K=)_()0_NH]IN(?]^G V]!EH#B$XZ&W0/=L%
M*)YQS&L$_6S=(\-3[\U(-Z?V0/5C^C:E8.P]*#FLU54I@%2^,=2LWQDY!&6*
M^5L*S)+O0Q<UR!HZ29BW(8>F[+</A3WC+#3\.W//FV G+NB_ YK;@*=M&I9V
MNDWG"W6!B>K$,0=](/6+3 ;AE<6:]0\'/M63V*Y)^0E;H6 A<V.!E^W!&NTM
M,6QSJ^C&/4C0<LR"/(MEI,7D4?O_QC).-?'_QC+^9N9_85DXV-OY+Y:-VS/^
MQ;*WQ^ =W1-QMH<;)(0CE5#,7_C&@*A[H],6_U2-))J1FXMC\Y)N_@MEJ .?
MT@K/ :M;!$^Q8QWZ2(I*WBSGL5K(,O:+8V:0H]9]AW\X=F513OP]^E?5/%W6
MAM)Y5Z?O]F4I[R8URVC7SZV-3YC'3FO<M^YV:XPS''"!4G9I-BFB.5'PLSQ#
M#@9V0AO&Q9W] D4"PC867T@8-X)W@ =N< .HQPLAP1'0K<'^H</5:"F>9^HA
M%.90+;=%9MJ=,51N626X(I/I-CJ=>=^S1;">Z0((7P@45?*E@"*?.0?BHD(Q
MCF[( MC;P!90QEER'EES5BM4%PB4IFN; ZG /)<9#&^0[J@X=LNY"I\.T^Y!
MW1\BP]K\M!5]?YP^A^51\K)+:4F%E'K>/YP^;FJ"8U.TT'YE'WYB-,M>?^1-
MS=V]4WX-/]@V.8_H6H8^J$G/M^VD;GI6?3NX[H]V*FWUS?_"T&^-J#"]1KK(
MUD2J//L8*JQ7EB&B@E4VON).V>Z6;:B4OH>J:+2*?%*_1.?N5$Q,KW!VC5M1
MF-TN(ENZC/[%</"^];@_DI)7F:[&+H'P1_1SB19CKA6SK=6B*]QH$)X+F^?A
M!JBBI_3K_T:2*_(Y2_$$G-Z>;G*XKE'2N$U_E"E!;/CUG'!#48+)IG+-&2[#
M5FE;=3^2_E/KYT_[/NX!#W!**-/K!SM;R?-'B7T.!V[!?]!31)R:W$PBS0]0
M7$$M))$]C8?-HA2X,2/]>@BO<A!QKO<)C.#M^MWT&8RH8+-V3P%&"A/!43\)
MLAYJV+^WVQ58 A]]0SC)A8:ZO\C%8<775VDSZ)D1_-J>N)J!3H% D46NE6K<
MM=6M\CK6V&Y]#+T,]0PM!!0:Y$!K';15CE]C>D&^+7GD2^AV9<U&NZZKNYZ
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M<SNTX$D(Q6-OOFG3W4>+_/<A$3L_Y/E%WWE4$+J.-G83-QD(2%%!>.,#K!&
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MPN90LS+2!D\,UKJWR%%EZ[[?3^"?+RR'2,&2\A-?-,>?U^>\JG^>[A8>_N[
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M2(_>[2YJOR%_V$A!?D)/]QZPXE >S'9U+G+N)S0=V^\\@^$)%(4HK3H@OP*
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M &P&J%FP!5YG63,KF='C%HQ-(,".0]PA(U70R S&>K+3"@):C'>!E9EJ+\_
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M)4(<K11*K6!8/=Y[.\\@37.1>(FOU)97M9]UXG[.VW38Y\>_'Y2V[;\TI^W
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MEJ<$?9 =NE[Y'!#2[F3.8+"SA>I^!KITS XR%'\.CQ!]8:]19"$*O;[]>E=
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M8'MQX@"]#CB>T$!/:22DPAH$Z6RO+G>X'$^'#?,<O4&Q?@GF=2D9C'MJM\N
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MFM^608VNG9TD/IO8<KE[F7#ZW:YB?1#9D0F:V#-17; 929HO9*)=%BW3RXD
MD]EV%P$H_I)"^R_Q3&I"8Z;,4J[@$+":M$$,@,F&S"J/W=0)I#2-81 E5]"_
M__PC[D6?-55FIEMGM;@(/=+KD2?';K)F9.[\@CGS /BBP;;R>_8UYZ1S%W.!
M[[=D>L<QL7P!*2U^E=T8-%KMU!@R(.EV^;$<P"9U9X-V'6]P^VXE1C#5%;^:
MJNAG$HSWS9U^UE*D:X+10513K. &72Z<IF(-OY,Y(2,5E[/+]CJ85#6$U\X+
M(9IYX\8M_BNS!94>GX*W,@@1ECG\A W*>%Z3>VY]H[%1WIUF\4.<":,?JMT6
MLK99W9H&MX^V_&%)[T+6HU8<&5"IBC2>!]< .VBE"&#J@Z5MF%1IC!*8_@*\
M>0%S)C:X(NA4>6LE^N:,?8QAVUE!#^V\38M.I>_LM.>4>,6;1&/!0U&-8Z(F
MN6]5H)F,@978.8=]-%H^/8/G;TP;2&$O-!%184S"?GJ0^^PO "FE]FB&:V.\
M=QR<5G2D?ORFTUC@^(/@S6@GPT_DOR:0+=3&S=XP+<YU_CT2->@PHL,(M[\,
M])B#)7AR[C/"SL[-7/%!=PHA'D!T(N7P2^3%YZ\;!BGVM0MWOPQD68W_,E)8
MHZ*\02[2TS/:NGB]ZI80DN!!%P?(AV9DF6KA&7^&'S0R5@&>/-L7?K_''RUV
MC^8GIZ"$N](=H$!CLO<GZ%4/0).(%Q\7>IY<OTTMX2@=_);L 9<-/^[= 'W[
MU UJ1OLZ>4FFB\%^ZFLL^83E9BR=<#OW*-R==K6 E%!\8I0#D&QS/).=J^$,
M:(\0\JIY)1V@,[@\9S9]>82=*3HX=*Z^893$0U2!,,_$7KL1TIRBPJ;@E_2P
MHE5:DY>G247+A$XCJ/W]:W,=)4NR+^F7;-@<?1G%=18,YA]?36Z7Q.P$"]B*
MM#N*6H'A3!@4'; 5)DZ2O)P9'%K]\7@[ 1=UD[.FL]*6WOW7N/9UQ>1MK^/[
M!</4N2PZX 27Q7788*!LW$60"*QVMA]@?^NLIDK1F"<L8+N?%T'8B$3L$5)*
MMK6]@V)7_D321L'AL_T66M63H1SWZ?*RBMD>CC$G6CJ56ZA^"9R@$0#W)U:2
M(DEB )O<P<A\B\2;(99I#$2JF=CR&T8'X\^-%6BODF):.=NW<,Y<")&6+"">
MX9G&,C[I]R@JY?LN2#'(8QNIO\=%"&2XK>_RM68EL*8@S?DDRW=_9F+,3G#B
M <#^$*%R:0TY^?BVJ)*E4JF^\N$QB6J)ZI)>VR1,ID^1;,G!KL7XZH>16ILN
M *KSR56T70HLR>,CVCXUM._$VQ._LP43U87\@'*%V2\'G3OG;FV\O![L%^@N
MYN:B.5RBY!HNQ[Y(AGUV[IG=Q6ZF(65#L!)@ZMRJ'"C6XZGJ5=[ @"NA<6Y_
M/Q;*:VU\(!B*TI'T;JP;TW882Q\CKKQZ0TX=:'S3_"85HV^[LEATFO\8'B*"
MP9*:A#V"[<?!*.+/?4/NWDD-KD7WS7WK0NP-VO3LJ=-[5+I@M%74S.A3/K%A
MZ83ZN# N?7G"O5[P??H$,D60+4JH+X3$62@"BNV'*<P-ZQ QT59D%A*RZ/FI
M4:'.)]3J0&+OA8E((MSMM<+7[]\M=SC%.85)2[VW#N13B=]3 EK3B2+Q*H2@
M,C,$XOP\(<1_Q9F3R,ZDS6/5?3#'QWCJ3-AVM-,BNT;[*XBO'!!"]N0E;IBW
MEDB-[C_S0M3E+L16%J2F2FXV9DV;?SJ]9Z,O3'=MPALQ[&Y:31-(!_S4V_W;
M7^&"8ZP?O*)VA';W4*6=T;N(O0V:)79ZW:-I&K:)UU)[?U2!W7T/GS,TVX=&
M*@=R8?,_<YP',+^];[BI3;S7<6N?Y+'^H(!J2-5(=>Y7\!#M--'K<$+Y-X_Q
MMXQ7WAD9TC^N5Y_0Q/:[/,@$[)G(R4#..P!%6Q!HHALX2/ +@PZ9FD'$5:)3
MKX!AS((]D6&GQW1+7X\;+FFEFQI:BIU+T;H0$(?RJ*\;/@<-A<_L=1]'A*\1
M<;<(P 4<J!6=#D<A#_'.@Z?8M+=4*$6'M2)+DT&O=D93]]7P+EQC].,ZQING
MW>*9AU7=ABU<26 3TS+TPFA4X>E%K4F10FI8\KQ9;2%9?.7P]D6N"\^93Q;(
M83_  ,0 J!6(IS@R!Q*CB_3XA2HL.Y ;!N!I)ST6WOG'52W,_F(6$%_F^=%[
M?OJ00'$(JQ-4%^HF4 E,/:LB<Q]S)";XY?29J+"8C8\PEKH"TX2:0H&SBB2+
M<]EW'/Y@FN0=[[C%L?2[]5.P+WV/>Z)/8M?U*MN47G?72FMH<F'(%<\<-[7<
MHT42Y<JYI#XVXB'OE'7":U2&B7%J:, AO?QO+B8XXY[ U^KQI*SK5>,Y!UE+
M@[2.,;29;N&%B6(EUU-R"Q3+B_*G;I'Z$3_\&!7+JEQ_WK7!JVP$#365S;)+
ML3@5$WSM97#[L69 Y8W?\U CLV<ZX7ZQSY?,B,3$0I+GP,UJ^+1!:,%\26*H
M1P":U4H.IF@Q]3H'DNE[##> BFX"WLH<1#+Q=?$N""F>-9"99*%(LGH:^<,F
M]&7Y(Z8#W&%4I?.K?6S2RJK"QYG+P*6Z\U^-)?EXS%D1"19Q_PX'[,FE6>E,
MCJ+H<QS&%B#=;_PDT;/9E0=OI'9^LNZLKEW,#IEH&F]!)6QXT0^#,)H^Z&2I
M0D<8ZR_D/QIGMK2TN9OYI!<6KFR^$6T7UJXTC]Q/G7LJ, 'Q;-5.)?\\$1]/
MZ&7 TQI-([D=T>H)%NXDD-6)%6-;/0HEVLCIATQ+!F-/3]3,#GL';V[^MG"W
M*[=GT^%5+O117_L?'WT>,@7[_P1;$TWLQ>)9WHL9%Q+ZUE2T:%]Y#C0R&TTQ
MDA1WAW<.5;H]J/"LU4TX?WNDL^H)+LSDPEC9LOJZ2%]M?XV4[_SH_.P653K<
M2D^QT]3A!ETZX\/KD'9WVM3*(2.%=GU9^V-=XQ47&RIM<Q4:U?LM[!.B+^JG
M5#A/]X+-0/-R*_<2R.HXQ;,7L:45]D0/;)\:>8ST KS/0#W$PMEB#_SK!V^B
M;FST_<ES+P6QJV=C?116'4;#HD(3J"<7)HP47_E:G)[^4/>I753.@GVTYGAT
MV$;F?;K,.OP!^TS)IXJN]-C.EB(\(W4&NA]1[A7D69X35WTFD%]7&JJH]*%@
MW]/JA5.S"WGUWO+-K7_0PK_@;L  VR>-IG__8H'<?95M645'AX2ILWB^1^HC
M8YQ^6&>SU+O/C1%]3::./;JI+=6E_:BE%:]94W,&=@_>C. I+"'YM>U[,0[\
M9Y$#4UR:8!L8P9RR@*-*0A$LY16O[KLAH'U/BW&RP5)K=9"! ]SZ%-(C*/E:
M>(G76>K5_-4!O"<E9?1,Q'?@6UK1438NR<*AT\+R[=1E=?6Y[Z:YUEVF_!M3
MOZ$M'N1&I/:5I5;$DY!09\5\-]K5</1K)UJLIXLO+"LRU&S]!04C*H[8'8R;
M8HQ9C0'T@#[MZS/WCKH/:]JYN6Y+VK[1[B<Z_<85T%5RH32I/,<NOUN3P:-=
ML9HYKE$:8Z4O1[-Y&2"<>QH[!&N4?&\ESI,!">RST]-K<5:;K@ JWO!3Z*\C
MJ)5EUNCQ^C&*3>COTPK9D3KJ33DZ&SJVXQ[8B<!#Y]=F/4M'>-?YN=1@V!3'
M1!=KQ),$*P&J0VM[ZJ6Z"8S?7"'.#ABOJ.S_/4INI)$@Y^T!A88T+_U>C] I
M*JS\Y#V3I.N$+LF:9J@*2GF20L@N?;",*.AOAX#(OQ]VBO(JAA=E.ZQ\!D#&
M8UQ9N,3FHE] O0K0[]=7HXV?;J]M]BI!DXDU>A3OEHSLP$"U"B951MMX<VW)
MO450%E[3<;B\9(O!A<\CE7$AL*G=/SH(P&^9\472 "X#@RM'4SM5C $[_+?[
MR]]Y>AB4 5$=F:(5%MMMW2E0>S/\S6NR=(1B'1Y=%E)G7;/ .OL:'5FH_P4D
M+,!ZGL%2/?+V T@I?XI% W6Y$N#[ZG2XLW<?\!I%&5;F,+0FBB^G7;L87JAN
MZUB18B_E+'O@H@E^'6,^IR@>[B;_Y:>B GO?M2*<GQ 2W&M103O08B&E;9^N
MY?_JKW"#H/%*CP\UQR52JG(NZ:.3KGTLT93\J2<"PP#[MDB97X,U1#_XP4D%
M#[-EN^@-;T![)M^:YFNL0)6V@,V9KR9MP=,IXJ4SP2VX+KA4WXO@EMRZL#)?
ML/(8L.[Y^7OG-(<9JI!]Z;37B&C+=ER'51C.GYH^D9^YO (H,\N3N48+R'V\
MP]5@?*]]"<]&U*K[=W2;]33$O?#Q"D'*&/ZYD6[L\+J5DFU-=C!W9&]O650J
M+"-3SF^.OS*>S^,I?^(B>1?'>8%$09>[F>+]:Z#C' P/EQ%HS4_SFPJ8N\#X
M<.9!P7&T9G]-E(XG2G: ,;5ND]KC^=0^%B7AB5QM?J53>3*%<3-/(+G 16-\
M 7P2Q8<K&5QT"$3!.Q')A+V"0VB2#UN>\X@9@U7U##$J,E=1SSBLZM[,3FA.
MO%H?*@JDA5N4Z")IZK.ICR'2Q/?].FW=M? E7 IJX8R52LD[BYPOC67\^\Y)
MI^K>E72N]0RF7SZ6(5;(P(WOF3M47:-96E#[22\T8)6T1610>?;/(J8I0_WC
M5J6XYB./YF;#=%6O>-8G_LI^5BVS9IQ^,;ZKI78TS-6YQ6Z--4??A>YCZB5'
M4G?QK("\9%XTZ_#M"XPA"_6Y3V*N;'AR5#(Q3%?O^_7A=1V98:[+Z+'FNL:6
MMD(=G8"@,)U:W=\E]YXVXQLR":#ZMQ7J'$F<E,YSY)[@W1FVT/\\X^V-' !8
M75G]Y3.??IV0'B NW!G77YS>>^K%S^C;2T9&XGZ1; ]?<MOGH5^%D'$<3^;;
M'+T3/NDL$&]57PFN!>_T7F'WI@B@2U2811PS5EE9FMEFWQE:XL D2/+,A@S-
M%U(]IW4S@TNG:16&*^5/HYG5,X67OYLHW>CX8<>3[15(%K!QG )^#<844&39
MT9")TWH/!2=FT2F];_,G[BWS'/UJT<YNKX;)B/W!GKCD8V,4:Z8D0GIA8MS,
M>;YGD79QL#9L(_2EH3)>T*]/"UX-:#=GSP:FLRB!>(QDSC>,.J-=518_\,."
M;EC]L#?@=E^N6JV_-D'*X<Q9 XUK5>,/0^P4W2)5+S?71]49 +?8M^F[0'V]
M#L!7-@/L._W>A- E87+WIXI/SI?';!.+=I--?$5>KV&72\3MG)#)?)<*#7O)
MBX9E9KY#3K31;ON?AX8,=%!=+;./&*1]05ND) L[II0;[>P@!OXB>/-N;3-Q
MZ2[QHR<VKV1!R?6A/GW1L[8,9Z'@IA3W3-9GUJ=?GDPY[7!4-;:H@7L$.^Y[
M:-SB%&-UOZ!/"&FTC2>!TUN;EX  ? U/#LPI6U+1%94LJS OQQ'>J7(D.D#R
M$W:+9M],<&IK''[>^IH\PLA?0[.:TS\CYZ$"B1-<%7 ')T*4H978MT*(O)7B
MO)N*'$!:$>/:8#3&#%%[@]V(H:53F%^!BAX<A" ?XNG:\C[LQHV-5KCLO.+P
MPATWSGA3?C:R?V>PU.=;9[A1HJ30XY,IYMR=&$T UWM0H&C-MN_US$NYB3V$
M5KW\>CP3'Q;YFF)7<3BZ*WJSI7,AO^O5U!.+X^6VG-R66!^ZM^25K*_#4S>_
ME)AOV0:0E]"!^W8PE"QLX#*WTWIE'[QE->SY E)TP^*[W/N^W"\ZZI0A[M@9
M<.#N4,]U39>'Q_'%;F4GSKR7TB:\O=24KK>_HN>9H_O13$C D[U6^LKQ;RDW
M%65SF?/7V$,]G6DN==@)V?LD!T;06=G'H>,5$H^RTD8$N["G>;O!;JX%6-37
M05#&JJ"S&14IY,,R,UUW/*$I.@I]3@1K"J7]%7DT]^,%51W*9KX_3SI/\\M*
MZ<_M*SJK2G">;#8'F*#H0U/7"5-:K+;QA(AK5I6A)\"XVIE%]SLGM6O5&@9U
MB<\GOO>/AA^,G"2NOPL<NYXUZW/:_/5W8CYJ!C:ISJD'\GAR>(%$![#*4NQ%
M;0>UWL[J@C%<4[# 'O1@M"*EO6>#S3:[2%+HJC@[A]'(0KCG^8I1<IOY6]]3
M[*;*W6G]59:/9P\6]!BA0HURH)S I<R5(7:!0*(::&"IW0_G_H+]0( *3F-V
MU@.UV=5@!NLWL]\%VJ,69PUUSEA8,Q@A0H@,SY)YP-/RM(Z1CQK+%BA;#K#_
M&JY+U&D;2VCR=F0U'_Y\4"3P;UE>/CQ70TBMLS!%6 [46;AVA;]'WSZ03ZZ3
M8^3\/MF;S'&M^F!P=.&Z5H"\)3EFC%:U?XNRV.=["/![\(.2;<E2BME4#*#H
M6<,KLSX_P2K]>?SIMY'BR[DJ$7\U>!_]FXVP--<XCT]<K6QQN7:YE0A'280+
M]EKXS9$.8LS9:I5S]"05&;;Q?0SRA?TAI8D$C-_S19'45WMD,6@3M=>L'$^<
MOK*8*],79F$LW1L=*DN1M3D=?RBI=^LJV%<AA-!$-G1LP\J J,YWV\%J#G4<
M(U4)#G0KR8BHCU[5A3*,8^,85A>VHEQHJJ=KR J<(^U%1S!N%N_BE 5%A>W^
M^NVO*P:37P:5.W!S#<AF.QI\.KNS:#N@4,=5YT6 4NS-MP*-IO$:RAEV7X<9
MZ@'&VIBF_ G>U:34GG X+:\!G6@O9=?%7C!+2+O=:Y2#BBA=9$H^BCHFB&[#
M=?QZ'9&*!*P1DWI,Q?NE@JE!JP->F,/ 0.J7>V_I4]&^,#"B%J,[\>WI...Q
M=1GZAXV*2OYQ>A2GFHL[O>><^U'=HN-,BZ6TD^T[F.AJ_!>:7 1"%KC=7U_)
MNO4S<7>[N?9;5IWIKHNFB0K>.:^>+/\NC]%5*"5ION*X^B6A@\8(<.CO!^TD
MF)@@&C ;K7*T.@\=E9+A_M1.'+DCK23^K_#72@?'S%X?NA2S</T5VJ/EP#,;
MDRFG@NK++I:42FM6)IX.N$N9<Z[S$WA27!-!#Q5*ACW$'8:YD,?:=3 AXXW(
M7>"#P]&_O?8JR)0)V9*O?=[2S,EHK1I0R2Q>:,&G1L9.4LSG9L2&UJM-2$>&
MHG245Q&@5A.9",8+Q,.Y1Y=PY.]/KY4+IK9Z4PR\4N7#1(+&/<V_"4^;?@?>
MM^07/7Z@HWJF[54+<+F8I0.CG5H8'R_2;P4>*IK9%DB]>=6X 0>/-O-DN)U%
M$F X SJ#8CJ0\.U',,[L3#R.<0(\R- Y^Q5MH35GK]47C+2;B$H50I:)3F=8
M4AZ45RV%[9E5O7.?K )>C]S8T E.;@*C!1(K7&F1WS;,]90%TTBR<;?>O;NK
M\3S#ET$"&/"--I#8K@OF5*K?Y\&94K</Z]L-8DZ4BDI,=&)DTP/)@M>U4?U.
M/]SQ3F.U5D,O/Q84)&9\LCJ:&,BX&<S"NN;<^JZN]2[<V[SG]<=O%DQ*K[1O
MLUQXGL)7+%TW4_SSZY17E6FY-OBNL1P+W'BH]LZ?JHE]+YWQ7#>]92W_6=4O
ML]"O'D5Q^+\B,%:Q':!%A1KCV3Z5=-U#C,N*?6V)EFPCU-EG"PR_0G>:LW-'
MG._CNE=..9BHD"PA)*"3J]?K<P1W(Q/\);.#E-ZR$4_'(/@YWUX-AY$)#?95
M2Q/8PP ]E04:D[QP0>3'S5D>2^V'5*39S2D!>HI;@0G7WHP:2CXJ[SL^L+:"
M'"7$HUB@M!"R^QM8_L,G$09%XUD9;57!@H,C%(?#W0\%JMG==,5B\@.?H^^_
M<\:_KGG1$]L5QGBNQ>_\]C]8=7B5Z>UESM?V]O$60G1RN(C[ER-?@B5YOU$Y
M:J[,S8-S:P>()W[KO%@.E4_I9#C=SAS3"#!)\RK3>%?I4NG)JT][03W&+CQ;
MAMQW:FR%7_<4[=6)IBPBP)PZS5QUJ<0NII=CWGCUU:!K.>??G^C97Q;:72Z$
M_ :?>P2KM\KF^@HF!;+ 0%KC2S(N$;G/H)64 MO?N+0DKF>0'N$PB&I<TE'M
M;$F5++AB0=H?.EWXX*/'I4W8M))E;H/LE8_398S4#6/!OI/\BM7L+IR$$.)'
M%?=)A4D%W97*%&EQV'3P0'CHKI[J.*.24E"?EG>K(UJ^,7?+Z%%@>&VJ:>//
M:\[$!>/]WLG$(HTX>X%4,7 \I_F^$!*BEUPCXV#GP0Z\1Y%4$4*.?VYL 'HR
M:T+7"C!3-9REEPY,,&'*Z^?U5K.P)Z'FT0T>M3A)ZERUP 2^'_[WWS+(EQM1
M,ERN%M-_]3[O\X.O'\]9'9J\@M[I\;C5]1$=H7)(0<_BZHQW6ZNW1X-GGR3L
M0>=HG@I?,T+SP*;F3WC"(?W+,;8*%P:D]JZ>*LN[V*3K,LVYU17Q%9V@5+MQ
M;(TB5UQV;(%?J_8,K34_<:_Z@6-)/OBTZW1B<'*J8Y>]^EN7WEAM[1"U;YK[
M#D:):8;F2GODZIX>+^$09@(S__ZSP ,1X5E=C@L% KNQTH.-J<B#&#V@\8[*
MT<'U5"D]+V U:7D]SDP(^94ME;Z23C&6TGU:W1$:%1ZL2JZM#&HV"UMW]IA%
MR HA!,2*&*#5*X0TV/4@83PIL/#:/@(+@6_YW&)5KG.L*,S<L2GK *HQ+M;N
M=0NY_DW+D(5-B<]D:+[.6'?.LTU/W^)@BZ;<M?.#%9M+W/^#N3<-:BJ+VD;3
M[8 R& &1F;0B(K,V((.!M-* @! %F8>(B B($0&)$))6AC#3@D#+E$8$9 @1
M(8PA$1*@%66>D2&)S" ),AS)P!??JEMU;WW?_7FK[H]4JD[JG.RS]EK/>IYS
MUEX;+AB,VEA+X8HL8>N//2V=",Y"@6T!J<F:%*R8O0J!41A-%XBR%Y/OAR1[
MCY,H57JX[1#+>KNN9C?M[;BWS>2$S8]:^5KX7B*@);*6-4<$SA'7BN>P4]B=
M@'1N)_XX#S*GB)2\]SCJ9+YB$%9:< +AU5T1-*/0-H14&+L1VXD ?VT:C5C7
M<HA/K]S42R9KAX?X>0T;R(7/TLW3*:J+2F+Y#KE2-RMY4):/UJ<FK$3>;2T'
M%#HC]?R+MX85<$F3[]9B"9_>_O-%5X5<:>R462[N5^&0X)F*W &K&(MHLJ[5
M%%Y[=F),Y6&&^/R/:71#VCD+R0)VC6:99MK5@;@0J#V:*AU'=_WWWU+CEJR.
MRC#"/[XAJQ"V,_@P8'%52"PM45,W!M%:C#:]ZRK'@..O]D$._5L]6N_? :N,
MW;Q7*Y.C&AQU7KTB>Q_4F2>06^6V"T^JK=+C"<&A6_2C<VX'Y)?L[*?BU=!(
M-D_FUL/+!X]?EC]X:XR1P9,2"G&>5/1[["_DT%+,C >"YKF1/(:0C8BQZ-@$
M^N;ZZ'J)DYD\LZQVBDC#$*MQ%*TZAS@1N/-8E9Y#4;\SI*OW+SF94:-;-/ ;
M^5G@/LAV#\IY8!2/_HVYMI,!#H7(,350+U\R2EZPOTG5!.3?C$<W_A9+@(-E
M3%KDHIM',UWBO+>:?^RF%UR(8R).-"'.$O!WH!I7RG'-CT^[E\4DE^;.OUBT
MAA1\<"Q\8GS9A<AV3(DLR,YX_U&+J[T/2DC;!\4^Q"[Y .!]4&(=IVX?5"B!
MN8YM=Q5H" F)'O0)>Y7A@^<>",0>TT:[![ D[FYT#Z+TYS;2,4H^E+_"$V\/
M.JXZ<7!/>7K*VXU3DU]3M,1:<5*'\I@@*5G$!,JSZ_YLDCZO496.@C$SC@U\
MTAPN=3+M:XJ4>?;QH6BA*(E?9B1C:GNBV,CF1FR6K7.E4_R&ZF;Z&7:^%H.7
M=;[W'*J"T17C>L!6YM2+.\T[$-F7+*]5QY(U]C\HYT=5QIKIU8/VE3<7M>ZM
M[\WO@PZ* T_FD&*"=LAQ@09JC(:!C*J."+1X?W#N[Q75,F)4[*;@$H!U!T5Q
M8/YMPP@II">F?,H+B':CQL\P/W;T[EZG-OJG7_U6LU"LQY.=$ARM._'N3^S=
MC?1/?L]9VG@1RJ\O;J?>S%9G_:9F(^_XQW_M[VNB!4=UN-X".D9HP&>/)M&B
M0"O7"I!F-*9*-';9P1(I*IRS-8(38UM<L!PJJ]-J$"G1P]0Z.82&8\,86OS?
M!>WH"\?(%3&FRXTGI59RQG*LL3NW.7C>\>B='(Y_]QJ1/;83Q?8O:JR:#/*0
MC2?!$JD2&^&?PY@'+P1JA<7 8@6:*PJ]%1RI(4]/1(-981>I!N79F191/N.]
M?*2WH=%I'W0V]*Q]+A/Z!P=KSIH!<9S,W]]"X24]CZ8Q6MRJZW1[FK B3M)6
M-7X(R414E%NEX=OAATVI2F]7P@-B2SSE725M4YP#^)?^OCN^!CN(<LUDPQ6!
MD$R_T()+N/+DCM!#7A=],[H744V^54[O;Q1?=JW"$>PD7:4M9!1Z9?R2J^S$
M'.(]>B9H;*I 5)IKQ5,2VBE), X3B0!/"'FON080P(B)ILV",1+Y6&44HF/R
MT#0^D82$!/=<K&^!/2/?8(:8+EY+UY-Q^\]KY?'NF-24]Y^C'$V: 748O ;G
MBF#:$6]W4PW@L2?W9F,%6H(Q%5VV#4>WN1I@]L%'>*%AC#:HM4KY&R"X_<EH
M^#XH?D:T:5CWM=U-?6S0:O)OM2/"?V@VB+:N$P1BYPC8MQ+E/.DA5M\SGCT[
MS&>T&B.#OI[KS$%V?-XK7 %*&'U)Z%-OEG,5NA-TH%=TIUR&3[&')QMQVPAQ
M5 X316I:VU;TU+FR>'UD*Z4P^N8V!/@-TTA "26/$9:I)[FR5YX(O5S#4P?P
M5:M1WQK?>*^T]-95!9EVQW_;EH [#V\L-+4-&RJN5O@WD]M:BX+S\Y/.Y#WQ
ML;X+(X;N6,8QL;^>E^\&<<HBLH$P&D\^C[7\M3Z[3INK&/MF5%&D<$$_DZ!@
MXJ.;KIL $X$@K:63XUE: \7)&?,%DH6WFR*[4N\Z=_'47MSUBBX*?>#^M")_
M.'#N=R\57;%5.3+^ER-<>9=/#TD/1]ZZ-;QQIC$6 ZU&@GWG1X58\'.%T+^8
M<>H1@H$.Q'8@Q)^?!S4*U6G(*I\,;-CT$E+,E!L&FQ8!XA?(GY5N6 V^R]50
MNN<9= Y2L@-C(^# V>FV[$(RM2ZR.S)'S!-U)P(P8\MGOTX^8^U_%^BJ;G]I
M<^C%!9$S!YXCBO#L1]:\(F3[!O>BGO@^:&4$:$7\-2/#[FIE(4^@D.U%LD.S
M+ARC%-(ZA*:B/%B2-SEC#_<>VQ:+T;HZQ&HBYTWVBI"'==?7<X*K$G5>!1[H
M,[BA9<K](LG '05>SE'CLYLH97>+__YJO#(>-0Z=;/"4LU9.BJN-N!#A%^$H
MF8ZPNI%MHV:E6=+B&(+ZXL?4DP:>,&>33J!<BKP6"P.,19V7F)L?W79-;K$_
M^_HFE&L9VSIVNZ26V!LY?Q0=2X;U5^VH\ G4NQE3JS3!1:'K@/]2T613X\D2
MU1.HQ_L@'Z!P#AR79U9609QV*RL/?;TT.G."0TTS-'E@\-ETT8$\K#Y\WZ '
MHG?SG9U6ZU1\6T+?#Q:0Q7VPA*C+Y<E>ZIZ5%,BNMMS%L\-N<F;_PAS@W1JB
M/T0Y=3C>RX/'DY79+.:A^=V=A)?*A&H8&!U:LJ*B53=VOZ0NU@D)OM8PR00B
MZ0KQGV?7 KK DJAHP9%U(716#O'T&8I?(=)S[#45$-NG](2KW5D29XJIUE!<
ML2HP=-/SY9#BDU$18W3!)=+@]ET\35:"P04?(8Q4>]04X0"[''?U')O2D,W/
MJCVJ<Q*#5SNGW_Y[[@N]  3J!?U*-6,?H#E F-5#G0ZGV_N[]8[5>>D&,'8E
MYKYK6]X/N=;WBTO9L0:_@N$B#<V_"4=OO=L#3%\TNT!DDN@#Y<8N/<,9S1PJ
M7>E[PKM9B7?:SO<569\:)7-#NX_?WMP[\?9A#Z>^@AEXZ]$;:_%I$\>"4-2*
M7$N$WCI['&WFWG&SMD9]VW<?) (6='EHNJ&,=J;9*H7:1KN[DT8T;.K)%H?L
M$SD>S^#^V- Y8J)'Z4C\WT5BKQ/Z!,?;$"XC&_[OFA-1LM?>>7K6GAJFOF@1
M[&*#RC)V7@J!3"O81X]C:O/*!]6ZXP@$<-+=PC^<]/4C+$W"XC!G+,KIFYTG
MPMS[GI1C_;]<FBJ)25]P+T[7BH\O$1RIVH:_:CQ^UST#]R/CV-WM>83R>[+-
M/P\[33Y_)^5>+[_2<"R7Y)IVE;%RL]/W7*E&-/2B2ISTU^LPPSV;KT\P!]+/
MRPN<;0T>H@/_OH5*#GWV,*7;M=##K9+R8?)ZSNF"\^-YA"[H]NIHEM<W7\L3
MKEL?>)LRW)]U;2?V02^2 (C@PRX=R]>G(5*S_X^'\U ]/POFZ'#N&?U9_A_5
MF'B&$:]@YL ^Z%V5VCYH>$5]-U]X7> UMJ:[%_*_-Z\8V6/][VTN_OB_U_#]
M_^4#Z<7QE"_M@]1EN++8B9<HQ#[(B2H_MCF-&,[X?_EATD=)>&NTV1T1&-^6
M#H$)]3BJ2J W(+P<XGY8_/]U\2AL.R*6>AQ[#Y8" V..HC7[=7EP#I@9F5R/
M/X)RM:YK;"GH>;,RIG64W';Q\:[CQ-*D?>.D80S6&:4P9MF_%B'A\^/5NW=-
MV= .RC/^2U@07$C7:L<Z8XQ8&6L;3(+J^UF9<&]U]X%PF%P0 BQ00EN0^W6@
M%O?"U^_&_-K##(@C^[U>\F@3O-CUT)[Y;3"<:_8D7 ?NT<\<+AF,^'S[(Q<O
MNTVL9)J_>F.GN!84XWR[W+%(GFD"J=WY7NI N#JP.!^A;!J&U_GAO&:\^5TW
M>',ZS./SY-[DNM94R U!T@QL6"#$YW8R@GWUAP'U,+8#QM1+,K7"F^,8,0XQ
MOTH8"DP$(S.PP8"C+,2)I6#B5%#DY+&\O2LK>UW"Z#EJV5OW&GV6K5,>5Y]V
MVR:<(.<"X4G%[OSWTU\._2L,KW#T%4"$>U4?B&7B<6BEV0/8P)@+WPRX]F&=
M+=:)]28$GCJGRB):RY T2(0Z*Q>NSY.^NARW^Y=GP\YI-:LI5'EY.#[B#?8
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M)C[U@27AZC!,R)GJFJT#)UK.)IT:U7Z-*K?W8#$V$K?].>;QR("(,II>/"^
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M43:VK;</.BS,#>T69 C7D(?A[*X5<G!TC\@$<V7!D.-25#EM5GIUDI2>]2^
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M7;YB&_GG9@TM_X_-&OX_W5!!BTOXB;_H8,!>&(H_:UDBK+E&:.N1(0].1JQ
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MM"FZ1%!9[7C;!YMXH&"CS=,+GJ>41HU6/;@]!*MC&;'S.QWDF-3C84C1[P_
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M<4O63/!EGRH;HPPQ,+[O@U(#B78'5%H82-_4O(>$:-RGO/\BUM;1& -)=D>
M3H?^X5HK','MSP[2?4Y0X%SV6CQE;#:H-)"V&4A_UP"J=7"DWJR?8 H-^%5"
M/2<3;*&/P\7X5]0/IE]F^6667V;Y999?9OEEEE]F^5^?):8COFV'/AQG/(C7
M7^<G&T@3GD@>Z-*IIX$-+R>U/"'WI>+!7;E#>1%SAQR7TN97/>;[=1R=F*]Y
M'R2E?7NJ.M]_PZW]Q2;/FE>8_,,JT:IA)O3[1EP&#ZV'Z>05RW(:7@S=RC&0
MHH4U9_)G.NO50A3:,F^GS]F2%\0[Z?^+%QCZ'^P)R'T,-@1Y^:CTWHT"..#J
M_>Z3S+=3RS6<XLQ\6&]])N_JTXJZ%#/Z\XJ:.2_>]K]=E;W&^-2VZW:_'H&^
M 2M.&DB?\7(#Z<GO %J#7X'7W5RD"IJU=7?23_=_US7O\A.B^_\*+ZGHRA&\
MC<QR<Y8U<=VN+.^\<OCZCN-7HE_L9.H\I]_+"=ATLKWDE_1B?6$QH=,) 3Z]
MP4!J:OWG9O>(@YR/32TX<UZ*R9[1RM(,I#_/&$CH2N(CQ[>B#V^LZ#I?HOP4
MC "8<:*!E%'X[YJ]NXA6A8$$KS>0?C\;8FD@?4<P57@O'?=]?O;-LY4";9;
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M]!?&K@ZFGOM5DX[XH@=$OUL,I%81N]9 (@N;!?@Q9YZ^"'@3 :%.'OKK0JE
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M/A1LO5CB4[.GE]-];"Y+S0W_X;\I8.$?!E+HHVH\_2B!Q?R1 @\CR.41**C
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M_FV7Z)N^&,&<LJ(LRJQW#A;M=4N-4H@*@YS-,)HPD%!G<'2%;C4J5<HTD;H
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M,.  "%WND55GJF;-85.;^TWUJ4",@63-]FRF67;%4<S9I8W<E?#@$Q:%Z>"
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MB6[$*&5"D<6PH"UCGUJ&7AX YL8@4<$=MF-9E69K Y'#>$;T5T3 ;7@G_-M
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MOHW_MI2S1;92,1J"\)IQ<X0L%1AA.V$SX?DER*>+;M!YOF@],C'Q22R8S3F
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M+DY B<'AEZ,C(^\.Y9-11^0$'>%F*H?<1S)#]F9L119'N2SEIYPDSPQC*KS
M!L<ZCP*N!(!WTGN[<6-_>*W:58@D:/>A>^$1%4]#5_E-])$;;?F90*3B(F#K
MY5WFBW@JNYM8&;AU6T59I!I,P\)8R\X/0-.'*9:[1J0;Z6+-.G'C+XR82^S
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MZTA-I6X.MU\P"U 6.TPMY_N0D/9&S!VNU9Y#P#0"^;C^&A1%[4D<,,HZRET
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M<:+T/!$9(\'@Z.,_V::A^CO049D\1 6-EL&+/ZKK;PGC87&C@R.:6>)S4S;
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MXT(^*(_ 9STEL@"@OT6XBMY._8GG!J6!9N,,$W;SF+K["74>.[ZIRE^=;7I
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M4'.3-%]+&)$@<;2*;C@,74)5X?Z:]$63QO; _J! C[0$^6&@$8):;LG;D:,
ME HTQF@)\UI586DL#P6W"FA<C3N 2P)05:\EC)$>Z=[81=D\4],D]5_<.>5_
MSI!)H1W4+SO"4.-J[+F+3(K=G8YBKP:$"RKC*:K]NH)P@# */$Y<U@;(+6D*
MKY8A,,+ADM4RV.17*TN&"7.1NIFR."8X;/_+#?E=46.5A\E$6"RR>+L>6##T
M2]<$W9)VL-[9-"NJ*N>$Q@YKHI53T4W58^EJ-_8SW*196D(C/JZ)>E"V$#0
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MEF:R\8S?7MVCL_6A$^DM)71%GX]/.L,K?FO,&GA-QK?(94AZM *[IB6<(B6
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M:3;!*1JJ%=/'&/4,=8-)8UIG 1BY@YIABV7$M+@29D@KV4*\#O$3U4,!.9/
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MK;;+Y*W(K%\PJZ%-89R_'HHN)*:BBRMH-7X93-*Y2'AM ^L;$4I6FN8*M*4
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M8JK\.,D,#,_@]%D!:8*5M>>*!S*"%X_+VUIL0Y6ZR*!">S1RSX*]:[)>YB^
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MOZ"V<O^)>^'KGL*$#.\+L5=O>N?A2NGT19P"27E !6727G46:ZR9N@B&"K*
MI:ROL$X2D1E0A/HAD0E2:EK^1L0O$K;[[-'AMKL@ M1E!LFI^A%BO[YICLEH
M_JIG->U3,SO,#G351A4P0H(#5?LAM.;#-/@+MAA/.U?PB]QCZZ*NH1!'R=4J
M>]9@;L[D-[([D;AD,9-\Y68FQRD=<S-RAR/N"_0G&B/>1[A(0OD K<8O#:58
M%=,CBY C5(13Z!^T6V^4;P];OKGI'Z A!&7\7;_1].6[;U]:K[SA^E7\XD#"
M/[80WR95L"<'50%@O0\3]] %.+&YG(FNY*I_C4UTE=FCFS2$_C E]2FLCRN
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M="P>D)/R[+%?TG [PF>R\7JUAO!G2!:2.NRM(3RX#]8?!N&U^)6_Y!2HK%/
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MZ(=%MA/E)U-G*P8&O7^XX;..6KOW_2G*;XM1.;XP]F#]KMH3.- ]ZE0W9U4
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MW8=;'VI[J[/COFLY&QD;>=;"\VS4.?K6VB,#;4:U1SPW._S4_.;ZX\<>V Y
MFINOTPY([U"AG]B3L&H><SGO_V+OW:.:R+I]T2@J(F)47@I";!51$=(M(-T\
M$FT55,2H*"@(::651PQI!9HH(:4H;S&MMM#B!U%!(B)$Y1&%0(0$:*41E4<$
ME+Q:Y16I4@@EJ51.I?<8]XY]=W]W?^/<<^[9XQS_R!A8(ZZLM>;ZS?G[K5IK
MSGJP8[1<NY?=X6FM_D;.25OO&9E.V P&2Y)7P*'-03_W6=1P(HB8SU<\%$9
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M,?:+<P/V&TV]XZO& M.(O604@Q/8SDL_=G?<F8#.6:RUHH:/3"7\6JXQHQT
MQ]*J1T8*DJO*;)='\D;R;+BC]8!/=_=06E)OM5E<T.7=2;(%[?0D+28B9X08
MRJTRB] Y^_[MJ&"@=CMK$_@A6P%D/8AA?PV?A()W@$_?\%+?0R(Q%@[A$Y-4
M\,_@NHJU52*K_2%##:LYOM%CK>F1/8X@V)UP_!80_09=@X6H[QD5WLD8QJA
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M[1FE*G-YT#7?+I:KBD9WW-R%(2I:Z%S4IBCP#?M&$E+_KJA\Q)QF_W6/"_>
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MHY(^6LNW%=Z;9MX]]>;UUV$QYIL+;V"+2S/?<!XDAI CJF2TRBZPYW<+3ZJ
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MKMV76WGK#=?D==MMV&AS3?;.R@>57;&C.\N4?-AW*;1D:F49'S9MY6WOS-N
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M.C91X97\T0)P3!,*^Z^8JA>E*1]*O4^JZK]_'4JCFK-7CC0Y<1?#VOUGU=;
MCWD'NN9O*8G^_L,'9Z,-E2_=3&E7U?$/?V2T[,5Z^Q,VX6$8::'DR&HB@,:5
MK#BMV0BY4J:N@[PD!+N03DUE#7RUA+59=Y7]#?--0ZLRB3L3"Q9&>\#6\ZP%
MMP[4UTO/JI'=/&8^[7CQH,9&FNI.&$V.>:^D3. QEL4 &AU%<JZG'V+NJ'&
M#VF=^IE5K W0SO0X)641:SOT9]!D2')Z5L,R6!4JA/"9+N-A:]Z=],U3J->%
M_LXB*T9^S.HY&1^VK$6[+RT@9FQ/[4-DO>%N8W2A@Z&ZB)P/KPY&+$YXW;XL
M=QPM+3G(;I(9[TEVW;*0F==\RJ+0_B7+KSPJL8>3D*R[$D&7ER<VQ[T9F6X7
MCG:JK-/OCL:.5ND< \$WG F."F\Z-. !<K)8UF4==_J&2$3PG4"1O&?D^V[^
MN-F)_IW2\;;RE9IDV["7O)INM[ @6]JC'SNKZ>O?#>AQ.X7[&6O?9RD7_4F=
MKN, $9S>20T>ME:,];9ICH"!3&M%9%HUU9R6ZQDV4%D&Y^VOZ_$.XP_;K^B9
M<&9(T*_JNMQUIS3T37MR36D%H;OJ\ENWUW16)?FE[^@\1O\!-_6OO%/]7[<G
M^LX8G6.NW8Q8Z*YBX!4!]SR:*9CPG3].29/AA<Y:6V0_93ZS*"ST\UJW&@@3
M038(6?'B1#Z]0#?@3O_1CO2J]9BJ(^C3G&5YA&(NB%#A%9,Z>VD3%YD!89)U
MW160JN:!K0I^,P!_&XF:C"GP652\MQGDU!0B&J5#_Q@>L,;8P[EQ_"(X<:^G
M&]5FPGGIL*=C1I7.;T>]9]#- #0_EGYKO4?QFY#/@9<=V$\!L0CXH6-J':77
M6H];()!+];AOKDS9TUR6' #FW.VYD!AHCI;O>IM+S7R\^\8H4.T:OE>5V11\
M>SA.&_1G2='3H5L67=?>\M0G1[0> <1C8\^*WWQ>K3YZI1R>&OJHQR%D:]3$
M1X_SJP9Y>MPTPX7,/VX1_F9@$\:(UZ1F+J8/5^@N I MVPSXM-CO;YZ%.Y)G
MZ''//2PP!?ES("8O]HQ1Q7]TZGCU>&06]AL.(SH?$F;%=,RE8Y ;U#1@WY0[
MY@"??RU""9CA9A1B#?;!F(LZ;> M[_8T7,>^S48;N>,_<A\0T>6,1CX:L>KO
MGKV7<Z=F*;F(RU.6:#AL!#Z9KJ6<(L!F%-1?.G6*)=+C\(:-+PKP0FW(/_#8
M<#K@TVJ_OYV$Y(UZW#R=[BQY\ GY1RKB*SM+15IV_]VSCD;RN%DS&0[[]3/0
M52<%/^$UA>-DT(:+Y/''QS\#?S\J#LPF(@N34 Y-04&G,S&[7MT^=1:UTVIG
M 2\NL7\7P3FB6:+/YXO^YA$W!1BTS0+ NM68"4L3^8IW!+7/("!W)W\F4H?^
MY]C5[^_,2NY+PJ3,XQC@8[BHLQ-[^C>#(BM@$;AM; K37V381$5%CS@-X^'$
ML5&,/?INTR[3XY3K$<P0[]9Q_O;I!;:)'G<]%K-7TRBO#;TU($K_#:B:O('-
M9)<>]V<]P..U87+M/PSM5T , ?++LO$DZAP -&\1(4^#NPC@F.R5*WK^LF:+
M'B>APY@I_CCRMP^7(.9ZW(;7F,%2>REY.O]Z /\U1G?'-F'36:K'/<&B/X62
MA\W&_W-TJ_YV;?-ODQ4RT;U(W6+'46PY9/2#F$E^>_JW#[^#'=$S#S&[F3[@
M$J?R3J'VA]#.@734".O,I0FTD$O4X_[#V';__>*F[OH[#_+KWSZ, RDZH^,4
MU/H(B3KA,H%XB[^@]@MJOZ#V"VJ_H/8+:K^@]@MJOZ#V"VJ_H/8+:O_/0NWG
M*FQROP4:=P(_B'HG=QN.SK1#US1YH./IY? C/6ZF$=P-!2OJ1M:C#L>5'>D-
MRY.,;C)Y.[6SSC*#*5V;]RP*&@T-,^/](=CIJ@W^)ZOP-RJXF=CKH0F&KQ@2
M&^R,@'.T;NR. 3)E)M"XE>W%)#>6JAAGJ?-8>PL7@A?R5O[#K<.4>21!9B;+
M,1;G_Y1HY;GR5V>WM@WMFJ3]DTO0#Q@"_F;K:)QU@+3PX$;.?B%Y0=N"8X0J
M)NOH@3G.R7ZF3Y[8/%S<SO[P]&!G8D%?58C_&GM9K^^SG/J1<%>11+O]#=;Q
MO/\9?H3U_N],(/V"K/_]D?4E'GZ)AU]0^P6U7U#[!;5?4/L%M5]0^P6U_P)J
MT6,B>0X9#.2\<M6< N!5N^$.K3_37 '#?"V;%0GSP#'M49D$6V<FP>*Q!9MN
MNF0K<\BC-F;O^LTVEO/FETM[/YS)$;;%J\C5HK^!W>>SV)1YZBX#1X!,CN&R
M-&&!'G?4D&E-B0,9B 5-Q3WGO=2; =(4TJS65)9CR<;K!1Y-J"TZ &(PTQ#2
MXS^M+6G=W$EJ*^E;O&*]YL78,73L;U_E?]%C_^57VY<8\25&?(D17U#[!;5?
M4/L%M5]0^P6U7U#[!;7_15'+7F>XF0'(>;)[9#4VO!EC$*^)<9I:U7$:78EL
MZ6(O8WETWQ6NOAX*Y_KXJG:^F#CYP=VIBD[9>*]J0=_W;2OJ*BPSEA^^KQ05
M\?\68"(S0*XD]CII]L+;L.:?0]+SJ 7ZAZCRO9BP* 39 5./T)6B=-$LTA(F
M45*C2>SKE@37_$)KL 4'KMW90C^Y:,&;C78OFW\ZO>+V,(Y_0[$:S%:R4@_]
MA/@M\6__*;QI__FC!SSG\ 6\WX>;"F=9.@1L1UZ<4ZVLVD,)7(/*7G6_BZ>/
MODWR3:RNKGY+&ZM%QM%K5?C/TZ)$&I-.T?@%FYZ[!?_^2/RG:,,!^(36(X.B
MY9^'=+?(;R-$L*.'[BJ_E:M;C]#X@R&B0FY?(!KD9;@U"/3F(R?UN$Y&2ZWA
M@O6W>;K^<WK<:*X8&.[_[ILBZ#!Y!!&-O_GZ9A8:(I)?$]5@\PPQT'GSL?]\
MG_T'>2')G=G9+,.19C%MIB85Q*;R/1^ZX,#'DR>8;0K+&X]>.M/52PMX_F'!
M@8*TT/YL@2 %_;C*QNWAKQYMMMRN<HO@3_Z@6-.B*ZGFP)[&FFS=^01R-NI0
MK\L3KM;.'V1[@6.-5V^^Z$AUXRX^."B:GG  V183O"-L7T(TD;6MHBZLX>;8
MG\.)ZR.LCM"[C*9"_NW>W).>!)VI./>^C)D>^M+-=G6L58]3>^2>RI?J'VN9
M;Z\Z%SULR)]=J%"FG RRC%ON-[?"XF[LAEG5A@MPEI=YM"DK?D+I_B'/@8MW
MP@<%TZ7[*SNKG;SZRU<./CD^NZ:K7%V2&VIZUKF\ZWO;XBS*NC[%^@]I&VJ[
M<+NIZ5QP^QB\QJ^9W]_Y5]Z%A^@SPGS4#O$$&6ED>2&WJI[?2$RK'4O!W*,#
M.@ UG"4W$_M"'^>4P2IM7&BWFQZG3NA$3:(\LG5G(HM[DP5!W9^._:!=$B1[
M&(_;O7^]_1JPI13K5GYDQKB=7TAGPPO=C>+]-)OD=Z6'-%[GJNJT]-1Z2=[/
MHB-UE[Q".:152';FPL4___Z4=^K_+N4W,G(MR<O)ZV0%G^A2<F&@IZ=G8'V^
M\MT[Y=&MUP7_OI8?=4=W?'ULBQG%M^NN>_+Z]^W:]3=*PD-EKUZ?=-W&\+B8
M2%M1\_%S\ +_&0T'<]ZV6UQ<;[=XP\RI57=M\9;,B+W=Q/@ 5\FI>47ET;(H
M]/G+M>XYI$][[VGMFD+"=#5- TK_.NJ#-T_LRENY%NPMDLRY=3\>V3.M?@NK
M51O)LH,KM1O93V5V;%/6'%BA)/0*,"<K =+[6M-0 O(36!8NYB,^D-GS+&R%
M4>I?5HRZEZ]X4[QN<-)F+)U_EQ5P/20FV$::QG=.&#'S9"(R0R[-[Y!3NLO
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M"^SI;!\/B<=D9O01C/G185>%E"-TOA-]HI^9)O67BOPQKH+1$8&Q&".)Y%$
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M)SPNU^/"L1547#G)_P^WY)\\)_\Y\Z8>]\H1\[4OOZ6%-!P-%05_SO\?O6O
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M32#AL-QHZ06=CDK67D&/2ZF[V%3<2,Y?&^@H2ROEC[1^+=Y5^2A-/.7?)C1
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M4"1/!2 R^1)K-YS5)$L250U>UQ[214>Y#?IY'T0V0]QMO8RYROOK>FAY1MP
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M\/E_*3YU.=CB.YDRD8"@GJ5=0!<HFIN)R#IB([O/6Z&?S-#-+@IA'(?#FOR
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M*O5]&&UKW<<WDK!O1;E+EVANN4A/OV4G1&TK2"CUV_1OS?19]:J/1,3E-B[
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MX](,^TK=[<^9PK5(KE+_+MPNEJT(?PZ1TYFG[D_6V44G":9Q/0P:^87SD.R
MZ],O*-OZN*!B.R1I:63)PD1/H.GW$:AI*69DI/7%U^#H/"%VGF#V4OLMJ\,]
MS 1?&7]$3U'YE/X(ZQ.M1:U5Y*7,@T@97']H@.Y2G@+(W]XO910=1<#'D0&O
M_>@:V>+7D1X9F>AVA80X4?@U/'VMP5*)@P6@^.$%J?O_Q+KC?[;V^.\<F[[@
M//^R/OAG(+8,#ZVHO;K[P,R9N[0N00K5:I[PTO]NTH_@;.B5[?ATZY,TG[';
MZQY<=7R3<_GJYGM?_>]>HAS9$*N'A#BUHY:>>!DU P/K%KQ[-0[X^T5,&&J]
ML;8+69O2[RNHF22SF:%97P'QZO%QBR??RR<\A%PX;O< 37Q'>F5NH=Y&?<Z[
M',8$8B)T>"JELH%STZ;82]&3%G"1T. U-5%[$FS:R3PLJN),?;D7%:@9H-A=
M'VSCED;2S+Q./_2+2R[.]YUA$Y%</VA;=F70Q)U H25R"09>A&WP75*9?W$C
M[1X(^0%#X6(2=(@^%"X'IKCW5F^;92]!PKQ#E(=$RUZW>07"M%9_73U,;&$=
M&^!56C/(7OL2$_4+(O1+ST>$/Y2>" HZ*ZC-,M.;L<7OG_B/I2;R>1^3AO/[
MWQ8>DZT?3 C=_6%0D8B::IN^87PK^?O7D*@\UGTY;RCZXZ3?LBYGP96ZVA:R
MV>09UYL[1 +RWX47:X_7@),3HM_HTFVX&/X90#Q#-/Y(M7)-I0N8P:F53+%3
MH)2&8\D/3@IS@)9&V_86UII>IO'I1S7%C)# W!,('?(_T]@[HSW )2DMLDZE
ME/K$)CQ"KE,GW_X*_"9!MM!1[G:\!.$2J<H&-ITG' "COL8:)K\LQ]?HSCSA
MKUZ<9@/:];)5P$R&YB9O3()\355+<.JS6*;+9&W'!J5@DV@EFE"'G"*F/\AX
M(;4M7W$ITAX.S)KA+!O!&3RL=P*OBPY7XOVX848%/\T3#G4)ZGO\N??X@IJZ
MYP,N+XA=24@JMLQ02\%Z97S1E-9=3!\F:9[WBWX297.@NPB]Q1#.\(%<>>QS
ME4S7XI)BBVKYL$M]0<SN6(IQU/19WDB@X'FA<HM+)/]3Y( TIT6#MD_MTAYA
MY/Y?+IB32(CVX(*)6_L45T64[EDXM_VF9RHAWR@EH 5<WN![GIR)K@E7R9:5
M<&,B8I0B(VK9^%/F7B2(&WW!P@)SAO!1T@0=G1YMWF%^WX%_B(9S,2,8;L<,
MDT$5=6@$,]+):5(38LZ8-2RZ.HV980,4$R1"(5G%W((HH*%.,\UG6])SJ.TV
M-)LPZGSPV?.:[-VP0YH+R>Q[C52$VH$K*S 2H[2Y-LE?;M >"!B((MG(>@?4
M+%SNHWZ'D_E?&GM%\B+."I8+<H.U# G1('U,7.R<0"YI-S#$K1?"'(4>% XT
MV"Y<#QJ,%ZX)M7_7FM=VNS@R^ ![%_0M P,SI.FYCX;]Y3DQ6AE,3O=R4HF,
M)\;,X-R,>-)JAD]+7;ST3*."8Q8YQQ(IU,F^C>S85P45[^L$C6/Y94.A^R^<
M#!H;H=*_-:G:+[Z*6>)%_@'.,+'G"P]B6R$Z9KCP/?Z_$7.X626/9;=+%J,'
M=?@5L?2L0@,!)!$3,^8LTU#@T7C>G;NE49;2.PE!?"-BUA&D<-*GKX$JY]@R
M<D]"8QP%SY 1=[PKX:77P05OH$PT /JD82">CQ&1DIC-GS9@;D/<Y88"T((Q
MV!KXFS1*:I"*FM[_4G>GGANV\<C>LIB2\8\G7ULG)T0]U/<,.7/SP/UU)(F[
MNEO.1NP3T94!BB6?%PZ[:#5?(PY%V)C,-H'K)Q^<"E>D.#;/2:XR8Y33.:)5
M1WO%4989YV9C"I(#(-XEU%V_D?X8J=T#O2J5-Y);[A"CH+>28ST)9.OQFZ0U
MNKL41^:"7\Y2)J4'.#.]%MVN*P/D]W$:1)?.V03B0OX)DZPE,5UAHMH0]J/U
M-_@KC0_)CB&IRL:C,TA2+* HS4@H;PP12YV&TS_3!KT"DLL9]0'0AUL&.<5]
M <\6O'B8WR$Y>"P$Z/A>@?CO+MTCII$26,S<#+WE5*"V^"4GT&5PVE0A/55H
MQAN)%UFR>JS>7J*[OLVWS,;6%;\M*XJL[9H("#KI7\:0SAG9A(OKJ$VRU6PS
MI![F*.BH23ZVPEE7)HJECK2'#6(66">IAC85(9<9LB0<FVU>2U1D&QRV6F1&
M,Z1+<_06\I6R9'FH0ZL4NZ4TRI>DU6+;Z"ND[W&PB_(M9R1%<:T^!755NAXF
MOJ=K]!<D%R8104?85^8^MQ(O%;535O=[&:IBDQ6<5DDJ;;67L^4EBCMJAF0K
M.LJ<9LE+T*.02U))K45JQ9<#N1?4X171<V?__#2$LY]MU<4Q>6&YZ S8]+>E
M6^$J71T@'YO.2MHWY4;QQC63>MCI>NZRDZVQ;M6*<>'76(=E7J/PODUY2(Q'
M^HT8+XN\A+_=/D-#35'*E(.OQHTFCWSS>9Z N+_%8>TZ1P"@%C0<C^1$(J-\
MK^XF>!:4TA0@ZGRN5$5<,3%FT$=9#S9SN[#U?K"!DL66CP9+I0=01]4:X0;&
M45S9GK"48D6GN5'!LS7Y2O+RZ+I0C@2 CKWM!6/(R X];&FMUC[JN-!N,% 3
M)AB<)\20;3N*1B3V-Q36^?ZGA?9(DG\P[+HWXY!)-*E:=FGPQ,U):J^Z,A8]
MIO"WQU55GR Y=D6+GE8OX/;BSP3LISO_^Q,O_\_)ER_O%I[8I.!W^C5=]_"3
MYM(\H0=<,3BSG?;?N'[-%;K.$V[F?SOS8IXP4;\T/ -;#JBG=5_OVF<6V&']
M?T0Z\D10$/G+/AS*W+%.2Q4;NU?7R,0IJ;X4KRUFHE,<K4E#PCRA/*Y]%E=!
MJ(4?=@2G4TN,<46T#U'-$QYMX]&^ 9MJ1!_3R$,16 O/!IQX#>L(K'\&/Q(7
ML"=T(KA6W8H/"#%=;QT3"2#V=4!^S] ],W[$/7U[8DHQ>DIWP\7?+L#8Q?2Q
M+,H#O.;E8YY:Y[O,YJB\<_&+Q[Q9F/92A-I4XU5A)1*N"=5E@V>GC:*DZ66/
ML#9.3;N8LV:B>^B]^K'X(2.BY7Q-R9A=__(\03K'YHJM&P+*J2LV"6;YV8\F
MPK[N5=_ZH2=<NWN"0.H*1,V(W\.VY5H];"3//944D2T@#QMH;O5Z;;$+$;R5
MK!ICKH:+*Z^\[?'TWO6A9N*7X*>U_I0OI>UW:A(W72%^P1%6OR3&RAZ74XO]
M=7GQ:K?O3(]![W)$D8UVK;'+@AY63>:2^)8M!1?&_(IB[5Y[B<72M@P3MR*;
MQJ&:ZTM5F4/%?U1A7QB>+4)CY"54+Z8X09HBNI)-8!Z![&_Q(J7%]QL$ MC@
M2L/I>TTIIY//M@331IK*QCVNQ.T]4%.?9A^@O9O[!K.;)X33I;(6G/F?);=3
MI32-J:Z!8HW2!X$?R9DT2X$LF_.4K0Y0&'\%9LZEI'.4F8+5/T&\G&W<MUTN
M,7A&K4*2FSU.MSV73R^-G+N _[IZG/+MP(B8L@'R83MYQ3[XE=4(-@W4W;Z=
M@:X*T&35U.?_E7\";G_1Z'Z(NBV*TIW$L?!R?LSW?)#3L_9$5&[OEUO\PQR[
MOTS6%*?O $X!/Y:'1G=H2#KV%'I@D*BTI@WGRF.%SSXG9C\*=>,2Q33C]D>N
MG1^IO]3>RA?\NR.^UK3B0_ 1ETNU')58P]<]$> )X4'6I.HXP(^<H6P%I\V8
MJ"$@Q^#D?4B3]F>LA^4)G<5,>T]70YK;9;N*(O/.E9=&)S6_3PQN2RU#1+LA
MARN"8G:+T DNY)4P2J;%<Q%I3+V*R3KZ[&D\ELDZ/A$U==:8(&7:HTBRO*06
M?D!*3?))<QEU5LC2Z6JF:VF(&+_<YTJ\+K EN/E$]"^,Y*:ZY7DY?&GQP.U[
M,99''@FJK[<-#"A5"U\7WC,IQXF;)6KF+,>II(,F$):H 5CXGC82Z;N"+2=F
M>%S@/1QG.2'5L-$/]DYZ+S#3T*.G3:C.>-5<%>TV4/='H35T/9?'N,UO]'7A
M36DKC33^.#3<8"2K/J,FG\0R*(":13-DID AS3>8BQ V/-DN,Z9/I9<I<YS%
M(L/X>8+Y!&6+"(H8 9^T7VWP5'*=FP;'''#"%%J9[G5*81,AMOH;&K<[%LG%
MQR6FTJ 0<-A(\VA!L$[(H,,RQ!&O9*VR-8B?_$Q9<H36$/N3MH)B.1[FA@1!
ME:/3/]7WH"G*/MC@.C_47MN6M#MX*#H@--^8?A0FL1_PX;V?,5*/EZ&<1 PA
M@$=PBDH?RM84(*/:W4P</BX/X%#V/=,Y3C$M!56OV+HL[3;4M$]@?!'_.&>
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MW1](PQD:GZO),>Q%B-Z!GNFB''XHO4USP<H]4_#GAS E9J/?WJQ./JU@KY[
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M,&(^W;EM1?UAD9TYV9]XWWWXVLG7=\VZ]JPS;S=&=YD<8YD3+1OM6<1:7KE
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MF[GS24B)<W+I&\/_AKD# *!0* #  @   0 0  !^_>$M8F$!L  !+"  "QC
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M5NU?'=9VM^D:MO6^[<R*[R48.PE&;1.O&?NG.=%#C>+;MA8B!XGV+K;ZK\%
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M7!Z:L3\#%X6>$'Q%QYLR7Q3)FYZ#N22G0))2/+US?A$Y:K:EH&B&5-"Z$?G
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M(& "E51*:66544ZIY953<H- "0($, ,T  " " M4(G+F/5(*4.6782+  IL
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ML\""!:C5)W/I@!^ E)05\0$!&B2B3\0" +AZ5<L^]0D1"-%!&JU(2T#JLEO
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MF>5O=$#?^W334Y^;!7?F:?.ID4)B"(N>CAS]IHHR)57QQ6.J:/>_8X+S[WZ
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M>](G>'S'#,F>>@.X&@NGYJFWN?$W$F&!C?*)=J0;*!@J "@=9)(!??"'=!"
M@02 =UB'F[ F#/$3&]FG>'1'C'2F$OBX?Q*YK,(('2#(64"$ZCD*\,F1^@F6
MY&&QF)O"3FF>X/_)D8@*2:Z[.*4*NIB0'X,HNI0*BOSI&Q 3PEFX08ERNN]9
M0DXINI832CAAGY0B")C2NE@)'JP"*)I4H%$I()H4!*>RJ(U:BI!CNZWJ*G4T
MQ[)$1['"#L,B#GNI(L"K"^53J_&80\\J!W)HHFP@ 7<HHWG8*]VSBM03#9AQ
MEZM OK?,EN#JR[?LELIJ(<N2AS<33$*RCGMHH[?<AK?2I6$K![::(7FPF'"
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M[N[N[E+<H9 '[_S(S&;/?K8W,S<24N+</'I&L-!0]P  ! (! -@  "    8
M1M^^>*_8V !L0  ;&, V"F"#O#>!;  @$  $ X"C "#D_2Z8#0 & L!@ '@4
M (:\CXZR 4:!@%$P8'04, IY0P) V  0(  "!D!&WYC>@=^AW[#>AM]N0]YY
MW@^0C0W,QC;*Q@9YIWVK@$ V()@-.,H&A+RK>&N"@6Q@,!MXE T,>1?U=G<4
MR#8*9AL=91N%O&E\&V6# -D@8#;(*!L$\B[YW<.;Z#>5;[(@[P[>F=Z@W[#>
MAB'OAM[KMP,& D>!0,B[OS?:MPH,!H)'@6#(N]TW%6_-43!P=!0X"GES_R;J
M[2X0 @9"1H$0R'L8[V&]3;_%\>8?\I[-NZ4WL#?1;RHA[U&]$[]AOT&_84'>
MDWMOO]5O9Q0,AKP'^>;OC?:M&AT%CT+><GVS^Z;BK0F&C((AD/>8W[<"?+_[
M'C3D/?7W[(#OH^]Q0-Z7\.X0^([T+AKROI-W'<!WX'=HR/N*WF\#WWG>#^1M
M8V]!OOE[HWVK1O]_,B#_KQ_R_X(A_Z\0\O^2(/^O ?)_T)#_HX3\'Q;D_S@@
M_QN&_&\)\K]HR/^R(/\30_Z'AOP_#/F__3\5 !X>_L.'#UA86'AX>,3$Q)24
ME/3T]&\/!P\/CY"0D+BXN*RLK)*2DKJZNJZN[MO.+"PL[.WM75U=?7Q\@H*"
MPL/#X^+BWJ+,S,S,S\\O+2VMJ:EI:FKJ[.SL[^]_<S@S,[.TM+2YN;F_O__W
M[]_KZ^O'QT>21UBH-VX _?O'^V]" A$"@!N*0[!>[_1#0/VH'&RCUPU"(^-,
M':PD%0W%99">#;8UZ(\B$G$B&*HBEXRED@M5#K$S&O[#:!!)(*F0*9J"9<LZ
MZQIM/!8FN 5'B%Q[*)?#$W.FO!Q7))K,D%.=BJQD]JN8M4ICS*V.;J'B=P]K
M0'%=J6J5\9C?KS GR^4&JYWZM)'ZLR%&^*,Y$>4*I@UW]V=X^-$%:X%N/P@\
M9WC2Y797%#9N$+^ZW79/#(OJO$<3R]XX6."W4ZLZN_%TI@Q(NZS9\7BAT, [
M4<"M_G2Y\60J;J$/%GJCTQL%$<WCX7R',AQ+-3+5U7:[.XOJSQD_K]W)2)%Y
MAV":^^W94ILUQ/CRC##@&GF\1*)#V_/I#F.]X4]'>KO[P^7EBC&ZM_?KZQ,<
MXJ;/-9(:L>\M7A*QWSW+X(8O!N-G/7^$8T"4=FV:4TI0$WB?Q+S2\B'+'"_R
MLSZ(.#$I.Y@N6Y(TC*G9A13$GERH'TXPS8;.CW@4F!/!/(Z8&\Z5_B#'*4E9
M9,BYVHE%;O:0Z;\+=?%O<5O@ACQ$/MH'27\<ZEB-)C^:85YM/YK];![?>9&C
M84T T$MSD!I<22PD8+^/5_"-K7)2.O7?Z 4!M.H#5@$Q_6!.07J-$,E@MJNV
MKP] 5:C9F.ZG[D!WCATRJ8_=1B"OMNLG:1.SHK-376I "#^B,)Z=%V1KTQNK
M.;2XK'':S:S\]1%!F-2VWJZDO.?NF*@4<&C05=K/6J);=: >O&5\WYDS%BMM
M=HW*[].%J,:W&<XV =Z-5-]M^I$O0QZ^KAN6R[E>F(,GN$?\.,9_3WR%QBT=
MY!_,NTH-CFPZ3I:Z: Y>W4&+/=HD0T>1\NLYU=XUQ +J;QE>RX7S7B6I-AD2
M6=@,DL_T6W,N6]1$<$)98/EPZFXK_1!4!&)%\@?4I8QAWP_:EW&>[+HG\4A*
MAP?SGYK-H.D^3"K9<FZNSHS7K93&3>@I*D6P"4 9QXUKGVFZ^_"QDEW5?KBY
M\0#$XN:$70Q:]6A5FII)+^QG;E$,0%<"'B [?05=4V3&WVHN#%RV:CJQM% >
M>D."D1@.[:G7.UPQJ009, 9H "\72@];_UQX3?-LG03#4AWM)-PR,[Y?4@%4
M/U 5N]3&&1-53&Q[$>$4P&S"P6JG"HZ<WTUE^A.WP2@$N56@9*?O 6J_PUS8
MCK,*>&'<8!F37DU-/I]K?S;S]"B^:^LYFX.\FJ=VN*-W/F"T"B)6'5]Z1KG%
MTE6LXW8=$^NY;;E_Q;D2@7GL0U O4TM$JT7P(6PU1O"9]H5VZNQ4OR'#/"[!
M?N%<I#=MR]?0,@"/J"62TP[1&RPQ@R*=R&'(8V"^WA>J<_<[UM81"A%=JZES
ME_?YN4E*X1]FXL5"NG_FN8Z*$$(-]D/M"T=99GY@$@\8&"KW0??@E]-$B@-A
MU6U%MAU*$ODQZPMH(-;5WHIA:,D,")S%H)';YA!ZAV3A7^[A9B_]969-E=#K
M]\VUFX3!O+#9YESOJG7-M"$@XUU*Q+"/<BYEP#\4@A7\R]WC(1!!D 0&C<_^
M%,-KA\$4%\W^N.<;Y41, Q!>01%<-JGQ"[ E7+B";X?=ZDTKJR(ZIOXBH&+*
MY(&]'W7?*;%8O87*S3I%:*Z4;'2F-R@X/,IT$TRIXX08E3\DPA2@ET]J/5-%
MY$MO98)\P#67@&87[@^WRUSP8=I5WJ[6@.F4N8#W\%#$GC?$]$9A@&?$%]+C
MF"\2)2FBSK<?@^90OQ.5K&[ -R^%YK7.JG?#C,#;XL)NGPUC[/X3Q-.B*ZZ7
M7$-PE;S"O4$I'S,5P>4$$Y6R: C-A+B=QQQ11-RJ6T W>)/OU^@GS76K*+5W
MRL6)W4OT42@U<_M3OF!:E\Q&#,_)YSI"9L<!:3G=V?S7>#O_:L+:U+W,'0IH
MS-<<#)SV9,2#*6),?\G>VV$?Q _%!Z7!U#VW5SMPM8D<I:>79K_9DM)KT+Z7
M[\J4$"?"0346SPGP#FX\!G/,UY)NH]BG;6K/D057N&T)\&+0!P"H!>D/.?P/
MEH1_IS6D-[\ZNB5@PZ+N&FC40CNI$HRN>?,')Z=#6&K3CNDE>(O!GSL;<U*/
M- ?XAYT^^^7'921-4?/ UXN[E,X0G+OL:[LEH@4EPQB'YTK@CF:-.Q+L,QT+
M%?#Z\$395682R'\9^UK2J& GA(O)>^)G_1*BT,/.D+[_C\KVY0K-/EP$?MUS
M@'>A:D0(:!!]+30@BLE+ZE 8E[8]MR.2=[?A\&!"N'_#J$<@B_8(5"(ZK&1T
MNH=&=YS^R?+@(\&S$!)YZ(2"N2=)U0"8"73P.NU[M*#B+>;9(F.M)3C?##>&
MG2JG;&LT9@P[TQ[].6()1_EGB1B!C&QF+ KLD&M'1I,HH\$:H_TXHC7/FM05
MLM=<Y>"DVI:2_"MTCB/'%5)L8\66LM::QC[1Q*<QEP:?4F>\=(57[[UNEM'$
M>_@=9GDBF/(F"T'T-Q.(9R1ZGQ4\\/=0ZIO&=,)X;1)3FQ'M^6!*_'IMGD39
MD:0S[VR^.$>^F)89VP+/N$-^&M+Q5I2Z)A3*8U+@-XTJT*&"M'N5B _-U4WD
MC@TM)@UV)Y&\*I7T+2I*PC$HDV@O\.\G9,!C<%W:1NHOQ2/7J5.>DV)D*KI_
M1T^K=>6WQ Z3H;O8\@CKUQ*DE9.A&B@G_-J%#>5KR!D>!2W8'G#IY2,*"QK7
M.Y4GPNFI0!;$;OE)^]M)*-)_/T_N$K+F7]36 Y;7H@AA)];WQ-'A/)V)VD]I
M=CT@)2"?:(YOB!?6+DP9Z\22KYF;5<CNOO-:.>ICU\H%\#)X*_U\F%N1Y-!E
M%DZM6Z!-EDCS)7/=Y,?^NEVQ)$=R5(*K3'(:=)CM!)JI[GAAT%1?WX!%O$A4
M =06EIXD>C!80.^VDHSWAKO< RHHBFW7@.>8)0K&1H1(\XM!+#]!TE>W'L+'
M8E5.0Q\P(^PH/C!@ -NA']IY<O(@]ZS)I-AC3,E>8RY]@G]?INUXRESP)G<B
MO,0(]80O!T\>@-%K*VEL#B6ZY3 G.%X)I1!U9&'E3K,7+UA:3("3U#T? ^/#
MA\P11OWY@+!+OPNLPW"PM,=3'P"O>YM?X-/;C[1G]_T!XO8P?]6=/OX51C0*
M[4,?.B$Y\;=S;_2-LS(BKUZIG<DXHNLS;Z+3QYP/5PT"EY=PK[@JK=>""S5>
MJ3 :=Y>\9=\%,=F%@[[S4U#Y'%WRVF7; 5CMIPSHMN&M"Z[AOH)4$>--_.OM
M\__XY:E*_LM&W>^4/)GDV $XAVVA-5# !'.Q/2F@GVSJ:AD87O0QSVT[H,(X
M&SFS!2LXH<:AWV>B/T6C/Q!+Y9,K_ RFX+5W:H1"/\U$8YMWDF1% V6Y;$SB
MLHI(!4WA7G6B;C*C:W6RCB>@[BCHS'Y'I]Y%C8V7*S5D"0&1ATM\/B;F_.SH
MEHEKEGI EN$<G-W@5T@5')SDY@]9# Y/(BEIL)PML"P;L$Q\(%#-%&C;=W/:
MH:JB\DP?=)OCHFWP]PRB--FL#RU>#-W8#RT<#*TH-.:\A^/A^KWLC[B(%?8[
MT"_T(5C,CX+!060:.R02,82V,5BP0.XGI^;@0]C$H2G1C.N(Z-N[3,0BM>%"
M8<02M]%:8\3Z8,3VY\A=Q,C]AXA#[LB#PL@CM<C3QLBSP<B_B)^O,I5&20 6
M?E&365$+75%=6U$#4-'M)-%QL5'P35$(2U%(CU$H>-&H/-'H1Y8MW#&?U&-P
M7&,^@V.^-,40+,40/<80X\4&[Y%??8ZB1(JB?HRD58^E&8JE<XUE6HIE/HIE
MYXGCI(GCAH1$IA90)T['"3[&">'%?^>)%U6/%W>-EP3'2S?%RR[%VVUCR.,E
M*/(D**O'(W3%_0(G:#0E:"XE:(/CN0,2='@2#=43@:Z))N!$(5<,U*Q$J\=$
M&[P_=DB)B"Q_G%S_ &P27)K^>"S]T<%+],)+\N-)"@ G6A1A1&\S2GZD"@6C
MVDTG24$#I*^28L!4$33@L*$D,!(X,@2<=@1>A$Z6^0[.D$K.00)GJX-3B\"A
M0\EGV\EQX.0J4W#J8W+81W "4DJ.>GQ-$54;F$KA,:X*G)))DP*62ADX2NGE
MH:K!2TZ<3NU]3.DXBFOC27/+_C/+ YYK2BTO2AT:2ETY2AJ!+"6OJR<7FJ9N
MN*:LFJ8%FB;!0\7_54\/&4J[ *<OF69T2V4TXZ7G+:6_/F8(NB;!L&34F:;L
MX*7]#4EN*DI&&<Y,*\K\<P2^0DHO<P67A*2C)Z<NJV=AAJ;"'Z<*+&4>J&<<
MN68MJ/\A>LK:#<E:D\K:=4VG-$O.1\JFUTBE_)+Q0PI#ORFC!R\+ES:-+#1U
M0BICTC3KVW%FO7HJX#C1!YQ-W)Q%=YSUO2FY "GGJ2B7D3:=+#1'9CDOD":3
M[SA/GS??T"V^2SW?!)EF$9QOL9ROM)1K]:7 CK= !BD?%CFSPC5/:2B/O#A>
M:CE;?:C@-TVAB&N^@W2^N5MA:'-A)^0Q/?RI,%JZP*DX?;\I22@Y*\&L:$,J
M!W8YYXM;*IQ;GC=O&BUO5KY93C9M-G@YBS:YZ!-MCG)QL<]R?-"7HE=P87UR
MB2ER0?-R2?M3'NQ48@=O:6]H?)U&J7M(R6!SJ>=0R>A3Z>1R0MR7LMG0T@&-
M,MGBG,7F,MGCPM6GLDW:^!G:O%RI\G77XJWD\M^N9<=/?Y:7RR^D$\:_5-R$
MENW0YE0<9SN[E=\N5SB&9K_2EIU_J83]7;BN48GX7'*?7/G!_<_?Y4I'WDH,
MOBI7U\I/[E5VR/D70CBJKI@$)3E$^-4_2*JQ+JOP9:H-?*L)^:KI?U?3HE0S
MI%2SM%0S\M4P0W[7<-/5\,C4\*[4\#_7<)W4"*/44K5@XK?4B*34BH75RM#5
MRLG44N+7,3W72M/5<<K4J8U@JHS4_CZIU4*I4WJN^X5?;^A>IQ]69YQ2;S12
MQX2?"&RIUT9IT'VN=QBI=\1O<.9K<&II<!EI<%MI\'EN\..K_^&;]-F]T>2Q
M,OAWX<>61EB^BDC\)D!S9<U38H!&Y9^5M!9PQ@-/O%MQ/'I+$XUT45I87C9?
MS@M>[E-H<^Y*!LE341X?U7!Q2MIQ\[-4<RU?[H-K<TE*B[I9RUY3\25R4]MS
M<X9[4^J7UM;?+2,GN0ET35K2387(Q8TAN9^36\6*\V916C^:-2,6%U5!W L*
MW(O@0LNKFMO*S=/2-<HK-=JV1I(O?B?\3<[=-6]'X&W/6<YZ<&M[&&G[^[O5
M;+FQ\!G\;ZCCV;WEX:EM8J6M(ZS=6Z,I_;AC5KH5P:(<XU\;4W(KZK\FF-(,
MKN&N2?RD:90\V/"NLI;BHY/VY9;LG\U-[-*%]*,9]<^YV2,MJ1IYJR?=:$\=
M:W0]\LW@<_-\P$EK64L7[6@K56EK_^]NI.6.I.5B<YK.]N<6J=;.(M>,9I36
M>[H>BM"N(I3N2>0F">26O)2FQ9-.G=4F8]E^4_HN$OJDZ>=^._I>'+X!*-H^
MIP_EGU('/%++9C[GQX3F(+<6I!SW(7SHERTJV(*8=CTB=ZH7-7H24-7@#]UI
M#,1[# 'Q!E13V]26!R/YFTN?>^9+6M(_Y(F;=N\6MU-]Z+5H[<;6[/J]6G1(
MVR$2/E0=-E#_K]0]=:25OJ++K+'M;W[PWR9AV9*ZT9$X@M&^YI'AU5'=QQ&8
MX]&D#T,Q%A@7DW#3I2.)J6.K%@E=RV.;!./;_..[LF6N7;IAON,=N=I_/;X<
MK^*>E^*?KGZ^U)RX3AV_;QT_2YVX&)VX:IT R$V\6DQ 14S E4U >TZ^E$Y"
M4B?1+"?1QW!O;,:VMJ+Z]:8P>*@_:T5_:5/$?YDB(IPF%)B>AYHF7R.DU)HF
M?<'_2/.548Z$Z86818Z.#:(UP^PYPQHQPUXVPYDV(]@V\VUM1DA@]KO6++_G
MK'#$K"CA5QS62?FQ25C"*12&.534*96(256!.76M.;6U.8W3.<V7.7W">4/"
MN=^6\[H1\P9E\T8OL\IEXRTL$=.P<U:>\XYI\\YM\ZYK\PYK"]9M"Q:$BSX"
MBUZ$G[':*/,D0\&-BSF2(:%KBW_40J+7@ M48:W<87_2EAH:ERA-EE++3"H?
MEHH>0M=4*0(C%@K*%HK&%KS;EOU.EP/6EJLM%RJU5FHBEAM>YFS7R"K25DKE
M5MK75MRKY&2O%9)BT.,=R*6J46,<9,XF.>Z@T19(61ZC@V0_HM4%L-Y#?_:N
M99*!5*-NLVK)]3+KLE'PQ9,O,_LK^C,8(*Z>1:R<ERUW6>*!3A<C&0 ,E>YE
M +@,/X!?C[M3K$4N#,!]<H/2!S'/X-<@E$ 2#%&J(CI]M&(.##7;9A2;KK>7
M$H&7HKFJ$.\3,7541$@"X7)3'&+0-+H+'-3CM<^!+^)0#56N(U&;$CK3.O+'
M&_ZV&MK73-_'*2M[15N'.:X:']]S)1O_:S@D!4'J<B*4&\\#$BO7;/2P.D&
MS;<#/>_2:MJYG6_]T (BZUQS/3O(/D+(M;0D!;MAM[:N=L+<"TN%BLO7']"A
M:E#UKA1N%)R.A3Z/Y9)#53J[^WZ7)H7Q"]#J,61#LD=W@ABBR22*OK"R()$=
MR(/('00_&W&A3::A0D4?J)>Y:-BQFI%+*.2P 1%$6#X?(02A=>Z*B/D[W2HX
M[69*S/L=';PP;NJ*7_*O2E9+%I6[@/XP.]4&/6\[+'>B;@BAA4<>K6Y*!!,[
MR=BQ_>*BH((!^<2@+96MD5$B?NN!SI<7#8U!^Q/)6BC_^?3B%*&2725-1/:[
M!+:_(YZ_U'DGZI9N<'"7=+##7(OG>!7A1@?JQC_&C<9VERX'= 5$$85@BA%!
MT<]BZ+P];#<VK&RP@1>9;+.$"IS^3(\ ]&$M-#3_[UL*Z+_8T240?VJ1,8ER
M41B*L'@D<7H.,,-5G'>OG3^?G;] M#=BQMP>UKCK]M$RJJ]]=C9LI]WYO]XD
MY^R=[WC0]&V"<PC0QZ&A,&X$SBT G>B\M_@,T>AVBA8/@S2OT>@A/NAEF[>O
M"\A0XXMS+-M)8TNBZ[YY<UQ/"YZQU][/N.X36/0S.X( YF\ ]MV]?IHG9Z)4
M5L$M)?/5@EUX-5X\0_M/SO<[QM1/-CO&CL(+<78/UY[G7=^F['< ^O9<?^Y!
M=D)=V4)JKSX*ZUY)'*K*Z^@!>TL3T =0# <(]6A/"F+0.N@_<E #1,77B1%_
ML4_ML&J5*I_\FL6=:G>YQ3B1ZF;+8S]0@1$Y[Q0-\/TNT.N$NWT)VCH>/V2C
M%OF9!"6"#-ESX+?G<'TXZHAR,M]UV445T>@%F?=*KVZB*3R<><*>L"9Q/EZL
M4E_[-=BRLF)<R#Z@\6*! +Z'Z4T62]UC):!@36&<F[.YE(.RS&;WAV6X01Q=
M+4&/^_4Q^R0;K2Z8*R)DAP:&E7JG^ZLU?X0?FR+"M#5:3??,6L(V-Q=-,YQ5
MZR..JVJE)0CHFIR6^Q<"@51,Y-ENMX<_V[B8-+OL'H[32C7.I>OM;F>-=N"M
M#QI<H0\\Z8+/B'Z5J&%-Q^':I\^6Z&"IG*+4E^LT^T+0<"P:*]?Z J#8O/Y^
MOM3KB\$225]]J-X=!G\=Z4FR)%P<RZ,Q.$O]<FLV7BIG+KBF<0<Q'ZDRG?%?
MZ(/U6Z.$O=D?>W:^6._Q?19DY.>QVQY.8?MFE=IXLSU2Q!=EI?5\?3)98(TP
MOKW&A[@W)J)@L^[Q)G6EQ7I"N^W?]<U"1X..X+=_CP\O _<3* #XV8.P^X>2
M\XY7 *Q")U2;T(4@/&XN<Q<20ZE"]ZU#M"GGBF  0^^RZ$VIZ!P_^12SQRX+
M*,5/^Q]E&I8IFVV=L]]P/^&T$$'5P)>?-[;B1-ZY/P<_X5U34S<%*5O0V6BV
MT#&YW&4/#!)G\7^4) 7W7DDSE*VRCI"V?)@98>D@QY+E:.F5:SAOA#D?^[N9
MB\4-53Y9D$ 'ZU.0P)\E).2SN7J)A8D#V?U4GJ9R82H,P(&]5(J^P.@R#EJ#
M]2Q(<%,+KFGFQ;QE;[W\U%NIC"HW%S5[Y>!ST:VD(S<WI\:6BCV':!YXJW+?
MFB3VE9!84C1#72-+N(TU )M<%2Y2+E=-]Q&<-W=E4EBP=-T^286I[K@V(0C'
M+<NFR3X@<$UNUR@\4.)^>.27"E//HYOJ_$3+5F/3N 1?-'8A=0"P&HR1T&(D
M;!G0<C@Z+27$:=SJQW?,?PI-=_@<]$??QD$6F<"JT_<@*V#Y$9Z0!3)<'&9[
M(0!(=?PD@J"#=]PED1:/68V2X=SJREK@.[+6=!"#V27#U-Z[]VC,YBFX?.BV
M0(Y[E!?BE'R4#8G+;Q[CJ8#';BF5:QSX"KC:^N1+![@P3J2#;LO^"KC[/!X/
M=1*2G0"%AQWP5Q3M5MG'J76^ &YS76HWW5$V*2M#10V#^')WG^3YHJS%OU4)
MMI?,>L4*.SXJB/ !;U+HE0 V,T-G1,90R&TT1P]GADMY)8/PHP^Q+V$K#N$B
MU*/O#X0**&HR 03CQU]0*#=XE1\ II*]YI;8#]WFWN('CIV&)(MZG5ZMC9I6
M@%JQ\[ 59VJF)\)%&2]W0NX-HL<&G;*5#)7P-BI,1"5O'<$G:81-(J-??;<K
M: 5>&C/Q3MANX?XT^XM3LLNV/GX>9.0BKJ$R](H8EID[9,PEP3K')#$0B]P=
MHBN;GYR[I-%N%GW$5PJ2PH;$PJ*?F?%9'Z04:J<^-MA4$EQ?2 .G?7-PVR3Q
M*5T1>#J%(UU'C0BY:0=$=EG0;,)S@@\'@WB9'V*_;L$0"F_U\U4JHV$_]87R
MTY".=K/&%0I;^@ _O/U?H!0JAL/P4:0CPU_[/,"57!5APY]#0&=0-R USI=%
M*D_7JA*U&5YF\3/)=P$6DT"X"140>3*V^ 7$(:%-PF/0(Y&IMEG/WX1NVS*$
ML$0_-_ #:CH^#C]A[P$A@Q##6NA5,N N>"]P#74P<7Q&V U>N![JB-@1W0P=
M]3"+]W?]=XV])6%28%6+.F(W=%$Q/@#XDWXK"S+A@J&@PS*"X'/I&F4Q64.!
M$VTZ<ODHX;YJL$[G*55OGES@<<Z'?G@#HM--0/U^=TUT?\Q3*I$M[SBSFD%[
M L,HL&P;*>$G!7,4@\%X-YFURBQE=+:%AF=S(;;E H(7>:@&3?H3< [!\V@D
M1EC_8R*4<9WB'(:*(I@W"!%DE^#Q^]Y+0 M/24F/R+/\$[MT,H=PLS.&L[\J
MLG_6@";'MDBZTS?&(?J#Z(DT HI+(ZH=QB]CFE%X%$3_:6?-VTCXOAU5I#AQ
MVL#;3/TR ^&Y9)7ZZ:DR5PLZ3=?> :77G^:.$9HTY\VJ+7<<%6H])5\AR1S#
M95=VT'G8#1]:U'J7CRLA(9ZE!G@H2T/2]5455U_5.%KF&[+K:HSARM3%6I8:
MW53*2:0-M*]8HPIK5>K* T_-C?!_+X_/U]?UG5HZIOQ>/YMO:(,[LP[$U]Q&
M6VCL$SNS3<#7="U5(7+'[+7?P]0ZE/[3/%-GY532HO77[KYY8\[*N0]%^SSH
M3^L.A[7;2(OV3?5]J[LMH_D>'\73^$+[;=^YYVV*SNO90L<+W(4W'($N-/IB
M)YSXA2]VJBX\TV+G6,*9'46J)O*/Q6[L_HM CE0]-.O%'D+X2ZNMDO["Q>E>
M*G';T%^M^C@-BWU,0;;A1OP&7Q86^[GZ;2,=PPT.SA8'OL';1?NNKGY$61J4
M$(?8Q2:T&E)^^V,K&V07G\=O1*NZ-"QN56;^ZZ\":+T1).0UY=/\;YOI@'M4
M5;PF8F1UFR4,/&(,O$[IH#_P*VT<H,ZO";FV&!$X>1SUS+?G?%@U_K:P-&8M
MR/)'G>!0&+^Y3S01(1VIS5A<IGD\0?XF&07U0):O>3I)OBJ;*PVH>+(XE)5X
M'2J\9BK<HS9;3,E>JKIVJ&K>/-O0[UC^.]5HS@H\DT)T73'"?Z #D[D(LKK)
M^FWY]QO^\GPM6GV.*:J%*%GRTC1:365-Q"G0F6=R.NBN,LKSE-_]>66>LJ%B
MP'*$CTEC=42^(7^AU<JNAV_U&+ZA3/7%PMD^>1W&KS8,,C9F:4/GOO0OR*FM
MY.54'J9E?9C3)17%RU)+]=_4M8M=!Y75D?Z(^P;^06.;5H1-\#?^)1P)U^&9
MT1-2'? N;</5B)Z@O5))U3 KB'4\KO3:YT?3F,D\3ZR_O#U=QM,^1/!JTKG4
M(9MK[8@1Z)J;(>A8K"JP<%KO-F^]:E_FO';2R/FTT"?H5'W >_Q0[E@<(W"J
M7)*VO"+84%-V>F<S0+CFA-O4%?)B%LC6>E[&Z+QR^>K4B4"TQM/OMH2-?J'-
MM'X9M6&[2/+-=5A5L-]8@J/UWNO""I?H+/G HWWKG]4D*'WE2.5^2.J;92@7
MP2DFU6/KR^GE?,[Z3IXQWZD1$\0Y>H7[,G&!=\'WV[\MF?2' 8GV;98,CWTN
MG:$.9\&QP*^>Q\9K#W,#7G>V;1Z1"X3G5?->#R%HGI<Z;9=[$M^&*S*\[AHV
M!E:-7X9VSMV>6C9>32@A+R7\GB_W'4.?[SL GX2P_3L>9^HC3AK7\3OA2IO:
M=#M?^#H0XH5Z83J1:H7NZ#I19CLO:YI0/=H1;SHQE*MNL;H^PK9_8._Z)%OS
M3TEX Z8+YX/PQX NO$]\GW*[\&59<7J[<'<Z"..%\&ZZB,EY/ZWRQ<UP_7CF
M$0OCZVYIZ& 3\!,1J*UI:)'ISE#B-NOYWCW2$DS7-,77NI+2MB+"2OCW.Y-H
M)\QJ-[4A!^1QIO'A=UML3>UR2@>F1]?H-?^,OXA'7-VT>WV/?0^SLHC7B@#_
MI\[;G):SD1Z>>)8  UZQV1Z!3]WE9-T3SSTF2D(K;"+".2UK_B+,RCT2\3VB
M__A8983D"!J$17LY2MN8V?MD^#CE/_21G B%V(N1U_:%Q/'0.8C&K?2QMHKY
MTG&GG@B+BHK]".\[X^.B$A7A_"?Z\V^O+($0L47_3ZP^<0=NQ591A=Q^ZMI^
M278^FJ*>@AT^:WY!UE+^7)EF"\/61'-!1W96!\-OIJL\SK.\+N02"37"]S42
M)2/]GIHMQ-<2O2E][@Y5>N2#SW$#_LJ#M".=J@'B:]?=0J5]RK("$!U9$1YZ
M<9._#5JKK3$[;2JP0\J:#62IW4KT?6'_6.SY)?TU!UU*.Q,#AA)@))QN!,];
MQ*;Q>WU[I$ .+;:S?.&CHJD[4AD$8I*C C]'AEJQ>BR5^[0_L":02R:&2UW*
M#!;52I.,#)0H2Q:V2A3-#A^7#%=\&L$?87UP RWY@6H"RFI%9>H\&.HU91I&
M69OB/S:'([4$C#3TCK19C+2'RW3,RG2FRG25RG2WRO2,CG3]&^G[(-NO/-H?
M,#H0/]KM(#L</KHF+3N2.MI3*CO>*CNQ.CH**S=&/C;%+C<E*M=>*BOI7SNC
M/#8A*]?K,3:9.C8=/C;>*K=8*K<0/[;>.P99&QT;<V!<NY';_C>VG2NW6RNW
M:2B_MSNV$R"_$S^^&RY_G#J^IRQ/BO+%#8!4="A_UHMR<3-^\6_\BGSBFF#B
MYM/$+?N/6XL?=Z(_'APF'CPFGG(GGE,G_L5/O-3^>/G[X[7W!^!V O R 4TQ
M"3,WT6H"HE-#@&^#=K29A+=40$Q00,B;1/14^)"F@#HVB;RF@'ZJ\*%M$IGP
M)\K>Y,<7!4R!*6RXGY]0?WXT^HE@"6J]\'.\\&,LG,(?^TE0]Y-H;HIH;8H8
M;IKD98KT=HH,6Y%,3I&<0I'RUS2EUC1UX#2-YS2MXS1=@B+=F")]GB+CW#0C
MZC3=!33'QTE6CDDH,24(FY@"A]P,F]$,E^,,MY82C^4,3]T,;Y\2=YO2I2$#
M:4FHXU&14,1G8;A988[9[V*SG0K*W[5F12QG18UF)1V5I0)GI>IFI?MF)>:4
MI==F94YG9?=F%6Z5?\+-_>28$W6DD7&+_*6%IN(XIQ(XIYHPIY8WIUXWI]$W
M]YLBLE8Y"L$%7<<27?=T3H=B7I=A7H]CWE!LWD@ 7<]RWL!3Q2A"!<B!;ERF
M8M*F8CJF8L: ;GZJ8O&B8HFZ\+@934LR]T-LP?[7@I*<JI/6@F+@@E/$@G/"
M@EO>@KOC@D>:JJ>G<GA82.N#DON>JL?:@A^VFC_%HO^OQ0"C15]'M0"C!>6Q
M.4C(W*_0NL70OL6P.;5P(RCM-73K0$ TMKH-JGHLH;HM@WJ\@+J5G'JBUI)I
MX))EQ))MVE)BV=*?A*74/'4PPT*@IUI&X&(FW'*6I5H6@T;VRU+.+PW/VX5Y
MY,4\CN7<! W1P,P_FX@E?: _"G\"'9'^)"V+G2Z7":A6O6@4BFED)2R&>\[U
M2J4*Z?WNLUUIP/[4A(W66(?6DK#2E/![8_!W&_8GOJ'?#7ES]2^_Z_I^:;>I
MQWFB+_Y4T>M;2@O43)E3'XI8'<A;'8%3[W=4[[-<':I;G=C3M M$L*^;C6S4
M0)I>!F'G%!JMU3AJU5 HSR:L>=C,%F2NI;.NE6O]6<U;@\P'KE7?:I1.:O6X
M(!4SK/^PU/!A6-F[72MZ"0*;(;C8@)QM$(X(H[[U9:[=9HN,K6<M(OGKTF1<
MD*:1_#[U#+YJ"RT=RUP;0[H4V CN @7K(N<^K>W7;;C)K43(H5$G^=HE0;U&
M0 LO$C)=H/;;9M ];. )D;\&0O>"H<8O$42YT7 0\_[Q?,*1W 3<)7LT0K\R
M('0(!T!MZ<*K;,*^DDMM(S 1Z_$O$?Z*R%WY2>B]B/7B.!=)$16%NF8:003@
MIK30H 0DI5LFH.L1;EM2Z$_,80Q@ZY.)ZQLQ;*OS; \+J%"H1.V[DG]QV1XC
M5)W\M71]J"[>A^"B$&+)C'!4IPVQZXQQV%J_*@.=CX'O\S0XUS5\A3>2+XNY
MU]?]M-;^_HKA/S.8?M@1RC>XXIAS\PF+#ET_LL1$/BY>^Z53:I-E6XC@&;R!
MH0@J#=3Y5F]P[4C+J[W#3XF'3;(K>FOH(A<2K5]H 4!P7426:@>E14.!#L.8
M@<0VG5DR<MHN+AK[GEK:E','1LB6G7\L,8"6%T$.F5H>S @$-$6NF]F90LBB
M/MD)S BKT;YA^C0NNIE^DJ"#+PAXS;MN/J04-'!N:L!\(5 E(DEN)2+!$KQS
M)J@&,=1,/"!%+]2AL_'I=.]Y;_8?AZ9J&[1^-FB?>7/R",'D".1OE;_I\JEB
M"T%F"A_B?9%<HXX&!0_P0$Q91]2K!@<&B!_Z)WY:C\ZMOCR,W*<(/T/%<:F.
MSD>H9HGW#OK5:ZG/</8+!9%"S:Y@Q9720CK=1#CJFH;H^F'K9@IJFR9%?RC?
M"Y QAH?A\Q&CPA1.A]9_OBJ1\ Y[5X^2OA+05$6%&$QI7E1PBJ2.T&6J5YUW
MY%H0RV%&' 2@)Z;4^:G2X$6Q,P5U>FF*6*FO[PK(O .IN/H<(Q%>5.F_^!+N
M-B%,2*TR1D8QE6NQH &M,/8M%9 LDTA8[!#R!^'MHT.#>'W*DT&FKT$'7Q I
M+D."IH,L#VDQAN&M-\?S)N$CP2"G3DS/INP$DV+GQ= %;6J(AQIB_F=0Z^&I
MQ2"UY OQ(&51FAD"+E)H_O> <X[]FEQD-P#0RN6S"S/QL!,HX&'=GQD7^RK$
M>1$XM1A&A8B<6+A3 =@W6U_VJ#Q /@XV/4,J001E(H*F\D#.S%8.0H@J0.3%
MQ%._25Q'FX,H-6HW(9KPT ,,:80&8M\K^8-=8*@-]87(F86;&LCR#CZ3!%'/
M"N1:>8 ;:[2:\'EC?<W9)^QJO2A(C^8L#0%7^/2.8E9SW<CK;N_+P.R-T\9<
MVIY]N75%)L*.>*AK9PRCR8;'XIG%^K[CXO+Y2Q#2<-!X/ZCD C%E<L^MTC#I
MT=K*!,'Q<7^TG\0U&M$R,]B3TA[B"53VSM_"M2)H!:/!M*><4&MN(!Y"+?E'
MM"-TZ/T*$S?=KK3O=?WU*=VW%WP]696[I0OE59@GB@#P_)S';FP2-;8%YD2G
MPTE#9H0Q[LNHQ@QH1CN^>M@2IEXJ<#K.=TI,E(N:%[:P^$A.%.1S>(E@/)4V
M.06E,P<5&13=MD\PM937GHZCC[QM(F>NPW%L[@:P]CL923A1QR@P[<J8Z3(O
M[-=OOS-'^'DL-0'*JG<<C7!(-K)0=+*P4KB:\]S#Q=-:6(>/-_ULQ0VPFT1*
MMPD&?0ZQ^(S Z'9@+HX+SXMHQ!AL?Q\4>@GO:%V.*^SL\"?;X]"2U"W8M1*)
MD(:8*#D+DN9BF5R$O ,\.Q?PB8RY0OV&&+N4-6<59NI$*N28I5:/M^>$4)H$
M,N=$E.+8]5.P?K $>:([/WC=2]Z%;*<'AQ(')RP&>=WC6A/[QF(0T-LA^#ZN
M4UE_]KX/(OUH-PP\X(R\(%5\M$D*2?FVD60<FGY_G[EA)Z:%B?O5_OO+/N@2
M?C@(V,%\T>AS*9)@B\]DWT"EK)M/_-4-LTD!^,0(]Q7!+B,)82'?_4G<KCGC
MV2[ZJMWY 3?$*$K=F!X=V=H$M'YJ9]^XMYJ?B>?M_F7@7V L F[0T9#ZK6HS
MQ8DO-!2UR237BSMW)$XC@C8T8+S"I&+)/H+3<_X@SQW#%'H)"R*X02C5!+U\
MZ<?=@:6_["]T]&\]VI1&Y:_1"T4DXZWV5PP#LXQQ3#,Q9,=]]*7L_)<UJ!/+
M[)="M(S/3C@:L8X:$T[.^OF*]W-:Z)ZF9@FZ(!^]# =HO#33A)._3$2Z8^9?
M)+V?&])UJK9/H1"9>%M'K[A&4 (0,'!H-0^9MT1 J&3R'H5""/QN-QAS+0U5
M9 (>%_5&,XFGN5+Q2_5%/0LQFL.Q5#6$-J#S]!8PY=Q<SWWD;RG+BV,26A!K
MJH3H_?*0LJNBUJ#KCL,Q+%<%55/<WOY:"5>483TC,0_E*1BM5#:6<@93SIF5
M8"'J89DPTRWV=W,Y:1M'@JFB^*"S8QID6%3"@7[;?4.?5=MT?*_-_5#>+P?7
M-77(]MIJ_+H^CEK>,B+#2=EX&I]_\.:J3LD<-VW:E5RTXD1]HJQ^6& %RK*T
M+%71=57<>$5C/D?&D2+&ZV8P&;\Q\J3:-HZ+)W7/K;MH)&RU];'5]6)S"#_Y
M@4_]YF"F1N?\M='MX72O(\K:^_7EZ>&@![_5JL,+:II+UPL6VB33!X[69=./
MV-0Y$ E1E#LK %O1)2L03[\Q*XC0[B$+1.+'G1U,$>NB#Z+OO$:#11;MG0S#
M:%.+$6691MP)YSQ.(HOZ='IH$(4^I0!/"@=%'!PN1/LX&2'%BD>&4P/81,?A
M@#?=BU43=*6 1*H[(4&)?V'A!OH9DKH _4VJ03.<"-'^D3Q'23#R4JN:1L#D
MRQ=E13Z7)W7*3#/XY(.,FT=891X0"0A=<&PN#EWPD8!246NQB%/'92=!=2(S
M\.,R3:%?Z-.1;91X,751D5NS66%Q?>B&/_6P&6E9S;(&77G#L=EVJ#9O$46E
M#OQS267?1W>+N*'71J/88;N0O]5J\KNE%;.L[J>5\[P./\7+(X>/&RKFG94$
M[X6./S;F)M.:-I^&XC.VKF<;,Q8#DT_6?,&QQMJM9W?/Y:VO\!\J.^&P/"HE
MJO:;+\H)D(D!H>@2H\Q]J'\*2<,8!4O*J@A$6FQK"4'_;.O(W#VJ(4,T_JU7
ML7IH_YA&+^=6ID:9%^AKNDRTDS\7\Y$YIT^X?G>Z]A E^W<U\F3EYC NR?7"
M/O-SX,/M["V-!<L\SO>_)*2 U1X_P(TL#T4 ]C@, % 63AW\#:#I"_BDB$S*
M^8U!E/INY5/U9*@PO?*_^\ V?3K6D1EI<R-22ZKIOUM:BN:-.Q%LZV2[<73J
MKGOW@,H'F)!,2XSOJ!1G'+7IS_[1:/ DL0_T[$)"_@>\LN:^@H##N+)A3%NZ
M_%EYJN H_HW)WE\",VFU$2:L=5C3[@)K.[$3JEJW:W*,>P;C4CN#,]3JXSDC
M]K<"@?8?=6'RL; T=BUPIIVR8P):N4XU,R(@7"<71F@2%R;^:85' $>/*]GN
MB$0;9,H^)"2!?F>?V5E_H@U)!.MNDBBNVT@S.,4O'1ZJ=:AFE?XX_W3A1+B+
M2Z#*]<L>5NEONKAJZ[JM,7E7!/X& :KP<BU?A7I1IIRBT,<RG5Z3A .VG7+=
M%B/A5 %" FJ=)$J9<ACJ*]C]&O$M76WC]A(:@X< 8C[$6M+ FD/]E603W]ZE
M2NS[2@!J.*S/IWIH$FTA?,#3%+*7[!$Q!@LAX($ES*L34PH%$Y8 -1:=X[A3
MS/I&@DY3(IJ2<1=%;S0GIOM0#$>C4XU*- M]AC*GEZ+;$:-RFPS3MZ]^K<?.
M5#.'2HDK3)2\'!L#8K.['5S7/;D5::1[C(/(,TB<;[B#C\!*K.F13]BN3,7Z
MFA/)RZT8M65(1DAB"I(2O8Y8&A5U?T@:T#7I'K4(\%=ZL!FY;/=M!<?WL%X/
MAYC,ZI7#)O;B7UT@J^E7?W2^,61U@4*V.*R-S-Q"^'JB$,9[K80.DXC%NJ4F
M(SF?A<KW,I-&>K/ISCQ(HR7(_@<CCUJ<J?@G2NQ%2%,SN0"M0R]WO@B 7O<W
M768EQQ=2/SCZ083EIZRF6D_$:,"@! IL)DG<<<Y755UA@>7^J&JP$.!"-PM%
MII"N:Z[:$&T*BL@\N)X)44I:B59$5'R AQDO)+'"@URM8%A,O'O0H:K6%'*"
M\]U_&0I04D$'\W4J'[UD/B>&<Y54^,-V,\(A<3[?X12%P>.O%<LJ\[)"P^^E
M:@OLR(X.>1:QBYP'0\ CW7+VRDXDU&Q_N?JQ!&KW^3-.C:GTP1S&92'01*04
MH<NF.:L<S8!FP,!GJU)_UQ'-,"?9[W[.+E1?R^>T!?@-<,$>.40\6Y'.%RP)
M%O'HQJ?4 UC#EVBK%CMINXK*E_+;J&[$\%^/%^%Y0KF2;&5G!1^YOV8T<B4Z
M#QIPP+%+"8]]_SA[85^+UQ?O<O=+.^QJH3V[K<+[.64JDO8VQP3%-*"<.,]+
M% K*9Q0!@TZT1Y3\EM#@>AE4WBGA)?KPW?I3 ( =\I<34T<OSZ0$)&&-+1;!
M,Z=J(C9(U?, U^XU;JZ#(8IG$XX!%S[^-43HH\$I-V8*Z26*&#2AJ$?C,"O&
M92^:< G5 N^O+SJ.)&&P  &-W4'N[3KBFD7ZA.?+!0.X>9+?\P- @84AD!K+
M"!H4Q1%MPZ!H/V*TI,8NVD4I2YE&9.B\'=B'B1<=SP2.-4^-T7[*-]*N4XKP
MNC.*K[LJPC(W7W.S5%8UZ4CV/'O7=W<PG^/9'I>;QH9 A&;XY[1P)(301NB0
M>8BS/VL9QB**:"4KA&>R"_?)$IU\05/6N5+B9(B F!$@K2O=#E5@!QOM Q/(
M='W6]=?")+\=T.[D0?YE$V)IP#>YOG_G?2VZ^2GE4.]W2G03&7G5!_#SZD>S
MAA:63W!>Q*Q%F*'=/QAF_>@TL[JP["16UG]N!K$DV#!X24*C'60',)%O,;*N
M]A!VVU#(::JC_"'8)^>R!4D8;B-"?N[1,O91B;7*D&;$H#VH21.@YHJS#UX#
M2: EO142#+TB?YIT1/S,IJ;"/_Z+G#N,[6#/4BQTDKU@&URNG2EQ[#H>IZP^
M..>@A[;F)CD1-7G95U-\'4YT,BAYOUL5Z13?O7P<X]94J.V0QRR&O[\9/]XC
MAV/IC+]JV]&R=AUY:HO>>KX[O_(A4X@%!Y8(BO>%KUR%OR]_?34QW+NU"]_;
M9G %DGHEERT\2H$.Q3Z]68. 4+O.(9E^-BAPXQ*%=]%O_S2]X7]6ZOUR;&#]
MM!2E0"1ZRW>&6?&\NE"\F1#5NH>+_F\+TOZ0ON!Q0?CCWPXZW4$MZ.7:2.?^
M2$1'^7/N +]%A.>I<4?;VD;[?1/3ZT7<UW_[$,&G 6^OVX*.?Z<Z'<]+3)"'
MF:^O=][?7@^\O5\..EY?-CH@EQD >&*H91W7UI[0UAX^!U]H4ET8UDQHRDUH
MSDS8[YDPM)EP*L1P@IOP^KH(\KJP=KJ(;IN(?IMPR9GPB;KPH9M(Y<1(]9L(
MS9M\H_[\B-U\+EVH^YFHV\3H[3UH^\1HK[KHR%EHT'J8=Q!=C"]Z'TFST&GU
ML%A),!FS,,6WL.2SL!1)<+2S<+YOX6B0X'IEX09M83AM??;3PPO-0N_NX8^'
M!M1O0=JV ,UZ!-UZ4--9!/-;!/LD1&=;A'=9A*]91$]ZQ$X9+H,BKJFH!!39
MI(RD9)S99(*DY.+9Y/*D%"K9%-JDE,!L2BM2*J=L2ISMGZ[9U)&D-(G;U,4D
MKDG9M.6D=/79=.VD]-!";R#T\]D,ZZ2,^]F,9_I4XYGYA21,\#G,:&0L.&0T
M?MDLE#FLE*2TT]NL@F3LXF2,X]GL*CD<VF2<.&2T9RBDP!PN+S)N1C+6(#(>
M-WVV1#+>_!TVQ1S>^AR^=C+V)P@I%^^VK$(?93\L33XL018LQ389U3@L/RV9
M$*.^@$HV_U(@Z;$!>:0!V1690#HL.1HYV;$HJ?2N*%!$!&U!)#& E'=71#%;
M#!H@)KW-8[5+%F0H9K<KI4$N_9%<E#=;JG17YBQ'HIE<W&]7;GI7%MZ0H7I'
MXLY _GOV=XUM^?)<3DU]@3LQ!>"N(@[Y#T$C=JL=$M:\GSA[)@" 8)"AC/Z>
MI)V1/&^N;'#NM^PQA5@CU6Q4/7)]]6P*T?0\ 15R@TPCV;M F<@\5;<]Q5!R
MK7Q#M>'<[VBJLIR&FLE[\N44DJ]&"IR!9*SDFE=[/T/W9(MA]?;W2)\,]-!R
M)2*-=,0ANPK2E+^+#74^4^J<&:C34I(G[IITQQA948K-[ZH?&^DF[FMPBAN1
M&FIYY9FW&UHI[ALO4_R&IU1NSOZ1GZMA961L!90@-1;-WY,2!%H#M\V/<^W-
M\DW@"QR/L_GE]\0H*6PH#V26C53\**3%#[1>]XVW]YV/@7*"AKJ1!U9$AK^;
MC0VA<TV'C3S&J42?@(H?X:VO]N3F"^1>C7\>&ZG.DWD4[]JS&GD/;[=3']HZ
M41E^I/;>-E;Z8J+47>!-:^1SO&N#G:=DM?L[=M^'D=3,K<#X8Z%]-C7HRSXH
M_<#=*]_[.Z51?6[@/%!16C_L==]/VY@*S3CH>Z'<,)92O@G(#+(7W+VK8K<?
MT[T7T4\=)5C$*$W!;&4<NES@UI__2]K09/S0[2.EG"#0TXU2G[0P6/M(KOHP
M3#S;,,A4#;I0?WC?!WJ?O)HF2>4@D5?,M1@8^S'76J.(G!7X:_CPCWYN2J1I
M@N)1=/5!(&-1J).A(ZFIH2 M04*A;'*! V7Q'_%LP8\2+NLTX&Y*-[<#74KJ
MW/V]D.]'+-.;J4Y%NOTT)=O4.?+[6>7%=I2Y8HK&I=G%Y;'Z3O*F/LO &&!Q
MNC:PU*RP,I0J$/G$4/'P]_!!J7YA6-"QMAVUS%FNTEE!B&!QH,I)>K=)D%=Q
M\O1A !%-9GEAR7YAI/AQC-U!=K9YA!^$NNY[H2(G'=".*N.,>EG!K'5_3QC>
MQ#G]N&&\6'XZQV2?NF79)$S[Q$OPL#PQ.^JL)*?XH%:;/-JO4+P[/T"^,)/6
MA&S;K-O)O">(GDK:E&N?U"?TK]X^[3"\01,GO6OW]DBL"4EY:?6Z?L;T7PI!
M"P;I8[Y^^O'7O^1W9D/0#%,X#!3UI5.T.>V4##/E.<6<#+/B#/2Q]+\2=WK+
M_PY)6U*0ELU?;4\[,2RN9X\',2PEGI(A6\[Y[0QLGU#[T4>J6%!0%DVXD3:O
MZ\_;D2XD6S)XE:W?61;SYFS 6VTH,F1;6:B64\9<D:5KF.4]F>:XG?1K',VA
MG82_TOF1GF5_A%BT11Z)RQ]LK1=;^AT;XA2 D:DETHNWD_<EUT\I]\LVJTDW
MVLO_:FPOCI>?XC L6U$=21<Z?V<\A[:H!=+57YUU\IX%,1X<S].U:!^U7>TO
MZ^^.Q1Y?._WUNMM;SM\_GS]VM2N\#,T^63^C&:=_B#R?$F1X3&<:_U@N%UON
MHVW4')1_B$9[D4U=V5[0.TUYLITWX$:[S<G4>'Q^P$BCVWSPRX[6S:JX#MH8
MT',>4LYHZ;9]GUU!V5\.&V=]JL(,CV!\!F1&0#& =;X@5V1&[#B#BZI$BLMY
M2J]$1C'V+[>A#*U$^6.)-,",^FT'?H$9;<<2Y8!9*I0)_?GT Z02XP"BCTQE
MO'UU#L#J+T2K6O=B1N]AQJ*RQ)!@P6[81N4K.O]X_O2%947%=HK7%DVD"A?R
M]U-4%5Z*@9=I09D;-3Z$R5>>?"*=!>_\ B^LBB#, F^CBDAU&]O>^O+I$J>
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MQN[#MUHQ_QQ1:W:L@FJ)#";QE&URW#+QN.R5('9*IUKI:QNQA;=GDEH6RX@
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MQBO*>\ CO54(KPK ,=B"_[P#N-G@!C?*D5L!]Y:W!=[M:N!4P;J=+2G<F),
M C #:.03$20U 2+R>8^3"  E*'$P2NR93WU<@2;JV.<[%H42>.1SI +X, (
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MM.D2+-[-FP$A]H/8$&;+IFV[-N[=MWOK]IT[.._?Q(4#'VZ\./+EP!,!> [
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M=4O&>)ND5YGH>LLA60_9D!,IF=226J15?3[A$'K :\J5(1N1']E@#@+Q#N4
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M??'T7+86FOFQGK@7%.W :]Y@#N5 #NKI#@B!?+N$GLR9'_B57+:E#N2$'^#
M@/<P#](4FJ0U?E.1:J;8M^T@%:*UMB]1$D:AC_5V?>N)?^%@-%&16L&UMMR
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MC/.H/%H0E6A!\3&H++,5HBLDHZHYW7F>9;E!K)#!H;,Y:3I /@+"^/%!>%-
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M]T7%2W,48CHZ:CH*>W'_(NKEKBD,8@H;-87!7L-X#>ME^B6.%_^PUVQ>+;V
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M(QS(G4B=G)\T%4/WMQ1,@?:M,\V \$I*I&/U)3<>QA9*R1^9D#F$R .#O%8
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M<H[4BJ?=4FJBDD@YQ,?=CO]V0,YX/"QRV \:"G)4W!8=W">[4_?3_D G_5L
M%HA(298;&WNW"P]SF<0123E900D>2W^'#9L+RSD").?4'?6OYQO9R2_,_FRE
MDP0F+-P4^?ZHE?Z,E;'G$]KV%???HS-K4+#;Z6SF^MSX2D#S.M=9"!#SC/OY
M5)GL;%?T3''4E%?TI%?_Y)2U_V37R>4?YG+#"<$3B.;.I0[N]'S\Y,_X^;_
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M0U/-IBY1G@7;X:FQW][UY(+<C;[NI.*IV#B9])C,6A9YMQ"]*+SMR &SN>V
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M3' %VJ$J)9C>1E@/Y1.6BRJ7ZQ&7"T$<BD@?;"P#VV5C.*(,NJ(030)2WT5
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MR\<6O_;I!R;LYH]54H1NX>$0-)?MY8,#Q!$YU)3I0\6=F7LNVG$!YD&UW1W
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M&$U1"GX/LC,'D@5J.YE'Q4T9VO!K1009G<QHSZTL]C5L1?K"P_DJRQ'CJY4
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M/'/HP-'/0M ?M823P9R^"S\PO$N_L:+^Z)N3 -*X S2<S)L3.CIPZ*JW.CD
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MF(B6[)*/>ZP#*9PBH*(,V"URX,,=E>(&/*"!,8UE(QSU6$6NQ(2/?+CC*MP
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M2U'6P1W>D%&<*QN01;EX;F?:H1T>2(4@S"B&SQU4!E1$!7_(X1W6@6+\"R?
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MRD5C%$8IBT;K249K="042(!V5(2 1H0T3H$JK!YV],%^%+<F0H$8 B5Q#Q^
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M&-;HQWX#F(!A>( -6(;Y=X8+.(9K>(=UN(=IV(=S^(>%.(B)&(?W1443-Z#
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MS#@ \$QTKI(/'23 8UX@3G:6YAS_OFQQ:HD(2A@Y!@!\6( ON=E-;^0#GJE
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MT_,FUD$9$NXQD-+6]M:7 X$^&MR_9=Z#/UW$J([Q5Q%N?V8Q.,OM.6D]:\X
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M%>PUR,=,D=W[..JS$25-4/.5[A:/MER7]3&W!?O7%W/XYW[+]<LM! Z"Z\D
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MW$M\=NOI$!W-',4@<$$]8<G0^A,"YRBR==!O7FIUO *3V3/W;<D3)!@$N[1
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MU*ZBZO!6P9QF@55[KG#IM*?2])/=NJ6)[80^.-K<[T="/PAM?<\ ">R'G3-
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ME0%ML<P <INV_ A.O&/<S'?(7V/\SW;;>M)!.=F;?ZSF43CCX5%3<>96A?U
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MMB<,2>TZF>YQX]65G&%1+SD]EUOW-8/#;FB8/GXEOM/A\4SR-"_U%))+'F&
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MS=(%FCM.@<%>,%Q9>"S&^\?>_VK&&S-1R_=[*!]!I-O=G,BY0]B/W]D'[YV
M/YMN I2YJ)%T-W]8F/GB'4(76BT& TH'L7XYNU0^=MT<%OOZ^EY;XIT"1?%7
M!N1!VVXCNZ-#C YX3+A;X^VEVKKJ=PEJM6^C+NW=?]AB3X6-7'R[F_R)B@S!
M=H(CN H+;ESS:0<SIT<)2F 1ZSQ@UYD02%;@HDY%Z@_NWZ^KT9G9<WCR%VO8
M)DA)1LA3S.O,4W/R(SV,NNDF<.X<XI-J)(&[SF-\R3P_*8KEG#2B-W&;N4 T
MWOO5K\QSS=/V\37Z/)=)MN'\W8^$=O*GGAN-RXG.=%ML<@5EX6V>G#>:XG0"
M$L+VK?G*6V:.F!>-W3YO[6CL95K-D<-K@); P%1:=!4-A1#TRS%36$$_L;70
M70IWO.6?%&C</G0T6KG,#-6E47_/</AP(>$3AN^F?8K";LZS97*<J7P%., H
MW=7;.KD;C!$IT8[7M=O5S'O^UZJSRH?&ABUY5L]X4"%YHFV]H#9U09/9.34<
M;;H9;PR&3T_X3\6UDI+<C[SI(^S%A_9-I7-1]"W]"FL7_6V[[^[3U QZIOG]
MXT?>%S:_D(X4< RZC09LTZ))%?*DE&5:6B6AC[HKQ,[>(LTFLX4H+IH0J%5M
M5'AGALE?G/\K-X4Q-JK\6B5GP4_,?/?IV\6;V'[@!*!$5UN0!]C.H"N3W#2&
M;D/S^K\J*<81W6O8E@4?[]R]GK_7QB/79/[T\2?G;3[A=@!!+5P4N*<7DK"G
M;ZUKF!3CY$"2EX9J"T>'[%@5Q9M6:FM26=^FH[8?O)WT]B+^ZRF!:6=(TFI)
MD#J5Q44!_SP,U/)P?-2.W=IV.I!'3K>P.'GOS^-'\]C1V$%J<X8L7;LU]+2@
MZ1: SG=3\5?HB&X'KI[E"FZ:[N4%M>E%2; TZ.,.:+?6)QF1-^,"X;Z"@0:3
MX*(85X.;8'2TA&N,@\*YVZB=>QH[3PZ\KDH2-M&VJTWM;[6OB?WT:6AWC4:D
M_\US]-B#G\1U'!WE;^>)?C>"M_R1*F4?(#;_@YDB88!3I<36=6H\10#22VM7
MX >+7IX;;?Q*$+(7S_=;)]3N=KQ4>X>OPR\0K>#>X6FV8UV?;4ML]J)Z$>]0
M1:$=#*(@W@[(Z:#NP)\8JG(3;G;G 8/)OR95F"J<3V^5#O2&O_#+D9@8'7==
MZRL=)LG9RY8[H8K)_>0$M(BQ #.RN8[6NIC@+MV/]YA:%!LS2:W,FW,J#O&.
M#%!L5<H7>=\*7DK)L#0NV0)!(!H!T#4$"#<(O>CM.8P<Q"^CE2V[[%-*R9_R
M"Z^LED:^>K(M-&#&3VIU6'Q\3)'X@+ P>BWOP/A[@9D<2(K6MH2+GO:!Q)+:
MQGKN 7 1(V@LI[FV_^>-C(R1GA"5U]U7'"D>>X1"*YY::&Q:]4_DU%+]J'&D
MBE5(>F"*'$]1KUZ(BS&V WZTUKD-)SRO/>1'D-7D.ZCYNS8L6C[EQ?0?V]T.
M51)/-=:#P6+V$4@,G"B%,$QT.Q9!"+.L%JC$1K>C1:OE+P_V8F*JV9=%@E[Y
M797GTS]X*"HE=I.\!A#$NL_)#B&GHH'S*7NP\32^$(P"W&N(,"8[60NF:NU+
MOU+]&.\GF@X*0[93]<]RI;L\Y-(I5OK;JGB:B,U$XE7T;5*5VGS"<T(GM7(Q
MK4&7V3D=ULE%)6!$!>Y"AX%AQW+FS6S#P#B&K?^$Q=FADYFZ?0-YQZ,W_XDZ
M,O8M*MEG$[RE/J\;F/X'L;(SB#Z7?G4E2&2.BQ*^Z?K3Q4I$GI-L&%#]=5_G
M=\\<(67<M&QP(N<1YS%FZC[VC?T\:7J.E/"?UY(^B\(XY\XS7<'*"KO3RU9L
M)W0#S^<>K^H85'UR=7IS:N_^(/<#:ZBT$HHZW(OE-]69-97^0E&'3 $N*GD%
MO?G*@=E)J?JA@.2EGW4I#4^OZCM=E<>_\[K'?]H<]2<1M28*;R$#VNV8JC!(
M(I^5#IZ9NOOV'9,8;RJ%M:'/"5_L52TN'G5MO\'_I'K;=^E(F0.'L\<[@YED
M2#P)WH)A:YTC-).$&H2800QLE*D@_@3G"23J!?0R[)%JA9X;P\943Q@Y 8YW
M:NKJ*_M#9!;*RDJ#LB=F[I0RT@L?79/QDT1/9J7LD%+,LWJU7?70,\G-PM%/
M4:B++/+'WE0L8$T$U7P69)@'H L@F7T$9X]EMK>_K_\2HGZ),N QK,+WQK"Q
M,*9MNYL(%W48_]+U7MOWVQ@-ZE3ZY3^L5XC='\$T#." %?9UH20!%IUU3@G
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MT\=0FT\)W,BPR1/]_@<6;/W/R\Q'\$Y")P;XA%6@J. BIVK;%D=- YR;"!K
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MQOK?NN.&?_W*ED) 3CEK$1X9I+3@.\F 3LCR- OA#VM$]KG#<=CJC253VD7
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M<J1X7+]#V2/)X(.@1CJA]AEZ-O9DD G_R0\EQ\DFRS,32X-+K: J6F0@W\*
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M2(L]#W9UN\V=KCC %5I@'4>%T7+2PAW4>YHL1%MSJ.,/<I\5 K58F9DVD]S
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MB+*E&/G)]$&F-:!+)PUPA7E8+K,.5 ,H,']F2#^QACJ[@WLRM4=5?;PT_D.
M*_\3?2+)3N-FX@,%TUU-L&I8'?PM5)S[D<R+WDG'=[4@$M=:!X4 ^.G/$6)6
MQ,TSBM[Y514_F$(A^RN-#MJDJ\]>UFE^,/"F_YI0[TZT-VL?J#W,K>D#S!?
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MD-OO4IQO)>5NP:^.3I17P-,OK^Q GV)$LB4'7.CCL?27OQ!).:2%3MUE))5
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M?;Q\<X&=48MGB1.W(#]\/U712[FR,7TL@RU(?QL;!!HUT!-;D&%'3X8GE&7
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M@',YM)R>58V:'N_"G\X583>9F9</NHP%!FGOB+RVH_I*GWK&QQ!15,9ID*U
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MLSYSRFG1J?.\+Y6NJKS>R/=-AD4#9=?WI;-C,' 6L@(4)[.#6IT0<8$N3ES
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MC;UY=_U>7?B6B@F")ITHP[.V)3,^7[WX&+T7IQH#8)N'K*=L-MPV<>,(FAV
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MZ%Y^<WKHPJ!AB]=>I)Q4V9$@O9M'%HLV36GT8RGY< _XFA9!$$LCHR J3 _
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M6UVLFC)21E%8,[!EK&A>"N5Q*GWTB&HN%W!#["!G(J\*N3UXH,R;C.C%_JO
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M%9K+Q$+S/>GUAGXJY\$%M#8>3\?5Y7?/F'.R5_E9!U<X@N5<X ]).*V0#CF
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MY#,N/^ZXW]4S*XLG@L^#*T^Q=B2^Q9V@Y7/E91(*W8^U;%WWX/P'OU684>4
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ME,%%Q&3W6S$PM2 &5N4RL$(E-  RU!ETD8?SGZYX+"X#FWU%-/0<#+JR783
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MB8%OSY_VB4YQK='S*GUB(&A.GKU>#+R'H;S.%0-PE^=.\! #:"KDAI %OV5
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M7AS=.?P)[3G<'+QS4]1JP^^?%2HV]7V%54/$\XN7\.9,AT#^0[G.4E((8R2
M?JRVROE5:<F.\[\[U!:=<]DP8\!(4W;9\/E8('\[E YSXV;A;7PH5YKWJ+_!
M7.#/\6\WBM;< /-ONJ@+H=P@B5NU(S"M8(P:8X7PR\=%M2+E!4B=+*G*!GG.
M5VJH=1DS<??'X3VU(:>O76)0,TY5C/2 8T^1Y?E1_%.B+K79N\@+I,$^-*?Z
MMDB+,-1@U2LR*F@EJ\$5P?^F0)6KVJC6E3Y&EL*16I?&F\ERWWS7<L+BYCNR
MC-PY8%.@1,DGZ @7X?2#57FSXNW+=C,>OOLV5\!M<F]Y^8+R:NM>O[+V9GF[
M#N!%UXO'K.@2?NKTY-L/_9@"1]KO,21JU,*#:^CN/X87IE-\YT+#?+U(?RPT
M=@]VL*K9$MPU- :J23Z:L)M+;)&M1QSG*D+7#!3Y#AFTYB6#!S4Q!:639FJ5
MZZXM74L*"H+;PY:FF:,E^5DYE%MVACIW]WPO2I3UK8SC,<?WT\8J^["E)IU'
MEGSDW9.<?O]@X!\1&*_?:3,]\'9@4H^%RY89O^L67/E$>[GP-J&;SG&A#G8<
MYAH)E&I;&_8(BZW,,5QUT082KP72Y_:U+:517S1'C+$#6Y;RJXL$2DG,KGIL
M@? %_;=;W[SM&)E3!1]*YLYG=$QSAZMZZT(7V#2^W@2R7)YH9:G::C2XP%Q]
M774ZB^O/^*D# ]OI&^HBM00G(%HQ[JU#242;]7JX1<0NHQ_@.K2!:TNS$2J0
M$2N[D#FRVW&/NJL*T]/6$'9_R:-/P=9=)XUCL_0^Y!U9]9B[*CBC]>O+@'F?
M@(_V5PN<<EZ?'H^)C];8=?S3Y!NW?*.SJ%3"HNYY>I.HTWS;H%TM__M7.J/G
MPJ!@4* B3(+)ZCUR%1*3%.^K$(0XS$F:;N;DT)C=B07<JQ:\--%6SFA>"6)-
M*V;,\F'EG;D1K/NM^=OINQPB@H)47KE<LFH[CIR$!9=DP6;J6 ;]]]HUB7PC
MO(;6OLOX#7F:@8L:$(T?2.BTUA*2P$MI'!3;CY/=/%;0*@8@'?KT. ?D!0E3
MMW UOA0DU,ESL:_C+Q&TH4LHXB[,F>:FI68'=6'%\9A%,< PO!\M2/EMTV[R
M?#.\6YXDV&B*/'T*I\7S@?:N7-"4[;U)?BMP[=RUF.]PNRBQ"26U*OS3V>CF
M#P7N*GI]A<F,*?<"ESROXY$4KQ,O4@O[+\='6]Q+W=85L+&[6FIET[,'?N]&
MD.'Y&37/>S$ZTX\O]L^'U=J/?Y-2=D9':SYTME$&_H,?"8'OOWUZPQ<_)&18
MS6^ F^'^3L9VT6MK@PK=)M*=XH0_IC@+;0FE"7]\ZV#4'RW2*ER=\&Q9\;/=
M]U9N2J!Q?[YGZ^?G+*0^@!54#7T&(HL!#[/;14NPA6K%@#:)"0I3NM7$P*19
MX4 E,LE6U !KK5ZFWD4AXC.84*>IQ[W6)@;B^N!?4Z7(KU>YM@*!@QAP#L@4
M*2:I@N\G6*# P I65!T!XT_XB6+ IQ0YE^.507VO>13< 7)41+8=)>DY>V ;
M;^.&"==DFXF!IKY6I* J]T\+M)#KP7-&D$X[&\6_A MI]=T+F>5 6K90Z-A(
M0%_34G=+4AS!XKU($Z<--0@.7L0C3A<'NFZAXY+9EX(2U/ *%;M>WC3#IBK_
M.,,]L5%*YDPPA?/Q-ZN-9[=_O-.4:JKWYHC"U]24!Y][$]R^Z.;\]NQQ1H+K
M@^PW.J.9WVH,R6>9:,C>RD<,'"J 87 JN7!G;_!<#-S.;:7/6>#H8D 6I2P&
MO@_5Z[.PTXO<)-XUJ)O9/?B#2;])P:X1^'!\YJY9T*+83-''^M/!YS-2$WF/
MKU(IAD\+ KS.W9]T-[O&3P[46X=]<$Y>HRJ.R9O4U]?WKNT8'&'%=/7V?F5.
MVFGMT$X\%:/[X(UFNV%FV!/W'8#D0&4!D6R?%; [USW1ZW*)?8F93%^A??#7
MZ!-.9@F%7=9SYS,3T@HK=7,QW_HJ4$<R>O*KG81R27\-285U>R1/CX+\'0TK
M\V'?_,R0PGC]W/SAR=UZN+G%V1:T7\S\!V.#XN3B=R^._K;J .;Z@/R+DL0?
MF%V^I5F&Q3MFG-(U<[AW7)H<#[WEJ_E:V79ZGW]HWR-@[.K$=,A_@7OM2VR_
MJJ42L_XP%=K5 +#)F3F[I&$%"_/H@CAP,<A6L%734 P\_1E=D!>N0 RD]=]7
M-C/V^D1OQD081#^HXOC2\[(Z/#T=K[U+N^\S$EL7'VZ8Y1F4AEG;];9IWT?3
M+4.^]0E+.2?HUJE!8>M((2_@T1-I"S^>IJGK4:1BAVS"3$Z]T:A]5UZS[.VS
M5>:G!64C!FDS ]Z79HIK1L(.A(Y$?B7]^1 ?_G12WV'^;E$'6E4,!";%3G&J
MQV92SH8P[:Q4N;+M]T9P<5\CE9H7U!#-<JM0"E"5?E"  R;(O]^@\F/W8/$6
M VV:_,;?SJP^@1]7CC?!;/<_F]AQ/RHI>*@\\3>3*;?FMN-YO@EZQTOLKM0\
M>.K9G[C!R;+U>.JJMW(S$ZC%$]/3695A%=_8@8.+(49U]%^X\1?>+E*,HR4C
M.A "*? >XEN2&%A!FE1+RX7)8!Q*LBXHG,R@-(GZD8I,[RRT*[7_DOM63O?-
M52W5:M&M[Z84T\Z4R2S3.[_YP!G4W ]T!UV@YB\&MK&@^V+ WY,+9[ S2<)C
M7@;=ZKM)^V7?'45W]%!HI>\]ZR@9$=M65-_^?=6VG(:]WU:)EH-C;/;9DWW@
MQ>Y!+PTC-'?-_=74"H_8+VER"/2 R4.=5((./:?#Q"*47>SR5NFSXM$$AO6Q
MX?TJPD6/11',?"/H[]<1Y>G"3.0=Y+P_W6-B=*TVQ%J6X1CI8-Q31%[83OZQ
MMTP,S/2* 0VD4 _Q=ORO>/-$ZMSX-)&_17!6^-+:9 B_'%+ ,FI)L:H-REQD
MHA9ZW509+N10_ %.='W]0'5P2!%*N6P_ISE4X8[/LE<&KWJ.9XC*6]R:&-O<
M6IC^1V(TH\W=2KS(._1Z"R2_6*2D].Z*<WQ3K^AA=3P3HST<I)W&KE?T#2(A
M_U+\\U#L5-A-$T(X84_+HJ0"29IUY@QW#JK%CGRQ;@,7P9A-N IJX.1]^N<^
MR@WD/?4.K+'JW1*X;MV+2X8&YQ.-UQHH-0PL9QH<[%TXFCD]1(EYFO=)F"U;
M%OC\X\C@R4SOYRT#U?I2[W:]'5A0V-TA^3;&_*S?U3//U!)T=*62GJ*4;I40
M6QF3/R(L/H8?+#'_;M<4L#NZ[W)&<,:HHM-NNV]ZNNM8VJRM-<D5'AX>U-!J
M0DS!7S&YI\<ZVC7PO&I:6-7Y[P/JPUMK*U]5!0Y;$B^P9Z9[<?=+2PKN;]B<
M(:%]I:8\=Y>D1R^1=P@:04R7%!$&/;PTHHF-CO+,WR'C%Y\"S,BGF45(]2H2
M]H6V(G1E<E0_M>]<1<W-7NBEA^&>IR=WU5 N5ZKH>EW%;.\O9'SCVZ[G>\W[
M%/84@''/A@)V>57G]#\;<AQ]4ZLSDCJ=6DH/ZAE#<![@:D5$E#I<IC!,DLC[
MY_\@VL93OUWE4D7KLO7$P!>*WZB7[P3=3]3S.[5/-'(^(S%IN/A2L6BDX.V[
M^VA/V=A<LVM7:BS:@Z4?*97O=-_JZ(#-GZR.:0TR2?2=H!S8U=L[[$!]1$%6
MC+,1@U,:M>K=%6.P\O!7#-]K??Z3VG":C$_;NK"*\HJJI45/^OO,TF_4/Y_A
M3^?TR-%M3 R"E^&3AW;@:AF]4$ ?\S%21ILCBRO]A$='!@1MFD)RDEO'-LM0
MP>4VJS+UZFR_QN9^:*S<.2-)2Y1A6MX](;7A#/>/&_)%.4FOKT2LBKN2ZT$:
M_(X:/)ZJEA:W$' H/4/>D6:"[3MNEE<Z\&+J_V'NS<.A[A__W[G;%#'9BYA*
MD3U%"LW<$4+(.EFG4C$DR38Q9NZR[W>$LDU"LD[VK!-C"3'9,V*VD"TS9'IG
M%K_I>\X?O^N<[_><SW6=?\X?[^O"S/6>U_I\/I[>\WJ]G)J""O]#$=)BC_ZZ
MEGZAP5!^[;Q+U<V.IYIFPPL#+JO5S_6JOHI_[9$<\G]4K"MI5G6T_++9L:G1
M)D0MN$\$/.VZSNX?#U97T*=6I?7X0:)DSRWKI[N@JK6/+LL\0KC.$&)_^#-:
MK"^M%=WC^+6D.I:??>>;*.CT2VF-^7*(&U6V8)/\7BBY'>X;7$9AE.DS>WRW
M=UG/#;"M6_WN5(5R7+>__N;\W_!C"S_-Z>9K!) EV6AS5G;*27-@DXE4O&CD
M14<J/8/0S6,S&>GZ$RXG4\8S@T/NA)RZ<>@J7ACOQL/!OM&PWGB.-G8?;.LN
MZEZ6VJ'M1J79-*9ZI& J0^>_7?C1#E_ UFD*<.^#T%B,E-W?1_&I_8@]J/[G
MF7>9^'C+VO3*8J1LM/3-R_;@8T_W&T7E[( .#U*D4*T<$Z?_PB\&7\658GL$
M> 7:AP\'@7R_@$"@W?^ =B<*^EY;$?LQC0'C2!L)4/E-TL .2%:=\GN_+X$M
M-P7[R8I$?)[;4[S$NC0:6F#K5\P?1G[=J+OT/=R)NR2'_0\&_FTXA5)#X4IZ
ML1-XS6@=.D6&*ST%%4&Z(J+T5@+$?)G<ZT#I*V"W \Z^I='JO4UVZ?(G+3T1
MY]0KMO5=;V"&9Y()TIS&<])/!K];2:=6F8C$127?=6U-5NT9MCQC8VLU8'VR
MI?%Q37+Q^.V\8K85_,V/.0_;.-C_.R]N9[,_\F(Q,$P70E87_(2BL&JDK=(=
M((FZW=?3XIE"%<7 CF2-;ADV5ZZ>R$,R-;OE4F8^C,Y,Z^ZSJ,HQC/]E?B)C
MF$_: =6">_%D+R)"D>O")%J/0*[R<M"04M0*O9^E6*FKW@XA;A=4:*4=S,J:
M.B/;W/+TQX&YC>EN[8" @^DUOP/MCF+<C!2,NBY4:KS3\[)T9/D&\V*N3E7(
M2;FK(;(LJY!=S^4P/[^]KO[RJ-_J6<]F1:E\Q,# CY5(&?R@PR+I/R,UPN6V
MOP2N\/[/\S]#>G9O0"P4#*1QSON>QX*@,BA;AE"/;5(?8U\>]  JJ*M KUY?
M3KH"V#94];\W5?!PV^/'B\9!MJBS?L/[ER 7<"Q_'%>#Z$O[PNG> 1U$'V?%
MF8_@W( >:@0LG@"^R?1\BW;,^16S)?^F_EUS$T?T?>8/K6]V)V58IDH6>YX-
M%,=)9QZ=4L4GI(JEGCO@(&T06'74("^RKE1-O+O75U35A38O-^3**CD];&%F
MY__>VOQES]NUT/KVW_Z_EDHFQN#-FXC_R#+L7.?</:M?!MR-#"QK_Y2%+.GT
M#CI?//5OMHN_3->%G.]?NT=:^H4R%Y24A.SJ&12H!O\30@8CS#7BY7:H !2;
M,3@1T1#V- 0'04/BKK9EV$^N_[PD)&#=:+_K4:ZC]K-:P>TW?$OL%0PE!S5L
M\/]VOUK+OZ:G]ASIF'_:L7O@>N&!1V7.>0(PNS"&0/:FJ#6XNAGGS=>[J#N2
M)]0]JNQ;+1 -,U8+J+[_J#;VKK/$\.T[D_!WR\]F>4^MM=P,7VR=[-">YZ54
M*AX/U6HCS?Y6A+\DS,_DL+5C"+N-K%BN,XR3;$\5 $OU2WL*$=,+2, HCV)4
M@!SMO7[0XS4CU;3:9F;ID^!9,W ]*J.OSN),!.S@E7^_?C5.OUI]GMI25V@F
M5@*WD9K2_#;:1+C0):]27'K!]!+^U%>9ZD'XC*TA;S+LI_?+_XA+4O; ]<^?
M77XX38'F!^BU-TPP:ULX"B439-VLQB:X)_Q90%"@W%4F42-Q0^/!]4/%8WXV
M5[$G@T<X%>9WUIKNX8K^%MC4__6#$-]W"] TR]>@H(@C@@[/=IP(\7?UV0'Y
M!DCT'=WN*'OK.R7>;21$=18WAQ8%!>D&[CL5?95^YM,G*9F3.R"< O95&E?N
M\@Y(^11KDS]<VDW8?H*2(>BP,#KNDDF^.K8KOT/+!&],'FX#<SYA.QTVS+<0
MIE+PC8L_<$D49J 0M]"/_2<BUYH*T'AY@*F'^3Q%_\4]*KCE:5>>P(!7GPE*
MLUW;)HJHU_T+(/P/>_J]PO?L@/ZG<S;6]H*D[$S_'R]I?CB,&?I*2% 60/1?
M,/=V"<X3N_ 6U4'XW$(@6?'%!)D\X\]K.Z![90(4KS#IV=K.CB)LN-TBK")>
M[("6HI+.[(!"LX$EP<\^?+?]0D_/7A)5GN@]GQQ^TROU>3U\JX9^H"$P^6!(
M[[YS*V9"KZ@W'UY0Q-GZNI[>7<(,>&ITER7?339_VJ&(,NDN,&1EM3_TU]46
M1IE<Z6 )Q8?X_9NF?KD4Z7K_W.S7EIZCZ81LQ?&4([.9E_66SU-J^]8NAK%$
M[ &+NQP#]/UFH*S(IY%_:A)ZU U]GJ7;H3MFI!_LY18@CD!A#'='[(LQM);H
MJS"(C$FN28-IJ*\($K_MFBFS@GT7B./\[8IVFS RH5;)LZ-Y+_G'T+M&H&=1
M<+/WK'VM3/-NC,:&=PUK5<XL]Z3KUGR22.A(2##S:U)5=2[V(3M)2^[<=@*5
M!*B25E\R5SKY$. BI!LOBQI=I.ES)8H8MJM)I?P1-G\?JSJ_'.T!]+'4'2.]
MC)GL_%)?%*L@CHH7U<!-3Q8<9]UL1"V 3QK+7V_8F*X.S+^ED_D0.)KUYOQS
MU='@%354@EE1_L7AD/:2"QP583VOH[KO?*UD]>UN9Z0J:N?>,,ZP&'B=U&J-
M?%-CX1;IL+  V%MJ.U=Q-P _*J*7) <L=D,.HH\PL73;)/Y)P(%C@7:@@@\"
ML!M31K=HG45?13QNK.2(X?P#L:7*V<&# 6\O=5LI%%=*.-O[X:/8%KSRZK:0
M<K1V(R\':NB.MOS\4QTLN0+]*XZ&32QAA6;0(IU-9%[2+YE<\3":<_TN%YTX
M0O8=/5:3/UY^[>HQC" O=;:5!6FO7>18G1JN*5NR)ZR>8DWK@0^1&R;8)25E
M([>M\KW#=;.SZVZD/_A:T1\6./_L@%]6&LP:T.8+1PIRDR& #&2&@@6>)8XY
MM@S=NP-Z:HNBL&$CT$OZQ!V0W%(81 9S%ACL(9<FK.IRU"]9$VCG/K?IT-P,
MW_]41QQ"U53U986Y[8FQ#KKG?CF75G?MGML_ XP71@H']UH,YVNX-WN>ERY>
M<0Q^OM3[7,74^ (&6^GHY'&C?XPXZ15SX8)94&[<N72+C94!VMVJ!C2Y/<-Y
MMIL?H1<PG<M._6PD2==.,%C\ $YVU2?B]B\;I*;1"8K+,+"1.9*Z+KH<;@V,
M-OB)^B'2NY&3DDLY15KY;P^\N;&F[>&_\.SDS3<>WNQ;O!+T19JM&&JE&U9'
MZ4T!=RKJ='S6)1Q M3H#@70_;5$@VYYURY19G?]Z>0RY@HQ\3+^7KO=9DX$]
M!S][K$;RQQ'>=^8B5QK"]A=,7B]"M)S92_JL4!?E,/\HO]/S..^9D3>SJ!>[
M&WH2[3#9%E*%\%V>@H>#X[&TF]]QN];0.@R?4] 3D^C+=!QX&:H[NI6O]5&W
M)=%J_O(H^KZ@O7&8CQ1Q ?P1A'#RW!LL[QY$2L&>*=@==4K<&:XFX,4"4Q4[
MMO4[\\/^'D=[O<*,0B&X[G#*A_6$?U'W^LS?US,?$&AOK&_U?'VXU+CM?N+^
MMSJ^$GN<"H3617U2NZ5R^GKO9KE.A=QUO*R:G^BJZX.V&JQ+L(?*H&6^A;$]
MV-N2[&RQH7H*169;]_UN;GE$_K52WK3YA5)GOB:O,%QVAP*"ZI3,)3#:]6D/
MFGPQ"JC,![II"2T#)W/,B>TVDC<52;WDRJ KVV&QI2+E'L4U]>=7%8(H3:O'
M.0$J+U(X"I@QX=M/?RR8PO:A_39,O(XG;GT1/4VKG'=.7=;>^MQ2VX:&_XQ@
M0  UV]6]M^BX!,733%(?5@9H@&H+QK<3!L2?:9*[C]C'/_8] X#0 J+NU[O9
MRB -ZEM*RB]7 *57,FR:TPW]%=Y$.33Y72YM2W]I#Q-G@KG2&>S($2,O#G0Y
M9[$W(-&Z"#C'%]'D6&&^P,1-? HNML@BZN!IP2F8,5IC8=#]*B4__4-?9Y?H
ML%VOOWI^CW@YUPNKFV]F=*,=[+/K2XE.QQC6UET=\CHI%M8W"TXX,F2%'Z74
MG,F2T.S9M G.<VA9\,W?,QHR@?<K<ZBUM//0'MET\<WD"L3"AU!'ZB-) $((
MH(Q&>D*1WEJ/X4OA'!I9L.Y+D _0XP0F(JY:UT)&\X&F5[<,6[OT2W^1Y8IB
MN?)SK/?'3JU/U_[&OR-X40#EL%XLN:D3)]MQ:OD0JH)*(8)C=T!_H9&LOBZ$
M!-J).=4MVR$,O$?+*O5%4BE"?@L>9[O\?G?KBY'S)!%N,TE($[?^=\\X\F^P
MG2Z$.Z*&U*:H5TS91%WMF )#0(=*(@O" SN;!I- "P&%+.5?=$P^JZ+;=;*$
MQK,BUB 5#9C8KG;H%%TA52 ]TMTXJ?MZUD'$;+8,7 :"W$C7(S%EN5(K;(&#
M15LY 4_PW& @BH8]Y$=@6@QILV7CV-[86*C>>+V AM$WF6_;DE'E@]WA?V=_
M,"<JGO,2_36S9KF<%>;0G8/KE_I4ET074ZV(ZS8'_TM_&"*C/FU7L77-4[D2
M290\76&WW?9]G V$!U9M]:C$%)=;1M/DRE,LJW6_EYGGU-_):4W3M6_/RFZ?
MR&W22G\P9.BA/1\JY%*8>+,0_7&DBVD9=WWF$6@I+_C(2F*V[^:'Q8P/W[9S
M8J?EU'V4L!W_]J9$Y9U])53 C2*%%Q",(UK]P[Q>WL>W9W9_6'Q"\C3@1?J0
MFX5\/GY_>%9G3*K>_HCK&GRUR=R'-+VPN!NV/-..K48(;(IOA^<<Q$[CN0H[
MH/%S5O@-O=8=4)H5?OM7[@[(M %;#?]OWD3D!NV GFF9"[3&4D L\21S+?XI
M6Z;V$ 1K9RK-'0ZGF4I=_^M_N(18$?_Y8X*IC;_^OSQ32/H&"22L-/3QGULY
M.)Z)%!!F]11DVT[3&O']R 9K.ES[H_KV'8&^P02TZ$\G?1FCZW>E* MX2XGW
MND/.#U>OG$FWC:?49*^Y,0Y #Z*:NI)*EP[I_>K#"@:UI/*DIG\(W!I*GKNP
M:IT<=;5Y=+YM4^G.+>U-_6LZ9G<D5G?9'7V7\/?,Z=@[.D.'GCVDJQ;=2_4A
MWL\Z?^>9RXVH;]XOX>SAO51>V\,U>*&G]%W3*;O\ YN=)<)??']^*ZBIBNVF
ML:2^9<0XR5ZPM0QB/UIH^.D[U9@Z-3EJ:RT7^!SA5(>8B7OJ3_#&[D*["&KQ
M J7./T!DK=#$:CC!",B3#*XTD,$Q17&(T#/,A33J8(3F!?15X#&30@_H-B>,
M<$T#:,@B0DW6#^6LI?I";^\]Z3,S%?@"]"U>10-XFL"&"F[ZG'N%Z=UM^Z7N
M.J_:C?T,@!5;5*.EF*2G(6G"E,$*M"IS.(,%=@ ":#CQW)G!UI^XM4;/4U-<
MPP?D,U,S#LUCY+,;<GQ=^\.OQ?<7W4 GQQ]4ZC]SUQ)RJHA\>R"]=% ]\Z2B
MF&J2W_W4=,TV-9;JU:]7GHP<3A](EGU4(6$!^L?BY(8UNO["OKC&F&LV=QT4
M]FK4AF":HHK@D@DNX8-%&GIHJ_)FIEZ6>][#@L&LE&O.R@^<\M+/;W^J7-NK
MH)RMD9/\N+DAV;\X(^,7/FQ0NI"W0NC%3C_2!E36HP52<@T0H4ZE8>^FV+*U
M6-*EW7@Q%(Y1V@F.#412CNA=,E@.D#2G@_>CDHAD0H^' \/18.7K<H<BX=W[
M%*WB\Y.-9T]&R!4"2:PP-KQ!T%H1IJ7<_4SM#^M',1\-XE9UP@K=ORLJ PRF
M^8<L.94>)/KL7]96'\A]<7K@I&U2[RRD6[@E/^43_$Q_^5GS@_:F!\O2J-U$
M\3U2]E5JPQ_-?Y"#Y>U#TW[H?B2H71NX8TJ[(:9V)NL3Z;!XC4O,^+.'CN[^
M7YJT(;.2J[_WS*-GBWS0!^%J3,K!TB."6$._V__22G&<EH"9&+"Q#/E];G^0
MU]+<>,W/]IC,B6MZ5M7PK:9[>4J5CV7*W*Y4XH5^M/H)":;FV<D=T%Q?O. &
MVM';BTG<(,X9!$!BWV[E%6R! :7YM*3JX#$D\S5DC4 6[J-1F]ZYX:6[5Q[K
M)Z\&B#N3_G;K':\J=;K3)/%/5PR^AS*=3N0?&*0:0IYZ'@"., C33U?8DN/!
M,$4@J <BC]F/OC JT-H4293]U2T?KCF5)($*<P3J*KB>C2SCP?+O<.=L<?GW
MDR(1+DHQXU-,KZ-RP?_T'95Y4*:=\_&9L3$I[W>K,=4"Q^A=_556<W_E.&_L
MV O;TP,O^&-RJY(?"0^_FN%.?/HP4+81*]*C3^N0T"G<?R^$(:?'_)+X?$[Q
M>HEK@W"(*DGRPO6>SSF]UC9G2Q+8J8Z/+[JK]3K'USR:V#"=U<7IS>:FM8;)
M-#MUR+O\AGP7Y\"X'B/!5PG>*X08R-$=T*T=T$%L)VR-0,TM./:YJDU^!W0
M3"2 T8\:>$4_^#((,JHN6"XZJT-C;#U$P6>XI7R6M,OW3&Z\I3M)PY1 &OX@
M7==T4/C9X3UGCJ7:7G]HJK_JBO[D?3XKO;[$?>!FPLN!?YV2GI^*/W;(8MC4
M U]$^R%72MS2V8Q5I7M>O/4\[]WG0KM(US?G7Y=Y/BR#5=WV;;N3B;Y29..D
MH*=E.N3#L*^HZ ].?YI9I7+R]W.9A))!Z?X0*3*\X6?KZ=>)VU[G>& 8=0SV
MVQS2G<8Q("40MI,!8<);2[X1ECJ]'H^KUW]*H!;,Z30 .IP+R!V0?' KB1Q%
M3R8W5CUF%1$A!Q'F;0@QE*A]3_!:F/'$FW&G,3]>]9%;R1*.2EY*VX<% 7R3
M$X8=>>*#!;+^+)/^G8QG8(P&:Z3?]\67=[WYR^QQYKU,]S&-0CNT^EP)XHA-
MI<*VC7CHY.3XKW=U5F!3/4W5/A_KJM:W]?QK''(BH,*7):W-[H#,]A;N@.AN
M?U:=+YQ- Q"PIC#>89FX'5""_Y\E^"\&?FNOYL&YO$$8<TL0:3>QN,7I7,Y5
M-HXO4K8#^HB+^.^?^_P(X$K#V2S!="[&D+![^;( B=JTFB%$7)=;1AQMDZ6]
MN#7:<0+EQWX:(._B^]GWZ6(GW',ODQ1;SW.>G+JQ <<FT%M2+^TM=$L0?BD>
MM[&U Q(20KOP2CKTN/:\)*,PS@T,Z?P.J,Z\I]V$[35%J$?_Y4_GP*3-C;19
M)W[/V&\<,XF@%2WP5SBRSLWM'>Z_4RX@T@DWF/@XUGLMI8%SX0T;2[0:W;H\
M7=5;FQHR2I)RSQ\Z+&04&3>8V^<NPO-EG>QW0-D#F8PA8FK%$;M\W5+4P//<
MA^DI>5/.61TV<W 8+H=7(*B?"(I"6R>29@:[H<I :?GW;<33V[QG!%\1!==+
M?CTRBJ)Q'K(=(G5VM$A8MT'*4.5YUZGXXQ:KND4'WS#=WV>1514UX Q1<PT=
MFT+EQ(O7S[ZW$/<P*1MHG-SSP.'CA8]KB)'FZET7J]U2![V='6^E$IV(EI72
MBS9Z-ZF+>X? X:JSKG9ATU4D-8EO>?<RO]X]<I*-KC*\I,A>Y8%7<9U\=5XV
M5 ]]0E!0$T")[00D,(O8MKQT<!\D'G$(HPS &?#D>D@J0A8J@QFQ0_XBFC))
MR0+P_Y5M\ !/HQPRNY=FPA*KN=UQ-,HU:W#MCMN+<?Y+/X0XUCLW+07'M*6(
MHQU8B \O,2<!?0$;-()CVR+*T7\#3YC@GAPN5#&.!FU6B9;LS>:#4XE=C7):
M36]-2N=007^GS[X:E5L@F=>\CX@?P&T6^?F%/7OC<QSYTKC^C>[9LV5[+Z,?
M'+^Z]S'U'[/]4GVU=<]*D)HWGRV2[ST^8?XX,7_@;IC]J/2#RX^Z%8,0X"3F
M<I9:H-_%[K'2_0OE6BB?R9ZFG$$==FU5:L$I>(^-SB<I;[4?#_ 39S8\!P2^
MD"_>8PG;^*$YEXO9M.-1ZFKMYGU5W^O??;V8/N%*^0KI(I&Q;%^ 4R08VIJ8
M,YAI165>;@/L""J(/<Q[S94/?*S\C+D#^CN*:*"53R-)N:+%DGK"]\6^2P+O
M=0$29\RRQNPGU^!7O*W\RE1V&:\OX60P6J@K_.$=D.A/6T 5T6L[K4_W3Q?<
MWAZM1[_D?1E0H5/B##J>R7Z -!J@8>/HL$*4W)4,N]'ZS!MNB*R%X1\+FL?<
M9I:S;>M\L?NP]QHUE7)1(E:'$YUUE)=.*"C]NS;XZD/7>?B3OETOI5.>B[;(
M&_KD(JU'.B444GYEJ[U:N]1G,E>.4;AUUS/3\G&FK]3;B3+[%+4;KH$%$I*]
M7H&)!0@79]M=&7U_XF(>#S_!' M,*AWH24QW_I;D[]*DL@Z]8;;I7,\7F6[P
M:PB+P,V9]X*/ #8'.A3-.0%H.UXJ-X#.60?4 CIG(]BR.%IH#9-@%["/_\D.
M-; [O$.SF?GIT(WOGONB.D\SYV: LJ&\L 4OP_H?KB]IZ\#IYTV>DD -_BO7
MC/>BDFM!!0,:P5@07\[=A(:("M4/A=1J53!$SQ/A.(LGQ\U;F4/\C$MCGMR_
M4^[$FCY^4#QN,QG(5=1K?^=,D3+<HWAYKMS1[2!.:6&/!B@=71B_83&3[JL;
MV_7WJ51UN&/TC'H\_?C-W?M H2R9"SK,%XS#96FQ@*I#M#ICUOM [_7$P243
ML!4EJLQ6-(Z]F2*,BG=H0*F2R!-EGI6$1)KT5C/E:DD$K_';SX9OOYV^!OSH
M2,I\T)RV"F:7M@'A1N=8@U=XS]$!'#V4/ITO@.V]HR-ZV!C,R??CT,-??0S
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M5&P]I0?V%SJ &?<A( I1-X@.8&'C.V2!*'IO6<ACEA<1(O*S:C>Q1391%WM
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MN\R>;1BJ:B>>)E?IZ@P,%"^"6FIV&U$#"_RVW!E_(<X-UMP0/CP]O]ESV;Y
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MX(S3'4*\90BU[+?2-OYUHOKOP[]L__^SL%N (E0&87J&KK+F+3"08-Z_!.^
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MSLZ));Q9)K]Y>2LD).#F%:VBRES^_BV.FTJ754!2Z#;EPYJQH8!O6P+(?9:
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ML]>N*/YYP-;YDJ3D,_R!9,E>:R/),K7A%-_4+.7BVY/*4G*);T_%M;06+.^
M9(F1;K_L%RRG+)=_U85EMOP4U,<,%4!?7PWBR*/JV % +A.+X+W!Z*$O\TJX
ML')2!=J!9=T4#84MP82"/VX-*0]2E?/+4<8BIN.5P?%Z\KF]DPSFH.\%TS#-
M?PAR@#G_@ /'!1BC+F2S(JSJ@<=^8718C$"[SJ/.48?+Z*T5B!3!=+%E$J_[
MZ_="]05VIS12.J:M.WBDJ"#",*(*0[*?T/!_$'!?8[$IOGDK8)K$%VX(XT !
M6_Z!)9HC<,2?/LY[:O28M0/J9?_",Q)T,U@6'8: _0ZH:V.ISEC7L(862'O>
MP;GM7K0<9Z_S6UG=GS-%>/?'3@!!"+U'VH>68LD2;8_. 8.T["Z2 OH$4S9)
MD'=V0#T448R".RJ@Q_7K=D'<6[0Y@*0I0 <$G[0]%5T_4T$2>XU/JJ^"($8?
MS*>YCFFY[;E'F$K66+8OM(P]&[VI87IUJF>\:Z#^3$/0P05'AO16N06-$1-K
M!_/FM-0C;ZM=?_6\;.!"8*1'\4R@KXZUJ>6P>WWU^L#L[_PK<S7^GFXK&VFI
M!.H+;'U3-/8.[A#F"\L7(FSDS8PCRD&B&O!R?52(O"T=<0BE8L-BZB#!U59B
M*>#HZO7@_OF&1H&MTBA2*^&$F.IU?W^])/F(.-083QM&S52",*W3OMR!;.OM
M@*((V['($.X^S&<*T]5:GH%8;> 88TAD[&I=(/62%>-7)R%*X-A;'G[7 ()F
M'Q$+PG>^_SG5. &5YZI$=9V7P\95M7D$E5J\!;+Z&ZQR9]IM%@P3]/2O'@S@
M;6,[U79 \_*P=R1>SI^#^G@FNN5<0H_K]/P#Q<&2 AJ2YB<PQD/O_BU5DUSH
M,JJ-YOV^7N4JD6ETK4;J.:[N.<U&,E,/@PRE.NDY8X9MK*:U[HUY_C(D+SUH
M1C@69(_@,':FTL#QY;U2=G__3Q>D9_V_CJ>T_W,\9:31#=@Z+D51TF$[*LV7
M3^!K[8#Z5?YLG7YGLY>PG;(<POT'^U\+Y;4!K2;>T YHNX6KCICZ,Q1^G]P!
M2>Z 5@M0@E_MVFT:"KGAL"TVCI\M;N7]?0>DQ$4<^]^6KA=&_=#GA;[? 8TF
M^/KN@/XF9:<.CF NV]D>CSVP</UPS\':F(O$PPQO$./? ^X2%SOI)6\LY :/
M/H.&6LGW A<,[]BG1 V+C3Z,4/1QJU@;]UY-XG?":N>*:!1)M"ZSKYN2 L?6
ME\9A;ZWOY<_ MQ=JBE&6X&BY^^&4*%W;PRL0H?EW]3!F^IR[Q9N5?2OF+'>M
M$S'I(E8?IS]5(79A!&.XK@>WID^?=>OZA976A42?06(4=D#13T(HXBB3WH)S
M#6U>&G;5+Z7CGM3/.M@UY4?G]@Q].H",5KMS\.^JE'/L88!1C)KJ[H#5M3#C
M69 D[#T>A&T_J8@X2-1,0A__W';J#4K%MJFA3O^X/_=:B\RS>QFH)QXE.:M6
MP?X3Q:>-L#18;T 2=I=>!.X0^C"01E^/=5W[\9*7$E&),H'G6HYKZU9][.U:
M1C7GS!;H/DJ&;C_5\12#',@;ZV*HDHZ6)E;9BFIH^M:6PFXE"$#8SQGETJ5[
M\;G380-I>W=2YOF91NH\)'3$>O-41+_'H[63OZLB6O$X&PZ[@(>K(GAK*TZC
M) ;IL7$L5_6U?10W0=5SB7-2K+BHU5?ZDD;6I0KG>LFA+\O[C2[KR[]_Y6<V
MVW"T]AD"W_$74^4#:4;DSU* UDYQK@00R53O]-3B-:(#F$D]UP'#-7C!<59<
M+/H2U5_2;>(.JR]%S\P#T1W>E+2E'O%,_=/GSC=8I+S_6>D;GYOH0CW@9)@T
MYCP0"Y9!(X 8.CX!JM(X1A^MVJ+(^F;XDI_+W=?P5#]<K?P[?5KAY>2IO\(D
MNB6'0N6\UU18?B9 "#.-%AM7^>7[' 209T78 8M,AMU8,,N/'JE"URH5RS](
M3NE]7W<D0..6A]905?UBPNV$2>.A$Q_M2^6S[QUN4T3()MI]>CC<6J"EI[+?
M+.3=X3;]QA0UW>]V%08AY9_S+GXW2==YN[1QT>):<M$1J]DVB&;1W4B5 RZ-
M,PW/,R;FEG]]Y1D!3:RZ3D0][ .>W-2#DX3=PT<WGB?4F*\9,HM, 6O9KAV0
M6"E1W=J$!D_$'$.5TM@U3*N>%G9TU=L55C^2EJ3PR,/W9W_59<V>E:+3N2FV
M:00IZ"$D1 %+S:'(:V'O4)Y,A8.["=,XVA8#+?;NW7@P(L85D=! B@_RD0,+
M3$?]8FP1O8G94"M2Y%_YM19XN@DNO^KP#1\%\X',D!BP-5EJOC=M,=Y(F^E-
MZXMIN\OX#E7GVM8!VDPZB<8ER&)49ESDY;'R7+,L\O962*3]A*M;JU7$X9]#
M!I3K[YO;W<QR0O7H_+.\5QU**!9F%S[^WN<\S% 'F+GXI.-P9)QY*NGC9R-U
M/"$A.)HE-HWC/-H*L3A2_>#;AFA/X['310O5&EJF+FI:)7JQT;Y>MYGU00<=
M:>:B"0/?:7=M\JA+?63GOK&RY/RKI\<3*S A4)280_C*IS7(XR[]1RDV?ELC
ME]].-V$\JKR^"B)!28MR$HTPL\G&?^8:%BUA(".Z.Z#$J;)2GYQ3R7+WTMZ8
MG$\K]KC4F%OJIN8V[:JQ.<!R^[OBZ*UX.\0A>"D:";0S8&D$:6X8JXA^,L=Q
M[B*05@V+;[/5BBM5?E9L47:IJB'W/*ZD[V2_E] SY/Y#E;4@6F[8T),%O9\N
MD7(OT/N$P"ZE;N"G7=<KQ_/&*LS!-ID6JKIY&7EWQG-L+&:+IR60 ]8^><6C
MJWFY5M]>"#1Z4NE_^B::IZ ^_]W?3[.$^%:> LFMR0\8$/I\"S;[%COUGG_9
M5 K>I[#G[(S;,--"K^V<A?_QK.GYQ(N*<_:5L3>.C-?;2]TS9F7>KAS,DP S
MA039/P3;_QTS@&#?_W-BW@0N$O%]+V*1\]^]4 I<W@&=ZA7B?ZBSY1E7!MZ#
M_)\; FA"!D2E[!!3*O'26Y352QPC%(3]"EC7)VHG*)YC:?]C)%O"505J6":N
M+.UHW79#ERE&'"T[1H5U%ID5*E=QZCF.O"[T1=%%/H204Z=L? 9V E[%E0)F
M&:1I 4H8X%([C@X5F>"7^7M8!&+NU%1P\>3]7"+D4#!2%R)A+EV<WE6#Z"^U
M7/$*/]J0UWWM[3?_:O=@';TS-\I1!HFI6L%JYJ).]9EJHRF%]ALQ5YH]RYDY
M[7B9^J.N]DGI;8X9R!"+BJHI6]V('=":%U.%BO\'JH#Y1% @>*\AZ YH?5X)
M6IOA;P;>AW9%@ 6391<011MNNDM;>S3L[TT\'ISO9S5YJC7)<>R'TI6<+U::
M>8G.)_6^0_;_.<0O!]X3\-15J->"X O>!6@MNG\.R0]L^ZN,>QKHJ5[>#D)*
M4CZT!,\=%T3HN ?<<T&7@!H)TR!DY*F2]\VF[X-]2G8S*$>X2-94&N8P6@ZX
M3#\2',=$?'!#'';A&B4.6EE9.Q]&AY2[KB@>DYLKKFU=_O&K\;J\2OH%Z^+C
MC.N<?@52-.Q^ +F5M@-Z4@D]@I)GQP!E-%A<CC,NH@19</ SUS;D+HTC>LX^
M_3%^U?^^E_R)QM:LY?G%%-OA*8ETC.^F=^QPUK[,HU #\9ZQWMM':Z1+;(K*
M_D$E6Q$=\LIOUJB%%,5FR>F=7#(KRE.>=[5?")%[V+J0UCHHE=Y27R6M7'5A
M"7,O<RX%69)V6T 8ODC*@2T8F=(UN0.263,Z_G:&C#*A>ZP3/0SICA%\*0H7
M.896+;-@UL(2'ZFUNJ*.H=X8JC;(OSSO\O<5;^=T=?"EN"7P6B'M(O\P6H,G
MP D_'-F<)K1:R#)D_UL'3+,</B D,>("I%'7CB:(&YVBY6N;3!H=@AY7(;Z\
M-U8=DK;?]FT[NPP2.UV%;[L45.*V8E^,UX*)=^SEWF<15M=9YG\#K4R6T<5
M>N0NT0=$CF&O(J2.!8_1FY7O)OL/I]"M=W=W*!!ZWN"+_%JLYV=CB_R4E"P.
MKH[T'WWB'O&CE!/)?91!U^ZTA0 F)L E9IT-+W\'U$2@V:%5@"#FF.5HAR@0
MQ)=8?-;F?6K]J9[%5OS6#/X(4>5+F_7C<H1M8.1=T88VL$_CY^?T3[5Y&)6+
M1:G$ =Q$&4W!X%W!B2JY3/^X3\A!(9NJ4Z38HL2R!*)E^U6SXMPBX?ZQLN@B
MX5]'>HSMTL,>M;E:E%3!'I<6/7]\]\Y:46-3**]S%+J?J\ZKT2,!*E,)&'7(
M]"!#8!)\ Z[+.Z"()<1V8B8CQ#KD4 BBH@3@(="<O?Q!@E3]X.G[J03Z3(J#
M5=N=B;5C[M^S90VPY/D7-9!<0CT\;570"]I?K'IA]0$I_"-H':9MC^T32@/[
M)=.V"WH,,*>F:-,6X@1CGI655.5.I.+%D0;FV]!V+$T^?Y=ZE;9+RPXH(=G.
M5[*$V-+"6$P[A.TT[8"Y$[J^0^6_8X4(WOF[:9 >66"*AMN/!@$1LD^,=,JX
M3@47:,VL[,15[_&MEUN<_C5G-W -*4PF7S$_+.QVX]RU;K%S[&A> U\=,U)P
M:!2CL.(I!<"83;2%7(:'']W_UY,.(=0N<%R!/,N\FR#>]>^*YR66TW/X=I)O
MQ['F*^KW^??/AP<_&I3.K%=5VMWYS\>Z:U"5 _:EM8YOX3&6,MT-1GOWIO3=
M#M3U,LL\3?O&^H(V@QPP")8ZW56@:,0=?1I4YAB=\6.R8[U/ZX:99N.,C=C9
M] =KS9=:T#$"D?YZ>&\X9?7W#DA%A',).QT!Z.R *M2)>M\R5[!UB]P\[=6M
M'=#==6H?OQ)_</(P_M=]<QZJ:@?TYG_?YF"1]7.Q,Z>/6SSV@<*^4P 3Z/0,
MU9<SW'%P$C:O7+!/ +$G!3&-7TW9#9\+65I [',1Y.X!R#96XHH^#J#,2Z:R
M&AK:"4^X#_VIL;MAL6@+HX7#Z4JZZT4>ZD.JIHBSSHY.2$C0.Z>]\;LA]#_K
M5XZ+POE$UT5^@78%KPC]> =T I8L@'Y'EBP_1UN=ZX['?CM>O@/ZXN>^ QKK
MV<(L46V90!'WL3X_(T?Q@7<[V)*2?Z)=4/;/*B^DMU]R+O+[L;5Q\1@A# DF
M _/1ED>C%(_SWNR ?'AA;"03&P.57)H[:*W2^8N=4-B'9,EZ3!B98:;>3G^9
M]6ND^#!YM15SW1F_'ZFK>6\,M^^ 3'EOH*H ]L,.: ]&$=FDJ(@0Q9"PA]<Q
MAFC]U$@Q5?PK(.JM1?%@T/E6E+=HY?>2GU80;8MGQU.DKADQ%O(>3V<>O'<B
M4PVE<84YRAYV*G?(B3$WO<42UHF>-<C"NJ >6PYHCB5/G;7NM=%2[?#95'=1
M:?A=5#'AKQB0ZQJ:ZP+LUDK@V %);)]Q(^]2Y/HK](TI_N$AQDH^Q'E<]V/1
MJ)YAQ>D03@K8+';%I>#BJZ>J;VK&UA:;73Q&3]YQGZKACQ-JG/,YNB@3$Y9'
M]MH!Z@XHB52Y0BKL2*)18G= 4FCYH%*USD51,[\=T%&?<,_\0)&CW9I5;R*J
M*-"AADWS>,PYKBE+J/=2!(,Z-<_\U0,[A"+9 4_TX[FGXTPBS_48E'S*#M/?
MEGIHF*\C@42LLOX7>^\9U>36MHMFB8H40:2#&A60#B*]2):ZD"8@39H0$2D!
M 1&0(($HO2,@H"!$FDB-=*5%NH*(= &!)$@'21#" VGG\3W[[/.]:ZWW*V-\
M8^R]QSD_GA_,A/G,>=_WO.[KFIE%7RSVR?JWCB9T_%P]= -*'M%_0]KM\4V:
MXPD[MVSO]'*J*K<(V=DEJ%4?E5E$WC,)/=3R\NS-9VUFRH?"24?=5MP&>;),
M;B- FA,IX')U=*]\8F%WP:1%PO#UN]5W2D*!?6VB/R;DBP.FJ5P_/B(*=[/R
MR%D?Z(7TR!9-DC$^9MV<)#KO\VY^\-$<=]BYL#%X';;+-V)W"M.S^=@^I7>,
M;)J"S\F5U2,M=29X&8<\.PTXXD_>IUJE^0H!GV<DQK.]7HN:27FO?6YA*0"T
MWS^ DV[@)K%=Z!I,A^(!FAF)NWTNN4VYA9SFV=2;HFIV.%?1;GB!A YO$_+4
M/<W>)D)*?IJ%GLK,;C%O>%=J-V,_Y=1_W,$9IQL&8<Q@!-'N.):O*(UAU$F2
M&3$K J4YOPU@P6RM#Q!(L]-$/C0'XYS^@0X=5[Q@EOE(CB$N-TVV?,T8TXB8
M:'SB\,W$T^F,D^^KL%$F1'@;]%[8EUF5MQ,5JIM\C-$\'C(Z/$S)R^GL"*]U
MR[B*V0E/GE7[GPC3GW^HA/S44=(K^=8A[L!A,#PEU%)W74<PU4VY>S'#T]HR
M69*74X^MY1I^KN93*?'>$[]\TZ>Y<@IL5IU]>0K(UTW5121&3UIV+O6/I\=;
MB17;;:0Z3,ML34:VGWD-3G4F9;F38@1(DW:)<X]A[HJ188=(N/7&4"H7[0]Z
MULXBL/8:8(QTCF/J,WHW]"5C=(Q+/7<;>A;2>QNTHO):2SPV\,WT4X*D0N1#
MM6S$&W?L M=9HS>:VA)Y2LV9TWS#5YMC>QP\C_:R2)YK(Y.6:'S&\Q-1NJ)
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M1IJ6/H,-C).KTM0+:$(I"7S_&7,FA"L5# .P 4/Q89\P@.>ONT<^6*&[[G\
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MU%6RIMQW_9F0@YM /U7-$\,-\P U&DJ //'>;'(7+[^Y$41N[&H3!>I?HO0
MFT*4/FGB<;U9W957-U&V@#(YHG/095XQ>N)0JHX$XM6,DUUKQN><VPW2(;P\
MPXP>Z$F0S\X=#NMO8QD!67+(X.0:D36:ID16I"0R(=&O4WJ8$,$VGK#/#P63
M=F13>%:'/$ =_)@ %40JP\?K!P\"TY>S/\./V"(O<X2J=R(DDJ)RJ]/X;7'A
MPO*5"]]<HR5G$T0W];2)5[FJ/Z;&))U@M9V3JBK#'X8\SF_,"O8@/C$H/X&1
M>9,J=FOE1$11G.BCY91WYN]=?WNDFBG9F:APUK91;H+W8WP7@7R\Q"(A^\5K
M EDHV%CPAD89,M':3NY*N:E?94SQU58-J^13IM::40E/@T,_S"HA5(81ZH?W
M;&03+1;J*V5+O"KEZ6.,#MA)74$$F@-]:VUS4FS>;#V"JH,Z0)K8$"0WVM#?
MZ0K2;,F8QV) 5.E)_9Y&99JVKO HS<;5G>A[##'.(>?2>>KT2'(&GY;72GJ?
M/#[<-I^AA\:_U!I/(L*F&RF]9.X856]M)Q*CD6J LAI3,?'7;VL<W<Z%7VLF
M2WQJR$[.*;4WE"^F9XS^87AHIJ[FTH5CY&:6;&#5P9@C^L* -T+Y\9N/<N<_
MM#_D4^CKXO2K>_&@VPSZM*RZ>Z'L;)15BH>5^7OV\H[7ZQ"(#2[M7N6)K N]
M;BKD0*7C/2.5)CW%1ZXVRM\-O8G6E13<D+01MG]1KG-1J][JSIO1Y9$@2E!F
MH*Q6:N()BX7:H94BL:-B7GK:CD5S+=.KAGI\-F-"40^SWI?ZW (V2>="9,U#
M0UA[-B/])VWK.B9]L<Y !&%27BY[(6-\TN>'@+;_O0]KD/2!.[<BH?)8A[_(
MU3<@_C;?5L']D%G>=*>^\U@?H6:'N3A@K?<PJVRO&5^A)(L0Q\N,\1$&F_-%
M>G']QDQK\7[8./QH@?&:AV2:;,AH'$W&2;PISB(P[C/0]5ATT=(*1(!J4&B\
M@F['.V!HQO!H#*W/9LV;GZ92>_. $4T]O=$;/JZ\@=K^7(E-W4:E,R&8,1A)
M!$[#3NS;,\0!EQX8R0(NRA@3">H%U3T@N12)8D40<(^FF) .ZR&4"]4:>0?M
M>1.(Z)V%DCU7,[528FB_56ZHW5M.LS=Q]2_I@6[(:LVD*/;Y8G&$>R"L7F9"
MEOO:CC(AQ)M8)D33B$J,?W'5]\JQE<8TU^M)(N:%ICQY=T<1[>\D@MUJGK:N
M&#:>FVL9V_!BS[&AK^\$/;2<TV-"=&DI"]KOT0V[-($<>SH.YSD8P4*Q^*(3
M2E5=SHX:R&OVP@+/ WS9:*+U321VIV\.2+'Y3WDGAD^3FV8<C2GEN5IP3D]O
M%S^Y3)[IJ?->CQEH00PHQ=E$#<=5T_ISVV^N-D9]41?MT+QC\_[G@1CV_(84
M2@*YQ;P;GR(2[%<4YAZMHR^>PV.)2BIRC$ZE/'[W%2(\+7?O I*?H9#U3Z(^
MO^7,P/G)PL$RYYK$PQ9OOOI .T:36:>QE5:%5\Z7R)F@O6[<"W27TO2_?"S'
M(FRJ^&%6&:TBX,1)!<_TTD]KAOX.,R8CNRX^>94;Q9E1#Z4*<!X:K&(?^5('
M.&O:=13$HXFS=J??ANLMN(8C[<Y%6^M4I&IIY5D_K@S9/([$6+VM:QE#61,K
M;_PTM794^VE%5FM^/;.2#V$/F"X?N(Q8%X*P/D>(7SC!6?V^1ZRAR[WG0;F:
MEKN')#19=B>F T<RF8O1:HQH.VKOQ8347VQ+(D]34NDO:&;4JS0!P,6;U&C;
M2II>9AP9!BFT%X.;7)(<7?5FQ>GTZ/;<T57]SI\.B&%[[?>GEJ.>'[LW7PWH
MM*F4W5Z2DDDN0KR]7NETH\1D'"LMPU>F%5!J'EDV7JIK?Z^$S<CBBU]$QIY%
M"-RJ$2$_U>SS4>+!M*'8%H[J8'>8CFO8&9AZW5.%;JB_N2:FC2,&A(&BC3<E
M!XPH7L5ZU'OUZT?-H+$H0ZZG 4(H,R)2A:59Z^ IL7'\EUB_^M'E(?BKG(6W
M!")5,7-2^TF:21",I8UW#0-%^14 +)VZ9TG0R$"3^QU+UQO'V\X!5?WM8<?K
MD\</ODV3!:4AO-S!X:9!2L/L.8L1#9F6^&TH*%3@Y*SUD2!"CJ(@<A>/2W8E
M6U<NS#S%L3+$$7 >^>WMFB=_D-?25CPBKF7?T*XD9IWS:'?=3)*(Z]#GY3RQ
M.FQ;VCMU.8(AEFC5NEWIS>?J'C*ET&%8_RD=@0@):AQTP"HL#?2?CIN78EC%
M]@T)S?6G"A^1(O/)?""_X4R,O'">L^C8D5;=ZO+!4(&2P*JU()$67U&'U5W[
MV1*_BDYQG<OC4W6[*:6729RQG.I27\+_T/OM-&,>W:Y".T3590PY"=4#L$"J
M'(IO?#M)\!+9NW=#E9Q#[.V.K@>8D*I5RV7[GA+":]@=WX-?9VR_&58A>.SL
M>ET(.2$G3=?L1SDW0F&9L[8? 4<\=C*=X@'84=E7X (X-QP7#=5$Q[4XS)\C
M+R6B G7?.9.Y"6:=!F%GIU"RI%=)I$WC$1]Y[Q9M,JM)\Z@@?&)']%G1X:W)
MBFS^Q L320ZQ"(LNXCW?W^)+$SK'HC2N1Y(L<CW].^?]?(I<=XK9;3I==];*
MK$M,*PAR%[Y;EA%,Q]1&79%;K=.+-\9YZM_Y[&3;&'V<:\ E\@"]/6HO8W7\
MYT,NR26)R>.24&:>-9^ "T9K7)5":<%'#MO9JM0<XZ@]Y9G[N;%JMM?OZ&ZL
MSA7TT>_]_B&'&+@*^*70@'@>A<V7S:W9LM-OAZS%FIL,JWAX^.^PE[%N#U'Y
M&1WPPV(D7%R ]EPDK+:DFZ.+WA*F'/89PT.SI%K0KKPCG6K#'=(]Y;DK(I#@
M3]6QY^@74F5"8KGBQ+-;INX$"?JM);V:W.CNF6($A*D"[G^0;'I2$D]QDKKS
M:DL EPX8'RJ8@#UJ"\1K%DRLTV %0);YR':(MZ?VH]I7)5R80TU.;+_[G[_]
M[<7XGEM0^"?RLV_G1)[.Z_ Y:UIE52^4"IM:C9A'+ECD6$;X6;NP:FA\UO*(
MLWPJ)JQM;U-CTU3?7'[QU,KD1=7Z0>6">-EOI__-;30X2F#8.29DE.6]]3_=
M1C-'U<+QHE=_P\O0.D$ING=6"4V!9J%7*(%X]&P^@QV3!BO;!\$J-27@7XI.
MG" .3^3>NSRQ\6L;Q9T$?29D+ /O2<]_R?WO;HGX5XMGI" %\?_AP_(=G8BI
M%V@DS<]SQ^@>00KB85V*26&J$[JBGG/\BKSM^X./MT]J7R(U9!!#U3L<-C=1
M[L2C1R5;6L;JI3)GI[INGH_6E'CZ<KH9%.K1V?0"V'*GKBJ:T OP,R&#!W"*
MM%^-O00X%H&ISBO =[( 'CDG_$-76K)];6YRBT-*1]LC8+K2QHE,B2"?'>DA
MP57Q2306:.3V6LYT4DA4=*!:$D^&"?I*QO;S9+;OVS7="1^7?[K4K&HL6W>-
M=Y=.1"%&ZVWUN9-*3"S\S*VFPBWJ-\\5N;!1]77MD[_D1!CJ7WWJ4Y^TV;H3
M0OD"I#!$O"BQ3$@A)P"JCQ@H'K2F#CN,\ KGD;)_?C )#O@Q#J%_OL<V2F&5
MUY[!]_GP:-(#=[ GW/ 5+U0-(S@4U!#?0]'%V"XT:01>IT\7<N_!TC28D .X
M/;PY$W)4E?H'>B@:Y<F$=*:00(S,.Q3Z3@]ZLX,)^5+" GJ^%L9 _MKB:)D)
M'U1L@M%2L-OU_Y5V%?ZY69[W^_<6=L%@2?VU9XL'?*])V!!TVQDC@B/-T]B9
MD*7'<$V4!GEBPQ"45U.RE"S@'9K*27/ 7 )Z2VA<]:2%8EQ7RN/>Z_59A-XH
MU)6"-=R47V-*Y+V*QH>5U6\\BK(&H^X$\1P3P-E[5"+< J2O\)@*WV#-XKVJ
M(L/8O1!4(K*M)'V.O)E!O7E1/9#B>ZJ1-\)'_K/36M.P]F3O7H@Z\&""" ,0
MV"DQ1J+RO WC!/HQG$:2^KMX:?M64+._*,B(TH#23CYG0GYV@K2KS0ZMT[;,
MA&SIXH;_*S6E5#FCERT?@X$WB0'M>1%=7-JON)0U V7H@[72]/_66]"_NM5F
M^JGYSB=%.OL]&*"M#!HT!O29IBMMZ]=MN!]^G48#!WWW%V<5_JU3J?=K W/V
M BK%K,?.O&D:<QL)6)L&ZOJ/)86^_NCN+=]A.UE>4^@X4W>;(_"!-:+H]T\O
MTPXE=#2D]=U3]Y:@KG_TW!A;%' ,HJO^OPU@G*PGP2?G*8^SYNL;NV1#+0F8
M! 8O4$)(21(GZ<?K2,Z+@NPCZ,LJR[6:L9?-=:,ZLN5>(M9C&0.Y-$71WJ!%
M61^;) /A_0LX" S_%$ZR5(R"-;!N7*&ZT%2 0%(_D1)5H=[% 2)TVSD<.25F
MHZY5N3USRC4S"Q]% DM='9Z?FNC*RJ9DE%XY_"S<_=A4OUSBZYR<74:3\GI-
MF^5SJW;B^;1VLZ^$<KK]??^ ,=1%K4I)Z5&,HDKQQT%-X_2,1O'1[&)5"W8C
M(Z,-?X4&[P!#>&L3Y>NO[?-)_[7IB_\Q/P'_'R=O6_XZ>1O=3,31;\X>QVZP
M_\<7=/UZF!#8)J!=SC"#42R@.]ZG)$"LS0UA\#,>J3+0&%*0@Q2]#N8J]P0V
M+TPS' 4#3%67.OYO%OR@]Z-LB;\6_!C3 IB0[3JTE)5E4,EN%F,?.G]UF['%
MA,Q=H7GMKP[6,G"$B5EDD..O(T:XVLACV^CU#*KF7-@X#(KB)XF:DAL22(OS
M/>>!\%4S$2#!M&VLSOM ?V>V_&(S.BBT9*5&+^1^^.>^6W$LT8KUP7*RBQLK
M] 4FI"T&F&AE?,+4"=12SZ/<2)L]&"X@1(_L4TD84.S6LA(1: T.=BV>T2-B
MN>> AXMV/P(VM^O2ACEVWS7:,NS.)1V_=D:U/]FV,;R[XFBF$J%<3BPM*E-B
M).N-[U2)2;%Y>[VY!JS^1X/*_( H+BA;9XJ>4[Y15;KB'7CCHC$ECOZLY3?2
M($&Q YV".]BFIM[+'0GC;3&?3XE1]MPO>1P(BW$Z#09.EUF,R6V=2[>G!(J#
M4?LQ,8$:OL2V+ZJQQ4E%#4=/?I*5*@T[PNC \#-T 7;NV%D>((&J 7CIY3$A
MUT>RC(#GY,Z.V8-D^X%74<K]DC'U+I0/&VZ<AW+;114,SFC9I*[!H(%)7A0W
MP(]Z?H! %^'FHJD!)6068@.&^ &K,.TXI@J+59L*K:>DA-YF0LB*,68CEJ9)
MZTN-,,3S8C_= _';N A88\P&+XGC_1N4!N!=@;K80*ILW:#D<^J* S9XJ* G
MPO_U(X44RD2LBL.,88'VI7C!W,+'-2[F+VQRM8+7SRODB12SOUV>]^KAK_Z6
MFG2-M;%\)WATOYC?;+J)*QY5AU@+TBAM?&B:DS$SZBWZNK78XZ?$IQ_S#W::
M9SQ'5''.<^$8=H8D8QK&T<9&^[^H>\^HIKJN;3266T2$2&]"5$2D&0M%()!;
M$1 0D"XUCQ5#A$B/$A*E2A,%@5L0(@+2B92 0B#25=1(ER"D($J51#!L33OQ
MO.6\[_?<[QC/-\X9XQOG1\9(]MC9:\VYKC7G=:V]]USXB?5!<,H$SI C<Y\E
M60<[$5)Q=49_@FQ1L:BLJ<D.(:8-]J&"G@*KO5Y>Q9 $?_L+&7YTR=D\R\6Q
M7]8\=]Q;N#16EZW.&%@)XSGB^G5Y:@=N\_P_816 0K844X82\0>U#QY?548E
M+FCJMR3XCT8Y$J51P^]*%WWEECB..]7FRGOH?>HJ^W)%('6A//_Z6*<2/_QW
M82 ?_A$&%;)(0Z1!L?9U&'B_N?\QC$4?LJ;P=MV"Z:^H)[9&2ZCY;Q5^?D7&
M^PBG'_1%5-R9BX?%!7 @7.$0.4:G:U72#_<^4.V9@"!4XKL19@]1V%IB^:\D
MU.+;DH#VV1I"TU-8+$>^S_T3YB5P\4Q3:P#D3_8X87^TN?-][7?-^FV+5V!F
M>1+'ZPH8#2K(B5^UA]=G4[G'"1=RXOOCKN1NAUW>7@U00Y(3];VZ65J2KJ5N
MQNSP<EV/2N>"Q)RFG)RY-HI#=.A0?EL17>^!7[M7T3#"AH\7!^X@J@1_EZ"
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M4J#&")$<P-)0[@Y4;8V+Z)W1&C>B@^=]#Q2_-BFI6O+M6U:+?ECA]Z?*,?^
MF4_66X,__GP45!YGRCLA[*,WFRZ_9D'OX-0! M-)[PLZ$<J,A:;?I-_"VE4
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MQU_D2.2$VUV]CNBR4MLR_V"'(KVPJOC>-X$[=4<>7%P-Y]W#3CB9F=[HR>,
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M0TBFRR_$G-T+#QST3L/I\Z\ #V==Y '',P":<Y'ADH:#! XR0] N?@(MKV:
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M@J=!)N[^(Z7@];-P&UR"< ;1M(LSL6+&\Q".KW F&-[I\"M92GP7,1T88KI
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MVO&M4)Q(X=U9B5Y]VA\B$9I(W"[V-V(M C/1;^Y73V1:;NG)NUDY:K@IR3\
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M:X@%$Y\N J'1R8CFY 8>XAWO"-+*5" .4I<HF9#&K-YV0HK5 4Y%PH]TB@0
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MO9_GO3L4,O--P?X*R:<4=:<TY\[G/%#_N:%7>S5&]2_.':#DHX&#_[8,<@I
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MLNM_>.7_5+-^W- D7?CZ?==#!]&(!ZC/14+9+FKYYVAG?9T0KR_095P@O@7
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MX?Z=UBE0<CE_R4[OY-!]ETM[KA\!;3O"),N8[YK@[2'_.<(7.W'G\23O4/L
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M)IG[6TI^Y$2@K7TX(K5%4QJYE"B%1@N?"]JL9 8KO/S#Y6)%TI\^OY9S6&6
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M,LU?\-0(FH]GG@;^8L[4Z _K68]9GJP=,R-5GZ8RAS4 #H=6N,_39 4G,;Y
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MO&X'WG-J#"X_.T8=(!^9?#52LU*7KUJ]H'KJN7IRW943>N]WLC(\-HN&N/N
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MF FYE-8AS=P^_NL_"A0U/SJ\8K=-0<%4ZO2X$64ZHO$@VKK/D \UV&J*!&;
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MBLJH+A2Y**TZ@ZQ$M$)C&T^R4A!^#.(X@CPE6@GVTGCI1:RL>KL<D-<,3*#
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M.>>XEM1#_1=070H#3K@R1;-(\7^+X,?]&V#M)BY<^(LW!-BJU\0-B=(!A;9
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M2F+IF*#H^S'IYXU^1-[N.IS8=7.R0=2%30S$G-.C19]_]Z/QMF/*Z*TTS3/
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M 7U>SU)F,M?9TB;D_=,\UNBM;J:MGTP,$BJNWKG8=OLV.U0K!.+^7HN_1'9
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M4$=4(I\BRA[])NJ0"!]FQVGG_'Z:*P^U_@_D0L5Q1#)XY]+<QN\O(5Y/-^.
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M[H"L;T+<K*.: 1_D]L2C.^@7/U 67$J(8+\I@'3"\.@/>^T !NW[,#WA]R%
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M#!]3?2IL"R?M(0M;/;UHNBKJP.7Y#*;P)'8O>P1*M1U/SI_UEGI)"TOLM6#
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M)EDE)NI6G3O.DT43>J9*V@O6/W5KFK<W;M_1Z<<!IU"91A),:1:F7?)7F"3
M =$+6&V&)ZJ8:@":80=0R-BN^J#"@/Y8[9^VW2@PW/N(Y\$O/33KI<[2'I_?
M>XT-DKJF>HM.19+"A.5P:D P_0FKJA=,G6005Q)0@>#T95' .#:@T8W U)I
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M'@Z-T2*7H.(,Y#]U7+1 \RMML^3ZY@&DH!NV^<-A2^I*ZJ]"_CT<Y"+R#Y1
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MVJRMG[J@N4VR'KS%[ZCR4!7@RP[NCX6GTU1;&-ED55HX; >&I4"0X;4"5L7
M!IWU.L&\RU^S+9UN:F[5%, M<>@K]+% XP<V7";T-2Z-K=(7@ ^!KJ.>5IS_
MN?;U-GB[7]KW):W/&7] 8W/XJJ7,K;_3\O?WF;O5/DK03JD^T>2:'W;G8[?W
M*>>:SSXY':\=[?T7PRYX-Q>Y/CA:,#3_Q9:'EA@W+/\QM"7U7(B2!,K^-;7O
MXM/C1$.AYZCX+/Y=>)<:I];W)?7X]WG-]-Y4+EG&G^G5'\%^)]GX/<I/N%@4
MK+NB*H5SGOG4#3GL-]U#@HY35N( "\YT$A5&. &2D@X#C,1EZI$0?VD_%,<V
M7HCAD607T*I:!2RN83)!@]OM:S.!<*G 4$\;=:(QYGYO[4YZV>'4D=(_R_O@
MP-7L&5COEM1.A$P%E,Z-#V&I=?D*#(26HHK;!(*5]M*#.7%G T3K/W64O*>0
MO3>9[7=Q_#)@,)C\-9<."'W:P><.5?C7\MJKY#TG;R#/8]  BC5CU(MLYE=5
MBAE%P8.H!*K9KT0Q'.U3%><F>=\Z+FUJWG@2X5M!P$1$UBTR33-)G,MCA,-<
MI.R2RR RV9!I>8,9>X6_:&JHI:CJP7@3P*E(\O9LH;OF^S0O7!MZ!?3H.F^V
MHE'[\I[F5+GSC@<</F%\X@9F[.GD;4MS%TR+4TW,MR:,7G6;'C*.<BTWM],E
M3,^NF[9'GX1#,;,=H?P 4+<KLGP>:KL(Z943ASTWD2D(64Z8;Z_Y6@\.AB%]
M8@;3R2EPV+JCJ9]T_X/H[J3]T: RV?*?MBN%D4AFN:=_YR7)FGLH_C2"SQZ4
M /K76LZ[<.(A6$)KT6IN&4$.B!++CL'9]YYMLGK/$@YS#.!TTB?-/5U )G,X
MHM(T.PP7%P-C[N>L!ISA\6/Y1:(B*RFAVRM1X4'Q]L]#E7@8.WBE!7S$(_7Y
M;DEE/3#K33&!K.#$$7]MH(*68840NI%^=XS!!;Z$\LLGPJ-+X!>G$-88N65-
MI5'CR?$RW\?(0</$7VV(XN^+AUDM^;1E1FWHIC^90\DD U?)6?.PS@G"I0B>
MKO&P+Q<9;T)37.PP:4L+;Y[;O]$WKU2 32_6L"A>,>]9+]G]C\&7O[U+C=(8
M9ZY>I+M6_<4IM5 RQ]M'Z8WWQ*J.EY<$_ L-5(2>IK@6)6("P+QJASV%.EH)
M3SD1 O.T-::5^YKI4TJ,X_L%"YVH"N6)3M8]XE$\6KS;2("&D#X30EL.*[4C
MK)121[@'TE;T7OHAXPEZ43K0,*C2NSGX"!' ?2PW4 KVXZJA&/_)VVX7K?U.
M#/@F=K2V9GU5G0N"="3A_O"O/(Y@N#04_'9+2I: 8Y?H7 9N=?-68M].EQZ%
M?-F&*OC"G@>4_A3'MKX0(9R;+;]@5C3P*)CGA<JM7V!&?W#VM_DM;/<NI#6!
M),I%F'')D-Y:"O*6H12$\I@0:H$*W.DDDS7H(D*K[CM1D=8X*CZ$1SI!A5P2
M[+LYOT6%KY*D;QSY<E&Y8&-CQ&%G=M7%CZ]0^J<'6#4TV2VI&Z1/T^Q'=J#G
M9<BE@F -; Q0(!W22C\72Y;^3 BE0K1?AT40G3W5@JLXULA&I70P_C3&1(=Y
M".QS9(U!N:S4<()>PPSK\W<5S]&/L^81_U7)<8 W=M?>O;P1](1]Y\VBUQ7.
M':OU<YQ&DQ WRDJ0IIT^<GKRG/W3E\V-BGG_U;QQM%&Z7K'6LOP/^Y\OVDUI
MX:;4PCMA?B:KG188(8-P0V)%'7A?UAZ:P-*HAUK!'2PZ,ME<NA>WH[LALS*D
M^@4DV_O#_W-(D?YCS#W^0ISVTX[,&?/$3SG\H,>NWMZ!YQ&)_R=?8T?3BU>7
M]$-&^_4Q1UVZDH+3=!41+HAEI2I\N9Z&T_MZ(]W'>4;[=/S+%Y$E<2WFU[Y?
M-'XYGGCB3D>F^9V,PQJM3)=X%\^PMK!9G._GWHW)SK8PW[!NBV[_$L;/U2VI
M1SCDEWWP)KB()/3;DIKLY-F+1BF]:Y#IFMAEF^#TEM2T1%]9(E^J,65.77R0
M!_M/[VRA>+"=(J[RM$J'B=<NB;O&MJ3&CI 4D0 >)7P@?IM,XP^N;-^2JB0E
MFPB)D ,_&5H'))OVWOP.R0J$][3.;VL&,POCCP#?T@Q_OA1J!8&[=[2"ZPU_
M&I20FNJ%0;=3I5-X*8D3SZV]>YB[Q&]I;( ,K8L>(I=/"\YO22V0.</$,'$?
MZ;796UH*^?7TLAH%:N.?!\C]<GK\)&A.8">T$E4A0\*<\1]":;O$ZI >/;LZ
M1%.W9=JXY"Z#7KJ]$^@K%]C,]G6L)$RIN/BVYAXU8MS]E:OQ7P%,#UA*7@J\
MPU"RK[@]E5-9GIS_%/OM;%'6IR?C5?<#7JTOV.BV3^9?&74)?9&M(Z^&4O,_
M?8_4&3,=;G_:]YA85Z<A;9J:(KP*DOI0S,&>4GE@.K'K/L\P4U,5,.M#/RJR
MRF2+I/N*"FH#GN&GV8JEA\A]ZCO)9;[7;QAX<NA0I5YFH.,56>^26^?"RW'G
M[-2+LE?:!3=#1T),F>056[!7<B4WK:HX6U*P?F16BV7'K=3Z[T@@':M^D^AM
MT]XV(33:DE(4\5C%G:E1\;>[./*'MJ3.PY7%BD)U:!8@<SQ[<$I"0X"4FLL)
M%LH;N4G>+.<575\R)2G]+(GA4/H$]<B>0!2HZ/,2^.F_<S(*LWOI0=!T\LG2
MY5 SGS3TV\LN55@SH8(G/Z89T$FZ33Q$^ WRK<17]:!;<,L'@:G%'YRJ1/&I
M$*9G&D(>;'(<?PZEETOB("-KO?&%>$1Y_G"A:QL-IT$X-QIE($MG]N1>2>->
M/&3#ITW5%1DO=-USV^'OE3;J7)78>RT]8^F2[('+U[\QX+=K7*O0S.-V%KT/
MS%U*B0,5+ /'<Y[,G!F=(=RQ8H_Q+:ECR+\I<N(1DB;B($#I(VU':(/I7)TD
MZA[\VWFRHO#D:)==3!"[&Q^*#>]XCEZ0+ZD\Z!YFX'DM7N;P(U=??.+/F&WW
M%]=I3 &_'M1YV(Q,\C\D>BXVQ,+W"L^4[D^FS^^A@G'_="AGXMAJ]>$(N>"
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M@?EL^6+K(=$YU\]7U+:.<<G>V>&M8Z_F"HQUHQ?6L8LB^A4%[20U>'CV#'.
MKVCS"_ M8#A[03$U2%0B;<I);".V!*%W3^FZJLVF-D<4,^7X@ )GCI!2O>"#
M!&,TD%?&D%83%'/SQK+\V0D?-0=  C&&;"W@'XBP ]G &18\U9 TJP)ZO%Y4
MT;.0K_?63L'+@[%,Y2P+=3_<H:8Q0Q)DA2HM/(0N;%46*G*LMI(>284L0,<:
M]/W7/MMJ-+[-*8EF(?G*PW^!:)X=WPX,8"#C%Z! <B_[ 579[+R(;,(JX%E?
MZRU.K7>?F/Q:K[<U3V!$T^K\]@JE";T+TB7_.98:E-5X^:_]33><"O^S^@R+
MRKDB,G<Z.V*;^BQD_(Y8^Q9QHX"3[#R"EQ$.QB0G"E7 =&Y5$[#5ELIZI<;T
M;Q:IPN=.BRH&^;=YKZ/M>-GQ5H&[M+'SJ]B>ZOJ"6Z.S-_^R7QLE0J?ZEY^7
M-[UT4'=4^TW52$?O^;F0V]7/S31,)N<]WU?XWD2-OJVUSD.@,E 7,_?QSCD^
MN29PL[;][HIZNQIK/><_YOC&ZT3=D)^W[EUV8-PFBPIJ"8M9&"E"ST7^'XN:
ME 8C."9.F^%?$!<-?1@Y,\>HXNO"9%":4-N-PW%^RGVA]8W9!A7V4\U*Q/-I
M9W2>WOVZ*)3(;%Q9I,@4\.QQ)H)*,[<EW4T$%\ZIVG@ &-/<N_=RIMJAZ3BC
M)1_3!PRX4K!W4K-1'UYIJG73^[.#^^>A'_/711;V][';A_40 U".%Y%(H,#O
M$Y9*H,\9H'+-NLE="M!)WQ%KF7Z(/\R_.&*&%>X%WNZ(]094K=07*J77T:]%
MFR=TFTT&Y2 FS2SWOHE4\5PH=UE^9F[<1P9/LOL),\SOS.A>:#RTQ>A+_Z+4
MKUV^0DG^>2!H\Q$+H\$/^-;E4MY=P^@,#?#@4.^SO[:BPBRTP)8+HXE3#7'D
M$'25U_K%T:E]8ZAX6,[%9*7K')48$$>32/%\P^+<Z9W(\G(\0%M:_?2?9<D1
MS^K>7(U[XV\Y_WA'$"EY(9$A/;64\U]"1S)F;X<O7\DNH.)1YX=.5,^OO%P^
MWDJ9>CO0*J0A.;8'J3>HLS;>@@J^%S VQQ1/^PS&PFA^9RYQE'O),GQY3G]S
MY4>DVCI1D6\U8G:LVC=X00_HJE^P6_M[==NOZ_!NH.?SOTOXX5^/1?8,@SIP
M.F06S>TA<N-^M=O6,.ZC[OM!_ VG"G:R,)E"+3 =_<PO&"XCU%MQ6@,JJ ^*
M_N+YL5-_K'[.^M?K0LTP^E 6,S#/KK^!=P%YNH\PY]Q_I8YD5]3OUG.MRO$
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M$6V;'SFV=?Y68VOHG4&/MJZ':SW'\B7*"B_;% BG=L2:"73, >$P28YO&P'
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M5X)ZK\P&'T#ZM]77X=J>O;]KD=B GT12]+F=2Y!X"VG!DR[Y*OQH1]6#+C=
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M>E\05^LU0VOPG_.WKQR*WE//,(7.)B\1^Q9G> QJ#^1WD3XV7ZL!"[_TEA@
M>H26+!*3"-J1J8'SQEX3GTK&--Q:!P6(G@X9,K#G /@0([UBO!D7O-:"=AK0
M6R7-S@?1.F3:>98X=/-(*RS9X@@XR?@UCG!@8]R8+\^BP>5:V;O6_*&34?^9
M:3'L28I#3T',@'\T;0A-![Q]L;,LN^? ;A>?L[6SN?EO?]8^EWG[#]] '!)?
M@Y#*]ZCPNU[KWI! LY%(:MBO9 RQSO0\?[+6E95*'QN8['O#K+E2FDR_'FSR
M9KS1+J-BZ)[#N1?EE7/98<KHR+D0 PEO ^?PC.QHFT]!64*C7TT4GB?WP2$A
MHD@- \8,<A_B(.X &"!(K"'T!I2BE54'7M=$KAAA$E71N7X>MB9G\ZKJE2TT
MFCKOAQ3*.BT7H=*_W!^E8I!S,-KVW@9&@S*W"GP5P! $. $&=?6>Y'1W]F9A
M<E9?&?W;<#729WXMG,X<#8=QYS,\1CU#_ -70[T>*@JK< @&?"\XP*WN!DDL
M\X EI<YZT'ZI@"]/[8'*=JN#F->DEB]]O&+Y2UUC8<M@537* ZZ L\=PV(S%
MWLV3]>6CPN,A_@?&^1>8 @VQ>,OGXZPDN.DGMCK.3)!GJ"'._0+.7UN"/]R$
M\^4+F-1-JR6(-%;6$++?#^O#'$@BA'C^16KQV^PONR;]F<22(B;['R-YQM-,
M'AAGKZJZSH:67SR-5K-A,+ %^F3)*WTW5.P^/+[RNN-]DF9Z>1WSFK6*G3JE
M:;/:7C:C]RIGR\V[E;5%"IX_9WW%*+*RU<T[[4Z[82&NF;) C+5VSKU%ZD2?
MQ1_ P41V:C.*Y\UW)?9K[@.T4\T" %T&)+Y+M\86L*=;6(SBI-&<]AXXI)O^
M%*L::L]$I%(TI"YR\HL9G]'2RKV]/YW;\Y:_W6HP^\_">T4DZ_!97>X6Y]<?
MIT=P)P2EW6=Q'LG]A7<3F9A$J*R940TV_7*LAGUOMT&LAF7?]K&/W:KMQ(N
M3#S+J&W<Z/S6NJW!<$H]JZDKW:WD8S]B7*1]?V4&.;X0D A+3PGBAHO)>#%P
M$4 RD0^I09WLY,7=PF/KWU9BH'V",Z]% H,Q,(L*,G[$1(I_7+<O7=U^E44U
MR!1/,ZR9WRB=:(F2*3Y6WWV&YX8["&J5B=8GBT-\94$)_V -'P,Z**<:ZAO;
M@0%+Q/13J],FR2D8LX,5B^!W!CF^&X:6#?G;9Q6_'ZB?G4YJ-0_\SG-P<1Q[
MVL[S6_W],Z(T22?A>U?8+MD'O3H' Q4G>X:6.!^!4@0DWZ/&^5S:AW\LI>W<
MPEM*K9\T_3CABO4>VY[%QG"R?!M<,B8J[G7:1IA&&!\+S/7)^>E"-:Q@PZ+F
M-<W+A//(-E)\ETL<*TZ+FPOV/,52KW"&$W'Z-6ABK:5F&8%!V/UG,WC\[3<-
M&[MLJ1?\TZ&JL.0H5.B-23W&I;,=CUPO6CQJY;#YBC :H:4JP\RA"F<#\.&[
M^"+9):7#97%&H4!.CPDUHY1CTZ_O/&XS97$22^WY ZV\(R;/5UPB:"SZ?B#)
M82E+HX8^@^A_HO3=HR@O4'.K4-# YJ&9:3G?$_1AP67XTM-FRD'1',LEFX3C
MX#\D-9PNH-V[/<1.%*J@VJ*ITE<YI&2]LC@8W7_O"^MQOA73BZV";J]^/]7V
MGHY6LQ646,#P=&33 )T$1?F+(U.IBM1;Y/L!%\ \YCRT'R\UV0T5OJ,^;]C:
MJGQ9O1+#HC.GILP<@/2!P/Y^^V&(U^IS3[XI9_LH3/$]^>X4YW8]7EPV_Q.X
M82&NW<L\\Y>US)-3V%H5U87Q&=>$H'W7@Z<K[#*:7#6\<]=<W;0E8LW,3HWV
MN2<>G-;+K9*P"W5Q>&GM[#YJ.NL46M.:XWV<;!"8$]1KL1^(%BUA ; #^#%H
MRY?^X63CF*QX0&3K<(9@\9*]>:P#Y:7<O%45.,?PZ(-(81O?FWO8ODK_<PKZ
MU_0&)O)S9]-TI*[ ^NW"\M&.+.R]9EZ$<&:( 97!*F%F(Y@3)8J<9]A3P=Y'
MUH%C%?%\DZZ6"=Q>)J%9PPX$SUP9WPCK.C7;L,4O-/7NS6]\I*L56\574)D;
M9B!![<\5C;;WM.E#]EQ9\/JB H&RJ[+IUH9(B-#P)/FU9EM*_KTN606I4*UG
M0T8)[@T&2\V%?!8Y8I>-Q#_75EG-Y\P, <6*F/>1;MX8^83<)J+L1<5752UN
M6A<-\BX)RCD K>9]R!/]HC!]NNU,:% 0RAO7./6JZ&?.>%'AF^-QOW%^<LF"
M2KP\MFA > 9$ >-,V,,N#\##B>0%YC6N%+Y#Q;+\PKXX=4PN3T?1.RD=E (_
MX41W%S7=NZV];5*_,>QF+/J%92@T"M^/Y+BPP1NP9'+5!]">99R*/^ZUAE2.
M^O=X.SBI3MAC=H\)3;-0+J!Q\4? *L[//@OH5-<%F18&.CV5(I7:K88E]=X&
M>ZXVI?<U^]NJLXT_-2BVG=$>//VC]@K]ZLK[8@^'J2N.&74ZI_)TPAM,#)ZL
M]1:??WL@T=;.<-Q1\H^,8W)GGGB'YSCXSSMW.K06CX66S[4)Z[=AC@(R-:18
ME^$*W]7*GI5BQA7TJAQ6&N%;M *[+)]>N-[Q&I!$76F*Y[D97MZB.SB;'UBS
ML5,.SJ84*5;2>7[XB29L?%^W7C)K1ZP/[$*P8*J@,1.1;O0#D))&]"$/6&BT
ML7\#!]U)_^Z(V4[SCWQ<\:APG2E)F?Q.41S?4I?^+*R(?^5E%P6=K/8O_W+"
M,:*&1\7?*=9QR:VX9Q>Y^J;]A%7%D+[Y*NK&J]7@_%3]R'%$T5?VUO%4'@;_
MP4)-$ZH*W3P,(! (20>65Y>I)/IL@=*V#\ZVLW!'; "P"8VM^C@W[P7V"N^Q
MM^9-A+JO+-:X[AT^GE_FCGQ=A;85](L@LY-&YMGR+X-D8)UQU/\$1SD%?XBO
M-]%U#16  52'&9E#0S\?1DI[7.D8^_K, 6Y=\CG6WCI[P4LOLJYST%1>!OP+
M"75RTFN'%9S9SI([DXV>':>-57D;N$2IEWH_T7)_,FEKTEPCT1]>*ZB_41O;
M,P3[G//M3NBM_*'9*5OOJ;:BL[%?,JDH0KKPE*!<1++N7F"[.P?3;Q[!E!:%
MU4^[3ZA +>D5\>UL^??+AD5PZ?G3]_1O=<$K_XF,^T-9SD8CL>/BOZO?IN\1
M>#CAG$GEJU(LR4E0W6VP@!:J- &!>8PA:[\[;WPLQW#W=M]=,!J+'+S<^N\/
M7J@N_8J5>LQ"83[I>M<'C:=>4N?_TTS#P%[;.F=P/.W2$A63RS9/_0@QB=02
M=W!*$$F(X4NUY".XQC^R436F3\8Z<6,>N/=#=9U5T4%U'8Y"R^)"FVP;TQ*O
MH_G6K]4^Y<W:JB?^=B$Z\+K"GMV,/U5^4Z[>)GZQM7ME,T$PV9 5%B]R0A?Y
MSW9Q W;$R#MBZ=3M=AP*V6$$^HDLT_R.V-M#\$#XMHCN.G?$ZJ+[\WAE2)KO
MM1VQ8T%R.V(??AKMB$VL?1D5O3&_0I@N1&Y?0C"3A1 )T1*-_" OI$%;(<+'
M0O7I;XE,R.PP<R %?G-'+!'Z_-7?132X3+<,2&1JI_2_9.BCZ1WN54PN6!9>
M-5BSL@!/&W1*IVTG$8,,BE6#N=%*I3=1Q^7*WUO#ZQ9!,VVA.>$J@K?_USRJ
M(# "F;(CUH)XK2'%7'S-!K6#-JJ-4#C]FSR"<')1J<L%J!K '_S&WGK)/\DY
MIA<)VXO]C?GBW960*71T?8AW6,G! *+71.NFHV?8C4LN K77GD^.R]\_%R2;
M\:S..DO7L,'1.>P#H6[J?;/*$SN[/^[DZ75GG9D9=\JI<;[R</D.]^]OI^V<
MZ=-.=S$S9)_^!%?\G=RP;=U7H4$@4Q0=1?IN;1Z!_LA;XPA"VN=R5'&,[EG.
MM[\#.:_J*U=#27]>=!UF?%!9#;9[?,O:=2IW1^R \,B\CZ>7']\:3(X.**\H
MCW'(G,[J\@B_63Y0];9E=73U;DX(&U-UO-C$QJ*D+?RU7F#6^5"SQ[*>!"N3
M@M?$!]16R$843UYD0=@]\#156 \Y>5$5OE11H@\$)5'8F=VJHXT_-DV7A$1&
M42Q9">2)9".U2[_2!SS#F%WP]$8PZU;XI^M"_#4[2EA68WKLRANY@/^I';&'
M=GP)()I>1'Y $L-T(>\!-B)CUT+=>,1S!\41.<RV'!9\+S$)+H?SWH9LRC\+
M%NH4T+8UIOL@X*4N"TAFESQ+I77S[$*HW()'2:]5_DG(I&7ZG4:4S<&+C7+E
M.@$*$U.:M:4(B<>N@\6^?]5,AB7^IW2DK'5EO/S+H']=/ 8: &]!H=3"&I?W
MF-HX1(9&AI87>L!5NF1Y-M@6D0'IP63!Q<V,2U'Q3H(R@Z[S53A[L"RJ%DN\
M BPT+,7M<D[W)3)>%><6##]K+&[ EDCY1;A/J[XGR"\.[XZ)GE-]4Z(-##:@
M^SNB!F;(463558_FX-5G^HU5U6".8T<Z[=:[T15D +5P(9R1JOZO==IU5;VY
MBM\GV\WQ;<+7PET"TE-1C'IFL98].2$%BWLL-+#MW <=( *6U?K"++QV3<0]
MDD(-[/OOO3'=[=?U]9>F*%)(V6 $4__DD>8+41&AE7-TI1MR$+U?>P!62TX#
M<!KIPP#W_A0A&)Y"U12JX3 <)!V-3-K^,@ 1!]$7P+FE%UV[ )/O-D!)(DLZ
MH'<\)+G?7SG=@RH<X5C-+[RJ\UWMB%U8:1JX.C44ZM?Z7<_P3 A6Y9IYSKL3
MU\*_DU.X0(USMZYT!M=504-R(B_$T[?$KD+GGT+91)-0YXQEA_X[S(_J10[6
MCDKNSVU[OVZ;GG<=G6F;G[.MO+THNOR72BUT@>&-+29Y9K@7N;M;&:?"H?:Y
M@M'B??,^KU5_]J4#S'DXH[A36MYZS$R-.2R/UI0$(YZ%Q)2UIW1956+E[<9"
MMT)O%[TL4+D Q VG";6Q:7XP[T[ @PZ10RP])7TP^232GLRN"["'%W]- VB.
M*NA\A9'8.-"W<LN@=:QNOZ/,A[_)JS8#PS/I7$>.R/S$<_W!U258UL)^ $9G
MJ_'M0:!LS>1K,6>1R27& H]QNM7!5V:PDF_-X_8F,W1)22,+\T7%$2Z4YF9
M;+]>F,',L\;O0@DB$,N"]*;'(C(6984P/_ZOG.#Q0[,[8FE&Q#1_=;2TC,AT
M)0+M&9%[*<G<.%4)2A*;^3/-[(Y2[U1LG+^?.SQY08/G2)9'_?VF[=;)@%/G
M?%L.9KSE0'YZ\D,E1OH%&.D4.NN$HZ<X J(#XMR/O/)ULU.X_<(;UW8EO.*8
MG6O01?U^YR<!Y[6Q5@MFSYW2[3SNAJ?9VKYU\/&+Z@CZU-C PJ3$='R$'L N
M,I7J-%LPASM-1/IMYE%MV>CE9Z\^KI93&W+&JMYSWG>.9M:/:)W]Z.=#/\,N
M5+A9\PP[T.^OTCY1SX>QX"I8_V'O!)]U=_^#@#N5L6X>\E&K_]"4?F3<Q;?2
MSK(*S_N.=&=%RMH?C;U[>8UP&7>A'MS%)&](,*"9U -F,NUWH2T#F\DL=GR)
M!N<SD?E?EWXC$J<AJDT>.U6H L8%,.6OU6;"+X,>K(.'7HY=3W?H>I\4.%86
M:QJ[>-HLF?NK>==YG ] H =34=(!SJ.&$$G<V8(^"[&L]0%E@@0>BA::$ ZL
MYM\M4003@><P*6S' ..)=WYZ>#6A]TSM>HP)2G4Z9:EE+*QQTVKDVDI]?\9M
M[-NMIJAK^Y6.1.J.5$BZ?:R]V'K-P<7NBG-.A9G1O9>UD2NUM0;UK_)LK>^%
M,7/\OSD8?ZTS;%^8_7Z4@BGP\8.J#S 7E6D*4QR01A^9^XB2!6,^+\ 4T*-S
M'\&[1[QA,A]?%]Y/(T N;0PK)>M8Y,FWF-U->V<[T@4$]<5Y#UJ_F.CR ;3=
MQOC:X;]Q)A=*F7"5-56/!/8A*:X+8W"N;J9U1TS&_[7<Z5!!GE'>A,ZCE(NU
MC?"GD/MPCBTB(8:]*<V")NV(:>+5<0@.@D:2$X[[2X!:'$)?R3%!N4A%3+CC
M%P#2??D!I_8D.$.#\S/MBZ#4+$JC>#.16X!BS/F)TWZ6J(F4/;\T[F:T7AL0
MI\^ S+@PM/L1'[YSK06/M]#L@Z :8YIV_M>%3%7"Z](J^0')O3'(_EC23/O
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MWA)3_.7X5;2R]YC8*ORT$I,';&V<==&LL]W58+_:.3=/K[;G8X%[S=..6+X
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MD#/E&Y9&;$V'[4<]=,<F3"A9PC[""S7BIA6VP+&1%]$1G&(63"?*$UHU<4%
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M=R\MF9^W8CLVWVW[JL8X I5/?B:DYP;'4X].@)UO6:I44^P%=FD)#\'E6M0
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M_8(R:IR\4.1=>Z+QE<?1T^])]9D:VHC54MZ^^$B$<=&B3K^]6;I<1)&^EVF
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MM\><._+3$TY"C%+J^7ZK?@@D]5GF#W>OZ!\_?G??0;6LK5>$-K4-Y!:,=I\
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M)O;Z'SN6FYW%Z2("5!2S#4(#C![%2H(K+JX4C,,[T-(X#'=^',/8HU_(3KO
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MIO(F%7D[)A*3S&$\Y/=.-<*DS7,"U%:A$501^10T[6CPO$'F-70P$#Q60@E
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M:5 Q";[>,GB#G.#;'RY[ZT;&1%\D5&!!>DM;22L CXD@0ET#KIB.'NJWA,"
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M@O=LF^%9GDT38:3=_M#JF?8:5_@B'[LL)2HWB?\43_GZ=T2J'OE/4!7'7Y1
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MT*3A@(<UHZZH_\5R9>6(([ 07)"AC#K/.DW:3L;]*QC"I,C@VAIX1%\M#BK
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MXCXQ>C#K44=/O&M3FQ>!&#6HVNXU#GSG"&^*[&+)BLB27M;Q%\SVJ,YBW38
MQX2DSV@,&^K.44Z74U)(SLQRERSJ=;H3K6E"Y([W@>;Z;#=Z>*&1W<S'S@.O
M@MT^Y\DB*']Y0(!K0_.:*3RE>,8BT!N\<\43!<:8#AS,AW9Y&+PFNA$A@.TF
MNM.N^'0V[80IRP9S'-2K\:IV'O"P''!=_A90?.*)31=3\XCU@YF+[$]E;QO,
M(]]):;MJU,@AJ-V6X887X^WU#R6X@@#=3L:39^A;W^.7=WC@^H[-&O?-FR^.
MAHJF/%/NH)=+#F6>=8B_;O-I!QWT]?W1"S>JA^[46%\@*G?H1JQ4K;_/#EG%
M1Z[WYXU1;OR(=?BI.M<_+LYL[I:^X#'GO)YL+(><H5X#'CQ'AK)T-YN:&>@3
M2'^JMQ&I^,L/ 0/-WX.CQ7)?N@6\O8THD:P5MW#!7"/J-WR4O'IY]CCEEEZ<
M%'*!<2U:= Y*A8[/,A9222<9G*JEYNW*5)U^">3\6N>8]R@1WFPT-JYV9B"<
ME<<Q0VNC;P]+2MG$V*A:SD'KOGV=.?Y0HDZ!C8\O>3BC6,P*5/_3DI$HKZE&
M;_-*2%3*$<NR.EH6)&"@M'^H(HTI<5(>TRDCDJ7L()=J^8,C=]?B7%*FY6>K
M]U:GD]]__6K=>MY/WE([+RIS4^-1C6N>='6UMMS8J[)E>I5US0LS'6N,CIH9
M\B[]T9^Y[L0#RLJRXTZMJ.JEB0T43B>J;?3"R'+)\,^#_V^I6M/_KW"G;>PP
M2/E\H0S]R<E^#S3T-OA']#K/>(VRS K=/34R=TE?/"%AXRG\$.!WRFLR-X)^
MYVWG7RKO47.)CK\YQ3_\#?]GN^]F+]ER#V2%_=L..MI^S[6@,,VJ1K&]=;(Q
MYK=.7A?V6Q#V=S[^F-(I/R+Z8J_ -?_/[V"WH-_.]Z _W5+= ]E_^ =UDN_*
MT'(B#F9A.?P#Z+_T<9++TO.][Q>>JO2D+,M*PE%OSDQM;8VF<DY)[0--Y:7<
MXP,WD>@N[U,<O[)FGBA')IX5+!63HJY(8O/J*Y<O/9[NPEP:]<C09\V?6I-]
M^_ULE+NP[-UTND.VG;5ZE_:SK$C;F7?MV9&1Y,W(?=&I;^@D5R8"[CRB+:U(
M:SU851?@YPH;)*SZV[6/A"?>%#6OJO3P[+U?F7=3U&SJ?);E/KF1HE#X $FK
MHK\6R(8-H:!EL)4=EQK<TJ5HET+$_'E+[L[R3]RJS\SG<_>SZN;/FEO]CI7[
MF7/?[\-JP#>R?Y^_E*K7M/9(7K/+/ECJPCK*@^FE98+IDL2DD*"5P"VWU8HT
MFFOKQZ+ %U:"<^<F;&3P1A^B8WK"A\Y-6C8?\/>_<O+F&VF%X1_#!9W3&U*B
M6&=WB$U"W>HHPNKL(\]KHR>?[IM1<UE1?((;_>/Q$]43CW1.-UBO721^QOL'
M=WG;(%C$K*_$2(&Z/1!]<EW3P4STS+\O@+<I!S/WJWK=^/J5>@Z4#[VIWD<
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M+]B3.CHC  6L_&T^R0L'X_V"$7X:51K+[VIQ#$*>:W.*K.1YE!3;J'8&_)H
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M^+@@6KO@T688Z9(8R\MZ<]O#5O-:HOO9(8*'>-.0]LN_D(0=J8#IG)U<U,?
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MTD:#$!)$I).$)BS2WL4^^YRO]JY]G[OON>?']V/](&2N->=HWW=DKC$I;D5
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MWBT-^S(> (2S]WZ--MR.TY)N?Q")J3'+44C"G>24<?6&*2?EQJN9*9L!OC.
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M21QR\BNM\$,M-+8)RDGD^.VR\V&6>8:[OABLZ=$7?;&X<8U09*XOV"0L;M+
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M.R?<@3-W3P<(/RXFNB6!N)Z<S "M6+3O:)_HAB&/JRS"PP4*3MW\)L*]>4*
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M'GRJH;!ZZ62BCZ+E[CS[FXY9Y[4=$IO4PT?+$+:CSH/(/:/AC413W,]@9(D
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ML3' )O16<XY3 U("VL,/Y$B"#DPNB6W(S:*COW<JKUI-BTA(=E'NAHVQG8/
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M:<C#V<C%PK0T)=##4W!$</BO*OMK2OP@[2Y#C.9%N@?($64)V]@'GG(.(Z,
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M:)BWF:H6VH^4:,T2"E>J%W695NAA*B),;[<7O9HT#F9HMY@'W*!+Q-?[IBW
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M<B,MRD1$L RI#4$D<LFW3;OM6H?KW\>RT92%6H#2C"\76 ZMMV0:?"'/$PB
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MY-G$=;KQ/+4!"LG<APTAYGMR[N F1@A;\OA*,#LI80]N3KMP>&T1,=G=!^5
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MEKR*EWV9+G/CPA^)$K9[WM("6W/.3Y95J7%M>/8_% ";S0MH)WJ!"?\)Y0"
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M _<ZH1?I34ESP\$H,H -ESSQ/7F"[_,[8,+U8:F0$ZD!U!%YIBY6+MKRC6E
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MMQ\<3W(M.:%ELKC4G^+C$KE&O+* DI=K'LSU#NRS&S-<@D%Q(M;X'.G#KQ>
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M2=F=+U((#A9$I$LE>M,[8#%O*IL1X'NINC["8S)H9D.G.FT$"^+9#4*/8F0
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M!#5A\X84)U#]9&[+]!&"DL8E.&+S*FQBA-)P6KP&D/@4'>/,0<1@5/CXT)!
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M;FUW8NYN@+YHC@C?F9ES(! EXVEK@-=_-QA1:!=AE>>^S3K/M-W%PUAU\>J
MY8"(*;L1#CFVP,&*.^R+[F>OUKB.H3*C<FUD7PZ.K>GE]!I0=!+I7BMC%6Z6
MD,=Y2OP*+,(&TNQUH@'(UEIV'N"!V<E>@"=K%#[1V)5!1Z\Q24E,]@"E=1',
MTV*OI80&^C%5<DJTNQKP4CQK_;'TP*@[&I2A<D*JPOXF'!<N&#35 )#E(]/K
M1KK) B5!'W9'M!3/G".&;XW:Z 24BM_#[&/WM3:9]AE;%/(VPI0L4*7(F^-
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M%=_Z DW>.3-?X72:_YQB6V"IUY<_EM]*&]?7[&\^)3C1!PW )]'#D_1A"6D
MMST[O-E]P>$LYQ!'OA1QNPD\H,=+N3-X2KXN<9&LI)=@2?PR\RI X:A[?G?$
MB?CMMCD8P6*G)V;U=+JM82X16:1!LAY>_+!N(O]^JDO/20A*P&@S(1+=16Y
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M=Z813IY\"$DFKBP)<@D6*[*+P&;-UF'0\9MR*V$N%E=*K%=KRRW)-\@\4+A
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M_K:P6Z-N#]97DA4.Z+)OBT&>@/G%_K'/D =J3,CC8Y8:.X\;.=A$X>AEZ/)
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MR9]2;%C<B@ Y*=]YE%K>=].A9'U"V[[[>V;N"NIV0J-AA4LR;"3? )Y>XF
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M^A!*HXT()H3:#@T+1&DVK<,C.3+Y@-BR)AF NW77N,N5Y30X ]$C#FYW;O-
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M,@J"8E7-$@J"@HE>4H].PA\^9Q1)I5J8I!:'8LIMHSBF RFS@8Z4:(S#WN#
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MHU=+T)BJGO&F9-$KWU,JCLC3%]NK_A2Z>9$:4!+)Y);>\>55P'A+"Q>&F_"
M2:?# +)KC(0X,=SLUNY'>T,T/'B^A#%1P4#@>(-CR\M"V-P-ZW1W->XOZSH#
M!15I&_MT$']X('_A2TKY]?<T&"M%7R?<9()/RV'Z EE!G+)8$JJYY0W?RZ4I
MGZL1MC-*XP4Q^[U.GB2BR&QKK:?5MO( X4CQBCBL%]$5M;]1[.@!1]C@4N]P
M=O][22^-CU[!1RE'4U!@(FU'%FC*\X985-BD/(2]!.:/27,_OQKMQJ-*-<P\
MDX>W_JHB'SLJP^/%+2]?)/^G \I69$P/J+BK#Y8R3$G@*<LL?!4I\T-1?]NN
M=]YLF5<295",,TQVBI13(?0 4X"MGNP:O:W_BF>$[L5LIIBH0(7WRC ,V$K#
M\5Z"UE9TW?FG<"R1'%V @[R9[* 9G&AK4M;8'1UF,H\W/NN*JQ!<F>9]N\KZ
MP#3L5V,6(<24?>BKDQT16)8&1Z1(DG06N<%_QUAQ3]HXKLLC#3K3FLUZ@QAE
M7_E!.)/H*T/$0!/=[*G'-,P'*^]15][9.X^XT86!HCPML9U_1"EQ&(2^6<I0
M=E14#V/ED1$'FBB/!W5D3,3V4$Q]CPZ[C$G><-WQS:IB\;]XK?+\=_X'T!C^
M 4A3Y-XS!"FT8T+HH^^4]!Q."&3-Q"Z;M-4X^]PK,^Q77G>CP7!H#4)C<*G(
MFL0*_II-(D)"KUJ4,D%EIP;M_S*MLI1U&-82 _:]E:,4KY!D_E/1P]P=PI/*
MN4XM#?\M,"\_/.$.DJ0R9;7!S1\C;%J/??#4MZ3R;_UK7TY!F#0OO/F==,^R
M$MX?F"4S2@5V5^WD$?,*.25YTY5\0%O;R W1:1I52Y!%CW2DFT&9*#=P8V$N
M7;8)<9?]R'>4;4M^F@C7PZ[M%[]P*)VSE3/^*X7@ICNA^W=LS>^5!'.I2["!
MY!L*["@HGC]3QSETVE+$>0D@DZ_]B9[]12'O9SU'5US@DJ%L@B628/#P0SCY
M&0@+,OY=P:5@RM)1X-A>#_K*91PS-) 5'K9U&_VC+B_-9Q\2/& RLL.F4-JO
MI)[ZI:;+N\:.K#6H^TBU<I394S+N,P((@?425\KRUWQBPQ7_RP+Y[;3^QZ$U
M*83AU0+'6^O$U+:#I#^9^H%H9R+,G[]([.]"V+SCPU_+(60T<Y47O[XFL\A^
M?:P]^E(@XH0!OMM-6EF#R-=V-5M$T:V+[,/IZTOO)V^WC\O/BJG\&E]C(BS7
M1%F\8,[I'#8SPZ5A,+;J-ZT;MB^T*#GLK)RP4/659OR;I'K?=M"]BU5)CJG$
M?,AG>7J-,-^"!!61/]$"U,QAN_O5G(71^LA@@^DQLH",>*=-W./.ZD@#U-B8
MS.(U,9GNB20#66,_1;G]4+6?S-_)I4FB>W.<<8=;)@_LNB;^_FBX^W7B72(Y
M?SW(P64@\?DK?T< =V/1@BG!;4MMRL//S5TFN_$;',2E<=,KR8]\GT;/L*E/
MH\ N9O4_;C['[PYKZR(6?^-?J$)EAD_DUJ@ZY"+)\T<$#4KD;$M'<=UG(VV=
MJ1RS?O$D<G#]I/8* K]6F#EL@0Y,P'DT=XXI3X]OCB #K--^EVO"-2%WD?QE
M6,R_=AL*Z"C/WI,A$&["49M7/6WG(D57W332/B$5&B;<1R>':^CQK9$[L3P3
M D/SY*:DXYK>$3?92#=AJ,Y<8S2M\U<FVP\D\/NZ&'7PE*O'/BGKF BVSYH+
MEL7"LM-+34KTSU&5!QNGNG$J[4WO/KPHQ/=G[@XV/< ;0\.@^^HSD?F^@L*3
M]%^=[QOE:KG@H;IM&@4;CIXE,GN[A;2?PCKW:J*WGEK0P%"+S=.,-:')-K9E
M&HKSD(J>F3O\LH#)*66X#/-U!FFNKA[U2;Q-!QHE5/@7@(#R6]$(2WA?V(J:
M6%WW9*A:@2(L+Z-+F*5WB!\M(U21=J1?ODY1P."9+>)#6D; V4&_1#EH^$][
MM*R:][+A@F3Z=#&N$FDG&HGD,5-D@:)D_SY.7F2*2<CD^\3QG%[H)_.0(V'D
M,!&9UBA/A-9XA_AP9 Y6-("N/\@X\.LU94V<XJ&:G#W3B/BX1.QWHV[N3K#(
MC[#JY\8(-*GO^/0B<;+\G<H[P4';DDC;UY]#,A;SV_T]/Q/!HG0>YMBHX$*^
M\F*,$2[A:NYJ+TA?MD5C!BO;D*=@):NX=@B./P]8!\O;S%'""0P_1V*VM$?C
M9?Y6)/150DV-Q:8F1:.V4=F1"ZNVI&9QDQ0:ECY)#\P/4BM4DCP5Z8DF_>Q4
M#E>>IY10-!*D;(.D*^<2IW.BOWC&]IM+M.M%<\<T(Q%UJR&S_M#%^\P>_J%W
M5%+0XM0>XTA*RLXAK4\DK63\A[U^ G'L5$&@2WE?*N2 PO;SP;AP"#&N>MBB
M,HB&L)CX;X_N"V<$BZJIPKK$],24<@BIE*:B&%:2$+W<911"?'!,(3)C.4C#
M7])L%*_S9"9,V6 M R<8XP=NQ(*)@NN$U*NQ[Y9F8??Z,M28K_"U)"TC_F2/
M(,PR5):#%?M@>L=K$J21;W)P7Z&MCY@AN,CI0KEIU-G,G:N"-(K:N6TS("+A
M6HAHG1T#L12#F?$%\3P9,ON1?TWSW_:SM-X;JIB_@AB,O+)'8U">Q-N1] [)
MD+B,J3!?!K124P^TX<'1##(Q60YBQ&Z4UZHH=1\(9V]B%D4&!/>SU..P==S#
MKC#5:@T">5^JZ#?_@H2@"@<CQX "V3]=DQ7AIB35;7;<,)7!(,_I[!'V:2M.
M5)3;Q(?C;('M1=+RK!Y*T[5[P_*#<#&E-&L[ \F.N _*"8+F$(5 ]4RG.-VV
M;,_W'>CQS]7D%>4-<WXFTKWV7E:';'77$1!9;7']0Q4[3<0A?_F>9$"5<5T2
M.\%:4D,Z)ZH*53U%:H!E/H#JU;RK9Q:1$Z&V(&I65;ONB1;!QH3I!P71= D^
M450?^'/#:@LB-46*!TE!RQ3EK(!Z.WW!KI]:&S_"1B1$__1>2BZ]CN\C8L7X
MYJ3CES39.JQ$]*Q/WWNR"(M.H>ECJV^'_69R,X<F2:CF"U;-&449]ZH@N)QF
ME]-(."G24H*Q_\I1]UA-Z38<,;]L%D2T)*FJ9_!K-I(3-3WO>2!=0KU-^G8(
MKA/63_?TL'DGH@H.2>[@J,CWDB$OZ"E37DK/,!"V*B<PJ?0^\TUHSBK1#)7#
MCPJ;296P_ 0C"4SFB)N?" #VM=213@39_[3[.L/@/!@Y$TO$TVEW&.12%)CN
MSI";&J+NO/LE8_V:#NWS?N\I)N-[ 17SX*@^TF@)L]&"DGBAH*BE/[2WY[+R
M<#3M4+V/;O"KSA33#$E'[-C /,B?>PO.Z (I1M145IK^9XPV5(5Q3"I%V+%B
M.#*$)X02&;OARV^3_&BM.Z%2F'O;9DER;R5/5[(!P7+670I07&2<.JB'D W*
MU1!6GA.UO#\N ="O?CDN26+5>S^MPX@V408M^ S*HR\B_&[Q^ZU-;\>/KNWQ
M/'G)ZXR"]D\V+9R;O/G/BPR'E.LD&-K:2TQ8>@=W>BZC,2T1G^BLV[S,>YN+
M1BQ1J6?0BSJ[R^NTGOLS(PYMKE**NI>!5;U$?Y11J>M8AL@/FH^?UW_X65%'
MN8Y5A#U*-*IL:QTDZZ)N:Z,T\6#,.N5\$&Q' G OGH:Q6KDNRT:SSN8<*!A,
MQQ44SS4?1.UOO&EE79@L'FK)Z)QEG?0N6+PL7OK'NHQ>LHS-MD)0LD+.MDI?
MLLK&MB9*L\3+MBY=LJ[,MJ%=LO&);1."+-G\RK;E7++%V['F7;(-8]N)+]E)
M9=O-*=DM8=NK*=EKL]UN+MD?9#N8+#E89#O<+#D\9#NZ/%SI*CE"+SW&?G="
M4'I"_NZ4OO24[=L)RKLST7?GTJ7GRN\NM$LO/KV[A)3V\)=>.I=>>;^[#BZ]
MAKV[B2^]46>[2BV]+7EW5U-ZU_SNOJOT?O H)NO;!G8;!I[OO\-WR,M2Y.X1
MAN>S4$V@B@#E@APJI /3H,:Z.2R30HWA.8654)$$854[:F, FA$%Y>=C5!T[
M(-C47JT,K?1YW*FYX'IQXDT[5RP*9R0*)ZT$)PNKE>I4_WNKFF%FA70E;^Z=
MU2PZ89!"O.-B @P)-"IY#M1@CPXU1^5CUT*Q*5';N$($E"5.@YKF4Y0E-2;9
MA3N(,I9AL^KCS$Z#3='H(F%EP#<<T2)!N,GE:!H_6U*_HREL?Z;?_[(<T!4-
M<IH]+A;@D"3]%6O"H=4L,=;;WI>SW6]0AJ:1ZA"Z\H$V1V\\WJ(A0#C+P \K
MIYFM<ZRGW3Z%".UC1> +0X?[+:)OLC>&'.6QIU].-LB$NK&H#/*&VXDIOF=6
M<%"[J'_LL!?*TUA+K'BVVTY%^J$]N+O#KT/8DU2DI;TBD+5<:D:6OD"ABIQZ
MZ]0<9F\;2TCV?5LS,D'YNBB-4=LW&E_2,UPW)T H<5HH;TO9,UFWN5U$$[G4
M3>4_YLM8+$ GO/Q<=+M=>/LT650R-CVR3TD*7_Z-NN6"8,@QJ@*V4?-H<3A#
M[V8[J/\TC8";K3: >&(-*.K(=I8MQ<X].WNT_N^=+-01Z0QZ9J3HK2K[ZT/A
M!]HRB9ZQ.E$[MS;)V_G<$M$NNVKKK75MR\QQ3OIV1E0)!M1V%>"%*@:/ZAL>
M-8H+1DH)Z/"Q6F)^X7"H,,.;B)9D#7&K%N-@,W2X1I$]OM';E,2H1<."#0-)
M<6K3%V_GVYB"^)DWA88#A+8KF?GLV=LV4(&. IK&^)]:4:W/9[#!!@4!0K1?
M\AZR>&A0A1$2TF+A=]OA]M7^=R\F9'0QWY9&HPLA"2&_-#Z"$1\QI)NE,W3/
M*P6*^I]9).N=%R90^=,S7'[!\*<_JW"-Y0TMOB"<I1[9[.;'[@DD[[T<5A-O
MGO_N1AG+F4B<@1W+JR$@G*-?>OI!&&M%U\Q>#'7VSZO&:R>3K5-C3J5O[1MC
M-K!N[#"A+%(1V4N(NM/'O.=^Q1*QO;Z9L13W+"J$/;:*8-19RB3)=PPK=DJX
M_>W"=>WQDZ&..M59+>'LMB="-E=&;IF"B #C=0=<4[LTQT'-H]ZOC8%OK2GD
M?U$?GCOI$R1(]_L*@28..S8D//D$?O*YZ6!A\,"ZB*9G:@*U>L45JCIIK,AD
MN.;?AK02V+42;/,3 E "2)$?(HZN(S6XS*;!=LVH^M1QHE45[$[K=D7C:@/5
MDK0G)J)C38&_N/^2]J D_=1D=TG;$Z?=%;3AP&\,3AS:DZY4]7;E@]AQN2]P
M6B><C)51P=,[UJUTA"@=]#^]E;11<92^D6PQ?_Y"<4ZPP_U/X&2Q9ICI8'&Q
M!+[\!(@'-M%#-/['R2X_-^4O7,HWU6+V14"3$4;-\\$%>PML189V.DKG;.VA
MF[2O@O0>J(4;4"<4W\5K@1GWJJD:?]FKAE*D8!FPL>SH6W%"E01_^MW\@KR'
ME'CG1ZI>UL]6*8IMD6FAG4J5DLI\J*^T\D?$ ]1]/-2A0NH1'FH)0G4Q=_7)
MC76%2*&&TKOZ4A32UNQ"WX//LM4.;$,.UV3JUQ);JF9A!G6P.FD%(3N)\QG-
M"$IU2AH'!VRCX,Y+G$F'_P 90.:_FMMTW_M'7"I<DE^!@(EU,(0&$Q8,]1KH
M4:4Z:%EE@_!%6-=PU*AGZL3"M_33D+8DFD1;M/RK^(,\N#8ANQ<AXSQK[_QJ
MZSP\\#S0"WUK_WS1Y_S1]WS0&[W/(WW3*[W0[V1I6T];@,<>TXI%7*H'VF9M
MK.P0*P1PLP0R.E8+1L2SYE/!8P92>*DRKX1S(T8'-<3$+T2F>1M</*!KBD9$
M=!UF6S)?^@K87&C).T2?+6G&VTM-+OI$\*@3#_Z$,3L@RZLGE?#CU/\B]D%$
MG]E*@BIH4@!\\_27IGA$)[6R[I%^0_#]RO<]: =+(#]&C,]X3+,<Y+O8D/.X
MC]<^[M^^[A/Y[ML^[_^^[P=_[@/_\ M_[^=^PYJIG*KY3OC*K0V,K]19I4'S
M&K=#>-.\2X38FBX$ZO2?D(XV1 @ZJLR#15,GICB$-W-_FP/6U"]%/_2'^;.T
M[@!=A* $#Z]X[$0$M2M$?+#\1"@^0   H*^<C'+F] E4N%"ANH/E6C&4*#%=
MP7+KUG5IURYC/7X3&=8S:.X=2('S+,X#V0]1.G,67\HP%[-</HGU8I8TJ5#D
M3)T3^\4TM]/ARXA Z:4;67 F3(@[H2ZDV2__*H"B3QG*D_D2456O7\&&%3N6
M;%F!K?3I0YO0;%NW;^'&E1NU0%V[=_'FU5M@KM=W6^6!A/>0'E1!#[>68PO5
MG45T3.]%70?XJ]:'L\Q.GEG/ZV"#*DW2F]J7=.FP_$@%&Q6LDVK6KENOCJT:
MFNFH02U2W5EQJ8QV$F<UE:$[ZBQT,>$IG/=273U_$OMY/OA383^FYCY*Q"?H
M^/7($O4MQ5S5G\N7@1GZNRH#G?.)]]8A3O>\K#N:YMP=7=@O:4R&!$=29[R%
M]#&OG"M 6JX@T";"9Z1U=J)I(@43*VP_<T9"9\"%^!%.'?H(Y,T<"!<*3A[B
M%KHG0(E0DHG!A?*!_RD[D.Z!J9T-&;KG'1S'RD>HJOA)C,>%E)J)1-N03!(
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MF)'YFM?6'Q9Y+P:!G6J CE'$FE7YF,=9G'&YG.NL%;+@!=BYG=WYG>&9G;-
M<@)JF9N9G)-6FC%-.O"EE/I!'M#AF7L%)MP!'Y F$0G#FNKA(3XD/1016?YI
M'D"GE"0:*!>B;,JA<CH)H['#F,VYF$DJ"^HX"ZIJE_=B"O 9I+'YG%E:I=%9
MS[:YE.TXH_HAB(<8745:IAGY!6BWD]4/?$#F1*R)(%[B;'!)$2.P'+H@=^A#
M*?E0#BU"'C3)1Q 'DP(1/8CZ9A#Z)00!FCWZJQD"F.F8IY%K"NC8E\%ZI5VZ
MI5.ZK3\ZNF):I_7BE/\#J:;O.6;C6J[Q8@%ZNF#C4D4.H@@M*:N-6ICF1094
M@@?+(: 3Z?[*09-)*20Q"2J'0PE?(ATLJ3'<1JW=.JUER:3W(@4VQ+?Z8:S7
M^K0[VZM5F[/?VIC$6J]E.@OXP:8S.*]ANR[X>F3U.<7T 1': 6K,01W>81[.
MI(^ VRGP3ZIAY @C\$94B1[BHV26^I'PX3%&))&>)@+S(YR,![G+82C9NK5G
MN1]&F8X3P=%R6B^ZF;4].[S;&[7%VV\38:<#:K9/. IP&ZWO-1IL^[;W(K?5
M=K??.[79&XK36R](6MW\P;3A>\#CN\ A_*6;%K3WX@74V)&2 86!.#9:6%7_
MHF$!&'F]U;45^MLN7N!1WEC 5UO"65R/3Z&.7R :KNZU\Z(/'/S&5]R]<WRP
M2EROZ1K'BXS"]6(!9-R7,CR(D;P3AOB>#EPO7F \N+,50+R.:^ Y'OPB_1K(
M6[S!=_R7/KR.]4/MRELO9)S+(US'S]S,&ZS'Y?K'N_R[I-R.CR*@X'?#JWC)
MPVJ^&3DBHE#(]:(&RIS 7TK%TUS0T;QQOYF.11SX:!POA%G+#SW2U5S2"8O-
M]9JDKQS"6F',]R+,*<J^S;<?H*$4D,& 2UV!U:L?V/S1O:[1$5Q5,MV="'W+
M#7W2O?8+1CHU2SR<(=W6:_W78UVN2IS/DZG)\V(0_X)=H[1YS_.JIE&8UZ7,
MU1VY<P1-VAT]V2EJUBD=V]\\+_6\PJ$<,_W<+C"]UX'=W+D=FV=AV)O*V/'B
M%-"]1-A<Q$/+'U(X.\YMTT-<R/J@D;_ UW'5IP$^WKM=1BU=IA= 0\VZTPL]
MW6G=X5MZV1G>O_B;V2$\&A)=T2O+WM/X\=S]+F)<N3[^+N@=XK-.X,^]X!M>
M3/TA$=;9OQLYX3&TM/>B!@9>Y1^>X'-XW>D8WBE-W^FXE]/+@*L8@DF!*D)P
MX35^M>Y]"E^<D<][I4;>+NC]YB],VZT^YW'>UUKA"PY>IZ?@"X@= +Z>E&5>
M24<^ZK5^Y;<^Z_>7W5EMW/]!WE26JH'M'(5)(=]AGI&_0+0X'H%#A31G8>_S
MHA5,'F-1_O 57^<C2>YA>[WM;!"F'K9?( N0_<87O,*WG?$WO^W#E><GON>L
MW2X O9O\H=23O.A5OW*3 =85K>QC_K>8V7S98CQAGY'O>/%M,_$YW^U]'Z!N
MG_#OPO*IO??U:?2K_O=UG^V9_THE7B_T>_'$V@4\0<.7EQ0REZK\(1ELFNX/
MS.6%/^@MJXJAP46#GXYSW_BS"^M3OOFW_?S_6_G7:_#I.-"7?^WQO_,)=18X
M'2\\?>D HM^S8*."=2)H$.'!@@N#(8.6I8#$B10+# ( P!_&C1@U<NSX$61(
MCQ__26),UC E0E+0-IIT&3)CS)?]!J6HB#/GQ!2#HG%\H3.HT 4C9QHMRO&8
M2H;!\B$M>13J4XXO14J]2C5JUJDPN5K=BK5KV*]BP9HMBY:L6IE>V8YU>W9M
M5;AIZ<K56G>N7KQWV^[UR]>N8).M\NDKK._O6\5Q!P=FG/>Q9,"4%T^V7+DQ
MY+Z8.VN^_#ES9-&<0WL>?;HT:M.L5[M6#=LQ:=FI:5,%*C1W1:*V7_>.O?FW
M\.#$0?LN/AMY;<:#@GY1WAJX<>G)IP^W#OTX]NW5NR_G_MU[].OBM9>G'C[]
M^.SHUX-W?YZ\>O/SV].'7U\^_ILZ6^F_#Z!TT)"B4(%,_QT83#+\8#?+%+F=
M\I]] $!C8$),.07 *1'I%M04%^7'7H2"(8-@0RT%*&*(*KZ'XHKQN0@BBQ*F
M*".-+]9(F&&(P8A?CRWB".2-0L8XI(\S\OACD4D2R:21-C:Y9(^)!,4/DD<&
M">652FJ9Y9/KX993/TY:Z6649G(Y)I9I;EDFFF>V"2>9<JKYYIQLVMDEGFOF
M2:>;?GHY"W\Y^71GGS(]0V")%9JH9V3]@*G3"Y).2FFEEKZ0A7]ZS3((I#JA
MX(F%HBZ43)R&KHC,4@D]\V>CK9X*:Z&R\CGKGK;6^1YB.\9*:Z^WOEHKKL$"
MZZNPQ1+[JZG#*OM6*T'YEZRKS/]&RRNUR^)Y2E!93&NLM<=RBVRWXH9++KCF
M2HMNM>.>&YBG' :5PKKI7JMNN5;Z(RA.T,IK5*J+_JMHP,CT,R^1[KZ+,$4U
M##(+</[X&W""!7M+XJ@(/3,QO_1N_&W&]M;++L<]ZFJ8QR%W#++)*J?,LL@:
MH^SRQS&S-4M0B<@,<\[>[OPRSVLYV)_./0^-L\\G&[WRS$D+73311Z-X<,(4
MQ=MTU4];K7*@S\K+SS.E5*QJV !;S)33=D8MM40+I.M/HF0;A$S+IT%L\2I*
MRXTTWF;KC37?5WM)<F)^+YWWW88S_3?A>Q]>..*-]A/4AXX/3CGCB\/LK$XU
M]&TYYY/_=YYXY9^/WGCIEQN-=MI4APZZXN3Z\\PSR9""3.S^*)=O13[IY0\T
MJX ]MM@1JXH,,OF<V-4JP?]+RDNNVYBZU&O+G<SPP;"$./ (EF*ZY]VS3OKI
MXGL_/ER!/X^^Z-^GW[KZY;,?/OE':IV3Y."O[[[\]X^_84XWQ[\__<$/?^TK
M(  '^+[\P0EH:>/0"PZH0 22!1K">UL%+[@\!-$.&L@38 0_R+A\6! A'9P3
MW51BMP"J4((K!"$$#4A SYS/A3&L80)A>,,7ZM"&'JQ5U+;%PB#2,(<\I!$_
M@O+ 'NZ0B$Q48A&%B$,G-I%=_HC:"QH6H>8(Y0M/'*+WE(=!_^MYP@4X6<""
MNAC%%J8120,*7JG04[VW-<^+:ERB%.]81S22;H9KI",4[9C'*?Y1CX1T6M0V
M!\A!"M*/C.1('X("H3Y*,I&-I.0D"XE'12(K<SEYCJ'ZIY-(!C*3..+'"3,X
M0J9X B>$&J4K-?G*/O5#>ZFLY4&X9\E<8C*6EUQD+TO#1UWZ4IBD_"4OB7G,
M77H$E!1)8C*'N15]T'(AM8.E-0=7LZ"T\IK&Y"8RO:G,2H8SC<RDR+ZP5@.A
MI !:X+SAPZS'%.R9)'H)X\TXORE.:+K&ELL[XSW_J<]BXK.;- PF0 5ZT&<B
M-* *;2@"RRF1%[13H--$94,<FL^B:?^Q?A/%*$$_.M"0)K2C*_+' B(ER%;D
MKB(UT A)Z?2,8Z"2%*S*##T19D^&OA2D__0'/ZV'H9%FU*,BU>E0)V90H_)4
MJ45=J%.)*E2_?"$H3>5E,BPZMF3LM*IR0AM7CPK6I3YUJU$5Z91T,HB7;E0G
M0 SK6]H8QC=J9Q G;:#TQ I5ID95>?"\'DG(JM? CM6M9;554@>+5\ B]JN)
M)>S+UEH1,2EV?Z>,6/'Z&L:$8*^P@A617:FZ6,Z&MK.3+:UCRP51B9R3/!3"
M;(%26+BI"B6MC&PC9I'AD>+XPR8(FP([3YO7T0HWN,0U;6./RUB=';:XP#5N
M<D7+7.1&AY/_^I+NNF;'3YKZ2A_9;8ESH?M9G9"VN>2U[G"_.]ZBF%0G4T!1
M15T;,=K%3A_^]!8#<[* U>*L'V#,X#$$1QE_I):MDBWO<]-[X/,:&+KH5;!Y
M];/<!D<WP1-F\(+'2]V*B%+"*[)M+4<AUR#RH[L4AF5X<X)@"S^8PQ=VL"[/
MRE$6/0RK$>,@-))QV9_J.+-BTT,=HH "=UW1*P.!+S^AX;RHM"*=".L#P5I<
MX11+V<4J+C&46;QBK43XRES.LI>M_&5;93/&848-7#,XL.]R%X/R[#+B!IRV
M]E)YRE&>LYWK3-S[5J2^_ZFLJ$@AIM#R QK/0 :!>$QC'<]Q*HFX_^E$:%OF
M.V,9S,N9Q2$.$=1)5WG3I^N'/.0!CWE\.M2?QH>;"[OE2.-9TW1FM:1Q5%><
MV&_5>.$O5OE,Z^2,F,T=S+4=K7CJ5@?[U:IVM6..R%[Z]./0 (L;I^WS2(K4
MP<A+627"7B#*9_M:V\:6DRRVP(4MB '<6SB$1@XQ[G"G&[;='O:VCS.+48L:
MU/,F-;T_G6EW#S+5E.:VOO]=;#KV0Q_)P/$JD@$-7-/FA\0N"84R6T* -VG-
MRVMSP#F66MZT^^+]%C;'"PM9BD"Z,^]-2"F2_/'1H,T%=- #0O1 !R!W2+\;
M[WC#_5V>0ZB;W.D6-\]_OG-S2QSG-J<-/O_JC71Y*_W>3#=URIW(;Z)+W>-%
MKSDF6[OCUWXD:G*VY(BIO;Q5%/CI*]QUQ7MM]3K)-B=8O#G5I^[VN+\;(U$S
MHV5F/#QG5SU(CN;0],B>=KD'GAX^W[GA"X_X=.MCZ&]OO%7RD?1[UR/P%8ZZ
MX^>.><IK7ETH232BP0[ZK(?^\YH5_((I/GH#Q6WS7,DP1;)]>=;O'?",OQ*R
M<[*MN_BY(2>OO;*8?&*UR1[NF?>]1@!Q^'$;PC2 Z+GS33W\V%>2'_18.JGI
M$>C9]]ORIJ>]][5/_.)XF/3"ZT1.'KA3K)->KL4O<^=3/PJ]=S\\8Y;U_,-O
M_/Q_GS4A?_1<],'_; +3?N G??M7@"&E#^&6?':S(CJ7>.#&;OI'@)[C#_5@
M?:(V#XMG@#?'?0.(?QOH@0<(%K#S4\A0)8\Q"Z(6:@L2;66$<A,8@G%79*)7
M>C"H(K%6$;DG@CMX?U)&09X78A+X$SKQ=QC1#V'7@TD8@TL8?4YU" \8;FWW
M)JO@?#QW"#8HA-V"#Q>(;UEX?QW8A$SHA6(81>_$3\F0?:HA9%Q(;U*0$ZO3
M<-0W:FFHA($'.[]3$/&'#&.#A>5A16$(B&-H)U<%?PFQ"DCV@5#A>A.Q+?S@
M-F$3A" 8B)(HB)4X$K. ? ]XA4.3#\D';H!@B7WH&?G AO40BHD( &!X_XH\
M2(:BB#\ B$H@%B7]  ],9V^W&'FXR(:Z:(NYZ(N[^(N]"(Q*1P_T@ CUD _X
M8!C]<'2[^%N4^'$#$3:]5H?<D5HI@$63""5]IQMPV(J<M6R>)XZAAPP*<DEK
M5Q&=4$&P]8VLJ(VHZ(ZBHP]5J&[W4$<)"'3B!HKON#?XX(GAA@A%XVG"* _S
M((75"(T8H8H)"8\(B87^"(4^)W3BH0]*@4H8(V/WP(L;&8P<.6I>X(WMY _]
MP ^SH _Y4 \=J9+SD _\:'H_J"@IY)*"T7^JY8KBPHVY$9*KZ#EG%C&K\%<L
MXSLE1W[7\Q#4""=@ BJIQ'[MZ) -Z911*4%/2/^/6W"0L<0/_P@(V<B3IH*/
MSF<(_-!\0+<*3WAXLH F*4B0\G"5,VEU"WF33QF/%T>5^5B5=[F/,8$H).8D
M^%!]!'F+?PB5>H$(PPB8\S8/<NB13"</ #:710<PPA"7^@%C.)$(;BD9-7EB
M.\F0_/(,&*2!VL8/TK2'A5B43'$%G2F7JRF572DGF.B)FSA<_7"76Y"&F)D<
MLL %_RB15&B7/.<4V5%]&]F6KBF$<#F8QJF: =0/]%";O#EN8E"6OVEX?_"<
M$<D%AR +*C(+%KB8H88%NI$%N'DL^C /*BEO+)E]Y$E(_54B2(F9BR@1??"8
MX]$*.(A[[3$+J<-%D^G_*F8H/+B%'/+90"-7.HG0"EG0!Y(2?!*Q!S2H$IZP
MG.Q9GQ7*FLJ1#W<)?1?F#^T0D6CIG]-Q#Q&9;O1@'G7YCZ&)$?< F"IZH<J)
M%<AIH:TYH8:B#XB0B==)CX" "'SV%SY5B( 6%?J@<]!IEUS@#KI(#PNBF2(W
MHZ6EF.B);RX%H_@#DQ934Q2:$2LE$3I8H=$0/2^P36JRGT+AI2^:&:AG09$8
M'CG9H&_J=YC2!X-P"E((';A!!Z!G;3F%IB%:HW\:ERA:>%OY<6;Y@)-WBHA
MG>+&CLS2#X9ZEW2HI30:HSI2,EZ8#N4@ Y**):,9G)?AJ6W"C"[:&_R0C,4)
M_ZA4,0N^J:-V>0B#E@_899KC6$L8^10W:IB-:83WD*.+6H6'0*J4^H'4)Z6A
M-@_X0(=]VCU 2C;R)ZRK 6R3%@W 1X2KI3AP5@.<ZGV$.$*;)2QN&A1%F)RI
M^J156JZ !YN:.*Y2(:@]MXGMY@_M"G1.5RS], \;B0@DD94D6F[KZJ]1(J-S
ME@_FH*GN<!K^  \JJ@_E0+#P\!3O( ,,:XI%T0\$*P/FX!80*[%&4;&:BK&;
M 0^:6@[V6!:SP+":RA'P8+$3*Q;]$+$$BZK?A!M,P!"=<)V 8"%UH #IT*J>
M^ >=,*NC( RDD SZL'ARXI[NP'0%TGL T)V'*6^35_\5_$!/8FH;EF:DGF@(
M$0@81*J=RJI7_>"=4BH/+0D YVE])OJL:%(*;W,,\&F< S:F'P5G$@%["]6"
M^&6M4 :+%30PL'*?<$J$DTJXY@JVAWM,&6J7&SJACO";LHEGC^JK1TNF*IB8
M+D$/&RD(VOH6G;BH(%JX'Q>POM8/B* .%GNRZ&"*C+&P#8L4]R"R\_ 7L!NQ
M\N 1M%L.LGL4N&N[>%$/%CL/8?&[FBH/&($()ZNV9G&\!!N\OC(+AI$/B!&]
MT"N]U4N]UWN2UIN]T*N @RIJ68MX[U"+WUFLY6N8Y'N^YGMO\U /VCN]^B (
M^)D3OO6^]>N^]XN]]IN_1 K_OGAYDI!*;IBVO0.LOP2,OP:<OP=<P NLP V<
MP ^,P!',P! \P1+LP!;\P%N8=/  ".OP#K9(#Q1\P15,PB-LPB*,PABLPB5,
MO:4@-J60PBR\PB<\PS%,PS(\P>A8$8E@PSU<PS]<OSJ<$WP Q#=LQ#Z,PZT@
M"+EA"D6,Q$?LQ-E;"GDX0JOPQ%?,6[F1!5<<Q4G,Q5[<Q5 ,QF,LQF7\Q68<
MQF>LQFG,QF2\QF[<QF@,QW,LQW7\QG8<QVKL#E#X!R>9QW],QW<LR(1WEX(,
MR":,#^O KUS0OH9,PH4)M?1V#X><P/( G5QP#X%,R9LLP_[TCJ,[:>OPLBQK
M%JU;_PX.>Q7U\++I8!3M8+&,"P"JS+"L7!2NK*FP'!>XJPYFT04G&U2Q;+&[
M#!;M\+(DRU4OX +WUK^ <&^D@ (+D 7@*C53\ 6M<#OJ,ISFJ[L=T:03X4E1
M)*_1Z:OY^*IK2U1HN\?T&&J]JF[,K(OW$)3DJA;,NA3.2I[9$DH!1*",6*'[
M;!$Z1)0$(0SUA2>M0$]G&KI^JM#_VGV>-F_!2KBSL)OJ>JY-T@_4F:S@,X^+
M.@8^6BWZD+[R]LLG8PC/2:@++8*@7%[]H*FLG- ,;2JMD C1++CX]0)?4*<B
MD07H>YANZ*1V)J]<<-+1Y(#]2V[9J:(OK1W^P*+=V[.+#/_5.FH(A[ *( K3
MC!& HO*VAIL1!&H_>F+0N3$%)L&/T2"_/YTDZD>KG>"LK1+66JS4B!O7YCQ1
M_+"8^0:H^'"7E"O/-H*)=[D@Z?*5CYO1\^(/:!O)/ T/$TLXZ7J7D$O7"Z;2
M?3W7<UT3-%W3NS&I_&O40;<*,0N5^N ([!S50%>V5/H4Z$;.J-T9S6B+\/ .
M[3"6G5W:O,D%4UW5G&L6WP:=C;HRG_DO66JX9UT 78<?>H83ZT39>%%%9EH;
M >U:9O(HXLF5RVW=*"W7?O2\]:#8ZGM]GNR%03W4%;T^C@UTH1DBBLN;0I<U
M8WN!]'#-YJ4/B\RUV U5DVW?E<W_U2XBS?BEWU.QJN+<V8!P#V.W1$0ZV[6=
M>, J6B =C/+PC.K1#_EP"/,P!N-,VV) VF(0,_2L>OE]%/X<?-:\WS*2.@C]
M$<!=B 0]&?V W#B1K2!^W>Z1S:,6D#*.X_#A#\EHN2'=B_2 #^@=$_2 =.\
MOEW@X_#0HU4GT;%YU724X,\WHNOV$:M@I,G[-_?PX-5M@XX+G7R=XT2$WT\^
MX^1MYMD-&$P=Y1C.J";AF[QYXR2!#T6JX%4HG: =C_QPK\%HS-ZBVAG.<UR
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MWK* NTS@+S.9RU@&,YG%_^SEDS .P6NILGW*^%4TFAG*9,JJD7_LXPP#>;G
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MA,,WG$/\0<,\[$,[Y,- +$1"_SQ$/TS$053$.FS$/63$1UQ$271$/:Q$\Q!
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M@-YG@:[F<'X_M.3*JL"',0&*>W#).$,)%WT'^,"'(TU2E;A1D.1)Y0!310,
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MU$-+\(8IG!9)=X \Q)0!%4<)_2Z'.0(Z?6AQ=)CHD\CSCTP'J9N'E70'I 8
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ML[@'/-;1A7G82R(>TZ*W&)5'/'+D6Y1"!V$,,@O!)21O&IF6##H8Q4..)(N
MZL+9X&$EI*RL58C,GTR.5RY+.@@A0H$'7G(&E@KB+DGZJ)X1*V81[U0)B6AA
MEBXQZ4M8_I*4>H%<?8(IPF."<93(O"0P_S7B,33"@TDY\>%B\+$I1H5.F, T
M(]#<8BZ.5>EL?1)$RV2@#@$:$UGSP@Q%,M8MP*TD8*'!1\;HU\!DXLX?"-J9
M0$ZWQJ<@;RB>FH<JH30/5VD33?H0G&0F)<^TF+$<6^P3/5:4$'?$*Y8:I<A+
M?$41];#3(Z.;W4?NT33+R&,AZ;S4_#)*-7XVY4N-[)<\Z)8.72KS:UY)1UB\
M)QG>R*IA-)2!.X;7S,TACTT2N29=..+)NF'E'N[X9#V:MTPH7K <]N)?.3(*
M$O7IQE/P>)C:-G;5C:K)5P1!$#K,<B(T#FNH[PCD447HCZ(U%0 7DH%2/1(K
MLV*D'_3 (#JJNO_1N@JD;^5(#+D>.I/3R> \ QV8.=[1.V;2;%.WFHA0?H@1
M4(WM)/68%NGF$;>$)JLRD?U?0F(B%BMUDR'\D <&U4%'U YM0PP;B!,1"D 9
M9$@L^7A6.>"QQ</2[$^;!4 ],VJ1=U7V)O7P7CG68<F<-DYAZ%"I0(!E$I%,
MRAS(H4PTK<0[[$*12C\$P(K:FI,LP@5P3JR4/(Z[TB2IJ!P"7%2[KM*RRX[$
M'_(0HSIZB=C& 9"G'5$.<SX"UG*<5GZTM9([KHA;S)[UOLA5"C&C=6#T;AB?
M&A[QAQOR2,N<"R_$V@Q%'+:2WUQ8F4]5,&C ^L-2E0G$>;QK) %SHM?_191.
M(<;P112VIQG%BB(YBVZ,-_S4B#AF8!=AEJ5T?&#(&M@FH+*/0R!Y*A+33'<6
M5HHA'6BEY1(9PP%EI6-^*Z[Y&<NH3=8;9 LHEI[%SYOEL-:0=3RZW>)E4NUH
MIY5PVN<-;^^&CBE5O QS/KK.67544PA@5N+>AO2LN%86YO( ?9/S!3B@YBC@
MINU*)GR<AI*2F33)1%QBC'"U47EI+$&>U$$PL^]/YK!=*S4&N^VM,,.O%H@$
M]>N9'QLD/S* *ZZ'1L59=69B)*7A;85-RO"*"R_LFJG"U,:V0T</6.]TC&5V
MNZ[!N?K"5(1K6QAED'[HVAQC3K>UZTWO>]^H_SZ1BS2_[9WF4N,[:D;6JD[X
M\; K^1O@!Q$*&G>EL8"#FR8+38AD:X(@(3>;R- UMU06RN2$1UPC 5TNJ6KH
MW&%'FFK;78QW F55B*?3>^M-2VK0K'#T/AB='$$>\&X><<6N7"SJ8U[(06X1
M!.V:+- U=,;9N%>)[L4?N8%@T6$.@&@&BCA4PY_14=X0</WS*5-=":FK_N_?
MBM=+YHRPU;7IQ ;;#X1F+W47MW,3?_PIV&U/N+C9#H"M,=OK,(^H((B#]6KO
MG=[W@.U-CE?=;S<]EH-4:U1[G/A_F[AE*?;(\N3M\\B#7O!FZG#H^WWYSXL>
M2=YMS2<16I'1R7KNA_\E%&:4W5\!^>/4I4\6L_):D8@2-2JQ-KT!R77II8BL
MJR'1-:]3?U@]!<SV$:M+[HVV>V3),1_P!A3&&8-U:&/^BT9V;%S&Q*=@A;_$
M]31K5.:VNY\FMH;]N/Z0<L:/[9?[GE=Y-O'9^+ N ,!O<4]TU!U@.5_E%(WR
M786+K1)09%%;T5^F3!ST> 1TJ=!W.5++A%8$SH8_6 9<". W$:"5Q L'4D?/
MZ(._C(S?@<0@A53_78QBP1U_ $KI.!(DP13J*<ORL%]+J%8\O8<<F4WZ"=/H
M\(,*)D2K?<8@!=<!UM5% <"2/9$4B5+720^X -A(=-M*A-W5J<WIQ1(^N(S_
M63R+.?2.1 Q,ISBAYE0?7$@A$_W$MAR9%=(A&)H@YI#>&M8A$>ZA#NY$7\P#
M/F0A]8D:*.D5N @0N#"='DX(/2#"97F&] V$G)B;&!I+'\)'/@3BO"'ALCG%
M;W%<05#1K3$B;?0%/<P40RP>H-S18C@1'/+%P=E7*8:&/L@#(GA5)!:*N)2*
M8]5#$F(B=<P"/FQBDN#?98 '$MH2>TF3[,4(/R!"/7B81@BAYRW&OU3;*J8=
M#)Z&+6H?3M#-*S6,4*##1PQ2X'&C1\Q"/<S#/<S;61PCQD54*_I#1"UC.NJ$
M/M3#/8S*>(3@9N4,E F$'"EA,#I&/LB#/H@37]"-_SS@A1P)I$$PRW4Y8W&L
M8ST<C46((>E HD;PTN]5X1T*!#[0 RH^2 C&3SV)(P#(T4K:(6/X S%.XWUT
MHA(ZF@QDY,#8&2V&R#Z6H$'HCCHL)$.0E9T96;?X883D SWXQ4=(G>S<A9%=
M&J&5@T/RI&?P0^=\HX?4I$1,6C=524?B8T4(UCW$5G2\(=J\&$&DAJ>-Y5*0
MI/8YV)=\3UND!@]11$ 9UEM>15;2 X 5!%<9R_S=Q/:0T:NHC$&2AR9B)(BD
M94,L#^7Y@\WX!A^^)%\FY>CI6S%=96=B9D7:B#\P$$,0BB%>Q-"I556P#46X
MGSF<D&+F13_HTHI-WT \U?^HB,@9:D0*U>9G4D0]6-@@Z1\ 5 NQ&8C6#!*@
M7('O7293B"8.K65(I$8'Z4/9B>:_R([K->=%Z$,/TH-0(!&AF4T]CLA>X!C[
MB20 T(.%(82"%45QZI6'><J_?)EG,H5@682T>01E5DQY:D0_S$,YJ5 VP69G
M^*>9E8-N"D1N0*"(0)H^U-/(G)QO3J*%/0S#%$:XC.1Q>@0N[=G+62: 9*5%
MI$9H0>9*J%1]W(00+J)O(L(+!52$N0QYGE8^G!2&*&B!LD:VD09\PEHSJJA,
MS,(\M$Y5@FAF/D8^'"8 I ;3+<]"\$-5W$2$6J=]7@0B8 2#XH0$*54_I.++
M#$S_08*F^^09 %!-X44%UB4%/M"C(\%#Z]C0D8ZI6?"C17C/(&J%/'GI<0U7
MK:Q#E7XF?C($, )%MZV&/T2&66S->HED=V8$5\&B0%"13\3D.TY$ID5JB I)
M/1!F8* H1[30<A ;B2324)5#.W@5DK(%-,I-0J"CG-"%/G2D@&%00EBEIM8(
M/F1D%%H&XC$C*%$(EW'>'*EJ>FXGKNY('E+HLNJHJL[8>!D$/]:$G'B4E?H(
M9*EA2 @64[1,JAJK5/SB'"Z%-(K&*L;>G*9+0%%>5(@FY$EJCWTK<4 6=WA*
M#T*GN"(KYD"7:3;%>HI&2QZKXFQ/;PZ$H.9$[Z%KZDS:_W VA)26!;D@9;-F
MR<9)EZ5ZH:;EZ\'DW/0L:4N$9<)>3*S):5>(I4"DQKEF;- P7TWXPT&)1M.$
MI[4BR<;VY9=Z[%: ;+Z8#P5*YU!VUTJL:\HB"X^9@XE*1,N>Q?9,J,2>1M^9
M!3[8[$8HAZS%:YL$E5URA4%09A=6+6M:20^"A#X&CU#(&=,ZQ@,R13WTHTUP
MU=_(['1$U*V 5P[*A*ZUJ-GF(PG6!(5@1;&Q8,Z^;==:J;+B;>$&+. *Q)K5
MQ196EG8*[:5,FL\"P"S,%SI<5]=N:V=XST.)!'_Y#08RZYE4GT#5A";MFN,6
MZX]$+E/H4*@L[>'BBZZ1%$=HX_^>,6QZ J> %-O:XD1RJ@;J(NZ+?-^JE)-M
MP2XP(5WS:43MLIG@SH<ECJ?%*0U%IJY=Z*-GK-M/3 S E.WQ8DEX&:!&))\@
MC&S@^J/\U06S7 :@&BZ _,L& B6EN&35]L.+0@4^,-[+EDVF5F^RN.!B3)S:
MI&KP"DU$42^)4@J:.2]4""&T$D0"FL-K$/!GS-)G,$M\T<2D?<4@FN\( 0I@
M&@1UX4W[*HX<T1A;8% ZM&GH/F[_>J^$$.X+RW +;UC=I>H6DMQ_GMH,(\D@
MY4VF66Q![*P+ TD6T:LZYN(#BTT'$PA_G?!%6. (?P3T_FV\,DO0UF/K!AU-
M#/$$WXG_\5G84Q877K2<W;'PC!B?MU@JL!R?%P_'(&69P;6>35B4W#*Q@0+*
M7_PFI-Q$ =XQ;024HAD$UE&:>1(J#>/)MDU/U&8>BA'QG1A9.G B<<4L?KC0
M'[N(XE8$L[2Q.0(,"<\&U3PQ:4!E*/7J(\/'Q*F56"CD3CPK)H]&0'7L2"H1
ME''%P$C2&4?%PE:$[FQ>OX0D+(N%W;8$CG7J3JCD I>%]PRP1$3I5=09*'L&
MU8!?"U(+TZ6&(2JS$B<=2-Q5F>E$,@OS..NRL<8P(I.S-#>3GDSE0.!OUHPD
M^J:SHIX13I2*>&&$1<%O.1L$#6D'*C'$I!5&_KJQ+E*+.W0!_W:&)YE 6A:]
MH#H/2,YTK#Y)LD'H,S^31^<):\%"$IHFFY7 'T93!IFH _(\])3=C$104K6*
M]+N)D3GUD0E=$15Q'5\0*T3+2+E)I\P,)#@7]'AL(9N)+SF.U\#T54MGQ'Q1
MD;?&WP19Q, !KTB^T9ZU ]V@FCM;B4B,G6-M<W!09IDVA#H,VDBDX4^/4.NF
M0T<&,'.&ZV(A]5-XKCH@"%>39C-:=*_PL!1A9W6]@\? )V_9*DH$<,6]]6B
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MIOHIJJNJ.FJKL+XJ*ZNSNDKKK;;F&BNNN^I::Z_ _BHLK\/Z2NRQQB8[&)Y
M(ANLL\4^JVRTU$)K[;372JMMM=AVNVVVW'[K;;CD@FONN.>*JVZYZ')9JI#M
MKILNN__RQDOOO?/F:Z^^]?:+[[X ^\OOOP('3/#! R=LL,(%"\RLG@M'W##"
M$E,\,<,69XSQQA5S?'''('\LLL8ADSRRQR:GC'+"[T97\LHOQWRRS"K3#//,
M.-><\\TZ]\SSSS8'O;/0/A,-]-"S/>PRTD4S?7334#\MM=%4.UUUU%=/;?76
M6'.M===@?RTVNBV/[776:)^M=MAIL[VVV6['#??<;=/]=MUXWZVWW,8J;3??
M>_\M>-Z %SYXX(0?;GCBC"/N^.*/*RYYXVF63?GDD5^N>>:<0^XYYI]O'GKG
MH)<NNNFDGZ[ZLWZO/OKKJ,/N>NRTSVY[ZKC+GGOMN]^N^^__O/ML>>_$ ^][
M\,@?KWSQR3._O/'.1P_]],U3__R/S35[_?;25^\]]]9W#_[WXI<?_OGDHS_^
M^N:K.;SZ[;,/__SIUR^__?'G3__]_.N/__[^2USK DA  !KP?PCLWP$5F, "
M-G"!#F2@!"-(00V][X$8G" $-YC!"G:0@QK\H A#2$(/EA"$3AL@"E<X0A.Z
MD(4G;"$,7RC#&L;PAC3$X0QU=$$=VC"'0-SA#X7HPR(&<8A(-"(1CZA$VJDP
MB4R,XA*G"$4J-O&*4JRB%K%HQ2QR\58]]*(8NTC&+8[1C&7\HAK/N,8TLO&-
M;N3,$]N(QCK2\8YPM&,>\1A'/?:1_X]^#&3=POC'/1JRD(@4Y"$5F4A .G*1
MCVPD)+\UQTE*\I*,S&0D-6E)3F)RDZ#L9"@_N2SHF&J4GDPE*E<IRE:2\I6J
M=&4L8<E*#E:2EK*LY2QWJ<M>YO*7N PF+X$Y3)41LIC(]*4PE9E,8C+SF<Z,
MYC*EV4P>9@]BU(3F-+=9S6YJTYO9#"<WOTE.<;;EF.4<ISG3"4YUNK.=\&2G
M/-=)3Q;>,I[UQ.<[Y[G/?/)3GP#]IT#]F4)3PHN@_4QH0!&Z4(4.U*$,?6A#
M)[JO>TKTHA'-*$0W2E&-=I2C& 6I1UN$SI&:5*0H_:A*0[K2D[8TI2S]IT5=
M&E.:VA2F-_]]J4YKBM.>[C2/)?4I3W\JU)P.]:A&36I1ETI4[\V4J4B%JE*;
M&E6J3K6J6+VJ5C465*M*]:M>#6M6P3I6L6[5K&0UU%/1RM:RNO6L;TVK7-L*
MU[K.-39=C2M=[VK7O?I5KX#M:V#Y"M:U#O:O@DTL81&[V,,Z5K&,W65>(?O8
MQE+VLI;-;&0KNUG,:M&PGN6L:$-+6LV.UK2E[2QJT3?9U:KVM:>%;6IC2]O9
MVM:U+P,M;F\KV]WZMK? K>UOA1M<UAET:</E+7&7J]SF)O>YQ84N<R.EV^A:
M=[K7=6YVI:M=['JWNQAI[7;'^UWNFI>\X#UO>='KVNJN][WI9:__?.&KWOC2
M=[[Y%.]]]VO?_M;WO_@%,'\%G-]K(C? "!YP@OV[8 ([N,$0#J%^&:S@"E/X
MP@^V<(8Q'&$'NI?#&N[PAD<LXA*'^,0@+FB0#HQB$K?8Q"EV<8QA+&-A\@,9
MHPA&)X*1XQXCXQG]Z..':TSC(K_XR#-&,I&5'#MH])C'4'ZRE*.<C#).>,E)
MSC*6MVQD+7>9R]O#L8ZC#.4=3]G,9&[BD+_,9B:[V<MO!C.<YYPQ?I""S%/.
M,YZA3(HL7KG-= :TG <MZ$+'V= CX@<TD'%G-#_9T67>,Z1S/.E@),//!D8T
MH0_-Z4!W>M.>#C6:^J$/1N]9SZ@^M:I3_RUE:*CYN)J.]:=E+6I:@_K67_:'
M/I+1:$G[^LQ[)@4RA&06,3_ZU\C(#Q+7/.MFU]K9N(:VK:==RWY (QFK0$8R
MDI&/(,^&'\E QJK'S>I@' ,9T'!U3O\L[78_^]W1AC>UY=W+9%#ZUV3N!#*X
MPH]GB+O2 ,?WD\^]"G5KEMGT3GB\%SYOAKO;X:W4![DG7NZ*1QD9!<<NNQ7>
M\(X_W.,<_[C(,V?O? L\TL &=L9GC'"(NQSD+Q]YS$-.\P4:F^*KWC>;-S[S
MGL/\YS('>LV%;K%5F#SE1P]&LAG><J([/>A0'WK4?3YU8CW#XN5^.<^?+O6N
M4]WK7/^ZV,%U\_]*ZX,@UQ:SOG_<CZ$WO>IP!WO<QS[WL-L=0S?7<]OI/I:M
MU_WO<@\\WP=_=\&OJ.Q[WKO=WVYXP(.Z%5EX@>0E/X4:3'[RE;\\Y6N0A58T
M_O.$=WSA%Y/WQ(/^G+ 6O>I#_H("N/[UL(^][&6?@M"??O6VSSUA$#]EQ>/^
M(8S7_>\K/(79&__XKZ_]Z)<__-LKO/12/H:RF^\0OSM?^'!N/?*W'WOE4Y_Y
MUP?_H'D?9>F'GU29_K[ZX5Q\[KN_ -X_O_RQ3W];0[_\TY__CU*O__5O6OOO
MMWWQ5W_^)WX&6%[DYV/Y1X"3$7P'V'^W-0@!^'X#^( ,>($6&%WWYV/_!4@J
M_(>!'1ACIS"!$Y@%$ B")YB!S.4/"<AC^Y:"H>& (8B"F=4*R+< T7 6$FA\
M@S"#*@B#0,A7_G ,K/:"--@;UG>$/CA6T;  R-<*?Y$%QP>%/ZB$05B%+36$
MQR9E1HB%D2&#ZM(.-X$/5EB&H.,/ #A[IW 9:0A["^"%5[B$<5A 4DB"Q_<"
MF*&%.2>'K)&$Q((/Z! >2W$?VS$5&K$?VP$5\# 6]S"(@@@5]_$.6)$/XV$.
M[8 .D*@2ZQ 8_% >(I$.ZZ .@N@.1]$0^A"(\N$.(1$>FPB']=>&L=>#J3$+
M=SB'9LB'KE@]L&B'R8<8_9!T')A#D$=YFD>,_\4X!9?7>6J6?D/3#S_1BG?!
M#U5!#PBA#]JQB%QQ#]I!C7M1#_<!#UA!#S^1#G6!"-OA'2VAC3:Q#@HACC<!
MCA[AC2JA#KA8=75H?%D0'(EP?/E8C[:8B_[H.;O(B_"'%[]8A#XTD+RX '[V
M@1XC#_%1#U^X%-C8%8T(%?.0%[.P'>X@%O2P'1)Y%OP B="H$?( B>AH)%#1
M#F.1'E!1#_]8=3MH?'@H(5]P?(D0DSIYBSL9/ IIA[67%@>)<A?71#])@@Q)
M16!8+/T@CH0H'NEP=FQAC391D5CA#EA)#_) #_!PB>2!#ATY$>:8$O0@%F-)
M#N=Q%NYH#FD9CC_1D?\ 4 _;R(C76"'6Q@_Y@"=Y"1UYV1Q[B9=Z"21]"9A\
M&9B%Z9>":9B B9B'29B+Z9B#^9>1F9B,^9B2J9B3V9B769F9:9F4"9F8&9J<
M*9J@.9JF69JHN9FI^9FJV9JL^9J:"9N>&9NT.9NVV9FX29JN69NY>9J[>9NZ
M*9N]N9J\&9S%Z9O":9S Z9<S.7LOT K(>9S$>9L*F0B_.9S7J9S8F9S1N9S3
MN9W2F9W="9[>*9[?J9WH.9[I>9[JV9[L^9[F&9_<"9_S*9_A69_X>9_Z69[Y
MR9_[29X NI[VZ9\$&J#N.: &2I__*:#]F: (RJ +>J -"J$%2J$..J$2&J'_
M"EJA&<JA&WJA&OJ@'0JB'BJB'VJABGF4) B;^$!NR("A)SJB*"JC-!JCJ:FB
M$UBCYNEMAN.' 9,/UR$#9=EW%&D9Z? 3_S$0&RD2\*@5]; =] $6(WD3<(D5
M\P")_Z&2Y? .8_&14)$/%](/LS 38DH09>H/90H 9YJF:SJF:CJF:.JF;6JF
M<,JF=2JG=TJG9(JG>ZJG<>JG=MJG;RJH<SJH?VJH@7JHA;JH>8JH?*JHC<JH
MA!JIE#JIE@JIEYJHFOJHFPJHG/JIGAJJCBJJDHJIIMJIHYJJI8JJJPJJJEJI
MI^JJK4JJL,JJM2JK8VJ#QY<"K3"KKYJIN$JF3CA[_[7GJ\9ZJ[0*K,D:J\MJ
MJ\KZJ\P*K<X:K<?ZK-5*K<@JK<&*K=::K=<ZK>"ZK>':K.):KN1ZKMJ*KM]J
MKNG:KNNJKMX:K]TZK]Q:K^/JKO)JK^SZKOA*K_?*KP";K_\JL/M*L/#JKP6+
ML >KKPL[L K;KPP+L0X;L0'[L/QZ"L-*D#Q8IQ*WA1='L08KL0D+LA8;LN^*
MH^^W !-[KY&SE.!"#_=Q'GU7EY#AB3EA$/:A$C);$?7P$^B(%N]1#F79$OB@
M'3!9$(AH#O!H$?=P'T/*DSXW"RGPA%>BJ[,W!5 +D#T9D%/3!QH;@"Y ;L_
M1\WYM:Z7E#7DH[VB#IE('O]MBQTA*1'K$!^)2+<B@8X$L0XP40[JL [NH+>.
MR(Y7V;;IT [IT+8[RQ#OL+>^AQ#O((A]NPZ".+04X0Y/"9;J\)1MN;6UAH;(
MEY-PXK4\R+6DR[E9^S)2>X-4B!A8 (P\5F6&5+9F&WMHZT,N.RU$<;JF>RWM
MQX./TKNRM[J[6[JZ6[SY<I/(9X*5 0WD%@6S)XM6)+NRE[$$N0#YV) K=C3]
M( _S<+/#^[V3<H^S]P6M,K6S]X;$J[7&F[Z^$@U'Z7E@L6ACAG0>VV-C2Q#2
M"WN\2D/Y"WL]B$RW"[[J:S^BBX_ 0HLT*<#LJ\"Q8K6S"[V"UK^NA[5FX62J
M5FG_>7:_7"&^LU<#.9@^!7Q\@Y!?#KG Z[M'$OP"W[*/QO<% VS"+QPK*.M^
M01EOL_"3"["&:M$/ 4>_*&=P;9&ZR-<'X</!SRM3S'C"2BQ((UB+]&+$KP>Z
M,;S$,.PJ,\Q]-0QC$EP -;![6$=NQW 8&+M]B3 Y4!Q[92Q1:DO%#&P]#CR]
M'[PP"FF(;%S'4RPJ5RR 2%8#V_>_BJ$//>RZ]S8*&BP9R.O$@7/&L+>&*A7
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MRK)'P8RQQ<J[5P'M>B_@IKYQSJW2"I4L>WZL*:C<R:_,6?,<TA>=+BQL?"G
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M)>H+-BIGL$X[=>KL^7-G4)\\BP)%UL_F2J9+9[:"&57J5*I5J69IM9*?4:%
M=SX[65-L6+)-:V[UVC68O[).QYIM^]9M7+IP[<Z]*U=O7;Q]]^;E^]=O8,*
M#0/0EX^?/FC\!A\6'+GP8\J2(4^V7!GSYLN=-7O.')KS9]*B08\V;?-+U=2M
M4;\^';LT[-FR,R>J^J7V;M>V:??F_5NX;^+!BP-'/MSX\N3'E6M\856ZU!3-
MF3_'[EQ[Z997K0M&=E2\6O)%CR$[F/UZ].GMIR[HD]4TLO)"D>G;_ITAM/K_
MP8XYOBX_]?03L,  #R00P0$7K(BQQ113T, $)V0P0@LIE+!"#"_4L,,,95N
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M;H*'V^#HEC2FS[WP@FMZ%HW69%*M]N*L@;-2IN[K,5+-\'&_!.$,/WAZ_5P
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MEH.=/'JR!8@]G N&4*(R]Q"X#US ;:F_^\N_&[0__,.__9O!9?,]X0L^X O
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MOXH[K;;4DCNNN>F6NRZZ[)[[KKKMJCK6G!J9&"^\[NI5[UE<9"OON_EX>N>
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MJ#&SQ?SL%QM"7H_&>1IMF9JV3HHT36,Q>(T2WASS/\-%[:)I,)#")8M'4BZ
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M'I%L2$2#-PMUU"@=B=2B,^&1#WP8\[DO4=XO@_G%=" B'_EPA\*"V;KI>A<
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M@_S2^G:B;$7HT0YR.U5_2J6MU#&2G$:IM>21%+A;MZYX)G_0$Z]3"%?BM'*
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MK^%%I*N]@RB/(DL3O8&6=1 _.FS';^PG#/DG0)S']6,0.*2)P@-"CX"M.8Q
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MSYH4PY,@VRNAN,FMQYDDD>>+T_F1"7LET]",N*65A]3K.YI87B,]G720!WP
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M4IH_3B+WH7AR><_JY$#<>=2@$=+:-4V*$K4M>\?5BH;><^<'=UUVM:$4H>;
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MWGIJ_ZZM!MMKL;_N.NNPU2Y[[;39?MOMN,F6&^VY[:X;[['S/EOOOOG^V^S
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M_;KV[]S!>P]/?KSY[NC%IR^__KSZ]^SANX]/?[[]]OCEYZ^__[[^__P!Z%^
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M( VI2$=*TI*:]*0H3:E*5\K2EJ8RH!:-:48ONE&9UG2F-J6I3G/*4YSZ]*9
MW>E/A1K4GA9UJ&:[(3__J4]Q+M6I_H1J4]/9SZG6LZI896I6I;I5JFKUJUP%
MJU?#2M:QFO6J8D5K6=5ZUJ>V-:IOM:I;V4K7_[G:%:YUQ2M88(K4OA[UKT0-
MK%$%ZU?" G:PB"UL8@^KV,8R]K&&C>QBQ=11EUKVLIC-K&8WR]G.>O:SH VM
M:$=+VACQ%;*33:UC);M:U:*VM;!]K6Q9.UO7TO:VMLUM;'&[VS4I5:_ E6MP
MNYI7X1J7N'<];EJ3B]SA+M>Y:V7N<Y4;7>C&M;G4O>YTL<O=[7JWNMDM;G?!
M.U[MDO>[YDUO<4_+V]KV]KWNC6][YZM;^=:7OO#%KWWS>]_^\O>_^XU494M+
MX (;^, (3K""%\S@!COXP1 6+7O]&V#]6IC"%P9PABN,X0YKV,,<_K"(0TSB
M#9OX?+\-KW3/RV+UKO_8Q=85+WIEW&(:PUC%,7ZQC7>LXQ[G^,<X#G)Y>0SD
M(?M8R#,^LI&+G&0FUUC)32;)A$=\8BJ#N,HEOK*6K<SE+'<9RV#>LI?''.8O
MVW; $4ZSFM?,YC:[^<UPCK.<YTSG!D^9S&(N,Y[-S.<]^UG/@,ZSH/L<:$(/
M^L^'+G1]4KQD)#_9R3=NM*2C/.E'.SK2E,ZTI2N-Z4UKNM.@)O*E1<UI4G_:
MU)Y.=:BAK&I4KQK2KH[U7@5CI43;VM"X1G2N%<WK6^OZU[W>M:^##>QA&WNF
M:*ZSLI?-[&8[^]G0CK:TITWM:GOHSL3.]K&++>QN<_O;VO9VN,&][7&;N]S_
MZ!9WI9+),UG#FM6O'C6\W2WO=]N[WO@N];SW?6]]]_O4_,XWP/_=ZH#[6^ %
M)WB\#\[P@2-\X<G#=KK)K>Z*4_SBY[9XQC$^\8U[O.,@UWC(%9EL:YO\Y"A/
MN<I7SO*6N_SE,$>:Q$5.<X[7_.,W'SG.;<[SG?M<YT#/N=![WAU&.[SA"7\X
MO9$.\:0S?>E'C[K3I=[TJD-]ZEBWNL&I?G6M*[SK8-]ZUL/^=;%[7>D%F3G1
MA_YSM@=][7!O>]S?+O>ZT_WN;L\[8$L>\[[[_>^ #[S@!T_XPAL^P6JWN]X5
M/_?%X[WQD&>\Y!\_><=;/O*47Y31QVYVLJ.][*#__[SHG][YTH>>]*?GNNE'
MK_K4<][U9T<]ZU\_^]BWOO:>E[WN[4AKA67^\I7'//!_+_SB!__XQ$?^\)=O
M_.0[AN^'C[[TIT_]ZEO_^MC/OO:5E'CG,U_YS?^^]\-/?O";?_SG%[_ZRV_0
MS=N>]KN'_^WC__[ZYW[^^)>__NV_>OK??___QW^P%X $V'_Y)X"X9X  J( (
MB#"]YS7KEW[L%X'H5X$4>($3F($2N($6J($=B$P,PC/;-X(D6((F>((HF((J
MN(+4UGT8R($O^($R&(,TZ($U"(,VF(,XN(/HYWX%.( ,^(,)"(1$.(1&Z']!
MF(1%B(1+>(!"R(1'Z(1*&/^%"]B$54B%#2B%5F@]#\B#-SB#.@B&7AB&7UB&
M9'B&8YB&8CALT,>";OB&<!B'<CB'=%B'=AA +HB&:VB&:LB'>ZB'?AB(@#B(
M?4B(?[A!/CB%4+B(6HB%3]B(C'B%D9B%D@B)EEB)F$B)FOB(F<B)FZB(E_B)
M6^B)I'AD>5B(J'B(JBB(J<B*JVB(KAB+L#B+K;AH[.8@=YB+NKB+O-B+OOB+
MP!B,''**KUB+QEB,R"B+QZB,R4B+S;B,SLB*B3B*H-B)U2B*CGB-I4B-W)B-
MW3B)V^B-X@B.VEB.WQB*X4B.YVB-ZXB- $.,S!B/T3B/T%B/SWB/\FB/^8B/
M])C_:&THC  9D (YD 19D 9YD'(&C_VXCPRYD ZICP_)CQ YD1)9D0UY2],X
MCNAHCAK)CAWICAO9CND8DA\YDAZICB7)D2BYDB3)DB?9DC#YDC*)@ I)D1=I
MD1%YDSJ9DSQIDSV)DSX9E)IWBPA9E$9YE$B9E$JYE$S9234)E%"YDT(IE5'Y
MDU1YE5:9E5.IE;V1D2X)DC-IDF YEF)9EBH9DV1YEF&IEFDIDFQIEFX9ERDI
MEU\)EW,I>D^)E5NYEU7)EWK9EX#YEX+)E8.Y@__8E(B9F(JYF(S9F([YF#.2
MEX0YF7Y)F8%IF85YF96YF9K9F6SGE6AIEW7YEJ1)EZ%9_YIW.9JFN9:KV9:I
M>9JM*9JP^9JL29NNJ9JVZ122R9F9V9N8^9N\"9R>*9R^&9S&R4N'"9G*N9S,
MV9S.^9S0^8N[.9S'69S4>9W6F9W$N9W5R9W8N4>@69NX.9ZS29[B69[H>9[J
M>9OIR9[K*9OOB9KFZ9[T"9_U*9_M*833J9W=V9_?Z9_\^9\"&J $ZIT%2EE$
M&9T*NJ ,VJ .^J 0ZG+[:: 4"J 5.J 7>J 8:J$<NJ$>*ASA>9^QB9_Q.:(F
MFILD*J(H>J+S:9\NFJ(ORJ+Y":,T*J,ENJ+X-J$=JJ$\FJ$^NJ,_^J%!VJ-
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M>ZW($+PFW+LF?+?/X,!=\0PG_+7T*\*_8[S]F[__Z[\X;,,Y7,,\+%\D++U
MG+C6N[/'X PKG![F.PH7JZT*87QZ2_^^4!S%4CS%5'QXUG"^\:NM(?+#\=O%
MZAN_P6#$UJ!R-'S#.GS&/;S#9IS&:+S&V?.P"\RS*UL:/QS'=@RZVMJM!PK!
M&/S!?<S!(!S(?QS"&3S(@NS!@&S(BHS(A.S'; 3'+^R[]^H,"$'"D7S)* P,
M3.S('EG&:OS);0S*;#S*;BS*I;P?R"#$TWN]K/RSV-O*$ZNM8^RL3US%MGS+
MN)S+NMQF6/S%OJRX7@S,7RS+&F%]GAS*R$S*IKS,R7S*RMS,QZ$/=]RY2DS
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M_=W&$=JG?=Y#TPH%L-[LW=[N_=[O/0CH/=_TG:30O;[2_9RNK=W\'=LU -\
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MUO[J[L$J\C _\AS:#SX/WZWP&_VP\$^?]3>O]9]]TI_K\5R_)0*_>_1@#E5
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M \/':#IQT8XN,Q?]P4^T]$'16Z8TIU,#60@_),^=+G6C/UWIGF1UCX[QGE!
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M?@PD3]R#8ND78V'D&7!"@6>':0@881_(?F@"8OK'0EH741.%@BW88AH% %-
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M#L!!A/X0+E2(L-_ =PWQF8.X,.'!?%4HPFMHT5^]@57:'6R8<6-'AB )C@2
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M?O!AV&%X&AZ8'IWOE$<?F8-N>>B8B9Y9Z$[[.6;>=Y'9MVBHCS8:::FC=G;
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M$+O\PD$I5F\=(O*=7SS/7Y5JU(^.L(VBI2=M$I3]44]\L35*3"@[O=>;(]8
ML#WYI)?[W5,O'SNA'CU"$NO9F\.9T@/@0&+/1F0II!_( L#TI4]]ZU<?^]N_
M?O>UKQ!/_(&27''@)LF57">J4OT.,^5TU[]>]K__,NUG8OSM#__%W*,SV><_
ML@;!QP<9!._KOP'DON\[0 )$0 /,/F@XA$( - CLBD)(C;1JA 2\P 7,P +<
M0 7D0 ST0 WL0!'\P!$,01(\01-,P0'4AX49N=9HH"7"!Q0$01HLP1J<01O,
M01S<015\!K[0(O;@P1M401TD0B$LPB'D0 ?)_X_],T(G3,(<Y(>@RYHFA,(C
MO,(G1,(#/(6T 1HKS$(LO$%H.(8[RJ*[<)HO_$(T.I$%Z ,P?,,TU,(PE$,X
MI,,XG$,\K,,\O$,][$,^_$,[#,0]%$0_)$1 '$1$+,1$/$1%#$%5>$%RJ4)#
MG,1%I,1&]#Y-&K^N^ -^J$1/W#Z"@T2ND(5/I$'=<3_[\X=2%,'6"24QD8Q5
MC,5+;#U:/+60"2Q<1!S2$B>6&"QQHJQ,D15S\!0]\)6$$$9B-,:7J:91X91W
MJ";J\X=?'$9-:8=?]!W!ZBET"@;7"9YNDX=5:B>/ 012*,<]P (L\()V\((]
M:(=UW ,OR!G-HZMY%/\I>ZRK>ZQ'?-Q'?>S'A@&:35G#$YFA7"2:TDDK<$O(
MK0"$@LQ&AVS(P.FGD'+!O2(YNMH]58-(K%(:EJ(79'C(C%2>/2*01 #)E?FI
M_* ODUS)D^%"J;,IEI29?D"&CHR;R+@I?YC"_*B!A-+(U//)F/S)D!1*H@Q*
MHP1*I!S*HXR6S3&=-E'*I(2ISW/*J(26O *]C?D<LIJK?.R9;;JJJRPX,<#&
MJBQ+J#Q+;H*4PA*U4E.4P[(1H*"(>9"L\0D/> B*>G"*X2,(\FF(NZ2(O&R*
MO:R"OJ2/=^ >>AB,Y%L^ ("'D$C,I3")<N (MV1+0!&1*;B"58('0$"N=@#_
M!#XIN9P)!CT )-,TBRGX@E,@"A&QAG[H1->$S7R($VAP%!Z[AWL K]S4KGN@
MO^9B+RDBB9Q$$9ZL3..<D$D*,.+ZKS^ J+8<M42!SK>43LM\B>O(#(J4(-!4
M$P=B/Y*ZS.-\3O$$3]W (O7@(NH,3_(<3T$9SJPAM?6$CUG0R="8 OB\S^AD
MS^#@A[39C_3\3P!XL0X9T+KXH.JTE*0;HUF(3_R<3OUT4 ;-SPB%T 8]4 J5
MT I5SPP%T FU4 \-3VB0P0L=T0_ET.5(SC 9)1+54 QMT14]".84@\XHT23Q
MAX.,T>]QT2RA!TK[S11BT2#I![5@SC#02B"ET0X]_U(E-5$=10A;+,JJ;(=T
MB+U+V9Y6,8>&\$5:TQ1T6);$G)1[^$5U^)0N#94OO8@P'8@QG11X<(=U@!Y)
M28=6*0?VD91L0A7_Z0ASD!7(5 K+:I6<6,KCF8)X[)G.5,CB&IAW@!"?:(5!
MR +Z/$VQR8)!\,^IDL@0*S?+(*E^2%#1>(&=@M*4:;QU.02T@B>*0A=#N(>G
M,4M1?=6HZ2=YH$B-N8SMA*"2PQEZ($NT%%3*42E[@1>7<E5?#1Q/+8"@,LK_
M2YL#(5:D;(7^A-6C\ <R[+JY$8N/M"B4))#]Z%5G]59PE=9P+=9Q_58HY<K%
M@,QR75=^.54(8E=RQ:N"._^$8M6'S9G7F&1!=]O7V_FKR6,H"90%>#77>'VI
MU0M.6F0C5N&>/74LC6C8/K6([7G8QV+8]?&(=@B)/76'4G '=6!8TT**C&58
MCO58D#6*OQR(+EJ(==C3\Z&'=FA9[B$GHW 'BBV'=IB'=RC&AJ79A 4A/D#%
MQ>A&]*,_+R CZFF%+YB"-)+4O4F!%^B#1,@3(FH%W[S:)NHR%+'4GXV>QE.-
M( ( 4)*@5WI!5:#:KDW;0ZJ'[-0KLGW![EPO85-;NJV^#-J0CZS;UH-6 H%)
M1 *;$RE.O2TD_I0ZKF6C9WB&#L*7GO#!NS7#8W A*X(ABAE<R[U<S,U<S=W<
MUN/_T?3[4<[%)$UR6U4(W<NE0$U4446BD@A4W4+ZB/K#O_DCH9!%I-%-J[6@
M5]/=74AZTH+5R'OP6&'YQ768-T_9TU89WE<;WN63E'GH'N4UAW3(AVAYWE[Z
MQ>G-E#LMASRM#7@0IU],7G4@J$WQA^>5E5=+AU@;6*'! GX\U(7D1RQ0D:!Q
M5$AU6M-, 4I-!)GA WK\7WL,&P(Y$/:=%E)%2'09L&U#8 ;> N?\W0)FR4=4
M)PE*U09.EP9ZAY 240@65Z.AN8ZDO@X>8:7HAZ8-C3XHR%,XX?P00 _^77Y@
MX=!H5M'Q!Q V*C*LIYJDE[J9*L ]$?LDX0@F6"(>8B-^_^$B1F*%L)U_FMLC
M+MCD1%5+>N(D+AI[?:O/6<E#0]5'^TE9Y4< !BEU13T;I3PQB"PE3F,AYIJ#
M?=$'1=*7X)XF95(W3E(ZAN,M&03ZC()V\ 1L&05/T(,HD&%!NI3U[(=6Z(,:
M $#\39O4/(59>(IW\%%*=JZH PV"Q.,ZWHT;):XL7HA^L"'E=#1#J(>5W= W
M7M)4EBU9^%='>^51CN6N, 13)<55OF4[-A)HL+*6VN0YQN4&/:A/O6.+.%:S
M>($%1>5<7F94-F$3.=PY=EP8TR "I>:#(>8EA".T_65FYF9E_F9O#F=?'F=-
M+F=5[F9R/F=POM!3E*[:36=BCO_GP9C@-3EC> 9F<3;G(26N[S3GUB%2USCE
M?":/D.O1Z*+D/C5GV=AB %LK=%9H?+[GAR8/WZUB7)R]=J!BC59CB[X4^XW4
M1O[4*1@$FYH"+)CD>!,H.Q$$K9T*P>WHJ3E@U_AD3?$'6;A5"T95OIH^CM[H
ME[&&@4-4+AYJK#3CG(:@/S"$59"%[_%IME(:KEN:O'5JI=Q6LSB]DQI)$TEA
MJOY)9PY Q_&':XT7;*FYL5ZI41C6XB&R^>+?GG[K-8YKF);KKJ9KF&H8E9Z.
M5JUK7 0>+C92NPYLLYDDT(NKK7)7X2F9U)N%57HW>>-7<P,FJ&1=BC)LOKYL
MKFICWC7_(GUP!ST(OLT.;='6HR_( AD.:=3NV]&.GEAXP-(M('YHM+=UQ8_)
MT=5^I&=PP @4Q5 2(,)6#0PN6]IV6^*&G0E<:H%&)/XZ!-MF)/-\7/2\[3F*
MX0'V(F.>BIJ2[D+ZZNH>HA>K.7CY0;YPAN2>(BE$D136;O5>;_9N;_>N(GZX
M!_F;KO>FHM]N#=>M;UIRG=G.[R,2TMG^"D/8YD+"A]E=F%TUW6>X5TCT;_U^
M<"=ME%L2;,RF<+B>ZZK\Z-3>\+ZQ\)CD!U<6:K@26 P?5Q#OQJ,VN$)PSK R
MZKBZ%'ZH!]3XMA0'6!NO2*7>U2PUI_M6*U$%UII4ZPL/UTBM_X'*$<@'R8*]
M'G(D5JJM]IL=QN$=GA/1F05A?A C+W$F]W MY_(*[_)O]8=\0(3&!F-[I(>>
M_/+,"<6]4O,MIQD&?QV&Q)PT0=2G1+U^T!T IMXWCQ841V#%=G,O[ZDVANB)
MEN=#CVA#7^=%'VA$SU!_2.1%WO"]H5]U=G1%)P^;WF=8QJ%5P.I,?_0FM6E5
M !> 5DY#B(7D5HA'9,XLGA%_L)W,. 1QE.7EO/5.#X,)5(58();X1%'B<FA&
M=Q&.K.9@R%M,3W1EQQ&Q2\E(#L]L3DF_'791EV@6<?('2>\$D69C[W:^0/8+
M;783 =5DI_90/_=E+W=UM_9U;W1V?_]W=T<2?< '63?H3&6N4OA.<T_W3?8'
M0 N#UT;W?1_X=<^TU1#V,FG% (NE>.>]2E8,GJYV0P=VY!I+@6_W2X=W$)5P
M5!MTCP=S00=YKN*'0>@#D&[D#A?Y>OW:&W>GYFSJ/C^>?F@$RKY@L5QJE6%S
M;GEQKN&'.LGK>5CJ&6_Y&J_(ED_J5=A54)>4'D_(OOI)FN,Z$59YI'3)_+ I
MI)E/((YYP<9V M'VE*')8+6GJ&::Y5EA-J1AKJ?ZD&_[M7=[NW[-#P-ZS7OL
ME 9CU('[R=GBX)GBM_][B^D'&K\2RYE*A/P#OP?)6-=4WLE[P#\:(454P&;[
MQS<>S89PS,__?,TOHRM';:3=?/@N=4W$W1_:H4ZZ[5!...$.\.9<A=//GLG3
M72+2!RCRSNBQAE8V!#9G?=+O_=&G)$-0!987DX.@YV\1]D3:90T"0M W(D8V
MBS4B(*L&C06 YN8WHQ\F$(+$'FDNP_!>_O$V(JT_D4&Z?O,_?_1/_R+J!WQH
MY\^57:$]<,RH]2UH!_FO_192?^/OF$]6?UIR)8 (LR7,'X%B_C0"H' APX8.
M^14<&/&@P#"&_#G,J'$CQX[YY,V#)P]DJ9$AY^GKJ'(ERY8N7S9<15&BP8*%
M^,',J7,GSYX^?P)U"$U?OGS\H"W$J% I *9.DT)=&K7IU*=2KU+%_VHU*]>M
M7JN"U1JVZ]BO8L^216LV+=NU;LO"51NW[=RW<N_2Q6LW+]^]:Z<4""QX,.'"
MA5/43:Q7<5_&?AW#]4?/4$V# [?,%'/YH*%5_AXO#MU8M%-9,B=N1ET9\^;.
M_4;#!@W[WCR0\&J?M$T/YUYHI@]1QJQ:N.75FHVG+BZ\L[_@F5=!)@VWW[%@
MU:];#X9,.O?8T;UWMYO%<($7B?V]("^XQNOPWV7#?R^_>[\:Z@MDJ>LO._;^
M_/_[]XQ["O4SWGT%3#%+? ."U^""#LX'(8,/4A@A/[C!TUZ%$T:XH80?>AAB
MAR-VEP\^\^26XFVV8=@BB_/DDQ(]*LX#2/]FE[6S(HTLVG;/:R)R&&2#_6AV
M'''0 0DBB4H*F>13_AB9V1\:1G;(<)FEU"1C_=3#HXKW8.3DDF**161RK ET
M")E,LKFFFV-"910T0^7#%4-,W9D1GE/EZ=">6/79T)]V\EDHH(82>JBBB3(Z
MJ*-Z0NIGI().&JBEB#XJJ::4;GKIHIER&JJGC5:*::F?GDIJIU !=J"K@ID'
MZJBRFKHJJK:J*FJMNMY*J3Y65A010<$2*]$A[>TZ:ZJT]LJ0-;%0)JRTQ0Y+
M$V:JR&)-KLKBRNRV5=UCFTDBB4L/GM[N:<UOT5([K;75PNNN(<'!"UVWR^++
M$#*C %,=O_X&HRW_K]\VFZS!!2-,,*F#J/?""U/4,,7#$4\L<7H'#H)NO@-K
M?*_''&_,+<A+V:=>?JL^<TR_P?S+\LHMP_QRO]N)'"C#!R[0RL@[UWRPPAWS
M[#/0/2<\M- A'^TG/^*"A-3'1/^,=-%21_UTTD%/;7766!/:CS[TC!LVTR&)
M37:/^7SF$#[DD@U(O,7F6#;;<X.DC]%;0WWWS[*\&Y$L>5.MM^"!$ZYUU0NM
M\O9 ]NJSRB&\-42DN]6J>37@0F%8=BE9#FYXYUPSV\CD$1DB\.&7@UYXZIZK
MCGJ@=,H)IY:SMRE[[;2_B;OMN=_>NVRMONHJ8KH3[_ON=34>Y9578EN\_X>_
M_G$C<M-OT1E.QCM?EF0JCEN;C[:KZ[C;:!)'OO3E*T\0]K$] ^#*QPB8O?SK
M[V5@\/<']H*"Q\_/N_]3U><^)R.+,U3F'P.Z[X K>\:"$I&" Z5@$/WC'_TH
M^+\)3E ?W).'W2SH00Q6$(07=! _\%$/'<TM<UY*H3SH40]^A*DL^F"1C513
M0^7$#23T )O9-C@/<XGP@W0Q1/HP,\(C"A&):O%'(8J8/B0!@(C+(X@LE,@5
ML*W0)/-0BA6[J!A93.1*]@HA&;T8Q,7(B4Y!62,;V^C&-\(QCG*<(QWK:,<V
M @]_Y#'/'?OHQSX^JR!A+-9,JL4<GD#C$,T#"O\_5F$(:Q5RD)"TR2&R],=+
M:H0?]"C)V#@Y#Z?]D5WEJU8D5U,Y3&[$&M>1676<@<I7]C&/>KR/!&%IRUL"
MQ7Z&F4)#D(' EOWR?:RTSLJ0@2R8\*-D]^D#+IOIS&="\R?]8)LG15*G:&(S
MF]JL(S1H,X]JF@2<)-%<"XWRD],0RQ , 5;Y$G*G>O10G-^$T3;E: TI5405
M]=PG/QT2BU%*<EC1<Q=%](G+?LC3DZ#L9S3I%="+- 2,!ADC0RMJ2]@=)8D:
M/6,9-]I1CIKQHR*5Y2P'PT>1AC2EC'&D^::(ID(TPG1K21SY3MD8?\A"%45R
MJ1,'8@AZR-2C*@4 /TK_X:(4;6Z"AY >=&32TN+\P:8A]26 LI,VD IU220M
M*:P@A]6OHO0]NBS,%*!15?\@XZQ5=49\QFJ8%R!KJ&$%JUSKRA@-KA!#G,LJ
M7?DZU[\^A1\:/"H*"7O44N C)2)")YH,P<Z>ILDJ"#4LC^YQ/<#RCV_(^1MF
M^^K9-A7I3) 5CAB\&E9_K(VR]8BK7^V*%WWL5#D'^9MFT3=&UW8VMV])(U%.
M9[G?X@VXO@TN<8=KW,^Y3KC(56[KF,LZ  SB8EPM0 J^$,/GKBZ[R2WN<A&6
MT^.,KEUBP-:@:*HX>ERJ'XT8G^+:*ZW.<):[S94O=AD"#;EUS[3;)94JWK8*
M_XGVC5H0/6[AH#',?PFHNP2NKW-!ME6NQFJ^"]9N@_>K8#RYM0![<)F_AKG0
M?D #&6EM)3*>8;JBW>P^*6C%A27<8@;3E\(QMK"+0[:T'M(-)/>H,(]GW.,)
MTQC&_O"D)?76#W[<@QXYQC%^F58/:%RVQ^QT;[N(%=557(\I_0@7DSNY5Q@#
M^6H.#988?&SF,)_YQ3+."H"IW+=#@-EH_5!RDZ^9YAK'6<+]>*2;VTO1'ZLY
MR&L.]%0P"DK<(KJUBOYLHAF]:-T^NM'&LX;H9,O3ZC75TLI14S\<)]I/&^?*
M5X6TH[7"91:2;1[[RYX4-?W4ED+4B_T )G^ 03-)2__ZP24='JE[C>ND?"$P
M*/ $,15X#&2,.DFG6("K)/CK4OLZTHK6X)(+.S9ZQ"C:T'YV@V;(HPZ&!K6G
M[M[84$CND[R0M<Z[QZM'>[X;P5=;7S-W%NNQ:FW#QDQ,Q3>WGUW;=T\1BD$\
M$:I%LL5^2ULM]4#?F8!CG-LFG-^*YJV=+6KQBV,\XQK?.,<[_D9_.)*@(B>D
M.@'PV)%/DI" 6,4Q/?[,[5%3;-^[8W\E><H]$W):AK#D*_<E3("=V.6OU/4L
M3RKTH_\D9<7F<+%=*<=9$#TP61@4TJMN=4Q^+:'AW'HGPS8/?$"CY5<?>U!N
M'/.*9X0?^=!ZU]N.(GQ$&9/__.!S0.N^&E*BG)2 V/LA8LXT>N##XWPKY1;B
M2_;#[T0?DC2$W0$:AC_W<7M:WS'BGXESNT.GOY"$?.6K;NB((WS;H!^]Z$LO
M<=.'GGZR:'6[0<UPZF6&O*>?_5LT:>T44;Z"2XV(5!>RY]>CK\A);-\!K1,_
MVD<\ZOCC=>J;;SNJ%K\ZG7!!>>#DCPP3!JZH)SWRMR\D).<U_#L:_^WA40]\
M]$/=W5\_$JE-V"P)MAY*IBSY770/?' QJR%WM?(@2E-\ A_ \1\@O,,*?0_"
ML5Z4.)_WZ=8AV%93,)YLJ4M+)=$,U9]I+>#I_=L4 4(4/1SW9:"84!R:D2"A
MW5F>_Z'@H.&9"J:@H+D@H*W@"YX@"]*@#);@I%C#(11"GX57@&%:W-U@"\*@
M$%Y%4379-Z%=$'(,R/&@X<V@LW18%&J'#9J@$BJ+\MU/A!&A%0YA#3J7/QR#
M%,:,'J! ]C77(##;?>1,%U)A#++A&SXA'$:-/ZS=$5:;'>)AN8T$/:R"/OR(
M&\9A(')AUDQ3'G;9(<X-/5C65K3AIC@5#U;9NY1<4WB-P_D@)/:-& !".P!"
MW3"B'-(*E$P.YU5A*0+B()*@YM4+ %A#!!9"+.!4WTQB%\Z9'MI&/>R)*6ZA
M+NZ,*C8>0909 /BB0?!B(WJA((+*YS%@"()@,RZC,[(?-/\RHZ,1D>L)(&L$
MXS1&(UJ$2Q:Q" ;R%3U<FA@('!E!W_M8QS$DFS3Z%18&#_.QXS/.CC[4F@*5
M@HI1"6FT@G2I1\;$XS8"9 A>B _1&T&J4#Y PXG@F H99+G]4+;)8T!N23_$
M"(HXY$4NY+694UV!G+M-A"%PEC\XH!--XEJH2P):XZ75Q"&PG&L!F/)\F41&
MI!4YQT3<UN"E1LGQ#C0PI(Z40I;]H_,QUG$XSG!<!$ZNY$P&I7R,8.<YY5-"
M951*Y51BTDCF74&PWK#,(E4RE#]PF=8!$30Y%>'-A$W9D8%)H0$='U?VA#N^
MBM&Q)<<YP\\Q77683HH91@I4S%[_0HS$]&7%I*$ Q>5@2F4WQA,YN9W?D4T2
M$M77,"3;'68GW0/:$.8E^8-@W0,\1>9F*F9G@@3849TS]<,P.AYQ[-Q&6&5%
M;&7B.<X.-AY9HAQ\A>8=C=ER5.9M"B,A_=<DK>8<8=$WE8UGX"8LU5QE_-?X
MB($^:%88]>9P[I,RRF1T:N-T+J526J=T!N5(ID8C? 9&#*5/8>=UN@7,4=;,
MZ98LV(@U#MB;4(=:W5IUCM1T'09\4N=B6 ,IJ-5UT$Q7X*5\OB4XBB=]"BA6
MY</\B5_YT=_MS<-<\ .2G5""0BB/U,,BAF='\4,_X$.2U=^!1JB* -Z](9H^
MH"3L&4(^_[9%+$0/Q&D)/P!';+4>[*&&&#C690')OXUE<I1C?58H[]2DI>DD
M_TR6^ 5>@"KE[A4'DB"E;>[H@#;&"!8C*)[BDR)CE%+I+E;I,:*BE&;IE1IC
MEUJ. \9+(R2.SFVIE9HIEM+*G-VACD'IJK1B#Q)$B7*ASXEA,'!IFZJ@6[J*
M%J+IG4ZIE3Y#S(CA6O))*_@G!.E,GYZIE_ZIHCJJ,8(?(H839>(##ZWI(2+6
M<X%8ETBJ+2+B/-2#/@2=C]&A>>+II?@#AN:#_%UJJQJBJS;-J=8*>D9BO)#C
MJ#'JX81/!%XBG(X.2_)<Q[19#P:KGY;IH\IJ<9%FG)KIVC39:O\9JY9**[X4
M9Z^NYK0N:K).&'3J:+<RJ;<2Z9*&*[B"B'9.CSJ1:[HJ1%'U)&Z4PC4-57/
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M>_*$F&6*H97E,!4OFUF5:OVQAB:;:IIIYYQYUAF8$3W.F.B6,3;ZXJ2'1AJ
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MI GG)H-+6FZ-EEI5IGSK2V'XJM<:O&M=& ELWZO)J&<A!@97/=SAU<4.;O+
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M$4VI44W1<48BI.LL+MQ@2MC.=$U#J$E&2$J=-$^I:-O4*!Z[9/N@5*[ZH;(
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MTQOD(/TQ(7F"'KZV^@-0)I,UH@U,UC=KUW4?^GO__G_?_O<?__^E:[$S'B
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MT(4JM* 0;6A$;?A0B5J4H@[-Z$3_J=&+<G2CZ,&D83;IT8-B%*38^\P:N5-
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MCN(KKN(;[N(:'N,>SN(OWN(V7N,X+N,A3N,Z7N(WWN,\/N,P+N0_3N0Y;N1
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M7]_\VB\_^J'_X]GOWOW ?__PXU]\^-=?_O:G__WUGW_^S[_"I(^] !3  23
M C3  T3 !%3 !=R?]L,__WO "-P_")Q ">P_"Z3 "ZS #=3 #LS ,CD^\EN_
M]!N_\RM!]>L^$4Q!$R3!%AS!%UQ!% 0_&)S!&#S!&W1!&\S!&N1!%>Q!%J1!
M'Q1"@G- #OQ #$1"(TQ"#US"(U3")V1"*'3"**3":@- !L3"+-3"+>3"+O3"
M+P3#,!2W(JS")C1#_RD\PS)$PS54PS:<PC=,0SAD0SD\L]< 'B#4P2#$PQ^4
MP2'LPSWT0QS4PS\D1$',PT/D0T-,Q!T,1$8$Q$<L1$>,Q$%4Q$:D1$E$"#*D
MPTV,PTZ<0T]T0U#DQ$\DQ5 LQ5$TQ50,BBL4PU9TQ5>$Q5B4Q5FDQ5JTQ0O1
M1%'4Q5/<157L150$QE\41EXD1E\LQF#4LA"$Q$I<1DQTQDN$1D2T1&ELQFA<
M1&N<QFNDQDG<1F;D1FT$QVP4QVKLQF<L1VPD1X'*Q6,<1F-T1V1\QW:$QWF4
MQWIDQWN,1WS$(%:\Q7[TQW\$R( 4R($DR()$O77,QX2D1WVT1X5LR(5T2/^&
ME,B(I$B(M,BN4,9O'$>-3,>-],:/-,=P[,B1Y,B2!$ET-,F0]$B5),F3/,>7
M%,F41$F7C$F:7$FC0<B+G$B=K,B'],F=_,F>!,JA%,JBY,F:XT>#5,JE9,JF
M=,JGA,JHE$IERLF@/$JKQ$JBO$JMS$JC[,JM]$JN%$NGRDB;;$F6E$F8O$FU
M/,N91$NS3,N:?,NY=,NZ9,NX7$NYM$N]O$NX]$NZ[$O %"JI8Z"O-,RQ!,O$
M/,RP9$S%1,S%=,S&A$Q62LJIM,S+Q,S,U,S-Y,S.]$SM(<Q-DLS'),W1-,W(
M1,W)+,W47$W5/$W7C(JR%,R\I,VV#,R]K$V\M$W_ON3-W/Q+W-Q-WYS-X"1.
MW33.W[S-Y.S-XD3.Y<2(JFS-Z'Q-Z63-Z;3.ZL1.V-1.ZMQ.RJO,SP3/\!3/
M\23/\C3/\VPZZ+S.[LQ.[G3/]7S/]H3/^93/^F1/*)--X#S.X=Q/_6Q.X?1/
M_OQ/YA30 @W0 U5. $U0 D50YQS0_EQ0"'50 \T)];3/^+Q/#-50^LQ0#MW0
M"_70$ 51V_E.]#31$T71%%71%671%K4F"^W0$8W1&?U0&A51&Y71&M71&]U1
ML0HZ'I)0!9W0!A72(F70"'W0)*70(472)372(#U2)I72)U52(HU2*G72*WTM
M&.U1'/72+@53'A73'!W3_R\MTS"=QQ)UT35ETS9UTS>%TSB5T_[@TC.U4S+%
M4S/-4S35TS[ETS^]4PS,SR:U4B@UU"HEU$2=4BT]U"QMU$)%U$5]5$7%4DAU
MU$BM5$IE5$RUJ#K=TT %U$\553\%U5(=U5 EU5/].C6=TU9UU5>%U5B5U5G=
M3$]-U5M%U5PU55S=55U5U5_E56"MIT&55$Z=U&*]U&2UU&75U&/-5&1E5FAM
M5F.E5F6=5FN5UFQ]UFTE4%OUU6 %UV\5UUXE5V$MUW ]UW$-#5:EU79UUW>%
MUWB5UWEE/6]-UWLUUWQ%5WU5UWWUUWX%6'S%R!_E5F?=5&PMV&J-UH1%V(-=
M6/^'O=:'-=B)5=B(M5AMA5B,I=B&G1I[Y5>!#=B/%=E_!=F2'=F0)5F195=Z
M9=F6==F7A=F8E5GY\MB4M5F4Q5F3O5F=S=F3Y=F??4-B95B)K5B-+=JAO5BD
M-5J./=J,5=JG==JHW5BB9=JJI=JK35K!J]F>W5F?]=JN!5NN%5N@#5NR];F5
MG=FT5=NU9=NV==NWS9^M-=NY_=JQK5NZ+=N[U=N\Y5N7$UJI;=JIS5K!75JL
M+=S!#=S$M5K$7=S#=5RH)5S(55S#E=S&5;G0W%N[[5N\U=S.Y=S/S5S0W=S_
M(UBX-=W31=W45=W595W]D-O0A=W1E5W/C5W:G5W1M=W_W 6=OXU<P+5<WZ5<
MX&7<X.W=XIW<X47>QQ5>Y37>WVU>XCU>YOVMU[W=VL7=Z[7>[*W>[=5=[>U>
M,D';UA7?\27?\C7?\Y55ZOW>]<5>[FU?]O7>]Y7?^,U>WHW>RH5>Y[W?Y<7?
MY.U?Z=7? ,[? ?9?_C7@YRU@! ;@_%7?^75?^GW@"(9?"7;@";9@$0U?]-7@
M#>;@#O;@#V;*!H;@"Q[A"C;A$D9A"DYA$DY5^Q7@!-Y?!?[?&3[@&+;A%UY@
M&,9A&I;A&MYA'R;@'!9B\A-A%39B%D;B$SYB)4[B%6;B_LM@$);B*:;B*K;B
M*W:](F[B)7;B+N;B+][B,'YB_R\..Q<.8AZ^X3,&8AU6XQYVXS1FXS@>XC6>
MXS?^83MN8SBNXVW1XC$&8S\68S(&Y$$6Y$+^XWN+8BQ6Y$5FY$9VY$=NLSXV
MY$ ^Y$JFY$LF9$O.9$Q&)3.68S2^8ST&Y3P.Y5(FY5/^9#H>Y53&8U86956&
MY59>1$G6Y$G>Y%NVY5RNY5WF9%X.IT2&Y& 6YF$FYF(VYFBBY5Y69ESV95U>
M9F=FYF=NYL[PY#TV95>^9FM&96W&YFU>96X&YV\6YUA^95D>9W,F9R!+YFAF
M9VAVYVF6YGAN9WB>9[  YF/&YWS6YWWFYW[&D'5^9WD.Z'HFZ($V:'H^:($>
M6#L$TO]R=NAL/N>']N9TGFATMFB)[N:,#F>*UNB(AFB.WNB) 6B$)FF%-NF"
M+FF4/NF$-ME[]N>7ANF8ENF9IFGS&.F53FF6UNF<YFF<]FF5OM-J]NB*QNB0
M+NJA[FB01FJC_NB+;NJC5NJH=FJB?NJYO&F@WNF?SFJL[FFNUNJN'E&7KNFQ
M)NNR-NNS;N2KWNJU!NNV_NJW]NJX9NN=%&JIANJI3FJ\9FJJYNN\ONN_KNJ^
MWFN_#FS"%NREGB2U=FNY7NRY9FRX=NS(;NQ?%&NTMNS+QNS,UFRV56S(GFS/
M!NW'%FW)#FW2)K:ZUFO$MNO"'NS65NW47NW#CFW#IFW7GFW_VX;MW'[HSA[M
MS^[MTO9MTQ;NX"9N1JOLS4;NY%;NY69N%^7MX0;NZ/[MZ89NZBYNZ_XKU 9L
MV=9MUG[M[:[M[_;NVQ9O[@9OW#[O\@YO\C[8Y[[NZH;O]Y9OZ8YO^I[O7R[=
MYM;O_>;O_O9O\W1O^Q9P[";P^B[P^S;P!)<T@F7O[C;O\7;P]8YP](;P]&YP
M"Y]P]:;P!^=P"<?! #_P 5=P$4?P$B?Q$P]QK#CN_V;Q%G?Q%X?Q! 3Q$4]Q
M&K=Q$Z]Q'+]Q%#<^!L_P"Z_P(._P#?=P(2_R(=?P) =R)%_R(W=R(E='S-7Q
M*>=Q*L_Q*L?R*]?R'F?H&/?R+P?S_S 7\P"<<2O?\2TW\S3/\C-G\_?6;B.'
M<B7_\3G'\#J'<SFW<R:G\SMO\CCO<SP/\C)?<S5'\T$W]$)']#;OWA4?\T9W
M]$>']$C'+T%/=$)7]$H_]$O7=$L_Y#?7\SQ_<D#_=#[?\U$W]5#_\U0O=51?
M=3]O=2*6\DSG=%FG=4RW]4VO=9UF=$GG]5[W]5\']FFB=%R_]5DO]EPW=F)7
M]I3U=%8'=5=_=E%W=E*/=E6O]E>W=FK7]E.']FUOO&%/]G!']G$_]G)?=G(_
MRET/]G5G]W9W]W>W'W!'=W$W=WH_]WJ?]WROPF;O=FZ7]GZ?=G_/=H'']H*_
M]H/W=H!7^/]_9_A.C75\A_A[EWA[IWA]GWB[57=XU_B-Y_B.]W@!D?>(KWB1
MM_B1OWB21WG;X_>&-_B$9WF$)WB8#_B97_B!I_F7=WF;K_D]#_F3]WF3!_J2
M%_J4#WI[R_B/1_JD5_JE9WK=Z/FB__FACWJBEWJHMWH*6WD?]@?MT'F<C_F<
M;_FO%_N;[_JR#WNR/_N=EWFF?OJDRH>1:(>KI_JYG_JZEWN[KWI[SN_\\@=]
M: >": =\\ U]J!Y:69YZ8)7UZ)1V$)9U:(?LX0U^D <]6(=R<(=U*)^FU_S-
MY_S./\"V9R=\4(?!68C'L9&:T(?C('VVB1$]B(NTX9O5;X>;2'W_NT$<TE>'
MO*?[N^=]W<?[W0_5K-]8?ZA\Y# > ."'>E '<[ 5FM #[7!]VKB'5_F.?UF'
M5$F1CQ"55,F'0UG^X8C[01$(YA!\LU][KT?[\S=_L%?_M$=_M6?_^!][^)\Q
MT!>G>:B1\O>*=A@<V8")?@ (=.7,E?/G#P#"@PD1 E (8!U!=/<8.C1H#ATY
M<_P:(G27L9R^B@SY"<38;R%*CBE%KJ3HLB5,E3)9SGQ9,R;-G#9UXMSILR?0
MFT)Y#OU9-"C1I$:5(EWJM"G4HU*93GU:-2K5K%:U8MWJM2O8JV*YCOU:-BS9
MM&;5HEWKMBW<LW+9SGU;-R[=O';UXMWK_[<OX+N"^0[^6S@PX<2&%2->[+@Q
MY,.2&4]^7#DRY<R6-6/>[+DSZ,NB.8_^7#JTTGS\H$'3EX\A[-BR9].N;?LV
M[MRZ=_/N/=L=07,3>>,S5\6<.]OUS!F'MQO?P"K):Z\*_H[AO>#M;-\[7DZ>
M[_#BQY,O;_X\^O3JU[-O[_X]_/CRY].O;_\^_OSZ]_/O[_\_@ $*.""!!1IX
M((()*K@@@PTZ^""$$4HX(8456GBA>ZWEHQHTII'VH8=.W2,008A0]4Y$^/SD
MST?N,"7/0"#I1-) ZW $#XFOY=1/.0)M=QJ0(*(6XI!%!DGDD48*F2232SJ)
MY)-*0CFEE%4V2?_EE59&F2676WJ)Y9=:@CFFF&5V2>:99H:9)IMKNHGFFVK"
M.:><=;9)YYT]<:BA3+ YY.=L?]H$J&R"ID1H;(;V.2BCAS:ZJ*.10MJG/LQY
ME\X[&TUZ4#O&F7.2H@=9BHZD?[83W4F)PA:<.0Q!-) U@3(48SJAREKHK:KB
MNJNNO2+ZZZ.V\@ILJ;D2NZFQP29;[+#*-LNLK\Y&"^VQPDZ+[+/87FMMM<MJ
MVVVVW$H+[K;>BDOMN.FBN^ZWZK;+[KGORALOO>;:&^Z]Y>*[K[[]DONON_7R
M"S"\^1(\K\$!)USPP HWS+"_#D<,\<$"3XSPPQA?;''%"VO<<<8<2PS_\L8>
MBTSQR"FCO/+'*K?,\LDORQPSS2;;'/+-)>.\L\X]D_RSRS7S##3,.1.MK88<
MXAEGGC/YXPZ)/69DCCR:RL1<CT2A$Y'5/*7ST5'J?&00 !=EU%,Z&'UZ)3^K
MN>8VAV]K"#?=<]LM-]YQZUUWWGSO?????0/N-^&#&RXXXH$K7GCBC"]^^..-
M0^XXY9-;+CGFD6M>>>:<;W[YYYV#[CGIHYLN.NJAJUYZZJRO?OKKK</N.NVS
MVRX[[K'K7GONO.]^^^^] ^\[\<,;+SSRP2M??/+,+W_\\\U#[SSUTULO/?;1
M:U]]]MQO?_WWW8/O/?GCFR\^^N&K7W[Z[*]O_WZJ3,OOUIZN87@_;_6X$QUS
MYI02FZ5:=9MT>&HWP:D";M(1G5D%!S=Z:&!^^.$:?;1&'Q2<8 4OF(\+6E!#
M'-3@!SV801%:$(0CQ& )2=A!%*YP@R=T80I9:,(8PK"%(92A"F=HPQ?>L(8Z
M_&$.@XC#(?I0B$4D8@^3R,,ETE")363B#I\HQ2A2$8A(A*(5CZA%)U;1B%S,
MXA>]B$4Q3A&,8[QB&<G8132N<8MG=&,:V6C&.,*QC6&4HQKG:,<WWK&.>OQC
M'@.)QT'Z49"%)&0?$\G'1=)1D8UDY!X?*<E(4A*0B(2D)0^I24=6TI"<S.0G
M/8E)44X2E*.\9"E)V?])5*YRDZ=T92I9:<I8PK*5H92E*F=IRU?>LI:Z_&4N
M@XG+8?I2F,4D9B^3R<L**@I_^TG::I8F33OI!!]J*T<['+*U'G7-)C%:!U/4
M$2.RP81$Z>!(V@:R$9U<I!SJH.8TFS8_>-)3GO&<ISWKB<]]WK.?^O1G/@/*
MSW\25*  ':A!"XK0A1ZTH0IU:$(CRM"'4E2B$)VH12OZI?KIR&A!\VC1AO;1
M .J#(R@ZCHI"I8_H7.=;\(B.BGH%C>!,!P H&LAP=*4/[\!#:#[[J$A#^E.A
M'LVG107IS)!J5* .-:E!=6I3ETI4IA[UJ5*%:E6CJM2M6I6K6NTJ6+\JUJS_
MDI6J9ITJ6K%Z5K6F]:IN]6I9VPK7M;XUK'%E*U[K.E:ZSE6N=N7K7_VZ5\'>
M5:^%[6M>$6M8P/8,FAW2Z$61M$UT6*TX/7HG3-X1HY \11\?R:9/VJ&VCN9#
M;3;*R?XP\IJ,LA:CKHTL9&/;6MC.5K:OM2UM;UO;W>JVM[G]+6Z#RUO@#E>X
MOC4N<8];W.4JM[G)?6Y3..K,Z0*@'^Y8+6W\ 1'CM)0A[_!.=V,#'.;\+U&E
MJ$>JQ.NIFL8&'MX!#VSV9QSVPN:D5*,N?O.KW_WRM[_^_2^  RS@ 1.XP 8^
M,((3K. %,[C!#GXPA".<8,="E[D[N4>/:+6.=JQ#_[Y20T='%X*C&+4#'ANJ
MASHB0HZ8.H0?$?G.2F!D6GK<0Q_S:,=')&(3>*BX'?+0!S[HL8YKYL.YR#VR
MA9%LY"0S><E.KO"3E0SE*4NYRDVF\I6M'.4L<WG+7L;RE[4,YC&+&;+272QA
M&7M8A/1C'BGVCJ<&HH>8 DL><;XSB''E#W1XYQZA@M&=+T5G197B@(9&1TG5
MK.@T,SJQ@77T8"&]YDBC6=*+MG2C*ZUIQ7+ZT9OV=*<I'>I)D_K2GQ8UJ%.-
MZE67.M.C-O6K7:WJ5F.ZUJ>F]:UA/6M=LYK7N(ZUK8&=:UGWFMB_1@B%RYSD
M>0QD'ETF\[.5'>9H4WO:UO^&]K6EC>UM:[O;U>;VM[V=[7"3>]SF!O>YQ8WN
M=4M9NA(N4*?,\=AWT[O>]KXWOO.M[WWSN]_^_C?  R[P@1.\X 8_.,+YF^QR
M U=LZ#A(NAFN[HE+O.(1OSB[+9YQC%.<XQKO^,9##O*1?[SD'C^YR$V><I1W
MYLS"?OFNC>WKF<N\YL&.^<V+G?-CZWS8.Z?YSVWN\Z'#O.=%YSG2@4YTG"_=
MZ$P_NM*A+G2I![WJ34_ZU)^N=:=S'>M6I_K5H[YUKX<]ZUUG[,)9KG*2J[WM
M*W\[V^&^]KF[/>YVI[O<ZX[WN^N][WG_.]\!O_?!^WTA[DXXXA.O^,4SOO&.
M?SS_Y",O^<E3OO*6OSSF,Z_Y!Z5=\(4GO.=#'_C1@Y[TGS^]Z$NO>M2;/O6L
M7[WK8]_ZV<.>]J_7C,O'+O:SFYWL8/^][GN_>]\'_^O%+[OQ>9]\XBL?^<X'
M?O.AS_SI#[_ZPK_^\JV??>P___C2UW[WH^_]\8N__-3G_O?13WZ>=][VLJ\]
M_&__?OF[O_[QGS_^[4__^^L___S___X%H/\)8/^!W.%M'@(FH (N( ,VH ,^
M( 1&H 1.( 56H 5>X 6V'P .( <6X 9Z( %^H B&( EVX B:8 F"( JNH JV
MX FZ8 I:6.Z9'_BEW_;=8/B='P[:8 [6X/KY( VJ7Q#N_^ /"J$.]J 1 N$1
M\B 3%B$1#B$2/N$2.F$45F$30N$53B$64F$6*J$7)J'9:6 ,CB$+OJ 9DB$,
MEB$:GJ$:MF$:OB$;PN$:SJ$;QJ$=TN%#'2 &[B%MK()HF8,>P$.B\2$A%B*"
M](,^I%>]\0-VV1LT*"*]Y<,]S!N]]<.&X-MJ6$V];1 D2I@^U$,C2IAVF0,@
MW-M,E4-.T9M[I4,G0A@_$% I.F)P#.*[N<-QV,@B;DT5U(.]%1JL&*)YB&$=
MXF&208>*O1ASX(/;U0-&.-OJ[4\Z8%?A]0-S; ?JX0@Y../G08,X10U&N,C>
MU4.,7!,Z."/>#5F.#00KZATT*/^0-Y(#.-8=/8SC9W43VVD7.0Z$<^C=B&18
M1)A#HKF=/P":U!!$.]BCRD%-CN'BX-%(U)B(Z&&8BJG#.H6>0D8$0_)C2:!#
M_(2>/V@60<C#Z;D81J!#2J6>+Z)#1@YC9,V@%K[D%TIA3%K+-KF#(N8#1'@'
M.((A6^W4 6EC%\J5?95#.E#B3'J5/QC:CQQE8.4#G%4!4'+AH[UB=,!#/>##
M31E'5&[A5W4'0:1#*>0#/;2#=Z"#4?+D4G7*<;1#/4##/.BB.2PE6B+5*8;D
MAF0E5,XE6,T#>*W"/0"'=]"#%=J5/[P9U>2#F_&/)LID6M6E'M #/C!;<,0B
M8SK:=X7_Y#W@ X]Y1ST,9J3Y(C-.9E ZFCI403G&62IZ)EGEPT"\PSI$!RM6
M9J7Y(CU@#2F.YE75)4?JI:@]#4^IIIJ1A*?0&6_>E2_>9G$R9?D)HQRRI'&=
MBHZU!#/&R$Y:7&K-@XIMI=H-1#MXQ%?.F]O10S.V4UP2'G36IM1HY\KQ0X8%
M)$-8%CHX!\GQ6#F TTO PT?T \H59D8X6T7T SH(!"Z>''0(A'LB1';TB'R6
M' &5@V"ZQ%MF1$6"G#Z4Y(0V1#>N9,?)F(:N%$$HH]QM4Y&YA#RHS>@IT#OM
M&49Z7H'^SUO&B)\)7J>40W6])D90)-[M67T"@(NM*,GU8X!V_V3@?62,])3K
MD20YF*3JI:2&WF%+K@:? .,>>@HMSH8U!::!46,5P%=U1(<Y,EAMREM''(<Y
M%.6#/1!F">=:/EBEY"4 =*E6-AB?K<UL\(-WA"*!90<@UH:=5<$Y)1@@$ 2>
M)@0!^4^"[=EQU(:=$D0K"AAVF@,OSH:--NJ /1"IU.EQA->!Y4-ST,9F#BJ!
M\9B8SH8"_6EU-5B8K@*;/1!S4":#L2I#8&>?.5B;RF<_O*9QQ&:#/>IP]&BK
M(IB''D>DRD8^/!!L$F> H0ASZ$&CRD,ZD"DI4NI^ 2A/T88^C!>9TD.!&:.P
MTL8]&&NN(JN4S@9S.FESVA9T-JE(]/_C152<+\H$>C:CW8E-2T'<.WQ$-.;=
M2D5G0Y D=\Z=LL)K=K*=9CUH2XR8?')<4FK$4)3$H(6<>*HK0N1#1IS3R>T/
M1+;$.P@$?'$<>_Z(2-"(C:9CQZX;CFCK2C";.C1HU*1#3HU;/Z284##'D-&C
M.9P6NZU4PKI$:;E30698R5(<<UAL0DR6C6PL.8!LR/4CRA[$BY8(/W3CRVZ<
M9E$60]RJU%"D,;:*QPVM2E#CBHH6.>RLM,VCVO#B0?0#CB%C029'Q!EKD"9$
M<;SCB['8NEE3C(@D0P#'ST:-.J27N9EM1J M .B#V+"MVKBM<]Z)2RHG3"8G
MY!K?PA*EN*C_Y<-Q)='TPUF^Z4]&;LT@*\39XG?B9LY8XJ&H:7D^+ELAXFS
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M"BJW]+,_A/1TR*\_%.F?B&- \\MU,[0-"\I+(_]KH/KQNE#S;A8[H<I9B0-
M:9$I:U>+I0^H OLD'?\)I#.SM=0EL2<G8.8K18#KD0- @I8SJS^*BW%GO!][
MNQK*90Y$N]<PH0PO/5<$2&YIH73[_UH\H^3DW_H)N 8WPAM: N?ZI-1E$ /
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M!$#( P# WT""!@L.[#>O'+IR[08F/!@1846*%R=FE+C1HL:.'#&6,E<.'D@
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M;B-(4HM2=4W&!!7"K(L8F\W25O1/OA0PQ@NC'N=0V'/;R,<SWP-5J^"F%&)
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M/IOKFH]NY--!6+X#[(Q@HKHJM-UF*6LY #:D3SJ?5HEF6&+R<ZFS[G[+UIO
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MC^DL<(+"BU6*SI,^@ER/@AS4SU*.YQ-SH*^#) 2 @,)W/.F80ULE[""&9)7
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M235*39+1#P2CHRS*,GFW9U@"H5B:*?P@#U:C#N\0H$N2:/%I)?3PC6 *-NV
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MK;WWVW]15:IH)R&)J11GZ/$5>OA/@6:Q'SH4)9![ &4=3%')5MK1&'_THQU
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M$EPN9#U8#.2F.U5'R/I#M1J>R('<@8\W9D2((^G1*5VM)^Q,,"$Y*>9#_!'
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MA@G>?CG9P&FGJ(=V> <[ENY7*25SL.)1*FUZR.S\IHG]AF&"J&AY2&#49O
MSU:WC5\1#Q]2<HYR*<-@B4,1OX^2H6GBJ:_XM88![%QB$<7(_<;6R1AUH-N#
MB)_&?=^/+AD]:$5?F441EQ,659$;'ZB0)7)PK,,')T]C*<81_XF2J4PGMX^6
M$7'>IAT>OT87&W%]2!QJJ=Y@62(N9U%W1!91SG)OA :0_HAV*.=?&9#P!?+B
MN198-A8T_X_??&Z7F306)R-?Q05&%2V6G$A<$0\>:NDD,#P(:5YR:^1M0R4I
M.K?2!1OQY7L<W<7 U8E?':X6SSP6*WQG^-5AK]&#+P< ;EE?N"T%PR+>8<E
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M> @D/&WJ!8]"[80;KW7T9&?C;5O)22AK_OBJ[+3$GEHME;.IBA^AP^GC+;@
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M24QL*'"/(G:O)D@(]DY.),!$'OSJ.G0I.GJ)BF;BXY)C_O).[O0GS)A)F<2
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M2;%+YG@>IT<#C+SBBIBSA-^J_:'9/Z=8Q/](L[\K]N]ZC0/,M#34Q:/E ,#
M82\&W?Y6J$M4, QB$V:]>;-NV)]&/->V,9&]-O7,XU+)F\=*'E-M[S.<:)[%
M30&R[&K);-X4@+@#.@Z>R^ZD '=%C"F \8;,Y_*S4KZ:!O'6^DP4@-&B+7NK
MUYH"M*Y3  H@FDOF+HP"+Z:74X#("0I UG08X:Z?GZRP^H&!8XQ@%N0@]QFB
M)HH"X$;,#S&@R&WBN'WTL.P=<UIC<*Q\FK8X<-&UR_!4^)DFWF:/HUJ2@'=Y
MJ-:0TD3IT141D.W@]'2;3*I(Z=<QO/PK<><C#TEQ ";T*3%>=7Y2U<9YN("H
M@KGE++=<(EW4XUPQ UQ0!:_6D8*M9/DPJ,<D0Z\Q-9/YT4+WLIN3ML3D7_<F
M+XO)/ RJ\-C],GP=!&C8>(N,=GI7EO_*>ZSVLVE22EU8..K7MU>:%]B,^HF>
M><M:?$?%C1YY,*-!] T\#F9__7/CIR'G6^NYC5N+!C_.A);T 8XOQ8_OBB]F
M/)QW0!A"(IIYI-G22BC [,'OR4&84X"V-'PAZ=<("A\"IP#=I<98_:131.]9
M$7BGBO*6H]W2J/ETKS>3Y'.K)"8>\VZ!RYNW-]OE8Z=E"-^BJM$QF3&1#[)^
MRIUN:!SV].)U^K%_K&--NQ6M]<*WM^Y115<,2<J4D0*@9>TI $,M!2 %1Q-E
M,+>%=4O9#I-G* !A9<-&70_*_[8@0Z,A(2W@\CFB+.;AE5\[WB11")RP(D:4
MQSA]8W3OGCA\=$B5UT:!L+F+& H'] MNNY-!HTK&0@L*1Z4WKMV+.Q3CO;O%
M?A*DXX!H0\?;\76B&7[ 8K0;XD,\BIS39CES>[T<=((>'9?P>!PLB(2G]=K[
M*Z8)7%5X;6U^!G0\5 :Q\W?[DO\M-?P_"-W@]Z!(,_S%RNW!#=>O#<(J?[V.
M^*N%!EJ:H>5P\P[)?'^U/OW_Q+M$\H_5^1?IOTC_1?HOTG^1_HOT_T)21S@F
MC JJ]#\V?Z@9]@[O@Y:X\^+C*NZEI2LVOK(*K#__\!W-<]BQII7FD$$*,.8!
MWA4<I@#;GX,'6;[NG2[59#,B2E$ <;+\X8D5R '$QV'D(>JO,*XLGW Q]R.C
MY/N\=V5(=J+'=8)UUJA@<[9G\4\!L1>M_OQ^T\DB0@QU+G0A\2/O'ZL>(NG<
M L<K<HHGEW9M5,:C7@Y5+&:>6M?\</Z:?%9Q1C@;2*%DFI;HBH%'!URRA=E?
MJ?PN*Y':EZXN&1&$2#S67=PR&\S*P#,\<$74_O#F8["K?!P,M"4_#5\JJ,"U
MNH,QK-\K*8 6.WRIND)B]QT%2/4E9E  IZ--<IS[>B,/!3CC%4D!''DIP(&L
M&ZU[YDP@]XI.UN1-!EI"!N9&"B&UY7-,U,[C'L]'-(8XQGM1K70:(4]H8I Y
M2@2;M?6B5?A'U+JJ_RP;CT%I >P#+7<*NQ/7IDMM6.4[JT#+<7W:Q+$E7ZF=
MA6;%HTHMEHE5"$\C7[FCQ'@5DL,0%+UYZOD\EOUZ:+OGHYP3YP<^J8=AWC O
MUEJ+OC?]V7?X<8"<N/,P-<W=MZVYKW1/_R?OAN#9[AOM\=EO6$>V0&L)A ;=
M.B+D'<RB0TM^T)40D.WKDUM>.,XAY\I^G: 7^K$SSN5*V,'8D%E//4^3GH?@
MMHN>UWE"CI9_!6[9[?TG1>HR/?Z_NNUO4LW*H8P"_/"PH "#RZM+1O^IRSW,
M('TQ/Y2*W9[#^8Z>^LL?R==5K-1!(K)_F6(IP(?D? J0O\<S9?V(^!+WIV6^
MC]]"Q$%$&J7PA>:UE6->&^0QI09'1<&PQ%I/;_>G#/4O]?*ZV26.3]!&+KG1
M#BQ5>#@2G[PC0EIKM62&=^Q#("P3=@D_E<X<OO]E0'<QK>?!G+- O]Y%6%EV
M- 7@KV*+9X'SIIZ=5!D5M?T\5"VD*BN78TNC4!E_1<@#,/!Z(PCT'A6!YR;)
M9ZE:H$(HP'N[!@@=!?CRFFJ?8U$H<H(=%@[=HK):),BC2!9C,P=G2ZOQJNB(
M;5H*</,0?L1;15.KRWV3]L1"8\)N%O%&N'SH^>'M!"?GD?7*D()O[]*3%\"O
M%+98#8X';SL[-OXLRKMR&,F<Z)?OD3E0LF299+"!Z,^.#5?"H^*UV*8G9Y;3
MFVF(K;.>1OTK?C7&'B'UB^99#U"GT&EQ_*E#FJL;%. 820^_UR$BA0Q5K;BU
M6C-P(=JVS-76"N2F?BLYZ0NV.>2H(E0MFRU4&R,?/VIG\G;T;=ZD9G;L^;GJ
MN*B^O'GNAO35JJ@5-CN<_VJ3RJQ\LB(H@0*P[0B]M<# 8Y$2HF)#VQ^WQB>>
MOSR\?J'CW5VZ>YPP 9Y5L_E.<TOQHYUPFYE>_/WZ*![1V_['W4S]?^Y0@$L;
M/ ^*\A>]?#-;\-D)BM39<JNQ*\AXE,$;^.SLMUMB =VW*_2=PE;]@\P<+=_C
MY QE%!_I%KN__8Y_) 7E37\2Q6UVY?A_JPT&#Q!QJT:SLMSF\*RJQ_[<T^">
M/!PI4^YQ&'<_N"<7\0LZ!1Q(O8&GZH/F!OQHEPI\R";"\%3=[VSO7W7O*U+/
M^*YHQ;M2+U+/'/YW2;W@_6Y39%^C6;5X+QCVY: REL%(CJ[*7'Y*9-G]L>3[
M>."_:C*+3?)' 9^HP;S<E!K,"Y$Y?^TI+]XY8Y^5AK<@&Y(@NQS#J.UF;$,)
M)IP1W@-.(+>I99 S)FW\;7NQSLE?J!R?1S0[$O.Q'O)1$)%0GW+B\^GE;10'
M3'G&=+ @8M#^B>8W^4>.?0%2'8A%O:^%F_<.! ^B<UW4X]ZQI7E5J=\[2ED+
M%R#&5<>&&KZ'69@T-\0857J4)BC'#>3ZFRM_'>AAZ^-7E7X:2)]W]-J%P)!,
MUH#5=@<>D$3/#J(P(A\';*P^#,X-K;F\DL@T?R8>]78WIE?A,HN4V6!SWJ^P
M)XL:!T-IC#O+RU=$G0]-N"@ \RI!(O 4+.!0+'M_=B9[I\P[\C.X\[4QA,T4
M"^:&N9KCL<L#&]5#54'OZA]T*#OIO<HXA=.X<\ X=53037)&=93Y4 #NG3UJ
M7EDET>>2V>&L;^#?U*B95U<6\*H(V!H;?ZO+#;PL4&'(43K+39-1"JT9[WN3
MGA% F)SX<@'_[75:3%WK0;):_'[&+AQ?-GV2B""88LX>%.1B1%)6TI5_&?1]
MG-[\9OTX^5BQ9#? U@2QNAB9;;<?@O6<+VRC .-;+=,2GY_OCK9W9(:.Z\Y]
M-:R&VM!/0=Y("3R;.[#LJ1I.69VU+V6L"RSQT%VHIGK0L]$J$Z%=A:-WBB+>
MQM$L;)C !"I8^.A_8H^N=F@C]_C[%Y\4+I]J]GG2@O3[>%2FQ;["9[V;3@$X
M% 6\[OO'B]OG9-R_?%.SYW+%H*=%N^C97[(5<G[E)F\_<7,9<C>\'M&6>!-B
MDQ7^'47GAXX%,9#T\Z""FHUJO?:OMO?/<ZI#HP9%OF.O,X?.!FXZHFK:L6_$
M[%;L5> =^S_-BV,\NS=<JW5/^7]1_#5"C85K X?:=J$ZE:FM!^,B?-WC@+)=
M<HK_PT^W5:.<;>J^$JI?->TK;7J<FO-#:E4+?$]].MHU7"*=4J\D>^9HP-A6
M\+_C[BRAZY>WD?SXO2?G-?QQWK$9=GV[]:<_C5GW3\GZ'TX8Y,3>LJVS2A9(
MT^\3J_%Y?FMNK$IE"FRTA8K"D:7A\;<IP+=OX.V)N]?I*4 ; M^\)D R)!*1
MELL4X EX41'>EH"OF66>%NNA ,6%EFCRBU&;.*3X&,K-FP46 !7P.Y*_E@UA
MS\L3J+C>X\WAPK!@:?,"5[!@,5XG'Q5^<MA?7H 4A$?&:E@4$^,VS@U]&:X0
MOGH'^B"M\M@Y7LF!#U9Z8;VB;@L9#S4-P^F)M[8680C0KI)[-BE%FRB$>9!H
M@M69H>U4*Z1BN6$43:-+$(%I=C&R4;>H8N)(YT:R87_X]F//^R0#"0+R!=@9
M,B[6%=!\X74[G$O)<"=,J,NNJR+T=(7#E]O=FN63SWH+#;KKK]F*B48]7H_I
MDYL-LZ( C"IM4\>[8WNZ8 3KXB%J\H#:SWI'1?N"8\>$WQ!++4'(<8\N#3["
M@7R,6L8Z#Q8D[*&R9\<0W6C/DI[MD9YE,+(N6V-OW_VC\?G#W(8PCS)\X+J)
M5C%.1*6M^0+1&PN.">ZOI:L5I L>3O^E6\+_K*%-E.^N<&O0KQD&9+[PX :#
M/U4(<%O3AH:>.C6OCI3 ?^DK;A+-PODFODV+HX^2['XK/Y8:W@GG:_0F.!L0
M)K,4\.3\@FI$[&9.;0.JOO9A_,?U0_Y;R3I7 >8?[5S/3/Q1G!0 *A4J1J W
MI27:M 0O=IARV]TZ5UHT#KTX,9'_]M,G:=Z@*9U+/)>M%I*A@;2EWD^:>5G(
MJ X8!:@LM:0 <YF/2$SX2L@.65P"1;+Z4X9^E"#*'<VY8B??LLE.4L5W-03E
MP5YWI&@'/D"SO/V6KS$2IF;Y(B+9@8D7)'=&X]>E9?+YHX(=3?E.-51,J!@>
MV4'6;/[N]'35'/K<7IOES7,]\5MFBRFA^\=V."(TEZA6H)Y.%,"$XM"$<]0
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MDG\*$90//^4Q?1J_6_VN.\=C_+QU[<7\K'<9NQ]U'I8-I+VZLM_5Q9SGURK
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MX)J4?*)]F_5!>F:F RF]P;OP.>Y(JH:CL>O4E9*?CO:G%IHSD)>(K_%\[12
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MZ;;@$WQ%-6_% P'.N3-J_ G,CP-IQGBFY&SI6<%V^V+8_(7ZPXLDZ+#6F58
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MTI%NC_@=Z7>HA75DU'!H*&_]G#9^L)*L[?+MP<63M,C\1\:'7*0+X^"!'2I
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M^_[=ZQ_78\QQ7>><ZYS7Z_EZ/J_K=<Z(,U(5^"*,1CNV_^QG!B%=1;@E'<K
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M+XI6[NHA3V;BPQ2,>;WQ[2F"[?/PU# -E:';>L)\/:C?YS"GT4>FC7^2!^W
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MM3R=$YCJ@Z2B^C/]RIH.B54&RD/5^.,?F]5?*3$RN@.EBP?^SB=9>4;JRJ.
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M#VFK!U.7UF7.5+\A$D#P[+ 35JWGE?.]('HC?I5?Z4.*#3EEWERZ4(9QMW0
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M[B;GWM5$WKX=)*T=_W=BO;81[B6IFI#4/@3-HL-"J1>\'7VKVG1>V>TMYT
M:VK^XU>?I0^BH:WBF9RKD$>SVQ&9.?V[&Y <.)T*1;HLHD3-\0DLB[P1?!T<
M'*3W,.V%2V1GTT >W.!GH89RAXL7C93N+@@%,J45P".N7&Q1LK@M^:]$0'I(
M4_PMACH-_N4T!MY-OYZSB*&D@(XCIMA[:("KD@9$5,YSJBZPB")^&$U--;&
M":PLT@#A24=ZOQ"[63*,7_X&)6<E.T H=]>3$!I ED7TB1O#KL5M/19#E7?E
MLIGE /G_S#SL?ORH9."3_6P-SKY!?%M\QX5]3;MF9=D;*BQZ4U,0@#)T-2RS
M=Y"L-@Q@88F<Y[2V7 9<NNXWJ%-M_?%!W\FM 8!N;,*[S59Q'=G,]);FP'XW
M[P]\-PJZFHR1]YV"6#+Q$4.B46'*,OD.&\NQ@-^C^\-$4.<6D&1@.-$,Q,:!
M1=Q4)S] \]IWIN)**LO8U8*N^WUK YXR'V37M81PNR$%AI"JU%'0J3UT& W
MI'V;\ E_=4(,111M*K$5$M+W..$:U\=^:^GNF+-W(-Y'Y;!U..I'_,B[\:KD
M3/\! -R7Y-.9'OWK@+BSGS.J@F:&?J+BN[>%*ME$I$W2U^3U^ M_'X\ML!1]
ML/0N[(-:D:Z(SR+H-#W8G*0 1UP("R7[WW3%:M)4%>^?3U&G3$IFJ?Y0X%@0
MYR$++"F*0%<'5)HR;P'[P(1;& 9/-0P;3(<HUZ[ZU!$ZBAVL8O[JS-/(EP(-
M_(3FY3YCP)8?/FT6!.S(B6S<2Z-PT0!XHWB8?L$\" 0SIA/%V5E+UJ@?P+FS
MT>Y"#0+G0GPJA^2$UKVN&GNM1"TY.PLIGP&>:KU7TF. -@^N/C=3D 38TZ'6
M,/Q&X3FBJ))51Q'P8S CPD+R4QK@M*X BXZ=$*@:-2/YHL'^I>!%M:>J9T[\
M+%^W<V(D(? 8)G@KZC3%_3X6&K 5"SFM\(,H0LTH=L<1*2520CP?DHW]A._G
MG^I[\AVJOK+UE7([SVZ0Z+"V?]'AFC%TJ='01?>%][=2P@#/F+NL<>I5O&SO
MSGD1:$\M 'Z3 JX=4Z$!9JKWO8G<%I1K1/DWGX0<36V(-U/ER]]DC5Y!#'L]
MX!0S%.1E>2-TTYKUB?&ASSYH*$!'>C_ZJ-C;QW^V7RX$S1TC7_"U'IKRD$WM
M^XOXBZO?U)>1@S:3B2N3.B5M>LMA/$'<-=V2P7YW*FKC3,]_?([;7SBY1 -8
M"Z=\JCYB: -' MQNWZE4X??_:>=9@J\/]VVT?2<6OF:"RZ]M3MSD3A?(R^83
ML!6_U]<QQCD1=F'8N$6CX*_=)CA2P8O%,PJY.(ZIE:YGFBX)W7G!!\^8M3R-
M[=R%^&ZG1MXR9]38YUF$U %_V1+ZVVB JC*J&,&UXVH]L7ZZ9L*DANBG\BT0
M^@+5-#<?YRH>GWZD*"M4G#\%] !0,*3>,FBI$0E-0$[:U1.-(F$,-,")NS4G
M<>;'W<16K)L:MR<#4N?*S"7$U848;JD]W/M&]VM7&B!.].+16QK &1R3NHID
M)PIGJ[40LP9S"J><IFX<\*(OG+JZPU;T1%]HYYL"0!=3F@&41DT4SRWH>RK?
M-E-VVSE3)=Y@]2H\$V .CG)CW+'<]_PZ!&,A:Y+(-PCP]Z70'3PJIB8CR_IN
MFA.A924U1)5%I<H==U+LP[/?)SN3LC7P_<K0/0@7=';?96()Q%E;FJ#H6!/G
MZ 6YFH(V&79QC9=O*3MYYN.G5YA+SU4C>X'AAX<S66G[T5/4<8Y9U2VRVCO6
MAO6L]VB]D. QNZC:^P6/R0%'M1G&[)B:FU4KA;X-.TD% %@ 69I$IWLWC^II
M  ^VZUNF7VOJ&INK>=-2[97=92G8YJ^GL-&,N;N5"B3+4H^<ZJNH&G!'$@])
MO'-F*P9F^PFSILFR&GRU_MDA/=2IZZ_(R#8L900!7!J38X]X'3W-&ZM"IK8V
M)&J2SE7PNKB](F9^5N=';Y<\&I/'?U%+\CTU_6*'==GP!%?%QKQ2HM](F*[]
MGP49/P^CZ;+>N9)E:BTX=# C2&2)2O;\YB3 IZ:@+]MZ^H3N&]PP];NNP-$'
ML ]'4AT<3*A=VH^?<2P953EYQNVX)7>,G;$DO]4]CA(!_BYX?+MSNHK+[^0H
M _87P:.N_I$"6<\_;G_O"=-Y&NS_@6/ 9_HK+)!\^2<-($ %]"YZZCAWJMJ%
M+N1BS>ZM,OYJ)&Q/Y7,U.'ZI$Y*M"-'D:N7!\9E40-/!TP=6+4DXA=*2G]DR
MM3ZG[3 _+6Q_!C/L.-, 1G7/U6\#YQ[-?2#&OX*"JIYIEK\M09K*-2@DWQ3Y
M\.8A8R7P^.&86>5JN4B'R+5Q*][MPH L):[4L#*_-@D\L.0#1[RR5D92)(I@
MZ2.R9C>16LXFUQW,EIB3MZ9ZZ#\ZVZ^^S2AG'/:):7ON3*>S2#5$'1JR&)U(
M\25+PZ[7#%,T/CFL"5IW.>-.^FO(IY]7T3*>9'^9"'RG&W"/^:DEH_0QE /^
MUAUAOYO;D_0A!Q"+7A8=?0:[589-+APGI+VLR5)K/5BQG@S(\C3.,$\<OM9^
MH<.XM"4FON2N)-SGQB1F6'4)J+%E]+;YB5^\J[3RHA(]POW_0$C^/==S)4=0
MEQ]FX!,KZ-,)B:QO/ --\+=MU@IUQ:FD_1JQU_YH4W M:9E#^*ND.6M^_'.Y
M(>H_-J[PJW%57ZY.Z^P12=[V+B(KDP9!+Q <5);5>D$_J )OU$Y7MG3#>^2T
MKYA#')VQ1/OH/LYRS%ARB'?EV7L1U'VB;;] 1JBX , >P2/)XJ1(!./57NZ"
M!3$DYS:X0"U1*B_O)]YIW&SO=^V=\*P)]0?MJJLY?:\2IFYQ/]QQ&G9B(EYN
MI6H,P:6AT5WPD\,7FHUH@)/@Z+QAA;.-*'L#9U^NZ_<;),-WQ,0>"%@O][&Z
M*C,L(-K1FNAV(7-ADKUA,U'.0_.Q7516_I55X4G1!R57+_2P]+-F^T9,5%'9
M*4[CS;XX<UZ2J].H\KJ\9X?78P7I81^SI?CLX.H+#Z[$]LL^/C<<=>W.[GW;
M!5$"(I$J2)$=I7!@Y1P5[,N!'?O/]@6[<S6V%15&E][RO6#[5F =<^F)PY,G
MGEJ+B ['0'U2!FZ+SPGZH!^[GUIF.VN?Q+IZX*Z)]D\2-PT]'W]BXAI[5<+7
M1R??:K0"1*.)5?4P >("!X0#LZ=. Z2YGZ<!F"$^;1C&[!RB6-4Z#>"T>H,T
M,D #G KLN8H'3:E1=NFG!59J'&52C_\4Y2$@PBEFKB70E)#E8:^<;RV3FQ7R
M^E"^P$W'/N=E=7Y\O#,WP]:GIQ]&1IVQ@.[S;@R>BIWIFJ1HPS'_$@7IVJC#
M&5/7].FZOO"QDH?>3UJY(F*1#W]7'8'1W-03RV%@&>1%>.\S% <=!&F " QK
M&5P&9I1SA1C/]Q0SY[#^8ZYG28YG^YM>GOIF(3*1X-IS!-H/(+[!_-K"FI^D
MZ)'R<%[,#,$*CQKKLD->+HL9N;Z?/_8I*/;KXP" 5=H&$Z&C*UO\J.G/*QK>
M52=0,XHP$>,3G/ZVX-0C.8LULD$F,<5HQ8*B1G+&94E33YTG@KOKLT'-$>V-
M:5$;Y1?VWG,=7+Y>>.Q;>3;J//XH'3!.3-N8SJ5S+*1<U3",$X<2M(%JGR?>
MK,KMX'[;:.JL\*(ZXIR>T+-6W]HFULG;^*09<CM5F' 0MM6L4>2!!(\U^V?[
M1.^&,DOL;'X\)6AB\ZVOZE/$($[C># >A^:B]BU<(@7B,7$37%#&'EVM:J)W
MGFHNEHQA@2;\4J[G>CO/F__\KBS?,_[%%$9V!N8F.ITY!I<D ?5)(M@F,"LI
MR9YDGV]CRA?3++<H[S*"WTCA?8+T_/;%Y%0*4#Y1*-L0$&P>#_9>F42Y@F-%
M%0CF+_8R0 )057?E#0.3\0<OD&FZ$UV=[U[E=6;<?)82FG"/Q+)_V$!"D#5A
M%XG@3M0):+HI^C3:ITBA@+\^N9896I_1@#-"OS5IO<'\$U"I00*2+Y$V>["*
M&^:+33G1!TBVU"YCEZ$+WM*VY_RA2TKM]4(OGT%>*^UY#$Y2!2AFQ*U6Q'1I
M1P0V,$:YW+I55_ISW?B90WZJFW."P;S4)+AQ(S71$!#*R;%QY"Z=5&O.8$+(
MZ7E"T:N/\7Y,49X84CZH^Y7;/(]S3 YKSNI!:OZPUL?2)7T/%EE%8#[ M:#W
M"],*IQ:RI/!&#?7S\/K? /L+'L:N&G@@_V"P\--DBA+1C1[WWCN0EFI8,"2#
MC#9G<\')-'*$[B*L97J=Y!S[^U/'ON8?EYLVZA'D)"Q1W^-"M7 .2-G1W=GW
MD67I;[[T?'ZYA.XS?GHW\>*M!V&ZDR1GLHT-%-^3"@5UZIXF\G6@^.LRCLI=
M\TFQ_&W(.H$Y0K-WWW7\&XF+;?@()VMZU&*Z1*"6$W;N$ LS"/W=,]'1NZ9U
M-1-;'Z(PO:,OGWRH?J_[-)"YG;&&,_/15\CTSN+-TG(8?)02H-B1(T!RO4'8
M3-.^N 8ZW6RNLU\@^:-*VXNMV<DY-^Q"]-ONFQPB7^GZ#,% /4N_4<)-<-S"
MJ1;"LR)7/!O$8DRJ>D3B)4O<F\ (3QGTV4CM%5)H,6/Y41[X,9K_)T9 EVD5
M"2#LEY9"#;KT Z[L>QX;J.QTOF;O=B->^TM&^)/9I\9MW9ZZ&"<")$9;BTCN
MI 'XY2N]_%M,N_?M))>:E^_8G[B?R%,31<R%E7]^TYN:]>+K>GH?<;(=!")!
M](]>:;NX+(IX=JJ),M1N[VUPW+09V!7*?<%TXON'K+[%G:E'R$Y"3KL(NXA?
MM].Y]&Y(-71-SC[!N2,]_[:IUXJ$KN7EW..\#Z<J+MWY?>] (@PF3CBX$]V1
M<XPB&9+??U^A"@M.2+:Q71,4+I=*]149PTI&WY1(D;<[7^?5^_MUYF[/ZH]0
MLG4F*6X1$5U+KCR6?U$A.0]J9$F=K![VGW)^/F@:+G3AQD^^L/A?BPJZC[G2
M=]U(M[L ,%/ZC*F3:HG2V,HH&-!]L6J?3<YFLGS#)X"%+C[%<.Z7;.55(_NZ
MR4]'&+M5%Y>;)W%)"3"O?$2; 9)K[0M)4(L&$)F'*K@AL,)5X]RS79=U>N3]
MOP%B]"3J%C*9!B_O6F\0">)=$!$X/^DIB-ENUD.0!HB&&;I7&#D'/)6?6%;O
MB(XWQLBF?KUI/[17X3U+Y\V=E7SP:0R[KJ)G-D_-D'(3Z-2 \Z=9PY*>IQ.!
M-UPZ3>N9]:/,W['ZZ9W,I<ZG'8#8J2I.ZT['J9W$GO8N^9*?XK=W-HIZ[T5I
M19HW7E&].;>[N%P#$R*[>RH2%&^1^O'H8X:+J.C2@JZ0HE[1LOK @QVMXYQE
M6MQG7;&V&:_TSP7UI'M@O@1V9C1MS1SA1^3?Z])5#Q2:,84:.:&81:%N%9.G
MUIT2RJF]P>C.RBD.?=+EBCF##Z3L4:.:I,$%J5B6;P(.<I=69*YO2#R3%D[4
M.SM* WA5<I.L'0B7*7=)MHIAS>?QGB]J1U1>!CQL=GOTZI',)FZJ4*Q/?[%.
M VW@V-,.F8E=P05V^<13.1 <AD6&A.T?>FEQ4!>UQ1CVZX]%(8=5\XW[E;Q$
M4"LF$5%3WM-.#WH44T)/-(4':\Z$F5W3S"XM\FC?=/2P81ZS.7>7F>?^9!!>
M QC&MHYX#A:DGH8/801JT8Q0'WWBM7#B>2NW6C,C*U[4-%?D_??W9^Q<F&9?
M=.LY&8F%*?SQM=MQ(973(2:D@J#%7HZ7*@//S#G<J'Q5J!VV^:''"H]D5".>
MF_?W,&9.4*/)#Z#;F/T$ @==80E1I*/;TXMBRBL4<FY%.]I/\8A'V?+US9[&
M4$L]F6>?0[^U@77TR<(D?%M.566X?\)3LAZAI],<2.HS/[TZ,=-=ROHL,+_J
M/C K*S?KFA&Y&:]1D60SV1Q*YV\DF<E?Y"!\*-"4L#3C=IA9DKL:'+T?,7/-
MJXCMP@Z@=*=N_@,K0Z*),D,KO(?>E69W@BL6U:/CW(YB,XKW#Q7JFCS,KBHV
M^U20T@5@/']B:N!";+%-TFN&^FS/7<1B3Q?;93RD'<,&73&."@D%.]38%^?2
MX<>6UX0U(1$;P9K84)E*/4'MQW#"N,@JU&'1T^.[I6ZU6P(>FN6#2<><NM<U
MS9FG^B]B+\W=6R2?.@3NZY,"*V'B1^D4)KJ-<]GWN%:LJEX3:A!_+WG'1V4*
MT&>LS3DT!*0##QL-X(**H@%JZC=RR3?LH62C'$O!FZ7>$XA'S>ESW0_9A73M
M 7XU 71+2?M57NH!^G*PP4#<PIYNG&@V731G<;]-2C(>'=-9^G7]-N@704;@
M0;^,D-[:^S632_J$R?UTDB+Y.NPAL:BC,GI!B"@5@]>YHH%KF%!Y&/_;-Z(F
M\DR)P)Q?@U51!,+9/$XS.H*J2AKM7)"N&M%5AEW[PEN'SK^.PYB&V]I<^9((
MOQ<G>B?K$U^*GYX(^ 4-X&,6A)2#@0E)"51A ZP-+%"NJR!(<#?0>C_ZK/2L
MUS,Y/?LG>(GGQBM>_@L<1W5BC:008IXMT35JLB-XI8.E*<[+P,04K>X@&_%#
M4TLV\WH'8R)>H#*=PD,6@EF.-'L10/9)6,4H;4G@<Q45S1^-WE^%#PZKE<PO
M[1O=8X"DBNE\;VUZ)LZ#\$)%!"Z(']7"5!91+&N01Z-(>?OI)![W9Y\N.7_)
M"<HB#CV^L8UX<1@+(),7I3O-(+C)=D46$MI^*(\POE_OIGCMO4AO3F_"H#-3
MWWF)P@EQG^,XI.11#=@%$NW$0CCHK(R#<,-\R]:I"N/ST2\^<JDT33EL2+&X
MB1GI/F*?^P'@,5G<1EPM\R?5S.O.=(^<8RIO-CVN]*']H\RI#P&+#%WP !(&
M:[ZAC^.8L;<FI882*MNIRK6C/Z#:<O<KUV\+.<J>7GD\W%XM<ZF!(0Y\-ELI
M7$_4DWS5UM,NL ,Q_0 QPTZ^BR0(?$X!GW';3W/Q66K0@+*^Y-=Z$]]>9KW,
MY  K"*_,12R^@3_,X:"*.?P\C)S#L-MWIA1%EJD(U::O#8X;'/LB(]'SREGK
M)@>K[^ -,)_N20J"F!9'/0/S'?7G.(7JQ+#9S$VOP5E;&C'WU)IS):(L.KVG
M%C,;SD:>)1@& W^9DG5(6]AK)43Q;@RGO>EGHF)B@,J8Y%#-Y0Q328L5QN//
M.U&/"<#OG9F 4)NO,Y<NAN"RS)SX*A"G'&B S%O'ADUR=F(O4WWIPD\*,2B#
M_MT%.#?H"^&96JN'\*,6/V;+/?FX-HJUCJ0D2,WH;RL4//M0\R+X]86O^$AA
M8L],=.H&A \F.?J(%$B/8C*DMD+(9B)(D/0,[3CZ$/'ZQCF7F/%0XP<8L\(P
ML$8 7<48=-  )_;,13R<I"8?(SP2P%W?MR^,.L18\:1).H#F7[:BA<],.65:
MCX/KHB)PF!E&O'2[:03!SX'T'AL'/L%F@>LQ?_]+OO#K5T>T0)/3Z<)O@T-/
M_<+8/?UZ<KY(;_ 1[2TFM1EP)=KB"*R(O7WBVCI.7/^4)]?JS[55MRLRSL_#
M%BN!I+K))M@C0O2&".$ )Y543N%I&8%9+G[S?[?;J\U7T?=VU4M,83SK8=];
MK#6)I!4U=UH/.!!LEA,!/T?M=>*,PZ9UH$_;0=7T2>'<"[H$B4L#Q0N_[HJY
M[5=A-!^VSZK_A'XKKXPZO%E?0CE'\&D=>*I5R>J&/#M1"^):FPC.=9,<@9UC
MZGG/?28:W&";\_B>$M;TF!+$'-Z%JAZL)>O M"8SN@+K#J/CFV^7HBO7P=.+
M[\33;\#7+H2_4IK\JFV=0%<J7$06')WM)NA>;"#L=8).:_L@//?![([JL5!_
M>Z'\B]-*TJ>VNU.:%)YTWY)AW# _04K3)UI%^(1@0RW-QG=]]I[,K5[NT4'U
M=X\_E(3N;D $J!.0&5 -<,.7@%\\?KA<D$L2PQMG= K.K#[];8'!?S]Y\OXW
M!Z,DDL#B*[9 U&<:H&,@L#T-PP,S#%U<3XK6%2+JUK(MQ&'E&E(T+N097WWZ
M-5;[H\_C)^"F 7/R7?@@4I5HW0D&4B DTY(I&Y@1H<S"5DCG#JC:XYFWR<5J
MCD9]U^XGNL[?6I49[+$Y%*Z#-L1QN((;]3+)!P<Z#;TR./R'Z7#T0"=5T]]>
M [SJ;PC?W6^S8(."?JT3-GMP=3%D+Y+=FN3%-=VS7VT<TZ0T[CAH7V(]L+Y[
M+_2:YQR5=P8^ 5<E??WHB3@M04!UH(Z[YU(G/_PL\'$9ZQ5F?H"NKO_.?X\Q
M4H,G@6"-K8Q!/3K2VL\CYL2783^/!)1?VW$<_6&:_[K?NT3+^UZ1+-P%^SGH
M X?IT7.J@A/,X^@-A1,G<MTZYVXB\ZCW\JNE_+?S\2'H)B8+>.VNS"I$'M&F
MHLT82B#O:Q$,:RD^/!/Y4N,WO/-Y$H-L\=_$R1GF>(C%<AAO[ VZ7]ZF.R7
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ML]I8K?7DQ4611RP"7U][?5Y0N)!"_(/7ZP +N+1=)DZ$NR-=3A;CU.6NC_O
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M!**T3-$];( _A.;#BF[L8G$'0\%&**7"F _[Q<65#;2J=+$!L=\AUG8P=39
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MZX)RB><K5]- 30X$P'_64-J-9/'/LH&TC3'H6B)8S09L)#TQQ\<V=AE2K6Q
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MIG<<(O_6P?8-<&?D"=2IV\2$D>\S]_.\X.[17(N63[&AI*I4QFN7C]B=&VQ
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MEAK$V)W3.?Z7!O]&-C:0[K6<E9/_MRBTYN^MJ92B[PGM<\AUZUDL CMI1<[
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MK\?]S=EJ&O6;.FO;NK.)[X N_#$C_9<I/6)VL4/M8:[!2(L$^A9-FT3[V?5
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M;>&.$GCI&\*B^Z#3Z(F_GZIE^RUC, W$?FC,XF'.098LPYX$CB4*LFS(LKP
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MQSY(R8Y5RHV8$$P7 5:?PQ(:H]EA]RP!$DTC :V)W/Z0^P2G&*6N;U/\ RU
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M09]=!/4D@H$GHQ(H>7H2Y9<FRX/02.<A(536DE)4S++7."=T:9V,(Q5R*94
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MAC*Y0%*0GW 66PT]BZU?CL;X8J=A?;#Z?5 2RA8<Z4PUSXXK LQZQC[5D$H
MYL#2K!/]V6OIZ/;FSHF&_QKVJJ#\@1AXZ-7B9Y(O)Q\27RS2S8C V>9>V6DA
M9BIL!DS#I['X\2Z SHVI!DP<1X9^:*9C3B<7&U_Y;32@<?&$>94/4\:\L21'
M:]FLOL$C6..[R4\W7?))<Z _=GHY^@_F.4?!:\XV;L"K[W7*[0E/K-O@*=2P
MR%"V.]S3\GQ?F\@I<7)02$(5[.M4 ?VG=46\-<Y:?[$BD&E)?7"E#PP.9.G
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M']30.#0<$[(9]32@;_C$FB0TM@ H-Q!S@SNA&ZF*';E]?9-C_4& KY3*E=*
M):07X]2G7/\WFG.5))?62)@>48NK!C)^.I-92/#C8[X81RO,L0S9;U&04#CE
MJ\&IE5VM74N6LO.\RW\\"8U7(@Q,?K&?#CJV;OV:9IF'GZI:>&G=U_?$LST&
MN[P/.H#I:EMLG,?UXOG@G>J,Y6Z$;*P3+/%7>Q6BWTFTHLSW:1(RW*PS<M>Q
M 7/<;64WXMM,U9PV=7)RAEVY4=C^PBSH4?9_G@$SPUQ4T4^,6>39!]U;C(<>
M@6SX\S"6^SJ$S.C&I.'CO(:?:Y^TN=47KH;NLN<NGKO:E%/BN*(N/^XON+"
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M,Y8Y^Z"_RZY?M6USBSG];@!P'M>?%M<I#Y@S<I@DH(LA1<$E5YVI8=A'$FY
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M(GYT7:E7-]M2?FIG5&!BRI,LVMJF9\=BPF\?=B0_(Y_X]03N?SV4!2_%B#4
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M^GLL?YC.^AI^HOW&$D@S%!83KF)$<4<8'0Q>)D"$QV*$]WG<BO$S>>JB%#,
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MM2GO%Q+HP+F3L$P_9$])K*1370Q79. L.TH/I:P<:$C$ *_Q%"%/_[=#R75
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M8EA;)PEM"U=;-F[+EO/C>J<W8S@;H];=.4UY-KUC5G6HP;=[4<>CZ5CHH8"
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M3N[/!CV9BGC/@./L?6X_7]05S+ (7S(A.;0H'D((@T ]W@M^FJC05NLA^7T
M&@SG.7B)"NSE0MFJ2Q]L+W$RK_WZODWC)&W6PAX)9"9G'0'>949S*RE,2^M'
MI=&!I3H/_WSKICFL&GD<07&C//TA5 F$UL'.7+V!Y[APF1Z4R4([\"A,/T.-
M^:-D36*. T^/P=:>L=Z?K5QGY_<GT)"^5(D\,FPV;V&9X;]ORODJ[^R#FWJ-
M"OM<,[LS09LD"1A I\ '!R0STZF(O__^2N%8IIV.T=RPRV:#M?JO73>N]@K7
M@CL%ZRBM,/0G4BBUR+DR@-%*64T*Y>$F*^RUP)N!P.*^9P EL=G_!%O!=C5'
MSL-5I+<WXUV'S,M(6 4J-+MRTCWPAGY1C7VE*=N+\DY*+?5 \EPQXO9.TF$Q
MXMDP@!0C/).^2CP#87&W&M;N5\/_M3X'4C_X<=#SKH(]OJ G]TR9P("D-H1Z
M9:\ "TAH*TAEK/PI1B"%-I&/<"#-!3!)K7+CX./.C$\']:KZJ7C,1.R-VE;L
MX11NB)[)G/O53GS;KTQY2%8<M/43;!6>!X;;U]:N22-F,4X9.S *;( W!S=_
M-['=.T'8P HEZ_?-E89R4[3V31Y4V? .3BG7K-T[,[L6P,UBA'!#,#\8=!2L
M$:Z#Q7?/!)5!2*?4]G3"N: .IO/P7$H[>^U7]H9F)UO[;769QX"<^-I1FGHH
MZU8H60O )9B8I2.=:_K/SBDYAG7LU==W^D00JJ3RSP).0H4>2-H8C@H(NZ$0
M:K=7ZX?6AJ!46FS$B+8<40E9&S1AA2,Y]#14NW=JQ8RB&R=?G<OJ&T*I$AV;
M3XJJ"Z>'#H=N/0+T)$956@PQ/&M"@Q'09)26$[9W23#OY]52T[=4:?)N]O#
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M5UN'9'TG)#P)$U[=HLG<7[_R.@.K6MIBW4J&M^LC2Z>@V(-].5@==2!LKW)
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MIW51#.PH%0UI*[]H"IN\I=W&ZEW0E-PT5DIVE12EOVTN'0B-">I.V- 7J:*
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M8K$A^A_BP\\U.(^=5>#Y*TM"_0QU+E8D.MS9B/3\C_>N_M?K_V.O&.#!54N
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M,.?=X>&7?J03^G5-O/0(;WM&>EXOR1Q__?\T<,5^3D/T4(-DKM,\!"9_,EV
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M5T.=<AMJJ=YY,D0HK@@P'WY33D_J,,II[SWB4'MYF_HP],\5;N]0E/JO!1K
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M,3_#&P4A3G[%R6X>%>1KOLXK0HT-'SP-TPL* IC4]GL)'R!$&]Z+Z!G,U\G
MUNWY1HI\5/]S%_2[64AMC?BS!QKA[B*OL*B=6L=J^RXM^N<H_(N.99WJQ./
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M. ?;E VA4Y6C[G\O[ZE@!&N%YF3<D3;F6>WB!#\=&6BK2.ZQ\2G39.F&/,3
M/HANJ.HHTDZ$O+MAZ\YV_*"]$HWP+2P=I ?@]L>CA)YA!ENHMI]"N6;^UIM
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MM/W$1A/MYRE$+U^3K Y5N3$[F-::IX2=]*L!]LH\3:,ZKDS-A)-BGVV.YZ^
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M24&(BH**,:V J QI141$C(K()$1%A8B8M@&)$%*MR"S0: LM"%&91(: 3(I
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M6Z3XRY>6V' WZE#I(XCBQUU3W]PS\[70SY?S,V5:M*@_=]? 5_2<JNZEA4.
M_!+MC"*.);A->-S;ST"%P/DA%@_K ET5E0*+7I@WG07KG5G@AXX[9T^)[!1&
M7(\TM2GK&)2>=]+-XT=<&"UYVN"#$-_VQ^P2;_$,0U:'GLY @N .4!O4@36
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MS;&OX[9%O&%B+E!RHF MYT"/Y+B;Q,_C20WWPIJ\+^-+2) _Y 0FB BP'D<
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M(IRIMPUN*S,T=O"]6\@F^[I;[_T<3]_IA50G9T&B;"<ZAB>0-\T+%8QF[$3
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MI$5][^?IF)]<:*#O^[%',J,A]05SJ-I>-*M(;MZ \$G@048*0ZUYH0^'20L
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M*3K&"Q3%0E"6?ZJ8_A:HG4UM]!1T&7W8]^)CM[WC7*\L*F;0,V;/#B;M+*7
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M]6A5MB$+K)TIRC!MOABQIY(7<)X$QE*+A1\*7_H,?5O\E6VZGOJ!<#9[R4:
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M1SZ-GH05%QZRP<,?.*LZZKAK*8O6O7/6<EI9RIQ>R[O;MOV$H7X<)[HH6U?
MJK" #[%XE=SRSM89A"8NK*;:P&Q&Q[ 0OY/80D$@0\"]48F-YRI)U,$?S=0M
MH#VGV*9G;.9F);&0NXZ,:'*&"6'%$#[([*=%]D^+3Y_N[ @2_1BIC?,-P/1/
MHP =.AAB5*?! MVXT.[@T7YY4K$ 0FYX4X(B.2MZS0"L$3*][FJKVN%[SS^F
MWCZVTZ'%Z2*N-*>R@@62 R1J"==(O+1(YVA/O:%._1UMIH7M($X4&N/*O-];
MMVK[]JY#73O7;O1/:CNX7HJHQZ7;H$7"8;ZS1-T%5JP7+A'$LH$$UFHK16'
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M#L K[)'$I=?!PRUT TR%"%-%NM*;IKBU[E#B0E$" IW1W/$A6L(%BDZ!;51
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M4.]='8HIOQ1>X.Z!1P'',172Z=R'R-G>#=V7-EU-LP!><Q/=F.DG4C96552
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M3?^R9FP:__'=[$[]+9N761VNH\VU8H_1B2!/R4#Y!(,X442]_)^9D/8?R//
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M'NV=<_+YP=EZ532?FQ=&KL&)[J:U<H9,8Q+]EG QX%'L^UJ1!+'LP@B]DT;
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MXG$.NUH^DUJ"]1MIPOS&-K_BZEK?/WN@[N3E0:7/ROV% <3E8R;K/T ;?%!
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M%'PW-<Z*7!%$JL$QPA;G%I 4DH%/.\/#HC2X:X;^\C+]<7:[Y4)HP7^O'-J
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M2%GQR!S*+,>GMG:Z^L81)PN3SK"ZVMBV7(SG[N ]/[=1JF)+#RA6E!E,/T'
M+VO^H.4]XM)H/&3KE<@7E]ZC!4(W3)J17$C;6@.%:392IT2Z&%0P*2L$)4=?
M-X7CO$L8R7VC=FX>N*+GYL+'O.K$+2V=3Q/XA]S")*^0#]J(NFML+-:6: 11
M3H!#[;(7+3-.=\@U87U9CKTU^UDZ!(IYMX_^NW2SO:F6?H=WCJY_A&['0U:
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M+QW)HCU.RQHL#V_2/%B1.-PH_4[JK+H_A_*9.JCY'JCJD-F(,1\G%:'0B/(
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MG[ %H0*UYH747('JJI>I(_SF+6# IYW_[<&Y4B4%*MMJ_:P"]5!"_ 3\N+N
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M^VO.//'7+#QI69^[JSSR>HW)%7%SA ZM<N>.;\5&)YWR"Z;..-0OF&7][W(
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M'1M,KFQYG1@=ZTPQ,YWRK&19_V/Z!GQIGWK&#05W!+(;L9"1NTS+71(C?ZY
M!3ZW7?FOWII.]/?$LK98?Q"?:./%WTBW)-F:/P./6HWH6P=6@-P.MDP/M&!(
M2FLE/W#E[\@7KTDWM>[?'[/>G%A?\7^.I2"F8D!W -H)(_Z]/%W^5P6'Y]X,
M*%6RDU-UF,T FK9?7^.=[/QY04;Q]4KI@=-3%B2+X".'Q6L(JM62\PDLOYXW
M]RJ^CEP*O$.>]18"R2+H(=@CY#=3S<="J?3-5-TF7ZLX^RS1_E>S177NCT@+
MLS="!Z[BU[B??I\/5=T3_9J3$A[_^F[.TU-+/G3]Q]D9]./(-39%+%FLKX]
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MW!XE6O4I\6CH&I1-N(@_50BJ"]&3$2)@*,-%; /OE#.1LK^J1S3,B*>I%WZ
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MZOP9\;''X%"+=5I<1:?:A/M>._7V4C)]0]*AWK 7^+_*@ZJU0TIN.U8")X!
M@B9M.;0?G&DA5L2UM6.7>U ) JO8,"!>&]XO/IF0S0_27]<CPU&V9QMVQLWI
MN2T+\R_^<.(Q.7>(5.TVGQ[+#B/Y!31,CV\[A_Z(EYR3YS;L!AK7<@2W@)4T
M*Q%Q9= "8THL]9<Y08F<9\#DJR*/3JND"N)&V27QBH_P^H8^VH[[+:S./.H1
M?,81<7A\*+^<%/)*Q%'_2E_] I&M/F$KY C**"Q23 F0_T/@-VD8L,S"H2Y,
MZ@-W>7%D9E@>7]2:'W'],5G?%&**-K+G'H9:-M1E4:P(("W]<S:B+C7BI&2/
M#(^!TO!71:U/86796JC]O'A9"Z:"(M/30Z)+'60GA')NX9;-&O-1B]L> EX(
MJR,/0KJG^\QHJL+.^&LU].R0L/.444*"[U:Q^8VU"4]>:5@NT*N+J>Q6]?V!
M/*7;,X\6JD\@N?HV< GY?8VXQ/8 /,P''3GKX$[@Z9<I(Q%S#00T8O1H^\5X
M@C@\@:9=*#M8DSCS,FLKE"14-IGZV'.IDJ#R.DQ(LI+8C6235)NKMICE,H[_
MM6RA>:*?<P<-&3A]:IN,4*"4%I_4$A6H<SY;QR-Q0EQSPC0GD* $>4<,\SRH
MN6ZU8%HSZ\#LX+K!P4$/+\A*-%V;5Z=&^O[A=H]YL.7G!9)Y6CIELKL)[CQ3
M]JQW=B*>;2X_ULV#6Z=7\E7[,C_LO!I\525%9Z?PKF$R)V&#_ISL-T(5 3JP
M[*#UQ0$/X +K#/G+2:[)93H*RFC7X0_N46M_E3<)=W$O1V(I;_JOH^"NHO\%
M<2I#5$04!WB-!2[/2"V9"9R%W[*>(IKE#NY;$NY]$OQ/2K("57C JQHG8/._
M)?&':N&.0A$%_JNP! <9H&4YG9*M"M0S@UQ@K-.-74K\=J@=?OU5@1I/OXCY
MOIXSP56@>N[B3A;]+^S\VH%BBSBP2H*0N19^QP>O&,G4,B3GH1^%@^.X\DPY
M:S[1'YS.?=*R-DG$7^\D0J\+4B&Q!C_LK+RG,D5I;- $/]:$-?U3,\*\'I*_
MSL79GS)UF(-&(%7Q07NDB%AA">$%.&W:5G$>L&K1808SSMYO4Z#*"2W$W24E
MK?7DJZ1B]$IJ[NF*RA>]%7+MTWT5]5:GN\-J=TQO!SOC34WG=OM'!%CFDJXL
MD5(H :0 THJ8?%8E*X95=RVUWPVT6Y%?G[<[_GQE%,_0X[?J1$V/W%ASCVZ+
M54\TEA";.9-A;"I6<A1QU#(@B#G(%*Q)34<W<GC>PLNY(F(\$SVK>KH;I_R5
MJ'4./)8IWC,]WGFD3&K+/%^TO5R?'2K!:O!2F$9)%A[GJ<%FMBW:K#&<+H)N
M.N^=KN1*K3Q-@?(?L_G]A)<U_3TOMEYH!PY7)G^TTDHH?I5/@HWN-8TC=8:]
M;=_5QT8WMS^8SJ_ZZVOU17PU+I,(GF1"1K%LZ2Z@L1WQ\P9M:JWH2SP02+RC
MOT;^H,Y9>A3NPVBR=4^G\KZ,*E#-IMA60FF)E547GFKNH.X+YG@<^-YN**L^
M?:)IL%"J^8?2@N: KEB[-3V "\3!^Z XUE,GS$LZ6HR]4^GF5V&6*<S4F?>J
M-[RY#<@==/AG><K+ 7^B/M!XN#3,&_?>4<)]\6YD^H 79K!\U-CSP!TG"]YK
MVHK2G;\<+7O]=L3SRL'D!I^V31=0@#4 DB09(F*R+WIQ/ _0>,1VB\?0"-0N
M>2$OL<@M@*K&^X?#I/PU5%_C3-_(K:+/J,1T>F8Q5#)TY$+9D[RJX/TVR=OQ
MW0H4>"T\A4(S0K)((%3[:.P;0;6SF9G(7T;3Z S>%W6L@ACO14QDFR:9OEGO
MH#GINU&JV;PK;:=%97.7D]*]&9.S?)G.EI5,;9E:[<MO7J;/:Y]#W\7=3J>:
MA/D1>6*]OW_1S5_;NL_NMEN2SK-LRXDUM^RO3$DCI"1Z$^;9O$Q#5TAG@.$2
M-D3!-'<N@8 6B:W-N]F"_KGAE3Y[6V[0TXJ_IM;4UX]$%Y&^USW.F^#5)\1^
M*JS:[?L/;/]P2^HO:"YNL U6$2/+!^2Q@#]Q4$E"@F*DIP=]J/R72,IN9"FU
MI%.XG&54J>ABIA"CX0T9'&8TT_7$^B\$'>K$;O/Z$/O^CPU5?>8O++2?]WR*
M"BQ,7)F0S5C0D/\-D#IO,BL[FX;1HX1)H=BQB:AMJP/=NC9(36OR^ML='/+-
MN^H8DD?68AI*$DH]$G*U%RQ9P0%%@^5LYJ5;[ZK?^"X.3\(O[HVF*8/=G4),
MW.+8VL$ZZM;V$\^[4WO<H//"^@B/%U5U=POJ4Z4M7GT/%*A$+(5B=-TH:V'4
M(R+7).75KJ4:@!FQC-WT"H=0%/A["?$IY2538^(*O8U8'<[5<VF[ 7 9ZX8_
M$#V@O:YQC?1?Q0&QYWNV7;\H=8)OC6*73/BBN\)BJ^-.933Y;J[HGDO*:.U)
M_HX"0LV=[5 A6;O%X7$V2X18=6BB5:>R(%I(6/E5AY-HX\@BOGXZ2++6BCY_
M]?%X37)OZ>$\K6N6Y9T&ZO.G;MV_16RS0BKNII'%?6BE",93'#(.,HUK&;9>
M(,;@T!9R=X'1I/.CB:UNE5VSP;;#LX,6PY;#!55J3GG0L5#I"?[Y=!7&>JBG
MV2[/>]CJ=SD6"4!;^D#6_DH(![K RL%2RP[;0ND)H-'.AI1/73]SHMOK>I@>
M6M!$ON9F/=<R/L@-N4H*&-4+<HQ<?3W+T U\FSEJ'!.<ND=-VB%=3O_'=X7\
M-NX"\1;_61M72G6WAUP%+*OC?6$[<NP_B3%)T[E2X(Z-\_6GN^J_Q-O8A10%
M[7WNJO36=55B]D$E(4.VB0+.B+2C;)'8:-R)$^2DXVXC]:HNH@LF5TA]QAHL
M(82".E&!X;:;^V;Y*"BWF:E:>56\ULFVX].+>T/<:AR:R/TTVC-]- 1J&OZ<
MU<WO"/^Q=Y0RY0Y6PRI7$59&4FJ4AY5,'?XB4DJA;Z2W9IF)B6ULGO%H_@"7
MLY%JQ,6H5E0P[#,(8,Q4VYU0)OHX[5#Q!]([DOI[DW83*Z]GWB96ZCQB"T6>
MY:CATK)-O6W3NP[=%O,].:\TRNSSMZ78?]"XMV_=@]!SKG\^.'=H*R<##9EB
MIUQ%1-00I XK[UP<>0ZFQN33AXC5W.&QA3<*%#K4!W.X MH)[O?T[K 2$5JQ
M6@TW%RZEGRP/R1D:WUD09%7&&NLJJ>SP>DNBE,P^+T79GH;20JQDFPXAD Y@
MEIJ/AA0!C=LY@H>PM75;RY3;Z^]G%*C; 1*VO+"$]]VI LS/8N6.>(TM,&)M
M+)1K*BM3>=.BSP-<(G@_Z.Z'K;+#7??:%J"*BLJGE55E9551;Q'NTW7<[^CA
M5UU565F=?+ZZJCK*T#X[:M7=K;$;^OQ2+,[8N9Y2^N8GQ/'*/1<'D$)<(2!;
M-P\K[Y;J^-)YBSLY&QFQ.N$M#)YQR\AV<2D3[&Q*OY8[NH,5QE&#.*U96^YU
M$RNI&<WA#5O Z2*;]L^57>:9?D? 5*;J9#HUFB!?O(GH@GB"ASN\6KV(!D"F
M8HH GP#X T,J$F>Q_D,A,T6!6DHC%'N17_G)G]PW+(R784MX)<$1N7J'^[\0
M7L2*MD=<"[:4\.9/]\Q%['^"DKU#$F*]K=I($%(4X6(PE>CHPMJNAEWP/\B"
M.3=MR(BK:9'F^>=[:58%U(JS))W,Z;_'5!RWYRHESG:B@BRISV]M#K9TO.-H
M<N6) G6,_PS?>E2>@RQID#,JTC08);SDQ. T,H)K>2O2VNA*739.>R+O.28]
M-EWM]-C:HJ1Z;_OEU^=3/;<=\_OAC02?664Z E -=_EN:'_C$!>S6JM]:N7F
MCNL*E(I4Z*!"_OSM,OVMV:IU\/PK=;5O2NQ@Q"1JICQ$9'($S-_F+J<"4 "P
M^EE2V2\9DYU7B^KO.N,Z)=?* W7>,89U792CY[=;H^1!_UU!]"]1]$4%7GM-
M@;JO!>$4J( DJ2VBLAP- 7RE3 @TON5_^XVOA(2C& C@RQTNL$L$Q!\FOT;
MK6< R2A3&YYQE^&>X+(Y_[<]1&=G;N,^G@8Y\J0:(SC#E)S#?L!LPXH=OU\4
M#][ _F/\(VWQZ9D"]?H&1U#)ERR#-BI0N7/'X?3_],G"B(X"=1>O"PSN.Z)
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MI,)  N@4?)GGW1GFHCU'Z^5N,I :%N7Z$MDF*IGJD.O'][_[UBUG+GO@[_1
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MO_8 ..\_AE?_K&7XC8=96JY+.LVJ8'.2PE:-E7"M' =-/O86,YD?*J\(Q+J
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M_&:4=;&*[O)(Z.P5I=-PI>W)FQ _XL\NGOO,54EU[#YQ6\3ZN]Y>/OR:<+V
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M,8<SAQW6)"S-0RTY@'D[*]/M$B<@!C *NLPNA5LS51U[X1UP'Z8\@,>D9VX
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M?-C]])J8 YBFYFG$3U#HL%JBO 0((O"K)4U0O!CCC"AH).T]8QW33A5N1<C
M,E$B=XU74'KOH\MDD]FP';XZ4&CK69OMA42.OCCMMLD]_-K)Z]P[Y]M#Y?;X
M]M"_!+IIL@W-\*H9X2RTG1Q=CH9V]<G6X1M&->Q603P)(&Z^1:9A90:)C9Y]
M\;(E"#6^_ACL(,^23<Q7&]9$K=ASN7".NQX"W*JX'5_F'@<I4*?+M:_E$\F_
M <<1873X:!WL @1)\)+N\ON7^<QXVGYJ:(_L3'LB8,LJ(&_(B0TB>Z[WR!1
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MU@!8/Z5MVRPQ'3YW(\H1&6BGG,O9+=,'^^I3(*.4:9P5B0">;!L<=%>@8L-
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M^D5CV2 @1'H%(2H@*F!L:!20J(BHB*@H2)M21 @1T0(D0$A4I!<I0:&$@HB
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M14[HUA'T\!0"S(94>F$"OA5ZB14?E3K+$67>@N6D4^2FJW+$9ULRL \MV<I
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M'38-EB.>(=FQ_I#B2PPOQ]K 4M1-W(*J;LN6;$:A#D'PPA&?,J+2W; T$%A
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M"TPX:(O0U1/&Z/)B[X[;Y=EU]C>*?(S0IMZQ&9_[X<2C&#MH(CX@HV#.==Z
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MUK/&X<JSN)V$N/818\(T+V.XJ)^X(]P+5>/=9"U>\F]0N:V-^A(S-"IVD27
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MOFQ+GW-.(8_E=K* 'G@&GPW(E(L&(XE2J!C.:S9 @4)?+;!4CE!#PI-'D<>
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MR;J,#MUQ]'!R=W(Z\=?8RS)3TU_6GE5?>WC]S?UK+);\H,H1R_@PH:Z"VEC
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M*>0J87B/4$HL7BX%.$L>+.$G-L_HD=X#P7&\[#;L+9U(;9)V/SWI<V](P]X
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MEM E@V]'];5?.\<$17C2R*NDAF"<+)NLYSN9O[YGUE6[SF?"AA:I@QJ2(;1
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M+<] #Z^8F>:.L;,+[_VHIAH GG$67_M&57H4?50W!8NV'3>>^C'0OV4T:>&
M^'FH.6PB3D&DX'/H[[BQJ>=40V@?-RZXJ69GYX;X?5/X4KJNR1OC_9[T,M>F
MH *?GC_D=8^4!L<&ONTB7YD\#D8S&B"R$)7289_0 & .<+/8%84\0E_PT+V*
MLB&Q^B!IG!81:MQ6KH"!#U9UZ*=8O^FBD^4I]_1_!DX:=V_+2IL>LD)UQ*MW
M.<&=E9'#1;1%127:0Q$)&_[K,.%>9EE"7=_5R'I"%'.%05.X7@%;YTT/;,G3
M]+<2=#_AK1L,CG72EF#NMI/E<'<SG(>/>M@1L](#?-Z_P]X3<D"_J<FRIU0L
MV#0Y([!%5FSE)TBC7 4F\,D*HRK8]86AII#C::@PFT*HM]")K#NGA7\#^1NG
M>^3[N!@)\X=MLG)A[06#.R_+N],O> PY\ZK*NXN!_*EE5$N07$^(S%@+Y?,T
M;S2? 17BJ!LS*5.L&AW% A75&N6>V=B0(+LNMO-'_;?T*K=.QU.&W\WNZ@]?
MV=:+K$*V +4.%EK4Z^@]:L'[%Q>/4_=":B(;'R;HT"S!W,$NPU^R+>YK'^8V
MQ1N*)O?46_SQ%LR],T=3<X,BIFQCK2/K&EM9"?D-@69?LK-;V,X^6]H'/PL1
M!0;SJ@03@]5BX$062!T3O-HT\82?TL.\@HO'+ZG1H.+%+VJV$H-236A@*[X,
M2>"UX.R@N"*?CI%YP+N#<[X\\DQ'P;>,GPKXVA1_UTTAN?7L$QB\)\"E$<"S
M2]'HOAZ:$]E# #?AG>9EA3Y987!/^COW=>(2HX1U[JXC$LQZ9+.K/5&EA#<5
MR5Q5!$OE?@RPD][<551.6-,RY/I(?[*_KE4<1U/RL/W&Y)9S*G"3KF@$F8=6
M@#/")DB*S&6J4K=!9P6GZV[@R_$L[%KH>LAI1X%"'5;%1[A?OY')#?&R#[8=
M4*K7TF0\.5[L1TTCL0>SZ[^<Z(Z3DV"H2 .S5*&6TVLM)$)N(@-8]LOS-C,I
ML/5@?(,GJUR"B:9:WVH4-;COZ=GRP#DC)*BA:K:'_>,%<B'&-);EZ_-77RU9
MCBRN#%T^0J G3 "BX]25@LUA/K<<Z]&G1%L-ZW7;ZQXH)0Q /HB;NJ6AG[T.
MP:O[SXZ?AQ-9.E$7Y*+.+SF@50*2^)P[->;P5LA?4,Q+*4J;9TW%A,I_,0OD
MBB]H4T(Y3RE))\)/=^10+OUQ]/+J\SO.'^":[<E*--E&:A]?/+\OW*IF/Y3.
MMX>5MM;CI1F$O$&?6TT3>0)1$T=FTFZ<4>SQE-"0 PT=:Y_T2N$[9W?0/S"L
M7_02>4_I,>S!@2L7HA]TOD%R7V">QVS[MVWI3"2R4BS!;'LKKF9.L$.W2#"C
M,;=8BU7\)9B/>A+,19QHTWX3Y/&<S^(Q*$S@(PZX.B4RID4S%RYFO$+)[WW\
M="R^-Q9Y'Q\GP>2:N]2\ 3[(X$2ZF1+,2^)#X-,Q":88U9(G#HOW/X_1_697
M]V\/G&;D#SDVX>YBRU)9Y+74/Z%Q@48=826B!IF<2#TCV'J?02QP\:XR?D):
M<_;,3%&68_7;JD?\\E<=5S)?=QII]#TM+2E_796QCM!%FL$C*]%PL:Q,3%L\
MAV1_\437!=%Q#I1^#G(065!0&8!=8X2[6[5Y8L$X04 XTPV;DI\170BQ@9/[
MISM<.^AV*D<]&6GRJUS12!L_%JS<21_)L+F$@<F0 RJJ7*A2XN<2#)EYAU8B
MP4P(1#BJC:"XCA9/4Z'3[H:N%^=0/?E0C:;3X)BC2U*O3^@F<)AEFB!%8L>7
M\<;7#7Z<;C<G-&2H"J0^F41KY3T;,=G@RIR[0V#-P\K6/#(+" / :[GP:B6>
M5QUN*<655\E*D!Y%5K?#."Y-:J3" @O^B+[$5(//M6C&I^9:2I7:^FTGI??G
M6%<S&0](S7T_#7)2O!"N-Z:X%0_ML)\<YTY!6Z8FS@K"A33!#E<?%S2-!_@_
MH^+ QSW&8.L0/B946R$'PAVLC+CI\>#G5Y\'.;D%UMYEYQN>C2XDU_N9)"<N
MJ!$:*^'U1'Z(J_ QZAB):";0!+B/TO2_[8$6CQO1F 7B"4IT4C[9HBZ8A%=B
M4X)9_CX.2MA^0Q&PBLA1S&+0=S_L\XS^1-[11%^Z<!CMA$S)%+X4H"8D@I9\
MK\EG+Z!0,GLI'PBG<Z(L]+Z8X7BV^.7>-2OI@N,K7HY8*,:>J'C;>2E#9-MV
M5>]$<4C@C?;FO)9 ]7YVT\I#S&0\Z$"&]N)9G#*9R1VT5U,3;B)]>/&8DK#0
MWOWDOA_HA6Y;J-CF;8VTT&@P>E8=@CO3">_CM:XC[1^.U1M*MTMU:2L(B-74
M9E54/3 NXY-\709]5S$#:RS@XZ704I$Y[ -]$#].&N5(A<I3K:%'XB02QNE'
M*>3'C?-JP/=U=W]Y>-MF0UM-B]R:=>].E32>], V)\#J&\']_8[B% F&B(.V
MJ2847N@)-4-ZF/2@^FUS9"Q'U[9XD*+!4JU0[5&GSDS&L)>^A&VZJ!<*?/Q&
M02NI?M>1R3VFSI923V6RJ*IHT$A M.'=XF<UFJ&?F. YH%=V,8#,U].4Y[+:
M8 4!FFV<J]%(:IK_Y!BE,,!ISC9]4KWC?4>:T(DN/EU?I1K%L/'(_GK>TKCX
M0I:S5:"_S)S#VA+[M?Z6F^SDVK)*;)7RF_1.;:-\B^M,#@C<F-B9[+DA[* T
M<P7 _8;KVU,GP9238462,#'A3'E'#YJ__YC=BYC#IMU7^;?ML\=K_O#WRV<?
M#-XPH\?K@?7]"HDFMDJ^KXF%*8<O)I;>DF#@U8["),'6_TH(C\1QB!ZEU:E*
MH'#_ A3H!XXWN(CGWE=W&KWUYUE'&0&1CK>*,O<>'GA!4)!O,O]YT./Z]"Z=
M<DPHT[$6"SK0H&WS$P-H/W7BC'(L6T.8T!UHU/ZMDPMRPLQD>:[!;M9--$4&
M(4BCA<QK74$,"KJA4@2Z-!EGYH]5Q4VF)&827]GX!=_8FO*Q?6;J%K*3Z=OB
MP4N=!- Q;D U@>Q$)Z#TNK;0#WCP>$*?AI,XS^S",\K8G&^->BU_W23#M'A,
M:X/@2?SK]A'5YQV.@F+6AZEOQLW*PB>\8'FM;^<+_ _NE1Z.PG.'$J ="I%4
M_-9)A3QTW*Q 3$>!TN4=!0QG[/U 7U*3<:BN%J:FXLZDV=E ] _JRGRWM+?/
MZ:@S3'"\G/;G[3_U[W3F5N@6M(J5@-J]3&X6MBP!5I814DK$S_%>FK8N=ILT
M+X[7#1J!]K$%DW2.!FPFN'=_Y_D!2G!]A8ICVKU8P^X@8W9\\DMBZGS5Y<*<
MKRP_\K6R[('"XA\YV>C='@5JE7OX:R68%3^9WB&DDV7I9ZK AI[[0Y#M$(ES
M[_0A P/#OJ+O K5V%PW:JO,-2L>JPD8[G,\3YU=_F-')ENE!)4@QM!4_01)M
M&.-HX+VG>@$^+L;,&@2$/6_;:G0/\GSQ#0L*T:$K>LN[NO/S>TF ++<]@&0S
M.ZYVL<> WJOOU87+[*"_UY\-C%CZI^).!1J3^PP/.A7'<)9(,*2I94 MRJ#^
MY/2MDF"$;#&=>AH4(]N@7-8>^% ;@E(>Z"QW@$,J26] M+LR7?&3FH[6%6]J
MIN?TO>JJKJ:NRN8%(9U=Y/)Q-\VWELB*FXM[[+KP5^VCF'3\1*7H(-+J4CF1
M)+J"? QBG\>KUBSG0"Q;@3#VYC,?07]A:BRLR1_8,LCNEF".FP09"]SZBOMY
M%96= :[CFOY.Y9V?4CA) 'VJ/A: =!+@]5B!![)RH^@X1. 7Y8DTD3Y.2>,]
M,(<U)!/&4"B"A@] E@*9=]/PEC(F6!E5 .];E1GLX>&G6D?2#VCUDW]Z6?"U
M\L:7KZSLL5--D2)I^!98F0!PGV/!,V3( *4W$W @&(2LF..UWG97@7S!J29
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M[RZX%^9\_45>GV$U=Z^KH6#P?!1ROK"DZQ5K)E](1=UG+^H^NYB>O\RL_$!
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MK;;"K+W_DB7W\MWN5W)+EB2&9_[Y[:KU64_SL[<OA"W)1IVK\*87\85+JR=
M\@WQ#-2P]"?>7.9H7+EF+ZO!G/%18*NQ2DWGR#G-@_F&)Y==8\DS;*08#@?E
M2!5[+\1=C#$:+]<^\"+V >6D%#I*,:=6KU/^<^5?!Y?]L5Q[V6K*AOCE9FML
MK3"G2SKHXMW;-W1<N3(+>6:0\BZ4E(>U;S>XJD&=5[3^XTB"6>N,W9ZE.G$S
MIKM^,-51'HAFG9*FQ;@JM1S:#O8+S:"E^9#2.V!9S3;X!-@R->DKV%.?H<?L
M8)S-I6X$NXL]\KY2;-_5*+WZ0I9@>)LZ8<OK8=-\UQ8/&WJD:!.[T4$G:/J\
M:^@7AP-:?B# LP^KD:+N@ )!+UYCLE8T%W>O1@Z<NF.FG7U$&^OQA;HGNY^X
M__JQ-FM%F^N@JUZE?U32I.IN.]-MQ.7%UO_!RI'%!O/^W?+?2CRWF#,=R^FO
M1EIR^63D86X!'M)6@)^W"C>A,4([$QAM/5=<1)@^V(Q\')%@QM(N8V<4F>.H
M0NQ(Q)]X\1\Y_?_5BF\SN;F$5Y'ABYOQ4*-'-DSU>36HWF!KY?-;##2]>$WW
M<RN"<T%<_=2JHX%8:2AG'?_!]ALN8\NO%,,YNS4-%J##<28INE/L;4MY>&@+
M\RZ>5!R)+2FNI=V38"J7:2U/%]Z!"+Q>"RTHO)ZI 'L$#KG)-NW'WO-(. Y6
MWM_22:;NX\7FFWN=^<(KBW7IR'WUI,.!GC$QV"K\9#U_^$N#W]J*^3769DJ-
M8(O<^](&PU-Y-IM23.0>6&_:HYV9YWCJ[)UE,0]B,(5$+V)NOZ77!9*OI]?5
ML+WZOAMBV.SE/??BUVT\$Z/C\.[,68?>LVG;GBY;^;1DY1*/-U$8E3]?/GL8
MG^OS\MNWR;.:F+5TAP-JB2-I>OL?IW7N/Y*J4F;TAIY^+KZNS6B?[_$:OXH'
MXHNJ]E<OBT?O9>]Z!% < :/<_Q6UC@W9=10;Z!O\G!7IYN>OH(YKI,<Z;7U=
MFGXI\5=%DJV&#1F7JI?WX]#[?IU$__)>C:M.NFM/3JQ-/M5ON5-FI:N,]]:E
M-U;M>:P>N'8)M%4D#=0: ][R&LA*&]%%H/84<'6[F;3%'OB4+!@N)$(A*.=M
M" HU_((H(JWJ%T='KU05E07QF'(L?[[8I_]HVY5<T9;'KB=<[:YZ,A]3'OS8
M)L$$_P<S O_5D&M,[C#YURXRZAA""K-L"LDJ=9P-_N?LNO!92H)YP(ID3GA:
MHT1UGP#X.0>P%C(7-,!(.,8=96XE06AL[/ L##C[&;)$K'"R$DQO]7-@M+2[
M:L<O9_BZ!+.6:4S^G\49HNQEJ*@6#(NE2#"(K!\: ZZ6B6_7[(6W0D9\,?X,
M1+HID#T%T7A$,]L+112+L2]6/'/<L4I;4CCIQ6C:?9?Z^1[/LYO#QM;5ZDD!
MY$ 8U9FU:,K];DX 7:9$2V Y":9M(3ND29H_?*?6+W['VFNOHQUX[-UG2A[>
M<F(83M$N@>7GS;T_/CG\YLV#!S?2[J>46%MLVG&=U?!&M^M6XPG<L4!CTMEI
M?8!E!-0V [.H$4IQB'IP G)VL:97EP0CHX]>8AYYSX2(/_&_' GM<\I-R&N^
M!#-B6\>$XCTS"+/#S8*0ICEO":;UHP0#[0]U#R5T)3/3L-#E8F@?&4E@+@HE
MECUZ^Q^K\+PT)O<[<\$")2ZH,>7-FR28'>,+[L\3YIK0SX?<E268>G^]:32,
M6!!B?V+/)< PRO+"<[\/?Q<[N_YZ)L%$^*"?4U  (@GF$@$VG,?"^9F(6CZR
MRE6"R9P2)P)@QU=@NHB9/8:ZRWD_8'8SCP!;[V[%+?A_AVIXOY'^1OH;Z6^D
MOY'^1OH;Z6^DOY'^?Q5I-J%O$>E[">8^"E7&W+Z.%(&-0IK5X/$%MW_9-Z2!
M\O/ML!;ZLQX:1C5)X<M0%H$^]8YPER8[(<$0@>@J0BS57(!]-PTE.'?6;&/W
M0IX,9[ZN+)W^6F7!.'M9U2%G]H-LE\%S2U]@7W' %@)XG2/& A.Q*.J,(0DF
M.8 )D@CPP^%)5"MX-0LZ)!@[BV7%HS=JTN^_SE2ZR[\_)2^7&ZE[)'[_M;-^
MSBI+UT2E.82_=>G:OJ\S]:9-I:_<M=E-(QVA[:6,TW2?ELT5'\R-D2>%\!?4
MOO\!;9_!C\?CD+L,70DFZH?S=PGF!)6I^K5_#/T/6K($ P; #)B9KPL8XO_I
M%OY!(?3,OK7"_E.?%H787[\(* C[YM;FA=+*&<M_!&4-[W&$UU=*,-8<T28)
MAI?[&E4V;H!MI\,_" S6;YR_<?[&^1OG;YR_<?[&^1OG;YS_QW$*.D3!\%*4
M.<.48*&!.&>NE:TD_"!^"'N!>%MHWY M)R94$:QD$>G,-5!L[<[1T\;562-5
M242!?DIFD%>-+O%^=/0ZN1EG)FAO?YL)ND\I+JY;+;M1+3)9K/]D<@>1]@'D
MZ>/%$>YK!%ZLFW-D10K D@\.K4B[499G0-L]Z&ZUZ5/+ML17\8D9)WMF4:HO
M%2K!_.V.#'"$OG@E8+;!?''[]3K@NPI0HBI.U$39_HE;Y2&[^??M%QX+@#ZS
M?9]?I^TE>XC#4\7.3:(=9T,R62+<Y?&!ZR)2L/WE =/IZG6BY:) +-%EL.$C
MTGV>?6)'S]O)[^5S(X6_*O^SQ^3X28(IVLM<4 2+$>U'7JGB?=,PP9^<;XV$
M.J(@.Z9GII&"_Y36KP7^MRZO+="!X>\ K(G'X7%C'SDM"O^("/L/[A HQCE8
M+PRAGY_A5DHP_'TI-X$.&JYA7N$WRM\H?Z/\C?(WRM\H?Z/\C?(WRO]S*$-M
MT8MZA"H M1X,>=%>JA':_U5[=CA7M8%V]Q32CI4I"&#*P::@WB"VNY 1Z,>7
MTE+KOOK3I;WWZ^A^ZG->L>^:^?=Q]-67I)D,GW]<']-^#5A[T8]J_^!"=O*U
M[^NZF]ISQGC7US,5HL*(HL[\CJS<8S[L$_(V;GUC'E'/UIW,VWRJC'XCV=E0
MZ)(ST9,*RP*',J1=DT''\.[IHSG5!%E*R-7L,..8%5>/)'EO?;#N89FUTD>U
MS+A'CU;?TTE,&R,]^=_7U_RBSCWFW+3UK0S6+.F[A7NO^RMUL3*L!//QUF(!
M4>'2Q6++F7/'D+3_[IN%074))M%: ^C;ATHJ%[F_&RL%.R68N3D)9O1EY&R;
MU5K']QKWE%NALOH%DS"J/I^@1HF9UL>S$,4O1@F*XZDS.X]>H<?)VK_NG-/-
M<XM:F2*\47:L_C$F@OE)57@#O69X:$\*%CS)B22 YPG1&?L%$4DB)>HM,1-V
M%1F/N2N154D[*?X'P!O/N"+;M1U&"=(?\MPAX&@IF,MZ:UU7V>ZSZV"0U(_*
M+)_4[8'*LU;?,!*,P\L=Y<F3.9E>Q!?$^9WNO83^@\&>-TD[['V#B(&*]K[^
M9+,K;2W+P/</6'I7/NA<+2HX$W[:1L?OR/3'T;4.VC8Z#W9G^37&. \,1)TY
M?-+Y4=39DS8;5F)"E*?O,BMI$_L4XEI9-LPKS+Y3N"B6D_TJ&N:#R)*J8Z^N
ML-IF4WV:&EA->4WR<+KI?-'-9 +O2U0[><CI#L%15W='Z2O//]6<C^[X>,1R
MN]JRU0>7K5_S_NDJUZ."GC"S@\64\+HJA?M4W4*(5D=>YKX#'$SD:VJ?ZF'L
MV=R>4IY0KVZ>_(T=<7]^A^R!M+BW9<>?/F0M21O+__4+M:,_ZM';\)=Q?3+(
M2DO1U=!.=-3@KP1+,'%,E9H]',K+F4;.TLN"R/!R.P+/,-1<\)+2?%K+J"-
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M34&(BHC*DAG9',!D7! 1,8H* D+<D"5BQ@6)$M(C" @(45&8@8&H"(@L$2&
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MR741Z$V&MD9*XV&=0?DU*%=&0MWSF?JXJV)],%F/)9X1D%;2XB7*_/I68]I
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M T;'ARBV:P?=28)=12OS Y5YN6'*2ML D](NKZ']__1^A-&D:A%".R0U@%<
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MSP9410=H5P^LVL4O!^I^S'\JV!CE4%^T0/NM3;33ZO?J V3P #M%A3%$RV
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MO@ ?S?4(/%7B4QDS9>5Z%H3(]=W8O-'+\FYD34JWLU\K17?O"CN,(@99,M?
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MTM[[H0[(IK;Q2;KKW.B-G>-" M=JVF/=X/;W'(N58?E(D04T]PS4.UI^'6
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M#/_>)NXL7O>]8F"G9".UW8(6CC6 =G^C)A+%)4!97I;"FF[]__00-P#.L%9
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MN? 37\-VN]T_&ZU]C7\]KFT8G B$V,''@-J#Z]+%E; QZH)JJ5!O\1JJ-CT
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M%%2EQU4802\0Z(3M344,MD.ZE@PS6I#4 -ZP\^5.Z<9T9'E?V'Z18OVP><.
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MEZ2^#LGNO]'@K0N(LT6&,%%VZDB7[8J*  MRS&Q*;BY0%ZB?7EC\^5[7(\>
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M49P@J0;)U\^%??(I_NK\ZWV2VN,+=P3V]T+6>Z[]6G*S*+]J7?75+UR#U7]
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M]C:-Y_\)TL7,_J\./%M(2- FYD3ZE;GV[,HX'A'Y4('#AB&;^^'E[[F_%@E
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MS5XM6?FK<B+;6*26)#$M?>(4^+SRVI7$KK/51\<!0=GB@U^U.XSJJ18^?#5
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M?X3T(D1LF5J&M'$T.20US5'/ZH2P4B,!ARNQ]*Z'7%_5?BQ2+<@O.4\,]-D
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MA:8"X6*_]+*:N\*_:@^>H:2<Z/(Z5>GJ[[&#M>'IB='M.[V710!@&(-'3%S
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MAXY3\:S*GC^O1!:/S;<T>!L<3/0\3S!E%L'IQ)GH$-T362[ >(GT.SR52_L
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M#9@9R"L]W4XSD@Z]GEF1)C*4:M%.@N^S"H44I:$ CJ89937-"ECKMM8$)A9
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MRJJ U'3[J QG4!8EV>4.N0\>9#]E.'<_*B__U;KF1M!ZQVYZ/;[,ES%E)-U
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M*LYVFPP\8DI=PHR_/UBV8]^F.F.T8:C"KU>FH?=<'BYF30E&6>KT3CH!PA?
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M L+W N9; SYEBEQ <RF%-/D1P<Z@7PP!*/9/Y;V/N;M\MGI-=4A;@+M=78+
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M7,F[\_#DFK.^VA'K/;PN[ VLN*M\I#<O/=)Q7[.IU SXE^U*8\VSFTBS&]\
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MJVN>/K7MF]Q'\9_:L?*!_P)02P,$%     @ X8-97#[ "_-E\P$ Q?,! !$
M  !I;6<W-3@Y-S4U,E\T+F=I9AQ:951;71 ,KB4X!8J[N[MK<2GN4MS=W=U;
MW(N[4YP"P:VX%G?W?/#='SEG<W=G9V9?WLO-B92,)#>/40_T$>0]   &@P$
M-@# ' #(! ! [V]\1&QL #9S %LF@ T$8 -_;)JS <S- >:9 ',0P!S\D9O)
M!L@T!V1F C)!@$SP1RF(#0 R!X R 2 0  1^1P* V0!@<P X$P &O7?Z /Z
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M"7Z:[U=B"-F7D>,+6><OBL'Y,E;6UG\!+XS4(U;[3ZR66!B3&/*/::3@G)+
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M'=(=_=(I/=,K7=,M?=-%/=1)'=1-_=-1W=-5'=-9O=-;G=-A?=1/7=+M7!W
M@35@V3;$M@0$XL5__->+_,J[?-B!O<FUG-C_@_W8BYW*EUW8FUW9D]W+HQW9
MC5W:JYW:F7W:G]W:L[W:303/.+S\+$8 ?IS;G5W;T?W:MQW;SUW=T[W;X;W=
MXQW:W;W>Y]W<Z?W>V3W?SQW%PWS,7=C,T5S-V7S67UW64_W@2SWA7;WA8WWA
M5]WA$3[B'][@)1[B%=[B*Y[A-Y[B)S[C.?[C+U[C1?[.:_W6T2'7_6+7>UW?
MU_WEWUW>99[?:1[?;7[?;Q[F[7WF<S[F:Q[G@5[GG_S;(V;KQ%TWR'W&>W[G
M?U[H>3[H?7[I73[JH9[II?[IG;[IJ3[K9=S?Q9S,Q4_@TWS-,7[D0[[L.Q[D
M/1[M2[[MV?[M21[N_\\^[NE^[NU^[>L>[^]>[07]Y'%=0E@> 7Q]ZPG?ZJM^
MZ@V?ZP\?ZPL?\1V?\1._\2%_Q(G^IJ480<>]W(-^!O:BAIB(Q!]@!G3@,$#.
M_6:@ZQ-@]-O+V@1!!TX?QTN<\\ND7O+Y@H3N]4/_8SR?R9@,Y%H!\UP?]&F@
M3"R"'G0 R#G?5?UA*T*_5$'NK7G?7H!_!KX\ 63?56:!R60CU;P ]V&?R6?
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M^*E'(C9\(W()Y"$[]).5WRFP<3I15F(LLY:__,Z!7-1H2C[_E=(ZVC3A?K1
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MBJUHBEX1(/PS-5.U5JV *AW2/4(1((Z1.H'1#_D #^Z0'6RC#^_ 6\6&5_1
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MO$- I,=[U*0\A+,]K,-Z_,=\Y$.!)*<X-!39N8=]LY=RD1PQ28"C 9#XZSX
MF8$H"#6:Z)5YV42%5)>P<1>8(PF,-!A\2@C^:#KM*<C(&!J'G)*2I)?X^Z=S
M_ZE B:P7[,.)K#":@0 _+;3'0,3'GNQ#GPR5?=RIY?/'@#3*GQQ(G@Q*H$03
M="D@I&1*I03(I(S*IIS*FAO*GBK*I;Q*J\3*JORSHV Y6RS&=F.7?M@X]=A"
M5[LB47-+D>A "3(!3VN'2G1+J'G'3L1+L\F96!0,DK0(N*2(FMQ+@3@:!LJ(
M_LD*\6 )&-3)]3@<G@&,MJRE7NJA>? '?0 3F-05R&R(&=@#)6%&#'/,(4J$
MJ B+=F/$7LRZ>8RWP)1,B#A$O"0[!*@6O""W=6-$?*!&M$/'G(FZN@"<G($7
M3NM*L)3*KUS.G.L_I])#:_)*Y&1.JE3.;"H=]WA"?O_(F2^)@K%+I'Q8(<>I
MAU*\"JUHDIF!%L=Y#WV8!W<4@"A A*_8&=?IQ?0L'9;+-&D,EONLOK'+BB.$
M'/V11GX(H,2$B>T[S-?!"YT9H 1XAQ0RQ9SLBWEKFU \FJR(&>&<EWG)O%G#
M"G#9SHV# O!#S$04(V>I(_5+0.($0@Z] GE8Q?D(T>1Y&@RRC\V4(I1P2/JC
M%J>;A73#&UC3(FAIB> 1EOS@M"P"$S&!R,/D(F'<"\FY KS8N+)C(BFMC#**
MT;!3FT9"M78)EB%,A"\\SNJ4SC--3C0=,ZU<- "DSJ.<3CE-TX@)#X8!TBA4
MMY6+-;G M;CQ!SYR07HP"P#_2-&A\0+JX;B>819JLS:&(,1*U"/[T LIVI?M
M($*^\8)>?(H2,AMU/-!2<P_DB9*ER!.= 8\,*M"Y*%5J!!/ZB)EWL9)Z:!8@
MLYIY<Q=!.$L^A8<+:B01S=6]$18@FTCBK =7-,9"G%*W*$LO$!W(N3PI@K7B
M9#=>_#?.1!B8&:%W:3=Y(-3, ;^XD;4B!+6-G#:YP#P4%!9$^,+LV$"I:-9J
M]0JU;,SRH+;TL(F: 9>\0#Q'PKQYH(J#:8_<^1S67$7CI-,YC5.$75CW:5-[
MZL>$#4N&E5B%K5B*O5CK]+R$@")'4M2=G-B,M=B0Q=@^=%C4BTXU35DX)5F5
MC=B1_WW9-679E879E@79F/4FDV45<@B ;$@-G_U9H U:H1U:HBU:HSU:I$U:
MI5U:IFU:IWU:J(U:J9U:JJU:J[U:K,U:K=U:KNU:K_U:L U;L1U;LBU;LSU;
MM$U;M5U;HAT@GC6'>8(J%XLR*%.Q)7,RNLU;NZW;'-M;O>U;P$VROQ5<ORW<
MP&4RPR7<P\7;Q$7<Q;U;*5.T8SL]RI7<G:O<R;5<S+U<S>W<S/U<S@7=S1U=
MSPU=TR5=T2U=U#U=U6W=U'U=UH7=U9U=UXU=VZ5=V:U=W+U=W>W=W/U=W@7>
MW1U>WPU>XR5>X2U>Y#U>Y6W>Y'U>YH7>Y9U>YXU>ZZ5>Z?^M7NR]7NWMWNS]
M7NX%W^T=7^\-7_,E7_$M7_0]7_5MW_1]7_:%W_6=7_>-7_NE7_FM7_R]7_WM
MW_S]7_X%X/T=8/\-8 ,F8 $N8 0^8 5NX 1^8 :&X 6>8 >.8 NF8 FN8 R^
M8 UN77PPAP#8AI\] )\EX=0PX0! 814N818^X19.X1=>81>>81BF81FN81R^
M81V.81ZVX1[.X1_>81\>8B F8B$N8B0^8B4.8B8VXB9.XB=>8B>>8BBF8BFN
M8BR^8BV.8BZVXB[.XA;>A@-HA[G+8.%UGB_>8B]>8S!F8S5N8SA^8SE.8SIV
MXSJ.XSN>8SO>8SSF8SWN8T#^8T'_KF-N2!WB182>6RE%3BE&7F1';F1(?F1)
MCF1*GF1+]H@47H<RYN S3H?4.,1+#N5*'F51+F52/F533F541F6W30?6Z%U$
M3CU5GN55IF5;KF5<OF5=SN51'J #T.0.%MY[\&0"VF5C1JAF3.9\J>2D6: %
MNAT?S56\\5%W>%&&6\O.#!AG#AA>QKV+&DR1TLMW/&9R+JA6?N7<C>7H+&=V
M[F9W;F=X?F=YCN>/\F5@-N/CQ0=B!N5Y[N=]P1Y^2"% ;3E ;85QA26$X>>6
M<"63I!?%=*"8Z8>!#CQ9"T]X4%28F2&2(\ZWZ =>U8I\RX<: M7#9)M"91P_
M<@]V";R6_^N'R[-+':4H;K89V\QH-9+0D22[OY'H67@']= HV8&/8R%1KL.C
MKUEF>NYG\$@-5S[D1%9JJ$YJJ8YJJIYJJX9D>][D#1[>8?[DJRYG29R',G:6
MOG$EICFY6:!$AD"2O2E"F.:67HG'%ZT+>+#+QW$Y>NB"F':@X7DWO@C0V%A
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MCQ?X=&NUIZ3M'?<21-CX7)7QC".W:GX<92<\)O>*?'#!O9$\   :_N@=!N<
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ME1E(Z%D1>0Q.O,2GIEPA=E= 5@#_[N>>/:#MA?'SS)IFT48$D",GN6N%:%@
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MX:%%^6^ B^*.?%PU)BTXF0Z#DN!6N*/_0--A-"(@_%/^V1LA]1 E6TF6X%F
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MD 49D0]9D0V9D0O9D1.YD2'YD1=YDB.9DB49DR]9DRV9DRO9DS$Y^=0A' X
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MQ$]<QFG\BX'8Q6$\@X"X!2S(Q'.<R&GJQH\<QI7<B+]8RJ\<"U1\R9_XBVG
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M5Q#QL^R/G@[3,Q+U ^!OEB O,T;/\()O%FO:B:Z0?C!#AZ!9E0&PG94/N64
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M/, "1,#3DSGR8ST%;, )9, *E$ +7, +Q#S? S[AR\ /I$ -!$$,#,$1%$$
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MP^C+JST#%"R(/_P5\_P.@'7E[[$^CL-?OY_QX6.??-SXOZT_NOQOZ[_XDH>
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M<P<(]3&/S3%/'E2,WN$$P0]6XD,0\SCB@/SAQAF\ Y2"0&/DU!B@;+H1C@@
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M17SC%L]XQSJN,4&X1J*QB0T[Z7L,V(:<Y"(WQ9AJRS&.5\SC&D/Y*G13U"S
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ME$=#!/$)&M@%3/E:-4B4'O03-4*9%LO,X\"SK^6H'#BJH22&8DIRE(.E26:
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MC0'HCDM7(!  "_#XHQ<^70F@(C3]U-/10S.VXQ&%%G;G13X Y //>";, ,^
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MQ5DPDA4'(8GND)CP,&%E1P_CXB^5@V30A37S()L5T80**I[W,BM=HVJKH7@
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MU<,[V+E<9C:C22X91G-9+8[DB:83'!*K8?F8ASNLBCUB 6>"]F&<52)5CUE
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M7C[4L93KK[U""^RNTD;+ZYK48ENMI6"ATX4ZPH$U+:[A:AMLN=FB>RZL 1R
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M"2)/D%+9IJ2DC=E1F<'2QCN=:(A# >H;"P2('+LI#@K$&F<^Z%$;>KB6)/[
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MCJ=A$R%@.H!=L $/@N8%_54W,Q!Z!!E,0?==F(>"((B1B, /LX!KU[A@.?"
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M[RTD25%?/GGO-*:#IQ0LT;,>[^D#H*_>QY#P6K[T*[3CQJXX];V#.-,=/6@
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M%Z(/^!Z2D2D/W7EM%KVNB/?B6=N%H-C8XTSP@"?R81@+N%X/R6T^J<>1%N2
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MZSA<+'WA=8P6-"4"V#%/L$&3/GC!=NW:L83<-!T3 )!7!T+$_;"89L7<MLS
M./'70ER/,^&:]" "QF7<U4$)O;Q#:[E8AVW+VPV7&LI-8E6:'^%3=RGB-OG#
M/7@!+%W'>?&#)$JA44V<>NEA0SG2VV7:^G 8A>D </!#(A32.$&6*LD2&()'
M_[[ !P!%%W3EQW[TAP$%41N=T16Q4884V8'!U)(U67W<&@#X5#H "%W=QRR$
M50AIF3RL68G 4$GY U))F8+<4#M$T*;=0U6$40H=$S]T40;Y7Y+5@Y\M6H4
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MI4:3.F6JM"G4IU*K1KU*%>O4K4W-R6#!(APY@ERU6LV*MFS:LR/1K2O5#P
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M_@/ ]A- ]BM ^=._/AD0:[$B_F$0I_B&+S&3""03"IQ "QR3"Y1 #-Q #>S
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MQG"$QW241W>,_\=MM$=SQ$=VU,=WO,=Y],=Z_,=\%,A]),A^',B 3$AZ7$B
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M+-NR"A4:?$B'KLP*%.5*JY!1 >P]$]4]T!/_"*&4T AM4B9]TL_D24&[#J8
M2C&<2[N,R[*D2[;L4B[]TBRMRRT-4R\E4TJD4 L5"@P54N.4 73H@G>X G.P
M3!EE 77 !_[2!W@H4;&L3CCM G3P3+\XSZ*H-!I5TJBX@G9XAW68@>\(BW2@
MA^C)T59R!SS#!W08LN]XTS@-U*RT+PZ-"E"%D%&-QE'EB1D]U5'%KW:X@G1P
M5&LLTS&=52REU;NT52VM55V]U5W-55[]U;S<O$CZQ" ,4B@]5B=-5F1E0B5-
M4P# 4!80@(@ SWN8A2/KAUEHFGP0A$ UAQO%C@TSU ]KAWI@FBRS5GZH!R^
M@B/-BAF@AUG(3C7M_X=[6-?OL#-\T =K!0!L54ZJJ,XO&PHM<]0N$!I$R-0
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M+A:P,[[U!WY(3H=-BGQP!W) U8(( '+@7'EX70$P!_0<"HR=T "0@7DHD'J
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M):1 2WG/F"@%!>_E@RO^*,T;HS*5FG).*3=KJ0EFP,AZI"YU'G/'+5OE5'@
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M*>051#U )#]5:I++<,1\XDN')7ST3R.6!&@]Z(&]I!/3!('OASMFW=49W ,
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M*(%VY8%RI8$F:(,RZ-0DA//81/8=%70)Q>'<H@.FVZEHFVR]0[',6E/N2D;
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M6<6URY!XZK1PXAX]BS\@D+38'5#-[LQDB<VL80[.0.=@B3PLC#OXA(!5!W_
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MB?\:8*+X:O(!!+]^^@8.Y'=/4+L9+!"80,#BRCQ^!//IPZ>/(#Y!5UB4:"@
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M[WK:W][VN8\][G>O^]K7)2  .U!+ P04    " #A@UE<#AE$_KU* 0#MHP$
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MO>.%(OF1GH0;_A</W<_[L[F29:B:8@.J@0?]>HRC-(= \&>:CY%0B?-LE.P
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M:J_U2%+#UG;-MD>#2OOLLX KMUWJP)-X?#TND@PQ3TN:((G_X%T%?34*$8P
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M55G;_M/)-,68S64C^:2272"PL6E'V/?=FP,)CA@>?LAS IE'$1D0!3!%?[[
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M?)$1W-$HI5A2,<;D(?CF2!]K;' @94X[VC5N=F9;OVFX\PK767D(_$8O>;9
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M%:D\#:ZN3ER5"<^6U9K:]*O_M=51/>H1>.A]]WRX *$%] ;A[Y1VP18T4!E
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MI/&^J#TF$YG]=L."[2;UL/T@W]A,S\*6?Y(B;<T?7_FF-PKY".VR(*OKV$L
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M("4!1'J"$!Y,2&Y\Y\Z<\GO/G'ONW'/.O7._?^P99K.?YUE[K\_ZK+6RVZQ
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M]$408SQ-.7]$VV5X5YE&D$H:YL)1TT9DOO/$N%'D$HH*>C?4#4U"" U7V]\
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M:2=(EV(+[/9,<OD_Y@UE+["9E-V!O_M1=!9TLH]MZ+L:!F\"!2YXDOF&B+D
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M'WC%S<I'K<_57G&@N\_Q$012QS"5S].BP<>+'1@Z9[@HWG);$'L<T+6&,TQ
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M<\;?>]BTFAXBEM!U7D7MH?P)5<G=MMV31,1DP\>UK<I;;RQS^\,;*GKYEAJ
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MGR'\;"7<PC)UZ3I!TZX0[.K#U%XK8.H]/YF%PRY*>O/)L=T_([<?U&=P!;S
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MH-IJGQ6VGRE]4;_O;RMQYG<'>LF2>(V VCK&>U)8>?&A?<@Z*BBYS0J)K^]
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METKCGMEH@8X2V",J2$LZ;S!;=6^B:%"H0I)';G^*PAI.>@(4$Q7PZEW;$&Q
M3 -:F.P.]."\R!+X*?TI3[59!4J]9JHV;,?_6CQ]V_N*,Y<ZL2V7T!E(MUU
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MY+?$#,PW?HJ^I#H^56_)9Y?N)!N6$B35];[SN3Q2,RO?D/>G0JH7_0#_FJL
M@,&C^K22_QA%4J1A;#TM-4U44(-WNR@A)*IFL6-U!9+G70[],9AW*70GV:]C
M\))OR52;$S: +2(>EM.=*Q@W6 J9:2#4^$R*.+1_6#X4N$>$<7Q?5*+LG-[]
M?4J3CVYXY$;B[;44Z=AKV1?X=/X/]MX\&LK__Q^>BA"R4Y:F0BJDK(E,)5N2
M-@DQE629D"0C8ZY0]B6$4AF5)=FR9YWLJ20[(V8399T1XV)FKKDO[]]]_^[[
M?-Z?<SZ?W_?^?G_G_,[Y_G&=XUQG7*_M^7H\'X_7\GS>,6^BW[V6>B- U<%R
M0MQR-^%_WB#\KWGLG*9J$CXS9Y/<ZJV=(BNBOTE:IT9_%>PHJW\EDWC51MC>
MA\M:#>5\6H^&4OT#*,^;I>=RQ!FY;_C&]X.E@3)51;Z8O9@&U)GR6ON1VV\#
M7U^9->IY7UCG_X(2LIZO;SOWC8D(U$\NS8L(\%;[B!;C[&-N:B'A7(29J0GQ
MV9=)7AG+52^]WL-TT^O5=2EGX2SD-T^A^&B^N!1T5QY'3A@26K\$NPM\PPRG
M\1!SJ4P=6T8_>J/QP:H%MQS'Z7VZ:S<)FK.7]%-,O<H;F[MU]T^89\E.37JQ
MD9 @+"+XEM?Y.=1!E*X@Q&7,IU*?=X^LP!\*7_H"ZK;D:Y$T*AJ\!HT*;*QN
M<1B==W:FPE[ /NV;N5W!RA47BY8G'.U79R)@RH\Y4=?Q^2[32UTB/O6(?TE:
MHWWGD8K;BSD>=:1SYQT_+WR-=R0[>_=EY/;&9PP>ZMDW]_I.(XGX >JHUV*X
M4[7"?'V7D0(<?89MA-:R6:J>^IAPR_U+SP)P*5/?G&KF-*\G^QVP?:IR<RSE
MQ40OUI5";+;E]R(EU%'%(AH%&=\J"RJ*WGG5(B,JBK1YB'.>H5)Z/P=R"B]<
MV7[<Z&MQ6YG_BZ'<<^@H8[,@_S_VA=S7YUY.V_QI1XFX!P5_/BI5ZRQVZDM9
MG]WKGA5CXGJ:'D@,M&VMC8RKUV%T?*P5B V G1@)K])K?"C[,B:0_8<XEY%:
M61@8J% 6&%16=<??.I<C#9J^ =^A%7^C1>I%\[#?O*' F%OU.MFC,XNK#]/_
MZ%TNNL1<2;;V>3J1L;2V%QMG.NG3</,G_QF;@>>3N15GTQL*)7O,QM7?.]Q#
M^TW>QFT#K3"T"&9E=0N:[SA=("D'D&JC%NT_&I#CVZ#L%>NE)5Q]3SO9D\C(
MP4L S1=Q_CS$EFX8$1G/*F)UL'F0Q$LU-NYS?6&D'5MK5#B\IWZ6/91WSF(0
M]N/=:V2!<D@%=N0\A FD%<XFBCUVN.?,FOFQR%X(0PLLV\JI)58B(TSX&YGU
M3CBB[!CH;DEH/32[,[?+T?I2@W/VQ@]/73=)UTXUV3[<H<HT)]!]Q3G:#/UJ
MNNB^U*5NJ>G,[;V^ 6-'^Q3DNR]^J$Q>_%&\N4^Z(,[/A6 F+ &3#OO"%U=_
MF[TKK_>L=#^C]=Q2[TU8A>,O6>>TX@6S@H7I($*TB0A.A9E0XT[SE>'H,2RB
M.*9Y]><O8^X/12P565\LQ_I--%0N#Q16BU=<5I WE"[>+/@QAVG01'C8J--_
M*P"073>DZ #G0]>=C<X-<@QRO.S3U+<:O\+X!6(TW@LR](-NU=T^%+=EJ7;O
MY1CFQ,\2A^##'_HJK8HM&^C"UF.QTZDIT_]O=?*B&T4XJLR<]O1 VD+$N!!3
M<S JJ>/-#TRF0F^E845%[ ['RU:!&'72NZNWQ)\(A\9,01H<>=",WBTT7I+0
MN!VKW'X0]&\AE;!43'8S)M/?[4E7/'+WY^Z^^(&*HNM9.^WTV_5/;\P6%PUV
M]F^$"562=1N2=6 &6+M56_3^:<R,U,.?)8XFWQKTA.TR)B;S=_A86]WYXTQ.
M&YIV<]:ZYF16M#_]SXH*D-;1.K?I1!58R3Q/ZK,LK:PHA_5M],[RRC!^2\V=
MB1<^2!S?N"&*%G_LXKGFMQMKM&9'Q5:7(Z%5'F)FZ!7G @^1W,3TASXCHWF(
MI=_^5^R ^B!<=AEGT_G4\4U\XR7VRXZ.C;,PA]#9UT5GIK]X62J3O)(9^_)7
M94^0-%"N@9KJ1;(G$V>_B*TNP5\MZ+='&_,0&>CUE0J=V$R@2XLCQ$,\LV!K
MMT ANWB(1@_H*XQJ!$M@(:/!3/$/Y E0;#DM__W#_]4?8I9@,;CKFCMR??4C
M^$;5(P>]O("KX?N'E7<N"RC:3_W$1P+K07E_[B:6+W CD&M#[=A$0U@>'J43
M[J,7K?P$2,"2>NLJX1J5DPW2'UYXDH&S2LY][JW'S8GH*9@&7@_ U)C:!+7\
M1SRH2"H]P5#E6>KUD^ZI+Q[$RN<?^&:[X428D[&K8<FD%K3%C E+:#33E%;@
MB=_)["*' I[(B.K'+7FXDXR(U !WS]?3W8>L;PX>T!T>T-M9K2I<,?8DK?-'
MQYH34_\Q"0:Q@"Z) RJ5(4ZGB'UID[LO6<K/DRQE+U[[=./ -J07=+D^B'UP
M/<<EPMB/J?ZQ-G!VB!%.UT]E&IVMV;$%#"WZI9]1E8_9\4:]?4A^X'?")8<B
M65]MU*&6]ND-6XY+;Z 0%!N5P8[V'=MA=?*%]?U#'1/=@A:99IEH@$CV+<^S
M7?J$UUZJFK2^ZS76 3<3,&X1Y*\BIA$G+*?46.JL7=SP5K(T3HU] W>6^ZH(
M\$R4<P #*A8B=VA6ITXE6C.6^[T5STJRT_8]U.!+*EBP^+8LFN1"9\M"S>\Y
M1MR4.6@SOO?^O6BFWG*\_5FF$BNZT,DTW].1+^.KQY1UK^N3PQ6QMM<O;=C1
M)X70C_]0<IC['$7))$JA7$M(,?16%+^)RO21Q-D6NI'1:+<LYRC3/-MG#V.\
M?->SHKEZ3:]>[98\H>W;SZMNB5Y,2CJ&?"]]S@P19- A)H1=Z8 =V3FJ;T3F
M0=L-8,OE]QG=UDRCUC\',OI:-+34TN7K4J(W\*^?7'QA_T>8?19H@JWRIM9#
M'J(,V8%,1"J:[,.VM *5)J&O,2Z&U6 G#R'$RGD][(210(_\\$P:]0@4%<PX
M;$O8=NS3#0.5_4BM*:ABAMD";5G/?IW$,.!(ZYSLUT-*<%S /$J#J56/KTH?
MQX :[V.-VC)C?^_]]KFB@"_\&7HU59F7SRDY7-Y\M?6J/ +48NWFUN,-/&!7
M:,9#1)&W-2I;AP32Q39@45<8[BTH"7(VHZNHXG[().$U9N^?1T&MV@T-'4]S
MJ@6;^%B<SXQ(CB3[#/@2KD-I/XKR*F,EWO@>L3JBKL %9U$.)B)CEP\OQ9L8
M'74[[>C..NBK]HDMK2WK_4/63L)5TP':S'T'*>-[D(Q3):0\UC5F>N22K3 V
MEF4)1OHS1EM2L)?XJ\N)C)*(G,QOZG,7.NWLZS-EQ(Q*53YT&I:,^(:N'$1Q
MQ)UL[]9%)T'R,Y=^WU&ZM[W^R]-0T1?N7_GN3U4BUN?R7I@+>KNS7G'C3>37
MM3*WO$V>_Q$Q'&?Q=OY'@*;]\8JP0=K2BY3:ZS77SUC-N(RR_7'WTEG^W'2\
M%LZVS&:M/8DRAE="S(_^Q*0[VDPXNK7?T6%ARJ6'!5!JIN@T-,-[*'*9N!66
M^2B;XCK=E!\_<+9,YQ_:5B\J*[HE8GV 2*5#[8?05NNG$8^B7?Z?TX@Y?YU&
MG$P5XO>F5M=H3R3$)EBIW%W)$IMD4]4X4F*GN:_74Q$!XD3**X)XO3N]D^CC
M[7^9*1;/4:?/^,IYW5LS>9AA7N[-?>[&32X3S$"66OM-*L9)R#^\VI:^9.#$
M_8 _@#L%%Z>+=6W5ER\:Q;;OG8-$.39,S>>?A^1D>U[_KHW(GVIC?]IA>7'^
M:>K^(!7[#_BVZDM3D*"I;MB\VG%*HNSH\\?39[^JANT.=/?!=>/KETO6#PQL
MYFSJ;50'F@Q,M'%J8+E/0*(8]@_--JXPUO+=']*PU^TODLZ7C1]$%>_44 TS
M:U?<E%FQ@>'^$+@)/$0S;(%X'N*];1LPXMZ>J5++]&U_N55A(8:5CM=YWB:[
MUAHX7S9MGSS<$>#/THO\EI28$?U>1-%^#-BN-DBDO"4P+OANY,CTZMGXVX)J
M[%VY24R!UOM0..#OGH=]?KDV6/]#[[Q:Y36^GS>%)!X-/[Z3+3(DQXR$A-K8
M^X FQ48%D,C*^5[OS[2@D1-]BM#4CA8M(=S)(52UINY1T_8%?S<?"/G>\V;P
MW=(T,[_=.R]N*6@RQHTPD.W(*M_9W]2%3?BOR/??4BE=IJQ^,.>=%UH*,L"F
MTW**&@:>N(@-%DT.5CQ7"&RPDL%_<N$[WOXQ6V0+ OIVMT%_R**OL*).]49%
MW]SKBBK[Z_/OFT.51:;2=AW[LB,O@XA.@"?A*=3H#"UQSOD-YRSHQC;S6#./
MAFD)A1 SSU&CZWW?&3-JVE^L8=UQ=/REHF72T]/13_:;_)XRMI\U0ZR#T7_E
M@[>!+=S7N0\2*F";SMUT7O,)*ZI(J@&J"YTPKN]^7J0P'XMYK9%9<O> X2F6
MI_O->SS$(P/*M9IHUT<]WJGF9\[('#OW"[$I%*T,-/G"#E:>6*'%#5]"<DT<
MAF"7\SZ/\XPXV\-#W/!O0J[=K"YY6\!#J-P4@SZ?!J""VWN$N9/ \C1R[6)B
MP:_7,:O^M]?CYOQ_G^+ -AYB<1_V#=0V!G_?)MVNQ]X(UF:KTO7G>(CK\]4\
M1.Z7=V1AZ ],Y4N6@*6)TW )&ZNY]_-YB&Q+'N+ 0@RP>-GD #!BRD1!+P]@
M8HJ': 1.FE@L@75V_5I,GG4&K8 [^86'F$"G\Q##FX77U1.2]LV-AU 6\>4^
MA)O1.P%W5L"+X_]J<Q#]BLRP0JU:ELRR>8AKD5#E*OUOKYB9RCQ$9P.=P%;Y
M$,Y#V&%39HU-8.8Y]1 UF]T)++M%H'J\8O:6,'[![?N/G,+:ZMY^_\ ;&DH(
MFWZL5R^H0O2"0X^>IL&9(<U0 WF;GS^SWSMY'0P-GW0\-:/M^O+3H2[@B(L*
M^ Q6T(G<1WIOZY&O./LJN*6-DL5YP< [G,W@P@'7H;NCZM$3R7M=+_NX?G"K
MCA2,FGA%,G&$GOQ.-D]^8[%?):DV%3MQ]M>T^9:R]_L_6_")'U<R0P#&]P,Y
MLD;T*9;FU]JAV:+"$0QK](WW$:.CY][H'# ?  XFY[S726F:&:^?]!V] &WA
MLB]ZS5!L'Q++\ 1&'34Q>C:WKQ(5)V<0>'L:4C0XU2/\Y;*/CXF#]Z*J<TSA
M\$(O,5N?$?EP+);XB'/D6X=&UVO/PJ\AU@K7K5;V5!7=FM.XYA2L[A1L%*!2
M*/O>S'=+2EQJC.I)/HK[EB-BIQ"KU2Q3T()I0$G\V"T,;H*MJDW)EBZ06'BC
MOF&PWKL@*&)^WOJ/=(';,R%7F6C[&)T7XF>T#5$V\+S! G/;&5/M9)E&"6QY
M$VHK)^0M3I<9D>^FQ5*+7>HB>_65N(8!.S<6%BJGW8NR_,AY5]/4KK[ZN!Z,
MY2$$Y'!&H ,=-?+&G/L"I\4\$_PL('$K-IB5W+^\NGM([N2 6L+XT7-%)B3E
MH*+9MB_*5@J'#8S%SQWB^O8<0W8OS*Z?WG'L@3;AF\D*)H*<TTSC<16PDWW.
MTS$O"J\*5OVT[L["=K3>,Q#S\W75GW1/:)Z?V <LF!_[G;**$IM=/_N=R;"8
M_;(>C%8=I\8(/]:/<L\WOL3*L)TSVE/VA::.VGQENG3:0+PHCV3Q5;]V\Z&@
MT,NOWYN[H49EI#>LME#1#Y&PIKF6..QT$@QA'\*A^AKW<QP9!@]U^ZL8DV_N
M#%X:W\\\5A&JMV_>1]+RY>F^:-B5'I2*2SZ^;1E3$@D=YA:B7 WKA=FFH'DW
MM;L5B %$*Y6TVANWOW]6/%>_BZ9Y1KC.SMIJ[&<0?Y:'VU;GYUN'#=M"DF";
MDKZ'+!/CR&(HD;-T>C>H2FP1>[@#R;28G:,!4NC17\2*HF_%%UH=Y1XM=YT7
M9B_'C,YML3ZIN>NBJG"6I\R6PN3-4-YZU4<"+;F/B3=+(LB;-9Q]*ITWM9"\
MP#P[A.] _4GOLUX&R?K:LWVR"@E631-Q]D,59P4H4W-F;!6H'ZA<X$BK4_ %
M3(&6JOO K!\#U_EV6E8]H 'G5#CJW!5\+2#0X]NG!<6XJ#KZX7.A<?8$H.D8
M"H:3474*:LZ,DCCJ"@FM,DI.@@/TKO.?@<W8(>I\]9TT>7PBM<!&:W8MI.NY
M;E3>@4N[*N85+"EQA%_),8CU#8:P8_@V@J()?PLSA=X]9Y [BO6EHSJ [2Y@
MB1W#AW PHZ69B:Y([KPF$O6U4-E37TM->0_1]W_#.3?4'H "(_%B/)HD!S6M
MB4$$C9D98/@"=)K,@FEHF2$ED:OC--2)9#C!T&U>,@=C[%6N  ]AFQ:P3)S=
MQT/L\67K B.*# OH6=',]'X8(;?#X%B6@N0AWOT0"N,A@@C<^Y%0JO+TVM[7
MC5=^_.-M(_673( 3XP+SPM) N(P^MX&[=M] (F2F)0T,UQ7Q$+_+IJN;>8AZ
M*JSUN4BNH11<QD?XO<L[X+<DZDO=WWU")0C;B6HX;8K[! 4;^^_>R0_OX'J4
MP2V0^\E#L#; M>IWM #+GP&?6A1@D](C+M7 >L_97?Q?[9C8_PKD2-I"Y]79
M,/(/7^,ABO#8H;^]P[E'P7WJBYV".@_LY"$&7%388F+$B1JJ&'N?-IKK<"UQ
MR?%UC#KG"&KXP3_ZS7_G*7D.8'QC( -0E2'7@9+"[\"Z^&['YC6SSI$O@_?&
M-]<0SL6C#21,MT1XJBPV#2.^87[O7T0E /(FBOANHHBQ+=.=UIY[%]@ GN^;
MRY@#RS%_1&L^;:M 9UQO%1</,#XK0 _\*WCB(C?31,LK#1("6RBH*&(Y#Q%7
M\4LYMM6 AY"XZ_Z=<S#=(\OF:,X<Z83)MZ]8A:=;LQ[MLIBS;UF(18LTJO].
MPJ!$<8%40.&W_XD#RO6,\5+W_-9KUQ&/8X.V]]PY9C1@J;)QPVYB6@G)"=IB
MR+!GK5;5,NQG2]B"5_"#]_%9>WK=!DMP)I!TW3ZM3^5%TTYM.N;9JZ63]L,'
M-RG>;+S%S8#96#2:<9Z\L3H:.HS;R\TQMF'OEA"=+,W";;">L[:OKK*4M2[-
M6HU7B8DU,7X\;W=G8]AER@/ ^Z[]A 5'LH[5 I8S1UOP!T #]C$0N-37J,/9
MEKK4+8U)9P7*,L"8P_.N59%G8QP>6#EZMY^XF!(Q\7@SROG7__*0_2<]FQ;=
M(6& A]@[P'T%S"*S8.M>_-98S7V$FNB")6PB6SE3$)Y$>@VX)'CXB#S$$R_H
M.Y$E]AU86G5'.T'-A,6;/$2Y!3>IFP_XG3'>^+J$D_04Q=YWB(=8*_KX5&L%
MIA-#;X'?YTU*8 O]V=7\CSREABS'0WS*H26RY0*(7'UG>[,K"[!KG#C/M.#&
MUI*AYP<*<%KL;TB(")/'OB3M$LX6\O)T'I2DS*EKA/&B\RI8PT.XB;7"!=ZM
M*=Y?A_Y'FE>R\GQ](1&/AJ%FFQ;7+!N(-4SGQ!TBLJ1@@+!^?,Y,9M#O7R[?
M_&WA:"K^GZTEP0"VD@#,)M/$N'8TV_<,-F2=*;Z.7ZKPO$W;QD.8O=O[FMCR
MAAOU'X)8#@PZ8:EX$J%TX2,YM/'H=[PQMKR9U)_6YWG0"RU://QC^@B!@$N*
MRBG'MGJ+>#E/K Y3-E1$J. )7K4O,^-SR=.DAP7\"<\]_4("=<1EU8,],ARR
MKULB]BM+6BFI,_Q97[@I\"3()##.D2, &9SG.S#<LKI?5_/$H*T,=F:.*F>5
MUDS7L5 IV)6P\Z?EU:X?;,2&9?>/J%%32"B=BHX<%QEH5."<!.48)/)E1F,\
MKM8ER=7]-=DAMLADNTI%'493U_)/LP,M-=-3J>KEK-7N^A+K]1PYG%T@7##_
M5M">+<L1'M!=B*G5BN7(Y(/I;2:&C,]=@6_ .XL]!U02;6OJ/20NV2>H\"-O
M*CU%?-R,VH]58UV"OZ'I82+$B(PL-K:A",^\%#A>VJ?6K] JOIK>V[1%(UU;
M0DM3>;/*GSGT+:@-)8*B/$4+-^[ZX8#_<HF\M=ADWS33-G!/7LY84P@-67:-
M,TQ]<OI&PH]\U7[S$>6%#6T(?)[GN"QC,.DMV6OM4N@;S]K<_,0Y3?,6FXJ*
M!F(37TCQI.!YISAQP3_.-8C!Y74=X.^BQ4R,,-Y$';-MPQ\:TB5O!8,M*C,7
MS@[H.7W0*-H9(WCC95,&E6ZJ;"&UZK=92UGT;383W;T @SUETA=4XR$B*N<P
M5A^^FQQQ^>VXM=(D-I@NBJ*.C74_,OZ"R:E(7CSJ<'-Q1ZOE9[/VN4?;G8R_
M"RS9FF%]0XD>Q$=("4AH%/]]ARCS:$(-@T9O%J5?ZI_-"POROOMT%GGVI=:N
M& O]H=NFT@4JDJE7F57:'_3 R'= 4Q>983OJ'>SXO4)K*R>(26#)YOCGN$QG
M2H-^006>-Z<';X:YQ<P+Q1R65$=8G-4YANP)D/F3.%O.M@&1K$K0^@WG.AB<
M@WUCP1BO5$ER<L 2+=-/#KIZ#&Q[-GM3E<YWN$DM)6--<HTU9%-6W^^;ES#X
MN7F0QEJ<O"0DTU!4:'NT=;&4ZAJS;=S"M?E=\OVS_._4&<_;8?%\FSS+3_&-
MNY_8+#QG2I/-UHV_K[75BR"^E"AL%<R8;CF7=BG<K3OZ/%#6GO2Y3N7FS@)Q
MP0G[&4(T9,+18A":@HF)&7G1MXA4)R>L6;VG;*5(SQ&T1W/WW-M;QV\?4$O3
MEM@='ZTM>62CQZ:1MR4=8B,"D' L>QM^A"RG#.HP:&@D&-@6F!^P)UXK@:,-
M*?4N3U0&QH]:U7]XFM-;MVMQ1'N;N']XQMH*JX!;#VV$.FI7FA-%< X#>GI#
MD XV"HMI<G2)OJ&G4%?'PB8Y>J29>61I:H?NV7K;4FGOIKG]ZD96_5F#=[^(
M7AIQLPXY,:CPX?R-0Y]+OX7V6T:FWA;[FO<88_[?_.V_^=L_<>(";?KWS5]1
M&^YWH,^3E,:3WCI-3PMOO#OBG6W=E,H?<57K<UC(!CW.%)C.ZH=Q4H8CT&-R
M -\EO]+:0AU#M1^)_XJ6X)C4 C'N&;35;/\C14OZ:E]65_S%KRW$0,FY$>I1
M;F'87H^;\;2T?=+:5@KY]A876M3W[?_(.+YSZ".APO>C[[  52VTWIM)I_M^
M% M##Z_Q%V:41.%,"T&YEB&Y]/.E)HY6_GX>79IM_:T6.VAM+VMW/-G ^=.R
M'O<VM3KF\'4P'%O:^DK<FUG:G/#BI4X&.QT2(C,%(,$DFAC)R:*"&U/OY%_
M":CMJ=R4Z_C)^+3$TA>/CE$G^9=/9+->6YK\B3"D2*K_J6LE,BZ3057;R/J3
MF<A$2&@?S?N*EWV9 VA__CVH0[4O8]ZZ5M44^,:0T1?$<!8QUBAD/PE/0?NN
M7RH!*#GD]^YSF]B.GF@^_%:@Z6B]&=L ASZB7X3%.11R]+\;']J3A/$6N6/K
MJ<E-B[X6L+T^_L%%AXLFO8*Z&[C:Z^>?)E"*C9LYQMS7C4K31&'\WM_5CL3P
MRORBW'X-32VWOLEG1:<C=K&>'K]-J+_]:[.BX@[U"2))@05PDR ^?"M9%J=>
MA#O*0$:82(#^U,'2K6^.SD>_KOQZ5O=<=J"VEX%^@9]^EH_LC^SQJZD9>CN5
M<AN93'0,YR@%$/."E?:E L_7OXZHIK:_RO>R[U.190T.OJ]?K/OT\Z)24E7/
MX\MQ6Z"+)H? /!9L\F$+N#N-H 0C4Q1-G>)(]5';B3+$-G34^5-ID;2LRL:*
MA!6+[SX7WW@)W-%9E=BNWZH4\]#\Z@8ZDF'!#6Q%PA[T\7K,':F9(X-O@BG>
MMN? )+$FJX!G4Y;=D0%*4JWR]U)]\QIZA)7>9BZ.O!$G:/"MWK<WY"'XU@5L
M,MS?FC##1 \7-#5NX&8UJF(5;$!R$;:\-1"O'>G,4#GR?'AL;$;2S-5C;=2S
M6I ISB99?!"NB3@F* J8$Q4 5V!$N)E8N@7Z;&(XZ&TBB>]FN2B6,^)(]0:L
M-6GHI/["QB[_MW."0^7S02X.VM;T%PCUB9E$4&6!(R7\$6#8BDGC4(R%EL2(
M\9V@=S;G$-QYN3CW_EG=A@NM*_9"_,O+Q?6XBU%J&53?02./!T^R=NZU-1!!
MH#Q-D#-X028J? DIR3'\\'W!6(DF>F3('O[#2.G%?>>Q^*5]QE(?J_:_W]A3
MNW#V55*HQ88G,2 :VE+)#+0#==CB."_F@?BW5:EOO5QD!^KUE!9U5!YW%'NF
M5UUX.F9YPU\Z3B:4WW;G)%$911D@*W(LAG@(5R :$F?JUQ5C2SY"&\$OM#%A
MZE!4Y4AN31I:;-1%5[9*W]\F^=9<5H*6JD3,6Y_#O]<BUX_;@H!!J]:P,OWH
MP[-?C.^;1/N7_,C>[S X:E-1D^8@B'CY-COM\+R (4QO3*!/J#+W9B5_2)3+
M3(_4ZQ;YM=:P$J]+W@867&$ZSQ/<_&@.RVH#MRH%%Y0'?SXD9S\6K/^P[8QQ
M19K=68-DG#]5+*I1!>H%&">?5? 00B[3^%UE(#]MIDO@8G68PV0=P =>^S)&
MLGU?D6ZEE WHWCCHMTAKK.#&-FJ"@D!3(XF<@'2HB&TF(1]QW+*]TGM/Y2O%
M,;QD'7%)9QQ"'62MHXY?B#"Y>GAW0S<D2@5-!1X2KX[=(=OU/AJ*Q*MB9YR9
MJH7RJ1_2NAUZ])Z^#'QZ\WP*Z4?;GM[MI\J2!;/$.D51K&3N<QX"0XQ%OB=$
MHER+] V8Q(]H@<92YOV94XPW6+MZE#=UV4$O..0\9.1A,CR[\XF43BG>5F^E
M>_9Y3@E'VA7:LIT.D$IH?*PCZ;._&5O'OQP#C3!%]5:PAVD.RNX6+<[7BW'!
MT^P3L-EI5JZ^3RQ>CL;DKZ#!_<6O&)$L&]#.G5'-.@^>8\Q\)%>0YV2*?KO(
M?D=111G?4M]@5L:W#904Z_(0DF//[K(]YMW0^T:<@F^I^1]4\T0^568=;@1;
MF-U4)$>RXQ(83T^$)[$87M%#B^ETA2G08G/*6;@5OX=YB9AM'9A/FK8_V+GI
M2M3\_ TC1_.6O6K;LL3F-I*<'%Y9E"<+>;-"%4:-?;?V?%<^><I[4VY?3";Q
M!1'<16C3BEK3BD%Y$D90;7B=0;PRB*:@6T/L6\9%X0\'[GE35)R:UZE[<'0Z
M\(Y.Z8O7!QA7./1&]37=__)("&*=!!!&#,X;>]8C'N(]'F85>5^.K)%9TCQ$
MB@$W S6;@%7F(4X/+B]:<&1Y".A< 1M&FF'4<9A%_'P9XLO> G0^A[J0+ MC
M"1XB%W-_+8:X:'Z5AYC-[N AIJLW7B6.N\,\XA4/D6.YUABSMR3=X&\<:0H'
MR\C=Z3&H6>=!'F)I),!9YF_G5!C$A</ &@]AP4.<.?F9R% 'AMX1UDXF+L[_
M$R(RA_\G(I8X?@MF/*L ]\%5XK)L$J0QB5X\")/@81M?[H'C9M+V#JW_:D-'
M9DT)AEI84CV)@;J)K&W ##I3[^_OMM-0G.?C,"J764>AENVC35I:%E8/8$VA
MSZ?3>8A+EUVYLF]?KY^53&3M_(\$_U%G]D'"+QDM'40IXE54%&L'HG?!V.:M
MY_W(R&5GTV;]L)M'YM.OO15^_NESLVG-(V41*3[%I"Y\V]!'8A5Y#J;] BQ#
MT)FV(,<QZ]<P/AZ<97W-S9_RT"-SC3,MM\_GT_=NZ<?U?F]T/A4F"")<^2B;
M&#JL<K#'56[VU7KV56Y.HS!./T-L*T>=N1".4V>6==9K^=1&1MPM0MKV4 ;W
M9"C[N%RF-B:>W^,9J8P(C^\:-&.?Q1JQUK-"?8:Z3-2X\=YZZB6;G$"!<ZAM
MRP7 UCW/<UW&V_2HL7.!!W?%'Y#]U*0@\"S#_OQ<V*C%[%0$RH,XK$"+;'+6
MLOXPB$=ZXH7 ]"P',&*E64Z_ZGN'YX%J=YFQKS:^2N4M_ /U94>V*U^9/W][
MDS12&+>)^YZXGIT$Q3@K%@&;.#";Q.@^Q52::D,*S>PXQ/1MY4K9&LA"4C5E
MF$XYJY1+3A[W8J->QV>H25 )5\??*3U 95&_NY?<APW51 /^4"C^TQ"R&CG;
M0.\>:12+=MD)GC;V9QV>-W:G)M,OE56$=SO%>IR^T\P^0'^1_?3Q[==$?CP\
M-9IJ4!7VLVS*<W0$D0]%R2<H-2)!V<_STQ#9M$_WCWS1SS^;ZY[]C%DS /12
MS_0M%A_<?%!@.=@,@;>$S8IQ^JAK,[F\I)4PPF:5<%]QO-G.E[$LVC0&)0XN
MS,FN)49PV-;//8CE(SX_;P]V'[%!?I.[>U6B&_EL!<7PB6QK[U,!?5UAY[4;
MG')C\%>&WB4*RO@\-W<6'X_-OXL\/&VH7]91NUD53U<,.XSJ7Y;>P- CS^ZB
MHC=!GZH)9=6S'31,]\C@OKNQ&",M1>R1'[GEW@4=&/Z&\<91M_AL(A%[>D5T
M$N%BWA9,;%X([</ZLNXR%CZB8QHU^TT.67E3\NN5Z$@Y;)+.6[!7O?)#S/S*
M>0M//UW&-_&?A!V.F??MOU\\*_!'B$8$#;:TG&-J1>,T*=VD%1H02G2SE<.^
MQ%D40U])5\XG"HS+UAC8Z]\HHNUN\=M[@F*:^-@/W9/>Q$,\<I$ E1G=380M
M]<)YIKE8IX]KFU]2N;L'I2]_K.J;Z^5/:@Y]IC+LW-G9V:2VO<0*5F8'.5:P
M10\PNA, 'UM^B-1H#$:78-_8@0'N 9Z4DHWD]AO?*\[=6;1N5 ERW',C[<3T
M:<-OAL5BT!88-?F*(EG]0_7"3#$JND-,!OJ*E.,HOQVW!9@*'\^6>T&[^@X4
M=KWS3)]-^3BYUUJGY)M]%DE0!:H_=PR9"5,E-*C6'09<)43>)T>L'VI$2^#\
MZ4HN-L$=2(G*7ZP9%Y6!FP+?:FOV6&W;[OSLAYPQ?9QH^K_AROQ_R]7_ ^4J
MHN2C+:A!G'5E:X =E)58:#_'G[FY[I59(29#M7YHL,SXWJ4A'>?LV]%*:*\"
MPA.?32JWU5?F&S?"B/:"LV6(Z$$>'J*5-).W@ >0.\"\RY5E-8R5R)OIG7+R
ME7&3&*N'+2(10H)XP2X$+H21" E.L36]T$+0=I??M0LQ/G=G$C>!]_Z<J4W
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M:DL8UHF^RC%UU@U0R8UFN,/9$171*(F)N&/-EVY6GL9GJ,)Y7(\9J@1V (S
M=YOR\5_-N0YW[S&+HZK/GW&X=4\ARC3:RNC0#.S<!Q&K8BTH,8!"28P%RNPZ
M.-(MIN"48-AT,[T]#25 \XPH]W]-,B!!?4H)=\1WV1WR74VX:+CA*6"*9AP3
M ]7),>M)Z] ;.6AJ=SQP,X45#9[T]>8XYXZ<K/HSUI*KD3::7=W.]-=LJS%7
M\_OC'*ZS [-$9YW8@:R A^@>QP0;D8D[3-BXD*NY+>KWPHU&I3J=@X<72=J7
MS%3"T_CN'"NAS4"B!PU@#\MO"O]'N(VG4@='>;$DSJ:^-!+JUB9$X_=C![;A
M?W6R+MRZN(&@_F5"-.O!-8X92%]W1,3M*)\%$LR768_K04.YV5BZ\WTR=2'L
MYJ!:WX7S-ENLPS%YG3<6I*YT'GHDSA>_XOX LZ) )7!D1FG%ZZ?]8T YII:]
M.@U%HM/CV\@/("2('U%)YB'.U8:MW@4K@?)'.@_2WO5JE&S;?FMY8X,3BPO7
M4@UJ67%18P[-1=()49F[01356[,$Y\\4:*I59%X&W3O6&K(ON%A<R]\]=G(H
MT+'P]X3%EM$SO;H/RZ(&K>28! IY[@+;$.I"BQLKL.TX 0RQJ 6<P#NRLR>Q
M%-74H'XZ>7+Q<XC2R $]LY[66P*CLKL.IGQ6J-Z4<@PYU,V1FJ$:M&E%H#;H
MJA/CCW G:YAJ'>(D;%VK9Z!N\LL]"_:5"<RE2LFK[=XNK@I[-_'?#NH*Z4.G
MH1AG;,%U298([AU\5NS$.=IG;$;54L">RXYMQ8LQ;9Y?]KKG+;3;BD_RX1/S
M0^$UMH:&FT+77O[+NS[(%-2_)SHG$O_-9<UE&6 B#L:2$2O8+@9\^)J ^FZH
M ;:/4TG+(=+GT =\_K8&^(]*M';_W]8OG:C ^&T>8AE*A%Y$IP*42SQ$B1UJ
M*1KY<XQI"UD+M'6S]ZZ'U^S+Z?*S(_W3JW$C "=VD8=@(YJ :4UECL-7XL2U
M]4L &>2U*V$Q>XO+H_[E*N&2$20$%[)/ADL 9F$,&R0:8_[VKE&G%5@UJ/?G
M(6ZDBP/3)9(AD9'DQ2N,2.Z39UI0X?N.-4V8WT)*R-EC_Q%A9 _W+>-<]RC*
MEON0Z+:@P+F7;N$K@7$\X3@,^A\[.]*_''+BFK>WQ-5C&VZX7=]&_;!M=R.C
MI),(:CI7-W4"5[5BY5#RNY)#-IWV5K_0FU5)/_MAJ'"^ODM;6/O@Z,2'_=NV
M$@_ (@['T5A/W\#O#5(IWF*TMH[F$#'K<F8[P8UF(V;;7V_D'>R_.;'@1/J]
M_>X9(V.1(Q/F?(>^F86TL7<Z TWF"G2[>.+<IC<=.;B]-@?HWR)Z/XV05)GV
MBV$GHY)*NM[?%NB3 ;^PC8"F*RA*#LF]&;G94Q8HDXL-L-WJ >WHT2WA][*A
M$H]8DX4\UP(:,B.-^_12C(O7[NI/Z,@:W7MP&X',(;YW7X\V\P/621Y%*"JA
MG3A2WHK<:BS@_^;'>#<MEBMX>;0M4/J.[FV%Q+)F4R-^A,_VI:,?42$>Z^'>
M4?#8;X*4H!ZD6(#M([)TQ;-EXN89'2?;MY[?76RN_VG(]Q<W$,<SU!84M1/^
MV@#E(4A:%-_9YPPYUAZPDAKO_]&%GU'=C!3E& Y>[9=?L.CA#!>15"RG,#//
M S*#_]S6'%']8SR)_9Y8A[X+UK6-*S'4(O4 66RY746/,>K5R!4O^;2<$.WC
MOK[>&.%N=9T:N[$R?5*-0E0;L!\EB[-@'P>:L(V&XQQIT%6VB+$ "8TRZ*T2
MHQP;YNCGJBZF^VQZ5=*XI[Q2\RQFMDSND$6]1O!PJ'PI BD+-*%P@71T*)EA
MECA*:#V$C75,;-YQE+D2JZOU\/Y+3O4I5J/(H!F+(.\9?VBSNK_;W=]"#V:O
MA#7HH'TX\MP4O/@TBN&+XNR6SXM8*F@?J#]:@/URB:DR*)M(4XB_>=2N4N(M
M<*MB#^<,P3U:TA:E+KN,\#%D=T!;DMAJH  UD".9UX86,)$&_71]-^)V,UX8
M''08/A:KXTF2>?*\>,%16M1X4:G71GVCM;A.W)955TIDNU9D"R0Z6<&<71O(
MWB$=_G&M/3(H1.5=*6E<_]6>ERQ/;5.-\5O?2]*.I:S$W*-,/C 9@N%<F./:
M#QV$/HYO)9P=V#-PG6%>_194./TATSSM8E^%2L0X22ZIT_U0UA:AH_PAZQ&X
MG,'J=QP%;F2C+IAHWH\^1>SG:+T#/;7>7$\4<1Q_%N1V^UQ_A,7!3U2'H N?
M?J/W $T-1.%Y:!O^H[Q,/2M0MJIQ'S.BAM:E.65N6_F;]#[""?.V&N&X[X)(
M_ _Y-20DC&1 OE' >XOV6,&L-*INB.1,J]R^+6D!57T:\VX9)Z2E*N4,/RX<
M0SX&R@1F\Q@ICCQ$.+[>E1J/:7$T+_"C']5I=]D[9&P3=,W=CZ;^TMSFTI>S
MUFV#N=$EO9=QCQ\?)!Q227ZW8?*0R3Y&H#.8Q#X%<RG)8@UCY:!\,**;(A"G
M==?F%$G(/6/:EG]]*]/QE)3_V'Y'LZ^GMQUNIC66<6,;M4!^@$)V]N^P+229
M4D,$6DRT>Y8QG6YVUMLI_1H5J[L(&H5E0@=VK0J*!(9)QV6L$$"#2*JTBQ@W
MO/)I@+/*%6PP#9T00)0<:<IW*JRZWQY=>'*FOD7[2>8@;9]^65EJ@(JX_S%D
M4JTOK!B-\,-D&1[BFJ\H_I.\-0_1[,E&88_8N-+FQA(?$IH)C,11,.22LR/Y
M?+]R537;]6#8K=5OULM',0O B,*91&C+>GP4 =AA8YB2T\ULUCU0AI\0V2A*
MFEELD85Y@-!DDI]H;O[1,/+U<?<8CYPT*]>KB,3DR^\(0;!]%'GQ$%M0;L"C
M6J#9=N0"U;>EFP_?!U3<K,[!NI\PV<KXEO0&LY(I-Z"UOJ,IY;Q*"B@,/!\N
M55;J7ZXP'';[RRKL[T2\#=J1B2A!F$^EN>P$']&!<*)HHP(V!-HW(T]N\3Z/
M%@,C6QLUABJB?9:M0T[-;]]I@'<>:XVOS+Z^W7[G60%6$,;/TW^CM=O1AK92
MA(5J89+UAK.'!1GEYL>4]%]<+[3_ _,]/FWP.5/J!!,]9\C>"Z:W.W:WH@4Y
MHF 2S&N;,M6&%E3Z ]XN%1V=C%#P/K5H?N=/ZG'BU*WW4SF ^=*_'?AF<6BN
M@ +(<*RXZ28ZH'*3O"O&9#\3&:97I'.R3_SQ4/J0OK\%W\XX2GW<&V;)SVY(
M% /WHC]^!/5^I;5[5,J>FV\B/HT662J)8LF?=)&I(3X^/%!,'8H?&*GJL)3]
MH=[Q(=K0N^55R6P[K)2D4-Y(4,V"(]/"DN=^J+=FVP--)G)V()V*C#KR<CR?
MAA*8GC.I='?CI^M8N\ODT'7O?9(9\=_VU1W#=\O[,+E<C".9 FU9C\QHRJWD
MJ+)AO]]TJ?ZH'X.'H$XU!W^Q)F[B&&08[JI(O<N.M:X[3*E$U6PX4"13]DY0
MX'7<%/OKZP<H@ABHV;;"D;%HVB'.?:FK!:K&%V>I50QJ5B0BFW+-G6F,N8?G
M2)X]EH>/>\N;^:1;+!259%R[]&1W*MSR5T#3(6@7T&1#I#PWX6.H)8SHDDF)
M+2[2WXTM]+,ZV:O&;FXW5?OOTEI]=X1,[U4G/)45,+9?6K]-]$+@80 :/-Q!
MM9V=0G&D\DZ"$C2C6/UJ0M,.!2:IDAIL*W+%\M8X4.E]&+W;=-=U2^%DB?<P
MGSI#8!Q'@2KW<F"3& '5"[#AM$>S]XD=OC%#4IA&@WIL4VUI^ED__P,$C3;3
MZG3U@_N=C$*OF]PB_-K9L?WQ*5?3_?EVC]\]D['J/ O^D,ZT%.!;EEY#<&#P
M"XO%B7 +4=Y$$D"UGZWSI8Q9M "E _'M!#H0A90JRLLXK*=YP3Q(+?'$,^55
MMX2?5@];1\0^B"C^8:SGJ_K#T@*_,-)9C[E1*"_?D7"*<W4[<B/T-0,W>*2Z
M^=,MU^=G:CVH&.S\CH\GO^NFO%:N&4G^>B:H"W!XTJF<<-'CY\ED@VW8";N[
MUWY]_E@@=ETP2^QG(B28Q#!@93!MYQR8"ZQ!D,Y0@;YEV+:^K510DJ,NZ3>W
M]_!_.635VZ4<H[=3,4S.>+ED&O],T:\U5M$RJ3U<2-'K;<Q1F8O\YV81TO\J
M8\V[\1_<A,_S?SX'09T8/_^)#JC,=[=:^N?$\#^=Y==OXZ\?SDWQ5JV[YU(H
M]AGU;_)=3BMLDJXP,M01RA.CH.W0=^1[M^X6(.J(01O[;>%=JDF)>*)U-4;4
M<7QNWGSTLI.DF<\7"4]GP7N'U3R1SO _[R52:@GE0W,RKHQ UC$PF-%!4QE'
M,=1:8. !,>C^2SM)JA6U)L_Y7PZPZ%[?-$=HG@YQ$QN=MEW9RU67:#:VL@V[
MO:SVY/J;,VF8V*_3-FP3RY_+91Q%S^LO&G(:GOP4VELQZNU=VJ9HABSL#+8<
M:SYH[52SSZA]L*&'JP=3T=57I/^FY/^_*/E/.8[L<ZI/-/,":R-8GHL1G^Y3
MVFJ#;+TG]-K).C#?.BC'F?M:'>M-%5F,'K-S/J:\*8/K_"Y]4/;(RXHTQ]34
MW%?N!UNKT@>_CXV>$CBN(I6=='A'7,0#5+K6B!HD7(VAEH2Y"#)\VVQ'%F@[
M'A6 :BWWY1XNP1T%VI\WZ]?MVG2ZJG?.-R=&[_*;-*SWN1^[=[G?O/=CUHJ[
MAYN"HA22Q8A>Y+A!0$!7+&+<B#&>$YC;_;8XO_C7D4<)F?D;=9Z2:+>5MYYX
MO&%*Q?XW$_1ES)76?701OB4B CJ9'MX1KF\LYM60BU5OJM4<)O9P5*DO]ZQ>
M?#W^.V-KZK5[XLOG_#">TDVV 6+AOX\IZ:V+2CF(S$.4J7$,#&:;Z,21FD9E
M,)9Z<8>AOM\8MJ.YK;W4'>,[%3V7M4]71')NS[X]*HI[9]!AZXZ:,DJ.)VPP
MEL,PR!18Z4NQPL$0BI-Z7=&)T>.]WGSG5'_.;*Y[VBG[1L$@XW/>M55[Q-YM
M,MPK<)D9Z%+"K# -%IYL2D=K8CBZ0F!.CIY(&CH%/M;2U%/@(:(ETC*'+!HC
M+A_0_7#).I;PH\Q2T/!CP/F+=)E5WR*@J3I3D<C<DT\-T6)5@46O\9]KJV-3
MVM)1Y:*O#S,,G_F<_UV$D/L<)I"FIR+H!W5[02\]LL22\?OQ7XIH6B,AQ)OD
M\,RC@_C-IM>HWD;-X]N9D0]=A0JP]\DVU1$D]>=V5KN^?DWR\:^7_'K'+V:N
M41:WU7<+]&U<$11B&K7=3VS?X$:IJ5>BD66QSP*]7'0B?ONXUM7W#XRCR;:B
M'^-^DG<XOGAA_UWZK, ?!1H9U.<A6C)*8NHMLK 6K$JPB)(X$MR6J68KB2&6
MFR0G- HU^-_V*=;<IKFX,X+FG/,Q$KGSDQY7%J<,.E&18031>@5&^<?:NX[H
M1SB)K-]KFQ,]M^SGK^R;Z^4+W(+0MBKWETI)"3NCXQ(/B\$;8#@D5$!%RD,_
M=FSE5N("F *M)GN'3':,C#F 6DUROR<]Y'?_J$CV>;3CYHE.C4?]JX:?*#$4
M(N4U@7&JRX@U.E@O2E^(1,EST&QMG",CXDV07Q!3@3I[$F.RLZ^X$/I<>S-K
MQL^G2V2[^^F:*Q1OOAM03<\Q) '%L"6 :N10U%5"I&/WHR5;22^".,Z=-N:P
M3%; F3'Y@@.Z):?+(OX4%P]W[AM3KS/Z^<U)9DWT7Y"@^&)L8LOXM@HY2&6H
M BUVN3QJ<.7*@,;=Y^:/E^*NH+M]A?R3'HG5D6IL02>88!)_O<49P<1UM 7-
M*2^99$-;&P;TQM0@H1GJ%YA<1%YAC$UQ-$95,6,"YVKZ#HRC]OQXFA'LGF"Z
M?4J]3G$JO O(_.&B"Q)^FO$0<A@:>JV"AWA69P?]XB%RE]=6-F.==FA\HKXP
MGID^@"T\HS#-0YP/F%L.M/%GF[D0VKJ#[_S&7/G#W#9UHB [WY^TWWZR"KJ$
M&DF'9%>:?=?V([?R$(Q*!BR&-. //FI@/(=B(EN('$V<'@_QY0@/L7T!M#&!
M\;#'$4R'?W O_W]DR7S81P.X,B71 &CO1>#@&PN@G2=1OW+1X"WX5WKW>0C;
MTT#%3Q["!+48 %FP81QM'@=M> @S4RH9DFV4YR%^OD0RJANE@)ZS8"#\X9((
MXJH[FGX4[K&\];T_=;0D7+/B@;^R56;@;'F(UY5,+7B6SUWX'WD_Q7<CERYH
M<?1A49#1 .2]XN9IK3)A_UJRB!J)_,]M72(8*@Z7_PR@EJ$Y S/<HV)SAD!W
M(N<ED 1]1?VM%18<S86'Y*6+)DHPSX3A%W(8 KN!9D\F"HH9:B5RU"MMUS-=
M[B' I.I7$6Y=U=1=_"M=:*M@)%?Z"P\AFLQ#3):@?_\"/+] .&!BAI/(NO9/
M&H"B^N+VP#5[Q5C@(831HL#B-V)[,"1EN^XE+S6JPN4[O_LK=:CN^GJ,&6P^
MD PI[Z]$K/\X7J;L,^@_=!Y"#3T!P,SY'YL ][AP,-6 *R,6"8".(,SKTP(@
M'?(_'9J_CR!SXRZX>&T8=6X05PN&UNXC27=X" )R%1X#9>Y3X._M2 2=R/]S
M[@S]-7>8F?]D9/[9\$5)B*WM2X<4X/9WN1#[OD-]Z1R0A^@<6D6N7]'\QW;<
M!?YNFT#<RC\;H+\-XK$HH.<TD3&B!7DM0YF1K!?$J0[H#/$3#W$3^;<6O/F[
M6<YPW(G_9'#^/H(T/E,HQHV'B.@$_MB7+"VA_K-FEQX';A,&:".!Z2NVG"Y2
MWBL86):T-NZ$3? O^TCGFOW-/HPX#J"]3'YC"LV]!9P-CXJG@]TMT5XJ1Y4-
M1/,%33,_H0,K/;U0XCC^;,^JC&]%=$#0\_Y1R*3EW;2):D]AQ>C8CY(1K6+?
MZY4UGR:"M!N#[9DPF=T\A6]'"_$0/F+#_C1'J.=^=RNPW3:'8Y>@KOZ069SC
M'B BI#3Q+NQ7],1>E3"-7 2])&]9AND."1'9NAP/$$5!AXX;]''<#$)-E*(L
M(G?VX9R"\KS\HC9&02/Y%L+6@2OF@6^[?R9V_IF-5/OD7VANB]9K'\P4WJYA
MHEUI7)L1YQF\M_^1HT2:]O+-'T_<SIS)L+8S*!T[572J8L!,,&=OOIEAPP(&
M%6BC55R[9-+>"(93-'7,PUOOI\=S=N5A[_]Z5#7D6V_]QM%C2.3'_J9W5UPZ
M7/>I/5!^&3UWIA8&IU"-"EWFT85XG*HG-7_SA58#%Y6>HB4#I3L9%=7Y5UL4
MF;<Q=-]H-,.&/$*@$6=7J=TCZ6TDW[@<T)GJ2:WI+2HT=@IR+=)X?]#CZUKS
MB;[3-9ON5%S=L6P01Z2\():O!V"Y^1PU@D+WU5_G(01G)23'!X?:TM-(X$4[
M,W*QRAYJ@K3_^QL30['RANH7:TK_+_;>,ZRI<%L7C8)TB-30HP*BTI2J",0&
MB(A@H0M1$6E"1$&BQ 1!>E-04%"*H'0B73 D0"@B37H34E#ID@B&J4DF)^ZS
M]_VQ]SUKG;/O^7?7#QX>"&%F?M\8[WC?,<<8W\0WS:2G6AH/"T<.[J\\>PH^
M-FZQNZSQZE22]*!3>);G6^(*5F:<\"LCTW[FKOODKY74=\-=L_SIQY$R1<D8
M=5 ^^!E3$9UJ';@C]G)EI9Y$#AF2HRNN@6^';J/XIJ$S>CIG)0F,KZ?*B;OJ
MF'N3@U];D2.K_:L\FR-WWH]Y*8G<Y8IK-47<6(9.)HRSK!N&.5<LH%/[3P?"
M.S(#Z9 W9S!3:VFZ\M0<3-6 $;(UE\&S\,F"%EQ-3!%;"\"=8S[%"?_R^_J>
M4-?$#/S6WS1D^ZK3W"_?M4"9P8^YFS_8?>_ZV%'EKU6E+Z5;AFRH>I5[[)>#
M)A[5DPNILSF304='0!<.#+L.;&QB5;R(32'#'A9=M<!#ZE'NGKEV.0MC1O+W
M*-_336.K9C8%E_WDVD-ABD]-\-["*NWIND>'%F<M&+I5;V:6LZQY^UGJ6R_B
MR78>)E@74/SNGL[+"&\^,?73W=;;05C'\".$/[T#<X>* S2A*\.,3:IF F^C
MUB069P^ETG*3IIS&*M9X&QM:_L'NU?=I9U^G "PA\&1"-@W.$_ZL($"3X=Z%
MV&8F7@2T06-YD6]U;S5363$WX<<O%:?3FE8I]M7^MT^D31''#WL[M;9VR9Q+
M.5/@2E9)?5J04"0BXJ)XWO%@8->44_&8#MN4>>YR[9XB!5?/4F+TDA^ZBS8V
M%#2T0)0-G2_J_<-#$-[](Z1<9ORQ*LR&1Z%<XPY7?*@XK#W+N,3K1LFKU= P
MKW#SYJ:W$G.&<3!!]6O9^9P3#,%XZH@NP6@N51"(F;;1-7)/AK9/Z58(//?J
M9Q;;70T/5GEQ5H7^K6 ZZN4UXE'NJ_]YK&*-]0J),=Y)$;&0723JUS,R4U?Q
M.IB3<HWTY9D;X&G\)C?/#6DGAO+OZ@TL3[C+')=U9_EL02(#L+VX:E0,<3]@
M3Y/(GCMJIS8G/4M*&O9D/OC1&&S@KP0.<E^9M^\;@ZP=Y;]:STPX<+[;>=P\
MXZB*B4BMDV#NMC-PEX*]S83E:05$67_6AR*ATD\%-D>.'XTWS5F=VQ&^/A4X
MN='PH>)/0\!=B[Y!XFXT7SLJ'!Y+"*9R[]L9N=;)#!+L7B^E%I7ZA'M6)*^L
M^I=%O>]7$XU*.V1;P#G.@,4%!9770I6 DY<)U<X!/3PIUV1<=,>W:KXWH%@;
M[Y,Q<U'PWK.=NA+!2 7L ()AAYM,9UTE :DE&.UA@D] *//<U(_QCEAW9NCW
MZK2.^Y4UW&C-ASO2=Z[6=IX;'LJDPCC27JSKW&PSKSFX,D=_&.,3B$<O3;'&
MD>FNS- ?>'^F_XZ^EMKZ+!EWI[U6$Q^[;J#[!41J;U]B>O; 4[,>[3=3RMG^
MU)PPY3EEM)J4^2Y)9?2(]51CF7'!W<>O[.\R(S]@QK+O>NC\6*(XOOG  GEN
M1UV 3K!;3(B[/B,"$)%N U&A6Q!I_ZSX(:+VR?QE1<_\8K\>F4050L-YOW$3
M <G=^PHO"WV7TGY8(%J7O6$"BJ=P(Z\"1QE[YUDOF<1X%C2.LO-9A6')C7I1
M-2 (?;GK%G[7%_[B[JKT-8&;.4>X[MF@4!];RBZ0N6<6)XJN<4 FN$6,<,YE
M41(JZQ*]PEA/0CP[Q[[+VEKJIS8]BCB\V(%-XQP&'M!RHST%&"3R@*"+Y5MT
M0)NI>4Y\H6M[O&*'MY<46>A*Q':VLW:7>LZOS2-XE=*7"C$T,SDU6-REI4[9
MX.=9!\G]:'DK@QA8FFR9Y\'2;W;A4T./E&SJ4WRO!L9G[#F?T#2T?^9.:$:)
MZR+.>6*U^'4"IV7U7]T3_U^[)^;MIVI8F0SX2BKC9"="&52SV<>@/*JX8*.S
M^A%FDADFYE5;%['3UFPX\#+D'%3Y"=)R_!N4(X=B/0#BV98@.?=O-0_IW(.P
MCB;S[T_HX0CH_BM-!%.CE;#,6_I%NDY"+YX=# OI@&"=T$A05(T=#!2PX@!I
M5FX4J,I(71EF=G7*9>D^#*>K&&NAI <**?JB[@N>IS.<7,^3M:*BGB"+9[?]
M[>:[;,/&!5#>S;?C!6=\%6=+KO\9("??FOXMU_3]F9BX=C^^[E2OBJK9-^(5
M2YP1HM::(VO""@>B2L 63R4F(I800*7 L'U-/#9&.,*TMJQC)'^1^^,.!.OH
MH'P:)H/*U%UKM96O'ZWI3ALZA"C@+2AVW]\$GRV)BL_=0?+#3:Z13;\B:M96
M%JF)O%>708NQVJ/)$O-.HY4YWY<_)=]P-#GXXH=XD]3/'9:.8L?RH$L)_]TV
MI&\D4**;9P1H]!WP4V@F&-> 7^^)Y5Y"_NI#;$@B%_RV((+7MR"?S,QX=N%M
MRE,LI]S'?W\C@Z5Z?[[G_A'"+Z,$<5_C>3?A=;9K/0]]> NRV8@;?R]UWE+V
MSY-/_W18VS@[&5S&J9U[2_J"VG3_K1@\<Q_?"UV;!L5A/(6G#C3PKNJ"6T@^
M02K_!)[EP=,@[K>^?2*.Y1@+QHUH_>G%TRE2B*^-='LV= OR1<8>)P@N6W-$
MUZ_R/*-=9??_[OE'_Z5T]?5_'=%&A''G>1=!\G3'XL<7SN .U)]?/!UT^@GH
M09'AO?L=YC+/=V)YLL7T\KBL![X#\5L;#D.LY/\E_><RC3J<V7T\1_I(XF'$
M.S$8^'H(T?&R![22I["%*[8@;S[RG&3Y<.0_VS;221(U#??S"7)R$R1#N0'K
MG?_Y-W-F/+A)#^]"L&R"!<%2IN8$^@$/; :$<),V/+VYU"/V[Y-?!\'V_];L
M=,PHVPT<]N3G/B$*HC_,A;6?"D^5 /SETVR%7"T["X+OSEXROA7C+#94->7L
M=5UYYW'\FX"?%%#D-_L0YA2W!.>%4@*T:&=W^GN:#576DB1]LU06$5=&4]+O
M-H0YK1=?;>XC!'[3E3CGRT=?2Z'4^JR$PE:>Y8,3%"G2=92$'_$P4!'&369T
MM69BY8:OC1.0);-=,E/>;>5.&:O!1KT7W;L))US;/[G42-DBJ)EPQH4%PAVF
M_CC+'OC UDV==*8'-7J%X=$P<I=EZ@F<-/KNB.V!V0'Y2+W:[J]Y(5?7,7TO
M&8(M3>8-JSR-LN,84,56P8B.$F67*:)F,+:D_ZP"$Y84*HX\FVTW]*L"US:F
MZ)T\(B>Q+&/0>L#OD/HN >=K J*'-%>1DHNYDKPX"NB8D'%P $&;K:*1HGFB
M^Y&1O1"0W?6G_H5&<G])^5G4WO '>Q\4Z][,NI<%F7XI7[^A#($N"B0<.PA9
MCA# /JV%G+?$1+%=L5]P-0,KR/R%^P-=4(5)7WUT!FA^],20E"_<::0H[50\
M=N#&3^V4&!O9XWSI+T/RH/ABO,X[H)FFQ!/4YSD!-D6QK2B:,.%FT-XDC3;?
M=Z[=#]3QJK>4CTL;?_GC3 W=Y"@OLJ&OPMP',3J, 58<\XN;1%'H&X]E52G@
MP9W21;U0/X/C>NFAVZZ'2NV'1/W^++@1:XF99A_ #F,EN15829YOR&-D:6MR
M@->),>^T?89X1;\+OE-?K8RL]H;O/W9=$ WY$X4\N01C97E$_R@JME>IB'GE
M=P<7'JJU(V%J: CVOC''R4S[%EGIXPI:I##GZ;:@!(X$D\11=F2+H#7I8!&C
MDMY#OUOUUI>X*Y%\OZ'#7(FL<X\Q;C^B_BS_ZAVZ^IU Y> S']1O!-<^-F4B
MWUGLY[ZVD 5LJ0\&5H5+T&E]H"*9RF)6U./Y!P^/A#SQ9DV,M<"VT[]?WW.8
M?L+F\5S>W@CSM@2.!S<51^4%XFK8Z@LF=IK:%6F(C[<09>H6J8PT[9AOUY-H
MB-W(W=GEOZ;P8,^/,-&0:AGN]-[C_*J_6/!5;S86(\I-(5@R$MMP,KJAB7A)
MC/_?ZM,H0SQT2OS$C_ QM)=KT!XG<=E&OZ?"!^]$WA?[+#B]X73W2<G)<K^[
MBN62/3*FT>4FP=:F*R^DKDN4'<")1MSJF6"Z&?[#C"6'AY>MDXB?J5 )W.2Y
MZBW(H-PO\-ZM+4AI(MA8!$9J<<41U)7<W]:QL8B5(E?<0B)/\)N]QXU:;D$N
M#V]!CLMR ZEKG">&N!6_YV (5! .;NK]V=Q^9M]KTH4C)_X9-&5M08)),ZBO
M?B/_@>M'\8Z_'W+9N-;7/#"]GBNW!5DI@W(EBYTW!-DW,"B@B!%%6YW"* /A
MI>BYKJSOKQZHQFH\M3.J3 V3,LF\%ZY8\"-%G^\Q9?]EAKW:;\X6)(KW2;]V
M6^CP!*(3_(^: WZ)?;[-A7(F'_-QI3+AB(/+-=C-ZU&=Q]1##G]5!'68:J!M
MCCH/;[<@W-93FPS<CUI<"\D8*X1KW;,%"4!-GYPS2<;JH-58C6,$\_)E"V63
MAC\Z.=$^LH5-#P@W5U5S;ZNEF ]WYI]OV!X66IJSAVG-D>-CO00JF%[G 5@I
M@&3Y ^Z,-=</C+78VH$XMPMVX7-^<EI%#:,K>[-&)V]N'I>_]RI#=MT9$Z$\
MAN)(Z]/V<&L0?MD]+Z3V76L:\\ZY)U)X?M_S#!^O:$N(E$T+Y ZR$%F72:8H
M@"-;$#&C"E%6*##@71 @YS25D:F;3TL.&G*L'?T>/7885:E3>;=CKY7B?@^/
M$U+.2>/M*IH1O/T_B NP3T;"X'1$"W+JPIS].-&$HT)XC,[L:))M(N<'R U]
M>5.[9_R3Y<-7HGS/N^?NWCYGO=#018*CLVFI;?9* *65*$5D=L5OZ$C\7+-D
M]&>5;]Y_F_>X83(O7M;U>6TV&L*./(R(R658#L17H;7F]%:UV%".;57J16XA
MR$\P;6BW5XW0R&R_CWT3SN\4H/&9_Y/CVY1SUX.L O[L',?8TM9$%ZN75=7&
M-IJA9R)N!%H[-C=45\=)O+7-CI?2X".Z. BN>Y<M(1F7C_)@2Q&_:J#7@8RA
M2'".[+/02:4)-!=.:\9MP,7<D/T-IAXKU5/%[!#6.WRF9/HJG. DN7*T;"E7
M&==Z@J@!]+"4&- .^QC;0)I>@JI)L[V@+7[9..F/53I=:]_8+/MB%BS1?\KV
M=L6!(*6#Z,,MLB1J$:D&NJK /HXQ'R5J8/B SX$$K0*_GP!Q[<QPG:_[J7&"
M4=[D0+&_W+OG069EA5E30[[6F=\%=SW\D+6"H+Y4-0!$>4&#GT<D,;YM7:WU
M]_5B:GNX=VA@=:307-IPAZI\ -KH@?]H:D:)=J;8=7VI;1=LKFX6\W4AO/#3
MPW/6$15F*%ZLRY7BJ#&ESP]BM(J!=$NF9K0.O6YX;4WG_+>H$W%M<<GW$#U2
M>3T99F(;[%A0>),9P$KDYH7 %3 W@?J,+$TR2<$_4XN!;^WSU_F5K&1;0SB4
MG7SL^9"U^W,K+[V7\P?.22 DS,*HJ*AJS(D1(AS0=9^Q9@4"=G3I.W0]N/M:
MNBM/J+[]Z(80)92&$5\%WXK4C$M[<\XXBXOA)B%0\N N=-8 E9*"$< J4^R_
MN6),JR.'5\:F4IX%QA4\?COBX)UZL^/I]1JIX]V&V_Y8,R_2$=%$:4"Z'6O&
M3*E!Y2VX"62'/@@M\1#PS=]Y:DB7FC>O<:RK"'_RMSU/F,SREJ^>(\=MP)QD
M%K4YS9H.IL:!*D#*3QVM<RZSL!$S/2\6OG9YW_3!J['==M^JHM6C.K5^:<TA
M'G%TYI Q%@:,O]/X;!$[?6%9$J_U0CY\FT'=BIPZIWS?9WD1V8?B2$Y38:TH
M(0 *BAR:PXM@##Z'(*1]W>930P)A[7??R38-;]30<F6_J)B..3A?O^&RYVE*
M\+>4I]O8W6] "KP*K*-7:+::6G?A^?P]]X\;"==6:%G5$-YG+:T[-&1VYXP=
MS.C@K_ID?##, 7K_"]#-]@-[<#6L#[ 8["&,#P/W,/1W>0?GOE-%Z*V@OFR(
MTQV5BN:62[NBN@4%'VLQ,D&A +8F1V2,* .PYY )9M!"H(8NGIO"<0W/7_I#
MN/WERX(^N?A+/]+N;KJDG7I<+J(W+TA)*,A"B1N[%RACNW+<N*5$+<XE0#@/
M$S["V<T,:,=!-U0T.^_^]/CB@K[]Z8=OX.R8W$S]CE-VA7J[)&JW<>,XYL @
MHX9.BAQH1\1B#W\FN%+KZK.8O[@'EONJ$V9G]V;YW= MT3YQ^,FKALXBD5O"
M_,Z]/.'+N+ VX;;<$4"-0_CIQ>+I,2/P,XKVTWIRJ%6AKS]S1CZ.G=CQY/IO
MB>NB.0;(N-PJ9"0AC UWP4YXZG+?<HZCJ(@(BT-C0?W1##9Y\R:>6JS;7AP2
MKG7B6YY4Q^X(J^+">8AS%Z4N[!%!KP1L1RI8J&'[$-4^,1M(J!S,%-&%D_$;
MFD17M[G/N'VZ9_1>3UV(5@41WDM[<JCU2!YT00T4"?Y[8BL0P!; Z#&LD_0(
MY]\D7^STU!BZ6:XCDOW0(CJ\=J#4ZM,;,<D"-:WM-OSS\O,+J;%;D(;<E0XZ
M\A$H [PJP5QGO(I)Q?NR,E=QN&"-0HN0=^HU5ML>_8R.:U%G=KW!0G"MI["*
M@%H7B6&#G[!M)TGS5KO+0C\+&7W?>R!>;]U\]*NS [R^;:\&X>./TY;FX,6T
M\% 2XR)RDD3SSFQ!3BS3UJ()F@%4<4&WU#94R?$"[?HMB%\RO?K>ZZ=6GUR#
M^*1^=YZ/%2R!<$<8_W9^XGYF,_CA#>#%T[@/2BF _R#^5YDO_H=7VJ?!;3H&
M]UA5PC*0<WMTN]Y5X&-P#;$KB<S$KEL8?2" .=YJH<W\UFMG3HHQ7"[+73U"
MOQS)M#0O/S.W*P6NSDP ?1!4/(_[#+2L/9P:YTB]L1!'PZR!X#"FUQSJ$4:!
M>6(+0@X>\#-)(1CL3:1Y&<4TG2I:W?/=-O&%IE>TUZ%V+T&$*_@%#B&*8GMQ
M]:DK@W/X"))X"#PV1WOF*BHLC/;Q37WZI7C\=^2>2^M*82_D+]VR107V/7SI
M(+@&ZUR;(K'"N"\UAG8!TTSW-@HTR(A.MFD8^W'#/;&OL3M%R3=(W9'ZV./2
M3GU]H7Y2&VG*EHKJI CX(W<293DVC/ED,Y6"VK+2@/N6O:F!5ZXX^6&'JCMD
M!J,=O=)5)88C[64YKX +R_3<516>9=AP2[<@-$, 68C]?-_^(>%H07T48[ZC
M>#,#*Z[?$FFS$BAJVC94HKE;)NW^^%!N-;Y%;TJ4AEL-9SNB!QP_AT ?D6J"
MJAB(BW((OHW]64*!&&N=IZUUB)49:MZ7#D*K_*^/ A&(((PC[UK:W&B";+&*
M7CNE-I?<K,MU?;+ZC?CAR>"3A/>/R3Y[\IWX57H/12U>GE]UY_TU'Z#&,&&=
M8)JLVM"V('&>\'',P2;7W-:IND>I85YXY&^F-2O@SK<R.<G:E-;1TY/#P\PB
M4/@.6Q#L14A;2&*'B5H GC%\#,BDB]N[,=59IIGQ^5D_'VSG\ZZ$:YZ]\?2>
M;LI@MW)$==DI"?+T\T&L(,=T",>3DG5%9-)./P>@H8W(/Q9ZE+3#+6#'MU2R
MG<9&_K5WL[WGU9PF"MX*;H] !).HN? &9-O:=#B5%$.X1^71?[\F2AR^=J-I
M;"/[%/K[\'4U':42!XDORB^CNLZPP_^SJ/[-^\8?".QGX&E=*U<9V1X,$S)7
MK>W^VP^TY7MU*E:=4NG^EG-*A3>H.V^'*2M_#>G %J+_U9'^#SO27R'\U^))
M,"P4(\(DM<,?XH1] !KSZ+&:%)PXQZ#^?<882NJRP;. D!PYUYVEM.IRT_'!
MT*\D9>Q!7_AV"P4@G1X;OQJT9H@4FZ[H^]8<US<2UU<K%-,UG_HC"P*B\WFQ
M^0V/9UXK/SL\C6M5,'*W?@Q[GT'Q&-ES+WA=[LGK9XHG.[&WVW-^X_\>Z7 ?
MUWH%X8^;^L JRV7=XREP 4_L@%Q&1E9%5SS'HWC)V=:\ON :[.-#G:#+1HQ&
MW*&S+3:U^5_O(,_P;&4'GOMJ;YW[&T9N$LO0T[\DZ8>:WQ7$7%=)IZ"*'1;)
MX0?^,I_?O,N,8'2 348Z#9D**F#[D,(6\ "L(K.^J'2ZVZ<0F&YWML$P*)XW
MZ^LBE[PSCNUYG'\[X<WDE\PKT.5K/.DBAI#N*!V@X7>2\\]<&?O^^9=O[;TN
MEU!7;5UI^Z?A77>O!F_@UP=YE\G#M9KC G)C[L^WK4WELI:X!77VR:9K"42M
M+WX6 L"M<6FR'[7/W&@+@CC[:K7GWNU[QB9R#C\;VT\RMR"G2D%/$O4[ZK<&
MI4:/^\P%X=YL\)MY#/Z&(H\)\Z%" 75\?-UT65Q@Y5[N"R,=/=MUCUTV1N:V
MY$SCNW$J":57"_5]ZON?<7[C6B6W(-02!..LWJ0SZP #2<Y-S94,L3.8.U=&
M'Y"<0?<N8;=YG!.U[>GSIK^K#T2[VB@_V<F>_/K^@*B$0&_NPM]^3O$MB,]
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MCZJ98J&!>5 ?PZ9E1/DH9WW/-43XPKY;3P;Z/T:=5.O1E3VFR;]A#AT:_:W
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MXW>[HEXJLF&LNBU(9 1&G)N"L6'$ML&EO<?P!!LFOMV+;"$^9';4UTBT$:5
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M4:]=J4FS C+R6S, Z+GN*8L:!)(0FW'=0N:AQ>6<+N/7C0\?GX&Z]=SN"C"
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MB[0W8I89G<3NH>HU=?%AL?1+27)\W7?>>:=!&G&+!C>'.E\:1+H?:"E9O9;
M<>> T"9L*>4#%@0F_LGX>KB1!+[>F(&D.#>E[<&)L3I9 OT,$9*=2E/>R2JJ
MQ:3?!]8X;]<!9Q3\X<H-B!6W)'LX4Y(9B2=^A/'BW5!OC#APW2Q1*'>MWJC>
M+V_H7LQ:K]II2ZK)F.-UHR#.!?F?BL<FS&(>/KR!X S3Q:GAQI%"+'Y\_2V8
M8Q>@LA5@($'RA04@Q8W$4;6:@^5F!7=#K/K*^757?QZ_=?3P&O&Q1T;#YBG%
M^&8(KN=_>/N-E97E?#4/#;1S^&!OKY2ZNH>S=[CDP2#>]F,EFCRQ+>'6PZ$\
MZ7&H/YO  $BH#N!:)_<::6&*2(9=C83("<T^K 395H,/M0,1J3Y"ZL,3951'
MVP,KK)$(L]1#'%:PU5O?3SQ_=.$P^[;P^R]%(2#6T*!:U-O+4+<"O$_[V3;6
M'NDI&T=;?JM(4((Z]2^1:L*/7!06QF2^L7+I.G+P[ASJ\Y<O_H/<A86.T;R^
M+EFI3Z?OQ!KS';Z?:"T;>CU:YZ:/T\&C_N9UZ=PN1;-3M$ P643@[VN J&H*
M%FDD9(<U %JG%I%[W :E86&U"AB%QMGK%/443_Q#M<:.3UEPZ6;V.&<GS[(]
MET^U+GG'+"M14D&4<PQ9YF6D!&:XH/LL_I"6$K<63#$ZN^-.Y<3YIA/]WTS0
M2N\?0(_+:9Z16S?!2>$Z\11[,#==HT4QWV^@AU<O4$R;D7O;R*ZZH=6:5-46
MF\-]1E#,BXT7>TDY*"UYX\/?7 ?<WS@>"D5?I+?2ZI@UK+VLY@JDH".0^13O
M^XEQ;="ANYH_W<4LR::0X*=Z+K?B^*.^(^O=_N%G#P2<@7I<_=NB.%>4P9%T
M3.'@CZW+E=2]2:A/Q@ZY+7=KRZ/G.2+X^\^S'_@N(&O&(:=II_O7M\Z_OG7^
MO_"M<Q9K][XRS$"-K"&8U>&Q/1CQT35,/ZY Q'[$PJ/D",?^JUE\^P[Z:^TK
MFKE&@P*KGW#UA(K99MBPZ=1JHSO"I!@H)W.KUTHS3#_W.!/@0F^*K'N\94T4
ME.X=>JYZ+.5Q>?%: ++?_=$(X46U1-%"HO[$5Y(&_Z)TY^NS?>7N\/-]Z'+5
M/:?V=F[/C%BD/#K]U"K[]!6NZ4F&: B+.X)(&+5HK((WP4-& K!:S/?5W-.+
MJ1 @+.-/HD3)^(BI*.V)?L@PG]/]V(QH75?MJ.;;4QQX0R1;K0IN$+H?3R00
M2M#/86XQP<D3,63";B\* W-2/%7(:[2RSP 589')_.B3*\GJ.C DT&N6V^O1
M+A3]AD4\P[,GE^TZ!"()87L.68(0>6:5*.A 9RJ'W+&4!I9<4O.)[A1?O+!Y
MIFM783V;S"5-MPX/]%1H(:+=O($8&RD-F?]7V^[V50^A:JV2])9DZ!9 Y>7J
MN,;K(22?L *OT>^WLBJV$/K8XOSBDI<_%E*>WSG+\5L(&4&@7"SRM]\#!(".
M(#J@6R0]IP\/]5X-PXD#,>15X<6JZ#17[SS[A9L^PC6!!;EPD7%N-9LQ'?C,
M"ERS[J (L@1*N9$64H+=;3J+9_6-<%8+WQYOI!0U2R>4"1UQ5?)5TW>UNW%=
MW&$Z^,%AE>F38G] S,(1 903HR18_,PX=P2BI*_UA0&4JMTP<=!_@7Q8_9CN
M$0\5BULY_@CSJRO2I)NB]\=5DI0'[D2>X?J,KR_=@4ALKH;C/R>%+6%-/]UV
M0TRP >U3@MS#:C]C5&U<$D7VZ;1[.3O)ZT1SW;@=Q';F:C@3#%'_0,:%+P""
M+HGKP6F55/FJG6LDH2/N]:U,[2YRWY[;\E3,K?//_V2+$KC^-OI,T?<NX,1I
MDD<Q994F2DW\6#@_)"Y1>Q(8G8()V>@VN4-'-E 1,7J67T-/<K3*PQ7VMNPS
M0"RJ,$1]ZJRP9LS0'8@KE*^>+TE"BZ%*=9\N$]K3:Z&4&..C>>,*M]ITR!V(
MRO14,H2QN[E%#2M#@8&!#LAK1&/A4QT2%ZE&!*H+ S& O5JP4.7W@9;CM?V@
MQ>XTTVCFB'I"0>>EW15NV1K4-!)0<<J@GJ:!_-I?E36*Y-7AS5OV;9KDKU4$
M&AOMH3WB3T?(:('YQ^.Z%4GLJE*7G'HGKN2^ALKG'GB!M,/7\]<>Q6@T3E+.
MK8J.HJ0+LM]H-&I2?<RHAC6_J;9==PU_MJB:)$N]4[KY]O<%J;./L@[>VR>;
MPY"1H%1>H^"74JB33?JLE&.[R&DU?'/\Y/BY\]*I+QXKM=M<+K[XPC'X^IN0
M0[$)H;OMKQ*E8<N'*"FT,D";+LAJ(.RI5B&KB=#> D>>;!<U57ZE>(UP$D*\
M=B#<$S9CBV2\B%J^EB4T5KY4IY)/\?;L(=2&'G$Z$D:Y,@D<7L.>![XJ)Z#I
MIW&-(Q(A]X#3Y *D57EE=_ED:-6#P9O2X]7:$Y>2_19';Q_K,W_#>_1\1Z<F
MTAM$D+=QZHQ3S&@CR((/6!*,A $1EK3(U.4"1\K4.2-A2D5(-F:\+$;BYXC]
MM_QZO^Q;S9^.!ZM8KNG$R+@[O10W^X4[ I32=)(:1PA+N^'R@QH377V-A Q&
M"FT>HL):)@Y16$7J4>0.AVO4Z[ 1G^0;+26*@=\'*R4$(F/4+YR"4,] 1U)C
M\N>2IY,G7*0+$_)^[7&P*)#;[KM2RE=SU;DDT>513?\)TP]N0^L@>>$(#;'^
MVR+W:@SR<TY@M1T9+8>5ID27YZ.2!8K)'5;N/HB^G' 9_PJ-C]_7"W_&OA[T
MN/A1(1KV801R)/_'\]*2]]'Y38>A5F:B"UT#.K]T4:>.%4I?#[\:[()TB,E\
M''!#3.+P1SW)BE=92=H7M\L*"WL'AQ![T)76^*[I(A8'.(7F'MJBQA]&^0ZD
M+I0 5*U#@6L34FTPMX$_BE0L,$O1P3>D4KH83!04 .D?R3ZDN!TVIP=6LD 0
MVNV6"QPBHI^UV[H&WDZO)0RRWOV[\8S&028#2R0 0A)@4-L[[$!X?!MAZYOY
M>.)C$$9!*3G5VN #-JTL+AAP=>E1US8_&">DW?MW=R #:0GM?XW]_]W8.Y!.
M/8;L\TK]&(9(>^/GN4&]JN7OP+O[EJD1'MM1W<9\[$_]1WT#N?*$7B!G\\1C
MR5U'-8 ,+(I5 )NY3?C;_>K>K+9G0TNK8+&XF0FG)@4O8QVS5?]\S,8DGMRT
M$'W]4-GV:<]+,RZVXM@7MUL9FJU+U;"9$(;!#J3A"8CNHA"+;V7('M<:K!6U
MG)^W3(UIWGH+'U18RE79C'%>\3UU/?[R@>1O9:O9K7L5.*UJ$#<N'Z]V$'\W
M,;CH454$H C42=9WJC-S7ZTN.."C'0@X8@\3G.:V$!;TWL#IW5]DBF@'=R#!
M)YE)A+E_(QFD^'R>= U\CR#P%'QT.60'(EWT<0<2.OT*WQT/!?E$+G[-"39<
MCI]=@E$DIJ=_LW8@"@PPZY086.] SFE$X2EO"2#=\,+?QY2R I&@B4FG\#N0
MED5F*(P4#7-<W3ZT Q&$4=Y]!I^ZCF\\@&N?W#!FR>%)I^^"C^7^G:R[S!0$
M"P=.C0UG;P]?78.UXND*S6D;\L 0F%/;=R L/5.::01LSH1:Q!(!(Y/A0?@5
MP)*<HH$<Y#V4L@X^-2K(TC7=M7(-B)QAI%F62 64X18#1%N;,KG!0@7H@VHJ
M0_]2ZB^E_O^MU%"O@74Y@1Q$+1J'K:LCMZ';SL@EDW\2LIG_; :F!AGXG_^/
MBKU- W3\U#= YA5/[D7I>[,"'DZ*O;"P\QBQ/#%S?DV7?<:4OSMJPB@ (]EV
M8!TY"!W-)\RN@5;8([\#(2\V;\"&NTAZ@<NI[?7V$B44N\"BF:Z[I->9O<LJ
M*6F3YGS[<GOOI+V.7/-#H5BB6\'XV44PX];-@IF:@0C3-B@*?3S6KG_#\Y;)
MZWN&58T6@M*%,2LD 825[OL<RL2\QOJ&2\.'HU=R7-ICE3J>%'T:''PRO@.Q
MW?;Y=].8HWLG,5@V8"H_CV38/8UA'%GEVX%T#1;O0%YTL43_KJBK_&-1[]V$
M)<( D376:M$F(<>OJIV%5\-3Y#58ZC'_%CT,O083YK\=R_3O)/D>*&4%>,*
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MRL!_NU')N+QB#OZB[-#'<BHS(,RW%DV-VPH"\3]-F1(G/=+6E0J8HSN0GSX
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M:]2*NB)LGH10:NWB,<H+3QDM%O1O/E]&AO:;L>Y!2XOY3MY!Z;%X0 +(\1U
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M_HS\!)5:.)DN^-GEDXU'AG.>*TVZ,$W_]B^W)T^J@J)^.FN.V=B?21+O.W1
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M?^( W?_*W]&"#1]M:[MFY^.5W^(F[E>\C0QU=OEE<DCRU+[?FI*S8KN-0J0
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MG#_$??:;?20J9]JD._K=N5].OWCW=G&RB!%K:I_$VY-%2XY)>FJ\6WX+6!<
MBY2SR=\>?XA_$_O@/>\?GRT_:G-_:_QX?WB>]LPEFV>E?)2=U[@TPRKIY4<=
M0\\G/SL7M04=9!#ZE/VM#AB/(4#KUP%;#WN 51NKQ ?W-W\?VO(_6KK]\$X[
M[A^7#]5I[=H][U+UQ+7N#X]OR]0-<!5I,R[^5B>Y[7&YVO[D/;J+][?O,7YX
MELFS]?"+*K&)B_<>8.&\[W/Y[9M9"7P<0C.X&QR42_,NDGX+TB@>D5C^_TT
M4$L#!!0    ( .&#65PPXWHVQ_T  %#^   1    :6UG-S4X.3<U-3)?-BYG
M:68<6'54DUT8'SD$V6A$::1#!*D1@B EW2T2H[M3>H!TC^XNI5.D8R#=,;J1
M+F,??/>/G?/LWN?W_.)]=^Z9C)RTH- G?,QL]!L  (5" 0"\   4 ( # (B'
M+QXK7EX +Q3 "P?P(@"\J,=-*"\ "@5 X0 H @!%/9Z%\P+@4  <#H C '#4
M8RN"%X"  A!P  (!0* >D  H7@ *"D#! 2C$PZ1'X$?H!ZR'YH?3J,<YCPO*
MRPOGY47P\J(>QSY44"@O%,X+1?!"48\L'C;A4%XXG!>.X(6C'DD]G$5 >1%P
M7@2"%X%ZX/C0RHN"\J+@O"@$+PKU2/E1PP/I!Y8/M%"/"AXG/4 _8#TTHQX%
M/=8/"PZ%(J!0U*.^A[$/%1P.A2.@<-2CW <6#YL(.!2!@")0#^H?2#V<A:+@
M4!0"BD(]FO%HUD/W@QT/^E&/WCQ*>@![(/W $O5HU>/@!^P'Z <LU*-SC]L/
M]<-"P.&H1R,?]#V,?:@0"#@"]>#K@]P'%@^;<!0"CD(]VOR8"O3Q[*/1J$?7
M'[V#/K8^VH%Z#.%1(?01Z9$TZC&31Q[01^!':-1C1(^GH8]S'A?J(;$'(Q_T
M/8Q]J!#_/QFH_^-'_1\PZO\(4?^'A/H_!M3_1J/^MQ+UOUFH_^U _2\8];\D
MU/^D4?_30OT_&/4_-.K_9M3_V_^/ F!C8S]]^I28F)B"@H*6EI:)B8F#@^/A
MX1 2$A(7%Y>6EE904%!75]?5U34V-G[(S-;6UL7%Q<O+*R @("PL+"HJ*C$Q
M\<'*W-S<XN+BRLK*NKJZEI:6KJZN_O[^!X534U,+"PM()')G9^?HZ.CBXN+N
M[H[N#A/M83: X_'C\9V0P4$!T' H96MS?P3C$+,9#-;F]< (&.0S9;_F]WUY
MQFN]//BU8""65C*24NY;X5 BBWJYP="WHI%4;M/A3+FZXM$,09>#Y:&ZDI\Y
MXL&X5/+UI1,%LHELAL/U95,E*@7R6?(-Y3,5.G76*\/).QSJ1OFUW('B 0$
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M+%K\,ED9W&1_6A.J=5J8C64HV-P_^ 7P-.SU[@^1H'13RGV5O0;<X!B'WDO
M&H#I8D\@UBVNA_)7N-[I06",72\)Y19M29^L_$RYWE6Y3L/+SO[X:%M+C/*^
MI^+:<G$@;Q%[LE.6 ?[6X5E;2A<Z)LT!@=;A:*<D#*J^:6G^QD\@+ZEH&L-;
M:4#W.LBS$H,2[=F ".:W&;\-TU+=Z$HSY@\+$7NF5"Y7Y:_; &"O2DELFU%L
M/.3KZ?:NX K#]S)71J$X;B&2+Q;GL07[Z8*=45$])=XKTKH+:>1.9Q@T59PR
M'R]><PDI?OTVJ%CMG%P1ZS'8]<(0OTN@ZP=^AS,#I:%G<1\)#J@QI<#[C^4
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MFVGOPL>MR"W\1LU!E4P$7[^ R&7 60+A3>&M!W&@['"MG0#0G[I/O[B5^!+
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M060X,<<^W";??VOM$7V$H/8KCU>(G* D"N<.VS]5^(,L,S36 @3@I*6 5#'
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M!^<8GX!<+*(ZG8M8[U*8><6TK-NT7M&T_LR,G*A&FZ^&T5_-#UA:!G^9_>B
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M$:S5%(5M[<-T$->_F'\"]BXGM7+;STO78@D#>H5;>Q)LY:"]$/%F8)*;<3T
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M0"CR<CAU*%B4<!<BCE4DN^L^%,#O&(Q.NBM"&R3Z?OB*@OAM9CQ_% 8] 3M
MG,D,&?H5.X!?95ATX43TK&^ZE5/=-19YI_QW@5C$-1 [M(=48\Y_.UC(-EB
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M4)2L631&D9F^7G-P86$P%M;$=+[LWBF3J$N/8.&@W'3PTV=.OWHQE12KXHI
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MW+L2MH*8X<-AB?O$ASJLDWC*CWN?TT\4'."P"X(@S(/"'SMI[D$BD!@&L4
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M6_1+2\E%R51,PPU&PT%&O:$=7*6*T,% N:$<JC(A_$$?@G1(BY1/2)$<P>$
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M!'GP7'KP(\G-N'F !WFX(U%DHRN @AF0GM*UC)0 I1F  N:I.T<I7'J8!WE
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M:*% _0P'M@E=S 26Q&2*-X,Z7;B#^17HO#G>E8*4IM 5Z_0FSSR(9%O@O_Y
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MW#Y2(-(-Q*RT1T8>TW4$"A0)U4%:25J@R2MB2" 1HT-6TP^FW9MXBY:\V\T
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MWXQX=5??=&+O]$LOMD[G]&$S]F,KMF0W-F0[M@MGM57"6/*T@SJTPSJT0SF
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M.[+?0SJL]SLP!7M4 8ZG@QZ8PVO']E\8E1[(W.*4PMN/ Y2;@VZC0X"[5CX
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M^I%<M!&.*JRC'>EX L&V\81YE"MT[Z@2<Q98O"=PPTNE$(@_5J$.U:4E'.E
M1U\()B0B[41_XD('/*!A)'FH[4OW@$=\6 =%(-X1CWG4XQ[Y"$0<UA"0-!3D
M'P>90U7U8RSI\ :7@E,VO$"G(0@\5K+T44*"D4,>-$,(/TKAQ68))QO@2$?>
M'C*+__2 8U=WP@=WO&%";W"C'.W(!Q0)64M#%C*0MLSE+76)2U]*"'OM*Y\P
MSS?,8!Z3?<ATGS*-F4QG+O.9.^F'V.I1BGG,HV4IK-$T\7$/>M1C=K_2#CVT
M:9!?=9,>]"C%-_-1)!/I Q__@U@]I+2.6>$#&L",9C'YJ3YF]C-] 26F/_=)
M4&@>M)D(!>A !?I/@_82HKR4Z"XI^LN)6E0U6[QH1"O*48Q^U*,AW>A(8]1'
MDYX4I2E5Z4I9VE*7OA2F,?V02#M*4I#:E*8WK>E.==K3G/X4IT'E*5"'JE"#
M)A2I"W5H0PO*5*,Z-:E'56I3&5K5I5J5JE?5:E:Y^E2L>O]UJV#M:E2A.E6Q
MGO531/6I4-=:5+>V%:YJE2M;Y_K6NL:5KC.4Z5[YVE>__A6P@17L8 EKF;L>
M-J]V32Q>%=M8QCX6L8Z-+&07VTNI7K:LF/TJ63=K5LZ&];-C]>QH-0M:TF86
MM5C5:&I-6UK1NA:MI^TL;$,;VS]-%JC^N$<ZR#&.WL9RE@[!ASP"$\)TR$-O
M+A$//-+AVW&H Q[ZH"4 ZM$.WY(C'>Z8F43$E+MZM%&RE;4(/^[ACBNHXPKK
M2.]YK]!>]:H7O>Y=;WS7"]_VUI>]\K6O?O.+7_J^M[\ _N]\[RO@ A.8OP/>
MKW\/O& #)[C! 48P@?/B*SFJ]PK_@F"+/A#1CO9ZH1XT*]X5S'&%X@"KO.:8
MP3H001_;>1@*[;A'L+C6!?0R!H/UZ$(ZKN .1(1%'X)0QPRN  \[^6/$Y3"Q
ML&91#_/.H!WU</$\W(N=68CM'>=U!ST0(:5[4#:\80;SF'-:6'SI5@\)*X?=
MT#$.%81#'<GRQSRJ (XPIL,<X$ >]8!RRER)RX2%.8@^ZI%F^<2'3O<HUWO2
M1K+AF9DR_( '"P(0  &40 "6QK2F,WWI3F_:TYP6=:A)#6I3?QK5HSZUJE-=
MZE:OVM6LEG6L:0UK6[^ZTU!X(@#P<3MXR.,>](&G/. !CWG@8Q:_HJ<[!$$U
MFN$#$>[H_P(\\D$??G#M'<P^<C_H(8]W"((>KM/M/-[Q:[>1]QU=> <ID:SC
ME87XV8C(-G*%C0AOP^.[(B;WM^71!2BP8!W!AO3 "4Y8W"ZV'K<)ASONI ]W
MJ&,=#_-'/9A'CO8@A$IF"G%(Q&8.O\QC(/T8W7.M->=UR,TPQ5NS.Z3+CW>D
M(Y;A$:^8$\(/0;#@T@@P@<YYOG.?]QSH/Q=ZT(D^=*,7'>E'5WK2F;YTIS<=
MZD_?>0D04 Y$3)?FI!+3#%C0]2O0XTXS)[/8#YYU_-%6MJT5Z,G:8:MUA,5"
M)W-'VM0!27_00T[F8+F&_$'")X1QNQ/70SG,P<;WB$O& +"&\?_0T8X4%BL<
M;\](VE_+6NW9' H"F'K064!UH7>>\Y[O.>@_+WJ?DW[TIM<YZD^O>A.P?O6N
MA_WK95_[T-^^]+A/_>VIKFL'J7VVZ0LR%!! ]1( O-J5#_[R@=]\Y3O?MI:/
M?OO*OE9BF<,<Z8 '.>L13VT*A!^( !F=H#,0)\^I6B"YNYS*H8=DR=T<3PCX
M+(:+#KO- QX@XYB381YELO]_(((,YUPOZ@I0Z@P0 0]0 1.0 1?PZ*C.ZK!N
M[#*JDKBN^'B.!;Y.D\QN CNP^CXP<0JN,J#A9<P!'7@K'%3@E0Z@"G;-&FQC
M')Y NPBBO)[@&\SARWPB@-3A"<A!E@C_ A\ 81R\8A4(@B^XX97@#)_D84ZT
MZTF@01_$300? _-XSO-0[PI%+PNM,/:XD/:\$ N[</.^< S#D PO\ RWL RU
M4 S1T S?D W3L W5T W9L/? KK BAOC8,  08$AN9@H#41#S" 2+2A^Z!BMD
M)1\6L9.V!0?)J\W&X1W*C[K<X7G*(0<IPA]*P2K*81W>SVG(X83H02%^!0IG
M21^(!61D3!\$QAN^093@P74 $*YL;@ ;$!<=,!=W41=[D1>)#@*OCA;_XTCD
MX0I8 .B0L?>Z@&HXL! ]<!BCT330CAJE;Y@.T1S"00:3B]>8YQNFAA[6P59F
MD&9JD.0TA"JL_\L' \]IXD,=BM!#I ,PM@Q<[.8=$(,<MK&V]I'RC KS- \-
M=R_W!E(@"[+U=.\@"3(A#;(-%](A&Q(BS_ A)3(B0:_WYN'WGD\C620*\P&>
MYL$< .X>4NB!Z&/RJI'Y-I(?41+Z5M(:^[&VGM&6^&$[[B\L"&(\N 4\VC'R
MRJ\VVJ[QY,PB[F$Z&J;\J.+DR$\C?J44VDS&X$8&T $/WV)CYF%X9'*&!##G
M?)$K?[$KO](KPW+H@E$"L1(DQD,&W@$:G5$:U](M_V,0(P/)B,LKP,0]BL5Y
MY,$: J@<- ;D$ *$Y&_C?H(JKB@<_M(?WN'OAL2==H($"4]F_"$?!O]OE(0E
MX9Y '9PM+I>B"M<0#.,0#C]3-#V3-.MP-$VS-.E0->>0->70-4,S-2\0"O"0
MX/#A"M+2CC93-W>SA\SRH[!Q3M8!XH80E4IA>"JIMS!3'> ">=QF(.Z!;BQH
M(21-!KZ!'!HO&[]AE,)N(*[-NK[A$R.(GGH+'=;AMXJC+7O)%K=2+-L3+-_3
M/>-S\R(P/0L$$=)!!AC.-_>S/MF2 UE2)6'24XBES1"F'-[!@$(''E:H!X\+
MO,33/"/N(A )'M !8=+A'0(/C<IK'2:1(5S.5D+('58A-U-R^EIR1/YQ#!F2
M(EMT]E[4]A2R(F.416$4(6?T1EW4]BXR(T__-$!3!!_P$T%?$D!]U$A=TD21
M%$6+-";[\RV=E#\/1"L)$#ZK5#ZOU$IUD2RAM#[N,S\W\$G],TS'M/IXTTS/
ME"@Z$S77=#5?$S3?]#3;%#;9M#7G5$[A-#;=E OO$! #RS9Q$TT#55#[)4K)
ME$O%]#_6DTJQE%&SM%';<TL1U3[Q4S\/U5 E%5/=DDD%=%,[E4@_-4DYU414
M-" GTD9E5$=S]%1KE$9-M55Q%%57]2!Y5$E_5'."%%!#U5-U%527M%=ME5>#
M544*E5@M]1FG]%$=55F3E5$C]5)/PTLK-5.+=5J-E:T&%5L#54WO-$[K%$_I
M5$_SU$Z]M5O#%5S'_U4.^;3@_G1(L]5=WU4RJ/59Y76R%)59EQ5?[S4LG95>
M!R):P;1?JU5@Y_66=M57A158#U9A$_;R!"'S5M155?554S56)U968955)59C
M<X]6115A(P57VW5AC]1C1[962=9@&?:@ I9@!_98;XX]\U5F]75FNY)?K14F
M_I5E=Q9G6[8_X!5H!7%;R55<OY5;B[9<T55IC99HSY5IU;4V;[-=@Y9JJ_8H
M>-9E>[;Z[+5F:=9KNW;I;C9K<Y92 59KSW9L?79O4A9EKVV=I,QU?*5$/_9D
MZ[9D599[2-5B]W9C,[9B^S9B_U9P_7;W.I9M[78A0C9!4?97&9=N[]9Q3?\6
M<A.J4.6NN4QH'-(!G,8"'<R!,=!6;1<+6<'V:TN7=.=3&-.6)G06=+$V=%67
M/_ZJW=KA"3R1=L-!*A_(-IX@>2#(:GES:,WU:)TV:9E6>)MV>),7>9<7:@>.
M7>?V=Z-7>OE3?\0HXG[EY:023:Q&'7KW=;]7/6%V44_7=,O72L46?/VU;%V7
M?5O7?1&W<7="'\@B'8S3/=PA^\*M.SO)00]W<O_7?R]+;P$78P.7< T8@0M8
M@2GV@+O0<.,7@(%02!<7?A\W@"'X@BT8@QN7/Q')'?",9>ZA'4SPQ/"N'# T
MN-H7=@-I=,W7A<G74=&76EEWA=.WAE7X)@)K?A/_1E?^SA/= 7]C\ >E=S>#
M=VF+%XF15HF)=XF5]WB/MWDA[7F)F(J)F%@EL[I@CHZ\91W(R8:_F)"X]H7'
M&(9_48;?EX;!^'W5^(9-(H-;"X,>* H?2%A:\B0W6(/S>$D'>' 3F(']^&+_
M>($#F9#Y]H'U.&$5%X\E]XWQ-H(1.7*[BC^1;"1GAB-H4IW<1E38SD*?9PC#
M(8SR@B!T*UO (5?@ 9)<PH/S;!R01[NFBQZ\")3EYF$D@A\^>%<>%(?_HX7+
MV)?)>%^K+G79.(UW>8V-.5/W:HO\ 1KF 8A+X1YFR1KXX4FFN;JJ0&X$3BK$
MY G\PF[<H1V &-@,J&O _V$W $$=GN=+^O0@^,*<LXL[5(!D<)(>] !MUL&>
M?9!$!V+QR@%WF[&*C=AXC[B)E_>)"9J)$]J)PS"*S6R*JQBBJQ8K:8:>T($<
MOB$<L,MNT@&?U0'BXF,<VN&)5@M4]*$=,/KM*H)FEB=Z_G(6K"L<\(:":^X>
MS.$;G"CDI"AS%:T?.DGO4@X^T('ECL0=QJA.V)AOQ/B7EQJ8;5:8RQ*-U_>8
MI[J-JYHU&AFASFD>Q 5M3MB>]* =D BLVP$>2F&[IBH?U($$PD$><$3NW$YO
MUH\<].ZL,Z3O%/.Y N\XS.% G20<8^G+%L_^6!'RVJ$Q%MF1!=AA 9)O^WB0
M&_^[@059L@N9@+_PD!FY5Q49DBL8LS?[D3L;M)\I2ONAD@7I1UII5^:!'K I
MN6AR_-R!$L\/N\I/$_'NGD$1?S'SRYJY<]?H@WT0FY)([W(0J86FEYL:N9DZ
M;)^:JB6BF)L;F8O;20N+9GQ%Q##H5S2)G8T"D<A"*[CA&U00BYY %A4/!O41
M(6KP!HF;)P)(B4):SH)P",T!'@$@/5[18&0I8M F0U.QDC&(B@4ZB17:H!%Z
MH0<:P0=<>1NZL!XZHA_\78F5O.@!B,-Y998$B=P!FV9Q0!!I'<;AA.1AFC@I
M';"H'*3L'B)Q$@_"R=0Y$Q]B$SLQ/(TD%$>Q%*]LFI#_+!_R+]'2>@5O,"^B
MVS64.KF+7+F![HRK^KFM6LBAVU*Q^K.0\E;LQ@8W!A#,$QRTLV3NV'-^Q8$6
M%Q^\<43_^@E^L!S=H0?K#AVKJP<_<8O:<6/J&T)N.5?6S1W6H3Q+P<G&D1(1
M.Y+]<;$A]K$KF[(=>[(A&Y 1W8$1P/<X.[$E.%=#^\\=?=(_^]$]^Z'.MA\0
M81W285>T V18I]KF8837 2Q(VEURTAMV<NXB+P=KPSR#,B1(B#R/LAZ2$K:7
M4M+:K$X")BJGLKEXXRJ=7$K%U\B/_<A_+LE?=\FEF\F)W6?_JI+LIA3JN!3:
M 6_ BY.$4QX>U"E(&UP @3:'_P4>KH@XGF1__#+DVD$;9:Q/)PXXV)H@T!P<
M N[14*?M]$XO\D$<*Y.Z+#0SP91J!;R@#SK!"][ "_S@"3Q=&7W<I5AJH1?"
M)YXW._@>],#^Y,%:H!.L25$R1[@<HFM4NOMX,EJ,CL>4-;Q<L+&53="F12FX
MGO-CNGTAHB4=3/F$!4-([++F F8(S9RTF3"C([&";M+9087(DQW9D7O9H[39
MF_S9HWY,H5RI2-NZ/+<?K&$[>FLY;66-I,N@D*16; 5FUJ&^7T<>\ PPNEB7
MTY&N,>(0UZ%V/?'4403+W(':&$),+/J$\:U$)9W2\S;02W70#;W0(_OP$YW0
M#9G1,?\R\#];LP'?TBN=ZBO?SRF=6(D%F[8H'''%G.T=VJ&^I(U=Z4M_Z96=
MN:6^()X^]%M?]:?;K[P<P"E>6QU6P17^]@T^]Q->]Q'>#AU^N_W*P6F?^'>3
M>HE+^\#^]9?_HY+^])^?=)L>;5F?^47?^B_*\JN*M!_NN+CQ)";_\;-?\DF$
MCQ%?T0]]\=/?\,_?1B_[TILO\M]?_BG_\L'?_K$Z2F<A',,AA%8&__X?(.#)
MDX?H7C]_ ! "2+B0X4*%#B-"G-B0XL.*&"]JE)B1XT:+'D."'-F1Y,>2*$^J
M%)F2Y4J3 /0)8B&@! (3-W/BW*FS)\^?/H,"'2JT*-&C1I/_(EVJM"E3G#;+
M(>K7$J;5JEA?9G7I$%$Z&>[\7=5*ENM8LUO/JDW+MNQ:MVW1PITKM^Y;NW'O
MPFS(MZ_?OX #"QY,N'#%?O?@H2M7+IV>=9 ?JUNG!UX]?A -:][,N;/GSZ!#
MBQY-FB\_05!RVC3!8C6"U:U5WXP-=;9KV+=MRV:=F_=NVJ]UU_8]'#CNW[V-
M"P].G+GRYL>+Y[8)A5[FTMBS<\9W1<8[JMK#BQ]/OKSY\^C3JP^M-Z][NB01
MZM.'3]\]?/?RU<.O'_]\A>W!]QY> A9(X($!(C@@2*?1Y-I33D4(X8025DCA
MA18V%=54"W9H8((6>0666!XJ^&&)_R"BJ.*)+)KH8HHMPOAB2QWQ==U&-OYU
M8T0Y^K7CCSH&Z:.0?0$YY)%%$MECDD@NZ62-4.(8)8]3&LGDE4]*J2656UJ9
M)96G02' <#H!MY.9RYWY8)IL-J>F3VBZV6:<=*XIYYUUPFEGGM3-<YV752H9
M:).#8EDE/E]]UZ6@BQ+:J*&/?@EHI(4^Z4\_T.23#S^8:>D/-/KDHP\TX$T:
MD36ACJH//U?VHT\]])123SZ9 3@?JZ;FRBB7O.KJ:*^[^@HIL#/&N&*QR,JH
M[+'+&NMLLAW)Y&"&&%9+[;769HMM4AN"!^VSS7HD8ECAELOLN0+ZD\\[ZY0C
M SGKS,./M_\(\7./.^N84\X3Y)"C3COTY(-6/_S,XPXZYCPQSCCFH/-./?UX
M2[ \Z8 33CC]NG,/B0O1@^\\!H&+[K<DA[O>R2BGK/+*++?<5YC(Q2R=S,XE
M9S/-T=6,\W(Y]\SSS] !_=S0TR%0W8XNM\R==]XF[;3+]ZSSC3;95!T.(+16
ME \@X62C#0G>?/,-"55S4XZ\A/%32CG<4,W--^"HL$TVVSRQSCT-Y0//$W"K
M X@YWH"CQ\8QR6-...98]_3BC -FKLB0ESSRXY)'3OGE'358T[;:=L[YYYZ'
MWE.WDY?N[+@<5ZXZYI'K0P\ZWWBM#=7@M*./M_2HXPW5X[23#ZC_[\A =3;D
MN,-J2*X#3L(WZ2#"ZKJQ9P/..L?/DP[<Z.0W#SGCI%,/-/>HTR\\^*QNNOF6
M;U7I^I2V3^RP%(F5:3X1L_^^I,'F_ZNP^.^O/_S_ZQ\ _4>H,(V).67:DP+U
MQ,"?Y,F!"X1@ Q,XP3=)\((4Q* %,TC!/OTI@/;C7PB#A2BFN4^$)P1A"@DX
M0/CQXQWD(($VOH$.=(1C&X(36$+RT0YP5.T;[[!&1>Z!CKEEHQP0@Y*K5C&/
M>> #&@WIQSS*,;=OK"-K^'@'WXKW#G1X(QQZD >[&@./IJ'P?B-DH0#7F,86
M]H]UZ#-+/SQ&#G!\T7N:@D<[VL&A]/DQ_XYP#.3Y0"*MS8GND*!+)"(7&132
M_5&0!4(=) $Y2/?<:VK;<!@]VA'#Z>D#(?Y E#>RP0UR*$XA_.BAUYX #WVP
M!)0 X <^X#%&$N 08 J9F#J^X8W C<,=\X ']]1!OTH^TIB4;)QZ+G4O<C1&
M'4\ !SKH 2IYH.,)Z:!'IY3)S6YZTS PFYDX=39.GP7MG$3;&3IO5DZAL9.<
M\#2G<JBCN&^B;&F*LJ<^V8.HV#'/(/IH1SBTD<.'A"]VW$!'$ANB#QAZ+1SP
M@*)AZ&$.6U:-H.9 &U]<!2M9W6,>>FB,/ S"*6@@;9\H'<\D5PJ ?M1#'>C(
MYJK>X1AMQH0>Z_](ASILRM)C^C290$V0YNRDR*(R\JA&K9 C@XI,DTBRJ5#]
MJ4GZ\0XJ:L,;=YN%+-?1M6\0DU7]P(<>1GD <]0#EK$4J-? \0Z!7<5UZW '
M3*/Y#; 4TR+]*(4ZQH&.=LRC'3+@%SG2T0Y\H)6I4HWJ@=K(QA6Z<4KZ4(PZ
M2D&55)HCFT*,92G6H0YY2!2-CFTL:$=[QM*JD+2G-6T!47/ "')P@["=DVMC
MBZ?9RK:"M]5@;E^K&P\^-K2,#6Z72IA/U?X6M6H4+G);-8]Q5(UNY&A8.<CA
MC;EMPQOF:,?W\"$UKXW#3WS)1SJX4353'@],^:!'/>KQR8IPUX?2T^[_C?#1
M#H8!\V!BXRLXKMN.SXK6N/]-K8"3N\*>4A(Q[:BA//"1#W>DPWM4R6),VQ$R
M UM8L1=.[$(*252D>CBI'_[P4C.,V*=J&+%,?94>Q@&.<< -;KW<QMRTL0W$
MS>.3:QN>.>0Q*G[4HQVCS(8571G+]-*#'K<#0!;)P4MSO..)_$BO.6(W0PI'
M!!KT2(<Y,JJIO9(CHOZ0QSA(H-!9D/C,&)Y22D<32G<HC+!5"$<YVO$.>(C/
M;AL[Z9KWS.?RA#.>[E1G.MNY3D&_4YZ'#C2A!PUH>NJYSZ/!9],@#>E+S8?!
MH@(5/N;AQ6Q@=QY9B^7KHD>"<3!F:IX>QY,;_T+$JFUC'5#TQSWT@&H2R!D=
M+IY=J=U1S(6X"H;8Q!L &KPO)X/4&]Q0!^$HS6S/H/F1LH9'.<+!#6^ C1MR
M?MA!TGSB9Z-XDD,%L;A#/.YRUT8J].)VB;]"+G5[>Y+]6%<YO%&\;3)DEN78
M+S=(P(UM'( <[\ ;1*+V#6Z @]<,L8_X>@FV;8@MN_<@\KTEVU9O)8;)RPL;
M.>2!*W=[O-M1 K!R1?Z12V&*'ZN"!J>6&V "LWSD SXNR5\.7"D9D$RT?2!O
M:XM;GNO6YSO7><YM"_0W^;;E,H\YTFTDZ9K3_.DSC_JN(C:O=#_D4OR 1CWF
ML=XD_PE3JTH=*/VQJO_Y@ HS5D](Q"[E(WS40Q[T6$5]H*YTF+M<ZG<'>6+Y
MD3N_;EOOW_YXX '/87,;GMR(_]R(!8\YA("GA.[X^^ G_V[&6Q[PE5])LSW#
M]YSJP:9):S Z/G_>A4#C'>88QYL]^^@HZNV:X>C>DZ^3NX4]P<FA7@@_[*R'
M&V]^GW]&M*&'O^A$%[KXQ ?T\97/:)LX^O>@N50]WJ&.*Z1C!BQ@ 12L?X5V
M""+/T ^_^,=/_BME?D:7FL<ZG)D.>8!,O?2XAWIG9=+#+NL>[2#O-R(:17E,
M^PF3H0[@0$-]Q!+6] V#=3#AX W9U!!8E@[E, XP%8'R52_T4$?H@ @2=W[_
M'-@2X99X('AX(D@ABX=Y@Q1*74 3 ? :+& " A   @ %7F!8)EB#E'=Y-VB#
M'9AT>=>#,N=2[D .L5=#ZC 9.E6$ZO .V@022Y<08C5*VL!*N.(/]5!1WZ5V
M]34]9P4D864.V 9>_J!%X: .^$ PZE<.=P, U@ /#<-K_L /[K!E[E /=L>#
M=MB$3G<=-X= 0]=S0K=;??AS?UAT@%B(A.@;1U>'>$AW2!)6[C #/&$3+# #
MK>2#BXAW=ZB(FIB'=<>)EKB)C)B)C;*#Q?(I^B%_L(((\/=1Z_4[)-(LNY<O
M8U9C/)80 35MZU ^ # +?U4.?:5#('$/,#0.>J"+_RZ5+P!'/_.@#N8PA[$T
M#PU36- @#]RS#NU%BM@8+3-A2"/8C2'XC8V$ .B&@W"T9,%!'8+@5N2XCCK(
MCCGXCG!4?H4A%M9 ,/U0C_-2CP>!&8>5'?W@?TYF.-X@A;%4#^WR!+YC4&XF
M@;KX%R[5#OR2D$[8#A%X-^K":>7060<S9Z5 #S0U9PTIC\H4?(K&?,;7?"4I
M?,BWDB:9?"IYCD933R*I&>KB#C* $Y,H#ZTWDSS9DSZY,MEX(M)G,/CB#G06
M5^T@5WO$=9VB+'ICE/2 '_,&#APG:JFG:@U9#^X0#N!0#L)F$?Y0"ND@9U?D
M:_1%78F3$&$F V_C#0RI#_]B5CSSD2JD0A5!"8^9LXT=YHU\"8[D5H)XF3[X
MX 50D'U7H$UV&4OQ1C ,T0^SL"GZ, MV^9BAPG8;MI@2-R^W\TF.1W;QQG;R
M$66,Z7CQ-A]FII:0"9JS4':CJ9B;V9B>>3O\H%67HE62:9N..9NY>9NZB9N^
MV9O R9O"N9O$^9O#:9S%&9S)>9S*B9S.V9S0R9S2N9R)V8[6>8F=&(HV8B]$
M26> X [@J0=720[:)7FF%5"W1X>R-I5EI(:<MC ()Q;WPC?FL&Q%(D450YY9
M$TKU14.K<!@E%3'Z();EH#'<-3:!XS ZA)V?Z(FBB$9[2'2#.*$26J%^:*&"
MB*'_0;= B>B@#/J@/\)#V<<"Y= %]! Q#38#V_=D!T$/5Y!]ZX!DPV8X", "
M5X WCHA]8'$[<W0%4" #ZJ"!H?0.A6D.77!68;4.ALEC8N&B+(  $ 8 PH@.
MVM<%]Z!5!JFB5P /\\(/\N"C,[ .SJ-D*9A],S #-("F,P !,V !-/"F;@H!
M-."F<$H#<DJG<VJG>5JG=_JF>=JG?+JG?RJH<4JH>HJGA8JHA^JGB<JHBQJH
MB@JH@QJIABJIC0JI>JH#@C +'@J*F/A&[B@C^_@I!/.&!%,P^0(PVY8B/I93
MZ_ ]"W$/Y&!P_(<8XE,\61F$@Z6+8+E)SJ0'.N2(":,._^H9+4'85_/P#NU@
M#IUED-PS>]=YEQ!1>'[9E]::>( IK25R:3TVA=P:F?4B2YHBF2T52OE0AKA"
MF?6ACJLB*K12+Z59EVKYK0S!*?GQKBTU"YF"K@E!F9"9</11F0AQ#SJ0  ]@
ML \  0F[L!#0L R;L ZKL!(;L0Q+L1,KL16+L1?[L VKL1#KL1W+L1;[L2(+
MLB,;LAI[LBIKLBQ;L@D  5YPFM$J>#_9&7/T&"R*'= @-=Q@<!?#-S($-N8
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M*I5P(%,:H'?XAFT(!WF ADJYE'&8!Y*:'K 1&F&J"7(PO':BB'< I:WX0=9
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MU <OZ[?-1=W455W6J$_^_$\!]<_[A-T =5W9K=W][,\\(U QI(=R^(9VB$C
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M3U#EP /1/.HX1!0_\QSU4#[MC:-./@59MV%Z_WG(H7H?=@BBB"&2:!U7+ C
M%E@MIN4BC"_*&".-,]I8(XXWZI@CCSOZV".0/]I5#B(1F3@BDD<J62*3)R;9
MY)-.+BDEE-/AHP-HOJ&F99:T<4G:EUJ>%B:86WIYYIAHFIDFFVNZV66;<+H)
M')5U1GGGE'A6B=!Q?$[4IW-^2@3H=((F1.AUAFKWS3M&'II0A'J@,Y0U@5I:
MZ*7/X?/..."D_X,//_CHYU(^R/ESCSM/7(@/HO[T4P]#Y/2DX4+EC#.03/(T
M]50IZ92S3BGTP*-.%4,].NB?R2*[[+'-&OILIJTJZVRTD'8E %XO]M7BMGMQ
MRZ*WX0JF+;CC?CMCM^:*FRZ[Y;:+KKOQJ@7%/(!*RRRTF.J;:+7X]DOMOO<"
MS&_ T^9+,,+27GE;;[GQ]C##$#L<,<436]PPQA*_]EMP"1O\[\$"A_QQP?Y*
M9V>>*>]IIX3?F .//HY:5PHZX)CSCCX:ZNFD/_JH$XXWZ,###S_UH#/...\8
M:%!XX8!3SCWJS=)K.+*6"D _"[EG#CW(]0-/.21X4U,Z]U3X!#D/Q?_,3S_\
M^*.SRBBOO#/=<3^ICR JEBMDD'WS_;??@0,^N. YBD6DS'7/;3?CBSLN-^2*
M4WGEQFK*>7F9<6;^YN:8B\GYYYZ7*3J9I5O>.00)0$"GY*TW'GGCQ<E>F34(
MCN.RTM!$I2$_I;1##CA/O&,>HICUT^LWX* SDC7S'/W$0SBA^H3+45/4SSSI
MJ-K.U?[@ \CMYJQR4-OYY .-/OSH4XHZY+R43SO@<.--..G /#O^^1/'E5>&
M!8;8N!0CP,00,( %!" "#Z/ _RW0?PY<S ,'V)C'Z*^"%KP@!K&BF8IEC(,:
M^Z '0W@Q$(Y0A WC6 93B#_8/<YU>P)/.]#_L9-OA(.&X*CA-[ZQ'W@0A(4@
M.EXZ:(B.>G"D($5K'SF4=I#PD(,<GU*//^CQNU]=+6ON,,<3U$$4% F(/_.
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M.G##./]T!W*H SB  S/MCG,8)SIX SC(@Q$-5CA@R#;EAU-T#3_(PW[@3-O
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M)1+[B<M<BA^^I9/DH9_0@:G4C]" ZQ99L2#E!^BP,BOW:)*F1B++@1SLD.#
MHPJ\H>N>X.;*@:=TC*OF3J9^C=D$)P(GT$RVCAR 2WE*0;_"L$QB:EK$C^[.
MZ@F":6; P;BBSS5*2P4_K4S(CCQ:+1M)R1V&$"SI!!W: 1#<X6;@TC6TC=N\
M[1W,:QWX0;G6I>3<0P7*X3Y*(?,6\*N2T/_=X$TK95--5L\$VV4S&<*:]*$=
M5 #:2$T@%!%XNBRBEDNISL_YVJ4_=BG'O%+31&N1E*,&NZSQ$.7O<$DE)0S
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M0:"#0MG%5):(VSI@JF+3V/8KR:$4' +U9S^9K8W93!:?,(I\B0+^OD1;$/A
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M]C_ACDB $,3NK] CB#'.^Y8'L'C(GMDA"3BE)7]]K0<F!]ME!)W6<A.;#4G
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M20(F7_!'C'2L3HBJLZ@KYFDQ6<HF.YOD.I8VB"G4'*E_+M+E#-"V&'MIL%8
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MM'^(NW 73D[!C="!6"G,\PAT%78=4P##"]2>9&>GS^]I./X43.@I1+ZFT/E
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M.JMNIA6<RYYX<22DDUNX*VL35#4Y/#07,)&HP28Y$2!D(9E1+II1NX'W)P8
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MI_*<%5[-U5&E9KC9E_NE9>Y-PW A._)%@,^)@P_M0$FND9%/H1+'1DVBC]O
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M<0:SOI.QI*NJX^E9G1 X]]47YRE3EID:?O^W15K$S[ZA<>:4>&QCLO!PD%0
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MM4ZDD4;)DHL ZI^J *?"UB=; O+X&%1,ORS!$,UH:F5M]" H2&% DVGI&9J
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MM7_V!-N_N^I?7?-VB_Y$[/@E)/LH #(*W-&D)[VA\/?CZ3][6I/&1N#K8A1
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MP7%!3X[Q0+D#W66Y?Q@DZ%E#!F1A20%G1_]%>V0GG!>X?J$(LJP!1^J>HKN
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MN%^PG2_VZ"3?IX:<XR.OR4XFEOK/TW^#U_H/_ *3*@JZR7FR;Y<!Q,'N/6,
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M!_./%SQ.>V-X]]@?\"[^:[SS?Z:7A$I8\#L_FSSQ9ENQ ]#K*?NX/7O8O75
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M'9,/A2].C&$)!N9LF@F4?:#1V\+=I/4$]72]K<_0L/W1*CTR4)4GF3W+OQ@
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MLKD)1\R53'X]O__XU '6Z%.&GK^"R ^*Z'-H@@6:C_R\$W*PV;J"?*'=[\N
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MT^L^@I/3TTV?#5D><E;M7Z;6P 9YJ(>;2,NUM-)6H9!LR@T2;S !/W)YK.[
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MW@6K]6U;3]%GJZ0H=:<V&SCYGES%;WSYU=!VYG*U%#OMMM?B0LP J@"!N<(
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MZH6HR8$4M87P&<,:8XABN#RM$>."FH21C=I )X+^@&>]H567-K_!E*OZ0&"
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M::?]$;^NA;@D*.KN)NJNI44T=L)J,*M+^ (C0WUCT+OX1GMFZ>T\CTF<"VN
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MJV9\T4&&0CO%0E.W@^5B&FW6M$G>>/<H%0-S8M_9O&O-S77"?=+VB^&/Q5T
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M:Z@;%#PA3H(E^QB)TT<_IW/"YVV?^E17^SYWM.3M>F?*XF2;V1Q]2IUSJ1B
MC-P164"*&IT"'0@V7<VXQ-#O6W:>@M^2*Z]/?G7[R]IOJ;W]<;3$^0R."O0B
MK(\!$*_[8>/]DI\/$/IB[GY%2+PN)5E6GG5;[%01\BG[-"!ANX]G26<]2XEU
MK_MYFP4MBP%X%DB1XXDJ:67DQ)SNC"EYKP8/AX>75B_+W1;'7FV\[58^ALJ
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MC"4)$_\P7<!3S&YF"K<\KGV"],;E[4U'<^5#<H57D_DB# .,90+_(T-F#D0
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M][*,-XRS!)RUU+(.<%3R85[V02T0HP@-#,ADTVR+1%0BU4I_QKKJ!_'(:MS
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M@?5K4\6X^X)Q4BU.!'14PTY6B);DEMQ4^T)-3_^'VY>'9[<,^%\@JW/I1QB
M1UCRN@BRXPJJ"]O2L_57BQE%_LDOF^QUUN\&+OB':V/U -(&]J8OLHP(777"
M\W-<ZSS46D\L&"R]+7==,F3MJN"WJ *<^KRN 1>UGE:,P6>U28)?R^ [<[!>
M*4I'L,O)]56Y;/.-#_8A\KNG4R)FOU+6B)56=9];6 FM1A^4&F,N1AZ=9F<
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MQS;EF)Y7:Y_"">H=LK[+G*22^+&D$/;L(^CSTT1+Q],]+<Q_<<'C2J,)G38
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MZ<8M#*5%/3N(DD+4M4[];B2WC\O]*/J2T/#7QLY)&0.U-AUIY[IS4"9==88
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M]@%7\GH+=&HUA@A7?>V_:PT9D=73%0J?C%N^]7-,H&YM&X9FU K3Q?SQ,)H
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M;4 [GU77/]-:HL"CVLS.=B\6P,HP0.$? $$&R C2A ,DF;6BL E58[T>NZ=
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M3 C0)-LQ0'P+HE[<GV/Y>3F?I$EY)_7E:/LI%"P(K?V:?WPM\^I#W[\>[J;
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M+#W>S_;@S=.5<4UP$" TTDK7JR[K5?J=;F;EV#6'[689YRJ9VZ0'!@?]@I]
M^M"*4"+4@Z2K\02HR,\O9Y-+;@OENIEV;+9S;)0D/*[RI_OMTF8L :6(IOB9
MGL- 8/W>35RD%_5ZD+>+Y.2[VA71-*-S8Z_>(GZ"]1_#4^!$>XS0SY](7X!_
M-C"_HF^KRTQ#MU PRSWA(%S^685I ^AQ&JJ,A>8.0%N>H6,T% W0YG)?L!FQ
M[@ZZW"4*=\*B)0Z<B;-V-$(=1NC1.0,(*L\AW%1(^I(6+R);W.MTNZ4?JT:&
MM'2TZ8\^J5&VWUM[(XN0U6K*,RJ$EE6Q9'^Z,L<>^'2TQ#W?-]PO42(]YGV5
M+MYG)/<WR' UH[I' *ALJN/J/[W=P[=<D7KUG0M;"O]/Q\O%N;&JYLX^HOJW
M49] %JB+5,O];M54=6+;J\(MR,'1"42%GF)X:&#42:E'[VSSSVA<_:X6&@C^
M=0Y2^@36C"Z-6^LB1LVNJGH,CY/?9@&?'<,H/.9_.82[U8_*N)V&^+2JQ64%
ML9,>SWHW>8=*05*:T;RUEMG TX8[":86M,8+#[EO4XO77=B5M!8,J]@%6%8T
M8 0&Z!4:7S+%6CI<6$#53+^(=7_ZN\'/\VF"J9/F W:>Z.LB"[IM6S0.6BJ.
M&6H8H#)8!.QZW[:7X< -FYLI5[2YYG\5J>;:5N";#^2(=IL<"#:LS CV53\K
M920 LOYOO&";(11O=$>K+0,T:J-"DU#<@V(76,E3#%!B=#$#5/0%OJ<#&WZ$
MID9[HD>5X>V-N/IO,'H2_XXE.8 !2K @H/>VX31!P4 7!&9UDP&2?=?( &TO
MX_9.G2)_WZV%4X9EZ+@;#%#_6-E3IZ@-3H6,ZE8!:R/0/W>9MMTO1?N94</=
M61-($;'4DW@+?NN16HN"I:^.X>^\E'^L^0>P<=O(JI3?_*FF''WO)*NN/FQA
MO4D%. 5=I9!@,Q;337!N>%9WON<3<K;[^O%D;;_7;4F<M:$FSG!FFB5:60:C
MR[777&:P_( *H17W&7A\H21VSER6WY+M\85(?^Y,!>E<P\D7*$5Z*P-4FA()
M=?4>#S/MU3?+^WG_[*K]5Z,@/]E^/7/Y--8$V_=SB8,,T L0^IG3,9+-!T+/
MD9^(M-V*)3+Y%6+M-=1/]NY-W07  G46R40[= ;U8YH3>?,Q0=EXZC?E6OF'
MM3GSP"3Y9WS@[S+.@X$C8_"*G#@X87W59\9;F#NYG-B:F&8*K1L0C9,9\$*?
MPA3YKV81(>12(*R Z@"T%8YZ[#T:^BV90)_7O,+Q4TK.ITU',F ^&.KQA,D
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MYI4)?+=#/0OKR*5+/J/DT.&[UZ"?61IU>Y")=]:;A4Q6U'^6E?[6ZLQ\>M;
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M4[Q;:27SRCL_AVK=["[X4!%?N;F*(&A8<\Z)+DOO\MU%E(DNC7I0UINO6=]
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MC.AU%-*H)$XZQ+JDTO!PM5F_(_*MR#3O(.\/=]OFC9U,TF]A:[8;Q$2-GU]
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M.UK[*>%6I_(#L+3_ZV'BN7JEU !*?F/2SQ:93N$$KF<V9ER)59' (848Q4_
MP?ZE@$EL*9&>XL/#!$B?68&2ES^B-'?*7-GRL(I@P14F8''GY] CM?9C[^/F
MQ/ZM;6]V/O@"C1'S57SAD?*RBH1.@^8?@MK9+E^6'K&YA$Z,)R!X:YWRNCZ
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M-J@*08C132BSD0_%#T]^J^'J,.7@%][0EQBE<+82(G'"J3\H?(G^""'5TTQ
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M F3F1MA<5X.B-G>5$(D("JM\;A]F*072#\*.)&FIP)\*IR>7JNUR87<N&5N
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MYPP5'\Y&S C]T&2(?57^:-E(;#P2WHHNFWE#DB4+#I.9G"S[9$K>_%J^Z^+
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M!N2, 5V5EU"R'I2B%"MH ./RV$;(MK&&B8:-_S5C^: V9;\G>RMZH"XD66"
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M<9TUND!@,Z8_M!7/G(J%G.".L#OQU5DI:M(#I7K&V@<E;7HUV?4NA^LUH2:
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M@\R#W0K791Q4 7-Y!EF??==2?D6@0DLF2$^HBO\(&]9Y;0W2*T@61,RZQU:
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M@WNREF-SBC[Q^T3SYD$R*[Z]O2AVEXBRMS57GE_'GW#Q=)NIF<HIYT$Z&84
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M8&Z#)=#N /CF2%&F8W,#M76H5R_@W=0AZ0#IHG'M.>C72)(_$=[M"$8&+T7
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M]9+[!A&FYD+V)]K_0W.4GH+))RXL+O+'8MC/B#^>QNF+N]K4:!Z!SI:H7;L
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MR&T,F]R,7#3>^U;STS,O#POO1KRY?#[,XGSX*:F8M7OXV8.A:K3LYW"I ;6
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M*R&$<XURZ215LMVFF7ISKL6G*\I6HC3I@0UE4/P>,/=[BCLA=SZ_10\CT&+
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M]W@S4P:$)QU;B^2O/O5+B>$\R>U2XD-F@%288<UY"H@%ZO37@W ;$PS0>]&
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MB!>OC?U,??RL*JG;@@6Q_-EW5I<"(QB1R@C NCSAZ.H\1SOEPPZ/%\R@4E[
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M^%"EH+-^<N.>T^IF?BG+G@#* 40*5OTU2-"GBFQAZ1!RX>\6?.*2Q.G ZHZ
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M$H&^6&E(B[4M[S>RYX3&3]?,$QFW];(#W#(&'Y2->/>N<1W%L#.+\IKQS)3
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M-;\815"<AT3;4? ,4+SFB[>M(QL5'9-8F(_FT[6A#U'[8K_FI9U8>O&<GYW
M096L(-@[$)*0'5<)]K'#<_W)T3F253I7'J,HEX>&C$R/(7L/+&9-!L"[-W*]
M@]#O'T/,R+/$7-)N#7E@3J0%:382>DX37_MX5:5#?38G_N.#0#LI<\!I#%KU
M^S=M4QUU'?,GB[/:OU;>K4(ZP<Z>].RV7I8.%%DWN_Y26WXX1?CE_:-]&1JB
MB^C.C0EC_74FC]FO/+H-['/O:N/SR/E65@)U/&T37A?]/>A\9=G"^M<3V*-A
MD'* @WJ,T-.%G%CJ,#E$C$9)+620(GF/_R*JI75W@S4?S&BG<)X,\5N'9F%$
M =PSX!UDK?DEN9J4,H;;W&GEGH&=Y80;/XU8_%YM[$\B'C[\_>'#"4ZA_2K!
M$<!]N";U)*$'^]#)4_2@QYY^3$UWFI7\K=AW4SWIO>\/'\5D(2=GY]%Q#! <
M.NEVFFQ$:*?;7,%G5*S79L7)#"\&P6X<\8N'ZYSMXD,\G$(B@G18-C?>PSFO
M4R^3EWTHSEZ$VGKL ,<*WW+QS<HI*UB%W,<Y!=K4/:&M9$"%MO W7PZA92%D
MR57@&&?I^O0.XN0 +=M-#7F@+I^2M7GMMBFWDO.)7PE:W],NV"[VK)?@RC0G
MO/ ]T0B^'X0#/.]SFB8L*IV$-V\K^(@U:"H( [%+<M(/O;;*Z-RU>" < #%
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M">@=*'!<(X8!\EPUF:,7E'B9.<WLHPA/=( _8EV4TY/?W%M93VG %%.O4HX
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M*YHE7E*<6"3;$#$K<[0"8AB!Y\$+8.QLK*#7._GS)XKSW2\IZ[QXJ,K_/70
M50A"7:2? ,KF4+PA%@C7O;3RDN?5CB'OJIX>B^N5K=<*E%8PN=TF,N^<.]]R
M@#X(Y46J?'6X 9A?KVEJKN+Q\2YX*AW2U+3V]5F&DL"B?A:5C&H[J:_O"9/
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MTM&],J_68;W8UI($'ZCW5$Y6G3*)0YI"*X^ 5NCLFW9VF9VIKH/W"ZC[O/;
M;O"\9;J.+(QV0,*DY.L3/=FK[\3%O+@:VC:5#:2B <%GO-^@=*XIB@,0UP81
MUC^ X"-.CS! -TF.+XI_3#;='5)ZW_#TRAD*KQ2/B7[<)#8$=0L:E2\*"!*Y
MVK=WC:KDU^.;5 N7[SV&ALZLC<H^Y[62"7 C;A-V?&E5@6JT0JS/ 'MM">]D
M:FR3&==9>Z&)><=G]F[C?@-EJ-LP[LWWI70Q0-$LG=7(:R[\T,<"\3M1W2+M
MA&%.,#/J96(G9W%CJT$41^0,E!@_;K^<AA#P]GB1.Z,E8VY5]?.M\>>[@B<L
M(81$&BM0PJ0V.X![C@&*U)<>5>,*+=,_\EU?I.G+S9'H-*'=_L'BV_QQ,KZ!
MO7I*^EO(T1"T!7$[0LTBK#L7&B?/? -%[,&K21%62YTW_)?2?]Z,->C1TNKW
M I9I35@<#C(9W)&[V F+=!0#.$I^3#J,),_5D5QLC4:[JD=DPDX6"1\_SEER
M0*'+QL5-.A&TM0X<1JVRDIZ/$<8ZL5&P TV&?GANL%'SB!I-0O);N=#$D0SW
M ER5-[L Q G*26-C>E$_?4Q?D8B-FL+)M'VZ: Y)0$K#*]OECYT,?A+]C?L=
MNY-2A^3.FM>\(J#Q@AQ*[$]_ _01LFOP%.^P[A;51#S=X<B:D-F*CZ+XNVBA
MU>^#'#!1UBS,!UY <7O5%<\[\8[.B<))F%^HS;%.4"S5;590&HH+)T:PG>$S
MN[VIFQ)V";SLML+-!#$+""5@HH="!LB=).D A,68S8 7[?7KJ8X GS'VH=+Q
MYOJ$EY,?GTF'WITG[N.5$%[Y0GI'UJ*]4+M*M+0:"4+%'<HO3\.2$1N?[M1F
M7'AEIEQU?/9$?LVWX!8^6A4#Y UG^8X5:@*_\<KG' ZD24[NSII%KLD+7<GN
M.WSYD #X+MA(:]D.4F%-%4!U0]CH\K94,.U-M=EB0\JFQ^3=BM*S9AE."VR!
MV4&]O8?GE9_Q#F& 4ZBN 4EWU!ZJ\O-6'UR<X[#WF.U3T4%GE<Z2(^GUH.1/
M>7E(]9V])"ZR/\!%M"1S?8%Z\K*%Y [])"@]=*3EC^XX[OCX2W=WIM7K#$B)
MT&1WG]%>8-W0[,BQV3W[DMVSWVK$!P;5#P;Q9IT[&<!A,^'RO> B>YL$)9$>
M+H_%Q:/X]<4\](]%X^.ZHL.(C\S\$*,'/9][F5X2SM;,EU(]Y:( <E+]S,,-
M"L^D\--GUG%8X'A1)LD9_Y3P->3Y6M^5JK=U]5DM0S*YK5,3_"+K.K?9Q[>V
M]C4ITCD**+H(&V"'U-&)JM;HVMD20^]9JLLYE!J[ZN.:UB[E(>ENI=3YBDV
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M@?!0W_='31N=P*[6\B,*H:#\J";K5A2$SH.X0^QYL(846LZVG9QPSVUW-/>
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M.4*6YDL\F#\=6/A\^4YXR[NM)^8<IT>+'RYDB47JAD1'S+,X,BX?70=)1W#
M93Y6(Y1GH9\I@Q]5VJ@W44I%7A;=KK_N9FW(@GN(OZH8_(^(J=W@O4S >Q7A
MLOQ% RSFEV^.&_$JNF)..,N)DCG).U>X<CF8_MF.&\^]NG^^T(=,H5=AKT/%
M8:(_W%RL1L_'J]R[\"7?]].'KL7D.]F5%N,0/0^3!_06&H2XBDZ 2^/3^=Y\
M49\?K3?6GLH2TUQ3K$]]IR)'Z_Y$BV39X=JYNO+T_:AYR603=2=;>(LRB_P3
M4<,5Q3DWKRX.Q<S4Q] >&V35$Z0[Y[%U97:5E:5\CP_)QPBP4=A,^:&]EC19
MEARI^%$/("=]3)G Q\EE:CCFZR,&_S.6(DQ3Z%0?Q <F4(?.8.QU<7U7"N.^
M-/+S>&,L_Y$!_]O9UJT<:1I(:!D0O8<EC!9*R"Y=$S&1+OF](\C-&1]WUC=S
MJN5:0[Q:;_U\N]<)Y>M5<%TUC; <BRZ[P9C%UH;WSJ6C:T ]:_$=PHD^)(<$
M_*IV]Y:(=?#Q]@?UVNS <HONZV7W,M:W%-$+VJ*HVHAW62S;F226Y9_ZK*S+
MR4SPZ]T"^;:M8%-P,I;H>N(;FJ#7<SK?(LORWLK+YR%<&A)8*R9P4X&;)CK3
MHR# AI?1 E89<0WS6.*EM<F]!)]5%9)A)^, !1D4K)Z87CT]Z_;'V$L12ZT[
M2AD\_:&K4 O$K+R,"3M+AX(F86#WL0"%B7H(O\O,YQD;;;4U'8?G&<72\=>T
MY%I(8W;<[R'$DY?\(-?!*14QN?X!=@#7^3LV&1".7XZ+>BOJ&+]CR"ZWX^_$
M%ZV"6&&]RBN[G)<H=&-L;*NTT2UN)>K$DB--YAOB"U%E7KF V&)^\/$'[Z[>
M+!O%?JKU#Y[ SXZ+MC2Q1PS>,*HG3)+\8 SI!YDL$3P-RX\^$V F5/2"]_K#
MK[;-&=:*RP/S;'019)>=40 >R<EXVZ':1E)?T*V9]6MYT/XRV]PQ8L\KH\,G
M%+\!\@]?OT,<0':)!U9O0>Y"P6&&!T6O?!EX/ACXBU.[J:AGN4N<5)1.565)
MF0?6'\7K+R]$?P;!*Z!L,W@)+R7E;PE^$S657MW011ZALUACW$5$)U2*I0C8
M."8@2@,1*C1$J2Z-'4GGM*NX0[4-GFIK1V;<]2'JL*USKZB&!DNNIE>KA;1H
MTI1R;I5S,$SRL2]<[EV8YUU=D+;&YTIR%UO;9\7N)!ZG+3+>0%]"^H<3D?6-
MSTC<O;K;_,6?E[-G%0VT;)5?2'<-@K\HH@/GL:4W (8!!/?2^7PI51PQ,B?$
MLGK<9P,@YS]MS1BN7F6\5W]4$I6YH9,6XQ$];R-OD/\+2\XE!=91X8PQ2!TH
MN8T[7+>ZS"^I9QV6K#YT;E]] '?AMQ4E#:W0UM$E:#N$Z!ITUUV8@J9JPN)L
MJ%^.@/;ZM5Q>(VO;JAT@OGVFV#O"9=@U>^8%]^7CE TFP#6$>(\XG@*]5W2
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MFM+:#:V7[$3=0X-TJ)C:@\^>NOG735O,V/&7:=<_C^<3^AAB>U)UQY^>TW'
M%RL!\5D#K(/"Y/K>P#2M7WX:D36TU'8J:XN-.2$8H\V[G ^0-/E9:F+! &!-
MA/O8NO;^!F\FP)N6!_(@ZX%$JUY?6V]L@;P9>A5C)FWRV;$1'D3/90 T4R(H
M'4?2[+'EDGZQ*>@0<3QI9*6XK2E?YL13FYS;B@+2<J%Y2@(+'C@4RY'R05DP
MIU"6RN%!0=/Q9(N.3ZP0WT1OM2(U2N6^(,/ST9Y+. ]B-(@ /48I8$TFE.:%
M@[4)DRA9U\>J(;4-B>P>W9_B!@Y:+?[$8'[X<K@P>$>?#5 AC"\L?8GOD(65
MK+E\T&@S"PLPR1$;-G[P).#6<HW=WGV5BP#(;,F=I?M[:B@<7KLWJ"TZ1.!>
MI/?Y&G 5B?*GMI$3PI)-@"U_2[/')8%(0GF(*MF6P;O[D.,52;+3*YSD0R@(
MEP2+AEW0^"GX(^]AX-> GR$+68EJH0.$3LP'".60YHHF/FBZ%!]8MZ<A&[7O
MRDQ$OO(;BXY;N3H>)7I@K8 9'N V-PG8.4:VAPB&(6/=>=HH44^7[&&1 ?O&
MQ\J>V&D;O9SI5G+2C6.;'GJ@3R@(A;Z6I,E&5%/V@5 0]OJUV,8[(K M(_.K
M'4IY9LE&_5E!I:+2>SJ<SFO)Z.^I-05B+Z\B1)%=+&9598A.0O-QW_M&-&[?
MZIZL_?6VA LDZI$QZR1%D&MQ'$,2;34IRGH#Z!2()'<_>N8J_^I)ADQ=Q<RI
M*L5SM68JC^[E7K"8[]SSW7!O6C[ R(=X]8\A\7D=W+HO76] B9CZBW#OU\%Z
MN5^'?G9Q2ZE TA&&R*Z+R)N721EU*BL1Q#FG7$U)2LJ.C)_2J-+!D];K5CY)
MWP;69( "P;?<%Z$89+U*4EL8?FUJT84XW'6H++5W.C!-9TZH+U"W1>G6F7N5
M51_8'6/[$(>174807#Y:3 .A_0-='[[JH/&S+<BGZOCL ZX2Z?62JZ15T3LX
MA!C;^MSJ8?P02_D-R>>)[EE[LE#SJ/2?ZJMK8<.:^^(>35SY,ANT%9,8$MJZ
MA7G0H4,3I*12%6%Z..2J)7=O@*W]&&*_ZU+33F(AO5BI[!RA3U75\INLUSN%
M-,=-$9;,Q-/3C7RH%VD'/UCVN%S/Z2N2:\YV\<6?+:S1">D^6;'2&1NC+WN[
M#R&V#'Z)764"I(_@NUC!-J1?I=Y=(_[P:SE/JO8G*S1D']VVZI39.RJU.!L#
M>1XTR03FJP?ZYN+D!4GF^#NMC\Q'>U=PB3Y: C7#%ZR6Z4>A;T"K^'DZUR*#
M[VLQ3)<_<X<*2^$9_R(3*B%YAON-0>@.U7$KB3C3/2VY,DCDMVYHN=V(ZC&1
MJG,A9][[X-;EOR&0#;DGN[EP%9N]QL,8CMQ>A;!6 ZNE/PFX,+_6DP^]-^[S
MX)3U#5TWKG[\_>_ETH1J .D]QZ\6>'N.G1+YGB00+CSIDG2!1^&7R!V37QBS
MIR5JOA4IXB(G*V-CQ$T!P!  RO^UVT)_GXDYDD);W$UX0@Z6PWH8+>9,X/'Q
MR&8P+2-DF"K8PS+=K[,NXO**<7]_TH@XCNR280(+B39, *K-\N-!T-J&T?],
MR&3]ZU%Q3?PIVB&&ZU>6+WA #*??K89LW@RCF_A!UOE&(2M@EH5[,N*X(70U
M ND7Q'U7&C+M4("<N8196K2YT'*]X+G6D*?ODTB1("E%XH%V=PU*2-G$CT^0
MS8J'>#*:DL?(3MVT-X=[?OA+H"',HQ!C)J6PSF-L)M?%8FH8P;+JUF-F 4$<
M)X;JM09DCAK;B%U6LVT^?O5/K/.)@M:13G&%.!Y.80L>!:*9K##L0&X*$"?C
MXA(PY],8)[BHOM CZX)R;>QS99QX]KTDAN_0?PV%HO'IA3W-37'X2U]/CR@]
M!MO)N7 O72A1NB%Z_)*YU"5SODIC]AA OO-BQ6/VE$-_&9P*PF9 '(]"6AR(
M4QBFD,%C?$,J(""@*;IHFD>OH"E'(#C0.&1&/)3RK;PDYBC<\IEN5O&/_)3]
M6:MJ+Y1/VUG[7/GCL=1:JSC-"?$9*@@)!,W8D-$UQ*;8GV'O]/"SZ.<\&$^'
M9A>_  G"XH52GDM/5Q8\)LA]1L*?>XFV^X;$4BZ/)%Z^GR9L62P^M.3.040D
M1QTL*Z-$G:O#/DBU#A-O27Z(NG!E,6<Y[0/W6V2-RLJ$%U67)DM<2Y2?/K3U
M2Z?5?/SIE4]*V3B+=)4_3#ES% :'(671.7^Z_>7^TRLH(%C?K5_JVOW#[Z5*
M) !"D14'ZJWC>BQ+_'4H?E0'QBAVWXJ1"*XYS!_)Z?;C,%>Q+%?PS?%O-_6/
M8 _JYA204.=5=_J]'2\\9W/@U#+F,1*.3@_=38H3*,.-<:5ZDC_,) S>E3[E
M<T+ UG7C8XR)QFYF F*0%2W6YG71(=UE[#_"QQU";_@ AJY2X]9Z.([,@8*-
M?.KX?^S[\R#A'^I/ON<_+:FX%F6CFIS%Q0)VL@((.1_L<ER,>"I4+),%ED"E
M@]7, V^60/4!2#%(DV,/<@9)_D!_NM*FC+,I##U+B2Y?-M0L<6AQ\;LYOBA4
M9B$<]Z@E#3P,&6M:,:/J."'>L6)R0_Q#]1)4K[9?;KSS0Z_+V3:Q8@$'R8#H
MV=2<HJAM3/DFEHT",>_(N?B19OQT:NY-7]'/0\##Y!-*-2K9$>^/K;F%_4O1
MMC@-AYB96P_.A9#%4YF )1\#M?QKD/XJ0,5V6K=7VX,)^)\V8 *C-W;>@_RI
M%B^P&_R7_O,&N.K?W0#'KM#%,FF'B)6O6VV<JM@8@U:=D/Q\<LK_I7O@8G?9
MM4P5MCBO@3L_CIARG[^_NX)O$ F$&.PB@?MN Y@/5F>;PGC_8WI>7^*:Y16?
M7.UG"HX7M(5.X&+?^X]6/ 8-0B>;R&#2\,H(*;XO<G,Z52\N3%I3Z*%'[;=#
MV=<S^R44[KS@.(0+ ^<M7Q:S8_?PT9?N/Y81O%3TJNP_GND<UGT1'B!3DSXI
M/? T<IZE_I11<C,%3 !G(/8%\7QW' YX<D,K&GWYGDE?KNZ;EYX%(@TH^TO8
MJTQ@"M0#K@V_NZ6^UZPQ12;=.S? ;,1.)R=(]*C:XVL2TB=^<D4ZSOSK%SK_
M^8N=*KN'*TWWW^$.L],R/@28M ;RH5_'0R,8/0[K?<0H\W#7PR\;[:*M3RMN
M7OSE..V5SP0NA;QS)%7N&O8"(A. 53&D&/8FGTI25.??Q_RS#^O^8[ !@ ?
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M9&V>\W)H=Y$!->E-314Y<0;_T?MJ\+,I1P&A:.LGDNC,/W3.BWRAC>1=^-K
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M@W%(_N7@)5%K1:-[B'Y2-J]2''M:*$O=?7?+UCIH)F#K?CXN8B>^>)*/R=!
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MST97AADVEL[_?*.G/[=$I'C]XQ:,7/_H>&;:"[N0-019WH+23^PM J^)(WO
M;U1F[MN;PYT^_*NG0>(D[&H5#BP%MZ:XA.)MN0>#Q6>?YLP,*]=X'AC0OLF0
M#XY#]G>\?IQID&E2ST:)H@*LZ:G 98@<O09YO7-R?4'S4&%_;1M#YQL?U$><
MGGKMO[Z7:_K>N_>W7!X/*\%98?>>5LIE(KC;.:P\&7Y<(PN_EFSU@17$?._G
M"61\$+I\5G=%3KJ XV6%HH*\.2(/V74!SDV]"EO&-U3GK60]<U^:/6@3(6&M
MYF[U^8WS23VIUTJX%\9)4-OYF5XP&Q,(0B<@P9O(9&Q3^S?L<PK8>DS]:X?_
M+PWO6JN/N&,117Y'8QRILT7WV>@YK(E+&YD1AH410XVC%!+&??WPJE==-D7_
MP>K="PD>UQ;BBL\A.B9ZYUZ&]V'CYR1-N+\[#W3=K[$%34WYD?/XKRGR:&1/
MJJY-]:^^^>+/HJD4&0:?/<D FCA7:]OWZ)T!KNOY+.P&>;JW:C7SV.FW?!Z)
M[Q<X%*6ZEJ$)<\0 3%(85-8/*L50H)VJU]MY:S"V]M1UKN_;F3@WLY/W([AP
MG#?/6[J;E*Z!*>JZ[94S<(.&#]5/O&O'JAT,$P1.U@XVN]QZ#R*X0(BGASG\
M$"#*B1<VY4IG=C)37.+W56:OZ@1L> @49- ^<*]^ZB4YS[P+/:9V:Z9':;U5
MN#+K9+IBC4I,)<O Q^Q!RH")5S2G+SK3FS6-/*E':;)CFB8S>/TMU>C+]8MW
M3M;HQ+GU:_#\.*%$D-U';V&9AI>(J9WPE2FB^X^>4Z0]A7FIQY]='X7'A\F&
M/G&T^T-+\I8'(GP88XOI@A#/!DVNX=O1W9A[D 9D&LVIU!U6-R^?A+D1I8E1
MOP:3OOFD+:3;[U2 4H(,Q]&K6J]TV'XI,@&N3;@(,G9.XG@ZA]VKB#8S_\B1
M&URNOSI\,]?FBD(SS8:;W!OHOJP-/ L_NMNJ!/$:8?C12'2"%W..4_1D0/C#
M1O6&]T1=^.2O1,0#VG?6!S7";/D'J;?@E^^0)/+\ QD*[5H<H:(6.+<SW'FY
M_*CRB65ZNMODDLG^C]=&?YJ\>^8W8:<6LL?W6\J5:>/'1+>(BUF[#3N4L-[(
MZ8MD!+W(1)R2V@FM/Y@J/M>;.HA1OQD8QF\>A6TX<3NMZDS"QC>M+NZE00R2
MGLP$_*8@/G2?>6@O4MC-U@??'CF['K3'^>T[@?/K25&7$V0 ^@)_/<+-GXPF
M2-)$;<G&E.3Y*&RR">1C7^D5H_PGV5E! 3Z!'WZ^BO"^?DOZHI]'BIX^)^B/
M6.CP6C^6E^)#KJ#@@XB...]6/P0_Q;(B84PSP#(O(-R__$QQO(&GK/;)J +4
MFQB39GHB@IUF2F]#0&#EA,4!6% QD1Q;:1V-O]2:>$KV0W67;H==#MM]QO?@
M?N,]R(L.^[R+"LN=_>X03S;FWLET&A!.9X]P("D=XO/B7C K6#3>@,8C!9&X
M2F2=WLK7 #QDZM?MPWLO$5?3B[*J;^3RR^JN1O-J#1T?2]TK>3/M*QKP 41#
MJ?;$JGGL7806Q7FTKTAHS ,[^J(DY:3G0^7UM*I7BO<)"AS3,9#,H&DH?A6S
M4L4R%V(0^8!O43Q;6!&)]9QM>[#VXATNK1."2YN;F.4!'"8C9]ZV!\)'>2<3
MN>Q\6\\P]GU(ZONH+<PW50;_4)F+7\M:W);JY?5 M%O3EP/ \]!;,0M;2U L
MDF@[6(2<4L4+U!X-1X*Z;?9FWZHP0+.\3N&_4Y;M?V8%S7]T@<O]3Q>XAD$L
M?MN+W;SON]O9-\F,5L[2FMZ\QL8BR4:]O4JG K"S^BL0] TJAL%S.%1P>"4\
M2$E4+9F\?+3YO.5.:L;6)F:5-1W.)2)ZM?WI0#D,=?G<"461]/=*1@H<%!'4
M#3)J\A'9Z@/6"Y5PF-C3LSV$O)9S2J^@N/.@4A;WW&6CI$TFL!QSF=YVS0KK
M,R=CE"9ND521;6N[)0B-A1*#VND-<WUKZ8<YEPX[-;AU6>GWUFYAEJH(CMU5
MFFDF7.-&DA7G%9H^/5^LCQ!"7"[DV]MIS+;Y#FY.%6"M0X^F2)6 5?7-'B3^
MK)8OUDLI6EH\[<0U7%]W+'K3_5'SLJG\49:H;;>DC#)XGY&>6B]<*9GR:R[
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M<(&!&J[92Z;#/Y7$]3[-*(T7C3VBU-M*FQH0 >?%^1(Y6(Q MR)/"B "=:,
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MJ@T-L%:?W!0'"M"J[U,X0,A!&=GDFOVU[KX"D5\U/.;?I"@'KV_6VS<DJ<5
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ME1GMV?.(8TP;<X#S(*Z8 Q#R,=11#A"#_OT%J$KXL_YE*7$ VGG,BL0BD;F
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MC&%37$5!$1"/U5->=/RSINP$JH;.XS;=:1_T;Q1O31SK))]GH+&)]QEEW*1
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M@TB#F@BC&%T[HS3GM>+2?UR1'[,E ($%6Y?B2%X\B!+*'*$YP+M(F&CD</Q
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MKMGR#Q21WZ$;2+VZZ?F[6IV]ZB8_!]4WBZ H4*#- E+A<&(%)';_.[Q3-S*
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MDDZ+U%#7,<*+(;Y*<D=J,K?&8[1(RGX@DM(%^3'^Z*%K]P.4E/OJR-,YHU&
M')JL=EBF:'LVT<@4K+PB@\2[)XW[M>^/$,LTF>Z93XJ?1D<SSQ!$[(5&@G>S
M 3H8.?I3Q5F91]]+U6.GSWI)[6J';-PPBBA$SQB\Z")FI_L86?.YL[80(UDR
MZ<L,)U ^^^=_?U=@#C<+54TB#P7E<$2?N')1A:Y*&H<LRT1B,Q<VQ2&(@G2#
MU,D_VU\P54A<:Y \5AC:4S]X%0-]6E-3#U@VZ+N @5T=PYTJ,4 / PH1C,^
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M2*DN=V$(CF70<T \*O)GZ HO*?UPU4MIF=V"N$MQ>]JG:/*C4-S"K_;#V/L
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M%3V3#>*\-.9%.<#O;Z0.\4M)V*/IJ$+!#DC&]-,%0#SR!V!@OV=Z6+1(U ]
M0X<$'SH<&!$BQ8D1+S[,*)%B18P=-S:\Z*\?J3Q0="3Z2#!9.BA8$LVR")+F
M3)LK<6JLF9,CQ6>DT.D0)!.BM55ZK@B:1ZJ+%Y4]>8K<J?/_)M6H'JUFY6@T
MSPP:B0;^?,*B7!=X\MRM(R?C2B)^1+5*K0HU+E:Z=^5>W?C,TY,97N "^$F.
MK#ER,X;.S9N-<>.0=O/6?3QY*E[(ERDKQEPYLN7,>CEOUOQ9<FC2GDVG'DV3
M)% H7N[U@U:*#F*!JD&OUIV;=[]^I?1 0=SJ+3_?@3LG%\V[].[F#ONMZC0.
M'(MPX\*%\_;-VP%P?\'B?CX>M?/R &;G*==67SY2>LQY081\.7GEI^^+OQO=
MDV'8L_+)QQ-TXFN%*/SJ.\^^!/-KR#A]I"N'!1WNF:4?"W]SR2E^GJ%'CW+6
M68C!$1$L4;^!C,NGE#E8F*$,?2Q$_P\X<ZX@(Y]^BNO'1/,:9$Y!CGQKCQ0)
M:1BJ'WV2T>.; ZX#ASIPN-FNQ2]:(5&_'A?\#$6# ($" ?9TG,4??8!BP8MZ
M9KFGE')F@&E''['\,<Z&=.2'S#S&06R6MT@Z2#A!6M'G-T#8!"S+*ZWD$2)^
M!"RGG#/WQ%%,B*!YY\]$ B0%BBB^F&521=\\U#Q&^WL-37Y0G?1(H!Z=SSCC
M_*$O5#D3A9,@@X)+BKA(8YVM"G# R>Y);@[P!H%'#9QUSEI%]><92V<(45 8
M+YS(GV2Z1 S35?K["T90$54V09)*40>*I!YYU4(QG0WNKT Y;$<XIYYKS+%P
M\0577UO%[?\W7W[_%17@?04NF%9_"3XX8(437A;A@2$VV.&%)VZ8688CQECB
MBRO.N..-'P:98HY)#EGCDS]&N>2134[9Y94M;AEFCV<6.6:6<;Y99YIE[CEG
MGG^V&2=[&?-Y9Z&15MEHH(]6.FBGFWYYZ:2E?KKJJ&N&FNFMJ<[Z:JZU[GKJ
ML,G^6FRKO4Y[;+/+5AOMM=W&&NZYWZY;;KO!9EOON//F^^R&B,Z&[KL)[WMP
MP_'^&_'"%6^\[<,=WQORQQ.GG''+%\\\<K\QWWQRR2L'_7+1->_<=-(]#YUS
MU$]?W?7/7U?]X<!AKUWVVT>//7?;=\>]=-:!U_UWX5/OW?CA>4?_WO<L2X("
MBC)D&LD?:/3YMG1_^"$EG;88ZLPH%F'JWNV?U*%AD$^5/[[X]-E?W_W6DW\_
M^/CA7[[^XVFW?W[]B;^_??_EU[_]J0^ !1S@_PX80/HET( "="""?$.*)[RF
M2A?Y'@MH4 9_6(,4YC"3@1KRC"ZU(#'H@8=?O,"/))5@!NZ8ASO>H0=RE* %
M@+E(=/* CJ_0J7G/@\L%PR>2#KFC'>0(QX1BDB24+.09[6B!#JJ4GG&TR!UN
M\<@S2O$G6?%O@0_DXA<)R$ Q>C&,9$2@&17XK_R5L8N/J5.J!C*2/1EGBSM[
M8ZS8&"X,X7$YQO%-&\%X1D#FD9""#&0:_PN)2$,FLH$0+ DZT$$ECT3G0T[9
M8$LH2)2?0*%(1)D-'=#5$&C4XT-/P X+:E1!C3QC#Z^)B4@&]83LS* +B"C%
M.Z[@!7RXQQQC,9,\Z-&.*_#A-OW(QX>N4(;N.<L=LCQBBP UD9)L[T6';*0U
MQSC(16Y3D=V\)B.SB4V^K9&;WUPE()Z @!;F(1PF2,DLH"'!%FE0'YTH@0F^
M$KV#) $!-'@$2_0P%G1T81WH>,(W4/F.8*[CH-ZH87B2-!9R=*$=ZI E-,,S
M2CT02 ;EH)$7#(0C[4%A'>HPARL# XU[$-$<Z!C'%/6D4AE&R1LL& =;R !"
MAQAEH^981Q[(4?]#?$B0ALKL1S**Z"@9#%00CS#(=/!I(+$D!*1U+&<XP8E&
M<WH3JU?5:E>Y^E6Q:C.LXH(&/>B1"'ULE:U@;>M8Q4G6M\K5K76%:U:71LZR
MZL]9Z.SG4^SDB1F. Z%M&5,GGH#/5[:+GUCXIS],DH0:W@8:?G41BI[!S@E)
M-: L<&Q!]-&7"=6#'G.H3E4I<J2^*!9](N'@#/\RB^]]HP62],<J\/3! T5D
M-G- 0&W7*DI2L*@%T*O(].8Q!X3N(!^AA:D[+-H"-]W5JW2E[E[Q&E?M9I>[
MU=VN=[N+7?".5[SEG>MWS6M7ZZX7O9C3ZWG#"U_RRC>]UZ7O?=7;WOS_QG>_
M\^UO?=G+7_O^%[\#-G" _7M@_2I8P+,C&H(!O& (%WC"!+8P@Q-<80Q'N,$2
M]G"'09SA#XLXQ!PF\8E-G&(*X^:]G<$5.<AAW(J5Q(-0% PZ8]LS?R!##ZP%
MY 8]48X85TE1%^1>@C896Z1=*P])R*>*I0(-=\SA"N?#3[N,]94XCC@K!C'7
M.YO35R>H4X,H]HQ!UL')F#QFE/(0!#T0,0]XZ$$&[]IMB:&"/:"X"#D7@08^
MX/,$<M0TF?S8,*UX6H[/VH4DR7"'H[Y1'1K,!\_Y\<<QSR6BF1B3%%?()3WJ
M 0B35E7#IYF-.91\E]D@)2GTF,=&DTGD%6LF_X*;*H,J+>*L-"?%EO!(QPS:
M<9M2[P0:1T$E(NIQCWH@XAZ!$I-[TE&6>:C)7'H:MF:*C9 9(%O9S';V;?.
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MV +A&@V=@H4MJ"3XN PJ5@4=CNB(\J0+U(H^S@HI+(D-$80KL..4H*D51@(
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M%9;>HQS,!W)7%!$-#X/.C6%1*G(9Q%GD2>ZVK%QKZ$+N,U^3*7I*8BQ2@B#
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M;&["%G5"><FW?,H'AW,X?7%HAW38+3('?317AWA(04,G' SB%#(B"*>#"/>
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M5AE46?4O63E42:4,G9>56KE4ON.56ID,4\D4:!E4EW5$;$D/805I:#E4;@(
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M0?T!#0*8#N0@ ^B D/NF#J5S.@M:2=J9'8%Q='$D$/15BGYA$?,!@$1!<:L
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M0W@8@@8%K/:P&1NQ%JNW?<NW7#,,G?":>?M7&/NWUM--$+II,V Z]U C##)
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MWI\,G=?]C63]S*_^W27\KR\M!P2A!HD.24VE )Z_=.W__.Z__/J?_Q';R\$
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M88U-%EEBF>4Q'V$NV2694/NA1QAL/<$V&$^2"2Z9;+$51MMZ/ 57VW"%\1:
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M]N.9;P**$#\8"M3/G#-\45]N,E&:UH@TA+BHITWJPP\_LUBSRAQC LB1I'E
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MP3OHZ.8[$#$/>LB#'J#.!S%W),SNJ8XRDT2(%?_SH%U!6QYZ&$>K3%0J.K1
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MGN>'>FBZT21F],@5R(,\S ,\L-IE440=B01)[)+]P(ICR,,>M!YR*4U(0):
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M@0K'_>_[_V;/YWW:)X#]-X#_5X (2( *>( +:( .F("<<F7B!S7D9WF?XF7
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M!>@05G]9"G1@#NT4!3(:&\Y948"H!\TZ#H6*$HE15<V:F1:%"**$F1M4!>3
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MR.&F1T'LX[+U&2V7N:OG@.O+)K,H_JA&*?(#6-\*)0<*EOPJB+A?\!S4PM6
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M7;/(OJL_*Z87_ X,N^[%2Z9R>,RI-_W31_W43RY5G552-5< X =9-=9@D',
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M33OS['-//?G\T\] OTP1JK80353111EMU-%'(8U4TDDIK=322_OA!YI^^@'
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M$^9ZX1M?^;9*NM2=[WWQFU_UP>V[^O7O?P$<8&-:U+SD/6]+_''()XSC">0
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M&'NQ&(,Q&9L1),CO$ NQ3';0EE1BI'[)SN;O&<R0 !\$!9^@!6@F.YXA#V2
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M(3%.,(C2H1V*4C &"1$FRS*"[QE1TQ<-TQGO*,HL@?\6]/ 9I@OM@@'MJ!(
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MQ _1B)*<9(U7N1EM!V@;F9 $H8[;U9/O:&'T((_<:(_XB&?\Z(\AY@\"29"
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M!E@*88$Z8.@@7(]P,34SF@*UG,>YB9\ZGKGIJ:$ZJJWYG;1SAZ2@#N70!>^
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MXU-QNJD+Y9?QVT ,O=&[U%%-P X<8.H0L]HD0=4PDU= #[/PP(0JU@H$O(!
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M-*8T.XEI'F#LF*_9-5_\:WAMP;T&;% #1L0N;*K.[+S>;+SN[-_):5YY(GW
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M(0</(C\:[(@AZ7%&O;"003W_E ,+_7KAT;H /8<PQ$$(T1SGVH.C<>Q-)7E
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MSDW.(UB 48#Y_]2@ .7KA(@]3>,?ZI#YK$CZ)%Z#/ @_\)! *M,]>I SK(-
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MB>4(PG!V(]PQJ+L$I&(I6<4P*N<L2[/871RJBZV])S\*%V'5)N\]A9Z,PSB
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M+#GHY?]!H@DCZ]L%>GG#M04_IC[ ,T753G<WC8]X_L.X_H\UO63]A &$M62
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M3 <>Y"$PYY(%H:$OWV$=2((8&PX:_^I!!P7!M(0S^\B&*^ .KDR#'QC1';H
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M\UJO]YJO^]JO_QJP UNP!YNP"]NP#QNQ$UNQ%YNQ&UNQ P( .U!+ P04
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MIKKHWCM!#(6(8#*KS4K+.JOL.[*BUKCROI="8^DGEH?YTAC TDH,;FPL84.
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M=MM9/'FG6/I%K_4>35.J, J=02&W@&U1O(#_QV/M_T04_PU61N&HSIWQ(Z#
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M)OOH1)F&DIM"$9?MEO$H-"?);X1)))0GS<TFT.D*4JR3,"MZ!9PMO'/C45E
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MS54W22!5[;QG]"Z=]IT=*Z,4RUJ_.@JG-*!R-184,XYKFDD</ -=]=/9(Z"
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M+#%6IV3BD9'),^(G*T)>A?1I8U]78"QTCT+K>\3G#BMBM\/IZ,4H>#C'HU@
M1*[YH=6XZL7V)A\/55DO"VE9R"V@ZVI/W'^O839J.U=74]_4QD%2M1^EX6WL
MY<@#7[SH3<01'VUN-7X+NILEHW%4:0D?8JFTH2HZ:UVQ+^U!CZT-$>C%1_*M
MX.SUE027F#V47/L'Q^_93RWLTA;?O'L-%FMAW(..:;>/;@2>F,O> @C6CV5>
M'RT,BSCZDE0A3,T0Z00IYRE\M*,D<<0/\38\X$5UX)OOHH$@PB  FJ4IXL7O
M"]U8)9 />]2OG\. =T0*H=(>N8@"9JE.)T&?4:,5I:MSU972Y:%UD8J9(K7T
M#$3IKS7N\5S<08+ZR['\=(\ICJIYG )D"/<\+\BMH;ZS0#WGX.SS-"MQ1C\4
M1%#@0_9Y6U99QO"TID&>VC1:I\1#5A4ALD!T:6F(;KP6\RM?)PDRRPJ)-H[J
M,G^&@X'L* ?.2]B+P9O?/%8WP_"3NZ6V>EV#2) A"^DZZ-I"F_6V+7H9D6*S
M7Z*VT2)TPZHN"<G"JA)R9TUKOZJK,PNABK> 1Q=!/:X]; MZ,)>ZFIM#61?7
M[+,&D#%QC)5XOY6. H/_HG2%K >J,""I[A3%8-O9UA7]0-\HYZ TF94ZX'A/
MRBKLLE#3T C]5N[Q41V6/0"+CG41+>'84I%WG9;=N[\7JDI D=R^/P%Y'*1[
M4]7#@@W _"Q\! 'N"CL@V*_BC<9^4O:8-CSXF\.VL\*>=S$J-EE0X],ZN?5D
M9^<60'YR<'KZY^;[;*^]6U0'QV(+G'Y=7:K=\.D^U1A#T0!?.0 Y76UOP8RC
MQR3O.->(?4;F&O1?0NFMZU==!5X$U^^/UN7+T4 &EPFFO9Q,>AF_[(.-NL(E
M[?R\22(MA#)$&(5<_4=_KI)YS'5UGN?=I.]A>5=1A;188-K%VYFF-(&MQL#*
M QN__0MUMN="G^Z=]"$>0"NM@67:$R[ ;.&Q1L2BRS%[8IR>T+9T=E@?XTDR
MAB6^H<] ,44Z*PB[%!AP!<F[(82\@0STML1C5O2Z,4;(+S_$OE [J6LU294T
MCXUN\E18=<>QS3!KWO>OF_N7BHQC!4F_*@%[KT4KR TR;I<S:=EF(LR6(C=6
M\](ZC4OO_,.6CG@T]6>U#;9&GI8 UU^T^Z%:Y@%>[/'';G% ZB"Q(Y.![("1
M^-H/T5.4!DVYMAK'FE]_)-+\Y*3]202*O==M^+Z[I056ZUK+H>WDP)C]1+6-
M4#&2#@CV"/W^[>S71=UF*^YASO4[S)?UE#AG+/XJJC(F]+1&\?UN5O6*7<&.
M5K8'$8+U>O(!C_;GL%_#O&/#<^_M.C6ZJ<]<%G*:YXW'EK3J5\T?%5+9N@J7
M^^EW?7]992(Q9+Q\$LS07'OX'51R"X@J?"*ZDBCWN %MGL3##AZTB1H]7L_T
MI1BGQ%OU2!9!]+R\!8170L93KC_@1GJ$,$ZE)LH>Z[*LN]"A.<JQ,&NC(%&.
M'@_2W]]:/UMI%&FJF@-JM#"<S6VW@&C/(\)2F"J8Q$&-;(15:=P:NZ2Z*'W\
M(M#P7][3:'4'%X&N\H9<A(DNGG;7PCB=<M(HH)[GO3@X#VY.WSFH&Q\R_KU[
M15T:%3Q;M^N/U4K37EM<>1)9[NHHQB2;9IA46[O@4EXV-JYAA.&^DXXL3)35
MM2YD"/+L)A?W?S'WGE]-?&$7Z"!($T41$*0$!:5)[RT!E2Y-FM2 @(CTWA.*
M5('04:1(5Q 0Z37T*D2*1 )(%^FA!TC"S>_>M>X?<-]U[WL_G$^3S,QYGF?O
M9^]99\X\^K-YU_V=9/#"K0 )BV^&:V\JE[88,/8N^[I_;!M?_]P6SK-8M6/I
M\]B'=]5#O\V75E;.XZ#]^;<5!;]L26A*ESP,ERI)2=6T*GZ0)_4TA!G2'[IU
M0K^$V'Z'A2RN]^DQA#AB;\1Y%@>@^C+5GTT/MMB6UG])&W,RU7O,%?]\42Q#
M[:\BIT3^YVF-PA>I=!)#*>PK%%K>:9$+7_9F*]WOPL;VMUK;)X]((?IYMKIZ
MG'D)Y!__A5$%4!&O+Q$RVJB6V[G[_$!,8)$W,N=":_53'IMWIL?2=)Q%,Q07
M\A^53%'>TV-=;[>'=[G#9!NCB+?P0H3T#K8/Q_EL(<K[TC&+H:;/C"04K5E^
MN=I,]/V:Z-8&QI-W?Q0PUIRC]W[XKY6DK&5*ML;]\.S6H-M'M#WVY\3M83KL
M]K.V_;&WEZGZ9Z$(&!^6,+K7J\VF+6@AI+OY;ZBX^Q&ULQU33FOA;35]ARG!
MB_WL@IP%_.U+X,2MD9 .=X!$+UQ=;VBL:9WPZ7<N>OGYA38,-OU735?%)#F"
M?MXE@FP,/-N(L7M1]*C[7FWPNK<=+DX)3COV#I5J%<=Z1<HHSPK9DB>E7\Y%
M7@JL?NES?3J>TB!.;4W-H7($)M:1/6 T<M'%*EP1PRW_KVSO0)9$23.@Z'UN
M:*<LUZ]$ZE7@J1-9SO5/2@2GE(Y=@C<:?0G\PAD--=ZY6AY<W4JD,A)Y77AF
M47\)+/I>M#5NTQ77<,$4C9TL0P:]FP-8MSUG)\]L+HS3[G%XGE\"B::^)O/W
M-@/!N3%+^#X'6K<T0Z?Z4=B[6O,2W''C)ZF1O7K[>B3\D-@J,= !'KZ/TUSN
M][HAV=IS9CZ"T/V FD8F(2/S'H&P+4<!+_/M!Y85WQWD>1**1<4F04MGEX -
MI"Z] 'P]8*AKS>?C#_@BS\PQ1PPNGLA.I,7%\NYP%#RV'X3'_6@2FB0^_&03
M!*J>;G]SXV.D[NA08U6F[MB"U *J^>]R1LC3M$*,OM-(QBS,=/(<C]H3Z3HY
M&%E"7)]3Y>96JJ,/Z$F3/Q-,O 2>A0H>2A!I)_>K+I;*.K=VR'7:TO1:IL$H
MT>R' C_R;-6>);5^-THX/5TYFNU,$\5&AZVD.PO"0^@?0.A\\4KRIFOY>&;0
MXLY>+WQFZ_G^C12ZK#L8T,P4CY95 Y5X(WD>I0K$\*<I>WFYKYQ;3EH0^$N]
MNUK#GBM".\](=#]]GC#U$8EY0]/1$*3D&NH#848N?C1_T-BKAZ&<-)IZ?Z?Q
M0@B?+'NH.&V6@GF2D].\>KR'@&^KJ=9JOZ!P (\RBL6Z,BDK7Q'^U=FU$3X0
M1 3!%S\LL%;"0+#Q%A?K>TV-=1?&HZ71X\.;[WV;-.(<7@)R6_F6H9!&2F1]
MCM-Y?95PW>S[PE3IQBO&]J^G$"W4W%3DC66-JD]+&+=_3?I/H-S]K1:,SLUV
MFF6#=(W^W-><F2\+%:XLP4^ZZ\:?F\UR+]/'U.W=P=%#?QZ_X&;VEW>8ZZ;2
M'_Q[+9 33-W9$QZ9L+K.X8R+Q&546^.5<$N?-_5U3QA>6PLW-T5Q>\E8S%@K
M](.?R]Y3'G#OD2(TX=7WW5*6Z(& LMZ\>\T(O0G;2?>&(858*[K,">H,_T6Z
M',^-GW2FV"<K0CYX)T*9%(=@3^FZOCPBP>WK^#W*UWDTQY2J=K7^%#*\.1'>
MHYYE/OGP#<;BLCVA_& B,I#PF8BZ!&[K]<%_'^KLKZ9]<*O&2_F@'_5FF3;,
MWJ2S2)5.B-S*":)?75_)BOT!9U6T1-\.K)&)?T9&L\(PMWUMZIS(1+ .N8WS
M%.F&_IXEWE*(-<?L#G0WZGG2L"DV9-SW)?.@7AH:.M[H@[-"6!0?N\.4 EKU
M,I\)X*8?.;2\[:!BWS\CQW])((Z1*AT!;.31XU@+YE3*>IS]RY]<7]&]<YK(
M,=HB"QQV/9(8L#2=Z9_A[G)@4+1/YTVLW%3PV<I!#'? "6EN$WN+ZN&Y1GR(
MIY-VBW9@JV+V?,OCZJ*3./$>UO4I>,PFO,3(7,]Z8=4V-E%332!W[\?''5<9
M8FM^ZB6 -5&HL(!&JOU]/376D,_S]OJFXO*-&_+K>1U%)3!]DGD0#'EQ$!*<
M!&R/Y\KUCPZP?T_(X 65076OPSZ0CMI7%TT2*5M;72^!)UQV["^]),[6)P^D
M<".DSA:#+F@C%'Y"^/F_$-V&)\+U+@']DY#*F0JS$O1W[<;C57GO',FT&:)?
MZU[5^>;Y*>2[T/<?L5TS0+PT@F4QG0J_KFB7EX''DR[SRC>@SLIYJ?<@V<U4
MIP6SFMRYN]4%0DPC/V&57RB# F_2!>VL')*DWG3UWR+BM9HO0M'-V#D-#S;M
M5JXDG.?0)<";<_)%OSTWLR/K#XITQL6/P7R_D$.[%\[HPDL@\LL6!*LVJB5D
MN7EJ?Y9V"931B^:_%^[6PGHF..*7D1Y@_E:+$(7]J4$M^8"@_8P!?1/>+KP$
M40<.AF,?YQI>J"U8W3L5&/H<CN,-\=\Y\^Z#JT#NO*"/S@,/+H7(A)YW_R8X
M:]95NF'*&C8(&-@KR8T+H?GM/\1W>MJ\P?D]97TZ_B"0U%:XL A5[ KA]&J<
MC!9;4DYD BR#4$Y$F4B;0BB(H+WZJ+Z!:,DXAQ^>^>)J]0FU#*9?%/.)S=5+
MVLNE7_(QW+W)69W0V_T B@"^(8:>50SRJ]Z=/'$^ZZ ,D?;PTGM[]%))U/7^
MJ5*[J*"(^QH.WJ7 N-$T\\!O.2_/B<CF@T=8(*7EI1&>/D(K+R2;BEL3 =J:
M[U?ZHH%K1"9\)&S^$KB[!^,+"48?"5J<*2;RFCO[J2:GJXI76WL$,!%<\)J.
M('K%E^.[AY21,,,1*K^EVW:OV=<W4"5P\@4V*5=K" )Y6TC8(=BG9?^F@>37
ME\W*CABM5!6J5&_5O>I0>#7.SW["M 'MO*M-9%N%0T'?="L7(31XYDD&XB6@
M\^W7'S8GSF7->V88B2OK3KP)-:LWO>@Y+X'7O+U[,7]?!2H:.$AZ(_C]=>B'
M>U>XUP=/9 ?@;_":!%*=+N;)R_331W%R[H? F8E<3A,HVU<\]9/U,R_K&=IH
MMPN8&L**DH+M-OY[!?=&\?A+_D<+K."'@=]%GSY%_Q6+WO8 L0X8$JB I$,B
M[9-E9(SYZ?;%,J)VRT_&_$]&:<T$K:+>(W$Q5C%7N2' EZ,C W=!JG\DX1-;
M%_*NSPZ5P72)O'4!Q?CHJ^T_1ED2]$+L"2G-9DTK\03Q:<AB"N9.K&-CW32,
M+^#@$M"DJ%R5"9I*_?HEB4S]%3T"OF4!N8Y<3%FX!KL=,**WGQ5=/^JV_OS;
MAP=)"D,_NPWL;_A[#JTLI.FXM;RIWY;M,,EW]#YNX5NQ" Y^G[3>\C19CGT[
M]TD5S1AP?6!K"QH+Q9I? @V@2.:DAV*5)<5K[Z^R9^G9YIVAR+>@3<PIX0[.
M[([WQZ;9O/.(CQ\%GN/;SL]-EWGQS#]J0Q@:$ HFFV.+]HZ*&F]/3_!;ZX=L
M7<-H"XORH/Z=ZI&R15C:$O?)7&!Z=W5;:453H]O[P 7=DQ9GY[M0K&JZW87\
M9A]DK;3BY2Z\XQGYWW7$<UCS.7'Z:4+J]X)[(=6M2>+JQRN70)7@OC.1NC0*
MXBADX)V;G1L[Q)/RSD.,R+["NA%/^')H[&:F!IE*HJ^N4E("\(%5;4QKU \F
MLH_FM\XX'6.3?7$5DND^B8^,S8++,6J2D\C0YZ;.98_3,PO-[F5DB7?V]J[>
MM.-53%J 5J_HQ@^J[3URCGO ,[CHU7O,2W&,PIFD6ZZN?);%DT$6WQAW<G\[
MJ=82&$81V4BR(3I1W<!;V[_T]#<J:?0EF[ZK55]W@HV<G-#0,4E7);>7Q[WR
M0$IU7O-0_FO,(7&T7M8@6XFQ5>5)6]@@DLCJ<\&W^\4&A4!Y113Y)\[T?^>@
M+P1//79 B1\ ;/2O_"\MN?D?#Z-G'WB3P$A"4&8\\+: F\)S(P6Q;GWG0OU'
M YRJS8+;ULBIT>;<H7+M/R.>?5I^-G)2E3:,XUAQ')/>\%=7DC<?@Z.JM9Y_
M+&V>WJ^%!A'?E]"_SA&"N3Z"<\.!-G7&?)"DA4.RBQZH]CYY=S-R;&DLZ'!V
M EF[<+U6NSC 3_WEZ(.O@7*KX5=2=LX2T%C'"SE<,G)'<.G"DU^A@YMQ*5J,
M4!2>!#\_)OP+T*'"<W>PVW99\-&O7R&_!#:KW-UC*WVKJG9V7*O=110VD,E&
M9:QJV3GI&2P'Q><N1SMNK?"L0Y).N/I^GW!<U5@2X&9Q9E.7URO:.$+A];63
MLVD%<&PL=2;A.,&<PH3(-.5;YRDUNGJ'F>@^;"TEE#RWNO(;&XBB_(Y<K$?6
M[L4KVBT)0F.)UR=7D2WCE781RWQ%@7ZI?1_7$AA4#')NS&OVA9B2R -*^+*(
MA?3JF"[E][86%%ZK$*G!J'H\HQ6Q3Q=8>^A _A=@D./ >M'KW-7E;W[S9SXX
MR&_S^$ %\D='Q^)IT;^,.F*[WN:PK'6W4>#NW5V%B*=C/614;F\]Q"6&\(('
M=D3:O3(G43P7G.%/>G"K;&'$Z._KX^J"J;,W)"(T78[Q^]#*YY:_V>BEE;3U
MY.W4_VKZ/_CQ])%JR.@(U\O()/71GT?5?Y'$:U87%@$F 3Z0"")EF]Y-Y[M1
MA<7[9DQMB;R:'Q[G/YB]&D#E[T'=[^Q08>*OM;569/[ _GAVD&FG:OT]O(N3
M*+#U9*7^-&)'N*QYDDWGPM#"#<X?,G-'*$G-P_/W_F1]: HI[-%-SHS8U9U[
MJF;VK[-D:9\YM[(?HZKANLXCR,7XA>]9B2&"OC+]R+M.X[\YG@]M[Z0:O5X3
M4 [XE@K,<(/R68HO@8A_6[5.S'DWC;V^2$T-!W(M&4B@8$A=@0[TT,;A$R4]
M(O5AB1.F+Q-9W5[G]88YJX+=M%A0(WY\+<,[QY&%9#T%5>@F)7Y$J#_+L)MR
M5;PUFR0J!D6=XF^N&#LO7,%]U^\:.,D!4KT"+4/E.2%CD$_?"OPYFX>46DXN
M 0BQ*5][9_(87::;T*3@[70"<S:NW2#XU9YIG\QE\\%?P>,FALGXEUI+GZMI
M)1?;^Z.:Y%:RB:\ABWEWMZR(4T3*\-)'3:V8#RO1(1Z:B_;KDU($#N("6FWV
MQ Q7\5"#9NE=;==>!(3> #I<AK\MTOOP\*05RP-^I;OUC3)H^;&H&(YHG6MD
M_LY_&\D&V2*RK/4TO?04?X>1+W&8G@[>@.59-4 :G55='I_Q!(I%;E*5L8=Z
MDG15+@+W**\.8]*X=-4/ S)RL,VY(IU$WWB&DB(PFFLP"^KKRG2QXC4ZAS:2
M(/)$&^1B*_C^.RUT"$/"K/:;T;S\.<O@_7STW-WIVY:CK6;JZJX^C7@.G\,Y
MC*9</TU]925:VV)_%H]"PA>39;Y\QHOL5ZPJ.AI\[QQ3IF2] 8' Q*!6Q#]H
MB ,AKTU;(.>EG*D2V-"=BYME#TI!DH.WI$1V(&\[9-.EEPA%=@GK;7J(LJ6D
MTHX%4K+CGPE= J^JF;4GWVCC7F&@W=^-7V[R$K;V0B6A2JZ5Y\<_=?2<D8+M
M6:W..Y5ID(\BN(<GC32$TNT4)JAC+#?7L5A-BYR-W&J>\\7#[(V"UQ^@0>)?
M[#%RPPDAO^=15-6LY!Q7X3?A6.W14+:3TOKP820&K\ZNV>3X]\*6W7N )XAH
M5KUSHAX]S16"%!LN);/JM#6"D9-+59JISJK7UJ--W7+OPK\(B%NECK>?^^#U
M1B'_/0;JDP-SX.F:&VN;7<$K^JUQ,FJ]$C2_TJLI0I<U=A#]R-LDAX!\!Z=3
MO+4OO-*[<+O^?4'RC[3^R=Y#<9ELD <U6XZ7Y\8$4AN^6)_M]X6W2\%*;0(3
MZ&J'K#'CE)V)N*G)DTQ-ILZ3"NQ!DT#89TI42^C>O01T'N-^J]"4JFLJL,6^
MZ1#(R'2OASPA+V=_5S#C8<['!B3\V!4,A>7,#5DXE$&GB%GT>$:[$^L_MI$#
M-\5[KU2$IL+3:,6!F? $'PZD?-\^%,\H<V+>@<V/Y7[7;W+J;>DDGUC8/>V-
M/]1QY7DCAZCZ2W%KCMY\>V";#4LKDS+YN/&)' 7E]SHN#XF(F^0YC@EVLHR]
MA' B</];*"VEVLM=\- KQCR\B]P1'BM73G[F@77OMQ)1(936P6\%Z#I'1:SW
M#2G6]KA[WM5V.PWO;C!TFRA#JOQ$G^AA22%-#JCNQ(C$R;!OFHB.<M_T%SN8
M8E]/F]PXVH#*FA&[(;7M[5-WHQ!1+O>;ZY.UV8?*,#$W8A3"#Z;6N1M"*Z8Z
M'@;T/,&!L B+Z>U'?YU%*#=V:SHS5Z/GHDQ7]<4I5<B!*_)^)?Q>9<*8$ZD"
M/0RZ1 N]GF/G=NJL/3.["Y8D-)&D*=L\\QAJL;HG>.8!+FIYJ-*>^>09[*?D
MQQC1/PSCJU=_]W[/9&6_]9MH2B35+L57V#7B6/[U[8+OB6V&P<N^4\>SWYN:
M[3L2],1;:WC"=M7DU\']K7LSJ),/.(70?>T^""M1'.YJB2M'FW748(^K?X^.
MUG=D>0O;85(=BL1676F-KH@#<E6F1%KXA7Z($&YV$7[M7P=9\Y3]+\E*!]]K
MR$9EKEB,"_ 4T;2G:,.WZ#-@?D:'NEGAK25AB5Y+\-7A^87Y595I?NR_#5</
M<%(+A-]>E:4URBZ*-18P+D\WK?L8J45O7 AG*IQM"PQTY3ZN(-*@'C047"C@
M[A6$EE[GEY9>:/$>$Z>"$3J*3?^!U8P4HSS$FI+:.-N3X .5, ,2F$6(H@$6
M_1 J23BU4Z&&;R)#OV#P8.]CV=ZW^_5=ZUQ$6-/ZL9>@;]JI80V=+)62'P$^
MD$<OM;7&\":'O?[T?JN%<<M>XY;=@1XSWS+?_K0=:[?'VYJT=+F/3@/9BF-*
MCR[\6_P[/M^/-DDQ)KM18G7Q/3E@ .D2Y#D@]49!4F/YJ7+%C6?*-A0H2R^)
M@: 0L:]:5_!SQUMY :!)UI.*^EVCU#0=J$/%KVVDR ;W\F93L[ 5@Z90L"^L
M=3NA<6+'VM8+*ZC[*9QWG^ZXG[Y>Y/=R"O.=!,G7L[]T1=F20B\!]J1?H?E4
MY(V64^\Y,RCM/4O[J"E_Z5\)_^U-#"S1F%":910^;*Z9.\\/"F4$GMLXRK*6
M%(;1\OU_/VY%JR/?)')C@LZ);<%&=0;3!%^\/SXVG?OAQXX\./H8-QWP(99]
M,0@6"A>F7\)42+X-3&XP0*Z]MR'+FI%8J'X)IYWXJI/<46Q5A7$J$%G#?+MG
M]X">=EY^$0%KBW=M2'57;5PC*(WRS'U:$I2M=U=PFIVL1%$1OLR[P*[BEO^:
MWBIWNO.!#AZ+T:LCS[%?) 9L.N.8<&Q?"=4G63^+,SW?T/=):ZRD+[U/M*!5
MY[H9T'ETCC[*O_#&@8BTW/O^?9A+X"V8TPE#0(:Y"[LM)^Z(C-L$J_D9@<UL
M/.RX$5KXV GD8B*\'B__&WWT[KHU_<T-&75H8W/2BTS#SX)GG52/*)>X-N7.
M:;F+TTQUZD.A63I1:E/<?).:_!;9FZ??-=U7$3O>2T.O<,%+W3O1Q-$&S  (
M;&NMSBM'S&V62MR7%[D"BL'@H8R^' KJV+<_A[/0+6U#5PL%>X>_6BL#LF,2
M0TH#YO@.4I?R?PUJ&'CKZ$IU$E<W[>83JF0;/6:EM?/*.)&R7Z!<SQBXL-N"
M,L.[X!WB>#6L6TP!7FE":D=='=L8N^.ZM^=0YW\0/R ]Z;:DL:QZE49V &KN
M5<1J]->_/:\1IEE)<LN*YSH:Y34>>37!U=D[&P<0/J2+>Q2$7E(OT3 @\@3B
MN%_W\\WR@<("K16XX KT7<0!W5,K%4W/C)-^P6/W$RW2+280IQ:N*]ZFBB:*
MAMS<OP1B9[5K-5QX8W3$[F  %D>$MXU=Y$:.B3N>X>.*__;M1?HPC N<P;#;
MF@,7BTF8L)S?9#Z8L[*B,K[O_7!YA <1(W=54ZDFGA"8=C)(B"B.N_]Q ,S@
MJWSE3FU: 'GXJ1%9)T>+W72C[X.1H5<3H<A*)*@]^_'SLB>;^WYE&,S1UL$D
M^B?>DU#2(02;SV]DU\0>=G*2[[OWP,DWMRL"?2N<Q*FY$3]8%B3%JL1SO+R<
MM]U_4Q%I.!8O@1G\[Y"GN+SI/[S[-2G"O<EG\>-6;F9/4WG:'!PH,K9VP@?^
MW-7;6;NX.Q-;E\NV'!WIQNX@5.DZ3&F\J_W)DH[S[*A:"QNS8WP!P2M/%TV&
M".YSZ[2W&9M(QV_0Z4637RT1'!JD\)+X>5+EZ/8Q\$._@  &*=/J6!QB<0-V
M)V GO?AUR]7N'?(W ^P&^#DZX,KB(AT@2@F0XX\Z%-Z,4NW0+)^&2>/PW@Q5
M].>_9%8>Y0U\(H9NG>-(28C]39PABDPNC4->Y=XG7@(]UMR'0E(?YP4-HFZ:
MB=M(\(6(KLN"#*$HU0'\K863P7W0NT=XPZH-\Y:%^<U,3.)2H)V?N-"PYCV[
MIM5%$!2F>A6$1F^[\N>?!&/I$LD[+50FKPD>VYVPT,B>0O*<-RJWQ;M8TA#S
ME\#- >\!5E ,QU87Y)7>55SDTGH7BC;@29^:AI2KH'9-?;J&O_R9]+A:D+TC
MG_J6-3[U?DLY\OT/93]N*HZF@8/C3TZSJ!98XP4>U;. $^98JL$!C@=YEC-V
M+PF[;M0;LU3H@E$8)XG_V7VMY$$8O^Z)W7.^5_E:9BD\R91G\V*<-$-RBA?G
M/M7_T$3:^@M)O#JAN(-.9ZDZQL1[?E/;Y>4U<H&.O[DYON"8H^IUT%(^GJ'L
MY"].IMH,M]*%@34[+7^4B<NHW&60TZD+AK["]JSQ>,D2!-*+,](FQ^'00(;X
MC.;Z^@Z_?Q=%%]%GJ)EA?@>-%9<(T1D6@//#"O@8W_S?SH"-GK-O%J[OEF;8
MOCYJ11V]5$Z)LST-7&%%E;$RG9=@[UX")\@Z0EZ(\A^%\>-[^[1HE5S)TKQ]
MZXWJEVH:?M(KT;)4U1P7IDM4.Z +DMWL4D$Z0QB?+,/CI.7Q&.OWA\*Y[M[^
M[.-GM\6X1%"=[##.*6\EJ1FSUPW$%.WY63V<,T@=WM71TI'OZUX]VU'BUKCW
ML'1_8WMEYSHH4\.C><AR/P<N3TP#"\W.H;"3 S6SW8=ZGDNSOQ<C(-GJ<*$P
M6C+%W)F!:60R)"P?JP?'\5%MUZYL0>^&2$[4_SY:HI^IXFIHU; #VXYD]AQX
MHL/TJFT)-L311NC-8TBD-1ODSM>_[_KO4 :'6O\Y4'F4\)9/3RQ\E9W]<%-I
M0WJVE3%+:N^7U&D%3/WL$L#[3SMBUW>$5NAWG -=+/3VGU^+=1P67][1G*-F
MZ4[(DTCZ7;U'=<*/JUF$QT)K]\+<VB!5&VCXS!_."1<1NZ2_TJ^%[]?&F8'6
M>3T4;_U."I#"D5CG*A<)!> _(<[[KRKV>9=HY=^<GMZ&OFE@-N"!N?;D?/;G
M81;<E&4]JAY;B(9_<\0S[BT)9T&B\->702PXBYXTRQS+%U;EQ5Z@# #Q8W"
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MWE!F?EW^K>V".J>71UB#5DVQ;7^AB@JRSJPBQ\U.9_/SRO@S.FV[!'OBA^+
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MZW=W.YD7_UWN?VU6P9T6@.IQ7=: E@-) -KS%+!@P">C>A$2VI2O;",+^GG
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M3]O)IA%M/]UQP,-7 !H,OI7C6?GYO*&'NU@(^%R2PHWX7IIZA)NFI_Z-TO!
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M]W!+."(63BMRY!^=@#J=/_DK:%;68E1',36G<V[<MN3+3F'.9_K@R:0G_/V
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MKBAS/6XMJ/PVZ+Y.0J2>RX>6D6F[84++\,^B^I=E1/_;RK=XKX0]VK6-ZS#
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MQ8(1UV)1X*-/B6FY],=9 !)!XSY]PGZDLJ]PA2%9O#(Q0&*ZK>]$%^/^$X"
MHZ;=LRL!M&<"T'^X6.7=$J8[8X>X]DAF*"TT3L&B+R=^&!JWD=7CKK_C>.E^
M9EVQRO&]P7K2*7?#K) I@'LL^=:'@70UV6S[[IZ1IYZ)Z9))< F3:)_WQ?9/
M2VQB#=7U%%[-JR-\_BFU+5"?5SH^8A-=.VPXL+^FKC5KHF@QF*.';8<P/:#
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M6,-'E'\MF,^X+]DLV13A _5K9,JJK;T_]*G7EE<>7!4[]'*A D6F_G$F7!&
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M]6/C,>CC3G=J?WFRK&/+!"#Z0>9;?A&<5MMD3^E% <<SUNH)W%,3&XDAB^9
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M!#4<S<2='$'5VN^@90<5VL_OX*1;ZNX8@[&QL[ATHJ[M#LJU/,Y-5TE8W,*
M/10MD#[6\ 0?5I=ZT:Z&Q?B.?#D47;4HL35Y\Z7-U.^0<?W.5?9S_-1)R0YT
MR/K1(;-D?$?!-; R.((2W/;HR@GXI' 1=R-/+IE#(3-5:.Q38W2O<I\9RE]G
M$(-GM8.V^RE/%]5G2.E14]4M[\[K(UUB]719=<+#!'<TOAM+5>XSIE&G )YM
MPR'R35(C^&*[K(!@'?H(QH+["HW FE:ZG BK ?\,"84K<J%:_D]$I)MWE?M$
M[,V0-3>")G4>+FD$^\=N[2('CIKW!T977!S,/O.-B2B@%__QJKAQZ4_I3R&<
MNH%E!_2&NZ$TZ1GXXD@K2:BCWXE@Q/>U/I]?G#DJUGM=L(Z1/S1,<)SEW-0]
M)L9EZ+VAVX2*'-^/7GC3:AT/!%(#8Q.HI;U4D^25_,YS>G=^HYV48U9P[T4=
MF3^I["BW-5<U__VD1%O#T+5L=>E<L>%1O1?>AS.=HYV3+7\4C6K=N5GS[9V_
MBWO0DFP<'US1F<W\U!L;4AWJU])>P7HS *NL( H_B/41!3VTV?>ASV+BK'E;
M"4N]7>L#1Y>!A;YVY5TNN/!@WM9LQ(R9LIW&M1.;I*0]%(T[W"8KT*9^'C;_
M>\]IDX^$DP]#UI*3"U(*8H,"J# ?Z"CG?+J]\=!?$DS<P5F-H&]FCV A"SYR
M=EX:"TSZR_Y!S=Y=1&7\W3H&UDI?QQC@(53>7DX4.ZYC/#6>A_0+'C==\YO5
MQ6ZRVTDWT?H[T"[9O,_Y3I!SO;U"A/>)^X$615MX!S.+=CRX[?3B92R]9"K,
MNK$%BF8P$DA?3CRX:?1M:14K!)!M#%D-,83_![$1VT&5IV^1E1&#R=<+U4:!
M0*("E'X.'.@D9>)4;+4AP%6\J;>;G[$6V-,"%-.LNYHM"C;$-R7N,LNB+"),
M;ZG!.SJY^/4;KZE>7/'&_'PNK&&/*K02X#)IJD^TTD74@(B2RRP1L9-\8\V^
MHR! DCI:5TEA;-E?6D2BFK+ %KM6I'/D<BN8DY-5R9Z&QOBGQ$#F.[O1^GP_
M>^^V3^19(F0=A+AN G'(JT4TD]::$6O/KT3IWG7,BRK&:Z+D)**^CEG0*/;\
MZ%5SY5G\'S1+Y>M]AQ\]>S7\P]\7C (.G3\ZRG9.:E(C!QQXF>\>,I,7?7GN
M@%W>V<8C0?E;XGW=HPWZ[522[@08&55Z+[H'AC'?HRG;\@CHB"2&L'C3: 1(
MD_K/61J<(.:D;^@:P&TCSNHGFYL$=*S)9;)<KL]\]8<RQ=HB:I()&PX5\K_C
M.6R:*5#/%TI=PDR9BI-^$XN\PE:S;^N8W9PPCAQ:N62B( 4Y!FG/^CDB"MA9
M\DU=;2B[@I;N KZ^)]?-3RLT!1G5U30#PN$9HR%"- B(HM^]SGQTOC^P)OCN
MBZHI[X7PL>PDC;5M#QJ.MYT483>>8FW:6'N'BO .IU8OJ29=3?8(/B[="Q^D
MZM!/@^/)4;@?(':7[7?#7]@_T,T:QZO-K0=4%OQ_:!XFA(J-NFWW#%VI8=?C
MM_$7>[F->:53>FTU?PIEIII1 W^A^-G  7]M(4'ZF9SG^4Q=!J_PL*R:80W[
MY/>,6[4RS(;>#9J3E6B*W-KYVY2XBJ%Z*@[^56QX/K1PSWAT7ZB-O:M8Z6%!
MQ8*51VM4GW5ZI1]YB>C)_?MT(%2H(VR=!%]KG7_UU/T1B*CN9?]]L58K^N!H
MZ>HKKCE;_FR1OVG&G-?GE_??ZMOEW=<Q.*GU]&JF]XBL]EU!CM<Y%Q?ZX-<
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MNQSBG!S["<1WKT '[+/H).E!BT;9$Q&0Q%)JU:Z!5  =BX*HKU8'GM6-,?9
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M(\>AC&]43TT>0HW_C0=\>#J=KY#!')1++?YSAY]]08R[:[KG0;2,MC=MWZ\
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M.T LY5EZ'TPT;IJ ]H/Q73'?J=N2CM1R3H0&%P=I$)NKK(V1V#HPR"O:E,W
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MHQBNV,-_4T17BMH6*1GX\KT=-5LOY3EE[#B>-7>Q.JGS"C?IZ716:=+ZC.Q
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M&XHZS'79;I,1C*WSQ'UC <TCF7[WOC.=AMJ</T]A"[5&C"WM0S%,_SE844W
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MR;FTK[]OT,R.YCV.T\L89E8]*GM>]-+E]A=ZW>#9W(<2,V<,D]&Q#)HM")?
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MJXWZJ^E%EJE $ "G @68JP<P@J<I"/RH\*PD6:Q;*=8!#$LKT!4(*?%V<$K
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MRFO2Q'*1GW_2O#11FCB( 3#H^ZA&6['R"12HTYL$28G/#UF@45W4-,8. ^@
MUNH@T-4JAP:BF)"E0%Y8?2+A6F;(+NO::7#'%SD?M_8G2X?&_C)"'[?>;\K#
M=2B )]F0; >OWV5%F"106S0K$5^4I%L@J^9A<%6.(,53MA!/6'-A)A+D;5-:
M,-!LV=SS*V)#2AV//B- )MVH.T)+=X64=H45.TI_>N'KA8]ANXQ&:"%6%B"9
MW_A4!?%%F!TE6FD2[(&LE1F\#V];+XJUUE.HV=+:E/?V"_^,P+:#36Z=R#3I
M+N@L[:X9^3#[YL?T0/(1P_X]*74E"A.WV?)Z?]_^KM\5IJJ=$/,D\G1:3\#X
MK4M)M/+$]T<_W' ,=NZJ4HIWK[P]G%_L;_B4-QU?D?4+'YCZI4#:KK'<_5R(
M<T/835V3B(;7X]BYYU!VEN=*PX:4=#:<2E? 0$BFHZX;V,9IOAN.2\70#CTO
M"M;>/U8LN+^>AI*CJWS+8\91+^3WJ+:J0+D\E I(]AF]HJ9!NA\>%]@Y%U@Z
M'ZE]8(QPX4%3S(YF<(:'!D^>@N0<12?8> <>:<E5I(BW9I*V$B+VT5.Q/,I=
MA(;5SB!O%E8U5X/^I!0\Q;-JX:6'R#G>GNV9JGLV2JNP<*[4VF5XG3%2DG/>
MQ >7];;-G'>#O26I=Z@X_KF#YNY!9&EZSW G[\[V3CW?#_8F"./B \LR;N'\
MPZPBXMN+3YL+#=,.\#[FD[OX:@>U0I=-UC%-ZXB9=A5 87%ULR4 O"3RA[JL
M]DKJ28&5_3-EF8"H-Z:=G4"X%&@10XXG[@/W=TYZ3Y1S,+LO7?+S,6X(SNT+
M:E::,_]WXX1Q[&M'UW-CK'<7&]M0*13@+ XTM%T*V#RK35)'N ,H\"E,]A2[
MLU !&'R#5A>[OABC*X%HGD<"[U+;:>XR0GP4J,TN^/PUS<H 7';(/)?K)*BK
M-AEO,S=I7YB=GOMA4W'Z#\\3:T2;'<H#U5RC]X'C_#-[S,?N>'LE5WFE&-T,
M^Y1^*/]I9KG^U/3U?$<C6_^\[).ST*27<5WA3,Q-\GP9PPQ.)N4PZF.VD3J.
MHP(WI/X4$P4,)DF)<'&$X"C ,MDRSX"UA(@XI,U8:(3"3CRZU^I(DF?.LF<*
M-K"AN1FP'"_)^584E0?-VOS]\+S"ETFQ6A0D]YO(@=2!%'N*3@5AI-H4 *-N
M(47-PI(O\>EZ1,  DV2:*%^?(COOK]DP.GJ6)"V^ ))4&I5L:GQI\VQFI=V!
MAV_^?C3C89/+H8"&U-Y!=>(8!3B-^1 H3 3OEH%86T%YCT(&XW?Q'9X?LF,B
MIHS"C=7R\05W"X3SW]EG7D[0*#OG)UCAMX_YX'&K[4Z?E7[W:<G_0HU*.FFT
M*[G[5MTIXV+[,MNNW?D=9XP%Q]-C"@<79$L"- @T7<,;%DL']5\;IKUMVGO.
MI'CKN+>S2Y2W_JNU8;'MSP*8=BU)7EG 9I.6ESPA6(H<\>@WWI/,]&U=]/T"
M7-)BFQ%/R[_7>YQKI3A19ZQ?_;JZ]L0$JT]Z9J;DQ^D_K,)\< <_93GL9ZI]
MI$%1J!=(L4JUD"4I9/P]F$AI4!,KC0HO"K;UXC1 .6<PD\_.P"BZ<K=U8U)9
MZ']"+1P%V[J\F]*Y(I0"P2K5J6$T0!N1A)Z@853!),^QQLS VJ9,;(EW2,R-
M]:>8:C9@!X,5OY?4R("9HP*QC]$TR5R6!JU[&3M7I^$K!&.P&("8[D#9PPTI
MF9">D;G-3MB]>*.NF!Z:049EM9_/O(93,L]1S8UVR21IB& 2Q]T?$1W!LU_F
M(>3OU!R\L::5PSWLH/].@.\;Z6!JRDZE[VG*ML_(V%<J8^_N>_",]H3>G8AY
M5_]AU^!,!S4G^RP=G<&3W6:W63M"]:N78E\'U12F%_]T@&3C88..@#ZP>3O
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M$M\$T6'%EP@7P&AMAC:CQ,\;&^:7KME#EV<4LM'C <"7!JO\B@ZK)Y4?-&%
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M$H'+\[K*U3;<3PMWZ%IP]5J+**R_-3R,.$WYEB53)LOYSQ],D -N#4!K@VJ
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MQE1(?NUE'.6S4PAZPBAJ]7L6A[P=Y],^I3MH#@NGXHB=.>/$%(%GNPUA#_Q
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M8N[X_?>YMJA_$,![*'#+6*J5!27RSN)5UQ6FIXDAS%KR6WG?R#Z2?Y5I292
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MJ J.V2$G&JMWUZI?#,$P%+RCD"@QK(D8$079QI5F4R98W(HKC(?^D[HCI^C
ME]+]?<_K[TW(S0@1<&/*37/K.6*(J@O'-MUZ#*_!:];NT(+#0:10:ZISQ1A
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M4WZ=TRP:6D36:+$&[2>\!E'&+ :I3:8!3)%VO]@6OF9]_YCT/^/5?3+5C<'
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M.G!DR<-5 VS-S-U)4/"AQN[WF(R,W?]%*VO;_A+MP6B^1;O:^[U3_2>O1OK
MRU.']9VJ+G#\#W>YZ[\.*YHZN=17J)6L3EYTSZJ[G)&!K<BO<0ZX4NV6V_Q0
M>5[/I."9>S&J\.5*:UXSHMM;KX)2.G)9KR(#\O]&,P WKRIT1ZVU@],"C;?(
MV%KS5$.Q*O9")_UH5?%*ZP73SA'53\!2D;O9Y\%!0Y?%01IU-*S%IV)V)#2X
MTA8S+-^=AOS\FK(7P6I# 0[[*"PBI866$H/:LL1 I%@AL"J3L;F*V%\F+!VC
M;X2R';VARM:5TR"S%Z?=U4Q?<Y@UIO>[>ZMF)A 7)]O4#$,;0;S=W17ML=58
MN;^MZ-1WS&WW>%%NN:\.UP1H'[7>27Y?XHFO9]>^20[U,BM7+SA8^P*K7'5R
ML8+^<>"LFY[3KQY%'6.K0X<8_C>=9N=2QRB  U06:S8JI=O%L";W1):FT5L0
MYBGZNT<U;-TB]GWAQJ.>"<M0UBRBW]_<@G-KJM ES)N48=IP&[]G@4=X.K/H
MX<%7\)Z9.=_6A-\E5>Q,E,PTOE?J8*%'Q5HS"S?+?FX%>8+?9S!&4^>3?#Y-
MSBDGLF5HH!"Q/7]+[5&+" L7AFV08D7]S2'%9,A/*"_Q2]C35>'^818:LHAO
MHMQ9HZB)7V]NM#Q>GU.>6A5&\F18-D0V<^LG_T/C\$CA&7/INU1"UWM.@G45
MH9^CUB+]I"34P<\GJC 4'OGA[E>7UN*E<>GP"@G ><K,ZG_L?[8*=4 Z%_WG
M5!NJ1;=O51.+(;>"3=5"=W!?W:)Z:B*9D Q3$2JP$'N8& <J0@'=]4>4T.Y6
M(QCC.ST#.IUJL(AT_#!>'[/DXT,CBTYM2WT!XN4Y)G71N'-_NXTT/YS$[-P;
M\;K FYS0L N[4/OY1I9N;H/E17TZE?TQK<9TV%1W15LIQZ74*\#P;+V;/O7!
M/R:%3[L;6CT,/R_W<+^NTM034OLIX,E@Y]&>DUXS3[)CI51<+=56/,QSG"N;
M5!_,9N.U;(, DF.'S]O INXQ(3*X$F/QDG;F64I@G>?B3<;/F2\:)9 $T=]2
M&Q$70_EY$0'846;V8C[/(//MZ%@H.]O6)F_M29(G.#C#,4^\ ISGNS*Z/%37
M29STUCJ-V!SK%%[4>SI\+,&8SV>@7S)!0Z)P3SR'N6+*(^.CH&]=/=J:1(_@
M'X#YU7YHRKJ6;N+S.._U=*S28]M(=FXZ3+XK&E\;VH%,L40K6T!3OM65&O-7
MJ1N1<T0T-$LF[=NL[^*714014Q4?E N>3!3OU&>CM^&&F*W$%,MS,GVST %U
M__):,)&C^?$Y/L5?,>?#Y*EXQU/]S#VFI-2[,"7A&;K0,+A.(VW%1!,Z>+MK
M73^^VK9\"7>(?KALRB+OY8D*K%S9)8XO0;^2BO'M*0POXO+J9++Z1GYR2?;J
M4ME'8L8'V[ZEUPSO>'FL7*\C[P-QRX1>O;6N3:QFL*[LH.5HD7'SAP3#^(W9
MT,K3%+'\W^.6/KK+@=)U\!YK_"#SO*U,AAXKOP5J]'ZOT*<:>P1LB>0L9-7?
M'>YG6#U@)2E0M7UI[U6?G<_PL<F?1X,FZV(79]X-\:LE3IRX$77'5)2%[X7C
M60]Q6Z7R&(U[P4 M"T+Q1,S7@;)#W>.67KS*0725M7QNMC"8Y#D3NE%*)F>/
M.Y["("^,11X5GBSW7/29+W%H"9_YI-TSOLI%T(IH4/" FE#%AZ\LJH=;&>%[
MK4PD$$50T%<,3R=K(MG0 >D\G@!L4X3Q[&&87WN';M^<*9":B442P]1<O!?6
MU<JT)C\?;)H2:G+"]2;]?F-H_A'RJ[]2FK'6(1IXKZB>+G.?EE9^-\<M\]75
MIV]]SSYGERG&ZECD%"<VG'"M+S]<][(TU-Z$:.%ZQ[[ WKEW*,^5[^04G?$A
MO-C>G4YFK,2&3[_;2!7O%D@@>9D"1?S; EZ^-$;OV5Z+ B[#O[O'B673I7Q
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M3 M?2_K?23R%;]F=F?!(Z":JQDOG4KKL6@$\PX_)J[OSV:7!'/,L,31<+ O
MI3&)W)+5\1(JGP?&VS_[IX4>V67'\<3"MWTHKPF[_:$NLMS+-Z&0QB:!Y@YB
MV3\%-W!]""VQ%3C%KP-A$LA.$M7*%'0K!]%4=8+P*"5)ZX28/EDO=.G('BYZ
M*]XO#>0'-I*+BO[8Q0P=-S0TA(E\;[12.ANQS/1F2[H^SZI1 Y:8^*KIUF7C
M195HY6I.-*\WX.E>;S+P3U@>T;_U"!)J43-8$B9_<OI=M7.-+(N>13A84F)'
MU@H]J7.XU?%PH: !*AT$>,A#6&\.?!0/T59N2""UJ=S9*[BWN/UONJ1,6$9]
M%F,[H.[WY!F;H(+O/2?>BKG1[VU4#BL-J _Q_MA/22V^2JJ:Z[OP-=)4WFJ1
M,_;!,AMXM72O6&2SN5>&[_T%P:H@;$&PFGMVBNIP!K@1!) AW#)F98@;Q>F.
M6\9+)S&<%?6,GP"EX7?CC$*LE'LDD"0?*E[)-%?=0517AR&<:Q68:&D6?J&M
MS.&JT,&1D;=,G_&88MF?-O<N> 2AFAQ2]-325""-^D)QK__"O8-MZ_G5@:<D
M5IUZ/G.:LKM+AP=]OK&:9FDMI40%$DC_$&I_.Q]74+EHCIHV8.<WSHH(_S;3
MC:*NWMV'RR#N>>^0SO/\._B!_6/A2>)=8EI.<.+E.:N3*4<J^L[6DH;6R/ML
M<'W&_)=&QN];+@Z:U,;KZ3K%;=#SG13!6[\_*VZG5GK<CL*Q\+T#4NO_N5TJ
ML8DBXBHY4NNE>+77 [^MRY9]*O/O]A>/PINQ:#"6;3YA\N'?+T8S5)PN;WO6
M'_N&<QIN[3YF9,NF"/=X7.:IM L5 L4[Y[62JY<NA:G'I2!"LEVI30MJ<:/^
MGI@,U/19TT3G4??7UF53WGD)B(N>4<MG499M[C\=@D>B6S:0TG7X5SR"VHL(
MHX"'IU8, #D6+ G!M@3)O"TC[!A_!8# ES(+(5S4H)MJ988UX]ULILST')\4
MGF+709O ^-\FUG8MWA[.>Y>0OUSX)'YAI>&)</,J1&(\A45 M1*6T8)?Q6.H
M'1)(!"$1$%IU@S6\LY%G1Z@>6N;@+:YTWEG=MNS/Z>Q29V(/&,J%J7IYG;MQ
M5#TYJ;"]:-+[S]_HMCO2.0\H)B]N1&Q7HUH.R?GL2\8L8KT2!]\,$=,KF@JN
MC9<YGQRO3'XX$>H<5?K'XEFMD6+3J,_$J)?WW_/NY67.Q^BH67F\?/Q]XF%#
M.(/ASV_:O#:S/1^\\9Q1M)(LL 'SO9O54'N$IP"MP9G>.-<1#<.4U$9PQA&Y
M'ZGYL$4F_GNCR:JLCVWU0.2A-O>\1=7(&Y&J#4?-"9O4E'D[[DX@G7+%T-/S
MDQW/ZO,2U[_4B+BMWH 33MJR,"H\]:RU:7SU]S/19LF!I+"B=77-1J+VF?#J
M,*N#1=;G"U?]0ZULP%&I&&S:F09IAY;X\%D'+DJH9(+)'YS;H3[7% ^TTW 0
M7OL=%F\D!:O?$*9F;L:4%\-!;8[\7#(1T[W<4!]Y9?)J)K7G"'B#\T?;Z)K/
MIYCL*Y\PP;:I_)?2?HVE_<8@(N1EI&:Y56U%0U94@0@UO+J!EYO#6C6#Y0)+
MT-8>M -HUF]:P[L5]2/8DSV:6,.6"3)%<1%W($<"<0 #S4A7HKYUCNP)]VC?
MR$USY.+N+K[?VV/Y$F1'X^P<#!L2+[/ODOZVR;$J0"]OO U.;;"IO S\$[NB
M>7NL__+CB;AE-WW[^B-6R+EZ$V"NKZXX+\K>//O9."FV+D'1;J%A^8'(&]^[
M6\J>5&!-N:(\:>1'%[>@ZLA@%7#:ZOCFP7!6JCRB/WO[U'.8%N(J<]J68U;1
MH<*O9,/W>GY"*-9O1KN^F",:2\-RJ'&A <DS5]'_$_S6]M)&_X%;$5\8OT49
ME4:BBJ7SL0/'H) )*ZN"7X5VX*K -0RG0BF&9:GG_HG3@LF!'DB@M(L!E5(J
M=N>*CW/>ZSYSGZHBU.1JZWA'\=K[KS$E?UN7-I]O5Z-D!7O9:&NXIH-%4!]9
M5P,J3U5W9ZT-Q82G<NSO6G+(D-P+69<&Q[&\V@^U5<NB3U^U1XG.MF]'P^RC
M[@>%1U0J$TQGZ1WDAF<"! ]&F]L+.@-?:03EKG L(S@1IX$Y/J!EQ8MZW&2R
M0@0#>QF:ZVGDI?GD"Z'%='MZXT<%??D#6;_\\E<X^!",E)J[/-$S1 0RM^PD
MD"I4E!'+$@3FF*M?[=^0XT]8QM6 4&J>T/$-5BT!'Q2M5<4AI1MC6MCF?8AM
M^#Y4''LF_AL0G%;2;V;.2,[N*2&BP H)Y+=,MR+!>7 >J+L K@"N7)E>>;S+
M>$RD'%>WCYD&VTGN#K15I7F,M>:FX90FA-HU8=Z>W2D?7BV:F=WNFG(_^'DN
M/O"&LC_6>*!; W06%6]>\R0 J%7P$).&R&"8+\<#J7U21M(*37?WAJ>2X6JA
M4@L)510>Y<WF%$77M"=V77@#?ARPDN&9)YM2=OJ&,]Z?L;0-9R^%GX2OZ<>>
M.AU(_1JZD226,O-+_X:QCG\///)'\\B!7>9\=XTTWL0UK]/>OB-+BO7E[EG'
MC#.BOE7IV[\\8O5:J<XY,"/V<HU>;=GKU;++5ZJ<(_\H:[B]\#54^PM2+"<3
M*L ."#QG%E& <R=!3@*18IS"J8/!KN31+A@BZ?"HI2G+=)PL.D4M-J4(?UDZ
M_*?&K4GULL=#JI5U<Q:+!F:5U:;?6F9FQ!W2<)!!R= 1/4'\D;W] X.'50L0
M')= PC^UYQIK6J&5P^80/&M"^DH#2T%6NZMMK!6U8^C6\8L+1]7<]>Z=?_/O
ME^\C*])P<NMFJD,F3FHG5"S->71.<-(W B.8P^P?2>VP3;/279R#@4T O$\+
M!OIQ#DUBSSP)1>TPR88/]!B!Z) 7;.3V4+%:U_AG2[5R)JBW5/RZ9GLN!Z7X
M8MM<2YS(3FH= BFLO VD4)G+QP&QN:EK,_"?<:.HK?7D!ENV>1K9M! )#<?/
M>/N7=:Q327M-'Y<_&NTZAZ\(:?;$Y)TP/460751MGIWVG/4**YXH7?_TMM'@
M7^/E$6J]M2]5N\'AYY21:UZ)_U;M^[VYX^_B?3BM GM/3WO/+"LE!OVAOGVK
M]I&_@]R[ D^=>-A4Z1[#LSM;<;U WY9A8'_S>M27T9->LS,-A:DSTH@T[D^<
MQB?F4X]E$@LMLX#3'!?O>X<;1LE%'%UFI3I,?(,J?O)FWHEY "?!LQ3LGF!2
M$,I5:\/BI@1C7QI'EJS1.4-[%C]=ALS&LPB4YG6A I)%HZ$4,2UB638'.<UT
M ]?C@=5^"UAZ?8\R;LI[G892L@;FOO;/*?7PE-MQ,N,]IMAS9+H)1HA\ MJ<
M:KB-@#)>$/WM IX\J8PHKF3,2B!P?TU1,8+U,?=/_'93Y-M3[(_)8AUKP"H\
M =5WVQOCV@]K::LB6K,CK_!=:T+%JN!TS>(]#*W/?^^4T[/]-4$W.,S=<POJ
M5]XM_,7XI&I6=I"NM+XJWG%:*@41/(10*;Y/? *D\M8]WZSE,CRXAY,K0XK$
M,&!8L,B ]J&W>;\S:S%/4O,_?W>FO\Q@,C:XZ1FOL>J/]AY-<L<;DX;C?<4I
M54'A\1R8 B[AX?NWEOE&G/V!W(=61K?:=$M^+GA_,JM)SJS*G6Q?1K>H<HI.
M"G12"39[4DO/*O \V[KHEH5RL\BKL7#>:,E(2EB82'ZF;N==$N[GUF%>&7IH
M9)[.?RR!%!284 1V\.4E":0ND$W&!S"!:P1A^1+_7^D2!O?B12',)!5PLV92
MJ52LC^)FRW1$G6OP&2I? 2@MRBGG>:1AM_%VA5KMXL6E2N7=@(T:R/WI+7AE
M&NNUNX@;+]I.\VF=[+*K9&#:+W8#K^M(BS=O=RYI>[Z)23@\V"<E+-\\:/CM
M>%8MOLU#N">72WQ.8:2R^\OT1!V6D:208G0J]F1\/.##YI.YT)T@FI\()G!/
MR8FB/IZ9$IH"A/-=]"[]RB5G']5\JN*BA7LRT73@225I<;L$XK5Q=&9?P0=C
M@&))_7CR;.5]=_;R]J"DNIPJ!UA2#5(IL<:?'&&YL@R\#4JI;E*I=5*X&[-H
M6Y8U>V'>Z7A2]/U2BZ+B.CT[ZR\O3K3F)?@VUA=L-*@W\7*%ZJX5H?XZHC()
M))*T.[S-.<S[,(7+W!%2_+HTFO(O98R,VAKFKIY\?\[G4)G;Q..O9P[3;*>U
M(X,B%+YW"[8]296*1YZ4=MVU] ,,:!;=/7\"=%>>>3_TSS;Q$=YNBB@5'0"L
M<K*?%/%^9DT^(\TN(J8GU>#U)=!4,T9V]TK?PAN_L"]A9G%Q7T+YVU?7/VY>
MFOT3$8YZ:\Y.7=%A,QF=;(3P2$,@;>XTD$)F&R! )[$ZYJ/ Y^*8\'1L(/X&
M/S=%;,Q+;DB]%WO0^OWBC>EW#J7 P*'?__D>+-ZM)EUHA'B"V09;40)\^-FB
MS!X5.QZLGXZU^@= #H3'(].8NWI@PX\6M60GBUP \_1)5+K6KX#/''/) I]&
MBDDN^HTRCJ-"$R/*OHPX%&.,R'X!9?-[RRRY%^M4BEGE?T7;H-:0*RI95)%-
MV9$4GW.+X-^<662=/T'@J#=7D;74$5-RW5[>PDU5 WJBSW\RZ]FSDZCC3E%+
MA5-B]V^,U< OTJ#A%B"!.$F15FQNFHCU<?3BP0='8?)6,*P3[^.*ARKA1K7_
M19Y#!<A@3+&(J</?"M&&K\N?+)DS=O<H/!J+:#2TA%73%-_:\B.-O1% K!:)
MLV(KWND,K-I,1:#$"K,P/@:,A=XU)&?V/WU#3M"]Q,O-@9N&CT;O9UQJ;2'T
MMX1;F%55#]?8WH#Q+]]9+&R;+&R:QEO#@*A5H9('%RY4$K#@@PT^_ +  'L:
MY/%*.&:EHBKV! _U9U> /(&:N^73!^BVH\64.V2F\H(BRC>\["!OL,HX&W<U
MAW[I:?(W@<'?C4&=2WC6,QA@&[X*ZA/^[()R*4D6$D@J5D=@BX71R:7F9_('
M7,(N?8+M$>Z[V6Y1BY'2LDODPG@\=-%L0V 7SYZ][F?,&3NY%NE$]RR4,TA#
M?^O;'YP?@'6@.GG6(E._=#5<XZ.RB:Y+>\,4/#'FF=GV+GD%)SDGGXZ19!TM
M+,G[[Q]\9YM:#43J4<)/"KP&)]$^UZ?7[%\SPF.7OG^M\93./]U*#TRHQEJ,
MXZ"X(34"M,N6M32R/4Q+PX=RQ^QV[,?$M5)51\6OUK*!W*70R(C/,>$/(J)#
M=;J>2IWU/WFZ;D'OI-J E3*.^X1VY#)4< $;#F8+'#'0/O$VP#R[1X'*]C,V
MU.7(W,4&)M1BRK%^58O\JZ?0.Q=OO^*;W;Y9@JX[^F7VW33M4-%D^GZ/^BP^
M?F<O"P]:$)\SM\Z+<F)(VS",U>>%C*TP^6^4O0M2&U8:BU3SP=C,'VY-H5T
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M(?6_)\6]0Q\*N"!UC$\>2*W&BTE\Q*G5:>Z_HH=208M"I1/V-HBEOJ^/ 6K
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M5>A((B9J^G#'U"KN0-C3Q9N%ZL7>#! M,(-]FA'OT!%HB]\0FH*7#=1Z*8Q
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MZH1Q>#3B^X4IH7*G>$Q'$(1?7.,EXZBL=N%]D"!0<Y- QBJN?8#UHCBH8JN
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MJ$L"F==& 2ZK@@M%*P422-W4H(JXWTVJQ^T$X>-P\4[I(H<JBIHI:[?!/DH
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M8PPN][)U#-S[SR9MJJ/-W!?B#B?7*6O5EY?RLYY4O L,TH_QN.FQ%B$<DI*
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MO_9EZ)$NW/F/.>]I '4$NW!3$DAK$75567@9W"8X);P$4EBP;8NWGV1RT'O
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MF1++O"NR;94F.6 E?KKP_P#DF.\F@9-+![:$.H4[Z9CE&1.V^9W1.6Q3]@Z
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M[[LT?MCS5"NTUFF+E79.6^B+*SCQUQFOVPZI1^-]V]\V1YH=JLYOGSVE&1?
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M^13\]NS]^P59T69?<5%TE@S]IM)\C!VQ.+HD1B^<!_M%M'D02..@!TB_2/W
MO4@#8#ZPM=3H7JG@8/VK 99'V/D!HZ/_U/=^4]7A> _;!M2QV .%Z/YG87W?
MQM'>R<'(S]_F)&(84+;)QX3/$:\+A8(]4]LK@),="+5O3,THI-Y0OB@QQRF
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MOCTEF6T+CVN SQE&8LF0?UT#>X4ZTBW?R@ 6Q2BICH^D4'93;O6!L*[ 1?T
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MFCO1_2;;P>9FP43IDM[V<T<?&Q\<;?=V:ET::S]86];:&OP)L2PU';_1P5^
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MC][>2#,@)XD"_O(,9/<[-9,#DDZ/K]:$*]G6)-A;>;PSCT#H#5/CEJ,D<I\
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M(C^^^KP^=)V-R;@!N25$M".26A0/@PF][&SIU!7U>I7H-FP6;\DDW8?TI:I
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MDEJV$=8'U\W+<DH+W<:R,V^4!#F=[>;N.J]X8'Z/>I4\@:P\I:A&C)&G1 W
M7X"2,S4;#/QC,W0#[/2$7!BP]^-NEO>?Y.M?['CP05Q2+5XKF+H.;6U*.66K
M)<WB^4.2A=?UA&*(U)KI]2[[W(2PQ&S**L;4%;GXL<@C8=^%VA5-ZF[;6X]>
M=W'I?_YKP3[6^F%;+]^.\_>"MS\K]]O?\K3U0MJI_*\G$GQ++P87,LV#)J1!
M(50OXL79+QW$OP-7)PXD.(9!VRH80MR5-4K,HBD*5HC#=(J;#[0*-,Y 57P\
ME[D&(G5X;7T^48_7-H$-(@XPW%H;*;KESX6VM7FMI+\8NR9#M\2."W20Y?UH
M-V8H'G&$V0.7F?%L#2)$Z 264PY5>),:.UN)*9>L!JI%J=Y" WV/8V#"J_2*
MCU[,>/.8,X/=OL,GAT\%97G478[Y5)P_?G;D9"A@&,CPYWJN $^^:(QRUR3O
MHIJ0)\_J'O]:,M!Q_-UH6^VVMR1\@-KQN+2"9PU>?;[\8K.S"PS'SOB EU'@
M/*E^!/@97TN UW^14ZC=@I7PD87KT?0@@GS_1QN3[M 9K 8Y1]1/2ZX%DF\.
M!M\8'AR7S>-264[,D2!D;:S\EP;'GYDUQ!5#Y+*CCSUK4?YG84DX=XYMMJ L
M%S9=!!-187F% H#30ONK-HO(7#N()MG.NE@Q A/!SC;"JF#9/,O+.#%Q8Z\)
MRBH(3]PK3QZLR%W!U'^?/MOK8]VC5JFW9<?7U;877PN1M?>SW)^5_/9XNS^4
M<GM<_ /RRLFCQ+;$-3?XYBW&B9[@F:_C#H>G,XR:ZGVKLW-*3'XKSY41PC.?
M*<)Y);,ZDTER+]@>':I!74F<VLC689T6*R6FC9!8CPJV<&.]SOG0IE*RR2=@
M+81O&UG>QW/O91T0$U0G;K4OS1 S#HM;SL'VOTJ#5PTZ_C[G_KHKZ/P$IYX&
M:Z5*YF MG&0NCA-DFM(8<,5F/>4HB(NWWB]48E:<@K%5TN+X73-_47:(#UYL
M]]K63+*\!D=(G*A=;0.7V<WGK:T>T"L&&9S!75MJ:NL:KW[:!BU*F37,\._?
MJQI5#M[VO]/3RE*W]G;JOZ[I>N_](=+SR;>E3C7BX7>SF_."UZ<0;N7D9!6;
MW^0P;N(+L.N!EN?T.J"=/F@D-IQLD@*B@">X:SH<#63M!%[5G)D:J:N3&H[5
M& GD*S%)!:"L6)Q.X-K@I"=H\0^D'YY&J)]Y[M)=;FTN<CQXP<DB CR>?8EN
MDU42!4QN1#W3"N0MYU$72BM64-2KJU$!QQ-AXQ)>%B>$$U(S?7<T2,/B*38#
M0V:"Y9!'QPA.:G/K(#,QW+O=TRQ];YL5(9GW<\^[+&[CKFS?U)!\_D=!W(P'
M#2GZO;3US ^X-V1<B;C22,<#^]3T;.7.E=D,>P';X&C.[[3^X2WY;UT=J@GE
M[A_<9#<_.&8<F""-=#6R&T=&IW6F4"6JHHX,+ZP0<NFK8>U,7!)]D0V6_*J#
MYR@-2*1J!67_);5,-;L&ETS/$#7($VW9KYBE2HS?>'TE"@ N 6PO3KC?9Q;O
MI'(2Z>^M,/?O!U0"\YO/E1D^^_R+9?^>>RMQWR5=D-TL/KR>W5.\DU939C%\
MM':_WUKYT9OWOI[),K_YDW/AN$W0TZ=3EZ;]!\,=G^+*B*"S*;3+?FHA\UQK
M-]N03!3BD]@KH5XNH#4;LIC8/T-,H^I)'W#\[T]<UL[]=&^^.)$62]U(.?BX
MMI&WRV17B'EE:5?YD5U>:V@*^LK<3<2#2DQ&(!UT[>*;_H0.K]CGJ"/9O@;Y
MKH^-=Y (5D.?#^JYO68=1B5FB* -T1N@Z)DF_/KZ',O#3WQ5='!S:W8??RF-
M9)KV?L#O44T5TLTSU\MH>-P S^=712UUVN5^.CWJDK:X^I39HZAT($#^PG=-
MN.1H^,ZFB>6]\9O-;GYX[^S4?(3?5[.YR^2D8[;JO)U',R\[^A+>!2\L)(+N
M'+X]HHJR2-5T*AXZ(NR,/P/M5F*6WP?+<<O,L :!JWP=)!S(SJ[6HEXGG;J%
M\J-W<@%Q^9A#P+9<Q>UG>9>'%8]B<B:'.UO_M?DS=>'(9^G"[6X4RX5-EH+O
MS6G+*8Y@2%=*;9<:Q;8!*LT.:,=KD6GM[ UYZA>XX@=W1=J<ZCX* 5B:OBMO
M:>;(R#.]?=,A$>LDV1\DGU>FO/Q]Q.[16NM*_SO^5YY+73J$CUA5LI.4XX;N
MA:3>4[Q1-Z:[1TA97\9 @:QV?Y%-U$6'"\\\^CN>>G[U-'VLL%K(HXA6QQ-8
M\&FFUV#O"/ H<3F9(T(Q9-CS0<IK)29?II:50@?<^L)+7(QAPOV7^23=-?4B
MXMKVPMH/U\UC]KJ&F+K5Y#U'-)E8Z X9X)X?PQ.@+D3MB]R9)*BO2$=-^AW(
M:Z$-CG+IFC >/(@L&D,T^FKHUY -8,QT0H7Y7?A0!&-B*DBJP\T>*1 SZ]\^
M#?*/.EWRD>]4D116_(:0/S(R1"CSI:YV<4D6I<7II+=]V)=6IN:FE];:I9+:
MMN_9GC91Z6&S4>>J^ +5>WVB91=?F>3'^RTQU_IC9[_?VG;GH[MOWG8?,_N4
MS<FKXX_V$^OJIV*D1K)I12$E1NY"\>F&U45=.-BV'DROJU^8KC17;&Z154*F
M+7DXT"(SG(%O0[9)$VL7OPVR65_YN$]=<,TTT\?.NX$Q,# HJHF;P@]U(FIN
M<C>@Y0AU,1DK(T.]J($-UH(>W*XU'WWWO(X@)""H),R'\B>.HZ$^,8*I.GBH
MU!>J%C/3:^Y.;NV='6JHR*]YO:O"0'8@:%-CXO>9(V%_[30J>A?E&.5&5E5_
M=_[8,V]75!BD%#NGI&.C?RIQ*<)&YPS'^K1/&4[+N^;HN+E:-L=B\".P@K)[
M8:_3?>O]$H*!%VQ>U5=>L;&'12P=T\VL%+VT]/VRP6)Q^_G &[ZD =_U>;LC
M]&7%?WY$-O27_V;QF?]1E]EU3C!@.%FVL$L!=H66@U]:B6J40W)[BC&D$ T;
MV:<^L5DDQ7>&Q2DQJVN E$9JY9]K)0:;H-<2^F)([EF5)7I;MTE   >8^61O
M<4"[L>^.WUC2>+_CW52!5 V"\MF1*8^M*&Y6YYDY5FNM=CMGKHQR]TY+MT*^
ME'BMO6=KRF@U/_4#F&MUHF2$QMO8-442&;U78KS_&&699XKTU_/BW2-2,X(:
M_ K:UN5Y;DVZ&;_QZ%J*V4Y1?_#YDK32LKZ$DX[:A.TENPZT"K^<6A.C6 JT
MV"DQPC^Q*!@/\68V2SUDG-<4+/C\:%_%C!(3)UA:@XL;V0$*8EG:DI\WQ'9Y
M0TG2E&A@%5G@TU=C'-JQW1C>S1S3S6HC:+X!@B?&_(1$%4]O<]IU!5[6NG#7
MT<F%"VVK1ULY@UEB#AJJ1K@BVE5D WFQ+VCF3O^.?8!L[\.21K9VJ4^PM1[3
M)0^8#^ H:<MKJCK*'Z3F,^ZWX&WU ]1M+%[/JTU@6YYNI8T%$K2=N8F>1"[5
M^LP_OB^;L>^WWA(/HY2_+FQ7N#*<?8-+>EI[+I1Y=G,=M5WV.=>,GW6+?_A<
M.RZ*^ AB7OWP8534O'7J7%FTB8EXV<>I5P_E =?>'5>P]XZGU _$9/5_WIH\
M/_YD%)BPG&'(J4"+JS>BZ@3:M]"K4=Z-O8[_#E5T^->4\P43U$6I3S@8FQ_(
M>-=>.'HA7P/)8*W57/M@+3&-HS,93DO0\0JX%M893[ABAN+N[<N2X;K:@L%.
MT<1V5LC79-#;&<*"!/$H%Y\.J.))#UY3PH1A^F0_'^@T/A71)F<_ZW20CEZ-
M(.G[?CD)M:@DFC>[B[D+"\;\@8,V';P6G3QSZ:62PO'Y5W1FH(5&T)JD#N#>
M;0]WE=B]OU0OV=5D*G[KC%MLZ,FRE*VQW7E"/XPV5!2?6C*58:6V^MF8W-9C
MS_'FV/9?,SWVB/.6EIA<SM-][7KI0SBYZ=H&2?1%.39X0HX/F)("QV4"3QG1
M_2]J[:S@X=\]<W\A*2(AG EM5TD# K XV!EBRJW(;NV"ZFF:VRG(F$$&9%2H
M7^1XQYKX8'Q$>V#V*?M@.6>]C:$MKL4GTA7,2S\O"D1PALG(!J]:I&GTS<?$
MCKT2:B2BNA@%XT8<Z)K*N6)5W$;@'Q&%M1Z\*#S;)+X$Z8E-$_!+;793K*0J
MB=2-P3V0KL1+.MKNY#LA1LW3U+62;*+7]1U$E8L>,, JPBIHVKF9W5\1P=#<
M$:ZOS2+ 'U^?>ARV4GIRO__G5NG!X O/_%(23[Z_\=O%^?+S]Y28DVFNW$/[
MQ$#D[,-VMQ,'V6?'=AUH_Y53-7[*LV7UAQ/6EH7-3*.R27(3/K'QHI5-/^^=
MC#JD,TL(F:7[SYY+FB#ZS%^/1*J!H+^O%A2^HR=35X!Y-T2 'N57:+64^LE1
MW["%O5I:3&.K4GZ! ,E&,1'K&9/5YFL!O3>]8ATAQJD-0I;M>RKH4:*FZ42J
M-H_BM)YW^<V ]<9SV:%_L#?!I0LZFSHR7P]K#<BY/\"ABEHSX\5/^.X%,?Y@
MO<@C$5&!LIZ@:(1QDD>5ARH@)4:<P4 KL@&*)2X+=M^DCF^QJJ5?H^XB]SI6
M<P8VA:T,M!L88V^D+GI]"L*NP%=)!7S/2U3PS9NZ,=ZI@W\\[;UTWGG5R9-N
M^:-K7:YO%)U.C/#SWIMN>7A?N>:SMX_K8X/M;S*3M+[Z2TM/$=M6U1_,)9P9
M9QVA;6:FD@GE,:3!&.^-\UT\:D&N$E,^C$^;M#8N(A=X]E)T*L8-#,'V= E_
MS&9CO]F=&KV7P<LPZ;6&K^_W183W;F[*\"5%[RT1//T>J^L8L>OJO2]:+L2'
MW?%C+D7.14'BG6Y%RXZW'4_?=YRYK]WN1+'J#\5']Y9L&=W>4ZQZ_D+PJC17
MQR\OG(Z>J-0>[^9RU>P8P;7;1:>M:D\G%NU_=OSCX:*H/H:KV:_]^UZ5C[H&
M[W2[73CDK^7B=2?A?W0Y#6"'!X/Q<%%7)TYVAJB-G[T(KV*.6G$*<) Y#G$=
ME=#DNTU3Z/,-R#*/4?8.X*E.MA+S%JO8=[U<1]Z.I[_KFJ'EIQA![^9B4[;_
MN>B_+?]P(%2NX0%]0D: SS>8T(Y(1:&C[)D2TS\A454DM81]W2'%RTS0D%3T
MD^@%/I;3QC&C<&VU/&;WB_^'S?A_>,&-%2@Q2]N 9ZN ,]/S7Q<29,TR;*QX
MTS'494!+)>YS/.Y-$\(&@O *$N%ZK5Q ?#+(A-/WFLJQ'<"X[9$Q=/RMI$.;
ME9C"/]'>OO+H?[+(_1^+W5 (&O:> ^\"T4'F!?!&IXJ5F =A@P\XZ;K(<X[P
ML^"K+EZ829_]*D>_,)8C"V)*[#CEL)X2<W,/3K:W$PDGK,8A4B4FU'[A6B?.
MB7W_G9G_WU+^4TA_R26^IL&Z-"5FQT5II^).5CM!<6HAS= 7@1;G7>I+X),*
M<L_>74TAIG=]#IBW?VVK#5^(;OGW:Z6(DB9YE!+SS(XC+!+(;I@.&2DQ'LPT
M(\6U,NBHXC9'*)A^(T!4F5()HLJ3'Z%V"S25F"#Z4JBWA0.>G!YZ+NS(*H+7
M2K-:N[!D7T -BN[PU9>V9R@46==M5L _]1?QWO>S-Y$NS7FXSP]7W)N/J,C2
M\CJE\X//L" &5<-O;8\D?%E_-B2Y8.?,_81T%>?5[R*9+K:.=]T>3F;W7VB:
ML[?8=HNQY/O)H68^FS]'O M?=B$*L/"AC(4\6$I,_K3\LA(CZE;D<>9UMBLQ
MU_9P%A)KSO@H,6%$V I7S5-B#K^G-B@Q&DV&2LQ]7Q2)JEN5F!= /ST# JJ+
MX0DEYCLE9HHFO)R"0(!X!1-"?U;H $/HDRN3)F>5F.X&^W_^WO M]!^8&DI,
M MHQ'_#C7<]&9>%*3"X@Q"LJ8>S_B<KBI'I5P+RV& _F$^%.A>?74\@K^A<F
MK*+$U.&OCAO)1?_\Y%(/&*T&DLJ90IN5=$2&?N[CJ0)D\R4"^CO+'M%R5&+N
M*#%E>"/Z8"\2H<1<46)DG>!!6X""_Z>'-SQ;2+VEQ+R.5#0#X$=J%U&A=AMH
M"WV*_NQQ38EI30:^X&8#WE^46P&O." .>8.H/&1.)_W3@^N((%J+>1,EIIZ)
MZ&,'T8_=OT"#T@?Q"E4I#G(Q1?R0<K@"""!\Y2$H!QG"/9G55J":Y)^>C#-"
ME@-*C*U AAJ+>U]^$)@Q<?E/#=XU.:;$H*+R"2#W@PSR.6S</SV\RA]H,44;
MV(2,<*!P?  327B&%UO^AO:Y41L@^HGSE39?_;E!D8L?)4(H:S\'+.[SF./^
MTX/_@"J[23J20*;!VU%;HL+=G>J!_X;(;XC\ALAOB/R&R&^(_(;(;XC\ALAO
MB/R&R&^(_+\/D0N9"?[S&:#E0$OE-;06L9NH';LKCG9&RH_^:;AN(T B7G^V
M]\K2W_<_67PP@2KC?<DC*3&;K9\C7"E]_L:QV1UEA]5J-G&^_[_H$,)'6R5F
MR8PBG;V0)^Y'CO ^ /Z$'UPM,6F2=*V +:#FAT"+W6:I23WX_#@H2Y>D:H/X
M)UWQ',WP6_?'?7>"G+09/;_S%="!7VKZJ (1XQ?'PBY@R:,:5N8(PNOB_.<#
MAU@/$JX]7JDAFC3Q3FGI;SO.]-"^[I;@X;3]1!MA97X/M[_)E7O4XX/7@0ME
MVV#83O/$>$/)]L("/?.8#'G%Z/]Q8&;,TO]]^!"QW_S0-S_T_Q<_] V1WQ#Y
M#9'?$/D-D=\0^0V1WQ#Y#9'?$/D-D?_?0V39/Z6"I[[Y!T@V$"!#(JPY)]2!
M-6\A:DI,,45-D0L3I7$=5$WI-*R9TZG$K(E(MY?8<80<#?+UH;;+M*DCPBZ5
M+O\'PQ .[10N8X^^AEF72M"M]I"(0E^B\<S<9W:A[/,0GP_/:9/O9DGMCMQY
MO^^<NI=VL(OL6>'$_O:=FFGO&GP-\BID'(O<NXSUZQ_V)]B;]5RJ93367P).
M'W>QI:I>/O3?;;B(Y8"'IK^^X"B*RQ#5C4H,B\JY7 9Z(,L.*C'[4;O4S (M
M/^'G:#PJ3M&Y>Z85&/M,;,?)HS_C+S_,3Q%N_\><\\Q.++0S -9.;<.!SD"R
MH+*^A?8=]:^1 PJFS7:$[\7I.*@B&HV%%TL7_P1:5(:44S;50Z<CSI_6G:#J
M\1BS4;,30/(B;PKAP=;80(]M[@WRWZCV[0;6J 6_(@,<3/AC9#.UGP@>80[Y
M">E/C%>23:G;*:=[8'\1/KF.HT[98#HC5R>T9]<EW2=[_%)'<C*N-8I.2CHA
MQ27=;ZAW+#G#40NXX(=![CYDKE/DX0.Q\8):0@LND5Y#>,+1'H($(M/V+K63
M$*?%8&M]'>L12;$3?+KB#]^QQK0UC9FWRL8B97/9=O4%P>YU_.NT\I/$H"P9
MZ,-WTI2;8[1<B#N0I\0ZYN24_'>RG[@X#3@[O8X(#7&!I>Q]D$1V23I2 (@(
M6I#])$Z+K3^&Z/5;NQ1Z>D+5#J^9LT9JWM@U']V&)BPRJX+JZ23RG[D/ZAJN
M;\"6;6>^F(XCUM*G;DBZH!VXJ<WRG11;12), )DR!\@-I#M(ZUO#AG1<I$LZ
M2E @I>49]9D#2\<&$)T><75/5^*:";?:?M;%DJ?WWY 3O[3;K*@"]0O99KWA
M7REA^4->R)WN_P4;VI_I4R1Y,/)*\$B)2;190WXNNR%%!W\LQ5*:):%=56("
MPA8%6QAH2>U3V0*IHW@;7>SDUCIO.T6/G\D]J\0X/6JL!/.:#G941P9GA] '
M-7>,>E:$%-Q>//YL>_X5U?]:C,1$:#LPM41NBSP75(6U<=*!*N8DAXF\P:V#
M-V3O:L2VF*X0O!T*YK-S(\OX7A/SP^R<PL%QZG;I$2CRYYL3KJFMOBMZS(E:
M4.R' ]'Z5@/[\L9EO<T]0.!=EHY\[1@'[:Q#PB$EYJJ.@:;B#@,?2.-O%LW-
M1Z;.$N+< O&J!5"&E-0BD.[L[2@2IZ+N@A8D5M=!MC:>9 ]\,J/-',#:?#AP
M&3-_*47*'!R5S+5V\>G"+"Z!CQ-F73.Q=@.+Q:,)Y=9^PA#JA.T ZT!$26!V
MTIU*QXOYY!3N+P/A0]<^I)"B&-/EOY[?\LOKKX_,W!P^XU G@*@:BZ:AG1Z3
M<:)I?B^7J#9+CYNG-DD(ZR%C6*,"RNQLYV5&VBR<%JO>TNQSB>O0+6R(<[%/
M>;_9RK\F\U7/CQVG=;NVJXRI_]<-<MI?F\5,:'M]$LM8B5GBLK!G[7O68XA8
M/@S1Q/:3-$#N/D@A)K75[<@/RK2PL99.Q^JU6/IJQ&P1O(PPA#=$7LZ>>#01
MJR&31V\NHHY[5]/!,%FUHLHZ$GW=9D6!$N-/N$9_)$A&UE"?XE79J\=\+2 G
M^9EQFPV/^ZWQ4EK[Y42F<,I&T#K_FWNV)]@Z''R)7W_=W+![TOI(I)BVU).L
MV4-<-U:G"0W9UM5B%+O_WE[',0OOXC^7=2R<S:9#J;*?.8HD=#!0.W0]6JY9
M^^53AVY-?!F&(MOQJW[KF3'V#5GZZE6G$]V^1UC79VY,?)(N\@EPJ9;&-]8G
MF;#\-<+4@JU.-//&(OXU5TO,&=F)OCF5'-W* 4_@$@6@XQ M8?ZEX!JR!?EK
M3HFI#<EJARB.9[*WW?4[+>DR(&]DK8X0Z?0XP3Q7H'5Y9$E%T\K'&XGU0X/Z
MV[^Z#O^![=']#P0S7_R=]A/M))O%U%[<H[E6PN"T3$^*G]H(DF2)4"7JF_AZ
MDE>WQ&JI(3C9[V!11WT^?]QF^T!-[F;'_HI=C'"BZEN(UG%A(L\X1J657\/&
M58(6M!(?,K.M[L8@AGK'Q9:2*P]'^@: 2L/)5.FT[%&?M<Y%J2972+@R;1T5
M(\PY>,ETQ0@YY56K[-G(AU;>*?K1 5'OIU\LP\PTG8J&;;=4;M&,VK'C\;7%
M$[I&+:@1Z=?=@9JYR4ZY%;6G$4@*I6P\+3\,JT(.TH7<48UI7LVCB<8V1I *
M%SE0!\X.,)84Q5L5O4I=R<H^-Y]F8>'B^_P<;S??NS!?:^Z?O/\+&F24!6L%
MH-$ZUH?:X;M#\<">&^,HGD[[Q/(4$1/HJM3U;X:=BOE0CCC@^CN.TR+U2->:
M6@ZGNKM\UPS#V[V9YO2HJ6\V:I<Q"U^LN#[MD>I:A9(P(1U8A1<6L6W N38U
M)K1#Y4G8H$08<,VX&,SHY*IA!^6=V?7I4Q$^EBY5_>^D_L5IN.,\^,<ZW5=7
MH\,*CBP.RKH0%%DI>!42REQ2_?.?N/Q_@21;B0%_ :#M'3=0K&^#PN2'X$,]
M5*UQXG*\B*[$D+ IQ*J*XL)@&Y-::1:\Y3*G58G!0E@?EC0A\7X(ZFG5%4G.
M_1S1_I2!H:./J[(_".06#N^;;DT9:6%P15H>[SFP=B^BFK&0T7ZSW!AM20VM
M#?=],%XKC.(@M>3BU*RU09ZM= 5U;3_+C3G!IS8Q!2\-:BT2Q$8Q>SH/@5V)
MYB]]/W^6.ZUQ)2RY?D/V.$*?Z)0B&:.]\9,U0='R*.0OP7< B9DP)B.H4L+
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MF_Y55#ZCA&-)17\- XNHH8\M'1[/'B@N_CCO7]\)#&TY-6Y5]+Z.[A<::GU
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MF-VA[N>^P^:NN&27L9G/GNEVODES5&&@E5W&>?\ W(2@C9.4IPDU@1*Q2BN
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M!O%ZHRH"ZSV\S#$&XI,ZC+@WLTP"J8E0A5M^ H7'+!KB1*!QA2.5(>NE(GM
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MF'32%9!)&KRLX3B-R7V.!<'$5(Y/);RSM5TA7S(J6%"[34GG]0H68XZL3=(
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M('OOQS]I>EK*5P[^/'98U'DOV4X"#=E(6%0V4R64R$TP/_A\470IVU=%:&E
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M[NXNOU>5\FMV+.YY)(R!]]R72"L,I62KMCG+N[EK%V@?4%V'6!6*><L;W=4
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MQ%#G*[F(N0Q=$J7W5+ [&F0B2G^P#U@W9PZ(7\44JB-$!)L6R$H]U9'NIB#
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MM%6TY]D*F\NDHYJ0X .R=X^N[PFKJH"XR-H&[XJ*BJ8,OY"@U]&N>BE6ZJU
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M E; = 44Q/6T1EO%VRA^*HPB1'R.576,TS%&73Q!@)[HJN'3X!,=4 M#D/
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MOM $]2([PE1/VHZ<VF_;DU)&SDH(+PD>M%LY 30OH+PUHX%4FMZ#BY'($7'
M;7P#0&?(A9@NI^C)K&\-]X61'98T>)=2)IZG.J0A6D3EV\M81Q.+\;;, 3&
M9U'>, %Q@&U^': 3+H.K=E7DC =L-63;W22>8CWQC7K'E;-LU.T$Z9 9R+O:
M2)JVC'1P WN3U>UFOO=M>T?]'"5!(>7\>TWM5=;TA)2JQN1[%V_F;C#9O=<E
M%UF/J8L[L[BW"REU'GIAE0]:BQ\WT![Q*CN06X3Q82P:G%4$]+8#X3;>^E_[
M@SN*2LY$$GA($S&Q1$]B?@R$M"(^!LM2GB79CN4MNPOZ7"%MB*.K.Y)#K5ZR
M&.H!5Y?OH?Q,U438CW4<<;[3*\9)1D&E;W _T?3.GKJ Z1_$GT?4#'@[#5VR
MX38S07GV21'K%%3,)0*1.QQID W&@Q?#=BH\MX:R8J=*:PIK6VEF[J;TUJ#=
MA7??0_":'N2P$K_<)XJA#FZG'.3MZO+)\+O$/#C9$<3[,(M#3?FSN#]V ,V!
ME/%/E%,T0[CVX@T=%[$]!SJJB&(%[%B,R12((PI=!*(W((I&D2KP8F:H^5?O
M=&T2JC9 (;++0"0A3;BTT?UX8KGAKVAN063^,M AB7'OO=_9F? ;G[NGO.B1
M_#CZYQ,XPP5#P[_]LBL]$*L$E3<?$X[R 4S3@1^_[8TSZB2M5HW1Z3QS++"E
M,XVN)XAGM/.9CGM],Q,D?G=;@(@X/FT@>#-7->!5&ER6<+#KIX::<X*E( U9
M%8&%=@D$B(29P'(^>RL\\-2:ASM#70Q7J?$7!6N15? U%24=KP16,?48.)JP
M*!J>$6RKV?FXAY2@BH7FM\@I*7%M0B/[$UI1_"%QO+K-WLJW^PS=0%53<+#5
MGCGIKARER'/\86BA,.T, 7;V&;\&[@/Z(U3:]+(W/9^\B#;(X9?DE; B$!Y0
M96X-J/<,OUJE-#!:\S>"T[K\&W=H^TG>E.0X_L2$\S'PU+53@X&(?;W>"_D2
MQ@3/@BMP,21NF7'ZG;R1_2)T&[Q=3;PLV/"K:\W[84C6HEC$<H4"DY5/TM_U
MQNS:V\URT>31@^I?G;+RK[+)-;U7GKTE).K5J/4%PJO\,NB6*H*#FK]&$B'G
MJXT4%9 40/Z"FFZ;(Z$N#\&H&U'5Y/@4?\<YM2/=O;0LT6WXU9GWU4<MT6%]
M@(M7QH].+G^NR0M:#5_$"*8!&UDB5VI+2<[1<"5;5:X)+0$.9IWH-\<0([CJ
M+@O_N(<?4E;$0ZT2$\2V/SXK',F]8C/#+BX37&D(K^^L<0WPNHEX1<=E(R-8
M+J4(G."J/1B T#!5L($\+YA);1W:#OOK_9!XP^\D&TCVE((_<7V@!8/!)2KJ
M@DCVYD?PNCN#C)H4TS!I_H::5S6 F6?T^<,SS.+F\\MZ915R\?W<&6=_[)%_
MLK[O$<SSTV^*)LSM.BXS!OI? !P(<6%<TJ@B+O\$)Q#$?6[O/]VB&<OALT,B
M.SO7KY\_7W_PZ5'I IU5\\*)OUZ&-IN*<.P9=J>B%A@?UCNQVP3K#%7D+:QO
MZVH-?S6Z%L)XB8?"@K6R>)1B<49OF*]FI#>Z*+7SQ]CV=:"?H#Y>'>(HL>W(
M9&T[6>-J9C>VW6W0.^[TEJZPZV^!KU ,YYO_!D!??/]TJQ73JY5GA3K1OQZQ
M=K![#/%3D84@32IP!QGBLD#)-?DQY\N-,>H8.[\<:A=R_(X\.NBP-/6,Z?::
MX*8M4\'VWWR6B]OOB9%W<,930@V^N0-VP^L@V%[OCX63$ STA[=C*M9.1%N$
M0;)XM_ E*RX1] @RE E_F<6E#JWHW>PV]O[.59<5R&$-WPYF6Q3==$N=/&/2
MEK!HC^JK788;:#.EBC'7YD$!4A7];;I$D"BF+AY1+"ZG1  +HAJF+YTZ8^^D
MWP6E0M*+U7HA0<$<\'M<1<<O'Z68NYN&'>UFG8Y_*!_T2-/&)>Z+.7QJX>O[
MWWJ>$S(H_2> /MV8[B-8+!FC816T\K6#=0/T!\4"M1NQE5TY4%0P@J[-$GD*
M=8$IU6U&T Y=U1UF]I#^NU[2%NMKL[@EVWAE4;G9:>3?&]K_:F"B,8#R&@_\
M58I!X15%#6.B /30_0X/0A%27\@7-<8_@.UTBSL).A;TG9S)4.9(.E+ETLMD
M2R:UQ99_F>QP9(AI:9(XY%#;1%EY:E.<GZ5[8WT/L3/8C^T+%&)9WSUVI-%+
M;\.6\Y9^2GE<!U*PR=Y(F_ 'VU3WDMS?#B*AR\#-7.5<O^3R/-68U^!W"67[
M1H=,?8_U:.7#!QN;A(^?=&\N;GB2N]?D,!?VJ$(/)*!F"V9QU2+V*\4,CXE>
MH!3O@ZUT6NP1?Z$M<QT6.\R86X,-I>@FKE&TPG+*J\E.Q15CZ!XA$5#@FQBW
M?K0G2$=<RG1LEH?R2VN2;[WN#PIE9@1R]X)-^24ED3/NO75F%67O=1A13I1]
M7#+G%F[(%\8(^Y-08Q4H1DT6ZC>SI0%"\ <&;D11Z3T]/@AM5=9>T_#Q3 \-
M163O1SI>0B-*>$FZZ8;OZ^2&WK("YB6%=]*!3C=*6NCJAD=-<$GA:._0LI<U
M"E,F1WR!4,2KL$&LPW2+#4(LS<5*QE-M6JCS2Y0$.\C'#LK(BUF_P'$:_&6:
MU=J7XV&5">T,GY?(\7M'@^G9O<3SCCUN$R[^3R#KM%7._KV?0KSV/.ERMYO%
M%9,)[ &@2M:"EW=IAL?W*CN61<_PL.KZ-1SQ-'\3_$QUL]&5/S)#2:D&TMCV
MH"(=L=8)-@@KZEYB7*?T?>B&3JVMZ1<?_6.V"[IB2FYYW?^>" _K,2;7O$>H
MO$D#?^#!ZVV:O:B9A,H<*:_?"#5.!HDJZ157=-%[0BU-'.*CC)!\_H1?V2\E
M2'A+D2W"+M(ONEF<^9=U&?^+LG>/:N)JWX9CK2(B!@2A@A M*EJ$U,JA(F2J
MB&@I1J6*@)!:5 X14ZM(E)"I(H2#D*H5*CP0$3F)(0H$E$,B)(%:'T4(!PE*
M3E7D$)E1#%,R&=Y)G_?[UOO'^ZSU>_\(K,5A9L^][WW=U[5G[WU18?^\*Q7,
M#P&]?GM'[!XB->0T=%-EG&@M4A.;+&-W@._K"U![%^P/8!+7;'<-T)Y?@)-
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M2KBQ#H]EJZD>TE[$:@_SZD&9,@=;"P=UM3A&;E5:H5\@FR%Y)V]YZVZU6VK
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MAMZ[VO5KAQ.)OQ^@0FTX/_C<**9LQ+KQ85P@)>6Q'?"AM8,]+&YD='4K*K6
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M8Q$<PC2 A&>+;-:W(&XU;$7$GBL0;?]@@\ :>UKXDC(/CLWT\\?+W+()MME
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M<?[?M <->\W>UZMIII?1N.Y:$&@R-&5+P<8NG<"P!MF*F8LA,\Q<[T?7*#F
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M-P.+ZL_(\6:,.N7F![EX7*3=NF[6ZLB5P<^.OPIFI/BW3SP:5:3X0_%9$S;
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M@:5P87,0F 94$:O]AXS4:TM3C)L%G4'W7\V.GK>[C=!9]>__5/[?KFG_D\,
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M<R8GZ&IEV;"L:G_1M=N]P9\33YY)/#6S?I7']N4\UVGZ^>W4W\G(IC;4S,.
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MXDH.! >_F[*G2"_T6-7\V':BXU 3;]" :UX'0%LX4QNX2!^W'TL=;\Y]F F
M)?^[P4=C$1!SM%ZP40#,K5^H%&=0S87'J'C8PG@LW!NXP[C;RG+14-0AND,1
M!3906]I'_TWTB6AZ<#?/@(M@K/VH]R)7)@=GY>5E[-VHVOK$?OI39 &&T1E
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MZCH$3V]&2B2!->V1)P-BIT%4Q)*-SMT.?= J]46@G#TXLTNP *'KKP"1]/,
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M2?N?1K_>/F.GH!];W9]?N#I187MCWS^V7TU[;%[2BKWZ9##,J\QO1\JN2G:
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M!PLRQ<ZH)])CV(62Z[HYQ%=:FLW62&<SC5EV7'-7+8GKL&Q-?X$%I?+N\,#
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M=>>E/1^5%D@#>9%$XQRZ$_>C,(G$OA#,JB1[#Q:%'N[=1KW_&YH%*U';+1H
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MNQ[GBFEMJ!M2;V!AO: Y>%)VA00=!'/KPJ/G(&YP./T-9QT[2'X"R=&:LU=
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M/NFKBBO#W8ZVE21B&\@:Q2+[E)722/1GR!1/9.G:)T =<9H</;\4"^A;@M6
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ME'TK;N=6?ZQN+"WM*IRN<O!P=>=P!CALQ=82I:8%\%F@KA,''B/W.:)*[AK
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MR9&LR&8FXZ"X<3':C(<FP+"EA0;JZ*LYOS>F /F>&\^<(K\HEF&6OV CQRX
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M6BM?E6%$>K\Q9U\@K,>,H>9OFI+%] ?F+$.18$,^78;9K4D0*,[7A3P@22"
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M6MX?)IG&,_]:0.0(_J3H?TK#/Z7A'XL[^ X*.IVT.A&-"_R:UT"/073:U8]
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MG/UH)]:[B/ -VS@]2=3]'H+5#,Y;88-ZVB\C%RLBB4$/*9>Y-FUJ9\LZ?E)
M: 1Y@@];@[IYO@XDA8[(;WDTO\7_ILZI5LL&BVTB823A;)J44:/6"P'\F0:N
MQ@FW?4\H[;A8;_[MP32&SSL_S>3$4OQRBDX_ORF:NC&TP$?9U6]L4+DCL!1
MN^_W0<[H@.WX@#(E.]7A2@NDD%"30\02MS<U?GCQH=O3-3,GBFZ\.M]\\9YC
MU_(4ZH_['[,IM=\V5 ?=YN>J[SDF4KC:*7RM)?*P GUFTR2TCC;&ADKZWS0
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MI,8;V0OSTHI*5YMA2I4W<S&&AWRK:^U/.3F%.";_TY4U5:9$3G\]E2_[>2H
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MT@1O(.DH^O;&R=T_L,/GU[[S?@-^<$KIMP6:V7;)O?H89:",E9UT%\C3EF_
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MB7-3*P7WJ0122FOQJ?3>G;J_7H]$H:"-"VO2,_QL:ZHVD:3:,WZ*J_G9R[?
M_WF?:U&@B6&L?)8[\G R^FI7EW*4GO,9VR<$:YO:]B]]!37RCFE+=Y^>+K"N
M**BZ+%UA&E[Y0DW>ML#&U=936ZYM;88M(,!#AP$MHPWHKK@0F^)A\0RX-,:;
M<Z]N5QZPH@CU 0_.(CUL:SNUUMUA]5?7*>P04E07X\DL.M4S09[^VGZPD2%T
MC 7;S,P7RLI)%SU]QENJB,:!"CZD*D\$:0\D8HSKAA&&,SKP[W2!LY#UY7(A
M"45#LK5Y^]BZ3._BU&H/1%BM->MBP "5&\W93J:;8L*]/-$5USA7A0H08U7K
M@RXP^^.^X*C%JZ 2'9YM304GFP-A(BFX#.7S-/-3/ _@+U98&OP(Y@H?OP<Z
M+)(E. 74>'/:,@@+ZYD:_9='2:TP!!/%1WB.">';P$[?[M?B@=8%!%=;$]%(
MW2#6V-JB_;9)8,$\J0W^B*C)V/P=<.5^XM=B].G9AR:#"I")L..,/="T+NM@
M)@,I'EPLC[)DSQ<Q-L'!77JMHP:>8# A,3TH+S:TB-#UE.:2U&,6&2HYY*%T
M&*G9R^X*?C+QSE=?"Z]1^G1IA;&,$"NZEJ10I)&KH2&J[[SH[E1;,Y9IDY/S
MSZI)W*$^)XY&1)UHFD.F=3MUW,0QIL.Z*]7=W?U.;OWPUGE^$PF%3$2R+\,!
M-:OU=O8WY*-67(M,@7?^7_# C]*,#UTZ!+9S0[H_6QC.NH3L%+@4H>C.;K>Y
M7MNNS'1?7K2$S:CNX;<^:P)]JE\2U:[1Z.@D[U>IFU]U -/,(=A))(%$W@--
M>>A.)E_E%Y8#[\$I&P8X9322.9_,,C.!V3)T1=>Z=$=;LJ6^7%@XV'7L@U:T
MK82*!S5JSF7!9?Q.[8^UC?/#N_*UT7863E3XH\T,9$O;AN+N'[@>LSV0Q&^<
M/1 KL!_^:VV;T$ RCNZ!$GLYKOTX:1P#L@=ZE+"KNQLGD%H [*(WPG:E=X6;
MI6!"\&%7EYO/M<SG#INMRQ6[YJ-1E"X5-C)%&)M0$72")QN?3E2K6_$YPVY+
MPQA6+WSQ46%/I&QI H9VX%\>W:!](_JBHN<(P<S3V\IF/&JM!L4W%4R+O;5F
MO$DR@7SH 6R?#JOUC7Q<_C%_HH\8';S$IOBM.%2D4P9>O?Z1)WFL&AT[D#&K
M,>8<U.:"X83EY]$XS<ZG5NH]KE^WD;C4)I,[8:0]_L/FH[NGQ7:"0/(J/Y?$
M*(+3R^9-.4.II7N@0+0T]R5[*)4S\<<3,ADYV2&NK->E#W@RR_/EJNY\K$ )
MSG1R&I+K!:?1Y4R#YO&3N-386].]+YH6/-<\)C;#>(KRG,(>4LL>B"<]P<W@
M)V#5"N-1=H!?#;J9G /<N_D?$B"U>S58^52.XRCKX8Y9C6VC,!=>\IQ"[6V#
M%@FMZ918F$=6D4Q^A%?(@G"$^Z#3%MP4?DG9)S6 SUEC6?6K\]25R\")Y0"9
M8]L/E3[#'O,8=.MJE/M++=-P+G0KZ$<@U6!B+,<>Y=\5:MY;_ZA\=+;?D0'>
MV,=9YL:/&X9&TG7[%M))^Z/KL#W:FMXT\R,\:TX^V=O18Y3^QO/?J#G/:^P
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M%%+<FY":']^\'B>6C+*N7G/=Q2\4UJZ5!DQ71R.T5BB56#?W4=TY#\\1N6'
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MY,UI,.TR+E2Q:!SAO<*!2_SWO77/O<KB85(6C%\$L^>(IA YK[>Q3>L^$@-
M1CT2K4_;2I:K2Y):Z?1WZZ:ZP*,%5M0!&'$#,GXO+BMH@=GFIY 9S'RRTF5
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M=(7S3AAR=/9RS0U15VDHDQ; GX-F5^9&8211MMU4GJT.K7.2K57 /\\*2*G
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MURZ<?D\XO50I%LQ79UOB]6O+*=71TOF,O2/O]D$NDW>Z:%^_;;6>[>@LJ>K
M][S\6_.BS<9>/F;PO_N@$&(ZN%N;)]]0PY\@2NC!CP!P=W;@9J1_#<+\.,NR
M-&I<! D9,A=G$W-,]1F0HVO'W_SP]K*H#2H-K=%=]+GY8V%!/F,Y]\U$2R<7
M0@G_G3/CA.O2.$]RA*._U\2S8!'_2X0#:G"*%L8:B&2%,P,$X:Z'.8$,800.
M.H8SRL:/A[CLMN(3@DOM<!'QJMD7F-063<*5@%: 9 &XQS,%F,>796V^[4=-
MP\DE Q"U,1WQUPC"G'"%R[_+?U5G%7KI:3BV7"UH,VKV^Z?VZ 59ET(O9X^H
M0*1]?JW\.[50]5O9S'+H%9JS0FD'HF[SY**[B8?:0&^_V%OMS,HV 96'L+3_
MFS>,D<<$C,]J+&VEK)2'^K%5AV&)< F^TA<)+\*+_Q:Q-Y2T6.\>8TVWS*::
M-8Y\+)'S?'KVB$\0";4!GR;RQ,'\(T+<>^@%.'XQ@WA'>W:+XL"?)K974N!)
MB]+;X#RT&- 7N#3S,^\ $G-C8G/K)TX)(9-1NV:\6:J:+9!X6=8Y):7WT><[
M$_1-'RYH)%EV3?*T:D-ZP=^QRWUB(@@?(W91\5)",%P"J6'+=DV_9PIFJC$)
MB:'Q0]-Q_2O$M.V2?R;UR@_Q9:-M54R@:V<&WO_T_'?A(;1<U>ZIV3/S(ECI
MYY/9))TWNO<,CA69_)'V:MFLR].GZZR0J]A3J-01^WR<98Z7N8K4Q>B7]9.P
MBGRLQ[-G=R;]:LY4"P^^IH39=U(='-*T.*%ZOPI+9^;-7+KYBCQMH)B-(3]&
M&C(,241%U"TV:CHF+MG\!!##T,)0%LX5#0TZ;^&>OR?H8]?C:HH>WOBR$Z,6
M[-OMXE+R_J)J"FY-DB_JNP\JJ)S?!\W@?Z_]2%LE[:Z@3V &_VCEA6*!0,8.
M&0><%_J:P0)SQME%3[J-85\]E\>EUKHKI:*T)4)*3386#K)<\ZHG3&&1. !.
M7CA#O4N-MH59OF!9I6_W'[";:OF4=(,>?A7QXP&SIT][M"-[7&ML_9H(]&#2
M&[93,*5"5=RC78"C0:8WL59BELUKOJPL8:M9/P5GN3""L\??D74URY:.R8$'
MQU;4AELDO!JEISK+BG7;YV=F3'1_K3SOWP=QZO9*^.K\$7BG$'E\IFGY;ED=
MHE*"+[7Q<-:.J)312&H)BDNI:ZI>&U!FT=.CS.S.I4++)8?-I:8[81)K_^&/
MWYR^38L."0F-L9K /PW_V03YL'7X-]/R+)8619$FKGN]^Z"P\9D#'"&V%9EX
M[ O_/(!A-2W+Y#0K R7F^4C:2./HLIF\YS1!J!JP_UGRB:8E&[5U'-ER\.=L
M?VJ'RJ/XJM<'5QNRF4?+_D@;9+89K0?G^MHZO^H]WI+5D%VS-H3##[T?<L3Y
M])^G-MC5K#M@SU]]MGSYC0[BL9SSN14I&62?#2<SJ[]%5>5)C*U[7U<GI%)=
MXZ<8_\CO>6(+P+;@>XT]DOA3+,NPXBB[\A%:,Z@T+W/@*,H?0#0/$%D[3$RJ
MWDRG )D7@KII<^X?Y]8?&A@O"A3=$UHDZX?'LY5R8GSKUV?O5@?4?_R=D$YR
M[R^"_^]): ".-<YPS3'%,"K3NRM/F/\)&"Y//VX"X'93>GVAD/^RL1FFH8Q1
M41E[_%3'^6FM );MU-2R)]3L[]S=!:,PY:!/P7-BY0%(XM=]4.-R$-V]5M/V
MWH':M^>9:DL?I=4H-J8O"H6=LM6'JI.7309'*BYE6]E%K!(\/B%L.+0R!G?7
M8_65D^N7NM^6>Q&H:O@-:=%;@)J7D@E+ J7/VAK^@CZQP#,KXTM(L<EU"5"K
M]ZX^^!Y;)=L_7M&C^VZ4W2R^E<97UOD8?.V68892GO8'3/L.[WC2LM6F"5>-
M=W2O[1X:PA,#/%F>S)1%<H(K$YPYH+:PCI9F[;PBINZ#CIC&,A?_ /HH Y?8
M%NL6__CXS <KR;B;:C ^X** :/L&V>C*X\A JXGM_K"1,BGR2^EC.5Z6JCK5
M-CD*;^KL'1[D!(Z6.%1K7F<]S+ELX]Q?H'R^OJYN\_!E._NLX$)KD_,&'Z7L
MLCZ&*FOYT$-^?."=?TZTQU<"RCO9J&CN?2">H[R7-:"+TMO#X\TPI I%]O5]
MD"S_Q,('<+*Y](2^D6\/^T+_,E@B*&XG9],4PE@$#<?X"V7@PB[43,M[$#I8
MK7F,/>AP:5U2U08X&E')"N_'D8/TX2#^.)CE"/[@*0"Q31AC[Y1/"+BC,@D5
M'RJU]ZZI1GD(2;=DC60>:JL/CEODG74M15>'E:96+7G_YR-)*F<U4W+P[^!;
M]T8DAY]!DG*$_2(/3[AEFVEZ.;& =\%N'F\;W;+O2"N._V$9=LFFSM@(Z2/9
MY_6DPTG]#2?EZ\>8G#+/^KY96.C9!'KDK_'GG=O],NZLZ8XF9 S9PZ[V'R#I
MOY-;/[UCKDTWAW7V^UM.Z_4UW(LV4W6A:3]/W+&;[-SXH-HQT$9(E&^"U@=T
M]V1>]H^2+?RI5I=OJT=%8*-H4WK3.?J-(9%G18;!WS6!+/XK#R*_[)O&7BQQ
MJ1#R/6L+4-D'[3T-_)JT#VKFLCC$?P/_#P^L($0"W\$L)L:HHM4;#W/^=1;0
M[=L'Y0M@)[%>X%.=,:&+>^XMWN41Q?]S:17<3]W!Q5_Z/($%\E/07M7E/66/
M\.WHBON@#]]Q_*?_G+"W0!>@'?[7,I=4I./@@#9[ 0=.XXDQ!/W.J$^I:H66
MY%"I4@-3R\?-/XAJ74V+RO(<I6<:%IV+E9;(I%HV7XD6*L-]@?*%V=S;O/,L
M[+#V3"3'?Z_,7!2A=**7_:V8X8F9M5J&I/O)+!BP=[(U40<;@"3R[J'D_-@?
M:PLG:2A?Q4\>T9N?JTRU_<]Q=E73.I6O3^'!J>P#F9&YDO_JQ-99D_!&:5*I
M@Y^-=M\@WUQ&>Q8OM8\IW@S3EGG*7(^WV8Q7#ZN0$4XD^448$:XY4:LL]=OT
M!I;_,H*K,@E<X<)5+PM8&NO#L[OP1\\9R2UY8QU'PP*SL8E#C$M?-2^?5]T,
M5G_:[*(KF4;RO<B.EF]Q<7JQC:F<][2>BE)T=7B_/:][:R*Z7^86@1J= W;I
M>$G#>ZLZT5K/=4SJS4-AA%SY/L6KE&^R+>&:WZHRF=-,M5,5>H6RE@D)6(&L
MR0AJBK%7A_E:OP'?/8A'O63]&-R!'^=AEL)!;A];RK=R4;Z,2J&9>8*$MU8+
M/0/?I"6]L-+B&U"Z<KMT6_GB]=%S@S>#!I_*[3RX]UFV6#3 ZUIF\L4H]B\E
MH<MD1X?"&[Z^F:\<1EP2*]7+;]S*L;: /K8)-ERQ_<#JR*Z(C1'_3("D/FN+
M?+6*_%HI9GB25J&"O)?@):76\\/(L3#P<+=2S,F7GB6UD56"#@:R#!O^/;Z.
M 1\2RX1(?.V,3P_5#QE/XX/8@=DM47U-3V=#XD,METFE=K52A63VV=&CAMHG
MGE"ROS0WWF 2H R,!*#K262-9YN:M *.Y%+/824LXW<^3<-=Z6ZL=42XZ$=A
M3&UP$:>;$ZY?2Y:QUQHFA"H36&./JA_+$N]CEJH6\95YF#O[H'2T^%X.Y Y$
M>@&E" 2P1 :5Y-KHL.2634W"-29<'ID'S2+'%"^<I@\_P2!,@F:[\AO6Q?Q%
M.];1FM,HVT9DXK(#,40^0;(<H#$WH9QU05NY.\^G+DIJ=5:SMS@.0%O 4OAQ
MY'?J]!LJEVGXR#0@@J%X27_R9[^BGJVA;:\WE.)S\DX,;1NY^9GUL"6R&G,7
MEQW=%R(V]ATG#A3U7Y!BWJ2G/1@3.QC1BBA>*3&SN5RACI4(>#]>]X5%\2V[
M';R$N*U^ZYV&J:;&K5?+JIX7W"NDP]QZ;I%?HTM*D1&D*(T(JV,!7A8ERTAZ
MTB4".K",VE+DB[C_V=\T4[R%/(-VS,7F->1AX:K/VQQKX8I)*9K#*SWUEB>M
MZ20+_AE[BX02[CDT>5%<<)LXJ0T7N<4TM"SJ-! =8%#%/KL,R0OS_SU3X\;S
M]N);!HF(;YHT^TG_]I1M>6!XOJ*\:LU77Q3C1%TF4/,=]F#&[[Y7*(Y&7*;$
MY%85!_18",&EO$<+;6J6;7+4HQBR4[ATG,?]ZC32+:RC>'J+D7V57:T[1>S[
M6/&YM\BL2Z0 V0N'!OR?,E>4KXE>L2IIO%_H@0^V>Y"B?N*\0_*&GX[4NF-5
M6K7P=(M#N9$-=-E88WO52E A-X!BIG8V0;F6=W"O%BV$BF(IM24T!"U<!)*6
M0F\%GV7DX@,8\Y'DA_X4)06JON@#9*=6A-Y;B"55O\_6+C 4XY8JP#C;%\GN
M"\&0P@$#5EWU$D06V?UJES#M:MR=A++%(5T=>VAW*D*-$ZZ19FNG'\?K)W>[
M<&(NS4 C$6=G7T<@0DQ>_4N=(YT.HK]A\ T886IDOXNQTJ%0Q>Q!1I"_SE/#
M-(JOSE-3<Y4!5;&K;@050[%4LF^P4T-*2[#4&JVU@:O^O:;>[^*V^N[OU(@1
M5B(,%D#XH=;T:)#)=F8A;_KADH=OLY]FZQ\U/T.X_[19^JQXVK C%BIEN?W%
MJ>'*)*?SK#.=Q%2C?CZ/LP2L6-4C$ 7T.224844*E=W>DD?2'8SO9M0UM\U1
MWHJV4*HP\;'1.FXM>O.JT(Z!*3ST];%1,X,WZRM)FM?!DQK:P+G,CXO>/"/,
MW#4.'#-K/*-O8L_2A;'_VS?YF2WZ!!8CE)KOV$N@16]M7M;[E_ER\HR2$"+J
M-7]&/'&=0K&UNPEDY1E!D]DG7I3P(Z$',EO2D%.IJ6#Y'!ST/XUV!1U'O16(
MHID-B:/5+N4VD6,ZCZL2LQE&-KT%=XH()J^>>0XCXWJ:DU2:<H<FR)J29*AX
MXN"MIMQ"(^=<>$I3'IF!6(Z4=1  YP/>N:9E9>&AB'^6SW<#6Q8)WJQBS@WV
M5MX^",'5GC&D=!@*NK>,G=**E_^8HB]05_K::-&;,M?ZV0H/>_/7=M#^:[T+
MA=A1E4>M022/%]-*W&LOVW2_]-9/AQ(.,&42]7&I%69L(BE/O,R1"08A^\@5
M1^@YV?G0.]&5(B&&I4IU]U9ZNCM[GDPN?!CGQ*KBNTJ8'ZAS0RO5<'^1BI63
M'P=7D#=)8AF"^ JX_>-?:K6:4XI7]<6F]*K$L8M ^C"#??*>A9=^T%#M$;S6
MJ*RUI;[:2P!XEF4X>%LZ,.N5W\4/VILW[UJKXY\WO"L*+:96P66+F>=MH.*I
M9,::7]";J UJW:)>06RMW?.TTQ8)25Q[_@A::Z^ 9\C2=F%W9_X4A<$!^M)=
M-KGB*"T4QQ!P?K FRN1^+R9]I>>:?V343N\4OZ =D3_^1Q^+7S-(*.Z.-7_.
MV@?Q))I<69P<QN8U3N5>/21P:P;NP:YXC-VH.,$R)&M+>%@O6]^[(.<T@!%'
MS%9@&=Z0JR'"'F_^H[D=&FTQ5IK2^GS6^=U3MA>*HTI&'QD*B'T8Z6I6K7DH
MPE712KU(7N2IOXY[P?>QZZR7R2]D'XH)PW6&J8/36.UFUZJ4\B-1SS3>8%\(
MZG<@290Q+L?\<7-$M?:Q2R[D?.VCEM(1R<Q7MUDS]W1-S4Q=X H/?;.&WX^R
M\!$%P1;O2?3AJ_TVF5%2D'"[6B.TG3W<CC\%;@\?AL^ 1]X#ADS]\EK.XU:/
MUTV R,CNGWGQ2XM@($'N5+39 7OU_\Q[B&0%3.MY5BG5UII-%7P?OE#<\&6W
MHG;W(!,.G,5DF,MMQ(2RFSAU@!@KGO&=A$7,0LAB\HL#2>',/-E@$<X(:S6M
M$R>^;@[.Y=!N3@SV3T5W3Y^Z."_=T4G=^J=].EI478>OS+K@GO@Z\JBKN*]Y
M QF)<M$XTY!2FSTRJE^;6"%=H76[?NGBA]+M)@8VAS34):TW@+=[T"!K[T!B
M2JF_0H:,R!89&H^R"&99NXO'F!=[O+Y7J+>*_:'0VFI@U,!0SFX1M(]Z^ZJ,
MU&.$+\QR6..[(\^JW2D#BE.\V\\'1MB0KPG-:YB.8UBN(^ YPI=CTQ,[P=EQ
MV"$Q<82'/N%UXQ=#Z1A#]MK"N8$>SZ9^K9\M=Z<(6K$(T?+YJ5=Y%&.H6NF4
M,N&>V >!?;W%SMO,8?MM,.!)J&N,K2.P6@#BR:9T,\4D1:_\W#2Y.A'VL^62
ME3ABFB[QUG2VKJ_64X#1+ZR.TCZ:#2+]NWJV R@*^D>QE\<#2R>PA??W4'=E
M+@]/8M/KVGF6?S@6J>?$Z58K6'5BY28#3@X5S =-U:J;4_5/K7RV2@*>Q';!
M'I/46TQIZ>=]=2X;2)=[Z<,VCYI?GLR5QA]YWZ()Z6A0=_97LVN6DG5HDEMX
MY_2Y^GN_%ZUS\YK;I*9>N<K0#Z>I:.BHM\E-FMZ&^Q9>U.K60+E6<[.F9LL3
MS[+1T;X2OVX\OCO3^IOJXS,92E;.!O@-+9.;=/URDQO39]C'\GT;UZ4][A(/
M%GXN._82.SO_]F 1[EAY_<BQ*E_IVGN/%ZP"$TZX%C5<3/RL5Z)HM0!^ =D$
MLP(YSOT C1U/\9'M84,H>X:,'T&+'7<<@RYNS!Y[O!P:+'IWSI&N7UMI3[4K
M"0]RO=+=/WE/7R0T@*<3R\S1L FL=$16HD^_C9CQN9;]]E)VI53EW8NU5P)^
M62C=T[_GHRKCDRLO)O>CR79<*+7:F$V^*[5JZ3BXM.:G89.]8DU#\2"%MR-O
M[@@5W9T9D#DSNNK2-Z8;_,XHT^BF@43*/=O86SGJF2<)%D&W_B_&WC.JJ?5[
M%XT_MZ(@1J1)C0J"= M-6GZ*@( 0J:%'0+HQ(@0B1+*W]+XM@-*RD1)ZI(0F
M$.E;:=(A2$F0#I(HA"4IG/@_XXQQQ[WGP_VP/JRU,E:9[YS/?)[UOIDSXU1[
MJEY-W'4).-A4JU"R_-VOG.Z%.MXK+%8=7^HQNL;!M^M@++O$7IS\WFI&0\4:
MZ7\)E?(_!=/-7H)/A$I9&9U+$?ITY:5E+$Q)]NZ6HUQW!3.()PG)9"0T"4_*
MZB3&SZL#L:5L+WIZ#T*TBPI-@)YN=2@!S+A"><8=DAFQ6T:JX_=K]0SSVC,.
M02?(\::%M.&:-20A+WCW:J%'1[E+H(X><G65O)U(A1[!"#,) &=Q)T[MD8$@
ME9R4?W544\K2I$4LXK9C1-L O%VV5B<S,Z0M/5[KPM-_9BQK5R2J0M>*&\9)
MD7[Q#JV_JJ5IC^3+NJ?;S](&&N6[5D)_J.H(4:_FWDCO77HO_'&BSZ$_D%KS
M]\!C)VE'8?%3#HJJJK^4/1D #JEG2X"?3"P$%]/4):F?L5HQM"&1@9!*4U<[
MP^['WS7XNIU.B?%!3B%5!55[,Q7Y#,A2J9TT^JLNAWL]QOGG4HY?&$EU&B].
M[IK$#V<[9I0'M93D%*Q%(+EU54$ZS C'%X7KCN&2:67E&]FIW6$143DEZ\S@
MP?!GN&?AFMH-86'O^X-#@E4?WY3ZO$'P[ID_P2!T<3S9^DL+)P!\A^SYM'F!
M9DT-<7])8APIAM1B.SFE41*DG0FO0#TN'_QC$)3F8^OM"YK:PK&%ES[F2W%>
M<\]]8H5BO4;5<515!O,#DN[*-*>W<3."(K00HIBVHMH)(X6<I^+;F2Z^6<B
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MA#]"_]-^&>C[.'5U#0YWU/N:R56C[\229/[S8(3X$(74<DR_YS-67?F]ZOO
MM=F!Q%T\^RR8Z4K';Z<?@HZ)<K+;_V#?&D,;PJF]=;1G(3U1T/JQ?YSOM]"G
MNM+Y@/B^X:+-)Y\\2SN"J+R;;^1+C[(A%?T&]Z22<6<.07XS"TZ!.@WPX*AH
M7,<MW&+S(:CQ4N-V%D._"U$[U=MFS'P&G*3ST4Y7T8F+?5W$.$=9$5G!9CJY
MLRH"=3K Z.*49O_P:;=U#[GD'K/;Z7"<X 8S(CTN-$_RQT*G8P,\VZIH+%!J
MQ;G=CU-UZI5\Y_T*&O7/-+_4;E_=I/$K;["&+GM7IEV$G )%-^V[:8$C1/EM
MR=" >Z^+AS9N*=TZ\XV9<4D^-_?BNU?(HMS\*OF7+_=0X]QPM(S^O9$]@6U%
M^/NVT3WW:S]68>/U@Z:3D3+&,'+=V^WO6ZC*:N^DE=$?D[0;YYL;FM)N_/-6
M5LG&W=E$CYL)76SD2M'AVS=8&E$?R71'Q!^ 1@?W! .V;49]AJ+N;(OZ42,_
MP-.= -)BO7:8WAC/3#P*'_'\*P;5QY6=1%4C*_>J],:ZYB5']J+1Z"/)UMR
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M;2OI/RM,FF]I%5KG.=M]L/B1HF+WBC2Z4H?]5'P]YI]MW:8&HM^L ZXC5O0
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MV3B6-=N30>QPU0>X$$S7QRA!!CP9/0L6]<_NVK@W3)5!W?Z"AI[*$YN7'[_
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M]]_O]KO]OK?;]X_9B[TVK^?C^7C<'_?[Z[G'XREE8]EDP)'.FOC'9QM8)LP
M#03G&1*I?PJR+@TVQ!]=P=OPB+^$[5DNG=0B;(XK)UX;\PK %?N_!N-KTNR/
M#(1%.0;QAX?K4^)?L'P7<LG94, 5,6$GQ(NKVU  L8/]AKK8R66/=W-D%^>
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M)'W4FS$3>3@G]'V;\7K>DJBAEMY2B,IZ_R/U<7&JVZVG-"4MN<$.!L2\YKE
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M?A-\F&'=J#%<MCJ!=RB4XSP\FH0+%A0V''&U/A[\Z.(K6\_,"]?M;'>_NJ^
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M FS[F5R-#VGR5 5<=\==ZO(J6P-WV*.YMGE$9!)]YW6?U;,C/^9:",6E\[G
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M,P#1(6=LKVX$/QH<5!J:75I4B<+5=8Z8)]P0YK4\J+4/CHP.-A4&Y$*R\#(
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MKF3DV4EV0:7I5#J@3U)FODI6C"_F$T5*,-Y(RJ8Q^-Q:D;*;Q>X@JK- N_8
M1:0L6N-Z,4]%H%)4J>#)47EX*WK!_Q ')^74LZ+#5]#Y\<.Y9)XB2B)?5L'8
MA.%W_L+_7SU>1#!"K;?D$_$_]2MI1(VEJ+=+?_6OT3/H2@KC;>]:[\N5RI>/
M35,SX:[HK\;EC:C]1TPU2JDQ1ZCH;[_$HRRSP)JQ)5-/77(&%I@TZ& TXF^:
MCKC@D#3EQ?@.5Q]].P@_&0]X=IE'LQ-@:V>_-&M$SE&#^$A-RT\9.@45H?G/
M6.VQUVK1+58M3=![[,:FI<,\!&M%6 /^V+3#Y2^XO&T%RP2:3 UA-J;RWT?^
M-ZP@J5_F"K<#^6HSS1?> ,2$XU$P^;G7E-Y_$YP&# ,W';OS9A$9C[\.CZI>
M?5/Z\CM!J^LJ2-K1W%R\1CO\(A>JL%@PC"@?*8P+@.2+WE;#A\W0NA1[:J#Z
MEDS/A_X,/;3PQCLI,+X+E0K/W0^_+Q$^2ZW4MB7S_0EQC"^A2\YLR2R<$5VE
M=LZ+MTMMZ$48WI+Y7\R]=U13W?LOF/?U543 B/0B44'I!(70(5_E!00$!*27
M"$@-100D0B 6>E5I2A4Q1&KH32!"*$J5+J! @G20!"E'4ICPFS5K[IT[=]WY
M8V:M8;%#<M;)X9Q]GN?S?#YG[_T\9X] +.8S.[8 V3*DNNE3<7&1$+I<,Q"O
M&J>,B<U^%%N&ZJ%J.5'2>MO_'M-/Q@%I79'G1Q2$N=RZ-2(&*6W4L[GB8RZM
MV2>"0D3Y0R'>7:_#OK5?&*8T^3RLB.OZV5P) 1OQ!Y79-YQJT[A+SC'.#DIW
M$ZFKG,1I\Q=9I^?46%V<#9=XGQ,P(@JF\QHPS3;VIXY M16,M_ ]'U1Q.^/X
M/#$=\$A!5"VQ79SUZ3FFXS\OZ>PLJ-T%1 ^4)&;:OL]XE- ,Z*9C_EWV9BP'
MCFVY/)MLW!-V>=VZ,2PTX>IHY>ZW>BY7**"GO&7DYK)85L >&8:V!IHIB$7X
MUO3B$2@E7W5$YZ(A38M^AU&*OD$UZ-$1'26/R.E(]U,"6+R"SQ]M3M86N!V%
MK $>#??6H!28^WV=2F3/D0KZ?[Z6(3V^<.UA;LW7L]"YB'G:G>8%0$G@SNT$
MQ#\LO?)>1PB 4Z!ZL?J .R64=#69IH-6 SQ)K,N<N?HFH!3,R7)PD3F1-HM^
MO9C9FZ/W6[*-M3D,$\BS-VK&(#93V(G((,VN%5O?QJM]#X0>^2PF=IICLY?5
M_:2LNMV;?.Y*=U:(2DA:IUO#N65'<<X/?W;>,&U)MD_(Y:];-!D*2B>A^BA)
MLT8F_0:2GK\J9NS[_?BFCTLOGKS.ZLUH%(UY1I+VKP^<)P050!>G9'5:$RAQ
MZ!. AD)YP;^ '67GLRY??71%0Y8[SGMG8V8S<ZT,E66-?/QKI3G<24QVZJOR
MA;][S>@;^''$;$#W/.6623@I-7:3=>$%1R .C"_K'Z'M4WLF574D)PA>6[JD
MI?FHJY0S7BV;H?O"_T:"@43R+(G,7K^&AFM!@XJ)OLHTASV:K\5UW< _(0B3
MEP9<9K*=7SN6OI67<<3$3JS>JTXOTF]3LQPQ#4RV_SY4Y/^P3.95B;5_B(RJ
MNF&K#R*OV<2DS?'=K[R]S8:924/[?MU#ED\\FT/%.D*JV.CG&CO+RGPX2 V,
M&+H(_DOAE?$2[&!%:C0+KH*!/;O-B2B>^1MN[:,SR_<?^]W+7]=\%.__Z]^/
M$,IMY&P>DGGZN%Y)"B6R:JT4A3!LHY@E*@]RW'G&,:C2W]6H")@L3<EOX1+^
M-;EM3()P.NH&P\/]@@J]&ZT'^;K+'Z8.(P"IQN-%?_LMC%Q6#^5@3D>*H(+(
MIO%DQ+?M?=>O.ASHV^W4GE12LJKNE)8E%F7Y29B/98!/_8,A@JC,(Y#E5['M
MSNRD%S]0SV]3>MY-CMEIKIGW2U!FD4S6;I0[\.>(6MSQP.D9-IH$:I;(NJUF
M<4>@^I"L&#_FA8U(OI%6V8B%9*%=VT+CHD438QMJ<2S>^\NEY.3FKW15\O6%
MU&NNZB?(16D>',\I@GQ//U37H7*X4O)."I96%8DIH*;)JB-R/"&Y:<O[?GN/
M-+3?1[1B!YJ=!$1V [X]Q+).U"MBGB22%TH*I8MP+,H'+63F4]<1(@3?"<K*
MEC;>X&HA?Y'+0KB=0H7RB&?XA?W77]<.;-HY 1/2;-GIF-KW9DARZCFBRNO&
ML)ZBQ^Y_6%CPCS:51=VX6=UNP4C9;N4+>LRUWT@5V^C4&*PO#Q7@]M'AH1I$
M[VV)=^TW[C]0="A34\Y)3#:W)]U_;MHV5K[WJDPEA[/Z%PL)58Z=<8Z=\9H)
M07LQ7L"1\.AL?"_AF_A^!JH>GE!P5DL^* "+ODDI2-Y=^OISM/TR6FO<?8*N
MZA=>*H26)MGN7>"QIIY*%6JAK,2$#(H[C7J.A,@K=<-#T!J,1M;!$XZSQ[)(
MTG&ED^-P3F+;LJ+=C)P0SHK>]HUDW\#4NQ.((Q3$@GX9WJ34=MWF4-C+@#BG
MG7.W=DSA7L*Z<9YXE\9D-6DU-CH8'Z]S'L$-]-YI164+I;"!NZ?A^U=5KU=T
MJ;7V\V0M*E**M/A\'E?RI_#GR1%YK.MT2N3:'<=7A*ON'.:=>4ALJ4$7"K!K
M\&F_OU>B?\8\XT]:\:_OYYT/=-:'Z(-SLP61=-X1-(2%03-NS+/IHZU<I[*0
M;V_0-)A?1V'%R<&-&A'YS2$D:$I6I%1=G,3O;G=Y?+SGQ+V641=%8M$/ Y4L
M+FRZM;<W^#?+<?Y!'X'2\R.["O:=M:3IE1M3+(990+%"<!^;9$-!5\&,PZ)S
M&AF3Y QFO*M+%?4JJ/.,">:@<8D=@;IMQ-2GR%2KJ60YY5-IAI3D(U"\<D5(
MP)1I71OS2_US ZID?-T/U3NCXA-7'C%X@2"6'1S/L 8S>R"0=G[F"+SZ"+29
M2+L-X'IQ]J/;];3A1.&*XK(B.B>EH9IOHC%IGD2(AA4DA,Y3LNA.&BY-(\'3
M(?-\N*BZ&Q7]%=Z12N/V/4YG#K)1M^>O'H%LKR^E>ZC7U>8FRA/O4;]!7;24
MNN_MP#?+_[U6CYPJTM+<3R^*2_HNH_'UPZ+I^0H^]M%TR4W/X=/A&C4/DW(L
MEC+TE,FOO%=G?DA,5LX4%,W7K- K+&DLHC@M3[5A%LZ?W "> JGD[6,;(0ND
MH(,6Y5U_=^DH4%,36PW(&)Z-F>?B\T@-9G/9CW7[AA(4];W7E,W!E-+WH2_"
MTJ^L94H5V795*9Y,#B':=;0FJQ\FT(]8KRD;D2>!K1"*+AGS'(8_NRK&-TJ_
M1F%B$AI"6S*?4VC&SYS<=#\"!6XDD?"[3106M6C+2@EASQ0J?W/QY<]\S8#E
M7\S@EO:VYB3%%/(O<O!9T(.TVSM2#[#IBM9_/?$ K?R3@IPB<>)%GG:/ER5U
MFL;275LA3Z.-7B9/BI^,'7!+(99<G<D0&GI6)O)^]OEDW[1UKCMOD<01"!.7
MD>6M@<:O> :\82@ X'W6W7IFA^G0/0+=AT^+[UNP/CY!T1;QFQG4K'T]RDVZ
M%("@XC^UZ.$2F& @EOA[VLN>/T<UH<X/2IR3(-3EAT,YO3R[KCNCD,2KDX>"
M]0Z$>-66X):,MMC/+.\SAP"2*]UFTP;[SL %JBH)O,62-<=I7'Y1#Q(K=[=!
M0$ZG_5PM"7,"!5T4I0+%^[1;!0MMVZFMGN^\6N:*_'"HSZGG5ALM?:K7PQ")
MP7B!M3F!<?N^"Z'?6J5IUBP0$3X"(1%/X+6-+*(QBUO(ZL5/%RV"-S<H2UK_
MZ"A&=CN+ @:%* 2Y_0VRQ,G9&)J(OA9.:K,8[>W28.)+UYW5)W UE//Q=+L*
M5,,V\SS2P6%#6V:Q#QY@!DBK;JXLXK]M++  /&?_'\"&ZD8B;)90B%V!= -J
M:)*.-E+X+DN?M$O3]7OCM+Z$S$)/ &EVE)#B:)U"L@FB:Z;NFMF5&!S>I% R
ME@Y=D)?L5+&/Q*TL*/ZI%%#I=-D9.!L:U7$$\G7=\'C\R-OLKX3/54WVM3T3
M):E]00+@2B*W<[VM=6$L<2I77$[/*&1U+,HQ,>=Y5"[6U&+?^^:#H&1#V.=T
MGYOT!J.UAK1')JJU]'_?)<CNCKU@=K'0;Q#_1P9.L9RGG8CLA1Q*[L?BQ[8!
MC1SF[:)]+1;-SF4.( ZCT('X 0B@A&0:I=)Y#YB?YJM[F?&,PHU=&O-L\1$H
M38J1"M^2A-<*, LAHL@_!BP4E<S,8F1,8YCO79*#YO](_,;3N#TPA\\=F:$?
MCH?T$:G46__MT#WC.(VR"^9+.:;#G 4-\W50AAY3Q8:\%_F,V0NOQQ )TQL+
MA*TWE)6>;-5DF'; ?CS@5 Q(=M@X"XS5:?Z0-9[PW0V(RPYN%),NL*:*)8:Z
MX^J8\F/VZL$Y%_Q_=I_\#7O7^N#*L#R-$VW#R(CD0?^'FE]"LZ%?; 7J2=J(
M3V'Y&:2R<"?-VU-3>E2V'+Z1'V_7IV:LFEHF_5S\X*94[08<?R&IC"20YB\?
M8OS#QH">=9)S)09XWLT4=]3.]ABO;D[E6+R./NM<=01R&"I9 ,RN]E<CH8?=
M8<HX.9VK&:B[R48OTH)E]'-]3#JO,SQ%M'+BU3"=8J+H&QE+L =V&)Z%WTG^
M]ZB0NU]\W-3PJ@.*J9"],+[2'K4DF#U/\=I8K@7>U.J*Z9F'L5,8BL%J1:O3
M<;INX5MX!1900FH.$N5V^YTT'XPKW&ML&&^%/>9*-/0.O-_XRA$U:Y(R_N,6
M@1 LC0P]U\0*J,FU72[Y7K<N=LN]//?M.Z=_GZ[;"7'1A;^R#[:G:?O15.CF
M,'6>2!!F"NH&LM'%6P87(5P^]B]?70CO%$XT#"A!F3FWUM8U-'Y,^7W[Q>4Y
MC/L?:_NVMIAF)*YB+L^KFIFQ3A!AV59JRWPJG%2X1WA&J)/?3M[;NA'""%^X
M4$T9)YS90KOK8!G5)1L6\I/-K@'!QA7Z<W>9Q$0$AN/[6ECV-)SX4<3R:D%Q
M$'G#4TNHAVZ6;TF*O$C6PB75?(_ECG6$&W D=BTH;:9QQ/67+2B=@5%?HT@?
MW*K,_K(!OU9O%97YVC6*MS@?[&2:=$6T(*E)-N:Z1J[9BP?+R([FE(B;'X<W
M7*M0OI%Z>>2J/\F<C_ZN%[UZV38;$/7I'>MR7^<0T+"B3'A9YEI9<0X#,MIM
MO<^9K #6H:'##42)0"\ (OO!M2U4_>C "+_''[S!'U;GN$8LV-L_CSF(W-HS
MX]BPY@^:_>%X [J/'NG:?,%^GS[">+.I_,-R/Y514#?H <LQ&(]414M73;@$
M_S[OI/*[-XRK;=<W1V(.CY0H_;+4OG#KV_1,V/#,['X!-74KD%K@!#22-T1,
MSHHDACN!.R-YQY8SEXF=SMRCK1.CRIKA)9GJ4$F$1O@6"YL_U[$<S+9M'"I?
MKKSA3:IJ^--K-@[=S:')VQBU?1R#:5__-7MG+$1>9QFIR=!A#MUOKFVK:6U
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M=OHY?6IJ+7:S@^:*OE@'7 ND23"G=?ZFLG693?^"GX/P 2<<*5I5T\ !"9$
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MST;8U8;@9,N;^1'^<^#G;HB/S(')3>4M_;E_J7KMQ1V5OFG#[CP]8WJ7C8Y
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MRU6QR:B]1Y#30XDMIM<F[[9;::GEW5+C%;I1+(<ED?+]H>']="6<@5))U^.
M,QYO&OPZ7VO47PN>^[O2SD$%GYC!::V0U9 /9WO6XZJH+&YVNL0H]X=18$*"
M%'["K.]9@M3;OUD-+ -L'8$D=!<E&:_P<9C#N T^Q@JFX^(1:(FO@&*:2KL^
M//WQ"&0%CRX#KOT_WU5\K8#)Z(#OL[/NV]JZP<$1Z.L8\U\MOR.0&QK/DDQE
M!>]VS?4P8,C,)3W>.W\=M_])%52&B\U.^!&(+0;3IX[Q"*#=RNI(99@CZGZ$
MTV6/0%?$C%F'%%5EYNJ'8*+AE%K@KW<)LK3W?ZK>)4B!_MM6H2U@/ZFE6NZM
M<YGRJZ)D5>?BUQ!-+N3-J6 '6@74=B0D66%==DO)>C1$4^A>VUB]ML;^::@<
M=',E9GUH7;!2?BG%:Z3'G3?;1'G4NSC;9PU79*(MC-3/7\#H"4O2105*T;H4
M?'0YQA\/2$YM>M."Z?J4V^?6YB# %RK\.$M$<*JHD_<UYHXQYGQWX,*PP*IJ
MEH# 7\++<,ZU2#!E[SO__K,#8J@-U;C$,?(!\\<1B&(9,(-DGA$(HC#[%Y4+
MP*T0R@9)&[N')T*?0TZA1;78*/@.^5*';_8^-MG.R3I8/#*T,4LEVRD:VYI]
M$%<?5X>\Y5%/H6N8M!>5ZH7_V=!#J2GPD^@?^40]..0*]=M4S;^B)THM.S5*
MS3]0U,+J)6,_T6X-W2D87[NS')5[@;SI+3/A*2!D4K<5@9>UJ_3(6/)(<QS<
M*,'C4<^=J:85H7A4@<,$W: 2\0?B/QFR971@,X'7Z??CRFN<V;MP$YG8GUH[
M/3L[<V/E-M.D[ER'V+=W_SJRS._Q%=XBWG2+_[T\PRM[B<QX^?-*9VAF^R(,
M L$;"D@6=#L,)Q!J&^/K/AJB;V"[6=T'07'T"%NBTDB-7<-<NH^R1KQT8)29
M'VL'2MTG^S[[PBK8K+YJV;W7?5PZXS5WB85D%:X<1Z!$J?)KJ-L*FEP.;$F%
MQGS173?&*FZVBEMDW%+)P[)?S<NV2)R[;F3N8ZB\**U7HM?T1;,X+]MSU_O#
M$:BCHR&?JZF-NKU)8$%/+^,9P>,(-"-B]RI@*S757I)H(NE,5>9>MU8MPSL!
MKF/&QYD:%>HB JPFL=43/]LG]K9YO+-DD4$!^-7(2Q];$^]6T]D!'-6@]P@D
MHB.!6B1O=YOQK(LI :E42-<,(4G+FYQGXE?4.MFJ6^EL'/'!&5:?Q)\=$MV<
M;7DA,PL[/>VM897^Z- _P\T=9S]K3SQD&?X_'HQG[<=+X@S@OAR$Z<5%MH3V
MBX!F9S7],A6?^G8R4G@>]9#8Q5&.\K2B8+'8NAI4$=%99LQ]3+)A<EMO0!I'
M#/9TL'-M35$K?K:X<@0"I'";,"J$R;Y$LT+1]H. :-XL:PUT;#><@VY_*QP3
M!V>'_3"^VTA!)-T+::B[$:KA'7HH&2]_N?&6,D%PU5E\9.M]2^,8N;7I3VZQ
MJ'SZRNOR-(4B49V@O3-JI>TSJ 0@X9N A7F4M"LU!&F5)Z/D.$J\^2Y:L\<G
MK][!9#(/9F'2@OZE(?$J+V-;\'T:TM/O43-EB>^0Y0W_'+(Z&(U69E3![R,
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MP<D.)@D<"$X@^\ 6<YJNWS9YGP*)H8,?DQ/G[QP72?[G(R.:"8_\ A>%(\'
M%8$M:6HJ^7U!3?%3U22,%^()INY1+*E"DNSQ9L&Q/QR:M,L5?HLR3RPX6YE7
M"-@0Y]2H&8/O52*O"C/3"IV\#IV+W!>Y-*!<&[E[2OF"A?G6W?U<<:AO-KA7
MY*#N)]T3_56OL].PINH1MWLS;7WEENQMPV#?U:7U6TLLNB:2;S7UI,MJ^,@8
M9PZ]PPWR2?+AX5=^[7ZTF?Q25T'X/:W':S,C2OH_",K_I)WZ?SV'N];_F</=
M\?_+'.[_78Z(+<2TS?X:@*?)>>=+4%3>%*%DR:$="#$G[=Y4)@?]]E>_O7DV
M5/RV^&@YS._F=Y)"W9;/$>@_HT4CPL;/2X%'R]]G!RL!A'.$ZFT'LX0/>$G-
MSS4IXOUE[G;+B-B!FL,=G#JI6O%A0IF^#U9X%R<@7'>-5T8?)N7J99H7QG>Y
MU**$_?VPS95AI<@+ U++S6(N\?U!9[A+3KL^&%M*P]J?S?/A<[DB8T796^N[
MNT$JZ\2>V?VY-H%34Q4XK"?C 9FL^+I43F2^$",+XPE]@JEQS)<?T\\@SPNB
ME2DQR4&+;19]ZDNO9(W]?+U:5/("_*N<$ [EV2G1%3Z/3FU5[G*9_=N6(!M-
MQV[H\7436Z\06Z7-^,PN]4O?<T\I,:W4Y)'YENL/OZ"A&+RJY>^>BD\8N(8$
MFUK$" LFF=QR(:GW)'GW/#1KC$.Q?DN+^8LCWHSW])XPQ<J=%59^\$WKU"D^
MK-"4K=S'OW0YGG0:<ZO=1+TA4<97XG(OR>R42-U@,51\D4ZPU#N":SL+PCJ@
M%17P>X28(U#]<*>\9S=3@JK7^U09'D?@HT,J?JR.K<V$1E7NVK11S]8O '4_
M3IBU<Z-\0IS,[M1-A(CT)!(-/\PE-BLH#RL<+ &I20_/\G;=5T,?".T)=+VI
MNWZ[IIPD&9OI8IV[;H&-*V\;4);9"5>S^L"*'U+Z%JFP81QI#CP,5,9$Q'VN
MPC@[JF>8:0RL=@;:QBWMEG;F^32%0>>Z3+/@=7DRH26;B^KZUP-KZ2'O$FB+
MS#-*M*N TKXJ<("ERU$@\5IF9 QXG7!62W/Q?BLUR-L"R3\5UH GFUQ>[UX9
MJ=NZVD?^(?(?A]<2PA&M<8WZ[%ICI_.=Z<X16?=J6PMBJ_ED#)2&'[QI5U4H
M+C&]6WKG\YP3X^VZ=<(#K)3<V)FU'K_PN^L//W;@B%&?@T3]#7,#3XGEJ;LW
M\\M*=2S#KEASEYDVA#+>5HD-I?F$N*EFDJT,;S*_? B2-=U8")-ZUY;6HS/_
M7T-(>%'FYWQAZM4LRB+)LT,[M#OL(&X+MH&(U]&B1!96 E-$RHWW)ECCHM7#
MY/RV]W%R IB9W5T9BR'D$>@<1US]R8D%YL ?V5X=-2JB"R\(Y/0RU2<K6_46
MP8)(&^9%JEACV"7#O0LVEDWA.<T#*B,WO)'@UTORY>456^6^?J]D-460X;<N
MQ<!9 <UM^%L1Z:#;+!K!#?<>GD&2]?&4Q'T_("0LFV-]#E*7@A!$]7>?,E'^
M@@7<85P0VSJ4N)/^O$E*> 34MJEE2F&Q-F;  +>>YD"[#:]FV_2D&:/ O6#:
M2?0# $N&)K>#OKZG9DQUPE,R#T^]"2?/<]H:*POG.HN,*Q-. Z9]\L9!TSG&
M]:V3=1OA&\FJQE3P/J?&KO!0#K#G#*4LQ@"XN,"O_8%?!]R3/BTYVO4(^J9>
M[[G_QU_A#I'AH##8%&U9%MV_YC*!EJ@.+AD2E.,S&O=QRQ-.[H/C1TD0;E1J
M-!!^0JO_A%:+VFU_9&?NI?BAG>]B :]);C)'(-N!Z_F0$&G7VC--L;I\HE?L
M7^2KBI@F>]VS\GF41!#UPC]@Y#+_ L;VWP!?%H:?,?\YIUN):CCT6IZ %K6D
M&5.8J;B9P0](C?WRR1>#,BSESS]VBU<FYV-#_1@I,/ Q"%Y<&SF H!A".( 9
MZ+/V:XR*=G5GM-Y8Y28=2@;'"U_-(\G#%ZJHSW_<P,W]L3F/@G19>&O(5_RL
MA ;XMR)*5C5N*WXW#B<?/)M$/MU#Z_4V0[D6%S-LB)YO&KSW(%OV?S#@^X]3
M0A,ZW",G@\5?NQ4]+;(0]-4VVBT=?5MJ8M-EFH%PT2_%6A&74*%/:BLE/IG!
MBN(_[Y37;O3+%KX./!N:]?.UK[_W9LE4)N)9IDJ].CF0=W4":_T1QV8 /E/7
MUN;SL,S$C.J3<)BX7\A(U[D<V7\$NN#?SH;T@ BNVS\9K8?$SO1&5RQ]A)Q#
MJY*-OVRV0DN\PV"U<^O\,\6XT "=K,"W/*&!IQJ1(9XX)R0_F]E$/82@Y4T3
M/BX;2G!/PZ(U&)4L(H%/FIGJ)16MSDPEM4K3X&OYD#1B.Z?&5NI^=.7+QZ%D
M^$D@P?"7>*.7O_QRVWBP'\)B%!]<$=(JC5V;J7_C2V5>IDSRL+\@5P4--#VE
MJIPO=GOEHA8@T[,B^-W?Z:::MVL06RS1XF$G21$O%(V+*TM"A9JV7\Z_T#O;
M;)GR&GP62!-(&'[0]'EI^F]2N9,<0;.;*N;][ O%5JZGE<I-O,<OR6-EP)/8
M57Y5IE(LD\M5NQ("MCR/W>3U,:;&)##^9M017-M$]E%?(P7H]P%M*C<3RAR"
M".].M%(@*0'*8^\V&C1>/_TU_Q_JJ2RY1VGLRU7)>'F%>9.17Z/A$0B#B6!M
M&9K!_(?(R*FO#UA.[NYHGN'R.S>'6TZ?@UMFEQ!^LUV )[:+A!PGNBFB!L1D
M\N1,>82BND;+6!NK>4M8]RPW+3GW/OWL11)]*D;)Z(].8&P*1.0FKPQSO8W3
M680[IOLK+K[S^,OR1DV^SF"!F#*C=@A/;)E%AE&0B?$;(U98EIW1NO-_?9#Q
MWS;\1\P"*]CG@B]@9N1:_8Y %0C*L_;S_[>;"?G,=,B.5Q">=K;O"+0GP4PY
ME,5\^?X)\RU+XP@TCH+\N,!KCEBR8Q:>/,Y9];]JF+C0)X2?-C5'('P;BS&:
MV4=C&I/_QXV1BPL!])0@ HV?Q5S&/X@]<J-K8!8QA\::PJQ@AQV^^#\0D=U0
M)CN#Q71N,MX3%O(.\8ER.H)@-O0- $Z5K\@B-WZ")MJ+H' D3$I1S(R3.CZ_
M0\%WC^M$EZ1QOH-XF==!U<SZRP[L+-!H2#7-*O*><83DWK6YJGGB^4!5_0,4
M'29GS5]CA!4>L8AJOH]E5ZC.E10<RKO5-)2[*-1IGFYI)61TWB(Q\-4TCG4!
MG/M(C[HPR->I.,S" H(;=<)PLH@1=02ZA_A6ML]+Q2>6AYC N^?YF$)T1<ID
M,_6L<7B:SXP]RGD'S(G2),XH:]POF'GXQ84,/XN:-<IVF/4.WH+K9PXMFQA3
M9"VIN"18F;:!Z:26#5G;DO7'(&B1R\%L'-9FM$.TH/K]-#LYGP#=7&E^-;/=
MI:IH+,&SH=1UF%3UF:K=K]]M!M-[R IUENDRA&E S3POU&2J0GVRBXP,5PAP
M+2576\FZRNBG:DT(#I4E7Y&6\9&N'GJ_XN_M)#MM)X%'3DN\:LO8G9R)YC5W
MKOX+\=7@"7R!X,S2_D_HD 7\;.^^/",=OE#8@B=JJM5MQ\SSM*L#(O]))/N_
MQ!F'A*A@W<C:KMN=<_)?6_5.#K:&G4SX4@QX=AZT)'CIFE,KYI-#9E<F*HY
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MG@26-B4M(NO.Z]O;JK@S9%5O(1%+YL2:-5THME3.MZ._5*EJO,:D*%MYQ\=
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M]D=+\;G7L+"2#<6)E$I=TGQ(^3<UUZ#&1J;ITC1+ GYE'&7+J^XU[.+."]5
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M,7*$!>ZD\W1_RV*RU\< E K=LT_J8'<W1IZ&3]I-??"I)CWS]="BXNUTBXD
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M,Y+RB[C#!=D $0$4+NAXSZ+;U1^! 9OB#&:OM9_22[?YFOF:FH]M6&B&1VA
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MV'X5_MQ7_)ED?":C/;8OJV7.05[WX*E$VQ[?6N<?#K"D/G+#40>7OQ.I-,0
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M%+X2%Q%DQ%NC[I>2;8#FKW 2+J8O07>H\T]$0,06VD"J[D(OMC+.I[3\(7T
M^5Z\@?L'Z$06G:A@I\DG)IC!=CM[4X"O(\:^,-(."TN>E*[J$6KCDV_O[W/_
M]!-1FX3KH8MU0/-FC\XL._[*I]1$<*!0H_+B:VZ3LXNXWC+Q)B0V4G8/UI65
M!:M=2":+N@3DR?*^B62SR*9XWZT)ZY+*!^CTE9'A4;N)4>4X^NP%E7S[=AZV
M MU48W@!QA[AKD=CNK#E8PI3CM%C]  DSE)/7K:GMPF(G[D;D0#OK!IS/"'3
M>H0,\?K/I>NAZ?Z+K@E5>#*4%HQ%Q)241QX=37T6#OX[!32_ *"=_(%NS+0
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MEZ+U)U2#):F&#6ZA9N&>9K#GW3ZAM["QYL;LQQ@L@*J\SJ^K0"U9*O+X' &
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M)<*YG9<)V*=D+&P!+2<\:&9(Y6Y1WA&H2)H7/I4J0[TU@+F<'8A/6-,S.+'
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MP1J!U?!H!W.-_,.':&EA7]_9LV=KGW./<BQP&OH-P*3JW=*H6&W[N/X_I,'
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MT>MZ/-PH3+U#1D#DLV[WY$JSRD'?R(YZ=_<[5_:UJ\G:;KT]N@;I59$')&I
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M*],[8'+;)H-TJEP?B*Y#8-?,I15(Q2$D19/N$ &3LM8+[TQ8>'T0LVT#L]&
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M%KX]'OUS&/V.UYWO?]OI6[5ZV=F;BAU? I7$ZR0H!$!<A%,+!#@<O$JR%R:
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MOJE\*,IOQ;A@DXSE&:,:G87-22O]JLNW,3,W]X;/>V.__3?LTEYZBVG#V_$
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MT98@O;Z.R@_DS'L#ZP?8SLB<&-LL'&0%/HH-?Y=3-_Q13^0T^7&'60$QZK0
MP?S_9LCM7,2S2+?+4"V,$8Z\P\RWWV>Q_J.)K\Q+)41CV\"/_*Q4?\D" 5=]
MUFS[.-#2TV][.ZG^KT?ECQ!;42=[3>^%E@CPT1MF@>B.3)>Z)#Q34MR5[7'P
M@O.-H)#V&!TN#R)T1XPM+*)Q%EKJ@-?O D,A&$L<46#65_0;P Z;!8)YOU(A
MIEWC03^#'1Y@'!$YB!=[7/Y=PP58R?^X*_SI#WJ0M,(I7CU^+3!AG,30 [K;
MO.)YHT[[?R<\7$1I0;T=>UA@/-'_W'>S/H#)P)^P%-VCWQW![L=19YKM3J'$
M\A:SM\8IEE9]))EA4AZACF83G\@*?@I5=5VYW^?K61DK%^#V\U!0\OF/"=1#
M Y6>:ZNJ*R_<SWN-T\LT"7$5:DOA(@U_*E]/9_]!6]S"T.]A BJJ2,_G"+YX
MQ;9C!H<A5]0*$X33@5&$"%?5FB*.6@K5\#I3"ZZR@F*J)AIDE W0].U+I<QO
M:<MI^]7:"!&7CQRK!^6*_W>KH?;=C<?]4_PW/Z'&0Q6N[ %2 TW$'T[LY"T5
M7L#1(A-LA[I$BLN43_%47CSV]]S!WEGA(O=ZF-96LAHI*$48X4BAP ;Y7LVS
M19KW/'W:[YFP7:Q8Y;OH,?*)["!\H#0:5'7/X )-F4VJ"]7.Z(]B[6-KD-+_
M])S>GP[E:?X<\X,?<4HC)J.6#+)MD((NGH5'^\- %9C-WHQ$5XRG>HPM'TA.
M./1![.-VN_A147SI)$:"='F:2/<M4RW4%?0/BO\%R^/*/;2'UD">JH":=0I#
M >;%_IVTMO)=$Y(""]ODW&N>>16;ZFZ%0-.E;T<G!-:PD)-UCW&IK"R7M4AM
M\-X#"S-=!G;P*]W0 )7!/6W4H?OD7PT%$O T5^ZLFT+F<,#Z8PZAF!D>_15F
M"X1E9>@& *H"-.[LE=@@"6H &D&5.P[;;BR DO, K_'&#[GJ@$SP3T#'0P)P
M='^.&_E07+ MTY6^-2P0OB1UR:8:]8G&PREX'/-XRS\RAE-T.+:OIF-]M(8R
MD>)JB+V=2#@2K^,;KODN(DN(*YBU*E>.[Z[2".1,&]NG+ZB XPKI2I5NJ\*1
M>-%\678":[?:,9':2_8H_TA>!60RV.L17J)X"(2.D1#R3-?,B.(P+)VJ@?F8
MF?$;;IL,_V;OP)/A,DRY!W=I,5.CP(NC.C(/R=_*OH0:;JKB0Z!W>;ZF*C_J
M5S"E];Y_VB,JJ%J35!P8!@^4>,.,W 344BG$81CI<=3T0[T^%K5">M2X9,S
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M,:#F%9IXYJZT\CTT&<JV$PRZ?7R1'.FU>WQ]VN2Q;6![.,6,%8-P\0PQ'DO
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M/R/L6%]< RRZ5-'X"!XK2+\W9&D(O%-T-]F-+>Q(_B+B[0QNM]5T'!\!X",
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M#G:45%WQM]_1?F&))-DZOQX@*RJ>+6:-+'">AWU+>-,*!AD?&Z3"D1QT(]5
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MV0V@U?B%R6.CK(*C:^"QX@IN<:?L>HDUP1X2"&W$PI9=,[Y$*_3@D) ( !5
M/ O=(+D"QCWFN_'.FK_'G(".%CNHJ!I*3!UU.EJ'5M\:W[#M58ZV[X'TPXFZ
MT5^JQQ)+K@_>A#8TT):\QE<^[!_+\)Y];J&)5'3#])3*= "S,3\%XV7H)N44
M&RZ.-M]Y+[RL693*&GYE%)F_I6^.%>HX0JEULEMCE2Z80\$\)(_[&J):(I0Q
M'H/^[D<;J(O&E]K''F627R]SVW89GACSEM7]Q?$ VSASI-,B=<5NN+M-B*[C
M8(ZQQC$XS;!2;Y^R\Z&*L1[7 !^(M*^FE'#L]JA<W_?3#ERAXK"GOZ7FV/4%
MA7=JX^,KQS2H=^33+]2OY)$1!?3/&_GD%KS\]8^+.4N48OF/"5>Y#][N[J<S
M/:]75>5RZGV")D-[./Z5#;E):4%[KV?<FRPN.7?37UL2%NQ=&__EXT9)@JX$
MG_@\413W_YL!AI\GXDHC%?Y2IJZR=&\+(5!N"^["_TUCXT<M2L&'RGP('*+6
M8ANO[3V$R(3-B=IT3J9;6IML(0IT4L96]IXE"V;C\WAL9'M]MR<JB^K%MGMF
M0;M.-YC"_![W--?\1'[]=3Z69[[B/XUN#&VS9'UGH(CES@'AWRZO938\ .[@
M[>_U8PX_92*=I56\Q0_AUXBP0.H=BE@=182"/;,2 <]56T CVP<?ZL-8NNK/
M!V/6Y_PU'5W4%X8$U/U=!>\P/B70PV1I>BOUG! U %.AD'A(;G0S7V]H2>LP
M:NK."4T1:+J.=H7OCZ7 [)N_W8AD=;!<NZ$HYG)N2AN^0OJT+UM:5$(5U/ZY
M)1K->?DKB\J-4[7';!QL!>YM]$8J_C?WV0NM-AWFUAFOF(MDI\#+D6FM(G2]
MU]2NN^B.$$)M0(#M!%6ML<-7<M,[F_;U8RZ( #HT)0D,RA8)Z*P[YN*CQ?*2
M;U6]B4'QN?0-U9&3D9=C5E[;^T*V#5^$_P["1V6H=W:Q8EKMA-L\O,]7:!Z)
MIE*U8)X40)GP[FF"J,@*\56\K]')&I3V>9]T0$]UUA VMPQUDGO:2I$P=>+L
MB3&'AI:G+WS>,YUV;.%]42P/.O3RP3PSLX?U'14.UZCCC3VH"!;I8[XG!K36
M7/:..5RACY_Z$_&*@?>VZ(DELH\--Y?Q S'&BW?)Z9.L(HT=;X?>[MH9#I3\
M]Q2V8]U#=EKZM@>%=Z(2FA2C8]\S).<AD3U_+\$[6P!";L,1[L)<S0I0^[V:
M-95A6L]O9U"0Z5SZ CA>)S$<@KISQ_Q0A2GT&#?JP-.>][+EB5(WV-Q@+(#
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M,S^I*4=D/W.%X<:5=$8&%"ZL94/!PQ%[2B:CZQ%_M)?S#3[36MS#J-2Q%I+
M0\X1;RW--U.)2?F56V \8KE_C'> DNXICCF+ ))Y_ %J??&4&2+"3"./&EA
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M3"?>>I^:Z&@);7?YW;BQBM5*GH]@NK ?HI&+VPI#ICK%*X%3_S*.#A6R:8Z
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M>X^N)BMIW*"MNE+]J5&W+5\KT"WI&O/G856LVO91G]<H8SNY=Z=#I,83=2C
MEB28]K&IYEJ1#2C9(E:7S!&6B!Q1NODI9S/B,Z%M*4 /P^+#BCN(L\F?[=S2
M7]4+:KY$;C#5$\^ Y>,N-Z=NM<P<:3U<=:?DUHTS05O2B-ELYED=?=E[TO-_
M0W-WX6?&OW&)Z@$EGZ81N71W0%TUWQAHK@6/,YV1=U)<Q38A!B/]-3M-32\
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M#W*L'\,\(''N5,&=?:3978V5\G/Q&6<ZXOP33\4[]+Q8>G=]88_EQ%M=!ZP
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M_47Y&DA4J"40Q[[/QS*!>":R@:=OA&X8U9 *M9^/+7FFYF6'PR/:=U>$-#C
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M:AXHNI0Y99HV!]:WX^DS+LFCQX+K]?\=._LVY.,<H8M> $+?XT:$8\?B&_^
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M9?U3;=C8GB:HY6I=RE1I:1*Z(]/!:-#:X':(=<&#%&UN>LSQ3Z3;@^IWE#R
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M(SY2UB5 70,^X;:+E0'&6'"HT1@+R43D_E23P9'3X[X4KM3/$?3SX$]^TV8
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MYDV==#BX?>'_UR]P,PA%\?_9)T9=<=]Y<L0HGR/TQQA/\\=Z10XXU%?SR(N
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M!4#[OT'JZ^@LGC:@73YTPWBI%=D)91R#S]\W_CT>Y]G')L57A'ERF6E)WIK
MZS>JDU50OL2MO#A%HR*R+@X^EWPW#P?5$C_<S9(_P;K)T"%<5ZJ-V;@!=BRA
MC?",CWN!!#>*NDN_ AKI:/64RJT0E<:0,QV>KJF^SK;1T7-OQ3G!G;7IIV=)
MW" ;)VZ%O/[]YS:Q)%G#D_'!!X^B8R_0LT'UC]'I!4$[82O+-E]QP&>,$VW
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MGP52/"%&1[F=N1Q43U!&SH4AHX.8XP"8PAQ2J2.PWZA^<).3,IR71[S$]H-
MJ;L?3K,4L?WED?T-_X>U-XUJZGS;1U-141'#(* @I)8J*D*J3)4A*:6*BAB5
M"A*$U%)EB)A:0**$["I"0,2TI4H+E:B(B!"BD(!B2 P)\%JJS"!!R%1%ALC>
M"F%+=L+9\?>>\[[KO\ZW<[ZP%F2Q\^SGN8?KNI][8$2IL9_0"UK]SOFR3U>2
M)QP5/^-3:-[#SY(5WY3I=:8"<UN-LKV--%S]GXYE= XJX5,$+V;[J"W,54[G
MEJWM2N>M("/;!KT[+[NL@D@7&.'$*_R4$,FYRDN" +VS>ZO\:EN.YWD-:>7P
M<++5D8Z[Y(DSW9U)J1],$WXJ(#_$NE)=W,89$NM,?;)O26H9'M"<C&,.FR:>
MS>FC7PY1$ ^0)]&/V+;&X>K$7=XHU;KTKT0U;0X7R8J;3OKGEJL,<1ZI$G]?
M#@K,>;(_&>OOPAR5MW$+YKT8#J!H@!8>"P>&4@HX*Y DWAM[CC60"."0M2 @
M$5O&[>ZE%Y '&,NAS"> G?!X]1MR5G/AK"S2!?V7;$%F;(;,(?QV8DDJG;6[
MZ^ULQ8 P0C5B(7/Y!%W^S +F]^. Q)ZH_0RELT3# =R:ZO<DXPH%B#<NF]5[
M,R6*=<:EQC8./[Q1RT/_P=+P8!88&M.=A,]F<)E]#114D,PJZ0EAAMO,M0P:
M;:D\5*4-B^H5K:5'''T$:OGVOW16T+^!'Y/[TXX<$P^<NA9V%N"RY:[&Y:6@
M5"='"4P\Y6<%GY9G=(7W4H;0\YR:AC3[BE4.>8%N=T;BD"C8"9R. 5.NY7,5
M<+4DSK>N#\'^A!('IT,-/35I*2=T82F^5)Q54G?H:<L7YB\6, (WI!2O=5C
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MC?FFF8[_X7* 9-L"YD063G<8-G%HHP><>8O>V#JZ73# ])R,6STH3-A8I0F
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MS]$M,?R)HH%AM7TI&*%+-!01[&&\K"P(G+L8Z*K)RE09:PB?,DX.JD'%Y9K
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M;/5^3BT=+R.//CB68/XS/Z/[%BC.8SB?IGD\OSTX2+X43G4V3?;;^7$^V%)
M68FK]ZW7;V&<0Y\^O9P1.!@8K<*O&9DD+A.@KTGP8D> *?H)_Z/V\^S+0@>-
MUG*K6]G7Q:@=':K=D+>DL4G >(1!X?2%6N#OK6+E[06,[CM< ]Y8SY.1C3L!
M&N]#!$VW8P%S/V$*-1)5SYLI+TE:<S"B1<PO?H(O7,#4<ZZD8ZV2XI;#'T!
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M3*^MX=74WFKHXZ<DA#^J&TAS/O&W-*8;/V.@D.J:&S$(E@)_CB*TO\9#CN+
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M6L#@<& T4;_/7!N,"(F47@'#36^%VEWC2N:33GW84S!3IK!%=@/)''E(.T>
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M=.-SCD \A5?S8#?FXW@>LL[P%\J3%;EE-G4]S$5 RP8EER*)<X(/:L1+D*_
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MV]$CR4U+2I*;<M 73N%Z3M\2&CORM>N-]P'E+3&XES@D-:X(/0YRCL#HV@N
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MC83=G9!7/&ZE8LPE $AE(3?-=2$+F ?9NK\6, .U\%#<!O3_%RU@BEI,+:L
MK;MX'3#[!72=.<24$!_@6WBF(N@'X)CN&]2D8_,(F^ 4L.5]>T;3TD8H[##X
MNE%3\(CY*1(,D637D](+PUJ8J\%=V:>=:Q^I1_;VAMG'.?;*G3=:K/$<U;W;
M,?WV+&W([*-SUFV!B_3?,0["T:84I05,'C$%D&-;*?SBUC!BGN-@CD\L[BNH
MLV#6@_1MWPR/I4.A)R6'EL9;+CE][^6&0G;>+-9NTOKK7[AMCW^:>+?[$W@:
M14W&R&YX9 &3R$9M6O]3<*.PVK@<71I*!-%M5]%@S[$6R^2W<H4Z2L8-4_(N
M"\U7CG]7-PI356EQFWH18$F%;,Y:\>%I!N0N<< ?CZ>=MGLFM(V-"\0-Z8RT
MMSKV?]S3+4 2(HQ G9XG'W7J'P@!],>Z=+;N>)_0[327?M!H(U%^B82IB':>
MW/B;H<J'PGB'@BLWE=KMM@"1[9E&>] )K.E:_&[X)7D!XX6K]YM: H;ID/\N
M[&4PW"$2&:X$-:@S7&$DH@S=RFB)9!@X2+I?"X^M6(H<7\ L8VFQMT8FB9;&
MSX?&YZ^/YOFD>,Z'Q=+V/GK0EQ9T3)M6,!*R[V&?MX?-- FC#S"N:H9.%=QC
M/N&8$T]X+%*EHU!(5VFH)5C .-V/(+/4YR9THEQCZ199I!5M[.;F_'-NRI&9
MG<Y#V97?O")W:M8C;/^ ,$N5LH,;Z7RZ,I](VU21;5SEA2[:,OC+S^A,6^;@
MMGU. 1<?($M@_F]+.W>L6K9C+.@LC[> ^:$3_G1L:AQ=13<9KZ6B8.6B ?TS
MC2-W?=*UH;(%GP<T=+8]7L 4U"$NV5,9NBB_N.6]9.F^W/#OWSGO33=V0=[&
M]=FAU"S"^Y8F@)5^Y-0L"J\:1-O^4T'$H!D:%C#'L<.#K2A(X%0B% /;FY1/
M-I<2+>%,,EA1*4WYJ5/-R0G<H\):A6FXN$-@'%==N/]UYSYH)S+O!0-MA#67
M1N>==M".]7EH2N1*LW]1 OMEPA."Y\<@U?>&9L1+F3>;[]-!RR&;7QZ+7;6\
MEB96K853(.(3P%IX:MJY^=GM['UL2=QJ:'')OVT1=J*\IIQ6F<./.S?4*$Q-
MH;:(MJ#\!R5SBY6&?.-ZQH;ZWAG.HF2@/J/E.GXOJ+N:L)03KW+GK:2'[4,Q
MG/+AR1KMR2D/=K;@F>M!\)\'20/C=V[+CV;OWQY]UL9/X1#9,-@P:!_5 ,8.
MC4@\N",5?0=?QL3&'-W53:*=7GP/"E_<'="^]9!KZ.<G_VOB;QENC-TJ!D\Y
M3$'Q&H4C7*H[8A 0E>7 ?=)YIAMU4#['-BYFHNA8IK 065!(5:-'1Y.M8)I$
MTS+_"_CJ]G35I#OM]K,,+DS;4W# _IS+^8KQ7PB<'S]1+6#NMSU0X0LI8*H#
M8I>J,6]Q#I..>H X4Y.+8ET6[ %9M,6M%?:F.V^G72KV)UV8>M5]I>)V1[JE
ML>)&."AM95H-Y,R E/$2\45\&FV]JK>_M]C %4RS%.">3AC/:P&&23*O(TB0
MX0]4C6_CZD-;\;DHF0C-IU5<(5J\ =81$PRK>ML&"%^6.5%+PP#L*#5N=5>@
MA>I-0M^GCF=XM7!EF]%5_*CD=5;\MUT+F'/$[TSQB;DI4T\A)>P4#UKHCH*!
M96O >Q,9S/40,4_P6#;( "#;UF*5O;Y5;,4X,M!03/AL\$3NIJW<%Q+JG7''
MV(IKA3?'Y7'L^(1CYJ6 )!Q=6S%ZFH@=H$Q@$18Q>\ZQ9)15B2Y6<,X=9 \X
M>)E@/2&R1JV4S-DIIG<F)3680ZH?0.*5;%Q2OLJ0+(TMU:?N2;'L/=#4RX^I
MWYKA&'X[[Y,/#Q8P2^6P16M<(&RFWP](]A"V)$7Y$NV)R@JQP$$F+M2G[SY1
M%-E-L*+39"6#.2('>+OS]T;WK) H\%IA6MFVP<#E_M'C_I\S5T/[2T2X;F4O
MV;T#70467D^:LM:?0.+AX_H8! ^C9F5)!OQ![P@K='3#?9$[@P@_T@?!7BJ'
MBP)M# KOPQ,LX+DV!Y2N;*BMG>\L$%CZD7MO9Q0?R%TNW)9:4?"A-JWC=H%>
M"A\$VR7B)<PUC$"8"$[OR0X&'5H42^CQJKD+,V&)*5SM#,>"'K*KOBO-V7_9
M5JYVJ^I2Y[[[#8V[M2DIW.YXBY76N^P<WA5]C'VL9SX3"]K;(_2'83<-3KM'
M;V/L:R3O+&.I25> !Z36!MA#S<OSS[IHFZ0#P <V@SO[U)!]>=*MER\3[U,'
M#KT1K>>$Q3A[?=LO"'+=5]<;CT%FNXC*JZEPA''%'CV6WJA#1?6"$N[0Y1EN
M&U<HZ!UJUM2T/H@1!4:U*#",8&B.)?"P/=S+.$U5_GI,(X!<!+<[XU4=P]-6
MY"3__<V?^Q-9Z8]SZ_GWPR-U!*GN"Q3 E*'B4 ?H4%S\@&6L(N78S55.V:+B
M=M102CP&%!"V&BIHH@VF:7N"3A3%.OO/2>=9VAWZ6.2 $.9!(;O!PHGQI_B+
MR+:?=.?B2BO&WQ5N7^XI*.CPB&F=6ZHYT-N>?PS4_D.V;.P1KP0^DL+5S!$%
M'Z6:[E+11U)8KJL"25+\)\C78)L 94T:E!.6(YM ,4NX037,6?JF@6#1*XRJ
MG(A".>%4PL"= 82J=H\I&#KU+\H);_SFE(@A.IO(X+LZ/&)5;WPZJ$7]Z#VB
M6HL2W^P*\;_=XF,D?9C#% J![G:VW3,P3$SP(W\SE=2C_(UH3__(WP!=8#?S
M\S>4E<@.E9;:<HUC*>@@72+80;B+@<%N5_A989)SC?FS :5!?K*Y]V^F4:.R
MAOZ]>^:;DZ^:60<:KU"I^0"-;8HE\>!-/"GOX@)FI<A4CDC+F<%E<_AX*4<>
M(?4#+'PX*]Z4-,]=$:UY 9>3NKROG]&TBE9"S5<'+[Y50:=NR9NO<(Y53#K8
M2'X8(.O*?GU>_"GN&0FQ!Y2*5L !D)Q%Y6*NS,90$TC5V\H9R88_4%!)5'6V
M+V!6P5]+6\,K4"+S6@RYROP;T:-9];B*G)BDICE%P_HG(@?Q6:;$GSPAWW!I
M-"Z\9BBZ?49A:G&]N-!0Z\W^&6=_PE -*-4T.7:WX2\!UCPYSAF69$)^RF*4
MZ3V)ES"WOD/P=^7TTH./(:[0WO_,+;G0__1C:D'&A<R[QW/5RZ_M*)ICZ7H-
M.<03"YAAO?*X8FH!H]\#^])LZ=\D.YX0J]A6B7/:&XROX'2-\\JQG5"[E+>&
MW#)GM(/B_EIYGVNX%20PY#Q[^VMU=+)_D$&+[N,5.8 X!8-FLI+."S,<.4GW
M'M6%4N8+,8: 2SZ03%AG*"8F3LLYAR"2)+\XK,$W;EVO@.NVLRN0>,Y[9.G@
MTR]BZ+LF);S3'E>O"^L]63JM#6*FG(:W8I^(%S&?$<%=1-AU4(+-4:SU !*)
MN:.F1K$7C%)_RL],GZ1!\LZW;,A-\AYVU_C>5"GL$AV8N/Y9PPJ-M*2L*(-*
M9+WJGFV.VI>R;LC)75\*>$8:'Z!/^>!+*5S Z+YF;@ FQ /58[SA#)07HE8<
MA(/!,&6&C!O:+EXE7 *::3@MG6P.=HIIH: 'M-0%JRD7'4GYWJ1E\/<ZG W=
MM>W<(7A-DM&M.5>_N\?[F6O$,6IE+8<[WAWBG8%+@-LE\H1"Q$+-8\EKYG3S
M?@5"MUIZP*%'O:\:"R*R]PW.9')MWF6NK4TYI?U>?&G@[1Z/BH=UCQK#<D*O
M#21*OWF"NTC\B+I==2@$>%!NRK@9J(([XU#XLO0J\/<FU _5_P;/+6"JR*AR
M3=GI;1A;3#.KC1T4+/ #<*'L4SA;S4:=G24-R;C[AJQH]8B2EB@*WX[!.9H%
MC"T2.E <B<).%7%QHE<KM9;..RCH&>B41F)77;7\W8&6F;%N;I!HAY@VW=7X
M'*C+T%9EZ>.9_^#6BI.Q%\[1"@+#-&P'!LGPNQ /[9)3AD+5GF)-(?9 K^?T
M+"UW<-2Y^%M^2D!$<P/D<G4Q85-)QYX^OL>BSA!!]TQL$+_C9^S0)6,T45E
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M)&+11'LG'EW6WY7]0T.Z^WT?O?+4V ?2P@U_M2'!5,19 '07'[B;P".T03%
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M8LY2M4W3C6';ET8,F:=W$4?[)>6=MC.FEWQK6+A=L!,P?.]+=*!=)O<4MX!
M>?*]M<GNDR>?$I;._/]L%,82,AA\P!\-60MGWX ZOI ?N*@<4A=I+*AG>T^>
M( (;6*#.F6:0G/;C:PZ'SVD _9.?XRHK*02EPJ>Y?N!:C>L)<MG$1.3P35%J
MS<91H?'LBB6T.Z4060X;%6Y*K%.N+KL*#0*=D\IX+C!-X?GD+ 7D..J3I8%
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MM&L(&JV90M#H!?0,W+N,DBTRZ-\31^,[F :<G$3-QIS$RTV0K[3B>] YHV2
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M-@IEM[R3?)Z/+&X"8'_SC/XX4[[W]SM:*\9V<TFAV[OW_^:Q1G?QNCOM%$V
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M!8[J6HXE]C?Z7_^G+M@E[BO)4ZFD7,H\Y7<U\H6750^6XE:U[;F?X6ZUEAF
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M7S,6UB(\=R9MK5D;TXU&;,P\QYIT&\-6(&N;IX_B.>2_^%/[GKL#3.+(H69
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MR$TVL.>SL.7BOF#9@K&GYB<^M>:;]YAAQ2W6/_I#W!+?'HE.9J_,?H];IQ9
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M!(%C'.[<>TEC4_LC&CMN/@ E>WV7(33!29I^*^)9^R$*]3+9'N>$%;_=N[!
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M<[?/<Y$2F@D#?F&K>23*!O/]>(V0/.5U'^MBDWK1"Q\JTM>HUTA7+J^!(2W
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MR8.J#C<;E80^G8,GS8_'-*N$U.7Q_LMXVB[+\6B *[^$.4'"NJI,G[L>(<_
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M@H:J.!$PNB.UYLW0\_(X; W#+EXSD*(:7JED^>H,KUC6^I-7@=I<;!408[U
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MQ9+37&33Z%1)(@YI0J'8R0 X3!<K!ZQ!Z0Z)]I<%@E SM<CX ];%<Q""'"R
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M6KR9E@]W\?&G1+^RX;BT70^:?L<7;Y#_-]/)8I1Q/'\VR1O=OF;([5N]M9A
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MVZUAR=$:7CGCFQ:T%=@X*_#LM401^+O-:\'A]_8A?\*>[WXZ*K7Z6FT!&]O
MB:#8;L5:^2=C%;]E8UR7#"<#0.(7)XDO,&Z1J4)EY9\R0"$&2,<X&8A$^"9(
MM&8303>)A2@<@QM"R+D-VS!20VR-TL(;09(,(YWNY.7>E]P#7W)0&<[*MYIG
MJFT0C6-UE[0G$*A<,D12EHW+\-=:A^UPST2))2D7^8PR,%8/EF%ZL>!<#IA"
M2KET9\^[*F$9:,<]FSQIGO,G.4#N.>:VP#$W8&0KRIR<4QE\\8HMJG& PFIP
MR;N<77$R=U<FMEUDTX&S&I7(B%&"TJ;USA0#L0I6TKQB1K!)B1W#H)MH( 8<
M:=.A-MDN"%K[C0TX[:0?5==&7TGE0'K>.@99Z<7H6=]%;7WU$F7NKJRPKW+/
M'E2?%L&W\7!.^D8(T6KA)7D^>S Z6T37;UGSE\K4ETVM5/Z.HUUG/NH@K!2U
M)L&H!JQJS,\"+6!M\W MYM)&K!?97;KNOAEY*05R?8&1P[6%11U,]>R$.R<L
MFP9&52%( :EZAEJZ1/3=:A6V^M.W]!K?'YPP8)A=I'HO_);6N77 6'C*&.&O
M;+/G990WT^"WH8")"54*(T%2:Q=7?.YD^>PEM2)$5YVTLM?%&2(,H#K!G&<U
MQY\LAKL/ ^PVU7RT57K'L%CR_@)3JFNC=Q605P%MM#G$[D)M-U1E+^DD)SC^
M^?UQRY\-G$]IC=8+>CN_NOH7TXA?K9YB3S&XTU2%R."#9D=*E%9M0@CHC"G9
M*LM?]B8L7]_M\VI:%[_CLK.GY>1.6)HN#MZ9;>U\J@$36 JN-5MHP*P2%*7;
M\)I2@^C.Y5T#B_)'.!_-7[_AW7:\C'[,SPO9-IT(4B \R&$6I]%^*>.@Y-8E
M96.%A#)#;3767EH,J=\JW3].',YH82^)PS>T@X/4M0H'0;2)\659@\JJ5PO$
MY'@'N]"MKKW@C%B!RZ9%IY-F%?]HP/=.S:4P_)(',9=!\W^L?ZMI)8>DJ(4<
M(Q16S$X$Z]!UIX2_%0!^5[[3KA? LP G3=)"09? U*0@21_!64-)"^6HO]*Z
MKX^=+V=>WD7L?$OU%,$IJUW@*Q=>1+0$29< )?JD0TXR]$NFO(%%7/O:G^Y,
M_(3">762IC.&H0V+;,;[[T&*8JV5C18(K!J,L>S]E2Q FA2"\9D"[6AP_7R&
MV'E#/ROS%F;>5Y1Z+7Y^*_. ,7I5$600$8QR!I*C-IS"F!#:6CK3JTQLC5;M
MCCC/UH,X=\UJVD,8"U-,Q54(FC<":RZ65V/Y1H(G$TD64[MMEE\E?2Y6K>5V
M/@SV_4" ,*?F@Q_P2VJ)A.DR=G46#]U/VY10H3 M0M.(_HD*A&@U1"0IE?2D
M:K<PM4-7:YTHS\')T<E\L=$PSXTC"LXO].& G0GO)$Q6IS;+2V8P-A2VF:T?
MIJ*N.F<,NEM(OAN&\WZ\YHY;Z2RK6S8!D!=@0IL 9&6%K(TC2='9_FIY]J+N
M_IY]H^_L_Y#1O:RL*$:!20R'C5NRLP4/I684Z)S6H5LKU$<FJF.1W4?4E&U4
M[**!P#91L-H(_)&&'"HI[Y.(>1>;]0]/)V5V:[1P8\1T=9FO,R"WQ0YV.=AH
MW3K@H6;,-+XRE5(;I.R7@Y05H! )BLW$4E*\#]UFV ?@(7W]9C3;[]%:II%'
M2+UF0O?RH;<4*^>SB) 2(ABL%J)IK"&^!I<CRX+KCD.F8P-U8T?865Q^DP;Q
M#_8VW94GL//IXTQ1-+8&Z=A,&^ULXP=/0,ZYZ V[>+D[1LE-S:WN!T45&3$4
M"<XNF9@M00RMT;Z:1*;ZI'5W29L;:G[__O/_?OWSRX/]#(04*PT*!XV)$$P+
M<"?//AL&F8K2D=VV+@,AWS+HW4KS6VGSC).$[-NV1E\9]%8',J&P&)/'V*VN
M7;-B\/5LB4=.ES6#J_+!_4QGE:#0\-K%[!08JAK0-S)V)RAGTEF6[N(R-Q$Q
MX^P=SLIODQ%OQ/EHX_-0MK4'DXW&\_93F?])JDVPL09TS4U7:VOZF]CU-?RM
MRXUW,"GG%3-[52+3A?R4'+)!<)AXXXO$>-FP$%652V,QL!Z[;7E\C>^?S*B,
M%D]8.$[K=/8[[_=/%R8,Y]%UTP+;A?"0KK6)C X,%%L??(BMH2^8(%ET=%#=
MM0P,2.FSUK6&(' \'Z'Z%QK_ ?[&?GSS4AD5Y@(U4<L "<'XHB@0 K5$;7W0
MW8YXZ8)E;8!,U/1D=I^)NK-,U)";AW3*@EIO3Z,<%J9"J$2@V637XHQRHCM#
M?0-"?S*=\<E70&MG0ED4?!;2@=7"@-%:L_%#7N=H<P[:66&[P]M_>,S?5^RW
M0G4T&2WHD+TMMF/\?H]:[.-@/J?%G!7#LJAHC//+=G85R:1R%F;;G7!F:T2J
MNC4F-0H#'R-@P@)D4D314G[]CBK[!IFAMA-$11&2;(0%UH0 QCB$J!G[D"TE
M:J5<U-U5#O0[GFQ;:XBQ5K1@ GE6]B5!BB:!5QXCJWH,V%V LXN\Q7:"F"AU
MIC9]S*?B6"^+"LFDS+]F:@P(_&5WMOG;)6.[8IN%'<@VHW08E&&U2ZT_3&,
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M3&BDZ8XD!$,Z"X\11;>08LWJF]>SI6X^7>;O5J4X^UE(Q6MFK"U GMB!J(D
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MC,>H3,* >8R?=91X&1+1003)0#/7OK<YEV=!\YV2A:V^QZ,VRNI2@YB)'XR
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M>B;R9 &R7&9*<-UG^.V=.G!#0N;+=W][]>*/@Y=/#K:'0$I)SE&2?,I$2N6
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MW^0/TV';;PYDVT,_!,(8P'\FX]%*<MB^*]2R/W*.8-EQ14F)5A&I,B4NN$Q
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MK:AN.Y9VT44($JG%9>.>.)$%*3'Z'(*Q/:RZW-_"QQ?*Z=\*"$N0QL**6*F
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MO&!K3%8Y:B:<(%&71&21ACA>,O'&91-+S)+UUDW7BP9 &V+EQ>;B0497$A,
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MPQMJ2^*$JZ2(5#P2[Y/&Z@U4)!J+EKTCZ[/2[Z F72+5:Q0I3ME-^7C]68U
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M'6V^PIKU#=)DSYCSLW%=38YR508-S%QUFGU=9?C\=$%5N![K9,J2NZ  M[S
M=C 1L$YAT3LCBW4V*:-6A76O6R_V0>?;O@AV&$-!CN$M1W@;2?Z4X&>0/'KP
MM='[(!W'(NRNH(.'F41<QB9N*3M:BN)*WEII>3*M:XQ!:B?W?V!0RW[ V=CO
MA@J>YMA%1V 8P5?!^^[&]' )"@PV"A^%(2P5="GQ0 *'-8S1.AF,4<6M3/$\
M7\1G<*2YT_7!*(^;N.H2S/9:.-\4AO=';E0;LG=MB19PG[CS5BG.&&RU4_ZV
M2/GS%'0_$'I(P3X>4@,G\EY+HF**5K HB[8KLX-B=\[6I7J- DB:'(':QL/@
MA\/Q)(P_W[T>*'=ZX+KG^>V;_9>'SUN%;T.ZX(^)-=LJ,&QPDZUJRNZEG76+
M9>=MEJ_FMH_)&2NMNF#Y-JJMNO"_R?CK! )_H(NN=V$Y8F_##G7Y3?8PMDW1
M%5B 9]!@+DGU;##,U<OQW@T.]IO>_26G DW!Y\P(-SP0&0*6L<F:,.X4]5)R
M$VYMYFB3D$[Q.^#=741\'^<<WDX$%<PM(5QN(MSCINVX/=$MWZ04?6_DB C"
M<%XXH0K3]P0-)/CHB.*T!&4$]_S6[K*.LM_D#VW]VM$$4Y;[&D'R_.7+5W\\
M_V/_8?7\Y9.]GM+XLK.UXJW_T\%G'R?MPE;C4M5G"UKYIFI.<L0TP%0-1M5@
MTE3QR-<P]I_O2^"-HM\1=;/$35\3<;G:XW=L4+K_ML/K@= FQID$4'-<&R(9
M$R0$*XC3C@=L#<Q6Q>*Q 'A]TK9<Q>J!0*RSWDM/QBE?M2(U>,5)/?Z(S[ES
MM]30?_*8);IRG]12[_]3J'_Y]Y_:.:I 5QB#LE!7?Y_6@R8-8JLOC$M[S6!Q
M3MM+ZP]^-/AG^WOU84\],7@M0]<L<:%IIB1ES N/-A#898:X'!)+QD1C;FT2
M[>CZK?_\?)8,WI6T7ZT<NQ3!.$D$U\IINEF2?;[W9N]PKSHX/AF.3W/='KPX
M.:BL7$^8.SO?#VWGNWU(Y;;.VLZO=G<&ONN9!<?\UY 2L4(%#"ABQ&< ?M'B
M?H;1,KH:9K&?4HU5S;I_7@Q&F=TIHV!"T>K5,%6_^M/F:%SGZB_PF$_^]&%U
M.(5759*N@X5\WV!;]G%S,(ZB7KL0*3%,.R(-1RL5UT11GJGENA@65KIZ3^#/
M5_7;\:>[E4I_G=;8' ?&U)L56B96RN@0F'&%V%1 P\!B8T$E2SB-W@I!K9&W
MCM:[L#RMW/RJ?@VZ \C'=QN)_&2_-VM37=D^:Q'\?IK-.II&3FJ8\,&)'U;Y
M<XYMZS\X#*)?;NYS#L92+$9:G7Q)Q#E% :2 K*WVB:0@"PW)R:C82G?!ZS&6
M9OG;X*15K^]6&:%LPWH(?':%WWV#IO$MSK.;+.C?X4_J=T;J3<;E-3K05FS
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MGG^VT_#Y$7\,;.4S28.9J063UJ;'H\=IT)P,_>DC/'LE)&9/#4;M^\\2N_#
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MNLET/V)AD:(A<_NG;13F;9C<%S[!/%/Z+4_YM8A1CRAT=IG.? =*S"DO'X&
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MM:EJVA(<[?8"AYK LQKL+KKM3M;%E+E"I3Q:4*?:H4BP[+E4PSS;\FQKU?D
ML'NQ3Z-<CFN-<.E< \UA7-I6>]^L$&TW!^8>X,^Y9</=44#8869GV;F(7:,+
MB\C:>I[(>EP !(=1XO3@6(_;/(37ESAN;A ,W/1O[R_R'&GE. 5P1>%=1DN[
MH?$S&F/ 1;:)*:%F$<T9#[ @CN%/"BVA6+!4!")!-N!XIRUCPGRPZ3SB7PUJ
M2U,&P0*'PD=/O\&B?,]#SS6>@O"OQ-]9(GU ?$G\$O$WF!H1ZC%M\>6+VE[4
M9IJ<.J'(8*TTQ)&QRX!SS&=@WH"^@*YK%LUGR50E2HH<>,76U>7[<SVT2+ W
M2R31YIGGZ@N67^=354RF.0XW$BQ(I7;=F% 5:"&YU$H(<I;211U0636(BQN.
MYMH8K,@97=9AQZI].TC/G#:$P]E$Q ]0Q3KLRNA%I:Z$-UB:P\+QH@S@9\4H
M*'(>"U5D9@EO8S_U>T<,EDMF"XFR#W:2F44(84E2M"<M&[[7"JWKEYX+>RZ\
M:H3J:5Y<\[EGP\NQ81%G<@Q_I+"EE@7K.%M8 "<$5IHE6*HKT$'$*:?>N,,:
MV,A,<N(?B^S#%IFXOO8&KU8&K!M.7M;H*R_1*N@$2O)1V4.YL#9+ EC0O6MS
MOA<;-"*/)J")EN:IL#ECF<XR-N6@8E="IP;O%\.C,+^LB$@^D:(\#*]!=+V\
MA!7/L1)B*^/13.@ZBY=N$[2J/$-WYKN<ST82W86U]N/C8D;[^-)-5(.%"6"+
M03R"6"UU<3#\0?@)$!X9^B!'*2> Q?([BZ"!XAC)28 A $)\8K$338\U3%4A
M45JY'EIP;Y8(,C>B>8<-HPA?%08!BA5CF&Z.P\,>94B2B<)E)4U S1)8AE*2
M8DLWN%$5&,M.<Y@83- ^OK-61[<2IHL0)AZH:4. FO8;M] #-7F@IL0#-3T+
M4-,OKU60\.51R\A*I[P2;;D4'7;_*62J36ZXDS",:XW7X'B0T0QB%OX;S%N@
M-%(B!)G8H$V0L 8%!4N<L[Q 71('"P58^.3E!Q$-S[@&K9,,3U5J!J7<YQ$P
M-;#_&^(&9"AGU<@X9]=-X#XFG_*<[C,J1PG*/ 75!+_/.$9RM=<25@]>&TW<
MK0PTXU!EZ&)$S:?%+#AS"W04H*LBU;['6VO!S+@++V3G;*=1OGZ>M:SN5&#:
MKA!Y-2_Q%6<&ZM!_0#.7^1QF :/R-*2RK,4U:UGU"Y="XG3B/)JS2&09PW O
MXE;C2N. \$$K:;K^JNREIQ=,C]@X6UIM0T+H[T5&!H.I\5B012!39P]S@VR=
MP" BPS4H8)8DJ(R[)=?7FL((7C[1:FDJA>O=%T*?#,I[W!FM[\%2P2O2[:#*
M+2R*]F#8"='+X2+IX85Q6!2P^HOW2;AZGN#6XA+"ZED5=8&0"/=[""\8&;#M
M,@L@RPK4@%F8P@NS22%#\K*$*BC(2@J K&DOWCH:^%O=AOCE9QFA807JMF!7
M:*F!4H[TO/7V[<O/I]OZ,;?(-L,::$J)O#AY_WEXX0WD)9J>OKXX.?,+MX1Y
M<O+^_>GYU="OW??/B+B(A37K=[_-18!??IJ)"KOMM<9N<_@&LHUQR38^?3@Y
M?A#C&'X\N_#DOPP&@*?^I:G?U?A7;/JL4AF_T2;R2$7AC[$;SPI$\L_%)"4G
M[+&-7AVC4O82?AJ3OZ?(V!N9"?3=#K-,..:EN[X-@97U7O(G6=)C-9N!1BDI
MYDC0DMIS>6YTQL:E>S+3\;:AOB9V(U)>&2P-N+%^9$5PH2&X1*7Y&$Z HJPO
MM)THCIEBU)5D#\BW/@@@L"BT<4Z:^PDH]!FHW%>4$4OY]#JN^)ZS/U04\854
M>],"1VA7.$Y3QH6V_B:INF$4)-;/1,>NZ9/#.,@[BC)JQ?\U/#,2)O!:31R-
M@Q1>!Z:/4C*4:-N0]SBG8J228#*R0DI?,0T#0X#-0R86V499,8,MAMW(:":E
M9]S>]>H)>=\WJ>D'>G;^'\;8_Y@ETI,Q;D6<#0X'D\=?VQ&?J\(X0?7(O6ZW
MTWUQ9*X/D#R23+S*1$*(4? T'!Q&+[VJUT!K(XD6]"M[N;T*+@O+Y:#A^_U.
M?^^%Z_"TOB;R>+Z\\[Z]3K^_S'W[G>[!,O?M='9VOGG?_[S,TUOK87R]!["]
M(QY\@2,#XJOM\):]/3>TK/W+^,4]/M0:E=V:LMDLXWQ.<BTEF65D=>=T%^,.
MYH[4>J7OO$?[,.&.!1T*].$P$K?"'-705>#CUMCF"CWT/<^VLZ,9-SO##U9T
M?DV08U5R]$&GU@C!FD,V#S=^=W^1W3N-+>:'W\"-W,!S>:URT#,NC:/[VS8;
MOF)[T-G?[<-K?Z]6O=L9[,%MMZ,F#Y_Q5F_;T]I&TMJ%P'SX7*5S(#>>%UGC
M/MZG31PV:A-C^M^*M8FGH!$8:SD"<8W!75R#Q^H.M=ALY[#_HO:(KG-B#]?
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M6/4?1>1Y]6IX=<QGNE>&1I@38Y$BV!F<&:#11KH_;J+F&KVP$<=68;&4SGG
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MB58*D"*'?2OA=#5I(>^BG8\BL(." )T2IN W45G>KOBE -(OM,6R=7YU8GI
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MJ3E=RXK[4L@(TTQ7\S:;56$ZH=WAK&CTB)A4&HTJ4Z:H@&K<'72SECNB];3
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M3\50PK!"[<P0>L*%U(>12E"5K"..#)%>P,;JAS6D-3!$BP$,1>75O"4P(Z/
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M!&__\I T!,?)J;T88ER![H/9GT7A.KY2@G6?PT=@NTK+1HL0I]9W63AV>^D
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M8M3Q3*LHZ@Z_2M=YA'BF,JM2O!VA<*+GE,KKYOFN.<9%:UX[D+,Q1ROOR]%
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M!0FG'42_BKTR[N-Y]*N?R@.PJGR@L[N3@$;S!B'I@2ZI>A9]5B59,["N 8'
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MS0 ]#SW!1<TT-H9%%(PYC;[17Z/2V9@GFJZJVV4HF),/X'( 1I,?V,4>+X'
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MT<T*9[#J@8T0X?M[6%\/!2O%*9%"\/W9JCDX6;^R'W/F!0"CA_0IN-@!G3=
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M<G4-;HL:XD^A5+CMVD44;1Z0ZYFLPD_M47;G[IV[][^^$X#1&>L3%022]<+
MUH"=[ZSD [^9-=Z;:SR&2$R6,O2LG'5%8YU@0A(IW/)S2]U5P.?%J[:/& QW
MW]Q@N.U79LIB^/*U+ :%P>:6)^Z.VO5D)G*1@'0+T3>07PZL-@!"NL/>HG1F
M[9+QODK[[X]H(CGQ];LX_7[4PT21DB?F"T\?__XMXIE3'R(EY6'M#X5A7KWV
M=^Y>92R^5JPF,185Q=BA(%06^I;!@DXF+-ZG]W?#6TY^^O5?/__XST<_G3YZ
M5_[31W&=/[SK!%#?YD":YLN#XAXJ19E8]95RGRBPO:?)7C5XX=^'KNK+RMAP
M0L/*";!_:8Z+/'O8%?^IZCP[+9JBI)]/SZN&_D-63='C[_N8HWGV/5!!?FC1
MX/:$QDM7/>F[ J7<_RAHJ0!S_D>U;'.>Z'^YHJ9-G6?/SJNZVFQ0 )QG+V@8
MQ8:AWU^T X@G5AU]H?WT _V%?OBEJ"Z+QGLMBCOX ]U;MJ04GT1S'0/FQKK$
M_HT9\P&I1#_%=^Y;$".CG:7@Y^6V10A-;/9_% V+A,_U(%*%R-H'MBQ>N76N
M3;'87!-[4VIBOYQK8N>:V+DF]GK7Q'Z\^/1',$]_07.6XFKQO[,7W*@EI_T/
M://ZOKV<??JX'7%K<Q;5:2G*0<T(1'W5;Y7Z1;I=.L!B;!E'+=P<P2(S84+&
M&U""9G8CK\QKV:"OA6_O+<J3#E18;)J^VG@]I;E>+W#!A*6Z=&*.TL\T;WUL
MO?Y8N>4Y7/*MJV#%DN&ZXPLF[=F?VH[.+AGU\Z'O05@DR%KBX[XHZ$-IX 6/
MY HK]\5EM?T/:7%^JIB\]-]S< CQ;X;NI:/WZ&3A@=FC==7YCK%]TUACV(8W
M'1NUX+!A9SE9&,;2FB)9-,R*/3P7Z9NRWK08OS%E2:DF(,.3QBKN@&L*Q9P;
MB0NZ,ELP=:(UD_FX @3.1-NK2!]WH@KFF+;?":,1.'F,G<M+=;\GUL#Y Z!Y
M8''"%?2[)D:Q2=#'A'LD.!W1AO.##"VFPX;QQN0&VV':;RKW^V[5"$J=1^T[
M=X7#I6DO"GN_KE#:/ZQ];QN'[D7 "ND1PY$<F\]#/;-1OVAN?<MY)D3*5W2D
MLNR,&^[HUL9)+V_MX0,0 @N]L/JMU@^;I]VD<5/JU,O\@ZS5,[J(@2T9?3'M
M\+SB@S/>>BJ\RZ+W^:97#"AG@!:$-;EOUK-%X>ZH[5K)/SL/E,2,HH)Z5&AD
MJVWX3O["0GAD>1YW$U^H%)6PK)?GS)X-D17J2G0Z2PJJ=/\>!%T/':<*IXFX
MH=PW M1K[>3PHHFG!;C%!5FA:\>RRO2E0$0*5(;USG<&"TZPB:&U:PM61 BS
MOKW$<!YENCY9(C2+G<7_96%),P#>@J=AD%;F#1-+,8QMAX\L>L/ST,.N"H1#
M#(:+EV-#)%LV]$#?Q$#C1_$Q8*>\8,(74FX,BVI;AS? "RQ'7Q@FR@V<U0]D
M'X<Y/!$L@5UV8GIBMHJ]M#79MVZIA7#'',J]S0<TQV8D:P <H:MF,_LL@B[W
ML,;^S[[F<TI^R;9LBC-YS(_/?*GHZ*H ALYVBP(I" ;0^(&>:2D!/^K]^+U!
M)H@.L TZ1CQM^2#KM_K;*? ^I4N7O#5#<RS_/52:RM97[!(,A;)B]*/53B[O
M>[-L4B:CGOZZE)BJPO0>[7W892% EH!-5;XG9V>DTQ,1Q.,#/;(6XC]FPQ1
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MT=K=G#YAIA#9>TM\8Z#67;;]EK.Q< H[:UV@!6-_F E\'$Y)?B':]M;"1+Q
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MT*[UCU?4?@_G6[>797O9] _HIUF\9_%^Q^)=*8QD"CK F06AE" !5;(TAFT
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M9%JM?75H#7[4GDZCAT_A<D9J4>/^6B&*9HE.M-2DM\1-2^*>N?((AQ&^Q X
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M# 3>*Z8E/   ;P E32HD\$W-&5, Z',2P6<6F&;;%0H;HN<<#M7H6I*6 (<
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M^N#[Q<Z-6[^Z\>OE<* DWI#.<5&J?EC=K+5,':K(ZB(LUBBYAK2=K $ F.@
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M)A:/@MB \[;H%EEO'YY5:2L(?M >=MW"*OT:VEB:T3_@]AP.ZYPE@RPC]78
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MG27H(P,?J8KW%L\GH@5]2AV77!#I9N^7)GV@$123\@8'MS?G0$P@<WRP"_Q
MTOCW:#?A%8Z-PJ'Q[FBZY6*Z-H-C"%K2N&@M6M%>'\GMU(&B>A*I'MGT__S5
MRYCMY.XA4-D541/61EERY,Z<!6ZL]$:@;4C$ZFIH* :42I&P?5G*7G%3-@8O
M;40ROG;498]L)LZW9>M7LN,K;]A?Q?(P5+T,$TMB(/:B2O8;EA=Z,%'L1KFN
MEGW)SN8,=%5I=M,4@N0Z(X_D-87YP)@@VSFVKV,0IXIBGT8K\<\8K)+-F3P
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MXV16D;^XK>FC-5#'P%,'-'S0 Y?QH>B4_SQ5L42_@34\>S7N^&&:UE;?V1\
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MQ/%(2AYVZ5\66(K%%HM]KH;P=4H927#99AH+ZU#).:K,33U$@HABKL5<GQ?
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MQ3Q@"1[I;.F3)QH7;UO$RWKQ2_\@?HS]C D;CU*L??+1QQ]7XM6(,EM8MQ4
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MD%1@^"";(5P).!$@3:C$8!!V=W7.JL6.*0#E19Q:ZM;C5F]0_[UT/<G"4[
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M%O3 /LT8%+9H/PA>$C/BII:V$5=<[0KNW3.E1 DW<F$)/E1F>R U;520-*?
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M[B9NWMIV\_(#^I[4NY1?K;1';O*S!]+!).C!X3*",B_5:1!VP7O$#0Z%88_
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MK(C &8.5E%UD.7>74I?9$D)!Y=FWVL#*NC/',BK-3)K%6#\ YO_,X3@@!I'
MK&.]/O;Q("L.DH?'B!;L>A15L^0Y2$P>5]C!NZ)GX?97E]3)W ,I@S*K"?Y
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MDOF_>E$CE @)\<&-JF:&@<FD*CLF!?MLN>U_U2_"=I*)[;>M.0%Y4977V(S
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MHV[CY(%)*6?7<UF%JCX&A3BAR4(Y6Z51-!R732%(,"MXDQY#+>@/J4/_H4F
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MF[ G!@E8QT6..;MN!.U!TFY8I!,CF[ASI/"OUGU]-4F,2!I]'<CCKP/9[>M
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MO34?TUP]GZO#C+K@S;S>+L@<,$Z<U0Q6*0*].%LI&WL!D(XV/XK'U+:$+O*
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M=@BK8SN+QZ!PFP7>6K*TZ)R-XC :P6Q,VG%M_G*[F!VT4;U)2L>,\E8!??G
M=B%*EPKH&"U&/VO&EN/]O1S?F*&W;M2S@'A,\K'-*[(DG=*?9*"-$YR%^9Y*
M]R$Q^ //W&<?9 'XQ3RR"$RT&*J>"@/7TRO$3_M%1;F]K'?&QH6<.=_E,Y"2
MNLK#-%)?']5!OB\-7)1-S+TG9^X\\YF7SG84>Z4H=5$HU0.] - 4#XA-RZKF
M)*7:.AFMU-_,$8]G^,J,?K7OI1!9/*>810?FIQX+&/;%/^57:/<3D_Q(0H6I
M@26K.*HAT7ECP[C<$'G<4"^_6$6,<-Y"/+2DCF L-A58Q_%BZ6RK>+$R>J_+
M1Y8E9$6*(&1JM<*RF@9(I4'))2DGS33PT(=6*T21F(;R NQ(UHH+;*B.@'$Q
MN,3-\PEO(9,THWVBCC]H\0HC>UCCMZK]VI[DRI(9O])1JT(XX+DK5C(/N5*V
M=4FOEP[TJ2EA=LX([\PLL5+&W..)2R^PLC?PFQLTD3CY78JI+W=^@]FG^<K&
MXC8JAP#RR&>)_X<\%P+-6'*4/BNO*P,&9?(:C$K",]N%60#"0&9&1?V Z8)8
MR-2DKWY;NN93J#84\G16J M "ER>RHU3=;KVGZDO,\JU+?8+C\!<J:/N^>]=
M5;,AO<'%1U7Y76MVD1 ].W6C%E4^8JH]UBZ=6_4"+*L\56MD.#G;T%HFETQT
M$@:.,8=>I!=%5/@X9[\@9.PMC_P0=%$NG\KB:J$+[\Q]U5+ >'D>)/UDV4P]
M"\H.ZBZ<PQP#/\:_7\@$?Y'D _"&X379TV1J/GT(0#[ FV9!\QO>(V-4LC4M
MN>A3C,3:;N**F-PWDH>C<)=FX5!2%O<%G^1'6O.\^/H\I\/C"1MC(N7&QMU7
M"C*I2I!)GX),*,B$@DQ,R&]UMO[)@W8]]U.^S0$:+V0_>F'LR&#*&--_.HTB
MQZ>ZHJA'+=-183(F=6P 7(B?<8'UDTBCI6?\;<$)P@!K<&0P@S'Z0V6OYA/,
M2&4*4O!8;&FE"X=&G>X#^WTK R1\0$_E.]+#'K.)@"G/:+Z07C-/B5#*AI6E
MBIBE,/UR<#LJXEFRT&6W(HU5R_!S--IEOT6=RO-3/65??4EN_<O3CS0(1Q@"
M(DE!KH\4?\H-M;BTP*)FYWA ;JFM,X&!&.$4A$RN/BQY*MEP/H#[*3TUG:$L
M]X)T<ZT5%RYWCTK>V[)CAQ/@13BL_+VX8ZFS-/-, _#X<@S/]V(\2_?;XJ#&
M<CKJE=.L;2EQI0-Y:GD&[OO]XILS"7T17_P"2.DS0S+A!KY3K1<]"'QQ$D$V
MSY'2LB2/( 7_*^8+4&<[Y5JN],SW*2TJ#W"4Q45DPUP:W!C<,3QI4>"FE>71
M[F3>L'J\3%Y2RBF@)AP//P2C!-#ACF:A/JA4ZKK,P%>XWZ5#MJZ 3L! RR.6
M>C=9*^X\7RA<D+?R\5<Y";#PF*B\H2RR^1Y!<6Q*QHGAP;*Y!Z*RD/ZG$&):
M+LL-UD*2O6R79<T<&H3L(W!&Q%%,H#4RC:&V-J7#R$^?X:XPZ,HK]S7C6WLJ
M.I_VG==F^A,#/?,T4I_S3!QG ,Z.*W>8/%(G,3 ?I)/,Q[[*2CWS991,X+\C
M[XX:&[/Z7<8Q17J@="2;3(PA;:CT]$JI8V8R[0B6Y,2(:1Z7ZY$9AN@)I]<P
ML68_)-)UU(W1:SO8&GP<-!Z_O?#Y/$SU2I1ZLHUYC%]=Z>L=+!,ZB\5EK'(X
MXDP;'PY/SY>V;CV]M3N_S"[/KH++W!P.^?A6MS$<O"JO.F43?KGL]&;3??:1
M[ND;W#;J3_WZ,VST.L=J7L/N'6N4&OUCO>J(O>H=D;J..58'>M4/;Y)HQ5CH
MW8@!V#[,.X*I4 +W0CL?8_FO?,A-[8#@!P]XE0LF>*6YB_LC3=S[RCY2J^3P
MP5)!2V7A5W;22G?J%77UN/6;)8.3N!:[+L<G+B&W!^1 D/&K?[QHO2 42?X(
MN<H@1YI+\D?(51$YTER2/T*NBLCEFFMW#J.Z>41;%@HY2]1V \L6ND\ M YK
MW-<^TU,SJP8WXK@R_ #X:J+?;)L#_^$DG99!*CELA-W>R+U)Y'Y0<O^WX!%[
M)ZN@YY7=V[9%;$^T43WL<MKH$6L<E#4PTIHH@BBB>M@111R/(CI$$31GK*]6
M[37B]TFC_OH#!HR':<P#-_X;:=?)C<B!=@V,%'?R,\]-S,G/)(JH D60GTD4
M44'LB"*.1Q%MH@BBB.IA1Q1Q)(IX2?Q _% ][(@?CL0/KX@?B!^JAQWQ _D/
M)T>>^,%8[(@?R'\X.?*GV0J7*516]\(=P&;L;-@+?]HV]]K^/#:6</^3B6C-
M'K2I52JWR+2$Z3!E8CW[BGU]]_&WZZ]O?OSZ[O,NBK/3"&QI#0P8A),9UO*+
M@["FZ"Z*^(%=P2-+;$'$AT15OOV@S-%J=JQFRR89WB##QR8#(ELB6R+;VI)M
MWQKN%H]U%C),9$MD6PETB6RK0+8#J]EID0P3V1+95AE=(EOSR?9UVQHV=XHB
M)A%^ -:=3B@1Z1+IDG=08ZXEGW;O/+O3[C(1+1$M>;?GP+BVW2<!)M^6*+<6
MZ))O:R[3-DEJC^/;[A#9]V"6&XKL.U)DW_6GSU\IIH]L)]E.LIT+@'=Z5FM
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M?#Z_Q&]7W.M&%[QD?+4^$=5LM-!O_F\:)]YXGC5#WGL!>G\U"V-//CP2/D_
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M-*U!]_0G1HG*B<J)RD^.?P5%F:@\+XK9M5I-HO(SDW]3H20J)U$F*M^U=L'
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MUJ>=FO@0L&02IC$/W'C[1"GUTJBZK>.;)^#D.9Z%J2#/D>C 8#H@SY'H@.B
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M/F=RF<?O$Y%7Q,QB]/(ZG3,1>:$;,VA"C PC2WKZ*:9BQ*_Q*1%WDI3[J\_
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M\$)X7K1AX$H0XM-6F@.#_](&KR!O\Y-8<JD!2R_\!N,AO+!!VI=IWU<Q!O@
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M@4%Q)NP._L0P02\2;"1@E!%C>&^[^4#[-'JJ+= GP2-X%#;8%="U<(9E7&4
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MA._U%'<BB6>11(\XXD <\58N&Q(E&%, HI*.GGFZM-?%LZ<=\O^ R]1A&O/
MC;=,(D8:=8RR0343\1/5VNV2:)/_6 W4B!".00@=(@0BA&J@1H1P#$+8,ML5
M$0(1 A%"G0F!I@Q$"!5!C0B!I@SU$^UC5QS>-57LT\H-FYBY])EC]TDD*N*_
MG!^I"/WFF#)+ADQOK3B'3=EKQE"<QI(>,C^O&;@>*7?_D:6T+EFE[6'/&K:W
MS-Q_%G)[5-4G4B52)5*M#:D.!E9O2*1*I$JD6B%<B52-)M6.;35[VR_ZU%]N
MB52)5(W%E4C59%(=6*T.^:E$J42I%<*5*-5D2NWTK5ZK1V)[&$[=81/RP6,O
MM EYC$W(URGF]O*"O^DL5;0=2<:SRBQDBG#6QF8VK<Z0;"9)ZZ&DE=B4Y--D
M^=QOI?!>V^H/B$[W6"C<:+DE%[5>N!*I&DFJ/:O?LTE<B52)5"N(*Y&J@:1J
M-SM6:] B<:VWN!*7U@O76@EG7;BT90W[VY^1)F&ELX]&S!L.N^U8U&:A;4<R
MF55E(5.$LRXF<V!UN[2B0\)*NXXDG^<HG_M=(+?;5J>[?=JV^HLK+9"3AVH^
MKD2J1I)JW[8&[2')*[$JL6H%<256-9!56RVKV:23Y#675J+2>N%:*^&L"Y7:
MW8'5IECC@^\[PB]8L]HD-CMX(>]]]U7>NZ=-R96LQ5N@(5]UZ270"F<+?&0I
M^/=8V9V-HW#*/N>97:_7[FGFZ,DN>X$+C[EL-]KM]JOE)AL Z+ZEZ>U3$N&R
M<1BQ9"+8'*N<BI4JIPSSSK,['K.7]K#7&#)HE.^%@<7@1;&G#K+.(@]@@=:R
M<,S"-&*!2)@7..%4X"<O6WV[T<KN9-S];QHG\!Y\-5X)O9 ;UP#,-)8W=)L-
MN[@^<.5ECJRQ&,.#RSV)8Y'$\AK?X[(./?9*OK53O+3!/BV\!!KGI]A7#OWJ
MV8U>_C;=]$CP6."KQMR+V"WW4_54\4?J)7,V%<DD=/59WBG@K9J@OY6M"9'K
M130M7V2Q&0=&Y[Z$:@Q-QW%YV6DW!GD#X)VN&(LHDAOW$L.$WPNX]V6KUVB7
MK^/3$)[V)R !?T/CN /O5_<E@)4'=*D!@IOM3J.9WXP7+]WL\)E4R#]Q9(10
M'7(%R*CCY1>!. 'TNHO8VQGV"YX^;'3++8N3T/G]8L0Q^@"Z,!-!K)XA[O%W
M(>_H+/2E:/L%O,41<<PB$8-4.A/=E%OAA_)]1:<ZB\ AU$$21O/2L&EY4X.4
MCSM<[(1QHOODI@Y\&0.5R5>]M M!7X>S*T8)<[W8"5-L#-SAQ7'* T?(A\8-
M]ATT:AMY+;5+B5ZL,)%O0" <X=VB^9.2#4/9*Q2QZ+3\KE564AB]&??<#':M
M78W^@G*%H/]1UC+YC$+[+(W]8JNB%)H*?8K#(!#^121\C@I=>IB^9EDGNZ7Q
MPJNSZSST!4%+0#_F13>+B]<K#L\;ANTJ0-+F 8C7YZ,P4N/&HPC'0\D!/KY?
MTGHYAFNA+S>H56Y0KJ01"&:0JBO:2[Q5*/#"@SK%90TR6'LW6!UML :#0M*W
M,UCM$CD]P5[9_59A:];+ZBX6K&1O'S1@"\W%%Y758L\&[&6K^S YGM (V>U]
MFP,+!Z&SG663%J15(H(=+,@&1P'(O5>&;ZVCL"_KLV(6VH.RD"^:G5Z9&C?9
MK6[9-$GZ7Y#4M9R[8.K6&H%@L=F;*-<N>2AET[.L=.V2A*ZV<5LCTRZ:O\#T
M;USO%J>U/\#/C'?_E(Q_?]FZ&OOB_L(%+7+PJ9?PCG0:7(&\S'P^O\1O5Q8!
M&EV8]".SZIC<9J-EPR<HZ]YXGK&LO/<"6/-J%L:>?+@TWMZMN!J%]TCI2--Y
ML9?[)ZX;/&H%'IASZX4@?85:^\C^TNL9IEBH87OM&$[R@&C=;"_PO0":E("\
M7O(T":\6OX !4!_/^(U0L=$7? PH7'+_CL_CJQ=OEH5C8?E(#G8A+@O#CE_M
M=W"?MYKRV+AR-HG$^!\O_@+$NGF8,7W5QOKLH*!: 2]3@"1"C%5QHL.(P?>,
M5=ZJCXI%!WZ099OM035E_6J!YAP?C GJ"-RN;Y(_X6\1O5AFP>X:*7Y!+O*>
M7.2V=I$["W.]+5QDNS\L.]>;7%[HS<6RL]PN.9#/6-P9+/C&%QN<8Y@#=!=\
MXV,O[K3ZI;6O?3FE+7O1T]W."2\/P-Z=\.YBRYZP$M0I>=B;G-J]>-7[\HRW
M=0)AUC/<Y#B#2]]\BN=<TM)5Q_Q!EW5EG<8JEEM65VP65HI:Q<@\905F[6I3
M?TG;'U]F:2\M$FWPZ.V"?]8OHIAG#@S8,_F0IY\\U9[)WH[%[=NXKCU!MRY=
MY],V3>2LL[FP+J[)Y.6PM)(H'S9+(Z"E6/-<S'VE/$HURX8(>@13!MFR#]^^
ML/?@[[*/7RRT;&@62C-T^=S\2=IX/?XH1;2#Q44/N2 O7"U"2<1Q*L)BX:21
M! 0L\).Q0[]CK:'L-4M,L0@*=&#UI6C)^B5X5VYYPF+6TB:$Z@%2&#YLIRT)
MO7]@;V[6>LMYY'7@:NQZGS$'Z8.[._-/1RW++:Z(9OS3'9;6$9^F:NU6:>]Q
MDZH]E5XZ[<7M0O3+GTF!)0IZ$+J-]--?=ERWILY#>B%GKJ\FS\GWIK)MI;*]
MM2K;ZVZT*>OUU5YR!7;35TNNG+?WK*R9E7R\A1N-]_/UO;44LF"4OM=LUO$^
MSSY!D5I/G'BL2]CQ](G'H&3@"Q*QFZ70CU6_'AXL[D7D>+&<8=_)A8PD7WOI
MK;# PNW96HM4(IBQ3T.]^K,IZFG)=\?71V*!!'#=L?PD)I?WY94!X*P^*^[!
M!MU$?)HKI@F#RTC.-UK*766\DRTDKYM<VYVER?5V@K5)J#9MR:_Q9)^F%B2E
M-9?2MMXH*:_5ZQT6N!JWP=3NBI9//B]6C(>]DF^4SN _4YZ@<Y??()__*4S4
M.NH_>9#R:*X^E73=+T?Y[4\+R.?9[// ;Q%(2,I]]GD$/9"[ >3FY !=2Z%;
M\5<LM;TH13E?W\_Q*Q%[JV>7-CJRH-,DE/?#DP9*'RP&77(F0+S,3>6^!'[7
M8+_FPHUSB;BD2,6- O3L=[$0CIHK9:MAM[JOE-XD<0):IO=)@1MFW&^PK[AQ
MA>W!IS&[9;&__F70:C6O?A*C1/YJ7^'7^%80%AF@(+N@O6.0FV\)?*#>B#H[
M#2-L#/PZE6!0L&@N3)]AS.-)&"5J9K@X3RS$!YQ7/PXS(4+ZS74T']LE22HV
M!7VU3\6GN$>%'\ 52YMY=UXR87P&['COP1@)7[H$A91F JVDL&?IA\%+<5L6
M'CD2R9T0P>)L6$^/N^L>(SC(MI9=-#XQ/KB/36LUVTTK6[]?O1?GYD)&&:V(
M:CL7U;=@#KS2IC>2&C13@'B*>/\R3&%PE0R#ZU 8'(7!41@<A<&=SI/$R7@V
MAY$;M0HD_.@C9__$@!SISX'Q"&\"&<OD@44J3NV$<^[C=*KL::)_$"AKHRP[
MFKGL<=!*=<OU322D@5/7_,_;KQN=R_Q2"R]#EQ1^]Q)?>1LJR$>P/V#N!K>!
M[Z!:)8/<H 5AY+O0?2%7%?+UZ9\_7'_Y^NX_USLN'RR=*8]3<'=*H]1IM+O=
M?:I"OW-EU$('NG(^$Y[<JOC_[+UY<QO)D3[\51!:^Q?C""1=]Z&Q-X*6-%[&
MRI)6DF??_6NBSA%L$* !4"/YT[]5#? 22(D"&T2CD8XQQ0,-=&=EYI-W7OC-
MC2O"Z:#8*[]]*-98/;M35TRZ\V):_EH.L;!(NN292\OQ@RNGYZOY=NIB6CD>
MJ5!X, WAO)AF>32;+XX&_W-YP)>7EN.O'''E<:]S5X.; U?^N[R7BSLH:CZM
MC,_Y(IU!G/Y63-UEE=UT>?O%3!R56VG>J1;Y32;5Z%W%IVHQX8JC%@5WBB$]
MCJORN-L^JC(N-;^_^0$W&-U=W/7R3;XB,^6MYN?^'T7**@WN0>05I9IZ-":O
M;&MTAJ[T83&*JM*JP<E&ZS6,&8JDNZ526]KPE_[L#0=IR8(?W6PT/:_!)!B/
M0BW?NSK3^<JC+F_L9E6EKNIBFO/[YRU'5LW^46&N1;GIJ]\V<:SY>:B%-/E\
MW)2#CM/BJB'G!L->W/WE&\V_=%O$I=?R<GG'PV*)W"C$+._ZNI'SXVLEF>B)
MM\M\_YN6/G;CORQ+CJ=%955/LN:2*BW/S\[&:[CYK!K@D\&;#Z[0=/#LOUZ\
M^G__P2C[\><7@W?'[P8_7'JD]66K0_O#<,6NEPR9)K\VJ=G5NS4L.3G/U<<O
M)]9DIY>??L%/EZ74U]S^_^_XV?._OWV]'4151[K/>%I)7$A8GKD*QR69YVGV
M<10N"@06Y[$I$[PRD]R59?1;:J+0H\7J-,I'-9APK<+APVQZ_NN'M=BA/AK<
M&52\T()?!F?XM3C+WX_>'0UBU1FS)NW_L2!BA:C)S1#?10P\7 N.7 !W@;,K
M[$.E<*M26*F$*S@9+2V(2=6F%0>*J=0XDOY\7IR@^7RI(#ZF29S.5OKW4JC+
M1P^+#U5XI(C<8#$K"F;)9/6!+G^_XKCAM0KW&QQYJ07JFU]%_,I1%W>K<.JC
MISD&H_CG)[5]Y1?M?BD.0743&F_OEW*[]1?CU<\[2(C<Z\1/WK_XVT ?'PT&
M@__Y^_&K]R?OC]^?%%U^_.IY_<7+BY^?G[Q[]O+UN[^_??%N</R7UW]_/_C;
M\=O_?O%^\/;DW7]C%>BW,R5-EXMO(K]Y].GZ\(S&5*_<W>B^6.3KAAYK+EQ*
M5C'V5O'D:Y<6_5RCZDWN,S>U.TM+O\AF<^F-J/JLBN_BNBF_?-/:.?-YX,HK
M:JWT^7AIRUVUW'SQB1T[\'Y747:6W_]WZ5BD3U7Y-C; -8ZI2'&M5>Z::[ *
M_UROU*L)DJO*P89MK[<I_#0^K\F?)0^OWGL9*_U<)>3FQ]0_7G_O@E/C>,'5
MHR8EGRK\#'XM-],X/>/I?+[NIZ@+-^7%U9V]K+FJ]S57=?)%F^%/]1Y^;N[A
M;\G-BQ6[!:^E"X?^R"4G*/O=E/V321XOW?5B8U]V!Q;9;4R]AMF+>3::QBJ
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MGH SUBI9_RI:623<'3I4T;LE\W-'*FAK;+G4?F=N-OA8*3 <[$@07%3$*V/
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M)2)#2,&ZXH#S:%J9-?AHD,8)'1)UVS"^+NN PX"T2Q>^?./*<V_W,:X$]WZ
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M_O8!7T]AD(N?5JJB*Z=OS:UG^.$R[;2Z[=%D/)J46UJXV>*I.U],?[SYAW(
MRU^?%?A89J# Y4*%IV[\F_L\__')'[]DCILJG)>CO6*7F\=>&:'=TWV8FOK6
MP;K!AUG%QO]83,/=YUS3=;>=<_-I!2"G,]<\\'FAR:P2>=!(XW;XX'W5\(-I
M'CQ;_FI^R19N^PKQ7D3]#F!HD2ZWX.-U/1?&;CZO0E(N7UW4_%M^3K,G7ZI!
M>0L7;YE?'X8UORU%T$_'6V*[DU>O7O]\\O/Q<'#RZMG18P-P8V1?1[E?KK#M
MEVDN/TW#/S^4AT^S>5<I^.SUJW>O7YX\/W[_XOG@W?ORS]]>O'K_;O#ZI_+3
MZV?__5^O7SY_\?;=__L/PZC^<?#B?_Y^\O[_]L/2V3KM?CB9#!8?IN?SXM7,
M_[!;HNQ0I34V?F/B7]S,"D_KW=2W*[=?_PK%5)N>K^!_^<Z4%*?G]Q?>4JAS
MC<[FZ>D\G;F"7NFB\N1:&<O'T7SD1^/1XO/3BY??5I^R?'LF?G\=YB\T;(/S
M?[SK(OI(U^@C8CI\>YM<HXY4WQ[)'-$N,]$FU]C^,5X/94D?]8_OY'8>Z6OU
MCKJEF6GKH:8=C$VXW=@W?:RG0\IU< C*[534.S)L^\"!2+O=TPZE=T^IB)1#
MRJ'D=BW*=B\R'Y>GK(%L-^X]DR(THX!WD0.W*^!O4Y/$BH.+*?>]YU64<Y1S
MY$"DW>'1#J47.1!IMZ^T0^G=5QO[_72!_O.CSN[&;&*7U0I2[L$*66U'(=]L
MAR%'M1NFJ9K\>I]6_U3VL^GIZ70R>%<K0Q^7D;]R!%_O1^J7=N^"HD#+K4M4
MW(4:>.-&$4XFO>=0E&Z4[BYRX':E^X?C$,Y/S\=NPUE]/2 PBGC711PM_2T'
M9V;)S<]GG]'61U6QYZH"K8&'*()WU[I 5VV4O>=6C-EBY'$OU/,>4V[;ZADM
MN0L%W@RH0@L.+3A4$:@B;B]G/RVVQ0)5!*H(5!&H(F[/_+JST:.7ZZ".0!V!
M.F)O=,3SE$=AM/@#*@E4$J@D4$E@. )5!*H(5!$8CD 5@2H"542+*N+%O\Y'
MB\^H(O8B61T*:7)XT';FG2YC?AS5M%V!^8L;NTE( S>O8^Z?IY#JCIL!I\,!
M(XQU8!U21X^E'ZN].DK<QZ9CO[?0W3RS1]C/%;+GD=3%D=(1$-QJ\(PF((D'
MJT)(7L0O]W-QJHT(@8/1+((@)H$A@8)*@@?O&*.<?+F?:]EVUE2B;7$9E[)#
M:DSWEG&A["+$(,2T8U;=GZJ_VP-^/22L(5);'GT$R66J.XLU&)4($&4B\S*[
MF&@;6'.]WGGI99Y,POB\GL.;Z:S>T/%B,1OY\V8IR/OIJ^FD?NAL.AZ7EYS4
M TGSQ0U4^ON[YQM#$D,\0CQ"/.H/<1&/^H%'/AD>F5*@8](@K M@' N@A7.&
MY*"8(U_B48ZN.$;"@P[1%'^)!G!"&$BA_IYY*B3M-![1(55\:'@'5Q9W5-P1
ME1"5]H"XB$I;0:7OVFNL+W8<WF]*PP7E=XJ"E&?JB*3 ?)0@3!!0H$Q#,#[E
M0*G17GR)@CIJHX*(8'U@( *18 V7D)/*+,IH TV[1L%Y.=+RW3?@D!$QM)0B
M&&Y9RVQ448JHB*B(QEN'P/#1P4G33+BA$HQEN;A;WH(I;AE($Q)Q/B:F[)?@
M1(R2D:<,V13OK/AR&JPHX&2+V\:UXI0&_24X7<Q*:4!JE:M:):+:RDUQ-B1$
M(M <KN BOO2/N.AUH=>U"; 9P;,QU(*FPA>O2P3P20B((=N<;!+*L#: K9M>
M%[=\:)A%,$2O"U&QA\1%5.R'^R6R2I8)!EE8 X)H"SY2!LSJ2'AP-/GT)4HY
M10*E@H,++I5K?"HHI25([HC.N;AO2NP:I;X*3E+)H<8JPL?UU%J>GX<M"=]I
M2-^O9>=3FH71/-7^@WD5V<'TK(K&?. F<? G/_OCZHBO?QW-Y^=-WT*Y*"R7
M3RROK<(ZO^NJ^H;+E[G?W"S.AX-)6M2WN./ULW1V/@L?W.KFFD#-8#$=S-UB
M-,^?[[ILX3X-?ALM/E3=4QY_#^ 'S:7^$;>'L:Y#LI)\)D(&8X&R2$&$',$Y
M&2$2&WS2P7*QYLM'PFA@BD-648"(-(.GT8#CQ?//WGC-;O?E3XHZ3?'Y^:S:
M1FDVFL9EH+KY^I>B_^*SZ>E9FE3%-YVT%[YFEJ-%=+CRC+#3/^+VD$T/"7:B
MSI(X88#J4&"'40XF. V1,>*]*2@2S!9AYV<W/D_W0)W-'7$$G .69 2<_A&W
MAVQZ2(!#B7;>5L"A/()P(H#5P8$P.L=D [FE?\^K;)W5&710IEQC))A4OB1G
M0U8AJ )6G0$<@QG) Q9E1)S^$;>';'I(B!,CYTEF"<I("R+Y "9+!RHI$IG*
M7";W)>((3I-EDD .!6>$3 2LMZG0('"?";,AA5TA3AY]2A'^G6;3RG"&4?8C
M(L[ABC(B3O^(VT,V/23$24E21@KBA"!2\6RX Y<Y!>J-UL5=X3ZL=</9*'GR
MGD+0K"".*]Z.(UF5:QR1SGI='*!=YG(0=5"<=T])1!UD4T2=.R9C$<XEXQRH
M-;SV4PLP4B9PT3OM,W-!R2VB#OHY*,H]I"0B#K(I(L[MB".#X-2&XN+P[$%X
MZ\&XI(NS(XB1QDHEUVK6+ E,%P<(4HX6A,H9/-<)B&/*BY0HC;DSN1P<N]CU
M OY=[138N_-I51V\O5$H?[T@?S@8733=#%P(LR*R=Y7-IT]-&\#"?=H#M8[6
M1_^(B]8'=MM_A[5C760ZR0!,A6+MA.)D>V5),62\,H1[$N1:'^/WE$J.)A_=
MS1DRRT#N<?C7^6B6XF4WX_%2K[YH].=[]^F[8KKWZZU70ZH%VC[868_ UT/B
M(O A\'W/>A]F$I&:@XR-KV\T>&<LA"P9L\RH3%H&OL:SO\"]9]/YXF]I\6%Z
M3P1L8;2,0K\?L0^QKX_$1>Q#[/L>IT]9&[(.4/"*%1Q3 1SE :3A*DLN!%%K
M_7'?TZ[0/>S3:B@8XA_B'^)?'XF+^+?7*5=6'"L39 $3E>HP-2? LDR B"2"
M=REGG1_2S/"8>(3%/BC2W:(D(@^R*2+/'8W;,49-H@;IG:]+5 -8RAP$JIT.
MKOS%K7E"WU->^CCI+\0<%.9N41(Q!]D4,>>.E@:F:."!0[:IX$?V=5B(-A +
M>#CG8N9NO<#T09B#W@Z*-"(/(@^R::>0I_=Y)J%UC(D:((P4[TI1!E[Q#-I&
MXYSA7CRLE:*;>2:#-8:[R3/AIH0]Z+)HQ!1\[6VJ/1:7S4U[ !5HT?2/N&C1
M[+4OG0V5FG$*.LH @IJBQTE4X"0A-!E*;5@;O/G=59S'\1_G\\5IN8_Y^^EQ
M(7Z] 3=^XT;%L'CFSD8+-[Z]8_-M*I;(O#SWNS3[. IIV>+Y-H7IKY/F71ZX
M2A==;I3\W5,2 0K9% 'JCC7MC.G,3 (OZC0!EP48XSRH1+P,7OO(UJ:F;;**
MX-X8Y;\;HQJ?&D/"*/C[2DG$)V13Q*<[0K0BF4@R@Z"T I$8!T-T!DJ(RLY9
M(J1O8W-!-_%I?</MT'"-$'6XLH\0U3_B]I!-#PFBK*N-V05NE+$4A*C.E)$:
MB$E>,FVC2@_J#N@V1*$+A8*_>THB/B&;(C[=CD].%8^)6@V>9U'<H2C 4<6!
M&DHSX\DDOI:#^NYZ3LQ!H>3OA>0C0/6/N#UDTT,"J. Y%TP1""0Z$)99,#$I
M\"''1*1E(3^HR0T=*!3\O1%\Q*?^$;>';'I(^)18<#%P ;;V"@B2)%A?%_U0
M*VATSA&_OEEN@XT+W<0GS$'M7O;W9T7# 7<.O$J+NH=A>IKV0'^CF?$ XOHB
M1&EV^9LC>;88S*?C41Q<L%)'R;^'ALC#:7U(I@H1,M+,(A"E13$[C ;G0P3#
M-!4B:^,">7"_P9O9M-S+R^E\?@BAV:\PX+(]CW 4=\0MQ"UD9,2MC6MHN#)*
M$ :F>-8U1UEPBW!;@,AD8;-R0KDVVA"NH*O'P5I$+$0L1"QD9$2L+2*6"29Y
MKABXZ R(D"S8J G$)%W.D=,DUJH^-VE,0,1"Q$+$0L1"1D;$>F"9C5#**I%
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M=JY'RQVKHTQ5<+P04S/PP0K0F2D6M2@0W-A/T2OZ6<(FFF'^AP3LIR21@$A
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M\W>IVT(U&D.7Z^*TW.?ZI__ZB?UT+W+])B.W)]DK(7EO42&*<R#B1*M'-1V
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M* B='#C)"7 J<Q!92*DV]AG=IG!];^S#15MD'[)OO#J+[$/V79-]+GGOA63
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M^W6[:OG_[#361Y\57_:FN++#3YYL2V5.PPD&%IB=(FB&+5@$S?!!HTV*.M,
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M^(CUPBDGO4:CRF@\I4$5XN=8RG%>UZV];:.6387*%]YO6S-V!I*-T_)U"[X
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M; =R)V_&UUW^W*<EKKG*,?^MUX)BY">X[9!%<G5ZMI)O_WW,C&?XJ45LJ2/
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MF[+&VPA2PR\(!?J7;L?>K T?P.^RNIR2'AJ>?=/COH5(!WY7<^V!HMF?;/J
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MY!W3?+]2D/?)J]/?QR3?H]^_(]8Y&@TY+(']MK$.IE$Q#+@ER< 0%Q0CS81
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MY+;7KT]R+HWD% 6>>_PY29 VS"/OF6$ZI A+]C6TECD*</XMV#II8=*Q9HB
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MJY6(T]O%?+%<GD6[B3J5@/411!B"T=92C9$AN6N7$ $9[15*H"5Y$(Q(W3M
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MB*2&O\6MCA@SSY$RFF?^ (\L%A9)PT-0061FSEYM@':6@ 5 T<9",R<R=T&
M6W A%9=,:C+Z7ON^UQ"&=3A9Z:B]OEOFE#T!F)\36[=YG\^FYSE'8OC+]5WZ
M[5=/NZ]=OVWB;O.+#V2.=;E>W;VNR_9JC\9[Q^)Q=#0_1[@[/+-:1KOJ6 QW
MZ^VF\]72(NO"XCS3O<'?*;9]M;M%]D]/GV[YO3>,+CO9]OV.OY/JC9V^M_-)
M];<%>(W_ ?^95+]:;]>3ZO5BO3J#CTKBU&MX!WL!_VXRHGZU,WM93VUF?@>
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M#5$J%I"P,B >M$&6V(2$(YK::+D(]QWXHD?B[3:=&II8[XT#O$-ZD5ZP^4J
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MCNQDW;!'KCRSZ[D_*^!RS_P5YJBFH5"72=4UY9O.2^^ LE2%$:JL4;[S3AO
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M_UC7JVFZ["2G7(KB/#R\6-33<N]EG '4>!<!KOV9Q32+W@:Y_7E#Y/51R?X
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M=RX7#E XQ0:I2$, O6FL[7&C!06JU3J!C+,R6_R$C)8X\^!(QZF@+,A19]Y
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ME\X3K:1FG+/@3"?6H#3($"!$4K1O<:--P1&EI0G&9!5IITKK,14$[PEN[(5
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M_4U9;(JR<.<[P#'2(G4&IX33#,JI4&QU)"SQ/*8D/:<N?J;4/"!PY*R?8M,
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MUC425#=ZY59>S@ "S['7SPB<CFEJ4"QR(O\^7M1^Z?[=/+?@MM+B-O[D&5P
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M>JKTX'.XB3JOCRNNETV(=K2V94\]RVTT[*$"7I^T#&_R];(]LZ)G3RS%=ZQ
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M>*_G,*)EAB%?YDD:A?'L^M*#B8CU 7Z"XX*5N@'#$5<+& ^,,>7W>3*[AKF
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MO"UP,FBPI3D3'@ *2A<4<2R!Z'F?;+"!:LN??2?IX(SR/A!:, \W"H>EPYX
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M&.#=L\*[0+-+H#K!IP>;[$L .VX9T9X6$4/BLDNA1(6QM#A&9&$)U&T$VU_
MHEL?!%A^C^0E@QWO-;PSE -^CYPPS0W84:M) %M*1%8\V*!S,1VF6@#U2*Q5
MB((+B$R%$6] GA2881&Y![-JGUHL3$^HM8[ NZIN<[J#2VFMV^\ ?8M&_WZE
MV"]GDSFEA5"3'2BC +XF=ISVUAGKN8Q4=8J?K),,BYQ 2&. >T0$_Y1Z0J5G
MUBF57>@P30S8[SCV&^#6;A2-B>/4CZ.WE^/YO?#69P;3[OZ> 7,]:PF6%MXD
M'PB^%+8^4\11&DC.D<88"^"Q#N^;1]HW)<&NYH"Q$UD <R5'LBJ TA13+G3:
M_ [&M5>8JW@::/0),1=8,DD-"5&#E%@=1;94<]]I#!Y+ 5$*"K"WI$3R'(G7
M\&/R6>925 83^,1B(41/H/@1S+6C%1$B'<=5RZIBOU)8I;(,W%-'K!4%]0W\
MBRE05(9*#5+J:+=,U,7,>0B2*&K :2C@/GC4:TG%; )-QG0+2098-834^H/Q
M7JS>K?"P_@Z ]_-L-0<,]_@([R-?-$"\YZ7V3<%2E@@89_0PO2&>6U"?-E)K
MO% BJ4ZS6,T V\'EJ6"_90<Z- @  0+).+3B6IFGSF3NC2WO"<0+)7#JI238
MTHE(RPVQ!=NV9)48UT:PKE@8851(.9"H=6P/X&5@A$D7O(DF%_;4837A>D+5
M\J40KS0Z]FO%>$K[C(%[;2T2Q !4<TE; LYER-Z75'2'I%4#*E2>9L"%&#HS
M&B08&Y/Y$JQS/D?M.NRS \8;,%Y_,-[KV?NV]^5=<;R?Q^5I4-Z=WS. O.<E
M6Z!,QL((5RH1*3,E/DE%"A.!Y1*B5AUK;J/U-KM F$T4?&2E24B.$<J"9$&)
MS-Q3Q_%Z8\U[ O*\4BI(L*A4!<#QFE+B:,PD"<\!^H<<9">.Y[7@T0M)BLX>
M1$D%$B3FQUE*BP3@[YEY8K%0?6GP^<4@KZK8KQ3C46UD4LF2&-%[,)D3YVN\
M.%NO8O:N2RE5?!+9 2YD!1MCA1*1B)\3+["JAV;A32=]]RE[S-"^@;R!XOZK
MH[AG \7]0'$_4-P/%/<#Q?U <=_737EZ%/?Z?A3WYDDH[D^6H>L"2:7FX +M
M-3*\%;&ZBZ_MMW73^SLB6 VLQQ+TG0==;Q]4&02/<,>HH]PQ:[J(0S&L/KA7
M7%#G62#)FD0DIXEX60H)O"@M;>&!=2N/1*':&DJL4H9(%QUQ&A[!C!(<4^JC
M?VKJ_=Y41S95_7=*UM= [Z,\3U2 TBO94B*5TU@IR0@UG$4I8N#!/KQ8#?0^
M^_0^M6]K99CX0HDY0KE2DN6A>$^"#H[(D!D),6H,T.18@O;*=59994IE=I$4
M80*1\ CB>.8D"<8TF$(O0[E[E7]MN]'^"*N\OU(8^")7\'67>#])_H8@43,X
MJ2=BYS9',W@H YM?]X!JXE,TUEUD4BV=R"+7,I"CA% =OJ<-?5-M/;OA;]IP
M+KWZ[6)M@\^>GH*J/QQ/IR!#I\9$>Q*!A&\2YF\/I]D=4/_+CJ6["NJ!N5J.
M:<%>'@*S+&+T*I-H&, N@;DPT2H2;.(4@!=+I5- .W@ 7_TAL&2>,^$3L:Z
M8Z@=(YYK0&R."D5#4;9+95LT=4D5U_9DXTB@XZPC6G-#%8]4)??4-3ZJ)[D!
M7WH(_)4>_UH=:"Z:$04Z!9E1,O%&"%*,Y%QRY52WU$RXF!U('(DE83^0*$!T
M12;&1<JH]26H3GG_</S[J>6Q T3[FB':"W#D9MA>8+3NP33"7; X@( .I,'Y
M3P%CH.(P1@]J;#5MNK6D4=JV5O+80 [W&TA@WBE/6PSB^&UFM*[FMYN4K<4K
MS2JKZ/5\AERLH]5BV^)OW=X/P!8^:CZ;8(P W/$\6L ;@K,<T1L83\MDA5[X
M"/R2^?K!& %@YGL0^NNV&0=V-O1MVXX9#"AO*$5KMZ\=XM7JI.]RC([^_NJG
MLU%8+?'"-1%J:]JOL-P^Y&F&X8SQW^TN@UO.1__(S7AW7G'CW_OZ.LU&7:RN
MKV?S91L>:'NH-3?E]^/9:C&Y:>8 3,W*(\_L/%<3EW!VUI.WLP/AI<>S5(,9
M"$1R.A_A(ESYW\=7JZM1_OUZACT8\>[);+' MSS$#_PA[W5TP-_@KE[>#+0+
M&^'^1UYWOJP=6&#$EP^F9C&*M-]"LS:,.84.FCN\O'DG)'?6::T)LI;C<A,!
MJX3'MQMN8A_!ZPP;H6%EKR^Y_M[*L RS.YX@R?(NW_'<CV$_GU:4;*ACV.*0
M@QU155W8IJ;A</O)W8US4FM[,%H$RG%\U?"++_O@C17&5*+&$^L$)5)J</ I
MMJZQ21:9O&*\PZ6KLLPI*T:*II)(9C0).EKBA= J,69RM^#J$?N[:G[N>N%]
M55'O@4S0Y*56L+Y,9([]N/'\+U527%>$=XSQ3M^%(&6(ME#L\IF)M"415X(E
M01G*$DLZE$Z@Z#%[_M*>R,09GA-=-^?:DYNS]N2H[33[(!U^%Z?5"^D?_>I_
M75+@1F1)#/=8-2\9<4DE4DS,PBBK4PB=JGEA1:*J$&&I)Q)/TH/DBE ?&5=&
M<BHZY=%/UKV6\1ZUK[W5NK8BZH\T:U9GVYZQ]VT9^P =8T]JS^%Q_Z$90=1\
M^EM0F^P+;!N2-;:@!U1"0N2< $!A2M! 19?7G7&1"G>"&"W A!GXEX.M!S<&
M&XP7F:;/W(*_@%_\B5M0[VU! JX:;L,/H/,6F+<RG9WT_EMNXX2?L-UDC6KT
M2:-;ADPH2*LN0"JD97BDA<6R.8J@F> T=6HA071\L3J"VA<*4++DQ$E/B0&H
MQ*V4+N1.+>2#B=/'^Y'+DQ:H(PJ]!IJ^6%4_0'?O3Q%S<5IAA2&J\)&HPB<$
M$]1)K>A7$4S05AJ56<9./*!:G<"P0LFH)@$*)V.*[.8(,QNT%8Z4&H#0S!//
ML=;<<##RFDK%.AU8'M%Q!(/6$WJIA_<43PNT]@Q6&$\5"R$313- A"Q!]HO3
MQ 7E&&4^<MV1_9@B10I=XC*#>U+*))1$28K! # Q8'<Z5*E/!BO8N>C'1C@
M*_KC)Y[4C ZPXB!Y.FTR^_O8@_"K(C>R-+B8O$*="OX:HP T(N"%PER).O.B
M6(<X9&"Q^;*\UAY(!8O22"H(UUZ"X<7B)6$,2<9+"A8XQ=CIMI&UD2:!/Q^2
MC$0JI,G"W%:K/#9H*\;EIV[[I^F0UMKGM-82LI42\^VEAS^\0]_':^*%XI)E
MAZJGX_MXZ:Q'WR=ICK1<@ 2CH41[[@*WDH<X-/S[E K<EVVVRO(2A V;4&-D
M:3&+XXK(-CDN*9=:@]:TC3[4-KMF6DW&_\P?QHM-KZ/ST9?E4':S(Q\Q[_$A
M4=67$&?4K_INO(11Q,]8T\:]&6V%&3'V:S\%>/T^#_ATP]$R15GC"$E?;G/R
M>J FX6%<4@NFULA I,#^#3Y9HDU1TG"#S7@[12@%7&CK++$B (8+QI) 06%&
M&7W0L4CC-[D%,!?^NZUWO&:1V*#F![79O6&I'']QO?A3I)V4G)Q4FN@0-2RS
M9P#T<R8F9$ZC "#O.Q&4SQ&-M05] RM]4=Y@^N'K%88$X(=:9/RJUM^^FKZ=
M^^FB&=J>H#2ER+L2\NKUSQ^+HM@SH^@93-II2\JVS/I ??5:_X[>O!C]Z92&
MW=9[K\>WK1[WHS=@P3'A>?P>+/;D9G29)PDL>\FPU<=-E7:377H#"QA7;29X
MRN_S9':-4* RWP&@F*W> 1R]\N]JVNULLFIR7FMN-L#</,F5Q .Q<"6\@;WV
M;C[[L,1_I176@&.M_ I^ Q@XS5?O1FF\B)B<WH27X D3!!$P23?G-<1PV5:+
MU\IR=,)2Q@SW2A4RS:.K)HX%G^^^=\UN#S,_3\U#0#YG=ST);FT 37T:@OI9
M4_0?X!M6;5HYOM_ULC+*P<WUL16NMVGJ*!^(MO#^.X9SY(SFE 3IK ?Z,20E
ME V2Y,2QOSVF%7EI2%!1R^R$8:)C.I.WC@<C25+!$G H&+&<.H)ZEE(=DJ=\
MSW2N->++9F\L?L E_+4NW.+E"M3"=#FY>9/G2()P,:V_O2@-6LO[="P_5HK0
MV?PN?=FWW C I=/9>U I[4;*-85FT4P'ZH_.%CA]L<J&6R9S(C;22. ?',1*
M<%*R*<D;EVWH5(O?6ZQVQ>DAY68Q_OVD!8>T2GM/(Y[2 (_GY9_2*&MI5K7D
MI[^O9++"*I5)*E* I\,CL1+PJ0A::V^4,MTNP*+XP&(L1"3#X1Z=B$=2I5Q\
MU$ZR($RG75WC,?^:EY>SM'6;+SY,88M=CJ\_GRQ+? 32'E$C3L@@M2%:8XFV
M5J!&9 ;K9$4VC,F@=*>LFT>;<F;PNAG9!9 )' "< HN6B@E% ^!__M=EXF 8
M[(25S1_W,'M[DCE;S]!0J[<]Y=LK1-V--(W2#)[YL*6H'6QPWUK4S2"'8M2/
M%J,.'/=?%<<]'SCN!X[[@>/^\XDF'F$B^LS8/G#<#QSW \?]#EG]O3CN[9-P
MW)^R!_%#CGZUR%ULWWI=6YJ.#39OV&\!)B.5!Z9N3].:]J;B<0_XV2<8U@;W
M5VNWS4^M/L$NQ\CLJ!NS&<Z;AK+W9>=TIR$)0?#<LHC41_@)?/.TBM?1\/V6
MN.&4?-\^G($K'HM-%DL2N2?26$>\]8Q()E1B*IM,NS7%GQ%Q?8(RB2/U'PH&
M9STEH3@DDS"*!"$3H?"VGF7G4NPR3')#&56)""H-3 :\D\WPBH5)FQR3+K.G
M?#%V.#GSA*,]FT/^FFU^,)B!Z;X/3"JP(>29-X^?SM:Y]*V7'OU\?E,)B#9Y
MR?MZZC%15\^3H%[>T1<%EN:7FVF:^R&,=RA9GYMU=<>;)9[+OQO'T6]^OL3@
MY^W<_=H>YGK=9\;OI^XWDXQ,^3#NO%J.(\C\JVD\W[#,-U=LN.7OU9"F_9;;
M*8-?22L:Z9*A"0\!E,5Z0 "1+E!!HE)>NF*5MQTB&4J#8]$5;#D!]B (1P*E
MAI3LDL],N9 [G3X?.37;G?->6(#SM=#6N'"<C*?8H "C8._R)MFEE:CI['V>
MM.DH&8T$2.<U.!0X$4VH-U?<V>2/^ 3?/5XLFR /2M]J C^0:CUP1O#T>^Z;
M!RZ:_A)'1/MKZ(7#$A56ED0L$YCPS0",66%),-H';6D)W4*4+Y?KH1?.T_;"
MH;PH&Z* J2E(B0]+'01G)$N?H])!<M9)C"@%H&QT$C2>4D0*:8EC &F]=T&#
M7%!M_3?0"\?L9WB=?"^<8[JJ:<T2#[?!.9 HV3[G>)N9F@.(50C;0ZL-[C@?
M_2?>=]4* )[ K5DX=[@WQP6Q]J%'8[+?+$9,TDJ=XL I5A]<^_&!TIPK?S/*
MXWK6%S"/L5Z%%;&K"6KGIA[G>K*J1J4=$+S[U7AU5<?XN;-SUQ0,H/;XV70[
M?8]P,KU%LE]T+KV+/H93Z=NGTJ-;S,#+._2.QRF\1?5[\S&BW^FFV/P:WL_'
M2W#9V\6KQ4^8=;S"-]M2HFS(>,NJVM*ZU<MD]N$(-?LWN1-?34<3A*9-/U.8
MM<:_;-<NY'<PQ \P*;@(:?9A6NF+MWL(A*Q*C8>G-'IPI^D8//M-OEZV9G/W
MN8O9I"D7O_+_-9OO$"/[Q:+&7T!. 817[F,T-FWT!:F;VXW?U;/'Q.U/?T-=
M75.X\4<FS];^Z0O\LE&M-&R.'=:>:6NLUE&BU=75QC58;MGFMJ,Y:]^EM6VI
MQ?IWC0K#2ML$^]1$G"HU]-VEIB%'P$<X[>>C'YNYOZ7@,*2^T9-H\&X:NB T
M>,T^;H9;W?4/C?JMR?/%PY37;VV_9+$*_P4[J%G?TW=<%/.).LV)J3F)J6AB
M$P>'G#IFL@BNY [;KTN*24\U*8IBC-HG\',D)^"[![C721WR7J[O/I[=.BB_
M-9CA8OK;>OTNIC\V4_I0O@L_[2J;/VYQT_060&NCJZ@16C%>=V"LIW)-= D%
MO>4^K[):17</-YW"6PXT(MNI /U^$9>SK7;_4%F-,GCNH+GZ$,/C5!E3,B/6
M*PE><!(D1!F(3RP;$XMAPG141E2.2Y<)]:P0690C\!&H&0OZQ9A 7>QXP7];
MR_("R_$ VKT%;(FJY(&">*(O=$;7?EZ[I&XV]UI9'+&3B 32*JYQ[&RU7"Q]
M@T:VZJ4?'>JR4<DY)HDH>#":320NTT!RC#Z;5(+.'5D+,1@:O 4)TW /]9BH
M '^8&(KDJ43+.G&UC0%JPL07VRF[*+_,_'3Q[WF27DU_ RDL,UB4!^-3Z <G
M^8#]-U/RF?22=T'9OI$Y>LYR3J"UB\/BC*03<89:$B/SW*NBK>]V$:76N<(H
MH:5@UA +Q%+FL4Z1&>4#EZ)#:/*(A_GB6^9R[!E_HJ;*YR($\32C:R) =+@O
M1.4 *KXHJ5PG=^1S7),GYT_D/:9E_A3^Q"U]XN(9R9N'+)+/H]+Y(7NX8C#P
MVP1.G(_1#^-9)4:8W$[R:'Z_R<<8UY/K%Z](FH,,3D&(5W,P\/%R"N-_=[,Y
M9=_AD5C"UFJU-FZK>@=<BT?S9Z/KQ4V\'/OE?!R;^-9BDO,UQFIKD<CB?'2Q
M]2#-\?;JOVU.6RJOR6C->W.;D+)YG3/,>MF03#9T;I7<(;8A\M,W%S%SC@PO
MR)6KVU3# +YI3M%E9GW4IN,J%)E2D1;\T) K?Z0C5CG\ERU)92M@M,]+%G,F
MI3T3],0]U>TAWW9W[&89_] 11Q3\'F 0YP)VZRDD^Q*)#(P1SP(@8.V8E98Y
MJM*7"-63DE,QTQ/T>UJTXT<]OOXP#[!H6. JDBB01<!80T ?2J)9B0%T)B!M
MWTE/\BE$FR/1*60B.>>H3SFAF6;PWK(Q-CY[*;XZ<>+</VYUXE!V_SFI#>V<
M/4)JPRT+==_4AG: 0VK#T/WYD^K!;HG=\U:#'4-I#U<+=M8'=*=I%L+K0DSQ
M@,^$T\0K[%UKX?]<H-+9#KHS7*=BE2&:<@%N!OSAA9<D%I.XLD$;WSG)>LSJ
MI+Y@NFXQ4JM!'[X4Z8$KD0;"D*^*,$0,A"$#8<A &#(0A@R$(0-A2%\WY>D1
MAMC[$8:XA[=?/3^D^QM80O#_)^--^O1/6T2,K5T(YL'M'.*!X]:@W\6NA.S@
MCL\8^)'"MYB,D5EE\)&P+:$#]\?ZP B5FAI=DN>A$S^TV89<M">Y,'"N8DXD
MR!@(,T9('ED0.>R'P>-E3BL\7-F?@HO23,"+:<+7?[O?V:9]]VK/W\*W_S !
MQ_4/HPS>U#7&'.:K_,USTF!!6YE-)K,/U9VOT&?>SG%;S[MM>]BZ4M7/:H\\
M/R: [6%HV](I-X4F.PY93>[_;D<Z07/5__[:C*6=GA;5XHS@*X%VQM\2\)=F
MJQ:#-V_'*#VG?_R^O1YF=>*O%_F[1;[V6!@ ;[S^ OB&#;!_/UZ,FXCA=^M;
M=J^$2]-&M=>OL?1<2OG'7>"]5J\5>?_EKIO9N;WOG?>]3YT;91[U2__ZE^7\
MX-RVKHL%D0T^_O/='/SJ1%IY+_6_[Y&:NW&4OFO<)?S@#I=@;Q\='/J^0T49
MNDWM1XT%AP]JVAT6O3>/:W9KQ_6&"S<^U=H9OUXV#LAHO6'7-[5XH/G"P_;+
M/B0H>2C;]4FZXD^O,+PR6RU@MR_VP-=?ENEYEZ&1(RI.92&^,"9Y -5U9AC6
M&G]=ZUR^&:%O?9RGG^UO2)Z?8XX_9CTJXNF:CPAS5.(1\_'IEN'@NWUL7>'^
M0XMZ<,$.:(M']U?O:1H^)UOP>"#>'SSZ$??=8_=:H.,;[U37Z%GUV.Z73V=?
MZ0SO[X)/G]I_[8GD;G7W8\YL_?9'53!'*,)HYHZ'0JQ1E0$S$U>H([0(064Q
MD7:Y,+TNE"(=#\]9$JFT)B%I"_^*4@;G;!+A]J'L@5C"T3-9L7<F^[&D)' :
MSZ0XSA V;-H#F_:Y4<:=3NJ ,AY-":Q37IO.R?L$)^/]D.8)J^0!3 QZZ>$F
M<\ 07X@AC$K,6%8(+\X1"2" .)<"$9$;QI./P77.*[21+#%/B97>$YF2)B['
M0$JR%'.=553=LO&6H.#GV7RMQR[*-L_KHLDMG;Y[@<R,]:,'@AA:G''*!H31
M)X0QQ#&>!V&\/%226JM->Z*K!W QJ*0!7#P#N/BBSO9?$@)AW@1K&;;V, !%
M:"'!"4>8B,)8$92UZDO@2TVW^#<_GB*YP<7T E.E[Q4&P3(;^-?'BK3<&=,#
M6'F2&.;Q$]LA+M(KU/*W7-/Z:A';.A&L,CE/ER,L!AOO<S:<L#48X,O7JJ0&
M^#+ EP/PQ6K%@N6*"&\+D5AH;B6GI#@J,K<JJ=3A"?ML^');/UZ4EXUV_*U1
MC@\-8A@U9VHXU.DIBAEB+\^#8JIKT1.U/^"4+U5#]\PF/($UZ"F2^?()_UJP
MSI%SH!(3RS(1ZV@ 5('LH\8AF:0WR1>J9.FTF[O/.5 ;04'ZP0<ZX#'\.%?D
MJ>[QN_-9OZ9=/L12>H5"[IG)*D]$RY_J&GT]P.549WC(9.TS^N V%TZ+)C**
M2*2WA@0>+%$AZ9B$HH)ULE"*2BG%0DDI FXLK+:+9-CU0'FJ@E?*/ETFJY#L
M3.L312*GNFF?&V4,L8XAD[5_NV8 $[W12Z<EL%\WABA)>Z.%(C$;260&-.%L
M2D3YX!TSF@?7Z<_W.<P;SY_)RLX,/]X%:=C))X@PACC&,R&,^2SFG!:C,I]=
M#1!C@!BG-L,#Q#AIB/%<"2'%49V=<R08YP&06$-L=)P$YFW@6DN;W8. F%8_
M_@SJ<0?0O&T4Y1;-/!!TL6>2FP&Y# DA X2Y7Y!DA^J[:71P\'2F)T9B0#5?
MJ](:4,U)HYHCG:.#TJ;80G*VD4CJ!, -'0GV(3>&B:)-AT;DLRE+-]ILAZ.T
MYH(\WI$,PS34X^W@A@T\Q$L&L+$F',_+T<(CQ2U"C.M=Z+&;_0'#].^PB<C-
MZ-6;WT8_P\KU1(4/F&-060/F^(8B*8HF)J,11"M&B922$6<B)90KJID5.M@O
M1S6@-K')[0+ S [ V8$ROS8*\X<;4)>H+1^\UH;3,Z>.][4:-,806AG0SL!S
M,J"9GLSP@&9.&LT<B:#$:()ACN3D 6LX:TE(@""*U"JS(&GRY8NQQD.PD-R)
M)0!*@$0-4&*(EPP(8N <&:!$WV=X@!(]A!)>Y4C_?_;>O+G-Y%87_RHLGS-5
M296@](+>Y.14.9Z94SYW8L^]=G*K?O^DT%O,&XI42,ICY]/_NJG%DNA%EB7J
M)8FI1.;V;N@'>(#N!N!5 I5RZGFX!0*6 ,$&;5Q.A'HM#_>;78G[JPCR18<B
MR ,O>&YBJQP*GI+@\A]#%?CNN Q<_H/+?PS+[;!::--<"%F* [3>@H_&@@A5
M*6]TH83WL>_T_LM_!.^'Z6%P^0^>UM@V+^2.Y3_,0*S\4,=H5QT7=:BZ5<NS
MT]Z;>NBNR[:7"+D/V>^V%^-*S2&(!%51GSS) <@'@HS"*J.HZJS7&N)1"HZD
M@UQM 40K(2A7(%NK,5HABB@;;(@G\ ##0%-EO@C /?5IVAMJS_]?%R/V\O2X
MS,>IO<_C=[=Z2*G:^]L_Y^KP>_()UOJ>?[S!+]W0V4_[I8[&RW87Z1L4]]D[
M&D^ZQ*#I ?3-4Z/7G\S*;>+[C.R^=&N7EN%\'"[J"U53?(@1O.I*+HJ!J*4'
M2TK*G)PC]UVSJA>&X<<2EQ\?Y_)9?Y[-^Y.^Z:_?M"O\>3)+_WPR*LU$G+2C
ME_/3<E4A5J,[GN8FL2-]J+7^X>;H/+8S^0TXN14JWKPM31K+9@.7)5_9D].=
M3;J&F+Y)^4H>]VB\&$5:M(,:"?SK=-8/;\_\S[(<G;3A;S]H!XU:T+EHYVK!
MQ[C=*,VON;3+M[0<_5;FY>.)S@^=Q26-I_V&>A(Y-7P<-U"E,4U6OQBO,LKG
M[]IO#T?/OGB7U,Z^.#UN=]8$ET>Q3&:_'5U%^P#&?G.CO69?+XWIRI9>W- Y
MW?0[ZJ=L#["2[X0^S$Z71W2ZG#T].[L4C65^N*"GAN$)G2S*T:*<T+P!ZFK
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M*2L3#&-VVS"[B0V'@EKLDC)H= B8O8"H9 *+)F @%%';FP0C=4$95(MZ<LR
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M@&I,\UF\:@&NU1:*RTZ0J&A4X "7E76_E)4)AC&[;9C= ,$T#M'2V-SW@01
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M)A0PH3V1"IF2#)121%T$FT.!S:&YBBAB'I@R0B6^DBA)B-($3!)DI-*YXG5
M(#T.!4P(X2FHA-/^2X4BW8=MG38)1<.1>\!JP7F'I00&\SH@T*H!.:88,D$
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MBXKN;!EQ).M@(POB[/[X72FGN\:E6EXP5$>/>E_112^$.#C*0JPM]S@@I94
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MUH];H\>STW%=#5,U9Z<VC&BQOWN5^_-VJO%%!,UUN]H/;\=[6/O*#D)S"3
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MRY)UAC.YTEZ*8FE4H"@Y2Q!W7.84-(^H4)HFI8VP*R59V^X%$]9A8AU'!HK
M%X$O(%5X]N!Y]GXW6 @C@PD:">URLW3%LDL+'J[QW 41!'8K-6">TV#]5;C!
MNKC!^^<&E_#PKMS@YS1-?"W:NE@8>Z=_"L]NSPWF$?Q@JG*?9(;!!&$"Y?Z)
M*"B,O8^<\5R&;MEL24HH;,%A]@2#V>(P0Q9[BP1<%"V76HJ5TG5M=X/I.JK
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MF:N^)&1H_I,SC"/A4?MP$1,9^(-&!8J2LP1Q!Q=JXSVB0FF:E#;"JD<X/O^
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M?0Z[9A2:CJ< ,I>XQMEWON & U9M 7$>PS_PG@&-\2A(J?.)"X^L=@YI!L;
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MGJU^:G8*/'8?3+U@A E8;BC%0!"L5XILR&?,&2$A$BVBVS#U3F/N!$](1EC
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MZ3%16TASQ'G/4Z$.$;4E,SXFYW-O7P+FT>3^4BDB0P6S@F/,TKVTJ6>H3<Q
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M\>1N53>GH#FIAN4?OV8WKPT,A5F[=[>P'#!A]3B S<CO77;W?$N S>S=7_H
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M9@[VE$/?7^"'S57:8VLN&*0]%8@321!P%X9BY(:SR$F0>!O1V56+^"']4H_
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M!#%O$F),D"Q809"T@#,TY 62+@^(.@5((P6U?*W7(A<4.ZQS)*G6<*3C2'F
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M]/; 3<?77H\;,N*JRQ<CLC8CU@=J5X\9)59F>N"JNO UG7.]TL82\BSV!<H
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MS*,E5CKQBY<&:)Z9JFO &+24,K]<X/M"37Y\R1+/%Y ?*G-#&5>(2"H0#:)
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MK21&-.<>::$L$*( =*C("UJ\CG\_MY\;<O!)01/I2>Y](PQ% K<$;FW3V;T
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M[!;/'I$TDDTZ;^LC^5B=E_S^96;W>X$K5O:I28$-+SN[VZ&6^UHUE*3WN/1
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M-L)[O7Q[A/D[&3SG3-VH#!YPD,?5&G<)=PUD4:MV?5^)C^@;^P_?7 VV6MW
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M,YUZ"A_QN<B'IT6:%Z<ZZQ:NG:YUK:K918_SQW<0=E4][&@%< JD;("/\]Q
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M4<69%PEI<R>&I_!UN"-.#P9&W@C)+!D98MC-8MCM-C))$/NNZ_DLC'G(; [
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M<->S',=6BINK#)BN&*\$/>YX9%>HDC %15]%:>B$^R8B2M4;R,U8/X7)S=A
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MYV'.P\<M'='4'* :T6:N[!M@^W"DTAA59JSE2R1I,31FL;29"=1F2RLDO+5
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MTW"WU!5W6DM$>H$5$X+TI.E5YVHC46N/U92(,Z'I&Q_U'H%ZNP[0:Z9->EK
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M)#R_\7C>VB';1WB^$WC>M%TGX"[GC@B"/<E=%KBF><G571#$8NUH?E@U]D6
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M0"0M01@2AH2A1=*'-&V!->UN;V]M;(4T[:IKVETQDH$D25ML'YA )! )Q,*
M2%*","0,"4.+E ])V@)+VH/NQ[6Q%9*TJRYI#_A0^*1FBTMB I% )! + R*I
M",*0,"0,+1(]I&8+K&;[Q[VUL152LZNN9OM*:"A(LXX+[@43B 0B@5@8$$E,
M$(:$(6%HD?8A45M84;L^6YB1H+5>T.Z$@ 3K\]/;UD%^?]_ECG^THE/('R80
M"40"D4"TP24F# E#PK 8&+ZFO(4_^- 7EQ[S&DX./.IS/?D0)+)0\]_E5C.*
MF=EK,R^:]D2K4=[<;+U[O, Q;=W,6WY+ZY["RL42NEYN-*Y+Z'JY7G\9"?T4
MQ7+1DN=!Z%_&0K_P .2-V0$&3Z'$8:&"OR>1"#2/0S5CD0^MA8-<*1YDA97X
M*Y$*A$\<LJ%@(U!#'HL2I1,.9^'@?BPFS&F^'_Z(>Z_NA0I^57]XNU6KMK<_
MEZEC;N^8GTS'[(3!2"(4N)%MK 2/#>YCK@%O$;!3Z O<[1:WJ'5AZ.2@/J-0
M87)5,VBL.S;[\803&6.Q3)NZ833#_L"_Q?E8#F7,A"_<6(4!#K[^+.M*U+.F
MU$"XB9*QA(?A@<=ZY^X820#MFTRDQL1NF9V,+]\(6C1)D[SSQJ9U:A%QQ6,!
M-WE ]5=9%03A5$YYNFLOTLEI;6O<L\B'YIN;&D 6@D>L^R?6(>U.+AGS<,8X
MH.89V@'T\5AJU@V"!" ]%D@U!FAGAKU!)OU/X+XU)KV70%$]!FS'0@DT@3EH
M-C2277$[/#E%;^,#_)LW[&_3D^>=VO;(%^<;'HS_+II<!UJ<3()M3VIX5<PZ
M>/:&[U9N@J^&M\XB\NF!/Q,=R]$L;X6Y= -(MQV%VGS+WU$"UZF;"O!$SO&1
M\3'F3LGY/;V].U&ZV^'+2J3NZE7?IVH+S9QF;6$?CN?ID*S=TH0H-W3,5=SA
M21QN7ST!/9 >CL Y2%,F&WP$,'2X?\9G>OM-Y3HYKOCWIF\OZ'*CVY^W=Y\V
M1#RD8U^O*Q>HJLL6Z?I<:^Q.N#R[R/P+OX5Z<]U@FPL ?WYHS;4+E!*3WL]O
M-!SA<:*$?J2MG*7\&8:^]S*(#_9_/>R>_'[<&]SY)EN/EU;_DM^%KEKF\J,_
MH-&''*2C/W/J* [ U?=^S%W+2U[=W*/KHK(8,:==;Y1,H6-Q*G6,;JQQ%+T$
M_$*SK:27^AHJ=3)2@8'\@1-P.]QS<BC&W!^ABX(5)= K*BU@:E8B"> J4R&,
M8N-0 3+>8@=EZ8F]%Q\X3,C 1 RNO03,B&=&^6S$Q>9A_? T6'P#WN5ADA5)
M;^54J^7JN[P\$-/GD1:=W+&_.GJ:Z][<R,A/I0;9X<MXULDK6)1N3V_8:)4;
MM7>7WP[Y:&=>#Y7;KJL_[K)&N^QLWGG=<TXTN,F;)4X\L&2BP1(RX\!$//7S
MF]J;VV!_$90M>X7<;YKWX>'1U_VO7=#@ASN+]_%=:"%D%6055EG%RZ%';XAG
MMP7GJKAX\5%N%_R9#ML30Y5P-6.U9HG5JK7-Y>6Y7D"PO3*D'V>=9X<O?91E
M(G@]0W:1('O=K&%%5UB_^[5WP(Z[^WN]@]T7U#O.8J7_@D_7YU/ALV,N1\+W
M/@Q5Y9<GA4ZQ>$?&T'SW(?,!QU*,0-&"NC43 8]&(^D*]=!T[<N&6ZP1GJ\:
M7XK",Z&^A:-O',JJ0,QL#3/UC_[=.V9'>ZQ[<G)T?-C[XW6C3==!M"G@]/GP
MZ-^L>W# ^KWCP='A@'W\@YU\Z@UZK'\,_S\\&6!XA\=,<'?,(J%T&+"S<:C3
M\) )+V(J4'"%(2(_/,-$H(YEG,19?A'.AA+C5U?&DQ+C&@-'4K%8)<*4]/G9
M*/%93J<L<RV#[(\1)LI-C:?0^%*:T(0+?&:8B)$NG0S3>V.0#(LJ<?E0R60J
M=7+Q*%A&!@QC7W!F#+4$?")*F']WTT;I6'!HK<2RL_3V<$>78^ &HVTEC)8A
M%E?.S]-X.@_EW9;&R_/S)7,M%,94H+E"FY:8I\0JL]RQ3L-M4!#+A_AC/N59
M8S,!_R +$\9YTJOTD.QO*4UT W>8">II+KU[=LKE[C 'TU!@/,,'\](F _*8
MKDX9A0<$^!> 7%8/SND^30.?&JS '(/G$5JC3YA&)CV@=-HC<(MAF,3FR<!2
MX FP1X!:V!!3'*&3AN[I T>)BH"^&@MA#AWX8)+TB>]A"S&E;ZA1,AG#X8PI
MCNDR;!1>;M+<:F)^0LW&-AX 4,G0#-@VIR6V=\)G&?FAS= (3*=C5/;RXT)+
MIE+%8"K8KG!T=_*70N8/B(U?!+_G,RBR^'<ZJF5Q[U'HPR_L_90E&BTY"XUG
M-U,7,?9L=#&S0.8#1FJWZ5&/XR@)_84S*2A>OI+Q\GJKO%7=>E3 O%IU'G,=
MW+#VFC=TMLKUS<:38O35<NO%0S"OH%M7,C*VS%#)V@%&)".2$<F6$./?LOC]
M<GN\\K[]M65)X/!&K.9^\WSR4,%K#1VW L[>CLQ_U?J:0)^:S:N-/^O.]!,9
M^\1R8GFQX<9$K2V34"Q.]A;_0]!"S2!Y"F(3Z7F^(-"(9NM"L]<>SY8\O\MB
M+M.,F.7,B"G0<'B/:6DT("Y[$OAM4Z%P9M;[OI*!*R/NWRRPQ(70B*F6,/7U
MQ\K[3>,EP6B-@U4$S&@X*#1H1+,5IAD)1ENX;)M@')ST^I]ZA^QC=S X*I1@
M',0B&HN ?>1:AT4:#LD-7XG/OU+)N"<##N(0M&&F"-F%7#3J\48!DHS$59*,
MJT!NDHSDRQ-H1+-"THPDHRU<MDTR?ND>?V:[^_WNT4&Q%.,7KKZS7=GG4&F)
M]?1?BU?[66$:T:"X K*12S7!%<C33QH_AEQ1OIMX2))P!<E-HI"&!(*-J%8T
MJI$XM(G/-HG#WWX_Z W8I^[^EZ.O^R?_7RA]^%OB0WL^<3D)IS+^FX9%&A9?
M>Y5.LP=)N'@)/J+>&E./]*"5Y*84(>5N"#2B62%I1BK0%B[;I@('W>/N)S;8
M^01B</_PU]YQH73@@"L^9@-W#'(0"@M58E_*NY0LI.&1]"!1SP[82 ]:2>X5
M=3II.%CQX6!U8".JK3C52!7:Q&>;5.%N[[CWF0V^= \.:-AXSF%#A6=XZBD;
M%UHUA%B@FYX!4J)D@2AIMYZBU]W]8M//.X@();ZSP83[/KW.7M*9(T:OEAQ9
M5_(61L*M#FQ$M16GVM*B!2^U3ZW->[U]J'ARBD__ ?[-V_.WV;/PO%/;'OGB
M?,,STDB& 6Z_EDR";4_JR.>S#IZ]09IR$TB"]Y_O-88'_DPT[MN8-\5<NB$"
M;SL*M31U*^%S7"?S\KYF\U#%^3UI=R=4=_N'68G45/)?&?T?ZSP^=S<ZS?K"
M/AS/':2LW3+P90!MBKG*MM>[>@)Z(#T<\5.1.E0;? 0P=+A_QF<ZW4WN0V48
M>K-?_N=#91Q/_%_^"U!+ P04    " #A@UE<R>K;<KSH @!_#BP $0   &EN
M=F$M,C R-3$R,S$N>'-D[+U[<^NXE2_Z__D4O'U/U21UMWL_NCLSG9J94W[N
M=L:V/+9V]\RD;G71(B0S39$*'_96/OW! D 2)/$B!1)THJJDMRQA+;R!A?7X
MK7_]/U^WD?>"TBQ,XG_[YN.W'[[Q4+Q*@C#>_-LW7QY/3A_/KZ^_^3___K_^
M]?\Y.?$NKJ[OO#OTZIVN\O %7839*DJR(D7>[QYO?^_]U]G#C?>X>D9;W[M(
M5L46Q;EWXCWG^>Z/[]^_OKY^&ZS#.$NB(L?59=^NDNU[[^2$,3]/D0_?>Q=^
MCKP_?OKPZ0\G'SZ=?/IA^?$/?_SP_1^___3MC]]]__W_]^'#'S]\X,B2W3X-
M-\^Y][O5[SV@PG7',8HBM/>NPMB/5Z$?>8]EK>^\ZWCUK7<:1=X#D&7> \I0
M^H*";RG3KUGPQXQV(O?3#<KO_"W*=OX*_=LW7%?"^,4G/<!5_O#QTW<?O_'\
M/$_#IR)'5TFZO4!KOXCR?_NFB/]:^%&X#E& !S=","J- MS/>#;B[(]!GI[D
M^QW*&A5^?4JC;Y-T\Q[__!Y^AIJ_/_GP\03JII2KI(CS=%_1$9H,K;[=)"_O
MV8^DP24!]$+7+5H2K8*3K'@2LV8_-ECC[Z2%&P7Q@#>:\/H=Z>:G#Q\^OO^O
MVQNZH,K"41C_)AX67/Z[]_#SDY^A:BA1*&X$_J'9"/QCD#?+,JX_O*<_\D5#
M11OP$L_QJJO:L-I+!@+_T!RQN-A^$C7ATX?WZ&N.XBQ\BM )%$,IV2O9R2?8
MLI0\2^OVK_WLB1#C+QMU%-G)QO=WW8+LAT9A3-Q:B#Q?^E-S%#O3PR;SXX\_
M_OB>_/K-O_\OSR.;+-SNDC3WZ%Z[25:D1XIQA;].RL$]@:]./G["B_];S.P;
M+Q;N4LG,O#^L$>4J&]2(:HD.;42Y'J'V'V3U"A>P48V9;+^270X?E'5V=GF_
M2H7K\3V*\JS\1MD$\7(V;D)KJ-7[SF#H-1MW6+L$YS_Y.S-:@Z+;8]BZX.^3
M\@_S]=&XC0:ND?)PH^NC.I+,5DCK!+/6!-/*AU0KW)+XXNVU+>N;>N"\LVL+
M/O28[_V@\Z!]7\,'\TJK6W[P"?#=^Y4?K8J(%#OY^*WXH,]:V[Y#Q37 C^,D
M)S_ 5^67NUT8KQ/Z#?X.+HD_IDF$EGB%>O#AR\.U6E![G_M?DSC9[M]#\?>E
M %[^>QH'EW$>YOMK7$^Z)0WXQ@NQ:&)4LFQ9V;8 85$^)+WXYQ\^@$#.B_S5
M1S\./,K,X[C]Z_LVCQ;W(D/!(OYW\GF78OD\IB-V@[]@Q*R(@I";@EYT=;.D
M9.S+<H(L3MLC[BAY(IPG\%(* _QG<.9'(+8\/B.49W32#,JII^PC3%G%!7\^
M7]P]+FZN+TZ7EQ?>V>G-Z=WYI??XT^7E\O$X7P?,U[V?XI^?41[B#II.7I-(
M/9.?>LRD][L&Y]\?9[;?S%9?9HOU=8RI$3XMSY,M'IIG$/->$/WVHV*BS7FH
MY_T[Y;P_+O$_MY=W>,X75][UW?GB]M([O;O I6[O'RY_NKQ[O/[YDOUP7 ;C
M+ /3O3^,GWIY?&]O>1Q/#7O+Y3%/5K\])U& TNSRKP66C S7A8!0O0!^Z+$
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MU@:O:(!X=/A!]]^C*,_@&V">D1$AHP'5'#[-/ ++C[3],=K 4-WX3\@ >PB
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M1>:4(RT_LW-8!.O;Z[@5,K M;]-G?X5O<.M_#;?%]C[)X=T'0O0^*7*Q$\4
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M';_;]J_N#;)"^"G1. [G,X/W'\#3X8NQ\A4&G)L5 (Z$40&B1[_G8#]NLU'
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MO4HK/-I*JM8)X79XNU570%NJ(&X2_7>:T^Q>Q+LVH=LX([V 1Z(6"O]0KB,
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M3$-)5:A+/9BXC(\#*8IJ .!^/4/QZGGKI[\I4;*T9+:US;#"4QB_$V:S$?L
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M3)T \+$P"G[T 2V92TX;(U_/;NE9>\^?@\'Z+$D#?,N#'8?= P<XS\LXNE>
M<0!;G,\S/<5T*C EK;.N2;(PEA$KH)LO(A N0=-TGX9)2N/K<=E*ER_IN176
M,U-CT3.(P&7"DL3K& YZ]0H8PLFYR7.8E7,:PZ;F]=JZ%:1X,N)RKI&_/^,A
M2WU 9#T-MF%,G-1@=; 1%2/Y#./AKJL^00J&MV#Y/*0Z0OHRO(XY/TE93_NP
M<(CBC[<]Q$MI+OYNN9F=>P9:]DXH4(5ZQ02WG_$C"F:&GO*VE?Q]JY\'2L3/
M?AJ")%LI*&FDDNHZ,:<?-7X>@I$NLSS<@BV\#WZDC'!NJ(@R 592VCW8["/:
MD(6OO"%DI2VOE=J!E6Q#$[V+.=T;<K6XPF6M>5H09I.*4LLPAVOV.@["ES#
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M?OD7A?#.-Z!R&&Q#1HS:?6FD%> 9E9YTU"X,]W26(?R_0)Y<?0@GZPXD6=Y
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M-. 18[OZNX4U4EC;'02^-56\@'4N@-^,U'MR*ZVBY;*$C!2BE2SD78K-7),
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MMP^SZ^GE>#ZY9)/;^70^G3SX/Y+H1J6+3KVA3M/519@NT.Z#=^(O>5\R8W4
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M+11;?NCN9Y\WH%GCN=G8IFO""@'Y\#H23%&EA+1UZF-_@7.*2A.D3;_GQQY
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M\LX6PCVS_,,!;I=9*I08V%%"Y;S'8@!G.F"5"1CH^5#_C7="/KMA4N9D3'=
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M+I_E>'ZVJ%ZZD5E>K.  CPF'O=1LU.>:+\\$Z+5-_>*?];L'R/NW]V 86PZ
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M%= VB+]K4_BFJJ;)JAADD5%JMNF(=_^M;E:G:Q+O$G/]Q2US0W9'(2/>14F
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ML#(.,LD#!1%JD;)E4.1B)C=D;P+O-W.?-JLM\PN86RJ8U8I54&A6J8AC=R;
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M>W-"\5*,]<0"G3GRIQ^=!7],CC'>Y]#E-^PWIVX0BF+,'$(4Z/1[TQS(-,1
M+.M2MOR/(?V/$YWE[6&^*@N,J9/'7B-1I!48:LT"LD H=GM(\-(78KBM/K@V
M^\!49\*\285.N^ N2$K(;&8?5_+R!#%T9+Q;TDREFK8Z^5KR"2H@4H-.%_9S
M]G5F:V6Z'V?S>9IJU='W:J>&]'DN)GANRCG%.YR@ .U+YI)Q3E]PO6GX8YN<
M0:UE1)0>(Y-0DDL3KNN\#3<'^O=G?251GDWP1;2!:F5>%;!0]L/U5"J0>=WS
M/"5PU\&S$R%(>DF3Q6H=9+]=I9#0>/K.I,7R@+023'[EHMTNS&->>\ &[T*
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MJL5#!GU.6W! Y//;J1_*O=5^=6V?$5_,=RN^3.*CLS++0CX\/&;.BZPSIJ<
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MC1:(/;LTXFQW@%!?JV&6:$V&]/.TIY+\537*DP?GR+8:_O?8WX =0Y*&,(*
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MHOEHG8\]\2%3_-QL=&I3E9!2V[91MO&$GC7*=^NH3Y,D?8U> ]Z,[LR2<O^
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M<?IFP]MZ29IKNM.^C1(Z92O=J;Y^S:4VB"0HTW&6JPH-B%S'()XFS"5?BPC
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M4WAP5<30-2)74$')GO9WH>^Z'ZR</FXQXF06J41+Q6V=8YI  AC)X:F_>L"
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MB- XSW63X>7K($OP=PO()M@9S/<*Z-]D/4@V</IL*6X&DU".F'&A)A).FN=
MU[+[[Z@=HKU90AL#!0W?^@DR^C?<&)II8J=-[1BXY]E^;_JVX3\GVV<HD%G
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M='':V5$RG*X[!?!+6/43%GR?CL7G7O4PNED'LGZL[0OC[X-H<.TUZG9O".O
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M+)1[6J59(6OIZH:P\>%!F"+#T[?[2AQV'AI$T]OR&QN$T97ZNT<*+AR67%O
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M%)5<\F9@BDHQ89C7,X+6)JMX$P'=<5,,:UQB619SX(\A0Z4A5JA+_=!.4Z%
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MGA.(Z"S6!8+?Z**X!6G7A].#HS@5KEKE(5HZ\4 *B&,+%;T0L%O7&J5[T8Y
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MM&=3+=)&>^TS#PH$Y.;JH=Q>O6=S?W'STNN%B5.8D6ZC>^][L-UO'ZF@0#<
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M;\IUY(,#J>E#E@*A.)_>2DXUT7*_Y9:DAC_MESBDLT$SNJ<&3D[_=?=<N6H
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MK;3V***V(&8TE?^D-@4/.3\*A+5+EH@.V;D"*W?A&P:AV)JBSCM7PZ5L5S<
MQ984I4KZ!(3UG H%&F2*>6%^R&7X]&I/H+W>RS=I!^:.4[CGZA?$6RF#'*L_
MHCBAAA73VMR)8 L,H2)21+R#E!]\_NGS)P7ZM=#N-P,&JN7Z/@@IKN.(Y-1-
M;_H#R>!U;RO-QA$HB.P7+PG )@,\2F7]:,*@6/AMY%.=5-DY]-[[5YPP:XT^
M;KO'-.Z)L9H!EJ>EYGFKS *SC!:KMX!*$=RYPXTOE.H>D]C?KSCQO;PE)(5.
MZVW"'71V%+32B'\15JDKL&/F452IH4)DQRG<TTBC031$BO+6N71UHG.K7S59
MP2L-L<+M()N^,SD/X^ )1S>!+'A!]KO[4V/M@.,PWAR$EF0J\VD<X7Y3O<W'
MG+=PE8(E" U<%T,^OWN$%?8 5:A__7?G]^P2+(HR"VSK1_>XO:> ;^TD"?KX
M7U+=.\B848);4$U7K_]4[M' L^DW)*=Y'LNM=EGKP=UOA^&9F?>%\3,_ L,1
M6HY#(<6P/D_$9\40A'9-U0G*]D'B*)VQ,O'%=BS^X!A9J0^+,4A.D.RH])1[
MU41C#6/N@L4P]S=06"]?O.\52_X5V25DQ<UB=.%5*?%3ZS)VGP+%J99F3C!7
M7X*;+4[R%>KZMIE&H=C<\WZW"QDG],(++P2OX?,;(5DEME[?L+'#> Q$_)KQ
MMR %]V"\W<81+[@+R4\O<?D;^\,3G):\D\H T^$X?U#G<X\$5?+5]"P%='^B
M+%,RHD(^9YZJ4KQR, 3+WWJ;(%J\ZO)^6R#NE_WHL783*F]U]5<45"[,.84O
MPZ9J:PL8Q5:XJYGW\_*V])^5EA%J,ZAYE'NB^F<<!NLP]KU5H/+AM$%PG$FC
M$V_Y^.G?3O,P]Z<B*KG HT4E<*A(__FG3Y]55>QUT"C.Z@N)Z+6&H.R%OPTB
MUMZ*J1;J?%S#$/=G5+7HYZ;\92340%[2@\?N/N]?0]XD6>+0ZC4+BC/E74 O
MZMT.-:*,&MS]6?:RQF=O"6F+I_VGPG&J8--]-9M]7[75_>I-+Z7D,,)WW--1
MG;H-;71UP.ZW4B\I7K;,,&AF^B'NMZ6MQM$N5:('1W%C*P8>;KUBABS9G9-#
MNC^3ESACE9_S^$V?W,1)LV1TVT5G,0C%^91I/LV\G=S/?7'@1@Q&:Q;90M;3
MX-C^&WWJ(&P'N(.^>JH"%,4V&AT6*JZ-NKE)6@+(>K#[N[B,H%8&LWYXKVG%
MN@:!)R11U3*T&87B')NQ2%^2.,TS[>B=@@;&WX)0$9=J,Q+))J4AM/9Y'ITF
M<$^TE_LTH^M-($)*9=&3P* XJR^4PZ50CIVD2ZCH0&EI'Z1O/ X,&(=4.38-
M<G\FBX1J.I["FQ_O$^#S=[&R,U^WX>ZW^^!%<4AU=<5VZC^C(+SQZ[@WPOMJ
M->^4.J&S%:$X%&6KS:\I6>_#NV MQ9S%,!3;:TEXRMQP&2"*+3R0;V5;38KW
MB/YS12KY.!8E.+K.@6+CVL24>R]C(5E,[]#NO<<T*+9OD_I*_\@CG=(\6TF&
M@%X3H4#!D64J[F09UD//[5X2:%E9OD8)X09A(;&582J-4L2])G"_Y4JO(.DA
M*X'<+_V*0*N?R(-2@Y)86Q4,BOO(-.S;--T3_XI>&/J4L!@];@PO30NUUJ[Z
MB,;C9D2!E$H@YF/1Y;F\+\7#LP >',@;*W>=PST9"XGW;W'H%\?6=A3+H-PO
MOD),5!C:!FD*#03BC!3)_L*@>Q.LL[<%_9>O"3\^;CI,1%PDZ5-2B_SB<D*\
M']1:D0<EVPU%L<U+=9,FM2/9. C%UGJTV;NB_TBS8"7;]!'3(4*'5?M3A>U1
M5XMHN-E1(*L:G"UW)Y2_(UFPRK]1ZT2]7+^\$1ZL!,)\'"E"\X^8SOUC5O:V
M;<GQ,I%8!>M^([J.F,OH9D\U=9%_3S44OY(BJ8]RZCB7>T3\$C-9KTA>XMG;
M_*\\9TO5]]AZ)(I;++/,\'H+EWF!-UM[3GT4BLTMDXT7Y1%7ET7[1)[]\DC)
M$*B3FQ:*NDA%?<JTC!$%62K81,$Z6(&EM33B@<$N,*1MG'H-*! O.II5ZA9)
MR:@-AF+Y%5^V54D#'3R*#>G+S4O)5CL"Q:8NXY#^&O,(X8K#"*JAL5[5\I\K
M\?ARP]48\V.NC,DR6L'$"(_S!HI;^LW^'/UF<)Y-+UHBL2-A5<]Y!D!U:SHX
M%&3>DA(K&9V*IG:&(2BV53 8D2BFY4("",7218UYR@>NR#L)8^9UU:0U: >@
MV!*8AY9K39'%&H![\;RH\)AG3[R&P8:)490Q2UXUVS$HSJ)BB"[#J4&R+H0,
M@_E:,0K%YLJ(UD)]3\',+K7EF!W+1TSGGHCM"RO3AQ7\@:QYQW\87\^WI-1"
M!YP;!]V4+7:@T^Q-&']++5ORM.!Q;*AOW%.KX3L+Z'^A9YE'1#W$3)TB?B/P
MB=5E@J:01;.X)RK"4GX!LPX:FC7.$MU?6)[.=BFR=GC592BL84CZL1SG?H/\
MX$KG[O);),F/D4*AN%3Y,WY#?$@C[=*H034$Q;:X$"_IQJGC@,9![LFM8O>Y
MC13RC180Q>E4<AY2?C7 [VR;F6X[&,56;]3U7;6F%)MQ*#;8ZK*D.SLE,(JM
MR&M V>0)-L$_F/%*>F9'3(/B-"M%KHQ*D0H6Q4:.C?>OF-;I625!E :K5C'3
MT3^& I7MQA=P\E$6)XI(/^T ]^* \/"+11U$[!;5%[*+( PELJC%&/<;L\C4
M4-_J?C,@(=#\4+3"01L*PXF5GMDGLH+L:N9Z-;1;[3K6_4;OO+^#'TO5L+GZ
MJ_O%EBIG*ZJ3\P&)YFT8X7Y3K4S':S")@!:@,B<81Z"X_'4/,O@/S'YF@')_
M(LV2)GDAG[SH)A3W^;J+(Y:VU K7ZS4!BO/J7_O=]YG/U OS\EV5BJ1:$^V8
M'T2!THK!CT=^5>1)B'N18<4T!L7&>A]=88ZBRO]^RX5LD:!P%;P'/J';5M0G
M&/VC*%#;M(\\D*Q7I0K9./>L55+Y3C@NZ?MU#5U$0DCASHO@M66K;N-1G&C]
MB1/+-3^& A+%)FS\B3=^$$C\D3VG0+%M?I?,9G94S\Z@C!+L9#=49!:1VR?A
MSK*/(F!>K!IG".V!?.+_C5#N\[:B6X(->U&@E-<MQZ&@G2>RR]F.NA!-$P;%
MPJO5-2MY<"SO#>*NJ(@(^IX\#]URK'L2?(BCIWU(/OUT\?,G>K?N8S]8!^UX
M31,LBA,3T=] 0A=%%0@=K]6/0!-N>D/IQ0MY[[;5OD9Q&C#WQ%6F)Q"?B5*4
M-4$IYM6_]P$/BTWUKN?^L[C?_+T7[==T)2P#_ADD3-N^<=8C4=RZ9B<-EF<'
M;EEAKN 9#+P>@+*PH?T,*#9]&;,ZZ=S: L+%!8E6;ULO^5U=F-(TQCW)LBN5
M .;_F/LOY8'&BD3$;L-1G"-5:B&:CRX7M';_XO"5M3?F#L^R-D.@-SQUGP7%
MYO.DKY0*S^#JT23OR"'=$ZPJHR;7Y%EW=^@A3/P[(+]E)*FTWGD*]]NN12\)
M^YX^QDE H2"\8<JVWT:\]$BA[TD?E[&^Y9X*;H(DS4QE3&1 *&B Z:Z"KW#K
M&K 6=<4.[0 46RIS![A!JE%,0Y32H(]A7H^M2SI"KRG=$VDEME*(!WEH-BC#
M(M!-PI5MAJ$X=6TNEIJ<+8:AV)X(X\OCF169,'*QWF8DJDUJ\M4:("B6S03I
MBAX,B0[+=>4/TL8'W4>CV*RBJAQ[C>6V8BE#[3R+>QXJ\7/4?!S/A"6'OWR+
MH139X8J^&.P/BA"6XZ9#00N">9K9*P).6LW8^6QJ=&4$=K^51WIM5L'."XL"
M2GD5=45VCP'>_88J 1&??_K\%UVDE!H4Q;W0I$5471+Y"_Q Q<27;R1\)_=Q
ME+UU3;2PF!$%4JJ)O*U"!CJSCM5 %%LT6E#YU>MG?<W'NK^GM]$EU<N]2BDW
M7>]=#;#[K?3J[W<C"V#I/1,*PBU*E+.B?&N>ETN92<"MY%>*V "+82BV5]3]
M+4I#7.VIV&7#>"V'HM@F2^JJ)'E)0Y$:,"@67I8]>X97G1)1^G4'CD;ZN/_T
MTY_5XJ750/=L)J^)2!D?7:L7W@<A23/ZI.5VSK:U4 ^/XLPD"<C:5UP'CV)#
M8.L*,E$(C)>;W9 (BO#9)69WF@#%EK7M.T28(N5W-HRR[UPH$-$[R.TASDM?
MM$MCE"K*TTCE.+I^W#TCK =D%0EB9:B@_Z]][BM3M1+K.@,*^GH@65GT>_'N
M!2'S#\2MYHHI/61YT?".4[@_ZVJ,9ZFXM8IT230&JW$HSO5BGP8197P5:^UC
M$M/KMO5NHS7\#S/AZ5Q+':= L>UZ'I2J[5<;"L7B;1^JQ9K2H4S?.VHB%"@H
MQ1%>7TV\.4\D!#65Q<>VO/%:Z>ZX&5$@I:+!BV+7L.P[;2E9PQ@4&[O>[L+X
M0,@S2=Z#E<*]4E3N8I)%RAIR5W^';3W$V?\CV5-14DZ&D=$^A@*5RMI+2L>>
M#!C%VURS(=][R>^$G@=]><#+U*P_:SL&Q1D][U_3P ^\Y/#L0<0&CUY0M:94
M :/82BM4M4R3D]J0=?#NB4[;!9@^C<<T$6X-=[_=.\K^HA0*_#.;6QZPH"K(
MH %&08IU8:Y@:F:YKP!U?R+%VP277!AVH?(*)Z+\_]>T'>\Z 8J3RVE)RO[$
M;^[/9K%:)7OB5RS3MY%/ME%18245=Z-F6&MSB7[SH#@I^_AUA8' <K3[TX;'
M-FV:M2O1I.U0#,, %.?WF-#%9, 05HJ\(CVD\T2WO*K.X=/GUQ=(N*\N7?8[
M"JPS9ER61J?TOTF\;>%\7>RSMS@!#:*$T;CA^\^& QDF6W)JJ(QW$R=K$H#[
M*17!]HU:SM??J5 9 &JHS-++GCWP&CX&XGO7U*Y@PUA5>U#WPJ K0_#FD"B(
MDZ\1*Q3*[#75B!1UB6^+4>XWEYO'BU#A)\*C]?/SI"=UD1!O];9<%R#Y3U27
M:FWZJ-E07,=[*B4<N(7B9A_YDM/50Z+81&X\??22[*#.9VU#H5A\F1QC5S!;
M!X]B0Z#6EF4'"P\<O0P@G"[",/X&5>#H?_.8*/#3J=3CKO.@0$"U)\O1'=1>
MFF+^>%]!PYW+)MZ&R@,&>/<;RB/C(<RE$1W/(E\*C[0^L-YR. KB;\;- 0%J
MNBPJH9UN)DTR>1F/AG5<!^>>^+[0)5'9DS[63))5T)@4RKF&?4<V7LC0>6@B
M7?(S"LJO9R45O>)N*- SV3"&#%$H);4H67N_F=P37&Z<SY<K]W]J 5&<8[M(
M?!&ZD+NQ=0Y^^]$H-CM@@X#!S1_#?-K]M9#7[(0KNXP>2,9,MJTK8C,(!05)
M]!'#_5"!H]A.M1HC82)T13RYIS<:K!M+J&M/Y100.9F,G8C_A)A"M<P^V.0H
M4*7HFBC;N (4Q3;*:MJ0C 1Y6(Q-:Y(I= ,0L)N&S^0QSJO.\6![&V->]RG<
M;_LVBN)WNNQG".L@FV"UW$$+ZWW$+M==L VRTMUYN(R379SHY.(CYW./D$<(
M  ?QL1EGL,H],>*9E*1 6P]UVQH+EI(<?OMR4=U!^5?W9]",!;N-])7F5JO]
M=A\V4R"-(6;]ID7!?8LG,7_^&)TEY-][$JTTQER+82BVIXAZ+NT<E3Z]N1F+
M/BLYN[W^GE&Q&([Y+K#I'G+4].XORP/Y5N<WU0P'%AQ>;>RM>[]ZSX2"9KB(
M7)S<7<P#<E2AF1IP%-O)GTKPNT0D25G\=_"ZAVAW+CC)-F4<Y-Q"!?7=()_V
ML'V-:UMH_8CB%$IW@:9$AH6SP30:V6:K3K^JP^/B4/O%O.\.$Z% 0;-']<W[
M0R#;H0P.QP8LNF70=\[GY9XHVO.:+M)-]IS+N1/B*J!Z<Q8G[7>N_2N*4X,\
M 2:%9=>0<?I"/Z9+*9" XMB&-;^S+(=I/8U[,8P[':\^@0[1WVEI/=[]AAN1
M+;!(+WUK[4L.AH)<1;Q]_A15C(J:(MG&02BVIHC6+EW^QU0\U\R"8O.]BT'K
M.KY!_L^PI:>-7T.!3)G)("U,[6ISK\TX!$S,D^9[Q?L\.HJR*Q&5;N[GT7<J
M%.=LFVXN53LMQ^+?Z-?(S[LV$?_Z.]@&V^55CYH(!0IL!/NB^%IA'>VK(K1G
M0H&$9Q*&W%G(I1.HI*?6A=30.#;3-RK@WOL>;/?;(O60:A>K)&"/T> M^PS?
MPH%(81#D&GY9'%2IC^D&N'_@FFI3)>JU4OJ[KP>ETVPHSK=Q2FI7B100Q19*
M]5AQ$[E4?NBB:'>9"042"O'RXL!(\3+T4N4=50*CV(IHLTS?EN;]L@L.ZC0!
MBBU7FA;)?3/%S^XY:+TD7*,0+_,8[Q*R$D&G5%>F B$5\2.6X+:3%N \?DH4
MIU@U\XLPI5L?BHI"P] \6$OT=:D%;3&--P_ M>10@WS"/35!W/@#V2=QN@H(
M!=6$E[?!G'OO1 _2113MO?")0&A/TXDG@T%!KI)2>*H'0P&*8AL*A7.4B(B/
M% >A]A4(HUJ5[995\^*]K)]:[[G<(^(E81:W _,6\*:J9<_.5;CWF>66U3&Y
M_@[A:%1!;V&@SR3NMRXID]\(<O^:DO4^O O65C7VE8/=;Q6BFD/B*=Z/VJ_.
M_;'WWK_BY'*?9O&6)-)TL#8$"EY[[250EB,5K>BN@G#/G#Z:HHVF,2@V)HRR
M+W%^JZ%'.N5B6X-D;C/._=U81D0= B"'0'$J3>WM =Z;G-D62IXV2\1^/(H-
M<R/+/<G>8K^DH*(0R O90GAX<KC=[J@*KVIQUWT6]R1Z1[[30\GBZ-Y+4V_U
MMJ?GI:Q*K@-&P-R955<>:U/[T3W6>9%'JTJ0B.H]RBL?5C)*+HO&3D\@D"H;
M0%D-1K'5BB)O60Y7/\+Y+7D"YXA,\BE^0('WHXMKB107=^6].JW /4OZ\OP/
ME0U(_(*",G0M LW>H_ZSH-A\)?Q.60BM"8-BX<)V#%5DLZH!65<\4CL$Q;;L
MNY7DVI=LHYTG0;'ULH %M/*@_UH=M!9T'3R*#541+6H"YCI+GE"YR'@6"S\>
M5ILIRNCT=+*-2%&2N^:'F-G]$_&PAXNW7->-)*WW0@Z&XHSS4@R:1LY5 /<8
MO_/^#I$-CU3.V'HKLL^"%6\AX46235@.<;\MB8734#ZOPS 4A-9JX%LZ-BB3
MK_81513/LQ[N-H7[X/]V>: TE>81I="-X=Z+/"XBYVG-4* J@7VD*? S[C8]
MB"@V"DS_">7DO2R5'OYX7T%!*]+VLBJ/H!+8_:VFY[#F=1RYGZ9U?YL *+#?
MKO@$IF2PNI1EUW5Y&%W&H]APNW5 OKJ\WJ1ZJW8C46S2)AZ8.94A6".F+V0!
M)^\Z<,Q\*!!2#_4I,F=8QS+I66O@W;.:O^_#0RO%@74DZ9PNT7\J%.<Z0E=5
M:6&94WS/>5@1+TGYN'^EVNE-&'NMF*(6  H:J/ :D(D?2&95PJT%C6(S]933
M/.*C:$<A-Q3I1J#8E-#A\QJ 6G%"!HEB$[ENK$E.J4.@6+3&T'MQX!8*;<2V
M_7 4VRU;!C$#]DM,[_FO0?8&UB?Z?$/U=2D#U\58=)W+O7C0^Y&ZA?)P7LB?
M*-;=HV5F'^4#*&BGS$[P0BC-__Q&2/8EB?<[.&T1=EF$8EYZW,]UIPM".G9.
M!+2TWVZ]Y+!</P<;WEZ-)19!#B6SWU))@!44E""ASW@4E*"HEJ,]:=,8)!LK
M2G%?YHV,@:,)([76@6$[%HD4^T0V 8AU4?;@;5LMSF0P*$X(PD,L6ZDH0%%L
M0XAQN2ADX1_3CT"QJ683ET:+E])O3AE\FD+18&ZL!XO?!5G'23/">]")D=R[
M7^*0LG;*\6^"L.$=4P*A.%W!R"X!M-I=6>TM,PQ!L:W<:%G1>JV,G%)X%!O2
MA:Y4C'8Y'X%TD$;OLZ,F0H&"5O2WH8*N3KNQG0/%QEDL,:7'6+@#.9EJ5'+]
M"!2;NBK,-S+[>;[2O.:\SEEJ,Q[%AO,2:W6[E9K+:L!Q;*=>"5!;R4L%ZU[/
M>]AOX8;$B6SY<@C4KG=1\W^90!Q9D&6$ &?;Q3Q7\B;T-EU\[!;3.8]MOI3T
M\FH7UM!#HKA1/5YF<%@-],C#5"C0T.$-P,CN>8]#L@'5)88,5B^!!_B>$ET2
MR#J46 U <3*50B:R"OX6]4]4P]R?V,/7?R[O?KE^N+Q6E:=O * X$2:[$C\%
M\]1MFN[!V J]18L08KGGS# (Q=9Z&]NU]LKC9T6!G(7_#J>6+B/(.(R ;SSF
MK1'D<1T:>"06E K]<6=NI56<W)RB&X'BE%H&$AY; O^2VE74X.[YX__U5OX^
MB17,L?:K^\7>;B'NTWM5=8FJ_8R"5!IV8#"%&E*M5>#NL0^1D%"[+=I<D,S[
MO-C$49!FBRA6DH]Q!"(E@]Y-]@[HVPI7H5 06"7E%JC%7/M*.\ ]D=DY6%L]
M0KJ.=;]1D5=3>>U :"/^%2GJE\J,%L9!*,BR98]5YO]967.5H]V?8Z58Z3NI
M")QYH3(60\4*QU6;R(JFL3<Q&&!>Z:/%\NB2&'J>M*,.1O@&"BKYX@41>/VX
M^*HI$",%1+$%;GR1RN;L%Q2++)4#&\^U'!;%1LK"C4J.8-$^2C\6QT;[MG^H
MERN _30*%3P1,(RRX'\>]D(YR/!=*/HO P7Z&VW\S '8+5 4V[#)<[F$((R+
M./&I7 '>Q?P)D6WUB.E0H*,P6%;J3E8R%SC#TUHZ=0-1;%'1VUNDLX&39Q^"
M- Q&PL<DB!->S83"%DXA&0:&F!<%@N2&0LZN6*5KH%9*XO V:"BBQS0HMB^\
MZST<\AB=,J"<-QX6><4P*1"*$\E;@'RAV$P\*+:^\+=!Q (Y@8!R9$MJN/6:
M ,>6/=8< +17H=!R0R_796^C2L2Q=,<=QJ/8,"M_#,F6.D&B!81BZ;T=*ZW$
MP*)R8BX;_D+U.#@L_E ,ZM3I^&T4B*[9&'_QD@"$YL(>S#,5E<^1]6 $]I):
MV0_(6;Q.LV +L1O65905HU"<HZ)0KU2>EH.BV$91HN29;-@54C] "E#WI%:&
MEK/[;[0V60]"<4+=8X%N*.PP444PDW/![R7(0 ZXC?S@/?#W7@@)/"QQ"5C\
M6[![B3GKDT>-=1R.XLQ+Q5O1"^\F3JBD*Y6:;,>BV"BC/HN6&C(XYX$/EU!=
M@G*1R]AOI6I5?W//(9](L'W=)RDO@4H)0!XM+XE([S'<^;DL]I3,XT2605?Y
MR?VI/._#5RK_>]NK?1+&_)^J_MY*4!37N%X>^L9;$77C4Q4LBHW<!1'$TC%&
M29?&VMCD5<@OXB2)OX$EV]O17S*I@-YE/(H-RY6(ASA[3 )PLG/KSRJ@_U1+
MAITG<7_W0 CP$^^;%[(PRD+F:]T\%:#[+8Q0U(?KR^ J$YW$8_A3)3"O86 K
M+.9"MVES+HRK="[3/I%='K]9E*>Z9.V>DQVDXL/[))=FK0>BX"Y&6537'=IZ
ML/NK*,U,T7;?[# ,Q4D*%E]8+W7O0 'D_F2>P3Q.-L%J$5+ZH;#WWJOWF,2;
MQ-NV>94&V/U6Y/7NZ"LK\QK8C7"_*4EUX)>X6I5$$\K2:P(4MZG>,%$5,L%^
M5,9L=)W#_5D7 6QYF31NE6?]#V^"),T@VA'B2+R0>W[R&+:V.MIO'O<(^#][
M2JC0>K:HS*FXN"I %,3+2(J*7@'/=+BB-TU*H#(X]V<@X1?%92E\#55SZ /E
M')1[AN_D/HZR-TG4YK$SXCE5U<..Z4'OJT_D:C@W-BQ2%H\&W1M8J=SK,-CP
M=E;RZGHG_C0*BJ@X0O2!<2TP%,N_]%*P3\+_@ ;Y3I^"(H9+GSEA,]#]1:@$
MJ^7=!I)*C6\6&K$FR07)OA$2W8&5MLVZ>LSA?N.UYL)L]:*W,' HT<BQ5ZOB
MKK.A('1EF/,#D6==:.#=G^Y%WCR]DLL@(M- 70Y\DLBYL^U ]UND:@D5"7ZO
M-WM)*9$II$$#/ HB7-8K%8$K7:NTE& HEE^1X42@.EQ_99*!#AX!@8G<<"I=
MY,;3XHWFU6'\B\-MNKO91_[=KDUOG8:C.#]P*FGJ<U=^1K'<)Y)1_8 ^)'ED
MD*:UE132/8G=>-#].EWP5 %([]CN*)MBHH/19M-E,(KSRAMBZTL0-F!0+-R^
M;CC"JN#---$\%EC4/%%V0='!N[\Y/*>7REVF2G)F:/>;N8VB^)VJ2)5$9571
M!A6D^TWPVF@BMN7S3Y__ZR6^(%^S@+WOMQ']R\^:X[$;ZGZ;15*YL0<DCO:/
MO)TZLYDL(ZJ;Y&9<ENS\5&0IM39A'(&"IU74;/VS(@5T?R[/7A*DJ9?+P67)
MP;N=*H+), #%J6A]*N"9!=*"9$A-]F37.1!N7-#<04^:QD$HME;8N&ZCW3Y+
MF17KDUK@UH CN'7Q.OM&Y30P3U(I;9^11-.3VW((BE.BW!H,KI1COP<^Z)=?
M4W@_"_\7E!=Z9UQ0=FCVH]V?H7A<EY$DAU$.X7[1+9, )2>6-R':9NI2+;H,
M1D&,A;O+7&9) 8IB&U\CCWL=H6[0:R;T($W=<?T(%)MJ90)H7%,J6"P1ZE#S
MO*F/2WY&@?=6>GA5,)4[&@Q#4&S+IM;%C1\$ZGCV;C.X9^65PG#/) KBA,6#
M:75<_0 $6VI'8-SL,PBAK$1=J*,PNXQ&0;1EB:,O<>Q_"\+0HAI2#13%-JBB
M\%5C^J[\C&*Y)2H741;XD,1+;WW9\>CZ.WB)*1$ET&L,1.V\#W,S_U<K4 S_
M%13(*YACWN-5EJUI@G7/:""\GF(:*J<U,Q5EOZ/ ?*,M5Z-IEY)Q6 QS+D;Q
M/".6=>2Q)_C*RSR)&] $ZYZP6I':D'G=*;2[,0 %Z35JI@EYUG3S%0/<G]+U
M=TH]D1<^D^0]6"G/1@Z&XD04AI+"DE<:2G1Z5?=94&R^J0[>Z3H-*('=DV$I
M(E2JU*WC9)M+ M)T3%$16>V5'V9:%">=5RAY(KN8-6/)N\ 62EFT@:/4GG_'
M*=Q3!>6=7N)[2O=KY5?WBUT 57F+_6:?9M*G#,R"=[$7*;;3<3P*H@1I/8YX
M8((PC=2-(CJ>:S_:>7+K)6_\"D7IF&V$Y^=0A<:/=_+WWWX4BI,4^+\A$%0:
MUEH8=JJU:#4!BBWS5.S;R"??(=^:5>!+4F[.?Z%?5LMT=B.1Z!(4^;<^E/2$
MK@(L5V??Y#]&8/?<]0NA0\BO5$2CSU061U\C>JN2%&I1R-FI:0 *$F16C<>$
M2M32][KXU3W^Z3+>Z8T.#P]D$V<!Y']=>CNV.%6(MVD$BA, ?QV5_;:LH0C]
MDJI:DPP.Q0;JM6= 1E"9/NI0[DGJDOX!POXKY9;H@U&V';P/0BJ24P$AY7Z&
M/#6V;>SN-X][!'")[^_[\"#/:K<2&&V'.W^-F"3P^$;/0?X -7]W?S[0(UBT
MIBE*DRPC\A)L24%4>60N"\YC47EM);37-.ZW+\);#=&O",B+FP\IN2_7383R
M%C*5W/FVV=%N' IFWPB]JY>0KA0+TFE=7>=PSCCRT('ECK+Y.)(:>S1@*,YM
MA(I1E$#7) "?[K!=1:V^Z/ZV2T(4:N$)SX354*<OXTVPS@Y7!**FH8E4.\IU
MB/G<(Z1SR0;68OM;;!,[8#41BHM62<6H,[9'CX? BCB]LB:5R435>S[W-%$]
MI>6Z" ->^/_:Y[&)T(\OS8IZ,NES'$K3#WI,@X(>Z+%X&RIS;?+%YR;O.YV9
MW#3&_;F*XAOY*@FO'G0026)7^[:48QZ"XKQR7/-($)Z$#-4J1?@PCQ0!X21-
M"?T_OU'^X(AIW)\J7*%:66)E\)H4#L7YW0$ZB2*+HD)LK!)[O)<&276=P_W)
MY9>I4.Z>""^W4>H2%PGQ5F_+=0%2Z'N2TM3'S(:""NK6IK*^I]^EC+)T&(KM
M789>*C)QU4Z"-I1[0I55YX2V2V5,0"I]&CL/1G%._76@FJA7#13[0L=*:7>L
M;Z% Y/5V%\8'0O+H'_E>'V*6\D)U ]A6^A)3):+Z.SQ;#W'V_TA6YJURARBK
MOL_^!'#2PGNG78'[B_I/+[CS7A4"0/5'Y]89[C>\IE+5!EJY)?$W*F=!\8NH
M5DW> .H>XW_SDG=*-4:_H@(.Q3T%C_1:W1'GXG#O_2M.V,.D\G-UG +%MHOR
MV9=>DAS6<<+XJK3>N.60YK;^Y\=R5_2-^[WR"_MA1UDW9>A>'E7W>_[%UA:!
M@GY8Q=L?(=7DT^<_??HQ\[['4;P]_,@V>Q6OF.PC_A=*F>5!OD746K$=: +T
MO__0_/0?:B@GWS-"3]3_@^2(XOKIA!"9&A<$_Y:0-5][2A?/SB8EJQ\V\?N/
M]"ZS#< __@C_^.%[ZO]_K$5,3"]%TY["L):WD*G]+J.;$1;%,?A$-JRQ9)15
MFZA4UB8%.]$2Q7F#9UFRM-K/)U[2(HKV7LAC!C5+JX&=>(G\#;^.?*C'JUEC
M'>[41PN5)YEX8<1E"_2D%^4F"!L>VM8EJ8"<=&E@FT\H1KA%'B+,6*.(Y%!M
M5]5:K7[423=@B,5J+5T%?])%+WR?OC%I_C^@XGU2+E@&ZV*QT*MLF;S$WR+3
M4BN0+A;*Z'&9L+R#:*4F8@6XBR4_4C7*"_\9[+2W3@I\HN7*NMA5I9#JSR=:
MDBKZI;*L%LB)EI:GQ!T^?7YEC24E2VN!G&AI]"4$,_WS8?L:AY)UU7\_,;ZN
MOZ_>P+JCD">E8">]K[^2,/Q'1#G;,_%22E8^#U167ED5_$D7_4L<TL?92YB0
M419T:RVV"7?21>9)ED4F#;#EO7JM"O 3RTZZE%*)T"0%/[DDFEQ"^Z(X.6B%
MT1+JI M\WGIA*(IT*Q=8ASKI K5FN=9"Y= G6O#M:IWD(5R++",IMVC<A-Y&
MLEX-\(G5NIN JA3;[#I)(&"07I*59MD6@TY+OV^4XYNHH@9TTN4][E_#8'43
MQIZ:3U5A3OL$E)%!K=!)]4.@&W3:Y1,(BPA9#M,_B/KTFW"GDN#Y>W,3I%0F
M!D>_VKJC!#TY)Q +N*%_D3T'*D@G"Q6.+YNE5F%/M-@%_;K/5B!GI?7?3XS!
MM#0I0:F )TA])%0=;\4F2S!J'GLJ#+=;BE?Q6_GUM MJ5I!K+ZJ ..W";H)D
M>^NKEY7_?MI%J:+BV\MK04H66G4F#>*]VWG F_^X>@O*N-+2=RQU%]6]Q4VW
M39SX)/G??_BOO_[PTQ_^UXZR)5"Q__<?/O_A?^U3NB">5^V%\%N>D'S',:%<
M*ELG]RXBQTC=2Y1CXN>?9HR)NG-*8.33C#'2\(4)E'R>,4K:GC>!E3_-$"MM
M)Y_ QG_-%AL&OZ) T,^S19#2;RE0\^?9HD;J'15H^>^YHZ7JAQ5(^<O<D=+R
M^0K,S%&HU;F6<[S\>8XB;MV'+3 Q1]&V[3H7V)BC5-OVU@MLS%&:;00("%3,
M4925AR4(C,Q7=E5&00C4S%=V;<5:")3,5VY5178(S,Q7>%4%D C,S%=X;<2I
MY CY[SE*K=*X&(&0.0JOVC@<@9@YRK&Z>!^!ESE*M#:!10(_ XNYE+^GY.XC
M($D6OB20,E])MQ8O)= Q7^E6'Z$E\#-C4;<9 B90,D<95QUP)K R1_E6&=N6
M(^4O<Y1Q-7%T BUSE'0;$7L"%7.4;3O$"0HT#2SJ?AQ1KA:&*+ Q1_MM*_Q1
M(&.. FTCY%*@8H["K#+04R!E; DV+W[2+#0R5@V4HE5>M=[8A1="UVZJ\9%*
M-_:35T!9>^DK0U=>1X;'YI(P2\5?RB#=HC(8*"!O<>@7+6(4!5(L!@P26]QG
M$X^"A-CB6/E7Q>IED,Z676TE%?F=3\)Z.(8-YAJ,_9:: YQM@I>6LEN_'-;9
MTJ%G)"4-^!\@B7<O!+%OP<M*!=%&=U/LQKH[E=4*@B#3O%V*/&'8 .QL\<4C
M4NG\^!CS*& C^[48ZOBN6%T2]XNM6."T%Z$)YHZ=QM'F)>_R]!!'*RW-*X"=
M7]@GLB*4F]!K^$!,][4.ZVSIHKSG$PE!VFL_4HIMF,<YE)CB'4FRPR,57%D=
M/\KB66\J]:%HA[@C*]\/N"8!K2!NH[P_1.72JFC,/-#9IEC/A@JY&"^[9H"S
M3927-Q6\2%2[3UEX\2;QMLWLWHZ#G6U.M&2V$C\4P'T7#RKJ'X5ZRE;%>\0P
MH?^>9&\Q)6<H-;QM+TD'Z9!2,B^(B'_M)=#&):7LG[>F)?X560>K0(58BX'.
M-B4ZSA8=>ZK74\ED3:,<$OP[I9$X.:C77@-QCO>\R8;^9BJ G4MXY:U4,4@9
MI$-]IFE[L#8>.15(DWWEIED\L]HA+JU?.RK"Y#VL1<NGFBE";0TSCD1T/D8E
M7P'OT/Y2-"L3T@NK\J]DH9H!3M7D@',8L ?19=&GED2K@*AXDV[$P$)/?L2/
M$ X-W;!NGQ]O]I&OYI^VHQR^7Z^9Z=$J(=RI*+4&2$_0M'.Y_IKR0OPJ+44[
MQJVV9<,N$7+'N@^@J0;J.:5AK+.M?8EC_UL0-BNJMG[&X-:0.EYZ^FM<FVT-
MSRL.NK<VOF&RMC7[E-#WO&CR9Z!VJZ'.E:U"Z"H6::O?E@,P\'\[0UL+UO'%
MU=Y8QP$D:LU/U]A6ZM#/(TJF&8EF^TCHL*9SM\\">5I7?:W[H9UC?!9(,P=I
M5#&G\KO/ E5=_/8UI#7<XK- ECP6H(V6>;*J;IR]':J0(^G3I)%TU&.H"):8
M!>*L'T)%5,8LD-3MX;,( ID%UOJ^@?9W>0PTOI/D-<:%2//[J _2F0FU=>'Y
M-L% .=H^3QIMQSR<NN"C62#/^O&TC7":!=:ZO::J^*DQ4/6A>+\VE&L6A-2-
M6]G$CN5H^].DT78,RS?&JLT"@]9\OQX+-PO<=./NJAB\6:#*+-=+H_QF@9MN
M;$GF61<=5@9%4TR5!$QH.H:7Z\,:1T$?-BJS9N16D9-CH RA2-K9#:0*SIP1
MB>E=C.K8SUF@Z!@FIHTY%?T()GXAC5S,.@!V#(1A)C<K";4293LK@M*:_O1!
MO3/!TS&,R\*O\>>)H\]:^M((6X/BZ(.S*LM([UE@SLS"RG#:62!DH'!!11B[
M*"XZ:67;/E9"RJJFC9QNK$H3%#%M-)GYDET*P"C(PL:SS,C2I16(NH(S1Y$B
M:2''SE]GCAV1%R%B9(:-)95R'W1U*!\9'M](%JR\(KOHHQ2EG&A]M'I>"SVA
M9<(6[+.HWD>2L%8 BJU9#D:R.=[48+'/WNBU^P_QK3;5&H1J,ZPU6Y>-Y -0
M;:+69L)Z)]51& KV=;PZ-B,Q;,ORTNA&X-F&]KJHH/$LWWQ1M$.<;>0E(5ZZ
M3PYL7?D2V>H4NU##XY#V^@:<V[ZU,TDW&@*);?8TDR#TX9 GF.),0CF'0YRL
M/=;4@Z7Z8<]*3)I%",( &%2RO&E[TP?#7(/?3=L;,QC6I+T SZB3H$XC[9[.
M4HS!]E?\,5VNN=V<14YMZ4??2)0&[X3_]=/',@46(2EYD*:IN8 :WEUU5!*&
MX.4A$5U:2$]EX6^#*(!E0;OR?*$J>Z;=X&$WER9996/TO\I-T?^ O%1_O\JH
M9$&2]V!%%M^#IG*I!'.Q4.;>YFM(K^*M%T3JU4I@'=;%9ND3-Y11BA#27X/L
M[7*?9O0BMUIR-2C'=C36[17N47#FT/_S7[SO_;8JG<E]\Y<7R'PTN3$XD/O%
MTJ>!W-)_JJQ($D!WA!4?O!#R)[>O)%&13 W&76N1/&U1*&:&.ZT$1[.!"R\-
M5I:KY[ .JS*"/%00K@'U*FAGR_^50'PN\1?O5#+8D(<]4/)RW5(@#/OJ/ WZ
M#>M(L-L<#I_&E%#="6K47=&W+8Q9V0^]I*@?X]"ODE*=#D*<JJ+5<QRJ/4/*
M 2[;)8%PJ'U1ZC!H&/)5$.XSI1M.!8WMDN?KLO7,=9W%?1EUH:[:JK6N+W0N
M<FOOL( 9N.;_'>4'E73-_"O2NVF&=W_R7+"XBU/CV5<@!T;I8@OY8__Q> [9
M8O7O?<#"+^LQJS+D6HYT6"^<';Z6<]=AW-6]3^C)TE=DK>QW585P+#8#%8*^
M+2]5HR)EN[$#$_<7+XC@D\N(W7]#;Q -M/-N<R#:!>^!3Z(\-+I@#4I\&P<Z
MWY1>JFU"N:T2_Q!'<9T;ZU=O&(3D#O/\ZCU=7DX6<91>D'6<D$I^__5WJO[%
M"167O.3 ##P0=P[6MIA9J,5!6=W\8;_H&(UTL?F!7I"(J+FW"MJE5D._KY$\
M*@ XO(1&;U M%]?2[S+I #"3OP809G"53!H_/7TM]1)T/?P8LT"JW-71(+D&
M68Z!F! C3NZ:'I4.-#638OE6/MP:VNJ>GTDCQ]:%5"MB+O?6S )/!G=/O8I'
MG6]-G2?U=255<=;1.S,+DNLDKAI\/O.*M&\)#+KG<PS48+J>=B*#SM$V:>+I
M+"4TO'F31LX04D+A0IP%ID9\#-5>S%E@MM-S*/&,CI(SA:V43!=F7SAA)YU-
M9LW?+;S#DT;4<?>LZH<>);_N8]VT3G[Q2><C=I:O&C[W22.G&]NNN?AG4<K>
M#B\:CC6O=$LMEBPC+^:5:JEFWKJXCWGE5!JHRAQ<,HNB>]W0U33,#5-R[Z\<
M-Q'9L":C'PX[IBB9<0KR?51*&C$(1R!Z6(O"QY0NE&$Z DG#J(/UN_OR,8FR
M&A,DT#-G-=!L/Q58FDDI%2V6NMM.!?9.(-]_I"H-V(JWGBL"H*@(<,X='WO1
MBK9=54.@8A<V(\\I\3:YKZQ[+^6 V>$E\:*4(I()PX?J+Q(.TV,"%)N4,B -
MX-#I,<__4.?.E3].+TW_'(6-5\H\!PQW=0C;O%N3IJ%SL+!5FD/7Q[4>HMA^
MM6:'-D7<0>49G05*SN'41T2Q=KF&LXEN[1/S>X) 'FQF(UFC/N?VH<G;,#BF
MP5(71W .&OU3/\;]5CZ2.8:^,E#@EUP1_K^W49O\G^(PO(F3;UZBJG+4=1:'
M9]1<%ETZSQ[-.WPOLBP)7O<97(N7N%,*_D"3NR=@&0^T;PNF&7M24_3E?KL/
M>2;Z>DU6V2.A#YF_7"]\_GXI;.A6PU!M1&E@MQSHKI1:G7]K[71R6 S=C+0V
MWS8<*M)9^/_:\Y@MZ2YZ38'A3#YVAZF%[P=<PG[T O\VRFU/6D+3CYEFLZQ3
MN1(RRFJ(+R(4]#X>.; [4EJMXCT$/FV>@:RI\)5^W8'*<PUJ2@HQ]G>!4J*Q
M'8V)O+3'HX9W*Y+R+BY7^P1D1<9@63LA44. L! &BG&=?[3'1-@VS:_Z$+O6
MSH1MV^R(+N/HG4K,+!&&_SN#^_5,5A02.K[W.';SG-A0P<]M8%S83CJPXU>[
MFNOO)%D%*5FN?_62Q%,42^PZQ6EVP&CKJ VH9AAX_35VS[XI4LS =R=2.T3Y
MJ-4JH<N\_@YK:O?"&&#",7>7]U$K,NCZ;LIVGJ$+Y#;F7T85T?R)[/;)ZHWR
M\<5N%P;$7VRHD)5F%.XN\%Z#L&*CK6[L^$FQ[5(J.P\ZM4.E1^B1Z4NLT&;8
M&E^;[_D3H<2:!AG)7=*<Q3R15;R)V"SLHBKUII$_.S0)V:ZW)?88UZLAKM$_
MZE8.*>^'OXCHZC+@?:WW2B=T6,Z ?)M:U;S3%!^UYNHQ5[.<67V36C!G5XAZ
M\M\^_S09:^)OGS^A,I/TL\+]]OGSQXMJD+N69Q,D<V=(W>OF_YU+[%4?KWB=
M^H9AKV/@>\=?ZLQ+,DQ8[^1_GF/\6U>OMHCKMG4@3Q5OG8*-:DFI<@?U+'B@
MUCFO:*X^BP#=[B$9MO>P[8V?-"+MDE+L&-[4@W@'D$CT"LT8"$0J9UAS-D,<
MQBQJBF*/'O_8=U*CF(^!PH]^(56A.&=RLR,WZVB@,4I*8GI.K2E.$V TB[*;
M0UE".@8XC5&Z\YTDK_%<L*N/I!JCYN>LT&L;L36+4J%C4[$]GJ==;O0(//>+
M1YM%5=*1L*J,D1NTG.E4D7IDX-X\JJ .BF3K^,%Q"I].#;<#Q#,.6SSUC&A#
M2.4XQ5@GA.[3!6K.H^+KT90_?B3H"8O'?LR#Z!5%*K ZJ%8X8?7;.FQ5('90
M-7":B)65(3_K>3IVVX[N%7@[JW(GB86#:.#"TS-"/-QUA*H?R,@>?XA'+K Y
M@M=_>MC4!D47J!S!7RM#);:B:9=>^G83QM_*,+ISK;2A%WL71QO*"K=7Y#5[
MH=_1E$B3@KHO+'7W@2JC/9 ,B)H^^]"SR[\X?$W!+E8T[5JLLN"=N1\,I;%Z
M3(0C"1,4PF@5A(3NH.RE]!(/@Y91/N4,<5<Y6U>V0I+BP#3*W8W=[W8ANXE>
M*%C[;;2.DRU_M W%X"Q'.ZQZR$5*L)50BE-LHPF%AO%K"Z4I@ ?.=:SZ8?>O
MO&,:%0D>XHRD%/I/ZHX'EB/=\7W*B"C-\FZ6P&4B_X8ND7(GJHK DV1B]];C
M,=1>^:1\B2L@[@6'BH!I7XBR/02;,%$2R9'"A&XB=ZG8WD%8I[E;L=W76[I'
M\SA$Y7(+:22WN)O;I]A.@&B3>=QH2L4T$KQK5"6KH=AN8<&>C[V%NHF<W\*;
M."D-Z1!(5=B&#-=0,W".51ZJ'5_@C2G:PMP0 GU1KL@N(:L@_YVN@][O[$!_
M "/3#C JDXH&F-5Q RG6/]<D4+< 1Q1+213$B1 K?[832*5CQBD");0+CA1N
M$(>_@OS^0N7W6CMU"<%TG\4Y"RH>]'LO^9TP8[^QI)_=6$1OI<!\^>"EE_LD
M:=_[7E,X/\.\?\I+3*_QKT'V!A9T^N+11Z)3V<[>T[DSC=4XM*4H:Q@T,&>A
MJB>();GT(2V)UP1Q^8*O"/%9:_:*I/&2>'#^9K9@.QP19P!>'-$/J7>E'X/B
MK, F0(5<.PG2. Z;*B"Q+1]MU7?9:S=]@_\',N*[%W)^2_618$59+F,#$$Y3
M_4,%DH?6M"DR=]Q??Z?Z0+0A3Y ]R!+S%8@Z\2(&9JGB_AUNO"#A*6L9V7W=
ME=Z+4N:"T'0FFT.+Q&>Z :G@=N2,S@6 0A 3AF:UH-II*")&_9B0'=5/<F>,
M-:]N#$/!KO.\$Y&(8O.<MH9\3/XU!CMR: GO5!-_6-%95>XR-PFER[4(ZBIN
M\[T7>1MX%6_3W<T^\N]V,E;8<09$'&*9O9&D?.MU*H#E8(?M378Y>UZNOU*^
M125GXH/S4+$?-?R93PC(WW[&HJ<6)FD0)9@A,4BY0=Y*8]4,'[K5 ,5<;T9B
M/Q@1#Q&>$2H=]?*HB''8="B)%^1H-XIKXS8X$D VXB0F\D]-<J_=V)&>96C1
MSJX%>VYZO\U=IL%UN< \+K+\NIA<)$,'/J*O$?T4\^XPI'[Q@@B(9!D9;/Y6
MX_ HB* 14;4BA8>3>)2<F!_KG82QS W6>QI$5%=&C#'6K/6$F8<.[G<2N=U_
MU")4*LWVF0$/)0I_Z6-(%5N-*[;'!(BH3T23/M&3B)3M*LSCG&V)<;4B?@[>
M3KT)1@V/PO;"W\W.M-=A!D3$5_BC*R[^SG*M8@9L$JXDVN[H<#TD>5+F<I_R
M+)39E Z_TW53Z),S,HL2SV/FE50/P)B&,0ML=\S>J/<#:61&S )A^@2+(@7<
M-NEA%CCKG">AJ/?W:2;XLLEEF&-3D^ZBD@YK%CD'@R+RKQR1$=D )\!$;]U3
M%?1]H60Y #-!9?^\ 1EIZ@+QYXW0CL*>I(;-M)\070$ G8HVN_Y.?7I53+9U
MS%&JJ_;YG44#E+%5U\&2BF9Q&D>IMNTTI5G@K(=V*\^=F@6V>NFUO1.[YH'2
M<50[>1;9H!C%*T(/K=[ITM9F@M)AU;SNB7+S1G-'Y6\<L6P6[/@HA4![&V;1
MA^U4OBQ3PNDLD-U?&FLEP\X#7\.(6M;)N;- ZM"R5BT1>% ,?KA7OZMP9<Y$
MG@5%#B-#=4F"'@6M,;TZF-!J)QF=.JUZE$:CV%!_$C/KL=G<LVCY.I*U1IHN
M/BA"ZX_?"S:\#BU%-+/41\0E)C0.+TBT<^1G<<]/\-B-T\@9:1?[4]D%3MDS
M&QW1'O<X]:I;,"A>\?+5H9\G>8F$F2!SF$=*4YIA)G@\P1OUV\\%-@=M<XBR
M#9(;V[6N",48J)_BJ]6A/L8L4#I6>'.1M3@++ [S3G4I!#(*6K$9L^R>+>M8
MMAQG@_:+14>*IWJ:+ NZ#(ISO +6@/I4IX(S,T'O"*]4JZS-++B#9<R*?;1
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M*!S2RI'*F<>P<P\2!W)RU)0$!92C(QA52(VS9>#(U!N4,&MITB<_UC&<RE3
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MI7J NW/RTC?P:]#_@?B!=R\$Z<'R^;,:ZVQK]U[R.\F ;IYY[44A9:K.1S/
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M\/V !W, !=Q&.57(D6P<-7PV08Z32KD:5IM D4>@@AYI7;=1*U11MS 9.(X
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MDDY+D0QB,6IJHN;A[S+>G;-SQ:(B*FKN U'%%\AAAQ;\*!>F'(.*F(8RW')
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M5 EK8-6X##'5::&3ISBL88$8*,X^(O!TL<H8\&*A$Y]#^R3X&L(S)&=;-1O
MI'E6-YWIZ+=BTK%^G=4FL-],&B-CYTA-+MRVC[1O:9F;!Z%IV9C.,CB+X-"^
MYHNC]/@Q,(OAKG:@.97]=XQ@VRD0G0ZU8^#LXY"3U"Y_NE!C9\%ZG,70BW,7
M1QNZMFU568K\&R_@TN<]\0"<_9V/J<8;+Y*MEWEX8O?.D3*X(V6.=I\5='EQ
MN/!":"OV_$9(]B6)][L@VNC"S:R&#NIT]DG ]T3_46Z%_L=O=V3CA3Q&5D);
M,H@12_N(\]7XG'7@[F@AB.@I!A!33-7A/2N^KJZTI8)VMGR6 4D?D+*+)J7"
MY5JRSO2%+B.5_Z0MR#7H)]P5',I?J"ORFL$RM5M6  ]\?9X)2TJBU^*=)!GT
MN+FD_QED165=]56R'>H,W8"Y\O25KX01?&B.Q;$$A$P1"&S1C&OCF!.Q>\['
MI6AL_3QXW$X4OP?OWG.64.:]"5;+W2Y.LGW$%(6\#HQ(6#Q<QLDN3FH]4&41
M/L=-^?^S]V9;DMM6NO"[^+XE2VK9UK_Z7.183G=61I[,+.ETWW@Q240$+089
MYI!5H:?_ 0X1'#"2 #&0:W5;514 "'S8V-C8XZR2SQL21ML!* 19#M].[U1_
M"_-]&1J)PFWWX?$MH1#2F!&D"Q5G+3\\<XTJB"954-KK%S'Y_9:I7;1[TJZN
MO_.\2#"/BK,X=59"W'A'?.YRXFMEY+#R_57A%X^0+U;U;[<HG?UC N7+S=<8
MGV>1U<6P),E/22XE3S)M',F;LHE!53XTP6>X)322/(M*"?2\]^!_?5#DR$:7
M/<0^>4J,'L:\-"C/26S363GG"RJ)0.#ME]\D[_4_BNCT]C5YVR=%YL7!VU?(
M>TZHQA,8(Y]/&$WRNAKAHRE,'SS$L-&?R5.G=Y"=];9V#&@^2F2Y^(:29P-W
MK&$H%.$.TTIV$( 'H1^0SWU2I&-H<<)HL]#B#Z*T^(-N;MK5#%!X*:;A_)P4
M"V__5VU8X@T,Z'B72;\NV<$($//WG^>0AA^C+HP)H\UR2'\4/:0_JKTPKA,O
M#3;;,R.FW1F#MK+%Q&)79+DT4I@RG+9C7!,!]571;2-Y$RH^4.,"7\]$20+?
MT(2D)53PANT,N?YNP;G\'M<MV&X_ZV58E](E7H?=WY4\)5NV$?B8QM_,S.:&
M[#O2>7!M>-EPWIVN*OJ2=[KSNY*=;C1"K"WNM=-8^R0&FVUUO]Q[?FG@J&&Z
M3M(T^1K&NQOO"'_)3R3%@<@02D GO[IYMX-[!-5*R-[1%]!%XGLJP9O\LN3%
MFWL$0YA>HQ!%A=A+%77 ?* (###G)D%I<N(F#4<P9),^>WDI'%<UQ#DVI=-!
MR2909'K>7> ?0O(*?DURR+DO+XV*I5?_^A+N]O#E5Y$P;N[\G?5)X)&796?-
MXB8MIW7W#14NS@!DKSYHJ1VK7[,?2%+ZJ+%TO]J0%U4UETV19SFD+>0V2);O
MF-TT:Y,NC[O[CZ>0JCCJ-35JXMULO@++Z'4T=%$HV^ZH194=#;.Q\BLL^?O+
M=NT[ F191P?T!<!7>+B+/<2&2_58=76\);6NK'&%Q?KYC1E'?[#<FF)$7N2)
MB+,ZP@SK&>XJ2",B,ZE.ZPNI5\=P>F^'-,EU,%]$U#[=U?Q,B-SNWXL C>4P
M?CF_3#./TWB1/,%;D=03?;6=AH_IS=V('<)^U*Y>L2HCC5J7,LWIVVF*%/$8
M;U_,?'*AJU1I<E8O<TEKHG=Y.[L)W8_;:5AEU5"E^HH[C^#(0*4S#6+<UIW&
M;'+<P1DYEJO](F"D>>EWRC 2'G.+ $E4]]2+*' U'YCPFW5*P,,B,H0I?5PP
MPC(6 ;!T$9 03>+JD9<AL>!"7A9&?/S7"#/+Y(^ND9CPK3(E=&D1B14UW"H_
M+ I@<G!66X0F$W0#TG=NBM&4)%V-I1:K0Y:,APG,#1MKW'DR] ^.>QBHD,5&
MA/8M@C.)BAQ,R[CK"4ZG2AU< 7B+R*RK0>KX<5$ *WO+#@-=%X8G__.,8$-7
MD?/82BXY*4YYOLS1#K))0I3T(C"5SAD)D=X+ Y.?+4JIR?"SJ]Q3]9''Q/>K
M@-1@2I7WH*0D'E@8IF(/2+Q=N8;L+ZZ=;$+BHX8=]M) -"@XJNZ;Y0%(36ZA
M@LR,@U<]MZO",1<&IAB;PVG^:\#^NC0FU\V TJ"P,KFI3*X?K:^"OHS#505W
M>Q1*.+,PF 7M Y.WIX;W;T[#.P-WX$] I )Q$X,ZE7OY$Q(EK10MAZ+Y4SS5
MB/^R4O1$29^>8TH%S"MATQ(R->Z0;LO.ZNFZFY9K&:C.0,@"J<4:S)?BV2M)
MYA!(@+8B/)97C,S"U@"^%,\Q>8"S<[\UV"[%TT2VYV,_#5V#YU),U&KQ[&?'
M:]"5:@)<R .$)U%?@Z]4V\-"\!7(&=C O!15IR09;5QRPP;L&=1$__7] &NX
MFM];#;"_U^L< (\6_9V?'+YO\CQ^GWO?DC@YG*I)7!*V5&<;WO*-%\#%\P?=
M_>>=^ P\U+S\]]?B<( D"\_^>2_@J\V[!;D71A?PD;_E__E3?\I_ZA 0^):#
M. #!GW3EZWR((4S@3$IE;"0(^$N@\O?7EI+T!7R N #W\(C=)'$Y&10&>@/?
MA7#JZ=TW/RJ06'>590#^7_#F?2,L=LQ(VI;=YAW"V\K96=OB$,)Y=E.D*1AD
MUL:WT5\HMIH/8C5U*K<09;$LV4JPB5^0>)$BXHF#IP1*%_5?K[TLY*\:*^4;
M^J$RL@3SS'O>,6@JV.]J?.U%G]<JU?.GX[:PY+$[Q88W1Y"6PG<E.E'RO.-:
M:KYQ(1?Q.2[=5C/9A>R@*(V8UQY"<RQW-?M[$B&ABTX-7/VT@?N<)MLPIY!"
MJX'&(ECG*X8N>&$:FC!I)NWBVYJA$A!^I[45+*->0(M(ER;V2&ICVGN!+ (M
M)4^9-JB\V[$LM$73"T]_=*PYB-<<Q/(?L=R)PA9#=VO^X367KGWB)/8%JR(M
MHH'VSZD"8_L1LJQ,DJID1@%27@$?>VTKVLV%,(WIEQ:?VFL1]#WIZFHKVE1D
MU3.0^,;?6#B%WR)2$4J!#'/3S^ J:I4C3=7GTO AAH?;2P,MKC0$@P/*];/9
MWGW #V,M?X1&DLT>_[?PHG ;GCV.XAW9U$%L.ZOI5$9!V99Q==)PLRZ<K[AI
M:VF,#OJ=&*Y/YS_^/80"2.KO3X_@ T28O1+LK']Q;7XTG"EVT\:-H=$'("I*
MGOD&_'T<_KO G3%&8X,F3]T28G/]A,:1MH!\ALA=)5\TU%K+P[N&UEP?Y/1:
MR7V4":VU35]%5&1OS5(_(9D"-Z4\C&+:D.22!""Z]OS?(95]@//I)A.D0&\I
M&YP!_[M=\O%] ,)J;^$?+EM**OU;SWCPLV0HF\+";R\WC;;@\?&&#!ZUO7X.
M^A ?BSPKA8>?J-YJM![2^25*8 F/T7/S>.LDL\1Q3%H'_2 ;Z7J[^I4:YE<J
M*T*)*/&,'%8;(*\>>IN61[G)3?^Z]^")>,BR LE&Y94+3T:9CQ6[>*$AI-\4
MI=Z%=C6T&TC^>DM]@CFVV";2UW^#EK?Q\P3%PF&3P.,3>.*@&CF6-N+M)5['
M4F>WC63X*])O8N[[A0K91VCD(&J(Z!Z\IX67#E.=C:&B$8/)?Q&V/P(EEP92
MZK.0WF<FV9M0RJLE?O=;R";L<]!X4_[EG"BE2M&&)61F)S6$BR],*$BP H-H
MXW>8K/-8GC=L)_OBJYD4_-#1BT]9*QZ[,;E%I_*!#I_G\2! &W--3AI0#5F)
M4M L7 UB@"3_'WB?;=3VBJBBO7E\VT[HH02[6T'L".VU,0&!^GM8YL#?7PW\
M/PK"CV^O&?Y^$B *TKVFBFB:)@I3&LJ.<OMV!#Y\[M=:.$A+81+@9H-OJ(C@
M>+'Y42DV+V'V^ST4A]J)0'&3P;;3IQ\HH;GA.+,\/21#>HLJPH$X^)\01%@R
MZS900EXWK8QK-1VQWQF\727/^,+;-]N[+ \/2#7W:X+*RD=E0O;A3%E=U&+*
MC: 9M\+@4LWW('W;>_$;.!R3%#Z''Z!X&Z8'<BSGB('4<$W>+5!,LE"R3D_P
MABBUJ[^E4*[>;!O=2)-'$ON2Y^FGF:O>"G-5? ^C9*%^@CENR:C749&<!%EM
M7Z*$_\1Z6(\:0J]/*-T)\.R@37;0<SJ>2):G7Q,:R'*><S5 <)S/'38R@\^A
MS74@Z4YOW4A+DH>9ZQA-KZA#)U)7\>/W\CU?#U2W.A4X&1B(PG#+:U.87!<X
MIV]@7D?9,RF*^-<YC1S).>^,%-U]SFEL)KG)8^\*G//>(B!46N2$X7ZX"(!'
MY\FABCTN"R^FIL Q 1_9'HYMRA-S$G1<+.3/B8/S4'2:L]&<(L^ 8'12RSF3
M8@]6DC) 1;X$$_ :\4 =[P"[B*03JH0X@@?N(C"57^5$W(MX(0EH1FOZ2"H;
M%6E [.:<8[R^%Y%,1?'[E^6<[GB6'XJ7.P)IJ.-J\/AN 5*BK'N%[<2_B),L
M>HM,-PZKR)MD JF.OV9$8C3FRSKEX/5"B159!*[2N>C$6)>%@<[/89G9M*46
MU+6;>](9I=N5AY7*X?1PJD7@JXQADL+ %H8J'T?$OH=JI*36OC:!$<YXM$G1
M?BJ@-9@(91<5YPH_5(&Q02J,L4<=;R6KP9):AWUI9YT06JH"V@6=]7ZLZ\+@
M'.MC/'8;:GC_ZC2\L]S\>..DV\!*E^8)(=V+ '.6.PM/I7]S&ECI5(H/KE\$
MEJH5R=0, #7"OSB-L'1J[>4M6 2(,_!2CE0,C=^,F_Z7R@B6F3AB&;C.2<-]
MBEU]ZB1IJJ@Y.9:!]AQR+8F.E^)J(HGS\N4_60:X\TBZA*PL#<1+,>2KU2+V
ML\0L ]U9M%[<&6X:S&<PQ-I>W>_@[>!&O.LH[S>J3L-:Q,ZA(G9&E=^RKLX)
M.3O\6B]LK1<V1[VPR4#=@O?\,ATB.V,VEWR$[L,TRZ_@-P+T'?+9P;9;BYCU
M89JQB!F371?(C +EV?Q$D0JPS6:=Z LX]@-;^I,B7OS\?1>>>UF>*.-*B;:U
MXME:\4Q?Q;/Z+4JY2+HM9)<YC>'2FT]D+;7"'EY:(*54..7JZ%R!I<GT:DS1
M'SMJ0KE2V+0KQ5/>=9B&DB&]\OVT9&N5;TVM30Q+U<\]? ?C4&7V45,X0+"X
M#*&]MDV'0JEW*M^<FRW:5\*6#YJI 1-MVJ1<Z=PC&'+*&F,;EIUQ=5%TV?.7
M(J-V, 3FMI->*2$&S*)5 @,8LLA[SP<"=-1JKFT!SS53>4NN_'\780HP1A/"
M8KBZJBPW!QDA_*H/^^++\)+:FE8QQJ R;I*62#+\?B)K,#DZ&K4H@648$(*^
MUKTP//&!<VBMA0?6P@,FT"&O0>U,A7@3E],Y?-?J JS4SV3C6,/A!>Q2KA\U
M$Z*3W"3&M8S 6D; +D=@_64$C#F\HD4$>D8_Y[$1]NRXE(GBLT\ZC:"*)%3.
M%1O0GXC3[2 SC>F,EP*LB,X)]VIQ-1O^3"G<>4J8N1V11W92:'- LKK%W:3N
M:WY[]1<"VR]E$8=059$4Y[+7SYG&@9Z*T.TP5Q6Z@Z%GE HH330"Z2I>X5SZ
M]3F//[?KW,*28<MC"'3/O87!*G;QXZ3V-=7XA$//<--<<XU+.>-TM]&%@:PI
M*_%2DCZKHN&V5_ *Z4A(^?R4560H-NE&4UNWI>-/O8@\NF84RY":!-;HY^Q<
M"<8^M=6KCB<HG;T(Q!R),JU*'M9Z CS#K0FS+$E/Z#'P$+^>X@"$R7689'X(
MX.YD:SZQ-9_8FD_,OCCI-7/7FKG+YLQ=Y4V4#$HR;V+ '6@L.L2"TF>L"9-T
MY7I<,SRM&9X&;/2SEZ.7R^FV+ G$P7<['21SWD]PS"=0I,T3@,Q@"2U5W 3A
MD(_?AQ^"=X'0(/*3N>(?70-'46J&5[$Q#"'OME7D;KL%?@Y1GY!/ S>&&J)K
M/829M#5L*WE.#$FF2Q+DZ8X91E%:C)9 4\77W(+,3\,C)J\=?S]M!Y<CS^SX
MP0PYRO.GC)F\+:_ 3^) ZN;@AUR3XLC>NK=]F,K=.>R(+B5JF6=C[I,BS?=2
M=P8_I%%;HSLQT/1M"[>R=PTWHJ&;5I7Q&;%I94=MFX;^\8RPU%<"=63] ;9K
M$BC]7ED4/TQWL5IS&FG.:22L_%]$J+R^*'"W<5VSTZS9:53>N*H<=;M6 Z>/
MJF N&I()PWF,9(G,8PTO:W*+L0E5G<U=PRWTB5O(%D9M<P0M8<US*G VR.];
M\'(AFP871H\S!WL[FP*(FT..,@ O(K_(FN1'6R@6W8:_".I;L]OHEPE)&=#7
M-#;2HX&7 JFF^'6W$X(H./H$!Y]%P*D]=MUM>!50*]ZG:6&I068*_74;3@7$
M2?#K6M. J _[=QM<%;2*=693D5+%.#3G)]7*=VX1X"H@5;H+WWRI:ZQ*4U'U
MN31\B)^\.(G"#[#FI%AS4JPY*>R*>R:[09-K:'9FQ6R^9LI8,V4H!8I:QP^[
M;EH/_2S-E=0-:R8$FS,AB%7<PQ\SD2%DAS+7,BGYSNJUT!<ERL^WI#(L4H0]
MNU36$$MV)W61ZD<O/F5EXM$*D.RF2-%;,CJ55QJ\T.(Z+6DCF6"I8=* BE;7
MG@3?] D]-$?^<64QQ5(\?W^C@ANIJV$'"UOJG;P&]"ER0G8.+7Y=1%NK1WZ1
MJL#)($_8-0+2\A"^M=3\&LRW!O/987#37VK>H)M', :C_^I>%FN3[&;L;.B9
MZMN6>LTN)0IHK9RN_5VWAE?IBGP9HQ-<0V+F\*)?2I""BL):&$WPBNILY;6D
M>M0;).*[X05. M0JUSI*!:C'4QRDGCD>=JNOEBDU*D;GC#:FIDQ%V]PU VC-
M]?N/K-X[6EG,ZKW#"!;F..GJLL-71Y=UM'6?92OKPME3VD/R4HTJTM/]T@6L
M9RCAA<5A$S^G(60:1R_:Q+=@ZQ41UI]JS# N.< L-RWYY$6]@&,5)[[9(KDH
M>P$^"#^0H'P/GQ0O($+W]K.7HGD3EB<TA/Z%9LA EZ3Y&WQDH8/#6M6@O4;7
MS_H45[?MILBSW(N#TAKRF'AQ]G<0!0_Q,YSL%HI<"=$M5' 8TQ0.JZN4Q/!'
MZFMJ60;9U==D]34Q6C_*S.GDYD$5]"KIOAJ=1F:JG8Y2%\19=Q)',_$Z0Y/2
M;,?.ND*L:5+UGW%LU8:E.(-(\E88I?U:71A4&-?=SO^G.=&2V_GK5( KII5<
M1.HUI3 /=:*+R!&F).VJL))V31S&F3CL&GA^$IOCU+2F#5O3AJVN:$M/&[9Z
M<AEQ0E=/KA'AJ-C%Z\S#5%WQ9!;0^5T;R#>1EV4U1%276$Q#S7GOKH7SWN%[
MN)U&:CK89];0H@"*:R"Y_9J+R2I7M#47DP-&@]7!:,W%I(JX5B>CU<G(: 6F
M_H0VQNB)!1V/NH\7IY%AOX2&^<P(3X]%X*0M'\CJQK6FKIG';XORY'7=(8OY
MVF_CA&.9JT?6/$DYEN*@Y4*VGF50+\$?:P;W-JN< 5Y0<6 _C,)R'HU$5(_Q
MUAVCWJ/,'$<!9\R)(L&*M6?1?9(V\A2\],[4OCF"%.Y!O+M"WO$A);QTQ$!F
M+;IU-?7F>A)9,FT8C2&IB0] D"&WO-:LWU(/>3Q==HFT4-[NDLU-J&0K<M'<
MQ)M\#]).1>RAG8G26O*\FMW.6ARN_":&S>%F*M1?=A42D"/5$6+AK6FT/OC9
MBZ$L%ER?'EZ?[XLXP"U ?!#)JX 7#9+/PVWHUU=-G0L2.>P-;>9\?;0=SYI>
MX;5,LM*U6VB;)INZ:2T-$Q$Y%?QC[L=EJ<JF $F]<Y>EQN&%D?LFE_J6_J6"
M+P8[I&"W$4"F0*'B26>QA7.$H+.L("4>_$8(6\L*1N(!D2WK+2NRB/.FZ B5
MRXH3XD2(QL36,)^N9N_JPPLCI)G>)FD&6=I%TK!2?W<QVIX7!J6HU\["!FKA
MOC.HT!C:7FW]R:' P<L$KPZ(B?X!@ILDRZ^]C.CZ*CS,6B%^K1"O%*C/20Q.
MG[WT=Y CT0D?D<1HK#\BQG8#0H\/]+@$+?:.IZ>I7-/WBT-1AK=_2N%[\I)1
M +TPK]$E"1?P;1PKY1S;.FC0PUL5--VQC8&F+26U%\*Y>F)W0T_[510E7Y%1
M%_[]!@K'84Y)MSMJ*#,>&J.DQ_;+0UPF4Z)33G(O,NH!YU(E9..>QZH+-)+D
ML46 *ZI[X!*;7(^+$) =14JL.HN7ZGN'5ZI=A&5N)'$*[M$BH-1&M[TGQT),
MHM+A)C]C%I'F<3*>XUY-<U:HM,H6@=F/@56B;A]<Y><A-O'5"_H]A6)O^:JZ
M!?F/!I@MUOQDR\E/=O[CWT.00@ZT/SV"#Q#1[!-\G?4OKGU"AS.EVB/$QM"V
MU,LA0>]CRIYA&AHRZ1LHJ^S@7?)'R>&H%A..CI*=>J_2@Y=[SWL/_M<'11[Z
M7I0]Q#XYSQ2CQVJ"7$V0:CVB0^\]C*JXL*$"B&'/X^QLZ.)&+<J4ZI+&%$E^
M^YJ\[9,B\^+@[2O\TND^_"A+>U'R:S+[Z)<%KK(,E/)[BQP:B7P3GZ5PV. I
M@8_UME ^>$B19 4IWY"?*;6IS_9:O,,''.19.0@0->$4Q+C=%1UBYD2D!2J:
M Y_,^8GRQL VFW6B+^#8SP[1GQ3Q&<'?5_]!>XB/19Z5SX ?J-(<K<<B/7@(
M)[B?SAPQ&*YIBO;6E_.R74$ R5;4BY#46E]2UPM_1%.BD@R^K3G(TS*-8MOJ
M<VPI+UMQ&9?=S[PEB2[%@&O =B="&4(=5YK_R>-KS_L^5RV A2>J;VDB[U/P
M[P+$OK@.L]_3J&5E9VKG$QQI7;4M[%<O#=&Y;&IYEG1T@H_AYS0\>.GI&L1@
M&_HA_"-UE>+CZ-_+ZQ..U/A,"<2>DL7IA^R(A-['(UEF[C>1+=#'><F]]R#U
MCJ6*./M[$J%@:;IJF:N?:FW07;C;YZ+JH$$GA4H.$(=).E:]0>^L_X"UGLH_
M"C^N?]3-)VZ2PR&)V>4CANV,2?1/G3>AL7ZR:5^4;2E2_)K%]);-GV/?2P./
MPIT[#4QY]7-P&Y&>^FFFQ3A^$F8U/ZFAC<JXBG00J" BRPC;:R?[9JQ'OZC6
M*!<BJ:TAQB>*A(9I*/O '[Q=&%^](_F <NJ'K>0+$2C;#UQE2<TO2&;)FD=Y
M/^$>3P]MF_N;EZ8>@1[Q;61GHTO##_B&?HX\O[PVGI,L+/.:7L5!B_LQQ,@1
MHTB_BV[053,T;R9%VIL![;X2'<00KG!F[%RLX=):Z_2I1"]!Y4ZGE'OPGA;P
M18XUB(M2S(C!I)_C=MV%FF503RREO1K$-WZ>P-&E "X^EA+YYA]%--SS-]@1
M\$H^W"/(+L9WB@,0)H-/;V+^O1 >0S;->VE>YX$_&]L?(35_06GAPP2;?)39
M1PF=?$8NJ-AKA9=.N$>8B4Z$#JWX(!K]U@YA#H*&3)#<F(;O!?RG&^\8YBAH
M GM?L?O-25@0UXF$-1Q!\OP?(4VD'C<)T9I+GMEO8;Z'W_KJ12A/YN4AB)L6
ML:V2W;XJ=D663]IN_B'TE^5:"U\JJ1O"$4:"K1S"%Z.QB(!]<C!'&SF>Z FG
MX1I11Y05QN$T7IP1(&LJDTGHBL5==')^,H(:%I%GAQ4,<3[*[/"$19";DKB&
M=MUEL: !IS%GA1DTTJ" A[_3>(V4\2A"(BZF8!$0K@FR9I.W:7'(9\8H$HNQ
M" P9H1N=\J7X,(EEPD22O(EXNJY*X [GZ&0%(@=,+(*L1%/\20QJ<)4>>8(<
M&H&/%ENP+/J3%20CM8*]<[0Y(B2$J7,=A%PX3;A\$4%MT$:$<SB-X(B8#Q8-
M#DC7:0!'Y0(X/T &T2O.8R6HZN<+KEE$CM/Q.M5AD,\B )M/J<H(4EH6VC+5
M@S\NBF!5JP<Q 5N+P%5,,\B*%5L$9,J>@N3'N I<77WFX:+^G*;+$:)C+_)0
M:FIVT^!1+O((A4DN"VJ9\LY/BZ)65?(.);AT$;B.L(22PU\7@1@Y?K9?90'_
M F] ^LY]);5,@5!(^ZB"$$U >(QH@XFQ7D2A%.4J'6K(N J(2?52'+R6"?'L
MBR#<$5?RF*C[16"I]"K"20(J4+7UYA%/H:"BRI23-$E]>!-S.2B!U[1X M57
M$L:#<:57&>(\-8Y0!=)V\]4Q"4=J%']>Z74*?^5P6%T$T$IU<O0$-(O 5RGC
MQ84<JT#5;B8[(L=0#>)?5M*<PF-Y@VH7@?8,Q@_^S%,J$#=0LZ56ZB4%Y*L
MUU(.+)Y1K ;OKT[S K5J;78*M$6 / /#Y4_AI@+QI3!<<@"_"E0=X[1L(?=O
M3G.!&81<9G+ 10"MC]UB,MTM G&ETBTAY%T%L)9R7&JRRAJG7U8"'"W&DE-N
M+@+<&?BI0.K014 ^CY%,SF&9;T/^Z_O!?L!Y_-YJ@/V]AF"P.8C^OO.3P_=-
M0MOO<^];$B>'4S6)BX*PXL<(J"3>P;FU> ""#^N0?14$8;7XAWB;("J'?[D%
MN1=&%PX3YFA._0G_J4-BX%L.H$0=_$E[)1_-I5@)R8?/W]IL*X+>I"UZ;IC7
M-<B_ A"7-F!L];8QPQC&+!C)6\:C-5]LN+8C7C^1PC] < ] ]NR%P25W".9'
M<TXRHV[M<YH$A9]OTNKJQA7F)C:;M<!N/8.+E$&IKTMN.^N47\$.\?I/(-FE
MWG&/L@$3ITQN*V7*&?"_VR4?W_M(/96>JEG7?[E,NOZ'?WYY[<VP]8.VX@8O
MR<F+<GHQVVZ;>3<;'FO0WT+":2*WU8<NB+Q:.W0JV3R\'9!/[_6I_0NE@)O
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MH""4D8VRZV".5!EU[44C&.?"<>6-AN?,M.!VS(;HQ2*B>5L$@..NE=$LPO7
M#BGTR*=;75C PACRY-L-5X,7L :XCE#8NRI^_,[9.U?*N:0JY!<17##V'<>K
M]E?BXFU:W60E,@M1%2G5O?27"M(8[-"'3 "58+%KV%S/F-'X0LIE=-8?4ZFF
M%Z==<EGDUC78-(ZC*[F-O5Q95";')]<\MJ9.<<J\*>2XZW8A?5O$'5R:<6H4
M?UE/_,0+IHWF#RL#'<E .RBZK<J2]3C!VS ;#.7J6[!\45LTP[47>;$/7O<
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MS](D]3@X>!6YH/P73B:U\D@35?^C4E&M6VGL4T$XU=7*JW4\&U3= .O)M,>
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M"LH*FA9:K\RW^AZ\*%8HER:FL1H2OY!IE1GF&3+&. ^1O\(I*9"2W!_.=,0
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M,D(KN;KJRSS"F!TU:)NSLR%Q>X/3:U<6DGO/!P(92%K-U^0="TK>84Y%0$*
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M8U^M!H9<&!C?1JY[ ]=/ >VT'Q=G-4<)X%O2NX-+68-=56G"B(K7-W3V@_\
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MNO;HDI6OH]%Q'921FJ$V-7%J6YQ'DJ69:6.F[CIQ'F9Q[5$'>%%Z=QU/FC&
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MHKO3Q&N2 "FSH>@H5NWY="Y &M%H& 1)8-*0II%__<+L+.4VA"M,J\@6L6/
M',UH.AB)A92A3:.+F[+&^4-\%T/Y!02C9#["&$;3@-"Z)PQHVG[#?[A)01#F
M7"$-'-V-WF7>U8X;R]R];3*NC-W<<W]+=I>QWI&#2<[#BIE%5Y8 95#\V]?D
M/MSFIUN ,@Z@YP9.0I<QHB'KPTNC4H8T[80VET1CJ8(-JOA^E/&G>EM&4?+5
MB_V15S#/P$:?Z>D(R?Z*:33TE"!E/*+S]PC0\]J+C& T50BL>?1PDKDA]:!F
M#_&7.(4_[&*4LP*VJO6DV-SO8X=2S]\)!XL\)S%>/WIXT\YLI1@+_E5D.2[#
MOVAOH\\JYUI'#678PG%&(:'E8@?03[RR/?0UN!1(MAFW_0M$[:U273_-+5DK
MWS*+=3J28])<?9RY_;I&;>!"//,-X#)GB4JJS^A2V8P4P_(BW-$UDS[)C+T(
M?TDM5RW9>KH(S VC]S[;E^O-:AKX^ID^D_K7#9#.<=AV^D5D=-5/_-P;(34-
MZL(V0M!!0T5"T84A/L5/I(;_KRO\:N'GD:CJO?C;NA>RF0_&?Z8&^Y=5S:"8
M],G8_["JDI72^L6;J %\5:K-1^U#].4H%I:&OA2?LV8+UM?MS!LP4.NO;UQE
M3RLN7[-F']8G[CP/+J%-65_!T@\'WN6N 7Q]]ZH]!73TUY?NR-MXM%-F@[R<
M9^\"D9?J/-H8'!?BOC,GVQ]Z;S9@N^W.H)_EDY%WV["N WF\XVZ#]PR9H9S%
MF^A#W( K]QUK;-JM)Y"W_O;LA8&5J;?.:[@J\GVY:>VJVB2/\&YC_?[LY_G<
M)@<O9(8\]YL;%G705YRVZKN.BGM%_?7O$3HBUZ>'. @_PJ#PHG\4:9@%H5\?
MC&Z=3=+.\0VB?[$51X \@K6@2T.#)LV;(&O805^=C:2JFW>#U-KIJ5O4ME]/
M ]M6V]0[GF=M@J8N@M5+VW)J8R;/1F";&B9$8>]%K$ TN(1<3PDO?'O18>N4
MO7<6M''W(1:YUB6C)-S)V(<-\:(2-TJ7U+D8FB/(R9T<Z_B+=!'Q='(8&N?!
M5A%$9"O1,46@A=1+$,$,+V?-%ZIC@A*F94-&?RGU+S_9I8"Y:=5O&)C$T9$(
MO7?(>_(0B)1@Y1W)B"JTP\E.6:CVI0VF5.M;XQTJM'WCI>EIFZ1?O30@J3M$
M1M"O-K [L3:!F"8?.YFGC9"O!_^U6P YGE\K\N/@ZI"D>?A'^=<?>DL8.XHY
M1^OL5=HY%(QL@:*CF+#<UM8\Q!^ GGJ'W<^$)578MR9(5I>R>JD[6-7GD+^"
M%R%O!<2 0;:)+V .9SUNC%F8 _IDC#(:W'MABASNP,4@S<\<J*-H)ZWS-=.:
M,8.NL%U4$U7S#R_)R8ORT^8]"G>5;Q@G15$'T+X-731+YP<A=E7U,&$9YTNB
M^;?:](TNB!0>870_^GX*G_I9\T\"-X_ H.: P;F=[<;F3/X3BCGDG7S5V)S)
M<Z=)-3KUZ6!R G<_@;MIKKTH^'8GU1ZFO(47H8(5T@O@:H-RO;H7 :5@=KA1
MQ+P((,55!&>OZ#%/](6DDU3+/&G4ZK:CLSP.RE*N+!E.3NKDT. L)*VCI./.
MU!\MHT:UZ!D?J=9:1.(_Z=<[7<DF%=/%G'>\4D]J:KXNEF^.GGFZUG$1N0Y5
M7.FU0DPA05J X#@94T2KNHA\D!)U(!VJ=#NSA3S4:OVPD@2,UM\J0HIIJ4D4
ME\ .VY>PW"00Q@927@5!6*WI(=XFZ:'\BHY82E:=+Y#A0O'P;?1[9=D8SWE=
M9&$,LNS*_W<19B55E'], : &=K+[R:Z4!HDP"[,W>+MZ1U#DH9_]/8F",-ZA
MD&ILS!-_/X-H9]YP6O8!?"3$B9+;Z00S!5X&;D'UWTO"JTYR>1*R''WUTXG=
MGI\XKD'FE:36VJ:/U<Y3%D!N;]82GKP#G=NS>JTQR.)3;XPZU#GW&DEF\X_>
M/Y(H\I[W'I0!_?)R]"(D67LQ'DK>7MI %?;[-]'-W['H= $WD:<D?RW>_P7\
M_"VY^W8,JYPYTT,V".,:2*:7V=V6-1$$B;;7W:QKIDF +'!75CW,6@;7%O'T
MU"]-WGWS#F%<SN@9Q%Y4*N)C*/+F +[[\U(9# *6A,DYBE[%$56QL&9)$- $
M7/)/<CW)%U*VU-3L)<88#9B*A1Y&/$]YIP$3="HE,+@ELBW"P>/@<*ZCQ=1@
MM/%BZ@J6=?S63"[BI#74++7AZJM G,:)6P"EG%'7$]B(RZ \*BRGG::%Q"J.
M !TW41K#S+5D2#(&,6YV113 5'@RF\"LA$Z<!.6GTQ[A3#*CH.VTYZPDOMY7
M5JZ8<:FHG79ZG0X3@:K<]'8555R)J=;GJSEN@N?A:W$X>.EILV75);*[LH/=
M7CK$BEW8)9!:FS;]1I6,0AN*"%V6]_!X/Z-#]PS@_Z*VSTDEP JN56QHTX!I
M=.T*@!$;VK G(E\.!U9Y.S>567+!$CR:3K^[Y2(K>+87D,KX%>Q04/ +.*(,
M(/'NU=^#H(C 9MM+.IZ\[5%-LRR)P@!%OYRK3YDCFF1IWN+[\&\7G@__\L_G
M-$'E3C?I*T@_0A]@/%6)S>1>4GP31?)Q/8<,ZXY*;SOKE&LR^@227>H=]TCK
M3)PRN:V4*6? _VZ7?'SO5T:G:M;U7RZ3KO_AGU]>>S-L_3 K@I>S!4],^9XB
M DALJM^!K][;C.J:26JM;?J/\-C$&:!.NMMFWL.%-._](T/@7N2V^OQW>U<,
MXPU(;*[1-;U31!7>C!\@+@ 2'1H*?DO:=R.M8-[(P30Z1P90=(K#'#R&'\C?
M*/?B'2H97NGO/WO_2M*;R,LR9M3$F)$T+AO>K/ R/2>;@A?L+=RJ*#FB/:*R
M"KZ^FMU=SXP"V?,8D4>T'J8M@R-@D-1'\WU/X.B$AI)C7]H9 #=;6OX@_-T^
M<A!C+J6:#9^Y<[Q#4 ]TVXR[BC6*QBOL?,N@*LSH/OTMS/<W<#O@@4COOOE1
M@3R5$2N&_X?>P<3[2WPD4R^OZ]/ETJ&R/[%1M"WW*8F_T$7O=@O9$>GP39_&
M7M0\0RDQZ/B6&@NP9/EF^RE)@O8S^C6)2*$>E [2(\\KJ.K,1!10"2TU@UIS
M"RJ.31N-=T&$6#7<RL]>^CM C+Q&D<CVB1VT+>(3B.&K.D(YJX(#9%;HT80*
M"=)7PNJE/1RX*SK3%T/OHVTI?:FH>WL0UL+HI%GJ1GXU2 *X^W<1YJ?/(-\G
M ;LH$%]?R1ST$Y3LT2<W<9F*C#Q+5FN-D-<^$I"L44%/$-=1/V<]&A%O9D?M
MBZ*?Z'XKC4';?OL9ALADDR)"H0;QLGKINRS@3+(FXRX4QR I%&&V1X2.\H>]
MDQ;$[J=/!8W.*Q1ODX:V*U*GTQ>CDPD1R>5,:OLERVNFUUK;])_3!'[_D5SC
MIM5 KWF991=$-F6&2<[5&#DNLQ["IVU*<SRZF<=0AW5$[MO%G/:&X;)AMV'J
MV=^<!X=IT&O8#N7\N<IV>*V&W<#)<08ZUS&<8+OK.G%SV<*</K9R;,$]<:(G
M<KA/CDS#XS!V@&C@<Q4MMG&PH2*R).(J-D*VWW.XW C;YB)XV4@;:/?F'6%7
M7 2X(TV/708XXOIV]>AS/T>QQE"G?>2YWUM4.ZW3$,D5WRCO-]=3DDBX,VCF
M=A7P&:8_XC^I).._TQD0Y)W4T3>QJYDZI)_ALW?'2I&"%$EY"*M(2>$8]=$<
M=IS.Z"%7C"%I&51D^W", IG>5DYG3)'/$86W1$6*%<=HE.%"YW22&HDPLMSW
MYLM88S>.G)Z#"RG8. %0IENCU.J-3D(HXEI9H_G+BB8OFOTKY@>W-?T2D&.Z
MES9(RE&,]>K,.P@HAX-K ZD<I873!YOE6]M Z7K1>6E2$,:SM\'0[1>C! 3;
MSL4-:'(?,685JAXXPIE2K7I-#/)4((/,9CMP\R6L@-Q>^Q(J5)%ZAG,-F [&
M!//?),'A(0Z01%]XT1LZ#%#";Q*[;=)/:5(<-^E-<CB$>0X \I] 9O$X0P_[
MN[@X &JI177?,PK""Z?]##S$BOZ>?/V2@> 69'X:'@4!XAG-S$N*YGI,80&N
M>N),@0G'9I;F,D'#22$G6YI56Q1F+FXWBW&64]2LO1JZ@F9/M!LK?IYMTVWK
MS?D?,Z0'1^\82(NHN% *]HCB/NK4YC_HDRC/)G56XIYA0[WUK=%<:&GC>HWT
M9WILG)(80CNYO>YT'^,29G!VUI$O=DUL:^J4_PE9M5=$6E-84OWT&8>8M[>I
MRW,UO=E+<O*B_$3-^-5MHVVJ=UX:HTK8SR!]W7O,0B#$YL8LX-K+0I]S]E5;
M;5/_#82[/93?KC[@G;4#S5NLG%JV*?(L]^* K7\3'L;X!=/V4&R,-4^6&VGX
M9*0^03( E25WVQC#T6[#J,@!"6Q2:],.>3VOP3D5.^;$4<QY>/$^N'0?Z#E2
M0!)RO]5Y12!S*"W8]5?(.32I[?7O_,6#CK7WK99*\T37U:@',34X<#E[+K8(
MA,!4/Z5P9RM])6&B[19KKL@U5^2:*W)&?NU>)L+F'"*52!@7<'HU621Q=@VV
M2:>HZ=TW^/Q+4B@N>>FIU*W#=?E(F9*4NM-FH[A.OMPOK@D=M21TO%BJL+;
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M$$L(A7S_\*DXSI<.YZ/64C FB3.CWL>6>K*-EUIX'N F@Z)-9F%R+Y-1D\>
M!HH12Y<M\^4T5D%CJ0NC%"Y-5NA8ZD8G^>Z2I"6RU-5+"IC".B3KG BJ).N(
M$(8%RU!BZ*8FW&?@H>95CKE)7@63%7OG.=7$W"'B>I[!)GY!CB%IY?GTE,1I
M\]=KI'(9['I/[2?W&]ITH#*6@7-XD#_^O*8/LEP_U0#".[)V _CJ9J#RX&&I
MX/24Y,]I>/#2TS6((7N'Q)/B;9;CQY%\D*X08??>>G0O&T8/90>]R7L:U@>Q
M<[.]=6^V:R\Z!YASGO;IPR_7"TK@X*!B:)=:Y%<?7AAY5?@ERG?,9<$4&L+^
MJYD%AX(/66?D5"HZMA\,$@4N2Q6PRJ&6*M\9#?+B#85,3:VR=X[E)F89NMH)
MHJREV$P6WB_U9AA2LZ4:[[EYNP21WG*DIY.B/A^C&>P(L\EU8L\22^T/]DG)
M-FO>$4EIUJ2C*3S$&7R#88M&8M[5N-9:=067"='TU+B6!OAQ=Z<E$'1![&C(
M7E"BDC -#9GTDW>@QR$1F\L.._J:O.V3(O/BX.TK_-()!>P#>.DCYD@,.6)V
MLAUF_?%W\.'T@;),0/9QYMZL0TOO(YERGN%S&6+VXW<__[GW73+A,/MHC-BI
MA-ZJBAE*Z]-(P551P,M=RAG1,W(XU<?[/OP0/MW]/@;<9I^]O):/-]OF@<9]
M3(2'4;TI=RCUA.BN##I9JREGB(;]M]% #+-<!22P?!YQSF0TN)6L%'&;3 Y6
M*TMY!9B+;SU;<C,:"JYH%+*H3R:#-F:6($"+/YD&@=J(DQFUDP)<DB$Z.P4$
MA4&P!73+-;$")#%>O'<*(Y'K9/!2L%S3/$K,XGUG.(6-")4,GRX6*L<S/PV/
ME=FO+C*>Q,A2\%H<D.%KLWT-=W&9XA=>P+Z?%#&JI_V<1*&/S-GX_K<@]\)(
M=D(\OBF1U.NCAI#M1<GU>7+J.X'N.I5WZ.JM**%,.'EZ@Y^CJ*II/<Q9!IH2
M59]*Z^'&,A1IAAE.ZL]I$A1^ODE?0?H1^CA*(C;3,=&2>U9S(#O3D]O*3N,%
M;^XK'_&':\B4?[S:)7&8Y2\@^O#2ZQ0DE%1>?#VUD3:BR\WV*DV]N$I&2V$Q
M^+;:IMZ:2%89W;W+O[S!/V6>7UZDU* %T5&6M5Q5R0H?O7?O!@7FOR<5CZ0E
MP\,WG94K(8D6"?/_2M*;(LOA$S E<B5R6\D@-J-O8D"&;]C(G&OT&KF$^7LH
MCOTN)METNQFTH&9>8L)!OYMK"])O#(<7+G(@+FNOM+G<]:G]"X4(!08P8I'4
M_<(TU$=R-7\:T!#U&F/UFO5R>$'W)W:Z_5]GG=;G, X/Q8$XL>[O^FSR7H2J
M'7R N !/ ._[06\K^5K]]/K?Y.OT\J/V&.,U*%KZB6G+;"1\,8WL$T7U*"%*
M5DB ]?*;F;Q;OPQ3!91\!OD^"2ZQ))NO,23#?7BLK77>CN17S-]?31)T9KYS
M->P<KX&YBI-46&W3[J3H+??VE3*K8:.9V>,WND#1^5V?2BOU E!K]*&PX(/P
M RGSJ8(%O8]L X:7AEGFW7C',/>B2QTH6O9]9A_9]'C1N'R EM+H)3EY47YZ
M@5?U+3*N@> 1BF/1)L;:6D:,HHUL:F4RE4RZ;52Q .2&Q<$$6LUFVOS7(_#+
MS&RE'%YNV7V2W@*4B@L^)N)=:U]%R$%H7+V$#EFO!$)'H\RTCJLX+KRHFD>9
M-^]RSV^V\ U50@[1ODD.[V'<E* MS2HB"YWR&<E(/!7H3&RV9QD=MXYA(T6S
MZ#X7:%/IM31'"7C9RA]X%8#M+K()O;H"4:K(>P">O3"XR_+P@-Z.7S*P+:+'
M<(OG/EP=)<^6H#=$=1Z3^#5/_-\Q GA7J8A;BXQA):_T%O@I\#+PED YJC@4
MY9=NRX#O'+<$:GOINX X#<I^F5P%05AY$R$*>(AKJL"#S.PENPQ3W&#2<K@L
MG:-P\Z.T5C2OAQAN$$A3E'CU6Q4/39L8KKEU0293O*8N:2)$?)8L\3FG>-US
MN"_U_*W)_C66H$'SP)<'AR7U'YC)H&CN2$TZ(XHGD-&+I^<S8OHW74H7<#H=
M&0T&%[N@.B&U3X:P#XPEV-"8ARIP+&$E;-_SD8Y1K1(A!%\D2W'A,A*=5X]Q
M(C)ZW6/E#ZRG$?76'?B^6(*+H"0R&1A+& D7X8C[";61PCG@&(T)F[ERN+YW
M:(7ES6,I' 13<2.J]EQM+%VDJ!=@)^(-[\5C.1)DC[KS_=GR%C)ZL8O/S\M&
M@.S^TZR=(E99LG12#=,):W?A_L=Z)S4K[S!^2]9(VF>>15JRH8QR6A-4MB,\
MKBQ%2K :8L^3R^1%<Q;.%(\E;A,(03=C:8(0&>K)CE^=Q3B(*U!:GGL6KYOV
MR.FZ_UFZR"F/'(9GH>6(<#QVV)Z+EF(@Q<@[QF?29+QFN4)%-&Z6IE+BOE<)
MKJ@6+WO$-=KV?K5TY4JYB9@3KLD(*N4O9"\#2U-MZ;BB2F]GD_%23D(M?8G-
MM<55T<TD[W*3 9U%]J'ZA:E YV=+R WCPF\R'+J(I6>Z5P'17RRCF'ZXA<F8
M*+^\YBT(^5?S284OQ,5D<)33#,X0J *0OYE/+2+A1BH@^L42B*3$."E1A%E@
M:^2(G5("C2U*59[0+24 V:(GHL6,*0'&%ET'-6AM<4G&X;,;=BH+$B.WAB-Z
MO4_,,"XCY4(YI^<(3;DUL<&F#O,PL#H:4&.,.$M:]4_N[CH39>#GQ<Q1SM/3
MO&4QDWWS]'1S6?J38A$G>?6>P?>=WP\]Y^]GWI*(Z0U$>LI/Y(RTPDEZ.G_L
MODCA=0BO+#B#^_ ;^A.E+*'8 &;FAEM.7D^M"?Y(Z;22;?[5*ZD%/CF/10[2
M,RE1$FJQ>]F57,WL+ KB(A^^GA)+IC+9)94O!$U O.KYC+#O>4O0H44PJH/'
M>K?W:6>,0Y)R%9>^K,@%BVKMKPG X(,]QPA^EB+D4-SG N*?N*M#B^IHN!B"
M:N>-&5W!QS $'C'<4EC<"8Q0>D)&^<LYI&(GN;+K5K,3YL52LC.[&:!BYXL>
MX-.WBXQE1(V?M9"1Q$)&%N=JMRO'K!UZ*EZ>B==2";$EDR7J-6N26Z&4&E]:
M(ZYJD^($-5$/B_?,[8!GD+C^!/*'&+8$<$VO>_CRO/:RT(?2^FT8%<CC^:A=
M\K[S4A21ES4SK&?&DKR9W0R0O ESO#Y55'<3>5G&)W?SCR2[1$-#0(])=OXZ
MP6^ HX.^PF ] ,MSP$E:55MM4[\%[Q!2"&"![CX4+4R5]XG-)5/&V]?D;9\4
MF1<';U_AETYE5'+I5$D6^]F=#(&9\CK$-)1>)@+R<A0*F*2THX9KI@V^WT"X
MVT.6=/4!4GAS-K%&Y0'*-D6>Y7#/42(<RL$3&T-^,1J0LB ?-M(&>(?17GW
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M+6^=F0]E':*B"5Y$KR3*&#3S+@J;\=/.P?]U4982'VUR'[KL+0EF@-%%.:\
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M&2&F;Z,@B,QRU.F_?/QPM4NU10'ZVH%PE_*! V3)!=U=JN-U>1H[]N]2Y6U
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MLP["%>MZK.V7 #2,XC.6"'KDE"+@!!=:CA>U#+WZ,BCH&* 1="G)JJL2J4R
M*&3$V%KH?0'"F&YE&$376HH)!<5Z0BROI<@1*9/=0%]+@926(3F!PY:#KBA:
M\<.0+<?%K.)4)_;YI JQLH4(V?AJR.B86W08FFH@0[^(,@:[^JQ.AQT_PATR
M5NPM]P^K2-J(I #(2)F;+.0B!LZG?K%"8@5DI,Q9Y[]E\3S]*L[JV2>G7\.9
ME[!R^A6:E3)?3K\4LVS&S!E48IZ<EG,&%9LE<G?.I6:S3);0&91Q%J48G4'A
M9ME$I3,HSJR0YJ0%&S"E3\4,*2V8@26#&NO>:(,P"J1)W<\P)55J6I<6FS L
M\50]/TP+4F#*H[R<,BUH@"602OD6K.^&D'=Y;?=!^.72!^'2!^'2!P%X'P3K
M6P2LO']F29I;.^XP T(?*S<7RK!2\Q1CSI5A46S?CQSO%Y-36L,8J(1>UIN5
M%XG+/U*'VKIQ\Q63&WIX29W0<V(O^7KPL "#1_[TTY^Y$,G-/;M:KG-7!;R*
MXCCZP%A.U$H&4^9! >GT"P<OV9V#45^F$%QK,WE+I!54K96;".1AO_1ZT-6A
MR GP>Y4'S1*DK3>OL1,FF(O@>\9%N,1$<Q(OIN15$$2Y2"11;)H]'@CY6]+C
MX"5[2WS/=^)CBSIXK:Z8XT_Q/I@7 ^&T([.XG8:%!<[M;/[&WG7;E5-X_%J6
MZC0JPBO6FQ8"&1",6.CLB\R?8)<X65GOSG]7%O7Z<\SUW2@N[%/@%,8@?OL-
M^F"X=0N+JYJ;)[W1U0N[BP"YZ637/4^MU'6GS=-]06[][2Y5O2&#24"$[A/M
M>' 2W2@NC1K&@6B^CX'6\JR79@RCO( GT2+C*8Y<A+SD+H[V+=KG\#?>C)E?
M2B)ROT:WA*$2Q:+1E!)B-TCNB302HMQ8\,U/=_3 !-IK.L_"6FN>,Q@139)1
MG7UIQ#?%&D2D71[[:@T \F!0@A>EW@W:/ VTTU8N:HM!CL#7J/<&Y[*&N.?'
MA!4UPS>,#,0?X-]]C1VO(!HUZ)36TWOO"2+7FU;218'OUQU2;M^@L)8YIZ8?
MHO7F.D:>3R)B_" WEKZCT E3$@O+=*<+YP'A&A9V#7DBW*K2XFD!2[??\6_[
MC(:("K.!'-')- <SWW=JNB!=;*AE,%Z%7O[P=%(#6$*UY&S3X"7E[9 'B3H#
M !BJ1T.?<FE[-$[^/*^V1V0W55P3N=<[O&_R;RR=OF%QP!,R;HG)('HZ<6*Z
MZB% B+*M(3MQ?"RBY7*/)A8S>\YO9=.A>,5+FR1KZ^^>=9ND2^\?22H9E:+0
M1@X]?MX2Q/!:/6C!C"6=(,37AY<VT:E;*I>= !D;]E;@,]<I@)WQ<);] L3M
MM%3B_2U'ABCZ_PPZ1M5>&.F(Y(Z$Q@Z!!XV/2W\AN?Y"HDC[3D=&"0JR!"4\
M86QFG%@BAEW:4=G;2N#2C0C4+;ET(Y*JK#4R 0,R=BXMB?0H;R?=D01\_V-C
MO$-%7QODU%B.B7'J&BLYQ_)V)'-6GNME^$#&S-S/B4!\AXR*95X6:HZ4Y6@9
MSU*'65B0F]=<6OHLPD+8QA'(:%C0JP"[E\^EP=$"ET31G0NYJ<^ET]%)-\2R
MH12]_D+)L,K.<[(^SZCUD=EF6#"KRG-34\^E^=%,*;!GT =).8?V7+LBB?-S
MSZA'4CN=]XSZ(DDD")]!:Z194I#/H&G2#*G,Y]E 224I^HQZ*SV(<Z?/J'N2
M8MKU&?154D[F/MNV2@LVR07:7VGAMJ>?8(JQTMGG6G "4\;EIJQKP0,LZ58N
MYUT+(H"*KPMWMOP$2SZ=+3E?"ZY@2JJRF?M:4 )37.WF^VMQ@\.21F>I'Z %
M3S E5(G0 NOZ7A*SD%_XN#$;P&=/O-L(/R$H67F>7^S]/MQ$\3ZWH9;=,(TU
MPWQ 28+0 W)(E$;BQOZAQ!"W*:9HEKD:(]2-\9ID\F;,"T82IRT0\%_-]O$?
M_W@IZF]\1M$V=@X[WW4":ML-_MB9ZPQ=93$>M'7VF'<%/J;:T'?8M<<YHPU2
M!#Y9<@\)0\F<@+Q(O"9VK.&@ . W1F-/. 4@S/?YP;+M,S&R81:QBI'#@* _
M:EEF4H4TMUD$A>SY8V=F)K<8&XF?Y$?+9B*448NB[IK(9B@^.'%Z)&'!#*Q1
MARVZT<:DM]K&"!6R9G=3S =$?N[LE;JQ2!H^[1PL_[!I@#)JYGU\<X)TY^P?
MG21QW!V6+-.4TU2#,]I@Q7E$W/#A-K\IWQ")2L=Z9N%;JYWW^9>$>;(KSRLN
M,SM!U +S713C[__X&EVAKZD?$$O#?4AF\ A%>O;,^WY WS%>4A(/(45"W/'F
M>N'@EXFX'9W@-B'/P%,<87I(CPQB80XW*UA@!=(O0E)(,"2+TJE##6LJW=MW
MB]\0K(FZ:+TIXOQ>(W+G\G1&KOJBL Q,?E59%(DSL_1ACN%7M&5 G3 Y!Y*X
M'?):4$M,-%<7MQ0;UF^!ORWN48;NPR_H>_KZ@8)W](BWN&.6R)6<#0V\%^1&
MH?<WY/19N_P\<RS>=>,,>0^^\T;B)WR47&=Q3,)P0N]+%+K%'RR&+S=YYK=U
M^*LDX'D?^ANLFA#D$MO:.MVAN&-@HSV[8Y>RMNJJI$&O8ZCG&<U UQUAFZ.E
M+&JUSX]GY@*- +G"*P(36)<6V(8:2S#!*V(U#RHLJ5TE46-#G5D,C%^@4<"]
M'U*&,@*[@)E QH!T3IZ$YZ1&!1MGD%$A=1]$9NKZR: 9,T%#+[P*/,-G=?0*
M-D?0R. +#LJ6U586UM"\:6G%'34)BF=/M10!$QY)==LL9!SI>$/HS 8R%N9]
M/E3,WI96VE%C('Q[NJ4HF,!"V)9YR+B8FU6(]3;+R^N,,M?07!Z0"\GHPH.J
M!P5R\10#@@C5Z6)Y.969Z*COI[&\O,H(K$@[>BROO3(?:MI.(LN+KXR15R3=
M3+;78U% S31?EG6A[RN,F'3E_BOSD^+$(,:[]S<Y.+B^ Y0YWIQ#M[<E7G0[
M?>RB88I8<?$R-UW'+RA^]UU6/"5UF(F-DOM8[B%AQD^RQQHCBSO'CW]S@JRX
MAUAS=LBE]-;A,TEUCO-"/HF?? VCMP1OF1#"?7C(TF?R;)'2"OG]O#KFTZ\#
MK(5S [2U_9RYV(]2PWX*G/S5(JE9AW:U<'KDAV#6[(V?WU$0'8J4_FT6D(E'
M_+//T=$)TB,[_E!N(ABFQDG1H X%LW'NI6$,GCLT]1AZ,2>ZNO.].7Y%1!+T
MX+_G34V<<$LR)$MFXOPSBG.>P QB'[N*,7#OP[Q,89(\HP2K".XNSYJN[R27
MQ\C-73;Y *.:GL31_W;1;3TZW_U]MF=NK/N]^;>Z_?YQ6!Y[O'D0[!8W-&63
MR=P>AB#<? >1-5\=&[;*(UB%%6Q^NLTG(]*?A#*EG@$+?PZ<\W!2TN"Z)>E5
MT1BR9\1>8&:1Z^MA$T=A>NTDNZJ*#DWRH@T#@^[K*$Q\#Q5>I;RMT@;%F,>V
M.BR1TBZ2N)==S1CXU\[!3YW<W5[9^<F&OJ!4&!4O-75F"KO+4OS@/44I7MMW
M@D<_0$D:A:BD(QJUB:880_T-.L3(]<LBPE04=X98&XPOM#9V+.ATNQ[H.#IA
M4"'/^E?% G$,;Z"!%SL+= O)O2KX?/.5I;B4,LVVJK=)V<<@XT(ZAH;K".!Q
MEI.(U>9+[TU<6<<89CG,(VUFW:);4G8H2Q'%,$U5+TW// 0:2*G4+J$AJ7WT
M^EXC2Q#)RPP#@4E+$LN$4M_ OE7GC[3OIKTP3C"4=<A(E9W;CS&>GX\GLEB&
M 1ZGF88"2UB$NOS&U8T%5D[(>2/SB_.<IPHR(N:F"15S\4GD3 @)I/?T0@9Z
M+F)@6]\A)X;,>^1T&QMD^'6S FE7!N2L&0T/AXJX"ADU<]./G"_(\O0A>7XJ
M]#59GB2D1!M=9Y5U4?GW(1Z&7IWOB/3D:/U%^GF:CL:OMT,V<W6\#SW_W?<R
M)_AK%ON)Y[LR(?J*BQCS>M9-VNH-D\2[KDF(%\LO/]]@D&.YLU66[O)[PHD1
M8@P&M'EN0!!SN.T F(]IZG&IO)<0'X1FH+F@!KR3)/7=O+)%3(_$YX\UMO6\
MH-,J]![PZAVNR05"-,M<^&(4(W\;RAP$=:BUX2;CGM.VL*/P1H$V/TK9HOFO
M5==IRN*LEF"!9X^>C@8[;-+2^K2RH,;'T4E$6TQG+;1'_520PA"X.FHD73RP
MW&"O@@&AE&&YO5H%%W01Q6;C@HYL?T8H=.M76;8!]KB9P[);OT'3W>ECS"M6
M-NKG5UF"3S%)VAX^\L\8\5-$Q?/T]+EZW:'8.: ,,_WDURCP2&=+C%-AYRO^
M/$"T8Y]Y)"[*MA3_O<?LJ7 +M2XH&QJ)N:"N!OMBLT8;VS[&WC5&I9_F#7+Q
MZ_'AQ!X' /9X6" (L]=%LTX+'/.&18MM=%4$%'?/O4%SUY5P_AH%@5-4MW;S
M!\H)2.MJ)^04'I&8!: G590D;:)E<1[.A(OU=J[DP#)6 XL.>6@"&^=?HO0E
M>_LG<M/7J"F(RKK/D]<%2*;=,K#*1-N;#NNY6>T)YU42 8H9L,"0.B*9F>8E
M_]OO3EY*%^_H"6%-GU0SQ"SDGE1RQV]E6>I0I!!(KF*=%T9HFZCC:X9& \B&
M4*'=G&L(.0/;N+1AHM\\1F A (V6BX>-3QQ2W$#1- $:%5($(3!4M'$B<:OL
MQX?0\M'&B% IMP0?/&?TG BQPRUMKY]Q00Q(VJ-H*6,V>%KG$[$X]P<R K1(
M63+V*DN1HB1=\*Q<EL)_=O$'\W$(I@@&&?RYKL(,QD5+\^IFXAA]:Y:E66)*
MV.!:)RU-"IN.@"4H88&<,%4]7<T2:EU$5]FP\1D=HI@P@!=WA[PL0*0582?^
M-7K=D89\213X'CY_KTXN,YU3UH?@&;VC,&O"=\,M.=[!,??=8XJK&/0+MX^%
M'%.^T3M,W"4,R6O4/BA>BMG(Q2[]9&SI)R/8LK!=:VO+[+&S;#E![@_;Z/U'
MM[!C%+LN_V@V77[PCZ\OO1VVOE@4@\WEP!<H9PU,!#*'FO<S5Y>=&T' &FUL
M^P_XVH0)O2L%?<RREXOHG_TKP^!>[+$&O<"E!#*Y9\N8E2Y]6W3Y]6M2(W81
M0>0H;P8T,"2BDUES#+\8#)[ &&C;\S8Y"I01G8@5<BRI_[N47.]#++F2VL]-
MJ4[OGUF2LI^UD8L8%/QKV;RJ6?/-3W?7>'^8M./;[VZ0D8@"PE3Q_Q&3%U/J
M5U\)ZC,DV9]&=15CX'Z)PJ]\,:P]8NY$EN\IBD,GJ%023NH*?:2YYAY1DJXW
MGZ/(:ZM4+U' BD[C3)@]8ZQ 55F\DH-4QDC#2"VY!1>/U1AS,=$H(#8:?)2/
M3OP[(EH*OR429X(Q(#ZC$&M8 =[3RMMC9I6D1-]Z1WQ(1+.,9S"<0J>JGIC0
M?3T8L @F&9:?B:>'2 "D;0CIDY'N(H_(/Z6TPY6C17-GYJ"?L11)?G(=YGW3
MV;L4C3:(\M)/@,F:U%% 81GH5]M4F/@63C0.%/]&]T<9S#-QVQH*(9-U3 B%
MFW<@FF7NL< [2<A&$*9T+(YA4LC\9$<(?;VY06\L@,3SS)DCR7W%XFU4T79!
MZGSZ$DR"D$21[^0*/],;7UC8K#?:V/:?X@C_/J$3QHY; ZS+W)CH.NQ&'8YS
MQX&.S[QT>6,V&Q)ZS CX;2^5Q;"*C'_4"**^*\EB^*6ZT#&<4:#!%MYOH>NJ
MNN2<ZP : S*1IJ/=7R?6?DVZCMZTT)3ENQN8R(WC>M^&H6=,+Y>]^!#[P"I*
M8+\_ED!/2WR:#OZ)I3D)'+EU=L<(?Y_E^)E%/1GA- 2--DE>.\IIV.6_(]Y_
M2[-KI!4;JI?28J#E^TRS7*.0@5]8<.,H#9"QM PCYCFH+4W$4KM +#<X9. 7
MO$"C7R[(^%OR:M5A"I#S]8P0%$?MA(RK98B'%S@".==QX;>=I;%"1M$R!"0,
MVK$T8716)73Q9LX+-A>< 4&B\"(=&/I/JS D&;.D U'_906BA(%2.E#S%RM0
MHQ*$I451M<MD. CKTH(3N[1W8>R8%AS9I89)!*1IP9)=^H8HQDT+BNR2J)F1
M<UIP8Y<HW0[+ U!K9!!9F*,"(6__(S&88[442[&W8;9'1>68!ZP>F:L4\N [
M;QC-I';+=='C??66Y#ZQZH<&R>/,">92$8I2,ZVM87DFYRJMCQCPR,TUF,]?
M;P)S2%?UB"ASS(8R4_?&@(,S <)YR)^">=QWR?LEC=S?=U& N7U2Z(T2,%"G
MF?=]BY\8,8OKV!WD> GH>  EG/"0(2:;&1]<UPG<+'#T5/>JC?UML^Z5$SBA
MBUYV"%&?X-:.J.=&.9>D?3!X+[_4IY)D^Z(AY'_X>"?B8^%=4\8975?LM"&H
M#^1O=VGN&192J4EPK[LO0>]&$H4R>7*.Q QO&Y!RI_@4EU4Y\^%Y\)8U$!8F
M6<X)7CL),723_Q ,O#L!L;^MBE**6,2W$5PJI78180D\HYA.%&Y?4;PG-HRV
M'-?$H=@",H=L;_>'(#HBK(P&Y+7@,%KH\,H=ZG6TWT<AA0%!!T_(@*HGY!FY
M"+,?_(KDK=>M H]A^CB@.#T^83F&V/#)V>:.1)O &\-_>+ID$[!C"]@<RJT\
M#PSA!SJ0<J?9]$U_<GSO/KQV#GZ:MRFH^)$U  M94<."DNH1K:+0DW6,+_0V
M=HB=TRIX!UY7NC?:&JC&L*1!MZHV>VJQXU_L@9U#QA6TI;V^SY>@ REWI,^D
MC'>(O%LG#DE?.BQ&9/LL%P8Q_+[KVP.PD"_5R4,VT2I;,JIX:R?>PQ*HI,TB
MQ%#9*MO?OX1_! ZGD":?8G3  D'I\ZSLL'0MVPY@Z=:17-KQ_XV\2A(@X=OM
M>P@=N#'OY9!^*4+\G^P!G/M8OJ5]>H4.&?-RYO)=^?D3<=KG\9DO3W=9Z-&X
MK1V 4I7,N@,0Z4?Z3&!8;[XF10BJ-?"-N9NT44T4,6APV<=)$LT^?%+WR!)0
MQIP<T9G]X@82BSM^3S#]HM#-G99-F#-HN-E'V \#QV]DG:X].%[H8"J)>2)_
M=!.8#1IF]M$.U.?ZA"T#CG.6'/'U9^A>(LXSV4!%<P4I G9R\3"FXOBDX_>,
MQNU1/?O4C3,&FRNO+4LTD,B$&F9 W35MI#E"H7'6/GUTQI@K$"\7ZT %06ZN
MX5/@HM\@ V1$)-"9('VPL<U+1!I0X1#/,]@HH1],0"?Y_C#CCU$O1H#[%G7'
MFBQ,S D#8+!WSI1+B/@<->"EI!K&8'.W0,(53[\2XHD&NV[(^=RI@$E.GKOM
M$,.!WMDB;Z3!G@("/S@5RZ)9QL'I.[JY4/0&&R1\L0.;0?3"B0;Y:]M3S>"J
MK2'&15)Q"QG:2-/9=#3',DL88HPWJ>:*'<<LM5<XTZ!NR?84,Q1*Y@1 Y"64
M\KA3#+X,+:\NXSEH1LPL'\@X8(>R@L0L<[(_W]M*%_^Y<\SU(:I=4=1=UU\;
M5<Z97D*FGLZ:85+3DG 'LO0N\533//(4$]IY?CXYS:"98-9.(2-.0)(>&'XZ
MT;[I3VV9T=O+V5TTI??&3TB>=!8C#G-Z<7?(RP*TWMQE*1[ZZ(?^/MOG[\63
M<\SGW!!E)T@^@<@ )B7G4?==J^[ML=YP1BUKRIW[-?0POHC5$FMUWTGWE:I.
MDRUIBA,PPY@U-D5J(?51$>"^3BD['2: ;'I5AY:Y%A!AMT60$F)N,QHJ/\[U
MG@@K%5C-P!+62_:&[YD?$NO1ERA%L!ANRQ7(BG8EW]V'21IGY-(\Q3Y^6@Y.
M8!L#Y4/:5EH;8+^&3E&(%7DWY1UZBM'>S_9YY5H\-$DR4D2#V!421MKI?P!B
MJFPD<'S$FI1X 5T-]7?^!*.6D$DDP[2>3%D5,G=LQ%+R%R1^2/9#2#_%I$]B
MW'88Z6GN\]J_$8] ESA%60[0>>)X:.>M@+'</96'EG(=)2:?N#D66IP2*,Y6
MN*(Q<51TTC(LXT_KMG2/6(S%P_//&TZX>L=,D/C9-U&<.%AL1!C>W%I5CO=6
M:;W$.EP]D^_Q$[B]<A*?R)2_0."?+2-;O=D&0P/1LC96I/G(W(2=#!54Z$'4
M'%#9\<>T27.[203HI;A(^#.@7KW*9KT*!_V17@C5QD=\P1HG?K>[ JFVNPV)
M:-6?"TDR4;'VMUML]7H4DHXVR*N:=+4U%NC"RBP(N(X"3.Y147MXM8T1LJU>
MT"QH$/2@;N-#L5C)>;N^&'Q8ZAH.F;',-,T[Y=P7\7[9DS7O6H:\Q=N76 7J
M>RAI@@0A,O:ZBQ1](88:)V58TZNX]9[;])[)P-V55>[P(88N!CFW\\#6MSD
M,L+ VR,A;9M!:+*PT*>;"Z_@4A0]JH(W!183I):ZKC],2#,U$DF1>\KWAQCM
M2$^*=U1\^C,$AO@YCI*D:.M!8PBC&KA;PA/;S4QH3T"[Y5NAJF88TM)!B,_[
MBEA/4"M2\O8[1E#Q]L7'O(<*,201M$5YE\_JMEJ#(:TXX(0.-+]K#:KJO5<-
MIFD EMU>A3T[;8.Y?5Y#J#LLQA+0!&R1UTY]I$\6)/NC=,&R!;R%>9=DAU!+
M[#Y2W$S05]<V4/E,C((16VX"@Y?E9HBNK+UR,=W&0],TS3X'$]:%;KVPW:TE
MQ9>EGKE2!Z#5=#UK(N@KX;S&OI:4PS6$N?Z;\<<+A2EU;1U7'G.A!*TAB^GG
M:+5&&$S?'F'HH((S9B63Y4QZ2L"P>$DUP*"15/MM&]A5]?VB^4#XH:3+"H)O
MC32_[;XNPMIT/<Y<O3I).P\5#LG)!A-:V;8/*D"<"899"L6\P6$'P]% ."+3
MVB#!VUAS#3[$7*L"X\GES9G9_R^K,@]]_I(S9]XO3TT=[I$SVC#'J=50#I.I
MQACWY_)T0:XGES/1.%#\2]@?93;YFJ,MT:4'_B3+W,ZDK.E=$'V Z+3\!:5D
M/UB3('3M71V_)H3KU82]<K%<TRFST.N[6&LHECB/"+2]PK+XA4ICW\7'5!:>
M[7[0&OF$8I\\Q6Y,$E!O4/%?_'>A-6+U<8>?"_2,#_MVLT'T9N(J*+<$J0R0
MB@=*3$5E$O9K5#Z[3!/W3]!M3].NTZ#$A]B_!Q(+8.\8E2 M0>HXTJ+(MJUB
M:'<HKXIS@PXQ<OWR^ZHD;KL:KC5.$["D5X?*44@/.E)50&*S][LH?D:'#*N"
M&*F8#/E=;:WB[[(/'8DB1UZNV[>P\AH[A+R:/#]K7%+S$$99M?TUPB\>L<:3
M'A%X,L;,R\Z)T14FESQ$$S^%W<!N\,[."3R[+MU:9P>^I.CP];#R_ID52G_!
ME\AZA7Y=)H.\8%Z6T+QU-F%HK.18),:0Y%G*;0+ON9PF/79?>:8,#;U/W\P4
M04G!IJ'"*H(0X"+G'T_E0YNL-X49N86 1R=TMF2Y^^1 ZIX^'&B] *U"B>23
M@P60DD#6FZ]8LW)).GV1CV(Y J3T@-JJ_1_<A+8>QX#>0'"B%-(2RKXY<>P0
MYP2*73^QJ%7DM)=#(&9![S<XN_6)>SEH:#DE3B&3Z94[0HKB4\T=^<MIDTF+
M31 1N[&3#%H'V=/,<C[.654=H^OU/Y^P<>UK&*/"FI:[J1H?+36WX$0M'#DF
MBFNA(FW^;*GE2Y*%*N:=V&K.4%%'2)!13B;]" 8>E=B*&'DRZ1F<JWIGK9Y;
M@T;)MEHSQHIE$L^MK2@932?Y)6IF]_*!3MQ;6D6%N'@)>LS]I[,CB&%#S@89
MMEJ[1B.C,J%W7&TGKK4-L=#MY-4@XB_GAHA>4\+&BW3R0BB#292]5AM$6.HL
MFH*(7C^U 4HL]99,14FGO5*%BS^?&2YZ/8G;M1!_430(+Q-<JXZ 7J"MP@*7
MK#A^ATH384B#KI>+;@(:V7,433FRIRU@CNS%0;+TVR"<!Z<%GE2^EVB6UHRB
M<;&3'3CF6A7:=>,X#>2N&VT!X]>-%[3(O6^<B2:?3LGX0];#*C?=^*FI1Q1R
MSU)YN=FK&D^+!1SRGXDK&C]@0<"?W$M(G0ND&*ODZRZ8!.><J&%X<L=$FSKS
M!5,-EAM>*,45#&9P,P/@J*?!'C^WG*48FT:1J=16 /$*#P/.A"_O8(JY2AHJ
M;^G,+Z4.?4H0]B6K7O&7 ?*^\.*Y)%X:SG00]TH8H26\9J(50(#)B+H2 D>?
M-S-'EPN,&O)QJ7DS[U4A=&FX8?G)EYHTJA*94KP06RQ36<;D(2G$ ;'.2GX)
M.&^O,J.67P#0:=*C=23/D3K9>!D72NP-%1[V>$#G0PN>D3P=RE1 @'4"820A
M:L\!!$H_FD42FMXT0  -HE(D(>K/ P32(+Y$\1)5\V"!Q(H4D0>.L0(\,#O1
M'VKPM:<" HP6RB'-" =3814<:YK]X;T5]/6$:L^$[^;:>9"ER+L]5/W^()0>
M^Y;'SR!O]8Z%FBWZDNW?L(2S*?>:[S]99VF2.J'7JLW7CMEA+#&8F^/!IFI:
MC<Y5=P-_C5JZ.O% H3@I<45#C?PB=B%G!JK)[SA1#IR@Q$8^:Y6FL?^6I16>
M2-/,)+=V$7LWI9Z$!4EMT^FH8G_KL-5&E" $K[[>M%O*04?'4I336+I+-75%
M#/9;-*G[R#(/YT@4]=Y0U56@@<MZ/E2 9:QA,FAG'"\8QNXHKF,!R+SS55W%
MK- [Y55CR\,35C5>%YGS;C$ %LV#?<*"UV?\(?,7AJH2E>:19^1&V] GO_;B
M[I"7$5\ /M%./YAVC_H&-D :TX0^.)W.84VX:;4,<>.*>J?#S!*;B).BKCYI
M<C1BH:+/##>6%W9C]C-MK"1U :A@RLR<NT6$3N(<>DQU_AS41Z+P::]"CQ)J
MB#^M8V0?D4.&%Y]7HB &.W':(:2 'HQZDR14V2GDF&:CY6$14DY2(KW2ZT#Q
MUW#=;)_EX=$YY33!&R1NHR *1M]YF.^)2901%6.(,NAV%1T8:]\FJNT-I/ED
M+";ZH7:JRT %6)8WC,&"Y-K6H:;' V9%37=M,*AA7W8IZ)G33TG<:+16MN!1
MCO=6:;W$.EP]D^_CT@))A)-/$"03<E3W89+&&0&OWN] -6L985ZRMZ*%9UID
M(-23&LS:TS%G#/PH]*-8"#ET<4$"\EK;ZEK@N&"#% @$L XRF^FC9U8HE:_4
M4$E474(C!()+P=\[?[+!GHH2=$^W3TC,A/HL]JP%3X[O-:\>Y4M >C;#+-0*
M,Y*PO^;"FC4/V"P@MT15JO7Y9T5K@5'S(3NHC#,!&A E$:J 44R!!@B3M)3L
MNHQ%H+)0TL?[PP](8_)^+O@+N=/QD;0VIL)$^O/F/K)_#[L>EYSV%PBLMK^W
MG/IJ@W2%@($<W9_6]?9M8Y2K67:QX#Y,F)]P$:&*0DO0<.>'^,L'_WU(N (F
MP*2.HC($\LJB%^QU+$'13)=&D-O<O3W0]="QMV<,N8T49T[A*@EH1@%E(#$V
MT\WJ,YSN58)>H%8#V=#?9Q&U@#0"J9'(,!Q-9O+L!:<4I*6AB45E.IACX?%_
MP:%0IQH#;/QM[($Y8B'-="@MEXEI4G8IS1#)B51B<*36,0O+A,,:N?+"U"A]
M6/2)1GCXA$-16Q"JR>3*"4@EG)<=0BFI3!6%77=K72D1D+FYWA/#VEI__RV*
M?Z_O3A[ 3BY0_&Z1HU0:UF?GXQ%37>P[ 0-4^+J$)*CD84XP@1)9@P$K4$EX
M".! M&H-,;]1W@7B[Y\STSQ8G+O"AXH]T3Q0O%O!AXHST]9G*R^X,ZS) .@1
M&VX."W7YMBGE)UHMK/-9E9/FT0FS#?YO1@*<JGE':QZW:3C G_IXRT47AUPL
M'F( ^ILW"0.DTP?FKCDT+_B^^F[K!83>S$@9\FIB703L@10HJ8^\WR 2>N>B
MT?"7$Y^CHQ.0,7W H;<I&D?R=;VG'.SC^BWPM_DO]<&'WJI^THU_P%<\3%#9
M):,F 6M:U8^_](,QX[JN+Q3AK0)F/[Q;:N[LU<>EQ(JA441NHJ;=<@4 ]EYY
MT_3LE/Y0,W=('6ZNUJ7@O:52L6"2Z9LY?#QY=W$P>F8J$;]M0U(1SM%#R<P'
MB$G,K!EF:[>*^3"/Y=JG"E>I-C!UX3ZN2:7<+NF+Y< O0U$0NOHK![: I;8G
M6:+T*L)-1K]DH1<?&7,@VWS%L KX3FO"4L_.EW$OSY?ICX\N846,=>$\LQ3$
MI7\V'?&F07W/\BS6^O4B?T&*OR;[J1Y3TE5A%\4I^3=^>=_\,'?Z9G0^UDUO
MNW;B^$A*B)3C+7FR^$ ,WNKVX">L$[K^ 2M>]H$\QXE_#9VJ=$'5+>@I1GL_
MV^?1''AHV94F[RG4[K8-,PU(#2^47$^)R4 R5^ETSDU?[4V9_>GFWBS:H\V;
M  3-(VZ(Q$FHKPKY923__^BD\&HMR;X,U?BJ,4\7H':_Q9I*[\,O&(NO'RAX
M1X]1F.X:\^\O%CP>VK#R-^3$K_@F(FN<?OK1\1&-]0">U\,R&9")]Y<*Z;0U
M[4!%Z]).QT&SF$7 DRLZ$^AX*:B/-:DD[-=%C8B##%]:A'>/6K;9QEZ[WA#+
M0YYU#>A1SZTA9$]B@V0QRA*=C@O7;T[LDP)30[! 6A@'L/1O5?T]$*L<9Z^4
M@<8V32$#ZIZ'XZQF27<99KSHT0_]?;;/8:JZ34(RPSV0NKN(8;6M-TPOJR4[
M=[5)44R>F3O_'5G$VO1C9H 4Z!ZGQ9 29;$U:<M+(<4N%74QK(S75$\2)TP3
MCV(\ZU)"EQI&!C*9Y'3P /8>R4G0=M<"#_I,4%L&</["30>8+&,%P%Q;C?(Z
M=H#,MM HK@(>7%G#Y-CEH*J"K3[,37NWHC9Z_579+1R0.:K9:M6:Q0\S?![E
MP41A'P24W'Y/8Z>HT!L?[_'*>0@,"5>/ OP+VZK?&4UT&?%S-_@?26I1/UGX
M*+W#?_K;T26Q%NM-IQN-PZ9UVG[1)C0V-VXN--4KVH2&^I;,A85J06M>,) O
M5AD0V]_A%0K1QJ>7BBYFW"',[)R ,L6JAT4%9.8,2R"N J/+HWM)G13E74Y<
MZCD.\=!;P'9\C*9]$>8L,3HK *Y(.I8@8+8+T9DINA;0L3+^22A>9#;D(-W3
M<N#VZ]'S)YD&AOTX\Z!ASC(L9\J" >XT1O&707"=RAI00%4[.,G)IF_5J/.3
MFVO\W.1>,.[I22UA^@S9;Q27,[)F6:!\DK8AH>L'?OZC@%3/V\T&N:G_WFSV
M&1,03?>GR1STV5U@5VF+:V:DDEQGL#6*BH(HU@#8P01CA5-!D'Y2HC,WJXJ7
M3J4AZU&@GTK*=Z(SXL;'$\DCXCN!-:%7TZGE9%"AGVJN=TZXQ0-N0\=-D==G
MOM #TJ;3BN4(&$<A>=HK96J7YY)OH_#U([KS-^GQ!I%Z]/B#)Q2[-A635* 1
M*3[K^7XO2_]/BCGHEE")*E;ZA/%GZ&B9F3*N2:N&JQSXHL1RETJ@UQY=X+'I
M(:A/,-#+DTY_;? 'US'R_'00N?&?T"^+?O)@(^>_H"-G3LJH"F_: _V2I#'
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MC_%%($^@Z\:9$R351^> D"[C!]ED@2?@,8KD=(;"V7CG6$1;+P8;WSR/V3!
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M<J@ECL;_E-TVVPO^K 1.P.^D2OD;V?9P7^)\68E#SW8I?_//5= V*DI3 8B
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M]!IWR5:O^*$0I2F71*?=_M$AAJ8F[GC^/NF>G)R^6C?X?]![_2Y;_)RS,9\
M,S 1,(4<'2@L>Z=4C<OU"U"L9XC)#]J4K!^W./PGX>]<*3T1$QX2D>'.Z;<Z
M?;#L= 0MNAK]6L[8E=)3"?DE=(+O37!ZKK$CI1UK(C/C:L9JY4P-.!1,+'U*
MBM/ 68G?#-%KP8D9#-.E\(SBY38$%&1@+3<S$BGY%7BJF>NT6):C,=BE].EH
MPT69,)@'HYC"YF@)IED,W9>-F:WISZ+]%#!_#DIH *6P$A-,]!";"C?& =H*
MJ8YZ)[T5FJ9S'.8$F^4LG2V[88>JVU%U>"=4 2OF(7@Q3QV$%(ICM5FJ%ZK
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M<#GE,^O#Y*A'[TR^?3'J^;<M_P-02P,$%     @ X8-97-^/"(/G!@  AD0
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M?H73<W4.K#"K,/L*9A5YWIJ\5)7KJW)]6T+ ;YWK&XW]\_?^*7K7&XW.MC'
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MCF0& &EM9S<U.#DW-34R7S$N9VEF4$L! A0#%     @ X8-97+;[D'4M^
M?#<! !(              ( !@JX' &EM9S<U.#DW-34R7S$P+FIP9U!+ 0(4
M Q0    ( .&#65SXNYI0EF,& /9@"  2              "  =^F" !I;6<W
M-3@Y-S4U,E\Q,2YJ<&=02P$"% ,4    " #A@UE<_MY:S,E8 @" =@, $@
M            @ &E"@\ :6UG-S4X.3<U-3)?,3(N:G!G4$L! A0#%     @
MX8-97(V-'!(5H0  EJ$  !(              ( !GF,1 &EM9S<U.#DW-34R
M7S$S+F=I9E!+ 0(4 Q0    ( .&#65Q("ACPN'T  #Q^   2
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M.3<U-3)?,3@N:G!G4$L! A0#%     @ X8-97-TN+$LHQP( ?<<" !(
M         ( !,N$8 &EM9S<U.#DW-34R7S$Y+F=I9E!+ 0(4 Q0    ( .&#
M65P6)AEQ!,8  !GE   1              "  8JH&P!I;6<W-3@Y-S4U,E\R
M+FIP9U!+ 0(4 Q0    ( .&#65QK\W,+\L$# ":C!0 1              "
M ;UN' !I;6<W-3@Y-S4U,E\S+FIP9U!+ 0(4 Q0    ( .&#65P^P OS9?,!
M ,7S 0 1              "  =XP( !I;6<W-3@Y-S4U,E\T+F=I9E!+ 0(4
M Q0    ( .&#65P.&43^O4H! .VC 0 1              "  7(D(@!I;6<W
M-3@Y-S4U,E\U+FIP9U!+ 0(4 Q0    ( .&#65PPXWHVQ_T  %#^   1
M          "  5YO(P!I;6<W-3@Y-S4U,E\V+F=I9E!+ 0(4 Q0    ( .&#
M65QI<DP60O(" .#J!  1              "  51M) !I;6<W-3@Y-S4U,E\W
M+FIP9U!+ 0(4 Q0    ( .&#65S=>7OS95(! -!2 0 1              "
M <5?)P!I;6<W-3@Y-S4U,E\X+F=I9E!+ 0(4 Q0    ( .&#65RVZC2A7]('
M &7?"  1              "  5FR* !I;6<W-3@Y-S4U,E\Y+FIP9U!+ 0(4
M Q0    ( .&#65RO%H[#4#8& '8K60 1              "  >>$, !I;G9A
M+3(P,C4Q,C,Q+FAT;5!+ 0(4 Q0    ( .&#65S)ZMMRO.@" '\.+  1
M          "  6:[-@!I;G9A+3(P,C4Q,C,Q+GAS9%!+ 0(4 Q0    ( .&#
M65P>U65Z;@8  %R)   /              "  5&D.0!I;G9A+65X,C%?,2YH
M=&U02P$"% ,4    " #A@UE<VML8I!P$  !@$0  #P              @ 'L
MJCD :6YV82UE>#(S7S$N:'1M4$L! A0#%     @ X8-97#<P"O),"0  \3T
M  \              ( !-:\Y &EN=F$M97@S,5\Q+FAT;5!+ 0(4 Q0    (
M .&#65RQ17V2/0D  % Z   /              "  :ZX.0!I;G9A+65X,S%?
M,BYH=&U02P$"% ,4    " #A@UE<WX\(@^<&  "&1   #0
I@ $8PCD :6YV82UE>#,R+FAT;5!+!08     &P ; *,&   JR3D    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>inva-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:inva="http://www.inva.com/20251231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="inva-20251231.xsd" xlink:type="simple"/>
    <context id="C_807e8809-f1a2-4c0a-ac41-7942e7f10fcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCAndC2PreferredStockAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_80b69809-f556-4828-a636-e7d70a0f4529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_80f755ab-2884-4b9f-8f1a-e93170c6f575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="C_81f83795-0714-4c71-99b4-f4a03319bbcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_82023995-c0c9-4e2f-af7b-9dff1c4313ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_820fc30b-7e3c-4f31-9d93-e486eb026d85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_8227b866-0a9c-4af9-b3ec-85e210a8c096">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8290bc3e-4b79-45b4-8dd5-a2d83da40c0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_82eb691b-750a-475a-837f-1b1397fcb267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">inva:LyndraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_83fb2c06-5584-44c0-9816-0548d07c70bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_845eaa74-fc53-4af0-b138-f622d45b3c0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8480b31f-e5a9-455f-8428-4e043a8d826b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_8636f737-54f5-4f04-95a2-1c6e8e58eb52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8683d1cb-18f6-4da0-8993-dbb80feae90a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_86b41774-5017-4fc1-8e1b-cf811b6c4737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CostReimbursementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8714bccf-5bf2-42d4-bc52-49b4f39a126d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:InterimSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_874e94af-935a-439b-ab00-df1390a5e34b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_87678ce3-d91f-42c7-8014-482b4e96c0b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8807e583-90bb-4bf2-b789-04fcccd5635c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_88e66bcc-24ad-406e-bb93-f1e47d153eb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_89417c7c-4dcb-4c3c-be0a-04a18955e9b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-06</startDate>
            <endDate>2023-10-06</endDate>
        </period>
    </context>
    <context id="C_89c9f170-6554-4259-8589-a870931960d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-31</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <context id="C_89cd5c2d-43bc-4a05-9084-5d42b8515c2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_89ffeb43-b4e5-4cd3-b24e-9d0133812b42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8a0737aa-6de6-4c43-ae8f-624230637866">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_8a27a178-7498-4039-b7ec-3acbc3e22557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8b6e7ffc-19c9-414a-8790-449480c681de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:ManufacturingStageTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8baf7a29-4878-46db-844e-4be322782050">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8c3d0ea3-a6a0-43b3-ad32-fa7162ce8c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8c7fde10-e15b-46cf-8152-abd34dd01bd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_8c8a8e9b-18d0-4f56-bd91-01b41b53e196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-05</instant>
        </period>
    </context>
    <context id="C_8d1ae2b7-8b25-4684-9b73-d88cea1e9a93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8d782d9a-b93f-45ae-a7ce-ee978ddef5a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:SarissaCapitalManagementLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8d85403b-c00a-43af-9139-4133780be452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8e78c83c-a602-4c9e-a0ca-fd8929e943fd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8e7f501b-989e-4f9f-9cee-6b92a787012e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonAndPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaTRCHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8f658d7a-8b07-41db-8980-8e9b1025a6a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_8f7758c5-cb43-4beb-b145-ea2ab98c407a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_8fdc954b-b47d-4c5f-a782-7e29908c95eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_8ff7ff5d-59d7-482d-b9ff-48452108446f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9064ceea-cc8b-4413-9774-0740e1e4c1bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_91adb269-1218-4185-8ed5-66c8ab8bbcdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_91cb662c-7d72-4446-a053-6b76cc6d61c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_920caa91-234c-4ad4-9f03-0cc64046f9bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9290e126-1791-4a2c-9976-a9357f71a1c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_93087703-617b-4b4a-81e7-31843c5aa650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:AmendedZaiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_933e0662-5284-40a5-af01-95acd4469d1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_9384f77e-6605-4a4c-8810-bf720c3d9a70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_948f1041-1e2d-4225-b512-dbe9786f6151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_95f17691-1422-4df6-a2c2-e728a595c89b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:InternalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_963ef00c-7831-40dd-b4ea-a644dc525f00">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:SoftwareAndComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_967bf8ab-5e86-4683-ac2b-d23837fdf808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-11</instant>
        </period>
    </context>
    <context id="C_97c7c246-dcd0-459f-ba1c-f296e715a8bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9813ff06-8065-4d1b-980c-30aab6fdf680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="C_98398386-f407-4e2e-a939-d8ab60856a68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_983b3e15-da6b-4fb2-b179-654eb3026eeb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_98625368-01db-4a5e-b3d8-d97b38cb185c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_99fff56a-0af3-445d-bdc0-14b8847ce8ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_9a9972fa-1809-4264-b6eb-ab4488000164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9ab9bd6f-8303-47cb-a451-087e49e1d4f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9ba2a047-11ad-4eed-8953-9ae11217e2fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9bab53bf-5b1c-458d-ab5d-5fa3f3cca83c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9c1f6269-1e70-48f2-b51f-c346e1e9651e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9c250d42-4b6f-46b7-8b87-dfca0a66338c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9c59249e-0a1f-4f59-9c53-c8fe277b09ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="C_9ce22bb4-5077-4fc2-a00b-d5ce7b0d778d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-13</startDate>
            <endDate>2024-02-13</endDate>
        </period>
    </context>
    <context id="C_9ce67c09-bbaa-4af5-9443-47f86c908063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9ce90413-1653-4365-815b-e666974c1fc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9d19a8d1-6525-465e-9818-4f4be4f7b334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ZEVTERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_9d514a06-f501-41ad-b742-a81bd23946be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_9d82a4f6-9c62-4ef3-a79a-b60ecce3c1dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_9db59475-42c5-4b23-ad54-3fcbd23354de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_9ddc8c4a-6ab2-40b5-8423-f2cd290e57a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_9de3ffb5-8381-4662-89f6-a8481e573820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PrivatelyHeldHealthcareCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9dfa9bcd-fbe2-4b00-b6d2-00a31a357835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_9e3bc0e6-f47d-404f-8fee-30b5fd642601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:CordenPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9e87c016-5304-4333-83a4-195cc836505e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">inva:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_9eb30f32-b122-4799-abad-e4b9a0d5cea5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:AmendedZaiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a08b10dd-5488-446a-93cd-e5dd9322693a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a0a9ffa5-48e7-43db-b94b-727a9650a8a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ZEVTERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a13ce0ca-7bd6-470f-b4bc-7bce7c7cce0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-31</instant>
        </period>
    </context>
    <context id="C_a16a824d-5e09-43a8-8e7c-eb26e31d2066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_a2de673d-5a6d-4d89-a1af-5b182aea45da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a53dc6ea-0c8a-49d1-a28b-56b625f3832d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:DurlobactamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_a549f046-b516-43a9-94af-3971494cee27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a5a5f201-5589-4683-9f98-e0775b868585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_a60c1143-acae-40be-9475-53a07ff86264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a632ca34-f6ea-445b-b4f9-b800f457ca17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="C_a676b1bd-fe43-4060-abbc-19a8821970e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a6940b34-904b-444f-9ffb-b6b2e2a80b84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-11</instant>
        </period>
    </context>
    <context id="C_a6f00937-2ee4-4566-bd68-45c44b998d3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_a73231bb-c2af-46c2-9a92-d48cf8356bc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:DurlobactamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a7a1c802-2b70-41a1-b1ab-0f6ea7991b5c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_a81a0298-20b0-4919-aeae-4999deb69182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-07-10</endDate>
        </period>
    </context>
    <context id="C_a94d4668-3b04-4736-b7cd-35be25a3ced1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_aa99c31d-93ff-49a4-ada3-316eb33c9414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_aac97a17-df6e-4461-927e-d6634b600e0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ab3f6fa0-6707-4052-910b-d4481b963aad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_ab4cbb1c-525e-4e91-8915-9c00d3a0db21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaTRCHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_abebdb2e-7b66-4a80-a391-a715e9a19b73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ac9f1546-4eb3-464f-9fd9-e5fcbd5159b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-06</instant>
        </period>
    </context>
    <context id="C_accf2b2f-48d9-429a-b115-90bfc9822af1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-07</instant>
        </period>
    </context>
    <context id="C_ad016aed-b782-4802-bf40-a81d9aac47a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ad7b15a7-04fe-4b2d-aaa8-50707a9474c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GeorgeWashingtonUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_add7605c-d6b6-415c-ad09-46eb5bbbfb4b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_add7b0b6-f915-44d8-9105-5a165235bb5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ae3b7e65-0767-4226-b024-9f30a53a662d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ae44ab8e-7504-455a-a5c7-18b720494066">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-15</instant>
        </period>
    </context>
    <context id="C_aea5d4fa-0e83-4b75-87db-300c5e0bf84e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:BurlingameCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_af13deae-2d89-4cf9-98df-3d7c55d81d4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_af252bef-3fef-4ac4-af1c-26d65e57e80a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_af50c412-1762-4092-9219-e0cb77f51b0e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1AndD2PreferredStockAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_af76bb07-dc3c-4511-8750-d747dbdf4012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b0306b74-2ec2-4940-b3af-88916e13af8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b0999027-f0c9-4ef8-ad7d-78766bc3abbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b0a0b85c-bd15-4eea-be59-38094513a363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b17848ff-54df-4b86-b3cd-386a1ff12968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b1909c77-5037-4101-951b-72d1da39afc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_b1c1c252-d197-4e74-b2b2-f01842ca2233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:DurlobactamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b1c51e57-65da-49fa-ae45-c34168f6b7ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b25d8758-99b0-4893-a9e8-7d66f0af9020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b2a12880-40dd-4a30-8ea9-b9ba0ea9cc66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b2be7da7-0eaa-4d69-b26f-885c2d1e7254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b335f87a-f5ca-4232-8677-8903d59dd87c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b3b3003f-d16b-4948-beec-32f75f482d34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanTwentyTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b3eec335-a345-4b7c-9e97-3ceddf99d1e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">inva:LyndraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="C_b3f2abfb-4337-4fab-9c5b-7e5c28bbffed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b4012fc1-478c-4326-af9a-abfcc793f2a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_b4075dc6-049f-43ce-ad83-c920b6727849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-10</instant>
        </period>
    </context>
    <context id="C_b4464bad-246b-476e-bbdb-5189b9e3455c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanTwentyTwentyThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b44bc8f0-aa9e-48fd-9fb8-b5701d1d6bf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SyndeoTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b4c7d24e-1946-466d-b882-1f82aca2913e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b4d781bc-915c-4c41-9106-511763a665d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b531a65e-a381-43b5-9fc1-7c2a415d40f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:InternalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b59f5a94-681e-4e5c-b302-d0358109e1fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b657fd3f-8dca-44dc-a4ed-6c972e7986a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-23</startDate>
            <endDate>2026-01-23</endDate>
        </period>
    </context>
    <context id="C_b6b5484e-26f7-475f-aad3-d4fff0a4c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:AmendedZaiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b6f9a97f-7c68-4a85-8e85-ea9cf6cc6220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_b772694b-7101-44aa-8dc2-322e6c88ba68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b7886827-2301-4eae-ac39-e1b0cfe79560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_b804b54f-6e17-4b9b-bc14-506d13cd2e58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-03</instant>
        </period>
    </context>
    <context id="C_b931adf2-501a-4565-a5c0-0fce4fa655a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_b977836a-3754-4918-ab34-119c8e6e97e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b996eed8-dfe9-4e4c-91e3-6efd62f73797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b9c78e4a-7998-49df-8911-c4a60d08df86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_b9d838c8-9363-4704-8fc8-ac7fe6933ce0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_baeb567b-ccbe-4999-a205-466cd47101ba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:BasileaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bb0d3213-3fd7-4233-90d1-9955a45217a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_bb1be382-95cb-4b4d-9141-588145edc4e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bb34b526-ff51-4bd5-9372-e24b00a45ea7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_bb80b0bd-8c31-447f-bb15-56034f4a4f2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_bc424098-7c86-48ee-a261-2e346af6f356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_bc6304c8-3e91-4a96-bdf1-8803fdcad919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_bcb70ba8-9c6a-40aa-acaa-7cbf42dfc814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="C_bd8929dd-2601-4ff3-b3c5-49946bfb7b0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:LexingtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-30</instant>
        </period>
    </context>
    <context id="C_bdd9c91e-8090-4b5c-afa1-5fde995c9182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_be14d1aa-9ffc-4de3-b4ae-142c0c538bae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_be450a6d-2206-415e-accd-57ca23a7c915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_bec30008-f686-4815-ac74-3fb4d99703f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_bf1e7354-aeed-4914-83a6-37a509ddd35f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_bf257858-aaa7-4585-83a4-5200623ef35c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c010fb75-cf30-4376-bfd0-a2b399f45c3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c0f46e83-20e1-4f0a-ac38-a2cdd4a209c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c10fa9b1-45fb-45df-9763-f7e84d16c427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_c2aa978f-4b90-4e27-bcd0-10e52fef449d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="C_c301f3b4-0e6f-4ec9-97f7-2af4d7bc4e41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c43a1118-656f-4694-8c43-8a7ccd87ef7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c44315cf-58b6-4df1-a7fb-545a3c2a85c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-06</instant>
        </period>
    </context>
    <context id="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c554b608-b6a5-40f5-8cdd-07a2aa79f2ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c5950ca0-b841-4a30-a532-7b67bb117316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c66f1b13-03bc-4b24-a6a3-cd400090f9ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c6c8e559-7887-449a-bda4-21ea384a9d5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c6f23cff-6ae1-42a0-aeb9-137bb05864f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="C_c76fc58c-a666-4494-993c-5441e34ded35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:BasileaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_c7ab2f82-2276-40f6-9084-327d9a8463bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginAbNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c7bb82e1-094a-43f1-9fb5-4b8ca5b929fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c8120c77-f833-4318-8b71-285654ebe1a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="C_c92d98ef-aaeb-428e-9c70-9239d3850fc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_c9724995-83e8-4e3f-ac0a-df8eb2d7e801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_c99c2a28-4992-4873-a475-9fde89e0026a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_c9dd44c1-e335-4444-826a-cca2d606205b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_c9ea7908-47f3-4091-b474-5d9827ca0b02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ca4eb91e-0456-4f17-b035-ed0e47cc770a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_ca9df07c-03f1-4863-b309-11e88116df42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_cb2b5dab-8579-446e-acf0-02b095195b73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cb9d2f79-476b-4ddd-9d0f-a6df0b98ff4c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ZoliflodacinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_cbc75e73-16d5-41ff-9fc0-e3415e4303d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:Outstanding2028NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_cbc79b2e-83c4-4eb8-a3b9-5535187253c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ccbbfa18-4020-412e-b2de-ffea359a8cdd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PrivatelyHeldHealthcareCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cd026123-bf98-4ceb-963d-51e954864642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_cd1ae492-3baa-4fd2-89f9-afa8f30347b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="C_cd448608-93c9-4efb-8910-d496892f68f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cd6017c9-4e6d-48a6-b778-fdb58ebeeb24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_cd9cf8cd-caf0-4230-972b-b59ef42f7629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_cdc0f154-9e15-4dde-bfd0-dcb748170232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_cdd50e55-f430-4309-b1e7-fe3c5bc72c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_cde889ec-684b-433c-ada2-fcc698632fea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ce943a5c-4a0c-4116-8b1d-c757694d1ea7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_cfb09673-608d-4b9a-af24-b826da8f9edc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_cfe17d12-81a1-4510-9340-bf18810ec8cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_cffa7db5-8a40-42ec-a6b5-dae4eff5e8a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementThirdAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d029c0a8-0421-4544-b742-f93ceeea6d0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d16801eb-dbe6-41b0-b0a9-f2ce69282a79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-03</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d1a545a6-5a9b-4ad3-bbfb-5c5207b1a1f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d2c0826f-e79a-4fce-bf90-c8a92ab2dc99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-04</startDate>
            <endDate>2024-03-04</endDate>
        </period>
    </context>
    <context id="C_d3132f94-898b-45b9-b231-38bb9e3c6785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d34cdf08-8e0e-4cba-93ee-569a80e0e67a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d383d05f-380a-46b9-b425-0ac125742038">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SyndeoTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d4b33ce8-c2ef-41f9-aa40-07f4e9d94111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GARDPCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_d4eb0f40-5fd8-4cae-9d09-795c67481067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d5482eb7-e694-4625-b420-b8cb85d4fcf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d5a54e09-f59e-44b6-9cef-6b6ac8a95a30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_d5e9003f-7e55-4b05-bab9-c11fa367b435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d616bb07-0b13-4397-853a-6fd375bf2296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d61eb3bb-dfd5-4977-b307-3cce0652657c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-13</instant>
        </period>
    </context>
    <context id="C_d68a48b8-3d2b-4af8-8344-60a112a209cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d7a7bab5-9ba6-49af-9860-25a6b42523d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:OneDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_d8352266-b969-483f-a6e1-84e3c07a9a0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d84e455d-e7e3-4fbe-a104-3abc49e8a445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d8ba1e61-eae2-49b5-9a4d-794567463681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CostReimbursementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_d93a2eff-6ca3-4b72-bc94-7f262d74a800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d94e644a-a7b1-4e62-874d-457ce3a49fd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d9b8c46c-1584-49b3-91b6-cc0e6d57dc59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_d9f02cfa-bf5e-4cd1-b720-fcc2c4210f0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d9fc309a-2db6-4a93-97f8-d69062730902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_da7cd9c6-74d8-41bd-9505-fc9787b73b1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_da892b74-d5b8-42b1-8209-9456006bda02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_dc46e272-bbf4-4eab-89a7-9149f700ad25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dc58284d-69c1-4202-ab83-45c4db4ecabd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dd617a60-08f2-42eb-9dd4-dfab3845fa6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_dd8d8977-0825-4ede-9687-2466de66c5ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSeniorNotes2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_dec7ee2e-9d77-490d-ada1-7ee27d46f370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_dedec735-1cff-4546-aac3-c4141f2f6fda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_df134efd-b2f5-42e0-9b07-1a512098141d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_df4709cb-5656-4808-aaeb-b3ae91bc5fa4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_df4f1b43-9d3e-4a14-9590-f19507b86007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_df8082d5-dcbb-46aa-82da-38d9db7a2979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_df9c0c3e-3b7d-4a88-ab6a-0a4e4f883405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e04b23c0-4934-4a7e-8859-cd38d15f9bd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e1ad7b2e-47ad-4939-9a26-e2ea2a39b2c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e1b0f380-3db6-410d-886f-3625779ce5c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e24022f1-53bf-42f3-8620-65afbf8aacaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ResearchAndDevelopmentSupportMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e3289eef-c9f9-4a85-b3ce-87f3497ce8fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e593a339-fd70-42b1-8675-8d814fad602a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_e63ec4f7-4b80-482a-8302-9464099a0226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonAndPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_e6682ffe-c7e9-4815-8a85-1e4bef9f2711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_e6747d6c-bd4c-45e0-a2d0-85a45a6f79e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementNoteAmendmentAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-02-10</instant>
        </period>
    </context>
    <context id="C_e6c84643-3ac1-485b-96c6-e0bf066aa3a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e6f36795-3f29-431e-b5be-67d9a5b96459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_e78081be-df8b-41c7-9089-842b6fe1de71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:OutstandingStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_e7b60c9b-de37-4c35-8699-180e5b96d972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-02-13</endDate>
        </period>
    </context>
    <context id="C_e82b4635-6ed4-4056-a68e-3a47f6f2bf52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_e874e2c8-b06d-4058-bc9c-21db422ef0fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_ea6a953f-2b67-4ae3-af96-53ae33c766eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSeniorNotes2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_eb066d70-0444-4376-99ff-812e92abf2af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_eba3e649-4d0f-4556-81f6-48a349c1b9b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_eda262e4-057f-4998-b423-d9e9d577d4f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_edb34f03-0687-4952-862d-bb3107aa1b2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_edc82119-8135-4036-9cd5-7abc8eaec84c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_edcdd009-7706-4509-a58c-1bface603eba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:AmendedZaiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_edef9231-0188-4d5f-a4e7-cf5bc1070d0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ee82b043-3066-4252-90eb-266f31f3d243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_ef64ca1c-fe1e-4b9a-b5ff-0a15d056fed5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ef7ae83f-f2f0-4dcb-9863-3d6a3a3a1d5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f09d870b-77a3-4a19-9ef4-c0fee32e4890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_f0a0f488-206c-45bf-a6fd-b8fcfefad049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f0b8d42e-b800-4698-921e-c7324bfbf8ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-01-31</instant>
        </period>
    </context>
    <context id="C_f112be36-1143-427f-b42f-2840c6a15d3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f1250457-5420-4587-a034-747d2328f6e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f2435011-c3ca-4e3e-a7fb-09a9fb137c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f270105d-3047-4709-8eb8-f148d9149e12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f35060c4-ee1e-4ad2-ba59-f9405ab750db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginAbNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f39f8aa8-a20f-4ba5-a3cc-dabb232aa3b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f3dedb00-89d6-46cf-b991-17d8708476a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistRelvarBreoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f3e35d02-64c1-4f38-892b-bd07f5fe2a4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f3e8c321-fbbd-46fe-ad52-a5cf85e12e92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f41b7af1-e738-4a48-990d-dc1756c13b91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-10</startDate>
            <endDate>2023-07-10</endDate>
        </period>
    </context>
    <context id="C_f46cd1ad-fe1b-4bf9-a5a9-24eaba3fb3e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_f4ab2bfd-74a0-46cc-b06e-1c474c19a909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f4ddf483-cbed-4109-859d-418fd5e83000">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:BeaconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-07</startDate>
            <endDate>2025-10-07</endDate>
        </period>
    </context>
    <context id="C_f4e52e0e-68f9-43ec-b6ac-caf887da2c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f609d5f9-7bd6-42d0-b989-6627052c05d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-11</instant>
        </period>
    </context>
    <context id="C_f6149710-30b2-49fb-9741-3ac89487f3da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f6ee4728-a9e0-452b-8662-22a92283709d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f729f8a6-0459-456b-904e-a2336cd2e856">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f7570aba-c10f-4b03-a0ca-5d70ea46865a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f7d4ec88-c122-4840-9402-055ba9f5e83a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_f8268174-30fe-44ea-9afa-6854f75ab23e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ExternalServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f82e39f9-72f9-4bd5-b3fc-b3493d1d8807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f8691cc5-0a6c-4194-a0e6-b3ab90155c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_f9011696-e416-424e-81a2-652447e4d8f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f9044951-f126-4cbd-81bd-331f45565190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_f94f64d0-bc96-4573-be4f-370b739bbc44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-24</instant>
        </period>
    </context>
    <context id="C_f95dc6c1-8efa-49b3-a724-7a4ea46f1fbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginAbNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f96d3f3b-e048-40f2-a04c-39e52cb01dc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_f9ab7abf-030e-4411-a666-c1a654015dea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f9cd9435-3b1a-4e9d-ac1b-86dd50e61463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_fa0155b6-2f2e-4092-af25-363aa5a35539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_fa06863c-352c-41d4-8c55-7aa19e82ca77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_fa3ac63f-9ac1-406d-b258-7e778b64bfce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_fa5bcc25-8b49-450a-9892-dbd82bc86c2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fad3e9f3-1f85-4bfc-bf22-a300d00e3a74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementFifthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-13</startDate>
            <endDate>2024-11-13</endDate>
        </period>
    </context>
    <context id="C_fb40e1d0-39fb-4a52-b44c-a1ea5cf0b3b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fbf1519b-20bc-45f3-9a32-993d11ff1a9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_fc19a322-7a4a-4f36-9e91-32fa80c03ca7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_fccd77c7-2dc9-4f27-8f85-1f5935f7a45a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSubordinatedNotes2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_fda3c94b-7cd8-431c-a448-eca3c92b1451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fdb03ab5-f84c-4ddc-bd5f-542862b94835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_fe69aeef-ca75-4945-996a-5e2bef7daf59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:FirstAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_fe80c249-d33c-4cd6-b2cb-331be1cd34ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_fef5d651-506c-49a8-b89f-8a979f8b0712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ff05dc94-b555-4348-9109-aa9b60fb068a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-27</startDate>
            <endDate>2025-02-27</endDate>
        </period>
    </context>
    <context id="C_ff24ff88-61ab-4e42-8c4e-2eef4914adc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_ff2f5579-9b38-485b-a615-3c335d3187e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_ff591898-83ba-4b78-b062-c4cab6cf47a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ff805685-7f62-44bb-b91d-537b589a7c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_ff91d1f1-1412-41c3-9883-093cc75f3130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_00b91c9f-9ab7-4b39-b007-fe9dae159be4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-27</instant>
        </period>
    </context>
    <context id="C_01846029-76af-4077-9228-68d2343d26d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_019d5edd-4fa8-40e3-80df-2efde6dc1a3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_01c6be5d-cc54-49d6-8b11-353961389b35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_02167381-4ee7-420f-9702-aa51b2304727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_034d4c49-cf20-473a-895d-63d5870c2084">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_03780f91-4f1d-4cc3-9ff3-8ab31a4af745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="C_042d99c8-ff64-4441-b079-f3c23a00eb99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_04a98a7e-c9c5-4c07-a755-8f30a3c84501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2026-02-13</instant>
        </period>
    </context>
    <context id="C_04b74a31-e5ca-4397-96ef-3eea91f0c2cf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="C_04c59b2e-4232-4562-8d3a-6d189af3be61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_04f37986-0461-4c18-9d26-c9e485b3a1d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_057e1553-e322-46f8-92dc-4d5d487f40f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_05ee92da-ae00-447e-a688-0afb8debabd7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-09</instant>
        </period>
    </context>
    <context id="C_062943f2-bfca-4bcb-a912-8bfca3373967">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_06e9c678-095e-4291-8f2b-762451638db9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_07023259-2cd5-439e-8af3-725f79e6d197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0708cf2c-c327-4fd6-b98e-80fa56ca9fbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_077e2b7e-cd2f-4e0b-80c3-1c50fe7f09df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0865d3ef-f81c-4aa7-9435-994b376311c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_099aecd1-7b7a-4a20-9f80-16d10bb47ae5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_09b660d0-0222-42bb-8926-d6f07d1fabb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PrivatelyHeldHealthcareCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0a0ea9ec-344f-4309-a3b8-19f6282767a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0a146130-5ab1-47b0-bf0f-7f7c0ba94af3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0aacff4b-e1cb-4189-b234-c765198bc587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0adbc8ec-6dbe-4222-bbd2-0e0eba4e778c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:BeaconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-07</instant>
        </period>
    </context>
    <context id="C_0b8a3f4c-cf7e-42af-8db7-51c367053d7d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_0bd76c2e-9aae-4309-9bc2-e14f04493aff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_0c2b17b3-b563-4774-a444-c68ee381c769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaTRCHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0cd22ebb-1d13-4b31-83ad-8d641740a1a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0ce3d616-f0eb-477a-96e3-62c320ccd76a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_0d289cc8-a708-4fdd-8986-e982ca8d731d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0d761fab-b600-43bb-8587-3a27bbbece94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_0d77cda3-d1e7-4fcc-b01e-02245e7164be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:AugustTwoThousandTwentyFiveCreditAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-11</startDate>
            <endDate>2025-08-11</endDate>
        </period>
    </context>
    <context id="C_0df4c929-c558-43df-b2be-57f8e85bb27a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0ea6bee8-0b7a-4347-b4e1-f57199a4e9f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:LabaCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_0f301d28-22f6-430f-bd52-f18b4ca91181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_0f3c27be-b222-4d28-80f0-06ce24daba5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_1006311f-1cec-494d-8c58-386104bc8113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1087a715-1e7f-4e3f-96b3-efbc3f9782ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">inva:LyndraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="C_10c7d0e1-daac-48c6-9186-bfc925a49e65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_10e3877c-4d15-43d4-acb6-50c1c5281ab9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1178105a-9678-4a5d-807b-d01114fd7f0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_11d1f4e6-b778-4765-a18c-a66d5f46ca1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-12</startDate>
            <endDate>2025-03-12</endDate>
        </period>
    </context>
    <context id="C_123df293-7632-4793-9257-bcb8b7a3e0d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SyndeoTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_12c637ab-fa44-4ddd-a290-1d17a74cbbc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyThreeNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleSubordinatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_12cd7049-aa8a-4e80-8d0a-bdec0949c7f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_12d3c44d-918f-48e8-85fa-931a2e84dfd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:DevelopmentRegulatoryAndRoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">inva:LyndraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="C_12d5315c-63c8-4bf3-b585-41fbafc8766c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-31</instant>
        </period>
    </context>
    <context id="C_133b0bae-f820-43d4-8c70-d35ec0ec6a0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_13e41928-9dbd-429d-b2f6-fb0ccfd61a94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_13f8e3e6-05d2-4d76-8e06-db660bf31271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_147f547c-e68b-4615-a58e-a8401c3a3cb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:WalthamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_149ef97f-f1b9-4b0e-9127-348ee02e361e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesC2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-14</startDate>
            <endDate>2023-09-14</endDate>
        </period>
    </context>
    <context id="C_14b19da2-3f85-45b5-891e-2a495389f972">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="C_151edb34-8ed3-48db-aae7-373a462d2c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_186b003f-7e82-489a-af51-10f17f0c7193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_19c66b49-0137-43c6-92ab-0b70a3008556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_1a3c43a6-afc9-4c65-b428-40d7849855d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:InterimSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1b2e2593-a2a8-48e9-bddd-edbd0e4ece93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">inva:TwoDirectorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="C_1b6e4f2c-7f64-4b60-808a-20645b1b5b3b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1bf402f1-50ee-4c77-b54f-409f40ba6ea2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1c0b66f1-46ef-4338-a79e-85c6fc2d1f95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1c131411-afe9-4c15-b977-6fd724e284dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_1c30d3c2-8973-487f-b385-4efcc897f79b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1d50a9ae-0f26-4ddd-b236-2070a1bd7766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaFebruaryTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1dcbb1f9-1291-4438-a7e7-46fd2cf48bf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSubordinatedNotes2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1e11bcae-e1f5-4912-8d5e-346484926bde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_1ef1ff30-e8ef-4d5c-b296-a140e0ecefb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_207224f1-5a67-4870-8fb6-e8fa25e508c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_20899f10-0ff4-461b-801a-ba4175ab2431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LyndraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:LyndraConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_212cc57d-e685-4590-a4bd-6b3b410d36af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_21888485-64fc-4d1a-9d3c-4e0fc17c7633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_218b6839-f930-461a-a25b-b72c22604510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_226618bc-59f6-409f-b441-d4d85c7c9b01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-02</startDate>
            <endDate>2023-02-02</endDate>
        </period>
    </context>
    <context id="C_22dbc318-90d0-4d6c-ae97-fa8f97e6f8e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_239a2a88-4dcf-4e6d-8f3b-5b1398ae730c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:WalthamMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_23f06870-8557-49c9-961b-175324f1dcae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-03</instant>
        </period>
    </context>
    <context id="C_24ba47ce-629c-49d4-9f18-e4bf2ecc9008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:InterimSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_24bf9896-d71a-45ca-9736-8cff19c13d9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_24d3732a-a2a9-4442-b464-10be5d29362f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_257af86c-f735-4442-94a0-70da28449be7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SyndeoTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_25dacf96-e93e-4daf-a92e-ed8eef93dd64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSubordinatedNotes2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_26dbc208-56e7-4883-9c81-a880c188cbbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ParatekPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_2707906b-3b85-4cd4-95b1-7be4334def0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_27624d2b-fd4c-438a-9721-62e1806ce67a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_27718624-7715-45b9-a713-59141c2cdf0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_27af781c-37f3-46f9-b219-825ba2161b60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-02</instant>
        </period>
    </context>
    <context id="C_27e7d8d1-9232-4c08-b557-38898257e2e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:CommercialSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_280efd9d-8c7f-4e28-aa7a-2c064a232238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2840f754-c1e0-45a3-adde-c440dc45dc18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_29299cb7-d62e-4e08-9bd3-8a43b64d6f1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_298833d0-f7cb-4ad7-b8ba-9b8369ac087f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_29938f9f-8929-463c-8242-1fd072e3246e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:InterimSupplyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2a02f41a-febe-490b-af61-93b34070abed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="C_2a498a39-fd62-4604-9c70-6a29b2842bc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-02-10</startDate>
            <endDate>2026-02-10</endDate>
        </period>
    </context>
    <context id="C_2aaa98e6-3d27-48b0-aad0-9021ae880dff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2b3a7dbc-4a58-4808-a400-3b7b5bfb3e69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_2b4116ec-1fff-40fc-9ca2-09b0c69e59bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2bdbcb89-e8cf-4578-a8fb-ed71c2c5c84c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2c380213-e903-4976-8194-728662767074">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2c8dee1f-3ed6-47e2-8225-b5df7bf62a8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_2d1f6be5-5863-4cef-a634-37c4e6881e96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">inva:LaboratoryEquipmentFurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2db96a8e-31d6-4b8d-831e-e5ed59bdbb06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_2e76908f-28df-4262-a9d3-0d9661155721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_2f40b780-c413-4e18-8a24-befa2c076cee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3144e120-55bf-4537-84b6-260e15c16e75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_31784cc3-872d-408e-80c1-6e43cba22130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_31ec6e0a-cd1b-4e7a-af9c-54600d0d24cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-24</startDate>
            <endDate>2021-11-24</endDate>
        </period>
    </context>
    <context id="C_320697d2-fba1-4b46-89cc-25782f7895a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_324ea22b-17bb-44c8-a2ce-76361d644371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_325eaf5e-1225-4fc5-8b0c-361313195292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:InternalExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_32606254-e0d2-4b64-9791-54065180e259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_32dd02d8-2a15-4776-ae72-8afc37de465c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_330d6cb8-f79a-453a-8e56-a035cce53878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_338be7e3-2228-4533-9b23-3397a873d3d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_33a0dd32-8b33-4cc0-a555-d73ff67cc33b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:Outstanding2028NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_33e42f5b-3543-48dc-a026-c6016772a37c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3417b179-deaf-41ea-bd39-7e434b1db032">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:ZEVTERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3429ea6d-1cb3-4c6e-8042-4861d0863d2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3495636e-7fc4-46b6-af0e-05bbaa199981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="C_354e4e76-7396-4ce2-83c0-4f6d52adcbf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ImaginAbNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_35672b5e-10a9-4748-974c-cf69a518b68a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">inva:PrivatelyNegotiatedCappedCallOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_36784711-520b-456d-b873-8cb8b780364c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_36cd9246-caa5-48b0-9537-3ae622ca29e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_37077e55-6b0c-4d75-94c1-1392a17c7ed1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">inva:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_380b4395-2715-4251-a2b6-448e3fa77f25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_382677ef-0151-430b-8242-c000796ba331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_382fda11-b7da-4cb9-a380-3dfa11099b27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_392076d3-b2a9-4556-8800-6b9f6d3a290c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:BurlingameCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="C_39ac42ec-d15a-4d4a-8811-92be23f2bc67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_39ce9270-cfd2-49c3-a23e-79c0108afb55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-11</startDate>
            <endDate>2025-11-11</endDate>
        </period>
    </context>
    <context id="C_3abf2681-e826-490a-9f8d-3f1f04055925">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3acd791d-ece0-41d0-bc86-551014479aa6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3ada3581-7aa9-4d91-ab9a-3ad5ffab6e1d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3b0f0144-4aec-4d86-b2d3-8de8224c3e06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_3b12d761-39cf-4255-8780-b3b2751a6c1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">inva:LyndraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="C_3b886698-cb56-435a-ba7f-fa72f4cd20b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3bff7c8d-4fd0-4e48-9974-ccd04b2d1f78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesD1AndD2PreferredStockAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_3c82e86c-b476-42ba-91a7-f0f73b075d88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:WarrantsPurchasedIn2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3d13bbf9-1c66-4a28-8180-8bf6ce3c7cf1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3d42c24b-11b8-4363-8d74-c335ae153268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:NUZOLVENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3dffd990-dade-4459-b4ce-3100fb9fd1df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3e7b3a72-d1b3-43e4-a867-2e38a049c660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_3e958a1c-5aa6-4afc-bf9d-697d696cd0d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3f151714-cd61-4ea6-ad22-1659ee2f8ad5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LicenseAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_3fab1ccf-3d72-436d-a37b-efac6941b37d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:NanoliveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_418a0dcc-491c-4849-aebf-ba4f6c3031b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_41a7f5f8-871b-473c-8a7c-344fe2fe6e67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_41adb887-7a52-48c3-afd3-50e8cb0adad6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:MassachusettsInstituteOfTechnologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:DevelopmentRegulatoryAndSalesMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_431e9250-fc85-45e0-9b9e-fac3bf029cec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4486e6d7-5936-40be-8a70-b6ae40d88127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_44c21172-b919-4027-9bf1-950d87ebeb9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_45a109c5-a8b5-4d0e-89f8-924a6b01af29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_45abe52e-ab8e-4973-995e-7e872a676421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_469092aa-cbc1-422f-9923-e5ef71f3d779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_469524bb-7a40-45d6-add1-6f69d2db9a3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">inva:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_471e4740-1ef6-4b64-a705-0ba2683dbdf6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:EverestMedicinesLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_47f20a31-1968-4d82-910b-3b3a4558e7f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_486828c2-55c2-4eca-a8e9-7c9edc91e774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_488c264e-0d44-4a7b-be6f-0dd0449e0750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_4960e33b-4020-48cb-aad3-a6b5f4fac807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_49a08cdc-4904-4992-b261-91482376f0e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_49e868c2-e9b1-41c3-8d56-b409dce02365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4a06a460-8b26-42e1-8a9d-000242e512f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4a9464c6-6ed0-4486-afcb-9d89092af626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4ae30dd2-d091-4534-84e4-23090114dd52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4b612ee6-394a-4ddd-9bcc-6ab2bb1b034d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4b63e0ee-2b5b-49b5-91dd-4aad8b8b0682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4bf5fc18-5406-4a53-bdcc-a726e4be6261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4c9b62cc-926e-4197-953d-72eddcf7b41d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4cbd448a-5be2-4867-9b30-17f58446ee15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4cc8caa7-35e9-4140-a986-58a3062ca160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">inva:MarketedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_4d8365a9-4d70-40de-b8a9-6b5b33f255fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_4d8ac49a-79f0-4d4e-96ea-3e8f524a2c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_4daceff5-03ad-4f3b-9aab-ba819d229412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_4de9fb1e-acdc-4b5c-a627-40990c7b5d38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-01</startDate>
            <endDate>2025-11-30</endDate>
        </period>
    </context>
    <context id="C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="C_4fb4788c-8450-4c40-8d91-a0ffb3b4ba73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="C_4fd4e6e2-8b75-4ad1-8522-73d454c9804c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5038c961-a52a-4d07-b20a-2ec350ef35a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_51398c9e-10f3-4ea8-bf6f-402b631244a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XacduroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_51b3b591-fbb0-4d6e-bbcc-a2b9316cdd48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:CommonAndPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaTRCHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_5269be09-0f8f-4632-b948-cb713105102a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaTRCHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5328b425-8576-4d5b-b1db-1f14e4c9c1c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_53386bc7-321c-4778-9d99-1014173440f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_535e864a-6312-4cf7-8e63-b685970f14e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:SyndeioTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_535f3e0c-ae46-4c2a-8349-1e7df0cae7a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_54e7dc78-e88a-4740-abbe-66bd616fae5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-15</instant>
        </period>
    </context>
    <context id="C_553bd178-313c-476a-ad6e-7c4ee1a08840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:Outstanding2028NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_555d4978-0156-480e-84ba-fa2f5dcd4d7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_5569e7b8-6eba-4eab-95a9-c63e219f2e99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_55bf4b19-2b2e-4acc-9932-1d7bd7182c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_56003be5-dcb8-4576-a7f1-796756b2432a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SecuredConvertibleCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-12</startDate>
            <endDate>2024-11-12</endDate>
        </period>
    </context>
    <context id="C_56591878-41f9-499d-94f3-2f81c2c8216a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">inva:OptionPricingModelBacksolveValuationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_569306e7-f6a0-459f-8db9-5647b77e5c0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_57143738-0b15-4679-be4b-a0bb824f5ceb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PrivatelyHeldHealthcareCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_577dc48e-2a7c-47ff-9812-6a80348a1bd8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_579c7936-813d-4e3d-9f7d-e6cfc757d33f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_57a06a6f-d5cd-460f-9bf8-b3b9d0f6d3ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_57b6c234-c606-4323-ad48-c327ece76f82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_58579f73-59ce-4061-ba55-4d11270a76d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5860c68c-4659-40da-819c-f9dc3f832bf9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GatesFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_5883bac0-e505-42e6-8df8-70275b1d4f0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_5a6dce6c-043b-44f3-bc89-efae60e40aff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5a9347c1-884d-4675-bb79-fefe358e833d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5aa5d39a-f76b-4524-93e9-30d0fefb1a3c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:JulyTwoThousandTwentyThreeCreditAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-10</instant>
        </period>
    </context>
    <context id="C_5b273474-f0c1-4173-8aa0-26b3ab51f2c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataJulyTwoThousandTwentyThreeTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5df29ec0-a027-4d1e-9bcd-9baa6703c4dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_5e004e9c-f37b-4fd8-92e2-d31164aba4bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-03</startDate>
            <endDate>2025-03-03</endDate>
        </period>
    </context>
    <context id="C_5e4ede51-f604-4176-b6c8-a3365d117e9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:SyndeoTwoThousandTwentyOneConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5ec47d1f-c03d-4375-b74a-6537aa407098">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_5f25c1f8-433a-423e-bc21-4d71d0ad9d56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5f2ad567-e08d-4636-8f55-1c301878579d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-23</instant>
        </period>
    </context>
    <context id="C_5f44da0a-72da-4d0d-94ce-34a247a0ea76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_5f76e50f-7b05-4925-b65f-40d08587b5e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-08-31</instant>
        </period>
    </context>
    <context id="C_60ac9e5c-2514-4f92-bf1c-12266b1917e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:MarchTwoThousandTwentyFiveCreditAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">inva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="C_60c399b5-9347-43a0-b627-5c8557009839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">inva:ManufacturingStageTransferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_61fa56d2-4262-4f72-ae36-ba8d54b9623c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:LongActingBeta2AgonistAnoroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_624b9c2f-920f-4d24-9aec-1525f5843027">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_62615169-458a-41ad-b0f4-aecf5d54890a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_627f6c4a-256d-48b2-9ebe-195f372836f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_63c51235-4b1c-4afb-8d74-575ce49ff152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_64469642-d4d1-4b61-893c-cc3938dfe822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_647c691b-abd8-4afb-8bcb-ba9c9d68ba72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_65d91678-0767-41c7-b95e-8b5037c60129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_65e0e8e3-95a0-4c30-a38e-3f2f6d7a9494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:EntasisTherapeuticsHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_65e207cc-7ebd-4bcd-bb6b-e27d80d3a005">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_66187a73-ceaf-4466-bbd1-1b86eb8fc0ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_661f58ec-6b2b-444d-8088-4abba363c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_66b32c2c-80ce-44d4-8bd3-c90a4562ba4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GeorgeWashingtonUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_675639ab-20e9-408c-8ece-4bd0da8c908c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_67ee3158-4444-4bb2-b548-1b1d24bb1077">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_689c9adb-8230-4574-87c7-dc46032a5878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_6975b245-2632-4293-87d4-04681539a20a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ImaginabConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-05-01</startDate>
            <endDate>2025-05-31</endDate>
        </period>
    </context>
    <context id="C_699a8187-6daf-4c19-b630-e6a4a350936f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:LaJollaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">inva:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_699b00df-194d-4b74-87b8-434384a664eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6ab3cefd-f2b3-40bc-8f3e-a411da14524e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6ad32d18-a6d7-4bbe-9f9f-6e1ebf92e327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6b2a5a0e-88cb-4767-81b9-afb899aec69b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-05</startDate>
            <endDate>2024-08-05</endDate>
        </period>
    </context>
    <context id="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_6cf653d2-0adb-45e8-8c5c-d69aedde6497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IncardaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">inva:OptionPricingModelBacksolveValuationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="C_6d3c556c-fb3c-4b80-9075-4471ffd20f1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ConsolidatedInvesteesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyEightNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6e51128a-27f4-498a-bddc-0169559f0163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataMarchTwoThousandTwentyFourTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_6eab99bf-0d7f-4d97-8fbf-07f56573bf4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_6f8efa75-54a0-48d2-91ec-df3a956405f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:SeniorUnsecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="C_701cd6fe-36d1-47db-83fe-0af44777997c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_70f1d216-d03c-43ba-a8b1-76808b9d2366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:EquityInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_71ded7c0-3708-4f52-b6c3-6791c394800f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:MarchTwoThousandTwentyFourCreditAndSecurityAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-04</instant>
        </period>
    </context>
    <context id="C_71f99e54-19e3-4788-8727-45db0240d021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_725e5a87-52ac-4ac2-b62f-1bd660bfb6b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_726df857-6023-4423-a3a4-cf7d258b67aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:BeaconMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_734a0615-eb7b-4e06-bf8d-3b288821b245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:PaionAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:CostReimbursementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7359dc8f-bf3a-4063-889d-7a710c70a4de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7375bdeb-c66c-40d4-84b1-149ba7c7ef18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:ConvertiblePromissoryNotePurchaseAgreementFourthAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-05</instant>
        </period>
    </context>
    <context id="C_752dd2b0-0df3-4258-a0cf-06ce4b3c92b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">inva:LexingtonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_75c1d9ea-1aaf-4126-af63-8748312d93ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:SyndeioBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyOneConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-24</instant>
        </period>
    </context>
    <context id="C_75cd5b3a-0884-4009-a949-d0f1c664d036">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:GeorgeWashingtonUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:GiaprezaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_768acc31-d49a-4b35-b48a-e542af02b049">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesC2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-14</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="C_769493ad-88b4-4914-8b59-414f7ab2d4da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_76beba6f-76b3-4d02-8823-4ee147f6a8e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_76c325ef-f27e-4ba8-812a-698b1f542dd3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_772c1d45-e01c-4ce3-82b8-60c2d33c65c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">inva:XeravaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7750e87c-0533-4d37-95fe-b10ee03f2aa0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">inva:EquityIncentivePlansAndESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="C_77ce6bd4-4c92-464e-b740-78890313ec04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HarvardUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_77e3e771-6d57-4a46-9631-a87f355431a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_79652bcd-01ee-4bef-9367-fe4171e3c756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="C_7a37ea45-0a90-4314-9d33-c1291075e4f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:PubliclyTradedHealthcareCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7a5124fd-be46-415a-bd57-ce5d37c15986">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaTwoThousandTwentyFourConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7a708fd2-25d5-452c-aad6-d6903d0cf646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">inva:EquityIncentivePlan2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7b057564-e9a8-48fe-95f4-7b1c776ce39d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:TwoThousandTwentyFiveNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7ba50ae3-7184-4972-bf26-f59e81848d23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ImaginabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:SeriesCAndC2PreferredStockAndCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7c5e8ad9-8a6d-4d11-ab0d-a7fdde037e56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:InCardaOctoberTwoThousandTwentyFiveConvertibleNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7d17d6ba-9603-4070-a7ab-088eeb43a446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7d786c4d-9bc2-4c05-9835-fe6f2d5d9c1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7d8daa92-8559-4d7e-9e07-c21e30f977fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:ArmataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="C_7e124fea-d3ce-4c96-a71c-c223da3547f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">inva:LaJollaPharmaceuticalCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-22</instant>
        </period>
    </context>
    <context id="C_7e31beca-2974-46b0-a791-da8703f2803a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">inva:HealthCareRoyaltyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">inva:RoyaltyFinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7f44cb79-0c20-42d0-9a50-561aefbd0d23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">inva:ArmataAugustTwoThousandTwentyFiveTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">inva:TermLoanInvestmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="C_7fba1762-844e-4c04-b43c-b15c482e2679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">inva:IspFundLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7fd95b23-44ee-494d-bdcf-53246745fc95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001080014</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">inva:ConvertibleSeniorNotes2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <unit id="U_Director">
        <measure>inva:Director</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Item">
        <measure>inva:Item</measure>
    </unit>
    <unit id="U_Customer">
        <measure>inva:Customer</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_BoardMember">
        <measure>inva:BoardMember</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_Installment">
        <measure>inva:Installment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_b7b36e0b-b301-4469-9fab-d0f484005491">0001080014</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_53b1dad4-f054-41cd-9ce2-8adc44e8f7d9">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_39bb3937-57a8-423d-bdaa-2f559b4b98e4">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      id="F_535b341f-6db5-401b-a3a5-8bf671fbdba5"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      id="F_ccc3aab4-a06b-4ff8-8274-4eb2a635f659"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      id="F_6a206859-f8ee-400b-9d66-43ec2846665f">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      id="F_17be60db-4ed3-4806-a6df-7a78528c373a">http://fasb.org/us-gaap/2025#AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      id="F_e88a4c0d-7875-4370-83b2-18dc892d7674">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      id="F_4bc47aec-cd74-43b5-88dc-6e2c9250c57b">http://fasb.org/us-gaap/2025#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_392076d3-b2a9-4556-8800-6b9f6d3a290c"
      id="F_a8d055de-5223-43f2-950c-df6e42a40b2d">P36M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_aea5d4fa-0e83-4b75-87db-300c5e0bf84e"
      id="F_0cf4230b-14d7-4c03-83f4-80f2b6b31b1a">2027-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_147f547c-e68b-4615-a58e-a8401c3a3cb7"
      id="F_f563af2d-08d9-49fd-bae4-6b8f93526198">2029-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_752dd2b0-0df3-4258-a0cf-06ce4b3c92b9"
      id="F_7683dbb5-aa29-4655-8dae-71a88a149d59">2029-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      id="F_f5f169b5-7b43-492f-b75e-5037a78edaec">http://fasb.org/us-gaap/2025#LiabilitiesAndStockholdersEquity</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:AssetAcquisitionDateOfAcquisitionAgreement
      contextRef="C_b3eec335-a345-4b7c-9e97-3ceddf99d1e9"
      id="F_886ab7f6-fedd-4b48-b757-553a486cfc22">2025-09-30</us-gaap:AssetAcquisitionDateOfAcquisitionAgreement>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="C_a676b1bd-fe43-4060-abbc-19a8821970e5"
      id="F_d97c91ae-1703-4480-a2ca-20778c18458e">2030-01-01</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="C_9ddc8c4a-6ab2-40b5-8423-f2cd290e57a1"
      id="F_e2ca3e4b-1265-4708-9028-4bacbb4bf6a7">2033-01-01</us-gaap:TaxCreditCarryforwardExpirationDate>
    <dei:DocumentType
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_cc67307e-4d30-4970-8f0d-e09c2c17e6a3">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_3ab6ec7f-ae3d-49da-a26d-0e2f401e8966">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_4de429b5-efa3-4f5c-a253-1474f898d575">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_ab492e06-9ff9-417d-9ed2-9de90ff52543">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_b8c3ac37-1dff-442b-b2d2-cc894b775f93">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_a06ec575-fc8f-46d2-aa64-5cdc831c4f68">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_30dbaee1-272b-4bbd-a7e6-12950a4427b3">000-30319</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_3b3722f2-054e-430b-bac9-520fb5732a26">INNOVIVA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_8d12146a-9267-4113-bb83-9692b1b241b3">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_1d2360e0-deee-4c8b-8677-9ebd1d77c778">94-3265960</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_2c74ebdd-835b-4f51-aecb-37342ce88810">1350 Old Bayshore Highway, Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_50a69bc0-7169-472d-a726-502e0826f71b">Burlingame</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_76bb179f-8df7-4c20-b5d8-20ca83308745">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_2486dafd-9950-471d-86ad-db4f0bd94c51">94010</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_f6482f74-99c6-400c-b18a-73a0116e44db">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_7a792e13-3bb8-46a5-8783-0d349d8edeba">238-9600</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_84b77f46-7c0f-485d-a90c-ae93521e9dbe">Common Stock $0.01 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_f41dd007-30b0-478c-8a94-c4ca552bdf3a">INVA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_4474cf7a-459d-4f29-80aa-b79fd8cce3da">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_a50ffbb7-b411-44af-a290-df0925ac9610">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_b2d53ea1-7a2d-4155-a5c9-7091236dbebe">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_a8bd089f-a4b8-41d0-8e40-58bea473f48f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_fe4b95fa-bfad-4af9-a2ae-0dccb174ee50">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_58499c67-be7d-4212-9331-e1d622e776a6">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_97f21cc6-fa5c-488f-a3aa-b51a644d4eb1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_d1a67592-4272-4881-8a4f-8033b4fcc28b">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_85ee244b-744c-4766-8ef2-56fc38d31823">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_ce9a96d8-2334-4e7a-991f-c502dc490a1c">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_a907693b-aec4-4a3a-90b2-ca9fcbe95673">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0d761fab-b600-43bb-8587-3a27bbbece94"
      decimals="-7"
      id="F_4b8e835b-df1a-45b5-b8cf-d0ee4e2ba250"
      unitRef="U_USD">1260000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_04a98a7e-c9c5-4c07-a755-8f30a3c84501"
      decimals="INF"
      id="F_a88f43dd-4d5c-4326-ac8b-002a1c35245f"
      unitRef="U_shares">74073646</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_894bfa2d-53b1-42c6-bca9-569975fe8b94">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Specified portions of the registrant&#x2019;s definitive Proxy Statement to be issued in conjunction with the registrant&#x2019;s 2026 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant&#x2019;s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_72d9685b-bcad-43f2-81bf-b2c6617ebbb3">&lt;p id="item_1c_cybersecurity" style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ITEM 1C.   CYBERSECURITY&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We conduct risk assessments to identify cybersecurity threats at least annually, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. We devote internal and external resources and designate high-level personnel to manage the risk assessment and mitigation process.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of our overall risk management system, we monitor and test our safeguards and train our employees on these safeguards, in collaboration with human resources, IT, legal, and management. Personnel at all levels and departments are made aware of our cybersecurity policies through trainings.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We engage internal auditors and other third parties in connection with our risk assessment processes. These service providers assist us in designing and implementing our cybersecurity policies and procedures, as well as to monitor and test our safeguards.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025, we did not identify any risks from known cybersecurity threats, including because of any prior cybersecurity incidents, that have materially affected us. However, in the future, we may face certain ongoing cybersecurity risks or threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#x201c;Risk Factors,&#x201d; under the heading &#x201c;Our operations could be disrupted by failure of our information systems or cyber-attacks.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Governance&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our executive team, primarily consisting of our Chief Accounting Officer, Chief Financial Officer, and Chief Executive Officer, in conjunction with our information security team and third-party consultants, is primarily responsible in assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The qualifications of our executive and information security teams include a combination of formal education, current trainings and certifications in systems, network, and cybersecurity and over 50 years of combined experience in information technology and cybersecurity matters.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;They oversee our cybersecurity policies and processes, including those described in &#x201c;Risk Management and Strategy&#x201d; above.  The processes by which the executive team is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents includes the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;They provide briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.  &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, they provide briefings of any significant cybersecurity matters to the board of directors as well as an annual update of cybersecurity risks and activities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_592bbf51-88f6-4fd4-8d34-8a4b84b5120d">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_49ec6755-9725-42b6-8ae8-44dfdc57e56f">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_f1096183-9881-498c-a628-ac60842d8379">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_8efdffc1-0972-425d-8c37-8cf9b7cd1a2b">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025, we did not identify any risks from known cybersecurity threats, including because of any prior cybersecurity incidents, that have materially affected us. However, in the future, we may face certain ongoing cybersecurity risks or threats that, if realized, are reasonably likely to materially affect us. Additional information on cybersecurity risks we face is discussed in Part I, Item 1A, &#x201c;Risk Factors,&#x201d; under the heading &#x201c;Our operations could be disrupted by failure of our information systems or cyber-attacks.&#x201d;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_1b084be6-93b6-4b70-aeb5-e3dec83a8ac9">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_9bcaff1c-eea0-42d5-a8b8-ab6357c45492">&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our executive team, primarily consisting of our Chief Accounting Officer, Chief Financial Officer, and Chief Executive Officer, in conjunction with our information security team and third-party consultants, is primarily responsible in assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The qualifications of our executive and information security teams include a combination of formal education, current trainings and certifications in systems, network, and cybersecurity and over 50 years of combined experience in information technology and cybersecurity matters.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;They oversee our cybersecurity policies and processes, including those described in &#x201c;Risk Management and Strategy&#x201d; above.  The processes by which the executive team is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents includes the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;They provide briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.  &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, they provide briefings of any significant cybersecurity matters to the board of directors as well as an annual update of cybersecurity risks and activities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_62e8ac27-a7bf-4380-acbb-e1c1a37f212f">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One of the key functions of our board of directors is informed oversight of our risk management process, including risks from cybersecurity threats. Our board of directors is responsible for monitoring and assessing strategic risk exposure, and our executive officers are responsible for the day-to-day management of the material risks we face. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_f1386672-e0ee-41c0-b387-0ef9f696b8d8">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our board of directors administers its cybersecurity risk oversight function directly as a whole, as well as through the audit committee.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_8b847483-46e5-4bbc-ad0c-f9144ecf3a6a">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our executive team, primarily consisting of our Chief Accounting Officer, Chief Financial Officer, and Chief Executive Officer, in conjunction with our information security team and third-party consultants, is primarily responsible in assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The qualifications of our executive and information security teams include a combination of formal education, current trainings and certifications in systems, network, and cybersecurity and over 50 years of combined experience in information technology and cybersecurity matters.&lt;/span&gt;&lt;/p&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_b866d93e-c989-4a68-9c46-7cbc6447580f">&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our executive team, primarily consisting of our Chief Accounting Officer, Chief Financial Officer, and Chief Executive Officer, in conjunction with our information security team and third-party consultants, is primarily responsible in assessing and managing our material risks from cybersecurity threats.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_e2ed6135-f2d1-4f9d-bb70-5b056362089d">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_cc7f68a8-f441-44b8-93c0-cdee7f904a9a">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;They oversee our cybersecurity policies and processes, including those described in &#x201c;Risk Management and Strategy&#x201d; above.  The processes by which the executive team is informed about and monitors the prevention, detection, mitigation, and remediation of cybersecurity incidents includes the following:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;They provide briefings to the audit committee regarding our company&#x2019;s cybersecurity risks and activities, including any recent cybersecurity incidents and related responses, cybersecurity systems testing, activities of third parties, and the like.  &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, they provide briefings of any significant cybersecurity matters to the board of directors as well as an annual update of cybersecurity risks and activities.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <dei:AuditorFirmId
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_f1002141-7227-47c2-b072-47d6ee4557e1">34</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_bda131b1-875f-4961-94b9-eaf011ae65a9"
      unitRef="U_USD">550941000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_06d593fa-3983-4e6c-8e11-5e684f8b6a0f"
      unitRef="U_USD">304964000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_836da64b-2345-4ca6-99c9-664848c7b040"
      unitRef="U_USD">34966000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_0d4becb9-50ed-4dc1-9841-a3c5f9924923"
      unitRef="U_USD">20392000</us-gaap:AccountsReceivableNet>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_cdf07704-ca6f-45ae-975b-fc60fe89bedd"
      unitRef="U_USD">58351000</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:ReceivablesLongTermContractsOrPrograms
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_12adb937-b0a0-47f5-861f-7aa2d3aeded2"
      unitRef="U_USD">65974000</us-gaap:ReceivablesLongTermContractsOrPrograms>
    <us-gaap:InventoryNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_bf42a752-85f6-4d27-9282-e4e5b739f971"
      unitRef="U_USD">39172000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_32ecac78-2d39-4ea7-856c-0aba6b9a62e9"
      unitRef="U_USD">33725000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_dc2c6ae4-2b83-41ae-b6fb-706d651be38a"
      unitRef="U_USD">26721000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_e9b66df0-a4bb-442e-a9c9-bd0dcf940869"
      unitRef="U_USD">21063000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <inva:CurrentPortionOfISPFundInvestments
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_0e6bd114-f1f8-45e4-82e0-7e5ffdcfe229"
      unitRef="U_USD">15727000</inva:CurrentPortionOfISPFundInvestments>
    <inva:CurrentPortionOfISPFundInvestments
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_45191efd-af54-4f7e-a38a-dd913076cd11"
      unitRef="U_USD">107532000</inva:CurrentPortionOfISPFundInvestments>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_042f6b68-18b9-4ef2-af7d-cfa6fb6f9c45"
      unitRef="U_USD">1637000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_0001e971-606c-4dcf-bdf0-ab9d4598ac14"
      unitRef="U_USD">656000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_2a769caf-d515-453e-9247-513b30a1a512"
      unitRef="U_USD">727515000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_a5d453c6-131c-45a7-8b56-a19ac7c24f1e"
      unitRef="U_USD">554306000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_36645973-be1c-4289-b93d-291bbb4883c5"
      unitRef="U_USD">1555000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_a4a7cfa5-c61b-4b40-924d-2d140d58aeb6"
      unitRef="U_USD">514000</us-gaap:PropertyPlantAndEquipmentNet>
    <inva:EquityMethodInvestment
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_1f7c93b3-2ee4-4151-ad79-fd04e905a683"
      unitRef="U_USD">193726000</inva:EquityMethodInvestment>
    <inva:EquityMethodInvestment
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_27fc7a08-d8b0-4358-8650-cc8eed5881e9"
      unitRef="U_USD">52293000</inva:EquityMethodInvestment>
    <us-gaap:LongTermInvestments
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_fd763a46-5efa-492c-9d65-433a2d437bad"
      unitRef="U_USD">404497000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_a60a91be-3b94-4b45-b895-75514c54047d"
      unitRef="U_USD">341664000</us-gaap:LongTermInvestments>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_5f92539d-6493-4cee-b088-022fe52a9e3e"
      unitRef="U_USD">56138000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_1d54e2cf-eec0-4457-85b0-4f9ab0a79cae"
      unitRef="U_USD">69961000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_fae98d4b-265e-4a21-906e-2b726bb627fb"
      unitRef="U_USD">10929000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_b8a2b257-7268-43c8-af7b-f0419866986b"
      unitRef="U_USD">2453000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_88287724-d84b-444f-b7b8-e3e889dbc902"
      unitRef="U_USD">17905000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_51cdeee9-1e3f-4fe4-8e27-503c03b9f22f"
      unitRef="U_USD">17905000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_49b7922b-db0f-4914-9b79-c45819fee0e1"
      unitRef="U_USD">182156000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_6905722e-5fa0-4e41-abcb-d4f7eab08910"
      unitRef="U_USD">208433000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_71c08360-efde-4530-ae13-e624ef2389bf"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_cb963adf-ab82-4c16-8a54-f1c379f36d5d"
      unitRef="U_USD">12054000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_123d5a32-144c-466c-95e8-439a457ffc33"
      unitRef="U_USD">40744000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_78b7e5db-8b55-426d-88fb-b71dcea2cee4"
      unitRef="U_USD">41477000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_b5c53f92-0107-4f8b-ac4c-dfac503ef4fe"
      unitRef="U_USD">1635165000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_4ce92927-e4e2-4c49-ae94-c4131953a276"
      unitRef="U_USD">1301060000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_05ae33cd-eecb-436d-8169-2c56521e5036"
      unitRef="U_USD">4966000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_e88c79d6-44cb-42a7-a4db-a100ee18efb5"
      unitRef="U_USD">2132000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_b7153af8-24f4-40d1-a719-bc44f78c16fb"
      unitRef="U_USD">9100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_5b073105-df80-4cb0-a9f8-e4b96af068b0"
      unitRef="U_USD">7376000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_c2d545b8-73c2-4ade-90f9-c9665853671d"
      unitRef="U_USD">1618000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_b04bd0d1-feba-403b-8c08-af1e0e03b8cf"
      unitRef="U_USD">3422000</us-gaap:InterestPayableCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_8429c4bb-12e7-47e4-9b05-bacb0c4377e4"
      unitRef="U_USD">4270000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_22e2950c-f994-4e95-9238-c8d834a9a584"
      unitRef="U_USD">1126000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_991c409d-858e-4e99-8223-bcdca145b672"
      unitRef="U_USD">274000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_be5dea84-3fff-40aa-81b7-af55d21e0ca7"
      unitRef="U_USD">0</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DebtCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_11dd66d7-a3f2-4c90-bf85-037b6519657b"
      unitRef="U_USD">0</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_7b0968ee-dd12-417f-9723-32729f0f0627"
      unitRef="U_USD">192028000</us-gaap:DebtCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_febe2dd0-06b7-40b3-86e3-2b8db828df47"
      unitRef="U_USD">29468000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_270632b3-3604-4830-b269-ef1f9f388baf"
      unitRef="U_USD">29999000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_6398ee21-8bf2-4411-9648-42e8f2d7ef80"
      unitRef="U_USD">49696000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_4fb47cb6-7a08-4685-b9b2-b8ecba21a17b"
      unitRef="U_USD">236083000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_c34ae4be-4b8e-4446-a1d1-11676347ed71"
      unitRef="U_USD">257731000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_97e05a48-699b-4045-8eb7-ba71ffc81e2c"
      unitRef="U_USD">256316000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_5c2dbc2b-be0c-4609-87e9-89cb92b0a273"
      unitRef="U_USD">66091000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_5da4192c-d52d-455e-8214-75177180679e"
      unitRef="U_USD">64275000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_74fe9b1c-f424-4464-bbd0-033f1f9887c3"
      unitRef="U_USD">31793000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_72e6ad1f-0ad7-4d7f-8d96-e107f70d4e40"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_7a5cef67-d483-4ac8-a904-f6ab2235eea0"
      unitRef="U_USD">57013000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_d68ac886-187e-4f80-89f2-4f67512d1080"
      unitRef="U_USD">53227000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="2"
      id="F_122f15c8-45cc-41f6-9945-fe08b5437cb1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="2"
      id="F_e4dadf41-9f5d-49e4-a0b0-a89965e4da4b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_ad60b688-b51f-4fac-8de6-a78ec092ba11"
      unitRef="U_shares">230000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_03097ffb-874b-42f9-bf7f-db4a4b9793c8"
      unitRef="U_shares">230000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_5037a487-f152-4428-adeb-792cf4e228f6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_ad54e1f8-90b9-4e99-8bb7-c683ac849d2c"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_a706ddba-8c13-4559-9e36-0d23a83c234a"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_b5fad122-3e63-4a68-a49f-693e498e55dc"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_ede9362d-15a3-4f12-9d28-0f1d39bca636"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_ad26a199-d4e0-4792-af20-aee35e0e4df4"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="2"
      id="F_6e06be84-8302-47de-832e-a81513766646"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="2"
      id="F_64f05725-c21c-449c-b4ae-807ff69cde33"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_cbc16de0-e988-4b59-9ce7-c10a1c4dc125"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_20567659-dfb3-4f87-afb6-e571678b3cd7"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_ad7e9db6-2a1e-4865-aec9-029c0207e3bc"
      unitRef="U_shares">74636000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_201fea28-6620-4d97-b1b8-6e6d4479448a"
      unitRef="U_shares">74636000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_e4682dae-25a4-48e6-88b2-1eb93839d19e"
      unitRef="U_shares">62665000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_d28538bc-3b4a-4b02-b5ce-dfbe2cf66568"
      unitRef="U_shares">62665000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_9574bb18-14db-42cf-8c1c-5ee0fc14f4df"
      unitRef="U_USD">747000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_0af5412e-d38b-441e-bd78-19dafd9030da"
      unitRef="U_USD">627000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_e7353766-e812-45cd-ade0-91cb64299ece"
      unitRef="U_USD">902726000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_522cce04-6628-4058-8fb0-dca327c987ec"
      unitRef="U_USD">692329000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_2731bbc7-e3c8-4f22-bba6-f75fd4958c72"
      unitRef="U_USD">269368000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_5567859f-378b-4872-941b-611d9c296707"
      unitRef="U_USD">-1797000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_d881f102-b3d1-4f4d-992a-7951293ed26b"
      unitRef="U_USD">1172841000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_38b54920-44df-44d9-8d90-5ef8b5337e1b"
      unitRef="U_USD">691159000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_81728e74-5b2f-47c1-9fe5-29cbc3cd93af"
      unitRef="U_USD">1635165000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_6db9ff1e-5cf5-4e32-904f-cec9ae053d85"
      unitRef="U_USD">1301060000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054"
      decimals="-3"
      id="F_30b2cc72-46c2-4ddf-b72c-523421e25c0d"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_24d3732a-a2a9-4442-b464-10be5d29362f"
      decimals="-3"
      id="F_87112ed2-b339-4b55-8f95-8bc52f35fa5b"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_8290bc3e-4b79-45b4-8dd5-a2d83da40c0c"
      decimals="-3"
      id="F_b5a130c7-8ef4-46be-98f1-2014d3fd64e7"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_486828c2-55c2-4eca-a8e9-7c9edc91e774"
      decimals="-3"
      id="F_e6d68ec7-25e9-4b6d-8f88-a6df6f0e71bc"
      unitRef="U_USD">236479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8c3d0ea3-a6a0-43b3-ad32-fa7162ce8c28"
      decimals="-3"
      id="F_0d40bcd7-d5e4-4865-8fc2-7eb6861f5519"
      unitRef="U_USD">241733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_02167381-4ee7-420f-9702-aa51b2304727"
      decimals="-3"
      id="F_2929c706-5904-4132-a274-af3f6eecd92b"
      unitRef="U_USD">238846000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e1b0f380-3db6-410d-886f-3625779ce5c2"
      decimals="-3"
      id="F_68a148be-27ee-49de-aaa5-26b93991dbb9"
      unitRef="U_USD">172130000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0f3c27be-b222-4d28-80f0-06ce24daba5e"
      decimals="-3"
      id="F_cea20a73-93f6-4235-9616-3b62fd80576d"
      unitRef="U_USD">97492000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d5a54e09-f59e-44b6-9cef-6b6ac8a95a30"
      decimals="-3"
      id="F_1910daf0-f43d-4136-92b3-07e6c90a836f"
      unitRef="U_USD">60617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_33e42f5b-3543-48dc-a026-c6016772a37c"
      decimals="-3"
      id="F_ae740c85-e210-42f4-b3cc-724f8cdea377"
      unitRef="U_USD">2719000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b0a0b85c-bd15-4eea-be59-38094513a363"
      decimals="-3"
      id="F_0845b96d-6e07-4d4b-ae14-4933320518f8"
      unitRef="U_USD">19486000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b2be7da7-0eaa-4d69-b26f-885c2d1e7254"
      decimals="-3"
      id="F_64b7b432-709d-404e-bb63-47706bcbc3f3"
      unitRef="U_USD">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_57e97d1b-af9b-4475-917f-18c38f8574c3"
      unitRef="U_USD">411328000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_1f33b903-f2f1-4914-bfa5-55f266bbb5b1"
      unitRef="U_USD">358711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_22c25aa7-e85c-4fa6-863d-d0e521be6f93"
      unitRef="U_USD">310463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_e1b0f380-3db6-410d-886f-3625779ce5c2"
      decimals="-3"
      id="F_5b9485d7-5193-4577-b5f2-6066a6ad0f6f"
      unitRef="U_USD">77384000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0f3c27be-b222-4d28-80f0-06ce24daba5e"
      decimals="-3"
      id="F_c97c0b47-693d-416c-98b3-c65dc9ec2d67"
      unitRef="U_USD">36598000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_d5a54e09-f59e-44b6-9cef-6b6ac8a95a30"
      decimals="-3"
      id="F_3d457142-8140-40c2-842d-896bf3130ced"
      unitRef="U_USD">41040000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfRevenue
      contextRef="C_8fdc954b-b47d-4c5f-a782-7e29908c95eb"
      decimals="-3"
      id="F_5f3d4a39-261c-48af-8526-47a6c471b5d8"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_3144e120-55bf-4537-84b6-260e15c16e75"
      decimals="-3"
      id="F_879d0226-a7a7-4c21-9f36-1e5301488759"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_45abe52e-ab8e-4973-995e-7e872a676421"
      decimals="-3"
      id="F_87c0ac08-0b9d-4b77-89c9-4ecddf5630ce"
      unitRef="U_USD">1600000</us-gaap:CostOfRevenue>
    <inva:AmortizationOfAcquiredIntangibleAssets
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_b780e45b-95bf-4b27-84d8-7f889ef637bb"
      unitRef="U_USD">26277000</inva:AmortizationOfAcquiredIntangibleAssets>
    <inva:AmortizationOfAcquiredIntangibleAssets
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_6c4298d3-f012-433f-92fb-648f253ca2b8"
      unitRef="U_USD">25902000</inva:AmortizationOfAcquiredIntangibleAssets>
    <inva:AmortizationOfAcquiredIntangibleAssets
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_ad8dbfd7-6078-4a90-aa8a-f41681517415"
      unitRef="U_USD">21784000</inva:AmortizationOfAcquiredIntangibleAssets>
    <us-gaap:GrossProfit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_32151735-1b13-4d96-b093-0793470e8e1f"
      unitRef="U_USD">307667000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_7b874894-8085-46db-8803-7e2814847668"
      unitRef="U_USD">296211000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_f6949fad-2280-40cf-9ea2-e5f0f03c15cd"
      unitRef="U_USD">246039000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_04caaed2-2b01-4188-8420-f05d7987b3b0"
      unitRef="U_USD">113318000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_ffa72dbc-44bc-48c2-97bc-c48e50ade38c"
      unitRef="U_USD">115690000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_743fcaac-41c4-4242-9cc7-f1d2f645e457"
      unitRef="U_USD">98232000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_8212c623-e718-4541-a338-4b3fcbf510b6"
      unitRef="U_USD">30604000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_4f044d0b-d02a-4ba8-9321-c592b4482366"
      unitRef="U_USD">13654000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_2d7a9508-a7e6-4689-b456-7cc7ba96cfde"
      unitRef="U_USD">33922000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_bbafee88-e662-4104-bdba-13d87803f05a"
      unitRef="U_USD">143922000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_9e7ceb35-93d0-4cc9-81b9-5fca2ec19374"
      unitRef="U_USD">129344000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_4881ed19-8841-4dcb-a7c7-0443a6cc3c18"
      unitRef="U_USD">132154000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_8c4d6ad9-c77a-4071-9dbd-6f38887b29b9"
      unitRef="U_USD">163745000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_beb959b6-9107-4a58-a1d9-82c9329c08ae"
      unitRef="U_USD">166867000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_811e6947-f3d3-4a92-8f7c-7563c5fd2c57"
      unitRef="U_USD">113885000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_c553fcd1-ac9a-455f-a49b-fd9723bafc20"
      unitRef="U_USD">141433000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_f2f56222-55d9-42cf-a6c3-5ebd2245f841"
      unitRef="U_USD">-64253000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_a805a5e2-f2f7-49ba-b605-6eb774ab88f1"
      unitRef="U_USD">77392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_e9a7447b-d6e5-4687-a0fe-0bafa3142627"
      unitRef="U_USD">20160000</inva:GainLossOnOtherInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_8a4754c0-a7ad-4f00-932a-3de997197f95"
      unitRef="U_USD">-59161000</inva:GainLossOnOtherInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_d1d68301-9436-4334-9a5a-68cf4dada681"
      unitRef="U_USD">11129000</inva:GainLossOnOtherInvestments>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_854bcba9-131c-447f-93c2-09318a93906c"
      unitRef="U_USD">21086000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_0310bf30-a9d0-4d48-93ed-945f7ee8ae55"
      unitRef="U_USD">19141000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_a61cb18b-2f7c-4c1c-96cd-f607cb9ca1f1"
      unitRef="U_USD">15818000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_b6a22ea7-6887-4baf-8bc3-fe9e5cea1655"
      unitRef="U_USD">16698000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_7854109b-66e1-4a47-8767-64948c89ba84"
      unitRef="U_USD">22209000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_4bcc1756-ad52-4628-820b-b95b96478f02"
      unitRef="U_USD">19157000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_d5507844-c01c-48ea-a3c6-ede5297179c8"
      unitRef="U_USD">-2864000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_7a1280d2-b64b-492c-a0d8-80b255289ebb"
      unitRef="U_USD">-2997000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_460f0312-9395-4b47-bff9-14ca36e2a25f"
      unitRef="U_USD">-4969000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_05bf4cca-8a2d-4b02-a958-64313027ff74"
      unitRef="U_USD">326862000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_f519e944-e841-41aa-aa90-2d06947d66ad"
      unitRef="U_USD">37388000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_ed9e45c3-d1ff-4a6f-8208-5a451dc8e8aa"
      unitRef="U_USD">194098000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_be368389-1b3e-48d2-bc65-aee985d37e63"
      unitRef="U_USD">55697000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_746598a6-b0b8-4e5e-988b-29a5b219a3ac"
      unitRef="U_USD">13996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_6ad3f234-fb7c-48c2-92aa-0caa7caafff6"
      unitRef="U_USD">14376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_468be4b0-0e50-4fb4-b312-7be2c79f361d"
      unitRef="U_USD">271165000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_b8b9f0b8-35a9-4181-9eb8-c27fd9494e84"
      unitRef="U_USD">23392000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_82541dcd-1019-415f-a312-ed2a1bc3357d"
      unitRef="U_USD">179722000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="2"
      id="F_775392c1-4910-4135-b24f-fad760da67df"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="2"
      id="F_7d414d52-a5a2-4f81-a635-0f210232680a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="2"
      id="F_86a3a82e-7a36-4b2e-9938-deb3c438192b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="2"
      id="F_d7bdea1f-3337-4edc-b0bd-4bfb30c2ddd8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.3</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="2"
      id="F_9391de5d-388d-4a42-9b5a-6b7086da17d5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="2"
      id="F_6e790c25-40c7-4f1e-9004-baf95361fe7d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_a653b0b6-f7b8-4418-be84-0a1fb695bea0"
      unitRef="U_shares">67395000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_0ec3a426-d068-4aa2-bada-84f047d90557"
      unitRef="U_shares">62726000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_26a384f1-5201-450f-a877-a91bd8a7d6ee"
      unitRef="U_shares">65435000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_eadcfd64-fe67-4d02-88fa-e61b0c2ea148"
      unitRef="U_shares">84760000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_1f8aa9e6-f264-4890-a9b2-9ad0bf1c9cdf"
      unitRef="U_shares">74187000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_16a5a9bd-a0b5-4694-8262-669076308f06"
      unitRef="U_shares">86876000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_31784cc3-872d-408e-80c1-6e43cba22130"
      decimals="-3"
      id="F_cfb3d0cb-f5a0-4397-b21e-0e3c96cceb4d"
      unitRef="U_shares">69188000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_31784cc3-872d-408e-80c1-6e43cba22130"
      decimals="-3"
      id="F_05793dbd-535e-4dd7-86e0-068d2b5fade1"
      unitRef="U_USD">692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_fda3c94b-7cd8-431c-a448-eca3c92b1451"
      decimals="-3"
      id="F_be83d266-7de7-49ac-8a2c-74aa80fc62a0"
      unitRef="U_USD">1163836000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_7d786c4d-9bc2-4c05-9835-fe6f2d5d9c1e"
      decimals="-3"
      id="F_13f1a051-2bd5-48c4-a3c7-c8befc1187b4"
      unitRef="U_USD">-204911000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_0865d3ef-f81c-4aa7-9435-994b376311c7"
      decimals="-3"
      id="F_71f03815-892f-43b9-862a-58ce0abde269"
      unitRef="U_shares">32005000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_0865d3ef-f81c-4aa7-9435-994b376311c7"
      decimals="-3"
      id="F_843f8819-714b-484c-be44-dcf9fe9e4682"
      unitRef="U_USD">-393829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a60c1143-acae-40be-9475-53a07ff86264"
      decimals="-3"
      id="F_4f6e9242-f498-4079-bd12-297d03ca1ebe"
      unitRef="U_USD">565788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="-3"
      id="F_bf045c89-12d1-4cfd-aa5d-d09cbe7c9342"
      unitRef="U_shares">293000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="-3"
      id="F_d7f50a48-17c1-4213-8ca7-d220bb88fbc8"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_b6f9a97f-7c68-4a85-8e85-ea9cf6cc6220"
      decimals="-3"
      id="F_107ab948-113d-4a4c-97ca-487fde9c0de1"
      unitRef="U_USD">89000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_431e9250-fc85-45e0-9b9e-fac3bf029cec"
      decimals="-3"
      id="F_dd33e5f5-6859-4ebc-8f5a-6e60d26f35ea"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97"
      decimals="-3"
      id="F_ee5120f5-cc4e-483a-af31-1b877cc63bc4"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97"
      decimals="-3"
      id="F_00335233-1983-4c04-855e-adba7bf2ac65"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_5c4319ce-43fb-4b9b-8ae7-af4085895652"
      unitRef="U_USD">92000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="-3"
      id="F_9ad27e5c-26cb-4c83-b690-efb6803b0c5e"
      unitRef="U_shares">-6174000</inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="-3"
      id="F_c28e0573-5dce-4387-ba89-cf5229286f0e"
      unitRef="U_USD">-62000</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_b6f9a97f-7c68-4a85-8e85-ea9cf6cc6220"
      decimals="-3"
      id="F_9699cf7c-7272-4d6c-a13c-5836f5344068"
      unitRef="U_USD">-76422000</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_431e9250-fc85-45e0-9b9e-fac3bf029cec"
      decimals="-3"
      id="F_2d028c55-e6e8-40a4-92f0-04e4cbaeff7f"
      unitRef="U_USD">0</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax
      contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97"
      decimals="-3"
      id="F_1ddd70d7-5bab-408c-912a-c17a7ca0d7a8"
      unitRef="U_shares">0</inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97"
      decimals="-3"
      id="F_0261c3c3-f9e5-4fbc-9778-d5a9aaadf3a2"
      unitRef="U_USD">0</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_477dde18-020b-4612-b63f-79d8aa83b452"
      unitRef="U_USD">-76484000</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="-3"
      id="F_f8157231-7d5c-418d-b0d6-a5001e8119c1"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="-3"
      id="F_7227f28e-b4fb-4af4-88ab-6e0b5cb7bd24"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b6f9a97f-7c68-4a85-8e85-ea9cf6cc6220"
      decimals="-3"
      id="F_44e8d0f2-c676-4e23-807f-1006faa9045b"
      unitRef="U_USD">5837000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_431e9250-fc85-45e0-9b9e-fac3bf029cec"
      decimals="-3"
      id="F_9aba897f-6891-448e-b857-08eb5279d6ef"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97"
      decimals="-3"
      id="F_a6807197-b3f4-4ad4-a163-1811f23e8e31"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97"
      decimals="-3"
      id="F_cb334260-c0da-4929-8de6-bcfde0592cf8"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_e2cadc34-9e18-40e5-9b04-81941daaa0b4"
      unitRef="U_USD">5837000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inva:ProfitLossShares
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="-3"
      id="F_045d1f2d-0674-4687-abcd-827144f78ac0"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="-3"
      id="F_93686402-89b0-4ad7-a039-b18f49f6a46a"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_b6f9a97f-7c68-4a85-8e85-ea9cf6cc6220"
      decimals="-3"
      id="F_8c8eb362-ada8-4ce9-9d70-de5affd31e4f"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_431e9250-fc85-45e0-9b9e-fac3bf029cec"
      decimals="-3"
      id="F_c466964e-4846-45c5-922a-d620f39548f9"
      unitRef="U_USD">179722000</us-gaap:ProfitLoss>
    <inva:ProfitLossShares
      contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97"
      decimals="-3"
      id="F_c1a19650-56d5-4d33-9f89-48677983f87d"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_9d53ebb1-c725-4a7f-a0f6-1ba05a9b7a97"
      decimals="-3"
      id="F_328a3969-b3c0-4748-8875-6ce2bd4886ba"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_2f9d0261-02ae-4b59-8749-d71b046565da"
      unitRef="U_USD">179722000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_c9ea7908-47f3-4091-b474-5d9827ca0b02"
      decimals="-3"
      id="F_c60b783b-e01b-4ed6-b1d8-2adc0cca351c"
      unitRef="U_shares">63307000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_c9ea7908-47f3-4091-b474-5d9827ca0b02"
      decimals="-3"
      id="F_f0c00b01-967b-41ed-8cdf-139dc751b695"
      unitRef="U_USD">633000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_71f99e54-19e3-4788-8727-45db0240d021"
      decimals="-3"
      id="F_2c0e89ca-74a5-4a26-80da-dd1648e12f7d"
      unitRef="U_USD">1093340000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_212cc57d-e685-4590-a4bd-6b3b410d36af"
      decimals="-3"
      id="F_23ad3c41-e3cb-43fc-9906-48b7755596b0"
      unitRef="U_USD">-25189000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_e874e2c8-b06d-4058-bc9c-21db422ef0fb"
      decimals="-3"
      id="F_6a1562fe-e086-4925-9997-6bc5863942bb"
      unitRef="U_shares">32005000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_e874e2c8-b06d-4058-bc9c-21db422ef0fb"
      decimals="-3"
      id="F_0bee4f42-b518-4aa0-b49a-bb09c00e2162"
      unitRef="U_USD">-393829000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_a6f00937-2ee4-4566-bd68-45c44b998d3b"
      decimals="-3"
      id="F_b06aa5ff-4d35-4390-9ba9-375cd8f1da7b"
      unitRef="U_USD">674955000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_87342330-ec91-4046-ac8b-5495a4ab21f0"
      unitRef="U_shares">345000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_c28c4ce4-5aee-4675-9ab1-1d2b571f20b0"
      unitRef="U_USD">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316"
      decimals="-3"
      id="F_e21c207f-fa9c-4aa3-b646-9a560ad4bc13"
      unitRef="U_USD">1321000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5"
      decimals="-3"
      id="F_042a8873-d6d4-43ea-b974-5d33172cef51"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_13a70b61-e406-415c-95b0-ed5749310a0a"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_1ee38898-3fa3-4fca-abb4-dd2972454bb4"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_e6255fa1-caf6-4ff9-96ae-95033ec33361"
      unitRef="U_USD">1324000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_367c648c-90cb-44b2-9ec1-1d19d2fe0c49"
      unitRef="U_shares">-987000</inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_d21e1e6d-3736-4363-8805-b68047a64c6e"
      unitRef="U_USD">-9000</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316"
      decimals="-3"
      id="F_e778bb2b-b567-417b-9b45-f9047369b2b8"
      unitRef="U_USD">-14916000</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5"
      decimals="-3"
      id="F_bb220150-45ce-4754-b6cb-9334a1aa4828"
      unitRef="U_USD">0</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_2f72ec4f-b4a8-4af9-ab49-acf6d5eb43be"
      unitRef="U_shares">0</inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_93db332c-3617-4035-8985-70c3dcaaa033"
      unitRef="U_USD">0</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_331ceae6-df25-4af1-8785-755d9c796d8f"
      unitRef="U_USD">-14925000</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_4cad5fea-1e0f-436e-a2cb-7cdc5898c2ba"
      unitRef="U_shares">0</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_75b401da-f78e-4f14-909b-fcfa528d3a62"
      unitRef="U_USD">0</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability
      contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316"
      decimals="-3"
      id="F_dc2b1282-5a41-436a-a1c4-88c74c5de479"
      unitRef="U_USD">39000</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability
      contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5"
      decimals="-3"
      id="F_3c8a51e1-376f-46f0-9567-ae69f4b314f5"
      unitRef="U_USD">0</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_58357360-5dda-4050-9d9a-72bc42b85c26"
      unitRef="U_shares">0</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_1942f8d1-89ec-4081-a4e6-8c6bc54c2112"
      unitRef="U_USD">0</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_bfb689f2-347d-44fb-86c0-885ea58d5b2b"
      unitRef="U_USD">39000</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_66b93687-e1d7-4fa0-93f7-6c2fa622a36e"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_2ec1a025-dee7-4ed5-9ae6-f7ba8b9fb35c"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316"
      decimals="-3"
      id="F_0825cf4c-8553-45c1-95a7-eccad367aea7"
      unitRef="U_USD">6374000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5"
      decimals="-3"
      id="F_d7a81435-1aa9-4167-9da1-14df9eb94a40"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_eb896aad-e4fc-48ea-8903-088e8a82984c"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_6f4258a3-0bc0-4f46-a3ae-61c55bd1182f"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_b763b9e8-e948-4d4e-9707-6edfdffb66d5"
      unitRef="U_USD">6374000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_4f52565c-c627-4282-aba2-c98daba0bebd"
      unitRef="U_shares">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_be5c61ef-5952-4031-a88f-84c0f2ac5413"
      unitRef="U_USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316"
      decimals="-3"
      id="F_09c1e40e-196d-4a22-a2b7-2219f0b6044c"
      unitRef="U_USD">-393829000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5"
      decimals="-3"
      id="F_139d312d-f47f-490d-8729-12a72b710819"
      unitRef="U_USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_b45ea0cc-2856-419e-8465-160cad593e83"
      unitRef="U_shares">-32005000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_a82d50cd-e3c9-4354-abb2-430e93588d34"
      unitRef="U_USD">393829000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_6a658a40-7499-4e1f-be89-dbaf74b2ae79"
      unitRef="U_USD">0</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <inva:ProfitLossShares
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_7749aa84-5e3d-4855-b374-9a44e4d8fd20"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_6c9ac12e-e12a-4974-aa5e-e6dd68c6be76"
      decimals="-3"
      id="F_49673229-2b29-4ef3-b47a-f07548c316e3"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c5950ca0-b841-4a30-a532-7b67bb117316"
      decimals="-3"
      id="F_0e91443c-1f1b-49c9-b6c4-936d60d95f24"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_c52e24c0-682d-4338-a8ae-1f943c7feaf5"
      decimals="-3"
      id="F_91208728-0bbd-4ed4-80b4-ab2f289acdc2"
      unitRef="U_USD">23392000</us-gaap:ProfitLoss>
    <inva:ProfitLossShares
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_5641778c-a5a3-4e73-b063-ad2bab4c2bac"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_d8352266-b969-483f-a6e1-84e3c07a9a0c"
      decimals="-3"
      id="F_b625f2c2-0a2c-4f14-94ac-9f3ab4ccabc8"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_0b7b4de5-0273-4084-a4cd-c15f261d170b"
      unitRef="U_USD">23392000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_76c325ef-f27e-4ba8-812a-698b1f542dd3"
      decimals="-3"
      id="F_30e11723-3401-4aa7-a2e0-8e589286daff"
      unitRef="U_shares">62665000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_76c325ef-f27e-4ba8-812a-698b1f542dd3"
      decimals="-3"
      id="F_dbc78688-cabb-428a-8917-e743fd2ba102"
      unitRef="U_USD">627000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_add7605c-d6b6-415c-ad09-46eb5bbbfb4b"
      decimals="-3"
      id="F_e8996df6-5f4f-4174-ac1c-05183bb80b33"
      unitRef="U_USD">692329000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_6ab3cefd-f2b3-40bc-8f3e-a411da14524e"
      decimals="-3"
      id="F_d1ba2a30-2518-4594-b0a1-7b81978763ea"
      unitRef="U_USD">-1797000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_4486e6d7-5936-40be-8a70-b6ae40d88127"
      decimals="-3"
      id="F_e2bc6c9e-a32c-4788-8b5d-644bd607d133"
      unitRef="U_shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4486e6d7-5936-40be-8a70-b6ae40d88127"
      decimals="-3"
      id="F_21789d2c-af87-4f00-a4f8-cc5f30ccc83b"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_314bf8b0-a495-49ef-8836-0481bb5c6391"
      unitRef="U_USD">691159000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_d87aa5d0-8745-43d3-998d-d17d63b024d0"
      unitRef="U_shares">459000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_601e9a80-34e1-4859-80ee-1225eb8f1a0f"
      unitRef="U_USD">5000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_f9044951-f126-4cbd-81bd-331f45565190"
      decimals="-3"
      id="F_353e5382-98bc-4220-b83b-23f2782e4c8f"
      unitRef="U_USD">2405000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4"
      decimals="-3"
      id="F_e095c2d3-062d-40af-b336-a4adb2b7729b"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_a957a5d3-ee68-45a3-a7a5-994abd954bdd"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_8f9c9b96-cdf3-4679-a737-2749c9592f27"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_7539f36e-7214-40ce-ba6e-bb072006b5a6"
      unitRef="U_USD">2410000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_30ce65fa-dd43-4e4a-b668-211b30d2b2e8"
      unitRef="U_shares">-228000</inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_6f105317-0ac0-4659-81e0-3576fc531e9f"
      unitRef="U_USD">2000</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_f9044951-f126-4cbd-81bd-331f45565190"
      decimals="-3"
      id="F_b7bc165e-9352-49a5-b7f7-06339d44ac79"
      unitRef="U_USD">4575000</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4"
      decimals="-3"
      id="F_0d9dd3a3-3412-42bf-9170-40e6f2c7d9b4"
      unitRef="U_USD">0</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_9b5fb495-2e82-4537-bb2f-6ff06fb8c5ad"
      unitRef="U_shares">0</inva:TreasuryStockSharesAcquiredIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_0b2be2c0-7fc6-42c2-8c0a-a0c47f8e24ed"
      unitRef="U_USD">0</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_39717bda-e9f9-46f1-bbfd-06df28a47670"
      unitRef="U_USD">4577000</inva:TreasuryStockValueAcquiredCostMethodIncludingAccruedExciseTax>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_61ce6766-54c8-4182-90fa-72ba1b48f8cf"
      unitRef="U_shares">0</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_868d73a0-9157-444d-b8d2-6abdf3ef95fd"
      unitRef="U_USD">0</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability
      contextRef="C_f9044951-f126-4cbd-81bd-331f45565190"
      decimals="-3"
      id="F_87dadbcd-7292-4a17-a1c0-3cf632116ac9"
      unitRef="U_USD">59000</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability
      contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4"
      decimals="-3"
      id="F_f4ba9a34-846a-41f5-a739-bcf76471d3cb"
      unitRef="U_USD">0</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_86344fa2-4e8d-455c-a7bd-fb39a3519a80"
      unitRef="U_shares">0</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiabilityShares>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_1554ff8a-b209-4c7c-a289-b69cf1f75c0b"
      unitRef="U_USD">0</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability>
    <inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_314103a8-0698-498f-8f87-88a5745cfaf3"
      unitRef="U_USD">59000</inva:AccruedExciseTaxOnCommonStockRepurchaseAppliedAgainstTaxLiability>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_8953fa58-0c3e-4ee6-b421-f889b8d395b3"
      unitRef="U_shares">11149000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_b30f8a92-f40f-4c25-84c0-9bd2996a7c41"
      unitRef="U_USD">111000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_f9044951-f126-4cbd-81bd-331f45565190"
      decimals="-3"
      id="F_f596f949-99b2-410b-813a-f4361cea8c6f"
      unitRef="U_USD">192364000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4"
      decimals="-3"
      id="F_3c466df5-c2e1-40cd-909e-e0f7b6a4552d"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_f69ef65f-d4ce-47a4-be5f-7caad1e7e8b8"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_8296a3c3-405c-4321-aff0-005722328f22"
      unitRef="U_USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_2f3154dc-c97e-4271-98a8-944e59fb8022"
      unitRef="U_USD">192475000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <inva:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_a3741ff6-4aa7-4b1c-befe-a8d912efe6be"
      unitRef="U_shares">591000</inva:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <inva:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_94cc403e-2b03-468f-8813-c1a8cc0d33fe"
      unitRef="U_USD">6000</inva:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <inva:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_f9044951-f126-4cbd-81bd-331f45565190"
      decimals="-3"
      id="F_2c16b028-4845-4b35-bbbc-297f3bcf3b83"
      unitRef="U_USD">10692000</inva:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <inva:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4"
      decimals="-3"
      id="F_42ae9744-38ce-4938-9b79-7905ab20f098"
      unitRef="U_USD">0</inva:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <inva:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_6f7bbb24-8821-42d7-bea6-4f3400da976a"
      unitRef="U_shares">0</inva:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <inva:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_7d524011-50eb-4eee-8e14-683f403e13fb"
      unitRef="U_USD">0</inva:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <inva:StockIssuedDuringPeriodValueExerciseOfWarrants
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_16e90c84-7c25-4a96-953e-8f61b041bfeb"
      unitRef="U_USD">10698000</inva:StockIssuedDuringPeriodValueExerciseOfWarrants>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_649c660d-d77b-4311-b04e-0f58f634a771"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_a6722c0a-ebde-46e5-8ffa-c5e60bcfe156"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_f9044951-f126-4cbd-81bd-331f45565190"
      decimals="-3"
      id="F_5c603895-cc56-40dd-a2cc-fc920acd9d88"
      unitRef="U_USD">9452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4"
      decimals="-3"
      id="F_7a98e9e8-b774-4e36-a07e-caa8c4cbfffd"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_0341ba2f-2057-4421-aeff-743ae0f4378e"
      unitRef="U_shares">0</inva:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRequisiteServicePeriodRecognitionShares>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_c06ce27a-862c-4d9f-b294-d914f78a865d"
      unitRef="U_USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_78bfd34f-bd52-498d-b21b-99b51fc4faa7"
      unitRef="U_USD">9452000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <inva:ProfitLossShares
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_1815757d-71c4-44e9-aa2d-b94360f619f5"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_ae3b7e65-0767-4226-b024-9f30a53a662d"
      decimals="-3"
      id="F_7a9cfd95-beaf-47a4-b47e-99a37581fe06"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_f9044951-f126-4cbd-81bd-331f45565190"
      decimals="-3"
      id="F_7c150f09-e59d-4ef9-8f78-7f1efcf5efcd"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_627f6c4a-256d-48b2-9ebe-195f372836f4"
      decimals="-3"
      id="F_c7ca43db-6282-4b61-85b5-b1f1cb07bcdf"
      unitRef="U_USD">271165000</us-gaap:ProfitLoss>
    <inva:ProfitLossShares
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_d9f28aff-49cf-49ca-82f5-20e0ac5720cc"
      unitRef="U_shares">0</inva:ProfitLossShares>
    <us-gaap:ProfitLoss
      contextRef="C_06e9c678-095e-4291-8f2b-762451638db9"
      decimals="-3"
      id="F_34355ba9-7ddf-422b-8349-d0275ca4d272"
      unitRef="U_USD">0</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_c997fda1-3465-4e9d-93fa-8c5e75029cfa"
      unitRef="U_USD">271165000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_577dc48e-2a7c-47ff-9812-6a80348a1bd8"
      decimals="-3"
      id="F_5566e9c4-a858-488d-bada-19c5ce677b3a"
      unitRef="U_shares">74636000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_577dc48e-2a7c-47ff-9812-6a80348a1bd8"
      decimals="-3"
      id="F_91706d0e-342d-4bb8-8bc0-0d407e263809"
      unitRef="U_USD">747000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_d93a2eff-6ca3-4b72-bc94-7f262d74a800"
      decimals="-3"
      id="F_bd5b1196-c2af-4d84-8f32-dd6442848e25"
      unitRef="U_USD">902726000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_edb34f03-0687-4952-862d-bb3107aa1b2e"
      decimals="-3"
      id="F_3554d100-0d8e-4711-acf1-da5e491f6c9a"
      unitRef="U_USD">269368000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares
      contextRef="C_4cbd448a-5be2-4867-9b30-17f58446ee15"
      decimals="-3"
      id="F_c14064aa-9b71-4ca7-8f66-797b040c5c8f"
      unitRef="U_shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_4cbd448a-5be2-4867-9b30-17f58446ee15"
      decimals="-3"
      id="F_1c419b3e-4257-4b2c-a69c-af5856595004"
      unitRef="U_USD">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_7c96bc88-9a8e-4c8c-af7f-09de96b0ddfe"
      unitRef="U_USD">1172841000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_8263ac0c-a668-4a9f-9ba0-d3af6e10da6a"
      unitRef="U_USD">271165000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_8b4b8870-1f87-48cc-a870-46ea00d9d77c"
      unitRef="U_USD">23392000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_2ca305eb-0040-4fed-85d6-a3e61d15dc93"
      unitRef="U_USD">179722000</us-gaap:ProfitLoss>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_8a24797a-6ed4-4871-878f-6ce514ebc881"
      unitRef="U_USD">43847000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_33b8aa41-5781-45cc-b9cd-ee537b49a52a"
      unitRef="U_USD">-12617000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_3977d79a-c799-4fa3-a6b9-836c738fdd7e"
      unitRef="U_USD">4400000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_8f0c8136-4b90-488c-a479-0c7231c55a3c"
      unitRef="U_USD">13951000</inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment>
    <inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_78c62aca-ccbe-411e-9033-2fd7d2c5f0ee"
      unitRef="U_USD">13951000</inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment>
    <inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_3b0e3da3-fdb1-46c2-b422-3691905fdd5a"
      unitRef="U_USD">13921000</inva:AmortizationOfCapitalizedFeesAndDepreciationOfPropertyAndEquipment>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_d4dbb42b-5bf7-433f-8904-b9a3f2861591"
      unitRef="U_USD">26277000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_c13e1b03-7efd-4494-95f3-85ecd4491ef8"
      unitRef="U_USD">25902000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_576d85b6-d658-4718-8af0-a236af0a5585"
      unitRef="U_USD">21784000</us-gaap:AmortizationOfIntangibleAssets>
    <inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_2a3d3a2e-102a-4425-9b72-c1d3c523c923"
      unitRef="U_USD">4841000</inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales>
    <inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_de8c5119-5a86-4be5-8546-22f8c5546a12"
      unitRef="U_USD">13820000</inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales>
    <inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_56d7358d-bc17-44b2-b1c3-80a2594ce3db"
      unitRef="U_USD">27164000</inva:InventoryFairValueStepUpAdjustmentIncludedInCostOfProductSales>
    <us-gaap:ShareBasedCompensation
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_a4a0e39c-0876-45fa-aec4-998fd76af611"
      unitRef="U_USD">9452000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_0bb2eba9-5c03-40d6-9ff7-8ffd8966fe3c"
      unitRef="U_USD">6374000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_b2f253de-3ea5-46b5-8e42-7eddc557562b"
      unitRef="U_USD">5837000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_48407010-37cd-4c56-b4fd-dc6a8d852046"
      unitRef="U_USD">1887000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_c921db62-4381-4a0f-bbb2-76c2c781b36f"
      unitRef="U_USD">2110000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_f38f0dc4-6458-438f-9924-4b1f0bec0404"
      unitRef="U_USD">2065000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_ad6bc8ec-beec-4b6f-976f-c6063bd15033"
      unitRef="U_USD">141433000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_324264fe-7f68-4ac5-b1f6-14a11d8bb9f2"
      unitRef="U_USD">-64253000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_141355d8-4323-427e-8983-1851cc415c0c"
      unitRef="U_USD">77392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <inva:UnrealizedOtherGainLossOnInvestments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_962bc7af-bdf6-4785-b82b-427b14a55d00"
      unitRef="U_USD">20160000</inva:UnrealizedOtherGainLossOnInvestments>
    <inva:UnrealizedOtherGainLossOnInvestments
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_02714b89-5473-4f50-99f6-013ad0156692"
      unitRef="U_USD">-59161000</inva:UnrealizedOtherGainLossOnInvestments>
    <inva:UnrealizedOtherGainLossOnInvestments
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_cad3c6eb-2c1a-4dbc-bb2e-08b6760706b3"
      unitRef="U_USD">11129000</inva:UnrealizedOtherGainLossOnInvestments>
    <inva:AcquiredIn-ProcessResearchAndDevelopmentAssets
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_07366f3d-117e-4169-ad15-40a74bdc1c5e"
      unitRef="U_USD">9368000</inva:AcquiredIn-ProcessResearchAndDevelopmentAssets>
    <inva:AcquiredIn-ProcessResearchAndDevelopmentAssets
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_5e7ccd13-3d85-43ba-b391-f3248dfd094e"
      unitRef="U_USD">0</inva:AcquiredIn-ProcessResearchAndDevelopmentAssets>
    <inva:AcquiredIn-ProcessResearchAndDevelopmentAssets
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_eea2286e-d5e3-4042-aa72-c8eab7edfecc"
      unitRef="U_USD">0</inva:AcquiredIn-ProcessResearchAndDevelopmentAssets>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_1fa0807f-2af9-4dbd-9d8a-e99048a27555"
      unitRef="U_USD">-1897000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_6ae4c9f8-ac48-4c7c-8fb5-3fb6602d77ad"
      unitRef="U_USD">722000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_fabdcbbc-9cfd-4548-b72b-2d0d5573e58e"
      unitRef="U_USD">517000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_f1618ff9-d63b-45bd-884f-329f32b6a8ec"
      unitRef="U_USD">14574000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_06f829b3-59d4-4461-81c5-f6fde1b33b42"
      unitRef="U_USD">5938000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_4740c2f8-1a4c-4595-a0cc-27a79f4d032a"
      unitRef="U_USD">5053000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_a8b57cb6-2755-4a97-bc0a-aee1e4a4051a"
      unitRef="U_USD">-7623000</us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_c1297d0b-0695-4aaf-8895-1568edbf1826"
      unitRef="U_USD">-3647000</us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_b0f24a90-51e1-4826-bdae-878480d1d504"
      unitRef="U_USD">14949000</us-gaap:IncreaseDecreaseInLongTermReceivablesCurrent>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_95f10898-1e1e-4efd-a324-dd69b93e7a1e"
      unitRef="U_USD">12919000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_c0ce99aa-47a1-44ec-aa20-b2c93bf9d369"
      unitRef="U_USD">6808000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_8e48c8a8-9e29-485c-94fb-eba8fa30455c"
      unitRef="U_USD">12004000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_42ee0a62-5603-4d21-96b1-2555edec0189"
      unitRef="U_USD">5658000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_ee576d75-1c2b-46e8-8916-175fa8ae9964"
      unitRef="U_USD">-567000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_2b5095d1-29b2-4836-812a-f43b5317d7c2"
      unitRef="U_USD">-7929000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_b2e1ad2d-d6fd-4cf5-b6b6-934eee7da0db"
      unitRef="U_USD">1078000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_b8dda26c-9342-44d3-bdf3-44a7df9c5052"
      unitRef="U_USD">38186000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_edc4445e-fe01-4c27-8bb0-0acd3ba5e89d"
      unitRef="U_USD">2965000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_4b767ae7-89fd-42f6-bdaa-1f1bc8cc04c3"
      unitRef="U_USD">2834000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_0c1dddcf-73a4-46b2-bbb0-22dae95a3c5f"
      unitRef="U_USD">-4585000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_89c6b688-a9b5-4e20-bebd-f2e791387092"
      unitRef="U_USD">3778000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_b4501536-f493-4f2c-acc0-cc106ef513d4"
      unitRef="U_USD">-5790000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_5ae95183-7193-47e0-a405-c13349973289"
      unitRef="U_USD">3044000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_52eb7515-9da1-49a9-bb92-444ffef68231"
      unitRef="U_USD">-1498000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_18ce0725-f680-484c-a322-87a3c7dcf704"
      unitRef="U_USD">-1804000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_c2817b8f-6fb0-4f07-97a4-7ec2f1459fb5"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_3c8757ba-c452-4d89-b897-f4f5d21ae3fb"
      unitRef="U_USD">-937000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_5eaa3b76-bcfa-42ec-b444-2c7081e45713"
      unitRef="U_USD">3144000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_fc43896f-58fe-4d32-ac6b-35164b5e8537"
      unitRef="U_USD">-151000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_d4d31799-882e-4175-99db-057a82aa98c7"
      unitRef="U_USD">-817000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_5789d6d0-950b-4853-912c-85ff1acacf32"
      unitRef="U_USD">4060000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_f134b829-4b33-4d97-b59a-a82b59c8379b"
      unitRef="U_USD">41476000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_7691e5ad-2d5a-44f6-997f-14d5cf3a8131"
      unitRef="U_USD">1725000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_66f26ef6-9c39-44c0-a10c-c55415cd9d47"
      unitRef="U_USD">196930000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_12dd8760-c5e6-416b-b8a9-0413f48e4b31"
      unitRef="U_USD">188690000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_14ef2f1d-7d4f-4dd7-9e56-bd5f86c56c3a"
      unitRef="U_USD">141064000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_1dd4981f-4d92-4641-8ead-a757ce79370a"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_3caad89b-a02a-43d6-887d-c45185d4dca6"
      unitRef="U_USD">4000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_1c1d3379-0ee0-4dc5-b65e-67b423afef18"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_2f1413eb-4aa8-4bb9-95f0-aaa0e2e1e558"
      unitRef="U_USD">60899000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_597011f4-3c0a-4eb9-82d3-b34aab9234f8"
      unitRef="U_USD">59617000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_17f4945b-57d6-4293-8db2-389e2cd2e97a"
      unitRef="U_USD">65132000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromPaymentsForTradingSecurities
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_9db4edd1-d418-4ab8-8173-eff8d179e7b3"
      unitRef="U_USD">8427000</us-gaap:ProceedsFromPaymentsForTradingSecurities>
    <us-gaap:ProceedsFromPaymentsForTradingSecurities
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_1e287127-f697-4c9a-9b4d-abb72e253168"
      unitRef="U_USD">0</us-gaap:ProceedsFromPaymentsForTradingSecurities>
    <us-gaap:ProceedsFromPaymentsForTradingSecurities
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_e1498eef-06f7-476c-84b6-2ba89d2003a9"
      unitRef="U_USD">0</us-gaap:ProceedsFromPaymentsForTradingSecurities>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_22755102-de7d-40df-8054-9e574fc704de"
      unitRef="U_USD">17500000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_a25852f8-2fd2-4d20-8a6a-daad4e5930f5"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_294f8476-5c0b-403b-bfb5-fb6fbe87b122"
      unitRef="U_USD">1218000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <inva:PurchasesOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_7a6b6787-858d-42aa-80de-0ac192d6f7d3"
      unitRef="U_USD">0</inva:PurchasesOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchasesOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_21e38eb7-86f9-4e0d-9ec4-ec82d6dd1559"
      unitRef="U_USD">32270000</inva:PurchasesOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchasesOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_f94917c5-9939-4dea-a472-d925811b153c"
      unitRef="U_USD">31164000</inva:PurchasesOfEquityInvestmentsManagedByIspFundLp>
    <inva:SaleOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_43341ee7-dda4-4731-a8ba-0d250db8fa50"
      unitRef="U_USD">28164000</inva:SaleOfEquityInvestmentsManagedByIspFundLp>
    <inva:SaleOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_ef7b5253-d9b7-4acb-b94b-622df57bdf98"
      unitRef="U_USD">75756000</inva:SaleOfEquityInvestmentsManagedByIspFundLp>
    <inva:SaleOfEquityInvestmentsManagedByIspFundLp
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_5eb40c60-1ac7-483f-aa99-8aaa74d981f0"
      unitRef="U_USD">72500000</inva:SaleOfEquityInvestmentsManagedByIspFundLp>
    <inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_61a78aaf-5308-411c-bed3-cf7f63156f3a"
      unitRef="U_USD">-92791000</inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp>
    <inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_d09ad77f-9528-460c-8aa9-30c6eeea5e67"
      unitRef="U_USD">43486000</inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp>
    <inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_1fab50cc-a70d-4518-93e7-5f809b94b500"
      unitRef="U_USD">41336000</inva:PurchaseAndSaleOfOtherInvestmentsManagedByIspFundLp>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_fc269883-79b2-4178-be37-17f050e27619"
      unitRef="U_USD">9368000</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_65f41b82-9aa6-477b-abc4-7b344d7d51a3"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_4446a30b-1f17-4c63-94c1-d4c11c4de983"
      unitRef="U_USD">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_7943af97-abbd-4666-b76f-5d0f2a476e11"
      unitRef="U_USD">1131000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_e0774587-778a-487e-b30b-e7d5e90e17dc"
      unitRef="U_USD">270000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_e8c6f7c1-3c6f-4ff7-a45c-adb7d3322f30"
      unitRef="U_USD">411000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_59531326-464b-4a66-bd0f-98b2b2cd4e32"
      unitRef="U_USD">12000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_30215e40-28ee-403d-a1c3-c6374d5c3a19"
      unitRef="U_USD">101000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_39db054d-ff4b-49a0-b733-3726e3073e79"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_11daf70f-6ce7-48e5-85ec-ede812d80584"
      unitRef="U_USD">40496000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_46887879-f019-4127-9087-2b62a16a8308"
      unitRef="U_USD">-63786000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_08588378-3702-4ae4-a695-2d7b7b376e42"
      unitRef="U_USD">-66761000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_d81d5396-668c-4e57-84b3-652d35fa9035"
      unitRef="U_USD">4532000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_1fab8219-dc32-4d4d-bd98-e59c26f93c27"
      unitRef="U_USD">14777000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_c9493e6f-2e7e-40c4-a3a0-8637f70943ba"
      unitRef="U_USD">75728000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_ba219256-86ba-48b1-aaa4-b9cadd0825ed"
      unitRef="U_USD">143000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_8ab97abb-60a1-47ea-a530-315fc4f45562"
      unitRef="U_USD">142000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_aebbb452-390b-42af-a2bf-d47eee646b29"
      unitRef="U_USD">77000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_fe376838-c9eb-45c2-b8d3-350ab4d03f41"
      unitRef="U_USD">2553000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_b52f6541-9bfc-41e2-a568-c38511bb825b"
      unitRef="U_USD">1466000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_760090ab-a981-4671-9b01-b031ab4bc9e1"
      unitRef="U_USD">170000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_9ac71d85-424f-464d-8d49-70811d6f84be"
      unitRef="U_USD">10698000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_50abd2b6-e78d-464c-9997-3d076a32881c"
      unitRef="U_USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_feaccf45-7dfa-4632-b4a4-dd796ba3208d"
      unitRef="U_USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_1dcbb1f9-1291-4438-a7e7-46fd2cf48bf6"
      decimals="-3"
      id="F_fa375c2a-94c7-489f-981b-501cd9d8368a"
      unitRef="U_USD">0</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_25dacf96-e93e-4daf-a92e-ed8eef93dd64"
      decimals="-3"
      id="F_8cfe903f-bab9-480d-bdfc-d01faf984507"
      unitRef="U_USD">0</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_fccd77c7-2dc9-4f27-8f85-1f5935f7a45a"
      decimals="-3"
      id="F_93c6073c-44bf-4d7f-ad8d-a38b0fb153e5"
      unitRef="U_USD">96204000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_7fd95b23-44ee-494d-bdcf-53246745fc95"
      decimals="-3"
      id="F_ffe96784-af24-46e5-884d-de25bc8ac168"
      unitRef="U_USD">25000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_ea6a953f-2b67-4ae3-af96-53ae33c766eb"
      decimals="-3"
      id="F_6708e6dc-b6e6-44f2-ae09-444378c2c13e"
      unitRef="U_USD">0</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_dd8d8977-0825-4ede-9687-2466de66c5ad"
      decimals="-3"
      id="F_440e7806-3f8e-4fb5-a3a0-673111d6d7b8"
      unitRef="U_USD">0</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_329c7e6d-0d7d-4d1b-8c58-05e124ceeb48"
      unitRef="U_USD">8551000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_386729bd-38d6-4821-b0bb-8813dfebb451"
      unitRef="U_USD">-13453000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_372e1ccb-3940-44f9-8a40-6063e1d1b132"
      unitRef="U_USD">-171839000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_99131d8a-2408-44dd-a45b-2307aeca052b"
      unitRef="U_USD">245977000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_b27883b6-bb55-417b-93e5-e3607bdeefbc"
      unitRef="U_USD">111451000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_3ef7b32c-b2ec-4073-a914-411a32c62d93"
      unitRef="U_USD">-97536000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_83910247-5f26-4a41-8c6e-1b90428ebbcd"
      unitRef="U_USD">304964000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a6f00937-2ee4-4566-bd68-45c44b998d3b"
      decimals="-3"
      id="F_4103c1a8-6877-4d35-a86d-58e642a8f762"
      unitRef="U_USD">193513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a60c1143-acae-40be-9475-53a07ff86264"
      decimals="-3"
      id="F_8531854d-64e7-4122-8d30-f08f1419cd80"
      unitRef="U_USD">291049000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_ddb4b89a-01d5-4f20-8ab2-12e20dc224a1"
      unitRef="U_USD">550941000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_17340a13-8530-4f1f-929e-fff401b0ea98"
      unitRef="U_USD">304964000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a6f00937-2ee4-4566-bd68-45c44b998d3b"
      decimals="-3"
      id="F_64967c97-eb15-4b00-9e15-bc2e59c6749f"
      unitRef="U_USD">193513000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_ded85536-fa0a-4270-8de3-afa111320fc7"
      unitRef="U_USD">10353000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_e9f0d197-aedd-4276-8439-4dc5459a9235"
      unitRef="U_USD">10359000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_8e4d4559-b69f-40cc-8a44-e5585c0aaec8"
      unitRef="U_USD">11381000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_3290129e-a0ad-448d-a3fc-b44424e6f926"
      unitRef="U_USD">19113000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_d0341845-375b-4147-b679-2acd885c3d57"
      unitRef="U_USD">11793000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_ab9acae0-f0f1-4fa9-8e8a-9eaf7036dbfc"
      unitRef="U_USD">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:StockIssued1
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_ef66e67f-f3a1-4afa-b3a8-117da2d4bfe6"
      unitRef="U_USD">192475000</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_f064feae-6819-409e-a820-6dbdc7cf036f"
      unitRef="U_USD">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_49d00607-effb-46aa-82d0-f5e88f3cb88f"
      unitRef="U_USD">0</us-gaap:StockIssued1>
    <inva:AccruedInterestIncomeIncludedInLongTermInvestments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_2857a8a8-463f-4a87-a9c5-d0c6aea73b53"
      unitRef="U_USD">830000</inva:AccruedInterestIncomeIncludedInLongTermInvestments>
    <inva:AccruedInterestIncomeIncludedInLongTermInvestments
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_78ed7f1c-d98c-442e-93e9-ab2424050aac"
      unitRef="U_USD">3584000</inva:AccruedInterestIncomeIncludedInLongTermInvestments>
    <inva:AccruedInterestIncomeIncludedInLongTermInvestments
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_999d6f62-a619-40fc-96e2-2ea5bde77b10"
      unitRef="U_USD">2666000</inva:AccruedInterestIncomeIncludedInLongTermInvestments>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_c21c06b5-3a45-4780-9344-37ef0ec3f0ac">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;1.  DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Description of Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#x201c;Innoviva&#x201d;, the &#x201c;Company&#x201d;, or &#x201c;we&#x201d; and other similar pronouns) is a diversified biopharmaceutical company with a portfolio of royalties, a critical care and infectious disease platform, and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#x201c;GSK&#x201d;), including RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (fluticasone furoate/vilanterol, &#x201c;FF/VI&#x201d;) and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (umeclidinium bromide/ vilanterol, &#x201c;UMEC/VI&#x201d;). Under the Long-Acting Beta2 Agonist (&#x201c;LABA&#x201d;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;as follows: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on the first $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion of annual global net sales and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for all annual global net sales above $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion; and royalties from the sales of ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which tier upward at a range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our wholly owned, critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Acinetobacter&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, commercially launched in 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(eravacycline) for the treatment of complicated intra-abdominal infections in adults;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;staphylococcus aureus bacteremia&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including those with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia, licensed from Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) (&#x201c;Basilea&#x201d;) for U.S. commercialization and commercially launched in the third quarter of 2025; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NUZOLVENCE&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (formerly known as zoliflodacin), approved by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, we own other strategic healthcare assets, such as a significant stake in Armata Pharmaceuticals, Inc., a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies through our portfolio approach.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income and comprehensive income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Management&#x2019;s Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk and of Significant Suppliers and Partners&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#x201c;API&#x201d;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Currently, we derive the majority of our revenues from GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. If GSK does not devote sufficient resources to the commercialization of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our analysts&#x2019; or investors&#x2019; expectations due to a number of important factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our revenues also include net product sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which we commercially launched in the third quarter of 2025. In the U.S., hospitals and other healthcare organizations generally acquire our products through a network of specialty distributors, which are regarded as our customers for accounting purposes. We do not believe that the loss of any one of these distributors would significantly impact our ability to distribute our products, as we expect that the sales volume would be absorbed by either new or remaining distributors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our top three customers each account for approximately:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively, of our net product sales for the year ended December 31, 2025; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively, of our net product sales for the year ended December 31, 2024; and,&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively, of our net product sales for the year ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our top &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; customers for the year ended December 31, 2025 account for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivable&#x201d; in our consolidated balance sheet as of December 31, 2025. Our top &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; customers for the year ended December 31, 2024 account for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivables&#x201d; in our consolidated balance sheet as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. Refer to Note 16, &#x201c;Segment Reporting&#x201d;, for more segment information.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#x2019;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our property and equipment consist of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation, and are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
         &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining lease terms or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment, furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity and Long-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 825, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of equity and long-term investments, net, within the consolidated statements of income and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If we conclude that we do not have the ability to exercise significant influence over an investee, we may elect to account for equity security without a readily determinable fair value using the measurement alternative method under ASC 321, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments - Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. This method allows us to measure the investment at cost less impairment, if any, and adjusted for observable price changes in orderly transactions involving the same or a similar investment of the same issuer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also invest in ISP Fund LP, whose investments consist of money market funds, trading securities, and equity securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered into in December 2020, we became a limited partner of the partnership. In October 2024, we elected to unwind our capital accounts in the partnership in accordance with the terms of the Partnership Agreement and expect to receive distributions through April 2026. Accordingly, the portion of the cash balance and money market funds expected to be distributed within 12 months from the balance sheet date has been classified as &#x201c;Current portion of ISP Fund investments,&#x201d; while the remaining equity investments have been classified as long-term investments in the consolidated balance sheets as of December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Unobservable inputs and little, if any, market activity for the assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Capitalized Fees Paid&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#x201c;Capitalized Fees&#x201d;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#x2019;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#x2019;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with an indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Asset Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We measure and recognize asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost of the acquisition is allocated to the assets acquired on the basis of their relative fair values. The cost allocated to acquire in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) with no alternative future use is charged to research and development expense at the acquisition date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We apply the guidance on principal versus agent considerations under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASC 606&#x201d;), to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalty Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on their own methodology and assumptions for estimating rebates and returns, which they monitor and adjust regularly in light of contractual and legal obligations, historical trends, past experience, and projected market conditions. Our partner may make significant adjustments to its reported sales based on actual results, which could cause fluctuation in our royalty revenue. We have rights to conduct periodic royalty audits to evaluate the accuracy of the information provided. Royalties from GSK are recognized as the net of amortization of capitalized fees related to approval and launch milestone payments made to GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Product Sales&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#x2019; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#x201c;GPO&#x201d;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Returns: We offer customers a limited right of return, generally for damaged or expired products. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each state&#x2019;s eligibility guidelines and services. Under these programs, we pay rebates to participating states, typically within three months after the quarter in which the product was sold. Additionally, we may offer customer incentives and other forms of consideration, such as volume-based or performance-based rebates. Estimated rebates are recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We may also enter into contracts that involve a series of manufacturing processes for products and related components. For any distinct performance obligation where the manufacturing process does not create an asset with alternative use and there is an enforceable right to payment for the performance completed to date, the related revenue is recognized over time. For these performance obligations satisfied over time, we use an input method to measure progress. Specifically, we apply the cost-to-cost method, under which progress is calculated as the ratio of costs incurred to date relative to the total estimated costs of the contract. This method most accurately depicts the transfer of value to the customer because costs incurred are determined to be proportionate to our performance in satisfying the obligation. Estimated total contract costs are reassessed periodically. Changes in estimates are accounted for prospectively as changes in estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of a licensing arrangement that includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price. We generally include these milestone payments in the transaction price when they are achieved because there is considerable uncertainty in the research and development processes that trigger receipt of these payments under our agreements. Similarly, we include approval milestone payments in the transaction price once the product is approved by the applicable regulatory agency. For delivery of other goods or services related to a licensing arrangement, we determine whether the performance obligation is satisfied over time or at a point in time. If the performance obligation is satisfied over time, we use judgment in determining the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Grant Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize grant revenue from non-governmental entities in accordance with ASC 958-605, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition Not-for-Profit Entities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, when qualifying costs are incurred and the conditions of the grant agreement have been met. If grant funds are received after costs have been incurred, we record the amount as grant revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as grant revenue when qualifying costs are incurred. Grant revenue is included in &#x201c;License and other revenue&#x201d; in our consolidated statements of income and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interest Expense on Deferred Royalty Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#x201c;Debt&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Stock&#x2011;Based Compensation Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#x201c;ESPP&#x201d;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#x201c;simplified&#x201d; method as described in Staff Accounting Bulletin No. 107, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,&#x201d; for the expected option term. We use our historical volatility to estimate expected stock price volatility.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) are measured based on the fair market values of the underlying stock on the dates of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#x2019;s best estimate as to whether it is probable that the shares awarded are expected to vest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#x201c;more likely than not&#x201d; standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sarissa Capital owned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of our outstanding common stock as of December 31, 2024. Transactions with Sarissa Capital are described in Note 5, &#x201c;Consolidated Entity&#x201d;. Sarissa Capital was considered to be a related party up until the annual stockholders meeting in May 2025 after which there were no representatives of Sarissa Capital serving on our Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The ASU requires the disclosure of income taxes paid disaggregated by jurisdiction and enhanced disclosures for the entity&#x2019;s effective tax rate reconciliation as well as other income tax related disclosures. We adopted this guidance prospectively as of January 1, 2025, which resulted in additional disclosures in the notes to our consolidated financial statements. Accordingly, prior periods were not retrospectively adjusted. See Note 15, &#x201c;Income Taxes.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires disclosures about specific types of expenses included in the expense captions presented on the face of the statement of income as well as disclosures about selling expenses. ASU 2024-03 is effective for the Company in annual reporting periods beginning after December 15, 2027, and interim reporting periods beginning after December 15, 2027. We are currently evaluating the potential impact that ASU 2024-03 may have on our financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-04, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;which clarifies the assessment of whether a transaction should be accounted for as an induced conversion or extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. ASU 2024-04 is effective for annual reporting periods beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. We are currently evaluating the potential impact that ASU 2024-04 may have on our financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2025, the FASB issued ASU 2025-05, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses for Current Accounts Receivable and Contract Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which provides a practical expedient for estimating expected credit losses by assuming current conditions remain unchanged over the life of the asset. The amendments in ASU 2025-05 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the potential impact that ASU 2025-05 may have on our estimation methodologies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2025, the FASB issued Update ASU 2025-11, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The ASU intends to clarify and improve existing interim reporting guidance by consolidating disclosure requirements within Topic 270 and introducing a disclosure principle requiring entities to disclose events and changes occurring after the most recent annual reporting period that are expected to have a material effect on the entity&#x2019;s financial condition or results of operations. This ASU does not introduce significant changes to recognition or measurement guidance. The amendments in this Update are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the potential impact that ASU 2025-11 may have on our financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2025, the FASB issued ASU 2025-12, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which provides technical corrections, clarifications, and other minor improvements across a number of Topics. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are currently evaluating the potential impact of ASU 2025-12 on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <inva:DescriptionOfOperationsPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_4ca43962-17d8-4727-9875-76cade69ddb0">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Description of Operations&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Innoviva, Inc. (and where context requires, together with its subsidiaries referred to as &#x201c;Innoviva&#x201d;, the &#x201c;Company&#x201d;, or &#x201c;we&#x201d; and other similar pronouns) is a diversified biopharmaceutical company with a portfolio of royalties, a critical care and infectious disease platform, and a portfolio of strategic healthcare assets. Our royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (&#x201c;GSK&#x201d;), including RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (fluticasone furoate/vilanterol, &#x201c;FF/VI&#x201d;) and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (umeclidinium bromide/ vilanterol, &#x201c;UMEC/VI&#x201d;). Under the Long-Acting Beta2 Agonist (&#x201c;LABA&#x201d;) Collaboration Agreement, Innoviva is entitled to receive royalties from GSK on sales of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;as follows: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on the first $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion of annual global net sales and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for all annual global net sales above $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion; and royalties from the sales of ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which tier upward at a range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our wholly owned, critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(angiotensin II) for increasing blood pressure in adults with septic or other distributive shock;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Acinetobacter&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, commercially launched in 2023&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(eravacycline) for the treatment of complicated intra-abdominal infections in adults;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (ceftobiprole), an advanced-generation cephalosporin antibiotic for the treatment of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;staphylococcus aureus bacteremia&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including those with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia, licensed from Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN) (&#x201c;Basilea&#x201d;) for U.S. commercialization and commercially launched in the third quarter of 2025; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;NUZOLVENCE&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (formerly known as zoliflodacin), approved by the FDA on December 12, 2025, for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, we own other strategic healthcare assets, such as a significant stake in Armata Pharmaceuticals, Inc., a leader in development of bacteriophages with potential use across a range of infectious and other serious diseases. We also have economic interests in other healthcare companies through our portfolio approach.&lt;/span&gt;&lt;/p&gt;</inva:DescriptionOfOperationsPolicyTextBlock>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne
      contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0"
      decimals="2"
      id="F_d1ae42a5-bb9c-442d-a025-2bb1ab1904f6"
      unitRef="U_pure">0.15</inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0"
      decimals="-8"
      id="F_ad7695e2-1a85-4669-8254-5a30a887ec6e"
      unitRef="U_USD">3000000000</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo
      contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0"
      decimals="2"
      id="F_6ed5a6ca-b4a1-48da-8eaf-9a5a597dceaa"
      unitRef="U_pure">0.05</inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0"
      decimals="-8"
      id="F_c43f6d1b-bc48-43ab-9981-fd606a901a36"
      unitRef="U_USD">3000000000</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_0cd22ebb-1d13-4b31-83ad-8d641740a1a8"
      decimals="3"
      id="F_50e49cdd-d5cf-4054-bcc8-9795395b01a3"
      unitRef="U_pure">0.065</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_0ea6bee8-0b7a-4347-b4e1-f57199a4e9f9"
      decimals="2"
      id="F_b0f0a2a6-278a-49e2-8add-84e1d38546dc"
      unitRef="U_pure">0.10</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_9f87ca55-5a63-4b98-9f84-5eafe95fb52b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Innoviva, our wholly owned subsidiaries and certain variable interest entities (&#x201c;VIE&#x201d;) for which we are the primary beneficiary. All intercompany balances and transactions have been eliminated in consolidation. For consolidated entities where we own or are exposed to less than 100% of the economics, we record net income (loss) attributable to noncontrolling interest in our consolidated statements of income and comprehensive income equal to the percentage of the economic or ownership interest retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_d1f6f43c-f3a7-497c-82b0-b2b59a0a74f3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Use of Management&#x2019;s Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The preparation of consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles (&#x201c;U.S. GAAP&#x201d;) requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates. Management evaluates its significant accounting policies and estimates on an ongoing basis. We base our estimates on historical experience and other relevant assumptions that we believe to be reasonable under the circumstances. These estimates also form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_d71d31c8-85bd-4d26-b283-a15e7ca1f49a">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Concentrations of Credit Risk and of Significant Suppliers and Partners&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents and equity and long-term investments. Although we deposit our cash with multiple financial institutions, our deposits, at times, may exceed federally insured limits.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We are dependent on third-party manufacturers to supply active pharmaceutical ingredients (&#x201c;API&#x201d;) and drug products for research and development and commercial programs. These programs could be adversely affected by significant interruption in the supply of API or drug products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Currently, we derive the majority of our revenues from GSK. Our near-term success depends in large part upon the performance by GSK of its commercial obligations under the GSK Agreements and the commercial success of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. If GSK does not devote sufficient resources to the commercialization of these products, is unsuccessful in its efforts, or chooses to reprioritize its commercial programs, our business would be materially harmed. GSK is responsible for all clinical and other product development, regulatory, manufacturing and commercialization activities for products developed under the GSK Agreements, including RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Our quarterly royalty revenues may fluctuate due to a variety of factors, many of which are outside of our control. Our royalty revenues under the GSK Agreements may not meet our analysts&#x2019; or investors&#x2019; expectations due to a number of important factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our revenues also include net product sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which we commercially launched in the third quarter of 2025. In the U.S., hospitals and other healthcare organizations generally acquire our products through a network of specialty distributors, which are regarded as our customers for accounting purposes. We do not believe that the loss of any one of these distributors would significantly impact our ability to distribute our products, as we expect that the sales volume would be absorbed by either new or remaining distributors.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our top three customers each account for approximately:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively, of our net product sales for the year ended December 31, 2025; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively, of our net product sales for the year ended December 31, 2024; and,&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively, of our net product sales for the year ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our top &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; customers for the year ended December 31, 2025 account for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivable&#x201d; in our consolidated balance sheet as of December 31, 2025. Our top &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;three&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; customers for the year ended December 31, 2024 account for &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively, of our receivables from net product sales, which are included in &#x201c;Accounts receivables&#x201d; in our consolidated balance sheet as of December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_4bf5fc18-5406-4a53-bdcc-a726e4be6261"
      decimals="2"
      id="F_1d8609b5-81dd-4085-9fc3-f2b7f4c3f4c5"
      unitRef="U_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_8636f737-54f5-4f04-95a2-1c6e8e58eb52"
      decimals="2"
      id="F_abacd4ba-de30-476d-a577-f343f5bcae97"
      unitRef="U_pure">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_df4f1b43-9d3e-4a14-9590-f19507b86007"
      decimals="2"
      id="F_0783c518-7a87-4d19-9034-9309ab608305"
      unitRef="U_pure">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_b772694b-7101-44aa-8dc2-322e6c88ba68"
      decimals="2"
      id="F_052974a9-ec39-4004-955d-4c35e8f65147"
      unitRef="U_pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_9bab53bf-5b1c-458d-ab5d-5fa3f3cca83c"
      decimals="2"
      id="F_2497c4df-10b2-4903-91a4-195f61c3faa4"
      unitRef="U_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_699a8187-6daf-4c19-b630-e6a4a350936f"
      decimals="2"
      id="F_3087370f-a213-45cc-a34d-a5be2352bc0c"
      unitRef="U_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_dc46e272-bbf4-4eab-89a7-9149f700ad25"
      decimals="2"
      id="F_dd5ded57-42e3-46cd-82aa-98e8b50f3af6"
      unitRef="U_pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_fa5bcc25-8b49-450a-9892-dbd82bc86c2a"
      decimals="2"
      id="F_32331d2b-4248-4ec5-842b-18a7638114a2"
      unitRef="U_pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_12cd7049-aa8a-4e80-8d0a-bdec0949c7f8"
      decimals="2"
      id="F_b9f04100-f2c9-4528-8cae-18a7f11f8e98"
      unitRef="U_pure">0.27</us-gaap:ConcentrationRiskPercentage1>
    <inva:NumberOfMajorCustomers
      contextRef="C_e1b0f380-3db6-410d-886f-3625779ce5c2"
      decimals="0"
      id="F_e8affb29-40fc-449f-8bad-2acba4087cfc"
      unitRef="U_Customer">3</inva:NumberOfMajorCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2707906b-3b85-4cd4-95b1-7be4334def0b"
      decimals="2"
      id="F_d3bf5612-4bb1-4f6e-9c8c-2e1a2d8777ff"
      unitRef="U_pure">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2840f754-c1e0-45a3-adde-c440dc45dc18"
      decimals="2"
      id="F_0ab52b51-f33c-40c3-892b-5437f30faf0e"
      unitRef="U_pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_36784711-520b-456d-b873-8cb8b780364c"
      decimals="2"
      id="F_2db83414-47ae-4237-a503-f4d152b04731"
      unitRef="U_pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <inva:NumberOfMajorCustomers
      contextRef="C_0f3c27be-b222-4d28-80f0-06ce24daba5e"
      decimals="0"
      id="F_3f1254bb-91b2-4af2-b92d-6c53fb7b92e1"
      unitRef="U_Customer">3</inva:NumberOfMajorCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_cd6017c9-4e6d-48a6-b778-fdb58ebeeb24"
      decimals="2"
      id="F_dcdeaaa8-f87d-4d6e-9937-ba2055b86178"
      unitRef="U_pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_aa99c31d-93ff-49a4-ada3-316eb33c9414"
      decimals="2"
      id="F_fc64f121-b480-4a25-86c5-7ce5f61498c1"
      unitRef="U_pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_488c264e-0d44-4a7b-be6f-0dd0449e0750"
      decimals="2"
      id="F_aeb27cc6-9f75-4c30-9522-2b580c584c40"
      unitRef="U_pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_81d7e5d1-7278-4e64-b9e4-9e0b23ed9f4e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;) in making decisions regarding resource allocation and assessing performance. Refer to Note 16, &#x201c;Segment Reporting&#x201d;, for more segment information.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_1a8c8a23-5f93-4b7a-b22a-d7d7f9ed853b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Variable Interest Entities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. When we obtain a variable interest in another entity, we assess at the inception of the relationship and upon occurrence of certain significant events whether the entity is a VIE and, if so, whether we are the primary beneficiary of the VIE based on our power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance and our obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To assess whether we have the power to direct the activities of a VIE that most significantly impact the VIE&#x2019;s economic performance, we consider all the facts and circumstances, including our role in establishing the VIE and our ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE&#x2019;s economic performance and identifying which party, if any, has power over those activities. In general, the parties that make the most significant decisions affecting the VIE (management and representation on the Board of Directors) and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To assess whether we have the obligation to absorb losses of the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE, we consider all of our economic interests that are deemed to be variable interests in the VIE. This assessment requires us to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to the VIE.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_9d4aa7d9-9fb0-42b9-9eb4-8cc85fde469b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We consider all highly liquid investments purchased with a maturity of three months or less on the date of purchase to be cash equivalents. Cash equivalents are carried at cost, which approximates fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_80ccafe6-b9a1-4683-b2a2-ca13d8a492e0">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Accounts Receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Accounts receivable are recorded net of estimates for prompt-pay discounts, chargebacks, returns and rebates. Allowances for prompt-pay discounts and chargebacks are based on contractual terms. We estimate the allowance for credit losses based on existing contractual payment terms, actual payment patterns of customers and individual customer circumstances.&lt;/span&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_6bf03cb8-2dca-4f96-a253-4b1e635ab22b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory is stated at the lower of cost or estimated net realizable value on a first-in, first-out basis. We periodically analyze inventory levels and write down inventory as cost of products sold when the following occurs: inventory has become obsolete, inventory has a cost basis in excess of its estimated net realizable value, or inventory quantities are in excess of expected product sales.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_43174d08-da99-419b-86e2-2c35caef3492">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our property and equipment consist of laboratory equipment, computer equipment, software, office furniture and fixtures, and leasehold improvements. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation, and are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
         &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining lease terms or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment, furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_b7e138a9-2c5b-41b2-800e-deaecefacb0b">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation, and are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:&lt;/span&gt;
         &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
          &lt;tr style="visibility:collapse;"&gt;
           &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:1.66%;box-sizing:content-box;"&gt;&lt;/td&gt;
           &lt;td style="width:49.17%;box-sizing:content-box;"&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Shorter of remaining lease terms or useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Laboratory equipment, furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#x2013; &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
          &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Software and computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
           &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;/tr&gt;
         &lt;/table&gt;</inva:PropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_2d1f6be5-5863-4cef-a634-37c4e6881e96"
      id="F_4cbcd9bc-16d4-4709-89fd-2ac8e89a06a3">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_8c7fde10-e15b-46cf-8152-abd34dd01bd9"
      id="F_12b99b7d-047c-4f67-a2d3-71a4dbc1d1c7">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_963ef00c-7831-40dd-b4ea-a644dc525f00"
      id="F_4e0027b9-d579-45b6-bed2-30b82f6aae00">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:EquityMethodInvestmentsPolicy
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_68cf4d3d-794f-47e8-b231-1cca9accc72d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity and Long-Term Investments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We invest from time to time in equity and debt securities of private or public companies. If we determine that we have control over these companies under either voting or VIE models, we consolidate them in our consolidated financial statements. If we determine that we do not have control over these companies under either voting or VIE models, we then determine if we have an ability to exercise significant influence via voting interests, board representation or other business relationships.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We may account for the investments where we exercise significant influence using either an equity method of accounting or at fair value by electing the fair value option under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 825, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. If the fair value option is applied to an investment that would otherwise be accounted for under the equity method, we apply it to all our financial interests in the same entity (equity and debt, including guarantees) that are eligible items. All gains and losses from fair value changes, unrealized and realized, are presented as changes in fair values of equity method investments, net, and changes in fair values of equity and long-term investments, net, within the consolidated statements of income and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If we conclude that we do not have the ability to exercise significant influence over an investee, we may elect to account for equity security without a readily determinable fair value using the measurement alternative method under ASC 321, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Investments - Equity Securities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. This method allows us to measure the investment at cost less impairment, if any, and adjusted for observable price changes in orderly transactions involving the same or a similar investment of the same issuer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also invest in ISP Fund LP, whose investments consist of money market funds, trading securities, and equity securities in the healthcare, pharmaceutical and biotechnology industries. Pursuant to the Partnership Agreement entered into in December 2020, we became a limited partner of the partnership. In October 2024, we elected to unwind our capital accounts in the partnership in accordance with the terms of the Partnership Agreement and expect to receive distributions through April 2026. Accordingly, the portion of the cash balance and money market funds expected to be distributed within 12 months from the balance sheet date has been classified as &#x201c;Current portion of ISP Fund investments,&#x201d; while the remaining equity investments have been classified as long-term investments in the consolidated balance sheets as of December 31, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_85abbff2-8baa-402c-a27d-ce918af91c8e">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our valuation techniques are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect our market assumptions. We classify these inputs into the following hierarchy:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Quoted prices for similar instruments in active markets; quoted prices for identical 3or similar instruments in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2014;Unobservable inputs and little, if any, market activity for the assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financial instruments include cash equivalents, accounts receivable, receivables from collaborative arrangements, accounts payable, and accrued liabilities, equity investments and convertible promissory notes. The carrying values of cash equivalents, receivables from collaborative arrangements, accounts payable, and accrued liabilities approximate their estimated fair values due to the relatively short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <inva:CapitalizedFeesPaidPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_9c0c4202-1d92-4d57-a1f7-102f78c48d1b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Capitalized Fees Paid&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We capitalize fees paid to licensors related to agreements for approved products or commercialized products. We capitalize these fees as capitalized fees paid (&#x201c;Capitalized Fees&#x201d;) and amortize them on a straight-line basis over their estimated useful lives upon the commercial launch of the product, shortly after its regulatory approval. The estimated useful lives of these Capitalized Fees are determined on a country-by-country and product-by-product basis, as the later of the expiration or termination of the last patent right covering the compound in such product in such country and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from first commercial sale of such product in such country, unless the Collaboration Agreement is terminated earlier. Consistent with our policy for classification of costs under the research and development collaborative arrangements, the amortization of these Capitalized Fees is recognized as a reduction of royalty revenue. We review our Capitalized Fees for impairment on a product-by-product basis for each major geographic area when events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The recoverability of Capitalized Fees is measured by comparing the asset&#x2019;s carrying amount to the expected undiscounted future cash flows that the asset is expected to generate. The determination of recoverability typically requires various estimates and assumptions, including estimating the useful life over which cash flows will occur, their amount, and the asset&#x2019;s residual value, if any. We derive the required cash flow estimates from near-term forecasted product sales and long-term projected sales in the corresponding market.&lt;/span&gt;&lt;/p&gt;</inva:CapitalizedFeesPaidPolicyTextBlock>
    <inva:CapitalizedFeePaidEstimatedUsefulLife
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      id="F_2c3c4e29-f7ca-494b-99bb-cefa49d88131">P15Y</inva:CapitalizedFeePaidEstimatedUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_36f25b09-992e-4e2d-aa09-6545d248813b">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill is recognized as the excess of the purchase consideration of an acquired entity over the fair value assigned to assets acquired and liabilities assumed in a business combination. Goodwill and intangible assets with an indefinite useful life are not amortized and are tested for impairment at least annually on the first day of December of each year or more frequently if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying asset amount may not be recoverable. Intangible assets with definite useful lives are amortized on a straight-line basis over their respective remaining useful lives and are tested for impairment only if indicators for potential impairment exist or whenever events or changes in circumstances indicate that the asset&#x2019;s carrying amount may not be recoverable. Significant judgment may be involved in determining if an indicator of impairment has occurred.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <inva:AssetAcquisitionsPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_40df869b-0e04-42be-8793-49e111ace049">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Asset Acquisitions&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We measure and recognize asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost of the acquisition is allocated to the assets acquired on the basis of their relative fair values. The cost allocated to acquire in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) with no alternative future use is charged to research and development expense at the acquisition date.&lt;/span&gt;&lt;/p&gt;</inva:AssetAcquisitionsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_c0d5da26-a399-41de-b940-3d2bc4e4d17f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Right-of-use assets represent our right to use an underlying asset over the lease term and include any lease payments made prior to the lease commencement date and are reduced by lease incentives. Lease liabilities represent the present value of the total lease payments over the lease term, calculated using an estimated incremental borrowing rate. Lease expense is recognized on a straight-line basis over the expected lease term.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_69da4ed6-62c6-479f-946b-586e3c8dbccd">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We apply the guidance on principal versus agent considerations under ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(&#x201c;ASC 606&#x201d;), to determine the appropriate treatment for the transactions between us and third parties. The classification of transactions under our arrangements is determined based on the nature and contractual terms of the arrangement along with the nature of the operations of the participants. Any consideration related to activities in which we are considered the principal, which includes being in control of the good or service before such good or service is transferred to the customer, are accounted for as product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue is recognized when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract with the customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price for the contract; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue as a performance obligation is satisfied.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalty Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize royalty revenue on net sales of products with respect to which we have contractual royalty rights in the period in which the royalties are earned. The net sales reports provided by our partner are based on their own methodology and assumptions for estimating rebates and returns, which they monitor and adjust regularly in light of contractual and legal obligations, historical trends, past experience, and projected market conditions. Our partner may make significant adjustments to its reported sales based on actual results, which could cause fluctuation in our royalty revenue. We have rights to conduct periodic royalty audits to evaluate the accuracy of the information provided. Royalties from GSK are recognized as the net of amortization of capitalized fees related to approval and launch milestone payments made to GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Product Sales&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Revenue from product sales is recognized when our customers obtain control of the product and is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, discounts, returns and rebates. Variable consideration is estimated using the expected-value amount method, which is the sum of probability-weighted amounts in a range of possible consideration amounts. Actual amounts of consideration ultimately received may differ from our estimates. If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These items may include:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Chargebacks: Chargebacks are discounts we provide to distributors in the event that the sales prices to end users are below the distributors&#x2019; acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (&#x201c;GPO&#x201d;) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Discounts: We offer customers various forms of incentives and consideration, including prompt-pay and other discounts. We estimate discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:justify;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Returns: We offer customers a limited right of return, generally for damaged or expired products. We estimate returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to our customers. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Rebates: We participate in Medicaid rebate programs, which provide assistance to certain low-income patients based on each state&#x2019;s eligibility guidelines and services. Under these programs, we pay rebates to participating states, typically within three months after the quarter in which the product was sold. Additionally, we may offer customer incentives and other forms of consideration, such as volume-based or performance-based rebates. Estimated rebates are recorded as a reduction of revenue on delivery to our customers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We may also enter into contracts that involve a series of manufacturing processes for products and related components. For any distinct performance obligation where the manufacturing process does not create an asset with alternative use and there is an enforceable right to payment for the performance completed to date, the related revenue is recognized over time. For these performance obligations satisfied over time, we use an input method to measure progress. Specifically, we apply the cost-to-cost method, under which progress is calculated as the ratio of costs incurred to date relative to the total estimated costs of the contract. This method most accurately depicts the transfer of value to the customer because costs incurred are determined to be proportionate to our performance in satisfying the obligation. Estimated total contract costs are reassessed periodically. Changes in estimates are accounted for prospectively as changes in estimates.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;At the inception of a licensing arrangement that includes development and regulatory milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price. We generally include these milestone payments in the transaction price when they are achieved because there is considerable uncertainty in the research and development processes that trigger receipt of these payments under our agreements. Similarly, we include approval milestone payments in the transaction price once the product is approved by the applicable regulatory agency. For delivery of other goods or services related to a licensing arrangement, we determine whether the performance obligation is satisfied over time or at a point in time. If the performance obligation is satisfied over time, we use judgment in determining the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, adjust the measure of performance and related revenue recognition.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Grant Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognize grant revenue from non-governmental entities in accordance with ASC 958-605, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue Recognition Not-for-Profit Entities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, when qualifying costs are incurred and the conditions of the grant agreement have been met. If grant funds are received after costs have been incurred, we record the amount as grant revenue and a corresponding grant receivable. Cash received from grants in advance of incurring qualifying costs is recorded as deferred revenue and recognized as grant revenue when qualifying costs are incurred. Grant revenue is included in &#x201c;License and other revenue&#x201d; in our consolidated statements of income and comprehensive income.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_970c751b-bb7a-46c2-9b11-1e140681551f">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Research and development expenses are recognized in the period that services are rendered or goods are received. Research and development expenses consist of salaries and benefits, laboratory supplies, facilities and other overhead costs, research-related manufacturing costs, contract service and clinical-related service costs performed by third party research organizations, research institutions and other outside service providers. Non-refundable prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the related goods are delivered or the related services are performed. We also utilize significant judgment and estimates to record accruals for estimated ongoing research costs based on the progress of the studies and progress of research manufacturing activities.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InterestExpensePolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_d3101d5b-10a6-475e-b7e1-ce8c41dae2cb">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interest Expense on Deferred Royalty Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Interest expense related to the deferred royalty obligation is recognized over the expected repayment term of the deferred royalty obligation using the effective interest method. The assumptions used in determining the expected repayment term of the deferred royalty obligation require us to make estimates that could impact the effective interest rate. Each reporting period, we estimate the expected repayment term of the deferred royalty obligation based on forecasted net sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Changes in interest expense resulting from changes in the effective interest rate, if any, are recorded on a prospective basis. Refer to Note 12, &#x201c;Debt&#x201d;, for more information.&lt;/span&gt;&lt;/p&gt;</us-gaap:InterestExpensePolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_d20c0fad-7018-444b-b14d-f273713206cb">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value of Stock&#x2011;Based Compensation Awards&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans and rights to acquire stock granted under our employee stock purchase plan (&#x201c;ESPP&#x201d;). The Black-Scholes-Merton option valuation model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. We use the &#x201c;simplified&#x201d; method as described in Staff Accounting Bulletin No. 107, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;,&#x201d; for the expected option term. We use our historical volatility to estimate expected stock price volatility.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted stock units (&#x201c;RSUs&#x201d;) and restricted stock awards (&#x201c;RSAs&#x201d;) are measured based on the fair market values of the underlying stock on the dates of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. Our estimated annual forfeiture rates for stock options, RSUs and RSAs are based on our historical forfeiture experience.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated fair value of stock options, RSUs and RSAs is expensed on a ratable or straight-line basis over the expected term of the grant or expected term of the vesting. Compensation expense is recorded over the requisite service period based on management&#x2019;s best estimate as to whether it is probable that the shares awarded are expected to vest.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Compensation expense for purchases under the ESPP is recognized based on the fair value of the common stock on the date of offering, less the purchase discount percentage provided for in the plan.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_42c69e8a-24fb-4174-95c1-db140a5529f1">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We utilize the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and the tax basis of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The recognition and measurement of tax benefits requires significant judgment. Our judgment might change as new information becomes available. We continue to evaluate our deferred tax assets each reporting period to determine whether adjustments to our valuation allowance are required and deferred tax assets will be realized based on the consideration of all available positive and negative evidence, including the differences between our anticipated and actual future operating results, using a &#x201c;more likely than not&#x201d; standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We assess all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position&#x2019;s sustainability and is measured at the largest amount of benefit that is greater than 50% likely to be realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and we determine whether the factors underlying the sustainability assertion have changed and whether the amount of the recognized tax benefit is still appropriate.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <inva:RelatedPartyTransactionsPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_f08871f8-7439-4dec-9ce1-e1f45334c0da">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Sarissa Capital owned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of our outstanding common stock as of December 31, 2024. Transactions with Sarissa Capital are described in Note 5, &#x201c;Consolidated Entity&#x201d;. Sarissa Capital was considered to be a related party up until the annual stockholders meeting in May 2025 after which there were no representatives of Sarissa Capital serving on our Board of Directors.&lt;/span&gt;&lt;/p&gt;</inva:RelatedPartyTransactionsPolicyTextBlock>
    <inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty
      contextRef="C_8d782d9a-b93f-45ae-a7ce-ee978ddef5a5"
      decimals="3"
      id="F_0e955540-18be-4b42-9a94-baaf38163b40"
      unitRef="U_pure">0.116</inva:RelatedPartyTransactionCommonStockOwnershipPercentageByRelatedParty>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_2b61e2ab-b031-4e39-bc11-06772ab1cf8d">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Improvements to Income Tax Disclosures (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The ASU requires the disclosure of income taxes paid disaggregated by jurisdiction and enhanced disclosures for the entity&#x2019;s effective tax rate reconciliation as well as other income tax related disclosures. We adopted this guidance prospectively as of January 1, 2025, which resulted in additional disclosures in the notes to our consolidated financial statements. Accordingly, prior periods were not retrospectively adjusted. See Note 15, &#x201c;Income Taxes.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2013; Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which requires disclosures about specific types of expenses included in the expense captions presented on the face of the statement of income as well as disclosures about selling expenses. ASU 2024-03 is effective for the Company in annual reporting periods beginning after December 15, 2027, and interim reporting periods beginning after December 15, 2027. We are currently evaluating the potential impact that ASU 2024-03 may have on our financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2024, the FASB issued ASU 2024-04, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Debt &#x2014; Debt with Conversion and Other Options (Subtopic 470-20), &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;which clarifies the assessment of whether a transaction should be accounted for as an induced conversion or extinguishment of convertible debt when changes are made to conversion features as part of an offer to settle the instrument. ASU 2024-04 is effective for annual reporting periods beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. We are currently evaluating the potential impact that ASU 2024-04 may have on our financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In July 2025, the FASB issued ASU 2025-05, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Financial Instruments &#x2014; Credit Losses (Topic 326): Measurement of Credit Losses for Current Accounts Receivable and Contract Assets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which provides a practical expedient for estimating expected credit losses by assuming current conditions remain unchanged over the life of the asset. The amendments in ASU 2025-05 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. Early adoption is permitted. We are currently evaluating the potential impact that ASU 2025-05 may have on our estimation methodologies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2025, the FASB issued Update ASU 2025-11, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Interim Reporting (Topic 270): Narrow-Scope Improvements. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The ASU intends to clarify and improve existing interim reporting guidance by consolidating disclosure requirements within Topic 270 and introducing a disclosure principle requiring entities to disclose events and changes occurring after the most recent annual reporting period that are expected to have a material effect on the entity&#x2019;s financial condition or results of operations. This ASU does not introduce significant changes to recognition or measurement guidance. The amendments in this Update are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. We are currently evaluating the potential impact that ASU 2025-11 may have on our financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2025, the FASB issued ASU 2025-12, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Codification Improvements&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which provides technical corrections, clarifications, and other minor improvements across a number of Topics. The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are currently evaluating the potential impact of ASU 2025-12 on our consolidated financial statements and disclosures.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_a23b68a3-57dc-449f-873d-2e8c14f03054">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2.  NET INCOME PER SHARE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Basic net income per share is computed by dividing net income by the weighted-average number of shares of common stock outstanding. Diluted net income per share is computed by dividing net income by the weighted-average number of shares of common stock and dilutive potential common stock equivalents then outstanding. Dilutive potential common stock equivalents include the assumed exercise, vesting and issuance of employee stock awards using the treasury stock method, as well as common stock issuable upon assumed conversion of our convertible subordinated notes due 2023 (the &#x201c;2023 Notes&#x201d;) up until its maturity date on January 15, 2023, our convertible senior notes due 2025 (the &#x201c;2025 Notes&#x201d;) up until its maturity date on August 15, 2025, and our convertible senior notes due 2028 (the &#x201c;2028 Notes&#x201d;) using the if-converted method. If the results are in a net loss position, diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for potential dilutive common stock equivalents.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows the computation of basic and diluted net income per share for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net income, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;179,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: interest expense on 2023 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: interest expense on 2025 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: interest expense on 2028 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net income, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;279,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used to compute basic net income&lt;br/&gt;&#160;&#160;&#160;per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dilutive effect of 2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dilutive effect of 2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dilutive effect of 2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dilutive effect of options and awards granted under equity&lt;br/&gt;&#160;&#160;&#160;incentive plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dilutive effect of outstanding warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used to compute diluted net income&lt;br/&gt;&#160;&#160;&#160;per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net income per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Anti&#x2011;dilutive Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#x2011;dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding options and awards granted under equity incentive&lt;br/&gt;&#160;&#160;&#160;plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding stock warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding 2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_9329f78d-aa56-467b-aca7-5f5d06e9fbd9">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table shows the computation of basic and diluted net income per share for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net income, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;179,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: interest expense on 2023 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;89&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: interest expense on 2025 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,882&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,116&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Add: interest expense on 2028 Notes, net of tax effect&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,776&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net income, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;279,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;191,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used to compute basic net income&lt;br/&gt;&#160;&#160;&#160;per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,435&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dilutive effect of 2023 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dilutive effect of 2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,150&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dilutive effect of 2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dilutive effect of options and awards granted under equity&lt;br/&gt;&#160;&#160;&#160;incentive plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;491&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dilutive effect of outstanding warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average shares used to compute diluted net income&lt;br/&gt;&#160;&#160;&#160;per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,187&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,876&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net income per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_5cd80f25-3c44-4b69-9857-7e46d713e808"
      unitRef="U_USD">271165000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_6f2f0a63-c515-4e35-a360-460eec8fb980"
      unitRef="U_USD">23392000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_45d831c9-3540-40c5-95dd-f7024701b534"
      unitRef="U_USD">179722000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_bc424098-7c86-48ee-a261-2e346af6f356"
      decimals="-3"
      id="F_4a6c8488-0e23-483d-9f18-a1c3272b1175"
      unitRef="U_USD">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_f4e52e0e-68f9-43ec-b6ac-caf887da2c67"
      decimals="-3"
      id="F_4393a9ce-47f1-49cd-82c6-479b2e9d0f3b"
      unitRef="U_USD">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_983b3e15-da6b-4fb2-b179-654eb3026eeb"
      decimals="-3"
      id="F_f4d60a0a-7e20-41b7-9e0e-cce169714d7b"
      unitRef="U_USD">89000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1"
      decimals="-3"
      id="F_2f29100e-c2d6-4da6-98f6-d3780f5d834a"
      unitRef="U_USD">2882000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_a08b10dd-5488-446a-93cd-e5dd9322693a"
      decimals="-3"
      id="F_301b2d6e-e5f0-48db-9aee-601596911d49"
      unitRef="U_USD">3468000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_689c9adb-8230-4574-87c7-dc46032a5878"
      decimals="-3"
      id="F_88ac724b-5d8c-4dd9-a5e5-26b423ab564b"
      unitRef="U_USD">5116000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6"
      decimals="-3"
      id="F_380dbeee-e551-42bd-a074-06fbe555be4a"
      unitRef="U_USD">5776000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_9290e126-1791-4a2c-9976-a9357f71a1c8"
      decimals="-3"
      id="F_d7a7aad8-dba1-4045-9c2f-88f9edfecfa6"
      unitRef="U_USD">0</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:InterestOnConvertibleDebtNetOfTax
      contextRef="C_3e958a1c-5aa6-4afc-bf9d-697d696cd0d9"
      decimals="-3"
      id="F_5e68a952-ea41-4402-ba11-36edd193bcc3"
      unitRef="U_USD">6377000</us-gaap:InterestOnConvertibleDebtNetOfTax>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_70fac540-7c3a-470b-bf01-4fb4faff7988"
      unitRef="U_USD">279823000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_c186fc9e-b7dd-4576-a0c8-7734390671a3"
      unitRef="U_USD">26860000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_f8786295-43c8-4b24-a278-c46c9c629a51"
      unitRef="U_USD">191304000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_27aa4759-23b3-4582-bb32-90a33e7ce4dd"
      unitRef="U_shares">67395000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_62ffe1bd-7be4-4999-ae4c-0cc586459056"
      unitRef="U_shares">62726000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_ce4af715-c3c7-4625-a282-fc4ecfc98609"
      unitRef="U_shares">65435000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_bc424098-7c86-48ee-a261-2e346af6f356"
      decimals="-3"
      id="F_6d5eeb09-38da-456d-a55e-df149fddfa16"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_f4e52e0e-68f9-43ec-b6ac-caf887da2c67"
      decimals="-3"
      id="F_0bf96634-ac5f-43f7-8386-cca2be7333af"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_983b3e15-da6b-4fb2-b179-654eb3026eeb"
      decimals="-3"
      id="F_472e7f6c-3df3-456c-aa09-41fab22f630e"
      unitRef="U_shares">187000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1"
      decimals="-3"
      id="F_c5e6c8a4-1640-41e1-a6be-94c9635451df"
      unitRef="U_shares">6900000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_a08b10dd-5488-446a-93cd-e5dd9322693a"
      decimals="-3"
      id="F_a7efcc6e-0bda-436b-84e0-2d95a59707ac"
      unitRef="U_shares">11150000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_689c9adb-8230-4574-87c7-dc46032a5878"
      decimals="-3"
      id="F_70f6a865-6c80-4c49-b485-b34666f68188"
      unitRef="U_shares">11150000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6"
      decimals="-3"
      id="F_c467c127-a83f-4385-b526-68c2ca43ea23"
      unitRef="U_shares">9955000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_9290e126-1791-4a2c-9976-a9357f71a1c8"
      decimals="-3"
      id="F_1b822f15-4839-4081-aa5d-2693fb665e69"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="C_3e958a1c-5aa6-4afc-bf9d-697d696cd0d9"
      decimals="-3"
      id="F_a6101ec5-8e03-4497-a197-4d04df062a7f"
      unitRef="U_shares">9955000</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_8bd1d9b5-2098-47b7-b22e-7230e75f0c25"
      unitRef="U_shares">491000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_e68a9337-3df1-4099-acf8-88fb6e84f76d"
      unitRef="U_shares">311000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_ff7bbfee-6081-4b89-a645-75f89ff51d81"
      unitRef="U_shares">149000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_59ef0c37-24ad-4e62-b6da-5dd477de5794"
      unitRef="U_shares">19000</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_762852a4-1ef3-46f4-b300-2889a8796736"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_bc7c57d3-843b-4af5-aeb0-0ac98caf7840"
      unitRef="U_shares">0</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_4a3a873c-fe06-4b56-acdb-9cfa278dbce9"
      unitRef="U_shares">84760000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_dcf9e8ee-f10e-42f6-b05b-ddab50061cdd"
      unitRef="U_shares">74187000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_d880542b-2890-4381-be1e-f2be43bae188"
      unitRef="U_shares">86876000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="2"
      id="F_f5775455-802a-48b8-b3ca-2695f437709a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="2"
      id="F_86136894-99ee-47f8-a85b-f4e20438f036"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="2"
      id="F_69504b57-70a6-498b-9949-2ab6c910be69"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.75</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="2"
      id="F_a19142ba-00a2-4a4e-8e32-1dea79f1c57a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.3</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="2"
      id="F_e8dcc25d-0cc7-4ce4-a3f7-cf2c0e2cb81f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="2"
      id="F_c115bf0f-8c0d-4bcb-a9b5-5e55ef79f36b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.2</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_5437323e-56fb-419b-a897-8a5e31db7ede">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following common stock equivalents were not included in the computation of diluted net income per share because their effect was anti&#x2011;dilutive for the periods presented:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.28%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding options and awards granted under equity incentive&lt;br/&gt;&#160;&#160;&#160;plan and employee stock purchase plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding stock warrant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Outstanding 2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,742&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bb0d3213-3fd7-4233-90d1-9955a45217a9"
      decimals="-3"
      id="F_801d34d2-6cfb-469f-bb15-5df48440e77c"
      unitRef="U_shares">1535000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7750e87c-0533-4d37-95fe-b10ee03f2aa0"
      decimals="-3"
      id="F_08663329-8644-403a-9d07-14fbe7ac4348"
      unitRef="U_shares">1196000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c7bb82e1-094a-43f1-9fb5-4b8ca5b929fa"
      decimals="-3"
      id="F_f35dbed5-5c86-46ad-8d3e-3d06023bbaba"
      unitRef="U_shares">1333000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d3132f94-898b-45b9-b231-38bb9e3c6785"
      decimals="-3"
      id="F_c3abe9db-4d7f-460d-aef0-5731d7a684f0"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_e78081be-df8b-41c7-9089-842b6fe1de71"
      decimals="-3"
      id="F_e1eb02ec-0d38-4486-801d-5b0a0b602c65"
      unitRef="U_shares">591000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_dc58284d-69c1-4202-ab83-45c4db4ecabd"
      decimals="-3"
      id="F_79a2d2e5-044e-4691-8197-7149e5782532"
      unitRef="U_shares">591000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cbc75e73-16d5-41ff-9fc0-e3415e4303d3"
      decimals="-3"
      id="F_cb238373-4c89-434a-b2ba-4e98164e8a96"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_553bd178-313c-476a-ad6e-7c4ee1a08840"
      decimals="-3"
      id="F_8f37db21-f502-4ee3-b105-ae25bfdd3d80"
      unitRef="U_shares">9955000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_33a0dd32-8b33-4cc0-a555-d73ff67cc33b"
      decimals="-3"
      id="F_1d1b1658-b01e-423d-94ec-0df77fe80d0a"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_b0f51610-a531-41cf-a37e-d59f59629836"
      unitRef="U_shares">1535000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_0ba3d5ab-e72c-4c00-9a2a-d4a16c6a1c0c"
      unitRef="U_shares">11742000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_f17ced66-397c-4f35-bc21-eafec19392c1"
      unitRef="U_shares">1924000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_f199754e-2c81-44f2-a0b1-99ee701b05b5">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;3.  REVENUE RECOGNITION&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Revenue from Collaboration Arrangement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are entitled to receive royalties from GSK with respect to RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net revenue recognized under our GSK Agreements was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties &#x2013; RELVAR/BREO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;204,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties &#x2013; ANORO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: amortization of capitalized&lt;br/&gt;&#160;&#160;&#160;fees paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;236,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;241,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;LABA Collaboration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As a result of the launch and approval of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the U.S., Japan and Europe, we paid milestone fees to GSK totaling $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 2014. The milestone fees paid to GSK were recognized as capitalized fees paid, which are being amortized over their estimated useful lives commencing upon the commercial launch of the product. The amortization is recorded as a reduction to the royalties from GSK.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are entitled to receive annual royalties from GSK on sales of RELVAR&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;/BREO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as follows: &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on the first $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion of annual global net sales and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% for all annual global net sales above $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; billion. Sales of single&#x2011;agent LABA medicines and combination medicines would be combined for the purposes of this royalty calculation. For other products combined with a LABA from the LABA Collaboration, such as ANORO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ELLIPTA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, royalties are upward tiering and range from &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Net Product Sales&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total net product sales were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;XACDURO&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;XERAVA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total net product sales&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;172,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We derived our net product sales:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% from customers located in the U.S. and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% from the rest of the world for the year ended December 31, 2025; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;83&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% from customers located in the U.S. and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% from the rest of the world for the year ended December 31, 2024; and, &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% from customers located in the U.S. and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% from the rest of the world for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;License and Other Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Refer to the out-license agreement with Zai Lab and Everest and the Grant Agreement with Gates Foundation in Note 4, &#x201c;License, Collaboration and Other Arrangements&#x201d;.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_ce4ec64f-96c1-44dc-948a-f9d09239dd8c">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Net revenue recognized under our GSK Agreements was as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties &#x2013; RELVAR/BREO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;204,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;207,925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalties &#x2013; ANORO&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,631&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;250,302&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;252,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: amortization of capitalized&lt;br/&gt;&#160;&#160;&#160;fees paid&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total royalty revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;236,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;241,733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;238,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_845eaa74-fc53-4af0-b138-f622d45b3c0f"
      decimals="-3"
      id="F_1193fe3b-6f2c-44aa-a4f6-7abccb2384fc"
      unitRef="U_USD">204021000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_da7cd9c6-74d8-41bd-9505-fc9787b73b1b"
      decimals="-3"
      id="F_1ded4573-db8f-4da8-a32f-a7c5a674b891"
      unitRef="U_USD">207925000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_f3dedb00-89d6-46cf-b991-17d8708476a1"
      decimals="-3"
      id="F_9460e98c-78c4-49e0-ba37-e5aaac21114e"
      unitRef="U_USD">208042000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_61fa56d2-4262-4f72-ae36-ba8d54b9623c"
      decimals="-3"
      id="F_0718c395-e34b-4937-9340-50b90b25e7ad"
      unitRef="U_USD">46281000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_5883bac0-e505-42e6-8df8-70275b1d4f0a"
      decimals="-3"
      id="F_7b1296f2-a1f9-491e-a88e-adb8bc3b7056"
      unitRef="U_USD">47631000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_0bd76c2e-9aae-4309-9bc2-e14f04493aff"
      decimals="-3"
      id="F_65c5b9b2-22a7-4ac2-88d3-4a7360f5018f"
      unitRef="U_USD">44627000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054"
      decimals="-3"
      id="F_475134f4-7cd0-4881-a0ee-fa233e8ddfb1"
      unitRef="U_USD">250302000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_24d3732a-a2a9-4442-b464-10be5d29362f"
      decimals="-3"
      id="F_05cbe96c-44ee-46b5-a1ab-47e0ebe55863"
      unitRef="U_USD">255556000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees
      contextRef="C_8290bc3e-4b79-45b4-8dd5-a2d83da40c0c"
      decimals="-3"
      id="F_eb04b8cc-ba7a-4581-b569-1f351cdf1ef4"
      unitRef="U_USD">252669000</inva:GrossRevenueFromContractWithCustomerExcludingAssessedTaxBeforeAmortizationOfCapitalizedFees>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054"
      decimals="-3"
      id="F_abf7d19e-69c9-4a69-9d41-1c7651507518"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_24d3732a-a2a9-4442-b464-10be5d29362f"
      decimals="-3"
      id="F_2e7dd012-a2d2-4c5d-8215-45fda931ab09"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_8290bc3e-4b79-45b4-8dd5-a2d83da40c0c"
      decimals="-3"
      id="F_7b339ec4-dc76-4922-8c46-053e3b1ea67d"
      unitRef="U_USD">13823000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_fe5e17e8-222b-40a5-a127-1e0b2ec7f054"
      decimals="-3"
      id="F_cddd8fe5-0f42-4d67-ac72-a8853466b186"
      unitRef="U_USD">236479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_24d3732a-a2a9-4442-b464-10be5d29362f"
      decimals="-3"
      id="F_8a3f07a3-3b0d-40f8-baa3-af5c32c73be8"
      unitRef="U_USD">241733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8290bc3e-4b79-45b4-8dd5-a2d83da40c0c"
      decimals="-3"
      id="F_a85650f4-3f8e-45c0-b16b-14c2f140b45e"
      unitRef="U_USD">238846000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_80f755ab-2884-4b9f-8f1a-e93170c6f575"
      decimals="-5"
      id="F_656b75de-7cf5-4725-b9b1-2a95c80923f6"
      unitRef="U_USD">220000000</us-gaap:CapitalizedContractCostGross>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne
      contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0"
      decimals="2"
      id="F_a174de5d-ce6f-4f13-84ce-93f7d7547dc4"
      unitRef="U_pure">0.15</inva:CollaborativeArrangementRoyaltyRateDefinedLevelOne>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0"
      decimals="-8"
      id="F_ddf6012b-bb3b-431c-b858-30edbd46388c"
      unitRef="U_USD">3000000000</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo
      contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0"
      decimals="2"
      id="F_d730aedc-8622-466b-ab89-3b5534561be5"
      unitRef="U_pure">0.05</inva:CollaborativeArrangementRoyaltyRateDefinedLevelTwo>
    <inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
      contextRef="C_e154e0d1-1fb6-41aa-bdd4-000a808222f0"
      decimals="-8"
      id="F_64034362-b47e-4f9a-a46c-041340ab5da2"
      unitRef="U_USD">3000000000</inva:CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_0cd22ebb-1d13-4b31-83ad-8d641740a1a8"
      decimals="3"
      id="F_e1f37369-a891-42c9-84d8-0063676c3edf"
      unitRef="U_pure">0.065</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
      contextRef="C_0ea6bee8-0b7a-4347-b4e1-f57199a4e9f9"
      decimals="2"
      id="F_a800a9b9-f1b4-4db5-aaae-c82d6a2c985a"
      unitRef="U_pure">0.10</inva:CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_5eaa990e-a9b6-4737-9e56-1e314cd57f49">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Total net product sales were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,037&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;XACDURO&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;74,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,070&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,003&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;XERAVA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,385&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;Total net product sales&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;172,130&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;97,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4b612ee6-394a-4ddd-9bcc-6ab2bb1b034d"
      decimals="-3"
      id="F_7604d8e5-d77a-4070-8d85-3fdb3cb367a1"
      unitRef="U_USD">73611000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b17848ff-54df-4b86-b3cd-386a1ff12968"
      decimals="-3"
      id="F_81679e98-bde3-4674-99fc-d360c8f55721"
      unitRef="U_USD">55037000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2db96a8e-31d6-4b8d-831e-e5ed59bdbb06"
      decimals="-3"
      id="F_cacdba34-3fd1-4fc8-abb1-8eab5e1d73b6"
      unitRef="U_USD">41294000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_51398c9e-10f3-4ea8-bf6f-402b631244a3"
      decimals="-3"
      id="F_c22794c5-4d3e-4db4-a49d-c8fcc8631ba1"
      unitRef="U_USD">74393000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_bb1be382-95cb-4b4d-9141-588145edc4e6"
      decimals="-3"
      id="F_3185745f-660b-431f-891e-1c119a208d2d"
      unitRef="U_USD">21070000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_44c21172-b919-4027-9bf1-950d87ebeb9c"
      decimals="-3"
      id="F_5a566b01-4e2b-4641-825f-d15ca7ed8425"
      unitRef="U_USD">2003000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8d1ae2b7-8b25-4684-9b73-d88cea1e9a93"
      decimals="-3"
      id="F_02e73072-f6d3-4520-8355-6948829041be"
      unitRef="U_USD">23516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d029c0a8-0421-4544-b742-f93ceeea6d0a"
      decimals="-3"
      id="F_89da9dfe-837c-4368-875d-42975a2ad6f0"
      unitRef="U_USD">21385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_772c1d45-e01c-4ce3-82b8-60c2d33c65c7"
      decimals="-3"
      id="F_de3ac594-e6d6-4b33-af65-057126e39b0a"
      unitRef="U_USD">17320000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_3417b179-deaf-41ea-bd39-7e434b1db032"
      decimals="-3"
      id="F_bb96c033-292f-4127-bdfa-e155de5a28f4"
      unitRef="U_USD">610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9d19a8d1-6525-465e-9818-4f4be4f7b334"
      decimals="-3"
      id="F_60e959b7-9101-4ab7-84a3-24c5dd52c111"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_a0a9ffa5-48e7-43db-b94b-727a9650a8a7"
      decimals="-3"
      id="F_2d84e499-4493-4f36-8cd3-c84f36f0b1bf"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_e1b0f380-3db6-410d-886f-3625779ce5c2"
      decimals="-3"
      id="F_e5d69fdc-efb5-468a-aa90-026a6484a302"
      unitRef="U_USD">172130000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0f3c27be-b222-4d28-80f0-06ce24daba5e"
      decimals="-3"
      id="F_8025fbe6-3ae7-493b-9388-b901dd902b70"
      unitRef="U_USD">97492000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d5a54e09-f59e-44b6-9cef-6b6ac8a95a30"
      decimals="-3"
      id="F_109835d3-e027-49dd-9a92-e4b395b46d38"
      unitRef="U_USD">60617000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_8a27a178-7498-4039-b7ec-3acbc3e22557"
      decimals="2"
      id="F_4b4e3c13-dba1-4d0b-b8d3-015ee5b10cb8"
      unitRef="U_pure">0.69</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_0a146130-5ab1-47b0-bf0f-7f7c0ba94af3"
      decimals="2"
      id="F_38532a3a-1171-4929-866c-74bd4744bcf1"
      unitRef="U_pure">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_9a9972fa-1809-4264-b6eb-ab4488000164"
      decimals="2"
      id="F_b7063d14-8f73-4676-8be3-4b34232ff11c"
      unitRef="U_pure">0.83</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_27624d2b-fd4c-438a-9721-62e1806ce67a"
      decimals="2"
      id="F_57d3c4d9-96c0-485e-8ae0-b0f584440d8a"
      unitRef="U_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_64469642-d4d1-4b61-893c-cc3938dfe822"
      decimals="2"
      id="F_55c4330e-4eac-4f6e-8ecd-3c1fc443e4a6"
      unitRef="U_pure">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_49a08cdc-4904-4992-b261-91482376f0e3"
      decimals="2"
      id="F_6adec083-1532-4621-87be-a36f31d83bb5"
      unitRef="U_pure">0.09</us-gaap:ConcentrationRiskPercentage1>
    <inva:LicenseCollaborationAndOtherArrangementsTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_b3a40032-18e2-4488-95e9-0a8fab95bebf">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4. LICENSE, COLLABORATION AND OTHER ARRANGEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Out-License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Zai Lab&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Entasis Therapeutics Holdings Inc. (&#x201c;Entasis&#x201d;), our wholly-owned subsidiary, entered into a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. (&#x201c;Zai Lab&#x201d;) (Nasdaq: ZLAB), pursuant to which Zai Lab licensed exclusive rights to durlobactam and SUL-DUR, in the Asia-Pacific region (&#x201c;the Zai Agreement&#x201d;). Under the terms of the Zai Agreement, Zai Lab shall fund most of the registrational clinical trial costs in China for SUL-DUR, with the exception of Phase 3 patient drug supply of licensed products. Zai Lab shall conduct development activities and plan and obtain regulatory approval in a specified number of countries in the Asia-Pacific region beyond China after receipt of regulatory approval of a licensed product in China. Zai Lab is also solely responsible for commercializing licensed products in the Asia-Pacific region and shall commercialize licensed products for which it has obtained regulatory approval. We are obligated to supply Zai Lab with the licensed products for clinical development and for commercial use for a certain period unless Zai Lab notifies otherwise. Zai Lab may take over manufacturing responsibilities for its own commercialization activities within a specified time period following the effective date of the Zai Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;are eligible to receive up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in research and development support payments and development, regulatory and sales milestone payments related to SUL-DUR, imipenem and other combinations with the licensed products. Zai Lab shall pay us a tiered royalty ranging from a high-single digit to low-double digit percentage based on annual net sales of licensed products in the territory, subject to specified reductions for the market entry of competing products, loss of patent coverage of licensed products and for payments owed to third parties for additional rights necessary to commercialize licensed products in the territory. Payments received for research support and reimbursable clinical trial costs are recorded as a reduction to research and development expense during the period in which the qualifying expenses are incurred.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Such amounts recorded for the years ended December 31, 2025, 2024 and 2023 were not material. SUL-DUR was approved by China&#x2019;s National Medical Products Administration in May 2024, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and was launched by Zai Lab in mainland China in January 2025. Royalties under this arrangement based on the product sales was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year ended December 31, 2025. W&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;e recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in license revenue for the year ended December 31, 2024 under this agreement as a result of the achievement of a regulatory milestone. Following the approval of XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; by the FDA in May 2023, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in license revenue for the year ended December 31, 2023 under this agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2024, we entered into an amendment to the Zai Agreement (the &#x201c;Amended Zai Agreement&#x201d;), pursuant to which Zai Lab shall share costs associated with certain new manufacturing and technology transfer activities for XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(the &#x201c;Services&#x201d;), which were not contemplated under the Zai Agreement and are crucial for regulatory approval in the Asia-Pacific region.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Under the Amended Zai Agreement, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in license and other revenue for the years ended December 31, 2025 and 2024, respectively, of which &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million were included in &#x201c;Accounts receivable&#x201d; in our consolidated balance sheets as of December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We entered into an interim supply agreement with Zai Lab in June 2024, which was amended in February 2025 and August 2025, under which Zai Lab shall purchase XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;inventory (the &#x201c;Supplied Inventory&#x201d;) at cost for their commercial use. We recognized &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mil&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;lion and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net product sales for the cost of the Supplied Inventory for the years ended December 31, 2025 and 2024, respectively, of which $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million were included in &#x201c;Accounts receivable&#x201d; in our consolidated balance sheets as of December 31, 2025 and 2024, respectively. Advance payments received under this agreement of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as of December 31, 2024 was recorded as other accrued liabilities pending finalization of the February and August 2025 amendments mentioned above.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We also entered into a manufacturing stage transfer agreement with Zai Lab in June 2024, which was amended in September 2024 (the &#x201c;Zai Manufacturing Stage Transfer Agreement&#x201d;). Pursuant to this agreement, Entasis shall provide assistance to Zai Lab for building out Zai Lab&#x2019;s manufacturing site for XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and be compensated for Entasis' services and associated costs. We recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in license and other revenue for the years ended December 31, 2025 and 2024, respectively, under the Zai Manufacturing Stage Transfer Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;GARDP&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Entasis entered into a collaboration agreement with the Global Antibiotic Research and Development Partnership (&#x201c;GARDP&#x201d;) for the development, manufacture and commercialization of the product candidate zoliflodacin in certain countries (&#x201c;the GARDP Collaboration Agreement&#x201d;). Under the terms of the GARDP Collaboration Agreement, GARDP shall use commercially reasonable endeavors to perform and fully fund the Phase 3 registrational trial, including the manufacture and supply of the product candidate containing zoliflodacin, in uncomplicated gonorrhea. We recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in reimbursements from GARDP under this agreement as a reduction to research and development expense during the year ended December 31, 2025.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; We recorded immaterial reimbursements from GARDP as a reduction to research and development expense during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, under the GARDP Collaboration Agreement, GARDP was granted a worldwide, fully paid, exclusive and royalty-free license, with the right to sublicense, to use our zoliflodacin technology in connection with GARDP&#x2019;s development, manufacture and commercialization of zoliflodacin in low-income and specified middle-income countries. We retained commercial rights in all other countries worldwide, including the major markets in North America, Europe and Asia-Pacific. We also retained the right to use and grant licenses to our zoliflodacin technology to perform our obligations under the GARDP Collaboration Agreement and for any purpose other than gonorrhea or community-acquired indications. If we believe that the results of the Phase 3 registrational trial of zoliflodacin would be supportive of an application for marketing approval, we are obligated to use our best efforts to file an application for marketing approval with the FDA within six months of the completion of the trial and to use commercially reasonable endeavors to file an application for marketing approval with the European Medicines Agency (&#x201c;EMA&#x201d;). Each party is responsible for using commercially reasonable efforts to obtain marketing authorizations for the product candidate in their respective territories. An application for marketing approval has been filed with the FDA in 2025. The FDA approved zoliflodacin, marketed as NUZOLVENCE&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, on December 12, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;PAION Pharma GmbH&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the PAION AG and PAION Deutschland GmbH (together and individually &#x201c;PAION&#x201d;) License, La Jolla Pharmaceutical Company (&#x201c;La Jolla&#x201d;), our wholly-owned subsidiary, granted PAION an exclusive license to commercialize GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the European Economic Area, the United Kingdom and Switzerland (collectively, the &#x201c;PAION Territory&#x201d;). PAION is currently a subsidiary of the Humanwell Healthcare Group. We are entitled to receive potential commercial milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;109.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and double-digit tiered royalty payments. Royalties payable in a given jurisdiction under the PAION License are subject to reduction on account of generic competition and after patent expiration in that jurisdiction. Pursuant to the PAION License, PAION will be solely responsible for the future development and commercialization of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the PAION Territory. PAION is required to use commercially reasonable efforts to commercialize GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the PAION Territory. We have not recognized any revenue from PAION related to commercial milestones. Royalty revenue recognized under this agreement for the year ended December 31, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Royalty revenue recognized under this agreement for the year ended December 31, 2023 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t material.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;La Jolla also entered into the PAION commercial supply agreement (the &#x201c;PAION Supply Agreement&#x201d;) whereby La Jolla supplies PAION a minimum quantity of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; until the earlier of July 13, 2027, or until a new supply agreement is executed. During the term of the supply agreement, we are reimbursed for direct and certain indirect manufacturing costs at cost. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in cost reimbursements under this agreement for the years ended December 31, 2025 and 2023, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Cost reimbursements recognized under this agreement for &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the years ended December 31, 2024 were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t material.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Everest Medicines Limited&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Everest Medicines Limited (&#x201c;Everest&#x201d;) License, La Jolla granted Everest an exclusive license to develop and commercialize XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the treatment of complicated intra-abdominal infections (&#x201c;cIAI&#x201d;) and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, the Malaysian Federation, the Kingdom of Thailand, the Republic of Indonesia, the Socialist Republic of Vietnam and the Republic of the Philippines (collectively, the &#x201c;Everest Territory&#x201d;). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the Everest License, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in license revenue for the year ended December 31, 2023 as a result of an achievement of a regulatory milestone during the period. We are eligible to receive additional sales milestone payments of up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are also entitled to receive tiered royalties from Everest at percentages in the low double digits on sales, if any, in the Everest Territory of products containing eravacycline. Royalties are payable with respect to each jurisdiction in the Everest Territory until the latest to occur of: (i) the last-to-expire of specified patent rights in such jurisdiction in the Everest Territory; (ii) expiration of marketing or regulatory exclusivity in such jurisdiction in the Everest Territory; or (iii) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years after the first commercial sale of a product in such jurisdiction in the Everest Territory.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Royalty revenue recognized under this agreement for the years ended December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, 2024 and 2023 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;La Jolla also entered into the Everest commercial supply agreement (the &#x201c;Everest Supply Agreement&#x201d;) whereby La Jolla will supply Everest a minimum quantity of XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and will transfer to Everest certain XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-related manufacturing know-how. Under the Everest Supply Agreement, we are reimbursed for direct and certain indirect manufacturing costs at &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;110&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of cost. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; W&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;e recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in revenue under this agreement for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;In-License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basilea&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In December 2024, we entered into an exclusive distribution and license agreement with Basilea, under which we were granted exclusive marketing rights to ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the U.S. The agreement will remain in effect through the expiration of ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s market exclusivity in the U.S. in 2034 (the &#x201c;initial term&#x201d;) and is subject to automatic renewal unless terminated by either party with prior notice. We paid an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which was recognized as an intangible asset and is being amortized over the initial term of the agreement. Under the agreement, we are required to exclusively purchase ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (in pre-packaging and labeling form) from Basilea for the duration of the term. We are also obligated to pay Basilea tiered royalties ranging from the high-teens to mid-twenties, as well as tiered milestone payments based on annual net sales in the U.S. ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was commercially launched in the U.S. in July 2025. Royalty expense incurred on the sales was immaterial during the year ended December 31, 2025. There were no royalties or sales milestone payments for the year ended December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;George Washington University&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the George Washington University License (the &#x201c;GW License&#x201d;), GW exclusively licensed to La Jolla certain intellectual property rights relating to GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including the exclusive rights to certain issued patents and patent applications covering GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Under the GW License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. We are obligated to pay a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% royalty on net sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on payments received from sublicensees. The obligation to pay royalties under the GW License extends through the last-to-expire patent covering GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Royalty expense incurred under the GW License were &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; m&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;illion, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Harvard University&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Harvard University (&#x201c;Harvard&#x201d;) License, Harvard exclusively licensed to La Jolla certain intellectual property rights relating to tetracycline-based products, including XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including the exclusive rights to certain issued patents and patent applications covering such products. Under the Harvard License, we are obligated to use commercially reasonable efforts to develop, commercialize, market and sell tetracycline-based products, including XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. For each product covered by the Harvard License, we are obligated to make certain payments for the following: (i) up to approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of certain clinical development and regulatory milestones; (ii) a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% royalty on direct U.S. net sales of XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;; (iii) a single-digit tiered royalty on direct ex-U.S. net sales of XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, starting at a minimum royalty rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, with step-ups to a maximum royalty of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% based on the achievement of annual net product sales thresholds; and (iv) &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% on payments received from sublicensees. The obligation to pay royalties under this agreement extends through the last-to-expire patent covering tetracycline-based products, including XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Royalty expense incurred under the Harvard License for each of the years ended December 31, 20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;25 and 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; mill&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ion. For the year ended December 31, 2023, we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as cost of license revenue under this agreement as a result of the license revenue we earned under the out-licensing agreement with Everest for the same period.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Business Transfer and Subscription Agreement with AstraZeneca&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Entasis &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;entered into a Business Transfer and Subscription Agreement with AstraZeneca, AstraZeneca UK Limited and AstraZeneca Pharmaceuticals LP (collectively, &#x201c;AstraZeneca&#x201d;) (the &#x201c;AstraZeneca Agreement&#x201d;) in 2015, which was amended and restated through 2018, pursuant to which Entasis obtained, among other things, worldwide rights to durlobactam and zoliflodacin. Under the AstraZeneca Agreement, we are obligated to pay AstraZeneca a one-time milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;three months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of achieving a specified cumulative net sales milestone for durlobactam. We are also obligated to pay AstraZeneca a one-time milestone payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of achieving the first commercial sale of zoliflodacin. Additionally, we are obligated to pay AstraZeneca tiered, single-digit royalties on the annual worldwide net product sales of durlobactam and, the lesser of tiered, single-digit royalties on the worldwide annual net sales of zoliflodacin and a specified share of the royalties we receive from sublicensees of zoliflodacin. Royalties on sales of zoliflodacin do not include sales by GARDP in low-income and specified middle-income countries as discussed above. Our obligation to make these royalty payments expires on a country-by-country basis for each product upon the later of (i) the 10-year anniversary of the first commercial sale of a product in that country or (ii) the expiration date of the last patent right covering the product in that country.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The royalty expense in respect of durlobactam arising from our net product sales of XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:2.68pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t material&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; for the years ended December 31, 2025, 2024 and 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Massachusetts Institute of Technology&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the asset acquisition described in Note 14, &#x201c;Asset Acquisition&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, in September 2025, we entered into a license agreement with Massachusetts Institute of Technology (&#x201c;MIT&#x201d;), under which MIT licensed to us certain patent rights relating to a drug delivery device. Under this agreement, we paid an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and are obligated to pay a minimal annual maintenance fee. We are also obligated to pay MIT up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in development, regulatory and sales milestone payments, and pay royalties in a low single-digit percentage on future net sales related to the licensed product.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Paratek Pharmaceuticals, Inc.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Pursuant to the Paratek Pharmaceuticals, Inc. (&#x201c;Paratek&#x201d;) License, Paratek non-exclusively licensed to La Jolla certain intellectual property rights relating to XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, including non-exclusive rights to certain issued patents and patent applications covering XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. We were obligated to pay Paratek a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% royalty based on direct U.S. net sales of XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Our obligation to pay royalties with respect to the licensed product was retroactive to the date of the first commercial sale of XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and continued until there were no longer any valid claims of the Paratek patents, which expired in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;October 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. For the year ended December 31, 2023, amounts recognized under this agreement were not material.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Grant Agreement with Gates Foundation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In November 2025, we entered into a grant agreement with Gates Foundation, under which Gates Foundation shall fund up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in qualifying expenses through January 2027 toward the development of a certain product candidate. We received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, of which we recognized $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million as grant revenue included in &#x201c;License and other revenue&#x201d; in our consolidated financial statements for the year ended December 31, 2025. The remaining balance of the upfront payment is recorded as deferred revenue included in &#x201c;Other accrued liabilities&#x201d; in our consolidated balance sheet as of December 31, 2025.&lt;/span&gt;&lt;/p&gt;</inva:LicenseCollaborationAndOtherArrangementsTextBlock>
    <inva:FuturePotentialMilestonePayment
      contextRef="C_e24022f1-53bf-42f3-8620-65afbf8aacaf"
      decimals="-5"
      id="F_42bafa43-0b98-4d60-b65c-590e25d0f0f3"
      unitRef="U_USD">91000000</inva:FuturePotentialMilestonePayment>
    <us-gaap:Revenues
      contextRef="C_535f3e0c-ae46-4c2a-8349-1e7df0cae7a9"
      decimals="-5"
      id="F_719289e5-635b-41b7-8553-f47c5cb07d89"
      unitRef="U_USD">2400000</us-gaap:Revenues>
    <inva:LicenseRevenueRecognized
      contextRef="C_c9724995-83e8-4e3f-ac0a-df8eb2d7e801"
      decimals="-5"
      id="F_a3aa86a6-2a46-48ea-b0b5-2714ac57a2f0"
      unitRef="U_USD">8000000</inva:LicenseRevenueRecognized>
    <inva:LicenseRevenueRecognized
      contextRef="C_32dd02d8-2a15-4776-ae72-8afc37de465c"
      decimals="-5"
      id="F_a3f8507c-caf4-41ac-826b-17268ab4da97"
      unitRef="U_USD">3000000</inva:LicenseRevenueRecognized>
    <inva:LicenseRevenueRecognized
      contextRef="C_93087703-617b-4b4a-81e7-31843c5aa650"
      decimals="-5"
      id="F_8de4535c-4a32-4693-ade7-9fdbcf685b7a"
      unitRef="U_USD">1300000</inva:LicenseRevenueRecognized>
    <inva:LicenseRevenueRecognized
      contextRef="C_9eb30f32-b122-4799-abad-e4b9a0d5cea5"
      decimals="-5"
      id="F_46195adc-378f-4b4e-8917-d00a792d58d4"
      unitRef="U_USD">8100000</inva:LicenseRevenueRecognized>
    <us-gaap:AccountsReceivableNet
      contextRef="C_b6b5484e-26f7-475f-aad3-d4fff0a4c327"
      decimals="-5"
      id="F_17539648-03d4-4ac7-ac36-a62129b5b10d"
      unitRef="U_USD">1800000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="C_edcdd009-7706-4509-a58c-1bface603eba"
      decimals="-5"
      id="F_bc235be4-6fcf-4f42-8725-d2912390a780"
      unitRef="U_USD">1600000</us-gaap:AccountsReceivableNet>
    <inva:AmountOnNetProductSalesRecognized
      contextRef="C_1a3c43a6-afc9-4c65-b428-40d7849855d1"
      decimals="-5"
      id="F_722a9cb2-132a-4dcf-8eea-1cb7c849549c"
      unitRef="U_USD">37900000</inva:AmountOnNetProductSalesRecognized>
    <inva:AmountOnNetProductSalesRecognized
      contextRef="C_24ba47ce-629c-49d4-9f18-e4bf2ecc9008"
      decimals="-5"
      id="F_84860cba-b59d-47a7-9536-ecaf61b6589e"
      unitRef="U_USD">6300000</inva:AmountOnNetProductSalesRecognized>
    <us-gaap:AccountsReceivableNet
      contextRef="C_8714bccf-5bf2-42d4-bc52-49b4f39a126d"
      decimals="-5"
      id="F_ecf97167-4dea-4bcb-939b-0a3bb83a2a7f"
      unitRef="U_USD">6700000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet
      contextRef="C_29938f9f-8929-463c-8242-1fd072e3246e"
      decimals="-5"
      id="F_1bc782be-9561-4785-8545-2e9aee2490c4"
      unitRef="U_USD">600000</us-gaap:AccountsReceivableNet>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="C_2bdbcb89-e8cf-4578-a8fb-ed71c2c5c84c"
      decimals="-5"
      id="F_c9e8c47c-7ce4-4ba7-a596-657988de25c9"
      unitRef="U_USD">5300000</us-gaap:AdvancesOnInventoryPurchases>
    <inva:LicenseAndOtherRevenue
      contextRef="C_60c399b5-9347-43a0-b627-5c8557009839"
      decimals="-5"
      id="F_73a0e1e4-e354-4699-85f1-bcaef1fba090"
      unitRef="U_USD">1100000</inva:LicenseAndOtherRevenue>
    <inva:LicenseAndOtherRevenue
      contextRef="C_8b6e7ffc-19c9-414a-8790-449480c681de"
      decimals="-5"
      id="F_5e6e563b-9a44-4a45-a96d-829de83fe955"
      unitRef="U_USD">3400000</inva:LicenseAndOtherRevenue>
    <inva:ReimbursementsForResearchAndDevelopmentExpense
      contextRef="C_d4b33ce8-c2ef-41f9-aa40-07f4e9d94111"
      decimals="-5"
      id="F_d98aa280-9173-455d-98c7-f0a84d531684"
      unitRef="U_USD">1000000</inva:ReimbursementsForResearchAndDevelopmentExpense>
    <inva:FuturePotentialMilestonePayment
      contextRef="C_0b8a3f4c-cf7e-42af-8db7-51c367053d7d"
      decimals="-5"
      id="F_4f0b3702-157d-4413-aa16-046f255918b6"
      unitRef="U_USD">109500000</inva:FuturePotentialMilestonePayment>
    <us-gaap:Revenues
      contextRef="C_bb34b526-ff51-4bd5-9372-e24b00a45ea7"
      decimals="-5"
      id="F_470845ed-1b71-4c7d-901d-7721a30ece43"
      unitRef="U_USD">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_8f658d7a-8b07-41db-8980-8e9b1025a6a3"
      decimals="-5"
      id="F_08fa7c74-d972-4421-a4df-95dbd7218f7a"
      unitRef="U_USD">1500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_63c51235-4b1c-4afb-8d74-575ce49ff152"
      decimals="-6"
      id="F_0a27f083-6d85-4dad-bc22-339f0bb6e565"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_86b41774-5017-4fc1-8e1b-cf811b6c4737"
      decimals="-5"
      id="F_4723af77-6680-4d98-97b1-e841ffc15e61"
      unitRef="U_USD">2700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_734a0615-eb7b-4e06-bf8d-3b288821b245"
      decimals="-5"
      id="F_48738bfb-fb94-4077-9f8f-c26d0fec8210"
      unitRef="U_USD">1300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_d8ba1e61-eae2-49b5-9a4d-794567463681"
      decimals="-6"
      id="F_a8e003c4-7984-449c-a05a-694dd7d5afc9"
      unitRef="U_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_3f151714-cd61-4ea6-ad22-1659ee2f8ad5"
      decimals="-5"
      id="F_e2913099-388b-40c8-96df-839e923a9074"
      unitRef="U_USD">8000000</us-gaap:Revenues>
    <inva:SalesMilestonePaymentsReceivable
      contextRef="C_471e4740-1ef6-4b64-a705-0ba2683dbdf6"
      decimals="-5"
      id="F_993bb486-58e7-49f8-90c0-786a9755705b"
      unitRef="U_USD">20000000</inva:SalesMilestonePaymentsReceivable>
    <inva:RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct
      contextRef="C_b7886827-2301-4eae-ac39-e1b0cfe79560"
      id="F_06b54e57-dfec-49ed-958f-4e7efedf60b6">P10Y</inva:RoyaltiesPayablePeriodAfterFirstCommercialSaleOfProduct>
    <us-gaap:Revenues
      contextRef="C_ef7ae83f-f2f0-4dcb-9863-3d6a3a3a1d5a"
      decimals="-5"
      id="F_02520822-f418-49ef-9597-6ee4491682f6"
      unitRef="U_USD">3600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_2b4116ec-1fff-40fc-9ca2-09b0c69e59bc"
      decimals="-5"
      id="F_2517e088-8d37-4008-b196-68047148fc0e"
      unitRef="U_USD">4700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_f729f8a6-0459-456b-904e-a2336cd2e856"
      decimals="-5"
      id="F_6cc37537-9387-48e1-8ccf-772f6fbd6e7c"
      unitRef="U_USD">1400000</us-gaap:Revenues>
    <inva:PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts
      contextRef="C_a7a1c802-2b70-41a1-b1ab-0f6ea7991b5c"
      decimals="2"
      id="F_8452d778-3937-402e-9332-f9e632e49e43"
      unitRef="U_pure">1.10</inva:PercentageOfReimbursedForDirectAndCertainIndirectManufacturingCosts>
    <us-gaap:Revenues
      contextRef="C_a7a1c802-2b70-41a1-b1ab-0f6ea7991b5c"
      decimals="-5"
      id="F_d15ab99a-630b-458a-b9fe-02770666cddd"
      unitRef="U_USD">4000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_27e7d8d1-9232-4c08-b557-38898257e2e9"
      decimals="-5"
      id="F_b246f09d-06d5-4c2d-b307-8f4eb03f1d19"
      unitRef="U_USD">3200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_a2de673d-5a6d-4d89-a1af-5b182aea45da"
      decimals="-5"
      id="F_21e73007-c5d6-495e-b857-5d4fac98bd82"
      unitRef="U_USD">2400000</us-gaap:Revenues>
    <inva:UpfrontPaymentUnderIntangibleAsset
      contextRef="C_baeb567b-ccbe-4999-a205-466cd47101ba"
      decimals="-5"
      id="F_e0fdef9f-f30d-4b3a-9172-f372608bc5c8"
      unitRef="U_USD">4000000</inva:UpfrontPaymentUnderIntangibleAsset>
    <inva:PercentageOfRoyaltyPayableOnNetSales
      contextRef="C_75cd5b3a-0884-4009-a949-d0f1c664d036"
      decimals="2"
      id="F_6876ecb8-b6ed-425f-9de0-c8f53f7ef518"
      unitRef="U_pure">0.06</inva:PercentageOfRoyaltyPayableOnNetSales>
    <inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees
      contextRef="C_75cd5b3a-0884-4009-a949-d0f1c664d036"
      decimals="2"
      id="F_23ed9732-35b7-437a-adfa-731de13e9c0d"
      unitRef="U_pure">0.15</inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees>
    <us-gaap:RoyaltyExpense
      contextRef="C_75cd5b3a-0884-4009-a949-d0f1c664d036"
      decimals="-5"
      id="F_9ffaef94-b249-4b30-be8e-8eaf29d163c0"
      unitRef="U_USD">4500000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_66b32c2c-80ce-44d4-8bd3-c90a4562ba4a"
      decimals="-5"
      id="F_33ed1543-1803-4c3a-8050-fa26610101ab"
      unitRef="U_USD">3400000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_ad7b15a7-04fe-4b2d-aaa8-50707a9474c4"
      decimals="-5"
      id="F_478db8a7-8b20-4b2d-8607-e65003b3c610"
      unitRef="U_USD">2500000</us-gaap:RoyaltyExpense>
    <inva:ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable
      contextRef="C_77ce6bd4-4c92-464e-b740-78890313ec04"
      decimals="-5"
      id="F_c3319f0a-9c65-4b9e-a55d-d26c2ac8e4db"
      unitRef="U_USD">15100000</inva:ClinicalDevelopmentAndRegulatoryMilestonesAmountPayable>
    <inva:PercentageOfRoyaltyPayableOnNetSales
      contextRef="C_47f20a31-1968-4d82-910b-3b3a4558e7f9"
      decimals="2"
      id="F_7a1bcb62-6645-4468-b4f1-fbe8913e5f21"
      unitRef="U_pure">0.05</inva:PercentageOfRoyaltyPayableOnNetSales>
    <inva:PercentageOfMinimumRoyaltyRate
      contextRef="C_cbc79b2e-83c4-4eb8-a3b9-5535187253c1"
      decimals="3"
      id="F_e776230e-fb22-44b1-8796-5ea823af7b49"
      unitRef="U_pure">0.045</inva:PercentageOfMinimumRoyaltyRate>
    <inva:PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds
      contextRef="C_cbc79b2e-83c4-4eb8-a3b9-5535187253c1"
      decimals="3"
      id="F_f45c37c3-4f34-4775-9845-aac12bf85f10"
      unitRef="U_pure">0.075</inva:PercentageOfMaximumRoyaltyBasedOnAchievementOfAnnualNetProductSalesThresholds>
    <inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees
      contextRef="C_9d82a4f6-9c62-4ef3-a79a-b60ecce3c1dc"
      decimals="2"
      id="F_37778605-d719-4a24-857a-11a75b455fc2"
      unitRef="U_pure">0.20</inva:PercentageOfRoyaltyOnPaymentsReceivedFromSublicensees>
    <us-gaap:RoyaltyExpense
      contextRef="C_9d82a4f6-9c62-4ef3-a79a-b60ecce3c1dc"
      decimals="-5"
      id="F_f2d9f7df-a3aa-4da9-8134-3a7aff236c5b"
      unitRef="U_USD">1400000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_bb80b0bd-8c31-447f-bb15-56034f4a4f2d"
      decimals="-5"
      id="F_dffabb26-f616-470a-b92d-fb74ca0f0f33"
      unitRef="U_USD">1400000</us-gaap:RoyaltyExpense>
    <us-gaap:CostOfRevenue
      contextRef="C_042d99c8-ff64-4441-b079-f3c23a00eb99"
      decimals="-5"
      id="F_5bc532c6-ca52-44da-8603-6fb0a0ef025d"
      unitRef="U_USD">1200000</us-gaap:CostOfRevenue>
    <inva:SubscriptionAgreementOneTimeMilestonePaymentOnNetSales
      contextRef="C_a73231bb-c2af-46c2-9a92-d48cf8356bc1"
      decimals="-5"
      id="F_62a7ba1c-aaf0-4d95-bc45-2e86a4089bff"
      unitRef="U_USD">5000000</inva:SubscriptionAgreementOneTimeMilestonePaymentOnNetSales>
    <inva:TermOfMilestonePaymentForNetSales
      contextRef="C_a73231bb-c2af-46c2-9a92-d48cf8356bc1"
      id="F_f1c68da8-c103-4547-8438-32a1a449b68f">P3M</inva:TermOfMilestonePaymentForNetSales>
    <inva:SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales
      contextRef="C_cb9d2f79-476b-4ddd-9d0f-a6df0b98ff4c"
      decimals="-5"
      id="F_6c18d6d4-d52f-41ce-a332-3766803a25da"
      unitRef="U_USD">10000000</inva:SubscriptionAgreementOneTimeMilestonePaymentOnCommercialSales>
    <inva:TermOfMilestonePaymentForCommercialSale
      contextRef="C_cb9d2f79-476b-4ddd-9d0f-a6df0b98ff4c"
      id="F_a71464fd-d1e7-4e46-b669-efad14d3f1ec">P2Y</inva:TermOfMilestonePaymentForCommercialSale>
    <us-gaap:RoyaltyExpense
      contextRef="C_a73231bb-c2af-46c2-9a92-d48cf8356bc1"
      decimals="-6"
      id="F_f0ffafef-2b98-4744-a86d-5b2ffac45c7e"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_b1c1c252-d197-4e74-b2b2-f01842ca2233"
      decimals="-6"
      id="F_a2a2db98-8799-4f88-a15b-ffdcd1968709"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_a53dc6ea-0c8a-49d1-a28b-56b625f3832d"
      decimals="-6"
      id="F_d8481489-6bf1-4114-8987-24797c8f0bbf"
      unitRef="U_USD">0</us-gaap:RoyaltyExpense>
    <inva:UpfrontFeePayment
      contextRef="C_0708cf2c-c327-4fd6-b98e-80fa56ca9fbe"
      decimals="-5"
      id="F_1affb77e-05c6-4a9b-ae47-ce99efaa4561"
      unitRef="U_USD">500000</inva:UpfrontFeePayment>
    <inva:FuturePotentialMilestonePayment
      contextRef="C_41adb887-7a52-48c3-afd3-50e8cb0adad6"
      decimals="-5"
      id="F_6ad06b08-e44c-4f55-b71b-6e125b08c376"
      unitRef="U_USD">17500000</inva:FuturePotentialMilestonePayment>
    <inva:PercentageOfRoyaltyPayableOnNetSales
      contextRef="C_26dbc208-56e7-4883-9c81-a880c188cbbc"
      decimals="4"
      id="F_2041b8b0-524c-4754-a9d5-e59b3342ffbe"
      unitRef="U_pure">0.0225</inva:PercentageOfRoyaltyPayableOnNetSales>
    <inva:ClaimExpirationDate
      contextRef="C_26dbc208-56e7-4883-9c81-a880c188cbbc"
      id="F_c2f8c494-a44c-4eeb-89eb-b9935d6cb9da">2023-10</inva:ClaimExpirationDate>
    <inva:GrantFundingMaximumAmount
      contextRef="C_4de9fb1e-acdc-4b5c-a627-40990c7b5d38"
      decimals="-5"
      id="F_7a716df7-cae8-42f3-85cf-9a9c0772d2a1"
      unitRef="U_USD">5000000</inva:GrantFundingMaximumAmount>
    <inva:UpfrontFeeReceived
      contextRef="C_5860c68c-4659-40da-819c-f9dc3f832bf9"
      decimals="-5"
      id="F_ffec31b2-a56f-456c-aec2-1b2408e6f649"
      unitRef="U_USD">1600000</inva:UpfrontFeeReceived>
    <inva:LicenseRevenueRecognized
      contextRef="C_5860c68c-4659-40da-819c-f9dc3f832bf9"
      decimals="-5"
      id="F_37ec151a-dda6-4bd9-8278-0aa0aa8d77cd"
      unitRef="U_USD">100000</inva:LicenseRevenueRecognized>
    <inva:ConsolidatedEntityTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_7af14af4-40df-4f07-abda-326e2cdadc53">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;5. CONSOLIDATED ENTITY&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;ISP Fund LP&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2020 and 2021, Innoviva Strategic Partners LLC, our wholly owned subsidiary (&#x201c;Strategic Partners&#x201d;), contributed a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to ISP Fund LP (the &#x201c;Partnership&#x201d;) for investing in &#x201c;long&#x201d; positions in the healthcare, pharmaceutical and biotechnology sectors, and became a limited partner. The general partner of the Partnership (&#x201c;General Partner&#x201d;) is an affiliate of Sarissa Capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Partnership Agreement provides for Sarissa Capital to receive management fees from the Partnership, payable quarterly in advance, measured based on the Net Asset Value of Strategic Partners&#x2019; capital account in the Partnership. In addition, General Partner is entitled to an annual performance fee based on the Net Profits of the Partnership during the annual measurement period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We consolidate ISP Fund LP under the VIE model as we have determined that ISP Fund LP is a VIE and we are the primary beneficiary of the entity. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ISP Fund LP is determined to be an investment company under ASC 946, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Financial Services &#x2013; Investment Companies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, as it meets all fundamental characteristics of an investment company, and its activities are consistent with those of an investment company. Since ISP Fund LP is subject to investment company industry specific guidance, we have retained the industry-specific guidance applied by the Partnership. In addition, as our investment in the Partnership is a passive investment for the Company and is not part of our main operations, the investments are presented as part of &#x201c;Equity and long-term investments&#x201d; in our consolidated balance sheets. In October 2024, Strategic Partners made an election to unwind its capital accounts in the Partnership in accordance with the terms of the Partnership Agreement. Accordingly, a portion of our investments, which consist of cash and money market funds that we expect to be distributed within 12 months from the balance sheet date, were classified as &#x201c;Current portion of ISP Fund investments&#x201d; in the consolidated balance sheets as of December 31, 2025 and 2024, and the remaining equity investments managed by ISP Fund LP are expected to be distributed through April 2026. We received cash distributions of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;121.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the year ended December 31, 2025. We report in our consolidated statements of income and comprehensive income any investment gains and losses by the Partnership as part of &#x201c;Changes in fair value of equity and long-term investments, net&#x201d;, any interest and dividend income as part of &#x201c;Interest and dividend income&#x201d; and any investment expenses as part of &#x201c;Other expense, net&#x201d;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, we continue to hold &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the economic interest of the Partnership. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, total assets of the Partnership were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;with the majority attributable to either current portion of ISP Fund investment or to equity and long-term investments. As of December 31, 2025 and 2024, total liabilities of the Partnership were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;0.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Partnership&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s assets can only be used to settle its own obligations.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2025, the Partnership incurred&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million in net investment-related expenses, generated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million interest incom&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;e, recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net realized losses and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net unrealized gains as changes in fair values of equity and lon&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;g-term investments, net, in the consolidated statements of income and comprehensive income. During the year ended December 31, 2024, the Partnership incurred&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million in net investment-related expenses, generated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million interest income, recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net realized losses and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statements of income &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and comprehensive income. During the year ended December 31, 2023, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the Partnership incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net investment-related expenses, generated $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million interest income, recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net realized losses and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net unrealized losses as changes in fair values of equity and long-term investments, net, in the consolidated statements of income &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and comprehensive income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is a summary of individual investments held by ISP Fund at each balance sheet date:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;In thousands&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock - Publicly traded healthcare companies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Preferred stock - Privately held healthcare companies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants - Privately held healthcare companies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund and cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total investments held by ISP Fund LP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</inva:ConsolidatedEntityTextBlock>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="C_f1250457-5420-4587-a034-747d2328f6e0"
      decimals="-5"
      id="F_a184cab4-796f-4de8-8e99-f959aaa9c7b3"
      unitRef="U_USD">300000000</us-gaap:LimitedPartnersContributedCapital>
    <inva:CashDistributions
      contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2"
      decimals="-5"
      id="F_13f275f5-ca5a-4458-8d0b-235773f55391"
      unitRef="U_USD">121000000</inva:CashDistributions>
    <inva:PercentageOfEconomicInterestInPartnership
      contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2"
      decimals="INF"
      id="F_63461a4a-92d4-40d3-a274-8b8e31c3d44a"
      unitRef="U_pure">1</inva:PercentageOfEconomicInterestInPartnership>
    <us-gaap:Assets
      contextRef="C_f1250457-5420-4587-a034-747d2328f6e0"
      decimals="-5"
      id="F_2b912d41-c251-4e92-a8de-633d7b64c854"
      unitRef="U_USD">79700000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_7fba1762-844e-4c04-b43c-b15c482e2679"
      decimals="-5"
      id="F_fa17e47f-0a54-414c-af1b-65a64ccfdf1e"
      unitRef="U_USD">255700000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="C_7fba1762-844e-4c04-b43c-b15c482e2679"
      decimals="-5"
      id="F_95388280-97b1-46c6-ac88-562cee0f1ab0"
      unitRef="U_USD">200000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_f1250457-5420-4587-a034-747d2328f6e0"
      decimals="-5"
      id="F_c0b6cffe-aa49-4b15-8c2f-db81c445146e"
      unitRef="U_USD">200000</us-gaap:Liabilities>
    <inva:NetInvestmentRelatedIncomeExpensesEarnedInccured
      contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2"
      decimals="-5"
      id="F_42a36743-96df-444a-bc18-2bb100bfdc5b"
      unitRef="U_USD">-2500000</inva:NetInvestmentRelatedIncomeExpensesEarnedInccured>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2"
      decimals="-5"
      id="F_e2da3659-611d-423e-aee0-8080956bedf4"
      unitRef="U_USD">3400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainLossOnInvestments
      contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2"
      decimals="-5"
      id="F_f08eea45-0a30-4b18-9073-3cfcbba945f0"
      unitRef="U_USD">-68700000</us-gaap:GainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2"
      decimals="-5"
      id="F_181dd8a0-a4a3-4716-b72b-e3bf8f4327d8"
      unitRef="U_USD">12700000</us-gaap:UnrealizedGainLossOnInvestments>
    <inva:NetInvestmentRelatedIncomeExpensesEarnedInccured
      contextRef="C_91cb662c-7d72-4446-a053-6b76cc6d61c0"
      decimals="-5"
      id="F_22e96f5a-529d-4cb0-8aec-bb27cd7ff9d4"
      unitRef="U_USD">-3700000</inva:NetInvestmentRelatedIncomeExpensesEarnedInccured>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_91cb662c-7d72-4446-a053-6b76cc6d61c0"
      decimals="-5"
      id="F_2957cbdf-74f7-4053-ac97-f0e0deec4b5f"
      unitRef="U_USD">4400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainLossOnInvestments
      contextRef="C_91cb662c-7d72-4446-a053-6b76cc6d61c0"
      decimals="-5"
      id="F_b3c1bd0d-b145-4e88-bd3c-405d3998cc3c"
      unitRef="U_USD">-5300000</us-gaap:GainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_91cb662c-7d72-4446-a053-6b76cc6d61c0"
      decimals="-5"
      id="F_0391e1a2-e464-4c30-b74a-c0ed9b3dcc71"
      unitRef="U_USD">-51500000</us-gaap:UnrealizedGainLossOnInvestments>
    <inva:NetInvestmentRelatedIncomeExpensesEarnedInccured
      contextRef="C_45a109c5-a8b5-4d0e-89f8-924a6b01af29"
      decimals="-5"
      id="F_6be2c94e-f842-40e6-b7be-b278ef21f725"
      unitRef="U_USD">-4300000</inva:NetInvestmentRelatedIncomeExpensesEarnedInccured>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_45a109c5-a8b5-4d0e-89f8-924a6b01af29"
      decimals="-5"
      id="F_bbc4b343-6c03-4533-ace0-6bc88d70121b"
      unitRef="U_USD">6300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:GainLossOnInvestments
      contextRef="C_45a109c5-a8b5-4d0e-89f8-924a6b01af29"
      decimals="-5"
      id="F_1fddfaaa-84ca-4841-9952-c031dcf2eb1f"
      unitRef="U_USD">-2400000</us-gaap:GainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="C_45a109c5-a8b5-4d0e-89f8-924a6b01af29"
      decimals="-5"
      id="F_934b3018-01af-4c91-add0-2d6a7cef968c"
      unitRef="U_USD">-6700000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:InvestmentTableTextBlock
      contextRef="C_b16a83bb-dee6-4ab4-a7fb-8ef209e7a5e2"
      id="F_cc5d5c59-5860-4cfc-95e7-883fcb5660ad">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following is a summary of individual investments held by ISP Fund at each balance sheet date:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;In thousands&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Common stock - Publicly traded healthcare companies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;52,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United Kingdom&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Preferred stock - Privately held healthcare companies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,591&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Warrants - Privately held healthcare companies&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market fund and cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;&#160;&#160;Total investments held by ISP Fund LP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:InvestmentTableTextBlock>
    <inva:InvestmentsInCommonStock
      contextRef="C_5569e7b8-6eba-4eab-95a9-c63e219f2e99"
      decimals="-3"
      id="F_e0fbc7cb-4b6a-4ae1-a1af-e278338cfb2d"
      unitRef="U_USD">52392000</inva:InvestmentsInCommonStock>
    <inva:InvestmentsInCommonStock
      contextRef="C_7a37ea45-0a90-4314-9d33-c1291075e4f4"
      decimals="-3"
      id="F_c648c508-b638-4d51-a8f0-0721fad17f1f"
      unitRef="U_USD">84039000</inva:InvestmentsInCommonStock>
    <inva:InvestmentsInCommonStock
      contextRef="C_b9d838c8-9363-4704-8fc8-ac7fe6933ce0"
      decimals="-3"
      id="F_a3687e57-4f7b-4970-a7c1-1be4b44634c2"
      unitRef="U_USD">8874000</inva:InvestmentsInCommonStock>
    <inva:InvestmentsInCommonStock
      contextRef="C_f6149710-30b2-49fb-9741-3ac89487f3da"
      decimals="-3"
      id="F_be7531a0-8851-4f98-980e-47ee3c55c09c"
      unitRef="U_USD">1989000</inva:InvestmentsInCommonStock>
    <inva:InvestmentsInCommonStock
      contextRef="C_8ff7ff5d-59d7-482d-b9ff-48452108446f"
      decimals="-3"
      id="F_5d82f2c4-be52-41b3-8b1a-59f0a44854f1"
      unitRef="U_USD">61266000</inva:InvestmentsInCommonStock>
    <inva:InvestmentsInCommonStock
      contextRef="C_77e3e771-6d57-4a46-9631-a87f355431a8"
      decimals="-3"
      id="F_87edf8f5-e4ff-4fb7-a97e-d8736e2b1cc8"
      unitRef="U_USD">86028000</inva:InvestmentsInCommonStock>
    <inva:InvestmentsInPreferredStock
      contextRef="C_09b660d0-0222-42bb-8926-d6f07d1fabb9"
      decimals="-3"
      id="F_5500bf4e-13a7-48ef-88c0-6d454f304c3b"
      unitRef="U_USD">2748000</inva:InvestmentsInPreferredStock>
    <inva:InvestmentsInPreferredStock
      contextRef="C_ccbbfa18-4020-412e-b2de-ffea359a8cdd"
      decimals="-3"
      id="F_03ad9e84-1eab-41ea-8329-0eca4732f2ee"
      unitRef="U_USD">53591000</inva:InvestmentsInPreferredStock>
    <inva:InvestmentsInWarrants
      contextRef="C_57143738-0b15-4679-be4b-a0bb824f5ceb"
      decimals="-3"
      id="F_96fa1451-9301-45a5-90d8-1ac260e5250f"
      unitRef="U_USD">0</inva:InvestmentsInWarrants>
    <inva:InvestmentsInWarrants
      contextRef="C_9de3ffb5-8381-4662-89f6-a8481e573820"
      decimals="-3"
      id="F_2a05c84d-25a0-4c80-8f04-361e6361a5ce"
      unitRef="U_USD">8507000</inva:InvestmentsInWarrants>
    <inva:MoneyMarketFundAndCash
      contextRef="C_f1250457-5420-4587-a034-747d2328f6e0"
      decimals="-3"
      id="F_39ec029e-5b5c-41cf-9e8f-f9342f94a1f6"
      unitRef="U_USD">15727000</inva:MoneyMarketFundAndCash>
    <inva:MoneyMarketFundAndCash
      contextRef="C_7fba1762-844e-4c04-b43c-b15c482e2679"
      decimals="-3"
      id="F_ea1af617-1046-4657-bd89-fc0ecb328f9d"
      unitRef="U_USD">107532000</inva:MoneyMarketFundAndCash>
    <us-gaap:Investments
      contextRef="C_f1250457-5420-4587-a034-747d2328f6e0"
      decimals="-3"
      id="F_28ceee38-b44b-44aa-b167-79ea283f70a2"
      unitRef="U_USD">79741000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="C_7fba1762-844e-4c04-b43c-b15c482e2679"
      decimals="-3"
      id="F_7410f9ba-23df-4f5e-a8d8-ade5c04028c4"
      unitRef="U_USD">255658000</us-gaap:Investments>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_90286cd0-ee34-465a-acf6-673b6771f4ab">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;6. EQUITY AND LONG-TERM INVESTMENTS AND FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity and Other Investments in Armata&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since the first quarter of 2020, Innoviva and its wholly owned subsidiary, Innoviva Strategic Opportunities, LLC (&#x201c;ISO&#x201d;), have invested in the common stock, warrants, convertible note, and term loans of Armata Pharmaceuticals, Inc. (&#x201c;Armata&#x201d;), a clinical stage biotechnology company focused on development of precisely targeted bacteriophage therapeutics for antibiotic-resistant infections.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the first quarter of 2021, Armata entered into a voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of Armata&#x2019;s common stock for voting on the matters related to election or removal of Armata&#x2019;s board members. The voting agreement will expire on the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 9, 2022, Armata entered a second amended and restated voting agreement with the Company and ISO, pursuant to which the Company and ISO agreed not to vote or take any action by written consent with respect to any common shares held by the Company and ISO that represent, in the aggregate, more than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the total number of shares of Armata&#x2019;s common stock for voting on the matters related to election or removal of Armata&#x2019;s board members or amend the bylaws of Armata to reduce the maximum number of directors or set the number of directors who may serve on the board of Armata. The voting agreement will expire the earlier of the second anniversary of the agreement effective date and approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#x2019;s board of directors, and for so long as the Company and ISO hold at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, but less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#x2019;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 10, 2023, Armata entered into an amendment to the amended and restated investor rights agreement with the Company and ISO, pursuant to which the Company and ISO agreed that the voting agreement will expire on the earlier of the fifth anniversary of the original agreement&#x2019;s effective date, January 26, 2021, or the approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Armata, under which we invested in a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; convertible note (the &#x201c;Armata Convertible Note&#x201d;) in an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million at an interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Pursuant to the Credit Agreement, the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, will convert into shares of Armata&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x2019;s common stock upon the occurrence of a qualified financing, as defined in the Credit Agreement. Any portion of the balance on the Armata Convertible Note, including all accrued and unpaid interest thereon, may also be converted into shares of Armata&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s common stock at our option once a registration statement covering the resale of such securities has been declared effective by the SEC. The Armata Convertible Note is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries. On July 10, 2023, ISO and Armata executed an amendment to the Armata Convertible Note extending the maturity date from January 10, 2024 to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 10, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. On November 12, 2024, ISO and Armata executed an amendment to the Armata Convertible Note extending the maturity date from January 10, 2025 to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 10, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On July 10, 2023, ISO and Armata entered into a Credit and Security Agreement (the &#x201c;July 2023 Credit and Security Agreement"), under which we extended a term loan to Armata (the &#x201c;Armata July 2023 Term Loan&#x201d;) in an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Armata July 2023 Term Loan is subject to an interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum and is due to mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 10, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The July 2023 Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries. On November 12, 2024, ISO and Armata executed an amendment to the Armata July 2023 Term Loan extending the maturity date from January 10, 2025 to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 10, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 4, 2024, ISO and Armata entered into a Credit and Security Agreement (the &#x201c;March 2024 Credit and Security Agreement&#x201d;), under which we extended a term loan to Armata (the &#x201c;Armata March 2024 Term Loan&#x201d;) in an aggregate amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Armata March 2024 Term Loan is subject to an interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum and is originally set to mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;June 4, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The March 2024 Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 12, 2025, ISO and Armata entered into a Credit and Security Agreement, under which ISO extended a term loan to Armata (the &#x201c;Armata March 2025 Term Loan&#x201d;) in a principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Armata March 2025 Term Loan bears interest at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum and matures on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 12, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Credit and Security Agreement is secured by substantially all assets of Armata and its domestic and foreign material subsidiaries. Concurrently, ISO extended the maturity date of the Armata Convertible Note and the Armata July 2023 Term Loan and the Armata March 2024 Term Loan to March 12, 2026.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 11, 2025, ISO and Armata entered into a Credit and Security Agreement, under which ISO extended a term loan to Armata (the &#x201c;Armata August 2025 Term Loan&#x201d;) in a principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Armata August 2025 Term Loan bears an interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum and matures on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 11, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Credit and Security Agreement is secured by substantially all of the assets of Armata and its domestic and foreign material subsidiaries.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s of December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;seven&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; members of Armata&#x2019;s board of directors are also members of the board of directors of Innoviva. As of December 31, 2025 and 2024, we collectively owned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,076,769&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Armata's common stock, representing equity interest of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, respectively. As of December 31, 2025 and 2024, we collectively hold warrants of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,653,847&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,364,647&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, respectively, with exercise prices ranging from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share. Innoviva also held $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in principal amount of the Armata Convertible Note and a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in term loans.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The investments in Armata&#x2019;s common stock and warrants provide Innoviva and ISO the ability to have significant influence but not control over Armata&#x2019;s operations. Armata&#x2019;s business and affairs are managed under the direction of its board of directors, which Innoviva and ISO do not control. Based on our evaluation, we determined that Armata is a VIE, but Innoviva and ISO are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We account for Armata&#x2019;s common stock and warrants under the equity method using the fair value option. The fair value of Armata&#x2019;s common stock is measured based on its closing market price. The warrants purchased in 2020, 2021 and 2022 have an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.87&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.00&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, respectively. All warrants are exercisable immediately within &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; from the issuance date of the warrants and include a cashless exercise option. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The warrants purchased in 2020 expired during the first quarter of 2025. We use the Black-Scholes-Merton pricing model to estimate the fair value of these warrants with the following input assumptions: Armata&#x2019;s closing market price on the valuation date, the risk-free interest rate computed based on the U.S. Treasury yield, the remaining contractual term as the expected term, and the expected stock price volatility calculated based on the historical volatility of the common stock of Armata and its peer companies. We account for the Armata Convertible Note as a trading security, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. We account for the Armata term loans as trading securities, measured at fair value using income approach based on the discounted value of expected future cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the fair values of our holdings of Armata common stock, warrants, the Armata Convertible Note, the Armata July 2023 Term Loan, the Armata March 2024 Term Loan, the Armata March 2025 Term Loan and the Armata August 2025 Term Loan were estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2024 the fair values of our holdings of Armata common stock, warrants, the Armata Convertible Note, the Armata July 2023 Term Loan and the Armata March 2024 Term Loan were estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the Armata common stock and warrants, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized gains, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized losses and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized gains &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;as changes in fair values of equity method investments, net, in the consolidated statements of income and comprehensive income for the years ended December 31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the Armata Convertible Note, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized gains, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized losses and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized gains as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the years ended December 31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the Armata July 2023 Term Loan, we rec&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;orded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized gains as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the years ended December 31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the Armata March 2024 Term Loan, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized gains as changes in fair values of equity and long-term investments, net, in the consolidated statements of income &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;and comprehensive income for the years ended December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the Armata March 2025 Term Loan&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized gain for the year ended December 31, 2025 as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the Armata August 2025 Term Loan, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized gain for the year ended December 31, 2025 as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On January 23, 2026, we entered into various amendments to existing agreements with Armata, extending the maturities of the Armata Note, the July 2023 Term Loan, the March 2024 Term Loan and the March 2025 Term Loan to June 1, 2027. The expiration dates of all outstanding Armata warrants held by us were likewise extended to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 26, 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In addition, we entered into an amendment to the amended and restated investor rights agreement, pursuant to which the Company and ISO agreed that the voting agreement will expire on the earlier of January 26, 2031 or the approval by the FDA of any of Armata&#x2019;s product candidates for marketing and commercial distribution.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.799999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.799999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Noncurrent assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Twelve Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity and Other Investments in InCarda&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since the third quarter of 2020, Innoviva TRC Holdings, LLC (&#x201c;ITH&#x201d;), a wholly owned subsidiary of Innoviva, has invested in the common stock, preferred stock, warrants and convertible notes of InCarda Therapeutics, Inc. (&#x201c;InCarda&#x201d;), a privately held biopharmaceutical company focused on developing intravenous and inhaled therapies for cardiovascular diseases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ITH has the right to designate one member to InCarda&#x2019;s board of directors. As of December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ITH designee is serving on InCarda&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-member board.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, ITH owns &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,742,250&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of InCarda&#x2019;s common and preferred stock and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,490,033&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; preferred stock warrants. These represent a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% equity interest as of December 31, 2025 and 2024, respectively. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our investment in InCarda does not provide us with the ability to control or have significant influence over InCarda&#x2019;s operations. Based on our evaluation, we determined that InCarda is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ITH also invested $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in InCarda's convertible notes issued in January 2024 (the &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;InCarda 2024 Convertible Note&#x201d;), February 2025 (the &#x201c;InCarda February 2025 Convertible Note&#x201d;) and October 2025 (the &#x201c;InCarda October 2025 Convertible Note&#x201d;), respectively (collectively, the (the &#x201c;InCarda Convertible Notes&#x201d;). We account for the InCarda Convertible Notes as trading securities, measured at fair value.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;With the exception of the InCarda Convertible Notes and Series D Warrants, which are measured at fair value, we account for the aforementioned investments in InCarda under the measurement alternative. Under the measurement alternative, the equity investment is initially recorded at its allocated cost, but the carrying value may be adjusted through earnings upon an impairment or when there is an observable price change involving the same or a similar investment with the same issuer.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain InCarda warrants held by us expired in March 2023 and we wrote off their carrying value of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Due to certain changes in InCarda&#x2019;s business operations during the second quarter of 2023, ITH reassessed the value of its then investments in common stock, preferred stock and preferred stock warrants&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in InCarda using the Option Pricing Model methodology. Key assumptions used in the valuation model included an expected holding period of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, a risk-free interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, a dividend yield of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and an estimated volatility of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;114.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. The estimated volatility was calculated based on the historical volatility of a selected peer group of public companies comparable to InCarda. We recognized an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million during the second quarter of 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, we recorded as equity and long-term investments in the consolidated balance sheets $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in carrying amount of InCarda&#x2019;s Series C preferred stock and approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in fair value of the InCarda Series D Warrants. As of December 31, 2025 and 2024, we recognized as equity and long-term investments in the consolidated balance sheets $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, for InCarda&#x2019;s Series D-1 preferred stock, Series D-2 preferred stock, and common stock using the measurement alternative. As of December 31, 2025 and 2024, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, in fair value of the InCarda Convertible Notes as equity and long-term investments in the consolidated balance sheet. During the years ended December 31, 2025 and 2024, there were immaterial changes in the carrying amount of our investments. We recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized loss as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the year ended December 31, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity and Other Investments in ImaginAb&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Since March of 2021, ITH has invested $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,825,301&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of common and preferred stock, and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in a convertible note of ImaginAb, Inc. (&#x201c;ImaginAb&#x201d;), a privately held biotechnology company focused on clinically managing cancer and autoimmune diseases via molecular imaging.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of ImaginAb&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; board members was designated by ITH. As of December 31, 2025 and 2024, we held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of ImaginAb equity ownership.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our investment in ImaginAb does not provide us with the ability to control or have significant influence over ImaginAb&#x2019;s operations. Based on our evaluation, we determined that ImaginAb is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;270,568&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of ImaginAb Series C-2 preferred stock for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. On September 14, 2023, ITH entered into a securities purchase agreement with ImaginAb to purchase another &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;405,852&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of ImaginAb Series C-2 preferred stock for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 23, 2024, ITH purchased a subordinated convertible promissory note (the &#x201c;ImaginAb Convertible Note&#x201d;) from ImaginAb for a total purchase price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The ImaginAb Convertible Note carried an annual interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and would be due and payable upon the earlier to occur of January 31, 2025 and certain events defined in the ImaginAb Convertible Note. Under certain circumstances, the ImaginAb Convertible Note is convertible at the option of ITH into ImaginAb&#x2019;s equity securities at defined conversion prices. The ImaginAb Convertible Note is subordinate to certain existing indebtedness of ImaginAb as defined in the ImaginAb Convertible Note. On October 31, 2024, ITH entered into an agreement with ImaginAb to amend the ImaginAb Convertible Note. Pursuant to the agreement, the principal amount of the ImaginAb Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which represented the principal as of February 23, 2024, accrued interest as of amendment date, commitment fees and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. On January 13, 2025, ITH and ImaginAb executed an amendment to the ImaginAb Convertible Note extending the maturity date from January 31, 2025 to May 30, 2025. All other material terms of the ImaginAb Convertible Note were unchanged during the aforementioned amendments to the ImaginAb Convertible Note.	&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Because ImaginAb&#x2019;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in ImaginAb&#x2019;s Series C preferred stock, Series C-2 preferred stock and common stock using the measurement alternative. As of December 31, 2025 and 2024, our investment in ImaginAb&#x2019;s Series C preferred stock, Series C-2 preferred stock and common stock amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and recorded as equity and long-term investments in the consolidated balance sheets. There was no change in the carrying amount of our equity investments in ImaginAb.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2025, ImaginAb fully settled the convertible note of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, including $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in accrued interest and commitment fees. Before the repayment, the ImaginAb Convertible Note was accounted for as a trading security and measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of risk-free rate, volatility of stock price and timing of certain qualified events. As of December 31, 2024, we recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in fair value of the ImaginAb convertible note as equity and long-term investments in the consolidated balance sheet. Changes to the fair value of the ImaginAb convertible note in 2025 through its settlement date were immaterial. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;During the year ended December 31, 2024, we recorded &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in net unrealized gain&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; on the ImaginAb convertible note as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Convertible Promissory Note in Syndeio Biosciences&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Syndeio Biosciences, Inc. (formerly known as Gate Neurosciences, Inc.) (&#x201c;Syndeio&#x201d;) is a privately held biopharmaceutical company focused on developing the next generation of targeted nervous system therapies, leveraging precision medicine approaches to develop breakthrough drugs for psychiatric and neurologic diseases. In May 2025, Gate Neurosciences, Inc. rebranded as Syndeio.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From 2021 to 2022, ITH invested in Syndeio a total of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in convertible notes (the &#x201c;Syndeio 2021 Convertible Note&#x201d;). &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Syndeio 2021 Convertible Note bears an annual interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and will convert into shares of common stock of Syndeio upon a qualified event or into shares of shadow preferred stock of Syndeio (&#x201c;Shadow Preferred&#x201d;) upon a qualified financing. A qualifying event can be a qualified initial price offering, a qualified merger, or a merger with a special-purpose acquisition company (&#x201c;SPAC&#x201d;). Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#x201c;Capped Conversion Price&#x201d;) and the qualified event price (the &#x201c;Qualified Event Price&#x201d;). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Syndeio are at least $35.0 million, and (iii) the stated or implied equity valuation of Syndeio is at least $80.0 million.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 2, 2023, ITH entered into a Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Syndeio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2021 Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which represents the original principal, accrued interest as of the amendment date and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 6, 2023, ITH entered into a Second Note Amendment Agreement with Syndeio to amend the Note Amendment Agreement. Pursuant to the Second Note Amendment Agreement, the principal amount of the Syndeio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2021 Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which represents the amended principal as of February 2, 2023, accrued interest as of the second amendment date and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 13, 2024, ITH entered into a Third Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Third Note Amendment Agreement, the principal amount of the Syndeio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2021 Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which represents the principal and accrued interest as of the third amendment date and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 5, 2024, ITH entered into a Fourth Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Fourth Note Amendment Agreement, the principal amount of the Syndeio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2021 Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which represents the principal and accrued interest as of the fourth amendment date and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 13, 2024, ITH entered into a Fifth Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Fifth Note Amendment Agreement, the principal amount of the Syndeio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; 2021 Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which represents the principal and accrued interest as of the fifth amendment date and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 3, 2025, ITH entered into a Convertible Promissory Note Purchase Agreement with Syndeio to acquire a convertible promissory note (the &#x201c;Syndeio 2025 Convertible Note&#x201d;) with a principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The Syndeio 2025 Convertible Note bears an annual interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and will mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 24, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Syndeio 2025 Convertible Note will convert into shares of series seed preferred stock of Syndeio upon a qualified initial public offering (&#x201c;IPO&#x201d;), or into shares of shadow preferred stock of Syndeio (&#x201c;Shadow Preferred&#x201d;) upon a qualified financing. Shadow Preferred means preferred stock having identical rights, preferences and restrictions as the preferred stock that would be issued in a qualified financing.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 11, 2025, ITH entered into a Note Amendment Agreement with Syndeio to amend the Syndeio 2025 Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Syndeio 2025 Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which represents the principal and accrued interest as of the amendment date and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;All other material terms of the Syndeio 2021 Convertible Note and the Syndeio 2025 Convertible Note remained unchanged during the aforementioned amendments.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our investments in Syndeio do not provide us with the ability to control or have significant influence over Syndeio&#x2019;s operations. Based on our evaluation, we determined that Syndeio is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We account for both the Syndeio 2021 Convertible Note and the Syndeio 2025 Convertible Note as trading securities, measured at fair value using a Monte Carlo simulation model with the probability of certain qualified events and the assumptions of equity value of Syndeio, risk-free rate, expected stock price, volatility of its peer companies, and the time until a financing is raised.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, the fair value of the Syndeio 2021&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Convertible Note was estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, and recorded as equity and long-term investments in the consolidated balance sheets. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized gain for the year ended December 31, 2025, as change in fair values of equity and long-term investments, net in the consolidated statements of income and comprehensive income. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The change in fair value is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t material for the year ended December 31, 2024. We recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized loss as change in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income for the year ended December 31, 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the fair value of the Syndeio 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Convertible Note was estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and recorded as equity and long-term investments in the consolidated balance sheet. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized loss for the year ended December 31, 2025, as change in fair values of equity and long-term investments, net in the consolidated statements of income and comprehensive income.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 10, 2026, ITH entered into a Note Amendment Agreement with Syndeio to amend the Syndeio 2021 Convertible Note. Pursuant to the Note Amendment Agreement, the principal amount of the Syndeio 2021 Convertible Note was increased from $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which represents the principal and accrued interest as of the amendment date and an additional cash investment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Certain thresholds associated with the definition of qualified financing were likewise amended. All other material terms of the Syndeio 2021 Convertible Note remained unchanged&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Investment in Nanolive&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2022, ITC invested $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,750,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of preferred stock of Nanolive SA (&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Nanolive&#x201d;), a Swiss privately held life sciences company focused on developing breakthrough imaging solutions that accelerate research in growth industries such as drug discovery and cell therapy. ITH has the right to designate one member to Nanolive&#x2019;s board. ITH also has the right to designate another member, who will be mutually acceptable to ITH and another stockholder, to Nanolive&#x2019;s board. As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Innoviva designee is serving on Nanolive&#x2019;s &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;six&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-member board. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, we held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of Nanolive equity ownership.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our investment in Nanolive does not provide us with the ability to control or have significant influence over Nanolive&#x2019;s operations. Based on our evaluation, we determined that Nanolive is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Because Nanolive&#x2019;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Nanolive&#x2019;s Series C preferred stock using the measurement alternative. As of December 31, 2025 and 2024,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of investment in Nanolive was recorded as equity and long-term investments in the consolidated balance sheets, and there was no change to the carrying amount of our investment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Convertible Promissory Note in Lyndra&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 27, 2025, Strategic Partners entered into a note purchase agreement with Lyndra Therapeutics, Inc. (&#x201c;Lyndra&#x201d;) to acquire a convertible promissory note (the &#x201c;Lyndra Convertible Note&#x201d;) with a principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Lyndra is a clinical-stage company with a novel drug delivery platform that enables the administration of ultra-long-acting oral drugs. The Lyndra Convertible Note bears an annual interest rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% and will mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;November 27, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The Lyndra Convertible Note would convert into shares of preferred stock of Lyndra upon a qualified financing as defined in the agreement. Upon maturity or certain events and if no qualified financing has occurred, the principal and unpaid accrued interest may either be repaid in full in cash plus a certain premium or convert into shares of preferred stock of Lyndra as defined in the agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our investment in Lyndra does not provide us with the ability to control or have significant influence over Lyndra&#x2019;s operations. Based on our evaluation, we determined that Lyndra is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity. We account for the Lyndra Convertible Note as a trading security, measured at fair value using an income approach based on the discounted value of expected future cash flows.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In late March of 2025, Lyndra began winding down its operations due to a lack of financing. In September 2025, Lyndra sold the majority of its assets, resulting in a change of control as defined in the Lyndra Convertible Note (Refer to Note 14, &#x201c;Asset Acquisition&#x201d;). Upon the consummation of the change of control, the maturity date of the Lyndra Convertible Note was accelerated, and its principal and accrued interest became due. Due to Lyndra&#x2019;s inability to repay the full amount, the note went into default and became subject to a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% premium on the principal balance. Interest will continue to accrue until full repayment.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; In October 2025, we received a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million partial repayment on the Lyndra Convertible Note, reducing the outstanding principal to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the fair value of the Lyndra Convertible Note was estimated at $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and recorded as equity and long-term investments in the consolidated balance sheet. We recorded $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in unrealized loss for the year ended December 31, 2025 as changes in fair values of equity and long-term investments, net, in the consolidated statements of income and comprehensive income.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Investment in Beacon&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Beacon Biosignals, Inc. (&#x201c;Beacon&#x201d;) is an AI-driven neurotechnology company developing treatments for neurological, psychiatric, and sleep disorders. On October 7 2025, ITH entered into a Preferred Stock Purchase Agreement with Beacon, pursuant to which ITH acquired &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,448,303&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of Beacon&#x2019;s Series B Preferred Stock for $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, we held &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of Beacon equity ownership.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our investment in Beacon does not provide us with the ability to control or have significant influence over Beacon&#x2019;s operations. Based on our evaluation, we determined that Beacon is a VIE, but we are not the primary beneficiary of the VIE. We have not provided financial or other support that we were not previously contractually required to provide during the periods presented. Our maximum exposure to loss is equal to the amount we invested in the entity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Because Beacon&#x2019;s equity securities are not publicly traded and do not have a readily determinable fair value, we account for our investment in Beacon&#x2019;s Series B preferred stock using the measurement alternative. As of December 31, 2025, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of investment in Beacon was recorded as equity and long-term investments in the consolidated balance sheet, and there was no change to the carrying amount of our investment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Reconciliation of Equity and Long-Term Investments Balances&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the change in balances in &#x201c;Equity and Long-Term Investments&#x201d; as of each balance sheet date:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity and long-term investments as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;444,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchases of trading securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reclassification of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity and long-term investments as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;341,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchases of trading securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Proceeds from trading securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchases of equity and other long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net sales and purchases of investments managed by ISP Fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reclassification of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity and long-term investments as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Available-for-Sale Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.867%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents in the consolidated balance sheets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.867%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025 and 2024, all available-for-sale securities were money market funds, and there was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; credit loss recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our available-for-sale securities and equity and long-term investments are measured at fair value on a recurring basis and our debt is carried at amortized cost basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:39.772%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.678%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.678%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.678%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.678%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2025 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Price&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments held by ISP Fund LP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - InCarda Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata July 2023 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata March 2024 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata March 2025 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata August 2025 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Armata Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - InCarda 2024 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - InCarda February 2025 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - InCarda October 2025 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Syndeio 2021 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Syndeio 2025 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Lyndra Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;764,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,101,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;267,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;267,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:40.468%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.402000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.402000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.402000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.402000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2024 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;in Active&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments held by ISP Fund LP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - InCarda Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Armata Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata July 2023 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata March 2024 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - InCarda 2024 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - ImaginAb Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Syndeio 2021 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;529,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;229,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;765,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fair value of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;473,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;473,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; transfers between Level 1, Level 2 or Level 3 during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair values of our equity investments in Armata&#x2019;s common stock and publicly traded investments held by ISP Fund LP are based on the quoted prices in active markets and are classified as Level 1 financial instruments. The fair values in the warrants in Armata classified within Level 2 are based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers, and reference data including market research publications.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The investments classified as Level 3 financial instruments are securities that are not publicly traded and the assumptions used in the valuation model of these securities are based on significant unobservable and observable inputs including those of publicly traded peer companies. There are uncertainties on the fair value measurement of the instruments classified under Level 3 due to the use of unobservable inputs and interrelationships between these unobservable inputs, which could result in higher or lower fair value measurements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair values of our 2025 Notes and 2028 Notes are based on recent trading prices of the respective instruments.&lt;/span&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <inva:VotingAgreementMaximumVotingRightsPercent
      contextRef="C_555d4978-0156-480e-84ba-fa2f5dcd4d7f"
      decimals="3"
      id="F_1f9c400a-80e6-45fa-8afb-f8e0d055fc93"
      unitRef="U_pure">0.495</inva:VotingAgreementMaximumVotingRightsPercent>
    <inva:VotingAgreementMaximumVotingRightsPercent
      contextRef="C_8f7758c5-cb43-4beb-b145-ea2ab98c407a"
      decimals="3"
      id="F_42fd1fe8-f937-4d11-be06-c5560f896019"
      unitRef="U_pure">0.495</inva:VotingAgreementMaximumVotingRightsPercent>
    <inva:SpecialTermReDesignatingBoardMemberToBoardOfInvestee
      contextRef="C_8f7758c5-cb43-4beb-b145-ea2ab98c407a"
      id="F_12141b02-c0ec-49a9-a2c8-df5a10e5a0c0">In addition, as of February 9, 2022, Armata entered into an amended and restated investor rights agreement with the Company and ISO, pursuant to which for as long as the Company and ISO hold at least 12.5% of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted, the Company and ISO shall have the right to designate two directors to Armata&#x2019;s board of directors, and for so long as the Company and ISO hold at least 8%, but less than 12.5%, of the outstanding shares of Armata&#x2019;s common stock on a fully-diluted basis, the Company and ISO shall have the right to designate one director to Armata&#x2019;s board of directors, subject to certain conditions and qualifications set forth in the amended and restated investor rights agreement.</inva:SpecialTermReDesignatingBoardMemberToBoardOfInvestee>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_1b2e2593-a2a8-48e9-bddd-edbd0e4ece93"
      decimals="3"
      id="F_a0fe7361-432d-4a7b-a513-e2c2e8585e09"
      unitRef="U_pure">0.125</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_bdd9c91e-8090-4b5c-afa1-5fde995c9182"
      decimals="2"
      id="F_e6a51f96-cab6-4a4b-9f85-a2de04b00444"
      unitRef="U_pure">0.08</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="C_d7a7bab5-9ba6-49af-9860-25a6b42523d6"
      decimals="3"
      id="F_f6c04525-d351-45b1-b209-7e2dd2c29aaf"
      unitRef="U_pure">0.125</us-gaap:VariableInterestEntityOwnershipPercentage>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_4fb4788c-8450-4c40-8d91-a0ffb3b4ba73"
      id="F_6931b723-709c-463a-b88a-dc793725825b">On January 10, 2023, we entered into a Secured Convertible Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Armata, under which we invested in a one-year convertible note (the &#x201c;Armata Convertible Note&#x201d;) in an aggregate amount of $30.0 million at an interest rate of 8.0% per annum.</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentTerm
      contextRef="C_4fb4788c-8450-4c40-8d91-a0ffb3b4ba73"
      id="F_e458e759-ed06-4515-9a81-0b53167292bb">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_b4075dc6-049f-43ce-ad83-c920b6727849"
      decimals="-5"
      id="F_99c7ded9-acc7-48a8-ab0a-11360b39d156"
      unitRef="U_USD">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_b4075dc6-049f-43ce-ad83-c920b6727849"
      decimals="3"
      id="F_8e8c8dac-7ca6-485a-8a7e-34393fac456f"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_a81a0298-20b0-4919-aeae-4999deb69182"
      id="F_155b24da-c849-40bb-a1ba-9ac6d4947b22">2025-01-10</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_56003be5-dcb8-4576-a7f1-796756b2432a"
      id="F_1e19e73f-9538-4c3d-a8d2-b3ff24d2b6ac">2026-01-10</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_5aa5d39a-f76b-4524-93e9-30d0fefb1a3c"
      decimals="-5"
      id="F_f0717e4d-47f0-4600-9c57-ad7dd5754b74"
      unitRef="U_USD">25000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_5aa5d39a-f76b-4524-93e9-30d0fefb1a3c"
      decimals="2"
      id="F_6e397333-088e-45e9-914f-f48f9d7d643e"
      unitRef="U_pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_f41b7af1-e738-4a48-990d-dc1756c13b91"
      id="F_29e6d1f0-6834-4d84-9b92-086e6e8e0bde">2025-01-10</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_2a02f41a-febe-490b-af61-93b34070abed"
      id="F_89282c05-ccfd-477f-ab45-05dd7af203aa">2026-01-10</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_71ded7c0-3708-4f52-b6c3-6791c394800f"
      decimals="-5"
      id="F_f43f8c1a-ce53-4223-9eee-bc240ed82516"
      unitRef="U_USD">35000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_71ded7c0-3708-4f52-b6c3-6791c394800f"
      decimals="2"
      id="F_a242958a-27ed-4641-b487-abf58586e6d1"
      unitRef="U_pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_d2c0826f-e79a-4fce-bf90-c8a92ab2dc99"
      id="F_a00c96cc-5ab3-41cf-9e9d-ed07c2b49fb4">2025-06-04</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_60ac9e5c-2514-4f92-bf1c-12266b1917e1"
      decimals="-5"
      id="F_deebe8c1-a142-4d70-b1ae-b5529acf2ce0"
      unitRef="U_USD">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_60ac9e5c-2514-4f92-bf1c-12266b1917e1"
      decimals="2"
      id="F_7cfb8067-9265-42bb-8232-1b49de4d61d8"
      unitRef="U_pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_11d1f4e6-b778-4765-a18c-a66d5f46ca1e"
      id="F_ea17b9e8-19d2-44a5-802d-154c03276a64">2026-03-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="C_a6940b34-904b-444f-9ffb-b6b2e2a80b84"
      decimals="-5"
      id="F_c5d06ad8-381b-42da-8459-bf98dc2c9bda"
      unitRef="U_USD">15000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_a6940b34-904b-444f-9ffb-b6b2e2a80b84"
      decimals="2"
      id="F_6020c562-46dc-4015-a949-8d8de78db88f"
      unitRef="U_pure">0.14</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_0d77cda3-d1e7-4fcc-b01e-02245e7164be"
      id="F_078c0ce7-0e54-4702-bc51-b9dc71d9a9df">2029-01-11</us-gaap:DebtInstrumentMaturityDate>
    <inva:NumberOfBoardOfDirectors
      contextRef="C_057e1553-e322-46f8-92dc-4d5d487f40f6"
      decimals="INF"
      id="F_6972e287-8f9c-44d0-afa9-d0d83bc2c71a"
      unitRef="U_BoardMember">2</inva:NumberOfBoardOfDirectors>
    <inva:NumberOfBoardOfDirectors
      contextRef="C_5a9347c1-884d-4675-bb79-fefe358e833d"
      decimals="INF"
      id="F_700b2e37-a19c-425e-8f1a-eec6472d5df7"
      unitRef="U_BoardMember">7</inva:NumberOfBoardOfDirectors>
    <inva:EquitySecuritiesOwned
      contextRef="C_5a9347c1-884d-4675-bb79-fefe358e833d"
      decimals="INF"
      id="F_9fe3e33a-42c1-4c93-a23d-5ebd16110ce1"
      unitRef="U_shares">25076769</inva:EquitySecuritiesOwned>
    <inva:EquitySecuritiesOwned
      contextRef="C_5328b425-8576-4d5b-b1db-1f14e4c9c1c0"
      decimals="INF"
      id="F_903600b9-f219-4683-9fbb-1283f4123f65"
      unitRef="U_shares">25076769</inva:EquitySecuritiesOwned>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_675639ab-20e9-408c-8ece-4bd0da8c908c"
      decimals="3"
      id="F_02cf6f34-236b-48ea-9d4a-b345bdd7832b"
      unitRef="U_pure">0.688</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_5038c961-a52a-4d07-b20a-2ec350ef35a7"
      decimals="3"
      id="F_1cb4bf4c-a45c-4b2e-a339-b1c897911f4e"
      unitRef="U_pure">0.693</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <inva:NumberOfWarrantsOwned
      contextRef="C_5a9347c1-884d-4675-bb79-fefe358e833d"
      decimals="INF"
      id="F_b0311e5d-908a-4ddf-a8a8-141d6ac90562"
      unitRef="U_shares">10653847</inva:NumberOfWarrantsOwned>
    <inva:NumberOfWarrantsOwned
      contextRef="C_5328b425-8576-4d5b-b1db-1f14e4c9c1c0"
      decimals="INF"
      id="F_5525e0f3-b50b-4b48-83d8-82bdc166bd89"
      unitRef="U_shares">19364647</inva:NumberOfWarrantsOwned>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_cde889ec-684b-433c-ada2-fcc698632fea"
      decimals="2"
      id="F_b2994077-e3d7-45d9-922a-f3207f4af858"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3acd791d-ece0-41d0-bc86-551014479aa6"
      decimals="2"
      id="F_778ce802-4fbf-40b9-b179-31878bd3080d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <inva:PrincipalAmountOfConvertibleNotesOwned
      contextRef="C_057e1553-e322-46f8-92dc-4d5d487f40f6"
      decimals="-5"
      id="F_b1871df0-7a38-4eae-b75f-e88113ad03e7"
      unitRef="U_USD">30100000</inva:PrincipalAmountOfConvertibleNotesOwned>
    <inva:PrincipalAmountOfTermLoansOwned
      contextRef="C_cfe17d12-81a1-4510-9340-bf18810ec8cf"
      decimals="-5"
      id="F_47f24e3a-ae14-4d91-85bf-cad2cda9d8ed"
      unitRef="U_USD">85100000</inva:PrincipalAmountOfTermLoansOwned>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3c82e86c-b476-42ba-91a7-f0f73b075d88"
      decimals="2"
      id="F_d86b7fae-d575-479f-8f18-08cdf4e5d10f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.87</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_df134efd-b2f5-42e0-9b07-1a512098141d"
      decimals="2"
      id="F_0ce33234-1622-4595-82b9-e1e3c38eb14f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">3.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_2aaa98e6-3d27-48b0-aad0-9021ae880dff"
      decimals="2"
      id="F_389eef3d-ba0a-4ebc-9a9c-744e33397110"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_e6682ffe-c7e9-4815-8a85-1e4bef9f2711"
      id="F_80674145-95e4-49cd-91b9-019d85c4225a">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_99fff56a-0af3-445d-bdc0-14b8847ce8ee"
      id="F_2eea72d0-1e7c-4930-b5c7-3630f92899b7">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="C_05ee92da-ae00-447e-a688-0afb8debabd7"
      id="F_213df821-7137-40fd-b8c0-49a30c6dd527">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_65e207cc-7ebd-4bcd-bb6b-e27d80d3a005"
      decimals="-5"
      id="F_4914cd94-5df4-4d75-9d90-86784e8b7108"
      unitRef="U_USD">157500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_820fc30b-7e3c-4f31-9d93-e486eb026d85"
      decimals="-5"
      id="F_88bf2299-f25c-46f1-b5d3-9529589fce37"
      unitRef="U_USD">36200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_cfe17d12-81a1-4510-9340-bf18810ec8cf"
      decimals="-5"
      id="F_cd0ae110-c802-4a31-ae52-bbc63bc11f5a"
      unitRef="U_USD">101400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_bc6304c8-3e91-4a96-bdf1-8803fdcad919"
      decimals="-5"
      id="F_531b097c-84cb-4ad0-81e4-0457922e24ec"
      unitRef="U_USD">32900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_cd9cf8cd-caf0-4230-972b-b59ef42f7629"
      decimals="-5"
      id="F_c74d001c-c082-478a-bf91-c00432c168cb"
      unitRef="U_USD">43300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_97c7c246-dcd0-459f-ba1c-f296e715a8bd"
      decimals="-5"
      id="F_c4c1fc4c-80a1-433b-aebd-fc5da11be8e2"
      unitRef="U_USD">11100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_b335f87a-f5ca-4232-8677-8903d59dd87c"
      decimals="-5"
      id="F_a089d186-e7af-4db4-9764-28257c5cc326"
      unitRef="U_USD">15500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_ce943a5c-4a0c-4116-8b1d-c757694d1ea7"
      decimals="-5"
      id="F_efb91edd-cea6-4bf9-96a2-911fde6f1eb8"
      unitRef="U_USD">46400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_1c30d3c2-8973-487f-b385-4efcc897f79b"
      decimals="-5"
      id="F_40930f16-c738-42f6-aa24-cf8a57165a11"
      unitRef="U_USD">5900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_569306e7-f6a0-459f-8db9-5647b77e5c0a"
      decimals="-5"
      id="F_ea2f2a9e-f7ce-4a91-a49a-65461221b97a"
      unitRef="U_USD">42100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_d34cdf08-8e0e-4cba-93ee-569a80e0e67a"
      decimals="-5"
      id="F_109da6f2-1104-4ba2-911d-4805414bf036"
      unitRef="U_USD">30200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_21888485-64fc-4d1a-9d3c-4e0fc17c7633"
      decimals="-5"
      id="F_9f978b26-a698-4bd9-a38a-d6a8c4d085f5"
      unitRef="U_USD">39300000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_9db59475-42c5-4b23-ad54-3fcbd23354de"
      decimals="-5"
      id="F_c6ac5b3c-56c1-437e-9a89-fc0078527e47"
      unitRef="U_USD">141400000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_ad016aed-b782-4802-bf40-a81d9aac47a4"
      decimals="-5"
      id="F_b12bd9c9-7d59-4a69-ac83-ac999b3b0474"
      unitRef="U_USD">64300000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_8480b31f-e5a9-455f-8428-4e043a8d826b"
      decimals="-5"
      id="F_6b71794b-75cb-4bcd-be8d-d0c452bb371e"
      unitRef="U_USD">77400000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_661f58ec-6b2b-444d-8088-4abba363c175"
      decimals="-5"
      id="F_8f5fdf97-5c01-4534-b675-308006f4ad5d"
      unitRef="U_USD">59300000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_22dbc318-90d0-4d6c-ae97-fa8f97e6f8e4"
      decimals="-5"
      id="F_af61ccee-4a18-4c62-8a7c-ea1bd117bdda"
      unitRef="U_USD">9800000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_c0f46e83-20e1-4f0a-ac38-a2cdd4a209c4"
      decimals="-5"
      id="F_cc5a2582-07c4-49ba-8754-34f8dc4f29ae"
      unitRef="U_USD">21800000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_2b3a7dbc-4a58-4808-a400-3b7b5bfb3e69"
      decimals="-5"
      id="F_e3d4e650-7e30-4971-bf0f-2c7c2e8fb07d"
      unitRef="U_USD">2700000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_f0a0f488-206c-45bf-a6fd-b8fcfefad049"
      decimals="-5"
      id="F_d0b3705b-6142-4c7a-9505-8037920bba59"
      unitRef="U_USD">3200000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_8227b866-0a9c-4af9-b3ec-85e210a8c096"
      decimals="-5"
      id="F_31307d11-1c41-4f0e-848e-73a16de3e605"
      unitRef="U_USD">2000000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_b0999027-f0c9-4ef8-ad7d-78766bc3abbe"
      decimals="-5"
      id="F_7d9696bc-3679-4145-8b8e-f8c80bc55e2c"
      unitRef="U_USD">4000000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_8683d1cb-18f6-4da0-8993-dbb80feae90a"
      decimals="-5"
      id="F_26c658be-6975-4de2-ae78-911e66f312be"
      unitRef="U_USD">4300000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_380b4395-2715-4251-a2b6-448e3fa77f25"
      decimals="-5"
      id="F_c5656f04-3517-4906-9221-65e91f5204eb"
      unitRef="U_USD">1100000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_7d8daa92-8559-4d7e-9e07-c21e30f977fb"
      decimals="-5"
      id="F_dab7a1a9-c8c0-42f5-9979-cbde20366841"
      unitRef="U_USD">500000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_b657fd3f-8dca-44dc-a4ed-6c972e7986a9"
      id="F_d22a183b-11ca-44c0-b243-d15f4cc0d300">2031-01-26</us-gaap:DebtInstrumentMaturityDate>
    <inva:ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock
      contextRef="C_fe80c249-d33c-4cd6-b2cb-331be1cd34ee"
      id="F_b7e4ab80-d5f0-4d7d-ba59-6907a7098999">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The summarized financial information, including the portion we do not own, is presented for Armata on a one quarter lag as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.799999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.799999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Noncurrent assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;72,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,848&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;139,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;118,204&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;45,154&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,006&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Income Statement Information&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Twelve Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Loss from operations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38,476&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,639&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</inva:ScheduleOfFinancialInformationOfVariableInterestEntitiesTableTextBlock>
    <us-gaap:AssetsCurrent
      contextRef="C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88"
      decimals="-3"
      id="F_469aa03c-6e90-427d-a3de-43ec09591005"
      unitRef="U_USD">16930000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_14b19da2-3f85-45b5-891e-2a495389f972"
      decimals="-3"
      id="F_c7d7e485-9f96-439e-98af-d31c59b7cb22"
      unitRef="U_USD">22389000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88"
      decimals="-3"
      id="F_e4c3b970-9640-4b53-bb50-1b687463d0f8"
      unitRef="U_USD">72586000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_14b19da2-3f85-45b5-891e-2a495389f972"
      decimals="-3"
      id="F_a66d4e1c-f9a3-4b12-ad83-018b3d62c74c"
      unitRef="U_USD">75848000</us-gaap:AssetsNoncurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88"
      decimals="-3"
      id="F_f2310912-b9cc-479f-a8c8-110715777dca"
      unitRef="U_USD">139950000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_14b19da2-3f85-45b5-891e-2a495389f972"
      decimals="-3"
      id="F_d962b83c-57e6-45fd-9b2b-6ccb5df31a98"
      unitRef="U_USD">118204000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_4f6c6f33-c08c-4b2a-93e3-fccaebb78d88"
      decimals="-3"
      id="F_9f14d2ca-bd1a-49e1-a455-b965914a0bca"
      unitRef="U_USD">45154000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_14b19da2-3f85-45b5-891e-2a495389f972"
      decimals="-3"
      id="F_85bcd7d3-38cf-438c-91fa-28e904ba4d4d"
      unitRef="U_USD">31006000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_fdb03ab5-f84c-4ddc-bd5f-542862b94835"
      decimals="-3"
      id="F_e15a6cfb-8779-4347-984e-f2117dc238c5"
      unitRef="U_USD">5054000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_53386bc7-321c-4778-9d99-1014173440f8"
      decimals="-3"
      id="F_53819d26-55c4-4045-97d6-4d34298547fc"
      unitRef="U_USD">5467000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ff805685-7f62-44bb-b91d-537b589a7c39"
      decimals="-3"
      id="F_9c1eec64-8b6c-4838-97c8-cacab7cd819b"
      unitRef="U_USD">4052000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_fdb03ab5-f84c-4ddc-bd5f-542862b94835"
      decimals="-3"
      id="F_695d08ac-22ea-47ca-a981-4333c0b70e38"
      unitRef="U_USD">-33350000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_53386bc7-321c-4778-9d99-1014173440f8"
      decimals="-3"
      id="F_e721beac-cb1f-4ae3-bf42-e271973a5512"
      unitRef="U_USD">-38476000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_ff805685-7f62-44bb-b91d-537b589a7c39"
      decimals="-3"
      id="F_5906f413-6871-4827-adbb-4fb004031573"
      unitRef="U_USD">-41639000</us-gaap:OperatingIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="C_fdb03ab5-f84c-4ddc-bd5f-542862b94835"
      decimals="-3"
      id="F_3b8cdd05-a85d-4605-9304-8d35f021a238"
      unitRef="U_USD">-46901000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_53386bc7-321c-4778-9d99-1014173440f8"
      decimals="-3"
      id="F_39866aee-04ac-4e5a-b628-07d9e612b949"
      unitRef="U_USD">-41363000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_ff805685-7f62-44bb-b91d-537b589a7c39"
      decimals="-3"
      id="F_88002745-a9f6-46d8-937c-31e738c01dd3"
      unitRef="U_USD">-59512000</us-gaap:ProfitLoss>
    <inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee
      contextRef="C_280efd9d-8c7f-4e28-aa7a-2c064a232238"
      decimals="0"
      id="F_1cd8c962-47f2-4a4a-8baf-957c188d481f"
      unitRef="U_Director">0</inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee>
    <inva:NumberOfBoardMembersOfInvestee
      contextRef="C_280efd9d-8c7f-4e28-aa7a-2c064a232238"
      decimals="0"
      id="F_23db3656-02a4-4f36-8527-bf5be20f369d"
      unitRef="U_Director">6</inva:NumberOfBoardMembersOfInvestee>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_51b3b591-fbb0-4d6e-bbcc-a2b9316cdd48"
      decimals="INF"
      id="F_d819742b-a1b0-4016-a709-6ec1f99d0a1c"
      unitRef="U_shares">36742250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_8e7f501b-989e-4f9f-9cee-6b92a787012e"
      decimals="INF"
      id="F_0b6141d4-edd6-4786-8c30-7d814dfba0d5"
      unitRef="U_shares">36742250</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction
      contextRef="C_0c2b17b3-b563-4774-a444-c68ee381c769"
      decimals="INF"
      id="F_aab7a476-0519-41fa-91e9-51fe92c9fcce"
      unitRef="U_shares">2490033</inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction>
    <inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction
      contextRef="C_5269be09-0f8f-4632-b948-cb713105102a"
      decimals="INF"
      id="F_353e7530-771b-4d69-99f6-9eaf84468ce5"
      unitRef="U_shares">2490033</inva:SaleOfWarrantsNumberOfWarrantsIssuedInTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_dec7ee2e-9d77-490d-ada1-7ee27d46f370"
      decimals="3"
      id="F_22770d6a-4ccd-4b3f-bd59-fec111148c6f"
      unitRef="U_pure">0.095</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_5df29ec0-a027-4d1e-9bcd-9baa6703c4dc"
      decimals="3"
      id="F_8623a925-cb4d-44c9-9564-b58e1850a0af"
      unitRef="U_pure">0.091</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_0aacff4b-e1cb-4189-b234-c765198bc587"
      decimals="-5"
      id="F_63722b30-614d-48ac-b0f8-ceba742641c6"
      unitRef="U_USD">400000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_1d50a9ae-0f26-4ddd-b236-2070a1bd7766"
      decimals="-5"
      id="F_48320fb0-7567-4304-a23a-8e49e88bf4b1"
      unitRef="U_USD">500000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_382677ef-0151-430b-8242-c000796ba331"
      decimals="-5"
      id="F_c896d944-0b5c-4891-a718-81d3a3d6dd3e"
      unitRef="U_USD">1200000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:CarryingValueWroteOffWarrantExercise
      contextRef="C_5f44da0a-72da-4d0d-94ce-34a247a0ea76"
      decimals="-5"
      id="F_87f6e7c4-1039-4220-8643-65c300300748"
      unitRef="U_USD">100000</inva:CarryingValueWroteOffWarrantExercise>
    <inva:ExpectedHoldingPeriod
      contextRef="C_6cf653d2-0adb-45e8-8c5c-d69aedde6497"
      id="F_8d490887-4010-4153-8f84-24dc65a9a300">P2Y</inva:ExpectedHoldingPeriod>
    <inva:RiskFreeInterestRate
      contextRef="C_6cf653d2-0adb-45e8-8c5c-d69aedde6497"
      decimals="3"
      id="F_1739e484-1182-4d2a-bd56-34d52740f3ae"
      unitRef="U_pure">0.049</inva:RiskFreeInterestRate>
    <inva:DividendYield
      contextRef="C_6cf653d2-0adb-45e8-8c5c-d69aedde6497"
      decimals="3"
      id="F_3fc66433-3d93-45b4-ba0e-cda6cbb219c3"
      unitRef="U_pure">0</inva:DividendYield>
    <inva:PercentageOfEstimatedVolatility
      contextRef="C_6cf653d2-0adb-45e8-8c5c-d69aedde6497"
      decimals="3"
      id="F_88c7e093-4890-40b3-a25b-b0bf10ef59f6"
      unitRef="U_pure">1.142</inva:PercentageOfEstimatedVolatility>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment
      contextRef="C_56591878-41f9-499d-94f3-2f81c2c8216a"
      decimals="-5"
      id="F_de43e0d4-8e9b-4a73-8f16-dc8aa8d8d4a1"
      unitRef="U_USD">2900000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_29299cb7-d62e-4e08-9bd3-8a43b64d6f1b"
      decimals="-5"
      id="F_e301970c-a09a-42f1-8ae3-794dae3cce13"
      unitRef="U_USD">4800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_699b00df-194d-4b74-87b8-434384a664eb"
      decimals="-5"
      id="F_8c5f58c3-ec3c-47a6-b6fc-ea79b6d750d6"
      unitRef="U_USD">4800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_4b63e0ee-2b5b-49b5-91dd-4aad8b8b0682"
      decimals="-5"
      id="F_fe2206b0-2e85-4651-9c8f-695ab8d86734"
      unitRef="U_USD">100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_a549f046-b516-43a9-94af-3971494cee27"
      decimals="-5"
      id="F_6b975aab-0f67-4c39-a70a-cf66de134788"
      unitRef="U_USD">100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_af50c412-1762-4092-9219-e0cb77f51b0e"
      decimals="-5"
      id="F_b3a79f79-4634-44e3-9ecc-4ee9264f7636"
      unitRef="U_USD">2700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_3bff7c8d-4fd0-4e48-9974-ccd04b2d1f78"
      decimals="-5"
      id="F_d6c1132a-e826-4568-9013-b40e4ed523c2"
      unitRef="U_USD">2700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_d94e644a-a7b1-4e62-874d-457ce3a49fd3"
      decimals="-5"
      id="F_9f7fe863-0f75-4a69-a35e-401decbcf131"
      unitRef="U_USD">2100000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_d616bb07-0b13-4397-853a-6fd375bf2296"
      decimals="-5"
      id="F_53105968-ea0c-47ae-af9a-981629679753"
      unitRef="U_USD">400000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_5f44da0a-72da-4d0d-94ce-34a247a0ea76"
      decimals="-5"
      id="F_2467bb39-b95b-4637-ac21-abb479d0f2a5"
      unitRef="U_USD">3100000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_e63ec4f7-4b80-482a-8302-9464099a0226"
      decimals="-5"
      id="F_9a1bb59b-e1d6-4290-9314-9943a73fc3d9"
      unitRef="U_USD">7600000</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_e63ec4f7-4b80-482a-8302-9464099a0226"
      decimals="INF"
      id="F_ea4578ed-5511-4365-8d6a-c88ec47e28d8"
      unitRef="U_shares">8825301</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_933e0662-5284-40a5-af01-95acd4469d1e"
      decimals="-5"
      id="F_8c417a43-d717-48e7-a314-49904e951ebd"
      unitRef="U_USD">4800000</inva:SecuritiesPurchaseAgreementAmount>
    <inva:NumberOfBoardOfDirectors
      contextRef="C_ab4cbb1c-525e-4e91-8915-9c00d3a0db21"
      decimals="INF"
      id="F_59e1787c-3074-4a7c-ab6d-5fd00d609e9e"
      unitRef="U_BoardMember">1</inva:NumberOfBoardOfDirectors>
    <inva:NumberOfBoardOfDirectors
      contextRef="C_07023259-2cd5-439e-8af3-725f79e6d197"
      decimals="INF"
      id="F_83e092b8-012f-4015-8fa7-92729118ff44"
      unitRef="U_BoardMember">6</inva:NumberOfBoardOfDirectors>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_6d3c556c-fb3c-4b80-9075-4471ffd20f1e"
      decimals="3"
      id="F_d93a3e2a-9bbc-4c9d-8070-078f8770eefa"
      unitRef="U_pure">0.118</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_d4eb0f40-5fd8-4cae-9d09-795c67481067"
      decimals="3"
      id="F_885be0bb-674b-4716-8664-f9486d250331"
      unitRef="U_pure">0.118</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_768acc31-d49a-4b35-b48a-e542af02b049"
      decimals="INF"
      id="F_4d0f2f2a-a793-40ea-952a-793c2f123caa"
      unitRef="U_shares">270568</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_768acc31-d49a-4b35-b48a-e542af02b049"
      decimals="-5"
      id="F_d1942b8d-fa3a-40c3-8163-e5772e55249b"
      unitRef="U_USD">600000</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_149ef97f-f1b9-4b0e-9127-348ee02e361e"
      decimals="INF"
      id="F_f9ee99a2-b862-4661-93d9-96f757cbc3cd"
      unitRef="U_shares">405852</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_149ef97f-f1b9-4b0e-9127-348ee02e361e"
      decimals="-5"
      id="F_bd69d869-9d52-4a50-878b-7ced1ac62b6e"
      unitRef="U_USD">600000</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_5f2ad567-e08d-4636-8f55-1c301878579d"
      decimals="-5"
      id="F_95939219-5682-4997-9e07-638f5d9432ec"
      unitRef="U_USD">2700000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_5f2ad567-e08d-4636-8f55-1c301878579d"
      decimals="2"
      id="F_03710a5e-8035-4ef2-a2a0-639187115ca8"
      unitRef="U_pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_12d5315c-63c8-4bf3-b585-41fbafc8766c"
      decimals="-5"
      id="F_05139969-d704-4b9c-a40a-cb6ca2f99850"
      unitRef="U_USD">2700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_fe69aeef-ca75-4945-996a-5e2bef7daf59"
      decimals="-5"
      id="F_ee84a6a7-93f9-4f46-8d95-eddfb699c1ad"
      unitRef="U_USD">4800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_89c9f170-6554-4259-8589-a870931960d9"
      decimals="-5"
      id="F_9d2f6185-ff29-4064-8c93-d55f745f5046"
      unitRef="U_USD">1500000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_807e8809-f1a2-4c0a-ac41-7942e7f10fcb"
      decimals="-5"
      id="F_c6918cbc-c300-4ad6-a88d-f0a752f53b90"
      unitRef="U_USD">7600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_7ba50ae3-7184-4972-bf26-f59e81848d23"
      decimals="-5"
      id="F_76ebba59-eb83-4c2c-9db7-4795cb8b25d7"
      unitRef="U_USD">7600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_a13ce0ca-7bd6-470f-b4bc-7bce7c7cce0e"
      decimals="-5"
      id="F_326e6ff7-6c6d-4166-be52-907f15df2c94"
      unitRef="U_USD">4800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_6975b245-2632-4293-87d4-04681539a20a"
      decimals="-5"
      id="F_a67dadbe-4b0b-4a11-9471-acc87498aa7b"
      unitRef="U_USD">5100000</us-gaap:RepaymentsOfDebt>
    <inva:AccruedInterestAndCommitmentFees
      contextRef="C_6975b245-2632-4293-87d4-04681539a20a"
      decimals="-5"
      id="F_119a9619-18ed-4eec-b113-f20728fc8e7c"
      unitRef="U_USD">300000</inva:AccruedInterestAndCommitmentFees>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_36cd9246-caa5-48b0-9537-3ae622ca29e0"
      decimals="-5"
      id="F_252d92e8-99ec-4a6e-b68e-9313208588c3"
      unitRef="U_USD">5000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_b0306b74-2ec2-4940-b3af-88916e13af8d"
      decimals="-5"
      id="F_78ea51ed-aa90-4854-9189-5f5b2770770c"
      unitRef="U_USD">100000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_75c1d9ea-1aaf-4126-af63-8748312d93ac"
      decimals="-5"
      id="F_dd8b6b77-960e-4b69-b4b8-1ac1e940908f"
      unitRef="U_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_f94f64d0-bc96-4573-be4f-370b739bbc44"
      decimals="2"
      id="F_cb2d74c4-240b-464c-b098-7c9859b40123"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <inva:NumberOfCommonStockIssuedDescription
      contextRef="C_31ec6e0a-cd1b-4e7a-af9c-54600d0d24cc"
      id="F_0b2ca0d4-8cd3-4b83-998c-001e480ce201">The number of common stock shares to be issued in a qualified event shall be equal to the amount due on the conversion date divided by the lesser of a capped conversion price (the &#x201c;Capped Conversion Price&#x201d;) and the qualified event price (the &#x201c;Qualified Event Price&#x201d;). The Capped Conversion Price is calculated as $50.0 million divided by the number of shares of common stock outstanding at such time on a fully diluted basis. The Qualified Event Price is the price per share determined by the qualified event. A qualified financing is a sale or series of sales of preferred stock where (i) at least 50 percent of counterparties are not existing shareholders, (ii) net proceeds to Syndeio are at least $35.0 million, and (iii) the stated or implied equity valuation of Syndeio is at least $80.0 million.</inva:NumberOfCommonStockIssuedDescription>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_f94f64d0-bc96-4573-be4f-370b739bbc44"
      decimals="-5"
      id="F_5d0d976a-1aa3-40d4-8103-911c8d870fe2"
      unitRef="U_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_27af781c-37f3-46f9-b219-825ba2161b60"
      decimals="-5"
      id="F_6bda0826-e37f-4a43-94fd-f3fd701a466c"
      unitRef="U_USD">21500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_226618bc-59f6-409f-b441-d4d85c7c9b01"
      decimals="-5"
      id="F_a0c9ff14-21ce-4c90-8c6a-45a66c10d40c"
      unitRef="U_USD">5000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_03780f91-4f1d-4cc3-9ff3-8ab31a4af745"
      decimals="-5"
      id="F_5b0e9d14-8223-4afb-9481-6a0f3cbd2450"
      unitRef="U_USD">21500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_c44315cf-58b6-4df1-a7fb-545a3c2a85c8"
      decimals="-5"
      id="F_7024d0c2-1627-4586-ba66-3e52b8b6ef7e"
      unitRef="U_USD">27700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_89417c7c-4dcb-4c3c-be0a-04a18955e9b3"
      decimals="-5"
      id="F_ee7e200f-07e9-4cb3-b2da-a8978a24c054"
      unitRef="U_USD">5000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_ac9f1546-4eb3-464f-9fd9-e5fcbd5159b6"
      decimals="-5"
      id="F_163a7dab-2021-4475-900b-eec0cccf9d16"
      unitRef="U_USD">27700000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_cffa7db5-8a40-42ec-a6b5-dae4eff5e8a2"
      decimals="-5"
      id="F_fa0b0cad-1629-4407-bc6b-286c3e8062a9"
      unitRef="U_USD">33500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_9ce22bb4-5077-4fc2-a00b-d5ce7b0d778d"
      decimals="-5"
      id="F_5e4b2a09-883f-4649-8155-970460ca907c"
      unitRef="U_USD">5000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_d61eb3bb-dfd5-4977-b307-3cce0652657c"
      decimals="-5"
      id="F_9ddb801d-7dbb-4ca7-a285-98c087a353d5"
      unitRef="U_USD">33500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_7375bdeb-c66c-40d4-84b1-149ba7c7ef18"
      decimals="-5"
      id="F_bfb20a44-ef97-4827-8f19-5e5d126731d5"
      unitRef="U_USD">39800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_6b2a5a0e-88cb-4767-81b9-afb899aec69b"
      decimals="-5"
      id="F_556aeff3-688b-4a0b-9d68-64fbeaafdf67"
      unitRef="U_USD">5000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_8c8a8e9b-18d0-4f56-bd91-01b41b53e196"
      decimals="-5"
      id="F_78014cf1-255d-44e0-ad45-f13b1efbc655"
      unitRef="U_USD">39800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_a632ca34-f6ea-445b-b4f9-b800f457ca17"
      decimals="-5"
      id="F_a555b48b-05b5-4600-90ce-d3a27a3beb49"
      unitRef="U_USD">50600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_fad3e9f3-1f85-4bfc-bf22-a300d00e3a74"
      decimals="-5"
      id="F_0674d5d8-cc6c-47e2-9ab5-8ae8a5cea9c3"
      unitRef="U_USD">10000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_23f06870-8557-49c9-961b-175324f1dcae"
      decimals="-5"
      id="F_02309a1b-d87d-420d-a4ff-b2f5648f2b1c"
      unitRef="U_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_23f06870-8557-49c9-961b-175324f1dcae"
      decimals="2"
      id="F_5a2d03d0-fe80-4596-b211-0721c43cb2b8"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_5e004e9c-f37b-4fd8-92e2-d31164aba4bf"
      id="F_fd82bfaa-b6b9-4be1-bcc6-9abecfb6a598">2026-11-24</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_23f06870-8557-49c9-961b-175324f1dcae"
      decimals="-5"
      id="F_1e3cca5e-c717-43b9-ac85-b8d203241df0"
      unitRef="U_USD">15000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_f609d5f9-7bd6-42d0-b989-6627052c05d9"
      decimals="-5"
      id="F_41a213ad-89fd-4691-a26b-490350bf588f"
      unitRef="U_USD">25800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_39ce9270-cfd2-49c3-a23e-79c0108afb55"
      decimals="-5"
      id="F_86b0ef61-5dca-4c9e-a733-f74224259516"
      unitRef="U_USD">10000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_5e4ede51-f604-4176-b6c8-a3365d117e9b"
      decimals="-5"
      id="F_f115d07a-8930-4460-b0ea-18d4f4da5122"
      unitRef="U_USD">62900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_b44bc8f0-aa9e-48fd-9fb8-b5701d1d6bf9"
      decimals="-5"
      id="F_0da46551-13e2-4ee6-9ad9-8259f3a91121"
      unitRef="U_USD">50900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGain
      contextRef="C_d383d05f-380a-46b9-b425-0ac125742038"
      decimals="-5"
      id="F_fdb273e4-72ab-4c41-9d5d-f7ce37586dbb"
      unitRef="U_USD">12100000</us-gaap:EquitySecuritiesFvNiUnrealizedGain>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_123df293-7632-4793-9257-bcb8b7a3e0d8"
      decimals="-6"
      id="F_67eaf574-e6ec-4f4d-bc22-d4f1530b036c"
      unitRef="U_USD">0</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_257af86c-f735-4442-94a0-70da28449be7"
      decimals="-5"
      id="F_819ddb41-d393-4810-b95d-4ec3b61320d9"
      unitRef="U_USD">400000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_218b6839-f930-461a-a25b-b72c22604510"
      decimals="-5"
      id="F_68475e1e-9113-493a-89fe-70d380d77f48"
      unitRef="U_USD">24500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_cdc0f154-9e15-4dde-bfd0-dcb748170232"
      decimals="-5"
      id="F_7a051bbe-50e5-4e4a-8f96-9b59101ac268"
      unitRef="U_USD">1300000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_a632ca34-f6ea-445b-b4f9-b800f457ca17"
      decimals="-5"
      id="F_80b9cda5-9b5d-410e-9c1a-f19fc6e2f513"
      unitRef="U_USD">50600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_e6747d6c-bd4c-45e0-a2d0-85a45a6f79e0"
      decimals="-5"
      id="F_81c47403-26a4-4eaa-b377-d7a40f96dcc4"
      unitRef="U_USD">60800000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:PaymentsToAcquireLongtermInvestments
      contextRef="C_2a498a39-fd62-4604-9c70-6a29b2842bc1"
      decimals="-5"
      id="F_fbe84417-44a7-4a9a-89a6-a35241e9445b"
      unitRef="U_USD">5000000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_ff591898-83ba-4b78-b062-c4cab6cf47a9"
      decimals="-5"
      id="F_ace24080-874b-4355-9ad8-67f54727781c"
      unitRef="U_USD">9800000</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_ff591898-83ba-4b78-b062-c4cab6cf47a9"
      decimals="INF"
      id="F_0fed9456-6bc6-4ba1-9bee-7be20c3632a8"
      unitRef="U_shares">18750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee
      contextRef="C_da892b74-d5b8-42b1-8209-9456006bda02"
      decimals="INF"
      id="F_bd5358b4-ed2f-4ab9-ba47-b5c64e93713c"
      unitRef="U_Director">0</inva:NumberOfCompanysBoardMembersCurrentlyServingOnBoardOfInvestee>
    <inva:NumberOfBoardMembersOfInvestee
      contextRef="C_da892b74-d5b8-42b1-8209-9456006bda02"
      decimals="INF"
      id="F_e72814ed-8c0c-4ed2-ba32-fe7fda79e8b0"
      unitRef="U_Director">6</inva:NumberOfBoardMembersOfInvestee>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_3fab1ccf-3d72-436d-a37b-efac6941b37d"
      decimals="3"
      id="F_4d83855e-df43-432c-8478-3b666a755754"
      unitRef="U_pure">0.13</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_2c8dee1f-3ed6-47e2-8225-b5df7bf62a8d"
      decimals="3"
      id="F_e934b467-66d2-4652-b4e7-b83e7114b566"
      unitRef="U_pure">0.13</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_da892b74-d5b8-42b1-8209-9456006bda02"
      decimals="-5"
      id="F_52cf8d83-922a-4789-a8a1-4135d15e7e0b"
      unitRef="U_USD">10600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_f270105d-3047-4709-8eb8-f148d9149e12"
      decimals="-5"
      id="F_655b88a0-bf90-4475-b34d-08d8a1e99dcf"
      unitRef="U_USD">10600000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_00b91c9f-9ab7-4b39-b007-fe9dae159be4"
      decimals="-5"
      id="F_49d70de7-b583-495a-9b03-c55a49f85a81"
      unitRef="U_USD">9200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_00b91c9f-9ab7-4b39-b007-fe9dae159be4"
      decimals="2"
      id="F_1d0384fd-8137-4411-8838-b76ab680fb13"
      unitRef="U_pure">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_ff05dc94-b555-4348-9109-aa9b60fb068a"
      id="F_02f58bc3-def7-4937-b321-e4aec56b4210">2025-11-27</us-gaap:DebtInstrumentMaturityDate>
    <inva:DebtInstrumentPercentagePremiumOnPrincipalOnDefault
      contextRef="C_9d514a06-f501-41ad-b742-a81bd23946be"
      decimals="2"
      id="F_51ad0962-7f43-4df6-8d23-c0917e3b9fe2"
      unitRef="U_pure">0.20</inva:DebtInstrumentPercentagePremiumOnPrincipalOnDefault>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="C_9c59249e-0a1f-4f59-9c53-c8fe277b09ca"
      decimals="-5"
      id="F_20577fe1-8a54-49d3-bc4b-ad1e77cf7137"
      unitRef="U_USD">3300000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio
      contextRef="C_bcb70ba8-9c6a-40aa-acaa-7cbf42dfc814"
      decimals="-5"
      id="F_e75d9914-3f2a-4e7c-9e0b-eccae7dfb6e7"
      unitRef="U_USD">5900000</us-gaap:PrincipalAmountOutstandingOfLoansHeldInPortfolio>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_20899f10-0ff4-461b-801a-ba4175ab2431"
      decimals="-5"
      id="F_a21eed53-f9d6-4d6d-9708-cc1a2a5f68a0"
      unitRef="U_USD">3500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiUnrealizedLoss
      contextRef="C_9d514a06-f501-41ad-b742-a81bd23946be"
      decimals="-5"
      id="F_605aef33-a0e3-4d3b-82af-5ebbcbf5459f"
      unitRef="U_USD">2400000</us-gaap:EquitySecuritiesFvNiUnrealizedLoss>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_f4ddf483-cbed-4109-859d-418fd5e83000"
      decimals="INF"
      id="F_ce22ab6c-dcb6-4475-bbd3-edc9e18ac677"
      unitRef="U_shares">1448303</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <inva:SecuritiesPurchaseAgreementAmount
      contextRef="C_f4ddf483-cbed-4109-859d-418fd5e83000"
      decimals="-5"
      id="F_99b46b9f-eafc-4b11-a1b3-f6918481905d"
      unitRef="U_USD">17500000</inva:SecuritiesPurchaseAgreementAmount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_0adbc8ec-6dbe-4222-bbd2-0e0eba4e778c"
      decimals="3"
      id="F_1c71b25c-c372-4787-ac64-61fcbb6c05aa"
      unitRef="U_pure">0.056</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="C_726df857-6023-4423-a3a4-cf7d258b67aa"
      decimals="-5"
      id="F_60e33a6f-7fad-4396-a576-b8b8b9b0498d"
      unitRef="U_USD">17500000</us-gaap:EquitySecuritiesFvNi>
    <inva:ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_cd774e5e-4315-4957-8ab1-046076fda2ba">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table reconciles the change in balances in &#x201c;Equity and Long-Term Investments&#x201d; as of each balance sheet date:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity and long-term investments as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;444,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchases of trading securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reclassification of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,532&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity and long-term investments as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;341,664&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchases of trading securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,729&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Proceeds from trading securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Purchases of equity and other long-term investments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net sales and purchases of investments managed by ISP Fund&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair value, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Reclassification of current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;988&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity and long-term investments as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;404,497&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</inva:ScheduleOfReconciliationOfEquityAndLongTermInvestmentsBalanceTableTextBlock>
    <us-gaap:LongTermInvestments
      contextRef="C_a6f00937-2ee4-4566-bd68-45c44b998d3b"
      decimals="-3"
      id="F_40e292bf-8751-413e-9f09-0f3304f7c00b"
      unitRef="U_USD">444432000</us-gaap:LongTermInvestments>
    <us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_75d1781f-2f99-4c44-99db-3c2712dacb9a"
      unitRef="U_USD">63201000</us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities>
    <inva:GainLossOnOtherInvestments
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_41a7b881-d5b7-4d0f-b939-13c3783b5885"
      unitRef="U_USD">-59161000</inva:GainLossOnOtherInvestments>
    <inva:ReclassificationOfCurrentPortion
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_8651b825-3a8f-4c64-8420-f903e285d5d0"
      unitRef="U_USD">-107532000</inva:ReclassificationOfCurrentPortion>
    <us-gaap:OtherIncome
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_7fcd1e4d-890b-4d1b-8793-4da7daf054f1"
      unitRef="U_USD">724000</us-gaap:OtherIncome>
    <us-gaap:LongTermInvestments
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_28ef20f6-4c3c-4a87-b2b8-5bd6cd35031a"
      unitRef="U_USD">341664000</us-gaap:LongTermInvestments>
    <us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_fd6a7635-ce74-4ef6-98dd-5aba91762b92"
      unitRef="U_USD">61729000</us-gaap:PaymentsForPurchaseOfSecuritiesOperatingActivities>
    <us-gaap:ProceedsFromPaymentsForTradingSecurities
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_f906e999-b79a-4c87-8c92-b1a8b26648e9"
      unitRef="U_USD">8427000</us-gaap:ProceedsFromPaymentsForTradingSecurities>
    <inva:PurchasesOfEquityAndOtherLongTermInvestments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_eb567f8f-ee8c-4093-b16c-59247713f67b"
      unitRef="U_USD">17533000</inva:PurchasesOfEquityAndOtherLongTermInvestments>
    <inva:NetSalesAndPurchasesOfInvestmentsManagedByISPFund
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_50d14c73-6510-4441-97c0-025061836b8b"
      unitRef="U_USD">-120955000</inva:NetSalesAndPurchasesOfInvestmentsManagedByISPFund>
    <inva:GainLossOnOtherInvestments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_ecc7b719-eda0-4988-bd1d-f465e1b40daf"
      unitRef="U_USD">20160000</inva:GainLossOnOtherInvestments>
    <inva:ReclassificationOfCurrentPortion
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_a5ec082c-2cdc-4d1e-94e9-969357dca431"
      unitRef="U_USD">91805000</inva:ReclassificationOfCurrentPortion>
    <us-gaap:OtherIncome
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_a630356a-1ee7-4686-8b56-09f22853eac4"
      unitRef="U_USD">988000</us-gaap:OtherIncome>
    <us-gaap:LongTermInvestments
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_7efd990c-f2ac-4dd9-a89a-d406252af3d3"
      unitRef="U_USD">404497000</us-gaap:LongTermInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_2f5e89bb-826e-40e5-b318-6a211dc77a71">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The estimated fair value of available-for-sale securities is based on quoted market prices for these or similar investments that were based on prices obtained from a commercial pricing service. Available-for-sale securities are summarized below:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.867%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents in the consolidated balance sheets&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.867%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.222000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrealized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Money market funds are included in cash and cash equivalents in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_9ce90413-1653-4365-815b-e666974c1fc7"
      decimals="-3"
      id="F_b904a8ef-a45a-4492-8701-2393c7419d8d"
      unitRef="U_USD">530278000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_9ce90413-1653-4365-815b-e666974c1fc7"
      decimals="-3"
      id="F_9fb85da1-cbc3-41d4-a51d-07fc5150ec6c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_9ce90413-1653-4365-815b-e666974c1fc7"
      decimals="-3"
      id="F_9118e54a-a9f9-49ab-b4bd-5e6b51bfb0c2"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_9ce90413-1653-4365-815b-e666974c1fc7"
      decimals="-3"
      id="F_b8527f5f-0ade-4a50-82cb-a323f0a7eeff"
      unitRef="U_USD">530278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_579d0a3f-fa5b-4187-9a69-d9d562b35dae"
      unitRef="U_USD">530278000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_2077ac35-fe88-4a43-a84f-969a9c99cdc0"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_5f9152b4-6c9c-4e14-b33a-eef7294cab19"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_1db657c6-2160-4ab2-88b2-39cf189dea2c"
      unitRef="U_USD">530278000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f39f8aa8-a20f-4ba5-a3cc-dabb232aa3b7"
      decimals="-3"
      id="F_7e0f8737-3df8-4207-9d21-7b3dde1346c3"
      unitRef="U_USD">289441000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f39f8aa8-a20f-4ba5-a3cc-dabb232aa3b7"
      decimals="-3"
      id="F_fe172cbb-06cd-4ace-980b-f77c69728f3c"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f39f8aa8-a20f-4ba5-a3cc-dabb232aa3b7"
      decimals="-3"
      id="F_e7e2aa43-24df-4446-a31c-e9588f387342"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f39f8aa8-a20f-4ba5-a3cc-dabb232aa3b7"
      decimals="-3"
      id="F_c1a4bfda-d5e2-4288-afe3-91da9698ed2f"
      unitRef="U_USD">289441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_aa9b4387-6009-450c-982f-b4df5299d4ea"
      unitRef="U_USD">289441000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_7c463401-3ed3-46ad-89ec-0ee19e452cff"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_f5e04d02-5a3e-4846-abe4-05e098b47149"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_7811a636-5103-4429-9abb-d9cc0b5c1a96"
      unitRef="U_USD">289441000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_0757825a-49f0-4a62-a20f-d1f1ca0acec4"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_2e83fa3d-a278-46a8-9cf9-8db6a6bb0dd4"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_37f390bc-0ad5-495e-a717-65944cca787d">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our available-for-sale securities and equity and long-term investments are measured at fair value on a recurring basis and our debt is carried at amortized cost basis.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:39.772%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.678%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.678%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.678%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.678%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2025 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Price&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;br/&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;530,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments held by ISP Fund LP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,748&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;157,482&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - InCarda Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata July 2023 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata March 2024 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata March 2025 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata August 2025 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,534&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Armata Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;101,358&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - InCarda 2024 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - InCarda February 2025 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;475&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - InCarda October 2025 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Syndeio 2021 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Syndeio 2025 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Lyndra Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,492&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;764,753&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300,052&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,101,049&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;267,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;267,013&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:40.468%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.402000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.402000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.402000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.48%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.402000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Estimated Fair Value Measurements as of December 31, 2024 Using:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Quoted Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;in Active&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Markets for&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Significant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Identical&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Observable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unobservable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Types of Instruments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;289,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Investments held by ISP Fund LP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;193,560&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;255,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - Armata Common Stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - Armata Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Equity investment - InCarda Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Armata Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata July 2023 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,197&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Term loan investment - Armata March 2024 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - InCarda 2024 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - ImaginAb Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible debt investment - Syndeio 2021 Convertible Note&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;50,881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total assets measured at estimated fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;529,393&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,901&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;229,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;765,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;222,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;251,213&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total fair value of debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;473,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;473,566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_62615169-458a-41ad-b0f4-aecf5d54890a"
      decimals="-3"
      id="F_3385c849-0e0e-48f4-aaf2-49a2a6f4fc2a"
      unitRef="U_USD">530278000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_df8082d5-dcbb-46aa-82da-38d9db7a2979"
      decimals="-3"
      id="F_ba9d7e60-a84b-4e9d-ab64-38f653839f37"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f6ee4728-a9e0-452b-8662-22a92283709d"
      decimals="-3"
      id="F_209a33bc-0b8a-45bb-9feb-de61d2fdbd10"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_647c691b-abd8-4afb-8bcb-ba9c9d68ba72"
      decimals="-3"
      id="F_8a32560a-55a8-454d-9b09-1257f555bb65"
      unitRef="U_USD">530278000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3ada3581-7aa9-4d91-ab9a-3ad5ffab6e1d"
      decimals="-3"
      id="F_854d5c73-7f01-4545-95e8-e2cf9a535941"
      unitRef="U_USD">76993000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fa0155b6-2f2e-4092-af25-363aa5a35539"
      decimals="-3"
      id="F_c85971a2-1083-4862-9188-16ee90c71474"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_70f1d216-d03c-43ba-a8b1-76808b9d2366"
      decimals="-3"
      id="F_685aad3a-8832-4e25-96b6-cf8c3c03554a"
      unitRef="U_USD">2748000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_88e66bcc-24ad-406e-bb93-f1e47d153eb0"
      decimals="-3"
      id="F_70d130c8-c8d0-4215-ab3b-e1349c288725"
      unitRef="U_USD">79741000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_49e868c2-e9b1-41c3-8d56-b409dce02365"
      decimals="-3"
      id="F_efe5fdd9-9a6d-440b-88d2-55e1c4429b67"
      unitRef="U_USD">157482000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2c380213-e903-4976-8194-728662767074"
      decimals="-3"
      id="F_b6c90d78-9e2b-46a6-82ae-4c033587746a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_24bf9896-d71a-45ca-9736-8cff19c13d9f"
      decimals="-3"
      id="F_6d52007e-a9de-4793-9983-8f2ca0c860aa"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_13e41928-9dbd-429d-b2f6-fb0ccfd61a94"
      decimals="-3"
      id="F_c0a9e2cd-3474-4d80-b21c-645949a40b36"
      unitRef="U_USD">157482000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1bf402f1-50ee-4c77-b54f-409f40ba6ea2"
      decimals="-3"
      id="F_c58912d4-0670-464e-9545-6c8f6e296a24"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_133b0bae-f820-43d4-8c70-d35ec0ec6a0f"
      decimals="-3"
      id="F_c54f1b25-6181-4ec2-97c5-5702fa834a43"
      unitRef="U_USD">36244000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7d17d6ba-9603-4070-a7ab-088eeb43a446"
      decimals="-3"
      id="F_23aa11d9-b8b8-4877-a256-1c5083f7c671"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_04f37986-0461-4c18-9d26-c9e485b3a1d5"
      decimals="-3"
      id="F_e11949e6-ce29-42b3-ac62-528809f20ab5"
      unitRef="U_USD">36244000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3e7b3a72-d1b3-43e4-a867-2e38a049c660"
      decimals="-3"
      id="F_e6a3ea3f-1243-42bc-bfd2-0376d29c5ef5"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f96d3f3b-e048-40f2-a04c-39e52cb01dc4"
      decimals="-3"
      id="F_2a128ad2-6d19-4607-949f-f43c5fa1c1ff"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fef5d651-506c-49a8-b89f-8a979f8b0712"
      decimals="-3"
      id="F_4753a701-b63d-4543-a1ad-f285ac18d207"
      unitRef="U_USD">43000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5ec47d1f-c03d-4375-b74a-6537aa407098"
      decimals="-3"
      id="F_94206293-9352-4579-862b-be0f954f954a"
      unitRef="U_USD">43000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_eba3e649-4d0f-4556-81f6-48a349c1b9b7"
      decimals="-3"
      id="F_32cb61c0-a54f-4e9a-a515-e3777a476887"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_151edb34-8ed3-48db-aae7-373a462d2c87"
      decimals="-3"
      id="F_0ef0b0a9-c692-4398-bf4b-a31753f7e849"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_af76bb07-dc3c-4511-8750-d747dbdf4012"
      decimals="-3"
      id="F_17978b09-de37-4346-90ec-7460e94b02a7"
      unitRef="U_USD">32899000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2e76908f-28df-4262-a9d3-0d9661155721"
      decimals="-3"
      id="F_a176a085-dad8-4d38-aa67-3313b57fb863"
      unitRef="U_USD">32899000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c010fb75-cf30-4376-bfd0-a2b399f45c3f"
      decimals="-3"
      id="F_d736cb49-4653-46b1-9b62-9c4898dce009"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_077e2b7e-cd2f-4e0b-80c3-1c50fe7f09df"
      decimals="-3"
      id="F_d3f59b6d-fac1-4025-9411-603052b26f36"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_57a06a6f-d5cd-460f-9bf8-b3b9d0f6d3ca"
      decimals="-3"
      id="F_45fbc447-208b-46a0-ad6d-0c4c2f5c084b"
      unitRef="U_USD">43290000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6e51128a-27f4-498a-bddc-0169559f0163"
      decimals="-3"
      id="F_4d15c624-845a-4574-b5e7-96ae0ed24e8b"
      unitRef="U_USD">43290000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4a9464c6-6ed0-4486-afcb-9d89092af626"
      decimals="-3"
      id="F_c936d40b-b6e3-409c-9013-693a9c964dc7"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_062943f2-bfca-4bcb-a912-8bfca3373967"
      decimals="-3"
      id="F_8c8b5a20-fbfd-4fa2-a576-b20500f68ca7"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_207224f1-5a67-4870-8fb6-e8fa25e508c4"
      decimals="-3"
      id="F_3ba1a8ed-1f96-41ff-bcd0-bd97e20d8a6f"
      unitRef="U_USD">11125000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9c250d42-4b6f-46b7-8b87-dfca0a66338c"
      decimals="-3"
      id="F_833fd626-9e0e-4bff-a3d0-2f224ff6a388"
      unitRef="U_USD">11125000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_324ea22b-17bb-44c8-a2ce-76361d644371"
      decimals="-3"
      id="F_f11a2501-0e6c-451a-be44-00275a9c894c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f112be36-1143-427f-b42f-2840c6a15d3e"
      decimals="-3"
      id="F_0d0eab59-9d7e-4e49-a572-2e11405f5962"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7f44cb79-0c20-42d0-9a50-561aefbd0d23"
      decimals="-3"
      id="F_8c20a5ae-183c-43c4-a03c-1e7fc757836d"
      unitRef="U_USD">15534000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9ba2a047-11ad-4eed-8953-9ae11217e2fb"
      decimals="-3"
      id="F_422adbf4-1243-47c8-b006-5eda373adee4"
      unitRef="U_USD">15534000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_01846029-76af-4077-9228-68d2343d26d6"
      decimals="-3"
      id="F_cf388846-54f4-4d94-a9d6-ee4a0662e4b8"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1c131411-afe9-4c15-b977-6fd724e284dd"
      decimals="-3"
      id="F_e8375d0a-9805-4377-9ae4-49835397cd4c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_10c7d0e1-daac-48c6-9186-bfc925a49e65"
      decimals="-3"
      id="F_a13e671a-c3bd-4c63-a4bd-4ec1afcd4a68"
      unitRef="U_USD">101358000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9064ceea-cc8b-4413-9774-0740e1e4c1bf"
      decimals="-3"
      id="F_cd6fba17-9d58-4982-b506-7d839cd7f785"
      unitRef="U_USD">101358000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f3e35d02-64c1-4f38-892b-bd07f5fe2a4a"
      decimals="-3"
      id="F_909081c8-86cf-4e80-b90a-e11826bb856a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4c9b62cc-926e-4197-953d-72eddcf7b41d"
      decimals="-3"
      id="F_4614d736-dd34-4508-886e-709e43e8006e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_df9c0c3e-3b7d-4a88-ab6a-0a4e4f883405"
      decimals="-3"
      id="F_63498d0e-d9c3-4645-9867-fc8602477d88"
      unitRef="U_USD">436000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7a5124fd-be46-415a-bd57-ce5d37c15986"
      decimals="-3"
      id="F_1c005982-454b-41a1-8e7a-b22c2653c409"
      unitRef="U_USD">436000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_af252bef-3fef-4ac4-af1c-26d65e57e80a"
      decimals="-3"
      id="F_29fe241d-bb70-49e1-b159-478da69c07f0"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c99c2a28-4992-4873-a475-9fde89e0026a"
      decimals="-3"
      id="F_fd2ae677-7c0c-4602-bb86-2579a118ed0e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b996eed8-dfe9-4e4c-91e3-6efd62f73797"
      decimals="-3"
      id="F_b3041495-2bc1-4ef4-b2e0-5e735673dc6b"
      unitRef="U_USD">475000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fc19a322-7a4a-4f36-9e91-32fa80c03ca7"
      decimals="-3"
      id="F_ce750aa1-08d6-4155-aeef-1109da06b25e"
      unitRef="U_USD">475000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3d13bbf9-1c66-4a28-8180-8bf6ce3c7cf1"
      decimals="-3"
      id="F_cdc5c55a-d0c1-43ac-a5c0-7400f5fbefaa"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e6f36795-3f29-431e-b5be-67d9a5b96459"
      decimals="-3"
      id="F_7fe7fba6-5300-4cac-a313-49517fa4dfd3"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_725e5a87-52ac-4ac2-b62f-1bd660bfb6b3"
      decimals="-3"
      id="F_c9055cbe-256b-445a-8f54-e02c884e1e77"
      unitRef="U_USD">1225000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7c5e8ad9-8a6d-4d11-ab0d-a7fdde037e56"
      decimals="-3"
      id="F_4b81f6ba-5f89-4010-be15-91db2b0873af"
      unitRef="U_USD">1225000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b59f5a94-681e-4e5c-b302-d0358109e1fc"
      decimals="-3"
      id="F_6a317afb-a289-416c-8dbd-4208f2cf89ce"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_034d4c49-cf20-473a-895d-63d5870c2084"
      decimals="-3"
      id="F_c03b1e0e-25ef-4d96-8d3b-792903a98ce4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ca9df07c-03f1-4863-b309-11e88116df42"
      decimals="-3"
      id="F_1cb7358f-b12d-479b-bbaf-2dd509356fd9"
      unitRef="U_USD">62937000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_535e864a-6312-4cf7-8e63-b685970f14e7"
      decimals="-3"
      id="F_79c81cfc-0c68-4692-aee3-7f0d689f10ed"
      unitRef="U_USD">62937000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a94d4668-3b04-4736-b7cd-35be25a3ced1"
      decimals="-3"
      id="F_8297cf80-7b8b-447b-8759-3fb6ad192ba3"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_948f1041-1e2d-4225-b512-dbe9786f6151"
      decimals="-3"
      id="F_b31e9123-6376-49c0-a3c8-8571c33a5999"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d1a545a6-5a9b-4ad3-bbfb-5c5207b1a1f9"
      decimals="-3"
      id="F_6f5607d9-c85b-49fb-90d5-830b1390d352"
      unitRef="U_USD">24490000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d84e455d-e7e3-4fbe-a104-3abc49e8a445"
      decimals="-3"
      id="F_c96d4d58-7e46-462a-a74e-c80e4c654edb"
      unitRef="U_USD">24490000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e04b23c0-4934-4a7e-8859-cd38d15f9bd3"
      decimals="-3"
      id="F_6cd40079-d9a1-48b7-bd3b-0d0c0fc28be8"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0a0ea9ec-344f-4309-a3b8-19f6282767a8"
      decimals="-3"
      id="F_18474b6a-d2f8-46c1-89a8-81b40896bc02"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_13f8e3e6-05d2-4d76-8e06-db660bf31271"
      decimals="-3"
      id="F_a30a4351-ff51-477d-bc48-1342f53a7b6c"
      unitRef="U_USD">3492000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_83fb2c06-5584-44c0-9816-0548d07c70bb"
      decimals="-3"
      id="F_c2b0235f-a1ca-433a-8ecb-4df81fd125b2"
      unitRef="U_USD">3492000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d9fc309a-2db6-4a93-97f8-d69062730902"
      decimals="-3"
      id="F_6924f6b7-c4b9-4bc7-980c-90aad54af7d4"
      unitRef="U_USD">764753000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_be450a6d-2206-415e-accd-57ca23a7c915"
      decimals="-3"
      id="F_60e1f6d1-cbc6-491d-9ed5-04a659773c96"
      unitRef="U_USD">36244000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_76beba6f-76b3-4d02-8823-4ee147f6a8e0"
      decimals="-3"
      id="F_5f4b274e-f185-4dce-b742-f58e44b36a01"
      unitRef="U_USD">300052000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fa3ac63f-9ac1-406d-b258-7e778b64bfce"
      decimals="-3"
      id="F_92928db8-b1fb-4125-a62b-dbb19f3a4ca5"
      unitRef="U_USD">1101049000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_c66f1b13-03bc-4b24-a6a3-cd400090f9ef"
      decimals="-3"
      id="F_fddd53ee-ab09-43bb-82e9-ce1d32020e02"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_abebdb2e-7b66-4a80-a391-a715e9a19b73"
      decimals="-3"
      id="F_f60c3796-bea8-4445-985e-a97ec89f447e"
      unitRef="U_USD">267013000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_f4ab2bfd-74a0-46cc-b06e-1c474c19a909"
      decimals="-3"
      id="F_0395d39a-91bf-4696-8eba-45a41e6cbd64"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_1006311f-1cec-494d-8c58-386104bc8113"
      decimals="-3"
      id="F_d07c4497-d553-4c26-9242-814d496a2164"
      unitRef="U_USD">267013000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_874e94af-935a-439b-ab00-df1390a5e34b"
      decimals="-3"
      id="F_19efe3fc-5064-4ba5-8f48-1360cd40afba"
      unitRef="U_USD">289441000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4d8ac49a-79f0-4d4e-96ea-3e8f524a2c51"
      decimals="-3"
      id="F_ce4cfce5-55af-4135-b112-e1983893bb4e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_58579f73-59ce-4061-ba55-4d11270a76d1"
      decimals="-3"
      id="F_81ec6b14-e9af-470c-b451-ceebdda3f29b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f2435011-c3ca-4e3e-a7fb-09a9fb137c33"
      decimals="-3"
      id="F_467d8066-26e4-4971-8be0-f3a6be3b626b"
      unitRef="U_USD">289441000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_04c59b2e-4232-4562-8d3a-6d189af3be61"
      decimals="-3"
      id="F_78c61fe2-ce4d-488c-9696-1c7788273c08"
      unitRef="U_USD">193560000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b2a12880-40dd-4a30-8ea9-b9ba0ea9cc66"
      decimals="-3"
      id="F_74972aa7-9db7-4fe4-b2fe-c2ede31b901b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_186b003f-7e82-489a-af51-10f17f0c7193"
      decimals="-3"
      id="F_76b841fb-d0ff-4bb4-88a4-a68db0a1c672"
      unitRef="U_USD">62098000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5a6dce6c-043b-44f3-bc89-efae60e40aff"
      decimals="-3"
      id="F_1ee6234d-dce6-4737-829f-20048ef5f29a"
      unitRef="U_USD">255658000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d9f02cfa-bf5e-4cd1-b720-fcc2c4210f0b"
      decimals="-3"
      id="F_7ed08e95-1f1f-440c-a18e-d05df3f9b9f5"
      unitRef="U_USD">46392000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_cb2b5dab-8579-446e-acf0-02b095195b73"
      decimals="-3"
      id="F_48fa713d-08a0-4dea-967d-43225d7125e6"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1c0b66f1-46ef-4338-a79e-85c6fc2d1f95"
      decimals="-3"
      id="F_ce39dcf7-e01f-43dd-9bfc-4a55be9a2b37"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_920caa91-234c-4ad4-9f03-0cc64046f9bf"
      decimals="-3"
      id="F_c90d2e95-fc96-431b-b0d9-9693a5fc92d6"
      unitRef="U_USD">46392000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_80b69809-f556-4828-a636-e7d70a0f4529"
      decimals="-3"
      id="F_0e1c5a67-4b4e-4b9e-8768-77d07f0d5745"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_41a7f5f8-871b-473c-8a7c-344fe2fe6e67"
      decimals="-3"
      id="F_f0d3156d-1f19-4530-b0ef-a540cb653eef"
      unitRef="U_USD">5901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_edc82119-8135-4036-9cd5-7abc8eaec84c"
      decimals="-3"
      id="F_ec0f8b73-d6f5-4933-ac77-52fd4d2863b4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9ce67c09-bbaa-4af5-9443-47f86c908063"
      decimals="-3"
      id="F_b148f9a0-3623-4e17-82ac-d0a0d1356588"
      unitRef="U_USD">5901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b25d8758-99b0-4893-a9e8-7d66f0af9020"
      decimals="-3"
      id="F_e76980d0-76b7-46b6-8a99-cc154975b57d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d68a48b8-3d2b-4af8-8344-60a112a209cf"
      decimals="-3"
      id="F_134757c3-8e01-46b0-a4ef-6f66e962cdd0"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c6c8e559-7887-449a-bda4-21ea384a9d5d"
      decimals="-3"
      id="F_e1bac985-3f87-49e7-8111-78b2f048f677"
      unitRef="U_USD">59000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_4a06a460-8b26-42e1-8a9d-000242e512f8"
      decimals="-3"
      id="F_8e1151ec-470b-407e-a8c2-77809c0547d4"
      unitRef="U_USD">59000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8e78c83c-a602-4c9e-a0ca-fd8929e943fd"
      decimals="-3"
      id="F_6912d824-772a-4f68-8b0a-ab7a06786a7e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_df4709cb-5656-4808-aaeb-b3ae91bc5fa4"
      decimals="-3"
      id="F_a830ba07-72df-4bc2-a671-560f980b315d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b4c7d24e-1946-466d-b882-1f82aca2913e"
      decimals="-3"
      id="F_df1a7419-35eb-4e59-a705-01702846dd78"
      unitRef="U_USD">42095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_98398386-f407-4e2e-a939-d8ab60856a68"
      decimals="-3"
      id="F_aa914f92-9deb-42b2-91fc-de5938eb8933"
      unitRef="U_USD">42095000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e82b4635-6ed4-4056-a68e-3a47f6f2bf52"
      decimals="-3"
      id="F_3ac1554a-bcbb-4b90-ad8f-e0d81e8e8e78"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b3f2abfb-4337-4fab-9c5b-7e5c28bbffed"
      decimals="-3"
      id="F_90c264b0-151e-40b4-baf1-f18b96933210"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5b273474-f0c1-4173-8aa0-26b3ab51f2c6"
      decimals="-3"
      id="F_131b6cf9-d35d-44ff-8b63-2236450225da"
      unitRef="U_USD">30197000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b4d781bc-915c-4c41-9106-511763a665d8"
      decimals="-3"
      id="F_72d5f8b3-1691-489d-afdd-c52cc0558656"
      unitRef="U_USD">30197000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_bf257858-aaa7-4585-83a4-5200623ef35c"
      decimals="-3"
      id="F_6bf19212-52aa-489c-bd57-6024cf61ccb9"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d5482eb7-e694-4625-b420-b8cb85d4fcf2"
      decimals="-3"
      id="F_e695b5ac-d17b-4afb-97aa-0fa49e038af2"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9dfa9bcd-fbe2-4b00-b6d2-00a31a357835"
      decimals="-3"
      id="F_0fc8ccb6-74ea-4932-ab87-cf409d286ddf"
      unitRef="U_USD">39275000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_019d5edd-4fa8-40e3-80df-2efde6dc1a3e"
      decimals="-3"
      id="F_6071f9db-47f6-4142-af6b-7da9f7265259"
      unitRef="U_USD">39275000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9c1f6269-1e70-48f2-b51f-c346e1e9651e"
      decimals="-3"
      id="F_9ccab1b1-9e09-4cb6-9246-a1396af324fd"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6eab99bf-0d7f-4d97-8fbf-07f56573bf4d"
      decimals="-3"
      id="F_b5c1c9dc-e6f6-4c7b-bc99-4a249b70b8a9"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_91adb269-1218-4185-8ed5-66c8ab8bbcdb"
      decimals="-3"
      id="F_b497b768-5600-490b-90b0-db012b4de052"
      unitRef="U_USD">436000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_e1ad7b2e-47ad-4939-9a26-e2ea2a39b2c6"
      decimals="-3"
      id="F_576141b2-d303-496e-b66c-f8969b6a493d"
      unitRef="U_USD">436000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_c7ab2f82-2276-40f6-9084-327d9a8463bf"
      decimals="-3"
      id="F_bf6fca22-7e1e-4d33-9b57-63cdbf955b80"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f35060c4-ee1e-4ad2-ba59-f9405ab750db"
      decimals="-3"
      id="F_da8dee64-e9b9-4d15-b434-f4fd9039474c"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_354e4e76-7396-4ce2-83c0-4f6d52adcbf7"
      decimals="-3"
      id="F_d42780db-7120-4a65-b14f-c12045dada37"
      unitRef="U_USD">4950000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f95dc6c1-8efa-49b3-a724-7a4ea46f1fbc"
      decimals="-3"
      id="F_ba8a67a9-1065-437e-9ad5-262be17b5b6c"
      unitRef="U_USD">4950000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f9ab7abf-030e-4411-a666-c1a654015dea"
      decimals="-3"
      id="F_653c732e-4d09-4e54-a6d6-831b299bf58e"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_382fda11-b7da-4cb9-a380-3dfa11099b27"
      decimals="-3"
      id="F_41f2f8fa-5c1b-41e5-bd89-5351470b422b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_27718624-7715-45b9-a713-59141c2cdf0f"
      decimals="-3"
      id="F_98d16eaa-9414-479e-9e43-dff4be1e125f"
      unitRef="U_USD">50881000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3429ea6d-1cb3-4c6e-8042-4861d0863d2f"
      decimals="-3"
      id="F_76283d83-93b7-4f72-8c83-e908f37fa28d"
      unitRef="U_USD">50881000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d5e9003f-7e55-4b05-bab9-c11fa367b435"
      decimals="-3"
      id="F_04851793-707d-4e81-b70e-794d659d23bb"
      unitRef="U_USD">529393000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_f9011696-e416-424e-81a2-652447e4d8f0"
      decimals="-3"
      id="F_9974db22-e22a-482e-a51d-d6bcc950ffb8"
      unitRef="U_USD">5901000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_87678ce3-d91f-42c7-8014-482b4e96c0b6"
      decimals="-3"
      id="F_8e16c2ab-05ae-40c7-acce-38e11d1f2415"
      unitRef="U_USD">229991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0f301d28-22f6-430f-bd52-f18b4ca91181"
      decimals="-3"
      id="F_4487f626-08d5-4a4b-8ca9-65ad5470be25"
      unitRef="U_USD">765285000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_4960e33b-4020-48cb-aad3-a6b5f4fac807"
      decimals="-3"
      id="F_89d301bf-3f72-43f6-b9e9-003d327bb567"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_7b057564-e9a8-48fe-95f4-7b1c776ce39d"
      decimals="-3"
      id="F_c06e74e1-0fc3-4e63-ab85-62c69dd1b627"
      unitRef="U_USD">222353000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_c9dd44c1-e335-4444-826a-cca2d606205b"
      decimals="-3"
      id="F_c10df1cb-8c34-4177-9103-16c0d69222b4"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_3b886698-cb56-435a-ba7f-fa72f4cd20b9"
      decimals="-3"
      id="F_a96d51cb-c30a-42dc-9d7c-ef36b34548e2"
      unitRef="U_USD">222353000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_10e3877c-4d15-43d4-acb6-50c1c5281ab9"
      decimals="-3"
      id="F_98bf1499-fbe9-491d-a81c-2dbf099e09d8"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_edef9231-0188-4d5f-a4e7-cf5bc1070d0b"
      decimals="-3"
      id="F_167d3406-06d7-4744-9849-9604239efced"
      unitRef="U_USD">251213000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_8baf7a29-4878-46db-844e-4be322782050"
      decimals="-3"
      id="F_d22a06c1-7be8-47f9-a4d5-678095c072c7"
      unitRef="U_USD">0</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="C_dd617a60-08f2-42eb-9dd4-dfab3845fa6f"
      decimals="-3"
      id="F_8e357086-0c0a-4155-9bb9-bb8b7a32a972"
      unitRef="U_USD">251213000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_39ac42ec-d15a-4d4a-8811-92be23f2bc67"
      decimals="-3"
      id="F_b4c43cab-86fa-4d7e-85ed-6a47edd3859a"
      unitRef="U_USD">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_0d289cc8-a708-4fdd-8986-e982ca8d731d"
      decimals="-3"
      id="F_0098ca04-f1c5-4f5e-8765-5a47596dfcca"
      unitRef="U_USD">473566000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_55bf4b19-2b2e-4acc-9932-1d7bd7182c58"
      decimals="-3"
      id="F_b07d18f0-f895-4531-8ca0-ec45f7c0973e"
      unitRef="U_USD">0</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="C_81f83795-0714-4c71-99b4-f4a03319bbcf"
      decimals="-3"
      id="F_5c7caaf4-5c3a-4912-ac68-aeee76ff49dd"
      unitRef="U_USD">473566000</us-gaap:DebtInstrumentFairValue>
    <inva:FairValueOfAssetsOrLiabilitiesTransferBetweenLevels
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="INF"
      id="F_504f5e78-1164-474d-8fef-c81dfd51af2c"
      unitRef="U_USD">0</inva:FairValueOfAssetsOrLiabilitiesTransferBetweenLevels>
    <inva:FairValueOfAssetsOrLiabilitiesTransferBetweenLevels
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="INF"
      id="F_413dfdef-d7f7-4da6-b191-33bccfaa74fc"
      unitRef="U_USD">0</inva:FairValueOfAssetsOrLiabilitiesTransferBetweenLevels>
    <inva:CapitalizedFeesPaidDisclosureTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_44838ae3-e65b-462a-b753-df241229ffb1">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7. CAPITALIZED FEES PAID&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.749%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortization period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2013-2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Europe&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Japan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These milestone fees are amortized over their estimated useful lives commencing upon the commercial launch of the product in their respective regions with the amortization recorded as a reduction in revenue from collaborative arrangements. As of December 31, 2025, the weighted average remaining amortization perio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;d was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; y&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;ears.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Additional information regarding these milestone fees is included in Note 3, &#x201c;Revenue Recognition&#x201d;. Amortization for each of the years ended December 31, 2025, 2024 and 2023 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The remaining estimated amortization is $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for each of the years 2026 and 2027, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year 2028, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year 2029 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the year 2030.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</inva:CapitalizedFeesPaidDisclosureTextBlock>
    <us-gaap:CapitalizedContractCostTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_ba72ce08-8b98-41e2-a106-ad27b6eb974f">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Capitalized fees paid, which consist of registrational and launch-related milestone fees paid to GSK, were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.749%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortization period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;United States&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2013-2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;120,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Europe&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Japan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2013-2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Gross carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;220,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accumulated amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;163,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,039&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net carrying value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;56,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:CapitalizedContractCostTableTextBlock>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_cd026123-bf98-4ceb-963d-51e954864642"
      decimals="-3"
      id="F_95e341dd-7bfb-4870-bf2b-669b1d8ce094"
      unitRef="U_USD">120000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_89cd5c2d-43bc-4a05-9084-5d42b8515c2a"
      decimals="-3"
      id="F_a0617387-b1b4-4de6-b0da-477a9d8c3bca"
      unitRef="U_USD">120000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_be14d1aa-9ffc-4de3-b4ae-142c0c538bae"
      decimals="-3"
      id="F_aed12c6a-d60a-432e-a379-76ccb5ffcb61"
      unitRef="U_USD">60000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_c301f3b4-0e6f-4ec9-97f7-2af4d7bc4e41"
      decimals="-3"
      id="F_5669f72b-d352-4ec7-a91a-f152b4b6c5d7"
      unitRef="U_USD">60000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_298833d0-f7cb-4ad7-b8ba-9b8369ac087f"
      decimals="-3"
      id="F_91601a06-e544-4a0c-a69f-0bc3006ecd6a"
      unitRef="U_USD">40000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_0df4c929-c558-43df-b2be-57f8e85bb27a"
      decimals="-3"
      id="F_bfe41d78-d05c-4e06-a953-59c3b96abf19"
      unitRef="U_USD">40000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_c08689e5-8e73-4bec-a6a7-a9a41245e752"
      unitRef="U_USD">220000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_62a55d4d-3eab-4dcb-9692-4514419693b7"
      unitRef="U_USD">220000000</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostAccumulatedAmortization
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_7a8f346c-ae45-49cb-bceb-5bd6e987668a"
      unitRef="U_USD">163862000</us-gaap:CapitalizedContractCostAccumulatedAmortization>
    <us-gaap:CapitalizedContractCostAccumulatedAmortization
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_8b876b20-f656-4c9a-bd56-9782b4ed7e59"
      unitRef="U_USD">150039000</us-gaap:CapitalizedContractCostAccumulatedAmortization>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_4efbb3a6-c0c8-48a7-8790-b14ffd4f420f"
      unitRef="U_USD">56138000</us-gaap:CapitalizedContractCostNet>
    <us-gaap:CapitalizedContractCostNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_d66490f7-8bda-4230-9400-df583ce2ada5"
      unitRef="U_USD">69961000</us-gaap:CapitalizedContractCostNet>
    <inva:CapitalizedFeesPaidWeightedAverageUsefulLife
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_bb93a92b-6c12-4812-b76b-59fc9094a264">P4Y2M12D</inva:CapitalizedFeesPaidWeightedAverageUsefulLife>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_486828c2-55c2-4eca-a8e9-7c9edc91e774"
      decimals="-5"
      id="F_ad3e61d9-22f7-4805-8095-df701f792579"
      unitRef="U_USD">13800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_8c3d0ea3-a6a0-43b3-ad32-fa7162ce8c28"
      decimals="-5"
      id="F_90d8775b-7892-4dd6-977f-22c43af3dace"
      unitRef="U_USD">13800000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="C_02167381-4ee7-420f-9702-aa51b2304727"
      decimals="-5"
      id="F_94e7648f-d1fe-475f-b415-e0eb66b0fd71"
      unitRef="U_USD">13800000</us-gaap:CapitalizedContractCostAmortization>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_bce541df-568e-4eca-b538-b8d278de7e73"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationNextTwelveMonths>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_a0755e13-9157-48a4-ada0-4cb89f2886c7"
      unitRef="U_USD">13800000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearTwo>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_30dcad74-1282-4d9c-bd4f-8bc59d64e863"
      unitRef="U_USD">13700000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearthree>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_fef21174-e954-4355-a304-b7b8eabab2db"
      unitRef="U_USD">9400000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFour>
    <inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_f719e638-3b17-4e28-ad6a-0af9ca4005e9"
      unitRef="U_USD">5400000</inva:CapitalizedFeesPaidRemainingEstimatedAmortizationYearFive>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_7d6a4308-a54e-4fe9-94c2-e65ffb173aad">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8. GOODWILL AND INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Goodwill and intangible assets acquired are recognized at fair value as of the acquisition date. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognized goodwill of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million from our acquisitions of Entasis and La Jolla, respectively, in 2022. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying amount of goodwill as of December 31, 2025 and 2024 was &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. We have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t recognized any impairment losses related to goodwill and intangible assets during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets with definite lives are amortized over their estimated useful lives. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying basis and accumulated amortization of recognized intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 were as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net Carrying&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketed products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;226,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="12" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net Carrying&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketed products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets recognized as a result of the acquisition of Entasis amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;106.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which consisted of Entasis&#x2019; in-process research and development related to its antibacterial therapeutic product candidates and a collaboration agreement amounting to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;71.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. Following the FDA approval of XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in May 2023, we started amortizing $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the then in-process research and development as a marketed product, as well as the collaboration agreement, over their estimated useful lives. Following the FDA approval of NUZOLVENCE&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (formerly &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;zoliflodacin) in December 2025, we started amortizing $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the then in-process research and development as a marketed product over its estimated useful life.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Intangible assets recognized as a result of the acquisition of La Jolla amounting to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;151.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million pertain to product rights and developed technologies on La Jolla&#x2019;s marketed products. These are intangible assets with determinable lives and are amortized over their estimated useful lives.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As discussed in Note 4 &#x201c;License and Collaboration Arrangements&#x201d;, we capitalized the upfront fee of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million that we paid to Basilea &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for the exclusive commercialization right of ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the U.S. under our exclusive distribution and license agreement as an intangible asset. This amount is included in marketed products in the table above and is being amortized over the term of the agreement.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We recognized amortization expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years ended December 31, 2025, 2024 and 2023, respectively. Future amortization expense is expected to be $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for each of the years from 2026 to 2030 and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million thereafter.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill
      contextRef="C_967bf8ab-5e86-4683-ac2b-d23837fdf808"
      decimals="-5"
      id="F_9c313ae4-ca1c-4c28-9af3-4b803bdfb63c"
      unitRef="U_USD">11500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_7e124fea-d3ce-4c96-a71c-c223da3547f2"
      decimals="-5"
      id="F_fc16915a-b196-4628-bbc4-dba4d82ae4bb"
      unitRef="U_USD">6400000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_3ac88cb9-f9ba-4187-af17-73531171569a"
      unitRef="U_USD">17900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-5"
      id="F_d1df9ce0-9052-4436-bf52-eb30c0928f0b"
      unitRef="U_USD">17900000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="INF"
      id="F_5e1982a1-eafe-4045-9519-20a663cd5844"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="INF"
      id="F_7945f361-cdd0-468f-9b54-c68ff6227156"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_12d3dc73-37db-410b-aa12-1bf235409905">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The carrying basis and accumulated amortization of recognized intangible assets as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 and 2024 were as follows:&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="12" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net Carrying&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketed products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;226,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;70,299&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,001&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,155&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;79,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;182,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:36.86%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:14.24%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.22%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="12" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Useful Life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Accumulated&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Net Carrying&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Marketed products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;223,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;47,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Collaboration agreement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,708&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,692&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,267&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;208,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_4cc8caa7-35e9-4140-a986-58a3062ca160"
      id="F_4e60471c-a6a4-4d6d-85d7-e42c02d0c63c">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_9e87c016-5304-4333-83a4-195cc836505e"
      id="F_6b206486-2d9d-471b-9b6e-3a46f95fa28f">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <inva:IntangibleAssetsMarketedProductsGross
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_02d23618-2cb9-471b-8b78-9bc39e3eec40"
      unitRef="U_USD">226300000</inva:IntangibleAssetsMarketedProductsGross>
    <inva:IntangibleAssetsMarketedProductsAccumulatedAmortization
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_f7f1e0af-b8f3-46f1-be30-c13719e37951"
      unitRef="U_USD">70299000</inva:IntangibleAssetsMarketedProductsAccumulatedAmortization>
    <inva:IntangibleAssetsMarketedProductsNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_eb71fc8b-fafe-4ea8-ae14-e17b72634d28"
      unitRef="U_USD">156001000</inva:IntangibleAssetsMarketedProductsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_eb066d70-0444-4376-99ff-812e92abf2af"
      id="F_832a74ac-1922-4023-bce7-a14bdbbef3e6">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <inva:IntangibleAssetsCollaborationAgreementGross
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_3a433aa4-680a-44fe-bcce-a671930fef52"
      unitRef="U_USD">35400000</inva:IntangibleAssetsCollaborationAgreementGross>
    <inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_a0ee6594-8afc-4889-b7c1-d97a8ec25ced"
      unitRef="U_USD">9245000</inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization>
    <inva:IntangibleAssetsCollaborationAgreementNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_0e1aaea7-b609-4844-9d72-10f93ef7627f"
      unitRef="U_USD">26155000</inva:IntangibleAssetsCollaborationAgreementNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_4e71149c-36f4-474b-8381-c9d58e39e295"
      unitRef="U_USD">261700000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_89e00000-0662-4a19-8c6b-4b1fcb727ef9"
      unitRef="U_USD">79544000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_f4af87aa-d948-42f2-a6d9-23214bf3a47d"
      unitRef="U_USD">182156000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_469524bb-7a40-45d6-add1-6f69d2db9a3e"
      id="F_8d652d9e-1bba-4dba-9744-5720a8568096">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_37077e55-6b0c-4d75-94c1-1392a17c7ed1"
      id="F_7cfed12a-b71e-443c-8b3d-b82c624abce2">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <inva:IntangibleAssetsMarketedProductsGross
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_48b1f2f6-12b5-4d16-b382-482288eb1a53"
      unitRef="U_USD">223700000</inva:IntangibleAssetsMarketedProductsGross>
    <inva:IntangibleAssetsMarketedProductsAccumulatedAmortization
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_697d16c3-1ded-4a54-8502-43d68b365dcf"
      unitRef="U_USD">47559000</inva:IntangibleAssetsMarketedProductsAccumulatedAmortization>
    <inva:IntangibleAssetsMarketedProductsNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_65f7bdbb-341e-417d-bc32-afea58f889cb"
      unitRef="U_USD">176141000</inva:IntangibleAssetsMarketedProductsNet>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentGross
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_07b21d2f-500a-4f50-bd26-038155a87b69"
      unitRef="U_USD">2600000</inva:IntangibleAssetsInProcessResearchAndDevelopmentGross>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_13d4ce30-b7fc-4507-9333-a12d4b893114"
      unitRef="U_USD">0</inva:IntangibleAssetsInProcessResearchAndDevelopmentAccumulatedAmortization>
    <inva:IntangibleAssetsInProcessResearchAndDevelopmentNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_4870ef58-cf74-4fc0-9b3d-ecdcdf2550c4"
      unitRef="U_USD">2600000</inva:IntangibleAssetsInProcessResearchAndDevelopmentNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_7359dc8f-bf3a-4063-889d-7a710c70a4de"
      id="F_0e4c6c69-8326-41c3-b330-8292eb49eb85">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <inva:IntangibleAssetsCollaborationAgreementGross
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_98f3a623-14fa-4882-b29d-7b253e70b4a2"
      unitRef="U_USD">35400000</inva:IntangibleAssetsCollaborationAgreementGross>
    <inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_1fc683bd-15e4-40f4-a947-b679f25ff303"
      unitRef="U_USD">5708000</inva:IntangibleAssetsCollaborationAgreementAccumulatedAmortization>
    <inva:IntangibleAssetsCollaborationAgreementNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_3f6a4cea-fba8-4b32-95fc-f90298fdbd44"
      unitRef="U_USD">29692000</inva:IntangibleAssetsCollaborationAgreementNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_e1842942-a677-4fa3-968e-86ef98c1a9e1"
      unitRef="U_USD">261700000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_5c67a854-d68b-4ca8-b738-8ba790a1e14c"
      unitRef="U_USD">53267000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_e5ad5eb3-c2b4-429c-85a1-36ceead11f49"
      unitRef="U_USD">208433000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_f9cd9435-3b1a-4e9d-ac1b-86dd50e61463"
      decimals="-5"
      id="F_0709cde3-1abf-4b5a-872c-c1a7cf8807fe"
      unitRef="U_USD">106700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_1178105a-9678-4a5d-807b-d01114fd7f0f"
      decimals="-5"
      id="F_6ff6d222-2be6-4718-847e-e04d37957f43"
      unitRef="U_USD">71300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_65e0e8e3-95a0-4c30-a38e-3f2f6d7a9494"
      decimals="-5"
      id="F_dbcb0668-8c8d-435d-b373-9d5471a3226d"
      unitRef="U_USD">35400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_cd1ae492-3baa-4fd2-89f9-afa8f30347b3"
      decimals="-5"
      id="F_99ee53b3-25db-414c-95df-f1fb497af612"
      unitRef="U_USD">68700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue
      contextRef="C_3d42c24b-11b8-4363-8d74-c335ae153268"
      decimals="-5"
      id="F_b4be0731-3ffe-4920-a9f4-c2a9850416ff"
      unitRef="U_USD">2600000</us-gaap:AcquiredFiniteLivedIntangibleAssetResidualValue>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets
      contextRef="C_624b9c2f-920f-4d24-9aec-1525f5843027"
      decimals="-5"
      id="F_cc7dd3c8-16fc-4215-92d7-15b15ee0faa6"
      unitRef="U_USD">151000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <inva:UpfrontFee
      contextRef="C_c76fc58c-a666-4494-993c-5441e34ded35"
      decimals="-5"
      id="F_27081c65-53c5-4c65-b7d7-d7dacb1003bd"
      unitRef="U_USD">4000000</inva:UpfrontFee>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-5"
      id="F_8e487f20-a4d2-49b9-8fba-35eaea0e929c"
      unitRef="U_USD">26300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-5"
      id="F_dbb1f632-f7e6-449b-8790-e313dff81adc"
      unitRef="U_USD">25900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-5"
      id="F_48ff2f17-430b-4160-85b1-d0ecb18d2442"
      unitRef="U_USD">21800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_bd56f22f-9aa7-4354-ac91-832a54924399"
      unitRef="U_USD">26600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_acbb6081-fba8-448c-b8bb-a3583bd33a11"
      unitRef="U_USD">26600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_ca260027-6ae2-450f-bf72-096cc59373b2"
      unitRef="U_USD">26600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_e4499451-7ad1-4477-aaa0-a644a6a5ebae"
      unitRef="U_USD">26600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_6ca8b2d3-0546-40d1-9ef6-4ed2d26ff1c6"
      unitRef="U_USD">26600000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_ec5eccfe-63fa-4e6d-806d-aae603bbd3ac"
      unitRef="U_USD">49200000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_14c62ab4-c6f1-47cc-8c0a-46f65124c613">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9. BALANCE SHEET COMPONENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and 2024, total inventory included net fair value adjustments resulting from the acquisition of La Jolla of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which will be amortized and recognized as cost of products sold when sales occur in future periods. The fair value adjustments recorded as part of cost of products sold amounted to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;27.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million for the years ended December 31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Accrued Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued contract manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical and research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_6a206859-f8ee-400b-9d66-43ec2846665f;"&gt;&lt;span style="-sec-ix-hidden:F_17be60db-4ed3-4806-a6df-7a78528c373a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty obligation payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued license fees and royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amount as of December 31, 2024 includes $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;advance payments received from our partner for inventory supply as discussed in Note 4, &#x201c;License and Collaboration Arrangements&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Long-Term Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other long-term liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_e88a4c0d-7875-4370-83b2-18dc892d7674;"&gt;&lt;span style="-sec-ix-hidden:F_4bc47aec-cd74-43b5-88dc-6e2c9250c57b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_5e4c26cc-e8ea-455a-aa06-af0f12b42e55">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Inventory consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Raw materials&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Work-in-process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Finished goods&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,971&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total inventory&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33,725&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_2832720d-a2d5-407c-8c2c-e3681e0155aa"
      unitRef="U_USD">16330000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_c046cf95-39da-4c31-843e-cc74d92457b4"
      unitRef="U_USD">11113000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_e4e1eb1b-e072-47fa-b5c0-ae70de9439ae"
      unitRef="U_USD">17871000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_2f373b60-676d-47bd-9ed2-083f3d0c6cee"
      unitRef="U_USD">20529000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_4e8cdfdd-f1c7-4cf0-ad4e-c21949cd3b2b"
      unitRef="U_USD">4971000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_cb223db6-315e-4391-802b-66d34ee69e01"
      unitRef="U_USD">2083000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_583620e2-0aa7-4dba-ac64-5e2d9428dab3"
      unitRef="U_USD">39172000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_934f3582-ce2b-472e-813f-93792a76e578"
      unitRef="U_USD">33725000</us-gaap:InventoryNet>
    <inva:FairValueAdjustmentsOfInventoryFromAcquistion
      contextRef="C_099aecd1-7b7a-4a20-9f80-16d10bb47ae5"
      decimals="-5"
      id="F_ce4a14cc-eedd-4a94-8f9d-582873f55d12"
      unitRef="U_USD">3400000</inva:FairValueAdjustmentsOfInventoryFromAcquistion>
    <inva:FairValueAdjustmentsOfInventoryFromAcquistion
      contextRef="C_701cd6fe-36d1-47db-83fe-0af44777997c"
      decimals="-5"
      id="F_0fe040f2-e358-4c33-afc8-a42e2158b422"
      unitRef="U_USD">9200000</inva:FairValueAdjustmentsOfInventoryFromAcquistion>
    <inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold
      contextRef="C_fa06863c-352c-41d4-8c55-7aa19e82ca77"
      decimals="-5"
      id="F_906c3220-84b2-4dd9-aa44-592d6e734c4b"
      unitRef="U_USD">4800000</inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold>
    <inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold
      contextRef="C_65d91678-0767-41c7-b95e-8b5037c60129"
      decimals="-5"
      id="F_22fa091e-c3b6-4447-8b82-49b4f84f2be3"
      unitRef="U_USD">13800000</inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold>
    <inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold
      contextRef="C_4d8365a9-4d70-40de-b8a9-6b5b33f255fb"
      decimals="-5"
      id="F_8f6d2bce-ab3a-4ec8-86f5-1297a7708d8b"
      unitRef="U_USD">27200000</inva:AmortizationOfFairValueAdjustmentsOfCostOfProductsSold>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_c3c373ad-2809-4a9e-bcfa-db999123a047">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other accrued liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued contract manufacturing costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,220&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued clinical and research expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;185&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;611&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_6a206859-f8ee-400b-9d66-43ec2846665f;"&gt;&lt;span style="-sec-ix-hidden:F_17be60db-4ed3-4806-a6df-7a78528c373a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;418&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty obligation payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,690&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,951&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accrued license fees and royalties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,727&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,468&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;29,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:9pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:3.333%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Amount as of December 31, 2024 includes $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;advance payments received from our partner for inventory supply as discussed in Note 4, &#x201c;License and Collaboration Arrangements&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <inva:AccruedContractManufacturingLiability
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_8d9961a1-2bd5-413b-b436-cce4f0f9fec7"
      unitRef="U_USD">8220000</inva:AccruedContractManufacturingLiability>
    <inva:AccruedContractManufacturingLiability
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_5c0418eb-4e6f-4f47-a9c9-cc5303cb36c0"
      unitRef="U_USD">1071000</inva:AccruedContractManufacturingLiability>
    <inva:AccruedClinicalAndResearchLiability
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_d4cd8463-1c6a-4fc2-b4cc-cd34392a66c8"
      unitRef="U_USD">185000</inva:AccruedClinicalAndResearchLiability>
    <inva:AccruedClinicalAndResearchLiability
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_d49e95e1-c9b8-42e6-a448-99f3cc0158c0"
      unitRef="U_USD">611000</inva:AccruedClinicalAndResearchLiability>
    <inva:AccruedProfessionalServices
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_3fac3efa-2ef3-4e3e-9fd3-a3caf77d61b6"
      unitRef="U_USD">5845000</inva:AccruedProfessionalServices>
    <inva:AccruedProfessionalServices
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_e5a3a576-2cc5-4e02-94b9-e5aeccb2dbe3"
      unitRef="U_USD">8682000</inva:AccruedProfessionalServices>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_f32db5d1-2c6a-4b5b-ae37-ccdd6daf937c"
      unitRef="U_USD">418000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_e5aa0fac-f7dc-498f-9200-f0a9eaca7541"
      unitRef="U_USD">1572000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_c9336df0-235b-4277-979c-d69d0f7f7aeb"
      unitRef="U_USD">3690000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_4391b2a9-54a2-4f64-8aec-451f27695715"
      unitRef="U_USD">2951000</us-gaap:AccruedRoyaltiesCurrent>
    <inva:DeferredRoyaltyObligationCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_78855998-5049-4a83-b4b4-209d09e74305"
      unitRef="U_USD">8124000</inva:DeferredRoyaltyObligationCurrent>
    <inva:DeferredRoyaltyObligationCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_4d2b98d6-1107-4f36-8b8d-1e94c2805f62"
      unitRef="U_USD">6438000</inva:DeferredRoyaltyObligationCurrent>
    <inva:AccruedLicenseFeesAndRoyalties
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_90457a70-7c28-4c99-a666-429e4b675ee6"
      unitRef="U_USD">1964000</inva:AccruedLicenseFeesAndRoyalties>
    <inva:AccruedLicenseFeesAndRoyalties
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_ce37d009-3822-409f-b4a0-41c594b97885"
      unitRef="U_USD">1727000</inva:AccruedLicenseFeesAndRoyalties>
    <us-gaap:OtherLiabilities
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_7107755a-0b4b-4d35-b156-55487a5c74e5"
      unitRef="U_USD">1022000</us-gaap:OtherLiabilities>
    <us-gaap:OtherLiabilities
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_caa0e40b-6bde-47a3-9868-50a819fdb087"
      unitRef="U_USD">6947000</us-gaap:OtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_598c0a1b-d70e-4fb5-8ad8-d045219f420f"
      unitRef="U_USD">29468000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_26319f32-b8d7-407a-9f68-0a2a3bbfc250"
      unitRef="U_USD">29999000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AdvancesOnInventoryPurchases
      contextRef="C_2bdbcb89-e8cf-4578-a8fb-ed71c2c5c84c"
      decimals="-5"
      id="F_13fa68ce-74d2-47dc-b13e-5bc34b32b3d5"
      unitRef="U_USD">5300000</us-gaap:AdvancesOnInventoryPurchases>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_a0499a3e-0db5-457c-b6c0-41c909b0aef0">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other long-term liabilities consisted of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term portion of deferred royalty obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,104&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;63,096&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_e88a4c0d-7875-4370-83b2-18dc892d7674;"&gt;&lt;span style="-sec-ix-hidden:F_4bc47aec-cd74-43b5-88dc-6e2c9250c57b;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,091&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,275&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <inva:DeferredRoyaltyObligationNonCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_35d6ad47-4e5f-43fb-a591-832347eb8594"
      unitRef="U_USD">54104000</inva:DeferredRoyaltyObligationNonCurrent>
    <inva:DeferredRoyaltyObligationNonCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_e84e633c-4b20-4f87-891d-a58194f62f47"
      unitRef="U_USD">63096000</inva:DeferredRoyaltyObligationNonCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_02af73e0-a26f-4e17-b21b-9ebed3614e27"
      unitRef="U_USD">10868000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_8d4f8c00-744d-4b34-bc03-d8b19c8f6455"
      unitRef="U_USD">1179000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_28d185e5-6d31-4b30-8795-7e251485e438"
      unitRef="U_USD">1119000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_343f4c05-d396-4360-8d8a-e8b433886129"
      unitRef="U_USD">0</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_3dae1fe4-ef9c-4f69-98b5-c812ea548973"
      unitRef="U_USD">66091000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_41ef06c4-0e88-4f56-897c-12c8a964b8c5"
      unitRef="U_USD">64275000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_9bcbfb5d-49ec-4a97-8104-1ddd440b5e64">&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;10. STOCK&#x2011;BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In May 2012, we adopted the 2012 Equity Incentive Plan (the &#x201c;2012 Plan&#x201d;). The 2012 Plan provides for the grant of incentive stock options, nonstatutory stock options, RSAs, RSUs and Stock Appreciation Rights to employees, non-employee directors and consultants. As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, total shares remaining available for issuance under the 2012 Plan were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the 2004 Employee Stock Purchase Plan (the &#x201c;2004 ESPP&#x201d;), our employees may purchase common stock through payroll deductions at a price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lower of the fair market value of the stock at the beginning of the offering period or at the end of each applicable purchase period. The 2004 ESPP provided for consecutive and overlapping offering periods of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;24 months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in duration, with each offering period composed of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;four&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consecutive &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six-month&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; purchase periods. The purchase periods ended on either May 15 or November 15. The 2004 ESPP contributions were limited to a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of an employee&#x2019;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. An employee may not purchase shares with a value greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in any calendar year.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On April 13, 2023, the Board of Directors adopted the 2023 ESPP (the &#x201c;2023 ESPP&#x201d;). The 2023 ESPP, which supersedes the 2004 ESPP, was approved by the Company&#x2019;s stockholders on May 22, 2023. Under the 2023 ESPP, eligible employees may purchase common stock through payroll deductions at a price equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the lower of the fair market value of the stock at the beginning or end of each applicable purchase period. The 2023 ESPP provides for offering periods of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;six months&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which ends on either May 15 or November 15. The 2023 ESPP contributions are limited to a maximum of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of an employee&#x2019;s eligible compensation. The maximum number of shares that an employee may purchase in any purchase period is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. An employee may not purchase shares with a value greater than $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in any calendar year. A total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million shares of our common stock was reserved and available for issuance under the 2023 ESPP.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, total shares remaining available for issuance under the 2023 ESPP were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,385,766&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Director Compensation Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our non-employee directors receive compensation for services provided as a director. Each member of our board of directors who is not an employee receives both cash and equity compensation for services as a director, member of a committee of the board of directors, lead independent director and chairman, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Each of our independent directors receives periodic automatic grants of equity awards under a program implemented under the 2012 Plan. These grants are non&#x2011;discretionary. Only our independent directors or affiliates of such directors are eligible to receive automatic grants under the 2012 Plan. Under the program, each individual who first became a non-employee director will, on the date such individual joins the board of directors, automatically be granted a one&#x2011;time grant of RSUs covering a number of shares of our common stock calculated as $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share (the &#x201c;Initial RSUs&#x201d;), plus a one&#x2011;time grant of RSUs covering a number of shares of our common stock calculated as $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, which would be pro-rated for the number of whole months remaining until the anniversary of the prior year&#x2019;s stockholders&#x2019; meeting, rounded down to the nearest whole share (the &#x201c;Pro Rata RSUs&#x201d;). The Initial RSUs vest in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;two&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; equal annual installments, while Pro Rata RSUs vest in a single installment at the sooner of the next annual stockholder meeting or the one-year grant anniversary, in each case subject to the non-employee director&#x2019;s continuous service through the applicable vesting date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Annually, upon his or her re&#x2011;election to the board of directors at the Annual Meeting of Stockholders, each non-employee director is automatically granted an RSU covering a number of shares of our common stock calculated as $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; divided by our common stock closing share price on the date of grant as reported on The Nasdaq Global Select Market, rounded down to the nearest whole share. These RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the non-employee director&#x2019;s continuous service through the applicable vesting date. Following the amendment to our non-employee director compensation program, both the annual RSUs and Initial RSUs described above remained unchanged with the exception that the number of shares of our common stock subject to each award has been reduced.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;These RSUs will vest in full upon the director&#x2019;s death, the occurrence of a change in control, or the director&#x2019;s disability before the director&#x2019;s service terminates. Director RSUs carry dividend equivalent rights to be credited with an amount equal to all cash dividends paid on the underlying shares of common stock while unvested. Dividend equivalents are subject to the same terms and conditions, including vesting, as the RSUs to which they attach and are paid in cash upon vesting.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Stock&#x2011;Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense is included in the consolidated statements of income and comprehensive income as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.583%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense included in the consolidated statements of income and comprehensive income by award type is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.799999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrecognized Compensation Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Amortization Period (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total unrecognized compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Compensation Awards&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32.386%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.7219999999999995%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.7219999999999995%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands, except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of outstanding options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Exercise Price of Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of outstanding RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of outstanding RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Released RSUs and RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest &lt;br/&gt;&#160;&#160;&#160;as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the aggregate intrinsic value of options outstanding and options exercisable was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2024, the aggregate intrinsic value of options outstanding and options exercisable &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. As of December 31, 2025, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,267,886&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; options were exercisable. The weighted average remaining contractual term of options outstanding was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;7.68&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;8.04&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; years as of December 31, 2025 and 2024, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total intrinsic value of the options exercised was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t material for the years ended December 31, 2025, 2024 and 2023. The total estimated fair value of options vested was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million the years ended December 31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total estimated fair value of RSUs vested was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million for the years December 31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The total estimated fair value of RSAs vested was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t material for the year ended December 31, 2025, 2024, and 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Valuation Assumptions&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Black-Scholes-Merton weighted-average&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; assumptions used in calculating the estimated value of stock options granted by Innoviva on the dates of grant were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.748999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.748999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.748999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.07&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.09&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average estimated fair value of stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_7a708fd2-25d5-452c-aad6-d6903d0cf646"
      decimals="INF"
      id="F_bd49fbc3-9fdf-49a9-8a4d-dc0db55780a1"
      unitRef="U_shares">20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2"
      decimals="2"
      id="F_8639a926-8aae-4e58-8594-5159a54b314e"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod
      contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2"
      id="F_a49317ad-8474-4b1c-834f-aefdbac75654">P24M</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods
      contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2"
      decimals="0"
      id="F_98f3c29a-556c-45fb-ad45-340cd4c37683"
      unitRef="U_Item">4</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPurchasePeriods>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod
      contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2"
      id="F_cb654271-2575-4c82-978a-5a037b5e8ab4">P6M</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_32606254-e0d2-4b64-9791-54065180e259"
      decimals="2"
      id="F_9cde8b3b-5e99-450a-bcc0-96b02144db81"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2"
      decimals="INF"
      id="F_2fdd3286-20a0-4d21-a2c0-08100e0fe75d"
      unitRef="U_shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation
      contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2"
      decimals="0"
      id="F_901f7ca3-a566-4a28-a22d-e1e94a08a62c"
      unitRef="U_USD">25000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_b3b3003f-d16b-4948-beec-32f75f482d34"
      decimals="2"
      id="F_00970dc0-1f11-46e9-a878-6130f8df5342"
      unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod
      contextRef="C_b3b3003f-d16b-4948-beec-32f75f482d34"
      id="F_2b83f3e5-62fc-486e-a560-060a54ced877">P6M</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardConsecutiveAndOverlappingOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_b4464bad-246b-476e-bbdb-5189b9e3455c"
      decimals="2"
      id="F_bf3aff15-4236-4478-86fd-c3d14e328fcc"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="C_b3b3003f-d16b-4948-beec-32f75f482d34"
      decimals="INF"
      id="F_b38e2a79-7c1d-4173-a47e-e338a3f12a88"
      unitRef="U_shares">2500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation
      contextRef="C_b3b3003f-d16b-4948-beec-32f75f482d34"
      decimals="0"
      id="F_640b3dce-8a8d-458d-ac68-5847a8e363c6"
      unitRef="U_USD">25000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountAsContributionOfEligibleCompensation>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_b4464bad-246b-476e-bbdb-5189b9e3455c"
      decimals="INF"
      id="F_2082fc1d-e700-4b79-a0af-db84fd4e5546"
      unitRef="U_shares">2500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_b4464bad-246b-476e-bbdb-5189b9e3455c"
      decimals="INF"
      id="F_9020750c-0965-4d1a-9524-b560a07c0200"
      unitRef="U_shares">2385766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue
      contextRef="C_f46cd1ad-fe1b-4bf9-a5a9-24eaba3fb3e3"
      decimals="0"
      id="F_6aeb307c-b11e-4584-996b-93ffd499b74e"
      unitRef="U_USD">125000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardInitialEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue
      contextRef="C_f46cd1ad-fe1b-4bf9-a5a9-24eaba3fb3e3"
      decimals="0"
      id="F_2b64d138-a650-4a3e-a25c-5f97d35e8969"
      unitRef="U_USD">225000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalEquityGrantValue>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments
      contextRef="C_0ce3d616-f0eb-477a-96e3-62c320ccd76a"
      decimals="INF"
      id="F_d57c869b-5f01-4473-986d-dda2b4ef0b49"
      unitRef="U_Installment">2</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAnnualInstallments>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue
      contextRef="C_f09d870b-77a3-4a19-9ef4-c0fee32e4890"
      decimals="0"
      id="F_3713e3da-e18c-4622-865f-f0247739b699"
      unitRef="U_USD">225000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualEquityGrantValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_a1cadf08-9a7a-4025-b9a3-7f1c61a043ae">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense is included in the consolidated statements of income and comprehensive income as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.01%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.203%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.583%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,930&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,645&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,192&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e593a339-fd70-42b1-8675-8d814fad602a"
      decimals="-3"
      id="F_c1987feb-3253-494a-96cc-653e4a297f1a"
      unitRef="U_USD">8930000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e3289eef-c9f9-4a85-b3ce-87f3497ce8fa"
      decimals="-3"
      id="F_7259d33f-3f49-4fd7-b4ff-8740617de08c"
      unitRef="U_USD">6040000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_79652bcd-01ee-4bef-9367-fe4171e3c756"
      decimals="-3"
      id="F_e39c2d45-005b-475f-8e1b-00f143544b33"
      unitRef="U_USD">4645000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_338be7e3-2228-4533-9b23-3397a873d3d9"
      decimals="-3"
      id="F_323115da-6a99-4517-be53-874ea73344e8"
      unitRef="U_USD">522000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6ad32d18-a6d7-4bbe-9f9f-6e1ebf92e327"
      decimals="-3"
      id="F_8152b947-4ab0-4d6f-b387-39533c0727e2"
      unitRef="U_USD">334000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9ab9bd6f-8303-47cb-a451-087e49e1d4f2"
      decimals="-3"
      id="F_e445f0e2-1b0d-49af-9011-5868d9aa1dfb"
      unitRef="U_USD">1192000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_e413f49c-ade7-401d-9a0e-b5a02f0fc6ea"
      unitRef="U_USD">9452000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_a1b874ab-b96c-4976-97e6-1ae58670e980"
      unitRef="U_USD">6374000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_bb8b28fb-8ab4-4578-98a1-cbb44f6fcaab"
      unitRef="U_USD">5837000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_386eb123-f45b-4146-9291-b81afcc59a40">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stock&#x2011;based compensation expense included in the consolidated statements of income and comprehensive income by award type is as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,738&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,348&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;123&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,374&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,837&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="-3"
      id="F_fb16dfe0-2681-45a4-b475-4c1a602127c7"
      unitRef="U_USD">3995000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_579c7936-813d-4e3d-9f7d-e6cfc757d33f"
      decimals="-3"
      id="F_0e0228ba-ded4-47bb-8f80-f83e3db1c38b"
      unitRef="U_USD">2738000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f8691cc5-0a6c-4194-a0e6-b3ab90155c90"
      decimals="-3"
      id="F_c8305bd1-f547-4280-826f-6d13e1253419"
      unitRef="U_USD">1980000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4"
      decimals="-3"
      id="F_24a1fca4-7b9c-4c21-a8b7-ee87045021d3"
      unitRef="U_USD">5041000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_dedec735-1cff-4546-aac3-c4141f2f6fda"
      decimals="-3"
      id="F_dff59639-d59e-47f3-824b-a3b6a19f34d7"
      unitRef="U_USD">3348000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_330d6cb8-f79a-453a-8e56-a035cce53878"
      decimals="-3"
      id="F_3d2ad6bb-54b8-4f39-92d4-ebe9042102c2"
      unitRef="U_USD">3663000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a"
      decimals="-3"
      id="F_ff034418-16c8-4ac8-b45f-f1aa5082a891"
      unitRef="U_USD">76000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_57b6c234-c606-4323-ad48-c327ece76f82"
      decimals="-3"
      id="F_1a51f8ac-5771-457a-b347-dddf51633ebe"
      unitRef="U_USD">123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_c92d98ef-aaeb-428e-9c70-9239d3850fc7"
      decimals="-3"
      id="F_5f9a7159-d729-4bc0-93dd-aeeea37ebc55"
      unitRef="U_USD">168000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2"
      decimals="-3"
      id="F_98be852e-b16f-42d1-a145-a0182f418c45"
      unitRef="U_USD">340000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2f40b780-c413-4e18-8a24-befa2c076cee"
      decimals="-3"
      id="F_429cdd37-ba18-495f-a9f8-bdd375e7b06d"
      unitRef="U_USD">165000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b1c51e57-65da-49fa-ae45-c34168f6b7ca"
      decimals="-3"
      id="F_53202a82-8439-40d3-a997-4cdae2927ec0"
      unitRef="U_USD">26000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_5445ee4b-5106-425f-ae93-1d116e04557b"
      unitRef="U_USD">9452000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_ed194fcb-586c-43a2-a1db-74479fb80e88"
      unitRef="U_USD">6374000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_1f11813a-cd87-484d-b2db-647c29a69b3c"
      unitRef="U_USD">5837000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_4737853f-89c1-48c5-92fd-738fa2ba6dc1">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, the unrecognized stock-based compensation cost and the estimated weighted-average amortization period were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.799999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Unrecognized Compensation Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Amortization Period (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,354&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total unrecognized compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,741&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585"
      decimals="-3"
      id="F_a07c4f09-cdf5-4e0e-87dc-6b5d18b425b9"
      unitRef="U_USD">9140000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      id="F_889e0ee5-9abd-429a-84a6-e5dd52ff6d12">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_320697d2-fba1-4b46-89cc-25782f7895a7"
      decimals="-3"
      id="F_8699767d-61f5-43ba-93cd-347a3fab9436"
      unitRef="U_USD">13354000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4"
      id="F_5596d9d8-58bf-4a73-9aa5-09c4bd5d50b0">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_f7570aba-c10f-4b03-a0ca-5d70ea46865a"
      decimals="-3"
      id="F_4e69927a-8e30-4a35-aa50-d700cce434ca"
      unitRef="U_USD">22000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a"
      id="F_0bb9a773-e7e7-4928-8c73-8535445d99df">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_32606254-e0d2-4b64-9791-54065180e259"
      decimals="-3"
      id="F_fe169bf1-5ee8-400a-a395-2bb80e5e3986"
      unitRef="U_USD">225000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_eda262e4-057f-4998-b423-d9e9d577d4f2"
      id="F_503e5737-e9b6-485e-b4c9-f79e897c83a2">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_47a7fb8b-6f8a-4dbf-a7f4-50b836ef74e6"
      unitRef="U_USD">22741000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_71428a3c-5716-478d-815f-0192b8d867d7">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes equity award activity under the 2012 Plan and prior plans and related information:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:32.386%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.7219999999999995%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:7.7219999999999995%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.642%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.02%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.182%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands, except per share data)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of outstanding options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Exercise Price of Outstanding Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of outstanding RSUs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Number of outstanding RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted-Average Fair Value per Share at Grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,067&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.50&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;662&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.18&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.09&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Released RSUs and RSAs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Balance as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Vested and expected to vest &lt;br/&gt;&#160;&#160;&#160;as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,834&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31"
      decimals="-3"
      id="F_139997fa-08f8-4100-aa9d-c2902d8fc9d1"
      unitRef="U_shares">2067000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31"
      decimals="2"
      id="F_7bd26451-b2a1-4ed9-b586-c276b111aa3b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_e6c84643-3ac1-485b-96c6-e0bf066aa3a4"
      decimals="-3"
      id="F_80ac40ef-a020-48a9-af8c-feea1bb1c9ac"
      unitRef="U_shares">598000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_e6c84643-3ac1-485b-96c6-e0bf066aa3a4"
      decimals="2"
      id="F_4aff13ee-3cc4-407d-907e-f63c08a40524"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_4ae30dd2-d091-4534-84e4-23090114dd52"
      decimals="-3"
      id="F_504cdbc9-78c0-49e6-b8bc-000133ac316b"
      unitRef="U_shares">7000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_4ae30dd2-d091-4534-84e4-23090114dd52"
      decimals="2"
      id="F_d364bf56-aedc-4340-890c-f2b34064f830"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="-3"
      id="F_8dfefffe-6f5c-4809-ab88-6e8364f9c2d3"
      unitRef="U_shares">870000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="2"
      id="F_7dd75754-a979-4fec-9701-aed6f863660b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4"
      decimals="-3"
      id="F_4ddf2a50-cb19-4c6b-a6cb-6fb8db42b1a6"
      unitRef="U_shares">662000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4"
      decimals="2"
      id="F_8c9a63fd-8ae6-4744-91ee-4c56abb463fa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a"
      decimals="-3"
      id="F_38dbdad0-ad03-4d7d-990b-a928ce2b7f94"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a"
      decimals="0"
      id="F_ea2fcc7e-18ce-4f2a-9a2e-d13a52a57228"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="-3"
      id="F_cbd7d669-60e7-4f23-8840-77eeabff07ec"
      unitRef="U_shares">85000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="2"
      id="F_e6534f2f-68b6-473d-870f-3dac050dd549"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4"
      decimals="-3"
      id="F_d317ce33-f6e5-4ded-9a36-245a7a1600a6"
      unitRef="U_shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4"
      decimals="2"
      id="F_1ebfd5a3-887c-4940-aa1e-7f390fe8b95f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a"
      decimals="-3"
      id="F_3b15e368-41bf-459d-9da7-a1b33cd2a30e"
      unitRef="U_shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a"
      decimals="2"
      id="F_91b628a9-c280-4f75-bc4c-bbf6895cc4f4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="-3"
      id="F_7a5160d5-6395-4506-a300-0e7d1f443449"
      unitRef="U_shares">17000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="2"
      id="F_21f9d959-0356-4f0f-9a88-b0dc24522ee5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4"
      decimals="-3"
      id="F_4fe295c8-4f42-4e69-8d92-a26c8e50ba8c"
      unitRef="U_shares">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4"
      decimals="2"
      id="F_44636c43-e272-4bc1-92fa-971deb12fa82"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a"
      decimals="-3"
      id="F_80d920ce-e2cf-41a7-9ae4-472a2e57e013"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a"
      decimals="0"
      id="F_2aea4196-d7d3-484e-b183-f1f592021c4b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="-3"
      id="F_fd774c45-dc64-4d14-ac62-2fafc8bde5d0"
      unitRef="U_shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="2"
      id="F_d60dc821-6a3d-41c4-8a2e-57f7e5f9c8db"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585"
      decimals="-3"
      id="F_82402064-a123-46f2-b101-5c99ea36c976"
      unitRef="U_shares">2834000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585"
      decimals="2"
      id="F_f51ce16f-627b-4ff8-aea2-de153d63c76c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_320697d2-fba1-4b46-89cc-25782f7895a7"
      decimals="-3"
      id="F_3e8ffd69-1a46-4a4f-9269-14300e14e8cd"
      unitRef="U_shares">924000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_320697d2-fba1-4b46-89cc-25782f7895a7"
      decimals="2"
      id="F_8c2ef59c-9b2f-4d7a-8856-a5735ed1e2fc"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_f7570aba-c10f-4b03-a0ca-5d70ea46865a"
      decimals="-3"
      id="F_171b7ee8-1595-4f70-b8ff-87fbd9201306"
      unitRef="U_shares">2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f7570aba-c10f-4b03-a0ca-5d70ea46865a"
      decimals="2"
      id="F_722c23fa-91a4-41cc-b6a6-ef4d508765b5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">14.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585"
      decimals="-3"
      id="F_51870688-a6f6-45c0-9c12-fd95604e5b79"
      unitRef="U_shares">2834000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585"
      decimals="2"
      id="F_40165ff0-027b-432b-b471-099219d412c5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_320697d2-fba1-4b46-89cc-25782f7895a7"
      decimals="-3"
      id="F_e50f1b17-c808-45ab-b688-97e2dff66fd8"
      unitRef="U_shares">924000</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingNumber>
    <inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare
      contextRef="C_320697d2-fba1-4b46-89cc-25782f7895a7"
      decimals="2"
      id="F_7cb1fcb6-b36e-4957-aa14-88abcd00eba8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.22</inva:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVestedAndExpectedToVestOutstandingWeightedAverageFairValuePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585"
      decimals="-5"
      id="F_fee90bc0-d36a-4203-875d-0ab300068b8f"
      unitRef="U_USD">11100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585"
      decimals="-5"
      id="F_3557f2e0-08d6-47a7-8bc1-49d34919a70c"
      unitRef="U_USD">6400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31"
      decimals="-5"
      id="F_781b03b5-05fe-4152-aaa6-524ec22ce428"
      unitRef="U_USD">5000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0e4284fa-acc0-4cc8-a682-fbb6fc8cbf31"
      decimals="-5"
      id="F_26bbc157-35d0-4944-92e6-320a63ee388f"
      unitRef="U_USD">2400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_a5a5f201-5589-4683-9f98-e0775b868585"
      decimals="0"
      id="F_99214317-6312-4288-8653-65c345221a4d"
      unitRef="U_shares">1267886</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      id="F_6a056ec9-2b2c-46b0-91ab-6047222cc7c2">P7Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_579c7936-813d-4e3d-9f7d-e6cfc757d33f"
      id="F_be206e0f-ef75-43c8-be3f-3f97359cf299">P8Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="-6"
      id="F_2cc3585c-d668-432c-a8bb-83f7db2ededc"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_579c7936-813d-4e3d-9f7d-e6cfc757d33f"
      decimals="-6"
      id="F_20d96862-65c9-483f-83d7-f42789ab5f5f"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_f8691cc5-0a6c-4194-a0e6-b3ab90155c90"
      decimals="-6"
      id="F_d4030fea-bc79-4c8d-873c-e82b2d71b8c0"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_4daceff5-03ad-4f3b-9aab-ba819d229412"
      decimals="-5"
      id="F_28588aa3-8ef8-4f1d-8975-81adad7e544c"
      unitRef="U_USD">3800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_579c7936-813d-4e3d-9f7d-e6cfc757d33f"
      decimals="-5"
      id="F_0b7e03dc-a12b-4375-9301-e77c1ec6619f"
      unitRef="U_USD">2500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_f8691cc5-0a6c-4194-a0e6-b3ab90155c90"
      decimals="-5"
      id="F_a54f65f2-f369-42c3-99ca-967fdb7eea9a"
      unitRef="U_USD">1900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_25fb684b-4cff-4a4a-8d48-0d3652f597c4"
      decimals="-5"
      id="F_bc0b5374-e634-4599-a5b0-40987a3da4af"
      unitRef="U_USD">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_dedec735-1cff-4546-aac3-c4141f2f6fda"
      decimals="-5"
      id="F_21eced27-cb3a-4eef-8678-66d922667a70"
      unitRef="U_USD">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_330d6cb8-f79a-453a-8e56-a035cce53878"
      decimals="-5"
      id="F_41c26569-b435-4489-b483-542883c927b9"
      unitRef="U_USD">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_6ec61393-c6fd-4f47-92fe-a79e7cfce41a"
      decimals="-6"
      id="F_aaaf9a84-7b8f-4f78-96bc-1680ff29ba6e"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_57b6c234-c606-4323-ad48-c327ece76f82"
      decimals="-6"
      id="F_23907c3d-3c1b-4313-8bf6-947ceda5d3b2"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="C_c92d98ef-aaeb-428e-9c70-9239d3850fc7"
      decimals="-6"
      id="F_70316d3f-ab22-4061-8cb1-a9ec1c8edec0"
      unitRef="U_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_77d2331c-0b8b-4a4a-ae7d-6b7417ce880b">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Black-Scholes-Merton weighted-average&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; assumptions used in calculating the estimated value of stock options granted by Innoviva on the dates of grant were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.748999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.748999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.748999999999999%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.07&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.10&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.09&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;34.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Weighted-average estimated fair value of stock options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.57&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_c10fa9b1-45fb-45df-9763-f7e84d16c427"
      decimals="3"
      id="F_05963f0c-6b15-4713-9c59-2fd216325166"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_ff24ff88-61ab-4e42-8c4e-2eef4914adc2"
      decimals="3"
      id="F_2fc53f8d-a08a-4d59-ba45-46d09d797524"
      unitRef="U_pure">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_cfb09673-608d-4b9a-af24-b826da8f9edc"
      decimals="3"
      id="F_b77c682e-d167-4270-bb29-ddd627b9d59c"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_c10fa9b1-45fb-45df-9763-f7e84d16c427"
      id="F_b18b67b3-24ea-4c9f-b747-d39b0327d8f1">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ff24ff88-61ab-4e42-8c4e-2eef4914adc2"
      id="F_40bc170d-ec4f-4c10-8f1b-cd2526eedfc1">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_cfb09673-608d-4b9a-af24-b826da8f9edc"
      id="F_abdd416d-b555-4ab6-937c-e735cdf30fb3">P6Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_c10fa9b1-45fb-45df-9763-f7e84d16c427"
      decimals="3"
      id="F_6c2802e9-f3a4-415e-a4fa-64e1235f0df1"
      unitRef="U_pure">0.345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_ff24ff88-61ab-4e42-8c4e-2eef4914adc2"
      decimals="3"
      id="F_4970a789-a168-416a-9189-aaa48953225a"
      unitRef="U_pure">0.355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="C_cfb09673-608d-4b9a-af24-b826da8f9edc"
      decimals="3"
      id="F_62070e64-4a67-47c8-9077-10cc9f624fa7"
      unitRef="U_pure">0.378</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_1b6e4f2c-7f64-4b60-808a-20645b1b5b3b"
      decimals="3"
      id="F_d54856b0-c4bb-4353-b8f3-5c073b4b8869"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_b931adf2-501a-4565-a5c0-0fce4fa655a8"
      decimals="3"
      id="F_3cd7381c-1bbc-46fb-aeb0-a07cb1fd1bff"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_c554b608-b6a5-40f5-8cdd-07a2aa79f2ec"
      decimals="3"
      id="F_ac28a052-1d5b-44ce-a5b9-e639d2550f1d"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_c10fa9b1-45fb-45df-9763-f7e84d16c427"
      decimals="2"
      id="F_530edd5c-66e0-443d-96c9-7c98c82d04bb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_ff24ff88-61ab-4e42-8c4e-2eef4914adc2"
      decimals="2"
      id="F_0c31c49e-fc18-4534-ba3c-449809d4b1d0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_cfb09673-608d-4b9a-af24-b826da8f9edc"
      decimals="2"
      id="F_6fc864c8-14cf-437c-8f33-c1a1238329c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_c1762124-0d63-4a38-aa37-4a234e5cb527">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;11. &lt;/span&gt;&lt;span style="text-transform:uppercase;color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the year ended December 31, 2025, a total of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;590,703&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; warrants were exercised into an equivalent number of our common shares at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.11&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share, resulting in approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in proceeds. There were &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; outstanding warrants as of December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On November 3, 2025, our board of directors authorized a new share repurchase program under which we may repurchase up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;of our outstanding shares of common stock. The timing and amount of any share repurchases under the share&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;repurchase &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;program will be subject to the Securities and Exchange Commission Rule 10b-18 and Rule 10b5-1 requirements under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and will be determined by our management in its discretion based on ongoing assessments of the capital needs of the business, the market price of our common stock, prevailing stock prices, general market conditions, and other considerations. Share repurchases under the program may be made through a variety of methods, which may include open market purchases, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. This program has no termination date, may be suspended or discontinued at any time at our discretion and does not oblige us to acquire any amount of common stock. From program inception through December 31, 2025, we repurchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;227,855&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares in the open market at an average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.09&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for a total amount of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; millio&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;n. Subsequent to December 31, 2025 and through February 13, 2026, we have repurchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;569,443&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares in the open market at an average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for a total amount of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. All repurchased shares were retired.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On October 31, 2022, our board of directors authorized a share repurchase program under which we may repurchase up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of our outstanding shares of common stock. The repurchase program authorized the repurchase by the Company of its common stock in open market transactions, including pursuant to a trading plan in accordance with Rule 10b-18 promulgated under the Exchange Act, privately negotiated transactions, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination thereof or by other means in accordance with federal securities laws. The authorization permitted management to repurchase shares of the Company&#x2019;s common stock from time to time at management&#x2019;s discretion. Repurchases may also be made pursuant to a trading plan under Rule 10b5-1 under the Exchange Act, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions. For the year ended December 31, 2023, we repurchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,173,565&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares in the open market at an average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.39&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for a total amount of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. From January to April 2024, we repurchased &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;986,928&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares in the open market at an average price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.12&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share for a total amount of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. The share repurchase program was completed in April 2024. All repurchased shares were retired.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2024, we retired all the shares held in treasury resulting from our strategic buyback of GSK&#x2019;s common shares in the Company in 2021. We recorded the corresponding cost of treasury stock of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;393.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in additional paid-in capital.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <inva:ClassOfWarrantOrRightExercised
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="INF"
      id="F_551b1ceb-4468-45e0-aa4a-d4a027ecd446"
      unitRef="U_shares">590703</inva:ClassOfWarrantOrRightExercised>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="2"
      id="F_65bae589-0a9a-4d21-9c8b-57f5327853ca"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-5"
      id="F_0e83ce75-e3f3-4e9f-896e-25e243300095"
      unitRef="U_USD">10700000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="INF"
      id="F_eef3e058-de02-4421-bb2b-a142b3c86378"
      unitRef="U_shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_b804b54f-6e17-4b9b-bc14-506d13cd2e58"
      decimals="-5"
      id="F_53135600-fed1-42b2-ad65-a311de185eb5"
      unitRef="U_USD">125000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_d16801eb-dbe6-41b0-b0a9-f2ce69282a79"
      decimals="INF"
      id="F_0a5d3300-1479-4466-8bed-e30c4d365d90"
      unitRef="U_shares">227855</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <inva:CommonStockAcquiredAverageCostPerShare
      contextRef="C_d16801eb-dbe6-41b0-b0a9-f2ce69282a79"
      decimals="2"
      id="F_2917d833-cac5-40be-8012-97bec502fe99"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.09</inva:CommonStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_d16801eb-dbe6-41b0-b0a9-f2ce69282a79"
      decimals="-5"
      id="F_244f57e9-bbba-4da4-b9a9-b3f071708e53"
      unitRef="U_USD">4600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_e7b60c9b-de37-4c35-8699-180e5b96d972"
      decimals="INF"
      id="F_cd19fb40-ec60-42c6-8c8d-cc97fcd24a55"
      unitRef="U_shares">569443</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <inva:CommonStockAcquiredAverageCostPerShare
      contextRef="C_e7b60c9b-de37-4c35-8699-180e5b96d972"
      decimals="2"
      id="F_639cefbc-f3a1-4198-90fe-9253a54003f5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.88</inva:CommonStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_e7b60c9b-de37-4c35-8699-180e5b96d972"
      decimals="-5"
      id="F_0f5f12e4-5423-4940-b572-d0a02caf071c"
      unitRef="U_USD">11400000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="C_04b74a31-e5ca-4397-96ef-3eea91f0c2cf"
      decimals="-5"
      id="F_396a2663-e72b-4650-8411-8d76deb1e330"
      unitRef="U_USD">100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="INF"
      id="F_7c29b8c1-0abe-4ed4-81c9-cd1aaff88900"
      unitRef="U_shares">6173565</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <inva:CommonStockAcquiredAverageCostPerShare
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="2"
      id="F_136b7976-10a3-48fd-af3c-eba55dea16b4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">12.39</inva:CommonStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_d021c263-f6d4-4d1f-b1d8-a3468fb8b727"
      decimals="-5"
      id="F_e29baa3f-df8d-4a6a-9100-7a27ebb5c304"
      unitRef="U_USD">76500000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="C_9813ff06-8065-4d1b-980c-30aab6fdf680"
      decimals="INF"
      id="F_07a84511-9f78-4be2-84a4-413584c6309b"
      unitRef="U_shares">986928</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <inva:CommonStockAcquiredAverageCostPerShare
      contextRef="C_9813ff06-8065-4d1b-980c-30aab6fdf680"
      decimals="2"
      id="F_26e43b58-8935-488b-9b03-09d446237b12"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">15.12</inva:CommonStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue
      contextRef="C_9813ff06-8065-4d1b-980c-30aab6fdf680"
      decimals="-5"
      id="F_680ab9e7-a25e-4b49-861b-05baaa2e48b4"
      unitRef="U_USD">14900000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="C_c8120c77-f833-4318-8b71-285654ebe1a5"
      decimals="-5"
      id="F_9fa69b4f-79a6-4202-bf8e-93b7aac1d872"
      unitRef="U_USD">393800000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_103ad023-d365-432c-9b72-e81fa5944bfd">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;12. DEBT&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our debt consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.799999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.799999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;453,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;448,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Current portion of long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Convertible Subordinated Notes Due 2023&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In January 2013, we completed an underwritten public offering of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;287.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million aggregate principal amount of our 2023 Notes, which matured on January 15, 2023. The 2023 Notes carried interest at the rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per year that was payable semi-annually in arrears in cash on January 15 and July 15 of each year.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the total face value of the 2023 Notes was reduced through partial conversion, retirement and repurchase. The remaining balance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was fully paid in cash upon the maturity date in January 2023.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2023 Notes for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:75.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Convertible Senior Notes Due 2025&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On August 7, 2017, we completed a private placement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million aggregate principal amount of our 2025 Notes. The 2025 Notes were senior unsecured obligations and carried interest at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per year, payable semi-annually in arrears on February 15 and August 15 of each year.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2025 Notes were convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In June 2025, we elected to settle the 2025 Notes in shares. Holders had the option to convert their 2025 Notes at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. During June 2025, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the principal amount was converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,962&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock. During August 2025, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the principal amount was converted into &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,119,956&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares of our common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; The remaining principal balance of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; was fully paid in cash upon the maturity date in&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; August 15, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The annual effective interest rate on the 2025 Notes in 2025 up to its settlement was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.90&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. For the years ended December 31, 2024 and 2023, the annual effective interest rate on the 2025 Notes was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.88&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our 2025 Notes balances consisted of the following as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.034%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.941%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:25.025%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Convertible Senior Notes Due 2028&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2022, we completed a private placement of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million aggregate principal amount of our 2028 Notes, which will mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 15, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We used approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the net proceeds to fund the cost of entering into the capped call transactions described below. In addition, we used $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;165.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the remaining net proceeds to repurchase $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;144.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million aggregate principal amount of the 2023 Notes in separate and individually negotiated transactions with certain holders of the 2023 Notes, which closed concurrently with the issuance of the 2028 Notes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2028 Notes bear interest at an annual rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.125&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% that is payable semi-annually in arrears in cash on March 15 and September 15 of each year, beginning on September 15, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2028 Notes are convertible, based on the applicable conversion rate, into cash, shares of our common stock or a combination thereof, at our election. The initial conversion rate was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;38.1432&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; shares per $1,000 principal amount of the 2028 Notes, subject to customary anti-dilution adjustment in certain circumstances, which represented an initial conversion price of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26.22&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Prior to September 15, 2027, the 2028 Notes will be convertible at the option of the holders only upon the occurrence of specified events and during certain periods, and will be convertible on or after September 15, 2027, at any time until the close of business on the second scheduled trading day immediately preceding the maturity date of the 2028 Notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Holders of the 2028 Notes may convert all or a portion of their 2028 Notes prior to the close of business on September 15, 2027, only under the following circumstances:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;after March 31, 2022, if our closing common stock price for at least 20 days out of the most recent 30 consecutive trading days of the preceding quarter is greater than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the current conversion price of the 2028 Notes;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;for five consecutive business days, if the average trading price per $1,000 of Notes during the prior 10 consecutive trading days is less than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the product of our closing common stock price and the conversion rate of the 2028 Notes on such day; and,&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental change (as defined in the indenture governing the 2028 Notes) or a transaction resulting in our common stock converting into other securities or property or assets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On or after September 15, 2027, holders of the 2028 Notes may convert their 2028 Notes at any time until the close of the business on the second day immediately preceding the maturity date of the 2028 Notes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The 2028 Notes will be redeemable, in whole or in part, at our option at any time, and from time to time, on or after March 20, 2025, and on or before the 75th scheduled trading day immediately before the maturity date but only if the last reported sale price per share of our common stock exceeds 130% of the conversion price for a specified period of time. The redemption price will be equal to the principal amount of the 2028 Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. In addition, calling any 2028 Note for redemption will constitute a make-whole fundamental change (as defined in the indenture governing the 2028 Notes) with respect to that 2028 Note, in which case the conversion rate applicable to the conversion of that 2028 Note will be increased in certain circumstances if it is converted after it is called for redemption.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If we undergo a fundamental change, subject to certain conditions, holders may require us to purchase for cash all or any portion of their 2028 Notes. The fundamental change purchase price will be &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the principal amount of the 2028 Notes to be purchased plus any accrued and unpaid interest to, but excluding, the fundamental change purchase date.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In connection with the offering of the 2028 Notes, we entered into privately negotiated capped call transactions. The cap price of the capped call transaction is initially $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.9850&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per share and is subject to certain adjustments under the terms of the capped call transactions. The capped call transactions cover, subject to customary adjustments, the number of shares of common stock initially underlying the 2028 Notes. The capped call transactions are expected generally to reduce potential dilution to our common stock upon conversion of the 2028 Notes or at our election (subject to certain conditions) offset any cash payments we are required to make in excess of the aggregate principal amount of converted 2028 Notes, as the case may be, with such reduction or offset subject to a cap.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The annual effective interest rate on the 2028 Notes is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.70&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our outstanding 2028 Notes balance consisted of th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;e following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2028 Notes for the years ended December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Debt Maturities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate scheduled maturities of our convertible debt as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Deferred Royalty Obligation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As part of our acquisition of La Jolla, we recorded the fair value of its deferred royalty obligation in connection with La Jolla&#x2019;s royalty financing agreement (&#x201c;La Jolla Royalty Agreement&#x201d;) with HealthCare Royalty Partners (&#x201c;HCR&#x201d;). Under the terms of the La Jolla Royalty Agreement, HCR is entitled to receive quarterly royalties on worldwide net sales of GIAPREZA&#xae; until either January 1, 2031 or when the maximum aggregate royalty payments have been made, whichever occurs first. Quarterly payments to HCR under the Royalty Agreement start at a maximum royalty rate, with step-downs based on the achievement of annual net product sales thresholds. The maximum royalty rate through December 31, 2023 was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%. Starting January 1, 2024, the maximum royalty rate was increased to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% based on the terms of the Agreement. The La Jolla Royalty Agreement is subject to maximum aggregate royalty payments to HCR of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the years ended December 31, 2025, 2024 and 2023, we recognized interest expense of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, on the deferred royalty obligation. The carrying value of the deferred royalty obligation as of December 31, 2025 and 2024 was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;69.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively, (refer to Note 9 &#x201c;Balance Sheet Components&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;). During the years ended December 31, 2025, 2024 and 2023, we made royalty payments to HCR of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively. The deferred royalty obligation was valued using Level 3 inputs, and its carrying value as of December 31, 2025 and 2024 approximates fair value. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The fair value of the deferred royalty obligation was calculated as the discounted deferred royalty obligations based on risk-adjusted revenue projections for GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, the annual effective interest rate of the deferred royalty obligation is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.03&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the La Jolla Royalty Agreement, if we are unable to meet certain obligations, including the obligation to use commercially reasonable and diligent efforts to commercialize GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, HCR would have the right to terminate the La Jolla Royalty Agreement and demand payment of either $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;125.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million or $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;225.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (depending on which obligation we have failed to meet) less aggregate royalties already paid to HCR.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; As of December 31, 2025, inclusive of the aggregate royalties paid to HCR by La Jolla under the La Jolla Royalty Agreement prior to our acquisition, La Jolla paid approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;aggregate royalties to HCR. In the event that we fail to pay such amount if and when due in a timely manner, HCR would have the right to foreclose on the GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;-related assets. HCR has no recourse against any asset other than GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Certain contract provisions within the La Jolla Royalty Agreement that could result in an acceleration of amounts due under the La Jolla Royalty Agreement are recognized as embedded derivatives that require bifurcation from the deferred royalty obligation and fair value recognition. We determined the fair value of each derivative by assessing the probability of each event occurring, as well as the potential repayment amounts and timing of such repayments that would result under various scenarios. As a result of this assessment, we determined that the fair value of the embedded derivatives is immaterial and, therefore, not recognized as of December 31, 2025 and 2024. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We estimate the fair value of the embedded derivatives for each reporting period until either the features lapse or the La Jolla Royalty Agreement is terminated, whichever occurs first. Any material change in the fair value of the embedded derivatives will be recorded as either a gain or loss in the consolidated statements of income and comprehensive income.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_7e1fe5f5-529c-43ed-ad97-a4903d98a653">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our debt consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.799999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:18.799999999999997%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2025 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total debt&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;453,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Unamortized debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;448,344&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&#160;&#160;Less: Current portion of long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total long-term debt, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_bf1e7354-aeed-4914-83a6-37a509ddd35f"
      decimals="-3"
      id="F_9ba22168-638f-4e3c-84b8-d374a70e5cb0"
      unitRef="U_USD">0</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_b977836a-3754-4918-ab34-119c8e6e97e3"
      decimals="-3"
      id="F_09d1e89d-cfc4-4596-a395-b07b50fe6b97"
      unitRef="U_USD">192500000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_b9c78e4a-7998-49df-8911-c4a60d08df86"
      decimals="-3"
      id="F_57664cd8-5ce6-4e71-8834-b74c97b9f4a8"
      unitRef="U_USD">261000000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_89ffeb43-b4e5-4cd3-b24e-9d0133812b42"
      decimals="-3"
      id="F_7fb5e87e-cc5c-4ee1-95f4-be2f7d82a7b5"
      unitRef="U_USD">261000000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_570187cc-50b5-44c6-8368-cca3d9263e33"
      unitRef="U_USD">261000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_01808c12-5e22-4a0a-9f69-728a20079018"
      unitRef="U_USD">453500000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_243026fc-94b7-402b-a7f1-69225897f762"
      unitRef="U_USD">3269000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_49aca042-23fc-4693-8fb9-5e16cd6ddafb"
      unitRef="U_USD">5156000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_2b11370c-9afb-4e28-8178-769b62bf5fca"
      unitRef="U_USD">257731000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_05880a9e-aff3-42a7-8fd1-2368c3b0f46c"
      unitRef="U_USD">448344000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtCurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_2bddb95f-50ff-4e2d-b503-d1a7a643d192"
      unitRef="U_USD">0</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_3ac43667-4247-45ec-9819-8e5205a509e8"
      unitRef="U_USD">192028000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_4556677d-8a5e-4bea-b0d6-1abb47c8784d"
      unitRef="U_USD">257731000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_171a6559-74c4-4267-bcee-6ab34ff8e7c2"
      unitRef="U_USD">256316000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_f0b8d42e-b800-4698-921e-c7324bfbf8ad"
      decimals="-5"
      id="F_a745afc5-c56b-416f-964a-28ac01b44ab4"
      unitRef="U_USD">287500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_f0b8d42e-b800-4698-921e-c7324bfbf8ad"
      decimals="5"
      id="F_de56549b-4d7c-4334-9679-3393add0ab1e"
      unitRef="U_pure">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <inva:DebtInstrumentRemainingBalancePaidUponMaturation
      contextRef="C_c6f23cff-6ae1-42a0-aeb9-137bb05864f8"
      decimals="-5"
      id="F_560115b8-aeb7-4743-a962-a73ad705d6e4"
      unitRef="U_USD">96200000</inva:DebtInstrumentRemainingBalancePaidUponMaturation>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="C_bc424098-7c86-48ee-a261-2e346af6f356"
      id="F_93261363-538d-4c1d-b8dd-fba8ea22b405">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2023 Notes for the year ended December 31, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2023:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:75.96%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.2%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:19.84%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_98625368-01db-4a5e-b3d8-d97b38cb185c"
      decimals="-3"
      id="F_65f2b891-5c7f-4f55-9638-0bc783ae2dbf"
      unitRef="U_USD">85000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_98625368-01db-4a5e-b3d8-d97b38cb185c"
      decimals="-3"
      id="F_0f639910-cfef-4c08-83be-dec4310932e4"
      unitRef="U_USD">11000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="C_98625368-01db-4a5e-b3d8-d97b38cb185c"
      decimals="-3"
      id="F_9690eeaf-b7ae-4480-8445-9d50f1bb6d66"
      unitRef="U_USD">96000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_accf2b2f-48d9-429a-b115-90bfc9822af1"
      decimals="-5"
      id="F_3f854b81-07a3-405d-98f2-3c0ee09289a2"
      unitRef="U_USD">192500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_accf2b2f-48d9-429a-b115-90bfc9822af1"
      decimals="3"
      id="F_8f46b953-8f80-478c-a87d-8b8d1bf73416"
      unitRef="U_pure">0.025</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <inva:PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock
      contextRef="C_6f8efa75-54a0-48d2-91ec-df3a956405f4"
      decimals="-5"
      id="F_2a639ad2-5749-4eb9-916a-18ae0b69d5fc"
      unitRef="U_USD">500000</inva:PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_c2aa978f-4b90-4e27-bcd0-10e52fef449d"
      decimals="INF"
      id="F_50f44a92-4a62-4613-8a79-73d151a17bb8"
      unitRef="U_shares">28962</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <inva:PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock
      contextRef="C_5f76e50f-7b05-4925-b65f-40d08587b5e7"
      decimals="-5"
      id="F_282d3503-2638-466a-9392-6733a8fcca1b"
      unitRef="U_USD">192000000</inva:PrincipalAmountOfDebtConvertedIntoSharesOfCommonStock>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="C_3495636e-7fc4-46b6-af0e-05bbaa199981"
      decimals="INF"
      id="F_ecbddee1-576f-4728-8793-f4eee9133cca"
      unitRef="U_shares">11119956</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <inva:DebtInstrumentRemainingBalancePaidUponMaturation
      contextRef="C_ae44ab8e-7504-455a-a5c7-18b720494066"
      decimals="0"
      id="F_b2e1fe63-06cc-4a8f-85cb-abec503918ff"
      unitRef="U_USD">25000</inva:DebtInstrumentRemainingBalancePaidUponMaturation>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1"
      id="F_905a8833-bbdb-492d-9685-a8c8b6e63aa2">2025-08-15</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_54e7dc78-e88a-4740-abbe-66bd616fae5d"
      decimals="4"
      id="F_887b1eaa-ebf8-4c83-9178-163987c0208d"
      unitRef="U_pure">0.029</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_b977836a-3754-4918-ab34-119c8e6e97e3"
      decimals="4"
      id="F_d710d844-14ff-46a5-ab12-9dd51544a307"
      unitRef="U_pure">0.0288</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_c43a1118-656f-4694-8c43-8a7ccd87ef7e"
      decimals="4"
      id="F_6038378e-584d-44f9-ac83-4f21887804e1"
      unitRef="U_pure">0.0288</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1"
      id="F_1b12d0d6-0dcf-4d7b-9edf-dd85a5967014">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our 2025 Notes balances consisted of the following as of December 31, 2024:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:70.034%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:2.941%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:25.025%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;192,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_b977836a-3754-4918-ab34-119c8e6e97e3"
      decimals="-3"
      id="F_4130ab61-09d1-474f-9f67-19a34d4aba4a"
      unitRef="U_USD">192500000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_b977836a-3754-4918-ab34-119c8e6e97e3"
      decimals="-3"
      id="F_629079d0-63e3-441f-9706-e679da060568"
      unitRef="U_USD">472000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="C_b977836a-3754-4918-ab34-119c8e6e97e3"
      decimals="-3"
      id="F_3c6a2ad5-cd14-4341-86cd-b4db43b27b2c"
      unitRef="U_USD">192028000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="C_2ff1d571-1f1e-4d04-9274-1397b426e2d1"
      id="F_03ddf773-2dcd-4eee-aa6d-3e946edf1f50">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2025 Notes for the years ended &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,002&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;733&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;712&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_8d85403b-c00a-43af-9139-4133780be452"
      decimals="-3"
      id="F_d20e2d19-7cdc-475e-823e-7513722e63a6"
      unitRef="U_USD">3002000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_8807e583-90bb-4bf2-b789-04fcccd5635c"
      decimals="-3"
      id="F_862b80a9-cd26-4b16-8524-fadbbbdd6cba"
      unitRef="U_USD">4813000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_f3e8c321-fbbd-46fe-ad52-a5cf85e12e92"
      decimals="-3"
      id="F_0d0a33cb-c476-4431-942e-a38f8ea97430"
      unitRef="U_USD">4813000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_8d85403b-c00a-43af-9139-4133780be452"
      decimals="-3"
      id="F_692b0b21-ac79-4b8a-b733-a7cd9a23b838"
      unitRef="U_USD">472000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_8807e583-90bb-4bf2-b789-04fcccd5635c"
      decimals="-3"
      id="F_2a83fa47-ef74-45f1-a123-61f3725dd5e7"
      unitRef="U_USD">733000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_f3e8c321-fbbd-46fe-ad52-a5cf85e12e92"
      decimals="-3"
      id="F_da519cfa-49a3-402c-9f7b-4244eca26bb7"
      unitRef="U_USD">712000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="C_8d85403b-c00a-43af-9139-4133780be452"
      decimals="-3"
      id="F_bd152ee4-19e9-4663-8bdb-85c97cd7450c"
      unitRef="U_USD">3474000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_8807e583-90bb-4bf2-b789-04fcccd5635c"
      decimals="-3"
      id="F_169a3c1a-6c7c-41df-81dc-9b0ef88614bc"
      unitRef="U_USD">5546000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_f3e8c321-fbbd-46fe-ad52-a5cf85e12e92"
      decimals="-3"
      id="F_b8860725-d3a9-4b33-9f81-19e7a667b204"
      unitRef="U_USD">5525000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_19c66b49-0137-43c6-92ab-0b70a3008556"
      decimals="-5"
      id="F_7e529e2a-40b1-43eb-b55f-f21e932f5d39"
      unitRef="U_USD">261000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_ab3f6fa0-6707-4052-910b-d4481b963aad"
      id="F_60d2e0f8-5f4f-49aa-84db-3a9205643aed">2028-03-15</us-gaap:DebtInstrumentMaturityDate>
    <inva:CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes
      contextRef="C_8a0737aa-6de6-4c43-ae8f-624230637866"
      decimals="-5"
      id="F_17ace163-0347-4ff3-bb32-3313f06c0d41"
      unitRef="U_USD">21000000</inva:CostToEnterIntoCappedCallsSalesInConnectionWithConvertibleSeniorNotes>
    <us-gaap:RepaymentsOfUnsecuredDebt
      contextRef="C_12c637ab-fa44-4ddd-a290-1d17a74cbbc4"
      decimals="-5"
      id="F_e68b3b67-6db0-4ace-9d62-8fb077c51ef1"
      unitRef="U_USD">165600000</us-gaap:RepaymentsOfUnsecuredDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="C_b4012fc1-478c-4326-af9a-abfcc793f2a8"
      decimals="-5"
      id="F_25d5555d-0a76-4aa3-9ff2-9689bcace6b7"
      unitRef="U_USD">144800000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_66187a73-ceaf-4466-bbd1-1b86eb8fc0ce"
      decimals="5"
      id="F_eeea7640-3c07-4fda-b5d6-ca05bab83005"
      unitRef="U_pure">0.02125</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="C_b1909c77-5037-4101-951b-72d1da39afc1"
      decimals="4"
      id="F_e0b601f4-05c7-4ebe-9d67-2a65d283b243"
      unitRef="U_pure">38.1432</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="C_f7d4ec88-c122-4840-9402-055ba9f5e83a"
      decimals="2"
      id="F_a8851237-7ac0-4f5f-9ee4-c4af9406e8c6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">26.22</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage
      contextRef="C_ab3f6fa0-6707-4052-910b-d4481b963aad"
      decimals="2"
      id="F_42e23d0a-2baa-4a8a-916a-2822716f994e"
      unitRef="U_pure">1.30</inva:DebtConversionCommonStockPriceToConversionPriceRatioPercentage>
    <inva:DebtConversionConvertedInstrumentAverageTradePricePercentage
      contextRef="C_ab3f6fa0-6707-4052-910b-d4481b963aad"
      decimals="2"
      id="F_7709e6a0-34da-4af1-a0b2-c5f61f6d9c9b"
      unitRef="U_pure">0.98</inva:DebtConversionConvertedInstrumentAverageTradePricePercentage>
    <inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount
      contextRef="C_ab3f6fa0-6707-4052-910b-d4481b963aad"
      decimals="2"
      id="F_7dd4f899-37da-46ed-8a36-4370691bf36e"
      unitRef="U_pure">1</inva:DebtInstrumentRatioOfRepurchasePriceToThePrincipalAmount>
    <us-gaap:LineOfCreditFacilityCovenantTerms
      contextRef="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6"
      id="F_71d6271a-8ae4-47bb-857b-6b7d26167f8b">The indenture governing the 2028 Notes contains customary terms and covenants, including a merger covenant and that upon certain events of default occurring and continuing, either the Trustee or the holders of at least 25% of the aggregate principal amount of the outstanding Notes may declare 100% of the principal of, and accrued and unpaid interest, if any, on, all the Notes to be due and payable immediately.</us-gaap:LineOfCreditFacilityCovenantTerms>
    <us-gaap:OptionIndexedToIssuersEquityStrikePrice1
      contextRef="C_35672b5e-10a9-4748-974c-cf69a518b68a"
      decimals="4"
      id="F_0877ba05-3cd1-4ec0-b347-daa294b80f29"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">33.985</us-gaap:OptionIndexedToIssuersEquityStrikePrice1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="C_b9c78e4a-7998-49df-8911-c4a60d08df86"
      decimals="4"
      id="F_f45caae7-a668-4489-b19f-707cde4bceac"
      unitRef="U_pure">0.027</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6"
      id="F_e48d1317-a2de-45eb-af76-02b592dae487">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our outstanding 2028 Notes balance consisted of th&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;e following:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:67.313%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.5%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.843%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Principal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Debt discount and issuance costs, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,269&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net carrying amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;257,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;256,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ConvertibleDebtTableTextBlock>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_b9c78e4a-7998-49df-8911-c4a60d08df86"
      decimals="-3"
      id="F_d5445b04-a36b-4817-840b-efa8d07cd5d1"
      unitRef="U_USD">261000000</inva:DebtInstrumentPrincipalAmount>
    <inva:DebtInstrumentPrincipalAmount
      contextRef="C_89ffeb43-b4e5-4cd3-b24e-9d0133812b42"
      decimals="-3"
      id="F_4176cfc5-f747-41fe-a1e5-35c3bfee9aa7"
      unitRef="U_USD">261000000</inva:DebtInstrumentPrincipalAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_b9c78e4a-7998-49df-8911-c4a60d08df86"
      decimals="-3"
      id="F_93201433-5d67-4b2a-8a18-c81d95647ab4"
      unitRef="U_USD">3269000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_89ffeb43-b4e5-4cd3-b24e-9d0133812b42"
      decimals="-3"
      id="F_45bb28d9-1b51-42f3-ac9d-e83163ee2bc2"
      unitRef="U_USD">4684000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="C_b9c78e4a-7998-49df-8911-c4a60d08df86"
      decimals="-3"
      id="F_d229739f-4979-49ae-a62a-daef110b69a8"
      unitRef="U_USD">257731000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="C_89ffeb43-b4e5-4cd3-b24e-9d0133812b42"
      decimals="-3"
      id="F_58d8cc0d-1065-45e9-ac47-3d121593e6fe"
      unitRef="U_USD">256316000</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="C_6e2f078a-9044-4e13-96e5-bdbddf0c0bc6"
      id="F_b96d9119-1893-4ffc-b5d6-cc8ddd3e8dc7">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table sets forth total interest expense recognized related to the 2028 Notes for the years ended December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:51.311%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.481%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.75%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Contractual interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of debt discount and issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,342&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total interest and amortization expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,888&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_1e11bcae-e1f5-4912-8d5e-346484926bde"
      decimals="-3"
      id="F_c8c2d339-2b3c-403c-a016-e2bb17845f0d"
      unitRef="U_USD">5546000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_82023995-c0c9-4e2f-af7b-9dff1c4313ef"
      decimals="-3"
      id="F_8b49db20-1a18-4f22-b96f-b52bef1fc32a"
      unitRef="U_USD">5546000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="C_cd448608-93c9-4efb-8910-d496892f68f5"
      decimals="-3"
      id="F_3b4bce4a-37e7-4f1c-9c35-29dbf38c0e71"
      unitRef="U_USD">5546000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_1e11bcae-e1f5-4912-8d5e-346484926bde"
      decimals="-3"
      id="F_0c0bcbd9-8c25-4161-bce3-ee4943e41d60"
      unitRef="U_USD">1415000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_82023995-c0c9-4e2f-af7b-9dff1c4313ef"
      decimals="-3"
      id="F_e50ea378-36ac-47dd-9dc0-dad4efadba00"
      unitRef="U_USD">1377000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="C_cd448608-93c9-4efb-8910-d496892f68f5"
      decimals="-3"
      id="F_1bd7b73e-770b-4413-bbcb-de0ba33feda7"
      unitRef="U_USD">1342000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseDebt
      contextRef="C_1e11bcae-e1f5-4912-8d5e-346484926bde"
      decimals="-3"
      id="F_638381ee-ac23-4bb9-a286-6e90c69d9fde"
      unitRef="U_USD">6961000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_82023995-c0c9-4e2f-af7b-9dff1c4313ef"
      decimals="-3"
      id="F_9e8ee47e-71b0-4c3c-9e19-d0bd283dc8fe"
      unitRef="U_USD">6923000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="C_cd448608-93c9-4efb-8910-d496892f68f5"
      decimals="-3"
      id="F_6192912f-fb71-44fe-a792-38d51e0d8ed0"
      unitRef="U_USD">6888000</us-gaap:InterestExpenseDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_bd582b93-5914-46a5-b678-1e6720e0fe27">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The aggregate scheduled maturities of our convertible debt as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;261,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_fee10808-8a1d-4045-b31f-af5ad55780bb"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_f7ba3f7a-0439-4c12-9458-88eb84f2eebe"
      unitRef="U_USD">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_4ea94c78-3831-4990-a562-4fb74bad3927"
      unitRef="U_USD">261000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_ebf17459-7dd5-4bc1-8ec3-f6cbfab2c418"
      unitRef="U_USD">261000000</us-gaap:DebtInstrumentCarryingAmount>
    <inva:RoyaltyAgreementMaximumPotentialPayoutPercent
      contextRef="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077"
      decimals="2"
      id="F_b3a9c01c-ba71-4233-a67c-4a841295e29b"
      unitRef="U_pure">0.14</inva:RoyaltyAgreementMaximumPotentialPayoutPercent>
    <inva:RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent
      contextRef="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077"
      decimals="2"
      id="F_b9151546-382c-4dba-9600-24f3663d0c76"
      unitRef="U_pure">0.18</inva:RoyaltyAgreementIncreaseInMaximumPotentialPayoutPercent>
    <inva:MaximumAggregateRoyaltyPaymentsDue
      contextRef="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077"
      decimals="-5"
      id="F_ab333c18-32e7-4bee-9c2d-d70b6491a491"
      unitRef="U_USD">225000000</inva:MaximumAggregateRoyaltyPaymentsDue>
    <us-gaap:InterestExpense
      contextRef="C_af13deae-2d89-4cf9-98df-3d7c55d81d4f"
      decimals="-5"
      id="F_ae38111c-eeae-4fc1-9fd1-fa58c25a51bc"
      unitRef="U_USD">6300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_418a0dcc-491c-4849-aebf-ba4f6c3031b4"
      decimals="-5"
      id="F_8cb9846a-e43b-4968-8659-ee4b8a033808"
      unitRef="U_USD">9800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_469092aa-cbc1-422f-9923-e5ef71f3d779"
      decimals="-5"
      id="F_2eaebba5-84eb-4e79-b975-c0f2217ddd1a"
      unitRef="U_USD">6500000</us-gaap:InterestExpense>
    <inva:DeferredRoyaltyObligations
      contextRef="C_ef64ca1c-fe1e-4b9a-b5ff-0a15d056fed5"
      decimals="-5"
      id="F_9cb666e3-94bc-4e12-83ab-d623bb755085"
      unitRef="U_USD">62200000</inva:DeferredRoyaltyObligations>
    <inva:DeferredRoyaltyObligations
      contextRef="C_7e31beca-2974-46b0-a791-da8703f2803a"
      decimals="-5"
      id="F_4d410318-bbf7-4e8c-a932-87f8f47529eb"
      unitRef="U_USD">69500000</inva:DeferredRoyaltyObligations>
    <inva:RoyaltyPayments
      contextRef="C_af13deae-2d89-4cf9-98df-3d7c55d81d4f"
      decimals="-5"
      id="F_bac1da46-85f6-4727-a163-141a8a98226f"
      unitRef="U_USD">12800000</inva:RoyaltyPayments>
    <inva:RoyaltyPayments
      contextRef="C_418a0dcc-491c-4849-aebf-ba4f6c3031b4"
      decimals="-5"
      id="F_3f9d8ffa-93c1-48e1-82fd-6a7bd9a1be3a"
      unitRef="U_USD">9100000</inva:RoyaltyPayments>
    <inva:RoyaltyPayments
      contextRef="C_469092aa-cbc1-422f-9923-e5ef71f3d779"
      decimals="-5"
      id="F_a29aa0b1-f2b2-4a0d-9c0d-bd8419d927ac"
      unitRef="U_USD">5400000</inva:RoyaltyPayments>
    <inva:InterestRateOfDeferredRoyaltyObligation
      contextRef="C_af13deae-2d89-4cf9-98df-3d7c55d81d4f"
      decimals="4"
      id="F_ead1629c-6073-46d2-b6d6-db781bf774fd"
      unitRef="U_pure">0.1003</inva:InterestRateOfDeferredRoyaltyObligation>
    <inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne
      contextRef="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077"
      decimals="-5"
      id="F_202c0632-1ed6-4cc9-a524-0239123f28ca"
      unitRef="U_USD">125000000</inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentOne>
    <inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo
      contextRef="C_8dc0cc08-5c99-41cd-84dd-e9ce296ea077"
      decimals="-5"
      id="F_a2a7df80-3434-446f-9f95-6be6de4bb0af"
      unitRef="U_USD">225000000</inva:RoyaltyAgreementRequiredPaymentForBreachOfAgreementPaymentTwo>
    <inva:TotalPaymentsMadeForRoyaltyAgreement
      contextRef="C_d9b8c46c-1584-49b3-91b6-cc0e6d57dc59"
      decimals="-5"
      id="F_9a5f8d06-10a2-4443-bdad-9f318fcae74d"
      unitRef="U_USD">40000000</inva:TotalPaymentsMadeForRoyaltyAgreement>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_fbdd7324-426c-4165-9771-635c8167c7b3">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;13. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Operating Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have operating leases for our corporate headquarters, office spaces and laboratory facilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In 2019, we entered into an operating lease for our headquarters in Burlingame, California for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,111&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; rentable square feet. The lease commenced in November 2019 with an initial term of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a8d055de-5223-43f2-950c-df6e42a40b2d;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;thirty-six&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; calendar months, which was subsequently amended to expire in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_0cf4230b-14d7-4c03-83f4-80f2b6b31b1a;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 2027&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. Our operating leases include a facility lease consisting of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,500&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office space in Waltham, Massachusetts, which expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_f563af2d-08d9-49fd-bae4-6b8f93526198;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 2029&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In November 2025, we entered into an operating lease for approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,881&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; square feet of office and laboratory space in Lexington, Massachusetts, which expires in &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_7683dbb5-aa29-4655-8dae-71a88a149d59;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 2036&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. We have the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;option to terminate&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; this lease, for an early termination fee, before May 2029.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease costs are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Straight line operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Supplemental cash flow information related to leases are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of &lt;br/&gt;&#160;&#160;&#160;operating lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets obtained in exchange &lt;br/&gt;&#160;&#160;&#160;for operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, our operating leases have weighted-average remaining term of approximately &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;9.6 &lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;years and the weighted-average discount rate on our operating lease liabilities was &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum lease payments on our operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 are as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_f5f169b5-7b43-492f-b75e-5037a78edaec;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Purchase Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2024, we entered into a Commercial Supply Agreement with Corden Pharma CHEN&#xd4;VE SAS (&#x201c;Corden&#x201d;), under which we engaged Corden to manufacture and supply certain products related to XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and to perform certain services and studies. Under the agreement, we committed to minimum purchase commitments through December 31, 2027. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million U.S. dollar equivalent in purchase commitments under the agreement for the years 2026 and 2027, respectively.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;From time to time, the Company is involved in legal proceedings in the ordinary course of its business. We are not currently a party to any material legal proceedings except as discussed below.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 15, 2022, La Jolla received a paragraph IV notice of certification (the &#x201c;First Notice Letter&#x201d;) from Gland Pharma Limited (&#x201c;Gland&#x201d;) advising that Gland had submitted an Abbreviated New Drug Application (&#x201c;ANDA&#x201d;) to the FDA seeking approval to manufacture, use or sell a generic version of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; in the U.S. prior to the expiration of U.S. Patent Nos.: 9,220,745; 9,572,856; 9,867,863; 10,028,995; 10,335,451; 10,493,124; 10,500,247; 10,548,943; 11,096,983; and 11,219,662 (the &#x201c;GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Patents&#x201d;), which are listed in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations (the &#x201c;Orange Book&#x201d;). The First Notice Letter alleges that the GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Patents are invalid, unenforceable and/or will not be infringed by the commercial manufacture, use or sale of the generic product described in Gland&#x2019;s ANDA.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 29, 2022, La Jolla filed a complaint for patent infringement of the GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; Patents against Gland and certain related entities in the United States District Court for the District of New Jersey in response to Gland&#x2019;s ANDA filing. In accordance with the Hatch-Waxman Act, because GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; is a new chemical entity and La Jolla filed a complaint for patent infringement within 45 days of receipt of the First Notice Letter, the FDA cannot approve Gland&#x2019;s ANDA any earlier than 7.5 years from the approval of the GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; NDA unless the District Court finds that all of the asserted claims of the patents-in-suit are invalid, unenforceable and/or not infringed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 22, 2023, La Jolla received a paragraph IV notice of certification (the &#x201c;Second Notice Letter&#x201d;) from Gland advising that Gland had amended its ANDA filing to include a paragraph IV certification alleging that all claims of the newly-issued and Orange Book-listed U.S. Patent No. 11,559,559 (the &#x201c;&#x2019;559 Patent&#x201d;), which covers GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, are invalid, unenforceable and/or not infringed.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 22, 2023, La Jolla filed a First Amended Complaint in this litigation adding Gland&#x2019;s marketing and distribution partners for its ANDA angiotensin II product, Fresenius Kabi USA LLC and Fresenius Kabi SwissBiosim GmbH (collectively, the &#x201c;Fresenius Kabi Defendants&#x201d;), as co-defendants. On April 7, 2023, La Jolla filed a Second Amended Complaint in response to the Second Notice Letter, adding claims that the manufacture, use, sale, offer for sale, or import of Gland&#x2019;s ANDA angiotensin II product will infringe the &#x2019;559 Patent. On November 14, 2023, La Jolla filed a Third Amended Complaint adding additional infringement claims against the Fresenius Kabi Defendants.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 18, 2025, La Jolla, as well as The George Washington University (collectively, with the La Jolla entities, the &#x201c;Plaintiffs&#x201d;) entered into a settlement agreement (the &#x201c;Settlement Agreement&#x201d;) with Gland and the Fresenius Kabi Defendants&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(collectively, &#x201c;Defendants&#x201d;) resolving the Hatch-Waxman Act concerning Gland&#x2019;s ANDA filing. Under the terms of the Settlement Agreement, Plaintiffs granted Defendants a perpetual, royalty-free and fully paid-up, non-exclusive, non-sublicensable, non-transferable right and license solely to make, have made, use, sell, offer to sell, import, and/or distribute the product that is subject to Gland&#x2019;s ANDA in the United States commencing in the early 2030s, subject to certain exceptions as is customary in these type of agreements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As required by law, the settlement is subject to review by the U.S. Department of Justice and the Federal Trade Commission.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Indemnifications and Other Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the ordinary course of business, we may provide indemnifications of varying scope and terms to vendors, directors, officers, and other parties with respect to certain matters, including, but not limited to, losses arising out of breach of such agreements, services to be provided by us, our negligence or willful misconduct, violations of law, or intellectual property infringement claims made by third parties. In addition, we have entered into indemnification agreements with directors and certain officers and employees that will require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors, officers, or employees. No material demands have been made upon us to provide indemnification under such agreements, and thus, there are no claims that we are aware of that could have a material effect on our consolidated financial statements. We also maintain director and officer insurance, which may cover certain liabilities arising from our obligation to indemnify our directors. &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;To date, we have not incurred any material costs and, as of December 31, 2025, we have &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;t accrued any liabilities in the consolidated financial statements as a result of these provisions.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:NetRentableArea
      contextRef="C_392076d3-b2a9-4556-8800-6b9f6d3a290c"
      decimals="INF"
      id="F_c0c863f7-7c6d-43b0-8d86-00977435d93b"
      unitRef="U_sqft">2111</us-gaap:NetRentableArea>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="C_239a2a88-4dcf-4e6d-8f3b-5b1398ae730c"
      decimals="INF"
      id="F_362310dd-3335-4093-8da3-935b3e0b8dc7"
      unitRef="U_sqft">15500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:NetRentableArea
      contextRef="C_bd8929dd-2601-4ff3-b3c5-49946bfb7b0d"
      decimals="INF"
      id="F_86a71894-92d5-48fe-8c3d-32085285cb0c"
      unitRef="U_sqft">22881</us-gaap:NetRentableArea>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_b521682f-1e2a-4476-814a-0867e26b28a6">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToTerminate>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_fab46960-5621-48fe-a145-eab943b70eeb">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of lease costs are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Straight line operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,200&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,515&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,214&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_c782be48-5b54-4be6-b76e-1fc278e98a2d"
      unitRef="U_USD">1424000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_bf85fc73-8c48-4f02-8d0f-4d976e874c6a"
      unitRef="U_USD">1200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_fedd62e8-3ee5-4bfe-9d47-0d3360b8007c"
      unitRef="U_USD">1428000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_3014efa8-cec6-4519-9723-9c1da6e34d0f"
      unitRef="U_USD">91000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_5b9ffcb1-8beb-4f66-9c9d-4fc7df7a415b"
      unitRef="U_USD">14000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_d68bcd71-cba1-4b25-9569-a261ed362a57"
      unitRef="U_USD">189000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_63a5477f-30b6-474b-af19-07c9fdc65d93"
      unitRef="U_USD">1515000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_43eb498f-a8f3-4843-b742-5117fbeb650a"
      unitRef="U_USD">1214000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_23e927ab-12e0-4766-b147-bb300fa7f84b"
      unitRef="U_USD">1617000</us-gaap:LeaseCost>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_826b395c-627d-4590-b998-cbc02ef351da">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Supplemental cash flow information related to leases are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.863%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.281%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:10.764000000000001%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash paid for amounts included in the measurement of &lt;br/&gt;&#160;&#160;&#160;operating lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,464&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,542&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Operating lease right-of-use assets obtained in exchange &lt;br/&gt;&#160;&#160;&#160;for operating lease obligations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,156&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_5d55c0b8-7328-4a5f-ad33-ec82f4344e34"
      unitRef="U_USD">1705000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_9f0b1302-524a-4469-bfcb-b5e68c38dc17"
      unitRef="U_USD">1464000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_3ee024c3-089f-4093-9e69-3d787609d7b1"
      unitRef="U_USD">1542000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_e5b4c551-f7cf-48ac-bea5-363075e26f1c"
      unitRef="U_USD">10022000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_e5b75eb6-c9f7-40fb-8155-77d4ed51ba57"
      unitRef="U_USD">1156000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_5a280a69-d6e1-4058-a54f-d4fe155a50be"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      id="F_02133af7-cac9-4e07-b78d-a189f6ccdeb5">P9Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="3"
      id="F_cca661da-5c3b-4980-9104-c57aee7a7ee5"
      unitRef="U_pure">0.053</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_3dd7dd7b-15ce-457c-8fb9-359cc0536fe9">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Future minimum lease payments on our operating leases as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2025 are as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Year ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,327&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,335&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,454&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;8,516&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,861&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,575&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span&gt;&lt;span style="-sec-ix-hidden:F_f5f169b5-7b43-492f-b75e-5037a78edaec;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_e32f54a6-a909-408e-8520-f139c093754d"
      unitRef="U_USD">1005000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_c0c035ea-da4b-4f6d-bce3-b2e8619f40af"
      unitRef="U_USD">1327000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_0b56be65-626d-4ffd-b508-7b09818c5f28"
      unitRef="U_USD">1224000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_c54d6845-8402-4b9a-b9c8-2c384bd215e5"
      unitRef="U_USD">1335000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_30f80d49-f191-45de-b817-bbcf2eae5b45"
      unitRef="U_USD">1454000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_4b1cf3a8-e24d-4057-9065-426f73ccc078"
      unitRef="U_USD">8516000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_70cdc319-a8d6-485f-951f-e642d88aad61"
      unitRef="U_USD">14861000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_b51d8a85-dc63-467a-a672-e5491aa42114"
      unitRef="U_USD">3575000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_99ebf561-bc1e-4da8-8f87-7dcd24266b8f"
      unitRef="U_USD">11286000</us-gaap:OperatingLeaseLiability>
    <us-gaap:PurchaseObligationDueInNextTwelveMonths
      contextRef="C_9e3bc0e6-f47d-404f-8fee-30b5fd642601"
      decimals="-5"
      id="F_88f8deed-cdb6-4265-a464-6df08c05e5fe"
      unitRef="U_USD">7300000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
    <us-gaap:PurchaseObligationDueInSecondYear
      contextRef="C_9e3bc0e6-f47d-404f-8fee-30b5fd642601"
      decimals="-5"
      id="F_af9363e9-0f15-4bb6-8a84-b4d50d0f3fe5"
      unitRef="U_USD">5900000</us-gaap:PurchaseObligationDueInSecondYear>
    <inva:AccruedLiabilitiesIndemnificationsAndOtherContingencies
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="INF"
      id="F_77a26267-8a9c-437a-bfd1-621398d5bf04"
      unitRef="U_USD">0</inva:AccruedLiabilitiesIndemnificationsAndOtherContingencies>
    <us-gaap:AssetAcquisitionTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_a83b1041-7383-43ff-8acd-36ff44c0dcd4">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;14. ASSET ACQUISITION&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_886ab7f6-fedd-4b48-b757-553a486cfc22;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;September 2025&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, we entered into an Asset Purchase Agreement with Lyndra to acquire the IPR&amp;amp;D and certain fixed assets related to its Lynx&#x99; long-acting drug delivery platform. We made an upfront cash payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and incurred $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million in direct transaction costs. We are also obligated to pay up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million upon the achievement of certain development, regulatory and sales milestone payments, as well as royalties in a low single-digit percentage on future net sales of the first approved therapeutic product.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Based on the qualitative and quantitative assessments performed under ASC 805, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, we concluded that the set of assets acquired did not meet the definition of a business and, therefore, accounted for the transaction as an asset acquisition. The assets acquired in the transaction were recorded at their allocated costs based on their relative fair values. The allocated cost of the IPR&amp;amp;D acquired was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which was charged to research and development expense as it had no alternative future use at the time of the acquisition. The allocated cost of the fixed assets, which consist of laboratory equipment, was $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and was capitalized within property and equipment. The fixed assets have not been placed in service and, therefore, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; depreciation has been recognized as of December 31, 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:AssetAcquisitionTextBlock>
    <inva:UpfrontCashPayments
      contextRef="C_b3eec335-a345-4b7c-9e97-3ceddf99d1e9"
      decimals="-5"
      id="F_b6770e5a-064d-4294-9253-d8bc6452905c"
      unitRef="U_USD">10200000</inva:UpfrontCashPayments>
    <us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost
      contextRef="C_b3eec335-a345-4b7c-9e97-3ceddf99d1e9"
      decimals="-5"
      id="F_5a94abec-ed6e-442b-812b-9293a87da87e"
      unitRef="U_USD">300000</us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost>
    <inva:FuturePotentialMilestonePayment
      contextRef="C_12d3c44d-918f-48e8-85fa-931a2e84dfd8"
      decimals="-5"
      id="F_349c11b9-6d14-42d7-a7b5-336395d67867"
      unitRef="U_USD">20000000</inva:FuturePotentialMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3b12d761-39cf-4255-8780-b3b2751a6c1a"
      decimals="-5"
      id="F_9f239bc2-368c-4e5c-bbbb-ba175bed0383"
      unitRef="U_USD">9400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CapitalizedContractCostNetNoncurrent
      contextRef="C_1087a715-1e7f-4e3f-96b3-efbc3f9782ab"
      decimals="-5"
      id="F_6cb33453-bb38-4c84-80bc-599e977f4aee"
      unitRef="U_USD">1100000</us-gaap:CapitalizedContractCostNetNoncurrent>
    <us-gaap:Depreciation
      contextRef="C_82eb691b-750a-475a-837f-1b1397fcb267"
      decimals="-6"
      id="F_ebaa776e-54a6-438e-9444-c0ba02548846"
      unitRef="U_USD">0</us-gaap:Depreciation>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_8bb927a8-2e95-4a34-9a87-6df0598ab8c2">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;15. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of income before provision for income taxes are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.371%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;327,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;326,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income tax expense consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.371%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We adopted ASU 2023-09 on a prospective basis beginning with the year ended December 31, 2025. The following table presents required disclosure pursuant to ASU 2023-09 and reconciles the U.S. federal statutory tax amount and rate to our actual global effective amount and rate of the year ended December 31, 2025&lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;: &lt;/span&gt;&lt;/span&gt;&lt;span style=""&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.447%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.738%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and local effects&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign tax effects&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other - Withholding taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Enactment of new tax laws&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cross-border tax laws&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)	&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For tax year 2025, state taxes in Kentucky made up the majority (greater than 50 percent) of the tax effect in this category.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As previously disclosed for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income tax rate as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected tax at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income tax expense, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal and state research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Section 250 deduction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the income taxes paid (net of any refunds received) for the year ended December 31, 2025 in accordance with the new guidance in ASU No. 2023-09:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and local jurisdiction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net cash paid for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. &lt;/span&gt;&lt;span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant components of our deferred tax assets and deferred tax liabilities are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;172,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred royalty obligation, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;187,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventory fair value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We record deferred tax assets if the realization of such assets is more likely than not to occur. Significant management judgment is required in determining whether a valuation allowance against the deferred tax assets is required. We have considered all available evidence, both positive and negative, such as our historical operating results and predictability of future taxable income, in making such determination. We are also required to exercise significant management&#x2019;s judgment in forecasting future taxable income. Specifically, we evaluate the following criteria when considering a valuation allowance:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;the history of tax net operating losses in recent years;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;predictability of operating results;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;profitability for a sustained period of time; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:10pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.447919145106397%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;level of profitability on a quarterly basis.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, we had federal net operating loss carryforwards of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;497.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;448.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of which do not expire. We &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;also had state net operating loss carryforwards of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,028.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, which will expire&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; beginning &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_d97c91ae-1703-4480-a2ca-20778c18458e;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2030&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, and state research tax credits of approximately $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, which will expire beginning &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_e2ca3e4b-1265-4708-9028-4bacbb4bf6a7;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;2033&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Utilization of net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code and similar state provisions. Annual limitations may result in expiration of net operating loss and tax credit carryforwards before some or all of such amounts have been utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We conducted an Internal Revenue Code of 1986, as amended, Section 382 (&#x201c;Section 382&#x201d;) analysis through December 31, 2025 to determine whether an ownership change had occurred since inception. The Section 382 study concluded that it is more likely than not that the Company did not experience an ownership change during the testing period. However, notwithstanding the applicable annual limitations, no portion of the net operating loss or credit carryforwards is expected to expire before becoming available to reduce federal and state income tax liabilities as a result of those identified ownership changes. If we undergo an ownership change, the utilization of the pre-ownership change net operating loss carryforwards or pre-ownership change tax attributes, such as research tax credits, to offset the post-ownership change income may be subject to an annual limitation, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. Similar rules may apply under state tax laws.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of December 31, 2025, $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of Entasis&#x2019; federal net operating losses and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;351.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of La Jolla&#x2019;s federal operating losses from the acquisitions in 2022, both subject to annual limitations, were available for future utilization.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December 31, 2025 and 2024, we have accrued interest or penalties of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net increase in tax portions for 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net increase in tax portions for 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net increase in tax portion for 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We are subject to taxation in the U.S. and various state &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;jurisdictions. The tax years 2006 through 2013, 2015 and forward remain open to examination by the federal and most state tax authorities due to net operating loss and overall credit carryforward positions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_1a7ced56-41f0-4c33-b20a-1872aca58634">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The components of income before provision for income taxes are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.371%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Domestic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;327,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,362&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194,034&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;198&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income before provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;326,862&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,388&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;194,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_b0018f21-36e1-4754-8c78-5cb6f0413340"
      unitRef="U_USD">327060000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_670382c9-0cf4-4e55-a205-c69952ea3063"
      unitRef="U_USD">37362000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_7c7b11e1-521f-4061-ba4c-dc504388b5bc"
      unitRef="U_USD">194034000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_480b4569-3847-4f72-9875-262070abf10d"
      unitRef="U_USD">-198000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_53bb8c4d-a5cf-4755-9bbc-5468aa863863"
      unitRef="U_USD">26000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_7408528a-bf3b-4d82-b420-618d738eec5f"
      unitRef="U_USD">64000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_dd1c17d0-eb8d-4d22-940a-0325c7fcf995"
      unitRef="U_USD">326862000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_dd424ed8-7d49-4d08-9a89-eecfd66190b7"
      unitRef="U_USD">37388000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_137ea0dc-f825-418e-a466-389c229f6da9"
      unitRef="U_USD">194098000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_33d6838d-2417-46d1-b28c-bb9918661412">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income tax expense consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.371%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,578&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,438&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,799&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,795&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,976&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;42,745&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,606&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,594&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,102&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,194&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;43,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:30pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:5.56%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_ca108d24-ee30-47e1-825f-cf1204030348"
      unitRef="U_USD">6578000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_264c2d3c-9a5d-4b5f-bec4-a865195c771e"
      unitRef="U_USD">23438000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_9437d738-1a02-4013-a921-2637e64b297e"
      unitRef="U_USD">7799000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_ef0d7bbb-97ac-4121-8125-d4f7a3a17614"
      unitRef="U_USD">3477000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_140d65c1-ce3c-4c3c-83e8-b022390de17c"
      unitRef="U_USD">3175000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_9de96713-cb74-47db-8240-8e5ca01ab794"
      unitRef="U_USD">2177000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_0d9b57c9-98ca-4df6-af44-25301e479491"
      unitRef="U_USD">1795000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_733feb5f-06b4-4daf-ad3a-9ab268ddbf89"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_be98fff9-6f02-450c-9f9a-3cc7ec3d2023"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_c97aa92b-850a-4cb6-ae49-af01e2bc533b"
      unitRef="U_USD">11850000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_1a9db334-0b4a-406f-8fb9-a66bdaf0e989"
      unitRef="U_USD">26613000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_ae685665-8ae4-4184-a280-00434425f4f9"
      unitRef="U_USD">9976000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_9d6d1584-bdf0-4379-8fba-2fc358b97e3c"
      unitRef="U_USD">42745000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_8b52a30a-33df-4c51-8f8a-0cef052bc5f6"
      unitRef="U_USD">-12606000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_cfa80010-73a3-4afb-8bc5-d55d5da1e327"
      unitRef="U_USD">6594000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_16ce860b-0029-4dd4-942d-141bdb28285d"
      unitRef="U_USD">1102000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_57da6b5b-cc5f-4084-8879-c35475301bba"
      unitRef="U_USD">-11000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_66f97dbe-dbf5-4fc5-8984-6a9c835956ae"
      unitRef="U_USD">-2194000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_a488ade8-6f24-4c2e-8006-b0975dd83635"
      unitRef="U_USD">43847000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_ff527c21-3635-4309-a442-2f2679fb61de"
      unitRef="U_USD">-12617000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_3a6fafab-b009-49c9-a658-26f6db2f8520"
      unitRef="U_USD">4400000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_99539bd2-1b8a-47be-b589-1ddf84c4747c"
      unitRef="U_USD">55697000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_3a874f4f-8976-4ea4-816c-7adb8f52b918"
      unitRef="U_USD">13996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_40c4534a-019a-446a-a18a-5475d74c9885"
      unitRef="U_USD">14376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_298434e9-3a46-4796-b625-e5e6c7c203f7">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;: &lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:64.447%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.88%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:16.537%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.4%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.738%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;U.S. federal tax at statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;68,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and local effects&lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign tax effects&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other - Withholding taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Enactment of new tax laws&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cross-border tax laws&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign tax credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,555&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:5pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:0.92%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development credit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in unrecognized tax benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Effective tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid;margin-right:74.667%;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;(1)	&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For tax year 2025, state taxes in Kentucky made up the majority (greater than 50 percent) of the tax effect in this category.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As previously disclosed for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income tax rate as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:47.56%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.38%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.58%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.26%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Expected tax at federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,846&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;40,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State income tax expense, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal and state research credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Section 250 deduction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18,386&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,219&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;0.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table presents the income taxes paid (net of any refunds received) for the year ended December 31, 2025 in accordance with the new guidance in ASU No. 2023-09:&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_1e78d809-678c-4dcc-89ca-3ecd230da355"
      unitRef="U_USD">68682000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_5002674f-6455-44fd-8a52-b071ae4f19ae"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_517fc5ee-af94-4656-b409-1fd12f23ccf1"
      unitRef="U_USD">2739000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_9109e66c-349f-4b2b-9c9b-cdbaabe2fdff"
      unitRef="U_pure">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_98209e3d-dd48-4e95-ab1a-7801b867aeef"
      unitRef="U_USD">1796000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_a0dd9ce5-72a6-49ef-b2c1-5d37a546d152"
      unitRef="U_pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_d4046e45-e91a-4059-8417-704db0dd9342"
      unitRef="U_USD">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="2"
      id="F_97b8812e-ebcf-4706-870d-89731e495f9f"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_2bcc8c2b-aebf-46bf-a866-ffcdbac45743"
      unitRef="U_USD">7543000</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_5ca7eab8-bd79-45db-a4f3-21bd7f6b0b64"
      unitRef="U_pure">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_5c8bcf0f-b4c6-4f39-ad60-a80ae537229a"
      unitRef="U_USD">1555000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_7e9f38f5-7b1d-47b3-971a-3bd9d116b7b5"
      unitRef="U_pure">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_428ee736-a981-406e-a79c-7bf47b20242a"
      unitRef="U_USD">324000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_10951b3e-9023-499b-b657-f42b23bcbe10"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_2bc51f83-656f-4638-b5c6-4271e390e1cb"
      unitRef="U_USD">-11726000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_36fa9619-33eb-4939-b173-b769de50b29b"
      unitRef="U_pure">-0.036</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_69c101cb-19c0-4b7a-b269-1f6644bbc7bc"
      unitRef="U_USD">407000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_b0e5b1d3-06b3-4d27-8739-2117604ca7cb"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <inva:IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_695fec17-42f3-4011-9c43-f25ef544c99f"
      unitRef="U_USD">3709000</inva:IncomeTaxReconciliationChangesInUnrecognizedTaxBenefits>
    <inva:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_8caf3ba6-70c1-4deb-b029-9c4d29330602"
      unitRef="U_pure">0.011</inva:EffectiveIncomeTaxRateReconciliationChangesInUnrecognizedTaxBenefitsPercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_49a37162-4b30-4155-80f3-6eefc9e956de"
      unitRef="U_USD">-488000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_bc1ead2c-dabd-457f-80e4-75331b9dfafb"
      unitRef="U_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_d75b4103-f846-4080-a8ce-cf73317e0267"
      unitRef="U_USD">55697000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="3"
      id="F_01c24fd1-99d9-4c53-98f4-d3a863f90abd"
      unitRef="U_pure">0.17</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_07bf816a-4947-4a4c-a5f3-ce34db7d3178"
      unitRef="U_USD">7846000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="3"
      id="F_14d57082-6e4f-490c-ac02-5bc9f40a62d2"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_4d4fd102-9300-4795-9d35-7159339cf18d"
      unitRef="U_USD">40747000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="3"
      id="F_5fa6d3a1-b8eb-473c-a92d-aba4e6a8b189"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_97535dbd-af98-44e4-8b10-887a950c395e"
      unitRef="U_USD">1864000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="3"
      id="F_69c864ff-7489-46c2-8f99-f7daedd166e8"
      unitRef="U_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_663a5e46-b7a2-47b8-835e-4f31bc282a4f"
      unitRef="U_USD">1433000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="3"
      id="F_5d495d8d-170e-4f7b-97d9-7937a76c4f99"
      unitRef="U_pure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_c94eb1de-716f-4656-8a88-afa8501c79e9"
      unitRef="U_USD">90000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="3"
      id="F_bfbbc144-a33c-4e84-893c-bcfd88afda96"
      unitRef="U_pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_acd60602-f854-42d9-8785-d76163778955"
      unitRef="U_USD">1582000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="3"
      id="F_ce5c873f-17db-4fab-bf6d-d8140ec153e1"
      unitRef="U_pure">0.008</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_b0c9514f-a315-4e34-89b5-c9973283c300"
      unitRef="U_USD">-11767000</inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount>
    <inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="3"
      id="F_6339f31c-5424-4060-8662-4b0ba3890d52"
      unitRef="U_pure">-0.315</inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent>
    <inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_31d5ce56-5bc0-4b64-9749-8bc134f25a4a"
      unitRef="U_USD">-15274000</inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionAmount>
    <inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="3"
      id="F_2e5987a6-0b36-425b-80a8-d9970307c6f1"
      unitRef="U_pure">-0.079</inva:EffectiveIncomeTaxReconciliationSectionTwoFiftyDeductionPercent>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_fe8eb88a-9c43-4fb7-a647-31d2d3e0dabf"
      unitRef="U_USD">18386000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="3"
      id="F_e25aa395-956a-42d4-9949-cf228e96ae0f"
      unitRef="U_pure">0.492</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_f017ee22-ab74-48bb-b3ff-4383c35d1744"
      unitRef="U_USD">-12167000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="3"
      id="F_d7d0a17e-ab99-471a-9ab4-bcf885850df8"
      unitRef="U_pure">-0.062</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_1164a2f3-6c5a-4548-87fe-6610d52e6e94"
      unitRef="U_USD">-2243000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="3"
      id="F_566092b7-0132-40de-a6c8-dde6ccb62e6c"
      unitRef="U_pure">-0.06</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_2c04e4a5-5e0e-43fe-b25b-abe70c152e19"
      unitRef="U_USD">1219000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="3"
      id="F_3427f054-9596-4371-8d69-157751881585"
      unitRef="U_pure">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_1b706d5f-c857-4b69-b874-6882569c5d46"
      unitRef="U_USD">13996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="3"
      id="F_ba5ea9f9-9cce-4751-a608-f35e00635c60"
      unitRef="U_pure">0.375</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_09869c84-05d7-413a-9236-2b89fdad6044"
      unitRef="U_USD">14376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="3"
      id="F_a014bcf6-9fdc-42a3-b2b8-fc6dd5e29c35"
      unitRef="U_pure">0.074</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <inva:IncomeTaxesPaidNetTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_128ad636-d5a4-4305-8d97-5554b754b383">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&#160;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;State and local jurisdiction&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;436&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net cash paid for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</inva:IncomeTaxesPaidNetTableTextBlock>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_1ef1ff30-e8ef-4d5c-b296-a140e0ecefb8"
      decimals="-3"
      id="F_ddbc688e-9966-4e1c-8e0a-26a66a19a261"
      unitRef="U_USD">17300000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_a676b1bd-fe43-4060-abbc-19a8821970e5"
      decimals="-3"
      id="F_21086e88-3ea4-4709-93e9-2e995d8156c1"
      unitRef="U_USD">1377000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_769493ad-88b4-4914-8b59-414f7ab2d4da"
      decimals="-3"
      id="F_715328e2-b8e6-498e-96de-e7e92b7971f1"
      unitRef="U_USD">436000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_d837cacc-43b2-46b3-9011-5ea46b98cd73"
      unitRef="U_USD">19113000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_b0b66eaf-3a89-4bf5-af33-ae91346bdcfa">&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Significant components of our deferred tax assets and deferred tax liabilities are as follows:&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:61.232%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.78%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.603%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;172,440&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,989&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,270&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,359&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrealized losses on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,481&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred royalty obligation, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;17,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,479&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,942&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,832&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;217,785&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;234,113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;176,151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;187,635&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,634&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;32,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrealized gains on investment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;37,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Inventory fair value adjustment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,798&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,413&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:20pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:3.707%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,793&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;12,054&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_aa4b3c78-2bdd-494d-a059-1edb8a2b97fd"
      unitRef="U_USD">172440000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_ce636520-1230-4ded-ab91-bda713703523"
      unitRef="U_USD">176989000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_edaf70d4-c68e-400c-ab69-bd2255aceb66"
      unitRef="U_USD">21270000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_020dd3ea-a9bd-4494-8417-e41af0474885"
      unitRef="U_USD">21359000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_520c1826-e2d0-456d-9f3d-69feced8bd88"
      unitRef="U_USD">0</inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet>
    <inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_b88b22f4-4914-4c58-9c7e-729f35325e52"
      unitRef="U_USD">11481000</inva:DeferredTaxAssetsUnrealizedLossesOnInvestmentNet>
    <inva:DeferredTaxAssetsDeferredRoyaltyObligationNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_4b3c19bf-ab39-4f07-95d4-56545ead6412"
      unitRef="U_USD">15654000</inva:DeferredTaxAssetsDeferredRoyaltyObligationNet>
    <inva:DeferredTaxAssetsDeferredRoyaltyObligationNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_059900d8-f359-41a8-893a-91481f7563a2"
      unitRef="U_USD">17452000</inva:DeferredTaxAssetsDeferredRoyaltyObligationNet>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_09fd6e8d-4ac7-42ec-8b66-f592b7c14a72"
      unitRef="U_USD">2479000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_092ccbbb-45ca-48cd-9374-bd3f1a5447ec"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_832f9b21-f58d-42ea-8f47-04efb32681c9"
      unitRef="U_USD">5942000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_af3ce170-cc06-4be1-a889-9af7d502ce14"
      unitRef="U_USD">6832000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_e41f2ea1-158d-4243-8112-9935787100bd"
      unitRef="U_USD">217785000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_f776ebd5-40dd-4d99-801d-14a622078960"
      unitRef="U_USD">234113000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_b3e81f64-e7f7-421a-9c99-a306deb86ce1"
      unitRef="U_USD">176151000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_b32db38f-65b6-4b0d-9e69-37998bb2acf7"
      unitRef="U_USD">187635000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_6d336dab-9219-4870-9214-aedfefcbc490"
      unitRef="U_USD">41634000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_8f26497a-486d-4f32-abe5-bf3db4768669"
      unitRef="U_USD">46478000</us-gaap:DeferredTaxAssetsNet>
    <inva:DeferredTaxLiabilitiesDepreciationAndAmortization1
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_8fed6e15-b3e1-4cc9-a282-476a6729746b"
      unitRef="U_USD">32205000</inva:DeferredTaxLiabilitiesDepreciationAndAmortization1>
    <inva:DeferredTaxLiabilitiesDepreciationAndAmortization1
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_eae6c5c2-25ed-4996-b53c-a64af843ebfb"
      unitRef="U_USD">31626000</inva:DeferredTaxLiabilitiesDepreciationAndAmortization1>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_ff1cc3ad-8ad1-446c-9a28-b7cdae18cfea"
      unitRef="U_USD">37823000</us-gaap:DeferredTaxLiabilitiesInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestments
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_69cfc4ef-0d7a-48ed-97b0-c5aab0d088cc"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesInvestments>
    <inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_5b8ad3dd-6177-4e98-ab0a-fe2c573cdc6a"
      unitRef="U_USD">986000</inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment>
    <inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_c6f68ef6-5416-4995-a97a-83a701837e91"
      unitRef="U_USD">2798000</inva:DeferredTaxLiabilitiesInventoryFairValueAdjustment>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_725a8f78-5407-49ec-b7b5-7dc445111736"
      unitRef="U_USD">2413000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_a33381c0-31bb-481f-ba9b-e82d7517a6a1"
      unitRef="U_USD">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_70b42814-1a60-428e-926d-11abd4227c2e"
      unitRef="U_USD">31793000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_b9ecd144-3aea-4cda-b062-dd2aabf6efd3"
      unitRef="U_USD">12054000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_f82e39f9-72f9-4bd5-b3fc-b3493d1d8807"
      decimals="-5"
      id="F_3b9dff14-ed28-4d00-9be4-46a9e378f484"
      unitRef="U_USD">497700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="C_f82e39f9-72f9-4bd5-b3fc-b3493d1d8807"
      decimals="-5"
      id="F_8bd2cf39-8b0f-4fc8-9514-412381d86686"
      unitRef="U_USD">448200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_9384f77e-6605-4a4c-8810-bf720c3d9a70"
      decimals="-5"
      id="F_a432c2f1-c1db-472a-87e8-c29638f253f9"
      unitRef="U_USD">1028900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_ff2f5579-9b38-485b-a615-3c335d3187e6"
      decimals="-5"
      id="F_9648c101-fb67-4346-b1f0-e8b206d08995"
      unitRef="U_USD">33600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_3dffd990-dade-4459-b4ce-3100fb9fd1df"
      decimals="-5"
      id="F_fec180d6-6c2e-458a-8bde-b4133ee2ad77"
      unitRef="U_USD">146500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_cdd50e55-f430-4309-b1e7-fe3c5bc72c13"
      decimals="-5"
      id="F_3752130c-0e24-49ef-afdf-baa78aa00557"
      unitRef="U_USD">351200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-5"
      id="F_006bc325-8870-403e-99a3-ac97089dde54"
      unitRef="U_USD">3300000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-5"
      id="F_c41b75fd-688d-49a2-9d02-63a5dd0248ba"
      unitRef="U_USD">400000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_105968db-25a0-4375-98e4-ec8cbf024860">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:80.444%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.8%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:15.757%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,324&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net increase in tax portions for 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,119&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net increase in tax portions for 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;61,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Net increase in tax portion for 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,415&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Unrecognized tax benefits as of December 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;62,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a60c1143-acae-40be-9475-53a07ff86264"
      decimals="-3"
      id="F_4ac575bb-e99a-4e4f-9ff2-50ec2d689fc7"
      unitRef="U_USD">16324000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_90c273bc-efd9-46ff-b37e-0a26b4ee11df"
      decimals="-3"
      id="F_4688d703-0e05-40d3-8c63-6198f7f249ea"
      unitRef="U_USD">3119000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_a6f00937-2ee4-4566-bd68-45c44b998d3b"
      decimals="-3"
      id="F_e4aa85f6-a7f2-4923-a9a7-ae3714d5d8ff"
      unitRef="U_USD">19443000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_6741d1a0-84aa-4dd6-9ecb-fd80778c5c54"
      decimals="-3"
      id="F_d10aafd8-0dd5-4099-8d28-0f053dcd040b"
      unitRef="U_USD">41851000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_f5dddcf0-ff36-4f18-9101-9e05a05ba558"
      decimals="-3"
      id="F_b48941aa-17db-43d4-998e-f2739eef5cca"
      unitRef="U_USD">61294000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      decimals="-3"
      id="F_35561e2f-a360-426c-810a-e7bc0f45e562"
      unitRef="U_USD">1415000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_aac97a17-df6e-4461-927e-d6634b600e0e"
      decimals="-3"
      id="F_5a5b8420-28ce-497c-94fc-9661c8b9387c"
      unitRef="U_USD">62709000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_e712617a-4573-4b84-8475-52358b2a12ba">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;16. SEGMENT REPORTING&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We operate as a single operating and reportable segment, focused on creating value for our stockholders. We achieve this by maximizing the value of our respiratory royalty portfolio and growing our investments in innovative healthcare assets that address critical unmet medical needs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our Chief Executive Officer, as the chief operating decision-maker (&#x201c;CODM&#x201d;), evaluates the Company&#x2019;s financial performance and operational efficiency using consolidated net income. This helps guide decisions related to commercial operations, product development, and regulatory compliance, ensuring resources are allocated effectively to support growth initiatives. Consolidated net income also helps inform reinvestment strategies to strengthen our market position and drive innovation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting policies of the segment are the same as those described in Note 1, &#x201c;Description of Operations and Summary of Significant Accounting Policies&#x201d;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our revenues are generated primarily from our collaborative arrangements and royalty payments from GSK, located in Great Britain. We also generate revenue from net product sales of GIAPREZA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, XACDURO&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, XERAVA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and ZEVTERA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:4.355pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, as well as license and other revenues. Refer to Note 3, &#x201c;Revenue Recognition&#x201d;, for more information on our revenues for the periods presented.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Our long-term assets are located within the United States. The CODM does not review assets at a different level or category than the amounts disclosed in the consolidated balance sheets.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below presents the financial information used by the CODM to assess performance, which reconcile to the consolidated net income:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.371%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;411,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;358,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;310,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of products sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of license revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development - External services and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development - Internal expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development - Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair values of equity method investments, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair values of equity and long-term investments, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and dividend income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consolidated net income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;179,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_648bc704-5c66-47cf-8a02-fb6d650236c8">&lt;p style="text-indent:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:10pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The table below presents the financial information used by the CODM to assess performance, which reconcile to the consolidated net income:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:53.371%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:12.122%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(In thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;411,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;358,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;310,463&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Less:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of products sold&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,598&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;41,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cost of license revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Amortization of acquired intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;26,277&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Selling and marketing&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;36,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;31,441&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30,739&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;76,816&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;67,493&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development - External services and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,705&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7,408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development - Internal expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,531&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,246&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Research and development - Acquired IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9,368&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair values of equity method investments, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;141,433&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;64,253&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;77,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Changes in fair values of equity and long-term investments, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;59,161&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;11,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest and dividend income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,086&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,141&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16,698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;22,209&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;19,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,997&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Income tax expense, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;55,697&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;13,996&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;14,376&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Consolidated net income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;271,165&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;179,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;text-align:left;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_ec6e9697-1dec-487f-a01e-fc0d317535b0"
      unitRef="U_USD">411328000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_9b81202a-d99d-4507-91be-57206751d2ac"
      unitRef="U_USD">358711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_b41d0218-0a17-4bda-8231-27cbfd962038"
      unitRef="U_USD">310463000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_add7b0b6-f915-44d8-9105-5a165235bb5f"
      decimals="-3"
      id="F_a9b975d3-1832-4511-9005-57ff9f43315c"
      unitRef="U_USD">77384000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_fbf1519b-20bc-45f3-9a32-993d11ff1a9a"
      decimals="-3"
      id="F_e725f5ee-4a79-49e9-a18c-80bcae8cb560"
      unitRef="U_USD">36598000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_5f25c1f8-433a-423e-bc21-4d71d0ad9d56"
      decimals="-3"
      id="F_93ad22c2-31e0-4369-b3ad-11c946377a22"
      unitRef="U_USD">41040000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfRevenue
      contextRef="C_3abf2681-e826-490a-9f8d-3f1f04055925"
      decimals="-3"
      id="F_575dcbed-a14a-48c2-9fcb-394c2d4baeda"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_fb40e1d0-39fb-4a52-b44c-a1ea5cf0b3b5"
      decimals="-3"
      id="F_de22f2c3-e771-42e2-8162-18bc3d5b9b5e"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_4fd4e6e2-8b75-4ad1-8522-73d454c9804c"
      decimals="-3"
      id="F_c8dc362a-6c8e-4a77-a6f9-d041424cd3b6"
      unitRef="U_USD">1600000</us-gaap:CostOfRevenue>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_9f75fb62-cbce-4827-a043-1d7932b8d0f3"
      unitRef="U_USD">26277000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_fe1d75ce-e79e-4fb3-8f6a-e06a5077fed2"
      unitRef="U_USD">25902000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_c3042e71-3c9d-4093-86ea-6d57ac118fab"
      unitRef="U_USD">21784000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_4ddb1109-045d-4cf1-b052-c78aa6c1cb38"
      unitRef="U_USD">36502000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_c6ab699c-50bf-45a4-a935-f872627d6873"
      unitRef="U_USD">31441000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_5c4defac-4840-4858-8edb-5cb0daba494f"
      unitRef="U_USD">30739000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_d6820cd4-f942-42d1-ac07-01b494d4325b"
      unitRef="U_USD">76816000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_d5f1bbcd-b533-4b56-a6ee-8dcd53077dd9"
      unitRef="U_USD">84249000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_a968f83d-a4e8-4647-be56-3e052a2f809e"
      unitRef="U_USD">67493000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_f8268174-30fe-44ea-9afa-6854f75ab23e"
      decimals="-3"
      id="F_a835d353-fb3f-458f-99bb-cf18ac2d5f14"
      unitRef="U_USD">15705000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_a16a824d-5e09-43a8-8e7c-eb26e31d2066"
      decimals="-3"
      id="F_952daf13-46ae-41f4-923a-4cc0c161ebfe"
      unitRef="U_USD">7408000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_bec30008-f686-4815-ac74-3fb4d99703f8"
      decimals="-3"
      id="F_d791bc24-bb4d-4b7d-a262-ce4ce184c76a"
      unitRef="U_USD">20051000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b531a65e-a381-43b5-9fc1-7c2a415d40f1"
      decimals="-3"
      id="F_ebf10f27-a1a7-40f2-9af8-945381a753d9"
      unitRef="U_USD">5531000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_95f17691-1422-4df6-a2c2-e728a595c89b"
      decimals="-3"
      id="F_f9d86678-bd1b-414d-bbc9-d056807104fc"
      unitRef="U_USD">6246000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_325eaf5e-1225-4fc5-8b0c-361313195292"
      decimals="-3"
      id="F_a416e1a0-e05b-4911-aa45-3a011381b851"
      unitRef="U_USD">13871000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3b0f0144-4aec-4d86-b2d3-8de8224c3e06"
      decimals="-3"
      id="F_1854cd08-7e85-4aa9-b410-3799b3ea6e27"
      unitRef="U_USD">9368000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_67ee3158-4444-4bb2-b548-1b1d24bb1077"
      decimals="-3"
      id="F_b39fc078-2950-4489-b3df-546a43b9f82f"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_ca4eb91e-0456-4f17-b035-ed0e47cc770a"
      decimals="-3"
      id="F_97607b7c-754a-4619-9f73-6e958f3f4be5"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_d875dbf0-f2aa-4e5c-9423-06d297a278df"
      unitRef="U_USD">141433000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_c30f436f-c08b-44dc-8fbb-0daff351d607"
      unitRef="U_USD">-64253000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_c6d86d48-c9a8-4334-848d-54d4666200c2"
      unitRef="U_USD">77392000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_ee08c616-fa9f-4e0c-bb93-bfa9a908ec9f"
      unitRef="U_USD">20160000</inva:GainLossOnOtherInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_303adb9c-906a-4ad3-a906-9e5befba8255"
      unitRef="U_USD">-59161000</inva:GainLossOnOtherInvestments>
    <inva:GainLossOnOtherInvestments
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_3d402515-6d17-4b04-bef0-b1b6ed26f522"
      unitRef="U_USD">11129000</inva:GainLossOnOtherInvestments>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_566884c8-9a19-455d-9792-aeef5436195c"
      unitRef="U_USD">21086000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_3bf4f2fb-4953-4aea-8499-e85913ac67cb"
      unitRef="U_USD">19141000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_82131da8-b1f8-4038-9daf-12a6dceb6239"
      unitRef="U_USD">15818000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_0aeda1aa-f6f3-4674-b559-1d1c5ce25aec"
      unitRef="U_USD">16698000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_a374d1be-75b2-4ed6-b9ad-682e2c99a1f8"
      unitRef="U_USD">22209000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_1005386f-5069-4ce5-8ad1-51673554ee10"
      unitRef="U_USD">19157000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_61a0e9b4-5330-4130-b40b-1e5d65a99a0c"
      unitRef="U_USD">-2864000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_9582d89a-8365-4b64-9e4f-916479c39e08"
      unitRef="U_USD">-2997000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_2ee0a9ee-b696-40c0-9e2c-d9cf030d17ba"
      unitRef="U_USD">-4969000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_07e9e0e4-ea8e-4a43-a299-a1285269f3d6"
      unitRef="U_USD">55697000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_15c03031-0ce0-435e-a47b-381776552fff"
      unitRef="U_USD">13996000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_649d3448-124a-450b-a3c2-4f132cb84132"
      unitRef="U_USD">14376000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="C_01c6be5d-cc54-49d6-8b11-353961389b35"
      decimals="-3"
      id="F_9199d056-fe33-46bb-9c2e-be6d24c1d1aa"
      unitRef="U_USD">271165000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_ee82b043-3066-4252-90eb-266f31f3d243"
      decimals="-3"
      id="F_812a9cf2-19e7-4dec-b0a0-b71e07099f23"
      unitRef="U_USD">23392000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_ff91d1f1-1412-41c3-9883-093cc75f3130"
      decimals="-3"
      id="F_938810a2-66c6-4c5d-8302-5748127659cf"
      unitRef="U_USD">179722000</us-gaap:ProfitLoss>
    <dei:AuditorOpinionTextBlock
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_4d6cff2a-7254-40e3-9ef6-d50be41fedf5">&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Opinion on the Financial Statements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have audited the accompanying consolidated balance sheets of Innoviva, Inc. and subsidiaries (the &#x201c;Company&#x201d;) as of December 31, 2025 and December 31, 2024, the related consolidated statements of income, comprehensive income, stockholders&#x2019; equity, and cash flows, for each of the three years in the period ended December 31, 2025, and the related notes (collectively referred to as the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025 and December 31, 2024, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#x2019;s internal control over financial reporting as of December 31, 2025, based on criteria established in &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Internal Control&#x2014;Integrated Framework (2013)&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25, 2026, expressed an unqualified opinion on company&#x2019;s internal control over financial reporting.&lt;/span&gt;&lt;/p&gt;</dei:AuditorOpinionTextBlock>
    <dei:AuditorName
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_1f0529a2-7096-4fd0-bb5e-18121d977f1f">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_8e8bef6a-ef1d-4ced-b4cb-177342c1b3eb"
      id="F_f114cd43-1997-4c6a-a0be-687ad92c7b9f">San Jose, California</dei:AuditorLocation>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b"
      id="F_c32b468e-c77a-4106-aca0-e007f94863d8">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b"
      id="F_2a476357-8882-452d-b8df-1c93bcce2793">false</ecd:NonRule10b51ArrAdoptedFlag>
    <inva:Rule10B51ArrModifiedFlag
      contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b"
      id="F_a1818786-fb0b-4267-9d3c-6ca9c7b6166c">false</inva:Rule10B51ArrModifiedFlag>
    <inva:NonRule10B51ArrModifiedFlag
      contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b"
      id="F_8d45587c-1c08-484f-abd8-754505e0fe08">false</inva:NonRule10B51ArrModifiedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b"
      id="F_30f27388-7eec-4973-a60f-4fd8887cf2f5">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="C_ef345ad5-b2e9-4551-a15e-1bc65d1cb88b"
      id="F_f8fc4b6b-633c-4946-bddf-2bc747bdedd1">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_9118e54a-a9f9-49ab-b4bd-5e6b51bfb0c2"
          xlink:label="F_9118e54a-a9f9-49ab-b4bd-5e6b51bfb0c2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b904a8ef-a45a-4492-8701-2393c7419d8d"
          xlink:label="F_b904a8ef-a45a-4492-8701-2393c7419d8d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_b8527f5f-0ade-4a50-82cb-a323f0a7eeff"
          xlink:label="F_b8527f5f-0ade-4a50-82cb-a323f0a7eeff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_9fb85da1-cbc3-41d4-a51d-07fc5150ec6c"
          xlink:label="F_9fb85da1-cbc3-41d4-a51d-07fc5150ec6c"
          xlink:type="locator"/>
        <link:footnote id="FNT_fa630cd9-d3b9-4ce5-bce3-2719848ceec9" xlink:label="FNT_fa630cd9-d3b9-4ce5-bce3-2719848ceec9" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9118e54a-a9f9-49ab-b4bd-5e6b51bfb0c2"
          xlink:to="FNT_fa630cd9-d3b9-4ce5-bce3-2719848ceec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b904a8ef-a45a-4492-8701-2393c7419d8d"
          xlink:to="FNT_fa630cd9-d3b9-4ce5-bce3-2719848ceec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_b8527f5f-0ade-4a50-82cb-a323f0a7eeff"
          xlink:to="FNT_fa630cd9-d3b9-4ce5-bce3-2719848ceec9"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9fb85da1-cbc3-41d4-a51d-07fc5150ec6c"
          xlink:to="FNT_fa630cd9-d3b9-4ce5-bce3-2719848ceec9"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_c1a4bfda-d5e2-4288-afe3-91da9698ed2f"
          xlink:label="F_c1a4bfda-d5e2-4288-afe3-91da9698ed2f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_fe172cbb-06cd-4ace-980b-f77c69728f3c"
          xlink:label="F_fe172cbb-06cd-4ace-980b-f77c69728f3c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e7e2aa43-24df-4446-a31c-e9588f387342"
          xlink:label="F_e7e2aa43-24df-4446-a31c-e9588f387342"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7e0f8737-3df8-4207-9d21-7b3dde1346c3"
          xlink:label="F_7e0f8737-3df8-4207-9d21-7b3dde1346c3"
          xlink:type="locator"/>
        <link:footnote id="FNT_30a29ac4-a358-403f-922e-b22439018a34" xlink:label="FNT_30a29ac4-a358-403f-922e-b22439018a34" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Money market funds are included in cash and cash equivalents in the consolidated balance sheets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c1a4bfda-d5e2-4288-afe3-91da9698ed2f"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fe172cbb-06cd-4ace-980b-f77c69728f3c"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e7e2aa43-24df-4446-a31c-e9588f387342"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7e0f8737-3df8-4207-9d21-7b3dde1346c3"
          xlink:to="FNT_30a29ac4-a358-403f-922e-b22439018a34"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_caa0e40b-6bde-47a3-9868-50a819fdb087"
          xlink:label="F_caa0e40b-6bde-47a3-9868-50a819fdb087"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_7107755a-0b4b-4d35-b156-55487a5c74e5"
          xlink:label="F_7107755a-0b4b-4d35-b156-55487a5c74e5"
          xlink:type="locator"/>
        <link:footnote id="FNT_c6ef9b64-150e-40fe-8567-e348fc66452f" xlink:label="FNT_c6ef9b64-150e-40fe-8567-e348fc66452f" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Amount as of December 31, 2024 includes $</xhtml:span><xhtml:span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5.3</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">advance payments received from our partner for inventory supply as discussed in Note 4, &#x201c;License and Collaboration Arrangements&#x201d;.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_caa0e40b-6bde-47a3-9868-50a819fdb087"
          xlink:to="FNT_c6ef9b64-150e-40fe-8567-e348fc66452f"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_7107755a-0b4b-4d35-b156-55487a5c74e5"
          xlink:to="FNT_c6ef9b64-150e-40fe-8567-e348fc66452f"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_9109e66c-349f-4b2b-9c9b-cdbaabe2fdff"
          xlink:label="F_9109e66c-349f-4b2b-9c9b-cdbaabe2fdff"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_517fc5ee-af94-4656-b409-1fd12f23ccf1"
          xlink:label="F_517fc5ee-af94-4656-b409-1fd12f23ccf1"
          xlink:type="locator"/>
        <link:footnote id="FNT_36a39a6f-dfa4-4a07-a213-6e12c7dcf21d" xlink:label="FNT_36a39a6f-dfa4-4a07-a213-6e12c7dcf21d" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For tax year 2025, state taxes in Kentucky made up the majority (greater than 50 percent) of the tax effect in this category.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9109e66c-349f-4b2b-9c9b-cdbaabe2fdff"
          xlink:to="FNT_36a39a6f-dfa4-4a07-a213-6e12c7dcf21d"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_517fc5ee-af94-4656-b409-1fd12f23ccf1"
          xlink:to="FNT_36a39a6f-dfa4-4a07-a213-6e12c7dcf21d"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
